<SEC-DOCUMENT>0000064803-23-000009.txt : 20230208
<SEC-HEADER>0000064803-23-000009.hdr.sgml : 20230208
<ACCEPTANCE-DATETIME>20230208063738
ACCESSION NUMBER:		0000064803-23-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		142
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230208
DATE AS OF CHANGE:		20230208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		23597021

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cvs-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:062ae674-cc97-4efd-81c6-d89202a3d450,g:ffc34178-e241-4c21-bbb1-7b57d93a8581,d:1ae8e8cf4da649e4afa2b073939999d2--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cvs="http://www.cvshealth.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cvs-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl80L2ZyYWc6ZjgyN2RiNGQ3NDU4NDNlYjk2NjM1MjBhN2JiMGMyNmIvdGFibGU6NGQzYjAxZWZmMzY4NGI3ZjljODVhOThlMTY2OTdkNDMvdGFibGVyYW5nZTo0ZDNiMDFlZmYzNjg0YjdmOWM4NWE5OGUxNjY5N2Q0M18zLTEtMS0xLTE2NzkwOA_89719c21-d57e-416a-9b72-f668398848e0">0000064803</ix:nonNumeric><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl80L2ZyYWc6ZjgyN2RiNGQ3NDU4NDNlYjk2NjM1MjBhN2JiMGMyNmIvdGFibGU6NGQzYjAxZWZmMzY4NGI3ZjljODVhOThlMTY2OTdkNDMvdGFibGVyYW5nZTo0ZDNiMDFlZmYzNjg0YjdmOWM4NWE5OGUxNjY5N2Q0M180LTEtMS0xLTE2NzkwOA_d243e4a7-bf75-475b-ae32-7eb70d17eac5">2022</ix:nonNumeric><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl80L2ZyYWc6ZjgyN2RiNGQ3NDU4NDNlYjk2NjM1MjBhN2JiMGMyNmIvdGFibGU6NGQzYjAxZWZmMzY4NGI3ZjljODVhOThlMTY2OTdkNDMvdGFibGVyYW5nZTo0ZDNiMDFlZmYzNjg0YjdmOWM4NWE5OGUxNjY5N2Q0M181LTEtMS0xLTE2NzkwOA_ada4dcd3-f6e2-4911-9ea5-e298327076c9">FY</ix:nonNumeric><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl80L2ZyYWc6ZjgyN2RiNGQ3NDU4NDNlYjk2NjM1MjBhN2JiMGMyNmIvdGFibGU6NGQzYjAxZWZmMzY4NGI3ZjljODVhOThlMTY2OTdkNDMvdGFibGVyYW5nZTo0ZDNiMDFlZmYzNjg0YjdmOWM4NWE5OGUxNjY5N2Q0M182LTEtMS0xLTE2NzkwOA_6a243782-4cdb-44d6-a0de-009e7e05e5ae">false</ix:nonNumeric><ix:nonNumeric contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMC0xLTEtMTY3OTA4_1e4004b0-6498-4ea3-8ab1-ac09269493b2">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMC0xLTEtMTY3OTA4_3e2cf2f7-df85-4376-a35e-0669e17c468e">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMC0xLTEtMTY3OTA4_5eed1e85-5f6b-489c-9018-e11e62bf23d7">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="ide6581f173394288a53fc090546c297c_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzY1OTcwNjk3NjgxNzQ_dd91000a-d118-4a7c-8b68-d85f1dcfda5b">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMjY0_8d034ca5-401e-4526-8bb8-d8fed86877bb">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i5b05aa08f755455f9dc89cacf2875829_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xOTIxL2ZyYWc6NTYyZjZjNjAyNmU1NGY1NWE3MzkwZmUyODc1YTAzZDUvdGFibGU6MmNjODdkOWQwNmJjNDA0NGI5NWMzYzZmOGJlYjkzYzAvdGFibGVyYW5nZToyY2M4N2Q5ZDA2YmM0MDQ0Yjk1YzNjNmY4YmViOTNjMF8xLTEtMS0xLTIyODk0Ng_a478b74f-99e9-416c-8cd7-d78631080796">0</ix:nonNumeric><ix:nonNumeric contextRef="i131cd8cfbdc94fcdb157a2c4f138ad2e_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xOTIxL2ZyYWc6NTYyZjZjNjAyNmU1NGY1NWE3MzkwZmUyODc1YTAzZDUvdGFibGU6MmNjODdkOWQwNmJjNDA0NGI5NWMzYzZmOGJlYjkzYzAvdGFibGVyYW5nZToyY2M4N2Q5ZDA2YmM0MDQ0Yjk1YzNjNmY4YmViOTNjMF8yLTEtMS0xLTIyODk0OA_91c2161e-2c81-4de2-92bb-7a77b0d82e37">0</ix:nonNumeric><ix:nonNumeric contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_136d726d-4e4c-47e6-89b0-66598c753e01">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_f7e749bb-d161-4304-bb3e-6fdb8d5e52ce">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzE3Nzc_8d034ca5-401e-4526-8bb8-d8fed86877bb">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cvs-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef592c79265415e9514a93ffb9ae4ac_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i40ddf3f5cfcf4be7a0d007238cbe2748_I20230201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i21d91c5c532243ef9f94c642820dbac4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a740dd129184890b8bde10a27ca4208_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia465cf35ed0f45939b52004b01431e3d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db92dc898a14220a458e7987f33b9ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdce439e9a164fc590536f15958f67f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic793b82f8aae4503ad92cb8081fb8628_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b5114192110480ab4f260049ee8b103_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43471633110c4d35b96ffaf743cb0e4f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ae6bc100814ca88c4440dbb572bbdc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a7763da9eb4043aa8f22f5c692da1a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if00d0ef5531f491687905cc2a31dbad1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a3fb0fbc894ec1b2c889d8507c98b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7b2f5710c3d416fa6c9cc7c92282465_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i888d803efa36451abbcddc3e49ab4600_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3c8cd4bb654446b90531ac0de6b52e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if44510fc0a4b415b835ac61565cbe142_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e66d5c8619f4ded8782d4028fa2b01b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifab9f0d4beab4f98ae87761afaae6ce3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ebc7adf3c3345cd9cae049928aa937b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9cd17faa9b459393d314bd5dc139b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a79211767d44618caf1f746ea964d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dda31d68ee44ac380464c0d7b42864e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506db4d0bb51485db8a39fec0af261da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id118cd6fcaeb4d16b525a15d0b586564_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic935f384ec884760808c5d3d56f93b58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a2c447554b47278dafaa81be11f9d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i215e39f051a24c26a9fcfe870c6bb597_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia036bc4a7dac4d75a3807b027b89ffa5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ac8c51a1484aa2a5345657f72786b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3b3a385f98e4970a3c4003641ffad00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06ea169a39a1448695c8f5079e17a681_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ab1718255d495ebfab5b03525f0868_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d6dbba9b47e4c87b541de1f1350e1c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6a2b778a2b648ebbfa53406c5d05497_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i835f93d2a91243ffa5e213ffac78aa2e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib06f1a367c1c462cb54add04957c2b6d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ccf20c4b2cb4cbfa96ff019488ea873_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifedcfb6c0f5f44d9bedcaae64ac0cd39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2d25a04a6754b1498c8f7da3b006bcf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90c39d6e1188460db9fc0eac4c5c73ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia074c2e908ba4d4d9f8528b440cb9e61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ba6af5137d4355a39e538ff11c3f70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14bbd86e337e40b5b909ba5b0eec8986_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c919cbd9e14d14b0126701eccb5f78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i403b748d2961411884d18591a7536a94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972cf157c8074bc5ba5d6d1d1d0a0ee3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i109b0efa62914aa7a4f584e9303e07d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife2124c0776c4afab6cf27697b98714d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22bba5ead4dc4a12b105fb70a7664473_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90073196b804847ae7989cfd2058161_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34594b0b5acd443a9120b077623df7ac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bfa8a913ea04eee9d8522298e6fc681_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e1ce9835a2445c995772377b12325fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69b40434e129497fb044508149145574_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40913455599d4dbe8925b15950ed63ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief98321000924065a5a2817038f6cd96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ef2fda83394a2d8e020112d6facee6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1778905608134b9da2d0fe7767917336_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc357653e2c74c68a77d7f6658e76744_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide6581f173394288a53fc090546c297c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ec77f9083d4e5aaa261f4838a994dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fef13855a34463aaa68cd3b16edb43c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="store"><xbrli:measure>cvs:store</xbrli:measure></xbrli:unit><xbrli:unit id="clinic"><xbrli:measure>cvs:clinic</xbrli:measure></xbrli:unit><xbrli:unit id="people"><xbrli:measure>cvs:people</xbrli:measure></xbrli:unit><xbrli:unit id="patient"><xbrli:measure>cvs:patient</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>cvs:Segment</xbrli:measure></xbrli:unit><xbrli:context id="i780b19498a144075a22a573432132bda_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>cvs:state</xbrli:measure></xbrli:unit><xbrli:context id="i42d18c1100d94a559f0d7d4c757498bf_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18de26c953b4c36b64633eff1121e28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4974a8bfcfe4424d800583e6f9ed22ac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef0140101e7410aab67b7c7900a5d71_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c831fb209894939826991737cbd7475_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvs:FixturesEquipmentAndInternallyDevelopedSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37cf62163d84a58bb4468ebd3f5cfed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvs:FixturesEquipmentAndInternallyDevelopedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bbfa6bdf0b24740a26dec57554e595c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ada219a77914d62bea752d3c03e225f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c18d654fb324895a611580a5ec5b3dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53b91392b604092b359e0652c0bf806_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fde8ef39b534e14afcac581de49b996_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb3a83ef19240adb23daa081377a140_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcd7ff4f57ff426ab9b84721b8a4497c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6748d4d91a3f4e1c9f9bf83409587fc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d2d5b42e5da4c468ab576df84378112_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e8b9d6224854f2aa4c4798da79217fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b3fce48e974e0cba8970c7c61dfc90_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e0fac73260b479989119ffb924ad3e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d6894378d3433197250c8e10ca47a7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cvs:LongTermCareReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7945c60ae0e48268a21dc60ec7256ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cvs:OtherInsuranceLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide9ac130c868441a9b93b609dc8b28e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cvs:OtherLongTermInsuranceLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6d2a400d30483eb5535b2a740cccbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cvs:OtherInsuranceLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc50f23b90eb443283a4ee5cf88abd97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cvs:OtherLongTermInsuranceLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63500a3d0dc40e8b098d64a2fbfe2ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i26333704d6224942a7b55db5b9a7c2cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3625815087434552b838d92f5f5f5e0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i262f23d50a0d45db8328a0d433a34f63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87aec70e323d4d80b7919dced5a91e73_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72800db1d6214a588b0e32ee81cf20b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fab4c813ab3488e9e07378a081f8db9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e7024e7b3e47b3b5530bee96e98c10_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b832667ae304814964afa70f9b6228f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab45872f08734ce1a3dacf338ff1195c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4b2b74efa8424bb6186fd1ce6f571f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i428e6eaf7d9c401a824a54e771b1843c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14f4ace6f2c42638909cf217d548c72_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916017148df94c918c5f7fd143ce2d88_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if010e49d412b4111aabb4d53c35c0289_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia131689becf644f4bc5a732edb3c22e2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78e819b5e8cb45e5ab8dbfaf05b504cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209085ef2a2445ddb82ac68f9a34c386_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib59f410a5b084b5c88a7afb76702b6d0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefc8faa2206e496e97d8bd1eff35cdf0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317658c2ffcc45ea83ffebbec7222ac9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5fcff7cb6c46f987a53e2a78bc0fb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i786d650a37ad452c813aff2f3ba2b66f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifefecdea33b5434f8044bd84cd050b73_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3279e91422224439968bc192db36cdb1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5f8050b163245d58912d4aff32e4a28_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875b6ff05a00444daa0d40d607318115_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6a4492c873942499213da78e615d60a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc263ef676c41c7a9714817863cd0b5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531a5f41bdcc4e98bc63759f201375c0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b49c00627e4fb69a66285d6f3f5b64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">cvs:SalesChannelOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f9a334ea554cf6923ae16a198dd1f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5470c0948d3447daa6b553072d68b21c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5218b8d02245eea6cb1c1964bc2d56_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ebe5b02e9154d92b2659182b87bcc17_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e66c2cd601c4549a5ef3b24ccbaf9fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee9b96bd1eb4291996ceb2ce4ecb8c9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2694cdfde5e94542ba60918fc678d54a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bebe76ce83e46589a14f0b7cb047cb7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99cbec53a7ed47e3ab88190772305c5a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57e0be74304456489f0a228ba4952ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dee4299a044434bb9587326355c6d37_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15504530953c4bf689166fcfe8f7868d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c90e55b42a466ca5aa922c38dd414e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cde5b8c7bef4de38fb102a05d7d6a29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icba757607c0e44ffa9ce352a6dc203fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86521d12a18428cb6850612e4806b2e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26cc5da453684e30b0e7f61d0c214207_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a89142a03e46a08448375f4b02bc4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10be60b83a684a8c8d1797644e6037e5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec13ef8ea98a4f52953499317400e068_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id041b9cf96944df2825c84f9dbb638ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f8c85482214ae78d33982d2c28ceaa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9915652c392941698dd07b170ae9d044_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c774395798448abbb90933427cbc204_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66c5e92146f4978aeaff863da389857_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85235bf2dc3145338feefdca3630aa3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf6ff2650b194f6f9b88d08a7d679daa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">cvs:SalesChannelOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i710619ea82ee47b2b0f1faa66681850c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe5733b07b8443d7b51ad01e0f283bc6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id91c69b620814b2a9f51d3084dada276_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d0cba2d7a4b49d68120f1ad1e3b59f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047c32c6681c48a280f39c07fbb64103_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50a613e7cb5b4f9fabfb569ae06de8c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa8c79cb8ce4f9fa3d25b293e92eafd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b4cdb3407c14f1282544e57e58ecf04_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5bc5d4b76344af48fea40efd9a549c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86040f73a11474b89670e351fab892e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e8afb1516f445db8c04046e7f9619f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b3c892261d42ae91d2522773ceeffa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f6f283d4c04e2dac7883355902fa5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab6442d127e4d5abf45e0a1fd8044a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40a69bf319414885a2af9b145fb0daa3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d1804d8c6b4ac494abb73ef6b710bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed9c24157b04f799ff19ca1d9a73070_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52962d31d6d1400aa5bdf2bab550bd30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae8e30495c1f4923ac883d572d156bd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a458accfa84019adc7131cfcc882ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id854bc7a2aa64ef3bbcea56dffab6dbc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa3187fec8b406b816c24249fb2dbce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b2481d581d48a38dab150c09f95d26_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfcca160913463291592340d0f000aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6504396ad13b404a809b4be1782f4962_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4e4149eed634db283cebe9c5c27cccb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c934f6d7dbd4623a30db94c93317b44_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">cvs:SalesChannelOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d26d3b0edca40eb8a286991043bc26b_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ea54e1ccb34d709c3b44454e7262f0_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a79d946b244fbe83b985e471a79655_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia397b0104e7f454a9a66b55e5fdd1a14_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cvs:RedOakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i651ae9dd5f5d4e19b29b67ad25f2d822_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cvs:RedOakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374b0364197f455da3648efc785175d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a9c3eb37cc44017ab6afa84684e32ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0122d8f1aa4d48aa8ad7d46a51217f28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb39cc57c844ed0b532aa62c0a86627_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f81ec31a44f49e1b4a933ac7e20273c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4fc6318928c4432959e25e083008a4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d3dc349650457fbc2c1be5f20979d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dda9edc70414970a1c368f6c420d65d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie74c8e518d644daa9a788565f2dc3c08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:HeartlandHealthcareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd811ca9ceb5442fbd696e20ec9278ed_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201812Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5acb58a875864a49b737f2cb40ddee47_I20230207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:OakStreetHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4dd0513fdda4dfdb136f1594d393298_D20230207-20230207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:OakStreetHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5afb8727270f42b8ade9125cb3443778_I20230207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:OakStreetHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:OakStreetHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1773809e56854492867bb26fea3c6b89_I20220902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:SignifyHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i742e5d3d548546f4a2efaf4d89ecd9d1_D20220902-20220902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:SignifyHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-02</xbrli:startDate><xbrli:endDate>2022-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f859fc0dd5e47f0a5e763378f21729e_I20220902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:SignifyHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:SignifyHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bf59ea1890f4d16a13351da96cf6411_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:OmnicareLongTermCareBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7bd61bc8784946b9cec8dcc1fcb6b8_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:OmnicareLongTermCareBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96e78b501bc842a2affc4033fa4a4eb3_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:BswiftLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6fc4ecb20e54148beb244c5579a6256_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:BswiftLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i879da25a180b4cf6b770b94022fe1214_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:PayflexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6c8114b5924bed84e9fc58f5696afd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:PayflexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c3596e68a249cf9f084af72dd00f23_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:ThailandBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="member"><xbrli:measure>cvs:member</xbrli:measure></xbrli:unit><xbrli:context id="i36ec68c9bde84569ae25dc7eda071a52_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:ThailandBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b0f113479a4ec0b9e699b726fa4b6b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:ThailandBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i674eb260757d402f9e56019767496299_D20200731-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:CoventryHealthCareWorkersCompensationBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa94d302f25457a8ffe0851c4d7bf19_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:CoventryHealthCareWorkersCompensationBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i779c59619b9643cbb118540ac3605d26_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:InternationalHealthCareRenewalRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717e63c6c0e941a3ab348dc4fa490a30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">cvs:DebtAndEquitySecuritiesAvailableForSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a45d333346c4b16814c08207dbd06b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">cvs:DebtAndEquitySecuritiesAvailableForSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5de346073b1b4e83be2a8d87564b444d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">cvs:MortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb1627c01b1430080b3f6a0a40addeb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">cvs:MortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7bc5f7c69e7441cb31da4729c7de4bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdbc67676d794d47817f10d53a42b996_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i794d05f87c014f5ea664e007d8ef553e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13df1984aa1d4ec0afb4004f690df554_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7308db8487343dab3c870126d9b4513_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99148b9bb5954a1c86c55a80ac65caed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i221ef7845f854689af410277963cd5bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8de7e486f7b414bb32dfafca43b2196_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2ec623c034486c985ed3eedbbba076_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628bda68e4a846798004771ed7fa1e30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3def4d721b4452a9745ed4ff29dd91f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae5d28fdba744f89bd9b16b1f10ec56_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58f18f7922d480dbb9758608a9e7dd8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>cvs:security</xbrli:measure></xbrli:unit><xbrli:context id="ie67471467f9945e5bba43415e678c6b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingRemainingProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40478cffecf64191b267758251c37050_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1af20438bbb64d5f8b78df4ed91c4fcf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingRemainingProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d14838d61d4f28a334a6fa3ae5859e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f4db8d8e9d486f9039b51a301eddcf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingRemainingProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc1e6e162ae5412285a67bd88bbd3ed8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdd4738946f44c8961343c0e3d3fae3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingRemainingProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fcec899c0a848d4b4ebc10f773df4c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c5943b5b1904c6b846ccf841c464d39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecece3fcd8be4303aa5cbc5c092cf500_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb3635c7aa14bb79761106ea93cc68a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7f8117025154ef69cad75e991abfff1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0458817c19b448f08f9c914f63356b8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebda2282c15f4559817dfaba4fdac117_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed8619550174d168c4c4cd42b101642_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd7eba7b3fa241f3aeeb456afa8bdd4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ce9ddcb63246efb0e31193bee2ff73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia44809c2621249a5ae15e084e9a2de19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc19163e572465e81ae33a610b8f94b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de4c16e901d4eccb8965e3fae43dcc6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i828b576776fe424bae9270ea200522e2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id756e63e2e754f359f0f9ae581e0a94b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i360bfd4546d74642b59856ededd82514_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fbbf77e09bd41508b2178ad8c2442bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec7149199d0463a92cc968f65f45f43_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9ff2cb5e224b209b049e6f94fc2d50_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3fc6e014927402abca82128c1ddf524_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2597e031daaa40e6a6ec272f1341abcf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38c112ce5a634675b6bdc212a46b02b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6f2a4d7a5a4af9a3d311013668f24f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72bbda77b88f4cdd9fb87a318a29fedc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia294054d10ac417787c1944ee543fe6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6beca7e4f8864e93aeba97040d6f5a37_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97612fc3a2f44d73bb819a717d41d0a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if14f3e4b96e04557911ee9a9b62f5e0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a9138a58c84726a45e23bb6e6167e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia570fc5031314098910825a767b2b0cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea6ac9f0b5a5421dbc9cb6e72f8396d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707228ea268b4fa1b8fc7634fc9a941f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d7e7b8abcda4b75a158f71a15390c9f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i588aad1d73dc43329473d13fcb268e7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d1acd38b204e20a8c2a44bb0f10148_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf70115e4b0543e3a96629490f5ae0dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3808d834e07e4b3b9e287f3834d21fdf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e10c1576ee434cbb42319cd9c8ab0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6e024d3cf14d86a2923481e9e6e304_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia44ab5a60f90433cbd73992a1d0566db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4f2cc1ce7924cb5bfc1eed1de05f7bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib19d3a4e66794458812e357f78f43e74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34a5f10b00974911867bfe65ff417616_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516ca7a24b4e45d98df8d70dc8459538_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8c11020a34479a954004c76070a1b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c568b1356424e30b16ba09859cf6b43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f9b7af276014284bf1cbe79e6f1d940_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfda10eea1e946608a7bbd50cf284c24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90857bdf1da64bc0b9e9cb8b2c306c07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54c71d8deb84041b2ac5c9187940c7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4854a804064145bf94625cb963eff0eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c97f2c2663d47269fef701393c390f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ebaa434a774f55944633b91503f6aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice10fbdb03344142bf872d80c624c2ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b39b49a3b54b80924c011dd5d61684_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b6ec53ccf44d16bb1cf7ea10345d8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04ba64ca88a842a8b016d348b2518392_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76d3139b44e495aa8b5d3c2e3fe365d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f39590e349c47e1b6655543883e658d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4503868833d04c6e92dd980faabe8e9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b22cfb2e4fb49ef994eb2fe50637d3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6f5d37438e4e24adc486dfc220e330_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75817f6d10a64edb95908711e7b84a5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd337cc2997f4c9a8bf96e1b1038b176_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f411adda394690a887804f07c4085b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12a1e132dac44a7aa77f7b5045148074_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e80630b4afd497383aa2e7e0825756f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b0b007394094a3a81527483fd8a8975_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i548886065c29409da2eebb0e5740162b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie285042dfe4440d68f48b4adebe96861_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cvs:MortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b9bf6c2c8e24bf0a220cd7210ee97fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cvs:MortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0bc2b4239f48e1a3a714d4cc3d7203_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cvs:MortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i313f0ade641941b4a6bef1dd870a48da_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74585cf162b14135ad3471e993c71df9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20751ec3912a4de2a34e1c394c86a641_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5fc81ab5334092a75354e9e0cedebb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c9389120bf34657b8225887b8754f61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1333c10377854683a2d760e2dc527ff2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f243d98dd94b418abfc33c268175f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d831efff9ed4012a3c45a15c640b22f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6777feef9d4cb08a3526828f50afc8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0c69d485444837bbae724a028fb845_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39f877dc08449f49c5fa9feb476a432_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88708d7db67144f6b9034fc9b683ea9e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0a49e1f8ed54cc797d186700b9962e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic83971584eb546e2ac5fdc1e7bc8e84b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice45b349609443519e8d645943421f9c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a23915f279344c1bf1087035f0fdf12_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c2d8598a124c19a68198d84bdafaf8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i785d19a7b609421eb9246c77f19956fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67f0cd92f49b4b2ba3ae745e22916f37_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e9b578731f4c5baff668f1e8bc6d6b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id86084968a414700a75a774a5a97ab5f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1814e1657e4cec8407f309d332126f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb1f815761e4abf81f0b8c3d4f8c6c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a671ec5023946d19ee290bcc33442c9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied933a3ae1c44c37ab908d407bf9b9d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8590aa625abe4bb3957876a8242f244e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6fb3a28663f4a6ba9eddda9e82c83a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a985a5355bf4bfa9414b48bb67b83bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40b71f09b498454fa6e14cfd770e0f13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26131a59b6674c21be2b2f35ac3585d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85dd5660a59b410b8d5600445dd2db73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b09513b5025488bb89a6666751b3eec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc3450471ad405a95c9f384be0052d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f137c3bff994afabf3e08f84adaf0e2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08f51346b999445e9d94877366425a3a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia214d8b8ca6049f29665c2a7f42886ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f05a7cde4614b0ab28a1cca18e30c59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i624b1a999672495b9d45af07b54e6b76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dd5e7556c1145898755e2b6da40bee8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a5333835ad4c71aed5cd82b4c95855_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c8648eedc854d2cb3b880ba07b81e53_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida77e918f5de47b4b67cfca0da2b8226_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6906b59b585c4d4b85fc1db92b4aad26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795b096e03294f5da8368aac1b682f6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideffc599afc64e2eb2ba34d383e611f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9e565524b0f4bf687a1dabcf4928828_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81efa365424d49cebe90328cadafba3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ec5e8d0dd14482a058a46dd16eab76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i701d4495212945b99d951fd9a0dcd6c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7773f5873dab49a8ba60de1ef7a255d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i348bc1177736419fad69fa81d958c8ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32773f424e5649049efc564c1400fd60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddfb3509175a421fa38431213004bc2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i949fc998576e45bfb3cf3c21865aa98a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4b742130f941fe94db85e807e7a06a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb4af948251483fb59540de78e273f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f4ad698b6cb4a918854adc5690c6f16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a543a47bdbf412ea03cd80a7e5147aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f2c37f0c80248f98f71a7fc479de9ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib999956c1a1844f0a5f0f337b58d6d66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fcc6959ebd747668932580c12c9b80c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia921c1e5944340c0aa0256f19c8b20a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a2d79c756c41b2bea5dcf9fc87f998_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i206c3b9628b7444ea6df2624ea2118ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7f4bc4698994fcab1897c3d0a92ad88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ee0b6a29d934c78b07a74d71c61d1db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee7db71ae1ac40fd91ebfa23d481d8c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i190edd6b8c6944fd9697dfc9489f8a9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387ffe71e44b4f0daa62a18eae1f74ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i431cc5a5826c442fa78d95415014f874_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6ddcd1cd3484e58887f45b9ad5e1006_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eb6d4a5fe79457293a854403dbb6e69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff589f47f514ece9b347067993f1a0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae1a142a6834907b1e6b0fa40a2a994_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic83ed3a7dee542e08edcf3a6a2ea4b25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2050ac0edb04a31adf7f234fb6390a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75346ba9d76e4cf0980dea9c58ccaa81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07516a7d0c4d4a0eb9c8cf019d26a2e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b6787f48b3442d8a63c30333c6b458_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f194dd99c7e4f68b3ff5746bc03b35e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i992ef56bb420411cbbef3826241d452f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77abf1713bc54af78884466e31b453cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15dac8898949438694ba2abf0c059910_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95dfe2b0be4243cfad329e2e411e3303_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7975ad7519e54b6db43ace8eb80066d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ee925bb3e5402b955f9868457737db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3892577d13a4a62a891505c7f399a79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia091e18719b84015824f1dd5f80bc7eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7619afe50a794a4a84a50dcfbf630c38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79c1ae91ff3442528fb1f71c91933d34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i662d2dd29a2a4a22b0b5e93c396ed6f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia37d53d84cb44bc39778f9546e36542d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66bcf7a88ef8420db041c82d229c682d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic858e8e5cf2d4617b20fa3fa03a4a293_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe1938eb02c435297cc130427df950c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb6be9b43dab4ff69cd98c57e4510019_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c075490097946eb8ba4e98465055bd6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734643ad1ae34563ab562dd2a9a185e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i699884ef14c74682af2d844bfa691e05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863995f01893429ba0b90278c34784f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i355cdb170edb433ca79e61e309a40c6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53c500be5647438295ed663bd07d0536_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf216acef3094d348747eeef4045d573_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7844b63d898f426f84d9c961ce7de5ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0582621bb34df0a6675d029c295a94_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e64cd8ab5fb4322a855fe783aaa1050_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd86471ead2541e4b8e2ee2e52429bcc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1caa2a8534f942fdb15c0e68a3ba7cb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1901bac7f448c48fe0d4065b09e0e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i275d0ec6124c46a7ab946d9a16477a75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749066de634e42b3816f92927cdd0c23_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f70ae1bf3c746fe82376b68d9bade16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76610efce5044b078fe774b073da1159_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799622beabe24d068a330216378ec7d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i303c9460e5aa40ba8797ef57bc7a6665_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69cb21ce24c45138129b0b0b0258605_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie43f9bbeac1c48f09d85ab8bda317b67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i790c87349c0545a0a15037b5863ea17b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796a9a2e1f724310a3315d9fc1be5789_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a6cb4a9a1a4a34a8a63c650df4220a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22d221a134574691acb5e35393d71d09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id68f0f4d9e054479ba78b7c748a66258_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc0567d043f4a288311dc383ab5b569_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if034f6862b3d4fd4936961827df503fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i960dac857f814d2aaf3da5e41ab12bea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e1564d3fac24665bd7b402ab4a1fdea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769ac61262e54e7ea669fe5223c1a8a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieff1acae7f1f4a61995476442d7613e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b34eb9a40f14a1392d66709b0113c87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i842dc9cc1f984655976affbd54127c54_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d6d75b00af74666a638509a7b9e9285_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if35e951e7f7044a78bdf58c5c994e504_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f80eb74b06647c996981ce7bb5b9d6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ceec40d348b417d9dc7a41eb39aa1b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ad03180d40f4e7f900eaf9ce57d2f6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2314c70272ad44729021b8b7c81f68d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6247aa5d844b4cefa1e771f6ef8a7da7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74b7d5d8bfba43248a819e81b1b296b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i194bc2ab09d84172aea4a9682706e5a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:SeparateAccountFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id206ebf70f104468bb9392e4f8e41a61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:SeparateAccountFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f9799c87004ca590fa53584c7e24f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6f1f557fab4461b4f09715be534c58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4751bc253ec4ddf90922f866ccf2b7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefb4b1c3d63e4323ae108f339bf86ea0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifffd3cc38a8b4021a53283d65a4c0964_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7e4c14ecb14064a1e1cb88fae9be52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09cd220413f4c58b188c10acdaca66c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief0e8d9ed04c418a948fd84835bca811_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i508064fb813a4f16a124a4de02fbcd59_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef4eb7b015b4186b848a7d8272984a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96931f5310964061af361408b2ab6730_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8d9089fdf7c4007bbe779a88d4715e8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b3902b297a43b9a015149f29e45bf7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c4edc5b99644fa3997863adf1255293_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bc72442418741689eed1454ae87700b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cvs:LongTermCareReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264d976e57564672b0babd9565bb98e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7e8be7f4e347beb8eceb156d106b36_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d0930b2b2543929971d15fba0e45ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8e8c8634f0645dfb503773210e8249a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ProviderNetworksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdf8ae9241fe4e3481243778aef0f6e7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ProviderNetworksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b5b7dc71ff1469ab8a6a25decd8cfd6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ValueOfBusinessAcquiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21cba4373fef485faa84dab5def0f790_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ValueOfBusinessAcquiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if745b6dc0a754cd8914c4f5726b7f6bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5c2c83314342409224f6f5d753bd47_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a19e9a51cc547949bdde2b93fb44a8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7424dfa102ba4c84917a87df011344b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58636af2c05a4a5d816b65538e4b45c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f8326f384345448eaf5b58a4b2a7df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ProviderNetworksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida22ed7ae3e1481db1884a9cb038c03f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ProviderNetworksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32bdea3056074d3b98bbd8937ef4391d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ValueOfBusinessAcquiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b7e0efc2e614022be02cce608679450_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ValueOfBusinessAcquiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd3a6f7782284dbb9c5b5e9b11d670b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9626105cd75b4a3a9391af2fd8b0ea24_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i749b13bb01c043f9a3cb673b0a199669_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:OmnicareLongTermCareBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b05aa08f755455f9dc89cacf2875829_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131cd8cfbdc94fcdb157a2c4f138ad2e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a7b9e629c14bcc9865d4798fa5e15c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e150d3db673482e817a73aceedfec35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife6ff41a415343de94e5806faaabb281_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id427563c92b54e5f88ceb5b6ec87195c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64f5c37ce66141f7a204dfe6e993bb22_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie936009c1c1e420dad0ba447530546c3_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60dd33f11cc2409080bad57679954d47_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id630be41a4e14306bcd92700167a1f05_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5695f9deb5d42f399db0a5df5333d03_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id562208e84834686a7620f76d36a5e86_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13d80e15e3f94cb0927c69c6bbb18ad5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if99f5cc945cb4089b78aeb74c829d2d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic76c4e64c26444a5bf8225d71e995baf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6259c8555abd4bf5b6dac136069d1316_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9affe0606d974499b83f0e139cb17dd2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3477564c46a4d1d89c214c39d6753d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ac261a946f441689f0b6c8226695ff7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i376c8a46e57d495d82198a8924218c06_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d32e81675c1411abb9e6dc0a83223c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i104c7351c43f4dd9ba23acf27dc2da0d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2661ac2447ad404b9093ebf03b2f3a2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4d0589b63754b6d96499af470071fa3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ea0975c6434c688a6304c9a35567b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueJuly2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23b4e48800ec47c1a7b0ec56d1d395fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueJuly2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d193754e1d94c0494f9956393440f77_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueNovember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a906779cfe446a2987d8b5241fbf0da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueNovember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if71e011d823142598cd37f46f2e49a05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueDecember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1c181073c4542f099d25eb5c5d40655_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueDecember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61839e753d2f451b9587d89360867561_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueDecember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d2bd8ff5b14cb5a635a188ee174c8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueDecember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a3d976289814f1ebda72b277cfb0e32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.8DueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ba734b33ac429899c73244e0b3e4a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.8DueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e0c4baf78af43da8c871e2cf0d3776e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb44b3665b4246f1bf997c90b24c21d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d559325531a42c38fc46ff0a8fe2921_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.375DueAugust2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b0484677d3d443eb00b519000bfb3a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.375DueAugust2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e27d861e9545b9aa31b1102e04c153_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.625DueAugust2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42ac987c67784c1186308edd0aea70d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.625DueAugust2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic180b72151a4402f8310dadcfc70fb01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueNovember2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74b6f748466241afa934def47b3887ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueNovember2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4ae74a63944a4ab738561dee76b7fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5DueDecember2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89e4d23924994b228cd71cb68d806750_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5DueDecember2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefa4fc8c856647a0a132eb36186e08b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21a0aa5c9d141bdbe4a207bb4f293ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fb06588816f472bb29f99b8d68219cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.875DueJuly2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42c9969b99bb4ad798109c43cbdc6881_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.875DueJuly2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb8a5e549c1f40079912cf72b576f3e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.875DueJune2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c887883f1ce42688222f658a393184a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.875DueJune2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b8c6c77f294a97b96b4e9060102c49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3DueAugust2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f841196e9745d7a5bd741b956cb571_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3DueAugust2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3120aef7a1a74f9aa9ad6c90254ae7da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point625PercentApril2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21b2c11292246968e32e95a7e2d5d46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point625PercentApril2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83a34a6019c9487ab8dc8717a85803b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.25DueJune2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d2292eae624df88e3cb7a81e75175e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.25DueJune2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a05b1ec70b4ceda24080b978863c80_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point3PercentAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9e78fd616384a38bdb3bfc812db60ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point3PercentAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i208edaa424b244c2a575cd9b2b4b9020_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.3DueMarch2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3609fe1a0966404993bebd381e7eda7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.3DueMarch2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5aa28ddd1e8430eb577239a8f77bef0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.25DueAugust2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0fa0101d32487d87f11b2ff81e35e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.25DueAugust2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide032eb9e5684d3bae628ecb6f5fa55e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point75PercentApril2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763321b4294a490a99ed2699ea5e64f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point75PercentApril2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15f98dc5d2143468b8eb2d34e1a74e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point75PercentAugust2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8b28c2e4ea4f158253162f1d64b8cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point75PercentAugust2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e62497573243ac88b9afb7d5cd0de3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point875PercentFebruary2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe1a138e88c4de09bec060efb8de7da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point875PercentFebruary2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaceac4401a17451a9894899abe75d058_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point125PercentDueSeptember2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609d3103caff4c93b86c00a3a2aed350_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point125PercentDueSeptember2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d4aa00402164f00b89144874d2e4a98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.875DueJuly2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide1da8f0468d4f0e87617230289c5bdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.875DueJuly2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe3a3d79b0d747d9803a516b3766b9b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.625DueJune2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f90f74479324fd08ed524bf5c875c87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.625DueJune2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia363edf7d95a413cb5fecebeb23ed972_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.75DueDecember2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac58136f46f242a19ec676141946c7f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.75DueDecember2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39294c665ef74fa1983f27c408f039c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.78DueMarch2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9cbfd1800fe44faa82ca6d39ee57704_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.78DueMarch2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1512c04482e5447b84fbd0e3188e529a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.125DueSeptember2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9699d6696c9c4911bb010f0b9af5282a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.125DueSeptember2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3de7f45720594c44b73f3eab7ce10e70_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point125PercentApril2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f49a86ef2b485f829d66fae1ef44f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point125PercentApril2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id028ea3d52c44a2394695e4f43e9d046_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point7PercentAugust2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i650090a57c324b8498f059399f541fb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point7PercentAugust2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if44aa963bda44e8fa075b47f30535a24_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.75DueMay2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6591fe0e06444dcb90f36c98760ac910_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.75DueMay2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i472c295552a045b6bcce82be7abd296a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.5DueMay2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie807ae7adfd345cbb44996f1818e4a05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.5DueMay2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib71cdfc8616745bda08bb51063716d02_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.125DueNovember2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b979d90da5452a905826924ce27d25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.125DueNovember2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64cb7a0107874445b5ef1241ac268ddb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.3DueDecember2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6197c2e1f545da9f71938fe1794bba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.3DueDecember2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c6a9cc0246481db45b0f13ad35ae23_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueMarch2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3054d36c450a4f1a949a59076296c836_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueMarch2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a1d56e01764a95aa6ce0389dadcc42_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.125DueJuly2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d368fcdffdc46d3a0e01d94c43c30e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.125DueJuly2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c67e77d27e244a0a68d18b65e0bfd8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.875DueAugust2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d3bf9e9c15461f91c2413227e037e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.875DueAugust2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24053ea29d834108aadea2e1babdf1a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.05DueMarch2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8aad75638974bc3a8cc67695f56c0c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.05DueMarch2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2904af2c2aa44bf0b544d9d2553f8e9e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point25PercentApril2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e7542864f1465cbf09bf46b7a5efd8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point25PercentApril2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142b09e623c74fd48e7fa4f8a407f130_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88943c99762a48acb5314b7f2e6035c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9857095e8f8462c8443313d13593edd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5DueDecember2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a5bd02c59b48d08a90b3e9dc305deb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1fc6bc460b24a2d9f9e56bbbcc00fdd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i178a89f691034c3f89a0f58dd76f6e00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay162025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8df175e7a746b1966ad9f58331ab59_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay162025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1d90e160df4c6987e1a3d97b3ee6de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay112026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d274b43ce6b460b819a8816627a53ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay112026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e418d01a724140b2e4c98ed177fb58_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay162027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ac034e6bd446208baa342a62985862_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay162027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d9e769f3ec4ff9913f2a8111d4261a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:BackUpCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672e486d94cb40d7a527afc4274d487f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:BackUpCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia959e4c514254a2b8079572e46d8906d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:BackUpCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee13a60d394448b5ac976fd2d9a8bc06_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf725ff0cd64d81815fe8e8b14333a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5673d7807e4ec1a5450a0e6653c02a_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueJuly2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65160d516bd047099c2e54b984917a8b_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueJuly2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b72957684f401f892d85f44495d314_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueNovember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f6ffbd37304fc48f79a5e9b0b46aeb_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueNovember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822fccc0619141489184c841adb873a6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueDecember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c47b439eae34e66b4c6b711b0356a0f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueDecember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic145b33260a44d0e8f2212d9f0defd82_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueDecember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc7cf66f76f4d89843f2feb6ead05a9_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueDecember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e5f9ad0e20745e2b8738a0b8561987b_I20210818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point125PercentDueSeptember2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d2af0f86c541af9571d4910bbca9be_D20210818-20210818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-18</xbrli:startDate><xbrli:endDate>2021-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5a0d766445d4eabbf62b2cae9bdafec_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point625PercentApril2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1250e762a87140739d6c5e728a186e5b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point75PercentApril2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d14dd77d014595a362cb2ecc741ab3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point125PercentApril2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12df8267bbe141b3a7404c266a874107_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point25PercentApril2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdbbb74b83b14c429e04b647517a9a11_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c8ed04608904ccf99b54ecc1dc6986f_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point70PercentDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261fa7d2be3a4e558c47f8185e46e39c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point70PercentDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a3e435c4d424340a17b5f25797bcf4c_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4PointThreePercentDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2bac05524ef4721a76e0eb616aa0666_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4PointThreePercentDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd21192d1e424d908a21238c5796151b_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:OutstandingSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c312e3832345d184ca98519e12b9d1_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f4471edaf148c9a01efea628761e98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa1dd2e3d7514370b3370e9417b8eb05_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.7DueMarch2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i849a0c4d3cbb471192475ee1fb23de1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.7DueMarch2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida81c2c8d73c4e8bb5a9daa090b941df_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f5b8050a2fb4ad5b42037c800d80489_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6897a260054377ad600720e4fd68b9_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes43Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56faf938b6bd44ff9f91b9e6bc18f5ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes43Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3f962b140e4d8bbed1c0e619a28998_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:OutstandingSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad0865b66832421a88a82f88e92f6b90_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if76853d3efe14948b0d921504f1a2b1f_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8d117be10d448ba3e9812c1e7e4b01_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.7DueMarch2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91226dc64fe84ffcb8769e52de99bd30_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.7DueMarch2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c996ffe9966457d93cce263d0c3eaac_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d884e077e99498da60db16f252f707a_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc75d0fe4bd2436da019eb75a7875218_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i325dd5d5aff14a35ac1931e4f56f744d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a134d0c0ea465cb742a54750a08aa5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10042502b67476084251422c4796803_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id982dba0c5764350bf4b2c0dec65cd31_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if29585373b5145568d76c31491c626ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ba0d622bb9e4ee59cdc9b56b5daa62d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacd0213cc5bd41f29e44134f2087e2df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c02066515524b6ca358e7ec25ba43ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a598f7ffb4474aa216bbef8ffec30b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0242ebe0da9b43369d3dbd9a25daef7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9c35ee561744abb94e564009d6735fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ea9fc5313346938adf5e13ee0bfcc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f0ff1789f6444ab4732281654fe93d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762b6378140b484aa6d1ca34c23de494_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e20cd8a6c7f4c69bb7918f0d9cd2739_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if267949f5fce4681b947f1a16a3838d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb053251d3444e3901668a924f82d40_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f95fdf743e477a8ac66cfd99745de0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i252d55800dcb4295b654fd0658f6f573_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20101ed8d3e04a40b26eacb5e37c8c4f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbc938e99b50474b91e168dd07faea18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b279e1f6f0b40a982401b8df9857736_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42da0c7a9d2b475584b0d47002072fc2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a50108c30e41368e58ccdb0e40fbda_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib79129f099714bef8ef8da1d8903ece5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bea816135474568b9b0446d98520e27_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6875cc4cb5c6442fa8caebb5f3329dd5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92730350ea67406b893ebd2e0ed6b301_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8772a8c1e2e8403a88d7445ac2fed106_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdbf916e80cb46918ba4e4c0df3ed889_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ba20c704434ed2a8fab1c6dd389b1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca7c2e9a27a4a1fa7a8bef02337334a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162216dad2a6425bb441d4b6af324060_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01262b340a894b3c8b1efb258d3b571b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea00c6da074b480bb9fe7cc6bbcb98a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ac6571e3d74f1dab3aee2141e35e2f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46dd8c46c55e411d908696c36b38b5c8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e53b4aa76b4272aa433d30914b2324_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7900ae2c578549589f4451568700c87b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5f3a8c54054f17989a4b4993615c41_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4ffcb36d78416695e1e547f71c05d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a5a7f84e8ec40208e181a61a9d3aa89_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i860b2109de434ad680884c679dbcb1b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aae37978eb34a42bbc35e64ec3c07a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8efc5986c964403b550888010f694f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87d7c0e5807e4c26ba8a3d14fdf19033_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e026ebe0d1141d08ec5920a50dddbad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide5901c6898f433fadeff64551df32fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0b828e6576e4f34bc10d207dbb869a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d343d8f5c2b4a6e8190984fc1f95d35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cd82a6b704248499547541eb8ba6115_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab524d12dfb04d818c70ea4d09acb204_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2feba394cc284f1c8866c717b615d08c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic071fdd73a984fef8ee7bfd1c930b231_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6db2a706478c4614aec9544e1bfa5a50_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefa80d56f1e74e55bffe7ec59a51f1f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674b362cb43f4f2cafbbd57f9e56a196_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d54224ea00f46f9a1e275c80a61b003_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce41f46d8e84b7789c994f5feff9651_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if82b640a199e4868b36a915526dc2053_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i124f4f560a234bdfb5ec62a90aa60693_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib411c0d8ea7a4e8192645865166e5bc4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d545bbe52647728f7c485d029e3b33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i282d5c6bb1c644ce9a4a5ffafc468287_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a6639e48973497fa396c0a952816890_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b6f9af914a43a38de124a97f2cc7b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie55eb2e1866d4936acc91c5cfaf163e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f3dfc3b0af4263962bc11ed03e1717_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i981507be87f94c918c4f5777451702ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i530d696f8fca4111b2384705d88e2528_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b34d8cf62304c8ab8b6b20efdeddbbb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c03a30159a84819aa7bf2d4b44b4940_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61796b34679f4c6cbef7783824db21ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8311648bcc5f4c0e9ba53519e18563bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95da6fe526324fc7915c89f6c760058b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if634ee5b01e4418e9eecd02c2b108b45_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef579c6f5d94978a2551abaa400aaad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe781c3ffb934d7283abdcde5259b578_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c76370e6bf4af2ba18b89ca655b55b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2a1ee87f2954456af17415d6e80fd4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800dc1b5ac544829a5f96bf812a6959d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcf8da529f3410db68a945ba211481d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5889f8a183f94f0986fc8d265f0b65e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a9186dc3884c56aed01709c057e146_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac90be0d15f44066902ebe3c398edd6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a27b2b60c0a4875ae1e21929139b434_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i448d068b73fe457c9473c2cf2c869646_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be3d440d0034da59689eb9cb1b8e2a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id07efc7eec504e4dbd1c06bcc97776e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80434d583b9145699f6467db52e671d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c53fd3ce91e4d35b310ab8338e5a336_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a0c74c41ebd402f965dc97f83e3927e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i433675d63b154f81aec4043380ed969c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec12e1923db4bf5b50d8480155727db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id027a3124e1a442f91f769b2d20a79cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc2ae24835514052914a58a5ed8c6960_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i276e89b1f499438e87a8b8ff11bfb821_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a32ea5d8145486abd0eee9eb65e2bc4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a17a9c673d747659358cf61fca64e75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb420b7594364d6893ae2d9594cf961d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a86bf692f18486d933d45d22e8027f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaef94353787243699d29dbbef2ede4aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3962569b68340cc9aacb0b0b4055650_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b93f4fc09a3435ea3369ffd815f169f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6c1ec54592a466aa4dc5711ca9dfd07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d5c1701e6c488d94354e33e98ea977_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i107ab07b1f1242c2a31146ba192ea630_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d9fe69ee87141b0a74150684361d6d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c75d0c4c0d64349a39b959decd4ec41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fea1b150cad403f92fe062910c70247_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie818f0ce1b2d4700bf8a50b52e1ea2aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib37677b4bebe40289a4b9b7576269f3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib765d894de694d2094ea42b1892d468e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32eee2f391f44fae9f98ce3ecd31a02b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7671aaeacd046c9838da466ff4e34b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414e18de330f46b88b7101cb98dd39ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i733ba5d142df4f60938808824882bdfc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20703722f40e44c4835113f54e1e12c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie12f7e25dae34ed19c14ceed1716dd91_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f089b62038641eca565000d9846ae75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad31584585d475ea5dc99cd84a40282_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d3653f149da49b29def0497a05f984f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2a6c29224644307a2a9eb78032ad4e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd0bc158bfa4d8c9a1eef38aeb153e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6419521af8914bc08f951b1558c156a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia201e25566f84e35aa96a9f051384c05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id46442f3513e4d8ead71ef391f535a91_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdbe5c58d7d04ef294e397fd28124004_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd84d2bfaae34c2589bfdb10af6646d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbdafb297a2242e5b3fb68a537d6f098_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08dd758138b84d4bb3085c8c44048020_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4696cfd2126a49aca34be6569c415e4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdf302d352334c7eb29f6daa43872807_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eb696de5db242c795422c37920e7842_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077b6285cc31461598b42554e2d8d9c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28aea62135614aab87e0943dbebccb07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee69f393002463ebc8b873e9f00a9e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d019c669092417cad902aabe452c43a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8340f5ec7e64baf9924bad129344c57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb435009ac34bbba8afb4a9051ebcbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff3f6572a7984acc83891d6ffe51dac6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i721f414643aa4d48a77204540a59ca02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b3e6fd20854c36bac655b5705bd8c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i714696085e3846d5996660ba69ae9916_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616fe276b0c14b9ea335de3ffe9e254b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89296715dad54dadab6556fc2a883b22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i236e33efcde54e91a4243a0e24ed6b08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af8d0600cbc4be881c45d46a38b22c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6812d37c933b481db36130a6e153ad52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26e065eea181432cb10971a1ef6fa9dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia048e730866c404db59cbf7a969bb920_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic430f4dcb0f043c8b9a2999c5816e5e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1381345c3d5840459cf0370ce99902da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766450bb0604426f8bdb03f539b684e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia34c0f80bd2e4e66bd5efc598c7695bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00ba36ca870d489badec2a4b43f49a11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ab04d328c64e48a9513092777617a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41df18924e1d461c9545e50ad75b2b04_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e58d7651f6c4f319612d35334a716cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d63903b589946129164b093427d20a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bb557e906c74f7e8c3d94d93011a01b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91633285ed494358864442a95f7cd753_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeb33c37ed48461980e0c720a0c2fc11_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida2e4bf976d74179b0af33275865eebe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8ccea9aa6e45ac9a3904384d0f7055_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0119b0ae5984713b7d9259c8207911d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05bf309692224b32a5d32bdbc5a3fbfa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fef45f25f3a4337982d480409e2d989_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55e008f794224642a71737a4f1c9d5ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f60b453fe2047f2af3b79714d2105b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80161528cfbe4d46ab7481e07799b74f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad61766b42d4fafb3023b422e73ce62_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48c5af8bad60417f9e93bd229edece75_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd0c40f6d4d4d38ad212af3d36f1535_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvs:CVSHealth2017IncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59ded7dac1144889cba911dcf81ff67_I20181128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvs:AetnaInc2010StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef82093f7f0425d98a812a8346206e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dac89aa5750413097fe5ef4affd611a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idde68710333b4abcb62273527c7aef07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a23a3d9f60548f3aed4bd07d81cc620_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b8b6ee31b984216878b4a06ea213f22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9667bb2fd2c24aae86f872138c4421cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63eef8534a884ca5866ee784287deaab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b15b8c19a5e466e8372796316b9b51c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc5be713ef141589563587eda40b96e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0254b09e69d04105bd0d52aecaece8a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77dc266c0f374e01a14893d1a6ea3f8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb4c5c9645e411fbac5109bc755e0aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i225620d3fec84216a7b76440b5de5139_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7d5aaeea5cd4364a999d22bc0e526c2_I20221117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2022RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5463bac593422d85e68f6a31c6cd24_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2022RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51eec47e53dc4a1c9685a39a8e5b3b47_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5316d30a5a634b0eb7ebde97e6094f70_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8233d450fa5745639d54e56448f03464_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic28fda85c05b4594a00f0a3402b95859_D20220104-20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:BarclaysBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-04</xbrli:startDate><xbrli:endDate>2022-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dba707cd749450ca1bc96a22ff0d254_I20230104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:CitibankNAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ff381caf73a4c2db6637a9d0b8f3632_D20230104-20230104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:CitibankNAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-04</xbrli:startDate><xbrli:endDate>2023-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c14530c00c646478ca97544065c4fbb_I20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:BarclaysBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie70904e10fad41e29c390bf6b19d6203_I20220104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:BarclaysBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c40ac9da1342d08ae7f70b317ddf53_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:BarclaysBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5735f8f8c5444a2a0384aa456ca592f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d782259b904c979e113b78787ed48d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9289877d9c2c4ffcbaa2d99b1945576b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9209a44ddd41178541daa30bd6749f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a1252a04a84b3898c7e327a9c92b60_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e56c9158aa4a519e48b89d4b91b42a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd8499c4fb34af58a98efbc5d640ce2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5561cc39474810bff93b9bc55eddd3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec46daf9900b4a90868ccafe21f74ebb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfbc41d71b734bae909dc80277dec2bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i297b60290a1245cc886da0051e954eac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66102a5aa12440b29e51c2d516b74676_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e896501d7c436b96f31503738ed740_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia18c761ce4364ea2973eb59d2fd584ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c2106ba1184ea692fbc96551d6d7b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cb15071b54d40feb50954c737252518_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4ff8f1d92a425284f720815593c158_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a0eaddda21c4a00be59a3852a2fda53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d6c784677034efab4d3c3761a6becc8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e299f2c18e43bdae5d151661e82ef0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a7074798cd4f7da8207ad643b5286e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7348d8b55d1847e59482a4dd6cabd5cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1acf0930000a47a28b1f1859847b12aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb67b8f18d2a41819af3ed1f45173118_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d024dd953342978e381ef9ad09e97d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34691a75be1a40a485b08377e0d95591_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7cab5985f934b68b073707b0db81f68_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053181ca045a4428aee792436b90324f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40550f17612e4e1c9a2bdb2e12646807_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae0bd8dfb5cf4f9e8b8252cd49e75e9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75fd10d334be4f38bba49ac3d51dd978_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e3ddd79ec9406fbd5b0334e0a7cf99_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1de85626af2543b182ac0c8049528d59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48cedd332752429fb7fdcab29fe151c0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5dc45a20214840ba91115d7f1be610_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63a9007fcb714cb09cc20b1eca666273_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id41faef8f0db4ed59ca3aaf9b30913d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dbbb5af69624415b1974a87c4e00ef6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie82b5c6e85e2408ab675d8ef44a98158_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:StockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a690cfa922477e90e45bfe9cff5f29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:StockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0842c61fceff4047b49c7ff6a4a293a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:StockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc14f04c8d094020a89b8124e4d67afd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36f054975aa46feb063b56007b02a5c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf686621016a49b4a70be7291894b149_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e2b473c47f6447294d190668407b467_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reinsurance_agreement"><xbrli:measure>cvs:reinsurance_agreement</xbrli:measure></xbrli:unit><xbrli:context id="ieae0c3b0cc27418aa65414f0b7e927c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:HartfordLifeAndAccidentInsuranceCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic60de804b23546b8a91437fbf72dc2da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:HartfordLifeAndAccidentInsuranceCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf72aa41b4d449d0a2ac299a8c83a884_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:LincolnLifeAnnuityCompanyOfNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b933e2ca792484e85ec73f2fc18e41a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:LincolnLifeAnnuityCompanyOfNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81da46ae9e64349a9aa6e17d4d8c486_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:VOYARetirementInsuranceAndAnnuityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f47abf8fc3f40f983bcf19e1da82db5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:VOYARetirementInsuranceAndAnnuityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad53a23fba3447a8ca121fa57cf7591_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibde18ae73cba460eb19c034e2419cf09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9822742126ab4315872808cfba42b81c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:AllOtherReinsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id80e156bb7874df1abefdc699fdc0426_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:AllOtherReinsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>cvs:lease</xbrli:measure></xbrli:unit><xbrli:context id="ib94af6bb921a4ca98da673595b30f6b8_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:FederalCourtInOhioJudgmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i674238d29a96415e993c632fa76902ca_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:FederalCourtInOhioJudgmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c90b72fd40546a18c44fdd0f007e70d_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:StateOfFloridaSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f7c5a81f337450ca2ce09d3e8db9ce6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:StateOfFloridaSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fce56acdb3745c9979b048ae472c0b0_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a63bb22a404440f94e6605a0d60ed27_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57858d852b8743a5b17a414d3e2943ec_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:TribalEntitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b86d678e65d40eb8ee5c07845a9969a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:TribalEntitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf08dadd0964ffeadc4c69adb91d80b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636ddceefabd4069a95a70b2bdaf5197_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7962defddb614936891d31be39fb3eac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f3002f09a51435f89d2352f78379bf9_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe8dd796c0b4f6ea8bd03f8afa02daa_D20240101-20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a4ebb735c614e6f82dbc3e891377121_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:RadcliffAndFlaimVAetnaIncEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>cvs:claim</xbrli:measure></xbrli:unit><xbrli:context id="iaeb70648911a491891b5b5b40830d2fe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cvs:USFederalGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7e1c1a8e154045870fe18d7ed128a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cvs:USFederalGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd64cbb3284d45b6bf1aa429308ea5b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cvs:USFederalGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aff3de0cc7c488a8aaa1c33fd802ab1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14525e9b549048f4b399842e4567a558_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55c34d747b754e57bfd880817586c1fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7714f3521cb4944817a68243192c7b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e89b8dd8884731928828b40d4e94d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c6773f805e4bd59d68e8f7a0aa3308_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3fe920a5d654530aaf6d123f400d878_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id26c945fe20b40d684582e97afbd1616_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99de3811ad9244d2987587cc4326b954_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51c77ad05d064fde8d6341467c3515ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000064803</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtMTAtMS0xLTE2NzkwOA_4d9dee0a-de0c-4824-96a7-b2568bdfa528 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtNi0xLTEtMTY3OTA4_99031c0f-9bb1-4e9b-a04b-d1f529a110ab id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtOC0xLTEtMTY3OTA4_e9262b61-efbc-4ef7-a559-88549e16e324" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyMw_46f4594b-33de-4e6a-93d6-a2d142101981" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTItMS0xLTE2NzkwOA_b320eab6-797c-4b05-8ca2-c960aa530c2e id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTItMS0xLTE2NzkwOA_a802b61d-e3fc-401c-8a0e-c9a451456886 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNS0xLTEtMTY3OTA4_899a6f82-b6f8-43bd-b579-b98c84fb2c90 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTItMS0xLTE2NzkwOA_61a94270-718d-49f2-8a89-ac9a52290499 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTUtMS0xLTE2NzkwOA_d103f2c8-8949-463e-a6a6-bc4b87160d51 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTItMS0xLTE2NzkwOA_803aff9c-7641-44f4-b3a5-a5093fcbccd2 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMi0xLTEtMTY3OTA4_cc9c228e-d25e-42a5-afe7-dd4be4f4ded9 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTUtMS0xLTE2NzkwOA_6b7272ad-9760-4165-8a9f-eef3576673fb id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTUtMS0xLTE2NzkwOA_6be73b7d-7940-4a20-a6a2-d323e75cf34c id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTItMS0xLTE2NzkwOA_2493e6ed-878f-4a03-8082-5b7df50b5510 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTUtMS0xLTE2NzkwOA_a3020230-8e8d-4d1f-be1c-451c50e0569a id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktMi0xLTEtMTY3OTA4_cf85c9c6-30f6-47f0-9d82-59780ed91d16 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMi0xLTEtMTY3OTA4_a1102af3-6a6d-4ab7-9a37-152583f52aed id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktNS0xLTEtMTY3OTA4_4b2d1fa7-2942-4c9a-bc7e-a667d42a0eb9 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTUtMS0xLTE2NzkwOA_ed5a3e75-ed47-445a-843f-f11cccade6f4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTQtMS0xLTE2NzkwOA_915df060-9a88-4dd4-b0c9-35ddb417b3c1 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNC0xLTEtMTY3OTA4_419c9387-c859-4bde-b2b7-4f1cf9bbe844 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTQtMS0xLTE2NzkwOA_7048f323-3d7b-43fa-8f4f-ce5446e41c03 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTQtMS0xLTE2NzkwOA_33f5dc1a-2a4b-4a8a-b80d-440f0c6eb9d5 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTQtMS0xLTE2NzkwOA_7dbb9dc7-db89-4602-a8ab-d1b447187c94 id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtNC0xLTEtMTY3OTA4_2a36882f-dd82-4bf8-897e-323895e9187e id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTQtMS0xLTE2NzkwOA_da19b8fb-1267-4760-a39d-cc06e134509c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_1"></div><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzcy_c6bf79c6-edfe-4b51-88c3-f4dd1962b553">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Mark One)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzcz_5710ef66-543f-4928-a3e4-4b9edf41b03f">&#9745;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8yMTY_7a8e17a8-5eb5-4755-8bbc-e9b916cc9d01"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8yMTY_1e6ebf93-9114-44f8-b42f-eb07c5a70eb6">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzY4_45f35a18-2a92-449c-8c31-4f67ccdf8752">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from _________ to_________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzc0_8c6dfbbe-40d2-4731-9eef-958003a205f9">001-01011</ix:nonNumeric> </span></div><div style="text-align:center"><img src="cvs-20221231_g1.jpg" alt="cvs-20221231_g1.jpg" style="height:14px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzY5_d0ed2d06-1179-406d-85df-6c0ffe07964b">CVS HEALTH CORPORATION</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6YzZkNzdiMWUzZGU4NDkzZThhMTlkZTk4YzIzMjMzYmUvdGFibGVyYW5nZTpjNmQ3N2IxZTNkZTg0OTNlOGExOWRlOThjMjMyMzNiZV8wLTAtMS0xLTE2NzkwOA_f9ca81a9-3a01-4ba9-8632-c89b3720b640">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6YzZkNzdiMWUzZGU4NDkzZThhMTlkZTk4YzIzMjMzYmUvdGFibGVyYW5nZTpjNmQ3N2IxZTNkZTg0OTNlOGExOWRlOThjMjMyMzNiZV8wLTEtMS0xLTE2NzkwOA_5353ce62-c449-48bf-8218-65ba20d1d757">05-0494040</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:17.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6N2UwNGY2NWJhZWY0NDUwMzkzZDIyNDhhZmVmNDdhOTAvdGFibGVyYW5nZTo3ZTA0ZjY1YmFlZjQ0NTAzOTNkMjI0OGFmZWY0N2E5MF8wLTAtMS0xLTE2NzkwOA_30c0d94c-6202-4ff8-9e2b-d5700283df03">One CVS Drive,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6N2UwNGY2NWJhZWY0NDUwMzkzZDIyNDhhZmVmNDdhOTAvdGFibGVyYW5nZTo3ZTA0ZjY1YmFlZjQ0NTAzOTNkMjI0OGFmZWY0N2E5MF8wLTEtMS0xLTE2NzkwOA_42aaa699-e645-4727-834d-412ebf58e2cb">Woonsocket,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6N2UwNGY2NWJhZWY0NDUwMzkzZDIyNDhhZmVmNDdhOTAvdGFibGVyYW5nZTo3ZTA0ZjY1YmFlZjQ0NTAzOTNkMjI0OGFmZWY0N2E5MF8wLTItMS0xLTE2NzkwOA_05587c8e-819c-400b-941e-02a430d1abef">Rhode Island</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6N2UwNGY2NWJhZWY0NDUwMzkzZDIyNDhhZmVmNDdhOTAvdGFibGVyYW5nZTo3ZTA0ZjY1YmFlZjQ0NTAzOTNkMjI0OGFmZWY0N2E5MF8wLTMtMS0xLTE2NzkwOA_bf39c512-788d-4901-ad2d-478e3cfa7c4d">02895</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.194%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Registrant&#8217;s telephone number, including area code:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzQ2MTFjYTA5M2I2NDZmY2FhNjU1NWQ0NmVhMTgwNjcvdGFibGVyYW5nZTozNDYxMWNhMDkzYjY0NmZjYWE2NTU1ZDQ2ZWExODA2N18wLTEtMS0xLTE2NzkwOA_a8d7af59-14d4-4688-8156-d34fdeb14da3">(401)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzQ2MTFjYTA5M2I2NDZmY2FhNjU1NWQ0NmVhMTgwNjcvdGFibGVyYW5nZTozNDYxMWNhMDkzYjY0NmZjYWE2NTU1ZDQ2ZWExODA2N18wLTItMS0xLTE2NzkwOA_bcb5c5d7-a88b-4e8c-b130-a550d1e13680">765-1500</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MWJkYjYzODQ1OWI2NDdjNGFiNzI1MmYxZGMzNTJkOTEvdGFibGVyYW5nZToxYmRiNjM4NDU5YjY0N2M0YWI3MjUyZjFkYzM1MmQ5MV8yLTAtMS0xLTE2NzkwOA_23ff76f9-7c5b-4685-934f-e83130c453d1">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MWJkYjYzODQ1OWI2NDdjNGFiNzI1MmYxZGMzNTJkOTEvdGFibGVyYW5nZToxYmRiNjM4NDU5YjY0N2M0YWI3MjUyZjFkYzM1MmQ5MV8yLTEtMS0xLTE2NzkwOA_2f5a6a11-7293-4433-90f9-965820df1844">CVS</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MWJkYjYzODQ1OWI2NDdjNGFiNzI1MmYxZGMzNTJkOTEvdGFibGVyYW5nZToxYmRiNjM4NDU5YjY0N2M0YWI3MjUyZjFkYzM1MmQ5MV8yLTItMS0xLTE2NzkwOA_241b0c7c-ccb8-49ce-ae32-df414c287d6e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(g) of the Act:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">None</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8wLTUtMS0xLTE2NzkwOA_cd65779b-edd2-475b-b7f1-5dfc711987cf">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8xLTctMS0xLTE2NzkwOA_9db59914-4329-46b5-ac16-893342238494">No</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8yLTUtMS0xLTE2NzkwOA_97055b92-edac-4b28-8f2b-80594b9b3a7f">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8zLTUtMS0xLTE2NzkwOA_dfe22229-12d8-4b70-bea2-f34894a746b4">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF81LTAtMS0xLTE2NzkwOA_94d5da12-098f-49ee-81e4-9f3f96eb0fc5">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF82LTctMS0xLTE2NzkwOA_f05a2f14-da98-4bbf-b85f-661932c8109d">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF83LTctMS0xLTE2NzkwOA_1bb66db2-e71f-4f65-be94-bcb670887527">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF85LTctMS0xLTE2NzkwOA_9a424a65-038c-4df2-91b3-2a91e978d810">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;&#8201;240.10D-1(b).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8xMi00LTEtMS0yMjU4ODc_9ae6be34-066c-4207-ba17-9a8e3153e8c8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="ieef592c79265415e9514a93ffb9ae4ac_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF81OTQ_d88a31ef-7a29-49b4-9d48-a99ae8c52dc5">121,258,020,752</ix:nonFraction> as of June&#160;30, 2022, based on the closing price of the common stock on the New York Stock Exchange. For purposes of this calculation, only executive officers and directors are deemed to be affiliates of the registrant.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February 1, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="i40ddf3f5cfcf4be7a0d007238cbe2748_I20230201" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF84NTk_1f1cbee8-9ef2-407a-a639-7effdaef8987">1,284,111,667</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzcx_b0aa3516-5075-4d83-81fc-c29a545bf56a" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following materials are incorporated by reference into this Form 10-K:</span></div><div style="margin-bottom:0.8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information contained in the definitive proxy statement for CVS Health Corporation&#8217;s 2023 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2022 (the &#8220;Proxy Statement&#8221;), is incorporated by reference in Parts III and IV to the extent described therein.</span></div></ix:nonNumeric><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.903%"><tr><td style="width:1.0%"></td><td style="width:20.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.489%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span><br/></span></div><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_34">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_34">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_37">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_37">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_40">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_40">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_43">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_43">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_46">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_46">63</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_49">Information about our Executive Officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_49">64</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_55">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_55">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_58">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_58">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_61">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_97">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_97">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_181">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_181">182</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_184">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_184">182</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_187">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_187">182</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_2199023257430">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_2199023257430">183</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_193">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_193">183</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_196">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_196">183</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_199">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_199">183</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_202">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_202">184</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_205">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_205">184</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;IV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_211">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_211">185</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_214">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_214">189</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_217">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_217">190</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, references to the terms &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; used throughout this Annual Report on Form 10-K (this &#8220;10-K&#8221;) refer to CVS Health Corporation (a Delaware corporation), together with its subsidiaries (collectively, &#8220;CVS Health&#8221; or the &#8220;Company&#8221;). References to competitors and other companies throughout this 10-K, including the information incorporated herein by reference, are for illustrative or comparison purposes only and are not identifying that these companies are the only competitors or closest competitors of the Company or any of the Company&#8217;s businesses, products, or services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Private Securities Litigation Reform Act of 1995 (the &#8220;Reform Act&#8221;) provides a &#8220;safe harbor&#8221; for forward-looking statements, so long as (1) those statements are identified as forward-looking, and (2) the statements are accompanied by meaningful cautionary statements that identify important factors that could cause actual results to differ materially from those discussed in the statement. We are taking advantage of these safe harbor provisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain information contained in this 10-K is forward-looking within the meaning of the Reform Act or SEC rules. This information includes, but is not limited to: &#8220;Outlook for 2023&#8221; of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) included in Item 7, &#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221; included in Item 7A, &#8220;Government Regulation&#8221; included in Item 1, and &#8220;Risk Factors&#8221; included in Item 1A. In addition, throughout this 10-K and our other reports and communications, we use the following words or variations or negatives of these words and similar expressions when we intend to identify forward-looking statements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.348%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.348%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.348%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Anticipates</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Believes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Can</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Continue</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Could</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Estimates</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Evaluate</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Expects</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Explore</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forecast</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Guidance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Intends</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Likely</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">May</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Might</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Outlook</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Potential</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Predict</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Probable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Projects</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Seeks</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Should</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">View</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#183;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Will</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All statements addressing the future operating performance of CVS Health or any segment or any subsidiary and/or future events or developments, including statements relating to the impact of coronavirus disease 2019 (&#8220;COVID-19&#8221;) and any new variants or viruses on the Company&#8217;s businesses, investment portfolio, operating results, cash flows and/or financial condition, statements relating to corporate strategy, statements relating to future revenue, operating income or adjusted operating income, earnings per share or adjusted earnings per share, Health Care Benefits segment business, sales results and/or trends, medical cost trends, medical membership, Medicare Part D membership, medical benefit ratios and/or operations, Pharmacy Services segment business, sales results and/or trends and/or operations, Retail/LTC segment business, sales results and/or trends and/or operations, incremental investment spending, interest expense, effective tax rate, weighted-average share count, cash flow from operations, net capital expenditures, cash available for debt repayment, statements related to possible, proposed or pending acquisitions, joint ventures, investments or combinations that involve, among other things, the timing or likelihood of receipt of regulatory approvals, the timing of completion, integration synergies, net synergies and integration risks and other costs, including those related to CVS Health&#8217;s proposed acquisition of Oak Street Health, Inc. (&#8220;Oak Street Health&#8221;) and  pending acquisition of Signify Health, Inc. (&#8220;Signify Health&#8221;), enterprise modernization, transformation, leverage ratio, cash available for enhancing shareholder value, inventory reduction, turn rate and/or loss rate, debt ratings, the Company&#8217;s ability to attract or retain customers and clients, store development and/or relocations, new product development, and the impact of industry and regulatory developments, as well as statements expressing optimism or pessimism about future operating results or events, are forward-looking statements within the meaning of the Reform Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements rely on a number of estimates, assumptions and projections concerning future events, and are subject to a number of significant risks and uncertainties and other factors that could cause actual results to differ materially from those statements. Many of these risks and uncertainties and other factors are outside our control. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain of these risks and uncertainties and other factors are described under &#8220;Risk Factors&#8221; included in Item 1A of this 10-K; these are not the only risks and uncertainties we face. There can be no assurance that the Company has identified all the risks that may affect it. Additional risks and uncertainties not presently known to the Company or that the Company currently believes to be immaterial also may adversely affect the Company&#8217;s businesses. If any of those risks or uncertainties develops into actual events, those events or circumstances could have a material adverse effect on the Company&#8217;s businesses, operating results, cash flows, financial condition and/or stock price, among other effects. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should not put undue reliance on forward-looking statements. Any forward-looking statement speaks only as of the date of this 10-K, and we disclaim any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation, together with its subsidiaries (collectively, &#8220;CVS Health,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;), is a leading diversified health solutions company reshaping health care to help make healthier happen for more Americans. In an increasingly connected and digital world, CVS Health is meeting people wherever they are and changing health care to meet their needs. The Company has more than 9,000 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with over 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (&#8220;PDP&#8221;). The Company believes its integrated health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company seeks to reimagine the consumer healthcare experience to make it easier and more affordable to live a healthier life. This means delivering solutions that are more personalized, simpler to use, and increasingly digital so that consumers can receive care when, where and how they desire. CVS Health is also shifting from transaction-based care to addressing holistic health &#8211; physical, emotional, social, economic &#8211; which will lead to higher quality care and lower medical costs. The Company is a leader in key segments of health care through its foundational businesses and is seeking to create new sources of value by expanding into next generation care delivery and health services, with a goal of improving satisfaction levels for both providers and consumers. The Company believes its consumer-centric strategy will drive sustainable long-term growth and deliver value for all stakeholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and its emerging new variants continue to impact the U.S. and other countries around the world. Our strong local presence and scale in communities across the country has enabled us to play an indispensable role in the national response to COVID-19, as well as provide seamless support for our customers wherever they need us: in our CVS locations, in their homes, and virtually. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offered COVID-19 diagnostic testing at more than 4,700 CVS pharmacy locations, at community-based testing sites in underserved areas and through its Return Ready</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solution as of December&#160;31, 2022. During 2021, the Company also began selling over-the-counter (&#8220;OTC&#8221;) test kits in its retail locations and online. The Company began administering COVID-19 vaccinations in long-term care facilities and in certain of its retail pharmacies during December 2020 and February 2021, respectively, and began the administration of COVID-19 boosters and pediatric vaccines during the fourth quarter of 2021. The Company offered COVID-19 vaccinations at more than 9,000 CVS pharmacy locations as of December&#160;31, 2022. During the year ended December&#160;31, 2022, the Company administered more than 15&#160;million COVID-19 tests and nearly 28&#160;million COVID-19 vaccines and sold more than 63&#160;million OTC test kits. The Company expects to continue to play a significant role in COVID-19 testing and vaccine administration in the future, while maintaining a strong commitment to testing and vaccine equity by optimizing site locations and targeting outreach initiatives to reach vulnerable populations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of COVID-19 on the Company&#8217;s businesses, operating results, cash flows and financial condition in the years ended December 31, 2022, 2021 and 2020, as well as information regarding certain expected impacts of COVID-19 on the Company, is discussed throughout this 10-K.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Care Benefits Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment operates as one of the nation&#8217;s leading diversified health care benefits providers, serving an estimated 35 million people as of December&#160;31, 2022. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services, and health information technology (&#8220;HIT&#8221;) products and services. The Health Care Benefits segment also provided workers&#8217; compensation administrative services through its Coventry Health Care Workers&#8217; Compensation business (&#8220;Workers&#8217; Compensation business&#8221;) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment&#8217;s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (&#8220;providers&#8221;), governmental units, government-sponsored plans, labor groups and expatriates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Products and Services </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as &#8220;Insured&#8221; and administrative services contract products (where the plan sponsor assumes all or a majority of the risk of medical and dental care costs) as &#8220;ASC.&#8221; Health Care Benefits products and services consist of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial Medical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Health Care Benefits segment offers point-of-service (&#8220;POS&#8221;), preferred provider organization (&#8220;PPO&#8221;), health maintenance organization (&#8220;HMO&#8221;) and indemnity benefit (&#8220;Indemnity&#8221;) plans. Commercial medical products also include health savings accounts (&#8220;HSAs&#8221;) and consumer-directed health plans that combine traditional POS or PPO and/or dental coverage, subject to a deductible, with an accumulating benefit account (which may be funded by the plan sponsor and/or the member in the case of HSAs). With the launch of Aetna Virtual Primary Care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2021, eligible members now have access to health services remotely, paired with access to in-person visits with providers in the Company&#8217;s network, including at MinuteClinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">locations. Principal products and services are targeted specifically to large multi-site national, mid-sized and small employers, individual insureds and expatriates. The Company offers medical stop loss insurance coverage for certain employers who elect to self-insure their health benefits. Under medical stop loss insurance products, the Company assumes risk for costs associated with large individual claims and/or aggregate loss experience within an employer&#8217;s plan above a pre-set annual threshold. The segment also has a portfolio of additional health products and services that complement its medical products such as dental plans, behavioral health and employee assistance products, provider network access and vision products. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Government Medical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In select geographies, the Health Care Benefits segment offers Medicare Advantage plans, Medicare Supplement plans and prescription drug coverage for Medicare beneficiaries; participates in Medicaid and subsidized Children&#8217;s Health Insurance Programs (&#8220;CHIP&#8221;); and participates in demonstration projects for members who are eligible for both Medicare and Medicaid (&#8220;Duals&#8221;). These Government Medical products are further described below:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Advantage: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through annual contracts with the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the Company offers HMO and PPO products for eligible individuals in certain geographic areas through the Medicare Advantage program. Members typically receive enhanced benefits over traditional fee-for-service Medicare coverage (&#8220;Original Medicare&#8221;), including reduced cost-sharing for preventive care, vision and other services. The Company offered network-based HMO and/or PPO plans in 46 states and Washington, D.C. in 2022. For certain qualifying employer groups, the Company&#160;offers Medicare PPO products nationally. When combined with the Company&#8217;s PDP product,&#160;these national PPO plans&#160;form an integrated national Insured Medicare product for employers that provides medical and pharmacy benefits.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare PDP: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a national provider of drug benefits under the Medicare Part D prescription drug program. All Medicare eligible individuals are eligible to participate in this voluntary prescription drug plan. Members typically receive coverage for certain prescription drugs, usually subject to a deductible, co-insurance and/or co-payment. The Company offered PDP plans in all 50 states and Washington, D.C. in 2022.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Supplement: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain Medicare eligible members, the Company offers&#160;supplemental&#160;coverage for certain health care costs not covered by&#160;Original Medicare. The products included in the Medicare Supplement portfolio help to cover&#160;some of the&#160;gaps in Original Medicare, and include coverage for Medicare&#160;deductibles and coinsurance&#160;amounts. The Company offered a&#160;wide selection of Medicare Supplement products in 49 states and Washington, D.C. in 2022.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicaid and CHIP:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company offers health care management services to individuals eligible for Medicaid and CHIP under multi-year contracts with government agencies in various states that are subject to annual appropriations. CHIP are state-subsidized insurance programs that provide benefits for families with uninsured children. The Company offered these services on an Insured or ASC basis in 16 states in 2022.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Duals: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides health coverage to beneficiaries who are dually eligible for both Medicare and Medicaid coverage. These members must meet certain income and resource requirements in order to qualify for this coverage. The Company coordinates 100% of the care for these members and may provide them with additional services in order to manage their health care costs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has a portfolio of transformative products and services aimed at creating a holistic and integrated approach to individual health and wellness. These products and services complement the Commercial Medical and Government Medical products and aim to provide innovative solutions, create integrated experience offerings and enable enhanced care delivery to customers. </span></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Provider Networks </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with physicians, hospitals and other providers for services they provide to the Company&#8217;s members. The Company uses a variety of techniques designed to help encourage appropriate utilization of medical services (&#8220;utilization&#8221;) and maintain affordability of quality coverage. In addition to contracts with providers for negotiated rates of reimbursement, these techniques include creating risk sharing arrangements that align economic incentives with providers, the development and implementation of guidelines for the appropriate utilization and the provision of data to providers to enable them to improve health care quality. At December&#160;31, 2022, the Company&#8217;s underlying nationwide provider network had approximately 1.6 million participating providers. Other providers in the Company&#8217;s provider networks also include laboratory, imaging, urgent care and other freestanding health facilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Quality Assessment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS uses a 5-star rating system to monitor Medicare health care and drug plans and ensure that they meet CMS&#8217;s quality standards. CMS uses this rating system to provide Medicare beneficiaries with a tool that they can use to compare the overall quality of care and level of customer service of companies that provide Medicare health care and drug plans. The rating system considers a variety of measures adopted by CMS, including quality of preventative services, chronic illness management and overall customer satisfaction. See &#8220;Health Care Benefits Pricing&#8221; below in this Item 1 for further discussion of star ratings. The Company seeks Health Plan accreditation for Aetna Inc. (&#8220;Aetna&#8221;) HMO plans from the National Committee for Quality Assurance (&#8220;NCQA&#8221;), a private, not-for-profit organization that evaluates, accredits and certifies a wide range of health care organizations. Health care plans seeking accreditation must pass a rigorous, comprehensive review and must annually report on their performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aetna Life Insurance Company (&#8220;ALIC&#8221;), a wholly-owned subsidiary of the Company, has received nationwide NCQA PPO Health Plan accreditation. As of December&#160;31, 2022, all of the Company&#8217;s Commercial HMO and all of ALIC&#8217;s PPO members who were eligible participated in HMOs or PPOs that are accredited by the NCQA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s provider selection and credentialing/re-credentialing policies and procedures are consistent with NCQA and URAC, a health care accrediting organization that establishes quality standards for the health care industry, as well as state and federal, requirements. In addition, the Company is certified under the NCQA Credentials Verification Organization (&#8220;CVO&#8221;) certification program for all certification options and has URAC CVO accreditation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality assessment programs for contracted providers who participate in the Company&#8217;s networks begin with the initial review of health care practitioners. Practitioners&#8217; licenses and education are verified, and their work history is collected by the Company or in some cases by the practitioner&#8217;s affiliated group or organization. The Company generally requires participating hospitals to be certified by CMS or accredited by The Joint Commission, the American Osteopathic Association, or Det Norske Veritas Healthcare.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offers quality and outcome measurement programs, quality improvement programs, and health care data analysis systems to providers and purchasers of health care services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Information Systems</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment currently operates and supports an end-to-end suite of information technology platforms to support member engagement, enrollment, health benefit administration, care management, service operations, financial reporting and analytics.&#160;The multiple platforms are supported by an integration layer to facilitate the transfer of real-time data.&#160;There is continued focus and investment in enterprise data platforms, cloud capabilities, digital products to offer innovative solutions and a seamless experience to the Company&#8217;s members through mobile and web channels.&#160;The Company is making concerted investments in emerging technology capabilities such as voice, artificial intelligence and robotics to further automate, reduce cost and improve the experience for all of its constituents. The Health Care Benefits segment is utilizing the full breadth of the Company&#8217;s assets to build enterprise technology that will help guide our members through their health care </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">journey, provide them a high level of service, enable healthier outcomes and encourage them to take next best actions to lead healthier lives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical membership is dispersed throughout the United States, and the Company also serves medical members in certain countries outside the United States. The Company offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, many of which are available nationwide. Depending on the product, the Company markets to a range of customers, including employer groups, individuals, college students, part-time and hourly workers, health plans, providers, governmental units, government-sponsored plans, labor groups and expatriates. For additional information on medical membership, see &#8220;Health Care Benefits Segment&#8221; in the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (the &#8220;MD&amp;A&#8221;) included in Item 7 of this 10-K. </span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company markets both Commercial Insured and ASC products and services primarily to employers that sponsor the Company&#8217;s products for the benefit of their employees and their employees&#8217; dependents. Frequently, larger employers offer employees a choice among coverage options from which the employee makes his or her selection during a designated annual open enrollment period. Typically, employers pay all of the monthly premiums to the Company and, through payroll deductions, obtain reimbursement from employees for a percentage of the premiums that is determined by each employer. Some Health Care Benefits products are sold directly to employees of employer groups on a fully employee-funded basis. In some cases, the Company bills the covered individual directly. In addition, effective January 2022, the Company entered the individual public health insurance exchanges (&#8220;Public Exchanges&#8221;) in eight states through which it sells Insured plans directly to individual consumers. The Company entered Public Exchanges in four additional states effective January 2023.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers Insured Medicare coverage on an individual basis as well as through employer groups to their retirees. Medicaid and CHIP members are enrolled on an individual basis. The Company also offers Insured health care coverage to members who are dually-eligible for both Medicare and Medicaid. </span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Care Benefits products are sold through: the Company&#8217;s sales personnel; independent brokers, agents and consultants who assist in the production and servicing of business; as well as private health insurance exchanges (&#8220;Private Exchanges&#8221;) and Public Exchanges (together with Private Exchanges, &#8220;Insurance Exchanges&#8221;). For large employers or other entities that sponsor the Company&#8217;s products (&#8220;plan sponsors&#8221;), independent consultants and brokers are frequently involved in employer health plan selection decisions and sales. In some instances, the Company may pay commissions, fees and other amounts to brokers, agents, consultants and sales representatives who place business with the Company. In certain cases, the customer pays the broker for services rendered, and the Company may facilitate that arrangement by collecting the funds from the customer and transmitting them to the broker. The Company supports marketing and sales efforts with an advertising program that may include television, radio, billboards, print media and social media, supplemented by market research and direct marketing efforts.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government is a significant customer of the Health Care Benefits segment through contracts with CMS for coverage of Medicare-eligible individuals and federal employee-related benefit programs. Other than the contracts with CMS, the Health Care Benefits segment is not dependent upon a single customer or a few customers the loss of which would have a significant effect on the earnings of the segment. The loss of business from any one or a few independent brokers or agents would not have a material adverse effect on the earnings of the Health Care Benefits segment. In 2022, 2021 and 2020, Health Care Benefits segment revenues from the federal government accounted for 14%, 14% and 13%, respectively, of the Company&#8217;s consolidated total revenues. Contracts with CMS for coverage of Medicare-eligible individuals in the Health Care Benefits segment accounted for approximately 74%, 79% and 78%, respectively, of the Company&#8217;s consolidated revenues from the federal government in 2022, 2021 and 2020.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Pricing</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Commercial Insured plans, contracts containing the pricing and other terms of the relationship are generally established in advance of the policy period and typically have a duration of one year. Fees under ASC plans are generally fixed for a period of one year.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, a fixed premium rate is determined at the beginning of the policy period for Commercial Insured plans. The Company typically cannot recover unanticipated increases in health care and other benefit costs in the current policy period; however, it may consider prior experience for a product in the aggregate or for a specific customer, among other factors, in determining premium rates for future policy periods. Where required by state laws, premium rates are filed and approved by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state regulators prior to contract inception. Future operating results could be adversely affected if the premium rates requested are not approved or are adjusted downward or their approval is delayed by state or federal regulators. </span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has Medicare Advantage and PDP contracts with CMS to provide HMO, PPO and prescription drug coverage to Medicare beneficiaries in certain geographic areas. Under these annual contracts, CMS pays the Company a fixed per member (or &#8220;capitation&#8221;) payment and/or a portion of the premium, both of which are based on membership and adjusted for demographic and health risk factors. CMS also considers inflation, changes in utilization patterns and average per capita fee-for-service Medicare costs in the calculation of the fixed capitation payment or premium. PDP contracts also provide a risk-sharing arrangement with CMS to limit the Company&#8217;s exposure to unfavorable expenses or benefit from favorable expenses. Amounts payable to the Company under the Medicare arrangements are subject to annual revision by CMS, and the Company elects to participate in each Medicare service area or region on an annual basis. Premiums paid to the Company for Medicare products are subject to federal government reviews and audits, which can result, and have resulted, in retroactive and prospective premium adjustments and refunds to the government and/or members. In addition to payments received from CMS, some Medicare Advantage products and all PDP products require a supplemental premium to be paid by the member or sponsoring employer. In some cases, these supplemental premiums are adjusted based on the member&#8217;s income and asset levels. Compared to Commercial Medical products, Medicare contracts generate higher per member per month revenues and higher health care and other benefit costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;) ties a portion of each Medicare Advantage plan&#8217;s reimbursement to the plan&#8217;s &#8220;star ratings.&#8221; Plans must have a star rating of 4 or higher (out of 5) to qualify for bonus payments. CMS released the Company&#8217;s 2023 star ratings in October 2022. The Company&#8217;s 2023 star ratings will be used to determine which of the Company&#8217;s Medicare Advantage plans have ratings of four stars or higher and qualify for bonus payments in 2024. Based on the Company&#8217;s membership at December&#160;31, 2022, 21% of the Company&#8217;s Medicare Advantage members were in plans with 2023 star ratings of at least 4.0 stars, compared to 87% of the Company&#8217;s Medicare Advantage members being in plans with 2022 star ratings of at least 4.0 stars based on the Company&#8217;s membership at December&#160;31, 2021. Refer to &#8220;Medicare Star Ratings&#8221; within the &#8220;Government Regulation&#8221; section of this Item 1 for further discussion of the decrease in the Company&#8217;s star ratings. </span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rates for Medicare Supplement products are regulated at the state level and vary by state and plan.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Insured Medicaid contracts, state government agencies pay the Company fixed monthly rates per member that vary by state, line of business and demographics; and the Company arranges, pays for and manages the health care services provided to Medicaid beneficiaries. These rates are subject to change by each state, and, in some instances, provide for adjustment for health risk factors. CMS requires these rates to be actuarially sound. The Company also receives fees from customers where it provides services under ASC Medicaid contracts. ASC Medicaid contracts generally are for periods of more than one year, and certain of them contain performance incentives and limited financial risk sharing with respect to certain medical, financial and operational metrics. Under these arrangements, performance is evaluated annually, with associated financial incentive opportunities, and financial risk share obligations are typically limited to a percentage of the fees otherwise payable to the Company. Payments to the Company under Medicaid contracts are subject to the annual appropriation process in the applicable state.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Duals contracts, the rate setting process is generally established by CMS in partnership with the state government agency participating in the demonstration project. Both CMS and the state government agency may seek premium and other refunds under certain circumstances, including if the Company fails to comply with CMS regulations or other contractual requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers HMO and consumer-directed medical and dental plans to federal employees under the Federal Employees Health Benefits (&#8220;FEHB&#8221;) Program and the Federal Employees Dental and Vision Insurance Program. Premium rates and fees for those plans are subject to federal government review and audit, which can result, and have resulted, in retroactive and prospective premium and fee adjustments and refunds to the government and/or members. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2014, the ACA imposed significant new industry-wide fees, assessments and taxes, including an annual levy known as the health insurer fee (the &#8220;HIF&#8221;). In December 2019, the HIF was repealed for calendar years after 2020. For additional information on the ACA fees, assessments and taxes, see Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; included in Item 8 of this 10-K. The Company&#8217;s goal is to collect premiums and fees where possible, or solve for, all of the ACA-related fees, assessments and taxes.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Seasonality</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment&#8217;s quarterly operating income progression is impacted by (i) the seasonality of benefit costs which generally increase during the year as Insured members progress through their annual deductibles and out-of-pocket expense limits and (ii) the seasonality of operating expenses, which are generally the highest during the fourth quarter due primarily to spending to support readiness for the start of the upcoming plan year and marketing associated with Medicare annual enrollment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the impact of COVID-19 within the Health Care Benefits segment has generally stabilized as a result of the Company&#8217;s ability to capture COVID-19 related medical costs in pricing, and the segment has experienced a return to a more normal seasonality pattern, as described above.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the customary quarterly operating income progression was impacted by COVID-19. While overall medical costs in the first quarter were generally consistent with historical baseline levels in the aggregate, the segment experienced increased COVID-19 testing and treatment costs and lower Medicare risk-adjusted revenue. During the second quarter, COVID-19 testing and treatment costs persisted, however at levels significantly lower than those observed during the first quarter. Beginning in the third quarter, medical costs once again increased primarily driven by the spread of the emerging new variants of COVID-19, which resulted in increased testing and treatment costs that continued throughout the fourth quarter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the customary quarterly operating income progression was also impacted by COVID-19. Beginning in mid-March, the health care system experienced a significant reduction in utilization that is discretionary and the cancellation of elective medical procedures. Utilization remained below historical levels through April 2020, began to recover in May and June 2020 and reached more normal levels in the third and fourth quarters of 2020, with select geographies impacted by COVID-19 waves. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Competition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care benefits industry is highly competitive, primarily due to a large number of for-profit and not-for-profit competitors, competitors&#8217; marketing and pricing and a proliferation of competing products, including new products that are continually being introduced into the marketplace. New entrants into the marketplace, as well as consolidation within the industry, have contributed to and are expected to intensify the competitive environment. In addition, the rapid pace of change as the industry evolves towards a consumer-focused retail marketplace, including Insurance Exchanges, and the increased use of technology to interact with members, providers and customers, increase the risks the Company faces from new entrants and disruptive actions by existing competitors compared to prior periods.</span></div><div><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the significant factors that distinguish competing health plans include the perceived overall quality (including accreditation status), quality of service, comprehensiveness of coverage, cost (including premium rates, provider discounts and member out-of-pocket costs), product design, financial stability and ratings, breadth and quality of provider networks, ability to offer different provider network options, providers available in such networks, and quality of member support and care management programs. The Company believes that it is competitive on each of these factors. The Company&#8217;s ability to increase the number of persons covered by its health plans or to increase Health Care Benefits segment revenues is affected by its ability to differentiate itself from its competitors on these factors. Competition may also affect the availability of services from providers, including primary care physicians, specialists and hospitals.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insured products compete with local and regional health care benefits plans, health care benefits and other plans sponsored by other large commercial health care benefit insurance companies, health system owned health plans, new entrants into the marketplace and numerous for-profit and not-for-profit organizations operating under licenses from the Blue Cross and Blue Shield Association. The largest competitor in Medicare products is Original Medicare. Additional Health Care Benefits segment competitors include other types of medical and dental provider organizations, various specialty service providers (including pharmacy benefit management (&#8220;PBM&#8221;) services providers), health care consultants, financial services companies, integrated health care delivery organizations (networks of providers who also coordinate administrative services for and assume insurance risk of their members), third party administrators (&#8220;TPAs&#8221;), HIT companies and, for certain plans, programs sponsored by the federal or state governments. Emerging competitors include start up health care benefits plans, technology companies, provider-owned health plans, new joint ventures (including not-for-profit joint ventures among firms from multiple industries), financial services firms that are distributing competing products on their proprietary Private Exchanges, and consulting firms that are distributing competing products on their proprietary Private Exchanges, as well as non-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">traditional distributors such as retail companies. The Company&#8217;s ability to increase the number of persons enrolled in Insured Commercial Medical products also is affected by the desire and ability of employers to self-fund their health coverage.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment&#8217;s ASC plans compete primarily with other large commercial health care benefit companies, numerous for-profit and not-for-profit organizations operating under licenses from the Blue Cross and Blue Shield Association and TPAs.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provider solutions and HIT marketplaces and products are evolving rapidly. The Company competes for provider solutions and HIT business with other large health plans and commercial health care benefit insurance companies as well as information technology companies and companies that specialize in provider solutions and HIT. Many information technology product competitors have longer operating histories, better brand recognition, greater marketplace presence and more experience in developing innovative products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to competitive pressures affecting the Company&#8217;s ability to obtain new customers or retain existing customers, the Health Care Benefits segment&#8217;s medical membership has been and may continue to be adversely affected by adverse and/or uncertain economic conditions and reductions in workforce by existing customers due to adverse and/or uncertain general economic conditions, especially in the United States and industries where such membership is concentrated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Reinsurance</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currently has</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several reinsurance agreements with non-affiliated insurers that relate to Health Care Benefits insurance policies. The Company entered into these contracts to reduce the risk of catastrophic losses which in turn reduces capital and surplus requirements. The Company frequently evaluates reinsurance opportunities and refines its reinsurance and risk management strategies on a regular basis.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmacy Services Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment provides a full range of PBM solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (&#8220;Covered Entities&#8221;). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers. The Pharmacy Services segment&#8217;s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care (&#8220;Managed Medicaid&#8221;) plans, plans offered on Insurance Exchanges and other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. During the year ended December&#160;31, 2022, the Company&#8217;s PBM filled or managed 2.3 billion prescriptions on a 30-day equivalent basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PBM Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company dispenses prescription drugs directly through its mail order dispensing and specialty mail order pharmacies and through pharmacies in its retail network. All prescriptions processed by the Company are analyzed, processed and documented by the Company&#8217;s proprietary prescription management systems. These systems provide essential features and functionality to allow plan members to utilize their prescription drug benefits. These systems also streamline the process by which prescriptions are processed by staff and network pharmacists by enhancing review of various items through automation, including plan eligibility, early refills, duplicate dispensing, appropriateness of dosage, drug interactions or allergies, over-utilization and potential fraud.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plan Design Offerings and Administration</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assists its PBM clients in designing pharmacy benefit plans that help improve health outcomes while minimizing the costs to the client. The Company also assists PBM clients in monitoring the effectiveness of their plans through frequent, informal communications, the use of proprietary software, as well as through formal annual, quarterly and sometimes monthly performance reviews. The Company administers pharmacy benefit plans for clients who contract with it to facilitate prescription drug coverage and claims processing for their eligible plan members. The Company also provides administrative services for Covered Entities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes recommendations to help PBM clients design benefit plans that promote the use of lower cost, clinically appropriate drugs and helps its PBM clients control costs by recommending plan designs that encourage the use of generic equivalents of brand name drugs when such equivalents are available. Clients also have the option, through plan design, to further lower their pharmacy benefit plan costs by setting different member payment levels for different products on their drug lists or &#8220;formularies,&#8221; which helps guide members to choose lower cost alternatives through appropriate financial incentives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Formulary Management</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes an independent panel of doctors, pharmacists and other medical experts, referred to as the CVS Caremark National Pharmacy and Therapeutics Committee, to review and approve the selection of drugs that meet the Company&#8217;s standards of safety and efficacy for inclusion on one of the Company&#8217;s template formularies. The Company&#8217;s formularies provide recommended products in numerous drug classes to help ensure member access to clinically appropriate drugs with alternatives within a class under the client&#8217;s pharmacy benefit plan, while helping to drive the lowest net cost for clients that select one of the Company&#8217;s formularies. To help improve clinical outcomes for members and clients, the Company conducts ongoing, independent reviews of all drugs, including those appearing on the formularies and generic equivalent products. Many of the Company&#8217;s clients choose to adopt a template formulary offering as part of their plan design. PBM clients are given capabilities to offer real time benefits information for a member&#8217;s specific plan design, provided digitally at the point of prescribing, at the CVS pharmacy and directly to members.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail Pharmacy Network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a national network of approximately 66,000 retail pharmacies, consisting of approximately 40,000 chain pharmacies (which include CVS pharmacy locations) and approximately 26,000 independent pharmacies, in the United States, including Puerto Rico, the District of Columbia, Guam and the U.S. Virgin Islands. When a customer fills a prescription in a retail pharmacy, the pharmacy sends prescription data electronically to the Company from the point-of-sale. This data interfaces with the Company&#8217;s proprietary prescription management systems, which verify relevant plan member data and eligibility, while also performing a drug utilization review to help evaluate clinical appropriateness and safety and confirming that the pharmacy will receive payment for the prescription. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mail Order Pharmacy Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment operates mail order dispensing pharmacies in the United States. Plan members or their prescribers submit prescriptions or refill requests, primarily for maintenance medications, to these pharmacies, and staff pharmacists review these prescriptions and refill requests with the assistance of the Company&#8217;s prescription management systems. This review may involve communications with the prescriber and, with the prescriber&#8217;s approval when required, can result in generic substitution, therapeutic interchange or other actions designed to help reduce cost and/or improve quality of treatment. The Company&#8217;s mail order dispensing pharmacies have been awarded Mail Service Pharmacy accreditation from URAC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Specialty Pharmacy and Infusion Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment operates specialty mail order pharmacies, retail specialty pharmacy stores and branches for infusion and enteral nutrition services in the United States. The specialty mail order pharmacies are used for delivery of advanced medications to individuals with chronic or genetic diseases and disorders. The Company&#8217;s specialty mail order pharmacies have been awarded Specialty Pharmacy accreditation from URAC. Substantially all of the Company&#8217;s specialty mail order pharmacies also have been accredited by The Joint Commission and the Accreditation Commission for Health Care (&#8220;ACHC&#8221;), which are independent, not-for-profit organizations that accredit and certify health care programs and organizations in the United States. The ACHC accreditation includes an additional accreditation by the Pharmacy Compounding Accreditation Board, which certifies compliance with the highest level of pharmacy compounding standards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers multiple clinical programs and services to help clients manage overall pharmacy and health care costs in a clinically appropriate manner. These programs are primarily designed to promote better health outcomes and to help target inappropriate medication utilization and non-adherence to medication, each of which may result in adverse medical events that negatively affect member health and client pharmacy and medical spend. These programs include utilization management (&#8220;UM&#8221;), medication management, quality assurance, adherence and counseling programs to complement the client&#8217;s plan design and clinical strategies. To help address prescription opioid abuse and misuse, the Company introduced an industry-leading UM approach that limits to seven days the supply of opioids dispensed for certain acute prescriptions for patients who are new to therapy, limits the daily dosage of opioids dispensed based on the strength of the opioid and requires the use of immediate-release formulations of opioids before extended-release opioids are dispensed. The Company&#8217;s Pharmacy Advisor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program facilitates pharmacist counseling, both face-to-face and over the telephone, to help participating plan members with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain chronic diseases, such as diabetes and cardiovascular conditions, to identify gaps in care, adhere to their prescribed medications and manage their health conditions. The Company also has digital connectivity that helps to lower drug costs for patients by providing expanded visibility to lower cost alternatives through enhanced analytics and data sharing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Management Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s clinical programs and services utilize advanced protocols and offer clients convenience in working with providers and other third parties. The Company&#8217;s care management program covers diseases such as rheumatoid arthritis, Parkinson&#8217;s disease, epilepsy and multiple sclerosis and is accredited by the NCQA. The Company&#8217;s UM program covers similar diseases and is accredited by the NCQA and URAC. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Benefit Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s NovoLogix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">online preauthorization tool helps identify and capture cost savings opportunities for specialty drugs billed under the medical benefit by identifying outliers to appropriate dosages and costs, and helps to ensure clinically appropriate use of specialty drugs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Group Purchasing Organization Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacy Services Information Systems</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment&#8217;s claim adjudication platform incorporates architecture that centralizes the data generated from filling mail order prescriptions, adjudicating retail pharmacy claims and delivering other solutions to PBM clients. The Health Engagement Engine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology and proprietary clinical algorithms help connect various parts of the enterprise and serve an essential role in cost management and health improvement, leveraging cloud-native technologies and practices. This capability transforms pharmacy data into actionable interventions at key points of care, including in retail, mail and specialty pharmacies as well as in customer care call center operations, leveraging our enterprise data platform to improve the quality of care. The technology leverages assisted artificial intelligence to deliver insights to the business and bring automation to otherwise manual tasks. Specialty services also connects with our claim adjudication platform and various health plan adjudication platforms with a centralized architecture servicing many clients and members. Operating services, such as Specialty Expedite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, provide an interconnected onboarding solution for specialty medications and branding solutions ranging from fulfillment to total patient management. These services are managed through our new innovative specialty workflow and web platform.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacy Services Clients</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharmacy Services clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Managed Medicaid plans, plans offered on Insurance Exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. Pharmaceuticals are provided to eligible members in benefit plans maintained by clients and utilize the Company&#8217;s information systems, among other things, to help perform safety checks, drug interaction screening and identify opportunities for generic substitution. Substantially all of the Pharmacy Services segment&#8217;s revenues are generated from dispensing and managing prescription drugs to eligible members in benefit plans maintained by clients. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacy Services Seasonality</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of Pharmacy Services segment revenues are not seasonal in nature. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacy Services Competition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the primary competitive factors in the pharmacy services industry include: (i)&#160;the ability to negotiate favorable discounts from drug manufacturers as well as to negotiate favorable discounts from, and access to, retail pharmacy networks; (ii)&#160;the ability to identify and apply effective cost management programs utilizing clinical strategies, including&#160;the development and utilization of preferred formularies; (iii)&#160;the ability to market PBM products and services; (iv)&#160;the commitment to provide flexible, clinically-oriented services to clients and be responsive to clients&#8217; needs; (v)&#160;the quality, scope and costs of products and services offered to clients and their members; and (vi) operational excellence in delivering services. The Pharmacy Services segment has a significant number of competitors offering PBM services, including large, national PBM companies </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e.g., Prime Therapeutics and MedImpact), PBMs owned by large national health plans (e.g., the Express Scripts business of Cigna Corporation and the OptumRx business of UnitedHealth) and smaller standalone PBMs. </span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retail/LTC Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (&#8220;LTC&#8221;) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of December&#160;31, 2022, the Retail/LTC segment operated more than 9,000 retail locations, more than 1,100 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. During the year ended December&#160;31, 2022, the Retail/LTC segment filled 1.6 billion prescriptions on a 30-day equivalent basis. For the year ended December&#160;31, 2022, the Company dispensed approximately 26.8% of the total retail pharmacy prescriptions in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retail/LTC Products and Services</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A typical retail store sells prescription drugs and a wide assortment of high-quality, nationally advertised brand name and proprietary brand merchandise. Pharmacy locations may also contract with Covered Entities under the federal 340B drug pricing program. Front store categories include over-the-counter drugs, consumer health products, beauty products and personal care products. The Company purchases merchandise from numerous manufacturers and distributors. The Company believes that competitive sources are readily available for substantially all of the products carried in its retail stores and the loss of any one supplier would not likely have a material effect on the Retail/LTC segment. LTC operations include distribution of prescription drugs and related consulting and ancillary services. The Company&#8217;s MinuteClinic locations offer a variety of health care services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retail/LTC revenues by major product group are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage&#160;of&#160;Revenues</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Front store and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy includes LTC sales and sales in pharmacies within Target Corporation (&#8220;Target&#8221;) and other retail stores.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">&#8220;Other&#8221; represents less than 12% of the &#8220;Front store and other&#8221; revenue category in all periods presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacy revenues represented approximately three-fourths of Retail/LTC segment revenues in each of 2022, 2021 and 2020. The Company believes that retail pharmacy operations will continue to represent a critical part of the Company&#8217;s business due to industry demographics, e.g., an aging American population consuming a greater number of prescription drugs, prescription drugs being used more often as the first line of defense for managing illness, the introduction of new pharmaceutical products, the need for vaccinations, including the COVID-19 vaccination, and Medicare Part&#160;D growth. The Company believes the retail pharmacy business benefits from investment in both people and technology, as well as innovative collaborations with health plans, PBMs and providers. Given the nature of prescriptions, consumers want their prescriptions filled accurately by professional pharmacists using the latest tools and technology, and ready when promised. Consumers also need medication management programs and better information to help them get the most out of their health care dollars. To assist consumers with these needs, the Company has introduced integrated pharmacy health care services that provide an earlier, easier and more effective approach to engaging consumers in behaviors that can help lower costs, improve health and save lives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Front Store</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Front store revenues reflect the Company&#8217;s strategy of innovating with new and unique products and services, using innovative personalized marketing and adjusting the mix of merchandise to match customers&#8217; needs and preferences. A key component of the front store strategy is the ExtraCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;card program, which is one of the largest and most successful retail loyalty programs in the United States. The ExtraCare program allows the Company to balance marketing efforts so it can reward its best customers by providing them with automatic sale prices, customized coupons, ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;rewards and other benefits. The Company also offers a subscription-based membership program, CarePass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">goods and services. The Company continues to launch and enhance new and exclusive brands to create unmatched offerings in beauty products and deliver other unique product offerings, including a full range of high-quality proprietary brand products that are only available through CVS stores. The Company currently carries approximately 5,500 proprietary brand products, which accounted for approximately 21% of front store revenues during 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MinuteClinic</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company operated more than 1,100 MinuteClinic&#160;locations in the United States. The clinics are staffed by nurse practitioners and physician assistants who utilize nationally established guidelines to deliver a variety of health care services. Payors value these clinics because they provide convenient, high-quality, cost-effective care, in many cases offering an attractive alternative to more expensive sites of care.&#160;MinuteClinic also offers virtual care services to connect customers with licensed providers to provide access to health services remotely. MinuteClinic is collaborating with the Health Care Benefits and Pharmacy Services segments to help meet the needs of the Company&#8217;s health plan and client plan members by offering programs that can improve member health and lower costs. MinuteClinic also maintains relationships with leading hospitals, clinics and physicians in the communities we serve to support and enhance quality, access and continuity of care. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">On-site Pharmacies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also operates a limited number of pharmacies located at client sites, which provide certain health plan members and customers with a convenient alternative for filling their prescriptions and receiving vaccinations, including the COVID-19 vaccination.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Diagnostic Testing</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers medical diagnostic testing primarily through its testing sites located at CVS pharmacy locations, in its MinuteClinic locations, at community-based testing sites in underserved areas and through its Return Ready</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solution.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Care Pharmacy Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Retail/LTC segment provides LTC pharmacy services through the Omnicare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business. Omnicare&#8217;s customers consist of skilled nursing facilities, assisted living facilities, independent living communities, hospitals, correctional facilities, and other health care service providers. The Company provides pharmacy consulting, including monthly patient drug therapy evaluations, to assist in compliance with state and federal regulations and provide proprietary clinical and health management programs. It also provides pharmaceutical case management services for retirees, employees and dependents who have drug benefits under corporate-sponsored health care programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Community Location Development</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health&#8217;s community health destinations are an integral part of its ability to meet the needs of consumers and maintain its leadership position in the changing health care landscape. When paired with its rapidly expanding digital presence, the Company&#8217;s physical presence in thousands of communities across the country represents a competitive advantage by allowing it to develop deep and trusted relationships through everyday engagement in consumer health. The Company&#8217;s community health destinations have played, and will continue to play, a key role in the Company&#8217;s continued growth and success. During 2022, the Company opened approximately 40 new locations, relocated 4 locations and closed approximately 300 locations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s continuous assessment of its national footprint is an essential component of competing effectively in the current health care environment. On an ongoing basis, the Company evaluates changes in population, consumer buying patterns and future health needs to assess the ability of its existing stores and locations to meet the needs of its consumers and the business. During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced its plans to reduce store density in certain locations through the closure of approximately 900 retail stores between 2022 and 2024. As of December, 31, 2022, the Company has closed approximately 300 retail stores in connection with this strategic review.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retail/LTC Information Systems</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has continued to invest in information systems to enable it to deliver exceptional customer service, enhance safety and quality, and expand patient care services while lowering operating costs. The proprietary WeCARE Workflow tool supports pharmacy teams by prioritizing work to meet customer expectations, facilitating prescriber outreach, and seamlessly integrating clinical programs. This solution delivers improved efficiency and enhances customer experience, as well as provides a framework to accommodate the evolution of pharmacy practice and the expansion of clinical programs. Our Health Engagement Engine technology and data science clinical algorithms enable the Company to help identify opportunities for pharmacists to deliver face-to-face counseling regarding patient health and safety matters, including medication adherence issues, gaps in care and management of certain chronic health conditions. The Company&#8217;s digital strategy is to empower the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consumer to navigate their pharmacy experience and manage their condition through integrated online and mobile solutions that offer utility and convenience. The Company&#8217;s LTC digital technology suite, Omniview</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, improves the efficiency of customers&#8217; operations with tools that include executive dashboards, pre-admission pricing, electronic ordering of prescription refills, proof-of-delivery tracking, access to patient profiles, receipt and management of facility bills, and real-time validation of Medicare Part D coverage, among other capabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the collaboration of its digital and technical teams, the Company has established critical tools which enable patients to schedule diagnostic testing and vaccination appointments through CVS.com and MinuteClinic.com. Key elements of the offerings include landing pages which highlight services and answer common questions, screening capabilities to determine patient eligibility, service location locator and appointment selection tools to efficiently identify the requested service on a specified date, time, and location and registration pages to collect required patient information, accelerating the administration of the test or vaccine once at the store. Once scheduled, the tools provide the user with instructions and notifications including SMS text message and email reminders, and, following administration, also provide digital results for tests and records for vaccinations, enabling patients to view and save their medical records for convenient access at a later point.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retail/LTC Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Retail/LTC segment&#8217;s businesses is dependent upon the Company&#8217;s ability to establish and maintain contractual relationships with pharmacy benefit managers and other payors on acceptable terms. Substantially all of the Retail/LTC segment&#8217;s pharmacy revenues are derived from pharmacy benefit managers, managed care organizations (&#8220;MCOs&#8221;), government funded health care programs, commercial employers and other third-party payors. No single Retail/LTC payor accounted for 10% or more of the Company&#8217;s consolidated total revenues in 2022, 2021 or 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retail/LTC Seasonality</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of Retail/LTC segment revenues, particularly pharmacy revenues, generally are not seasonal in nature. However, front store revenues tend to be higher during the December holiday season. In addition, both pharmacy and front store revenues are affected by the timing and severity of the cough, cold and flu season. Uncharacteristic or extreme weather conditions also can adversely affect consumer shopping patterns and Retail/LTC revenues, expenses and operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the customary quarterly operating income progression in the Retail/LTC segment continued to be impacted by COVID-19. During the first quarter, the Company saw high volumes of administration of COVID-19 vaccinations, as well as demand for OTC test kits in the front store, particularly in the beginning of the year when the Omicron variant incidence was high. In addition, the Company administered the highest quarterly volume of COVID-19 diagnostic tests of 2022 during the first quarter, however a decline compared to the prior year. During the second and third quarters, the Company continued to generate earnings from the sale of OTC test kits, as customers performed more in-home testing versus diagnostic testing, in addition to earnings from the continued administration of COVID-19 diagnostic testing and vaccinations, albeit at lower levels than those experienced in the first quarter. During the fourth quarter, the Company saw an increase in COVID-19 vaccine administration from the prior quarter related to the bivalent COVID-19 booster. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the customary quarterly operating income progression was impacted by COVID-19. During the first quarter, the Company experienced reduced customer traffic in its retail pharmacies, which reflected the impact of a weaker cough, cold and flu season, while it administered the highest quarterly volume of COVID-19 diagnostic tests. During the second quarter, the segment generated earnings from COVID-19 vaccinations and saw improved customer traffic as vaccinated customers began more actively shopping in CVS locations. During the third and fourth quarters, emerging new variants drove the continued administration of COVID-19 vaccinations (including booster shots) and diagnostic testing, while the segment also generated earnings from the sale of OTC test kits in the front store. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the customary quarterly operating income progression was impacted by COVID-19. During March 2020, the Company experienced increased prescription volume due to the greater use of 90-day prescriptions and early refills of maintenance medications, as well as increased front store volume as consumers prepared for the COVID-19 pandemic. Beginning in the second quarter and continuing throughout the remainder of the year, the Company experienced reduced customer traffic in its retail pharmacies and MinuteClinic locations due to shelter-in-place orders as well as reduced new therapy prescriptions and decreased long-term care prescription volume as a result of the COVID-19 pandemic. Beginning in the third quarter, the Company saw an increase in diagnostic testing related to the COVID-19 pandemic and in December 2020, the Company began administering COVID-19 vaccinations in long-term care facilities.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retail/LTC Competition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The retail pharmacy business is highly competitive. The Company believes that it competes principally on the basis of: (i)&#160;store location and convenience, (ii)&#160;customer service and satisfaction, (iii)&#160;product selection and variety, and (iv)&#160;price. In the areas it serves, the Company competes with other drugstore chains (e.g., Walgreens and Rite Aid), supermarkets, discount retailers (e.g., Walmart), independent pharmacies, restrictive pharmacy networks, internet companies (e.g., Amazon), membership clubs,&#160;retail health clinics, urgent care and primary care offices, as well as mail order dispensing pharmacies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LTC pharmacy services are highly regional or local in nature, and within a given geographic area of operation, highly competitive. The Company&#8217;s largest LTC pharmacy competitor nationally is PharMerica. The Company also competes with numerous local and regional institutional pharmacies, pharmacies owned by long-term care facilities and local retail pharmacies. Some states have enacted &#8220;freedom of choice&#8221; or &#8220;any willing provider&#8221; requirements as part of their state Medicaid programs or in separate legislation, which may increase the competition that the Company faces in providing services to long-term care facility residents in these states.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate/Other Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management and administrative expenses to support the Company&#8217;s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company&#8217;s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.</span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_28"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Cardinal Health, Inc. (&#8220;Cardinal&#8221;) each have a 50% ownership in Red Oak Sourcing, LLC (&#8220;Red Oak&#8221;), a generic pharmaceutical sourcing entity. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak. Red Oak does not own or hold inventory on behalf of either company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital Practices</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company funds the growth of its businesses through a combination of cash flow from operations, commercial paper and other short-term borrowings, as well as long-term borrowings. For additional information on the Company&#8217;s working capital practices, see &#8220;Liquidity and Capital Resources&#8221; in the MD&amp;A included in Item 7 of this 10-K. Employer groups, individuals, college students, part-time and hourly workers, health plans, providers, governmental units, government-sponsored plans (with the exception of Medicare Part D services, which are described below), labor groups and expatriates, which represent the vast majority of Health Care Benefits segment revenues, typically settle in less than 30 days. As a provider of Medicare Part D services, the Company contracts annually with CMS.&#160;Utilization of services each plan year results in the accumulation of either a receivable from or a payable to CMS. The timing of settlement of the receivable or payable with CMS takes several quarters, which impacts working capital from year to year. The majority of the Retail/LTC segment non-pharmacy revenues are paid in cash, or with debit or credit cards. Managed care organizations, pharmacy benefit managers, government funded health care programs, commercial employers and other third party insurance programs, which represent the vast majority of the Company&#8217;s consolidated pharmacy revenues, typically settle in less than 30 days. The remainder of the Company&#8217;s consolidated pharmacy revenues are paid in cash, or with debit or credit cards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At CVS Health, we share a single, clear purpose: bringing our heart to every moment of your health. We devote significant time and attention to the attraction, development and retention of talent to deliver high levels of service to our customers. Our commitment to them includes a competitive rewards package and programs that support our diverse range of colleagues in rewarding and fulfilling careers. As of December&#160;31, 2022, we employed over 300,000 colleagues primarily in the United States including in all 50 states, the District of Columbia and Puerto Rico, approximately 73% of whom were full-time. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe engaged colleagues produce stronger business results and are more likely to build a career with the Company. Each year we conduct an internal engagement survey that provides colleagues with an opportunity to share their opinions and experiences with respect to their role, their team and the enterprise to help CVS Health Corporation&#8217;s Board of Directors (the &#8220;Board&#8221;) and our management identify areas where we can improve colleague experience. The survey covers a broad range of topics including development and opportunities, diversity management, recognition, performance, well-being, compliance and continuous improvement. In 2022, greater than 80% of our colleagues participated in the engagement survey, of which greater than 75% responded that they were actively engaged.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board, our Chief Executive Officer (&#8220;CEO&#8221;) and our Chief People Officer provide oversight of our human capital strategy, which consists of the following categories: total rewards; diversity, equity and inclusion; colleague development; and health and safety.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Rewards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize how vital our colleagues are to our success and strive to offer comprehensive and competitive wages and benefits to meet the varying needs of our colleagues and their families. The benefits and programs include annual bonuses, 401(k) plans, stock awards, an employee stock purchase plan, health care and insurance benefits, paid time off, flexible work schedules, family leave, dependent care resources, colleague assistance programs and tuition assistance, among many others, depending on eligibility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recognition of the critical role that the attraction and retention of talent plays in the success of our business, during 2021, we also announced a significant investment in our employees through an increase in the Company&#8217;s minimum hourly wage to $15.00 an hour effective July 2022, with incremental increases to the Company&#8217;s competitive hourly rates beginning in August 2021. The new wage structure also incorporates additional increases beyond the $15.00 minimum, with higher starting hourly rates for roles such as pharmacy technicians and call center representatives. In addition, during 2021 we awarded incremental bonuses to select colleague groups in recognition of their ongoing contributions throughout the COVID-19 pandemic, the most significant of which included bonuses to our pharmacist and distribution center colleagues. In 2022, we awarded incremental bonuses to select colleague groups including our front-line retail store, pharmacy and MinuteClinic colleagues. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity &amp; Inclusion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that a diverse workforce creates a healthier, stronger and more sustainable company. We aim to attract, develop, retain and support a diverse workforce that reflects the many customers, patients, members and communities we serve. Our Diversity Management Leadership Council, a cross-functional group of senior leaders appointed by our CEO, works with our Strategic Diversity Management leadership team to intentionally embed diversity across all facets of our business. For our efforts, we have been recognized as a DiversityInc Top 50 Company, one of Seramount&#8217;s Best Companies for Multicultural Women and earned a 100 percent score on both the Human Rights Campaign Corporate Equality Index as well as the Disability Equality Index, meaning the company is recognized as a &#8220;Best Place to Work for Disability Inclusion.&#8221; The Company discloses information on our diversity, equity and inclusion strategy and programs in our annual Environmental, Social and Governance (&#8220;ESG&#8221;) Report.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foundation of diversity and inclusion, we continuously focus on increasing underrepresented populations across our business. In 2022, 70% of our total colleague population and 55% of our colleagues at the manager level and above self-reported as female. In addition, in 2022 our colleagues reported their race/ethnicity as: White (49%), Black/African American (18%), Hispanic/Latino (16%), Asian (11%) and Other (6%). The appendix to our ESG Report, our Strategic Diversity Management Report and our EEO-1 Employer Information Report include additional information on the diversity of our workforce.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our diversity management strategy emphasizes workplace representation, inclusion and belonging, talent acquisition and management and a diverse marketplace. Beginning in 2021, we incorporated a diversity metric into our annual cash incentive program for our most senior leaders who have the greatest ability to influence the overall hiring, development and promotion of our colleagues. We also continued the deployment of conscious inclusion training for colleagues designed to enhance awareness of biases and rolled out our INCLUDE program to activate inclusive behaviors. Our ESG Report and Strategic Diversity Management Report include additional information with respect to our conscious inclusion training. We support 16 Colleague Resource Groups (&#8220;CRGs&#8221;) that include more than 28,000 colleagues across the enterprise. These groups represent a wide range of professional, cultural, ethical and personal affinities and interests, as well as formal mentoring programs. Our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRGs provide our colleagues with an opportunity to connect and network with one another through a particular affinity, culture or interest. Each of our CRGs is sponsored by a senior leader. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Colleague Development</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers a number of resources and programs that attract, engage, develop, advance and retain colleagues. Training and development provides colleagues the support they need to perform well in their current role while planning and preparing for future roles. We offer an online orientation program that pairs new hires with seasoned colleagues and the training continues throughout a colleague&#8217;s career through in-person, virtual and self-paced learning at all levels. We also provide mentoring, tools and workshops for colleagues to manage their career development. We offer a variety of management and leadership programs that develop incumbent diverse and other high potential colleagues. Our broad training practices include updated, tech-enabled tools and keep our colleagues informed of new developments in our industry that are relevant to their roles. During the year ended December&#160;31, 2022, our colleagues invested approximately 17&#160;million hours in learning and development courses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our colleague development program also promotes the importance of compliance across our business. Our colleagues demonstrate this commitment through our annual Code of Conduct training, which nearly 100% of active colleagues completed in 2022. In 2022, we launched more than 70 different training courses as part of our Enterprise Compliance Training Program.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health &amp; Safety</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a strong commitment to providing a safe working environment. We have implemented an environmental health and safety management system to support adherence and monitoring of programs designed to make our various business operations compliant with applicable occupational safety and health regulations and requirements. Our Environmental Health and Safety Department oversees the implementation and adherence to programs like Powered Industrial Truck training, materials handling and storage, selection of personal protective equipment and workplace violence prevention. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize Safety Service Plans to analyze data and concentrate on key areas of risk to reduce the chance of workplace incidents. We focus on identifying causes and improving performance when workplace incidents occur. We also engage leaders in promoting a culture of safety. With safety task forces in place at each distribution center, we empower leaders and safety business partners to identify policies, procedures and processes that could improve their own operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the outset of the COVID-19 pandemic, we took a comprehensive approach to managing occupational health and safety challenges presented by the pandemic, including implementing facial covering requirements for our workplaces and providing face masks to colleagues, providing sick leave, implementing symptom screening measures and implementing additional protocols in accordance with applicable Occupational Safety and Health Administration (&#8220;OSHA&#8221;) requirements and guidance and Centers for Disease Control and Prevention (&#8220;CDC&#8221;) guidelines for workplaces. We have emphasized the importance of taking immediate steps toward full vaccination.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Social and Governance Strategy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health believes the health of our people, communities and planet are linked to the health of our business. Our ESG strategy &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthy 2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is focused on achieving our economic, environmental and social imperatives and outlines how we are shaping a more equitable and sustainable future for all &#8211; across multiple dimensions of health. Designed to use our assets to transform the health care experience and invest in community health at the local level, while working to reduce the environmental impact of our operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthy 2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of four pillars: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthy People</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthy Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthy Community</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthy Planet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe this strategy is achievable without materially adversely affecting our businesses, operating results, cash flows and/or prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthy People</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through physical and virtual assets, we provide convenient, personalized and integrated access to health care support and services. We continue to implement and expand initiatives that build on our innovative health care model, with the ultimate aim to transform the health care experience for every person we reach to improve health outcomes. These include helping to improve chronic disease prevention and management, helping to reduce and prevent prescription drug misuse, and improving the social determinants of health, which include education, transportation and behavioral health. Through our ESG strategy we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are leveraging our expertise and resources to make the health care experience simple, equitable, convenient and deeply personal for each of us. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthy Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we work to transform health care, we are committed to operating a healthy business for all our stakeholders, including our patients, customers, stockholders, clients, partners, communities and colleagues. Throughout our large operational footprint and including our supply chain, we are committed to acting responsibly with respect for human rights, privacy, information security, public policy, marketing and advertising. We focus on diversity, equity and inclusion as well as colleague development, health and safety. Through our ESG strategy, we are focused on providing people with the opportunity to be as healthy as possible by expanding community-centered solutions that advance health equity and improve outcomes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthy Community</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By working with community-focused organizations and through innovative programs that can be tailored to and executed across different communities, we are driving positive health outcomes and reducing overall health care costs. Our philanthropic strategy, which includes grants made through the CVS Health Foundation, Health Zones initiative and Project Health program, improves health outcomes and reduce health disparities in under-resourced communities. We are investing charitable resources, leveraging CVS Health assets, and working in partnership with non-profits to help our communities be as healthy as possible. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthy Planet</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working to improve the health of our planet and make a difference in the lives of the people who live on it</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by advancing our sustainability commitments and addressing the environmental factors that contribute to health inequities. In October 2021, CVS Health&#8217;s science-based net zero greenhouse gas (&#8220;GHG&#8221;) emissions targets were validated by the Science Based Targets initiatives (&#8220;SBTi&#8221;). We continue to make meaningful progress to reduce our environmental impact across our operations and supply chain. Key priorities include the advancement of our GHG emissions-reduction targets, reduction in our energy consumption, the advancement of sustainability in transportation, logistics and our physical locations, which includes retrofitting community and corporate locations with LED lighting, exploring investments in renewable energy, reducing water use, focusing on smarter consumption through a &#8220;digital first&#8221; approach and the reduction of our use of paper and plastic.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has registered and/or applied to register a variety of trademarks and service marks used throughout its businesses, as well as domain names, and relies on a combination of copyright, patent, trademark and trade secret laws, in addition to contractual restrictions, to establish and protect the Company&#8217;s proprietary rights. The Company regards its intellectual property as having significant value in the Health Care Benefits, Pharmacy Services and Retail/LTC segments. The Company is not aware of any facts that could materially impact the continuing use of any of its intellectual property.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations are subject to comprehensive federal, state and local laws and regulations and comparable multiple levels of international regulation in the jurisdictions in which it does business. There also continues to be a heightened level of review and/or audit by federal, state and international regulators of the health&#160;and related benefits industry&#8217;s business and reporting practices. In addition, many of the Company&#8217;s PBM clients and the Company&#8217;s payors in the Retail/LTC segment, including insurers, Medicare plans, Managed Medicaid plans and MCOs, are themselves subject to extensive regulations that affect the design and implementation of prescription drug benefit plans that they sponsor. Similarly, the Company&#8217;s LTC clients, such as skilled nursing facilities, are subject to government regulations, including many of the same government regulations to which the Company is subject. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws and rules governing the Company&#8217;s businesses and interpretations of those laws and rules continue to expand and become more restrictive each year and are subject to frequent change. The application of these complex legal and regulatory requirements to the detailed operation of the Company&#8217;s businesses creates areas of uncertainty. Further, there are numerous proposed health care, financial services and other laws and regulations at the federal, state and international levels, some of which could adversely affect the Company&#8217;s businesses if they are enacted. The Company cannot predict whether pending or future federal or state legislation or court proceedings will change aspects of how it operates in the specific markets in which it </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competes or the health care industry generally, but if changes occur, the impact of any such changes could have a material adverse impact on the Company&#8217;s businesses, operating results, cash flows and/or stock price. Possible regulatory or legislative changes include the federal or one or more state governments fundamentally restructuring the Commercial, Medicare or Medicaid marketplace; reducing payments to the Company in connection with Medicare, Medicaid, dual eligible or special needs programs; increasing its involvement in drug reimbursement, pricing, purchasing, and/or importation; or changing the laws governing PBMs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has internal control policies and procedures and conducts training and compliance programs for its employees to help prevent, detect and correct prohibited practices. However, if the Company&#8217;s employees or agents fail to comply with applicable laws governing its international or other operations, it may face investigations, prosecutions and other legal proceedings and actions which could result in civil penalties, administrative remedies and criminal sanctions. Any failure or alleged failure to comply with applicable laws and regulations summarized below, or any adverse applications or interpretations of, or changes in, the laws and regulations affecting the Company and/or its businesses, could have a material adverse effect on the Company&#8217;s operating results, financial condition, cash flows and/or stock price. See Item 3 of this 10-K, &#8220;Legal Proceedings,&#8221; for further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company can give no assurance that its businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or regulations, including the laws and regulations described in this Government Regulation section, as they may relate to one or more of the Company&#8217;s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iii) pending or future federal or state governmental investigations of one or more of the Company&#8217;s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iv) pending or future government audits, investigations or enforcement actions against the Company; or (v) adverse developments in pending or future legal proceedings against or affecting the Company, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits, or affecting one or more of the industries in which the Company competes and/or the health care industry generally.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations Related to COVID-19</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) put in place a public health emergency (&#8220;PHE&#8221;) in January 2020 and HHS must extend it every 90 days to maintain certain health care flexibilities and waivers. The Biden administration most recently renewed the PHE on January 11, 2023 and has indicated that they intend for the PHE to expire on May 11, 2023. The Families First Coronavirus Response Act (the &#8220;Families First Act&#8221;) and the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) were enacted in March 2020. Each of the Families First Act and the CARES Act requires the Company to provide coverage for COVID-19 related medical services, in many cases without member cost-sharing, in its Insured Health Care Benefits products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provides relief funding to providers to reimburse them for health care related expenses incurred in preventing, preparing for and/or responding to COVID-19 (provided no other source is obligated to reimburse those expenses) or lost health care related revenues that are attributable to COVID-19. Under the CARES Act, the Company receives reimbursement for uninsured patients in connection with COVID-19 testing and vaccination as well as monoclonal antibody treatment. Aside from such reimbursement, the Company has not requested any funding under the CARES Act. However, in the second quarter of 2020, the Company received $43 million from the CARES Act provider relief fund, all of which was returned to the HHS during the second quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also allows for the deferral of the payment of the employer share of Social Security taxes effective March 27, 2020 by permitting them to remit the associated payments in two equal installments on or about December 31, 2021 and December 31, 2022. The Company elected to defer approximately $670&#160;million of its Social Security tax payments during the year ended December 31, 2020. The Company paid the first of two equal installments in December 2021 and the second installment in December 2022, as required under the CARES Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress enacted the American Rescue Plan Act in March 2021. Among other changes, as a result of this legislation, Public Exchange plan premium subsidies increased for low-income individuals and became available to people with incomes higher than 400% of the federal poverty limit. In August 2022, the Inflation Reduction Act subsequently extended these subsidies through 2025, which could cause shifts in enrollment into Public Exchange plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Families First Act, the CARES Act, and the American Rescue Plan Act, the Company has experienced legislation, regulation, directives, orders and other requirements from federal, state, county and municipal authorities related to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the COVID-19 pandemic. These governmental actions included, but were not limited to, requirements to waive member cost-sharing associated with COVID-19 testing and treatment, provide coverage for additional COVID-19-related services, expand the use of telemedicine, extend grace periods for payments of premiums or limit coverage termination based on non-payment of premiums or fees, modify health benefits coverage eligibility rules to help maintain employee eligibility, and facilitate, accelerate or advance payments to providers, and other requirements related to the PHE. Many of these requirements remain in effect and continue to impact different areas of our business differently and may continue for different lengths of time, and present financial implications with respect to implementing and unwinding our compliance with these requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operations that fall within the scope of COVID-19 vaccine requirements for federal contractors, certain health care workers, and the requirements of certain jurisdictions such as New York City. Several of these are subject to judicial challenges. We are continuing to closely monitor and update our practices in response to developments or changes in the COVID-19 vaccination policies established by various federal agencies as well as the several state- and municipal-specific COVID-19 vaccine mandates that provide expanded exemptions, modifications, requirements or restrictions regarding employee vaccinations. We have a process for employees to request a reasonable accommodation if they are unable to get vaccinated due to a medical condition, sincerely held religious belief, or any other legally recognized exemption. Employees must apply and be approved for a reasonable accommodation in order to be exempt from the vaccination requirement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in January 2022, the HHS announced that commercial health insurers must cover the costs of up to eight rapid COVID-19 OTC test kits per individual per 30-day period. Coverage for COVID-19 OTC test kits has subsequently been required by Medicare and, in many states, Medicaid. These requirements may increase benefit costs in those businesses and jurisdictions, and may increase revenues in our retail business. The requirement may also result in a decrease in more expensive tests and treatments, which could partially mitigate the increase in benefit costs. These impacts will be highly dependent on the overall supply of testing products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some activities that were suspended during the COVID-19 pandemic, such as Medicaid eligibility redeterminations, are currently scheduled to resume later this year, and many of the requirements set forth above may change once the PHE expires. The impact of this governmental activity on the U.S. economy, consumer, customer and health care provider behavior and health care utilization patterns is beyond our knowledge and control. As a result, the financial and/or operational impact these COVID-19 related governmental actions and inactions will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the collective impact could be material and adverse. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations Related to Multiple Segments of the Company&#8217;s Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Laws Related to Reimbursement by Government Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company is subject to various federal and state laws concerning its submission of claims and other information to Medicare, Medicaid and other federal and state government-sponsored health care programs. Potential sanctions for violating these laws include recoupment or reduction of government reimbursement amounts, civil penalties, treble damages, and exclusion from participation in government health care programs. Such laws include the federal False Claims Act (the &#8220;False Claims Act&#8221;), the federal anti-kickback statute (the &#8220;AKS&#8221;), state false claims acts and anti-kickback statutes in most states, the federal &#8220;Stark Law&#8221; and related state laws. In particular, the False Claims Act prohibits intentionally submitting, conspiring to submit, or causing to be submitted, false claims, records, or statements to the federal government, or intentionally failing to return overpayments, in connection with reimbursement by federal government programs. In addition, any claim for government reimbursement also violates the False Claims Act where it results from a violation of the AKS. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both federal and state false claims laws permit private individuals to file </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or &#8220;whistleblower&#8221; lawsuits on behalf of the federal or state government. Participants in the health and related benefits industry, including the Company, frequently are subject to actions under the False Claims Act or similar state laws. The federal Stark Law generally prohibits physicians from referring Medicare or Medicaid beneficiaries for certain services, including outpatient prescription drugs, to any entity with which the physician, or an immediate family member of the physician, has a financial relationship. The Stark Law further prohibits the entity receiving a prohibited referral from presenting a claim for reimbursement by Medicare or Medicaid for services furnished pursuant to the prohibited referral. Various states have enacted similar laws.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The ACA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The ACA significantly increased federal and state oversight of health plans. Among other requirements, it specifies minimum medical loss ratios (&#8220;MLRs&#8221;) for Commercial and Medicare Insured products, specifies features required to be included in commercial benefit designs, limits commercial individual and small group rating and pricing practices, encourages additional competition (including potential incentives for new participants to enter the marketplace), and includes regulations and processes that could delay or limit the Company&#8217;s ability to appropriately increase its health plan premium rates. This in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">turn could adversely affect the Company&#8217;s ability to continue to participate in certain product lines and/or geographies that it serves today.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety and issued an opinion preserving the ACA and its consumer protections in its current form. Even though the ACA was deemed constitutional, there may nevertheless be continued efforts to invalidate, modify, repeal or replace portions of it. In addition to litigation, parts of the ACA continue to evolve through the promulgation of executive orders, legislation, regulations and guidance at the federal or state level. The Company expects the ACA, including potential changes thereto, to continue to significantly impact its business operations and operating results, including pricing, medical benefit ratios (&#8220;MBRs&#8221;) and the geographies in which the Company&#8217;s products are available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, HHS issued a new proposed rule to significantly revise the agency&#8217;s prior interpretation of Section 1557 of the ACA. Section 1557 prohibits discrimination on the basis of race, color, national origin, sex, age, and disability in certain health programs and activities, and the proposed rule specifically includes sex stereotypes, sex characteristics, sexual orientation, gender identity and pregnancy or related conditions as bases for sex discrimination. The comment period on the proposed rule has closed but to date no final rule has been released.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medicare Regulation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Medicare Advantage products compete directly with Original Medicare and Medicare Advantage products offered by other Medicare Advantage organizations and Medicare Supplement products offered by other insurers. The Company&#8217;s Medicare PDP and Medicare Supplement products are products that Medicare beneficiaries who are enrolled in Original Medicare purchase to enhance their Original Medicare coverage.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to expand the number of counties in which it offers Medicare products. The Company has expanded its Medicare service area and products in 2022 and is seeking to substantially grow its Medicare membership, revenue and operating results over the next several years, including through growth in Medicare Supplement products. The anticipated organic expansion of the Medicare service area and Medicare products offered and the Medicare-related provisions of the ACA significantly increase the Company&#8217;s exposure to funding and regulation of, and changes in government policy with respect to and/or funding or regulation of, the various Medicare programs in which the Company participates, including changes in the amounts payable to us under those programs and/or new reforms or surcharges on existing programs. For example, the ACA requires minimum MLRs for Medicare Advantage and Medicare Part D plans of 85%. If a Medicare Advantage or Medicare Part D contract pays minimum MLR rebates for three consecutive years, it will become ineligible to enroll new members. If a Medicare Advantage or Medicare Part D contract pays such rebates for five consecutive years, it will be terminated by CMS. Due to potential lower utilization of medical services by Medicare beneficiaries during the COVID-19 pandemic, it is possible certain Medicare Advantage contracts may not meet the 85% MLR for consecutive years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Medicare Advantage and PDP products are heavily regulated by CMS. The regulations and contractual requirements applicable to the Company and other private participants in Medicare programs are complex, expensive to comply with and subject to change. For example, the Medicare Advantage Overpayment Rule, issued in 2014, implemented the ACA requirements that Medicare Advantage and PDP plans report and refund to CMS overpayments that those plans receive from CMS. Failure to notify overpayments to CMS could result in liability under the False Claims Act. The precise interpretation, impact and legality of this rule are subject to pending litigation. Payments the Company receives from CMS for its Medicare Advantage and Part D businesses also are subject to risk adjustment based on the health status of the individuals enrolled. Elements of that risk adjustment mechanism continue to be challenged by the U.S. Department of Justice (the &#8220;DOJ&#8221;), the Office of the Inspector General of the HHS (the &#8220;OIG&#8221;) and CMS itself. Substantial changes in the risk adjustment mechanism, including changes that result from enforcement or audit actions, could materially affect the amount of the Company&#8217;s Medicare reimbursement, require the Company to raise prices or reduce the benefits offered to Medicare beneficiaries, and potentially limit the Company&#8217;s (and the industry&#8217;s) participation in the Medicare program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has invested significant resources to comply with Medicare standards, and its Medicare compliance efforts will continue to require significant resources. CMS may seek premium and other refunds, prohibit the Company from continuing to market and/or enroll members in or refuse to passively enroll members in one or more of the Company&#8217;s Medicare or Medicare-Medicaid demonstration (historically known as &#8220;dual eligible&#8221;) plans, exclude us from participating in one or more Medicare, dual eligible or dual eligible special needs plan programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS regulations or its Medicare contractual requirements. The Company&#8217;s Medicare Supplement products are regulated at the state level and subject to similar significant compliance requirements and risks.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in November 2020, the HHS released the final Rebate Rule (the &#8220;Rebate Rule&#8221;), which eliminates the regulatory safe harbor from prosecution under the AKS for rebates from pharmaceutical companies to PBMs in Medicare Part D, replacing it with two far narrower safe harbors designed to directly benefit patients with high out-of-pocket costs and to change the way PBMs are compensated. The new safe harbors are (i) for rebates which are passed on to the patient at the point of sale and (ii) for flat service fee payments made to PBMs which cannot be tied to the list prices of drugs. It is unclear whether the Rebate Rule will be enforceable, whether pharmaceutical companies will respond by reducing list prices, whether list prices in the private market may also be reduced, and what the resulting impact will be to PBMs or the Company. The Pharmaceutical Care Management Association (the &#8220;PCMA&#8221;), which represents PBMs, has filed a suit in an effort to block the Rebate Rule, claiming that the Rebate Rule would lead to higher premiums in Medicare Part D and was adopted in an unlawful manner. The Bipartisan Infrastructure Act of 2021 delays the effective date of the rebate rule to January 2026, and the Inflation Reduction Act, enacted in August 2022, further delays the Rebate Rule through 2032.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the 2% Medicare sequester required by the Budget Control Act of 2011 resumed, meaning that Medicare claims incur a 2% reduction in Medicare payment. The sequester had been suspended during the COVID-19 pandemic.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going forward, the Company expects CMS, the OIG, the DOJ, other federal agencies and the U.S. Congress to continue to scrutinize closely each component of the Medicare program (including Medicare Advantage, PDPs, demonstration projects such as Medicare-Medicaid plans and provider network access and adequacy), modify the terms and requirements of the program and possibly seek to recast or limit private insurers&#8217; roles. It is also possible that Congress may consider changes to Medicare Advantage payment policies due to recent recommendations by the Medicare Payment Advisory Commission and to reduce the potential added cost burden of costly new benefits, or policies that impact drug pricing such as price controls and inflationary rebates applied to pharmaceutical manufacturers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not possible to predict the outcome of such regulatory or Congressional activity, any of which could materially and adversely affect the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medicare Audits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- CMS regularly audits the Company&#8217;s performance to determine its compliance with CMS&#8217;s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare Advantage and PDP beneficiaries. For example, CMS conducts risk adjustment data validation (&#8220;RADV&#8221;) audits of a subset of Medicare Advantage contracts for each contract year. Since 2011, CMS has selected certain of the Company&#8217;s Medicare Advantage contracts for various years for RADV audit, and the number of RADV audits continues to increase. The OIG also is auditing the Company&#8217;s risk adjustment data and that of other companies, and the Company expects CMS and the OIG to continue auditing risk adjustment data. The Company also has received Civil Investigative Demands (&#8220;CIDs&#8221;) from, and provided documents and information to, the Civil Division of the DOJ in connection with a current investigation of its patient chart review processes in connection with risk adjustment data submissions under Parts C and D of the Medicare program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2023, CMS released the final rule concerning Part C contract-level Risk Adjustment Data Validation Audits (the &#8220;RADV Audit Rule&#8221;). The RADV Audit Rule eliminated the application of a fee-for-service adjuster (&#8220;FFS Adjuster&#8221;) in contract-level RADV audits but continued the use of extrapolation in such audits of Medicare Advantage organizations. The FFS Adjuster that was announced in 2012 was to be used by CMS to determine a permissible level of payment error. By applying the FFS Adjuster, Medicare Advantage organizations would have been liable for repayments only to the extent that their extrapolated payment errors exceeded the error rate in Original Medicare, which could have impacted the extrapolated repayments to which Medicare Advantage organizations are subject. Under the RADV Audit Rule, CMS, in most cases, will conduct RADV audits for payment year 2018 and subsequent payment years using extrapolation without the application of a FFS Adjuster. The RADV Audit Rule may have potential adverse effects, which could be material, on the Company&#8217;s operating results, financial condition, and cash flows. CMS also has announced that it will not conduct RADV audits on all contracts; instead, it will only audit contracts it believes are at the highest risk for overpayments based on its statistical modeling.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medicare Star Ratings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A portion of each Medicare Advantage plan&#8217;s reimbursement is tied to the plan&#8217;s &#8220;star ratings.&#8221; The star rating system considers a variety of measures adopted by CMS, including quality of preventative services, chronic illness management, compliance and overall customer satisfaction. Only Medicare Advantage plans with an overall star rating of 4 or more stars (out of 5 stars) are eligible for a quality bonus in their basic premium rates. As a result, the Company&#8217;s Medicare Advantage plans&#8217; operating results in 2023 and going forward will be significantly affected by their star ratings. The Company&#8217;s star ratings and past performance scores are adversely affected by any compliance issues that may have arisen each year in its Medicare operations. CMS released the Company&#8217;s 2023 star ratings in October 2022. The Company&#8217;s 2023 star ratings will be used to determine which of its Medicare Advantage plans have ratings of 4 stars or higher and qualify for bonus payments in 2024. Based on the 2023 star ratings, the percentage of the Company&#8217;s Medicare Advantage members in 4 or more stars plans is expected to drop to 21% (based on enrollment and contract affiliation at December 31, 2022), as compared to 87% </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the 2022 star ratings. The main driver of this decrease was a 1 star decrease in the Company&#8217;s Aetna National PPO, which dropped from 4.5 to 3.5 stars, while many of the Company&#8217;s other plans remain rated at 4 or more stars. The decrease in the star rating for the Aetna National PPO will mean that it will no longer be eligible for CMS&#8217; quality bonus payments related to 2024, though the Company&#8217;s contract diversification efforts, which will partially mitigate certain adverse impacts associated with the decrease in the star rating for the Aetna National PPO, have received regulatory approval. CMS also gives PDPs star ratings that affect each PDP&#8217;s enrollment. Medicare Advantage and PDP plans that are rated less than 3 stars for three consecutive years are subject to contract termination by CMS. CMS continues to revise its star ratings system to make it harder to achieve 4 or more stars. There can be no assurances that the Company will be successful in maintaining or improving its star ratings in future years. Accordingly, the Company&#8217;s Medicare Advantage plans may not continue to be or become eligible for full level quality bonuses, which could adversely affect the benefits such plans can offer, reduce membership and/or reduce profit margins.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medicare Payment Rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In April 2022, CMS issued its final notice detailing final 2023 Medicare Advantage payment rates. Final 2023 Medicare Advantage rates resulted in an expected average increase in revenue for the Medicare Advantage industry of 5.00%, excluding the CMS estimate of Medicare Advantage risk score trend. On February 1, 2023, CMS issued an advance notice detailing proposed 2024 Medicare Advantage payment rates. The 2024 Medicare Advantage rates, if finalized as proposed, will result in an expected average decrease in revenue for the Medicare Advantage industry of 2.27%, excluding the CMS estimate of Medicare Advantage risk score trend. CMS intends to publish the final 2024 rate announcement no later than April 3, 2023. The federal government may seek to impose restrictions on the configuration of pharmacy or other provider networks for Medicare Advantage and/or PDP plans, or otherwise restrict the ability of these plans to alter benefits, negotiate prices or establish other terms to improve affordability or maintain viability of products. The Company currently believes that the payments it has received and will receive in the near term are adequate to justify the Company&#8217;s continued participation in the Medicare Advantage and PDP programs, although there are economic and political pressures to continue to reduce spending on the program, and this outlook could change.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">340B Drug Pricing Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; The 340B Drug Pricing Program allows eligible Covered Entities to purchase prescription drugs from manufacturers at a steep discount, and is overseen by the HHS and the Health Resources and Services Administration (&#8220;HRSA&#8221;). In 2020, a number of pharmaceutical manufacturers began programs that limited Covered Entities&#8217; participation in the program through contract pharmacies arrangements. In May 2021, HRSA sent enforcement letters to multiple manufacturers to curb these practices. In September 2021, HRSA forwarded the enforcement actions to the OIG for potential imposition of civil monetary penalties. Those enforcement actions are currently subject to ongoing litigation. In November 2022, HRSA issued proposed rules that would overhaul the 340B Drug Pricing Programs Administrative Dispute Resolution process. The revisions are designed to make the process more accessible by making it more expeditious and less formal, as well as more equitable by requiring fewer resources to participate. A reduction in Covered Entities&#8217; participation in contract pharmacy arrangements, as a result of the pending enforcement actions or otherwise, a reduction in the use of the Company&#8217;s administrative services by Covered Entities, or a reduction in drug manufacturers&#8217; participation in the program could materially and adversely affect the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Remuneration Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Federal law prohibits, among other things, an entity from knowingly and willfully offering, paying, soliciting or receiving, subject to certain exceptions and &#8220;safe harbors,&#8221; any remuneration to induce the referral of individuals or the purchase, lease or order of items or services for which payment may be made under Medicare, Medicaid or certain other federal and state health care programs. A number of states have similar laws, some of which are not limited to services paid for with government funds. Sanctions for violating these federal and state anti-remuneration laws may include imprisonment, criminal and civil fines, and exclusion from participation in Medicare, Medicaid and other federal and state government-sponsored health care programs. Companies involved in public health care programs such as Medicare and/or Medicaid are required to maintain compliance programs to detect and deter fraud, waste and abuse, and are often the subject of fraud, waste and abuse investigations and audits. The Company has invested significant resources to comply with Medicare and Medicaid program standards. Ongoing vigorous law enforcement and the highly technical regulatory scheme mean that the Company&#8217;s compliance efforts in this area will continue to require significant resources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust and Unfair Competition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The U.S. Federal Trade Commission (&#8220;FTC&#8221;) investigates and prosecutes practices that are &#8220;unfair trade practices&#8221; or &#8220;unfair methods of competition.&#8221; Numerous lawsuits have been filed throughout the United States against pharmaceutical manufacturers, retail pharmacies and/or PBMs under various federal and state antitrust and unfair competition laws challenging, among other things: (i) brand name drug pricing and rebate practices of pharmaceutical manufacturers, (ii) the maintenance of retail or specialty pharmacy networks by PBMs, and (iii) various other business practices of PBMs and retail pharmacies. In July 2021, the FTC approved several resolutions that direct agency staff to use compulsory process, such as subpoenas, to investigate seven specific enforcement priorities. Priority targets include, among other businesses, health care businesses, such as pharmaceutical companies, pharmacy benefits managers and hospitals. To the extent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the Company appears to have actual or potential market power in a relevant market or CVS pharmacy, CVS specialty or MinuteClinic plays a unique or expanded role in a Health Care Benefits or Pharmacy Services segment product offering, the Company&#8217;s business arrangements and uses of confidential information may be subject to heightened scrutiny from an anti-competitive perspective and possible challenge by state and/or federal regulators and/or private parties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Privacy and Confidentiality Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Many of the Company&#8217;s activities involve the receipt, use and disclosure by the Company of personally identifiable information (&#8220;PII&#8221;) as permitted in accordance with applicable federal and state privacy and data security laws, which require organizations to provide appropriate privacy and security safeguards for such information. In addition to PII, the Company uses and discloses de-identified data for analytical and other purposes when permitted. Additionally, there are industry standards for handling credit card data known as the Payment Card Industry Data Security Standard, which are a set of requirements designed to help ensure that entities that process, store or transmit credit card information maintain a secure environment. Certain states have incorporated these requirements into state laws or enacted other requirements relating to the use and/or disclosure of PII.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 and the regulations issued thereunder (collectively, &#8220;HIPAA&#8221;), as further modified by the American Recovery and Reinvestment Act of 2009 (&#8220;ARRA&#8221;) impose extensive requirements on the way in which health plans, providers, health care clearinghouses (known as &#8220;covered entities&#8221;) and their business associates use, disclose and safeguard protected health information (&#8220;PHI&#8221;). Further, ARRA requires the Company and other covered entities to report any breaches of PHI to impacted individuals and to the HHS and to notify the media in any states where 500 or more people are impacted by the unauthorized release or use of or access to PHI. Criminal penalties and civil sanctions may be imposed for failing to comply with HIPAA standards. The Health Information Technology for Economic and Clinical Health Act (the &#8220;HITECH Act&#8221;), enacted as part of ARRA, amended HIPAA to impose additional restrictions on third-party funded communications using PHI and the receipt of remuneration in exchange for PHI. The HITECH Act also extended HIPAA privacy and security requirements and penalties directly to business associates. HHS has begun to audit health plans, providers and other parties to enforce HIPAA compliance, including with respect to data security. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to HIPAA, state health privacy laws apply to the extent they are more protective of individual privacy than is HIPAA, including laws that place stricter controls on the release of information relating to specific diseases or conditions and requirements to notify members of unauthorized release or use of or access to PHI. States also have adopted regulations to implement provisions of the Financial Modernization Act of 1999 (also known as the Gramm-Leach-Bliley Act (&#8220;GLBA&#8221;)) which generally require insurers, including health insurers, to provide customers with notice regarding how their non-public personal health and financial information is used and the opportunity to &#8220;opt out&#8221; of certain disclosures before the insurer shares such information with a non-affiliated third party. Like HIPAA, GLBA sets a &#8220;floor&#8221; standard, allowing states to adopt more stringent requirements governing privacy protection. Complying with additional state requirements requires us to make additional investments beyond those the Company has made to comply with HIPAA and GLBA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cybersecurity Information Sharing Act of 2015 encourages organizations to share cyber threat indicators with the federal government and, among other things, directs HHS to develop a set of voluntary cybersecurity best practices for organizations in the health care industry. In addition, states have begun to enact more comprehensive privacy laws and regulations addressing consumer rights to data access, deletion, protection or transparency, such as the California Consumer Privacy Act (&#8220;CCPA&#8221;). States also are starting to issue regulations and proposed regulations specifically related to cybersecurity, such as the regulations issued by the New York Department of Financial Services. Complying with conflicting cybersecurity regulations, which may differ from state to state, requires significant resources. In addition, differing approaches to state privacy and/or cyber-security regulation and varying enforcement philosophies may materially and adversely affect the Company&#8217;s ability to standardize its products and services across state lines. Widely-reported large scale commercial data breaches in the United States and abroad increase the likelihood that additional data security legislation will be considered by additional states. These legislative and regulatory developments will impact the design and operation of the Company&#8217;s businesses, its privacy and security strategy and its web-based and mobile assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, each Public Exchange is required to adhere to privacy and security standards with respect to PII, and to impose privacy and security standards that are at least as protective of PII as those the Public Exchange has implemented for itself or non-Public Exchange entities, which include insurers offering plans through the Public Exchange and their designated downstream entities, including PBMs and other business associates. These standards may differ from, and be more stringent than, HIPAA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Protection Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The federal government has many consumer protection laws, such as the Federal Trade Commission Act, the Federal Postal Service Act and the Consumer Product Safety Act. Most states also have similar consumer protection laws and a growing number of states regulate subscription programs. In addition, the federal government and most states have adopted laws and/or regulations requiring places of public accommodation, health care services and other goods and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services to be accessible to people with disabilities. These consumer protection and accessibility laws and regulations have been the basis for investigations, lawsuits and multistate settlements relating to, among other matters, the marketing of loyalty programs, and health care products and services, pricing accuracy, expired front store products, financial incentives provided by drug manufacturers to pharmacies in connection with therapeutic interchange programs, disclosures related to how personal data is used and protected and the accessibility of goods and services to people with disabilities. As a result of the Company&#8217;s direct-to-consumer activities, including mobile and web-based solutions offered to members and to other consumers, the Company also is subject to federal and state regulations applicable to electronic communications and to other general consumer protection laws and regulations. For example, the CCPA became effective in 2020, and additional federal and state regulation of consumer privacy protection may be proposed or enacted in the future. The Company expects these new laws and regulations to impact the design of its products and services and the management and operation of its businesses and to increase its compliance costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transparency in Coverage Rule</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In October 2020, the HHS, the U.S. Department of Labor (&#8220;DOL&#8221;) and the U.S. Internal Revenue Service (&#8220;IRS,&#8221; and together with the HHS and DOL, the &#8220;Tri-Departments&#8221;) released a final rule requiring health insurers to disclose negotiated prices of drugs, medical services, supplies and other covered items. The rule requires group health plans and health insurance issuers in the individual and group markets to disclose cost-sharing information upon request, to a participant, beneficiary, or enrollee and require plans and issuers to publicly disclose in-network provider rates, historical out-of-network allowed amounts and the associated billed charges, and negotiated rates and historical net prices for prescription drugs. Insurers are required to implement a consumer tool and disclose data in a machine readable file. In August 2021, the federal government delayed enforcement of the requirement to publish machine-readable files related to prescription drug pricing until further rulemaking occurs. The public disclosure of insurer- or PBM-negotiated price concessions may result in drug manufacturers lowering discounts or rebates, resulting in higher drug costs for patients and impacting the ability of the Company to negotiate drug prices and provide competitive products and services to consumers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Consolidated Appropriations Act of 2021 was signed into law in December 2020 and contains further transparency provisions requiring group health plans and health insurance issuers to report certain prescription drug costs, overall spending on health services and prescription drugs, and information about premiums and the impact of rebates and other remuneration on premiums and out-of-pocket costs to the Tri-Departments. No later than 18 months after the first submission and bi-annually thereafter, the Tri-Departments will release a public report on drug pricing trends, drug reimbursement, and the impact of drug prices on premiums. The first filings of plan year data were required in December 2022 and will be required annually in June of each year on an ongoing basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Telemarketing and Other Outbound Contacts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Certain federal and state laws, such as the Telephone Consumer Protection Act and the Telemarketing Sales Rule, give the FTC, the Federal Communications Commission and state Attorneys General the ability to regulate, and bring enforcement actions relating to, telemarketing practices and certain automated outbound contacts such as phone calls, texts or emails. Under certain circumstances, these laws provide consumers with a private right of action. Violations of these laws could result in substantial statutory penalties and other sanctions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmacy and Professional Licensure and Regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company is subject to a variety of intersecting federal and state statutes and regulations that govern the wholesale distribution of drugs; operation of retail, specialty, infusion, LTC and mail order pharmacies; licensure of facilities and professionals, including pharmacists, technicians, nurses and other health care professionals; registration of facilities with the U.S. Drug Enforcement Administration (the &#8220;DEA&#8221;) and analogous state agencies that regulate controlled substances; packaging, storing, shipping and tracking of pharmaceuticals; repackaging of drug products; labeling, medication guides and other consumer disclosures; interactions with prescribers and health care professionals; compounding of prescription medications; dispensing of controlled and non-controlled substances; counseling of patients; transfers of prescriptions; advertisement of prescription products and pharmacy services; security; inventory control; recordkeeping; reporting to Boards of Pharmacy, the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), the U.S. Consumer Product Safety Commission, the DEA and related state agencies; and other elements of pharmacy practice. Pharmacies are highly regulated and have contact with a wide variety of federal, state and local agencies with various powers to investigate, inspect, audit or solicit information, including Boards of Pharmacy and Nursing, the DEA, the FDA, the DOJ, HHS and others. Many of these agencies have broad enforcement powers, conduct audits on a regular basis, can impose substantial fines and penalties, and may revoke the license, registration or program enrollment of a facility or professional. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State Insurance, HMO and Insurance Holding Company Regulation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of states regulate affiliated groups of insurers and HMOs such as the Company under holding company statutes. These laws may, among other things, require prior regulatory approval of dividends and material intercompany transfers of assets and transactions between the regulated companies and their affiliates, including their parent holding companies. The Company expects the states in which its insurance and HMO subsidiaries are licensed to continue to expand their regulation of the corporate governance and internal control </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities of its insurance companies and HMOs. Changes to state insurance, HMO and/or insurance holding company laws or regulations or changes to the interpretation of those laws or regulations, including due to regulators&#8217; increasing concerns regarding insurance company and/or HMO solvency due, among other things, to past and expected payor insolvencies, could negatively affect the Company&#8217;s businesses in various ways, including through increases in solvency fund assessments, requirements that the Company hold greater levels of capital and/or delays in approving dividends from regulated subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PBM offerings of prescription drug coverage under certain risk arrangements may be subject to laws and regulations in various states. Such laws may require that the party at risk become licensed as an insurer, establish reserves or otherwise demonstrate financial viability. Laws that may apply in such cases include insurance laws and laws governing MCOs and limited prepaid health service plans. In addition, several states require that PBMs become directly registered or licensed with the department of insurance or similar government oversight agency regardless of any arrangements they have with clients. PBM licensure laws may include oversight of certain PBM activities and operations and may include auditing of those activities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The states of domicile of the Company&#8217;s regulated subsidiaries have statutory risk-based capital (&#8220;RBC&#8221;) requirements for health and other insurance companies and HMOs based on the National Association of Insurance Commissioners&#8217; (the &#8220;NAIC&#8221;) Risk-Based Capital for Insurers Model Act (the &#8220;RBC Model Act&#8221;). These RBC requirements are intended to assess the capital adequacy of life and health insurers and HMOs, taking into account the risk characteristics of a company&#8217;s investments and products. The RBC Model Act sets forth the formula for calculating RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual company&#8217;s business. In general, under these laws, an insurance company or HMO must submit a report of its RBC level to the insurance department or insurance commissioner of its state of domicile for each calendar year. At December&#160;31, 2022, the RBC level of each of the Company&#8217;s insurance and HMO subsidiaries was above the level that would require regulatory action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding restrictions on certain payments of dividends or other distributions by the Company&#8217;s HMO and insurance company subsidiaries, see Note 12 &#8216;&#8216;Shareholders&#8217; Equity&#8217;&#8217; included in Item 8 of this 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holding company laws for the states of domicile of certain of the Company&#8217;s subsidiaries also restrict the ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. Under those statutes, without such approval (or an exemption), no person may acquire any voting security of an insurance holding company (such as the Company&#8217;s ultimate parent company, CVS Health Corporation) that controls an insurance company or HMO, or merge with such a holding company, if as a result of such transaction such person would control the insurance holding company. Control is generally defined as the direct or indirect power to direct or cause the direction of the management and policies of a person and is presumed to exist if a person directly or indirectly owns or controls 10% or more of the voting securities of another person.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states have laws that prohibit submitting a false claim or making a false record or statement in order to secure reimbursement from an insurance company. These state laws vary, and violation of them may lead to the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreements and Mandates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - From time to time, the Company and/or its various affiliates are subject to certain consent decrees, settlement and other agreements, corrective action plans and corporate integrity agreements with various federal, state and local authorities relating to such matters as privacy practices, controlled substances, PDPs, expired products, environmental and safety matters, marketing and advertising practices, PBM, LTC and other pharmacy operations and various other business practices. Certain of these agreements contain ongoing reporting, monitoring and/or other compliance requirements for the Company. Failure to meet the Company&#8217;s obligations under these agreements could result in civil or criminal remedies, financial penalties, administrative remedies, and/or exclusion from participation in federal health care programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental and Safety Regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company&#8217;s businesses are subject to various federal, state and local laws, regulations and other requirements pertaining to protection of the environment, public health and employee safety, including, for example, regulations governing the management of hazardous substances, the cleaning up of contaminated sites, and the maintenance of safe working conditions in the Company&#8217;s retail locations, distribution centers and other facilities. Governmental agencies at the federal, state and local levels continue to focus on the retail and health care sectors&#8217; compliance with such laws and regulations, and have at times pursued enforcement activities. Any failure to comply with these regulations could result in fines or other sanctions by government authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ERISA Regulation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;), provides for comprehensive federal regulation of certain employee pension and benefit plans, including private employer and union sponsored health plans and certain other plans that contract with us to provide PBM services. In general, the Company assists plan sponsors in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administration of their health benefit plans, including the prescription drug benefit portion of those plans, in accordance with the plan designs adopted by the plan sponsors. In addition, the Company may have fiduciary duties where it has specifically contracted with a plan sponsor to accept limited fiduciary responsibility, such as for the adjudication of initial prescription drug benefit claims and/or the appeals of denied claims under a plan. In addition to its fiduciary provisions, ERISA imposes civil and criminal liability on service providers to health plans and certain other persons if certain forms of illegal remuneration are made or received. These provisions of ERISA are broadly written and their application to specific business practices is often uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s health and related benefits and large case pensions products and services and related fees also are subject to potential issues raised by judicial interpretations relating to ERISA. Under those interpretations, together with DOL regulations, the Company may have ERISA fiduciary duties with respect to medical members, PBM members and/or certain general account assets held under contracts that are not guaranteed benefit policies. As a result, certain transactions related to those general account assets are subject to conflict of interest and other restrictions, and the Company must provide certain disclosures to policyholders annually. The Company must comply with these restrictions or face substantial penalties. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preemption</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - ERISA generally preempts all state and local laws that relate to employee benefit plans, but the extent of the preemption continues to be reviewed by courts, including the U.S. Supreme Court. For example, in December 2020, the U.S. Supreme Court upheld an Arkansas law that, among other things, mandates a particular pricing methodology, establishes an appeals process for a pharmacy when the reimbursement is below the pharmacy&#8217;s acquisition cost, permits a pharmacy to reverse and rebill if they cannot procure the drug from its wholesaler at a price equal to or less than the reimbursement rate, prohibits a PBM from reimbursing a pharmacy less than the amount it reimburses an affiliate on a per unit basis, and permits a pharmacy to decline to dispense if the reimbursement is lower than the pharmacy&#8217;s acquisition cost. Subsequently, in November 2021, the U.S. Court of Appeals for the Eighth Circuit upheld a North Dakota law that regulates employer-sponsored ERISA health plans and certain PBM practices within Medicare and in April 2022 the U.S. District Court for the Western District of Oklahoma affirmed that the Oklahoma Insurance Department could enforce a state law against PBMs that contained provisions that alter and limit some of the options that an ERISA plan can use, because none of the provisions mandate that ERISA plans make any specific choices. Additional litigation has been filed in several states to challenge ERISA and Medicare Part D preemption.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Legislative Initiatives and Regulatory Initiatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The U.S. federal and state governments, as well as governments in other countries where the Company does business, continue to enact and seriously consider many broad-based legislative and regulatory proposals that have had a material impact on or could materially impact various aspects of the health care and related benefits system and the Company&#8217;s businesses, operating results and/or cash flows. For example:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012 significant, automatic across-the-board budget cuts (known as sequestration) began in March 2013, including Medicare spending cuts of not more than 2% of total program costs per year through 2024. Since then, Congress has extended and modified the Medicare sequester a number of times. The CARES Act temporarily suspended the Medicare sequester and extended mandatory sequestration to 2030. In July 2022, the 2% Medicare sequester resumed. Significant uncertainty remains as to whether and how the U.S. Congress will proceed with actions that create additional federal revenue and/or with entitlement reform. The Company cannot predict future federal Medicare or federal or state Medicaid funding levels or the impact that future federal or state budget actions or entitlement program reform, if it occurs, will have on the Company&#8217;s businesses, operations or operating results, but the effects could be materially adverse, particularly on the Company&#8217;s Medicare and/or Medicaid revenues, MBRs and operating results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The European Union&#8217;s (&#8220;EU&#8217;s&#8221;) General Data Protection Regulation (&#8220;GDPR&#8221;) began to apply across the EU during 2018.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other significant legislative and/or regulatory measures which are or recently have been under consideration include the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasing the corporate tax rate.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Eliminating payment of manufacturer&#8217;s rebates on prescription drugs to PBMs, PDPs and Managed Medicaid organizations in connection with federally funded health care programs. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposing requirements and restrictions on the design and/or administration of pharmacy benefit plans offered by the Company&#8217;s and its clients&#8217; health plans and/or its PBM clients and/or the services the Company provides to those clients, including prohibiting &#8220;differential&#8221; or &#8220;spread&#8221; pricing in PBM contracts; restricting or eliminating the use of formularies for prescription drugs; restricting the Company&#8217;s ability to require members to obtain drugs through a home delivery or specialty pharmacy; restricting the Company&#8217;s ability to place certain specialty or other drugs in the higher cost tiers of its pharmacy formularies; restricting the Company&#8217;s ability to make changes to drug formularies and/or clinical programs; limiting or eliminating rebates on pharmaceuticals; requiring the use of up front purchase price discounts on pharmaceuticals in lieu of rebates; restricting the Company&#8217;s ability to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">configure and reimburse its health plan and retail pharmacy provider networks, including use of CVS pharmacy locations; and restricting or eliminating the use of certain drug pricing methodologies.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasing federal or state government regulation of, or involvement in, the pricing and/or purchasing of drugs.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricting the Company&#8217;s ability to limit providers&#8217; participation in its networks and/or remove providers from its networks by imposing network adequacy requirements or otherwise (including in its Medicare and Commercial Health Care Benefits products).</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposing assessments on (or to be collected by) health plans or health carriers that may or may not be passed through to their customers. These assessments may include assessments for insolvency, the uninsured, uncompensated care, Medicaid funding or defraying health care provider medical malpractice insurance costs.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandating coverage by the Company&#8217;s and its clients&#8217; health plans for additional conditions and/or specified procedures, drugs or devices (e.g., high cost pharmaceuticals, experimental pharmaceuticals and oral chemotherapy regimens).</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulating electronic connectivity.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandating or regulating the disclosure of provider fee schedules, manufacturer&#8217;s rebates and other data about the Company&#8217;s payments to providers and/or payments the Company receives from pharmaceutical manufacturers.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandating or regulating disclosure of provider outcome and/or efficiency information.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prescribing or limiting members&#8217; financial responsibility for health care or other covered services they utilize, including restricting &#8220;surprise&#8221; bills by providers and by specifying procedures for resolving &#8220;surprise&#8221; bills.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prescribing payment levels for health care and other covered services rendered to the Company&#8217;s members by providers who do not have contracts with the Company.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assessing the medical device status of home infusion therapy products and/or solutions, mobile consumer wellness tools and clinical decision support tools, which may require compliance with FDA requirements in relation to some of these products, solutions and/or tools.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricting the ability of employers and/or health plans to establish or impose member financial responsibility.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Proposals to expand benefits under Original Medicare.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amending or supplementing ERISA to impose greater requirements on PBMs or the administration of employer-funded benefit plans or limit the scope of current ERISA pre-emption, which would among other things expose the Company and other health plans to expanded liability for punitive and other extra-contractual damages and additional state regulation.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is uncertain whether the Company can counter the potential adverse effects of such potential legislation or regulation on its operating results or cash flows, including whether it can recoup, through higher premium rates, expanded membership or other measures, the increased costs of mandated coverage or benefits, assessments, fees, taxes or other increased costs, including the cost of modifying its systems to implement any enacted legislation or regulations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s businesses also may be affected by other legislation and regulations. The Dodd-Frank Wall Street Reform and Consumer Protection Act creates incentives for whistleblowers to speak directly to the government rather than utilizing internal compliance programs and reduces the burden of proof under the Foreign Corrupt Practices Act of 1977 (the &#8220;FCPA&#8221;). There also are laws and regulations that set standards for the escheatment of funds to states.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health savings accounts, health reimbursement arrangements and flexible spending accounts and certain of the tax, fee and subsidy provisions of the ACA also are regulated by the U.S. Department of the Treasury and the IRS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also may be adversely affected by court and regulatory decisions that expand or revise the interpretations of existing statutes and regulations or impose medical malpractice or bad faith liability. Federal and state courts, including the U.S. Supreme Court, continue to consider cases, and federal and state regulators continue to issue regulations and interpretations, addressing bad faith liability for denial of medical claims, the scope of ERISA&#8217;s fiduciary duty requirements, the scope of the False Claims Act and the pre-emptive effect of ERISA and Medicare Part D on state laws.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Audits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The Company is subject to audits of many of its contracts, including its PBM client contracts, its PBM rebate contracts, its PBM network contracts, its contracts relating to Medicare Advantage and/or Medicare Part D, the agreements the Company&#8217;s pharmacies enter into with other payors, its Medicaid contracts and its customer contracts. Because some of the Company&#8217;s contracts are with state or federal governments or with entities contracted with state or federal agencies, audits of these contracts are often regulated by the federal or state agencies responsible for administering federal or state </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits programs, including those which operate Medicaid fee for service plans, Managed Medicaid plans, Medicare Part D plans or Medicare Advantage organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Federal Employee Health Benefits Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The Company&#8217;s subsidiaries contract with the Office of Personnel Management (the &#8220;OPM&#8221;) to provide managed health care services under the FEHB program in their service areas. These contracts with the OPM and applicable government regulations establish premium rating arrangements for this program. In addition to other requirements, such as the Transparency in Coverage Rule note above, OPM regulations require that community-rated FEHB plans meet a FEHB program-specific minimum MLR by plan code and market. Managing to these rules is complicated by the simultaneous application of the minimum MLR standards and associated premium rebate requirements of the ACA. The Company also has a contractual arrangement with carriers for the FEHB program, such as the BlueCross BlueShield Association, to provide pharmacy services to federal employees, postal workers, annuitants, and their dependents under the Government-wide Service Benefit Plan, as authorized by the FEHB Act and as part of the FEHB program. Additionally, the Company manages certain FEHB plans on a &#8220;cost-plus&#8221; basis. These arrangements subject the Company to certain aspects of the FEHB Act, and other federal regulations, such as the FEHB Acquisition Regulation, that otherwise would not be applicable to the Company. The OPM also is auditing the Company and its other contractors to, among other things, verify that plans meet their applicable FEHB program-specific MLR and the premiums established under the OPM&#8217;s Insured contracts and costs allocated pursuant to the OPM&#8217;s cost-based contracts are in compliance with the requirements of the applicable FEHB program. The OPM may seek premium refunds or institute other sanctions against the Company if it fails to comply with the FEHB program requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Services Regulation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The Company provides clinical services to health plans, PBMs and providers for a variety of complex and common medical conditions, including arranging for certain members to participate in disease management programs. State laws regulate the practice of medicine, the practice of pharmacy, the practice of nursing and certain other clinical activities. Clinicians engaged in a professional practice in connection with the provision of clinical services must satisfy applicable state licensing requirements and must act within their scope of practice.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Party Administration and Other State Licensure Laws </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Many states have licensure or registration laws governing certain types of administrative organizations, such as PPOs, TPAs and companies that provide utilization review services. Several states also have licensure or registration laws governing the organizations that provide or administer consumer card programs (also known as cash card or discount card programs).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">International Regulation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has insurance licenses in several foreign jurisdictions and does business directly or through local affiliations in numerous countries around the world. The Company has taken steps to be able to continue to serve customers in the European Economic Area following the United Kingdom&#8217;s exit from the EU (&#8220;Brexit&#8221;).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s international operations are subject to different, and sometimes more stringent, legal and regulatory requirements, which vary widely by jurisdiction, including anti-corruption laws; economic sanctions laws; various privacy, insurance, tax, tariff and trade laws and regulations; corporate governance, privacy, data protection (including the EU&#8217;s General Data Protection Regulation which began to apply across the EU during 2018), data mining, data transfer, labor and employment, intellectual property, consumer protection and investment laws and regulations; discriminatory licensing procedures; compulsory cessions of reinsurance; required localization of records and funds; higher premium and income taxes; limitations on dividends and repatriation of capital; and requirements for local participation in an insurer&#8217;s ownership. In addition, the presence of operations in foreign countries potentially increases the Company&#8217;s exposure to the anti-bribery, anti-corruption and anti-money laundering provisions of U.S. law, including the FCPA, and corresponding foreign laws, including the U.K. Bribery Act 2010 (the &#8220;UK Bribery Act&#8221;). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Corruption Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The FCPA prohibits offering, promising or authorizing others to give anything of value to a foreign government official to obtain or retain business or otherwise secure a business advantage. The Company also is subject to applicable anti-corruption laws of the jurisdictions in which it operates. In many countries outside the United States, health care professionals are employed by the government. Therefore, the Company&#8217;s dealings with them are subject to regulation under the FCPA. Violations of the FCPA and other anti-corruption laws may result in severe criminal and civil sanctions as well as other penalties, and there continues to be a heightened level of FCPA enforcement activity by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and the DOJ. The UK Bribery Act is an anti-corruption law that is broader in scope than the FCPA and applies to all companies with a nexus to the United Kingdom. Disclosures of FCPA violations may be shared with the UK authorities, thus potentially exposing companies to liability and potential penalties in multiple jurisdictions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Money Laundering Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Certain lines of the Company&#8217;s businesses are subject to Treasury anti-money laundering regulations. Those lines of business have implemented anti-money laundering policies designed to ensure their </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance with the regulations. The Company also is subject to anti-money laundering laws in non-U.S. jurisdictions where it operates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Office of Foreign Assets Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company also is subject to regulation by the Office of Foreign Assets Control of the U.S. Department of Treasury (&#8220;OFAC&#8221;). OFAC administers and enforces economic and trade sanctions based on U.S. foreign policy and national security goals against targeted foreign countries and regimes, terrorists, international narcotics traffickers, those engaged in activities related to the proliferation of weapons of mass destruction, and other threats to the national security, foreign policy or economy of the United States. In addition, the Company is subject to similar regulations in the non-U.S. jurisdictions in which it operates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FDA Regulation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the Company&#8217;s compounding pharmacy and clinical research operations. The FDA also generally has authority to, among other things, regulate the manufacture, distribution, sale and labeling of medical devices (including hemodialysis devices such as the device the Company is developing and mobile medical devices) and many products sold through retail pharmacies, including prescription drugs, over-the-counter medications, cosmetics, dietary supplements and certain food items. In addition, the FDA regulates the Company&#8217;s activities as a distributor of store brand products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations Related to the Health Care Benefits Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the laws and regulations discussed above that may affect multiple segments of the Company&#8217;s business, the Company is subject to federal, state, local and international statutes and regulations governing its Health Care Benefits segment specifically. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Differing approaches to state insurance regulation and varying enforcement philosophies may materially and adversely affect the Company&#8217;s ability to standardize its Health Care Benefits products and services across state lines. These laws and regulations, including the ACA, restrict how the Company conducts its business and result in additional burdens and costs to the Company. Significant areas of governmental regulation include premium rates and rating methodologies, underwriting rules and procedures, required benefits, sales and marketing activities, provider rates of payment, restrictions on health plans&#8217; ability to limit providers&#8217; participation in their networks and/or remove providers from their networks and financial condition (including reserves and minimum capital or risk based capital requirements). These laws and regulations are different in each jurisdiction and vary from product to product.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each health insurer and HMO must file periodic financial and operating reports with the states in which it does business. In addition, health insurers and HMOs are subject to state examination and periodic license renewal. Applicable laws also restrict the ability of the Company&#8217;s regulated subsidiaries to pay dividends, and certain dividends require prior regulatory approval. In addition, some of the Company&#8217;s businesses and related activities may be subject to PPO, MCO, utilization review or TPA-related licensure requirements and regulations. These licensure requirements and regulations differ from state to state, but may contain provider network, contracting, product and rate, financial and reporting requirements. There also are laws and regulations that set specific standards for the Company&#8217;s delivery of services, payment of claims, fraud prevention, protection of consumer health information, and payment for covered benefits and services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required Regulatory Approvals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company must obtain and maintain regulatory approvals to price, market and administer many of its Health Care Benefits products. Supervisory agencies, including CMS, the Center for Consumer Information and Insurance Oversight and the DOL, as well as state health, insurance, managed care and Medicaid agencies, have broad authority to take one or more of the following actions:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Grant, suspend and revoke the Company&#8217;s licenses to transact business;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspend or exclude the Company from participation in government programs;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspend or limit the Company&#8217;s authority to market products;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulate many aspects of the products and services the Company offers, including the pricing and underwriting of many of its products and services;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assess damages, fines and/or penalties;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Terminate the Company&#8217;s contract with the government agency and/or withhold payments from the government agency to the Company;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impose retroactive adjustments to premiums and require the Company to pay refunds to the government, customers and/or members;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrict the Company&#8217;s ability to conduct acquisitions or dispositions;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Require the Company to maintain minimum capital levels in its subsidiaries and monitor its solvency and reserve adequacy;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulate the Company&#8217;s investment activities on the basis of quality, diversification and other quantitative criteria; and/or</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Exclude the Company&#8217;s plans from participating in Public Exchanges if they are deemed to have a history of &#8220;unreasonable&#8221; premium rate increases or fail to meet other criteria set by HHS or the applicable state.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations, current and past business practices, current and past contracts, and accounts and other books and records are subject to routine, regular and special investigations, audits, examinations and reviews by, and from time to time the Company receives subpoenas and other requests for information from, federal, state and international supervisory and enforcement agencies, Attorneys General and other state, federal and international governmental authorities and legislators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Product Pricing and Underwriting Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Pricing and underwriting regulation by states limits the Company&#8217;s underwriting and rating practices and those of other health insurers, particularly for small employer groups, and varies by state. In general, these limitations apply to certain customer segments and limit the Company&#8217;s ability to set prices for new or renewing groups, or both, based on specific characteristics of the group or the group&#8217;s prior claim experience. In some states, these laws and regulations restrict the Company&#8217;s ability to price for the risk it assumes and/or reflect reasonable costs in the Company&#8217;s pricing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA expanded the premium rate review process by, among other things, requiring the Company&#8217;s Commercial Insured rates to be reviewed for &#8220;reasonableness&#8221; at either the state or the federal level. HHS established a federal premium rate review process that generally applies to proposed premium rate increases equal to or exceeding a federally (or lower state) specified threshold. HHS&#8217;s rate review process imposes additional public disclosure requirements as well as additional review on filings requesting premium rate increases equal to or exceeding this &#8220;reasonableness&#8221; threshold. These combined state and federal review requirements may prevent, further delay or otherwise affect the Company&#8217;s ability to price for the risk it assumes, which could adversely affect its MBRs and operating results, particularly during periods of increased utilization of medical services and/or medical cost trend or when such utilization and/or trend exceeds the Company&#8217;s projections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA also specifies minimum MLRs of 85% for large group Commercial products and 80% for individual and small group Commercial products. Because the ACA minimum MLRs are structured as &#8220;floors&#8221; for many of their requirements, states have the latitude to enact more stringent rules governing these restrictions. For Commercial products, states have and may adopt higher minimum MLR requirements, use more stringent definitions of &#8220;medical loss ratio,&#8221; incorporate minimum MLR requirements into prospective premium rate filings, require prior approval of premium rates or impose other requirements related to minimum MLR. Minimum MLR requirements and similar actions further limit the level of margin the Company can earn in its Insured Commercial products while leaving the Company exposed to medical costs that are higher than those reflected in its pricing. The Company also may be subject to significant fines, penalties, premium refunds and litigation if it fails to comply with minimum MLR laws and regulations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company requested increases in its premium rates in its Commercial Health Care Benefits business for 2023 and expects to request future increases in those rates in order to adequately price for projected medical cost trends, required expansions of coverage and rating limits, and significant assessments, fees and taxes imposed by the federal and state governments, including as a result of the ACA. The Company&#8217;s rates also must be adequate to reflect adverse selection in its products, particularly in small group Commercial products. These rate increases may be significant and thus heighten the risks of adverse publicity, adverse regulatory action and adverse selection and the likelihood that the Company&#8217;s requested premium rate increases will be denied, reduced or delayed, which could lead to operating margin compression.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the laws and regulations governing the Company&#8217;s pricing and underwriting practices also limit the differentials in premium rates insurers and other carriers may charge between new and renewal business, and/or between groups based on differing characteristics. They may also require that carriers disclose to customers the basis on which the carrier establishes new business and renewal premium rates and limit the ability of a carrier to terminate customers&#8217; coverage. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medicaid Regulation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is seeking to substantially grow its Medicaid, dual eligible and dual eligible special needs plan businesses over the next several years. As a result, the Company also is increasing its exposure to changes in government policy with respect to and/or regulation of the various Medicaid, dual eligible and dual eligible special needs plan programs in which the Company participates, including changes in the amounts payable to the Company under those programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to a quality rating system that applies to Medicaid and Managed Medicaid plans, federal regulations give states the option to choose to establish a minimum MLR of at least 85% for their Managed Medicaid plans, including those offered by the Company. Regardless of whether a state establishes a minimum MLR, it must use plan-reported MLR data to set future </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment rates for managed care, so that its plans will &#8220;reasonably achieve&#8221; an MLR of at least 85%. For Managed Medicaid products, states may use more stringent definitions of &#8220;medical loss ratio&#8221;, use discretion in choosing a quantitative standard for determining provider network adequacy, or impose other requirements related to minimum MLR. Minimum MLR requirements and similar actions further limit the level of margin the Company can earn in its Insured Medicaid products while leaving the Company exposed to medical costs that are higher than those reflected in its pricing. The Company also may be subject to significant fines, penalties, premium refunds and litigation if it fails to comply with minimum MLR laws and regulations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States continue to consider Medicaid expansion; however, to date 12 states have not expanded, which will drop to 11 states once South Dakota&#8217;s expansion takes effect in July 2023. States may opt out of the elements of the ACA requiring expansion of Medicaid coverage without losing their current federal Medicaid funding. In addition, the election of new Governors and/or state legislatures may impact states&#8217; previous decisions regarding Medicaid expansion. Although Congress enacted incentives for states that had not yet done so to expand Medicaid, this incentive alone may not persuade holdout states to expand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Medicaid MCOs faced new requirements and state flexibility that were finalized in the 2020 Medicaid managed care final rule. States now have flexibility related to rate setting and provider network adequacy that could adversely or positively impact our Medicaid plans. Other changes related to managed care operations include beneficiary communications, appeals and grievances, and provider directories.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economic aspects of the Medicaid, dual eligible and dual eligible special needs plan business vary from state to state and are subject to frequent change. Medicaid premiums are paid by each state and differ from state to state. The federal government and certain states also are considering proposals and legislation for Medicaid and dual eligible program reforms or redesigns, including restrictions on the collection of manufacturer&#8217;s rebates on pharmaceuticals by Medicaid MCOs and their contracted PBMs, further program, population and/or geographic expansions of risk-based managed care, increasing beneficiary cost-sharing or payment levels, and changes to benefits, reimbursement, eligibility criteria, provider network adequacy requirements (including requiring the inclusion of specified high cost providers in the Company&#8217;s networks) and program structure. In some states, current Medicaid and dual eligible funding and premium revenue may not be adequate for the Company to continue program participation. The Company&#8217;s Medicaid and dual eligible contracts with states (or sponsors of Medicaid managed care plans) are subject to cancellation by the state (or the sponsors of the managed care plans) after a short notice period without cause (e.g., when a state discontinues a managed care program) or in the event of insufficient state funding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Medicaid, dual eligible and dual eligible special needs plan products also are heavily regulated by CMS and state Medicaid agencies, which have the right to audit the Company&#8217;s performance to determine compliance with CMS contracts and regulations. The Company&#8217;s Medicaid products, dual eligible products and CHIP contracts also are subject to complex federal and state regulations and oversight by state Medicaid agencies regarding the services provided to Medicaid enrollees, payment for those services, network requirements (including mandatory inclusion of specified high-cost providers), and other aspects of these programs, and by external review organizations which audit Medicaid plans on behalf of state Medicaid agencies. The laws, regulations and contractual requirements applicable to the Company and other participants in Medicaid and dual eligible programs, including requirements that the Company submit encounter data to the applicable state agency, are extensive, complex and subject to change. The Company has invested significant resources to comply with these standards, and its Medicaid and dual eligible program compliance efforts will continue to require significant resources. CMS and/or state Medicaid agencies may fine the Company, withhold payments to the Company, seek premium and other refunds, terminate the Company&#8217;s existing contracts, elect not to award the Company new contracts or not to renew the Company&#8217;s existing contracts, prohibit the Company from continuing to market and/or enroll members in or refuse to automatically assign members to one or more of the Company&#8217;s Medicaid or dual eligible products, exclude the Company from participating in one or more Medicaid or dual eligible programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS or state regulations or contractual requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the Medicaid program, nor can it predict the impact those changes will have on its business operations or operating results, but the effects could be materially adverse.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Federal and State Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The Company is subject to extensive financial and business reporting requirements, including penalties for inaccuracies and/or omissions, at both the federal and state level. The Company&#8217;s ability to comply with certain of these requirements depends on receipt of information from third parties that may not be readily available or reliably provided in all instances. The Company is and will continue to be required to modify its information systems, dedicate significant resources and incur significant expenses to comply with these requirements. However, the Company cannot eliminate the risks of unavailability of or errors in its reports.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Design and Administration and Sales Practices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - State and/or federal regulatory scrutiny of health care benefit product design and administration and marketing and advertising practices, including the filing of insurance policy forms, the adequacy of provider networks, the accuracy of provider directories, and the adequacy of disclosure regarding products and their administration, is increasing as are the penalties being imposed for inappropriate practices. Medicare, Medicaid and dual eligible products and products offering more limited benefits in particular continue to attract increased regulatory scrutiny.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guaranty Fund Assessments/Solvency Protection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers as well as health insurers. The Company&#8217;s assessments generally are based on a formula relating to the Company&#8217;s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payors such as not-for-profit consumer governed health plans established under the ACA. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations Related to the Pharmacy Services Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the laws and regulations discussed above that may affect multiple segments of the Company&#8217;s business, the Company is subject to federal, state and local statutes and regulations governing the operation of its Pharmacy Services segment specifically. Among these are the following:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PBM Laws and Regulation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Legislation and/or regulations seeking to regulate PBM activities in a comprehensive manner have been proposed or enacted in a majority of states. This legislation could adversely affect the Company&#8217;s ability to conduct business on commercially reasonable terms in states where the legislation is in effect and the Company&#8217;s ability to standardize its PBM products and services across state lines. In addition, certain quasi-regulatory organizations, including the National Association of Boards of Pharmacy and the National Council of Insurance Legislators, have issued model regulations or may propose future regulations concerning PBMs and/or PBM activities. Similarly, credentialing organizations such as URAC have established voluntary standards regarding PBM, mail order pharmacy and/or specialty pharmacy activities. While the actions of these quasi-regulatory or standard-setting organizations do not have the force of law, they may influence states to adopt their requirements or recommendations and influence client requirements for PBM, mail order pharmacy and/or specialty pharmacy services. Moreover, any standards established by these organizations could also impact the Company&#8217;s health plan clients and/or the services provided to those clients and/or the Company&#8217;s health plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s PBM activities also are regulated directly and indirectly at the federal and state levels, including being subject to the False Claims Act and state false claims acts and the AKS and state anti-kickback laws. These laws and regulations govern, and proposed legislation and regulations may govern and/or further restrict, critical PBM practices, including disclosure, receipt and retention of rebates and other payments received from pharmaceutical manufacturers; use of, administration of and/or changes to drug formularies, maximum allowable cost (&#8220;MAC&#8221;) list pricing, average wholesale prices (&#8220;AWP&#8221;) and/or clinical programs; the offering to plan sponsors of pricing that includes retail network &#8220;differential&#8221; or &#8220;spread&#8221; (i.e., a difference between the drug price charged to the plan sponsor by a PBM and the price paid by the PBM to the dispensing provider); reconciliation to pricing guarantees; disclosure of data to third parties; drug UM practices; the level of duty a PBM owes its customers; configuration of pharmacy networks; the operations of the Company&#8217;s pharmacies (including audits of its pharmacies); disclosure of negotiated provider reimbursement rates; disclosure of fees associated with administrative service agreements and patient care programs that are attributable to members&#8217; drug utilization; and registration or licensing of PBMs. Failure by the Company or one of its PBM services suppliers to comply with these laws or regulations could result in material fines and/or sanctions and could have a material adverse effect on the Company&#8217;s operating results and/or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s PBM service contracts, including those in which the Company assumes certain risks under performance guarantees or similar arrangements, are generally not subject to insurance regulation by the states. However, state departments of insurance are increasing their oversight of PBM activities due to legislation passing in a number of states requiring PBMs to register or obtain a license with the department, including through market conduct examinations and other audits our licensed entities. In addition, rulemaking is either underway or has already taken place in a number of states with the areas of focus including licensure requirements, pharmacy reimbursement, network design, cost sharing and pharmacy audits - most of which fall under the state insurance code.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmacy Network Access Legislation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Medicare Part D and a majority of states now have some form of legislation affecting the Company&#8217;s (and its health plans&#8217; and its health plan clients&#8217;) ability to limit access to a pharmacy provider network or remove pharmacy network providers. For example, certain &#8220;any willing provider&#8221; legislation may require the Company or its clients to admit a nonparticipating pharmacy if such pharmacy is willing and able to meet the plan&#8217;s price and other applicable terms and conditions for network participation. These laws could negatively affect the services and economic benefits achievable through a limited pharmacy provider network. Also, a majority of states now have some form of legislation affecting the Company&#8217;s ability (and the Company&#8217;s and its client health plans&#8217; ability) to conduct audits of network pharmacies regarding claims submitted to the Company for payment. These laws could negatively affect the Company&#8217;s ability to recover overpayments of claims submitted by network pharmacies that the Company identifies through pharmacy audits. Finally, several states have passed legislation that limits the ability of PBMs and health insurers to provide special benefit structures for use with affiliated pharmacies, which could result in reduced savings to clients and consumers.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmacy Pricing Legislation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A number of states have passed legislation regulating the Company&#8217;s ability to manage and establish MACs for generic prescription drugs. MAC methodology is a common cost management practice used by private and public payors (including CMS) to pay pharmacies for dispensing generic prescription drugs. MAC prices specify the allowable reimbursement by a PBM for a particular strength and dosage of a generic drug that is available from multiple manufacturers but sold at different prices. State legislation can regulate the disclosure of MAC prices and MAC price methodologies, the kinds of drugs that a PBM can pay for at a MAC price, and the rights of pharmacies to appeal a MAC price established by a PBM. These laws could negatively affect the Company&#8217;s ability to establish MAC prices for generic drugs. Additionally, some states have passed legislation that would restrict certain types of retroactive reconciliation or recoupment from pharmacies in the network or create a reimbursement benchmark mandate, such as the national average drug acquisition cost and/or the wholesale acquisition cost (&#8220;WAC&#8221;), plus a set dispensing fee, for pharmacies in the network. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Formulary and Plan Design Regulation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- A number of government entities regulate the administration of prescription drug benefits. HHS regulates how Medicare Part D formularies are developed and administered, including requiring the inclusion of all drugs in certain classes and categories, subject to limited exceptions. Under the ACA, CMS imposes drug coverage requirements for health plans required to cover essential health benefits, including plans offered through federal or state Public Exchanges. Additionally, the NAIC and health care accreditation agencies like NCQA and URAC have developed model acts and standards for formulary development that are often incorporated into government requirements. Many states regulate the scope of prescription drug coverage, as well as the delivery channels to receive prescriptions, for insurers, MCOs and Medicaid managed care plans. The increasing government regulation of formularies could significantly affect the Company&#8217;s ability to develop and administer formularies, pharmacy networks and other plan design features. Similarly, some states prohibit health plan sponsors from implementing certain restrictive pharmacy benefit plan design features. This regulation could limit or preclude (i) limited networks, (ii) a requirement to use particular providers, (iii) copayment differentials among providers and (iv) formulary tiering practices. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations Related to the Retail/LTC Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the laws and regulations discussed above that may affect multiple segments of the Company&#8217;s business, the Company is subject to federal, state and local statutes and regulations governing the operation of its Retail/LTC segment specifically. Among these are the following:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retail Medical Clinics </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- States regulate retail medical clinics operated by nurse practitioners or physician assistants through physician oversight, clinic and lab licensure requirements and the prohibition of the corporate practice of medicine. A number of states have implemented or proposed laws or regulations that impact certain components of retail medical clinic operations such as physician oversight, signage, third party contracting requirements, bathroom facilities, and scope of services. These laws and regulations may affect the operation and expansion of the Company&#8217;s owned and managed retail medical clinics.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Laws - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other federal, state and local laws and regulations also impact the Company&#8217;s retail operations, including laws and regulations that limit the sale of alcohol, mandate a minimum wage, govern the practices of optometry or audiology, or impact the provision of dietician services and the sale of durable medical equipment, contact lenses, eyeglasses and hearing aids.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation was incorporated in Delaware in 1996. The corporate office is located at One CVS Drive, Woonsocket, Rhode Island 02895, telephone (401)&#160;765-1500. CVS Health Corporation&#8217;s common stock is listed on the New York Stock Exchange under the trading symbol &#8220;CVS.&#8221; General information about the Company is available through the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.cvshealth.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company&#8217;s financial press releases and filings with the SEC are available free of charge within the Investors section of the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://investors.cvshealth.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers, such as the Company, that file electronically with the SEC. The address of that website is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.sec.gov. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information on or linked to the Company&#8217;s website is neither a part of nor incorporated by reference in this 10-K or any of the Company&#8217;s other SEC filings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to disclose material information to investors and to comply with its disclosure obligations under SEC Regulation FD, CVS Health Corporation (the &#8220;Registrant&#8221;) hereby notifies investors, the media and other interested parties that it intends to continue to use its media and investor relations website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://investors.cvshealth.com/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and its Twitter feed (@CVSHealthIR) to publish important information about the Registrant, including information that may be deemed material to investors. The list of social media channels that the Registrant uses may be updated on its media and investor relations website from time to time. The Registrant encourages investors, the media, and other interested parties to review the information the Registrant posts on its website and social media channels as described above, in addition to information announced by the Registrant through its SEC filings, press releases and public conference calls and webcasts.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.  Risk Factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider each of the following risks and uncertainties and all of the other information set forth in this 10-K. These risks and uncertainties and other factors may affect forward-looking statements, including those we make in this 10-K or elsewhere, such as in news releases or investor or analyst calls, meetings or presentations, on our websites or through our social media channels. The risks and uncertainties described below are not the only ones we face. There can be no assurance that we have identified all the risks that affect us. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial also may adversely affect our businesses. Any of these risks or uncertainties could cause our actual results to differ materially from our expectations and the expected results discussed in our forward-looking statements. You should not consider past results to be an indication of future performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the following risks or uncertainties develops into actual events or if the circumstances described in the risks or uncertainties occur or continue to occur, those events or circumstances could have a material adverse effect on our businesses, operating results, cash flows, financial condition and/or stock price, among other effects on us. You should read the following section in conjunction with the MD&amp;A, included in Item 7 of this 10-K, our consolidated financial statements and the related notes, included in Item 8 of this 10-K, and our &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221; in this 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks we face that could negatively impact our businesses, operating results, cash flows and/or financial condition: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Businesses</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact COVID-19 will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be material and adverse.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to accurately forecast health care and other benefit costs.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adverse economic conditions in the U.S. and abroad can materially and adversely impact our businesses, operating results, cash flows and financial condition.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each of our segments operates in a highly competitive and evolving business environment.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A change in our Health Care Benefits product mix may adversely affect our profit margins.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We can provide no assurance that we will be able to compete successfully and profitably on Public Exchanges.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative public perception of the industries in which we operate can adversely affect our businesses, operating results, cash flows and prospects.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must maintain and improve our relationships with our customers and increase the demand for our products and services.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks relating to the availability, pricing and safety profiles of prescription drugs that we purchase and sell.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The reserves we hold for expected claims in our Insured Health Care Benefits products are based on estimates that involve an extensive degree of judgment and are inherently variable, and any reserve, including a premium deficiency reserve, may be insufficient.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are exposed to risks relating to the solvency of other insurers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks From Changes in Public Policy and Other Legal and Regulatory Risks</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to potential changes in public policy, laws and regulations, including reform of the U.S. health care system and entitlement programs.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with applicable laws and regulations, or fail to change our operations in line with any new legal or regulatory requirements, we could be subject to significant adverse regulatory actions.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our compliance or other systems and processes fail or are deemed inadequate, we may suffer brand and reputational harm and become subject to regulatory actions and/or litigation.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We routinely are subject to litigation and other adverse legal proceedings, including class actions and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions. Many of these proceedings seek substantial damages which may not be covered by insurance.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We frequently are subject to regular and special governmental audits, investigations and reviews that could result in changes to our business practices and also could result in material refunds, fines, penalties, civil liabilities, criminal liabilities and other sanctions.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our litigation and regulatory risk profiles are changing as we offer new products and services and expand in business areas beyond our historical core businesses.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face unique regulatory and other challenges in our Public Exchange, Medicare and Medicaid businesses.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Programs funded in whole or in part by the U.S. federal government account for a significant portion of our revenues.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain adequate premium rate increases in our Insured Health Care Benefits products, MBRs and operating results which could magnify the adverse impact of increases in health care and other benefit costs and of ACA assessments, fees and taxes.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum MLR rebate requirements limit the level of margin we can earn in our Insured Health Care Benefits products while leaving us exposed to higher than expected medical costs. Challenges to our minimum MLR rebate methodology and/or reports could adversely affect our operating results.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may be adversely affected by changes in laws and policies governing employers and by union organizing activity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Associated with Mergers, Acquisitions, and Divestitures </span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to successfully integrate companies we acquire.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to continue to pursue acquisitions, joint ventures, strategic alliances and other inorganic growth opportunities, which may be unsuccessful, cause us to assume unanticipated liabilities, disrupt our existing businesses, be dilutive or lead us to assume significant debt, among other things.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div><span><br/></span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to meet customer and investor expectations, including with respect to environmental, social and governance goals, may harm our brand and reputation, our ability to retain and grow our customer base and membership.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our vendors have experienced and continue to experience information security incidents. We can provide no assurance that we or our vendors will be able to contain detect or prevent incident.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data governance failures or the failure or disruption of our information technology or infrastructure can adversely affect our reputation, businesses and prospects. Our use and disclosure of members&#8217;, customers&#8217; and other constituents&#8217; sensitive information is subject to complex regulations.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability, product recall or personal injury issues could damage our reputation.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to our success.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales of our products and services are dependent on our ability to attract and motivate internal sales personnel and independent third-party brokers, consultants and agents. We may be subject to penalties or other regulatory actions as a result of the marketing practices of brokers and agents selling our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure of our businesses to effectively collaborate could prevent us from maximizing our operating results.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pursuing multiple information technology improvement initiatives simultaneously could make continued development and implementation significantly more challenging. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to payment-related risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and disrupt our business operations.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Both our and our vendors&#8217; operations are subject to a variety of business continuity hazards and risks that could interrupt our operations or otherwise adversely affect our performance and operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Risks</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We would be adversely affected by downgrades or potential downgrades in our credit ratings, should they occur, or if we do not effectively deploy our capital.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Goodwill and other intangible assets could, in the future, become impaired.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adverse conditions in the U.S. and global capital markets can significantly and adversely affect the value of our investments in debt and equity securities, mortgage loans, alternative instruments and other investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Manufacturers, Providers, Suppliers and Vendors</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks relating to the market availability, pricing, suppliers and safety profiles of prescription drugs and other products that we purchase and sell.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We need to be able to maintain our ability to contract with providers on competitive terms and develop and maintain attractive networks with high quality providers.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our suppliers or service providers fail to meet their contractual obligations to us or to comply with applicable laws or regulations, we may be exposed to brand and reputational harm, litigation and/or regulatory action.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience increased medical and other benefit costs, litigation risk and customer and member dissatisfaction when providers that do not have contracts with us render services to our Health Care Benefits members.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continuing consolidation and integration among providers and other suppliers may increase our costs and increase competition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Businesses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The impact of COVID-19 underscores and amplifies certain risks we face. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 has spread to every state in the U.S., has been declared a pandemic by the World Health Organization and has severely impacted the economies of the U.S. and other countries around the world. Although certain of the economic impacts of COVID-19 have moderated and the restrictions imposed as a result of COVID-19 have eased, a rise in infection rates, the development of new variants or viruses could result in, among other things, a return of the following: a reduction in discretionary utilization, the cancellation of elective medical procedures, reduced customer traffic and front store sales in our retail pharmacies, our customers being ordered to close or severely curtail their operations, the adoption of work-from-home policies and a reduction in diagnostic reporting due to reductions in health care provider visits and restrictions on our access to providers&#8217; medical records, all of which have had a negative impact on our businesses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of legislative and/or regulatory responses to a rise in infection rates or the development of new variants or viruses, the premiums we charge in our Insured Health Care Benefits products may prove to be insufficient to cover the cost of medical services delivered to our insured medical members, which may increase significantly as a result of higher utilization rates of medical facilities and services and other increases in associated hospital and pharmaceutical costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the course of the COVID-19 pandemic, we implemented various initiatives, such as COVID-19 related support programs for our customers, medical members and colleagues. If there is a rise in infection rates or the development of new variants or viruses, we may have to re-institute, extend or expand these initiatives, which could adversely impact our businesses, operating results, cash flows and/or financial condition. In addition, measures that were imposed to limit the spread of COVID-19 may also be re-instituted, which may lead to impacts including, but not limited to, complete or partial facility closures, labor shortages, financial difficulties of third-party providers, supply chain disruptions and re-introduction of remote work arrangements. If any of the foregoing materializes, the Company&#8217;s ability to operate its businesses effectively may be adversely affected and other risks to the Company, such as the risk of cybersecurity attacks, may be amplified, and the impact on our businesses, operating results, cash flows and/or financial condition would be uncertain but could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe COVID-19&#8217;s continuing impact on our businesses, operating results, cash flows and/or financial condition primarily will be driven by vaccination rates; the severity of any new COVID-19 variants and the continued effectiveness of vaccines; and whether federal, state and local governments reinstitute and/or intensify policies and initiatives designed to reduce the transmission of COVID-19, including new and existing variants, and to address the financial impacts of a pandemic through additional legislation and other support programs. These primary drivers are beyond our knowledge and control.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to accurately forecast health care and other benefit costs, which could adversely affect our Health Care Benefits segment&#8217;s operating results. There can be no assurance that future health care and other benefits costs will not exceed our projections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 has caused and may continue to cause unanticipated and significant volatility in our health care and other benefits costs, including COVID-19 related testing and vaccination and post-acute care skilled nursing facility and behavioral health costs. In January 2021, the President of the United States issued an executive order to support government efforts to expand access, availability and use of COVID-19 diagnostic, screening and surveillance and addressed the cost of COVID-19 testing by facilitating COVID-19 testing free of charge to those who lack comprehensive health insurance and clarifying group health plans&#8217; and health insurance issuers&#8217; obligations to provide coverage for COVID-19 testing. In January 2022, the HHS announced that commercial health insurers must cover the cost of up to eight rapid COVID-19 OTC test kits per individual per 30-day period. In addition, the timing of vaccine administration to the general public and related costs as well as the identification of new, more infectious strains of the COVID-19 virus and whether the vaccines will be effective against such new strains are uncertain and may impact our MBR. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums for our Insured Health Care Benefits products, which comprised 93% of our Health Care Benefits revenues for 2022, are priced in advance based on our forecasts of health care and other benefit costs during a fixed premium period, which is generally twelve months. These forecasts are typically developed several months before the fixed premium period begins, are influenced by historical data (and recent historical data in particular), are dependent on our ability to anticipate and detect medical cost trends and changes in our members&#8217; behavior and health care utilization patterns and medical claim submission patterns and require a significant degree of judgment. For example, our revenue on Medicare policies is based on bids submitted in June of the year before the contract year. Cost increases in excess of our projections cannot be recovered in the fixed premium period through higher premiums. As a result, our profits are particularly sensitive to the accuracy of our forecasts of the increases in health care and other benefit costs that we expect to occur and our ability to anticipate and detect medical cost trends. For 2023, those forecasts include adjustments made to pricing based on prospective expectations for liabilities due to testing, vaccines, direct COVID-19 treatment and deferred care. Risk-adjusted revenue has been adjusted for deferred care, and forecasted enrollment considers assumptions about the economic environment, though COVID-19 related impacts remain uncertain. During periods when health care and other benefit costs, utilization and/or medical costs trends experience significant volatility and medical claim submission patterns are changing rapidly as a result of COVID-19, accurately detecting, forecasting, managing, reserving and pricing for our (and our self-insured customers&#8217;) medical cost trends and incurred and future health care and other benefits costs is more challenging. There can be no assurance regarding the accuracy of the health care or other benefit cost projections reflected in our pricing, and whether our health care and other benefit costs (including COVID-19 related testing and vaccination and post-acute care skilled nursing facility and behavioral health costs) will be affected by COVID-19 or other variants or viruses and other external events over which we have no control. Even relatively small differences between predicted and actual health care and other benefit costs as a percentage of premium revenues can result in significant adverse changes in our Health Care Benefits segment&#8217;s operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of factors contribute to rising health care and other benefit costs, including COVID-19 or other variants or viruses, previously uninsured members entering the health care system, changes in members&#8217; behavior and health care utilization patterns, turnover in our membership, additional government mandated benefits or other regulatory changes (including under the Families First Act, the CARES Act, and the American Rescue Plan Act), changes in the health status of our members, the aging of the population and other changing demographic characteristics, advances in medical technology, increases in the number and cost of prescription drugs (including specialty pharmacy drugs and ultra-high cost drugs and therapies), direct-to-consumer marketing by drug manufacturers, the increasing influence of social media on our members&#8217; health care utilization and other behaviors, changes in health care practices and general economic conditions (such as inflation and employment levels). In addition, government-imposed limitations on Medicare and Medicaid reimbursements to health plans and providers have caused the private sector to bear a greater share of increasing health care and other benefits costs over time, and future amendments to the ACA that increase the uninsured population may amplify this issue. Other factors that affect our health care and other benefit costs include epidemics or other pandemics, changes as a result of the ACA, changes to the ACA and other changes in the regulatory environment, the evolution toward a consumer driven business model, new technologies, influenza-related health care costs (which may be substantial and higher than we expected), clusters of high-cost cases, health care </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provider and member fraud, and numerous other factors that are or may be beyond our control. For example, the 2020-2021 influenza season was impacted by efforts taken to reduce the spread of COVID-19; and the 2019-2020 influenza season had an earlier than average start and had a higher incidence of influenza than the 2018-2019 influenza season.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Health Care Benefits segment&#8217;s operating results and competitiveness depend in large part on our ability to appropriately manage future health care and other benefit costs through underwriting criteria, product design, provider network configuration, negotiation of favorable provider contracts and medical management programs. Our medical cost management programs may not be successful and may have a smaller impact on health care and benefit costs than we expect. The factors described above may adversely affect our ability to predict and manage health care and other benefit costs, which can adversely affect our competitiveness and operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we are not able to accurately and promptly anticipate and detect medical cost trends or accurately estimate the cost of incurred but not yet reported claims or reported claims that have not been paid, our ability to take timely corrective actions to limit future health care costs and reflect our current benefit cost experience in our pricing process may be limited, which would further amplify the extent of any adverse impact on our operating results. These risks are particularly acute during periods when health care and other benefit costs, utilization and/or medical cost trends experience significant volatility and medical claim submission patterns are changing rapidly as a result of COVID-19. Such risks are further magnified by the ACA and other existing and future legislation and regulations that limit our ability to price for our projected and/or experienced increases in utilization and/or medical cost trends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the requirements set forth above may change once the PHE expires. The Biden administration recently renewed the PHE on January 11, 2023 and has indicated that they intend for the PHE to expire on May 11, 2023. There can be no assurance that future health care and other benefits costs will not exceed our projections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse economic conditions in the U.S. and abroad can materially and adversely impact our businesses, operating results, cash flows and financial condition, and we do not expect these conditions to improve in the near future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse economic conditions in the U.S. and abroad, including those caused by inflation, high interest rates, supply chain disruptions and COVID-19, can materially and adversely impact our businesses, operating results, cash flows and financial condition, including:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In our Pharmacy Services segment, by causing drug utilization to decline, reducing demand for PBM services and adversely affecting the financial health of our PBM clients.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In our Retail/LTC segment, by causing drug utilization to decline, changing consumer purchasing power, preferences and/or spending patterns leading to reduced consumer demand for products sold in our stores, potentially increasing levels of theft at our retail locations and adversely affecting the financial health of our LTC pharmacy customers.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By causing our existing customers to reduce workforces (including due to business failures), which would reduce our revenues, the number of covered lives in our PBM clients and/or the number of members our Health Care Benefits segment serves.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By causing our clients and customers and potential clients and customers, particularly those with the most employees or members, and state and local governments, to force us to compete more vigorously on factors such as price and service, including service, discount and other performance guarantees, to retain or obtain their business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By causing customers and potential customers of our Health Care Benefits and Retail/LTC segments to purchase fewer products and/or products that generate less profit for us than the ones they currently purchase or otherwise would have purchased.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By causing customers and potential customers of our Health Care Benefits segment, particularly smaller employers and individuals, to forego obtaining or renewing their health and other coverage with us.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In our Health Care Benefits segment, by causing unanticipated increases and volatility in utilization of medical and other covered services, including COVID-19 related testing, vaccination and behavioral health services, by our medical members, changes in medical claim submission patterns and/or increases in medical unit costs and/or provider behavior, each of which would increase our costs and limit our ability to accurately detect, forecast, manage, reserve and price for our (and our self-insured customers&#8217;) medical cost trends and incurred and future health care and other benefits costs.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By increasing medical unit costs and causing changes in provider behavior in our Health Care Benefits segment as hospitals and other providers attempt to maintain revenue levels in their efforts to adjust to their own economic challenges.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By weakening the ability or perceived ability of the issuers and/or guarantors of the debt or other securities we hold in our investment portfolio to perform on their obligations to us, which could result in defaults in those securities and has reduced, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may further reduce, the value of those securities and has created, and may continue to create, net realized capital losses for us that reduce our operating results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By weakening the ability of our customers, including self-insured customers in our Health Care Benefits segment, medical providers and the other companies with which we do business as well as our medical members to perform their obligations to us or causing them not to perform those obligations, either of which could reduce our operating results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By weakening the ability of our former subsidiaries and/or their purchasers to satisfy their lease obligations that we have guaranteed and causing the Company to be required to satisfy those obligations.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By weakening the financial condition of other insurers, including long-term care insurers and life insurers, which increases the risk that we will receive significant assessments for obligations of insolvent insurers to policyholders and claimants.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">By continuing to cause, over time, inflation that could cause interest rates to further increase and thereby further increase our interest expense and reduce our operating results, as well as further decrease the value of the debt securities we hold in our investment portfolio, which would further reduce our operating results and/or adversely affect our financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, reductions in workforce by our customers can cause unanticipated increases in the health care and other benefits costs of our Health Care Benefits segment. For example, our business associated with members who have elected to receive benefits under Consolidated Omnibus Budget Reconciliation Act (known as &#8220;COBRA&#8221;) typically has an MBR that is significantly higher than our overall Commercial MBR.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Each of our segments operates in a highly competitive and evolving business environment; and operating income in the industries in which we compete may decline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our segments, Health Care Benefits, Pharmacy Services, which includes our PBM business, and Retail/LTC, operates in a highly competitive and evolving business environment. Specifically:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As competition increases in the geographies in which we operate, including competition from new entrants, a significant increase in price compression and/or reimbursement pressures could occur, and this could require us to reevaluate our pricing structures to remain competitive.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In our Health Care Benefits segment, we are seeking to substantially grow our Medicaid, dual eligible and dual eligible special needs plan membership over the next several years. In many instances, to acquire and retain our government customers&#8217; business, we must bid against our competitors in a highly competitive environment. Winning bids often are challenged successfully by unsuccessful bidders, and may also be withdrawn or cancelled by the issuing agency.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Customer contracts in our Health Care Benefits segment are generally for a period of one year, and our customers have considerable flexibility in moving between us and our competitors. We may lose members to competitors with more favorable pricing, or our customers may purchase different types of products from us that are less profitable, adversely affecting our revenues and operating results. In addition, our Medicare, Medicaid and CHIP products are subject to termination without cause, periodic re-bid, rate adjustment and program redesign, as customers seek to contain their benefit costs, particularly in an uncertain economy, and our exposure to this risk is increasing as we grow our Government products membership. These actions may adversely affect our membership, revenues and operating results. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We requested increases in our premium rates in our Commercial Health Care Benefits business for 2023 and expect to request future increases in those rates in order to adequately price for projected medical cost trends, required expansions of coverage and rating limits, and significant assessments, fees and taxes imposed by federal and state governments, including as a result of the ACA. Our rates also must be adequate to reflect the risk that our products will be selected by people with a higher risk profile or utilization rate than the pool of participants we anticipated when we established pricing for the applicable products (also known as &#8220;adverse selection&#8221;), particularly in small group Commercial products. These rate increases may be significant and thus heighten the risks of adverse publicity, adverse regulatory action and adverse selection and the likelihood that our requested premium rate increases will be denied, reduced or delayed, which could lead to operating margin compression.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The competitive success of our Pharmacy Services segment is dependent on our ability to establish and maintain contractual relationships with network pharmacies. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The competitive success of our Retail/LTC segment and our specialty pharmacy operations is dependent on our ability to establish and maintain contractual relationships with PBMs and other payors on acceptable terms as the payors&#8217; clients evaluate adopting narrow or restricted retail pharmacy networks. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In our PBM business, we maintain contractual relationships with brand name drug manufacturers that provide for purchase discounts and/or rebates on drugs dispensed by pharmacies in our retail network and by our specialty and mail order pharmacies (all or a portion of which may be passed on to clients). Manufacturer&#8217;s rebates often depend on a PBM&#8217;s ability to meet contractual requirements, including the placement of a manufacturer&#8217;s products on the PBM&#8217;s formularies. If we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lose our relationship with one or more drug manufacturers, or if the discounts or rebates provided by drug manufacturers decline, our operating results, cash flows and/or prospects could be adversely affected. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If laws or regulations are promulgated that limit the number of PBMs available in a particular business or geography, competition in those businesses and geographies could be amplified and could adversely affect our revenues and operating results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The PBM industry has been experiencing price compression as a result of competitive pressures and increased client demands for lower prices, increased revenue sharing, including sharing in a larger portion of rebates received from drug manufacturers, enhanced service offerings and/or higher service levels. Marketplace dynamics and regulatory changes also have adversely affected our ability to offer plan sponsors pricing that includes the use of retail &#8220;differential&#8221; or &#8220;spread,&#8221; which could adversely affect our future profitability, and we expect these trends to continue.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our retail pharmacy, specialty pharmacy and LTC pharmacy operations have been affected by reimbursement pressure caused by competition, including client demands for lower prices, generic drug pricing, earlier than expected generic drug introductions and network reimbursement pressure. If we are unable to increase our prices to reflect, or otherwise mitigate the impact of, increasing costs, our profitability will be adversely affected. If we are unable to limit our price increases, we may lose customers to competitors with more favorable pricing, adversely affecting our revenues and operating results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A shift in the mix of our pharmacy prescription volume towards programs offering lower reimbursement rates as a result of competition or otherwise could adversely affect our margins, including the ongoing shift in pharmacy mix towards 90-day prescriptions at retail and the ongoing shift in pharmacy mix towards Medicare Part D prescriptions.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PBM client contracts often are for a period of approximately three years. However, PBM clients may require early or periodic re-negotiation of pricing prior to contract expiration. PBM clients are generally well informed, can move between us and our competitors and often seek competing bids prior to expiration of their contracts. We are therefore under pressure to contain price increases despite being faced with increasing drug costs and increasing operating costs. If we are unable to increase our prices to reflect, or otherwise mitigate the impact of, increasing costs, our profitability will be adversely affected. If we are unable to limit our price increases, we may lose customers to competitors with more favorable pricing, adversely affecting our revenues and operating results.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The operating results and margins of our LTC business are further affected by the increased efforts of health care payors to negotiate reduced or capitated pricing arrangements and by the financial health of, and purchases and sales of, our LTC customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors in each of our businesses may offer services and pricing terms that we may not be willing or able to offer. Competition also may come from new entrants and other sources in the future. Unless we can demonstrate enhanced value to our clients through innovative product and service offerings in the rapidly changing health care industry, we may be unable to remain competitive.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptive innovation by existing or new competitors could alter the competitive landscape in the future and require us to accurately identify and assess such alterations and make timely and effective changes to our strategies and business model to compete effectively. For example, decisions to buy our Health Care Benefits and Pharmacy Services products and services increasingly are made or influenced by consumers, either through direct purchasing (e.g., Medicare Advantage plans and PDPs) or through Public Exchanges and private health insurance exchanges that allow individual choice. Consumers also are increasingly seeking to access consumer goods and health care products and services locally and through other direct channels such as mobile devices and websites. To compete effectively in the consumer-driven marketplace, we will be required to develop or acquire new capabilities, attract new talent and develop new service and distribution relationships that respond to consumer needs and preferences.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in marketplace dynamics or the actions of competitors or manufacturers, including industry consolidation, the emergence of new competitors and strategic alliances, and decisions to exclude us from new narrow or restricted retail pharmacy networks could materially and adversely affect our businesses, operating results, cash flows and/or prospects. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We can provide no assurance that we will be able to compete successfully on Public Exchanges or that our pricing or other actions will result in the profitability of our Public Exchange products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into the Public Exchanges in eight states and further expanded to a total of twelve states in January 2023. To compete effectively on Public Exchanges, we have developed or acquired the technology, systems, tools and talent necessary to interact with Public Exchanges and engage Public Exchange consumers through enhanced consumer-focused sales, marketing channels and customer interfaces. We have also created new customer service programs and product offerings. While participating on the Public Exchanges, we will have to respond to pricing and other actions taken by existing competitors and regulators as well as potentially disruptive new entrants, which could reduce our profit margins. Due to the price transparency </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided by Public Exchanges, when we market products we face competitive pressures from existing and new competitors who may have lower cost structures. Our competitors may bring their Public Exchange and other consumer products to market more quickly, have greater experience marketing to consumers and/or may be targeting the higher margin portions of our business. We can provide no assurance that we will be able to compete successfully or profitably on Public Exchanges or that we will be able to benefit from any opportunities presented by Public Exchanges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there can be no assurance that our pricing or other actions will result in the profitability of our Public Exchange products in 2023 or any future year. We have set 2023 premium rates for our Public Exchange products based on our projections, including as to the health status and quantity of membership and utilization of medical and/or other covered services by members. The accuracy of the projections reflected in our pricing may be impacted by (i) adverse selection among individuals who require or utilize more expensive medical and/or other covered services, (ii) other plans&#8217; withdrawals from participation in the Public Exchanges we serve, (iii) a rapid increase or decline in membership, including as a result of individuals losing Medicaid eligibility as redeterminations resume after being suspended during the COVID-19 pandemic, and (iv) legislation, regulations, enforcement activity and/or judicial decisions that cause Public Exchanges to operate in a manner different than what we projected in setting our premium rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A change in our Health Care Benefits product mix may adversely affect our profit margins.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Insured Health Care Benefits products that involve greater potential risk generally tend to be more profitable than our ASC products. Historically, smaller employer groups have been more likely to purchase Insured Health Care Benefits products because such purchasers are generally unable or unwilling to bear greater liability for health care expenditures, although over the last several years even relatively small employers have moved to ASC products. We also serve, and expect to grow our business with, government-sponsored programs, including Medicare and Medicaid, that are subject to competitive bids and have lower profit margins than our Commercial Insured Health Care Benefits products. A shift of enrollees from more profitable products to less profitable products could have a material adverse effect on the Health Care Benefits segment&#8217;s operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public perception of the industries in which we operate, or of our industries&#8217; or our practices, can adversely affect our businesses, operating results, cash flows and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our brand and reputation are two of our most important assets, and the industries in which we operate have been and are negatively perceived by the public from time to time. Negative publicity may come as a result of adverse media coverage, litigation against us and other industry participants, the ongoing public debates over drug pricing, PBMs, government involvement in drug pricing and purchasing, changes to the ACA, &#8220;surprise&#8221; medical bills, governmental hearings and/or investigations, actual or perceived shortfalls regarding our industries&#8217; or our own products and/or business practices (including PBM operations, drug pricing and insurance coverage determinations) and social media and other media relations activities.  Negative publicity also may come from a failure to meet customer expectations for consistent, high quality and accessible care. This risk may increase as we continue to offer products and services that make greater use of data and as our business model becomes more focused on delivering health care to consumers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, by working with the U.S. government in the distribution and administration of the COVID-19 vaccine, the Company may be subject to negative publicity related to the government&#8217;s actions in response to COVID-19 that are outside of the ability of the Company to control.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative public perception and/or publicity of our industries in general, or of us or our key vendors, brokers or product distribution networks in particular, can further increase our costs of doing business and adversely affect our operating results and our stock price by:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely affecting our brand and reputation;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely affecting our ability to market and sell our products and/or services and/or retain our existing customers and members;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring us to change our products and/or services; </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reducing or restricting the revenue we can receive for our products and/or services; and/or</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing or significantly changing the regulatory and legislative requirements with which we must comply.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must maintain and improve our relationships with our retail and specialty pharmacy customers and increase the demand for our products and services, including proprietary brands.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our businesses depends in part on customer loyalty, superior customer service and our ability to persuade customers to frequent our retail stores and online sites and to purchase products in additional categories and our proprietary brands. Failure to timely identify or effectively respond to changing consumer preferences and spending patterns, and evolving demographic mixes in the communities we serve, an inability to expand the products being purchased by our clients and customers, or the failure or inability to obtain or offer particular categories of products could adversely affect our relationship with our customers and clients and the demand for our products and services and could result in excess inventories of products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our retail customers proprietary brand products that are available exclusively at our retail stores and through our online retail sites. The sale of proprietary products subjects us to unique risks including potential product liability risks, mandatory or voluntary product recalls, potential supply chain and distribution chain disruptions for raw materials and finished products, our ability to successfully protect our intellectual property rights and the rights of applicable third parties, and other risks generally encountered by entities that source, market and sell private-label products. We also face similar risks for the other products we sell in our retail operations, including supply chain and distribution chain disruption risk. Any failure to adequately address some or all of these risks could have an adverse effect on our retail business, operating results, cash flows and/or financial condition. Additionally, an increase in the sales of our proprietary brands may adversely affect our sales of products owned by our suppliers and adversely impact certain of our supplier relationships. Our ability to locate qualified, economically stable suppliers who satisfy our requirements, and to acquire sufficient products in a timely and effective manner, is critical to ensuring, among other things, that customer confidence is not diminished. Any failure to develop sourcing relationships with a broad and deep supplier base could adversely affect our operating results and erode customer loyalty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also could be adversely affected if we fail to identify or effectively respond to changes in marketplace dynamics. For example, specialty pharmacy represents a significant and growing proportion of prescription drug spending in the U.S., a significant portion of which is dispensed outside of traditional retail pharmacies. Because our specialty pharmacy business focuses on complex and high-cost medications, many of which are made available by manufacturers to a limited number of pharmacies (so-called limited distribution drugs) that serve a relatively limited universe of patients, the future growth of our specialty pharmacy business depends largely upon expanding our access to key drugs and penetration in certain treatment categories. Any contraction of our base of patients or reduction in demand for the prescriptions we currently dispense could have an adverse effect on our specialty pharmacy business, operating results and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks relating to the availability, pricing and safety profiles of prescription drugs that we purchase and sell.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The profitability of our Retail/LTC and Pharmacy Services segments is dependent upon the utilization of prescription drug products. We dispense significant volumes of brand name and generic drugs from our retail, LTC, specialty and mail order pharmacies, and the retail pharmacies in our PBM&#8217;s network also dispense significant volumes of brand name and generic drugs. Our revenues, operating results and cash flows may decline if physicians cease writing prescriptions for drugs or the utilization of drugs is reduced, including due to:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased safety risk profiles or regulatory restrictions;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing or other supply issues;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reduction in drug manufacturers&#8217; participation in federal programs;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain products being withdrawn by their manufacturers or transitioned to over-the-counter products; </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future FDA rulings restricting the supply or increasing the cost of products;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of new and successful prescription drugs or lower-priced generic alternatives to existing brand name products; or </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inflation in the price of drugs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, increased utilization of generic drugs (which normally yield a higher gross profit rate than equivalent brand name drugs) has resulted in pressure to decrease reimbursement payments to retail, mail order, specialty and LTC pharmacies for generic drugs, causing a reduction in our margins on sales of generic drugs. Consolidation within the generic drug manufacturing industry and other external factors may enhance the ability of manufacturers to sustain or increase pricing of generic drugs and diminish our ability to negotiate reduced generic drug acquisition costs. Any inability to offset increased brand name or generic prescription drug acquisition costs or to modify our activities to lessen the financial impact of such increased costs could have a significant adverse effect on our operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The reserves we hold for expected claims in our Insured Health Care Benefits products are based on estimates that involve an extensive degree of judgment and are inherently variable. Any reserve, including a premium deficiency reserve, may be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">insufficient. If actual claims exceed our estimates, our operating results could be materially adversely affected, and our ability to take timely corrective actions to limit future costs may be limited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large portion of health care claims are not submitted to us until after the end of the quarter in which services are rendered by providers to our members. Our reported health care costs payable for any particular period reflect our estimates of the ultimate cost of such claims as well as claims that have been reported to us but not yet paid. We also must estimate the amount of rebates payable under the MLR rules of the ACA, CMS and the OPM and the amounts payable by us to, and receivable by us from, the United States federal government under the ACA&#8217;s remaining premium stabilization program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of health care costs payable are based on a number of factors, including those derived from historical claim experience, but this estimation process also makes use of extensive judgment. Considerable variability is inherent in such estimates, and the accuracy of the estimates is highly sensitive to changes in medical claims submission and processing patterns and/or procedures, turnover and other changes in membership, changes in product mix, changes in the utilization of medical and/or other covered services, including prescription drugs, changes in medical cost trends, changes in our medical management practices and the introduction of new benefits and products. We estimate health care costs payable periodically, and any resulting adjustments, including premium deficiency reserves, are reflected in current-period operating results within benefit costs. For example, as of December 31, 2021, we established a premium deficiency reserve of $16 million related to Medicaid products in the Health Care Benefits segment, but did not establish a premium deficiency reserve as of December 31, 2022. A worsening (or improvement) of health care cost trend rates or changes in claim payment patterns from those that we assumed in estimating health care costs payable as of December&#160;31, 2022 would cause these estimates to change in the near term, and such a change could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we are not able to accurately and promptly anticipate and detect medical cost trends or accurately estimate the cost of incurred but not yet reported claims or reported claims that have not been paid, our ability to take timely corrective actions to limit future health care costs and reflect our current benefit cost experience in our pricing process may be limited, which would further exacerbate the extent of any adverse impact on our operating results. These risks are particularly acute during and following periods when utilization of medical and/or other covered services and/or medical cost trends are below recent historical levels and in products where there is significant turnover in our membership each year, and such risks are further magnified by the ACA and other legislation and regulations that limit our ability to price for our projected and/or experienced increases in utilization and/or medical cost trends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are affected by the health of the economy in general and in the communities we serve.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. financial markets have been experiencing, and may continue to experience, volatility and disruptions, including diminished liquidity and credit availability, inflation, declines in consumer confidence and economic growth and increases in unemployment rates, all of which have resulted in uncertainty about economic stability.  Our businesses are affected by  economic instability and declines in consumer confidence in general and in the communities we serve, and various other economic factors, including inflation and changes in consumer purchasing power, preferences and/or spending patterns. An unfavorable, uncertain or volatile economic environment, as we have experienced recently as a result of inflation, rising interest rates, supply chain disruptions and COVID-19, has caused and could cause a decline in drug utilization, an increase in health care utilization, a dampening demand for PBM services and retail products, and an increase in theft or other crime that could impact our retail locations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our customers&#8217; operating and financial performance deteriorates, or they are unable to make scheduled payments or obtain adequate financing, as a result of adverse economic conditions or otherwise, our customers may not be able to pay timely, or may delay payment of, amounts owed to us. Any inability of our customers to pay us for our products and services may adversely affect our businesses, operating results and cash flows. In addition, both state and federal government sponsored payers, as a result of budget deficits or spending reductions, may suspend payments or seek to reduce their health care expenditures resulting in our customers delaying payments to us or renegotiating their contracts with us. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adverse impacts on our businesses of an uncertain economic environment may be further exacerbated by the increasing prevalence of high deductible health plans and health plan designs favoring co-insurance over co-payments as members and other consumers may decide to postpone, or not to seek, medical treatment which may lead them to incur more expensive medical treatment in the future and/or decrease our prescription volumes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, economic conditions including interest rate fluctuations, changes in capital market conditions and regulatory changes may affect our ability to obtain necessary financing on acceptable terms, our ability to secure suitable store locations under </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceptable terms, our ability to execute sale-leaseback transactions under acceptable terms and the value of our investment portfolio. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Health Care Benefits membership remains concentrated in certain U.S. geographies and in certain industries. Unfavorable changes in health care or other benefit costs or reimbursement rates or increased competition in those geographic areas where our membership is concentrated could therefore have a disproportionately adverse effect on our Health Care Benefits segment&#8217;s operating results. Our Health Care Benefits membership has been and may continue to be affected by workforce reductions by our customers due to adverse and/or uncertain general economic conditions, especially in the U.S. geographies and industries where our membership is concentrated. As a result, we may not be able to profitably grow and diversify our Health Care Benefits membership geographically, by product type or by customer industry, and our revenues and operating results may be disproportionately affected by adverse changes affecting our customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse changes in the U.S. economy, consumer confidence and economic conditions could have an adverse effect on our businesses and financial results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are exposed to risks relating to the solvency of other insurers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to assessments under guaranty fund laws existing in all states for obligations of insolvent insurance companies (including long-term care insurers), HMOs, ACA co-ops and other payors to policyholders and claimants. For example, in the first quarter of 2017, Aetna recorded a discounted estimated liability expense of $231 million pretax for our estimated share of future assessments for long-term care insurer Penn Treaty Network America Insurance Company and one of its subsidiaries. Guaranty funds are maintained by state insurance commissioners to protect policyholders and claimants in the event that an insurer, HMO, ACA co-op and/or other payor becomes insolvent or is unable to meet its financial obligations. These funds are usually financed by assessments against insurers regulated by a state. Future assessments may have an adverse effect on our operating results and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Extreme events, or the threat of extreme events, could materially impact our businesses and health care (including behavioral health) costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nuclear, biological or other attacks, or other acts of violence, including active shooter situations, whether as a result of war or terrorism or otherwise; other man-made disasters; natural disasters, such as hurricanes, tropical storms, floods, fires, earthquakes, tsunamis, cyclones, typhoons or extreme weather conditions such as major or extended winter storms, droughts and tornados, whether as a result of climate change or otherwise; epidemics; pandemics and other extreme events can affect the U.S. economy in general, our industries and us specifically. In particular, such extreme events or the threat of such extreme events could result in significant health care (including behavioral health) costs, which also would be affected by the government&#8217;s actions and the responsiveness of public health agencies and other insurers. Such extreme events or the threat of such extreme events also could disrupt our supply chains and/or our distribution chains for the products we sell. In addition, our employees and those of our vendors are concentrated in certain large, metropolitan areas which may be particularly exposed to these events. Such events could adversely affect our businesses, operating results and cash flows, and, in the event of extreme circumstances, our financial condition or viability, particularly if our responses to such events are less adequate than those of our competitors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to achieve our environmental, social and governance goals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to corporate social responsibility and sustainability and we established certain goals as part of our ESG strategy. We face pressures from our colleagues, customers, and stockholders to meet our goals and to make significant advancements in environmental, social and governance matters. Achievement of our goals is subject to risks and uncertainties, many of which are outside of our control, and it is possible that we may fail to achieve these goals or that our colleagues, customers, or stockholders may not be satisfied with the goals we set or our efforts to achieve them. These risks and uncertainties include, but are not limited to: our ability to set and execute on our operational strategies and achieve our goals within the currently projected costs and the expected timeframes; the availability and cost of technological advancements, renewable energy and other materials necessary to meet our goals and expectations; compliance with, and changes or additions to, global and regional regulations, taxes, charges, mandates or requirements relating to climate-related goals; labor-related regulations and requirements that restrict or prohibit our ability to impose requirements on third party contractors; the actions of competitors and competitive pressures; an acquisition of or merger with another company that has not adopted similar goals or whose progress towards reaching its goals is not as advanced as ours; and the pace of regional and global recovery from the COVID-19 pandemic. A failure to meet our goals could adversely affect public perception of our business, employee morale or customer or stockholder support. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, an increasing percentage of colleagues, customers, and stockholders considers sustainability factors in making employment, consumer health care and investment decisions. If we are unable to meet our goals, we may lose colleagues, have difficulty recruiting new colleagues, and be unable to attract investors, customers, or partners, our stock price may be negatively impacted, our reputation may be negatively affected, and it may be more difficult for us to compete effectively, all of which would have an adverse effect on our business, operating results, and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks From Changes in Public Policy and Other Legal and Regulatory Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to potential changes in public policy, laws and regulations, including reform of the U.S. health care system, which can adversely affect our businesses. Entitlement program reform, if it occurs, could have a material adverse effect on our businesses, operations and/or operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The political environment in which we operate remains uncertain. It is reasonably possible that our business operations and operating results could be materially adversely affected by legislative, enforcement, regulatory and public policy changes at the federal or state level, increased government involvement in drug reimbursement, pricing, purchasing and/or importation and/or increased regulation of PBMs, including: changes to the regulatory environment for health care and related benefits, including Medicare, the ACA, and related Public Exchange regulations; changes to laws or regulations governing drug reimbursement and/or pricing; changes to the laws and regulations governing PBMs&#8217;, PDPs&#8217; and/or Managed Medicaid organizations&#8217; interactions with government funded health care programs; changes to laws and/or regulations governing drug manufacturers&#8217; rebates; changes to laws and/or regulations governing reimbursements paid to pharmacists by and/or reporting required by PBMs; changes to immigration policies and/or other public policy initiatives. It is not possible to predict whether or when any such changes will occur or what form any such changes may take (including through the use of U.S. Presidential Executive Orders or executive orders by Governors or key regulators). Other significant changes to health care and related benefits system legislation or regulation as well as changes with respect to tax and trade policies, tariffs and other government regulations affecting trade between the United States and other countries also are possible and could adversely affect our businesses. If we fail to respond adequately to such changes, including by implementing strategic and operational initiatives, or do not respond as effectively as our competitors, our businesses, operations and operating results may be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to amend the ACA and related regulations are possible. It is also possible that federal and state governments will continue to enact and seriously consider many broad-based legislative and regulatory proposals that will or could materially impact various aspects of the health care and related benefits system and our businesses. Further changes to federal health care and related benefits laws, including the ACA, drug reimbursement and pricing laws, laws governing PBMs and/or laws governing PBMs&#8217;, PDPs&#8217; and/or Managed Medicaid organizations&#8217; interactions with government funded health care programs, are probable. We cannot predict the effect, if any, that new health care and related benefits legislation, future changes to the ACA or the implementation of or failure to implement the outstanding provisions of ACA, may have on our Health Care Benefits, Pharmacy Services and/or retail pharmacy, LTC pharmacy operations and/or operating results. The federal and many state governments also are considering changes in the interpretation, enforcement and/or application of existing programs, laws and regulations, including changes to payments under and funding of Medicare and Medicaid programs and increased regulation of PBMs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, changes in existing federal or state laws or regulations or the adoption of new laws or regulations relating to additional regulation of PBMs (including network restrictions, formulary management, affiliate reimbursement, contractual guarantees and reconciliations, reimbursement mandates or other PBM services), drug pricing or purchasing, patent term extensions and/or purchase discount and/or rebate arrangements with drug manufacturers also could reduce the discounts or rebates we receive. Changes in existing federal or state laws or regulations or the adoption of new laws or regulations relating to claims processing and billing also could adversely affect our profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in November 2020, the HHS released the Rebate Rule, which eliminates the regulatory safe harbor from prosecution under the AKS for rebates from pharmaceutical companies to PBMs in Medicare Part D and in Medicaid MCOs, replacing it with two far narrower safe harbors designed to directly benefit patients with high out-of-pocket costs and to change the way PBMs are compensated. The new safe harbors are (i) for rebates which are passed on to the patient at the point of sale and (ii) for flat service fee payments made to PBMs which cannot be tied to the list prices of drugs. The PCMA, which represents PBMs, has filed a suit in an effort to block the Rebate Rule, claiming that the Rebate Rule would lead to higher premiums in Medicare Part D and was adopted in an unlawful manner. It is unclear whether the Rebate Rule will be enforceable, whether pharmaceutical companies will respond by reducing list prices, whether list prices in the private market may also be reduced, and what the resulting impact will be to PBMs or the Company. The Bipartisan Infrastructure Act of 2021 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delays the effective date of the rebate rule to January 2026, and the Inflation Reduction Act, enacted in August 2022, further delays the Rebate Rule through 2032.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Consolidated Appropriations Act of 2021 was signed into law in December 2020 and contains transparency provisions requiring group health plans and health insurance issuers to report certain prescription drug costs, overall spending on health services and prescription drugs, and information about premiums and the impact of rebates and other remuneration on premiums and out-of-pocket costs to the Tri-Departments. No later than 18 months after the first submission and bi-annually thereafter, the Tri-Departments will release a public report on drug pricing trends, drug reimbursement, and the impact of drug prices on premiums. The first filings of plan year data were required in December 2022 and will be required annually in June of each year on an ongoing basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the enactment or content of new legislation or regulations or changes to existing laws or regulations or their enforcement, interpretation or application, or the effect they will have on our business operations or operating results, which could be materially adverse. Even if we could predict such matters, it is not possible to eliminate the adverse impact of public policy changes that would fundamentally change the dynamics of one or more of the industries in which we compete. Examples of such changes include: the federal or one or more state governments fundamentally restructuring or reducing the funding available for Medicare, Medicaid, dual eligible or dual eligible special needs plan programs, increasing its involvement in drug reimbursement, pricing, purchasing and/or importation, changing the laws and regulations governing PBMs&#8217;, PDPs&#8217; and/or Managed Medicaid organizations&#8217; interactions with government funded health care programs, changing the tax treatment of health or related benefits, or significantly altering the ACA. The likelihood of adverse changes remains high due to state and federal budgetary pressures, and our businesses and operating results could be materially and adversely affected by such changes, even if we correctly predict their occurrence. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on these matters, see &#8220;Government Regulation&#8221; included in Item 1 of this 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable laws and regulations, many of which are highly complex, we could be subject to significant adverse regulatory actions, including monetary penalties, or suffer brand and reputational harm.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our businesses are subject to extensive regulation and oversight by state, federal and international governmental authorities. The laws and regulations governing our operations and interpretations of those laws and regulations, including those related to human capital and climate change, are increasing in number and complexity, change frequently and can be inconsistent or conflict with one another. In general, these laws and regulations are designed to benefit and protect customers, members and providers rather than us or our investors. In addition, the governmental authorities that regulate our businesses have broad latitude to make, interpret and enforce the laws and regulations that govern us and continue to interpret and enforce those laws and regulations more strictly and more aggressively each year. We also must follow various restrictions on certain of our businesses and the payment of dividends by certain of our subsidiaries put in place by certain state regulators.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our Pharmacy Services and Retail/LTC operations, products and services are subject to:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical quality, patient safety and other risks inherent in the dispensing, packaging and distribution of drugs and other health care products and services, including claims related to purported dispensing and other operational errors (any failure by our Pharmacy Services and/or Retail/LTC operations to adhere to the laws and regulations applicable to the dispensing of drugs could subject us to civil and criminal penalties);</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state anti-kickback and other laws that govern our relationship with drug manufacturers, customers and consumers;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance requirements under ERISA, including fiduciary obligations in connection with the development and implementation of items such as drug formularies and preferred drug listings; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state legislative proposals and/or regulatory activity that could adversely affect pharmacy benefit industry practices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Health Care Benefits products are highly regulated, particularly those that serve Public Exchange, Medicare, Medicaid, dual eligible, dual eligible special needs and small group Commercial customers and members. The laws and regulations governing participation in the Public Exchanges, Medicare Advantage (including dual eligible special needs plans), Medicare Part D, Medicaid, and managed Medicaid plans are complex, are subject to interpretation and can expose us to penalties for non-compliance. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope of the practices and activities that are prohibited by federal and state false claims acts is the subject of pending litigation. Claims under federal and state false claims acts can be brought by the government or by private individuals on behalf of the government through a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or &#8220;whistleblower&#8221; suit, and we are a defendant in a number of such proceedings. If we are convicted of fraud or other criminal conduct in the performance of a government program or if there is an adverse decision against us under the False Claims Act, we may be temporarily or permanently suspended from participating in government health care programs, including Public Exchange, Medicare Advantage, Medicare Part D, Medicaid, dual eligible and dual eligible special needs plan programs, and we also may be required to pay significant fines and/or other monetary penalties. Whistleblower suits have resulted in significant settlements between governmental agencies and health care companies. The significant incentives and protections provided to whistleblowers under applicable law increase the risk of whistleblower suits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with laws and regulations that apply to government programs, we could be subject to criminal fines, civil penalties, premium refunds, prohibitions on marketing or active or passive enrollment of members, corrective actions, termination of our contracts or other sanctions which could have a material adverse effect on our ability to participate in Public Exchange, Medicare Advantage, Medicare Part D, Medicaid, dual eligible, and dual eligible special needs plans and other programs and on our operating results, cash flows and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our businesses, profitability and growth also may be adversely affected by (i) judicial and regulatory decisions that change and/or expand the interpretations of existing statutes and regulations, expand fiduciary obligations, impose medical or bad faith liability, increase our responsibilities under ERISA or the remedies available under ERISA, or reduce the scope of ERISA and Medicare Part D preemption of state law claims or (ii) other legislation and regulations. For example, in December 2020, the U.S. Supreme Court upheld an Arkansas law that, among other things, mandates a particular pricing methodology, establishes an appeals process for a pharmacy when the reimbursement is below the pharmacy&#8217;s acquisition cost, permits a pharmacy to reverse and rebill if they cannot procure the drug from its wholesaler at a price equal to or less than the reimbursement rate, prohibits a PBM from reimbursing a pharmacy less than the amount it reimburses an affiliate on a per unit basis, and permits a pharmacy to decline to dispense if the reimbursement is lower than the pharmacy&#8217;s acquisition cost. Subsequently, in November 2021, the U.S. Court of Appeals for the Eighth Circuit upheld a North Dakota law that regulates employer-sponsored ERISA health plans and certain PBM practices within Medicare and in April 2022 the U.S. District Court for the Western District of Oklahoma affirmed that the Oklahoma Insurance Department could enforce a state law against PBMs that contained provisions that alter and limit some of the options that an ERISA plan can use, because none of the provisions mandate that ERISA plans make any specific choices. Additional litigation has been filed in several states to challenge ERISA and Medicare Part D preemption.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our compliance or other systems and processes fail or are deemed inadequate, we may suffer brand and reputational harm and become subject to regulatory actions and/or litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to being subject to extensive and complex regulations, many of our contracts with customers include detailed requirements. In order to be eligible to offer certain products or bid on certain contracts, we must demonstrate that we have robust systems and processes in place that are designed to maintain compliance with all applicable legal, regulatory and contractual requirements. These systems and processes frequently are reviewed and audited by our customers and regulators. If our systems and processes designed to maintain compliance with applicable legal and contractual requirements, and to prevent and detect instances of, or the potential for, non-compliance fail or are deemed inadequate, we may suffer brand and reputational harm and be subject to regulatory actions, litigation and other proceedings which may result in damages, fines, suspension or loss of licensure, suspension or exclusion from participation in government programs and/or other penalties, any of which could adversely affect our businesses, operating results, cash flows and/or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We routinely are subject to litigation and other adverse legal proceedings, including class actions and qui tam actions. Many of these proceedings seek substantial damages which may not be covered by insurance. These proceedings are costly to defend, may result in changes in our business practices, harm our brand and reputation and adversely affect our businesses and operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PBM, retail pharmacy, mail order pharmacy, specialty pharmacy, LTC pharmacy and health care and related benefits are highly regulated industries whose participants frequently are subject to litigation and other adverse legal proceedings. We are currently subject to various litigation and arbitration matters, investigations, regulatory audits, inspections, government inquiries, and regulatory and other legal proceedings, both inside and outside the U.S. For example, outside the U.S., contractual rights, tax positions and applicable regulations may be subject to interpretation or uncertainty to a greater degree than in the U.S. Litigation related to our provision of professional services in our medical clinics, pharmacies and LTC operations is increasing as we expand our services along the continuum of health care.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation, and particularly securities, derivative, collective or class action and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, is often expensive and disruptive. Many of the legal proceedings against us seek substantial damages (including non-economic or punitive damages and treble damages), and certain of these proceedings also seek changes in our business practices. While we currently have insurance coverage for some potential liabilities, other potential liabilities may not be covered by insurance, insurers may dispute coverage and/or the amount of our insurance may not be enough to cover the damages awarded or costs incurred. In addition, some types of damages, like punitive damages, may not be covered by insurance, and in some jurisdictions the coverage of punitive damages is prohibited. Insurance coverage for all or some forms of liability also may become unavailable or prohibitively expensive in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of litigation and other adverse legal proceedings is always uncertain, and outcomes that are not justifiable by the evidence or existing law or regulation can and do occur, and the costs incurred frequently are substantial regardless of the outcome. Litigation and other adverse legal proceedings could materially adversely affect our businesses, operating results and/or cash flows because of brand and reputational harm to us caused by such proceedings, the cost of defending such proceedings, the cost of settlement or judgments against us, or the changes in our operations that could result from such proceedings. See Item 3 of this 10-K for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We frequently are subject to regular and special governmental audits, investigations and reviews that could result in changes to our business practices and also could result in material refunds, fines, penalties, civil liabilities, criminal liabilities and other sanctions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As one of the largest national retail, mail order, specialty and LTC pharmacy, PBM and health care and related benefits providers, we frequently are subject to regular and special governmental market conduct and other audits, investigations and reviews by, and we receive subpoenas and other requests for information from, various federal and state agencies, regulatory authorities, Attorneys General, committees, subcommittees and members of the U.S. Congress and other state, federal and international governmental authorities. For example, we have received CIDs from, and provided documents and information to, the Civil Division of the DOJ in connection with a current investigation of our patient chart review processes in connection with risk adjustment data submissions under Parts C and D of the Medicare program. CMS and the OIG also are auditing the risk adjustment-related data of certain of our Medicare Advantage plans, and the number of such audits continues to increase. Several such audits, investigations and reviews by governmental authorities currently are pending, some of which may be resolved in 2023, the results of which may be adverse to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments have made investigating and prosecuting health care and other insurance fraud, waste and abuse a priority. Fraud, waste and abuse prohibitions encompass a wide range of activities, including kickbacks for referral of members, billing for unnecessary medical and/or other covered services, improper marketing and violations of patient privacy rights. The regulations and contractual requirements applicable to us and other industry participants are complex and subject to change, making it necessary for us to invest significant resources in complying with our regulatory and contractual requirements. Ongoing vigorous law enforcement and the highly technical regulatory scheme mean that our compliance efforts in this area will continue to require significant resources. In addition, our medical costs and the medical expenses of our Health Care Benefits ASC customers may be adversely affected if we do not prevent or detect fraudulent activity by providers and/or members.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regular and special governmental audits, investigations and reviews by federal, state and international regulators could result in changes to our business practices, and also could result in significant or material premium refunds, fines, penalties, civil liabilities, criminal liabilities or other sanctions, including suspension or exclusion from participation in government programs and suspension or loss of licensure. Any of these audits, investigations or reviews could have a material adverse effect on our businesses, operating results, cash flows and/or financial condition or result in significant liabilities and negative publicity for us. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Legal and Regulatory Proceedings&#8221; in Note 16 &#8216;&#8216;Commitments and Contingencies&#8217;&#8217; included in Item 8 of this 10-K for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our litigation and regulatory risk profile are changing as we offer new products and services and expand in business areas beyond our historical core businesses of Health Care Benefits, Pharmacy Services and Retail/LTC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we focused primarily on providing Health Care Benefits, Pharmacy Services and Retail/LTC products and services. As a result of our transformation program and other innovation initiatives, we are expanding our presence in the health care space and plan to offer new products and services which present a different litigation and regulatory risk profile than the products and services that we historically have offered. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increased volume of business in areas beyond our historical core businesses and new products and services subject us to litigation and regulatory risks that are different from the risks of providing Health Care Benefits, Pharmacy Services and Retail/LTC products and services and increase significantly our exposure to other risks.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face unique regulatory and other challenges in our Medicare and Medicaid businesses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking to substantially grow the Medicare and Medicaid membership in our Health Care Benefits segment in 2023 and over the next several years. We face unique regulatory and other challenges that may inhibit the growth and profitability of those businesses.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, CMS issued its final notice detailing final 2023 Medicare Advantage payment rates. Final 2023 Medicare Advantage rates resulted in an expected average increase in revenue for the Medicare Advantage industry of 5.00%, excluding the CMS estimate of Medicare Advantage risk score trend. On February 1, 2023, CMS issued an advance notice detailing proposed 2024 Medicare Advantage payment rates. The 2024 Medicare Advantage rates, if finalized as proposed, will result in an expected average decrease in revenue for the Medicare Advantage industry of 2.27%, excluding the CMS estimate of Medicare Advantage risk score trend, though the rates may vary widely depending on the provider group and patient demographics. CMS intends to publish the final 2024 rate announcement no later than April 3, 2023. The Company faces a challenge from the impact of the increasing cost of medical care (including prescription medications), changes to methodologies for determining payments and CMS local and national coverage decisions that require the Company to pay for services and supplies that are not factored into the Company&#8217;s bids. We cannot predict how the rates will be finalized, future Medicare funding levels, the impact of future federal budget actions or ensure that such changes or actions will not have a material adverse effect on our Medicare operating results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The organic expansion of our Medicare Advantage and Medicare Part D service area is subject to the ability of CMS to process our requests for service area expansions and our ability to build cost competitive provider networks in the expanded service areas that meet applicable network adequacy requirements. CMS&#8217; decisions on our requests for service area expansions also may be affected adversely by compliance issues that arise each year in our Medicare operations. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CMS regularly audits our performance to determine our compliance with CMS&#8217;s regulations and our contracts with CMS and to assess the quality of the services we provide to our Medicare members, and state regulators are increasingly conducting audits to assess the quality of services we provide to our Medicaid members. As a result of these audits, we may be subject to significant or material retroactive adjustments to and/or withholding of certain premiums and fees, fines, criminal liability, civil monetary penalties, CMS- or state-imposed sanctions (including suspension or exclusion from participation in government programs) or other restrictions on our Medicare, Medicaid and other businesses, including suspension or loss of licensure. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Star ratings&#8221; from CMS for our Medicare Advantage plans will continue to have a significant effect on our plans&#8217; operating results. Only Medicare Advantage plans with a star rating of 4 or higher (out of 5) are eligible for a quality bonus in their basic premium rates. CMS continues to change its rating system to make achieving and maintaining a four or higher star rating more difficult. Our star ratings and past performance scores are adversely affected by any compliance issues that may have arisen each year in our Medicare operations. CMS released the Company&#8217;s 2023 star ratings in October 2022. The Company&#8217;s 2023 star ratings will be used to determine which of its Medicare Advantage plans have ratings of 4 stars or higher and qualify for bonus payments in 2024. Based on the 2023 star ratings, the percentage of the Company&#8217;s Medicare Advantage members in 4 stars or higher plans is expected to drop to 21% (based on enrollment and contract affiliation at December 31, 2022), as compared to 87% based on the 2022 star ratings. The main driver of this decrease was a 1 star decrease in the Company&#8217;s Aetna National PPO, which dropped from 4.5 to 3.5 stars, while many other of the Company&#8217;s plans remain rated at 4 stars or higher. The decrease in the star rating for the Aetna National PPO will mean that it will no longer be eligible for CMS&#8217; quality bonus payments related to 2024. A lower star rating may also negatively impact new enrollment in the Aetna National PPO as consumers seek out plans that have four star or higher ratings. There can be no assurances that the Company will be successful in maintaining or improving its star ratings in future years. If our star ratings fall or remain below four for a significant portion of our Medicare Advantage membership, or do not match the performance of our competitors, or the star rating quality bonuses are reduced or eliminated, our revenues, operating results and cash flows may be significantly adversely affected. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Payments we receive from CMS for our Medicare Advantage and Medicare Part D businesses also are subject to risk adjustment based on the health status of the individuals we enroll. Elements of that risk adjustment mechanism continue to be challenged by the DOJ, the OIG and CMS itself. Substantial changes in the risk adjustment mechanism, including those that may result from the RADV Audit Rule or other changes that result from enforcement or audit actions, could materially affect the amount of our Medicare reimbursement, require us to raise prices or reduce the benefits we offer to Medicare beneficiaries, and potentially limit our (and the industry&#8217;s) participation in the Medicare program.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The RADV Audit Rule creates uncertainty for Medicare Advantage plans. The lack of detail provided with respect to how CMS will select contracts and claims to audit and how it will extrapolate as part of the RADV Audit Rule may impact future Medicare Advantage bids and result in other implications.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes to the ability of PBMs to have pharmacy performance programs in place for clients and report payments via direct and indirect reporting mechanisms, including requiring all pharmacy payments to be included in point-of-sale pricing,  could impact the Pharmacy Services business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Part D has resulted in increased utilization of prescription medications and puts pressure on our pharmacy gross margin rates due to regulatory and competitive pressures. Further, as a result of the ACA and changes to the retiree drug subsidy rules, clients of our PBM business could decide to discontinue providing prescription drug benefits to their Medicare-eligible members. To the extent this phenomenon occurs, the adverse effects of increasing customer migration into Medicare Part D may outweigh the benefits we realize from growth of our Medicare Part D products. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Medicare Part D operating results and our ability to expand our Medicare Part D business could be adversely affected if: the cost and complexity of Medicare Part D exceed management&#8217;s expectations or prevent effective program implementation or administration; further changes to the regulations regarding how drug costs are reported for Medicare Part D are implemented in a manner that adversely affects the profitability of our Medicare Part D business; changes to the regulations regarding how drug costs are reported for Medicare Part D are implemented in a manner that adversely affects the profitability of our Medicare Part D business; changes to the applicable regulations impact our ability to retain fees from third parties including network pharmacies; the government alters Medicare Part D program requirements or reduces funding because of the higher-than-anticipated cost to taxpayers of Medicare Part D or for other reasons; the government mandated use of point-of-sale manufacturer&#8217;s rebates continues; the government enacts price controls on certain pharmaceutical products in Medicare Part D; the government makes changes to how pharmacy pay-for-performance is calculated; the government mandates CMS negotiation with manufacturers for certain drugs; or reinsurance thresholds are reduced below their current levels, which is currently scheduled to begin in 2025.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have experienced challenges in obtaining complete and accurate encounter data for our Medicaid products due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format, and with state agencies in coordinating such submissions. As states increase their reliance on encounter data, these difficulties could affect the Medicaid premium rates we receive and how Medicaid membership is assigned to us, which could have a material adverse effect on our Medicaid operating results and cash flows and/or our ability to bid for, and continue to participate in, certain Medicaid programs.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to report and correct errors discovered through our own auditing procedures or during a CMS audit or otherwise fail to comply with the applicable laws and regulations, we could be subject to fines, civil monetary penalties or other sanctions, including fines and penalties under the False Claims Act, which could have a material adverse effect on our ability to participate in Medicare Advantage, Medicare Part D or other government programs, and on our operating results, cash flows and financial condition. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The resumption of Medicaid eligibility redeterminations after being suspended during the COVID-19 pandemic could negatively impact the number of members eligible for the Company&#8217;s Medicaid plans.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Certain of our Medicaid contracts require the submission of complete and correct encounter data. The accurate and timely reporting of encounter data is increasingly important to the success of our Medicaid programs because more states are using encounter data to determine compliance with performance standards and, in part, to set premium rates. We have expended and may continue to expend additional effort and incur significant additional costs to collect accurate, or to correct inaccurate or incomplete, encounter data and have been and could be exposed to premium withholding, operating sanctions and financial fines and penalties for noncompliance. We have experienced challenges in obtaining complete and accurate encounter data due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format, and with state agencies in coordinating such submissions. As states increase their reliance on encounter data, and some states mandate that certain amounts be included or excluded from encounter data, these difficulties could affect the Medicaid premium rates we receive and how Medicaid membership is assigned to us, which could have a material adverse effect on our Medicaid operating results and cash flows and/or our ability to successfully bid for, and continue to participate in, certain Medicaid programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Programs funded in whole or in part by the U.S. federal government account for a significant portion of our revenues, and we expect that percentage to increase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Programs funded in whole or in part by the U.S. federal government account for a significant portion of our revenues, and we expect that percentage to increase. As our government funded businesses grow, our exposure to changes in federal and state government policy with respect to and/or regulation of the various government funded programs in which we participate also increases. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws and regulations governing participation in Public Exchange, Medicare Advantage (including dual eligible special needs plans), Medicare Part D, Medicaid, and managed Medicaid plans are complex, are subject to interpretation and can expose us to penalties for non-compliance. Federal, state and local governments have the right to cancel or not to renew their contracts with us on short notice without cause or if funds are not available. Funding for these programs is dependent on many factors outside our control, including general economic conditions, continuing government efforts to contain health care costs and budgetary constraints at the federal or applicable state or local level and general political issues and priorities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government and our other government customers also may reduce funding for health care or other programs, cancel or decline to renew contracts with us, or make changes that adversely affect the number of persons eligible for certain programs, the services provided to enrollees in such programs, our premiums and our administrative and health care and other benefit costs, any of which could have a material adverse effect on our businesses, operating results and cash flows. When federal funding is delayed, suspended or curtailed, we continue to receive, and we remain liable for and are required to fund, claims from providers for providing services to beneficiaries of federally funded health benefits programs in which we participate. An extended federal government shutdown or a delay by Congress in raising the federal government&#8217;s debt ceiling also could lead to a delay, reduction, suspension or cancellation of federal government spending and a significant increase in interest rates that could, in turn, have a material adverse effect on the value of our investment portfolio, our ability to access the capital markets and our businesses, operating results, cash flows and liquidity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Possible changes in industry pricing benchmarks and drug pricing generally can adversely affect our PBM and Retail/LTC businesses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the pharmaceutical industry, regulators, or federal policymakers may evaluate and/or develop an alternative pricing reference to replace AWP or WAC, which are the pricing references used for many of our PBM and LTC client contracts, drug purchase agreements, retail network contracts, specialty payor agreements and other contracts with third party payors in connection with the reimbursement of drug payments. In addition, many state Medicaid fee-for-service programs have established pharmacy network payments on the basis of Actual Acquisition Cost (&#8220;AAC&#8221;). The use of an AAC basis in fee for service Medicaid could have an impact on reimbursement practices in Health Care Benefits&#8217; Commercial and other Government products. It is also possible that Congress may enact some limited form of price negotiation for Medicare. In addition, CMS also publishes the National Average Drug Acquisition Cost (&#8220;NADAC&#8221;) for certain drugs; NADAC pricing is being adopted in an increasing number of states.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future changes to the use of AWP, WAC or to other published pricing benchmarks used to establish drug pricing, including changes in the basis for calculating reimbursement by federal and state health care programs and/or other payors, could impact the reimbursement we receive from Medicare and Medicaid programs, the reimbursement we receive from our PBM clients and other payors and/or our ability to negotiate rebates and/or discounts with drug manufacturers, wholesalers, PBMs and retail pharmacies. A failure or inability to fully offset any increased prices or costs or to modify our operations to mitigate the impact of such increases could have a material adverse effect on our operating results. Additionally, any future changes in drug prices could be significantly different than our projections. We cannot predict the effect of these possible changes on our businesses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain adequate premium rate increases in our Insured Health Care Benefits products, which would have an adverse effect on our revenues, MBRs and operating results and could magnify the adverse impact of increases in health care and other benefit costs and of ACA assessments, fees and taxes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium rates for our Insured Health Care Benefits products often must be filed with state insurance regulators and are subject to their approval, which creates risk for us in the current political and regulatory environment. The ACA generally requires a review by HHS in conjunction with state regulators of premium rate increases that exceed a federally specified threshold (or lower state-specific thresholds set by states determined by HHS to have adequate processes). Rate reviews can magnify the adverse impact on our operating margins, MBRs and operating results of increases in health care and other benefit costs, increased utilization of covered services, and ACA assessments, fees and taxes, by restricting our ability to reflect these increases and/or these assessments, fees and taxes in our pricing. Further, our ability to reflect ACA assessments, fees and taxes in our Medicare, Medicaid and CHIP premium rates is limited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2013, HHS has issued determinations to health plans that their premium rate increases were &#8220;unreasonable,&#8221; and we continue to experience challenges to appropriate premium rate increases in certain states. Regulators or legislatures in several states have implemented or are considering limits on premium rate increases, either by enforcing existing legal requirements more stringently or proposing different regulatory standards. Regulators or legislatures in several states also have conducted hearings on proposed premium rate increases, which can result, and in some instances have resulted, in substantial delays in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implementing proposed rate increases even if they ultimately are approved. Our plans can be excluded from participating in small group Public Exchanges if they are deemed to have a history of &#8220;unreasonable&#8221; rate increases. Any significant rate increases we may request heighten the risks of adverse publicity, adverse regulatory action and adverse selection and the likelihood that our requested premium rate increases will be denied, reduced or delayed, which could lead to operating margin compression.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate continued regulatory and legislative action to increase regulation of premium rates in our Insured Health Care Benefits products. We may not be able to obtain rates that are actuarially justified or that are sufficient to make our policies profitable in one or more product lines or geographies. If we are unable to obtain adequate premium rates and/or premium rate increases, it could materially and adversely affect our operating margins and MBRs and our ability to earn adequate returns on Insured Health Care Benefits products in one or more states or cause us to withdraw from certain geographies and/or products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Minimum MLR rebate requirements limit the level of margin we can earn in our Insured Health Care Benefits products while leaving us exposed to higher than expected medical costs. Challenges to our minimum MLR rebate methodology and/or reports could adversely affect our operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA&#8217;s minimum MLR rebate requirements limit the level of margin we can earn in Health Care Benefits&#8217; Commercial Insured and Medicare Insured businesses. CMS minimum MLR rebate regulations limit the level of margin we can earn in our Medicaid Insured business. Certain portions of our Health Care Benefits Medicaid and FEHB program business also are subject to minimum MLR rebate requirements in addition to but separate from those imposed by the ACA. Minimum MLR rebate requirements leave us exposed to medical costs that are higher than those reflected in our pricing. The process supporting the management and determination of the amount of MLR rebates payable is complex and requires judgment, and the minimum MLR reporting requirements are detailed. CMS has also proposed, but not yet finalized, a definition of &#8220;prescription drug price concessions&#8221; for commercial MLR calculation purposes, which would make additional PBM information available to plans and the HHS, potentially further complicating the MLR calculation process. Federal and state auditors are challenging our Commercial Health Care Benefits business&#8217; compliance with the ACA&#8217;s minimum MLR requirements as well as our FEHB plans&#8217; compliance with OPM&#8217;s FEHB program-specific minimum MLR requirements. Our Medicare and Medicaid contracts also are subject to minimum MLR audits. If a Medicare Advantage or Medicare Part D contract pays minimum MLR rebates for three consecutive years, it will become ineligible to enroll new members. If a Medicare Advantage or Medicare Part D contract pays such rebates for five consecutive years, it will be terminated by CMS. Additional challenges to our methodology and/or reports relating to minimum MLR and related rebates by federal and state regulators and private litigants are reasonably possible. The outcome of these audits and additional challenges could adversely affect our operating results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may be adversely affected by changes in laws and policies governing employers and by union organizing activity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress and certain state legislatures continue to consider and pass legislation that increases our costs of doing business, including increased minimum wages and requiring employers to provide paid sick leave or paid family leave. In addition, our employee-related operating costs may be increased by union organizing activity and it is possible that the National Labor Relations Board may adopt regulatory changes through re-making or case law that could facilitate union organizing. If we are unable to reflect these increased expenses in our pricing or otherwise modify our operations to mitigate the effects of such increases, our operating results will be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face international political, legal and compliance, operational, regulatory, economic and other risks that may be more significant than in our domestic operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations present political, legal, compliance, operational, regulatory, economic and other risks that we do not face or that are more significant than in our domestic operations. These risks vary widely by country and include varying regional and geopolitical business conditions and demands, government intervention and censorship, discriminatory regulation, climate change regulation, nationalization or expropriation of assets and pricing constraints. Our international products need to meet country-specific customer and member preferences as well as country-specific legal requirements, including those related to licensing, data privacy, data storage and data protection.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations increase our exposure to, and require us to devote significant management resources to implement controls and systems to comply with, the privacy and data protection laws of non-U.S. jurisdictions, such as the EU&#8217;s GDPR, and the anti-bribery, anti-corruption and anti-money laundering laws of the United States (including the FCPA) and the United Kingdom (including the UK Bribery Act) and similar laws in other jurisdictions. Implementing our compliance policies, internal controls and other systems may also require the investment of considerable management time and financial and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or employees, restrictions or outright prohibitions on the conduct of our business, and significant brand and reputational harm. We must regularly reassess the size, capability and location of our global infrastructure and make appropriate changes, and must have effective change management processes and internal controls in place to address changes in our businesses and operations. Our success depends, in part, on our ability to anticipate these risks and manage these difficulties, and the failure to do so could have a material adverse effect on our brand, reputation, businesses, operating results and/or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations require us to overcome logistical and other challenges based on differing languages, cultures, legal and regulatory schemes and time zones. Our international operations encounter labor laws, standards and customs that can be difficult and make employee relationships less flexible than in our domestic operations and expensive to modify or terminate. In some countries we are required to, or choose to, operate with local business associates, which requires us to manage our relationships with these third parties and may reduce our operational flexibility and ability to quickly respond to business challenges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries we may be exposed to currency exchange controls or other restrictions that prevent us from transferring funds internationally or converting local currencies into U.S. dollars or other currencies. Fluctuations in foreign currency exchange rates may adversely affect our revenues, operating results and cash flows from our international operations. Some of our operations are, and are increasingly likely to be, in emerging markets where these risks are heightened. Any measures we may implement to reduce the effect of volatile currencies and other risks on our international operations may not be effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Associated with Mergers, Acquisitions, and Divestitures </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to successfully integrate companies we acquire.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of any acquisition, including the proposed acquisition of Oak Street Health and pending acquisition of Signify Health, we will need to successfully integrate the products, services and related assets, as well as internal controls into our business operations. If an acquisition is consummated, the integration of the acquired business, its products, services and related assets into our company also may be complex, expensive, and time-consuming and, if the integration is not fully successful, we may not achieve the anticipated benefits, operating and cost synergies and/or growth opportunities of an acquisition. Potential difficulties that may be encountered in the integration process, including with respect to Oak Street Health and Signify Health, include the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Integrating personnel, operations and systems (including internal control environments and compliance policies), while maintaining focus on producing and delivering consistent, high quality products and services;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Coordinating geographically dispersed organizations;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disrupting management&#8217;s attention from our ongoing business operations;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retaining existing customers and attracting new customers; </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Managing inefficiencies associated with integrating our operations; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reconciling post-acquisition costs and liabilities between buyer and seller.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An inability to realize the full extent of the anticipated benefits, operating and cost synergies, innovations and operations efficiencies or growth opportunities of an acquisition, including the proposed acquisition of Oak Street Health and pending acquisition of Signify Health, as well as any delays or additional expenses encountered in the integration process, could have a material adverse effect on our businesses and operating results. Furthermore, acquisitions, including the proposed acquisition of Oak Street Health and pending acquisition of Signify Health, even if successfully integrated, may fail to further our business strategy as anticipated, expose us to increased competition or challenges with respect to our products, services or service areas, and expose us to additional liabilities associated with an acquired business including risks and liabilities associated with litigation involving the acquired business. Any one of these challenges or risks could impair our ability to realize any benefit from our acquisitions after we have expended resources on them.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to pursue acquisitions, joint ventures, strategic alliances and other inorganic growth opportunities, as well as strategic divestitures, which may be unsuccessful, cause us to assume unanticipated liabilities, disrupt our existing businesses, be dilutive or lead us to assume significant debt, among other things.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to pursue acquisitions, joint ventures, strategic alliances and other inorganic growth opportunities as part of our growth strategy. In addition to the integration risks noted above, some other risks we may face with respect to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisitions, including the proposed acquisition of Oak Street Health and pending acquisition of Signify Health, and other inorganic growth strategies include:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to obtain the required regulatory approval for an acquisition in a timely manner, if at all;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we frequently compete with other firms, some of which may have greater financial and other resources and a greater tolerance for risk, to acquire attractive companies;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acquired, alliance and/or joint venture businesses may not perform as projected;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the goodwill or other intangible assets established as a result of our acquisitions may be incorrectly valued or may become impaired;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may assume unanticipated liabilities, including those that were not disclosed to us or which we underestimated;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acquired businesses, or the pursuit of other inorganic growth strategies, could disrupt or compete with our existing businesses, distract management, result in the loss of key employees, business partners, suppliers and customers, divert resources, result in tax costs or inefficiencies and make it difficult to maintain our current business standards, controls, information technology systems, policies, procedures and performance;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may finance future acquisitions and other inorganic growth strategies by issuing common stock for some or all of the purchase price, which would dilute the ownership interests of our stockholders;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may incur significant debt in connection with acquisitions (whether to finance acquisitions or by assuming debt from the businesses we acquire);</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proposed or pending transaction may have a negative effect on the Company&#8217;s credit ratings;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have the expertise to manage and profitably grow the businesses we acquire, and we may need to rely on the retention of key personnel and other suppliers of businesses we acquire, which may be difficult or impossible to accomplish;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may enter into merger or purchase agreements but, due to reasons within or outside our control, fail to complete the related transactions, which could result in termination fees or other penalties that could be material, cause material disruptions to our businesses and operations and adversely affect our brand, reputation, or stock price; for example, if the proposed acquisition of Oak Street Health terminates under certain specified circumstances and the receipt of regulatory approval has not been obtained by such time, the Company will be required to pay Oak Street Health a termination fee of approximately $500 million and if the pending acquisition of Signify Health terminates under certain specified circumstances and the receipt of regulatory approval has not been obtained by such time, the Company will be required to pay Signify Health a termination fee in an amount equal to $380 million;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in order to complete an acquisition, we may be required to divest certain portions of our business, for which we may not be able to obtain favorable pricing;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be involved in litigation related to mergers or acquisitions, including for matters that occurred prior to the applicable closing, which may be costly to defend and may result in adverse rulings against us that could be material; </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements related to an acquisition could have an adverse effect on the market price of the Company&#8217;s common stock and other securities; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the integration into our businesses of the businesses and entities we acquire may affect the way in which existing laws and regulations apply to us, including subjecting us to laws and regulations that did not previously apply to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, we may also seek to divest assets that no longer fit into our long-term strategic plan. Such divestitures may take time and, even if such divestitures can be completed, they may have negative short-term financial impacts or may result in regulatory and financial exposure to businesses we have sold. In addition, joint ventures present risks that are different from acquisitions, including selection of appropriate joint venture parties, initial and ongoing governance of the joint venture, joint venture compliance activities (including compliance with applicable CMS requirements), growing the joint venture&#8217;s business in a manner acceptable to all the parties, including other providers in the networks that include joint ventures, maintaining positive relationships among the joint venture parties and the joint venture&#8217;s customers, and member and business disruption that may occur upon joint venture termination.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to meet customer expectations may harm our brand and reputation, our ability to retain and grow our customer base and membership and our operating results and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to attract and retain customers and members is dependent upon providing cost effective, quality customer service operations (such as call center operations, PBM functions, retail pharmacy and LTC services, retail, mail order and specialty </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmacy prescription delivery, claims processing, customer case installation and online access and tools) that meet or exceed our customers&#8217; and members&#8217; expectations, either directly or through vendors. As we seek to reduce general and administrative expenses, we must balance the potential impact of cost-saving measures on our customers and other services and performances. If we misjudge the effects of such measures, customers and other services may be adversely affected. We depend on third parties for certain of our customer service, PBM and prescription delivery operations. If we or our vendors fail to provide service that meets our customers&#8217; and members&#8217; expectations, we may have difficulty retaining or profitably growing our customer base and/or membership, which could adversely affect our operating results. For example, noncompliance with any privacy or security laws or regulations or any security breach involving us or one of our third-party vendors could have a material adverse effect on our businesses, operating results, brand and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our vendors have experienced and continue to experience cyber attacks. We can provide no assurance that we or our vendors will be able to detect, prevent or contain the effects of such attacks or other information security (including cybersecurity) risks or threats in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our vendors have experienced diverse cyber attacks and expect to continue to experience cyber attacks going forward. As examples, the Company and its vendors have experienced attempts to gain access to systems, denial of service attacks, attempted malware infections, account takeovers, scanning activity, and phishing emails. Attacks can originate from external sources (including criminals, terrorists, nation states, or internal actors). The Company is dedicating and will continue to dedicate significant resources and incur significant expenses to maintain and update on an ongoing basis the systems and processes that are designed to mitigate the information security risks it faces and protect the security of its computer systems, software, networks and other technology assets against attempts by unauthorized parties to obtain access to confidential information, disrupt or degrade service, or cause other damage. The impact of known cyber attacks has not been material to the Company&#8217;s operations or operating results through December 31, 2022. The Board and its Audit Committee and Nominating and Corporate Governance Committee are regularly informed regarding the Company&#8217;s information security policies, practices and status. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A compromise of our information security controls or of those businesses with whom we interact, which results in confidential information being accessed, obtained, damaged, or used by unauthorized or improper persons, could harm our reputation and expose us to regulatory actions and claims from customers and clients, financial institutions, payment card associations and other persons, any of which could adversely affect our businesses, operating results and financial condition. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these techniques or to implement adequate preventative measures. Moreover, a data security breach could require that we expend significant resources related to our information systems and infrastructure, and could distract management and other key personnel from performing their primary operational duties. We also could be adversely affected by any significant disruption in the systems of third parties we interact with, including key payors and vendors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of attempting to protect against the foregoing risks and the costs of responding to an information security incident are significant. Large scale data breaches at other entities increase the challenge we and our vendors face in maintaining the security of our information technology systems and proprietary information and of our customers&#8217;, employees&#8217;, members&#8217; and other constituents&#8217; sensitive information. Following an information security incident, our and/or our vendors&#8217; remediation efforts may not be successful, and could result in interruptions, delays or cessation of service, and loss of existing or potential customers and members. In addition, breaches of our and/or our vendors&#8217; security measures and the unauthorized access to or dissemination of sensitive personal information or proprietary information or confidential information about us, our customers, our members or other third-parties, could expose our customers&#8217;, members&#8217; and other constituents&#8217; private information and our customers, members and other constituents to the risk of financial or medical identity theft, or expose us or other third parties to a risk of loss or misuse of this information, and result in investigations, regulatory enforcement actions, material fines and penalties, loss of customers, litigation or other actions which could have a material adverse effect on our brand, reputation, businesses, operating results and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data governance failures can adversely affect our reputation, businesses and prospects. Our use and disclosure of members&#8217;, customers&#8217; and other constituents&#8217; sensitive information is subject to complex regulations at multiple levels. We would be adversely affected if we or our business associates or other vendors fail to adequately protect members&#8217;, customers&#8217; or other constituents&#8217; sensitive information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information systems are critical to the operation of our businesses. We collect, process, maintain, retain, evaluate, utilize and distribute large amounts of personally identifiable, personal health, and financial information (including payment card information) and other confidential and sensitive data about our customers, employees, members and other constituents in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ordinary course of our businesses. Some of our information systems rely upon third party systems, including cloud service providers, to accomplish these tasks. The use and disclosure of such information is regulated at the federal, state and international levels, including, for example, the California Consumer Privacy Act which went into effect January 1, 2020, the EU&#8217;s GDPR which began to apply across the EU during 2018 and the audit program implemented by HHS under HIPAA. In some cases, such laws, rules and regulations also apply to our vendors and/or may hold us liable for any violations by our vendors. These laws, rules and regulations are subject to change (and many are rapidly evolving) and in recent years have given rise to increased enforcement activity, litigation, and other disputes. International laws, rules and regulations governing the use and disclosure of these types of  information are generally more stringent than U.S. laws and regulations, and they vary from jurisdiction to jurisdiction. Noncompliance with applicable privacy or security laws or regulations, or any security breach, information security incident, and any other incident involving the theft, misappropriation, loss or other unauthorized disclosure of, or access to, sensitive or confidential customer, member or other constituent information, whether by us, by one of our business associates or vendors or by another third party, could require us to expend significant resources to remediate any damage, could interrupt our operations and could adversely affect our brand and reputation, membership and operating results and also could expose and/or has exposed us to mandatory disclosure requirements, adverse media attention, litigation (including class action litigation), governmental investigations and enforcement proceedings, material fines, penalties and/or remediation costs, and compensatory, special, punitive and statutory damages, consent orders, adverse actions against our licenses to do business and/or injunctive relief, any of which could adversely affect our businesses, operating results, cash flows or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our businesses depend on our customers&#8217;, members&#8217; and other constituents&#8217; willingness to entrust us with their health related and other sensitive personal information. Events that adversely affect that trust, including inadequate disclosure to our members or customers of our uses of their information, failing to keep our information technology systems and our customers&#8217;, members&#8217; and other constituents&#8217; sensitive information secure from significant attack, theft, damage, loss or unauthorized disclosure or access, whether as a result of our action or inaction (including human error) or that of our business associates, vendors or other third parties, could adversely affect our brand and reputation, membership and operating results and also could expose and/or has exposed us to mandatory disclosure to the media, litigation (including class action litigation), governmental investigations and enforcement proceedings, material fines, penalties and/or remediation costs, and compensatory, special, punitive and statutory damages, consent orders, adverse actions against our licenses to do business and/or injunctive relief, any of which could adversely affect our businesses, operating results, cash flows or financial condition. There can be no assurance that awe have or will be able to adequately prevent, detect, and/or remediate such data security incidents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability, product recall or personal injury issues could damage our reputation and have a significant adverse effect on our businesses, operating results, cash flows and/or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products that we sell could become subject to contamination, product tampering, mislabeling, recall or other damage. In addition, errors in the dispensing, packaging or administration of drugs or other products and consuming drugs in a manner that is not prescribed could lead to serious injury or death. Product liability or personal injury claims may be asserted against us with respect to any of the drugs or other products we sell or services we provide. For example, we are a defendant in hundreds of litigation proceedings relating to opioids and the sale of products containing talc. Our businesses involve the provision of professional services, including by pharmacists, physician assistants, nurses and nurse practitioners, which exposes us to professional liability claims. Should a product or other liability issue arise, the coverage available under our insurance programs and the indemnification amounts available to us from third parties may not be adequate to protect us against the financial impact of the related claims. We also may not be able to maintain our existing levels of insurance on acceptable terms in the future. A product liability or personal injury issue or judgment against us or a product recall, tampering, or mislabeling could damage our reputation and have a significant adverse effect on our businesses, operating results and/or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to our success, and our failure to do so could adversely affect our businesses, operating results and/or future performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to attract and retain qualified and experienced employees is essential to meet our current and future goals and objectives. There is no guarantee we will be able to attract and retain such employees or that competition among potential employers will not result in increased compensation and/or benefits costs. If we are unable to retain existing employees or attract additional employees, or we experience an unexpected loss of leadership, we could experience a material adverse effect on our businesses, operating results and/or future performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our failure to adequately plan for succession of senior management and other key management roles or the failure of key employees to successfully transition into new roles could have a material adverse effect on our businesses, operating </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results and/or future performance. The succession plans we have in place and our employment arrangements with certain key executives do not guarantee the services of these executives will continue to be available to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our products and services are dependent on our ability to attract and motivate internal sales personnel and independent third-party brokers, consultants and agents. New distribution channels create new disintermediation risk. We may be subject to penalties or other regulatory actions as a result of the marketing practices of brokers and agents selling our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are sold primarily through our sales personnel, who frequently work with independent brokers, consultants and agents who assist in the production and servicing of business. The independent brokers, consultants and agents generally are not dedicated to us exclusively and may frequently recommend and/or market health care benefits products of our competitors. Accordingly, we must compete intensely for their services and allegiance. Our sales could be adversely affected if we are unable to attract, retain or motivate sales personnel and third-party brokers, consultants and agents, or if we do not adequately provide support, training and education to this sales network regarding our complex product portfolio, or if our sales strategy is not appropriately aligned across distribution channels. This risk is heightened as we develop, operate and expand our consumer-oriented products and services and we expand in the health care space and our business model evolves to include a greater focus on consumers and direct-to-consumer sales, such as competing for sales on Insurance Exchanges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New distribution channels for our products and services continue to emerge, including Private Exchanges operated by health care consultants and technology companies. These channels may make it more difficult for us to directly engage consumers and other customers in the selection and management of their health care benefits, in health care utilization and in the effective navigation of the health care system. We also may be challenged by new technologies and marketplace entrants that could interfere with our existing relationships with customers and health plan members in these areas.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been several investigations regarding the marketing practices of brokers and agents selling health care and other insurance products and the payments they receive. These investigations have resulted in enforcement actions against companies in our industry and brokers and agents marketing and selling those companies&#8217; products. For example, CMS and state departments of insurance have increased their scrutiny of the marketing practices of brokers and agents who market Medicare products. These investigations and enforcement actions could result in penalties and the imposition of corrective action plans and/or changes to industry practices, which could adversely affect our ability to market our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure of our businesses to effectively collaborate could prevent us from maximizing our operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To maximize our overall enterprise value, our various businesses need to collaborate effectively. Our businesses need to be aligned in order to prioritize goals and coordinate the design of new products intended to utilize the offerings of multiple businesses, including our transformation and enterprise modernization programs. In addition, misaligned incentives, information siloes, ineffective product development and failure of our corporate governance policies or procedures, for example significant financial decisions being made at an inappropriate level in our organization, also could prevent us from maximizing our operating results and/or achieving our financial and other projections. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure or disruption of our information technology systems or the failure of our information technology infrastructure to support our businesses could adversely affect our reputation, businesses, operating results and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information systems are subject to damage or interruption from power outages, facility damage, computer and telecommunications failures, computer viruses, security breaches (including credit card or personally identifiable information breaches), cyber attacks, vandalism, catastrophic events and human error. If our information systems are damaged, fail to work properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and may experience reputational damage, loss of critical information, customer disruption and interruptions or delays in our ability to perform essential functions and implement new and innovative services. We use third-party vendors to set-up, service, and/or maintain portions of our information technology systems, and our vendors may suffer the same types of issues, which could adversely affect our ability to access and use such systems and the data contained therein, which could result in similar harm. In addition, our efforts to comply with changes in U.S. and foreign laws and regulations, including privacy and information security laws and standards, may cause us to incur significant expense due to increased investment in technology and the development of new operational processes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business success and operating results depend in part on effective information technology systems and on continuing to develop and implement improvements in technology. Pursuing multiple initiatives simultaneously could make this continued development and implementation significantly more challenging.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many aspects of our operations are dependent on our information systems and the information collected, processed, stored, and handled by these systems. We rely heavily on our computer systems to manage our ordering, pricing, point-of-sale, pharmacy fulfillment, inventory replenishment, claims processing, customer loyalty and subscription programs, finance, human resources, and other processes. Throughout our operations, we collect, process, maintain, retain, evaluate, utilize and distribute large amounts of confidential and sensitive data and information, including personally identifiable information and protected health information, that our customers, employees, members and other constituents provide to purchase products or services, enroll in programs or services, register on our websites, interact with our personnel, or otherwise communicate with us. For these operations, we depend in part on the secure transmission of confidential information over public networks.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have many different information and other technology systems supporting our businesses (including as a result of our acquisitions). Our businesses depend in large part on these systems to adequately price our products and services; accurately establish reserves, process claims and report operating results; and interact with providers, employer plan sponsors, customers, members, consumers and vendors in an efficient and uninterrupted fashion. In addition, recent trends toward greater consumer engagement in health care require new and enhanced technologies, including more sophisticated applications for mobile devices. Certain of our technology systems (including software) are older, legacy systems that are less flexible, less efficient and require a significant ongoing commitment of capital and human resources to maintain, protect and enhance them and to integrate them with our other systems. We must re-engineer and reduce the number of these systems to meet changing consumer and vendor preferences and needs, improve our productivity and reduce our operating expenses. We also need to develop or acquire new technology systems, contract with new vendors or modify certain of our existing systems to support the consumer-oriented and transformation products and services we are developing, operating and expanding and/or to meet current and developing industry and regulatory standards, including to keep pace with continuing changes in information processing technology, emerging cybersecurity risks and threats, and changes to applicable privacy and security laws, rules and regulations. If we fail to achieve these objectives, our ability to profitably grow our business and/or our operating results may be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, information technology and other technology and process improvement projects, including our transformation and enterprise modernization programs, frequently are long-term in nature and may take longer to complete and cost more than we expect and may not deliver the benefits we project once they are complete. If we do not effectively and efficiently secure, manage, integrate and enhance our technology portfolio (including vendor sourced systems), we could, among other things, have problems determining health care and other benefit cost estimates and/or establishing appropriate pricing, meeting the needs of customers, consumers, providers, members and vendors, developing and expanding our consumer-oriented products and services or keeping pace with industry and regulatory standards, and our operating results may be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to payment-related risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and disrupt our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accept payments using a variety of methods, including cash, checks, credit cards, debit cards, gift cards, mobile payments and potentially other technologies in the future. Acceptance of these payment methods subjects us to rules, regulations, contractual obligations and compliance requirements, including payment network rules and operating guidelines, data security standards and certification requirements, and rules governing electronic funds transfers. These requirements may change in the future, which could make compliance more difficult or costly. For certain payment options, including credit and debit cards, we pay interchange and other fees, which could increase periodically thereby raising our operating costs. We rely on third parties to provide payment processing services, including the processing of credit cards, debit cards, and various other forms of electronic payment. If these vendors are unable to provide these services to us, or if their systems are compromised, our operations could be disrupted. The payment methods that we offer also expose us to potential fraud and theft by persons seeking to obtain unauthorized access to, or exploit any weaknesses in, the payment systems we use. If we fail to abide by applicable rules or requirements, or if data relating to our payment systems is compromised due to a breach or misuse, we may be responsible for any costs incurred by payment card issuing banks and other third parties or subject to fines and higher transaction fees. In addition, our reputation and ability to accept certain types of payments could each be harmed resulting in reduced sales and adverse effects on our operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Both our and our vendors&#8217; operations are subject to a variety of business continuity hazards and risks, any of which could interrupt our operations or otherwise adversely affect our performance and operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our vendors are subject to business continuity hazards and other risks, including natural disasters, utility and other mechanical failures, acts of war or terrorism, acts of civil unrest, crime, disruption of communications, data security and preservation, disruption of supply or distribution, safety regulation and labor difficulties. The occurrence of any of these or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other events to us or our vendors might disrupt or shut down our operations or otherwise adversely affect our operations. We also may be subject to certain liability claims in the event of an injury or loss of life, or damage to property, resulting from such events. Although we have developed procedures for crisis management and disaster recovery and business continuity plans and maintain insurance policies that we believe are customary and adequate for our size and industry, our insurance policies include limits and exclusions and, as a result, our coverage may be insufficient to protect against all potential hazards and risks incident to our businesses. In addition, our crisis management and disaster recovery procedures and business continuity plans may not be effective. Should any such hazards or risks occur, or should our insurance coverage be inadequate or unavailable, our businesses, operating results, cash flows and financial condition could be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We would be adversely affected if we do not effectively deploy our capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Downgrades or potential downgrades in our credit ratings, should they occur, could adversely affect our brand and reputation, businesses, operating results, cash flows and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations generate significant capital, and we may from time to time raise additional capital, subject to market conditions. The manner in which we deploy our capital, including investments in our businesses, our operations (such as information technology and other strategic and capital projects), dividends, acquisitions, share and/or debt repurchases, repayment of debt, reinsurance or other capital uses, impacts our financial strength, claims paying ability and credit ratings issued by nationally-recognized statistical rating organizations. Credit ratings issued by nationally-recognized statistical rating organizations are broadly distributed and generally used throughout our industries. Our ratings reflect each rating organization&#8217;s opinion of our financial strength, operating performance and ability to meet our debt obligations or obligations to our insureds. We believe our credit ratings and the financial strength and claims paying ability of our principal insurance and HMO subsidiaries are important factors in marketing our Health Care Benefits products to certain of our customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the ratings organizations reviews our ratings periodically, and there can be no assurance that our current ratings will be maintained in the future. Downgrades in our ratings could adversely affect our businesses, operating results, cash flows and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and other intangible assets could, in the future, become impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and December&#160;31, 2021, we had $102.9 billion and $108.1 billion, respectively, of goodwill and other intangible assets. Goodwill and indefinite-lived intangible assets are subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate that the carrying value may not be recoverable. When evaluating goodwill for potential impairment, we compare the fair value of our reporting units to their respective carrying amounts. We estimate the fair value of our reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, a goodwill impairment loss is recognized in an amount equal to the excess to the extent of the goodwill balance. Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value. Definite-lived intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying value of such an asset may not be recoverable. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group&#8217;s estimated future cash flows (discounted). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values could change if, for example, there are changes in the business climate, industry-wide changes, changes in the competitive environment, adverse legal or regulatory actions or developments, changes in capital structure, cost of debt, interest rates, capital expenditure levels, operating cash flows or market capitalization. Because of the significance of our goodwill and intangible assets, any future impairment of these assets could require material noncash charges to our operating results, which also could have a material adverse effect on our financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse conditions in the U.S. and global capital markets can significantly and adversely affect the value of our investments in debt and equity securities, mortgage loans, alternative investments and other investments, and our operating results and/or our financial condition.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global capital markets, including credit markets, continue to experience volatility and uncertainty. As an insurer, we have a substantial investment portfolio that supports our policy liabilities and surplus and is comprised largely of debt securities of issuers located in the U.S. As a result, the income we earn from our investment portfolio is largely driven by the level of interest rates in the U.S., and to a lesser extent the international financial markets; and volatility, uncertainty and/or disruptions in the global capital markets, particularly the U.S. credit markets, and governments&#8217; monetary policy, particularly U.S. monetary policy, can significantly and adversely affect the value of our investment portfolio, our operating results and/or our financial condition by:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly reducing the value and/or liquidity of the debt securities we hold in our investment portfolio and creating realized capital losses that reduce our operating results and/or unrealized capital losses that reduce our shareholders&#8217; equity;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lowering interest rates on high-quality short-term or medium-term debt securities and thereby materially reducing our net investment income and operating results as the proceeds from securities in our investment portfolio that mature or are otherwise disposed of continue to be reinvested in lower yielding securities;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reducing the fair values of our investments if interest rates rise;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">causing non-performance of or defaults on their obligations to us by third parties, including customers, issuers of securities in our investment portfolio, mortgage borrowers and/or reinsurance and/or derivatives counterparties;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making it more difficult to value certain of our investment securities, for example if trading becomes less frequent, which could lead to significant period-to-period changes in our estimates of the fair values of those securities and cause period-to-period volatility in our net income and shareholders&#8217; equity;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reducing our ability to issue short-term debt securities at attractive interest rates, thereby increasing our interest expense and decreasing our operating results; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reducing our ability to issue other securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we seek, within guidelines we deem appropriate, to match the duration of our assets and liabilities and to manage our credit and counterparty exposures, a failure adequately to do so could adversely affect our net income and our financial condition and, in extreme circumstances, our cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Manufacturers, Providers, Suppliers and Vendors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks relating to the market availability, pricing, suppliers and safety profiles of prescription drugs and other products that we purchase and sell.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Retail/LTC segment and our mail order and specialty pharmacy operations generate revenues in significant part by dispensing prescription drugs. Our PBM business generates revenues primarily by contracting with clients to provide prescription drugs and related health care services to plan members. As a result, we are dependent on our relationships with prescription drug manufacturers and suppliers. We acquire a substantial amount of our mail order and specialty pharmacies&#8217; prescription drug supply from a limited number of suppliers. Certain of our agreements with such suppliers are short-term and cancelable by either party without cause. In addition, these agreements may allow the supplier to distribute through channels other than us. Certain of these agreements also allow pricing and other terms to be adjusted periodically for changing market conditions or required service levels. A termination or modification to any of these relationships could adversely affect our prescription drug supply and have a material adverse effect on our businesses, operating results and financial condition. Moreover, many products distributed by our pharmacies are manufactured with ingredients that are susceptible to supply shortages. In some cases, we depend upon a single source of supply. Any such supply shortages or loss of any such single source of supply could adversely affect our operating results and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of the branded and generic drug product that we sell in our pharmacies, and much of the other merchandise we sell, is manufactured in whole or in substantial part outside of the United States. In most cases, the products or merchandise are imported by others and sold to us. As a result, significant changes in tax or trade policies, tariffs or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, could result in significant increases in our costs, restrict our access to suppliers, depress economic activity, and have a material adverse effect on our businesses, operating results and cash flows. In addition, other countries may change their business and trade policies and such changes, as well as any negative sentiments towards the United States in response to increased import tariffs and other changes in U.S. trade regulations, could adversely affect our businesses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our suppliers are independent entities subject to their own operational and financial risks that are outside our control. If our current suppliers were to stop selling prescription drugs to us or delay delivery, including as a result of supply shortages, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supplier production disruptions, supplier quality issues, closing or bankruptcies of our suppliers, or for other reasons, we may be unable to procure alternatives from other suppliers in a timely and efficient manner and on acceptable terms, or at all. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may be adversely affected if we are unable to contract with providers on competitive terms and develop and maintain attractive networks with high quality providers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking to enhance our health care provider networks by entering into joint ventures and other collaborative risk-sharing arrangements with providers. Providers&#8217; willingness to enter these arrangements with us depends upon, among other things, our ability to provide them with up to date quality of care data to support these value-based contracts. These arrangements are designed to give providers incentives to engage in population health management and optimize delivery of health care to our members. These arrangements also may allow us to expand into new geographies, target new customer groups, increase membership and reduce medical costs and, if we provide technology or other services to the relevant health system or provider organization, may contribute to our revenue and earnings from alternative sources. If such arrangements do not result in the lower medical costs that we project or if we fail to attract providers to such arrangements, or are less successful at implementing such arrangements than our competitors, our medical costs may not be competitive and may be higher than we project, our attractiveness to customers may be reduced, we may lose or be unable to grow medical membership, and our ability to profitably grow our business and/or our operating results may be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe joint ventures, accountable care organizations (&#8220;ACOs&#8221;) and other non-traditional health care provider organizational structures present opportunities for us, the implementation of our joint ventures and other non-traditional structure strategies may not achieve the intended results, which could adversely affect our operating results and cash flows. Among other things, joint ventures require us to maintain collaborative relationships with our counterparties, continue to gain access to provider rates that make the joint ventures economically sustainable and devote significant management time to the operation and management of the joint ventures. We may not be able to achieve these objectives in one or more of our joint ventures, which could adversely affect our operating results and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our suppliers or service providers fail to meet their contractual obligations to us or to comply with applicable laws or regulations, we may be exposed to brand and reputational harm, litigation and/or regulatory action. This risk is particularly high in our Medicare, Medicaid, dual eligible and dual eligible special needs plan programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our suppliers, we contract with various third parties to perform certain functions and services and provide us with certain information technology systems. Our arrangements with suppliers and these third parties may expose us to public scrutiny, adversely affect our brand and reputation, expose us to litigation or regulatory action, and otherwise make our operations vulnerable if we fail to adequately oversee, monitor and regulate their performance or if they fail to meet their contractual obligations to us or to comply with applicable laws or regulations, including those related to human capital and climate change. For example, certain of our vendors have been responsible for releases of sensitive information of our members and employees, which has caused us to incur additional expenses and given rise to regulatory actions and litigation against us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks are particularly high in our in Medicare Advantage (including dual eligible special needs plans), Medicare Part D, Medicaid, and managed Medicaid plans, where third parties may perform medical management and other member related services for us. Any failure of our or these third parties&#8217; prevention, detection or control systems related to regulatory compliance, compliance with our internal policies, data security and/or cybersecurity or any incident involving the theft, misappropriation, loss or other unauthorized disclosure of, or access to, members&#8217;, customers&#8217; or other constituents&#8217; sensitive information could require us to expend significant resources to remediate any damage, interrupt our operations and adversely affect our brand and reputation and also expose us to whistleblower, class action and other litigation, other proceedings, prohibitions on marketing or active or passive enrollment of members, corrective actions, fines, sanctions and/or penalties, any of which could adversely affect our businesses, operating results, cash flows and/or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience increased medical and other benefit costs, litigation risk and customer and member dissatisfaction when providers that do not have contracts with us render services to our Health Care Benefits members.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some providers that render services to our Health Care Benefits members do not have contracts with us. In those cases, we do not have a pre-established understanding with these providers as to the amount of compensation that is due to them for services rendered to our members. In some states, the amount of compensation due to these nonparticipating providers is defined by law or regulation, but in most instances it is either not defined or it is established by a standard that is not clearly translatable into dollar terms. In such instances providers may believe that they are underpaid for their services and may either litigate or arbitrate their dispute with us or try to recover the difference between what we have paid them and the amount they charged us from our members, which may result in customer and member dissatisfaction. For example, in October 2018, an arbitrator </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">awarded certain claimant hospitals approximately $150 million in a proceeding relating to Aetna&#8217;s out-of-network benefit payment and administration practices, and in March 2019 that award was reduced to approximately $86 million. Such disputes may cause us to pay higher medical or other benefit costs than we projected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continuing consolidation and integration among providers and other suppliers may increase our medical and other covered benefits costs, make it difficult for us to compete in certain geographies and create new competitors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospitals and other providers and health systems continue to consolidate across the health care industry. While this consolidation could increase efficiency and has the potential to improve the delivery of health care services, it also reduces competition and the number of potential contracting parties in certain geographies. These health systems also are increasingly forming and considering forming health plans to directly offer health insurance in competition with us, a process that has been accelerated by the ACA. In addition, ACOs (including Commercial and Medicaid-only ACOs developed as a result of state Medicaid laws), practice management companies, consolidation among and by integrated health systems and other changes in the organizational structures that physicians, hospitals and other providers adopt continues to change the way these providers interact with us and the competitive landscape in which we operate. These changes may increase our medical and other covered benefits costs, may affect the way we price our products and services and estimate our medical and other covered benefits costs and may require us to change our operations, including by withdrawing from certain geographies where we do not have a significant presence across our businesses or are unable to collaborate or contract with providers on acceptable terms. Each of these changes may adversely affect our businesses and operating results.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_37"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.  Unresolved Staff Comments.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no unresolved SEC Staff Comments.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_40"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.  Properties.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal office is an owned building complex located in Woonsocket, Rhode Island, which totals approximately one million square feet. The Company also leases office space in other locations in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Care Benefits Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment&#8217;s principal office is an owned building complex located in Hartford, Connecticut, which totals approximately 1.7 million square feet. The Health Care Benefits segment also owns or leases office space in other locations in the United States and several other countries. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmacy Services Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment includes owned or leased mail service dispensing pharmacies, call centers, on-site pharmacy stores, retail specialty pharmacy stores, specialty mail service pharmacies and branches for infusion and enteral services throughout the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retail/LTC Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Retail/LTC segment operated the following properties:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approximately 7,795 retail stores, of which approximately 5% were owned. Net selling space for retail stores was approximately 77.4 million square feet as of December&#160;31, 2022. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approximately 1,880 retail pharmacies within retail chains, as well as approximately 60 clinics in Target Corporation (&#8220;Target&#8221;) stores;</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Owned distribution centers and leased distribution facilities throughout the United States totaling approximately 10.7 million square feet; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Owned and leased LTC pharmacies throughout the United States and an owned LTC repackaging facility.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain business dispositions completed between 1995 and 1997, the Company continues to guarantee lease obligations for 67 former stores. The Company is indemnified for these guarantee obligations by the respective initial purchasers. These guarantees generally remain in effect for the initial lease term and any extension thereof pursuant to a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">renewal option provided for in the lease prior to the time of the disposition. For additional information on these guarantees, see &#8220;Lease Guarantees&#8221; in Note 16 &#8216;&#8216;Commitments and Contingencies&#8217;&#8217; included in Item 8 of this 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the Company&#8217;s owned and leased facilities are suitable and adequate to meet the Company&#8217;s anticipated needs. At the end of the existing lease terms, management believes the leases can be renewed or replaced by alternative space. For additional information on the right-of-use assets and lease liabilities associated with the Company&#8217;s leases, see Note 6 &#8216;&#8216;Leases&#8217;&#8217; included in Item 8 of this 10-K.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_43"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  Legal Proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Note 16 &#8216;&#8216;Commitments and Contingencies&#8217;&#8217; included in Item 8 of this 10-K is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_46"></div><div style="padding-right:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Mine Safety Disclosures.</span></div><div style="padding-right:72pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about our Executive Officers </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the name, age and biographical information for each of the Registrant&#8217;s executive officers as of February&#160;8, 2023. In each case the officer&#8217;s term of office extends to the date of the meeting of the Board following the next annual meeting of stockholders of CVS Health Corporation. Previous positions and responsibilities held by each of the executive officers over the past five years or more are indicated below:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sreekanth K. Chaguturu, M.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., age 44, Executive Vice President and Chief Medical Officer of CVS Health Corporation since May 2022; Chief Medical Officer of CVS Caremark from September 2019 through May 2022; Chief Population Health Officer at Mass General Brigham, a non-profit hospital formerly known as Partners HealthCare, from August 2017 through August 2019; Vice President, Population Health Management at Mass General Brigham from June 2014 through August 2017. Dr. Chaguturu is also an Attending Physician at Massachusetts General Hospital and an Instructor in Internal Medicine at Harvard Medical School from July 2007 to the present. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;James D. Clark</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 58, Senior Vice President - Controller and Chief Accounting Officer of CVS Health Corporation since November 2018; Vice President - Finance and Accounting of CVS Pharmacy, Inc. from September 2009 through October 2018.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Daniel P. Finke</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 52, Executive Vice President of CVS Health Corporation and President of Health Care Benefits since February 2021; Executive Vice President, Commercial Business and Markets of Aetna Inc. from February 2020 through January 2021; Executive Vice President, Consumer Health and Service of Aetna Inc. from June 2018 through January 2020; Senior Vice President, Network and Clinical Services of Aetna Inc. from January 2016 through May 2018.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Shawn M. Guertin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 59, Executive Vice President and Chief Financial Officer of CVS Health Corporation since May 2021; Executive Vice President, Chief Financial Officer and Chief Enterprise Risk Officer of Aetna Inc. from February 2013 through May 2019; Senior Vice President, Finance of Aetna Inc. from April 2011 through January 2013.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Laurie P. Havanec</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 62, Executive Vice President and Chief People Officer of CVS Health Corporation since February 2021; Executive Vice President and Chief People Officer, Otis Worldwide Corporation, an elevator, escalator and moving walkway manufacturer, from October 2019 through January 2021; Corporate Vice President, Talent of United Technologies Corporation, a multinational manufacturing conglomerate, from April 2017 through October 2019; Vice President - Human Resources, Institution Businesses of Aetna Inc. from 2013 through March 2017. Ms. Havanec is also a member of the board of directors of American Water Works Company, Inc., a publicly traded water and wastewater utility company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;J. David Joyner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 58, Executive Vice President of CVS Health Corporation and President of Pharmacy Services since January 2023; Strategic Business Advisor to gWell, Inc., a wellness technology company, since July 2021; Advisor to Podimetrics Inc., a health care company focused on the identification and treatment of diabetic foot ulcers since September 2020; Advisory Council to the Rawls College of Business of Texas Tech University since July 2020; Executive Vice President &#8211; Sales and Account Services, CVS Caremark for CVS Health Corporation from March 2011 through December 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Karen S. Lynch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 60, President and Chief Executive Officer of CVS Health Corporation since February 2021; Executive Vice President of CVS Health Corporation from November 2018 through January 2021; President of Aetna Inc. from January 2015 through January 2021; and a director of CVS Health Corporation since February 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Tilak Mandadi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 59, Executive Vice President and Chief Data, Digital and Technology Officer of CVS Health Corporation since July 2022; Chief Strategy Officer, MGM Resorts International from July 2021 through July 2022; Executive Vice President, Digital &amp; Global Chief Technology Officer, Disney Parks, Experiences and Products from March 2013 through July 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Thomas M. Moriarty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 59, Executive Vice President and General Counsel of CVS Health Corporation since October&#160;2012; Chief Policy and External Affairs Officer since March 2017; Chief Strategy Officer from March 2014 through February 2017.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Michelle A. Peluso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 50, Executive Vice President and Chief Customer Officer of CVS Health Corporation since January 2021 and Co-President of  Retail since January 2022; Senior Vice President, Digital Sales and Chief Marketing Officer, IBM, a multinational technology corporation, from February 2016 through January 2021; Chief Executive Officer, Gilt Groupe, Inc., an online shopping destination, from 2013 through February 2016. Ms. Peluso is also a member of the board of directors of Nike, Inc., an athletic footwear and clothing manufacturer.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Prem Shah</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 43, Executive Vice President and Chief Pharmacy Officer of CVS Health Corporation since November&#160;2021 and Co-President of Retail since January 2022; Executive Vice President, Specialty and Product Innovation, CVS Caremark from August 2018 through November 2021; Vice President - Specialty Pharmacy, CVS Caremark from February 2013 through July 2018.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_55"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation&#8217;s common stock is listed on the New York Stock Exchange under the symbol &#8220;CVS.&#8221; </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, the quarterly cash dividend was $0.55, $0.50 and $0.50 per share, respectively. In December 2022, the Board authorized a 10% increase in the quarterly cash dividend to $0.605 per share effective in 2023. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividends will depend on the Company&#8217;s earnings, capital requirements, financial condition and other factors considered relevant by the Board.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 &#8216;&#8216;Shareholders&#8217; Equity&#8217;&#8217; included in Item 8 of this 10-K for information regarding CVS Health Corporation&#8217;s dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Common Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2023, there were 24,142 registered holders of the registrant&#8217;s common stock according to the records maintained by the registrant&#8217;s transfer agent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share repurchase programs have been authorized by the Board:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In billions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Authorization&#160;Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining as of<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 17, 2022 (&#8220;2022 Repurchase Program&#8221;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 9, 2021 (&#8220;2021 Repurchase Program&#8221;)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the share Repurchase Programs was effective immediately and permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (&#8220;ASR&#8221;) transactions, and/or other derivative transactions. Both the 2022 and 2021 Repurchase Programs can be modified or terminated by the Board at any time. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company repurchased an aggregate of 34.1&#160;million shares of common stock for approximately $3.5&#160;billion pursuant to the 2021 Repurchase Program, including share repurchases under the $1.5 billion fixed dollar ASR transaction described below. During the years ended December 31, 2021 and 2020, the Company did not repurchase any shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $2.0&#160;billion fixed dollar ASR with Citibank, N.A. (&#8220;Citibank&#8221;). Upon payment of the $2.0&#160;billion purchase price on January 4, 2023, the Company received a number of shares of CVS Health Corporation&#8217;s common stock equal to 80% of the $2.0&#160;billion notional amount of the ASR or approximately 17.4 million shares at a price of $92.19 per share, which were placed into treasury stock in January 2023. At the conclusion of the ASR, the Company may receive additional shares representing the remaining 20% of the $2.0&#160;billion notional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Company&#8217;s stock over an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Citibank which, at the Company&#8217;s option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that could be delivered to the Company is 43.4 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5&#160;billion fixed dollar ASR with Barclays Bank PLC. Upon payment of the $1.5&#160;billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation&#8217;s common stock equal to 80% of the $1.5&#160;billion notional amount of the ASR or approximately 11.6&#160;million shares at a price of $103.34 per share, which were placed into treasury stock in January 2022. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASR was accounted for as an initial treasury stock transaction for $1.2&#160;billion and a forward contract for $0.3&#160;billion. The forward contract was classified as an equity instrument and was recorded within capital surplus. In February 2022, the Company received approximately 2.7&#160;million shares of CVS Health Corporation&#8217;s common stock, representing the remaining 20% of the $1.5&#160;billion notional amount of the ASR, thereby concluding the ASR. These shares were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 &#8216;&#8216;Shareholders&#8217; Equity&#8217;&#8217; included in Item 8 of this 10-K for additional information regarding the Company&#8217;s share repurchases.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total shareholder return on CVS Health Corporation&#8217;s common stock (assuming reinvestment of dividends) with the cumulative total return on the S&amp;P 500 Index, the S&amp;P 500 Food and Staples Retailing Industry Group Index and the S&amp;P 500 Healthcare Sector Group Index from December 31, 2017 through December 31, 2022. The graph assumes a $100 investment in shares of CVS Health Corporation&#8217;s common stock on December 31, 2017.</span></div><div style="text-align:center"><img src="cvs-20221231_g2.jpg" alt="cvs-20221231_g2.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CVS Health Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Food &amp; Staples Retailing Group Index </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Health Care Group Index </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes CVS Health Corporation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes five companies (COST, KR, SYY, WBA, WMT).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes 63 companies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The year-ended values of each investment shown in the preceding graph are based on share price appreciation plus dividends, with the dividends reinvested as of the last business day of the month during which such dividends were ex-dividend. The calculations exclude trading commissions and taxes. Total shareholder returns from each investment can be calculated from the year-end investment values shown beneath the graph.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_58"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  Reserved</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. (&#8220;MD&amp;A&#8221;) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the audited consolidated financial statements and related notes included in Item 8 of this Annual Report on Form 10-K (this &#8220;10-K&#8221;), &#8220;Risk Factors&#8221; included in Item 1A of this 10-K and the &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221; in this 10-K.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation, together with its subsidiaries (collectively, &#8220;CVS Health,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;), is a leading diversified health solutions company reshaping health care to help make healthier happen for more Americans. In an increasingly connected and digital world, CVS Health is meeting people wherever they are and changing health care to meet their needs. The Company has more than 9,000 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with over 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (&#8220;PDP&#8221;). The Company believes its integrated health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of the Health Care Benefits Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment operates as one of the nation&#8217;s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services, and health information technology products and services. The Health Care Benefits segment also provided workers&#8217; compensation administrative services through its Coventry Health Care Workers&#8217; Compensation business (&#8220;Workers&#8217; Compensation business&#8221;) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment&#8217;s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (&#8220;providers&#8221;), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as &#8220;Insured&#8221; and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as &#8220;ASC.&#8221; In addition, effective January 2022, the Company entered the individual public health insurance exchanges (&#8220;Public Exchanges&#8221;) in eight states through which it sells Insured plans directly to individual consumers. The Company entered Public Exchanges in four additional states effective January 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of the Pharmacy Services Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment provides a full range of pharmacy benefit management (&#8220;PBM&#8221;) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (&#8220;Covered Entities&#8221;).The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers. The Pharmacy Services segment&#8217;s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of the Retail/LTC Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, coronavirus disease 2019 (&#8220;COVID-19&#8221;) and shingles and conducts long-term care pharmacy (&#8220;LTC&#8221;) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of December&#160;31, 2022, the Retail/LTC segment operated more than 9,000 retail locations, more than 1,100 MinuteClinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. For the year ended December&#160;31, 2022, the Company dispensed 26.8% of the total retail pharmacy prescriptions in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of the Corporate/Other Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management and administrative expenses to support the Company&#8217;s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company&#8217;s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and its emerging new variants continue to impact the economies of the U.S. and other countries around the world. Our strong local presence and scale in communities across the country has enabled us to continue to play an indispensable role in the national response to COVID-19, as well as provide seamless support for our customers wherever they need us: in our CVS locations, in their homes, and virtually. The COVID-19 pandemic had a significant impact on the Company&#8217;s operating results for the years ended December 31, 2022, 2021 and 2020, primarily in the Company&#8217;s Health Care Benefits and Retail/LTC segments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Benefits Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in mid-March 2020, the health care system experienced a significant reduction in utilization of medical services (&#8220;utilization&#8221;) that is discretionary and the cancellation of elective medical procedures. Utilization remained below historical levels through April 2020, began to recover in May and June 2020 and reached more normal levels in the third and fourth quarters of 2020, with select geographies impacted by COVID-19 waves. In response to COVID-19, the Company provided expanded benefit coverage to its members, including cost-sharing waivers for COVID-19 related treatments, as well as assistance to members through premium credits, telehealth cost-sharing waivers and other investments. During 2020, COVID-19 also resulted in a shift in the Company&#8217;s medical membership. The Company experienced declines in Commercial membership due to reductions in workforce at our existing customers, substantially offset by increases in Medicaid membership primarily as a result of the suspension of eligibility redeterminations and increased unemployment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, overall medical costs in the first quarter were generally consistent with historical baseline levels in the aggregate, however the segment experienced increased COVID-19 testing and treatment costs and lower Medicare risk-adjusted revenue. During the second quarter, COVID-19 testing and treatment costs persisted, however at levels significantly lower than those observed during the first quarter. Beginning in the third quarter of 2021, medical costs once again increased primarily driven by the spread of emerging new variants of COVID-19, which resulted in increased testing and treatment costs throughout the remainder of the year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the impact of COVID-19 within the Health Care Benefits segment has generally stabilized as a result of the Company&#8217;s ability to capture COVID-19 related medical costs in pricing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retail/LTC Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company experienced increased prescription volume due to the greater use of 90-day prescriptions and early refills of maintenance medications, as well as increased front store volume as consumers prepared for the COVID-19 pandemic. Beginning in the second quarter and continuing throughout the remainder of the year, the Company experienced reduced customer traffic in its retail pharmacies and MinuteClinic locations due to shelter-in-place orders as well as reduced new therapy prescriptions and decreased long-term care prescription volume as a result of the COVID-19 pandemic. In addition, the Company incurred incremental operating expenses associated with the Company&#8217;s COVID-19 pandemic response efforts and waived fees associated with prescription home delivery and associated front store products. During 2020, the Company also played a key role in supporting the local communities in which it operates through the administration of diagnostic testing at its CVS pharmacy locations, as well as in long-term care facilities, at community-based testing sites in underserved areas and through its Return Ready</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solution. The Company also began administering COVID-19 vaccinations in long-term care facilities during December 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, the Company experienced reduced customer traffic in its retail pharmacies, which reflected the impact of a weaker cough, cold and flu season, while it administered the highest quarterly volume of COVID-19 diagnostic tests. The Company began administering COVID-19 vaccines in its retail pharmacies during February 2021. During the second quarter, the segment generated earnings from COVID-19 vaccines and saw improved customer traffic as vaccinated customers began more actively shopping in CVS locations. During the third and fourth quarters, emerging new variants drove the continued administration of COVID-19 vaccinations (including boosters) and diagnostic testing, while the segment also generated earnings from the sale of over-the-counter (&#8220;OTC&#8221;) test kits in the front store. During the year ended December&#160;31, 2021, the Company administered more than 32&#160;million COVID-19 tests and more than 59&#160;million COVID-19 vaccines and sold more than 22 million OTC test kits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the  year ended December 31, 2022, the customary quarterly operating income progression in the Retail/LTC segment continued to be impacted by COVID-19. During the first quarter, the Company saw high volumes of administration of COVID-19 vaccinations, as well as demand for OTC test kits in the front store, particularly in the beginning of the year when </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Omicron variant incidence was high. In addition, the Company administered the highest quarterly volume of COVID-19 diagnostic tests of 2022 during the first quarter, however a decline compared to the prior year. During the second and third quarters, the Company continued to generate earnings from the sale of OTC test kits, as customers performed more in-home testing versus diagnostic testing, in addition to earnings from the continued administration of COVID-19 diagnostic testing and vaccinations, albeit at lower levels than those experienced in the first quarter. During the fourth quarter, the Company saw an increase in COVID-19 vaccine administration from the prior quarter related to the bivalent COVID-19 booster. During the year ended December 31, 2022, the Company administered more than 15&#160;million COVID-19 tests and nearly 28&#160;million COVID-19 vaccines and sold more than 63&#160;million OTC test kits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The Company believes COVID-19&#8217;s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic&#8217;s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company&#8217;s knowledge and control. As a result, the impact COVID-19 will have on the Company&#8217;s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information summarizes the Company&#8217;s results of operations for 2022 compared to 2021. For discussion of the Company&#8217;s results of operations for 2021&#160;compared to&#160;2020,&#160;see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 9, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Consolidated Financial Results</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,467&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid litigation charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,193&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,447)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,628&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,792)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,733)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,733)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to CVS Health</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,761)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commentary - 2022 compared to 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total revenues increased $30.4 billion, or 10.4%, in 2022 compared to 2021. The increase in total revenues was primarily driven by growth across all segments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Please see &#8220;Segment Analysis&#8221; later in this MD&amp;A for additional information about the revenues of the Company&#8217;s segments.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses increased $1.1 billion, or 3.1%, in 2022 compared to 2021. The increase in operating expenses was primarily due to increased operating expenses to support growth in the business, incremental investments in business operations and decreased gains from legal settlements in 2022 compared to 2021. These increases were partially offset by a decrease in amortization of intangible assets compared to the prior year, as well as pre-tax gains of $250&#160;million on the sale </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company&#8217;s wholly-owned subsidiary bswift LLC (&#8220;bswift&#8221;) and $225&#160;million on the sale of PayFlex Holdings, Inc. (&#8220;PayFlex&#8221;), both of which were sold during 2022.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses as a&#160;percentage of total revenues decreased to 11.8% in 2022 compared to 12.7% in 2021. The decrease in operating expenses as a percentage of total revenues was primarily due to the increases in total revenues described above.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Please see &#8220;Segment Analysis&#8221; later in this MD&amp;A for additional information about the operating expenses of the Company&#8217;s segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating income </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating income decreased $5.4 billion, or 41.3%, in 2022 compared to 2021. The decrease in operating income was primarily driven by the $5.8 billion of opioid litigation charges and declines in the Retail/LTC segment, which included a $2.5 billion loss on assets held for sale related to the write-down of the Company&#8217;s Omnicare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> long-term care business (&#8220;LTC business&#8221;) during 2022, partially offset by the absence of a store impairment charge of approximately $1.4 billion and a $431 million goodwill impairment charge on the remaining goodwill of the LTC reporting unit, both of which were recorded in the prior year. These decreases were partially offset by increases in the Health Care Benefits segment, which included the pre-tax gains of $250&#160;million on the sale of bswift and $225&#160;million on the sale of PayFlex and a decrease in amortization of intangible assets, as well as improved purchasing economics and growth in specialty pharmacy in the Pharmacy Services segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Please see &#8220;Segment Analysis&#8221; later in this MD&amp;A for additional information about the operating results of the Company&#8217;s segments.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest expense decreased $216 million, or 8.6%, in 2022 compared to 2021, due to lower debt in the year ended December&#160;31, 2022. See &#8220;Liquidity and Capital Resources&#8221; later in this report for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During 2021, the loss on early extinguishment of debt relates to the Company&#8217;s repayment of approximately </span><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3&#160;billion of its outstanding senior notes in December </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 pursuant to its early redemption make-whole provision for such senior notes, which resulted in a loss on early extinguishment of debt of $89&#160;million</span><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the repayment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of approximately $2.0&#160;billion of its outstanding senior notes pursuant to its tender offer for such notes in August 2021, which resulted in a loss on early extinguishment of debt of $363&#160;million. See Note 8 &#8216;&#8216;Borrowings and Credit Agreements&#8217;&#8217; included in Item 8 of this 10-K for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax provision</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s effective income tax rate increased to 26.0% in 2022 compared to 24.2% in the prior year. The increase was primarily due to certain nondeductible legal charges and basis differences on the sale of certain subsidiaries in 2022. These increases were partially offset by the impact of certain discrete tax items concluded in the first quarter of 2022.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outlook for 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to 2023, the Company believes you should consider the following important information:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Health Care Benefits segment is expected to continue to benefit from Medicare and Commercial membership growth, partially offset by declines in Medicaid due to the impact of redeterminations in 2023.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Pharmacy Services segment is expected to continue to benefit from the Company&#8217;s ability to drive further improvements in purchasing economics and strong pharmacy network volume. These increases are expected to be partially offset by continued client price improvements and regulation of pharmacy pricing.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Retail/LTC segment is expected to continue to benefit from increased prescription volume and improved generic drug purchasing, partially offset by continued pharmacy reimbursement pressure and lower contributions from COVID-19 vaccinations, diagnostic testing and OTC test kits as COVID-19 transitions to the endemic stage. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is expected to benefit from enterprise-wide cost savings initiatives, which aim to reduce the Company&#8217;s operating cost structure in a way that improves the consumer experience and is sustainable. Key drivers include:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in digital, technology and analytics capabilities that will streamline processes and improve outcomes,  </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implementing workforce and workplace strategies, and</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deploying vendor and procurement strategies.            </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company expects changes to its business environment to continue as elected and other government officials at the national and state levels continue to propose and enact significant modifications to public policy and existing laws and regulations that govern or impact the Company&#8217;s businesses.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic continues to impact the economies of the U.S. and other countries around the world. The Company believes COVID-19&#8217;s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic, as well as the pandemic&#8217;s impact on the U.S. and global economies, global supply chain, consumer behavior, and health care utilization patterns. In addition, as described in the &#8220;Government Regulation&#8221; section of this Form 10-K, federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 and emerging new variants may not effectively combat the severity and/or duration of the COVID-19 pandemic, and have resulted in a myriad of impacts on the Company&#8217;s businesses. Those primary drivers are beyond the Company&#8217;s knowledge and control. As a result, the impact COVID-19 will have on the Company&#8217;s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current expectations described above are forward-looking statements. Please see &#8220;Risk Factors&#8221; included in Item 1A of this 10-K and the &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221; in this 10-K for information regarding important factors that may cause the Company&#8217;s actual results to differ from those currently projected and/or otherwise materially affect the Company.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Analysis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion of segment operating results is presented based on the Company&#8217;s reportable segments in accordance with the accounting guidance for segment reporting and is consistent with the segment disclosure in Note 17 &#8216;&#8216;Segment Reporting&#8217;&#8217; included in Item 8 of this 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company&#8217;s segments maintain separate financial information, and the Company&#8217;s chief operating decision maker (the &#8220;CODM&#8221;) evaluates the segments&#8217; operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company&#8217;s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company&#8217;s business nor reflect the Company&#8217;s underlying business performance. See the reconciliations of operating income (GAAP measure) to adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company&#8217;s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of financial measures of the Company&#8217;s segments to the consolidated totals:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eliminations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total revenues of the Pharmacy Services segment include approximately $12.6 billion, $11.6 billion and $10.9 billion of retail co-payments for 2022, 2021 and 2020, respectively. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; included in Item 8 of this 10-K for additional information about retail co-payments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services segment clients enrolled in Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> elect to pick up maintenance prescriptions at one of the Company&#8217;s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.</span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are reconciliations of consolidated operating income (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income to segment adjusted operating income:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy&#160;<br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) (GAAP measure)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,609)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office real estate optimization charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on divestiture of subsidiaries </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid litigation charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on assets held for sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,785)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy&#160;<br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) (GAAP measure)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(711)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition purchase price adjustment outside of measurement period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,859&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,471)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(711)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy&#160;<br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss) (GAAP measure)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,641)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on divestiture of subsidiary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipt of fully reserved ACA risk corridor receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company&#8217;s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company&#8217;s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company&#8217;s insurance products, the services performed for the Company&#8217;s customers or the sale of the Company&#8217;s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company&#8217;s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company&#8217;s and investors&#8217; ability to compare the Company&#8217;s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company&#8217;s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company&#8217;s new flexible work arrangement. The office real estate optimization charges are reflected in the Company&#8217;s GAAP consolidated statement of operations in operating expenses within the Health Care Benefits, Corporate/Other and Pharmacy Services segments. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift, which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022. In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">sale of the Workers&#8217; Compensation business, which the Company sold in July 2020. The gains on divestitures are reflected as a reduction of operating expenses in the Company&#8217;s GAAP consolidated statements of operations within the Health Care Benefits segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities. The opioid litigation charges are reflected within the Corporate/Other segment.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the loss on assets held for sale relates to the LTC reporting unit within the Retail/LTC segment. The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria for held-for-sale accounting and the net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the third quarter of 2022. As of December 31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter of 2022, an incremental loss on assets held for sale was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. During 2022, the loss on assets held for sale also relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its international health care business domiciled in Thailand (&#8220;Thailand business&#8221;), which was included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021 and 2020, acquisition-related integration costs relate to the Company&#8217;s acquisition (the &#8220;Aetna Acquisition&#8221;) of Aetna Inc. (&#8220;Aetna&#8221;). The acquisition-related integration costs are reflected in the Company&#8217;s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. The store impairment charge is reflected within the Retail/LTC segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the goodwill impairment charge relates to an impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the Company received $61&#160;million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company&#8217;s GAAP consolidated statement of operations as a reduction of operating expenses within the Health Care Benefits segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">In 2020, the Company received $313&#160;million owed to it under the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the &#8220;ACA&#8221;)&#8217;s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA&#8217;s minimum medical loss ratio (&#8220;MLR&#8221;)  rebate requirements and premium taxes, the Company recognized pre-tax income of $307&#160;million in the Company&#8217;s GAAP consolidated statement of operations within the Health Care Benefits segment.</span></div><div><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Care Benefits Segment </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Health Care Benefits segment&#8217;s performance for the respective periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions, except percentages and basis points (&#8220;bps&#8221;)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,274</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,064</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,301</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,659</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,536</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,409</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,186</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,467</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,611</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,662</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,083</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MBR (Benefit costs as a % of premium revenues)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on assets held for sale </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,639</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,003</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,218</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses as a % of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,118</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,166</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income as a % of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,984</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income as a % of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premium revenues (by business):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,141</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,739</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,928</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,402</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,811</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,133</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,325</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,373</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See &#8220;Segment Analysis&#8221; above in this MD&amp;A for a reconciliation of operating income (GAAP measure) to adjusted operating income for the Health Care Benefits segment, which represents the Company&#8217;s principal measure of segment performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commentary - 2022 compared to 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total revenues increased $9.2 billion, or 11.2%, to $91.4 billion in 2022 compared to 2021 driven by growth across all product lines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Benefit Ratio</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical benefit ratio is calculated as benefit costs divided by premium revenues and represents the percentage of premium revenues spent on medical benefits for the Company&#8217;s Insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Company&#8217;s Insured Health Care Benefits products.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The MBR decreased from 85.0% to 84.0% in 2022 compared to the prior year primarily driven by the net favorable impact of COVID-19 compared to the prior year, partially offset by the unfavorable impact of the flu compared to the prior year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on assets held for sale</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During 2022, the Company recorded a $41&#160;million loss on assets held for sale on its Thailand business, which is included in the Commercial Business reporting unit within the Health Care Benefits segment. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; included in Item 8 of this 10-K for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses in the Health Care Benefits segment include selling, general and administrative expenses and depreciation and amortization expenses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses increased $636 million, or 4.5%, in 2022 compared to 2021. The increase in operating expenses was primarily driven by increased operating expenses to support the growth across all product lines described above, incremental investments in the business, as well as office real estate optimization charges recorded in 2022 in connection with the planned reduction of corporate office real estate space. These increases were partially offset by the pre-tax gains of $250&#160;million on the sale of bswift and $225&#160;million on the sale of PayFlex.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses as a percentage of total revenues decreased to 16.0% in 2022 compared to 17.0% in 2021. The decrease in operating expenses as a percentage of total revenues was primarily driven by the increases in total revenues described above and the pre-tax gains on the sales of bswift and PayFlex.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted operating income</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted operating income increased $972 million, or 19.4%, in 2022 compared to 2021. The increase in adjusted operating income was primarily driven by the net favorable impact of COVID-19 compared to the prior year, strong underlying performance and membership growth. These increases were partially offset by incremental investments to support growth in the business, the unfavorable impact of the flu compared to the prior year and net realized capital losses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Health Care Benefits segment&#8217;s medical membership as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Insured</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Insured</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASC</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical membership:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical membership</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,396&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental membership information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Prescription Drug Plan (standalone)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Membership</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical membership represents the number of members covered by the Company&#8217;s Insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on segment total revenues and operating results.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical membership as of December&#160;31, 2022 of 24.4 million increased 548,000 compared with December&#160;31, 2021, reflecting increases in Medicare and Commercial membership, as underlying Commercial growth more than offset the impact of international divestitures. These increases were partially offset by a decline in Medicaid membership reflecting the previously disclosed loss of a large customer in the third quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Update</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2022, the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) issued its final notice detailing final 2023 Medicare Advantage payment rates. Final 2023 Medicare Advantage rates resulted in an expected average increase in revenue for the Medicare Advantage industry of 5.00%, excluding the CMS estimate of Medicare Advantage risk score trend. On February 1, 2023, CMS issued an advance notice detailing proposed 2024 Medicare Advantage payment rates. The 2024 Medicare Advantage rates, if finalized as proposed, will result in an expected average decrease in revenue for the Medicare Advantage industry of 2.27%, excluding the CMS estimate of Medicare Advantage risk score trend. CMS intends to publish the final 2024 rate announcement no later than April 3, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA ties a portion of each Medicare Advantage plan&#8217;s reimbursement to the plan&#8217;s &#8220;star ratings.&#8221; Plans must have a star rating of four or higher (out of five) to qualify for bonus payments. CMS released the Company&#8217;s 2023 star ratings in October 2022. The Company&#8217;s 2023 star ratings will be used to determine which of the Company&#8217;s Medicare Advantage plans have ratings of four stars or higher and qualify for bonus payments in 2024. Based on the Company&#8217;s membership at December&#160;31, 2022, 21% of the Company&#8217;s Medicare Advantage members were in plans with 2023 star ratings of at least 4.0 stars, compared to 87% of the Company&#8217;s Medicare Advantage members being in plans with 2022 star ratings of at least 4.0 stars based on the Company&#8217;s membership at December&#160;31, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmacy Services Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Pharmacy Services segment&#8217;s performance for the respective periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions, except percentages</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,004</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,851</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,950</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,236</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,938</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,421</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,894</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses as a % of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,187</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income as a % of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,859</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income as a % of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (by distribution channel):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy network </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,668</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,715</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,466</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,547</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,071</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy claims processed:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,336.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,244.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy network </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generic dispensing rate: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy network </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See &#8220;Segment Analysis&#8221; above in this MD&amp;A for a reconciliation of operating income (GAAP measure) to adjusted operating income for the Pharmacy Services segment, which represents the Company&#8217;s principal measure of segment performance.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company&#8217;s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> claims picked up at a retail pharmacy, as well as prescriptions filled at the Company&#8217;s retail pharmacies under the Maintenance Choice program.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commentary - 2022 compared to 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total revenues increased $16.2 billion, or 10.6%, to $169.2 billion in 2022 compared to 2021. The increase was primarily driven by increased pharmacy claims volume, growth in specialty pharmacy and brand inflation, partially offset by continued client price improvements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses in the Pharmacy Services segment include selling, general and administrative expenses; depreciation and amortization expense; and expenses related to specialty retail pharmacies, which include administrative payroll, employee benefits and occupancy costs.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses increased $167 million, or 11.4%, in 2022 compared to 2021. The increase was primarily driven by restructuring and business integration costs recorded in 2022.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses as a percentage of total revenues remained consistent at 1.0% in both 2022 and 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted operating income</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted operating income increased $497 million, or 7.2%, in 2022 compared to 2021. The increase in adjusted operating income was primarily driven by improved purchasing economics, including increased contributions from the products and services of the Company&#8217;s group purchasing organization, partially offset by continued client price improvements. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As you review the Pharmacy Services segment&#8217;s performance in this area, you should consider the following important information about the business:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s efforts to (i)&#160;retain existing clients, (ii)&#160;obtain new business and (iii)&#160;maintain or improve the rebates, fees and/or discounts the Company receives from manufacturers, wholesalers and retail pharmacies continue to have an impact on adjusted operating income. In particular, competitive pressures in the PBM industry have caused the Company and other PBMs to continue to share with clients a larger portion of rebates, fees and/or discounts received from pharmaceutical manufacturers. In addition, marketplace dynamics and regulatory changes have limited the Company&#8217;s ability to offer plan sponsors pricing that includes retail network &#8220;differential&#8221; or &#8220;spread,&#8221; and the Company expects these trends to continue. The &#8220;differential&#8221; or &#8220;spread&#8221; is any difference between the drug price charged to plan sponsors, including Medicare Part&#160;D plan sponsors, by a PBM and the price paid for the drug by the PBM to the dispensing provider.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy claims processed</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total pharmacy claims processed represents the number of prescription claims processed through our pharmacy benefits manager and dispensed by either our retail network pharmacies or our own mail and specialty pharmacies. Management uses this metric to understand variances between actual claims processed and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of pharmacy claim volume on segment total revenues and operating results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s pharmacy network claims processed increased 4.7% on a 30-day equivalent basis in 2022 compared to 2021 primarily driven by net new business, increased utilization and the impact of an elevated cough, cold and flu season compared to the prior year. These increases were partially offset by a decrease in COVID-19 vaccinations.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s mail choice claims processed increased 0.7% on a 30-day equivalent basis in 2022 compared to 2021 primarily driven by net new business and the increased utilization of Maintenance Choice prescriptions. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Excluding the impact of COVID-19 vaccinations, total pharmacy claims processed increased 5.1% on a 30-day equivalent basis in 2022 compared to the prior year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic dispensing rate</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generic dispensing rate is calculated by dividing the Pharmacy Services segment&#8217;s generic drug prescriptions processed or filled by its total prescriptions processed or filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Pharmacy Services segment&#8217;s total generic dispensing rate increased to 87.4% in 2022 compared to 86.8% in the prior year. The increase in the segment&#8217;s generic dispensing rate was primarily driven by a decrease in brand prescriptions, largely attributable to decreased COVID-19 vaccinations in 2022 compared to the prior year. Excluding the impact of COVID-19 vaccinations, the segment&#8217;s total generic dispensing rate was 88.3% and 88.5% in 2022 and 2021, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retail/LTC Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Retail/LTC segment&#8217;s performance for the respective periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions, except percentages</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,762</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,652</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,944</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,436</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,594</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,105</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,198</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,832</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,284</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,640</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,162</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,274</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses as a % of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,640</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income as a % of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,705</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,146</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income as a % of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (by major goods/service lines):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,010</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,121</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,176</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,780</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,315</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,655</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,652</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescriptions filled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Same store sales increase: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription volume </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generic dispensing rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See &#8220;Segment Analysis&#8221; above in this MD&amp;A for a reconciliation of operating income (GAAP measure) to adjusted operating income for the Retail/LTC segment, which represents the Company&#8217;s principal measure of segment performance.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes an adjustment to convert 90&#8209;day prescriptions to the equivalent of three 30&#8209;day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product&#160;days supplied compared to a normal prescription.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company&#8217;s retail pharmacy stores that have been operating for greater than one year, expressed as a percentage that indicates the increase or decrease relative to the comparable prior period. Same store metrics exclude revenues from MinuteClinic and revenues and prescriptions from LTC operations. Management uses these metrics to evaluate the performance of existing stores on a comparable basis and to inform future decisions regarding existing stores and new locations. Same-store metrics provide management and investors with information useful in understanding the portion of current revenues and prescriptions resulting from organic growth in existing locations versus the portion resulting from opening new stores.</span></div><div style="padding-left:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commentary - 2022 compared to 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total revenues increased $6.5 billion, or 6.5%, to $106.6 billion in 2022 compared to 2021. The increase was primarily driven by increased prescription and front store volume, including the impact of an elevated cough, cold and flu season compared to the prior year and increased sales of COVID-19 OTC test kits in 2022 compared to 2021, as well as pharmacy </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug mix and brand inflation. These increases were partially offset by decreased COVID-19 vaccinations and diagnostic testing, the impact of recent generic introductions and continued pharmacy reimbursement pressure.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmacy same store sales increased 9.5% in 2022 compared to 2021. The increase was primarily driven by the 4.0% increase in pharmacy same store prescription volume on a 30-day equivalent basis, including the impact of an elevated cough, cold and flu season compared to the prior year, pharmacy drug mix and brand inflation. These increases were partially offset by the impact of recent generic introductions and continued pharmacy reimbursement pressure.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Front store same store sales increased 7.4% in 2022 compared to 2021. The increase was primarily due to strength in consumer health, including the impact of an elevated cough, cold and flu season compared to the prior year and increased sales of COVID-19 OTC test kits in 2022 compared to 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other revenues decreased 30.3% in 2022 compared to 2021. The decrease was primarily due to decreased COVID-19 diagnostic testing in 2022 compared to the prior year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Loss on assets held for sale</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During 2022, the Company recorded a loss on assets held for sale of approximately $2.5 billion related to the write-down of its LTC business. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; included in Item 8 of this 10-K for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Store impairments</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During 2021, the Company recorded a store impairment charge of approximately $1.4 billion related to the write-down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. See Note 6 &#8216;&#8216;Leases&#8217;&#8217; included in Item 8 of this 10-K for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill impairment</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During 2021, the Company recorded a $431 million goodwill impairment charge related to the LTC reporting unit within the Retail/LTC segment. See Note 5 &#8216;&#8216;Goodwill and Other Intangibles&#8217;&#8217; included in Item 8 of this 10-K for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses in the Retail/LTC segment include store payroll, store employee benefits, store occupancy costs, selling expenses, advertising expenses, depreciation and amortization expense and certain administrative expenses.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses increased $478 million, or 2.4%, in 2022 compared to 2021. The increase was primarily due to incremental costs associated with increased volume, increased investments in the segment&#8217;s operations and capabilities, as well as decreased gains from legal settlements in 2022 compared to 2021. These increases were partially offset by lower expenses associated with COVID-19 vaccination administration compared to the prior year and the favorable impact of business initiatives in 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating expenses as a percentage of total revenues decreased to 19.4% in 2022 compared to 20.1% in 2021. The decrease in operating expenses as a percentage of total revenues was primarily driven by the increases in total revenues described above.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted operating income</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted operating income decreased $918 million, or 12.0%, in 2022 compared to 2021. The decrease in adjusted operating income was primarily driven by decreased COVID-19 vaccinations and diagnostic testing, continued pharmacy reimbursement pressure, increased investments in the segment&#8217;s operations and capabilities and decreased gains from legal settlements in 2022 compared to 2021. These decreases were partially offset by the increased prescription and front store volume described above, improved generic drug purchasing and the favorable impact of business initiatives in 2022. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As you review the Retail/LTC segment&#8217;s performance in this area, you should consider the following important information about the business:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The segment&#8217;s adjusted operating income has been adversely affected by the efforts of managed care organizations, PBMs and governmental and other third-party payors to reduce their prescription drug costs, including the use of restrictive networks, as well as changes in the mix of business within the pharmacy portion of the Retail/LTC segment. If the pharmacy reimbursement pressure accelerates, the segment may not be able to grow revenues, and its adjusted operating income could be adversely affected.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The increased use of generic drugs has positively impacted the segment&#8217;s adjusted operating income but has resulted in third-party payors augmenting their efforts to reduce reimbursement payments to retail pharmacies for prescriptions. This trend, which the Company expects to continue, reduces the benefit the segment realizes from brand-to-generic drug conversions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prescriptions filled</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prescriptions filled represents the number of prescriptions dispensed through the Retail/LTC segment&#8217;s pharmacies. Management uses this metric to understand variances between actual prescriptions dispensed and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of prescription volume on segment total revenues and operating results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prescriptions filled increased 2.3% on a 30-day equivalent basis in 2022 compared to 2021 primarily driven by increased utilization and the impact of an elevated cough, cold and flu season compared to the prior year, partially offset by a decrease in COVID-19 vaccinations. Excluding the impact of COVID-19 vaccinations, prescriptions filled increased 4.4%, on a 30-day equivalent basis in 2022 compared to the prior year.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic dispensing rate</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generic dispensing rate is calculated by dividing the Retail/LTC segment&#8217;s generic drug prescriptions filled by its total prescriptions filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Retail/LTC segment&#8217;s generic dispensing rate increased to 87.4% in 2022 compared to 85.7% in the prior year. The increase in the segment&#8217;s generic dispensing rate was primarily driven by a decrease in brand prescriptions, largely attributable to decreased COVID-19 vaccinations in 2022 compared to the prior year. Excluding the impact of COVID-19 vaccinations, the segment&#8217;s total generic dispensing rate was 89.0% in both 2022 and 2021.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_88"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate/Other Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Corporate/Other segment&#8217;s performance for the respective periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except percentages</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid litigation charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,078</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,609)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,606)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,641)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,003)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,471)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See &#8220;Segment Analysis&#8221; above in this MD&amp;A for a reconciliation of Corporate/Other segment operating loss (GAAP measure) to adjusted operating loss, which represents the Company&#8217;s principal measure of segment performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commentary - 2022 compared to 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues primarily relate to products for which the Company no longer solicits or accepts new customers, such as large case pensions and long-term care insurance products.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total revenues decreased $191 million, or 26.5%, in 2022 compared to 2021. The decrease was primarily driven by net realized capital losses in 2022 compared to net realized capital gains in 2021 and lower net investment income from private equity investments, partially offset by higher average invested assets and favorable average investment yields in 2022 compared to 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opioid litigation charges</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During 2022, the Company recorded $5.8 billion of opioid litigation charges. See Note 16 &#8216;&#8216;Commitments and Contingencies&#8217;&#8217; included in Item 8 of this 10-K for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted operating loss</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted operating loss increased $314 million, or 21.3%, in 2022 compared to 2021. The increase was primarily driven by the decreases in net investment income described above and the strengthening of reserves in the Company&#8217;s long-term care insurance business, which occurred during the second quarter of 2022.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_91"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a level of liquidity sufficient to allow it to meet its cash needs in the short-term. Over the long term, the Company manages its cash and capital structure to maximize shareholder return, maintain its financial condition and maintain flexibility for future strategic initiatives. The Company continuously assesses its regulatory capital requirements, working capital needs, debt and leverage levels, debt maturity schedule, capital expenditure requirements, dividend payouts, potential share repurchases and future investments or acquisitions. The Company believes its operating cash flows, commercial paper program, credit facilities, as well as any potential future borrowings, will be sufficient to fund these future payments and long-term initiatives. As of&#160;December&#160;31, 2022, the Company had approximately&#160;$12.9 billion&#160;in cash and cash equivalents, approximately&#160;$5.4 billion&#160;of which was held by the parent company or nonrestricted subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in cash, cash equivalents and restricted cash for the years ended December&#160;31, 2022, 2021 and 2020 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:36.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,088)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,047)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,261)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,534)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,034)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(987)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commentary - 2022 compared to 2021</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Net cash provided by operating activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased by $2.1 billion in 2022 compared to 2021 primarily due to the timing of payments and higher inventory purchases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Net cash used in investing activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased by $214 million in 2022 compared to 2021 primarily due to lower net purchases of investments and the gross proceeds from the divestitures of PayFlex and bswift, largely offset by a reduction in restricted cash as a result of the sale of health savings account funds held on behalf of customers in conjunction with the sale of PayFlex. In addition, cash used in investing activities reflected the following activity:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gross capital expenditures remained relatively consistent at approximately $2.7 billion and $2.5 billion in 2022 and 2021, respectively. During 2022, approximately 73% of the Company&#8217;s total capital expenditures were for technology, digital and other strategic initiatives and 27% were for store, fulfillment and support facilities expansion and improvements.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Net cash used in financing activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased to $10.5 billion in 2022 compared to $11.4 billion in 2021. The decrease in cash used in financing activities primarily related to lower net repayments of long-term debt during 2022 compared to the prior year, partially offset by share repurchases in 2022. </span></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in net cash used in investing activities for the years ended December&#160;31, 2022, 2021 and 2020 was the following store development activity: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stores (beginning of year)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New and acquired stores </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed stores </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stores (end of year)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,674&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,939&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,962&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Relocated stores </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes retail drugstores and pharmacies within retail chains, primarily in Target Corporation (&#8220;Target&#8221;) stores.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Relocated stores are not included in new and acquired stores or closed stores totals.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Borrowings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper and Back-up Credit Facilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any commercial paper outstanding as of December 31, 2022 or 2021. In connection with its commercial paper program, the Company maintains a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2025, a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 11, 2026, and a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2027. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company&#8217;s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of December&#160;31, 2022 and 2021, there were no borrowings outstanding under any of the Company&#8217;s back-up credit facilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Home Loan Bank of Boston (&#8220;FHLBB&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A subsidiary of the Company is a member of the FHLBB. As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of December&#160;31, 2022 was approximately $915 million. At both December&#160;31, 2022 and 2021, there were no outstanding advances from the FHLBB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Borrowings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise of Par Call Redemptions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company exercised the par call redemption on its outstanding 3.5% senior notes due July 2022 to redeem for cash on hand the entire $1.5&#160;billion aggregate principal amount. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company exercised the par call redemption on its outstanding 2.75% senior notes due November 2022 (issued by Aetna) to redeem for cash on hand the entire $1.0&#160;billion aggregate principal amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company exercised the par call redemptions on its outstanding 2.75% senior notes due December 2022 and 4.75% senior notes due December 2022 (including notes issued by Omnicare, Inc.) to redeem for cash on hand the entire aggregate principal amount of $1.25&#160;billion and $399&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 18, 2021, the Company issued $1.0&#160;billion aggregate principal amount of 2.125% unsecured senior notes due September 15, 2031 for total proceeds of $987&#160;million, net of discounts, underwriting fees and offering expenses. The net proceeds of this offering were used for the purchase of senior notes in connection with the Company&#8217;s cash tender offer in August 2021 as described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into several interest rate swap transactions to manage interest rate risk. These agreements were designated as cash flow hedges and were used to hedge the exposure to variability in future cash flows resulting from changes in interest rates related to the anticipated issuance of $750&#160;million aggregate principal amount of 3.625% unsecured senior notes due April 1, 2027, $1.5&#160;billion aggregate principal amount of 3.75% unsecured senior notes due April 1, 2030, $1.0&#160;billion aggregate principal amount of 4.125% unsecured senior notes due April 1, 2040 and $750&#160;million aggregate principal amount of 4.25% unsecured senior notes due April 1, 2050 (collectively, the &#8220;March 2020 Notes&#8221;). In connection with the issuance of the March 2020 Notes on March 31, 2020, the Company terminated all outstanding cash flow hedges. The Company paid a net amount of $7&#160;million to the hedge counterparties upon termination, which was recorded as a loss, net of tax, of $5&#160;million in accumulated other comprehensive income and will be reclassified as interest expense over the life of the March 2020 Notes. See Note 13 &#8216;&#8216;Other Comprehensive Income (Loss)&#8217;&#8217; included in Item 8 of this 10-K for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Extinguishments of Debt</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company redeemed for cash the remaining $2.3&#160;billion of its outstanding 3.7% senior notes due 2023. In connection with the early redemption of such senior notes, the Company paid a make-whole premium of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$80 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in excess of the aggregate principal amount of the senior notes that were redeemed, wrote-off </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of unamortized deferred financing costs and incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in fees, for a total loss on early extinguishment of debt of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$89&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company purchased approximately $2.0&#160;billion of its outstanding 4.3% senior notes due 2028 through a cash tender offer. In connection with the purchase of such senior notes, the Company paid a premium of $332 million&#160;in excess </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the aggregate principal amount of the senior notes that were purchased, wrote-off $26&#160;million of unamortized deferred financing costs and incurred $5&#160;million in fees, for a total loss on early extinguishment of debt of $363&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company purchased $4.5&#160;billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $113&#160;million of its 4.0% senior notes due 2023, $1.4&#160;billion of its 3.7% senior notes due 2023, $1.0&#160;billion of its 4.1% senior notes due 2025 and $2.0&#160;billion of its 4.3% senior notes due 2028. In connection with the purchase of such senior notes, the Company paid a premium of $619&#160;million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $45&#160;million of unamortized deferred financing costs and incurred $10&#160;million in fees, for a total loss on early extinguishment of debt of $674&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company purchased $6.0&#160;billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $723&#160;million of its 4.0% senior notes due 2023, $2.3&#160;billion of its 3.7% senior notes due 2023 and $3.0&#160;billion of its 4.1% senior notes due 2025. In connection with the purchase of such senior notes, the Company paid a premium of $706&#160;million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $47&#160;million of unamortized deferred financing costs and incurred $13&#160;million in fees, for a total loss on early extinguishment of debt of $766&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 &#8216;&#8216;Borrowings and Credit Agreements&#8217;&#8217; included in Item 8 of this 10-K for additional information about debt issuances and debt repayments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company&#8217;s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Covenants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s back-up revolving credit facilities and unsecured senior notes (see Note 8 &#8216;&#8216;Borrowings and Credit Agreements&#8217;&#8217; included in Item 8 of this 10-K) contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company&#8217;s debt maturities in the event of a downgrade in the Company&#8217;s credit ratings. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of December&#160;31, 2022, the Company was in compliance with all of its debt covenants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Ratings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company&#8217;s long-term debt was rated &#8220;Baa2&#8221; by Moody&#8217;s Investors Service, Inc. (&#8220;Moody&#8217;s&#8221;) and &#8220;BBB&#8221; by Standard&#160;&amp; Poor&#8217;s Financial Services LLC (&#8220;S&amp;P&#8221;), and its commercial paper program was rated &#8220;P-2&#8221; by Moody&#8217;s and &#8220;A-2&#8221; by S&amp;P. The outlook on the Company&#8217;s long-term debt is &#8220;Stable&#8221; by Moody&#8217;s. In December 2022, S&amp;P changed the outlook on the Company&#8217;s long-term debt from &#8220;Positive&#8221; to &#8220;Stable.&#8221; In assessing the Company&#8217;s credit strength, the Company believes that both Moody&#8217;s and S&amp;P considered, among other things, the Company&#8217;s capital structure and financial policies as well as its consolidated balance sheet, its historical acquisition activity and other financial information. Although the Company currently believes its long-term debt ratings will remain investment grade, it cannot guarantee the future actions of Moody&#8217;s and/or S&amp;P. The Company&#8217;s debt ratings have a direct impact on its future borrowing costs, access to capital markets and new store operating lease costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share repurchase programs have been authorized by CVS Health Corporation&#8217;s Board of Directors (the &#8220;Board&#8221;):</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share repurchase programs have been authorized by the Board:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In billions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Authorization&#160;Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining as of<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 17, 2022 (&#8220;2022 Repurchase Program&#8221;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 9, 2021 (&#8220;2021 Repurchase Program&#8221;)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the share Repurchase Programs was effective immediately and permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (&#8220;ASR&#8221;) transactions, and/or other derivative transactions. Both the 2022 and 2021 Repurchase Programs can be modified or terminated by the Board at any time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company repurchased an aggregate of 34.1&#160;million shares of common stock for approximately $3.5&#160;billion pursuant to the 2021 Repurchase Program, including share repurchases under the $1.5 billion fixed dollar ASR transaction described below. During the years ended December&#160;31, 2021 and 2020, the Company did not repurchase any shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $2.0&#160;billion fixed dollar ASR with Citibank, N.A. (&#8220;Citibank&#8221;). Upon payment of the $2.0&#160;billion purchase price on January 4, 2023, the Company received a number of shares of CVS Health Corporation&#8217;s common stock equal to 80% of the $2.0&#160;billion notional amount of the ASR or approximately 17.4 million shares at a price of $92.19 per share, which were placed into treasury stock in January 2023. At the conclusion of the ASR, the Company may receive additional shares representing the remaining 20% of the $2.0&#160;billion notional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Company&#8217;s stock over an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Citibank which, at the Company&#8217;s option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that could be delivered to the Company is 43.4 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5&#160;billion fixed dollar ASR with Barclays Bank PLC. Upon payment of the $1.5&#160;billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation&#8217;s common stock equal to 80% of the $1.5&#160;billion notional amount of the ASR or approximately 11.6&#160;million shares at a price of $103.34 per share, which were placed into treasury stock in January 2022. The ASR was accounted for as an initial treasury stock transaction for $1.2&#160;billion and a forward contract for $0.3&#160;billion. The forward contract was classified as an equity instrument and was recorded within capital surplus. In February 2022, the Company received approximately 2.7&#160;million shares of CVS Health Corporation&#8217;s common stock, representing the remaining 20% of the $1.5&#160;billion notional amount of the ASR, thereby concluding the ASR. These shares were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020 the quarterly cash dividend was $0.55, $0.50 and $0.50 per share, respectively. In December 2022, the Board authorized a 10% increase in the quarterly cash dividend to $0.605 per share effective in 2023. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company&#8217;s earnings, capital requirements, financial condition and other factors considered relevant by the Board.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Cash Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain estimated future cash requirements under the Company&#8217;s various contractual obligations at December&#160;31, 2022, in total and disaggregated into current and long-term obligations. The table below does not include future payments of claims to health care providers or pharmacies because certain terms of these payments are not determinable at December&#160;31, 2022 (for example, the timing and volume of future services provided under fee-for-service arrangements and future membership levels for capitated arrangements). </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual lease obligations with Target </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payments on long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid litigation settlement agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities on the consolidated balance sheets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future policy benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (6) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid claims</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (6) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Policyholders&#8217; funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) (7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Refer to Note 6 &#8216;&#8216;Leases&#8217;&#8217; included in Item 8 of this 10-K for additional information regarding the maturity of lease liabilities under operating and finance leases. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target. See Note 6 &#8216;&#8216;Leases&#8217;&#8217; included in Item 8 of this 10-K for additional information regarding the lease arrangements with Target. Amounts related to such operating and finance leases are reflected within the operating lease liabilities and finance lease liabilities in the table above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings are reflected in the table above assuming equivalent stores continue to operate through the term of the arrangements. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Refer to Note 8 &#8216;&#8216;Borrowings and Credit Agreements&#8217;&#8217; included in Item 8 of this 10-K for additional information regarding the maturities of debt principal. Interest payments on long-term debt are calculated using outstanding balances and interest rates in effect on December&#160;31, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Refer to Note 16 &#8216;&#8216;Commitments and Contingencies&#8217;&#8217; included in Item 8 of this 10-K for additional information regarding the opioid litigation settlement agreements. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Payments of other long-term liabilities exclude Separate Accounts liabilities of approximately $3.2 billion because these liabilities are supported by assets that are legally segregated and are not subject to claims that arise out of the Company&#8217;s business.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total payments of future policy benefits, unpaid claims and policyholders&#8217; funds include $705 million, $1.3 billion and $170 million, respectively, of reserves for contracts subject to reinsurance. The Company expects the assuming reinsurance carrier to fund these obligations and has reflected these amounts as reinsurance recoverable assets on the consolidated balance sheets.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Customer funds associated with group life and health contracts of approximately $107 million have been excluded from the table above because such funds may be used primarily at the customer&#8217;s discretion to offset future premiums and/or for refunds, and the timing of the related cash flows cannot be determined. Additionally, net unrealized capital losses on debt securities supporting experience-rated products of $56 million, before tax, have been excluded from the table above.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restrictions on Certain Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to general state law restrictions on payments of dividends and other distributions to stockholders applicable to all corporations, health maintenance organizations (&#8220;HMOs&#8221;) and insurance companies are subject to further regulations that, among other things, may require those companies to maintain certain levels of equity (referred to as surplus) and restrict the amount of dividends and other distributions that may be paid to their equity holders. These regulations are not directly applicable to CVS Health Corporation as a holding company, since CVS Health Corporation is not an HMO or an insurance company. In addition, in connection with the Aetna Acquisition, the Company made certain undertakings that require prior regulatory approval of dividends by certain of its HMOs and insurance companies. The additional regulations and undertakings applicable to the Company&#8217;s HMO and insurance company subsidiaries are not expected to affect the Company&#8217;s ability to service the Company&#8217;s debt, meet other financing obligations or pay dividends, or the ability of any of the Company&#8217;s subsidiaries to service their debt or other financing obligations. Under applicable regulatory requirements and undertakings, at December&#160;31, 2022, the maximum amount of dividends that may be paid by the Company&#8217;s insurance and HMO subsidiaries without prior approval by regulatory authorities was $2.7 billion in the aggregate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains capital levels in its operating subsidiaries at or above targeted and/or required capital levels and dividends amounts in excess of these levels to meet liquidity requirements, including the payment of interest on debt and stockholder dividends. In addition, at the Company&#8217;s discretion, it uses these funds for other purposes such as funding share and debt repurchase programs, investments in new businesses and other purposes considered advisable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company held investments of $331 million and $450 million, respectively, that are not accounted for as Separate Accounts assets but are legally segregated and are not subject to claims that arise out of the Company&#8217;s business. See Note 3 &#8216;&#8216;Investments&#8217;&#8217; included in Item 8 of this 10-K for additional information on investments related to the 2012 conversion of an existing group annuity contract from a participating to a non-participating contract.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Solvency Regulation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The National Association of Insurance Commissioners (the &#8220;NAIC&#8221;) utilizes risk-based capital (&#8220;RBC&#8221;) standards for insurance companies that are designed to identify weakly-capitalized companies by comparing each company&#8217;s adjusted surplus to its required surplus (the &#8220;RBC Ratio&#8221;). The RBC Ratio is designed to reflect the risk profile of insurance companies. Within certain ratio ranges, regulators have increasing authority to take action as the RBC Ratio decreases. There are four levels of regulatory action, ranging from requiring an insurer to submit a comprehensive financial plan for increasing its RBC to the state insurance commissioner to requiring the state insurance commissioner to place the insurer under regulatory control. At December&#160;31, 2022, the RBC Ratio of each of the Company&#8217;s primary insurance subsidiaries was above the level that would require regulatory action. The RBC framework described above for insurers has been extended by the NAIC to health organizations, including HMOs. Although not all states had adopted these rules at December&#160;31, 2022, at that date, each of the Company&#8217;s active HMOs had a surplus that exceeded either the applicable state net worth requirements or, where adopted, the levels that would require regulatory action under the NAIC&#8217;s RBC rules. External rating agencies use their own capital models and/or RBC standards when they determine a company&#8217;s rating.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares the consolidated financial statements in conformity with generally accepted accounting principles, which require management to make certain estimates and apply judgment. Estimates and judgments are based on historical experience, current trends and other factors that management believes to be important at the time the consolidated financial statements are prepared. On a regular basis, the Company reviews its accounting policies and how they are applied and disclosed in the consolidated financial statements. While the Company believes the historical experience, current trends and other factors considered by management support the preparation of the consolidated financial statements in conformity with generally accepted accounting principles, actual results could differ from estimates, and such differences could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant accounting policies are discussed in Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; included in Item 8 of this 10-K. Management believes the following accounting policies include a higher degree of judgment and/or complexity and, thus, are considered to be critical accounting policies. The Company has discussed the development and selection of these critical accounting policies with the Audit Committee of the Board (the &#8220;Audit Committee&#8221;), and the Audit Committee has reviewed the disclosures relating to them.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company&#8217;s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company&#8217;s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company&#8217;s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise. A significant difference in the actual level of retroactivity compared to estimated levels would have a significant effect on the Company&#8217;s operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Premium Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the MLR rebate requirements of the ACA is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment&#8217;s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company&#8217;s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor&#8217;s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting for Medicare Part D </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include insurance premiums earned by the Company&#8217;s PDPs, which are determined based on the PDP&#8217;s annual bid and related contractual arrangements with CMS. The insurance premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company&#8217;s retail pharmacy network. The Company&#8217;s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see &#8220;Drug Discounts&#8221; and &#8220;Guarantees&#8221; below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (&#8220;retail co-payments&#8221;), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by third party pharmacies in the Company&#8217;s retail pharmacy network and associated administrative fees are recognized at the Company&#8217;s point-of-sale, which is when the claim is adjudicated by the Company&#8217;s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Drug Discounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue net of manufacturers&#8217; rebates earned by its clients based on their plan members&#8217; utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers&#8217; rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers&#8217; rebate amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantees</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Retail Pharmacy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer returns are not material to the Company&#8217;s operating results or financial condition. Sales taxes are not included in revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Loyalty and Other Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer loyalty program, ExtraCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consists of two components, ExtraSavings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offers a subscription-based membership program, CarePass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-term Care</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company&#8217;s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Walk-In Medical Clinics</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For services provided by the Company&#8217;s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairments of Debt Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews its debt securities to determine whether a decline in fair value below the cost basis or carrying value has occurred. If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related (yield-related) components. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income (loss). The Company analyzes all facts and circumstances believed to be relevant for each investment when performing this analysis, in accordance with applicable accounting guidance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principle payments; and any changes to the rating of the security by a rating agency. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the factors considered in evaluating whether a decline in fair value below the cost basis or carrying value has occurred are whether the decline results from a change in the quality of the debt security itself, whether the decline results from a downward movement in the market as a whole, and the prospects for realizing the carrying value of the debt security based on the investment&#8217;s current and short-term prospects for recovery. For unrealized losses determined to be the result of market conditions (for example, increasing interest rates and volatility due to conditions in the overall market) or industry-related events, the Company determines whether it intends to sell the debt security or if it is more likely than not that the Company will be required to sell the debt security prior to the anticipated recovery of the debt security&#8217;s amortized cost basis. If either case is true, the Company recognizes a non-credit related impairment, and the cost basis or carrying amount of the debt security is written down to fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded yield-related impairment losses on debt securities of $143 million, $42 million and $49 million, respectively. During the year ended December&#160;31, 2022, the Company recorded credit-related losses on debt securities of $13 million. During the years ended December 31, 2021 and 2020, the Company did not record any credit-related impairment losses on debt securities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks inherent in assessing the impairment of a debt security include the risk that market factors may differ from projections and the risk that facts and circumstances factored into the Company&#8217;s assessment may change with the passage of time. Unexpected changes to market factors and circumstances that were not present in past reporting periods are among the factors that may result in a current period decision to sell debt securities that were not impaired in prior reporting periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vendor Allowances and Purchase Discounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vendor and manufacturer receivables were $12.4 billion and $10.6 billion as of December&#160;31, 2022 and 2021, respectively, the majority of which relate to purchase discounts and vendor allowances as described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive purchase discounts from established list prices in one, or a combination, of the following forms: (i)&#160;a direct discount at the time of purchase, (ii)&#160;a discount for the prompt payment of invoices or (iii)&#160;when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30&#160;days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company&#8217;s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any such allowances received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes a receivable for vendor income that is earned but not yet received based on historical trends and data. The majority of vendor receivables are collected within the following fiscal quarter. Historically, adjustments to the Company&#8217;s vendor receivables resulting from the reconciliation of receivables recognized to the amounts collected have not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any material changes in the way the Company accounts for vendor allowances or purchase discounts during the past three&#160;years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value using the weighted average cost method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of ending inventory is reduced for estimated inventory losses that have occurred during the interim period between physical inventory counts. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. The Company&#8217;s accounting for inventory contains uncertainty since management must use judgment to estimate the inventory losses that have occurred during the interim period between physical inventory counts. When estimating these losses, a number of factors are considered which include historical physical inventory results on a location-by-location basis and current physical inventory loss trends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserve for estimated inventory losses covered by this critical accounting policy was $559 million and $522 million as of December&#160;31, 2022 and 2021, respectively. Although management believes there is sufficient current and historical information available to record reasonable estimates for estimated inventory losses, it is possible that actual results could differ. In order to help investors assess the aggregate risk, if any, associated with the inventory-related uncertainties discussed above, a ten&#160;percent (10%)&#160;pre-tax change in estimated inventory losses, which is a reasonably likely change, would increase or decrease the total reserve for estimated inventory losses by approximately $56 million as of December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although management believes that the estimates discussed above are reasonable and the related calculations conform to generally accepted accounting principles, actual results could differ from such estimates, and such differences could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right-of-Use Assets and Lease Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company&#8217;s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives. The Company evaluates the recoverability of its right-of-use assets as described in &#8220;Recoverability of Long-Lived Assets&#8221; below.  </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For real estate leases, the Company accounts for lease components and nonlease components as a single lease component.  Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recoverability of Long-Lived Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recoverability of Definite-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such an asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group&#8217;s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group&#8217;s carrying value that exceeds the asset group&#8217;s estimated future cash flows (discounted).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-lived asset impairment loss calculation contains uncertainty since management must use judgment to estimate each asset group&#8217;s future sales, profitability and cash flows. When preparing these estimates, the Company considers historical results and current operating trends and consolidated sales, profitability and cash flow results and forecasts. These estimates can be affected by a number of factors including general economic and regulatory conditions, efforts of third party organizations to reduce their prescription drug costs and/or increased member co-payments, the continued efforts of competitors to gain market share and consumer spending patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company undertook an initiative to evaluate its corporate office real estate space in response to its new flexible work arrangement. As part of this initiative, the Company evaluated its current real estate space and changes in employee work arrangement requirements to ensure it had the appropriate space to support the business. As a result of this assessment, the Company determined that it would vacate and abandon certain leased corporate office spaces. Accordingly, in the three months ended December 31, 2022, the Company recorded office real estate optimization charges of $117 million, primarily consisting of $71&#160;million related to operating lease right-of-use assets and $44&#160;million related to property and equipment, within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board authorized the closing of approximately 900 retail stores, approximately 300 stores each year, between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores&#8217; asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December&#160;31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1&#160;billion related to operating lease right-of-use assets and $261&#160;million related to property and equipment, within the Retail/LTC segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material impairment charges recognized on long-lived assets during the year ended December 31,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recoverability of Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of amounts paid for acquisitions over the fair value of the net identifiable assets acquired. Goodwill is subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate that the carrying value may not be recoverable. Goodwill is tested for impairment on a reporting unit basis. The impairment test is performed by comparing the reporting unit&#8217;s fair value with its net book value (or carrying amount), including goodwill. The fair value of the reporting units is estimated using a combination of a discounted cash flow method and a market multiple method. If the net book value (carrying amount) of the reporting unit exceeds its fair value, the reporting unit&#8217;s goodwill is considered to be impaired, and an impairment is recognized in an amount equal to the excess.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the fair value of the reporting units requires the Company to make significant assumptions and estimates. These assumptions and estimates primarily include the selection of appropriate peer group companies; control premiums and valuation multiples appropriate for acquisitions in the industries in which the Company competes; discount rates; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, income taxes, capital expenditures and future working capital requirements. When determining these assumptions and preparing these estimates, the Company considers each reporting unit&#8217;s historical results and current operating trends; consolidated revenues, profitability and cash flow results and forecasts; and industry trends. The Company&#8217;s estimates can be affected by a number of factors, including general economic and regulatory conditions; the risk-free interest rate environment; the Company&#8217;s market capitalization; efforts of customers and payers to reduce costs, including their prescription drug costs, and/or increase member co-payments; the continued efforts of competitors to gain market share, consumer spending patterns and the Company&#8217;s ability to achieve its revenue growth projections and execute on its cost reduction initiatives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Goodwill Impairment Test</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company performed its required annual impairment test of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill as of the testing date. The fair values of the reporting units with goodwill exceeded their carrying values by significant margins.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the closing date of the Aetna Acquisition in November 2018, the Company had experienced declines in its Commercial Insured medical membership. In 2022, the Company has grown its Commercial Insured medical membership, excluding the impact of the divestiture of the Thailand business described in Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; included in Item 8 of this 10-K. Adverse economic conditions may impact medical membership in the Commercial business due to reductions in workforce at existing customers. The Company&#8217;s fair value estimate is sensitive to significant assumptions including changes in medical membership, revenue growth rate, operating income and the discount rate. The Company believes the financial projections used to determine the fair value of the Commercial Business reporting unit in the third quarter of 2022 were reasonable and achievable. As of December 31, 2022, the goodwill balance in the Commercial Business reporting unit was $25.5 billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Goodwill Impairment Test</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated an impairment of the goodwill associated with the LTC reporting unit, as the reporting unit&#8217;s carrying value exceeded its fair value as of the testing date. The results of the impairment tests of the remaining reporting units indicated that there was no impairment of goodwill as of the testing date. The fair values of the reporting units with goodwill exceeded their carrying values by significant margins, with the exception of the Commercial Business reporting unit, which exceeded its carrying value by approximately 3%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5 &#8216;&#8216;Goodwill and Other Intangibles&#8217;&#8217; included in Item 8 of this 10-K, during 2021, the LTC reporting unit has continued to face challenges that have impacted the Company&#8217;s ability to grow the LTC reporting unit&#8217;s business at the rate estimated when its 2020 goodwill impairment test was performed. These challenges include lower net facility admissions, net long-term care facility customer losses and the prolonged adverse impact of the COVID-19 pandemic and the emerging new variants, which resulted in more significant declines in occupancy rates experienced by the Company&#8217;s long-term care facility customers than previously anticipated. During the third quarter of 2021, LTC management updated their 2021 annual forecast and submitted their long-term plan which showed deterioration in the financial results for the remainder of 2021 and beyond. The Company utilized these updated projections in performing its annual impairment test, which indicated that the fair value of the LTC reporting unit was lower than its carrying value, resulting in a $431 million goodwill impairment charge in the third </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter of 2021. The fair value of the LTC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. Subsequent to the impairment charge recorded in the third quarter of 2021, there is no remaining goodwill balance in the LTC reporting unit. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Goodwill Impairment Test</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, the Company performed its required annual impairment test of goodwill. The results of this impairment test indicated that there was no impairment of goodwill as of the testing date. The goodwill impairment test resulted in the fair values of all of the Company&#8217;s reporting units exceeding their carrying values by significant margins, with the exception of the Commercial Business and LTC reporting units, which exceeded their carrying values by approximately 6% and 12%, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recoverability of Indefinite-Lived Intangible Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate that their carrying value may not be recoverable. Indefinite-lived intangible assets are tested by comparing the estimated fair value of the asset to its carrying value. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indefinite-lived intangible asset impairment loss calculation contains uncertainty since management must use judgment to estimate fair value based on the assumption that, in lieu of ownership of an intangible asset, the Company would be willing to pay a royalty in order to utilize the benefits of the asset. Fair value is estimated by discounting the hypothetical royalty payments to their present value over the estimated economic life of the asset. These estimates can be affected by a number of factors including general economic conditions, availability of market information and the profitability of the Company. There were no impairment losses recognized on indefinite-lived intangible assets in any of the years ended December&#160;31, 2022, 2021 or 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Costs Payable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both&#160;December&#160;31, 2022 and 2021, 75% of health care costs payable are estimates of the ultimate cost of (i) services rendered to the Company&#8217;s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid (collectively, &#8220;IBNR&#8221;). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. The remainder of health care costs payable is primarily comprised of pharmacy and capitation payables, other amounts due to providers pursuant to risk sharing agreements and accruals for state assessments. The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; included in Item 8 of this 10-K for additional information on the Company&#8217;s reserving methodology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company observed an increase in completion factors relative to those assumed at the prior year end. After considering the claims paid in 2022 and 2021 with dates of service prior to the fourth quarter of the previous year, the Company observed assumed incurred claim weighted average completion factors that were 3 and 21 basis points higher, respectively, than previously estimated, resulting in a decrease of $32 million and $207 million in 2022 and 2021, respectively, in health care costs payable that related to the prior year. The Company has considered the pattern of changes in its completion factors when determining the completion factors used in its estimates of IBNR as of December&#160;31, 2022. However, based on historical claim experience, it is reasonably possible that the Company&#8217;s estimated weighted average completion factors may vary by plus or minus 12 basis points from the Company&#8217;s assumed rates, which could impact health care costs payable by approximately plus or minus $207 million pretax.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, during 2022 and 2021, the Company observed that health care costs for claims with claim incurred dates of three months or less before the financial statement date were lower than previously estimated. Specifically, after considering the claims paid in 2022 and 2021 with claim incurred dates for the fourth quarter of the previous year, the Company observed health care costs that were 4.8% and 5.0% lower, respectively, for each fourth quarter than previously estimated, resulting in a reduction of $622 million and $581 million in 2022 and 2021, respectively, in health care costs payable that related to prior year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers historical health care cost trend rates together with its knowledge of recent events that may impact current trends when developing estimates of current health care cost trend rates. When establishing reserves as of December&#160;31, 2022, the Company increased its assumed health care cost trend rates for the most recent three months by 4.9% from health care cost trend rates recently observed. Health care cost trend rates during the past three years have been impacted by utilization changes driven by the COVID-19 pandemic. The impact has not been uniform, with products and select geographies </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experiencing utilization impacts due to COVID-19 waves. Based on historical claim experience, it is reasonably possible that the Company&#8217;s estimated health care cost trend rates may vary by plus or minus 3.5% from the assumed rates, which could impact health care costs payable by plus or minus $487 million pretax.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are established for any temporary differences between financial and tax reporting bases and are adjusted as needed to reflect changes in the enacted tax rates expected to be in effect when the temporary differences reverse. Such adjustments are recorded in the period in which changes in tax laws are enacted, regardless of when they are effective. Deferred tax assets are reduced, if necessary, by a valuation allowance to the extent future realization of those losses, deductions or other tax benefits is sufficiently uncertain.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in determining the provision for income taxes and the related taxes payable and deferred tax assets and liabilities since, in the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. Additionally, the Company&#8217;s tax returns are subject to audit by various domestic and foreign tax authorities that could result in material adjustments based on differing interpretations of the tax laws. Although management believes that its estimates are reasonable and are based on the best available information at the time the provision is prepared, actual results could differ from these estimates resulting in a final tax outcome that may be materially different from that which is reflected in the consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement with the related tax authority. Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision. Significant judgment is required in determining uncertain tax positions. The Company has established accruals for uncertain tax positions using its judgment and adjusts these accruals, as warranted, due to changing facts and circumstances.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; included in Item 8 of this 10-K for a description of new accounting pronouncements applicable to the Company.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.  Quantitative and Qualitative Disclosures About Market Risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s earnings and financial condition are exposed to interest rate risk, credit quality risk, market valuation risk, foreign currency risk, commodity risk and operational risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Interest Rate and Credit Quality Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages interest rate risk by seeking to maintain a tight match between the durations of assets and liabilities when appropriate.&#160;The Company manages credit quality risk by seeking to maintain high average credit quality ratings and diversified sector exposure within its debt securities portfolio.&#160;In connection with its investment and risk management objectives, the Company also uses derivative financial instruments whose market value is at least partially determined by, among other things, levels of or changes in interest rates (short-term or long-term), duration, prepayment rates, equity markets or credit ratings/spreads.&#160;The Company&#8217;s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.&#160;These instruments, viewed separately, subject the Company to varying degrees of interest rate, equity price and credit risk.&#160;However, when used for hedging, the Company expects these instruments to reduce overall risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment portfolio supported the following products at December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Experience-rated products </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term investments of $17&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; included in Item 8 of this 10-K for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment risks associated with experience-rated products generally do not impact the Company&#8217;s operating results. The risks associated with investments supporting experience-rated pension and annuity products in the large case pensions business in the Company&#8217;s Corporate/Other segment are assumed by the contract holders and not by the Company (subject to, among other things, certain minimum guarantees).&#160;Assets supporting experience-rated products may be subject to contract holder or participant withdrawals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt securities in the Company&#8217;s investment portfolio had an average credit quality rating of A at both December&#160;31, 2022 and 2021, with a fair value of approximately $6.0 billion and $6.7 billion rated AAA at December&#160;31, 2022 and 2021, respectively.&#160;The fair value of debt securities that were rated below investment grade (that is, having a credit quality rating below BBB-/Baa3) was $1.9 billion and $2.3 billion at December&#160;31, 2022 and 2021, respectively (of which 1.6% and 2.0% at December&#160;31, 2022 and 2021, respectively, supported experience-rated products).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company held $202 million and $305 million, respectively, of municipal debt securities that were guaranteed by third parties, representing 1% of total investments at both December&#160;31, 2022 and 2021.&#160;These securities had an average credit quality rating of AA+ and AA at December&#160;31, 2022 and 2021, respectively, with the guarantee. These securities had an average credit quality rating of A at both December&#160;31, 2022 and 2021, respectively, without the guarantee.&#160;The Company does not have any significant concentration of investments with third party guarantors (either direct or indirect).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies debt securities as available for sale, and carries them at fair value on the consolidated balance sheets.&#160;At both December&#160;31, 2022 and 2021, less than 1% of debt securities were valued using inputs that reflect the Company&#8217;s assumptions (categorized as Level 3 inputs in accordance with accounting principles generally accepted in the United States of America).&#160;See Note 4 &#8216;&#8216;Fair Value&#8217;&#8217; included in Item 8 of this 10-K for additional information on the methodologies and key assumptions used to determine the fair value of investments. For additional information related to investments, see Note 3 &#8216;&#8216;Investments&#8217;&#8217; included in Item 8 of this 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews debt securities in its portfolio to determine whether a decline in fair value below the cost basis or carrying value has occurred.&#160;If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related components. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income (loss). The impairment of debt securities is considered a critical accounting policy.&#160;See &#8216;&#8216;Critical Accounting Policies - Impairments of Debt Securities&#8221; in the MD&amp;A included in Item 7 of this 10-K for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Market Valuation Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates its risk from market-sensitive instruments by examining, among other things, levels of or changes in interest rates (short-term or long-term), duration, prepayment rates, equity markets and/or credit ratings/spreads. The Company also regularly evaluates the appropriateness of investments relative to management-approved investment guidelines (and operates within those guidelines) and the business objectives of its portfolios.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company reviews the impact of hypothetical net losses in its investment portfolio on the Company&#8217;s consolidated near-term financial condition, operating results and cash flows assuming the occurrence of certain reasonably possible changes in near-term market rates and prices. Interest rate changes (whether resulting from changes in treasury yields or credit spreads or other factors) represent the most material risk exposure category for the Company.&#160;The Company has estimated the impact on the fair value of market sensitive instruments based on the net present value of cash flows using a representative set of likely future interest rate scenarios. The assumptions used were as follows: an immediate increase of 100 basis points in interest rates (which the Company believes represents a moderately adverse scenario) for long-term debt issued by the Company, as well as its interest rate sensitive investments and an immediate decrease of 15% in prices for publicly traded domestic equity securities in the Company&#8217;s investment portfolio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming an immediate increase of 100 basis points in interest rates, the theoretical decline in the fair values of market sensitive instruments at December&#160;31, 2022 is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The fair value of long-term debt issued by the Company would decline by approximately $2.9 billion ($3.6 billion pretax). Changes in the fair value of long-term debt do not impact the Company&#8217;s operating results or financial condition.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The theoretical reduction in the fair value of interest rate sensitive investments partially offset by the theoretical reduction in the fair value of interest rate sensitive liabilities would result in a net decline in fair value of approximately $595 million ($750 million pretax) related to continuing non-experience-rated products. Reductions in the fair value of investment securities would be reflected as an unrealized loss in equity, as the Company classifies these debt securities as available for sale. The Company does not record liabilities at fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the value of the Company&#8217;s publicly traded domestic equity securities held within its investment portfolio were to decline by 15%, this would result in a net decline in fair value of $20&#160;million ($26&#160;million pretax).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on overall exposure to interest rate risk and equity price risk, the Company believes that these changes in market rates and prices would not materially affect consolidated near-term financial condition, operating results or cash flows as of December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Foreign Currency and Commodity Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company did not have any material foreign currency exchange rate or commodity derivative instruments in place and believes its exposure to foreign currency exchange rate risk is not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Operational Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also faces certain operational risks. Those risks include risks related to the COVID-19 pandemic and risks related to information security, including cybersecurity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, or actions taken to mitigate its spread, could have material and adverse effects on our ability to operate our businesses effectively, including as a result of the complete or partial closure of facilities or labor shortages. Disruptions in our supply chains, our distribution chains and/or public and private infrastructure, including communications, financial services and supply chains, could materially and adversely impact our business operations. We have transitioned a significant subset of our colleagues to a remote work environment in an effort to mitigate the spread of COVID-19, as have a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant number of our third-party service providers, which may amplify certain risks to our businesses, including an increased demand for information technology resources, increased risk of phishing and other cyber attacks, increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our medical members or other third-parties and increased risk of business interruptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its vendors have experienced diverse cyber attacks and expect to continue to experience cyber attacks going forward. As examples, the Company and its vendors have experienced attempts to gain access to systems, denial of service attacks, attempted malware infections, account takeovers, scanning activity and phishing emails. Attacks can originate from external criminals, terrorists, nation states or internal actors. The Company is dedicating and will continue to dedicate significant resources and incur significant expenses to maintain and update on an ongoing basis the systems and processes that are designed to mitigate the information security risks it faces and protect the security of its computer systems, software, networks and other technology assets against attempts by unauthorized parties to obtain access to confidential information, disrupt or degrade service or cause other damage. The impact of cyber attacks has not been material to the Company&#8217;s operations or operating results through December&#160;31, 2022. The Board and its Audit Committee and Nominating and Corporate Governance Committee are regularly informed regarding the Company&#8217;s information security policies, practices and status.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.  Financial Statements and Supplementary Data.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_103">Consolidated Statements of Operations for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_103">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_103">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_103">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_103"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_103">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_103">106</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_106">Consolidated Statements of Comprehensive Income for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_106">107</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_109">Consolidated Balance Sheets as of December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_109">22</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_109"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_109">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_109">108</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_112">Consolidated Statements of Cash Flows for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_112">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_112">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_112">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_112"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_112">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_112">109</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_115">Consolidated Statements of Shareholders&#8217; Equity for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_115">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_115">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_115">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_115"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_115">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_115">111</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_118">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_118">112</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_175">Reports of Independent Registered Public Accounting Firm</a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">(Public Company Accounting Oversight Board ID: <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDAvZnJhZzpiNWEyYjQwNGQ0M2M0NGFhYjRlMmJiMmI4MTBmM2Y5Yy90YWJsZToyNWRlMDZiNWFlYTA0OTA1YWY1Y2ZmNWQ3NDAzNWM4Yi90YWJsZXJhbmdlOjI1ZGUwNmI1YWVhMDQ5MDVhZjVjZmY1ZDc0MDM1YzhiXzEzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmNlNTc2MTUxMzM3NDQ1ZTliNzJlYjViOTdjMWY5OTA5XzEwOA_2eacdf94-6bb9-44d2-86a0-c72ee972e7e1">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_175">179</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-right:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">Index to Consolidated Financial Statements</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except per share amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d91c5c532243ef9f94c642820dbac4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMtMS0xLTEtMTY3OTA4_479f11c4-79fa-43b6-a193-ed099d687983">226,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a740dd129184890b8bde10a27ca4208_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMtMy0xLTEtMTY3OTA4_badde249-5a2e-49eb-8b5b-f7364e7152bf">203,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia465cf35ed0f45939b52004b01431e3d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMtNS0xLTEtMTY3OTA4_3e68c4ae-7387-4008-847c-29f561d5f8a8">190,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzQtMS0xLTEtMTY3OTA4_1354c69b-7405-4503-9852-07875175fe82">85,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzQtMy0xLTEtMTY3OTA4_a7816565-33f5-418a-a2d0-3c2af99eaa90">76,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzQtNS0xLTEtMTY3OTA4_9441a206-7f66-4168-90d1-6e740391ee3f">69,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db92dc898a14220a458e7987f33b9ff_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzUtMS0xLTEtMTY3OTA4_a2df9ca0-86e8-4e28-b32b-f3a5674729e4">9,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdce439e9a164fc590536f15958f67f9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzUtMy0xLTEtMTY3OTA4_811a9f1c-4d3f-4440-ac66-4a64786d3823">11,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic793b82f8aae4503ad92cb8081fb8628_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzUtNS0xLTEtMTY3OTA4_35b82836-18d4-4e02-ad9a-0e5cde0a4bba">7,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzYtMS0xLTEtMTY3OTA4_efaca6be-afc0-45cb-bd32-fd2c915eb1b0">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzYtMy0xLTEtMTY3OTA4_ef1a4656-b233-46b4-9fb5-4b4442627c15">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzYtNS0xLTEtMTY3OTA4_232068a4-95e2-4cbb-b151-f2fb3b425910">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzctMS0xLTEtMTY3OTA4_9f004c42-1157-432f-a2f0-914bb1b2a7e2">322,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzctMy0xLTEtMTY3OTA4_682b9399-e100-4493-ba8e-da2852a1a3a1">292,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzctNS0xLTEtMTY3OTA4_ab63edc4-f029-40b1-965b-653749dfad43">268,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMC0xLTEtMTY3OTA4_1e4004b0-6498-4ea3-8ab1-ac09269493b2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMC0xLTEtMTY3OTA4_3e2cf2f7-df85-4376-a35e-0669e17c468e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMC0xLTEtMTY3OTA4_5eed1e85-5f6b-489c-9018-e11e62bf23d7">Cost of products sold</span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMS0xLTEtMTY3OTA4_bd00b793-35f5-4c24-b653-08672e9be2d1">196,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMy0xLTEtMTY3OTA4_3c4c0bf3-35cb-4c4b-b623-085f391ba77a">175,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktNS0xLTEtMTY3OTA4_afc80d66-9ee1-4365-8f0d-cba28a05f7e7">163,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEwLTEtMS0xLTE2NzkwOA_5e639e29-50b1-4cc8-a287-d3f139df18b8">71,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEwLTMtMS0xLTE2NzkwOA_120bda64-f68c-4288-a48a-a8ae18ae3bd1">64,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEwLTUtMS0xLTE2NzkwOA_5c518517-a52a-4425-be3f-e9519f8fdd35">55,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid litigation charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTEtMS0xLTE5OTE2Mg_5383cce1-9300-429a-af7d-02b284114736">5,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTMtMS0xLTE5OTE2Mg_b88b3392-8e11-4d4e-9d10-9df43ae01003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTUtMS0xLTE5OTE2Mg_a920327e-82b4-429f-b6e5-586526cd1e22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTEtMS0xLTE5OTE2Mg_c1d1c1e1-8c22-4c01-a725-54d07f3cd028">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTMtMS0xLTE5OTE2Mg_d694b2b6-916e-488b-b9a1-5db4a1ea3441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTUtMS0xLTE5OTE2Mg_94d8994a-915f-4a9f-be6f-5c8cccedce78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTEtMS0xLTE2NzkwOA_58caeb19-1c5e-483b-aa06-fd0e7abf68ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTMtMS0xLTE2NzkwOA_f16f11c3-2628-426e-82ea-7433d863f396">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTUtMS0xLTE2NzkwOA_f20784f3-ad06-41d4-b7b8-91c40b9fc8cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTEtMS0xLTE2NzkwOA_da20fed1-ad27-4aa9-bdfa-6ea3e80be346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTMtMS0xLTE2NzkwOA_2b1b5c98-5694-426f-a9a0-e4f3b1962c41">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTUtMS0xLTE2NzkwOA_9a9acd7c-fc54-47b6-b37a-fb8b55f1abe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEzLTEtMS0xLTE2NzkwOA_4f17f163-6b50-4819-8bc4-b89a553a7e3f">38,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEzLTMtMS0xLTE2NzkwOA_48b853c3-7066-4974-85f1-c2c6f60ca5f0">37,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEzLTUtMS0xLTE2NzkwOA_a9fb233b-fa2d-496e-a9ac-681d6f79438f">35,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE0LTEtMS0xLTE2NzkwOA_501013f6-2c30-40e0-96c8-62ff84b644ac">314,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE0LTMtMS0xLTE2NzkwOA_6694e6ec-e784-4120-8379-322d21bc0136">278,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE0LTUtMS0xLTE2NzkwOA_ff9309b1-9d24-4973-ad2e-57b584ef8eb4">254,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE1LTEtMS0xLTE2NzkwOA_4935b40e-b9c1-4963-81bd-8a8fe9d3e8c2">7,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE1LTMtMS0xLTE2NzkwOA_6e2b78d3-9384-4f3b-ab4b-0f53c9ae9bc4">13,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE1LTUtMS0xLTE2NzkwOA_6935221f-f715-4050-8c12-9c39414741f5">13,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE2LTEtMS0xLTE2NzkwOA_0860d32f-3425-456f-a036-9fa009c08c71">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE2LTMtMS0xLTE2NzkwOA_f970e5f1-56fc-49b9-8f99-60804bf298f0">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE2LTUtMS0xLTE2NzkwOA_42e81952-af47-4d0b-b4d9-15649a24548f">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE3LTEtMS0xLTE2NzkwOA_454cd8c1-add2-4e5c-9567-e081e08c8ead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE3LTMtMS0xLTE2NzkwOA_24894c70-29be-4f18-8b37-405c0641f3e8">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE3LTUtMS0xLTE2NzkwOA_a07696b0-3fd4-49e9-85ac-1f6521018315">1,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE4LTEtMS0xLTE2NzkwOA_5723ef22-2243-4a7b-8bae-504ff9ddabbc">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE4LTMtMS0xLTE2NzkwOA_8329b71d-1751-4ac1-86d6-5b70945c4320">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE4LTUtMS0xLTE2NzkwOA_1f25a498-e901-4ab5-a63f-0ef19d8a5adf">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE5LTEtMS0xLTE2NzkwOA_cbe7c529-b61e-4952-8d48-6638a89c693c">5,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE5LTMtMS0xLTE2NzkwOA_9dce002e-eac6-479a-86d6-0c29449947eb">10,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE5LTUtMS0xLTE2NzkwOA_02319f88-3bd9-4550-8745-abb6c17d4e0d">9,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIwLTEtMS0xLTE2NzkwOA_fe3a4840-68a2-451b-bf45-e9ec8052a9d2">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIwLTMtMS0xLTE2NzkwOA_20c963c2-ad1d-430b-b4a2-31e18b842901">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIwLTUtMS0xLTE2NzkwOA_0e7585f4-8159-4f5c-9764-f2c3c878d951">2,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIxLTEtMS0xLTE2NzkwOA_18e1c5d3-ac2b-405d-9c12-878ab7111207">4,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIxLTMtMS0xLTE2NzkwOA_5bd267c4-77aa-4034-b029-72ddc823e2b9">7,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIxLTUtMS0xLTE2NzkwOA_9474086a-57ce-45e1-b125-4780ebc7b517">7,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIyLTEtMS0xLTE2NzkwOA_2286d232-26f0-487c-93bf-9f9eafdb9fe0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIyLTMtMS0xLTE2NzkwOA_ced6bb05-3423-4dfe-bf1c-7a3e454063cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIyLTUtMS0xLTE2NzkwOA_9974005a-d3fb-4a4e-b91a-4ccad4e063bc">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIzLTEtMS0xLTE2NzkwOA_aaaf6e99-4146-437f-a302-445346162eeb">4,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIzLTMtMS0xLTE2NzkwOA_ca11db01-5f6a-4254-a20e-2cbc60f67f05">7,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIzLTUtMS0xLTE2NzkwOA_1b582bad-c97b-4ec0-a875-5deeb4b4b270">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI0LTEtMS0xLTE2NzkwOA_d9d0c7fc-7bd1-493c-8348-e86d5a3bcfa1">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI0LTMtMS0xLTE2NzkwOA_3632fe89-9ace-41a0-8656-7cb88506b169">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI0LTUtMS0xLTE2NzkwOA_b193f8e0-b351-4c4d-9ed6-ed56405c6a44">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to CVS Health</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI1LTEtMS0xLTE2NzkwOA_ac218e4e-a0b5-4d1a-80e6-e08c5a26a59c">4,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI1LTMtMS0xLTE2NzkwOA_01a53cd5-01cc-4234-b2c0-74cb5c530c06">7,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI1LTUtMS0xLTE2NzkwOA_30ba5e70-57f0-4707-80f5-50b91f1f0ded">7,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to CVS Health</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI4LTEtMS0xLTE2NzkwOA_2af0e80e-bb25-4126-96b7-f5bc9c5d9fc4">3.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI4LTMtMS0xLTE2NzkwOA_6429b5e9-c836-40ff-b67e-d453d59ab93b">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI4LTUtMS0xLTE2NzkwOA_2575dd51-e664-4ab0-93f2-c15f470aeb05">5.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations attributable to CVS Health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI5LTEtMS0xLTE2NzkwOA_080d095c-6439-44e3-b503-6245f0feabf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI5LTMtMS0xLTE2NzkwOA_625b81ea-0e56-414c-ac90-f08b7c8429a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI5LTUtMS0xLTE2NzkwOA_b72add1c-fd97-40ac-afd2-56a71a43c51e">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to CVS Health</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMwLTEtMS0xLTE2NzkwOA_dbe59e61-0e41-4053-bd73-5f1469cd5159">3.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMwLTMtMS0xLTE2NzkwOA_42ae7028-cca0-46f3-9e89-26315f803164">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMwLTUtMS0xLTE2NzkwOA_9b50c973-b401-4168-95a1-b061687c2ab0">5.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average basic shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMxLTEtMS0xLTE2NzkwOA_69afecf8-2c92-41ea-954a-b3ac18270135">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMxLTMtMS0xLTE2NzkwOA_20d3c409-9529-43cb-972b-5de40e9a3982">1,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMxLTUtMS0xLTE2NzkwOA_daaad5f3-3c44-46de-84c9-fdbcfef9c838">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to CVS Health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMzLTEtMS0xLTE2NzkwOA_6764d1d1-011b-4370-80f6-9ef991bec0fc">3.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMzLTMtMS0xLTE2NzkwOA_9e42b177-a1fd-4d30-9a90-5148839ee8dd">5.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMzLTUtMS0xLTE2NzkwOA_60db5555-33cd-465c-9ac3-8d5691776f72">5.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations attributable to CVS Health</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM0LTEtMS0xLTE2NzkwOA_0b7c8b83-ad58-4ef9-a507-6198e29bc717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM0LTMtMS0xLTE2NzkwOA_46f15270-44ef-46c1-b465-2720578a06aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM0LTUtMS0xLTE2NzkwOA_0f48500c-8aa3-4266-bc99-df49ce1cbd0d">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to CVS Health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM1LTEtMS0xLTE2NzkwOA_ec6f2a5e-aa12-483e-8c99-849494a016bc">3.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM1LTMtMS0xLTE2NzkwOA_ed4de78c-366d-436e-820c-9e3f7827aa9c">5.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM1LTUtMS0xLTE2NzkwOA_084d5f3b-cead-44f4-8fde-7020d54dace6">5.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average diluted shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM2LTEtMS0xLTE2NzkwOA_689e7e1d-7ba7-494d-9791-17e5e5a375a0">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM2LTMtMS0xLTE2NzkwOA_75fdec06-9847-46bb-a5a8-3222dd3cfccf">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM2LTUtMS0xLTE2NzkwOA_65709379-3da3-4358-a9c4-8f5e9d8d48d6">1,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM3LTEtMS0xLTE2NzkwOA_18332b5b-edbf-44d5-8d88-fd070fd15f2f">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM3LTMtMS0xLTE2NzkwOA_0a0e653b-a3bb-40f6-9c3c-7e9385b5f740">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM3LTUtMS0xLTE2NzkwOA_80ea5baa-41e5-4699-8d1d-55e0d179f459">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-right:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">Index to Consolidated Financial Statements</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzItMS0xLTEtMTY3OTA4_aaaf6e99-4146-437f-a302-445346162eeb">4,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzItMy0xLTEtMTY3OTA4_ca11db01-5f6a-4254-a20e-2cbc60f67f05">7,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzItNS0xLTEtMTY3OTA4_1b582bad-c97b-4ec0-a875-5deeb4b4b270">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized investment gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzQtMS0xLTEtMTY3OTA4_ac3f207f-ee1b-45dd-9d34-d4ee708644c0">2,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzQtMy0xLTEtMTY3OTA4_bf8dc250-1323-46f7-a2a1-d1d93ff32282">436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzQtNS0xLTEtMTY3OTA4_3ab1e12e-19d3-4394-9ba7-f78355970461">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzUtMS0xLTEtMTY3OTA4_7fed84dd-005f-4836-ad01-1ea773092926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzUtMy0xLTEtMTY3OTA4_7d9c6392-cfed-44a4-9aab-8006f0a4f3b0">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzUtNS0xLTEtMTY3OTA4_04296959-18b5-4a21-b2a9-04ccc09566b6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzYtMS0xLTEtMTY3OTA4_44d8b245-5c2e-4b58-82c2-5c92a25d08fd">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzYtMy0xLTEtMTY3OTA4_b4b4880c-4d97-4762-a9df-048e8d8890df">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzYtNS0xLTEtMTY3OTA4_02c10882-ade1-45f8-9aa0-d3449687b500">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and other postretirement benefits </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzctMS0xLTEtMTY3OTA4_71e2bc7f-2e57-429b-ab63-1e897bdb63a7">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzctMy0xLTEtMTY3OTA4_10dd053e-4e4a-44bf-a92d-6beea2020211">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzctNS0xLTEtMTY3OTA4_63bf1a6d-bb3a-4e86-ae63-2ed18fa45dae">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzgtMS0xLTEtMTY3OTA4_f53021cd-5423-4a97-863d-3286bf7d3205">2,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzgtMy0xLTEtMTY3OTA4_2194d3cf-9f3a-44ba-a312-6d65376fe997">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzgtNS0xLTEtMTY3OTA4_8a87fd00-8593-4fc8-9a9c-0b420cda3d84">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzktMS0xLTEtMTY3OTA4_18eb2f21-6b45-4bd4-abcc-46b7a4a3010a">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzktMy0xLTEtMTY3OTA4_54d08d08-3883-48c8-bb4b-f9e0d1d72b5a">7,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzktNS0xLTEtMTY3OTA4_b06f394b-5bc1-493f-baff-40bcad29514b">7,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive (income) loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzEwLTEtMS0xLTE2NzkwOA_65b51aa1-f36b-4a3e-b694-d8873dcddeed">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzEwLTMtMS0xLTE2NzkwOA_65cb226b-3fab-419a-b12f-15be6fbb611f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzEwLTUtMS0xLTE2NzkwOA_63b8b294-d3c9-4827-9740-7f50dce32739">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to CVS Health</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzExLTEtMS0xLTE2NzkwOA_d9a333c7-dbca-437b-bf7a-935fb7caf283">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzExLTMtMS0xLTE2NzkwOA_743ac195-278a-4a50-80a1-8c5ba344a648">7,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzExLTUtMS0xLTE2NzkwOA_0bccc0eb-832f-4fbe-b8a6-17eed6d437c4">7,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-right:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">Index to Consolidated Financial Statements</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except per share amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMtMS0xLTEtMTY3OTA4_f7255fd6-69e2-42a1-9f49-c68f0f0b49c4">12,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMtMy0xLTEtMTY3OTA4_4a733a18-a12b-40b6-8610-d1cbebec85f7">9,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQtMS0xLTEtMTY3OTA4_3c2acd80-33bd-420c-990a-6ad81f89c1a2">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQtMy0xLTEtMTY3OTA4_5eda9dc3-a094-4223-884c-6fae5f53c393">3,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzUtMS0xLTEtMTY3OTA4_1e92d328-f74f-4d3c-9eb9-4b87de109598">27,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzUtMy0xLTEtMTY3OTA4_091039c0-775b-4e42-9665-dc672c2b55d2">24,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzYtMS0xLTEtMTY3OTA4_b16584bb-3bc8-4fbd-a6e4-e0507807343a">19,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzYtMy0xLTEtMTY3OTA4_013d4488-72b8-4e70-9e45-d17d502a507d">17,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzctMS0xLTEtMTk5MTg0_4ba8c0d7-6936-435e-8ee7-2dc80b68bc3f">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzctMy0xLTEtMTk5MTg0_f0f4ef04-f0a8-401b-aa22-fad09fe3c3fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzctMS0xLTEtMTY3OTA4_07764d79-3c96-442c-9ec5-48778c3e6e67">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzctMy0xLTEtMTY3OTA4_82a0be26-576b-4861-b849-9648b4025df8">5,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzgtMS0xLTEtMTY3OTA4_36544427-7a3e-4086-b789-cf351c05ae1b">65,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzgtMy0xLTEtMTY3OTA4_5330fdfb-ab47-46c6-9fe8-d5afdcd8b175">60,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzktMS0xLTEtMTY3OTA4_c11c9c71-0d30-4f42-9448-74b652d0857a">21,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzktMy0xLTEtMTY3OTA4_7d4f964b-caef-402a-9b9f-8948c256deb7">23,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEwLTEtMS0xLTE2NzkwOA_42d96e01-9cac-4510-9254-eda2214f8b17">12,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEwLTMtMS0xLTE2NzkwOA_2a1bdaed-f546-41b8-8a60-56dc94010583">12,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzExLTEtMS0xLTE2NzkwOA_43b97263-a430-4a5a-a984-7df8a7599847">17,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzExLTMtMS0xLTE2NzkwOA_2827b636-9156-43a0-bf95-acca173f4808">19,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEyLTEtMS0xLTE2NzkwOA_8c4ecd21-719c-41e9-9475-595329a53fb3">78,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEyLTMtMS0xLTE2NzkwOA_094293ab-1e88-4a9c-ac8f-27c706fb6890">79,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEzLTEtMS0xLTE2NzkwOA_ecc846f8-4bfb-49e7-84b1-1a94b727bd03">24,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEzLTMtMS0xLTE2NzkwOA_48f65a06-85d5-4242-89db-df1d510b80cc">29,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Separate accounts assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE0LTEtMS0xLTE2NzkwOA_c3a3c354-e5f5-4ea9-b4a2-06e1f945fe82">3,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE0LTMtMS0xLTE2NzkwOA_07089818-b39e-42ec-a8f5-d7261fed1780">5,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE1LTEtMS0xLTE2NzkwOA_93dd7a8c-79c3-4457-96fc-0113dce33ab1">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE1LTMtMS0xLTE2NzkwOA_05a1107f-c1ef-4c65-89a2-e827ab54a24e">4,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE2LTEtMS0xLTE2NzkwOA_5cd4cb0e-be14-45ff-a712-6f6850c556d7">228,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE2LTMtMS0xLTE2NzkwOA_1b48b835-7d64-4335-826a-4b68b1b0dc96">232,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE5LTEtMS0xLTE2NzkwOA_79db4803-790d-4be1-bebc-57935ef5d8af">14,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE5LTMtMS0xLTE2NzkwOA_3785f330-3e5c-467f-9102-34cca46f7c23">12,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy claims and discounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:PharmacyClaimsAndDiscountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIwLTEtMS0xLTE2NzkwOA_e8f0978f-1d8f-4cac-9a42-0ee519c3aae9">19,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:PharmacyClaimsAndDiscountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIwLTMtMS0xLTE2NzkwOA_6f890bbc-2015-4d4b-983a-c25c5d6956b9">17,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIxLTEtMS0xLTE2NzkwOA_f87618d1-4277-4b66-8927-166fa1dad87e">10,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIxLTMtMS0xLTE2NzkwOA_60e679d2-a21e-4982-a3ec-77c8dcf6a483">8,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Policyholders&#8217; funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OtherPolicyholderFunds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIyLTEtMS0xLTE2NzkwOA_5b588b41-3153-4c05-b0f5-456397d24980">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:OtherPolicyholderFunds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIyLTMtMS0xLTE2NzkwOA_1f4b3e5a-95f4-4990-a1e6-ebae5cd82764">4,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIzLTEtMS0xLTE2NzkwOA_2a78fdd2-301e-4be8-b60f-91975c871ffd">18,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIzLTMtMS0xLTE2NzkwOA_4af4fcd0-2f8f-49cf-91c1-2f010562e561">17,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other insurance liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:OtherInsuranceLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI0LTEtMS0xLTE2NzkwOA_63ce9e79-e6b1-490e-be6d-f3bf698738d5">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:OtherInsuranceLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI0LTMtMS0xLTE2NzkwOA_84d81c79-e6a2-4567-acaf-35f3837a8009">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI1LTEtMS0xLTE2NzkwOA_3937310a-0af7-4d77-8d02-8e3e5a9684b5">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI1LTMtMS0xLTE2NzkwOA_d9c7b4cc-1753-4d82-b7eb-7fcb2f2709f4">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI3LTEtMS0xLTE2NzkwOA_9bf339b7-1dad-44f6-92e6-e8732e7f3c5c">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI3LTMtMS0xLTE2NzkwOA_7e95e145-27ae-40a2-a241-a83bb5b36eca">4,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI5LTEtMS0xLTE5OTI1Mw_d3b12a35-c2e6-4e20-af88-2b2bc105f939">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI5LTMtMS0xLTE5OTI1Mw_e931ebf1-497a-41ca-a826-e2df2bd50c4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI4LTEtMS0xLTE2NzkwOA_cff76885-ed0a-495d-988f-d06ac1f0e16d">69,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI4LTMtMS0xLTE2NzkwOA_3fd04bcb-7e4a-4d16-88b3-7207969e389e">67,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI5LTEtMS0xLTE2NzkwOA_45f95f69-7a9e-4b36-a230-a38d4cbb2827">16,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI5LTMtMS0xLTE2NzkwOA_db70339f-71d9-4ec0-b528-497db79fc993">18,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMwLTEtMS0xLTE2NzkwOA_39afec39-26e8-41b8-a303-f1590958ead8">50,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMwLTMtMS0xLTE2NzkwOA_9496aa6a-f9da-4926-bec9-b5e2e18f31c4">51,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMxLTEtMS0xLTE2NzkwOA_d2b4c510-2d8e-4fb7-955b-ccb0d50fda94">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMxLTMtMS0xLTE2NzkwOA_987f5d05-0c66-456d-9a9a-4e153efd9de9">6,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Separate accounts liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:SeparateAccountsLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMyLTEtMS0xLTE2NzkwOA_6bbdff50-9979-4769-aa4a-3edb652cdf39">3,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:SeparateAccountsLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMyLTMtMS0xLTE2NzkwOA_778cc845-d9ab-4ff8-b981-103ea27a2ed0">5,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term insurance liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:OtherInsuranceLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMzLTEtMS0xLTE2NzkwOA_087c70be-7e87-4bca-b967-2f83bea03678">6,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:OtherInsuranceLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMzLTMtMS0xLTE2NzkwOA_c5553a6c-0578-4681-9221-9d9c4002cac2">6,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM0LTEtMS0xLTE2NzkwOA_40e557e9-15c9-485b-b94b-e9876a256232">6,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM0LTMtMS0xLTE2NzkwOA_0a4f7a26-23f7-4eef-8539-763fd00c2ddb">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM1LTEtMS0xLTE2NzkwOA_1bdc23fc-3b3e-43a9-8958-c1bc5d0763d3">156,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM1LTMtMS0xLTE2NzkwOA_21189d50-95c8-45fa-8efa-a80a1ae86314">157,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 16)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM2LTEtMS0xLTE2NzkwOA_04f4bece-882e-4c51-bcaf-b0ba3fdc78cd"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM2LTMtMS0xLTE2NzkwOA_d2199c79-bf8a-4be7-b5e8-31368b569a15"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzMx_a6c807b3-1587-4ecc-b330-06f53023f341"><ix:nonFraction unitRef="usdPerShare" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzMx_e6960ba5-f774-4d46-8d43-6b641dde2699">0.01</ix:nonFraction></ix:nonFraction>: <ix:nonFraction unitRef="shares" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzM1_2d7aa49e-3454-45c6-96b3-b10982e5f4cf"><ix:nonFraction unitRef="shares" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzM1_d2a5e9cf-2fd4-4ecc-b735-84c30a02b261">0.1</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzU3_1a44ddd7-2f3c-411d-9729-6a5d148be903"><ix:nonFraction unitRef="shares" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzU3_1fe54f29-fb8e-45b5-a9a9-175c4080b52f"><ix:nonFraction unitRef="shares" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzU3_60a0c875-67cd-4e31-b0e5-0532ac653ad6"><ix:nonFraction unitRef="shares" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzU3_7be62911-4f32-4214-9166-c260dd62eeee">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTEtMS0xLTE2NzkwOA_fa554981-6dd1-4b2b-826a-0786e4e9aa14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTMtMS0xLTE2NzkwOA_607289ad-a289-4227-9d9c-88ff4f45698b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzI4_68e4e44a-ac16-4f3d-a939-45b742b8d93b"><ix:nonFraction unitRef="usdPerShare" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzI4_7d9cac7d-d38f-472e-9b8e-328835619659">0.01</ix:nonFraction></ix:nonFraction>: <ix:nonFraction unitRef="shares" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzMy_474cb969-d73f-40b1-a950-3e66a35ee0e3"><ix:nonFraction unitRef="shares" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzMy_c53ca34c-48c5-4b47-95dd-382bf3e8d7a5">3,200</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzU0_50172e10-d61e-47c9-8a20-609a85be49a0">1,758</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1Xzc1_f3d685bf-0be0-490b-9b0c-9c4e7837f10f">1,300</ix:nonFraction> shares outstanding at December&#160;31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzEwNw_b9926396-899e-46f3-8314-73b90ed0ef1e">1,744</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzEyOA_f63ee4e4-ec17-410b-aa62-ab3445873d8f">1,322</ix:nonFraction> shares outstanding at December&#160;31, 2021 and capital surplus</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTEtMS0xLTE2NzkwOA_19593fca-e8a2-4b12-aefd-15aa06f97191">48,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTMtMS0xLTE2NzkwOA_32a09429-aede-422a-928b-21678baee627">47,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost: <ix:nonFraction unitRef="shares" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjViNGY1M2I5MDgyNjRmY2I4YWUyOTIzODgxZGM0Mjg5XzI5_2d938b53-28d5-4c4e-baf0-4adc8ae679f2">458</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjViNGY1M2I5MDgyNjRmY2I4YWUyOTIzODgxZGM0Mjg5XzM2_c743bfde-d055-41b8-9d6a-d8f5fb43ca5b">422</ix:nonFraction> shares at December&#160;31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQxLTEtMS0xLTE2NzkwOA_7919042d-64a5-4a23-9e36-318f9553e513">31,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQxLTMtMS0xLTE2NzkwOA_1631e77f-004b-4548-97d6-efa90c9dbbb0">28,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQyLTEtMS0xLTE2NzkwOA_a4553852-8ac7-45b3-8a57-bd97a1d8b879">56,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQyLTMtMS0xLTE2NzkwOA_3d7dff6e-6122-4410-9de7-08fb9228abc6">54,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQzLTEtMS0xLTE2NzkwOA_340d8469-771e-490f-9cde-e0a6a1950d1e">1,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQzLTMtMS0xLTE2NzkwOA_358d1615-d1d9-4d4f-8e7a-14a307c9f6a3">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total CVS Health shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ0LTEtMS0xLTE2NzkwOA_76ff3588-0b3f-42a1-b3f1-b3bf62666dab">71,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ0LTMtMS0xLTE2NzkwOA_d956759e-2387-4322-afe3-054e066cd7c9">75,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ1LTEtMS0xLTE2NzkwOA_e1ac868c-7aa5-471e-a5b9-446a1466cd49">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ1LTMtMS0xLTE2NzkwOA_261fad85-a9bc-43e0-bd90-88e0336d5fe2">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ2LTEtMS0xLTE2NzkwOA_524281e3-c4c0-44b7-9577-26b7ad19b33e">71,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ2LTMtMS0xLTE2NzkwOA_08bfe77d-6b6e-446d-99b1-c1087976b27c">75,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ3LTEtMS0xLTE2NzkwOA_613f5980-6d3a-4f08-b7a5-5de27763e858">228,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ3LTMtMS0xLTE2NzkwOA_a60acfef-49b3-45b4-ba76-d48ceef81f7e">232,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-right:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">Index to Consolidated Financial Statements</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from customers</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromCustomers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMtMS0xLTEtMTY3OTA4_f327b92e-dcc9-4966-8315-ce6af5116306">313,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromCustomers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMtMy0xLTEtMTY3OTA4_a7daaa12-79d2-4e83-b7a5-242e8cffc1d4">284,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromCustomers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMtNS0xLTEtMTY3OTA4_a70e8792-3446-4e60-8195-4e9359ef8711">264,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for inventory and prescriptions dispensed by retail network pharmacies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzQtMS0xLTEtMTY3OTA4_25a05191-af50-4d47-a70d-41f8e7127ecf">189,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzQtMy0xLTEtMTY3OTA4_ce6140d8-7edc-45f6-a941-1f1b10c178f9">165,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzQtNS0xLTEtMTY3OTA4_db2a2d30-a6da-425a-b064-d975b5e95705">158,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance benefits paid </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:PaymentsForInsuranceBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzUtMS0xLTEtMTY3OTA4_0a9ecbc6-1daf-4b51-9741-7d3b4e23bd0f">69,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:PaymentsForInsuranceBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzUtMy0xLTEtMTY3OTA4_46604cde-8cd9-4420-a15b-f6ca2ddbad2a">63,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:PaymentsForInsuranceBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzUtNS0xLTEtMTY3OTA4_f76e8170-6baf-459a-8461-2baa9f47f704">55,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid to other suppliers and employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToSuppliersAndEmployees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzYtMS0xLTEtMTY3OTA4_3ef17e18-2420-476c-bc50-b4f1800fdcce">32,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToSuppliersAndEmployees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzYtMy0xLTEtMTY3OTA4_7dd09792-1137-4a5e-98e7-b5f7e527d160">31,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToSuppliersAndEmployees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzYtNS0xLTEtMTY3OTA4_ea154a35-9fd5-46ad-b2b9-4ea18ae0478f">29,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and investment income received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromInterestAndDividendsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzctMS0xLTEtMTY3OTA4_806b3a89-4210-417c-99d7-829b2791e3c8">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromInterestAndDividendsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzctMy0xLTEtMTY3OTA4_a67d9b9d-55f9-431e-a578-7670765665c7">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromInterestAndDividendsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzctNS0xLTEtMTY3OTA4_f3d5d4ef-3694-416d-a797-4084cb936348">894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzgtMS0xLTEtMTY3OTA4_912ce461-ce3a-4190-8054-444ec7e9a5cd">2,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzgtMy0xLTEtMTY3OTA4_6e2d9b70-84b2-4094-bb1e-a56bb72837d6">2,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzgtNS0xLTEtMTY3OTA4_911eb1ee-957b-49f7-a3f4-f52e1dc61fac">2,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzktMS0xLTEtMTY3OTA4_64646629-c7bd-4bb1-a570-99c856828032">4,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzktMy0xLTEtMTY3OTA4_3785e3d0-69e9-4769-8f5d-d0132cb017e5">3,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzktNS0xLTEtMTY3OTA4_bcd2ecdf-28c2-437f-ba6f-deb3bc76f33c">2,929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEwLTEtMS0xLTE2NzkwOA_43a88107-834d-4eae-a568-16170e15c3fe">16,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEwLTMtMS0xLTE2NzkwOA_ada6a4cc-91c6-45a6-a868-695da71a2fe5">18,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEwLTUtMS0xLTE2NzkwOA_2dac7f1c-97e2-400c-84ee-d52acc2276ab">15,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEzLTEtMS0xLTE2NzkwOA_1d428cac-5864-4af0-9728-3e51f919f42a">6,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEzLTMtMS0xLTE2NzkwOA_719c1776-079b-4318-90c7-a44ed6398a4d">7,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEzLTUtMS0xLTE2NzkwOA_b1c4c3ca-4e08-420b-8f60-85b96d502f02">6,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE0LTEtMS0xLTE2NzkwOA_d65d5470-5c19-4d9f-aebf-1e43e276bbf7">7,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE0LTMtMS0xLTE2NzkwOA_ad0c754d-53e5-430b-95f5-9ac32863cde9">9,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE0LTUtMS0xLTE2NzkwOA_4a0fa656-bc63-4ef9-ae2f-5198abc590f6">9,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE1LTEtMS0xLTE2NzkwOA_a93a49e8-bd66-464a-86d2-8055da065125">2,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE1LTMtMS0xLTE2NzkwOA_0346ea7d-d54a-4550-9296-85ed35600bb9">2,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE1LTUtMS0xLTE2NzkwOA_e2b50a65-f0bf-4129-9527-8870a8175cc6">2,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale-leaseback transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE2LTEtMS0xLTE2NzkwOA_4179571f-2623-41e1-bf48-92c9c268414e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE2LTMtMS0xLTE2NzkwOA_68ad3f5b-5077-4ace-bfcf-8495279deeb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE2LTUtMS0xLTE2NzkwOA_e9f6b8c5-2656-457c-a8a7-d043a67c0eed">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions (net of cash acquired)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE3LTEtMS0xLTE2NzkwOA_20dd1c68-8c7a-4967-865d-ed63340659b3">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE3LTMtMS0xLTE2NzkwOA_15f293db-fa97-4fae-ac85-0475e446e202">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE3LTUtMS0xLTE2NzkwOA_0959e627-9e23-4e65-8d88-935e4f43a6f9">866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmI4YTZjNmQ3ZDQ2ODQ3M2ZiYjg3OGU0Y2U0YzQwMTQwXzIxOTkwMjMyNTU2NjY_8321a82b-130a-4d07-9703-6534ab79f35e">2,854</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmI4YTZjNmQ3ZDQ2ODQ3M2ZiYjg3OGU0Y2U0YzQwMTQwXzIxOTkwMjMyNTU2NTc_18f49b18-2672-4942-ad50-daf3d338b6dc">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:CashDivestedFromDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmI4YTZjNmQ3ZDQ2ODQ3M2ZiYjg3OGU0Y2U0YzQwMTQwXzIxOTkwMjMyNTU2NTI_81002130-db9b-43bb-8c24-9f22ba5afcd4">9</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTEtMS0xLTE2NzkwOA_7d8c9d5e-d6ce-4f1d-9ebf-929ba01512bc">1,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTMtMS0xLTE2NzkwOA_a136ec02-b175-4fe3-9861-bb98188b09de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTUtMS0xLTE2NzkwOA_9beb2241-be86-4adb-b206-920ea9ca3a3f">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE5LTEtMS0xLTE2NzkwOA_b86f55ef-60c8-4d34-953c-a641e0270bdc">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE5LTMtMS0xLTE2NzkwOA_00b39dd2-31e8-43fa-9630-b79b67df3612">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE5LTUtMS0xLTE2NzkwOA_1b44b089-7dd8-4f2a-a553-90f8c9786145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzIwLTEtMS0xLTE2NzkwOA_799bdbed-4b00-4b63-bb9e-02a8a78f6c84">5,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzIwLTMtMS0xLTE2NzkwOA_90c758fe-0423-4683-aaba-03f08cc86f77">5,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzIwLTUtMS0xLTE2NzkwOA_231915a8-38d8-4684-893b-cf73b58a7716">5,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI0LTEtMS0xLTE2NzkwOA_11d9feba-5fc4-4500-8b13-5e859ad41ef7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI0LTMtMS0xLTE2NzkwOA_906f94b3-8367-4f5c-a038-1c8335997a72">987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI0LTUtMS0xLTE2NzkwOA_e9fd5efb-cd89-4ded-846f-1d98e140f6df">9,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI1LTEtMS0xLTE2NzkwOA_e7f1fc4b-b720-4bc4-b8c0-21e27e189069">4,211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI1LTMtMS0xLTE2NzkwOA_8e4c53cf-904e-41b0-9332-43d456b72d7a">10,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI1LTUtMS0xLTE2NzkwOA_e0806f98-aa78-4e05-926a-f2761572b504">15,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI2LTEtMS0xLTE2NzkwOA_d5841a7e-a24a-48f6-85c3-d50e4a8c2246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI2LTMtMS0xLTE2NzkwOA_aa53f89b-6f4a-414e-81d5-d0e35d2962c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI2LTUtMS0xLTE2NzkwOA_3a8cc537-27ad-49c6-b7de-97579965901d">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI3LTEtMS0xLTE2NzkwOA_e04b3edb-050f-4e51-ad8f-00a8fe66ca49">3,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI3LTMtMS0xLTE2NzkwOA_e5dbc154-8d67-47eb-a45e-58a48dc39010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI3LTUtMS0xLTE2NzkwOA_a451850b-afb3-4409-ae59-cb0023a59669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI4LTEtMS0xLTE2NzkwOA_ca028360-cbd5-4503-bd54-2d69fbbf5640">2,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI4LTMtMS0xLTE2NzkwOA_cbbb7a58-dd10-4dd6-adae-4a010b73dcdf">2,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI4LTUtMS0xLTE2NzkwOA_9ae2346f-c7c8-4254-9ea5-cf025e4f090c">2,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI5LTEtMS0xLTE2NzkwOA_b02d0aec-4993-47c3-8fd0-2c443bbd1904">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI5LTMtMS0xLTE2NzkwOA_80e0c0e9-4446-4623-8d0c-a32895fc4866">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI5LTUtMS0xLTE2NzkwOA_c7d2b7c1-f7ff-4f6e-89b1-80fedd3ea239">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for taxes related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMwLTEtMS0xLTE2NzkwOA_465159b1-ec73-45a3-81df-800346af6695">370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMwLTMtMS0xLTE2NzkwOA_17e81c76-9916-4645-b135-af78c13a1bf2">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMwLTUtMS0xLTE2NzkwOA_b8a662d2-dbf5-481f-a530-3e34842fe836">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMxLTEtMS0xLTE2NzkwOA_b79d8699-cb62-4123-864b-e401857b30f4">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMxLTMtMS0xLTE2NzkwOA_9dfc4bb7-2d9f-4ff9-969f-c11af50f8055">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMxLTUtMS0xLTE2NzkwOA_0f9d9ed3-b3cf-4514-b39f-effb03971c64">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMyLTEtMS0xLTE2NzkwOA_0b231df6-a409-4a98-a2b1-3427db800a13">10,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMyLTMtMS0xLTE2NzkwOA_d5ddff58-2527-4a73-913a-11a997c6b10b">11,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMyLTUtMS0xLTE2NzkwOA_984d50ef-183a-4983-98fb-af20f44ad9ac">7,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM0LTEtMS0xLTE2NzkwOA_8ec84b00-2c7a-4067-9056-5cefc5a6fe37">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM0LTMtMS0xLTE2NzkwOA_39ba9418-0eaa-4b62-9227-dffc7ef3aac9">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM0LTUtMS0xLTE2NzkwOA_11ec4ed0-7dde-48b6-8d55-9eddfb2a8b84">2,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM1LTEtMS0xLTE2NzkwOA_9c7794a9-41f9-4234-a6fd-3454b9f55fb4">12,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM1LTMtMS0xLTE2NzkwOA_425f9eac-1842-4f57-aabd-a5b71c3216a7">11,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ae6bc100814ca88c4440dbb572bbdc_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM1LTUtMS0xLTE2NzkwOA_b553f239-ded0-48d7-acc9-61d71348f1d2">8,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM2LTEtMS0xLTE2NzkwOA_4f391019-f4d5-4623-abfe-2be12003b63d">13,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM2LTMtMS0xLTE2NzkwOA_683005f3-75f8-46af-b3ed-1c6481584bbc">12,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM2LTUtMS0xLTE2NzkwOA_8d168ed4-91c4-4816-8bb9-8c1cd970ee8b">11,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-right:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">Index to Consolidated Financial Statements</a></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzMtMS0xLTEtMTY3OTA4_aaaf6e99-4146-437f-a302-445346162eeb">4,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzMtMy0xLTEtMTY3OTA4_ca11db01-5f6a-4254-a20e-2cbc60f67f05">7,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzMtNS0xLTEtMTY3OTA4_94e5a3b9-abf6-44f7-beba-ba392f0e04ee">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments required to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzUtMS0xLTEtMTY3OTA4_b2b13358-4379-4495-b5fd-8e90d4b97728">4,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzUtMy0xLTEtMTY3OTA4_c83d9adf-79ad-49a9-bb03-e2d6fa16484d">4,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzUtNS0xLTEtMTY3OTA4_5d03a0e1-821b-49c8-838c-6c03b3bc3e00">4,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtMS0xLTEtMTk5Mjc4_6dd16334-dd03-429c-bb6d-673d77ffdf65">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtMy0xLTEtMTk5Mjc4_4fe0d745-2bfd-43ea-b014-72fd64d65996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtNS0xLTEtMTk5Mjkx_7223f339-726f-4ce4-8d89-a2d2c48608bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtMS0xLTEtMTY3OTA4_5742872c-6706-419a-9b35-1c6789bbc75d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtMy0xLTEtMTY3OTA4_715e5914-73eb-4f35-8ccf-0019e0d3d743">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtNS0xLTEtMTY3OTA4_0f7dc44b-95f7-409c-9d13-bb0aa233fa56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzctMS0xLTEtMTY3OTA4_e50e334f-c963-4c60-a356-d1ee1f9aa9fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzctMy0xLTEtMTY3OTA4_a1a72e86-fd4e-4406-831c-5ebf6d5f41e7">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzctNS0xLTEtMTY3OTA4_a94d1a72-051e-43f2-85cd-91faaa3dfc04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzktMS0xLTEtMTY3OTA4_7a5d9f0c-1fa6-4386-ac67-f4ce8db48cf2">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzktMy0xLTEtMTY3OTA4_edad8786-2001-4943-a847-c2ca235d5ebf">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzktNS0xLTEtMTY3OTA4_3ac79989-76cf-4fae-92e4-e9923e0c4030">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEwLTEtMS0xLTE2NzkwOA_f8f56965-eb40-4b63-a0e5-b4efe5095740">475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEwLTMtMS0xLTE2NzkwOA_69dac48d-5d10-4660-91bc-bbde57c7609d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEwLTUtMS0xLTE2NzkwOA_fadda63f-0a1d-4c14-b8ea-045633a32cec">269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzExLTEtMS0xLTE2NzkwOA_2b4910f2-139d-4d64-80b1-b46d974c32ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzExLTMtMS0xLTE2NzkwOA_4cb70dbd-aa51-4509-bb28-a243372ba530">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzExLTUtMS0xLTE2NzkwOA_e28f05d0-45c1-46ad-8dbd-7af4f87e2459">1,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTEtMS0xLTIxNjEwMw_d82a0ab6-75f6-4e2e-b91a-4c4f168c5bbc">2,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTMtMS0xLTIxNjEwMw_7d5d363b-7f10-4db4-9ff9-31f8606dddf3">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTUtMS0xLTIxNjEwMw_c1a2c1a0-863e-4d61-a5fd-5480f30e4685">570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncash items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEzLTEtMS0xLTE2NzkwOA_1450c1e6-f62f-4092-bba5-942012a0a2f8">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEzLTMtMS0xLTE2NzkwOA_499ba8a0-a59f-489d-9b13-a26fd28e419c">390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEzLTUtMS0xLTE2NzkwOA_cc056025-2175-451f-a898-3217a90f2374">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTEtMS0xLTE2NzkwOA_b5750ce1-6d5f-4e72-8a6c-5818789767f3">2,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTMtMS0xLTE2NzkwOA_51da59cf-9b94-4391-ac86-32c8d3a49fc6">2,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTUtMS0xLTE2NzkwOA_bdd17985-777d-4213-9ebd-ae271ea6df42">1,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE2LTEtMS0xLTE2NzkwOA_c2f07549-2c85-4a6c-920c-a02f432c0046">1,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE2LTMtMS0xLTE2NzkwOA_59f928bc-b595-423a-9a5b-b94f0bca2cdd">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE2LTUtMS0xLTE2NzkwOA_3afb9e29-a9cf-414a-bd96-1ade0e1fde2c">973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE3LTEtMS0xLTE2NzkwOA_dd4f737e-9c3e-4d39-8b52-e68d2d922a19">566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE3LTMtMS0xLTE2NzkwOA_b8c5c095-1d7a-4867-aafe-040c01570dda">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE3LTUtMS0xLTE2NzkwOA_a86f91ae-a25d-433c-9c59-60d8aab91ac4">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and pharmacy claims and discounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE4LTEtMS0xLTE2NzkwOA_71680d1e-72e8-40f6-a8c1-db50a27fbccb">4,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE4LTMtMS0xLTE2NzkwOA_c1120119-22d6-48f6-a687-c122fd9717a4">2,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE4LTUtMS0xLTE2NzkwOA_819e45cd-ed87-4db9-890b-ebb92e0ab221">2,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable and other insurance liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE5LTEtMS0xLTE2NzkwOA_a383562b-f1c9-44da-ab6e-2419ff98c521">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE5LTMtMS0xLTE2NzkwOA_3b628673-61f0-4b3b-a99f-f152b4765009">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE5LTUtMS0xLTE2NzkwOA_f87a7dfb-1ac3-4138-9302-749187a2163d">231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIwLTEtMS0xLTE2NzkwOA_e5bfb917-a0a2-47af-a221-c7fb5ec0099c">6,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIwLTMtMS0xLTE2NzkwOA_9427c126-9f55-45e1-b838-7514dd4e0741">2,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIwLTUtMS0xLTE2NzkwOA_d814bc69-98ce-4505-8b93-c0322de3bb59">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIxLTEtMS0xLTE2NzkwOA_e8e35ba8-9040-4969-a814-5ca38844a242">16,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIxLTMtMS0xLTE2NzkwOA_75f6a739-4504-4b6d-b6bc-7bd19ce03985">18,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIxLTUtMS0xLTE2NzkwOA_78825d4f-f11d-4ad8-bfe5-5f3a9b08cd51">15,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-right:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">Index to Consolidated Financial Statements</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Attributable to CVS Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares<br/>outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Surplus </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>CVS Health<br/>Shareholders&#8217; <br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling <br/>Interests </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72a7763da9eb4043aa8f22f5c692da1a_I20191231" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMS0xLTEtMTY3OTA4_9ffd091f-e34f-4e1f-8ae1-9b3c5fef2855">1,727</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if00d0ef5531f491687905cc2a31dbad1_I20191231" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMi0xLTEtMTY3OTA4_a1102af3-6a6d-4ab7-9a37-152583f52aed">425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a3fb0fbc894ec1b2c889d8507c98b4_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNC0xLTEtMTY3OTA4_419c9387-c859-4bde-b2b7-4f1cf9bbe844">45,972</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if00d0ef5531f491687905cc2a31dbad1_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNS0xLTEtMTY3OTA4_899a6f82-b6f8-43bd-b579-b98c84fb2c90">28,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b2f5710c3d416fa6c9cc7c92282465_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNi0xLTEtMTY3OTA4_a911109d-821e-4c8d-8182-40a1a2719e1a">45,108</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i888d803efa36451abbcddc3e49ab4600_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNy0xLTEtMTY3OTA4_aa437aa1-422c-4c5a-a1d8-c76c1d3a7d9f">1,019</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3c8cd4bb654446b90531ac0de6b52e_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtOC0xLTEtMTY3OTA4_a8342b75-30a8-4287-b357-7ff0f560fec9">63,864</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if44510fc0a4b415b835ac61565cbe142_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtOS0xLTEtMTY3OTA4_84edb210-a8df-4141-ab41-ec19dc6d85ca">306</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ae6bc100814ca88c4440dbb572bbdc_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMTAtMS0xLTE2NzkwOA_315d22e6-6d40-4889-abcd-a9ace845350d">64,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adoption of new accounting standard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e66d5c8619f4ded8782d4028fa2b01b_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtNi0xLTEtMTY3OTA4_99031c0f-9bb1-4e9b-a04b-d1f529a110ab">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab9f0d4beab4f98ae87761afaae6ce3_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtOC0xLTEtMTY3OTA4_e9262b61-efbc-4ef7-a559-88549e16e324">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebc7adf3c3345cd9cae049928aa937b_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtMTAtMS0xLTE2NzkwOA_4d9dee0a-de0c-4824-96a7-b2568bdfa528">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9cd17faa9b459393d314bd5dc139b6_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzUtNi0xLTEtMTY3OTA4_5acf5a21-c3a3-46aa-985e-135b943536bd">7,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzUtOC0xLTEtMTY3OTA4_6aa86387-862b-41fb-a7cd-4bb3c49ef16d">7,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dda31d68ee44ac380464c0d7b42864e_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzUtOS0xLTEtMTY3OTA4_83bb214a-40a7-4a0c-bff9-a37de8d9838c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzUtMTAtMS0xLTE2NzkwOA_849d37d3-1a48-4469-9085-e7a63c955c6b">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (Note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i506db4d0bb51485db8a39fec0af261da_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzYtNy0xLTEtMTY3OTA4_c20f1228-9624-4a57-83e4-96cb1032bb93">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzYtOC0xLTEtMTY3OTA4_27fb790b-6693-4df7-98c9-00e6215e42e0">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzYtMTAtMS0xLTE2NzkwOA_214a387f-31ba-4482-9778-603c357a3a5b">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Stock option activity, stock awards and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id118cd6fcaeb4d16b525a15d0b586564_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMS0xLTEtMTY3OTA4_eb87a6b0-80ad-4100-a428-390a36dfdc69">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic935f384ec884760808c5d3d56f93b58_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMi0xLTEtMTY3OTA4_cc9c228e-d25e-42a5-afe7-dd4be4f4ded9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a2c447554b47278dafaa81be11f9d1_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtNC0xLTEtMTY3OTA4_2a36882f-dd82-4bf8-897e-323895e9187e">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtOC0xLTEtMTY3OTA4_38ba164f-bdda-48ad-849b-647546e58dee">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMTAtMS0xLTE2NzkwOA_cc822afd-68fb-4a9a-a999-5366785d8134">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ESPP issuances, net of purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic935f384ec884760808c5d3d56f93b58_D20200101-20201231" decimals="-6" name="cvs:ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktMi0xLTEtMTY3OTA4_cf85c9c6-30f6-47f0-9d82-59780ed91d16">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic935f384ec884760808c5d3d56f93b58_D20200101-20201231" decimals="-6" name="cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktNS0xLTEtMTY3OTA4_4b2d1fa7-2942-4c9a-bc7e-a667d42a0eb9">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231" decimals="-6" name="cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktOC0xLTEtMTY3OTA4_3fe7c230-91f7-4495-8e70-f610807326ce">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktMTAtMS0xLTE2NzkwOA_7d213755-2ad6-4bf2-ba0a-c278be20131a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Common stock dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife9cd17faa9b459393d314bd5dc139b6_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEwLTYtMS0xLTE2NzkwOA_e993f91f-1a04-4e8a-a65f-72d892524248">2,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEwLTgtMS0xLTE2NzkwOA_7bc0dbbf-1862-4427-b5b9-731d392d8cfd">2,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEwLTEwLTEtMS0xNjc5MDg_5a577054-efb1-4e31-aafc-ac1ac4ad8921">2,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other decreases in noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dda31d68ee44ac380464c0d7b42864e_D20200101-20201231" decimals="-6" sign="-" name="cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEyLTktMS0xLTE2NzkwOA_593fb463-1059-49ce-98b3-295aa1722f25">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEyLTEwLTEtMS0xNjc5MDg_7d44a44b-1bde-48f0-9861-d19b08bf02cb">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i215e39f051a24c26a9fcfe870c6bb597_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTEtMS0xLTE2NzkwOA_badb8685-fcc4-4533-a798-421aa6ac7e18">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia036bc4a7dac4d75a3807b027b89ffa5_I20201231" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTItMS0xLTE2NzkwOA_a802b61d-e3fc-401c-8a0e-c9a451456886">423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10ac8c51a1484aa2a5345657f72786b6_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTQtMS0xLTE2NzkwOA_da19b8fb-1267-4760-a39d-cc06e134509c">46,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia036bc4a7dac4d75a3807b027b89ffa5_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTUtMS0xLTE2NzkwOA_a3020230-8e8d-4d1f-be1c-451c50e0569a">28,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b3a385f98e4970a3c4003641ffad00_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTYtMS0xLTE2NzkwOA_3da62930-22ba-479c-91a1-767d2c159b39">49,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ea169a39a1448695c8f5079e17a681_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTctMS0xLTE2NzkwOA_1f0a730f-e5f9-4fc7-8a39-c62be6f4e82e">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ab1718255d495ebfab5b03525f0868_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTgtMS0xLTE2NzkwOA_b59ad877-6d28-4f0b-a3d0-8a72bc1ef6cc">69,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6dbba9b47e4c87b541de1f1350e1c7_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTktMS0xLTE2NzkwOA_d1948a20-9d0a-4ca4-aeb5-8ae6302f6ea3">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTEwLTEtMS0xNjc5MDg_f3f1fbb2-5a3c-44f8-90e3-3440a074e5b2">69,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6a2b778a2b648ebbfa53406c5d05497_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE1LTYtMS0xLTE2NzkwOA_a320e897-90eb-4ec9-88e9-da879fb87d54">7,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE1LTgtMS0xLTE2NzkwOA_66c9de42-aa8f-4d84-bac4-05cb16b159cc">7,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i835f93d2a91243ffa5e213ffac78aa2e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE1LTktMS0xLTE2NzkwOA_e45665ab-6bd2-46e4-b573-27a31ae28788">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE1LTEwLTEtMS0xNjc5MDg_1feffd38-ffd1-4549-be52-dd1a43d14b0f">7,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss (Note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib06f1a367c1c462cb54add04957c2b6d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE2LTctMS0xLTE2NzkwOA_1dfefbc7-3a9d-40dd-9aa8-39455915fa15">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE2LTgtMS0xLTE2NzkwOA_afa8f760-05c2-439d-b213-31327f5120fe">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE2LTEwLTEtMS0xNjc5MDg_450410dc-4c5a-4d7f-8c11-92a35c51f3a9">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Stock option activity, stock awards and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ccf20c4b2cb4cbfa96ff019488ea873_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTEtMS0xLTE2NzkwOA_49a1645b-45fb-476c-a34a-a5daa190418b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedcfb6c0f5f44d9bedcaae64ac0cd39_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTQtMS0xLTE2NzkwOA_33f5dc1a-2a4b-4a8a-b80d-440f0c6eb9d5">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTgtMS0xLTE2NzkwOA_99f968a4-962b-4a56-af2a-4206445f4726">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTEwLTEtMS0xNjc5MDg_9e06f13b-2394-4f44-b227-38bdc4af457d">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ESPP issuances, net of purchase of treasury shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2d25a04a6754b1498c8f7da3b006bcf_D20210101-20211231" decimals="-6" name="cvs:ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTItMS0xLTE2NzkwOA_61a94270-718d-49f2-8a89-ac9a52290499">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d25a04a6754b1498c8f7da3b006bcf_D20210101-20211231" decimals="-6" name="cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTUtMS0xLTE2NzkwOA_6b7272ad-9760-4165-8a9f-eef3576673fb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231" decimals="-6" name="cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTgtMS0xLTE2NzkwOA_24ba5806-8cd7-4b30-8dd8-d99e0ebd0a73">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTEwLTEtMS0xNjc5MDg_685e1491-de9b-4ca7-87ea-2c00ee23037e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Common stock dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6a2b778a2b648ebbfa53406c5d05497_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIwLTYtMS0xLTE2NzkwOA_4582a648-42c1-4b92-8316-e7fa66d51720">2,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIwLTgtMS0xLTE2NzkwOA_0f146955-d8fc-476d-b480-50dcfc541658">2,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIwLTEwLTEtMS0xNjc5MDg_d9178586-f0bb-42bb-ad80-cba48058db8a">2,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other increases in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i835f93d2a91243ffa5e213ffac78aa2e_D20210101-20211231" decimals="-6" name="cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIyLTktMS0xLTE2NzkwOA_d1388906-7265-4d9a-873f-736a8193a3ca">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIyLTEwLTEtMS0xNjc5MDg_75cbf495-bd13-4347-8103-0aaa672d03c2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90c39d6e1188460db9fc0eac4c5c73ae_I20211231" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTEtMS0xLTE2NzkwOA_70ff4c7f-34a3-4ca2-a552-d50aea7095d4">1,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia074c2e908ba4d4d9f8528b440cb9e61_I20211231" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTItMS0xLTE2NzkwOA_803aff9c-7641-44f4-b3a5-a5093fcbccd2">422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ba6af5137d4355a39e538ff11c3f70_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTQtMS0xLTE2NzkwOA_915df060-9a88-4dd4-b0c9-35ddb417b3c1">47,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia074c2e908ba4d4d9f8528b440cb9e61_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTUtMS0xLTE2NzkwOA_6be73b7d-7940-4a20-a6a2-d323e75cf34c">28,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14bbd86e337e40b5b909ba5b0eec8986_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTYtMS0xLTE2NzkwOA_678a854d-b8ef-48ec-bc42-809204df615f">54,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c919cbd9e14d14b0126701eccb5f78_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTctMS0xLTE2NzkwOA_12bc8c4d-0245-4bff-b6c8-ac30afafe9f9">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403b748d2961411884d18591a7536a94_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTgtMS0xLTE2NzkwOA_435c215a-241a-4ca4-abb3-b781325af5e7">75,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972cf157c8074bc5ba5d6d1d1d0a0ee3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTktMS0xLTE2NzkwOA_81ce7d6c-1dc6-43f0-a753-406b7275fc48">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTEwLTEtMS0xNjc5MDg_c9269ede-b4a0-41f2-b87b-b4e40b8ffcef">75,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109b0efa62914aa7a4f584e9303e07d8_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI1LTYtMS0xLTE2NzkwOA_a1de8e83-6626-4077-a4a6-08e714d008e3">4,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI1LTgtMS0xLTE2NzkwOA_67076d76-e3b5-4eec-a2ed-e7c1e0b7868b">4,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife2124c0776c4afab6cf27697b98714d_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI1LTktMS0xLTE2NzkwOA_287ad968-299e-4c0f-915c-8619c6a5f1ab">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI1LTEwLTEtMS0xNjc5MDg_df357cb1-3fc5-4ead-959d-d11ba8601441">4,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss (Note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22bba5ead4dc4a12b105fb70a7664473_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI2LTctMS0xLTE2NzkwOA_2f7e3b94-42e4-462d-90a5-2d1d885f8782">2,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI2LTgtMS0xLTE2NzkwOA_bbefc2b8-83a6-4695-a8e2-96162110523c">2,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI2LTEwLTEtMS0xNjc5MDg_2f9f138f-16a4-4a27-906a-eb851128b518">2,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Stock option activity, stock awards and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if90073196b804847ae7989cfd2058161_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTEtMS0xLTE2NzkwOA_847d1b1b-6374-4470-b667-4358e9be087d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34594b0b5acd443a9120b077623df7ac_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTQtMS0xLTE2NzkwOA_7dbb9dc7-db89-4602-a8ab-d1b447187c94">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTgtMS0xLTE2NzkwOA_89ee2102-b97c-4b0e-9f01-e3525a527c88">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTEwLTEtMS0xNjc5MDg_64259e37-6203-488b-a9b1-e0c251e43f6c">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of treasury shares, net of ESPP issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7bfa8a913ea04eee9d8522298e6fc681_D20220101-20221231" decimals="-6" name="cvs:TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTItMS0xLTE2NzkwOA_b320eab6-797c-4b05-8ca2-c960aa530c2e">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bfa8a913ea04eee9d8522298e6fc681_D20220101-20221231" decimals="-6" name="cvs:TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTUtMS0xLTE2NzkwOA_d103f2c8-8949-463e-a6a6-bc4b87160d51">3,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231" decimals="-6" name="cvs:TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTgtMS0xLTE2NzkwOA_c644804d-189e-4ce9-bfb3-1b91a983ac30">3,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTEwLTEtMS0xNjc5MDg_ea17e7e1-f761-4b20-b815-dffa0e98633e">3,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Common stock dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i109b0efa62914aa7a4f584e9303e07d8_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI5LTYtMS0xLTE2NzkwOA_1f3c0e9e-3723-4d2c-a47f-628cb52bd45f">2,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI5LTgtMS0xLTE2NzkwOA_b45c11fc-8fa8-44aa-bf63-919f0e6a8226">2,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI5LTEwLTEtMS0xNjc5MDg_a49d80d5-0663-4bec-86ba-ca54926447ef">2,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other decreases in noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife2124c0776c4afab6cf27697b98714d_D20220101-20221231" decimals="-6" sign="-" name="cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMwLTktMS0xLTE2NzkwOA_4801e04f-ffe1-4690-912b-673ce2073fde">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMwLTEwLTEtMS0xNjc5MDg_4e9f78a3-3fbb-4f2f-b58c-7a6d8cef2d5d">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e1ce9835a2445c995772377b12325fa_I20221231" decimals="-6" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTEtMS0xLTE2NzkwOA_bc64b42c-cc95-4a3d-974b-1691c53afaa4">1,758</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i69b40434e129497fb044508149145574_I20221231" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTItMS0xLTE2NzkwOA_2493e6ed-878f-4a03-8082-5b7df50b5510">458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40913455599d4dbe8925b15950ed63ec_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTQtMS0xLTE2NzkwOA_7048f323-3d7b-43fa-8f4f-ce5446e41c03">48,193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69b40434e129497fb044508149145574_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTUtMS0xLTE2NzkwOA_ed5a3e75-ed47-445a-843f-f11cccade6f4">31,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief98321000924065a5a2817038f6cd96_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTYtMS0xLTE2NzkwOA_ef9602b4-a57b-4d99-816b-bd5a8fd96bd4">56,145</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81ef2fda83394a2d8e020112d6facee6_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTctMS0xLTE2NzkwOA_24076103-40f0-4623-9393-40d9b45756e0">1,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1778905608134b9da2d0fe7767917336_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTgtMS0xLTE2NzkwOA_552ab9f1-d744-4252-8200-ecfdabf019ae">71,015</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc357653e2c74c68a77d7f6658e76744_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTktMS0xLTE2NzkwOA_9c40dd89-2c4f-4773-a568-12e32b40fcf7">300</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTEwLTEtMS0xNjc5MDg_3dff9097-e2e0-4ade-8639-1ebef2129c39">71,315</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3" footnoteRole="http://www.xbrl.org/2003/role/footnote">Treasury shares include <ix:nonFraction unitRef="shares" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:TreasuryStockSharesHeldinTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzEyNg_105927de-e680-4d24-b0f5-9cd519d0065f"><ix:nonFraction unitRef="shares" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="cvs:TreasuryStockSharesHeldinTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzEyNg_127df6ca-42c7-4f97-8c60-698ee4655459"><ix:nonFraction unitRef="shares" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:TreasuryStockSharesHeldinTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzEyNg_37fc7689-5b3b-46ac-9f50-ead383303ff8">1</ix:nonFraction></ix:nonFraction></ix:nonFraction> million shares held in trust for each of the years ended December 31, 2022, 2021 and 2020. Treasury stock includes $<ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="cvs:TreasuryStockValueSharesHeldInTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzIzNg_384a1f9f-f1f2-4e85-bcdb-d5be6bbf79a7"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:TreasuryStockValueSharesHeldInTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzIzNg_d193c228-d655-4240-a9c3-ee43a0bd8d6b"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:TreasuryStockValueSharesHeldInTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzIzNg_f91d5859-8832-40e1-ba20-01c506b0c0e3">29</ix:nonFraction></ix:nonFraction></ix:nonFraction> million related to shares held in trust for each of the years ended December 31, 2022, 2021 and 2020. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9" footnoteRole="http://www.xbrl.org/2003/role/footnote">Common stock and capital surplus includes the par value of common stock of $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzU0OTc1NTgxNTA4Mw_9cb20ea8-31db-4490-b77d-195c6d4edea2">18</ix:nonFraction>&#160;million as of December 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzQ0Mw_53250b4a-1f2f-4230-a152-a0d37e322541"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzQ0Mw_f059008e-35fd-40b6-a73b-2e26f165ed89">17</ix:nonFraction></ix:nonFraction> million as of December 31, 2021 and 2020.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyMw_46f4594b-33de-4e6a-93d6-a2d142101981" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzY1OTcwNjk3NjgxNzQ_dd91000a-d118-4a7c-8b68-d85f1dcfda5b">Accounting Standards Update (&#8220;ASU&#8221;) 2016-13</span>, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Topic 326), which resulted in a reduction to retained earnings of $<ix:nonFraction unitRef="usd" contextRef="ib2ec77f9083d4e5aaa261f4838a994dd_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzgxNw_d71a7bb0-f241-4720-a980-d2b126c61c22">3</ix:nonFraction>&#160;million during the year ended December 31, 2020.</span></ix:footnote></div><div style="margin-bottom:3pt;text-indent:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-right:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">Index to Consolidated Financial Statements</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_121"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzc0_e9bf8512-8bf6-4255-aeae-e312c03fb069" continuedAt="ie0f26f73972d4e89b3f9b7c885d154bb" escape="true">Significant Accounting Policies </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie0f26f73972d4e89b3f9b7c885d154bb" continuedAt="if6c9604f6545448ba2fa7814c1967265"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business&#160; </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation, together with its subsidiaries (collectively, &#8220;CVS Health&#8221; or the &#8220;Company&#8221;), has more than <ix:nonFraction unitRef="store" contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231" decimals="-2" name="us-gaap:NumberOfStores" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzE4Mw_6d839566-ba36-4db2-a4c4-3dbda813e61e">9,000</ix:nonFraction> retail locations, more than <ix:nonFraction unitRef="clinic" contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231" decimals="-2" name="cvs:NumberOfWalkInMedicalClinics" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIxMQ_47169163-f676-4df7-8ae9-fb9ece9b046b">1,100</ix:nonFraction> walk-in medical clinics, a leading pharmacy benefits manager with over <ix:nonFraction unitRef="people" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:NumberOfPharmacyPlanMembers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzI5NA_37ed37de-030e-4671-b034-03dcf46f7a63">110</ix:nonFraction> million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than <ix:nonFraction unitRef="patient" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="cvs:NumberOfPatientsServedPerYear" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQxOA_26b020c2-dd84-4e3d-93dc-3de9c0e280eb">one million</ix:nonFraction> patients per year. The Company also serves an estimated <ix:nonFraction unitRef="people" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:NumberOfPeopleServed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ3Nw_caca9968-1b7c-4207-a506-e82a05491abd">35</ix:nonFraction> million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (&#8220;PDP&#8221;). The Company believes its integrated health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus disease 2019 (&#8220;COVID-19&#8221;) and its emerging new variants continue to impact the economies of the U.S. and other countries around the world. The impact of COVID-19 on the Company&#8217;s businesses, operating results, cash flows and financial condition in the years ended December 31, 2022, 2021 and 2020, as well as information regarding certain expected impacts of COVID-19 on the Company, is discussed throughout this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzgx_4c612b84-af96-4693-b85c-77772f74368e" continuedAt="i7d35f92c477a46aa973e364371a70ab5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzEzMzc_aaa075f0-7767-4352-95da-a3844fde28af">four</ix:nonFraction> reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment operates as one of the nation&#8217;s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers&#8217; compensation administrative services through its Coventry Health Care Workers&#8217; Compensation business (&#8220;Workers&#8217; Compensation business&#8221;) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment&#8217;s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (&#8220;providers&#8221;), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as &#8220;Insured&#8221; and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as &#8220;ASC.&#8221; In addition, effective January 2022, the Company entered the individual public health insurance exchanges (&#8220;Public Exchanges&#8221;) in <ix:nonFraction unitRef="state" contextRef="i780b19498a144075a22a573432132bda_D20220101-20221231" decimals="INF" name="cvs:IndividualPublicHealthInsuranceExchangesNumberOfStates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDAx_524957c7-0839-4284-b120-fb68a9b41442">eight</ix:nonFraction> states through which it sells Insured plans directly to individual consumers. The Company entered Public Exchanges in <ix:nonFraction unitRef="state" contextRef="i42d18c1100d94a559f0d7d4c757498bf_D20230101-20230131" decimals="INF" name="cvs:IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjUwNjE_9ae74e1b-6d8b-4c7a-8df5-216aa64cf043">four</ix:nonFraction> additional states effective January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment provides a full range of pharmacy benefit management (&#8220;PBM&#8221;) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (&#8220;Covered Entities&#8221;). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers. The Pharmacy Services segment&#8217;s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (&#8220;LTC&#8221;) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if6c9604f6545448ba2fa7814c1967265" continuedAt="i2e8b5b67b6e74aa482dde5cb20e0c7a3"><ix:continuation id="i7d35f92c477a46aa973e364371a70ab5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">long-term care facilities and other care settings. As of December&#160;31, 2022, the Retail/LTC segment operated more than <ix:nonFraction unitRef="store" contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231" decimals="-2" name="us-gaap:NumberOfStores" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ5ODM_93e9f057-27aa-453d-a12f-3a977a79a897">9,000</ix:nonFraction> retail locations, more than <ix:nonFraction unitRef="clinic" contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231" decimals="-2" name="cvs:NumberOfWalkInMedicalClinics" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzUwMTE_8215efbb-9eb9-4591-9b49-3037f20d9e17">1,100</ix:nonFraction> MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate/Other Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management and administrative expenses to support the Company&#8217;s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company&#8217;s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzcx_b87a0d62-5116-4f64-8866-67cee5a2b5a2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (&#8220;VIEs&#8221;) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDEz_96285995-e297-4876-ab4b-33415e14e279" continuedAt="i9d6fba36ca96467a8e530286f12b4027" escape="true">Use of Estimates</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9d6fba36ca96467a8e530286f12b4027">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzEw_0ad14921-9fdd-4672-b59e-9a9d7c952f83" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other current assets on the consolidated balance sheets represents funds held on behalf of members, including health savings account (&#8220;HSA&#8221;) funds associated with high deductible health plans. Restricted cash included in other assets on the consolidated balance sheets represents amounts held in a trust in one of the Company&#8217;s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits and money market funds.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzU3_e516bac8-00d4-4532-b1b5-b3122382d8c6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzEtMS0xLTEtMTY3OTA4_f7255fd6-69e2-42a1-9f49-c68f0f0b49c4">12,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzEtMy0xLTEtMTY3OTA4_4a733a18-a12b-40b6-8610-d1cbebec85f7">9,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzEtNS0xLTEtMTY3OTA4_e89b7677-68d2-40d2-bea7-afd88403a6e0">7,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzItMS0xLTEtMTY3OTA4_e5db1869-62a3-4aaa-bf5b-842487ea0982">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzItMy0xLTEtMTY3OTA4_308e407d-1776-4663-95a3-b0c1683ad497">3,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzItNS0xLTEtMTY3OTA4_e0e35de5-a457-4b7e-93f5-e1bd1a77b6bf">2,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzMtMS0xLTEtMTY3OTA4_7a63318a-619e-462d-96a7-71a78106918e">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzMtMy0xLTEtMTY3OTA4_dfe5a126-796b-48de-9f0c-d5e75d9872ed">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzMtNS0xLTEtMTY3OTA4_862e915d-d269-4a30-bdbd-f3bfdb7263c7">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzQtMS0xLTEtMTY3OTA4_e272c9fa-fd9d-46e8-8c8d-f65241f244b8">13,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzQtMy0xLTEtMTY3OTA4_532ba4a4-b400-44a2-907b-7b253bbb3309">12,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzQtNS0xLTEtMTY3OTA4_3ac14fde-bee6-44df-be9e-b9bdcccc959e">11,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in restricted cash included in other current assets as of December 31, 2022 compared to December 31, 2021 was primarily due to a decrease in HSA funds held on behalf of customers as a result of the sale of Payflex Holdings, Inc. (&#8220;PayFlex&#8221;). See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information on the Company&#8217;s sale of PayFlex.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2e8b5b67b6e74aa482dde5cb20e0c7a3" continuedAt="i14bef601fe514f37bb5ea006503ebe46"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDA2_e26375c6-13f3-472e-bcf3-978b8841e6f6" continuedAt="if7104aac983545d1bedbcaee78e8b16b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 &#8216;&#8216;Fair Value&#8217;&#8217; for additional information on how the Company estimates the fair value of these investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related (yield-related) components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income (loss). Interest is not accrued on debt securities when management believes the collection of interest is unlikely.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company&#8217;s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics:&#160;loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i14bef601fe514f37bb5ea006503ebe46" continuedAt="i7225b0f000964a02b6a3ed2cf63195ff"><ix:continuation id="if7104aac983545d1bedbcaee78e8b16b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments consist primarily of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company&#8217;s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership&#8217;s investments through its review or prior to receiving the limited partnership&#8217;s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (&#8220;FHLBB&#8221;), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment income on the Company&#8217;s investments is recorded when earned and is reflected in the Company&#8217;s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders&#8217; accounts daily, based on the underlying investment experience and, therefore, does not impact the Company&#8217;s net income (as long as the contract&#8217;s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions&#8217; experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders&#8217; accounts through a charge to benefit costs. The contract holders&#8217; accounts are reflected in policyholders&#8217; funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments supporting large case pensions&#8217; experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders&#8217; accounts. The contract holders&#8217; accounts are reflected in policyholders&#8217; funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders&#8217; equity, net of tax, as a component of accumulated other comprehensive income (loss). Unrealized capital gains and losses on investments supporting large case pensions&#8217; experience-rated products are credited directly to contract holders&#8217; accounts. The contract holders&#8217; accounts are reflected in policyholders&#8217; funds on the consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzM4_b7afe912-d7cc-48b7-9405-bb4258cd2c74" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company&#8217;s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7225b0f000964a02b6a3ed2cf63195ff" continuedAt="i7196e516e6864fe195516ef7d161494c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzQy_7add3d18-456e-492b-bebd-6e14abb063fb" continuedAt="i9846fde807614d78bde8015e5795d370" escape="true">Accounts Receivable</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9846fde807614d78bde8015e5795d370" continuedAt="ia63e7a7e980a4f26aae96409d7b79270">Accounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations.</ix:continuation> <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDM3_f5f05ca4-4193-4ede-98c8-11b0a989ec33" continuedAt="i1d112d182d964b8dab2c87f4c1045b7c" escape="true">Accounts receivable, net was composed of the following at December&#160;31, 2022 and 2021:</ix:nonNumeric></span></div><ix:continuation id="i1d112d182d964b8dab2c87f4c1045b7c"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzEtMS0xLTEtMTY3OTA4_2a6c325c-9fb2-44ef-ad5c-dc5d68dfd45a">8,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzEtMy0xLTEtMTY3OTA4_c877a934-8fb7-4e42-9c8d-ac5342bf2740">7,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vendor and manufacturer receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:VendorandManufacturerReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzItMS0xLTEtMTY3OTA4_590b7a4e-942f-4bb4-b78c-11acff873e5a">12,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:VendorandManufacturerReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzItMy0xLTEtMTY3OTA4_c60be454-602a-4cf4-9b29-92ac7044ed58">10,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premium receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:PremiumsReceivableAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzMtMS0xLTEtMTY3OTA4_2be64380-3130-487a-a12f-9ade78a61797">2,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:PremiumsReceivableAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzMtMy0xLTEtMTY3OTA4_111ddf92-d66b-445d-8726-97b06c3c9808">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzQtMS0xLTEtMTY3OTA4_3a27b260-da60-42ef-ac84-7500e9665356">3,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzQtMy0xLTEtMTY3OTA4_860077ec-e546-4e55-8af0-43f398997eb5">3,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzUtMS0xLTEtMTY3OTA4_db29b9bc-8f1e-4748-a71b-18a3380c5d68">27,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzUtMy0xLTEtMTY3OTA4_70ad81b1-d8ba-46b4-bb93-597aaca98219">24,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes accounts receivable of $<ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="cvs:AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIxOTkwMjMzNDk1MjE_43f242b8-6f6e-4349-b36a-2fedf0d77033">227</ix:nonFraction>&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div></ix:continuation><div style="text-indent:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s allowance for credit losses was $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzE5MjA1_c4c477af-2a81-48c0-8334-2ea32b4559b2">333</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzE5MjEy_ce501987-9b7d-493e-ad6b-89b06879ed9f">339</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively. <ix:continuation id="ia63e7a7e980a4f26aae96409d7b79270">When developing an estimate of the Company&#8217;s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company&#8217;s accounts receivable are short duration in nature and typically settle in less than 30 days.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDUx_8bb97368-69c1-42e7-ac14-e30315c12360" continuedAt="i2a4d2de9cdc8494083380b0a84f2d3c4" escape="true">Inventories </ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2a4d2de9cdc8494083380b0a84f2d3c4">Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ReinsuranceAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzQx_10dbf94c-f4c7-4dc2-a4e0-ae0e9f6da4fe" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance Recoverables </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company&#8217;s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December&#160;31, 2022, the Company&#8217;s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDA3_2aeaf068-9faf-4d97-b0eb-cfb19d29965e" continuedAt="i9b89cd1f4a864844b57ad3cc6fcfae13" escape="true">Health Care Contract Acquisition Costs</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9b89cd1f4a864844b57ad3cc6fcfae13">Insurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations.</ix:continuation> At December&#160;31, 2022 and 2021, the balance of deferred acquisition costs was $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-8" name="us-gaap:DeferredPolicyAcquisitionCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyMjc1_05837e6a-54c5-4867-a3f3-86759f60a6c4">1.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredPolicyAcquisitionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyMjgy_d56d2dfe-4dff-448c-8ca2-d62fe6186fa9">895</ix:nonFraction> million, respectively, comprised primarily of commissions paid on Medicare Supplement products within the Health Care Benefits segment. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDIx_f37b1e86-a2d5-42fc-a108-e871f10d612b" continuedAt="i8dc091bd59994bb49affcf6f4f95a700" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from <ix:nonNumeric contextRef="i4974a8bfcfe4424d800583e6f9ed22ac_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyNzg2_ec4d6529-bacd-4197-9ea8-d2726a416369">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i2ef0140101e7410aab67b7c7900a5d71_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyNzky_730362ea-b18f-4e54-98fd-c4061528641c">40</ix:nonNumeric> years for buildings, </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7196e516e6864fe195516ef7d161494c" continuedAt="i038db7e4d8664251b73e7fe335250939"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8dc091bd59994bb49affcf6f4f95a700">building improvements and leasehold improvements and <ix:nonNumeric contextRef="i7c831fb209894939826991737cbd7475_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyODY5_892ca965-428b-4173-8760-c4815f24d106">3</ix:nonNumeric> to <ix:nonNumeric contextRef="ie37cf62163d84a58bb4468ebd3f5cfed_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyODc1_3a477ab6-1631-4627-a1b3-c65b35e237fb">10</ix:nonNumeric> years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzQ0_4d77d0c8-a04c-4d9b-8f95-366ea3d41998" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31, 2022 and 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbfa6bdf0b24740a26dec57554e595c_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzEtMS0xLTEtMTY3OTA4_b3c27dca-0e64-42ba-acff-a3c765b44a6c">1,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ada219a77914d62bea752d3c03e225f_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzEtMy0xLTEtMTY3OTA4_227d63e8-1e93-4738-92c7-df5e389e378c">2,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c18d654fb324895a611580a5ec5b3dd_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzItMS0xLTEtMTY3OTA4_36590bbb-2507-4a0b-ad00-9c276c9273d5">4,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie53b91392b604092b359e0652c0bf806_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzItMy0xLTEtMTY3OTA4_49d5f6b3-a795-4fd4-9e1c-f1a5f93e4f74">4,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixtures and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fde8ef39b534e14afcac581de49b996_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzMtMS0xLTEtMTY3OTA4_a71d3e84-3244-4ab7-88a7-e4578dcb2ab0">12,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb3a83ef19240adb23daa081377a140_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzMtMy0xLTEtMTY3OTA4_d8caa384-99e2-411e-8ec9-53da2b200716">13,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd7ff4f57ff426ab9b84721b8a4497c_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzQtMS0xLTEtMTY3OTA4_7e173426-731e-4faf-a703-35b126694e3a">6,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6748d4d91a3f4e1c9f9bf83409587fc3_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzQtMy0xLTEtMTY3OTA4_2afc5deb-4de8-4780-80f6-f45e0bb00ba9">6,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d2d5b42e5da4c468ab576df84378112_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzUtMS0xLTEtMTY3OTA4_89607997-5a6d-43fb-a800-25fa29a7fa15">8,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8b9d6224854f2aa4c4798da79217fc_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzUtMy0xLTEtMTY3OTA4_30cb0e7c-132e-415f-b7da-22c53e3e38f8">7,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzYtMS0xLTEtMTY3OTA4_874c2108-5aed-4352-8c3d-0e296f502a43">34,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzYtMy0xLTEtMTY3OTA4_f8a631ca-4ea6-413c-867d-c64bae848d1c">33,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzctMS0xLTEtMTY3OTA4_dbc8e065-99a4-40dd-b401-b3cbf862ac2e">21,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzctMy0xLTEtMTY3OTA4_5563e3f0-302b-48ad-bc2a-ca5f5840601e">20,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzgtMS0xLTEtMTY3OTA4_c761a288-85f2-4ff3-b94d-c9bdf787cca6">13,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzgtMy0xLTEtMTY3OTA4_28e65ddf-3cff-4790-a786-796d75cc27b4">12,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes property and equipment of $<ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="cvs:PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjUwODU_ac2a807e-c784-45c4-a159-7634526880e7">244</ix:nonFraction>&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense (which includes the amortization of property and equipment under finance or capital leases) totaled $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-8" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIzNDQ5_d688cb50-afc7-40a1-8961-d620037bedfa">2.4</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-8" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIzNDUz_0b3d5c21-a9ac-42a5-9378-d730ac2ad63e">2.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-8" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIzNDYw_2000fd3a-0348-4853-9d98-2699344de5d7">2.1</ix:nonFraction> billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively. During the year ended December&#160;31, 2021, the Company recorded an impairment on property and equipment of $<ix:nonFraction unitRef="usd" contextRef="i19b3fce48e974e0cba8970c7c61dfc90_D20210101-20211231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIxOTkwMjMzNjA2ODI_b97286fb-7efe-45ec-8cca-2d3d4d550182">261</ix:nonFraction>&#160;million in connection with the planned closure of certain retail stores. See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for additional information about these impairment charges as well as the Company&#8217;s finance leases. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzQ5_dfc081ea-e42f-4aad-9020-5c20413c984e" continuedAt="i6e177e0477f24b79810e2cc6d3b09854" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right-of-Use Assets and Lease Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company&#8217;s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s real estate leases typically contain options that permit renewals for additional periods of up to <ix:nonNumeric contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231" name="cvs:LesseeOperatingAndFinanceLeasesRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzI0ODA0_b83746f0-02b8-4b4a-bbde-c32b973d84c7">five years</ix:nonNumeric> each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6e177e0477f24b79810e2cc6d3b09854">See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for additional information about right-of-use assets and lease liabilities.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDM4_ed0fee4a-5906-4d79-9aff-fb5346764b51" continuedAt="i900bf0b4532b473e8ed04e419df5cd82" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i038db7e4d8664251b73e7fe335250939" continuedAt="i9e2743c904fe4776aedd764d7f91a501"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i900bf0b4532b473e8ed04e419df5cd82">not amortized, but is subject to impairment reviews annually, or more frequently, if necessary, as further described in &#8220;Recoverability of Long-Lived Assets&#8221; below.</ix:continuation> See Note 5 &#8216;&#8216;Goodwill and Other Intangibles&#8217;&#8217; for additional information about goodwill. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzU5_0ab2ef98-fbf3-4659-b2dc-f6962834a7f2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (&#8220;VOBA&#8221;). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently, if necessary, as further described in &#8220;Recoverability of Long-Lived Assets&#8221; below.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5 &#8216;&#8216;Goodwill and Other Intangibles&#8217;&#8217; for additional information about intangible assets. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzkw_b5e4ce75-b95d-4143-8151-3768bae1e40e" continuedAt="iff6a3e77263e4e3bb070c681a8f2338d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recoverability of Long-Lived Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group&#8217;s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group&#8217;s carrying value that exceeds the asset group&#8217;s estimated future cash flows (discounted). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded office real estate optimization charges of $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:OfficeRealEstateOptimizationCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzEwOTk1MTE2MzgxMTc5_49130952-8ae5-4f6f-b25e-45d660073354">117</ix:nonFraction>&#160;million primarily related to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to its new flexible work arrangement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company recorded a store impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i1e0fac73260b479989119ffb924ad3e9_D20210101-20211231" decimals="-8" name="cvs:StoreImpairmentCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzU0OTc1NTkwMDk5MQ_22eeb21c-0595-4657-b25f-50f5bc97a720">1.4</ix:nonFraction>&#160;billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately <ix:nonFraction unitRef="store" contextRef="i1e0fac73260b479989119ffb924ad3e9_D20210101-20211231" decimals="-2" name="cvs:NumberOfStoresPlannedClosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzI5Mzg4_3aaa14aa-93d9-4bfb-b7ce-8fafe2a822e0">900</ix:nonFraction> retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets during the year ended December 31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for additional information about the right-of-use asset charges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of both 2022 and 2020, the Company performed its required annual impairment tests of goodwill and concluded there were <ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjUwOTY_06bb3fff-63ea-4b75-9b54-a6a2618fe117"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjUwOTY_b83614f4-accd-4642-a34f-c353672c26f4">no</ix:nonFraction></ix:nonFraction> goodwill impairments as of the testing dates or during the years ended December 31, 2022 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="ie0d6894378d3433197250c8e10ca47a7_D20210701-20210930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzMwNDYw_2a53c550-bba0-443d-88c9-22f7b32a8c68">431</ix:nonFraction>&#160;million goodwill impairment charge on the remaining goodwill of the LTC reporting unit. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December&#160;31, 2021. See Note 5 &#8216;&#8216;Goodwill and Other Intangibles&#8217;&#8217; for additional information about the goodwill impairment charge recorded during the year ended December&#160;31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9e2743c904fe4776aedd764d7f91a501" continuedAt="i8231c793a2914aa1baa47d1c8cb41b04"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff6a3e77263e4e3bb070c681a8f2338d">income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzMxNDQx_647c1092-d032-4d6f-bb99-adfd37c47270"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzMxNDQx_aad69f7f-da33-4840-86b9-40079566f7ff"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzMxNDQx_f598dca6-5593-4919-b260-3d79025ff0fc">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses recognized on indefinite-lived intangible assets in any of the years ended December&#160;31, 2022, 2021 or 2020.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:PolicyholderAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDAz_f6955a3f-017d-47ff-a1d5-f27336bef7a4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company&#8217;s other businesses. Deposits, withdrawals and net investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:HealthCareCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDA0_61aa71a7-7f3d-4bfb-8421-25a642a4a616" continuedAt="i4a8a0e379c40420188503017d0a20f71" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Costs Payable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment&#8217;s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company&#8217;s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, &#8220;IBNR&#8221;). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company&#8217;s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company&#8217;s estimate of IBNR in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate &#8220;completion factors.&#8221; The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within <ix:nonNumeric contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231" name="cvs:HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzM1NjM5_e593c914-955f-4b46-8ea4-cfbaa388c197">six months</ix:nonNumeric> of the date of service, but it can take up to <ix:nonNumeric contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231" name="cvs:HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzM1Njg4_2478af1f-f4b3-4f6c-b2d1-b5703db8d32b">48</ix:nonNumeric> months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month&#8217;s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company&#8217;s estimate of claims remaining to be paid as of the financial statement date and is included in the Company&#8217;s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company&#8217;s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8231c793a2914aa1baa47d1c8cb41b04" continuedAt="i784dd2854720434d845442cb69a65b3b"><ix:continuation id="i4a8a0e379c40420188503017d0a20f71"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company&#8217;s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company&#8217;s business. The health status of the Company&#8217;s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company&#8217;s health care cost trend rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December&#160;31, 2022; however, actual claim payments may differ from the Company&#8217;s estimates. A worsening (or improvement) of the Company&#8217;s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December&#160;31, 2022 would cause these estimates to change in the near term, and such a change could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company&#8217;s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company&#8217;s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company&#8217;s health care costs payable, see Note 7 &#8216;&#8216;Health Care Costs Payable.&#8217;&#8217; The Company&#8217;s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mjk1_299d359d-5988-4c0d-a1b4-11d07f4e23e6" continuedAt="iaff28a848e594f48a0fe408724cd88dc" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Insurance Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unpaid Claims</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company&#8217;s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company&#8217;s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company&#8217;s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company&#8217;s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company&#8217;s estimate of unpaid claims IBNR in 2022. As of December&#160;31, 2022, unpaid claims balances of $<ix:nonFraction unitRef="usd" contextRef="if7945c60ae0e48268a21dc60ec7256ff_I20221231" decimals="-6" name="cvs:LiabilityForUnpaidClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQyODEy_c160dc4a-1489-4350-b19c-0a2a784cdc2f">243</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide9ac130c868441a9b93b609dc8b28e0_I20221231" decimals="-8" name="cvs:LiabilityForUnpaidClaims" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQyODE5_c2c3770e-1db8-4099-bbf2-646ec61f3a82">1.1</ix:nonFraction> billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December&#160;31, 2021, unpaid claims balances of $<ix:nonFraction unitRef="usd" contextRef="i9f6d2a400d30483eb5535b2a740cccbf_I20211231" decimals="-6" name="cvs:LiabilityForUnpaidClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQyOTYw_ad84c3da-1abc-4df2-abf3-557e1b1f50ad">324</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icc50f23b90eb443283a4ee5cf88abd97_I20211231" decimals="-8" name="cvs:LiabilityForUnpaidClaims" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQyOTY3_61201c23-c631-469d-8d78-4c695083979f">1.3</ix:nonFraction> billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i784dd2854720434d845442cb69a65b3b" continuedAt="ia6a867bbf8214564a2aef6a6cca9f76a"><ix:continuation id="iaff28a848e594f48a0fe408724cd88dc" continuedAt="i2f16cdb89ac04e98861798778a2d03b8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Policy Benefits</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f16cdb89ac04e98861798778a2d03b8">Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from <ix:nonFraction unitRef="number" contextRef="ic63500a3d0dc40e8b098d64a2fbfe2ab_D20210101-20211231" decimals="3" name="cvs:LimitedPaymentsContracts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQzODIw_011bed3d-f2e2-4667-ac15-62c35aa9848d"><ix:nonFraction unitRef="number" contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231" decimals="3" name="cvs:LimitedPaymentsContracts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQzODIw_2a0eaf06-00cf-47f8-967b-69f45eb4aa94">3.0</ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231" decimals="3" name="cvs:LimitedPaymentsContracts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQzODI2_17ccad57-3420-4cf6-8306-6d4e1d4b4ce9"><ix:nonFraction unitRef="number" contextRef="i26333704d6224942a7b55db5b9a7c2cf_D20210101-20211231" decimals="3" name="cvs:LimitedPaymentsContracts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQzODI2_af38cace-5ec8-41f0-846c-aca5f8efdf83">11.3</ix:nonFraction></ix:nonFraction>% in both the years ended December&#160;31, 2022 and 2021. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-duration long-term care contracts represent the Company&#8217;s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was <ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" name="cvs:AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0Mjk4_21886d6c-99b5-46a4-8a88-28a3380327e1">4.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" name="cvs:AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzk4OTU2MDQ3NTI3MTg_cf30799f-0d36-4970-bb2c-d2182d4f662c">5.1</ix:nonFraction>% in the years ended December 31, 2022 and 2021, respectively. The Company&#8217;s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions.</ix:continuation> As of December&#160;31, 2022, future policy benefits balances of $<ix:nonFraction unitRef="usd" contextRef="if7945c60ae0e48268a21dc60ec7256ff_I20221231" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0NTQ2_a21792e9-ab3d-4c75-9364-12e58ec1629d">385</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide9ac130c868441a9b93b609dc8b28e0_I20221231" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0NTUz_9023015e-23b7-4f29-a4d7-0f85353e22c9">5.0</ix:nonFraction> billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December&#160;31, 2021, future policy benefits balances of $<ix:nonFraction unitRef="usd" contextRef="i9f6d2a400d30483eb5535b2a740cccbf_I20211231" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0NzAz_f2c3069e-689d-4cc0-884e-4392a01198b8">416</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icc50f23b90eb443283a4ee5cf88abd97_I20211231" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0NzEw_5c63a062-caab-48cc-8bfe-05209ed437f4">5.1</ix:nonFraction> billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:InsurancePremiumDeficiencyReservePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzk1_88d6d65b-01b2-4bf0-a25a-1864f4c876ce" continuedAt="i7f139a8a07fa42bfac83b7ebcb1f6d0b" escape="true">Premium Deficiency Reserves</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f139a8a07fa42bfac83b7ebcb1f6d0b">The Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company&#8217;s method of acquiring, servicing and measuring the profitability of such contracts.</ix:continuation> The Company did <ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="cvs:PremiumDeficiencyReserveLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzEwOTk1MTE2MzgxMDg0_793990e3-923f-4bcc-b8d1-7f420b16c42e">not</ix:nonFraction> have any premium deficiency reserves as of December&#160;31, 2022. As of December&#160;31, 2021, the Company established a premium deficiency reserve of $<ix:nonFraction unitRef="usd" contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231" decimals="-6" name="cvs:PremiumDeficiencyReserveLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ1NjE2_f0574f20-aedc-4b4a-8c75-a5797df37879">16</ix:nonFraction> million related to Medicaid products in the Health Care Benefits segment. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:AllocationsToPolicyholdersPolicies" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDMz_852eea0c-cfcc-418a-829b-7f94e1fcfa4b" continuedAt="i98c8531c022d4215b3ab83ef3185c43e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policyholders&#8217; Funds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policyholders&#8217; funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In both 2022 and 2021, interest rates for pension and annuity investment contracts ranged from <ix:nonFraction unitRef="number" contextRef="ic63500a3d0dc40e8b098d64a2fbfe2ab_D20210101-20211231" decimals="3" name="cvs:PensionAndAnnuityInvestmentContractsInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2MTIw_a196a71c-f869-470d-b95f-744f7c46ea04"><ix:nonFraction unitRef="number" contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231" decimals="3" name="cvs:PensionAndAnnuityInvestmentContractsInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2MTIw_c7f051f9-12ce-41cf-bac6-d2ca43cd13d1">3.5</ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231" decimals="3" name="cvs:PensionAndAnnuityInvestmentContractsInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2MTI2_2eb33c3a-6e05-49df-9620-bc98bea2d2ed"><ix:nonFraction unitRef="number" contextRef="i26333704d6224942a7b55db5b9a7c2cf_D20210101-20211231" decimals="3" name="cvs:PensionAndAnnuityInvestmentContractsInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2MTI2_771f306f-68b9-4449-9d95-4e4b71df903c">4.8</ix:nonFraction></ix:nonFraction>%. Reserves for contracts subject to experience rating reflect the Company&#8217;s rights as well as the rights of policyholders and plan participants. The Company also held funds for HSAs on behalf of members associated with high deductible health plans prior to the sale of PayFlex in June 2022. These amounts were held to pay for qualified health care expenses incurred by these members. At December&#160;31, 2022, the Company did <ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-8" name="cvs:HeathSavingsAccountBalance" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjkwNTI_cb52629b-abc4-4da9-a074-d977588e376a">not</ix:nonFraction> hold any HSA funds as a result of the PayFlex sale. The HSA balance was approximately $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-8" name="cvs:HeathSavingsAccountBalance" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2NjA0_7eaf0f5d-1cf4-45fc-96f8-8d8b611632a8">2.9</ix:nonFraction> billion at December 31, 2021 and was reflected in other current assets with a corresponding liability in policyholders&#8217; funds. These assets were considered restricted cash for cash flow statement purposes.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i98c8531c022d4215b3ab83ef3185c43e">Policyholders&#8217; funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders&#8217; funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:SelfInsuranceReservePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzAy_f9e51cc3-54fd-48e8-8c86-f73beee2bbf1" continuedAt="ia24624530b054b11a430314d554c424a" escape="true">Self-Insurance Liabilities</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia24624530b054b11a430314d554c424a">The Company is self-insured for certain losses related to general liability, workers&#8217; compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company&#8217;s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company&#8217;s historical claims experience.</ix:continuation> As of both December&#160;31, 2022 and 2021, self-insurance liabilities totaled $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-8" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ3Nzg5_3db6385f-8d43-4877-8c88-680ad316c7e8"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-8" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ3Nzg5_69134b11-a455-4c0f-aed0-0a5586180558">1.1</ix:nonFraction></ix:nonFraction> billion and were recorded in accrued expenses and other long-term liabilities on the consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia6a867bbf8214564a2aef6a6cca9f76a" continuedAt="icc820bc45e574c58906ca010d116a3a6"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDQ1_7f7dcf84-a39f-4d66-9984-ee1af5e65f7f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from foreign currency transactions and the effects of foreign currency remeasurements were not material in the years ended December&#160;31, 2022, 2021 or 2020. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDEx_357e2c15-f6a3-49d5-8bcc-c5ade57a6d6d" continuedAt="i6525523413be46e7ba51cd44c1389931" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company&#8217;s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company&#8217;s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company&#8217;s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Premium Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (&#8220;MLR&#8221;) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the &#8220;ACA&#8221;) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment&#8217;s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company&#8217;s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor&#8217;s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting for Medicare Part D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include insurance premiums earned by the Company&#8217;s PDPs, which are determined based on the PDP&#8217;s annual bid and related contractual arrangements with the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). The insurance </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icc820bc45e574c58906ca010d116a3a6" continuedAt="i7ced4a5662794e1aac114a601574e437"><ix:continuation id="i6525523413be46e7ba51cd44c1389931" continuedAt="ibdd9cb4ba21a4b31b8f7341541a8fd29"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company&#8217;s retail pharmacy network. The Company&#8217;s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see &#8220;Drug Discounts&#8221; and &#8220;Guarantees&#8221; below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (&#8220;retail co-payments&#8221;), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by third party pharmacies in the Company&#8217;s retail pharmacy network and associated administrative fees are recognized at the Company&#8217;s point-of-sale, which is when the claim is adjudicated by the Company&#8217;s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Drug Discounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue net of manufacturers&#8217; rebates earned by its clients based on their plan members&#8217; utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers&#8217; rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7ced4a5662794e1aac114a601574e437" continuedAt="if76a9b9b9d9f47138ed7f88fe6db56ed"><ix:continuation id="ibdd9cb4ba21a4b31b8f7341541a8fd29" continuedAt="i361afc7e50b04c969f6f1a21a9f501a0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers&#8217; rebate amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantees</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Retail Pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer returns are not material to the Company&#8217;s operating results or financial condition. Sales taxes are not included in revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Loyalty and Other Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer loyalty program, ExtraCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consists of two components, ExtraSavings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offers a subscription-based membership program, CarePass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-term Care</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company&#8217;s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors. </span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if76a9b9b9d9f47138ed7f88fe6db56ed" continuedAt="i1a94c233fee74c0c84ccf149743ac2e8"><ix:continuation id="i361afc7e50b04c969f6f1a21a9f501a0" continuedAt="i44431c5b2e0b475ea1eac94e361e7b46"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Walk-In Medical Clinics</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For services provided by the Company&#8217;s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1a94c233fee74c0c84ccf149743ac2e8" continuedAt="id9478a8ada88409eb24bda81883d57d7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mjk2_f1821b24-2077-4030-bf43-46b67f5983fd" continuedAt="i87a5895cf1ba4f88a2efb769fcc09581" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company&#8217;s revenue by major source in each segment for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:28.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.462%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87aec70e323d4d80b7919dced5a91e73_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtMS0xLTEtMTY3OTA4_01726c97-3538-4068-9f58-32c94fa1e8f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72800db1d6214a588b0e32ee81cf20b2_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtMy0xLTEtMTY3OTA4_9fb06661-3f2c-40ae-ba6d-60e4929bb177">168,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fab4c813ab3488e9e07378a081f8db9_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtNS0xLTEtMTY3OTA4_1b5a047d-bad7-48b9-80ae-c53401fb30a1">82,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e7024e7b3e47b3b5530bee96e98c10_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtNy0xLTEtMTY3OTA4_3c4fc6c9-a104-4158-88c5-ad386e775040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b832667ae304814964afa70f9b6228f_D20220101-20221231" decimals="-6" sign="-" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtOS0xLTEtMTY3OTA4_7b314c30-b2d0-4055-a8cb-677a8485f1e5">45,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab45872f08734ce1a3dacf338ff1195c_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtMTEtMS0xLTE2NzkwOA_37fe5274-92c1-472f-8be7-0ad09e518be0">205,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4b2b74efa8424bb6186fd1ce6f571f_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtMS0xLTEtMTY3OTA4_e0950529-c171-4a97-8b23-3892ec466c6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428e6eaf7d9c401a824a54e771b1843c_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtMy0xLTEtMTY3OTA4_c6b83028-7490-4f0f-9fc9-a885faaad9ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14f4ace6f2c42638909cf217d548c72_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtNS0xLTEtMTY3OTA4_b6c0f20b-d7e3-496d-bd58-452abe4e6f08">22,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i916017148df94c918c5f7fd143ce2d88_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtNy0xLTEtMTY3OTA4_cec53c2a-55ec-44c6-ae74-4388f8a67fe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if010e49d412b4111aabb4d53c35c0289_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtOS0xLTEtMTY3OTA4_3198ed93-3225-490a-9557-8d5c44a1ea17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia131689becf644f4bc5a732edb3c22e2_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtMTEtMS0xLTE2NzkwOA_1e6de8b7-d789-4e85-bb9c-2308346cd004">22,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e819b5e8cb45e5ab8dbfaf05b504cb_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtMS0xLTEtMTY3OTA4_2d3dcaa7-046f-4d57-bc79-2bf2195fad67">85,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209085ef2a2445ddb82ac68f9a34c386_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtMy0xLTEtMTY3OTA4_89d1d120-dd2a-402a-9a17-ae9d55801c62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59f410a5b084b5c88a7afb76702b6d0_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtNS0xLTEtMTY3OTA4_eda2ebc9-fae7-4138-8f41-d45b090ccfef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefc8faa2206e496e97d8bd1eff35cdf0_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtNy0xLTEtMTY3OTA4_565ca3bd-6c6c-4dc9-99f0-193307521c6c">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i317658c2ffcc45ea83ffebbec7222ac9_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtOS0xLTEtMTY3OTA4_f78f5681-98cf-4fac-8b7f-6c333866909f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5fcff7cb6c46f987a53e2a78bc0fb8_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtMTEtMS0xLTE2NzkwOA_fc122059-3537-4f79-84c2-f8efd8786020">85,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtMS0xLTEtMTY3OTA4_a32b2e7a-0050-4810-b6e6-f6f1eae453ca">476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtMy0xLTEtMTY3OTA4_cd255e30-de0b-4a52-b7f4-d655c51cde6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtNS0xLTEtMTY3OTA4_058d67a7-2155-4811-add2-553bf382ebaa">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtNy0xLTEtMTY3OTA4_2180c008-314c-4655-800c-197fbd99d553">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtOS0xLTEtMTY3OTA4_72ed392c-6cb2-479c-a2fe-ab83fc4243d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtMTEtMS0xLTE2NzkwOA_a532d65d-5a0f-45ce-bfac-d48772268e3e">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786d650a37ad452c813aff2f3ba2b66f_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctMS0xLTEtMTY3OTA4_e0b8382a-b011-4c1a-8da6-c93fd5d09e53">5,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifefecdea33b5434f8044bd84cd050b73_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctMy0xLTEtMTY3OTA4_0ee44515-ddd8-44be-ba7f-e0b0677dbee5">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3279e91422224439968bc192db36cdb1_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctNS0xLTEtMTY3OTA4_a9e86640-777f-4751-ae53-f0c82f1b812f">1,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f8050b163245d58912d4aff32e4a28_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctNy0xLTEtMTY3OTA4_d06170d2-d9bd-43c1-b8a2-22f4caa241a5">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i875b6ff05a00444daa0d40d607318115_D20220101-20221231" decimals="-6" sign="-" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctOS0xLTEtMTY3OTA4_a48e68a3-ed43-4735-9927-b24233a94b34">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a4492c873942499213da78e615d60a_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctMTEtMS0xLTE2NzkwOA_3b88cb35-1369-4555-8bd7-d4aa6848bc84">8,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMS0xLTEtMTY3OTA4_a718b28d-82d7-49e5-94a0-2cf3f8e9f7b6"><ix:nonFraction unitRef="usd" contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMS0xLTEtMTY3OTA4_cce8e3dd-bd18-471d-ab21-c43bd2ef29d8">91,409</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMy0xLTEtMTY3OTA4_4ef0244b-4664-4ea7-ba4f-ffc775187874"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMy0xLTEtMTY3OTA4_f88c8356-5dc6-493c-b62c-56e4daac4ce0">169,236</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtNS0xLTEtMTY3OTA4_65dea28f-1fa0-43e5-ad5a-99629043103b"><ix:nonFraction unitRef="usd" contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtNS0xLTEtMTY3OTA4_fed8c70a-6eae-4c76-8377-4d6e99e43da4">106,594</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtNy0xLTEtMTY3OTA4_2ae9bbab-ccc2-4f9d-9093-f41008861d3c"><ix:nonFraction unitRef="usd" contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtNy0xLTEtMTY3OTA4_a87d0a1e-6cdf-4fe4-b4a5-d2c454b0e25a">530</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtOS0xLTEtMTY3OTA4_1e1f225c-a0aa-4a84-8d00-a03daa3d1341"><ix:nonFraction unitRef="usd" contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtOS0xLTEtMTY3OTA4_40850830-19f6-4605-a95d-77138e55935e">45,302</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMTEtMS0xLTE2NzkwOA_ec736ae0-87a4-4316-8cfa-e1a3e9ebc50c">322,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc263ef676c41c7a9714817863cd0b5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzExLTMtMS0xLTE2NzkwOA_40bfc0e8-cc67-4c08-ad01-9bd2ad517724">97,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531a5f41bdcc4e98bc63759f201375c0_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzEyLTMtMS0xLTE2NzkwOA_ae28d32b-c98a-4472-aefb-315c14bef3c5">70,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b49c00627e4fb69a66285d6f3f5b64_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzEzLTMtMS0xLTE2NzkwOA_9fe40e03-7fe6-4e55-b838-ab30c35364df">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE0LTMtMS0xLTE2NzkwOA_d774bf3d-a7a9-4763-bbe4-2fd0189236b8">169,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f9a334ea554cf6923ae16a198dd1f7_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTEtMS0xLTE2NzkwOA_5cd1bf04-39a1-44ba-a910-2c085f1a7083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5470c0948d3447daa6b553072d68b21c_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTMtMS0xLTE2NzkwOA_194ef024-c756-49ac-8f8c-38a953b53ec1">152,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5218b8d02245eea6cb1c1964bc2d56_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTUtMS0xLTE2NzkwOA_fe929311-9871-434e-af30-18754bc524ab">76,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ebe5b02e9154d92b2659182b87bcc17_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTctMS0xLTE2NzkwOA_073331ca-be10-48e7-90cb-1e3b7d539100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e66c2cd601c4549a5ef3b24ccbaf9fa_D20210101-20211231" decimals="-6" sign="-" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTktMS0xLTE2NzkwOA_b8ec7996-5866-43c4-b850-7ab9f7c0b86d">43,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ee9b96bd1eb4291996ceb2ce4ecb8c9_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTExLTEtMS0xNjc5MDg_0adf3d30-b14d-42fb-9d78-35272036a735">184,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2694cdfde5e94542ba60918fc678d54a_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTEtMS0xLTE2NzkwOA_15e9a3c1-ed94-45fc-9f4d-9e37bbe926d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bebe76ce83e46589a14f0b7cb047cb7_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTMtMS0xLTE2NzkwOA_d72f6ca5-10a0-4d83-8b47-95bc8fab2f62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99cbec53a7ed47e3ab88190772305c5a_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTUtMS0xLTE2NzkwOA_69b5d3b5-d214-4012-b7f6-681e463e945d">21,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57e0be74304456489f0a228ba4952ba_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTctMS0xLTE2NzkwOA_d8638ce0-0635-4f6e-8916-44cdda7083a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dee4299a044434bb9587326355c6d37_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTktMS0xLTE2NzkwOA_25baab59-4a8a-4918-9e05-9cd756d1dfa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15504530953c4bf689166fcfe8f7868d_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTExLTEtMS0xNjc5MDg_0fd567d1-787d-481c-b290-fbd0bdc9571b">21,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c90e55b42a466ca5aa922c38dd414e_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTEtMS0xLTE2NzkwOA_fa030d03-21cc-425b-a466-e7e13e0762aa">76,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cde5b8c7bef4de38fb102a05d7d6a29_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTMtMS0xLTE2NzkwOA_549188f5-a0ad-4c3c-a6bc-31c23302b897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba757607c0e44ffa9ce352a6dc203fa_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTUtMS0xLTE2NzkwOA_a79aaadb-10aa-45f8-a2f4-471b872c0f4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86521d12a18428cb6850612e4806b2e_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTctMS0xLTE2NzkwOA_361cb803-8473-44f5-9eb1-ccbb1b641071">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cc5da453684e30b0e7f61d0c214207_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTktMS0xLTE2NzkwOA_9ee462c5-3b9e-4770-939a-f1a2311f54fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a89142a03e46a08448375f4b02bc4f_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTExLTEtMS0xNjc5MDg_6358e80c-dfec-4379-bff7-16982a11b38d">76,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTEtMS0xLTE2NzkwOA_a94497d1-ea6b-4a6a-a9e0-ed96b5b6e070">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTMtMS0xLTE2NzkwOA_64d76e69-110c-46c0-9314-1be298a541cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTUtMS0xLTE2NzkwOA_edbda917-d4f3-406c-8fd6-9e5686015e49">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTctMS0xLTE2NzkwOA_e07c5084-b890-444d-be9d-36594699115c">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTktMS0xLTE2NzkwOA_1da31008-0453-4b71-a84c-5d5befeb09a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTExLTEtMS0xNjc5MDg_6f649bdf-0964-4d52-9021-0612daec302d">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10be60b83a684a8c8d1797644e6037e5_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTEtMS0xLTE2NzkwOA_57788b75-d52a-45bb-a6e3-b1fcb2cd2326">5,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec13ef8ea98a4f52953499317400e068_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTMtMS0xLTE2NzkwOA_eaaea8ba-72f3-4bec-8a5b-be557fb5415c">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id041b9cf96944df2825c84f9dbb638ea_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTUtMS0xLTE2NzkwOA_9824966b-8533-4062-a76a-42cf14b4d903">2,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f8c85482214ae78d33982d2c28ceaa_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTctMS0xLTE2NzkwOA_3bc71bbf-1e9b-4419-b978-7c386600baa1">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9915652c392941698dd07b170ae9d044_D20210101-20211231" decimals="-6" sign="-" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTktMS0xLTE2NzkwOA_c98e1198-df5d-401e-8009-58eb0e450661">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c774395798448abbb90933427cbc204_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTExLTEtMS0xNjc5MDg_137fd649-040b-4e8e-8ae8-2a8ddc11fada">8,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTEtMS0xLTE2NzkwOA_1c180e62-2e53-48e9-8b1b-b956ad6122e2">82,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTMtMS0xLTE2NzkwOA_b4735515-afa6-424b-bb7d-82461273cd33">153,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTUtMS0xLTE2NzkwOA_f37c2b19-4d29-4aef-8b9f-aac5c224ef9f">100,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTctMS0xLTE2NzkwOA_12cc1ca0-d675-4406-9797-00937e1ac0f8">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTktMS0xLTE2NzkwOA_c8a6f7b8-77b4-448d-8455-419ba3e984df">43,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTExLTEtMS0xNjc5MDg_9eaa3e6e-7823-4e51-9cb0-657c2e36a6ec">292,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66c5e92146f4978aeaff863da389857_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzI2LTMtMS0xLTE2NzkwOA_5718560b-3534-41dd-acb9-68e58ddc419f">91,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85235bf2dc3145338feefdca3630aa3b_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzI3LTMtMS0xLTE2NzkwOA_5e0c7d7c-2d55-4a45-954f-cb3bb17af79f">60,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6ff2650b194f6f9b88d08a7d679daa_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzI4LTMtMS0xLTE2NzkwOA_39c515e2-c2a1-4e4b-86b5-16c9b87ed970">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzI5LTMtMS0xLTE2NzkwOA_2e91e53d-791d-4633-bd0c-f024a3ccbd9b">153,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i710619ea82ee47b2b0f1faa66681850c_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTEtMS0xLTE2NzkwOA_05a59d5d-50ea-436a-a730-5d860db8dcc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5733b07b8443d7b51ad01e0f283bc6_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTMtMS0xLTE2NzkwOA_e4a54d5e-aa77-4f19-99b2-0c7b489fe00f">141,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id91c69b620814b2a9f51d3084dada276_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTUtMS0xLTE2NzkwOA_710f641a-e559-4ad6-91d9-336dd01424e0">70,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0cba2d7a4b49d68120f1ad1e3b59f7_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTctMS0xLTE2NzkwOA_cf5d9f4f-23c1-4c40-ac00-42adf5fc9246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047c32c6681c48a280f39c07fbb64103_D20200101-20201231" decimals="-6" sign="-" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTktMS0xLTE2NzkwOA_164251f6-caeb-4512-9b73-dd4636b2937f">40,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a613e7cb5b4f9fabfb569ae06de8c5_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTExLTEtMS0xNjc5MDg_1fa6caba-01c1-4efd-8af4-32b94fe6ca39">171,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa8c79cb8ce4f9fa3d25b293e92eafd_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTEtMS0xLTE2NzkwOA_e1ef2bf8-dd8d-420f-aecf-64f5329cf330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4cdb3407c14f1282544e57e58ecf04_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTMtMS0xLTE2NzkwOA_2853151e-c824-4480-bb65-532cad7143aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bc5d4b76344af48fea40efd9a549c7_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTUtMS0xLTE2NzkwOA_c231605e-d45c-41b7-a80f-210485e2c4fe">19,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie86040f73a11474b89670e351fab892e_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTctMS0xLTE2NzkwOA_4d18c220-eecc-4ddd-9e2a-2c51c27c1ba1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e8afb1516f445db8c04046e7f9619f_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTktMS0xLTE2NzkwOA_417b76be-1064-4b3a-becb-01234a3938b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b3c892261d42ae91d2522773ceeffa_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTExLTEtMS0xNjc5MDg_687dde71-bab0-40fd-9ef6-57330700dd2e">19,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f6f283d4c04e2dac7883355902fa5d_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTEtMS0xLTE2NzkwOA_1c76b722-8725-4af8-bb2d-30a8dd27d0c9">69,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab6442d127e4d5abf45e0a1fd8044a5_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTMtMS0xLTE2NzkwOA_9efb9263-24e7-4100-9b75-ba9b1604e0c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a69bf319414885a2af9b145fb0daa3_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTUtMS0xLTE2NzkwOA_a1975dba-df06-47a2-8d3b-61fcc4186bbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d1804d8c6b4ac494abb73ef6b710bd_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTctMS0xLTE2NzkwOA_48d8a216-2014-40c7-83ef-77ce231d76be">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed9c24157b04f799ff19ca1d9a73070_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTktMS0xLTE2NzkwOA_086639d6-1fba-44fd-b034-c60a1e010508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52962d31d6d1400aa5bdf2bab550bd30_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTExLTEtMS0xNjc5MDg_db896fce-d38f-45ba-8efb-39a1373d9659">69,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTEtMS0xLTE2NzkwOA_9349fcb3-7a57-4d7d-899b-5cc117caf45a">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTMtMS0xLTE2NzkwOA_b08d464c-a503-474c-aa9d-694b1e19df95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTUtMS0xLTE2NzkwOA_a30ed86e-27bf-4528-b9c4-6122b7dabcd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTctMS0xLTE2NzkwOA_4263b992-5eaa-4693-81fb-eb30ec62f21f">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTktMS0xLTE2NzkwOA_5225e211-abea-4a01-8291-b23211580098">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTExLTEtMS0xNjc5MDg_92bbf988-df85-4c21-92fd-4e26d0205fc0">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8e30495c1f4923ac883d572d156bd5_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTEtMS0xLTE2NzkwOA_46108488-842a-4c08-8f64-7b1572b41a89">5,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a458accfa84019adc7131cfcc882ba_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTMtMS0xLTE2NzkwOA_aeeebe87-9924-428d-bf19-67392b6d1abe">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id854bc7a2aa64ef3bbcea56dffab6dbc_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTUtMS0xLTE2NzkwOA_ff9825db-44cf-4050-8134-20e7a8af8f34">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa3187fec8b406b816c24249fb2dbce_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTctMS0xLTE2NzkwOA_16becb41-55b8-495d-b106-1b4e620f0f09">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36b2481d581d48a38dab150c09f95d26_D20200101-20201231" decimals="-6" sign="-" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTktMS0xLTE2NzkwOA_10d2ff06-6895-4417-bb60-ebc22654e61a">320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfcca160913463291592340d0f000aa_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTExLTEtMS0xNjc5MDg_75cfcf41-567f-4559-8943-eb9bd24b25b8">7,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTEtMS0xLTE2NzkwOA_031a6f31-3f10-45f6-b7c2-961f08a6369a">75,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTMtMS0xLTE2NzkwOA_76e97c61-3f84-4255-becf-517551f69a06">141,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTUtMS0xLTE2NzkwOA_c6bde48c-cf2c-4997-bac0-858740e4e957">91,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTctMS0xLTE2NzkwOA_99b95830-8a3e-4996-89ba-07fb2bd65ef9">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTktMS0xLTE2NzkwOA_93279363-0d9e-418c-b6a8-f91c79c62b84">40,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTExLTEtMS0xNjc5MDg_243861ff-1866-4bd9-a918-d39b46b3a6e6">268,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6504396ad13b404a809b4be1782f4962_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQxLTMtMS0xLTE2NzkwOA_05110450-b899-496d-b038-ecff996410e8">85,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4e4149eed634db283cebe9c5c27cccb_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQyLTMtMS0xLTE2NzkwOA_20eaa3dc-7ef1-4e71-a10c-da4bd2425bc4">56,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c934f6d7dbd4623a30db94c93317b44_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQzLTMtMS0xLTE2NzkwOA_24807dc3-2325-42a5-9b7d-ab9196c5f96f">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQ0LTMtMS0xLTE2NzkwOA_21b358f1-4966-44bf-9d67-bec7226d2d32">141,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id9478a8ada88409eb24bda81883d57d7" continuedAt="i3e2beff4e9c7445ab9f442afae5a0cc1"><div style="padding-left:18pt;text-indent:-18pt"><ix:continuation id="i87a5895cf1ba4f88a2efb769fcc09581" continuedAt="i35c3ebe50ba84544a5498b1df8cdec9d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company&#8217;s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.</span></ix:continuation></div><div style="padding-left:18pt;text-indent:-18pt"><ix:continuation id="i35c3ebe50ba84544a5498b1df8cdec9d" continuedAt="i2a75b4f0d1584297918fc74f601403d8"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> claims picked up at a retail pharmacy, as well as prescriptions filled at the Company&#8217;s retail pharmacies under the Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i2a75b4f0d1584297918fc74f601403d8">program.</ix:continuation> </span></div><div><span><br/></span></div><ix:continuation id="i44431c5b2e0b475ea1eac94e361e7b46"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily represent the Company&#8217;s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzkz_4ce0924a-ee62-4123-8ac9-39f5e1f9c562" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables and contract liabilities from contracts with customers as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables (included in accounts receivable, net)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3NTBiMDljMzlhNWY0NjM3OGZmNjNlODk3MjVkMDBhMi90YWJsZXJhbmdlOjc1MGIwOWMzOWE1ZjQ2Mzc4ZmY2M2U4OTcyNWQwMGEyXzEtMS0xLTEtMTY3OTA4_2a6c325c-9fb2-44ef-ad5c-dc5d68dfd45a">8,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3NTBiMDljMzlhNWY0NjM3OGZmNjNlODk3MjVkMDBhMi90YWJsZXJhbmdlOjc1MGIwOWMzOWE1ZjQ2Mzc4ZmY2M2U4OTcyNWQwMGEyXzEtMy0xLTEtMTY3OTA4_c877a934-8fb7-4e42-9c8d-ac5342bf2740">7,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities (included in accrued expenses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3NTBiMDljMzlhNWY0NjM3OGZmNjNlODk3MjVkMDBhMi90YWJsZXJhbmdlOjc1MGIwOWMzOWE1ZjQ2Mzc4ZmY2M2U4OTcyNWQwMGEyXzItMS0xLTEtMTY3OTA4_752169dc-7c06-448e-ae76-4503bfbdb5dd">71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3NTBiMDljMzlhNWY0NjM3OGZmNjNlODk3MjVkMDBhMi90YWJsZXJhbmdlOjc1MGIwOWMzOWE1ZjQ2Mzc4ZmY2M2U4OTcyNWQwMGEyXzItMy0xLTEtMTY3OTA4_a49af498-d0af-4b9c-8c9b-eed7ee37b98a">87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the contract liabilities balance includes increases related to customers&#8217; earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzEtMS0xLTEtMTY3OTA4_418dc22e-32d6-4bc2-97cc-a6bc40f7d5d2">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzEtMy0xLTEtMTY3OTA4_557bc92f-eaf3-4e4b-ac43-8f4d3326c786">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rewards earnings and gift card issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzMtMS0xLTEtMTY3OTA4_1271addf-255d-410e-9736-0a593bc71f4c">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzMtMy0xLTEtMTY3OTA4_918c6349-fd75-47ec-be3d-04f2cce2279d">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption and breakage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:ContractWithCustomerLiabilityRedemptionAndBreakage" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzQtMS0xLTEtMTY3OTA4_81e771f5-9183-4ce7-a2ab-b6f1b3214e78">356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:ContractWithCustomerLiabilityRedemptionAndBreakage" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzQtMy0xLTEtMTY3OTA4_6f0b1ca5-e897-478a-b151-a5db216eeabc">371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzUtMS0xLTEtMTY3OTA4_81ce14a1-b46b-41f1-9361-f93bfbc6ecc3">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzUtMy0xLTEtMTY3OTA4_b7ed0690-b1a6-4201-989c-9f3d6bd75aef">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-right:4.5pt"><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzM5_ed2a8a41-bc31-490d-b22d-d8eaa393e8e7" continuedAt="i31ef3fc466d2435dbaa69fc5940156f9" escape="true"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for cost of products sold as follows:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company&#8217;s mail service dispensing pharmacies and indirectly through the Company&#8217;s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company&#8217;s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients&#8217; benefit plans from the Company&#8217;s mail service dispensing pharmacies, net of any volume-related or other discounts (see &#8220;Vendor Allowances and Purchase Discounts&#8221; below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company&#8217;s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i31ef3fc466d2435dbaa69fc5940156f9">Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:VendorAllowancesAndPurchaseDiscountsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzA0_ef431078-e577-4a6d-9356-bf12f8ecaac1" continuedAt="i64a02af4fa8c40d79914e14c34b7a647" escape="true"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vendor Allowances and Purchase Discounts </span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for vendor allowances and purchase discounts as follows: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3e2beff4e9c7445ab9f442afae5a0cc1" continuedAt="ib6763c09af514f4f9a96468f07e9cd6c"><ix:continuation id="i64a02af4fa8c40d79914e14c34b7a647" continuedAt="if457f64a978d4b498c3401ecb8af7c0f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:PharmacyRebatePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY3OTMy_30c89a79-8ade-4fb1-b67b-9b44bbf46dfa">30</ix:nonNumeric> days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company&#8217;s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if457f64a978d4b498c3401ecb8af7c0f">Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company&#8217;s consolidated financial statements in any of the periods presented.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:HealthCareEntitiesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzU1_4db7ebf1-3c71-4986-b102-dbb239b0ab87" continuedAt="i79bf9fbcf0284fa39a870f342b2b482f" escape="true"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Reform</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Insurer Fee</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on January 1, 2014, the ACA imposed an annual premium-based health insurer fee (&#8220;HIF&#8221;) for each calendar year, payable in September, which was not deductible for tax purposes. The Company was required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was <ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="INF" name="cvs:HealthInsurerFee" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcwNjky_2f21e681-2894-4ac5-a645-8659a3521599"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="INF" name="cvs:HealthInsurerFee" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcwNjky_5eb766c5-4564-4d62-a273-8648a83fc773">no</ix:nonFraction></ix:nonFraction> expense related to the HIF in the years ended December&#160;31, 2022 and 2021. In the year ended December 31, 2020, operating expenses included $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-8" name="cvs:HealthInsurerFee" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzU0OTc1NTkwMDUzMw_86ed97c5-17fe-4b1b-99b4-869cb8ccbdf6">1.0</ix:nonFraction>&#160;billion related to the Company&#8217;s share of the HIF. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company&#8217;s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Corridor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) based on their ratio of allowable costs to target costs (as defined by the ACA). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company filed a lawsuit in August 2019 to recover the $<ix:nonFraction unitRef="usd" contextRef="i5d26d3b0edca40eb8a286991043bc26b_I20190831" decimals="-6" name="us-gaap:GainContingencyUnrecordedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcyMDcz_2ccaf3a4-c514-4a0d-a296-733a29391fbd">313</ix:nonFraction>&#160;million it was owed under the ACA&#8217;s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA&#8217;s temporary risk corridor program. </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i79bf9fbcf0284fa39a870f342b2b482f">In October 2020, the Company received the $<ix:nonFraction unitRef="usd" contextRef="i40ea54e1ccb34d709c3b44454e7262f0_D20201001-20201031" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcyNDE2_66dd82a1-9960-4859-8ee8-c975f709feb9">313</ix:nonFraction>&#160;million it was owed under the ACA&#8217;s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering offsetting items such as the ACA&#8217;s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $<ix:nonFraction unitRef="usd" contextRef="ie7a79d946b244fbe83b985e471a79655_D20200101-20201231" decimals="-6" name="cvs:FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzU0OTc1NTkwNzUxOA_cbb775e4-8d12-4ed5-8473-2ad409822586">307</ix:nonFraction>&#160;million and after-tax income of $<ix:nonFraction unitRef="usd" contextRef="ie7a79d946b244fbe83b985e471a79655_D20200101-20201231" decimals="-6" name="cvs:FormerGainContingencyRecognizedInCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcyNzU4_beec21f5-0f7f-4d58-bf2d-37f5d6560f65">223</ix:nonFraction>&#160;million during the year ended December&#160;31, 2020.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib6763c09af514f4f9a96468f07e9cd6c" continuedAt="i477eb622bf8e4e89bdb6aebe1f24b3c3"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzg4_4750fc67-b90f-4455-928e-d9d4eb07f5e8" continuedAt="if87069052b5a443e9e14d8450a168693" escape="true">Advertising Costs </ix:nonNumeric></span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if87069052b5a443e9e14d8450a168693">Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMDA1_6ee41f32-5321-4639-a806-736071add2f3">745</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMDA5_a0530eff-ac48-4cb8-a0be-e993f4986f5a">707</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMDE2_4527eb80-8bf8-471d-ab1f-8ab2b75944b4">613</ix:nonFraction> million in 2022, 2021 and 2020, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDIy_0502ff4a-1f78-45a6-8d1f-670d7640c5cc" continuedAt="i7d795d5f296842988682b4840b2c38ef" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7d795d5f296842988682b4840b2c38ef">Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMjY0_8d034ca5-401e-4526-8bb8-d8fed86877bb">three</span> to <ix:nonNumeric contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzcy_026b74eb-56d2-402d-bc2d-c3c5e3c040e0">five years</ix:nonNumeric>) using the straight-line method.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzE3_037b8108-265f-446d-93ed-2936f0596bd9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company&#8217;s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDE2_9ffd2f63-d909-4771-8ae4-4d349d46d1fb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit pension plans (&#8220;pension plans&#8221;) and other postretirement employee benefit plans (&#8220;OPEB plans&#8221;) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit income for the Company&#8217;s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time.&#160;Non-service cost components of pension and postretirement net periodic benefit income are included in other income in the consolidated statements of operations.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzgw_9bb3328b-69a7-4a2e-8de9-ad295ab0cf92" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is computed using the treasury stock method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 &#8216;&#8216;Earnings Per Share&#8217;&#8217; for additional information.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:SharesHeldInTrustPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDQ0_972e4490-0f88-4396-838e-f6bfac2b6c93" continuedAt="i887f9fb5f2d24e1d9341e204ec09447f" escape="true">Shares Held in Trust</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i887f9fb5f2d24e1d9341e204ec09447f">The Company maintains grantor trusts, which held approximately <ix:nonFraction unitRef="shares" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:TreasuryStockSharesHeldinTrust" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc2Nzkz_1dc6be3d-fb2c-4c39-9329-3a90392d77a2"><ix:nonFraction unitRef="shares" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:TreasuryStockSharesHeldinTrust" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc2Nzkz_e78c0411-c695-4607-8369-29eea9d7f7fb">one million</ix:nonFraction></ix:nonFraction> shares of its common stock at both December&#160;31, 2022 and 2021. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i477eb622bf8e4e89bdb6aebe1f24b3c3" continuedAt="idf510f75cd3240599ce5e99fa71a1a7a"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzE4_ae57165c-be70-42e9-8816-f602105dc407" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Primary Beneficiary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Company and Cardinal Health, Inc. (&#8220;Cardinal&#8221;) established Red Oak Sourcing, LLC (&#8220;Red Oak&#8221;), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own <ix:nonFraction unitRef="number" contextRef="ia397b0104e7f454a9a66b55e5fdd1a14_D20140101-20141231" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc4MDI5_188e4f95-ff4b-4b19-9c0e-2c0558998c98">50</ix:nonFraction>%. The Red Oak arrangement had an initial term of <ix:nonNumeric contextRef="ia397b0104e7f454a9a66b55e5fdd1a14_D20140101-20141231" name="cvs:InitialContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc4MDgw_44c61351-d43d-43bb-a19d-e03ffe37f145">ten years</ix:nonNumeric>. In 2021, the Red Oak arrangement was amended to extend the initial term an additional <ix:nonNumeric contextRef="i651ae9dd5f5d4e19b29b67ad25f2d822_D20210101-20211231" name="cvs:VariableInterestEntityAmendedContractExtensionTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc4MTcw_3a809760-ecc7-4dd4-b7a1-9618ef24a9ef">five years</ix:nonNumeric>, for a total term of <ix:nonNumeric contextRef="i651ae9dd5f5d4e19b29b67ad25f2d822_D20210101-20211231" name="cvs:VariableInterestEntityAmendedContractTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc4MTk0_fc3dc45b-4bbd-4155-860a-ec8e71c258bc">15</ix:nonNumeric> years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:ProceedsFromVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc5MTEy_0bf8c718-931e-426c-8273-d1b80c8e76f4"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:ProceedsFromVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc5MTEy_1f3816dc-b9f9-41a1-8188-3467b4eab093"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:ProceedsFromVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc5MTEy_a40de631-67c8-45bc-94a5-9f217a679500">183</ix:nonFraction></ix:nonFraction></ix:nonFraction> million from Cardinal during each of the years ended December&#160;31, 2022, 2021 and 2020. The payments reduce the Company&#8217;s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Other Variable Interest Holder</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hedge fund and private equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Real estate partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not the primary beneficiary of these VIEs because the nature of the Company&#8217;s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE&#8217;s income or losses in net income.&#160;The Company&#8217;s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzMw_0c5c7d2a-3dbb-4551-a6b1-066f8f985c29" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge fund investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374b0364197f455da3648efc785175d8_I20221231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzEtMS0xLTEtMTY3OTA4_34e39059-129e-481d-86c8-d9f7f1606e61">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a9c3eb37cc44017ab6afa84684e32ff_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzEtMy0xLTEtMTY3OTA4_e50e9157-ad10-4998-b87f-2dfddda2cad4">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0122d8f1aa4d48aa8ad7d46a51217f28_I20221231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzItMS0xLTEtMTY3OTA4_c84d6579-ceee-4dfc-8338-e1fe89232057">707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb39cc57c844ed0b532aa62c0a86627_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzItMy0xLTEtMTY3OTA4_8fa4a24a-d8d7-4b85-b4ac-097b9f80bf32">601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f81ec31a44f49e1b4a933ac7e20273c_I20221231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzMtMS0xLTEtMTY3OTA4_4a2c278b-46e5-4de4-a6b3-11bef344193b">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fc6318928c4432959e25e083008a4f_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzMtMy0xLTEtMTY3OTA4_c9782d7d-22d2-4cf0-ae5b-8f081949ed80">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d3dc349650457fbc2c1be5f20979d4_I20221231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzQtMS0xLTEtMTY3OTA4_40ca8791-0108-4fc5-a6c1-67de1b4e667f">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dda9edc70414970a1c368f6c420d65d_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzQtMy0xLTEtMTY3OTA4_bc7b2620-2d5f-4d8a-b350-dcd9838eeb1e">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzY0_18307a50-56c3-4748-99c7-50b05ccdecf6" continuedAt="i6750061e6e764620b0c9da6b10f024d6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in SureScripts, LLC (&#8220;SureScripts&#8221;), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNDMx_830900fa-780f-4d7a-90aa-bc9aad82ec06">60</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNDM1_b7019845-df29-4eeb-8b7f-a7f3d408e8ba">52</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNDQy_268e2c64-dbec-4975-94f9-e74eb63e111f">56</ix:nonFraction> </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idf510f75cd3240599ce5e99fa71a1a7a"><ix:continuation id="i6750061e6e764620b0c9da6b10f024d6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million in the years ended December&#160;31, 2022, 2021 and 2020, respectively. The Company&#8217;s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in Heartland Healthcare Services, LLC (&#8220;Heartland&#8221;). Heartland operates several LTC pharmacies in <ix:nonFraction unitRef="state" contextRef="ie74c8e518d644daa9a788565f2dc3c08_I20221231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNzQ3_e16f7ff7-2414-4d2d-a32d-12aaff7d8be9">four</ix:nonFraction> states. Heartland paid the Company $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNzg1_2432a6d5-a477-463f-8bb9-731ba95fe4a3">87</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNzg5_57676420-4f75-41fa-a93b-b0f177b9a563">79</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNzk2_d5b12efe-59c9-4bcc-a349-8b11480a14f2">77</ix:nonFraction> million for pharmaceutical inventory purchases during the years ended December&#160;31, 2022, 2021 and 2020, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company&#8217;s investment in and equity in the earnings of Heartland for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, the Company made charitable contributions of&#160;$<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:RelatedPartyTransactionCharitableContributionToNonProfitEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgyMjI2_f07f825a-3da6-4427-ae50-97061722fc12">25</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:RelatedPartyTransactionCharitableContributionToNonProfitEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgyMjMw_89f8dc64-d0a8-4c83-aa97-8d467e5fb0a8">50</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:RelatedPartyTransactionCharitableContributionToNonProfitEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgyMjM3_ef6c0e0e-d2de-410e-b610-47804dc46661">50</ix:nonFraction>&#160;million, respectively,&#160;to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December&#160;31, 2022, 2021 and 2020.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDQw_119ed71b-cec3-4cc7-98d4-8ffed917d986" continuedAt="i353562c80d2e4fa4a089960b6612ccfb" escape="true">Discontinued Operations</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i353562c80d2e4fa4a089960b6612ccfb">In connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens &#8216;n Things and Bob&#8217;s Stores, each of which subsequently filed for bankruptcy. The Company&#8217;s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees.</ix:continuation> See &#8220;Lease Guarantees&#8221; in Note 16 &#8216;&#8216;Commitments and Contingencies&#8217;&#8217; for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results from discontinued operations were immaterial for the years ended December 31, 2022 and 2021.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzky_ca03c773-51ae-4da2-82cd-c5796f6be6cd" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the results of discontinued operations for the year ended December 31, 2020. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1ZjM5YjllZWQxMDE0ZmMyYWFjN2M4NDA4NmM3ZGY5Yy90YWJsZXJhbmdlOjVmMzliOWVlZDEwMTRmYzJhYWM3Yzg0MDg2YzdkZjljXzEtMS0xLTEtMTY3OTA4_80a2b96e-ef86-4e96-9e23-34c5d83a85e1">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1ZjM5YjllZWQxMDE0ZmMyYWFjN2M4NDA4NmM3ZGY5Yy90YWJsZXJhbmdlOjVmMzliOWVlZDEwMTRmYzJhYWM3Yzg0MDg2YzdkZjljXzItMS0xLTEtMTY3OTA4_06b65866-9124-4005-b1a3-9924745472fb">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1ZjM5YjllZWQxMDE0ZmMyYWFjN2M4NDA4NmM3ZGY5Yy90YWJsZXJhbmdlOjVmMzliOWVlZDEwMTRmYzJhYWM3Yzg0MDg2YzdkZjljXzMtMS0xLTEtMTY3OTA4_d8bb3af5-1c4e-42eb-b46e-7165d200ca97">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzEz_f2213c3c-8c9b-44c9-9c2d-c8b914ce4b53" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Not Yet Adopted </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Insurance Contracts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board issued ASU 2018-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income (loss). The rate used to discount the Company&#8217;s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#8217;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company&#8217;s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company adopted this accounting standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented, January 1, 2021, also referred to as the transition date, for changes primarily related to the liability for future policy benefits and deferred acquisition costs. The Company is still in the process of  finalizing the impact of the new standard on its historical financial statements, but expects to record an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income on the transition date of approximately $<ix:nonFraction unitRef="usd" contextRef="ibd811ca9ceb5442fbd696e20ec9278ed_I20230101" decimals="-9" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIxOTkwMjMzNTMzNjQ_6b18cd0a-7235-4714-9e61-ea8bdc8d19c4">1</ix:nonFraction>&#160;billion as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company&#8217;s expected investment yield under the existing guidance.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzEwODQ_c65dd59f-7035-4c6c-8382-9375a7e1f9dc" continuedAt="i89fd6c6bd4c142b0b0e2b279f1a5ceb8" escape="true">Acquisitions, Divestitures and Asset Sales</ix:nonNumeric></span></div><div style="text-indent:-9pt"><span><br/></span></div><ix:continuation id="i89fd6c6bd4c142b0b0e2b279f1a5ceb8" continuedAt="ie4dc5eae85194d7fb76c5fd40ba12ede"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed Oak Street Health Acquisition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, the Company entered into a definitive merger agreement to acquire all of the outstanding shares of Oak Street Health, Inc. (&#8220;Oak Street Health&#8221;) for cash. Under the terms of the merger agreement, Oak Street Health stockholders will receive $<ix:nonFraction unitRef="usdPerShare" contextRef="i5acb58a875864a49b737f2cb40ddee47_I20230207" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzk4OTU2MDQ2Nzg2ODE_9b84613e-cc05-40ba-ba6e-48b7cc289835">39.00</ix:nonFraction> per share in cash. The total value of the transaction is approximately $<ix:nonFraction unitRef="usd" contextRef="ia4dd0513fdda4dfdb136f1594d393298_D20230207-20230207" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzk4OTU2MDQ2Nzg2ODk_9410eaa4-5eed-47cb-9226-8e79ef4f4b46">10.6</ix:nonFraction>&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proposed acquisition was approved by the Board of Directors at each of the respective companies and is subject to approval by a majority of Oak Street Health stockholders, receipt of regulatory approval and satisfaction of other customary closing conditions, including the expiration of the waiting period under the federal Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the merger agreement is terminated under certain specified circumstances and receipt of regulatory approval has not been obtained by such time, the Company will be required to pay Oak Street Health a termination fee of approximately $<ix:nonFraction unitRef="usd" contextRef="i5acb58a875864a49b737f2cb40ddee47_I20230207" decimals="-6" name="cvs:BusinessCombinationTerminationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzk4OTU2MDQ2Nzg3MDQ_2304f264-6108-4976-acfe-8062ea7c2589">500</ix:nonFraction>&#160;million. If the merger agreement is terminated under other certain specified circumstances, including due to Oak Street Health accepting a superior proposal, Oak Street Health will be required to pay the Company a termination fee of approximately $<ix:nonFraction unitRef="usd" contextRef="i5afb8727270f42b8ade9125cb3443778_I20230207" decimals="-6" name="cvs:BusinessCombinationTerminationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzk4OTU2MDQ2Nzg3MTg_2aa94558-2844-4a40-bafc-119399e573f7">300</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending Signify Health Acquisition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2022, the Company entered into a definitive merger agreement to acquire all of the outstanding shares of Signify Health, Inc. (&#8220;Signify Health&#8221;) for cash. Under the terms of the merger agreement, Signify Health stockholders will receive $<ix:nonFraction unitRef="usdPerShare" contextRef="i1773809e56854492867bb26fea3c6b89_I20220902" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTE5NA_808b180a-bb54-4f12-8ac4-72623e85bdad">30.50</ix:nonFraction> per share in cash. The total value of the transaction is approximately $<ix:nonFraction unitRef="usd" contextRef="i742e5d3d548546f4a2efaf4d89ecd9d1_D20220902-20220902" decimals="-9" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTIwMg_7d1bdfd9-c6f8-4231-bf77-3743ffbc1725">8</ix:nonFraction>&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pending acquisition was approved by the Board of Directors at each of the respective companies and the Signify Health stockholders and remains subject to receipt of regulatory approval and satisfaction of other customary closing conditions. On October 19, 2022, Signify Health and CVS Health each received a request for additional information (also known as a &#8220;second request&#8221;) from the U.S. Department of Justice (the &#8220;DOJ&#8221;) in connection with the review of the transactions contemplated by the merger agreement by the DOJ under the federal Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in the second quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the merger agreement is terminated under certain specified circumstances and receipt of regulatory approval has not been obtained by such time, the Company will be required to pay Signify Health a termination fee in an amount equal to $<ix:nonFraction unitRef="usd" contextRef="i1773809e56854492867bb26fea3c6b89_I20220902" decimals="-6" name="cvs:BusinessCombinationTerminationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTIxNA_f6872050-da5b-4341-88d1-51a1a49f3864">380</ix:nonFraction>&#160;million. If the merger agreement is terminated under other certain specified circumstances, including due to Signify Health accepting a superior proposal, Signify Health will be required to pay the Company a termination fee in an amount equal to $<ix:nonFraction unitRef="usd" contextRef="i2f859fc0dd5e47f0a5e763378f21729e_I20220902" decimals="-6" name="cvs:BusinessCombinationTerminationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTIyOA_503341b5-23b2-4e71-bfad-7a88351024ca">228</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its Omnicare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> long-term care business (&#8220;LTC business&#8221;), which is included within the Retail/LTC segment, was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria to be classified as held for sale and the carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell. Accordingly, the Company recorded a loss on assets held for sale of $<ix:nonFraction unitRef="usd" contextRef="i2bf59ea1890f4d16a13351da96cf6411_D20220701-20220930" decimals="-8" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzEwOTk1MTE2Mjk3ODY1_60aafa87-5f2c-4345-b2fa-37ff4b4c7a54">2.5</ix:nonFraction> billion during the third quarter of 2022. As of December&#160;31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter, an incremental loss on assets held for sale of $<ix:nonFraction unitRef="usd" contextRef="i0d7bd61bc8784946b9cec8dcc1fcb6b8_D20221001-20221231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzEwOTk1MTE2Mjk3Nzkx_015c4f3a-1295-4738-a284-f09640c8b02d">12</ix:nonFraction> million was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. The loss on assets held for sale represents the write-down of its customer contracts/relationships intangible assets and was recorded in the Company&#8217;s consolidated statement of operations within the Retail/LTC segment. The LTC business operating income was not material for the years ended December&#160;31, 2022, 2021 and 2020.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie4dc5eae85194d7fb76c5fd40ba12ede" continuedAt="i6456f61b9de64710aa622cd1ce42e0e3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LTC business met the criteria to be classified as held for sale at December&#160;31, 2022, but did not meet the criteria to be classified as discontinued operations. As a result, the related assets and liabilities were included in separate held-for-sale line items of the asset and liability sections of the consolidated balance sheet. As the assets held for sale are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, they are classified in Level 3 of the fair value hierarchy. <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzY1OTcwNjk3ODQyNzA_751a9a3a-0c88-44a7-b3e1-fdd3be61b4eb" continuedAt="i5d642ffb742b46628eda6db292a302d4" escape="true">The following table summarizes the assets and liabilities held for sale at December&#160;31, 2022:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i5d642ffb742b46628eda6db292a302d4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzItMS0xLTEtMjA4NDEx_e2ac0fb3-7a09-4d51-bdbd-a99208d93ba5">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzMtMS0xLTEtMjA4NDEx_623dd2ce-128a-444b-b5d7-ca6e7086c0d4">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzQtMS0xLTEtMjA4NDEx_36adbc2d-5210-47be-8ad0-cce5182d9d69">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzYtMS0xLTEtMjA4NDE0_13601ae1-b4be-4c55-95a3-3597e6236d14">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzctMS0xLTEtMjA4NDE0_01b9f58f-8fb6-4f5a-abc0-d897a30a8217">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzgtMS0xLTEtMjA4NDE0_b4f7d29a-9c45-4972-9d76-2f70c8d68fcd">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzExLTEtMS0xLTIwODQxNg_ca2b73fb-1a85-47b1-862f-5d911f9d4791">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzEyLTEtMS0xLTIwODQxNg_c18420e5-e33f-4167-bc1c-a94dea115b49">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzEzLTEtMS0xLTIwODQxNg_615ece20-7a7b-40ec-bdae-58ac6f8278cc">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzE0LTEtMS0xLTIwODQxNg_6be42021-c716-445d-89c7-564fb4166aae">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of bswift</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company sold its wholly-owned subsidiary bswift LLC (&#8220;bswift&#8221;) for approximately $<ix:nonFraction unitRef="usd" contextRef="i96e78b501bc842a2affc4033fa4a4eb3_D20221101-20221130" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgzMTkxMw_00f0c47e-5db3-458b-8d76-5db93ddca001">735</ix:nonFraction> million. bswift offers software and services that streamline benefits and human resource administration. The results of this business have historically been recorded within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $<ix:nonFraction unitRef="usd" contextRef="ie6fc4ecb20e54148beb244c5579a6256_D20220101-20221231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzgyNDYzMzcyMjU5Nzg_685540d1-2771-4f68-a990-ef2283510580">250</ix:nonFraction>&#160;million in the year ended December&#160;31, 2022, which is reflected as a reduction of operating expenses in the Company&#8217;s consolidated statement of operations within the Health Care Benefits segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of PayFlex </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company sold PayFlex for approximately $<ix:nonFraction unitRef="usd" contextRef="i879da25a180b4cf6b770b94022fe1214_D20220601-20220630" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzY1OTcwNjk3ODQyODU_a2203efb-bd40-48a6-8e48-4e95619e8d65">775</ix:nonFraction>&#160;million. PayFlex provides services to employers, their employees, and their former employees in the areas of tax-advantaged account reimbursement administration (flexible spending, health reimbursement, health savings, transit and parking), Consolidated Omnibus Budget Reconciliation Act (&#8220;COBRA&#8221;) administration and special-member billing administration. The results of this business have historically been reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $<ix:nonFraction unitRef="usd" contextRef="i9d6c8114b5924bed84e9fc58f5696afd_D20220101-20221231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzY1OTcwNjk3ODQyOTk_cae29cd3-6165-49f1-9e2b-fabe9d0f045a">225</ix:nonFraction>&#160;million in the year ended December&#160;31, 2022, which is reflected as a reduction of operating expenses in the Company&#8217;s consolidated statement of operations within the Health Care Benefits segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Thailand Health Care Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company reached an agreement to sell its international health care business domiciled in Thailand (&#8220;Thailand business&#8221;), comprised of approximately <ix:nonFraction unitRef="member" contextRef="id8c3596e68a249cf9f084af72dd00f23_I20220331" decimals="-3" name="cvs:NumberOfMedicalMembers" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTQwMw_eacf964d-1500-4bb0-97b0-ecbc1ffa5cfe">266,000</ix:nonFraction> medical members, which was included in the Commercial Business reporting unit within the Health Care Benefits segment. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and, accordingly, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i36ec68c9bde84569ae25dc7eda071a52_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzIxOTkwMjMyNzIwODk_79e8ff0b-ba73-41a4-a5f0-f9193084f6ae"><ix:nonFraction unitRef="usd" contextRef="i29b0f113479a4ec0b9e699b726fa4b6b_D20220101-20220331" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzIxOTkwMjMyNzIwODk_d462afec-ce6c-4621-b0fe-43c753069877">41</ix:nonFraction></ix:nonFraction> million loss on assets held for sale within the Health Care Benefits segment during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the consideration received and ultimate loss on the sale were not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Workers&#8217; Compensation Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company sold its Workers&#8217; Compensation business for approximately $<ix:nonFraction unitRef="usd" contextRef="i674eb260757d402f9e56019767496299_D20200731-20200731" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzE1NQ_d77bca59-8f57-4e26-8847-56448d1d9886">850</ix:nonFraction>&#160;million. The results of this business were reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $<ix:nonFraction unitRef="usd" contextRef="i3fa94d302f25457a8ffe0851c4d7bf19_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgxNDk5Mw_b2da0313-2750-4c54-a1df-85b4bd095ccc">269</ix:nonFraction> million in the year ended December&#160;31, 2020, which is reflected as a reduction in operating expenses in the Company&#8217;s consolidated statement of operations within the Health Care Benefits segment.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6456f61b9de64710aa622cd1ce42e0e3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Health Care Benefits Renewal Rights Asset Sale</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company sold the renewal rights of approximately <ix:nonFraction unitRef="member" contextRef="i779c59619b9643cbb118540ac3605d26_I20220531" decimals="-3" name="cvs:DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzEwOTk1MTE2Mjk3MDMw_20c8bb2a-2847-4db5-98e9-bcf86a211f98">200,000</ix:nonFraction> international medical members outside of the Americas, Thailand and India in connection with an Asset Purchase Agreement. As part of this agreement, the Company will introduce and help migrate these existing international medical members to the purchaser upon renewal. The Company expects the migration process to occur between July 2022 and November 2023. The Company ceased writing any new or renewal business for international medical members outside of the Americas during the fourth quarter of 2022. The consideration received related to this agreement was not material.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MDY_913a4050-8941-4544-bd92-83cdb48a5381" continuedAt="i01c7afb1ed89462e8c899b36ec61ee34" escape="true">Investments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i01c7afb1ed89462e8c899b36ec61ee34" continuedAt="i95f275a1720448f5b33887a61658238d"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:TotalInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MDE_38d151d7-8bfb-4c20-878c-55e99710527a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717e63c6c0e941a3ab348dc4fa490a30_I20221231" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItMS0xLTEtMTY3OTA4_d9bf7818-c12a-4593-8c01-e922d406c3a2">2,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717e63c6c0e941a3ab348dc4fa490a30_I20221231" decimals="-6" name="cvs:LongTermInvestmentsIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItMy0xLTEtMTY3OTA4_8210c72f-6c2a-4661-9b4c-127893689852">17,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717e63c6c0e941a3ab348dc4fa490a30_I20221231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItNS0xLTEtMTY3OTA4_4ee5a045-762e-42a2-9d07-a07968cf927b">20,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a45d333346c4b16814c08207dbd06b8_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItNy0xLTEtMTY3OTA4_72c1138d-f899-4916-be2e-a1edd4c2537c">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a45d333346c4b16814c08207dbd06b8_I20211231" decimals="-6" name="cvs:LongTermInvestmentsIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItOS0xLTEtMTY3OTA4_62a74890-8b80-4dd8-9219-7b3e46c88553">20,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a45d333346c4b16814c08207dbd06b8_I20211231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItMTEtMS0xLTE2NzkwOA_15926d97-f05a-4d6a-a9d4-3d8b16c8d66f">23,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de346073b1b4e83be2a8d87564b444d_I20221231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtMS0xLTEtMTY3OTA4_cfdd15e8-8ae5-400e-a45f-076b1b71c733">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de346073b1b4e83be2a8d87564b444d_I20221231" decimals="-6" name="cvs:LongTermInvestmentsIncludingAssetsHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtMy0xLTEtMTY3OTA4_5307740f-dad7-4528-8f68-85486fa6fab2">989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de346073b1b4e83be2a8d87564b444d_I20221231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtNS0xLTEtMTY3OTA4_bb75b304-f52b-4de7-9a07-a78d97d5a003">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb1627c01b1430080b3f6a0a40addeb_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtNy0xLTEtMTY3OTA4_7f50cae5-4e9f-4230-94cd-256869574960">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb1627c01b1430080b3f6a0a40addeb_I20211231" decimals="-6" name="cvs:LongTermInvestmentsIncludingAssetsHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtOS0xLTEtMTY3OTA4_085ba161-6c94-4c9e-bdb2-95adc8ed0a39">844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb1627c01b1430080b3f6a0a40addeb_I20211231" decimals="-6" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtMTEtMS0xLTE2NzkwOA_028ce5ac-c52b-4347-9004-d436dcb6aa41">902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7bc5f7c69e7441cb31da4729c7de4bc_I20221231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtMS0xLTEtMTY3OTA4_2c542c01-44cd-4d46-b928-744397c4deb7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7bc5f7c69e7441cb31da4729c7de4bc_I20221231" decimals="-6" name="cvs:LongTermInvestmentsIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtMy0xLTEtMTY3OTA4_037907a1-b292-495e-9ec1-c3bcf072bc28">2,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7bc5f7c69e7441cb31da4729c7de4bc_I20221231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtNS0xLTEtMTY3OTA4_672553cd-a778-4760-93ee-1962ba6631cb">2,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdbc67676d794d47817f10d53a42b996_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtNy0xLTEtMTY3OTA4_5e3e4750-eacd-4a6a-b5ce-faa53bd3cb80">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdbc67676d794d47817f10d53a42b996_I20211231" decimals="-6" name="cvs:LongTermInvestmentsIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtOS0xLTEtMTY3OTA4_50ced201-8f18-4cfa-9d8f-7636fe5f921b">1,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdbc67676d794d47817f10d53a42b996_I20211231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtMTEtMS0xLTE2NzkwOA_db5c92bd-57a4-4314-ab83-3fa963508e39">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtMS0xLTEtMTY3OTA4_0ab17696-3e19-41c8-8193-de22d35764ea">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LongTermInvestmentsIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtMy0xLTEtMTY3OTA4_10c62bbe-d31e-4a71-b076-4bea0f1975d4">21,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtNS0xLTEtMTY3OTA4_e1d33416-2fd5-48aa-9e26-cc2acdfe8f4b">23,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtNy0xLTEtMTY3OTA4_7a0eb3a6-886b-4e3b-aa61-be4cf3a6fb56">3,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:LongTermInvestmentsIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtOS0xLTEtMTY3OTA4_9979c923-dcf1-43b7-bd04-f775de99627d">23,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtMTEtMS0xLTE2NzkwOA_659d8b85-a8df-46b0-b116-9d5b499c92db">26,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term investments of $<ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="cvs:LongTermInvestmentsIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzIxOTkwMjMyNjgxMzE_ea0d5ad1-86b9-49ce-b52e-42e689adaa82">17</ix:nonFraction>&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div></ix:nonNumeric><div style="padding-left:13.5pt;text-indent:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company held investments of $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:RestrictedInvestmentsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzEzMw_807071d6-3ca1-4a25-9fd0-b08c774d0752">331</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:RestrictedInvestmentsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzE0MA_e0e230b7-4240-4c0d-b6ab-4612a10fb384">450</ix:nonFraction> million, respectively, related to the 2012 conversion of an existing group annuity contract from a participating to a non-participating contract. These investments are included in the total investments of large case pensions supporting non-experience-rated products. Although these investments are not accounted for as Separate Accounts assets, they are legally segregated and are not subject to claims that arise out of the Company&#8217;s business and only support future policy benefits obligations under that group annuity contract. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MTU_81803ca1-82b0-40be-a7c4-2890e2462812" continuedAt="i914f31523e6d4ac0b9ef3a70cc466b8d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available for sale at December&#160;31, 2022 and 2021 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Amortized <br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allowance<br/>for Credit<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Amortized<br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtNS0xLTEtMTY3OTA4_ea53e0ef-7343-4266-8fda-5a8d33037080">2,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtNy0xLTEtMTk5OTkz_bfc213bb-6f7c-41f9-adc3-1bccfe948bd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtOS0xLTEtMTk5OTkz_832ff0d2-7962-450e-b466-80ea94a6883b">2,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtNy0xLTEtMTY3OTA4_a76f2e3b-21b7-4c9e-9073-0e8ad3235872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtOS0xLTEtMTY3OTA4_74ba6270-870f-4e4e-b495-b054824dff4a">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtMTEtMS0xLTE2NzkwOA_b35fb7dd-49e8-4fb4-8b9d-14fb11464558">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtNS0xLTEtMTY3OTA4_f89eb6c8-41df-49f8-b47e-4a6adc0edba9">2,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtNy0xLTEtMTk5OTkz_b0e6f09e-a9f1-4bf6-906c-e968899d0f82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtOS0xLTEtMTk5OTkz_a580d5e9-c3d2-4c60-bec5-e28d2cc1c67a">2,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtNy0xLTEtMTY3OTA4_d9a816db-46cf-42df-a7b8-46fb28fe0402">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtOS0xLTEtMTY3OTA4_6caa4e79-f1f9-48d7-8ad4-61db9d88a25f">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtMTEtMS0xLTE2NzkwOA_46f48520-bf86-4d41-b781-fe99202d405d">2,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtNS0xLTEtMTY3OTA4_278c6373-c43e-4b08-8429-b42897df269c">9,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtNy0xLTEtMTk5OTkz_97d0de34-90f7-41cb-b1b7-b8ff5ea22e5f">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtOS0xLTEtMTk5OTkz_68256bad-14a7-4518-8530-17d5f02aa9ab">9,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtNy0xLTEtMTY3OTA4_45fd548c-a217-4d42-b7c1-66dbea8eec89">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtOS0xLTEtMTY3OTA4_f707ec90-b9f9-414d-aaee-e513926f925e">903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtMTEtMS0xLTE2NzkwOA_56538c6a-cc71-49c3-bddc-882b7621451b">8,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtNS0xLTEtMTY3OTA4_4c2c6a2c-fa35-4be4-8504-c94961180330">2,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtNy0xLTEtMTk5OTkz_2d644779-1020-428c-b118-f5615ee487b3">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtOS0xLTEtMTk5OTkz_60f200d6-0a4b-40be-b461-bad47020cbe0">2,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtNy0xLTEtMTY3OTA4_922121ce-0ca8-4942-9f62-4b208149250b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtOS0xLTEtMTY3OTA4_1fdb70ab-1efc-4364-be0a-f47aac63f49d">244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtMTEtMS0xLTE2NzkwOA_9e8d8473-1c09-4032-a980-23e713eade3c">2,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctNS0xLTEtMTY3OTA4_952492e6-537e-4d28-8736-d930d7f7c435">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctNy0xLTEtMTk5OTkz_8226cb7e-6fc4-4dfc-a078-b58768cb4b5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctOS0xLTEtMTk5OTkz_82fc1812-ff36-49d2-a5a8-20187e2bc81b">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctNy0xLTEtMTY3OTA4_81fef57c-72ee-4af3-a31f-e8273419b126">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctOS0xLTEtMTY3OTA4_64e2eb06-01c4-4580-9ca2-bca6829a76e0">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctMTEtMS0xLTE2NzkwOA_8a8b1d54-245f-4d90-a5a4-3d322197c083">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtNS0xLTEtMTY3OTA4_6e0c235f-1a5c-4106-b519-adcbcac538fa">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtNy0xLTEtMTk5OTkz_6a0f71e8-e705-4030-a3d0-583a2efb38ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtOS0xLTEtMTk5OTkz_b773927e-0bd7-4c54-a430-e7b54c4a70d7">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtNy0xLTEtMTY3OTA4_c1e6b5bb-f755-4642-8849-2dc24ea511eb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtOS0xLTEtMTY3OTA4_57d6ec0f-60c3-4c10-bc7f-a31561731635">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtMTEtMS0xLTE2NzkwOA_6a7af3e4-b70c-4c84-beb0-1fdaa3bf49d8">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktNS0xLTEtMTY3OTA4_9217b0d0-42b5-431b-90b9-4e48f7fb87c3">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktNy0xLTEtMTk5OTkz_a62f7468-de02-482b-aa0f-b585338f5efa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktOS0xLTEtMTk5OTkz_215e5f1b-a6f8-4f7f-97fe-790f1d42cbd3">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktNy0xLTEtMTY3OTA4_a43afeb4-1432-4a33-ba97-a068ab6f0511">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktOS0xLTEtMTY3OTA4_9ac3a060-8f56-40f4-8624-3c82eaac87d3">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktMTEtMS0xLTE2NzkwOA_d4d3780f-05d9-4575-b1f8-3b640a4479d9">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTUtMS0xLTE2NzkwOA_a54fd348-82b6-43db-8ac5-223485e694cb">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTctMS0xLTE5OTk5Mw_f2b52267-bbbb-45fd-8f9d-7f1ff6f44332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTktMS0xLTE5OTk5Mw_779bab5a-cb47-4534-a528-eda1e0c0b7d4">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTctMS0xLTE2NzkwOA_7d1a936d-4ad0-4fbd-84bb-38a546c27990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTktMS0xLTE2NzkwOA_8ca1b4d8-d9ac-4aa2-9d02-f19e64c92853">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTExLTEtMS0xNjc5MDg_4e639371-49b4-41d7-84b7-b1ff947cd83a">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTUtMS0xLTE2NzkwOA_332b4128-3320-4dc4-b884-aa33e6301743">22,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTctMS0xLTIwMDAwMw_a3922f20-28ca-4e6a-93b9-c0472237cbe9">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTktMS0xLTIwMDAwMw_4b478252-c4b0-4772-91c4-e7913f8b1ecf">22,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTctMS0xLTE2NzkwOA_2df7c34f-0478-4239-bd84-c4e740678de8">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTktMS0xLTE2NzkwOA_86a7030a-6825-4564-89b2-2b2e84d5e1dd">1,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTExLTEtMS0xNjc5MDg_f83a6067-91b9-49dd-a4f3-fc81a1481f58">20,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTUtMS0xLTE2NzkwOA_ebbeca85-64e9-40ad-9109-39c6fbd82581">2,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTctMS0xLTIwMDAzMA_e27c1d19-39d9-48b0-a507-f80681cd9e30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTktMS0xLTIwMDAzMA_00792f1b-0fbd-4f50-b3b6-d3cf22ab7c45">2,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTctMS0xLTE2NzkwOA_39134485-4e3d-4ef4-af2e-76885990dff8">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTktMS0xLTE2NzkwOA_7ad73e4a-bda2-4fc5-b8cb-2ec0d174fdf9">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTExLTEtMS0xNjc5MDg_906e3236-8999-4cdd-9f99-a61800a61611">2,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTUtMS0xLTE2NzkwOA_2662b091-1b87-43d8-a94c-e213dd4a721e">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTctMS0xLTIwMDAzMA_5920a4a1-384f-45c7-b3b7-a79e6714c2ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTktMS0xLTIwMDAzMA_171b51a6-0ac6-46ad-aa51-2f721f3235da">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTctMS0xLTE2NzkwOA_1450b3cb-f21b-4dca-97e8-da2928d27bf1">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTktMS0xLTE2NzkwOA_954c7870-6a95-4634-a593-3f8851804f33">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTExLTEtMS0xNjc5MDg_668ddcc5-5963-4ea9-87f4-c2a315972267">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTUtMS0xLTE2NzkwOA_fa2bafc2-fb01-4a94-926d-8b51bfd1e772">9,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTctMS0xLTIwMDAzMA_0ff62898-e4d6-4851-beea-588f77c8b9a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTktMS0xLTIwMDAzMA_fb0a7703-f3b3-4a8d-b477-d6f241dab89a">9,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTctMS0xLTE2NzkwOA_6a84ac6f-06a8-42e7-8272-7024ccfd9455">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTktMS0xLTE2NzkwOA_071e0971-ea5d-4d51-8ad0-446dcab6d59c">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTExLTEtMS0xNjc5MDg_069ab895-346b-4797-9f85-d8f66d722875">9,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTUtMS0xLTE2NzkwOA_434be7a9-2e32-41a6-8a79-cf23b129dc07">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTctMS0xLTIwMDAzMA_94d27b97-c295-4c18-8191-aff1b1fede57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTktMS0xLTIwMDAzMA_13b462b2-f3cb-4520-9a9e-718b36b51182">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTctMS0xLTE2NzkwOA_2ce72cee-881e-4896-9d4f-122a0833bd43">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTktMS0xLTE2NzkwOA_6c207f9b-6f8c-4ea9-a5fe-b23bb1cedc37">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTExLTEtMS0xNjc5MDg_eb5c4dec-38a4-4b10-90a5-8511de199063">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTUtMS0xLTE2NzkwOA_81f48214-1f9c-41d3-b23a-30df4adf6290">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTctMS0xLTIwMDAzMA_3bb85cca-c500-43ba-b618-03ca26130ca3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTktMS0xLTIwMDAzMA_2b3b2061-cd8d-49cd-aa93-8448d51f79f4">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTctMS0xLTE2NzkwOA_e5c6da22-d987-4f0a-a099-5c91187f3726">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTktMS0xLTE2NzkwOA_802715ee-709f-49b9-9169-3db2252ceb93">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTExLTEtMS0xNjc5MDg_77cf007b-2bc5-43eb-9525-a75883972f0c">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTUtMS0xLTE2NzkwOA_68c114aa-76bc-4c68-b26b-dfd644437737">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTctMS0xLTIwMDAzMA_cf09fadd-6f0c-421a-9c7c-ddd9b676b253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTktMS0xLTIwMDAzMA_de31f18d-8e84-472a-95ef-42ccbd960038">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTctMS0xLTE2NzkwOA_00fc9052-9d2c-4aac-a705-571d2b414a6d">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTktMS0xLTE2NzkwOA_e1769293-bcbe-408a-a0f4-07e9cb52b957">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTExLTEtMS0xNjc5MDg_2c4e2dab-fc81-4018-82dc-38f81035b72a">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTUtMS0xLTE2NzkwOA_400d84cc-73c7-4ca7-9822-59a296bd8fb1">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTctMS0xLTIwMDAzMA_bd207022-1717-4568-8a0f-2b88fee37615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTktMS0xLTIwMDAzMA_bb011473-5d53-4cb2-a69c-22eaadd888b5">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTctMS0xLTE2NzkwOA_c8f7c5ea-466f-43c6-8232-24f72749bb41">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTktMS0xLTE2NzkwOA_bdee02f7-123a-4fb3-a006-509421554409">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTExLTEtMS0xNjc5MDg_8bc68a84-eb6d-466f-a62a-94bb5e2a8a17">2,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTUtMS0xLTE2NzkwOA_8c6095d4-7263-408e-9d31-eccddc267839">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTctMS0xLTIwMDAzMA_e39dac0a-0a7a-4f7f-b99f-2ffe2b1237d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTktMS0xLTIwMDAzMA_17acdb91-8b1a-46e2-b9e2-35f1f60bfba7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTctMS0xLTE2NzkwOA_715c35aa-d345-4cc4-b599-dd785c153827">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTktMS0xLTE2NzkwOA_5ca898bf-3340-463f-b58a-ddeb6fce3cf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTExLTEtMS0xNjc5MDg_42d2b457-3e28-4cc5-a74f-38b792fc8d18">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTUtMS0xLTE2NzkwOA_e36c6736-5887-45b1-9be6-90cb3fea95e2">22,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTctMS0xLTIwMDAzMA_6563dda0-ee6b-4e7c-ac11-8c37b2dcfac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTktMS0xLTIwMDAzMA_60a5ba5e-3cc6-40a5-9888-baf754438e27">22,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTctMS0xLTE2NzkwOA_76acce54-4473-4f3d-a4b0-10f8a698a193">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTktMS0xLTE2NzkwOA_f7b39ac8-69a1-4337-b608-e13c66d1880f">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTExLTEtMS0xNjc5MDg_82590d2c-d981-449c-b7ff-4fd4fbe4e55f">23,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Investment risks associated with the Company&#8217;s experience-rated products generally do not impact the Company&#8217;s consolidated operating results.&#160;At December&#160;31, 2022, debt securities with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzExMDE_1fab81c2-69e9-453f-9aeb-69c2112c3005">609</ix:nonFraction> million, gross unrealized capital gains of $<ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzExMzk_8a856ce2-f877-4cbe-8399-72e4bcb26faa">3</ix:nonFraction> million and gross unrealized capital losses of </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i95f275a1720448f5b33887a61658238d" continuedAt="ic735ee4139fb484e931c48ed407a663a"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i914f31523e6d4ac0b9ef3a70cc466b8d">$<ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzExODE_e0240f5d-2d85-44d4-8dca-0853778f3181">59</ix:nonFraction> million, and at December&#160;31, 2021, debt securities with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i628bda68e4a846798004771ed7fa1e30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzEyMzI_5e985741-3181-49aa-9d72-07b426d73842">864</ix:nonFraction> million, gross unrealized capital gains of $<ix:nonFraction unitRef="usd" contextRef="i628bda68e4a846798004771ed7fa1e30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzEyNzA_ba7e78e5-a283-47a8-985a-d79adf866568">94</ix:nonFraction> million and gross unrealized capital losses of $<ix:nonFraction unitRef="usd" contextRef="i628bda68e4a846798004771ed7fa1e30_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzEyNzc_eb6d1c85-83c4-4785-986a-382bb8c91f5c">2</ix:nonFraction> million were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income (loss).</ix:continuation></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MDI_322b0e87-8c79-47d1-b855-7bdcddeacde3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of debt securities at December&#160;31, 2022 are shown below by contractual maturity.&#160;Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzItMS0xLTEtMTY3OTA4_020fc357-d7a8-44b4-acaa-329c35fd29dd">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzItMy0xLTEtMTY3OTA4_ae81c728-4d5c-4670-8d1c-5cb60be8efa9">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzMtMS0xLTEtMTY3OTA4_a9314e8b-363c-40ba-b178-aad6fa438939">6,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzMtMy0xLTEtMTY3OTA4_8e7505db-f691-4441-8c14-5184f1582a8c">6,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzQtMS0xLTEtMTY3OTA4_eee2ee53-24ba-4e5b-b2a1-ae0600139a75">4,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzQtMy0xLTEtMTY3OTA4_6707e0f9-4f0d-4952-b93b-f76e230acb92">4,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzUtMS0xLTEtMTY3OTA4_ca9d2edb-0b89-4093-b6e9-ae19de265e1a">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzUtMy0xLTEtMTY3OTA4_60f97a53-af1c-4946-8cd7-dca0ff0989e5">3,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzYtMS0xLTEtMTY3OTA4_93d7b0ef-eb06-4866-a57b-dc5bd8f9df33">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzYtMy0xLTEtMTY3OTA4_00a47223-2f39-4e8b-b979-724c14e22cfc">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzctMS0xLTEtMTY3OTA4_f54488a1-da6b-4b45-9202-9ffd7f17d4cd">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzctMy0xLTEtMTY3OTA4_3dda8789-f9da-47e2-85b2-5c9725e3d47c">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzgtMS0xLTEtMTY3OTA4_602577a1-c36a-44d8-9e00-348f8e368dec">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzgtMy0xLTEtMTY3OTA4_5e50d0df-213e-4215-a693-dad62a9ce16b">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzktMS0xLTEtMTY3OTA4_96687db6-7735-4e5c-9afd-3837641d6c65">22,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzktMy0xLTEtMTY3OTA4_cb33caab-6595-475f-9e8d-e591688012a8">20,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage-Backed and Other Asset-Backed Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s residential mortgage-backed securities at December&#160;31, 2022 were issued by the Government National Mortgage Association, the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation and carry agency guarantees and explicit or implicit guarantees by the U.S. Government.&#160;At December&#160;31, 2022, the Company&#8217;s residential mortgage-backed securities had an average credit quality rating of AAA and a weighted average duration of <ix:nonNumeric contextRef="id3def4d721b4452a9745ed4ff29dd91f_D20220101-20221231" name="cvs:DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzIyOTU_7f4f3a2c-a603-4953-a8e8-9848796da05b">5.7</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commercial mortgage-backed securities have underlying loans that are dispersed throughout the United States. Significant market observable inputs used to value these securities include loss severity and probability of default.&#160;At December&#160;31, 2022, these securities had an average credit quality rating of AAA and a weighted average duration of <ix:nonNumeric contextRef="i7ae5d28fdba744f89bd9b16b1f10ec56_D20220101-20221231" name="cvs:DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzI2NDM_4494d97d-d458-451f-b787-43c3aab51638">5.6</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s other asset-backed securities have a variety of underlying collateral (e.g., automobile loans, credit card receivables, home equity loans and commercial loans). Significant market observable inputs used to value these securities include the unemployment rate, loss severity and probability of default.&#160;At December&#160;31, 2022, these securities had an average credit quality rating of AA and a weighted average duration of <ix:nonNumeric contextRef="ia58f18f7922d480dbb9758608a9e7dd8_D20220101-20221231" name="cvs:DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzMwNjY_b37e5821-ca7d-4d96-9830-be0878d886ff">1.0</ix:nonNumeric> year.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic735ee4139fb484e931c48ed407a663a" continuedAt="if477ce169dfc40bb9c2d79240d7c1907"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MjY_be633d1d-e92b-48be-95c8-af25a8af5dda" continuedAt="i3b548f86febe4364a38b6fd918cc85cf" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the debt securities the Company held at December&#160;31, 2022 and 2021 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except number of securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMS0xLTEtMTY3OTA4_55ba085f-c372-4537-9bd8-72475ea51984">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMy0xLTEtMTY3OTA4_b22acc9c-6dd2-4115-b3c0-f0d585b9229e">1,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtNS0xLTEtMTY3OTA4_ef6b7d6d-8329-4738-93d0-d502d8f38773">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtNy0xLTEtMTY3OTA4_965961af-52af-412f-9d6b-836a7679a034">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtOS0xLTEtMTY3OTA4_c5e91240-e9eb-4449-a655-702b2ca7b228">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMTEtMS0xLTE2NzkwOA_4635f346-6960-4d2d-a3fd-23fb8a45bac2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMTMtMS0xLTE2NzkwOA_07fd97cf-4ade-47cf-a3ac-03963678ce61">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMTUtMS0xLTE2NzkwOA_e3ed8082-7321-4036-8ba5-d3db19e465a9">1,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMTctMS0xLTE2NzkwOA_17025096-8923-4c75-b907-f5795a10f702">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMS0xLTEtMTY3OTA4_bd5dc37b-a288-4e93-8a1c-1c785c2fab98">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMy0xLTEtMTY3OTA4_6177e0e2-3ddd-4dd6-910c-d1955895e566">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtNS0xLTEtMTY3OTA4_ef6790c4-3fe4-4383-a399-7e357cfb4ccb">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtNy0xLTEtMTY3OTA4_1d7c5b5f-13d2-454a-b57a-f7d280e7d947">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtOS0xLTEtMTY3OTA4_cc68d991-d843-4197-b797-9d04b3082e4b">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMTEtMS0xLTE2NzkwOA_1d3a9bfd-942d-4dda-a704-ac8030106d97">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMTMtMS0xLTE2NzkwOA_ac03c805-43fb-422a-93bb-c93043b32a9a">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMTUtMS0xLTE2NzkwOA_c0504ce7-222e-4b7f-9df0-3bd8690679f9">1,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMTctMS0xLTE2NzkwOA_a28b733a-a70a-431c-a100-355eead08c6d">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMS0xLTEtMTY3OTA4_13fa25e8-f80b-49d3-baa0-b0464a8bfbc5">5,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMy0xLTEtMTY3OTA4_93b05f6f-a152-4dc7-825e-c850a7dda93a">6,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtNS0xLTEtMTY3OTA4_30a0d4f0-dadc-4e5c-a932-7dd2f521debc">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtNy0xLTEtMTY3OTA4_55dc2746-d9eb-48e8-b0e4-e72504643641">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtOS0xLTEtMTY3OTA4_845067eb-ff7b-4b19-b2e0-71e52af3128f">1,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMTEtMS0xLTE2NzkwOA_2d47e258-f38c-4f39-9430-162abe54b178">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMTMtMS0xLTE2NzkwOA_59a20b30-1d18-4f0b-9ccf-3f9d8f90e6fc">6,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMTUtMS0xLTE2NzkwOA_c6e0f478-b37b-4737-9fe8-e822fd83b277">8,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMTctMS0xLTE2NzkwOA_9a181b51-426c-41e1-938c-401a9e8776a0">903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMS0xLTEtMTY3OTA4_983d5e41-410f-4e1c-a3f9-a9f72bd5587b">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMy0xLTEtMTY3OTA4_a928fc51-16b7-44b6-a72c-d719e5ae73fa">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctNS0xLTEtMTY3OTA4_44eb0bc2-4ed7-4184-bca8-474752dc745d">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctNy0xLTEtMTY3OTA4_a35d75d6-7955-4499-85dc-fe6ea23598b4">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctOS0xLTEtMTY3OTA4_07cd5737-a650-4026-90e8-d6bda034a88d">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMTEtMS0xLTE2NzkwOA_a42f72f1-c73f-4d0f-9b3e-7dfb48e70d9e">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMTMtMS0xLTE2NzkwOA_8a9aae60-426b-4f27-96bc-9f5151c8aad1">1,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMTUtMS0xLTE2NzkwOA_3416a4d6-935d-4be8-b073-c832f30419c0">2,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMTctMS0xLTE2NzkwOA_8fc5fc5e-a8b1-4f38-856a-119942998d80">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMS0xLTEtMTY3OTA4_c277bbed-7a6c-4b70-9189-9f847aead046">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMy0xLTEtMTY3OTA4_191d32f6-52cc-4f02-a87e-8e28eea1fa55">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtNS0xLTEtMTY3OTA4_713e64d6-880b-45a8-ad6f-475c15ee29f0">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtNy0xLTEtMTY3OTA4_4337ff27-6c50-48ac-91bb-f62cc040acf8">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtOS0xLTEtMTY3OTA4_30df8775-7937-411f-8aa8-f013b30d7919">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMTEtMS0xLTE2NzkwOA_42cd4f9a-5097-46d1-ae0e-4b9179e6961e">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMTMtMS0xLTE2NzkwOA_6fefef19-20f0-4ef1-a540-4bfeaffaaa99">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMTUtMS0xLTE2NzkwOA_e6fcdb54-91fc-427c-8600-4b78b99c35ea">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMTctMS0xLTE2NzkwOA_59792875-537f-4430-97ae-cb77d1bb2a6d">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMS0xLTEtMTY3OTA4_f563e249-1556-42c1-8041-afc639b96639">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMy0xLTEtMTY3OTA4_479a0ae5-ae23-46db-8cad-8402547ac80f">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktNS0xLTEtMTY3OTA4_e16ecc01-6dd1-4896-8409-27944b1a22db">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktNy0xLTEtMTY3OTA4_977931b3-bc50-49bb-9486-9fba530d60eb">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktOS0xLTEtMTY3OTA4_680eb5ff-a3dd-42fe-a7f7-e57587fd040a">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMTEtMS0xLTE2NzkwOA_0d315d15-4ae7-439d-b933-265a3c8682a2">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMTMtMS0xLTE2NzkwOA_a503c6bc-d737-4db5-83ad-b9b3389b720f">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMTUtMS0xLTE2NzkwOA_769b03bd-9c4d-41fb-9ac9-bb4dbd71ff5c">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMTctMS0xLTE2NzkwOA_a443eda1-5982-4212-a6da-85cd7cc70065">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTEtMS0xLTE2NzkwOA_c139759d-6f68-425d-8f7d-a32561a59bcc">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTMtMS0xLTE2NzkwOA_9591b5c1-829e-41c8-94f7-c1fa726f0351">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTUtMS0xLTE2NzkwOA_6627609b-f5b1-4b29-aef2-b4ccee1349f1">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTctMS0xLTE2NzkwOA_08f35a98-a935-401f-bebd-2be0c6e2994f">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTktMS0xLTE2NzkwOA_cef66028-0b6a-4ca9-8419-d9ade2ebc392">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTExLTEtMS0xNjc5MDg_6413460d-461c-4daa-bcd4-985a66eb4f77">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTEzLTEtMS0xNjc5MDg_453ca32c-492a-4bb1-afa0-9871b28ba694">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTE1LTEtMS0xNjc5MDg_728b51b2-fb59-46c3-a70e-eb2385fa4a82">2,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTE3LTEtMS0xNjc5MDg_edd4aa55-4cac-49e3-bdf7-0c4a836a4782">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTEtMS0xLTE2NzkwOA_3fc1a7bb-e9f2-4121-ad7a-43077d65592d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTMtMS0xLTE2NzkwOA_d3fc59a4-aefb-493e-b641-4976b68ce40c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTUtMS0xLTE2NzkwOA_a1709da5-9a6e-4fea-922f-c2d825ccd31e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTctMS0xLTE2NzkwOA_e4862c93-824e-4a0f-8477-316accf42e10">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTktMS0xLTE2NzkwOA_ad9af765-eed1-4da4-ae69-dc7d52d6000b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTExLTEtMS0xNjc5MDg_50b87f56-76d4-449b-bd60-06fe10e1471e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTEzLTEtMS0xNjc5MDg_d7bfb979-a11b-4f9e-a8e5-c446f4857a7b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTE1LTEtMS0xNjc5MDg_fc1e79d7-c315-4787-b5e7-cad36822fd41">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTE3LTEtMS0xNjc5MDg_15426571-d363-49ca-8ba8-396133f069bd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTEtMS0xLTE2NzkwOA_87068b00-bd58-416a-af85-9c8cda43b6c1">9,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTMtMS0xLTE2NzkwOA_1b6b766d-dfaf-4f3d-8a5d-70ea52b96d69">14,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTUtMS0xLTE2NzkwOA_62611916-bb78-4a87-bebf-99b83b736a2d">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTctMS0xLTE2NzkwOA_0ad0ce0e-3fab-428c-ad7e-fc2c5a06e52d">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTktMS0xLTE2NzkwOA_7d2f6dc1-bcfb-4580-9fb1-0096128e9d96">4,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTExLTEtMS0xNjc5MDg_b878cc57-4b01-4694-8921-a3d773dd9033">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTEzLTEtMS0xNjc5MDg_c9219ea0-6db3-42c4-a667-3b92af47d72f">12,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTE1LTEtMS0xNjc5MDg_408da80e-e8ed-49e1-8dad-d75200be2dce">18,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTE3LTEtMS0xNjc5MDg_d2a9faf8-a62d-44da-b9c8-5451c5f88e7b">1,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTEtMS0xLTE2NzkwOA_fe5e836c-73a9-43c4-af59-d2d295d2ddf3">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTMtMS0xLTE2NzkwOA_ef3c14b5-d80d-418f-99fe-0949a72d7f9d">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTUtMS0xLTE2NzkwOA_574405eb-bba8-4a75-8ae3-11e34c5d89f0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTctMS0xLTE2NzkwOA_a568de6d-12ab-4cac-ba40-9bc0cee85c1d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTktMS0xLTE2NzkwOA_f59faa0d-da7d-4f76-b926-bc7099418ac5">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTExLTEtMS0xNjc5MDg_5a91a8b6-bf0d-4946-b4bf-8896ab52eab1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTEzLTEtMS0xNjc5MDg_6a5f407b-6bee-462e-94df-5229e4d63d54">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTE1LTEtMS0xNjc5MDg_f8b75004-4c03-4610-a1db-a681265da055">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTE3LTEtMS0xNjc5MDg_a0a317a1-0924-45b9-83e8-d10865431223">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTEtMS0xLTE2NzkwOA_5a0ac97d-e1d7-4382-9512-c403c9b9fa5a">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTMtMS0xLTE2NzkwOA_6c3eb8c6-2961-4ead-aac7-5f51f7b9cc95">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTUtMS0xLTE2NzkwOA_994473f6-7dd9-424e-a52e-4fb9c585be12">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTctMS0xLTE2NzkwOA_37fbad75-6797-4bdd-86d7-76f3185180e2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTktMS0xLTE2NzkwOA_7b346232-9f22-412c-9bf8-61cb951b546c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTExLTEtMS0xNjc5MDg_c692d364-c375-4c61-bdf7-dbf44febfbcc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTEzLTEtMS0xNjc5MDg_2914c60c-aa70-4652-82f4-04e8c5ba0513">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTE1LTEtMS0xNjc5MDg_56e94630-0c2c-4498-bf8b-49564add30a7">461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTE3LTEtMS0xNjc5MDg_f5e2d7dc-910b-41ac-98bf-4b62687aafd6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTEtMS0xLTE2NzkwOA_9db09456-df20-4bf0-91b2-32e863adce76">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTMtMS0xLTE2NzkwOA_569d9427-2efa-4c34-b5ef-79dbdd2aedc5">2,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTUtMS0xLTE2NzkwOA_f0f8ed17-ea14-468f-8d18-4a5162ec8ce6">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTctMS0xLTE2NzkwOA_1ffa11cf-0a4f-4b65-89da-d888d53fea7c">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTktMS0xLTE2NzkwOA_a5a74ee0-2a72-4ea7-9b47-800a4a341232">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTExLTEtMS0xNjc5MDg_178de012-fe6d-40e2-a4a3-7dca0c5fabea">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTEzLTEtMS0xNjc5MDg_d9e28f04-03d4-4d43-86d1-25f4ee83a875">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTE1LTEtMS0xNjc5MDg_bb6302b0-4531-4742-95d9-327e822e836c">2,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTE3LTEtMS0xNjc5MDg_869e442d-383d-49fe-b283-5ee80fb1cb7a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTEtMS0xLTE2NzkwOA_2793a9d0-a13b-4f35-b72e-b22847903a7f">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTMtMS0xLTE2NzkwOA_9b782b98-c62e-4ac5-9a38-dd8acc0b1091">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTUtMS0xLTE2NzkwOA_1016d53f-a4dc-4ca8-8aab-25428c283b51">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTctMS0xLTE2NzkwOA_98167bac-1130-42bd-92b5-092f2fdbe3f9">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTktMS0xLTE2NzkwOA_d60ff4d9-93c2-4166-905b-eb3c6a41135c">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTExLTEtMS0xNjc5MDg_1ba423b4-0120-40cd-abf9-334161f8e46f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTEzLTEtMS0xNjc5MDg_5295a940-21e0-4604-97c1-9f6507c27b7a">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTE1LTEtMS0xNjc5MDg_30975ecd-d0f1-4ac9-a42e-fd05c41be672">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTE3LTEtMS0xNjc5MDg_0fbfe70b-464b-4b4c-bb47-bca4ea0f8ec2">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTEtMS0xLTE2NzkwOA_1f6ca240-8ab3-4484-88f3-66fd5d2bdc6e">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTMtMS0xLTE2NzkwOA_676f2f36-0fee-4b5d-ab65-d8746ddca179">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTUtMS0xLTE2NzkwOA_f45758e8-fce2-4b29-bc1a-b2f6086b047f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTctMS0xLTE2NzkwOA_330f90ac-41ec-4114-ba90-177b9651ed2f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTktMS0xLTE2NzkwOA_9806ddab-8d9a-4f3e-a175-74d04867cee4">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTExLTEtMS0xNjc5MDg_c0422936-47c5-493a-8393-f90318a0bf1e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTEzLTEtMS0xNjc5MDg_986b828a-f63f-4ae6-8f4f-eb9afa4e07c1">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTE1LTEtMS0xNjc5MDg_b704f0b7-0e6b-469a-827f-d30a2d402f7b">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221ef7845f854689af410277963cd5bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTE3LTEtMS0xNjc5MDg_62352ac3-0342-4075-bf60-7b5122e60afd">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTEtMS0xLTE2NzkwOA_cd84e5b1-32b0-488d-aa63-de1aeccc25e0">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTMtMS0xLTE2NzkwOA_b6f42e17-ce59-400f-8b10-5ec7053b8b25">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTUtMS0xLTE2NzkwOA_90ba7b2d-fa35-4050-9e68-1ab589e92553">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTctMS0xLTE2NzkwOA_d3f799c2-8f3e-4da3-901f-c179a100e41e">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTktMS0xLTE2NzkwOA_13f4bda8-9d18-46e2-a460-2dcc99fa8214">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTExLTEtMS0xNjc5MDg_3834e20b-d568-4e13-8c50-408418ffca4b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTEzLTEtMS0xNjc5MDg_c6b3c69c-41ef-4f67-8dc9-fd5f83aa4e69">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTE1LTEtMS0xNjc5MDg_6c6e03e3-5b20-45c3-9102-2ac9b3588385">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTE3LTEtMS0xNjc5MDg_e69788c9-5a7c-4132-9654-60a1120c020e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTEtMS0xLTE2NzkwOA_8076e96e-0661-480b-92d0-9f9f985ce106">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTMtMS0xLTE2NzkwOA_1daabca2-7206-4a15-b777-848096481260">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTUtMS0xLTE2NzkwOA_b888e1b6-8e4e-4e01-8108-f99cad625538">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTctMS0xLTE2NzkwOA_341abcf5-30da-47e2-87fb-3f42c0946628">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTktMS0xLTE2NzkwOA_44872f1d-ba15-46c3-9c19-e99c6177d54f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTExLTEtMS0xNjc5MDg_a5df4d2e-8eac-4889-9c3f-aecca6d39b02">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTEzLTEtMS0xNjc5MDg_3dab3da6-4287-4549-8dc7-b0851bdbb6a2">1,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTE1LTEtMS0xNjc5MDg_5c6eae09-ab9b-4503-80ec-c3ea75346ec0">2,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTE3LTEtMS0xNjc5MDg_0d065aec-65c7-4ac1-8676-32eee3f04b2c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTEtMS0xLTE2NzkwOA_b56c5293-914f-4ba8-8236-659676b768a0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTMtMS0xLTE2NzkwOA_f2250a94-ba8f-491e-9a75-dcfa71a2aa9e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTUtMS0xLTE2NzkwOA_8f9e4ea8-11f9-4f34-b235-69ee16550aae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTctMS0xLTE2NzkwOA_95ba0410-0ea8-4f4f-a19a-c160095a9e06">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTktMS0xLTE2NzkwOA_776fffd1-a6d2-489f-b7ac-20df225d8019">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTExLTEtMS0xNjc5MDg_2b6ca99a-2bce-4693-918e-137b24afe447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTEzLTEtMS0xNjc5MDg_e56ebd0b-2878-4c69-a698-7e42c36ac17a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTE1LTEtMS0xNjc5MDg_8cfa26b8-dd2e-4afb-b331-ae42e11b3508">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTE3LTEtMS0xNjc5MDg_5c57180e-a3d6-493a-9ed7-92e727434f33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTEtMS0xLTE2NzkwOA_b50b1b2d-7e18-41f1-a97a-40e7a819c574">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTMtMS0xLTE2NzkwOA_a76d0c1b-7ee5-4fe4-b817-bc7c092f40dc">6,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTUtMS0xLTE2NzkwOA_d3e3da55-41a6-4a30-90b7-81341881c08c">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTctMS0xLTE2NzkwOA_5c251bf7-b0b0-4fa5-b6d7-fc7322c3f6df">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTktMS0xLTE2NzkwOA_a139714b-6156-4a5c-8c96-21457d55ee0c">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTExLTEtMS0xNjc5MDg_0ba5ab5c-9782-4430-9534-e61e8f9435ea">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTEzLTEtMS0xNjc5MDg_151cad92-c0f1-4059-b307-8f877ea2fe4f">4,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTE1LTEtMS0xNjc5MDg_c6b9b130-22c4-4959-9568-9edd53657966">7,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTE3LTEtMS0xNjc5MDg_f53de482-cce7-424c-9819-32ff90fe1fdd">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company&#8217;s business.&#160;In performing this review, the Company considered factors such as the quality of the investment security based on research performed by the Company&#8217;s internal credit analysts and&#160;external rating agencies and the prospects of realizing the carrying value of the security based on the investment&#8217;s current prospects for recovery. Unrealized capital losses at December&#160;31, 2022 were generally caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. As of December&#160;31, 2022, the Company did not intend to sell these securities, and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if477ce169dfc40bb9c2d79240d7c1907" continuedAt="i1b22a7ed62f74414bbdd036565eea831"><ix:continuation id="i3b548f86febe4364a38b6fd918cc85cf"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity dates for debt securities in an unrealized capital loss position at December&#160;31, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting experience-<br/>rated products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting remaining<br/>products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtMS0xLTEtMTY3OTA4_ed76415f-15e0-413d-8365-d447abe7811a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtMy0xLTEtMTY3OTA4_d14b86d0-6234-469c-81c9-a6f0abf4e847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtNS0xLTEtMTY3OTA4_edd1dd71-7679-45eb-8425-51591bfe69f1">1,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtNy0xLTEtMTY3OTA4_390769ad-9682-48c4-9e49-aac2ede5f356">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtOS0xLTEtMTY3OTA4_c0d4e86f-4d28-46d3-aabc-f27a399d7ce3">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtMTEtMS0xLTE2NzkwOA_5a6b4326-835d-4b2a-8913-73207fb434f8">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtMS0xLTEtMTY3OTA4_5423f6df-8789-4004-9a3f-acb506eec084">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtMy0xLTEtMTY3OTA4_425558ec-cdfe-4fd3-8c7a-d55fec223ccb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtNS0xLTEtMTY3OTA4_c1a6e3c3-8c53-4352-b0a9-c7dab93143e4">5,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtNy0xLTEtMTY3OTA4_ef26a1e9-3941-432f-89fd-f1cf4ff8bafe">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtOS0xLTEtMTY3OTA4_3397a800-f7b5-4ad7-a1d8-eea4ddfc86ca">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtMTEtMS0xLTE2NzkwOA_7967c452-91d2-4937-89fb-57b2d421a4fa">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtMS0xLTEtMTY3OTA4_05601571-63bd-4d7f-8a1a-5bba155bc024">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtMy0xLTEtMTY3OTA4_8c385cda-5de0-443e-b040-6a1521f60904">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtNS0xLTEtMTY3OTA4_39380fe1-bdb4-412d-aab7-1228a71b4042">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtNy0xLTEtMTY3OTA4_4c6aedc0-0f93-4db3-8743-b527cdedaef8">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtOS0xLTEtMTY3OTA4_bcb9d6cb-e333-42d1-b878-fe0bb44f2e1c">3,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtMTEtMS0xLTE2NzkwOA_75beec4f-4e48-466a-b66c-5959c5f9da86">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtMS0xLTEtMTY3OTA4_a60d07ba-a99e-4ef5-a049-8eaba191f20a">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtMy0xLTEtMTY3OTA4_04f5b2f1-5299-403b-81ae-a48f3344935d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtNS0xLTEtMTY3OTA4_fb820f46-d046-4612-b353-b19f791e74a2">3,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtNy0xLTEtMTY3OTA4_23fcb20b-2354-4518-a8d8-854938d8d6eb">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtOS0xLTEtMTY3OTA4_0aad088d-1a5e-40a6-b316-f7e429a23808">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtMTEtMS0xLTE2NzkwOA_dc4423f0-4981-4ed0-a9fa-5f0d9307c43e">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40478cffecf64191b267758251c37050_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctMS0xLTEtMTY3OTA4_fc55cd2a-9094-43e0-a44f-2b01ba97b840">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40478cffecf64191b267758251c37050_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctMy0xLTEtMTY3OTA4_a91e4e65-ceff-4f04-8336-ad2954fd7d36">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af20438bbb64d5f8b78df4ed91c4fcf_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctNS0xLTEtMTY3OTA4_fc6d6cac-5fea-47d3-bcf8-6c3ed2470628">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af20438bbb64d5f8b78df4ed91c4fcf_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctNy0xLTEtMTY3OTA4_e29fc90e-5515-4051-abfc-044ca75ac756">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctOS0xLTEtMTY3OTA4_f0130c59-a35c-4c0d-be95-90b7f8fa3bdd">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctMTEtMS0xLTE2NzkwOA_f73079f6-0679-4e8a-9371-c592547a4a87">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d14838d61d4f28a334a6fa3ae5859e_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtMS0xLTEtMTY3OTA4_9233c667-bfb9-428c-a0ed-6d33d768d58a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d14838d61d4f28a334a6fa3ae5859e_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtMy0xLTEtMTY3OTA4_fd731755-ab00-4ef6-942c-902e10d4fb81">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f4db8d8e9d486f9039b51a301eddcf_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtNS0xLTEtMTY3OTA4_05149d5a-79f5-4774-b749-6afaeb63eafd">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f4db8d8e9d486f9039b51a301eddcf_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtNy0xLTEtMTY3OTA4_aec64ece-ccf2-4dda-934b-851f20879a32">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtOS0xLTEtMTY3OTA4_53924432-fdc4-4bc2-a8dd-94d538bf02a8">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtMTEtMS0xLTE2NzkwOA_b1840fe1-4878-4be3-8bd4-e3bf0fe1b9a0">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1e6e162ae5412285a67bd88bbd3ed8_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktMS0xLTEtMTY3OTA4_839d4089-b479-42f8-87d6-37bdff00ae76">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1e6e162ae5412285a67bd88bbd3ed8_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktMy0xLTEtMTY3OTA4_099c1c9a-ce2d-4536-8b24-88caf833b2ca">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdd4738946f44c8961343c0e3d3fae3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktNS0xLTEtMTY3OTA4_1f1d68ae-197f-468b-8098-e8e9b4ccdf96">2,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdd4738946f44c8961343c0e3d3fae3_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktNy0xLTEtMTY3OTA4_d4ad1e23-9a0b-4d76-9d9e-afe9fabcc725">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktOS0xLTEtMTY3OTA4_4f07ac87-6515-442c-8491-9374613d33cd">2,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7308db8487343dab3c870126d9b4513_I20221231" decimals="-6" name="cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktMTEtMS0xLTE2NzkwOA_41a4ecd4-4122-44aa-a209-7984b90e0806">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTEtMS0xLTE2NzkwOA_662b6135-b0d3-446a-bb26-6b86aac5f5c5">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTMtMS0xLTE2NzkwOA_7b9f6dc0-2dd1-4a4d-8e02-6bedad880cfa">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTUtMS0xLTE2NzkwOA_02e2c52d-abbc-4a4c-94ac-490600a9d1a5">17,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTctMS0xLTE2NzkwOA_84f4fd15-4f89-4374-bfab-71500830210f">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTktMS0xLTE2NzkwOA_00333398-dd03-4715-a5fb-1f735853c5b0">18,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTExLTEtMS0xNjc5MDg_07174f36-7431-48b3-8400-e51eb3ce3fb2">1,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:ActivityInMortgageLoanPortfolioTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MTI_636ea122-7cef-4ac1-8068-c315b16f7b12" continuedAt="i81e1d3a0148d4e4c8265d51df520cab6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s mortgage loans are collateralized by commercial real estate.&#160;During the years ended December 31, 2022 and 2021, the Company had the following activity in its mortgage loan portfolio:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New mortgage loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateNewMortgageLoans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzEtMS0xLTEtMTY3OTA4_79c804d7-b312-46c6-b0f1-7518f995945d">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fcec899c0a848d4b4ebc10f773df4c7_D20210101-20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateNewMortgageLoans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzEtMy0xLTEtMTY3OTA4_9e0551c1-fd41-431a-be20-8b3fe2bc2ac8">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans fully repaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231" decimals="-6" name="cvs:MortgageLoansOnRealEstateLoansFullyRepaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzItMS0xLTEtMTY3OTA4_42772320-624f-4664-935f-261876d69e88">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fcec899c0a848d4b4ebc10f773df4c7_D20210101-20211231" decimals="-6" name="cvs:MortgageLoansOnRealEstateLoansFullyRepaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzItMy0xLTEtMTY3OTA4_6a6ad660-ba4a-48f6-b599-22e0b59fdc2b">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans foreclosed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateForeclosures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzMtMS0xLTEtMTY3OTA4_7aa67540-7450-448d-9194-78f5f1786643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fcec899c0a848d4b4ebc10f773df4c7_D20210101-20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateForeclosures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzMtMy0xLTEtMTY3OTA4_ceb35c44-1479-4f89-afc3-b0ce8a4c3599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses mortgage loans on a regular basis for credit impairments, and assigns a credit quality indicator to each loan.&#160;The Company&#8217;s credit quality indicator is internally developed and categorizes each loan in its portfolio on a scale from 1 to 7.&#160;These indicators are based upon several factors, including current loan-to-value ratios, current and future property cash flow, property condition, market trends, creditworthiness of the borrower and deal structure. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Category 1 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Represents loans of superior quality.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Categories 2 to 4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Represent loans where credit risk is minimal to acceptable; however, these loans may display some susceptibility to economic changes.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Categories 5 and 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Represent loans where credit risk is not substantial, but these loans warrant management&#8217;s close attention.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Category 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Represents loans where collections are potentially at risk; if necessary, an impairment is recorded.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1b22a7ed62f74414bbdd036565eea831" continuedAt="if47cf14fc69543da90ae06029dea9b5d"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MTE_834c1f24-6b42-43ec-940f-0190a1c2779c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company&#8217;s assessments at December&#160;31, 2022 and 2021, the amortized cost basis of the Company&#8217;s mortgage loans within each credit quality indicator by year of origination was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost Basis by Year of Origination</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except credit quality indicator</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prior</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5943b5b1904c6b846ccf841c464d39_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtMS0xLTEtMTY3OTA4_e0ee791d-ac1c-46e4-b5d6-72b954857beb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecece3fcd8be4303aa5cbc5c092cf500_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtMy0xLTEtMTY3OTA4_67233128-180f-4b00-b68e-c8bc29dd63da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb3635c7aa14bb79761106ea93cc68a_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtNS0xLTEtMTY3OTA4_a8728e34-c418-4ec0-8be0-5e7e178271e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f8117025154ef69cad75e991abfff1_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtNy0xLTEtMTY3OTA4_13ea6a01-cef7-4fa8-a8b9-c8349711d608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0458817c19b448f08f9c914f63356b8a_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtOS0xLTEtMTY3OTA4_4370403b-c2bc-4ffd-853d-8d26c5d0bedb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebda2282c15f4559817dfaba4fdac117_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtMTEtMS0xLTE2NzkwOA_ca822b50-5c14-4658-8a96-117b4baa7a25">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed8619550174d168c4c4cd42b101642_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtMTMtMS0xLTE2NzkwOA_906a9998-8e79-463a-ba86-e6a99de7f53d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7eba7b3fa241f3aeeb456afa8bdd4e_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtMS0xLTEtMTY3OTA4_74826400-f7b8-4c21-bddb-101da21a3cd8">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76ce9ddcb63246efb0e31193bee2ff73_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtMy0xLTEtMTY3OTA4_cd04e844-bd1c-4388-9127-6f348aba0afc">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44809c2621249a5ae15e084e9a2de19_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtNS0xLTEtMTY3OTA4_4784594c-5150-4e00-be0e-f9823517b70e">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc19163e572465e81ae33a610b8f94b_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtNy0xLTEtMTY3OTA4_1c78d767-fbea-458d-a72a-385791bd826b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4c16e901d4eccb8965e3fae43dcc6_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtOS0xLTEtMTY3OTA4_80fc49ec-48e9-4768-99da-a6e16e8134fc">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828b576776fe424bae9270ea200522e2_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtMTEtMS0xLTE2NzkwOA_9459ebd1-902a-4dfc-95fc-57276b13e7bf">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id756e63e2e754f359f0f9ae581e0a94b_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtMTMtMS0xLTE2NzkwOA_07636a73-2bb1-4dd0-82ae-15c46e1d29cc">1,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i360bfd4546d74642b59856ededd82514_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtMS0xLTEtMTY3OTA4_0088953d-0d0f-482a-b8bb-3a5ed7c71089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fbbf77e09bd41508b2178ad8c2442bb_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtMy0xLTEtMTY3OTA4_49af8ead-277e-495d-bc72-172c623fbceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec7149199d0463a92cc968f65f45f43_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtNS0xLTEtMTY3OTA4_45821f3b-e43b-4837-9829-c2475921bad2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9ff2cb5e224b209b049e6f94fc2d50_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtNy0xLTEtMTY3OTA4_db7f999a-4045-406c-aa58-e27989b99d9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3fc6e014927402abca82128c1ddf524_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtOS0xLTEtMTY3OTA4_69d339cb-5ce8-408f-af9f-d6cbe60ebf00">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2597e031daaa40e6a6ec272f1341abcf_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtMTEtMS0xLTE2NzkwOA_0484fdf0-73a6-41d6-a148-2e727a485c44">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c112ce5a634675b6bdc212a46b02b4_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtMTMtMS0xLTE2NzkwOA_3924fd1f-3a6c-49b9-ae3e-b459e71f1f29">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6f2a4d7a5a4af9a3d311013668f24f_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtMS0xLTEtMTY3OTA4_9e51e251-a000-4550-8486-d45c4858c321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72bbda77b88f4cdd9fb87a318a29fedc_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtMy0xLTEtMTY3OTA4_74438232-6ff5-44d4-983d-0d8cc13cbb90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia294054d10ac417787c1944ee543fe6c_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtNS0xLTEtMTY3OTA4_2aad16bd-c3a5-4ef7-a890-151edb04640d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6beca7e4f8864e93aeba97040d6f5a37_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtNy0xLTEtMTY3OTA4_78a80ed1-5fad-4d70-8b27-88ccd5079328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97612fc3a2f44d73bb819a717d41d0a3_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtOS0xLTEtMTY3OTA4_1e7633ec-840f-43d8-b9ab-25b78a8b38d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if14f3e4b96e04557911ee9a9b62f5e0f_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtMTEtMS0xLTE2NzkwOA_57b0826b-c2a6-496a-90f4-579a7cd98162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a9138a58c84726a45e23bb6e6167e5_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtMTMtMS0xLTE2NzkwOA_e80adeb6-4eb0-4098-b7fc-3459ed70a2b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia570fc5031314098910825a767b2b0cc_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctMS0xLTEtMTY3OTA4_585a24c9-1a1f-4e4f-96b9-7fdd4a206f10">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6ac9f0b5a5421dbc9cb6e72f8396d7_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctMy0xLTEtMTY3OTA4_a9b6105d-066e-45a4-bce2-ea39cc76b550">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707228ea268b4fa1b8fc7634fc9a941f_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctNS0xLTEtMTY3OTA4_9f1eb0a1-7998-484a-a9d6-e446c3fe66e7">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7e7b8abcda4b75a158f71a15390c9f_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctNy0xLTEtMTY3OTA4_5bd80ea1-48c7-4e06-8f9a-35766213249d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588aad1d73dc43329473d13fcb268e7c_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctOS0xLTEtMTY3OTA4_5ca70603-c37f-4292-9494-e8d773f85159">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d1acd38b204e20a8c2a44bb0f10148_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctMTEtMS0xLTE2NzkwOA_7d6d6685-ea04-4d70-ab47-57cce2a2eb7e">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctMTMtMS0xLTE2NzkwOA_d93b60c0-ab9c-4021-95c5-daee7b5a8161">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3808d834e07e4b3b9e287f3834d21fdf_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTMtMS0xLTE2NzkwOA_a0880258-3b1a-44c8-b5cb-79d1d68fcd0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e10c1576ee434cbb42319cd9c8ab0d_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTUtMS0xLTE2NzkwOA_f903b498-5405-42be-b70c-665e3b681266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6e024d3cf14d86a2923481e9e6e304_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTctMS0xLTE2NzkwOA_ccc3e7eb-1d7c-4c57-b893-9124d68c4c76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44ab5a60f90433cbd73992a1d0566db_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTktMS0xLTE2NzkwOA_6f7c945b-f7b7-4886-b20b-4c17b49cd2b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f2cc1ce7924cb5bfc1eed1de05f7bc_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTExLTEtMS0xNjc5MDg_b7698c1d-0677-4afc-a328-00eeee0ada5e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19d3a4e66794458812e357f78f43e74_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTEzLTEtMS0xNjc5MDg_bebfeefa-7630-40b7-ae5d-dcba5178a14a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a5f10b00974911867bfe65ff417616_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTMtMS0xLTE2NzkwOA_3239d9bd-89f9-4fd3-a52e-6514e7f1a960">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516ca7a24b4e45d98df8d70dc8459538_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTUtMS0xLTE2NzkwOA_edfeab85-2f7a-41aa-bfa6-40da16d9a333">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8c11020a34479a954004c76070a1b3_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTctMS0xLTE2NzkwOA_f208bc1d-a254-485c-9714-106550ab4e43">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c568b1356424e30b16ba09859cf6b43_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTktMS0xLTE2NzkwOA_094d8257-6442-42bc-8586-1ee0098b9b74">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9b7af276014284bf1cbe79e6f1d940_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTExLTEtMS0xNjc5MDg_eb80b65c-b1d7-41d4-aba9-18a70895db3f">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfda10eea1e946608a7bbd50cf284c24_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTEzLTEtMS0xNjc5MDg_35d7ec3f-9e6e-4991-bee6-4bebc9229129">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90857bdf1da64bc0b9e9cb8b2c306c07_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTMtMS0xLTE2NzkwOA_9093d4ca-92ca-446d-baa9-c7504662ba19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54c71d8deb84041b2ac5c9187940c7b_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTUtMS0xLTE2NzkwOA_9eaca4d4-aea0-43e5-9891-540568c6f275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4854a804064145bf94625cb963eff0eb_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTctMS0xLTE2NzkwOA_1e7ca881-c788-4368-9c8f-ee85c1941572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c97f2c2663d47269fef701393c390f9_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTktMS0xLTE2NzkwOA_a0c1e925-d5a5-4ebf-8242-ab58b34d3364">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ebaa434a774f55944633b91503f6aa_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTExLTEtMS0xNjc5MDg_9ccd83ff-bd4c-4d25-95e1-b82c95e36f0c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice10fbdb03344142bf872d80c624c2ba_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTEzLTEtMS0xNjc5MDg_093b9284-5bfa-42ce-8f27-3ebf7f2d2dfc">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b39b49a3b54b80924c011dd5d61684_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTMtMS0xLTE2NzkwOA_9f0d945b-bf76-4993-97ef-3ba565557ebe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b6ec53ccf44d16bb1cf7ea10345d8f_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTUtMS0xLTE2NzkwOA_b1758c6d-533d-4bd5-994e-c6a59bbf0344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ba64ca88a842a8b016d348b2518392_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTctMS0xLTE2NzkwOA_2f86c2bc-59e2-473d-9347-6d9dcec98f99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76d3139b44e495aa8b5d3c2e3fe365d_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTktMS0xLTE2NzkwOA_16f423cb-dc5a-41b7-ae50-cc9d242fb835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f39590e349c47e1b6655543883e658d_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTExLTEtMS0xNjc5MDg_1228cf4a-4463-4dc8-86c8-59f82dea0f31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4503868833d04c6e92dd980faabe8e9d_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTEzLTEtMS0xNjc5MDg_1226b48a-b47a-44b8-a4df-ddcfdb1e2054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b22cfb2e4fb49ef994eb2fe50637d3e_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTMtMS0xLTE2NzkwOA_f1895522-aad1-4453-b2fe-c6e642df50fe">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6f5d37438e4e24adc486dfc220e330_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTUtMS0xLTE2NzkwOA_330d8057-15b9-4759-be1c-6ba471b6491e">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75817f6d10a64edb95908711e7b84a5f_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTctMS0xLTE2NzkwOA_32dc6442-c50d-4ed5-a6dd-44e64fb25273">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd337cc2997f4c9a8bf96e1b1038b176_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTktMS0xLTE2NzkwOA_c87c3c86-2945-47c5-a6cf-1eaf3ba55369">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f411adda394690a887804f07c4085b_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTExLTEtMS0xNjc5MDg_494e749e-7841-4981-8f60-3a199fae4ffb">484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a1e132dac44a7aa77f7b5045148074_I20211231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTEzLTEtMS0xNjc5MDg_397eca72-0d3a-407c-95ad-105f62beaed7">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="i81e1d3a0148d4e4c8265d51df520cab6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 scheduled mortgage loan principal repayments were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231" decimals="-6" name="cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzEtMS0xLTEtMTY3OTA4_1dbb980e-4d22-454c-b299-342cb8cdd7ac">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231" decimals="-6" name="cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzItMS0xLTEtMTY3OTA4_ac0c6fad-b957-46eb-acb8-82385f124828">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231" decimals="-6" name="cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzMtMS0xLTEtMTY3OTA4_2f70c66c-d34c-473b-adbe-1f48fa464bef">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231" decimals="-6" name="cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzQtMS0xLTEtMTY3OTA4_b7cc1ed1-a32a-4547-b89e-05f9b45d8acb">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231" decimals="-6" name="cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzUtMS0xLTEtMTY3OTA4_b60fca18-9126-4cc3-9edc-65674644cc85">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231" decimals="-6" name="cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzYtMS0xLTEtMTY3OTA4_5f2b2da5-d02a-4969-8a69-37cbde9dc5c9">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzctMS0xLTEtMTY3OTA4_663ec625-ad28-48ad-8031-db0626df6194">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Income</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:InvestmentIncomeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4Mjg_513a97ae-ccef-43ee-9896-0576d543abd8" continuedAt="i3bd5e43ee9d64885a8d8006cad32ba4e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sources of net investment income for the years ended December 31, 2022, 2021 and 2020 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e80630b4afd497383aa2e7e0825756f_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzEtMS0xLTEtMTY3OTA4_a56c06e1-1af5-4b4c-b1bf-f7ff593441c8">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0b007394094a3a81527483fd8a8975_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzEtMy0xLTEtMTY3OTA4_a84599a3-61c5-4900-8159-c96aaf0cab70">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548886065c29409da2eebb0e5740162b_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzEtNS0xLTEtMTY3OTA4_e267dd9f-f2cb-4cbd-8afb-8fa4b26c6be0">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie285042dfe4440d68f48b4adebe96861_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzItMS0xLTEtMTY3OTA4_b3dbc7c6-b818-428a-8112-4f929eb83d74">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9bf6c2c8e24bf0a220cd7210ee97fc_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzItMy0xLTEtMTY3OTA4_2269a106-819b-4203-8140-0a472aab7f76">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0bc2b4239f48e1a3a714d4cc3d7203_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzItNS0xLTEtMTY3OTA4_8b13e37a-bbb9-4ecf-84ed-8465c6ef4394">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313f0ade641941b4a6bef1dd870a48da_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzMtMS0xLTEtMTY3OTA4_9e52935a-e854-4c91-a96f-9f3c5b6ab1c0">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74585cf162b14135ad3471e993c71df9_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzMtMy0xLTEtMTY3OTA4_8032cd23-728c-4dcc-9db4-adb0332dab04">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20751ec3912a4de2a34e1c394c86a641_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzMtNS0xLTEtMTY3OTA4_7ff4c2de-141c-4cfd-b710-28658716463d">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross investment income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzQtMS0xLTEtMTY3OTA4_ab0a5b2a-7c41-4f53-91c4-eeb83d962356">1,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzQtMy0xLTEtMTY3OTA4_5b22b8b8-d9db-4d1c-a12e-47dfb2250d8f">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzQtNS0xLTEtMTY3OTA4_4ff59ac2-3e73-4f12-aa3f-4d3fdf59cb02">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzUtMS0xLTEtMTY3OTA4_1178b9df-2ef6-4a49-b030-8df835af4435">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzUtMy0xLTEtMTY3OTA4_eb4d55ce-a4f3-40bf-ab84-66477120a37e">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzUtNS0xLTEtMTY3OTA4_cb2b8528-9882-4091-a286-2a6b171549a1">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (excluding net realized capital gains or losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:InvestmentIncomeExcludingCapitalGainsOrLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzYtMS0xLTEtMTY3OTA4_31180e0d-d3f4-45df-a8fc-0ac258e0aa88">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:InvestmentIncomeExcludingCapitalGainsOrLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzYtMy0xLTEtMTY3OTA4_7ae5c35a-c542-46fe-98b7-63188314d5ee">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:InvestmentIncomeExcludingCapitalGainsOrLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzYtNS0xLTEtMTY3OTA4_0f68e911-2849-421e-995e-40e2d09339d5">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized capital gains (losses) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzctMS0xLTEtMTY3OTA4_8afe3a92-8398-4cbb-824e-00a36f9cebb7">320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzctMy0xLTEtMTY3OTA4_196f9bb3-066a-486e-a62a-e89e63c0dd1d">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzctNS0xLTEtMTY3OTA4_69fea21c-b173-41d2-b7fb-16c581ff6bab">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzgtMS0xLTEtMTY3OTA4_bef3ec70-a321-4c92-8590-19af9ae9dcfc">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzgtMy0xLTEtMTY3OTA4_e3a6350d-5c23-42c3-b1db-6dc3dab4acec">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzgtNS0xLTEtMTY3OTA4_f510d7db-cf09-4592-b29a-d9f43796c5d4">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net realized capital losses include credit-related losses on debt securities of $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzI3NDg3NzkwODIwNDM_ead5ffb5-c384-4e6e-bdd1-01fc69fe5637">13</ix:nonFraction> million and yield-related impairment losses on debt securities of $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzI3NDg3NzkwODIwNjA_f0f50c15-2369-4eb2-be2b-a23478d16f43">143</ix:nonFraction> million in the year ended December 31, 2022. Net realized capital gains are net of yield-related impairment losses on debt securities of $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzU0OTc1NTgyNTMzOA_31938dfc-6302-4dca-98e7-1b3d65a69ce4">42</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzU0OTc1NTgyNTM1NQ_df8555e4-9b42-41ac-8b6e-fb59c188800e">49</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively. There were <ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzgyNDYzMzcyMjA5NDk_2439273e-300d-43ba-b716-272c280bf612"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzgyNDYzMzcyMjA5NDk_d0716621-5e81-455a-8ad7-a19f97140b3e">no</ix:nonFraction></ix:nonFraction> credit-related losses on debt securities in the years ended December 31, 2021 and 2020.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i3bd5e43ee9d64885a8d8006cad32ba4e" continuedAt="id65a097257a74aaab96c5e0c0bca995d">(2)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:continuation id="id65a097257a74aaab96c5e0c0bca995d">Net investment income includes $<ix:nonFraction unitRef="usd" contextRef="iaf5fc81ab5334092a75354e9e0cedebb_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzYyNTk_a6b32b5c-42ed-49ad-b84f-467a1b94387a">35</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i4c9389120bf34657b8225887b8754f61_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzYyNjM_a890c261-d165-4739-8acf-ed6c9e93319d">38</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1333c10377854683a2d760e2dc527ff2_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzYyNzA_dba32b45-56d4-47c2-b314-0c4dbf96483e">42</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively, related to investments supporting experience-rated products.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if47cf14fc69543da90ae06029dea9b5d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital gains and losses recognized during the year ended December 31, 2022 related to investments in equity securities held as of December 31, 2022 were not material.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MzA_343b2378-148f-47e7-8d58-93e1b0eec8c4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzEtMS0xLTEtMTY3OTA4_d460bece-c22b-449d-b4c6-aa6a595afae1">4,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzEtMy0xLTEtMTY3OTA4_a4991bb3-ddcd-4853-9e9d-6d946fcfaad2">3,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzEtNS0xLTEtMTY3OTA4_516299a0-14c3-4690-8c07-69ac14772d2e">3,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzItMS0xLTEtMTY3OTA4_dae5c93b-e4e3-4a07-9a68-92a1c228d9d6">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzItMy0xLTEtMTY3OTA4_a4150e2e-17c7-43b2-9870-b79372f573b5">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzItNS0xLTEtMTY3OTA4_19f1ca6e-a592-492f-a46c-62c98b90de7d">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzMtMS0xLTEtMTY3OTA4_a5fac807-5f6a-4d49-bb4a-05bcc95fd60f">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzMtMy0xLTEtMTY3OTA4_1453c8f1-3d8c-4f21-8ea3-b0dac37f78eb">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzMtNS0xLTEtMTY3OTA4_19620041-8351-4f49-89da-fac28fe0cf2d">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_130"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjI2_07b68a6e-be83-45b3-97ae-53a3ec9ac56c" continuedAt="i632283661c6f4f4798918a67b55d25a2" escape="true">Fair Value</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i632283661c6f4f4798918a67b55d25a2" continuedAt="icb527a87907b4cb9b42a23ca24642d82"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis.&#160;In this note, the Company provides details on the fair value of financial assets and liabilities and how it determines those fair values.&#160;The Company presents this information for those financial instruments that are measured at fair value for which the change in fair value impacts net income attributable to CVS Health or other comprehensive income (loss) separately from other financial assets and liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Measured at Fair Value on the Consolidated Balance Sheets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value on the consolidated balance sheets.&#160;The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by GAAP.&#160;The following are the levels of the hierarchy and a brief description of the type of valuation information (&#8220;valuation inputs&#8221;) that qualifies a financial asset or liability for each level:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Unadjusted quoted prices for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Valuation inputs other than Level 1 that are based on observable market data.&#160;These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, valuation inputs that are observable that are not prices (such as interest rates and credit risks) and valuation inputs that are derived from or corroborated by observable markets.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Developed from unobservable data, reflecting the Company&#8217;s assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation.&#160;When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities in Level 1.&#160;In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model.&#160;These financial assets and liabilities are classified in Level 2.&#160;If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment&#8217;s financial performance and cash flow projections.&#160;Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of the valuation methodologies used for the Company&#8217;s financial assets and liabilities that are measured at fair value, including the general classification of such assets and liabilities pursuant to the valuation hierarchy.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. When quoted prices are available in an active market, cash equivalents are classified in Level 1 of the fair value hierarchy. Fair values of cash equivalent instruments that do not trade on a regular basis in active markets are classified as Level 2.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Where quoted prices are available in an active market, debt securities are classified in Level 1 of the fair value hierarchy.&#160;The Company&#8217;s&#160;Level 1 debt securities consist primarily of U.S. Treasury securities.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s Level 2 debt securities are obtained using models, such as matrix pricing, which use quoted market prices of debt securities with similar characteristics or discounted cash flows to estimate fair value. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icb527a87907b4cb9b42a23ca24642d82" continuedAt="i1772ea15dc2f443eaf06f34d612255a7"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company reviews these prices to ensure they are based on observable market inputs that include quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets and inputs that are observable that are not prices (such as interest rates and credit risks). The Company also reviews the methodologies and the assumptions used to calculate prices from these observable inputs. On a quarterly basis, the Company selects a sample of its Level 2 debt securities&#8217; prices and compares them to prices provided by a secondary source. Variances over a specified threshold are identified and reviewed to confirm the price provided by the primary source represents an appropriate estimate of fair value. In addition, the Company&#8217;s internal investment team consistently compares the prices obtained for select Level 2 debt securities to the team&#8217;s own independent estimates of fair value for those securities.&#160;The Company obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December&#160;31, 2022 or 2021. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also values certain debt securities using Level 3 inputs.&#160;For Level 3 debt securities, fair values are determined by outside brokers or, in the case of certain private placement securities, are priced internally.&#160;Outside brokers determine the value of these debt securities through a combination of their knowledge of the current pricing environment and market flows.&#160;The Company did not have any broker quoted debt securities for the years ended December&#160;31, 2022 and 2021. For some private placement securities, the Company&#8217;s internal staff determines the value of these debt securities by analyzing spreads of corporate and sector indices as well as interest spreads of comparable public bonds.&#160;Examples of these private placement Level 3 debt securities include certain U.S. and foreign securities and certain tax-exempt municipal securities.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two classifications of equity securities:&#160;those that are publicly traded and those that are privately placed.&#160;Publicly-traded equity securities are classified in Level 1 because quoted prices are available for these securities in an active market.&#160;For privately placed equity securities, there is no active market; therefore, these securities are classified in Level 3 because the Company prices these securities through an internal analysis of each investment&#8217;s financial statements and cash flow projections. Significant unobservable inputs consist of earnings and revenue multiples, discount for lack of marketability and comparability adjustments. An increase or decrease in any of these unobservable inputs would have resulted in a change in the fair value measurement. </span></div></ix:continuation><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1772ea15dc2f443eaf06f34d612255a7" continuedAt="i2dfe10a3714c486a953fe36026fa6dc2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231" decimals="-6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzY3MjE_68f5095f-fcde-4aa9-aa35-f9559c0f82e0"><ix:nonFraction unitRef="usd" contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231" decimals="-6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzY3MjE_87de695b-1373-4865-b29c-929b57064d78">no</ix:nonFraction></ix:nonFraction> financial liabilities measured at fair value on a recurring basis on the consolidated balance sheets at December&#160;31, 2022 or 2021. <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjI3_f4f9db63-18f2-4448-b1b3-3cf40075be4a" continuedAt="i91b0578a3d4b4aae844270346a04fbe3" escape="true">Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:</ix:nonNumeric></span></div><ix:continuation id="i91b0578a3d4b4aae844270346a04fbe3"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzItMS0xLTEtMTY3OTA4_61362b7c-fb93-4f7c-88bb-f49404962f41">6,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c69d485444837bbae724a028fb845_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzItMy0xLTEtMTY3OTA4_dd9fe26e-d20c-4e64-8883-63e1027cf89b">6,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzItNS0xLTEtMTY3OTA4_08a84284-fc80-4b5e-8596-379f87c7d973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzItNy0xLTEtMTY3OTA4_04f2fdba-6f4f-4e1a-8818-7d134c84ec6b">12,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88708d7db67144f6b9034fc9b683ea9e_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzQtMS0xLTEtMTY3OTA4_a8414798-a40f-487c-8c5d-a49e185b9b01">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a49e1f8ed54cc797d186700b9962e5_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzQtMy0xLTEtMTY3OTA4_820437e9-969f-4b63-931e-187a12344265">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83971584eb546e2ac5fdc1e7bc8e84b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzQtNS0xLTEtMTY3OTA4_d68d31ad-33a4-4e78-8923-e672a328c98b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice45b349609443519e8d645943421f9c_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzQtNy0xLTEtMTY3OTA4_174d44b2-eb62-422d-9058-352512d937a8">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a23915f279344c1bf1087035f0fdf12_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzUtMS0xLTEtMTY3OTA4_55e9af35-ed64-4f31-add5-c319f96d5b7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c2d8598a124c19a68198d84bdafaf8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzUtMy0xLTEtMTY3OTA4_3da656d6-29d0-46de-9869-fab68d888edd">2,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785d19a7b609421eb9246c77f19956fe_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzUtNS0xLTEtMTY3OTA4_0537dbc4-b6bb-42fa-ac74-d954789a6be5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f0cd92f49b4b2ba3ae745e22916f37_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzUtNy0xLTEtMTY3OTA4_a8fda15b-1684-4615-83b1-b6cd79c0153a">2,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e9b578731f4c5baff668f1e8bc6d6b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzYtMS0xLTEtMTY3OTA4_4f29f213-00d9-460c-b9d4-e81f7a4c684d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id86084968a414700a75a774a5a97ab5f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzYtMy0xLTEtMTY3OTA4_aa68440a-a606-4189-aa71-07c7dbf074f1">8,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1814e1657e4cec8407f309d332126f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzYtNS0xLTEtMTY3OTA4_ff2fb2ea-0543-4b61-9aba-9245b9a7ffc3">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb1f815761e4abf81f0b8c3d4f8c6c2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzYtNy0xLTEtMTY3OTA4_039af3bf-6c5d-477f-97c2-d2d6fbe11393">8,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a671ec5023946d19ee290bcc33442c9_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzctMS0xLTEtMTY3OTA4_2deb1c89-eb12-448e-846e-829ed744aff4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied933a3ae1c44c37ab908d407bf9b9d2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzctMy0xLTEtMTY3OTA4_a8d2873d-5571-45c4-95c7-db473495a093">2,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8590aa625abe4bb3957876a8242f244e_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzctNS0xLTEtMTY3OTA4_3ea272e8-f323-442d-891a-894eef5b49b4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6fb3a28663f4a6ba9eddda9e82c83a9_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzctNy0xLTEtMTY3OTA4_ccdddcad-6cfc-49c4-bedc-38ec545fe8f8">2,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a985a5355bf4bfa9414b48bb67b83bc_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzgtMS0xLTEtMTY3OTA4_601b95fb-547d-4b57-850b-b476123075bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b71f09b498454fa6e14cfd770e0f13_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzgtMy0xLTEtMTY3OTA4_85082d07-0f8a-4767-9a4b-f481a3130e5b">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26131a59b6674c21be2b2f35ac3585d0_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzgtNS0xLTEtMTY3OTA4_1baf0e09-d279-402f-ba71-54b4a41bc00a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85dd5660a59b410b8d5600445dd2db73_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzgtNy0xLTEtMTY3OTA4_7a0ff74f-b302-415d-b2f7-522b5e58f5d1">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b09513b5025488bb89a6666751b3eec_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzktMS0xLTEtMTY3OTA4_e540bd86-a151-43f5-be7f-eb505966ac1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdc3450471ad405a95c9f384be0052d2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzktMy0xLTEtMTY3OTA4_93ba9ed5-0344-4dd7-bf49-0b47981d0307">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f137c3bff994afabf3e08f84adaf0e2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzktNS0xLTEtMTY3OTA4_426f1436-a4d9-4209-8e50-608d415c7111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08f51346b999445e9d94877366425a3a_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzktNy0xLTEtMTY3OTA4_723c972e-3781-405e-add9-4d14e3547426">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia214d8b8ca6049f29665c2a7f42886ea_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEwLTEtMS0xLTE2NzkwOA_53da28c8-92a5-459a-8b08-325d86c93797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f05a7cde4614b0ab28a1cca18e30c59_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEwLTMtMS0xLTE2NzkwOA_8afad807-51be-4082-9579-ac617f3f837c">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624b1a999672495b9d45af07b54e6b76_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEwLTUtMS0xLTE2NzkwOA_3f8da63a-a804-4786-8150-cd1c5726041f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd5e7556c1145898755e2b6da40bee8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEwLTctMS0xLTE2NzkwOA_96668b67-b1a4-4403-8922-937b207c13b4">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a5333835ad4c71aed5cd82b4c95855_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzExLTEtMS0xLTE2NzkwOA_6c699c3b-ba20-4968-b533-9cdc402c036e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c8648eedc854d2cb3b880ba07b81e53_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzExLTMtMS0xLTE2NzkwOA_5951b4a8-096a-451d-8873-341a2bade346">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida77e918f5de47b4b67cfca0da2b8226_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzExLTUtMS0xLTE2NzkwOA_8862ffa7-ce3d-4a96-a39f-466dd46d2d51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6906b59b585c4d4b85fc1db92b4aad26_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzExLTctMS0xLTE2NzkwOA_dc588a5b-1ef9-4c40-8b62-549e09f79019">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEyLTEtMS0xLTE2NzkwOA_3949a073-c737-4971-993c-b10052b3a273">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c69d485444837bbae724a028fb845_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEyLTMtMS0xLTE2NzkwOA_7751fb51-ab9a-4750-af65-1966a17c2a2a">18,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEyLTUtMS0xLTE2NzkwOA_c442b7d0-ebda-4519-89fa-d8877d92f31d">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEyLTctMS0xLTE2NzkwOA_147ca4f8-99bb-4897-8d7a-9bf79e2b2a0b">20,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEzLTEtMS0xLTE2NzkwOA_dc455027-8ff4-4a58-9821-3ce6de66c5b9">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c69d485444837bbae724a028fb845_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEzLTMtMS0xLTE2NzkwOA_6d387caa-8b63-41ac-916f-5907fd63776c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEzLTUtMS0xLTE2NzkwOA_be6dd545-a3c4-4cf7-9f65-88f6589bad25">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEzLTctMS0xLTE2NzkwOA_21361bd8-f7f9-42d9-a917-2701c2c94322">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE0LTEtMS0xLTE2NzkwOA_a4f9a298-ba90-48d4-86de-ffc0f53c2804">8,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c69d485444837bbae724a028fb845_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE0LTMtMS0xLTE2NzkwOA_feef0d76-0a43-4698-a408-79d67bcf770b">24,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE0LTUtMS0xLTE2NzkwOA_a54cc68d-f1e4-4f6f-80d8-d923462c994f">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE0LTctMS0xLTE2NzkwOA_4ba8ea1a-9088-41bf-b134-76a7b7cc7411">33,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE3LTEtMS0xLTE2NzkwOA_e622a32c-8f83-4ceb-aef9-cafd04af7421">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE3LTMtMS0xLTE2NzkwOA_479db81d-6c30-40fe-8d3f-2c9839e4b43e">4,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE3LTUtMS0xLTE2NzkwOA_2afbdda7-8da0-4ef8-a3e5-89cfff9de8e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE3LTctMS0xLTE2NzkwOA_8ec735b9-dd4c-435b-a786-53771222650c">9,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e565524b0f4bf687a1dabcf4928828_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE5LTEtMS0xLTE2NzkwOA_434328b2-c479-42e2-a850-4c497c65b7f7">2,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81efa365424d49cebe90328cadafba3e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE5LTMtMS0xLTE2NzkwOA_14fe5c38-58cb-43b8-a989-52fa43ccc1c0">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ec5e8d0dd14482a058a46dd16eab76_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE5LTUtMS0xLTE2NzkwOA_1779d074-ab59-4fce-805c-d5d4d882720d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701d4495212945b99d951fd9a0dcd6c2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE5LTctMS0xLTE2NzkwOA_fdf06035-a600-437d-bb51-d17af045908a">2,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7773f5873dab49a8ba60de1ef7a255d4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIwLTEtMS0xLTE2NzkwOA_8e936cba-0731-49ac-8fb4-5ee7be91db16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348bc1177736419fad69fa81d958c8ee_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIwLTMtMS0xLTE2NzkwOA_51d7ad56-6673-439c-8301-faad60195762">3,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32773f424e5649049efc564c1400fd60_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIwLTUtMS0xLTE2NzkwOA_5a30b82d-3088-4d8f-9884-a98b2d21544d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfb3509175a421fa38431213004bc2a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIwLTctMS0xLTE2NzkwOA_90e4a554-7347-438a-aa27-5ad6e47e176a">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i949fc998576e45bfb3cf3c21865aa98a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIxLTEtMS0xLTE2NzkwOA_79314325-4b30-4fbf-b2a6-a11fadf2f59f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4b742130f941fe94db85e807e7a06a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIxLTMtMS0xLTE2NzkwOA_e41faabe-2bbd-490e-ba57-410b1d2478cb">9,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb4af948251483fb59540de78e273f1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIxLTUtMS0xLTE2NzkwOA_70fe08bf-ff84-43b4-9c89-9a9a68e518f5">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4ad698b6cb4a918854adc5690c6f16_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIxLTctMS0xLTE2NzkwOA_7a1c6113-dce8-45dc-850a-acae2c26a558">9,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a543a47bdbf412ea03cd80a7e5147aa_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIyLTEtMS0xLTE2NzkwOA_f8688575-5cb2-460e-9e2d-3044492416b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2c37f0c80248f98f71a7fc479de9ef_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIyLTMtMS0xLTE2NzkwOA_082c9c6d-5b58-4477-872a-e721da04ada2">2,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib999956c1a1844f0a5f0f337b58d6d66_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIyLTUtMS0xLTE2NzkwOA_b571700c-7a0f-441b-9354-067e97ff57c0">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcc6959ebd747668932580c12c9b80c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIyLTctMS0xLTE2NzkwOA_c3cdea17-68d3-4fd5-b0d5-212eb8b99763">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia921c1e5944340c0aa0256f19c8b20a8_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIzLTEtMS0xLTE2NzkwOA_81a114f7-8862-44a7-8da3-8a1c4d76c17c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a2d79c756c41b2bea5dcf9fc87f998_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIzLTMtMS0xLTE2NzkwOA_486f7f17-7be2-4e2b-a08e-4900c8cd82b9">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206c3b9628b7444ea6df2624ea2118ee_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIzLTUtMS0xLTE2NzkwOA_b3b15c52-16d2-4180-9a71-d6e1f272a242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f4bc4698994fcab1897c3d0a92ad88_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIzLTctMS0xLTE2NzkwOA_e87c9d85-db41-470b-ba62-cb674ca9a7be">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ee0b6a29d934c78b07a74d71c61d1db_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI0LTEtMS0xLTE2NzkwOA_496664bd-0e61-48c0-a0b7-7c1504899ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7db71ae1ac40fd91ebfa23d481d8c4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI0LTMtMS0xLTE2NzkwOA_6de92705-8b23-47cb-8317-3addcae5d607">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190edd6b8c6944fd9697dfc9489f8a9c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI0LTUtMS0xLTE2NzkwOA_b72d368f-dcff-436c-a21f-e7d945ede3ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387ffe71e44b4f0daa62a18eae1f74ea_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI0LTctMS0xLTE2NzkwOA_7ce502af-8cd5-404a-8566-df556c729844">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i431cc5a5826c442fa78d95415014f874_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI1LTEtMS0xLTE2NzkwOA_163e3d5a-6d9b-4516-8327-4cfc24d32389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ddcd1cd3484e58887f45b9ad5e1006_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI1LTMtMS0xLTE2NzkwOA_6f16c947-18d3-497b-85b0-faeb45e7fe6e">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb6d4a5fe79457293a854403dbb6e69_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI1LTUtMS0xLTE2NzkwOA_aa43489a-cc6f-4a81-9bf2-82122ba7907f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff589f47f514ece9b347067993f1a0a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI1LTctMS0xLTE2NzkwOA_60c1b19e-3500-465c-809c-a5dc2ca2b171">2,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae1a142a6834907b1e6b0fa40a2a994_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI2LTEtMS0xLTE2NzkwOA_608437ae-ec10-4f4a-ade6-e9a5dc1f18f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83ed3a7dee542e08edcf3a6a2ea4b25_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI2LTMtMS0xLTE2NzkwOA_4dc34266-7bb6-4b7c-8af3-8c5f1e2d4c5e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2050ac0edb04a31adf7f234fb6390a1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI2LTUtMS0xLTE2NzkwOA_29af8a39-6b6b-4c97-98a6-371f1ae97fec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75346ba9d76e4cf0980dea9c58ccaa81_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI2LTctMS0xLTE2NzkwOA_978bf76f-eed1-4d8c-97cc-84859f8fb8ec">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI3LTEtMS0xLTE2NzkwOA_c7c0abd3-f3c2-4547-8805-5ab9cc5af7f2">2,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI3LTMtMS0xLTE2NzkwOA_02e91343-e571-4479-bdbf-eeef270c256d">20,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI3LTUtMS0xLTE2NzkwOA_182ef995-10d6-4acb-bda7-26d5258a165e">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI3LTctMS0xLTE2NzkwOA_cfe167dd-11d8-4647-9dc9-3b4f71d2e077">23,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI4LTEtMS0xLTE2NzkwOA_99aafbe9-ea00-4bd3-9932-fc5e3edafc29">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI4LTMtMS0xLTE2NzkwOA_32c2d295-78f4-4578-9b7e-791b8ae7430d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI4LTUtMS0xLTE2NzkwOA_9ce0b912-cf60-4506-a565-2d98c7daef07">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI4LTctMS0xLTE2NzkwOA_1a12364f-baa2-4637-aa58-9c243e95b47e">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI5LTEtMS0xLTE2NzkwOA_efd75ff2-37f1-4b7c-b347-d09c9fb80ca5">7,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI5LTMtMS0xLTE2NzkwOA_ebe95828-438f-4b2a-967b-e567fb6e6cd4">25,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI5LTUtMS0xLTE2NzkwOA_8ef5f053-1c07-4802-ac29-51561860e0e4">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI5LTctMS0xLTE2NzkwOA_f06bd42c-f869-4d3f-9fd1-aef8b6ba8654">32,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i07516a7d0c4d4a0eb9c8cf019d26a2e9_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzI3NDg3NzkwODE1MDA_214f0100-634f-40ff-9d1a-61e0743a819c">6</ix:nonFraction>&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div></ix:continuation></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:13.5pt;text-indent:6.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2dfe10a3714c486a953fe36026fa6dc2" continuedAt="ice8fee9d836c4495bd26ba7ef1e24704"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjMz_d07fcf78-b6f1-448a-9304-49704d1b49d5" continuedAt="i42a80e9d2e10438b96ae3db37a9fc492" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/>&#160;and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other asset-<br/>backed<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfb3509175a421fa38431213004bc2a_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtMS0xLTEtMTY3OTA4_8c953488-4f08-44db-a136-9cf7482cbc9c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4ad698b6cb4a918854adc5690c6f16_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtMy0xLTEtMTY3OTA4_0a60c53d-5920-46fb-8ca3-635babccb53e">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b6787f48b3442d8a63c30333c6b458_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtNS0xLTEtMTY3OTA4_5877e1f1-c886-4c4d-9b99-8de130c18d19">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff589f47f514ece9b347067993f1a0a_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtNy0xLTEtMTY3OTA4_59e68da5-ff3f-4740-96d0-4b080da4096a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f194dd99c7e4f68b3ff5746bc03b35e_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtMTEtMS0xLTE2NzkwOA_0c361d6d-e5ac-45f3-ab8a-289522ec9d3f">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtMTMtMS0xLTE2NzkwOA_7c976f16-4cb0-47cf-85cb-03fbbd8adbe7">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital losses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtMS0xLTEtMTY3OTA4_2dfed2ec-3d0e-4673-b24e-e2f2aee23ff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtMy0xLTEtMTY3OTA4_3261cdd2-371a-472a-80b6-2749942ee825">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtNS0xLTEtMTY3OTA4_48153f01-31b3-442e-aa00-1ee62062ecff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtNy0xLTEtMTY3OTA4_eeea398f-7c9f-4b30-ba0c-c21bb6bebb3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtMTEtMS0xLTE2NzkwOA_86647c83-2940-4ee7-89f6-81191fa3f2c2">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtMTMtMS0xLTE2NzkwOA_f8191f4b-c923-4145-bbf0-8d7d3f9fa373">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtMS0xLTEtMTY3OTA4_3f7d1795-0e14-4ff9-8f24-ae9ec5dcbb5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtMy0xLTEtMTY3OTA4_f7bfebb3-f6b9-406b-afd8-d10932a83065">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtNS0xLTEtMTY3OTA4_c120aab1-df52-4a70-8159-c8be83a28f96">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtNy0xLTEtMTY3OTA4_5d032de5-6c5d-4625-87fe-251c03e9f4d5">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtMTEtMS0xLTE2NzkwOA_a2b059ef-db06-4523-bc49-cb6f54bfe441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtMTMtMS0xLTE2NzkwOA_3a297691-10d5-4d2c-b239-82b32e82f692">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtMS0xLTEtMTY3OTA4_decf5c37-94bb-4d0a-8a27-22e1afa88c6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtMy0xLTEtMTY3OTA4_ca23e75c-269d-46e3-9d03-ffdf42064448">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtNS0xLTEtMTY3OTA4_34285878-f1a8-416a-ae24-2da0fd4a0746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtNy0xLTEtMTY3OTA4_b4e1e3f5-0bb6-4a77-a4d6-048f8232338d">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtMTEtMS0xLTE2NzkwOA_4fb681e2-925d-44b1-9400-4ef9cff5cce5">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtMTMtMS0xLTE2NzkwOA_edd3ecd6-ada5-4b57-b148-fa2f23f46859">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtMS0xLTEtMTY3OTA4_3f442fe8-c206-4504-a2d3-2af9cf9c2ad9">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtMy0xLTEtMTY3OTA4_9673ffea-484e-4837-b26a-86b2654b26c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtNS0xLTEtMTY3OTA4_75259c98-1172-4180-849c-16f8af34f0bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtNy0xLTEtMTY3OTA4_72e5ef8c-d025-45ae-9d93-24591878061b">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtMTEtMS0xLTE2NzkwOA_134f3b79-fd52-4257-841d-9770d8846ee5">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtMTMtMS0xLTE2NzkwOA_1dc5af40-57bf-44da-b2d3-66624938ff60">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctMS0xLTEtMTY3OTA4_1567ff11-0419-4d15-8670-7ef35074f933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctMy0xLTEtMTY3OTA4_615b4a42-eae5-4c39-94b2-c28aeb42bcab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctNS0xLTEtMTY3OTA4_d756194b-5f51-4b9b-9192-43aa958390e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctNy0xLTEtMTY3OTA4_30d6d99a-b360-4ac3-8753-eb761a95fc8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctMTEtMS0xLTE2NzkwOA_6a0a8549-670b-47d7-ab86-57d26f314d77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctMTMtMS0xLTE2NzkwOA_ed31a081-e8a6-424f-b314-7ea669ca43e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtMS0xLTEtMTY3OTA4_1134e4fe-2297-4fd1-88e6-06b0d64d40b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtMy0xLTEtMTY3OTA4_8918cc91-d9dc-41ad-bff4-303772ef3360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtNS0xLTEtMTY3OTA4_94223afe-1f30-403c-bf1e-86773943241c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtNy0xLTEtMTY3OTA4_94ab2d81-4334-460f-8843-466417591deb">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtMTEtMS0xLTE2NzkwOA_9756a864-6011-42d1-88f7-8d75ca70d69b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtMTMtMS0xLTE2NzkwOA_4389e444-c85c-4104-b1b8-8c2b35fa2bcd">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f0cd92f49b4b2ba3ae745e22916f37_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktMS0xLTEtMTY3OTA4_d6a4dc83-b5a9-4065-a294-07e6e44cc20e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb1f815761e4abf81f0b8c3d4f8c6c2_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktMy0xLTEtMTY3OTA4_251c3b12-59e1-45bc-8f2f-313534d81e71">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95dfe2b0be4243cfad329e2e411e3303_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktNS0xLTEtMTY3OTA4_1a76fa30-14b3-4fad-a629-0bcc2b594bbc">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd5e7556c1145898755e2b6da40bee8_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktNy0xLTEtMTY3OTA4_abeefd41-3131-487f-9b12-a64191732b94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7975ad7519e54b6db43ace8eb80066d2_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktMTEtMS0xLTE2NzkwOA_eaca69a4-95a1-41fe-8d90-99190e87de36">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktMTMtMS0xLTE2NzkwOA_201639bb-d762-4227-8ced-1100c46f6482">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in net unrealized capital losses included in other comprehensive loss associated with Level 3 financial assets which were held as of December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzcyMTc_6cd263c6-ad5b-4f6a-b714-623ee2d67cf1">9</ix:nonFraction> million during the year ended December&#160;31, 2022.</span></div><div><span><br/></span></div><ix:continuation id="i42a80e9d2e10438b96ae3db37a9fc492"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.434%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/>&#160;and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other asset-<br/>backed<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Redeemable<br/>preferred<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ee925bb3e5402b955f9868457737db_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtMS0xLTEtMTY3OTA4_976cc7ff-2a37-4f51-bb0e-0924289c1cdd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3892577d13a4a62a891505c7f399a79_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtMy0xLTEtMTY3OTA4_713baab9-c1a8-4e25-89e0-43dfc7f3909c">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia091e18719b84015824f1dd5f80bc7eb_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtNS0xLTEtMTY3OTA4_c249d96f-9062-4fbe-9aeb-87373cbbb056">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7619afe50a794a4a84a50dcfbf630c38_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtNy0xLTEtMTY3OTA4_1f138d42-590d-4474-9aec-09a563fe3fb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c1ae91ff3442528fb1f71c91933d34_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtOS0xLTEtMTY3OTA4_db955d24-8d0b-41ac-8766-84fc239fa202">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i662d2dd29a2a4a22b0b5e93c396ed6f8_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtMTEtMS0xLTE4MDU1Mg_2469364b-4bda-4828-92fb-966ee4c44ec9">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia37d53d84cb44bc39778f9546e36542d_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtMTMtMS0xLTE4MDU1Mg_aeeaab73-22df-447b-9925-b06f0b24e60d">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtMS0xLTEtMTY3OTA4_0ca30c9c-fe21-45b2-a774-6fd7f71ad68c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtMy0xLTEtMTY3OTA4_894a4f1f-4cef-4da3-94d2-892b1a516f67">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtNS0xLTEtMTY3OTA4_b4d34b16-936b-4fc4-b8e7-187cd1c87f0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtNy0xLTEtMTY3OTA4_06718c07-dfde-4f08-8c93-1d502d4ebf73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtOS0xLTEtMTY3OTA4_a3193098-e268-40fb-a45b-f5a0d5131f2a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtMTEtMS0xLTE4MDU1Mg_736a5eb5-f507-47ac-b395-ff32d3247d1e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtMTMtMS0xLTE4MDU1Mg_40ab7a63-ec9d-4f00-b576-5acf6c7823a6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtMS0xLTEtMTY3OTA4_45d3361e-1942-43eb-8430-f6e53db7accd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtMy0xLTEtMTY3OTA4_9571fd59-2e84-431d-97cb-09ec7ccaffbe">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtNS0xLTEtMTY3OTA4_72823ea5-d3de-457e-bc90-608466f27a91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtNy0xLTEtMTY3OTA4_bf9fccab-4775-43fd-a965-42ef4418e196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtOS0xLTEtMTY3OTA4_e257ac10-7f1f-46b5-a2d5-874b2d3fbd83">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtMTEtMS0xLTE4MDU1Mg_2881a5e6-8d64-49cb-86af-5f5bb6003033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtMTMtMS0xLTE4MDU1Mg_e063cf78-2956-46f4-a460-55bfae5bead6">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtMS0xLTEtMTY3OTA4_76102c43-bfc7-435f-b551-5e326c1d56d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtMy0xLTEtMTY3OTA4_af5324cb-a9b1-4b18-9826-ebb22b5c998c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtNS0xLTEtMTY3OTA4_87c5698e-3efd-4bd2-b813-36af0001572c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtNy0xLTEtMTY3OTA4_17bfa1e5-d79f-4d20-873e-0f6c6e1d6cc4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtOS0xLTEtMTY3OTA4_ffc106f2-c44e-4824-aaa4-9b46d09603c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtMTEtMS0xLTE4MDU1Mg_9a395354-f885-4f27-acea-ffa6246b6bac">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtMTMtMS0xLTE4MDU1Mg_82732880-bb62-4ea2-8897-b66bdc43e979">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtMS0xLTEtMTY3OTA4_97ad9ebb-06a9-47a3-bbc5-4280ead4e4a2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtMy0xLTEtMTY3OTA4_04c6c56c-ca12-412b-b0b2-6d9145fd7cef">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtNS0xLTEtMTY3OTA4_1a0a691f-c239-41cf-9bf2-00a80fba4114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtNy0xLTEtMTY3OTA4_29fef5fc-645e-4cc6-b1a4-cab8e8d79a82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtOS0xLTEtMTY3OTA4_335b5546-6c1a-4265-b7c8-1d9544a9a296">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtMTEtMS0xLTE4MDU1Mg_ff38958a-dc40-4343-b697-759f1ad253f7">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtMTMtMS0xLTE4MDU1Mg_5600d4be-420c-48e6-a500-7c35ca59d975">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctMS0xLTEtMTY3OTA4_55183619-d238-4a72-b5d7-7a1508c6a929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctMy0xLTEtMTY3OTA4_9c782071-a937-42a9-a337-d295f35bf080">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctNS0xLTEtMTY3OTA4_8c34c450-2c16-4dee-bda3-2c9cbbae03a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctNy0xLTEtMTY3OTA4_9580579f-fc5a-4355-93f7-86ad62af0d97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctOS0xLTEtMTY3OTA4_84fac741-5ea0-4dcb-9cdf-1a28ff1901ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctMTEtMS0xLTE4MDU1Mg_9fc66548-3cc8-4dec-a329-d82f49162e01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctMTMtMS0xLTE4MDU1Mg_c94d7a11-d1de-42bd-bf77-2fb2a79d5da7">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtMS0xLTEtMTY3OTA4_f0acb6d8-bb72-433e-99ac-61039d3e2c16">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtMy0xLTEtMTY3OTA4_44dfe49f-7222-4f7b-bae4-4924e36d2278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtNS0xLTEtMTY3OTA4_e16acc70-63ef-4c2b-8711-b9f45e6ac4c5">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtNy0xLTEtMTY3OTA4_04916c3c-227c-4c8b-99b3-9f7945594ed7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtOS0xLTEtMTY3OTA4_8ffc5aa8-60ee-405b-a15f-18f93916b483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtMTEtMS0xLTE4MDU1Mg_0e8fa97a-927c-427a-aa32-92048ba6e3fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtMTMtMS0xLTE4MDU1Mg_60729c3a-e7a4-448f-963d-52864390717e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfb3509175a421fa38431213004bc2a_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktMS0xLTEtMTY3OTA4_21378612-6489-448f-8d05-26d6003f022a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4ad698b6cb4a918854adc5690c6f16_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktMy0xLTEtMTY3OTA4_816dda2e-398b-4e45-ae1e-63ffb5e5b977">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b6787f48b3442d8a63c30333c6b458_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktNS0xLTEtMTY3OTA4_f1e48793-9ce0-4aab-ac10-06e0fdf9864b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff589f47f514ece9b347067993f1a0a_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktNy0xLTEtMTY3OTA4_20a25326-936b-4487-9191-41fca9c2fdf2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75346ba9d76e4cf0980dea9c58ccaa81_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktOS0xLTEtMTY3OTA4_28bd6d47-57ed-4239-90f8-5b8447b5e81e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f194dd99c7e4f68b3ff5746bc03b35e_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktMTEtMS0xLTE4MDU1Mg_59ab7f62-6d92-4ffd-bec7-9bd85daaa02c">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktMTMtMS0xLTE4MDU1Mg_0f167766-69f8-4985-9207-fe3dab27fa29">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in net unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzc0OTg_c55b6b75-feda-4c68-abc9-f50831dfa812">4</ix:nonFraction>&#160;million during the year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross transfers into (out of) Level 3 during the years ended December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers into Level 3</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66bcf7a88ef8420db041c82d229c682d_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzEtMS0xLTEtMTY3OTA4_2d34b7ca-e86c-463c-851a-d9284c5684d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic858e8e5cf2d4617b20fa3fa03a4a293_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzEtMy0xLTEtMTY3OTA4_cf3a26d6-0c3a-4d46-84cd-02bc34b558e6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66bcf7a88ef8420db041c82d229c682d_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzItMS0xLTEtMTY3OTA4_e4e448a3-935a-4280-a3cd-5423f041f58b">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic858e8e5cf2d4617b20fa3fa03a4a293_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzItMy0xLTEtMTY3OTA4_0b1ea96e-d686-4a5d-a1cc-3a8308138efd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers into (out of) Level 3</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66bcf7a88ef8420db041c82d229c682d_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzMtMS0xLTEtMTY3OTA4_9fb4a528-842a-4e7a-9d02-9b0691d75154">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic858e8e5cf2d4617b20fa3fa03a4a293_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzMtMy0xLTEtMTY3OTA4_0ca0884f-f5d2-466c-bba5-b82e8c8546d3">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ice8fee9d836c4495bd26ba7ef1e24704" continuedAt="ia22ad68d97db4c499918631359bcc7f7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value on the Consolidated Balance Sheets</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjM3_ddd3cf9f-598f-4f6e-87f9-e93cabdff09d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Estimated Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe1938eb02c435297cc130427df950c_I20221231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtMS0xLTEtMTY3OTA4_9b592639-1222-46f9-8fdb-964c907dce72">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtMy0xLTEtMTY3OTA4_0f378cb1-f0b1-410b-b080-7353e184287d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6be9b43dab4ff69cd98c57e4510019_I20221231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtNS0xLTEtMTY3OTA4_04caee0b-f315-455b-be84-1cb2cccb5a93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c075490097946eb8ba4e98465055bd6_I20221231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtNy0xLTEtMTY3OTA4_afe6317b-4863-43f1-bbdd-c7bb9411a50d">978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734643ad1ae34563ab562dd2a9a185e0_I20221231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtOS0xLTEtMTY3OTA4_7cadf7aa-0cc2-427a-b673-edaa46836972">978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe1938eb02c435297cc130427df950c_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzUtMS0xLTEtMTY3OTA4_06b69b0a-c475-4296-94e4-103b2de4b437">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe1938eb02c435297cc130427df950c_I20221231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtMS0xLTEtMTY3OTA4_af9f1c8a-d127-41ea-a540-5fef356ab087">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtMy0xLTEtMTY3OTA4_6142c92c-9291-450e-8f9f-8dd59ef911b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6be9b43dab4ff69cd98c57e4510019_I20221231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtNS0xLTEtMTY3OTA4_bf3e8dce-0074-4fed-b0c6-7a9e5c3d6971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c075490097946eb8ba4e98465055bd6_I20221231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtNy0xLTEtMTY3OTA4_c310a6cb-1b60-49ba-9960-e3f3257d37f3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734643ad1ae34563ab562dd2a9a185e0_I20221231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtOS0xLTEtMTY3OTA4_12080207-3d15-4deb-a83e-0eb2acacc1d6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe1938eb02c435297cc130427df950c_I20221231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktMS0xLTEtMTY3OTA4_6f75d39b-db2c-4b03-aeb2-37597b8fd7e2">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktMy0xLTEtMTY3OTA4_797f23ad-6793-4951-a6fa-a3f0b26ab14e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6be9b43dab4ff69cd98c57e4510019_I20221231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktNS0xLTEtMTY3OTA4_ecfebc8d-b8d8-440b-87b9-9ed88fa5e953">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c075490097946eb8ba4e98465055bd6_I20221231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktNy0xLTEtMTY3OTA4_497d1455-bce8-4f81-8f65-c8c1bbfd6a3a">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734643ad1ae34563ab562dd2a9a185e0_I20221231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktOS0xLTEtMTY3OTA4_4e5609b9-4bb0-45c4-b671-1cf0ce533811">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe1938eb02c435297cc130427df950c_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTEtMS0xLTE2NzkwOA_7d3cfc70-8e3f-48be-80f7-664674352b73">52,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTMtMS0xLTE2NzkwOA_e5f39bb3-aee9-4225-a720-363422a15e45">47,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6be9b43dab4ff69cd98c57e4510019_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTUtMS0xLTE2NzkwOA_6301a198-ef6d-4bea-a68e-892043266a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c075490097946eb8ba4e98465055bd6_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTctMS0xLTE2NzkwOA_efa88c34-71b9-4e3a-805d-c40728884f0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734643ad1ae34563ab562dd2a9a185e0_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTktMS0xLTE2NzkwOA_fc669bf7-bb1f-475e-a6f5-685615b2242f">47,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699884ef14c74682af2d844bfa691e05_I20211231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTEtMS0xLTE2NzkwOA_eff5bd59-bf06-4305-8c8e-d06844560c0b">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863995f01893429ba0b90278c34784f7_I20211231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTMtMS0xLTE2NzkwOA_6ee62110-f737-47c0-8d18-fb5a8191a095">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355cdb170edb433ca79e61e309a40c6b_I20211231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTUtMS0xLTE2NzkwOA_60c78e6c-7733-43ed-a53a-e9fda11a6478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c500be5647438295ed663bd07d0536_I20211231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTctMS0xLTE2NzkwOA_f9ef2169-90cd-4395-8da3-92bde1b3c053">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf216acef3094d348747eeef4045d573_I20211231" decimals="-6" name="us-gaap:MortgagesHeldForSaleFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTktMS0xLTE2NzkwOA_c51cdef8-d88c-44f5-bf2e-4983deb7b026">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699884ef14c74682af2d844bfa691e05_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE1LTEtMS0xLTE2NzkwOA_8ed456a4-97d1-40f7-bdba-89acac25619d">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699884ef14c74682af2d844bfa691e05_I20211231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTEtMS0xLTE2NzkwOA_26f96c01-c069-4b09-adba-a1ba0c7cd67e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863995f01893429ba0b90278c34784f7_I20211231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTMtMS0xLTE2NzkwOA_ffaf4687-0de9-4a69-97d4-9dd5113683a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355cdb170edb433ca79e61e309a40c6b_I20211231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTUtMS0xLTE2NzkwOA_70f85ed4-85a9-4a04-9146-d944a2a87146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c500be5647438295ed663bd07d0536_I20211231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTctMS0xLTE2NzkwOA_f42287af-5bfa-4949-ac12-763843e27cd0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf216acef3094d348747eeef4045d573_I20211231" decimals="-6" name="cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTktMS0xLTE2NzkwOA_c56a3a10-29bc-41c9-b4b8-78f8760791cd">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699884ef14c74682af2d844bfa691e05_I20211231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTEtMS0xLTE2NzkwOA_9b95d19e-36e1-4afe-a7ff-685c804ba2ce">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863995f01893429ba0b90278c34784f7_I20211231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTMtMS0xLTE2NzkwOA_a7101b6d-d77f-4a89-97df-de3279d7b163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355cdb170edb433ca79e61e309a40c6b_I20211231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTUtMS0xLTE2NzkwOA_7bfe8b98-0f83-40a1-93ff-d3db9d50c164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c500be5647438295ed663bd07d0536_I20211231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTctMS0xLTE2NzkwOA_520c58fe-e320-40df-b803-4c5a347ede98">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf216acef3094d348747eeef4045d573_I20211231" decimals="-6" name="cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTktMS0xLTE2NzkwOA_561de765-160c-404a-9ea5-8e737dcbb316">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699884ef14c74682af2d844bfa691e05_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTEtMS0xLTE2NzkwOA_44aad2c0-b3e6-43b9-94e0-c0f38f1e1e8d">56,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863995f01893429ba0b90278c34784f7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTMtMS0xLTE2NzkwOA_a907b5db-7f0c-485f-be7f-b6e7eafe0b72">64,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355cdb170edb433ca79e61e309a40c6b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTUtMS0xLTE2NzkwOA_29491703-954a-4735-aabb-66a2f4bc39f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c500be5647438295ed663bd07d0536_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTctMS0xLTE2NzkwOA_d5505119-bd1f-4935-9cbc-5a01314c645b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf216acef3094d348747eeef4045d573_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTktMS0xLTE2NzkwOA_ff69a0ce-5c2f-4e0d-a386-37f86c2925a0">64,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information regarding the valuation of cost method investments. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term debt of $<ix:nonFraction unitRef="usd" contextRef="i7844b63d898f426f84d9c961ce7de5ab_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzI3NDg3NzkwODE4MDg_1900634a-efaf-4609-9bcd-e1ab2bfa0e8e">3</ix:nonFraction>&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts Measured at Fair Value on the Consolidated Balance Sheets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets relate to the Company&#8217;s large case pensions products which represent funds maintained to meet specific objectives of contract holders.&#160;Since contract holders bear the investment risk of these assets, a corresponding Separate Accounts liability has been established equal to the assets.&#160;These assets and liabilities are carried at fair value.&#160;Net investment income and capital gains and losses on Separate Accounts assets accrue directly to such contract holders.&#160;The assets of each account are legally segregated and are not subject to claims arising from the Company&#8217;s other businesses.&#160;Deposits, withdrawals, net investment income and realized and unrealized capital gains and losses on Separate Accounts assets are not reflected in the consolidated statements of operations, shareholders&#8217; equity or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets include debt and equity securities.&#160;The valuation methodologies used for these assets are similar to the methodologies described above in this Note 4 &#8216;&#8216;Fair Value.&#8217;&#8217;&#160;Separate Accounts assets also include investments in common/collective trusts that are carried at fair value. Common/collective trusts invest in other investment funds otherwise known as the underlying funds. The Separate Accounts&#8217; interests in the common/collective trust funds are based on the fair values of the investments of the underlying funds and therefore are classified in Level 2. The assets in the underlying funds primarily consist of equity securities. Investments in common/collective trust funds are valued at their respective net asset value (&#8220;NAV&#8221;) per share/unit on the valuation date.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia22ad68d97db4c499918631359bcc7f7"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjM1_63661af3-f6f0-45fa-be23-abe39b47b5f9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts financial assets at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0582621bb34df0a6675d029c295a94_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMS0xLTEtMTY3OTA4_e0117d24-f033-476e-b5ca-f1d5eeb995f3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e64cd8ab5fb4322a855fe783aaa1050_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMy0xLTEtMTY3OTA4_63918100-fb23-4ffb-a400-254ec9170859">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd86471ead2541e4b8e2ee2e52429bcc_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItNS0xLTEtMTY3OTA4_e0924231-bc5d-44b5-b0f5-85b599ceb909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1caa2a8534f942fdb15c0e68a3ba7cb3_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItNy0xLTEtMTY3OTA4_8ab7cd81-9077-49d4-acc1-684954af2c3a">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1901bac7f448c48fe0d4065b09e0e6_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItOS0xLTEtMTY3OTA4_3164b44a-4008-41f5-a3d5-0c8eff0614cc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275d0ec6124c46a7ab946d9a16477a75_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMTEtMS0xLTE2NzkwOA_5e9a4e98-0bb1-4c49-8bc8-34f0ec09ac98">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i749066de634e42b3816f92927cdd0c23_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMTMtMS0xLTE2NzkwOA_4a696873-cf05-49d8-866e-d4b218a77c2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f70ae1bf3c746fe82376b68d9bade16_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMTUtMS0xLTE2NzkwOA_70db5a20-21e0-4355-b9fd-5f2af572f951">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76610efce5044b078fe774b073da1159_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMS0xLTEtMTY3OTA4_4bf63c4f-d4d3-48b2-ab65-4d44624896b1">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799622beabe24d068a330216378ec7d8_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMy0xLTEtMTY3OTA4_4bfef901-a81c-4411-8be1-8992c863b761">1,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i303c9460e5aa40ba8797ef57bc7a6665_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtNS0xLTEtMTY3OTA4_855ac785-2c2c-411f-b131-d196e612fc7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69cb21ce24c45138129b0b0b0258605_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtNy0xLTEtMTY3OTA4_97ea7335-bfdc-47c8-9e33-98762ffa00fa">2,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43f9bbeac1c48f09d85ab8bda317b67_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtOS0xLTEtMTY3OTA4_6858ff1f-8010-4e4e-b774-e6c5ea73673a">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790c87349c0545a0a15037b5863ea17b_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMTEtMS0xLTE2NzkwOA_70b87e3a-94fd-4a0f-8f45-0bfd1edbb352">3,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796a9a2e1f724310a3315d9fc1be5789_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMTMtMS0xLTE2NzkwOA_0d2a9540-68ad-48c4-88ba-474585bb069c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a6cb4a9a1a4a34a8a63c650df4220a_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMTUtMS0xLTE2NzkwOA_ab1450ed-8e4f-40a2-98e4-76ffad3516e7">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22d221a134574691acb5e35393d71d09_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMS0xLTEtMTY3OTA4_0c3091eb-bdb2-4abb-9dd2-87baa8e3d5f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id68f0f4d9e054479ba78b7c748a66258_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMy0xLTEtMTY3OTA4_29487353-1776-4b3a-93e5-83848badf1cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc0567d043f4a288311dc383ab5b569_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtNS0xLTEtMTY3OTA4_6afd835e-1115-48fd-9693-a5a52a94453e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if034f6862b3d4fd4936961827df503fe_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtNy0xLTEtMTY3OTA4_f991885b-2246-44e1-846d-23007b5d980b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i960dac857f814d2aaf3da5e41ab12bea_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtOS0xLTEtMTY3OTA4_211b4887-18ef-41de-b0ba-6bdeeabfcbd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1564d3fac24665bd7b402ab4a1fdea_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMTEtMS0xLTE2NzkwOA_f17972e5-64ad-4411-8249-6980cc32ef96">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769ac61262e54e7ea669fe5223c1a8a5_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMTMtMS0xLTE2NzkwOA_90c855c7-7062-4247-9445-6bb5a9d1cffb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff1acae7f1f4a61995476442d7613e2_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMTUtMS0xLTE2NzkwOA_0fbce9fa-4a94-462a-9dc4-42403f0d0d23">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common/collective trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b34eb9a40f14a1392d66709b0113c87_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMS0xLTEtMTY3OTA4_60bb84c4-bef6-40b9-9925-26388ae2f167">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842dc9cc1f984655976affbd54127c54_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMy0xLTEtMTY3OTA4_3c75f1ba-f388-4517-b356-552279c8c18e">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6d75b00af74666a638509a7b9e9285_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtNS0xLTEtMTY3OTA4_a1c70f5a-35ac-44a7-9214-a93da9abe9fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35e951e7f7044a78bdf58c5c994e504_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtNy0xLTEtMTY3OTA4_729ef065-116c-4766-870b-9489d10df521">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f80eb74b06647c996981ce7bb5b9d6a_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtOS0xLTEtMTY3OTA4_fbc76e97-f2e5-4015-9458-61fcf5df10ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ceec40d348b417d9dc7a41eb39aa1b8_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMTEtMS0xLTE2NzkwOA_54dc04cb-0b70-4641-bbeb-a711b0a89420">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad03180d40f4e7f900eaf9ce57d2f6f_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMTMtMS0xLTE2NzkwOA_83b0f1e2-c97a-4ffb-b080-e262705360d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2314c70272ad44729021b8b7c81f68d2_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMTUtMS0xLTE2NzkwOA_b5cd9c12-6508-402e-a021-6642c6895a98">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMS0xLTEtMTY3OTA4_e7683847-11bb-4699-9d3d-2cc400c7c5a6">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c69d485444837bbae724a028fb845_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMy0xLTEtMTY3OTA4_3b50b8f0-95d3-4ff1-a139-8b7fa0933bcc">2,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtNS0xLTEtMTY3OTA4_22d6453e-5229-4d82-adfa-c0c8e2f08eed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtNy0xLTEtMTY3OTA4_1bfec79c-3d46-41f6-9129-19e44220be4d">3,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtOS0xLTEtMTY3OTA4_798e0d93-0dd2-4211-92aa-65431e61d8e9">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMTEtMS0xLTE2NzkwOA_0a5470f4-62f3-4f15-92b9-c78f44707cf7">3,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMTMtMS0xLTE2NzkwOA_53ca08a0-8ca5-4ee6-ba65-e4b650acf29b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMTUtMS0xLTE2NzkwOA_0d6f32f0-e351-4029-993b-cd370a7a16ed">5,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $<ix:nonFraction unitRef="usd" contextRef="i6247aa5d844b4cefa1e771f6ef8a7da7_I20221231" decimals="-6" name="us-gaap:SeparateAccountsLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMDIy_336ebc6f-bf50-4893-93ba-c07958a378de">85</ix:nonFraction> million of other payables and $<ix:nonFraction unitRef="usd" contextRef="i74b7d5d8bfba43248a819e81b1b296b6_I20211231" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMDI5_b1b77d1a-11ea-412e-a5b1-f1ec2ae76637">70</ix:nonFraction>&#160;million of other receivables at December&#160;31, 2022 and 2021, respectively.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022 and 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="i194bc2ab09d84172aea4a9682706e5a8_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMTQ1_cf8a3aa4-09c2-44cc-b54e-224214bac73d"><ix:nonFraction unitRef="usd" contextRef="id206ebf70f104468bb9392e4f8e41a61_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMTQ1_d958ea13-c566-47f9-a80b-40498e01fb77">no</ix:nonFraction></ix:nonFraction> gross transfers of Separate Accounts financial assets into or out of Level 3.</span></div></ix:continuation><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_133"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyODk_e635c5b9-33b8-4821-9eee-b86a67145fcf" continuedAt="i7ed1786f81dd4d05889ddaa3d02ee0f8" escape="true">Goodwill and Other Intangibles</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i7ed1786f81dd4d05889ddaa3d02ee0f8" continuedAt="ic08675e72b884d14912b6c6a1831e6cb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyOTA_e506d9b8-1195-415a-b224-140554322b69" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the changes in the carrying amount of goodwill by segment for the&#160;years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f9799c87004ca590fa53584c7e24f8_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEtMS0xLTEtMTY3OTA4_4e52efcb-64bf-4914-9fc0-9ca985fd69f8">45,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6f1f557fab4461b4f09715be534c58_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEtMy0xLTEtMTY3OTA4_282cc25c-cbcd-482e-a34e-823be426beed">23,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4751bc253ec4ddf90922f866ccf2b7f_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEtNS0xLTEtMTY3OTA4_ce4ceb3a-d2e8-4ca9-bc9f-b277dd5ddb8c">10,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEtNy0xLTEtMTY3OTA4_606a19bf-aa97-4e17-8044-94254e157d7c">79,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefb4b1c3d63e4323ae108f339bf86ea0_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzUtMS0xLTEtMTY3OTA4_2345b7c2-9328-4c99-9c5a-fb96bf843363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffd3cc38a8b4021a53283d65a4c0964_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzUtMy0xLTEtMTY3OTA4_eafd042e-1b24-4605-a0d8-00f58f8aead8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e0fac73260b479989119ffb924ad3e9_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzUtNS0xLTEtMTY3OTA4_f20e94b8-7103-4aba-9d72-a3f4aef5abe3">431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzUtNy0xLTEtMTY3OTA4_a3ec6914-8889-4b8f-8a5c-c8f6b4338d02">431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7e4c14ecb14064a1e1cb88fae9be52_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzYtMS0xLTEtMTY3OTA4_bd2e85cc-28fa-45c3-903d-6a3c974d5dc4">45,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09cd220413f4c58b188c10acdaca66c_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzYtMy0xLTEtMTY3OTA4_01dc82eb-3819-455c-8291-ba6237df2581">23,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0e8d9ed04c418a948fd84835bca811_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzYtNS0xLTEtMTY3OTA4_e76098e5-5f76-4ee2-8e52-2a8da4cb4e95">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzYtNy0xLTEtMTY3OTA4_287a31e7-d519-434c-8599-6c8b0537426e">79,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i508064fb813a4f16a124a4de02fbcd59_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzktMS0xLTEtMjE2MTMx_8b2d0e84-2f2d-4f86-b62e-1bdd3f90f0ec">971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef4eb7b015b4186b848a7d8272984a6_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzktMy0xLTEtMjE2MTMx_916f1d74-d1cf-413a-a9c7-050a62a864db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96931f5310964061af361408b2ab6730_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzktNS0xLTEtMjE2MTMx_eac527dd-0b08-4064-9410-6594f7efba81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8d9089fdf7c4007bbe779a88d4715e8_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzktNy0xLTEtMjE2MTMx_be7c9659-140b-4a3d-8e54-0373c5cd1dae">971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b3902b297a43b9a015149f29e45bf7_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEwLTEtMS0xLTE2NzkwOA_62abb7cb-fb0c-4be0-acd1-e37569d32722">44,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c4edc5b99644fa3997863adf1255293_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEwLTMtMS0xLTE2NzkwOA_91661278-6978-4f46-950a-d15318b92d3b">23,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEwLTUtMS0xLTE2NzkwOA_4cdb6ac9-5044-4d49-a53d-47d0549c8aab">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEwLTctMS0xLTE2NzkwOA_1f7004fe-54e4-4380-900a-c9aa8e8c7c75">78,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the decrease in the carrying amount of goodwill was primarily driven by the divestitures of bswift, PayFlex and the Thailand business. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information. During the year ended December&#160;31, 2021, the decrease in the carrying amount of goodwill was primarily driven by the impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated an impairment of the goodwill associated with the LTC reporting unit, as the reporting unit&#8217;s carrying value exceeded its fair value as of the testing date. The results of the impairment tests of the remaining reporting units indicated that there was no impairment of goodwill as of the testing date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the LTC reporting unit continued to face challenges that have impacted the Company&#8217;s ability to grow the LTC reporting unit&#8217;s business at the rate estimated when its 2020 goodwill impairment test was performed. These challenges include lower net facility admissions, net long-term care facility customer losses and the prolonged adverse impact of the COVID-19 pandemic and the emerging new variants, which resulted in more significant declines in occupancy rates experienced by the Company&#8217;s long-term care facility customers than previously anticipated. During the third quarter of 2021, LTC management updated their 2021 annual forecast and submitted their long-term plan which showed deterioration in the financial results for the remainder of 2021 and beyond. The Company utilized these updated projections in performing its annual impairment test, which indicated that the fair value of the LTC reporting unit was lower than its carrying value, resulting in a $<ix:nonFraction unitRef="usd" contextRef="ie0d6894378d3433197250c8e10ca47a7_D20210701-20210930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzIxMDM_2a53c550-bba0-443d-88c9-22f7b32a8c68">431</ix:nonFraction>&#160;million goodwill impairment charge in the third quarter of 2021. The fair value of the LTC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. As of December&#160;31, 2021, there was <ix:nonFraction unitRef="usd" contextRef="i9bc72442418741689eed1454ae87700b_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyODE_c7fb74a3-92e8-4d00-98ab-aa1a21ff441e">no</ix:nonFraction> remaining goodwill balance in the LTC reporting unit. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both December&#160;31, 2022 and 2021, cumulative goodwill impairments were $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-8" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzIxOTkwMjMyNjYzOTU_24ffe6a6-8290-45a9-a38a-fc683587d6ca"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-8" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzIxOTkwMjMyNjYzOTU_9bf9ca4f-01ab-4dd3-a5c7-3c709c926c07">6.6</ix:nonFraction></ix:nonFraction> billion.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ic08675e72b884d14912b6c6a1831e6cb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyODU_29cf2f62-906c-415e-8ae7-a87704623021" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company&#8217;s intangible assets as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions, except weighted average life</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzItMS0xLTEtMTY3OTA4_d926de93-8213-4ac4-8b0b-4324c6a65687">10,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzItNS0xLTEtMTY3OTA4_5e7b241a-1999-4207-a918-389337433577">10,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264d976e57564672b0babd9565bb98e1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzMtMS0xLTEtMTY3OTA4_8d6dfb59-f40b-4d88-9c90-74a7316426ab">21,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i264d976e57564672b0babd9565bb98e1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzMtMy0xLTEtMTY3OTA4_3e707306-aff0-4743-a7b2-37e8e0f50a16">10,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264d976e57564672b0babd9565bb98e1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzMtNS0xLTEtMTY3OTA4_4649f8da-7e0f-4e05-9be2-9986baf17bdb">10,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iab7e8be7f4e347beb8eceb156d106b36_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzMtNy0xLTEtMTY3OTA4_764b75a2-5fae-435f-979d-7854b5b3ab04">13.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d0930b2b2543929971d15fba0e45ea_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzQtMS0xLTEtMTY3OTA4_b08834d8-e6a8-4015-96db-f5894cb49c2f">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53d0930b2b2543929971d15fba0e45ea_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzQtMy0xLTEtMTY3OTA4_319fe20b-8e02-438b-8a68-bc15a547bfef">1,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d0930b2b2543929971d15fba0e45ea_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzQtNS0xLTEtMTY3OTA4_068ff31b-7461-4da7-adce-43e54a32c902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e8c8634f0645dfb503773210e8249a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzUtMS0xLTEtMTY3OTA4_221cbbc7-c1c2-4881-8c19-d8c61fab764c">4,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8e8c8634f0645dfb503773210e8249a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzUtMy0xLTEtMTY3OTA4_f94f4441-b588-4f54-b182-e7605bb87f97">862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e8c8634f0645dfb503773210e8249a_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzUtNS0xLTEtMTY3OTA4_5a85977c-411b-4e1a-9789-5e00e973a20b">3,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibdf8ae9241fe4e3481243778aef0f6e7_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzUtNy0xLTEtMTY3OTA4_6b377cef-ad24-4ed8-afd8-98580f7ed778">20.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5b7dc71ff1469ab8a6a25decd8cfd6_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzYtMS0xLTEtMTY3OTA4_af478ec1-f459-42f7-8f70-d8b3af003078">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b5b7dc71ff1469ab8a6a25decd8cfd6_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzYtMy0xLTEtMTY3OTA4_46714254-3ff2-49f1-8a25-bbe9f052bc63">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5b7dc71ff1469ab8a6a25decd8cfd6_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzYtNS0xLTEtMTY3OTA4_5d3b218a-6684-44a4-b96c-f596fc57904b">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21cba4373fef485faa84dab5def0f790_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzYtNy0xLTEtMTY3OTA4_7e70b598-165c-4982-8882-4806f401d989">20.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if745b6dc0a754cd8914c4f5726b7f6bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzctMS0xLTEtMTY3OTA4_ce32679f-6e9f-4f2e-af1f-1c8d9917648a">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if745b6dc0a754cd8914c4f5726b7f6bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzctMy0xLTEtMTY3OTA4_fe9c4afd-e981-4e5b-b5e5-4f5a1f6ee229">264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if745b6dc0a754cd8914c4f5726b7f6bc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzctNS0xLTEtMTY3OTA4_b85409a5-b7c3-4764-a0db-4610b0aaa3f1">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea5c2c83314342409224f6f5d753bd47_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzctNy0xLTEtMTY3OTA4_f38b8260-807a-403d-9369-655e2f3ed10f">12.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzgtMS0xLTEtMTY3OTA4_01d9bda7-b70c-457f-a288-c78fbae4ece3">37,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzgtMy0xLTEtMTY3OTA4_5ba72533-738e-4c61-9117-79ed493f9f75">13,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzgtNS0xLTEtMTY3OTA4_2432ffba-35c9-4377-8d75-86fcf380a7cf">24,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzgtNy0xLTEtMTY3OTA4_f482e107-59d0-43af-92ea-3d537f204aba">13.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzExLTEtMS0xLTE2NzkwOA_0710f8b7-afc7-4431-a314-1d3299f905ab">10,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzExLTUtMS0xLTE2NzkwOA_b4f6a630-496a-4b6a-823e-c551b95c882f">10,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a19e9a51cc547949bdde2b93fb44a8e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEyLTEtMS0xLTE2NzkwOA_2fb5627a-9870-43ed-b377-11d34b46458d">25,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a19e9a51cc547949bdde2b93fb44a8e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEyLTMtMS0xLTE2NzkwOA_fc1a93a3-adaa-4d6b-a203-a5e9b76d963b">10,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a19e9a51cc547949bdde2b93fb44a8e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEyLTUtMS0xLTE2NzkwOA_d3686f09-d3b3-42f8-8c58-e76cf72d671b">14,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7424dfa102ba4c84917a87df011344b5_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEyLTctMS0xLTE2NzkwOA_35b0e845-c134-4ba8-8ea7-8ed283e8bc7c">15.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58636af2c05a4a5d816b65538e4b45c0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEzLTEtMS0xLTE2NzkwOA_83eb2765-8967-465a-88b1-4382b7cb8e65">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58636af2c05a4a5d816b65538e4b45c0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEzLTMtMS0xLTE2NzkwOA_47b39030-6795-4459-b1f3-9e2586819a5e">1,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58636af2c05a4a5d816b65538e4b45c0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEzLTUtMS0xLTE2NzkwOA_cec3b7ff-a2e9-4f2a-87e8-a71690326e75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f8326f384345448eaf5b58a4b2a7df_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE0LTEtMS0xLTE2NzkwOA_15b8c836-c68a-4125-b763-d65d069c5cda">4,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8f8326f384345448eaf5b58a4b2a7df_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE0LTMtMS0xLTE2NzkwOA_a8bdae57-a559-458e-8d3c-f78aac938e02">651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f8326f384345448eaf5b58a4b2a7df_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE0LTUtMS0xLTE2NzkwOA_21968bcd-72b2-4b5f-8908-6534c898d834">3,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ida22ed7ae3e1481db1884a9cb038c03f_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE0LTctMS0xLTE2NzkwOA_72a5319d-a715-4e1a-aadd-039e8feb90f4">20.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32bdea3056074d3b98bbd8937ef4391d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE1LTEtMS0xLTE2NzkwOA_7d963010-24e6-4b15-8da9-94d8157bfd5f">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32bdea3056074d3b98bbd8937ef4391d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE1LTMtMS0xLTE2NzkwOA_7f115c9f-96e1-4200-b118-7ee3f3a92c16">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32bdea3056074d3b98bbd8937ef4391d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE1LTUtMS0xLTE2NzkwOA_06b086e2-715f-49d6-a409-47df45b42492">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8b7e0efc2e614022be02cce608679450_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE1LTctMS0xLTE2NzkwOA_abbe8b66-f0d8-498c-9270-fdd462e2d743">20.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3a6f7782284dbb9c5b5e9b11d670b0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE2LTEtMS0xLTE2NzkwOA_503a197c-247c-46c1-80f9-f2192da899a5">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd3a6f7782284dbb9c5b5e9b11d670b0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE2LTMtMS0xLTE2NzkwOA_2a93bb08-0bd2-467a-a044-7bf763537783">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3a6f7782284dbb9c5b5e9b11d670b0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE2LTUtMS0xLTE2NzkwOA_7be3ffcf-1724-411c-943f-64862c54f686">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9626105cd75b4a3a9391af2fd8b0ea24_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE2LTctMS0xLTE2NzkwOA_35a24589-97ad-4577-9429-6228a6a4271f">8.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE3LTEtMS0xLTE2NzkwOA_a1cc6565-62e9-4dc7-8dc4-ddbe1f7a4864">41,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE3LTMtMS0xLTE2NzkwOA_e2705d7e-78fc-4383-8bbe-40c8c6af501f">12,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE3LTUtMS0xLTE2NzkwOA_5f06427e-0daa-4d17-ac17-03de123e7ab9">29,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE3LTctMS0xLTE2NzkwOA_38d9ded8-f259-4990-9360-872b78cab71d">15.3</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes intangible assets of $<ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="cvs:IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzgyNDYzMzcyMTM4NTQ_b72325ad-adb8-4902-9aa8-c4813f114600">28</ix:nonFraction>&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the reduction in the customer contracts/relationships intangible assets is primarily related to the Company&#8217;s loss on assets held for sale of $<ix:nonFraction unitRef="usd" contextRef="i749b13bb01c043f9a3cb673b0a199669_D20220101-20221231" decimals="-8" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5Xzk4OTU2MDQ2NTg0MjM_90553cb1-9a10-4dfd-95b6-1ec8d2d55bd8">2.5</ix:nonFraction>&#160;billion to write-down the LTC business to its estimated fair value less costs to sell. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets totaled $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMwODY_d5fae5d6-9b1e-4efd-ad8b-c67b652105d4">1.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMwOTA_42aea2ae-cc09-4d8a-bcbf-565e6f42092e">2.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMwOTc_5180d960-af76-45af-8dfe-45a6858b23e0">2.3</ix:nonFraction> billion for the years ended December 31, 2022, 2021 and 2020, respectively. <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyODQ_57ee9463-1d50-4c8e-a2e8-0ca3cd76277b" continuedAt="iba97c5fdf3644a2dbd778326ab98dcba" escape="true">The projected annual amortization expense for the Company&#8217;s intangible assets for the next five&#160;years is as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="iba97c5fdf3644a2dbd778326ab98dcba"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzEtMS0xLTEtMTY3OTA4_e7fdc3a9-f1e5-44b5-a51d-c76d74c6456e">1,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzItMS0xLTEtMTY3OTA4_0cbb9ef3-09e5-42f9-a2fb-3d16ab06e9a9">1,577</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzMtMS0xLTEtMTY3OTA4_e9f5c7b0-abd8-48bb-96ea-12d8beaaf720">1,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzQtMS0xLTEtMTY3OTA4_d1ef15ec-d542-4d68-bedd-c20fe8876e21">1,290</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzUtMS0xLTEtMTY3OTA4_f6d54604-e0f1-451c-ac6b-9757ddc4207c">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3Njg_14665906-0fd7-43fd-b97f-0646b189bbf9" continuedAt="ic4c37227c05d4570bc001af26906b840" escape="true"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzA_c8247dd6-2a00-4515-a0ea-cddb544b27de" continuedAt="i870e4e98a36243f6ac3aa5c21d5de173" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic4c37227c05d4570bc001af26906b840" continuedAt="i60ca1473adb74810ae1ae06716cbccab"><ix:continuation id="i870e4e98a36243f6ac3aa5c21d5de173" continuedAt="ia9f22d5d8d15487e827b2a4803a7b65c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of <ix:nonNumeric contextRef="ic2a7b9e629c14bcc9865d4798fa5e15c_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzIxOTkwMjMyNzM4MTI_794bc65c-b583-44a9-bf35-ac34fa281853"><ix:nonNumeric contextRef="ic2a7b9e629c14bcc9865d4798fa5e15c_I20221231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzIxOTkwMjMyNzM4MTI_aed016fb-72ee-44f5-be1e-0d7f4aa062eb">15</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="i2e150d3db673482e817a73aceedfec35_I20221231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzQ_0e1c117e-fd6c-4c3d-b87d-b5ebe91fae1b"><ix:nonNumeric contextRef="i2e150d3db673482e817a73aceedfec35_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzQ_8f220399-e5f2-4db3-a3e7-4f9d641a5324">25</ix:nonNumeric></ix:nonNumeric> years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of <ix:nonNumeric contextRef="ife6ff41a415343de94e5806faaabb281_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzIxOTkwMjMyNzM4MjA_1a1b4726-1469-49c3-8d93-c21eb63a453a"><ix:nonNumeric contextRef="ife6ff41a415343de94e5806faaabb281_I20221231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzIxOTkwMjMyNzM4MjA_8f744123-ee14-4dcc-bb45-9d94a32f8e50">3</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="id427563c92b54e5f88ceb5b6ec87195c_I20221231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzE_4f7c045a-ea47-4cbe-ae7b-56a349ed5aaa"><ix:nonNumeric contextRef="id427563c92b54e5f88ceb5b6ec87195c_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzE_e795ccd5-4334-4d88-bdc5-5cd04e4ef1ca">10</ix:nonNumeric></ix:nonNumeric> years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzI_42abfb33-a9ae-4ff1-ade7-dee9be123362" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of net lease cost for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzEtMS0xLTEtMTY3OTA4_4af92a2f-7f7c-40b1-bc83-d4fccd23852c">2,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzEtMy0xLTEtMTY3OTA4_9a3c9f3a-6c10-46ae-8c03-b99c5b448d8a">2,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzEtNS0xLTEtMTY3OTA4_93e1a19a-f4ed-4615-b9eb-eeadbe48e47c">2,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzMtMS0xLTEtMTY3OTA4_5aa9cb14-4129-4e3a-b4bd-a4b4495f1b41">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzMtMy0xLTEtMTY3OTA4_587a6107-515a-44bc-8455-46f1b0698b30">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzMtNS0xLTEtMTY3OTA4_d0927cff-4514-4ae6-8ba0-eb3f8396c4c5">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzQtMS0xLTEtMTY3OTA4_6f1a008f-2177-4587-98b2-5dd6623cfb07">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzQtMy0xLTEtMTY3OTA4_b523b8e1-07b3-4188-aee5-ce4e3373c8ed">62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzQtNS0xLTEtMTY3OTA4_412074d2-b1a9-4bd0-af25-c2c9b3ddebe6">58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzUtMS0xLTEtMTY3OTA4_d1d0a764-085b-42fc-8e80-244f4fbbf4fb">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzUtMy0xLTEtMTY3OTA4_99f7cc91-0c1e-4ff4-8aff-e1cc942a242f">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzUtNS0xLTEtMTY3OTA4_62d1b4ae-732c-46d1-bb2a-981eebd8fd14">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzYtMS0xLTEtMTY3OTA4_310100c0-c927-4127-8ab0-a7771a5962da">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzYtMy0xLTEtMTY3OTA4_d1bbdfe1-f8a1-43a2-bd87-8b25c0590a11">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzYtNS0xLTEtMTY3OTA4_b2c565db-9b97-4035-b2c7-00711e8c0941">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzctMS0xLTEtMTY3OTA4_d20e5a6c-3115-4e6a-8d41-743bfd2db79c">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzctMy0xLTEtMTY3OTA4_9b9d8ebc-bfc3-4b1d-80dd-0583a481fbf0">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzctNS0xLTEtMTY3OTA4_7bffa87c-9205-4562-b368-1f4a10286f1c">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzgtMS0xLTEtMTY3OTA4_cd70e476-b7b1-4ade-8b3f-30145c3d7277">61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzgtMy0xLTEtMTY3OTA4_3c54918d-8e4f-4d97-9f84-4dc9122e076d">59</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzgtNS0xLTEtMTY3OTA4_683ce484-e847-4a3d-bf31-611adbdbccbf">55</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzktMS0xLTEtMTY3OTA4_ddabeb85-213d-41c0-af52-65e047b00d78">3,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzktMy0xLTEtMTY3OTA4_92a64bb9-d1b8-49fd-aee1-f5c15e97ae3d">3,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzktNS0xLTEtMTY3OTA4_25fb4f8a-aa5d-4234-b39b-02fb7d94f015">3,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzItMS0xLTEtMTY3OTA4_772fd34c-5f4e-49db-b32c-ded51cc2c271">2,689</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzItMy0xLTEtMTY3OTA4_3012b09a-0f97-43dd-8bb7-c5278a251272">2,714</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzItNS0xLTEtMTY3OTA4_6a2cc99e-fe93-42ce-8674-0ff4479e2c8b">2,724</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for interest portion of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzMtMS0xLTEtMTY3OTA4_fc74a6ef-e626-4f59-9e74-ec8fa4b4c480">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzMtMy0xLTEtMTY3OTA4_7be46d50-37a7-47db-b366-062eb0167384">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzMtNS0xLTEtMTY3OTA4_7d45f7b1-6f70-4e14-a4e9-b00fb5a0945b">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows paid for principal portion of finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzQtMS0xLTEtMTY3OTA4_6379f5bf-7042-4a67-adab-ac63537d943a">62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzQtMy0xLTEtMTY3OTA4_13cf0088-bbbc-4c27-bdcd-ae75a976490a">50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzQtNS0xLTEtMTY3OTA4_580b192a-1bdc-4a60-93b8-c9bea5564a76">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzYtMS0xLTEtMTY3OTA4_dfdb9d30-22f4-4d60-870d-0da86f8f9063">591</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzYtMy0xLTEtMTY3OTA4_0e180ed3-333a-4ba0-9cd6-fcd6ee9a3852">1,254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzYtNS0xLTEtMTY3OTA4_2eaf6b9d-e779-47ae-af25-a475ef719dbe">1,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzctMS0xLTEtMTY3OTA4_cdf4c869-1140-4373-9de2-247bc122345b">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzctMy0xLTEtMTY3OTA4_bca2bb13-f0a5-4930-9e56-3ab9bb5092c4">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzctNS0xLTEtMTY3OTA4_f6bb9af6-a9b5-47c2-a4f8-9d5e325693d8">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i60ca1473adb74810ae1ae06716cbccab" continuedAt="i03544f14aa1b4209add0f7db36f2c4ac"><ix:continuation id="ia9f22d5d8d15487e827b2a4803a7b65c" continuedAt="ie67436f2126b4db7a5bb0cf0f412b21c"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="cvs:LesseeLeaseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzY_778273b2-4c58-4bd7-881c-b6071d8fb7ef" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except remaining lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzItMS0xLTEtMTY3OTA4_916c3fed-ff4e-4f9c-81bd-bd18153cb848">17,928</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzItMy0xLTEtMTY3OTA4_d7ccd18b-e5e7-48df-ae0c-511623021f78">19,122</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzQtMS0xLTEtMTY3OTA4_52b6f1c5-1b81-4ac7-b782-81c0d153b935">1,699</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzQtMy0xLTEtMTY3OTA4_132de6cf-53ce-4d1e-81ba-2e6b30ee0b71">1,646</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzUtMS0xLTEtMTY3OTA4_3cb18170-6c5f-4bb8-b22e-01ac5cdfa2ba">16,839</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzUtMy0xLTEtMTY3OTA4_deb912a2-ffef-44c8-8895-f0952be82d1a">18,177</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzYtMS0xLTEtMTY3OTA4_7398c491-d351-443f-82a1-5bc847d5be4c">18,538</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzYtMy0xLTEtMTY3OTA4_8e88b11e-d074-4278-ac3c-7dd2674b8e61">19,823</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:FinanceLeaseRightOfUseAssetGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzktMS0xLTEtMTY3OTA4_5a183af9-d693-466a-a3a5-97ded7ce6514">1,608</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:FinanceLeaseRightOfUseAssetGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzktMy0xLTEtMTY3OTA4_8af09414-1f1f-434c-b8ba-ef19331a7bd8">1,375</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:FinanceLeaseRightOfUseAssetAccumulatedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzEwLTEtMS0xLTE2NzkwOA_0aa3adbc-ceea-40ff-8f6d-83763a755954">284</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:FinanceLeaseRightOfUseAssetAccumulatedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzEwLTMtMS0xLTE2NzkwOA_68591a61-3242-4ed0-bc7a-5c0c37ca7f52">188</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:FinanceLeaseRightOfUseAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzExLTEtMS0xLTE2NzkwOA_d03d14d0-a302-4c5f-b7d3-91faf0e21d9d">1,324</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:FinanceLeaseRightOfUseAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzExLTMtMS0xLTE2NzkwOA_254dcff1-50e4-4b74-8eb8-16926f46c277">1,187</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzEzLTEtMS0xLTE2NzkwOA_669d4f7d-e60b-4907-9939-413e61bb0517">59</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzEzLTMtMS0xLTE2NzkwOA_0650c60f-bfa4-47b6-a14c-ecb8889216bf">50</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE0LTEtMS0xLTE2NzkwOA_02e972cd-ec62-4cb6-821c-17d0405b01cb">1,406</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE0LTMtMS0xLTE2NzkwOA_1be2f287-5992-4a0c-968a-4b1640b8fcda">1,250</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE1LTEtMS0xLTE2NzkwOA_d8bae112-3caf-461a-8db2-d5d3b9b70f32">1,465</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE1LTMtMS0xLTE2NzkwOA_43c11955-04f3-4e48-86a6-f028e1fd628f">1,300</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining lease term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE4LTEtMS0xLTE2NzkwOA_34ab8d30-46f9-4b8c-b1b1-ca668f9a2b84">12.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE4LTMtMS0xLTE2NzkwOA_d90b2e6d-2522-494f-ade8-00b81725e184">12.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE5LTEtMS0xLTE2NzkwOA_71d91cb6-582a-4c7b-bb9f-f0a4c02957b0">19.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE5LTMtMS0xLTE2NzkwOA_2edd14fd-efc9-4f30-a55f-0999956fa803">20.0</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzIyLTEtMS0xLTE2NzkwOA_f4cb9296-d819-4f53-bc49-91fc17c75cd4">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzIyLTMtMS0xLTE2NzkwOA_ae253f84-6af6-40d2-9e79-8e5479d2c186">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzIzLTEtMS0xLTE2NzkwOA_ad0526bc-7521-4867-a046-ce5e99eea2f6">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzIzLTMtMS0xLTE2NzkwOA_12759060-f13c-4d55-8878-0c242db6acc1">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes operating lease right-of-use assets of $<ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzgyNDYzMzcyMTY3NDU_9a0aea9f-fbd1-4c26-8105-5bb23b382c1b">56</ix:nonFraction>&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes current portion of operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="cvs:OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzgyNDYzMzcyMTY3MzM_c9946f83-c5aa-47ba-8f3f-4b57634df89d">21</ix:nonFraction>&#160;million and long-term operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="cvs:OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEwOTk1MTE2Mjk1NDE2_b68a0c1e-045e-480e-a69a-e749abf59ee9">39</ix:nonFraction>&#160;million which have been accounted for as liabilities held for sale and are included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3Nzc_1d820dba-4837-46a6-ae1f-51621fb133fb" escape="true"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3Nzg_6db5e56b-2f8c-42d8-b50d-2f4f540e0a68" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of lease liabilities under finance and operating leases as of December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating<br/>Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzEtMS0xLTEtMTY3OTA4_68bc5b18-b544-4a9c-8dfb-e98789f55cc3">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzEtMy0xLTEtMTY3OTA4_6af85966-8432-42a1-b86d-a0db402d0a03">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LesseeLiabilityPaymentsYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzEtNS0xLTEtMTY3OTA4_d968a16d-45df-44a8-8120-e35d78a5e76c">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzItMS0xLTEtMTY3OTA4_24a209af-0add-4f2f-add9-21be9bf0f57c">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzItMy0xLTEtMTY3OTA4_0b51e3f4-1d25-408c-809e-0513519b9ebe">2,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LesseeLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzItNS0xLTEtMTY3OTA4_8e8e4c72-f6a9-4559-86c3-030cdf228db2">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzMtMS0xLTEtMTY3OTA4_4ff49f78-6dc8-49eb-abcc-8a99b1c41333">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzMtMy0xLTEtMTY3OTA4_0d8bfd38-d6e8-4a38-8d0e-295070c547df">2,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LesseeLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzMtNS0xLTEtMTY3OTA4_181f1706-4fce-4978-9ae9-a44c93bbdf84">2,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzQtMS0xLTEtMTY3OTA4_d6d5c8b6-8242-49cb-b280-0339874db5d9">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzQtMy0xLTEtMTY3OTA4_6930f71d-78a5-495f-a34c-9dd445a8408e">2,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LesseeLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzQtNS0xLTEtMTY3OTA4_e3c4fd33-3fc5-4f44-9d9f-8ffc2dee1493">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzUtMS0xLTEtMTY3OTA4_c8e76d97-15ea-4fb9-84c3-989be563b252">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzUtMy0xLTEtMTY3OTA4_8f5938a7-a1a3-4ea4-81a1-737773095a6d">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LesseeLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzUtNS0xLTEtMTY3OTA4_80654949-c57b-4c4a-9c05-afc38f06a48d">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzYtMS0xLTEtMTY3OTA4_ec252632-38c8-401a-9b6c-3cf5edbf4065">1,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzYtMy0xLTEtMTY3OTA4_87193b7d-268e-451d-bfee-569b69f0a238">12,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LesseeLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzYtNS0xLTEtMTY3OTA4_5a56c67d-5d9e-458a-bb12-402dc8a53649">14,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzctMS0xLTEtMTY3OTA4_9f4af7de-450b-4be5-9620-25027f16505b">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzctMy0xLTEtMTY3OTA4_f6cf67b4-e629-4d4e-a73c-0ccc357b5657">24,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LesseeLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzctNS0xLTEtMTY3OTA4_3fadc3de-ca5a-4a1c-9992-baa0c199069a">26,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzgtMS0xLTEtMTY3OTA4_e4165326-1a4c-4ee8-85f6-8ff9bca8f304">823</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzgtMy0xLTEtMTY3OTA4_16bb3dcc-f245-4776-9dbf-ab7311f7418b">5,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LesseeLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzgtNS0xLTEtMTY3OTA4_26704fba-dea3-4cee-be05-1065cf7372f3">6,324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzktMS0xLTEtMTY3OTA4_d92ef56b-a070-497d-93ab-370713ac961b">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzktMy0xLTEtMTY3OTA4_dcf490a8-35b1-485a-9c8d-145e2bd11cde">18,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzktNS0xLTEtMTY3OTA4_41564ba9-990f-4b6a-ba0b-19f6b98bff45">20,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Future operating lease payments have not been reduced by minimum sublease rentals of $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEzODY_793baa2b-b203-4d6b-8917-d7ad0f071f1c">290</ix:nonFraction> million due in the future under noncancelable subleases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-8" name="cvs:OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzE2OTQ_97b17059-ff96-46fa-8028-e409a4cee37c">2.5</ix:nonFraction> billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i03544f14aa1b4209add0f7db36f2c4ac"><ix:continuation id="ie67436f2126b4db7a5bb0cf0f412b21c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale-Leaseback Transactions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2022 or 2021. Proceeds from sale-leaseback transactions totaled $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzI1Njk_59813f2c-785a-4a19-9acc-05f0687854a6">101</ix:nonFraction> million in the year ended December 31, 2020. Gains from sale-leaseback transactions totaled $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzU0OTc1NTgyMDgyNw_c59395f8-eab0-4056-9529-ac5060fffbbb">3</ix:nonFraction> million in the year ended December 31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Office Real Estate Optimization Charges </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company undertook an initiative to evaluate its corporate office real estate space in response to its new flexible work arrangement. As part of this initiative, the Company evaluated its current real estate space and changes in employee work arrangement requirements to ensure it had the appropriate space to support the business. As a result of this assessment, the Company determined that it would vacate and abandon certain leased corporate office spaces. Accordingly, in the three months ended December 31, 2022, the Company recorded office real estate optimization charges of $<ix:nonFraction unitRef="usd" contextRef="i64f5c37ce66141f7a204dfe6e993bb22_D20221001-20221231" decimals="-6" name="cvs:OfficeRealEstateOptimizationCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEzNzQzODk1MzY1NDg5_6232c1a9-e5a0-4f84-9d24-17b0d5b88d50">117</ix:nonFraction>&#160;million, primarily consisting of $<ix:nonFraction unitRef="usd" contextRef="ie936009c1c1e420dad0ba447530546c3_D20221001-20221231" decimals="-6" name="cvs:OfficeRealEstateOptimizationCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEwOTk1MTE2Mjg4MTMw_85146ce7-42f2-453f-8148-8a0a06f459b4">71</ix:nonFraction>&#160;million related to operating lease right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="i60dd33f11cc2409080bad57679954d47_D20221001-20221231" decimals="-6" name="cvs:OfficeRealEstateOptimizationCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEwOTk1MTE2Mjg4MTQy_49332b4b-8c5a-437f-95d5-6dd365b29552">44</ix:nonFraction>&#160;million related to property and equipment, within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Store Impairment Charges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group&#8217;s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company&#8217;s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the &#8220;Board&#8221;) authorized the closing of approximately <ix:nonFraction unitRef="store" contextRef="id630be41a4e14306bcd92700167a1f05_D20211001-20211231" decimals="-2" name="cvs:NumberOfStoresPlannedClosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzUwMjQ_e7eedaf9-f977-4a73-8065-bb6724d32312">900</ix:nonFraction> retail stores, approximately <ix:nonFraction unitRef="store" contextRef="id630be41a4e14306bcd92700167a1f05_D20211001-20211231" decimals="INF" name="cvs:NumberOfStoresAnnualPlannedClosuresForClosurePeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzUxMDI_43e6fba4-9d3d-4d35-8277-086a17cc57c4">300</ix:nonFraction> stores each year, between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores&#8217; asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="id630be41a4e14306bcd92700167a1f05_D20211001-20211231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzU0OTc1NTgyMDg0NQ_33b37c7e-6c64-4aa4-bc71-1bd7db9d69c6">1.4</ix:nonFraction> billion, consisting of a write down of approximately $<ix:nonFraction unitRef="usd" contextRef="if5695f9deb5d42f399db0a5df5333d03_D20211001-20211231" decimals="-8" name="cvs:StoreImpairmentCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzU3Njk_db1717e7-893b-4cc9-a663-b0b49ec89180">1.1</ix:nonFraction>&#160;billion related to operating lease right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="id562208e84834686a7620f76d36a5e86_D20211001-20211231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzU4MjM_2ca12bf1-d3ab-4058-bb57-cd5536794683">261</ix:nonFraction>&#160;million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $<ix:nonFraction unitRef="usd" contextRef="i13d80e15e3f94cb0927c69c6bbb18ad5_I20211231" decimals="-6" name="cvs:OperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzYwMjg_6a703786-c3d9-447a-9bf3-ab3b2c018ca2">356</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if99f5cc945cb4089b78aeb74c829d2d6_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzYwMzU_215af2c1-b418-4948-be89-367fc84e1ff1">185</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzMzMDI_a1a52320-c292-4679-b3f4-cb244f362490" continuedAt="i4dcc0efaf7b84ab1b892d339713820a7" escape="true">Health Care Costs Payable</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4dcc0efaf7b84ab1b892d339713820a7" continuedAt="ifdfc8f646e3f4a8cb74a2a4006ff1370"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is information about incurred and cumulative paid health care claims development as of December&#160;31, 2022, net of reinsurance, and the total IBNR liabilities plus expected development on reported claims included within the net incurred claims amounts. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for information on how the Company estimates IBNR reserves and health care costs payable as well as changes to those methodologies, if any. The Company&#8217;s estimate of IBNR liabilities is primarily based on trend and completion factors. Claim frequency is not used in the calculation of the Company&#8217;s liability. In addition, it is impracticable to disclose claim frequency information for health care claims due to the Company&#8217;s inability to gather consistent claim frequency information across its multiple claims processing systems. Any claim frequency count disclosure would not be comparable across the Company&#8217;s different claim processing systems and would not be consistent from period to period based on the volume of claims processed through each system. As a result, health care claim count frequency is not included in the disclosures below.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzMzMDY_01399349-033e-494e-baa4-679f8abb1c9a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information about incurred and paid health care claims development for the year ended December&#160;31, 2021 is presented as required unaudited supplemental information.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76c4e64c26444a5bf8225d71e995baf_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzMtMS0xLTEtMTY3OTA4_359858cb-4e1b-4917-9921-206fe4dead3b">62,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6259c8555abd4bf5b6dac136069d1316_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzMtMy0xLTEtMTY3OTA4_4839ddf4-0550-4648-9b47-1aac228c9bc8">62,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9affe0606d974499b83f0e139cb17dd2_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzQtMy0xLTEtMTY3OTA4_ea5b5601-e3e8-4a88-aaf3-775d083467be">69,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzUtMy0xLTEtMTY3OTA4_0c22799f-517c-4e46-a906-c30ff3d5a40d">131,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Paid Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76c4e64c26444a5bf8225d71e995baf_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzEwLTEtMS0xLTE2NzkwOA_b08d90b6-0eef-4492-bb5c-f2ecd76ff846">54,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6259c8555abd4bf5b6dac136069d1316_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzEwLTMtMS0xLTE2NzkwOA_f223a4f7-412b-453e-b758-cb9e32f528d5">62,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9affe0606d974499b83f0e139cb17dd2_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzExLTMtMS0xLTE2NzkwOA_a5436c0a-6103-4f96-b393-6c52d43124d5">59,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzEyLTMtMS0xLTE2NzkwOA_8152ac0e-bb37-46af-bb63-0aed07ca7943">121,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All outstanding liabilities for health care costs payable prior to 2021, net of reinsurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzEzLTMtMS0xLTE2NzkwOA_a38b5293-e0ef-4f63-99c4-fac1200b37ec">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outstanding liabilities for health care costs payable, net of reinsurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzE0LTMtMS0xLTE2NzkwOA_796ff7ca-6f1e-4f17-a4b7-b74645448fe2">9,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company&#8217;s liabilities for IBNR plus expected development on reported claims totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ic3b3902b297a43b9a015149f29e45bf7_I20221231" decimals="-8" name="us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzE0MDg_234f5cd2-9917-4abe-961f-1a9ad21d3d04">7.8</ix:nonFraction> billion. Substantially all of the Company&#8217;s liabilities for IBNR plus expected development on reported claims at December&#160;31, 2022 related to the current calendar year.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzMzMDc_9aa03b32-0d1c-4ff9-b2f8-d1a24dabf579" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the December&#160;31, 2022 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-duration health care costs payable, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5ZjMxMmU1YzI2MzY0YzA2ODFmMjZjZWFhYzE2ODE1ZC90YWJsZXJhbmdlOjlmMzEyZTVjMjYzNjRjMDY4MWYyNmNlYWFjMTY4MTVkXzEtMS0xLTEtMTY3OTA4_796ff7ca-6f1e-4f17-a4b7-b74645448fe2">9,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5ZjMxMmU1YzI2MzY0YzA2ODFmMjZjZWFhYzE2ODE1ZC90YWJsZXJhbmdlOjlmMzEyZTVjMjYzNjRjMDY4MWYyNmNlYWFjMTY4MTVkXzItMS0xLTEtMTY3OTA4_3e863fdc-d906-4802-9065-fa3eaad2f842">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5ZjMxMmU1YzI2MzY0YzA2ODFmMjZjZWFhYzE2ODE1ZC90YWJsZXJhbmdlOjlmMzEyZTVjMjYzNjRjMDY4MWYyNmNlYWFjMTY4MTVkXzQtMS0xLTEtMTY3OTA4_db5131df-8ae2-4386-b47e-d49456d6d819">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total health care costs payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5ZjMxMmU1YzI2MzY0YzA2ODFmMjZjZWFhYzE2ODE1ZC90YWJsZXJhbmdlOjlmMzEyZTVjMjYzNjRjMDY4MWYyNmNlYWFjMTY4MTVkXzUtMS0xLTEtMTY3OTA4_c22f038a-20eb-4917-b297-c60524fa0ae9">10,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifdfc8f646e3f4a8cb74a2a4006ff1370"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzMzMDg_d600034d-942b-4c72-b79f-3948baf491b7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEtMS0xLTEtMTY3OTA4_c049a945-156c-4ad9-87f4-b661634c7c31">8,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEtMy0xLTEtMTY3OTA4_bb77e198-5adf-437d-9e17-6553ca542b84">7,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac261a946f441689f0b6c8226695ff7_I20191231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEtNS0xLTEtMTY3OTA4_aca53c53-9f8c-47e0-b071-7a6b20179fef">6,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzItMS0xLTEtMTY3OTA4_204c0b38-3f55-49ff-a3c9-f11d34038bdf">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzItMy0xLTEtMTY3OTA4_4d37a48b-b4c1-48dd-a5fd-cfeee0dd63ba">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac261a946f441689f0b6c8226695ff7_I20191231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzItNS0xLTEtMTY3OTA4_650f7a51-73da-445c-9a11-0ab6a1166285">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzMtMS0xLTEtMTY3OTA4_c66a2069-8093-4777-8034-13926f9528c5">8,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzMtMy0xLTEtMTY3OTA4_9e716e79-8fd7-4525-b7f8-3dfbd5255226">7,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac261a946f441689f0b6c8226695ff7_I20191231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzMtNS0xLTEtMTY3OTA4_0f4cdb46-a118-49d3-b510-c4f454b9a2a3">6,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzQtMS0xLTEtMTY3OTA4_977cdb00-3be4-4a04-903a-6f05b9933958">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzQtMy0xLTEtMTY3OTA4_0f1a4cb4-04a2-4b93-89cf-eface9fca95c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzQtNS0xLTEtMTY3OTA4_58894f8f-dcd7-4dab-9fa9-55e225bb240b">414</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzctMS0xLTEtMTY3OTA4_2c9d53e9-117b-4cf9-bddc-17fcadf252fd">71,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzctMy0xLTEtMTY3OTA4_4d8fc20a-281d-4064-b946-1d019bb2729a">64,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzctNS0xLTEtMTY3OTA4_3c5b2f09-b693-410a-8a60-7e1efe0538e7">55,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzgtMS0xLTEtMTY3OTA4_7f03a581-abad-482a-98e1-35b1a57fde50">654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzgtMy0xLTEtMTY3OTA4_0aefb807-19ad-4b21-8a0b-724709f650fe">788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzgtNS0xLTEtMTY3OTA4_71b628fd-f316-4a90-89ca-7d46126a0cc0">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzktMS0xLTEtMTY3OTA4_c748074c-9d5c-4712-9bf6-4c1b8c7b8e48">70,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzktMy0xLTEtMTY3OTA4_97e859f7-3cf1-4f66-9138-74ee2a11ddf3">63,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzktNS0xLTEtMTY3OTA4_c5f74141-9403-4911-8abc-4e4dfaa1d602">55,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzExLTEtMS0xLTE2NzkwOA_d38359e9-b8da-4a97-95e0-251676e303e5">61,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzExLTMtMS0xLTE2NzkwOA_d056b949-f3df-44e4-a560-bae3786d5103">56,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzExLTUtMS0xLTE2NzkwOA_62a36256-4c8a-481f-ab9a-ecd987f4cad0">48,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEyLTEtMS0xLTE2NzkwOA_44de877d-db96-4fdd-9d3d-6f5daf15f138">7,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEyLTMtMS0xLTE2NzkwOA_20216e9b-24cf-418a-b306-50cfbdeeabd4">6,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEyLTUtMS0xLTE2NzkwOA_a0593880-6557-4bb6-b5a9-014b903a3eaa">6,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEzLTEtMS0xLTE2NzkwOA_daa043e9-f885-4daf-9f6a-b82146675a7c">69,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEzLTMtMS0xLTE2NzkwOA_5b1dfc7b-c1c0-47cc-b976-62e3f9deca2a">63,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEzLTUtMS0xLTE2NzkwOA_cc4baf18-cbc6-4719-8b8c-2a377a46ed6e">54,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="cvs:PremiumDeficiencyReserveLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE0LTEtMS0xLTE2NzkwOA_793990e3-923f-4bcc-b8d1-7f420b16c42e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231" decimals="-6" name="cvs:PremiumDeficiencyReserveLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE0LTMtMS0xLTE2NzkwOA_f0574f20-aedc-4b4a-8c75-a5797df37879">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231" decimals="-6" name="cvs:PremiumDeficiencyReserveLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE0LTUtMS0xLTE2NzkwOA_287c6b46-81d3-4dd6-b434-58bca857d38f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE1LTEtMS0xLTE2NzkwOA_ae7fdfb9-4d8f-48c7-af08-25cde580bcda">10,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE1LTMtMS0xLTE2NzkwOA_ff8a23ef-da46-4960-ad69-adae26c121e6">8,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE1LTUtMS0xLTE2NzkwOA_f799c300-dba5-4f91-a512-d481838acfdc">7,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE2LTEtMS0xLTE2NzkwOA_5b85367f-5601-40d8-b86c-ae2ed6a32fd9">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE2LTMtMS0xLTE2NzkwOA_51b67e87-d658-421b-abfe-a75ae0a2731d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE2LTUtMS0xLTE2NzkwOA_10835f06-9c22-4ec7-b071-1f3c4dde69f1">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE3LTEtMS0xLTE2NzkwOA_e2e874f8-cfac-402d-8fa2-a56144963492">10,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE3LTMtMS0xLTE2NzkwOA_9bfe07f8-5a30-4558-9070-fed2d4af783f">8,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE3LTUtMS0xLTE2NzkwOA_76ef7038-5679-42d7-b02a-b83487b3c5d5">7,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the years ended December&#160;31, 2022, 2021 and 2020 in the table above exclude $<ix:nonFraction unitRef="usd" contextRef="i780b19498a144075a22a573432132bda_D20220101-20221231" decimals="-6" name="cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIxMzc_924480db-ce02-4bb2-8486-e9506df4fba1">75</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iefb4b1c3d63e4323ae108f339bf86ea0_D20210101-20211231" decimals="-6" name="cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIxNDE_c5e9bb54-77bf-4af5-b223-81ea0dbba54c">59</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d32e81675c1411abb9e6dc0a83223c1_D20200101-20201231" decimals="-6" name="cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIxNDg_5e655430-2c56-48cb-894f-6e5cc0531ec5">41</ix:nonFraction> million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and $<ix:nonFraction unitRef="usd" contextRef="i104c7351c43f4dd9ba23acf27dc2da0d_D20220101-20221231" decimals="-6" name="cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIzMjI_19959611-846f-4861-941d-0494a3717d5d">319</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2661ac2447ad404b9093ebf03b2f3a2c_D20210101-20211231" decimals="-6" name="cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIzMjY_f9cab839-c0d8-4647-a513-86c7fbb570b3">212</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie4d0589b63754b6d96499af470071fa3_D20200101-20201231" decimals="-6" name="cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIzMzM_aea38c94-91a5-4c58-af52-1d03f422e2ce">221</ix:nonFraction> million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets. The incurred health care costs for the years ended December 31, 2021 and 2020 also exclude $<ix:nonFraction unitRef="usd" contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231" decimals="-6" name="cvs:PremiumDeficiencyReserveLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzEwOTk1MTE2MjgxMjM4_f0574f20-aedc-4b4a-8c75-a5797df37879">16</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231" decimals="-6" name="cvs:PremiumDeficiencyReserveLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzEwOTk1MTE2MjgxMjQ2_287c6b46-81d3-4dd6-b434-58bca857d38f">11</ix:nonFraction> million, respectively, for premium deficiency reserves related to the Company&#8217;s Medicaid products.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimates of prior years&#8217; health care costs payable decreased by $<ix:nonFraction unitRef="usd" contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzI1NzM_7f03a581-abad-482a-98e1-35b1a57fde50">654</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzI1Nzc_0aefb807-19ad-4b21-8a0b-724709f650fe">788</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzI1ODQ_71b628fd-f316-4a90-89ca-7d46126a0cc0">429</ix:nonFraction> million in 2022, 2021 and 2020, respectively, because claims were settled for amounts less than originally estimated (i.e., the amount of claims incurred was lower than originally estimated), primarily due to lower health care cost trends as well as the actual claim submission time being faster than originally assumed (i.e., the Company&#8217;s completion factors were higher than originally assumed) in estimating health care costs payable at the end of the prior year. This development does not directly correspond to an increase in the Company&#8217;s operating results as these reductions were offset by estimated current period health care costs when the Company established the estimate of the current year health care costs payable.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc5MDE_04316a5d-95dc-460c-bdff-22e8082db06e" continuedAt="i3eb67eaff7e04bf2bf490a96045d1ad3" escape="true">Borrowings and Credit Agreements</ix:nonNumeric></span></div><ix:continuation id="i3eb67eaff7e04bf2bf490a96045d1ad3" continuedAt="i5c860eae6283448dbfd0c97984884dd2"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4MzI_a0b0f680-355f-4877-91c1-8a45a41a7ac2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company&#8217;s borrowings as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96ea0975c6434c688a6304c9a35567b3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEyLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjMwY2Q2OWRiY2Q3MzQ2ZDQ5ZWRmZDk5OWU4NzU1ODE0XzQ_e250dd9e-6e04-4889-b79a-be54e5acbbf8">3.5</ix:nonFraction>% senior notes due July 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ea0975c6434c688a6304c9a35567b3_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEyLTEtMS0xLTE2NzkwOA_d91b5102-b6b7-4aab-9f59-ca0506d66be9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b4e48800ec47c1a7b0ec56d1d395fe_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEyLTMtMS0xLTE2NzkwOA_9e44f218-329c-4aa6-a41f-5541638e3fde">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d193754e1d94c0494f9956393440f77_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjVlMThiYzZlMjBmYTQwMDI4ZDFmNWJhMGJjMzgzNjFjXzQ_b8868717-6204-4ab5-b7a7-e49748ff40fc">2.75</ix:nonFraction>% senior notes due November 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d193754e1d94c0494f9956393440f77_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEzLTEtMS0xLTE2NzkwOA_119e9f5c-db6e-44fb-8a6b-dfdc486d08da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a906779cfe446a2987d8b5241fbf0da_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEzLTMtMS0xLTE2NzkwOA_f387fcf1-8a5b-48c5-9aff-4b0721f0d881">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if71e011d823142598cd37f46f2e49a05_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE0LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmE4OTJmMmNjYWM4ZjQ3YmZhYTQ4OWY2YzEzMTVkYzU3XzQ_ed6bb8bc-24f3-4c40-be8d-3a16d9a984b1">2.75</ix:nonFraction>% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71e011d823142598cd37f46f2e49a05_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE0LTEtMS0xLTE2NzkwOA_e4e36839-14b1-4590-8450-da13585e837b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c181073c4542f099d25eb5c5d40655_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE0LTMtMS0xLTE2NzkwOA_21ab147e-6ce2-4b3b-821c-3cb309da60b1">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61839e753d2f451b9587d89360867561_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjc4M2JhZGY0OTk3YjRjNzFiZWFlMmIzYWY5ZTdkZDhhXzQ_9ba46b35-653d-4da6-8cfd-7150e14235b0">4.75</ix:nonFraction>% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61839e753d2f451b9587d89360867561_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE1LTEtMS0xLTE2NzkwOA_bac55596-fea7-4a45-a5cd-e985daf236fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d2bd8ff5b14cb5a635a188ee174c8b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE1LTMtMS0xLTE2NzkwOA_ea27553d-6f6e-4f66-afe6-6bfa33bff45f">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a3d976289814f1ebda72b277cfb0e32_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE3LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU5MTM4YmMxZmJmYTRmNDlhMjgzMTZmMTM0OThmNTUxXzQ_34e0b75c-7fc6-4479-8979-d8630cd327f7">2.8</ix:nonFraction>% senior notes due June 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3d976289814f1ebda72b277cfb0e32_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE3LTEtMS0xLTE2NzkwOA_73950778-7c02-4f78-97c5-431fe8b5c1a5">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ba734b33ac429899c73244e0b3e4a2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE3LTMtMS0xLTE2NzkwOA_df7deb5e-7056-483f-b85b-f401c8ca6725">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e0c4baf78af43da8c871e2cf0d3776e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmMwOTMxNmEwYmRmZjRhY2JhODczZjlkNTE5OTQ5OTY3XzQ_28c7c2db-1887-4f80-b3af-b77ace4e3d9a">4</ix:nonFraction>% senior notes due December 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0c4baf78af43da8c871e2cf0d3776e_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE4LTEtMS0xLTE2NzkwOA_f0623bae-27f0-45b6-ba1d-4370c8641c2e">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb44b3665b4246f1bf997c90b24c21d7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE4LTMtMS0xLTE2NzkwOA_825f4c29-eedd-4b90-bf21-5cebf59610ae">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d559325531a42c38fc46ff0a8fe2921_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjRjNmVhZjRlNWQxZTQzYzI5YWUzYmM5ZDI3MGY2Yzg1XzQ_4b6fa7c5-0737-41ba-80cd-eecb086cff8c">3.375</ix:nonFraction>% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d559325531a42c38fc46ff0a8fe2921_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE5LTEtMS0xLTE2NzkwOA_c9faeae0-7cc3-4803-9811-06913f3b8ff2">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0484677d3d443eb00b519000bfb3a6_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE5LTMtMS0xLTE2NzkwOA_91653c3a-46b7-4b19-83a3-0e1fb584467b">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56e27d861e9545b9aa31b1102e04c153_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjg2NDdlN2YwMWE4MzRjZGI4ZDlkYmIwMjBiYjNmMmIwXzQ_83692015-26e8-4180-a1d4-577c1964058a">2.625</ix:nonFraction>% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e27d861e9545b9aa31b1102e04c153_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIwLTEtMS0xLTE2NzkwOA_7d21363e-9b0a-474a-a454-53f090666c37">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ac987c67784c1186308edd0aea70d3_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIwLTMtMS0xLTE2NzkwOA_226eacef-0a38-4d44-aa45-2ec0426b50f3">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic180b72151a4402f8310dadcfc70fb01_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmFkYjg3N2IzOWMyMjRmYWE4Y2NkZjllNGQ5MDE0Yzc3XzQ_36ed2b84-f390-4bcf-9bb9-1451014b61c9">3.5</ix:nonFraction>% senior notes due November 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic180b72151a4402f8310dadcfc70fb01_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIxLTEtMS0xLTE2NzkwOA_483fb23e-5b23-44e4-8f5b-b4fd4d963cab">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b6f748466241afa934def47b3887ca_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIxLTMtMS0xLTE2NzkwOA_ec8a4784-0fb7-4546-a9ca-edbc3fab9d1b">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b4ae74a63944a4ab738561dee76b7fd_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIyLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjIwZWM0N2Y4YjUwYjRiM2ViMWRiMzIyM2RjZDhlYTk1XzQ_7aaf2d6d-b974-4c4a-b62c-437ba9828e6c">5</ix:nonFraction>% senior notes due December 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b4ae74a63944a4ab738561dee76b7fd_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIyLTEtMS0xLTE2NzkwOA_699e7a92-35fc-4aae-bc54-ddecf2876fc0">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e4d23924994b228cd71cb68d806750_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIyLTMtMS0xLTE2NzkwOA_bd577eda-0968-4e6e-844b-08ca852ceaae">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iefa4fc8c856647a0a132eb36186e08b5_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQ4ODM1YzkwMTkwMjQzNDBiODA3NjVlOTA2NzZlZTZlXzQ_b7675cef-19b8-4ce9-8366-919f10b58ab5">4.1</ix:nonFraction>% senior notes due March 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa4fc8c856647a0a132eb36186e08b5_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIzLTEtMS0xLTE2NzkwOA_3fe5572f-1b9b-425c-a21d-6f4de0f8836b">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21a0aa5c9d141bdbe4a207bb4f293ee_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIzLTMtMS0xLTE2NzkwOA_f5cb2453-cedb-4703-b387-395d21131143">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fb06588816f472bb29f99b8d68219cc_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI0LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmY0MWUyZTA5YjliMDQ3MjQ5NjJiNzc2YWRmYjk0N2EwXzQ_5cf6fef0-8f16-43e7-92e3-23d8d7304b2c">3.875</ix:nonFraction>% senior notes due July 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb06588816f472bb29f99b8d68219cc_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI0LTEtMS0xLTE2NzkwOA_863c0911-79b6-47d6-b5c4-25d3a0ab8240">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c9969b99bb4ad798109c43cbdc6881_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI0LTMtMS0xLTE2NzkwOA_175898ec-eca8-4907-870f-a0fd84316c96">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb8a5e549c1f40079912cf72b576f3e7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjI4ZmRkYWQ2YWZlZjRlMTM5ODUxMmIwMDY0NmJlMjllXzQ_60783301-e81b-4ac6-8085-1f8bd5142029">2.875</ix:nonFraction>% senior notes due June 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb8a5e549c1f40079912cf72b576f3e7_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI1LTEtMS0xLTE2NzkwOA_bd75636e-0338-4cbd-bbcd-0e54d378e090">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c887883f1ce42688222f658a393184a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI1LTMtMS0xLTE2NzkwOA_758d0117-7309-4291-a28d-a993a7fc1e4b">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38b8c6c77f294a97b96b4e9060102c49_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmMxNDBmMjcxNDBiNjRkYWI4ZDJjZGZjYzBlNGNkZWI5XzQ_bcd39f42-7981-4cc6-bdf4-63a8f391c8a1">3</ix:nonFraction>% senior notes due August 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b8c6c77f294a97b96b4e9060102c49_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI2LTEtMS0xLTE2NzkwOA_0dbd6198-bd40-42f9-bed1-72997da7ef75">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f841196e9745d7a5bd741b956cb571_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI2LTMtMS0xLTE2NzkwOA_7dd23291-a644-41ed-a5a1-6fe691e0ec44">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3120aef7a1a74f9aa9ad6c90254ae7da_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI3LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjQ1NjNjNjNkOTYyODQ4MjM5MmNhMTQyM2VhMmY2YmMxXzQ_7978d98a-8b8c-4448-aaed-c61290eccd8c">3.625</ix:nonFraction>% senior notes due April 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3120aef7a1a74f9aa9ad6c90254ae7da_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI3LTEtMS0xLTE2NzkwOA_119ad780-8b60-4867-b8f4-dbd500ad13bd">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21b2c11292246968e32e95a7e2d5d46_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI3LTMtMS0xLTE2NzkwOA_ef640853-89d1-4239-8acf-cdbd2bec4f25">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i83a34a6019c9487ab8dc8717a85803b9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmRiNmM4OTM3MWI5MjRlN2ZiNGMzOGQxMTc1MzUxYzQzXzQ_c71f743b-e155-4aae-becc-a00574d4619c">6.25</ix:nonFraction>% senior notes due June 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a34a6019c9487ab8dc8717a85803b9_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI4LTEtMS0xLTE2NzkwOA_e76e6b4c-14f1-4300-81ec-2ab0197d5b0b">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d2292eae624df88e3cb7a81e75175e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI4LTMtMS0xLTE2NzkwOA_22b97f2d-7b94-49c7-ad37-bfc97b8b3218">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6a05b1ec70b4ceda24080b978863c80_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjZiZDJjMmVlMDliMDQyNDBiYjkxY2MxYWFhOTY5YmI1XzQ_827afc07-6750-4cdc-a9f4-4c8d06e55aec">1.3</ix:nonFraction>% senior notes due August 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a05b1ec70b4ceda24080b978863c80_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI5LTEtMS0xLTE2NzkwOA_ab7a1dd1-01bb-46e1-9d29-b5699ba370b5">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e78fd616384a38bdb3bfc812db60ab_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI5LTMtMS0xLTE2NzkwOA_f0e81737-ef03-4119-8420-0f9953459718">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i208edaa424b244c2a575cd9b2b4b9020_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQwOTIyZDQ3NzFiMzRmZDViZGVhMWQyNGI2NGRkOGNhXzQ_ecae7c2b-7105-4431-98e6-ee7a97548281">4.3</ix:nonFraction>% senior notes due March 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208edaa424b244c2a575cd9b2b4b9020_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMwLTEtMS0xLTE2NzkwOA_6f3f90de-9139-4875-9352-bea0d7162407">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3609fe1a0966404993bebd381e7eda7c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMwLTMtMS0xLTE2NzkwOA_53330b49-509e-4ab8-91a6-ded257d23ff1">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5aa28ddd1e8430eb577239a8f77bef0_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmIwMmUyOTY3ZmEyYzRhOGNiOTg3YjJjNWZhYzA4ODg4XzQ_57529ed2-3154-4aec-8bbc-7f5dfc6c4caa">3.25</ix:nonFraction>% senior notes due August 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5aa28ddd1e8430eb577239a8f77bef0_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMxLTEtMS0xLTE2NzkwOA_1db55507-3028-4ce7-97ee-f10fd87b638a">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0fa0101d32487d87f11b2ff81e35e3_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMxLTMtMS0xLTE2NzkwOA_6022a61b-817a-4163-9293-2cafdc0d2fb3">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide032eb9e5684d3bae628ecb6f5fa55e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMyLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmY5ODNkYzc1NDM3NDQwNjZiOTAwMDBkZWI3NDE1OGZiXzQ_a1d477ca-06ad-48c2-b8a1-b8b1564134d8">3.75</ix:nonFraction>% senior notes due April 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide032eb9e5684d3bae628ecb6f5fa55e_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMyLTEtMS0xLTE2NzkwOA_c4641f6a-40e3-4618-b54e-47f70437de73">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763321b4294a490a99ed2699ea5e64f0_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMyLTMtMS0xLTE2NzkwOA_def3f3f9-2787-4934-908b-23ae26b6bf6d">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id15f98dc5d2143468b8eb2d34e1a74e3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjI5MTM5ODRhZTczMTQxYmVhZmViNjg0NWY4MjMwOGZmXzQ_86b726e3-613d-492b-bb8e-cc944c550c88">1.75</ix:nonFraction>% senior notes due August 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15f98dc5d2143468b8eb2d34e1a74e3_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMzLTEtMS0xLTE2NzkwOA_88e23172-2936-40b3-8624-f466085389e0">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8b28c2e4ea4f158253162f1d64b8cf_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMzLTMtMS0xLTE2NzkwOA_6fda3253-f869-4020-9bf0-2194f3dcab02">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06e62497573243ac88b9afb7d5cd0de3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM0LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmE5MjY1MWIwMWY1MTRhZDA5ZmRjYmNiNGVjZmU4ZjI5XzQ_4ecea5ce-0aa5-4339-9103-a321f2666700">1.875</ix:nonFraction>% senior notes due February 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e62497573243ac88b9afb7d5cd0de3_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM0LTEtMS0xLTE2NzkwOA_28cf7f2f-07b6-4f52-be1c-94274005f8f2">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe1a138e88c4de09bec060efb8de7da_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM0LTMtMS0xLTE2NzkwOA_edac0d64-6878-43dd-a5ff-d2b7d2cd2b3e">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaceac4401a17451a9894899abe75d058_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmYzMDNhOTAyNDU3NTQ4ZmE4YThlNmQ3OWIyM2IwODc5XzQ_8f705426-de42-4be3-94a7-475caf35516d">2.125</ix:nonFraction>% senior notes due September 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaceac4401a17451a9894899abe75d058_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM1LTEtMS0xLTE2NzkwOA_bf4d5c8f-26ff-4b8b-8349-7d651af069a4">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609d3103caff4c93b86c00a3a2aed350_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM1LTMtMS0xLTE2NzkwOA_549e1a0a-96ae-489e-83d7-29dd6e289483">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d4aa00402164f00b89144874d2e4a98_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQ3ZWI2M2VhOWIxMzQ3ZGNiNDA5Yjg3ODIzOWM2M2EyXzQ_daf67db7-f0e2-4c37-88d5-5a837219169a">4.875</ix:nonFraction>% senior notes due July 2035</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4aa00402164f00b89144874d2e4a98_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM2LTEtMS0xLTE2NzkwOA_4f819043-3e86-4899-aef5-e45575cb6b55">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide1da8f0468d4f0e87617230289c5bdb_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM2LTMtMS0xLTE2NzkwOA_92f2c7dd-3f21-4d3e-bab9-db96bb40acda">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe3a3d79b0d747d9803a516b3766b9b8_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM3LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjVjZmEwNGM3MWVkODQ0NWZiOTliYmRlZjgxMWRlMzg0XzQ_43a76470-1a31-4eb5-804d-f96a904a2c37">6.625</ix:nonFraction>% senior notes due June 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3a3d79b0d747d9803a516b3766b9b8_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM3LTEtMS0xLTE2NzkwOA_f7a50d98-cdfa-4841-a8b7-8e0cbc779738">771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f90f74479324fd08ed524bf5c875c87_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM3LTMtMS0xLTE2NzkwOA_a768652d-180f-4e37-b2cd-cc3aadf77102">771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia363edf7d95a413cb5fecebeb23ed972_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjFhNDA4NjUxODkzYzQ0ZmU4NmFkN2IwMjkyMjM4YTlkXzQ_f6ca6ce7-32ab-41d7-9447-ef0997dbdee0">6.75</ix:nonFraction>% senior notes due December 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia363edf7d95a413cb5fecebeb23ed972_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM4LTEtMS0xLTE2NzkwOA_88860727-50a4-4176-898e-765e669b35cd">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac58136f46f242a19ec676141946c7f2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM4LTMtMS0xLTE2NzkwOA_06a1954a-24ff-4a2e-8e46-045182880a49">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i39294c665ef74fa1983f27c408f039c1_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjcxZDQ0MGI5OWUxMTQwOTg4MDU5YzI5OWVhNzdkODBhXzQ_bf7c6608-28c2-4bb1-875d-0a799d1de550">4.78</ix:nonFraction>% senior notes due March 2038</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39294c665ef74fa1983f27c408f039c1_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM5LTEtMS0xLTE2NzkwOA_a4d5a3a5-ed26-4c25-8e08-c3d8a9b33e8a">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cbfd1800fe44faa82ca6d39ee57704_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM5LTMtMS0xLTE2NzkwOA_3192e6a4-0370-4d63-b4ff-ffbafdf06cf9">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1512c04482e5447b84fbd0e3188e529a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjgxMzkzNmYzODc1YTQwN2NiN2UwODc0YTIyZjdiYTliXzQ_7d005f3d-7138-46ae-899c-31cb206d90f3">6.125</ix:nonFraction>% senior notes due September 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1512c04482e5447b84fbd0e3188e529a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQwLTEtMS0xLTE2NzkwOA_205d18bb-3b32-4f96-95a5-41864e880203">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9699d6696c9c4911bb010f0b9af5282a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQwLTMtMS0xLTE2NzkwOA_05156a23-7694-4b7c-a00b-c89481812ac7">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3de7f45720594c44b73f3eab7ce10e70_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQ3OWViZGJlYmM3ODRmZTM4NGZlYjI4YTJhOWVmMDA5XzQ_66422226-3c27-46e6-800f-bbb02794cb17">4.125</ix:nonFraction>% senior notes due April 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de7f45720594c44b73f3eab7ce10e70_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQxLTEtMS0xLTE2NzkwOA_0fe3aad8-6d83-4c4e-ace6-b9cdd0c1c54a">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f49a86ef2b485f829d66fae1ef44f2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQxLTMtMS0xLTE2NzkwOA_d6e18eab-7d8a-4685-8a2e-672f01175573">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id028ea3d52c44a2394695e4f43e9d046_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQyLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQyMDE2N2YxNjk2NjQ5YjM4ODhkYzcyMTMwZmFiNjVhXzQ_ad6887fc-65b3-41b8-8adc-d4fc3dfa7e28">2.7</ix:nonFraction>% senior notes due August 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id028ea3d52c44a2394695e4f43e9d046_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQyLTEtMS0xLTE2NzkwOA_85a6bb18-a79b-4927-a99f-8eda1dd22120">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i650090a57c324b8498f059399f541fb4_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQyLTMtMS0xLTE2NzkwOA_01c492b8-4930-4c36-80e4-2a8c6b8f62e7">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if44aa963bda44e8fa075b47f30535a24_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjEwMjQwMjFjNzFiMTQ0ODU5NTA2NjBiZjZhYWJiZjI3XzQ_51b3c45a-6137-43d9-aedb-f1f9e40e40ff">5.75</ix:nonFraction>% senior notes due May 2041</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if44aa963bda44e8fa075b47f30535a24_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQzLTEtMS0xLTE2NzkwOA_caca8e71-e5f1-44d1-aff3-b2e50ca88ca4">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6591fe0e06444dcb90f36c98760ac910_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQzLTMtMS0xLTE2NzkwOA_d6518a8c-c961-4bb5-87b9-5ecf8201b4d9">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i472c295552a045b6bcce82be7abd296a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ0LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmY5Y2MyNThhYzEzOTQwYTNhOGIzYzRhMTIwY2Q0NDkzXzQ_d5b1002c-2a8e-47b4-8b14-650fdbdd92b4">4.5</ix:nonFraction>% senior notes due May 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472c295552a045b6bcce82be7abd296a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ0LTEtMS0xLTE2NzkwOA_b3e44c55-4408-4388-a90d-45c4ba9554f4">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie807ae7adfd345cbb44996f1818e4a05_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ0LTMtMS0xLTE2NzkwOA_a1207e44-98e9-46ee-aa0a-9f0ec2838874">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib71cdfc8616745bda08bb51063716d02_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjhjMGFiNzJhZWJiNTRiM2Q5MzE2MTQ0OTdkN2YyYjVmXzQ_d81a4bef-9e8d-466c-bb3b-2f38fdb901f0">4.125</ix:nonFraction>% senior notes due November 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71cdfc8616745bda08bb51063716d02_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ1LTEtMS0xLTE2NzkwOA_2a8a6a8c-31a9-41e0-be00-999bdbcf0948">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b979d90da5452a905826924ce27d25_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ1LTMtMS0xLTE2NzkwOA_5b75d9e1-0d8c-4714-b286-e6dae2e0d82a">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64cb7a0107874445b5ef1241ac268ddb_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmUxODgyODNmMDNiODQ0ZmNhMGY1ZjRkNzI5NWJiMzVkXzQ_7aa8fa6e-9876-42b8-a029-cc218201effe">5.3</ix:nonFraction>% senior notes due December 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cb7a0107874445b5ef1241ac268ddb_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ2LTEtMS0xLTE2NzkwOA_a24053eb-b0df-4c3c-8e69-033bc618ad3d">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6197c2e1f545da9f71938fe1794bba_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ2LTMtMS0xLTE2NzkwOA_73e4267e-2c26-4899-b816-767ce8835c78">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5c6a9cc0246481db45b0f13ad35ae23_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ3LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjMwNjJhM2ZiZDE3NzRlZmFiMTliNTcyNzU3ZWI1YWE0XzQ_30aa3756-420c-4f2f-8aa6-1638219ed333">4.75</ix:nonFraction>% senior notes due March 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c6a9cc0246481db45b0f13ad35ae23_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ3LTEtMS0xLTE2NzkwOA_bc1e92d8-abc9-446b-aef3-99ea6840a494">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3054d36c450a4f1a949a59076296c836_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ3LTMtMS0xLTE2NzkwOA_b2d22193-ee2d-43e1-8d75-84673784c59a">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8a1d56e01764a95aa6ce0389dadcc42_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmExNzI0MGRjZDVlZDRhYzBhNzc3MzQzNmMzZDQ3NTcwXzQ_d0f8dd21-0f3b-4770-8dfe-ecdadc620eda">5.125</ix:nonFraction>% senior notes due July 2045</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a1d56e01764a95aa6ce0389dadcc42_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ4LTEtMS0xLTE2NzkwOA_4a6a89c0-cfa0-4ad1-8442-4da32d51935f">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d368fcdffdc46d3a0e01d94c43c30e4_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ4LTMtMS0xLTE2NzkwOA_62184001-c7ab-4875-aba7-cfc1ae28014b">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c67e77d27e244a0a68d18b65e0bfd8a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmUzMWQyMDM4ZTEyODRiNzY5ZjI0MzBlYzdkMDYyNmJjXzQ_340f4794-6b96-4834-b6f4-961e592e9089">3.875</ix:nonFraction>% senior notes due August 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c67e77d27e244a0a68d18b65e0bfd8a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ5LTEtMS0xLTE2NzkwOA_e004160d-77a6-4bdf-b332-24a773fece9c">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d3bf9e9c15461f91c2413227e037e6_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ5LTMtMS0xLTE2NzkwOA_d82307fa-9f16-49cd-888e-04651983d42d">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24053ea29d834108aadea2e1babdf1a7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmExOWZjY2NkOGE5YzRhNjE4MzBhMzVmYjA3NTYyYmY1XzQ_6d6bb9f7-597b-4d61-bbda-b97d754a6a1c">5.05</ix:nonFraction>% senior notes due March 2048</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24053ea29d834108aadea2e1babdf1a7_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUwLTEtMS0xLTE2NzkwOA_c4bb2f78-27d2-4945-a453-05ca32ea2613">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8aad75638974bc3a8cc67695f56c0c0_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUwLTMtMS0xLTE2NzkwOA_907ca6da-abd0-48d9-bce4-aa63e3609b9d">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2904af2c2aa44bf0b544d9d2553f8e9e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjNkOWRlNTE3NmFmODQzMzNhNzJkN2ZlNjhjOGEwMmIyXzQ_6c873d16-e6d8-4c1a-8584-2bfab1c50482">4.25</ix:nonFraction>% senior notes due April 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2904af2c2aa44bf0b544d9d2553f8e9e_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUxLTEtMS0xLTE2NzkwOA_075f39f1-7a83-4179-9fb7-7aecb3974e3c">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e7542864f1465cbf09bf46b7a5efd8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUxLTMtMS0xLTE2NzkwOA_b90a2614-b20d-4658-aab4-ba84050d4400">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_136d726d-4e4c-47e6-89b0-66598c753e01"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_f7e749bb-d161-4304-bb3e-6fdb8d5e52ce">Finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTEtMS0xLTE2NzkwOA_eff8f712-4e80-48d5-b8a0-ee207c1c95c8">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTMtMS0xLTE2NzkwOA_0886477e-d511-43fe-a954-0bb0612a187f">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142b09e623c74fd48e7fa4f8a407f130_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUzLTEtMS0xLTE2NzkwOA_8d145742-a371-4641-aad9-12898f8e12c2">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88943c99762a48acb5314b7f2e6035c1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUzLTMtMS0xLTE2NzkwOA_04000f93-6128-4d43-9ec5-dd9c5b333b06">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt principal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LongtermDebtGrossAndLeaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU0LTEtMS0xLTE2NzkwOA_6c1666d2-4e8e-48f7-9078-125c04d0c354">52,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:LongtermDebtGrossAndLeaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU0LTMtMS0xLTE2NzkwOA_8209d4b4-9cde-451b-8219-d288c4e5fd07">56,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU1LTEtMS0xLTE2NzkwOA_f8db4a3b-46de-4801-9474-c5b761a814fb">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU1LTMtMS0xLTE2NzkwOA_c0a655db-0745-4eb0-b278-667af69cb1c9">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discounts and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU2LTEtMS0xLTE2NzkwOA_45d37f13-bd59-4bf6-9db6-0298ff30fb35">696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU2LTMtMS0xLTE2NzkwOA_a356a182-ddd1-4e00-9b95-e7518831bbbb">786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU3LTEtMS0xLTE2NzkwOA_b3f078c6-1c29-41ce-b38d-c1843641e422">52,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU3LTMtMS0xLTE2NzkwOA_51fc593d-4671-4628-b901-d61d92591327">56,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzYwLTEtMS0xLTE2NzkwOA_baf8b78a-78af-40eb-a99f-cfb7bc4e2471">1,778</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzYwLTMtMS0xLTE2NzkwOA_8eb2dcc3-314d-41a4-9700-95164adf7867">4,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzYxLTEtMS0xLTE2NzkwOA_1d8420c5-3633-4076-aa7b-35020dea903e">50,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzYxLTMtMS0xLTE2NzkwOA_1fe67f2d-6e4b-4de4-92f8-ab7549cecabe">51,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">__________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term debt of $<ix:nonFraction unitRef="usd" contextRef="ic9857095e8f8462c8443313d13593edd_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzk1Njg_ddb8c119-c1f1-42b6-9e2c-a3dfffd30489">3</ix:nonFraction>&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i5c860eae6283448dbfd0c97984884dd2" continuedAt="icd7539cce8c94832a5e42ced4700cfec"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4MjA_61a5ec1d-fada-40cb-bcd3-059465c1cd7c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s required repayments of debt principal due during each of the next five&#160;years and thereafter, as of December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzEtMS0xLTEtMTY3OTA4_0e3611e9-206e-4fda-87a2-8c50c1478081">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzItMS0xLTEtMTY3OTA4_1b98066b-d26d-4b1b-b720-6622e513b967">2,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzMtMS0xLTEtMTY3OTA4_7fa300f8-686d-4ec5-98f2-7ca5077f6166">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzQtMS0xLTEtMTY3OTA4_7836553b-2324-4cde-a08b-1a30b1a32de9">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzUtMS0xLTEtMTY3OTA4_eda0c75a-78a0-4f1e-a9a6-8e8e724f295e">3,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzYtMS0xLTEtMTY3OTA4_42aa06f0-10da-4792-a672-b93c357f0011">37,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzctMS0xLTEtMTY3OTA4_1736d927-e74c-4de2-acdd-8d2ed4c473f7">51,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzgtMS0xLTEtMTY3OTA4_eff8f712-4e80-48d5-b8a0-ee207c1c95c8">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:LongtermDebtGrossAndLeaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzktMS0xLTEtMTY3OTA4_2e530404-85c9-459a-bf20-9d0badf5a6b4">52,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for a summary of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">maturities of the Company&#8217;s finance lease liabilities.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Borrowings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper and Back-up Credit Facilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="i80a5bd02c59b48d08a90b3e9dc305deb_I20211231" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ4MQ_efca53e3-6ebd-40ac-a5e3-19dbaab0616d"><ix:nonFraction unitRef="usd" contextRef="ia1fc6bc460b24a2d9f9e56bbbcc00fdd_I20221231" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ4MQ_f1c73486-82e7-4de3-b029-9fafe27a7c13">no</ix:nonFraction></ix:nonFraction>t have any commercial paper outstanding as of December 31, 2022 or 2021. In connection with its commercial paper program, the Company maintains a $<ix:nonFraction unitRef="usd" contextRef="i178a89f691034c3f89a0f58dd76f6e00_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYyOQ_be320a14-8d90-4553-9bcd-23adcfb50d10">2.0</ix:nonFraction> billion, <ix:nonNumeric contextRef="i9e8df175e7a746b1966ad9f58331ab59_D20220101-20221231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4NTc_313e64a8-1b3f-4573-85e6-cbf3bbfa9f0c">five-year</ix:nonNumeric> unsecured back-up revolving credit facility, which expires on May 16, 2025, a $<ix:nonFraction unitRef="usd" contextRef="i9d1d90e160df4c6987e1a3d97b3ee6de_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzcxOQ_71faed32-6af6-401e-a624-10bea526e635">2.0</ix:nonFraction> billion, <ix:nonNumeric contextRef="i7d274b43ce6b460b819a8816627a53ce_D20220101-20221231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4NTE_930daf5e-317d-4b90-913e-932a82998a91">five-year</ix:nonNumeric> unsecured back-up revolving credit facility, which expires on May 11, 2026, and a $<ix:nonFraction unitRef="usd" contextRef="i09e418d01a724140b2e4c98ed177fb58_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzgxMw_90b43e57-3a60-461e-948b-bcc01644154a">2.0</ix:nonFraction> billion, <ix:nonNumeric contextRef="i81ac034e6bd446208baa342a62985862_D20220101-20221231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4NjI_428e6a90-ff08-4d89-9cb1-ce134fc4cd86">five-year</ix:nonNumeric> unsecured back-up revolving credit facility, which expires on May 16, 2027. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company&#8217;s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately <ix:nonFraction unitRef="number" contextRef="i69d9e769f3ec4ff9913f2a8111d4261a_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzExMTc_fa87094e-800a-4bd3-8617-cd036397b254">0.03</ix:nonFraction>%, regardless of usage. As of December&#160;31, 2022 and 2021, there were <ix:nonFraction unitRef="usd" contextRef="i672e486d94cb40d7a527afc4274d487f_I20221231" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzExNzA_a25adbae-7ce0-4532-a05b-ba3f68725a7e"><ix:nonFraction unitRef="usd" contextRef="ia959e4c514254a2b8079572e46d8906d_I20211231" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzExNzA_a5392d2f-bfcd-4586-a9b9-ed4596284d95">no</ix:nonFraction></ix:nonFraction> borrowings outstanding under any of the Company&#8217;s back-up credit facilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Home Loan Bank of Boston (&#8220;FHLBB&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A subsidiary of the Company is a member of the FHLBB. As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of December&#160;31, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE1NTI_e475f555-0cde-4697-820e-00a7102e6c1d">915</ix:nonFraction> million. At both December&#160;31, 2022 and 2021, there were <ix:nonFraction unitRef="usd" contextRef="iee13a60d394448b5ac976fd2d9a8bc06_I20221231" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE1ODY_35b4217c-1142-4a03-a01e-a9a4d025a8c8"><ix:nonFraction unitRef="usd" contextRef="i1cf725ff0cd64d81815fe8e8b14333a5_I20211231" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE1ODY_f027e1b3-e463-4ef8-a9fd-b4cd0b574dcd">no</ix:nonFraction></ix:nonFraction> outstanding advances from the FHLBB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Borrowings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise of Par Call Redemptions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company exercised the par call redemption on its outstanding <ix:nonFraction unitRef="number" contextRef="iea5673d7807e4ec1a5450a0e6653c02a_I20220531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwNDI_10bc7eef-602b-4c99-8713-ad5f7c8085a5">3.5</ix:nonFraction>% senior notes due July 2022 to redeem for cash on hand the entire $<ix:nonFraction unitRef="usd" contextRef="i65160d516bd047099c2e54b984917a8b_D20220501-20220531" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwNTE_37372966-7e93-4752-a383-887120153af7">1.5</ix:nonFraction>&#160;billion aggregate principal amount. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company exercised the par call redemption on its outstanding <ix:nonFraction unitRef="number" contextRef="ib1b72957684f401f892d85f44495d314_I20220831" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwNjc_1d1ead36-8041-4937-97f3-ac7d7a50ebc4">2.75</ix:nonFraction>% senior notes due November 2022 (issued by Aetna Inc. (&#8220;Aetna&#8221;)) to redeem for cash on hand the entire $<ix:nonFraction unitRef="usd" contextRef="id5f6ffbd37304fc48f79a5e9b0b46aeb_D20220801-20220831" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwNzU_5c9fb118-c854-494f-92c3-06e3a1d584a3">1.0</ix:nonFraction>&#160;billion aggregate principal amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company exercised the par call redemptions on its outstanding <ix:nonFraction unitRef="number" contextRef="i822fccc0619141489184c841adb873a6_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwOTE_ca866cc8-c688-45a7-92e1-f20e2a0f6644">2.75</ix:nonFraction>% senior notes due December 2022 and <ix:nonFraction unitRef="number" contextRef="i9c47b439eae34e66b4c6b711b0356a0f_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwOTk_bd3cb408-2e23-4e4d-9e62-bf9f5e67005b">4.75</ix:nonFraction>% senior notes due December 2022 (including notes issued by Omnicare, Inc.) to redeem for cash on hand the entire aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ic145b33260a44d0e8f2212d9f0defd82_D20220901-20220930" decimals="-7" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzEzNzQzODk1MzYxMzYz_6de0d55e-86ba-4d24-bded-bc5a55ae6958">1.25</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="iadc7cf66f76f4d89843f2feb6ead05a9_D20220901-20220930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkxMDk_b80c119b-b7e6-429e-a026-6b3f69d7bbee">399</ix:nonFraction>&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 18, 2021, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i4e5f9ad0e20745e2b8738a0b8561987b_I20210818" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE2OTk_ff45480f-d87c-43ab-a161-8d25a34f95d9">1.0</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i4e5f9ad0e20745e2b8738a0b8561987b_I20210818" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE3MzI_540f7107-56ed-4dde-9f23-abfab4650b2a">2.125</ix:nonFraction>% unsecured senior notes due September 15, 2031 for total proceeds of $<ix:nonFraction unitRef="usd" contextRef="i79d2af0f86c541af9571d4910bbca9be_D20210818-20210818" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE4MDM_d5ccf101-7cd7-4ab4-8ed1-006f6f6ad54e">987</ix:nonFraction>&#160;million, net of discounts, underwriting fees and offering expenses. The net proceeds of this offering were used for the purchase of senior notes in connection with the Company&#8217;s cash tender offer in August 2021 as described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into several interest rate swap transactions to manage interest rate risk. These agreements were designated as cash flow hedges and were used to hedge the exposure to variability in future cash flows </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icd7539cce8c94832a5e42ced4700cfec"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting from changes in interest rates related to the anticipated issuance of $<ix:nonFraction unitRef="usd" contextRef="id5a0d766445d4eabbf62b2cae9bdafec_I20200331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzYzMg_44e926da-9e93-4fa3-b129-bdf99ccbd34b">750</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id5a0d766445d4eabbf62b2cae9bdafec_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY0Ng_a6873e0b-1c34-435b-bec0-90c8ec9ac381">3.625</ix:nonFraction>% unsecured senior notes due April 1, 2027, $<ix:nonFraction unitRef="usd" contextRef="i1250e762a87140739d6c5e728a186e5b_I20200331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY1NA_7d0e9305-bd75-45d0-ab85-fd068920f6d4">1.5</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i1250e762a87140739d6c5e728a186e5b_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY2OA_94436392-9313-4797-9a8a-998141ab4419">3.75</ix:nonFraction>% unsecured senior notes due April 1, 2030, $<ix:nonFraction unitRef="usd" contextRef="i02d14dd77d014595a362cb2ecc741ab3_I20200331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY3NQ_69d94966-f2fc-414c-a8c4-59132e8011f4">1.0</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i02d14dd77d014595a362cb2ecc741ab3_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY4OQ_4ea00836-524f-4e58-bb0d-20b7c2f3fcf8">4.125</ix:nonFraction>% unsecured senior notes due April 1, 2040 and $<ix:nonFraction unitRef="usd" contextRef="i12df8267bbe141b3a7404c266a874107_I20200331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY5Nw_18beb7ea-6859-4525-a76c-5eb588de77aa">750</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i12df8267bbe141b3a7404c266a874107_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzcxMQ_23aebda9-73e1-4571-a634-94c41a416c8e">4.25</ix:nonFraction>% unsecured senior notes due April 1, 2050 (collectively, the &#8220;March 2020 Notes&#8221;). In connection with the issuance of the March 2020 Notes on March 31, 2020, the Company terminated all outstanding cash flow hedges. The Company paid a net amount of $<ix:nonFraction unitRef="usd" contextRef="ibdbbb74b83b14c429e04b647517a9a11_D20200301-20200331" decimals="-6" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQxMTY_50508e1b-2dc3-43d0-a646-65cb49a3adb6">7</ix:nonFraction>&#160;million to the hedge counterparties upon termination, which was recorded as a loss, net of tax, of $<ix:nonFraction unitRef="usd" contextRef="ibdbbb74b83b14c429e04b647517a9a11_D20200301-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQyMTA_4ee6cd00-47ec-4a40-b91f-c5cd50b9fd5d">5</ix:nonFraction>&#160;million in accumulated other comprehensive income and will be reclassified as interest expense over the life of the March 2020 Notes. See Note 13 &#8216;&#8216;Other Comprehensive Income (Loss)&#8217;&#8217; for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Extinguishments of Debt</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company redeemed for cash the remaining $<ix:nonFraction unitRef="usd" contextRef="i1c8ed04608904ccf99b54ecc1dc6986f_D20211201-20211231" decimals="-8" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ0Njg_57159691-8054-42e9-a698-3d6bca9f7823">2.3</ix:nonFraction>&#160;billion of its outstanding <ix:nonFraction unitRef="number" contextRef="i261fa7d2be3a4e558c47f8185e46e39c_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ0OTA_8a19e90f-4af5-4e09-9d46-8a2d21bb23d2">3.7</ix:nonFraction>% senior notes due 2023. In connection with the early redemption of such senior notes, the Company paid a make-whole premium of $<ix:nonFraction unitRef="usd" contextRef="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ2MTk_58870ef0-2d6f-42a3-aad1-743df68d380a">80</ix:nonFraction> million in excess of the aggregate principal amount of the senior notes that were redeemed, wrote-off $<ix:nonFraction unitRef="usd" contextRef="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231" decimals="-6" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ3MTY_d84c20e4-4516-4c79-b777-5d58202ff360">8</ix:nonFraction> million of unamortized deferred financing costs and incurred $<ix:nonFraction unitRef="usd" contextRef="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231" decimals="-6" name="cvs:DebtExtinguishmentFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ3NzI_d8abf2e7-875e-4b30-87b2-e5abd42f7ce4">1</ix:nonFraction> million in fees, for a total loss on early extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ4MzY_6d5734ef-ce73-4bc1-be0b-4177b963658d">89</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company purchased approximately $<ix:nonFraction unitRef="usd" contextRef="i6a3e435c4d424340a17b5f25797bcf4c_D20210801-20210831" decimals="-8" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ4OTM_8da6c06c-3445-4541-9beb-1e1e3d882356">2.0</ix:nonFraction>&#160;billion of its outstanding <ix:nonFraction unitRef="number" contextRef="ib2bac05524ef4721a76e0eb616aa0666_I20210831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ5MTU_2bc58bd2-7df8-4ad1-b152-e52d9cdb4758">4.3</ix:nonFraction>% senior notes due 2028 through a cash tender offer. In connection with the purchase of such senior notes, the Company paid a premium of $<ix:nonFraction unitRef="usd" contextRef="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUwNTM_cc479c7d-a9f7-49ea-a55e-f882412e5b86">332</ix:nonFraction> million&#160;in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $<ix:nonFraction unitRef="usd" contextRef="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831" decimals="-6" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUxNTE_bd01253e-13fb-45f8-81af-e4e4f98a4624">26</ix:nonFraction>&#160;million of unamortized deferred financing costs and incurred $<ix:nonFraction unitRef="usd" contextRef="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831" decimals="-6" name="cvs:DebtExtinguishmentFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUyMDc_b32542c6-53bb-406f-a991-c73c68046b0d">5</ix:nonFraction>&#160;million in fees, for a total loss on early extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUyNzE_e6f8814e-2247-4753-98d6-d5a29e76fc5d">363</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company purchased $<ix:nonFraction unitRef="usd" contextRef="ifd21192d1e424d908a21238c5796151b_D20201201-20201231" decimals="-8" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUzMTY_25935609-f650-46b0-832c-4257bb459419">4.5</ix:nonFraction>&#160;billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $<ix:nonFraction unitRef="usd" contextRef="i25c312e3832345d184ca98519e12b9d1_D20201201-20201231" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0MzA_49438a47-6a91-443d-b0d7-7419d0e1f944">113</ix:nonFraction>&#160;million of its <ix:nonFraction unitRef="number" contextRef="i13f4471edaf148c9a01efea628761e98_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0NDA_c2062c56-2656-4dc0-b4eb-9b2d17c1017c">4.0</ix:nonFraction>% senior notes due 2023, $<ix:nonFraction unitRef="usd" contextRef="ifa1dd2e3d7514370b3370e9417b8eb05_D20201201-20201231" decimals="-8" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0NjY_4f3a9f09-1b42-4294-ae2c-193a0be918be">1.4</ix:nonFraction>&#160;billion of its <ix:nonFraction unitRef="number" contextRef="i849a0c4d3cbb471192475ee1fb23de1b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0NzY_801155e5-4bd7-4df5-a33a-91fb71383fea">3.7</ix:nonFraction>% senior notes due 2023, $<ix:nonFraction unitRef="usd" contextRef="ida81c2c8d73c4e8bb5a9daa090b941df_D20201201-20201231" decimals="-8" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU1MDI_f05eaa87-f56c-4bf0-a092-1c25a478ff25">1.0</ix:nonFraction>&#160;billion of its <ix:nonFraction unitRef="number" contextRef="i4f5b8050a2fb4ad5b42037c800d80489_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU1MTI_18b6c595-dcac-4f5b-bff4-2b75aa717c76">4.1</ix:nonFraction>% senior notes due 2025 and $<ix:nonFraction unitRef="usd" contextRef="i8e6897a260054377ad600720e4fd68b9_D20201201-20201231" decimals="-8" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU1NDE_46d82395-bf72-46ac-98b4-9253182771ec">2.0</ix:nonFraction>&#160;billion of its <ix:nonFraction unitRef="number" contextRef="i56faf938b6bd44ff9f91b9e6bc18f5ec_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU1NTE_098be5de-57b5-424e-8f38-19fb3187f8d0">4.3</ix:nonFraction>% senior notes due 2028. In connection with the purchase of such senior notes, the Company paid a premium of $<ix:nonFraction unitRef="usd" contextRef="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU2NjE_7891a137-9b7f-416f-b4c3-fbb4a739d4a0">619</ix:nonFraction>&#160;million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $<ix:nonFraction unitRef="usd" contextRef="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231" decimals="-6" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU3NTk_75e569ff-85e4-4dff-81f9-09f1af8afec5">45</ix:nonFraction>&#160;million of unamortized deferred financing costs and incurred $<ix:nonFraction unitRef="usd" contextRef="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231" decimals="-6" name="cvs:DebtExtinguishmentFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU4MTU_25b59a7b-6e09-413b-a234-751ece34bd09">10</ix:nonFraction>&#160;million in fees, for a total loss on early extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU4Nzk_d9b56349-8b80-4f2b-9175-a10b5c006881">674</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company purchased $<ix:nonFraction unitRef="usd" contextRef="i0e3f962b140e4d8bbed1c0e619a28998_D20200801-20200831" decimals="-8" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU5MjI_a0cb604d-54a8-46b9-aff5-17f93843e2c6">6.0</ix:nonFraction>&#160;billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $<ix:nonFraction unitRef="usd" contextRef="iad0865b66832421a88a82f88e92f6b90_D20200801-20200831" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYwMzY_4f5ac5d6-ef7b-4457-8dcc-b031da722a1f">723</ix:nonFraction>&#160;million of its <ix:nonFraction unitRef="number" contextRef="if76853d3efe14948b0d921504f1a2b1f_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYwNDY_fea767e5-9be5-43a1-b26b-f1c53bc98d79">4.0</ix:nonFraction>% senior notes due 2023, $<ix:nonFraction unitRef="usd" contextRef="i6f8d117be10d448ba3e9812c1e7e4b01_D20200801-20200831" decimals="-8" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYwNzI_aa78c619-600b-4740-8a52-8f890e9afffa">2.3</ix:nonFraction>&#160;billion of its <ix:nonFraction unitRef="number" contextRef="i91226dc64fe84ffcb8769e52de99bd30_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYwODI_c27607e8-b634-4d16-9d37-1e0b786e87a4">3.7</ix:nonFraction>% senior notes due 2023 and $<ix:nonFraction unitRef="usd" contextRef="i8c996ffe9966457d93cce263d0c3eaac_D20200801-20200831" decimals="-8" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYxMTE_3960e599-e9c0-43bf-9692-707daef4cedb">3.0</ix:nonFraction>&#160;billion of its <ix:nonFraction unitRef="number" contextRef="i2d884e077e99498da60db16f252f707a_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYxMjE_ea2fca2d-8435-49f6-b39f-6f2893a28640">4.1</ix:nonFraction>% senior notes due 2025. In connection with the purchase of such senior notes, the Company paid a premium of $<ix:nonFraction unitRef="usd" contextRef="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYyMzE_3e9bbf03-ad31-43f6-bc9b-eaa4e00b808a">706</ix:nonFraction>&#160;million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $<ix:nonFraction unitRef="usd" contextRef="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831" decimals="-6" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYzMjk_61a31365-4213-4020-b62c-c70f18f76e30">47</ix:nonFraction>&#160;million of unamortized deferred financing costs and incurred $<ix:nonFraction unitRef="usd" contextRef="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831" decimals="-6" name="cvs:DebtExtinguishmentFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYzODU_9cfe7507-7a98-476c-91ba-48c70c285b5f">13</ix:nonFraction>&#160;million in fees, for a total loss on early extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzY0NDk_12dc4b77-a7fd-49b2-9a5b-911701e9bb05">766</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Covenants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s back-up revolving credit facilities and unsecured senior notes contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company&#8217;s debt maturities in the event of a downgrade in the Company&#8217;s credit ratings. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of December&#160;31, 2022, the Company was in compliance with all of its debt covenants.</span></div></ix:continuation><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_145"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTE4_f3319996-04b5-4f4a-a507-3656d7b10437" continuedAt="ic64b00f14e224b9d89cbeb80db6c460f" escape="true">Pension Plans and Other Postretirement Benefits</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic64b00f14e224b9d89cbeb80db6c460f" continuedAt="i8e6adee6da1040448992336da0050881"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company sponsors several active 401(k) savings plans that cover all employees who meet plan eligibility requirements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes matching contributions consistent with the provisions of the respective plans. At the participant&#8217;s option, account balances, including the Company&#8217;s matching contribution, can be invested among various investment options under each plan. The CVS Health Future Fund 401(k) Plan offers CVS Health Corporation&#8217;s common stock fund as an investment option. The Company also maintains nonqualified, unfunded deferred compensation plans for certain key employees. The plans provide participants the opportunity to defer portions of their eligible compensation and for certain nonqualified plans, participants receive matching contributions equivalent to what they could have received under the CVS Health Future Fund 401(k) Plan absent certain restrictions and limitations under the Internal Revenue Code. The Company&#8217;s contributions under its defined contribution plans were $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExMDU_185c2adc-300d-4420-a42a-4044c013390e">567</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExMDk_14253e30-360d-404b-8d7d-b5ae2d0a7895">552</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExMTY_9f9d91d3-397a-40bf-a4d3-8d9a9ad0a2bc">520</ix:nonFraction> million in the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i8e6adee6da1040448992336da0050881" continuedAt="i783c1d6e3e8c4decafbf81ecd44a3910"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a tax-qualified defined benefit pension plan that was frozen in 2010 and a nonqualified supplemental pension plan that was frozen in 2007. The Company also sponsors several other defined benefit pension plans that are unfunded nonqualified supplemental retirement plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Obligation and Plan Assets</span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTEy_7783c863-f5f0-492a-80c4-91867ed1e08a" escape="true"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTMx_15e4f53e-8e8f-416a-9162-8bed52eca5c4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables outline the change in pension benefit obligation and plan assets over the specified periods:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzItMS0xLTEtMTY3OTA4_0c62fb4f-2497-4ccf-811f-d617ea80d063">6,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325dd5d5aff14a35ac1931e4f56f744d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzItMy0xLTEtMTY3OTA4_a4408c15-5891-43ec-abeb-61e90b4346d3">6,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzQtMS0xLTEtMTY3OTA4_49af9157-64d9-4057-8bdf-296ed68e6311">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzQtMy0xLTEtMTY3OTA4_e4cdd871-cf18-49f8-b495-e0938590ae1e">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzUtMS0xLTEtMTY3OTA4_ad2878a7-5194-4a4c-b797-8bb3a6f3ccca">1,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzUtMy0xLTEtMTY3OTA4_8ecddfe0-d428-40a9-b588-5bc6baf83397">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzYtMS0xLTEtMTY3OTA4_4432a6c8-e215-4b4a-b20e-bab01a616021">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzYtMy0xLTEtMTY3OTA4_5eae5e7d-7a5a-483e-9d09-b7374a91146c">408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzctMS0xLTEtMTY3OTA4_dd08954f-767e-4db3-b2b8-44b9d27322da">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzctMy0xLTEtMTY3OTA4_9d0bca82-e183-44e1-8d7b-dcf234189fde"><ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzctMy0xLTEtMTY3OTA4_b9456bc9-5223-41b2-91ad-2e79ecd654ad">53</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzgtMS0xLTEtMTY3OTA4_0cce0df3-c73e-4f56-b2ee-a8508818f07e">4,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzgtMy0xLTEtMTY3OTA4_e9063ced-a5ed-407d-a49d-4e980f80a0e3">6,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzExLTEtMS0xLTE2NzkwOA_dbabdce6-64a5-4289-85a3-8246586f8b53">6,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325dd5d5aff14a35ac1931e4f56f744d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzExLTMtMS0xLTE2NzkwOA_b5ee7dca-a65c-4690-b4f8-648252c64812">6,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzEzLTEtMS0xLTE2NzkwOA_9061a87e-0aed-4547-8bda-e0e82cfedfd8">968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzEzLTMtMS0xLTE2NzkwOA_fddbca23-8cdd-4897-9787-84c6b0112987">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE0LTEtMS0xLTE2NzkwOA_ec5b89cc-c92d-443e-a753-4cf22bc85438">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE0LTMtMS0xLTE2NzkwOA_ad1697f9-6669-42ea-bcf4-b0c750187e74">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE1LTEtMS0xLTE2NzkwOA_8e9bbf42-ff4c-4f21-bb43-1366702fa7e9">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE1LTMtMS0xLTE2NzkwOA_6480a199-e0d3-409d-8c66-d77fc1a1fb81">408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE2LTEtMS0xLTE2NzkwOA_f2fe3e50-dff2-4cf3-9a5d-a291e0a8a215">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE2LTMtMS0xLTE2NzkwOA_9d0bca82-e183-44e1-8d7b-dcf234189fde"><ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE2LTMtMS0xLTE2NzkwOA_b9456bc9-5223-41b2-91ad-2e79ecd654ad">53</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE3LTEtMS0xLTE2NzkwOA_2f3f90a1-51f1-4922-aeee-252f19367aeb">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE3LTMtMS0xLTE2NzkwOA_053b23b9-5337-472e-af78-d872032d2773">6,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE5LTEtMS0xLTE2NzkwOA_66000f10-3b45-42e6-a0d1-4705fed1c120">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE5LTMtMS0xLTE2NzkwOA_3bfaf862-ac13-486d-8a67-2a406b49fff3">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the pension benefit obligation during the years ended December&#160;31, 2022 and 2021 was primarily driven by the change in the discount rate during each respective period.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTI1_b79a2a47-3a34-4cfd-8f35-67a50da96e3e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets (liabilities) recognized on the consolidated balance sheets at December&#160;31, 2022 and 2021 for the defined benefit pension plans consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets reflected in other assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzEtMS0xLTEtMTY3OTA4_8b1aac68-2cec-4eba-91cf-1de6a1ee1680">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzEtMy0xLTEtMTY3OTA4_ca44bf39-7d06-4773-a752-922001965ef7">946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities reflected in accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzItMS0xLTEtMTY3OTA4_28e09be1-42c2-4c49-9f9f-ca4a016e6358">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzItMy0xLTEtMTY3OTA4_e127e02e-666e-4e69-91a4-f4c0d52f0767">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities reflected in other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzMtMS0xLTEtMTY3OTA4_63dbea12-83ae-4a38-9870-56fce5a74dc3">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzMtMy0xLTEtMTY3OTA4_518906bc-be3a-4e74-b672-8055e11e9a22">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzQtMS0xLTEtMTY3OTA4_583a9854-130f-463f-94dd-eb5097c9eaad">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzQtMy0xLTEtMTY3OTA4_793a0dd2-7a94-42bb-b70a-0526245883e7">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic Benefit Cost (Income)</span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTM2_60b21ce6-be8e-4baa-99c9-6073f82fb4b4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (income) for the years ended December&#160;31, 2022, 2021 and 2020 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost (income):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzItMS0xLTEtMTY3OTA4_ca47f97d-f486-45de-9af9-44eb00be85f1">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzItMy0xLTEtMTY3OTA4_a1fa309f-55f6-4547-9356-d65292f2b91e">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10042502b67476084251422c4796803_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzItNS0xLTEtMTY3OTA4_d4d9283d-cd38-4e9b-97a4-1b21cc463b1a">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzMtMS0xLTEtMTY3OTA4_4711c82d-a472-4a03-a335-34c758ace153">309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzMtMy0xLTEtMTY3OTA4_3a6273e2-1718-4b15-b87a-5d8789103c93">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia10042502b67476084251422c4796803_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzMtNS0xLTEtMTY3OTA4_f4fd3f1a-d0ba-4e0c-b44d-bc34a05e26c8">388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzQtMS0xLTEtMTY3OTA4_8b296fa2-c3b6-4427-86a0-fbea7b248d0a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzQtMy0xLTEtMTY3OTA4_c60ebf68-3417-4cd7-b8a0-f7f77c0095c3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10042502b67476084251422c4796803_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzQtNS0xLTEtMTY3OTA4_3da7bb87-9632-46a0-81db-58ecc4a48b11">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzUtMS0xLTEtMTY3OTA4_ae7c25b0-e9b2-40cb-9807-1f2b130831af">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzUtMy0xLTEtMTY3OTA4_1beb1486-8211-4f74-843f-a51f30f6239c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10042502b67476084251422c4796803_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzUtNS0xLTEtMTY3OTA4_bd8a5bbf-1d0b-4ff2-9fdd-0a7598a8ebdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzYtMS0xLTEtMTY3OTA4_8cd93a5b-c891-416f-8bb0-9c0440544c42">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzYtMy0xLTEtMTY3OTA4_9cd6101d-bf2c-435b-98ff-f22406b20d43">186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia10042502b67476084251422c4796803_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzYtNS0xLTEtMTY3OTA4_e1ce34f3-c733-4de7-b6c0-3c323b9a5787">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i783c1d6e3e8c4decafbf81ecd44a3910" continuedAt="i976b84091fe247e7826b4655ca5164f6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Plan Assumptions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a series of actuarial assumptions to determine its benefit obligation and net periodic benefit income, the most significant of which include discount rates and expected return on plan assets assumptions. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discount Rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate is determined using a yield curve as of the annual measurement date. The yield curve consists of a series of individual discount rates, with each discount rate corresponding to a single point in time, based on high-quality bonds. Projected benefit payments are discounted to the measurement date using the corresponding rate from the yield curve that is consistent with the maturity profile of the expected liability cash flows.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Return on Plan Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets is determined by using the plan&#8217;s target allocation and return expectations based on many factors including forecasted long-term capital market real returns and the inflationary outlook on a plan by plan basis. See &#8220;Pension Plan Assets&#8221; below for additional details regarding the pension plan assets as of December 31, 2022 and 2021.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers other assumptions including mortality, interest crediting rate, termination and retirement rates and cost of living adjustments. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTM0_9e54c71f-4517-487c-ae70-b99d7a04781d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its benefit obligation based on the following weighted average assumptions as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpjYjg1M2ZiOTUxMjE0NjExYTYzYTU4NmY0MGFhZWIyZS90YWJsZXJhbmdlOmNiODUzZmI5NTEyMTQ2MTFhNjNhNTg2ZjQwYWFlYjJlXzEtMS0xLTEtMTY3OTA4_78b1e3e7-ceab-48f6-836a-e98991438ede">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpjYjg1M2ZiOTUxMjE0NjExYTYzYTU4NmY0MGFhZWIyZS90YWJsZXJhbmdlOmNiODUzZmI5NTEyMTQ2MTFhNjNhNTg2ZjQwYWFlYjJlXzEtMy0xLTEtMTY3OTA4_57175156-6e47-4ec6-b80a-0a0abcfea641">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzEtMS0xLTEtMTY3OTA4_734d194b-7b62-46ff-b14b-0e927a4328ba">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzEtMy0xLTEtMTY3OTA4_f454bf7e-d046-46be-a315-11c1e3d4ed2e">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzEtNS0xLTEtMTY3OTA4_7e40a335-e971-4316-b0f2-4a274ea35da3">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzItMS0xLTEtMTY3OTA4_8e0bdd5e-e6d0-40a9-8589-5eaf60626586">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzItMy0xLTEtMTY3OTA4_40fda278-4230-471b-a0d0-194c3d42e431">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzItNS0xLTEtMTY3OTA4_86ef0ff7-8025-4e04-9ac7-fcf5d89079b6">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan assets primarily include debt and equity securities held in separate accounts, common/collective trusts and real estate investments. The valuation methodologies used to value these debt and equity securities and common/collective trusts are similar to the methodologies described in Note 4 &#8220;Fair Value.&#8221; Pension plan assets also include investments in other assets that are carried at fair value. The following is a description of the valuation methodologies used to value real estate investments and these additional investments, including the general classification pursuant to the fair value hierarchy.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Real estate investments are valued by independent third party appraisers. The appraisals comply with the Uniform Standards of Professional Appraisal Practice, which include, among other things, the income, cost, and sales comparison approaches to estimating property value. Therefore, these investments are classified in Level 3.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private equity and hedge fund limited partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Private equity and hedge fund limited partnerships are carried at fair value which is estimated using the NAV per unit as reported by the administrator of the underlying investment fund as a practical expedient to fair value. Therefore, these investments have been excluded from the fair value table below.</span></div></ix:continuation><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i976b84091fe247e7826b4655ca5164f6" continuedAt="i8d42c9d1c4384c21b33b3731eb9c2768"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTIz_61129dc8-11b3-44a7-8446-6c946500ff91" continuedAt="iaa60d378e1bb4ccbaff4a9f6d8bb13b4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2022 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id982dba0c5764350bf4b2c0dec65cd31_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEtMS0xLTEtMTY3OTA4_2bbcabc7-8065-4304-a794-3d7098d168ad">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29585373b5145568d76c31491c626ad_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEtMy0xLTEtMTY3OTA4_5da9e13e-626a-48f0-96f6-5fe8794a627b">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba0d622bb9e4ee59cdc9b56b5daa62d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEtNS0xLTEtMTY3OTA4_0b208424-aa33-4a3c-bec7-318b1d3698f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd0213cc5bd41f29e44134f2087e2df_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEtNy0xLTEtMTY3OTA4_d852918b-dcf5-47da-b638-3010cc51990a">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c02066515524b6ca358e7ec25ba43ab_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzMtMS0xLTEtMTY3OTA4_e786bae6-665f-4c88-90bf-7f2e8b6f6cc4">566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a598f7ffb4474aa216bbef8ffec30b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzMtMy0xLTEtMTY3OTA4_5aa3c99d-cbfb-45df-b8ac-5552e0bdcf4c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0242ebe0da9b43369d3dbd9a25daef7a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzMtNS0xLTEtMTY3OTA4_bf46110a-160e-4e59-be15-e54fb0f83cc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c35ee561744abb94e564009d6735fc_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzMtNy0xLTEtMTY3OTA4_4cd7192f-786c-4005-bce3-0a9ee1217ae2">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ea9fc5313346938adf5e13ee0bfcc5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzQtMS0xLTEtMTY3OTA4_19f38f8d-c836-4eb1-92f7-6102bf661585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f0ff1789f6444ab4732281654fe93d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzQtMy0xLTEtMTY3OTA4_4e51f8b2-a2cd-4959-8bd7-814d7c05c96c">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762b6378140b484aa6d1ca34c23de494_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzQtNS0xLTEtMTY3OTA4_99e319ed-e7c7-450b-a658-3b0b06882c24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e20cd8a6c7f4c69bb7918f0d9cd2739_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzQtNy0xLTEtMTY3OTA4_5aee6289-a9c6-47ea-a858-1c25a4c46941">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if267949f5fce4681b947f1a16a3838d5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzUtMS0xLTEtMTY3OTA4_f5cebae9-9ed8-4aa8-b1d5-96478ff2fcc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb053251d3444e3901668a924f82d40_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzUtMy0xLTEtMTY3OTA4_c589c29a-26a8-4c47-8652-e739fc6c42ed">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f95fdf743e477a8ac66cfd99745de0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzUtNS0xLTEtMTY3OTA4_3cce879a-6616-4f66-be6e-6606c999c1c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252d55800dcb4295b654fd0658f6f573_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzUtNy0xLTEtMTY3OTA4_3b51fdc1-0e1a-4a45-9dae-ecef4d56f40f">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20101ed8d3e04a40b26eacb5e37c8c4f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzYtMS0xLTEtMTY3OTA4_20b69068-4bb4-4b6b-bbe0-a6b4bab9bd4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc938e99b50474b91e168dd07faea18_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzYtMy0xLTEtMTY3OTA4_a1cd0d1b-7cea-4976-a2aa-26a1d04ea038">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b279e1f6f0b40a982401b8df9857736_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzYtNS0xLTEtMTY3OTA4_da7cd8e2-9650-4217-83ee-524b41b18c4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42da0c7a9d2b475584b0d47002072fc2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzYtNy0xLTEtMTY3OTA4_bb763c42-3487-41a2-b8cc-810e435a2586">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a50108c30e41368e58ccdb0e40fbda_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzctMS0xLTEtMTY3OTA4_6ceef0ba-7388-4223-9af1-2b940815f092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79129f099714bef8ef8da1d8903ece5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzctMy0xLTEtMTY3OTA4_3e6d71c3-f75f-4c06-8d7b-ececb54cc48f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bea816135474568b9b0446d98520e27_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzctNS0xLTEtMTY3OTA4_016ac3d2-de68-4b42-b346-3830c6c604e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6875cc4cb5c6442fa8caebb5f3329dd5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzctNy0xLTEtMTY3OTA4_973a4348-9ea2-4607-8752-63242d0b3bfb">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92730350ea67406b893ebd2e0ed6b301_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzgtMS0xLTEtMTY3OTA4_e8feed8d-7e66-43eb-9dc4-1afadcd7166b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8772a8c1e2e8403a88d7445ac2fed106_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzgtMy0xLTEtMTY3OTA4_85e53ccb-9d8d-4651-9d02-607b35971ed9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdbf916e80cb46918ba4e4c0df3ed889_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzgtNS0xLTEtMTY3OTA4_3775e0d2-540a-4993-9035-107ad17d9dc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ba20c704434ed2a8fab1c6dd389b1b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzgtNy0xLTEtMTY3OTA4_b940904e-a61d-4da7-a4a0-f286bbd50cac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca7c2e9a27a4a1fa7a8bef02337334a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzktMS0xLTEtMTY3OTA4_7eecc447-c631-42a6-babc-e57e50f7e7c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162216dad2a6425bb441d4b6af324060_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzktMy0xLTEtMTY3OTA4_a6a730c9-7b25-4843-a223-f927f6457957">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01262b340a894b3c8b1efb258d3b571b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzktNS0xLTEtMTY3OTA4_0f09525c-7876-4b08-844c-b35b299b20a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea00c6da074b480bb9fe7cc6bbcb98a2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzktNy0xLTEtMTY3OTA4_e9017f2e-c98a-4bb3-a8ef-ddfb622f1dbe">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ac6571e3d74f1dab3aee2141e35e2f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEwLTEtMS0xLTE2NzkwOA_3e6a8090-0b4e-41cf-9db8-b9c267dec99f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dd8c46c55e411d908696c36b38b5c8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEwLTMtMS0xLTE2NzkwOA_8d8a0bad-98d6-4887-bee6-20e200461e5a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e53b4aa76b4272aa433d30914b2324_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEwLTUtMS0xLTE2NzkwOA_5fd45caf-712b-4ddb-8ed4-a25858c246b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7900ae2c578549589f4451568700c87b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEwLTctMS0xLTE2NzkwOA_07a40f84-53b6-4152-8d7d-dbf66dacdee6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5f3a8c54054f17989a4b4993615c41_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzExLTEtMS0xLTE2NzkwOA_bcda81c1-ba81-4148-b87e-ae706a365b23">566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4ffcb36d78416695e1e547f71c05d4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzExLTMtMS0xLTE2NzkwOA_98db60eb-1daa-4aa5-8dbe-d30559b23e41">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5a7f84e8ec40208e181a61a9d3aa89_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzExLTUtMS0xLTE2NzkwOA_29836e8d-ea34-4c3d-9ee9-c633dcb9f8a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860b2109de434ad680884c679dbcb1b3_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzExLTctMS0xLTE2NzkwOA_bfe2ad36-57ac-424e-89ab-0097eb963639">3,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aae37978eb34a42bbc35e64ec3c07a4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEzLTEtMS0xLTE2NzkwOA_952c106b-69e1-444e-88bb-b7b1ea2bb4b7">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8efc5986c964403b550888010f694f5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEzLTMtMS0xLTE2NzkwOA_6a976af9-72ac-4226-9565-0433f0d0451b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d7c0e5807e4c26ba8a3d14fdf19033_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEzLTUtMS0xLTE2NzkwOA_07977013-cc2c-4ce5-88d6-d267f5cc43f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e026ebe0d1141d08ec5920a50dddbad_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEzLTctMS0xLTE2NzkwOA_3b9b14b0-3726-445f-9915-8dc306b2aaec">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5901c6898f433fadeff64551df32fb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE0LTEtMS0xLTE2NzkwOA_7113cabe-8665-4495-83be-b254f6f7fea3">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0b828e6576e4f34bc10d207dbb869a0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE0LTMtMS0xLTE2NzkwOA_28b67b92-f74a-4b6f-806b-0e0b19b06873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d343d8f5c2b4a6e8190984fc1f95d35_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE0LTUtMS0xLTE2NzkwOA_adb13c71-d4c5-4281-91d3-6863a94e51ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd82a6b704248499547541eb8ba6115_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE0LTctMS0xLTE2NzkwOA_efdf9ff9-222c-458e-8e19-92528b95b729">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab524d12dfb04d818c70ea4d09acb204_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE1LTEtMS0xLTE2NzkwOA_c9222b10-f146-4d4e-865b-35e062426c08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2feba394cc284f1c8866c717b615d08c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE1LTMtMS0xLTE2NzkwOA_f6593dd6-a6da-4dfc-ab6b-bb3b55e83c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic071fdd73a984fef8ee7bfd1c930b231_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE1LTUtMS0xLTE2NzkwOA_f613e60a-dd2f-457a-ab9e-391229ffce83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db2a706478c4614aec9544e1bfa5a50_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE1LTctMS0xLTE2NzkwOA_da2ef53e-fc22-4207-9969-47ef2265cc24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa80d56f1e74e55bffe7ec59a51f1f1_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE2LTEtMS0xLTE2NzkwOA_009de54f-d5ca-4921-84ec-e920d796781a">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674b362cb43f4f2cafbbd57f9e56a196_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE2LTMtMS0xLTE2NzkwOA_d646368a-be32-4bd3-98da-2bd8f6911d66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d54224ea00f46f9a1e275c80a61b003_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE2LTUtMS0xLTE2NzkwOA_c8b4af9e-84d7-4492-8248-d61ae583cc3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce41f46d8e84b7789c994f5feff9651_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE2LTctMS0xLTE2NzkwOA_d466845e-50ba-448d-a876-f753e8f5f0b4">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if82b640a199e4868b36a915526dc2053_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE4LTEtMS0xLTE2NzkwOA_ddb97e32-491b-4f6f-8371-9a01c97ebdd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i124f4f560a234bdfb5ec62a90aa60693_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE4LTMtMS0xLTE2NzkwOA_b3aec0fa-6db8-493d-9c17-8a5d3246002d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib411c0d8ea7a4e8192645865166e5bc4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE4LTUtMS0xLTE2NzkwOA_5e12461c-46df-435a-97a5-d9956ccd8654">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d545bbe52647728f7c485d029e3b33_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE4LTctMS0xLTE2NzkwOA_7e63135a-5c8a-4d2b-b9a5-48a5d9b47872">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282d5c6bb1c644ce9a4a5ffafc468287_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE5LTEtMS0xLTE2NzkwOA_cc4b596b-89ff-428a-9095-618d3b650888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6639e48973497fa396c0a952816890_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE5LTMtMS0xLTE2NzkwOA_c875dccf-13da-4c5c-b1c9-63ef54492619">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27b6f9af914a43a38de124a97f2cc7b2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE5LTUtMS0xLTE2NzkwOA_d0da5d58-63e1-4844-bc90-4635c004466a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55eb2e1866d4936acc91c5cfaf163e0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE5LTctMS0xLTE2NzkwOA_9291a793-8f66-48e6-bb7a-6aa9f6a72056">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f3dfc3b0af4263962bc11ed03e1717_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIxLTEtMS0xLTE2NzkwOA_4a6dda61-b1cc-40fb-8abb-6c71a15671f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981507be87f94c918c4f5777451702ff_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIxLTMtMS0xLTE2NzkwOA_e64d182b-2924-4349-9a0a-7a495fbcd1f1">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530d696f8fca4111b2384705d88e2528_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIxLTUtMS0xLTE2NzkwOA_fb5fc5a2-bfe5-4240-a8a9-a9e453a7cfd6">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b34d8cf62304c8ab8b6b20efdeddbbb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIxLTctMS0xLTE2NzkwOA_ee26b096-a523-4ce5-94e2-5ebced293470">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c03a30159a84819aa7bf2d4b44b4940_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIyLTEtMS0xLTE2NzkwOA_15c45d0e-eafa-4b66-ac60-6d0e30dbd76b">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61796b34679f4c6cbef7783824db21ad_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIyLTMtMS0xLTE2NzkwOA_69ba9265-e344-44e6-9325-775dbd8cb7da">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8311648bcc5f4c0e9ba53519e18563bb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIyLTUtMS0xLTE2NzkwOA_a429feeb-1981-43f3-a42a-2c13e18cc0e1">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95da6fe526324fc7915c89f6c760058b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIyLTctMS0xLTE2NzkwOA_6d002305-52cc-46cc-93d9-fd31851f287a">4,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $<ix:nonFraction unitRef="usd" contextRef="if634ee5b01e4418e9eecd02c2b108b45_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU0NTc_b063427b-3fe6-4ea3-98e2-eed0ddff80bb">104</ix:nonFraction> million of equity securities and $<ix:nonFraction unitRef="usd" contextRef="i0ef579c6f5d94978a2551abaa400aaad_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU0ODU_0f12bef5-182f-4246-8fbb-c9dc66000d15">203</ix:nonFraction> million of debt securities. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $<ix:nonFraction unitRef="usd" contextRef="ibe781c3ffb934d7283abdcde5259b578_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU1MTg_b94ad2e9-2a71-4b71-b62a-1a3e9537acc8">390</ix:nonFraction> million of other receivables as well as $<ix:nonFraction unitRef="usd" contextRef="i22c76370e6bf4af2ba18b89ca655b55b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU1NTM_ee534579-9edc-4f99-a4d4-080cdbe7bcf7">432</ix:nonFraction> million of private equity limited partnership investments and $<ix:nonFraction unitRef="usd" contextRef="ia2a1ee87f2954456af17415d6e80fd4e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU2MTA_5e90c159-0cd9-4854-ae96-a50392b990fc">225</ix:nonFraction> million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8d42c9d1c4384c21b33b3731eb9c2768" continuedAt="iabade490a7b34cf2b6d92cb488238caa"><ix:continuation id="iaa60d378e1bb4ccbaff4a9f6d8bb13b4" continuedAt="i69db6a55564f4c19bf574f2878c72508"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2021 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800dc1b5ac544829a5f96bf812a6959d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEtMS0xLTEtMTY3OTA4_d845af00-495d-454c-a0a1-295af097217e">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcf8da529f3410db68a945ba211481d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEtMy0xLTEtMTY3OTA4_b32e1058-4b62-4d82-a93f-73566fe31a59">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5889f8a183f94f0986fc8d265f0b65e4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEtNS0xLTEtMTY3OTA4_a7def39b-3a51-43fd-a0e2-8c1b2c859363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a9186dc3884c56aed01709c057e146_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEtNy0xLTEtMTY3OTA4_bdfec78f-a9fa-4d0f-b604-3c439b23ed2a">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac90be0d15f44066902ebe3c398edd6a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzMtMS0xLTEtMTY3OTA4_32f9d678-7862-4957-827b-c3de22b16b81">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a27b2b60c0a4875ae1e21929139b434_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzMtMy0xLTEtMTY3OTA4_d56131bf-aa1e-4963-a7e1-217a6ffb8104">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448d068b73fe457c9473c2cf2c869646_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzMtNS0xLTEtMTY3OTA4_d8e9d4ec-d0b2-49f9-ace8-ab10788ac86a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be3d440d0034da59689eb9cb1b8e2a5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzMtNy0xLTEtMTY3OTA4_30d7e0f9-63c1-4f70-ab53-02a5da5f49e2">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07efc7eec504e4dbd1c06bcc97776e7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzQtMS0xLTEtMTY3OTA4_f2671b50-aa79-44c9-ae37-e966b62666f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80434d583b9145699f6467db52e671d1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzQtMy0xLTEtMTY3OTA4_a0c2cc61-84ab-4597-9bd7-6143a1f9f77f">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c53fd3ce91e4d35b310ab8338e5a336_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzQtNS0xLTEtMTY3OTA4_10a5ec72-9bd4-43c0-86bd-a62de4afdb4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0c74c41ebd402f965dc97f83e3927e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzQtNy0xLTEtMTY3OTA4_74e5a6ed-ebfa-41a9-a99b-f6263d76ecd1">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433675d63b154f81aec4043380ed969c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzUtMS0xLTEtMTY3OTA4_04b3b796-f9c0-4f9e-aa59-37534ce75a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec12e1923db4bf5b50d8480155727db_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzUtMy0xLTEtMTY3OTA4_d250fefd-3880-43f1-b187-ad244cc52905">2,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id027a3124e1a442f91f769b2d20a79cd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzUtNS0xLTEtMTY3OTA4_4b786eda-b975-486d-9fa2-2b32245db3e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc2ae24835514052914a58a5ed8c6960_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzUtNy0xLTEtMTY3OTA4_e38938d6-4f46-4c39-aca6-9a13f8f5ed6f">2,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i276e89b1f499438e87a8b8ff11bfb821_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzYtMS0xLTEtMTY3OTA4_227446f0-8e57-4986-b9b7-02c90b662910">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a32ea5d8145486abd0eee9eb65e2bc4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzYtMy0xLTEtMTY3OTA4_33a5b214-cb4e-4b77-86dc-d461109ca216">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a17a9c673d747659358cf61fca64e75_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzYtNS0xLTEtMTY3OTA4_e7593daf-e316-4ec5-9049-ba6b41acbd54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb420b7594364d6893ae2d9594cf961d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzYtNy0xLTEtMTY3OTA4_d1eb08ce-27cf-4652-a5d8-2aa4e1b26a2e">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a86bf692f18486d933d45d22e8027f6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzctMS0xLTEtMTY3OTA4_be9ddb35-24f6-48c8-900c-6c86c1e3a2a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef94353787243699d29dbbef2ede4aa_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzctMy0xLTEtMTY3OTA4_0943d0f2-20cf-44f6-bc15-7a42e7021ab3">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3962569b68340cc9aacb0b0b4055650_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzctNS0xLTEtMTY3OTA4_180ebfa9-c15d-4430-9e66-5a71133e5fa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b93f4fc09a3435ea3369ffd815f169f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzctNy0xLTEtMTY3OTA4_76d66cea-72ee-4035-92ad-e1faf0e0f21d">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c1ec54592a466aa4dc5711ca9dfd07_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzgtMS0xLTEtMTY3OTA4_53967840-1589-4f10-bc78-f86f40a3db39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d5c1701e6c488d94354e33e98ea977_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzgtMy0xLTEtMTY3OTA4_99005534-d113-4636-b267-fedd6cf4ce20">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107ab07b1f1242c2a31146ba192ea630_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzgtNS0xLTEtMTY3OTA4_9f322ba4-61c0-4454-9ff4-4f54ebfe642f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9fe69ee87141b0a74150684361d6d1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzgtNy0xLTEtMTY3OTA4_2aea8937-e18d-4ab0-89fb-6d5ced567cc6">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c75d0c4c0d64349a39b959decd4ec41_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzktMS0xLTEtMTY3OTA4_0184b672-9ed6-4a40-9df6-bda8f21d7506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fea1b150cad403f92fe062910c70247_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzktMy0xLTEtMTY3OTA4_091b40a5-cbe7-42d8-91bf-5f048c9025c2">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie818f0ce1b2d4700bf8a50b52e1ea2aa_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzktNS0xLTEtMTY3OTA4_7e0fb94f-99b6-4545-82f5-01bc9d768b0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37677b4bebe40289a4b9b7576269f3c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzktNy0xLTEtMTY3OTA4_878673d8-b9f2-4f7a-a6de-b8434e93bfa6">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib765d894de694d2094ea42b1892d468e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEwLTEtMS0xLTE2NzkwOA_a9c624f2-b3f9-43ad-bdcf-fdfc5852973c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32eee2f391f44fae9f98ce3ecd31a02b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEwLTMtMS0xLTE2NzkwOA_df9b6d2b-72c8-40b5-ae84-a19a75feaf63">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7671aaeacd046c9838da466ff4e34b8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEwLTUtMS0xLTE2NzkwOA_4767adec-cfb2-4052-912f-63424ac7aceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414e18de330f46b88b7101cb98dd39ab_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEwLTctMS0xLTE2NzkwOA_b63741cf-9866-4d43-8617-e67befb99687">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733ba5d142df4f60938808824882bdfc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzExLTEtMS0xLTE2NzkwOA_99380d82-985e-4c2c-95b0-dee3d88d23d1">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20703722f40e44c4835113f54e1e12c3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzExLTMtMS0xLTE2NzkwOA_3c385a4c-9d7b-41af-bbf0-9a406cea75e5">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie12f7e25dae34ed19c14ceed1716dd91_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzExLTUtMS0xLTE2NzkwOA_1e061174-3a2b-4ab7-a82f-724698feb341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f089b62038641eca565000d9846ae75_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzExLTctMS0xLTE2NzkwOA_8cf9b183-772d-4d87-84aa-3f075bb248c4">4,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad31584585d475ea5dc99cd84a40282_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEzLTEtMS0xLTE2NzkwOA_3f89fdc1-2583-4209-94d9-3bd7cb1f7b51">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d3653f149da49b29def0497a05f984f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEzLTMtMS0xLTE2NzkwOA_d26738cc-3410-470b-a519-0800c11d4a92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a6c29224644307a2a9eb78032ad4e7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEzLTUtMS0xLTE2NzkwOA_890c8bda-ecea-446c-bd36-23a7944c6211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd0bc158bfa4d8c9a1eef38aeb153e5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEzLTctMS0xLTE2NzkwOA_932fad68-2cf1-4438-886b-84f9c1c5447e">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6419521af8914bc08f951b1558c156a3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE0LTEtMS0xLTE2NzkwOA_7c959718-ed0b-4b1f-be00-5c67e052084b">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia201e25566f84e35aa96a9f051384c05_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE0LTMtMS0xLTE2NzkwOA_eccc40f2-ad8b-4a39-b1aa-42047c2e54be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id46442f3513e4d8ead71ef391f535a91_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE0LTUtMS0xLTE2NzkwOA_0ae46bfc-c9f7-49df-8ea6-39785c4d5470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbe5c58d7d04ef294e397fd28124004_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE0LTctMS0xLTE2NzkwOA_9a4b38d6-6c44-4790-b915-cd759f95e1e5">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd84d2bfaae34c2589bfdb10af6646d9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE1LTEtMS0xLTE2NzkwOA_7e95c77b-a09a-4d6b-b8f4-8c06385580d2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbdafb297a2242e5b3fb68a537d6f098_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE1LTMtMS0xLTE2NzkwOA_8869b66f-311f-4980-932f-5b6ac47a5278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08dd758138b84d4bb3085c8c44048020_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE1LTUtMS0xLTE2NzkwOA_3de7d614-b268-4a6c-9b4d-3bc37dda77e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4696cfd2126a49aca34be6569c415e4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE1LTctMS0xLTE2NzkwOA_cd70125d-b35f-4558-b777-15cffae5db97">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf302d352334c7eb29f6daa43872807_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE2LTEtMS0xLTE2NzkwOA_fa07fad5-d0c9-4d2a-a2f4-0d9003dd3a8e">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb696de5db242c795422c37920e7842_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE2LTMtMS0xLTE2NzkwOA_8576b275-882e-4815-b4e8-3538d4c9adcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077b6285cc31461598b42554e2d8d9c7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE2LTUtMS0xLTE2NzkwOA_4d82c000-8692-4eb9-9bd2-956a2577e57e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28aea62135614aab87e0943dbebccb07_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE2LTctMS0xLTE2NzkwOA_51a6cc20-5efa-418b-bc61-d2bff68b5d5b">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee69f393002463ebc8b873e9f00a9e9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE4LTEtMS0xLTE2NzkwOA_6ad1c2fb-52b6-4af1-8651-02a74ce36ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d019c669092417cad902aabe452c43a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE4LTMtMS0xLTE2NzkwOA_a723c768-9011-4726-ae17-11099209dc23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8340f5ec7e64baf9924bad129344c57_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE4LTUtMS0xLTE2NzkwOA_e1922452-0e83-4d3d-a7b8-40ee2e69d748">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb435009ac34bbba8afb4a9051ebcbf_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE4LTctMS0xLTE2NzkwOA_7fa6b5c2-dc5b-45b8-bc5e-e4473d4fc611">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3f6572a7984acc83891d6ffe51dac6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE5LTEtMS0xLTE2NzkwOA_2852223a-60dd-46fb-9e4b-83e22b3194c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721f414643aa4d48a77204540a59ca02_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE5LTMtMS0xLTE2NzkwOA_9335d15c-5148-4b23-bccc-9aa92377faa5">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b3e6fd20854c36bac655b5705bd8c5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE5LTUtMS0xLTE2NzkwOA_6218d9a0-c7d2-4c96-af61-8fdc9a39a5bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714696085e3846d5996660ba69ae9916_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE5LTctMS0xLTE2NzkwOA_07171084-c2e9-40d5-bf41-d407f08add4f">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616fe276b0c14b9ea335de3ffe9e254b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIxLTEtMS0xLTE2NzkwOA_550e7df0-5597-4357-be5b-af7ad685378a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89296715dad54dadab6556fc2a883b22_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIxLTMtMS0xLTE2NzkwOA_a60f352b-5ac6-491a-9210-b313c5e9a071">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i236e33efcde54e91a4243a0e24ed6b08_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIxLTUtMS0xLTE2NzkwOA_abe55351-0b73-48e2-83fa-23d5c7015d02">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af8d0600cbc4be881c45d46a38b22c2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIxLTctMS0xLTE2NzkwOA_fa074fa6-4ebf-4cd7-a780-302e507063ec">788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6812d37c933b481db36130a6e153ad52_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIyLTEtMS0xLTE2NzkwOA_d876aff3-ed1e-4ad1-932d-24124fa9d8bc">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26e065eea181432cb10971a1ef6fa9dc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIyLTMtMS0xLTE2NzkwOA_d0c73f14-8852-41b5-85f3-99e5d25d3d7d">3,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia048e730866c404db59cbf7a969bb920_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIyLTUtMS0xLTE2NzkwOA_922300b8-a6fd-4b23-ae2f-1179381a648c">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic430f4dcb0f043c8b9a2999c5816e5e9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIyLTctMS0xLTE2NzkwOA_ab1e264b-277b-4afd-bf59-4f717934fe55">5,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $<ix:nonFraction unitRef="usd" contextRef="i1381345c3d5840459cf0370ce99902da_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYwMTM_6de9ff35-e42d-42c2-bc9f-674e00d46442">261</ix:nonFraction> million of equity securities and $<ix:nonFraction unitRef="usd" contextRef="i766450bb0604426f8bdb03f539b684e4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYwNDE_f16ccd5c-652a-4bfd-ae1e-b669a29f1698">149</ix:nonFraction> million of debt securities. </span></div></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i69db6a55564f4c19bf574f2878c72508" continuedAt="ifd642b20529948d697b869cae84799ee">(2)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:continuation id="ifd642b20529948d697b869cae84799ee">Excludes $<ix:nonFraction unitRef="usd" contextRef="ia34c0f80bd2e4e66bd5efc598c7695bb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYwNzQ_2f3d0f5e-69a8-4c63-ae3c-fa78551814b5">76</ix:nonFraction> million of other receivables as well as $<ix:nonFraction unitRef="usd" contextRef="i00ba36ca870d489badec2a4b43f49a11_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYxMDk_5924547b-a315-4985-9e0a-76319a76e588">583</ix:nonFraction> million of private equity limited partnership investments and $<ix:nonFraction unitRef="usd" contextRef="if2ab04d328c64e48a9513092777617a4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYxNjY_39fea597-aad3-4437-a16a-ca52440b4c7d">237</ix:nonFraction> million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:DefinedBenefitPlanPlanAssetsCategoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTI2_d4356e74-1613-473d-adb7-b250f3c20769" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.761%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8340f5ec7e64baf9924bad129344c57_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzEtMS0xLTEtMTY3OTA4_ec463bf2-d2f0-4108-9ad5-8e8a6d99177b">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia048e730866c404db59cbf7a969bb920_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzEtNS0xLTEtMTY3OTA4_77729fdf-8c2c-4e7c-8c20-2a976baec8fc">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41df18924e1d461c9545e50ad75b2b04_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzItMS0xLTEtMTY3OTA4_91b7f1d5-13fe-485c-a1a6-8b973604494b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e58d7651f6c4f319612d35334a716cb_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzItNS0xLTEtMTY3OTA4_a4aa0e13-6de2-46ae-960f-87c2a52cca79">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41df18924e1d461c9545e50ad75b2b04_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzMtMS0xLTEtMTY3OTA4_2a965d22-9d67-4b9f-82de-4c7cce903afc">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e58d7651f6c4f319612d35334a716cb_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzMtNS0xLTEtMTY3OTA4_c1788010-8c49-4da0-a2b4-695584cafad2">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41df18924e1d461c9545e50ad75b2b04_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzQtMS0xLTEtMTY3OTA4_a266f805-8e3c-4547-af72-a5fd8cfcfc70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e58d7651f6c4f319612d35334a716cb_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzQtNS0xLTEtMTY3OTA4_3b637f54-a779-48c2-bc4c-7d5d1a3b972f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib411c0d8ea7a4e8192645865166e5bc4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzUtMS0xLTEtMTY3OTA4_85cbff0c-0102-40df-9559-7c803e81d42e">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8311648bcc5f4c0e9ba53519e18563bb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzUtNS0xLTEtMTY3OTA4_2a4c4e65-bdd9-4e80-a045-1b4972ac5b5a">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2021 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d63903b589946129164b093427d20a7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzEtMS0xLTEtMTY3OTA4_847c67cd-d189-473c-b05e-51824cc5cdea">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bb557e906c74f7e8c3d94d93011a01b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzEtNS0xLTEtMTY3OTA4_fd680cc8-074d-49d2-817b-4af77cb96932">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91633285ed494358864442a95f7cd753_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzItMS0xLTEtMTY3OTA4_4440572f-b061-4bf7-83af-87037e969cbf">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb33c37ed48461980e0c720a0c2fc11_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzItNS0xLTEtMTY3OTA4_6f9bbdaa-7fe2-459f-88e4-1c5c99b9cc9b">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91633285ed494358864442a95f7cd753_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzMtMS0xLTEtMTY3OTA4_e91b1837-947e-4a52-b40c-1615111e3101">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieeb33c37ed48461980e0c720a0c2fc11_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzMtNS0xLTEtMTY3OTA4_aa6ae25b-b484-416a-9ad7-283b60bd0ad3">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91633285ed494358864442a95f7cd753_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzQtMS0xLTEtMTY3OTA4_fd0f77ff-f4f2-498c-8595-ceaedb8789b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb33c37ed48461980e0c720a0c2fc11_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzQtNS0xLTEtMTY3OTA4_094f1cb3-920a-4bb1-a278-ba83f09b6367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8340f5ec7e64baf9924bad129344c57_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzUtMS0xLTEtMTY3OTA4_211c7f84-4e5d-48d8-9c0c-18008c521cf9">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia048e730866c404db59cbf7a969bb920_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzUtNS0xLTEtMTY3OTA4_e42bb373-e993-40f7-ab92-f3ce451bb805">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan invests in a diversified mix of assets designed to generate returns that will enable the plan to meet its future benefit obligations. The risk of unexpected investment and actuarial outcomes is regularly evaluated. This evaluation </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iabade490a7b34cf2b6d92cb488238caa" continuedAt="if169685cb17743039f8eabeea25a3b4d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is performed through forecasting and assessing ranges of investment outcomes over short- and long-term horizons and by assessing the pension plan&#8217;s liability characteristics. Complementary investment styles and strategies are utilized by professional investment management firms to further improve portfolio and operational risk characteristics. Public and private equity investments are used primarily to increase overall plan returns. Real estate investments are viewed favorably for their diversification benefits and above-average dividend generation. Fixed income investments provide diversification benefits and liability hedging attributes that are desirable, especially in falling interest rate environments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, target investment allocations for the Company&#8217;s pension plan were: <ix:nonFraction unitRef="number" contextRef="ida2e4bf976d74179b0af33275865eebe_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc2MDU_472debd3-b748-40da-ab25-3945ba66da6c">12</ix:nonFraction>% in equity securities, <ix:nonFraction unitRef="number" contextRef="i9a8ccea9aa6e45ac9a3904384d0f7055_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc2MzA_5dea5ff2-7520-4a42-aa6c-8f75efb175b7">77</ix:nonFraction>% in fixed income and debt securities, <ix:nonFraction unitRef="number" contextRef="ib0119b0ae5984713b7d9259c8207911d_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc2NzA_c9338134-3f08-4c50-9d48-57a1cc889cd6">5</ix:nonFraction>% in real estate, <ix:nonFraction unitRef="number" contextRef="i05bf309692224b32a5d32bdbc5a3fbfa_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc2ODk_90f94e83-2bf6-4106-b46c-c71a8df82b37">3</ix:nonFraction>% in private equity limited partnerships and <ix:nonFraction unitRef="number" contextRef="i8fef45f25f3a4337982d480409e2d989_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc3MzU_924b6d73-c5f0-4c99-a407-a5f2e56b64c1">3</ix:nonFraction>% in hedge funds. Actual asset allocations may differ from target allocations due to tactical decisions to overweight or underweight certain assets or as a result of normal fluctuations in asset values. Asset allocations are consistent with stated investment policies and, as a general rule, periodically rebalanced back to target asset allocations. Asset allocations and investment performance are formally reviewed periodically throughout the year by the pension plan&#8217;s Investment Subcommittee. Forecasting of asset and liability growth is performed at least annually.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally contributes to its tax-qualified pension plan based on minimum funding requirements determined under applicable federal laws and regulations. Employer contributions related to the nonqualified supplemental pension plans generally represent payments to retirees for current benefits. The Company contributed $<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzg2NDg_cc911412-9535-4e13-867b-fcc21853b03e">27</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzg2NTI_883b8425-55ed-4b5c-ae45-7709671daf33">78</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia10042502b67476084251422c4796803_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzg2NTk_e5ce817d-2c0c-4573-b218-4c155ef997d0">25</ix:nonFraction> million to its pension plans during 2022, 2021 and 2020, respectively. No contributions are required for the tax-qualified pension plan in 2023. The Company expects to make an immaterial amount of contributions for all other pension plans in 2023.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTE1_1c8c9bf4-9473-4d06-b925-bae4aeee545d" continuedAt="i938d93aaa2aa4500828ebe9b568b74f4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December&#160;31, 2022: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzEtMS0xLTEtMTY3OTA4_84cf56ef-dcd5-4cd1-b818-f1cb6cb01d30">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzItMS0xLTEtMTY3OTA4_45786f4a-6978-4a76-b231-2c77348905e1">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzMtMS0xLTEtMTY3OTA4_e2f833e7-87d4-495c-883b-5c8a7c3ccc29">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzQtMS0xLTEtMTY3OTA4_e0db4cf6-225c-4d47-b5dc-5b78bfb00845">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzUtMS0xLTEtMTY3OTA4_b7108985-b7bc-49d7-96e9-1a12b885174c">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzYtMS0xLTEtMTY3OTA4_8f179578-e88c-4190-9bb8-2fe5eb0bf330">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Multiemployer Pension Plans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also contributes to a number of multiemployer pension plans under the terms of collective-bargaining agreements that cover its union-represented employees. The risks of participating in these multiemployer plans are different from single-employer pension plans in the following respects: (i) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (ii) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (iii) if the Company chooses to stop participating in some of its multiemployer plans, the Company may be required to pay those plans an amount based on the underfunded status of the applicable plan, which is referred to as a withdrawal liability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the multiemployer pension plans in which the Company participates are individually significant to the Company. The Company&#8217;s contributions to multiemployer pension plans were $<ix:nonFraction unitRef="usd" contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231" decimals="-6" name="us-gaap:MultiemployerPlanPensionInsignificantPlanContribution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwMTQ0_b7412dd6-6d8a-4ec0-95d6-e9e3cb36d8a0">20</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231" decimals="-6" name="us-gaap:MultiemployerPlanPensionInsignificantPlanContribution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwMTQ4_4d1a7f5a-8ba0-454a-bfac-82c703f58591">19</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia10042502b67476084251422c4796803_D20200101-20201231" decimals="-6" name="us-gaap:MultiemployerPlanPensionInsignificantPlanContribution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwMTU1_ef075eab-14cd-4bb2-9209-2413be11cfc0">19</ix:nonFraction> million in 2022, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Postretirement Benefits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides postretirement health care and life insurance benefits to certain retirees who meet eligibility requirements. The Company&#8217;s funding policy is generally to pay covered expenses as they are incurred. For retiree medical plan accounting, the Company reviews external data and its own historical trends for health care costs to determine the health care cost trend rates. As of December&#160;31, 2022 and 2021, the Company&#8217;s other postretirement benefits had an accumulated postretirement benefit obligation of $<ix:nonFraction unitRef="usd" contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwNzI5_dd66ed59-4c9f-46ec-9f95-b2f4fcc17ee5">159</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f60b453fe2047f2af3b79714d2105b8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwNzM2_359e0976-c1df-4a3a-85b3-9fc033b52024">207</ix:nonFraction> million, respectively. Net periodic benefit costs related to these other postretirement benefits were $<ix:nonFraction unitRef="usd" contextRef="i80161528cfbe4d46ab7481e07799b74f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwODMz_dad81c33-b86a-4cb6-b17a-24eb3ce948b7">4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idad61766b42d4fafb3023b422e73ce62_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwODM3_158e09ba-e75c-4a7b-aa2e-613d2f938977">4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i48c5af8bad60417f9e93bd229edece75_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwODQ0_572d5709-16fb-4b20-a3fd-3fbba421199a">12</ix:nonFraction> million in 2022, 2021 and 2020, respectively. </span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if169685cb17743039f8eabeea25a3b4d" continuedAt="i68e20e514179435aa8ae96d5262e8ab5"><ix:continuation id="i938d93aaa2aa4500828ebe9b568b74f4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December&#160;31, 2022: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:86.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzEtMS0xLTEtMTY3OTA4_ec58d04d-3f26-4538-a1da-e90297237f14">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzItMS0xLTEtMTY3OTA4_61ce53f6-d61d-481e-a2b7-981b68625bd1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzMtMS0xLTEtMTY3OTA4_676f9f99-0338-444d-b2a3-0a69c3c180f4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzQtMS0xLTEtMTY3OTA4_80f0eefa-3fea-4cb8-b0d5-bc7c45f338ed">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzUtMS0xLTEtMTY3OTA4_f19bcb0a-38df-4edc-b1f9-c290929cb43c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzYtMS0xLTEtMTY3OTA4_32b67472-ea96-419b-8a33-ea1b8afc6503">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i68e20e514179435aa8ae96d5262e8ab5">Pursuant to various collective bargaining agreements, the Company also contributes to multiemployer health and welfare plans that cover certain union-represented employees. The plans provide postretirement health care and life insurance benefits to certain employees who meet eligibility requirements. The Company&#8217;s contributions to multiemployer health and welfare plans totaled $<ix:nonFraction unitRef="usd" contextRef="i80161528cfbe4d46ab7481e07799b74f_D20220101-20221231" decimals="-6" name="us-gaap:MultiemployerPlanPensionInsignificantPlanContribution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNDY2_0e4aa696-f0b0-409a-a400-056ef855880c">62</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idad61766b42d4fafb3023b422e73ce62_D20210101-20211231" decimals="-6" name="us-gaap:MultiemployerPlanPensionInsignificantPlanContribution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNDcw_be7d61bc-e67b-4df8-9a4f-80aff96ca374">60</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i48c5af8bad60417f9e93bd229edece75_D20200101-20201231" decimals="-6" name="us-gaap:MultiemployerPlanPensionInsignificantPlanContribution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNDc3_8cd6ac50-3648-40a3-8248-03deae7380ea">54</ix:nonFraction> million in 2022, 2021 and 2020, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_151"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NTk_cc94889b-2094-4bfd-ba5f-400909443077" continuedAt="i95eb5a73ed6f4f6782eb8d0a8a901498" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i95eb5a73ed6f4f6782eb8d0a8a901498" continuedAt="i11df29ee57ed485eb8839c627d7a8e46"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NTQ_aa21ac8c-d7ed-445d-8bb7-9959d5332f37" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision for continuing operations consisted of the following for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzItMS0xLTEtMTY3OTA4_8ab46591-1bb9-43ba-9dc5-eb4c15fd1e75">2,803</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzItMy0xLTEtMTY3OTA4_b2be9598-38da-4bd9-8f81-e70746f3a34e">2,285</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzItNS0xLTEtMTY3OTA4_d277e59e-2c2d-454d-b35b-24636a47c846">2,615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzMtMS0xLTEtMTY3OTA4_fb378b06-aeba-4a94-947d-3b640f7b43a9">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzMtMy0xLTEtMTY3OTA4_5f6c4094-0353-4f6f-82ad-bd2db10f36ea">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzMtNS0xLTEtMTY3OTA4_7f13d794-7963-4738-878d-e2595fb85a22">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzQtMS0xLTEtMTY3OTA4_b14fc4fe-515f-413c-a187-449efa0f21c8">3,538</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzQtMy0xLTEtMTY3OTA4_fe311379-d284-4593-8a24-c852de24471a">2,950</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzQtNS0xLTEtMTY3OTA4_ae98b693-2647-4cb7-926d-923fc3b35fb2">3,133</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzYtMS0xLTEtMTY3OTA4_9df95e97-424c-46f1-9174-988d2bb27519">1,569</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzYtMy0xLTEtMTY3OTA4_f19bc860-8cdc-42d9-b4fd-a03dfa7897fc">306</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzYtNS0xLTEtMTY3OTA4_bd7872a7-1a2b-42db-bce4-9baea59a81e0">450</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzctMS0xLTEtMTY3OTA4_e45350ed-a1f4-4d06-a029-e6e1579e9a76">506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzctMy0xLTEtMTY3OTA4_2c814769-2630-475e-8a0c-2cd115aa10b6">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzctNS0xLTEtMTY3OTA4_7ae2095d-3b38-432a-b98a-dad0d700095e">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzgtMS0xLTEtMTY3OTA4_bfb38526-e1c2-406a-ba79-1fcd8882e21a">2,075</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzgtMy0xLTEtMTY3OTA4_ddf6e053-a640-414f-a475-c69a27a117c2">428</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzgtNS0xLTEtMTY3OTA4_fef7d097-7a67-43c7-96e3-b3312bf3a490">564</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzktMS0xLTEtMTY3OTA4_ecca47ed-fbc4-4884-96bd-3d5e7f9f22b4">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzktMy0xLTEtMTY3OTA4_6dcb7847-e0c6-4674-b52f-946694bde641">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzktNS0xLTEtMTY3OTA4_588903f1-24b3-48f0-a2c2-ad56cdc2824e">2,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NTU_002392ec-d5ce-47fa-9688-bdf1dd6a6f60" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the statutory income tax rate to the Company&#8217;s effective income tax rate for continuing operations for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzEtMS0xLTEtMTY3OTA4_82164472-5ca8-4ff0-a346-b326bd175836">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzEtMy0xLTEtMTY3OTA4_b10791a8-dca5-43bd-92e2-781879d89260">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzEtNS0xLTEtMTY3OTA4_a32c8671-40fa-486e-b80a-5a6d06d503dd">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzItMS0xLTEtMTY3OTA4_e66d8820-c55f-4451-a26c-edc347f6d021">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzItMy0xLTEtMTY3OTA4_0bd00b5b-387c-475f-9fe2-6b221ce8a36e">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzItNS0xLTEtMTY3OTA4_2c8786f3-ac88-45c1-aad9-99b9d04c77f8">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurer fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" name="cvs:HealthInsurerFeeTaxEffectPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzMtMS0xLTEtMTY3OTA4_309b4c89-c191-4ef0-9983-064a1eb33aec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" name="cvs:HealthInsurerFeeTaxEffectPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzMtMy0xLTEtMTY3OTA4_e77830f7-e183-4e14-bb3f-4a9a262603e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="3" name="cvs:HealthInsurerFeeTaxEffectPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzMtNS0xLTEtMTY3OTA4_aa6261a7-9815-4e75-b381-b6d0a84ac730">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" name="cvs:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtMS0xLTEtMjIzMDYz_45265613-0708-4ed2-bac8-f568b98cd1a9">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" name="cvs:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtMy0xLTEtMjIzMDYz_811c98b5-7d4d-44b2-9e69-a3fcf34011c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="3" name="cvs:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtNS0xLTEtMjIzMDYz_e00ebc16-62b7-4f34-9122-a2fc43aeffc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis difference upon disposition of subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtMS0xLTEtMTY3OTA4_df5b3bf5-31b9-441a-85b4-1aee1e340a7e">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtMy0xLTEtMTY3OTA4_7bda2687-bcda-4eab-945d-5a02464735c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtNS0xLTEtMTY3OTA4_5b862906-3b9d-4e0d-92e9-49ee23680750">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year refunds and unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzUtMS0xLTEtMTY3OTA4_ddc0a468-4681-48e3-83de-e96aaaf18b58">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzUtMy0xLTEtMTY3OTA4_35a243b5-d0c8-4fe4-bf64-56adaf4487d9">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzUtNS0xLTEtMTY3OTA4_14ec5cb4-0625-4847-9c7b-04d2b1f85322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzYtMS0xLTEtMTY3OTA4_d875dc3b-a604-4c54-b0a1-4a0cfda8da54">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzYtMy0xLTEtMTY3OTA4_cd0ff6cb-328f-464a-bc36-6a48ced20d7d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzYtNS0xLTEtMTY3OTA4_4e1d28f2-2e5b-44f8-b92c-7dcb42342ffb">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzctMS0xLTEtMTY3OTA4_37150dca-9916-44bb-bc3d-cc1e9fe90254">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzctMy0xLTEtMTY3OTA4_93c1285c-aa45-4bb4-a4e3-658adc22308f">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzctNS0xLTEtMTY3OTA4_cb8a501e-56f0-439b-bf74-cd7558265bd7">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i11df29ee57ed485eb8839c627d7a8e46" continuedAt="ie97c7143c6874f6fa41904ca5fb358bc"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NjI_4729e463-bc03-41e2-97e1-0db3e0c4ae31" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of the Company&#8217;s deferred income tax assets and liabilities as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzItMS0xLTEtMTY3OTA4_780acc8c-48c4-4825-920c-045721feb4c7">5,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzItMy0xLTEtMTY3OTA4_91dab4d2-7466-454c-87ca-2b83576c2b85">5,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzMtMS0xLTEtMjIzMDc3_aa3ab52e-f02a-421e-a762-aa7e5140c0d4">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzMtMy0xLTEtMjIzMDc3_bd57a54d-63ff-4043-a843-be11da40fc62">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzMtMS0xLTEtMTY3OTA4_62a344ff-d3d1-4fc3-8b26-fb09e3c84b78">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzMtMy0xLTEtMTY3OTA4_da69d434-2b6f-42ba-9ee8-8e5fb0f5a685">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzQtMS0xLTEtMTY3OTA4_b5526503-7544-4b5d-97b6-965b6013dec4">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzQtMy0xLTEtMTY3OTA4_cd7f71d0-8760-4eed-9d79-b95a26273fca">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debts and other allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzUtMS0xLTEtMTY3OTA4_74df03e9-b9fb-4612-897b-1056e7fbbe7c">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzUtMy0xLTEtMTY3OTA4_b59ec915-f013-496d-8de2-b40f5667f5c8">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and capital loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzctMS0xLTEtMTY3OTA4_1c900f18-7892-40d5-9c67-8806c3a2a5ff">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzctMy0xLTEtMTY3OTA4_84518d6f-537b-4aa8-9a96-f454db525952">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzgtMS0xLTEtMTY3OTA4_e4605ef7-023a-4b29-a616-55ff4242dc37">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzgtMy0xLTEtMTY3OTA4_d79d5c45-2081-4878-ba61-d8eee869b48f">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzktMS0xLTEtMTY3OTA4_c5eb6881-6e1b-42e3-ab68-9490de9f4c6d">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzktMy0xLTEtMTY3OTA4_af604ea2-c77e-48f1-9fae-475f191d9067">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzExLTEtMS0xLTIyMzA4NQ_bf8ee500-fd01-426d-95ba-1a733158755e">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzExLTMtMS0xLTIyMzA4NQ_18279d10-bd56-4b44-bcc7-e9bab07af4ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax deferral</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DeferredTaxAssetsPayrollTaxDeferral" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEwLTEtMS0xLTE2NzkwOA_a06905af-680c-47b5-af8b-cefe027a44bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:DeferredTaxAssetsPayrollTaxDeferral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEwLTMtMS0xLTE2NzkwOA_fb747cd9-8738-4f53-b007-4f8bbf2990ef">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzExLTEtMS0xLTE2NzkwOA_8bf59f8b-e453-4703-9b6e-7c5a919d7b5a">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzExLTMtMS0xLTE2NzkwOA_bcb58c7a-009b-419c-b58f-fc09497e51fa">377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEyLTEtMS0xLTE2NzkwOA_243db7d3-9e31-457a-bc3f-b935c5f14133">532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEyLTMtMS0xLTE2NzkwOA_0f525ba2-32ef-424a-908b-eab94a371156">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEzLTEtMS0xLTE2NzkwOA_af9dab44-0c35-4343-9b0b-4a517ff1a3db">8,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEzLTMtMS0xLTE2NzkwOA_e84639aa-1e25-488c-bb83-a5e54a84935e">7,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DeferredTaxLiabilitiesRetirementBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE1LTEtMS0xLTE2NzkwOA_052f6dee-1900-4c4b-993a-3a78ce48b6e8">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:DeferredTaxLiabilitiesRetirementBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE1LTMtMS0xLTE2NzkwOA_72344e78-7b77-482c-b6f5-b83cc4910f4e">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE2LTEtMS0xLTE2NzkwOA_5d5bb76a-4690-46b6-a7b7-d6b78494aaf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE2LTMtMS0xLTE2NzkwOA_a1bf7566-dc00-4e18-bef9-f9bc4a52cdd1">334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE3LTEtMS0xLTE2NzkwOA_0bb13cba-8cbb-483e-a701-0d42f993a2c5">4,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE3LTMtMS0xLTE2NzkwOA_33e5942d-2066-4e9f-b3db-03d2c99f2047">4,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:DeferredTaxLiabilitiesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE4LTEtMS0xLTE2NzkwOA_da5273f8-13ea-4085-85ea-f5f07b2f27d1">7,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="cvs:DeferredTaxLiabilitiesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE4LTMtMS0xLTE2NzkwOA_c9918d81-2b13-46c6-b052-779298212fbf">8,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE5LTEtMS0xLTE2NzkwOA_df6c1aab-8847-49e5-9d7b-edac8bd1a9bb">11,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE5LTMtMS0xLTE2NzkwOA_13ef7879-3334-4ba9-9b76-7713aa4041f5">13,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzIwLTEtMS0xLTE2NzkwOA_1682058a-7e14-4de3-a1c0-4a6022cfb244">3,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzIwLTMtMS0xLTE2NzkwOA_645e6616-dbb4-46c7-9ea1-8eb6427b815a">6,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes deferred income tax assets of $<ix:nonFraction unitRef="usd" contextRef="if18de26c953b4c36b64633eff1121e28_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5Xzg3OTYwOTMwMjYwMDQ_3f3dab3a-04cd-4a1d-9b99-217c52913ff3">131</ix:nonFraction>&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating the realizability of deferred tax assets, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and the Company&#8217;s recent operating results. The Company established valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5Xzg1NA_243db7d3-9e31-457a-bc3f-b935c5f14133">532</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzEyMDk0NjI3OTA5ODU1_0f525ba2-32ef-424a-908b-eab94a371156">325</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively, because it does not consider it more likely than not that certain deferred tax assets will be recovered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had net operating and capital loss carryovers of $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzU0OTc1NTgxNzkxMw_1c900f18-7892-40d5-9c67-8806c3a2a5ff">266</ix:nonFraction> million, which expire between 2023 and 2042.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NTg_9710f2a6-34c5-4b62-a0f7-9ec571b2496b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2022, 2021 and 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzEtMS0xLTEtMTY3OTA4_37462a83-4a43-4ccd-8f05-c7e24690aa48">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzEtMy0xLTEtMTY3OTA4_2e9359ea-9750-4bd2-a5f2-258acf7e0ec9">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ae6bc100814ca88c4440dbb572bbdc_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzEtNS0xLTEtMTY3OTA4_cd10efbc-df29-4f96-8714-20862afbeb89">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzItMS0xLTEtMTY3OTA4_a3d0223a-434d-4380-87e6-a41c302c0cff">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzItMy0xLTEtMTY3OTA4_1cc71028-63cf-43c7-ba27-94b4632e98a4">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzItNS0xLTEtMTY3OTA4_4bfeb1a3-9e40-47eb-a500-a59d0b84c404">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzMtMS0xLTEtMTY3OTA4_5b4d2192-a2c3-411e-bb44-5bbf039e5a83">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzMtMy0xLTEtMTY3OTA4_de18459a-dfdd-47be-976e-1cd4f87d87c9">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzMtNS0xLTEtMTY3OTA4_ea5da00f-d6b7-4dad-abd4-cd158572ae3f">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzQtMS0xLTEtMTY3OTA4_b04b12f1-6dbf-4aef-8cc7-0d4cf9735dfb">166</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzQtMy0xLTEtMTY3OTA4_391aafbb-4ce4-4ad4-80f0-016c0c89ebaf">33</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzQtNS0xLTEtMTY3OTA4_903ac1bc-6475-4134-8f7d-578288319fb4">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of statutes of limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzUtMS0xLTEtMTY3OTA4_106ff2fa-83f7-433a-ab2b-1e44ce2c1500">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzUtMy0xLTEtMTY3OTA4_4e33369f-bb1b-44fe-b46c-716688b99089">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzUtNS0xLTEtMTY3OTA4_9f7c5168-5bf9-4861-b1ad-94dd3f54491a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzYtMS0xLTEtMTY3OTA4_adc0c4f3-aac6-4e86-8de8-e30a83067118">213</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzYtMy0xLTEtMTY3OTA4_549a6d23-64da-480c-a095-d87fc179d065">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzYtNS0xLTEtMTY3OTA4_976d273c-45e6-4d7e-91bb-2b02dbfa680d">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzctMS0xLTEtMTY3OTA4_ee4b6d21-fc16-4337-9c06-c2e30883dadd">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzctMy0xLTEtMTY3OTA4_2aaa79de-09a9-4851-b12f-4db195291b64">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzctNS0xLTEtMTY3OTA4_a3e68c38-4963-4f02-8eed-ad7ccc2d0cd1">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation and most of its subsidiaries are subject to U.S. federal income tax as well as income tax of numerous state and local jurisdictions. CVS Health Corporation participated in the Compliance Assurance Process through 2019, which is </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie97c7143c6874f6fa41904ca5fb358bc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a program made available by the U.S. Internal Revenue Service (&#8220;IRS&#8221;) to certain qualifying large taxpayers, under which participants work collaboratively with the IRS to identify and resolve potential tax issues through open, cooperative and transparent interaction prior to the annual filing of their federal income tax returns. The IRS has completed its examinations of the Company&#8217;s consolidated U.S. federal income tax returns for tax years through and including 2013 and 2018 through 2019. The IRS has substantially completed its examinations of the Company&#8217;s consolidated U.S. federal income tax returns for tax years 2014 through 2017.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation and its subsidiaries are also currently under income tax examinations by a number of state and local tax authorities. As of December&#160;31, 2022, no examination has resulted in any proposed adjustments that would result in a material change to the Company&#8217;s operating results, financial condition or liquidity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all material state and local income tax matters have been concluded for fiscal years through 2015. Certain state exams are likely to be concluded and certain state statutes of limitations will lapse in 2023, but the change in the balance of the Company&#8217;s uncertain tax positions is projected to be immaterial. In addition, it is reasonably possible that the Company&#8217;s unrecognized tax benefits could change within the next twelve months due to the anticipated conclusion of various examinations with the IRS for certain previous years. An estimate of the range of the possible change cannot be made at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records interest expense related to unrecognized tax benefits and penalties in the income tax provision. The Company accrued interest expense of approximately $<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMwODY_c3e43743-fd58-46b3-b4f7-a658faaf32c8">29</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMwOTA_19859130-f162-41b1-a4be-fa6572cce01a">40</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMwOTc_0f0ddd7f-91e4-4f33-ad75-647f512305a2">34</ix:nonFraction> million in 2022, 2021 and 2020, respectively. The Company had approximately $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMxNjI_7229f6fe-af34-4bc4-be42-0bedeafd3efa">112</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMxNjk_e29915e9-4b58-427b-a6d1-a7b979e15d36">151</ix:nonFraction> million accrued for interest and penalties as of December&#160;31, 2022 and 2021, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the total amount of unrecognized tax benefits that, if recognized, would affect the Company&#8217;s effective income tax rate is approximately $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMzODc_d9a34ea5-48c1-4691-8934-4f87125f12a6">336</ix:nonFraction> million, after considering the federal benefit of state income taxes.</span></div></ix:continuation><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_154"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzM_ef2b3322-a2fe-4726-86ff-164120b0049b" continuedAt="ic95128fd2b1a4383ad38ea1bbc8c2687" escape="true">Stock Incentive Plans</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic95128fd2b1a4383ad38ea1bbc8c2687" continuedAt="id40c6fc6a3dc4a7aa57d5bff2c031e50"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the CVS Health 2017 Incentive Compensation Plan (&#8220;ICP&#8221;) provide for grants of annual incentive and long-term performance awards to executive officers and other officers and employees of the Company or any subsidiary of the Company, as well as equity compensation to outside directors of CVS Health Corporation. Payment of such annual incentive and long-term performance awards will be in cash, stock, other awards or other property, at the discretion of the Management Planning and Development Committee (the &#8220;MP&amp;D Committee&#8221;) of the Board. The ICP allows for a maximum of <ix:nonFraction unitRef="shares" contextRef="i5bd0c40f6d4d4d38ad212af3d36f1535_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzYxNQ_e9e25456-70ed-496a-b307-60fde586ac8a">58</ix:nonFraction> million shares of CVS Health Corporation common stock to be reserved and available for grants. As of December&#160;31, 2022, there were approximately <ix:nonFraction unitRef="shares" contextRef="i5bd0c40f6d4d4d38ad212af3d36f1535_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzc0MA_2eb6e571-2958-4a4a-98da-e663fc00b2d7">21</ix:nonFraction> million shares of CVS Health Corporation common stock available for future grants under the ICP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the acquisition of Aetna (the &#8220;Aetna Acquisition&#8221;) on November 28, 2018, approximately <ix:nonFraction unitRef="shares" contextRef="ia59ded7dac1144889cba911dcf81ff67_I20181128" decimals="-6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzkyNQ_39ee9fa1-9624-4ce6-9a15-fbb16132494f">22</ix:nonFraction> million shares of Aetna common stock subject to awards outstanding under the Amended Aetna Inc. 2010 Stock Incentive Plan (&#8220;SIP&#8221;) were assumed by CVS Health Corporation. In addition, in accordance with the merger agreement, shares which were available for future issuance under the SIP were converted into approximately <ix:nonFraction unitRef="shares" contextRef="ia59ded7dac1144889cba911dcf81ff67_I20181128" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzEyNDA_e537454f-1318-4929-8ae5-4f78b96ab412">32</ix:nonFraction> million shares of CVS Health Corporation common stock reserved and available for issuance pursuant to future awards. Subsequent to the expiration of the SIP on May 21, 2020, the ICP was the only compensation plan under which the Company grants stock options, restricted stock and other stock-based awards to its employees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzE3Nzc_8d034ca5-401e-4526-8bb8-d8fed86877bb">three</span> to <ix:nonNumeric contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxODI_fd3bc7df-2c94-4af2-8f82-2a03cfa5ef04">five years</ix:nonNumeric>) using the straight-line method. <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzk_f06bbd1f-a765-425d-a582-d3d99d1c4fce" continuedAt="iabd0ff0193634559abe48c25eb10f0d0" escape="true">The following table is a summary of stock-based compensation for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</ix:nonNumeric></span></div><ix:continuation id="iabd0ff0193634559abe48c25eb10f0d0"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units and performance stock units</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzItMS0xLTEtMTY3OTA4_a6416041-2eaa-4a71-99db-12d0f76f9bf6">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef82093f7f0425d98a812a8346206e7_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzItMy0xLTEtMTY3OTA4_5b4c1a52-000e-4b19-bab7-4293dfb1b114">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dac89aa5750413097fe5ef4affd611a_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzItNS0xLTEtMTY3OTA4_76ffe5a6-050f-4b51-be8d-9ee9adf78a7e">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and stock appreciation rights (&#8220;SARs&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtMS0xLTEtMjI2MDI2_653adec3-d862-4929-a130-0fe08e48faab">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtMy0xLTEtMjI2MDI2_a489f99e-d4ca-4985-9039-8566b9b97846">80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtNS0xLTEtMjI2MDI2_5306734c-a824-4072-a44e-a34979b6cc65">71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtMS0xLTEtMTY3OTA4_6fa78901-8a29-41e8-978a-694c2991d2c2">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtMy0xLTEtMTY3OTA4_ef09b316-68fa-425b-86f4-d5c7c7488a94">484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtNS0xLTEtMTY3OTA4_f44cde28-1219-40fb-acb6-c8181375a156">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes the ESPP.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id40c6fc6a3dc4a7aa57d5bff2c031e50" continuedAt="i4383c5f25c3f4de09884af61a5c1440d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s restricted stock units and performance stock units are considered nonvested share awards and require no payment from the employee. The fair value of the restricted stock units is based on the market price of CVS Health Corporation common stock on the grant date and is recognized on a straight-line basis over the vesting period. For each restricted stock unit granted, employees receive one share of common stock, net of taxes, at the end of the vesting period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s performance stock units contain performance vesting conditions in addition to a service vesting condition. Vesting of the Company&#8217;s performance stock units is dependent upon the degree to which the Company achieves its performance goals, which are generally set for a three-year performance period and are approved at the time of grant by the MP&amp;D Committee. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance stock units granted with service and performance vesting conditions is based on the market price of CVS Health Corporation common stock on the grant date and is recognized over the vesting period. Certain of the performance stock units also contain a market vesting condition based on the performance of CVS Health Corporation common stock relative to a comparator group. The fair value of these performance stock units is determined using a Monte Carlo simulation as of the grant date and is recognized over the vesting period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i9a23a3d9f60548f3aed4bd07d81cc620_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzQ5OTE_60011a91-e643-4d54-b8e4-169e24a4c3ee">619</ix:nonFraction> million of total unrecognized compensation cost related to the Company&#8217;s restricted stock units and performance stock units that are expected to vest. These costs are expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzUyMTM_944872f3-feeb-4d33-bc1e-331cc1c1b537">2.1</ix:nonNumeric> years. The total fair value of restricted stock units vested during 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzUyOTY_1474034a-9e88-4b38-9140-8c92727fec54">328</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0ef82093f7f0425d98a812a8346206e7_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzUzMDA_6b82d351-c40d-4039-addb-5a827c498b8d">406</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7dac89aa5750413097fe5ef4affd611a_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzUzMDc_7617f0b2-2502-42b9-9434-2a94d365b904">229</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxODQ_4eeb5b41-a771-4fa9-a2bf-9e98aab1c296" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the restricted stock unit and performance stock unit activity for the&#160;year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In thousands, except weighted average grant date fair value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b8b6ee31b984216878b4a06ea213f22_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzEtMS0xLTEtMTY3OTA4_30b73d6f-67b3-4269-8891-1b5cda7c89a2">14,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b8b6ee31b984216878b4a06ea213f22_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzEtMy0xLTEtMTY3OTA4_2ece799c-0002-41b5-b76c-42477016f137">63.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzItMS0xLTEtMTY3OTA4_c0abee7f-2aaf-4ddb-9da1-2aa5c55be3d5">5,398</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzItMy0xLTEtMTY3OTA4_64535ded-477a-4ab0-b9f1-1c9fe7e69bc5">101.13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzMtMS0xLTEtMTY3OTA4_e0845595-33de-421e-8803-ab2ef8d6db5c">5,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzMtMy0xLTEtMTY3OTA4_32cdd6cb-286a-4529-9485-2b01154ec73f">58.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzQtMS0xLTEtMTY3OTA4_4fe03d36-292d-4069-8d20-f448ac343e97">1,421</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzQtMy0xLTEtMTY3OTA4_14966fb6-af68-45aa-9efd-11812485235c">72.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a23a3d9f60548f3aed4bd07d81cc620_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzUtMS0xLTEtMTY3OTA4_78ede00e-d5b6-46f2-822c-5f3e07729b68">12,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a23a3d9f60548f3aed4bd07d81cc620_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzUtMy0xLTEtMTY3OTA4_b16c9cc1-0ef9-4b47-9892-4624e4ce0a2c">80.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Vested performance stock units have been included at target level performance. Based on actual performance, the number of restricted stock units and performance stock units vested during the year ended December 31, 2022 was <ix:nonFraction unitRef="shares" contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231" decimals="-5" name="cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzk4OTU2MDQ2NTg5Mzc_b508f7cb-6332-471e-9afd-f432a48a992d">8.0</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and SARs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock option grants are awarded at fair value on the date of grant. The fair value of stock options is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. Stock options granted generally become exercisable over a <ix:nonNumeric contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzQ_f89d2283-38ec-49d0-84ae-23e5a2b02698">four-year</ix:nonNumeric> period from the grant date. Stock options granted through 2018 generally expire <ix:nonNumeric contextRef="i9667bb2fd2c24aae86f872138c4421cb_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzU4ODY_a3a93972-ff4b-4d8b-9389-f4318b9b43dc">seven years</ix:nonNumeric> after the grant date. Stock options granted subsequent to 2018 generally expire <ix:nonNumeric contextRef="i63eef8534a884ca5866ee784287deaab_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzU5Njk_939a502e-c92e-48c2-8c6e-75b342b41b7f">ten years</ix:nonNumeric> after the grant date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All unvested Aetna SARs outstanding upon the acquisition of Aetna were converted into replacement CVS Health Corporation SARs. The replacement SARs granted are settled in CVS Health Corporation common stock, net of taxes, based on the appreciation of the stock price on the exercise date over the market price on the date of grant. The fair value of SARs is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. SARs generally become exercisable over a <ix:nonNumeric contextRef="i9b15b8c19a5e466e8372796316b9b51c_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNjk_5c3f9322-cd5d-4af7-9fa4-b05299a155a8">three-year</ix:nonNumeric> period from the grant date. SARs generally expire <ix:nonNumeric contextRef="i9b15b8c19a5e466e8372796316b9b51c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzY2MTE_0963ef08-1d49-4fc3-857c-501f3315017c">ten years</ix:nonNumeric> after the grant date. No SARs have been granted subsequent to the Aetna Acquisition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4383c5f25c3f4de09884af61a5c1440d" continuedAt="ia79d7d719ece446285480a540bf953f9"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzU_8300e9a7-2424-450f-817e-c5e9079399be" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of stock option and SAR activity that occurred for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from stock options exercised (including ESPP)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzEtMS0xLTEtMTY3OTA4_8db9134f-da5f-4830-aed9-ba9421714f75">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzEtMy0xLTEtMTY3OTA4_587a8677-11cf-4e5c-98ce-95b75ae9023a">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzEtNS0xLTEtMTY3OTA4_33e93c65-4f12-40be-90d3-fb058e38eede">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for taxes for net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzItMS0xLTEtMTY3OTA4_dbdb0ce3-1487-4788-82ed-c06c357021a3">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzItMy0xLTEtMTY3OTA4_f9b03287-70fe-4e24-b9e5-5780324cd43f">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzItNS0xLTEtMTY3OTA4_e5a5ee27-832f-4c09-b5fd-c9ed65cde0ec">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of stock options and SARs exercised </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzMtMS0xLTEtMTY3OTA4_bc282831-11b6-4d92-a67e-0b71a8950e98">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzMtMy0xLTEtMTY3OTA4_a4560292-1ad5-49f5-871f-b381babed485">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzMtNS0xLTEtMTY3OTA4_9a88340e-d657-4e26-b67e-8e35b24eed0e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options and SARs vested </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="-6" name="cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzQtMS0xLTEtMTY3OTA4_7ba664e4-9cf1-4d6c-a6da-6ab4397f77ee">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231" decimals="-6" name="cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzQtMy0xLTEtMTY3OTA4_51e225bf-b92f-45f2-9280-e52434611b04">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231" decimals="-6" name="cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzQtNS0xLTEtMTY3OTA4_3b9b7e90-097d-4ba0-89b1-8b9ff0dfba75">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxODU_7fb7d535-b8d5-4957-a866-eab84fd1c7b2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzEtMS0xLTEtMTY3OTA4_62d75605-3aaa-4361-a9c3-2250f9b0bb01">2.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzEtMy0xLTEtMTY3OTA4_eba19caf-9c73-4578-8628-a7fbe13dddae">2.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzEtNS0xLTEtMTY3OTA4_bd77b5a4-76cc-438b-b685-1c2c8af629de">3.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzItMS0xLTEtMTY3OTA4_5a7bc619-8d67-44e0-b0ff-eb2319edfe7f">27.34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzItMy0xLTEtMTY3OTA4_13b3d951-79e7-4768-b629-81d791331609">27.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzItNS0xLTEtMTY3OTA4_b345555c-c0d5-4adb-a172-93b78043d892">25.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzMtMS0xLTEtMTY3OTA4_4fcbbad6-93b8-4d86-82ee-b75e40b0f6cf">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzMtMy0xLTEtMTY3OTA4_fa6c3ff0-3c35-4cef-ad3a-ea2144bb8f10">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzMtNS0xLTEtMTY3OTA4_dac4874d-4b45-45ae-9a92-84fe0c35be8e">0.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzQtMS0xLTEtMTY3OTA4_e1f14916-fec6-4bd3-979c-791226e79bb7">6.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzQtMy0xLTEtMTY3OTA4_1a41001f-5e3d-4472-aa7c-c2ee8cb54be0">6.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzQtNS0xLTEtMTY3OTA4_e89c666c-1f84-4927-a0ce-bdeab328b6bc">6.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzUtMS0xLTEtMTY3OTA4_83afb822-88e9-4746-8e9e-87b1fbe0ab7f">24.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzUtMy0xLTEtMTY3OTA4_865526f6-c7a8-425a-baab-9ff3e74bd7bb">14.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzUtNS0xLTEtMTY3OTA4_54efac05-9b15-4343-8264-d37869deaaf2">8.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#8217;s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected life represents the number of&#160;years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, unrecognized compensation expense related to unvested stock options totaled $<ix:nonFraction unitRef="usd" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzc4MTk_fa1207ed-8829-4caf-a603-8ae0d69d475b">41</ix:nonFraction> million, which the Company expects to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzc5MDA_6b9524d7-bfc3-47d8-aecb-0f68bb004b5e">1.9</ix:nonNumeric> years. After considering anticipated forfeitures, the Company expects approximately <ix:nonFraction unitRef="shares" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="-6" name="cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzc5ODE_ab11b34f-d4f0-48b7-bd35-143a4da5fa6b">7</ix:nonFraction> million of the unvested stock options to vest over the requisite service period.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzc_3c80f0da-0326-48dc-981e-ad8661501779" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company&#8217;s stock option and SAR activity for the&#160;year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;thousands, except weighted average exercise price and remaining contractual term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77dc266c0f374e01a14893d1a6ea3f8e_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzEtMS0xLTEtMTY3OTA4_1bdb9c14-4b6b-41ee-a69b-61f78db9ba23">19,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77dc266c0f374e01a14893d1a6ea3f8e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzEtMy0xLTEtMTY3OTA4_97244ea1-ae94-436a-aaa9-5274d6b59e01">71.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzItMS0xLTEtMTY3OTA4_4a2a50aa-fcba-44c6-a064-56cb0270c6f8">1,993</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzItMy0xLTEtMTY3OTA4_65f2a447-2836-4ba5-8798-4c8680fca095">101.04</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzMtMS0xLTEtMTY3OTA4_f44a1984-7f7a-4215-ad06-c02dfc3d0935">4,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzMtMy0xLTEtMTY3OTA4_ad35ed7f-dcd0-48c9-a33c-12fd4600d3a0">75.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzQtMS0xLTEtMTY3OTA4_a3f21b5b-25f0-4597-8648-a023ba7917bc">478</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzQtMy0xLTEtMTY3OTA4_6d03e434-531a-4a84-b481-ae7ee913ea20">70.78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzUtMS0xLTEtMTY3OTA4_6f565340-5cea-4c9c-acb1-a2d6594772d5">615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzUtMy0xLTEtMTY3OTA4_f515786b-c4e2-420f-b301-3392b62f28b6">99.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzYtMS0xLTEtMTY3OTA4_1187f910-720d-46ac-9055-48db14d903ab">15,040</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzYtMy0xLTEtMTY3OTA4_20a7dd71-a01d-463e-bd73-8a75a7070b21">73.15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzYtNS0xLTEtMTY3OTA4_d0a73297-a7fd-4370-82ac-1668893665b6">4.52</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzYtNy0xLTEtMTY3OTA4_0f97c231-8d67-4f35-924c-07c0bf9c34e4">340,507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzctMS0xLTEtMTY3OTA4_0bdb923a-883b-4e2a-8af0-ed4b173e057e">7,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzctMy0xLTEtMTY3OTA4_4c190065-1ca9-4b10-a214-a23e01354e93">72.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzctNS0xLTEtMTY3OTA4_399c5020-2909-4763-9b89-c29436ee5536">2.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzctNy0xLTEtMTY3OTA4_058ca142-f880-439a-bc22-7459124b47dd">184,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested at end of year and expected to vest in the future</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzgtMS0xLTEtMTY3OTA4_9b6aaf53-d9db-4729-9826-47f555b06cf5">14,757</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzgtMy0xLTEtMTY3OTA4_616dee7b-7cf2-4884-a30b-3f1f4dccd148">72.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzgtNS0xLTEtMTY3OTA4_3b407bfe-deed-437c-a07e-7a94fc829624">4.47</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzgtNy0xLTEtMTY3OTA4_9c4ce3e0-f13a-4def-8a21-5807b85b1224">336,664</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;) provides for the purchase of up to <ix:nonFraction unitRef="shares" contextRef="iadb4c5c9645e411fbac5109bc755e0aa_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzI3NDg3NzkwODM2MjQ_f257d887-1b6c-44d0-a282-e0470731cf8e">60</ix:nonFraction>&#160;million shares of CVS Health Corporation common stock. Under the ESPP, eligible employees may purchase common stock at the end of each six&#160;month offering period at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzE0MjAx_d4e5b195-e70e-470a-929d-5f192e17f1b1">90</ix:nonFraction>% of the lower of the fair market value on the first day or the last day of the offering period. During 2022, approximately <ix:nonFraction unitRef="shares" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzE0MjA5_1113f6cc-ea09-4a73-b422-d6c11afe029c">2</ix:nonFraction> million shares of common stock were purchased under the provisions of the ESPP at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="2" name="cvs:StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzI3NDg3NzkwODI1ODQ_92bdf90d-38b2-47d6-b86e-dc405493916d">78.55</ix:nonFraction> per share. As of December&#160;31, 2022, approximately <ix:nonFraction unitRef="shares" contextRef="iadb4c5c9645e411fbac5109bc755e0aa_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzI3NDg3NzkwODI2MjQ_5729b6f9-4745-42cd-941c-486234384260">29</ix:nonFraction> million shares of common stock were available for issuance under the ESPP.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia79d7d719ece446285480a540bf953f9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock-based compensation associated with the ESPP is estimated on the date of grant (the first day of the six&#160;month offering period) using the Black-Scholes option pricing model.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzY1OTcwNjk3ODIzODA_d8499f74-2035-4ce6-85f9-770446c64e03" continuedAt="i6511a080cc7845adb29eb79f7ec5df48" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the assumptions used to value the ESPP awards for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzEtMS0xLTEtMjI1OTU5_d8e1083f-e464-49cf-9d23-875052544fad">1.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzEtMy0xLTEtMjI1OTU5_0e6ea05d-7486-49c1-90b9-509a79444368">1.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzEtNS0xLTEtMjI1OTU5_04b5a38c-7c4f-441b-98ca-37da407226cc">1.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzItMS0xLTEtMjI1OTU5_b7704ae2-8d69-433e-8166-0b887aa8be77">23.54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzItMy0xLTEtMjI1OTU5_39175578-5153-4134-b862-976a281ae836">25.27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzItNS0xLTEtMjI1OTU5_6ae4f6c2-684c-45b5-8a1a-9cd4903d2dce">37.21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzMtMS0xLTEtMjI1OTU5_415e8491-134f-4c05-a3bc-2a3db11be018">1.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzMtMy0xLTEtMjI1OTU5_e40dd734-309d-4dd3-8328-3eaf67a468fe">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzMtNS0xLTEtMjI1OTU5_ac0e948e-34b4-4df8-a369-8c5d6b07f9ea">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzQtMS0xLTEtMjI1OTU5_eb54737b-26db-47f3-bc64-e40878fa7046">0.5</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzQtMy0xLTEtMjI1OTU5_9632a575-bb60-449f-8199-de2400c2c934">0.5</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzQtNS0xLTEtMjI1OTU5_3ef10942-bea5-47c4-b335-4e363ff6fc9e">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzUtMS0xLTEtMjI1OTU5_45de48cc-6188-4f56-95e4-17036ffba0df">16.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzUtMy0xLTEtMjI1OTU5_66cff1d8-eec8-453f-9787-3dd0c8f35414">12.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzUtNS0xLTEtMjI1OTU5_286cf4e8-e7a4-4021-a792-35a25596c955">13.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#8217;s daily stock price over the previous six&#160;month period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six&#160;months).</span></div></ix:nonNumeric><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i6511a080cc7845adb29eb79f7ec5df48" continuedAt="ieb6075f6828f4174bae070a1a4bab22b">(4)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:continuation id="ieb6075f6828f4174bae070a1a4bab22b">The expected life is based on the semi-annual purchase period</ix:continuation>.</span></div></ix:continuation><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_157"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM5MTY_b982213f-c88c-4238-a0f8-9e43854a82a1" continuedAt="ib4e0486dcb734627ba2e46b7a4d19a28" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib4e0486dcb734627ba2e46b7a4d19a28" continuedAt="ia93a47d0bcd642a69c8c09e4678feb82"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM5MDg_3d9d7ebd-19fe-4823-8b68-9a21777ac175" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share repurchase programs have been authorized by the Board:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In billions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Authorization&#160;Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining as of<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 17, 2022 (&#8220;2022 Repurchase Program&#8221;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d5aaeea5cd4364a999d22bc0e526c2_I20221117" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNWJiMTRkNDYyMTA0MzMzODUyZTIzMTFjN2JlMjljNC90YWJsZXJhbmdlOjA1YmIxNGQ0NjIxMDQzMzM4NTJlMjMxMWM3YmUyOWM0XzEtMS0xLTEtMjA1NzI0_f744fc13-b400-41e2-89e9-157f1f80891f">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5463bac593422d85e68f6a31c6cd24_I20221231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNWJiMTRkNDYyMTA0MzMzODUyZTIzMTFjN2JlMjljNC90YWJsZXJhbmdlOjA1YmIxNGQ0NjIxMDQzMzM4NTJlMjMxMWM3YmUyOWM0XzEtMy0xLTEtMjA1NzMy_0a472085-2718-4ca9-8528-90943377ea9a">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 9, 2021 (&#8220;2021 Repurchase Program&#8221;)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51eec47e53dc4a1c9685a39a8e5b3b47_I20211209" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNWJiMTRkNDYyMTA0MzMzODUyZTIzMTFjN2JlMjljNC90YWJsZXJhbmdlOjA1YmIxNGQ0NjIxMDQzMzM4NTJlMjMxMWM3YmUyOWM0XzEtMS0xLTEtMTY3OTA4_c9a95b5f-212c-43b8-a7b2-2b1717b01dd0">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5316d30a5a634b0eb7ebde97e6094f70_I20221231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNWJiMTRkNDYyMTA0MzMzODUyZTIzMTFjN2JlMjljNC90YWJsZXJhbmdlOjA1YmIxNGQ0NjIxMDQzMzM4NTJlMjMxMWM3YmUyOWM0XzEtMy0xLTEtMTY3OTA4_864e8949-5870-4f16-9882-75605d143e57">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the share Repurchase Programs was effective immediately and permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (&#8220;ASR&#8221;) transactions, and/or other derivative transactions. Both the 2022 and 2021 Repurchase Programs can be modified or terminated by the Board at any time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company repurchased an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8233d450fa5745639d54e56448f03464_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODE0MzQ_1351dfdf-da03-4f46-b8ea-473e9bd353d7">34.1</ix:nonFraction>&#160;million shares of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i8233d450fa5745639d54e56448f03464_D20220101-20221231" decimals="-8" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODE0NTI_76a04ab8-7684-4a5d-a117-f456c18f7a9e">3.5</ix:nonFraction>&#160;billion pursuant to the 2021 Repurchase Program, including share repurchases under the $<ix:nonFraction unitRef="usd" contextRef="ic28fda85c05b4594a00f0a3402b95859_D20220104-20220104" decimals="-8" name="cvs:PaymentsForAcceleratedShareRepurchasesAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzEwOTk1MTE2Mjk0NDQ4_5e47b3cf-2de6-404a-adf7-d46b2d7198d7">1.5</ix:nonFraction>&#160;billion fixed dollar ASR transaction described below. During the years ended December&#160;31, 2021 and 2020, the Company did <ix:nonFraction unitRef="shares" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NTk_6320e137-0f04-497e-9579-4ffef4120b64"><ix:nonFraction unitRef="shares" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NTk_abfc773f-3def-49dd-a357-c9389434431c">no</ix:nonFraction></ix:nonFraction>t repurchase any shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $<ix:nonFraction unitRef="usd" contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104" decimals="-8" name="cvs:AcceleratedShareRepurchasesAgreementAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE2NTU_e35af428-26f0-484a-bbc9-6f8a18361e16">2.0</ix:nonFraction>&#160;billion fixed dollar ASR with Citibank, N.A. (&#8220;Citibank&#8221;). Upon payment of the $<ix:nonFraction unitRef="usd" contextRef="i8ff381caf73a4c2db6637a9d0b8f3632_D20230104-20230104" decimals="-8" name="cvs:PaymentsForAcceleratedShareRepurchasesAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE2NzA_3be461e3-9a48-42e7-8717-256389445502">2.0</ix:nonFraction>&#160;billion purchase price on January 4, 2023, the Company received a number of shares of CVS Health Corporation&#8217;s common stock equal to <ix:nonFraction unitRef="number" contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104" decimals="2" name="cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE2ODc_76da89ae-62ae-4cc2-bbdd-b4f03f6a0bc9">80</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104" decimals="-8" name="cvs:AcceleratedShareRepurchasesAgreementAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE2OTM_7e70543e-bf24-47b4-b006-85b7ceed7d78">2.0</ix:nonFraction>&#160;billion notional amount of the ASR or approximately <ix:nonFraction unitRef="shares" contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104" decimals="-5" name="cvs:AcceleratedShareRepurchasesNumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzU0OTc1NTgzMDU4OA_e11d0d04-36e9-4095-b712-7b03a087d828">17.4</ix:nonFraction> million shares at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzU0OTc1NTgzMDU5Ng_1c8c2fc2-a28f-421b-b382-745b07dfc075">92.19</ix:nonFraction> per share, which were placed into treasury stock in January 2023. At the conclusion of the ASR, the Company may receive additional shares representing the remaining <ix:nonFraction unitRef="number" contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104" decimals="2" name="cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE3Mjc_824ac1ba-e7db-461c-9a6a-8020ab101eac">20</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104" decimals="-8" name="cvs:AcceleratedShareRepurchasesAgreementAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE3MzM_cd3fb13c-51b7-4f5c-8b7d-bd2eff77ae9a">2.0</ix:nonFraction>&#160;billion notional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Company&#8217;s stock over an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Citibank which, at the Company&#8217;s option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that could be delivered to the Company is <ix:nonFraction unitRef="shares" contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104" decimals="-5" name="cvs:AcceleratedShareRepurchaseProgramMaximumNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzU0OTc1NTgzMDYxNw_448781f4-51fb-4e2b-93d0-b0533ea7c5df">43.4</ix:nonFraction> million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $<ix:nonFraction unitRef="usd" contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104" decimals="-8" name="cvs:AcceleratedShareRepurchasesAgreementAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODA5Njg_3b468df1-0762-45f2-aa4d-bf3669c372bd">1.5</ix:nonFraction>&#160;billion fixed dollar ASR with Barclays Bank PLC. Upon payment of the $<ix:nonFraction unitRef="usd" contextRef="ic28fda85c05b4594a00f0a3402b95859_D20220104-20220104" decimals="-8" name="cvs:PaymentsForAcceleratedShareRepurchasesAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODA5ODM_5e47b3cf-2de6-404a-adf7-d46b2d7198d7">1.5</ix:nonFraction>&#160;billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation&#8217;s common stock equal to <ix:nonFraction unitRef="number" contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104" decimals="2" name="cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwMDI_2de84610-cc30-4487-bc05-33843140a7ce">80</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104" decimals="-8" name="cvs:AcceleratedShareRepurchasesAgreementAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwMDg_18ce42a1-5708-467e-92ea-e028c7d20717">1.5</ix:nonFraction>&#160;billion notional amount of the ASR or approximately <ix:nonFraction unitRef="shares" contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104" decimals="-5" name="cvs:AcceleratedShareRepurchasesNumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwMjM_5cba7002-e215-4fab-9cf6-59bb3e871155">11.6</ix:nonFraction>&#160;million shares at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwNzA_136d83a8-f732-43f7-8513-fc4d8ca9295d">103.34</ix:nonFraction> per share, which were placed into treasury stock in January 2022. The ASR was accounted for as an initial treasury stock transaction for $<ix:nonFraction unitRef="usd" contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104" decimals="-8" name="cvs:TransferOfSharesToTreasuryStockValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwNDA_7e4dfb8c-7f92-4ebe-b068-1a06c0c52842">1.2</ix:nonFraction>&#160;billion and a forward contract for $<ix:nonFraction unitRef="usd" contextRef="ie70904e10fad41e29c390bf6b19d6203_I20220104" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzEzNzQzODk1MzY3ODIy_de8d5799-7503-4fd1-a61e-eec5f600e746">0.3</ix:nonFraction>&#160;billion. The forward contract was classified as an equity instrument and was recorded within capital surplus. In February 2022, the Company received approximately <ix:nonFraction unitRef="shares" contextRef="ia5c40ac9da1342d08ae7f70b317ddf53_I20220228" decimals="-5" name="cvs:AcceleratedShareRepurchasesNumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzEzNzQzODk1MzY3ODM3_8b801c8e-fbdb-4bdf-8a39-9575359bfaab">2.7</ix:nonFraction>&#160;million shares of CVS Health Corporation&#8217;s common stock, representing the remaining </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia93a47d0bcd642a69c8c09e4678feb82"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia5c40ac9da1342d08ae7f70b317ddf53_I20220228" decimals="2" name="cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwNTk_ccda23fb-39a5-4f5a-857b-020b7f8ce5ff">20</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="ia5c40ac9da1342d08ae7f70b317ddf53_I20220228" decimals="-8" name="cvs:AcceleratedShareRepurchasesAgreementAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzEzNzQzODk1MzY3ODUx_e58901bc-d0a2-49e8-826a-ae2f006700a8">1.5</ix:nonFraction>&#160;billion notional amount of the ASR, thereby concluding the ASR. These shares were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quarterly cash dividend declared by the Board was $<ix:nonFraction unitRef="usdPerShare" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0Njg_006422a0-2c0a-4b05-acfa-7f31bde8271e"><ix:nonFraction unitRef="usdPerShare" contextRef="ieef592c79265415e9514a93ffb9ae4ac_I20220630" decimals="INF" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0Njg_582861c3-893c-4b42-a3d4-9b22965941b7"><ix:nonFraction unitRef="usdPerShare" contextRef="id5735f8f8c5444a2a0384aa456ca592f_I20220331" decimals="INF" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0Njg_658f4ab7-45c8-4a7f-a263-e7ed459e1356"><ix:nonFraction unitRef="usdPerShare" contextRef="i97d782259b904c979e113b78787ed48d_I20220930" decimals="INF" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0Njg_bea01a34-cecf-4e60-8f5d-82f6849ea6f7">0.55</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i9289877d9c2c4ffcbaa2d99b1945576b_I20210630" decimals="INF" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NzU_2d5f1531-46af-4c59-a7fe-e1d946075601"><ix:nonFraction unitRef="usdPerShare" contextRef="idc9209a44ddd41178541daa30bd6749f_I20210930" decimals="INF" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NzU_37752729-fb43-4205-8726-34dbb46089d1"><ix:nonFraction unitRef="usdPerShare" contextRef="i82a1252a04a84b3898c7e327a9c92b60_I20210331" decimals="INF" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NzU_65f81111-958f-4d71-9fe3-c936d6b98667"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="INF" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NzU_81554b5f-0b5f-44ee-ac19-f5b7f61fb59c">0.50</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> per share in 2022 and 2021, respectively. In December 2022, the Board authorized a <ix:nonFraction unitRef="number" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="2" name="cvs:DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzY1OTcwNjk3ODY0Njk_962edeef-ddb5-4fcd-864c-0200d257e208">10</ix:nonFraction>% increase in the quarterly cash dividend to $<ix:nonFraction unitRef="usdPerShare" contextRef="i95e56c9158aa4a519e48b89d4b91b42a_I20230101" decimals="3" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzU0OTc1NTgzMDQ5Mw_d6a73d64-c561-4019-b7f6-13939a295d85">0.605</ix:nonFraction> per share effective in 2023. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company&#8217;s earnings, capital requirements, financial condition and other factors considered relevant by the Board.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s insurance business operations are conducted through subsidiaries that principally consist of health maintenance organizations (&#8220;HMOs&#8221;) and insurance companies. The Company&#8217;s HMO and insurance subsidiaries report their financial statements in accordance with accounting practices prescribed by state regulatory authorities which may differ from GAAP. <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfRegulatoryAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM5MTA_10e01607-bf3c-408c-ac5d-3d0c741c7951" continuedAt="i6a631d26593c4541833e52f8b40c817d" escape="true">The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December&#160;31, 2022, 2021 and 2020 for the Company&#8217;s insurance and HMO subsidiaries were as follows:</ix:nonNumeric></span></div><div><ix:continuation id="i6a631d26593c4541833e52f8b40c817d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory net income </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd8499c4fb34af58a98efbc5d640ce2_D20220101-20221231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzEtMS0xLTEtMTY3OTA4_5d740c63-0dc2-43cd-a065-4995bfaf3ab7">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b5561cc39474810bff93b9bc55eddd3_D20210101-20211231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzEtMy0xLTEtMTY3OTA4_5e98a541-b201-4e3d-9374-79eef6123a33">3,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46daf9900b4a90868ccafe21f74ebb_D20200101-20201231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzEtNS0xLTEtMTY3OTA4_ee22503a-aff3-41e4-8480-97212b86fc49">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated statutory capital and surplus</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbc41d71b734bae909dc80277dec2bd_I20221231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzItMS0xLTEtMTY3OTA4_91aa3d56-bcd8-42ad-9c12-6f248b979c62">15,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297b60290a1245cc886da0051e954eac_I20211231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzItMy0xLTEtMTY3OTA4_37f690f3-52c1-4789-9189-7b6bd32c25ba">14,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66102a5aa12440b29e51c2d516b74676_I20201231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzItNS0xLTEtMTY3OTA4_e4bad0aa-dd67-4646-8346-f5572fc90bb6">13,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s insurance and HMO subsidiaries paid $<ix:nonFraction unitRef="usd" contextRef="icfd8499c4fb34af58a98efbc5d640ce2_D20220101-20221231" decimals="-6" name="us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI5MTI_9508652a-06f4-4a92-9c02-bcca1318b77d">3.2</ix:nonFraction> billion of gross dividends to the Company for the year ended December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to general state law restrictions on payments of dividends and other distributions to stockholders applicable to all corporations, HMOs and insurance companies are subject to further regulations that, among other things, may require those companies to maintain certain levels of equity and restrict the amount of dividends and other distributions that may be paid to their equity holders. In addition, in connection with the Aetna Acquisition, the Company made certain undertakings that require prior regulatory approval of dividends by certain of its HMOs and insurance companies. <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:StatutoryAccountingPracticesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM5MDA_2dcff450-aba0-4198-9d3f-7c8794f95e36" continuedAt="ib7e9375e4c80404b8baaf1c25cee61d8" escape="true">At December&#160;31, 2022, these amounts were as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ib7e9375e4c80404b8baaf1c25cee61d8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:88.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated minimum statutory surplus required by regulators</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTozNmU5MTg0OWVlNjc0ZmZiYmQzNDkyM2M4MTM0NWE4NC90YWJsZXJhbmdlOjM2ZTkxODQ5ZWU2NzRmZmJiZDM0OTIzYzgxMzQ1YTg0XzEtMS0xLTEtMTY3OTA4_3af0feb9-1da9-41b3-8629-dcbc53ed4140">7,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments on deposit with regulatory bodies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:AssetsHeldByInsuranceRegulators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTozNmU5MTg0OWVlNjc0ZmZiYmQzNDkyM2M4MTM0NWE4NC90YWJsZXJhbmdlOjM2ZTkxODQ5ZWU2NzRmZmJiZDM0OTIzYzgxMzQ1YTg0XzItMS0xLTEtMTY3OTA4_573ef415-1589-43cc-81a2-dd2048f9f769">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated maximum dividend distributions permitted in 2023 without prior regulatory approval</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTozNmU5MTg0OWVlNjc0ZmZiYmQzNDkyM2M4MTM0NWE4NC90YWJsZXJhbmdlOjM2ZTkxODQ5ZWU2NzRmZmJiZDM0OTIzYzgxMzQ1YTg0XzMtMS0xLTEtMTY3OTA4_e32b0144-4746-4710-8acf-7bbe10cc7c3e">2,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, noncontrolling interests were $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM2Nzg_e1ac868c-7aa5-471e-a5b9-446a1466cd49">300</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM2ODU_261fad85-a9bc-43e0-bd90-88e0336d5fe2">306</ix:nonFraction> million, respectively, primarily related to third party interests in the Company&#8217;s operating entities.&#160;The noncontrolling entities&#8217; share is included in total shareholders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity on the consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_160"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90ZXh0cmVnaW9uOmE0N2ViZTQ2NmJhMjRjZjI4ODVlOGY3OGEwNTA2MTRhXzEyNzk_c2cb4f3b-a6a3-4045-9f31-6ba6fcf5b9e0" continuedAt="ic96504fb58d248c79678ac7d3d2c3d8b" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic96504fb58d248c79678ac7d3d2c3d8b"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90ZXh0cmVnaW9uOmE0N2ViZTQ2NmJhMjRjZjI4ODVlOGY3OGEwNTA2MTRhXzEyNzc_de25885a-84f8-49cc-b038-9e8b012d67ef" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders&#8217; equity included the following activity in accumulated other comprehensive income (loss) in 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net unrealized investment gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e896501d7c436b96f31503738ed740_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMtMS0xLTEtMTY3OTA4_abc6bc47-db13-42e3-9fcb-195e9d916f5d">778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18c761ce4364ea2973eb59d2fd584ca_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMtMy0xLTEtMTY3OTA4_3de034bb-764b-4781-bc13-d4c887104faf">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c2106ba1184ea692fbc96551d6d7b2_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMtNS0xLTEtMTY3OTA4_8e9dc813-bb61-4620-971c-be5e0d9d79c1">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(<ix:nonFraction unitRef="usd" contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246ZmRmN2U5ZjRlMmQ1NDQxMzg4ZmI4YTFmYmEwMmRiNDVfNjQ_9112e157-7ee4-4030-a18a-159ffce57c84">2,972</ix:nonFraction>), $(<ix:nonFraction unitRef="usd" contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246ZmRmN2U5ZjRlMmQ1NDQxMzg4ZmI4YTFmYmEwMmRiNDVfNjg_0fcf855b-a471-487a-b14c-d04a3daefe43">489</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246ZmRmN2U5ZjRlMmQ1NDQxMzg4ZmI4YTFmYmEwMmRiNDVfNzU_ac3c40b1-7af3-423b-97c1-acb6e1d9db4a">497</ix:nonFraction> pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMS0xLTEtMTY3OTA4_175907a6-18c8-44ff-937a-0421bd61c508">2,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMy0xLTEtMTY3OTA4_81eacf53-fa3c-4eaf-96bf-f8e8da4dda93">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtNS0xLTEtMTY3OTA4_2c30ecbf-b5d8-459d-9952-011e9d302e74">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($<ix:nonFraction unitRef="usd" contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246YWYzY2ZiODUyNWZmNDQzNjg2YTJiYTBkNzk1NWU0OTBfNzA_0da94ac2-89ba-4d12-9636-646d56c77f8d">315</ix:nonFraction>, $(<ix:nonFraction unitRef="usd" contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246YWYzY2ZiODUyNWZmNDQzNjg2YTJiYTBkNzk1NWU0OTBfNzQ_95cb1bf2-a055-491f-a8f8-a4bf551fec4d">32</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246YWYzY2ZiODUyNWZmNDQzNjg2YTJiYTBkNzk1NWU0OTBfODE_b15b80c0-7603-4dc8-92f5-4e3237e3516f">31</ix:nonFraction> pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMS0xLTEtMTY3OTA4_62a90ea9-b80b-4c5f-944c-d4a5ac5cf5c0">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMy0xLTEtMTY3OTA4_7025e528-d22c-4305-9ed0-4cf043399a6c">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtNS0xLTEtMTY3OTA4_86672c34-0e42-4dbd-b88e-b51f51db7153">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzYtMS0xLTEtMTY3OTA4_6a073fe1-a19c-4c93-806e-c2b973c79a21">2,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzYtMy0xLTEtMTY3OTA4_a1555d39-efe9-402a-8985-ac154c1b70f6">436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzYtNS0xLTEtMTY3OTA4_f34171a8-7ba2-48a1-a428-cedb9c52e862">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d4ff8f1d92a425284f720815593c158_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzctMS0xLTEtMTY3OTA4_7599cac1-d20e-493a-aa95-f74047688401">1,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e896501d7c436b96f31503738ed740_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzctMy0xLTEtMTY3OTA4_b4cbbab9-59fa-4bb4-8f48-9c8a024eacdc">778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18c761ce4364ea2973eb59d2fd584ca_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzctNS0xLTEtMTY3OTA4_be8795b4-54af-4813-bca3-3dfd9d8bad05">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0eaddda21c4a00be59a3852a2fda53_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEwLTEtMS0xLTE2NzkwOA_15b0c7e7-80b3-44d7-9918-da453e367bd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6c784677034efab4d3c3761a6becc8_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEwLTMtMS0xLTE2NzkwOA_503a0171-454c-4966-bea5-fb9db944f10c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e299f2c18e43bdae5d151661e82ef0_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEwLTUtMS0xLTE2NzkwOA_d6180e36-3f3b-43c1-bfb8-ef37b5292f44">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a7074798cd4f7da8207ad643b5286e_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzExLTEtMS0xLTE2NzkwOA_4b07872a-3d99-4a31-8d59-f3d0b96991a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7348d8b55d1847e59482a4dd6cabd5cc_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzExLTMtMS0xLTE2NzkwOA_677feb57-f894-4712-9b8d-8841737d10b0">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1acf0930000a47a28b1f1859847b12aa_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzExLTUtMS0xLTE2NzkwOA_664e0d1c-8375-4ef0-aa15-bbc8003dfe54">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a7074798cd4f7da8207ad643b5286e_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEzLTEtMS0xLTE2NzkwOA_93ef9339-3533-4bf9-9f47-7de0f8a14c1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7348d8b55d1847e59482a4dd6cabd5cc_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEzLTMtMS0xLTE2NzkwOA_580b5323-8ae3-40e6-a6f1-a1b44116a7ce">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1acf0930000a47a28b1f1859847b12aa_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEzLTUtMS0xLTE2NzkwOA_988a2357-536a-46fd-989f-637cf0c83fb2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb67b8f18d2a41819af3ed1f45173118_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE0LTEtMS0xLTE2NzkwOA_64b48a00-06b9-4641-a4e8-a036c306b602">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0eaddda21c4a00be59a3852a2fda53_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE0LTMtMS0xLTE2NzkwOA_f49427dd-fc57-405e-8e34-4aa62010cc5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6c784677034efab4d3c3761a6becc8_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE0LTUtMS0xLTE2NzkwOA_709a8475-e044-409e-90b9-76b6141185b4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d024dd953342978e381ef9ad09e97d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE3LTEtMS0xLTE2NzkwOA_1abf5dff-e921-4a81-8f07-2e12e4125e4b">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34691a75be1a40a485b08377e0d95591_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE3LTMtMS0xLTE2NzkwOA_a7946419-fbc6-488c-9c16-e262308b9c46">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cab5985f934b68b073707b0db81f68_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE3LTUtMS0xLTE2NzkwOA_e3f58e6b-84c3-424b-b0b7-66fcf786056c">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($<ix:nonFraction unitRef="usd" contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjgzNGIzNDFmOWEyODQ4N2JiNTlmY2IyN2YzYzUxZjQ4XzU1_067d1681-e05d-4fc8-9ceb-df8602337dcc">38</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjgzNGIzNDFmOWEyODQ4N2JiNTlmY2IyN2YzYzUxZjQ4XzU5_6f1f9ae9-ee1b-477e-802d-10b5d7841ce7">0</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjgzNGIzNDFmOWEyODQ4N2JiNTlmY2IyN2YzYzUxZjQ4XzY2_afe697ee-1d59-496b-bd2f-27ebefabfd21">7</ix:nonFraction>) pretax)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTEtMS0xLTE2NzkwOA_699d8d41-4957-4d05-b837-e9e649b9a4b2">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTMtMS0xLTE2NzkwOA_c6913660-ef85-418b-9618-7b99c3c06731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTUtMS0xLTE2NzkwOA_3f2abbe0-5e9a-4705-aeac-f82347343e79">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(<ix:nonFraction unitRef="usd" contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBiNjI3ZmE1NDYzMDQ0NGRhNTc3ODY3NDgyNzQ1OGRkXzcw_2819d842-90c6-4559-bf2d-264358eae9d5">15</ix:nonFraction>), $(<ix:nonFraction unitRef="usd" contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBiNjI3ZmE1NDYzMDQ0NGRhNTc3ODY3NDgyNzQ1OGRkXzc0_ee8b4f96-daa3-41c8-89d2-7af5a164c71b">34</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBiNjI3ZmE1NDYzMDQ0NGRhNTc3ODY3NDgyNzQ1OGRkXzgx_544c54da-25d5-49a3-95a6-7b2c49800092">35</ix:nonFraction>) pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTEtMS0xLTE2NzkwOA_577b90e4-ac85-4a25-84df-6999927e199d">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTMtMS0xLTE2NzkwOA_8391d7b7-6ad2-4285-b777-890b6a3a3ee1">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTUtMS0xLTE2NzkwOA_5dab683f-d3d8-4bc6-899c-245fe8f762cc">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIwLTEtMS0xLTE2NzkwOA_3f2062a7-4120-41de-a9e9-f206784b9869">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIwLTMtMS0xLTE2NzkwOA_6df55d83-2ad6-428b-bd25-00d4699f7b37">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIwLTUtMS0xLTE2NzkwOA_2551a779-f362-4851-a51d-71c8a3dde6ef">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40550f17612e4e1c9a2bdb2e12646807_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIxLTEtMS0xLTE2NzkwOA_7787a82f-cb91-42e4-989c-626d179b2bd6">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d024dd953342978e381ef9ad09e97d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIxLTMtMS0xLTE2NzkwOA_9a6e0c3b-45ae-4992-854c-5fd04e3a3667">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34691a75be1a40a485b08377e0d95591_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIxLTUtMS0xLTE2NzkwOA_b668dc35-b751-4080-bdd5-27d6bcafc1ce">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae0bd8dfb5cf4f9e8b8252cd49e75e9c_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI0LTEtMS0xLTE2NzkwOA_0a06f792-4c64-425f-9771-f27df7a25027">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75fd10d334be4f38bba49ac3d51dd978_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI0LTMtMS0xLTE2NzkwOA_ced08393-1a6f-49db-bbde-a1b54e3f25d8">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7e3ddd79ec9406fbd5b0334e0a7cf99_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI0LTUtMS0xLTE2NzkwOA_96ecf6d5-21d1-471c-b32f-2f57f91cacc2">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(<ix:nonFraction unitRef="usd" contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBhNDc3MDM4YWFkMDQxMjFhMzZmNDY2YmZjZDgzNzhlXzY0_d0e774bb-9ff1-4d0f-ad67-aa9c573922f2">229</ix:nonFraction>), $<ix:nonFraction unitRef="usd" contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBhNDc3MDM4YWFkMDQxMjFhMzZmNDY2YmZjZDgzNzhlXzY4_a3167549-7a8f-461d-8d86-cc5e3ef516fa">20</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBhNDc3MDM4YWFkMDQxMjFhMzZmNDY2YmZjZDgzNzhlXzc1_454019ee-de18-4283-ab47-65916a8dd074">30</ix:nonFraction>) pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTEtMS0xLTE2NzkwOA_bf49dfb4-5769-454b-a472-8b856646edc8">170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTMtMS0xLTE2NzkwOA_26eec451-e360-43b2-b22b-b289cdec3c54">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTUtMS0xLTE2NzkwOA_7d1ae275-b632-438b-b4e2-5bf935eef759">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($<ix:nonFraction unitRef="usd" contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjQ3NTk4ZGI5MjRiYjQ0NDViNDM0ODQyYzc4M2E0NDFiXzY4_89936955-ed23-47f9-b72d-644973260dcd">3</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjQ3NTk4ZGI5MjRiYjQ0NDViNDM0ODQyYzc4M2E0NDFiXzcy_c703d2eb-e63f-4dbc-b988-cd58012bb63f">6</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjQ3NTk4ZGI5MjRiYjQ0NDViNDM0ODQyYzc4M2E0NDFiXzc5_5d59e84d-d2c0-46bd-8641-4f86ba581126">7</ix:nonFraction> pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTEtMS0xLTE2NzkwOA_6587ac8a-5c39-4af9-bb2b-a1c39c45908f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTMtMS0xLTE2NzkwOA_32f97a1d-ac50-446e-b621-9fd49671bed6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTUtMS0xLTE2NzkwOA_41262452-72ea-48aa-b207-41961a497c18">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI3LTEtMS0xLTE2NzkwOA_648a6cf8-07fb-43e0-9c72-fa6d61006ac6">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI3LTMtMS0xLTE2NzkwOA_89a05d3a-a565-4308-94c0-86923decb4d2">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI3LTUtMS0xLTE2NzkwOA_91aedb74-a122-4294-be3a-94eeb3425091">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48cedd332752429fb7fdcab29fe151c0_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI4LTEtMS0xLTE2NzkwOA_d6ae0eab-e423-4b70-999a-5495361f32c0">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae0bd8dfb5cf4f9e8b8252cd49e75e9c_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI4LTMtMS0xLTE2NzkwOA_84839afd-a4d6-4a5d-8440-197f7ad173b8">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75fd10d334be4f38bba49ac3d51dd978_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI4LTUtMS0xLTE2NzkwOA_9fb81d3d-e3ea-45f6-b8c9-9013f8594e35">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of year accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5dc45a20214840ba91115d7f1be610_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMwLTEtMS0xLTE2NzkwOA_9400e333-3934-44b8-b463-ed954d72f117">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a9007fcb714cb09cc20b1eca666273_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMwLTMtMS0xLTE2NzkwOA_672fd680-c73d-4982-a15f-400cdc51c90f">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41faef8f0db4ed59ca3aaf9b30913d8_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMwLTUtMS0xLTE2NzkwOA_dd7e444e-fc63-42a3-b629-4d816dfac030">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMxLTEtMS0xLTE2NzkwOA_f53021cd-5423-4a97-863d-3286bf7d3205">2,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMxLTMtMS0xLTE2NzkwOA_2194d3cf-9f3a-44ba-a312-6d65376fe997">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMxLTUtMS0xLTE2NzkwOA_8a87fd00-8593-4fc8-9a9c-0b420cda3d84">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of year accumulated other comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dbbb5af69624415b1974a87c4e00ef6_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMyLTEtMS0xLTE2NzkwOA_1c0b988c-0a1e-4a17-96c5-4747cb5a24c8">1,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5dc45a20214840ba91115d7f1be610_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMyLTMtMS0xLTE2NzkwOA_16a5d8db-20d3-4d50-9dd5-de777b68391c">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a9007fcb714cb09cc20b1eca666273_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMyLTUtMS0xLTE2NzkwOA_4475830c-75e1-4088-a6d8-e069728efcc0">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify $<ix:nonFraction unitRef="usd" contextRef="i40550f17612e4e1c9a2bdb2e12646807_I20221231" decimals="-6" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90ZXh0cmVnaW9uOmE0N2ViZTQ2NmJhMjRjZjI4ODVlOGY3OGEwNTA2MTRhXzI3NDg3NzkwNzE2NzI_25830e71-75b8-4002-96e9-77cebfb19be0">11</ix:nonFraction> million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzU3MQ_646d3480-9a03-422b-8130-b83637c282cb" continuedAt="ie88fc8a9e77e4a84ba79bb519411b5d9" escape="true">Earnings Per Share</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie88fc8a9e77e4a84ba79bb519411b5d9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is computed using the treasury stock method. Stock options and SARs to purchase <ix:nonFraction unitRef="shares" contextRef="ie82b5c6e85e2408ab675d8ef44a98158_D20220101-20221231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzExNA_f8855d32-61bf-435e-9bf6-e7a6e4bd8813">4</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i42a690cfa922477e90e45bfe9cff5f29_D20210101-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzExOA_fa535aaf-6e0f-437f-992f-2e061af3a345">7</ix:nonFraction>&#160;million, and <ix:nonFraction unitRef="shares" contextRef="i0842c61fceff4047b49c7ff6a4a293a7_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzEyNg_8b5f940d-4e36-491e-8063-b1ecbac8e2fc">15</ix:nonFraction>&#160;million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share for the years ended December&#160;31, 2022, 2021 and 2020, respectively, because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzU3NA_332da34a-9ac8-49b3-b1a8-393709e1758c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions,&#160;except&#160;per&#160;share&#160;amounts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzItMS0xLTEtMTY3OTA4_18e1c5d3-ac2b-405d-9c12-878ab7111207">4,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzItMy0xLTEtMTY3OTA4_5bd267c4-77aa-4034-b029-72ddc823e2b9">7,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzItNS0xLTEtMTY3OTA4_aace3cda-1d66-48c3-85c5-66a73c8111ca">7,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzQtMS0xLTEtMTY3OTA4_0087ed16-f0b0-40ff-bea1-43dfccd75161">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzQtMy0xLTEtMTY3OTA4_e6798578-c62f-4f7f-b31f-bda80b066ade">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzQtNS0xLTEtMTY3OTA4_186165f7-e212-4d1e-ba33-7abe46f1f347">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to CVS Health</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzUtMS0xLTEtMTY3OTA4_629cabdb-4f43-4604-94b7-2fbbe728847d">4,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzUtMy0xLTEtMTY3OTA4_3e976533-b362-4fc9-85db-a00b33960beb">7,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzUtNS0xLTEtMTY3OTA4_5cc297f3-7b13-4225-b96e-d7ea826f50a5">7,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzgtMS0xLTEtMTY3OTA4_69afecf8-2c92-41ea-954a-b3ac18270135">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzgtMy0xLTEtMTY3OTA4_20d3c409-9529-43cb-972b-5de40e9a3982">1,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzgtNS0xLTEtMTY3OTA4_daaad5f3-3c44-46de-84c9-fdbcfef9c838">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units and performance stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc14f04c8d094020a89b8124e4d67afd_D20220101-20221231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktMS0xLTEtMjAwMjA3_b7228abd-9bb8-4230-bfeb-bf047409d99b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic36f054975aa46feb063b56007b02a5c_D20210101-20211231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktMy0xLTEtMjAwMTEw_c7a7eda5-c5ec-4780-ae00-22ca83ac618c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf686621016a49b4a70be7291894b149_D20200101-20201231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktNS0xLTEtMjAwMTIy_be31414e-d658-427d-8e08-7102ea429ad2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and SARs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie82b5c6e85e2408ab675d8ef44a98158_D20220101-20221231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktMS0xLTEtMTY3OTA4_618d5bc8-ba99-406b-84e2-8881879a5070">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42a690cfa922477e90e45bfe9cff5f29_D20210101-20211231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktMy0xLTEtMTY3OTA4_8123485f-fa8f-405b-96ff-0613d23cb6b0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0842c61fceff4047b49c7ff6a4a293a7_D20200101-20201231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktNS0xLTEtMTY3OTA4_f60d3bf3-05d7-4cb8-912e-54fccfc67645">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEwLTEtMS0xLTE2NzkwOA_689e7e1d-7ba7-494d-9791-17e5e5a375a0">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEwLTMtMS0xLTE2NzkwOA_75fdec06-9847-46bb-a5a8-3222dd3cfccf">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEwLTUtMS0xLTE2NzkwOA_65709379-3da3-4358-a9c4-8f5e9d8d48d6">1,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share from continuing operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEzLTEtMS0xLTE2NzkwOA_2af0e80e-bb25-4126-96b7-f5bc9c5d9fc4">3.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEzLTMtMS0xLTE2NzkwOA_6429b5e9-c836-40ff-b67e-d453d59ab93b">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEzLTUtMS0xLTE2NzkwOA_2575dd51-e664-4ab0-93f2-c15f470aeb05">5.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzE0LTEtMS0xLTE2NzkwOA_6764d1d1-011b-4370-80f6-9ef991bec0fc">3.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzE0LTMtMS0xLTE2NzkwOA_9e42b177-a1fd-4d30-9a90-5148839ee8dd">5.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzE0LTUtMS0xLTE2NzkwOA_60db5555-33cd-465c-9ac3-8d5691776f72">5.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_166"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ReinsuranceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIwOTk_cb0d9384-298a-4708-a6e9-29e203bd9524" continuedAt="idebda9a6a6e14af1af9041ad0a07a0fc" escape="true">Reinsurance</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idebda9a6a6e14af1af9041ad0a07a0fc" continuedAt="i511ce397deb046c0ba76de232ec8b4a9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company&#8217;s primary liability as the direct insurer of the risks reinsured.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company entered into <ix:nonFraction unitRef="reinsurance_agreement" contextRef="i2e2b473c47f6447294d190668407b467_D20230101-20230131" decimals="INF" name="cvs:NumberofReinsuranceContractsEnteredInto" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzkxMg_0e826903-4a68-4da0-a036-d1f86d366ccc">two</ix:nonFraction> <ix:nonNumeric contextRef="i2e2b473c47f6447294d190668407b467_D20230101-20230131" name="cvs:FourYearsReinsuranceAgreementWithUnrelatedInsurer" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIxMTA_aa9fbf65-3204-40bc-82e6-ebb4b9432364">four-year</ix:nonNumeric> reinsurance agreements with an unrelated reinsurer that allow it to reduce required capital and provide collateralized excess of loss reinsurance coverage on a portion of the Health Care Benefits segment&#8217;s group Commercial Insured business.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIxMDk_5c14da3b-c6a9-41c5-a014-29001b57f5d4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reinsurer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hartford Life and Accident Insurance Company</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae0c3b0cc27418aa65414f0b7e927c7_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzItMS0xLTEtMTY3OTA4_2afe6b52-4103-4958-a015-e278696173de">1,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic60de804b23546b8a91437fbf72dc2da_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzItMy0xLTEtMTY3OTA4_3f671b28-171b-49c6-b107-15b5c2914194">1,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Life &amp; Annuity Company of New York</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf72aa41b4d449d0a2ac299a8c83a884_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzMtMS0xLTEtMTY3OTA4_d77f10a0-fd91-4de8-8b4b-e4b4cf04d081">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b933e2ca792484e85ec73f2fc18e41a_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzMtMy0xLTEtMTY3OTA4_ad5ce061-c54e-4e94-ae92-d3503a401ad5">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOYA Retirement Insurance and Annuity Company </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81da46ae9e64349a9aa6e17d4d8c486_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzQtMS0xLTEtMTY3OTA4_a81f327c-1fff-47d0-849e-a3c54390e06f">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f47abf8fc3f40f983bcf19e1da82db5_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzQtMy0xLTEtMTY3OTA4_fe82e499-a17d-4830-974a-be913ede55f5">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fresenius Medical Care Reinsurance Company (Cayman) Ltd. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad53a23fba3447a8ca121fa57cf7591_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzUtMS0xLTEtMjIxOTgy_b498744c-1b91-42fd-ae0e-39a2b2bde761">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde18ae73cba460eb19c034e2419cf09_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzUtMy0xLTEtMjIxOTgy_440b62c1-820e-4b89-bd36-81c387aaca3f">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9822742126ab4315872808cfba42b81c_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzUtMS0xLTEtMTY3OTA4_225e0640-187a-4fdf-8be7-d2e4b118d294">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80e156bb7874df1abefdc699fdc0426_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzUtMy0xLTEtMTY3OTA4_e9dd358b-2c6c-4256-92be-ac0727687bde">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzYtMS0xLTEtMTY3OTA4_360b37dd-7cbd-4dc0-ab9f-3807962900f1">2,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzYtMy0xLTEtMTY3OTA4_cc02478b-01e0-430b-98db-bae542f63778">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i511ce397deb046c0ba76de232ec8b4a9"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIxMDI_a041f572-3f38-40b9-894e-0d6f8ad0b3a4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzEtMS0xLTEtMTY3OTA4_290623b1-cb2e-47ba-aa59-168e1b0c8eda">85,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzEtMy0xLTEtMTY3OTA4_e75317f3-cd1a-45a9-bc39-660c3785728b">76,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzEtNS0xLTEtMTY3OTA4_40f72871-d6ea-4931-b456-9b917d56edad">69,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:AssumedPremiumsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzItMS0xLTEtMTY3OTA4_0601ad14-fcf2-4d09-8b16-f9d030176401">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:AssumedPremiumsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzItMy0xLTEtMTY3OTA4_f63cb0e1-bddd-45d3-b46a-fffe668f0563">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:AssumedPremiumsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzItNS0xLTEtMTY3OTA4_c0ed8b37-0aaa-4a3b-98db-1a14fdfb8e67">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzMtMS0xLTEtMTY3OTA4_b4c6cadf-fd2a-44b7-b4f6-7f9065aa3664">772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzMtMy0xLTEtMTY3OTA4_26929ceb-8a9a-4262-b9c9-716afbf836b2">680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzMtNS0xLTEtMTY3OTA4_5be54b7a-bbdc-4acd-87b1-99e7de4b1f27">825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzQtMS0xLTEtMTY3OTA4_0e0d7fb5-fac8-4824-9c56-ded0fbd276a7">85,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzQtMy0xLTEtMTY3OTA4_db3e870b-8d21-4a30-8a9f-69cd53bcb354">76,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzQtNS0xLTEtMTY3OTA4_7fcbb260-6d2e-4dc5-b064-75a0b82d926f">69,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:EffectsOfReinsuranceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIxMDY_1f45e1fe-0bb6-45ef-b8a1-fcadc2d33386" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of reinsurance on benefit costs for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzEtMS0xLTEtMTY3OTA4_d1c43128-dd42-4539-9c4e-e717317f920b">71,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzEtMy0xLTEtMTY3OTA4_cadca1a3-9801-453b-a615-7f80ff332bf9">64,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzEtNS0xLTEtMTY3OTA4_3f306e47-99a4-4f4e-8c1c-091b59655c5d">56,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzItMS0xLTEtMTY3OTA4_5789831c-e47b-4a4b-a498-0ad8d141dcb5">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzItMy0xLTEtMTY3OTA4_c9a2ecba-d017-4eda-8edf-7233b63ac09a">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzItNS0xLTEtMTY3OTA4_438ce59a-7c3a-46c1-afc5-7e5583ccfdab">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzMtMS0xLTEtMTY3OTA4_5f458d85-a325-4d22-ad74-4a6c1f0f6ca4">665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzMtMy0xLTEtMTY3OTA4_08592fdc-5ac8-4e80-bc0a-737057eafb0e">552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzMtNS0xLTEtMTY3OTA4_41353221-6844-4c7a-ac38-bfc7b5ea2513">727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net benefit costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzQtMS0xLTEtMTY3OTA4_27b0395f-fbdd-4202-a896-b2960ac5e0a0">71,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzQtMy0xLTEtMTY3OTA4_777b0e59-cbb7-4c96-8d2c-4ded9bb57908">64,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzQtNS0xLTEtMTY3OTA4_97859ad9-6de0-47db-aba0-664cf26d40ca">55,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is not a material difference between premiums on a written basis versus an earned basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various agreements with unrelated reinsurers that do not qualify for reinsurance accounting under GAAP, and consequently are accounted for using deposit accounting. The Company entered into these contracts to reduce the risk of catastrophic loss which in turn reduces the Company&#8217;s capital and surplus requirements. Total deposit assets and liabilities related to reinsurance agreements that do not qualify for reinsurance accounting under GAAP were not material as of December&#160;31, 2022 or 2021.</span></div></ix:continuation><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_169"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTIxMjQ_eb9acffa-130d-4072-b2d7-8de923ca357c" continuedAt="ib5e5d301531545f1b77ffdf5d9a1af8f" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib5e5d301531545f1b77ffdf5d9a1af8f" continuedAt="idb8487d8200f47b09e99b99a51608ed5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The Company believes COVID-19&#8217;s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic&#8217;s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company&#8217;s knowledge and control. As a result, the impact COVID-19 will have on the Company&#8217;s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following significant guarantee arrangements at December&#160;31, 2022:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ASC Claim Funding Accounts - The Company has arrangements with certain banks for the processing of claim payments for its ASC customers. The banks maintain accounts to fund claims of the Company&#8217;s ASC customers. The customer is responsible for funding the amount paid by the bank each day. In these arrangements, the Company guarantees that the banks will not sustain losses if the responsible ASC customer does not properly fund its account. The aggregate maximum exposure under these arrangements is generally limited to $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzE1Mzc_115be952-87c1-4ff6-81c7-3cd083897199">250</ix:nonFraction> million. The Company can limit its exposure to these guarantees by suspending the payment of claims for ASC customers that have not adequately funded the amount paid by the bank. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Separate Accounts Assets - Certain Separate Accounts assets associated with the large case pensions business in the Corporate/Other segment represent funds maintained as a contractual requirement to fund specific pension annuities that the Company has guaranteed. Minimum contractual obligations underlying the guaranteed benefits in these Separate Accounts were approximately $<ix:nonFraction unitRef="usd" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="-6" name="cvs:ContractualObligationsToMaintainLevelsOfSeparateAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIwODk_e82273c8-d9c2-437e-82bd-d0fa4d08a5cc">941</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5b5114192110480ab4f260049ee8b103_I20211231" decimals="-8" name="cvs:ContractualObligationsToMaintainLevelsOfSeparateAccounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIwOTY_1150d26a-9fe8-4c39-a429-5deee4f21af6">1.3</ix:nonFraction> billion at December&#160;31, 2022 and 2021, respectively. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information on Separate Accounts. Contract holders assume all investment and mortality risk and are required to maintain Separate Accounts balances at or above a specified level. The level of required funds is a function of the risk underlying the Separate Account&#8217;s investment strategy. If contract holders do not maintain the required level of Separate Accounts assets to meet the annuity guarantees, the Company would establish an additional liability. Contract holders&#8217; balances in the Separate Accounts at December&#160;31, 2022 exceeded the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idb8487d8200f47b09e99b99a51608ed5" continuedAt="i98d2d548700640fb8f5f4d631e72de78"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of the guaranteed benefit obligation. As a result, the Company was not required to maintain any additional liability for its related guarantees at December&#160;31, 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Guarantees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1995 and 1997, the Company sold or spun off a number of subsidiaries, including Bob&#8217;s Stores and Linens &#8216;n Things, each of which subsequently filed for bankruptcy, and Marshalls. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the former subsidiary&#8217;s lease obligations for the initial lease term and any extension thereof pursuant to a renewal option provided for in the lease prior to the time of the disposition. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company&#8217;s guarantees remained in place, although each initial purchaser agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries fail to make the required payments under a store lease, the Company could be required to satisfy those obligations, and any significant adverse impact of COVID-19 on such purchasers and/or former subsidiaries increases the risk that the Company will be required to satisfy those obligations. As of December&#160;31, 2022, the Company guaranteed <ix:nonFraction unitRef="lease" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="INF" name="cvs:GuarantorObligationsNumberOfLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzM5NjA_d25fc9a3-12b4-4a21-b250-985488054631">67</ix:nonFraction> such store leases (excluding the lease guarantees related to Linens &#8216;n Things, which have been recorded as a liability on the consolidated balance sheets), with the maximum remaining lease term extending through 2034.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guaranty Fund Assessments, Market Stabilization and Other Non-Voluntary Risk Sharing Pools</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company&#8217;s assessments generally are based on a formula relating to the Company&#8217;s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payors such as not-for-profit consumer-governed health plans established under the ACA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, the Pennsylvania Insurance Commissioner placed long-term care insurer Penn Treaty Network America Insurance Company and one of its subsidiaries (collectively, &#8220;Penn Treaty&#8221;) in rehabilitation, an intermediate action before insolvency, and subsequently petitioned a state court to convert the rehabilitation into a liquidation. Penn Treaty was placed in liquidation in March 2017. The Company has recorded a liability for its estimated share of future assessments by applicable life and health insurance guaranty associations. It is reasonably possible that in the future the Company may record a liability and expense relating to other insolvencies which could have a material adverse effect on the Company&#8217;s operating results, financial condition and cash flows, and the risk is heightened by any significant adverse impact of the COVID-19 pandemic on the solvency of other insurers, including long-term care and life insurers. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HMOs in certain states in which the Company does business are subject to assessments, including market stabilization and other risk-sharing pools, for which the Company is assessed charges based on incurred claims, demographic membership mix and other factors. The Company establishes liabilities for these assessments based on applicable laws and regulations. In certain states, the ultimate assessments the Company pays are dependent upon the Company&#8217;s experience relative to other entities subject to the assessment, and the ultimate liability is not known at the financial statement date. While the ultimate amount of the assessment is dependent upon the experience of all pool participants, the Company believes it has adequate reserves to cover such assessments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s total guaranty fund assessments liability was immaterial at both December&#160;31, 2022 and 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been involved or is currently involved in numerous legal proceedings, including litigation, arbitration, government investigations, audits, reviews and claims. These include routine, regular and special investigations, audits and reviews by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CMS, state insurance and health and welfare departments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the U.S. Department of Justice (the &#8220;DOJ&#8221;), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state Attorneys General, the U.S. Drug Enforcement Administration (the &#8220;DEA&#8221;), the U.S. Federal Trade Commission (the &#8220;FTC&#8221;) and other governmental authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, and governmental special investigations, audits and reviews can be expensive and disruptive. Some of the litigation matters may purport or be determined </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i98d2d548700640fb8f5f4d631e72de78" continuedAt="icfa556b23661486286603daa2ff88cd8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. The Company also may be named from time to time in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions initiated by private third parties that could also be separately pursued by a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company does not establish an accrued liability. None of the Company&#8217;s accruals for outstanding legal matters are material individually or in the aggregate to the Company&#8217;s financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#8217;s financial position. Substantial unanticipated verdicts, fines and rulings, however, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or loss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations of proceedings could be material to the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Usual and Customary Pricing Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and certain current and former directors and officers are named as a defendant in a number of lawsuits that allege that the Company&#8217;s retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions are brought by a number of different types of plaintiffs, including plan members, private payors, government payors, and shareholders based on different legal theories. Some of these cases are brought as putative class actions, and in some instances, classes have been certified. In October 2022, one of the litigating shareholders made a litigation demand to the Board related to these and other issues after his amended derivative complaint was dismissed for failing to demonstrate demand futility. The Company is defending itself against these claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PBM Litigation and Investigations</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is facing multiple lawsuits, including by state Attorneys General, governmental subdivisions and several putative class actions, regarding drug pricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal theories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The Company is defending itself against these claims. The Company has also received subpoenas, civil investigative demands (&#8220;CIDs&#8221;), and other requests for documents and information from, and is being investigated by, the FTC and Attorneys General of several states and the District of Columbia regarding its PBM practices, including pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs, and requests for information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States ex rel. Behnke v. CVS Caremark Corporation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al. (U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court unsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused to be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true prices paid by the Company&#8217;s PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company&#8217;s PBM. The Company is defending itself against these claims.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icfa556b23661486286603daa2ff88cd8" continuedAt="ib3fc77961ef04ac6baedc3cc9df52dd6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Substances Litigation, Audits and Subpoenas</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against various defendants by plaintiffs such as counties, cities, hospitals, Indian tribes and third-party payors, alleging claims beginning as far back as the early 2000s generally concerning the impacts of widespread prescription opioid abuse. The consolidated multidistrict litigation captioned In re National Prescription Opiate Litigation (MDL No. 2804) is pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes hundreds of relevant federal court cases that name the Company as a defendant. A significant number of similar cases that name the Company as a defendant in some capacity are pending in state courts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has been named as a defendant in similar cases brought by certain state Attorneys General. The Company is defending itself against all such claims. Additionally, the Company has received subpoenas, CIDs, and/or other requests for information regarding opioids from state Attorneys General and insurance and other regulators of several U.S. jurisdictions. The Company has been cooperating with the government with respect to these subpoenas, CIDs, and other requests for information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company was among the chain pharmacies found liable by a jury in a trial in federal court in Ohio; in August 2022, the court issued a judgment jointly against the three defendants in the amount of $<ix:nonFraction unitRef="usd" contextRef="ib94af6bb921a4ca98da673595b30f6b8_D20220801-20220831" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5MDM_f0912149-13ae-4546-8fe0-4ac99ed1e3a3">651</ix:nonFraction>&#160;million to be paid over <ix:nonNumeric contextRef="i674238d29a96415e993c632fa76902ca_I20220831" name="cvs:LegalSettlementPeriodOfPayment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5MjU_ccaf666b-4ae5-4176-a035-0f6c1c2464e1">15</ix:nonNumeric> years, and also ordered certain injunctive relief. The Company is appealing the judgment and has not accrued a liability for this matter. In March 2022, CVS Health Corporation and CVS Pharmacy, Inc. entered into a settlement agreement with the State of Florida to resolve claims related to opioid medications dating back more than a decade. Under the terms of the settlement agreement, CVS Health Corporation settled all opioid claims against it and its subsidiaries by the State of Florida for $<ix:nonFraction unitRef="usd" contextRef="i3c90b72fd40546a18c44fdd0f007e70d_D20220301-20220331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5NDA_2b491511-8454-4f41-b915-49e1055dcdef">484</ix:nonFraction>&#160;million, which is to be paid over a period of <ix:nonNumeric contextRef="i5f7c5a81f337450ca2ce09d3e8db9ce6_I20220331" name="cvs:LegalSettlementPeriodOfPayment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5ODk_ee3782e1-59c0-4543-a3fd-ee692d98ec3a">18</ix:nonNumeric> years. During the three months ended March 31, 2022, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i5f7c5a81f337450ca2ce09d3e8db9ce6_I20220331" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5Njc_11d3d0cb-ea9b-4579-8224-852419b703f8">484</ix:nonFraction>&#160;million liability associated with this legal settlement. In August 2022, CVS Pharmacy, Inc. entered into an agreement with the State of New Mexico to settle all opioid claims against it and its parents and subsidiaries by the State of New Mexico and participating subdivisions. In September 2022, CVS Pharmacy, Inc. entered into an agreement with the State of West Virginia to settle all opioid claims against it and its parents and subsidiaries by the State of West Virginia and participating subdivisions. Also in September 2022, CVS Pharmacy, Inc. entered into an agreement with the Cherokee Nation to settle all opioid claims against it and its parents and subsidiaries by the Cherokee Nation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company agreed to a formal settlement agreement, the financial amounts of which were agreed to in principle in October 2022, with a leadership group of a number of state Attorneys General and the Plaintiffs&#8217; Executive Committee (&#8220;PEC&#8221;). The agreement would resolve substantially all opioid claims against Company entities by states and political subdivisions, but not private plaintiffs. The maximum amount payable by the Company under the settlement would be approximately $<ix:nonFraction unitRef="usd" contextRef="i2fce56acdb3745c9979b048ae472c0b0_D20221201-20221231" decimals="-8" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4MDI_6eaaff43-6d37-4e7f-95ca-0db6189711b4">4.3</ix:nonFraction>&#160;billion in opioid remediation and $<ix:nonFraction unitRef="usd" contextRef="i2fce56acdb3745c9979b048ae472c0b0_D20221201-20221231" decimals="-6" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4MTY_b92a3bf1-1390-4f42-9a05-d8e1d1f83ca6">625</ix:nonFraction>&#160;million in attorneys&#8217; fees and costs and additional remediation. The amounts would be payable over <ix:nonNumeric contextRef="i5a63bb22a404440f94e6605a0d60ed27_I20221231" name="cvs:LegalSettlementPeriodOfPayment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4Mjk_20eeecca-54ce-4726-861e-6add18feb41b">10</ix:nonNumeric> years, beginning in 2023. The agreement also contains injunctive terms relating to the dispensing of opioid medications. The settlement agreement is available at nationalopioidsettlement.com.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the settlement agreement, before the Company determines whether to enter into any final settlement, it will assess the number and identities of the governmental entities that will participate in any such settlement. The settlement agreement contemplates that if certain governmental entities do not agree to the settlement, but the Company nonetheless concludes that there is sufficient participation to warrant going forward with the settlement, there would be a corresponding reduction in the amount due from the Company to account for the governmental entities that did not agree. Those non-participating governmental entities would be entitled to pursue their claims against the Company and other defendants. Private plaintiff litigation will also continue.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been informed that <ix:nonFraction unitRef="state" contextRef="i5a63bb22a404440f94e6605a0d60ed27_I20221231" decimals="0" name="cvs:LitigationSettlementNumberOfStatesElectedToJoin" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTIxMjA_f01f6b9b-b4f9-4aa7-9640-1c9efed26533">45</ix:nonFraction> states, the District of Columbia, and all eligible United States territories have elected to join the settlement. <ix:nonFraction unitRef="state" contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231" decimals="0" name="cvs:LitigationSettlementNumberOfStatesSubjectToEarlierSettlements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTIxMjM_4ab64207-1119-4a82-b61e-fc0cc158a761">Three</ix:nonFraction> states were the subject of earlier settlements. The Company has elected to proceed with the settlement process based on that level of participation. The settlement process will progress to the period during which subdivisions may elect to join.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company also agreed to a formal settlement agreement with a leadership group representing tribes throughout the United States. The agreement would resolve substantially all opioid claims against Company entities by such tribes. The maximum amount payable by the Company under the settlement would be $<ix:nonFraction unitRef="usd" contextRef="i57858d852b8743a5b17a414d3e2943ec_D20221201-20221231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4MzE_c5d40c4a-a78f-48df-b3a9-6f8defe11894">113</ix:nonFraction>&#160;million in opioid remediation and $<ix:nonFraction unitRef="usd" contextRef="i57858d852b8743a5b17a414d3e2943ec_D20221201-20221231" decimals="-6" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4NDc_988cc5c9-6c26-4ab0-a047-b6dea3fc3ba3">18</ix:nonFraction>&#160;million in attorneys&#8217; fees and costs. The amounts would be payable over <ix:nonNumeric contextRef="i0b86d678e65d40eb8ee5c07845a9969a_I20221231" name="cvs:LegalSettlementPeriodOfPayment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4NTk_7311b880-32e8-4876-951e-1707e34164e1">10</ix:nonNumeric> years, beginning in 2023. The agreement is contingent upon sufficient participation by tribes.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib3fc77961ef04ac6baedc3cc9df52dd6" continuedAt="i59ca4983eec44814b450c4addbb77bac"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that settlement of opioid claims by governmental entities and tribes is probable, and the loss related thereto could be reasonably estimated. As a result of that conclusion, and its assessment of certain other opioid-related claims including those for which the Company reached agreement in August and September 2022, the Company recorded pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="ibaf08dadd0964ffeadc4c69adb91d80b_D20220701-20220930" decimals="-8" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTMwOTY_03dfe1e5-e4e2-40e5-ac2a-9119034797b7">5.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i636ddceefabd4069a95a70b2bdaf5197_D20221001-20221231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzEyNjQ0MzgzNzY0OTgy_cd5b8faf-030f-4f4f-ad8e-ff505893a8ef">99</ix:nonFraction> million during the three months ended September 30, 2022 and the three months ended December&#160;31, 2022, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i7962defddb614936891d31be39fb3eac_I20221231" decimals="-8" name="us-gaap:LossContingencyAccrualCarryingValueNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTI3MzA_67c6248c-51cb-47ef-b969-d67e9f4755b3">4.8</ix:nonFraction>&#160;billion was recorded in other long-term liabilities on the consolidated balance sheet. In addition, the Company expects the cash impact in 2023 and 2024 to be less than $<ix:nonFraction unitRef="usd" contextRef="i8f3002f09a51435f89d2352f78379bf9_D20230101-20231231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTMxMjM_083750e5-37a9-4367-90d8-910285d1ccf8"><ix:nonFraction unitRef="usd" contextRef="i9fe8dd796c0b4f6ea8bd03f8afa02daa_D20240101-20241231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTMxMjM_e85145bb-4500-4168-9e14-28632fbe3e9d">500</ix:nonFraction></ix:nonFraction>&#160;million in each year. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment requires judgments about future events. Moreover, the settlement is in its early phases, and there is no assurance that contingencies will be satisfied. The amount of ultimate loss may differ materially from this accrual.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the many uncertainties associated with any settlement arrangement or other resolution of all opioid-related litigation matters, including the uncertain scope of participation by governmental entities, and given that the Company continues to actively defend ongoing litigation for which it believes it has defenses and assertions that have merit, the Company is not able to reasonably estimate the range of ultimate possible loss for all opioid-related litigation matters at this time. The outcome of these legal matters could have a material effect on the Company&#8217;s business, financial condition, operating results and/or cash flows.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the DOJ served the Company with a DEA administrative subpoena. The subpoena seeks documents relating to practices with respect to prescription opioids and other controlled substances at CVS pharmacy locations concerning potential violations of the federal Controlled Substances Act and the federal False Claims Act. In January 2022, the DOJ served the Company with a CID regarding similar subjects, and the Company is providing documents and information in response to these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prescription Processing Litigation and Investigations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its prescription processing practices, including the following:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ex rel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Bassan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> v. Omnicare, Inc. and CVS Health Corp. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. District Court for the Southern District of New York). In December 2019, the U.S. Attorney&#8217;s Office for the Southern District of New York (the &#8220;SDNY&#8221;) filed a complaint-in-intervention in this previously sealed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. The complaint alleges that for certain non-skilled nursing facilities, Omnicare improperly filled prescriptions beyond one year where a valid prescription did not exist and that these dispensing events violated the federal False Claims Act. The Company is defending itself against these claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Gill et al. v. CVS Health Corp. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. District Court for the Northern District of Illinois). In July 2022, the Delaware Attorney General&#8217;s Office moved for partial intervention as to allegations under the Delaware false claims act related to not escheating alleged overpayments in this previously sealed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. The federal government and the remaining states declined to intervene on other additional theories in the relator&#8217;s complaint. The Company is defending itself against all of the claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Company also received a subpoena from the California Department of Insurance requesting documents concerning the Company&#8217;s Omnicare pharmacies&#8217; cycle fill process for assisted living facilities. The Company has been cooperating with the California Department of Insurance and providing documents and information in response to this subpoena.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company received a CID from the U.S. Attorney&#8217;s Office for the Northern District of New York requesting documents and information in connection with a federal False Claims Act investigation concerning whether the Company&#8217;s retail pharmacies improperly submitted certain insulin claims to Part D of the Medicare program rather than Part B of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to this CID.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provider Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is named as a defendant in purported class actions and individual lawsuits arising out of its practices related to the payment of claims for services rendered to its members by providers with whom the Company has a contract and with whom the Company does not have a contract (&#8220;out-of-network providers&#8221;).&#160;Among other things, these lawsuits allege that the Company paid too little to its health plan members and/or providers for out-of-network services (including COVID-19 testing) and/or otherwise allege that the Company failed to timely or appropriately pay or administer claims and benefits (including the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i59ca4983eec44814b450c4addbb77bac" continuedAt="if55ec05698a048cb8cd72549fd81de05"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s post payment audit and collection practices). Other major health insurers are the subject of similar litigation or have settled similar litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has received subpoenas and/or requests for documents and other information from, and been investigated by, state Attorneys General and other state and/or federal regulators, legislators and agencies relating to, and the Company is involved in other litigation regarding, its out-of-network benefit payment and administration practices. It is reasonably possible that others could initiate additional litigation or additional regulatory action against the Company with respect to its out-of-network benefit payment and/or administration practices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CMS Actions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS regularly audits the Company&#8217;s performance to determine its compliance with CMS&#8217;s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare beneficiaries. CMS uses various payment mechanisms to allocate and adjust premium payments to the Company&#8217;s and other companies&#8217; Medicare plans by considering the applicable health status of Medicare members as supported by information prepared, maintained and provided by providers. The Company collects claim and encounter data from providers and generally relies on providers to appropriately code their submissions to the Company and document their medical records, including the diagnosis data submitted to the Company with claims. CMS pays increased premiums to Medicare Advantage plans and Medicare PDP plans for members who have certain medical conditions identified with specific diagnosis codes. Federal regulators review and audit the providers&#8217; medical records to determine whether those records support the related diagnosis codes that determine the members&#8217; health status and the resulting risk-adjusted premium payments to the Company. In that regard, CMS has instituted risk adjustment data validation (&#8220;RADV&#8221;) audits of various Medicare Advantage plans, including certain of the Company&#8217;s plans, to validate coding practices and supporting medical record documentation maintained by providers and the resulting risk-adjusted premium payments to the plans. CMS may require the Company to refund premium payments if the Company&#8217;s risk-adjusted premiums are not properly supported by medical record data. The Office of the Inspector General of the HHS (the &#8220;OIG&#8221;) also is auditing the Company&#8217;s risk adjustment-related data and that of other companies. The Company expects CMS and the OIG to continue these types of audits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, in the &#8220;Notice of Final Payment Error Calculation for Part C Medicare Advantage Risk Adjustment Validation Data (RADV) Contract-Level Audits,&#8221; CMS revised its audit methodology for RADV contract-level audits to determine refunds payable by Medicare Advantage plans for contract year 2011 and forward. Under the revised methodology, among other things, CMS announced extrapolation of the error rate identified in the audit sample along with the application of a process to account for errors in the government&#8217;s traditional fee-for-service Medicare program (&#8220;FFS Adjuster&#8221;). For contract years prior to 2011, CMS did not extrapolate sample error rates to the entire contract, nor did CMS propose to apply a FFS adjuster. By applying the FFS Adjuster, Medicare Advantage organizations would have been liable for repayments only to the extent that their extrapolated payment errors exceeded the error rate in Original Medicare, which could have impacted the extrapolated repayments to which Medicare Advantage organizations are subject. This revised contract-level audit methodology increased the Company&#8217;s exposure to premium refunds to CMS based on incomplete medical records maintained by providers. In the RADV audit methodology CMS used from 2011-2013, CMS selected only a few of the Company&#8217;s Medicare Advantage contracts for various contract years for contract-level RADV audits. In October 2018, CMS in the proposed rule (&#8220;Proposed Rule&#8221;) announced a new methodology for RADV audits targeting certain health conditions and members with many diagnostic conditions along with extrapolation for the error rates identified without use of a FFS Adjuster. While the rule was under proposal, CMS initiated contract-level RADV audits for the years 2014 and 2015 with this new RADV methodology without a final rule. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2023, CMS released the final rule (&#8220;RADV Audit Rule&#8221;), announcing it may use extrapolation for payment years 2018 forward, for both RADV audits and OIG audits and eliminated the application of a FFS Adjuster in Part C contract-level RADV audits of Medicare Advantage organizations. In the RADV Audit Rule, CMS indicated that it will use more than one audit methodology going forward and indicated CMS will audit contracts it believes are at the highest risk for overpayments based on its statistical modeling, citing a 2016 Governmental Accountability Office report that recommended selection of contract-level RADV audits with a focus on contracts likely to have high rates of improper payment, the highest coding intensity scores, and contracts with high levels of unsupported diagnoses from prior RADV audits.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently unable to predict which of its Medicare Advantage contracts will be selected for future audit, the amounts of any retroactive refunds for years prior to 2018 or prospective adjustments to Medicare Advantage premium payments made to the Company, the effect of any such refunds or adjustments on the actuarial soundness of the Company&#8217;s Medicare Advantage bids, or whether any RADV audit findings would require the Company to change its method of estimating future premium revenue in future bid submissions to CMS or compromise premium assumptions made in the Company&#8217;s bids </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if55ec05698a048cb8cd72549fd81de05" continuedAt="i5c624c2fe6224bd2b24a79f53c7dae11"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for prior contract years, the current contract year or future contract years. Any premium or fee refunds or adjustments resulting from regulatory audits, whether as a result of RADV, Public Exchange related or other audits by CMS, the OIG or otherwise, including audits of the Company&#8217;s MLR rebates, methodology and/or reports, could be material and could adversely affect the Company&#8217;s operating results, cash flows and/or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RADV Audit Rule does not apply to the CMS Part C Improper Payment Measures audits nor the HHS-RADV programs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare and Medicaid CIDs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received CIDs from the Civil Division of the DOJ in connection with a current investigation of the Company&#8217;s patient chart review processes related to risk adjustment data submissions under Parts C and D of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to these CIDs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company received a CID from the SDNY requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company&#8217;s LTC business unit. The Company and its current and former officers and directors are defending themselves against these claims. Since filing, several of the cases have been consolidated, and the first-filed federal case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">City of Miami Fire Fighters&#8217; and Police Officers&#8217; Retirement Trust, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al. (formerly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anarkat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), was dismissed with prejudice in February 2021. Plaintiffs appealed that decision to the First Circuit after their motion for reconsideration was denied, and in August 2022 the First Circuit affirmed the dismissal. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re CVS Health Corp. Securities Act Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (formerly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waterford</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re CVS Health Corp. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (formerly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">City of Warren</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Freundlich</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) have been stayed pending the outcome of the First Circuit appeal. Plaintiffs in both cases have since filed amended complaints, which the Company has moved to dismiss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August and September 2020, <ix:nonFraction unitRef="claim" contextRef="i3a4ebb735c614e6f82dbc3e891377121_I20200930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIzNjY5_414de537-90b7-434f-8685-1a5253145d6f">two</ix:nonFraction> class actions under the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;) were filed in the U.S. District Court for the District of Connecticut against CVS Health, Aetna, and several current and former executives, directors and/or members of Aetna&#8217;s Compensation and Talent Management Committee: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Radcliffe v. Aetna Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flaim v. Aetna Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al. The plaintiffs in these cases assert a variety of causes of action premised on allegations that the defendants breached fiduciary duties and engaged in prohibited transactions relating to participants in the Aetna 401(k) Plan&#8217;s investment in company stock between December 3, 2017 and February 20, 2019, claiming losses related to the performance of the Company&#8217;s LTC business unit. The district court consolidated the actions, and in October 2021, dismissed the consolidated action without prejudice. Plaintiffs filed an amended consolidated complaint, which the Company moved to dismiss. In October 2022, the court granted the Company&#8217;s motion to dismiss with prejudice. Plaintiffs have appealed this decision to the Second Circuit.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also received a related document request pursuant to ERISA &#167; 104(b), to which the Company has responded. The Company and its current and former officers and directors are defending themselves against these claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received a demand for inspection of books and records pursuant to Delaware Corporation Law Section 220 (the &#8220;Demand&#8221;). The Demand purports to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Legal and Regulatory Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a party to other legal proceedings and is subject to government investigations, inquiries and audits and has received and is cooperating with the government in response to CIDs, subpoenas, or similar process from various governmental agencies requesting information. These other legal proceedings and government actions include claims of or relating to bad faith, medical or professional malpractice, breach of fiduciary duty, claims processing, dispensing of medications, non-compliance with state and federal regulatory regimes, marketing misconduct, denial of or failure to timely or appropriately pay or administer claims and benefits, provider network structure (including the use of performance-based networks and termination of provider contracts), rescission of insurance coverage, improper disclosure or use of personal information, anticompetitive practices, general contractual matters, product liability, intellectual property litigation, and employment litigation. Some of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5c624c2fe6224bd2b24a79f53c7dae11"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these other legal proceedings are or are purported to be class actions or derivative claims. The Company is defending itself against the claims brought in these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards to the Company and others of certain government contracts, particularly Medicaid contracts and other contracts with government customers in the Company&#8217;s Health Care Benefits segment, frequently are subject to protests by unsuccessful bidders. These protests may result in awards to the Company being reversed, delayed, or modified. The loss or delay in implementation of any government contract could adversely affect the Company&#8217;s operating results. The Company will continue to defend contract awards it receives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be a heightened level of review and/or audit by regulatory authorities and legislators of, and increased litigation regarding, the Company&#8217;s and the rest of the health care and related benefits industry&#8217;s business and reporting practices, including premium rate increases, utilization management, development and application of medical policies, complaint, grievance and appeal processing, information privacy, provider network structure (including provider network adequacy, the use of performance-based networks and termination of provider contracts), provider directory accuracy, calculation of minimum medical loss ratios and/or payment of related rebates, delegated arrangements, rescission of insurance coverage, limited benefit health products, student health products, pharmacy benefit management practices (including manufacturers&#8217; rebates, pricing, the use of narrow networks and the placement of drugs in formulary tiers), sales practices, customer service practices, vendor oversight, and claim payment practices (including payments to out-of-network providers).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a leading national health solutions company, the Company regularly is the subject of government actions of the types described above. These government actions may prevent or delay the Company from implementing planned premium rate increases and may result, and have resulted, in restrictions on the Company&#8217;s businesses, changes to or clarifications of the Company&#8217;s business practices, retroactive adjustments to premiums, refunds or other payments to members, beneficiaries, states or the federal government, withholding of premium payments to the Company by government agencies,&#160;assessments of damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company can give no assurance that its businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i)&#160;future enactment of new health care or other laws or regulations; (ii)&#160;the interpretation or application of existing laws or regulations as they may relate to one or more of the Company&#8217;s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iii)&#160;pending or future federal or state government investigations of one or more of the Company&#8217;s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iv)&#160;pending or future government audits, investigations or enforcement actions against the Company; (v)&#160;adverse developments in any pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit against the Company, whether sealed or unsealed, or in any future </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit that may be filed against the Company; or (vi)&#160;adverse developments in pending or future legal proceedings against the Company or affecting one or more of the industries in which the Company competes and/or the health care industry generally.</span></div></ix:continuation><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_172"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzc1NTg_388ea5f9-2139-4d90-bfc2-a0f52384d389" continuedAt="ia367df3a40ae480294c8f2d153770d0e" escape="true">Segment Reporting</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia367df3a40ae480294c8f2d153770d0e" continuedAt="ib4a295f4b7be4d6090a7fee68892365c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzQx_8c786a14-e49f-4e8b-88ed-abaee5bead3c">three</ix:nonFraction> operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company&#8217;s segments maintain separate financial information, and the Company&#8217;s chief operating decision maker (the &#8220;CODM&#8221;) evaluates the segments&#8217; operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company&#8217;s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company&#8217;s business nor reflect the Company&#8217;s underlying business performance. See the reconciliation of consolidated operating income (GAAP measure) to consolidated adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company&#8217;s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.</span></div><div><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, revenues from the federal government accounted for <ix:nonFraction unitRef="number" contextRef="iaeb70648911a491891b5b5b40830d2fe_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzE1NzY_38c1526b-1c94-4054-bc0e-5323b95c1f8a">18</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i3a7e1c1a8e154045870fe18d7ed128a2_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzE1ODA_77456349-8cab-4c89-b4c9-89fca10f80ba">17</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="idd64cbb3284d45b6bf1aa429308ea5b6_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzE1ODc_20b7d2d0-980a-4174-bf69-5b14f7310d49">16</ix:nonFraction>%, respectively, of the Company&#8217;s consolidated total revenues, primarily related to contracts with CMS for coverage of Medicare-eligible individuals within the Health Care Benefits segment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ib4a295f4b7be4d6090a7fee68892365c" continuedAt="i76f8e40220ea441a8640cd0528b9e666"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of financial measures of the Company&#8217;s segments to the consolidated totals:</span></div><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzc1NTk_5d35aba7-92b9-43af-a73e-38eca4e1ccf1" escape="true"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.003%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy&#160;<br/>Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eliminations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItMS0xLTEtMTY3OTA4_efcacc5e-7c9e-4a19-b322-5f0b02316c2b">90,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItMy0xLTEtMTY3OTA4_095a9fa6-2c20-452b-be04-0c90039795c2">157,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItNS0xLTEtMTY3OTA4_174b76c6-cab5-45f6-8e69-ac9f37f0faee">72,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItNy0xLTEtMTY3OTA4_6317208b-a42c-4911-8c44-7ed1187edc42">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItMTEtMS0xLTE2NzkwOA_06d1e9d7-5208-4f87-96f9-5a6252c0cda6">321,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aff3de0cc7c488a8aaa1c33fd802ab1_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzMtMS0xLTEtMTY3OTA4_402bd981-f392-4d08-95f9-0a7e65b36ace">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14525e9b549048f4b399842e4567a558_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzMtMy0xLTEtMTY3OTA4_9d4813e3-5677-4e4e-b5c6-32ac22a8d630">11,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c34d747b754e57bfd880817586c1fc_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzMtNS0xLTEtMTY3OTA4_1522ebba-e4e5-47c8-8e4e-721a8bfc8b44">33,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzMtOS0xLTEtMTY3OTA4_9880ab81-f8c4-4f72-8aeb-6006370d986e">45,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtMS0xLTEtMTY3OTA4_a32b2e7a-0050-4810-b6e6-f6f1eae453ca">476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtMy0xLTEtMTY3OTA4_cd255e30-de0b-4a52-b7f4-d655c51cde6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtNS0xLTEtMTY3OTA4_058d67a7-2155-4811-add2-553bf382ebaa">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtNy0xLTEtMTY3OTA4_2180c008-314c-4655-800c-197fbd99d553">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtOS0xLTEtMTY3OTA4_72ed392c-6cb2-479c-a2fe-ab83fc4243d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtMTEtMS0xLTE2NzkwOA_5b80f155-a5c0-4ad8-a120-e575439d6a25">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMS0xLTEtMTY3OTA4_a718b28d-82d7-49e5-94a0-2cf3f8e9f7b6"><ix:nonFraction unitRef="usd" contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMS0xLTEtMTY3OTA4_cce8e3dd-bd18-471d-ab21-c43bd2ef29d8">91,409</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMy0xLTEtMTY3OTA4_4ef0244b-4664-4ea7-ba4f-ffc775187874"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMy0xLTEtMTY3OTA4_f88c8356-5dc6-493c-b62c-56e4daac4ce0">169,236</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtNS0xLTEtMTY3OTA4_65dea28f-1fa0-43e5-ad5a-99629043103b"><ix:nonFraction unitRef="usd" contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtNS0xLTEtMTY3OTA4_fed8c70a-6eae-4c76-8377-4d6e99e43da4">106,594</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtNy0xLTEtMTY3OTA4_2ae9bbab-ccc2-4f9d-9093-f41008861d3c"><ix:nonFraction unitRef="usd" contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtNy0xLTEtMTY3OTA4_a87d0a1e-6cdf-4fe4-b4a5-d2c454b0e25a">530</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtOS0xLTEtMTY3OTA4_1e1f225c-a0aa-4a84-8d00-a03daa3d1341"><ix:nonFraction unitRef="usd" contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtOS0xLTEtMTY3OTA4_40850830-19f6-4605-a95d-77138e55935e">45,302</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMTEtMS0xLTE2NzkwOA_379d3685-8fd2-4d66-9862-941bf277f76d">322,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtMS0xLTEtMTY3OTA4_0e6c6708-826a-4d5e-9e25-c113f196d20d">5,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtMy0xLTEtMTY3OTA4_91550341-d05a-4a5e-857e-3f3b300d2383">7,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtNS0xLTEtMTY3OTA4_c9aee013-bb7f-4730-8f65-5a5da5123a55">6,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231" decimals="-6" sign="-" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtNy0xLTEtMTY3OTA4_5545bbed-ecf7-4b7d-923e-9a3703e7d071">1,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231" decimals="-6" sign="-" name="cvs:AdjustedOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtOS0xLTEtMTY3OTA4_d14fb90e-6662-45a6-9a76-98d576569a8d">728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtMTEtMS0xLTE2NzkwOA_ed390f8d-7659-4215-b5d7-ff057ad4628e">17,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctMS0xLTEtMTY3OTA4_e6b86021-e793-4441-afd0-8352a279a8f8">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctMy0xLTEtMTY3OTA4_c9654708-4996-48fa-acfb-e4a7f0e0249f">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctNS0xLTEtMTY3OTA4_550921e4-401f-4229-b267-750bb7c16416">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctNy0xLTEtMTY3OTA4_c66b29b2-6e07-4132-b1f1-8aba1eb2be36">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctOS0xLTEtMTY3OTA4_eb8a2deb-13a2-45e7-9298-e3f882e626fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctMTEtMS0xLTE2NzkwOA_3648433e-1b20-4482-bf44-aa1c2df6e909">4,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktMS0xLTEtMTY3OTA4_9dbd460d-c076-47b6-b95e-41a70b963040">81,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktMy0xLTEtMTY3OTA4_2a00bdef-cb11-4681-a44c-89c129fbc6d5">143,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktNS0xLTEtMTY3OTA4_d484da23-2dc3-462a-aa38-0db20583f9b9">66,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktNy0xLTEtMTY3OTA4_91dc587c-a607-4392-86f1-42b3ea0ef182">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktMTEtMS0xLTE2NzkwOA_18daf97d-0a0d-442c-aa99-e03133bf875a">290,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7714f3521cb4944817a68243192c7b1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEwLTEtMS0xLTE2NzkwOA_fdd1e171-99b2-4dd4-a0c1-cd112507ac4c">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e89b8dd8884731928828b40d4e94d3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEwLTMtMS0xLTE2NzkwOA_71792485-1fa1-4f78-917b-7fe9096ca85b">9,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c6773f805e4bd59d68e8f7a0aa3308_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEwLTUtMS0xLTE2NzkwOA_4bda0fde-fdcb-41e0-b48f-c34ba0f2f50a">34,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEwLTktMS0xLTE2NzkwOA_480e229f-f5ed-484c-967c-7c3098c4cc2b">43,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTEtMS0xLTE2NzkwOA_c0f36c9e-b64e-48b0-9c38-e72f5b9321dc">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTMtMS0xLTE2NzkwOA_7eff9f76-e474-4e25-aa8f-45e3c32d7c8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTUtMS0xLTE2NzkwOA_062b683e-8128-426d-b387-6cbbba9ca0c0">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTctMS0xLTE2NzkwOA_215b8391-3f0e-4327-9ad4-1dad57fa5c49">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTktMS0xLTE2NzkwOA_6aef284f-8e82-4cbe-b670-5b47e52db74b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTExLTEtMS0xNjc5MDg_5adf357e-76fb-42f9-8b02-26349158834c">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTEtMS0xLTE2NzkwOA_411ade52-fff4-4873-9074-e6dcaf3c5df0">82,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTMtMS0xLTE2NzkwOA_0337b6fe-3dfe-47ee-92ac-7ea8bbe0f5f0">153,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTUtMS0xLTE2NzkwOA_380c6467-d797-417f-a7cb-c32512eba616">100,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTctMS0xLTE2NzkwOA_7b2b9fbd-1e99-4df2-98b6-cb0f0942e234">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTktMS0xLTE2NzkwOA_fab02010-9f53-499f-9942-ada6fbce3476">43,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTExLTEtMS0xNjc5MDg_760bde49-9d17-4943-9931-6a4b673a1cad">292,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTEtMS0xLTE2NzkwOA_54699239-17aa-4595-8441-41f3d6a046be">5,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTMtMS0xLTE2NzkwOA_9f4a2630-a34c-4ea0-8497-b1a1860b9065">6,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTUtMS0xLTE2NzkwOA_f753762f-d388-467d-8f04-d5136cbda1c3">7,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231" decimals="-6" sign="-" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTctMS0xLTE2NzkwOA_ed786146-cd4b-41e3-9041-e70ce92d1535">1,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231" decimals="-6" sign="-" name="cvs:AdjustedOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTktMS0xLTE2NzkwOA_3090868f-e49e-4fef-8660-69673b48502d">711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTExLTEtMS0xNjc5MDg_bcbe1a52-f5e3-4c05-ae43-229486c23833">17,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTEtMS0xLTE2NzkwOA_0766d67e-74a6-42fb-b47c-653b21f7909f">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTMtMS0xLTE2NzkwOA_73ba48b6-b977-4ff3-ab3b-be0c3df57b37">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTUtMS0xLTE2NzkwOA_e23ad140-5eb7-45f3-a53d-8f604ca28852">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTctMS0xLTE2NzkwOA_8295de76-9a56-47d0-ab04-bc86bba6ab3d">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTktMS0xLTE2NzkwOA_e6ec3336-b788-4981-81b0-c7caa7b2c903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTExLTEtMS0xNjc5MDg_b4e5cc24-e384-465a-8f1d-416fe74fcbaf">4,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTEtMS0xLTE2NzkwOA_1c42bcc5-9d45-4e5c-99eb-9837fe798e9f">74,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTMtMS0xLTE2NzkwOA_4bd58cd2-db8c-4dac-8571-177e8c43d4f5">132,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTUtMS0xLTE2NzkwOA_1326239e-9830-41e9-b4d8-e8918438fac9">60,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTctMS0xLTE2NzkwOA_7c82410e-156b-4ca4-848f-6a8fd909c36a">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTExLTEtMS0xNjc5MDg_17fdaf31-3101-476c-8980-901fcf26c869">267,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fe920a5d654530aaf6d123f400d878_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE3LTEtMS0xLTE2NzkwOA_49a76d93-11b3-4407-b81b-6fc9aed412aa">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26c945fe20b40d684582e97afbd1616_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE3LTMtMS0xLTE2NzkwOA_bdcc529a-8561-483d-80a5-0335314c1cd9">9,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99de3811ad9244d2987587cc4326b954_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE3LTUtMS0xLTE2NzkwOA_28a6c2ee-1c0f-409d-ab4c-b7dc70dac051">30,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE3LTktMS0xLTE2NzkwOA_e518a53c-3d40-41bc-9427-bd03e417c7a2">40,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTEtMS0xLTE2NzkwOA_507ad542-d180-4513-af00-c4d70fbc2915">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTMtMS0xLTE2NzkwOA_47fba327-65dc-457a-87b7-434885926f03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTUtMS0xLTE2NzkwOA_35ab4a29-5b06-4908-8f75-be08573c19f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTctMS0xLTE2NzkwOA_a42d7b2e-5613-453f-86d3-76560dca13c6">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTktMS0xLTE2NzkwOA_07fc4485-3f4a-4c35-a44d-194aa7a356a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTExLTEtMS0xNjc5MDg_4b183423-00ed-44c8-9d70-0dff6066e1ab">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTEtMS0xLTE2NzkwOA_a10f74a2-a63c-45c4-8fc3-6191e9861281">75,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTMtMS0xLTE2NzkwOA_b036dc54-ac0f-41f1-95ca-434d314c7552">141,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTUtMS0xLTE2NzkwOA_ef35134a-8836-4c4e-9987-72650f503964">91,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTctMS0xLTE2NzkwOA_58282756-cd61-48c0-929a-b81ade4ac52c">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTktMS0xLTE2NzkwOA_7af0f785-8f9d-48aa-8c0e-6d577d57ab72">40,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTExLTEtMS0xNjc5MDg_f0ffc924-48dd-4a73-8e90-52427bb19000">268,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTEtMS0xLTE2NzkwOA_832b7892-5596-4e70-a1d2-ae023451b497">6,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTMtMS0xLTE2NzkwOA_f593b718-e514-46a2-9cf2-d054ed260533">5,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTUtMS0xLTE2NzkwOA_e3169ca1-59bd-4611-a61d-7837bfe4e075">6,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231" decimals="-6" sign="-" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTctMS0xLTE2NzkwOA_5b365e40-c080-432c-8c97-f172ad5728e1">1,306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231" decimals="-6" sign="-" name="cvs:AdjustedOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTktMS0xLTE2NzkwOA_4991426a-fc63-46e6-a0ca-7cea1119139b">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTExLTEtMS0xNjc5MDg_55807ed2-8967-424e-aa1d-2c7d3ae21a46">16,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTEtMS0xLTE2NzkwOA_1464a6a6-2cd9-4292-95e5-2a520dc7403d">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTMtMS0xLTE2NzkwOA_a3d97aaf-bf4e-49f7-9f97-ab8f364efbb0">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTUtMS0xLTE2NzkwOA_b602ca44-41e2-43b8-9888-d9640c1f7726">1,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTctMS0xLTE2NzkwOA_1e6bbc89-785b-4ca9-9477-01a74ea8be15">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTktMS0xLTE2NzkwOA_51c54a64-fc63-4d42-8908-d68e0be045cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTExLTEtMS0xNjc5MDg_fd6b5b5a-88f4-4863-abb1-0dbd83da7d06">4,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total revenues of the Pharmacy Services segment include approximately $<ix:nonFraction unitRef="usd" contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231" decimals="-8" name="cvs:NetRevenuesRetailCoPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzIwMTc_ad4b4ff7-dc8f-4862-a10e-23dc0f3f98e8">12.6</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231" decimals="-8" name="cvs:NetRevenuesRetailCoPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzIwMjE_18c00fcd-0882-496f-886b-930cc6cc954a">11.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231" decimals="-8" name="cvs:NetRevenuesRetailCoPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzIwMjg_961f3edc-97e8-4ee0-bd48-39af280a9ca2">10.9</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of retail co-payments for 2022, 2021 and 2020, respectively. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information about retail co-payments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services segment clients enrolled in Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> elect to pick up maintenance prescriptions at one of the Company&#8217;s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i76f8e40220ea441a8640cd0528b9e666"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzc1NDk_95a32427-babd-49b3-921c-4a7f325b1502" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (GAAP measure)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzEtMS0xLTEtMTY3OTA4_6e1f3681-7c76-4716-a9da-f741edb594f0">7,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzEtMy0xLTEtMTY3OTA4_ddf26fea-ec14-4237-99fc-1ec40c140033">13,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzEtNS0xLTEtMTY3OTA4_4a96bd9e-ce29-4736-94ec-7c3960f05205">13,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzItMS0xLTEtMTY3OTA4_b9543cb2-d9c9-478d-b27c-7a7604491c1f">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzItMy0xLTEtMTY3OTA4_eb6a781b-9f51-48cf-b465-feba4d8da1f1">2,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzItNS0xLTEtMTY3OTA4_6f49f668-84b9-4ab8-9ef7-19c6b968e6b4">2,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office real estate optimization charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:OfficeRealEstateOptimizationCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMS0xLTEtMjA1MDQx_54321e3c-1363-4836-bafe-98544abe9332">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:OfficeRealEstateOptimizationCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMy0xLTEtMjA1MDQ5_91d2ddb4-e77c-4dbf-8bbf-2a263ed413ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:OfficeRealEstateOptimizationCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtNS0xLTEtMjA1MDU3_4fc360b2-813d-4a63-9d1c-9c224e0a5b3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on divestiture of subsidiaries </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMS0xLTEtMjEyOTk0_202d8385-7a51-4e18-84ed-57c6645f32fe">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMy0xLTEtMjEyOTk0_4aff3041-2e0b-428f-aad6-121dff6e3dbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtNS0xLTEtMjEyOTk0_397843c3-0097-45e5-bcb1-85457c9fb879">269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid litigation charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMS0xLTEtMTk5MjEz_cfead81b-2e34-4db1-b80a-5f6019f47ec7">5,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMy0xLTEtMTk5MjI3_373ffe44-71c7-4951-9f7e-bba29122f112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtNS0xLTEtMTk5MjQy_b623bbfe-7f43-4e3b-8233-1136fdb93f9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on assets held for sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMS0xLTEtMTk5MjEz_f44f1c2b-fc7a-43af-b088-9b69e02ef6ae">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMy0xLTEtMTk5MjI3_b7a7fd62-2841-4f1e-832d-10b8ab4daae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtNS0xLTEtMTk5MjQy_e435394a-969c-4618-ae27-f122d78de7c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMS0xLTEtMTY3OTA4_8688194d-e90a-4dcc-8bb4-5089e364c91e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMy0xLTEtMTY3OTA4_e28d0a4a-a69d-46fd-95d1-261479f89971">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtNS0xLTEtMTY3OTA4_961c87fe-65c9-4686-8e7d-b69ddad5c570">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMS0xLTEtMTY3OTA4_ddf2c31e-94fd-4ac5-bc92-2c20e90b340c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMy0xLTEtMTY3OTA4_c74e89d0-7363-472e-878c-7dce7911a0e2">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:StoreImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtNS0xLTEtMTY3OTA4_8229dfec-7b48-46c6-967f-802460e88113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzUtMS0xLTEtMTY3OTA4_42c3a0fe-c552-4d25-a1f1-086a0cbbf797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzUtMy0xLTEtMTY3OTA4_425ecedd-0f24-4483-b4e1-5e3563d114e8">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzUtNS0xLTEtMTY3OTA4_b9e886ec-b066-4152-bab4-48061d55850b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition purchase price adjustment outside of measurement period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzYtMS0xLTEtMTY3OTA4_b14f53b5-128d-404a-a439-b8086f1176ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzYtMy0xLTEtMTY3OTA4_36467592-263b-4c25-8c4f-f2a774d4e1bd">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzYtNS0xLTEtMTY3OTA4_fdf8c5d0-f8d1-4e87-bb20-084d9fc9dfb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipt of fully reserved ACA risk corridor receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzgtMS0xLTEtMTY3OTA4_51b2942f-b1f6-4992-bc9c-79e11ca79ec4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzgtMy0xLTEtMTY3OTA4_ab46efb0-4f69-4247-9f31-a248c51b628a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzgtNS0xLTEtMTY3OTA4_cd0afc84-3e08-42ad-89a4-bb6eece8b473">307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzktMS0xLTEtMTY3OTA4_149489ea-faba-45e6-9293-526771a891b3">17,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzktMy0xLTEtMTY3OTA4_bcbe1a52-f5e3-4c05-ae43-229486c23833">17,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231" decimals="-6" name="cvs:AdjustedOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzktNS0xLTEtMTY3OTA4_55807ed2-8967-424e-aa1d-2c7d3ae21a46">16,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company&#8217;s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company&#8217;s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company&#8217;s insurance products, the services performed for the Company&#8217;s customers or the sale of the Company&#8217;s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company&#8217;s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company&#8217;s and investors&#8217; ability to compare the Company&#8217;s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company&#8217;s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company&#8217;s new flexible work arrangement. The office real estate optimization charges are reflected in the Company&#8217;s GAAP consolidated statement of operations in operating expenses within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift, which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022. In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers&#8217; Compensation business, which the Company sold in July 2020. The gains on divestitures are reflected as a reduction of operating expenses in the Company&#8217;s GAAP consolidated statements of operations within the Health Care Benefits segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities. The opioid litigation charges are reflected within the Corporate/Other segment.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the loss on assets held for sale relates to the LTC reporting unit within the Retail/LTC segment. The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the third quarter of 2022. As of December 31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter of 2022, an incremental loss on assets held for sale was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. During 2022, the loss on assets held for sale also relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its Thailand business, which was included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021 and 2020, acquisition-related integration costs relate to the acquisition of Aetna. The acquisition-related integration costs are reflected in the Company&#8217;s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately <ix:nonFraction unitRef="store" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="INF" name="cvs:NumberOfStoresPlannedClosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzUzODI_74b680d3-ef03-4a79-8936-1e6060669882">900</ix:nonFraction> retail stores between 2022 and 2024. The store impairment charge is reflected within the Retail/LTC segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the goodwill impairment charge relates to an impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231" decimals="-6" name="cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzU5Njc_5cc63af6-bb7d-44ce-a8fa-ed44d068eeed">61</ix:nonFraction>&#160;million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company&#8217;s GAAP consolidated statement of operations as a reduction of operating expenses within the Health Care Benefits segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">In 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i51c77ad05d064fde8d6341467c3515ea_I20201231" decimals="-6" name="us-gaap:GainContingencyUnrecordedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzcxNzc_d697bb92-e4df-4c08-89c1-3b68cdd630be">313</ix:nonFraction>&#160;million owed to it under the ACA&#8217;s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA&#8217;s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $<ix:nonFraction unitRef="usd" contextRef="ie7a79d946b244fbe83b985e471a79655_D20200101-20201231" decimals="-6" name="cvs:FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzc0Mzk_cf459587-ed05-4053-b8a8-26b38fada4bc">307</ix:nonFraction>&#160;million in the Company&#8217;s GAAP consolidated statement of operations within the Health Care Benefits segment.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_175"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-right:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_100">Index to Consolidated Financial Statements</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of CVS Health Corporation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited CVS Health Corporation&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, CVS Health Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2022 consolidated financial statements of the Company and our report dated February&#160;8, 2023, expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzUvZnJhZzphYTZjMzRmZTMxYjE0YTZiODcyOWI0NzAxMzA1N2ZiNi90ZXh0cmVnaW9uOmFhNmMzNGZlMzFiMTRhNmI4NzI5YjQ3MDEzMDU3ZmI2XzM4NzU_c792fdfc-2391-4e0e-969e-6655500d254d">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzUvZnJhZzphYTZjMzRmZTMxYjE0YTZiODcyOWI0NzAxMzA1N2ZiNi90ZXh0cmVnaW9uOmFhNmMzNGZlMzFiMTRhNmI4NzI5YjQ3MDEzMDU3ZmI2XzM4NzQ_e6ce0747-693b-4f59-89da-805c57dff2b1">Boston, Massachusetts</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;8, 2023 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of CVS Health Corporation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of CVS Health Corporation (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, comprehensive income, shareholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022, in conformity with U.S. generally accepted accounting principles. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control-Integrated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;8, 2023, expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Valuation of health care costs payable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the incurred but not reported (&#8220;IBNR&#8221;) liabilities represented $7.8 billion of $10.4 billion of health care costs payable. As discussed in Note 1 to the consolidated financial statements, the Company&#8217;s liability for health care costs payable includes estimated payments for (1) services rendered to members but not yet reported and (2) claims that have been reported but not yet paid, each as of the financial statement date (collectively, &#8220;IBNR&#8221;). The estimated IBNR liability is developed utilizing actuarial principles and assumptions that include historical and projected claim submission and processing patterns, historical and assumed medical cost trends, historical utilization of medical services, claim inventory levels, changes in membership and product mix, seasonality and other relevant factors to record the actuarial best estimate of health care costs payable. There is significant uncertainty inherent in determining management&#8217;s actuarial best estimate of health care costs payable. In particular, the estimate is sensitive to the assumed completion factors and the assumed health care cost trend rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s actuarial best estimate of IBNR reserves for health care costs payable for its products and services involved a high degree of subjectivity in evaluating management&#8217;s assumptions used in the valuation process.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the process for estimating IBNR reserves. This included, among others, controls over the completeness and accuracy of data used in the actuarial projections, the transfer of data between underlying source systems, and the review and approval processes that management has in place for the actuarial principles and assumptions used in estimating the health care costs payable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test IBNR reserves, our audit procedures included, among others, testing the completeness and accuracy of the underlying claim and membership data used in the calculation of IBNR reserves. We involved actuarial specialists to assist with our audit procedures, which included, among others, evaluating the methodologies applied by the Company in determining the actuarially determined liability, evaluating management&#8217;s actuarial principles and assumptions used in their analysis based on historical claim experience, and independently calculating a range of reserve estimates for comparison to management&#8217;s actuarial best estimate of the liability for health care costs payable. Additionally, we performed a review of the prior period liabilities for incurred but not paid claims to subsequent claims development.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2007.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;8, 2023</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.  Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></div><div><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_184"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.  Controls and Procedures.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures (as defined in Rules&#160;13a-15 (f)&#160;and 15d-15(f) under the Securities Exchange Act of 1934) as of December&#160;31, 2022, have concluded that as of such date the Company&#8217;s disclosure controls and procedures were adequate and effective at a reasonable assurance level and designed to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to such officers on a timely basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s report on internal control over financial reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eporting. The Company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the Company&#8217;s consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the Company&#8217;s consolidated financial statements. In order to ensure the Company&#8217;s internal control over financial reporting is effective, management regularly assesses such control and did so most recently for its financial reporting as of December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management conducted an assessment of the effectiveness of the Company&#8217;s internal control over financial reporting based on the criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). This evaluation included review of the documentation, evaluation of the design effectiveness and testing of the operating effectiveness of controls. The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s system of internal control over financial reporting is enhanced by periodic reviews by the Company&#8217;s internal auditors, written policies and procedures and a written Code of Conduct adopted by CVS Health Corporation&#8217;s Board of Directors, applicable to all employees of the Company. In addition, the Company has an internal Disclosure Committee, comprised of management from each functional area within the Company, which performs a separate review of disclosure controls and procedures. There are inherent limitations in the effectiveness of any system of internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on management&#8217;s assessment, management concluded that the Company&#8217;s internal control over financial reporting is effective and provides reasonable assurance that assets are safeguarded and that the financial records are reliable for preparing financial statements as of December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst&#160;&amp; Young LLP, the Company&#8217;s independent registered public accounting firm, is appointed by CVS Health Corporation&#8217;s Board of Directors and ratified by CVS Health Corporation&#8217;s stockholders. They were engaged to render an opinion regarding the fair presentation of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s consolidated financial statements as well as conducting an audit of internal control over financial reporting. Their reports included in Item 8 of this Form 10-K are based upon audits conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control over financial reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in the Company&#8217;s internal control over financial reporting identified in connection with the evaluation required by paragraph (d)&#160;of Rule&#160;13a-15 or Rule&#160;15d-15 that occurred during the fourth quarter ended December&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.  Other Information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No events have occurred during the fourth quarter ended December&#160;31, 2022 that would require disclosure under this item.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_2199023257430"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_190"></div><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_193"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.  Directors, Executive Officers and Corporate Governance.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information concerning the Executive Officers of CVS Health Corporation is included in Part I of this 10-K pursuant to General Instruction G to Form 10-K. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sections of the Proxy Statement under the captions &#8220;Committees of the Board as of the Annual Meeting,&#8221; &#8220;Code of Conduct,&#8221; &#8220;Audit Committee Report,&#8221; and &#8220;Biographies of our Incumbent Board Nominees&#8221; are incorporated herein by reference. </span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_196"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.  Executive Compensation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sections of the Proxy Statement under the captions &#8220;Non-Employee Director Compensation&#8221; and &#8220;Executive Compensation and Related Matters,&#8221; including &#8220;Letter from the Management Planning and Development Committee,&#8221; &#8220;Compensation Committee Report,&#8221; &#8220;Compensation Discussion and Analysis&#8221; and &#8220;Compensation of Named Executive Officers&#8221; are incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_199"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sections of the Proxy Statement under the captions &#8220;Share Ownership of Directors and Certain Executive Officers&#8221; and &#8220;Share Ownership of Principal Stockholders&#8221; are incorporated herein by reference. Those sections contain information concerning security ownership of certain beneficial owners and management and related stockholder matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the registrant&#8217;s common stock that may be issued upon the exercise of options, warrants and rights under all of the Company&#8217;s equity compensation plans as of December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">securities&#160;to&#160;be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">issued&#160;upon</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">outstanding</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">options,&#160;warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">and&#160;rights </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) (2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>average&#160;exercise<br/>price&#160;of<br/>outstanding<br/>options,&#160;warrants<br/>and&#160;rights<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of&#160;securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">remaining&#160;available&#160;for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">future&#160;issuance&#160;under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">equity&#160;compensation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">plans&#160;(excluding</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">securities&#160;reflected&#160;in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">first&#160;column)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(c)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">Shares in thousands.</span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">Consists of: (i) 13,834 shares of common stock underlying outstanding options, (ii) 639 shares of common stock issuable upon the exercise of outstanding stock appreciation rights (&#8220;SARs&#8221;) and (iii) 13,871 shares of common stock issuable on the vesting of outstanding restricted stock units, deferred stock units and performance stock units, assuming target level performance in the case of performance stock units. The number of shares included with respect to outstanding SARs is the number of shares of CVS Health Corporation common stock that would have been issued had the SARs been exercised based on the closing price per share of CVS Health Corporation common stock on December 31, 2022, as reported on the NYSE, which was $93.19.  </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">Consists of the CVS Health 2017 Incentive Compensation Plan.</span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">Consists of the Amended Aetna Inc. 2010 Stock Incentive Plan (the &#8220;Aetna Stock Plan&#8221;). The Aetna Stock Plan expired on May 21, 2020, therefore there are no securities available for future grants under this plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Aetna Stock Plan was last approved by Aetna&#8217;s shareholders at Aetna&#8217;s 2017 Annual Meeting on May 19, 2017. The Company elected to continue to grant awards under the Aetna Stock Plan to employees of Aetna and its subsidiaries following the completion of the Company&#8217;s acquisition of Aetna. The Aetna Stock Plan was designed to promote the Company&#8217;s interests and those of its stockholders and to further align the interests of stockholders and employees by tying awards to total return to stockholders, enabling plan participants to acquire additional equity interests in the Company and providing compensation opportunities dependent upon the Company&#8217;s performance. The Aetna Stock Plan was not submitted to the Company&#8217;s stockholders and expired on May 21, 2020. Under the Aetna Stock Plan, eligible participants could be granted stock options to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase shares of CVS Health Corporation common stock, SARs, time-vesting and/or performance-vesting incentive stock or incentive units and other stock-based awards.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_202"></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.  Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="padding-right:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sections of the Proxy Statement under the captions &#8220;Independence Determinations for Directors&#8221; and &#8220;Related Person Transaction Policy&#8221; are incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_205"></div><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  Principal Accountant Fees and Services.</span></div><div style="padding-right:2.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section of the Proxy Statement under the caption &#8220;Item 2: Ratification of Appointment of Independent Registered Public Accounting Firm for 2022&#8221; is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_208"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_211"></div><div style="-sec-extract:summary;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.  Exhibits, Financial Statement Schedules.</span></div><div style="padding-right:2.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this 10-K:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statements. See &#8220;Index to Consolidated Financial Statements&#8221; in Item 8 of this 10-K.</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statement Schedules. All financial statement schedules are omitted because they are not applicable, not required under the instructions, or the information is included in the consolidated financial statements or related notes.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Exhibits. The exhibits listed in the &#8220;Index to Exhibits&#8221; in this Item 15 are filed or incorporated by reference as part of this 10-K. Exhibits marked with an asterisk (*)&#160;are management contracts or compensatory plans or arrangements. Exhibits other than those listed are omitted because they are not required to be listed or are not applicable. Pursuant to Item 601(b)(4)(iii) of Regulation S-K, the Registrant hereby agrees to furnish to the Securities and Exchange Commission a copy of any omitted instrument that is not required to be listed.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan of acquisition, reorganization, arrangement, liquidation or succession</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312522238304/d351652dex21.htm">Agreement and Plan of Merger, dated as of September 2, 2022, by and among CVS Pharmacy, Inc., Noah Merger Sub, Inc. and Signify Health, Inc. (incorporated by reference to Exhibit 2.1 of the Registrant&#8217;s Current Report on Form 8-K filed September 6, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312522238304/d351652dex991.htm">Voting Agreement, dated as of September 2, 2022, by and among CVS Pharmacy, Inc. and certain stockholders of Signify Health, Inc. party thereto (incorporated by reference to Exhibit 99.1 of the Registrant&#8217;s Current Report on Form 8-K filed September 6, 2022).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Articles of Incorporation and Bylaws</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312518184593/d456958dex31c.htm">Restated Certificate of Incorporation of the Registrant dated June 4, 2018 (incorporated by reference to Exhibit&#160;3.1C of Registrant&#8217;s Current Report on Form&#160;8-K filed June 5, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000094787122001199/ss1535680_ex0301.htm">By-Laws of the Registrant, as amended and restated November 17, 2022 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed November 21, 2022).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Instruments defining the rights of security holders, including indentures</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/0000950103-96-001174.txt">Specimen common stock certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement of the Registrant ((then known as CVS Corporation) as successor to Melville Corporation) on Form 8-B filed November 4, 1996).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000095010306001962/ex0401.htm">Senior Indenture dated August 15, 2006, between the Registrant and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed August 15, 2006).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312518079390/d547656dex45.htm">Form of the Registrant&#8217;s 2023 Note (incorporated by reference to Exhibit 4.5 to the Registrant&#8217;s Current Report on Form 8-K filed March 12, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312518079390/d547656dex46.htm">Form of the Registrant&#8217;s 2025 Note (incorporated by reference to Exhibit 4.6 to the Registrant&#8217;s Current Report on Form 8-K filed March 12, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312518079390/d547656dex47.htm">Form of the Registrant&#8217;s 2028 Note (incorporated by reference to Exhibit 4.7 to the Registrant&#8217;s Current Report on Form 8-K filed March 12, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312518079390/d547656dex48.htm">Form of the Registrant&#8217;s 2038 Note (incorporated by reference to Exhibit 4.8 to the Registrant&#8217;s Current Report on Form 8-K filed March 12, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312518079390/d547656dex49.htm">Form of the Registrant&#8217;s 2048 Note (incorporated by reference to Exhibit 4.9 to the Registrant&#8217;s Current Report on Form 8-K filed March 12, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312519222479/d791446dex41.htm">Form of the Registrant&#8217;s 2024 Note (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed August 15, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312519222479/d791446dex42.htm">Form of the Registrant&#8217;s 2026 Note (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed August 15, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312519222479/d791446dex43.htm">Form of the Registrant&#8217;s 2029 Note (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K filed August 15, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312520092890/d876921dex41.htm">Form of the Registrant&#8217;s 2027 Note (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on March 31, 2020).</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312520092890/d876921dex42.htm">Form of the Registrant&#8217;s 2030 Note (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed on March 31, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312520092890/d876921dex43.htm">Form of the Registrant&#8217;s 2040 Note (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K filed on March 31, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312520092890/d876921dex44.htm">Form of the Registrant&#8217;s 2050 Note (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Current Report on Form 8-K filed on March 31, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312520227082/d54415dex41.htm">Form of the Registrant&#8217;s 2027 Note (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on August 21, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312520227082/d54415dex42.htm">Form of the Registrant&#8217;s 2030 Note (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed on August 21, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312520227082/d54415dex43.htm">Form of the Registrant&#8217;s 2040 Note (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K filed on August 21, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312520319098/d57932dex41.htm">Form of the Registrant&#8217;s 2027 Note (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December 16, 2020). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000119312520319098/d57932dex42.htm">Form of the Registrant&#8217;s 2031 Note (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed on December 16, 2020). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000064803/000119312521250356/d209728dex41.htm">Form of the 2031 Note (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on August 18, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit421-2022.htm">Material terms of outstanding securities that are registered under Section 12 of the 1934 Act as required by Item 202(a)-(d) and (f) of Regulation S-K.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Material Contracts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000029/a06302022ex101.htm">Five Year Credit Agreement dated as of May 16, 2022, by and among the Registrant, the lenders party thereto, and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000029/a06302022ex102.htm">First Amendment to Five Year Credit Agreement dated as of May 16, 2022, to the Five Year Credit Agreement dated as of May 11, 2021, by and among the Registrant, the lenders party thereto and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000029/a06302022ex103.htm">First Amendment to Five Year Credit Agreement dated as of May 16, 2022, to the Five Year Credit Agreement dated as of May 16, 2019, by and among the Registrant, the lenders party thereto and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480321000028/a06302021ex102.htm">Five Year Credit Agreement dated as of May 11, 2021, by and among the Registrant, the lenders party thereto, and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480319000039/ex102-06302019.htm">Five Year Credit Agreement, dated as of May 16, 2019, by and among the Registrant, the lenders party thereto and Bank of America N.A., as Administrative Agent (incorporated by reference to Exhibit&#160;10.2 of the Registrant&#8217;s Quarterly Report on Form&#160;10-Q for the fiscal quarter ended June 30, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312509163865/dex106.htm">The Registrant&#8217;s Supplemental Retirement Plan I for Select Senior Management, as amended and restated as of December 31, 2008 (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2009).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480314000008/ex1025restrictivecovenanta.htm">Form of Enterprise Non-Competition, Non-Disclosure and Developments Agreement between the Registrant and certain of the Registrant&#8217;s executive officers (incorporated by reference to Exhibit 10.25 of the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480320000007/exhibit1011-2019.htm">The Registrant&#8217;s Deferred Stock Compensation Plan, as amended and restated (incorporated by reference to Exhibit 10.11 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000094787120000499/ss173456-ex9902.htm">The Registrant&#8217;s 2007 Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit&#160;99.2 to the Registrant&#8217;s Registration Statement on Form&#160;S-8 filed May 19, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480316000074/a1028universal409adefiniti.htm">Universal 409A Definition Document, as amended (incorporated by reference to Exhibit&#160;10.28 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000008/exhibit1010-2021.htm">The Registrant&#8217;s Amended and Restated Deferred Compensation Plan (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480317000006/ex1025partnershipequitypro.htm">The Registrant&#8217;s Partnership Equity Program, as amended (incorporated by reference to Exhibit&#160;10.25 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480317000006/ex1027performance-basedres.htm">The Registrant&#8217;s Performance-Based Restricted Stock Unit Plan, as amended (incorporated by reference to Exhibit&#160;10.27 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000094787120000499/ss173456-ex9901.htm">The Registrant&#8217;s 2017 Incentive Compensation Plan, as amended (incorporated by reference to Exhibit 99.1 to the Registrant&#8217;s Registration Statement on Form S-8 filed May 19, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000155837017006198/cvs-20170630ex1043fff6d.htm">The Registrant&#8217;s Executive Incentive Plan, as amended (incorporated by reference to Exhibit&#160;10.4 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q for the fiscal quarter ended June 30, 2017).</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000155837017006198/cvs-20170630ex105a3120c.htm">The Registrant&#8217;s Long-Term Incentive Plan, as amended (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480315000008/ex1029formofnon-qualifieds.htm">Form&#160;of Non-Qualified Stock Option Agreement between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit&#160;10.29 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480315000008/ex1030formofrestrictedstoc.htm">Form&#160;of Restricted Stock Unit Agreement - Annual Grant - between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit&#160;10.30 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480315000008/ex1031formofpbrsagreement.htm">Form&#160;of Performance-Based Restricted Stock Unit Agreement between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit&#160;10.31 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480315000008/ex1032pepcompanymatchingpr.htm">Form&#160;of Partnership Equity Program Participant Purchased RSUs, Company Matching RSUs and Company Matching Options Agreement (Pre-Tax) (incorporated by reference to Exhibit&#160;10.32 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480315000008/ex1033pepcompanymatchingpo.htm">Form&#160;of Partnership Equity Program Participant Purchased RSUs, Company Matching RSUs and Company Matching Options Agreement (Post-Tax) (incorporated by reference to Exhibit&#160;10.33 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000155837018003777/cvs-20180331ex10150a8df.htm">Form of Performance Stock Unit Agreement - Annual Grant between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000155837018003777/cvs-20180331ex102304379.htm">Form of Performance Stock Unit Agreement (LTIP) - Annual Grant between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480320000041/a09302020ex101.htm">Form of Performance Stock Unit Agreement - Annual Grant between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480320000007/exhibit1027-2019.htm">The Registrant&#8217;s Management Incentive Plan (incorporated by reference to Exhibit 10.27 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000008/exhibit1025-2021.htm">The Registrant&#8217;s Amended and Restated Severance Plan for Non-Store Employees dated October 11, 2021(incorporated by reference to Exhibit 10.25 to the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480319000013/ex1038.htm">The Registrant&#8217;s Performance-Based Restricted Stock Unit Program, as amended (incorporated by reference to Exhibit 10.38 to the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480319000013/ex1039.htm">Form&#160;of Non-Qualified Stock Option Agreement between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.39 to the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480319000013/ex1040.htm">Form&#160;of Restricted Stock Unit Agreement - Annual Grant - between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.40 to the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480319000013/ex1041.htm">Form&#160;of Performance-Based Restricted Stock Unit Agreement between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.41 to the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480319000013/ex1042.htm">Form&#160;of Partnership Equity Program Participant Purchased RSUs, Company Matching RSUs and Company Matching Options Agreement (Pre-Tax) (incorporated by reference to Exhibit 10.42 to the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480314000008/ex1031peppost-taxagreement.htm">Form&#160;of Partnership Equity Program Participant Purchased RSUs, Company Matching RSUs and Company Matching Options Agreement (Post-Tax) (incorporated by reference to Exhibit&#160;10.31 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480319000039/ex105-06302019.htm">Form of Performance Stock Unit Agreement - Annual Grant between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019).</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000119312509041089/dex1038.htm">Amended and Restated Employment Agreement between the Registrant and Larry Merlo (incorporated by reference to Exhibit&#160;10.38 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2008).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000110465913011354/a12-28799_1ex10d31.htm">Amendment dated as of December&#160;21, 2012 to the Amended and Restated Employment Agreement between the Registrant and Larry Merlo (incorporated by reference to Exhibit&#160;10.31 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2012).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480317000006/ex1037ceooptionagreement16.htm">Form&#160;of Non-Qualified Stock Option Agreement - Annual Grant between the Registrant and Larry Merlo (incorporated by reference to Exhibit&#160;10.37 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2016).</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480317000006/ex1038ceorsuagreement16.htm">Form&#160;of Restricted Stock Unit Agreement - Annual Grant between the Registrant and Larry Merlo (incorporated by reference to Exhibit&#160;10.38 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480315000002/exhibit101amendmentdatedja.htm">Amendment dated January 22, 2015 to Nonqualified Stock Option Agreements between the Registrant and Larry Merlo (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed January 23, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480319000039/ex105-06302019.htm">Form of Performance Stock Unit Agreement - Annual Grant between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480319000021/ex101.htm">Change in Control Agreement effective as of July 19, 2010 between the Registrant and Eva Boratto (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480320000007/exhibit1048-2019.htm">Restrictive Covenant Agreement dated June 21, 2019 between the Registrant and Eva Boratto (incorporated by reference to Exhibit 10.48 to the registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480321000028/a06302021ex103.htm">Separation Agreement dated June 9, 2021 between CVS Pharmacy, Inc. and Eva C. Boratto (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000110465913011354/a12-28799_1ex10d33.htm">Change in Control Agreement dated December&#160;22, 2008 between the Registrant and Jonathan Roberts (incorporated by reference to Exhibit&#160;10.33 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2012).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000110465913011354/a12-28799_1ex10d34.htm">Amendment dated as of December&#160;31, 2012 to the Change in Control Agreement dated December&#160;22, 2008 between the Registrant and Jonathan Roberts (incorporated by reference to Exhibit&#160;10.34 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2012).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480317000006/ex1044robertsrsuagreement16.htm">Restricted Stock Unit Agreement - Annual Grant dated April 1, 2016 between the Registrant and Jonathan Roberts (incorporated by reference to Exhibit&#160;10.44 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480317000006/ex1045robertsrestrictiveco.htm">Restrictive Covenant Agreement dated May 20, 2016 between the Registrant and Jonathan Roberts (incorporated by reference to Exhibit&#160;10.45 to the Registrant&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2016).</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64803/000006480315000023/ex101changeincontrolagreem.htm">Change in Control Agreement dated October 1, 2012 between the Registrant and Thomas Moriarty (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480320000007/exhibit1056-2019.htm">Restrictive Covenant Agreement dated July 8, 2019 between the Registrant and Thomas Moriarty (incorporated by reference to Exhibit 10.56 of the Registrant's Annual Report on form 10-K for the fiscal year ended December 31, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480321000011/exhibit1051-2020.htm">Amended and Restated Employment Agreement dated November 5, 2020 between the Registrant and Karen S. Lynch (incorporated by reference to Exhibit 10.51 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480321000011/exhibit1052-2020.htm">Restrictive Covenant Agreement dated November 6, 2020 between the Registrant and Karen S. Lynch (incorporated by reference to Exhibit 10.52 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480321000017/a03312021ex101.htm">Restrictive Covenant Agreement dated September 29, 2020 between the Registrant and Alan Lotvin (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480321000017/a03312021ex102.htm">Change in Control Agreement dated October 15, 2012 between the Registrant and Alan Lotvin (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.53*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480321000028/a06302021ex104.htm">Letter Agreement dated May 16, 2021 between the Registrant and Shawn Guertin (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.54*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480321000028/a06302021ex105.htm">Restrictive Covenant Agreement dated May 16, 2021 between CVS Pharmacy, Inc. and Shawn Guertin  (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.55*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480321000028/a06302021ex106.htm">Change in Control Agreement dated May 16, 2021 between the Registrant and Shawn Guertin (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000008/exhibit1055-2021.htm">Form of Nonqualified Stock Option Agreement between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.55 to the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.57*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Descriptions of certain arrangements not embodied in formal documents as described under the heading &#8220;Non-Employee Director Compensation&#8221; are incorporated herein by reference to the Proxy Statement (when filed). </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.58*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000016/a03312022ex101.htm">Form of Restricted Stock Unit Agreement between the Registrant and selected employees of the Registrant.(incorporated by reference to Exhibit 10.1 of Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2022). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.59*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000016/a03312022ex102.htm">Form of Performance Stock Unit Agreement between the Registrant and selected employees of the Registrant (incorporated by reference to Exhibit 10.2 of Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2022). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.60*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000016/a03312022ex103.htm">Form of Nonqualified Stock Option Agreement between the Registrant and selected executives of the Registrant (incorporated by reference to Exhibit 10.3 of Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.61*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/64803/000006480322000016/a03312022ex104.htm">Form of Nonqualified Stock Option Agreement between the Registrant and selected executives of the Registrant (incorporated by reference to Exhibit 10.4 of Registrant&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2022).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiaries of the registrant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211-2022.htm">Subsidiaries of CVS Health Corporation.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consents of experts and counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231-2022.htm">Consent of Ernst&#160;&amp; Young LLP.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rule 13a-14(a)/15d-14(a) Certifications</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-2022.htm">Certification by the Chief Executive Officer.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-2022.htm">Certification by the Chief Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Section 1350 Certifications</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-2022.htm">Certification by the Chief Executive Officer.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-2022.htm">Certification by the Chief Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interactive Data File</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from the CVS Health Corporation Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2022 formatted in Inline XBRL: (i)&#160;the Consolidated Statements of Operations, (ii) the Consolidated Statements of Comprehensive Income, (iii)&#160;the Consolidated Balance Sheets, (iv)&#160;the Consolidated Statements of Cash Flows, (v) the Consolidated Statements of Shareholders&#8217; Equity and (vi)&#160;the related Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - The cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2022, formatted in Inline XBRL (included as Exhibit 101).</span></td></tr></table></div><div><span><br/></span></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_214"></div><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.  Form 10-K Summary.</span></div><div style="padding-right:2.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189</span></div></div></div><div id="i1ae8e8cf4da649e4afa2b073939999d2_217"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ae8e8cf4da649e4afa2b073939999d2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CVS HEALTH CORPORATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SHAWN M. GUERTIN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shawn M. Guertin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ FERNANDO AGUIRRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fernando Aguirre</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JEFFREY R. BALSER, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jeffrey R. Balser, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ C. DAVID BROWN II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">C. David Brown II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JAMES D. CLARK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Vice President - Controller and Chief</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">James D. Clark</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Officer (Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ ALECIA A. DECOUDREAUX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Alecia A. DeCoudreaux</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ NANCY-ANN M. DEPARLE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nancy-Ann M. DeParle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ ROGER N. FARAH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chair of the Board and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Roger N. Farah</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ ANNE M. FINUCANE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Anne M. Finucane</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ SHAWN M. GUERTIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shawn M. Guertin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ EDWARD J. LUDWIG</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Edward J. Ludwig</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ KAREN S. LYNCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Karen S. Lynch</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Executive Officer) and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JEAN-PIERRE MILLON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jean-Pierre Millon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ MARY L. SCHAPIRO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mary L. Schapiro</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ WILLIAM C. WELDON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 8, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">William C. Weldon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.21
<SEQUENCE>2
<FILENAME>exhibit421-2022.htm
<DESCRIPTION>EX-4.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id68f3f54411b471e8363d060f0b4ce6b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.21</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF COMMON STOCK REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description (this &#8220;Description&#8221;) of the terms of the common stock of CVS Health Corporation (&#8220;CVS Health&#8221;) is a summary only and is qualified by reference to the relevant provisions of Delaware law and the Restated Certificate of Incorporation (the &#8220;Charter&#8221;) and the By-Laws (the &#8220;By-Laws&#8221;) of CVS Health.&#160;Copies of the Charter and the By-Laws&#160;are incorporated by reference as exhibits to the Annual Report on Form 10-K to which this Description is an exhibit.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized Capital Stock</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Charter as of February 8, 2023, the authorized capital stock of CVS Health consisted of (i)&#160;3,200,000,000 shares of common stock, par value of $0.01 per share (&#8220;common stock&#8221;), (ii)&#160;120,619 shares of cumulative preferred stock, par value $0.01 per share (&#8220;preferred stock&#8221;), and (iii)&#160;50,000,000 shares of preference stock, par value $1.00 per share (&#8220;preference stock&#8221;).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of common stock are entitled to one vote per share on all matters voted on by CVS Health stockholders, including elections of directors. Except as otherwise required by law, or by the provisions of the preferred stock or the preference stock, or provided in any resolution adopted by the CVS Health board of directors (the &#8220;board&#8221;) with respect to any subsequently created class or series of shares of CVS Health, the holders of the shares of common stock exclusively possess all voting power. The Charter precludes cumulative voting in the election of directors. The Charter provides for a majority vote standard for uncontested elections of directors, and a plurality of votes standard for contested elections of directors. Subject to any rights of any outstanding series of preferred stock or preference stock, (i) the holders of shares of common stock are entitled to such dividends as may be declared from time to time by the board from funds available therefor, (ii)&#160;no dividends may be declared, paid, or set aside for payment on shares of common stock unless full cumulative dividends are paid on any outstanding preference stock and any other preferred stock issued and outstanding at such time that is designated to have such dividend preference and (iii)&#160;upon dissolution the holders of shares of common stock are entitled to receive pro rata all assets of CVS Health available for distribution to such holders, subject to any liquidation preferences designated to any preferred stock or preference stock that may be issued and outstanding at such time of liquidation.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No Preemptive Rights</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Charter provides that no holder of any shares of CVS Health of any class or series may have any preemptive right to purchase or subscribe to any shares of CVS Health or any security convertible into shares of CVS Health of any class or series.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions Relating to Amendments to CVS Health&#8217;s Charter and&#160;By-Laws</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Delaware law, stockholders have the right to adopt, amend or repeal the certificate of incorporation and&#160;by-laws&#160;of a corporation. However, Delaware law requires that any amendment to the Charter also be approved by the board. Under Delaware law, unless a higher vote is required in a corporation&#8217;s certificate of incorporation, amendments to the corporation&#8217;s certificate of incorporation will be adopted upon receiving at a properly convened meeting the affirmative vote of a majority of the votes cast by all stockholders entitled to vote thereon, and if any class or series is entitled to vote thereon as a class, the affirmative vote of a majority of the votes cast in each class vote.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the&#160;By-Laws&#160;may be amended by the board with respect to all matters not exclusively reserved by law to the stockholders. Amendments to the&#160;By-Laws&#160;may be adopted and approved by the affirmative vote of the holders of record of a majority of the outstanding shares of stock of CVS Health entitled to vote at any annual or special meeting, or by the affirmative vote of a majority of the directors cast at any regular or special meeting, at which a quorum is present.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Statutory and Charter Provisions</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the Charter and By-Laws summarized in the following paragraphs may be deemed to have an antitakeover effect and may delay, defer or prevent a tender offer or takeover attempt.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential Issuances of Preferred Stock and Preference Stock</font></div><div style="margin-bottom:3pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 8, 2023, the Charter authorized 120,619 shares of preferred stock, par value $0.01 per share and 50,000,000 shares of preference stock, par value $1.00 per share. The Charter also authorizes the board to issue shares of preferred stock or preference stock, from time to time, in such class or classes, and such series within any class, and with such designations, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof as the board may determine, including, for example, (i)&#160;the designation of the class or series&#59; (ii)&#160;the number of shares of the class or series, which number the board may thereafter (except where otherwise provided in the designation of any subsequently authorized class or series) increase or decrease (but not below the number of shares thereof then outstanding)&#59; (iii)&#160;whether dividends, if any, will be cumulative or noncumulative and the dividend rate of the class or series&#59; (iv)&#160;the dates on which dividends, if any, will be payable&#59; (v)&#160;the redemption rights and price or prices, if any, for shares of the class or series&#59; (vi)&#160;the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the class or series&#59; (vii)&#160;the amounts payable on shares of the class or series in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of CVS Health&#59; (viii)&#160;whether the shares of the class or series will be convertible into shares of any other class or series, or any other security, of CVS Health or any other corporation, and, if so, the specification of such other class or series or such other security, the conversion price or prices or rate or rates, any adjustments thereof, the date or dates as of which such shares will be convertible and all other terms and conditions upon which such conversion may be made&#59; (ix)&#160;restrictions on the issuance of shares of the same class or series or of any other class or series&#59; and (x)&#160;the voting rights, if any, of the holders of such class or series. The authorized capital stock of CVS Health, including preferred stock, preference stock and common stock, will be available for issuance without further action by CVS Health stockholders, unless such action is required by applicable law or the rules of any stock exchange or automated quotation system on which CVS Health&#8217;s securities may be listed or traded. If the approval of CVS Health stockholders is not so required, the board does not intend to seek stockholder approval.</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the board has no intention at the present time of doing so, it could issue a class or series of preferred stock or preference stock that could, depending on the terms of such class or series, impede completion of a merger, tender offer or other takeover attempt that the holders of some, or a majority, of CVS Health shares might believe to be in their best interests or in which CVS Health stockholders might receive a premium for their shares over the then-current market price of such shares.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential Issuances of Rights to Purchase Securities</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health does not currently have a stockholder rights plan, although the board retains the right to adopt a new plan at a future date. The Charter grants the board exclusive authority to create and issue rights entitling the holders thereof to purchase from CVS Health shares of capital stock or other securities and to elect to repurchase, redeem, terminate or amend any such rights. The times at which and terms upon which such rights are to be issued, repurchased, redeemed, terminated or amended are to be determined exclusively by the board and set forth in the contracts or instruments that evidence any such rights. The authority of the board with respect to such rights includes determining, for example, (i)&#160;the purchase price of the capital stock or other securities or property to be purchased upon exercise of such rights&#59; (ii)&#160;provisions relating to the times at which and the circumstances under which such rights may be exercised or sold or otherwise transferred, either together with or separately from any other shares or other securities of CVS Health&#59; (iii)&#160;provisions which adjust the number or exercise price of such rights or the amount or nature of the shares, other securities or other property receivable upon exercise of such rights in the event of a combination, split or recapitalization of any shares of CVS Health, a change in ownership of CVS Health&#8217;s shares or other securities or a reorganization, merger, consolidation, sale of assets or other occurrence relating to CVS Health or any shares of CVS Health, and provisions restricting the ability of CVS Health to enter into any such transaction absent an assumption by the other party or parties thereto of the obligations of CVS Health under such rights&#59; (iv)&#160;provisions which deny the holder of a specified percentage of the outstanding securities of CVS Health the right to exercise such rights and&#47;or cause such rights held by such holder to become void&#59; (v)&#160;provisions which</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">permit CVS Health to redeem or exchange such rights&#59; and (vi)&#160;the appointment of the rights agent with respect to such rights. This provision is intended to confirm the board&#8217;s exclusive authority to issue, repurchase, redeem, terminate or amend share purchase rights or other rights to purchase shares or securities of CVS Health or any other corporation.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Action by Written Consent</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Charter provides that stockholder action may be taken at an annual or special meeting of stockholders or by written consent in lieu of a meeting, but only if such action is taken in accordance with the provisions of the Charter and&#160;By-Laws.&#160;Any person other than CVS Health seeking to have the CVS Health stockholders authorize or take corporate action by written consent without a meeting is required to deliver a written notice signed by holders of record of at least twenty-five percent (25%) of the voting power of the outstanding capital stock of CVS Health entitled to express consent on the relevant action and request that a record date be fixed for such purpose.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Vote on Fundamental or Extraordinary Corporate Transactions</font></div><div style="margin-bottom:3pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Delaware law, a sale, lease or exchange of all or substantially all of CVS Health&#8217;s assets, an amendment to the Charter, a merger or consolidation of CVS Health with another corporation or a dissolution of CVS Health generally requires the affirmative vote of the board and, with limited exceptions, the affirmative vote of a majority of the aggregate voting power of the outstanding stock entitled to vote on the transaction.</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to transactions with related persons (persons who own at least 10% of the outstanding capital stock of CVS Health), the Charter provides that a majority of outstanding shares (excluding those owned by the related person) voting as a single class is required to approve a business combination transaction with a related person, unless (i) such transaction is approved by a majority of continuing directors (directors who are not the related person, or an affiliate or associate thereof (or a representative or nominee of the related person or such affiliate or associate), that is involved in the relevant business combination and (a) who were members of the board immediately prior to the time that such related person became a related person or (b) whose initial election as a director was recommended by the affirmative vote of a least a majority of the continuing directors then in office, provided that, in either such case, such continuing director has continued in office after becoming a continuing director) or (ii) certain fair price requirements are met.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State Anti-Takeover Provisions</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health has not opted out of Section 203 of the Delaware General Corporation Law, which provides that, if a person acquires 15% or more of the outstanding voting stock of a Delaware corporation, thereby becoming an &#8220;interested stockholder,&#8221; that person may not engage in certain &#8220;business combinations&#8221; with the corporation, including mergers, purchases and sales of 10% or more of its assets, stock purchases and other transactions pursuant to which the percentage of the corporation&#8217;s stock owned by the interested stockholder increases (other than on a pro rata basis) or pursuant to which the interested stockholder receives a financial benefit from the corporation, for a period of three years after becoming an interested stockholder unless one of the following exceptions applies&#58; (i) the board approved the acquisition of stock pursuant to which the person became an interested stockholder or the transaction that resulted in the person becoming an interested stockholder prior to the time that the person became an interested stockholder&#59; (ii) upon consummation of the transaction that resulted in the person becoming an interested stockholder such person owned at least 85% of the outstanding voting stock of CVS Health, excluding, for purposes of determining the voting stock outstanding, voting stock owned by directors who are also officers and certain employee stock plans&#59; or (iii) the transaction is approved by the board and by the affirmative vote of two-thirds of the outstanding voting stock which is not owned by the interested stockholder. An &#8220;interested stockholder&#8221; also includes the affiliates and associates of a 15% or more owner and any affiliate or associate of CVS Health who was the owner of 15% or more of the outstanding voting stock within the three-year period prior to determine whether a person is an interested stockholder.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>exhibit211-2022.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2dc76061204a40a7b3c7aaaa20be0c89_1"></div><div style="min-height:79.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 21.1</font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Subsidiaries of CVS Health Corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Listed below are subsidiaries under CVS Health Corporation at December 31, 2022 with their jurisdictions of  organization shown in parentheses. Subsidiaries excluded from the list below are not insurance companies and would not, in the aggregate, constitute a &#8220;significant subsidiary&#8221; of CVS Health Corporation, as that term is defined in Rule 1-02(w) of Regulation S-X.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.5pt">CVS Foreign, Inc. (New York)</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Caremark Indemnity Ltd. (Bermuda)</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS International, L.L.C. (Delaware)</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.5pt">CVS Pharmacy, Inc. (Rhode Island)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Aetna Inc. (Pennsylvania)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Aetna Health Holdings, LLC (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health of California Inc. (California)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Inc. (Connecticut) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Inc. (Florida) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Inc. (Georgia) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Inc. (Maine) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health of Michigan Inc. (Michigan) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Inc. (New Jersey) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Inc. (New York)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health Inc. (New York)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Inc. (Pennsylvania)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Inc. (Texas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of California Inc. (California)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health of Ohio Inc. (Ohio)Aetna Better Health of Texas Inc. (Texas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Washington, Inc. (Washington)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health Inc. (Georgia) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna HealthAssurance Pennsylvania, Inc. (Pennsylvania)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Dental of California Inc. (California)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Dental Inc. (New Jersey) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Dental Inc. (Texas) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Rx Home Delivery, LLC (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Management, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Ireland Inc. (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Specialty Pharmacy, LLC (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Cofinity, Inc. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">&#64;Credentials Inc. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health Inc. (Pennsylvania)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health Inc. (Connecticut)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Illinois Inc. (Illinois) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health Premier Plan MMAI Inc. (Illinois)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Kansas Inc. (Kansas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health, Inc. (Louisiana)</font></div><div style="margin-bottom:3pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Florida Inc. (Florida)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Indiana Inc. (Indiana)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health Inc. (Ohio)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Oklahoma Inc. (Oklahoma)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Nevada Inc. (Nevada)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health Inc. (New Jersey)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of North Carolina Inc. (North Carolina)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Network Services LLC (Connecticut)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Risk Assurance Company of Connecticut Inc. (Connecticut)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Student Health Agency Inc. (Massachusetts)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Delaware Physicians Care, Incorporated (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Schaller Anderson Medical Administrators, Incorporated (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Medicaid Administrators LLC (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">iTriage, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Medical Examinations of New York, P.C. (New York)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">bswift Resources LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Prodigy Health Group, Inc. (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Niagara Re, Inc. (New York)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Performax, Inc. (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Scrip World, LLC (Utah)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Precision Benefit Services, Inc. (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">American Health Holding, Inc. (Ohio)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Meritain Health, Inc. (New York)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Administrative Enterprises, Inc. (Arizona)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">U.S Healthcare Holdings, LLC (Ohio)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Prime Net, Inc. (Ohio)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Professional Risk Management, Inc. (Ohio)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">ADMINCO, Inc. (Arizona) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna ACO Holdings Inc. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Pharmacy Management Services, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Transplant Network, Inc. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health of Iowa Inc. (Iowa)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health Care of Nebraska, Inc. (Nebraska)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Inc. (Louisiana)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">HealthAssurance Pennsylvania, Inc. (Pennsylvania)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Prescription Management Services Inc. (Nevada)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health and Life Insurance Company (Missouri)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Kentucky Insurance Company (Kentucky)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health Care of Virginia, Inc. (Virginia)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health Care of Missouri, Inc. (Missouri)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Missouri LLC (Missouri)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health Care of Illinois, Inc. (Illinois)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health Care of West Virginia, Inc. (West Virginia)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry HealthCare Management Corporation (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health Care of Kansas, Inc. (Kansas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health Care National Accounts, Inc. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Michigan Inc. (Michigan)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health of Utah Inc. (Utah)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Tennessee Inc. (Tennessee)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health Care National Network, Inc. (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Consumer Advantage, Inc. (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">MHNet Specialty Services, LLC (Maryland)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Mental Health Network of New York IPA, Inc. (New York)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Mental Health Associates, Inc. (Louisiana)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">MHNet of Florida, Inc. (Florida)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Group Dental Service, Inc. (Maryland)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Group Dental Service of Maryland, Inc. (Maryland)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Florida Health Plan Administrators, LLC (Florida)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Better Health of Florida Inc. (Florida)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Carefree Insurance Services, Inc. (Florida)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coventry Health Plan of Florida, Inc. (Florida)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">First Health Group Corp. (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">First Health Life &#38; Health Insurance Company (Texas)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Claims Administration Corp. (Maryland)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">First Choice of the Midwest LLC (South Dakota)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Continental Life Insurance Company of Brentwood, Tennessee (Tennessee)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">American Continental Insurance Company (Tennessee)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Aetna Life Insurance Company (Connecticut)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">AHP Holdings, Inc. (Connecticut) </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">AE Fourteen, Incorporated (Connecticut) </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Life Assignment Company (Connecticut) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna ACO Holdings Inc. (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Innovation Health Holdings, LLC (Delaware)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Innovation Health Insurance Company (Virginia)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Innovation Health Plan, Inc. (Virginia)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Texas Health + Aetna Health Insurance Holding Company LLC (Texas)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Texas Health + Aetna Health Insurance Company (Texas)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Texas Health + Aetna Health Plan Inc. (Texas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Banner Health and Aetna Health Insurance Holding Company LLC (Delaware) </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Banner Health and Aetna Health Insurance Company (Arizona)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Banner Health and Aetna Health Plan Inc. (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Sutter Health and Aetna Insurance Holding Company LLC (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Sutter Health and Aetna Administrative Services LLC (California)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Sutter Health and Aetna Insurance Company (California)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Allina Health and Aetna Insurance Holding Company LLC (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Allina Health and Aetna Insurance Company (Minnesota) </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Allina Health and Aetna Health Plan Inc. (Minnesota)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Aetna International LLC. (Connecticut)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Life &#38; Casualty (Bermuda) Ltd. (Bermuda)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna International Ex Pat LLC (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Global Holdings Limited (England &#38; Wales)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Insurance (Hong Kong) Limited (Hong Kong)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Virtual Home Healthcare LLC (Dubai)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Global Benefits (Bermuda) Limited (Bermuda)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Goodhealth Worldwide (Global) Limited (Bermuda)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Global Benefits (Europe) Limited (England &#38; Wales)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Global Benefits (Asia Pacific) Limited (Hong Kong) </font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">PT Aetna Management Consulting (Indonesia)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Goodhealth Worldwide (Asia) Limited (Hong Kong)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Global Benefits Limited (DIFC, UAE)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Global Benefits (Middle East) LLC (UAE) </font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Pt. Aetna Global Benefits Indonesia (Indonesia)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Spinnaker Topco Limited (Bermuda)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Spinnaker Bidco Limited (England and Wales)</font></div><div style="padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Aetna Holdco (UK) Limited (England and Wales)</font></div><div style="padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Aetna Global Benefits (UK) Limited (England and Wales)</font></div><div style="padding-left:198pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Aetna Insurance Company Limited (England and Wales)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Insurance (Singapore) Pte. Ltd. (Singapore)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Health Insurance Company of Europe DAC (Ireland)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna (Shanghai) Enterprise Services Co. Ltd. (China)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna (Beijing) Enterprise Management Services Co., Ltd. (China)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Global Benefits (Singapore) PTE. LTD. (Singapore)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Indian Health Organisation Private Limited (India)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">PT Aetna Management Consulting (Indonesia)</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">PE Holdings, LLC (Connecticut) </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Resources LLC (Delaware) </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Canal Place, LLC (Delaware) </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Ventures, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Phoenix Data Solutions LLC (Delaware) </font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Aetna Financial Holdings, LLC (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Asset Advisors, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">U.S. Healthcare Properties, Inc. (Pennsylvania) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Capital Management, LLC (Delaware) </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Partners Diversified Fund, LLC (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Workers&#8217; Comp Access, LLC (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Behavioral Health, LLC (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Managed Care Coordinators, Inc. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Horizon Behavioral Services, LLC (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Employee Assistance Services, LLC (Kentucky)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Health and Human Resource Center, Inc. (California)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Resources for Living, LLC (Texas)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">The Vasquez Group Inc. (Illinois)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Work and Family Benefits, Inc. (New Jersey)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Aetna Card Solutions, LLC (Connecticut)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Aetna Health and Life Insurance Company (Connecticut) </font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Aetna Health Insurance Company (Pennsylvania) </font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Aetna Health Insurance Company of New York (New York)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">AUSHC Holdings, Inc. (Connecticut) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">PHPSNE Parent Corporation (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Active Health Management, Inc. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Health Data &#38; Management Solutions, Inc. (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Accountable Care Organization Inc. (Pennsylvania)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Health Re, Inc. (Vermont)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">ASI Wings, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Aetna Corporate Services LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Echo Merger Sub, Inc. (Delaware)</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">CVS Pharmacy, Inc. (continued)</font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Alabama CVS Pharmacy, L.L.C. (Alabama)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Alaska CVS Pharmacy, L.L.C. (Alaska)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">American Drug Stores Delaware, L.L.C. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Arkansas CVS Pharmacy, L.L.C. (Arkansas)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">CareCenter Pharmacy, L.L.C. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Caremark Rx, L.L.C. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">ACS ACQCO CORP. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Advanced Care Scripts, Inc. (Florida)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CaremarkPCS, L.L.C. (Delaware) </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CaremarkPCS Health, L.L.C. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark IPA, L.L.C. (New York)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Accordant Health Services, L.L.C. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">AdvancePCS SpecialtyRx, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">AdvanceRx.com, L.L.C. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Caremark PhC, L.L.C. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Caremark Ulysses Holding Corp. (New York)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">MemberHealth LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">UAC Holding, Inc. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Caremark, L.L.C. (California)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Arizona Mail Pharmacy, LLC (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Arizona Specialty Pharmacy, L.L.C. (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark California Specialty Pharmacy, L.L.C. (California)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Florida Mail Pharmacy, LLC (Florida)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Florida Specialty Pharmacy, LLC (Florida)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Hawaii Mail Pharmacy, L.L.C. (Hawaii)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Hawaii Specialty Pharmacy, LLC (Hawaii)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Illinois Mail Pharmacy, LLC (Illinois)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Caremark Advanced Technology Pharmacy, L.L.C. (Illinois)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Illinois Specialty Pharmacy, LLC (Illinois)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Irving Resource Center, LLC (Texas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Kansas Specialty Pharmacy, LLC (Kansas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Logistics, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Louisiana Specialty Pharmacy, LLC (Louisiana)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Maryland Specialty Pharmacy, LLC (Maryland)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Massachusetts Specialty Pharmacy, L.L.C. (Massachusetts)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Michigan Specialty Pharmacy, LLC (Michigan)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Minnesota Specialty Pharmacy, LLC (Minnesota)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark New Jersey Specialty Pharmacy, LLC (New Jersey)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark North Carolina Specialty Pharmacy, LLC (North Carolina)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Ohio Specialty Pharmacy, L.L.C. (Ohio)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Pennsylvania Specialty Pharmacy, LLC (Pennsylvania)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Redlands Pharmacy, L.L.C. (California)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Repack, LLC (Illinois)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Tennessee Specialty Pharmacy, LLC (Tennessee)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Texas Mail Pharmacy, LLC (Texas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Texas Specialty Pharmacy, LLC (Texas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Caremark Washington Specialty Pharmacy, LLC (Washington)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Central Rx Services, LLC (Nevada)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Caremark TN SUTA, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Generation Health, L.L.C. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">I.g.G. of America, LLC. (Maryland)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NovoLogix, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">US Bioservices Corporation (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">APS Enterprises Holding Company (Delaware)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">IHS Acquisition XXX, Inc. (Delaware)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Pharm Plus Acquisition, Inc. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CaremarkPCS Alabama Mail Pharmacy, LLC (Alabama)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Caremark Part D Services, L.L.C. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Eckerd Corporation of Florida, Inc. (Florida)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Express Pharmacy Services of PA, L.L.C. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Ocean Acquisition Sub, L.L.C. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coram LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">T2 Medical, Inc. (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Alabama (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Florida (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Greater D.C. (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Greater New York (New York)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Indiana (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Mississippi (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Nevada (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Northern California (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Southern California (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Healthcare Corporation of Southern Florida (Delaware)</font></div><div style="padding-left:126pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Specialty Infusion Services, L.L.C. (Delaware)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coram Rx, LLC (Delaware)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coram Healthcare Corporation of North Texas (Delaware)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coram Healthcare Corporation of Utah (Delaware)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Coram Healthcare Corporation of Massachusetts (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Coram Alternate Site Services, Inc. (Delaware)</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Geneva Woods Management, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Part D Holding Company, L.L.C. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Accendo Insurance Company (Utah)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Silverscript Insurance Company (Tennessee)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Connecticut CVS Pharmacy, L.L.C. (Connecticut)</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Coram Clinical Trials, Inc. (Delaware)*</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Cabot Holdings Inc. (Delaware)*</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Shaw Holdings Inc. (Delaware)*</font></div><div style="padding-left:94.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare, LLC (Delaware)*</font></div><div style="padding-left:117pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Evergreen Pharmaceutical of California, LLC (California)</font></div><div style="padding-left:117pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">JHC Acquisition, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Geneva Woods Pharmacy, LLC (Alaska)</font></div><div style="padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Geneva Woods Health Services, LLC (Delaware)</font></div><div style="padding-left:216pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Geneva Woods Retail Pharmacy LLC (Delaware)</font></div><div style="padding-left:216pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Geneva Woods LTC Pharmacy, LLC</font></div><div style="padding-left:229.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Geneva Woods Pharmacy Wyoming, LLC (Delaware)</font></div><div style="padding-left:229.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Geneva Woods Pharmacy Washington, LLC (Delaware)</font></div><div style="padding-left:229.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Geneva Woods Pharmacy Alaska, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">AMC - Tennessee, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CHP Acquisition, LLC (Delaware)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Home Pharmacy Services, LLC (Missouri)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CP Acquisition, LLC (Oklahoma)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Managed Healthcare, LLC (Delaware) </font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Medical Arts Health Care, LLC (Georgia)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NIV Acquisition, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">OCR Services, LLC (Delaware)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.08pt">Shore Pharmaceutical Providers, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare of Nevada, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare Pharmacies of the Great Plains Holding, LLC (Delaware)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:15.08pt">Omnicare of Nebraska LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Pharmacy Associates of Glenn Falls, LLC (New York)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Sterling Healthcare Services, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Superior Care Pharmacy, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">TCPI Acquisition, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">UC Acquisition, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Weber Medical Systems LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Williamson Drug Company, LLC (Virginia)</font></div><div style="padding-left:117pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Med World Acquisition Corp. (Delaware)</font></div><div style="padding-left:117pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">MHHP Acquisition Company, LLC (Delaware)</font></div><div style="margin-bottom:8pt;padding-left:135pt;text-indent:-135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">___________________</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:161%"> *Coram Clinical Trials, Inc. &#8211; CVS Pharmacy, Inc. 75%&#47;Aetna Life Insurance Company 25%</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:161%"> *</font><font style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:161%;position:relative;top:-2.8pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:161%">CVS Cabot Holdings, Inc. &#8211; Coram Clinical Trials, Inc. 99.72%&#47;Aetna Inc. .28% </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:161%"> *CVS Shaw Holdings, Inc. &#8211; Coram Clinical Trials, Inc. 99.72%&#47;Aetna Inc. .28% </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:161%"> *Omnicare, LLC &#8211; Aetna Inc .28%&#47;CVS Cabot Holdings, Inc. 49.86%&#47;CVS Shaw Holdings, Inc. 49.86%</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare, LLC (continued)</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:117pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NeighborCare Pharmacy Services, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">APS Acquisition LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">ASCO HealthCare, LLC (Maryland)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Badger Acquisition LLC (Delaware)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Badger Acquisition of Minnesota LLC (Delaware)</font></div><div style="padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Merwin Long Term Care, LLC (Minnesota)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Badger Acquisition of Ohio LLC (Delaware) </font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Badger Acquisition of Kentucky LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Best Care LTC Acquisition Company, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Care Pharmaceutical Services, LP (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CCRx Holdings, LLC (Delaware)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Continuing Care Rx, LLC (Pennsylvania)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">CCRx of North Carolina LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Compscript, LLC (Florida)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Campo&#8217;s Medical Pharmacy, LLC (Louisiana)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">D &#38; R Pharmaceutical Services LLC (Kentucky)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Enloe Drugs, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Evergreen Pharmaceutical, LLC (Washington)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Home Care Pharmacy, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Interlock Pharmacy Systems, LLC (Missouri)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Langsam Health Services, LLC (Delaware)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">LCPS Acquisition, LLC (Delaware)</font></div><div style="padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Omnicare Pharmacy of Tennessee LLC (Delaware)</font></div><div style="padding-left:144pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:23.46pt">Lobos Acquisition, LLC (Delaware)</font></div><div style="padding-left:144pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:23.46pt">Lo-Med Prescription Services, LLC (Ohio) </font></div><div style="padding-left:157.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.09pt">ZS Acquisition Company, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Main Street Pharmacy, L.L.C. (Maryland)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of Illinois, LLC (Ohio)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of Iowa, LLC (Ohio)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">Martin Health Services, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of Kansas, LLC (Ohio)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of Kentucky, LLC (Ohio)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of Montana, LLC (Ohio)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of New Mexico, LLC (Ohio)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of South Carolina, LLC (Ohio)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of Tennessee, LLC (Ohio)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of Ohio, LLC (Ohio)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">NCS Healthcare of Wisconsin, LLC (Ohio)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">North Shore Pharmacy Services LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare Indiana Partnership Holding Company LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare of New York, LLC (Delaware)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">NeighborCare of Indiana, LLC (Indiana)</font></div><div style="padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Grandview Pharmacy, LLC (Indiana)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">NeighborCare of Virginia, LLC (Virginia)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare Pharmacies of Pennsylvania West LLC (Pennsylvania)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare Pharmacy and Supply Services LLC (South Dakota)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare Pharmacy of the Midwest, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare Property Management, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Pharmacy Consultants, LLC (South Carolina)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">PRN Pharmaceutical Services, LP (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Roeschen&#8217;s Healthcare LLC (Wisconsin)</font></div><div style="padding-left:162pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.59pt">PP Acquisition Company LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Specialized Pharmacy Services, LLC (Michigan)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Value Health Care Services LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">VAPS Acquisition Company, LLC (Delaware)</font></div><div style="padding-left:135pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Westhaven Services Co, LLC (Ohio)</font></div><div style="padding-left:117pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Three Forks Apothecary, LLC (Kentucky)</font></div><div style="margin-bottom:8pt;padding-left:117pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">UNI-Care Health Services of Maine, LLC (New Hampshire)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">CVS Pharmacy, Inc. (continued)</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS 2948 Henderson, L.L.C. (Nevada)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS AL Distribution, L.L.C. (Alabama)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Albany, L.L.C. (New York)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS AOC Services, L.L.C. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS AOC Corporation (California)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Care Concierge, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Health Applications, LLC (Rhode Island)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Health Clinical Trial Services LLC (Connecticut)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Health Growth Equity, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Health Solutions LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Health Ventures Management, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Health Ventures Fund GP, LLC (Delaware)</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Health Ventures Fund, LP (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Indiana, L.L.C. (Indiana)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS International, Inc. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CCI Foreign, S.&#224; R.L. (R.C.S. Luxembourg)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Beauty Holdings, LLC (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Pamplona Sa&#250;de e Beleza LTDA (Brazil)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:13.75pt">CVS Safir Sourcing, LLC (Delaware)</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Strategic Resources Private Limited (India)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Kidney Care, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Kidney Care Health Services LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Kidney Care Advanced Technologies LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">CVS Kidney Care Home Dialysis LLC (Delaware)</font></div><div style="padding-left:103.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.96pt">CVS-SHC Renal Holdings LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Management Support, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Manchester NH, L.L.C. (New Hampshire)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Media Exchange LLC (Delaware)</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Michigan, L.L.C. (Michigan)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Orlando FL Distribution, L.L.C. (Florida)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS PA Distribution, L.L.C. (Pennsylvania)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Pharmacy Overseas Online, LLC</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS PR Center, Inc. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Puerto Rico CVS Pharmacy, L.L.C. (Puerto Rico)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Caremark Puerto Rico, L.L.C. (Puerto Rico)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Caremark Puerto Rico Specialty Pharmacy, L.L.C. (Puerto Rico)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS RS Arizona, L.L.C. (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Arizona CVS Stores, L.L.C. (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS 3268 Gilbert, L.L.C. (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS 3745 Peoria, L.L.C. (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Gilbert 3272, L.L.C. (Arizona)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Rx Services, Inc. (New York)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Busse CVS, L.L.C. (Illinois)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Goodyear CVS, L.L.C. (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Sheffield Avenue CVS, L.L.C. (Illinois)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">South Wabash CVS, L.L.C. (Illinois)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Thomas Phoenix CVS, L.L.C. (Arizona)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Washington Lamb CVS, L.L.C. (Nevada)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS SC Distribution, L.L.C. (South Carolina)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS State Capital, L.L.C. (Maine)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS TN Distribution, L.L.C. (Tennessee)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Transportation, L.L.C. (Indiana)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Vero FL Distribution, L.L.C. (Florida)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">D.A.W., LLC (Massachusetts)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Delaware CVS Pharmacy, L.L.C. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">District of Columbia CVS Pharmacy, L.L.C. (District of Columbia)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Enterprise Patient Safety Organization, LLC (Rhode Island)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">E.T.B., Inc. (Texas)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Garfield Beach CVS, L.L.C. (California)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Georgia CVS Pharmacy, L.L.C. (Georgia)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">German Dobson CVS, L.L.C. (Arizona)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Grand St. Paul CVS, L.L.C. (Minnesota)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Highland Park CVS, L.L.C. (Illinois)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Holiday CVS, L.L.C. (Florida)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Hook-SupeRx, L.L.C. (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Idaho CVS Pharmacy, L.L.C. (Idaho)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Iowa CVS Pharmacy, L.L.C. (Iowa)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Kansas CVS Pharmacy, L.L.C. (Kansas)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Kentucky CVS Pharmacy, L.L.C. (Kentucky)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Longs Drug Stores California, L.L.C. (California)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Louisiana CVS Pharmacy, L.L.C. (Louisiana)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Maryland CVS Pharmacy, L.L.C. (Maryland)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Melville Realty Company, Inc. (New York)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">CVS Bellmore Avenue, L.L.C. (New York)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic, L.L.C. (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Alabama, L.L.C. (Alabama)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Arkansas, LLC (Arkansas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Arizona, LLC (Minnesota)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Colorado LLC (Colorado)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Florida, LLC (Minnesota)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Georgia, LLC (Minnesota)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Hawaii, L.L.C. (Hawaii)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Illinois, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Kentucky, L.L.C. (Kentucky)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Louisiana, L.L.C. (Louisiana)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Maine, L.L.C. (Maine)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Maryland, LLC (Minnesota)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Massachusetts, LLC (Massachusetts)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Nebraska, L.L.C. (Nebraska)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of New Hampshire, L.L.C. (New Hampshire)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of New Mexico, L.L.C. (New Mexico)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Ohio, LLC (Ohio)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Oklahoma, LLC (Oklahoma)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Oregon, LLC (Oregon)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Pennsylvania, LLC (Minnesota)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Rhode Island, LLC (Minnesota)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of South Carolina, L.L.C. (South Carolina)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Texas, LLC (Minnesota)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Utah, L.L.C. (Utah)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Virginia, LLC (Virginia)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Washington, LLC (Oregon)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Diagnostic of Wisconsin, L.L.C. (Wisconsin)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Online Diagnostic Services, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Physician Practice of Texas (Texas)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Telehealth Services, LLC (Delaware)</font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">MinuteClinic Telehealth Services of Texas Association (Texas)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Mississippi CVS Pharmacy, L.L.C. (Mississippi)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Missouri CVS Pharmacy, L.L.C. (Missouri)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Montana CVS Pharmacy, L.L.C. (Montana)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Nebraska CVS Pharmacy, L.L.C. (Nebraska)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">New Jersey CVS Pharmacy, L.L.C. (New Jersey)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%;padding-left:14.46pt">North 53, LLC (Delaware)</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">North 53 TAOH Limited</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">North 53 TAOO Limited</font></div><div style="padding-left:76.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">North 53 (Ireland) TAOH Limited</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">North Carolina CVS Pharmacy, L.L.C. (North Carolina)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Ohio CVS Stores, L.L.C. (Ohio)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Oklahoma CVS Pharmacy, L.L.C. (Oklahoma)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.46pt">Omnicare Resources, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Oregon CVS Pharmacy, L.L.C. (Oregon)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Pennsylvania CVS Pharmacy, L.L.C. (Pennsylvania)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">ProCare Pharmacy Direct, L.L.C. (Ohio)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">ProCare Pharmacy, L.L.C. (Rhode Island)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Red Oak Sourcing, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Rhode Island CVS Pharmacy, L.L.C. (Rhode Island)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">South Carolina CVS Pharmacy, L.L.C. (South Carolina)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Tennessee CVS Pharmacy, L.L.C. (Tennessee)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Utah CVS Pharmacy, L.L.C. (Utah)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Vermont CVS Pharmacy, L.L.C. (Vermont)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Virginia CVS Pharmacy, L.L.C. (Virginia)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Warm Springs Road CVS, L.L.C. (Nevada)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Washington CVS Pharmacy, L.L.C. (Washington)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Wellpartner, LLC (Delaware)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">West Virginia CVS Pharmacy, L.L.C. (West Virginia)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Wisconsin CVS Pharmacy, L.L.C. (Wisconsin)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Woodward Detroit CVS, L.L.C. (Michigan)</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Zinc Health Ventures, LLC (Delaware)</font></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:139%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:12pt">Zinc Health Services, LLC (Delaware)</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">12</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit231-2022.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iba5a89579bf14d90a09f9dfc330a5e97_1"></div><div style="min-height:72pt;width:100%"><div style="padding-left:18pt;text-align:right"><font><br></font></div><div style="padding-left:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consent of Independent Registered Public Accounting Firm</font></div><div style="padding-left:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-top:12pt;padding-left:27.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-3ASR No. 333-238506) of CVS Health Corporation, and</font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statements (Form S-8 Nos. 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 333-139470, 333-63664, 333-91253, 333-49407, 333-34927, and 333-28043) of CVS Health Corporation&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of our reports dated February&#160;8, 2023, with respect to the consolidated financial statements of CVS Health Corporation and the effectiveness of internal control over financial reporting of CVS Health Corporation included in this Annual Report (Form 10-K) of CVS Health Corporation for the year ended December&#160;31, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;8, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exhibit311-2022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibb375247522e42499c116eafa201fa89_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:5pt;text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Karen S. Lynch, President and Chief Executive Officer of CVS Health Corporation, certify that&#58; </font></div><div><font><br></font></div><div style="margin-bottom:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of CVS Health Corporation&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:45pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;&#160;&#160;&#160;&#160;&#160;KAREN S. LYNCH</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Karen S. Lynch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exhibit312-2022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iaf6e2ccf476a488cb8078c6121d4a056_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-bottom:5pt;text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Shawn M. Guertin, Executive Vice President and Chief Financial Officer of CVS Health Corporation, certify that&#58; </font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of CVS Health Corporation&#59;</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:45pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;&#160;&#160;&#160;&#160; SHAWN M. GUERTIN</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shawn M. Guertin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exhibit321-2022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibc932f3c5b3242a5923a6d3327e0a6ee_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The certification set forth below is being submitted in connection with the Annual Report of CVS Health Corporation (the &#34;Company&#34;) on Form 10-K for the period ended December&#160;31, 2022 (the &#8220;Report&#8221;) solely for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code. </font></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Karen S. Lynch, President and Chief Executive Officer of the Company, certify that, to the best of my knowledge&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;&#160;&#160;&#160;&#160;KAREN S. LYNCH</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Karen S. Lynch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>exhibit322-2022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie3b51f1365604815b45881872a8e4796_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2 </font></div><div style="margin-bottom:5pt;text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The certification set forth below is being submitted in connection with the Annual Report of CVS Health Corporation (the &#34;Company&#34;) on Form 10-K for the period ended December&#160;31, 2022 (the &#8220;Report&#8221;) solely for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code. </font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Shawn M. Guertin, Executive Vice President and Chief Financial Officer of the Company, certify that, to the best of my knowledge&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-13.5pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;&#160;&#160;&#160;&#160;SHAWN M. GUERTIN</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shawn M. Guertin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial&#160;Officer</font></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cvs-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:062ae674-cc97-4efd-81c6-d89202a3d450,g:ffc34178-e241-4c21-bbb1-7b57d93a8581-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cvs="http://www.cvshealth.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cvshealth.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cvs-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cvshealth.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.cvshealth.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.cvshealth.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows_1" roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000008 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityParentheticals" roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals">
        <link:definition>0000009 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>0000010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.cvshealth.com/role/SignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresandAssetSales" roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSales">
        <link:definition>0000012 - Disclosure - Acquisitions, Divestitures and Asset Sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.cvshealth.com/role/Investments">
        <link:definition>0000013 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.cvshealth.com/role/FairValue">
        <link:definition>0000014 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibles" roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangibles">
        <link:definition>0000015 - Disclosure - Goodwill and Other Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cvshealth.com/role/Leases">
        <link:definition>0000016 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HealthCareCostsPayable" roleURI="http://www.cvshealth.com/role/HealthCareCostsPayable">
        <link:definition>0000017 - Disclosure - Health Care Costs Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsandCreditAgreements" roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreements">
        <link:definition>0000018 - Disclosure - Borrowings and Credit Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPlansandOtherPostretirementBenefits" roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits">
        <link:definition>0000019 - Disclosure - Pension Plans and Other Postretirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cvshealth.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlans" roleURI="http://www.cvshealth.com/role/StockIncentivePlans">
        <link:definition>0000021 - Disclosure - Stock Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cvshealth.com/role/ShareholdersEquity">
        <link:definition>0000022 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.cvshealth.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>0000023 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.cvshealth.com/role/EarningsPerShare">
        <link:definition>0000024 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Reinsurance" roleURI="http://www.cvshealth.com/role/Reinsurance">
        <link:definition>0000025 - Disclosure - Reinsurance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cvshealth.com/role/CommitmentsandContingencies">
        <link:definition>0000026 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.cvshealth.com/role/SegmentReporting">
        <link:definition>0000027 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>0000028 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesTables">
        <link:definition>0000029 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresandAssetSalesTables" roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesTables">
        <link:definition>0000030 - Disclosure - Acquisitions, Divestitures and Asset Sales (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.cvshealth.com/role/InvestmentsTables">
        <link:definition>0000031 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.cvshealth.com/role/FairValueTables">
        <link:definition>0000032 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesTables" roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables">
        <link:definition>0000033 - Disclosure - Goodwill and Other Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cvshealth.com/role/LeasesTables">
        <link:definition>0000034 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HealthCareCostsPayableTables" roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableTables">
        <link:definition>0000035 - Disclosure - Health Care Costs Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsandCreditAgreementsTables" roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables">
        <link:definition>0000036 - Disclosure - Borrowings and Credit Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPlansandOtherPostretirementBenefitsTables" roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables">
        <link:definition>0000037 - Disclosure - Pension Plans and Other Postretirement Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.cvshealth.com/role/IncomeTaxesTables">
        <link:definition>0000038 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansTables" roleURI="http://www.cvshealth.com/role/StockIncentivePlansTables">
        <link:definition>0000039 - Disclosure - Stock Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cvshealth.com/role/ShareholdersEquityTables">
        <link:definition>0000040 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeTables" roleURI="http://www.cvshealth.com/role/OtherComprehensiveIncomeTables">
        <link:definition>0000041 - Disclosure - Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.cvshealth.com/role/EarningsPerShareTables">
        <link:definition>0000042 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceTables" roleURI="http://www.cvshealth.com/role/ReinsuranceTables">
        <link:definition>0000043 - Disclosure - Reinsurance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.cvshealth.com/role/SegmentReportingTables">
        <link:definition>0000044 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000045 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails">
        <link:definition>0000046 - Disclosure - Significant Accounting Policies - Cash and Cash Equivalents, Restricted Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAccountsReceivableDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails">
        <link:definition>0000047 - Disclosure - Significant Accounting Policies - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>0000048 - Disclosure - Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>0000049 - Disclosure - Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesReceivablesandContractedBalancesDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails">
        <link:definition>0000050 - Disclosure - Significant Accounting Policies - Receivables and Contracted Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesContractBalancesDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails">
        <link:definition>0000051 - Disclosure - Significant Accounting Policies - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesVariableInterestEntitiesDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails">
        <link:definition>0000052 - Disclosure - Significant Accounting Policies - Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesDiscontinuedOperationsDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails">
        <link:definition>0000053 - Disclosure - Significant Accounting Policies - Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails" roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails">
        <link:definition>0000054 - Disclosure - Significant Accounting Policies - New Accounting Pronouncements Not Yet Adopted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresandAssetSalesNarrativeDetails" roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails">
        <link:definition>0000055 - Disclosure - Acquisitions, Divestitures and Asset Sales - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails">
        <link:definition>0000056 - Disclosure - Acquisitions, Divestitures and Asset Sales - Summary of Assets and Liabilities Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofTotalInvestmentsDetails" roleURI="http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails">
        <link:definition>0000057 - Disclosure - Investments - Schedule of Total Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.cvshealth.com/role/InvestmentsNarrativeDetails">
        <link:definition>0000058 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDebtSecuritiesDetails" roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails">
        <link:definition>0000059 - Disclosure - Investments - Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDebtSecuritiesDetails_1" roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1">
        <link:definition>0000059 - Disclosure - Investments - Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDebtSecuritiesbyMaturityDetails" roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails">
        <link:definition>0000060 - Disclosure - Investments - Debt Securities by Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsUnrealizedLossPositionDetails" roleURI="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails">
        <link:definition>0000061 - Disclosure - Investments - Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsUnrealizedLossPositionMaturitiesDetails" roleURI="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails">
        <link:definition>0000062 - Disclosure - Investments - Unrealized Loss Position Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsMortgageLoansDetails" roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails">
        <link:definition>0000063 - Disclosure - Investments - Mortgage Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsMortgageLoansCreditRatingsIndicatorDetails" roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails">
        <link:definition>0000064 - Disclosure - Investments - Mortgage Loans Credit Ratings Indicator (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsMortgageLoanPrincipalRepaymentsDetails" roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails">
        <link:definition>0000065 - Disclosure - Investments - Mortgage Loan Principal Repayments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNetInvestmentIncomeDetails" roleURI="http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails">
        <link:definition>0000066 - Disclosure - Investments - Net Investment Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsRealizedGainsDetails" roleURI="http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails">
        <link:definition>0000067 - Disclosure - Investments - Realized Gains (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueFairValueMeasurementsDetails" roleURI="http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails">
        <link:definition>0000068 - Disclosure - Fair Value - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueChangesinLevel3FinancialAssetsDetails" roleURI="http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails">
        <link:definition>0000069 - Disclosure - Fair Value - Changes in Level 3 Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueGrossTransfersIntoOutOfLevel3Details" roleURI="http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details">
        <link:definition>0000070 - Disclosure - Fair Value - Gross Transfers Into (Out Of) Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueCarryingValueandFairValueClassifiedbyLevelDetails" roleURI="http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails">
        <link:definition>0000071 - Disclosure - Fair Value - Carrying Value and Fair Value Classified by Level (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueSeparateAccountsFairValueDetails" roleURI="http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails">
        <link:definition>0000072 - Disclosure - Fair Value - Separate Accounts Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueNarrativeDetails" roleURI="http://www.cvshealth.com/role/FairValueNarrativeDetails">
        <link:definition>0000073 - Disclosure - Fair Value - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesGoodwillDetails" roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails">
        <link:definition>0000074 - Disclosure - Goodwill and Other Intangibles - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesNarrativeDetails" roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails">
        <link:definition>0000075 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesIntangibleAssetsDetails" roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails">
        <link:definition>0000076 - Disclosure - Goodwill and Other Intangibles - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" roleURI="http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails">
        <link:definition>0000077 - Disclosure - Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cvshealth.com/role/LeasesNarrativeDetails">
        <link:definition>0000078 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryoftheComponentsofNetLeaseCostDetails" roleURI="http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails">
        <link:definition>0000079 - Disclosure - Leases - Summary of the Components of Net Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>0000080 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000081 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" roleURI="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails">
        <link:definition>0000082 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" roleURI="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1">
        <link:definition>0000082 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails">
        <link:definition>0000083 - Disclosure - Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HealthCareCostsPayableNarrativeDetails" roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails">
        <link:definition>0000084 - Disclosure - Health Care Costs Payable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails">
        <link:definition>0000085 - Disclosure - Health Care Costs Payable - Liability for Unpaid Claims and Claims Adjustment Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails">
        <link:definition>0000086 - Disclosure - Health Care Costs Payable - Components of Change in Health Care Costs Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails">
        <link:definition>0000087 - Disclosure - Borrowings and Credit Agreements - Schedule of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsandCreditAgreementsDebtMaturitiesDetails" roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails">
        <link:definition>0000088 - Disclosure - Borrowings and Credit Agreements - Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsandCreditAgreementsShorttermBorrowingsDetails" roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails">
        <link:definition>0000089 - Disclosure - Borrowings and Credit Agreements - Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsandCreditAgreementsLongtermBorrowingsDetails" roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails">
        <link:definition>0000090 - Disclosure - Borrowings and Credit Agreements - Long-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPlansandOtherPostretirementBenefitsNarrativeDetails" roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails">
        <link:definition>0000091 - Disclosure - Pension Plans and Other Postretirement Benefits - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails">
        <link:definition>0000092 - Disclosure - Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails">
        <link:definition>0000093 - Disclosure - Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Cost (Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails">
        <link:definition>0000094 - Disclosure - Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails">
        <link:definition>0000095 - Disclosure - Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails">
        <link:definition>0000096 - Disclosure - Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails">
        <link:definition>0000097 - Disclosure - Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxProvisionDetails" roleURI="http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails">
        <link:definition>0000098 - Disclosure - Income Taxes - Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveTaxRateReconciliationDetails" roleURI="http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails">
        <link:definition>0000099 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000100 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000101 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>0000102 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" roleURI="http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails">
        <link:definition>0000103 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansRestrictedStockActivityDetails" roleURI="http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails">
        <link:definition>0000104 - Disclosure - Stock Incentive Plans - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansStockOptionandSARActivityDetails" roleURI="http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails">
        <link:definition>0000105 - Disclosure - Stock Incentive Plans - Stock Option and SAR Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansValuationAssumptionsDetails" roleURI="http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails">
        <link:definition>0000106 - Disclosure - Stock Incentive Plans - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityShareRepurchasesDetails" roleURI="http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails">
        <link:definition>0000107 - Disclosure - Shareholders' Equity - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityAcceleratedShareRepurchasesDetails" roleURI="http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails">
        <link:definition>0000108 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDividendsDetails" roleURI="http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails">
        <link:definition>0000109 - Disclosure - Shareholders' Equity - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityRegulatoryRequirementsDetails" roleURI="http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails">
        <link:definition>0000110 - Disclosure - Shareholders' Equity - Regulatory Requirements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNoncontrollingInterestsDetails" roleURI="http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails">
        <link:definition>0000111 - Disclosure - Shareholders' Equity - Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossDetails" roleURI="http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails">
        <link:definition>0000112 - Disclosure - Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.cvshealth.com/role/EarningsPerShareDetails">
        <link:definition>0000113 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceNarrativeDetails" roleURI="http://www.cvshealth.com/role/ReinsuranceNarrativeDetails">
        <link:definition>0000114 - Disclosure - Reinsurance - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceReinsuranceRecoverablesDetails" roleURI="http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails">
        <link:definition>0000115 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceEffectsofReinsuranceDetails" roleURI="http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails">
        <link:definition>0000116 - Disclosure - Reinsurance - Effects of Reinsurance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.cvshealth.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000117 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.cvshealth.com/role/SegmentReportingNarrativeDetails">
        <link:definition>0000118 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" roleURI="http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails">
        <link:definition>0000119 - Disclosure - Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" roleURI="http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails">
        <link:definition>0000120 - Disclosure - Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cvs_EquitySecuritiesDomesticRealEstateMember" abstract="true" name="EquitySecuritiesDomesticRealEstateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock" abstract="false" name="ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cvs_OutstandingSeniorNotesMember" abstract="true" name="OutstandingSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure" abstract="false" name="InvestmentContractsWithFixedMaturityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_MortgageLoansOnRealEstateYearOfOriginationDomain" abstract="true" name="MortgageLoansOnRealEstateYearOfOriginationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes3Point625PercentApril2027Member" abstract="true" name="SeniorNotes3Point625PercentApril2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract" abstract="true" name="FinanceLeaseAssetsAndLiabilitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_EmployeeStockOptionsAndStockAppreciationRightsMember" abstract="true" name="EmployeeStockOptionsAndStockAppreciationRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_HealthInsurerFeeTaxEffectPercent" abstract="false" name="HealthInsurerFeeTaxEffectPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_InvestmentIncomeExcludingCapitalGainsOrLosses" abstract="false" name="InvestmentIncomeExcludingCapitalGainsOrLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_CVSHealth2017IncentiveCompensationPlanMember" abstract="true" name="CVSHealth2017IncentiveCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock" abstract="false" name="ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cvs_FrontStoreRevenueMember" abstract="true" name="FrontStoreRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_YearOfOriginationPeriodThreeMember" abstract="true" name="YearOfOriginationPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive" abstract="false" name="MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_DeferredTaxAssetsPayrollTaxDeferral" abstract="false" name="DeferredTaxAssetsPayrollTaxDeferral" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" abstract="false" name="TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_RadcliffAndFlaimVAetnaIncEtAlMember" abstract="true" name="RadcliffAndFlaimVAetnaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_TotalInvestmentsTableTextBlock" abstract="false" name="TotalInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cvs_LesseeLiabilityUndiscountedExcessAmount" abstract="false" name="LesseeLiabilityUndiscountedExcessAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_TotalInvestmentsDomain" abstract="true" name="TotalInvestmentsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LegalSettlementPeriodOfPayment" abstract="false" name="LegalSettlementPeriodOfPayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cvs_SeniorNotes3.25DueAugust2029Member" abstract="true" name="SeniorNotes3.25DueAugust2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_ThailandBusinessMember" abstract="true" name="ThailandBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SupportingRemainingProductsMember" abstract="true" name="SupportingRemainingProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_RedOakMember" abstract="true" name="RedOakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes4.875DueJuly2035Member" abstract="true" name="SeniorNotes4.875DueJuly2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_PharmacyServicesSegmentMember" abstract="true" name="PharmacyServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_PharmacyRevenueMember" abstract="true" name="PharmacyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes4PointThreePercentDue2028Member" abstract="true" name="SeniorNotes4PointThreePercentDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_A2022RepurchaseProgramMember" abstract="true" name="A2022RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeparateAccountFinancialAssetsMember" abstract="true" name="SeparateAccountFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_DebtAndEquitySecuritiesAvailableForSaleMember" abstract="true" name="DebtAndEquitySecuritiesAvailableForSaleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_AllOtherReinsurersMember" abstract="true" name="AllOtherReinsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" abstract="false" name="FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" abstract="false" name="ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates" abstract="false" name="IndividualPublicHealthInsuranceExchangesNumberOfStates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract" abstract="true" name="FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_PharmacyRebatePeriod" abstract="false" name="PharmacyRebatePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cvs_VariableInterestEntityAmendedContractExtensionTerm" abstract="false" name="VariableInterestEntityAmendedContractExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" abstract="false" name="OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_TotalInvestmentsAxis" abstract="true" name="TotalInvestmentsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cvs_NumeratorForEarningsPerShareCalculationAbstract" abstract="true" name="NumeratorForEarningsPerShareCalculationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts" abstract="false" name="ContractualObligationsToMaintainLevelsOfSeparateAccounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements" abstract="false" name="LitigationSettlementNumberOfStatesSubjectToEarlierSettlements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" abstract="false" name="OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_OtherInsuranceLiabilitiesNoncurrent" abstract="false" name="OtherInsuranceLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_FinanceLeaseRightOfUseAssetNet" abstract="false" name="FinanceLeaseRightOfUseAssetNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" abstract="false" name="CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" abstract="false" name="ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_LiabilityForUnpaidClaims" abstract="false" name="LiabilityForUnpaidClaims" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo" abstract="false" name="MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_DeferredTaxLiabilitiesDepreciationAndAmortization" abstract="false" name="DeferredTaxLiabilitiesDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer" abstract="false" name="FourYearsReinsuranceAgreementWithUnrelatedInsurer" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cvs_SettlementFrameworkMember" abstract="true" name="SettlementFrameworkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_USFederalGovernmentMember" abstract="true" name="USFederalGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_NumberOfPatientsServedPerYear" abstract="false" name="NumberOfPatientsServedPerYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_LesseeLiabilityPaymentsYearOne" abstract="false" name="LesseeLiabilityPaymentsYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes3Point70PercentDue2023Member" abstract="true" name="SeniorNotes3Point70PercentDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_TotalInvestmentsLineItems" abstract="true" name="TotalInvestmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member" abstract="true" name="ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock" abstract="false" name="VendorAllowancesAndPurchaseDiscountsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cvs_SeniorNotes1Point3PercentAugust2027Member" abstract="true" name="SeniorNotes1Point3PercentAugust2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes2.75DueDecember2022Member" abstract="true" name="SeniorNotes2.75DueDecember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_RedeemablePreferredSecuritiesMember" abstract="true" name="RedeemablePreferredSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_NumberOfStoresPlannedClosure" abstract="false" name="NumberOfStoresPlannedClosure" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_LesseeLiabilityPaymentsDueYearFour" abstract="false" name="LesseeLiabilityPaymentsDueYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_PaymentsForInsuranceBenefits" abstract="false" name="PaymentsForInsuranceBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SupportingExperienceRatedProductsMember" abstract="true" name="SupportingExperienceRatedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LesseeLiabilityPaymentsDueYearTwo" abstract="false" name="LesseeLiabilityPaymentsDueYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_FederalCourtInOhioJudgmentMember" abstract="true" name="FederalCourtInOhioJudgmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes5.75DueMay2041Member" abstract="true" name="SeniorNotes5.75DueMay2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes4.1DueMarch2025Member" abstract="true" name="SeniorNotes4.1DueMarch2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates" abstract="false" name="IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cvs_SeniorNotes3DueAugust2026Member" abstract="true" name="SeniorNotes3DueAugust2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_HartfordLifeAndAccidentInsuranceCompanyMember" abstract="true" name="HartfordLifeAndAccidentInsuranceCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_VariableInterestEntityAmendedContractTerm" abstract="false" name="VariableInterestEntityAmendedContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cvs_DebtExtinguishmentFees" abstract="false" name="DebtExtinguishmentFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_BswiftLLCMember" abstract="true" name="BswiftLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_PaymentsForAcceleratedShareRepurchasesAmount" abstract="false" name="PaymentsForAcceleratedShareRepurchasesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_ValueOfBusinessAcquiredMember" abstract="true" name="ValueOfBusinessAcquiredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember" abstract="true" name="USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes6.125DueSeptember2039Member" abstract="true" name="SeniorNotes6.125DueSeptember2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LongTermCareReportingUnitMember" abstract="true" name="LongTermCareReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_ProviderNetworksMember" abstract="true" name="ProviderNetworksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_LongtermDebtGrossAndLeaseObligation" abstract="false" name="LongtermDebtGrossAndLeaseObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_MortgageLoansMember" abstract="true" name="MortgageLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" abstract="false" name="DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_NumberOfPeopleServed" abstract="false" name="NumberOfPeopleServed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_ActivityInMortgageLoanPortfolioTableTextBlock" abstract="false" name="ActivityInMortgageLoanPortfolioTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cvs_OtherAcquiredIntangibleAssetsTable" abstract="true" name="OtherAcquiredIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cvs_SeniorNotes3.7DueMarch2023Member" abstract="true" name="SeniorNotes3.7DueMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_YearOfOriginationPeriodFiveMember" abstract="true" name="YearOfOriginationPeriodFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes3.875DueJuly2025Member" abstract="true" name="SeniorNotes3.875DueJuly2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" abstract="false" name="PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_AdjustedOperatingIncomeLoss" abstract="false" name="AdjustedOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_CoventryHealthCareWorkersCompensationBusinessMember" abstract="true" name="CoventryHealthCareWorkersCompensationBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_RevolvingCreditFacilityExpiringMay162027Member" abstract="true" name="RevolvingCreditFacilityExpiringMay162027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" abstract="false" name="IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes2Point125PercentDueSeptember2031Member" abstract="true" name="SeniorNotes2Point125PercentDueSeptember2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity" abstract="false" name="RelatedPartyTransactionCharitableContributionToNonProfitEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_InsuranceAndHMOMember" abstract="true" name="InsuranceAndHMOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LincolnLifeAnnuityCompanyOfNewYorkMember" abstract="true" name="LincolnLifeAnnuityCompanyOfNewYorkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes4.5DueMay2042Member" abstract="true" name="SeniorNotes4.5DueMay2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes4.3DueMarch2028Member" abstract="true" name="SeniorNotes4.3DueMarch2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes5.3DueDecember2043Member" abstract="true" name="SeniorNotes5.3DueDecember2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_NumberOfPharmacyPlanMembers" abstract="false" name="NumberOfPharmacyPlanMembers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_StoreImpairmentCharges" abstract="false" name="StoreImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_HealthInsurerFee" abstract="false" name="HealthInsurerFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_LimitedPaymentsContracts" abstract="false" name="LimitedPaymentsContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cvs_AetnaInc2010StockIncentivePlanMember" abstract="true" name="AetnaInc2010StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree" abstract="false" name="MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" abstract="false" name="DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cvs_YearOfOriginationPriorToPeriodFiveMember" abstract="true" name="YearOfOriginationPriorToPeriodFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_RetailLongTermCareSegmentMember" abstract="true" name="RetailLongTermCareSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LesseeLiabilityPaymentsDueYearFive" abstract="false" name="LesseeLiabilityPaymentsDueYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_LesseeLiabilityPaymentsDueYearThree" abstract="false" name="LesseeLiabilityPaymentsDueYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax" abstract="false" name="FormerGainContingencyRecognizedInCurrentPeriodNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes4.125DueNovember2042Member" abstract="true" name="SeniorNotes4.125DueNovember2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_A2021RepurchaseProgramMember" abstract="true" name="A2021RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths" abstract="false" name="MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes4DueDecember2023Member" abstract="true" name="SeniorNotes4DueDecember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_SeniorNotes2.875DueJune2026Member" abstract="true" name="SeniorNotes2.875DueJune2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_PremiumDeficiencyReserveLiability" abstract="false" name="PremiumDeficiencyReserveLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_NumberOfWalkInMedicalClinics" abstract="false" name="NumberOfWalkInMedicalClinics" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_TribalEntitiesMember" abstract="true" name="TribalEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" abstract="false" name="AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation" abstract="false" name="FinanceLeaseRightOfUseAssetAccumulatedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes2.75DueNovember2022Member" abstract="true" name="SeniorNotes2.75DueNovember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_Category1Member" abstract="true" name="Category1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract" abstract="true" name="LesseeLeasesLiabilitiesPaymentsDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased" abstract="false" name="StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes3.5DueNovember2024Member" abstract="true" name="SeniorNotes3.5DueNovember2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_TransferOfSharesToTreasuryStockValue" abstract="false" name="TransferOfSharesToTreasuryStockValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_PensionAndAnnuityInvestmentContractsInterest" abstract="false" name="PensionAndAnnuityInvestmentContractsInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cvs_MortgageLoansOnRealEstateYearOfOriginationAxis" abstract="true" name="MortgageLoansOnRealEstateYearOfOriginationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" abstract="false" name="OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract" abstract="true" name="ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_HealthCareBenefitsSegmentMember" abstract="true" name="HealthCareBenefitsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember" abstract="true" name="FixturesEquipmentAndInternallyDevelopedSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_InitialContractualTerm" abstract="false" name="InitialContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_SalesChannelOtherMember" abstract="true" name="SalesChannelOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LesseeLeaseTableTextBlock" abstract="false" name="LesseeLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares" abstract="false" name="AcceleratedShareRepurchaseProgramMaximumNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cvs_YearOfOriginationPeriodTwoMember" abstract="true" name="YearOfOriginationPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_MortgageLoansOnRealEstateLoansFullyRepaid" abstract="false" name="MortgageLoansOnRealEstateLoansFullyRepaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_Category2To4Member" abstract="true" name="Category2To4Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SharesHeldInTrustPolicyTextBlock" abstract="false" name="SharesHeldInTrustPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cvs_DeferredTaxLiabilitiesRetirementBenefits" abstract="false" name="DeferredTaxLiabilitiesRetirementBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract" abstract="true" name="HealthCareAndOtherInsuranceLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_Category7Member" abstract="true" name="Category7Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" abstract="false" name="LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_AcceleratedShareRepurchasesAgreementAmount" abstract="false" name="AcceleratedShareRepurchasesAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_InsurancePremiumDeficiencyReservePolicyTextBlock" abstract="false" name="InsurancePremiumDeficiencyReservePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cvs_RevolvingCreditFacilityExpiringMay112026Member" abstract="true" name="RevolvingCreditFacilityExpiringMay112026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember" abstract="true" name="DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes43Due2028Member" abstract="true" name="SeniorNotes43Due2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_StateOfFloridaSettlementMember" abstract="true" name="StateOfFloridaSettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LesseeLiabilityPaymentsDue" abstract="false" name="LesseeLiabilityPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes4.78DueMarch2038Member" abstract="true" name="SeniorNotes4.78DueMarch2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes4.75DueDecember2022Member" abstract="true" name="SeniorNotes4.75DueDecember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock" abstract="false" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cvs_SeniorNotes3.875DueAugust2047Member" abstract="true" name="SeniorNotes3.875DueAugust2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_HeartlandHealthcareServicesMember" abstract="true" name="HeartlandHealthcareServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LesseeOperatingAndFinanceLeasesRenewalTerm" abstract="false" name="LesseeOperatingAndFinanceLeasesRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cvs_OtherAcquiredIntangibleAssetsLineItems" abstract="true" name="OtherAcquiredIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member" abstract="true" name="ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember" abstract="true" name="RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes5DueDecember2024Member" abstract="true" name="SeniorNotes5DueDecember2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes3.5DueJuly2022Member" abstract="true" name="SeniorNotes3.5DueJuly2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes6.25DueJune2027Member" abstract="true" name="SeniorNotes6.25DueJune2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_Categories5And6Member" abstract="true" name="Categories5And6Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_OtherLongTermInsuranceLiabilitiesMember" abstract="true" name="OtherLongTermInsuranceLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_PayflexMember" abstract="true" name="PayflexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember" abstract="true" name="DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes5.125DueJuly2045Member" abstract="true" name="SeniorNotes5.125DueJuly2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes4Point125PercentApril2040Member" abstract="true" name="SeniorNotes4Point125PercentApril2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_BarclaysBankMember" abstract="true" name="BarclaysBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes2Point7PercentAugust2040Member" abstract="true" name="SeniorNotes2Point7PercentAugust2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure" abstract="false" name="OperatingLeaseRightOfUseAssetFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" abstract="false" name="AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember" abstract="true" name="SettlementFrameworkAndOtherOpioidRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_BusinessCombinationTerminationFee" abstract="false" name="BusinessCombinationTerminationFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes2.8DueJune2023Member" abstract="true" name="SeniorNotes2.8DueJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_InternationalHealthCareRenewalRightsMember" abstract="true" name="InternationalHealthCareRenewalRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour" abstract="false" name="MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes5.05DueMarch2048Member" abstract="true" name="SeniorNotes5.05DueMarch2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold" abstract="false" name="DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife" abstract="false" name="OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract" abstract="true" name="OperatingLeaseAssetsAndLiabilitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_HeathSavingsAccountBalance" abstract="false" name="HeathSavingsAccountBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure" abstract="false" name="InvestmentContractsWithoutFixedMaturityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" abstract="false" name="HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" abstract="false" name="OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_SeniorNotes1Point875PercentFebruary2031Member" abstract="true" name="SeniorNotes1Point875PercentFebruary2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance" abstract="false" name="TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cvs_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_LeasesWeightedAverageDiscountRateAbstract" abstract="true" name="LeasesWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember" abstract="true" name="RestrictedStockUnitsAndPerformanceShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease" abstract="false" name="NoncontrollingInterestOtherPeriodIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_PharmacyClaimsAndDiscountsPayableCurrent" abstract="false" name="PharmacyClaimsAndDiscountsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_OtherAssetBackedSecuritiesMember" abstract="true" name="OtherAssetBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_VendorandManufacturerReceivables" abstract="false" name="VendorandManufacturerReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent" abstract="false" name="DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cvs_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_SeniorNotes2.625DueAugust2024Member" abstract="true" name="SeniorNotes2.625DueAugust2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes6.75DueDecember2037Member" abstract="true" name="SeniorNotes6.75DueDecember2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_OtherInsuranceLiabilitiesCurrent" abstract="false" name="OtherInsuranceLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_GuarantorObligationsNumberOfLeases" abstract="false" name="GuarantorObligationsNumberOfLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_CommonAndCollectiveTrustsMember" abstract="true" name="CommonAndCollectiveTrustsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" abstract="false" name="BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_BackUpCreditFacilitiesMember" abstract="true" name="BackUpCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_OmnicareLongTermCareBusinessMember" abstract="true" name="OmnicareLongTermCareBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_RevolvingCreditFacilityExpiringMay162025Member" abstract="true" name="RevolvingCreditFacilityExpiringMay162025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" abstract="false" name="YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_OakStreetHealthIncMember" abstract="true" name="OakStreetHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes3.375DueAugust2024Member" abstract="true" name="SeniorNotes3.375DueAugust2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" abstract="false" name="PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_NetRevenuesRetailCoPayments" abstract="false" name="NetRevenuesRetailCoPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_StockOptionsAndStockAppreciationRightsMember" abstract="true" name="StockOptionsAndStockAppreciationRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive" abstract="false" name="MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_TotalInvestmentsTable" abstract="true" name="TotalInvestmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cvs_NumberofReinsuranceContractsEnteredInto" abstract="false" name="NumberofReinsuranceContractsEnteredInto" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_DenominatorForEarningsPerShareCalculationAbstract" abstract="true" name="DenominatorForEarningsPerShareCalculationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_CitibankNAMember" abstract="true" name="CitibankNAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SignifyHealthIncMember" abstract="true" name="SignifyHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_ProceedsFromVariableInterestEntity" abstract="false" name="ProceedsFromVariableInterestEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_OtherInsuranceLiabilitiesMember" abstract="true" name="OtherInsuranceLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_YearOfOriginationPeriodOneMember" abstract="true" name="YearOfOriginationPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_YearOfOriginationPeriodFourMember" abstract="true" name="YearOfOriginationPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_PremiumsMember" abstract="true" name="PremiumsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes1Point75PercentAugust2030Member" abstract="true" name="SeniorNotes1Point75PercentAugust2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased" abstract="false" name="AcceleratedShareRepurchasesNumberOfSharesRepurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" abstract="false" name="ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cvs_FinanceLeaseRightOfUseAssetGross" abstract="false" name="FinanceLeaseRightOfUseAssetGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_VOYARetirementInsuranceAndAnnuityCompanyMember" abstract="true" name="VOYARetirementInsuranceAndAnnuityCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes3Point75PercentApril2030Member" abstract="true" name="SeniorNotes3Point75PercentApril2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_TreasuryStockSharesHeldinTrust" abstract="false" name="TreasuryStockSharesHeldinTrust" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cvs_OfficeRealEstateOptimizationCharges" abstract="false" name="OfficeRealEstateOptimizationCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" abstract="false" name="AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cvs_SeniorNotes4.75DueMarch2044Member" abstract="true" name="SeniorNotes4.75DueMarch2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_LitigationSettlementNumberOfStatesElectedToJoin" abstract="false" name="LitigationSettlementNumberOfStatesElectedToJoin" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_ContractWithCustomerLiabilityRedemptionAndBreakage" abstract="false" name="ContractWithCustomerLiabilityRedemptionAndBreakage" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_NumberOfMedicalMembers" abstract="false" name="NumberOfMedicalMembers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract" abstract="true" name="RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod" abstract="false" name="NumberOfStoresAnnualPlannedClosuresForClosurePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cvs_SeniorNotes6.625DueJune2036Member" abstract="true" name="SeniorNotes6.625DueJune2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember" abstract="true" name="FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_SeniorNotes4Point25PercentApril2050Member" abstract="true" name="SeniorNotes4Point25PercentApril2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cvs_TreasuryStockValueSharesHeldInTrust" abstract="false" name="TreasuryStockValueSharesHeldInTrust" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_LesseeLiabilityPaymentsDueAfterYearFive" abstract="false" name="LesseeLiabilityPaymentsDueAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cvs_LongTermInvestmentsIncludingAssetsHeldForSale" abstract="false" name="LongTermInvestmentsIncludingAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cvs-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:062ae674-cc97-4efd-81c6-d89202a3d450,g:ffc34178-e241-4c21-bbb1-7b57d93a8581-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_26e75ac8-1ed8-4ebc-ad9a-9686ab7eaf22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f94f3aa-c898-4c2e-a17b-e4f9fb920f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_26e75ac8-1ed8-4ebc-ad9a-9686ab7eaf22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f94f3aa-c898-4c2e-a17b-e4f9fb920f48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9548b07d-bb10-49d4-aa8e-553884e9e740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_26e75ac8-1ed8-4ebc-ad9a-9686ab7eaf22" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9548b07d-bb10-49d4-aa8e-553884e9e740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e2cd2577-3872-4670-91a6-d09a7d974ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_97dbf1fe-0089-46e6-b25e-feb32b06ecf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e2cd2577-3872-4670-91a6-d09a7d974ab4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_97dbf1fe-0089-46e6-b25e-feb32b06ecf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_634cae68-7e3d-4bc6-b6da-161218201e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e2cd2577-3872-4670-91a6-d09a7d974ab4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_634cae68-7e3d-4bc6-b6da-161218201e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8ce64fa7-948e-47b9-ae06-080631d931d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_15e2c220-c246-4313-bbce-049501874df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_8ce64fa7-948e-47b9-ae06-080631d931d7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_15e2c220-c246-4313-bbce-049501874df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_dcc4f157-7733-4189-b86f-3a5281876d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_8ce64fa7-948e-47b9-ae06-080631d931d7" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_dcc4f157-7733-4189-b86f-3a5281876d17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7dae080a-3e9d-4c32-8858-109a38ec5bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_53bd083a-b77f-40ab-a1ed-a8ee6d18b27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7dae080a-3e9d-4c32-8858-109a38ec5bd5" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_53bd083a-b77f-40ab-a1ed-a8ee6d18b27a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_14f3da36-382e-49ea-9273-b0d7fff877fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7dae080a-3e9d-4c32-8858-109a38ec5bd5" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_14f3da36-382e-49ea-9273-b0d7fff877fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5e20df0d-59db-4797-b767-8952da17f399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7dae080a-3e9d-4c32-8858-109a38ec5bd5" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5e20df0d-59db-4797-b767-8952da17f399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement_be6f95b1-a78f-4538-9cca-d0d390f69578" xlink:href="cvs-20221231.xsd#cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7dae080a-3e9d-4c32-8858-109a38ec5bd5" xlink:to="loc_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement_be6f95b1-a78f-4538-9cca-d0d390f69578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9b273bb8-5f00-4de4-919b-f4c380ba1037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7dae080a-3e9d-4c32-8858-109a38ec5bd5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9b273bb8-5f00-4de4-919b-f4c380ba1037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_77f27043-727a-44c3-9c68-1f6b27effd05" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7dae080a-3e9d-4c32-8858-109a38ec5bd5" xlink:to="loc_cvs_StoreImpairmentCharges_77f27043-727a-44c3-9c68-1f6b27effd05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0fc07d46-380b-470b-81a0-375d99a3bb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7dae080a-3e9d-4c32-8858-109a38ec5bd5" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0fc07d46-380b-470b-81a0-375d99a3bb7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_23c3d866-f025-42ca-a27d-d96e59e5de43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7a6e500c-8cc0-40af-8d60-6b0c42ab5280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_23c3d866-f025-42ca-a27d-d96e59e5de43" xlink:to="loc_us-gaap_CostsAndExpenses_7a6e500c-8cc0-40af-8d60-6b0c42ab5280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5a7738fe-58c9-4d6f-9b7e-0b019f1f562e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_23c3d866-f025-42ca-a27d-d96e59e5de43" xlink:to="loc_us-gaap_Revenues_5a7738fe-58c9-4d6f-9b7e-0b019f1f562e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_eb3622ac-54d5-48b3-a059-7f8069d353f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_51b0ccd7-3442-4734-80b8-78319f08542f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_eb3622ac-54d5-48b3-a059-7f8069d353f8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_51b0ccd7-3442-4734-80b8-78319f08542f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_9710e67b-a708-4173-8ba0-3885df7b4933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_eb3622ac-54d5-48b3-a059-7f8069d353f8" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_9710e67b-a708-4173-8ba0-3885df7b4933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1407bf36-54aa-47ed-be93-943f5bd7ad2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_c7d41f5a-24d5-4c2d-a4f0-185e3b5453f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_1407bf36-54aa-47ed-be93-943f5bd7ad2a" xlink:to="loc_us-gaap_NetInvestmentIncome_c7d41f5a-24d5-4c2d-a4f0-185e3b5453f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_84363662-a3bc-4aae-9a89-aff2b3475b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_1407bf36-54aa-47ed-be93-943f5bd7ad2a" xlink:to="loc_us-gaap_PremiumsEarnedNet_84363662-a3bc-4aae-9a89-aff2b3475b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d53238b1-0727-4b51-9648-6ef5e44e316d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_1407bf36-54aa-47ed-be93-943f5bd7ad2a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d53238b1-0727-4b51-9648-6ef5e44e316d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f812ecaa-c4c0-4055-a3a0-70b1286f51e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_87402ccc-91c3-4256-9902-547a5084a1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f812ecaa-c4c0-4055-a3a0-70b1286f51e9" xlink:to="loc_us-gaap_OperatingIncomeLoss_87402ccc-91c3-4256-9902-547a5084a1a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e56ef58f-caf1-4664-9a41-cb28bfbb33ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f812ecaa-c4c0-4055-a3a0-70b1286f51e9" xlink:to="loc_us-gaap_InterestExpense_e56ef58f-caf1-4664-9a41-cb28bfbb33ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c70423f0-a7f4-49aa-9c3e-1b1d4f3d9297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f812ecaa-c4c0-4055-a3a0-70b1286f51e9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c70423f0-a7f4-49aa-9c3e-1b1d4f3d9297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41fe693d-4c26-4eee-829e-4277b8b97cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f812ecaa-c4c0-4055-a3a0-70b1286f51e9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41fe693d-4c26-4eee-829e-4277b8b97cc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b317b81-7c37-405c-8bd2-ff41f8f1de11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d0764533-82f8-4bec-8c90-ff03ff97f223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0b317b81-7c37-405c-8bd2-ff41f8f1de11" xlink:to="loc_us-gaap_ProfitLoss_d0764533-82f8-4bec-8c90-ff03ff97f223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_482147bc-2ef9-4c33-b647-93ed26812139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0b317b81-7c37-405c-8bd2-ff41f8f1de11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_482147bc-2ef9-4c33-b647-93ed26812139" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ce503cec-b499-47cb-a8a9-9cdfc532f4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bf503d53-12d9-461e-a34b-4c8c55b99117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ce503cec-b499-47cb-a8a9-9cdfc532f4e2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bf503d53-12d9-461e-a34b-4c8c55b99117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5392780b-d53a-40de-afd6-a936c95a2c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ce503cec-b499-47cb-a8a9-9cdfc532f4e2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5392780b-d53a-40de-afd6-a936c95a2c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b3d3c7e8-4381-48b6-84b9-cf22fe67b209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d13dc3c4-50b0-4ce1-8b09-2e969f230436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b3d3c7e8-4381-48b6-84b9-cf22fe67b209" xlink:to="loc_us-gaap_ProfitLoss_d13dc3c4-50b0-4ce1-8b09-2e969f230436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1a6c4fc5-fae0-474e-8fef-89674d6be510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b3d3c7e8-4381-48b6-84b9-cf22fe67b209" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1a6c4fc5-fae0-474e-8fef-89674d6be510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2833a797-d52a-4649-aeab-c38ec7755c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_588126cf-f94e-4a67-819d-244982e8bd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2833a797-d52a-4649-aeab-c38ec7755c12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_588126cf-f94e-4a67-819d-244982e8bd8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3c1d40e3-48b8-4d30-b9ec-feb9c764e49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2833a797-d52a-4649-aeab-c38ec7755c12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3c1d40e3-48b8-4d30-b9ec-feb9c764e49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3329b8bd-586c-4ed8-9a8e-9714212ce88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2833a797-d52a-4649-aeab-c38ec7755c12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3329b8bd-586c-4ed8-9a8e-9714212ce88f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_03179832-44ed-4340-8855-afaff391f363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2833a797-d52a-4649-aeab-c38ec7755c12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_03179832-44ed-4340-8855-afaff391f363" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5bae8f6-d197-4284-a45d-2f0a0b677d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8c2ef469-d0a7-49d8-bf42-a0b9405c9031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5bae8f6-d197-4284-a45d-2f0a0b677d0e" xlink:to="loc_us-gaap_StockholdersEquity_8c2ef469-d0a7-49d8-bf42-a0b9405c9031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_50e2e7db-6f38-4e31-857e-601959b5ffab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5bae8f6-d197-4284-a45d-2f0a0b677d0e" xlink:to="loc_us-gaap_MinorityInterest_50e2e7db-6f38-4e31-857e-601959b5ffab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f9320eb6-fd04-44ca-8a39-1dcad610c18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_40d83cea-8716-4afd-a137-d10f7d4602c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9320eb6-fd04-44ca-8a39-1dcad610c18b" xlink:to="loc_us-gaap_OtherAssetsCurrent_40d83cea-8716-4afd-a137-d10f7d4602c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ad75407f-a247-42e6-a0e3-c9ed8de82142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9320eb6-fd04-44ca-8a39-1dcad610c18b" xlink:to="loc_us-gaap_InventoryNet_ad75407f-a247-42e6-a0e3-c9ed8de82142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0a3e5ca9-b9de-4451-93ce-4fdc1698765b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9320eb6-fd04-44ca-8a39-1dcad610c18b" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0a3e5ca9-b9de-4451-93ce-4fdc1698765b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b81ba005-dd8a-46b2-8594-ccc387fae8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9320eb6-fd04-44ca-8a39-1dcad610c18b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b81ba005-dd8a-46b2-8594-ccc387fae8a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_90462fff-28dc-4f01-9684-c2b3a4d389c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9320eb6-fd04-44ca-8a39-1dcad610c18b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_90462fff-28dc-4f01-9684-c2b3a4d389c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_5e9e5782-3759-4794-88ab-20c3cd51925e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9320eb6-fd04-44ca-8a39-1dcad610c18b" xlink:to="loc_us-gaap_ShortTermInvestments_5e9e5782-3759-4794-88ab-20c3cd51925e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9aa4f686-dba3-4c60-a61b-8ffaa586fa27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_994f4b7e-0d99-4b90-a1ad-bcded3cbfddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9aa4f686-dba3-4c60-a61b-8ffaa586fa27" xlink:to="loc_us-gaap_LiabilitiesCurrent_994f4b7e-0d99-4b90-a1ad-bcded3cbfddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f293a4e7-ffe7-472c-868e-b7754ef74dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9aa4f686-dba3-4c60-a61b-8ffaa586fa27" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f293a4e7-ffe7-472c-868e-b7754ef74dfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_404d9d97-c102-407c-8c1f-55e8c3e16206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9aa4f686-dba3-4c60-a61b-8ffaa586fa27" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_404d9d97-c102-407c-8c1f-55e8c3e16206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability_1c4bb304-b912-42ac-b515-47e7223b22ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9aa4f686-dba3-4c60-a61b-8ffaa586fa27" xlink:to="loc_us-gaap_SeparateAccountsLiability_1c4bb304-b912-42ac-b515-47e7223b22ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherInsuranceLiabilitiesNoncurrent_26ee69ba-ede1-44be-8fb2-c48bc7529e82" xlink:href="cvs-20221231.xsd#cvs_OtherInsuranceLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9aa4f686-dba3-4c60-a61b-8ffaa586fa27" xlink:to="loc_cvs_OtherInsuranceLiabilitiesNoncurrent_26ee69ba-ede1-44be-8fb2-c48bc7529e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cd2d86e7-5ec7-4879-b973-034caa089d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9aa4f686-dba3-4c60-a61b-8ffaa586fa27" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_cd2d86e7-5ec7-4879-b973-034caa089d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ed17b5f-0ad5-4bd5-9d14-233220797f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9aa4f686-dba3-4c60-a61b-8ffaa586fa27" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ed17b5f-0ad5-4bd5-9d14-233220797f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7b8ce6cb-318b-4ed5-82b8-ebb8ddfa29a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b72e2536-f447-4b4d-a1e2-ae1230221b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7b8ce6cb-318b-4ed5-82b8-ebb8ddfa29a5" xlink:to="loc_us-gaap_Liabilities_b72e2536-f447-4b4d-a1e2-ae1230221b1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6c04a961-fd9b-42cc-9353-7479de82dd55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7b8ce6cb-318b-4ed5-82b8-ebb8ddfa29a5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6c04a961-fd9b-42cc-9353-7479de82dd55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b28596ca-c9ad-4ec1-8c2a-fd53f4f0ec60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7b8ce6cb-318b-4ed5-82b8-ebb8ddfa29a5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b28596ca-c9ad-4ec1-8c2a-fd53f4f0ec60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0c308400-b145-471b-95e1-3877134e8598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5aabf6be-b296-40b5-ade9-517372726b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0c308400-b145-471b-95e1-3877134e8598" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5aabf6be-b296-40b5-ade9-517372726b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ca525857-c497-47aa-8b6a-5a35d98a38c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0c308400-b145-471b-95e1-3877134e8598" xlink:to="loc_us-gaap_Goodwill_ca525857-c497-47aa-8b6a-5a35d98a38c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_fb07b10c-f8fc-481c-9ad9-9b8a34a10608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0c308400-b145-471b-95e1-3877134e8598" xlink:to="loc_us-gaap_SeparateAccountAssets_fb07b10c-f8fc-481c-9ad9-9b8a34a10608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b9e5d9e1-5d86-415e-9beb-047b773b8967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0c308400-b145-471b-95e1-3877134e8598" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b9e5d9e1-5d86-415e-9beb-047b773b8967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_08e5a7ef-8a4e-4da8-8399-e68e525bdc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0c308400-b145-471b-95e1-3877134e8598" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_08e5a7ef-8a4e-4da8-8399-e68e525bdc6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c8bb8ecb-314e-4633-8a12-5686896e3c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0c308400-b145-471b-95e1-3877134e8598" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c8bb8ecb-314e-4633-8a12-5686896e3c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_d4fa7f9f-55d3-413e-875f-793e516b7c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0c308400-b145-471b-95e1-3877134e8598" xlink:to="loc_us-gaap_LongTermInvestments_d4fa7f9f-55d3-413e-875f-793e516b7c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_79164e45-bb52-4533-976a-e46d739447f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0c308400-b145-471b-95e1-3877134e8598" xlink:to="loc_us-gaap_AssetsCurrent_79164e45-bb52-4533-976a-e46d739447f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc2e8d2b-fb68-427b-8e17-a5f76e0a61a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b3cec5a7-e16b-4244-a239-f76cfc36d2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc2e8d2b-fb68-427b-8e17-a5f76e0a61a9" xlink:to="loc_us-gaap_PreferredStockValue_b3cec5a7-e16b-4244-a239-f76cfc36d2a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_e4a3caf5-16b1-4b8f-bd8d-57483036604a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc2e8d2b-fb68-427b-8e17-a5f76e0a61a9" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_e4a3caf5-16b1-4b8f-bd8d-57483036604a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_9c3e2f0f-4cde-48ae-9a4b-a0f97cc8b922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc2e8d2b-fb68-427b-8e17-a5f76e0a61a9" xlink:to="loc_us-gaap_TreasuryStockValue_9c3e2f0f-4cde-48ae-9a4b-a0f97cc8b922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f80d0354-7e04-4a49-9e8f-d7d96f7c1e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc2e8d2b-fb68-427b-8e17-a5f76e0a61a9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f80d0354-7e04-4a49-9e8f-d7d96f7c1e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f56392fd-f99f-4f2a-934a-b81ac5bcbc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc2e8d2b-fb68-427b-8e17-a5f76e0a61a9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f56392fd-f99f-4f2a-934a-b81ac5bcbc3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_11d8e8a8-4a62-4b6f-bfc4-06e8a204496c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_11d8e8a8-4a62-4b6f-bfc4-06e8a204496c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_c5b7ff6d-d2da-4d4c-9b22-9444d11992ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_c5b7ff6d-d2da-4d4c-9b22-9444d11992ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_639b61b1-62e6-40bf-b57a-2a83f55a188b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_639b61b1-62e6-40bf-b57a-2a83f55a188b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c8c5d76e-0f77-4b68-a9aa-14dc635fde03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c8c5d76e-0f77-4b68-a9aa-14dc635fde03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a2bbb8e4-5a34-4746-aed4-17fe41ddc067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a2bbb8e4-5a34-4746-aed4-17fe41ddc067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_167bb6f9-6a86-4a46-ba3c-fcd25a24d0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_167bb6f9-6a86-4a46-ba3c-fcd25a24d0fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherInsuranceLiabilitiesCurrent_bbb1ee3f-63cc-454b-890e-274ee1e42878" xlink:href="cvs-20221231.xsd#cvs_OtherInsuranceLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:to="loc_cvs_OtherInsuranceLiabilitiesCurrent_bbb1ee3f-63cc-454b-890e-274ee1e42878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyClaimsAndDiscountsPayableCurrent_9b3bcf77-777b-4a91-b2c7-1bccd0b1cc3c" xlink:href="cvs-20221231.xsd#cvs_PharmacyClaimsAndDiscountsPayableCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:to="loc_cvs_PharmacyClaimsAndDiscountsPayableCurrent_9b3bcf77-777b-4a91-b2c7-1bccd0b1cc3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPolicyholderFunds_97338b91-0866-47e3-9d5b-aae3d31e2f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPolicyholderFunds"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fbd779cb-6f5b-4431-98ae-1f37bea93dc3" xlink:to="loc_us-gaap_OtherPolicyholderFunds_97338b91-0866-47e3-9d5b-aae3d31e2f1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49308fe9-974b-40f8-9ab8-28646048998d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a92bd023-edbf-4a27-b429-126277316225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49308fe9-974b-40f8-9ab8-28646048998d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a92bd023-edbf-4a27-b429-126277316225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a1baa5-4476-4828-aa03-5281dc9fb48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49308fe9-974b-40f8-9ab8-28646048998d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a1baa5-4476-4828-aa03-5281dc9fb48e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_888a582f-80c8-4c99-9d12-df26cf1b69bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49308fe9-974b-40f8-9ab8-28646048998d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_888a582f-80c8-4c99-9d12-df26cf1b69bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ce5d489-13bf-4006-8def-1e758b849572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_3f813573-560a-49a4-9705-9491d11d277d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ce5d489-13bf-4006-8def-1e758b849572" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_3f813573-560a-49a4-9705-9491d11d277d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2741fa38-3948-4512-830d-6763543cbeab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ce5d489-13bf-4006-8def-1e758b849572" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2741fa38-3948-4512-830d-6763543cbeab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_6a0deea5-c5c2-444f-8b9a-2b9c0509551d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ce5d489-13bf-4006-8def-1e758b849572" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_6a0deea5-c5c2-444f-8b9a-2b9c0509551d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_f526b05e-5356-48ef-97c5-4ace311106cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ce5d489-13bf-4006-8def-1e758b849572" xlink:to="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_f526b05e-5356-48ef-97c5-4ace311106cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03b2571c-0348-4003-8783-9deb0669a118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ce5d489-13bf-4006-8def-1e758b849572" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03b2571c-0348-4003-8783-9deb0669a118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_be3a977e-71b9-421f-b042-91eee4e6d425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ce5d489-13bf-4006-8def-1e758b849572" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_be3a977e-71b9-421f-b042-91eee4e6d425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8103ab80-9619-45cf-8e28-ada65b6844d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ce5d489-13bf-4006-8def-1e758b849572" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8103ab80-9619-45cf-8e28-ada65b6844d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0e5e8f8-ad7e-42ae-b857-88ff40a0837b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_9916e41c-fcb9-46e5-a63b-47531be75853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestAndDividendsReceived"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0e5e8f8-ad7e-42ae-b857-88ff40a0837b" xlink:to="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_9916e41c-fcb9-46e5-a63b-47531be75853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_8b0d69fc-7211-47b3-a9b8-01b408d555ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0e5e8f8-ad7e-42ae-b857-88ff40a0837b" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_8b0d69fc-7211-47b3-a9b8-01b408d555ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCustomers_001be9a4-5c15-42fa-bf37-6aa105f484ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCustomers"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0e5e8f8-ad7e-42ae-b857-88ff40a0837b" xlink:to="loc_us-gaap_ProceedsFromCustomers_001be9a4-5c15-42fa-bf37-6aa105f484ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PaymentsForInsuranceBenefits_47db7587-6e65-4050-93c3-430d865c2e00" xlink:href="cvs-20221231.xsd#cvs_PaymentsForInsuranceBenefits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0e5e8f8-ad7e-42ae-b857-88ff40a0837b" xlink:to="loc_cvs_PaymentsForInsuranceBenefits_47db7587-6e65-4050-93c3-430d865c2e00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToSuppliersAndEmployees_11df28fe-c478-4b97-9baf-ac41bfc4f146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliersAndEmployees"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0e5e8f8-ad7e-42ae-b857-88ff40a0837b" xlink:to="loc_us-gaap_PaymentsToSuppliersAndEmployees_11df28fe-c478-4b97-9baf-ac41bfc4f146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_063d55d2-15b0-48d9-b243-dca005931be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0e5e8f8-ad7e-42ae-b857-88ff40a0837b" xlink:to="loc_us-gaap_InterestPaidNet_063d55d2-15b0-48d9-b243-dca005931be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies_5b6a51da-35de-4d7a-a95c-0f6bda8e1b0b" xlink:href="cvs-20221231.xsd#cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0e5e8f8-ad7e-42ae-b857-88ff40a0837b" xlink:to="loc_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies_5b6a51da-35de-4d7a-a95c-0f6bda8e1b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7745b19f-13cd-4711-954f-1c0b83fd6b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cf19bab8-cc0c-40c5-96de-20f404c10f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7745b19f-13cd-4711-954f-1c0b83fd6b1f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cf19bab8-cc0c-40c5-96de-20f404c10f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8836e24c-2200-42c0-92c3-a8cb7733d278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7745b19f-13cd-4711-954f-1c0b83fd6b1f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8836e24c-2200-42c0-92c3-a8cb7733d278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_5c2127dd-cf79-4a08-b5a0-f377c72ab452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7745b19f-13cd-4711-954f-1c0b83fd6b1f" xlink:to="loc_us-gaap_PaymentsOfDividends_5c2127dd-cf79-4a08-b5a0-f377c72ab452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7a9405a3-7f0e-4554-886a-58ebdcaa29b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7745b19f-13cd-4711-954f-1c0b83fd6b1f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7a9405a3-7f0e-4554-886a-58ebdcaa29b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bce9eed8-17ef-4b61-bd0e-5ec62db5de71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7745b19f-13cd-4711-954f-1c0b83fd6b1f" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bce9eed8-17ef-4b61-bd0e-5ec62db5de71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_5347805d-6a7c-460e-8354-19e34aa28c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7745b19f-13cd-4711-954f-1c0b83fd6b1f" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_5347805d-6a7c-460e-8354-19e34aa28c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2d1be03e-06c1-4cc6-b7f0-6b7e5b8bbad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7745b19f-13cd-4711-954f-1c0b83fd6b1f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2d1be03e-06c1-4cc6-b7f0-6b7e5b8bbad8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_082b4315-df82-4a7a-872d-ec628b99b563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7745b19f-13cd-4711-954f-1c0b83fd6b1f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_082b4315-df82-4a7a-872d-ec628b99b563" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofCashFlows_1"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_bde26173-7809-450f-b8fb-64bbe5af9010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_bde26173-7809-450f-b8fb-64bbe5af9010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_70dc9200-117f-4f1c-a807-8799d7173a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_70dc9200-117f-4f1c-a807-8799d7173a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_d0558aea-a95d-4a94-9b6a-883009f20db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_d0558aea-a95d-4a94-9b6a-883009f20db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c20f491e-74a2-41bf-9eb7-81ca2cf6fe18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c20f491e-74a2-41bf-9eb7-81ca2cf6fe18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9fc4d615-3eda-4468-9d98-4cb81f1bb0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9fc4d615-3eda-4468-9d98-4cb81f1bb0a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6d95be92-63f4-4a95-acf0-65e41c2e490e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6d95be92-63f4-4a95-acf0-65e41c2e490e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_cf411003-4a2e-41aa-b711-f4fce23ffb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_cf411003-4a2e-41aa-b711-f4fce23ffb00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ae67b789-c164-41ae-bdd1-ac4690f14367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ae67b789-c164-41ae-bdd1-ac4690f14367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fcfff28b-29fd-45ec-b387-0691a528bb97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_ProfitLoss_fcfff28b-29fd-45ec-b387-0691a528bb97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b31e74eb-2c5b-438b-917b-7fbc31a84f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b31e74eb-2c5b-438b-917b-7fbc31a84f7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_0652ac5a-2114-43cd-8403-0dbe28f10a25" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_cvs_StoreImpairmentCharges_0652ac5a-2114-43cd-8403-0dbe28f10a25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_05c4fe5e-1ee8-4368-8345-31fade5f582c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_05c4fe5e-1ee8-4368-8345-31fade5f582c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_66cf3f01-7050-401b-b037-a44eb1748c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_66cf3f01-7050-401b-b037-a44eb1748c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9d049dbd-418d-4693-9856-e260314d0d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_ShareBasedCompensation_9d049dbd-418d-4693-9856-e260314d0d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b82fa4cb-d73d-45b7-bf2d-b2b05539f36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b82fa4cb-d73d-45b7-bf2d-b2b05539f36b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_76fa7066-e4a7-47c9-bea1-a73b22f0e160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3a6e4a-24c1-4af0-90e8-4a3812f5fcad" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_76fa7066-e4a7-47c9-bea1-a73b22f0e160" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7255ada5-219d-4c2f-aba2-69a2e20e9953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_32659238-ad7b-42ea-b22d-26c21fbde263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7255ada5-219d-4c2f-aba2-69a2e20e9953" xlink:to="loc_us-gaap_RestrictedCashCurrent_32659238-ad7b-42ea-b22d-26c21fbde263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0d368c04-84eb-4333-9bd7-701f9457deb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7255ada5-219d-4c2f-aba2-69a2e20e9953" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0d368c04-84eb-4333-9bd7-701f9457deb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb688b39-8214-4b3e-8d7b-8699e2a4edcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7255ada5-219d-4c2f-aba2-69a2e20e9953" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb688b39-8214-4b3e-8d7b-8699e2a4edcc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_97c8453e-7f10-4cc1-a32e-305661858168" xlink:href="cvs-20221231.xsd#cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VendorandManufacturerReceivables_b8b64210-fc5e-421b-8572-622660e91f41" xlink:href="cvs-20221231.xsd#cvs_VendorandManufacturerReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_97c8453e-7f10-4cc1-a32e-305661858168" xlink:to="loc_cvs_VendorandManufacturerReceivables_b8b64210-fc5e-421b-8572-622660e91f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_38247120-5a18-4ce0-a293-9bfaf5c87e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_97c8453e-7f10-4cc1-a32e-305661858168" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_38247120-5a18-4ce0-a293-9bfaf5c87e4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue_4dd0daf0-40cb-4188-a42c-0f6085a62406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_97c8453e-7f10-4cc1-a32e-305661858168" xlink:to="loc_us-gaap_PremiumsReceivableAtCarryingValue_4dd0daf0-40cb-4188-a42c-0f6085a62406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cc4b9e14-1586-481a-9e8f-f717b176151c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_97c8453e-7f10-4cc1-a32e-305661858168" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cc4b9e14-1586-481a-9e8f-f717b176151c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_d1ceebed-1d94-4a02-bb53-a97a3ce7ca5b" xlink:href="cvs-20221231.xsd#cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_74a9d261-794f-4c03-a2c6-e2ca9c9f4539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_d1ceebed-1d94-4a02-bb53-a97a3ce7ca5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_74a9d261-794f-4c03-a2c6-e2ca9c9f4539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f4a8c94a-7490-4ae1-92c3-7eb1325b1a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_d1ceebed-1d94-4a02-bb53-a97a3ce7ca5b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f4a8c94a-7490-4ae1-92c3-7eb1325b1a94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d6de812b-a6f3-49ef-bed4-fc11b67fc556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ca823801-a19a-43cb-a661-554b2984d0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d6de812b-a6f3-49ef-bed4-fc11b67fc556" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ca823801-a19a-43cb-a661-554b2984d0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f82d6515-1287-4690-bb49-4ba7e52f7047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d6de812b-a6f3-49ef-bed4-fc11b67fc556" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f82d6515-1287-4690-bb49-4ba7e52f7047" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_dbb66cb5-feb5-4c63-a9d0-4e44375a8da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_5a434761-9afb-43c2-9a1a-f6733c3485ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_dbb66cb5-feb5-4c63-a9d0-4e44375a8da6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_5a434761-9afb-43c2-9a1a-f6733c3485ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4a9dd587-e207-492b-b468-a31c3f5f5f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_dbb66cb5-feb5-4c63-a9d0-4e44375a8da6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4a9dd587-e207-492b-b468-a31c3f5f5f76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_b5d89159-c354-4373-8f10-4d00beb7ed81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_dbb66cb5-feb5-4c63-a9d0-4e44375a8da6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_b5d89159-c354-4373-8f10-4d00beb7ed81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_57953707-2713-4e71-aab7-2605f7b87257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_dbb66cb5-feb5-4c63-a9d0-4e44375a8da6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_57953707-2713-4e71-aab7-2605f7b87257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_55fc8eeb-2518-42f4-be87-0da8f9f9bf0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_dbb66cb5-feb5-4c63-a9d0-4e44375a8da6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_55fc8eeb-2518-42f4-be87-0da8f9f9bf0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0f156377-16c3-4b5d-9e36-0866a4f4dc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_6ed21cb8-3654-4462-8741-a069d3d1ce87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0f156377-16c3-4b5d-9e36-0866a4f4dc6c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_6ed21cb8-3654-4462-8741-a069d3d1ce87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_02992e83-8678-488c-8618-ef3aa291a424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0f156377-16c3-4b5d-9e36-0866a4f4dc6c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_02992e83-8678-488c-8618-ef3aa291a424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_70379b5b-33f8-42f9-9337-c9540a938fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0f156377-16c3-4b5d-9e36-0866a4f4dc6c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_70379b5b-33f8-42f9-9337-c9540a938fd0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsScheduleofTotalInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_3e3c83f2-be62-4fe6-a6ea-a82738f93606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermInvestmentsIncludingAssetsHeldForSale_87b9c571-3e06-480f-97d7-5dc438b26b90" xlink:href="cvs-20221231.xsd#cvs_LongTermInvestmentsIncludingAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_3e3c83f2-be62-4fe6-a6ea-a82738f93606" xlink:to="loc_cvs_LongTermInvestmentsIncludingAssetsHeldForSale_87b9c571-3e06-480f-97d7-5dc438b26b90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_652497ea-312e-4eb0-b679-3be087222b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_3e3c83f2-be62-4fe6-a6ea-a82738f93606" xlink:to="loc_us-gaap_ShortTermInvestments_652497ea-312e-4eb0-b679-3be087222b28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_f9fb025b-771b-4ba9-a666-7888f8314eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_69a0ebf4-5517-4fd0-bc5d-04b7ea62f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_f9fb025b-771b-4ba9-a666-7888f8314eec" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_69a0ebf4-5517-4fd0-bc5d-04b7ea62f88e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_97fee379-3dd7-4eea-934f-4891fa11c715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_f9fb025b-771b-4ba9-a666-7888f8314eec" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_97fee379-3dd7-4eea-934f-4891fa11c715" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsDebtSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_f3ab77d0-bb56-451e-a241-9ced9ae6597c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_941bee78-97ab-405c-bb16-db0ddee61560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_f3ab77d0-bb56-451e-a241-9ced9ae6597c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_941bee78-97ab-405c-bb16-db0ddee61560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_67d15d12-6553-4c22-96c3-571599999b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_f3ab77d0-bb56-451e-a241-9ced9ae6597c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_67d15d12-6553-4c22-96c3-571599999b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82090309-72b5-49e5-ba50-71040eb4e5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_f3ab77d0-bb56-451e-a241-9ced9ae6597c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82090309-72b5-49e5-ba50-71040eb4e5fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsDebtSecuritiesbyMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1eec640d-9f25-46c3-b8bb-439c17874017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_ca43c61f-f565-460e-8555-955268c0daf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1eec640d-9f25-46c3-b8bb-439c17874017" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_ca43c61f-f565-460e-8555-955268c0daf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_9c68f444-117d-4356-8d3c-9ad3b7403524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1eec640d-9f25-46c3-b8bb-439c17874017" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_9c68f444-117d-4356-8d3c-9ad3b7403524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_d51c7b23-5009-4fc0-9b25-09a5e3dbef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1eec640d-9f25-46c3-b8bb-439c17874017" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_d51c7b23-5009-4fc0-9b25-09a5e3dbef8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_be0abb9f-3ab5-4b3d-b4c7-e28b277adeba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1eec640d-9f25-46c3-b8bb-439c17874017" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_be0abb9f-3ab5-4b3d-b4c7-e28b277adeba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c15e5dc1-254f-40a8-9538-292753a08e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1eec640d-9f25-46c3-b8bb-439c17874017" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c15e5dc1-254f-40a8-9538-292753a08e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ead0c19-adc0-4833-a117-d276843d93b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_90900be4-f28e-46eb-8845-598f70cc88ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ead0c19-adc0-4833-a117-d276843d93b7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_90900be4-f28e-46eb-8845-598f70cc88ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c3f9b73b-6e57-4ee7-9770-061ab4a5318c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ead0c19-adc0-4833-a117-d276843d93b7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c3f9b73b-6e57-4ee7-9770-061ab4a5318c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f082fd62-30ac-4d90-8821-a3ca06d4d048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ead0c19-adc0-4833-a117-d276843d93b7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f082fd62-30ac-4d90-8821-a3ca06d4d048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_2d9fa441-d2ae-4702-a4ec-6e01f068a331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ead0c19-adc0-4833-a117-d276843d93b7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_2d9fa441-d2ae-4702-a4ec-6e01f068a331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_faaa80c2-fc76-4752-a070-88827300d853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ead0c19-adc0-4833-a117-d276843d93b7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_faaa80c2-fc76-4752-a070-88827300d853" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_07713773-088e-4f72-b874-a54ada6f7ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6e6ade95-b00f-4abc-b1b5-d0f20213d120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_07713773-088e-4f72-b874-a54ada6f7ae9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6e6ade95-b00f-4abc-b1b5-d0f20213d120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_067dd276-d075-4887-9dad-771e3abb0a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_07713773-088e-4f72-b874-a54ada6f7ae9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_067dd276-d075-4887-9dad-771e3abb0a55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4c482444-62e3-44af-b9d0-349b32184a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_e7bbb2c0-fb27-4f09-b919-5456f3cce7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4c482444-62e3-44af-b9d0-349b32184a94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_e7bbb2c0-fb27-4f09-b919-5456f3cce7d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e7ae5707-9dc5-4863-b1e6-536456330b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4c482444-62e3-44af-b9d0-349b32184a94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e7ae5707-9dc5-4863-b1e6-536456330b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_adcaceb7-074c-4e21-9a0a-275fbd3779ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_e4cf5355-e35c-419e-9b81-4a11fe9c2ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_adcaceb7-074c-4e21-9a0a-275fbd3779ee" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_e4cf5355-e35c-419e-9b81-4a11fe9c2ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_aafe3974-97db-435c-a8f2-d61be8d7a08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_adcaceb7-074c-4e21-9a0a-275fbd3779ee" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_aafe3974-97db-435c-a8f2-d61be8d7a08c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsUnrealizedLossPositionMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3414ceff-f22b-467a-9271-0ca9793c6eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears_d1a3a45e-7677-4a4a-89af-26e4c4ab5292" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3414ceff-f22b-467a-9271-0ca9793c6eef" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears_d1a3a45e-7677-4a4a-89af-26e4c4ab5292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears_86700cd5-d941-47f3-9eb1-f95a44759d62" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3414ceff-f22b-467a-9271-0ca9793c6eef" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears_86700cd5-d941-47f3-9eb1-f95a44759d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears_a2811fb8-70ce-4dde-b9f5-a824f6780b75" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3414ceff-f22b-467a-9271-0ca9793c6eef" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears_a2811fb8-70ce-4dde-b9f5-a824f6780b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear_f4863c51-0e08-4c63-bb9d-c10f83e61331" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3414ceff-f22b-467a-9271-0ca9793c6eef" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear_f4863c51-0e08-4c63-bb9d-c10f83e61331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue_3d84318c-0e4c-4d2c-8d40-947f8e16f445" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3414ceff-f22b-467a-9271-0ca9793c6eef" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue_3d84318c-0e4c-4d2c-8d40-947f8e16f445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3da83446-a232-4562-a9f1-b5ca09755d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss_9a6ab049-4f67-4a7f-a05d-cd68bc87a6da" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3da83446-a232-4562-a9f1-b5ca09755d25" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss_9a6ab049-4f67-4a7f-a05d-cd68bc87a6da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss_14644b37-5dfc-49c9-8744-a8b9e56a68c7" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3da83446-a232-4562-a9f1-b5ca09755d25" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss_14644b37-5dfc-49c9-8744-a8b9e56a68c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss_4cbb1a7f-e117-4da7-9d5c-08fef0ffd890" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3da83446-a232-4562-a9f1-b5ca09755d25" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss_4cbb1a7f-e117-4da7-9d5c-08fef0ffd890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss_aa109e3f-166d-4745-8f87-9025909963aa" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3da83446-a232-4562-a9f1-b5ca09755d25" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss_aa109e3f-166d-4745-8f87-9025909963aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss_205e97c7-2d13-4000-b643-f5841214b0b0" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3da83446-a232-4562-a9f1-b5ca09755d25" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss_205e97c7-2d13-4000-b643-f5841214b0b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsMortgageLoanPrincipalRepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_aea05796-8bdd-4bba-912d-0d97734d0d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths_9cc01842-4108-4f91-8c18-9deca6c57cc4" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_aea05796-8bdd-4bba-912d-0d97734d0d09" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths_9cc01842-4108-4f91-8c18-9deca6c57cc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo_9d21f2ac-8be2-4c4e-bd0d-0389ed916289" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_aea05796-8bdd-4bba-912d-0d97734d0d09" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo_9d21f2ac-8be2-4c4e-bd0d-0389ed916289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree_cd42945d-b2c4-4506-be7f-bac4e467fc5a" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_aea05796-8bdd-4bba-912d-0d97734d0d09" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree_cd42945d-b2c4-4506-be7f-bac4e467fc5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour_33a299bb-0cde-47d4-a7fa-54d3a557fc08" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_aea05796-8bdd-4bba-912d-0d97734d0d09" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour_33a299bb-0cde-47d4-a7fa-54d3a557fc08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive_5d97f385-7a3b-4dcb-8207-f4a7d4a16eef" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_aea05796-8bdd-4bba-912d-0d97734d0d09" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive_5d97f385-7a3b-4dcb-8207-f4a7d4a16eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive_1e15139c-5a38-431a-8887-49d885064b69" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_aea05796-8bdd-4bba-912d-0d97734d0d09" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive_1e15139c-5a38-431a-8887-49d885064b69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsNetInvestmentIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_18b1ed73-bb14-4d14-912e-26ebd1a0e381" xlink:href="cvs-20221231.xsd#cvs_InvestmentIncomeExcludingCapitalGainsOrLosses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_85796571-cfc1-463b-a305-81fc307cab11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_18b1ed73-bb14-4d14-912e-26ebd1a0e381" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_85796571-cfc1-463b-a305-81fc307cab11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_f487a478-1a5e-4ad9-93c2-bcac9219da52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_18b1ed73-bb14-4d14-912e-26ebd1a0e381" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_f487a478-1a5e-4ad9-93c2-bcac9219da52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_fe25e9b1-c40d-4624-bac3-b2c05e544b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_f3fe4836-6324-467a-9961-b2f3020d58d9" xlink:href="cvs-20221231.xsd#cvs_InvestmentIncomeExcludingCapitalGainsOrLosses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_fe25e9b1-c40d-4624-bac3-b2c05e544b5d" xlink:to="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_f3fe4836-6324-467a-9961-b2f3020d58d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_21370a9e-907b-4ae5-b49f-193d5419b8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_fe25e9b1-c40d-4624-bac3-b2c05e544b5d" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_21370a9e-907b-4ae5-b49f-193d5419b8c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueFairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2ee0efec-1f27-4a10-b12c-31d79a2a5f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0b4396d2-4e73-40fa-859d-f1ae2b554cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2ee0efec-1f27-4a10-b12c-31d79a2a5f6c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0b4396d2-4e73-40fa-859d-f1ae2b554cf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ab0b26f3-4f7c-4ec3-8ed5-6d8ce4320ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2ee0efec-1f27-4a10-b12c-31d79a2a5f6c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ab0b26f3-4f7c-4ec3-8ed5-6d8ce4320ca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_93b8eb71-a6e5-47c9-b4b2-d75e11381f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2ee0efec-1f27-4a10-b12c-31d79a2a5f6c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_93b8eb71-a6e5-47c9-b4b2-d75e11381f6f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueGrossTransfersIntoOutOfLevel3Details"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_8d2a37ab-17ef-4909-9c51-af9233f11173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_efc9497e-e92e-4141-b1a8-38b995d8f46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_8d2a37ab-17ef-4909-9c51-af9233f11173" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_efc9497e-e92e-4141-b1a8-38b995d8f46c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_e0a7691c-ffef-4541-8290-7fc79de52a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_8d2a37ab-17ef-4909-9c51-af9233f11173" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_e0a7691c-ffef-4541-8290-7fc79de52a99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherIntangiblesIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_288a91e5-9acd-4b78-a626-839fed0bc521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_db41afad-f38d-494f-824b-425768fbc0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_288a91e5-9acd-4b78-a626-839fed0bc521" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_db41afad-f38d-494f-824b-425768fbc0aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_be036eb9-60ff-4778-81d5-cc2cbd7140ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_288a91e5-9acd-4b78-a626-839fed0bc521" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_be036eb9-60ff-4778-81d5-cc2cbd7140ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_0bba8cec-edc1-4600-bad0-9d77712fcb3b" xlink:href="cvs-20221231.xsd#cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_65466651-9ef2-4449-941f-c457a17e36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_0bba8cec-edc1-4600-bad0-9d77712fcb3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_65466651-9ef2-4449-941f-c457a17e36d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6c1321db-d4de-4274-9785-0c961b5773e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_0bba8cec-edc1-4600-bad0-9d77712fcb3b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6c1321db-d4de-4274-9785-0c961b5773e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_70f505a6-2f76-4004-ba54-dfcf8ae9b498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b7abdbc7-52c5-444d-941d-ca8d225e5cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_70f505a6-2f76-4004-ba54-dfcf8ae9b498" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b7abdbc7-52c5-444d-941d-ca8d225e5cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a7d9686a-26fe-4679-8c06-647491ed6600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_70f505a6-2f76-4004-ba54-dfcf8ae9b498" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a7d9686a-26fe-4679-8c06-647491ed6600" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesSummaryoftheComponentsofNetLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9580da31-30e7-4bab-9518-9c14ffa1c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_03975526-fc80-44d2-a801-97eef1cd8d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9580da31-30e7-4bab-9518-9c14ffa1c90a" xlink:to="loc_us-gaap_SubleaseIncome_03975526-fc80-44d2-a801-97eef1cd8d9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_32718768-7713-4009-b716-d2172e69ef24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9580da31-30e7-4bab-9518-9c14ffa1c90a" xlink:to="loc_us-gaap_VariableLeaseCost_32718768-7713-4009-b716-d2172e69ef24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7ad5e2bc-e546-40dd-9522-6d4690a87d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9580da31-30e7-4bab-9518-9c14ffa1c90a" xlink:to="loc_us-gaap_OperatingLeaseCost_7ad5e2bc-e546-40dd-9522-6d4690a87d4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseCost_53c810d5-1ff0-4062-8c89-e298a9adf427" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9580da31-30e7-4bab-9518-9c14ffa1c90a" xlink:to="loc_cvs_FinanceLeaseCost_53c810d5-1ff0-4062-8c89-e298a9adf427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_b87a4213-5704-47b7-9efa-1c21d4790354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9580da31-30e7-4bab-9518-9c14ffa1c90a" xlink:to="loc_us-gaap_ShortTermLeaseCost_b87a4213-5704-47b7-9efa-1c21d4790354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseCost_edabdee7-b9b9-4e74-abf9-8c9311b07554" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_6a3f95b0-d504-4c5f-a6fd-aee205e0bcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_FinanceLeaseCost_edabdee7-b9b9-4e74-abf9-8c9311b07554" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_6a3f95b0-d504-4c5f-a6fd-aee205e0bcfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c0ae098b-aa27-46fd-960b-6709eef807a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_FinanceLeaseCost_edabdee7-b9b9-4e74-abf9-8c9311b07554" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c0ae098b-aa27-46fd-960b-6709eef807a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetNet_a67ce338-baf9-4899-872c-ee78b4988cdf" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetGross_94ad6d94-c865-41a0-a04f-955e74b16fb7" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_FinanceLeaseRightOfUseAssetNet_a67ce338-baf9-4899-872c-ee78b4988cdf" xlink:to="loc_cvs_FinanceLeaseRightOfUseAssetGross_94ad6d94-c865-41a0-a04f-955e74b16fb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation_71e00505-fdf4-4e35-87aa-95a14d4ba31e" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_FinanceLeaseRightOfUseAssetNet_a67ce338-baf9-4899-872c-ee78b4988cdf" xlink:to="loc_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation_71e00505-fdf4-4e35-87aa-95a14d4ba31e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_45e7e304-ecf4-4a85-9a19-371f07f4fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b8b45766-03c4-4f5f-b452-76da3e780ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_45e7e304-ecf4-4a85-9a19-371f07f4fad9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b8b45766-03c4-4f5f-b452-76da3e780ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_687b1239-cbf3-4e4f-ab9d-b042354aa451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_45e7e304-ecf4-4a85-9a19-371f07f4fad9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_687b1239-cbf3-4e4f-ab9d-b042354aa451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_16c80f1e-22bf-4d8e-82de-28b25fe21a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale_fa80317b-7988-4366-a798-957f7b811f13" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_16c80f1e-22bf-4d8e-82de-28b25fe21a5c" xlink:to="loc_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale_fa80317b-7988-4366-a798-957f7b811f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale_f56d4147-ef91-4483-b773-243656d8c73b" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_16c80f1e-22bf-4d8e-82de-28b25fe21a5c" xlink:to="loc_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale_f56d4147-ef91-4483-b773-243656d8c73b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e22c55bb-4b98-42af-a29a-362d0faf0375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bba699a7-76ed-49ea-b8bd-a6f284a55ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e22c55bb-4b98-42af-a29a-362d0faf0375" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bba699a7-76ed-49ea-b8bd-a6f284a55ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_28858d97-f8c6-4f3c-b336-a60c56747d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e22c55bb-4b98-42af-a29a-362d0faf0375" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_28858d97-f8c6-4f3c-b336-a60c56747d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5401b759-9af3-49b4-af35-28f9865cdcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e22c55bb-4b98-42af-a29a-362d0faf0375" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5401b759-9af3-49b4-af35-28f9865cdcf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c6114c63-2f88-41bd-9695-33d2b7d2a262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e22c55bb-4b98-42af-a29a-362d0faf0375" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c6114c63-2f88-41bd-9695-33d2b7d2a262" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_926f3b36-b558-44da-adf6-a6f10d31f059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e22c55bb-4b98-42af-a29a-362d0faf0375" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_926f3b36-b558-44da-adf6-a6f10d31f059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_587af7e4-90df-45ca-942f-befa317571ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e22c55bb-4b98-42af-a29a-362d0faf0375" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_587af7e4-90df-45ca-942f-befa317571ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearFour_8a4d41e1-c0f7-4d94-9f25-9f6a13931d88" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_99a8cc3e-cd37-4004-8e2c-c2acbf7e2489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearFour_8a4d41e1-c0f7-4d94-9f25-9f6a13931d88" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_99a8cc3e-cd37-4004-8e2c-c2acbf7e2489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6323f698-f89c-440d-8cb5-f05c7967fd75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearFour_8a4d41e1-c0f7-4d94-9f25-9f6a13931d88" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6323f698-f89c-440d-8cb5-f05c7967fd75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearFive_8e7dc381-fbd6-4552-8bd5-b36a40a227db" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_adaed305-73f5-46b4-86c6-c5a7980a2757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearFive_8e7dc381-fbd6-4552-8bd5-b36a40a227db" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_adaed305-73f5-46b4-86c6-c5a7980a2757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ee243b33-754c-4587-8987-df7d494f8a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearFive_8e7dc381-fbd6-4552-8bd5-b36a40a227db" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ee243b33-754c-4587-8987-df7d494f8a3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsYearOne_8e522e52-d120-4949-89ce-c0545832bf3b" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsYearOne"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d9b9ebf0-8643-404c-abdf-a01769aab573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsYearOne_8e522e52-d120-4949-89ce-c0545832bf3b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d9b9ebf0-8643-404c-abdf-a01769aab573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4ec56add-cfc8-4779-b3e4-01dc0fcfe55f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsYearOne_8e522e52-d120-4949-89ce-c0545832bf3b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4ec56add-cfc8-4779-b3e4-01dc0fcfe55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueAfterYearFive_2162b4c6-51a1-4b12-9489-eb298720d2ec" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_caf1a1fa-7a14-4054-908f-f7ec209ca35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueAfterYearFive_2162b4c6-51a1-4b12-9489-eb298720d2ec" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_caf1a1fa-7a14-4054-908f-f7ec209ca35e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d14cb6d7-fcde-417b-a261-b96e44697b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueAfterYearFive_2162b4c6-51a1-4b12-9489-eb298720d2ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d14cb6d7-fcde-417b-a261-b96e44697b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearThree_fd551de6-d0ae-4f2f-9738-620ac1e84591" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4a08c430-918f-4ad0-8cfd-ad11d96708fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearThree_fd551de6-d0ae-4f2f-9738-620ac1e84591" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4a08c430-918f-4ad0-8cfd-ad11d96708fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_84c0af40-c5c0-4bcc-80a5-eecd4cafc1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearThree_fd551de6-d0ae-4f2f-9738-620ac1e84591" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_84c0af40-c5c0-4bcc-80a5-eecd4cafc1d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_df6e5e0a-8403-448c-94d1-dca338a408f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_57c40f64-a1c5-4ccf-810a-28a14ed9b648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_df6e5e0a-8403-448c-94d1-dca338a408f3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_57c40f64-a1c5-4ccf-810a-28a14ed9b648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_a47c6e64-59d4-4d53-ac0f-f35bdeb34263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_df6e5e0a-8403-448c-94d1-dca338a408f3" xlink:to="loc_us-gaap_FinanceLeaseLiability_a47c6e64-59d4-4d53-ac0f-f35bdeb34263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearTwo_67f14211-8f4c-4d49-8e9a-615d19cb9d1f" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_686b1795-510a-479d-98d3-dd3c9330f89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearTwo_67f14211-8f4c-4d49-8e9a-615d19cb9d1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_686b1795-510a-479d-98d3-dd3c9330f89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4a7a51db-9392-4317-ba4b-49bab7886708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearTwo_67f14211-8f4c-4d49-8e9a-615d19cb9d1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4a7a51db-9392-4317-ba4b-49bab7886708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LeaseLiability_7f735848-e328-4b80-a2a5-eeb3eaa704fb" xlink:href="cvs-20221231.xsd#cvs_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_1b14d989-5600-4166-b402-35412478020f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LeaseLiability_7f735848-e328-4b80-a2a5-eeb3eaa704fb" xlink:to="loc_us-gaap_FinanceLeaseLiability_1b14d989-5600-4166-b402-35412478020f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f5d23816-19f9-454c-8894-ee033477a08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LeaseLiability_7f735848-e328-4b80-a2a5-eeb3eaa704fb" xlink:to="loc_us-gaap_OperatingLeaseLiability_f5d23816-19f9-454c-8894-ee033477a08a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDue_75f1ead3-6af9-45d1-a9b5-4dcfc31f237f" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityUndiscountedExcessAmount_d34eaa8b-1f5a-4d41-bf0e-0a60353a7f3e" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDue_75f1ead3-6af9-45d1-a9b5-4dcfc31f237f" xlink:to="loc_cvs_LesseeLiabilityUndiscountedExcessAmount_d34eaa8b-1f5a-4d41-bf0e-0a60353a7f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LeaseLiability_e0de6217-00d2-4620-b80f-4b97fd218763" xlink:href="cvs-20221231.xsd#cvs_LeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDue_75f1ead3-6af9-45d1-a9b5-4dcfc31f237f" xlink:to="loc_cvs_LeaseLiability_e0de6217-00d2-4620-b80f-4b97fd218763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityUndiscountedExcessAmount_18ca3790-5df4-4f0f-a426-ae119a4ad407" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_89ad72a9-9dc7-4049-9e7d-5d7dc9702505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityUndiscountedExcessAmount_18ca3790-5df4-4f0f-a426-ae119a4ad407" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_89ad72a9-9dc7-4049-9e7d-5d7dc9702505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dbb2486e-8d73-4b36-b35c-035a1a2572b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityUndiscountedExcessAmount_18ca3790-5df4-4f0f-a426-ae119a4ad407" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dbb2486e-8d73-4b36-b35c-035a1a2572b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7da2f60b-8954-4ef6-9da9-8b58064ace7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32b0c879-303f-416a-afac-b1b886ede2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7da2f60b-8954-4ef6-9da9-8b58064ace7c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32b0c879-303f-416a-afac-b1b886ede2ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3ff13f56-fcad-4a4e-8923-71b2bae41f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7da2f60b-8954-4ef6-9da9-8b58064ace7c" xlink:to="loc_us-gaap_OperatingLeaseLiability_3ff13f56-fcad-4a4e-8923-71b2bae41f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f65178a1-a2e9-4a79-9255-df11f45e6865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_41dd6d66-1642-4ae9-bd6e-fa2ec2663e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f65178a1-a2e9-4a79-9255-df11f45e6865" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_41dd6d66-1642-4ae9-bd6e-fa2ec2663e21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9806b982-1cff-45d4-84e3-177b670bc471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f65178a1-a2e9-4a79-9255-df11f45e6865" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9806b982-1cff-45d4-84e3-177b670bc471" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_61db1617-266a-46b4-a1c4-c73b3dd202e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f65178a1-a2e9-4a79-9255-df11f45e6865" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_61db1617-266a-46b4-a1c4-c73b3dd202e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_db9ef798-9c0e-4484-9169-0641d6da58e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f65178a1-a2e9-4a79-9255-df11f45e6865" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_db9ef798-9c0e-4484-9169-0641d6da58e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_dc52f1cd-8780-4911-bb6f-1633de7d56bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f65178a1-a2e9-4a79-9255-df11f45e6865" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_dc52f1cd-8780-4911-bb6f-1633de7d56bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_3794c6f1-b354-48b7-8c22-ef47a1d3723d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f65178a1-a2e9-4a79-9255-df11f45e6865" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_3794c6f1-b354-48b7-8c22-ef47a1d3723d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDue_1d84d971-c1a2-457c-a574-8819042bd435" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsYearOne_88a1197b-8b9b-49bf-9a4c-b25f2bc1a81b" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsYearOne"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDue_1d84d971-c1a2-457c-a574-8819042bd435" xlink:to="loc_cvs_LesseeLiabilityPaymentsYearOne_88a1197b-8b9b-49bf-9a4c-b25f2bc1a81b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearTwo_14ea50ab-294f-466c-a981-16a3cbab153c" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDue_1d84d971-c1a2-457c-a574-8819042bd435" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueYearTwo_14ea50ab-294f-466c-a981-16a3cbab153c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearThree_c391c392-f702-485d-a08b-efb6658f6033" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDue_1d84d971-c1a2-457c-a574-8819042bd435" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueYearThree_c391c392-f702-485d-a08b-efb6658f6033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearFour_865b4b15-6cb2-4213-b35b-03901bd19d4f" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDue_1d84d971-c1a2-457c-a574-8819042bd435" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueYearFour_865b4b15-6cb2-4213-b35b-03901bd19d4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearFive_a6d4b8f5-7122-420f-bb19-b7105a6a392d" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDue_1d84d971-c1a2-457c-a574-8819042bd435" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueYearFive_a6d4b8f5-7122-420f-bb19-b7105a6a392d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueAfterYearFive_69b99e8f-3c50-4ac6-928c-df53e2239b9c" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LesseeLiabilityPaymentsDue_1d84d971-c1a2-457c-a574-8819042bd435" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueAfterYearFive_69b99e8f-3c50-4ac6-928c-df53e2239b9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_8b014a78-1fb7-4d66-ab13-4346a33a30f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_083a2a7f-2cbf-4ea1-81ea-96d5be97fe8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_8b014a78-1fb7-4d66-ab13-4346a33a30f1" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_083a2a7f-2cbf-4ea1-81ea-96d5be97fe8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented_99b0a19d-4066-4b3d-9dbd-6b5851bea9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_8b014a78-1fb7-4d66-ab13-4346a33a30f1" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented_99b0a19d-4066-4b3d-9dbd-6b5851bea9c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_e236702f-f6a1-407f-9677-38261d7ecc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_8b014a78-1fb7-4d66-ab13-4346a33a30f1" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_e236702f-f6a1-407f-9677-38261d7ecc12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_706adac7-59ba-4121-a24a-cf6022359afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_853cb6e9-f3c2-4b4c-8f35-be61b340ff8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_706adac7-59ba-4121-a24a-cf6022359afd" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_853cb6e9-f3c2-4b4c-8f35-be61b340ff8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_29bbada2-1504-4699-a61e-4e8a368b1683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_706adac7-59ba-4121-a24a-cf6022359afd" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_29bbada2-1504-4699-a61e-4e8a368b1683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_15015203-b106-4b8a-951e-d53b93893fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_706adac7-59ba-4121-a24a-cf6022359afd" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_15015203-b106-4b8a-951e-d53b93893fe0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_333ae4ea-1455-4f2c-acae-79d7beb2d3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_42462aed-a900-431a-bcbe-24eb9b5cb07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_333ae4ea-1455-4f2c-acae-79d7beb2d3eb" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_42462aed-a900-431a-bcbe-24eb9b5cb07c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_78083dc6-35ef-4385-a008-d268993cc94e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_333ae4ea-1455-4f2c-acae-79d7beb2d3eb" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_78083dc6-35ef-4385-a008-d268993cc94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_8412af8b-4016-4394-9ab2-38388e83385b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0a94362e-dc6c-43d2-89e1-9c8a4adc1512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_8412af8b-4016-4394-9ab2-38388e83385b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0a94362e-dc6c-43d2-89e1-9c8a4adc1512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_87718491-d6ef-4c55-a7f8-56fcbd5f1a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_8412af8b-4016-4394-9ab2-38388e83385b" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_87718491-d6ef-4c55-a7f8-56fcbd5f1a77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_d57db822-bd6f-459e-b195-563033fa58ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongtermDebtGrossAndLeaseObligation_537f93ca-64cf-4db8-b421-480f587a16da" xlink:href="cvs-20221231.xsd#cvs_LongtermDebtGrossAndLeaseObligation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_d57db822-bd6f-459e-b195-563033fa58ba" xlink:to="loc_cvs_LongtermDebtGrossAndLeaseObligation_537f93ca-64cf-4db8-b421-480f587a16da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet_64a341d4-8b71-4fe7-8282-de56962edace" xlink:href="cvs-20221231.xsd#cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_d57db822-bd6f-459e-b195-563033fa58ba" xlink:to="loc_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet_64a341d4-8b71-4fe7-8282-de56962edace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_47a89de4-9539-4223-8af4-7a0e5adf479a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_d57db822-bd6f-459e-b195-563033fa58ba" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_47a89de4-9539-4223-8af4-7a0e5adf479a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongtermDebtGrossAndLeaseObligation_870da2c1-8c46-445d-a275-6a73db0e6998" xlink:href="cvs-20221231.xsd#cvs_LongtermDebtGrossAndLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_01fe8046-1005-44d7-85bf-579820bfc791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LongtermDebtGrossAndLeaseObligation_870da2c1-8c46-445d-a275-6a73db0e6998" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_01fe8046-1005-44d7-85bf-579820bfc791" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_a1c3dfe2-702e-45fa-a105-f4df41077e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cvs_LongtermDebtGrossAndLeaseObligation_870da2c1-8c46-445d-a275-6a73db0e6998" xlink:to="loc_us-gaap_FinanceLeaseLiability_a1c3dfe2-702e-45fa-a105-f4df41077e3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_84395ff1-29b4-40d2-8b3d-104ccd8797a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bc69d8ae-1ea3-4a5a-94ae-0d0d35b61961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_84395ff1-29b4-40d2-8b3d-104ccd8797a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bc69d8ae-1ea3-4a5a-94ae-0d0d35b61961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bf38ccae-e9e7-413f-83bd-b9b805b21fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_84395ff1-29b4-40d2-8b3d-104ccd8797a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bf38ccae-e9e7-413f-83bd-b9b805b21fdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_35590eac-5652-4000-a901-ec0239634a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_84395ff1-29b4-40d2-8b3d-104ccd8797a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_35590eac-5652-4000-a901-ec0239634a76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5e7a0f82-d1c5-4f4f-a211-e3770982a3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_84395ff1-29b4-40d2-8b3d-104ccd8797a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5e7a0f82-d1c5-4f4f-a211-e3770982a3b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_5ce90e89-0528-4273-9b91-1445246f5de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_84395ff1-29b4-40d2-8b3d-104ccd8797a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_5ce90e89-0528-4273-9b91-1445246f5de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5dc1dc90-f6d7-46be-9c5f-77e153803983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_84395ff1-29b4-40d2-8b3d-104ccd8797a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5dc1dc90-f6d7-46be-9c5f-77e153803983" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c96a618f-6969-46f8-a5fe-8360388645c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_90d50c9d-91dd-441f-af09-036556917d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c96a618f-6969-46f8-a5fe-8360388645c7" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_90d50c9d-91dd-441f-af09-036556917d9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_02376d23-571f-45b7-ab83-ab18dfbc9815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c96a618f-6969-46f8-a5fe-8360388645c7" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_02376d23-571f-45b7-ab83-ab18dfbc9815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_a65b4309-9edb-478d-aeaa-76467b67cbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_c96a618f-6969-46f8-a5fe-8360388645c7" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_a65b4309-9edb-478d-aeaa-76467b67cbf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_bb305807-ca48-49e2-bc30-9371d37c9974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_04462407-0f1e-4c3e-a90f-e309967d4146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_bb305807-ca48-49e2-bc30-9371d37c9974" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_04462407-0f1e-4c3e-a90f-e309967d4146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7e65b47d-96f7-4560-8ff2-37e8f48a0fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_bb305807-ca48-49e2-bc30-9371d37c9974" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7e65b47d-96f7-4560-8ff2-37e8f48a0fc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3342c8f5-ec50-4108-bfe9-44925b1cfc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1bccd4f3-992c-45a5-b960-5694c984bf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3342c8f5-ec50-4108-bfe9-44925b1cfc00" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1bccd4f3-992c-45a5-b960-5694c984bf5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_3d502e93-73eb-48a7-bb66-5541fdbdadce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3342c8f5-ec50-4108-bfe9-44925b1cfc00" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_3d502e93-73eb-48a7-bb66-5541fdbdadce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b23ccf32-0d57-4c68-acb6-954b9e7758dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3342c8f5-ec50-4108-bfe9-44925b1cfc00" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_b23ccf32-0d57-4c68-acb6-954b9e7758dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_5ced2315-1f7f-4bfd-b1f4-492b465fc665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3342c8f5-ec50-4108-bfe9-44925b1cfc00" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_5ced2315-1f7f-4bfd-b1f4-492b465fc665" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesIncomeTaxProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_edae8a4e-58d0-453d-b206-075cfa5350e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f7d44949-be2c-4a82-89d6-97f735dbcc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_edae8a4e-58d0-453d-b206-075cfa5350e6" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f7d44949-be2c-4a82-89d6-97f735dbcc0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_24df061c-babc-4f46-8873-8d75f8f1ba99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_edae8a4e-58d0-453d-b206-075cfa5350e6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_24df061c-babc-4f46-8873-8d75f8f1ba99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3e115bc8-08f1-4bc7-ba71-1755dc8839a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f5da8482-4c5c-4ea8-9620-33dfc5a17f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3e115bc8-08f1-4bc7-ba71-1755dc8839a0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f5da8482-4c5c-4ea8-9620-33dfc5a17f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_296c9e8d-aad7-4743-9157-5dfb4d1e831f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3e115bc8-08f1-4bc7-ba71-1755dc8839a0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_296c9e8d-aad7-4743-9157-5dfb4d1e831f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e7cbb33-462a-4309-a3df-40d886ef529d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_be696970-1850-4bbc-9e17-007491af14e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e7cbb33-462a-4309-a3df-40d886ef529d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_be696970-1850-4bbc-9e17-007491af14e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_dbbb1b79-3f3d-4b02-ad06-045b131eecb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e7cbb33-462a-4309-a3df-40d886ef529d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_dbbb1b79-3f3d-4b02-ad06-045b131eecb1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesEffectiveTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e9dada2-8564-4dea-a4ed-45edecded040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e32ad2fa-d3f9-42ef-a723-cdd176b0e1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e9dada2-8564-4dea-a4ed-45edecded040" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e32ad2fa-d3f9-42ef-a723-cdd176b0e1a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_a4c9493d-10d6-4a11-8ca4-a9f889e9d16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e9dada2-8564-4dea-a4ed-45edecded040" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_a4c9493d-10d6-4a11-8ca4-a9f889e9d16c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_03d9d08a-1fdd-4165-8dd6-3fbc6b8a806e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e9dada2-8564-4dea-a4ed-45edecded040" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_03d9d08a-1fdd-4165-8dd6-3fbc6b8a806e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent_6ef6b95b-7b5b-4fd6-9009-8ddfd1d7622e" xlink:href="cvs-20221231.xsd#cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e9dada2-8564-4dea-a4ed-45edecded040" xlink:to="loc_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent_6ef6b95b-7b5b-4fd6-9009-8ddfd1d7622e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic_995da40c-a412-440a-91dd-90a0547133a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e9dada2-8564-4dea-a4ed-45edecded040" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic_995da40c-a412-440a-91dd-90a0547133a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthInsurerFeeTaxEffectPercent_88f6f635-7bde-4860-b4ad-e17e87744949" xlink:href="cvs-20221231.xsd#cvs_HealthInsurerFeeTaxEffectPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e9dada2-8564-4dea-a4ed-45edecded040" xlink:to="loc_cvs_HealthInsurerFeeTaxEffectPercent_88f6f635-7bde-4860-b4ad-e17e87744949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_17b69cfa-9f5c-4b82-9720-222785bd922a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7e9dada2-8564-4dea-a4ed-45edecded040" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_17b69cfa-9f5c-4b82-9720-222785bd922a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_58cbf5d7-2d7c-45a7-b3c9-e8008d5aab74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_58cbf5d7-2d7c-45a7-b3c9-e8008d5aab74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_4b61682b-5789-4a69-ab8c-992a8109913c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_4b61682b-5789-4a69-ab8c-992a8109913c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances_5e904458-27ef-479b-8d0c-5bd66857d2db" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances_5e904458-27ef-479b-8d0c-5bd66857d2db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a0ed720d-bbad-4a80-a0f7-9346bde4c3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a0ed720d-bbad-4a80-a0f7-9346bde4c3c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxAssetsPayrollTaxDeferral_87c1ebb3-1a64-42a4-aa6f-a30266a12597" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxAssetsPayrollTaxDeferral"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_cvs_DeferredTaxAssetsPayrollTaxDeferral_87c1ebb3-1a64-42a4-aa6f-a30266a12597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_8c5f7016-b110-4312-9d0f-10946b3f8b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_8c5f7016-b110-4312-9d0f-10946b3f8b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_acc10bb2-6917-48a9-be15-e78bb743415c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_acc10bb2-6917-48a9-be15-e78bb743415c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2458322d-c164-416d-bfa1-f690045eb8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2458322d-c164-416d-bfa1-f690045eb8f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1f56e44d-91dd-4edf-b3ff-e6c8749f643f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1f56e44d-91dd-4edf-b3ff-e6c8749f643f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_c93f05c0-3e0e-4e90-a7f5-9b1d277720d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_c93f05c0-3e0e-4e90-a7f5-9b1d277720d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_92151261-6fe0-4fec-be3a-e365758c00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_92151261-6fe0-4fec-be3a-e365758c00a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_fd0ad09d-2a1c-4bff-b167-d6811d4b87d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e062308-d06d-4a65-b3fe-ea27bf17e8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_fd0ad09d-2a1c-4bff-b167-d6811d4b87d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9825157c-07f0-4eea-9017-f965790ab5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization_a56c9959-e557-41ca-8c55-a4e0550b900c" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9825157c-07f0-4eea-9017-f965790ab5fd" xlink:to="loc_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization_a56c9959-e557-41ca-8c55-a4e0550b900c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_4aec00cb-6f58-41f3-8c70-b9b66b4fe1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9825157c-07f0-4eea-9017-f965790ab5fd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_4aec00cb-6f58-41f3-8c70-b9b66b4fe1e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_f61034a8-e74c-4a3d-92a2-193f64e2ff36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9825157c-07f0-4eea-9017-f965790ab5fd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_f61034a8-e74c-4a3d-92a2-193f64e2ff36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxLiabilitiesRetirementBenefits_ab503089-df8c-4956-a57a-109adac5d570" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxLiabilitiesRetirementBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9825157c-07f0-4eea-9017-f965790ab5fd" xlink:to="loc_cvs_DeferredTaxLiabilitiesRetirementBenefits_ab503089-df8c-4956-a57a-109adac5d570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_dc289b30-b902-4811-8f7b-aedbf38d329f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b30d3ee4-5df2-4102-8eca-4660af5a4053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_dc289b30-b902-4811-8f7b-aedbf38d329f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b30d3ee4-5df2-4102-8eca-4660af5a4053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_07c045b7-e657-445a-b189-49d71a316b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_dc289b30-b902-4811-8f7b-aedbf38d329f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_07c045b7-e657-445a-b189-49d71a316b3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c849b3a6-3ced-4b88-b24a-85b79ce59af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ee88a1af-70b1-404d-a801-89bacecb35d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c849b3a6-3ced-4b88-b24a-85b79ce59af5" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ee88a1af-70b1-404d-a801-89bacecb35d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1489046b-577d-419d-9f09-790e17528f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c849b3a6-3ced-4b88-b24a-85b79ce59af5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1489046b-577d-419d-9f09-790e17528f26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ce57602d-fdb9-44b8-870f-d9f364a22c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_96782697-cb4f-4b0c-b995-9a0fe000ca4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_ce57602d-fdb9-44b8-870f-d9f364a22c32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_96782697-cb4f-4b0c-b995-9a0fe000ca4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9e40d338-7cf1-4599-b913-70e56e3f049c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_ce57602d-fdb9-44b8-870f-d9f364a22c32" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9e40d338-7cf1-4599-b913-70e56e3f049c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6697131b-b90a-43d2-be62-11d5e258dcca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_62e56742-cbb3-4234-87cd-9b78fa295c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6697131b-b90a-43d2-be62-11d5e258dcca" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_62e56742-cbb3-4234-87cd-9b78fa295c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ba134223-3b64-4b26-8750-c8d062259305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6697131b-b90a-43d2-be62-11d5e258dcca" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ba134223-3b64-4b26-8750-c8d062259305" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ReinsuranceEffectsofReinsuranceDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_f54dee90-0613-48c5-849b-870a0ff5d56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned_52b33925-cdb6-4e0a-90f1-9a50e616bb86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PremiumsEarnedNet_f54dee90-0613-48c5-849b-870a0ff5d56c" xlink:to="loc_us-gaap_DirectPremiumsEarned_52b33925-cdb6-4e0a-90f1-9a50e616bb86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned_42201b15-0c77-42f7-991f-c760117f01bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PremiumsEarnedNet_f54dee90-0613-48c5-849b-870a0ff5d56c" xlink:to="loc_us-gaap_AssumedPremiumsEarned_42201b15-0c77-42f7-991f-c760117f01bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned_f7f8e649-17b2-4fbf-bbae-bc34d757fa68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededPremiumsEarned"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PremiumsEarnedNet_f54dee90-0613-48c5-849b-870a0ff5d56c" xlink:to="loc_us-gaap_CededPremiumsEarned_f7f8e649-17b2-4fbf-bbae-bc34d757fa68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_ed02cbef-4e26-4811-af0a-d0aa3e8b7ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_4177925f-9d4c-4038-a695-4d17f53cd7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_ed02cbef-4e26-4811-af0a-d0aa3e8b7ad7" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_4177925f-9d4c-4038-a695-4d17f53cd7c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_d40de02e-59b1-41b9-8a8f-526e4de8f151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_ed02cbef-4e26-4811-af0a-d0aa3e8b7ad7" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_d40de02e-59b1-41b9-8a8f-526e4de8f151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_0440b0e3-4c53-44f8-999b-103314f3f38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_ed02cbef-4e26-4811-af0a-d0aa3e8b7ad7" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_0440b0e3-4c53-44f8-999b-103314f3f38f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"/>
  <link:calculationLink xlink:role="http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_792dbc93-e9c2-4877-9cf7-756be788eeda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_3704202d-bcff-4ca0-917d-3796a15b1eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_792dbc93-e9c2-4877-9cf7-756be788eeda" xlink:to="loc_us-gaap_NetInvestmentIncome_3704202d-bcff-4ca0-917d-3796a15b1eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_e401a056-06d8-4688-80d8-c0c76dfaf294" xlink:href="cvs-20221231.xsd#cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_792dbc93-e9c2-4877-9cf7-756be788eeda" xlink:to="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_e401a056-06d8-4688-80d8-c0c76dfaf294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8880b0e7-f8c3-41bd-b0b4-6e5c803fc1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_792dbc93-e9c2-4877-9cf7-756be788eeda" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8880b0e7-f8c3-41bd-b0b4-6e5c803fc1e9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cvs-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:062ae674-cc97-4efd-81c6-d89202a3d450,g:ffc34178-e241-4c21-bbb1-7b57d93a8581-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i9ab6296ea3314433a1c69c85d00dbd45_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31dc5060-ddff-4a22-a7d8-25958dc628df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31dc5060-ddff-4a22-a7d8-25958dc628df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_1d4dafb4-da0c-439b-b379-4b55f306df16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:to="loc_us-gaap_PremiumsEarnedNet_1d4dafb4-da0c-439b-b379-4b55f306df16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_b10f5a75-e302-4d92-9e50-2453160011e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:to="loc_us-gaap_NetInvestmentIncome_b10f5a75-e302-4d92-9e50-2453160011e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8f873fe6-ffba-41ec-89d0-b9aeabe8026a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:to="loc_us-gaap_Revenues_8f873fe6-ffba-41ec-89d0-b9aeabe8026a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8ee84170-e53a-4b15-8ed9-1b815b1f0c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8ee84170-e53a-4b15-8ed9-1b815b1f0c19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_c6f41280-1ae2-4629-919a-eeb863917ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_c6f41280-1ae2-4629-919a-eeb863917ae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5987978d-c629-4da0-9ecf-4198496d9f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5987978d-c629-4da0-9ecf-4198496d9f36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_dac4e3ea-d9b3-4e8c-8200-40c328d17043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_dac4e3ea-d9b3-4e8c-8200-40c328d17043" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_ab2e9dc9-2925-409c-b997-38dbb010be0d" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_cvs_StoreImpairmentCharges_ab2e9dc9-2925-409c-b997-38dbb010be0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5c6ceca2-2c90-41d2-a245-04455c577ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5c6ceca2-2c90-41d2-a245-04455c577ba8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement_bc481d3c-4ee0-4b66-a681-725bb78e6434" xlink:href="cvs-20221231.xsd#cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement_bc481d3c-4ee0-4b66-a681-725bb78e6434" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_106a1660-e029-4435-82fc-b779303f73cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_CostsAndExpenses_106a1660-e029-4435-82fc-b779303f73cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1b3ac6ec-1e55-4c19-ba28-3578476263f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_OperatingIncomeLoss_1b3ac6ec-1e55-4c19-ba28-3578476263f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0f553ede-4c95-4f82-9eed-fc864ba84847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_InterestExpense_0f553ede-4c95-4f82-9eed-fc864ba84847" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7200b479-056a-42ec-834c-9577a66c02ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7200b479-056a-42ec-834c-9577a66c02ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_151aa584-72c4-48fa-89ec-c721cb2bc29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_151aa584-72c4-48fa-89ec-c721cb2bc29f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25738e7b-5bd2-43de-9571-de575519a626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25738e7b-5bd2-43de-9571-de575519a626" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b0a0c60-9821-4556-8e01-7dd21772e054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b0a0c60-9821-4556-8e01-7dd21772e054" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f15c8aaf-92f0-4844-a18f-1b3a4617564f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f15c8aaf-92f0-4844-a18f-1b3a4617564f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ff81b678-094d-4789-a155-7d0741298575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ff81b678-094d-4789-a155-7d0741298575" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_241452af-c029-487e-8d41-88b5a486395e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_ProfitLoss_241452af-c029-487e-8d41-88b5a486395e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3ff96770-003e-4f32-a830-2722d4b69576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3ff96770-003e-4f32-a830-2722d4b69576" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7cefeab1-5aa4-4486-bcc1-231fd0ed1a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_NetIncomeLoss_7cefeab1-5aa4-4486-bcc1-231fd0ed1a71" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bdbdf761-5225-4411-81b4-f251bd217fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bdbdf761-5225-4411-81b4-f251bd217fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_bbd62b99-2198-4bf3-bce9-12e19f9b7516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_bbd62b99-2198-4bf3-bce9-12e19f9b7516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a86817a9-7d3c-484f-9f59-4c1be3133bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:to="loc_us-gaap_EarningsPerShareBasic_a86817a9-7d3c-484f-9f59-4c1be3133bd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0486de7-b250-4d15-9c28-2a846f52425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0486de7-b250-4d15-9c28-2a846f52425a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7935b12e-604f-4290-98bb-a41a41a64c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7935b12e-604f-4290-98bb-a41a41a64c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_63f79235-cd8d-49b6-a309-56345d651a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_63f79235-cd8d-49b6-a309-56345d651a8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7a97d7c6-2130-4748-a11a-ca33b63fcddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7a97d7c6-2130-4748-a11a-ca33b63fcddb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3949965c-3017-4441-b516-d9ea84de06d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3949965c-3017-4441-b516-d9ea84de06d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_00d10f73-f2e8-4bb4-8cfc-47c9696a970a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_00d10f73-f2e8-4bb4-8cfc-47c9696a970a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_159c1a5d-857b-42b0-8a45-701b8b2af8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_159c1a5d-857b-42b0-8a45-701b8b2af8bd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_effffeac-6748-4174-9c11-28648de55496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_StatementTable_effffeac-6748-4174-9c11-28648de55496" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_45e564c6-f717-4dc9-99fa-13d84a230ade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_effffeac-6748-4174-9c11-28648de55496" xlink:to="loc_srt_ProductOrServiceAxis_45e564c6-f717-4dc9-99fa-13d84a230ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45e564c6-f717-4dc9-99fa-13d84a230ade_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_45e564c6-f717-4dc9-99fa-13d84a230ade" xlink:to="loc_srt_ProductsAndServicesDomain_45e564c6-f717-4dc9-99fa-13d84a230ade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f67bf1e-52aa-43fd-8ce4-34200d247a0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_45e564c6-f717-4dc9-99fa-13d84a230ade" xlink:to="loc_srt_ProductsAndServicesDomain_8f67bf1e-52aa-43fd-8ce4-34200d247a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d680de67-f868-48d1-9ffb-a84d743d7b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8f67bf1e-52aa-43fd-8ce4-34200d247a0e" xlink:to="loc_us-gaap_ProductMember_d680de67-f868-48d1-9ffb-a84d743d7b22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_be62eb64-787e-4b89-88e5-3974004b6356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8f67bf1e-52aa-43fd-8ce4-34200d247a0e" xlink:to="loc_us-gaap_ServiceMember_be62eb64-787e-4b89-88e5-3974004b6356" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i9c5cd78861b743bd9dc1b6ae3f5994c7_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6c0ed4d-6cb1-45b6-b442-3938ea2e8d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6c0ed4d-6cb1-45b6-b442-3938ea2e8d0a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9d127cfd-0334-4a52-9ef0-83cc0fc1ebab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_SharesOutstanding_9d127cfd-0334-4a52-9ef0-83cc0fc1ebab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d11e9b86-2e80-4c70-8ead-3b65a2f8542f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_TreasuryStockCommonShares_d11e9b86-2e80-4c70-8ead-3b65a2f8542f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca59a0b8-94c5-4264-a7c8-0d168a9ca122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca59a0b8-94c5-4264-a7c8-0d168a9ca122" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1525a5e3-5de9-4c88-a257-7f26617c9c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_ProfitLoss_1525a5e3-5de9-4c88-a257-7f26617c9c8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e7836b44-0976-4983-8825-e59fe4d28359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e7836b44-0976-4983-8825-e59fe4d28359" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bdd820d7-8040-4d79-9673-9d6cbc0ee0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bdd820d7-8040-4d79-9673-9d6cbc0ee0fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2111a35e-76ae-41d8-8075-e3fca9ba7ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2111a35e-76ae-41d8-8075-e3fca9ba7ae0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod_4e7ed930-7731-464f-b8e2-8c05dce0d150" xlink:href="cvs-20221231.xsd#cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod_4e7ed930-7731-464f-b8e2-8c05dce0d150" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod_eb72fe62-2696-4670-8393-1f968f79eca7" xlink:href="cvs-20221231.xsd#cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod_eb72fe62-2696-4670-8393-1f968f79eca7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance_d17b3a86-9335-4305-8b02-f9bf9cbf433e" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance_d17b3a86-9335-4305-8b02-f9bf9cbf433e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance_35d46224-0593-441e-963b-d946c063b32b" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance_35d46224-0593-441e-963b-d946c063b32b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_31b27d50-6dd5-480b-80df-49b0409dc882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_DividendsCommonStock_31b27d50-6dd5-480b-80df-49b0409dc882" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease_fa12dd4f-fe21-41b4-ac8d-5aad2bb995bc" xlink:href="cvs-20221231.xsd#cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease_fa12dd4f-fe21-41b4-ac8d-5aad2bb995bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2a9fbc05-be6d-4164-9a84-a2a372c6ba07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e0c23e1d-4203-4cc2-99d0-047bba3bb90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_092bc742-c99e-49a0-bf23-41a4d2d53e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d4e146c-887c-476c-854a-88f99a0eb033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c6c0ed4d-6cb1-45b6-b442-3938ea2e8d0a" xlink:to="loc_us-gaap_StatementTable_2d4e146c-887c-476c-854a-88f99a0eb033" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b82568dd-d739-45f9-a290-57a54c849423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2d4e146c-887c-476c-854a-88f99a0eb033" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b82568dd-d739-45f9-a290-57a54c849423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b82568dd-d739-45f9-a290-57a54c849423_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b82568dd-d739-45f9-a290-57a54c849423" xlink:to="loc_us-gaap_EquityComponentDomain_b82568dd-d739-45f9-a290-57a54c849423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_77003d3e-5f31-4e34-952e-42f715430859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b82568dd-d739-45f9-a290-57a54c849423" xlink:to="loc_us-gaap_EquityComponentDomain_77003d3e-5f31-4e34-952e-42f715430859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_77003d3e-5f31-4e34-952e-42f715430859" xlink:to="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ba72840-8998-485f-9175-d463353cdb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_CommonStockMember_9ba72840-8998-485f-9175-d463353cdb4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_52f021ae-4b9d-47f8-bd32-f44e9336f1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_TreasuryStockCommonMember_52f021ae-4b9d-47f8-bd32-f44e9336f1f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_a8f2e9d8-a6ca-47a9-852c-9497d86b6073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_a8f2e9d8-a6ca-47a9-852c-9497d86b6073" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5b5f3004-8490-40cf-8dc1-ac5392e9b8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_RetainedEarningsMember_5b5f3004-8490-40cf-8dc1-ac5392e9b8f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a65b6b34-6ee5-4a7c-86e5-ed8745ccbfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a65b6b34-6ee5-4a7c-86e5-ed8745ccbfa2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f2a563c4-4db0-4431-be8a-9dff30e8bdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_77003d3e-5f31-4e34-952e-42f715430859" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f2a563c4-4db0-4431-be8a-9dff30e8bdd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e83d3f2-8a99-44c8-a93e-2dd5a927c223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2d4e146c-887c-476c-854a-88f99a0eb033" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e83d3f2-8a99-44c8-a93e-2dd5a927c223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8e83d3f2-8a99-44c8-a93e-2dd5a927c223_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e83d3f2-8a99-44c8-a93e-2dd5a927c223" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8e83d3f2-8a99-44c8-a93e-2dd5a927c223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_edbdb0e3-91e4-4371-a58f-6b2bc094919f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e83d3f2-8a99-44c8-a93e-2dd5a927c223" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_edbdb0e3-91e4-4371-a58f-6b2bc094919f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_495ba4bb-aba7-4a64-b7d2-1bf1884c8c68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_edbdb0e3-91e4-4371-a58f-6b2bc094919f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_495ba4bb-aba7-4a64-b7d2-1bf1884c8c68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofShareholdersEquityParentheticals"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" xlink:type="extended" id="i25ed4d958d9f4048a2c1df4a2a37a094_ConsolidatedStatementsofShareholdersEquityParentheticals">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockSharesHeldinTrust_6d07333d-e642-435b-9cd7-a56045059866" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockSharesHeldinTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_cvs_TreasuryStockSharesHeldinTrust_6d07333d-e642-435b-9cd7-a56045059866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockValueSharesHeldInTrust_ca3c2916-17c9-4154-89c4-a6454c91ca2a" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockValueSharesHeldInTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_cvs_TreasuryStockValueSharesHeldInTrust_ca3c2916-17c9-4154-89c4-a6454c91ca2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a17d00fc-0642-4a66-b9f3-0dcabc9ef991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_us-gaap_CommonStockValue_a17d00fc-0642-4a66-b9f3-0dcabc9ef991" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_65cf0914-5d70-4b32-9caf-6636175414d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_65cf0914-5d70-4b32-9caf-6636175414d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_a9362ac1-40e5-4af3-a5bb-b1e5fbe49119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_a9362ac1-40e5-4af3-a5bb-b1e5fbe49119" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_265f0cf8-a2b4-4fa6-882d-25b218e3941f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_265f0cf8-a2b4-4fa6-882d-25b218e3941f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_265f0cf8-a2b4-4fa6-882d-25b218e3941f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_265f0cf8-a2b4-4fa6-882d-25b218e3941f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_265f0cf8-a2b4-4fa6-882d-25b218e3941f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b7312a47-00c5-4703-b02c-c287b7446635" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_265f0cf8-a2b4-4fa6-882d-25b218e3941f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b7312a47-00c5-4703-b02c-c287b7446635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_138cbbf8-3694-42f6-948d-81bbfeedfe3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b7312a47-00c5-4703-b02c-c287b7446635" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_138cbbf8-3694-42f6-948d-81bbfeedfe3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e0d1356-57ae-48cb-94e0-be0206ef9a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e0d1356-57ae-48cb-94e0-be0206ef9a60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e0d1356-57ae-48cb-94e0-be0206ef9a60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e0d1356-57ae-48cb-94e0-be0206ef9a60" xlink:to="loc_us-gaap_EquityComponentDomain_1e0d1356-57ae-48cb-94e0-be0206ef9a60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_78f9ca8a-d5ec-4b0c-bea3-17e6dd4adaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e0d1356-57ae-48cb-94e0-be0206ef9a60" xlink:to="loc_us-gaap_EquityComponentDomain_78f9ca8a-d5ec-4b0c-bea3-17e6dd4adaa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f3069289-fdae-43ee-afe9-96a3cff8534f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_78f9ca8a-d5ec-4b0c-bea3-17e6dd4adaa7" xlink:to="loc_us-gaap_RetainedEarningsMember_f3069289-fdae-43ee-afe9-96a3cff8534f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7b35d734-0f3a-4448-b9a3-18ca8f13cb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7b35d734-0f3a-4448-b9a3-18ca8f13cb9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7b35d734-0f3a-4448-b9a3-18ca8f13cb9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7b35d734-0f3a-4448-b9a3-18ca8f13cb9f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7b35d734-0f3a-4448-b9a3-18ca8f13cb9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1b08cb15-2578-4edb-9528-5e2d42b1a919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7b35d734-0f3a-4448-b9a3-18ca8f13cb9f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1b08cb15-2578-4edb-9528-5e2d42b1a919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_8d3e2b3d-8391-4f62-b2ed-8b65ff12b70c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1b08cb15-2578-4edb-9528-5e2d42b1a919" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_8d3e2b3d-8391-4f62-b2ed-8b65ff12b70c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i6d415c44a0484854a05b63b95d7ee236_SignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_ec25cc26-c7b3-4b2c-91f7-10c15f4fc2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStores"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_NumberOfStores_ec25cc26-c7b3-4b2c-91f7-10c15f4fc2fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfWalkInMedicalClinics_4407e0c5-20b7-47ea-8067-84f9ce1e3d74" xlink:href="cvs-20221231.xsd#cvs_NumberOfWalkInMedicalClinics"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfWalkInMedicalClinics_4407e0c5-20b7-47ea-8067-84f9ce1e3d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfPharmacyPlanMembers_5107c7c2-08bc-4e97-8048-2ac4ea74637b" xlink:href="cvs-20221231.xsd#cvs_NumberOfPharmacyPlanMembers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfPharmacyPlanMembers_5107c7c2-08bc-4e97-8048-2ac4ea74637b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfPatientsServedPerYear_62f082ac-823d-45d3-821a-66108812cf96" xlink:href="cvs-20221231.xsd#cvs_NumberOfPatientsServedPerYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfPatientsServedPerYear_62f082ac-823d-45d3-821a-66108812cf96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfPeopleServed_480a7a4e-859f-4533-8e25-ca5359020ce7" xlink:href="cvs-20221231.xsd#cvs_NumberOfPeopleServed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfPeopleServed_480a7a4e-859f-4533-8e25-ca5359020ce7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_621e8d36-0825-4839-884c-1fd852c4ea09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_NumberOfReportableSegments_621e8d36-0825-4839-884c-1fd852c4ea09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates_70624883-4d98-4b58-a6bf-32063b98a507" xlink:href="cvs-20221231.xsd#cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates_70624883-4d98-4b58-a6bf-32063b98a507" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates_eb85c638-90c0-409d-8095-0ed62cab0c31" xlink:href="cvs-20221231.xsd#cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates_eb85c638-90c0-409d-8095-0ed62cab0c31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredPolicyAcquisitionCosts_baa69418-bc0c-4fcb-9691-46a3a28a33df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredPolicyAcquisitionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_DeferredPolicyAcquisitionCosts_baa69418-bc0c-4fcb-9691-46a3a28a33df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f94167a8-078f-4b42-a2a8-c20fc1f8d268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f94167a8-078f-4b42-a2a8-c20fc1f8d268" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_77740db8-a9d9-4b82-9e2c-17c889c42129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_Depreciation_77740db8-a9d9-4b82-9e2c-17c889c42129" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OfficeRealEstateOptimizationCharges_3583b334-c247-4ca5-b99c-8ab26a7e74bf" xlink:href="cvs-20221231.xsd#cvs_OfficeRealEstateOptimizationCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_OfficeRealEstateOptimizationCharges_3583b334-c247-4ca5-b99c-8ab26a7e74bf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_eafcfc89-f9aa-4b5a-b7b1-2ddb7f0780af" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_StoreImpairmentCharges_eafcfc89-f9aa-4b5a-b7b1-2ddb7f0780af" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm_93ea0039-0e4f-48c2-8d1e-90ebf0fe9555" xlink:href="cvs-20221231.xsd#cvs_LesseeOperatingAndFinanceLeasesRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm_93ea0039-0e4f-48c2-8d1e-90ebf0fe9555" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresPlannedClosure_8d9e0b00-6dac-4f2b-92cc-c7110cf22293" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresPlannedClosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfStoresPlannedClosure_8d9e0b00-6dac-4f2b-92cc-c7110cf22293" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_db83760a-e39c-4229-915a-72b9aceddb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_db83760a-e39c-4229-915a-72b9aceddb9f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7a096894-a7b4-4235-a3bb-ed6296754e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7a096894-a7b4-4235-a3bb-ed6296754e4d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid_f84d9fe9-cc7d-4dcb-8935-233a7610888b" xlink:href="cvs-20221231.xsd#cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid_f84d9fe9-cc7d-4dcb-8935-233a7610888b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LiabilityForUnpaidClaims_efb7aaf3-21cf-48c3-b9dd-13cc2fa09488" xlink:href="cvs-20221231.xsd#cvs_LiabilityForUnpaidClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_LiabilityForUnpaidClaims_efb7aaf3-21cf-48c3-b9dd-13cc2fa09488" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LimitedPaymentsContracts_760568d0-28a4-49f7-9dac-4984ec2e184f" xlink:href="cvs-20221231.xsd#cvs_LimitedPaymentsContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_LimitedPaymentsContracts_760568d0-28a4-49f7-9dac-4984ec2e184f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts_3bb2854d-fc7d-453d-b675-6eb74e946e2f" xlink:href="cvs-20221231.xsd#cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts_3bb2854d-fc7d-453d-b675-6eb74e946e2f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_d5b39ee5-2677-4352-8184-5e50fe7decc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_d5b39ee5-2677-4352-8184-5e50fe7decc0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumDeficiencyReserveLiability_038819a4-f909-4895-9f49-6d017fb56852" xlink:href="cvs-20221231.xsd#cvs_PremiumDeficiencyReserveLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_PremiumDeficiencyReserveLiability_038819a4-f909-4895-9f49-6d017fb56852" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PensionAndAnnuityInvestmentContractsInterest_740ea4c5-e1d4-4797-9ded-7a7b968cb926" xlink:href="cvs-20221231.xsd#cvs_PensionAndAnnuityInvestmentContractsInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_PensionAndAnnuityInvestmentContractsInterest_740ea4c5-e1d4-4797-9ded-7a7b968cb926" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HeathSavingsAccountBalance_64c0793c-1409-45fb-b6d4-232ef02928ca" xlink:href="cvs-20221231.xsd#cvs_HeathSavingsAccountBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_HeathSavingsAccountBalance_64c0793c-1409-45fb-b6d4-232ef02928ca" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_03d8efd5-900d-4b15-a0a1-f5282878858c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_SelfInsuranceReserve_03d8efd5-900d-4b15-a0a1-f5282878858c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyRebatePeriod_d9d570be-f1ce-4606-ba5f-6105c5211c1d" xlink:href="cvs-20221231.xsd#cvs_PharmacyRebatePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_PharmacyRebatePeriod_d9d570be-f1ce-4606-ba5f-6105c5211c1d" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthInsurerFee_9b39251e-b493-4cda-b3f6-cba9bd2fdc78" xlink:href="cvs-20221231.xsd#cvs_HealthInsurerFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_HealthInsurerFee_9b39251e-b493-4cda-b3f6-cba9bd2fdc78" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_c6843ef7-3436-4796-9ab6-bbfa30ddba0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_c6843ef7-3436-4796-9ab6-bbfa30ddba0d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_bd3c8b0a-383f-4ff3-b71d-c25898344e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_bd3c8b0a-383f-4ff3-b71d-c25898344e45" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_2cbbf8dc-c747-462a-a666-e7ac1be1efef" xlink:href="cvs-20221231.xsd#cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_2cbbf8dc-c747-462a-a666-e7ac1be1efef" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax_f09adadf-5a11-4a98-8af9-ffe81e0a1943" xlink:href="cvs-20221231.xsd#cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax_f09adadf-5a11-4a98-8af9-ffe81e0a1943" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_0918b061-bb60-4cf7-897a-86db5ec1b3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_AdvertisingExpense_0918b061-bb60-4cf7-897a-86db5ec1b3ff" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8b991190-9bd9-477f-a740-1d554ca970fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8b991190-9bd9-477f-a740-1d554ca970fb" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockSharesHeldinTrust_0ecc3fbb-2f63-41bb-a6e4-a55fccb6cda9" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockSharesHeldinTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_TreasuryStockSharesHeldinTrust_0ecc3fbb-2f63-41bb-a6e4-a55fccb6cda9" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_79aef353-eb9d-4538-8b80-1e7a07b26b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_79aef353-eb9d-4538-8b80-1e7a07b26b82" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_2591ef93-b847-4ab9-8573-af7b56625b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_2591ef93-b847-4ab9-8573-af7b56625b25" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_563bd82c-273c-4de7-9bbb-89c4084317a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_563bd82c-273c-4de7-9bbb-89c4084317a5" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity_50ebd8cb-4762-47ba-a6d0-f32e5421b56b" xlink:href="cvs-20221231.xsd#cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity_50ebd8cb-4762-47ba-a6d0-f32e5421b56b" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f44598a3-fc16-4e7c-9bd8-a7e5e44c81cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_srt_ProductOrServiceAxis_f44598a3-fc16-4e7c-9bd8-a7e5e44c81cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f44598a3-fc16-4e7c-9bd8-a7e5e44c81cd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f44598a3-fc16-4e7c-9bd8-a7e5e44c81cd" xlink:to="loc_srt_ProductsAndServicesDomain_f44598a3-fc16-4e7c-9bd8-a7e5e44c81cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_214547f0-8f6b-47ea-9f27-d56c46160bc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f44598a3-fc16-4e7c-9bd8-a7e5e44c81cd" xlink:to="loc_srt_ProductsAndServicesDomain_214547f0-8f6b-47ea-9f27-d56c46160bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthInsuranceProductLineMember_d72da6d3-8753-4326-8dc9-3f4783e57597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthInsuranceProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_214547f0-8f6b-47ea-9f27-d56c46160bc5" xlink:to="loc_us-gaap_HealthInsuranceProductLineMember_d72da6d3-8753-4326-8dc9-3f4783e57597" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_219e006e-c7f0-47ae-8ee8-6a4a5bf82465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_219e006e-c7f0-47ae-8ee8-6a4a5bf82465" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_219e006e-c7f0-47ae-8ee8-6a4a5bf82465_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_219e006e-c7f0-47ae-8ee8-6a4a5bf82465" xlink:to="loc_us-gaap_SegmentDomain_219e006e-c7f0-47ae-8ee8-6a4a5bf82465_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4a6bdad3-8481-4ec3-a7ef-c929c056513d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_219e006e-c7f0-47ae-8ee8-6a4a5bf82465" xlink:to="loc_us-gaap_SegmentDomain_4a6bdad3-8481-4ec3-a7ef-c929c056513d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_35b61220-82ec-4f85-9c35-e674477260f4" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4a6bdad3-8481-4ec3-a7ef-c929c056513d" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_35b61220-82ec-4f85-9c35-e674477260f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_250a8aa9-7799-466f-87d4-59ff84f03e05" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4a6bdad3-8481-4ec3-a7ef-c929c056513d" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_250a8aa9-7799-466f-87d4-59ff84f03e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_23107a75-493e-491f-8b17-38a674662f0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_srt_RangeAxis_23107a75-493e-491f-8b17-38a674662f0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23107a75-493e-491f-8b17-38a674662f0e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_23107a75-493e-491f-8b17-38a674662f0e" xlink:to="loc_srt_RangeMember_23107a75-493e-491f-8b17-38a674662f0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40ed7863-1deb-4776-83c9-03880487c244" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_23107a75-493e-491f-8b17-38a674662f0e" xlink:to="loc_srt_RangeMember_40ed7863-1deb-4776-83c9-03880487c244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cdb6c580-a25f-49b5-bc10-2c01e0a1bf86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_40ed7863-1deb-4776-83c9-03880487c244" xlink:to="loc_srt_MinimumMember_cdb6c580-a25f-49b5-bc10-2c01e0a1bf86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_607b238b-f9c9-4b1f-af13-d0acbd514b45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_40ed7863-1deb-4776-83c9-03880487c244" xlink:to="loc_srt_MaximumMember_607b238b-f9c9-4b1f-af13-d0acbd514b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f30736fd-c9e3-45a5-a38f-0e5cf14faf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f30736fd-c9e3-45a5-a38f-0e5cf14faf2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f30736fd-c9e3-45a5-a38f-0e5cf14faf2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f30736fd-c9e3-45a5-a38f-0e5cf14faf2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f30736fd-c9e3-45a5-a38f-0e5cf14faf2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f30736fd-c9e3-45a5-a38f-0e5cf14faf2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a05c798e-1de0-4c82-aee0-8e9931d55490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a05c798e-1de0-4c82-aee0-8e9931d55490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember_d9302e00-7e80-4353-aed7-aca1c6a6c44b" xlink:href="cvs-20221231.xsd#cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:to="loc_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember_d9302e00-7e80-4353-aed7-aca1c6a6c44b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_811bd883-57d2-4b9f-b530-07fde4c66bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_811bd883-57d2-4b9f-b530-07fde4c66bbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_99600885-d8f6-40bf-bdbd-7b436feaa907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_99600885-d8f6-40bf-bdbd-7b436feaa907" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_99600885-d8f6-40bf-bdbd-7b436feaa907_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_99600885-d8f6-40bf-bdbd-7b436feaa907" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_99600885-d8f6-40bf-bdbd-7b436feaa907_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8f8d7792-a433-4661-b8b1-e512304e29da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_99600885-d8f6-40bf-bdbd-7b436feaa907" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8f8d7792-a433-4661-b8b1-e512304e29da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherInsuranceLiabilitiesMember_674ce8bb-1c0c-4253-99e8-898db6a68167" xlink:href="cvs-20221231.xsd#cvs_OtherInsuranceLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f8d7792-a433-4661-b8b1-e512304e29da" xlink:to="loc_cvs_OtherInsuranceLiabilitiesMember_674ce8bb-1c0c-4253-99e8-898db6a68167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherLongTermInsuranceLiabilitiesMember_4952dcdd-8f82-45f2-ab83-c948d9cc2e7c" xlink:href="cvs-20221231.xsd#cvs_OtherLongTermInsuranceLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f8d7792-a433-4661-b8b1-e512304e29da" xlink:to="loc_cvs_OtherLongTermInsuranceLiabilitiesMember_4952dcdd-8f82-45f2-ab83-c948d9cc2e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_19db2452-2b3f-4a75-81ec-4516c115b742" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_dei_LegalEntityAxis_19db2452-2b3f-4a75-81ec-4516c115b742" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_19db2452-2b3f-4a75-81ec-4516c115b742_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_19db2452-2b3f-4a75-81ec-4516c115b742" xlink:to="loc_dei_EntityDomain_19db2452-2b3f-4a75-81ec-4516c115b742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6dfedea2-53b3-4139-8879-c57862b96697" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_19db2452-2b3f-4a75-81ec-4516c115b742" xlink:to="loc_dei_EntityDomain_6dfedea2-53b3-4139-8879-c57862b96697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HeartlandHealthcareServicesMember_ff0e643d-7b04-4411-ac79-e0939da4bdc7" xlink:href="cvs-20221231.xsd#cvs_HeartlandHealthcareServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6dfedea2-53b3-4139-8879-c57862b96697" xlink:to="loc_cvs_HeartlandHealthcareServicesMember_ff0e643d-7b04-4411-ac79-e0939da4bdc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_92c189c5-3c12-48e0-85a5-af412e1e08c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_srt_LitigationCaseAxis_92c189c5-3c12-48e0-85a5-af412e1e08c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_92c189c5-3c12-48e0-85a5-af412e1e08c3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_92c189c5-3c12-48e0-85a5-af412e1e08c3" xlink:to="loc_srt_LitigationCaseTypeDomain_92c189c5-3c12-48e0-85a5-af412e1e08c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2d37e8ff-f213-40a6-9eca-9d9645d4dd3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_92c189c5-3c12-48e0-85a5-af412e1e08c3" xlink:to="loc_srt_LitigationCaseTypeDomain_2d37e8ff-f213-40a6-9eca-9d9645d4dd3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_fea8d057-9852-46db-a26b-281fb18add4f" xlink:href="cvs-20221231.xsd#cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2d37e8ff-f213-40a6-9eca-9d9645d4dd3a" xlink:to="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_fea8d057-9852-46db-a26b-281fb18add4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_803cfe1a-d3f5-422d-9372-b56d1a185c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_us-gaap_LitigationStatusAxis_803cfe1a-d3f5-422d-9372-b56d1a185c15" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_803cfe1a-d3f5-422d-9372-b56d1a185c15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_803cfe1a-d3f5-422d-9372-b56d1a185c15" xlink:to="loc_us-gaap_LitigationStatusDomain_803cfe1a-d3f5-422d-9372-b56d1a185c15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_1b9251d7-cea4-4c72-b34d-28604e1807a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_803cfe1a-d3f5-422d-9372-b56d1a185c15" xlink:to="loc_us-gaap_LitigationStatusDomain_1b9251d7-cea4-4c72-b34d-28604e1807a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_499e6e95-3c78-4d1a-aa6a-b24bdcd6dfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_1b9251d7-cea4-4c72-b34d-28604e1807a4" xlink:to="loc_us-gaap_SettledLitigationMember_499e6e95-3c78-4d1a-aa6a-b24bdcd6dfc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6bb7d09a-be8d-4432-a175-0ebc998f7f99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_srt_StatementScenarioAxis_6bb7d09a-be8d-4432-a175-0ebc998f7f99" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6bb7d09a-be8d-4432-a175-0ebc998f7f99_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_6bb7d09a-be8d-4432-a175-0ebc998f7f99" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6bb7d09a-be8d-4432-a175-0ebc998f7f99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9a3d0c4d-09ae-44d1-af3e-9faaf04b05c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_6bb7d09a-be8d-4432-a175-0ebc998f7f99" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9a3d0c4d-09ae-44d1-af3e-9faaf04b05c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ce3b149d-f818-48ab-81f3-7263224e3335" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9a3d0c4d-09ae-44d1-af3e-9faaf04b05c2" xlink:to="loc_srt_ScenarioForecastMember_ce3b149d-f818-48ab-81f3-7263224e3335" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended" id="i0890d55c40734790b83c4dee30caadd5_SignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_feac6fa6-a544-426d-aa85-ada1983b1a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_feac6fa6-a544-426d-aa85-ada1983b1a08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VendorandManufacturerReceivables_7a4e9c4d-ff8a-4a9b-a38a-bfc05853fdba" xlink:href="cvs-20221231.xsd#cvs_VendorandManufacturerReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_cvs_VendorandManufacturerReceivables_7a4e9c4d-ff8a-4a9b-a38a-bfc05853fdba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue_f5f6e132-613e-430e-8847-6927b4609d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_us-gaap_PremiumsReceivableAtCarryingValue_f5f6e132-613e-430e-8847-6927b4609d45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_58ecb06e-9d66-48ef-9b57-5e9638a7a502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_58ecb06e-9d66-48ef-9b57-5e9638a7a502" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_c0b304e1-fc44-4090-97f9-e8166758050c" xlink:href="cvs-20221231.xsd#cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_c0b304e1-fc44-4090-97f9-e8166758050c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e77c7630-3554-4f18-9fc7-e58e410c5f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e77c7630-3554-4f18-9fc7-e58e410c5f69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_79bede7e-de44-44f6-bf2c-c4ddc61bb0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_79bede7e-de44-44f6-bf2c-c4ddc61bb0d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2402bb42-597f-4e05-b0aa-b62d078e9be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_79bede7e-de44-44f6-bf2c-c4ddc61bb0d6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2402bb42-597f-4e05-b0aa-b62d078e9be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2402bb42-597f-4e05-b0aa-b62d078e9be6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2402bb42-597f-4e05-b0aa-b62d078e9be6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2402bb42-597f-4e05-b0aa-b62d078e9be6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4a59a216-1b26-4690-8b75-c4e2fcfde34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2402bb42-597f-4e05-b0aa-b62d078e9be6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4a59a216-1b26-4690-8b75-c4e2fcfde34e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_0c265047-508d-403e-aea5-4be370482da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4a59a216-1b26-4690-8b75-c4e2fcfde34e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_0c265047-508d-403e-aea5-4be370482da5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="ie95e2c822b8e4b0f9c1d72b14f74bdd0_SignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_79f4c34e-ff1d-47ce-8e41-1661f9010257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_79f4c34e-ff1d-47ce-8e41-1661f9010257" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4d7175a9-ae70-4245-9190-59d0635426b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4d7175a9-ae70-4245-9190-59d0635426b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_191ec090-c0fa-4c68-b9a8-ab2519f55e87" xlink:href="cvs-20221231.xsd#cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:to="loc_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_191ec090-c0fa-4c68-b9a8-ab2519f55e87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db8a5c17-c50e-4115-b4b2-4b6bb4054a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db8a5c17-c50e-4115-b4b2-4b6bb4054a19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5fba793-7bda-4750-9c3e-9b02bd3e8436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db8a5c17-c50e-4115-b4b2-4b6bb4054a19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5fba793-7bda-4750-9c3e-9b02bd3e8436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5fba793-7bda-4750-9c3e-9b02bd3e8436_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5fba793-7bda-4750-9c3e-9b02bd3e8436" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5fba793-7bda-4750-9c3e-9b02bd3e8436_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5fba793-7bda-4750-9c3e-9b02bd3e8436" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3ff5260f-e627-493e-9ac7-c56c6e577c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_LandMember_3ff5260f-e627-493e-9ac7-c56c6e577c4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_79b58589-1b69-4e69-95d7-f3f9f4351646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_79b58589-1b69-4e69-95d7-f3f9f4351646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_df3d5f3b-0017-478b-9aef-f86505f5dca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_df3d5f3b-0017-478b-9aef-f86505f5dca1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bc73f6b4-932e-41a1-8794-7b486dfd9863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bc73f6b4-932e-41a1-8794-7b486dfd9863" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d69b2495-089a-47a8-afe9-47c4b3273752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d69b2495-089a-47a8-afe9-47c4b3273752" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c71b4cd5-7829-468a-b929-98a6c99e452f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db8a5c17-c50e-4115-b4b2-4b6bb4054a19" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c71b4cd5-7829-468a-b929-98a6c99e452f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c71b4cd5-7829-468a-b929-98a6c99e452f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c71b4cd5-7829-468a-b929-98a6c99e452f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c71b4cd5-7829-468a-b929-98a6c99e452f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c4836e56-51d4-45f1-a559-554995c7479e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c71b4cd5-7829-468a-b929-98a6c99e452f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c4836e56-51d4-45f1-a559-554995c7479e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_936ca3bd-759b-4c28-b373-19c33908d996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c4836e56-51d4-45f1-a559-554995c7479e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_936ca3bd-759b-4c28-b373-19c33908d996" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended" id="iebafcffe0b4241328351e546249511f6_SignificantAccountingPoliciesDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_220f4f78-38db-410a-b6ce-37870e4a3dcf" xlink:href="cvs-20221231.xsd#cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:to="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_220f4f78-38db-410a-b6ce-37870e4a3dcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_b34f8343-d020-47a8-960c-26c992bf2fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:to="loc_us-gaap_NetInvestmentIncome_b34f8343-d020-47a8-960c-26c992bf2fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_106b219a-cb43-4dcb-a994-888f47ff6b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:to="loc_us-gaap_Revenues_106b219a-cb43-4dcb-a994-888f47ff6b60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_6223e70a-3c83-4756-a531-2a8b3d17af3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:to="loc_srt_ConsolidationItemsAxis_6223e70a-3c83-4756-a531-2a8b3d17af3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6223e70a-3c83-4756-a531-2a8b3d17af3b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_6223e70a-3c83-4756-a531-2a8b3d17af3b" xlink:to="loc_srt_ConsolidationItemsDomain_6223e70a-3c83-4756-a531-2a8b3d17af3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_6223e70a-3c83-4756-a531-2a8b3d17af3b" xlink:to="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ec565f21-13fe-4525-bfb2-7efb9739a566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:to="loc_us-gaap_OperatingSegmentsMember_ec565f21-13fe-4525-bfb2-7efb9739a566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c24d892b-684a-4921-9d8d-7d6d8464a111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c24d892b-684a-4921-9d8d-7d6d8464a111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_3f385f49-dd4e-4445-86fe-1b43e1858c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:to="loc_us-gaap_IntersegmentEliminationMember_3f385f49-dd4e-4445-86fe-1b43e1858c52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_70aad851-507c-46dd-91d5-91218b000134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_70aad851-507c-46dd-91d5-91218b000134" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_70aad851-507c-46dd-91d5-91218b000134_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_70aad851-507c-46dd-91d5-91218b000134" xlink:to="loc_us-gaap_SegmentDomain_70aad851-507c-46dd-91d5-91218b000134_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_70aad851-507c-46dd-91d5-91218b000134" xlink:to="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_aade3176-9612-41b5-a0b9-67433dcc28ab" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_aade3176-9612-41b5-a0b9-67433dcc28ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyServicesSegmentMember_e9e878dc-a39f-4b6b-bc8e-bd54622af1e1" xlink:href="cvs-20221231.xsd#cvs_PharmacyServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:to="loc_cvs_PharmacyServicesSegmentMember_e9e878dc-a39f-4b6b-bc8e-bd54622af1e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_7a646baa-5f10-4664-969c-7307eca13e0c" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_7a646baa-5f10-4664-969c-7307eca13e0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f642ee72-5c85-4264-a657-2372ce85298a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:to="loc_srt_ProductOrServiceAxis_f642ee72-5c85-4264-a657-2372ce85298a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f642ee72-5c85-4264-a657-2372ce85298a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f642ee72-5c85-4264-a657-2372ce85298a" xlink:to="loc_srt_ProductsAndServicesDomain_f642ee72-5c85-4264-a657-2372ce85298a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f642ee72-5c85-4264-a657-2372ce85298a" xlink:to="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyRevenueMember_0891c6c7-028d-4354-926b-999049371600" xlink:href="cvs-20221231.xsd#cvs_PharmacyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:to="loc_cvs_PharmacyRevenueMember_0891c6c7-028d-4354-926b-999049371600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FrontStoreRevenueMember_79e0c4d1-a7cc-4a29-aa1f-522105bd24d2" xlink:href="cvs-20221231.xsd#cvs_FrontStoreRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:to="loc_cvs_FrontStoreRevenueMember_79e0c4d1-a7cc-4a29-aa1f-522105bd24d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumsMember_638b36ff-3ba2-48a6-bf7b-0f413cf84c51" xlink:href="cvs-20221231.xsd#cvs_PremiumsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:to="loc_cvs_PremiumsMember_638b36ff-3ba2-48a6-bf7b-0f413cf84c51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_780a2d39-a79a-4e1f-8adf-f065552fec75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_780a2d39-a79a-4e1f-8adf-f065552fec75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_e62c83e6-179a-4e41-aa3a-6304d2fabd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_e62c83e6-179a-4e41-aa3a-6304d2fabd14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_e62c83e6-179a-4e41-aa3a-6304d2fabd14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_e62c83e6-179a-4e41-aa3a-6304d2fabd14" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_e62c83e6-179a-4e41-aa3a-6304d2fabd14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_e62c83e6-179a-4e41-aa3a-6304d2fabd14" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_292cd083-aba8-404f-b62f-46dfda7badc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_292cd083-aba8-404f-b62f-46dfda7badc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_51006727-cd0b-4a24-8e78-15ef64a68cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_51006727-cd0b-4a24-8e78-15ef64a68cbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SalesChannelOtherMember_d2772e15-62a5-4e40-8fc8-83dfa0204aa1" xlink:href="cvs-20221231.xsd#cvs_SalesChannelOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:to="loc_cvs_SalesChannelOtherMember_d2772e15-62a5-4e40-8fc8-83dfa0204aa1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="extended" id="i6782f2ca36734649938a8adc2e11c1b2_SignificantAccountingPoliciesVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_95600714-1aed-489c-9335-5181f4c9f193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_95600714-1aed-489c-9335-5181f4c9f193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InitialContractualTerm_44f167b5-2203-480e-abda-a6784fb7ac56" xlink:href="cvs-20221231.xsd#cvs_InitialContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_cvs_InitialContractualTerm_44f167b5-2203-480e-abda-a6784fb7ac56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VariableInterestEntityAmendedContractExtensionTerm_9437a710-4ded-405b-ab42-63e5a90eebd7" xlink:href="cvs-20221231.xsd#cvs_VariableInterestEntityAmendedContractExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_cvs_VariableInterestEntityAmendedContractExtensionTerm_9437a710-4ded-405b-ab42-63e5a90eebd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VariableInterestEntityAmendedContractTerm_48b2eee0-cc9c-4d6a-a745-7853eb1fbc72" xlink:href="cvs-20221231.xsd#cvs_VariableInterestEntityAmendedContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_cvs_VariableInterestEntityAmendedContractTerm_48b2eee0-cc9c-4d6a-a745-7853eb1fbc72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ProceedsFromVariableInterestEntity_d5a26d13-7f91-4fac-a5de-5be90edf57f9" xlink:href="cvs-20221231.xsd#cvs_ProceedsFromVariableInterestEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_cvs_ProceedsFromVariableInterestEntity_d5a26d13-7f91-4fac-a5de-5be90edf57f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_6352f7ab-03b3-4ebf-80b2-796504610a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_us-gaap_LongTermInvestments_6352f7ab-03b3-4ebf-80b2-796504610a17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3f2cb660-00cb-42a8-b500-241f7e797c1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3f2cb660-00cb-42a8-b500-241f7e797c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3f2cb660-00cb-42a8-b500-241f7e797c1b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3f2cb660-00cb-42a8-b500-241f7e797c1b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3f2cb660-00cb-42a8-b500-241f7e797c1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2ab1369b-f339-45dd-ba12-a35198046084" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3f2cb660-00cb-42a8-b500-241f7e797c1b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2ab1369b-f339-45dd-ba12-a35198046084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_d2f7024c-679a-449f-9280-e09785c042e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2ab1369b-f339-45dd-ba12-a35198046084" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_d2f7024c-679a-449f-9280-e09785c042e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5f2814ff-bc81-4fad-8308-818fa7261cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:to="loc_us-gaap_InvestmentTypeAxis_5f2814ff-bc81-4fad-8308-818fa7261cae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5f2814ff-bc81-4fad-8308-818fa7261cae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5f2814ff-bc81-4fad-8308-818fa7261cae" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5f2814ff-bc81-4fad-8308-818fa7261cae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5f2814ff-bc81-4fad-8308-818fa7261cae" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_fec925fa-ac9a-4ec2-baad-7fb54bcdb7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:to="loc_us-gaap_HedgeFundsMember_fec925fa-ac9a-4ec2-baad-7fb54bcdb7fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_e8d0cebd-2bd9-4dd3-b61d-100c2e6d13ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:to="loc_us-gaap_PrivateEquityFundsMember_e8d0cebd-2bd9-4dd3-b61d-100c2e6d13ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateFundsMember_c0089b4f-e5f8-4d8c-822e-da5888cf2433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstateFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:to="loc_us-gaap_RealEstateFundsMember_c0089b4f-e5f8-4d8c-822e-da5888cf2433" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8cd032a1-9469-4bfa-b571-71d2ba7146e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8cd032a1-9469-4bfa-b571-71d2ba7146e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8cd032a1-9469-4bfa-b571-71d2ba7146e8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8cd032a1-9469-4bfa-b571-71d2ba7146e8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8cd032a1-9469-4bfa-b571-71d2ba7146e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f4cc09a0-37ed-4cad-9c91-cdb28afa5ed6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8cd032a1-9469-4bfa-b571-71d2ba7146e8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f4cc09a0-37ed-4cad-9c91-cdb28afa5ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RedOakMember_54538fa8-e516-4a86-8659-b51251b4ee1c" xlink:href="cvs-20221231.xsd#cvs_RedOakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4cc09a0-37ed-4cad-9c91-cdb28afa5ed6" xlink:to="loc_cvs_RedOakMember_54538fa8-e516-4a86-8659-b51251b4ee1c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails" xlink:type="extended" id="ice75104823c04a07a4f4fb000e9eaa56_SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3c1ca155-c79a-4251-a621-d562c6d2dc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2ab1ebf1-070b-4278-b338-a91c59eec68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3c1ca155-c79a-4251-a621-d562c6d2dc5c" xlink:to="loc_us-gaap_StatementOfFinancialPositionAbstract_2ab1ebf1-070b-4278-b338-a91c59eec68a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_eda271a0-0934-4301-83bd-3657b35c7e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ab1ebf1-070b-4278-b338-a91c59eec68a" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_eda271a0-0934-4301-83bd-3657b35c7e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3c1ca155-c79a-4251-a621-d562c6d2dc5c" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68c1fa73-b956-4148-a121-905287844aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68c1fa73-b956-4148-a121-905287844aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_68c1fa73-b956-4148-a121-905287844aad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68c1fa73-b956-4148-a121-905287844aad" xlink:to="loc_us-gaap_TypeOfAdoptionMember_68c1fa73-b956-4148-a121-905287844aad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a2694e7f-d95d-4303-bf09-cef1eb223547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68c1fa73-b956-4148-a121-905287844aad" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a2694e7f-d95d-4303-bf09-cef1eb223547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201812Member_aff5d686-037c-4d0a-8ded-b8b5dd315ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201812Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a2694e7f-d95d-4303-bf09-cef1eb223547" xlink:to="loc_us-gaap_AccountingStandardsUpdate201812Member_aff5d686-037c-4d0a-8ded-b8b5dd315ee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_647877bb-f387-4cf5-80e6-0c30f9de9b64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_647877bb-f387-4cf5-80e6-0c30f9de9b64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_647877bb-f387-4cf5-80e6-0c30f9de9b64_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_647877bb-f387-4cf5-80e6-0c30f9de9b64" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_647877bb-f387-4cf5-80e6-0c30f9de9b64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c8279535-5833-476a-a541-0b8084acbbfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_647877bb-f387-4cf5-80e6-0c30f9de9b64" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c8279535-5833-476a-a541-0b8084acbbfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f5d957c0-e163-4961-9d2a-515d499257da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c8279535-5833-476a-a541-0b8084acbbfa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f5d957c0-e163-4961-9d2a-515d499257da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f2f75f96-1d0e-4a37-8545-7c3230e6b214" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:to="loc_srt_StatementScenarioAxis_f2f75f96-1d0e-4a37-8545-7c3230e6b214" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f2f75f96-1d0e-4a37-8545-7c3230e6b214_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f2f75f96-1d0e-4a37-8545-7c3230e6b214" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f2f75f96-1d0e-4a37-8545-7c3230e6b214_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_37fa68c8-7a93-4eed-8115-7bfcac002230" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f2f75f96-1d0e-4a37-8545-7c3230e6b214" xlink:to="loc_srt_ScenarioUnspecifiedDomain_37fa68c8-7a93-4eed-8115-7bfcac002230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_34413dc0-ecda-435d-b827-488df75d2b6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_37fa68c8-7a93-4eed-8115-7bfcac002230" xlink:to="loc_srt_ScenarioForecastMember_34413dc0-ecda-435d-b827-488df75d2b6f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#AcquisitionsDivestituresandAssetSalesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" xlink:type="extended" id="i5bd10ed5a85d4dc083d1965738905a41_AcquisitionsDivestituresandAssetSalesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_c3229a34-6789-409f-90f8-410e932ca218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_c3229a34-6789-409f-90f8-410e932ca218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_317bc74f-2ddb-414f-97ee-1a404f4ad94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_317bc74f-2ddb-414f-97ee-1a404f4ad94c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BusinessCombinationTerminationFee_bcfa13b0-4cdc-44ca-a19b-2afacdf56899" xlink:href="cvs-20221231.xsd#cvs_BusinessCombinationTerminationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_cvs_BusinessCombinationTerminationFee_bcfa13b0-4cdc-44ca-a19b-2afacdf56899" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5a36d8d6-31ab-487b-afce-9180cc1d3f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5a36d8d6-31ab-487b-afce-9180cc1d3f09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_55121942-c1f9-4126-8a84-617152088293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_55121942-c1f9-4126-8a84-617152088293" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_22536109-4e0a-43b3-98b1-52b146e55166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_22536109-4e0a-43b3-98b1-52b146e55166" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfMedicalMembers_d04fdd36-488f-4cd3-a9aa-6598c2341a95" xlink:href="cvs-20221231.xsd#cvs_NumberOfMedicalMembers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_cvs_NumberOfMedicalMembers_d04fdd36-488f-4cd3-a9aa-6598c2341a95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold_cc01c5aa-3e50-44ba-89d7-5964752e6717" xlink:href="cvs-20221231.xsd#cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold_cc01c5aa-3e50-44ba-89d7-5964752e6717" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b7d6d34d-f357-4fcb-a1e0-b529a2401e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b7d6d34d-f357-4fcb-a1e0-b529a2401e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b7d6d34d-f357-4fcb-a1e0-b529a2401e04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b7d6d34d-f357-4fcb-a1e0-b529a2401e04" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b7d6d34d-f357-4fcb-a1e0-b529a2401e04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b7d6d34d-f357-4fcb-a1e0-b529a2401e04" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_c3e3a207-aaf2-4bf1-a608-6e3cf0ca7881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_c3e3a207-aaf2-4bf1-a608-6e3cf0ca7881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b663b9d9-1571-44c0-bf69-9d705da92a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b663b9d9-1571-44c0-bf69-9d705da92a79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1cbec5ed-a6bf-4316-b206-a6ad324612d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1cbec5ed-a6bf-4316-b206-a6ad324612d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f9ec40e1-7f0c-48e6-bd0c-48ac35c2b4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f9ec40e1-7f0c-48e6-bd0c-48ac35c2b4a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f9ec40e1-7f0c-48e6-bd0c-48ac35c2b4a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f9ec40e1-7f0c-48e6-bd0c-48ac35c2b4a7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f9ec40e1-7f0c-48e6-bd0c-48ac35c2b4a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f9ec40e1-7f0c-48e6-bd0c-48ac35c2b4a7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OmnicareLongTermCareBusinessMember_4281e646-0420-4d1d-8e26-443f05519f54" xlink:href="cvs-20221231.xsd#cvs_OmnicareLongTermCareBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_OmnicareLongTermCareBusinessMember_4281e646-0420-4d1d-8e26-443f05519f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BswiftLLCMember_01f4483f-e610-4caf-bf45-fecb2a542f9e" xlink:href="cvs-20221231.xsd#cvs_BswiftLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_BswiftLLCMember_01f4483f-e610-4caf-bf45-fecb2a542f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PayflexMember_971949b3-e91c-47ee-96b2-f14e37350b50" xlink:href="cvs-20221231.xsd#cvs_PayflexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_PayflexMember_971949b3-e91c-47ee-96b2-f14e37350b50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ThailandBusinessMember_62eb64a7-7156-43ae-80de-53fb0106455c" xlink:href="cvs-20221231.xsd#cvs_ThailandBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_ThailandBusinessMember_62eb64a7-7156-43ae-80de-53fb0106455c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InternationalHealthCareRenewalRightsMember_ccf62822-015b-4678-87b9-efbd6299e793" xlink:href="cvs-20221231.xsd#cvs_InternationalHealthCareRenewalRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_InternationalHealthCareRenewalRightsMember_ccf62822-015b-4678-87b9-efbd6299e793" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CoventryHealthCareWorkersCompensationBusinessMember_5959e2b2-f110-4875-9193-4eceb4b9973d" xlink:href="cvs-20221231.xsd#cvs_CoventryHealthCareWorkersCompensationBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_CoventryHealthCareWorkersCompensationBusinessMember_5959e2b2-f110-4875-9193-4eceb4b9973d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_68f22357-f58b-466b-b5bb-4efea074a813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_68f22357-f58b-466b-b5bb-4efea074a813" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_68f22357-f58b-466b-b5bb-4efea074a813_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_68f22357-f58b-466b-b5bb-4efea074a813" xlink:to="loc_us-gaap_SegmentDomain_68f22357-f58b-466b-b5bb-4efea074a813_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5651ec81-60c0-420d-bc8f-3f9b43840a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_68f22357-f58b-466b-b5bb-4efea074a813" xlink:to="loc_us-gaap_SegmentDomain_5651ec81-60c0-420d-bc8f-3f9b43840a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_fed3a96d-0a3f-4352-b0c1-82423a126d0f" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5651ec81-60c0-420d-bc8f-3f9b43840a5f" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_fed3a96d-0a3f-4352-b0c1-82423a126d0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_9ee711da-ba1a-4193-96ee-9a032e563358" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5651ec81-60c0-420d-bc8f-3f9b43840a5f" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_9ee711da-ba1a-4193-96ee-9a032e563358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fdf00213-9dbb-4f20-b65b-5e37c853cd78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fdf00213-9dbb-4f20-b65b-5e37c853cd78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fdf00213-9dbb-4f20-b65b-5e37c853cd78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fdf00213-9dbb-4f20-b65b-5e37c853cd78" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fdf00213-9dbb-4f20-b65b-5e37c853cd78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1140820-8371-4603-8e8e-521dee983963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fdf00213-9dbb-4f20-b65b-5e37c853cd78" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1140820-8371-4603-8e8e-521dee983963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OakStreetHealthIncMember_4f96655b-4d65-489c-8613-3d147bd201eb" xlink:href="cvs-20221231.xsd#cvs_OakStreetHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1140820-8371-4603-8e8e-521dee983963" xlink:to="loc_cvs_OakStreetHealthIncMember_4f96655b-4d65-489c-8613-3d147bd201eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SignifyHealthIncMember_1097c308-d674-480a-81b4-6c5361694330" xlink:href="cvs-20221231.xsd#cvs_SignifyHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1140820-8371-4603-8e8e-521dee983963" xlink:to="loc_cvs_SignifyHealthIncMember_1097c308-d674-480a-81b4-6c5361694330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f0798d55-bbb7-4161-b8e9-527dba24dbe2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_dei_LegalEntityAxis_f0798d55-bbb7-4161-b8e9-527dba24dbe2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f0798d55-bbb7-4161-b8e9-527dba24dbe2_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f0798d55-bbb7-4161-b8e9-527dba24dbe2" xlink:to="loc_dei_EntityDomain_f0798d55-bbb7-4161-b8e9-527dba24dbe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5bfe50b6-69bc-4722-8b2c-b9fea453366b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f0798d55-bbb7-4161-b8e9-527dba24dbe2" xlink:to="loc_dei_EntityDomain_5bfe50b6-69bc-4722-8b2c-b9fea453366b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OakStreetHealthIncMember_a1a047ba-5e8a-429f-8318-7dba373d37be" xlink:href="cvs-20221231.xsd#cvs_OakStreetHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5bfe50b6-69bc-4722-8b2c-b9fea453366b" xlink:to="loc_cvs_OakStreetHealthIncMember_a1a047ba-5e8a-429f-8318-7dba373d37be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SignifyHealthIncMember_e3cc9e39-16f8-4e2c-8cf8-07cf178909a9" xlink:href="cvs-20221231.xsd#cvs_SignifyHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5bfe50b6-69bc-4722-8b2c-b9fea453366b" xlink:to="loc_cvs_SignifyHealthIncMember_e3cc9e39-16f8-4e2c-8cf8-07cf178909a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_75d158ef-5a51-4b20-a907-564b4de9d15e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_75d158ef-5a51-4b20-a907-564b4de9d15e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_75d158ef-5a51-4b20-a907-564b4de9d15e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_75d158ef-5a51-4b20-a907-564b4de9d15e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_75d158ef-5a51-4b20-a907-564b4de9d15e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ec4fb16e-5418-46db-8cdc-268c41ce21f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_75d158ef-5a51-4b20-a907-564b4de9d15e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ec4fb16e-5418-46db-8cdc-268c41ce21f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8a2511bb-381c-43ce-8860-2f073937ee28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ec4fb16e-5418-46db-8cdc-268c41ce21f6" xlink:to="loc_us-gaap_SubsequentEventMember_8a2511bb-381c-43ce-8860-2f073937ee28" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="extended" id="i093b6e354e9e43aeb987c9c5595ac719_AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b50417e-450d-44f7-b8df-b34797130ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b50417e-450d-44f7-b8df-b34797130ea4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_8a706923-5430-4c08-aea4-c366f5e79345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_8a706923-5430-4c08-aea4-c366f5e79345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_9de52735-9cdc-4806-9e97-31e9410b1988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_9de52735-9cdc-4806-9e97-31e9410b1988" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_24164d1c-84bd-4a22-bf5e-7b02a994350b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_24164d1c-84bd-4a22-bf5e-7b02a994350b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_39e0d09c-30a2-4f3c-8754-7a28f93e979b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_39e0d09c-30a2-4f3c-8754-7a28f93e979b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_cd99d04c-64d8-4181-95a1-ea15ecf18036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_cd99d04c-64d8-4181-95a1-ea15ecf18036" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ae1eddfb-bdde-4bee-82d6-40e7e2dc21c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ae1eddfb-bdde-4bee-82d6-40e7e2dc21c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b50417e-450d-44f7-b8df-b34797130ea4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_8ae1dea6-ff4a-4a0c-8bb2-bd7c8e722eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_8ae1dea6-ff4a-4a0c-8bb2-bd7c8e722eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_56145e81-ab04-4578-af03-6ac6e7452747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_56145e81-ab04-4578-af03-6ac6e7452747" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_b5bf3cf3-8d68-4227-b965-8fab3c1b6c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_b5bf3cf3-8d68-4227-b965-8fab3c1b6c04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c4c54e8b-8bbe-44f4-bd59-bf5496903f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c4c54e8b-8bbe-44f4-bd59-bf5496903f67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de0af414-a83f-4c78-b955-b68c2479c49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b50417e-450d-44f7-b8df-b34797130ea4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de0af414-a83f-4c78-b955-b68c2479c49d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_1f704e5e-453b-4bfc-8558-df9f4de183ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de0af414-a83f-4c78-b955-b68c2479c49d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_1f704e5e-453b-4bfc-8558-df9f4de183ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1f704e5e-453b-4bfc-8558-df9f4de183ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1f704e5e-453b-4bfc-8558-df9f4de183ad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1f704e5e-453b-4bfc-8558-df9f4de183ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_598d1707-4673-4d5c-a45b-17f833ca8d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1f704e5e-453b-4bfc-8558-df9f4de183ad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_598d1707-4673-4d5c-a45b-17f833ca8d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e9a41682-db87-401d-91e7-3b75d13a4049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_598d1707-4673-4d5c-a45b-17f833ca8d5d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e9a41682-db87-401d-91e7-3b75d13a4049" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsScheduleofTotalInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" xlink:type="extended" id="i25875cafb6a348cbb9c5256b84bab7f1_InvestmentsScheduleofTotalInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ec3a6644-e0a5-4831-9c3a-99affa9e4559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:to="loc_us-gaap_ShortTermInvestments_ec3a6644-e0a5-4831-9c3a-99affa9e4559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermInvestmentsIncludingAssetsHeldForSale_e6b7cec1-a86f-46a2-b16d-3282cd875f6a" xlink:href="cvs-20221231.xsd#cvs_LongTermInvestmentsIncludingAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:to="loc_cvs_LongTermInvestmentsIncludingAssetsHeldForSale_e6b7cec1-a86f-46a2-b16d-3282cd875f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_f073e5d7-9e82-488e-a4d2-0e8a02333cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:to="loc_us-gaap_Investments_f073e5d7-9e82-488e-a4d2-0e8a02333cd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsTable_99ad3763-2f6c-4685-9d1b-e0c895209ae3" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:to="loc_cvs_TotalInvestmentsTable_99ad3763-2f6c-4685-9d1b-e0c895209ae3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsAxis_e152186d-1129-4673-91a4-77d1c64df493" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cvs_TotalInvestmentsTable_99ad3763-2f6c-4685-9d1b-e0c895209ae3" xlink:to="loc_cvs_TotalInvestmentsAxis_e152186d-1129-4673-91a4-77d1c64df493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsDomain_e152186d-1129-4673-91a4-77d1c64df493_default" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cvs_TotalInvestmentsAxis_e152186d-1129-4673-91a4-77d1c64df493" xlink:to="loc_cvs_TotalInvestmentsDomain_e152186d-1129-4673-91a4-77d1c64df493_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cvs_TotalInvestmentsAxis_e152186d-1129-4673-91a4-77d1c64df493" xlink:to="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtAndEquitySecuritiesAvailableForSaleMember_c3b5d5f8-23fd-4037-bbbe-b8b56e4167f3" xlink:href="cvs-20221231.xsd#cvs_DebtAndEquitySecuritiesAvailableForSaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:to="loc_cvs_DebtAndEquitySecuritiesAvailableForSaleMember_c3b5d5f8-23fd-4037-bbbe-b8b56e4167f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansMember_fa6907ad-5ee7-4a10-a7d5-076d8fa14349" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:to="loc_cvs_MortgageLoansMember_fa6907ad-5ee7-4a10-a7d5-076d8fa14349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_85139291-2040-4951-af3a-71a05f8a9109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:to="loc_us-gaap_OtherInvestmentsMember_85139291-2040-4951-af3a-71a05f8a9109" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6e9d6b99-734d-4ab3-9c9b-cca77c572fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cvs_TotalInvestmentsTable_99ad3763-2f6c-4685-9d1b-e0c895209ae3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6e9d6b99-734d-4ab3-9c9b-cca77c572fb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6e9d6b99-734d-4ab3-9c9b-cca77c572fb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6e9d6b99-734d-4ab3-9c9b-cca77c572fb4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6e9d6b99-734d-4ab3-9c9b-cca77c572fb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670cc0d1-42fc-4fb5-bbcd-d122d5a8ebc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6e9d6b99-734d-4ab3-9c9b-cca77c572fb4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670cc0d1-42fc-4fb5-bbcd-d122d5a8ebc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a176caf6-dd0e-477a-9d07-2aebdf181d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670cc0d1-42fc-4fb5-bbcd-d122d5a8ebc2" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a176caf6-dd0e-477a-9d07-2aebdf181d3b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsNarrativeDetails" xlink:type="extended" id="idd1517f619824174ad7c5b3a94fb038a_InvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8884c073-1197-4fbc-b20f-7077f3509047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_8b67bbef-7bb6-4f04-9660-db0c5eca3fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8884c073-1197-4fbc-b20f-7077f3509047" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_8b67bbef-7bb6-4f04-9660-db0c5eca3fdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities_e4c136b5-a88b-492f-95a8-d8291eec193e" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8884c073-1197-4fbc-b20f-7077f3509047" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities_e4c136b5-a88b-492f-95a8-d8291eec193e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1259664f-5dd3-4fa8-b41a-1d4c575f1b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8884c073-1197-4fbc-b20f-7077f3509047" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1259664f-5dd3-4fa8-b41a-1d4c575f1b26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_dbc7984c-896e-49bb-9bab-8590115a2c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1259664f-5dd3-4fa8-b41a-1d4c575f1b26" xlink:to="loc_us-gaap_FinancialInstrumentAxis_dbc7984c-896e-49bb-9bab-8590115a2c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbc7984c-896e-49bb-9bab-8590115a2c4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_dbc7984c-896e-49bb-9bab-8590115a2c4e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dbc7984c-896e-49bb-9bab-8590115a2c4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_dbc7984c-896e-49bb-9bab-8590115a2c4e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_5d10d46d-91b1-4439-bdce-15a565c4d986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_5d10d46d-91b1-4439-bdce-15a565c4d986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_16e39037-2e0b-45fa-b4e7-132a632f0b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_16e39037-2e0b-45fa-b4e7-132a632f0b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_523b3c6b-1059-4f81-8923-d08987641243" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_523b3c6b-1059-4f81-8923-d08987641243" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" xlink:type="extended" id="ie07c0e144b5841aeb532e534be85492d_InvestmentsDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c7a0a71b-f053-4239-8ae2-dbc0ac70c037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c7a0a71b-f053-4239-8ae2-dbc0ac70c037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ba6918a3-ef7b-4805-81d5-e826ec6a5e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ba6918a3-ef7b-4805-81d5-e826ec6a5e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_fe244a81-0d2b-4d36-b13e-59d622ebaaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_fe244a81-0d2b-4d36-b13e-59d622ebaaf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5c8dfd4e-39b2-48fa-81eb-221022b02c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5c8dfd4e-39b2-48fa-81eb-221022b02c72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16e7dd0f-5821-4408-825d-48f2cd8caf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16e7dd0f-5821-4408-825d-48f2cd8caf9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_582b200f-0f7a-4e91-9ce9-565cf572a3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_582b200f-0f7a-4e91-9ce9-565cf572a3d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_884ec79d-2d79-4f0d-91fe-4a3736513572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_884ec79d-2d79-4f0d-91fe-4a3736513572" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4ee0a16-8535-4c1b-bd94-5ac925bcd0ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_884ec79d-2d79-4f0d-91fe-4a3736513572" xlink:to="loc_srt_ProductOrServiceAxis_c4ee0a16-8535-4c1b-bd94-5ac925bcd0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c4ee0a16-8535-4c1b-bd94-5ac925bcd0ca_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c4ee0a16-8535-4c1b-bd94-5ac925bcd0ca" xlink:to="loc_srt_ProductsAndServicesDomain_c4ee0a16-8535-4c1b-bd94-5ac925bcd0ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b28e3d35-0fdf-44fa-9a4e-cc65ee165e4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c4ee0a16-8535-4c1b-bd94-5ac925bcd0ca" xlink:to="loc_srt_ProductsAndServicesDomain_b28e3d35-0fdf-44fa-9a4e-cc65ee165e4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingExperienceRatedProductsMember_b10ca5d2-7ea8-4e1f-93dd-43841be7b59b" xlink:href="cvs-20221231.xsd#cvs_SupportingExperienceRatedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b28e3d35-0fdf-44fa-9a4e-cc65ee165e4f" xlink:to="loc_cvs_SupportingExperienceRatedProductsMember_b10ca5d2-7ea8-4e1f-93dd-43841be7b59b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a2f9fbc4-2997-4893-bcfb-73016065abe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_884ec79d-2d79-4f0d-91fe-4a3736513572" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a2f9fbc4-2997-4893-bcfb-73016065abe3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a2f9fbc4-2997-4893-bcfb-73016065abe3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a2f9fbc4-2997-4893-bcfb-73016065abe3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a2f9fbc4-2997-4893-bcfb-73016065abe3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32771d08-adcd-411f-9d87-3463ea224450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a2f9fbc4-2997-4893-bcfb-73016065abe3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32771d08-adcd-411f-9d87-3463ea224450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32771d08-adcd-411f-9d87-3463ea224450" xlink:to="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f41331ac-8c67-43a7-ab21-b45c2ed070d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f41331ac-8c67-43a7-ab21-b45c2ed070d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_4dd6462c-7df9-4346-bc4b-1a5d85803613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_4dd6462c-7df9-4346-bc4b-1a5d85803613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_6c82ecd6-49b5-4ba8-aba4-bf6d3d534ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_6c82ecd6-49b5-4ba8-aba4-bf6d3d534ebd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_27a7d7cb-c407-4865-bbd1-7953e6d8327f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_27a7d7cb-c407-4865-bbd1-7953e6d8327f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_9d7f78ca-eb95-4f4e-a6b0-43cd0139015c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_9d7f78ca-eb95-4f4e-a6b0-43cd0139015c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_563b8188-79b7-440c-9df3-e36826f60fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_563b8188-79b7-440c-9df3-e36826f60fb2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_93225481-27f6-4921-a42e-55b143fc881d" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_93225481-27f6-4921-a42e-55b143fc881d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_de33339e-d72b-4e80-9216-b599e12b451d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_de33339e-d72b-4e80-9216-b599e12b451d" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsDebtSecuritiesbyMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" xlink:type="extended" id="i90cf9a8df9d448b994058d3b83b2f748_InvestmentsDebtSecuritiesbyMaturityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eea182a3-ef77-445b-bb28-a2cfd8532de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eea182a3-ef77-445b-bb28-a2cfd8532de1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_202c0cef-b18c-4642-92f1-55b5e984e6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_202c0cef-b18c-4642-92f1-55b5e984e6fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_715a59fb-ebb8-4e21-9edc-ac7cad8535e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_715a59fb-ebb8-4e21-9edc-ac7cad8535e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_a4c75b04-7ae3-496d-a8ce-5607a68d1d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_a4c75b04-7ae3-496d-a8ce-5607a68d1d05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_7e191d48-1a29-4810-9504-e632b7a38c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_7e191d48-1a29-4810-9504-e632b7a38c61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_53bf03c4-159f-455e-9150-b1deee3ae340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_53bf03c4-159f-455e-9150-b1deee3ae340" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_6ba52952-ff9d-49ec-8ea5-6ac3630a6711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_6ba52952-ff9d-49ec-8ea5-6ac3630a6711" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eea182a3-ef77-445b-bb28-a2cfd8532de1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0aec7946-80f5-41a4-a50a-39772d6dc6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0aec7946-80f5-41a4-a50a-39772d6dc6e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aee04773-f8a3-4592-82a7-e35258e44f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aee04773-f8a3-4592-82a7-e35258e44f06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1321b5f1-9e3a-4cb2-b5c8-1c505fea884b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1321b5f1-9e3a-4cb2-b5c8-1c505fea884b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_470131db-9a6d-4dad-abd4-59f5fbc1bf81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_470131db-9a6d-4dad-abd4-59f5fbc1bf81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_4373fc56-46f7-4436-b830-5e399ba1cb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_4373fc56-46f7-4436-b830-5e399ba1cb2f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91abe0f5-f106-43c3-bec4-86f03c1f3cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91abe0f5-f106-43c3-bec4-86f03c1f3cab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7dc4226c-9774-48e0-aaa3-feec540736a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eea182a3-ef77-445b-bb28-a2cfd8532de1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7dc4226c-9774-48e0-aaa3-feec540736a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4aff6eec-6fc3-4d15-b5bf-eec2e6105883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7dc4226c-9774-48e0-aaa3-feec540736a7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4aff6eec-6fc3-4d15-b5bf-eec2e6105883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4aff6eec-6fc3-4d15-b5bf-eec2e6105883_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4aff6eec-6fc3-4d15-b5bf-eec2e6105883" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4aff6eec-6fc3-4d15-b5bf-eec2e6105883_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4aff6eec-6fc3-4d15-b5bf-eec2e6105883" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_008da850-1745-4983-9db6-3346c4617a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_008da850-1745-4983-9db6-3346c4617a8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_f46ef2f7-0fe1-4412-9cbc-029d8ce26352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_f46ef2f7-0fe1-4412-9cbc-029d8ce26352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_13ed2bb3-c0b9-4048-8bfc-e764966c095f" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_13ed2bb3-c0b9-4048-8bfc-e764966c095f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" xlink:type="extended" id="ie4f07afb1580420d9bf9c31cf317681a_InvestmentsUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_c1f31d3b-1946-4299-b924-17ef14d1498c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_c1f31d3b-1946-4299-b924-17ef14d1498c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_69d28191-7976-49d9-bd7b-827d2b0fdee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_69d28191-7976-49d9-bd7b-827d2b0fdee6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_518e2e44-6bdd-4006-b72e-9b86f9adf7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_518e2e44-6bdd-4006-b72e-9b86f9adf7a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_61c44ef7-a824-4de6-b2d3-5173869dacd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_61c44ef7-a824-4de6-b2d3-5173869dacd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_db6fafef-a250-433a-bcdb-010f378788eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_db6fafef-a250-433a-bcdb-010f378788eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f1ac5bdb-d700-4caa-a3ae-674cf7a34684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f1ac5bdb-d700-4caa-a3ae-674cf7a34684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_962434a8-d3c2-40c0-bc5f-cb9ac0422f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_962434a8-d3c2-40c0-bc5f-cb9ac0422f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_864c8c48-6bb1-4a93-8196-b7639c330fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_864c8c48-6bb1-4a93-8196-b7639c330fa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fabb165d-9f52-401d-8e17-9bb41dd241be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fabb165d-9f52-401d-8e17-9bb41dd241be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_71eb8889-db13-4c50-bcb9-80f789c10d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_71eb8889-db13-4c50-bcb9-80f789c10d70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7b4d124c-f9e7-4a65-82dd-31de3b180021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_71eb8889-db13-4c50-bcb9-80f789c10d70" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7b4d124c-f9e7-4a65-82dd-31de3b180021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b4d124c-f9e7-4a65-82dd-31de3b180021_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7b4d124c-f9e7-4a65-82dd-31de3b180021" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b4d124c-f9e7-4a65-82dd-31de3b180021_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7b4d124c-f9e7-4a65-82dd-31de3b180021" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d0bd54a9-7b29-44aa-b838-95f2891c0904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d0bd54a9-7b29-44aa-b838-95f2891c0904" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_149204c9-ce1b-428b-91d7-b046899ebf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_149204c9-ce1b-428b-91d7-b046899ebf03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_595eab90-b735-462b-bf7b-31652957b94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_595eab90-b735-462b-bf7b-31652957b94a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_7f5bc19f-ba17-40fd-bef0-c99c93bf8cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_7f5bc19f-ba17-40fd-bef0-c99c93bf8cbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_8b039529-8481-4081-9f1b-3e1181d62db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_8b039529-8481-4081-9f1b-3e1181d62db8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_21bbf791-07cd-4111-9ac7-fd49992a4b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_21bbf791-07cd-4111-9ac7-fd49992a4b6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_c07687e9-590c-457d-826f-e6eb4d39322a" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_c07687e9-590c-457d-826f-e6eb4d39322a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_dcef4be3-be49-49e0-a2d6-e0c6fbb8e838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_dcef4be3-be49-49e0-a2d6-e0c6fbb8e838" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsUnrealizedLossPositionMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" xlink:type="extended" id="ic8d9fb56b28440a4b036cecfe3ed6fa1_InvestmentsUnrealizedLossPositionMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc7fda5a-683f-4296-9761-f5c4233e67b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc7fda5a-683f-4296-9761-f5c4233e67b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear_0b462baf-b9e6-4116-8812-0d9a8497db56" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear_0b462baf-b9e6-4116-8812-0d9a8497db56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears_7b0a4e9d-c9cb-4e93-8ade-fa5ff64bbce1" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears_7b0a4e9d-c9cb-4e93-8ade-fa5ff64bbce1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears_b3ff1905-c968-4d84-8646-1617568d4207" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears_b3ff1905-c968-4d84-8646-1617568d4207" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears_8b413a3a-8442-42e4-8892-5dc0651707a4" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears_8b413a3a-8442-42e4-8892-5dc0651707a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue_ff7a2c0e-1919-41a6-ab5c-bedabf5504ce" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue_ff7a2c0e-1919-41a6-ab5c-bedabf5504ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b373f37e-210d-4e60-95e9-a7c30ab9335e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b373f37e-210d-4e60-95e9-a7c30ab9335e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc7fda5a-683f-4296-9761-f5c4233e67b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss_3e4b236e-a402-45b4-82f7-116969a51ff0" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss_3e4b236e-a402-45b4-82f7-116969a51ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss_3110a513-6995-401f-b4c5-d05db6a665ce" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss_3110a513-6995-401f-b4c5-d05db6a665ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss_9d79391d-dd0f-4471-b7ea-7bc08f5ccf69" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss_9d79391d-dd0f-4471-b7ea-7bc08f5ccf69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss_25622dee-eb35-4d9b-8408-6094ab41e8d3" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss_25622dee-eb35-4d9b-8408-6094ab41e8d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss_684639b2-9193-459c-95ca-7b1760b764ef" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss_684639b2-9193-459c-95ca-7b1760b764ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8a0885f5-06ef-4412-8f81-a02662ed0312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8a0885f5-06ef-4412-8f81-a02662ed0312" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c57b5897-2ed2-4db0-a40b-61c0aba0113b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc7fda5a-683f-4296-9761-f5c4233e67b8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c57b5897-2ed2-4db0-a40b-61c0aba0113b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2578366a-7f38-42b2-87f3-64b74395e8d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c57b5897-2ed2-4db0-a40b-61c0aba0113b" xlink:to="loc_srt_ProductOrServiceAxis_2578366a-7f38-42b2-87f3-64b74395e8d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2578366a-7f38-42b2-87f3-64b74395e8d1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2578366a-7f38-42b2-87f3-64b74395e8d1" xlink:to="loc_srt_ProductsAndServicesDomain_2578366a-7f38-42b2-87f3-64b74395e8d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f636fe2-1a24-4a34-90b7-b1de2b08d7ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2578366a-7f38-42b2-87f3-64b74395e8d1" xlink:to="loc_srt_ProductsAndServicesDomain_6f636fe2-1a24-4a34-90b7-b1de2b08d7ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingExperienceRatedProductsMember_7004976f-c599-4e55-a3f3-dd5fb2349f54" xlink:href="cvs-20221231.xsd#cvs_SupportingExperienceRatedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f636fe2-1a24-4a34-90b7-b1de2b08d7ce" xlink:to="loc_cvs_SupportingExperienceRatedProductsMember_7004976f-c599-4e55-a3f3-dd5fb2349f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingRemainingProductsMember_0cb8f9f1-78ce-4e55-b8d0-b0426c071c5d" xlink:href="cvs-20221231.xsd#cvs_SupportingRemainingProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f636fe2-1a24-4a34-90b7-b1de2b08d7ce" xlink:to="loc_cvs_SupportingRemainingProductsMember_0cb8f9f1-78ce-4e55-b8d0-b0426c071c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e9a37d3d-e100-4bb2-b4e2-fb75cd978760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c57b5897-2ed2-4db0-a40b-61c0aba0113b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e9a37d3d-e100-4bb2-b4e2-fb75cd978760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9a37d3d-e100-4bb2-b4e2-fb75cd978760_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e9a37d3d-e100-4bb2-b4e2-fb75cd978760" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9a37d3d-e100-4bb2-b4e2-fb75cd978760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e9a37d3d-e100-4bb2-b4e2-fb75cd978760" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_4656f665-fc84-4172-8dc1-cd3a6517f398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_4656f665-fc84-4172-8dc1-cd3a6517f398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_ce9c2e1f-34a6-495f-b377-4428795c5e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_ce9c2e1f-34a6-495f-b377-4428795c5e6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_abc64e99-247a-4318-888e-dee3aa87f293" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_abc64e99-247a-4318-888e-dee3aa87f293" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsMortgageLoansDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" xlink:type="extended" id="i83b72a80b6884c67a4aa0386759a9a72_InvestmentsMortgageLoansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans_2a703764-dbe7-422b-86a9-79e2b680c333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateNewMortgageLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans_2a703764-dbe7-422b-86a9-79e2b680c333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateLoansFullyRepaid_2dea4938-f000-416c-bd26-80294f498351" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateLoansFullyRepaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:to="loc_cvs_MortgageLoansOnRealEstateLoansFullyRepaid_2dea4938-f000-416c-bd26-80294f498351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateForeclosures_6ef20085-8fb0-4cf5-994d-163e84188a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateForeclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateForeclosures_6ef20085-8fb0-4cf5-994d-163e84188a8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateScheduleTable_0bbacd10-8d45-433f-8571-8a7472514101" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateScheduleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:to="loc_srt_MortgageLoansOnRealEstateScheduleTable_0bbacd10-8d45-433f-8571-8a7472514101" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_220c010b-199a-4ccb-8790-5a043fcee15e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_0bbacd10-8d45-433f-8571-8a7472514101" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_220c010b-199a-4ccb-8790-5a043fcee15e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_220c010b-199a-4ccb-8790-5a043fcee15e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_220c010b-199a-4ccb-8790-5a043fcee15e" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_220c010b-199a-4ccb-8790-5a043fcee15e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_78188471-e9e3-41ca-9a37-80f2c6f9894c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_220c010b-199a-4ccb-8790-5a043fcee15e" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_78188471-e9e3-41ca-9a37-80f2c6f9894c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialRealEstateMember_a43648d5-9462-4f3d-8f21-3e0594f2fb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_78188471-e9e3-41ca-9a37-80f2c6f9894c" xlink:to="loc_us-gaap_CommercialRealEstateMember_a43648d5-9462-4f3d-8f21-3e0594f2fb81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsMortgageLoansCreditRatingsIndicatorDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" xlink:type="extended" id="i98c2785094e948958d9e33c0f8149dbd_InvestmentsMortgageLoansCreditRatingsIndicatorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateLineItems_ba8309a4-53d3-4da6-b466-b1b62912a91f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate_1d7cd5f6-0f15-4d84-a22d-ceed9ca50dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_ba8309a4-53d3-4da6-b466-b1b62912a91f" xlink:to="loc_us-gaap_MortgageLoansOnRealEstate_1d7cd5f6-0f15-4d84-a22d-ceed9ca50dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateScheduleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_ba8309a4-53d3-4da6-b466-b1b62912a91f" xlink:to="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_c0f7d12e-bacb-4290-92da-7ccad934aab6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_c0f7d12e-bacb-4290-92da-7ccad934aab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_c0f7d12e-bacb-4290-92da-7ccad934aab6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_c0f7d12e-bacb-4290-92da-7ccad934aab6" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_c0f7d12e-bacb-4290-92da-7ccad934aab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_3fbc8c09-ed85-4d04-98f0-10011fbf9d4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_c0f7d12e-bacb-4290-92da-7ccad934aab6" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_3fbc8c09-ed85-4d04-98f0-10011fbf9d4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialRealEstateMember_93fed552-1cf1-45fd-ae18-a082fa14201f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_3fbc8c09-ed85-4d04-98f0-10011fbf9d4e" xlink:to="loc_us-gaap_CommercialRealEstateMember_93fed552-1cf1-45fd-ae18-a082fa14201f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentAxis_e758c07e-662f-420a-a6a0-c64abc0a1a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:to="loc_us-gaap_InternalCreditAssessmentAxis_e758c07e-662f-420a-a6a0-c64abc0a1a2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentDomain_e758c07e-662f-420a-a6a0-c64abc0a1a2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InternalCreditAssessmentAxis_e758c07e-662f-420a-a6a0-c64abc0a1a2a" xlink:to="loc_us-gaap_InternalCreditAssessmentDomain_e758c07e-662f-420a-a6a0-c64abc0a1a2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InternalCreditAssessmentAxis_e758c07e-662f-420a-a6a0-c64abc0a1a2a" xlink:to="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Category1Member_abc27f7e-8620-4dec-bb17-619792aa24f0" xlink:href="cvs-20221231.xsd#cvs_Category1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:to="loc_cvs_Category1Member_abc27f7e-8620-4dec-bb17-619792aa24f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Category2To4Member_405c73bb-8ee5-4ac9-8492-8cf27f3dffea" xlink:href="cvs-20221231.xsd#cvs_Category2To4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:to="loc_cvs_Category2To4Member_405c73bb-8ee5-4ac9-8492-8cf27f3dffea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Categories5And6Member_f6dd004d-bb4f-4111-9db5-bd43b47efaf6" xlink:href="cvs-20221231.xsd#cvs_Categories5And6Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:to="loc_cvs_Categories5And6Member_f6dd004d-bb4f-4111-9db5-bd43b47efaf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Category7Member_14f073f8-7bc4-4525-aa81-520b866b427b" xlink:href="cvs-20221231.xsd#cvs_Category7Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:to="loc_cvs_Category7Member_14f073f8-7bc4-4525-aa81-520b866b427b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_3cc2fb1f-eaa9-4520-876d-9a56842a526f" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateYearOfOriginationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:to="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_3cc2fb1f-eaa9-4520-876d-9a56842a526f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_3cc2fb1f-eaa9-4520-876d-9a56842a526f_default" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateYearOfOriginationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_3cc2fb1f-eaa9-4520-876d-9a56842a526f" xlink:to="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_3cc2fb1f-eaa9-4520-876d-9a56842a526f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateYearOfOriginationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_3cc2fb1f-eaa9-4520-876d-9a56842a526f" xlink:to="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodOneMember_4ac4d736-21ef-4171-852a-47d9d438d28d" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodOneMember_4ac4d736-21ef-4171-852a-47d9d438d28d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodTwoMember_305bd21b-ead4-4203-af9a-fb6d0dab7fcb" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodTwoMember_305bd21b-ead4-4203-af9a-fb6d0dab7fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodThreeMember_2138072f-8639-4ae3-8caa-10f5c4d50ee5" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodThreeMember_2138072f-8639-4ae3-8caa-10f5c4d50ee5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodFourMember_4fb9a845-dc77-4ac6-a2bd-fd3599e8f4cd" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodFourMember_4fb9a845-dc77-4ac6-a2bd-fd3599e8f4cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodFiveMember_2d91ab4b-8c2a-423d-92cc-045d61ecdc90" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodFiveMember_2d91ab4b-8c2a-423d-92cc-045d61ecdc90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPriorToPeriodFiveMember_892ae6c5-4475-421d-9687-8745f1598d87" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPriorToPeriodFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPriorToPeriodFiveMember_892ae6c5-4475-421d-9687-8745f1598d87" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsMortgageLoanPrincipalRepaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" xlink:type="extended" id="ifd634a3f3ed84e46bc33a97096e8ca2d_InvestmentsMortgageLoanPrincipalRepaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths_5a6666e2-029f-4fdb-9c64-4b21f0a075e4" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths_5a6666e2-029f-4fdb-9c64-4b21f0a075e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo_d25bbeb7-74b8-46ca-a24f-8e7622dd67fe" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo_d25bbeb7-74b8-46ca-a24f-8e7622dd67fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree_d2c0c328-eb4e-47dd-8c67-bc13fc1f5f82" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree_d2c0c328-eb4e-47dd-8c67-bc13fc1f5f82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour_8270b72b-d7de-4aaf-a693-22038d61bb6f" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour_8270b72b-d7de-4aaf-a693-22038d61bb6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive_fdd30556-9465-438d-bc93-975cb0b6f8d2" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive_fdd30556-9465-438d-bc93-975cb0b6f8d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive_0db062a7-d7a3-4163-a4a3-922fe4682d9b" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive_0db062a7-d7a3-4163-a4a3-922fe4682d9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_6c2744d3-b239-479c-8c5b-033224ec6546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_6c2744d3-b239-479c-8c5b-033224ec6546" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateScheduleTable_d6a6d582-b529-4876-be81-e5a88bc53d08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateScheduleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_srt_MortgageLoansOnRealEstateScheduleTable_d6a6d582-b529-4876-be81-e5a88bc53d08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4770dba9-a8d6-4511-8775-94425a3716b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_d6a6d582-b529-4876-be81-e5a88bc53d08" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4770dba9-a8d6-4511-8775-94425a3716b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4770dba9-a8d6-4511-8775-94425a3716b4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4770dba9-a8d6-4511-8775-94425a3716b4" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4770dba9-a8d6-4511-8775-94425a3716b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_c8d6bed1-4eeb-4a65-a45e-8e35da853b74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4770dba9-a8d6-4511-8775-94425a3716b4" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_c8d6bed1-4eeb-4a65-a45e-8e35da853b74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialRealEstateMember_04880d8b-6126-4b91-bb70-5903967e5fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_c8d6bed1-4eeb-4a65-a45e-8e35da853b74" xlink:to="loc_us-gaap_CommercialRealEstateMember_04880d8b-6126-4b91-bb70-5903967e5fe8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsNetInvestmentIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" xlink:type="extended" id="ie6b9c6ff620c49d091c7cfc0e50783f0_InvestmentsNetInvestmentIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_92560b04-86e4-494a-9be7-c51cbe88b49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_92560b04-86e4-494a-9be7-c51cbe88b49d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_7179dfb3-de62-4348-b41a-b5bf2a3d7d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_7179dfb3-de62-4348-b41a-b5bf2a3d7d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_a736ec02-339c-4ebd-9ea3-b3c09c2ce651" xlink:href="cvs-20221231.xsd#cvs_InvestmentIncomeExcludingCapitalGainsOrLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_a736ec02-339c-4ebd-9ea3-b3c09c2ce651" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_a3c780c4-0fa2-4cf5-9249-c10eec796b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_a3c780c4-0fa2-4cf5-9249-c10eec796b54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_a8632f37-11e3-411c-9e3e-3baca2928fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_us-gaap_InvestmentIncomeNet_a8632f37-11e3-411c-9e3e-3baca2928fb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_9b92ef91-5256-402e-b8e2-ce19bec0b913" xlink:href="cvs-20221231.xsd#cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_9b92ef91-5256-402e-b8e2-ce19bec0b913" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_13e31ae4-05a0-49e2-93d8-e221a0c26192" xlink:href="cvs-20221231.xsd#cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_13e31ae4-05a0-49e2-93d8-e221a0c26192" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_a05743da-35b0-4a6d-8564-506d914b8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_a05743da-35b0-4a6d-8564-506d914b8c4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_be65506b-c51a-4ef7-9a63-0c5f1f8ca99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_a05743da-35b0-4a6d-8564-506d914b8c4f" xlink:to="loc_us-gaap_InvestmentTypeAxis_be65506b-c51a-4ef7-9a63-0c5f1f8ca99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_be65506b-c51a-4ef7-9a63-0c5f1f8ca99b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_be65506b-c51a-4ef7-9a63-0c5f1f8ca99b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_be65506b-c51a-4ef7-9a63-0c5f1f8ca99b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_be65506b-c51a-4ef7-9a63-0c5f1f8ca99b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_b759fe94-5890-4021-b813-b7dcf2e134e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:to="loc_us-gaap_DebtSecuritiesMember_b759fe94-5890-4021-b813-b7dcf2e134e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansMember_82468f8d-a4a2-4055-ac3c-fc8447203b7c" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:to="loc_cvs_MortgageLoansMember_82468f8d-a4a2-4055-ac3c-fc8447203b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_648d7233-1c47-4a88-be54-71f340931937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:to="loc_us-gaap_OtherInvestmentsMember_648d7233-1c47-4a88-be54-71f340931937" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8569c4b7-f279-4bfd-8447-a1b70549d0b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_a05743da-35b0-4a6d-8564-506d914b8c4f" xlink:to="loc_srt_ProductOrServiceAxis_8569c4b7-f279-4bfd-8447-a1b70549d0b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8569c4b7-f279-4bfd-8447-a1b70549d0b3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8569c4b7-f279-4bfd-8447-a1b70549d0b3" xlink:to="loc_srt_ProductsAndServicesDomain_8569c4b7-f279-4bfd-8447-a1b70549d0b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8ee8ae8-0adb-4352-b21b-5d5c99d95cb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8569c4b7-f279-4bfd-8447-a1b70549d0b3" xlink:to="loc_srt_ProductsAndServicesDomain_c8ee8ae8-0adb-4352-b21b-5d5c99d95cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingExperienceRatedProductsMember_83e16388-99e8-4998-9016-62dfc83fd3a2" xlink:href="cvs-20221231.xsd#cvs_SupportingExperienceRatedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c8ee8ae8-0adb-4352-b21b-5d5c99d95cb2" xlink:to="loc_cvs_SupportingExperienceRatedProductsMember_83e16388-99e8-4998-9016-62dfc83fd3a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueFairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" xlink:type="extended" id="iaaea7b416ec5457e9279a6ba608f8237_FairValueFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f4276657-e22f-4a88-a81a-c7c44dcd6231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f4276657-e22f-4a88-a81a-c7c44dcd6231" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e28c5995-f48c-4898-b584-e5ca2bedb12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e28c5995-f48c-4898-b584-e5ca2bedb12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1d0c7fa7-4762-44ca-913c-4816e192ea7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1d0c7fa7-4762-44ca-913c-4816e192ea7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f5ce26bf-129f-421d-9e22-eab8231be015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f5ce26bf-129f-421d-9e22-eab8231be015" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_572cce78-c512-428b-b2fc-d0f39f4c4746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_572cce78-c512-428b-b2fc-d0f39f4c4746" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c89a21ef-2f3a-4bbd-a959-13565a18a002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c89a21ef-2f3a-4bbd-a959-13565a18a002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c89a21ef-2f3a-4bbd-a959-13565a18a002_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c89a21ef-2f3a-4bbd-a959-13565a18a002" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c89a21ef-2f3a-4bbd-a959-13565a18a002_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cacbceff-4f75-47a8-8308-7284c7a7a212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c89a21ef-2f3a-4bbd-a959-13565a18a002" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cacbceff-4f75-47a8-8308-7284c7a7a212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_02d75c32-4e83-4505-bb7c-68a1c25a92c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_cacbceff-4f75-47a8-8308-7284c7a7a212" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_02d75c32-4e83-4505-bb7c-68a1c25a92c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c590adc9-df48-415e-af3d-a844dec6892f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c590adc9-df48-415e-af3d-a844dec6892f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c590adc9-df48-415e-af3d-a844dec6892f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c590adc9-df48-415e-af3d-a844dec6892f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c590adc9-df48-415e-af3d-a844dec6892f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c590adc9-df48-415e-af3d-a844dec6892f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_958b8e47-7346-4f7b-ae3b-ee592b7b360e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_958b8e47-7346-4f7b-ae3b-ee592b7b360e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_95e1fbd7-e336-429e-9dfb-e83bbba83dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_95e1fbd7-e336-429e-9dfb-e83bbba83dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5aa320e9-ed93-49b0-8729-a1d184ef2298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5aa320e9-ed93-49b0-8729-a1d184ef2298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_a81e61de-1433-483e-8f71-8134999fbfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_a81e61de-1433-483e-8f71-8134999fbfcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_6877b86c-3d5a-4d1c-a29b-628774531648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_6877b86c-3d5a-4d1c-a29b-628774531648" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c6005ad5-5b5f-4b28-9ccc-c53dae86f584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c6005ad5-5b5f-4b28-9ccc-c53dae86f584" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_091e1529-be25-410f-95aa-a3e7f19174a9" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_091e1529-be25-410f-95aa-a3e7f19174a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_d85d8e6e-0b4d-464d-8d86-1d735e97abee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_d85d8e6e-0b4d-464d-8d86-1d735e97abee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74295d61-a99d-4a0e-8310-916b3e6d0898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74295d61-a99d-4a0e-8310-916b3e6d0898" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74295d61-a99d-4a0e-8310-916b3e6d0898_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74295d61-a99d-4a0e-8310-916b3e6d0898" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74295d61-a99d-4a0e-8310-916b3e6d0898_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74295d61-a99d-4a0e-8310-916b3e6d0898" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ed8f7306-ebaf-4158-8514-569e358c3776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ed8f7306-ebaf-4158-8514-569e358c3776" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3e45b9e9-86f5-4216-9745-044d2d702f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3e45b9e9-86f5-4216-9745-044d2d702f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7430485f-9b30-4293-922d-d28a43adecde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7430485f-9b30-4293-922d-d28a43adecde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e0bcc3e6-2dd5-4e67-8a74-3ed6e52f67dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e0bcc3e6-2dd5-4e67-8a74-3ed6e52f67dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e0bcc3e6-2dd5-4e67-8a74-3ed6e52f67dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e0bcc3e6-2dd5-4e67-8a74-3ed6e52f67dd" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e0bcc3e6-2dd5-4e67-8a74-3ed6e52f67dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cae8be79-0e31-496e-af54-cc3c2a01f308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e0bcc3e6-2dd5-4e67-8a74-3ed6e52f67dd" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cae8be79-0e31-496e-af54-cc3c2a01f308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_bf3e4e82-7383-4743-a6d6-a0cc5e9b1d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cae8be79-0e31-496e-af54-cc3c2a01f308" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_bf3e4e82-7383-4743-a6d6-a0cc5e9b1d1e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueChangesinLevel3FinancialAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" xlink:type="extended" id="i62d62dbed2ed431f91294d6a9bac0f16_FairValueChangesinLevel3FinancialAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc282f9a-21a5-4752-b2d4-6b8e822d02fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc282f9a-21a5-4752-b2d4-6b8e822d02fa" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2d583924-e41e-45a7-9d25-ac13e9fac051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2d583924-e41e-45a7-9d25-ac13e9fac051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_40018571-4585-484d-9a01-d2deb4ccdaff" xlink:href="cvs-20221231.xsd#cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_40018571-4585-484d-9a01-d2deb4ccdaff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_09294644-ce4e-4f0d-b651-03434e404807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_40018571-4585-484d-9a01-d2deb4ccdaff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_09294644-ce4e-4f0d-b651-03434e404807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_26e4dfe6-0b38-4def-84c3-6bb2885a1ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_40018571-4585-484d-9a01-d2deb4ccdaff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_26e4dfe6-0b38-4def-84c3-6bb2885a1ab1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_4f27fa04-4496-48f6-89e5-f28846895547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_4f27fa04-4496-48f6-89e5-f28846895547" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_13b7a549-6d97-492e-b95a-7531745bf6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_13b7a549-6d97-492e-b95a-7531745bf6e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_3cc95156-8417-43df-996a-22f8c4b3902a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_3cc95156-8417-43df-996a-22f8c4b3902a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c6c19d90-8bf2-4870-85cf-4bca17c6806f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c6c19d90-8bf2-4870-85cf-4bca17c6806f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_cc7ba811-c1b6-40f0-b0eb-425fc99c1354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci_bd7de0f7-8881-423e-8c05-293dfd8597a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc282f9a-21a5-4752-b2d4-6b8e822d02fa" xlink:to="loc_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci_bd7de0f7-8881-423e-8c05-293dfd8597a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1a0935e-4e5e-48a7-8496-453f6ca68850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc282f9a-21a5-4752-b2d4-6b8e822d02fa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1a0935e-4e5e-48a7-8496-453f6ca68850" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5f30b340-bd88-4848-9b45-7e6b249592b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1a0935e-4e5e-48a7-8496-453f6ca68850" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5f30b340-bd88-4848-9b45-7e6b249592b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f30b340-bd88-4848-9b45-7e6b249592b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5f30b340-bd88-4848-9b45-7e6b249592b2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f30b340-bd88-4848-9b45-7e6b249592b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5f30b340-bd88-4848-9b45-7e6b249592b2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_bccfe53a-a1d3-4701-b2e3-75f287815929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_bccfe53a-a1d3-4701-b2e3-75f287815929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_0d0cc151-7d79-4731-9c7c-14ac231aef8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_0d0cc151-7d79-4731-9c7c-14ac231aef8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember_3e8fbe70-f93d-49b4-9373-be72ab7603d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember_3e8fbe70-f93d-49b4-9373-be72ab7603d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_556615d8-15ee-4916-8ba6-a38a129db826" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_556615d8-15ee-4916-8ba6-a38a129db826" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_2fb5399d-3258-4151-b764-a2f81cae77e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_2fb5399d-3258-4151-b764-a2f81cae77e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_3a68217f-2bf3-4de3-b455-a344461ddc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_EquitySecuritiesMember_3a68217f-2bf3-4de3-b455-a344461ddc93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7a7b8fe3-2307-4691-b335-a30fc2558770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1a0935e-4e5e-48a7-8496-453f6ca68850" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7a7b8fe3-2307-4691-b335-a30fc2558770" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a7b8fe3-2307-4691-b335-a30fc2558770_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7a7b8fe3-2307-4691-b335-a30fc2558770" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a7b8fe3-2307-4691-b335-a30fc2558770_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_254c2e71-9367-4253-98fb-65c327df9ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7a7b8fe3-2307-4691-b335-a30fc2558770" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_254c2e71-9367-4253-98fb-65c327df9ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d7ca5f78-41e2-4dfe-99f0-6495534491d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_254c2e71-9367-4253-98fb-65c327df9ae2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d7ca5f78-41e2-4dfe-99f0-6495534491d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueGrossTransfersIntoOutOfLevel3Details"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" xlink:type="extended" id="i5c8fb2a54732490b913de5192b7cb50b_FairValueGrossTransfersIntoOutOfLevel3Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_3c37f1a2-d770-4f23-86b4-354486fc4a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_3c37f1a2-d770-4f23-86b4-354486fc4a63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_87d1e149-67cf-468f-9503-2f03c12314f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_87d1e149-67cf-468f-9503-2f03c12314f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_3b6785dc-27a6-4bd3-b992-649b3f19c5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_3b6785dc-27a6-4bd3-b992-649b3f19c5d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144ab090-186d-4df6-94d3-0794058280e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144ab090-186d-4df6-94d3-0794058280e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7060f5e9-f1c3-409e-8b62-83fb5efa11a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144ab090-186d-4df6-94d3-0794058280e4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7060f5e9-f1c3-409e-8b62-83fb5efa11a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7060f5e9-f1c3-409e-8b62-83fb5efa11a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7060f5e9-f1c3-409e-8b62-83fb5efa11a2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7060f5e9-f1c3-409e-8b62-83fb5efa11a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ccf721-80f8-4bdd-b33d-652f6030caef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7060f5e9-f1c3-409e-8b62-83fb5efa11a2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ccf721-80f8-4bdd-b33d-652f6030caef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_195273df-72fa-4c23-8e5a-274ed4df0bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ccf721-80f8-4bdd-b33d-652f6030caef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_195273df-72fa-4c23-8e5a-274ed4df0bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0566e00d-a0b7-45a4-b114-1a043124f288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144ab090-186d-4df6-94d3-0794058280e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0566e00d-a0b7-45a4-b114-1a043124f288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0566e00d-a0b7-45a4-b114-1a043124f288_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0566e00d-a0b7-45a4-b114-1a043124f288" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0566e00d-a0b7-45a4-b114-1a043124f288_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd62915-9a78-4514-a138-32b34aa2dfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0566e00d-a0b7-45a4-b114-1a043124f288" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd62915-9a78-4514-a138-32b34aa2dfd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_de8aaebe-0b5b-4a7b-a021-def1584a912e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd62915-9a78-4514-a138-32b34aa2dfd3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_de8aaebe-0b5b-4a7b-a021-def1584a912e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueCarryingValueandFairValueClassifiedbyLevelDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" xlink:type="extended" id="ic36de05ec92d46ca9c62e34a8781617f_FairValueCarryingValueandFairValueClassifiedbyLevelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_98b1f1e7-78d2-45ea-b49c-1751aaaaa594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_6a097646-080e-4b76-a56e-ea8f4f673247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_98b1f1e7-78d2-45ea-b49c-1751aaaaa594" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_6a097646-080e-4b76-a56e-ea8f4f673247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesHeldForSaleFairValueDisclosure_29d5b32f-d75d-40b0-9d99-32748d1aab02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgagesHeldForSaleFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_6a097646-080e-4b76-a56e-ea8f4f673247" xlink:to="loc_us-gaap_MortgagesHeldForSaleFairValueDisclosure_29d5b32f-d75d-40b0-9d99-32748d1aab02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4d784204-d226-442c-8204-2663d91e7ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_6a097646-080e-4b76-a56e-ea8f4f673247" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4d784204-d226-442c-8204-2663d91e7ae9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_98b1f1e7-78d2-45ea-b49c-1751aaaaa594" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure_88bfb4ca-4c42-4215-b1ca-ee0b9cf183bd" xlink:href="cvs-20221231.xsd#cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:to="loc_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure_88bfb4ca-4c42-4215-b1ca-ee0b9cf183bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure_71ac0d8b-911d-49fb-b4d9-b7cec687e40e" xlink:href="cvs-20221231.xsd#cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:to="loc_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure_71ac0d8b-911d-49fb-b4d9-b7cec687e40e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3d4a0d7c-6deb-4c05-92d6-3e7553fba8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3d4a0d7c-6deb-4c05-92d6-3e7553fba8d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_98b1f1e7-78d2-45ea-b49c-1751aaaaa594" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_272a381a-566b-4afa-a3f9-f55a5dcbd896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_272a381a-566b-4afa-a3f9-f55a5dcbd896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_272a381a-566b-4afa-a3f9-f55a5dcbd896_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_272a381a-566b-4afa-a3f9-f55a5dcbd896" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_272a381a-566b-4afa-a3f9-f55a5dcbd896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a50d96a-cfff-40eb-9e78-2817b0853022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_272a381a-566b-4afa-a3f9-f55a5dcbd896" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a50d96a-cfff-40eb-9e78-2817b0853022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_3d1bf2c7-f653-4691-a9f8-3ce179b9295a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a50d96a-cfff-40eb-9e78-2817b0853022" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_3d1bf2c7-f653-4691-a9f8-3ce179b9295a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d985eeef-7c0e-4109-b1dd-05bdbb468d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d985eeef-7c0e-4109-b1dd-05bdbb468d7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d985eeef-7c0e-4109-b1dd-05bdbb468d7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d985eeef-7c0e-4109-b1dd-05bdbb468d7d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d985eeef-7c0e-4109-b1dd-05bdbb468d7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d985eeef-7c0e-4109-b1dd-05bdbb468d7d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_511f5c32-946f-4891-b483-fa8d0386544b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_511f5c32-946f-4891-b483-fa8d0386544b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a7df7b7f-32ce-4211-bb14-753c866efdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a7df7b7f-32ce-4211-bb14-753c866efdc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_717ced63-4e67-41bb-a178-8f2156d0c089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_717ced63-4e67-41bb-a178-8f2156d0c089" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ad19dd25-2e6e-408d-a9c4-a750b816f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ad19dd25-2e6e-408d-a9c4-a750b816f2a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad19dd25-2e6e-408d-a9c4-a750b816f2a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ad19dd25-2e6e-408d-a9c4-a750b816f2a5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ad19dd25-2e6e-408d-a9c4-a750b816f2a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5a1342d6-2448-4638-8d43-866313b153f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ad19dd25-2e6e-408d-a9c4-a750b816f2a5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5a1342d6-2448-4638-8d43-866313b153f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4a9d863b-08d0-470a-963c-50b0ef333131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5a1342d6-2448-4638-8d43-866313b153f7" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4a9d863b-08d0-470a-963c-50b0ef333131" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bea5eee6-e8b1-4c2f-8619-47d20fea5f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4a9d863b-08d0-470a-963c-50b0ef333131" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bea5eee6-e8b1-4c2f-8619-47d20fea5f5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6c898e9f-6a02-4ebb-9512-bf84ec44f54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4a9d863b-08d0-470a-963c-50b0ef333131" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6c898e9f-6a02-4ebb-9512-bf84ec44f54c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c721cab9-d0eb-473f-aee8-8dd9fb3a32de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c721cab9-d0eb-473f-aee8-8dd9fb3a32de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c721cab9-d0eb-473f-aee8-8dd9fb3a32de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c721cab9-d0eb-473f-aee8-8dd9fb3a32de" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c721cab9-d0eb-473f-aee8-8dd9fb3a32de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4815a800-4f9d-483d-a553-a905dc5cdf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c721cab9-d0eb-473f-aee8-8dd9fb3a32de" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4815a800-4f9d-483d-a553-a905dc5cdf9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_bd4e715e-c56b-487f-9a79-d0df93c2aa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4815a800-4f9d-483d-a553-a905dc5cdf9d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_bd4e715e-c56b-487f-9a79-d0df93c2aa0f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueSeparateAccountsFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" xlink:type="extended" id="ia87cf35019e44e05a5c51ebebf3ac49d_FairValueSeparateAccountsFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_353d7d96-5fd0-471a-b7ae-18f8f64cffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_89811978-5e72-464c-9325-d1f9b8693c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_353d7d96-5fd0-471a-b7ae-18f8f64cffc9" xlink:to="loc_us-gaap_SeparateAccountAssets_89811978-5e72-464c-9325-d1f9b8693c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability_02c9f730-ed30-4db4-8f2a-c2ef09a839ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_353d7d96-5fd0-471a-b7ae-18f8f64cffc9" xlink:to="loc_us-gaap_SeparateAccountsLiability_02c9f730-ed30-4db4-8f2a-c2ef09a839ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_353d7d96-5fd0-471a-b7ae-18f8f64cffc9" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c9b1e65-5611-4818-a4b2-1920d1b2cfba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c9b1e65-5611-4818-a4b2-1920d1b2cfba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7c9b1e65-5611-4818-a4b2-1920d1b2cfba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c9b1e65-5611-4818-a4b2-1920d1b2cfba" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7c9b1e65-5611-4818-a4b2-1920d1b2cfba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca226d16-fcb5-41d3-a836-b41aed22fc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c9b1e65-5611-4818-a4b2-1920d1b2cfba" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca226d16-fcb5-41d3-a836-b41aed22fc8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ec01c8c4-9a75-4a0b-88cc-d0117b4a71df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca226d16-fcb5-41d3-a836-b41aed22fc8d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ec01c8c4-9a75-4a0b-88cc-d0117b4a71df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97d9837c-466f-42ea-a5e0-0ebf96e976e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97d9837c-466f-42ea-a5e0-0ebf96e976e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97d9837c-466f-42ea-a5e0-0ebf96e976e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97d9837c-466f-42ea-a5e0-0ebf96e976e6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97d9837c-466f-42ea-a5e0-0ebf96e976e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97d9837c-466f-42ea-a5e0-0ebf96e976e6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_104f71fd-a7c6-438e-ba52-f951a7dc7d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_104f71fd-a7c6-438e-ba52-f951a7dc7d57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bd07dce5-d45c-40b3-8373-6b1673d64648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bd07dce5-d45c-40b3-8373-6b1673d64648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b393cca6-5dc1-478c-afb8-cd04a0346ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b393cca6-5dc1-478c-afb8-cd04a0346ab1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryAxis_6d5621dd-197f-4efe-8cf6-7821359e281a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryAxis_6d5621dd-197f-4efe-8cf6-7821359e281a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain_6d5621dd-197f-4efe-8cf6-7821359e281a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis_6d5621dd-197f-4efe-8cf6-7821359e281a" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryDomain_6d5621dd-197f-4efe-8cf6-7821359e281a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis_6d5621dd-197f-4efe-8cf6-7821359e281a" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_46f419a1-07b7-4677-a76a-434d342de333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_46f419a1-07b7-4677-a76a-434d342de333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_a877f2b7-583b-424e-b311-9c126406531a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:to="loc_us-gaap_DebtSecuritiesMember_a877f2b7-583b-424e-b311-9c126406531a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0145521b-1904-4dee-973c-0d229d7f3b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:to="loc_us-gaap_EquitySecuritiesMember_0145521b-1904-4dee-973c-0d229d7f3b0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CommonAndCollectiveTrustsMember_2188ca00-fc39-4871-b123-e0be9dbef4c9" xlink:href="cvs-20221231.xsd#cvs_CommonAndCollectiveTrustsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:to="loc_cvs_CommonAndCollectiveTrustsMember_2188ca00-fc39-4871-b123-e0be9dbef4c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3cc3fd05-43f3-41ae-96a6-5ac15655001b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3cc3fd05-43f3-41ae-96a6-5ac15655001b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3cc3fd05-43f3-41ae-96a6-5ac15655001b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3cc3fd05-43f3-41ae-96a6-5ac15655001b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3cc3fd05-43f3-41ae-96a6-5ac15655001b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f4e75106-e60f-4591-853e-6ce274f4ad85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3cc3fd05-43f3-41ae-96a6-5ac15655001b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f4e75106-e60f-4591-853e-6ce274f4ad85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_19567c01-c118-420f-ab4a-5994cb83d52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4e75106-e60f-4591-853e-6ce274f4ad85" xlink:to="loc_us-gaap_AccountsPayableMember_19567c01-c118-420f-ab4a-5994cb83d52b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_adeffc05-de79-4cdc-852f-05fd2043b697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4e75106-e60f-4591-853e-6ce274f4ad85" xlink:to="loc_us-gaap_AccountsReceivableMember_adeffc05-de79-4cdc-852f-05fd2043b697" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/FairValueNarrativeDetails" xlink:type="extended" id="iaca99d2b775743e5bf97485cd0ead42d_FairValueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c11499c-4ac6-42a4-b16b-149807edbd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_9285b800-0cbe-4a55-84f3-73d751178f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c11499c-4ac6-42a4-b16b-149807edbd81" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_9285b800-0cbe-4a55-84f3-73d751178f00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c11499c-4ac6-42a4-b16b-149807edbd81" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8e5f7d44-0ffd-4c19-80ed-aef0a11fef43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8e5f7d44-0ffd-4c19-80ed-aef0a11fef43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e5f7d44-0ffd-4c19-80ed-aef0a11fef43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8e5f7d44-0ffd-4c19-80ed-aef0a11fef43" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e5f7d44-0ffd-4c19-80ed-aef0a11fef43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6594f32-2e55-4d7b-8839-5b19fc9c01d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8e5f7d44-0ffd-4c19-80ed-aef0a11fef43" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6594f32-2e55-4d7b-8839-5b19fc9c01d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3af18a0d-8847-4c4c-b98b-1152c8d5c61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6594f32-2e55-4d7b-8839-5b19fc9c01d8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3af18a0d-8847-4c4c-b98b-1152c8d5c61b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5e37de39-3175-4264-a253-34e2b763334b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5e37de39-3175-4264-a253-34e2b763334b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5e37de39-3175-4264-a253-34e2b763334b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5e37de39-3175-4264-a253-34e2b763334b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5e37de39-3175-4264-a253-34e2b763334b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_11ea8c5a-896e-4887-bdb3-eba7c76c01e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5e37de39-3175-4264-a253-34e2b763334b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_11ea8c5a-896e-4887-bdb3-eba7c76c01e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ef1f3ce7-7485-445a-9924-bb28364f3a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_11ea8c5a-896e-4887-bdb3-eba7c76c01e8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ef1f3ce7-7485-445a-9924-bb28364f3a54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryAxis_2f62bf51-41e2-45e9-84f4-e9f5394e92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryAxis_2f62bf51-41e2-45e9-84f4-e9f5394e92dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain_2f62bf51-41e2-45e9-84f4-e9f5394e92dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis_2f62bf51-41e2-45e9-84f4-e9f5394e92dd" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryDomain_2f62bf51-41e2-45e9-84f4-e9f5394e92dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain_d621316b-6d10-4674-971e-2462c4d722bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis_2f62bf51-41e2-45e9-84f4-e9f5394e92dd" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryDomain_d621316b-6d10-4674-971e-2462c4d722bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeparateAccountFinancialAssetsMember_b2766dd7-1daa-4bc0-8411-61c35efc4c56" xlink:href="cvs-20221231.xsd#cvs_SeparateAccountFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_d621316b-6d10-4674-971e-2462c4d722bb" xlink:to="loc_cvs_SeparateAccountFinancialAssetsMember_b2766dd7-1daa-4bc0-8411-61c35efc4c56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherIntangiblesGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" xlink:type="extended" id="iee7991dfbe154069806fa2a172f72c74_GoodwillandOtherIntangiblesGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_bebe262a-2653-4c03-9374-440db3157733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_bebe262a-2653-4c03-9374-440db3157733" xlink:to="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1ee6830d-81e5-4c58-8cc3-d65650d9ebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:to="loc_us-gaap_Goodwill_1ee6830d-81e5-4c58-8cc3-d65650d9ebc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6dea3a55-bea4-4620-b778-886fefc83547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6dea3a55-bea4-4620-b778-886fefc83547" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_855fff4f-eba9-4693-a124-af9de6c7d151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_855fff4f-eba9-4693-a124-af9de6c7d151" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_83363e2c-42e9-4a6d-adb4-2cfc2091b120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_48a84bd0-0929-47f5-b159-76fc44fa4e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_bebe262a-2653-4c03-9374-440db3157733" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_48a84bd0-0929-47f5-b159-76fc44fa4e7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e4bb5c40-e684-4a75-9730-ed66ffafa4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48a84bd0-0929-47f5-b159-76fc44fa4e7e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e4bb5c40-e684-4a75-9730-ed66ffafa4a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e4bb5c40-e684-4a75-9730-ed66ffafa4a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e4bb5c40-e684-4a75-9730-ed66ffafa4a5" xlink:to="loc_us-gaap_SegmentDomain_e4bb5c40-e684-4a75-9730-ed66ffafa4a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e4bb5c40-e684-4a75-9730-ed66ffafa4a5" xlink:to="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_6a3ebbb3-ecdf-46ee-b0a9-785c3d8a7a67" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_6a3ebbb3-ecdf-46ee-b0a9-785c3d8a7a67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyServicesSegmentMember_81b45814-3796-485d-9379-4fe860609541" xlink:href="cvs-20221231.xsd#cvs_PharmacyServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:to="loc_cvs_PharmacyServicesSegmentMember_81b45814-3796-485d-9379-4fe860609541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_05e729ad-7f38-4c7e-bb0e-89294385014f" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_05e729ad-7f38-4c7e-bb0e-89294385014f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ffb26f0e-600c-49ea-91ac-6c81f77623f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48a84bd0-0929-47f5-b159-76fc44fa4e7e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ffb26f0e-600c-49ea-91ac-6c81f77623f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ffb26f0e-600c-49ea-91ac-6c81f77623f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ffb26f0e-600c-49ea-91ac-6c81f77623f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ffb26f0e-600c-49ea-91ac-6c81f77623f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e527f732-daae-4a56-834d-c1709fb3bca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ffb26f0e-600c-49ea-91ac-6c81f77623f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e527f732-daae-4a56-834d-c1709fb3bca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_00847c96-a66f-4885-801f-9daed973f96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e527f732-daae-4a56-834d-c1709fb3bca7" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_00847c96-a66f-4885-801f-9daed973f96a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended" id="i90d8d24999774680adafaeb873cb1a02_GoodwillandOtherIntangiblesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_28459b9f-7872-4c74-9bfd-20e826ed866e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_28459b9f-7872-4c74-9bfd-20e826ed866e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_81e71fd4-ffd2-442f-b75e-04ef4843e102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:to="loc_us-gaap_Goodwill_81e71fd4-ffd2-442f-b75e-04ef4843e102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6e0076ca-689d-4c19-bc4c-4091256537c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6e0076ca-689d-4c19-bc4c-4091256537c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1d3b74db-015b-4d2a-8ac0-5c6933147ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1d3b74db-015b-4d2a-8ac0-5c6933147ddd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_f014eb3c-49e5-458f-bc89-45fd04aeec81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1d3b74db-015b-4d2a-8ac0-5c6933147ddd" xlink:to="loc_us-gaap_ReportingUnitAxis_f014eb3c-49e5-458f-bc89-45fd04aeec81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_f014eb3c-49e5-458f-bc89-45fd04aeec81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_f014eb3c-49e5-458f-bc89-45fd04aeec81" xlink:to="loc_us-gaap_ReportingUnitDomain_f014eb3c-49e5-458f-bc89-45fd04aeec81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_3ef8fab1-1a5f-4e11-b673-3147ff913c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_f014eb3c-49e5-458f-bc89-45fd04aeec81" xlink:to="loc_us-gaap_ReportingUnitDomain_3ef8fab1-1a5f-4e11-b673-3147ff913c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermCareReportingUnitMember_6cead929-ddc5-45b1-92d8-ee8fdf0c1a1c" xlink:href="cvs-20221231.xsd#cvs_LongTermCareReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_3ef8fab1-1a5f-4e11-b673-3147ff913c93" xlink:to="loc_cvs_LongTermCareReportingUnitMember_6cead929-ddc5-45b1-92d8-ee8fdf0c1a1c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherIntangiblesIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" xlink:type="extended" id="ib1247f0a63224f82ab9817130091f3b8_GoodwillandOtherIntangiblesIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:href="cvs-20221231.xsd#cvs_OtherAcquiredIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ca9ed2a4-0108-474d-84f1-e9c953297ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ca9ed2a4-0108-474d-84f1-e9c953297ec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50151ad9-a07a-4a66-8ae7-16ec75595558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50151ad9-a07a-4a66-8ae7-16ec75595558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6cfde0c8-f64a-4f72-9510-d03593dbae25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6cfde0c8-f64a-4f72-9510-d03593dbae25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4ce7ec73-4ed7-4ff7-82ac-218059a08d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4ce7ec73-4ed7-4ff7-82ac-218059a08d87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_767f29b0-4e5f-46a2-b8f2-3d0be826d3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_767f29b0-4e5f-46a2-b8f2-3d0be826d3fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_218d57c8-1ed8-40c4-9385-a5c16441494b" xlink:href="cvs-20221231.xsd#cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_218d57c8-1ed8-40c4-9385-a5c16441494b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_734d99c4-6550-438d-9ff5-d1d4f8ecebb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_734d99c4-6550-438d-9ff5-d1d4f8ecebb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a61303a0-2d0e-4946-aa3f-f6595da05fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a61303a0-2d0e-4946-aa3f-f6595da05fcb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_669ad882-fffb-4c50-bbcc-3fcf2f050fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_669ad882-fffb-4c50-bbcc-3fcf2f050fa9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:href="cvs-20221231.xsd#cvs_OtherAcquiredIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a68e78ef-cbf5-41ec-b8b6-a8c730d792bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a68e78ef-cbf5-41ec-b8b6-a8c730d792bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a68e78ef-cbf5-41ec-b8b6-a8c730d792bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a68e78ef-cbf5-41ec-b8b6-a8c730d792bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a68e78ef-cbf5-41ec-b8b6-a8c730d792bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a68e78ef-cbf5-41ec-b8b6-a8c730d792bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_2d63dd2a-5330-43de-88be-27775ad4bb43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_2d63dd2a-5330-43de-88be-27775ad4bb43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_23b77453-11c1-4d39-a392-7b7c0e077fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_23b77453-11c1-4d39-a392-7b7c0e077fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ProviderNetworksMember_2842e0c0-0040-41d0-8044-78e6922d7f28" xlink:href="cvs-20221231.xsd#cvs_ProviderNetworksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_cvs_ProviderNetworksMember_2842e0c0-0040-41d0-8044-78e6922d7f28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ValueOfBusinessAcquiredMember_531dbd4a-055f-4897-b81c-c3d0d11d6f2f" xlink:href="cvs-20221231.xsd#cvs_ValueOfBusinessAcquiredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_cvs_ValueOfBusinessAcquiredMember_531dbd4a-055f-4897-b81c-c3d0d11d6f2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7b7842c8-1fc8-42ef-bc7f-f2d9626e3001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7b7842c8-1fc8-42ef-bc7f-f2d9626e3001" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_de495114-9c52-4773-b9fa-77b16c68a279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_de495114-9c52-4773-b9fa-77b16c68a279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_de495114-9c52-4773-b9fa-77b16c68a279_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_de495114-9c52-4773-b9fa-77b16c68a279" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_de495114-9c52-4773-b9fa-77b16c68a279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2f1fa448-649d-41a6-afc2-4cf922470ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_de495114-9c52-4773-b9fa-77b16c68a279" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2f1fa448-649d-41a6-afc2-4cf922470ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_08177452-a064-4392-b32b-7c5327b080e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2f1fa448-649d-41a6-afc2-4cf922470ad8" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_08177452-a064-4392-b32b-7c5327b080e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5813f9bf-6382-4202-a3a6-aba4bb3d2b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5813f9bf-6382-4202-a3a6-aba4bb3d2b23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5813f9bf-6382-4202-a3a6-aba4bb3d2b23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5813f9bf-6382-4202-a3a6-aba4bb3d2b23" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5813f9bf-6382-4202-a3a6-aba4bb3d2b23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a7bac6cf-e2a2-485e-8067-6bf0d68953a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5813f9bf-6382-4202-a3a6-aba4bb3d2b23" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a7bac6cf-e2a2-485e-8067-6bf0d68953a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OmnicareLongTermCareBusinessMember_28d5a0e9-b9d1-43c0-a2a2-3d69e63877e9" xlink:href="cvs-20221231.xsd#cvs_OmnicareLongTermCareBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a7bac6cf-e2a2-485e-8067-6bf0d68953a0" xlink:to="loc_cvs_OmnicareLongTermCareBusinessMember_28d5a0e9-b9d1-43c0-a2a2-3d69e63877e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b122e84d-2d86-4431-92b7-3024421a588d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b122e84d-2d86-4431-92b7-3024421a588d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b122e84d-2d86-4431-92b7-3024421a588d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b122e84d-2d86-4431-92b7-3024421a588d" xlink:to="loc_us-gaap_SegmentDomain_b122e84d-2d86-4431-92b7-3024421a588d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb7386a5-c7f1-4f1a-a06a-8a7a71fd673e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b122e84d-2d86-4431-92b7-3024421a588d" xlink:to="loc_us-gaap_SegmentDomain_fb7386a5-c7f1-4f1a-a06a-8a7a71fd673e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_da99341d-1be5-444e-9a7b-3436215bcfa6" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fb7386a5-c7f1-4f1a-a06a-8a7a71fd673e" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_da99341d-1be5-444e-9a7b-3436215bcfa6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i7ccdb5cb5b7b407c9427a79a09851e98_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_725875c1-a026-4649-9800-45e25ffceb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_725875c1-a026-4649-9800-45e25ffceb49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_085a1e04-6bbc-4127-804b-efdb466f3fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_085a1e04-6bbc-4127-804b-efdb466f3fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_d25fb06d-3478-4643-9ebb-2e07ac0b6949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_d25fb06d-3478-4643-9ebb-2e07ac0b6949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_093bff11-56c8-457c-9c25-efaef1b5c886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_093bff11-56c8-457c-9c25-efaef1b5c886" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OfficeRealEstateOptimizationCharges_871f0538-10af-4232-a676-7f4408fd6301" xlink:href="cvs-20221231.xsd#cvs_OfficeRealEstateOptimizationCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_OfficeRealEstateOptimizationCharges_871f0538-10af-4232-a676-7f4408fd6301" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresPlannedClosure_e3ad2269-f93c-4153-b281-5347476d07ea" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresPlannedClosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_NumberOfStoresPlannedClosure_e3ad2269-f93c-4153-b281-5347476d07ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod_e26539f1-7fa9-4471-bf2b-a4efd86d7e1b" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod_e26539f1-7fa9-4471-bf2b-a4efd86d7e1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_c9b55299-56c0-4aea-9e56-ee61093ac01b" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_StoreImpairmentCharges_c9b55299-56c0-4aea-9e56-ee61093ac01b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure_2ab14076-f2c8-46ce-8c23-c1fc8977e7e3" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure_2ab14076-f2c8-46ce-8c23-c1fc8977e7e3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_48c09f9f-f59f-4a44-96db-ec8eb3dfff18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_48c09f9f-f59f-4a44-96db-ec8eb3dfff18" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d414d2ac-c0af-4427-a46b-795787c5b20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d414d2ac-c0af-4427-a46b-795787c5b20f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d414d2ac-c0af-4427-a46b-795787c5b20f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d414d2ac-c0af-4427-a46b-795787c5b20f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d414d2ac-c0af-4427-a46b-795787c5b20f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d414d2ac-c0af-4427-a46b-795787c5b20f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_2374f5ee-fc5d-4c51-b74a-560084bc1a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:to="loc_us-gaap_BuildingMember_2374f5ee-fc5d-4c51-b74a-560084bc1a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1064a920-ab8e-4d56-95bd-4c47a1e22cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:to="loc_us-gaap_EquipmentMember_1064a920-ab8e-4d56-95bd-4c47a1e22cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_31ff184e-d53e-432d-a7b8-86c0b4dfb800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_31ff184e-d53e-432d-a7b8-86c0b4dfb800" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc1afe42-c188-420f-94d5-e310f5055987" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:to="loc_srt_RangeAxis_bc1afe42-c188-420f-94d5-e310f5055987" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc1afe42-c188-420f-94d5-e310f5055987_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bc1afe42-c188-420f-94d5-e310f5055987" xlink:to="loc_srt_RangeMember_bc1afe42-c188-420f-94d5-e310f5055987_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d555453-211c-4266-aaeb-5a011fde7339" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bc1afe42-c188-420f-94d5-e310f5055987" xlink:to="loc_srt_RangeMember_9d555453-211c-4266-aaeb-5a011fde7339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_78e981fd-d523-4470-8724-99e73561e121" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9d555453-211c-4266-aaeb-5a011fde7339" xlink:to="loc_srt_MinimumMember_78e981fd-d523-4470-8724-99e73561e121" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d88d991b-a0a3-4404-b831-c37248165e43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9d555453-211c-4266-aaeb-5a011fde7339" xlink:to="loc_srt_MaximumMember_d88d991b-a0a3-4404-b831-c37248165e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b42e2f7d-994f-418d-bfce-a906333604c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b42e2f7d-994f-418d-bfce-a906333604c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b42e2f7d-994f-418d-bfce-a906333604c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b42e2f7d-994f-418d-bfce-a906333604c2" xlink:to="loc_us-gaap_SegmentDomain_b42e2f7d-994f-418d-bfce-a906333604c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6ea3df12-4c25-40d5-91cb-a75b04694ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b42e2f7d-994f-418d-bfce-a906333604c2" xlink:to="loc_us-gaap_SegmentDomain_6ea3df12-4c25-40d5-91cb-a75b04694ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_d44c4d57-a17e-4cc2-b7fa-ed14c8f20d2f" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6ea3df12-4c25-40d5-91cb-a75b04694ff4" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_d44c4d57-a17e-4cc2-b7fa-ed14c8f20d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_a64c151a-8d9d-42f6-ba77-68fd45260742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_a64c151a-8d9d-42f6-ba77-68fd45260742" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a64c151a-8d9d-42f6-ba77-68fd45260742_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_a64c151a-8d9d-42f6-ba77-68fd45260742" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a64c151a-8d9d-42f6-ba77-68fd45260742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_c1ad9625-50ad-4877-a014-cc7910d8947a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_a64c151a-8d9d-42f6-ba77-68fd45260742" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_c1ad9625-50ad-4877-a014-cc7910d8947a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOperatingLeaseMember_7598be6a-7e2b-4383-80b3-a15524736fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_c1ad9625-50ad-4877-a014-cc7910d8947a" xlink:to="loc_us-gaap_PropertySubjectToOperatingLeaseMember_7598be6a-7e2b-4383-80b3-a15524736fab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended" id="iba869fe3ba054f9dae1ada1a519ef94c_LeasesSupplementalBalanceSheetInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:to="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale_fabd46c2-996e-4184-b855-de8c3342957b" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:to="loc_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale_fabd46c2-996e-4184-b855-de8c3342957b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale_0d7cae3a-312f-474a-84e9-ec5ca6ef28af" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:to="loc_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale_0d7cae3a-312f-474a-84e9-ec5ca6ef28af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale_6aae83ee-2ba0-404d-87f4-1e10a09c97a9" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:to="loc_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale_6aae83ee-2ba0-404d-87f4-1e10a09c97a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_43165e62-2c01-4060-af0d-64e8e4e3ea54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:to="loc_us-gaap_OperatingLeaseLiability_43165e62-2c01-4060-af0d-64e8e4e3ea54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:to="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetGross_d863a9d7-72e4-479e-b5ba-29aaffe2c8ad" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_cvs_FinanceLeaseRightOfUseAssetGross_d863a9d7-72e4-479e-b5ba-29aaffe2c8ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation_fd62fccd-e6b9-4845-ac1f-94169e0ab91b" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation_fd62fccd-e6b9-4845-ac1f-94169e0ab91b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetNet_dd36195e-a7ae-4011-9317-e9734af6d9ab" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_cvs_FinanceLeaseRightOfUseAssetNet_dd36195e-a7ae-4011-9317-e9734af6d9ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_db548fee-a03c-4990-8b78-08853149bb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_db548fee-a03c-4990-8b78-08853149bb84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_56dfabc5-9364-4da0-8c2e-ebf9a55a34df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_56dfabc5-9364-4da0-8c2e-ebf9a55a34df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_1492d855-58dc-4b2a-a063-07c91001ac16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_us-gaap_FinanceLeaseLiability_1492d855-58dc-4b2a-a063-07c91001ac16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_WeightedAverageRemainingLeaseTermAbstract_46fc60c5-c593-49a6-92e5-9f6593cb4c9c" xlink:href="cvs-20221231.xsd#cvs_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:to="loc_cvs_WeightedAverageRemainingLeaseTermAbstract_46fc60c5-c593-49a6-92e5-9f6593cb4c9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_65b4ac99-df84-42a5-881e-6030eb1daf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_WeightedAverageRemainingLeaseTermAbstract_46fc60c5-c593-49a6-92e5-9f6593cb4c9c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_65b4ac99-df84-42a5-881e-6030eb1daf97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_623c2073-2055-42aa-bee2-5a2b0295259d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_WeightedAverageRemainingLeaseTermAbstract_46fc60c5-c593-49a6-92e5-9f6593cb4c9c" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_623c2073-2055-42aa-bee2-5a2b0295259d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LeasesWeightedAverageDiscountRateAbstract_cb98234d-9cd7-498d-a9a3-d2afe22c1603" xlink:href="cvs-20221231.xsd#cvs_LeasesWeightedAverageDiscountRateAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:to="loc_cvs_LeasesWeightedAverageDiscountRateAbstract_cb98234d-9cd7-498d-a9a3-d2afe22c1603" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7f7571ac-524e-41cf-ae4e-6ddd2448c652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_LeasesWeightedAverageDiscountRateAbstract_cb98234d-9cd7-498d-a9a3-d2afe22c1603" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7f7571ac-524e-41cf-ae4e-6ddd2448c652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_46148f0f-260b-4cae-9879-056b10f095a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_LeasesWeightedAverageDiscountRateAbstract_cb98234d-9cd7-498d-a9a3-d2afe22c1603" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_46148f0f-260b-4cae-9879-056b10f095a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_35073e41-125d-4c68-ab65-adce98b97f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_35073e41-125d-4c68-ab65-adce98b97f6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0ae1c7ac-e7c7-4216-9394-37b3185ff875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_35073e41-125d-4c68-ab65-adce98b97f6b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0ae1c7ac-e7c7-4216-9394-37b3185ff875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0ae1c7ac-e7c7-4216-9394-37b3185ff875_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0ae1c7ac-e7c7-4216-9394-37b3185ff875" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0ae1c7ac-e7c7-4216-9394-37b3185ff875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_32c61a04-795d-4ae5-a3c3-0b7bbdd160af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0ae1c7ac-e7c7-4216-9394-37b3185ff875" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_32c61a04-795d-4ae5-a3c3-0b7bbdd160af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_98e86318-16d0-454e-9218-9cef9e77e53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_32c61a04-795d-4ae5-a3c3-0b7bbdd160af" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_98e86318-16d0-454e-9218-9cef9e77e53a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" xlink:type="extended" id="i7e0769e4c9c44bababbf280f47caa5f9_HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_03bebad0-8bf5-4f5b-8e73-7ef75a12c856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_03bebad0-8bf5-4f5b-8e73-7ef75a12c856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_20a4f33b-190e-461d-8068-b9f3d023f098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_20a4f33b-190e-461d-8068-b9f3d023f098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented_3ba44779-be53-4fbb-986b-5c1b58ca2350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented_3ba44779-be53-4fbb-986b-5c1b58ca2350" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_e69ef89e-1522-4dd5-8227-6c6d66251e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_e69ef89e-1522-4dd5-8227-6c6d66251e32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_5efbe32e-34d2-4bec-a79f-8975ec9c0a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_5efbe32e-34d2-4bec-a79f-8975ec9c0a46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3f734ccc-5969-42d1-8c79-a20b7d154ad6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_5efbe32e-34d2-4bec-a79f-8975ec9c0a46" xlink:to="loc_srt_ProductOrServiceAxis_3f734ccc-5969-42d1-8c79-a20b7d154ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f734ccc-5969-42d1-8c79-a20b7d154ad6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3f734ccc-5969-42d1-8c79-a20b7d154ad6" xlink:to="loc_srt_ProductsAndServicesDomain_3f734ccc-5969-42d1-8c79-a20b7d154ad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec80ed1d-3473-432c-9639-52b785acf461" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3f734ccc-5969-42d1-8c79-a20b7d154ad6" xlink:to="loc_srt_ProductsAndServicesDomain_ec80ed1d-3473-432c-9639-52b785acf461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthInsuranceProductLineMember_d9158c55-3a47-4ea9-9c73-3c1d1dbc728a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthInsuranceProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ec80ed1d-3473-432c-9639-52b785acf461" xlink:to="loc_us-gaap_HealthInsuranceProductLineMember_d9158c55-3a47-4ea9-9c73-3c1d1dbc728a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_24ee6e1d-44b9-415c-b8f7-1c0d251510ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_5efbe32e-34d2-4bec-a79f-8975ec9c0a46" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_24ee6e1d-44b9-415c-b8f7-1c0d251510ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_24ee6e1d-44b9-415c-b8f7-1c0d251510ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_24ee6e1d-44b9-415c-b8f7-1c0d251510ae" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_24ee6e1d-44b9-415c-b8f7-1c0d251510ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f37d04d8-84b6-4d2a-8cf3-7b23a2168dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_24ee6e1d-44b9-415c-b8f7-1c0d251510ae" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f37d04d8-84b6-4d2a-8cf3-7b23a2168dfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_46d33ee1-947b-4bd5-a64e-0c9fe67180c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f37d04d8-84b6-4d2a-8cf3-7b23a2168dfc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_46d33ee1-947b-4bd5-a64e-0c9fe67180c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_cd25cb6b-bff6-490b-a857-8720c1d7f404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f37d04d8-84b6-4d2a-8cf3-7b23a2168dfc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_cd25cb6b-bff6-490b-a857-8720c1d7f404" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails" xlink:type="extended" id="ie86f18ad2cd54e69b0a5061c11feffbd_HealthCareCostsPayableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_0bc7834b-be87-4077-a106-cec943f57d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_91132cd2-d12a-435c-9fa3-ebc2fa5081ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_0bc7834b-be87-4077-a106-cec943f57d80" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_91132cd2-d12a-435c-9fa3-ebc2fa5081ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_4313641d-9f7d-4b73-86d0-f2667bc2d529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_0bc7834b-be87-4077-a106-cec943f57d80" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_4313641d-9f7d-4b73-86d0-f2667bc2d529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_d72b0aef-00b8-428e-9f69-43980813fff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_0bc7834b-be87-4077-a106-cec943f57d80" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_d72b0aef-00b8-428e-9f69-43980813fff4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_aac4cd64-a834-4719-b405-27757ea43206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_d72b0aef-00b8-428e-9f69-43980813fff4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_aac4cd64-a834-4719-b405-27757ea43206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_aac4cd64-a834-4719-b405-27757ea43206_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_aac4cd64-a834-4719-b405-27757ea43206" xlink:to="loc_us-gaap_SegmentDomain_aac4cd64-a834-4719-b405-27757ea43206_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a39e35af-fcb8-4127-ba10-137613dbb555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_aac4cd64-a834-4719-b405-27757ea43206" xlink:to="loc_us-gaap_SegmentDomain_a39e35af-fcb8-4127-ba10-137613dbb555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_63b7f4df-0206-4284-89fe-1c57fdabd441" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a39e35af-fcb8-4127-ba10-137613dbb555" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_63b7f4df-0206-4284-89fe-1c57fdabd441" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" xlink:type="extended" id="i3ee8a36fcd7546c7a0844f815a2cd8c2_HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_529cd7e9-213d-480e-a591-13a6f133068f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_529cd7e9-213d-480e-a591-13a6f133068f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_912dd206-c59e-44b3-b2ab-b62927ebdd34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_912dd206-c59e-44b3-b2ab-b62927ebdd34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_d3cc8ba3-1c7e-4730-9011-a52d7fff42cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_d3cc8ba3-1c7e-4730-9011-a52d7fff42cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9f3cef7e-1f0a-48ce-ad2b-3f282dd6e8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9f3cef7e-1f0a-48ce-ad2b-3f282dd6e8bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_7402de5e-21f3-4067-bd84-f7dd9e9f644f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_7402de5e-21f3-4067-bd84-f7dd9e9f644f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1921d0b2-5948-433c-9ec6-2afb45b808a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_7402de5e-21f3-4067-bd84-f7dd9e9f644f" xlink:to="loc_srt_ProductOrServiceAxis_1921d0b2-5948-433c-9ec6-2afb45b808a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1921d0b2-5948-433c-9ec6-2afb45b808a5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1921d0b2-5948-433c-9ec6-2afb45b808a5" xlink:to="loc_srt_ProductsAndServicesDomain_1921d0b2-5948-433c-9ec6-2afb45b808a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_81fbffb3-a014-4754-8679-b421396675e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1921d0b2-5948-433c-9ec6-2afb45b808a5" xlink:to="loc_srt_ProductsAndServicesDomain_81fbffb3-a014-4754-8679-b421396675e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthInsuranceProductLineMember_94030e3d-464f-4844-849d-dfdd08060bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthInsuranceProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81fbffb3-a014-4754-8679-b421396675e5" xlink:to="loc_us-gaap_HealthInsuranceProductLineMember_94030e3d-464f-4844-849d-dfdd08060bdf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" xlink:type="extended" id="ieacb951250b743fda5218ffdc12196e0_HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b55a257c-8c23-4c6a-8b74-aefa195e2f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b55a257c-8c23-4c6a-8b74-aefa195e2f14" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5bd40fd8-007e-4733-84d4-e1c2d3d5af99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5bd40fd8-007e-4733-84d4-e1c2d3d5af99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ed272d35-30cc-48c0-8689-2b6faed67d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ed272d35-30cc-48c0-8689-2b6faed67d1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_b580fb57-c99f-47dc-a322-e665da572f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_b580fb57-c99f-47dc-a322-e665da572f3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_b8c0dd40-af3c-45b4-92f8-e1e63d88fd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_b8c0dd40-af3c-45b4-92f8-e1e63d88fd6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_a1eda030-4bcc-42c3-8ba5-5bedcc237e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_a1eda030-4bcc-42c3-8ba5-5bedcc237e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_2494e3a5-cf1f-41cf-bb72-206529f8e97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_2494e3a5-cf1f-41cf-bb72-206529f8e97c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6a790f4d-26e8-4ec5-a145-de8b3e95cdce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6a790f4d-26e8-4ec5-a145-de8b3e95cdce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c6dd50b2-9d68-43b1-b9f0-97468a231e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c6dd50b2-9d68-43b1-b9f0-97468a231e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_a9b587eb-bcb1-4629-b858-e9d01ef1e49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_a9b587eb-bcb1-4629-b858-e9d01ef1e49d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_416dfb94-30df-4c95-8be9-b5bdb6740499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_416dfb94-30df-4c95-8be9-b5bdb6740499" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumDeficiencyReserveLiability_35c4c784-6f6b-4cba-8866-75f3f429a064" xlink:href="cvs-20221231.xsd#cvs_PremiumDeficiencyReserveLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_cvs_PremiumDeficiencyReserveLiability_35c4c784-6f6b-4cba-8866-75f3f429a064" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_c79a0115-026a-4c82-8f66-0c6abb407f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_f1093fcb-31ec-4a73-ad34-db69e1b19a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9c7ea684-0868-43fd-9e2e-81ca50d3bc90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts_29f74caf-9f9e-4287-82b8-dba2d1405b8a" xlink:href="cvs-20221231.xsd#cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b55a257c-8c23-4c6a-8b74-aefa195e2f14" xlink:to="loc_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts_29f74caf-9f9e-4287-82b8-dba2d1405b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumDeficiencyReserveLiability_bd67d230-dc83-4b04-993a-8de4a7859dcd" xlink:href="cvs-20221231.xsd#cvs_PremiumDeficiencyReserveLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_65b9e467-9cc2-44bb-8e35-67b5a34da97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b55a257c-8c23-4c6a-8b74-aefa195e2f14" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_65b9e467-9cc2-44bb-8e35-67b5a34da97f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_560c84a1-f388-49f1-85c0-9a5e1f76d858" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_65b9e467-9cc2-44bb-8e35-67b5a34da97f" xlink:to="loc_srt_ProductOrServiceAxis_560c84a1-f388-49f1-85c0-9a5e1f76d858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_560c84a1-f388-49f1-85c0-9a5e1f76d858_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_560c84a1-f388-49f1-85c0-9a5e1f76d858" xlink:to="loc_srt_ProductsAndServicesDomain_560c84a1-f388-49f1-85c0-9a5e1f76d858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8d4ed2bc-4a67-4231-b697-dd25fbd9afcb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_560c84a1-f388-49f1-85c0-9a5e1f76d858" xlink:to="loc_srt_ProductsAndServicesDomain_8d4ed2bc-4a67-4231-b697-dd25fbd9afcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthInsuranceProductLineMember_a19f1327-1f3a-4108-be0c-a4e6a8b049b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthInsuranceProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8d4ed2bc-4a67-4231-b697-dd25fbd9afcb" xlink:to="loc_us-gaap_HealthInsuranceProductLineMember_a19f1327-1f3a-4108-be0c-a4e6a8b049b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cb2943fc-64aa-4598-b481-64c62384412e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_65b9e467-9cc2-44bb-8e35-67b5a34da97f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cb2943fc-64aa-4598-b481-64c62384412e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cb2943fc-64aa-4598-b481-64c62384412e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cb2943fc-64aa-4598-b481-64c62384412e" xlink:to="loc_us-gaap_SegmentDomain_cb2943fc-64aa-4598-b481-64c62384412e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e1f2712a-c826-4b50-b4cc-9a405b1985ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cb2943fc-64aa-4598-b481-64c62384412e" xlink:to="loc_us-gaap_SegmentDomain_e1f2712a-c826-4b50-b4cc-9a405b1985ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_3eb0ca61-cbc1-4688-8f32-888cc8b954e8" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e1f2712a-c826-4b50-b4cc-9a405b1985ec" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_3eb0ca61-cbc1-4688-8f32-888cc8b954e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateAndOtherMember_a0a773c0-f6a7-43ea-8184-d832a2a7128d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e1f2712a-c826-4b50-b4cc-9a405b1985ec" xlink:to="loc_us-gaap_CorporateAndOtherMember_a0a773c0-f6a7-43ea-8184-d832a2a7128d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" xlink:type="extended" id="idc1d8948880342268f3696b55d5d61c9_BorrowingsandCreditAgreementsScheduleofBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b9537118-06ff-42b5-a46c-b8bd032f479e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b9537118-06ff-42b5-a46c-b8bd032f479e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2e0911b0-9cb4-4ae4-a3d3-e6f5c342b566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2e0911b0-9cb4-4ae4-a3d3-e6f5c342b566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_38db9f0c-9aaf-4384-9f70-3c20adcbfde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_FinanceLeaseLiability_38db9f0c-9aaf-4384-9f70-3c20adcbfde2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongtermDebtGrossAndLeaseObligation_4900203e-b0d2-4059-a48a-55eb3ebec6ee" xlink:href="cvs-20221231.xsd#cvs_LongtermDebtGrossAndLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_cvs_LongtermDebtGrossAndLeaseObligation_4900203e-b0d2-4059-a48a-55eb3ebec6ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_b6edefa3-a87f-4db6-aff7-b6e6a7fea49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_b6edefa3-a87f-4db6-aff7-b6e6a7fea49c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet_78776f81-e884-4499-b3b8-755aff9fcc9e" xlink:href="cvs-20221231.xsd#cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet_78776f81-e884-4499-b3b8-755aff9fcc9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_29d4990b-84db-4e9a-992e-ced84e04b782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_29d4990b-84db-4e9a-992e-ced84e04b782" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_11152bf5-f532-45ad-9a2f-1349228fc804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_11152bf5-f532-45ad-9a2f-1349228fc804" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale_87b40039-0ed1-4592-b5a0-e3b49e9b8da3" xlink:href="cvs-20221231.xsd#cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale_87b40039-0ed1-4592-b5a0-e3b49e9b8da3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_3ec0eb5a-758f-408d-aed1-aec238f754b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_3ec0eb5a-758f-408d-aed1-aec238f754b4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f2c632b8-a22f-4557-896b-2b1e8092b6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f2c632b8-a22f-4557-896b-2b1e8092b6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f2c632b8-a22f-4557-896b-2b1e8092b6e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f2c632b8-a22f-4557-896b-2b1e8092b6e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f2c632b8-a22f-4557-896b-2b1e8092b6e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e2a1e746-63d1-4b22-8238-8bef6e9e6ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f2c632b8-a22f-4557-896b-2b1e8092b6e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e2a1e746-63d1-4b22-8238-8bef6e9e6ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_896323f4-1713-4f80-9047-e7e79f78f180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e2a1e746-63d1-4b22-8238-8bef6e9e6ee7" xlink:to="loc_us-gaap_SeniorNotesMember_896323f4-1713-4f80-9047-e7e79f78f180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_b87d4294-8593-4715-a0d0-0350ab05ceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e2a1e746-63d1-4b22-8238-8bef6e9e6ee7" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_b87d4294-8593-4715-a0d0-0350ab05ceb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_934c7e12-5efe-4d45-90ac-3835e008aaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:to="loc_us-gaap_DebtInstrumentAxis_934c7e12-5efe-4d45-90ac-3835e008aaaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_934c7e12-5efe-4d45-90ac-3835e008aaaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_934c7e12-5efe-4d45-90ac-3835e008aaaa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_934c7e12-5efe-4d45-90ac-3835e008aaaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_934c7e12-5efe-4d45-90ac-3835e008aaaa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.5DueJuly2022Member_e3c27ae4-deff-4c3b-a132-70d8efc4d6f0" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.5DueJuly2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.5DueJuly2022Member_e3c27ae4-deff-4c3b-a132-70d8efc4d6f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueNovember2022Member_2a5cd80e-8d19-4800-85e0-8a1b48fbc5ce" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.75DueNovember2022Member_2a5cd80e-8d19-4800-85e0-8a1b48fbc5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueDecember2022Member_55c1701f-9c1c-4a71-b8c5-0c65b6ca4aca" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueDecember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.75DueDecember2022Member_55c1701f-9c1c-4a71-b8c5-0c65b6ca4aca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.75DueDecember2022Member_c9fba5f3-dadf-4052-a90e-29731d842de3" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.75DueDecember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.75DueDecember2022Member_c9fba5f3-dadf-4052-a90e-29731d842de3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.8DueJune2023Member_52e16586-02dc-4803-b890-84f4da314072" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.8DueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.8DueJune2023Member_52e16586-02dc-4803-b890-84f4da314072" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4DueDecember2023Member_dc30f468-1131-4e2a-bb94-2834f89ca35c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4DueDecember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4DueDecember2023Member_dc30f468-1131-4e2a-bb94-2834f89ca35c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.375DueAugust2024Member_13fcba57-e8b3-48c7-a9cf-543c6219a509" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.375DueAugust2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.375DueAugust2024Member_13fcba57-e8b3-48c7-a9cf-543c6219a509" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.625DueAugust2024Member_70f3c454-32c0-4113-b788-dbedc9c03f76" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.625DueAugust2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.625DueAugust2024Member_70f3c454-32c0-4113-b788-dbedc9c03f76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.5DueNovember2024Member_4f58ea8f-8767-41ac-8a94-6506e2cd22dc" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.5DueNovember2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.5DueNovember2024Member_4f58ea8f-8767-41ac-8a94-6506e2cd22dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5DueDecember2024Member_68ea4e66-a178-46c7-9c90-59528622ba40" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5DueDecember2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5DueDecember2024Member_68ea4e66-a178-46c7-9c90-59528622ba40" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.1DueMarch2025Member_d9cb2ac8-ec8f-4893-9edb-327ca098b884" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.1DueMarch2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.1DueMarch2025Member_d9cb2ac8-ec8f-4893-9edb-327ca098b884" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.875DueJuly2025Member_b1524a9b-183f-4528-9b30-f6ae72196c0c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.875DueJuly2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.875DueJuly2025Member_b1524a9b-183f-4528-9b30-f6ae72196c0c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.875DueJune2026Member_8c5f4c0d-b3e0-4bde-b673-75d1a299414b" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.875DueJune2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.875DueJune2026Member_8c5f4c0d-b3e0-4bde-b673-75d1a299414b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3DueAugust2026Member_e3e50684-cdf0-4f85-9091-add62127da67" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3DueAugust2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3DueAugust2026Member_e3e50684-cdf0-4f85-9091-add62127da67" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point625PercentApril2027Member_d1b6dbb4-d70a-434c-b768-fa383d3943a9" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point625PercentApril2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3Point625PercentApril2027Member_d1b6dbb4-d70a-434c-b768-fa383d3943a9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.25DueJune2027Member_08b4aeb0-c3ce-4075-a1b0-38650143e5c7" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.25DueJune2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes6.25DueJune2027Member_08b4aeb0-c3ce-4075-a1b0-38650143e5c7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes1Point3PercentAugust2027Member_1f749660-0073-4a24-9edf-b3ced569f068" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes1Point3PercentAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes1Point3PercentAugust2027Member_1f749660-0073-4a24-9edf-b3ced569f068" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.3DueMarch2028Member_59697e77-8402-499a-a258-4b786fed6018" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.3DueMarch2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.3DueMarch2028Member_59697e77-8402-499a-a258-4b786fed6018" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.25DueAugust2029Member_5ed5ad4d-ce27-44b8-b3f2-1d3b410c6079" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.25DueAugust2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.25DueAugust2029Member_5ed5ad4d-ce27-44b8-b3f2-1d3b410c6079" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point75PercentApril2030Member_318bdbac-0159-412f-b4a5-f9625fcc142c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point75PercentApril2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3Point75PercentApril2030Member_318bdbac-0159-412f-b4a5-f9625fcc142c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes1Point75PercentAugust2030Member_ab2d277e-02b5-400e-ab17-845645bc4156" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes1Point75PercentAugust2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes1Point75PercentAugust2030Member_ab2d277e-02b5-400e-ab17-845645bc4156" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes1Point875PercentFebruary2031Member_da54d3ac-b463-41cb-bbed-e25d96b50f9a" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes1Point875PercentFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes1Point875PercentFebruary2031Member_da54d3ac-b463-41cb-bbed-e25d96b50f9a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_6ef46c65-9891-446e-a770-62a8a387b9fe" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2Point125PercentDueSeptember2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_6ef46c65-9891-446e-a770-62a8a387b9fe" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.875DueJuly2035Member_67538675-04fa-4a45-a996-dfb2a43cc30c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.875DueJuly2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.875DueJuly2035Member_67538675-04fa-4a45-a996-dfb2a43cc30c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.625DueJune2036Member_0bd5f1ed-3dac-4704-bc1a-74e8b5868b56" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.625DueJune2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes6.625DueJune2036Member_0bd5f1ed-3dac-4704-bc1a-74e8b5868b56" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.75DueDecember2037Member_fe0fb37d-9107-487c-b896-c7887639e7c4" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.75DueDecember2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes6.75DueDecember2037Member_fe0fb37d-9107-487c-b896-c7887639e7c4" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.78DueMarch2038Member_a0ff98dc-a5b6-44ee-aa37-4746dfca6a01" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.78DueMarch2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.78DueMarch2038Member_a0ff98dc-a5b6-44ee-aa37-4746dfca6a01" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.125DueSeptember2039Member_0dc7d538-2784-419b-aac7-cf3aa5cda3b3" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.125DueSeptember2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes6.125DueSeptember2039Member_0dc7d538-2784-419b-aac7-cf3aa5cda3b3" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point125PercentApril2040Member_f8ae97fc-8f7b-47f0-93f0-c2a9b44ba33b" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point125PercentApril2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4Point125PercentApril2040Member_f8ae97fc-8f7b-47f0-93f0-c2a9b44ba33b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2Point7PercentAugust2040Member_7bfa3b47-fcd2-467f-8e8d-a2effb884485" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2Point7PercentAugust2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2Point7PercentAugust2040Member_7bfa3b47-fcd2-467f-8e8d-a2effb884485" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.75DueMay2041Member_c1224add-08b3-4acd-8f4c-62925f256486" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.75DueMay2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5.75DueMay2041Member_c1224add-08b3-4acd-8f4c-62925f256486" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.5DueMay2042Member_66c5717f-40a4-404a-a0c4-8499745ab4e8" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.5DueMay2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.5DueMay2042Member_66c5717f-40a4-404a-a0c4-8499745ab4e8" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.125DueNovember2042Member_fad831a7-edc8-4c80-9b78-068d3aaeeef1" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.125DueNovember2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.125DueNovember2042Member_fad831a7-edc8-4c80-9b78-068d3aaeeef1" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.3DueDecember2043Member_ac1650ed-1434-42a7-bc1d-268961a341b2" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.3DueDecember2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5.3DueDecember2043Member_ac1650ed-1434-42a7-bc1d-268961a341b2" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.75DueMarch2044Member_af199760-ea93-4c58-a53e-8083952dc1a0" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.75DueMarch2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.75DueMarch2044Member_af199760-ea93-4c58-a53e-8083952dc1a0" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.125DueJuly2045Member_76883a87-e6e9-40fa-a218-222e6b36c1fb" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.125DueJuly2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5.125DueJuly2045Member_76883a87-e6e9-40fa-a218-222e6b36c1fb" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.875DueAugust2047Member_6e91eb7b-a612-4875-9d27-b11cd95728c6" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.875DueAugust2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.875DueAugust2047Member_6e91eb7b-a612-4875-9d27-b11cd95728c6" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.05DueMarch2048Member_d0218207-6890-478e-b536-dbf2ea006796" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.05DueMarch2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5.05DueMarch2048Member_d0218207-6890-478e-b536-dbf2ea006796" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point25PercentApril2050Member_dfd955e1-95a1-4189-8ec6-55dc9646280f" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point25PercentApril2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4Point25PercentApril2050Member_dfd955e1-95a1-4189-8ec6-55dc9646280f" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_175a5a2a-0539-428d-8207-d361c6cd60d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_175a5a2a-0539-428d-8207-d361c6cd60d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_175a5a2a-0539-428d-8207-d361c6cd60d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_175a5a2a-0539-428d-8207-d361c6cd60d2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_175a5a2a-0539-428d-8207-d361c6cd60d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3676b6bb-9068-4143-b0fe-48dba56315a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_175a5a2a-0539-428d-8207-d361c6cd60d2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3676b6bb-9068-4143-b0fe-48dba56315a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_18d99712-b265-429a-b7d2-d4941cbee3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3676b6bb-9068-4143-b0fe-48dba56315a4" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_18d99712-b265-429a-b7d2-d4941cbee3e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" xlink:type="extended" id="i21bef824d45c46fbbaad6089ae1453d3_BorrowingsandCreditAgreementsShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4b41e4c1-c660-4ee3-84c1-999c3714d534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_ShortTermBorrowings_4b41e4c1-c660-4ee3-84c1-999c3714d534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0c7e3d19-b8e1-4c6a-b856-aa6bf9999280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0c7e3d19-b8e1-4c6a-b856-aa6bf9999280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1b961a63-02fc-408a-9482-5dcb517e0a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_DebtInstrumentTerm_1b961a63-02fc-408a-9482-5dcb517e0a53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_39be464d-e9e6-455d-8be0-f1f581799672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_39be464d-e9e6-455d-8be0-f1f581799672" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable_31ddbbf1-ebf3-4259-b3a5-c9600d5c76aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable_31ddbbf1-ebf3-4259-b3a5-c9600d5c76aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_3073198e-aa95-40cb-9887-2dd911ad712a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_3073198e-aa95-40cb-9887-2dd911ad712a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_6098014d-636e-437f-9cae-918c93424ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3073198e-aa95-40cb-9887-2dd911ad712a" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_6098014d-636e-437f-9cae-918c93424ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6098014d-636e-437f-9cae-918c93424ae9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6098014d-636e-437f-9cae-918c93424ae9" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6098014d-636e-437f-9cae-918c93424ae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6098014d-636e-437f-9cae-918c93424ae9" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0c3b982d-5d67-4624-a33b-7aa98f32d869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:to="loc_us-gaap_CommercialPaperMember_0c3b982d-5d67-4624-a33b-7aa98f32d869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6e97c1a4-f100-4fbc-a1ba-4463fa049f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:to="loc_us-gaap_LineOfCreditMember_6e97c1a4-f100-4fbc-a1ba-4463fa049f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMember_4a9e9b01-03d7-46a4-83db-38edbce41a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMember_4a9e9b01-03d7-46a4-83db-38edbce41a8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a43b4adf-a942-4242-99de-33170e7103d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3073198e-aa95-40cb-9887-2dd911ad712a" xlink:to="loc_us-gaap_DebtInstrumentAxis_a43b4adf-a942-4242-99de-33170e7103d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a43b4adf-a942-4242-99de-33170e7103d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a43b4adf-a942-4242-99de-33170e7103d0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a43b4adf-a942-4242-99de-33170e7103d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ff0245d-4541-461a-bd42-348e59ea2caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a43b4adf-a942-4242-99de-33170e7103d0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ff0245d-4541-461a-bd42-348e59ea2caf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:href="cvs-20221231.xsd#cvs_BackUpCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ff0245d-4541-461a-bd42-348e59ea2caf" xlink:to="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RevolvingCreditFacilityExpiringMay162025Member_28849908-ec8c-45a1-aef4-c1fcad0d533d" xlink:href="cvs-20221231.xsd#cvs_RevolvingCreditFacilityExpiringMay162025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:to="loc_cvs_RevolvingCreditFacilityExpiringMay162025Member_28849908-ec8c-45a1-aef4-c1fcad0d533d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RevolvingCreditFacilityExpiringMay112026Member_5f033476-cada-40a2-9452-ce8d90706242" xlink:href="cvs-20221231.xsd#cvs_RevolvingCreditFacilityExpiringMay112026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:to="loc_cvs_RevolvingCreditFacilityExpiringMay112026Member_5f033476-cada-40a2-9452-ce8d90706242" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RevolvingCreditFacilityExpiringMay162027Member_c057e1ed-9326-424c-a612-9e8292524c74" xlink:href="cvs-20221231.xsd#cvs_RevolvingCreditFacilityExpiringMay162027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:to="loc_cvs_RevolvingCreditFacilityExpiringMay162027Member_c057e1ed-9326-424c-a612-9e8292524c74" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsLongtermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" xlink:type="extended" id="ifdf2d0fa957d4c8aab25da6ffb92f884_BorrowingsandCreditAgreementsLongtermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ff68466-d063-4174-aca6-f2684a0945a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ff68466-d063-4174-aca6-f2684a0945a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_91d2a162-0c2d-494d-821a-3887880670c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_91d2a162-0c2d-494d-821a-3887880670c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_323ff668-1c5d-4db2-a8dc-d2ecb973310a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_323ff668-1c5d-4db2-a8dc-d2ecb973310a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_25780077-572e-4ee6-995b-73b0e4cbd8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_25780077-572e-4ee6-995b-73b0e4cbd8f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_8f11e250-40cc-49f0-882a-c7ba6f178f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_8f11e250-40cc-49f0-882a-c7ba6f178f97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_eef2c50f-c5a7-40b5-a1a9-15beda8bfde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_eef2c50f-c5a7-40b5-a1a9-15beda8bfde1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_99dc2b2d-daf1-485c-8b1e-143ca8157174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_99dc2b2d-daf1-485c-8b1e-143ca8157174" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_f4e6c3f8-5ac1-497e-b80d-49f733324b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_f4e6c3f8-5ac1-497e-b80d-49f733324b46" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_c82acc94-0bf9-4f2b-a821-57a7688026dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_c82acc94-0bf9-4f2b-a821-57a7688026dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtExtinguishmentFees_e3b71a15-4ede-4b6e-8ee4-353983546414" xlink:href="cvs-20221231.xsd#cvs_DebtExtinguishmentFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_cvs_DebtExtinguishmentFees_e3b71a15-4ede-4b6e-8ee4-353983546414" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b92d072a-f979-4590-905c-b58fd675ede3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b92d072a-f979-4590-905c-b58fd675ede3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8b339c12-f72e-4e59-b2a4-d4b15a92982a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_DebtInstrumentTable_8b339c12-f72e-4e59-b2a4-d4b15a92982a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_69a6338d-b63a-4e13-b661-910291db4d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8b339c12-f72e-4e59-b2a4-d4b15a92982a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_69a6338d-b63a-4e13-b661-910291db4d58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69a6338d-b63a-4e13-b661-910291db4d58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_69a6338d-b63a-4e13-b661-910291db4d58" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69a6338d-b63a-4e13-b661-910291db4d58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6fed5115-cb52-4d00-95d5-392bf28e45ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_69a6338d-b63a-4e13-b661-910291db4d58" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6fed5115-cb52-4d00-95d5-392bf28e45ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a9e1ef81-2fd9-4d0e-a421-d6fbf00a2fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fed5115-cb52-4d00-95d5-392bf28e45ab" xlink:to="loc_us-gaap_SeniorNotesMember_a9e1ef81-2fd9-4d0e-a421-d6fbf00a2fba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3e533898-bf36-46e6-9cec-e0b576f3d2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8b339c12-f72e-4e59-b2a4-d4b15a92982a" xlink:to="loc_us-gaap_DebtInstrumentAxis_3e533898-bf36-46e6-9cec-e0b576f3d2c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3e533898-bf36-46e6-9cec-e0b576f3d2c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3e533898-bf36-46e6-9cec-e0b576f3d2c7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3e533898-bf36-46e6-9cec-e0b576f3d2c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3e533898-bf36-46e6-9cec-e0b576f3d2c7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.5DueJuly2022Member_f387e774-64be-45a1-812d-e748b066d294" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.5DueJuly2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3.5DueJuly2022Member_f387e774-64be-45a1-812d-e748b066d294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueNovember2022Member_2d601031-34c2-42e5-8fff-e18570b2efdb" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes2.75DueNovember2022Member_2d601031-34c2-42e5-8fff-e18570b2efdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueDecember2022Member_3ae26644-69cb-440e-bd0b-1f04efc1c417" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueDecember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes2.75DueDecember2022Member_3ae26644-69cb-440e-bd0b-1f04efc1c417" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.75DueDecember2022Member_0220eaec-33bc-4a0a-90e5-f0fd119eede7" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.75DueDecember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4.75DueDecember2022Member_0220eaec-33bc-4a0a-90e5-f0fd119eede7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_425f4209-607c-4ed4-b7ce-29e7694981af" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2Point125PercentDueSeptember2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_425f4209-607c-4ed4-b7ce-29e7694981af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point625PercentApril2027Member_0df67e12-8d1c-4115-b1c8-d38e4e4f7faf" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point625PercentApril2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3Point625PercentApril2027Member_0df67e12-8d1c-4115-b1c8-d38e4e4f7faf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point75PercentApril2030Member_12626a7c-26ad-4fa3-bbee-87a138e4039c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point75PercentApril2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3Point75PercentApril2030Member_12626a7c-26ad-4fa3-bbee-87a138e4039c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point125PercentApril2040Member_d9360006-527a-43b6-97ec-e219d39786c8" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point125PercentApril2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4Point125PercentApril2040Member_d9360006-527a-43b6-97ec-e219d39786c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point25PercentApril2050Member_2a1f0d66-4cdd-4950-84c7-9bbcd479228a" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point25PercentApril2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4Point25PercentApril2050Member_2a1f0d66-4cdd-4950-84c7-9bbcd479228a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point70PercentDue2023Member_056b1e04-7264-4f9c-bf94-bd7a88ab7812" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point70PercentDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3Point70PercentDue2023Member_056b1e04-7264-4f9c-bf94-bd7a88ab7812" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4PointThreePercentDue2028Member_62116cd4-34ec-4ba7-a4ad-4844caf7aa36" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4PointThreePercentDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4PointThreePercentDue2028Member_62116cd4-34ec-4ba7-a4ad-4844caf7aa36" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OutstandingSeniorNotesMember_c5f3b28c-3dd3-445b-ab82-a4290ed34170" xlink:href="cvs-20221231.xsd#cvs_OutstandingSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_OutstandingSeniorNotesMember_c5f3b28c-3dd3-445b-ab82-a4290ed34170" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4DueDecember2023Member_0bedaabe-d10c-4e37-991f-0d05e0d6f09a" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4DueDecember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4DueDecember2023Member_0bedaabe-d10c-4e37-991f-0d05e0d6f09a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.7DueMarch2023Member_f37aab17-35ca-4e4f-949d-acb259dfae4e" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.7DueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3.7DueMarch2023Member_f37aab17-35ca-4e4f-949d-acb259dfae4e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.1DueMarch2025Member_277ff36b-928c-43e6-a0b8-9edb8d194f3b" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.1DueMarch2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4.1DueMarch2025Member_277ff36b-928c-43e6-a0b8-9edb8d194f3b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes43Due2028Member_70c611da-ee8f-4865-8915-6b229a545d55" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes43Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes43Due2028Member_70c611da-ee8f-4865-8915-6b229a545d55" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" xlink:type="extended" id="if5b6658cc68347e59bd9baebe3b41209_PensionPlansandOtherPostretirementBenefitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_70a1ee15-f8a3-4378-b8ff-1754038b6dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_70a1ee15-f8a3-4378-b8ff-1754038b6dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_ce65fe06-f017-434b-af19-b1f5ba0b1036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_ce65fe06-f017-434b-af19-b1f5ba0b1036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_3d3d54e7-9fc0-4a3b-b762-60658fd123b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_3d3d54e7-9fc0-4a3b-b762-60658fd123b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution_a05a7303-922f-4bbf-878b-bdb5f4fb38d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MultiemployerPlanPensionInsignificantPlanContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution_a05a7303-922f-4bbf-878b-bdb5f4fb38d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_178147a3-5d4e-4088-ae0a-ef133d8c6678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_178147a3-5d4e-4088-ae0a-ef133d8c6678" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_616cdbf9-a11d-4a82-bbe6-731ee31d5ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_616cdbf9-a11d-4a82-bbe6-731ee31d5ff2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca17d525-fd8b-44f3-9937-345f4e3dc205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca17d525-fd8b-44f3-9937-345f4e3dc205" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7b269835-505f-4ff1-8412-02f9aeca6387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca17d525-fd8b-44f3-9937-345f4e3dc205" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7b269835-505f-4ff1-8412-02f9aeca6387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7b269835-505f-4ff1-8412-02f9aeca6387_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7b269835-505f-4ff1-8412-02f9aeca6387" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7b269835-505f-4ff1-8412-02f9aeca6387_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_16947266-c468-4f30-971b-ac3cc4f135e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7b269835-505f-4ff1-8412-02f9aeca6387" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_16947266-c468-4f30-971b-ac3cc4f135e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f191fee1-886d-4997-b815-cee20a8ac4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_16947266-c468-4f30-971b-ac3cc4f135e8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f191fee1-886d-4997-b815-cee20a8ac4ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4a761546-72f4-4367-ab0b-95b446f8c525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_16947266-c468-4f30-971b-ac3cc4f135e8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4a761546-72f4-4367-ab0b-95b446f8c525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f0064785-1dfe-46f0-b3b2-4d0c80e40334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca17d525-fd8b-44f3-9937-345f4e3dc205" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f0064785-1dfe-46f0-b3b2-4d0c80e40334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f0064785-1dfe-46f0-b3b2-4d0c80e40334_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f0064785-1dfe-46f0-b3b2-4d0c80e40334" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f0064785-1dfe-46f0-b3b2-4d0c80e40334_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f0064785-1dfe-46f0-b3b2-4d0c80e40334" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_73ad60b5-cf16-4ed3-91f1-1ef857dc7ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_EquitySecuritiesMember_73ad60b5-cf16-4ed3-91f1-1ef857dc7ca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_c2f19aee-62db-4fb3-ac70-bdef281ca360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_DebtSecuritiesMember_c2f19aee-62db-4fb3-ac70-bdef281ca360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateInvestmentMember_bdf39e4c-20da-42a4-873c-301cb10778c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstateInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_RealEstateInvestmentMember_bdf39e4c-20da-42a4-873c-301cb10778c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_6fd40296-ea17-429c-aa20-3271fd363f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_PrivateEquityFundsMember_6fd40296-ea17-429c-aa20-3271fd363f3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_cb2d7f52-728a-45d2-a1fe-68c2e84ab6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_HedgeFundsMember_cb2d7f52-728a-45d2-a1fe-68c2e84ab6ce" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" xlink:type="extended" id="ie176fff89e0e4a9c8bdc0d6d677043cc_PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5c9389d3-e0a4-46fe-9678-615c393dc298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5c9389d3-e0a4-46fe-9678-615c393dc298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_8ce2f2d9-0ceb-4700-9f2e-dc20902e7f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_8ce2f2d9-0ceb-4700-9f2e-dc20902e7f5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_012a31d7-e385-4b4a-b1ea-52046bb48a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_012a31d7-e385-4b4a-b1ea-52046bb48a39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7864a04a-6afc-4969-b54a-0d34fa1b9fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7864a04a-6afc-4969-b54a-0d34fa1b9fc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_7dc68e24-04f9-4f3f-8fcb-2c114b79eacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_7dc68e24-04f9-4f3f-8fcb-2c114b79eacb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_e8fd8606-0e8e-4f2c-838a-f8d1c67ede12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_565acfe1-4495-4040-a3d9-133dcec1d60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_565acfe1-4495-4040-a3d9-133dcec1d60b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_58404d8a-1705-488b-81a4-954be340bad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_58404d8a-1705-488b-81a4-954be340bad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6a23ea43-d2f7-4330-81fb-d6944b533386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6a23ea43-d2f7-4330-81fb-d6944b533386" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_f70369db-20f7-4881-9a9e-450df2d88a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_f70369db-20f7-4881-9a9e-450df2d88a6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_7d6107ed-f319-473d-b1b2-ef942a11eeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_7d6107ed-f319-473d-b1b2-ef942a11eeb6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_6520263b-3a65-4c4e-b311-40454ca14988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_73e564cb-f5be-4036-b04b-a6198398cc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_73e564cb-f5be-4036-b04b-a6198398cc7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_067be5df-ceba-495b-8056-345639ce4a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_067be5df-ceba-495b-8056-345639ce4a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0b4599e6-57f6-430d-94fd-70acf0ef1b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0b4599e6-57f6-430d-94fd-70acf0ef1b22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_9c9a49cf-4869-456c-9b9f-59b35b2dad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_9c9a49cf-4869-456c-9b9f-59b35b2dad5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a7405dde-2a17-47a0-a53c-1872e09dbc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a7405dde-2a17-47a0-a53c-1872e09dbc64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d4964132-1135-4cea-82d4-3d8517c357d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d4964132-1135-4cea-82d4-3d8517c357d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3548131f-0117-4ea7-ba8b-e17c3dc59302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d4964132-1135-4cea-82d4-3d8517c357d0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3548131f-0117-4ea7-ba8b-e17c3dc59302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3548131f-0117-4ea7-ba8b-e17c3dc59302_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3548131f-0117-4ea7-ba8b-e17c3dc59302" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3548131f-0117-4ea7-ba8b-e17c3dc59302_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_33dd804e-b72d-4c01-bbe6-d3be49e051e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3548131f-0117-4ea7-ba8b-e17c3dc59302" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_33dd804e-b72d-4c01-bbe6-d3be49e051e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3ceb5887-e7d3-4417-8879-f115f4599258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_33dd804e-b72d-4c01-bbe6-d3be49e051e5" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3ceb5887-e7d3-4417-8879-f115f4599258" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" xlink:type="extended" id="ib580a072f1a74d29ac6c5bf777ee173f_PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b450c83-ec4d-43a6-9fc6-e11d710bdd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b450c83-ec4d-43a6-9fc6-e11d710bdd1c" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_59f23e23-64f0-4c7f-bb35-a6f30ee5a452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_59f23e23-64f0-4c7f-bb35-a6f30ee5a452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ce4d8194-7cef-4556-bc93-234c9e070280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ce4d8194-7cef-4556-bc93-234c9e070280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f8cd8867-5c80-4706-907d-7019a4943dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f8cd8867-5c80-4706-907d-7019a4943dea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_145b638b-db31-415b-867b-77c5da869c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_145b638b-db31-415b-867b-77c5da869c49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8dc35475-33a8-4a06-8b1f-4a1cf3dd218d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8dc35475-33a8-4a06-8b1f-4a1cf3dd218d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58430494-45b7-45fe-b955-83680ef1e1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b450c83-ec4d-43a6-9fc6-e11d710bdd1c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58430494-45b7-45fe-b955-83680ef1e1f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_acfb8e61-3a2f-492d-8288-20e3bb12759a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58430494-45b7-45fe-b955-83680ef1e1f3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_acfb8e61-3a2f-492d-8288-20e3bb12759a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_acfb8e61-3a2f-492d-8288-20e3bb12759a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_acfb8e61-3a2f-492d-8288-20e3bb12759a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_acfb8e61-3a2f-492d-8288-20e3bb12759a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_647c63dc-86fa-4778-9357-98fa2ae99104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_acfb8e61-3a2f-492d-8288-20e3bb12759a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_647c63dc-86fa-4778-9357-98fa2ae99104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7703ef52-db20-4220-afd4-ef687b7c5747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_647c63dc-86fa-4778-9357-98fa2ae99104" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7703ef52-db20-4220-afd4-ef687b7c5747" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" xlink:type="extended" id="i8fa70cdc103a4d889be2697a8e61df57_PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_af85920c-814f-4516-85aa-3ddc75bdf684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1263228c-468e-4737-874f-16c0a4b9f12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_af85920c-814f-4516-85aa-3ddc75bdf684" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1263228c-468e-4737-874f-16c0a4b9f12c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_5b784d85-3c9d-4948-ab95-c4a3c7e9807a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_af85920c-814f-4516-85aa-3ddc75bdf684" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_5b784d85-3c9d-4948-ab95-c4a3c7e9807a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_af85920c-814f-4516-85aa-3ddc75bdf684" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_09d7807a-2532-4293-828e-fb72fca52c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_09d7807a-2532-4293-828e-fb72fca52c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_09d7807a-2532-4293-828e-fb72fca52c40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_09d7807a-2532-4293-828e-fb72fca52c40" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_09d7807a-2532-4293-828e-fb72fca52c40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8548764a-1ce7-4eb1-ad83-811fb89d89c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_09d7807a-2532-4293-828e-fb72fca52c40" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8548764a-1ce7-4eb1-ad83-811fb89d89c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_79b31135-ee8a-4b66-ba31-72ff7ee2f5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8548764a-1ce7-4eb1-ad83-811fb89d89c6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_79b31135-ee8a-4b66-ba31-72ff7ee2f5c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2dd8ed8d-7dcc-4017-825e-68d1829dd548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2dd8ed8d-7dcc-4017-825e-68d1829dd548" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_2dd8ed8d-7dcc-4017-825e-68d1829dd548_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2dd8ed8d-7dcc-4017-825e-68d1829dd548" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_2dd8ed8d-7dcc-4017-825e-68d1829dd548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2dd8ed8d-7dcc-4017-825e-68d1829dd548" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_0bb10ee4-f7d5-4ebc-a610-3a32655d6dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_0bb10ee4-f7d5-4ebc-a610-3a32655d6dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_c9c7f661-d5e9-41bc-8b58-8a1a003be4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_c9c7f661-d5e9-41bc-8b58-8a1a003be4a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_f76754f5-db98-4e78-a333-530e79f35dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_f76754f5-db98-4e78-a333-530e79f35dc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_bdf6c8ca-b102-411b-9bd6-73df855fdf86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_bdf6c8ca-b102-411b-9bd6-73df855fdf86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_02130056-893b-4719-b504-9273e0592614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_02130056-893b-4719-b504-9273e0592614" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_0e7ba3ed-3a29-488c-858c-eb901dec17e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_0e7ba3ed-3a29-488c-858c-eb901dec17e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_243a36a8-2907-49b5-b117-5f5c0dfc0ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_243a36a8-2907-49b5-b117-5f5c0dfc0ad0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9a00abd1-381e-42ff-997d-85167e8d2640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9a00abd1-381e-42ff-997d-85167e8d2640" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RedeemablePreferredSecuritiesMember_f2632931-9f46-4ff3-b427-b284135fa9b7" xlink:href="cvs-20221231.xsd#cvs_RedeemablePreferredSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_cvs_RedeemablePreferredSecuritiesMember_f2632931-9f46-4ff3-b427-b284135fa9b7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_32746672-f885-424e-88a8-2ae932efdaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_32746672-f885-424e-88a8-2ae932efdaaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_971cf8c2-dc76-4453-957c-7095b3d8013d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_971cf8c2-dc76-4453-957c-7095b3d8013d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EquitySecuritiesDomesticRealEstateMember_8eea517a-c912-4be2-8f60-30e3d35dc472" xlink:href="cvs-20221231.xsd#cvs_EquitySecuritiesDomesticRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:to="loc_cvs_EquitySecuritiesDomesticRealEstateMember_8eea517a-c912-4be2-8f60-30e3d35dc472" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_ccbc1662-1750-4e10-ad10-f5a2c6071a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_OtherInvestmentsMember_ccbc1662-1750-4e10-ad10-f5a2c6071a0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_d0013d15-f643-4c8d-a0d2-6fda1023272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentsMember_ccbc1662-1750-4e10-ad10-f5a2c6071a0d" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_d0013d15-f643-4c8d-a0d2-6fda1023272b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember_cdefde54-2134-445e-8503-07075c17eeff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentsMember_ccbc1662-1750-4e10-ad10-f5a2c6071a0d" xlink:to="loc_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember_cdefde54-2134-445e-8503-07075c17eeff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember_e58c7bda-7d43-4101-b2d2-9e67895f32ae" xlink:href="cvs-20221231.xsd#cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember_e58c7bda-7d43-4101-b2d2-9e67895f32ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember_693f6362-e316-4c07-bb92-7f00a65eae9b" xlink:href="cvs-20221231.xsd#cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember_693f6362-e316-4c07-bb92-7f00a65eae9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_70692f0e-1ae0-4fe6-87e7-58f8e94d3f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_AccountsReceivableMember_70692f0e-1ae0-4fe6-87e7-58f8e94d3f1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_e3cc271f-fb0b-434d-9fc7-30936ecd09d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_PrivateEquityFundsMember_e3cc271f-fb0b-434d-9fc7-30936ecd09d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_5e9e0124-2831-47f0-b267-881e06c3b794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_HedgeFundsMember_5e9e0124-2831-47f0-b267-881e06c3b794" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88309e2d-b06d-409f-815c-89d7c53e4360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88309e2d-b06d-409f-815c-89d7c53e4360" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88309e2d-b06d-409f-815c-89d7c53e4360_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88309e2d-b06d-409f-815c-89d7c53e4360" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88309e2d-b06d-409f-815c-89d7c53e4360_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de313573-0ccf-43a5-9339-a7b02107bc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88309e2d-b06d-409f-815c-89d7c53e4360" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de313573-0ccf-43a5-9339-a7b02107bc3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de313573-0ccf-43a5-9339-a7b02107bc3a" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_33bb5698-efff-4d7f-baf7-d5e3bbb9bdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_33bb5698-efff-4d7f-baf7-d5e3bbb9bdd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_19abc357-194d-42ed-950a-b3c54f7f7352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_19abc357-194d-42ed-950a-b3c54f7f7352" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2cc60adb-39b7-4577-841b-1c0d28eadbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2cc60adb-39b7-4577-841b-1c0d28eadbe1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_a2e4d771-85c4-43fa-9989-6b051d82653e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de313573-0ccf-43a5-9339-a7b02107bc3a" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_a2e4d771-85c4-43fa-9989-6b051d82653e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" xlink:type="extended" id="ie77f2c1dab984bf2953e3923cb835fd4_PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0dc412de-515e-4286-a0d7-457dd0f69c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0dc412de-515e-4286-a0d7-457dd0f69c4b" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7c331a75-c76f-4c41-935d-9da342ecb8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7c331a75-c76f-4c41-935d-9da342ecb8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_ef83f7d5-b9f9-498e-8657-e41eed7da0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_ef83f7d5-b9f9-498e-8657-e41eed7da0b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_db515281-b9f9-484f-8036-2819f8d4f0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_db515281-b9f9-484f-8036-2819f8d4f0b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_347d08fd-ce4b-4122-a1b9-723eb4c06e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_347d08fd-ce4b-4122-a1b9-723eb4c06e68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_decde615-6489-4a4f-bef4-4c13f628200e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0dc412de-515e-4286-a0d7-457dd0f69c4b" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_cc1ded0a-ea60-46cb-b34e-be07d6be4b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_cc1ded0a-ea60-46cb-b34e-be07d6be4b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_cc1ded0a-ea60-46cb-b34e-be07d6be4b5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_cc1ded0a-ea60-46cb-b34e-be07d6be4b5e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_cc1ded0a-ea60-46cb-b34e-be07d6be4b5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_2a04747e-ae56-4d4a-bfa3-7213bf5467f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_cc1ded0a-ea60-46cb-b34e-be07d6be4b5e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_2a04747e-ae56-4d4a-bfa3-7213bf5467f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_d75a0f05-b81e-42b7-8275-0ccf074bf1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_2a04747e-ae56-4d4a-bfa3-7213bf5467f7" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_d75a0f05-b81e-42b7-8275-0ccf074bf1f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1519cd05-9384-4426-af59-173bd5970f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1519cd05-9384-4426-af59-173bd5970f18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1519cd05-9384-4426-af59-173bd5970f18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1519cd05-9384-4426-af59-173bd5970f18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1519cd05-9384-4426-af59-173bd5970f18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aad29a72-17e8-4165-9d51-4c5e5491bf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1519cd05-9384-4426-af59-173bd5970f18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aad29a72-17e8-4165-9d51-4c5e5491bf9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0329fb80-37e9-4c2f-9b09-edeb21e9ea46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aad29a72-17e8-4165-9d51-4c5e5491bf9f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0329fb80-37e9-4c2f-9b09-edeb21e9ea46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_56a1896b-9fec-4118-9820-c50903065af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_56a1896b-9fec-4118-9820-c50903065af3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_56a1896b-9fec-4118-9820-c50903065af3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_56a1896b-9fec-4118-9820-c50903065af3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_56a1896b-9fec-4118-9820-c50903065af3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_54e1f248-3806-44cd-8434-a7ac009eb64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_56a1896b-9fec-4118-9820-c50903065af3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_54e1f248-3806-44cd-8434-a7ac009eb64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7678a176-9870-4701-9f95-3dfd99136199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_54e1f248-3806-44cd-8434-a7ac009eb64f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7678a176-9870-4701-9f95-3dfd99136199" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" xlink:type="extended" id="i54aa760970d041dcb04e119c2d078792_PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_4232cd7d-88e1-4a3a-845a-3c813ffd158f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_4232cd7d-88e1-4a3a-845a-3c813ffd158f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_42e51f1d-421f-409b-8c61-feb5d28e9629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_42e51f1d-421f-409b-8c61-feb5d28e9629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_6fdae6a0-cb2e-4182-b8f1-546610e05069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_6fdae6a0-cb2e-4182-b8f1-546610e05069" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_814e0081-d1b9-4ca3-b01f-f4c679ffece3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_814e0081-d1b9-4ca3-b01f-f4c679ffece3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_7452f379-3ac3-43c3-ad30-b51f1eb2e799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_7452f379-3ac3-43c3-ad30-b51f1eb2e799" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d69a9ad1-5e96-4151-93aa-8cbaf87699cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d69a9ad1-5e96-4151-93aa-8cbaf87699cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7482b323-f9f4-4b77-a4c4-c55b5c511aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7482b323-f9f4-4b77-a4c4-c55b5c511aee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2c3cbd4c-cad8-4e68-80a8-f09bbd0b0a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7482b323-f9f4-4b77-a4c4-c55b5c511aee" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2c3cbd4c-cad8-4e68-80a8-f09bbd0b0a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2c3cbd4c-cad8-4e68-80a8-f09bbd0b0a24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2c3cbd4c-cad8-4e68-80a8-f09bbd0b0a24" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2c3cbd4c-cad8-4e68-80a8-f09bbd0b0a24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4d803ebc-e368-40bd-bec9-a3842e1b7b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2c3cbd4c-cad8-4e68-80a8-f09bbd0b0a24" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4d803ebc-e368-40bd-bec9-a3842e1b7b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_98e5d542-d970-4f3e-9dc3-e64e54a94cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4d803ebc-e368-40bd-bec9-a3842e1b7b1f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_98e5d542-d970-4f3e-9dc3-e64e54a94cb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_aaf698f2-5679-43e0-9af6-cf55385d7de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4d803ebc-e368-40bd-bec9-a3842e1b7b1f" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_aaf698f2-5679-43e0-9af6-cf55385d7de1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="iaf458e595c7b4895bc201a23569c5d35_IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1c5afea7-cd23-4364-a48a-163efe50806e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1c5afea7-cd23-4364-a48a-163efe50806e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_b5a8af75-d419-415a-83dd-1fe8e1b45727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_b5a8af75-d419-415a-83dd-1fe8e1b45727" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1eeb780e-5232-4af3-baf2-e767d297b36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1eeb780e-5232-4af3-baf2-e767d297b36f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_4fa04b24-ed6b-4abf-a7a8-ad76ceb39aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_4fa04b24-ed6b-4abf-a7a8-ad76ceb39aad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances_3f96f93a-78aa-44e5-96cc-8e51a9a11694" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances_3f96f93a-78aa-44e5-96cc-8e51a9a11694" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5f25b901-5961-40ed-9645-5d7aaacb97a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5f25b901-5961-40ed-9645-5d7aaacb97a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_94f1a04b-fff8-49be-a910-eee761c926ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_94f1a04b-fff8-49be-a910-eee761c926ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_5b34d959-5277-478d-806c-c17771c74031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_5b34d959-5277-478d-806c-c17771c74031" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_be671905-1a87-4bfe-a986-00c6c277cc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_be671905-1a87-4bfe-a986-00c6c277cc46" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxAssetsPayrollTaxDeferral_2965fde3-da9c-42bb-8d02-337df011e789" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxAssetsPayrollTaxDeferral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_cvs_DeferredTaxAssetsPayrollTaxDeferral_2965fde3-da9c-42bb-8d02-337df011e789" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bdca91f0-5d71-4402-9294-42c2dc61b8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bdca91f0-5d71-4402-9294-42c2dc61b8ac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7d8b8735-baac-430f-8de7-9230b63a1208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7d8b8735-baac-430f-8de7-9230b63a1208" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7190fe64-3409-42a2-80f4-d9c6cb15e964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7190fe64-3409-42a2-80f4-d9c6cb15e964" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxLiabilitiesRetirementBenefits_ccc907f3-1b40-4f8c-9b10-c6be752456f5" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxLiabilitiesRetirementBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:to="loc_cvs_DeferredTaxLiabilitiesRetirementBenefits_ccc907f3-1b40-4f8c-9b10-c6be752456f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_1b268cb0-0bef-420e-9a5c-667b22b47a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_1b268cb0-0bef-420e-9a5c-667b22b47a37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0d8511d9-57f7-4c2e-becd-0817f6a5e14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0d8511d9-57f7-4c2e-becd-0817f6a5e14e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization_f23756f5-2c38-44d8-9873-be078833a99f" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:to="loc_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization_f23756f5-2c38-44d8-9873-be078833a99f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_79dc8c96-22bc-489d-a92f-3ad409f8633a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_79dc8c96-22bc-489d-a92f-3ad409f8633a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0f28a70b-0294-4381-8e0d-77e05ad55ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:to="loc_us-gaap_DeferredTaxLiabilities_0f28a70b-0294-4381-8e0d-77e05ad55ccd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_05071c62-f8c1-4cb4-9fb3-544e0482e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:to="loc_us-gaap_ValuationAllowanceTable_05071c62-f8c1-4cb4-9fb3-544e0482e58f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_afa9476c-be56-4aec-8b94-784474892b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_05071c62-f8c1-4cb4-9fb3-544e0482e58f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_afa9476c-be56-4aec-8b94-784474892b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_afa9476c-be56-4aec-8b94-784474892b52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_afa9476c-be56-4aec-8b94-784474892b52" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_afa9476c-be56-4aec-8b94-784474892b52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1754584e-0386-4cfd-a9d5-f9a584a08f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_afa9476c-be56-4aec-8b94-784474892b52" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1754584e-0386-4cfd-a9d5-f9a584a08f59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_43bfe497-1d50-4344-b6cc-b705aa311c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1754584e-0386-4cfd-a9d5-f9a584a08f59" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_43bfe497-1d50-4344-b6cc-b705aa311c40" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" xlink:type="extended" id="i9b491e13146c4273ae6d02006fef47b6_StockIncentivePlansStockBasedCompensationExpenseandESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bd8b672-2bb6-47ef-a9ed-dd81334c82b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bd8b672-2bb6-47ef-a9ed-dd81334c82b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e5bcc90-f232-428a-bc84-1517858e75c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e5bcc90-f232-428a-bc84-1517858e75c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8dc3b90b-7eab-43b1-b188-681bc9d22131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8dc3b90b-7eab-43b1-b188-681bc9d22131" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a09d413a-193a-4d21-815e-c2e73c9343ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a09d413a-193a-4d21-815e-c2e73c9343ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_118c1108-4386-458c-a796-c8af256e0906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_118c1108-4386-458c-a796-c8af256e0906" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_06418cb0-bbce-423b-8356-6b3a55a2e072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_06418cb0-bbce-423b-8356-6b3a55a2e072" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99582f9f-f673-43ea-bb9a-ccf9d6644294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99582f9f-f673-43ea-bb9a-ccf9d6644294" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_790dc8f5-699a-42ed-9a1c-2919eedc10c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_790dc8f5-699a-42ed-9a1c-2919eedc10c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f5da8bdc-9b02-4def-ac18-75d98bc3ca24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f5da8bdc-9b02-4def-ac18-75d98bc3ca24" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_69ee6264-895d-42c7-b076-cb7ee3d4b407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_69ee6264-895d-42c7-b076-cb7ee3d4b407" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_7ef596c9-327b-4ccd-81ba-f0abe0638dce" xlink:href="cvs-20221231.xsd#cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_7ef596c9-327b-4ccd-81ba-f0abe0638dce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_baab8b7f-eb4c-4835-91dd-9213dead6633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_baab8b7f-eb4c-4835-91dd-9213dead6633" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ce2dc1da-38c2-463e-b0ce-ec1da1966eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ce2dc1da-38c2-463e-b0ce-ec1da1966eda" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased_3886ca5d-7db2-4d81-97d5-79a64a09252a" xlink:href="cvs-20221231.xsd#cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased_3886ca5d-7db2-4d81-97d5-79a64a09252a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bb8d57a0-75c3-4fe0-99d9-e460172ef1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:to="loc_us-gaap_PlanNameAxis_bb8d57a0-75c3-4fe0-99d9-e460172ef1f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bb8d57a0-75c3-4fe0-99d9-e460172ef1f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bb8d57a0-75c3-4fe0-99d9-e460172ef1f1" xlink:to="loc_us-gaap_PlanNameDomain_bb8d57a0-75c3-4fe0-99d9-e460172ef1f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b14a1219-1024-4340-b536-22208d4e8dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bb8d57a0-75c3-4fe0-99d9-e460172ef1f1" xlink:to="loc_us-gaap_PlanNameDomain_b14a1219-1024-4340-b536-22208d4e8dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CVSHealth2017IncentiveCompensationPlanMember_72cfce9e-b30b-48ef-ac76-3417e08057a6" xlink:href="cvs-20221231.xsd#cvs_CVSHealth2017IncentiveCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b14a1219-1024-4340-b536-22208d4e8dab" xlink:to="loc_cvs_CVSHealth2017IncentiveCompensationPlanMember_72cfce9e-b30b-48ef-ac76-3417e08057a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AetnaInc2010StockIncentivePlanMember_0ad2fc90-4296-4656-b743-fb09e1fdbe1e" xlink:href="cvs-20221231.xsd#cvs_AetnaInc2010StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b14a1219-1024-4340-b536-22208d4e8dab" xlink:to="loc_cvs_AetnaInc2010StockIncentivePlanMember_0ad2fc90-4296-4656-b743-fb09e1fdbe1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5045216f-6c71-4566-9541-8db627357a04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:to="loc_srt_RangeAxis_5045216f-6c71-4566-9541-8db627357a04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5045216f-6c71-4566-9541-8db627357a04_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5045216f-6c71-4566-9541-8db627357a04" xlink:to="loc_srt_RangeMember_5045216f-6c71-4566-9541-8db627357a04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d06c778e-edc6-4c5b-86d2-dbd1462e020e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5045216f-6c71-4566-9541-8db627357a04" xlink:to="loc_srt_RangeMember_d06c778e-edc6-4c5b-86d2-dbd1462e020e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f50fa0ca-022d-42b6-874e-f5d216ee69c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d06c778e-edc6-4c5b-86d2-dbd1462e020e" xlink:to="loc_srt_MinimumMember_f50fa0ca-022d-42b6-874e-f5d216ee69c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2392e4b-3994-4b97-b174-6949ebfd41a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d06c778e-edc6-4c5b-86d2-dbd1462e020e" xlink:to="loc_srt_MaximumMember_f2392e4b-3994-4b97-b174-6949ebfd41a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c02f23e-7d2a-4358-a25e-1f12db39f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:to="loc_us-gaap_AwardTypeAxis_5c02f23e-7d2a-4358-a25e-1f12db39f80d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c02f23e-7d2a-4358-a25e-1f12db39f80d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5c02f23e-7d2a-4358-a25e-1f12db39f80d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c02f23e-7d2a-4358-a25e-1f12db39f80d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5c02f23e-7d2a-4358-a25e-1f12db39f80d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_bfb69f37-0e91-4837-b646-a55456932040" xlink:href="cvs-20221231.xsd#cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_bfb69f37-0e91-4837-b646-a55456932040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_b0a2b94a-c686-447b-b3d5-79be98d0fa16" xlink:href="cvs-20221231.xsd#cvs_EmployeeStockOptionsAndStockAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_b0a2b94a-c686-447b-b3d5-79be98d0fa16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6c0ba56c-c97e-45da-823f-022d3eb0005c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_us-gaap_EmployeeStockMember_6c0ba56c-c97e-45da-823f-022d3eb0005c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_45fc5c55-76d0-4d5d-987d-0feafed02f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_45fc5c55-76d0-4d5d-987d-0feafed02f59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_254b803f-d58c-4b39-823b-e0e4cf242bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_254b803f-d58c-4b39-823b-e0e4cf242bb9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlansRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" xlink:type="extended" id="i037eedd51d4740cc8f30596ca8045933_StockIncentivePlansRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f3c4daf3-b9e5-4c4b-a677-73bcb5e7177d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f3c4daf3-b9e5-4c4b-a677-73bcb5e7177d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_35538de5-eae5-4f78-bd20-baf9b24d59cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_35538de5-eae5-4f78-bd20-baf9b24d59cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_010ff23c-6ac2-4dae-9a4a-69c9a6d0aed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_010ff23c-6ac2-4dae-9a4a-69c9a6d0aed0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_359bde91-6b32-41d6-9caa-28294add139e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_359bde91-6b32-41d6-9caa-28294add139e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e286b8be-462b-4cf8-908d-388340207a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc3aa443-0ace-465a-8be0-ac7fa9b67424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc3aa443-0ace-465a-8be0-ac7fa9b67424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c30a238a-a864-4380-a342-b80d7e6f206a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c30a238a-a864-4380-a342-b80d7e6f206a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_faa76300-169a-4285-9fe1-32863ff65629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_faa76300-169a-4285-9fe1-32863ff65629" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3c1244f3-d820-4adb-82f9-cee8035e2d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3c1244f3-d820-4adb-82f9-cee8035e2d0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a44b9bd7-c3bd-4bde-82b0-c8944a827292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates_1a112330-6e25-479b-8ef1-b1319857d6a2" xlink:href="cvs-20221231.xsd#cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:to="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates_1a112330-6e25-479b-8ef1-b1319857d6a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b762f57-58a6-4ac1-9032-9427947c3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b762f57-58a6-4ac1-9032-9427947c3bee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ff34b042-4e8d-4fda-85e4-7b3c378885de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b762f57-58a6-4ac1-9032-9427947c3bee" xlink:to="loc_us-gaap_AwardTypeAxis_ff34b042-4e8d-4fda-85e4-7b3c378885de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff34b042-4e8d-4fda-85e4-7b3c378885de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ff34b042-4e8d-4fda-85e4-7b3c378885de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff34b042-4e8d-4fda-85e4-7b3c378885de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827059bf-73ff-4796-8ebc-da772b8eefdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ff34b042-4e8d-4fda-85e4-7b3c378885de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827059bf-73ff-4796-8ebc-da772b8eefdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_698ab91d-ac64-4842-ac63-0e230759614f" xlink:href="cvs-20221231.xsd#cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827059bf-73ff-4796-8ebc-da772b8eefdc" xlink:to="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_698ab91d-ac64-4842-ac63-0e230759614f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlansStockOptionandSARActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" xlink:type="extended" id="i22555b7eea45483380a7bfbe3ab84b14_StockIncentivePlansStockOptionandSARActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d43106f-b16e-4093-a629-bfbdbbb87995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d43106f-b16e-4093-a629-bfbdbbb87995" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5f84a5c0-b2c1-4ab5-a36a-2f1b60d0f773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5f84a5c0-b2c1-4ab5-a36a-2f1b60d0f773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a544fdd6-fa07-4398-bb39-ad30d42ccf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a544fdd6-fa07-4398-bb39-ad30d42ccf7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bf5cbc9d-9d04-4fe5-bdbf-6e047ca5d55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bf5cbc9d-9d04-4fe5-bdbf-6e047ca5d55c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue_4d1dcf82-745f-4f51-90b4-90aec705d9e5" xlink:href="cvs-20221231.xsd#cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue_4d1dcf82-745f-4f51-90b4-90aec705d9e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb9cee7c-25e3-4ff6-853a-62e3da8f5c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb9cee7c-25e3-4ff6-853a-62e3da8f5c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_39f10541-3015-4275-94d7-95c3fc02df8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_39f10541-3015-4275-94d7-95c3fc02df8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_980a2aeb-8014-47e2-9493-dafd34fef976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_980a2aeb-8014-47e2-9493-dafd34fef976" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_594db97c-e8d2-4adb-a827-cc4e2bb04773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_594db97c-e8d2-4adb-a827-cc4e2bb04773" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_26d7fa6b-35dd-4a83-a406-401002c4afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_26d7fa6b-35dd-4a83-a406-401002c4afc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a552056-cdbf-4b18-9cf2-5176ed8b372b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5ca78b59-34d9-42be-bf47-1206c22bfdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5ca78b59-34d9-42be-bf47-1206c22bfdec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_04797888-f9eb-4dcd-b14d-89bc8894cbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_04797888-f9eb-4dcd-b14d-89bc8894cbae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f9f6d941-f9a5-47a8-a799-9f3ce4350ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f9f6d941-f9a5-47a8-a799-9f3ce4350ff5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cd2dd946-e73f-44a5-bda6-3b76b92c4ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cd2dd946-e73f-44a5-bda6-3b76b92c4ba7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f4203ca2-f14a-47ce-ba86-2328a2806c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f4203ca2-f14a-47ce-ba86-2328a2806c82" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21e38d91-4c48-4615-bb4a-bbb8816b4e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56d006c2-133c-4c5b-a2a6-8ac84cfbb3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56d006c2-133c-4c5b-a2a6-8ac84cfbb3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aa7bbcbb-773b-496a-b1a0-20fb6210c4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aa7bbcbb-773b-496a-b1a0-20fb6210c4be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5845d750-090d-4d1a-b400-7c60e1a05f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5845d750-090d-4d1a-b400-7c60e1a05f8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_79770381-32a8-4166-8bdf-6a9700712b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_79770381-32a8-4166-8bdf-6a9700712b0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7d3ef423-bec9-411c-814e-4bd61bae5890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7d3ef423-bec9-411c-814e-4bd61bae5890" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8d781751-dbbc-48e0-b137-d8ae1183beab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8d781751-dbbc-48e0-b137-d8ae1183beab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9b821b38-1942-4a3f-bf16-128583ea4fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9b821b38-1942-4a3f-bf16-128583ea4fe8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f230f03e-772f-43c3-be01-fd6a0d05b72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f230f03e-772f-43c3-be01-fd6a0d05b72d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f4f7944a-68ad-4091-8886-470fd4750595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f4f7944a-68ad-4091-8886-470fd4750595" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_41d81054-039d-4626-90ac-dd6246e11cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_41d81054-039d-4626-90ac-dd6246e11cbb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55b4cdb7-3000-4f04-ab67-9b8e186bf23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55b4cdb7-3000-4f04-ab67-9b8e186bf23d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d20ff906-01e3-4c0b-8e31-85bfdd4e67fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55b4cdb7-3000-4f04-ab67-9b8e186bf23d" xlink:to="loc_us-gaap_AwardTypeAxis_d20ff906-01e3-4c0b-8e31-85bfdd4e67fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d20ff906-01e3-4c0b-8e31-85bfdd4e67fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d20ff906-01e3-4c0b-8e31-85bfdd4e67fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d20ff906-01e3-4c0b-8e31-85bfdd4e67fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d20ff906-01e3-4c0b-8e31-85bfdd4e67fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member_12537b82-4456-455e-83af-c6c8144d499c" xlink:href="cvs-20221231.xsd#cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:to="loc_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member_12537b82-4456-455e-83af-c6c8144d499c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member_9c752b55-79e4-4452-b3d9-61bd29309226" xlink:href="cvs-20221231.xsd#cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:to="loc_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member_9c752b55-79e4-4452-b3d9-61bd29309226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_e6491ff2-de98-4da2-b1af-892a4f2fd77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_e6491ff2-de98-4da2-b1af-892a4f2fd77a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_5b9b44e4-c8f2-42b3-8d22-72e7cddc9897" xlink:href="cvs-20221231.xsd#cvs_EmployeeStockOptionsAndStockAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:to="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_5b9b44e4-c8f2-42b3-8d22-72e7cddc9897" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlansValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" xlink:type="extended" id="i901904a4f2dc43d297b736763a817dcf_StockIncentivePlansValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3649d0db-5680-4d4e-8b64-ae34fdb2ebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3649d0db-5680-4d4e-8b64-ae34fdb2ebc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd29f611-a80b-40d2-a869-e8d10ad3200a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd29f611-a80b-40d2-a869-e8d10ad3200a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33c314bc-68fc-4854-a6eb-986d5ac493e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33c314bc-68fc-4854-a6eb-986d5ac493e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9f50b9a7-d746-4229-b9b5-c4cbc823526d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9f50b9a7-d746-4229-b9b5-c4cbc823526d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3dd65992-111f-4de0-8db0-2cf4588b8d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3dd65992-111f-4de0-8db0-2cf4588b8d2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_818b78e7-ceab-47ca-890c-c05d082c9d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_818b78e7-ceab-47ca-890c-c05d082c9d3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5a4c111-4eda-4a8f-8886-8d26cffa7efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_818b78e7-ceab-47ca-890c-c05d082c9d3e" xlink:to="loc_us-gaap_AwardTypeAxis_f5a4c111-4eda-4a8f-8886-8d26cffa7efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5a4c111-4eda-4a8f-8886-8d26cffa7efb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f5a4c111-4eda-4a8f-8886-8d26cffa7efb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5a4c111-4eda-4a8f-8886-8d26cffa7efb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1149c62c-35c3-491a-a2cb-5fed8250daff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f5a4c111-4eda-4a8f-8886-8d26cffa7efb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1149c62c-35c3-491a-a2cb-5fed8250daff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_62d3d0c4-b028-4a87-939e-b3446d0c6cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1149c62c-35c3-491a-a2cb-5fed8250daff" xlink:to="loc_us-gaap_EmployeeStockMember_62d3d0c4-b028-4a87-939e-b3446d0c6cee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5cc5f191-053f-44e3-84ce-3cb102664df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1149c62c-35c3-491a-a2cb-5fed8250daff" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5cc5f191-053f-44e3-84ce-3cb102664df5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" xlink:type="extended" id="i2ce143285d2e4a01987b5297a7e36b66_ShareholdersEquityShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bc5fc789-be1d-4786-addc-eeedc342ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bc5fc789-be1d-4786-addc-eeedc342ca70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_80155eec-3997-4398-9bea-e926a63ceb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_80155eec-3997-4398-9bea-e926a63ceb71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_178ef011-6fb8-4dec-9238-8585381a0373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_178ef011-6fb8-4dec-9238-8585381a0373" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f69a103a-9e7f-4572-a3e8-03d0136588b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f69a103a-9e7f-4572-a3e8-03d0136588b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_9afddf42-f451-404b-b3b9-fd2bcaee749f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_9afddf42-f451-404b-b3b9-fd2bcaee749f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_14741823-7cdd-4a0d-8dd5-cd4888b4ab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_9afddf42-f451-404b-b3b9-fd2bcaee749f" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_14741823-7cdd-4a0d-8dd5-cd4888b4ab4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_14741823-7cdd-4a0d-8dd5-cd4888b4ab4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_14741823-7cdd-4a0d-8dd5-cd4888b4ab4a" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_14741823-7cdd-4a0d-8dd5-cd4888b4ab4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f9cacc99-8603-4818-a1af-e7a36f18dd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_14741823-7cdd-4a0d-8dd5-cd4888b4ab4a" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f9cacc99-8603-4818-a1af-e7a36f18dd3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_A2022RepurchaseProgramMember_f6aaab9d-50c4-42c3-9f57-f4f3c377735d" xlink:href="cvs-20221231.xsd#cvs_A2022RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f9cacc99-8603-4818-a1af-e7a36f18dd3f" xlink:to="loc_cvs_A2022RepurchaseProgramMember_f6aaab9d-50c4-42c3-9f57-f4f3c377735d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_A2021RepurchaseProgramMember_46d18b62-1c1d-4bba-ba2a-fcd365a14833" xlink:href="cvs-20221231.xsd#cvs_A2021RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f9cacc99-8603-4818-a1af-e7a36f18dd3f" xlink:to="loc_cvs_A2021RepurchaseProgramMember_46d18b62-1c1d-4bba-ba2a-fcd365a14833" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityAcceleratedShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" xlink:type="extended" id="i3bc385c04f8c4a7a88af429b99b113a4_ShareholdersEquityAcceleratedShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesAgreementAmount_83170d42-a439-43d7-9156-361e1e1867de" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchasesAgreementAmount_83170d42-a439-43d7-9156-361e1e1867de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PaymentsForAcceleratedShareRepurchasesAmount_a757aafd-5353-4370-81fe-aff41e24f13b" xlink:href="cvs-20221231.xsd#cvs_PaymentsForAcceleratedShareRepurchasesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_PaymentsForAcceleratedShareRepurchasesAmount_a757aafd-5353-4370-81fe-aff41e24f13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares_851d9304-fe40-4b8a-b682-3dc0e74259b8" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares_851d9304-fe40-4b8a-b682-3dc0e74259b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased_db8bcb8b-8372-4c62-affa-ac2121ceebcc" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased_db8bcb8b-8372-4c62-affa-ac2121ceebcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_f69f0652-23fc-45aa-a105-021511185e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_us-gaap_SharePrice_f69f0652-23fc-45aa-a105-021511185e8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram_d012fddf-e425-4452-982e-de913057ba0b" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram_d012fddf-e425-4452-982e-de913057ba0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares_555dd58b-e8d7-4652-9bd2-412e9f7276d8" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares_555dd58b-e8d7-4652-9bd2-412e9f7276d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TransferOfSharesToTreasuryStockValue_9c5cd746-3786-435f-8a92-587c050d5e00" xlink:href="cvs-20221231.xsd#cvs_TransferOfSharesToTreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_TransferOfSharesToTreasuryStockValue_9c5cd746-3786-435f-8a92-587c050d5e00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4f5af9b5-d4ee-4142-a4cb-2c43cf3b45e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4f5af9b5-d4ee-4142-a4cb-2c43cf3b45e3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_da320251-35fb-43c4-8303-bb428ac6e32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_da320251-35fb-43c4-8303-bb428ac6e32c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_da320251-35fb-43c4-8303-bb428ac6e32c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_da320251-35fb-43c4-8303-bb428ac6e32c" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_da320251-35fb-43c4-8303-bb428ac6e32c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_82526397-c131-4e5b-bc62-b115a34d0ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_da320251-35fb-43c4-8303-bb428ac6e32c" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_82526397-c131-4e5b-bc62-b115a34d0ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_A2021RepurchaseProgramMember_964a72ef-cf43-4fe9-bc0f-ee5da9b981ec" xlink:href="cvs-20221231.xsd#cvs_A2021RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_82526397-c131-4e5b-bc62-b115a34d0ac9" xlink:to="loc_cvs_A2021RepurchaseProgramMember_964a72ef-cf43-4fe9-bc0f-ee5da9b981ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_367ba251-67a5-4565-8484-b89bbe2b3964" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:to="loc_srt_CounterpartyNameAxis_367ba251-67a5-4565-8484-b89bbe2b3964" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_367ba251-67a5-4565-8484-b89bbe2b3964_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_367ba251-67a5-4565-8484-b89bbe2b3964" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_367ba251-67a5-4565-8484-b89bbe2b3964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62a5a929-1590-4a75-99ff-0c7f8f8c0897" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_367ba251-67a5-4565-8484-b89bbe2b3964" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62a5a929-1590-4a75-99ff-0c7f8f8c0897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CitibankNAMember_adb6cba5-563d-49f0-911b-ca1751226a64" xlink:href="cvs-20221231.xsd#cvs_CitibankNAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62a5a929-1590-4a75-99ff-0c7f8f8c0897" xlink:to="loc_cvs_CitibankNAMember_adb6cba5-563d-49f0-911b-ca1751226a64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BarclaysBankMember_7bf31570-b07a-46cc-b393-0ae5ed67ee0f" xlink:href="cvs-20221231.xsd#cvs_BarclaysBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62a5a929-1590-4a75-99ff-0c7f8f8c0897" xlink:to="loc_cvs_BarclaysBankMember_7bf31570-b07a-46cc-b393-0ae5ed67ee0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fdb20b48-fd54-479f-9c64-676331884e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fdb20b48-fd54-479f-9c64-676331884e0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fdb20b48-fd54-479f-9c64-676331884e0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fdb20b48-fd54-479f-9c64-676331884e0b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fdb20b48-fd54-479f-9c64-676331884e0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9d712eb8-35ee-421c-976d-0e4ce65dff35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fdb20b48-fd54-479f-9c64-676331884e0b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9d712eb8-35ee-421c-976d-0e4ce65dff35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_12bbc846-4e2d-4c0f-917c-b1987344094d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d712eb8-35ee-421c-976d-0e4ce65dff35" xlink:to="loc_us-gaap_ForwardContractsMember_12bbc846-4e2d-4c0f-917c-b1987344094d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e53b5f21-4f3b-4808-9a66-94eaa34634ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e53b5f21-4f3b-4808-9a66-94eaa34634ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e53b5f21-4f3b-4808-9a66-94eaa34634ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e53b5f21-4f3b-4808-9a66-94eaa34634ef" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e53b5f21-4f3b-4808-9a66-94eaa34634ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_507cb298-3251-404a-825b-8da3a6d465a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e53b5f21-4f3b-4808-9a66-94eaa34634ef" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_507cb298-3251-404a-825b-8da3a6d465a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ea6f97ee-8919-4816-88c7-9047261575f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_507cb298-3251-404a-825b-8da3a6d465a5" xlink:to="loc_us-gaap_SubsequentEventMember_ea6f97ee-8919-4816-88c7-9047261575f3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" xlink:type="extended" id="i5ffc7fddeb744b819042384b067df218_ShareholdersEquityDividendsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableLineItems_a52e063d-ceb9-4689-b9c3-da0ee606e786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_96c93b35-2369-414a-87ce-5e3d7d36fa71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_a52e063d-ceb9-4689-b9c3-da0ee606e786" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_96c93b35-2369-414a-87ce-5e3d7d36fa71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent_c62b7b1b-c58d-47a2-92d5-f7f9f9a5e6cb" xlink:href="cvs-20221231.xsd#cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPayableLineItems_a52e063d-ceb9-4689-b9c3-da0ee606e786" xlink:to="loc_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent_c62b7b1b-c58d-47a2-92d5-f7f9f9a5e6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableTable_da5c0bd7-69e9-4c19-9551-3d1b041c4f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DividendsPayableLineItems_a52e063d-ceb9-4689-b9c3-da0ee606e786" xlink:to="loc_us-gaap_DividendsPayableTable_da5c0bd7-69e9-4c19-9551-3d1b041c4f52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_39df9500-5bb2-4903-bcb5-63788e13cebe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DividendsPayableTable_da5c0bd7-69e9-4c19-9551-3d1b041c4f52" xlink:to="loc_srt_StatementScenarioAxis_39df9500-5bb2-4903-bcb5-63788e13cebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_39df9500-5bb2-4903-bcb5-63788e13cebe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_39df9500-5bb2-4903-bcb5-63788e13cebe" xlink:to="loc_srt_ScenarioUnspecifiedDomain_39df9500-5bb2-4903-bcb5-63788e13cebe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9d2ca24f-6c5b-4329-84b9-6fd7e67a7140" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_39df9500-5bb2-4903-bcb5-63788e13cebe" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9d2ca24f-6c5b-4329-84b9-6fd7e67a7140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f108c2a1-9bec-46d7-bca0-6b681ff2462f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9d2ca24f-6c5b-4329-84b9-6fd7e67a7140" xlink:to="loc_srt_ScenarioForecastMember_f108c2a1-9bec-46d7-bca0-6b681ff2462f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityRegulatoryRequirementsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" xlink:type="extended" id="ia91e616336b94d069bd4b3e6254ac814_ShareholdersEquityRegulatoryRequirementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_a0b43931-4e78-4085-a321-c0aa480edd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_a0b43931-4e78-4085-a321-c0aa480edd79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_abe7d079-5a94-4e61-aebe-b55cc4b8c872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_abe7d079-5a94-4e61-aebe-b55cc4b8c872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_86bc6659-e8f0-429f-9157-bc65755fc28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_86bc6659-e8f0-429f-9157-bc65755fc28c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_b1307aa8-56a9-403c-8d6b-9832dcabe7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_b1307aa8-56a9-403c-8d6b-9832dcabe7f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldByInsuranceRegulators_422d5eba-9066-454b-8ad8-6e462d50b9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldByInsuranceRegulators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_AssetsHeldByInsuranceRegulators_422d5eba-9066-454b-8ad8-6e462d50b9ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_c8d03667-0162-41e1-a12e-5ff478986b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_c8d03667-0162-41e1-a12e-5ff478986b0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesTable_4de0b853-8e55-4321-9c67-990fb83ddf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_StatutoryAccountingPracticesTable_4de0b853-8e55-4321-9c67-990fb83ddf6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_46a4e1f3-226c-494d-9b91-0cc68e7a9070" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable_4de0b853-8e55-4321-9c67-990fb83ddf6f" xlink:to="loc_dei_LegalEntityAxis_46a4e1f3-226c-494d-9b91-0cc68e7a9070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_46a4e1f3-226c-494d-9b91-0cc68e7a9070_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_46a4e1f3-226c-494d-9b91-0cc68e7a9070" xlink:to="loc_dei_EntityDomain_46a4e1f3-226c-494d-9b91-0cc68e7a9070_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fb57333e-2042-4f7a-92fd-f44b3bcdd09f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_46a4e1f3-226c-494d-9b91-0cc68e7a9070" xlink:to="loc_dei_EntityDomain_fb57333e-2042-4f7a-92fd-f44b3bcdd09f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InsuranceAndHMOMember_6c02ec73-80b6-4f52-9082-a098e05a8dd5" xlink:href="cvs-20221231.xsd#cvs_InsuranceAndHMOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fb57333e-2042-4f7a-92fd-f44b3bcdd09f" xlink:to="loc_cvs_InsuranceAndHMOMember_6c02ec73-80b6-4f52-9082-a098e05a8dd5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended" id="if8259a70d385416cae0aa9f3bc2141b8_OtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27d80310-5d3b-4cf1-ad69-f82d6de4ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27d80310-5d3b-4cf1-ad69-f82d6de4ff5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2d166e15-dfff-480e-9f24-db0097423670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2d166e15-dfff-480e-9f24-db0097423670" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_b3a66778-97f5-4036-b788-9151ace26f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_b3a66778-97f5-4036-b788-9151ace26f62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_81a15e62-459c-4bef-9b66-e3630b1b4d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_81a15e62-459c-4bef-9b66-e3630b1b4d1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b06acd9-bd16-4fa2-acb2-3fe2bbbb0876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_6a5cf8c4-f155-4cd1-bc4a-da18a9653e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_6a5cf8c4-f155-4cd1-bc4a-da18a9653e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_04173926-d992-4553-bd23-ba9644a23b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_04173926-d992-4553-bd23-ba9644a23b0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_a347201e-3d64-43a0-89e6-3132fa06e5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_a347201e-3d64-43a0-89e6-3132fa06e5a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1ae317bb-897e-4631-bd64-0f932ae7a870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1ae317bb-897e-4631-bd64-0f932ae7a870" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4dc0e1bb-fce2-436a-97b4-57515be57b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1ae317bb-897e-4631-bd64-0f932ae7a870" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4dc0e1bb-fce2-436a-97b4-57515be57b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4dc0e1bb-fce2-436a-97b4-57515be57b62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4dc0e1bb-fce2-436a-97b4-57515be57b62" xlink:to="loc_us-gaap_EquityComponentDomain_4dc0e1bb-fce2-436a-97b4-57515be57b62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4dc0e1bb-fce2-436a-97b4-57515be57b62" xlink:to="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_66516169-2ee4-4c19-b680-4249b5b6e96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_66516169-2ee4-4c19-b680-4249b5b6e96a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_15671ead-73fc-49fe-9bf1-782c7f58d9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_15671ead-73fc-49fe-9bf1-782c7f58d9e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_7737e54a-825f-452c-95d4-6d92a18d5902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_7737e54a-825f-452c-95d4-6d92a18d5902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_4f5c2c51-9391-4f3c-9947-c4145b2cc900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_4f5c2c51-9391-4f3c-9947-c4145b2cc900" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_39bb6f9a-36fa-4759-9c50-673db7643da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_39bb6f9a-36fa-4759-9c50-673db7643da1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#EarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/EarningsPerShareDetails" xlink:type="extended" id="i5dccf0e60ded47eda9720f8ae6aca1e9_EarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_87458c38-4530-48e3-aacb-0f9899f19e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_87458c38-4530-48e3-aacb-0f9899f19e4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:href="cvs-20221231.xsd#cvs_NumeratorForEarningsPerShareCalculationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:to="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_88f2dd0d-ffe7-435d-a694-a4aff0132d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_88f2dd0d-ffe7-435d-a694-a4aff0132d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76781efa-ceac-4be8-a879-4ffb52457387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76781efa-ceac-4be8-a879-4ffb52457387" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_99c32665-e9fc-4ed2-90c7-0cc9c3e3a8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_99c32665-e9fc-4ed2-90c7-0cc9c3e3a8cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:href="cvs-20221231.xsd#cvs_DenominatorForEarningsPerShareCalculationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:to="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ede8bcd-36cb-4749-8fe8-70d9688246b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ede8bcd-36cb-4749-8fe8-70d9688246b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a75ab444-528a-4703-9691-9cb30a2ca6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a75ab444-528a-4703-9691-9cb30a2ca6dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1c278c60-3954-4e41-a69b-37349dba4f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1c278c60-3954-4e41-a69b-37349dba4f37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_88a1a21c-efc8-4b44-937b-398e9bb5285f" xlink:href="cvs-20221231.xsd#cvs_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:to="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_88a1a21c-efc8-4b44-937b-398e9bb5285f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b59c8e3d-3c9a-43cc-a837-99f811485f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_88a1a21c-efc8-4b44-937b-398e9bb5285f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b59c8e3d-3c9a-43cc-a837-99f811485f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9bd72b9e-f549-4e95-b9c1-1b424f5c0cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_88a1a21c-efc8-4b44-937b-398e9bb5285f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9bd72b9e-f549-4e95-b9c1-1b424f5c0cb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8401db28-d92a-48b1-9719-2376a459bd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8401db28-d92a-48b1-9719-2376a459bd21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96c4aaa3-38c1-4449-adae-d5a16b5c4cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8401db28-d92a-48b1-9719-2376a459bd21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96c4aaa3-38c1-4449-adae-d5a16b5c4cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96c4aaa3-38c1-4449-adae-d5a16b5c4cff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96c4aaa3-38c1-4449-adae-d5a16b5c4cff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96c4aaa3-38c1-4449-adae-d5a16b5c4cff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36da2664-6aff-47ae-add1-e2b098c9eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96c4aaa3-38c1-4449-adae-d5a16b5c4cff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36da2664-6aff-47ae-add1-e2b098c9eec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StockOptionsAndStockAppreciationRightsMember_70aa82e5-f7ae-4277-9844-5cd32137ab09" xlink:href="cvs-20221231.xsd#cvs_StockOptionsAndStockAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36da2664-6aff-47ae-add1-e2b098c9eec8" xlink:to="loc_cvs_StockOptionsAndStockAppreciationRightsMember_70aa82e5-f7ae-4277-9844-5cd32137ab09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember_a278396f-4ae1-4f8b-a38b-77bb0bd05e82" xlink:href="cvs-20221231.xsd#cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36da2664-6aff-47ae-add1-e2b098c9eec8" xlink:to="loc_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember_a278396f-4ae1-4f8b-a38b-77bb0bd05e82" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ReinsuranceNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" xlink:type="extended" id="i9ecfa3fae4eb40c6bed3615f628762c5_ReinsuranceNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_a8f69992-284f-43c9-8c06-ab4c9d2ab9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberofReinsuranceContractsEnteredInto_0943a62c-795e-4480-98a4-20732edc31c8" xlink:href="cvs-20221231.xsd#cvs_NumberofReinsuranceContractsEnteredInto"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_a8f69992-284f-43c9-8c06-ab4c9d2ab9d8" xlink:to="loc_cvs_NumberofReinsuranceContractsEnteredInto_0943a62c-795e-4480-98a4-20732edc31c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer_90ca25f5-0874-48ac-9ab8-5bf1b34e89c1" xlink:href="cvs-20221231.xsd#cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_a8f69992-284f-43c9-8c06-ab4c9d2ab9d8" xlink:to="loc_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer_90ca25f5-0874-48ac-9ab8-5bf1b34e89c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_0c27c28a-4c59-4489-9442-0a879138107b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CededCreditRiskLineItems_a8f69992-284f-43c9-8c06-ab4c9d2ab9d8" xlink:to="loc_us-gaap_CededCreditRiskTable_0c27c28a-4c59-4489-9442-0a879138107b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7accc59c-e6e0-4810-b28e-a9a723809a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_0c27c28a-4c59-4489-9442-0a879138107b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7accc59c-e6e0-4810-b28e-a9a723809a11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7accc59c-e6e0-4810-b28e-a9a723809a11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7accc59c-e6e0-4810-b28e-a9a723809a11" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7accc59c-e6e0-4810-b28e-a9a723809a11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_334425a1-41ef-45bc-847d-88707b74b5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7accc59c-e6e0-4810-b28e-a9a723809a11" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_334425a1-41ef-45bc-847d-88707b74b5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3493e77e-4b72-4d39-ab8c-e45da798b684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_334425a1-41ef-45bc-847d-88707b74b5d7" xlink:to="loc_us-gaap_SubsequentEventMember_3493e77e-4b72-4d39-ab8c-e45da798b684" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ReinsuranceReinsuranceRecoverablesDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="extended" id="i5a83fcc163ee4c10993fa5f47c303046_ReinsuranceReinsuranceRecoverablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_6c687b68-6676-4b51-a39c-7bc1c729f269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_85dc7927-08e4-4b25-bada-a14f56b98f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_6c687b68-6676-4b51-a39c-7bc1c729f269" xlink:to="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_85dc7927-08e4-4b25-bada-a14f56b98f80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_1671a8a1-60c5-42b6-a1c0-ca6e2c3e352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CededCreditRiskLineItems_6c687b68-6676-4b51-a39c-7bc1c729f269" xlink:to="loc_us-gaap_CededCreditRiskTable_1671a8a1-60c5-42b6-a1c0-ca6e2c3e352e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_2251b2c1-f34c-49c7-9a7d-e5a9e92bce90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_1671a8a1-60c5-42b6-a1c0-ca6e2c3e352e" xlink:to="loc_us-gaap_CededCreditRiskAxis_2251b2c1-f34c-49c7-9a7d-e5a9e92bce90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_2251b2c1-f34c-49c7-9a7d-e5a9e92bce90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CededCreditRiskAxis_2251b2c1-f34c-49c7-9a7d-e5a9e92bce90" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_2251b2c1-f34c-49c7-9a7d-e5a9e92bce90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CededCreditRiskAxis_2251b2c1-f34c-49c7-9a7d-e5a9e92bce90" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HartfordLifeAndAccidentInsuranceCompanyMember_ae0f48dc-7afe-4d27-be12-50a368b61d0e" xlink:href="cvs-20221231.xsd#cvs_HartfordLifeAndAccidentInsuranceCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_HartfordLifeAndAccidentInsuranceCompanyMember_ae0f48dc-7afe-4d27-be12-50a368b61d0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember_133a29e3-0357-447a-b34d-174c1e874a6d" xlink:href="cvs-20221231.xsd#cvs_LincolnLifeAnnuityCompanyOfNewYorkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember_133a29e3-0357-447a-b34d-174c1e874a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember_e9a19589-98be-441b-aa5a-402b1e9b5c1e" xlink:href="cvs-20221231.xsd#cvs_VOYARetirementInsuranceAndAnnuityCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember_e9a19589-98be-441b-aa5a-402b1e9b5c1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember_50e76484-c662-4f22-bee3-90e188983973" xlink:href="cvs-20221231.xsd#cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember_50e76484-c662-4f22-bee3-90e188983973" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AllOtherReinsurersMember_5b96086e-c751-4528-9d7a-e93674f593f5" xlink:href="cvs-20221231.xsd#cvs_AllOtherReinsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_AllOtherReinsurersMember_5b96086e-c751-4528-9d7a-e93674f593f5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i7cbaab3619f249ebb737e011b5f11df1_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a0af9cdc-65bc-4d75-a9e8-ae707910ca36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a0af9cdc-65bc-4d75-a9e8-ae707910ca36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LegalSettlementPeriodOfPayment_a739f43e-59c7-4a99-936b-c4d36a783564" xlink:href="cvs-20221231.xsd#cvs_LegalSettlementPeriodOfPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_cvs_LegalSettlementPeriodOfPayment_a739f43e-59c7-4a99-936b-c4d36a783564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_9994ab92-0132-477c-9031-4abad1d43df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_9994ab92-0132-477c-9031-4abad1d43df1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_a916cbf7-49a0-4634-95d5-9cc7b828da21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_a916cbf7-49a0-4634-95d5-9cc7b828da21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_47f7d3a5-e00d-4a78-8017-5a98f9605169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LegalFees_47f7d3a5-e00d-4a78-8017-5a98f9605169" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LitigationSettlementNumberOfStatesElectedToJoin_4fa07a41-5a52-49cf-b6cf-d97722b2bbbc" xlink:href="cvs-20221231.xsd#cvs_LitigationSettlementNumberOfStatesElectedToJoin"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_cvs_LitigationSettlementNumberOfStatesElectedToJoin_4fa07a41-5a52-49cf-b6cf-d97722b2bbbc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements_61559a6c-6a6d-460d-a3d6-0d17dca0b679" xlink:href="cvs-20221231.xsd#cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements_61559a6c-6a6d-460d-a3d6-0d17dca0b679" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_9f2d0fdf-b7eb-4999-9977-f828337cbce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_9f2d0fdf-b7eb-4999-9977-f828337cbce9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_3884f375-1a72-4747-ba7b-d4f50b74a307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_3884f375-1a72-4747-ba7b-d4f50b74a307" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_d7a36f79-99fd-43d4-8e0b-71267e3c360e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_d7a36f79-99fd-43d4-8e0b-71267e3c360e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c25584b8-cc5d-4ab0-b87f-8303a5ad7037" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_srt_LitigationCaseAxis_c25584b8-cc5d-4ab0-b87f-8303a5ad7037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c25584b8-cc5d-4ab0-b87f-8303a5ad7037_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c25584b8-cc5d-4ab0-b87f-8303a5ad7037" xlink:to="loc_srt_LitigationCaseTypeDomain_c25584b8-cc5d-4ab0-b87f-8303a5ad7037_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c25584b8-cc5d-4ab0-b87f-8303a5ad7037" xlink:to="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FederalCourtInOhioJudgmentMember_abec6391-bb32-43f6-914d-4b0c3ec5eee5" xlink:href="cvs-20221231.xsd#cvs_FederalCourtInOhioJudgmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_FederalCourtInOhioJudgmentMember_abec6391-bb32-43f6-914d-4b0c3ec5eee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StateOfFloridaSettlementMember_df286afc-6ee5-4047-a5d1-6396f8781a43" xlink:href="cvs-20221231.xsd#cvs_StateOfFloridaSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_StateOfFloridaSettlementMember_df286afc-6ee5-4047-a5d1-6396f8781a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SettlementFrameworkMember_18078d17-131e-4320-a51c-46430c35f50e" xlink:href="cvs-20221231.xsd#cvs_SettlementFrameworkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_SettlementFrameworkMember_18078d17-131e-4320-a51c-46430c35f50e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember_e27ad55c-06e9-474a-95c1-dc45ed9f6733" xlink:href="cvs-20221231.xsd#cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember_e27ad55c-06e9-474a-95c1-dc45ed9f6733" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RadcliffAndFlaimVAetnaIncEtAlMember_a3a5c0ee-5228-4ce5-8f61-ac13de3c6ae5" xlink:href="cvs-20221231.xsd#cvs_RadcliffAndFlaimVAetnaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_RadcliffAndFlaimVAetnaIncEtAlMember_a3a5c0ee-5228-4ce5-8f61-ac13de3c6ae5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e3d3650c-a363-4b4a-a931-07d8d34007e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_us-gaap_LitigationStatusAxis_e3d3650c-a363-4b4a-a931-07d8d34007e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_e3d3650c-a363-4b4a-a931-07d8d34007e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_e3d3650c-a363-4b4a-a931-07d8d34007e3" xlink:to="loc_us-gaap_LitigationStatusDomain_e3d3650c-a363-4b4a-a931-07d8d34007e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bc8a5d59-4747-4180-a717-3596d2124341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_e3d3650c-a363-4b4a-a931-07d8d34007e3" xlink:to="loc_us-gaap_LitigationStatusDomain_bc8a5d59-4747-4180-a717-3596d2124341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_5f482432-7cdf-4dd2-9b59-23403acabd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_bc8a5d59-4747-4180-a717-3596d2124341" xlink:to="loc_us-gaap_PendingLitigationMember_5f482432-7cdf-4dd2-9b59-23403acabd6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fa22d0fb-1698-45d4-9a9e-1911659ad3b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_srt_CounterpartyNameAxis_fa22d0fb-1698-45d4-9a9e-1911659ad3b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa22d0fb-1698-45d4-9a9e-1911659ad3b4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fa22d0fb-1698-45d4-9a9e-1911659ad3b4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa22d0fb-1698-45d4-9a9e-1911659ad3b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2bb8c5f6-af35-4000-956b-d056fc023f49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fa22d0fb-1698-45d4-9a9e-1911659ad3b4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2bb8c5f6-af35-4000-956b-d056fc023f49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TribalEntitiesMember_ea9444fc-3e2c-4755-bab8-84c829bd5fbd" xlink:href="cvs-20221231.xsd#cvs_TribalEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2bb8c5f6-af35-4000-956b-d056fc023f49" xlink:to="loc_cvs_TribalEntitiesMember_ea9444fc-3e2c-4755-bab8-84c829bd5fbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b46ad9cd-55c1-4171-a45a-6f591ae6ef57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_srt_RangeAxis_b46ad9cd-55c1-4171-a45a-6f591ae6ef57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b46ad9cd-55c1-4171-a45a-6f591ae6ef57_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b46ad9cd-55c1-4171-a45a-6f591ae6ef57" xlink:to="loc_srt_RangeMember_b46ad9cd-55c1-4171-a45a-6f591ae6ef57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4deafc0c-82b2-435b-be2d-f22d15a96c0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b46ad9cd-55c1-4171-a45a-6f591ae6ef57" xlink:to="loc_srt_RangeMember_4deafc0c-82b2-435b-be2d-f22d15a96c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3efbddc2-559f-46ff-a3ff-e14a9f308e20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4deafc0c-82b2-435b-be2d-f22d15a96c0c" xlink:to="loc_srt_MaximumMember_3efbddc2-559f-46ff-a3ff-e14a9f308e20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ade11304-8255-48ea-9bc1-0c17e53b6072" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_srt_StatementScenarioAxis_ade11304-8255-48ea-9bc1-0c17e53b6072" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ade11304-8255-48ea-9bc1-0c17e53b6072_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ade11304-8255-48ea-9bc1-0c17e53b6072" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ade11304-8255-48ea-9bc1-0c17e53b6072_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0132f079-7010-4a15-8925-fc048db5a8dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ade11304-8255-48ea-9bc1-0c17e53b6072" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0132f079-7010-4a15-8925-fc048db5a8dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3a2ca889-87c5-41ed-84b0-c5b6fe55b227" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0132f079-7010-4a15-8925-fc048db5a8dc" xlink:to="loc_srt_ScenarioForecastMember_3a2ca889-87c5-41ed-84b0-c5b6fe55b227" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SegmentReportingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" xlink:type="extended" id="i4c021eb726434f99a1195c689d46a346_SegmentReportingNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7debd8df-82f2-42b5-9cb0-7a44102b8d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a82503ab-7ab0-4614-829a-44d7d05b28e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7debd8df-82f2-42b5-9cb0-7a44102b8d37" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a82503ab-7ab0-4614-829a-44d7d05b28e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7debd8df-82f2-42b5-9cb0-7a44102b8d37" xlink:to="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7636a1f9-8d33-4da6-b60d-14ceeab832b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:to="loc_srt_MajorCustomersAxis_7636a1f9-8d33-4da6-b60d-14ceeab832b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7636a1f9-8d33-4da6-b60d-14ceeab832b3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7636a1f9-8d33-4da6-b60d-14ceeab832b3" xlink:to="loc_srt_NameOfMajorCustomerDomain_7636a1f9-8d33-4da6-b60d-14ceeab832b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_697befcf-e026-466c-95b8-c88a8041d626" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7636a1f9-8d33-4da6-b60d-14ceeab832b3" xlink:to="loc_srt_NameOfMajorCustomerDomain_697befcf-e026-466c-95b8-c88a8041d626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_USFederalGovernmentMember_531b1000-1c3a-4ca1-a37a-80b6b77ce0af" xlink:href="cvs-20221231.xsd#cvs_USFederalGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_697befcf-e026-466c-95b8-c88a8041d626" xlink:to="loc_cvs_USFederalGovernmentMember_531b1000-1c3a-4ca1-a37a-80b6b77ce0af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_46074bbd-6580-4724-94ea-cdfa058f4beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_46074bbd-6580-4724-94ea-cdfa058f4beb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_46074bbd-6580-4724-94ea-cdfa058f4beb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_46074bbd-6580-4724-94ea-cdfa058f4beb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_46074bbd-6580-4724-94ea-cdfa058f4beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_47f12957-2421-4682-a783-49fdbe1c74c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_46074bbd-6580-4724-94ea-cdfa058f4beb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_47f12957-2421-4682-a783-49fdbe1c74c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_75b566a6-3444-40f6-a513-c79d4a4ac5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_47f12957-2421-4682-a783-49fdbe1c74c0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_75b566a6-3444-40f6-a513-c79d4a4ac5f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f901c867-e591-429c-811a-40cfa893dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f901c867-e591-429c-811a-40cfa893dbe2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f901c867-e591-429c-811a-40cfa893dbe2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f901c867-e591-429c-811a-40cfa893dbe2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f901c867-e591-429c-811a-40cfa893dbe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3091948f-5314-4d7f-9611-a573cdece684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f901c867-e591-429c-811a-40cfa893dbe2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3091948f-5314-4d7f-9611-a573cdece684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d412b9bd-846b-4952-981b-66ff21e6a7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3091948f-5314-4d7f-9611-a573cdece684" xlink:to="loc_us-gaap_SalesRevenueNetMember_d412b9bd-846b-4952-981b-66ff21e6a7f3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="extended" id="i120e2a14b3ac4c7391c2b77e8038de4d_SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_09b64e1c-9d8d-4d7c-8384-41c4e1065989" xlink:href="cvs-20221231.xsd#cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_09b64e1c-9d8d-4d7c-8384-41c4e1065989" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4282aea8-264b-4b85-8fe1-459c1f92686a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4282aea8-264b-4b85-8fe1-459c1f92686a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_9c1b2bb6-c5a9-453e-aee4-e8e3a4497516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_us-gaap_NetInvestmentIncome_9c1b2bb6-c5a9-453e-aee4-e8e3a4497516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_36212d72-0544-4828-84ad-8e514f71433b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_us-gaap_Revenues_36212d72-0544-4828-84ad-8e514f71433b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AdjustedOperatingIncomeLoss_db03a088-8b2d-4b8e-ad1b-5c9d0eaf2385" xlink:href="cvs-20221231.xsd#cvs_AdjustedOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_cvs_AdjustedOperatingIncomeLoss_db03a088-8b2d-4b8e-ad1b-5c9d0eaf2385" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_681ad334-6c7f-4f23-8736-5966b30a768b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_681ad334-6c7f-4f23-8736-5966b30a768b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NetRevenuesRetailCoPayments_feb6b6ce-edea-4fd1-8130-15f1051acd97" xlink:href="cvs-20221231.xsd#cvs_NetRevenuesRetailCoPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_cvs_NetRevenuesRetailCoPayments_feb6b6ce-edea-4fd1-8130-15f1051acd97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b44b7a22-e81e-4985-b03d-c725c30cf4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b44b7a22-e81e-4985-b03d-c725c30cf4ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2df2e650-810c-4ebc-8323-074a339b8f62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b44b7a22-e81e-4985-b03d-c725c30cf4ca" xlink:to="loc_srt_ConsolidationItemsAxis_2df2e650-810c-4ebc-8323-074a339b8f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2df2e650-810c-4ebc-8323-074a339b8f62_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_2df2e650-810c-4ebc-8323-074a339b8f62" xlink:to="loc_srt_ConsolidationItemsDomain_2df2e650-810c-4ebc-8323-074a339b8f62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_2df2e650-810c-4ebc-8323-074a339b8f62" xlink:to="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_182575df-c912-4b40-8d72-731187c74dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:to="loc_us-gaap_OperatingSegmentsMember_182575df-c912-4b40-8d72-731187c74dc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_af40b6cc-0e82-47bb-85e2-6f619cee3c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:to="loc_us-gaap_IntersegmentEliminationMember_af40b6cc-0e82-47bb-85e2-6f619cee3c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a8e5ab57-a46f-407c-9d3f-c8973e2c8fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a8e5ab57-a46f-407c-9d3f-c8973e2c8fc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_808eec75-91c7-4e99-a9db-473cec44ebae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b44b7a22-e81e-4985-b03d-c725c30cf4ca" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_808eec75-91c7-4e99-a9db-473cec44ebae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_808eec75-91c7-4e99-a9db-473cec44ebae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_808eec75-91c7-4e99-a9db-473cec44ebae" xlink:to="loc_us-gaap_SegmentDomain_808eec75-91c7-4e99-a9db-473cec44ebae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_808eec75-91c7-4e99-a9db-473cec44ebae" xlink:to="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_025f8afd-9469-4e1c-ae46-68c3da4e7d43" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_025f8afd-9469-4e1c-ae46-68c3da4e7d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyServicesSegmentMember_498e958b-30ce-41c5-ab9d-25ec6845dd25" xlink:href="cvs-20221231.xsd#cvs_PharmacyServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:to="loc_cvs_PharmacyServicesSegmentMember_498e958b-30ce-41c5-ab9d-25ec6845dd25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_49270477-6a56-4a3a-a989-1322c055b75d" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_49270477-6a56-4a3a-a989-1322c055b75d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" xlink:type="extended" id="i95a66a3dccec4fecb6c198c57dd1c192_SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a9d2e8d-362d-49a6-a1b0-e7655d4a9440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a9d2e8d-362d-49a6-a1b0-e7655d4a9440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_06b044b1-c238-452f-825e-72da278b2b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_06b044b1-c238-452f-825e-72da278b2b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OfficeRealEstateOptimizationCharges_09db7fe8-5c1e-498e-a76f-9f9f38bf041c" xlink:href="cvs-20221231.xsd#cvs_OfficeRealEstateOptimizationCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_OfficeRealEstateOptimizationCharges_09db7fe8-5c1e-498e-a76f-9f9f38bf041c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_c179a0b4-9f6e-45ba-bfd6-73d6d98a9917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_c179a0b4-9f6e-45ba-bfd6-73d6d98a9917" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_156221d0-5761-4b0b-ab62-55c647ea3b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_156221d0-5761-4b0b-ab62-55c647ea3b7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_42da805d-19ee-4118-aa07-d0a417cb5dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_42da805d-19ee-4118-aa07-d0a417cb5dc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_ac805174-085f-43fe-82af-9e110fced7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_ac805174-085f-43fe-82af-9e110fced7ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_b550f0bc-a4cf-4491-9bea-8e6edf451e2f" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_StoreImpairmentCharges_b550f0bc-a4cf-4491-9bea-8e6edf451e2f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_eb13079d-454f-4dec-b81f-aaa342e77026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_eb13079d-454f-4dec-b81f-aaa342e77026" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod_fd71e88b-a5b1-4067-8cef-9f284c9e650b" xlink:href="cvs-20221231.xsd#cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod_fd71e88b-a5b1-4067-8cef-9f284c9e650b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_cfa46c2e-8464-4580-a5b4-75f8232497a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_cfa46c2e-8464-4580-a5b4-75f8232497a7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AdjustedOperatingIncomeLoss_c9db4f63-495c-4e1a-88c7-ec592fd84d45" xlink:href="cvs-20221231.xsd#cvs_AdjustedOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_AdjustedOperatingIncomeLoss_c9db4f63-495c-4e1a-88c7-ec592fd84d45" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresPlannedClosure_03d695e1-13c5-4846-b146-b8b40334e6e8" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresPlannedClosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_NumberOfStoresPlannedClosure_03d695e1-13c5-4846-b146-b8b40334e6e8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_7effa876-55de-41d3-b7a7-5beab6338f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_7effa876-55de-41d3-b7a7-5beab6338f76" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_7965e962-a59f-4e6d-89db-f61419616ecc" xlink:href="cvs-20221231.xsd#cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_7965e962-a59f-4e6d-89db-f61419616ecc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3b79972-d4e9-41e4-9637-81af78198673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3b79972-d4e9-41e4-9637-81af78198673" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ca3ca2d4-b4df-4268-9af8-de3a0a2315ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3b79972-d4e9-41e4-9637-81af78198673" xlink:to="loc_srt_LitigationCaseAxis_ca3ca2d4-b4df-4268-9af8-de3a0a2315ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ca3ca2d4-b4df-4268-9af8-de3a0a2315ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ca3ca2d4-b4df-4268-9af8-de3a0a2315ef" xlink:to="loc_srt_LitigationCaseTypeDomain_ca3ca2d4-b4df-4268-9af8-de3a0a2315ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d8831b72-52ef-46cb-9e4d-28d471231404" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ca3ca2d4-b4df-4268-9af8-de3a0a2315ef" xlink:to="loc_srt_LitigationCaseTypeDomain_d8831b72-52ef-46cb-9e4d-28d471231404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_bc6c2935-da74-4814-afe3-108f528235c9" xlink:href="cvs-20221231.xsd#cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d8831b72-52ef-46cb-9e4d-28d471231404" xlink:to="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_bc6c2935-da74-4814-afe3-108f528235c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a211232a-924b-449f-b927-3c34022c792c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3b79972-d4e9-41e4-9637-81af78198673" xlink:to="loc_us-gaap_LitigationStatusAxis_a211232a-924b-449f-b927-3c34022c792c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a211232a-924b-449f-b927-3c34022c792c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_a211232a-924b-449f-b927-3c34022c792c" xlink:to="loc_us-gaap_LitigationStatusDomain_a211232a-924b-449f-b927-3c34022c792c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_5d7fe839-4838-4a3f-b5e0-31c677adaa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_a211232a-924b-449f-b927-3c34022c792c" xlink:to="loc_us-gaap_LitigationStatusDomain_5d7fe839-4838-4a3f-b5e0-31c677adaa6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_cab5953f-ab78-4498-9f47-8ecb7a89964c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_5d7fe839-4838-4a3f-b5e0-31c677adaa6d" xlink:to="loc_us-gaap_SettledLitigationMember_cab5953f-ab78-4498-9f47-8ecb7a89964c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cvs-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:062ae674-cc97-4efd-81c6-d89202a3d450,g:ffc34178-e241-4c21-bbb1-7b57d93a8581-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_dec11f5c-cc37-422f-945f-44bbf88f7899_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_36dfca29-f6f3-4afb-b88d-35beacf08571_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Real Estate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:to="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OtherAssetBackedSecuritiesMember_5066bb77-86a3-4f7c-8faa-4086c5d30417_terseLabel_en-US" xlink:label="lab_cvs_OtherAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other asset-backed securities</link:label>
    <link:label id="lab_cvs_OtherAssetBackedSecuritiesMember_label_en-US" xlink:label="lab_cvs_OtherAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_cvs_OtherAssetBackedSecuritiesMember_documentation_en-US" xlink:label="lab_cvs_OtherAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities collateralized by a variety of assets such as automobile loans, credit card receivables, home equity loans, etc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OtherAssetBackedSecuritiesMember" xlink:to="lab_cvs_OtherAssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f4f11edd-3008-474d-8d69-bfa9d50362e9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_7a309a15-a800-4f80-9879-261c055a0507_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_2711afc5-315e-43e3-b5a7-ec85f70abab5_totalLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net benefit costs</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_992f08aa-2644-4bfe-bca3-4dc64ceba5e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_f51104ec-d684-4460-bbb8-38f2eaf3e39e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bc3d6abf-84a7-4178-90b4-bc8384ff7088_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FinanceLeaseCost_6d8ca22d-053b-4e1b-b8df-491568befaf3_totalLabel_en-US" xlink:label="lab_cvs_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease costs</link:label>
    <link:label id="lab_cvs_FinanceLeaseCost_label_en-US" xlink:label="lab_cvs_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:label id="lab_cvs_FinanceLeaseCost_documentation_en-US" xlink:label="lab_cvs_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseCost" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FinanceLeaseCost" xlink:to="lab_cvs_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocationsToPolicyholdersPolicies_2ccc7fb1-165d-4ee4-8d1c-e3e74c650518_terseLabel_en-US" xlink:label="lab_us-gaap_AllocationsToPolicyholdersPolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholders' Funds</link:label>
    <link:label id="lab_us-gaap_AllocationsToPolicyholdersPolicies_label_en-US" xlink:label="lab_us-gaap_AllocationsToPolicyholdersPolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocations to Policyholders, Policies [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocationsToPolicyholdersPolicies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocationsToPolicyholdersPolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocationsToPolicyholdersPolicies" xlink:to="lab_us-gaap_AllocationsToPolicyholdersPolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4e5bc230-15d3-4814-8d8f-a2706e6fe762_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_adce9721-842b-45b0-b0f5-b5fb78809a59_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8131a710-bcd1-4783-adf3-0d9cc4786431_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized investment gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a69f7bd0-51d6-4a76-b65f-a4f74edc148f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f41e15da-9f2b-4437-9837-d950a6b93789_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember_e0fedcc5-068e-4762-bdcd-933642def0b0_terseLabel_en-US" xlink:label="lab_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Framework and Other Opioid-Related Claims</link:label>
    <link:label id="lab_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember_label_en-US" xlink:label="lab_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Framework And Other Opioid-Related Claims [Member]</link:label>
    <link:label id="lab_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember_documentation_en-US" xlink:label="lab_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Framework And Other Opioid-Related Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember" xlink:href="cvs-20221231.xsd#cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember" xlink:to="lab_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_80a78881-a5d7-4112-981d-4bc03de3a746_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_fbe02543-f2b6-4ba3-afd6-8073ed47c2fa_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_600d6df4-8577-4add-bd14-a841741fc264_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_1ad3d3d2-61f6-4eb6-a38f-20463163ca8a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage_66e07d4f-8f7e-47a1-8871-cb082a1e3670_negatedTerseLabel_en-US" xlink:label="lab_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption and breakage</link:label>
    <link:label id="lab_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage_label_en-US" xlink:label="lab_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability Redemption And Breakage</link:label>
    <link:label id="lab_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage_documentation_en-US" xlink:label="lab_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability Redemption And Breakage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage" xlink:href="cvs-20221231.xsd#cvs_ContractWithCustomerLiabilityRedemptionAndBreakage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage" xlink:to="lab_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_ab099f34-cad1-49ad-b5d9-cf5df08a53d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_b67132ef-8e70-47dd-94b1-5b6b7ec203b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes5.05DueMarch2048Member_ce308eed-f192-499e-a69f-ebcc77322de7_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes5.05DueMarch2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.05% senior notes due March 2048</link:label>
    <link:label id="lab_cvs_SeniorNotes5.05DueMarch2048Member_label_en-US" xlink:label="lab_cvs_SeniorNotes5.05DueMarch2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.05%, Due March 2048 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes5.05DueMarch2048Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes5.05DueMarch2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.05%, Due March 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.05DueMarch2048Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.05DueMarch2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes5.05DueMarch2048Member" xlink:to="lab_cvs_SeniorNotes5.05DueMarch2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c5e8010d-3a56-4a4b-958b-afcb4fd1325e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care costs payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_6fddbe5e-4057-4837-96c0-ed5c39b89b81_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total health care costs payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_3ad8965b-ae86-42b5-b574-16c72eb3ffbb_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care costs payable, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_54877f33-505e-4082-a432-515636432f7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care costs payable, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3.5DueJuly2022Member_99237e5d-9614-4125-ae82-6dd25ae7b88f_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3.5DueJuly2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.5% senior notes due July 2022</link:label>
    <link:label id="lab_cvs_SeniorNotes3.5DueJuly2022Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3.5DueJuly2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.5%, Due July 2022 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3.5DueJuly2022Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3.5DueJuly2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.5%, Due July 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.5DueJuly2022Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.5DueJuly2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3.5DueJuly2022Member" xlink:to="lab_cvs_SeniorNotes3.5DueJuly2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_15647ec1-f8d4-46de-a5b5-eaa502a86f41_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_e8cf38c0-6b0e-457d-942d-94d9c6e90585_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e960560a-0795-49e6-a969-dade99bf8c76_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_Category7Member_9015f97a-d29b-4e99-b2ec-cbe31491cb78_terseLabel_en-US" xlink:label="lab_cvs_Category7Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7</link:label>
    <link:label id="lab_cvs_Category7Member_label_en-US" xlink:label="lab_cvs_Category7Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category 7 [Member]</link:label>
    <link:label id="lab_cvs_Category7Member_documentation_en-US" xlink:label="lab_cvs_Category7Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loan credit quality indicator - Category 7</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Category7Member" xlink:href="cvs-20221231.xsd#cvs_Category7Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_Category7Member" xlink:to="lab_cvs_Category7Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7cb22d93-7e75-4c2d-abd2-3850092a68ac_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b66aba88-4e08-4b0b-b88a-368965a213f0_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_627f2a84-7b41-4308-91b9-624a89374d68_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option activity, stock awards and other (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_54f90a8f-76b6-48b1-8ed2-323f4176636e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes2Point7PercentAugust2040Member_88dfbd5c-d9c2-4af3-b570-03e3bcdbd5a0_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes2Point7PercentAugust2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.7% senior notes due August 2040</link:label>
    <link:label id="lab_cvs_SeniorNotes2Point7PercentAugust2040Member_label_en-US" xlink:label="lab_cvs_SeniorNotes2Point7PercentAugust2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2 Point 7 Percent, August 2040 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes2Point7PercentAugust2040Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes2Point7PercentAugust2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2 Point 7 Percent, August 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2Point7PercentAugust2040Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2Point7PercentAugust2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes2Point7PercentAugust2040Member" xlink:to="lab_cvs_SeniorNotes2Point7PercentAugust2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_027d0073-0634-425f-a390-7806322e3460_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5e6e9273-d0c3-4617-b8dc-ae5ac62ec45b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember_6cfb20a9-3e5b-47eb-af82-3e09c085ea91_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common/collective trusts</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Common Collective Trust [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_746cddbc-4886-4a3c-87c9-50c9588f7262_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_4939fba6-d64a-4d56-8554-068311f17554_terseLabel_en-US" xlink:label="lab_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized and unrealized capital gains (losses):</link:label>
    <link:label id="lab_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_label_en-US" xlink:label="lab_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract]</link:label>
    <link:label id="lab_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_documentation_en-US" xlink:label="lab_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract" xlink:href="cvs-20221231.xsd#cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract" xlink:to="lab_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ec60e976-8857-494e-af93-5866ce1a68ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsYearOne_ad52ee9d-0723-47c1-b53e-7e5fd93f5efc_totalLabel_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsYearOne" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsYearOne_label_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Year One</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsYearOne_documentation_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsYearOne" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLiabilityPaymentsYearOne" xlink:to="lab_cvs_LesseeLiabilityPaymentsYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ded3477b-5d4d-4f2d-90ae-ed6a8c60d541_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_abd9d385-3617-4824-93ba-0430df676d40_totalLabel_en-US" xlink:label="lab_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_label_en-US" xlink:label="lab_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill), Including Assets Held For Sale</link:label>
    <link:label id="lab_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_documentation_en-US" xlink:label="lab_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill), Including Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" xlink:href="cvs-20221231.xsd#cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" xlink:to="lab_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6f88ec80-4ce8-46e0-8894-0b63898fd5cf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ca5c4232-0edb-4703-a1cb-a66d62cfa530_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_abf9fb19-6424-4594-889e-1d8eae2f7226_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80cd652a-9f40-466d-9150-c2d0b588b101_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of EPS (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_af7f64e7-f82f-469d-b4a2-d4f7eecaf308_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_05f2c754-65f9-4e3d-be79-d21bed94d12a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_8d35017c-fa8a-40da-b123-1481c4e320e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_340de6b1-1cc6-4b72-8675-660b246f057f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ca525540-e51c-4381-9191-298788bf7100_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_df2d66f2-b50f-4f62-be6a-04d14028602a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_BswiftLLCMember_0e819fea-03da-4027-ad05-475a25f251b2_terseLabel_en-US" xlink:label="lab_cvs_BswiftLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bswift LLC</link:label>
    <link:label id="lab_cvs_BswiftLLCMember_label_en-US" xlink:label="lab_cvs_BswiftLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bswift LLC [Member]</link:label>
    <link:label id="lab_cvs_BswiftLLCMember_documentation_en-US" xlink:label="lab_cvs_BswiftLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bswift LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BswiftLLCMember" xlink:href="cvs-20221231.xsd#cvs_BswiftLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_BswiftLLCMember" xlink:to="lab_cvs_BswiftLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentIncome_cb35f846-178e-45e4-9264-cb2e4391259b_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_6eda6b71-1e5d-4c3a-a26a-7610ef0d6ab7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment income (loss)</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_label_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentIncome" xlink:to="lab_us-gaap_NetInvestmentIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5b41706e-8260-449c-9293-96b63809b656_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_4b804012-7ae1-4d5f-8d50-8f6b3cbbda7f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liability recorded in association with legal settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Accrual, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RevolvingCreditFacilityExpiringMay112026Member_b78b72ab-7e8f-4934-be98-d4b231390ae1_terseLabel_en-US" xlink:label="lab_cvs_RevolvingCreditFacilityExpiringMay112026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Expiring May 11, 2026</link:label>
    <link:label id="lab_cvs_RevolvingCreditFacilityExpiringMay112026Member_label_en-US" xlink:label="lab_cvs_RevolvingCreditFacilityExpiringMay112026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Expiring May 11, 2026 [Member]</link:label>
    <link:label id="lab_cvs_RevolvingCreditFacilityExpiringMay112026Member_documentation_en-US" xlink:label="lab_cvs_RevolvingCreditFacilityExpiringMay112026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Expiring May 11, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RevolvingCreditFacilityExpiringMay112026Member" xlink:href="cvs-20221231.xsd#cvs_RevolvingCreditFacilityExpiringMay112026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RevolvingCreditFacilityExpiringMay112026Member" xlink:to="lab_cvs_RevolvingCreditFacilityExpiringMay112026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_e8c00b0c-98bb-4f79-b8d6-303255044d00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_af70d3f6-7037-47ae-a423-1a0c61bd4764_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NumeratorForEarningsPerShareCalculationAbstract_619ddba6-4198-40d3-b3c6-ace70e85c0ae_terseLabel_en-US" xlink:label="lab_cvs_NumeratorForEarningsPerShareCalculationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator for earnings per share calculation:</link:label>
    <link:label id="lab_cvs_NumeratorForEarningsPerShareCalculationAbstract_label_en-US" xlink:label="lab_cvs_NumeratorForEarningsPerShareCalculationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator For Earnings Per Share Calculation [Abstract]</link:label>
    <link:label id="lab_cvs_NumeratorForEarningsPerShareCalculationAbstract_documentation_en-US" xlink:label="lab_cvs_NumeratorForEarningsPerShareCalculationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator For Earnings Per Share Calculation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract" xlink:href="cvs-20221231.xsd#cvs_NumeratorForEarningsPerShareCalculationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract" xlink:to="lab_cvs_NumeratorForEarningsPerShareCalculationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_cfc6472c-0ca5-49dd-babc-687dc0d7bc86_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_244073dc-e890-40f6-b66a-34fc3829ba66_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_42a5336e-a434-4957-a84b-6fbf7da95126_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_c6276557-16a6-45f2-a5d9-123caa37a1b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountsLiability_891a44a2-87e3-4a95-b92d-ee7eaad2efa9_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate accounts liabilities</link:label>
    <link:label id="lab_us-gaap_SeparateAccountsLiability_86646d92-2c89-463b-a0d6-e925370f2062_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountsLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate accounts liabilities</link:label>
    <link:label id="lab_us-gaap_SeparateAccountsLiability_label_en-US" xlink:label="lab_us-gaap_SeparateAccountsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountsLiability" xlink:to="lab_us-gaap_SeparateAccountsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d75b6f26-383a-4be0-81fa-0b91352a77e9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91552f0f-0c32-41db-aa06-87f2180c2192_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f12e82b-fbee-4321-ab98-7145d4fb19a2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_b1a1eef6-5f15-4c48-8f63-35af8b1f3273_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash to be received by shareholders in proposed/pending acquisition (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure_6af220bd-7d13-4784-9aa4-36fcc2793694_terseLabel_en-US" xlink:label="lab_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment contracts liabilities without a fixed maturity</link:label>
    <link:label id="lab_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure_label_en-US" xlink:label="lab_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Contracts Without A Fixed Maturity, Fair Value Disclosure</link:label>
    <link:label id="lab_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure_documentation_en-US" xlink:label="lab_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Contracts Without A Fixed Maturity, Fair Value Disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure" xlink:href="cvs-20221231.xsd#cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure" xlink:to="lab_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fa1d584b-3d00-451a-998e-93884cfdc98c_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_69183f80-1897-4b34-b865-7546c61124b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f1fe65b1-c689-46a8-aaba-1cdf57e7b1b2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8f96438d-6072-42b3-9c7b-327509e3e66c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, forfeited ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_577a96a6-f5de-4da9-91aa-bc80a5e1e4dd_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_label_en-US" xlink:label="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:to="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_85579c65-3ac4-442a-8205-7e4624733bc2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation not yet recognized, other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_dfc8f569-6f5d-48c5-b9d7-9cf1a43af00d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember_034066a3-0c66-403f-ba02-1c51d06e0353_terseLabel_en-US" xlink:label="lab_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) and Performance Stock Units (PSUs)</link:label>
    <link:label id="lab_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember_label_en-US" xlink:label="lab_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) And Performance Stock Units (PSUs) [Member]</link:label>
    <link:label id="lab_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember_documentation_en-US" xlink:label="lab_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) And Performance Stock Units (PSUs)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember" xlink:href="cvs-20221231.xsd#cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember" xlink:to="lab_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SettlementFrameworkMember_b8d3a987-f3e2-49f0-9991-6169ee9c91ae_terseLabel_en-US" xlink:label="lab_cvs_SettlementFrameworkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Framework</link:label>
    <link:label id="lab_cvs_SettlementFrameworkMember_label_en-US" xlink:label="lab_cvs_SettlementFrameworkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Framework [Member]</link:label>
    <link:label id="lab_cvs_SettlementFrameworkMember_documentation_en-US" xlink:label="lab_cvs_SettlementFrameworkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Framework</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SettlementFrameworkMember" xlink:href="cvs-20221231.xsd#cvs_SettlementFrameworkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SettlementFrameworkMember" xlink:to="lab_cvs_SettlementFrameworkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d97fb814-5f25-4f0c-99b8-97420a28753c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_d51d3a28-a2c5-4bb7-9e5c-1b4160e39f08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_34eab473-652e-4864-a18f-26c440eff735_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_74943719-98e4-4d47-b808-58c85078bbcd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5f7d3acd-f803-48aa-8d7a-ac7a5fda636e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term, outstanding at end of year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_bd36a518-d66c-46e7-854b-982e58ceaf76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:to="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_869eca53-2b7d-4dac-93e1-1a027097923f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_a59ae881-219a-461e-afee-182e9aa79391_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gain</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_ee1be92c-a516-4cdf-a16d-544c6cd8b524_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_e282c8ab-0585-4ced-90a1-a35587ca2188_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_fa5b174d-e919-4c38-ad37-eb9bf16ee867_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.01: 3,200 shares authorized; 1,758 shares issued and 1,300 shares outstanding at December&#160;31, 2022 and 1,744 shares issued and 1,322 shares outstanding at December&#160;31, 2021 and capital surplus</link:label>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgagesHeldForSaleFairValueDisclosure_9f8d0c12-d039-44b4-b5a4-7321d27cee6a_terseLabel_en-US" xlink:label="lab_us-gaap_MortgagesHeldForSaleFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loans</link:label>
    <link:label id="lab_us-gaap_MortgagesHeldForSaleFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_MortgagesHeldForSaleFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgages Held-for-sale, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesHeldForSaleFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgagesHeldForSaleFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgagesHeldForSaleFairValueDisclosure" xlink:to="lab_us-gaap_MortgagesHeldForSaleFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8e38b144-f3a5-436c-a78a-541cd866e49c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_d5b10b96-fa52-448c-85a2-216c3ad39beb_terseLabel_en-US" xlink:label="lab_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit-related impairment loss</link:label>
    <link:label id="lab_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_label_en-US" xlink:label="lab_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit-Related Impairment Loss, Debt Securities, Available-For-Sale, Recognized In Earnings</link:label>
    <link:label id="lab_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_documentation_en-US" xlink:label="lab_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit-Related Impairment Loss, Debt Securities, Available-For-Sale, Recognized In Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:href="cvs-20221231.xsd#cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:to="lab_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8c66743c-02db-4276-8076-0bd384bd6825_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e075111b-a220-4c4c-9b8b-b6707bf6b758_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember_180796bd-61a4-4513-9663-349009194375_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Government Short-Term Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_2af7e582-22ab-49ce-a40f-dc55798d0697_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_8c2a8d02-ac1d-4a9b-86ff-2291a201082f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of subsidiary</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_Category2To4Member_5010416e-56f6-45da-9a6a-34e5978c2bf3_terseLabel_en-US" xlink:label="lab_cvs_Category2To4Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2 to 4</link:label>
    <link:label id="lab_cvs_Category2To4Member_label_en-US" xlink:label="lab_cvs_Category2To4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category 2 To 4 [Member]</link:label>
    <link:label id="lab_cvs_Category2To4Member_documentation_en-US" xlink:label="lab_cvs_Category2To4Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loan Credit Quality Indicator - Category 2 to 4 [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Category2To4Member" xlink:href="cvs-20221231.xsd#cvs_Category2To4Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_Category2To4Member" xlink:to="lab_cvs_Category2To4Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes5.3DueDecember2043Member_ec19ef62-c42a-45ca-993b-dec7c4c1201d_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes5.3DueDecember2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.3% senior notes due December 2043</link:label>
    <link:label id="lab_cvs_SeniorNotes5.3DueDecember2043Member_label_en-US" xlink:label="lab_cvs_SeniorNotes5.3DueDecember2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.3%, Due December 2043 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes5.3DueDecember2043Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes5.3DueDecember2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.3%, Due December 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.3DueDecember2043Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.3DueDecember2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes5.3DueDecember2043Member" xlink:to="lab_cvs_SeniorNotes5.3DueDecember2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree_81aea3b6-038a-4bf0-a95e-1ef36769c91f_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree_label_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Year Three</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree_documentation_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree" xlink:to="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToSuppliersAndEmployees_4920fa00-5e19-45fd-b4bc-d15888be8c47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToSuppliersAndEmployees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to other suppliers and employees</link:label>
    <link:label id="lab_us-gaap_PaymentsToSuppliersAndEmployees_label_en-US" xlink:label="lab_us-gaap_PaymentsToSuppliersAndEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Suppliers and Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToSuppliersAndEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliersAndEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToSuppliersAndEmployees" xlink:to="lab_us-gaap_PaymentsToSuppliersAndEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32a856c0-c435-481d-a1a2-f9335cb5dec1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_9adb2ea6-a95d-423d-a8ab-ad36ac7c1a57_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_85667796-b9ac-40ac-aee6-5f69fec98491_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_A2021RepurchaseProgramMember_6ff35580-4a34-46ca-a23e-1bf9817b33a3_terseLabel_en-US" xlink:label="lab_cvs_A2021RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Repurchase Program</link:label>
    <link:label id="lab_cvs_A2021RepurchaseProgramMember_label_en-US" xlink:label="lab_cvs_A2021RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Repurchase Program [Member]</link:label>
    <link:label id="lab_cvs_A2021RepurchaseProgramMember_documentation_en-US" xlink:label="lab_cvs_A2021RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_A2021RepurchaseProgramMember" xlink:href="cvs-20221231.xsd#cvs_A2021RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_A2021RepurchaseProgramMember" xlink:to="lab_cvs_A2021RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_2e08baee-2d4a-4990-a94b-3d664e93f0f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease and rents</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e799bbf6-e8b6-4512-8b15-583f8849ff9d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f16830-f7a1-495c-b1d2-122cdd250181_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56b7968d-070e-4adf-b528-5af0f0e601c2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_f23580b2-f935-40ee-a7da-e94e377c87be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Future Benefits Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_0386d067-c14c-4a64-b018-3810477c15b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Benefit Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Projected Benefit Obligations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_1ee75f0a-f261-40fd-8b59-7ae6b5617a80_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Year Of Origination [Domain]</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_label_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Year Of Origination [Domain]</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_documentation_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Year Of Origination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateYearOfOriginationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain" xlink:to="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_55bb6f63-a818-4669-86bf-25bae7e7e1f1_totalLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total outstanding liabilities for health care costs payable, net of reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_a45411ee-994e-45c1-8543-9d5bd3551204_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration health care costs payable, net of reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_34775fb1-3a75-4476-a8cc-3206765b921e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f9744818-3364-452a-9ab4-f60bd26c2869_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_fe647762-6cda-48da-9154-4110a884af2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claims Development [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9698c59f-82bc-488b-b3fc-d017682d9140_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_55f1ad03-bd4a-40e9-aab6-b897e106f18f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f66dc54a-0075-4f11-b894-f88448f36e2d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_544e61dc-f616-419d-8e1e-ef9aaa8fe58f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale_ad5ad02b-d231-4b39-a12a-2307097281e8_terseLabel_en-US" xlink:label="lab_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale_label_en-US" xlink:label="lab_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Including Assets Held For Sale</link:label>
    <link:label id="lab_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale_documentation_en-US" xlink:label="lab_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Including Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" xlink:to="lab_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e91d858-a119-4262-b79e-8db52a765a73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_81d46c23-d24b-4d11-870a-73747c790cb2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life of property plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1eb72b83-6125-4feb-9a36-ab6cc75c1f4c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost (income):</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TotalInvestmentsDomain_f59d105b-fafd-4710-b107-8a24837fca58_terseLabel_en-US" xlink:label="lab_cvs_TotalInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments [Domain]</link:label>
    <link:label id="lab_cvs_TotalInvestmentsDomain_label_en-US" xlink:label="lab_cvs_TotalInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsDomain" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TotalInvestmentsDomain" xlink:to="lab_cvs_TotalInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ea8b723-5778-4461-8203-9cfe984cd0e4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_YearOfOriginationPriorToPeriodFiveMember_a6faeaad-4cdf-4f3d-a8d5-a7bf6660101d_terseLabel_en-US" xlink:label="lab_cvs_YearOfOriginationPriorToPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior</link:label>
    <link:label id="lab_cvs_YearOfOriginationPriorToPeriodFiveMember_label_en-US" xlink:label="lab_cvs_YearOfOriginationPriorToPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Prior To Period Five [Member]</link:label>
    <link:label id="lab_cvs_YearOfOriginationPriorToPeriodFiveMember_documentation_en-US" xlink:label="lab_cvs_YearOfOriginationPriorToPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Prior To Period Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPriorToPeriodFiveMember" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPriorToPeriodFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_YearOfOriginationPriorToPeriodFiveMember" xlink:to="lab_cvs_YearOfOriginationPriorToPeriodFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f3745f65-659c-40cd-8116-f9cb14321e58_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fee6b928-1f79-41e3-b7f6-2c0a4da93664_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ecd9b121-8504-4e45-a810-9d9d136c3a21_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_e441754d-1a6d-4ad1-9727-076352eaf427_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_883879f4-a191-4258-a585-0200d2f2ff22_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_995bdd00-b660-40b6-a62b-d8f9502cf546_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_e506e45b-3c87-424b-a87b-930b5be8c66d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets reflected in other assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_0a077520-24cf-4f82-8bf0-6452fb61bd54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Income, Reported Amounts, by Category [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_3d3377d7-7d9c-4947-8f96-f29b6db74a77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_693000a6-03ac-4e46-9c87-caa17c513a52_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for derivative instruments</link:label>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3DueAugust2026Member_05f706e0-e45a-48f2-8068-5261e14a5f98_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3DueAugust2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3% senior notes due August 2026</link:label>
    <link:label id="lab_cvs_SeniorNotes3DueAugust2026Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3DueAugust2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3%, Due August 2026 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3DueAugust2026Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3DueAugust2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3%, Due August 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3DueAugust2026Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3DueAugust2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3DueAugust2026Member" xlink:to="lab_cvs_SeniorNotes3DueAugust2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLiabilityUndiscountedExcessAmount_96ba8eee-ae9c-4a69-bca9-5d4201e82c55_negatedTotalLabel_en-US" xlink:label="lab_cvs_LesseeLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_cvs_LesseeLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_cvs_LesseeLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_cvs_LesseeLiabilityUndiscountedExcessAmount_documentation_en-US" xlink:label="lab_cvs_LesseeLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityUndiscountedExcessAmount" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLiabilityUndiscountedExcessAmount" xlink:to="lab_cvs_LesseeLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_616e023e-1021-41dd-87a9-1ab740e24c33_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Included in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_94a25418-d6af-49cf-a6b2-7d5f7d1735fa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of receivables and contract liabilities from contracts with customers</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_611b81b1-bf1c-4d46-bd40-8751d569f649_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_USFederalGovernmentMember_fbef731c-b302-4c1b-aca6-95dcffcf1eb3_terseLabel_en-US" xlink:label="lab_cvs_USFederalGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Federal Government</link:label>
    <link:label id="lab_cvs_USFederalGovernmentMember_label_en-US" xlink:label="lab_cvs_USFederalGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Federal Government [Member]</link:label>
    <link:label id="lab_cvs_USFederalGovernmentMember_documentation_en-US" xlink:label="lab_cvs_USFederalGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Federal Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_USFederalGovernmentMember" xlink:href="cvs-20221231.xsd#cvs_USFederalGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_USFederalGovernmentMember" xlink:to="lab_cvs_USFederalGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci_0054cb49-b183-41e2-bfe3-9b3d934613bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized capital losses included in OCI associated with Level 3 financial assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci_label_en-US" xlink:label="lab_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), OCI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci" xlink:to="lab_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_16c0857f-3781-4275-bb0d-816deaa75f5e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_b2ae9c3a-8683-46d6-9a75-79f515b4fcd8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Contract Acquisition Costs</link:label>
    <link:label id="lab_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_label_en-US" xlink:label="lab_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Policy Acquisition Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:to="lab_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_GuarantorObligationsNumberOfLeases_c96e2b90-ef3a-4c8d-ad4b-411769117a54_terseLabel_en-US" xlink:label="lab_cvs_GuarantorObligationsNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor obligations, number of leases</link:label>
    <link:label id="lab_cvs_GuarantorObligationsNumberOfLeases_label_en-US" xlink:label="lab_cvs_GuarantorObligationsNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Number Of Leases</link:label>
    <link:label id="lab_cvs_GuarantorObligationsNumberOfLeases_documentation_en-US" xlink:label="lab_cvs_GuarantorObligationsNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Number Of Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_GuarantorObligationsNumberOfLeases" xlink:href="cvs-20221231.xsd#cvs_GuarantorObligationsNumberOfLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_GuarantorObligationsNumberOfLeases" xlink:to="lab_cvs_GuarantorObligationsNumberOfLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_bee3cd81-a43c-43c3-8113-3f94aadb33d6_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total claims paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8db2d185-3326-4cb3-866b-4b379140cdd7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateInvestmentMember_7e304a69-c582-4673-8b62-8d14edefd541_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate investment</link:label>
    <link:label id="lab_us-gaap_RealEstateInvestmentMember_label_en-US" xlink:label="lab_us-gaap_RealEstateInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Investment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateInvestmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstateInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateInvestmentMember" xlink:to="lab_us-gaap_RealEstateInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesMember_8c009f3e-d980-4034-9e95-7349e64cb59b_terseLabel_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Home Loan Bank Advances</link:label>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesMember_label_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Home Loan Bank Advances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:to="lab_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_694870ad-88c7-4e06-bf35-633a1b7f9797_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_06938ed2-d0a3-4b87-a94a-a0d82e253e5b_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d1788c49-6119-48be-bb6e-028413e65438_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PharmacyServicesSegmentMember_3a7ce2ab-7611-4a10-a31f-d22b2e3cc326_terseLabel_en-US" xlink:label="lab_cvs_PharmacyServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Services</link:label>
    <link:label id="lab_cvs_PharmacyServicesSegmentMember_label_en-US" xlink:label="lab_cvs_PharmacyServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Services Segment [Member]</link:label>
    <link:label id="lab_cvs_PharmacyServicesSegmentMember_documentation_en-US" xlink:label="lab_cvs_PharmacyServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Services Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyServicesSegmentMember" xlink:href="cvs-20221231.xsd#cvs_PharmacyServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PharmacyServicesSegmentMember" xlink:to="lab_cvs_PharmacyServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_80365dc6-095a-4f96-a2b7-b3883d6f1584_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FrontStoreRevenueMember_ef81f251-bb09-4111-90e7-fbe295ffeced_terseLabel_en-US" xlink:label="lab_cvs_FrontStoreRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Front Store</link:label>
    <link:label id="lab_cvs_FrontStoreRevenueMember_label_en-US" xlink:label="lab_cvs_FrontStoreRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Front Store Revenue [Member]</link:label>
    <link:label id="lab_cvs_FrontStoreRevenueMember_documentation_en-US" xlink:label="lab_cvs_FrontStoreRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Front Store Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FrontStoreRevenueMember" xlink:href="cvs-20221231.xsd#cvs_FrontStoreRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FrontStoreRevenueMember" xlink:to="lab_cvs_FrontStoreRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_cd933d7f-0d64-45cb-8f75-991ac5447f68_totalLabel_en-US" xlink:label="lab_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable, net</link:label>
    <link:label id="lab_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_label_en-US" xlink:label="lab_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Including Assets Held For Sale</link:label>
    <link:label id="lab_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_documentation_en-US" xlink:label="lab_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Including Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" xlink:href="cvs-20221231.xsd#cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" xlink:to="lab_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6d0934e4-0a80-429e-9061-ad59ba747c53_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer_cbd5b787-83b8-459b-8c68-2ea9d82d8064_terseLabel_en-US" xlink:label="lab_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of reinsurance agreements with unrelated issuer</link:label>
    <link:label id="lab_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer_label_en-US" xlink:label="lab_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Years Reinsurance Agreement With Unrelated Insurer</link:label>
    <link:label id="lab_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer_documentation_en-US" xlink:label="lab_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This line item represents the four years of a reinsurance agreement with an unrelated insurer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer" xlink:href="cvs-20221231.xsd#cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer" xlink:to="lab_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_3aa2d033-e57e-4916-80ad-506e83db3fb2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_33653b8c-bcbf-45ba-bb87-34b839ece2e8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_0b37cb6f-02e7-4fb7-bda7-9de4f4683127_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of subsidiaries</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_762bc51c-cc1d-47f1-af24-e93a711957bb_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of subsidiaries</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_e1754656-4370-434c-8f49-6b0d8a02ae18_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on divestiture of subsidiaries</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_d6e4e39d-fcd7-4e09-8905-176fa225e58d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_71e318b0-c749-45ac-aa8d-84039a891261_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_dec4396e-6a2f-415e-9939-d2f5684f988f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_bec3cc67-5011-411b-bb7d-4709c8673420_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_d17c7805-34c7-4394-9857-9488f3d6fa33_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_df94bd00-c64b-4f6c-871d-c11bdce1d9a4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivateEquityFundsMember_8a8251e9-71f1-4fa2-a565-da6f7da322b0_verboseLabel_en-US" xlink:label="lab_us-gaap_PrivateEquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private equity investments</link:label>
    <link:label id="lab_us-gaap_PrivateEquityFundsMember_label_en-US" xlink:label="lab_us-gaap_PrivateEquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivateEquityFundsMember" xlink:to="lab_us-gaap_PrivateEquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_36794180-4ba6-451e-af4c-42deae637ca4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_49ccdc54-63cf-485c-b155-cd1d3dfa525c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_11653b1c-8ed8-4dd2-bdb6-e3d81686732e_terseLabel_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_HealthInsurerFee_09a3ea7d-7085-498c-b886-20f66a18c539_terseLabel_en-US" xlink:label="lab_cvs_HealthInsurerFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fee</link:label>
    <link:label id="lab_cvs_HealthInsurerFee_label_en-US" xlink:label="lab_cvs_HealthInsurerFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurer Fee</link:label>
    <link:label id="lab_cvs_HealthInsurerFee_documentation_en-US" xlink:label="lab_cvs_HealthInsurerFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated amount of the health insurer fee accrued during the reporting period, as required by Health Care Reform.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthInsurerFee" xlink:href="cvs-20221231.xsd#cvs_HealthInsurerFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_HealthInsurerFee" xlink:to="lab_cvs_HealthInsurerFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a6148728-0839-44c1-8f15-dcbf5676c3b9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7a5732f1-a875-4136-933b-ab579d39583c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f8cdebac-f632-4866-a83c-5f99378a47f7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term exercisable at end of year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e86e2afd-bb68-4449-ad46-22242c7e4d1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on net cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_24cb7df6-fd70-42fc-9b5e-6491118be7c0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_79803613-a22d-40fc-b01e-4a41ecf98644_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Value and Fair Value By Level of Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_b4b38640-d604-44db-b6e4-cb9e6dce01f3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_b5162788-a112-45b5-bf8d-49e15ebeed25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium paid in excess of debt principal</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_e7129365-d062-4635-b825-4dd3819985dd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e3423581-3372-42c1-a9f0-c74f5c61d3b9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCorporateDebtSecuritiesMember_32a42ca0-8c67-4ab0-adf1-cb9fb166fe8d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign securities</link:label>
    <link:label id="lab_us-gaap_ForeignCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Corporate, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_41be5acc-82e6-46ec-8eb8-c11757b4c017_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_480e7a74-453e-420a-bfd6-d190469530dd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_57c21477-1957-4f9e-88ac-325c523a30b6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9608dacf-895e-4628-b957-bc55626c46da_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_5a96ee6c-1b40-454e-b488-ad34aafdf4c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit payments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_0e7338c5-f426-4f63-9885-3d02db3ad441_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred Health Care Claims, Net of Reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_547a3368-fefe-4188-b19c-c6d25c70e2b0_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plans and Other Postretirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_bdbe57db-6e2a-49d3-8a91-8bf867af9ba4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, maturity, without single maturity date</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_b134447c-6bc7-4684-a741-3959969cc467_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a4852af-98fc-415b-a80f-8d85550a9411_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_072195e5-1daf-4ff5-9037-492c8bb940f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6c4f4b4f-d3ea-4cbb-a9fc-be15f9758a8a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1ea2974f-f8a5-4a2e-9a4a-5d5f0f03fc62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to retained earnings as a result of new accounting standard adoption</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember_74dd4cff-17b2-469a-87e7-f07bc7a9ac8a_terseLabel_en-US" xlink:label="lab_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Life &amp; Annuity Company of New York</link:label>
    <link:label id="lab_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember_label_en-US" xlink:label="lab_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Life &amp; Annuity Company Of New York [Member]</link:label>
    <link:label id="lab_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember_documentation_en-US" xlink:label="lab_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Life &amp; Annuity Company Of New York [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember" xlink:href="cvs-20221231.xsd#cvs_LincolnLifeAnnuityCompanyOfNewYorkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember" xlink:to="lab_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_41ee20e2-1bfe-49b5-97fd-f5e750038ae8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss and capital loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_464b662a-590f-40e3-a10b-70fd6bba6d27_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract_19a85d91-87b8-46d3-b142-b181b4c2eb5a_terseLabel_en-US" xlink:label="lab_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</link:label>
    <link:label id="lab_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract_label_en-US" xlink:label="lab_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]</link:label>
    <link:label id="lab_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract_documentation_en-US" xlink:label="lab_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:href="cvs-20221231.xsd#cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:to="lab_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_71efff30-9dba-4af5-bb7b-54a328a09761_terseLabel_en-US" xlink:label="lab_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yield-related impairment loss</link:label>
    <link:label id="lab_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_label_en-US" xlink:label="lab_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings</link:label>
    <link:label id="lab_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_documentation_en-US" xlink:label="lab_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:href="cvs-20221231.xsd#cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:to="lab_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_7e32342c-66b9-4912-9302-e8fd1eba7ad7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo_845900a2-ada9-402b-a49b-99fd234a7aac_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Year Two</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo_documentation_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo" xlink:to="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LongTermInvestmentsIncludingAssetsHeldForSale_ec6ea02e-9694-42be-9d52-49da56d1224b_terseLabel_en-US" xlink:label="lab_cvs_LongTermInvestmentsIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_cvs_LongTermInvestmentsIncludingAssetsHeldForSale_label_en-US" xlink:label="lab_cvs_LongTermInvestmentsIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments, Including Assets Held For Sale</link:label>
    <link:label id="lab_cvs_LongTermInvestmentsIncludingAssetsHeldForSale_documentation_en-US" xlink:label="lab_cvs_LongTermInvestmentsIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments, Including Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermInvestmentsIncludingAssetsHeldForSale" xlink:href="cvs-20221231.xsd#cvs_LongTermInvestmentsIncludingAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LongTermInvestmentsIncludingAssetsHeldForSale" xlink:to="lab_cvs_LongTermInvestmentsIncludingAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0e27f471-9b82-45e1-bf9c-041e72588f6d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e403ff39-a20e-4639-b4b4-cb36d2219e91_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_189845db-97bf-4eb5-8b20-aaa4220cbf26_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c8039afb-0471-411a-89d2-c24635715d47_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_3111ebee-ec62-46ca-8bc0-ef4babbf5336_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations attributable to CVS Health (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4PointThreePercentDue2028Member_1eb938f2-6a64-4636-a187-735e7b51ff02_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4PointThreePercentDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.3% senior notes due 2028</link:label>
    <link:label id="lab_cvs_SeniorNotes4PointThreePercentDue2028Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4PointThreePercentDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4 Point Three Percent, Due 2028 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4PointThreePercentDue2028Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4PointThreePercentDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4 Point Three Percent, Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4PointThreePercentDue2028Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4PointThreePercentDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4PointThreePercentDue2028Member" xlink:to="lab_cvs_SeniorNotes4PointThreePercentDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c6b1845-a602-4b28-9fd7-1527920ce03b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3.875DueAugust2047Member_f6d6287b-7dec-4021-abc0-69adda87f0da_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3.875DueAugust2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% senior notes due August 2047</link:label>
    <link:label id="lab_cvs_SeniorNotes3.875DueAugust2047Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3.875DueAugust2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.875%, Due August 2047 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3.875DueAugust2047Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3.875DueAugust2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.875%, Due August 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.875DueAugust2047Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.875DueAugust2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3.875DueAugust2047Member" xlink:to="lab_cvs_SeniorNotes3.875DueAugust2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e8ac07b0-9d76-40a6-bbf8-df2c0fed3510_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_efdb614d-dc09-409d-8704-99d1355ae890_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_37a85214-b90d-4fe8-9ede-bf5d716a058a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ff7d3305-668f-496c-ae75-0d46eca8f50b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6925ab25-2a78-4f0a-a03f-d98b197586f0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock_6d837e50-7062-40a4-a054-2e6d3d954a51_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs Payable</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance and Deposit Contracts [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:to="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskReinsurerDomain_a09da54a-b4af-4427-9e44-efe6e49e9f83_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskReinsurerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Reinsurer [Domain]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskReinsurerDomain_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskReinsurerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurer, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain" xlink:to="lab_us-gaap_CededCreditRiskReinsurerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes5.125DueJuly2045Member_bc22291a-f599-4f0f-b784-a7c8959db0c6_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes5.125DueJuly2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% senior notes due July 2045</link:label>
    <link:label id="lab_cvs_SeniorNotes5.125DueJuly2045Member_label_en-US" xlink:label="lab_cvs_SeniorNotes5.125DueJuly2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.125%, Due July 2045 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes5.125DueJuly2045Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes5.125DueJuly2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.125%, Due July 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.125DueJuly2045Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.125DueJuly2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes5.125DueJuly2045Member" xlink:to="lab_cvs_SeniorNotes5.125DueJuly2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_225f2049-d182-455f-81f3-4d0dc562286d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock_0abc675d-b586-4fbb-b037-d3e1bc2bd5e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices Disclosure</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:to="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FederalCourtInOhioJudgmentMember_12512c54-0947-4784-b925-4e617773245f_terseLabel_en-US" xlink:label="lab_cvs_FederalCourtInOhioJudgmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Court in Ohio Judgment</link:label>
    <link:label id="lab_cvs_FederalCourtInOhioJudgmentMember_label_en-US" xlink:label="lab_cvs_FederalCourtInOhioJudgmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Court In Ohio Judgment [Member]</link:label>
    <link:label id="lab_cvs_FederalCourtInOhioJudgmentMember_documentation_en-US" xlink:label="lab_cvs_FederalCourtInOhioJudgmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Court In Ohio Judgment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FederalCourtInOhioJudgmentMember" xlink:href="cvs-20221231.xsd#cvs_FederalCourtInOhioJudgmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FederalCourtInOhioJudgmentMember" xlink:to="lab_cvs_FederalCourtInOhioJudgmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_9aefc96f-d77e-48ab-9489-5f2e11e2d094_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Income, Reported Amounts, by Category [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_e65c05b2-4209-44af-9b18-3970f8b02b53_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1bb65977-ae59-4417-8064-a33094e3e351_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ecc147c0-8f42-41fe-b2c0-bdbd43278f40_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_53033c5c-22a3-408e-8ee8-4db7247f93b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, fair value</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4ae764fb-cb6c-4b55-a1f7-fe6af9e4a5e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6fc1d248-eb78-4ba1-add8-9cebb49d7057_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedPremiumsEarned_eebff144-2d6b-4786-af01-71e35539d77c_terseLabel_en-US" xlink:label="lab_us-gaap_AssumedPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed</link:label>
    <link:label id="lab_us-gaap_AssumedPremiumsEarned_label_en-US" xlink:label="lab_us-gaap_AssumedPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Premiums Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedPremiumsEarned" xlink:to="lab_us-gaap_AssumedPremiumsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale_f48c5174-446c-4bac-813f-89ce93c87a0b_terseLabel_en-US" xlink:label="lab_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale_label_en-US" xlink:label="lab_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligation, Including Liabilities Held For Sale</link:label>
    <link:label id="lab_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale_documentation_en-US" xlink:label="lab_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of long-term debt and lease obligation, including liabilities held for sale, classified as noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" xlink:href="cvs-20221231.xsd#cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" xlink:to="lab_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_099c0b58-5dfd-4e2f-aa7d-b2e39c72de9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and pharmacy claims and discounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_6988c1b4-1174-49a1-b275-d46ddc0074c8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_bc195c67-979b-4d8a-b588-17ecb7a5b39e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Paid Health Care Claims, Net of Reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_dbc46354-e04b-4656-a3e3-4376664abc7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_ac20eaea-5b5b-4fb7-a916-3daa93b997d7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percent</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_405e8442-dac8-40b0-b3f9-d0a35cbc062c_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:to="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3Point625PercentApril2027Member_0efd7b1c-883f-4a92-8967-9426813195bf_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3Point625PercentApril2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% senior notes due April 2027</link:label>
    <link:label id="lab_cvs_SeniorNotes3Point625PercentApril2027Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3Point625PercentApril2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3 Point 625 Percent, April 2027 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3Point625PercentApril2027Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3Point625PercentApril2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3 Point 625 Percent, April 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point625PercentApril2027Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point625PercentApril2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3Point625PercentApril2027Member" xlink:to="lab_cvs_SeniorNotes3Point625PercentApril2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes6.625DueJune2036Member_7311f614-b13e-4f99-96de-cc69cbbbfb6e_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes6.625DueJune2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.625% senior notes due June 2036</link:label>
    <link:label id="lab_cvs_SeniorNotes6.625DueJune2036Member_label_en-US" xlink:label="lab_cvs_SeniorNotes6.625DueJune2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.625%, Due June 2036 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes6.625DueJune2036Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes6.625DueJune2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.625%, Due June 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.625DueJune2036Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.625DueJune2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes6.625DueJune2036Member" xlink:to="lab_cvs_SeniorNotes6.625DueJune2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_32f8b663-ecae-4425-92b5-3c6d3c9c15b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_5adcad7e-a193-47de-a538-ad09893e3765_terseLabel_en-US" xlink:label="lab_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Department of Health and Human Services, ACA Risk Corridor Receivables</link:label>
    <link:label id="lab_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_label_en-US" xlink:label="lab_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Department Of Health And Human Services, ACA Risk Corridor Receivables [Member]</link:label>
    <link:label id="lab_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_documentation_en-US" xlink:label="lab_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Department Of Health And Human Services, ACA Risk Corridor Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember" xlink:href="cvs-20221231.xsd#cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember" xlink:to="lab_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths_eeaf6fc7-3e3a-4a5f-a553-9b2bd18f9d11_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths_documentation_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths" xlink:to="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates_0cfdc671-ef40-4888-a1a7-c93d03c25adc_terseLabel_en-US" xlink:label="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which the Company has entered the individual public health insurance exchange</link:label>
    <link:label id="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates_label_en-US" xlink:label="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Public Health Insurance Exchanges, Number Of States</link:label>
    <link:label id="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates_documentation_en-US" xlink:label="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Public Health Insurance Exchanges, Number Of States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates" xlink:href="cvs-20221231.xsd#cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates" xlink:to="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OtherLongTermInsuranceLiabilitiesMember_273dc736-ab80-4cb5-b4e7-f9c3fa1b73b6_terseLabel_en-US" xlink:label="lab_cvs_OtherLongTermInsuranceLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Insurance Liabilities</link:label>
    <link:label id="lab_cvs_OtherLongTermInsuranceLiabilitiesMember_label_en-US" xlink:label="lab_cvs_OtherLongTermInsuranceLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Insurance Liabilities [Member]</link:label>
    <link:label id="lab_cvs_OtherLongTermInsuranceLiabilitiesMember_documentation_en-US" xlink:label="lab_cvs_OtherLongTermInsuranceLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Insurance Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherLongTermInsuranceLiabilitiesMember" xlink:href="cvs-20221231.xsd#cvs_OtherLongTermInsuranceLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OtherLongTermInsuranceLiabilitiesMember" xlink:to="lab_cvs_OtherLongTermInsuranceLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_e6e0cbe4-a7f8-463e-8f43-53552251cdfd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_51b6c026-a1c5-46a9-b67b-5185ed121581_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_4cf9a948-d7da-4f6b-904d-df974d393717_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8ab9e59c-309e-4bfe-9d94-495491e0685f_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to CVS Health (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DeferredTaxLiabilitiesRetirementBenefits_24e6ae63-cfac-459b-9576-c247c27f7594_negatedTerseLabel_en-US" xlink:label="lab_cvs_DeferredTaxLiabilitiesRetirementBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement benefits</link:label>
    <link:label id="lab_cvs_DeferredTaxLiabilitiesRetirementBenefits_label_en-US" xlink:label="lab_cvs_DeferredTaxLiabilitiesRetirementBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Retirement Benefits</link:label>
    <link:label id="lab_cvs_DeferredTaxLiabilitiesRetirementBenefits_documentation_en-US" xlink:label="lab_cvs_DeferredTaxLiabilitiesRetirementBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Retirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxLiabilitiesRetirementBenefits" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxLiabilitiesRetirementBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DeferredTaxLiabilitiesRetirementBenefits" xlink:to="lab_cvs_DeferredTaxLiabilitiesRetirementBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TreasuryStockSharesHeldinTrust_28b0e919-b24f-44ee-8889-0b310543deca_terseLabel_en-US" xlink:label="lab_cvs_TreasuryStockSharesHeldinTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares held in trust (in shares)</link:label>
    <link:label id="lab_cvs_TreasuryStockSharesHeldinTrust_label_en-US" xlink:label="lab_cvs_TreasuryStockSharesHeldinTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Held in Trust</link:label>
    <link:label id="lab_cvs_TreasuryStockSharesHeldinTrust_documentation_en-US" xlink:label="lab_cvs_TreasuryStockSharesHeldinTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Held in Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockSharesHeldinTrust" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockSharesHeldinTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TreasuryStockSharesHeldinTrust" xlink:to="lab_cvs_TreasuryStockSharesHeldinTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember_037c042d-b797-4c1a-9290-5bfda890fb75_terseLabel_en-US" xlink:label="lab_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VOYA Retirement Insurance and Annuity Company</link:label>
    <link:label id="lab_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember_label_en-US" xlink:label="lab_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VOYA Retirement Insurance And Annuity Company [Member]</link:label>
    <link:label id="lab_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember_documentation_en-US" xlink:label="lab_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VOYA Retirement Insurance And Annuity Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember" xlink:href="cvs-20221231.xsd#cvs_VOYARetirementInsuranceAndAnnuityCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember" xlink:to="lab_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_04c54904-0ca5-4c40-b845-3eb0864ab911_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified, pre-tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_57ddcd1b-9958-44e5-a4d1-176bc4d8da6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested in period, fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_69fa942f-93b8-4380-aa87-b6139183eb4f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fcd00023-3b8a-44f0-9ee2-69cd0e8d8608_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4cda4b9f-d7ed-4a4b-a98c-1deaed66b9f0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_2b5cb737-6e01-400b-b94e-ce8b359d3bc6_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate/ Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3c7d27cc-dd68-4901-bb1c-c8d5f95d220c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_f3282f38-30de-40e0-8469-bb0c223ce11c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_fa7c04af-3616-4094-95cc-fa63f64e74f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale-leaseback transactions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lease Payment, Sales-Type and Direct Financing Leases, Investing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity" xlink:to="lab_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_5fa388df-3e4e-42b3-8b86-cb5f89806f59_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_5b10a2f4-b971-4ae3-a1b3-1612f7fc7515_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_23e455aa-fb61-4514-b1d8-e6f6f84376df_terseLabel_en-US" xlink:label="lab_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions:</link:label>
    <link:label id="lab_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_label_en-US" xlink:label="lab_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions: [Abstract]</link:label>
    <link:label id="lab_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_documentation_en-US" xlink:label="lab_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions:</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract" xlink:href="cvs-20221231.xsd#cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract" xlink:to="lab_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1fbdd03b-19fd-47e4-bae7-94c8353382d4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_CashFlowLesseeAbstract_69756d54-6383-44f8-9570-7a137ed2af81_terseLabel_en-US" xlink:label="lab_cvs_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_cvs_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_cvs_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_cvs_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_cvs_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CashFlowLesseeAbstract" xlink:href="cvs-20221231.xsd#cvs_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_CashFlowLesseeAbstract" xlink:to="lab_cvs_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_0a9ce9e9-4ca6-48ce-983c-e1e58baa0f4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededPremiumsEarned_4c26b2ef-d631-496a-9b9d-a4f9613ad1f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CededPremiumsEarned" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded</link:label>
    <link:label id="lab_us-gaap_CededPremiumsEarned_label_en-US" xlink:label="lab_us-gaap_CededPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Premiums Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededPremiumsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededPremiumsEarned" xlink:to="lab_us-gaap_CededPremiumsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba2ffdf0-b808-45ed-9813-0f9309750a5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_4852d49f-8084-414f-b8c7-d389ce76e3fe_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LitigationSettlementNumberOfStatesElectedToJoin_eb0cf8ad-f050-40f7-a17e-0f6d1b4b59e4_terseLabel_en-US" xlink:label="lab_cvs_LitigationSettlementNumberOfStatesElectedToJoin" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states that elected to join the settlement</link:label>
    <link:label id="lab_cvs_LitigationSettlementNumberOfStatesElectedToJoin_label_en-US" xlink:label="lab_cvs_LitigationSettlementNumberOfStatesElectedToJoin" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number Of States Elected To Join</link:label>
    <link:label id="lab_cvs_LitigationSettlementNumberOfStatesElectedToJoin_documentation_en-US" xlink:label="lab_cvs_LitigationSettlementNumberOfStatesElectedToJoin" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number Of States Elected To Join</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LitigationSettlementNumberOfStatesElectedToJoin" xlink:href="cvs-20221231.xsd#cvs_LitigationSettlementNumberOfStatesElectedToJoin"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LitigationSettlementNumberOfStatesElectedToJoin" xlink:to="lab_cvs_LitigationSettlementNumberOfStatesElectedToJoin" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_38ad1a43-65b8-4096-8cc3-8441281bfb35_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears_9ab152c7-2600-4b57-a933-df3aed6f3d4d_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years through ten years</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalCreditAssessmentDomain_408727bf-3379-4b71-a026-e63d0897a21b_terseLabel_en-US" xlink:label="lab_us-gaap_InternalCreditAssessmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Credit Assessment [Domain]</link:label>
    <link:label id="lab_us-gaap_InternalCreditAssessmentDomain_label_en-US" xlink:label="lab_us-gaap_InternalCreditAssessmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Credit Assessment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain" xlink:to="lab_us-gaap_InternalCreditAssessmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_6766c5e3-dbac-4577-95f9-ebc03b4e99ea_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_80a7a85b-e2ac-4535-8617-6c5e0d89d4c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_7361f96f-a8b4-45a2-92ea-1186c227b459_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PaymentsForAcceleratedShareRepurchasesAmount_d4515038-6984-4dc6-9d73-8bb43c614415_terseLabel_en-US" xlink:label="lab_cvs_PaymentsForAcceleratedShareRepurchasesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for ASR, amount</link:label>
    <link:label id="lab_cvs_PaymentsForAcceleratedShareRepurchasesAmount_label_en-US" xlink:label="lab_cvs_PaymentsForAcceleratedShareRepurchasesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Accelerated Share Repurchases, Amount</link:label>
    <link:label id="lab_cvs_PaymentsForAcceleratedShareRepurchasesAmount_documentation_en-US" xlink:label="lab_cvs_PaymentsForAcceleratedShareRepurchasesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Accelerated Share Repurchases, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PaymentsForAcceleratedShareRepurchasesAmount" xlink:href="cvs-20221231.xsd#cvs_PaymentsForAcceleratedShareRepurchasesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PaymentsForAcceleratedShareRepurchasesAmount" xlink:to="lab_cvs_PaymentsForAcceleratedShareRepurchasesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_27f402e0-00de-4616-b86e-a6b6b0ab9510_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OmnicareLongTermCareBusinessMember_8b3418b0-2f3e-45dc-881d-8d04cb54bfc8_terseLabel_en-US" xlink:label="lab_cvs_OmnicareLongTermCareBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnicare Long-Term Care Business</link:label>
    <link:label id="lab_cvs_OmnicareLongTermCareBusinessMember_label_en-US" xlink:label="lab_cvs_OmnicareLongTermCareBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnicare Long-Term Care Business [Member]</link:label>
    <link:label id="lab_cvs_OmnicareLongTermCareBusinessMember_documentation_en-US" xlink:label="lab_cvs_OmnicareLongTermCareBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnicare Long-Term Care Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OmnicareLongTermCareBusinessMember" xlink:href="cvs-20221231.xsd#cvs_OmnicareLongTermCareBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OmnicareLongTermCareBusinessMember" xlink:to="lab_cvs_OmnicareLongTermCareBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_77fe59ba-963d-49d8-87a7-65200ec68148_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_62d52800-458c-4271-8c34-854994ce9e03_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstate_43bbc033-289e-4087-8c1d-4136f1ffb22e_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loans</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstate_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstate" xlink:to="lab_us-gaap_MortgageLoansOnRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_0731bc53-02b8-483d-b0ab-49d3428c0bfd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1cce336c-c6a6-4ede-8c4d-b3ed98c6b618_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_BackUpCreditFacilitiesMember_d0236344-60d5-4590-9770-7375e2c3ebf0_terseLabel_en-US" xlink:label="lab_cvs_BackUpCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Back-Up Credit Facilities</link:label>
    <link:label id="lab_cvs_BackUpCreditFacilitiesMember_label_en-US" xlink:label="lab_cvs_BackUpCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Back-Up Credit Facilities [Member]</link:label>
    <link:label id="lab_cvs_BackUpCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cvs_BackUpCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Back-Up Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BackUpCreditFacilitiesMember" xlink:href="cvs-20221231.xsd#cvs_BackUpCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_BackUpCreditFacilitiesMember" xlink:to="lab_cvs_BackUpCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9d6c8fc3-bb73-4a16-9678-6ca9b3f6a60f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_ae24558c-1672-46e8-8b6d-2dc17b38da0a_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_4ab4fbb9-8129-4172-a738-44b179b32733_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross transfers into Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_6c5ea107-2fe5-4799-98d4-2588bd3e4cb8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_d65bf7fc-74ce-49a9-bb30-5e7d047e265d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LongTermCareReportingUnitMember_dfad3e13-eb3c-4cc0-bc92-69aae013b307_terseLabel_en-US" xlink:label="lab_cvs_LongTermCareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Care Reporting Unit</link:label>
    <link:label id="lab_cvs_LongTermCareReportingUnitMember_label_en-US" xlink:label="lab_cvs_LongTermCareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Care Reporting Unit [Member]</link:label>
    <link:label id="lab_cvs_LongTermCareReportingUnitMember_documentation_en-US" xlink:label="lab_cvs_LongTermCareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Care Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermCareReportingUnitMember" xlink:href="cvs-20221231.xsd#cvs_LongTermCareReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LongTermCareReportingUnitMember" xlink:to="lab_cvs_LongTermCareReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_3a7de374-e9e8-4445-91e8-c0a2268af508_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_101ff117-49c8-4a8b-b8f3-f29420cd6422_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_472c1ed8-0bcd-4e3a-b186-1394ed5946ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price exercisable at end of year ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_bbb704a6-fbb4-4128-b196-6ad0f792aa08_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_56b9008d-9aa2-45df-bba0-cf8589f20d57_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_29732608-2d33-4345-bb0e-7366d3a336e6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_00611b22-2210-4d7c-8dd8-4229dcb57af9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_bfdcc260-94ae-4c31-86d0-a901df72f091_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows paid for principal portion of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_40d74ed6-45d7-44da-a166-1e98ce0e4162_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal charges</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PaymentsForInsuranceBenefits_d3deabe5-8add-475b-bae2-0cb778e4e6db_negatedTerseLabel_en-US" xlink:label="lab_cvs_PaymentsForInsuranceBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance benefits paid</link:label>
    <link:label id="lab_cvs_PaymentsForInsuranceBenefits_label_en-US" xlink:label="lab_cvs_PaymentsForInsuranceBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Insurance Benefits</link:label>
    <link:label id="lab_cvs_PaymentsForInsuranceBenefits_documentation_en-US" xlink:label="lab_cvs_PaymentsForInsuranceBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Insurance Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PaymentsForInsuranceBenefits" xlink:href="cvs-20221231.xsd#cvs_PaymentsForInsuranceBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PaymentsForInsuranceBenefits" xlink:to="lab_cvs_PaymentsForInsuranceBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_c6f51c40-55d7-478b-bee0-c8d796628a6e_totalLabel_en-US" xlink:label="lab_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_label_en-US" xlink:label="lab_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, Net, Including Assets Held For Sale</link:label>
    <link:label id="lab_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_documentation_en-US" xlink:label="lab_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, Net, Including Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" xlink:href="cvs-20221231.xsd#cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" xlink:to="lab_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_bc37d655-b405-4a63-834b-93760982c5dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity_b1c707c2-4a58-4885-aa1f-2b5c8f2d34b0_terseLabel_en-US" xlink:label="lab_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charitable contribution to CVS Health Foundation</link:label>
    <link:label id="lab_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity_label_en-US" xlink:label="lab_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Charitable Contribution To Non-Profit Entity</link:label>
    <link:label id="lab_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity_documentation_en-US" xlink:label="lab_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Charitable Contribution To Non-Profit Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity" xlink:href="cvs-20221231.xsd#cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity" xlink:to="lab_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_a128920a-fd86-4d0a-a0a2-5bb0f9d5bc94_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_a09d8438-2269-404e-b7a9-81cde1f3e64e_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_85f56a76-6f07-4792-bfae-4a5ca062cf13_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember_a5624364-1abb-4f19-89b1-2b4cc5867bf4_terseLabel_en-US" xlink:label="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common/collective trusts, Equity Securities</link:label>
    <link:label id="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember_label_en-US" xlink:label="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Common Collective Trust, Equity Securities [Member]</link:label>
    <link:label id="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember_documentation_en-US" xlink:label="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Common Collective Trust, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember" xlink:href="cvs-20221231.xsd#cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember" xlink:to="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearTwo_ab14d832-f1ad-4476-b19a-9f20abd7ac40_totalLabel_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due Year Two</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearTwo_documentation_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearTwo" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearTwo" xlink:to="lab_cvs_LesseeLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss_c77a01c8-32ef-4e34-ad53-5162b87cd5ba_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One year through five years</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_faa62082-b0c4-48ab-98f6-1a2044b646a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price vested at end of year and expected to vest in the future ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_HeathSavingsAccountBalance_12cce62e-0b32-4112-8006-1b80c8d5c677_terseLabel_en-US" xlink:label="lab_cvs_HeathSavingsAccountBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSA balances</link:label>
    <link:label id="lab_cvs_HeathSavingsAccountBalance_label_en-US" xlink:label="lab_cvs_HeathSavingsAccountBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heath Savings Account Balance</link:label>
    <link:label id="lab_cvs_HeathSavingsAccountBalance_documentation_en-US" xlink:label="lab_cvs_HeathSavingsAccountBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heath Savings Account Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HeathSavingsAccountBalance" xlink:href="cvs-20221231.xsd#cvs_HeathSavingsAccountBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_HeathSavingsAccountBalance" xlink:to="lab_cvs_HeathSavingsAccountBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes2.75DueNovember2022Member_6241576f-52c6-407c-8ee6-62d043e8ef46_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes2.75DueNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% senior notes due November 2022</link:label>
    <link:label id="lab_cvs_SeniorNotes2.75DueNovember2022Member_label_en-US" xlink:label="lab_cvs_SeniorNotes2.75DueNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.75%, Due November 2022 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes2.75DueNovember2022Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes2.75DueNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.75%, Due November 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueNovember2022Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueNovember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes2.75DueNovember2022Member" xlink:to="lab_cvs_SeniorNotes2.75DueNovember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RedeemablePreferredSecuritiesMember_eb41a256-b958-4fc4-a5a1-6f9317186286_terseLabel_en-US" xlink:label="lab_cvs_RedeemablePreferredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable preferred securities</link:label>
    <link:label id="lab_cvs_RedeemablePreferredSecuritiesMember_label_en-US" xlink:label="lab_cvs_RedeemablePreferredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Securities [Member]</link:label>
    <link:label id="lab_cvs_RedeemablePreferredSecuritiesMember_documentation_en-US" xlink:label="lab_cvs_RedeemablePreferredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RedeemablePreferredSecuritiesMember" xlink:href="cvs-20221231.xsd#cvs_RedeemablePreferredSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RedeemablePreferredSecuritiesMember" xlink:to="lab_cvs_RedeemablePreferredSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8b5c5e48-f580-4397-a274-2910ac1b81ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_29409459-18e7-4b9d-9c68-481c39b57f92_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPolicyholderFunds_73d64710-7450-45bd-9ce6-2ba642fb4df8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPolicyholderFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholders&#8217; funds</link:label>
    <link:label id="lab_us-gaap_OtherPolicyholderFunds_label_en-US" xlink:label="lab_us-gaap_OtherPolicyholderFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Policyholder Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPolicyholderFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPolicyholderFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPolicyholderFunds" xlink:to="lab_us-gaap_OtherPolicyholderFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_400b99f8-5c5e-4b1c-9b97-9426b7dac5e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_731e5527-2a66-49d0-bc6f-4665853c68f6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e0493c20-a6e3-4992-a4eb-98f201837d55_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_41687ca6-6e10-4360-9638-bc6bc8a3a5be_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_9e6259cd-82d4-4bcb-89d4-d6f0c117a2f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_label_en-US" xlink:label="lab_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care and Other Insurance Liabilities [Abstract]</link:label>
    <link:label id="lab_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_documentation_en-US" xlink:label="lab_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care and Other Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract" xlink:href="cvs-20221231.xsd#cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract" xlink:to="lab_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_b24d5b18-bad2-4f46-9917-bdb798d53762_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_508ab307-75ff-4c23-bde1-f3bd993b441a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_e4eec435-849e-4174-a005-b06e50372405_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_bf71fb7c-605f-460e-9952-def1b582571b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized investment gains (losses)</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a76ad7c8-f5a4-4290-b39c-28f0b6716bee_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e2ac36c3-75a7-4e88-b8db-6b4b6011e110_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_23c94200-85f5-4f53-b093-6e48b394652b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_253290b0-a0b2-457b-9e92-39e26a55521d_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_c7a2ee5e-0ac7-448b-8965-3e4dfd79f9eb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_a19a2e29-51a6-4d74-98af-665d6de146f6_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4af3b832-e72f-4f34-a54d-888fc7767315_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_7c6f06dd-6440-4c51-aae5-5fb3581ba013_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2f4cd9be-f2f1-44d1-addf-77f3dbae3f22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_92b7e322-f514-41b9-ab3b-f56a59921b7e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_BusinessCombinationTerminationFee_84eaf629-1bb4-44b0-9a1f-02d384199029_terseLabel_en-US" xlink:label="lab_cvs_BusinessCombinationTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination fee</link:label>
    <link:label id="lab_cvs_BusinessCombinationTerminationFee_label_en-US" xlink:label="lab_cvs_BusinessCombinationTerminationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Termination Fee</link:label>
    <link:label id="lab_cvs_BusinessCombinationTerminationFee_documentation_en-US" xlink:label="lab_cvs_BusinessCombinationTerminationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BusinessCombinationTerminationFee" xlink:href="cvs-20221231.xsd#cvs_BusinessCombinationTerminationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_BusinessCombinationTerminationFee" xlink:to="lab_cvs_BusinessCombinationTerminationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_1a19b1f2-df1c-482b-80b0-bda56f09a4a9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6d784025-c0e6-4671-b53d-5a7e30c42442_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_6f73eebc-e4ef-4b26-9056-ebfd52da6254_totalLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c43abbf1-2c7a-41ec-950a-f07936ea0eeb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d4c54fff-88a3-4eb6-8555-fae4a471169f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b12eb481-d1e1-4a49-8a36-bc47cdad8c3a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4DueDecember2023Member_4e12a7df-0888-4cae-b755-e0aefaa6bbd4_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4DueDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4% senior notes due December 2023</link:label>
    <link:label id="lab_cvs_SeniorNotes4DueDecember2023Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4DueDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4%, Due December 2023 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4DueDecember2023Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4DueDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4%, Due December 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4DueDecember2023Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4DueDecember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4DueDecember2023Member" xlink:to="lab_cvs_SeniorNotes4DueDecember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_e3946057-64ed-4e6a-a7aa-fe45484e5a88_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related integration costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_ce58a143-651c-4973-a1bf-dcc005181c0c_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans_bf67f951-2566-495a-b741-ce8532f64806_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New mortgage loans</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, New Mortgage Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateNewMortgageLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans" xlink:to="lab_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_97e9cdeb-86a7-4270-bee7-39bc6d559569_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities reflected in accrued expenses</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_c2fb60a7-c187-47c1-af9f-5d350b30edc7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c680dd1f-910a-4073-a766-187d570b245b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab0f79d4-76a0-47c2-ae7f-b41f5093f0d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a64b366b-ae25-41a5-8d19-4b1dd6ba1d78_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_76b30fff-5423-4553-aa50-03d9de6ae66b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3.375DueAugust2024Member_1830b265-8482-4014-a7f0-52b41340b576_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3.375DueAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% senior notes due August 2024</link:label>
    <link:label id="lab_cvs_SeniorNotes3.375DueAugust2024Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3.375DueAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.375%, Due August 2024 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3.375DueAugust2024Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3.375DueAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.375%, Due August 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.375DueAugust2024Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.375DueAugust2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3.375DueAugust2024Member" xlink:to="lab_cvs_SeniorNotes3.375DueAugust2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_6f76d279-8c7c-425e-b03e-95ca56724faa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impact of Reinsurance on Benefit Costs</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:to="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_a56a5a82-413a-447a-b7d4-ec073bcb058b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_ff99e1e4-b864-4ab2-bda9-8244de8eee96_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from stock options exercised (including ESPP)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9d2986c1-b68c-4a4d-a601-388c4899c547_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term vested at end of year and expected to vest in the future</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ChangeInContractWithCustomerLiabilityRollForward_bfdd168d-03ea-456f-aefc-8cffcb9384fe_terseLabel_en-US" xlink:label="lab_cvs_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_cvs_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_cvs_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_cvs_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_cvs_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="cvs-20221231.xsd#cvs_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_cvs_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7f851c2a-06b7-49d3-8d58-a3dd93916750_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities (included in accrued expenses)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_b745a2db-afd3-4a12-8171-7052d09a5183_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7421551f-5912-4a98-aeb9-a54977d39c31_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4.75DueMarch2044Member_dcc01fcf-c31d-486d-897a-7e9889caa354_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4.75DueMarch2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% senior notes due March 2044</link:label>
    <link:label id="lab_cvs_SeniorNotes4.75DueMarch2044Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4.75DueMarch2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.75%, Due March 2044 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4.75DueMarch2044Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4.75DueMarch2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.75%, Due March 2044 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.75DueMarch2044Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.75DueMarch2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4.75DueMarch2044Member" xlink:to="lab_cvs_SeniorNotes4.75DueMarch2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_31c4cef1-cb4f-43e4-b8c9-fc197eae9508_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod_ae8bdc46-5dec-401d-bb0c-f5a668a97c91_terseLabel_en-US" xlink:label="lab_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP issuances, net of purchase of treasury shares</link:label>
    <link:label id="lab_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Issuance, Net Of Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:label id="lab_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod_documentation_en-US" xlink:label="lab_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Issuance, Net Of Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" xlink:href="cvs-20221231.xsd#cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" xlink:to="lab_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_7a7ac2cf-90c0-4f28-b2de-c13512dd6e6c_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CVS Health Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_20028de8-0915-4bf5-bbcc-8cfd090f9da9_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c4345e14-2cc8-46fd-bbf3-59600a34ed3b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0a37e5f9-0e10-44d2-b520-6fdf55bff1c2_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_16b4e5bf-9fee-469c-8c32-4f1c38f94a6e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4960f24a-42a6-45bc-8dae-12ca1cf7924d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDue_4b7a1411-a5ee-4023-a126-080572d5df53_totalLabel_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDue_label_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDue_documentation_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDue" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLiabilityPaymentsDue" xlink:to="lab_cvs_LesseeLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansMember_568af0ac-8ace-4a17-bf41-49a6884aa2c0_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loans</link:label>
    <link:label id="lab_cvs_MortgageLoansMember_label_en-US" xlink:label="lab_cvs_MortgageLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans [Member]</link:label>
    <link:label id="lab_cvs_MortgageLoansMember_documentation_en-US" xlink:label="lab_cvs_MortgageLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents mortgage loans for the reporting period measured at carrying value. We carry the value of our mortgage loan investments on our balance sheet at the unpaid principal balance, net of impairment reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansMember" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansMember" xlink:to="lab_cvs_MortgageLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_23ea2bcf-1e0e-4af5-b3fc-aa97d520da43_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e9a1382a-dc39-4378-b93f-047abe1bff1f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c586e455-4368-486c-9147-a0c24c546b8c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearThree_ac6d628b-060a-49e3-ab4c-983d7c40e21a_totalLabel_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due Year Three</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearThree_documentation_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearThree" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearThree" xlink:to="lab_cvs_LesseeLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_cb36da46-b478-4e2b-839a-e65523b72394_terseLabel_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains from sale-leaseback transactions</link:label>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_label_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:to="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6177df1c-5dc7-4723-8672-f98fe1a098e4_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Divestitures and Asset Sales</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a5cfae05-785b-49b9-8ded-b12738ef377e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_8056892c-94a0-408a-b9da-e91439da5e7b_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_0af07c1b-924b-4154-9c69-d120a72fe736_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis difference upon disposition of subsidiary</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e295c07d-9744-4fee-aca3-e2d580778fe4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9563202f-f21d-4496-a022-f56579ad37ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ProceedsFromVariableInterestEntity_730453b3-c09b-4f69-a521-e807dff26fc0_terseLabel_en-US" xlink:label="lab_cvs_ProceedsFromVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from VIE</link:label>
    <link:label id="lab_cvs_ProceedsFromVariableInterestEntity_label_en-US" xlink:label="lab_cvs_ProceedsFromVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Variable Interest Entity</link:label>
    <link:label id="lab_cvs_ProceedsFromVariableInterestEntity_documentation_en-US" xlink:label="lab_cvs_ProceedsFromVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ProceedsFromVariableInterestEntity" xlink:href="cvs-20221231.xsd#cvs_ProceedsFromVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ProceedsFromVariableInterestEntity" xlink:to="lab_cvs_ProceedsFromVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes43Due2028Member_2576d6ff-d48d-4ea1-a868-218aa5c84d9a_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes43Due2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.3% senior notes due 2028</link:label>
    <link:label id="lab_cvs_SeniorNotes43Due2028Member_label_en-US" xlink:label="lab_cvs_SeniorNotes43Due2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.3%, Due 2028 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes43Due2028Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes43Due2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.3%, Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes43Due2028Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes43Due2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes43Due2028Member" xlink:to="lab_cvs_SeniorNotes43Due2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b30c48b5-5b7f-49ec-b9ba-22303e8f4ba2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exercisable at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_caf129aa-d2ee-4e52-a35c-58d7c233f7c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TotalInvestmentsLineItems_4d0fccfa-3dd1-4a04-b6d3-6da79028cfaa_terseLabel_en-US" xlink:label="lab_cvs_TotalInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments [Line Items]</link:label>
    <link:label id="lab_cvs_TotalInvestmentsLineItems_label_en-US" xlink:label="lab_cvs_TotalInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsLineItems" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TotalInvestmentsLineItems" xlink:to="lab_cvs_TotalInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_831dbd87-ba8c-4d5c-94ff-2ddd4a697f56_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_a45d19c0-4e12-46f6-a2e3-632f6fc5ee0a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_81ec845d-34cf-4d1f-a46f-7e7941f4ea9b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Claims paid</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OtherInsuranceLiabilitiesMember_4e78b374-f837-4b3c-b927-1fee4c29a459_terseLabel_en-US" xlink:label="lab_cvs_OtherInsuranceLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Insurance Liabilities</link:label>
    <link:label id="lab_cvs_OtherInsuranceLiabilitiesMember_label_en-US" xlink:label="lab_cvs_OtherInsuranceLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Insurance Liabilities [Member]</link:label>
    <link:label id="lab_cvs_OtherInsuranceLiabilitiesMember_documentation_en-US" xlink:label="lab_cvs_OtherInsuranceLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Insurance Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherInsuranceLiabilitiesMember" xlink:href="cvs-20221231.xsd#cvs_OtherInsuranceLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OtherInsuranceLiabilitiesMember" xlink:to="lab_cvs_OtherInsuranceLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_acf6440d-e354-4258-a0dc-6442e9e3455a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_09cc015d-1573-43fb-81de-0f71a1584430_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_b404fbac-6981-43f4-88b9-0cb7a0b454e5_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_a17bf01f-3870-4320-82e8-c3fb6fc895dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_BarclaysBankMember_83254003-262a-4b5a-bcbd-2f0706fbb0a1_terseLabel_en-US" xlink:label="lab_cvs_BarclaysBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Barclays Bank</link:label>
    <link:label id="lab_cvs_BarclaysBankMember_label_en-US" xlink:label="lab_cvs_BarclaysBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Barclays Bank [Member]</link:label>
    <link:label id="lab_cvs_BarclaysBankMember_documentation_en-US" xlink:label="lab_cvs_BarclaysBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Barclays Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BarclaysBankMember" xlink:href="cvs-20221231.xsd#cvs_BarclaysBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_BarclaysBankMember" xlink:to="lab_cvs_BarclaysBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_79b70c36-9fd6-4da0-a436-4ec00eef9880_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_c158b520-602f-4d33-9521-a62970f15dc9_terseLabel_en-US" xlink:label="lab_cvs_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share from continuing operations:</link:label>
    <link:label id="lab_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_cvs_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS [Abstract]</link:label>
    <link:label id="lab_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_cvs_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="cvs-20221231.xsd#cvs_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_cvs_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_97e6fb67-cb39-455a-a71f-1e6509639536_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LimitedPaymentsContracts_8b30651a-eb9a-4fcb-9937-69e3daac3cec_terseLabel_en-US" xlink:label="lab_cvs_LimitedPaymentsContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed interest rates on limited payment pension contracts on large case pension business (in hundredths)</link:label>
    <link:label id="lab_cvs_LimitedPaymentsContracts_label_en-US" xlink:label="lab_cvs_LimitedPaymentsContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Payments Contracts</link:label>
    <link:label id="lab_cvs_LimitedPaymentsContracts_documentation_en-US" xlink:label="lab_cvs_LimitedPaymentsContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum assumed interest rates on limited payment contracts on large case pensions business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LimitedPaymentsContracts" xlink:href="cvs-20221231.xsd#cvs_LimitedPaymentsContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LimitedPaymentsContracts" xlink:to="lab_cvs_LimitedPaymentsContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_372bc7ad-f9c1-414b-9009-12f555de2e26_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care costs payable and other insurance liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_e33d8ce0-3891-45bd-b3eb-807468b67c0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Securities, Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_94b75a87-2322-4c8e-8b95-c2cf066248c8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtAndEquitySecuritiesAvailableForSaleMember_b04645ef-227e-4d1f-9a7e-e8425e606223_terseLabel_en-US" xlink:label="lab_cvs_DebtAndEquitySecuritiesAvailableForSaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available for sale</link:label>
    <link:label id="lab_cvs_DebtAndEquitySecuritiesAvailableForSaleMember_label_en-US" xlink:label="lab_cvs_DebtAndEquitySecuritiesAvailableForSaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Equity Securities Available For Sale [Member]</link:label>
    <link:label id="lab_cvs_DebtAndEquitySecuritiesAvailableForSaleMember_documentation_en-US" xlink:label="lab_cvs_DebtAndEquitySecuritiesAvailableForSaleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in debt and equity securities which are categorized neither as trading securities nor held-to-maturity securities. Such securities are reported at fair value; unrealized gains and losses related to Available-for-sale securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtAndEquitySecuritiesAvailableForSaleMember" xlink:href="cvs-20221231.xsd#cvs_DebtAndEquitySecuritiesAvailableForSaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtAndEquitySecuritiesAvailableForSaleMember" xlink:to="lab_cvs_DebtAndEquitySecuritiesAvailableForSaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_bc1ea63b-1b4c-49df-a879-4eafd81529f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateForeclosures_5006b605-38c8-4436-8ae2-50c1f448490f_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateForeclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loans foreclosed</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateForeclosures_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateForeclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Foreclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateForeclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateForeclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateForeclosures" xlink:to="lab_us-gaap_MortgageLoansOnRealEstateForeclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_9f0fd5aa-949e-4ae3-afa4-d7eba7c0be1f_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_e0fa2243-340c-4f33-914b-654a13504ba2_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemed principal amount</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bdc5436e-6e8b-4ce5-a7e5-505f709df3d7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_13f57738-4045-4b97-b6d6-431658996ecd_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_e2686c24-d290-41d2-b3f2-2af7601f4de1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions used to determine benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_f1804af6-444d-42d0-885b-d341b38250ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost: 458 and 422 shares at December&#160;31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_bd4acce6-0475-4948-a824-d167d2dfc0b5_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_184bc000-6f89-42b4-b206-cad36918d2a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and other postretirement benefits</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_845184fd-a2ae-4b50-a2dd-d869173b331a_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated statutory capital and surplus</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus, Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_06fcee4d-2085-4964-a541-0a68d21d30bc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale_528bfd02-7228-4278-99cd-9867e73254f1_terseLabel_en-US" xlink:label="lab_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale_label_en-US" xlink:label="lab_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Including Liabilities Held For Sale</link:label>
    <link:label id="lab_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale_documentation_en-US" xlink:label="lab_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Including Liabilities Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" xlink:to="lab_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_adc63f77-76d3-4c47-9402-bd00fa9ecc22_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option activity, stock awards and other</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_3e357c57-10c0-49e3-8b67-8294e47c50bd_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self insurance liabilities</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserve" xlink:to="lab_us-gaap_SelfInsuranceReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5475f417-5b10-402e-a1de-8deb705e4cfc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TransferOfSharesToTreasuryStockValue_5e183c80-6a2a-4188-86c7-2f66bca6c8ce_terseLabel_en-US" xlink:label="lab_cvs_TransferOfSharesToTreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of shares to treasury stock value</link:label>
    <link:label id="lab_cvs_TransferOfSharesToTreasuryStockValue_label_en-US" xlink:label="lab_cvs_TransferOfSharesToTreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Shares To Treasury Stock Value</link:label>
    <link:label id="lab_cvs_TransferOfSharesToTreasuryStockValue_documentation_en-US" xlink:label="lab_cvs_TransferOfSharesToTreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Shares To Treasury Stock Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TransferOfSharesToTreasuryStockValue" xlink:href="cvs-20221231.xsd#cvs_TransferOfSharesToTreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TransferOfSharesToTreasuryStockValue" xlink:to="lab_cvs_TransferOfSharesToTreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_70f94a32-ad4c-4f44-b38d-31a9d78057eb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_25b5d5d9-40a2-4440-8f37-d59d577f7a87_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation_cae32c24-e6d1-4fd9-9351-9c0ff2bbca4a_negatedTerseLabel_en-US" xlink:label="lab_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation_label_en-US" xlink:label="lab_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-Of-Use Asset, Accumulated Depreciation</link:label>
    <link:label id="lab_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation_documentation_en-US" xlink:label="lab_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-Of-Use Asset, Accumulated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation" xlink:to="lab_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_53d8a366-4716-4314-84e0-dc1501592fa6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2af1b27a-7da6-4f76-bc21-c551426c6364_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold_f760aa5a-0d17-4194-80be-16e0bb102418_terseLabel_en-US" xlink:label="lab_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of international health care members, renewal rights sold</link:label>
    <link:label id="lab_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold_label_en-US" xlink:label="lab_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Number Of International Health Care Members, Renewal Rights Sold</link:label>
    <link:label id="lab_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold_documentation_en-US" xlink:label="lab_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Number Of International Health Care Members, Renewal Rights Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold" xlink:href="cvs-20221231.xsd#cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold" xlink:to="lab_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes6.75DueDecember2037Member_ccf72861-2dca-417c-9ca0-443398e00d65_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes6.75DueDecember2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.75% senior notes due December 2037</link:label>
    <link:label id="lab_cvs_SeniorNotes6.75DueDecember2037Member_label_en-US" xlink:label="lab_cvs_SeniorNotes6.75DueDecember2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.75%, Due December 2037 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes6.75DueDecember2037Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes6.75DueDecember2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.75%, Due December 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.75DueDecember2037Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.75DueDecember2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes6.75DueDecember2037Member" xlink:to="lab_cvs_SeniorNotes6.75DueDecember2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ab405100-a6df-46b0-b799-4f8d7abfdd2e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableLineItems_a444bd5a-9c21-4324-b0bd-e87078859b53_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable [Line Items]</link:label>
    <link:label id="lab_us-gaap_DividendsPayableLineItems_label_en-US" xlink:label="lab_us-gaap_DividendsPayableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableLineItems" xlink:to="lab_us-gaap_DividendsPayableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_09b7a6d3-0093-405c-b374-1ce096ad9f58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95fb09df-fa47-44ef-9f17-79f0e40dc4a7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_2698dd88-1483-4dbe-8e04-5584e64a1a58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Periodic Benefit Cost (Income)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountsPolicy_384e6d25-d76a-4fb5-a999-1627615dc19d_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Accounts</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountsPolicy" xlink:to="lab_us-gaap_PolicyholderAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_c10c6dbb-62df-4f03-af6b-c5ea3c232e91_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for future policy benefits</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_94056966-3b3b-4135-8cff-f2ac64882893_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) to liability for future policy benefits</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, before Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ee16f6c5-3acd-451e-b88c-6c05f9c3a49a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f06de58d-6607-4a56-9c13-98e809efc684_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ValueOfBusinessAcquiredMember_2c4719ac-828b-4b5c-8b4b-97d52ad8c11a_terseLabel_en-US" xlink:label="lab_cvs_ValueOfBusinessAcquiredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of Business Acquired</link:label>
    <link:label id="lab_cvs_ValueOfBusinessAcquiredMember_label_en-US" xlink:label="lab_cvs_ValueOfBusinessAcquiredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Business Acquired [Member]</link:label>
    <link:label id="lab_cvs_ValueOfBusinessAcquiredMember_documentation_en-US" xlink:label="lab_cvs_ValueOfBusinessAcquiredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Business Acquired [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ValueOfBusinessAcquiredMember" xlink:href="cvs-20221231.xsd#cvs_ValueOfBusinessAcquiredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ValueOfBusinessAcquiredMember" xlink:to="lab_cvs_ValueOfBusinessAcquiredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3.875DueJuly2025Member_d7eb44e4-55b1-4b17-a338-b9d12219e1ee_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3.875DueJuly2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% senior notes due July 2025</link:label>
    <link:label id="lab_cvs_SeniorNotes3.875DueJuly2025Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3.875DueJuly2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.875%, Due July 2025 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3.875DueJuly2025Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3.875DueJuly2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.875%, Due July 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.875DueJuly2025Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.875DueJuly2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3.875DueJuly2025Member" xlink:to="lab_cvs_SeniorNotes3.875DueJuly2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_4a8c9247-85a5-447a-94fa-b3903a0b65b2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Products Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueAfterYearFive_d73f7084-9195-4364-b3ff-455673c91b88_totalLabel_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due After Year Five</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueAfterYearFive_documentation_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueAfterYearFive" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueAfterYearFive" xlink:to="lab_cvs_LesseeLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_d61f93d6-60ff-4f1e-936e-9a0bba05d89f_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LeasesWeightedAverageDiscountRateAbstract_95a9993e-ef35-4982-a437-858f5f052223_terseLabel_en-US" xlink:label="lab_cvs_LeasesWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_cvs_LeasesWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_cvs_LeasesWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_cvs_LeasesWeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_cvs_LeasesWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LeasesWeightedAverageDiscountRateAbstract" xlink:href="cvs-20221231.xsd#cvs_LeasesWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LeasesWeightedAverageDiscountRateAbstract" xlink:to="lab_cvs_LeasesWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2e8d251a-9d9f-4328-a827-56049f4642db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_7808e30c-96d1-45b0-b960-671e51c4a669_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, maturity, without single maturity date</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c5a0e748-94bd-4ba7-a150-edd0b4b2edf1_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_e88f6dda-945f-4b94-833d-0efd2d9ec43e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_00c30600-723d-4199-9d73-e6a7c4271cc2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStores_92427bcc-91c9-408f-bc5c-f3fadc843891_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStores" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of retail locations (more than)</link:label>
    <link:label id="lab_us-gaap_NumberOfStores_label_en-US" xlink:label="lab_us-gaap_NumberOfStores" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Stores</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStores"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStores" xlink:to="lab_us-gaap_NumberOfStores" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_a5442aa8-f24c-468b-a019-a660e95d48b4_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes2Point125PercentDueSeptember2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% senior notes due September 2031</link:label>
    <link:label id="lab_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_label_en-US" xlink:label="lab_cvs_SeniorNotes2Point125PercentDueSeptember2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2 Point 125 Percent, Due September 2031 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes2Point125PercentDueSeptember2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2 Point 125 Percent, Due September 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2Point125PercentDueSeptember2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member" xlink:to="lab_cvs_SeniorNotes2Point125PercentDueSeptember2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_fff86ff6-8fae-4f9b-94bb-c769a91ae53e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5cfa16fd-3bd7-4f19-a946-776ee32ac50b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2ad92147-8461-4ed0-af3c-8f4ba5667daa_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased_78e52e56-6207-4154-a3be-03e1c828eb25_terseLabel_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased under ASR agreement (in shares)</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased_label_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Number Of Shares Repurchased</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased_documentation_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Number Of Shares Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased" xlink:to="lab_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_519cdd96-5247-4c30-b1bf-b0b5f92f293e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_4040a18a-7604-4ed8-97ca-9a1ded614c45_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskAxis_8d4d5301-594a-4286-8922-50160cd6ff95_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Reinsurer [Axis]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskAxis_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurer, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskAxis" xlink:to="lab_us-gaap_CededCreditRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesTable_14c1fcb6-a38d-429c-9d80-7384fb5ff243_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Table]</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesTable_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable" xlink:to="lab_us-gaap_StatutoryAccountingPracticesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NumberOfPeopleServed_2048debb-796e-41a6-80ae-c603ceb94d60_terseLabel_en-US" xlink:label="lab_cvs_NumberOfPeopleServed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of people served</link:label>
    <link:label id="lab_cvs_NumberOfPeopleServed_label_en-US" xlink:label="lab_cvs_NumberOfPeopleServed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of People Served</link:label>
    <link:label id="lab_cvs_NumberOfPeopleServed_documentation_en-US" xlink:label="lab_cvs_NumberOfPeopleServed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of People Served</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfPeopleServed" xlink:href="cvs-20221231.xsd#cvs_NumberOfPeopleServed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NumberOfPeopleServed" xlink:to="lab_cvs_NumberOfPeopleServed" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NumberOfWalkInMedicalClinics_cdd07a61-6951-4963-aa79-5045e44c5e02_terseLabel_en-US" xlink:label="lab_cvs_NumberOfWalkInMedicalClinics" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of walk-in medical clinics (more than)</link:label>
    <link:label id="lab_cvs_NumberOfWalkInMedicalClinics_label_en-US" xlink:label="lab_cvs_NumberOfWalkInMedicalClinics" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Walk In Medical Clinics</link:label>
    <link:label id="lab_cvs_NumberOfWalkInMedicalClinics_documentation_en-US" xlink:label="lab_cvs_NumberOfWalkInMedicalClinics" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Walk In Medical Clinics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfWalkInMedicalClinics" xlink:href="cvs-20221231.xsd#cvs_NumberOfWalkInMedicalClinics"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NumberOfWalkInMedicalClinics" xlink:to="lab_cvs_NumberOfWalkInMedicalClinics" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_2499fdf9-74b9-48b0-8421-6364789b034b_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases, sales and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:to="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_13cc19ae-a158-447b-91b3-59e8ae7dcfaa_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_e1546b85-617a-469a-8b3f-8364af0a98a4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b067888b-b2b5-4901-9cf6-127f1c636110_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_45eb2c7c-f27a-4ab4-b400-1f38b5067b01_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_4e8b85e2-4bbc-4a42-88d8-43ff1356267f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers into (out of) Level 3, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_3b16f4ba-703d-4979-8003-e908ffdb40f1_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net transfers into (out of) Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_30b85e7f-b655-4738-a916-5dee69e5d256_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities_8d63f663-9a9a-4db5-8ceb-851f23e8f104_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average duration of securities</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock_1242cf94-5651-47e4-87bc-560ec417f11a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Separate Accounts by Major Category of Investment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeparateAccountFinancialAssetsMember_b8cf4166-46c8-467a-ae12-8d3665798784_terseLabel_en-US" xlink:label="lab_cvs_SeparateAccountFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Accounts, financial assets</link:label>
    <link:label id="lab_cvs_SeparateAccountFinancialAssetsMember_label_en-US" xlink:label="lab_cvs_SeparateAccountFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account, Financial Assets [Member]</link:label>
    <link:label id="lab_cvs_SeparateAccountFinancialAssetsMember_documentation_en-US" xlink:label="lab_cvs_SeparateAccountFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account, Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeparateAccountFinancialAssetsMember" xlink:href="cvs-20221231.xsd#cvs_SeparateAccountFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeparateAccountFinancialAssetsMember" xlink:to="lab_cvs_SeparateAccountFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_e3cabb06-d488-4182-8dc5-47629a03ef5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Assumptions Used in Determining Benefit Obligations and Net Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure_61d9dd91-c54a-4709-9a00-f44fef08550e_terseLabel_en-US" xlink:label="lab_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment contract liabilities with a fixed maturity</link:label>
    <link:label id="lab_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure_label_en-US" xlink:label="lab_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Contracts With Fixed Maturity, Fair Value Disclosure</link:label>
    <link:label id="lab_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure_documentation_en-US" xlink:label="lab_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Contracts With Fixed Maturity, Fair Value Disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure" xlink:href="cvs-20221231.xsd#cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure" xlink:to="lab_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_02964334-a242-4133-b405-04f809757e07_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses, Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3.5DueNovember2024Member_c51ff33b-d1a3-4733-b68a-bbc70ba5c251_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3.5DueNovember2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.5% senior notes due November 2024</link:label>
    <link:label id="lab_cvs_SeniorNotes3.5DueNovember2024Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3.5DueNovember2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.5%, Due November 2024 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3.5DueNovember2024Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3.5DueNovember2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.5%, Due November 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.5DueNovember2024Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.5DueNovember2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3.5DueNovember2024Member" xlink:to="lab_cvs_SeniorNotes3.5DueNovember2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss_b3a1ca7b-b623-4a63-9492-d0554c112d23_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, maturity, without single maturity date, unrealized losses</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Accumulated Loss</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_f23baef2-7889-4f8c-a4f1-674f29ea7b65_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_058d2631-e7ab-4900-8b5a-3c1cc359a1da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses, Greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax_d4a248c0-4482-4c03-917b-3528981a2382_terseLabel_en-US" xlink:label="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former gain contingency, recognized in current period, net of tax</link:label>
    <link:label id="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Gain Contingency, Recognized In Current Period, Net of Tax</link:label>
    <link:label id="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax_documentation_en-US" xlink:label="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Gain Contingency, Recognized In Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax" xlink:href="cvs-20221231.xsd#cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax" xlink:to="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_37b74020-9728-4b56-bdcd-328320c1bcb0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bd1bafe5-9e21-44bd-8e10-f149e3008703_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OtherInsuranceLiabilitiesCurrent_ce433401-31fe-4a81-a3fb-adecfbcb3984_terseLabel_en-US" xlink:label="lab_cvs_OtherInsuranceLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other insurance liabilities</link:label>
    <link:label id="lab_cvs_OtherInsuranceLiabilitiesCurrent_label_en-US" xlink:label="lab_cvs_OtherInsuranceLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Insurance Liabilities, Current</link:label>
    <link:label id="lab_cvs_OtherInsuranceLiabilitiesCurrent_documentation_en-US" xlink:label="lab_cvs_OtherInsuranceLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Insurance Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherInsuranceLiabilitiesCurrent" xlink:href="cvs-20221231.xsd#cvs_OtherInsuranceLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OtherInsuranceLiabilitiesCurrent" xlink:to="lab_cvs_OtherInsuranceLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes2.75DueDecember2022Member_7cf191e2-49c2-476e-9870-c7b62002fa3b_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes2.75DueDecember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% senior notes due December 2022</link:label>
    <link:label id="lab_cvs_SeniorNotes2.75DueDecember2022Member_label_en-US" xlink:label="lab_cvs_SeniorNotes2.75DueDecember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.75%, Due December 2022 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes2.75DueDecember2022Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes2.75DueDecember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.75%, Due December 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueDecember2022Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueDecember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes2.75DueDecember2022Member" xlink:to="lab_cvs_SeniorNotes2.75DueDecember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_78374105-4fd0-4c5c-bcf8-0a41131e05e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1c03bb59-9f35-4498-b85a-dab1f04a9827_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlement awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_05f0533e-8cbd-4b2c-ac86-e1ddec956795_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e8f5f46e-d98d-46fc-8fec-dc6476008231_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AuditorInformationAbstract_label_en-US" xlink:label="lab_cvs_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_cvs_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_cvs_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AuditorInformationAbstract" xlink:href="cvs-20221231.xsd#cvs_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AuditorInformationAbstract" xlink:to="lab_cvs_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PremiumDeficiencyReserveLiability_25c980db-a4e2-4813-96b7-78481c906eac_verboseLabel_en-US" xlink:label="lab_cvs_PremiumDeficiencyReserveLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium deficiency reserve</link:label>
    <link:label id="lab_cvs_PremiumDeficiencyReserveLiability_a179bd78-fa05-4426-85c4-45abe6b840aa_terseLabel_en-US" xlink:label="lab_cvs_PremiumDeficiencyReserveLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Premium deficiency reserve</link:label>
    <link:label id="lab_cvs_PremiumDeficiencyReserveLiability_label_en-US" xlink:label="lab_cvs_PremiumDeficiencyReserveLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Deficiency Reserve Liability</link:label>
    <link:label id="lab_cvs_PremiumDeficiencyReserveLiability_documentation_en-US" xlink:label="lab_cvs_PremiumDeficiencyReserveLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of reserves related to expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), in excess of existing reserves plus anticipated future premiums and reinsurance recoveries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumDeficiencyReserveLiability" xlink:href="cvs-20221231.xsd#cvs_PremiumDeficiencyReserveLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PremiumDeficiencyReserveLiability" xlink:to="lab_cvs_PremiumDeficiencyReserveLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_161164c6-bbfd-4e76-83da-3fb1d7b3a461_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value vested at end of year and expected to vest in the future</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes1Point875PercentFebruary2031Member_ced08e5e-b858-4b62-ae34-429f8f0b3751_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes1Point875PercentFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% senior notes due February 2031</link:label>
    <link:label id="lab_cvs_SeniorNotes1Point875PercentFebruary2031Member_label_en-US" xlink:label="lab_cvs_SeniorNotes1Point875PercentFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 1 Point 875 Percent, February 2031 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes1Point875PercentFebruary2031Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes1Point875PercentFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 1 Point 875 Percent, February 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes1Point875PercentFebruary2031Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes1Point875PercentFebruary2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes1Point875PercentFebruary2031Member" xlink:to="lab_cvs_SeniorNotes1Point875PercentFebruary2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_cf69d8bf-ebde-4252-be5f-d0286ebd7c17_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to CVS Health (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ecbc809b-b529-4c9b-ab5c-004a19ab13b9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share from continuing operations, basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LeaseLiability_bef19a87-87eb-42d3-811a-709952080d9b_totalLabel_en-US" xlink:label="lab_cvs_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_cvs_LeaseLiability_label_en-US" xlink:label="lab_cvs_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cvs_LeaseLiability_documentation_en-US" xlink:label="lab_cvs_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LeaseLiability" xlink:href="cvs-20221231.xsd#cvs_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LeaseLiability" xlink:to="lab_cvs_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3b7c76b-1948-42c5-af64-fd7fec6c81dd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42466e72-1522-4d9d-80f9-d372b3940e93_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_c79d8db0-d521-48eb-93bf-02c014b8fd1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of variable interest entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearFour_d4f42b96-8143-43c2-9b28-26799046d998_totalLabel_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due Year Four</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearFour_documentation_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearFour" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearFour" xlink:to="lab_cvs_LesseeLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_8af4b9cc-c5b8-4195-bc51-f0242294150e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_a654eb78-b321-49bd-bc50-02fea3a3f3ee_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded in association with legal settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AetnaInc2010StockIncentivePlanMember_6222ea69-0c5f-4d59-bb64-6a7e4a3cb433_terseLabel_en-US" xlink:label="lab_cvs_AetnaInc2010StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aetna Inc 2010 Stock Incentive Plan</link:label>
    <link:label id="lab_cvs_AetnaInc2010StockIncentivePlanMember_label_en-US" xlink:label="lab_cvs_AetnaInc2010StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aetna Inc 2010 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_cvs_AetnaInc2010StockIncentivePlanMember_documentation_en-US" xlink:label="lab_cvs_AetnaInc2010StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aetna Inc 2010 Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AetnaInc2010StockIncentivePlanMember" xlink:href="cvs-20221231.xsd#cvs_AetnaInc2010StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AetnaInc2010StockIncentivePlanMember" xlink:to="lab_cvs_AetnaInc2010StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4.125DueNovember2042Member_1db741b9-9c32-48b1-8481-ba85e3c15272_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4.125DueNovember2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.125% senior notes due November 2042</link:label>
    <link:label id="lab_cvs_SeniorNotes4.125DueNovember2042Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4.125DueNovember2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.125%, Due November 2042 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4.125DueNovember2042Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4.125DueNovember2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents senior notes due 2042 with a coupon rate of 4.125%.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.125DueNovember2042Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.125DueNovember2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4.125DueNovember2042Member" xlink:to="lab_cvs_SeniorNotes4.125DueNovember2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_04b0b4bf-94ec-4f85-9f7f-16d4a649c310_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in prior years' healthcare costs payable</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_a3074655-bb6c-4faa-b78c-b1058115ab45_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NetRevenuesRetailCoPayments_fc03e403-714e-419e-b1d6-a13914c38594_terseLabel_en-US" xlink:label="lab_cvs_NetRevenuesRetailCoPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Copayments</link:label>
    <link:label id="lab_cvs_NetRevenuesRetailCoPayments_label_en-US" xlink:label="lab_cvs_NetRevenuesRetailCoPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues, Retail CoPayments</link:label>
    <link:label id="lab_cvs_NetRevenuesRetailCoPayments_documentation_en-US" xlink:label="lab_cvs_NetRevenuesRetailCoPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues, Retail CoPayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NetRevenuesRetailCoPayments" xlink:href="cvs-20221231.xsd#cvs_NetRevenuesRetailCoPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NetRevenuesRetailCoPayments" xlink:to="lab_cvs_NetRevenuesRetailCoPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_399578eb-e1db-4dc0-bc70-a456d1715449_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue_28f980d4-d0e3-4677-adfd-6e29d285a8e4_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, maturity, without single maturity date, fair value</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Fair Value</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b8ed247c-ff4d-4c1e-a4bf-4341de313426_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target investment allocations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_9ccf1ee1-efb3-40b7-a3c1-c3458a33e4c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_label_en-US" xlink:label="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Consolidated Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:to="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountAssetCategoryDomain_72ecce1e-dac4-49dd-ab2a-fc5e5e8b9b9e_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountAssetCategoryDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account Asset Category [Domain]</link:label>
    <link:label id="lab_us-gaap_SeparateAccountAssetCategoryDomain_label_en-US" xlink:label="lab_us-gaap_SeparateAccountAssetCategoryDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account Asset Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain" xlink:to="lab_us-gaap_SeparateAccountAssetCategoryDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_4c61d867-dad6-416b-8fb3-b4a0d35a3f64_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contract, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_db221019-4668-4102-aecc-80f5990c9131_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_3ba62664-496f-4414-8db9-1d2855869052_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash (included in other current assets)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember_8b1eccad-f6da-4d89-90ab-83286aec29a5_terseLabel_en-US" xlink:label="lab_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures, equipment and internally developed software</link:label>
    <link:label id="lab_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember_label_en-US" xlink:label="lab_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures, Equipment And Internally Developed Software [Member]</link:label>
    <link:label id="lab_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember_documentation_en-US" xlink:label="lab_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures, Equipment And Internally Developed Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember" xlink:href="cvs-20221231.xsd#cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember" xlink:to="lab_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_947bb4db-8d80-4f15-9fb7-0e91196804c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Separate Account Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:to="lab_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_dce5167b-7521-48f6-8743-b1a85bf6bc74_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_b968ec54-2b99-4c28-938c-2153c66cd373_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_074cf10f-1222-4d44-8a72-b6c281638082_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7e19c10f-2e32-476b-9d89-4aeaffb236dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_0625d01d-a86f-400a-b17b-cc3fbe18965a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Included in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c3a1bbd9-84c0-43db-8ba2-7ffe82d43341_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Level 3 Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_af826606-ec43-4337-a7a7-0e3efa1a6be9_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_2edc8796-94f2-418e-96c0-ee319c187ad8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5658160a-04c4-4504-ba18-637f319ecb3e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Assets and Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_75e33abe-59b8-4271-8c3c-79ad0ecb93ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears_1c34643a-0f70-402f-b03e-4cdb85b27b89_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One year through five years</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9ff94888-fc67-450a-a37d-2c4f31ce5de7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_a028810a-1b20-41e0-8f85-d4f1e9e96b83_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_1f114e5b-471b-410c-8c12-4fbac3f3ff2e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Held for Sale</link:label>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Long-Lived Assets Held-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:to="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_a39683e6-c6f2-4e6c-a547-a60e5e7285da_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs Payable</link:label>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_9552dea4-bb6e-487c-a701-da9249afc1db_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_953a4bd5-dd68-443f-b942-89d2632f9f95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance_113972d8-c884-4ac8-a66d-ef88aa4d1328_negatedTerseLabel_en-US" xlink:label="lab_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares, net of ESPP issuances</link:label>
    <link:label id="lab_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance_label_en-US" xlink:label="lab_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance</link:label>
    <link:label id="lab_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance_documentation_en-US" xlink:label="lab_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" xlink:to="lab_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_7dcdb161-534a-48f0-bc13-ca4552058387_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e7da7681-749e-49ab-963e-ceca4f4b1d6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_a7b26700-adfb-4b70-8d8c-7e57f58bb45e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_70b3fb4d-3593-4a03-9c10-bf7cb0d7cc29_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_a8d21d1d-463f-4333-ba00-8d3115e5bf9d_verboseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal of debt extinguished</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_3a530e43-349c-4d82-9eb7-fd695e18536f_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_71cdfde8-7e9f-47f0-9b3e-90d21d3f192b_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_132ad9ec-62b5-48fc-9db9-68d4f5fb053e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_15f021b1-e889-48fc-b0fb-37879c55946f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9f878faf-ae94-4db0-b9bd-8be10e57c32b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d6bf12a7-655e-4161-a639-f617d5ddd642_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions (net of cash acquired)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_09ce6f0c-1107-40e6-adfc-b0dc75e98cd8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SupportingRemainingProductsMember_034ffc21-d30e-436d-89fb-7d462d203c72_terseLabel_en-US" xlink:label="lab_cvs_SupportingRemainingProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supporting remaining products</link:label>
    <link:label id="lab_cvs_SupportingRemainingProductsMember_label_en-US" xlink:label="lab_cvs_SupportingRemainingProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supporting Remaining Products [Member]</link:label>
    <link:label id="lab_cvs_SupportingRemainingProductsMember_documentation_en-US" xlink:label="lab_cvs_SupportingRemainingProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities in an unrealized capital loss position supporting remaining products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingRemainingProductsMember" xlink:href="cvs-20221231.xsd#cvs_SupportingRemainingProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SupportingRemainingProductsMember" xlink:to="lab_cvs_SupportingRemainingProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_a2f6dbcb-159c-4ce8-a435-8e0125149fb4_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit costs</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net, Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_548af1a2-8360-487c-a0d0-6680b48090f5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_d7702edf-b01c-4577-9c5f-9020741dfcfb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c22a51c8-a42c-4a75-b558-95f995b463ba_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8870019f-f07c-444d-b724-9666b02f4c66_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PremiumsMember_b2e2fea6-5698-4860-bb87-148e786b8a63_terseLabel_en-US" xlink:label="lab_cvs_PremiumsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_cvs_PremiumsMember_label_en-US" xlink:label="lab_cvs_PremiumsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums [Member]</link:label>
    <link:label id="lab_cvs_PremiumsMember_documentation_en-US" xlink:label="lab_cvs_PremiumsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumsMember" xlink:href="cvs-20221231.xsd#cvs_PremiumsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PremiumsMember" xlink:to="lab_cvs_PremiumsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes5.75DueMay2041Member_d23d8f5b-e34b-443d-ad59-b0a9b47fa006_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes5.75DueMay2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% senior notes due May 2041</link:label>
    <link:label id="lab_cvs_SeniorNotes5.75DueMay2041Member_label_en-US" xlink:label="lab_cvs_SeniorNotes5.75DueMay2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.75%, Due May 2041 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes5.75DueMay2041Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes5.75DueMay2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.75%, Due May 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.75DueMay2041Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.75DueMay2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes5.75DueMay2041Member" xlink:to="lab_cvs_SeniorNotes5.75DueMay2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife_4fdb812f-30fb-427e-b9a1-6f1085e068af_terseLabel_en-US" xlink:label="lab_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, amount due in excess of remaining estimated economic life</link:label>
    <link:label id="lab_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife_label_en-US" xlink:label="lab_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life</link:label>
    <link:label id="lab_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife_documentation_en-US" xlink:label="lab_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife" xlink:href="cvs-20221231.xsd#cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife" xlink:to="lab_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_340cc121-9109-4080-8084-b6f36398778e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic_50c3207b-0101-4188-9215-5e4d25ba59cd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior year refunds and unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Domestic, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_e7cacc4f-b15b-4ce2-bbdd-62ef3749fce7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2dc197ed-4fe3-4246-8a64-77c45f9e37d8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_9be1a50f-e892-4be5-90d9-afd5c0e06782_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a067a05a-d296-480f-b7b7-32b294db9046_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_6c9cb8d1-cb2b-4d96-9c9c-dd895996998d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_178e557f-45e2-4765-a00a-89dffe887f01_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Insurance Liabilities</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:to="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_58a66e1a-006d-4565-a0f3-74e7bded97d7_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_da21ec15-e1d1-4c7c-bec4-0b586921d983_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care costs payable, beginning of period, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_a5dc69d4-86a4-4d2c-8465-6ce7508abbe6_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care costs payable, end of period, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_4d94a7f5-2004-4508-a613-d3d2e56c971f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c161c2bf-0e57-4955-8868-bf773bc8c46f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_3902e8fe-3206-489d-afab-0cf0f73bad11_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_31054559-2498-4522-9b10-9757f8b0d869_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance</link:label>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_label_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceTextBlock" xlink:to="lab_us-gaap_ReinsuranceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bdb8a3a6-3331-4e00-afd2-f298992bd164_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_53852dd0-4d24-4577-b013-a7ec94dd211c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets, indefinite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock_8132fa75-fc22-4086-8604-e958df9264db_terseLabel_en-US" xlink:label="lab_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Intangible Assets</link:label>
    <link:label id="lab_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived And Indefinite Lived Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the cost, accumulated amortization and net balance of intangibles assets and amortization period, in total and by major class. Finite-lived intangible assets have a stated useful life over which their gross carrying value is amortized. Indefinite intangible assets have a projected indefinite period of benefit (hence are not amortized).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="cvs-20221231.xsd#cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_3197f03c-15bd-4e0c-86e0-0223493ef33c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm_69a35692-b808-4120-9ca3-3a10c30bd410_terseLabel_en-US" xlink:label="lab_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm_label_en-US" xlink:label="lab_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating And Finance Leases, Renewal Term</link:label>
    <link:label id="lab_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm_documentation_en-US" xlink:label="lab_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating And Finance Leases, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm" xlink:href="cvs-20221231.xsd#cvs_LesseeOperatingAndFinanceLeasesRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm" xlink:to="lab_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RadcliffAndFlaimVAetnaIncEtAlMember_d1345368-98df-445b-b157-9546587e59ef_terseLabel_en-US" xlink:label="lab_cvs_RadcliffAndFlaimVAetnaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Radcliff and Flaim v Aetna Inc., et al</link:label>
    <link:label id="lab_cvs_RadcliffAndFlaimVAetnaIncEtAlMember_label_en-US" xlink:label="lab_cvs_RadcliffAndFlaimVAetnaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Radcliff and Flaim v Aetna Inc., et al [Member]</link:label>
    <link:label id="lab_cvs_RadcliffAndFlaimVAetnaIncEtAlMember_documentation_en-US" xlink:label="lab_cvs_RadcliffAndFlaimVAetnaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Radcliff and Flaim v Aetna Inc., et al</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RadcliffAndFlaimVAetnaIncEtAlMember" xlink:href="cvs-20221231.xsd#cvs_RadcliffAndFlaimVAetnaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RadcliffAndFlaimVAetnaIncEtAlMember" xlink:to="lab_cvs_RadcliffAndFlaimVAetnaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3Point75PercentApril2030Member_a31981bd-4b02-43ed-a8a3-28f5fa7bc76c_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3Point75PercentApril2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% senior notes due April 2030</link:label>
    <link:label id="lab_cvs_SeniorNotes3Point75PercentApril2030Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3Point75PercentApril2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3 Point 75 Percent, April 2030 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3Point75PercentApril2030Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3Point75PercentApril2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3 Point 75 Percent, April 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point75PercentApril2030Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point75PercentApril2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3Point75PercentApril2030Member" xlink:to="lab_cvs_SeniorNotes3Point75PercentApril2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_705f9e7d-7d77-493d-a0d9-be278c0a7fc9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss_9f7c7658-504e-4cc8-8f64-a66f8c5429e3_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than ten years</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_494df918-b255-46eb-962e-290805ce7087_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_013cbe22-c6ee-46c7-b861-6fd55422499c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total incurred health care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear_5acca4c1-e917-4756-b848-e97aa24f7436_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_649f8a20-e959-425d-aeea-3d8ca80f3d6d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (1)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TotalInvestmentsAxis_579ce72c-15bb-4ad3-aab6-fbef645c4d01_terseLabel_en-US" xlink:label="lab_cvs_TotalInvestmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments [Axis]</link:label>
    <link:label id="lab_cvs_TotalInvestmentsAxis_label_en-US" xlink:label="lab_cvs_TotalInvestmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsAxis" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TotalInvestmentsAxis" xlink:to="lab_cvs_TotalInvestmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_be281a34-86e0-44f1-a1ed-4b012d6e75a9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c19b827f-239e-46d1-8c48-a27d08368f92_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d789159c-e534-4b85-8b91-c8fe163c3cd8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_6d196c75-2939-424c-85b0-def55a1678bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3d2c6986-dde3-4b93-825d-b040ba0e0930_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_98726f3f-fd42-4e6a-880c-e87e16e85746_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_VariableInterestEntityAmendedContractTerm_f4af8509-faf9-458c-a4a0-a712c6b1209a_terseLabel_en-US" xlink:label="lab_cvs_VariableInterestEntityAmendedContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended contract term (in years)</link:label>
    <link:label id="lab_cvs_VariableInterestEntityAmendedContractTerm_label_en-US" xlink:label="lab_cvs_VariableInterestEntityAmendedContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Amended Contract Term</link:label>
    <link:label id="lab_cvs_VariableInterestEntityAmendedContractTerm_documentation_en-US" xlink:label="lab_cvs_VariableInterestEntityAmendedContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Amended Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VariableInterestEntityAmendedContractTerm" xlink:href="cvs-20221231.xsd#cvs_VariableInterestEntityAmendedContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_VariableInterestEntityAmendedContractTerm" xlink:to="lab_cvs_VariableInterestEntityAmendedContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OtherInsuranceLiabilitiesNoncurrent_8204410c-89d2-48a1-9d15-5c1cab44ab97_terseLabel_en-US" xlink:label="lab_cvs_OtherInsuranceLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term insurance liabilities</link:label>
    <link:label id="lab_cvs_OtherInsuranceLiabilitiesNoncurrent_label_en-US" xlink:label="lab_cvs_OtherInsuranceLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Insurance Liabilities, Noncurrent</link:label>
    <link:label id="lab_cvs_OtherInsuranceLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_cvs_OtherInsuranceLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Insurance Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherInsuranceLiabilitiesNoncurrent" xlink:href="cvs-20221231.xsd#cvs_OtherInsuranceLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OtherInsuranceLiabilitiesNoncurrent" xlink:to="lab_cvs_OtherInsuranceLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_24ad0dd9-d31a-4bce-ad40-eb67bf0a5bdc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU and Performance Share Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceDisclosuresAbstract_36a57a83-cfa0-4da9-95d9-3fdc9d1767e1_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReinsuranceDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract" xlink:to="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_422e3b9d-46ff-4963-a868-346c6a7033bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_d9269ad9-9d84-4bc4-ae97-42dce8b9aabe_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts_93974b9d-e8db-4f3b-a2ff-41f9025a8879_terseLabel_en-US" xlink:label="lab_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed interest rates on long-duration group life and long-term care contracts</link:label>
    <link:label id="lab_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts_label_en-US" xlink:label="lab_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts</link:label>
    <link:label id="lab_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts_documentation_en-US" xlink:label="lab_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" xlink:href="cvs-20221231.xsd#cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" xlink:to="lab_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure_f96835fa-1cc7-4efa-9e32-523b37b54ff9_terseLabel_en-US" xlink:label="lab_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset, fair value</link:label>
    <link:label id="lab_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure_label_en-US" xlink:label="lab_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, Right-of-Use Asset, Fair Value Disclosure</link:label>
    <link:label id="lab_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure_documentation_en-US" xlink:label="lab_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, Right-of-Use Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:to="lab_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_VariableInterestEntityAmendedContractExtensionTerm_49a9d12d-684b-4aa8-9faf-f40e1811bb68_terseLabel_en-US" xlink:label="lab_cvs_VariableInterestEntityAmendedContractExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended contract extension term</link:label>
    <link:label id="lab_cvs_VariableInterestEntityAmendedContractExtensionTerm_label_en-US" xlink:label="lab_cvs_VariableInterestEntityAmendedContractExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Amended Contract Extension Term</link:label>
    <link:label id="lab_cvs_VariableInterestEntityAmendedContractExtensionTerm_documentation_en-US" xlink:label="lab_cvs_VariableInterestEntityAmendedContractExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Amended Contract Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VariableInterestEntityAmendedContractExtensionTerm" xlink:href="cvs-20221231.xsd#cvs_VariableInterestEntityAmendedContractExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_VariableInterestEntityAmendedContractExtensionTerm" xlink:to="lab_cvs_VariableInterestEntityAmendedContractExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_9307c100-5042-4545-a8d1-ba587a4237f9_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor obligations, maximum exposure</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock_fa96317a-25e7-4dda-a3e8-0d96d73f05e7_terseLabel_en-US" xlink:label="lab_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Deficiency Reserves</link:label>
    <link:label id="lab_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock_label_en-US" xlink:label="lab_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Premium Deficiency Reserve [Policy Text Block]</link:label>
    <link:label id="lab_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock_documentation_en-US" xlink:label="lab_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Premium Deficiency Reserve [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock" xlink:href="cvs-20221231.xsd#cvs_InsurancePremiumDeficiencyReservePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock" xlink:to="lab_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_41495f63-a503-46af-974c-96fd7c97c648_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52b52277-c1b5-4ed5-8549-6a9fad765eb1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_081bb8f5-e2ef-4f5c-be31-e0c06c047b2e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8eac6d21-ccee-48fb-9dd7-a0b85eb6913e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_5786051c-f2d0-43b7-bfbf-366285246d5c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_YearOfOriginationPeriodTwoMember_9609825a-5d16-436a-b308-908866f42324_terseLabel_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodTwoMember_label_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period Two [Member]</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodTwoMember_documentation_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodTwoMember" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_YearOfOriginationPeriodTwoMember" xlink:to="lab_cvs_YearOfOriginationPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_71a00b98-c893-4c08-b379-b4e6940a2d31_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Accident Year [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution_ddff6fab-1931-4bd1-a222-36a4679979c8_terseLabel_en-US" xlink:label="lab_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiemployer plans, plan contributions</link:label>
    <link:label id="lab_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution_label_en-US" xlink:label="lab_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiemployer Plan, Pension, Insignificant, Plan Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MultiemployerPlanPensionInsignificantPlanContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution" xlink:to="lab_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4e03d2b-7005-4dbf-921b-2bce8028abbc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0ff2203-1d7b-4563-895f-75fa30fa08ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_d4b666e7-b57a-407f-8301-aaf64ba3e11b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of proposed/pending acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LegalSettlementPeriodOfPayment_903531f0-2446-4af9-b1d1-e8470c14bb0a_terseLabel_en-US" xlink:label="lab_cvs_LegalSettlementPeriodOfPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlement, period of payment</link:label>
    <link:label id="lab_cvs_LegalSettlementPeriodOfPayment_label_en-US" xlink:label="lab_cvs_LegalSettlementPeriodOfPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlement, Period Of Payment</link:label>
    <link:label id="lab_cvs_LegalSettlementPeriodOfPayment_documentation_en-US" xlink:label="lab_cvs_LegalSettlementPeriodOfPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlement, Period Of Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LegalSettlementPeriodOfPayment" xlink:href="cvs-20221231.xsd#cvs_LegalSettlementPeriodOfPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LegalSettlementPeriodOfPayment" xlink:to="lab_cvs_LegalSettlementPeriodOfPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_c52e4e38-82ab-4c07-9c49-ab7b62e4ce96_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:to="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_2fcb9fa9-04af-45b3-baa0-8c0f2e1ff88a_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d1e9a97e-35e1-40e4-aef9-789c0ebfa089_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b48e8204-2b03-42b6-9f8c-23229866e7c2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_af781fa4-6f04-456f-b055-39aea0fd6edf_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attorneys' fees and costs</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_135e3198-b688-4b35-a4f6-6618db5eddef_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_d8153b73-1411-4254-9c55-15b00a14a436_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Securities In An Unrealized Capital Loss Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_683cb6ce-4bb9-4084-90d8-8599ff90ba81_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f47b28a3-e96e-44c3-98c2-a53213cec93b_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4.5DueMay2042Member_045770de-57f5-4c3f-b3bd-7d0ec3b4b588_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4.5DueMay2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.5% senior notes due May 2042</link:label>
    <link:label id="lab_cvs_SeniorNotes4.5DueMay2042Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4.5DueMay2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.5%, Due May 2042 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4.5DueMay2042Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4.5DueMay2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.5%, Due May 2042 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.5DueMay2042Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.5DueMay2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4.5DueMay2042Member" xlink:to="lab_cvs_SeniorNotes4.5DueMay2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestAndDividendsReceived_08fe1ee5-2667-4052-8e24-47df9598f293_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and investment income received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestAndDividendsReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest and Dividends Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestAndDividendsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:to="lab_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_49d05db6-1d59-4506-abcd-4fffba3b5ffb_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_ce8194a9-7c1a-45ec-98f7-c458f4947ca7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7a52d82b-7d57-457f-9d42-b5db0909a0a3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_261d8b38-8d58-46f6-997f-95429f1c6521_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_HartfordLifeAndAccidentInsuranceCompanyMember_67ea0d49-4e6e-426a-958c-a643cabf5453_terseLabel_en-US" xlink:label="lab_cvs_HartfordLifeAndAccidentInsuranceCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hartford Life and Accident Insurance Company</link:label>
    <link:label id="lab_cvs_HartfordLifeAndAccidentInsuranceCompanyMember_label_en-US" xlink:label="lab_cvs_HartfordLifeAndAccidentInsuranceCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hartford Life And Accident Insurance Company [Member]</link:label>
    <link:label id="lab_cvs_HartfordLifeAndAccidentInsuranceCompanyMember_documentation_en-US" xlink:label="lab_cvs_HartfordLifeAndAccidentInsuranceCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hartford Life And Accident Insurance Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HartfordLifeAndAccidentInsuranceCompanyMember" xlink:href="cvs-20221231.xsd#cvs_HartfordLifeAndAccidentInsuranceCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_HartfordLifeAndAccidentInsuranceCompanyMember" xlink:to="lab_cvs_HartfordLifeAndAccidentInsuranceCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_46bf5bed-be57-4482-9a5d-4ddba5dd91a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OtherAcquiredIntangibleAssetsLineItems_e1ba0cd4-4e95-40d5-b2ac-172b4073fb8c_terseLabel_en-US" xlink:label="lab_cvs_OtherAcquiredIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets[Line Items]</link:label>
    <link:label id="lab_cvs_OtherAcquiredIntangibleAssetsLineItems_label_en-US" xlink:label="lab_cvs_OtherAcquiredIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Acquired Intangible Assets [Line Items]</link:label>
    <link:label id="lab_cvs_OtherAcquiredIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_cvs_OtherAcquiredIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAcquiredIntangibleAssetsLineItems" xlink:href="cvs-20221231.xsd#cvs_OtherAcquiredIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems" xlink:to="lab_cvs_OtherAcquiredIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_56b4bff7-41f0-47b8-b2f1-31f7afd65b54_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b6fbd31f-5e38-4821-a119-6d623ca3a0c8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_623e36c0-68ab-4f23-8779-4d165cf32e58_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_278d7f4e-0498-46bf-b0e6-bf0bb4c6628b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_c29e5aba-6d39-4de0-be5a-eb19d3a168bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation, beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_b0f6e2a5-527d-4f2a-ab78-39fa1a359335_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_3ea60bdf-8886-45af-ae43-34af6ccc27cf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_320973d8-0945-4d1d-96bf-67f73a2b32ef_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic and Diluted Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b12b4eb9-3114-420c-be7a-bab567aee848_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3f92b564-46b8-4e2b-ba21-eb023d67eb1b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized capital losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_6acbdd24-64dc-4747-9899-34141a4fb644_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8bca1905-90ea-43d5-9086-9ba41ebe77a0_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_bee0f13c-ca45-41ae-8563-e55d388cbb0c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2f714dd7-8a50-4a80-b766-b5e75e21e116_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_2095ba18-b511-420a-b1d6-6874de2e00ce_terseLabel_en-US" xlink:label="lab_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options and Stock Appreciation Rights</link:label>
    <link:label id="lab_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_label_en-US" xlink:label="lab_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options And Stock Appreciation Rights [Member]</link:label>
    <link:label id="lab_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_documentation_en-US" xlink:label="lab_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options and Stock Appreciation Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:href="cvs-20221231.xsd#cvs_EmployeeStockOptionsAndStockAppreciationRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:to="lab_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_daa5cec5-0c90-41c5-a822-721939e95393_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f3a07bfb-edcc-4808-b9b2-9cf19c49afbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8552cce5-15c3-4557-a4c8-acf332392a97_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c7f02a2f-698b-4494-bb0f-c0559f76205e_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_22f16af3-ee95-44be-9506-79604ccf235d_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_86f4c367-f09f-493d-8edb-b2126567f442_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_8184a0f0-8677-40f0-8278-55b562f5e951_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance lines other than short duration</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_877cce91-5c81-4119-aa01-5ab7d84b349b_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory net income</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Net Income Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f4c83a26-5738-4ec7-bb0d-eaf9f582202b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountAssetCategoryAxis_fb4273a1-7912-4d0b-a4e8-0bab3b2abf47_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountAssetCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account Asset Category [Axis]</link:label>
    <link:label id="lab_us-gaap_SeparateAccountAssetCategoryAxis_label_en-US" xlink:label="lab_us-gaap_SeparateAccountAssetCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account Asset Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis" xlink:to="lab_us-gaap_SeparateAccountAssetCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0cd19a36-44ce-420c-807a-55bce92b2260_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d7275fd3-509e-4d35-984b-ad11199e6d19_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DeferredTaxAssetsPayrollTaxDeferral_a798e1dd-c970-4c4c-b8a5-2be2e0739ac7_terseLabel_en-US" xlink:label="lab_cvs_DeferredTaxAssetsPayrollTaxDeferral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax deferral</link:label>
    <link:label id="lab_cvs_DeferredTaxAssetsPayrollTaxDeferral_label_en-US" xlink:label="lab_cvs_DeferredTaxAssetsPayrollTaxDeferral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Payroll Tax Deferral</link:label>
    <link:label id="lab_cvs_DeferredTaxAssetsPayrollTaxDeferral_documentation_en-US" xlink:label="lab_cvs_DeferredTaxAssetsPayrollTaxDeferral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Payroll Tax Deferral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxAssetsPayrollTaxDeferral" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxAssetsPayrollTaxDeferral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DeferredTaxAssetsPayrollTaxDeferral" xlink:to="lab_cvs_DeferredTaxAssetsPayrollTaxDeferral" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ProviderNetworksMember_53b6dab4-7d08-4c42-9bff-4f19f1a9d145_terseLabel_en-US" xlink:label="lab_cvs_ProviderNetworksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider networks</link:label>
    <link:label id="lab_cvs_ProviderNetworksMember_label_en-US" xlink:label="lab_cvs_ProviderNetworksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Networks [Member]</link:label>
    <link:label id="lab_cvs_ProviderNetworksMember_documentation_en-US" xlink:label="lab_cvs_ProviderNetworksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in a business combination or other transaction. This item represents the value ascribed to the relationships with the acquiree's physicians, hospitals and other health care providers network.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ProviderNetworksMember" xlink:href="cvs-20221231.xsd#cvs_ProviderNetworksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ProviderNetworksMember" xlink:to="lab_cvs_ProviderNetworksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2fa2e200-01a5-4bc1-a01e-08b6eea0c78e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_d114182f-be8e-49eb-9d59-b449d62115ee_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5ef62ff1-a98d-4bcb-b864-745ebff31af6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_3ccf2341-1e1f-40fc-89a0-93ab2c992fab_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_db714c28-8233-46af-9721-64f47051229f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_90556470-91eb-4d8e-9cdd-2217a2507e68_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_4f109c5f-c427-4738-bbcb-596b5b93365d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased_40c7eb04-ec31-422c-b3b2-295e6a1d0ab7_terseLabel_en-US" xlink:label="lab_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average purchase price of shares purchased (in dollars per share)</link:label>
    <link:label id="lab_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased_label_en-US" xlink:label="lab_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased</link:label>
    <link:label id="lab_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased_documentation_en-US" xlink:label="lab_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased" xlink:href="cvs-20221231.xsd#cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased" xlink:to="lab_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_0312999a-5e91-4d36-83da-83c55b14b68a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. domestic</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9716349a-4467-4ab0-b6fe-7634e156e4ed_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SharesHeldInTrustPolicyTextBlock_7ae62e0e-5ad9-4c12-9f52-6db715ac3a6b_terseLabel_en-US" xlink:label="lab_cvs_SharesHeldInTrustPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held in Trust</link:label>
    <link:label id="lab_cvs_SharesHeldInTrustPolicyTextBlock_label_en-US" xlink:label="lab_cvs_SharesHeldInTrustPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held In Trust [Policy Text Block]</link:label>
    <link:label id="lab_cvs_SharesHeldInTrustPolicyTextBlock_documentation_en-US" xlink:label="lab_cvs_SharesHeldInTrustPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held In Trust [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SharesHeldInTrustPolicyTextBlock" xlink:href="cvs-20221231.xsd#cvs_SharesHeldInTrustPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SharesHeldInTrustPolicyTextBlock" xlink:to="lab_cvs_SharesHeldInTrustPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldByInsuranceRegulators_38acd9a4-5289-4821-ad63-8fa660a9eaa8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldByInsuranceRegulators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments on deposit with regulatory bodies</link:label>
    <link:label id="lab_us-gaap_AssetsHeldByInsuranceRegulators_label_en-US" xlink:label="lab_us-gaap_AssetsHeldByInsuranceRegulators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held by Insurance Regulators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldByInsuranceRegulators" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldByInsuranceRegulators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldByInsuranceRegulators" xlink:to="lab_us-gaap_AssetsHeldByInsuranceRegulators" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares_edb42efa-f83c-459b-bba7-20788f8a374e_terseLabel_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR, maximum amount of shares received or delivered</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares_label_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Program, Maximum Number Of Shares</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares_documentation_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Program, Maximum Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares" xlink:to="lab_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour_14c13787-5d25-4f7b-92fa-44329d7cee39_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour_label_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Year Four</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour_documentation_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour" xlink:to="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d3af43b9-7da3-40c0-a1ec-ebb3b0782f6f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_feee7d63-773a-49db-895f-84edd1e642c3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3Point70PercentDue2023Member_0d14a280-cfe2-496e-9990-fb7818e67c43_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3Point70PercentDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% senior notes due 2023</link:label>
    <link:label id="lab_cvs_SeniorNotes3Point70PercentDue2023Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3Point70PercentDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3 Point 70 Percent, Due 2023 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3Point70PercentDue2023Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3Point70PercentDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3 Point 70 Percent, Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point70PercentDue2023Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point70PercentDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3Point70PercentDue2023Member" xlink:to="lab_cvs_SeniorNotes3Point70PercentDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ThailandBusinessMember_7a51b984-c636-4022-9f93-86481d1c3888_terseLabel_en-US" xlink:label="lab_cvs_ThailandBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thailand Business</link:label>
    <link:label id="lab_cvs_ThailandBusinessMember_label_en-US" xlink:label="lab_cvs_ThailandBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thailand Business [Member]</link:label>
    <link:label id="lab_cvs_ThailandBusinessMember_documentation_en-US" xlink:label="lab_cvs_ThailandBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thailand Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ThailandBusinessMember" xlink:href="cvs-20221231.xsd#cvs_ThailandBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ThailandBusinessMember" xlink:to="lab_cvs_ThailandBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_InitialContractualTerm_03b4582a-07c3-4412-bc93-d10f6dd70f5c_terseLabel_en-US" xlink:label="lab_cvs_InitialContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial contractual term (in years)</link:label>
    <link:label id="lab_cvs_InitialContractualTerm_label_en-US" xlink:label="lab_cvs_InitialContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Contractual Term</link:label>
    <link:label id="lab_cvs_InitialContractualTerm_documentation_en-US" xlink:label="lab_cvs_InitialContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Initial Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InitialContractualTerm" xlink:href="cvs-20221231.xsd#cvs_InitialContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_InitialContractualTerm" xlink:to="lab_cvs_InitialContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_5e419f61-0724-475f-85e6-c943f091a7b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6d3a5ece-b223-4d73-a3aa-364c6eee7a6c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7058accb-e03a-446e-b115-f679edb9c4b9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_dca37f56-2a56-46ca-8ba2-573841b26c96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration of statutes of limitation</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_944830c8-36dc-4bcc-acb3-0d737547ce80_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_06fb3e3e-9505-4938-82f1-d23c6de5a00c_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost (income)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_a663e969-fb8d-420a-a0ad-e47daa4500dc_terseLabel_en-US" xlink:label="lab_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases Liabilities Payments Due [Abstract]</link:label>
    <link:label id="lab_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_documentation_en-US" xlink:label="lab_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract" xlink:href="cvs-20221231.xsd#cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract" xlink:to="lab_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod_9f6c96e0-58f0-4129-bbca-8735684dec5b_terseLabel_en-US" xlink:label="lab_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP issuances, net of purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod_label_en-US" xlink:label="lab_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Issuance, Net Of Treasury Stock, Shares, Acquired, Cost Method</link:label>
    <link:label id="lab_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod_documentation_en-US" xlink:label="lab_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Issuance, Net Of Treasury Stock, Shares, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" xlink:href="cvs-20221231.xsd#cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" xlink:to="lab_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies_5b2d34f2-0784-4a61-aa2d-a7cbabf4c042_negatedTerseLabel_en-US" xlink:label="lab_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for inventory and prescriptions dispensed by retail network pharmacies</link:label>
    <link:label id="lab_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies_label_en-US" xlink:label="lab_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies</link:label>
    <link:label id="lab_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies_documentation_en-US" xlink:label="lab_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" xlink:href="cvs-20221231.xsd#cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" xlink:to="lab_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3aa13c6b-7eaa-454c-9ad6-bb54084ae8fa_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to CVS Health</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_58321395-40ad-4e54-b567-4eee2b9b1ed3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule ESPP Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aca51fba-975c-400a-a3e0-35b725d2405b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_b598f187-d30b-4f1f-ae5c-db97544a1285_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_57146d57-3277-4e32-844f-2e53033e24d6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_b5ea4072-a89f-47ad-b79f-b356968140cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_06226299-1a1b-458a-9fad-8bd784a5e687_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4e049f24-46b9-45e5-a4c3-767e5c607414_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_54ff8b04-b78d-4974-b8cf-5b504ab4a70a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RetailLongTermCareSegmentMember_7c3a74a3-e945-457b-855c-c92ece1582a0_terseLabel_en-US" xlink:label="lab_cvs_RetailLongTermCareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retail/ LTC</link:label>
    <link:label id="lab_cvs_RetailLongTermCareSegmentMember_label_en-US" xlink:label="lab_cvs_RetailLongTermCareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retail Long-Term Care Segment [Member]</link:label>
    <link:label id="lab_cvs_RetailLongTermCareSegmentMember_documentation_en-US" xlink:label="lab_cvs_RetailLongTermCareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retail Long-Term Care Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RetailLongTermCareSegmentMember" xlink:to="lab_cvs_RetailLongTermCareSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_4d9a9349-4319-4d87-973a-4a9da864c35a_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRegulatoryAssetsTextBlock_914dfadb-c28c-482b-bc2b-8a9927f1afc0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Regulatory Requirements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRegulatoryAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Regulatory Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRegulatoryAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRegulatoryAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_deccc5ed-5337-489a-b13c-dd7e4c354638_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_135ffcd3-5e47-4ea6-ab91-a14f70a53ce8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares_d0081b23-7e09-44b8-9b68-6bb8b741aa42_terseLabel_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR percent of notional amount received in shares</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares_label_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Percent Of Notional Amount Received In Shares</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares_documentation_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Percent Of Notional Amount Received In Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" xlink:to="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4.75DueDecember2022Member_4448136d-cbc1-4a95-b562-e7578f121a7e_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4.75DueDecember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% senior notes due December 2022</link:label>
    <link:label id="lab_cvs_SeniorNotes4.75DueDecember2022Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4.75DueDecember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.75%, Due December 2022 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4.75DueDecember2022Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4.75DueDecember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.75%, Due December 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.75DueDecember2022Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.75DueDecember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4.75DueDecember2022Member" xlink:to="lab_cvs_SeniorNotes4.75DueDecember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_3cbb9655-9702-4d72-a340-eac603753bf5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DenominatorForEarningsPerShareCalculationAbstract_052ddd5b-1f34-4f80-943d-a304ec5d4d0e_terseLabel_en-US" xlink:label="lab_cvs_DenominatorForEarningsPerShareCalculationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for earnings per share calculation:</link:label>
    <link:label id="lab_cvs_DenominatorForEarningsPerShareCalculationAbstract_label_en-US" xlink:label="lab_cvs_DenominatorForEarningsPerShareCalculationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator For Earnings Per Share Calculation [Abstract]</link:label>
    <link:label id="lab_cvs_DenominatorForEarningsPerShareCalculationAbstract_documentation_en-US" xlink:label="lab_cvs_DenominatorForEarningsPerShareCalculationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator For Earnings Per Share Calculation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract" xlink:href="cvs-20221231.xsd#cvs_DenominatorForEarningsPerShareCalculationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract" xlink:to="lab_cvs_DenominatorForEarningsPerShareCalculationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_fc2be5ce-ca35-4b3d-a3d3-7a73f92a2ae1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes6.125DueSeptember2039Member_60e76be6-9e80-4247-aa3f-1ac66a75b4f2_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes6.125DueSeptember2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% senior notes due September 2039</link:label>
    <link:label id="lab_cvs_SeniorNotes6.125DueSeptember2039Member_label_en-US" xlink:label="lab_cvs_SeniorNotes6.125DueSeptember2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due September 2039 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes6.125DueSeptember2039Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes6.125DueSeptember2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due September 2039 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.125DueSeptember2039Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.125DueSeptember2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes6.125DueSeptember2039Member" xlink:to="lab_cvs_SeniorNotes6.125DueSeptember2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_7a59c1f1-09e8-48c0-8edd-78507b4c111b_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">States, municipalities and political subdivisions</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_ad2498d3-3205-430f-a197-4ba3cc6e0220_verboseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">States, municipalities and political subdivisions</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_81d8e1af-1a9c-417e-9874-03bbf09260d1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c91157e3-f3f6-4a18-b002-d9d28ae7de94_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt and lease obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_e1b9a321-1655-429a-b4f3-d7c6393e19db_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b07ed41b-2438-4cc0-a215-287d888650d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to CVS Health (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4bf33bbc-c864-45a5-9c83-0fbba95698fb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share from continuing operations, diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_73ce299d-fbf3-4570-b2a4-14a0e9b8f3fc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesAgreementAmount_ae529da0-6172-49b0-9abd-a5072b6cf6f1_terseLabel_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR agreement, amount</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesAgreementAmount_label_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases Agreement, Amount</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesAgreementAmount_documentation_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases Agreement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesAgreementAmount" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AcceleratedShareRepurchasesAgreementAmount" xlink:to="lab_cvs_AcceleratedShareRepurchasesAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SignifyHealthIncMember_7c49df6f-3046-45b4-b8a8-14e1e278d497_terseLabel_en-US" xlink:label="lab_cvs_SignifyHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Signify Health, Inc.</link:label>
    <link:label id="lab_cvs_SignifyHealthIncMember_label_en-US" xlink:label="lab_cvs_SignifyHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Signify Health, Inc. [Member]</link:label>
    <link:label id="lab_cvs_SignifyHealthIncMember_documentation_en-US" xlink:label="lab_cvs_SignifyHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Signify Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SignifyHealthIncMember" xlink:href="cvs-20221231.xsd#cvs_SignifyHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SignifyHealthIncMember" xlink:to="lab_cvs_SignifyHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f1c5ea69-de0b-443b-a2f7-cadc7ac49166_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_c5677621-93b7-4c42-8590-2af52aa4e9b3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6e50e6e0-d1b4-4e43-9c33-36c1290ed9fe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_890c8426-b734-45d8-a5cb-cfc1373e2857_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_StockOptionsAndStockAppreciationRightsMember_094d8882-ab03-4f50-83d8-7e57a7917fc4_terseLabel_en-US" xlink:label="lab_cvs_StockOptionsAndStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Stock Appreciation Rights</link:label>
    <link:label id="lab_cvs_StockOptionsAndStockAppreciationRightsMember_label_en-US" xlink:label="lab_cvs_StockOptionsAndStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Stock Appreciation Rights [Member]</link:label>
    <link:label id="lab_cvs_StockOptionsAndStockAppreciationRightsMember_documentation_en-US" xlink:label="lab_cvs_StockOptionsAndStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Stock Appreciation Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StockOptionsAndStockAppreciationRightsMember" xlink:href="cvs-20221231.xsd#cvs_StockOptionsAndStockAppreciationRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_StockOptionsAndStockAppreciationRightsMember" xlink:to="lab_cvs_StockOptionsAndStockAppreciationRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock_eeb2a96a-7cb0-4301-aebe-91c8cecb4647_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Level 3 Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_13445a59-d510-44b7-a4ef-c66ecd28e854_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_23fa2fa2-c493-4fbe-9796-22bd6ce14e3c_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7f0887be-2789-4d54-b8f2-bdb4dfff80ff_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_acf10fdc-5bbb-4a98-a80c-51ad47435044_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e98957e-655a-48c4-8654-858398001435_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances_cd767ce4-5c89-4db6-952e-ec1359780c6a_terseLabel_en-US" xlink:label="lab_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debts and other allowances</link:label>
    <link:label id="lab_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances_label_en-US" xlink:label="lab_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances</link:label>
    <link:label id="lab_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances_documentation_en-US" xlink:label="lab_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" xlink:to="lab_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_1c74dfc0-0cbe-4eee-a4ba-f957f4f90b95_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e0bf9f7d-74bf-4144-b6c6-cc98a46bef7a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Securities Available For Sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_18eb0490-72a6-4023-b27b-8524b64dc5c3_terseLabel_en-US" xlink:label="lab_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases:</link:label>
    <link:label id="lab_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Assets And Liabilities, Lessee [Abstract]</link:label>
    <link:label id="lab_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_documentation_en-US" xlink:label="lab_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Assets And Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_5bb58183-777e-4614-998c-76550c128684_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_899c4266-b392-4a96-a931-e7c150dcf054_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information about Incurred and Paid Health Care Claims Development</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PharmacyClaimsAndDiscountsPayableCurrent_5c704736-3e4c-4a3d-983a-00546d60e5eb_terseLabel_en-US" xlink:label="lab_cvs_PharmacyClaimsAndDiscountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy claims and discounts payable</link:label>
    <link:label id="lab_cvs_PharmacyClaimsAndDiscountsPayableCurrent_label_en-US" xlink:label="lab_cvs_PharmacyClaimsAndDiscountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims And Discounts Payable, Current</link:label>
    <link:label id="lab_cvs_PharmacyClaimsAndDiscountsPayableCurrent_documentation_en-US" xlink:label="lab_cvs_PharmacyClaimsAndDiscountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims And Discounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyClaimsAndDiscountsPayableCurrent" xlink:href="cvs-20221231.xsd#cvs_PharmacyClaimsAndDiscountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PharmacyClaimsAndDiscountsPayableCurrent" xlink:to="lab_cvs_PharmacyClaimsAndDiscountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3.25DueAugust2029Member_64195a07-be50-4f68-a491-85b9ea0b9d2e_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3.25DueAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% senior notes due August 2029</link:label>
    <link:label id="lab_cvs_SeniorNotes3.25DueAugust2029Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3.25DueAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.25%, Due August 2029 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3.25DueAugust2029Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3.25DueAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.25%, Due August 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.25DueAugust2029Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.25DueAugust2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3.25DueAugust2029Member" xlink:to="lab_cvs_SeniorNotes3.25DueAugust2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_b75ec879-5b96-4d1b-aba7-2af58c6edbcc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount expected to be reclassified</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes5DueDecember2024Member_7f5756c0-268a-45e9-b249-aac978a45649_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes5DueDecember2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5% senior notes due December 2024</link:label>
    <link:label id="lab_cvs_SeniorNotes5DueDecember2024Member_label_en-US" xlink:label="lab_cvs_SeniorNotes5DueDecember2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5%, Due December 2024 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes5DueDecember2024Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes5DueDecember2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5%, Due December 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5DueDecember2024Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5DueDecember2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes5DueDecember2024Member" xlink:to="lab_cvs_SeniorNotes5DueDecember2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c905b325-7943-4a7f-be5c-014b906c4f90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_3360ecf4-f959-4e47-bf75-591a6ec36c58_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_d43f2090-561e-4d35-89c0-23f564f787d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of fully reserved ACA risk corridor receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_af99e033-68cf-435d-b94a-6e6063157b6e_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_1e7f3879-c924-480c-b621-ec26024151b8_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy network</link:label>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Through Intermediary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:to="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NumberofReinsuranceContractsEnteredInto_55857c56-0d7e-4e80-9319-ea85ab960e2e_terseLabel_en-US" xlink:label="lab_cvs_NumberofReinsuranceContractsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reinsurance contracts entered into</link:label>
    <link:label id="lab_cvs_NumberofReinsuranceContractsEnteredInto_label_en-US" xlink:label="lab_cvs_NumberofReinsuranceContractsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reinsurance Contracts Entered Into</link:label>
    <link:label id="lab_cvs_NumberofReinsuranceContractsEnteredInto_documentation_en-US" xlink:label="lab_cvs_NumberofReinsuranceContractsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reinsurance contracts entered into with an unrelated insurer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberofReinsuranceContractsEnteredInto" xlink:href="cvs-20221231.xsd#cvs_NumberofReinsuranceContractsEnteredInto"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NumberofReinsuranceContractsEnteredInto" xlink:to="lab_cvs_NumberofReinsuranceContractsEnteredInto" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_88c99048-399f-499b-aabb-3c259e921566_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities reflected in other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_793405bf-8575-4103-82f0-5e0b3c1c9fd4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_209f69c6-9d59-430b-b8a7-6413b3ae98ac_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ff65c3d9-a224-4dc3-ae74-3490a3a1c79f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_71a170a2-9447-423e-9a81-b3a80698df51_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations attributable to CVS Health (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_d17a7779-45c4-464c-9f63-5ecc297c78d1_terseLabel_en-US" xlink:label="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former gain contingency, recognized in current period, before tax</link:label>
    <link:label id="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Gain Contingency, Recognized In Current Period, Before Tax</link:label>
    <link:label id="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_documentation_en-US" xlink:label="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Gain Contingency, Recognized In Current Period, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" xlink:href="cvs-20221231.xsd#cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" xlink:to="lab_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_bb82b40e-90fe-4cd1-a5a3-6c025691910d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5091d698-0768-4c6b-b010-956c9526948d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_84a1ab3c-76bc-4a85-8d9e-b7133b4117fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_8c9e1802-39f2-483e-b75b-2268275431e1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskLineItems_3f3feac8-fd82-4441-8f2f-1f1b8d952614_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskLineItems_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskLineItems" xlink:to="lab_us-gaap_CededCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_49150377-f4ed-4e5f-9f8d-b11e4ba7e19f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4f47f9e7-8ed5-4cc0-af28-519f46db7297_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings and Credit Agreements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_e891148d-a773-42ef-a3e6-3ed71304b30b_terseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and restricted cash sold</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance_0286e94e-a623-4419-885c-402a85962e8d_negatedTerseLabel_en-US" xlink:label="lab_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares, net of ESPP issuances (in shares)</link:label>
    <link:label id="lab_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance_label_en-US" xlink:label="lab_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance</link:label>
    <link:label id="lab_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance_documentation_en-US" xlink:label="lab_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance" xlink:to="lab_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_2e4ef45e-14fe-4c4e-9a20-0f8f0696e469_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_83f11890-df75-41eb-9b57-3f835a1d3825_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_37a3d521-01a5-4376-b376-eebb00e5237e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_109dee9a-b6f2-4855-9eef-ee7aa7d4c104_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectPremiumsEarned_531b2a59-7a7a-47e1-88a2-ea15d80a3188_terseLabel_en-US" xlink:label="lab_us-gaap_DirectPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct</link:label>
    <link:label id="lab_us-gaap_DirectPremiumsEarned_label_en-US" xlink:label="lab_us-gaap_DirectPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Premiums Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectPremiumsEarned" xlink:to="lab_us-gaap_DirectPremiumsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes1Point75PercentAugust2030Member_ddeb684b-b919-4f75-bd35-c557f6a668a9_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes1Point75PercentAugust2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.75% senior notes due August 2030</link:label>
    <link:label id="lab_cvs_SeniorNotes1Point75PercentAugust2030Member_label_en-US" xlink:label="lab_cvs_SeniorNotes1Point75PercentAugust2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 1 Point 75 Percent, August 2030 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes1Point75PercentAugust2030Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes1Point75PercentAugust2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 1 Point 75 Percent, August 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes1Point75PercentAugust2030Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes1Point75PercentAugust2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes1Point75PercentAugust2030Member" xlink:to="lab_cvs_SeniorNotes1Point75PercentAugust2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeTextBlock_03329aed-6fa3-438a-9d31-5c130fcc6bd1_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeTextBlock" xlink:to="lab_us-gaap_InvestmentIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_eeb35eeb-cc81-4cd0-b390-aa8c9ba8700b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_638ff7e8-d6f0-49a9-a19d-244f034d2502_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_18af1d3c-870c-4885-82cf-ffb03ada2959_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FinanceLeaseRightOfUseAssetNet_5e97373a-3fdf-4720-9085-595478fac361_totalLabel_en-US" xlink:label="lab_cvs_FinanceLeaseRightOfUseAssetNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_cvs_FinanceLeaseRightOfUseAssetNet_label_en-US" xlink:label="lab_cvs_FinanceLeaseRightOfUseAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-Of-Use Asset, Net</link:label>
    <link:label id="lab_cvs_FinanceLeaseRightOfUseAssetNet_documentation_en-US" xlink:label="lab_cvs_FinanceLeaseRightOfUseAssetNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-Of-Use Asset, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetNet" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FinanceLeaseRightOfUseAssetNet" xlink:to="lab_cvs_FinanceLeaseRightOfUseAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4.875DueJuly2035Member_aa8ac270-cbcd-4324-bb3a-a3121ad11b81_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4.875DueJuly2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% senior notes due July 2035</link:label>
    <link:label id="lab_cvs_SeniorNotes4.875DueJuly2035Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4.875DueJuly2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.875%, Due July 2035 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4.875DueJuly2035Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4.875DueJuly2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.875%, Due July 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.875DueJuly2035Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.875DueJuly2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4.875DueJuly2035Member" xlink:to="lab_cvs_SeniorNotes4.875DueJuly2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_bbdcb05f-8dd1-411e-8bae-11bf972c023d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dfd9d680-5847-48df-b233-b2b41fe0a212_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_66eb3351-2272-4bf3-9424-b3b8db56cebb_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_d99576d9-4c22-4c71-8a08-96f16032bb36_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_68093069-c832-4be5-801a-9386971ab7b7_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_a5677902-eeb9-4d31-9525-26d34495f81d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_bea2504b-58be-4219-b170-9c1ceca82684_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9ab06b45-d4a9-42b4-af8c-bffceb3a837a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes6.25DueJune2027Member_8e6c3605-c34f-460a-a51f-077166a5ba6e_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes6.25DueJune2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.25% senior notes due June 2027</link:label>
    <link:label id="lab_cvs_SeniorNotes6.25DueJune2027Member_label_en-US" xlink:label="lab_cvs_SeniorNotes6.25DueJune2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due June 2027 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes6.25DueJune2027Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes6.25DueJune2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due June 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.25DueJune2027Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.25DueJune2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes6.25DueJune2027Member" xlink:to="lab_cvs_SeniorNotes6.25DueJune2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RedOakMember_bc0bbdfe-73f9-4dee-9ee3-883085e28636_terseLabel_en-US" xlink:label="lab_cvs_RedOakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Red Oak</link:label>
    <link:label id="lab_cvs_RedOakMember_label_en-US" xlink:label="lab_cvs_RedOakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Red Oak [Member]</link:label>
    <link:label id="lab_cvs_RedOakMember_documentation_en-US" xlink:label="lab_cvs_RedOakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Red Oak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RedOakMember" xlink:href="cvs-20221231.xsd#cvs_RedOakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RedOakMember" xlink:to="lab_cvs_RedOakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountAssets_35e4c1bc-aea1-4213-b3c9-bfa668831e71_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate accounts assets</link:label>
    <link:label id="lab_us-gaap_SeparateAccountAssets_label_en-US" xlink:label="lab_us-gaap_SeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountAssets" xlink:to="lab_us-gaap_SeparateAccountAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_48870acf-08db-4e7c-9ee1-1367754889c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_540c52f6-d1e4-4a52-8c7f-cb300f0993f0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PharmacyRevenueMember_62d2133d-c66a-4e53-a06b-b08a62dc2db9_terseLabel_en-US" xlink:label="lab_cvs_PharmacyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy</link:label>
    <link:label id="lab_cvs_PharmacyRevenueMember_label_en-US" xlink:label="lab_cvs_PharmacyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Revenue [Member]</link:label>
    <link:label id="lab_cvs_PharmacyRevenueMember_documentation_en-US" xlink:label="lab_cvs_PharmacyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyRevenueMember" xlink:href="cvs-20221231.xsd#cvs_PharmacyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PharmacyRevenueMember" xlink:to="lab_cvs_PharmacyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_fc6a7d8c-1060-4f61-a02f-12c4076f45f4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_58635165-ee0d-4022-ade9-73769c9977ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt premiums</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_a574e53f-fc78-4b4b-a273-6fa1623c6b72_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount awarded from other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes1Point3PercentAugust2027Member_7b26e91b-7ece-4a5e-a3f5-beec1459561e_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes1Point3PercentAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.3% senior notes due August 2027</link:label>
    <link:label id="lab_cvs_SeniorNotes1Point3PercentAugust2027Member_label_en-US" xlink:label="lab_cvs_SeniorNotes1Point3PercentAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 1 Point 3 Percent, August 2027 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes1Point3PercentAugust2027Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes1Point3PercentAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 1 Point 3 Percent, August 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes1Point3PercentAugust2027Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes1Point3PercentAugust2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes1Point3PercentAugust2027Member" xlink:to="lab_cvs_SeniorNotes1Point3PercentAugust2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9e0c76e-58ab-4a15-b92e-47d178f95a1c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes3.7DueMarch2023Member_d5cfa654-3527-4b2b-b7cd-5b84ca1e0738_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes3.7DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% senior notes due March 2023</link:label>
    <link:label id="lab_cvs_SeniorNotes3.7DueMarch2023Member_label_en-US" xlink:label="lab_cvs_SeniorNotes3.7DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.7%, Due March 2023 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes3.7DueMarch2023Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes3.7DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 3.7%, Due March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.7DueMarch2023Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.7DueMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes3.7DueMarch2023Member" xlink:to="lab_cvs_SeniorNotes3.7DueMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_0e54e2fe-309b-4d96-9ed4-e7523d2121e3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_WeightedAverageRemainingLeaseTermAbstract_c0ddb106-5965-4923-b4b0-e85099bfb9b9_terseLabel_en-US" xlink:label="lab_cvs_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_cvs_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_cvs_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_cvs_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_cvs_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_WeightedAverageRemainingLeaseTermAbstract" xlink:href="cvs-20221231.xsd#cvs_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_cvs_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet_8ce6d809-ff35-4e16-9efc-e6243801c601_negatedTerseLabel_en-US" xlink:label="lab_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discounts and deferred financing costs</link:label>
    <link:label id="lab_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net</link:label>
    <link:label id="lab_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet_documentation_en-US" xlink:label="lab_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" xlink:href="cvs-20221231.xsd#cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" xlink:to="lab_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4Point25PercentApril2050Member_a1b86d20-885e-44ab-b589-85f35aaa388c_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4Point25PercentApril2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.25% senior notes due April 2050</link:label>
    <link:label id="lab_cvs_SeniorNotes4Point25PercentApril2050Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4Point25PercentApril2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4 Point 25 Percent, April 2050 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4Point25PercentApril2050Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4Point25PercentApril2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4 Point 25 Percent, April 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point25PercentApril2050Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point25PercentApril2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4Point25PercentApril2050Member" xlink:to="lab_cvs_SeniorNotes4Point25PercentApril2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ad2a2e08-a157-4589-9ee9-029a82650da3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2eeef671-6283-41c6-9da0-181837e3f19c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_24e3279e-9e7f-4f2a-8574-3d8323d8b2fc_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2bed8b8c-fc13-432e-b838-d42a2dd3698d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_fcd87863-a5ed-4256-8b9a-da1fdca3df91_terseLabel_en-US" xlink:label="lab_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets And Liabilities, Lessee [Abstract]</link:label>
    <link:label id="lab_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_documentation_en-US" xlink:label="lab_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets And Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_62e04caf-1817-48fe-9d13-1d798631784c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod_57398fe9-da4a-498f-9efe-beb33c049959_terseLabel_en-US" xlink:label="lab_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stores, annual planned closures for closure period</link:label>
    <link:label id="lab_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod_label_en-US" xlink:label="lab_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stores, Annual Planned Closures For Closure Period</link:label>
    <link:label id="lab_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod_documentation_en-US" xlink:label="lab_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stores, Annual Planned Closures For Closure Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod" xlink:to="lab_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_122d9de2-d5ed-4ccb-ba72-711245d79ad6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates_954de914-24c3-4c2e-bba3-0973d151d3c3_terseLabel_en-US" xlink:label="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units and performance stock units vested if actual payout rates are applied (in shares)</link:label>
    <link:label id="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates_label_en-US" xlink:label="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Actual Payout Rates</link:label>
    <link:label id="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates_documentation_en-US" xlink:label="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Actual Payout Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates" xlink:href="cvs-20221231.xsd#cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates" xlink:to="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_bab2a715-57c1-4295-857d-1ac35dfbe02f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_d01fff45-2dde-4efb-8121-f5a6df8118ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_10452f9e-9a23-48fd-8d90-88498d797c2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyUnrecordedAmount_ed9bfe8a-a55f-4330-b360-2bda70723c64_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain contingency, unrecorded amount</link:label>
    <link:label id="lab_us-gaap_GainContingencyUnrecordedAmount_label_en-US" xlink:label="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Unrecorded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyUnrecordedAmount" xlink:to="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2af8e1df-6ca9-4288-a54e-a1cd5ab21fc6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts_422515c0-1ad1-4b2f-a3c5-a938b997fa36_terseLabel_en-US" xlink:label="lab_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligations underlying the guaranteed benefits</link:label>
    <link:label id="lab_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts_label_en-US" xlink:label="lab_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligations To Maintain Levels Of Separate Accounts</link:label>
    <link:label id="lab_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts_documentation_en-US" xlink:label="lab_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the contractual obligation to maintain the required level of funding in Separate Accounts necessary to fund specific guaranteed pensions annuities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts" xlink:href="cvs-20221231.xsd#cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts" xlink:to="lab_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_759a184f-34bc-46e9-888f-5d37f930520c_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_303e64bc-8320-4c44-923d-a86c97177704_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_f0723b75-fc87-443a-b33e-fcb96e7b470c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_c246e8d5-8224-4d8c-93de-f21a5d1f4af5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable for Unpaid Claims and Claims Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:to="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SupportingExperienceRatedProductsMember_d07f0665-21b2-4e5b-b73f-31057d418db8_terseLabel_en-US" xlink:label="lab_cvs_SupportingExperienceRatedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supporting experience- rated products</link:label>
    <link:label id="lab_cvs_SupportingExperienceRatedProductsMember_label_en-US" xlink:label="lab_cvs_SupportingExperienceRatedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supporting Experience Rated Products [Member]</link:label>
    <link:label id="lab_cvs_SupportingExperienceRatedProductsMember_documentation_en-US" xlink:label="lab_cvs_SupportingExperienceRatedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supporting discontinued and experience-rated products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingExperienceRatedProductsMember" xlink:href="cvs-20221231.xsd#cvs_SupportingExperienceRatedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SupportingExperienceRatedProductsMember" xlink:to="lab_cvs_SupportingExperienceRatedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8c103eb8-4ddc-4b28-bbc9-239c859db25e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_fb11c9ef-b340-4c0d-917d-8712e4150f82_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_657e17cf-f479-48fc-a3b1-5e967f4a1a7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_11cb420b-aba9-4924-b7a8-a30ad94b56d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_cffb2247-2e2e-42c1-bdab-0076f56ba0be_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_ee752451-d9a7-41cd-90d6-8fe5d822f71e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Ceded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_f7833bae-2ced-4d8f-a3ef-a2fd96659963_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets (liabilities) recognized on the consolidated balance sheet</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss_08b76c14-8d05-4617-8e4f-0620184329da_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization_42f23e1c-3dbd-4d43-92f0-4d4a759f7a02_negatedTerseLabel_en-US" xlink:label="lab_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization_label_en-US" xlink:label="lab_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Depreciation And Amortization</link:label>
    <link:label id="lab_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Depreciation and Amortization - Amount of deferred tax liability attributable to taxable temporary differences from depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="lab_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock_e8052cd8-1a73-4bfa-aef5-89c3c7fb1de9_verboseLabel_en-US" xlink:label="lab_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Proceeds and Related Gross Realized Capital Gains and Losses From the Sale of Debt Securities</link:label>
    <link:label id="lab_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock_label_en-US" xlink:label="lab_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds And Related Gross Realized Capital Gains Losses From Sale Of Debt Securities [Table Text Block]</link:label>
    <link:label id="lab_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock_documentation_en-US" xlink:label="lab_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item includes proceeds from the sale of debt securities and the related gross realized capital gains and losses, excluding amounts related to experience-rated and discontinued products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock" xlink:href="cvs-20221231.xsd#cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock" xlink:to="lab_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_886d7e45-1027-4597-9d25-bee6090a84dd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes2.875DueJune2026Member_62d4b48d-8607-4779-bfae-2d7ff85c77bb_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes2.875DueJune2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.875% senior notes due June 2026</link:label>
    <link:label id="lab_cvs_SeniorNotes2.875DueJune2026Member_label_en-US" xlink:label="lab_cvs_SeniorNotes2.875DueJune2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.875%, Due June 2026 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes2.875DueJune2026Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes2.875DueJune2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.875%, Due June 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.875DueJune2026Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.875DueJune2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes2.875DueJune2026Member" xlink:to="lab_cvs_SeniorNotes2.875DueJune2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_cfafccf6-cf37-4031-a803-30cf561ff12f_totalLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans on Real Estate, Commercial and Consumer, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:to="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8c35515a-373b-4e53-ae65-10a19018b38d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive_930de36d-288c-43dd-8ab7-33a1ec2fe2b0_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal After Year Five</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive_documentation_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive" xlink:to="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialRealEstateMember_7b447192-7057-4fe0-9ca0-8a86c24e7fb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Real Estate</link:label>
    <link:label id="lab_us-gaap_CommercialRealEstateMember_label_en-US" xlink:label="lab_us-gaap_CommercialRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Real Estate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialRealEstateMember" xlink:to="lab_us-gaap_CommercialRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5a3eaae5-1c5f-4a90-9213-3a50a63c0f49_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_02c2133f-48b7-4eea-923c-c8f0d5c3dc1f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) claims liability, net</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_67c2b6b6-9486-4c53-889e-60d8e200c4bf_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated minimum statutory surplus required by regulators</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_4b4fce38-d592-4b45-9004-f619e07a6afc_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_7ac43887-1730-4006-9112-604f1dd7b85d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement_c2f86c78-87eb-430a-a813-6ca68a4ad505_terseLabel_en-US" xlink:label="lab_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement_label_en-US" xlink:label="lab_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses, Excluding Store Impairments, Goodwill Impairments, Loss On Assets Held For Sale, And Loss On Litigation Settlement</link:label>
    <link:label id="lab_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement_documentation_en-US" xlink:label="lab_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses, Excluding Store Impairments, Goodwill Impairments, Loss On Assets Held For Sale, And Loss On Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" xlink:href="cvs-20221231.xsd#cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" xlink:to="lab_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_19eec94f-3091-4aca-8549-cd4f0f5e37d0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028-2032</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AllOtherReinsurersMember_37fa2c84-3c4b-4091-80a5-99c96e76d5af_terseLabel_en-US" xlink:label="lab_cvs_AllOtherReinsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other</link:label>
    <link:label id="lab_cvs_AllOtherReinsurersMember_label_en-US" xlink:label="lab_cvs_AllOtherReinsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Reinsurers [Member]</link:label>
    <link:label id="lab_cvs_AllOtherReinsurersMember_documentation_en-US" xlink:label="lab_cvs_AllOtherReinsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Reinsurers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AllOtherReinsurersMember" xlink:href="cvs-20221231.xsd#cvs_AllOtherReinsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AllOtherReinsurersMember" xlink:to="lab_cvs_AllOtherReinsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4.3DueMarch2028Member_9e12f8b8-9729-478a-8e7a-882c3f00b23d_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4.3DueMarch2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.3% senior notes due March 2028</link:label>
    <link:label id="lab_cvs_SeniorNotes4.3DueMarch2028Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4.3DueMarch2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.3%, Due March 2028 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4.3DueMarch2028Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4.3DueMarch2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.3%, Due March 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.3DueMarch2028Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.3DueMarch2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4.3DueMarch2028Member" xlink:to="lab_cvs_SeniorNotes4.3DueMarch2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_823be24e-db06-45b4-8300-fb4e84838b2e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c8d8937a-15b7-420f-bcb1-ed2da24e510f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClaimsDevelopmentLineItems_9f8eba2b-7d3a-4e4b-aa0e-87af45a20880_terseLabel_en-US" xlink:label="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims Development [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClaimsDevelopmentLineItems_label_en-US" xlink:label="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims Development [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems" xlink:to="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredPolicyAcquisitionCosts_70378768-4d37-4c0a-be2f-3319bd3f4d66_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredPolicyAcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred acquisition costs</link:label>
    <link:label id="lab_us-gaap_DeferredPolicyAcquisitionCosts_label_en-US" xlink:label="lab_us-gaap_DeferredPolicyAcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Policy Acquisition Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredPolicyAcquisitionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredPolicyAcquisitionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredPolicyAcquisitionCosts" xlink:to="lab_us-gaap_DeferredPolicyAcquisitionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72374a3d-1634-414d-90d2-e5d47736150a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_3b50c247-a06b-49f6-b316-a94e52bf4330_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a51db07f-ef51-44fe-8e09-8a9c46e0eb4e_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_b8ed9882-2335-4727-b16f-6860585389b6_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_90ab1b8c-b347-4893-9bb2-ca4ada8433df_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_0c237388-056c-4aa4-873f-688a69055e21_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Accumulated Other Comprehensive Income (Loss) by Component</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_753f187f-2d27-42f8-ad29-2fb792f3f242_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue_d236a238-04ae-45df-9c20-6696820fe335_terseLabel_en-US" xlink:label="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock options and SARs vested</link:label>
    <link:label id="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue_label_en-US" xlink:label="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value</link:label>
    <link:label id="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue_documentation_en-US" xlink:label="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" xlink:href="cvs-20221231.xsd#cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" xlink:to="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_8730ff35-c534-486e-9528-70a53d82102d_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares outstanding, beginning of year balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_d9212fd0-7025-472a-bd3d-158773c1f02c_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares outstanding, end of year balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LongtermDebtGrossAndLeaseObligation_82b727cf-7d65-43ff-940f-3fb82885e7d6_totalLabel_en-US" xlink:label="lab_cvs_LongtermDebtGrossAndLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt principal</link:label>
    <link:label id="lab_cvs_LongtermDebtGrossAndLeaseObligation_label_en-US" xlink:label="lab_cvs_LongtermDebtGrossAndLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross And Lease Obligation</link:label>
    <link:label id="lab_cvs_LongtermDebtGrossAndLeaseObligation_documentation_en-US" xlink:label="lab_cvs_LongtermDebtGrossAndLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross And Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongtermDebtGrossAndLeaseObligation" xlink:href="cvs-20221231.xsd#cvs_LongtermDebtGrossAndLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LongtermDebtGrossAndLeaseObligation" xlink:to="lab_cvs_LongtermDebtGrossAndLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_5d0e966b-e796-46f7-a640-071afb27cba9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_HealthCareBenefitsSegmentMember_f5323570-dc71-4fec-aa53-9a159607cee8_terseLabel_en-US" xlink:label="lab_cvs_HealthCareBenefitsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Benefits</link:label>
    <link:label id="lab_cvs_HealthCareBenefitsSegmentMember_label_en-US" xlink:label="lab_cvs_HealthCareBenefitsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Benefits Segment [Member]</link:label>
    <link:label id="lab_cvs_HealthCareBenefitsSegmentMember_documentation_en-US" xlink:label="lab_cvs_HealthCareBenefitsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Benefits Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_HealthCareBenefitsSegmentMember" xlink:to="lab_cvs_HealthCareBenefitsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLeaseTableTextBlock_058c2af6-75b8-462f-bba7-b505a054c6f7_terseLabel_en-US" xlink:label="lab_cvs_LesseeLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_cvs_LesseeLeaseTableTextBlock_label_en-US" xlink:label="lab_cvs_LesseeLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease [Table Text Block]</link:label>
    <link:label id="lab_cvs_LesseeLeaseTableTextBlock_documentation_en-US" xlink:label="lab_cvs_LesseeLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLeaseTableTextBlock" xlink:href="cvs-20221231.xsd#cvs_LesseeLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLeaseTableTextBlock" xlink:to="lab_cvs_LesseeLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NumberOfPatientsServedPerYear_a634934c-2004-437d-888c-7d0a0f1624e1_terseLabel_en-US" xlink:label="lab_cvs_NumberOfPatientsServedPerYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients served per year (more than)</link:label>
    <link:label id="lab_cvs_NumberOfPatientsServedPerYear_label_en-US" xlink:label="lab_cvs_NumberOfPatientsServedPerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients Served Per Year</link:label>
    <link:label id="lab_cvs_NumberOfPatientsServedPerYear_documentation_en-US" xlink:label="lab_cvs_NumberOfPatientsServedPerYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients Served Per Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfPatientsServedPerYear" xlink:href="cvs-20221231.xsd#cvs_NumberOfPatientsServedPerYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NumberOfPatientsServedPerYear" xlink:to="lab_cvs_NumberOfPatientsServedPerYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_30c4402d-fe9e-4bc9-bbfb-226cc47644f2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_6952b43e-3919-461c-9e5a-30c3229cba3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_569563c7-c28d-4251-9887-6ff53cfab4fe_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_A2022RepurchaseProgramMember_eb6f74a0-7836-4aa9-9d7f-03239bd337b7_terseLabel_en-US" xlink:label="lab_cvs_A2022RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Repurchase Program</link:label>
    <link:label id="lab_cvs_A2022RepurchaseProgramMember_label_en-US" xlink:label="lab_cvs_A2022RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Repurchase Program [Member]</link:label>
    <link:label id="lab_cvs_A2022RepurchaseProgramMember_documentation_en-US" xlink:label="lab_cvs_A2022RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_A2022RepurchaseProgramMember" xlink:href="cvs-20221231.xsd#cvs_A2022RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_A2022RepurchaseProgramMember" xlink:to="lab_cvs_A2022RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_adc77f2b-c441-4bd0-b9aa-1a9bd1ffbf18_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_f0ee807b-aa96-4cc9-84db-65b3ffba154b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_07bfd445-457a-4135-80e1-b50289b972b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested at end of year and expected to vest in the future (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable_6220a46c-c480-4da4-a1b3-701e5301016c_terseLabel_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal home loan bank advances maximum amount available</link:label>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable_label_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Home Loan Bank, Advances, General Debt Obligations, Maximum Amount Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable" xlink:to="lab_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb6ff261-eb51-48c2-8532-e746789c2812_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_6e56a84f-4539-48f8-baf9-c3d77f438ac7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_18a7d565-066a-4a2a-b021-e0d3d2ce3b2b_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a1e90427-c437-4db9-82c7-0fd0bec5ac98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent_7e059cdd-4c01-4cf9-b24f-bfaafda7635a_terseLabel_en-US" xlink:label="lab_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal charges</link:label>
    <link:label id="lab_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent_label_en-US" xlink:label="lab_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal Charges, Percent</link:label>
    <link:label id="lab_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent_documentation_en-US" xlink:label="lab_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal Charges, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" xlink:href="cvs-20221231.xsd#cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" xlink:to="lab_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_5bcb59c6-532d-400a-aefb-92c4fc21c60a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Securities, Greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_7a7c5af3-9b2c-42bc-a5af-a9f8544a64df_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f4dc6423-b99c-4b53-8b04-57195157d9a3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_CommonAndCollectiveTrustsMember_49e1f09b-9d42-48b9-97a9-ebdb9104ba50_terseLabel_en-US" xlink:label="lab_cvs_CommonAndCollectiveTrustsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common/collective trusts</link:label>
    <link:label id="lab_cvs_CommonAndCollectiveTrustsMember_label_en-US" xlink:label="lab_cvs_CommonAndCollectiveTrustsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common And Collective Trusts [Member]</link:label>
    <link:label id="lab_cvs_CommonAndCollectiveTrustsMember_documentation_en-US" xlink:label="lab_cvs_CommonAndCollectiveTrustsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount of Common/Collective Trusts held by the company, primarily related to investment funds otherwise known as underlying funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CommonAndCollectiveTrustsMember" xlink:href="cvs-20221231.xsd#cvs_CommonAndCollectiveTrustsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_CommonAndCollectiveTrustsMember" xlink:to="lab_cvs_CommonAndCollectiveTrustsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOperatingLeaseMember_baf57565-566b-4859-a038-de4233871189_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOperatingLeaseMember_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to Operating Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:to="lab_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_ed398d4e-ac27-4a44-9e32-b0e7fb9580d7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to CVS Health</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FinanceLeaseRightOfUseAssetGross_25e2b5b1-c2eb-47a5-8ec1-36665075d4de_terseLabel_en-US" xlink:label="lab_cvs_FinanceLeaseRightOfUseAssetGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_cvs_FinanceLeaseRightOfUseAssetGross_label_en-US" xlink:label="lab_cvs_FinanceLeaseRightOfUseAssetGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-Of-Use Asset, Gross</link:label>
    <link:label id="lab_cvs_FinanceLeaseRightOfUseAssetGross_documentation_en-US" xlink:label="lab_cvs_FinanceLeaseRightOfUseAssetGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-Of-Use Asset, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetGross" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FinanceLeaseRightOfUseAssetGross" xlink:to="lab_cvs_FinanceLeaseRightOfUseAssetGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e71b4e9b-6df7-4771-83af-4a5ed916713a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_f9c7b3e8-5a9d-49a1-bdab-40b4ea70188a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NumberOfMedicalMembers_335dacec-f964-4b7d-95c2-876938fc882d_terseLabel_en-US" xlink:label="lab_cvs_NumberOfMedicalMembers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of medical members</link:label>
    <link:label id="lab_cvs_NumberOfMedicalMembers_label_en-US" xlink:label="lab_cvs_NumberOfMedicalMembers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Medical Members</link:label>
    <link:label id="lab_cvs_NumberOfMedicalMembers_documentation_en-US" xlink:label="lab_cvs_NumberOfMedicalMembers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Medical Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfMedicalMembers" xlink:href="cvs-20221231.xsd#cvs_NumberOfMedicalMembers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NumberOfMedicalMembers" xlink:to="lab_cvs_NumberOfMedicalMembers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_66d3f431-4194-41c3-8fcc-d62c59a04318_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_d6b85f98-44a1-41f4-a7d3-c286b84d6a11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b3b8c539-22e5-48c6-9720-c9b276bcffd8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_0fe7b71e-9734-4f6f-99ea-53e961ea05b7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5f26e663-ad6d-428b-82e4-93e031f7a601_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_b33653f0-1647-4f33-85b1-a4b16653d5ec_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableMember_b5252583-b319-4c63-bfca-539a04036171_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other payables</link:label>
    <link:label id="lab_us-gaap_AccountsPayableMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableMember" xlink:to="lab_us-gaap_AccountsPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_CVSHealth2017IncentiveCompensationPlanMember_8721b6f0-04ff-4f79-9535-132c1c950e06_terseLabel_en-US" xlink:label="lab_cvs_CVSHealth2017IncentiveCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health 2017 Incentive Compensation Plan</link:label>
    <link:label id="lab_cvs_CVSHealth2017IncentiveCompensationPlanMember_label_en-US" xlink:label="lab_cvs_CVSHealth2017IncentiveCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health 2017 Incentive Compensation Plan [Member]</link:label>
    <link:label id="lab_cvs_CVSHealth2017IncentiveCompensationPlanMember_documentation_en-US" xlink:label="lab_cvs_CVSHealth2017IncentiveCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health 2017 Incentive Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CVSHealth2017IncentiveCompensationPlanMember" xlink:href="cvs-20221231.xsd#cvs_CVSHealth2017IncentiveCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_CVSHealth2017IncentiveCompensationPlanMember" xlink:to="lab_cvs_CVSHealth2017IncentiveCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_d3fcb17a-1c02-4dfd-a762-f62d359ec0a9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_aeb74a84-e230-4ff0-ab49-7661b68e9b81_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0182feb5-6eeb-4cb9-adae-a05942918d72_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_48326d93-3d5d-4aaa-a140-98d7f77be78e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CVS Health shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock_e6d29b67-9142-4fc2-9c57-3264ad80d9ce_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Reform</link:label>
    <link:label id="lab_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareEntitiesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_eb482a7f-4a16-43b3-8164-e7ab47496539_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_159d03dc-e66b-4752-94bc-73c0e0c455dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_98c944d4-8d82-4a73-9294-df9d20b4b634_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock dividends</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesLineItems_dde343a2-c489-4586-b6aa-cd294f861b1c_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesLineItems_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="lab_us-gaap_StatutoryAccountingPracticesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_a24199d0-be17-4310-b9b4-49e0b874f8ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OutstandingSeniorNotesMember_24732d2a-d744-4692-b20e-391fc0524ecd_terseLabel_en-US" xlink:label="lab_cvs_OutstandingSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Senior Notes</link:label>
    <link:label id="lab_cvs_OutstandingSeniorNotesMember_label_en-US" xlink:label="lab_cvs_OutstandingSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Senior Notes [Member]</link:label>
    <link:label id="lab_cvs_OutstandingSeniorNotesMember_documentation_en-US" xlink:label="lab_cvs_OutstandingSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OutstandingSeniorNotesMember" xlink:href="cvs-20221231.xsd#cvs_OutstandingSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OutstandingSeniorNotesMember" xlink:to="lab_cvs_OutstandingSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_30437d9e-e14d-44f6-b5f7-4f001ae19bf1_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_0c7da977-57ef-4f2a-90e3-d67b06139cc1_totalLabel_en-US" xlink:label="lab_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment income (excluding net realized capital gains or losses)</link:label>
    <link:label id="lab_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_label_en-US" xlink:label="lab_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Excluding Capital Gains Or Losses</link:label>
    <link:label id="lab_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_documentation_en-US" xlink:label="lab_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Excluding Capital Gains Or Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses" xlink:href="cvs-20221231.xsd#cvs_InvestmentIncomeExcludingCapitalGainsOrLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses" xlink:to="lab_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_e1f76c56-6f5c-4815-9bb8-2e97921b9773_terseLabel_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option and SAR Activity</link:label>
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Proceeds Received and Tax Benefit from Share-Based Payment Awards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:to="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_52dc13bc-0fb7-49fc-9aab-978e800ec330_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_158c8d92-439e-462f-8344-ba8609c0a87c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_27188bac-7d89-429e-b661-cb4647fe23fe_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b92cb082-e1d4-4791-973e-bd57c3623138_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearFive_2b5da48e-fe7b-459d-bd04-c118b89c6187_totalLabel_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due Year Five</link:label>
    <link:label id="lab_cvs_LesseeLiabilityPaymentsDueYearFive_documentation_en-US" xlink:label="lab_cvs_LesseeLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearFive" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LesseeLiabilityPaymentsDueYearFive" xlink:to="lab_cvs_LesseeLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c7f16f1c-5d79-4210-9026-156f6ade1635_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_73a24cdb-8705-4057-99ed-9193a915fe01_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b0c5d07a-80c8-4cf3-b354-782f1777fe47_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3bffe6dd-29fb-4bad-baf5-8211d7ca1928_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation not yet recognized, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_d904243d-2832-4234-8c36-5d3923f20f98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid litigation charges</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock_aced59c9-2730-442c-9412-050b95efa287_terseLabel_en-US" xlink:label="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Direct, Assumed and Ceded Premiums Earned</link:label>
    <link:label id="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock_label_en-US" xlink:label="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-17, Insurance Companies, Reinsurance [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:to="lab_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_97c8cce9-78c5-48d9-a60d-c0c472daeb2f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_ca0e3e22-77e6-4c84-9f7b-0f6ab9552253_verboseLabel_en-US" xlink:label="lab_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_43e0d7fd-f8c7-4b23-acc3-0b30815a7d91_terseLabel_en-US" xlink:label="lab_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from external customers</link:label>
    <link:label id="lab_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="cvs-20221231.xsd#cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9307e8f7-35f4-4a22-84da-c559cff9aac5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_e2ae19e1-458e-42a2-a051-3b7babe351d1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsReceivableAtCarryingValue_858f6c19-56f8-4b3c-bdb7-3b1453924dbd_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium receivables</link:label>
    <link:label id="lab_us-gaap_PremiumsReceivableAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsReceivableAtCarryingValue" xlink:to="lab_us-gaap_PremiumsReceivableAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_2083857c-3ef6-4dfe-a231-22f30db0e8ff_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_cd54d2e9-8f8d-4f33-90fb-2e20630b40ad_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Components of Net Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4363c224-3ab3-4d37-859b-78aba6474d0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_52f2c8f2-aa9e-4985-9358-28d9ac4a81c8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_85fb26f1-8fbc-44fd-a950-b084f73d792d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of discontinued operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60327f11-3bcb-4ac9-bf9f-09928279c537_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_0f55197e-b049-4ae8-bfd3-903b47808c96_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_333faca5-fbdd-42f7-a2fe-085156df798f_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b26fe49f-70bd-4cee-89a7-0468adb03700_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateLineItems_98017cd1-deb7-42aa-96c6-75f5c1c265ef_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans on Real Estate [Line Items]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateLineItems_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems" xlink:to="lab_srt_MortgageLoansOnRealEstateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_fb53c717-f5fd-4f5e-8299-2ff2d61bd454_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ea36d2c6-71e5-4bea-935c-8dfb50363d35_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_338e5790-d528-497e-835f-2d1efb54d409_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value, Inputs, Level 1, 2 and 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:to="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7fba5055-1c63-4cc8-92bb-526f3499312c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets, Trademarks</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2b338476-db6f-4841-812e-f644f6340da0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1804427c-916b-473f-b87b-a8eadfea83eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d69b2b18-29a4-45be-8e56-7b34eae6481a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_ab22ff8e-ccaa-4423-8aba-191743b1d394_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8baa5488-0dcb-45f8-9328-8cc6ed562315_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_8da49bc5-64d7-4884-b616-a32459c20851_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets (Liabilities) Recognized in Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableTable_9bba2a07-a9f4-41b7-ae94-65017570ae16_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable [Table]</link:label>
    <link:label id="lab_us-gaap_DividendsPayableTable_label_en-US" xlink:label="lab_us-gaap_DividendsPayableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableTable" xlink:to="lab_us-gaap_DividendsPayableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_e291aeaa-b81b-4cbd-8ae9-2e0238b8959c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Accident Year [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_aace928e-ded6-493b-935a-91b38a9ffcad_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_a57ea30c-5ac3-4ada-8486-ac5d3f942915_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b011d82c-cebb-482e-9d19-26f831ed18b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, expired ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1cd2e16f-96e8-454d-b127-0f12142b73de_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_be6e39f2-c752-4aa2-924c-2a362b9f3755_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Direct</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d59d56b-1fe8-4b24-b2b3-af233cf40190_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_055c92ce-18fa-47b8-b739-e8263af84217_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_f7e705a4-8553-414f-82ef-675911e263db_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_f440bbef-b04b-4e38-91ef-c0d55106cf82_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_498ad473-58f1-4f68-8407-c771d6f6d7c8_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Year Of Origination [Axis]</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_label_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Year Of Origination [Axis]</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_documentation_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Year Of Origination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateYearOfOriginationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis" xlink:to="lab_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_03518de8-0d44-4c42-8b9c-92a5cf8c1f5c_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b86e05b9-48dd-410e-9c22-62e51428cfb7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_b0af52fb-40f8-4f3f-9abe-b73dc2b2a534_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4Point125PercentApril2040Member_8f696902-f1c4-40cd-98b1-5ca03b8f6569_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4Point125PercentApril2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.125% senior notes due April 2040</link:label>
    <link:label id="lab_cvs_SeniorNotes4Point125PercentApril2040Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4Point125PercentApril2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4 Point 125 Percent, April 2040 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4Point125PercentApril2040Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4Point125PercentApril2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4 Point 125 Percent, April 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point125PercentApril2040Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point125PercentApril2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4Point125PercentApril2040Member" xlink:to="lab_cvs_SeniorNotes4Point125PercentApril2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_79a1fffb-826d-4d7d-b6f7-54d09a72ab38_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_YearOfOriginationPeriodThreeMember_a653973c-df81-46c6-9575-d2b75b1f4116_terseLabel_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodThreeMember_label_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period Three [Member]</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodThreeMember_documentation_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodThreeMember" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_YearOfOriginationPeriodThreeMember" xlink:to="lab_cvs_YearOfOriginationPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_b128da8b-b124-41c6-a320-a1a8e810da97_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_a9a5357f-3dfe-46b1-b7da-41d9212c3067_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6d165e3d-3a2b-437e-b0c6-684d2ca7e50d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_f229143f-8b33-4a25-b59a-3a7232ebf4c7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f86fbade-40cb-4bae-bc67-1e57589de5a1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember_9dfecac6-f56c-4a99-ae35-84dc531eac5f_terseLabel_en-US" xlink:label="lab_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius Medical Care Reinsurance Company (Cayman) Ltd.</link:label>
    <link:label id="lab_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember_label_en-US" xlink:label="lab_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius Medical Care Reinsurance Company (Cayman) Ltd. [Member]</link:label>
    <link:label id="lab_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember_documentation_en-US" xlink:label="lab_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius Medical Care Reinsurance Company (Cayman) Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember" xlink:href="cvs-20221231.xsd#cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember" xlink:to="lab_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_36df3395-079e-4b68-aa86-3b0a38d1e588_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f4feee61-9ce2-4bc7-98d9-29f74bbb4cf7_netLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (GAAP measure)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_6a91527b-315a-4b96-8bfe-10ce715d8d3c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d4318e5f-fcdf-4c0a-8b14-73790416eaee_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements Recently Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TribalEntitiesMember_c46aefde-cdb6-4cce-aa8f-9cdedcf50507_terseLabel_en-US" xlink:label="lab_cvs_TribalEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tribal Entities</link:label>
    <link:label id="lab_cvs_TribalEntitiesMember_label_en-US" xlink:label="lab_cvs_TribalEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tribal Entities [Member]</link:label>
    <link:label id="lab_cvs_TribalEntitiesMember_documentation_en-US" xlink:label="lab_cvs_TribalEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tribal Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TribalEntitiesMember" xlink:href="cvs-20221231.xsd#cvs_TribalEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TribalEntitiesMember" xlink:to="lab_cvs_TribalEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_d35b470e-3eff-4fd2-85cd-df24e6fa5ef1_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201812Member_14383d2b-996a-4891-9e0c-c59abb88f492_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201812Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2018-12</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201812Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201812Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2018-12 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201812Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201812Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201812Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201812Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_27c891a5-adf5-4eca-951c-ab9db51370d9_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_9fc6e883-49fd-46fc-82c5-de890d3cff95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements_bc262786-22c1-4dfe-892d-f2de654787f6_terseLabel_en-US" xlink:label="lab_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states subject to earlier settlements</link:label>
    <link:label id="lab_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements_label_en-US" xlink:label="lab_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number Of States Subject To Earlier Settlements</link:label>
    <link:label id="lab_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements_documentation_en-US" xlink:label="lab_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number Of States Subject To Earlier Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements" xlink:href="cvs-20221231.xsd#cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements" xlink:to="lab_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_2e73c0f2-f980-4c74-a13d-655c75e31873_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance_2e9e7fee-65e4-4b85-869b-dd185bcdcf2e_terseLabel_en-US" xlink:label="lab_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rewards earnings and gift card issuances</link:label>
    <link:label id="lab_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance_label_en-US" xlink:label="lab_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance</link:label>
    <link:label id="lab_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance_documentation_en-US" xlink:label="lab_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in contract liability recognized for loyalty program earnings and gift card issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" xlink:href="cvs-20221231.xsd#cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" xlink:to="lab_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83387366-ff66-4a9f-9dae-b49b0a4269f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments required to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_118a27d2-55e2-496b-b87a-34633ef2ec39_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0f2d448a-bc63-46eb-894c-a59140b67a60_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6c95fe0b-eadf-49b0-a2c6-2cc9d125ecbc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8950fef2-546e-4a7b-a6b5-747f5cd7ad58_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6e2ece04-27a9-4fd9-adc5-60fc884b6e40_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8db38bc5-c8a7-4881-be7f-5dfa968e2a2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_28ad1592-b17a-4a12-9ae3-680a45c79e81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options and Stock Appreciation Rights Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_79708a61-f532-44b8-aa69-cf840c464e75_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_da4317ac-c77d-44a5-a917-cb5b47192de5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LiabilityForUnpaidClaims_025fa97f-0f32-4405-b520-5ad0af3649b9_terseLabel_en-US" xlink:label="lab_cvs_LiabilityForUnpaidClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for unpaid claims</link:label>
    <link:label id="lab_cvs_LiabilityForUnpaidClaims_label_en-US" xlink:label="lab_cvs_LiabilityForUnpaidClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims</link:label>
    <link:label id="lab_cvs_LiabilityForUnpaidClaims_documentation_en-US" xlink:label="lab_cvs_LiabilityForUnpaidClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total liability on the balance sheet for unpaid claims for both short-duration and long-duration insurance contracts after reinsurance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LiabilityForUnpaidClaims" xlink:href="cvs-20221231.xsd#cvs_LiabilityForUnpaidClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LiabilityForUnpaidClaims" xlink:to="lab_cvs_LiabilityForUnpaidClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_1902def1-aabb-40fd-9a96-d7e513985e07_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash (included in other assets)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_7cd3f9da-97e1-4ec7-8dc1-b6c124c7255a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_80580527-e910-4f06-9364-635ef013208e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of stock options and SARs exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1dbe4ce9-e89d-48f7-8ec4-bb4e31237991_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_384dffa6-6757-4de8-b07d-77190d208640_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_915dd373-415c-4e22-a57a-48cadacece07_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b3435f98-2f15-42c4-b345-525d74715aae_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_09de298c-777b-4ed6-b4f6-7caaa58ba1b6_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36477c83-763c-4ac4-8499-1d35eb774302_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_91dbe935-77a7-451a-b801-1b2d56387177_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings, building improvements and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_24eae6f1-21ed-4af4-82d4-0e17f84a0251_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a74fe73a-60a1-40db-8606-f8462e47a35f_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember_c4a39737-01eb-484b-a8e7-b0a24e2c5cc1_terseLabel_en-US" xlink:label="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common/collective trusts, Debt Securities</link:label>
    <link:label id="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember_label_en-US" xlink:label="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Common Collective Trust, Debt Securities [Member]</link:label>
    <link:label id="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember_documentation_en-US" xlink:label="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Common Collective Trust, Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember" xlink:href="cvs-20221231.xsd#cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember" xlink:to="lab_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member_611454e6-3a42-44cb-a5eb-282339e4be1d_terseLabel_en-US" xlink:label="lab_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted subsequent to 2018</link:label>
    <link:label id="lab_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member_label_en-US" xlink:label="lab_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Granted Subsequent to 2018 [Member]</link:label>
    <link:label id="lab_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member_documentation_en-US" xlink:label="lab_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Granted Subsequent to 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member" xlink:href="cvs-20221231.xsd#cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member" xlink:to="lab_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d31e2c51-0fbd-4ba8-892b-3e0da6c2d689_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NumberOfPharmacyPlanMembers_4fdc36eb-8681-45db-9c82-c27c5ee277be_terseLabel_en-US" xlink:label="lab_cvs_NumberOfPharmacyPlanMembers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pharmacy plan members</link:label>
    <link:label id="lab_cvs_NumberOfPharmacyPlanMembers_label_en-US" xlink:label="lab_cvs_NumberOfPharmacyPlanMembers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Pharmacy Plan Members</link:label>
    <link:label id="lab_cvs_NumberOfPharmacyPlanMembers_documentation_en-US" xlink:label="lab_cvs_NumberOfPharmacyPlanMembers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Pharmacy Plan Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfPharmacyPlanMembers" xlink:href="cvs-20221231.xsd#cvs_NumberOfPharmacyPlanMembers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NumberOfPharmacyPlanMembers" xlink:to="lab_cvs_NumberOfPharmacyPlanMembers" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_Category1Member_ea2e9beb-3fd1-4fd9-bde5-91b6d5fb277f_terseLabel_en-US" xlink:label="lab_cvs_Category1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1</link:label>
    <link:label id="lab_cvs_Category1Member_label_en-US" xlink:label="lab_cvs_Category1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category 1 [Member]</link:label>
    <link:label id="lab_cvs_Category1Member_documentation_en-US" xlink:label="lab_cvs_Category1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loan Credit Quality Indicator - Category 1 [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Category1Member" xlink:href="cvs-20221231.xsd#cvs_Category1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_Category1Member" xlink:to="lab_cvs_Category1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8e64c5e7-9949-4306-bb73-a30dbeecb521_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38645213-157c-4576-8c7a-7d3d5047bace_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_c4bad081-f2d6-48d1-ae36-cd3eb7df53d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_d567e0e1-e599-4cae-a499-a899f10c88d6_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized capital gains (losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts_5faef6fe-daa9-4749-8684-de5defc176d6_terseLabel_en-US" xlink:label="lab_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit costs recorded in other insurance liabilities</link:label>
    <link:label id="lab_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts_label_en-US" xlink:label="lab_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs</link:label>
    <link:label id="lab_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts_documentation_en-US" xlink:label="lab_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" xlink:href="cvs-20221231.xsd#cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" xlink:to="lab_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_7c2d5615-e65a-45f9-ad31-ba3c31aa1b77_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mail choice</link:label>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Directly to Consumer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:to="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OakStreetHealthIncMember_4751f6f8-1df1-4c9c-88aa-7483295f358f_terseLabel_en-US" xlink:label="lab_cvs_OakStreetHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oak Street Health Inc.</link:label>
    <link:label id="lab_cvs_OakStreetHealthIncMember_label_en-US" xlink:label="lab_cvs_OakStreetHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oak Street Health Inc. [Member]</link:label>
    <link:label id="lab_cvs_OakStreetHealthIncMember_documentation_en-US" xlink:label="lab_cvs_OakStreetHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oak Street Health Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OakStreetHealthIncMember" xlink:href="cvs-20221231.xsd#cvs_OakStreetHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OakStreetHealthIncMember" xlink:to="lab_cvs_OakStreetHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PensionAndAnnuityInvestmentContractsInterest_1c4639a4-5a0b-40d9-876c-124df5ac8506_terseLabel_en-US" xlink:label="lab_cvs_PensionAndAnnuityInvestmentContractsInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate for pension and annuity investment contracts</link:label>
    <link:label id="lab_cvs_PensionAndAnnuityInvestmentContractsInterest_label_en-US" xlink:label="lab_cvs_PensionAndAnnuityInvestmentContractsInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Annuity Investment Contracts Interest</link:label>
    <link:label id="lab_cvs_PensionAndAnnuityInvestmentContractsInterest_documentation_en-US" xlink:label="lab_cvs_PensionAndAnnuityInvestmentContractsInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Annuity Investment Contracts Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PensionAndAnnuityInvestmentContractsInterest" xlink:href="cvs-20221231.xsd#cvs_PensionAndAnnuityInvestmentContractsInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PensionAndAnnuityInvestmentContractsInterest" xlink:to="lab_cvs_PensionAndAnnuityInvestmentContractsInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b5f14be5-bfb3-4c50-b7ee-56445a618e13_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_90740d8b-5077-4ded-a853-54f1458ddbb5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_7bb06f38-f48f-4367-ad74-169df2722d7d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and other postretirement benefits</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e8d87857-579f-4fb1-b78f-0bc170d65e98_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value exercisable at end of year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_516547f9-0776-4cad-9946-e39be88cfcd5_terseLabel_en-US" xlink:label="lab_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance Share Units</link:label>
    <link:label id="lab_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_label_en-US" xlink:label="lab_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units And Performance Share Units [Member]</link:label>
    <link:label id="lab_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_documentation_en-US" xlink:label="lab_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance Share Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:href="cvs-20221231.xsd#cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:to="lab_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_f8d8cf57-3a02-4d17-b551-464b441e83dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7b1ead76-347b-422e-83c8-85af58f54d34_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram_7ad2a6f2-48fd-4a02-b7df-76fbd0ae7e18_terseLabel_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR, shares to be received at the end of program as a percent of notional amount</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram_label_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Percent Of Notional Amount In Shares To Be Received At End Of Program</link:label>
    <link:label id="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram_documentation_en-US" xlink:label="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Percent Of Notional Amount In Shares To Be Received At End Of Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" xlink:to="lab_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8f55c685-44e0-470f-981a-adedd969964c_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6211d4e8-cd0c-4715-a707-e8c2af06ae11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (income) loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_320adb1f-3c4d-4020-987b-acdb894726e1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_69de0b8f-5237-4cc3-993d-4d6227703fbc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_eba743fa-4fa1-426c-bd20-acf1e4fd7e04_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e5df1a45-dca0-4949-a6f9-551336e75f2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c4e7f4b6-6064-4523-95b6-dcb760cd91ad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_c3d0748a-95e6-4892-a01e-f5e6afddf782_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_8a558cd4-dd2a-473f-afb3-0835473b0e60_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock and Capital Surplus</link:label>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_0524a69d-69d4-4bc5-92f9-22fdc1ebe836_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6f1f3bb6-67ae-4be4-b85b-d9b9bc457cb2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b86a4f63-b8cd-4d80-b688-79f804dba9e7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d0761a62-3441-46bf-9c21-496b469d6e1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_c28b3f6a-11c3-4d5b-8298-0c95020a9018_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateAndOtherMember_2965ca2e-145a-43af-9af1-38524ede00a9_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate/ Other</link:label>
    <link:label id="lab_us-gaap_CorporateAndOtherMember_label_en-US" xlink:label="lab_us-gaap_CorporateAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateAndOtherMember" xlink:to="lab_us-gaap_CorporateAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2932daaa-7412-493c-8393-5626a9af3471_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to CVS Health</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_d70061f2-bf36-4e15-9583-692ad01f6682_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_f199569e-eebe-48fc-8837-6ae2adc146ac_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_a2b14ea4-8459-42f0-8b6e-674bc35c8391_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Change in Health Care Costs Payable</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_AdjustedOperatingIncomeLoss_8d2312d6-4ec7-4196-998d-3980961a549d_verboseLabel_en-US" xlink:label="lab_cvs_AdjustedOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted operating income (loss)</link:label>
    <link:label id="lab_cvs_AdjustedOperatingIncomeLoss_ca0b7956-c771-4fa5-acd9-349c596540ed_terseLabel_en-US" xlink:label="lab_cvs_AdjustedOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted operating income</link:label>
    <link:label id="lab_cvs_AdjustedOperatingIncomeLoss_label_en-US" xlink:label="lab_cvs_AdjustedOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Operating Income (Loss)</link:label>
    <link:label id="lab_cvs_AdjustedOperatingIncomeLoss_documentation_en-US" xlink:label="lab_cvs_AdjustedOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AdjustedOperatingIncomeLoss" xlink:href="cvs-20221231.xsd#cvs_AdjustedOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_AdjustedOperatingIncomeLoss" xlink:to="lab_cvs_AdjustedOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ecb83d4d-3f10-4247-b015-c1a2e4186a4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Financial Information Of Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_ee68f5e1-c69e-40c0-a62c-821f8f16b4b2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_dc390bbb-4818-476f-860f-3b0f47820f08_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_7edddbd9-1e93-4516-94c3-130f64bf582f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_12f8a3ed-34d9-47cd-8276-81504bf3602d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c070edba-d2d0-4c38-b0e7-a09f217f6f34_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_24c89e15-79fa-4677-b085-192511802ecd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_d6c726fb-7590-42ab-b79b-493211eb7724_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend declared (USD per share)</link:label>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_label_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableAmountPerShare" xlink:to="lab_us-gaap_DividendsPayableAmountPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3035d190-81bd-4705-9826-4799529ea04f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_164a4182-a39d-4d15-9cd2-710bbbb28186_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db93d795-884d-4cb8-af6c-53af7a30fb50_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive_116cd2e9-e4a8-4a16-8250-7cdefca914d5_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive_label_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Year Five</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive_documentation_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans On Real Estate Collections Of Principal In Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive" xlink:to="lab_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_VendorandManufacturerReceivables_2eea55c8-3167-4b37-8d07-313fc00b6aa7_terseLabel_en-US" xlink:label="lab_cvs_VendorandManufacturerReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor and manufacturer receivables</link:label>
    <link:label id="lab_cvs_VendorandManufacturerReceivables_label_en-US" xlink:label="lab_cvs_VendorandManufacturerReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor and Manufacturer Receivables</link:label>
    <link:label id="lab_cvs_VendorandManufacturerReceivables_documentation_en-US" xlink:label="lab_cvs_VendorandManufacturerReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor and Manufacturer Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VendorandManufacturerReceivables" xlink:href="cvs-20221231.xsd#cvs_VendorandManufacturerReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_VendorandManufacturerReceivables" xlink:to="lab_cvs_VendorandManufacturerReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease_92e18609-a159-4541-8966-b5b24ad06405_terseLabel_en-US" xlink:label="lab_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other increases (decreases) in noncontrolling interests</link:label>
    <link:label id="lab_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease_label_en-US" xlink:label="lab_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Other Period Increase (Decrease)</link:label>
    <link:label id="lab_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease_documentation_en-US" xlink:label="lab_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Other Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease" xlink:href="cvs-20221231.xsd#cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease" xlink:to="lab_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e3250153-914a-4116-8232-6625a3a2bfa7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_200707ec-6697-46b3-961a-e5f77e402654_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_eda1350f-2d4d-487e-8129-c561fb101eae_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_723993ec-93ae-48b1-8ed5-e3a8ad590824_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_aa43ea7e-9f4c-410f-a9d4-3cb9ef0b2250_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_299e3824-4263-43bb-bdd4-215e864fd423_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1e58f9b4-b0a2-4152-a4ab-4d80959803bc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1d54fbd8-a215-420d-8762-d075faf2d6a0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Projected Annual Amortization Expense for Intangible Assets for Next Five Years</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5d966e05-516f-452f-9e4e-fba67d247b84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_db1b65dd-6a32-47ab-8eb7-82c39fcca28e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d9345b3f-0489-48e7-b318-c2a98b5e007d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes2.625DueAugust2024Member_e7bf2db9-f4d7-473c-af32-7857c0e534ca_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes2.625DueAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% senior notes due August 2024</link:label>
    <link:label id="lab_cvs_SeniorNotes2.625DueAugust2024Member_label_en-US" xlink:label="lab_cvs_SeniorNotes2.625DueAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.625%, Due August 2024 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes2.625DueAugust2024Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes2.625DueAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.625%, Due August 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.625DueAugust2024Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.625DueAugust2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes2.625DueAugust2024Member" xlink:to="lab_cvs_SeniorNotes2.625DueAugust2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4120d2b9-8ae5-45f2-9203-58c16f6c7075_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_f52b345f-08b8-4945-929f-b5ebc92b2942_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected long-term rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4747dce1-9078-414a-8597-4d0e412209b8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c97f09e1-cd40-496d-ad42-f36826a7c60d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_21dfe347-ffd2-48eb-aa6e-feec8d780f0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_b90f5744-0bdf-4e9a-b74e-1c0895284d28_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash impact of litigation settlement</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_3ce628bf-e573-4224-8aa1-5d79dd02213a_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes2.8DueJune2023Member_e9c2928b-4933-40fc-8bf2-deadd8418021_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes2.8DueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.8% senior notes due June 2023</link:label>
    <link:label id="lab_cvs_SeniorNotes2.8DueJune2023Member_label_en-US" xlink:label="lab_cvs_SeniorNotes2.8DueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.8%, Due June 2023 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes2.8DueJune2023Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes2.8DueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 2.8%, Due June 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.8DueJune2023Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.8DueJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes2.8DueJune2023Member" xlink:to="lab_cvs_SeniorNotes2.8DueJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8b1872e5-7dbd-4784-8b00-8c18f5788e2b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_ed3c0aea-1461-4719-aff6-46673c1a62d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OfficeRealEstateOptimizationCharges_38bbf0f2-8fd5-4ed0-8e77-d21d0d5aaa66_terseLabel_en-US" xlink:label="lab_cvs_OfficeRealEstateOptimizationCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office real estate optimization charges</link:label>
    <link:label id="lab_cvs_OfficeRealEstateOptimizationCharges_label_en-US" xlink:label="lab_cvs_OfficeRealEstateOptimizationCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Real Estate Optimization Charges</link:label>
    <link:label id="lab_cvs_OfficeRealEstateOptimizationCharges_documentation_en-US" xlink:label="lab_cvs_OfficeRealEstateOptimizationCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Real Estate Optimization Charges - Related to the abandonment of leased real estate and the related right-of-use assets and property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OfficeRealEstateOptimizationCharges" xlink:href="cvs-20221231.xsd#cvs_OfficeRealEstateOptimizationCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OfficeRealEstateOptimizationCharges" xlink:to="lab_cvs_OfficeRealEstateOptimizationCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f1423201-8f14-4d05-8394-21ba84f811d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding, beginning of year balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_e86db6a8-4233-48a9-be21-8cdb7761f596_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding, end of year balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_55098ae4-4f5e-49d0-8ecd-d168b127b057_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_b4387c66-6798-4141-88f8-70e3299b8ba4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_399e8f67-ee91-4cbf-bd0c-19e618cf91e1_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, net carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_bb709ead-c529-4e85-abde-646bd3b95756_terseLabel_en-US" xlink:label="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Insurance Liabilities</link:label>
    <link:label id="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:to="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OtherAcquiredIntangibleAssetsTable_8d33ee77-c79e-461d-ab65-76d23265128c_terseLabel_en-US" xlink:label="lab_cvs_OtherAcquiredIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Table]</link:label>
    <link:label id="lab_cvs_OtherAcquiredIntangibleAssetsTable_label_en-US" xlink:label="lab_cvs_OtherAcquiredIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Acquired Intangible Assets [Table]</link:label>
    <link:label id="lab_cvs_OtherAcquiredIntangibleAssetsTable_documentation_en-US" xlink:label="lab_cvs_OtherAcquiredIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAcquiredIntangibleAssetsTable" xlink:href="cvs-20221231.xsd#cvs_OtherAcquiredIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable" xlink:to="lab_cvs_OtherAcquiredIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_55dadbad-e1b3-4942-9ba2-983ad914e6dc_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_77937a39-d544-4ce5-a82d-3431387536db_totalLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net premiums</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_8aee0d7f-e8f8-4545-928a-d349b4273c87_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_faa9b467-c5c3-4c46-928f-653f12ea75c4_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. corporate securities</link:label>
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Corporate, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1b21d171-debc-49a2-9079-f02db45edf6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateLoansFullyRepaid_49907afb-fee5-4db1-a9ff-41bdbc83a511_terseLabel_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateLoansFullyRepaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loans fully repaid</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateLoansFullyRepaid_label_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateLoansFullyRepaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans on Real Estate, Loans Fully Repaid</link:label>
    <link:label id="lab_cvs_MortgageLoansOnRealEstateLoansFullyRepaid_documentation_en-US" xlink:label="lab_cvs_MortgageLoansOnRealEstateLoansFullyRepaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertains to amount of mortgage loans fully repaid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateLoansFullyRepaid" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateLoansFullyRepaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_MortgageLoansOnRealEstateLoansFullyRepaid" xlink:to="lab_cvs_MortgageLoansOnRealEstateLoansFullyRepaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_87bce7d2-f0c9-4ad4-887a-f6d3a0380cea_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable preferred securities</link:label>
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockMember" xlink:to="lab_us-gaap_RedeemablePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented_8ef1a4af-1214-4723-af58-78b8cd2eb203_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All outstanding liabilities for health care costs payable prior to 2021, net of reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_YearOfOriginationPeriodFourMember_44340b1e-4ba3-41aa-a5e9-8ffaf0e57374_terseLabel_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodFourMember_label_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period Four [Member]</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodFourMember_documentation_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodFourMember" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_YearOfOriginationPeriodFourMember" xlink:to="lab_cvs_YearOfOriginationPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_704750a2-2b92-4afe-9eb2-eccf10821c5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic value outstanding at end of year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_703f0c07-1a7d-42ed-bbe5-15b79a668105_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_9ca486cf-4aec-45c9-b559-638986ae6694_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_9499cbea-3bef-46b6-9b1c-acb978023d46_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskTable_3a4fddcc-40fb-4f56-b7f1-81bb3961c844_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Table]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskTable_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskTable" xlink:to="lab_us-gaap_CededCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7fec7d67-d8d8-4e9a-85b5-e67888ab8bda_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_93cd59a6-9145-462a-afb7-064cf22623e6_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateScheduleTable_9c6115a2-80b0-4438-94ed-915fef96ebeb_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateScheduleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans on Real Estate [Table]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateScheduleTable_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateScheduleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateScheduleTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateScheduleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable" xlink:to="lab_srt_MortgageLoansOnRealEstateScheduleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsAtFairValue_0a110279-66d2-44c9-bf5c-b50f3eb6d5ec_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments related to 2012 contract conversion</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsAtFairValue_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="lab_us-gaap_RestrictedInvestmentsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_916dd03d-4c3c-4e84-beb6-12d2ccc5582d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reinsurance Recoverables</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:to="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_NumberOfStoresPlannedClosure_309a492b-2e2d-4347-a3df-9bc14f51d639_terseLabel_en-US" xlink:label="lab_cvs_NumberOfStoresPlannedClosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stores, planned closure</link:label>
    <link:label id="lab_cvs_NumberOfStoresPlannedClosure_label_en-US" xlink:label="lab_cvs_NumberOfStoresPlannedClosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stores, Planned Closure</link:label>
    <link:label id="lab_cvs_NumberOfStoresPlannedClosure_documentation_en-US" xlink:label="lab_cvs_NumberOfStoresPlannedClosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stores, Planned Closure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresPlannedClosure" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresPlannedClosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_NumberOfStoresPlannedClosure" xlink:to="lab_cvs_NumberOfStoresPlannedClosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_a7904581-3a5d-4be5-ace2-4c85e7e4ee88_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:to="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_15f0a81d-498b-47ab-9879-413fefa81928_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ec6dfbcc-519d-4bc4-8d0a-768b60b0991f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7412c32e-a811-4bfb-a8e0-cabca2e64200_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0616696b-7008-4064-af44-2b0bc98ea9eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_c265feb0-f798-4d7d-88d0-cc1fc9e489f2_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_6ffe8890-f825-4b30-a873-d6bd077a7296_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4.1DueMarch2025Member_c8e8ce92-117f-4297-93a6-16b16d0a2334_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4.1DueMarch2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.1% senior notes due March 2025</link:label>
    <link:label id="lab_cvs_SeniorNotes4.1DueMarch2025Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4.1DueMarch2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.1%, Due March 2025 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4.1DueMarch2025Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4.1DueMarch2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.1%, Due March 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.1DueMarch2025Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.1DueMarch2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4.1DueMarch2025Member" xlink:to="lab_cvs_SeniorNotes4.1DueMarch2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7b993941-60c2-4866-9fda-97499dbbe85c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_7731215b-5bc9-4df1-9ee1-c91455d56ac5_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future noncancelable subleases, future minimum payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_1a9172f6-c264-469d-8dff-588758f6cd4c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalCreditAssessmentAxis_6458e338-e856-436d-9433-5495233da61d_terseLabel_en-US" xlink:label="lab_us-gaap_InternalCreditAssessmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Credit Assessment [Axis]</link:label>
    <link:label id="lab_us-gaap_InternalCreditAssessmentAxis_label_en-US" xlink:label="lab_us-gaap_InternalCreditAssessmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Credit Assessment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalCreditAssessmentAxis" xlink:to="lab_us-gaap_InternalCreditAssessmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c10cfc0-800d-41be-b5f1-31115351e423_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_3e97a60c-6dba-4579-a8c8-a36f9014e45d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit payments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27ee919f-3de3-4e35-bd83-f0dd7d03cfae_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_06e910ea-7170-4fa1-81b2-d181b056921b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_785d3853-a1e6-4899-a0b9-6150fca898ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_02ccd8e1-ed98-4538-b2e2-04a6315f4b46_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_bfd45836-4ac8-4575-99bc-9ae04866f8e6_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortized Cost and Fair Value of Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_6d5873cb-4417-4294-839d-424213708e79_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Life (years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PharmacyRebatePeriod_ae18abb9-4871-4fae-bcda-6251bed85211_terseLabel_en-US" xlink:label="lab_cvs_PharmacyRebatePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy rebate period</link:label>
    <link:label id="lab_cvs_PharmacyRebatePeriod_label_en-US" xlink:label="lab_cvs_PharmacyRebatePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Period</link:label>
    <link:label id="lab_cvs_PharmacyRebatePeriod_documentation_en-US" xlink:label="lab_cvs_PharmacyRebatePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyRebatePeriod" xlink:href="cvs-20221231.xsd#cvs_PharmacyRebatePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PharmacyRebatePeriod" xlink:to="lab_cvs_PharmacyRebatePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_52f977bc-25fc-4786-9265-8c8c5f9feeaa_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_c617ac9f-82cb-4cf5-a3fe-0915b35248d1_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_af53c9df-3a43-4b80-8709-e8074f9d8a14_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f3f5005-e1ff-4a2c-a18b-381c6ca164d8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_1fbe8884-aab5-4abc-8b9c-821edbdcf284_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TreasuryStockValueSharesHeldInTrust_6fc01064-1189-413a-9927-7a4467d2cd9e_terseLabel_en-US" xlink:label="lab_cvs_TreasuryStockValueSharesHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares held in trust</link:label>
    <link:label id="lab_cvs_TreasuryStockValueSharesHeldInTrust_label_en-US" xlink:label="lab_cvs_TreasuryStockValueSharesHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Shares Held In Trust</link:label>
    <link:label id="lab_cvs_TreasuryStockValueSharesHeldInTrust_documentation_en-US" xlink:label="lab_cvs_TreasuryStockValueSharesHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Shares Held In Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockValueSharesHeldInTrust" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockValueSharesHeldInTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TreasuryStockValueSharesHeldInTrust" xlink:to="lab_cvs_TreasuryStockValueSharesHeldInTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_557e5232-9e4d-4f36-ad8d-2f7680849e42_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_243a3c8f-b0bb-43d1-9d09-4c397dc42d08_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c710ffd6-dd93-4b34-9b34-c429b239d9d3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_925801a3-ceb1-4434-a860-d4146caf7d0c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding at beginning of year ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_81eb264d-cb82-49da-a7e8-e5d36e82eda2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding at end of year ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent_6f54cd70-6c55-41db-91ee-fd7eb74c4a22_terseLabel_en-US" xlink:label="lab_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly dividends declared, percent increase</link:label>
    <link:label id="lab_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent_label_en-US" xlink:label="lab_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent</link:label>
    <link:label id="lab_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent_documentation_en-US" xlink:label="lab_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent" xlink:href="cvs-20221231.xsd#cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent" xlink:to="lab_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3ba05e90-dc24-4e38-9b33-3a03d15c2044_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SalesChannelOtherMember_a83b3e9e-b0da-49ea-bc60-8ea54c8a53f3_terseLabel_en-US" xlink:label="lab_cvs_SalesChannelOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_cvs_SalesChannelOtherMember_label_en-US" xlink:label="lab_cvs_SalesChannelOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Other [Member]</link:label>
    <link:label id="lab_cvs_SalesChannelOtherMember_documentation_en-US" xlink:label="lab_cvs_SalesChannelOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SalesChannelOtherMember" xlink:href="cvs-20221231.xsd#cvs_SalesChannelOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SalesChannelOtherMember" xlink:to="lab_cvs_SalesChannelOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8f976037-3232-4da2-8358-ef965ba637bc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_6db751b2-d1fc-4630-8370-32a00d19502e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4530b3ab-83f8-491d-a6c5-a127a7a981a0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8d251bd6-3977-4d3c-b026-fdc382dbdef7_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_52ed5b95-9100-4a58-a0ca-d2d4068ed168_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_32755e7d-4b89-4b90-8200-a6a03a69b34d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_348806de-e6d5-498d-a24d-0e9c54a0adf3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears_9d944b8c-7c2f-4952-9acf-4e712d34a121_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than ten years</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d1306a1d-ff3c-443f-bd89-90220f079668_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_8eaafaec-ac6f-497f-8bf2-7a6683469d16_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_ed608e61-fafe-4b23-8a51-649b9e6539a1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_cdcbd028-6913-4f51-be40-6ca561849678_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_480d7c7e-2ed8-44ac-9a3e-273efffe29e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_7de92d96-10b8-4450-92b4-77eef5531230_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_006192be-cfad-4c89-9f8d-0434453fe486_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates_19740353-fbcf-4c10-85bd-7f23ef2e6230_terseLabel_en-US" xlink:label="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional number of states in which the Company entered the individual public health insurance exchange</link:label>
    <link:label id="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates_label_en-US" xlink:label="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Public Health Insurance Exchanges, Number Of Additional States</link:label>
    <link:label id="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates_documentation_en-US" xlink:label="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Public Health Insurance Exchanges, Number Of Additional States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates" xlink:href="cvs-20221231.xsd#cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates" xlink:to="lab_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_00fd718e-5944-445d-972c-82231c81a513_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_f604217f-3300-46b3-9947-dfe048958c98_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in benefit obligation:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_1eb850e7-d542-4f70-ab1f-61b246a36ffc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Components of incurred health care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_f6a0168c-3f84-4735-9577-a87996adf1ec_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_a734b10b-5ab4-4857-b0c3-b745fec1177c_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e52efa82-37e3-46b4-a874-b5e5d3ec6a9f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_81ce3946-f9c5-411e-b86f-c0e07221c3bd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_edf2107b-ff47-4d4d-ace0-bdc2f16fd066_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_81a32e50-5cb4-42d8-bbaa-fab73c0dc952_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7f159860-4d15-436c-954e-f43611ec6221_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_dd9d2c96-48fa-4355-9846-760ed7e9715c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for taxes related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_79e58139-8ffa-4d60-a5d8-87d66807e198_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for taxes for net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_43440b45-b813-4805-8b4e-ba2bdf9623a6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_42e5c8b4-dbf9-4d45-8b91-0796b7364b70_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member_5b11f03a-3ca2-474c-b323-78e7344497ca_terseLabel_en-US" xlink:label="lab_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted through 2018</link:label>
    <link:label id="lab_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member_label_en-US" xlink:label="lab_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Granted Prior Through 2018 [Member]</link:label>
    <link:label id="lab_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member_documentation_en-US" xlink:label="lab_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Granted Prior Through 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member" xlink:href="cvs-20221231.xsd#cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member" xlink:to="lab_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RevolvingCreditFacilityExpiringMay162025Member_736b5b27-56c2-45dd-b44d-82e23b69837b_terseLabel_en-US" xlink:label="lab_cvs_RevolvingCreditFacilityExpiringMay162025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Expiring May 16, 2025</link:label>
    <link:label id="lab_cvs_RevolvingCreditFacilityExpiringMay162025Member_label_en-US" xlink:label="lab_cvs_RevolvingCreditFacilityExpiringMay162025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Expiring May 16, 2025 [Member]</link:label>
    <link:label id="lab_cvs_RevolvingCreditFacilityExpiringMay162025Member_documentation_en-US" xlink:label="lab_cvs_RevolvingCreditFacilityExpiringMay162025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Expiring May 16, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RevolvingCreditFacilityExpiringMay162025Member" xlink:href="cvs-20221231.xsd#cvs_RevolvingCreditFacilityExpiringMay162025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RevolvingCreditFacilityExpiringMay162025Member" xlink:to="lab_cvs_RevolvingCreditFacilityExpiringMay162025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_fd7f8874-b673-4922-826a-d2e3547c74b8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthInsuranceProductLineMember_f457d1b9-3345-4da0-937a-10027d8ea800_terseLabel_en-US" xlink:label="lab_us-gaap_HealthInsuranceProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Product Line</link:label>
    <link:label id="lab_us-gaap_HealthInsuranceProductLineMember_label_en-US" xlink:label="lab_us-gaap_HealthInsuranceProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Product Line [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthInsuranceProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthInsuranceProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthInsuranceProductLineMember" xlink:to="lab_us-gaap_HealthInsuranceProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_13aadb14-8a94-4d21-aa78-ead4185f3a31_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e69b1f0f-59a3-4aca-8827-6a3b0cb85ed1_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_EquitySecuritiesDomesticRealEstateMember_efb14dff-029f-4cdc-9666-e3c84a4d02f6_terseLabel_en-US" xlink:label="lab_cvs_EquitySecuritiesDomesticRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic real estate</link:label>
    <link:label id="lab_cvs_EquitySecuritiesDomesticRealEstateMember_label_en-US" xlink:label="lab_cvs_EquitySecuritiesDomesticRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Domestic Real Estate [Member]</link:label>
    <link:label id="lab_cvs_EquitySecuritiesDomesticRealEstateMember_documentation_en-US" xlink:label="lab_cvs_EquitySecuritiesDomesticRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This category includes information about ownership interests or the right to acquire ownership interests in domestic real estate whose ownership interest is represented by shares of common or preferred stock (which is neither mandatorily redeemable no redeemable at the option of the holder), convertible securities, stock rights, or stock warrants categorized by other type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EquitySecuritiesDomesticRealEstateMember" xlink:href="cvs-20221231.xsd#cvs_EquitySecuritiesDomesticRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_EquitySecuritiesDomesticRealEstateMember" xlink:to="lab_cvs_EquitySecuritiesDomesticRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_031f851c-4c49-4311-8e4d-e3efadad7565_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_34c5c82d-7228-4ed3-ab46-50dc5010f198_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Consolidated Operating Income to Adjusted Operating Income</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtExtinguishmentFees_350475ce-ca5d-4670-8efd-47eacf535a7b_terseLabel_en-US" xlink:label="lab_cvs_DebtExtinguishmentFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment fees</link:label>
    <link:label id="lab_cvs_DebtExtinguishmentFees_label_en-US" xlink:label="lab_cvs_DebtExtinguishmentFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Extinguishment Fees</link:label>
    <link:label id="lab_cvs_DebtExtinguishmentFees_documentation_en-US" xlink:label="lab_cvs_DebtExtinguishmentFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Extinguishment Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtExtinguishmentFees" xlink:href="cvs-20221231.xsd#cvs_DebtExtinguishmentFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtExtinguishmentFees" xlink:to="lab_cvs_DebtExtinguishmentFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_c90bc59b-c30d-42cf-afc9-0707166db57a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_InsuranceAndHMOMember_1c30dee7-55c6-4f30-856d-348f63053c08_terseLabel_en-US" xlink:label="lab_cvs_InsuranceAndHMOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and HMO</link:label>
    <link:label id="lab_cvs_InsuranceAndHMOMember_label_en-US" xlink:label="lab_cvs_InsuranceAndHMOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And HMO [Member]</link:label>
    <link:label id="lab_cvs_InsuranceAndHMOMember_documentation_en-US" xlink:label="lab_cvs_InsuranceAndHMOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and HMO subsidiaries [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InsuranceAndHMOMember" xlink:href="cvs-20221231.xsd#cvs_InsuranceAndHMOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_InsuranceAndHMOMember" xlink:to="lab_cvs_InsuranceAndHMOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_StateOfFloridaSettlementMember_e8893e15-4ece-4afd-b4ed-aeee16bf0180_terseLabel_en-US" xlink:label="lab_cvs_StateOfFloridaSettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of Florida Settlement</link:label>
    <link:label id="lab_cvs_StateOfFloridaSettlementMember_label_en-US" xlink:label="lab_cvs_StateOfFloridaSettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Of Florida Settlement [Member]</link:label>
    <link:label id="lab_cvs_StateOfFloridaSettlementMember_documentation_en-US" xlink:label="lab_cvs_StateOfFloridaSettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Of Florida Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StateOfFloridaSettlementMember" xlink:href="cvs-20221231.xsd#cvs_StateOfFloridaSettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_StateOfFloridaSettlementMember" xlink:to="lab_cvs_StateOfFloridaSettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b79d64f8-dcfa-4afa-9d53-7b3c06593082_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax penalties and interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_0350d5d0-6eba-444e-8520-bd0d54e03df1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized capital gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2d28563f-9463-4a2f-9451-f36d2df39bf1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f0425d55-8932-4455-87d5-2a7d18a7d846_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c0bc276b-9c09-489f-b467-3188a37df0bf_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to CVS Health (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_b1e87ff3-73aa-4b40-9450-1177eb171d22_terseLabel_en-US" xlink:label="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest (in shares)</link:label>
    <link:label id="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:href="cvs-20221231.xsd#cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:to="lab_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_0a2af0a8-3f14-4e1a-8291-8ec78957cca8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_YearOfOriginationPeriodOneMember_fdffeefd-0710-44d5-aa9d-86072211d677_terseLabel_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodOneMember_label_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period One [Member]</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodOneMember_documentation_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodOneMember" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_YearOfOriginationPeriodOneMember" xlink:to="lab_cvs_YearOfOriginationPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_59b4d305-f2d4-4ff4-8a4c-0bc5b03d94de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_f3591e34-594b-4839-a5ed-7cb68e7a4fc5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2016-13</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_f15c634f-dc91-44ec-ae73-84fa7306caa7_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_57c6a375-3161-4a26-b9cf-e5ed049142e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_ec4e22d2-21b9-4b39-b64b-624a04231521_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_b7573bc6-a286-4e17-9449-45b291eff55a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_HealthInsurerFeeTaxEffectPercent_a5efbc1c-12af-427e-a289-ba9c0a346b56_terseLabel_en-US" xlink:label="lab_cvs_HealthInsurerFeeTaxEffectPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fee</link:label>
    <link:label id="lab_cvs_HealthInsurerFeeTaxEffectPercent_label_en-US" xlink:label="lab_cvs_HealthInsurerFeeTaxEffectPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurer Fee Tax Effect, Percent</link:label>
    <link:label id="lab_cvs_HealthInsurerFeeTaxEffectPercent_documentation_en-US" xlink:label="lab_cvs_HealthInsurerFeeTaxEffectPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the tax effect of the health care reform's non-tax deductible health insurer fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthInsurerFeeTaxEffectPercent" xlink:href="cvs-20221231.xsd#cvs_HealthInsurerFeeTaxEffectPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_HealthInsurerFeeTaxEffectPercent" xlink:to="lab_cvs_HealthInsurerFeeTaxEffectPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_64529c8b-3950-4707-8639-f2b971ae8c11_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6f9aa2ca-867b-4e13-935a-645c604b87dc_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_fb95037c-c5c8-4d2d-b532-110794a187a7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_89da68f9-1d5d-4a1c-bca1-e0542a03ffa8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_7244c04a-5621-4f20-a0a4-cd675b43a2af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_95c11705-e81e-402e-a678-b3cecf08b994_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInvestmentExpense_7a0a009c-638d-4280-acd9-0fe885734885_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment expenses</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInvestmentExpense_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Investment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_993bada1-9539-42d1-ade6-f0bbd1f074d2_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_23f96f13-a0a5-4ff7-986a-64f8966e0f3c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_eeb8e4e5-21e9-431d-aec4-239788fa0505_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI before reclassifications, pre-tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2422a0e6-6d74-403a-a983-bb38ab162036_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0106d4bb-55ed-483c-b52d-b657172f9d09_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock_995cfa54-ee2e-4dcf-b375-f6f7e418e4d6_terseLabel_en-US" xlink:label="lab_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Allowances and Purchase Discounts</link:label>
    <link:label id="lab_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock_label_en-US" xlink:label="lab_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Allowances And Purchase Discounts [Policy Text Block]</link:label>
    <link:label id="lab_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock_documentation_en-US" xlink:label="lab_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Allowances And Purchase Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock" xlink:href="cvs-20221231.xsd#cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock" xlink:to="lab_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_83fafd38-601d-429e-9c53-304ec767a46f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_03c449c1-2913-4c53-98f2-90eb84a22502_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_bf9165e6-b00e-4751-8081-09e5877daee4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_SeniorNotes4.78DueMarch2038Member_bee10896-347d-4acd-8253-61e4d26f8776_terseLabel_en-US" xlink:label="lab_cvs_SeniorNotes4.78DueMarch2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.78% senior notes due March 2038</link:label>
    <link:label id="lab_cvs_SeniorNotes4.78DueMarch2038Member_label_en-US" xlink:label="lab_cvs_SeniorNotes4.78DueMarch2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.78%, Due March 2038 [Member]</link:label>
    <link:label id="lab_cvs_SeniorNotes4.78DueMarch2038Member_documentation_en-US" xlink:label="lab_cvs_SeniorNotes4.78DueMarch2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.78%, Due March 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.78DueMarch2038Member" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.78DueMarch2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_SeniorNotes4.78DueMarch2038Member" xlink:to="lab_cvs_SeniorNotes4.78DueMarch2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateFundsMember_614dd4a1-1c4f-4769-9c29-9bae7781ca44_verboseLabel_en-US" xlink:label="lab_us-gaap_RealEstateFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate partnerships</link:label>
    <link:label id="lab_us-gaap_RealEstateFundsMember_label_en-US" xlink:label="lab_us-gaap_RealEstateFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstateFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateFundsMember" xlink:to="lab_us-gaap_RealEstateFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCustomers_073d2cc7-793c-4f91-8b8a-29148e646eeb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from customers</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCustomers_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCustomers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCustomers" xlink:to="lab_us-gaap_ProceedsFromCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3c303e5d-d54d-4346-a040-0951bf98cd61_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgeFundsMember_1ab4fe61-1f7f-4b74-a9d7-d7df65a2543a_verboseLabel_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge fund investments</link:label>
    <link:label id="lab_us-gaap_HedgeFundsMember_label_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgeFundsMember" xlink:to="lab_us-gaap_HedgeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_21d9baf4-defa-4d5b-980f-6b94dedd3c13_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_Categories5And6Member_b85c539f-51a5-4d1a-b4fe-70ba77f53b4f_terseLabel_en-US" xlink:label="lab_cvs_Categories5And6Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5 and 6</link:label>
    <link:label id="lab_cvs_Categories5And6Member_label_en-US" xlink:label="lab_cvs_Categories5And6Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories 5 And 6 [Member]</link:label>
    <link:label id="lab_cvs_Categories5And6Member_documentation_en-US" xlink:label="lab_cvs_Categories5And6Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loan credit quality indicator - Categories 5 and 6</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Categories5And6Member" xlink:href="cvs-20221231.xsd#cvs_Categories5And6Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_Categories5And6Member" xlink:to="lab_cvs_Categories5And6Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_70011e5e-69bf-46b3-8db5-f80ea655904d_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_64ae4c36-a748-4868-bb06-43edd3e0804a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_e8869f26-8c0a-4b2e-86d1-b7378de7bf0c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_b526b46b-866c-4923-aec0-e7882f1d67c0_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_3e5f547b-a083-4cf6-9b90-7e4d2cca378f_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated maximum dividend distributions permitted in 2023 without prior regulatory approval</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Amount Available for Dividend Payments without Regulatory Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7ca758d8-f06b-4dd7-b88b-700f89a75ac9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Company's Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f93b14b9-8dbe-4fac-b40b-28df00de24a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease and rents</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_894a2fe9-4bdb-4837-bcd4-f41548816faf_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution centers and Corporate offices</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_41846923-7298-4279-8fbb-f40a367e5bee_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_9481f53c-3b36-4143-8fd9-2db4c71cb574_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ActivityInMortgageLoanPortfolioTableTextBlock_8f6f371d-a0c9-4f5d-8a95-80f2b6a872c4_verboseLabel_en-US" xlink:label="lab_cvs_ActivityInMortgageLoanPortfolioTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity in Mortgage Loan Portfolio</link:label>
    <link:label id="lab_cvs_ActivityInMortgageLoanPortfolioTableTextBlock_label_en-US" xlink:label="lab_cvs_ActivityInMortgageLoanPortfolioTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity In Mortgage Loan Portfolio [Table Text Block]</link:label>
    <link:label id="lab_cvs_ActivityInMortgageLoanPortfolioTableTextBlock_documentation_en-US" xlink:label="lab_cvs_ActivityInMortgageLoanPortfolioTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Table representing activities in mortgage loan portfolio during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ActivityInMortgageLoanPortfolioTableTextBlock" xlink:href="cvs-20221231.xsd#cvs_ActivityInMortgageLoanPortfolioTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ActivityInMortgageLoanPortfolioTableTextBlock" xlink:to="lab_cvs_ActivityInMortgageLoanPortfolioTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss_ddf17906-066e-4232-9057-0be536573571_terseLabel_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years through ten years</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss_label_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss</link:label>
    <link:label id="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss_documentation_en-US" xlink:label="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" xlink:to="lab_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_adb0dad8-e546-4e53-9ba2-5f6172b45a9c_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_dba333dc-4ca1-415c-8d1d-9a7b46b04c06_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_2e5cda6e-392e-4f24-9769-7eaf3c8b34cd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid_aa48a770-44f3-4ce6-b9f7-e4eb1d1ff4cc_terseLabel_en-US" xlink:label="lab_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period after date of service a claim is paid</link:label>
    <link:label id="lab_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid_label_en-US" xlink:label="lab_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs Payable, Period After Date Of Services Claims Are Paid</link:label>
    <link:label id="lab_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid_documentation_en-US" xlink:label="lab_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs Payable, Period After Date Of Services Claims Are Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" xlink:href="cvs-20221231.xsd#cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" xlink:to="lab_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_2224f725-0cdd-488c-b6f6-0e2508a1e46a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_4e8144bf-7038-4a02-9412-06dfdd677218_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables (included in accounts receivable, net)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_f3b89df7-2290-445a-a6c1-a91ecf85b872_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIE, ownership percentage</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_20f4fbe9-5075-4a4a-8e6b-80fad7d00765_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows paid for interest portion of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelatedIntangibleAssetsMember_0e8f4e9d-b67b-4a8b-a9c5-f568216dfe66_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contracts/relationships and covenants not to compete</link:label>
    <link:label id="lab_us-gaap_CustomerRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock_a26b2be7-3582-406e-a304-3713bfccafe6_verboseLabel_en-US" xlink:label="lab_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Mortgage Loan Amortized Cost and Credit Quality Indicator</link:label>
    <link:label id="lab_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock_label_en-US" xlink:label="lab_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Mortgage Loan Internal Credit Ratings [Table Text Block]</link:label>
    <link:label id="lab_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock_documentation_en-US" xlink:label="lab_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule detailing credit quality information related to financing receivables by credit quality indicator and by class of financing receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock" xlink:href="cvs-20221231.xsd#cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock" xlink:to="lab_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a9cf3213-abb4-48f5-b660-992368590051_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions used to determine net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_0c1581b4-ca77-4cfb-a341-57900490886f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoverability of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_243ede0f-8171-4d32-9cc7-989ffaa9ca49_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_e3b9b5c5-5f07-4fc0-b60d-1bf5aee7b9e5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TotalInvestmentsTable_c81e9576-f512-453d-af78-26fa38012083_terseLabel_en-US" xlink:label="lab_cvs_TotalInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments [Table]</link:label>
    <link:label id="lab_cvs_TotalInvestmentsTable_label_en-US" xlink:label="lab_cvs_TotalInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsTable" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TotalInvestmentsTable" xlink:to="lab_cvs_TotalInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_47799869-9049-4ecf-b7a7-c2172c193a5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_TotalInvestmentsTableTextBlock_cf101029-e8d0-48b5-8efb-861acccbcb81_verboseLabel_en-US" xlink:label="lab_cvs_TotalInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Investments</link:label>
    <link:label id="lab_cvs_TotalInvestmentsTableTextBlock_label_en-US" xlink:label="lab_cvs_TotalInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments [Table Text Block]</link:label>
    <link:label id="lab_cvs_TotalInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_cvs_TotalInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item includes total investments, both current and long-term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsTableTextBlock" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_TotalInvestmentsTableTextBlock" xlink:to="lab_cvs_TotalInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_58d6ba93-3b41-4f03-b4e9-cc9ec3e15a08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_bb1c7f32-c58c-4a6a-b43a-7cd5dfd7764b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_CitibankNAMember_a2a2bfb3-7071-43cf-9003-1c6f32d88cc5_terseLabel_en-US" xlink:label="lab_cvs_CitibankNAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Citibank, N.A.</link:label>
    <link:label id="lab_cvs_CitibankNAMember_label_en-US" xlink:label="lab_cvs_CitibankNAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Citibank, N.A. [Member]</link:label>
    <link:label id="lab_cvs_CitibankNAMember_documentation_en-US" xlink:label="lab_cvs_CitibankNAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Citibank, N.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CitibankNAMember" xlink:href="cvs-20221231.xsd#cvs_CitibankNAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_CitibankNAMember" xlink:to="lab_cvs_CitibankNAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_15ee8557-6283-4d35-9623-ef6b8944e6a6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_CoventryHealthCareWorkersCompensationBusinessMember_b184b46f-2e39-409b-bce7-1f79d3de116b_terseLabel_en-US" xlink:label="lab_cvs_CoventryHealthCareWorkersCompensationBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coventry Health Care Workers Compensation Business</link:label>
    <link:label id="lab_cvs_CoventryHealthCareWorkersCompensationBusinessMember_label_en-US" xlink:label="lab_cvs_CoventryHealthCareWorkersCompensationBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coventry Health Care Workers Compensation Business [Member]</link:label>
    <link:label id="lab_cvs_CoventryHealthCareWorkersCompensationBusinessMember_documentation_en-US" xlink:label="lab_cvs_CoventryHealthCareWorkersCompensationBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coventry Health Care Workers Compensation Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CoventryHealthCareWorkersCompensationBusinessMember" xlink:href="cvs-20221231.xsd#cvs_CoventryHealthCareWorkersCompensationBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_CoventryHealthCareWorkersCompensationBusinessMember" xlink:to="lab_cvs_CoventryHealthCareWorkersCompensationBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_e207641c-24f4-4aaa-aa52-556b1ed22d14_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_50aca358-108d-41b1-b3b7-01ad6f5b8486_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale_08532bc9-34ec-492a-badd-b4c0ba848c3a_terseLabel_en-US" xlink:label="lab_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale_label_en-US" xlink:label="lab_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Including Liabilities Held For Sale</link:label>
    <link:label id="lab_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale_documentation_en-US" xlink:label="lab_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Including Liabilities Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" xlink:to="lab_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_bf37a883-3298-4b90-97ca-d99c0e3dd548_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:to="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4aa45c16-4d50-4946-9ce6-9501ffa09088_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_4168331b-049d-448b-9331-0c99c56ea8b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_534dede0-761b-4776-865a-bbea6b62bc81_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f07c53aa-239d-4fa6-97b0-75b590be707f_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_HeartlandHealthcareServicesMember_8c35b374-8002-462f-ab60-9424b7307af6_terseLabel_en-US" xlink:label="lab_cvs_HeartlandHealthcareServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heartland Healthcare Services</link:label>
    <link:label id="lab_cvs_HeartlandHealthcareServicesMember_label_en-US" xlink:label="lab_cvs_HeartlandHealthcareServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heartland Healthcare Services [Member]</link:label>
    <link:label id="lab_cvs_HeartlandHealthcareServicesMember_documentation_en-US" xlink:label="lab_cvs_HeartlandHealthcareServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heartland Healthcare Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HeartlandHealthcareServicesMember" xlink:href="cvs-20221231.xsd#cvs_HeartlandHealthcareServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_HeartlandHealthcareServicesMember" xlink:to="lab_cvs_HeartlandHealthcareServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_123ad574-badf-45c7-a017-8081125c0a9d_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7866bda0-a2e4-4e08-96b9-3cbb05f63b7a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod_15b4d349-9356-4918-b6ad-dc08b26fc19d_negatedTerseLabel_en-US" xlink:label="lab_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition purchase price adjustments outside of measurement period</link:label>
    <link:label id="lab_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod_label_en-US" xlink:label="lab_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Purchase Price Adjustment, Outside Of Measurement Period</link:label>
    <link:label id="lab_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod_documentation_en-US" xlink:label="lab_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Purchase Price Adjustment, Outside Of Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" xlink:href="cvs-20221231.xsd#cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" xlink:to="lab_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_992eca4a-3e18-48e2-a804-ddaf958dea4a_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_5e6a38e7-33bd-4a36-8202-e0fa2098c084_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_YearOfOriginationPeriodFiveMember_12b57cf0-784f-4dc8-a8ac-067fbcfa7ba5_terseLabel_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodFiveMember_label_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period Five [Member]</link:label>
    <link:label id="lab_cvs_YearOfOriginationPeriodFiveMember_documentation_en-US" xlink:label="lab_cvs_YearOfOriginationPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Of Origination Period Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodFiveMember" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_YearOfOriginationPeriodFiveMember" xlink:to="lab_cvs_YearOfOriginationPeriodFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_244df122-2245-4c7f-b046-c4bc64b7fe03_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_StoreImpairmentCharges_1b8bf576-a566-4c47-9a72-db62d7e4fcda_terseLabel_en-US" xlink:label="lab_cvs_StoreImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Store impairments</link:label>
    <link:label id="lab_cvs_StoreImpairmentCharges_8d1e28df-a916-4f76-be7e-2b8f5da717a1_verboseLabel_en-US" xlink:label="lab_cvs_StoreImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Store impairment charges</link:label>
    <link:label id="lab_cvs_StoreImpairmentCharges_label_en-US" xlink:label="lab_cvs_StoreImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Store Impairment Charges</link:label>
    <link:label id="lab_cvs_StoreImpairmentCharges_documentation_en-US" xlink:label="lab_cvs_StoreImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Store Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_StoreImpairmentCharges" xlink:to="lab_cvs_StoreImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_d84581f3-c2e8-42a1-a05c-fcaf6d610132_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_PayflexMember_3491b4b2-d431-4d5c-b727-7e0efe06cb15_terseLabel_en-US" xlink:label="lab_cvs_PayflexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payflex</link:label>
    <link:label id="lab_cvs_PayflexMember_label_en-US" xlink:label="lab_cvs_PayflexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payflex [Member]</link:label>
    <link:label id="lab_cvs_PayflexMember_documentation_en-US" xlink:label="lab_cvs_PayflexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payflex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PayflexMember" xlink:href="cvs-20221231.xsd#cvs_PayflexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_PayflexMember" xlink:to="lab_cvs_PayflexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_64c26757-a99a-4752-ac47-2707046e9a7b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_6bd8c285-127b-4db4-89d8-ad0ebd39e2af_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,854, $0 and $9)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_InternationalHealthCareRenewalRightsMember_4a17bdb2-44fb-45b7-a2e6-17de1c6e5245_terseLabel_en-US" xlink:label="lab_cvs_InternationalHealthCareRenewalRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Health Care Renewal Rights</link:label>
    <link:label id="lab_cvs_InternationalHealthCareRenewalRightsMember_label_en-US" xlink:label="lab_cvs_InternationalHealthCareRenewalRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Health Care Renewal Rights [Member]</link:label>
    <link:label id="lab_cvs_InternationalHealthCareRenewalRightsMember_documentation_en-US" xlink:label="lab_cvs_InternationalHealthCareRenewalRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Health Care Renewal Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InternationalHealthCareRenewalRightsMember" xlink:href="cvs-20221231.xsd#cvs_InternationalHealthCareRenewalRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_InternationalHealthCareRenewalRightsMember" xlink:to="lab_cvs_InternationalHealthCareRenewalRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_a42e8652-74cf-4de0-874f-a5c555fac831_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_40f011ad-61c4-4e80-93b7-dc4e02a397fc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets, investment within plan asset category, amount</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cvs_RevolvingCreditFacilityExpiringMay162027Member_6e6edc38-478e-4585-8ddc-55c9d955d45c_terseLabel_en-US" xlink:label="lab_cvs_RevolvingCreditFacilityExpiringMay162027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Expiring May 16, 2027</link:label>
    <link:label id="lab_cvs_RevolvingCreditFacilityExpiringMay162027Member_label_en-US" xlink:label="lab_cvs_RevolvingCreditFacilityExpiringMay162027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Expiring May 16, 2027 [Member]</link:label>
    <link:label id="lab_cvs_RevolvingCreditFacilityExpiringMay162027Member_documentation_en-US" xlink:label="lab_cvs_RevolvingCreditFacilityExpiringMay162027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Expiring May 16, 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RevolvingCreditFacilityExpiringMay162027Member" xlink:href="cvs-20221231.xsd#cvs_RevolvingCreditFacilityExpiringMay162027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvs_RevolvingCreditFacilityExpiringMay162027Member" xlink:to="lab_cvs_RevolvingCreditFacilityExpiringMay162027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_22c8c245-2871-42ec-abf1-02b1bb6e03e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cvs-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:062ae674-cc97-4efd-81c6-d89202a3d450,g:ffc34178-e241-4c21-bbb1-7b57d93a8581-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cvshealth.com/role/CoverPage" xlink:type="simple" xlink:href="cvs-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8363fe32-1103-49a1-8c45-244fd5e95e4e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_DocumentType_8363fe32-1103-49a1-8c45-244fd5e95e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_fad1c23a-a83f-4261-9e9a-ff4e7ad46c87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_DocumentAnnualReport_fad1c23a-a83f-4261-9e9a-ff4e7ad46c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f2465c20-5c11-44e3-9ee7-0409e4799f35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_DocumentPeriodEndDate_f2465c20-5c11-44e3-9ee7-0409e4799f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d40f9579-d883-4173-9b7e-6d5661a464b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_CurrentFiscalYearEndDate_d40f9579-d883-4173-9b7e-6d5661a464b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2ffdfdd9-b2bf-4299-a06a-feca5c02808c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_DocumentTransitionReport_2ffdfdd9-b2bf-4299-a06a-feca5c02808c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ed9e1776-f5dd-4dd0-9377-e836dd771b56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityFileNumber_ed9e1776-f5dd-4dd0-9377-e836dd771b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9c86a774-98bd-4549-9f11-fbbdd9ce28d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityRegistrantName_9c86a774-98bd-4549-9f11-fbbdd9ce28d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4845c589-8664-43f3-b7f9-ea365871fe8c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4845c589-8664-43f3-b7f9-ea365871fe8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_81be7912-92da-48ba-9092-a8589fd7adad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityTaxIdentificationNumber_81be7912-92da-48ba-9092-a8589fd7adad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a2c44880-f91a-40a7-96f1-22cbf70f2e6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityAddressAddressLine1_a2c44880-f91a-40a7-96f1-22cbf70f2e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8114dfda-1372-4225-ab93-72bcb8ce18c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityAddressCityOrTown_8114dfda-1372-4225-ab93-72bcb8ce18c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e0b35224-0ff0-4b06-ae9f-553309305f0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityAddressStateOrProvince_e0b35224-0ff0-4b06-ae9f-553309305f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0b0805a2-9edb-43d1-bab2-ff7a62905754" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityAddressPostalZipCode_0b0805a2-9edb-43d1-bab2-ff7a62905754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fbfba427-9651-4b65-b565-f866c2548712" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_CityAreaCode_fbfba427-9651-4b65-b565-f866c2548712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_603f7f16-1168-4d78-b3dc-e716f99c6cda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_LocalPhoneNumber_603f7f16-1168-4d78-b3dc-e716f99c6cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3a7be35d-3c03-4d70-85f1-8892dacc091c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_Security12bTitle_3a7be35d-3c03-4d70-85f1-8892dacc091c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6688feea-a02d-4de9-ae85-9a947389e268" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_TradingSymbol_6688feea-a02d-4de9-ae85-9a947389e268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_92614d57-dcf1-4f6c-aecd-5a008b884294" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_SecurityExchangeName_92614d57-dcf1-4f6c-aecd-5a008b884294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_95b73e32-dcf8-48b4-a994-b338a32eac9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_95b73e32-dcf8-48b4-a994-b338a32eac9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_5ddc1313-b9f8-4fba-9bb5-cd4f5bfc6142" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityVoluntaryFilers_5ddc1313-b9f8-4fba-9bb5-cd4f5bfc6142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8d94d667-9636-4306-a57e-32ab5c428088" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityCurrentReportingStatus_8d94d667-9636-4306-a57e-32ab5c428088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c162404e-9728-4ff9-a34d-f7aa5049aa40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityInteractiveDataCurrent_c162404e-9728-4ff9-a34d-f7aa5049aa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4cc40c5f-a3ba-4237-a0e9-d980f366dde9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityFilerCategory_4cc40c5f-a3ba-4237-a0e9-d980f366dde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_06c4b6ee-f347-459a-ba34-dac7ed164ba7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntitySmallBusiness_06c4b6ee-f347-459a-ba34-dac7ed164ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_69cc1b2d-1631-4c32-b004-9ce10fe49135" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityEmergingGrowthCompany_69cc1b2d-1631-4c32-b004-9ce10fe49135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_91a7d795-5520-4ec7-95e7-7876fc07c548" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_IcfrAuditorAttestationFlag_91a7d795-5520-4ec7-95e7-7876fc07c548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a6aa2d27-cc74-448d-8385-5214e5dc7fd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityShellCompany_a6aa2d27-cc74-448d-8385-5214e5dc7fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7568f1ee-babc-4f60-b779-41391e626df9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityPublicFloat_7568f1ee-babc-4f60-b779-41391e626df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d795b154-5f05-427f-9e17-1219f4b497ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d795b154-5f05-427f-9e17-1219f4b497ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f05ec08a-2b8a-4cf5-8778-529fbd26fc38" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f05ec08a-2b8a-4cf5-8778-529fbd26fc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_17c4d9c2-5fb9-4def-9345-e9e05851ba07" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_EntityCentralIndexKey_17c4d9c2-5fb9-4def-9345-e9e05851ba07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_da401a2d-dc5e-4c3e-bae9-c818412223b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_DocumentFiscalYearFocus_da401a2d-dc5e-4c3e-bae9-c818412223b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1b9f69c1-3b30-49ed-a1b5-a5fb70193ea7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1b9f69c1-3b30-49ed-a1b5-a5fb70193ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e879a09d-0b1c-47f2-a864-d999e42a692a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa30d679-a4b2-4c61-a51d-e74678543f52" xlink:to="loc_dei_AmendmentFlag_e879a09d-0b1c-47f2-a864-d999e42a692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/AuditInformation" xlink:type="simple" xlink:href="cvs-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AuditorInformationAbstract_db9920fc-d9be-4ae3-bedf-2b8ee7c183fd" xlink:href="cvs-20221231.xsd#cvs_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_883affff-20ff-4c90-8668-b77fd703bb5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_AuditorInformationAbstract_db9920fc-d9be-4ae3-bedf-2b8ee7c183fd" xlink:to="loc_dei_AuditorName_883affff-20ff-4c90-8668-b77fd703bb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_be947771-ef65-42a0-bdce-6c6579a332b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_AuditorInformationAbstract_db9920fc-d9be-4ae3-bedf-2b8ee7c183fd" xlink:to="loc_dei_AuditorLocation_be947771-ef65-42a0-bdce-6c6579a332b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_e080eb85-fc76-454a-a4b0-c72e422889da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_AuditorInformationAbstract_db9920fc-d9be-4ae3-bedf-2b8ee7c183fd" xlink:to="loc_dei_AuditorFirmId_e080eb85-fc76-454a-a4b0-c72e422889da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1395e853-35fd-4e0f-bf35-22eda81f280a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_effffeac-6748-4174-9c11-28648de55496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1395e853-35fd-4e0f-bf35-22eda81f280a" xlink:to="loc_us-gaap_StatementTable_effffeac-6748-4174-9c11-28648de55496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_45e564c6-f717-4dc9-99fa-13d84a230ade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_effffeac-6748-4174-9c11-28648de55496" xlink:to="loc_srt_ProductOrServiceAxis_45e564c6-f717-4dc9-99fa-13d84a230ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f67bf1e-52aa-43fd-8ce4-34200d247a0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_45e564c6-f717-4dc9-99fa-13d84a230ade" xlink:to="loc_srt_ProductsAndServicesDomain_8f67bf1e-52aa-43fd-8ce4-34200d247a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d680de67-f868-48d1-9ffb-a84d743d7b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8f67bf1e-52aa-43fd-8ce4-34200d247a0e" xlink:to="loc_us-gaap_ProductMember_d680de67-f868-48d1-9ffb-a84d743d7b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_be62eb64-787e-4b89-88e5-3974004b6356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8f67bf1e-52aa-43fd-8ce4-34200d247a0e" xlink:to="loc_us-gaap_ServiceMember_be62eb64-787e-4b89-88e5-3974004b6356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_effffeac-6748-4174-9c11-28648de55496" xlink:to="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31dc5060-ddff-4a22-a7d8-25958dc628df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31dc5060-ddff-4a22-a7d8-25958dc628df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_1d4dafb4-da0c-439b-b379-4b55f306df16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:to="loc_us-gaap_PremiumsEarnedNet_1d4dafb4-da0c-439b-b379-4b55f306df16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_b10f5a75-e302-4d92-9e50-2453160011e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:to="loc_us-gaap_NetInvestmentIncome_b10f5a75-e302-4d92-9e50-2453160011e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8f873fe6-ffba-41ec-89d0-b9aeabe8026a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1bd01ee9-e7c9-463d-9c96-cd3ad667c2aa" xlink:to="loc_us-gaap_Revenues_8f873fe6-ffba-41ec-89d0-b9aeabe8026a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8ee84170-e53a-4b15-8ed9-1b815b1f0c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8ee84170-e53a-4b15-8ed9-1b815b1f0c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_c6f41280-1ae2-4629-919a-eeb863917ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_c6f41280-1ae2-4629-919a-eeb863917ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5987978d-c629-4da0-9ecf-4198496d9f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5987978d-c629-4da0-9ecf-4198496d9f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_dac4e3ea-d9b3-4e8c-8200-40c328d17043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_dac4e3ea-d9b3-4e8c-8200-40c328d17043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_ab2e9dc9-2925-409c-b997-38dbb010be0d" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_cvs_StoreImpairmentCharges_ab2e9dc9-2925-409c-b997-38dbb010be0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5c6ceca2-2c90-41d2-a245-04455c577ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5c6ceca2-2c90-41d2-a245-04455c577ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement_bc481d3c-4ee0-4b66-a681-725bb78e6434" xlink:href="cvs-20221231.xsd#cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement_bc481d3c-4ee0-4b66-a681-725bb78e6434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_106a1660-e029-4435-82fc-b779303f73cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7ce3a314-ada1-465f-b6db-48298f7a9dad" xlink:to="loc_us-gaap_CostsAndExpenses_106a1660-e029-4435-82fc-b779303f73cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1b3ac6ec-1e55-4c19-ba28-3578476263f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_OperatingIncomeLoss_1b3ac6ec-1e55-4c19-ba28-3578476263f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0f553ede-4c95-4f82-9eed-fc864ba84847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_InterestExpense_0f553ede-4c95-4f82-9eed-fc864ba84847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7200b479-056a-42ec-834c-9577a66c02ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7200b479-056a-42ec-834c-9577a66c02ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_151aa584-72c4-48fa-89ec-c721cb2bc29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_151aa584-72c4-48fa-89ec-c721cb2bc29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25738e7b-5bd2-43de-9571-de575519a626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25738e7b-5bd2-43de-9571-de575519a626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b0a0c60-9821-4556-8e01-7dd21772e054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b0a0c60-9821-4556-8e01-7dd21772e054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f15c8aaf-92f0-4844-a18f-1b3a4617564f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f15c8aaf-92f0-4844-a18f-1b3a4617564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ff81b678-094d-4789-a155-7d0741298575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ff81b678-094d-4789-a155-7d0741298575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_241452af-c029-487e-8d41-88b5a486395e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_ProfitLoss_241452af-c029-487e-8d41-88b5a486395e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3ff96770-003e-4f32-a830-2722d4b69576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3ff96770-003e-4f32-a830-2722d4b69576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7cefeab1-5aa4-4486-bcc1-231fd0ed1a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_NetIncomeLoss_7cefeab1-5aa4-4486-bcc1-231fd0ed1a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bdbdf761-5225-4411-81b4-f251bd217fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bdbdf761-5225-4411-81b4-f251bd217fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_bbd62b99-2198-4bf3-bce9-12e19f9b7516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_bbd62b99-2198-4bf3-bce9-12e19f9b7516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a86817a9-7d3c-484f-9f59-4c1be3133bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:to="loc_us-gaap_EarningsPerShareBasic_a86817a9-7d3c-484f-9f59-4c1be3133bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0486de7-b250-4d15-9c28-2a846f52425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_177a0cf4-f875-4123-a0b9-dfcecffdb390" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0486de7-b250-4d15-9c28-2a846f52425a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7935b12e-604f-4290-98bb-a41a41a64c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7935b12e-604f-4290-98bb-a41a41a64c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_63f79235-cd8d-49b6-a309-56345d651a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_63f79235-cd8d-49b6-a309-56345d651a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7a97d7c6-2130-4748-a11a-ca33b63fcddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7a97d7c6-2130-4748-a11a-ca33b63fcddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3949965c-3017-4441-b516-d9ea84de06d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_169633ae-5d27-414f-a872-bcd0d31a0133" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3949965c-3017-4441-b516-d9ea84de06d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_00d10f73-f2e8-4bb4-8cfc-47c9696a970a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_00d10f73-f2e8-4bb4-8cfc-47c9696a970a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_159c1a5d-857b-42b0-8a45-701b8b2af8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6435b47f-5ae2-475a-a838-22790e5f18cc" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_159c1a5d-857b-42b0-8a45-701b8b2af8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c7d12d8d-63cd-463e-afbc-4ab41c6313df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2fbd458-3ab8-43c9-b43c-fa3b6a59a4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c7d12d8d-63cd-463e-afbc-4ab41c6313df" xlink:to="loc_us-gaap_ProfitLoss_f2fbd458-3ab8-43c9-b43c-fa3b6a59a4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bf38fd73-1ef9-4c5c-bef7-b6cd327f05bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c7d12d8d-63cd-463e-afbc-4ab41c6313df" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bf38fd73-1ef9-4c5c-bef7-b6cd327f05bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_eb069e90-9628-4be2-a0e5-a10aebe440bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bf38fd73-1ef9-4c5c-bef7-b6cd327f05bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_eb069e90-9628-4be2-a0e5-a10aebe440bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5dedbccc-b343-4db5-b420-3fb1d29f59e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bf38fd73-1ef9-4c5c-bef7-b6cd327f05bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5dedbccc-b343-4db5-b420-3fb1d29f59e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6919cb56-5de9-4391-9e40-dc415182d15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bf38fd73-1ef9-4c5c-bef7-b6cd327f05bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6919cb56-5de9-4391-9e40-dc415182d15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_65577b7d-039c-4963-9395-28e9c86f02a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bf38fd73-1ef9-4c5c-bef7-b6cd327f05bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_65577b7d-039c-4963-9395-28e9c86f02a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cd0812f7-ba31-4f72-8e9a-6b57915dc40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bf38fd73-1ef9-4c5c-bef7-b6cd327f05bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cd0812f7-ba31-4f72-8e9a-6b57915dc40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b07a514e-5c56-4423-afbc-46eb68c6d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c7d12d8d-63cd-463e-afbc-4ab41c6313df" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b07a514e-5c56-4423-afbc-46eb68c6d87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5052c2b8-0ebb-4e41-85fe-d4db8a10c17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c7d12d8d-63cd-463e-afbc-4ab41c6313df" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5052c2b8-0ebb-4e41-85fe-d4db8a10c17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4b6f5273-a817-433e-ad4f-cf7bd68f1bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c7d12d8d-63cd-463e-afbc-4ab41c6313df" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4b6f5273-a817-433e-ad4f-cf7bd68f1bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e7803fd6-2c11-4f37-9742-304d198d9ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7803fd6-2c11-4f37-9742-304d198d9ca7" xlink:to="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4df02d85-cfd5-4fbe-83aa-6b702d1b12b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4df02d85-cfd5-4fbe-83aa-6b702d1b12b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f2b88d53-d728-4c81-9d27-3ad0b4ad79bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_ShortTermInvestments_f2b88d53-d728-4c81-9d27-3ad0b4ad79bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7de887c1-3ba1-4f1e-b0d9-0e1227d12a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7de887c1-3ba1-4f1e-b0d9-0e1227d12a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d9212a76-0018-434b-ab8f-801bc1f31d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_InventoryNet_d9212a76-0018-434b-ab8f-801bc1f31d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d38b7de8-2de3-4f8a-a703-9e45e5f61440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d38b7de8-2de3-4f8a-a703-9e45e5f61440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3614c06e-a7d3-4bb7-9dc3-0c4dd8bfe55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_OtherAssetsCurrent_3614c06e-a7d3-4bb7-9dc3-0c4dd8bfe55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6d395674-d669-427d-8fd8-4085e3dd1dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_AssetsCurrent_6d395674-d669-427d-8fd8-4085e3dd1dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_c9f69f53-8b1a-4b5b-aa8b-8aea733ad855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_LongTermInvestments_c9f69f53-8b1a-4b5b-aa8b-8aea733ad855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9d19b8d2-b4e4-4fee-81f3-ec1ddfd9af1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9d19b8d2-b4e4-4fee-81f3-ec1ddfd9af1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c3ee818-e587-4671-bcb1-19cb9b017e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c3ee818-e587-4671-bcb1-19cb9b017e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_32006c35-aa3f-4f9c-8382-81d07f519ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_Goodwill_32006c35-aa3f-4f9c-8382-81d07f519ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5318770f-a555-491e-9592-d63dca3c55e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5318770f-a555-491e-9592-d63dca3c55e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_dc743df2-67ce-402d-8c96-c32c0f422763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_SeparateAccountAssets_dc743df2-67ce-402d-8c96-c32c0f422763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_66bf16c6-8eb9-40ad-ae07-1b1ca886bea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_66bf16c6-8eb9-40ad-ae07-1b1ca886bea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e86584af-d433-4641-931d-3bb4359e8563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_93cc7d0f-d451-4856-851e-3173b54a5e76" xlink:to="loc_us-gaap_Assets_e86584af-d433-4641-931d-3bb4359e8563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7803fd6-2c11-4f37-9742-304d198d9ca7" xlink:to="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_a5f2a6cb-2f75-4759-8338-48578999eaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_a5f2a6cb-2f75-4759-8338-48578999eaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyClaimsAndDiscountsPayableCurrent_76e5d2e9-75a1-4f54-b6de-601397eee16a" xlink:href="cvs-20221231.xsd#cvs_PharmacyClaimsAndDiscountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_cvs_PharmacyClaimsAndDiscountsPayableCurrent_76e5d2e9-75a1-4f54-b6de-601397eee16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_0e2a51e4-918b-4a74-baa7-7380e66c783a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_0e2a51e4-918b-4a74-baa7-7380e66c783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPolicyholderFunds_47d5d31c-d6a6-47f8-9fd8-1f10849006c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPolicyholderFunds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_OtherPolicyholderFunds_47d5d31c-d6a6-47f8-9fd8-1f10849006c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3ed5c747-65a0-44fb-9c31-d42177d4c6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3ed5c747-65a0-44fb-9c31-d42177d4c6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherInsuranceLiabilitiesCurrent_d823bdd2-bcc3-40e5-bfcb-d4b37093ff01" xlink:href="cvs-20221231.xsd#cvs_OtherInsuranceLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_cvs_OtherInsuranceLiabilitiesCurrent_d823bdd2-bcc3-40e5-bfcb-d4b37093ff01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_64f2cbb2-6f99-486b-8f05-fb4cd5f2b55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_64f2cbb2-6f99-486b-8f05-fb4cd5f2b55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_713c92e1-fa7f-4b86-864d-9009f6845e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_713c92e1-fa7f-4b86-864d-9009f6845e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_42e83d7e-3b8f-4b73-ad87-d61112bdd7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_42e83d7e-3b8f-4b73-ad87-d61112bdd7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_00159e65-480c-4da6-a09e-547097225f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_LiabilitiesCurrent_00159e65-480c-4da6-a09e-547097225f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5fcea8f1-e5fa-44d0-9b78-2ccc73551a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5fcea8f1-e5fa-44d0-9b78-2ccc73551a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8fe7cd86-34a4-48fe-bfd4-7616d83c8ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8fe7cd86-34a4-48fe-bfd4-7616d83c8ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_da838d9a-303e-48e0-9198-568ea6e21ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_da838d9a-303e-48e0-9198-568ea6e21ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability_f0767d11-71a0-43c0-b7fd-bc9a8011b942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_SeparateAccountsLiability_f0767d11-71a0-43c0-b7fd-bc9a8011b942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherInsuranceLiabilitiesNoncurrent_28f9e5b0-2268-4670-8bbd-a8df3cf9586b" xlink:href="cvs-20221231.xsd#cvs_OtherInsuranceLiabilitiesNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_cvs_OtherInsuranceLiabilitiesNoncurrent_28f9e5b0-2268-4670-8bbd-a8df3cf9586b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_28b3a03a-9c4e-4107-bf87-fbe5fb179c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_28b3a03a-9c4e-4107-bf87-fbe5fb179c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5fe43d94-85a2-49c9-b576-b7fa5522ce1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a6d4db8e-57d7-439a-96da-3c5625d5d3df" xlink:to="loc_us-gaap_Liabilities_5fe43d94-85a2-49c9-b576-b7fa5522ce1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_25845112-31f1-4fab-b2b8-c3a80f1c3b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7803fd6-2c11-4f37-9742-304d198d9ca7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_25845112-31f1-4fab-b2b8-c3a80f1c3b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7803fd6-2c11-4f37-9742-304d198d9ca7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a65c4e8f-ced0-49cc-ae41-eed3803d8028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:to="loc_us-gaap_PreferredStockValue_a65c4e8f-ced0-49cc-ae41-eed3803d8028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_412f2c50-dd47-4e63-819d-3ecb5e92c9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_412f2c50-dd47-4e63-819d-3ecb5e92c9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_90c764a5-e3df-4ca9-9b05-72f04a8c8140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:to="loc_us-gaap_TreasuryStockValue_90c764a5-e3df-4ca9-9b05-72f04a8c8140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a90614a8-eadf-435e-9d39-2d95c3b813df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a90614a8-eadf-435e-9d39-2d95c3b813df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71fce8d3-b7fd-4188-bf80-d80b75636f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71fce8d3-b7fd-4188-bf80-d80b75636f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dcc48c75-6c5f-41d2-ae2c-611027c92de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:to="loc_us-gaap_StockholdersEquity_dcc48c75-6c5f-41d2-ae2c-611027c92de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4b5b99bf-364c-4c9e-a7d6-b7383c037b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:to="loc_us-gaap_MinorityInterest_4b5b99bf-364c-4c9e-a7d6-b7383c037b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8cbd0c76-27f6-4798-a007-543c831558f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a37c09e3-0889-4c17-af1b-f17115642d03" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8cbd0c76-27f6-4798-a007-543c831558f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd50665f-9ec2-43d7-8b21-6651473cc7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7803fd6-2c11-4f37-9742-304d198d9ca7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd50665f-9ec2-43d7-8b21-6651473cc7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5e3fbd54-5c7c-4ec8-9c61-2b6673ccfd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5e3fbd54-5c7c-4ec8-9c61-2b6673ccfd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3b848814-68aa-4dd1-b6e1-12e3a754375c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3b848814-68aa-4dd1-b6e1-12e3a754375c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1d2106bf-ff9f-42c9-b935-d36c266c4aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1d2106bf-ff9f-42c9-b935-d36c266c4aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8f0113bc-5466-479d-9101-ef1f15d1a4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8f0113bc-5466-479d-9101-ef1f15d1a4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_67c97f38-a86d-4662-a6be-981ff8c775f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_67c97f38-a86d-4662-a6be-981ff8c775f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8429c72d-3bef-4194-860d-abc7d765be94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8429c72d-3bef-4194-860d-abc7d765be94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0497b672-7a12-4a83-9e85-3c871c2ae91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:to="loc_us-gaap_CommonStockSharesIssued_0497b672-7a12-4a83-9e85-3c871c2ae91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b84e8abe-eebf-409a-8125-402c4fd13bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b84e8abe-eebf-409a-8125-402c4fd13bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_79ad42b2-ab5b-459d-991a-b8d42c6c8e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f664df-d915-4b5e-a57b-c71792bfb623" xlink:to="loc_us-gaap_TreasuryStockShares_79ad42b2-ab5b-459d-991a-b8d42c6c8e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_84ad0616-3955-484d-a970-d62d6ec42516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84ad0616-3955-484d-a970-d62d6ec42516" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCustomers_3a1a22c1-e63f-4fc7-b8f2-6a1a5a0f2e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:to="loc_us-gaap_ProceedsFromCustomers_3a1a22c1-e63f-4fc7-b8f2-6a1a5a0f2e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies_8212ae83-bac6-4ba4-9219-30ae48ff75fa" xlink:href="cvs-20221231.xsd#cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:to="loc_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies_8212ae83-bac6-4ba4-9219-30ae48ff75fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PaymentsForInsuranceBenefits_ba0349a6-ada0-4fdd-984d-f06383e43d9f" xlink:href="cvs-20221231.xsd#cvs_PaymentsForInsuranceBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:to="loc_cvs_PaymentsForInsuranceBenefits_ba0349a6-ada0-4fdd-984d-f06383e43d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToSuppliersAndEmployees_57374261-072f-4ebf-8ec5-f016044f1b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliersAndEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:to="loc_us-gaap_PaymentsToSuppliersAndEmployees_57374261-072f-4ebf-8ec5-f016044f1b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_c3e20829-9daa-4b50-9603-7b109a85aa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestAndDividendsReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:to="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_c3e20829-9daa-4b50-9603-7b109a85aa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d31061a8-d1da-426e-a6d6-168235384e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:to="loc_us-gaap_InterestPaidNet_d31061a8-d1da-426e-a6d6-168235384e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_62300010-1c0f-4a03-b054-2937b98a49d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_62300010-1c0f-4a03-b054-2937b98a49d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fbe026e6-f1c0-4e2e-b889-ea75120e3553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ac00b34-8a86-4091-bdde-9fe9640109aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fbe026e6-f1c0-4e2e-b889-ea75120e3553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84ad0616-3955-484d-a970-d62d6ec42516" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7d991834-b625-42ea-97eb-9d1e3f14a38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7d991834-b625-42ea-97eb-9d1e3f14a38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_3e55c3e6-23a9-4ed8-9ac7-b97fab189982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_3e55c3e6-23a9-4ed8-9ac7-b97fab189982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e8d27cd9-47d3-4df1-9ae7-106ed4c31d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e8d27cd9-47d3-4df1-9ae7-106ed4c31d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_b5c00c8d-1185-4c65-a6fd-94bee70b4cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:to="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_b5c00c8d-1185-4c65-a6fd-94bee70b4cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_101fae02-3bcd-4bda-a1a3-5c614a9b920e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_101fae02-3bcd-4bda-a1a3-5c614a9b920e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_b2e5e70a-513d-469a-af02-09cd0281dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_b2e5e70a-513d-469a-af02-09cd0281dd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_915d29fc-d912-4227-b694-ac2c61092986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_915d29fc-d912-4227-b694-ac2c61092986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad0ea78f-0d19-47ec-9690-dcafb073b1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_28807f16-f4eb-4fb0-a229-b2523ffab8cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad0ea78f-0d19-47ec-9690-dcafb073b1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84ad0616-3955-484d-a970-d62d6ec42516" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fc99709d-a4a6-44a0-ad36-f9a9a9ca6fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fc99709d-a4a6-44a0-ad36-f9a9a9ca6fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1e519592-2a16-41dd-826e-940caf40f536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1e519592-2a16-41dd-826e-940caf40f536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_e9dde379-d9c7-4935-9dc9-9a6bf98e6c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_e9dde379-d9c7-4935-9dc9-9a6bf98e6c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_aec2732b-37b1-49be-873b-b6b3123f6641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_aec2732b-37b1-49be-873b-b6b3123f6641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c7501c91-03a1-470f-a9d1-c92238bc8d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:to="loc_us-gaap_PaymentsOfDividends_c7501c91-03a1-470f-a9d1-c92238bc8d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_eec4a53c-8569-473d-ad4a-20daaed88071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_eec4a53c-8569-473d-ad4a-20daaed88071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6b68a46f-6be0-44ff-bb8b-45c2d6ceba08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6b68a46f-6be0-44ff-bb8b-45c2d6ceba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4f72bdc3-bbbb-4f72-9701-a5cc869f0ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4f72bdc3-bbbb-4f72-9701-a5cc869f0ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ddbe670-ed82-4f36-b5fb-c70b5be76818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b04de60b-511f-4a3d-86c7-b4733c892b0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ddbe670-ed82-4f36-b5fb-c70b5be76818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c812175f-899b-43e6-89f0-11b17e9faed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84ad0616-3955-484d-a970-d62d6ec42516" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c812175f-899b-43e6-89f0-11b17e9faed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_704e87a4-fa38-402a-8ec4-84a9dd5eef51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84ad0616-3955-484d-a970-d62d6ec42516" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_704e87a4-fa38-402a-8ec4-84a9dd5eef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4900686-f65b-49eb-b298-41046c06ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84ad0616-3955-484d-a970-d62d6ec42516" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4900686-f65b-49eb-b298-41046c06ff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_92de53a8-db30-4de6-a53a-74827c6245cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84ad0616-3955-484d-a970-d62d6ec42516" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_92de53a8-db30-4de6-a53a-74827c6245cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ad5deed1-c34f-427f-bcfd-1d2a2bb78cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_92de53a8-db30-4de6-a53a-74827c6245cc" xlink:to="loc_us-gaap_ProfitLoss_ad5deed1-c34f-427f-bcfd-1d2a2bb78cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_92de53a8-db30-4de6-a53a-74827c6245cc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_84e64dc6-3aa7-401a-a2ff-0e0909a0f48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_84e64dc6-3aa7-401a-a2ff-0e0909a0f48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_aeebc9aa-dfef-4645-a9c5-eb6cc25a39dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_aeebc9aa-dfef-4645-a9c5-eb6cc25a39dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_e5fdf2fc-e921-4be2-83f5-df71fc036de8" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:to="loc_cvs_StoreImpairmentCharges_e5fdf2fc-e921-4be2-83f5-df71fc036de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_074b7369-9c6f-498d-888b-27c84a7d8f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_074b7369-9c6f-498d-888b-27c84a7d8f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_694f23cf-19ef-47c9-85ec-17353df407b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:to="loc_us-gaap_ShareBasedCompensation_694f23cf-19ef-47c9-85ec-17353df407b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_d8ea7392-6205-4b8a-95eb-83271a446783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_d8ea7392-6205-4b8a-95eb-83271a446783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_04d6a6df-275b-497e-8bfd-46178e097ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_04d6a6df-275b-497e-8bfd-46178e097ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_e9c2b905-c60c-4390-9a48-29a4d961dc31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_e9c2b905-c60c-4390-9a48-29a4d961dc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7d7c4ffd-1b9d-4b80-b3d8-4213bc595fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15f26cff-bf0c-427e-a87d-272ecc4d045a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7d7c4ffd-1b9d-4b80-b3d8-4213bc595fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_0d7dd319-4235-45c7-81b2-7ed9ef246c77" xlink:href="cvs-20221231.xsd#cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_92de53a8-db30-4de6-a53a-74827c6245cc" xlink:to="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_0d7dd319-4235-45c7-81b2-7ed9ef246c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f1ff4c6-c435-41fe-9a87-42cfc0f2583e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_0d7dd319-4235-45c7-81b2-7ed9ef246c77" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f1ff4c6-c435-41fe-9a87-42cfc0f2583e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_58dfc2bc-fef8-4338-a6fa-7ed958839730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_0d7dd319-4235-45c7-81b2-7ed9ef246c77" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_58dfc2bc-fef8-4338-a6fa-7ed958839730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8682c250-3dda-419d-a21c-efb44cbc4b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_0d7dd319-4235-45c7-81b2-7ed9ef246c77" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8682c250-3dda-419d-a21c-efb44cbc4b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b44d17ba-be59-4f45-88f3-bec4c88e2a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_0d7dd319-4235-45c7-81b2-7ed9ef246c77" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b44d17ba-be59-4f45-88f3-bec4c88e2a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0fd011ba-4934-40e8-a1a3-9a283c2bd4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_0d7dd319-4235-45c7-81b2-7ed9ef246c77" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0fd011ba-4934-40e8-a1a3-9a283c2bd4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_13c0d013-5f9c-4e44-b299-b5dec7a544f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_0d7dd319-4235-45c7-81b2-7ed9ef246c77" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_13c0d013-5f9c-4e44-b299-b5dec7a544f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_083cb97e-27db-4f10-86c5-67279cd8b532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract_0d7dd319-4235-45c7-81b2-7ed9ef246c77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_083cb97e-27db-4f10-86c5-67279cd8b532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofCashFlows_1"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f1ddf318-530d-4ce7-8f1b-175cd009ef27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d4e146c-887c-476c-854a-88f99a0eb033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f1ddf318-530d-4ce7-8f1b-175cd009ef27" xlink:to="loc_us-gaap_StatementTable_2d4e146c-887c-476c-854a-88f99a0eb033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b82568dd-d739-45f9-a290-57a54c849423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d4e146c-887c-476c-854a-88f99a0eb033" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b82568dd-d739-45f9-a290-57a54c849423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_77003d3e-5f31-4e34-952e-42f715430859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b82568dd-d739-45f9-a290-57a54c849423" xlink:to="loc_us-gaap_EquityComponentDomain_77003d3e-5f31-4e34-952e-42f715430859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_77003d3e-5f31-4e34-952e-42f715430859" xlink:to="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ba72840-8998-485f-9175-d463353cdb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_CommonStockMember_9ba72840-8998-485f-9175-d463353cdb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_52f021ae-4b9d-47f8-bd32-f44e9336f1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_TreasuryStockCommonMember_52f021ae-4b9d-47f8-bd32-f44e9336f1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_a8f2e9d8-a6ca-47a9-852c-9497d86b6073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_a8f2e9d8-a6ca-47a9-852c-9497d86b6073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5b5f3004-8490-40cf-8dc1-ac5392e9b8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_RetainedEarningsMember_5b5f3004-8490-40cf-8dc1-ac5392e9b8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a65b6b34-6ee5-4a7c-86e5-ed8745ccbfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4aa7b13a-056d-4b84-bd89-ad150e3a5775" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a65b6b34-6ee5-4a7c-86e5-ed8745ccbfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f2a563c4-4db0-4431-be8a-9dff30e8bdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_77003d3e-5f31-4e34-952e-42f715430859" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f2a563c4-4db0-4431-be8a-9dff30e8bdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e83d3f2-8a99-44c8-a93e-2dd5a927c223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d4e146c-887c-476c-854a-88f99a0eb033" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e83d3f2-8a99-44c8-a93e-2dd5a927c223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_edbdb0e3-91e4-4371-a58f-6b2bc094919f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e83d3f2-8a99-44c8-a93e-2dd5a927c223" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_edbdb0e3-91e4-4371-a58f-6b2bc094919f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_495ba4bb-aba7-4a64-b7d2-1bf1884c8c68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_edbdb0e3-91e4-4371-a58f-6b2bc094919f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_495ba4bb-aba7-4a64-b7d2-1bf1884c8c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6c0ed4d-6cb1-45b6-b442-3938ea2e8d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d4e146c-887c-476c-854a-88f99a0eb033" xlink:to="loc_us-gaap_StatementLineItems_c6c0ed4d-6cb1-45b6-b442-3938ea2e8d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6c0ed4d-6cb1-45b6-b442-3938ea2e8d0a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9d127cfd-0334-4a52-9ef0-83cc0fc1ebab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_SharesOutstanding_9d127cfd-0334-4a52-9ef0-83cc0fc1ebab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d11e9b86-2e80-4c70-8ead-3b65a2f8542f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_TreasuryStockCommonShares_d11e9b86-2e80-4c70-8ead-3b65a2f8542f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca59a0b8-94c5-4264-a7c8-0d168a9ca122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca59a0b8-94c5-4264-a7c8-0d168a9ca122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1525a5e3-5de9-4c88-a257-7f26617c9c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_ProfitLoss_1525a5e3-5de9-4c88-a257-7f26617c9c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e7836b44-0976-4983-8825-e59fe4d28359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e7836b44-0976-4983-8825-e59fe4d28359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bdd820d7-8040-4d79-9673-9d6cbc0ee0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bdd820d7-8040-4d79-9673-9d6cbc0ee0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2111a35e-76ae-41d8-8075-e3fca9ba7ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2111a35e-76ae-41d8-8075-e3fca9ba7ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod_4e7ed930-7731-464f-b8e2-8c05dce0d150" xlink:href="cvs-20221231.xsd#cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod_4e7ed930-7731-464f-b8e2-8c05dce0d150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod_eb72fe62-2696-4670-8393-1f968f79eca7" xlink:href="cvs-20221231.xsd#cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod_eb72fe62-2696-4670-8393-1f968f79eca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance_d17b3a86-9335-4305-8b02-f9bf9cbf433e" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance_d17b3a86-9335-4305-8b02-f9bf9cbf433e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance_35d46224-0593-441e-963b-d946c063b32b" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance_35d46224-0593-441e-963b-d946c063b32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_31b27d50-6dd5-480b-80df-49b0409dc882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_DividendsCommonStock_31b27d50-6dd5-480b-80df-49b0409dc882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease_fa12dd4f-fe21-41b4-ac8d-5aad2bb995bc" xlink:href="cvs-20221231.xsd#cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease_fa12dd4f-fe21-41b4-ac8d-5aad2bb995bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2a9fbc05-be6d-4164-9a84-a2a372c6ba07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_SharesOutstanding_2a9fbc05-be6d-4164-9a84-a2a372c6ba07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e0c23e1d-4203-4cc2-99d0-047bba3bb90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_TreasuryStockCommonShares_e0c23e1d-4203-4cc2-99d0-047bba3bb90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_092bc742-c99e-49a0-bf23-41a4d2d53e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6090364-2160-48ae-9c99-6ccf79adff73" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_092bc742-c99e-49a0-bf23-41a4d2d53e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofShareholdersEquityParentheticals"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5eee4769-2a74-49ba-8fd8-01c89df6f7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5eee4769-2a74-49ba-8fd8-01c89df6f7cc" xlink:to="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_265f0cf8-a2b4-4fa6-882d-25b218e3941f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_265f0cf8-a2b4-4fa6-882d-25b218e3941f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b7312a47-00c5-4703-b02c-c287b7446635" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_265f0cf8-a2b4-4fa6-882d-25b218e3941f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b7312a47-00c5-4703-b02c-c287b7446635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_138cbbf8-3694-42f6-948d-81bbfeedfe3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b7312a47-00c5-4703-b02c-c287b7446635" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_138cbbf8-3694-42f6-948d-81bbfeedfe3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e0d1356-57ae-48cb-94e0-be0206ef9a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e0d1356-57ae-48cb-94e0-be0206ef9a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_78f9ca8a-d5ec-4b0c-bea3-17e6dd4adaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e0d1356-57ae-48cb-94e0-be0206ef9a60" xlink:to="loc_us-gaap_EquityComponentDomain_78f9ca8a-d5ec-4b0c-bea3-17e6dd4adaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f3069289-fdae-43ee-afe9-96a3cff8534f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_78f9ca8a-d5ec-4b0c-bea3-17e6dd4adaa7" xlink:to="loc_us-gaap_RetainedEarningsMember_f3069289-fdae-43ee-afe9-96a3cff8534f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7b35d734-0f3a-4448-b9a3-18ca8f13cb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7b35d734-0f3a-4448-b9a3-18ca8f13cb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1b08cb15-2578-4edb-9528-5e2d42b1a919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7b35d734-0f3a-4448-b9a3-18ca8f13cb9f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1b08cb15-2578-4edb-9528-5e2d42b1a919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_8d3e2b3d-8391-4f62-b2ed-8b65ff12b70c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1b08cb15-2578-4edb-9528-5e2d42b1a919" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_8d3e2b3d-8391-4f62-b2ed-8b65ff12b70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_616c2394-1464-4673-baf5-fdaf7f7e4f36" xlink:to="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockSharesHeldinTrust_6d07333d-e642-435b-9cd7-a56045059866" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockSharesHeldinTrust"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_cvs_TreasuryStockSharesHeldinTrust_6d07333d-e642-435b-9cd7-a56045059866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockValueSharesHeldInTrust_ca3c2916-17c9-4154-89c4-a6454c91ca2a" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockValueSharesHeldInTrust"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_cvs_TreasuryStockValueSharesHeldInTrust_ca3c2916-17c9-4154-89c4-a6454c91ca2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a17d00fc-0642-4a66-b9f3-0dcabc9ef991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_us-gaap_CommonStockValue_a17d00fc-0642-4a66-b9f3-0dcabc9ef991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_65cf0914-5d70-4b32-9caf-6636175414d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_65cf0914-5d70-4b32-9caf-6636175414d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_a9362ac1-40e5-4af3-a5bb-b1e5fbe49119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65a5395b-35c6-4980-82c4-cd01885173e1" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_a9362ac1-40e5-4af3-a5bb-b1e5fbe49119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="cvs-20221231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2a6a89f6-a9d7-473c-a64d-58735ba85e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_33ded44e-399d-44cd-8e1a-2ec68b6ff60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2a6a89f6-a9d7-473c-a64d-58735ba85e53" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_33ded44e-399d-44cd-8e1a-2ec68b6ff60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5d594abf-0cbd-4a20-aac4-d34093b878d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_5d3f1768-5256-4748-84fe-52f8fa38fc55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5d594abf-0cbd-4a20-aac4-d34093b878d1" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_5d3f1768-5256-4748-84fe-52f8fa38fc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSales" xlink:type="simple" xlink:href="cvs-20221231.xsd#AcquisitionsDivestituresandAssetSales"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSales" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_eabae90e-7fee-49d2-afe7-1f73782264cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_c0755926-6b61-440e-ade4-d91443a5a33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_eabae90e-7fee-49d2-afe7-1f73782264cd" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_c0755926-6b61-440e-ade4-d91443a5a33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/Investments" xlink:type="simple" xlink:href="cvs-20221231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_223718d6-fdcd-49c1-a6dc-e656d423fc41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0e739800-4afc-4869-982d-cdaa626edc92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_223718d6-fdcd-49c1-a6dc-e656d423fc41" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0e739800-4afc-4869-982d-cdaa626edc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValue" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_74517358-f48e-4d16-9c8a-a44b0a6832e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_31908a01-da00-4aeb-88c5-74b80abb61bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_74517358-f48e-4d16-9c8a-a44b0a6832e4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_31908a01-da00-4aeb-88c5-74b80abb61bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherIntangibles"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherIntangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5013f307-2e7e-46f0-8628-3e12d880c3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_368ba4e7-b868-4cab-b914-9bf76d6f625a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5013f307-2e7e-46f0-8628-3e12d880c3db" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_368ba4e7-b868-4cab-b914-9bf76d6f625a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/Leases" xlink:type="simple" xlink:href="cvs-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dd8d5529-f37b-4e25-bab0-979267f83ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_2a775907-02a0-4139-8095-4e4b3745c942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd8d5529-f37b-4e25-bab0-979267f83ef6" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_2a775907-02a0-4139-8095-4e4b3745c942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c4ed3a24-7fed-4cc6-9a9d-419d018223cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd8d5529-f37b-4e25-bab0-979267f83ef6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c4ed3a24-7fed-4cc6-9a9d-419d018223cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayable" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayable"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_c7f8cbf1-0d10-4299-b61d-0129c6f9ec7d" xlink:href="cvs-20221231.xsd#cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock_967086bd-5217-4314-8081-fff57df52bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_c7f8cbf1-0d10-4299-b61d-0129c6f9ec7d" xlink:to="loc_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock_967086bd-5217-4314-8081-fff57df52bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreements" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreements"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_51d44ca1-a1be-4026-b014-b1fc7da8829c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5653f437-41d7-4a9d-837d-f086da190729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_51d44ca1-a1be-4026-b014-b1fc7da8829c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5653f437-41d7-4a9d-837d-f086da190729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefits"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b00a377-ec4e-4486-ac1b-ae4d3bba4966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_011a7e2d-8bc9-43cb-9f9b-652c05548a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b00a377-ec4e-4486-ac1b-ae4d3bba4966" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_011a7e2d-8bc9-43cb-9f9b-652c05548a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6e13d6d9-ae76-4f5d-998f-0d4e97a51610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9e8a869f-3cec-48fa-8036-05125a69de5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6e13d6d9-ae76-4f5d-998f-0d4e97a51610" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9e8a869f-3cec-48fa-8036-05125a69de5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlans" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_57d8ef7c-f48d-4443-8b57-b741fc09cccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c532de74-646a-49a1-9704-1fbaf1072c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_57d8ef7c-f48d-4443-8b57-b741fc09cccc" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c532de74-646a-49a1-9704-1fbaf1072c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8a33f398-8cfa-4efb-972c-06b0b0a8bbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3beccd50-b759-4db6-940a-9a5ddf133f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8a33f398-8cfa-4efb-972c-06b0b0a8bbac" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3beccd50-b759-4db6-940a-9a5ddf133f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cvs-20221231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_662786f4-4b1e-45c9-8fa0-38c9ab75e007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_daa55a59-6a68-4ba0-85a9-6a34a4ebe964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_662786f4-4b1e-45c9-8fa0-38c9ab75e007" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_daa55a59-6a68-4ba0-85a9-6a34a4ebe964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/EarningsPerShare" xlink:type="simple" xlink:href="cvs-20221231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_de54b18c-cabb-4c0f-aa44-5df7b5b2f775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a6b862f0-cce4-4dc8-9ad5-6a7b43d1a820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de54b18c-cabb-4c0f-aa44-5df7b5b2f775" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a6b862f0-cce4-4dc8-9ad5-6a7b43d1a820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/Reinsurance" xlink:type="simple" xlink:href="cvs-20221231.xsd#Reinsurance"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/Reinsurance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_eeb7f763-2a67-4bc8-ad17-344be58a3179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock_f43df286-fa31-4047-9684-56727bfcfd39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_eeb7f763-2a67-4bc8-ad17-344be58a3179" xlink:to="loc_us-gaap_ReinsuranceTextBlock_f43df286-fa31-4047-9684-56727bfcfd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cvs-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff98084b-15c3-4ed9-a03d-bb5465f46c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_de96c496-2906-4569-b361-21027387eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff98084b-15c3-4ed9-a03d-bb5465f46c15" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_de96c496-2906-4569-b361-21027387eb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="cvs-20221231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c1bdd282-5b73-4b50-901d-076b30e0d978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_486f765a-20a4-4408-a7b8-1784200e12c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c1bdd282-5b73-4b50-901d-076b30e0d978" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_486f765a-20a4-4408-a7b8-1784200e12c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7cd28e46-228b-4f07-b4e0-6cffe3f0fd91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7cd28e46-228b-4f07-b4e0-6cffe3f0fd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8d6793c9-34d0-4840-a0f7-152713079611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8d6793c9-34d0-4840-a0f7-152713079611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_88664527-e1f0-4990-b5ad-4fed99861d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_UseOfEstimates_88664527-e1f0-4990-b5ad-4fed99861d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8db6155f-56d7-4dfe-bf24-0d81a8c46ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8db6155f-56d7-4dfe-bf24-0d81a8c46ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_2ee20fa7-1020-43eb-89aa-ff61df8c7d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_2ee20fa7-1020-43eb-89aa-ff61df8c7d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_32c6f6a3-3042-45ff-90c2-63bcc76a4a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_32c6f6a3-3042-45ff-90c2-63bcc76a4a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_55a471f2-c21e-4894-ab85-955a72bbeb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_55a471f2-c21e-4894-ab85-955a72bbeb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_2952e982-6a2a-4333-a5bc-730a13f8bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_2952e982-6a2a-4333-a5bc-730a13f8bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy_bd29992e-b15c-4a39-b699-d23e65d70f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_ReinsuranceAccountingPolicy_bd29992e-b15c-4a39-b699-d23e65d70f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_475b199e-23ea-4e24-868a-b98412d28562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_475b199e-23ea-4e24-868a-b98412d28562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b6631f85-d7c2-4936-9800-487b1ff7dd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b6631f85-d7c2-4936-9800-487b1ff7dd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_d71d7a3d-fa77-45fc-9bbd-409cfe24261a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_d71d7a3d-fa77-45fc-9bbd-409cfe24261a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fee48a85-b467-4d40-a153-74d6c070d817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fee48a85-b467-4d40-a153-74d6c070d817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_ea68e5dd-1e9d-4145-b194-8dcd0df57128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_ea68e5dd-1e9d-4145-b194-8dcd0df57128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_24555b50-2468-41a7-a0f9-de705d14fcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_24555b50-2468-41a7-a0f9-de705d14fcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountsPolicy_4ef8afe1-4e24-432b-9385-bb32477d7046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderAccountsPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_PolicyholderAccountsPolicy_4ef8afe1-4e24-432b-9385-bb32477d7046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_26f6f78d-a9f0-4a28-8640-479c7dd2191f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_26f6f78d-a9f0-4a28-8640-479c7dd2191f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_c6c59e2a-62ea-4f08-af66-f07fabaafdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_c6c59e2a-62ea-4f08-af66-f07fabaafdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock_b6394232-7a96-4e03-b615-f24f932da984" xlink:href="cvs-20221231.xsd#cvs_InsurancePremiumDeficiencyReservePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock_b6394232-7a96-4e03-b615-f24f932da984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocationsToPolicyholdersPolicies_a7cb70c2-d920-4ad7-98e5-2ed22f8f6a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocationsToPolicyholdersPolicies"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_AllocationsToPolicyholdersPolicies_a7cb70c2-d920-4ad7-98e5-2ed22f8f6a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_38176aab-b2e7-4007-a6ad-18c37dfeceed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_38176aab-b2e7-4007-a6ad-18c37dfeceed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_34eec59f-468c-402a-a0ee-b01f70b71286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_34eec59f-468c-402a-a0ee-b01f70b71286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_93d4de33-234f-46ec-8762-2e9a1a88b140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_93d4de33-234f-46ec-8762-2e9a1a88b140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_e53da4b9-0af7-4175-8b21-cce81ec3bebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_e53da4b9-0af7-4175-8b21-cce81ec3bebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock_d4f4c2a7-1852-4776-acaf-ed750aa1f025" xlink:href="cvs-20221231.xsd#cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock_d4f4c2a7-1852-4776-acaf-ed750aa1f025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock_4f0240cf-4f05-4ed6-93c6-d398a82a0bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareEntitiesPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock_4f0240cf-4f05-4ed6-93c6-d398a82a0bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_5a06840d-aa80-4d4f-a4b4-44e6892b78ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_5a06840d-aa80-4d4f-a4b4-44e6892b78ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_08af34c7-002a-481a-b7e4-84e0f0c4159e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_08af34c7-002a-481a-b7e4-84e0f0c4159e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_843dec1f-1877-4c7a-892d-2cab3eb0fef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_843dec1f-1877-4c7a-892d-2cab3eb0fef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_446d3ff9-91bd-4a3e-9d36-4c65baa411e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_446d3ff9-91bd-4a3e-9d36-4c65baa411e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b1cd4395-327c-44cb-b9d5-bb677a164f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b1cd4395-327c-44cb-b9d5-bb677a164f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SharesHeldInTrustPolicyTextBlock_a4df32e5-e1df-4b41-9001-70f97c23e04f" xlink:href="cvs-20221231.xsd#cvs_SharesHeldInTrustPolicyTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_cvs_SharesHeldInTrustPolicyTextBlock_a4df32e5-e1df-4b41-9001-70f97c23e04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_68e0f834-c8d3-4522-8422-93e04e923309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_68e0f834-c8d3-4522-8422-93e04e923309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_296bf505-7e2a-41e2-b26b-d16d62e1bead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_296bf505-7e2a-41e2-b26b-d16d62e1bead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_63a2a1a2-8ab1-452a-ba7d-f547979cab06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_63a2a1a2-8ab1-452a-ba7d-f547979cab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ede86dae-4bfb-4f02-9ae8-938e33e7e7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb42538f-9955-4b7b-bfec-706edb8dca64" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ede86dae-4bfb-4f02-9ae8-938e33e7e7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fa111d3c-d80a-470e-98de-4e6868d0691c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_01c50065-a2d2-4bae-8d85-7eeef34192dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa111d3c-d80a-470e-98de-4e6868d0691c" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_01c50065-a2d2-4bae-8d85-7eeef34192dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_312ab6c5-01ee-4d81-9bf9-4934afb23c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa111d3c-d80a-470e-98de-4e6868d0691c" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_312ab6c5-01ee-4d81-9bf9-4934afb23c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7d71c472-40bf-47b1-8a39-346235881f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa111d3c-d80a-470e-98de-4e6868d0691c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7d71c472-40bf-47b1-8a39-346235881f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_da0e10a4-d625-44f8-84f8-98d5c399157d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa111d3c-d80a-470e-98de-4e6868d0691c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_da0e10a4-d625-44f8-84f8-98d5c399157d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_dab48e31-7a1c-4537-ad9f-cfc999e42bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa111d3c-d80a-470e-98de-4e6868d0691c" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_dab48e31-7a1c-4537-ad9f-cfc999e42bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_3e77e012-1e2f-487b-935d-e645629b357d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa111d3c-d80a-470e-98de-4e6868d0691c" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_3e77e012-1e2f-487b-935d-e645629b357d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ddd6d535-a8ff-46d7-beb8-7ad27d58fbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa111d3c-d80a-470e-98de-4e6868d0691c" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ddd6d535-a8ff-46d7-beb8-7ad27d58fbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#AcquisitionsDivestituresandAssetSalesTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_606f1a79-d3e7-4165-b3bb-a5bc632bd5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_d91255ad-2651-4d78-80c6-772922541930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_606f1a79-d3e7-4165-b3bb-a5bc632bd5dc" xlink:to="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_d91255ad-2651-4d78-80c6-772922541930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_f8939315-f211-4ab2-b122-b6cc386096d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsTableTextBlock_a8009b34-a577-464e-8979-bb3dea708763" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f8939315-f211-4ab2-b122-b6cc386096d5" xlink:to="loc_cvs_TotalInvestmentsTableTextBlock_a8009b34-a577-464e-8979-bb3dea708763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c6b8572e-627a-4d3d-8a93-68fa9bfa0d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f8939315-f211-4ab2-b122-b6cc386096d5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c6b8572e-627a-4d3d-8a93-68fa9bfa0d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fcbb8df1-9103-452c-aae8-01938203a7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f8939315-f211-4ab2-b122-b6cc386096d5" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fcbb8df1-9103-452c-aae8-01938203a7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_fb481a70-b50b-43d5-af68-5e3da9b2ae4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f8939315-f211-4ab2-b122-b6cc386096d5" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_fb481a70-b50b-43d5-af68-5e3da9b2ae4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ActivityInMortgageLoanPortfolioTableTextBlock_13ec72c3-18cb-411b-a881-c89096e5be60" xlink:href="cvs-20221231.xsd#cvs_ActivityInMortgageLoanPortfolioTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f8939315-f211-4ab2-b122-b6cc386096d5" xlink:to="loc_cvs_ActivityInMortgageLoanPortfolioTableTextBlock_13ec72c3-18cb-411b-a881-c89096e5be60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock_ab5e93fc-c357-40e4-bc42-13529a09884c" xlink:href="cvs-20221231.xsd#cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f8939315-f211-4ab2-b122-b6cc386096d5" xlink:to="loc_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock_ab5e93fc-c357-40e4-bc42-13529a09884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeTextBlock_d665f997-4c89-4a59-9b24-fc07c32b1a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f8939315-f211-4ab2-b122-b6cc386096d5" xlink:to="loc_us-gaap_InvestmentIncomeTextBlock_d665f997-4c89-4a59-9b24-fc07c32b1a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock_c4870684-33ef-465a-8e58-e501cd13f9b0" xlink:href="cvs-20221231.xsd#cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f8939315-f211-4ab2-b122-b6cc386096d5" xlink:to="loc_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock_c4870684-33ef-465a-8e58-e501cd13f9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63d47994-3910-457a-b3e6-c1df8bc4f98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3536f71d-2e0e-4a01-b274-e7244a3c1b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63d47994-3910-457a-b3e6-c1df8bc4f98a" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3536f71d-2e0e-4a01-b274-e7244a3c1b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8f91fe5f-1928-447b-af5a-915c8ad7c085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63d47994-3910-457a-b3e6-c1df8bc4f98a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8f91fe5f-1928-447b-af5a-915c8ad7c085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_fdaaa63f-de79-433c-b854-7787df2c2035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63d47994-3910-457a-b3e6-c1df8bc4f98a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_fdaaa63f-de79-433c-b854-7787df2c2035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock_7a16b3db-b2a2-4b8a-bbe0-b3967bd570ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63d47994-3910-457a-b3e6-c1df8bc4f98a" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock_7a16b3db-b2a2-4b8a-bbe0-b3967bd570ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bff9fdcd-ad6f-4b71-a67b-526d598791f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_85b27e4c-8e7e-4694-a820-ac9062e90297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bff9fdcd-ad6f-4b71-a67b-526d598791f9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_85b27e4c-8e7e-4694-a820-ac9062e90297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock_2259762f-d1eb-4dcd-ad47-4d72c7e219fd" xlink:href="cvs-20221231.xsd#cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bff9fdcd-ad6f-4b71-a67b-526d598791f9" xlink:to="loc_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock_2259762f-d1eb-4dcd-ad47-4d72c7e219fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_331649a4-5c6f-4126-9695-d2683831da93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bff9fdcd-ad6f-4b71-a67b-526d598791f9" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_331649a4-5c6f-4126-9695-d2683831da93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0531d345-fad9-41c8-af84-244a8b4c7e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_56f2fdbe-4e78-4075-b2e8-603b4ad81db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0531d345-fad9-41c8-af84-244a8b4c7e46" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_56f2fdbe-4e78-4075-b2e8-603b4ad81db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLeaseTableTextBlock_7cbb073b-9ea1-48cc-8f0c-d9e13934d0fb" xlink:href="cvs-20221231.xsd#cvs_LesseeLeaseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0531d345-fad9-41c8-af84-244a8b4c7e46" xlink:to="loc_cvs_LesseeLeaseTableTextBlock_7cbb073b-9ea1-48cc-8f0c-d9e13934d0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_37a4fdc4-26ef-4d79-852f-0792aa845cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0531d345-fad9-41c8-af84-244a8b4c7e46" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_37a4fdc4-26ef-4d79-852f-0792aa845cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_e18bab3f-c9f9-46f7-98dc-9d97b40e32f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0531d345-fad9-41c8-af84-244a8b4c7e46" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_e18bab3f-c9f9-46f7-98dc-9d97b40e32f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_59cc4e00-b118-4556-84ac-a715bf91b217" xlink:href="cvs-20221231.xsd#cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_d87afb91-5e2b-4fcf-a417-f8330ee1dfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_59cc4e00-b118-4556-84ac-a715bf91b217" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_d87afb91-5e2b-4fcf-a417-f8330ee1dfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_37eb2df3-3845-49a1-bb42-6c97a7de1c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_59cc4e00-b118-4556-84ac-a715bf91b217" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_37eb2df3-3845-49a1-bb42-6c97a7de1c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_4961e4b8-6891-466a-9612-af6ab92d446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_59cc4e00-b118-4556-84ac-a715bf91b217" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_4961e4b8-6891-466a-9612-af6ab92d446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_355f87c6-38ed-48b6-b391-55383fe58227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f3cbc38f-5cc7-4b6a-8079-17f942d4e90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_355f87c6-38ed-48b6-b391-55383fe58227" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f3cbc38f-5cc7-4b6a-8079-17f942d4e90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_08499b18-c44f-4e36-aa07-6be743dd8334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_355f87c6-38ed-48b6-b391-55383fe58227" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_08499b18-c44f-4e36-aa07-6be743dd8334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8fb4d7a-082f-456a-8a51-66267b6e02df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_e1b08003-1c6c-4dd5-9f50-cfc97c2d488b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8fb4d7a-082f-456a-8a51-66267b6e02df" xlink:to="loc_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock_e1b08003-1c6c-4dd5-9f50-cfc97c2d488b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_885a89b2-4a38-411b-ad26-d174ada529e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8fb4d7a-082f-456a-8a51-66267b6e02df" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_885a89b2-4a38-411b-ad26-d174ada529e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_ef2e0533-5710-4ff1-a3e3-1e088e0d1f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8fb4d7a-082f-456a-8a51-66267b6e02df" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_ef2e0533-5710-4ff1-a3e3-1e088e0d1f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3a05bf49-6e48-4874-bab2-dc2a4245d0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8fb4d7a-082f-456a-8a51-66267b6e02df" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_3a05bf49-6e48-4874-bab2-dc2a4245d0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_66e5dbc9-5dc2-430b-8d01-babfbdb179f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8fb4d7a-082f-456a-8a51-66267b6e02df" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_66e5dbc9-5dc2-430b-8d01-babfbdb179f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3861cd6b-4d33-45b6-92cd-b1c904933a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8fb4d7a-082f-456a-8a51-66267b6e02df" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3861cd6b-4d33-45b6-92cd-b1c904933a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock_5dcacd6a-8f7a-411d-bd43-4c89d561ebce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8fb4d7a-082f-456a-8a51-66267b6e02df" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock_5dcacd6a-8f7a-411d-bd43-4c89d561ebce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_a4e4a660-c890-4e00-9912-60599aa99461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e8fb4d7a-082f-456a-8a51-66267b6e02df" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_a4e4a660-c890-4e00-9912-60599aa99461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_52063242-cc5a-4d2c-af04-9195929e02a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_44bc28e2-00e1-4aa1-8fde-6fb5d381af39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52063242-cc5a-4d2c-af04-9195929e02a7" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_44bc28e2-00e1-4aa1-8fde-6fb5d381af39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b1a70586-8976-4109-82d1-78914af50fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52063242-cc5a-4d2c-af04-9195929e02a7" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b1a70586-8976-4109-82d1-78914af50fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_51a82947-042b-49ef-945f-a6d2c0e9f17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52063242-cc5a-4d2c-af04-9195929e02a7" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_51a82947-042b-49ef-945f-a6d2c0e9f17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_bba0bf5c-001c-4690-8a2e-1bc0d784d362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52063242-cc5a-4d2c-af04-9195929e02a7" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_bba0bf5c-001c-4690-8a2e-1bc0d784d362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlansTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95ff83ed-15de-45cc-a3bc-fa087b712d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a1510c8e-e2ad-4882-a041-e8fed55b9c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95ff83ed-15de-45cc-a3bc-fa087b712d53" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a1510c8e-e2ad-4882-a041-e8fed55b9c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_78b20f32-638b-42be-ac38-762ab0fa0c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95ff83ed-15de-45cc-a3bc-fa087b712d53" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_78b20f32-638b-42be-ac38-762ab0fa0c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_78c69df2-7f0f-4097-9c28-9ade29fdc3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95ff83ed-15de-45cc-a3bc-fa087b712d53" xlink:to="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_78c69df2-7f0f-4097-9c28-9ade29fdc3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e31ade93-80ef-46d2-9114-3e9d89fede39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95ff83ed-15de-45cc-a3bc-fa087b712d53" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e31ade93-80ef-46d2-9114-3e9d89fede39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_4db12736-368c-4c7f-9f2e-3bca1b2d2a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95ff83ed-15de-45cc-a3bc-fa087b712d53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_4db12736-368c-4c7f-9f2e-3bca1b2d2a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_0e487570-2436-4950-a6de-6e8563b2344d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95ff83ed-15de-45cc-a3bc-fa087b712d53" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_0e487570-2436-4950-a6de-6e8563b2344d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3138fbea-2d75-49e9-be1c-1688533b1ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_4b967af2-2484-4f27-ad78-8b15619130a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3138fbea-2d75-49e9-be1c-1688533b1ba9" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_4b967af2-2484-4f27-ad78-8b15619130a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRegulatoryAssetsTextBlock_6731ed5f-693d-4f26-b684-37feca75bbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRegulatoryAssetsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3138fbea-2d75-49e9-be1c-1688533b1ba9" xlink:to="loc_us-gaap_ScheduleOfRegulatoryAssetsTextBlock_6731ed5f-693d-4f26-b684-37feca75bbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock_2ee9a4e9-d11d-4e3a-9e23-a85fc6180df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesDisclosureTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3138fbea-2d75-49e9-be1c-1688533b1ba9" xlink:to="loc_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock_2ee9a4e9-d11d-4e3a-9e23-a85fc6180df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/OtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#OtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/OtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7937ccf0-bac3-4aa8-bafb-357a0c3c331b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_767fc106-22b2-40e8-a1d6-0a36692df5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7937ccf0-bac3-4aa8-bafb-357a0c3c331b" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_767fc106-22b2-40e8-a1d6-0a36692df5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2bea7c4d-7697-4e57-b7a4-22827c224d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_17f997f1-1dc4-42f4-9ecb-0b056d0d2ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2bea7c4d-7697-4e57-b7a4-22827c224d88" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_17f997f1-1dc4-42f4-9ecb-0b056d0d2ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ReinsuranceTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#ReinsuranceTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ReinsuranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_7eb23058-806c-4a9d-84ea-8ab1341a3b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_cddc3cc8-e4a0-4ec3-9929-915866a54191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_7eb23058-806c-4a9d-84ea-8ab1341a3b6b" xlink:to="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_cddc3cc8-e4a0-4ec3-9929-915866a54191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock_274ffdd0-2226-434a-8218-f1c48a6771a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_7eb23058-806c-4a9d-84ea-8ab1341a3b6b" xlink:to="loc_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock_274ffdd0-2226-434a-8218-f1c48a6771a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_76f88910-7161-46fb-87db-aab54d9a78ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_7eb23058-806c-4a9d-84ea-8ab1341a3b6b" xlink:to="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_76f88910-7161-46fb-87db-aab54d9a78ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="cvs-20221231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_89125019-38e9-44bf-b42b-8cdef500508c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7f976408-664a-4df7-bc8d-4bafcab270ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_89125019-38e9-44bf-b42b-8cdef500508c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7f976408-664a-4df7-bc8d-4bafcab270ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_43410a2e-3d9d-4ad7-91b1-08cc75bc1a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_89125019-38e9-44bf-b42b-8cdef500508c" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_43410a2e-3d9d-4ad7-91b1-08cc75bc1a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_673b467b-6920-4c86-abd0-e7ea577b4134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_673b467b-6920-4c86-abd0-e7ea577b4134" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f44598a3-fc16-4e7c-9bd8-a7e5e44c81cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_srt_ProductOrServiceAxis_f44598a3-fc16-4e7c-9bd8-a7e5e44c81cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_214547f0-8f6b-47ea-9f27-d56c46160bc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f44598a3-fc16-4e7c-9bd8-a7e5e44c81cd" xlink:to="loc_srt_ProductsAndServicesDomain_214547f0-8f6b-47ea-9f27-d56c46160bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthInsuranceProductLineMember_d72da6d3-8753-4326-8dc9-3f4783e57597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthInsuranceProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_214547f0-8f6b-47ea-9f27-d56c46160bc5" xlink:to="loc_us-gaap_HealthInsuranceProductLineMember_d72da6d3-8753-4326-8dc9-3f4783e57597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_219e006e-c7f0-47ae-8ee8-6a4a5bf82465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_219e006e-c7f0-47ae-8ee8-6a4a5bf82465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4a6bdad3-8481-4ec3-a7ef-c929c056513d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_219e006e-c7f0-47ae-8ee8-6a4a5bf82465" xlink:to="loc_us-gaap_SegmentDomain_4a6bdad3-8481-4ec3-a7ef-c929c056513d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_35b61220-82ec-4f85-9c35-e674477260f4" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4a6bdad3-8481-4ec3-a7ef-c929c056513d" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_35b61220-82ec-4f85-9c35-e674477260f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_250a8aa9-7799-466f-87d4-59ff84f03e05" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4a6bdad3-8481-4ec3-a7ef-c929c056513d" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_250a8aa9-7799-466f-87d4-59ff84f03e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_23107a75-493e-491f-8b17-38a674662f0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_srt_RangeAxis_23107a75-493e-491f-8b17-38a674662f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40ed7863-1deb-4776-83c9-03880487c244" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_23107a75-493e-491f-8b17-38a674662f0e" xlink:to="loc_srt_RangeMember_40ed7863-1deb-4776-83c9-03880487c244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cdb6c580-a25f-49b5-bc10-2c01e0a1bf86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_40ed7863-1deb-4776-83c9-03880487c244" xlink:to="loc_srt_MinimumMember_cdb6c580-a25f-49b5-bc10-2c01e0a1bf86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_607b238b-f9c9-4b1f-af13-d0acbd514b45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_40ed7863-1deb-4776-83c9-03880487c244" xlink:to="loc_srt_MaximumMember_607b238b-f9c9-4b1f-af13-d0acbd514b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f30736fd-c9e3-45a5-a38f-0e5cf14faf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f30736fd-c9e3-45a5-a38f-0e5cf14faf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f30736fd-c9e3-45a5-a38f-0e5cf14faf2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a05c798e-1de0-4c82-aee0-8e9931d55490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a05c798e-1de0-4c82-aee0-8e9931d55490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember_d9302e00-7e80-4353-aed7-aca1c6a6c44b" xlink:href="cvs-20221231.xsd#cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:to="loc_cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember_d9302e00-7e80-4353-aed7-aca1c6a6c44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_811bd883-57d2-4b9f-b530-07fde4c66bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6ae046d-f4a2-4355-bee1-1766652fc48e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_811bd883-57d2-4b9f-b530-07fde4c66bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_99600885-d8f6-40bf-bdbd-7b436feaa907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_99600885-d8f6-40bf-bdbd-7b436feaa907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8f8d7792-a433-4661-b8b1-e512304e29da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_99600885-d8f6-40bf-bdbd-7b436feaa907" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8f8d7792-a433-4661-b8b1-e512304e29da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherInsuranceLiabilitiesMember_674ce8bb-1c0c-4253-99e8-898db6a68167" xlink:href="cvs-20221231.xsd#cvs_OtherInsuranceLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f8d7792-a433-4661-b8b1-e512304e29da" xlink:to="loc_cvs_OtherInsuranceLiabilitiesMember_674ce8bb-1c0c-4253-99e8-898db6a68167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherLongTermInsuranceLiabilitiesMember_4952dcdd-8f82-45f2-ab83-c948d9cc2e7c" xlink:href="cvs-20221231.xsd#cvs_OtherLongTermInsuranceLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f8d7792-a433-4661-b8b1-e512304e29da" xlink:to="loc_cvs_OtherLongTermInsuranceLiabilitiesMember_4952dcdd-8f82-45f2-ab83-c948d9cc2e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_19db2452-2b3f-4a75-81ec-4516c115b742" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_dei_LegalEntityAxis_19db2452-2b3f-4a75-81ec-4516c115b742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6dfedea2-53b3-4139-8879-c57862b96697" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_19db2452-2b3f-4a75-81ec-4516c115b742" xlink:to="loc_dei_EntityDomain_6dfedea2-53b3-4139-8879-c57862b96697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HeartlandHealthcareServicesMember_ff0e643d-7b04-4411-ac79-e0939da4bdc7" xlink:href="cvs-20221231.xsd#cvs_HeartlandHealthcareServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6dfedea2-53b3-4139-8879-c57862b96697" xlink:to="loc_cvs_HeartlandHealthcareServicesMember_ff0e643d-7b04-4411-ac79-e0939da4bdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_92c189c5-3c12-48e0-85a5-af412e1e08c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_srt_LitigationCaseAxis_92c189c5-3c12-48e0-85a5-af412e1e08c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2d37e8ff-f213-40a6-9eca-9d9645d4dd3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_92c189c5-3c12-48e0-85a5-af412e1e08c3" xlink:to="loc_srt_LitigationCaseTypeDomain_2d37e8ff-f213-40a6-9eca-9d9645d4dd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_fea8d057-9852-46db-a26b-281fb18add4f" xlink:href="cvs-20221231.xsd#cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2d37e8ff-f213-40a6-9eca-9d9645d4dd3a" xlink:to="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_fea8d057-9852-46db-a26b-281fb18add4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_803cfe1a-d3f5-422d-9372-b56d1a185c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_us-gaap_LitigationStatusAxis_803cfe1a-d3f5-422d-9372-b56d1a185c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_1b9251d7-cea4-4c72-b34d-28604e1807a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_803cfe1a-d3f5-422d-9372-b56d1a185c15" xlink:to="loc_us-gaap_LitigationStatusDomain_1b9251d7-cea4-4c72-b34d-28604e1807a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_499e6e95-3c78-4d1a-aa6a-b24bdcd6dfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_1b9251d7-cea4-4c72-b34d-28604e1807a4" xlink:to="loc_us-gaap_SettledLitigationMember_499e6e95-3c78-4d1a-aa6a-b24bdcd6dfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6bb7d09a-be8d-4432-a175-0ebc998f7f99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_srt_StatementScenarioAxis_6bb7d09a-be8d-4432-a175-0ebc998f7f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9a3d0c4d-09ae-44d1-af3e-9faaf04b05c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_6bb7d09a-be8d-4432-a175-0ebc998f7f99" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9a3d0c4d-09ae-44d1-af3e-9faaf04b05c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ce3b149d-f818-48ab-81f3-7263224e3335" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9a3d0c4d-09ae-44d1-af3e-9faaf04b05c2" xlink:to="loc_srt_ScenarioForecastMember_ce3b149d-f818-48ab-81f3-7263224e3335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_986a36c9-be45-4b29-bddd-36cd66a9ce71" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_ec25cc26-c7b3-4b2c-91f7-10c15f4fc2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStores"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_NumberOfStores_ec25cc26-c7b3-4b2c-91f7-10c15f4fc2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfWalkInMedicalClinics_4407e0c5-20b7-47ea-8067-84f9ce1e3d74" xlink:href="cvs-20221231.xsd#cvs_NumberOfWalkInMedicalClinics"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfWalkInMedicalClinics_4407e0c5-20b7-47ea-8067-84f9ce1e3d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfPharmacyPlanMembers_5107c7c2-08bc-4e97-8048-2ac4ea74637b" xlink:href="cvs-20221231.xsd#cvs_NumberOfPharmacyPlanMembers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfPharmacyPlanMembers_5107c7c2-08bc-4e97-8048-2ac4ea74637b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfPatientsServedPerYear_62f082ac-823d-45d3-821a-66108812cf96" xlink:href="cvs-20221231.xsd#cvs_NumberOfPatientsServedPerYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfPatientsServedPerYear_62f082ac-823d-45d3-821a-66108812cf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfPeopleServed_480a7a4e-859f-4533-8e25-ca5359020ce7" xlink:href="cvs-20221231.xsd#cvs_NumberOfPeopleServed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfPeopleServed_480a7a4e-859f-4533-8e25-ca5359020ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_621e8d36-0825-4839-884c-1fd852c4ea09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_NumberOfReportableSegments_621e8d36-0825-4839-884c-1fd852c4ea09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates_70624883-4d98-4b58-a6bf-32063b98a507" xlink:href="cvs-20221231.xsd#cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates_70624883-4d98-4b58-a6bf-32063b98a507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates_eb85c638-90c0-409d-8095-0ed62cab0c31" xlink:href="cvs-20221231.xsd#cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates_eb85c638-90c0-409d-8095-0ed62cab0c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredPolicyAcquisitionCosts_baa69418-bc0c-4fcb-9691-46a3a28a33df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredPolicyAcquisitionCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_DeferredPolicyAcquisitionCosts_baa69418-bc0c-4fcb-9691-46a3a28a33df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f94167a8-078f-4b42-a2a8-c20fc1f8d268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f94167a8-078f-4b42-a2a8-c20fc1f8d268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_77740db8-a9d9-4b82-9e2c-17c889c42129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_Depreciation_77740db8-a9d9-4b82-9e2c-17c889c42129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OfficeRealEstateOptimizationCharges_3583b334-c247-4ca5-b99c-8ab26a7e74bf" xlink:href="cvs-20221231.xsd#cvs_OfficeRealEstateOptimizationCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_OfficeRealEstateOptimizationCharges_3583b334-c247-4ca5-b99c-8ab26a7e74bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_eafcfc89-f9aa-4b5a-b7b1-2ddb7f0780af" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_StoreImpairmentCharges_eafcfc89-f9aa-4b5a-b7b1-2ddb7f0780af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm_93ea0039-0e4f-48c2-8d1e-90ebf0fe9555" xlink:href="cvs-20221231.xsd#cvs_LesseeOperatingAndFinanceLeasesRenewalTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm_93ea0039-0e4f-48c2-8d1e-90ebf0fe9555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresPlannedClosure_8d9e0b00-6dac-4f2b-92cc-c7110cf22293" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresPlannedClosure"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_NumberOfStoresPlannedClosure_8d9e0b00-6dac-4f2b-92cc-c7110cf22293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_db83760a-e39c-4229-915a-72b9aceddb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_db83760a-e39c-4229-915a-72b9aceddb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7a096894-a7b4-4235-a3bb-ed6296754e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7a096894-a7b4-4235-a3bb-ed6296754e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid_f84d9fe9-cc7d-4dcb-8935-233a7610888b" xlink:href="cvs-20221231.xsd#cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid_f84d9fe9-cc7d-4dcb-8935-233a7610888b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LiabilityForUnpaidClaims_efb7aaf3-21cf-48c3-b9dd-13cc2fa09488" xlink:href="cvs-20221231.xsd#cvs_LiabilityForUnpaidClaims"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_LiabilityForUnpaidClaims_efb7aaf3-21cf-48c3-b9dd-13cc2fa09488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LimitedPaymentsContracts_760568d0-28a4-49f7-9dac-4984ec2e184f" xlink:href="cvs-20221231.xsd#cvs_LimitedPaymentsContracts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_LimitedPaymentsContracts_760568d0-28a4-49f7-9dac-4984ec2e184f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts_3bb2854d-fc7d-453d-b675-6eb74e946e2f" xlink:href="cvs-20221231.xsd#cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts_3bb2854d-fc7d-453d-b675-6eb74e946e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_d5b39ee5-2677-4352-8184-5e50fe7decc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_d5b39ee5-2677-4352-8184-5e50fe7decc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumDeficiencyReserveLiability_038819a4-f909-4895-9f49-6d017fb56852" xlink:href="cvs-20221231.xsd#cvs_PremiumDeficiencyReserveLiability"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_PremiumDeficiencyReserveLiability_038819a4-f909-4895-9f49-6d017fb56852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PensionAndAnnuityInvestmentContractsInterest_740ea4c5-e1d4-4797-9ded-7a7b968cb926" xlink:href="cvs-20221231.xsd#cvs_PensionAndAnnuityInvestmentContractsInterest"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_PensionAndAnnuityInvestmentContractsInterest_740ea4c5-e1d4-4797-9ded-7a7b968cb926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HeathSavingsAccountBalance_64c0793c-1409-45fb-b6d4-232ef02928ca" xlink:href="cvs-20221231.xsd#cvs_HeathSavingsAccountBalance"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_HeathSavingsAccountBalance_64c0793c-1409-45fb-b6d4-232ef02928ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_03d8efd5-900d-4b15-a0a1-f5282878858c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_SelfInsuranceReserve_03d8efd5-900d-4b15-a0a1-f5282878858c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyRebatePeriod_d9d570be-f1ce-4606-ba5f-6105c5211c1d" xlink:href="cvs-20221231.xsd#cvs_PharmacyRebatePeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_PharmacyRebatePeriod_d9d570be-f1ce-4606-ba5f-6105c5211c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthInsurerFee_9b39251e-b493-4cda-b3f6-cba9bd2fdc78" xlink:href="cvs-20221231.xsd#cvs_HealthInsurerFee"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_HealthInsurerFee_9b39251e-b493-4cda-b3f6-cba9bd2fdc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_c6843ef7-3436-4796-9ab6-bbfa30ddba0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_c6843ef7-3436-4796-9ab6-bbfa30ddba0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_bd3c8b0a-383f-4ff3-b71d-c25898344e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_bd3c8b0a-383f-4ff3-b71d-c25898344e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_2cbbf8dc-c747-462a-a666-e7ac1be1efef" xlink:href="cvs-20221231.xsd#cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_2cbbf8dc-c747-462a-a666-e7ac1be1efef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax_f09adadf-5a11-4a98-8af9-ffe81e0a1943" xlink:href="cvs-20221231.xsd#cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax_f09adadf-5a11-4a98-8af9-ffe81e0a1943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_0918b061-bb60-4cf7-897a-86db5ec1b3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_AdvertisingExpense_0918b061-bb60-4cf7-897a-86db5ec1b3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8b991190-9bd9-477f-a740-1d554ca970fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8b991190-9bd9-477f-a740-1d554ca970fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TreasuryStockSharesHeldinTrust_0ecc3fbb-2f63-41bb-a6e4-a55fccb6cda9" xlink:href="cvs-20221231.xsd#cvs_TreasuryStockSharesHeldinTrust"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_TreasuryStockSharesHeldinTrust_0ecc3fbb-2f63-41bb-a6e4-a55fccb6cda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_79aef353-eb9d-4538-8b80-1e7a07b26b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_79aef353-eb9d-4538-8b80-1e7a07b26b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_2591ef93-b847-4ab9-8573-af7b56625b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_2591ef93-b847-4ab9-8573-af7b56625b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_563bd82c-273c-4de7-9bbb-89c4084317a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_563bd82c-273c-4de7-9bbb-89c4084317a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity_50ebd8cb-4762-47ba-a6d0-f32e5421b56b" xlink:href="cvs-20221231.xsd#cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1fa4d61c-8d4d-425d-bddd-3c38359cfe23" xlink:to="loc_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity_50ebd8cb-4762-47ba-a6d0-f32e5421b56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_61928d65-64bc-44be-bfb2-a6dba015d5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3cbe515c-b276-4bbc-bab6-662cdff2fc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61928d65-64bc-44be-bfb2-a6dba015d5aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3cbe515c-b276-4bbc-bab6-662cdff2fc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_6a4fea3e-048a-4439-a35f-56924536f9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61928d65-64bc-44be-bfb2-a6dba015d5aa" xlink:to="loc_us-gaap_RestrictedCashCurrent_6a4fea3e-048a-4439-a35f-56924536f9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3de652b4-0b02-491b-86dc-afb07e595e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61928d65-64bc-44be-bfb2-a6dba015d5aa" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3de652b4-0b02-491b-86dc-afb07e595e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1ffd3cd-2fcb-4f6c-94e4-4cccd7143bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61928d65-64bc-44be-bfb2-a6dba015d5aa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1ffd3cd-2fcb-4f6c-94e4-4cccd7143bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_331d16fe-cf61-417b-9376-5b84f5abd654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_79bede7e-de44-44f6-bf2c-c4ddc61bb0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331d16fe-cf61-417b-9376-5b84f5abd654" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_79bede7e-de44-44f6-bf2c-c4ddc61bb0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2402bb42-597f-4e05-b0aa-b62d078e9be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_79bede7e-de44-44f6-bf2c-c4ddc61bb0d6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2402bb42-597f-4e05-b0aa-b62d078e9be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4a59a216-1b26-4690-8b75-c4e2fcfde34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2402bb42-597f-4e05-b0aa-b62d078e9be6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4a59a216-1b26-4690-8b75-c4e2fcfde34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_0c265047-508d-403e-aea5-4be370482da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4a59a216-1b26-4690-8b75-c4e2fcfde34e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_0c265047-508d-403e-aea5-4be370482da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_79bede7e-de44-44f6-bf2c-c4ddc61bb0d6" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_feac6fa6-a544-426d-aa85-ada1983b1a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_feac6fa6-a544-426d-aa85-ada1983b1a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VendorandManufacturerReceivables_7a4e9c4d-ff8a-4a9b-a38a-bfc05853fdba" xlink:href="cvs-20221231.xsd#cvs_VendorandManufacturerReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_cvs_VendorandManufacturerReceivables_7a4e9c4d-ff8a-4a9b-a38a-bfc05853fdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue_f5f6e132-613e-430e-8847-6927b4609d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_us-gaap_PremiumsReceivableAtCarryingValue_f5f6e132-613e-430e-8847-6927b4609d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_58ecb06e-9d66-48ef-9b57-5e9638a7a502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_58ecb06e-9d66-48ef-9b57-5e9638a7a502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_c0b304e1-fc44-4090-97f9-e8166758050c" xlink:href="cvs-20221231.xsd#cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale_c0b304e1-fc44-4090-97f9-e8166758050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e77c7630-3554-4f18-9fc7-e58e410c5f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_857f60c7-a436-4827-b0f7-cc7d130c7560" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e77c7630-3554-4f18-9fc7-e58e410c5f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_86163db1-5d5b-49ba-9839-3c38fc212f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db8a5c17-c50e-4115-b4b2-4b6bb4054a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_86163db1-5d5b-49ba-9839-3c38fc212f46" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db8a5c17-c50e-4115-b4b2-4b6bb4054a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5fba793-7bda-4750-9c3e-9b02bd3e8436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db8a5c17-c50e-4115-b4b2-4b6bb4054a19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5fba793-7bda-4750-9c3e-9b02bd3e8436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5fba793-7bda-4750-9c3e-9b02bd3e8436" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3ff5260f-e627-493e-9ac7-c56c6e577c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_LandMember_3ff5260f-e627-493e-9ac7-c56c6e577c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_79b58589-1b69-4e69-95d7-f3f9f4351646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_79b58589-1b69-4e69-95d7-f3f9f4351646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_df3d5f3b-0017-478b-9aef-f86505f5dca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_df3d5f3b-0017-478b-9aef-f86505f5dca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bc73f6b4-932e-41a1-8794-7b486dfd9863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bc73f6b4-932e-41a1-8794-7b486dfd9863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d69b2495-089a-47a8-afe9-47c4b3273752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88c90152-dc83-452b-8125-18cb385f6582" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d69b2495-089a-47a8-afe9-47c4b3273752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c71b4cd5-7829-468a-b929-98a6c99e452f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db8a5c17-c50e-4115-b4b2-4b6bb4054a19" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c71b4cd5-7829-468a-b929-98a6c99e452f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c4836e56-51d4-45f1-a559-554995c7479e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c71b4cd5-7829-468a-b929-98a6c99e452f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c4836e56-51d4-45f1-a559-554995c7479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_936ca3bd-759b-4c28-b373-19c33908d996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c4836e56-51d4-45f1-a559-554995c7479e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_936ca3bd-759b-4c28-b373-19c33908d996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db8a5c17-c50e-4115-b4b2-4b6bb4054a19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_79f4c34e-ff1d-47ce-8e41-1661f9010257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_79f4c34e-ff1d-47ce-8e41-1661f9010257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4d7175a9-ae70-4245-9190-59d0635426b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4d7175a9-ae70-4245-9190-59d0635426b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_191ec090-c0fa-4c68-b9a8-ab2519f55e87" xlink:href="cvs-20221231.xsd#cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_76df68e1-791c-473f-ba95-168e3fcdf25c" xlink:to="loc_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale_191ec090-c0fa-4c68-b9a8-ab2519f55e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_75194d1b-865b-44cb-bb6b-1bc8f3347aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75194d1b-865b-44cb-bb6b-1bc8f3347aad" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_6223e70a-3c83-4756-a531-2a8b3d17af3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:to="loc_srt_ConsolidationItemsAxis_6223e70a-3c83-4756-a531-2a8b3d17af3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_6223e70a-3c83-4756-a531-2a8b3d17af3b" xlink:to="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ec565f21-13fe-4525-bfb2-7efb9739a566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:to="loc_us-gaap_OperatingSegmentsMember_ec565f21-13fe-4525-bfb2-7efb9739a566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c24d892b-684a-4921-9d8d-7d6d8464a111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c24d892b-684a-4921-9d8d-7d6d8464a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_3f385f49-dd4e-4445-86fe-1b43e1858c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7a3ab8d5-8d6c-4ba7-b67b-100db3aa0c18" xlink:to="loc_us-gaap_IntersegmentEliminationMember_3f385f49-dd4e-4445-86fe-1b43e1858c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_70aad851-507c-46dd-91d5-91218b000134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_70aad851-507c-46dd-91d5-91218b000134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_70aad851-507c-46dd-91d5-91218b000134" xlink:to="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_aade3176-9612-41b5-a0b9-67433dcc28ab" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_aade3176-9612-41b5-a0b9-67433dcc28ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyServicesSegmentMember_e9e878dc-a39f-4b6b-bc8e-bd54622af1e1" xlink:href="cvs-20221231.xsd#cvs_PharmacyServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:to="loc_cvs_PharmacyServicesSegmentMember_e9e878dc-a39f-4b6b-bc8e-bd54622af1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_7a646baa-5f10-4664-969c-7307eca13e0c" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9d1fc5fc-98a4-4fc2-b2d4-55a469091c40" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_7a646baa-5f10-4664-969c-7307eca13e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f642ee72-5c85-4264-a657-2372ce85298a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:to="loc_srt_ProductOrServiceAxis_f642ee72-5c85-4264-a657-2372ce85298a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f642ee72-5c85-4264-a657-2372ce85298a" xlink:to="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyRevenueMember_0891c6c7-028d-4354-926b-999049371600" xlink:href="cvs-20221231.xsd#cvs_PharmacyRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:to="loc_cvs_PharmacyRevenueMember_0891c6c7-028d-4354-926b-999049371600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FrontStoreRevenueMember_79e0c4d1-a7cc-4a29-aa1f-522105bd24d2" xlink:href="cvs-20221231.xsd#cvs_FrontStoreRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:to="loc_cvs_FrontStoreRevenueMember_79e0c4d1-a7cc-4a29-aa1f-522105bd24d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumsMember_638b36ff-3ba2-48a6-bf7b-0f413cf84c51" xlink:href="cvs-20221231.xsd#cvs_PremiumsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:to="loc_cvs_PremiumsMember_638b36ff-3ba2-48a6-bf7b-0f413cf84c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_780a2d39-a79a-4e1f-8adf-f065552fec75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f3a2b599-ca42-4778-a9d8-e62779bc7920" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_780a2d39-a79a-4e1f-8adf-f065552fec75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_e62c83e6-179a-4e41-aa3a-6304d2fabd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_e62c83e6-179a-4e41-aa3a-6304d2fabd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_e62c83e6-179a-4e41-aa3a-6304d2fabd14" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_292cd083-aba8-404f-b62f-46dfda7badc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_292cd083-aba8-404f-b62f-46dfda7badc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_51006727-cd0b-4a24-8e78-15ef64a68cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_51006727-cd0b-4a24-8e78-15ef64a68cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SalesChannelOtherMember_d2772e15-62a5-4e40-8fc8-83dfa0204aa1" xlink:href="cvs-20221231.xsd#cvs_SalesChannelOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_930d7e63-cbfb-4f89-b947-6f934a7033ed" xlink:to="loc_cvs_SalesChannelOtherMember_d2772e15-62a5-4e40-8fc8-83dfa0204aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_15a733ac-0c54-453f-b79a-7d4f583f40fb" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_220f4f78-38db-410a-b6ce-37870e4a3dcf" xlink:href="cvs-20221231.xsd#cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:to="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_220f4f78-38db-410a-b6ce-37870e4a3dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_b34f8343-d020-47a8-960c-26c992bf2fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:to="loc_us-gaap_NetInvestmentIncome_b34f8343-d020-47a8-960c-26c992bf2fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_106b219a-cb43-4dcb-a994-888f47ff6b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_753a9d49-0615-4c0b-89cd-0c4662822240" xlink:to="loc_us-gaap_Revenues_106b219a-cb43-4dcb-a994-888f47ff6b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesReceivablesandContractedBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e3dd7f6a-79e9-43c0-a2a0-f8b133577750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_a074606f-026b-4f33-805a-f1aeac614710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e3dd7f6a-79e9-43c0-a2a0-f8b133577750" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_a074606f-026b-4f33-805a-f1aeac614710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a43dd896-0dab-4801-84f6-e36be8bf7330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e3dd7f6a-79e9-43c0-a2a0-f8b133577750" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a43dd896-0dab-4801-84f6-e36be8bf7330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_37dccb15-f17b-47dc-a11c-68919b4d80cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_52a3a6cf-0d99-4450-b2cc-d8166ad4dcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37dccb15-f17b-47dc-a11c-68919b4d80cd" xlink:to="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_52a3a6cf-0d99-4450-b2cc-d8166ad4dcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ChangeInContractWithCustomerLiabilityRollForward_432cea58-7a62-4025-bd6e-8d7326621de4" xlink:href="cvs-20221231.xsd#cvs_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_52a3a6cf-0d99-4450-b2cc-d8166ad4dcbd" xlink:to="loc_cvs_ChangeInContractWithCustomerLiabilityRollForward_432cea58-7a62-4025-bd6e-8d7326621de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_91a6533f-7f05-4816-964e-d0e2fd6d3cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInContractWithCustomerLiabilityRollForward_432cea58-7a62-4025-bd6e-8d7326621de4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_91a6533f-7f05-4816-964e-d0e2fd6d3cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance_e76757b4-2ef9-4641-a323-fbd4566767c2" xlink:href="cvs-20221231.xsd#cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInContractWithCustomerLiabilityRollForward_432cea58-7a62-4025-bd6e-8d7326621de4" xlink:to="loc_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance_e76757b4-2ef9-4641-a323-fbd4566767c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage_91970552-0431-48df-83f3-0ab410f566d8" xlink:href="cvs-20221231.xsd#cvs_ContractWithCustomerLiabilityRedemptionAndBreakage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInContractWithCustomerLiabilityRollForward_432cea58-7a62-4025-bd6e-8d7326621de4" xlink:to="loc_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage_91970552-0431-48df-83f3-0ab410f566d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_036e7a12-723a-4361-acd9-194654e421ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_ChangeInContractWithCustomerLiabilityRollForward_432cea58-7a62-4025-bd6e-8d7326621de4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_036e7a12-723a-4361-acd9-194654e421ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b99a11ae-5b7a-44e3-b557-bb905fa67456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b99a11ae-5b7a-44e3-b557-bb905fa67456" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3f2cb660-00cb-42a8-b500-241f7e797c1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3f2cb660-00cb-42a8-b500-241f7e797c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2ab1369b-f339-45dd-ba12-a35198046084" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3f2cb660-00cb-42a8-b500-241f7e797c1b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2ab1369b-f339-45dd-ba12-a35198046084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_d2f7024c-679a-449f-9280-e09785c042e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2ab1369b-f339-45dd-ba12-a35198046084" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_d2f7024c-679a-449f-9280-e09785c042e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5f2814ff-bc81-4fad-8308-818fa7261cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:to="loc_us-gaap_InvestmentTypeAxis_5f2814ff-bc81-4fad-8308-818fa7261cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_5f2814ff-bc81-4fad-8308-818fa7261cae" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_fec925fa-ac9a-4ec2-baad-7fb54bcdb7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:to="loc_us-gaap_HedgeFundsMember_fec925fa-ac9a-4ec2-baad-7fb54bcdb7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_e8d0cebd-2bd9-4dd3-b61d-100c2e6d13ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:to="loc_us-gaap_PrivateEquityFundsMember_e8d0cebd-2bd9-4dd3-b61d-100c2e6d13ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateFundsMember_c0089b4f-e5f8-4d8c-822e-da5888cf2433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstateFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d831d4ca-9f3d-4916-967b-5ff9e789405a" xlink:to="loc_us-gaap_RealEstateFundsMember_c0089b4f-e5f8-4d8c-822e-da5888cf2433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8cd032a1-9469-4bfa-b571-71d2ba7146e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8cd032a1-9469-4bfa-b571-71d2ba7146e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f4cc09a0-37ed-4cad-9c91-cdb28afa5ed6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8cd032a1-9469-4bfa-b571-71d2ba7146e8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f4cc09a0-37ed-4cad-9c91-cdb28afa5ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RedOakMember_54538fa8-e516-4a86-8659-b51251b4ee1c" xlink:href="cvs-20221231.xsd#cvs_RedOakMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f4cc09a0-37ed-4cad-9c91-cdb28afa5ed6" xlink:to="loc_cvs_RedOakMember_54538fa8-e516-4a86-8659-b51251b4ee1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_56bfaaf3-fbab-4c6f-9470-e191f6f28824" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_95600714-1aed-489c-9335-5181f4c9f193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_95600714-1aed-489c-9335-5181f4c9f193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InitialContractualTerm_44f167b5-2203-480e-abda-a6784fb7ac56" xlink:href="cvs-20221231.xsd#cvs_InitialContractualTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_cvs_InitialContractualTerm_44f167b5-2203-480e-abda-a6784fb7ac56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VariableInterestEntityAmendedContractExtensionTerm_9437a710-4ded-405b-ab42-63e5a90eebd7" xlink:href="cvs-20221231.xsd#cvs_VariableInterestEntityAmendedContractExtensionTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_cvs_VariableInterestEntityAmendedContractExtensionTerm_9437a710-4ded-405b-ab42-63e5a90eebd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VariableInterestEntityAmendedContractTerm_48b2eee0-cc9c-4d6a-a745-7853eb1fbc72" xlink:href="cvs-20221231.xsd#cvs_VariableInterestEntityAmendedContractTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_cvs_VariableInterestEntityAmendedContractTerm_48b2eee0-cc9c-4d6a-a745-7853eb1fbc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ProceedsFromVariableInterestEntity_d5a26d13-7f91-4fac-a5de-5be90edf57f9" xlink:href="cvs-20221231.xsd#cvs_ProceedsFromVariableInterestEntity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_cvs_ProceedsFromVariableInterestEntity_d5a26d13-7f91-4fac-a5de-5be90edf57f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_6352f7ab-03b3-4ebf-80b2-796504610a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ef7e02b5-78b0-4b84-b095-36f21cccf16f" xlink:to="loc_us-gaap_LongTermInvestments_6352f7ab-03b3-4ebf-80b2-796504610a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2addd936-6a14-4967-8621-af0debae2f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c14f9fcf-e57e-4c1c-8caa-2d6e38f91b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2addd936-6a14-4967-8621-af0debae2f1e" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c14f9fcf-e57e-4c1c-8caa-2d6e38f91b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_d1c003e0-868d-435c-afd7-1cea5347eed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2addd936-6a14-4967-8621-af0debae2f1e" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_d1c003e0-868d-435c-afd7-1cea5347eed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_258b13fd-1aae-4b99-a103-fbc6fc4fde4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2addd936-6a14-4967-8621-af0debae2f1e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_258b13fd-1aae-4b99-a103-fbc6fc4fde4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6344303c-04cc-4f1d-bd28-6988a24802ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6344303c-04cc-4f1d-bd28-6988a24802ee" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68c1fa73-b956-4148-a121-905287844aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68c1fa73-b956-4148-a121-905287844aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a2694e7f-d95d-4303-bf09-cef1eb223547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_68c1fa73-b956-4148-a121-905287844aad" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a2694e7f-d95d-4303-bf09-cef1eb223547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201812Member_aff5d686-037c-4d0a-8ded-b8b5dd315ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201812Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a2694e7f-d95d-4303-bf09-cef1eb223547" xlink:to="loc_us-gaap_AccountingStandardsUpdate201812Member_aff5d686-037c-4d0a-8ded-b8b5dd315ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_647877bb-f387-4cf5-80e6-0c30f9de9b64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_647877bb-f387-4cf5-80e6-0c30f9de9b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c8279535-5833-476a-a541-0b8084acbbfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_647877bb-f387-4cf5-80e6-0c30f9de9b64" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c8279535-5833-476a-a541-0b8084acbbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f5d957c0-e163-4961-9d2a-515d499257da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c8279535-5833-476a-a541-0b8084acbbfa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f5d957c0-e163-4961-9d2a-515d499257da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f2f75f96-1d0e-4a37-8545-7c3230e6b214" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:to="loc_srt_StatementScenarioAxis_f2f75f96-1d0e-4a37-8545-7c3230e6b214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_37fa68c8-7a93-4eed-8115-7bfcac002230" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f2f75f96-1d0e-4a37-8545-7c3230e6b214" xlink:to="loc_srt_ScenarioUnspecifiedDomain_37fa68c8-7a93-4eed-8115-7bfcac002230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_34413dc0-ecda-435d-b827-488df75d2b6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_37fa68c8-7a93-4eed-8115-7bfcac002230" xlink:to="loc_srt_ScenarioForecastMember_34413dc0-ecda-435d-b827-488df75d2b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3c1ca155-c79a-4251-a621-d562c6d2dc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f7f6a96a-cb57-438f-b815-d8afdd227bef" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3c1ca155-c79a-4251-a621-d562c6d2dc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2ab1ebf1-070b-4278-b338-a91c59eec68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3c1ca155-c79a-4251-a621-d562c6d2dc5c" xlink:to="loc_us-gaap_StatementOfFinancialPositionAbstract_2ab1ebf1-070b-4278-b338-a91c59eec68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_eda271a0-0934-4301-83bd-3657b35c7e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ab1ebf1-070b-4278-b338-a91c59eec68a" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_eda271a0-0934-4301-83bd-3657b35c7e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#AcquisitionsDivestituresandAssetSalesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_acf8706b-e4e8-444f-8ecd-3cc93560c33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_acf8706b-e4e8-444f-8ecd-3cc93560c33f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b7d6d34d-f357-4fcb-a1e0-b529a2401e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b7d6d34d-f357-4fcb-a1e0-b529a2401e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b7d6d34d-f357-4fcb-a1e0-b529a2401e04" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_c3e3a207-aaf2-4bf1-a608-6e3cf0ca7881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_c3e3a207-aaf2-4bf1-a608-6e3cf0ca7881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b663b9d9-1571-44c0-bf69-9d705da92a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b663b9d9-1571-44c0-bf69-9d705da92a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1cbec5ed-a6bf-4316-b206-a6ad324612d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_197e10d5-881f-475c-be15-168af6b13bc3" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1cbec5ed-a6bf-4316-b206-a6ad324612d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f9ec40e1-7f0c-48e6-bd0c-48ac35c2b4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f9ec40e1-7f0c-48e6-bd0c-48ac35c2b4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f9ec40e1-7f0c-48e6-bd0c-48ac35c2b4a7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OmnicareLongTermCareBusinessMember_4281e646-0420-4d1d-8e26-443f05519f54" xlink:href="cvs-20221231.xsd#cvs_OmnicareLongTermCareBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_OmnicareLongTermCareBusinessMember_4281e646-0420-4d1d-8e26-443f05519f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BswiftLLCMember_01f4483f-e610-4caf-bf45-fecb2a542f9e" xlink:href="cvs-20221231.xsd#cvs_BswiftLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_BswiftLLCMember_01f4483f-e610-4caf-bf45-fecb2a542f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PayflexMember_971949b3-e91c-47ee-96b2-f14e37350b50" xlink:href="cvs-20221231.xsd#cvs_PayflexMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_PayflexMember_971949b3-e91c-47ee-96b2-f14e37350b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ThailandBusinessMember_62eb64a7-7156-43ae-80de-53fb0106455c" xlink:href="cvs-20221231.xsd#cvs_ThailandBusinessMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_ThailandBusinessMember_62eb64a7-7156-43ae-80de-53fb0106455c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InternationalHealthCareRenewalRightsMember_ccf62822-015b-4678-87b9-efbd6299e793" xlink:href="cvs-20221231.xsd#cvs_InternationalHealthCareRenewalRightsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_InternationalHealthCareRenewalRightsMember_ccf62822-015b-4678-87b9-efbd6299e793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CoventryHealthCareWorkersCompensationBusinessMember_5959e2b2-f110-4875-9193-4eceb4b9973d" xlink:href="cvs-20221231.xsd#cvs_CoventryHealthCareWorkersCompensationBusinessMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c7422f95-187f-41f6-8d6c-fc4593bbfb34" xlink:to="loc_cvs_CoventryHealthCareWorkersCompensationBusinessMember_5959e2b2-f110-4875-9193-4eceb4b9973d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_68f22357-f58b-466b-b5bb-4efea074a813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_68f22357-f58b-466b-b5bb-4efea074a813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5651ec81-60c0-420d-bc8f-3f9b43840a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_68f22357-f58b-466b-b5bb-4efea074a813" xlink:to="loc_us-gaap_SegmentDomain_5651ec81-60c0-420d-bc8f-3f9b43840a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_fed3a96d-0a3f-4352-b0c1-82423a126d0f" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5651ec81-60c0-420d-bc8f-3f9b43840a5f" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_fed3a96d-0a3f-4352-b0c1-82423a126d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_9ee711da-ba1a-4193-96ee-9a032e563358" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5651ec81-60c0-420d-bc8f-3f9b43840a5f" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_9ee711da-ba1a-4193-96ee-9a032e563358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fdf00213-9dbb-4f20-b65b-5e37c853cd78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fdf00213-9dbb-4f20-b65b-5e37c853cd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1140820-8371-4603-8e8e-521dee983963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fdf00213-9dbb-4f20-b65b-5e37c853cd78" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1140820-8371-4603-8e8e-521dee983963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OakStreetHealthIncMember_4f96655b-4d65-489c-8613-3d147bd201eb" xlink:href="cvs-20221231.xsd#cvs_OakStreetHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1140820-8371-4603-8e8e-521dee983963" xlink:to="loc_cvs_OakStreetHealthIncMember_4f96655b-4d65-489c-8613-3d147bd201eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SignifyHealthIncMember_1097c308-d674-480a-81b4-6c5361694330" xlink:href="cvs-20221231.xsd#cvs_SignifyHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1140820-8371-4603-8e8e-521dee983963" xlink:to="loc_cvs_SignifyHealthIncMember_1097c308-d674-480a-81b4-6c5361694330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f0798d55-bbb7-4161-b8e9-527dba24dbe2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_dei_LegalEntityAxis_f0798d55-bbb7-4161-b8e9-527dba24dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5bfe50b6-69bc-4722-8b2c-b9fea453366b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f0798d55-bbb7-4161-b8e9-527dba24dbe2" xlink:to="loc_dei_EntityDomain_5bfe50b6-69bc-4722-8b2c-b9fea453366b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OakStreetHealthIncMember_a1a047ba-5e8a-429f-8318-7dba373d37be" xlink:href="cvs-20221231.xsd#cvs_OakStreetHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5bfe50b6-69bc-4722-8b2c-b9fea453366b" xlink:to="loc_cvs_OakStreetHealthIncMember_a1a047ba-5e8a-429f-8318-7dba373d37be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SignifyHealthIncMember_e3cc9e39-16f8-4e2c-8cf8-07cf178909a9" xlink:href="cvs-20221231.xsd#cvs_SignifyHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5bfe50b6-69bc-4722-8b2c-b9fea453366b" xlink:to="loc_cvs_SignifyHealthIncMember_e3cc9e39-16f8-4e2c-8cf8-07cf178909a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_75d158ef-5a51-4b20-a907-564b4de9d15e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_75d158ef-5a51-4b20-a907-564b4de9d15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ec4fb16e-5418-46db-8cdc-268c41ce21f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_75d158ef-5a51-4b20-a907-564b4de9d15e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ec4fb16e-5418-46db-8cdc-268c41ce21f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8a2511bb-381c-43ce-8860-2f073937ee28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ec4fb16e-5418-46db-8cdc-268c41ce21f6" xlink:to="loc_us-gaap_SubsequentEventMember_8a2511bb-381c-43ce-8860-2f073937ee28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ebd13f98-b203-4ab2-acfd-aff77c419def" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_c3229a34-6789-409f-90f8-410e932ca218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_c3229a34-6789-409f-90f8-410e932ca218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_317bc74f-2ddb-414f-97ee-1a404f4ad94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_317bc74f-2ddb-414f-97ee-1a404f4ad94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BusinessCombinationTerminationFee_bcfa13b0-4cdc-44ca-a19b-2afacdf56899" xlink:href="cvs-20221231.xsd#cvs_BusinessCombinationTerminationFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_cvs_BusinessCombinationTerminationFee_bcfa13b0-4cdc-44ca-a19b-2afacdf56899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5a36d8d6-31ab-487b-afce-9180cc1d3f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5a36d8d6-31ab-487b-afce-9180cc1d3f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_55121942-c1f9-4126-8a84-617152088293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_55121942-c1f9-4126-8a84-617152088293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_22536109-4e0a-43b3-98b1-52b146e55166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_22536109-4e0a-43b3-98b1-52b146e55166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfMedicalMembers_d04fdd36-488f-4cd3-a9aa-6598c2341a95" xlink:href="cvs-20221231.xsd#cvs_NumberOfMedicalMembers"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_cvs_NumberOfMedicalMembers_d04fdd36-488f-4cd3-a9aa-6598c2341a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold_cc01c5aa-3e50-44ba-89d7-5964752e6717" xlink:href="cvs-20221231.xsd#cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_add28221-c396-40eb-84f6-9adc64c85d4c" xlink:to="loc_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold_cc01c5aa-3e50-44ba-89d7-5964752e6717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_77a1e188-d059-4e27-b724-4676a4a42970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de0af414-a83f-4c78-b955-b68c2479c49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_77a1e188-d059-4e27-b724-4676a4a42970" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de0af414-a83f-4c78-b955-b68c2479c49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_1f704e5e-453b-4bfc-8558-df9f4de183ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de0af414-a83f-4c78-b955-b68c2479c49d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_1f704e5e-453b-4bfc-8558-df9f4de183ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_598d1707-4673-4d5c-a45b-17f833ca8d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1f704e5e-453b-4bfc-8558-df9f4de183ad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_598d1707-4673-4d5c-a45b-17f833ca8d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e9a41682-db87-401d-91e7-3b75d13a4049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_598d1707-4673-4d5c-a45b-17f833ca8d5d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e9a41682-db87-401d-91e7-3b75d13a4049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b50417e-450d-44f7-b8df-b34797130ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de0af414-a83f-4c78-b955-b68c2479c49d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b50417e-450d-44f7-b8df-b34797130ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b50417e-450d-44f7-b8df-b34797130ea4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_8a706923-5430-4c08-aea4-c366f5e79345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_8a706923-5430-4c08-aea4-c366f5e79345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_9de52735-9cdc-4806-9e97-31e9410b1988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_9de52735-9cdc-4806-9e97-31e9410b1988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_24164d1c-84bd-4a22-bf5e-7b02a994350b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_24164d1c-84bd-4a22-bf5e-7b02a994350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_39e0d09c-30a2-4f3c-8754-7a28f93e979b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_39e0d09c-30a2-4f3c-8754-7a28f93e979b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_cd99d04c-64d8-4181-95a1-ea15ecf18036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_cd99d04c-64d8-4181-95a1-ea15ecf18036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ae1eddfb-bdde-4bee-82d6-40e7e2dc21c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_bb46dc9d-20f3-4d20-9194-632ef09ec0ae" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ae1eddfb-bdde-4bee-82d6-40e7e2dc21c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b50417e-450d-44f7-b8df-b34797130ea4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_8ae1dea6-ff4a-4a0c-8bb2-bd7c8e722eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_8ae1dea6-ff4a-4a0c-8bb2-bd7c8e722eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_56145e81-ab04-4578-af03-6ac6e7452747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_56145e81-ab04-4578-af03-6ac6e7452747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_b5bf3cf3-8d68-4227-b965-8fab3c1b6c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_b5bf3cf3-8d68-4227-b965-8fab3c1b6c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c4c54e8b-8bbe-44f4-bd59-bf5496903f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_beb5f552-c08e-42d3-84b2-9e4ea1a93c71" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c4c54e8b-8bbe-44f4-bd59-bf5496903f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsScheduleofTotalInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_4b07ff35-e9f0-4050-9c98-d6be9155e677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsTable_99ad3763-2f6c-4685-9d1b-e0c895209ae3" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4b07ff35-e9f0-4050-9c98-d6be9155e677" xlink:to="loc_cvs_TotalInvestmentsTable_99ad3763-2f6c-4685-9d1b-e0c895209ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsAxis_e152186d-1129-4673-91a4-77d1c64df493" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsTable_99ad3763-2f6c-4685-9d1b-e0c895209ae3" xlink:to="loc_cvs_TotalInvestmentsAxis_e152186d-1129-4673-91a4-77d1c64df493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsAxis_e152186d-1129-4673-91a4-77d1c64df493" xlink:to="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtAndEquitySecuritiesAvailableForSaleMember_c3b5d5f8-23fd-4037-bbbe-b8b56e4167f3" xlink:href="cvs-20221231.xsd#cvs_DebtAndEquitySecuritiesAvailableForSaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:to="loc_cvs_DebtAndEquitySecuritiesAvailableForSaleMember_c3b5d5f8-23fd-4037-bbbe-b8b56e4167f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansMember_fa6907ad-5ee7-4a10-a7d5-076d8fa14349" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:to="loc_cvs_MortgageLoansMember_fa6907ad-5ee7-4a10-a7d5-076d8fa14349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_85139291-2040-4951-af3a-71a05f8a9109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsDomain_53be5336-72a6-4534-b4a9-183021ef43c3" xlink:to="loc_us-gaap_OtherInvestmentsMember_85139291-2040-4951-af3a-71a05f8a9109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6e9d6b99-734d-4ab3-9c9b-cca77c572fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsTable_99ad3763-2f6c-4685-9d1b-e0c895209ae3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6e9d6b99-734d-4ab3-9c9b-cca77c572fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670cc0d1-42fc-4fb5-bbcd-d122d5a8ebc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6e9d6b99-734d-4ab3-9c9b-cca77c572fb4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670cc0d1-42fc-4fb5-bbcd-d122d5a8ebc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a176caf6-dd0e-477a-9d07-2aebdf181d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670cc0d1-42fc-4fb5-bbcd-d122d5a8ebc2" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a176caf6-dd0e-477a-9d07-2aebdf181d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:href="cvs-20221231.xsd#cvs_TotalInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsTable_99ad3763-2f6c-4685-9d1b-e0c895209ae3" xlink:to="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ec3a6644-e0a5-4831-9c3a-99affa9e4559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:to="loc_us-gaap_ShortTermInvestments_ec3a6644-e0a5-4831-9c3a-99affa9e4559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermInvestmentsIncludingAssetsHeldForSale_e6b7cec1-a86f-46a2-b16d-3282cd875f6a" xlink:href="cvs-20221231.xsd#cvs_LongTermInvestmentsIncludingAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:to="loc_cvs_LongTermInvestmentsIncludingAssetsHeldForSale_e6b7cec1-a86f-46a2-b16d-3282cd875f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_f073e5d7-9e82-488e-a4d2-0e8a02333cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_TotalInvestmentsLineItems_8f8c33ea-714d-41f6-8c8b-f44e61e6adfe" xlink:to="loc_us-gaap_Investments_f073e5d7-9e82-488e-a4d2-0e8a02333cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_3fac0fd3-2d72-4c2e-a731-fff6360c3851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1259664f-5dd3-4fa8-b41a-1d4c575f1b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3fac0fd3-2d72-4c2e-a731-fff6360c3851" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1259664f-5dd3-4fa8-b41a-1d4c575f1b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_dbc7984c-896e-49bb-9bab-8590115a2c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1259664f-5dd3-4fa8-b41a-1d4c575f1b26" xlink:to="loc_us-gaap_FinancialInstrumentAxis_dbc7984c-896e-49bb-9bab-8590115a2c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_dbc7984c-896e-49bb-9bab-8590115a2c4e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_5d10d46d-91b1-4439-bdce-15a565c4d986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_5d10d46d-91b1-4439-bdce-15a565c4d986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_16e39037-2e0b-45fa-b4e7-132a632f0b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_16e39037-2e0b-45fa-b4e7-132a632f0b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_523b3c6b-1059-4f81-8923-d08987641243" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16c2f653-27f8-4840-9c35-d4788716eb2f" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_523b3c6b-1059-4f81-8923-d08987641243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8884c073-1197-4fbc-b20f-7077f3509047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1259664f-5dd3-4fa8-b41a-1d4c575f1b26" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8884c073-1197-4fbc-b20f-7077f3509047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_8b67bbef-7bb6-4f04-9660-db0c5eca3fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8884c073-1197-4fbc-b20f-7077f3509047" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_8b67bbef-7bb6-4f04-9660-db0c5eca3fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities_e4c136b5-a88b-492f-95a8-d8291eec193e" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8884c073-1197-4fbc-b20f-7077f3509047" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities_e4c136b5-a88b-492f-95a8-d8291eec193e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_b9af69c2-d1fa-4c5f-80e3-0e8b2f6c3c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_884ec79d-2d79-4f0d-91fe-4a3736513572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_b9af69c2-d1fa-4c5f-80e3-0e8b2f6c3c26" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_884ec79d-2d79-4f0d-91fe-4a3736513572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4ee0a16-8535-4c1b-bd94-5ac925bcd0ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_884ec79d-2d79-4f0d-91fe-4a3736513572" xlink:to="loc_srt_ProductOrServiceAxis_c4ee0a16-8535-4c1b-bd94-5ac925bcd0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b28e3d35-0fdf-44fa-9a4e-cc65ee165e4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c4ee0a16-8535-4c1b-bd94-5ac925bcd0ca" xlink:to="loc_srt_ProductsAndServicesDomain_b28e3d35-0fdf-44fa-9a4e-cc65ee165e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingExperienceRatedProductsMember_b10ca5d2-7ea8-4e1f-93dd-43841be7b59b" xlink:href="cvs-20221231.xsd#cvs_SupportingExperienceRatedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b28e3d35-0fdf-44fa-9a4e-cc65ee165e4f" xlink:to="loc_cvs_SupportingExperienceRatedProductsMember_b10ca5d2-7ea8-4e1f-93dd-43841be7b59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a2f9fbc4-2997-4893-bcfb-73016065abe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_884ec79d-2d79-4f0d-91fe-4a3736513572" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a2f9fbc4-2997-4893-bcfb-73016065abe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32771d08-adcd-411f-9d87-3463ea224450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a2f9fbc4-2997-4893-bcfb-73016065abe3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32771d08-adcd-411f-9d87-3463ea224450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32771d08-adcd-411f-9d87-3463ea224450" xlink:to="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f41331ac-8c67-43a7-ab21-b45c2ed070d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f41331ac-8c67-43a7-ab21-b45c2ed070d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_4dd6462c-7df9-4346-bc4b-1a5d85803613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_4dd6462c-7df9-4346-bc4b-1a5d85803613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_6c82ecd6-49b5-4ba8-aba4-bf6d3d534ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_6c82ecd6-49b5-4ba8-aba4-bf6d3d534ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_27a7d7cb-c407-4865-bbd1-7953e6d8327f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_27a7d7cb-c407-4865-bbd1-7953e6d8327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_9d7f78ca-eb95-4f4e-a6b0-43cd0139015c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_9d7f78ca-eb95-4f4e-a6b0-43cd0139015c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_563b8188-79b7-440c-9df3-e36826f60fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_563b8188-79b7-440c-9df3-e36826f60fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_93225481-27f6-4921-a42e-55b143fc881d" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_93225481-27f6-4921-a42e-55b143fc881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_de33339e-d72b-4e80-9216-b599e12b451d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_e702dc74-1bb4-4f5f-b769-c134899df35b" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_de33339e-d72b-4e80-9216-b599e12b451d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_884ec79d-2d79-4f0d-91fe-4a3736513572" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c7a0a71b-f053-4239-8ae2-dbc0ac70c037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c7a0a71b-f053-4239-8ae2-dbc0ac70c037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ba6918a3-ef7b-4805-81d5-e826ec6a5e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ba6918a3-ef7b-4805-81d5-e826ec6a5e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_fe244a81-0d2b-4d36-b13e-59d622ebaaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_fe244a81-0d2b-4d36-b13e-59d622ebaaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5c8dfd4e-39b2-48fa-81eb-221022b02c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5c8dfd4e-39b2-48fa-81eb-221022b02c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16e7dd0f-5821-4408-825d-48f2cd8caf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16e7dd0f-5821-4408-825d-48f2cd8caf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_582b200f-0f7a-4e91-9ce9-565cf572a3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a2caa414-46c1-4b61-b5c3-d560c3f95a4c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_582b200f-0f7a-4e91-9ce9-565cf572a3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsDebtSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsDebtSecuritiesbyMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_3c07f7b6-1f5e-4f35-a5e3-013adaca7387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7dc4226c-9774-48e0-aaa3-feec540736a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3c07f7b6-1f5e-4f35-a5e3-013adaca7387" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7dc4226c-9774-48e0-aaa3-feec540736a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4aff6eec-6fc3-4d15-b5bf-eec2e6105883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7dc4226c-9774-48e0-aaa3-feec540736a7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4aff6eec-6fc3-4d15-b5bf-eec2e6105883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4aff6eec-6fc3-4d15-b5bf-eec2e6105883" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_008da850-1745-4983-9db6-3346c4617a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_008da850-1745-4983-9db6-3346c4617a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_f46ef2f7-0fe1-4412-9cbc-029d8ce26352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_f46ef2f7-0fe1-4412-9cbc-029d8ce26352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_13ed2bb3-c0b9-4048-8bfc-e764966c095f" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_867edcf8-99c2-48dc-8322-bb10162737e1" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_13ed2bb3-c0b9-4048-8bfc-e764966c095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eea182a3-ef77-445b-bb28-a2cfd8532de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7dc4226c-9774-48e0-aaa3-feec540736a7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eea182a3-ef77-445b-bb28-a2cfd8532de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eea182a3-ef77-445b-bb28-a2cfd8532de1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_202c0cef-b18c-4642-92f1-55b5e984e6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_202c0cef-b18c-4642-92f1-55b5e984e6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_715a59fb-ebb8-4e21-9edc-ac7cad8535e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_715a59fb-ebb8-4e21-9edc-ac7cad8535e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_a4c75b04-7ae3-496d-a8ce-5607a68d1d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_a4c75b04-7ae3-496d-a8ce-5607a68d1d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_7e191d48-1a29-4810-9504-e632b7a38c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_7e191d48-1a29-4810-9504-e632b7a38c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_53bf03c4-159f-455e-9150-b1deee3ae340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_53bf03c4-159f-455e-9150-b1deee3ae340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_6ba52952-ff9d-49ec-8ea5-6ac3630a6711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_55dd371b-1c2f-4d88-87c7-30b6d3628a79" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_6ba52952-ff9d-49ec-8ea5-6ac3630a6711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eea182a3-ef77-445b-bb28-a2cfd8532de1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0aec7946-80f5-41a4-a50a-39772d6dc6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0aec7946-80f5-41a4-a50a-39772d6dc6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aee04773-f8a3-4592-82a7-e35258e44f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aee04773-f8a3-4592-82a7-e35258e44f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1321b5f1-9e3a-4cb2-b5c8-1c505fea884b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1321b5f1-9e3a-4cb2-b5c8-1c505fea884b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_470131db-9a6d-4dad-abd4-59f5fbc1bf81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_470131db-9a6d-4dad-abd4-59f5fbc1bf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_4373fc56-46f7-4436-b830-5e399ba1cb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_4373fc56-46f7-4436-b830-5e399ba1cb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91abe0f5-f106-43c3-bec4-86f03c1f3cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_90656b44-acd0-43a2-9cfc-fe58f5a3ce34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91abe0f5-f106-43c3-bec4-86f03c1f3cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_1a55d54d-9a3b-4c76-9bf9-5ccd7af8cdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_71eb8889-db13-4c50-bcb9-80f789c10d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_1a55d54d-9a3b-4c76-9bf9-5ccd7af8cdc1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_71eb8889-db13-4c50-bcb9-80f789c10d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7b4d124c-f9e7-4a65-82dd-31de3b180021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_71eb8889-db13-4c50-bcb9-80f789c10d70" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7b4d124c-f9e7-4a65-82dd-31de3b180021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7b4d124c-f9e7-4a65-82dd-31de3b180021" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d0bd54a9-7b29-44aa-b838-95f2891c0904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d0bd54a9-7b29-44aa-b838-95f2891c0904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_149204c9-ce1b-428b-91d7-b046899ebf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_149204c9-ce1b-428b-91d7-b046899ebf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_595eab90-b735-462b-bf7b-31652957b94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_595eab90-b735-462b-bf7b-31652957b94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_7f5bc19f-ba17-40fd-bef0-c99c93bf8cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_7f5bc19f-ba17-40fd-bef0-c99c93bf8cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_8b039529-8481-4081-9f1b-3e1181d62db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_8b039529-8481-4081-9f1b-3e1181d62db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_21bbf791-07cd-4111-9ac7-fd49992a4b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_21bbf791-07cd-4111-9ac7-fd49992a4b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_c07687e9-590c-457d-826f-e6eb4d39322a" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_c07687e9-590c-457d-826f-e6eb4d39322a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_dcef4be3-be49-49e0-a2d6-e0c6fbb8e838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b93bf0b8-fb6a-4c47-a3f2-f6ffd53d82ac" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_dcef4be3-be49-49e0-a2d6-e0c6fbb8e838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_71eb8889-db13-4c50-bcb9-80f789c10d70" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_c1f31d3b-1946-4299-b924-17ef14d1498c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_c1f31d3b-1946-4299-b924-17ef14d1498c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_69d28191-7976-49d9-bd7b-827d2b0fdee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_69d28191-7976-49d9-bd7b-827d2b0fdee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_518e2e44-6bdd-4006-b72e-9b86f9adf7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_83efcd92-8256-4771-943a-ccd1e8188c65" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_518e2e44-6bdd-4006-b72e-9b86f9adf7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_61c44ef7-a824-4de6-b2d3-5173869dacd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_61c44ef7-a824-4de6-b2d3-5173869dacd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_db6fafef-a250-433a-bcdb-010f378788eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_db6fafef-a250-433a-bcdb-010f378788eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f1ac5bdb-d700-4caa-a3ae-674cf7a34684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_6fafa1c4-adae-4a5a-9280-2371d0b92d9c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f1ac5bdb-d700-4caa-a3ae-674cf7a34684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5da55664-e6f8-4a75-adfa-15e5ff1cd259" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_962434a8-d3c2-40c0-bc5f-cb9ac0422f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_962434a8-d3c2-40c0-bc5f-cb9ac0422f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_864c8c48-6bb1-4a93-8196-b7639c330fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_864c8c48-6bb1-4a93-8196-b7639c330fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fabb165d-9f52-401d-8e17-9bb41dd241be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_77efe524-225b-4d8f-a16e-ac7cd35959e6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fabb165d-9f52-401d-8e17-9bb41dd241be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsUnrealizedLossPositionMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_789e81e6-38a4-4d74-b7e8-ec4af71e0146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c57b5897-2ed2-4db0-a40b-61c0aba0113b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_789e81e6-38a4-4d74-b7e8-ec4af71e0146" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c57b5897-2ed2-4db0-a40b-61c0aba0113b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2578366a-7f38-42b2-87f3-64b74395e8d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c57b5897-2ed2-4db0-a40b-61c0aba0113b" xlink:to="loc_srt_ProductOrServiceAxis_2578366a-7f38-42b2-87f3-64b74395e8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f636fe2-1a24-4a34-90b7-b1de2b08d7ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2578366a-7f38-42b2-87f3-64b74395e8d1" xlink:to="loc_srt_ProductsAndServicesDomain_6f636fe2-1a24-4a34-90b7-b1de2b08d7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingExperienceRatedProductsMember_7004976f-c599-4e55-a3f3-dd5fb2349f54" xlink:href="cvs-20221231.xsd#cvs_SupportingExperienceRatedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f636fe2-1a24-4a34-90b7-b1de2b08d7ce" xlink:to="loc_cvs_SupportingExperienceRatedProductsMember_7004976f-c599-4e55-a3f3-dd5fb2349f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingRemainingProductsMember_0cb8f9f1-78ce-4e55-b8d0-b0426c071c5d" xlink:href="cvs-20221231.xsd#cvs_SupportingRemainingProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f636fe2-1a24-4a34-90b7-b1de2b08d7ce" xlink:to="loc_cvs_SupportingRemainingProductsMember_0cb8f9f1-78ce-4e55-b8d0-b0426c071c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e9a37d3d-e100-4bb2-b4e2-fb75cd978760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c57b5897-2ed2-4db0-a40b-61c0aba0113b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e9a37d3d-e100-4bb2-b4e2-fb75cd978760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e9a37d3d-e100-4bb2-b4e2-fb75cd978760" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_4656f665-fc84-4172-8dc1-cd3a6517f398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_4656f665-fc84-4172-8dc1-cd3a6517f398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_ce9c2e1f-34a6-495f-b377-4428795c5e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_ce9c2e1f-34a6-495f-b377-4428795c5e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_abc64e99-247a-4318-888e-dee3aa87f293" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1210c1a1-18b8-4648-af54-f893ce658094" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_abc64e99-247a-4318-888e-dee3aa87f293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc7fda5a-683f-4296-9761-f5c4233e67b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c57b5897-2ed2-4db0-a40b-61c0aba0113b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc7fda5a-683f-4296-9761-f5c4233e67b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc7fda5a-683f-4296-9761-f5c4233e67b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear_0b462baf-b9e6-4116-8812-0d9a8497db56" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear_0b462baf-b9e6-4116-8812-0d9a8497db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears_7b0a4e9d-c9cb-4e93-8ade-fa5ff64bbce1" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears_7b0a4e9d-c9cb-4e93-8ade-fa5ff64bbce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears_b3ff1905-c968-4d84-8646-1617568d4207" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears_b3ff1905-c968-4d84-8646-1617568d4207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears_8b413a3a-8442-42e4-8892-5dc0651707a4" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears_8b413a3a-8442-42e4-8892-5dc0651707a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue_ff7a2c0e-1919-41a6-ab5c-bedabf5504ce" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue_ff7a2c0e-1919-41a6-ab5c-bedabf5504ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b373f37e-210d-4e60-95e9-a7c30ab9335e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5a3ef713-fb92-4bb9-91f1-bb0373cd020f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b373f37e-210d-4e60-95e9-a7c30ab9335e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc7fda5a-683f-4296-9761-f5c4233e67b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss_3e4b236e-a402-45b4-82f7-116969a51ff0" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss_3e4b236e-a402-45b4-82f7-116969a51ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss_3110a513-6995-401f-b4c5-d05db6a665ce" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss_3110a513-6995-401f-b4c5-d05db6a665ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss_9d79391d-dd0f-4471-b7ea-7bc08f5ccf69" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss_9d79391d-dd0f-4471-b7ea-7bc08f5ccf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss_25622dee-eb35-4d9b-8408-6094ab41e8d3" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss_25622dee-eb35-4d9b-8408-6094ab41e8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss_684639b2-9193-459c-95ca-7b1760b764ef" xlink:href="cvs-20221231.xsd#cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss_684639b2-9193-459c-95ca-7b1760b764ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8a0885f5-06ef-4412-8f81-a02662ed0312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_01f08026-4b77-4050-a0ff-0a61ee7ef580" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8a0885f5-06ef-4412-8f81-a02662ed0312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsMortgageLoansDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_50e729e0-62ef-4298-9c24-37379b96274f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateScheduleTable_0bbacd10-8d45-433f-8571-8a7472514101" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateScheduleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_50e729e0-62ef-4298-9c24-37379b96274f" xlink:to="loc_srt_MortgageLoansOnRealEstateScheduleTable_0bbacd10-8d45-433f-8571-8a7472514101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_220c010b-199a-4ccb-8790-5a043fcee15e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_0bbacd10-8d45-433f-8571-8a7472514101" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_220c010b-199a-4ccb-8790-5a043fcee15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_78188471-e9e3-41ca-9a37-80f2c6f9894c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_220c010b-199a-4ccb-8790-5a043fcee15e" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_78188471-e9e3-41ca-9a37-80f2c6f9894c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialRealEstateMember_a43648d5-9462-4f3d-8f21-3e0594f2fb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialRealEstateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_78188471-e9e3-41ca-9a37-80f2c6f9894c" xlink:to="loc_us-gaap_CommercialRealEstateMember_a43648d5-9462-4f3d-8f21-3e0594f2fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_0bbacd10-8d45-433f-8571-8a7472514101" xlink:to="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans_2a703764-dbe7-422b-86a9-79e2b680c333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateNewMortgageLoans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans_2a703764-dbe7-422b-86a9-79e2b680c333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateLoansFullyRepaid_2dea4938-f000-416c-bd26-80294f498351" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateLoansFullyRepaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:to="loc_cvs_MortgageLoansOnRealEstateLoansFullyRepaid_2dea4938-f000-416c-bd26-80294f498351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateForeclosures_6ef20085-8fb0-4cf5-994d-163e84188a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateForeclosures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_d521fcf4-75cf-4a1c-aab0-efeadeca8f1b" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateForeclosures_6ef20085-8fb0-4cf5-994d-163e84188a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsMortgageLoansCreditRatingsIndicatorDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_6b6ae81c-f137-4196-940c-6b5c21eee096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateScheduleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_6b6ae81c-f137-4196-940c-6b5c21eee096" xlink:to="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_c0f7d12e-bacb-4290-92da-7ccad934aab6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_c0f7d12e-bacb-4290-92da-7ccad934aab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_3fbc8c09-ed85-4d04-98f0-10011fbf9d4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_c0f7d12e-bacb-4290-92da-7ccad934aab6" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_3fbc8c09-ed85-4d04-98f0-10011fbf9d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialRealEstateMember_93fed552-1cf1-45fd-ae18-a082fa14201f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialRealEstateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_3fbc8c09-ed85-4d04-98f0-10011fbf9d4e" xlink:to="loc_us-gaap_CommercialRealEstateMember_93fed552-1cf1-45fd-ae18-a082fa14201f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentAxis_e758c07e-662f-420a-a6a0-c64abc0a1a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:to="loc_us-gaap_InternalCreditAssessmentAxis_e758c07e-662f-420a-a6a0-c64abc0a1a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InternalCreditAssessmentAxis_e758c07e-662f-420a-a6a0-c64abc0a1a2a" xlink:to="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Category1Member_abc27f7e-8620-4dec-bb17-619792aa24f0" xlink:href="cvs-20221231.xsd#cvs_Category1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:to="loc_cvs_Category1Member_abc27f7e-8620-4dec-bb17-619792aa24f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Category2To4Member_405c73bb-8ee5-4ac9-8492-8cf27f3dffea" xlink:href="cvs-20221231.xsd#cvs_Category2To4Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:to="loc_cvs_Category2To4Member_405c73bb-8ee5-4ac9-8492-8cf27f3dffea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Categories5And6Member_f6dd004d-bb4f-4111-9db5-bd43b47efaf6" xlink:href="cvs-20221231.xsd#cvs_Categories5And6Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:to="loc_cvs_Categories5And6Member_f6dd004d-bb4f-4111-9db5-bd43b47efaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_Category7Member_14f073f8-7bc4-4525-aa81-520b866b427b" xlink:href="cvs-20221231.xsd#cvs_Category7Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_6b0aa7fc-c066-4ce7-86ef-18257526f5e3" xlink:to="loc_cvs_Category7Member_14f073f8-7bc4-4525-aa81-520b866b427b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_3cc2fb1f-eaa9-4520-876d-9a56842a526f" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateYearOfOriginationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:to="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_3cc2fb1f-eaa9-4520-876d-9a56842a526f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateYearOfOriginationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis_3cc2fb1f-eaa9-4520-876d-9a56842a526f" xlink:to="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodOneMember_4ac4d736-21ef-4171-852a-47d9d438d28d" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodOneMember_4ac4d736-21ef-4171-852a-47d9d438d28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodTwoMember_305bd21b-ead4-4203-af9a-fb6d0dab7fcb" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodTwoMember_305bd21b-ead4-4203-af9a-fb6d0dab7fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodThreeMember_2138072f-8639-4ae3-8caa-10f5c4d50ee5" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodThreeMember_2138072f-8639-4ae3-8caa-10f5c4d50ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodFourMember_4fb9a845-dc77-4ac6-a2bd-fd3599e8f4cd" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodFourMember_4fb9a845-dc77-4ac6-a2bd-fd3599e8f4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPeriodFiveMember_2d91ab4b-8c2a-423d-92cc-045d61ecdc90" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPeriodFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPeriodFiveMember_2d91ab4b-8c2a-423d-92cc-045d61ecdc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YearOfOriginationPriorToPeriodFiveMember_892ae6c5-4475-421d-9687-8745f1598d87" xlink:href="cvs-20221231.xsd#cvs_YearOfOriginationPriorToPeriodFiveMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_MortgageLoansOnRealEstateYearOfOriginationDomain_e6be26db-55f8-45f8-aeb4-9464f2af3e81" xlink:to="loc_cvs_YearOfOriginationPriorToPeriodFiveMember_892ae6c5-4475-421d-9687-8745f1598d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateLineItems_ba8309a4-53d3-4da6-b466-b1b62912a91f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_4bd0b71c-424a-44c0-afc8-6bf5aad42515" xlink:to="loc_srt_MortgageLoansOnRealEstateLineItems_ba8309a4-53d3-4da6-b466-b1b62912a91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate_1d7cd5f6-0f15-4d84-a22d-ceed9ca50dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_ba8309a4-53d3-4da6-b466-b1b62912a91f" xlink:to="loc_us-gaap_MortgageLoansOnRealEstate_1d7cd5f6-0f15-4d84-a22d-ceed9ca50dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsMortgageLoanPrincipalRepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_70485933-2da2-42f1-82f0-ee056a70ea07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateScheduleTable_d6a6d582-b529-4876-be81-e5a88bc53d08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateScheduleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_70485933-2da2-42f1-82f0-ee056a70ea07" xlink:to="loc_srt_MortgageLoansOnRealEstateScheduleTable_d6a6d582-b529-4876-be81-e5a88bc53d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4770dba9-a8d6-4511-8775-94425a3716b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_d6a6d582-b529-4876-be81-e5a88bc53d08" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4770dba9-a8d6-4511-8775-94425a3716b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_c8d6bed1-4eeb-4a65-a45e-8e35da853b74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4770dba9-a8d6-4511-8775-94425a3716b4" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_c8d6bed1-4eeb-4a65-a45e-8e35da853b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialRealEstateMember_04880d8b-6126-4b91-bb70-5903967e5fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialRealEstateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_c8d6bed1-4eeb-4a65-a45e-8e35da853b74" xlink:to="loc_us-gaap_CommercialRealEstateMember_04880d8b-6126-4b91-bb70-5903967e5fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateScheduleTable_d6a6d582-b529-4876-be81-e5a88bc53d08" xlink:to="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths_5a6666e2-029f-4fdb-9c64-4b21f0a075e4" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths_5a6666e2-029f-4fdb-9c64-4b21f0a075e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo_d25bbeb7-74b8-46ca-a24f-8e7622dd67fe" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo_d25bbeb7-74b8-46ca-a24f-8e7622dd67fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree_d2c0c328-eb4e-47dd-8c67-bc13fc1f5f82" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree_d2c0c328-eb4e-47dd-8c67-bc13fc1f5f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour_8270b72b-d7de-4aaf-a693-22038d61bb6f" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour_8270b72b-d7de-4aaf-a693-22038d61bb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive_fdd30556-9465-438d-bc93-975cb0b6f8d2" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive_fdd30556-9465-438d-bc93-975cb0b6f8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive_0db062a7-d7a3-4163-a4a3-922fe4682d9b" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive_0db062a7-d7a3-4163-a4a3-922fe4682d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_6c2744d3-b239-479c-8c5b-033224ec6546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateLineItems_a487442c-bba0-46f4-9913-bdfd2480e807" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_6c2744d3-b239-479c-8c5b-033224ec6546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsNetInvestmentIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_f6b9a82b-aa9a-4bb9-97ae-de395c8ac4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_a05743da-35b0-4a6d-8564-506d914b8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f6b9a82b-aa9a-4bb9-97ae-de395c8ac4fb" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_a05743da-35b0-4a6d-8564-506d914b8c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_be65506b-c51a-4ef7-9a63-0c5f1f8ca99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_a05743da-35b0-4a6d-8564-506d914b8c4f" xlink:to="loc_us-gaap_InvestmentTypeAxis_be65506b-c51a-4ef7-9a63-0c5f1f8ca99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_be65506b-c51a-4ef7-9a63-0c5f1f8ca99b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_b759fe94-5890-4021-b813-b7dcf2e134e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:to="loc_us-gaap_DebtSecuritiesMember_b759fe94-5890-4021-b813-b7dcf2e134e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_MortgageLoansMember_82468f8d-a4a2-4055-ac3c-fc8447203b7c" xlink:href="cvs-20221231.xsd#cvs_MortgageLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:to="loc_cvs_MortgageLoansMember_82468f8d-a4a2-4055-ac3c-fc8447203b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_648d7233-1c47-4a88-be54-71f340931937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4c904e15-e358-407d-b15f-ecb55563d7e1" xlink:to="loc_us-gaap_OtherInvestmentsMember_648d7233-1c47-4a88-be54-71f340931937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8569c4b7-f279-4bfd-8447-a1b70549d0b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_a05743da-35b0-4a6d-8564-506d914b8c4f" xlink:to="loc_srt_ProductOrServiceAxis_8569c4b7-f279-4bfd-8447-a1b70549d0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8ee8ae8-0adb-4352-b21b-5d5c99d95cb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8569c4b7-f279-4bfd-8447-a1b70549d0b3" xlink:to="loc_srt_ProductsAndServicesDomain_c8ee8ae8-0adb-4352-b21b-5d5c99d95cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SupportingExperienceRatedProductsMember_83e16388-99e8-4998-9016-62dfc83fd3a2" xlink:href="cvs-20221231.xsd#cvs_SupportingExperienceRatedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c8ee8ae8-0adb-4352-b21b-5d5c99d95cb2" xlink:to="loc_cvs_SupportingExperienceRatedProductsMember_83e16388-99e8-4998-9016-62dfc83fd3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_a05743da-35b0-4a6d-8564-506d914b8c4f" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_92560b04-86e4-494a-9be7-c51cbe88b49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_92560b04-86e4-494a-9be7-c51cbe88b49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_7179dfb3-de62-4348-b41a-b5bf2a3d7d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_7179dfb3-de62-4348-b41a-b5bf2a3d7d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_a736ec02-339c-4ebd-9ea3-b3c09c2ce651" xlink:href="cvs-20221231.xsd#cvs_InvestmentIncomeExcludingCapitalGainsOrLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses_a736ec02-339c-4ebd-9ea3-b3c09c2ce651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_a3c780c4-0fa2-4cf5-9249-c10eec796b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_a3c780c4-0fa2-4cf5-9249-c10eec796b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_a8632f37-11e3-411c-9e3e-3baca2928fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_us-gaap_InvestmentIncomeNet_a8632f37-11e3-411c-9e3e-3baca2928fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_9b92ef91-5256-402e-b8e2-ce19bec0b913" xlink:href="cvs-20221231.xsd#cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_9b92ef91-5256-402e-b8e2-ce19bec0b913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_13e31ae4-05a0-49e2-93d8-e221a0c26192" xlink:href="cvs-20221231.xsd#cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_db03dca7-4770-4d99-a398-784a2f9dbd56" xlink:to="loc_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_13e31ae4-05a0-49e2-93d8-e221a0c26192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#InvestmentsRealizedGainsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_5dceafd2-2a31-48a5-a41b-2d1f9b25f6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_68ff7b7b-012f-42a8-ba4d-d8a28ccd7fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_5dceafd2-2a31-48a5-a41b-2d1f9b25f6bc" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_68ff7b7b-012f-42a8-ba4d-d8a28ccd7fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_33526394-7a85-43e5-adfa-e23d4ca12b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_5dceafd2-2a31-48a5-a41b-2d1f9b25f6bc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_33526394-7a85-43e5-adfa-e23d4ca12b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_714c0eea-aec6-46b1-9e3f-7d2a4bde0552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_5dceafd2-2a31-48a5-a41b-2d1f9b25f6bc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_714c0eea-aec6-46b1-9e3f-7d2a4bde0552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueFairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0cc8628d-3616-472f-b6b7-d4dc3acf3d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0cc8628d-3616-472f-b6b7-d4dc3acf3d73" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c89a21ef-2f3a-4bbd-a959-13565a18a002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c89a21ef-2f3a-4bbd-a959-13565a18a002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cacbceff-4f75-47a8-8308-7284c7a7a212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c89a21ef-2f3a-4bbd-a959-13565a18a002" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cacbceff-4f75-47a8-8308-7284c7a7a212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_02d75c32-4e83-4505-bb7c-68a1c25a92c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_cacbceff-4f75-47a8-8308-7284c7a7a212" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_02d75c32-4e83-4505-bb7c-68a1c25a92c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c590adc9-df48-415e-af3d-a844dec6892f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c590adc9-df48-415e-af3d-a844dec6892f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c590adc9-df48-415e-af3d-a844dec6892f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_958b8e47-7346-4f7b-ae3b-ee592b7b360e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_958b8e47-7346-4f7b-ae3b-ee592b7b360e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_95e1fbd7-e336-429e-9dfb-e83bbba83dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_95e1fbd7-e336-429e-9dfb-e83bbba83dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5aa320e9-ed93-49b0-8729-a1d184ef2298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5aa320e9-ed93-49b0-8729-a1d184ef2298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_a81e61de-1433-483e-8f71-8134999fbfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_a81e61de-1433-483e-8f71-8134999fbfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_6877b86c-3d5a-4d1c-a29b-628774531648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_6877b86c-3d5a-4d1c-a29b-628774531648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c6005ad5-5b5f-4b28-9ccc-c53dae86f584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c6005ad5-5b5f-4b28-9ccc-c53dae86f584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_091e1529-be25-410f-95aa-a3e7f19174a9" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_091e1529-be25-410f-95aa-a3e7f19174a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_d85d8e6e-0b4d-464d-8d86-1d735e97abee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5117777-0e6d-4209-a674-ecbc194fd10f" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_d85d8e6e-0b4d-464d-8d86-1d735e97abee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74295d61-a99d-4a0e-8310-916b3e6d0898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74295d61-a99d-4a0e-8310-916b3e6d0898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74295d61-a99d-4a0e-8310-916b3e6d0898" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ed8f7306-ebaf-4158-8514-569e358c3776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ed8f7306-ebaf-4158-8514-569e358c3776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3e45b9e9-86f5-4216-9745-044d2d702f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3e45b9e9-86f5-4216-9745-044d2d702f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7430485f-9b30-4293-922d-d28a43adecde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8affa0f2-19e0-46f0-b9c5-b44dc128c366" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7430485f-9b30-4293-922d-d28a43adecde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e0bcc3e6-2dd5-4e67-8a74-3ed6e52f67dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e0bcc3e6-2dd5-4e67-8a74-3ed6e52f67dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cae8be79-0e31-496e-af54-cc3c2a01f308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e0bcc3e6-2dd5-4e67-8a74-3ed6e52f67dd" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cae8be79-0e31-496e-af54-cc3c2a01f308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_bf3e4e82-7383-4743-a6d6-a0cc5e9b1d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cae8be79-0e31-496e-af54-cc3c2a01f308" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_bf3e4e82-7383-4743-a6d6-a0cc5e9b1d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36ee97e8-dc8a-4219-912f-a95443b8dd3b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f4276657-e22f-4a88-a81a-c7c44dcd6231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f4276657-e22f-4a88-a81a-c7c44dcd6231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e28c5995-f48c-4898-b584-e5ca2bedb12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e28c5995-f48c-4898-b584-e5ca2bedb12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1d0c7fa7-4762-44ca-913c-4816e192ea7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1d0c7fa7-4762-44ca-913c-4816e192ea7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f5ce26bf-129f-421d-9e22-eab8231be015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f5ce26bf-129f-421d-9e22-eab8231be015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_572cce78-c512-428b-b2fc-d0f39f4c4746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27bfb8c6-b1cc-475b-a32c-344b575b2d44" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_572cce78-c512-428b-b2fc-d0f39f4c4746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueChangesinLevel3FinancialAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7a565572-b3ef-4789-8758-0ba9f87c8da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1a0935e-4e5e-48a7-8496-453f6ca68850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7a565572-b3ef-4789-8758-0ba9f87c8da6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1a0935e-4e5e-48a7-8496-453f6ca68850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5f30b340-bd88-4848-9b45-7e6b249592b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1a0935e-4e5e-48a7-8496-453f6ca68850" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5f30b340-bd88-4848-9b45-7e6b249592b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5f30b340-bd88-4848-9b45-7e6b249592b2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_bccfe53a-a1d3-4701-b2e3-75f287815929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_bccfe53a-a1d3-4701-b2e3-75f287815929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_0d0cc151-7d79-4731-9c7c-14ac231aef8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_0d0cc151-7d79-4731-9c7c-14ac231aef8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember_3e8fbe70-f93d-49b4-9373-be72ab7603d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember_3e8fbe70-f93d-49b4-9373-be72ab7603d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAssetBackedSecuritiesMember_556615d8-15ee-4916-8ba6-a38a129db826" xlink:href="cvs-20221231.xsd#cvs_OtherAssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_cvs_OtherAssetBackedSecuritiesMember_556615d8-15ee-4916-8ba6-a38a129db826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_2fb5399d-3258-4151-b764-a2f81cae77e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_2fb5399d-3258-4151-b764-a2f81cae77e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_3a68217f-2bf3-4de3-b455-a344461ddc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63b796b6-0a28-49e2-8eab-19823b785594" xlink:to="loc_us-gaap_EquitySecuritiesMember_3a68217f-2bf3-4de3-b455-a344461ddc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7a7b8fe3-2307-4691-b335-a30fc2558770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1a0935e-4e5e-48a7-8496-453f6ca68850" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7a7b8fe3-2307-4691-b335-a30fc2558770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_254c2e71-9367-4253-98fb-65c327df9ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7a7b8fe3-2307-4691-b335-a30fc2558770" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_254c2e71-9367-4253-98fb-65c327df9ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d7ca5f78-41e2-4dfe-99f0-6495534491d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_254c2e71-9367-4253-98fb-65c327df9ae2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d7ca5f78-41e2-4dfe-99f0-6495534491d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc282f9a-21a5-4752-b2d4-6b8e822d02fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1a0935e-4e5e-48a7-8496-453f6ca68850" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc282f9a-21a5-4752-b2d4-6b8e822d02fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc282f9a-21a5-4752-b2d4-6b8e822d02fa" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2d583924-e41e-45a7-9d25-ac13e9fac051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2d583924-e41e-45a7-9d25-ac13e9fac051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_40018571-4585-484d-9a01-d2deb4ccdaff" xlink:href="cvs-20221231.xsd#cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_40018571-4585-484d-9a01-d2deb4ccdaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_09294644-ce4e-4f0d-b651-03434e404807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_40018571-4585-484d-9a01-d2deb4ccdaff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_09294644-ce4e-4f0d-b651-03434e404807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_26e4dfe6-0b38-4def-84c3-6bb2885a1ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract_40018571-4585-484d-9a01-d2deb4ccdaff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_26e4dfe6-0b38-4def-84c3-6bb2885a1ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_4f27fa04-4496-48f6-89e5-f28846895547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_4f27fa04-4496-48f6-89e5-f28846895547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_13b7a549-6d97-492e-b95a-7531745bf6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_13b7a549-6d97-492e-b95a-7531745bf6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_3cc95156-8417-43df-996a-22f8c4b3902a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_3cc95156-8417-43df-996a-22f8c4b3902a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c6c19d90-8bf2-4870-85cf-4bca17c6806f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c6c19d90-8bf2-4870-85cf-4bca17c6806f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_cc7ba811-c1b6-40f0-b0eb-425fc99c1354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_347f16d1-0231-4939-8d38-1fea65bd05fb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_cc7ba811-c1b6-40f0-b0eb-425fc99c1354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci_bd7de0f7-8881-423e-8c05-293dfd8597a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc282f9a-21a5-4752-b2d4-6b8e822d02fa" xlink:to="loc_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci_bd7de0f7-8881-423e-8c05-293dfd8597a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueGrossTransfersIntoOutOfLevel3Details"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_41f3833d-6040-4ae9-9674-33c0e633d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144ab090-186d-4df6-94d3-0794058280e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_41f3833d-6040-4ae9-9674-33c0e633d9eb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144ab090-186d-4df6-94d3-0794058280e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7060f5e9-f1c3-409e-8b62-83fb5efa11a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144ab090-186d-4df6-94d3-0794058280e4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7060f5e9-f1c3-409e-8b62-83fb5efa11a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ccf721-80f8-4bdd-b33d-652f6030caef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7060f5e9-f1c3-409e-8b62-83fb5efa11a2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ccf721-80f8-4bdd-b33d-652f6030caef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_195273df-72fa-4c23-8e5a-274ed4df0bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ccf721-80f8-4bdd-b33d-652f6030caef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_195273df-72fa-4c23-8e5a-274ed4df0bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0566e00d-a0b7-45a4-b114-1a043124f288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144ab090-186d-4df6-94d3-0794058280e4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0566e00d-a0b7-45a4-b114-1a043124f288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd62915-9a78-4514-a138-32b34aa2dfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0566e00d-a0b7-45a4-b114-1a043124f288" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd62915-9a78-4514-a138-32b34aa2dfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_de8aaebe-0b5b-4a7b-a021-def1584a912e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd62915-9a78-4514-a138-32b34aa2dfd3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_de8aaebe-0b5b-4a7b-a021-def1584a912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_144ab090-186d-4df6-94d3-0794058280e4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_3c37f1a2-d770-4f23-86b4-354486fc4a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_3c37f1a2-d770-4f23-86b4-354486fc4a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_87d1e149-67cf-468f-9503-2f03c12314f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_87d1e149-67cf-468f-9503-2f03c12314f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_3b6785dc-27a6-4bd3-b992-649b3f19c5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_055ae419-e20b-44eb-a67c-b71616840608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_3b6785dc-27a6-4bd3-b992-649b3f19c5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueCarryingValueandFairValueClassifiedbyLevelDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_57444150-92c0-4887-a333-7e54ed3b8b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_57444150-92c0-4887-a333-7e54ed3b8b73" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_272a381a-566b-4afa-a3f9-f55a5dcbd896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_272a381a-566b-4afa-a3f9-f55a5dcbd896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a50d96a-cfff-40eb-9e78-2817b0853022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_272a381a-566b-4afa-a3f9-f55a5dcbd896" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a50d96a-cfff-40eb-9e78-2817b0853022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_3d1bf2c7-f653-4691-a9f8-3ce179b9295a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a50d96a-cfff-40eb-9e78-2817b0853022" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_3d1bf2c7-f653-4691-a9f8-3ce179b9295a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d985eeef-7c0e-4109-b1dd-05bdbb468d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d985eeef-7c0e-4109-b1dd-05bdbb468d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d985eeef-7c0e-4109-b1dd-05bdbb468d7d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_511f5c32-946f-4891-b483-fa8d0386544b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_511f5c32-946f-4891-b483-fa8d0386544b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a7df7b7f-32ce-4211-bb14-753c866efdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a7df7b7f-32ce-4211-bb14-753c866efdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_717ced63-4e67-41bb-a178-8f2156d0c089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0efa6b3-d810-4307-9667-c590b1bb1383" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_717ced63-4e67-41bb-a178-8f2156d0c089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ad19dd25-2e6e-408d-a9c4-a750b816f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ad19dd25-2e6e-408d-a9c4-a750b816f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5a1342d6-2448-4638-8d43-866313b153f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ad19dd25-2e6e-408d-a9c4-a750b816f2a5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5a1342d6-2448-4638-8d43-866313b153f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4a9d863b-08d0-470a-963c-50b0ef333131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5a1342d6-2448-4638-8d43-866313b153f7" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4a9d863b-08d0-470a-963c-50b0ef333131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bea5eee6-e8b1-4c2f-8619-47d20fea5f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4a9d863b-08d0-470a-963c-50b0ef333131" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bea5eee6-e8b1-4c2f-8619-47d20fea5f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6c898e9f-6a02-4ebb-9512-bf84ec44f54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4a9d863b-08d0-470a-963c-50b0ef333131" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6c898e9f-6a02-4ebb-9512-bf84ec44f54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c721cab9-d0eb-473f-aee8-8dd9fb3a32de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c721cab9-d0eb-473f-aee8-8dd9fb3a32de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4815a800-4f9d-483d-a553-a905dc5cdf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c721cab9-d0eb-473f-aee8-8dd9fb3a32de" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4815a800-4f9d-483d-a553-a905dc5cdf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_bd4e715e-c56b-487f-9a79-d0df93c2aa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4815a800-4f9d-483d-a553-a905dc5cdf9d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_bd4e715e-c56b-487f-9a79-d0df93c2aa0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_98b1f1e7-78d2-45ea-b49c-1751aaaaa594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b8adc95a-cd80-45c1-8ab7-a39e55df9bb3" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_98b1f1e7-78d2-45ea-b49c-1751aaaaa594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_6a097646-080e-4b76-a56e-ea8f4f673247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_98b1f1e7-78d2-45ea-b49c-1751aaaaa594" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_6a097646-080e-4b76-a56e-ea8f4f673247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesHeldForSaleFairValueDisclosure_29d5b32f-d75d-40b0-9d99-32748d1aab02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgagesHeldForSaleFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_6a097646-080e-4b76-a56e-ea8f4f673247" xlink:to="loc_us-gaap_MortgagesHeldForSaleFairValueDisclosure_29d5b32f-d75d-40b0-9d99-32748d1aab02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4d784204-d226-442c-8204-2663d91e7ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_6a097646-080e-4b76-a56e-ea8f4f673247" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4d784204-d226-442c-8204-2663d91e7ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_98b1f1e7-78d2-45ea-b49c-1751aaaaa594" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure_88bfb4ca-4c42-4215-b1ca-ee0b9cf183bd" xlink:href="cvs-20221231.xsd#cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:to="loc_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure_88bfb4ca-4c42-4215-b1ca-ee0b9cf183bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure_71ac0d8b-911d-49fb-b4d9-b7cec687e40e" xlink:href="cvs-20221231.xsd#cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:to="loc_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure_71ac0d8b-911d-49fb-b4d9-b7cec687e40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3d4a0d7c-6deb-4c05-92d6-3e7553fba8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8759f83e-61c2-4a2d-aabb-390e6deb1160" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3d4a0d7c-6deb-4c05-92d6-3e7553fba8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueSeparateAccountsFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cb2354ae-846e-482f-99bf-e93a3280c36a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cb2354ae-846e-482f-99bf-e93a3280c36a" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c9b1e65-5611-4818-a4b2-1920d1b2cfba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c9b1e65-5611-4818-a4b2-1920d1b2cfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca226d16-fcb5-41d3-a836-b41aed22fc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c9b1e65-5611-4818-a4b2-1920d1b2cfba" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca226d16-fcb5-41d3-a836-b41aed22fc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ec01c8c4-9a75-4a0b-88cc-d0117b4a71df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca226d16-fcb5-41d3-a836-b41aed22fc8d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ec01c8c4-9a75-4a0b-88cc-d0117b4a71df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97d9837c-466f-42ea-a5e0-0ebf96e976e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97d9837c-466f-42ea-a5e0-0ebf96e976e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97d9837c-466f-42ea-a5e0-0ebf96e976e6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_104f71fd-a7c6-438e-ba52-f951a7dc7d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_104f71fd-a7c6-438e-ba52-f951a7dc7d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bd07dce5-d45c-40b3-8373-6b1673d64648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bd07dce5-d45c-40b3-8373-6b1673d64648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b393cca6-5dc1-478c-afb8-cd04a0346ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a63881c8-6e2d-46d7-9195-aefc722f2daa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b393cca6-5dc1-478c-afb8-cd04a0346ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryAxis_6d5621dd-197f-4efe-8cf6-7821359e281a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryAxis_6d5621dd-197f-4efe-8cf6-7821359e281a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis_6d5621dd-197f-4efe-8cf6-7821359e281a" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_46f419a1-07b7-4677-a76a-434d342de333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_46f419a1-07b7-4677-a76a-434d342de333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_a877f2b7-583b-424e-b311-9c126406531a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:to="loc_us-gaap_DebtSecuritiesMember_a877f2b7-583b-424e-b311-9c126406531a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0145521b-1904-4dee-973c-0d229d7f3b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:to="loc_us-gaap_EquitySecuritiesMember_0145521b-1904-4dee-973c-0d229d7f3b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CommonAndCollectiveTrustsMember_2188ca00-fc39-4871-b123-e0be9dbef4c9" xlink:href="cvs-20221231.xsd#cvs_CommonAndCollectiveTrustsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_a3099079-ddad-4169-a288-f30681cd8fac" xlink:to="loc_cvs_CommonAndCollectiveTrustsMember_2188ca00-fc39-4871-b123-e0be9dbef4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3cc3fd05-43f3-41ae-96a6-5ac15655001b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3cc3fd05-43f3-41ae-96a6-5ac15655001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f4e75106-e60f-4591-853e-6ce274f4ad85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3cc3fd05-43f3-41ae-96a6-5ac15655001b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f4e75106-e60f-4591-853e-6ce274f4ad85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_19567c01-c118-420f-ab4a-5994cb83d52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4e75106-e60f-4591-853e-6ce274f4ad85" xlink:to="loc_us-gaap_AccountsPayableMember_19567c01-c118-420f-ab4a-5994cb83d52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_adeffc05-de79-4cdc-852f-05fd2043b697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4e75106-e60f-4591-853e-6ce274f4ad85" xlink:to="loc_us-gaap_AccountsReceivableMember_adeffc05-de79-4cdc-852f-05fd2043b697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_353d7d96-5fd0-471a-b7ae-18f8f64cffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable_2789ef93-2cb8-4605-ba12-296becb34caf" xlink:to="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_353d7d96-5fd0-471a-b7ae-18f8f64cffc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_89811978-5e72-464c-9325-d1f9b8693c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_353d7d96-5fd0-471a-b7ae-18f8f64cffc9" xlink:to="loc_us-gaap_SeparateAccountAssets_89811978-5e72-464c-9325-d1f9b8693c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability_02c9f730-ed30-4db4-8f2a-c2ef09a839ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems_353d7d96-5fd0-471a-b7ae-18f8f64cffc9" xlink:to="loc_us-gaap_SeparateAccountsLiability_02c9f730-ed30-4db4-8f2a-c2ef09a839ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/FairValueNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#FairValueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/FairValueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4b42daa2-361b-4f65-bc63-a9bd0b439517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4b42daa2-361b-4f65-bc63-a9bd0b439517" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8e5f7d44-0ffd-4c19-80ed-aef0a11fef43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8e5f7d44-0ffd-4c19-80ed-aef0a11fef43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6594f32-2e55-4d7b-8839-5b19fc9c01d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8e5f7d44-0ffd-4c19-80ed-aef0a11fef43" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6594f32-2e55-4d7b-8839-5b19fc9c01d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3af18a0d-8847-4c4c-b98b-1152c8d5c61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6594f32-2e55-4d7b-8839-5b19fc9c01d8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3af18a0d-8847-4c4c-b98b-1152c8d5c61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5e37de39-3175-4264-a253-34e2b763334b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5e37de39-3175-4264-a253-34e2b763334b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_11ea8c5a-896e-4887-bdb3-eba7c76c01e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5e37de39-3175-4264-a253-34e2b763334b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_11ea8c5a-896e-4887-bdb3-eba7c76c01e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ef1f3ce7-7485-445a-9924-bb28364f3a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_11ea8c5a-896e-4887-bdb3-eba7c76c01e8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ef1f3ce7-7485-445a-9924-bb28364f3a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryAxis_2f62bf51-41e2-45e9-84f4-e9f5394e92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryAxis_2f62bf51-41e2-45e9-84f4-e9f5394e92dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssetCategoryDomain_d621316b-6d10-4674-971e-2462c4d722bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparateAccountAssetCategoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryAxis_2f62bf51-41e2-45e9-84f4-e9f5394e92dd" xlink:to="loc_us-gaap_SeparateAccountAssetCategoryDomain_d621316b-6d10-4674-971e-2462c4d722bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeparateAccountFinancialAssetsMember_b2766dd7-1daa-4bc0-8411-61c35efc4c56" xlink:href="cvs-20221231.xsd#cvs_SeparateAccountFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeparateAccountAssetCategoryDomain_d621316b-6d10-4674-971e-2462c4d722bb" xlink:to="loc_cvs_SeparateAccountFinancialAssetsMember_b2766dd7-1daa-4bc0-8411-61c35efc4c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c11499c-4ac6-42a4-b16b-149807edbd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39fa86fe-c6ba-49f3-b29e-00007a5a8ec5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c11499c-4ac6-42a4-b16b-149807edbd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_9285b800-0cbe-4a55-84f3-73d751178f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c11499c-4ac6-42a4-b16b-149807edbd81" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_9285b800-0cbe-4a55-84f3-73d751178f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherIntangiblesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f0a622-24b7-4959-b14e-c453d2eb569d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_48a84bd0-0929-47f5-b159-76fc44fa4e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f0a622-24b7-4959-b14e-c453d2eb569d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_48a84bd0-0929-47f5-b159-76fc44fa4e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e4bb5c40-e684-4a75-9730-ed66ffafa4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48a84bd0-0929-47f5-b159-76fc44fa4e7e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e4bb5c40-e684-4a75-9730-ed66ffafa4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e4bb5c40-e684-4a75-9730-ed66ffafa4a5" xlink:to="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_6a3ebbb3-ecdf-46ee-b0a9-785c3d8a7a67" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_6a3ebbb3-ecdf-46ee-b0a9-785c3d8a7a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyServicesSegmentMember_81b45814-3796-485d-9379-4fe860609541" xlink:href="cvs-20221231.xsd#cvs_PharmacyServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:to="loc_cvs_PharmacyServicesSegmentMember_81b45814-3796-485d-9379-4fe860609541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_05e729ad-7f38-4c7e-bb0e-89294385014f" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a1fd37b5-5776-4af2-acd0-a4066021a627" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_05e729ad-7f38-4c7e-bb0e-89294385014f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ffb26f0e-600c-49ea-91ac-6c81f77623f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48a84bd0-0929-47f5-b159-76fc44fa4e7e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ffb26f0e-600c-49ea-91ac-6c81f77623f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e527f732-daae-4a56-834d-c1709fb3bca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ffb26f0e-600c-49ea-91ac-6c81f77623f5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e527f732-daae-4a56-834d-c1709fb3bca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_00847c96-a66f-4885-801f-9daed973f96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e527f732-daae-4a56-834d-c1709fb3bca7" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_00847c96-a66f-4885-801f-9daed973f96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_bebe262a-2653-4c03-9374-440db3157733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48a84bd0-0929-47f5-b159-76fc44fa4e7e" xlink:to="loc_us-gaap_GoodwillLineItems_bebe262a-2653-4c03-9374-440db3157733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_bebe262a-2653-4c03-9374-440db3157733" xlink:to="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1ee6830d-81e5-4c58-8cc3-d65650d9ebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:to="loc_us-gaap_Goodwill_1ee6830d-81e5-4c58-8cc3-d65650d9ebc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6dea3a55-bea4-4620-b778-886fefc83547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6dea3a55-bea4-4620-b778-886fefc83547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_855fff4f-eba9-4693-a124-af9de6c7d151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_855fff4f-eba9-4693-a124-af9de6c7d151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_83363e2c-42e9-4a6d-adb4-2cfc2091b120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2cbf7616-a81b-4ba1-bb7f-7e5fb839a01e" xlink:to="loc_us-gaap_Goodwill_83363e2c-42e9-4a6d-adb4-2cfc2091b120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ae807f33-a2f0-4db6-9ebe-b0fb5681e9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1d3b74db-015b-4d2a-8ac0-5c6933147ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ae807f33-a2f0-4db6-9ebe-b0fb5681e9ed" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1d3b74db-015b-4d2a-8ac0-5c6933147ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_f014eb3c-49e5-458f-bc89-45fd04aeec81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1d3b74db-015b-4d2a-8ac0-5c6933147ddd" xlink:to="loc_us-gaap_ReportingUnitAxis_f014eb3c-49e5-458f-bc89-45fd04aeec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_3ef8fab1-1a5f-4e11-b673-3147ff913c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_f014eb3c-49e5-458f-bc89-45fd04aeec81" xlink:to="loc_us-gaap_ReportingUnitDomain_3ef8fab1-1a5f-4e11-b673-3147ff913c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermCareReportingUnitMember_6cead929-ddc5-45b1-92d8-ee8fdf0c1a1c" xlink:href="cvs-20221231.xsd#cvs_LongTermCareReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_3ef8fab1-1a5f-4e11-b673-3147ff913c93" xlink:to="loc_cvs_LongTermCareReportingUnitMember_6cead929-ddc5-45b1-92d8-ee8fdf0c1a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1d3b74db-015b-4d2a-8ac0-5c6933147ddd" xlink:to="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_28459b9f-7872-4c74-9bfd-20e826ed866e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_28459b9f-7872-4c74-9bfd-20e826ed866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_81e71fd4-ffd2-442f-b75e-04ef4843e102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:to="loc_us-gaap_Goodwill_81e71fd4-ffd2-442f-b75e-04ef4843e102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6e0076ca-689d-4c19-bc4c-4091256537c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c825f703-be08-4283-9015-4c3a4da8d2eb" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6e0076ca-689d-4c19-bc4c-4091256537c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherIntangiblesIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d850d111-a8df-425c-a01b-e86e0367b664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:href="cvs-20221231.xsd#cvs_OtherAcquiredIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d850d111-a8df-425c-a01b-e86e0367b664" xlink:to="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a68e78ef-cbf5-41ec-b8b6-a8c730d792bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a68e78ef-cbf5-41ec-b8b6-a8c730d792bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a68e78ef-cbf5-41ec-b8b6-a8c730d792bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_2d63dd2a-5330-43de-88be-27775ad4bb43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_2d63dd2a-5330-43de-88be-27775ad4bb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_23b77453-11c1-4d39-a392-7b7c0e077fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_23b77453-11c1-4d39-a392-7b7c0e077fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ProviderNetworksMember_2842e0c0-0040-41d0-8044-78e6922d7f28" xlink:href="cvs-20221231.xsd#cvs_ProviderNetworksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_cvs_ProviderNetworksMember_2842e0c0-0040-41d0-8044-78e6922d7f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ValueOfBusinessAcquiredMember_531dbd4a-055f-4897-b81c-c3d0d11d6f2f" xlink:href="cvs-20221231.xsd#cvs_ValueOfBusinessAcquiredMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_cvs_ValueOfBusinessAcquiredMember_531dbd4a-055f-4897-b81c-c3d0d11d6f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7b7842c8-1fc8-42ef-bc7f-f2d9626e3001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_871c1291-8c9e-44f5-80f4-db6b46600b01" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7b7842c8-1fc8-42ef-bc7f-f2d9626e3001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_de495114-9c52-4773-b9fa-77b16c68a279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_de495114-9c52-4773-b9fa-77b16c68a279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2f1fa448-649d-41a6-afc2-4cf922470ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_de495114-9c52-4773-b9fa-77b16c68a279" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2f1fa448-649d-41a6-afc2-4cf922470ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_08177452-a064-4392-b32b-7c5327b080e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2f1fa448-649d-41a6-afc2-4cf922470ad8" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_08177452-a064-4392-b32b-7c5327b080e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5813f9bf-6382-4202-a3a6-aba4bb3d2b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5813f9bf-6382-4202-a3a6-aba4bb3d2b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a7bac6cf-e2a2-485e-8067-6bf0d68953a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5813f9bf-6382-4202-a3a6-aba4bb3d2b23" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a7bac6cf-e2a2-485e-8067-6bf0d68953a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OmnicareLongTermCareBusinessMember_28d5a0e9-b9d1-43c0-a2a2-3d69e63877e9" xlink:href="cvs-20221231.xsd#cvs_OmnicareLongTermCareBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a7bac6cf-e2a2-485e-8067-6bf0d68953a0" xlink:to="loc_cvs_OmnicareLongTermCareBusinessMember_28d5a0e9-b9d1-43c0-a2a2-3d69e63877e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b122e84d-2d86-4431-92b7-3024421a588d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b122e84d-2d86-4431-92b7-3024421a588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb7386a5-c7f1-4f1a-a06a-8a7a71fd673e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b122e84d-2d86-4431-92b7-3024421a588d" xlink:to="loc_us-gaap_SegmentDomain_fb7386a5-c7f1-4f1a-a06a-8a7a71fd673e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_da99341d-1be5-444e-9a7b-3436215bcfa6" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fb7386a5-c7f1-4f1a-a06a-8a7a71fd673e" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_da99341d-1be5-444e-9a7b-3436215bcfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:href="cvs-20221231.xsd#cvs_OtherAcquiredIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsTable_f7b4e067-ee49-4a58-baaf-d1d5d29d7070" xlink:to="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ca9ed2a4-0108-474d-84f1-e9c953297ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ca9ed2a4-0108-474d-84f1-e9c953297ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50151ad9-a07a-4a66-8ae7-16ec75595558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50151ad9-a07a-4a66-8ae7-16ec75595558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6cfde0c8-f64a-4f72-9510-d03593dbae25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6cfde0c8-f64a-4f72-9510-d03593dbae25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4ce7ec73-4ed7-4ff7-82ac-218059a08d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4ce7ec73-4ed7-4ff7-82ac-218059a08d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_767f29b0-4e5f-46a2-b8f2-3d0be826d3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_767f29b0-4e5f-46a2-b8f2-3d0be826d3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_218d57c8-1ed8-40c4-9385-a5c16441494b" xlink:href="cvs-20221231.xsd#cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale_218d57c8-1ed8-40c4-9385-a5c16441494b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_734d99c4-6550-438d-9ff5-d1d4f8ecebb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_734d99c4-6550-438d-9ff5-d1d4f8ecebb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a61303a0-2d0e-4946-aa3f-f6595da05fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a61303a0-2d0e-4946-aa3f-f6595da05fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_669ad882-fffb-4c50-bbcc-3fcf2f050fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OtherAcquiredIntangibleAssetsLineItems_a2ba19c1-ccd3-43b7-9a60-0bcb1f7dc223" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_669ad882-fffb-4c50-bbcc-3fcf2f050fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ce55e586-b041-4fbb-b286-c101d174aa33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e3f97c29-ff54-4c8f-855c-787d634e03e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ce55e586-b041-4fbb-b286-c101d174aa33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e3f97c29-ff54-4c8f-855c-787d634e03e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b219d24e-10da-43b3-afe8-e4599e5d786f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e3f97c29-ff54-4c8f-855c-787d634e03e5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b219d24e-10da-43b3-afe8-e4599e5d786f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ba624673-09af-42ed-a50f-7fcff6477005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e3f97c29-ff54-4c8f-855c-787d634e03e5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ba624673-09af-42ed-a50f-7fcff6477005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_19ed6261-523a-4bb3-b158-03cf1518a5df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e3f97c29-ff54-4c8f-855c-787d634e03e5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_19ed6261-523a-4bb3-b158-03cf1518a5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_09914719-b0a7-4f1d-bf9c-87995e2b076a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e3f97c29-ff54-4c8f-855c-787d634e03e5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_09914719-b0a7-4f1d-bf9c-87995e2b076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a2c965ad-6c1d-4a14-996d-ea9d36776eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e3f97c29-ff54-4c8f-855c-787d634e03e5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a2c965ad-6c1d-4a14-996d-ea9d36776eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d55b9e15-3613-4c00-a926-b9d2bb268d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d55b9e15-3613-4c00-a926-b9d2bb268d7e" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d414d2ac-c0af-4427-a46b-795787c5b20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d414d2ac-c0af-4427-a46b-795787c5b20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d414d2ac-c0af-4427-a46b-795787c5b20f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_2374f5ee-fc5d-4c51-b74a-560084bc1a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:to="loc_us-gaap_BuildingMember_2374f5ee-fc5d-4c51-b74a-560084bc1a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1064a920-ab8e-4d56-95bd-4c47a1e22cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:to="loc_us-gaap_EquipmentMember_1064a920-ab8e-4d56-95bd-4c47a1e22cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_31ff184e-d53e-432d-a7b8-86c0b4dfb800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c92a5d20-d574-4f73-8d88-d5288e28b415" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_31ff184e-d53e-432d-a7b8-86c0b4dfb800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc1afe42-c188-420f-94d5-e310f5055987" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:to="loc_srt_RangeAxis_bc1afe42-c188-420f-94d5-e310f5055987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d555453-211c-4266-aaeb-5a011fde7339" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bc1afe42-c188-420f-94d5-e310f5055987" xlink:to="loc_srt_RangeMember_9d555453-211c-4266-aaeb-5a011fde7339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_78e981fd-d523-4470-8724-99e73561e121" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9d555453-211c-4266-aaeb-5a011fde7339" xlink:to="loc_srt_MinimumMember_78e981fd-d523-4470-8724-99e73561e121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d88d991b-a0a3-4404-b831-c37248165e43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9d555453-211c-4266-aaeb-5a011fde7339" xlink:to="loc_srt_MaximumMember_d88d991b-a0a3-4404-b831-c37248165e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b42e2f7d-994f-418d-bfce-a906333604c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b42e2f7d-994f-418d-bfce-a906333604c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6ea3df12-4c25-40d5-91cb-a75b04694ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b42e2f7d-994f-418d-bfce-a906333604c2" xlink:to="loc_us-gaap_SegmentDomain_6ea3df12-4c25-40d5-91cb-a75b04694ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_d44c4d57-a17e-4cc2-b7fa-ed14c8f20d2f" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6ea3df12-4c25-40d5-91cb-a75b04694ff4" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_d44c4d57-a17e-4cc2-b7fa-ed14c8f20d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_a64c151a-8d9d-42f6-ba77-68fd45260742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_a64c151a-8d9d-42f6-ba77-68fd45260742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_c1ad9625-50ad-4877-a014-cc7910d8947a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_a64c151a-8d9d-42f6-ba77-68fd45260742" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_c1ad9625-50ad-4877-a014-cc7910d8947a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOperatingLeaseMember_7598be6a-7e2b-4383-80b3-a15524736fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_c1ad9625-50ad-4877-a014-cc7910d8947a" xlink:to="loc_us-gaap_PropertySubjectToOperatingLeaseMember_7598be6a-7e2b-4383-80b3-a15524736fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1399cbe7-3bb2-4a07-9747-afeb698f6901" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_725875c1-a026-4649-9800-45e25ffceb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_725875c1-a026-4649-9800-45e25ffceb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_085a1e04-6bbc-4127-804b-efdb466f3fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_085a1e04-6bbc-4127-804b-efdb466f3fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_d25fb06d-3478-4643-9ebb-2e07ac0b6949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity_d25fb06d-3478-4643-9ebb-2e07ac0b6949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_093bff11-56c8-457c-9c25-efaef1b5c886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_093bff11-56c8-457c-9c25-efaef1b5c886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OfficeRealEstateOptimizationCharges_871f0538-10af-4232-a676-7f4408fd6301" xlink:href="cvs-20221231.xsd#cvs_OfficeRealEstateOptimizationCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_OfficeRealEstateOptimizationCharges_871f0538-10af-4232-a676-7f4408fd6301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresPlannedClosure_e3ad2269-f93c-4153-b281-5347476d07ea" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresPlannedClosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_NumberOfStoresPlannedClosure_e3ad2269-f93c-4153-b281-5347476d07ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod_e26539f1-7fa9-4471-bf2b-a4efd86d7e1b" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod_e26539f1-7fa9-4471-bf2b-a4efd86d7e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_c9b55299-56c0-4aea-9e56-ee61093ac01b" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_StoreImpairmentCharges_c9b55299-56c0-4aea-9e56-ee61093ac01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure_2ab14076-f2c8-46ce-8c23-c1fc8977e7e3" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure_2ab14076-f2c8-46ce-8c23-c1fc8977e7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_48c09f9f-f59f-4a44-96db-ec8eb3dfff18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_6cd796dc-2cbb-4218-9301-4d91b901bba2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_48c09f9f-f59f-4a44-96db-ec8eb3dfff18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesSummaryoftheComponentsofNetLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_10472a98-b038-4079-92e1-3c5ce81d19a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ee41b316-073d-4d44-bbaa-26e3c2634fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10472a98-b038-4079-92e1-3c5ce81d19a2" xlink:to="loc_us-gaap_OperatingLeaseCost_ee41b316-073d-4d44-bbaa-26e3c2634fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_ceecfde4-9c47-4091-9ae3-30296674ab5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10472a98-b038-4079-92e1-3c5ce81d19a2" xlink:to="loc_us-gaap_LeaseCostAbstract_ceecfde4-9c47-4091-9ae3-30296674ab5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_30009b0d-adc8-4a58-86fa-62337db5c7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ceecfde4-9c47-4091-9ae3-30296674ab5d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_30009b0d-adc8-4a58-86fa-62337db5c7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_5ba3184c-9007-4207-997a-93224c3c56b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ceecfde4-9c47-4091-9ae3-30296674ab5d" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_5ba3184c-9007-4207-997a-93224c3c56b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseCost_fb30adda-d205-4391-8795-dba188bcf6ef" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ceecfde4-9c47-4091-9ae3-30296674ab5d" xlink:to="loc_cvs_FinanceLeaseCost_fb30adda-d205-4391-8795-dba188bcf6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3d10c72e-96d9-4df9-b804-b632416d4309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ceecfde4-9c47-4091-9ae3-30296674ab5d" xlink:to="loc_us-gaap_ShortTermLeaseCost_3d10c72e-96d9-4df9-b804-b632416d4309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_6daa115b-e31c-480a-b1ce-1d51e8c6ced8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ceecfde4-9c47-4091-9ae3-30296674ab5d" xlink:to="loc_us-gaap_VariableLeaseCost_6daa115b-e31c-480a-b1ce-1d51e8c6ced8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9c851543-e73f-4ecc-94e8-624da2ea7769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ceecfde4-9c47-4091-9ae3-30296674ab5d" xlink:to="loc_us-gaap_SubleaseIncome_9c851543-e73f-4ecc-94e8-624da2ea7769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ee20642c-3e25-4e01-af97-6d6dcf123c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ceecfde4-9c47-4091-9ae3-30296674ab5d" xlink:to="loc_us-gaap_LeaseCost_ee20642c-3e25-4e01-af97-6d6dcf123c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19fe114f-85dc-4c12-b5f3-4faccc887469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CashFlowLesseeAbstract_6d4142e1-47d7-4178-8a2f-026337356856" xlink:href="cvs-20221231.xsd#cvs_CashFlowLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19fe114f-85dc-4c12-b5f3-4faccc887469" xlink:to="loc_cvs_CashFlowLesseeAbstract_6d4142e1-47d7-4178-8a2f-026337356856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_fb08121b-b7d5-482f-b563-66983e2b6dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_CashFlowLesseeAbstract_6d4142e1-47d7-4178-8a2f-026337356856" xlink:to="loc_us-gaap_OperatingLeasePayments_fb08121b-b7d5-482f-b563-66983e2b6dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_fb930f84-6234-48c3-ad63-1d7ee85dead6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_CashFlowLesseeAbstract_6d4142e1-47d7-4178-8a2f-026337356856" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_fb930f84-6234-48c3-ad63-1d7ee85dead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_8337c955-9416-4897-83c3-dc2ffa07c8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_CashFlowLesseeAbstract_6d4142e1-47d7-4178-8a2f-026337356856" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_8337c955-9416-4897-83c3-dc2ffa07c8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract_a354b19e-2063-4be1-bb4f-27368aafd5d5" xlink:href="cvs-20221231.xsd#cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_CashFlowLesseeAbstract_6d4142e1-47d7-4178-8a2f-026337356856" xlink:to="loc_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract_a354b19e-2063-4be1-bb4f-27368aafd5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6894211d-b445-4881-b808-443a8365d1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract_a354b19e-2063-4be1-bb4f-27368aafd5d5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6894211d-b445-4881-b808-443a8365d1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_2ee30f2c-d25c-474c-8c49-30c7ee0c51ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract_a354b19e-2063-4be1-bb4f-27368aafd5d5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_2ee30f2c-d25c-474c-8c49-30c7ee0c51ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c557fbf8-afb3-4f46-adf2-48e8a51b8021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_35073e41-125d-4c68-ab65-adce98b97f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c557fbf8-afb3-4f46-adf2-48e8a51b8021" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_35073e41-125d-4c68-ab65-adce98b97f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0ae1c7ac-e7c7-4216-9394-37b3185ff875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_35073e41-125d-4c68-ab65-adce98b97f6b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0ae1c7ac-e7c7-4216-9394-37b3185ff875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_32c61a04-795d-4ae5-a3c3-0b7bbdd160af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0ae1c7ac-e7c7-4216-9394-37b3185ff875" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_32c61a04-795d-4ae5-a3c3-0b7bbdd160af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_98e86318-16d0-454e-9218-9cef9e77e53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_32c61a04-795d-4ae5-a3c3-0b7bbdd160af" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_98e86318-16d0-454e-9218-9cef9e77e53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_35073e41-125d-4c68-ab65-adce98b97f6b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:to="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale_fabd46c2-996e-4184-b855-de8c3342957b" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:to="loc_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale_fabd46c2-996e-4184-b855-de8c3342957b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale_0d7cae3a-312f-474a-84e9-ec5ca6ef28af" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:to="loc_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale_0d7cae3a-312f-474a-84e9-ec5ca6ef28af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale_6aae83ee-2ba0-404d-87f4-1e10a09c97a9" xlink:href="cvs-20221231.xsd#cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:to="loc_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale_6aae83ee-2ba0-404d-87f4-1e10a09c97a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_43165e62-2c01-4060-af0d-64e8e4e3ea54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract_4c5fa028-f1fc-4550-9130-b46e25df5108" xlink:to="loc_us-gaap_OperatingLeaseLiability_43165e62-2c01-4060-af0d-64e8e4e3ea54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:to="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetGross_d863a9d7-72e4-479e-b5ba-29aaffe2c8ad" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_cvs_FinanceLeaseRightOfUseAssetGross_d863a9d7-72e4-479e-b5ba-29aaffe2c8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation_fd62fccd-e6b9-4845-ac1f-94169e0ab91b" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation_fd62fccd-e6b9-4845-ac1f-94169e0ab91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FinanceLeaseRightOfUseAssetNet_dd36195e-a7ae-4011-9317-e9734af6d9ab" xlink:href="cvs-20221231.xsd#cvs_FinanceLeaseRightOfUseAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_cvs_FinanceLeaseRightOfUseAssetNet_dd36195e-a7ae-4011-9317-e9734af6d9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_db548fee-a03c-4990-8b78-08853149bb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_db548fee-a03c-4990-8b78-08853149bb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_56dfabc5-9364-4da0-8c2e-ebf9a55a34df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_56dfabc5-9364-4da0-8c2e-ebf9a55a34df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_1492d855-58dc-4b2a-a063-07c91001ac16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract_1861bd22-ec1b-4faa-935f-26ee2f77ca9a" xlink:to="loc_us-gaap_FinanceLeaseLiability_1492d855-58dc-4b2a-a063-07c91001ac16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_WeightedAverageRemainingLeaseTermAbstract_46fc60c5-c593-49a6-92e5-9f6593cb4c9c" xlink:href="cvs-20221231.xsd#cvs_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:to="loc_cvs_WeightedAverageRemainingLeaseTermAbstract_46fc60c5-c593-49a6-92e5-9f6593cb4c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_65b4ac99-df84-42a5-881e-6030eb1daf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_WeightedAverageRemainingLeaseTermAbstract_46fc60c5-c593-49a6-92e5-9f6593cb4c9c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_65b4ac99-df84-42a5-881e-6030eb1daf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_623c2073-2055-42aa-bee2-5a2b0295259d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_WeightedAverageRemainingLeaseTermAbstract_46fc60c5-c593-49a6-92e5-9f6593cb4c9c" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_623c2073-2055-42aa-bee2-5a2b0295259d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LeasesWeightedAverageDiscountRateAbstract_cb98234d-9cd7-498d-a9a3-d2afe22c1603" xlink:href="cvs-20221231.xsd#cvs_LeasesWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9a045b4-9f9f-405b-af43-5ef498a96c54" xlink:to="loc_cvs_LeasesWeightedAverageDiscountRateAbstract_cb98234d-9cd7-498d-a9a3-d2afe22c1603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7f7571ac-524e-41cf-ae4e-6ddd2448c652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LeasesWeightedAverageDiscountRateAbstract_cb98234d-9cd7-498d-a9a3-d2afe22c1603" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7f7571ac-524e-41cf-ae4e-6ddd2448c652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_46148f0f-260b-4cae-9879-056b10f095a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LeasesWeightedAverageDiscountRateAbstract_cb98234d-9cd7-498d-a9a3-d2afe22c1603" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_46148f0f-260b-4cae-9879-056b10f095a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f3876d7b-d8a3-4883-a8d3-5ab5a1428030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f3876d7b-d8a3-4883-a8d3-5ab5a1428030" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_38d95621-2b19-4493-83aa-d800ffff1cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_38d95621-2b19-4493-83aa-d800ffff1cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0bdad986-c5c5-493a-9d90-9d1cf0796cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0bdad986-c5c5-493a-9d90-9d1cf0796cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_450e2307-e892-414f-a04b-a67601cd97e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_450e2307-e892-414f-a04b-a67601cd97e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_d975c7b2-8cca-45d7-b5e6-4f6a8da6985a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_d975c7b2-8cca-45d7-b5e6-4f6a8da6985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_20307db7-f42d-4b0f-972c-74d08b57191d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_20307db7-f42d-4b0f-972c-74d08b57191d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f9a84174-7495-442c-9f76-56c4deb96506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f9a84174-7495-442c-9f76-56c4deb96506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_84673b02-f978-43a5-8385-e6101a4f8292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_84673b02-f978-43a5-8385-e6101a4f8292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b238d431-8ce5-4c86-a806-679d8abc57c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b238d431-8ce5-4c86-a806-679d8abc57c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_3db44ac0-4319-452c-a171-ac0146baa378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18b9f3e3-fca7-4bcc-ab05-d8b6f8f13320" xlink:to="loc_us-gaap_FinanceLeaseLiability_3db44ac0-4319-452c-a171-ac0146baa378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f3876d7b-d8a3-4883-a8d3-5ab5a1428030" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cf00d6b8-095d-4af0-bb5b-39f7e30e6dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cf00d6b8-095d-4af0-bb5b-39f7e30e6dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_477d466c-a44f-4708-8ae2-7b55744c9766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_477d466c-a44f-4708-8ae2-7b55744c9766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_464f43d8-fad1-4d7e-8299-079fb9f95024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_464f43d8-fad1-4d7e-8299-079fb9f95024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cd3da067-9108-47e8-b112-4be5afd99c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cd3da067-9108-47e8-b112-4be5afd99c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_562ed755-0ce2-46b1-9815-1252f3b73e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_562ed755-0ce2-46b1-9815-1252f3b73e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_760daafa-84c0-43ec-9f05-4074b19190bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_760daafa-84c0-43ec-9f05-4074b19190bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3aa9a4da-9586-47c7-bfc1-390ed7e41bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3aa9a4da-9586-47c7-bfc1-390ed7e41bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5cfe54a2-e7ec-48c8-8c1a-291a44e6f5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5cfe54a2-e7ec-48c8-8c1a-291a44e6f5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_61a52f2e-5888-4083-9612-c16a6b5f3d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d714e813-6181-4b5b-9b3a-cea6cbf0f218" xlink:to="loc_us-gaap_OperatingLeaseLiability_61a52f2e-5888-4083-9612-c16a6b5f3d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:href="cvs-20221231.xsd#cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f3876d7b-d8a3-4883-a8d3-5ab5a1428030" xlink:to="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsYearOne_9e1b9c9c-41d3-4979-80d7-f13f3b89fb86" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:to="loc_cvs_LesseeLiabilityPaymentsYearOne_9e1b9c9c-41d3-4979-80d7-f13f3b89fb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearTwo_6be10d96-3d71-4198-8c0f-d9928bdbb25e" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueYearTwo_6be10d96-3d71-4198-8c0f-d9928bdbb25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearThree_daddeb79-81ac-4821-ba87-f81658760257" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueYearThree_daddeb79-81ac-4821-ba87-f81658760257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearFour_7eb12b6e-142d-492d-b009-5f4daee60179" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueYearFour_7eb12b6e-142d-492d-b009-5f4daee60179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueYearFive_3d588fa7-73dd-42a4-bd42-8b6b3272a1ed" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueYearFive_3d588fa7-73dd-42a4-bd42-8b6b3272a1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDueAfterYearFive_8fafe8d3-5f08-40ad-8d40-3d7d448f974d" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:to="loc_cvs_LesseeLiabilityPaymentsDueAfterYearFive_8fafe8d3-5f08-40ad-8d40-3d7d448f974d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityPaymentsDue_bf612216-c233-48f3-863b-6a6b2d02cf20" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:to="loc_cvs_LesseeLiabilityPaymentsDue_bf612216-c233-48f3-863b-6a6b2d02cf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LesseeLiabilityUndiscountedExcessAmount_09746113-9f6c-4208-baac-6a0daa486bcd" xlink:href="cvs-20221231.xsd#cvs_LesseeLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:to="loc_cvs_LesseeLiabilityUndiscountedExcessAmount_09746113-9f6c-4208-baac-6a0daa486bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LeaseLiability_e3dbd357-5c28-4624-8fc8-153b8b7e3781" xlink:href="cvs-20221231.xsd#cvs_LeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract_d23804e2-48b9-41d1-b339-d2b66d93ed6a" xlink:to="loc_cvs_LeaseLiability_e3dbd357-5c28-4624-8fc8-153b8b7e3781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c671e0f2-ecff-43a1-96b1-8de4c776e3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f3876d7b-d8a3-4883-a8d3-5ab5a1428030" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c671e0f2-ecff-43a1-96b1-8de4c776e3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife_92f0e31a-fd3d-44fa-9d69-be30ef105a83" xlink:href="cvs-20221231.xsd#cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f3876d7b-d8a3-4883-a8d3-5ab5a1428030" xlink:to="loc_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife_92f0e31a-fd3d-44fa-9d69-be30ef105a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="cvs-20221231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_2ef0a8c2-c7fa-4d47-9975-6cb2feb41d65" xlink:href="cvs-20221231.xsd#cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_5efbe32e-34d2-4bec-a79f-8975ec9c0a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_2ef0a8c2-c7fa-4d47-9975-6cb2feb41d65" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_5efbe32e-34d2-4bec-a79f-8975ec9c0a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3f734ccc-5969-42d1-8c79-a20b7d154ad6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_5efbe32e-34d2-4bec-a79f-8975ec9c0a46" xlink:to="loc_srt_ProductOrServiceAxis_3f734ccc-5969-42d1-8c79-a20b7d154ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec80ed1d-3473-432c-9639-52b785acf461" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3f734ccc-5969-42d1-8c79-a20b7d154ad6" xlink:to="loc_srt_ProductsAndServicesDomain_ec80ed1d-3473-432c-9639-52b785acf461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthInsuranceProductLineMember_d9158c55-3a47-4ea9-9c73-3c1d1dbc728a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthInsuranceProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ec80ed1d-3473-432c-9639-52b785acf461" xlink:to="loc_us-gaap_HealthInsuranceProductLineMember_d9158c55-3a47-4ea9-9c73-3c1d1dbc728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_24ee6e1d-44b9-415c-b8f7-1c0d251510ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_5efbe32e-34d2-4bec-a79f-8975ec9c0a46" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_24ee6e1d-44b9-415c-b8f7-1c0d251510ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f37d04d8-84b6-4d2a-8cf3-7b23a2168dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_24ee6e1d-44b9-415c-b8f7-1c0d251510ae" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f37d04d8-84b6-4d2a-8cf3-7b23a2168dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_46d33ee1-947b-4bd5-a64e-0c9fe67180c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f37d04d8-84b6-4d2a-8cf3-7b23a2168dfc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2019Member_46d33ee1-947b-4bd5-a64e-0c9fe67180c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_cd25cb6b-bff6-490b-a857-8720c1d7f404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f37d04d8-84b6-4d2a-8cf3-7b23a2168dfc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_cd25cb6b-bff6-490b-a857-8720c1d7f404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_5efbe32e-34d2-4bec-a79f-8975ec9c0a46" xlink:to="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_03bebad0-8bf5-4f5b-8e73-7ef75a12c856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_03bebad0-8bf5-4f5b-8e73-7ef75a12c856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_20a4f33b-190e-461d-8068-b9f3d023f098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_20a4f33b-190e-461d-8068-b9f3d023f098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented_3ba44779-be53-4fbb-986b-5c1b58ca2350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented_3ba44779-be53-4fbb-986b-5c1b58ca2350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_e69ef89e-1522-4dd5-8227-6c6d66251e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_7a40a96b-ee12-4351-9515-8df3916e623e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_e69ef89e-1522-4dd5-8227-6c6d66251e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_ed87c25e-12a3-48e7-9497-80f6b74a5849" xlink:href="cvs-20221231.xsd#cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_d72b0aef-00b8-428e-9f69-43980813fff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_ed87c25e-12a3-48e7-9497-80f6b74a5849" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_d72b0aef-00b8-428e-9f69-43980813fff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_aac4cd64-a834-4719-b405-27757ea43206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_d72b0aef-00b8-428e-9f69-43980813fff4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_aac4cd64-a834-4719-b405-27757ea43206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a39e35af-fcb8-4127-ba10-137613dbb555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_aac4cd64-a834-4719-b405-27757ea43206" xlink:to="loc_us-gaap_SegmentDomain_a39e35af-fcb8-4127-ba10-137613dbb555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_63b7f4df-0206-4284-89fe-1c57fdabd441" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a39e35af-fcb8-4127-ba10-137613dbb555" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_63b7f4df-0206-4284-89fe-1c57fdabd441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_0bc7834b-be87-4077-a106-cec943f57d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_d72b0aef-00b8-428e-9f69-43980813fff4" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_0bc7834b-be87-4077-a106-cec943f57d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_91132cd2-d12a-435c-9fa3-ebc2fa5081ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_0bc7834b-be87-4077-a106-cec943f57d80" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet_91132cd2-d12a-435c-9fa3-ebc2fa5081ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_4313641d-9f7d-4b73-86d0-f2667bc2d529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_0bc7834b-be87-4077-a106-cec943f57d80" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_4313641d-9f7d-4b73-86d0-f2667bc2d529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_19fec872-cc7a-4131-9f4d-316d72d028ee" xlink:href="cvs-20221231.xsd#cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_7402de5e-21f3-4067-bd84-f7dd9e9f644f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_19fec872-cc7a-4131-9f4d-316d72d028ee" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_7402de5e-21f3-4067-bd84-f7dd9e9f644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1921d0b2-5948-433c-9ec6-2afb45b808a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_7402de5e-21f3-4067-bd84-f7dd9e9f644f" xlink:to="loc_srt_ProductOrServiceAxis_1921d0b2-5948-433c-9ec6-2afb45b808a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_81fbffb3-a014-4754-8679-b421396675e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1921d0b2-5948-433c-9ec6-2afb45b808a5" xlink:to="loc_srt_ProductsAndServicesDomain_81fbffb3-a014-4754-8679-b421396675e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthInsuranceProductLineMember_94030e3d-464f-4844-849d-dfdd08060bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthInsuranceProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81fbffb3-a014-4754-8679-b421396675e5" xlink:to="loc_us-gaap_HealthInsuranceProductLineMember_94030e3d-464f-4844-849d-dfdd08060bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_7402de5e-21f3-4067-bd84-f7dd9e9f644f" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_529cd7e9-213d-480e-a591-13a6f133068f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_529cd7e9-213d-480e-a591-13a6f133068f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_912dd206-c59e-44b3-b2ab-b62927ebdd34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_912dd206-c59e-44b3-b2ab-b62927ebdd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_d3cc8ba3-1c7e-4730-9011-a52d7fff42cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem_d3cc8ba3-1c7e-4730-9011-a52d7fff42cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9f3cef7e-1f0a-48ce-ad2b-3f282dd6e8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_ed739ead-dd75-4a4d-ac23-faa3fafa03af" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9f3cef7e-1f0a-48ce-ad2b-3f282dd6e8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_89014c72-77dd-4d0a-a3e6-c9bba766283a" xlink:href="cvs-20221231.xsd#cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_65b9e467-9cc2-44bb-8e35-67b5a34da97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract_89014c72-77dd-4d0a-a3e6-c9bba766283a" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_65b9e467-9cc2-44bb-8e35-67b5a34da97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_560c84a1-f388-49f1-85c0-9a5e1f76d858" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_65b9e467-9cc2-44bb-8e35-67b5a34da97f" xlink:to="loc_srt_ProductOrServiceAxis_560c84a1-f388-49f1-85c0-9a5e1f76d858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8d4ed2bc-4a67-4231-b697-dd25fbd9afcb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_560c84a1-f388-49f1-85c0-9a5e1f76d858" xlink:to="loc_srt_ProductsAndServicesDomain_8d4ed2bc-4a67-4231-b697-dd25fbd9afcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthInsuranceProductLineMember_a19f1327-1f3a-4108-be0c-a4e6a8b049b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthInsuranceProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8d4ed2bc-4a67-4231-b697-dd25fbd9afcb" xlink:to="loc_us-gaap_HealthInsuranceProductLineMember_a19f1327-1f3a-4108-be0c-a4e6a8b049b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cb2943fc-64aa-4598-b481-64c62384412e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_65b9e467-9cc2-44bb-8e35-67b5a34da97f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cb2943fc-64aa-4598-b481-64c62384412e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e1f2712a-c826-4b50-b4cc-9a405b1985ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cb2943fc-64aa-4598-b481-64c62384412e" xlink:to="loc_us-gaap_SegmentDomain_e1f2712a-c826-4b50-b4cc-9a405b1985ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_3eb0ca61-cbc1-4688-8f32-888cc8b954e8" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e1f2712a-c826-4b50-b4cc-9a405b1985ec" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_3eb0ca61-cbc1-4688-8f32-888cc8b954e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateAndOtherMember_a0a773c0-f6a7-43ea-8184-d832a2a7128d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e1f2712a-c826-4b50-b4cc-9a405b1985ec" xlink:to="loc_us-gaap_CorporateAndOtherMember_a0a773c0-f6a7-43ea-8184-d832a2a7128d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b55a257c-8c23-4c6a-8b74-aefa195e2f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_65b9e467-9cc2-44bb-8e35-67b5a34da97f" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b55a257c-8c23-4c6a-8b74-aefa195e2f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b55a257c-8c23-4c6a-8b74-aefa195e2f14" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5bd40fd8-007e-4733-84d4-e1c2d3d5af99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5bd40fd8-007e-4733-84d4-e1c2d3d5af99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ed272d35-30cc-48c0-8689-2b6faed67d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ed272d35-30cc-48c0-8689-2b6faed67d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_b580fb57-c99f-47dc-a322-e665da572f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_b580fb57-c99f-47dc-a322-e665da572f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_b8c0dd40-af3c-45b4-92f8-e1e63d88fd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_b8c0dd40-af3c-45b4-92f8-e1e63d88fd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_a1eda030-4bcc-42c3-8ba5-5bedcc237e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_a1eda030-4bcc-42c3-8ba5-5bedcc237e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_2494e3a5-cf1f-41cf-bb72-206529f8e97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_2494e3a5-cf1f-41cf-bb72-206529f8e97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6a790f4d-26e8-4ec5-a145-de8b3e95cdce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_4b20107e-4236-478c-a3ad-7f33cb2c03f8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6a790f4d-26e8-4ec5-a145-de8b3e95cdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c6dd50b2-9d68-43b1-b9f0-97468a231e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_c6dd50b2-9d68-43b1-b9f0-97468a231e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_a9b587eb-bcb1-4629-b858-e9d01ef1e49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_a9b587eb-bcb1-4629-b858-e9d01ef1e49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_416dfb94-30df-4c95-8be9-b5bdb6740499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_4c1de9f6-14eb-4433-a201-fb871f1580f7" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_416dfb94-30df-4c95-8be9-b5bdb6740499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumDeficiencyReserveLiability_35c4c784-6f6b-4cba-8866-75f3f429a064" xlink:href="cvs-20221231.xsd#cvs_PremiumDeficiencyReserveLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_cvs_PremiumDeficiencyReserveLiability_35c4c784-6f6b-4cba-8866-75f3f429a064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_c79a0115-026a-4c82-8f66-0c6abb407f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_c79a0115-026a-4c82-8f66-0c6abb407f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_f1093fcb-31ec-4a73-ad34-db69e1b19a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_f1093fcb-31ec-4a73-ad34-db69e1b19a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9c7ea684-0868-43fd-9e2e-81ca50d3bc90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b1081c37-50c4-4404-965b-4a15840b9c90" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9c7ea684-0868-43fd-9e2e-81ca50d3bc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts_29f74caf-9f9e-4287-82b8-dba2d1405b8a" xlink:href="cvs-20221231.xsd#cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b55a257c-8c23-4c6a-8b74-aefa195e2f14" xlink:to="loc_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts_29f74caf-9f9e-4287-82b8-dba2d1405b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumDeficiencyReserveLiability_bd67d230-dc83-4b04-993a-8de4a7859dcd" xlink:href="cvs-20221231.xsd#cvs_PremiumDeficiencyReserveLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_b55a257c-8c23-4c6a-8b74-aefa195e2f14" xlink:to="loc_cvs_PremiumDeficiencyReserveLiability_bd67d230-dc83-4b04-993a-8de4a7859dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ba653b96-cd94-4bd1-90d8-ce11cec2afa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba653b96-cd94-4bd1-90d8-ce11cec2afa1" xlink:to="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f2c632b8-a22f-4557-896b-2b1e8092b6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f2c632b8-a22f-4557-896b-2b1e8092b6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e2a1e746-63d1-4b22-8238-8bef6e9e6ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f2c632b8-a22f-4557-896b-2b1e8092b6e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e2a1e746-63d1-4b22-8238-8bef6e9e6ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_896323f4-1713-4f80-9047-e7e79f78f180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e2a1e746-63d1-4b22-8238-8bef6e9e6ee7" xlink:to="loc_us-gaap_SeniorNotesMember_896323f4-1713-4f80-9047-e7e79f78f180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_b87d4294-8593-4715-a0d0-0350ab05ceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e2a1e746-63d1-4b22-8238-8bef6e9e6ee7" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_b87d4294-8593-4715-a0d0-0350ab05ceb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_934c7e12-5efe-4d45-90ac-3835e008aaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:to="loc_us-gaap_DebtInstrumentAxis_934c7e12-5efe-4d45-90ac-3835e008aaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_934c7e12-5efe-4d45-90ac-3835e008aaaa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.5DueJuly2022Member_e3c27ae4-deff-4c3b-a132-70d8efc4d6f0" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.5DueJuly2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.5DueJuly2022Member_e3c27ae4-deff-4c3b-a132-70d8efc4d6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueNovember2022Member_2a5cd80e-8d19-4800-85e0-8a1b48fbc5ce" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueNovember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.75DueNovember2022Member_2a5cd80e-8d19-4800-85e0-8a1b48fbc5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueDecember2022Member_55c1701f-9c1c-4a71-b8c5-0c65b6ca4aca" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueDecember2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.75DueDecember2022Member_55c1701f-9c1c-4a71-b8c5-0c65b6ca4aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.75DueDecember2022Member_c9fba5f3-dadf-4052-a90e-29731d842de3" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.75DueDecember2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.75DueDecember2022Member_c9fba5f3-dadf-4052-a90e-29731d842de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.8DueJune2023Member_52e16586-02dc-4803-b890-84f4da314072" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.8DueJune2023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.8DueJune2023Member_52e16586-02dc-4803-b890-84f4da314072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4DueDecember2023Member_dc30f468-1131-4e2a-bb94-2834f89ca35c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4DueDecember2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4DueDecember2023Member_dc30f468-1131-4e2a-bb94-2834f89ca35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.375DueAugust2024Member_13fcba57-e8b3-48c7-a9cf-543c6219a509" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.375DueAugust2024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.375DueAugust2024Member_13fcba57-e8b3-48c7-a9cf-543c6219a509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.625DueAugust2024Member_70f3c454-32c0-4113-b788-dbedc9c03f76" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.625DueAugust2024Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.625DueAugust2024Member_70f3c454-32c0-4113-b788-dbedc9c03f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.5DueNovember2024Member_4f58ea8f-8767-41ac-8a94-6506e2cd22dc" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.5DueNovember2024Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.5DueNovember2024Member_4f58ea8f-8767-41ac-8a94-6506e2cd22dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5DueDecember2024Member_68ea4e66-a178-46c7-9c90-59528622ba40" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5DueDecember2024Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5DueDecember2024Member_68ea4e66-a178-46c7-9c90-59528622ba40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.1DueMarch2025Member_d9cb2ac8-ec8f-4893-9edb-327ca098b884" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.1DueMarch2025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.1DueMarch2025Member_d9cb2ac8-ec8f-4893-9edb-327ca098b884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.875DueJuly2025Member_b1524a9b-183f-4528-9b30-f6ae72196c0c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.875DueJuly2025Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.875DueJuly2025Member_b1524a9b-183f-4528-9b30-f6ae72196c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.875DueJune2026Member_8c5f4c0d-b3e0-4bde-b673-75d1a299414b" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.875DueJune2026Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2.875DueJune2026Member_8c5f4c0d-b3e0-4bde-b673-75d1a299414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3DueAugust2026Member_e3e50684-cdf0-4f85-9091-add62127da67" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3DueAugust2026Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3DueAugust2026Member_e3e50684-cdf0-4f85-9091-add62127da67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point625PercentApril2027Member_d1b6dbb4-d70a-434c-b768-fa383d3943a9" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point625PercentApril2027Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3Point625PercentApril2027Member_d1b6dbb4-d70a-434c-b768-fa383d3943a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.25DueJune2027Member_08b4aeb0-c3ce-4075-a1b0-38650143e5c7" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.25DueJune2027Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes6.25DueJune2027Member_08b4aeb0-c3ce-4075-a1b0-38650143e5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes1Point3PercentAugust2027Member_1f749660-0073-4a24-9edf-b3ced569f068" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes1Point3PercentAugust2027Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes1Point3PercentAugust2027Member_1f749660-0073-4a24-9edf-b3ced569f068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.3DueMarch2028Member_59697e77-8402-499a-a258-4b786fed6018" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.3DueMarch2028Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.3DueMarch2028Member_59697e77-8402-499a-a258-4b786fed6018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.25DueAugust2029Member_5ed5ad4d-ce27-44b8-b3f2-1d3b410c6079" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.25DueAugust2029Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.25DueAugust2029Member_5ed5ad4d-ce27-44b8-b3f2-1d3b410c6079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point75PercentApril2030Member_318bdbac-0159-412f-b4a5-f9625fcc142c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point75PercentApril2030Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3Point75PercentApril2030Member_318bdbac-0159-412f-b4a5-f9625fcc142c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes1Point75PercentAugust2030Member_ab2d277e-02b5-400e-ab17-845645bc4156" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes1Point75PercentAugust2030Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes1Point75PercentAugust2030Member_ab2d277e-02b5-400e-ab17-845645bc4156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes1Point875PercentFebruary2031Member_da54d3ac-b463-41cb-bbed-e25d96b50f9a" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes1Point875PercentFebruary2031Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes1Point875PercentFebruary2031Member_da54d3ac-b463-41cb-bbed-e25d96b50f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_6ef46c65-9891-446e-a770-62a8a387b9fe" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2Point125PercentDueSeptember2031Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_6ef46c65-9891-446e-a770-62a8a387b9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.875DueJuly2035Member_67538675-04fa-4a45-a996-dfb2a43cc30c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.875DueJuly2035Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.875DueJuly2035Member_67538675-04fa-4a45-a996-dfb2a43cc30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.625DueJune2036Member_0bd5f1ed-3dac-4704-bc1a-74e8b5868b56" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.625DueJune2036Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes6.625DueJune2036Member_0bd5f1ed-3dac-4704-bc1a-74e8b5868b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.75DueDecember2037Member_fe0fb37d-9107-487c-b896-c7887639e7c4" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.75DueDecember2037Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes6.75DueDecember2037Member_fe0fb37d-9107-487c-b896-c7887639e7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.78DueMarch2038Member_a0ff98dc-a5b6-44ee-aa37-4746dfca6a01" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.78DueMarch2038Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.78DueMarch2038Member_a0ff98dc-a5b6-44ee-aa37-4746dfca6a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes6.125DueSeptember2039Member_0dc7d538-2784-419b-aac7-cf3aa5cda3b3" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes6.125DueSeptember2039Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes6.125DueSeptember2039Member_0dc7d538-2784-419b-aac7-cf3aa5cda3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point125PercentApril2040Member_f8ae97fc-8f7b-47f0-93f0-c2a9b44ba33b" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point125PercentApril2040Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4Point125PercentApril2040Member_f8ae97fc-8f7b-47f0-93f0-c2a9b44ba33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2Point7PercentAugust2040Member_7bfa3b47-fcd2-467f-8e8d-a2effb884485" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2Point7PercentAugust2040Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes2Point7PercentAugust2040Member_7bfa3b47-fcd2-467f-8e8d-a2effb884485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.75DueMay2041Member_c1224add-08b3-4acd-8f4c-62925f256486" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.75DueMay2041Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5.75DueMay2041Member_c1224add-08b3-4acd-8f4c-62925f256486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.5DueMay2042Member_66c5717f-40a4-404a-a0c4-8499745ab4e8" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.5DueMay2042Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.5DueMay2042Member_66c5717f-40a4-404a-a0c4-8499745ab4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.125DueNovember2042Member_fad831a7-edc8-4c80-9b78-068d3aaeeef1" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.125DueNovember2042Member"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.125DueNovember2042Member_fad831a7-edc8-4c80-9b78-068d3aaeeef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.3DueDecember2043Member_ac1650ed-1434-42a7-bc1d-268961a341b2" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.3DueDecember2043Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5.3DueDecember2043Member_ac1650ed-1434-42a7-bc1d-268961a341b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.75DueMarch2044Member_af199760-ea93-4c58-a53e-8083952dc1a0" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.75DueMarch2044Member"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4.75DueMarch2044Member_af199760-ea93-4c58-a53e-8083952dc1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.125DueJuly2045Member_76883a87-e6e9-40fa-a218-222e6b36c1fb" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.125DueJuly2045Member"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5.125DueJuly2045Member_76883a87-e6e9-40fa-a218-222e6b36c1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.875DueAugust2047Member_6e91eb7b-a612-4875-9d27-b11cd95728c6" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.875DueAugust2047Member"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes3.875DueAugust2047Member_6e91eb7b-a612-4875-9d27-b11cd95728c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes5.05DueMarch2048Member_d0218207-6890-478e-b536-dbf2ea006796" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes5.05DueMarch2048Member"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes5.05DueMarch2048Member_d0218207-6890-478e-b536-dbf2ea006796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point25PercentApril2050Member_dfd955e1-95a1-4189-8ec6-55dc9646280f" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point25PercentApril2050Member"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a67ea5b2-ec95-425c-8da0-05c577919655" xlink:to="loc_cvs_SeniorNotes4Point25PercentApril2050Member_dfd955e1-95a1-4189-8ec6-55dc9646280f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_175a5a2a-0539-428d-8207-d361c6cd60d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_175a5a2a-0539-428d-8207-d361c6cd60d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3676b6bb-9068-4143-b0fe-48dba56315a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_175a5a2a-0539-428d-8207-d361c6cd60d2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3676b6bb-9068-4143-b0fe-48dba56315a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_18d99712-b265-429a-b7d2-d4941cbee3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3676b6bb-9068-4143-b0fe-48dba56315a4" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_18d99712-b265-429a-b7d2-d4941cbee3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_662fc79f-9dcf-4664-ab1b-7741f83d4a8e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b9537118-06ff-42b5-a46c-b8bd032f479e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b9537118-06ff-42b5-a46c-b8bd032f479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2e0911b0-9cb4-4ae4-a3d3-e6f5c342b566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2e0911b0-9cb4-4ae4-a3d3-e6f5c342b566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_38db9f0c-9aaf-4384-9f70-3c20adcbfde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_FinanceLeaseLiability_38db9f0c-9aaf-4384-9f70-3c20adcbfde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongtermDebtGrossAndLeaseObligation_4900203e-b0d2-4059-a48a-55eb3ebec6ee" xlink:href="cvs-20221231.xsd#cvs_LongtermDebtGrossAndLeaseObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_cvs_LongtermDebtGrossAndLeaseObligation_4900203e-b0d2-4059-a48a-55eb3ebec6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_b6edefa3-a87f-4db6-aff7-b6e6a7fea49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_b6edefa3-a87f-4db6-aff7-b6e6a7fea49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet_78776f81-e884-4499-b3b8-755aff9fcc9e" xlink:href="cvs-20221231.xsd#cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet_78776f81-e884-4499-b3b8-755aff9fcc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_29d4990b-84db-4e9a-992e-ced84e04b782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_29d4990b-84db-4e9a-992e-ced84e04b782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_11152bf5-f532-45ad-9a2f-1349228fc804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_11152bf5-f532-45ad-9a2f-1349228fc804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale_87b40039-0ed1-4592-b5a0-e3b49e9b8da3" xlink:href="cvs-20221231.xsd#cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale_87b40039-0ed1-4592-b5a0-e3b49e9b8da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_3ec0eb5a-758f-408d-aed1-aec238f754b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c31ba0b-c92c-4036-b631-ae3c37a28853" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_3ec0eb5a-758f-408d-aed1-aec238f754b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e8053ebb-0c22-4110-a9d3-e26564b14d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_f5c2ad7c-ce5d-49fe-a26c-95124362be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e8053ebb-0c22-4110-a9d3-e26564b14d78" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_f5c2ad7c-ce5d-49fe-a26c-95124362be3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2947c522-8a3c-43ad-ab0b-8760ea65742c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_f5c2ad7c-ce5d-49fe-a26c-95124362be3c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2947c522-8a3c-43ad-ab0b-8760ea65742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a73d1c64-1297-412f-814c-fd6ab4cc85ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_f5c2ad7c-ce5d-49fe-a26c-95124362be3c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a73d1c64-1297-412f-814c-fd6ab4cc85ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_21b587af-d54f-4f83-bf74-f382f8b154b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_f5c2ad7c-ce5d-49fe-a26c-95124362be3c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_21b587af-d54f-4f83-bf74-f382f8b154b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8121b9da-b5bf-4e67-93f0-a93811af2fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_f5c2ad7c-ce5d-49fe-a26c-95124362be3c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8121b9da-b5bf-4e67-93f0-a93811af2fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9ee0baad-80e4-4063-87c5-7cb554a4225c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_f5c2ad7c-ce5d-49fe-a26c-95124362be3c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9ee0baad-80e4-4063-87c5-7cb554a4225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3f73cb91-2240-4a07-bb7a-7e84e5eebb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_f5c2ad7c-ce5d-49fe-a26c-95124362be3c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3f73cb91-2240-4a07-bb7a-7e84e5eebb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1f4bd721-66e1-4a39-9974-23e19abec939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_f5c2ad7c-ce5d-49fe-a26c-95124362be3c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1f4bd721-66e1-4a39-9974-23e19abec939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_23d70a27-32e5-47ba-98ba-06a5759dc401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e8053ebb-0c22-4110-a9d3-e26564b14d78" xlink:to="loc_us-gaap_FinanceLeaseLiability_23d70a27-32e5-47ba-98ba-06a5759dc401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LongtermDebtGrossAndLeaseObligation_9d8c2524-93e4-4c90-ae30-c3b9bcab1817" xlink:href="cvs-20221231.xsd#cvs_LongtermDebtGrossAndLeaseObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e8053ebb-0c22-4110-a9d3-e26564b14d78" xlink:to="loc_cvs_LongtermDebtGrossAndLeaseObligation_9d8c2524-93e4-4c90-ae30-c3b9bcab1817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_29a223ed-b1cb-4c1d-af38-f80396a070f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_3073198e-aa95-40cb-9887-2dd911ad712a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_29a223ed-b1cb-4c1d-af38-f80396a070f6" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_3073198e-aa95-40cb-9887-2dd911ad712a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_6098014d-636e-437f-9cae-918c93424ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3073198e-aa95-40cb-9887-2dd911ad712a" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_6098014d-636e-437f-9cae-918c93424ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6098014d-636e-437f-9cae-918c93424ae9" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0c3b982d-5d67-4624-a33b-7aa98f32d869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:to="loc_us-gaap_CommercialPaperMember_0c3b982d-5d67-4624-a33b-7aa98f32d869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6e97c1a4-f100-4fbc-a1ba-4463fa049f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:to="loc_us-gaap_LineOfCreditMember_6e97c1a4-f100-4fbc-a1ba-4463fa049f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMember_4a9e9b01-03d7-46a4-83db-38edbce41a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_09fb019f-da4d-4aa7-afb6-f3d6a0e0687a" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMember_4a9e9b01-03d7-46a4-83db-38edbce41a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a43b4adf-a942-4242-99de-33170e7103d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3073198e-aa95-40cb-9887-2dd911ad712a" xlink:to="loc_us-gaap_DebtInstrumentAxis_a43b4adf-a942-4242-99de-33170e7103d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ff0245d-4541-461a-bd42-348e59ea2caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a43b4adf-a942-4242-99de-33170e7103d0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ff0245d-4541-461a-bd42-348e59ea2caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:href="cvs-20221231.xsd#cvs_BackUpCreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ff0245d-4541-461a-bd42-348e59ea2caf" xlink:to="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RevolvingCreditFacilityExpiringMay162025Member_28849908-ec8c-45a1-aef4-c1fcad0d533d" xlink:href="cvs-20221231.xsd#cvs_RevolvingCreditFacilityExpiringMay162025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:to="loc_cvs_RevolvingCreditFacilityExpiringMay162025Member_28849908-ec8c-45a1-aef4-c1fcad0d533d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RevolvingCreditFacilityExpiringMay112026Member_5f033476-cada-40a2-9452-ce8d90706242" xlink:href="cvs-20221231.xsd#cvs_RevolvingCreditFacilityExpiringMay112026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:to="loc_cvs_RevolvingCreditFacilityExpiringMay112026Member_5f033476-cada-40a2-9452-ce8d90706242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RevolvingCreditFacilityExpiringMay162027Member_c057e1ed-9326-424c-a612-9e8292524c74" xlink:href="cvs-20221231.xsd#cvs_RevolvingCreditFacilityExpiringMay162027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_BackUpCreditFacilitiesMember_8deee335-ba57-41ca-861f-21f68e91ac5d" xlink:to="loc_cvs_RevolvingCreditFacilityExpiringMay162027Member_c057e1ed-9326-424c-a612-9e8292524c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3073198e-aa95-40cb-9887-2dd911ad712a" xlink:to="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4b41e4c1-c660-4ee3-84c1-999c3714d534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_ShortTermBorrowings_4b41e4c1-c660-4ee3-84c1-999c3714d534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0c7e3d19-b8e1-4c6a-b856-aa6bf9999280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0c7e3d19-b8e1-4c6a-b856-aa6bf9999280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1b961a63-02fc-408a-9482-5dcb517e0a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_DebtInstrumentTerm_1b961a63-02fc-408a-9482-5dcb517e0a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_39be464d-e9e6-455d-8be0-f1f581799672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_39be464d-e9e6-455d-8be0-f1f581799672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable_31ddbbf1-ebf3-4259-b3a5-c9600d5c76aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_03d4a1f2-a689-42e7-a5f9-fea6d1f6e47b" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable_31ddbbf1-ebf3-4259-b3a5-c9600d5c76aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#BorrowingsandCreditAgreementsLongtermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_eac29d0e-b135-4e95-aa0f-9e073b1858ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8b339c12-f72e-4e59-b2a4-d4b15a92982a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_eac29d0e-b135-4e95-aa0f-9e073b1858ad" xlink:to="loc_us-gaap_DebtInstrumentTable_8b339c12-f72e-4e59-b2a4-d4b15a92982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_69a6338d-b63a-4e13-b661-910291db4d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8b339c12-f72e-4e59-b2a4-d4b15a92982a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_69a6338d-b63a-4e13-b661-910291db4d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6fed5115-cb52-4d00-95d5-392bf28e45ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_69a6338d-b63a-4e13-b661-910291db4d58" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6fed5115-cb52-4d00-95d5-392bf28e45ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a9e1ef81-2fd9-4d0e-a421-d6fbf00a2fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fed5115-cb52-4d00-95d5-392bf28e45ab" xlink:to="loc_us-gaap_SeniorNotesMember_a9e1ef81-2fd9-4d0e-a421-d6fbf00a2fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3e533898-bf36-46e6-9cec-e0b576f3d2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8b339c12-f72e-4e59-b2a4-d4b15a92982a" xlink:to="loc_us-gaap_DebtInstrumentAxis_3e533898-bf36-46e6-9cec-e0b576f3d2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3e533898-bf36-46e6-9cec-e0b576f3d2c7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.5DueJuly2022Member_f387e774-64be-45a1-812d-e748b066d294" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.5DueJuly2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3.5DueJuly2022Member_f387e774-64be-45a1-812d-e748b066d294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueNovember2022Member_2d601031-34c2-42e5-8fff-e18570b2efdb" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueNovember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes2.75DueNovember2022Member_2d601031-34c2-42e5-8fff-e18570b2efdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2.75DueDecember2022Member_3ae26644-69cb-440e-bd0b-1f04efc1c417" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2.75DueDecember2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes2.75DueDecember2022Member_3ae26644-69cb-440e-bd0b-1f04efc1c417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.75DueDecember2022Member_0220eaec-33bc-4a0a-90e5-f0fd119eede7" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.75DueDecember2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4.75DueDecember2022Member_0220eaec-33bc-4a0a-90e5-f0fd119eede7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_425f4209-607c-4ed4-b7ce-29e7694981af" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes2Point125PercentDueSeptember2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes2Point125PercentDueSeptember2031Member_425f4209-607c-4ed4-b7ce-29e7694981af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point625PercentApril2027Member_0df67e12-8d1c-4115-b1c8-d38e4e4f7faf" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point625PercentApril2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3Point625PercentApril2027Member_0df67e12-8d1c-4115-b1c8-d38e4e4f7faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point75PercentApril2030Member_12626a7c-26ad-4fa3-bbee-87a138e4039c" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point75PercentApril2030Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3Point75PercentApril2030Member_12626a7c-26ad-4fa3-bbee-87a138e4039c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point125PercentApril2040Member_d9360006-527a-43b6-97ec-e219d39786c8" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point125PercentApril2040Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4Point125PercentApril2040Member_d9360006-527a-43b6-97ec-e219d39786c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4Point25PercentApril2050Member_2a1f0d66-4cdd-4950-84c7-9bbcd479228a" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4Point25PercentApril2050Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4Point25PercentApril2050Member_2a1f0d66-4cdd-4950-84c7-9bbcd479228a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3Point70PercentDue2023Member_056b1e04-7264-4f9c-bf94-bd7a88ab7812" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3Point70PercentDue2023Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3Point70PercentDue2023Member_056b1e04-7264-4f9c-bf94-bd7a88ab7812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4PointThreePercentDue2028Member_62116cd4-34ec-4ba7-a4ad-4844caf7aa36" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4PointThreePercentDue2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4PointThreePercentDue2028Member_62116cd4-34ec-4ba7-a4ad-4844caf7aa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OutstandingSeniorNotesMember_c5f3b28c-3dd3-445b-ab82-a4290ed34170" xlink:href="cvs-20221231.xsd#cvs_OutstandingSeniorNotesMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_OutstandingSeniorNotesMember_c5f3b28c-3dd3-445b-ab82-a4290ed34170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4DueDecember2023Member_0bedaabe-d10c-4e37-991f-0d05e0d6f09a" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4DueDecember2023Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4DueDecember2023Member_0bedaabe-d10c-4e37-991f-0d05e0d6f09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes3.7DueMarch2023Member_f37aab17-35ca-4e4f-949d-acb259dfae4e" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes3.7DueMarch2023Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes3.7DueMarch2023Member_f37aab17-35ca-4e4f-949d-acb259dfae4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes4.1DueMarch2025Member_277ff36b-928c-43e6-a0b8-9edb8d194f3b" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes4.1DueMarch2025Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes4.1DueMarch2025Member_277ff36b-928c-43e6-a0b8-9edb8d194f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SeniorNotes43Due2028Member_70c611da-ee8f-4865-8915-6b229a545d55" xlink:href="cvs-20221231.xsd#cvs_SeniorNotes43Due2028Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f3d69ba-c870-4f0a-83dd-f0917b22799f" xlink:to="loc_cvs_SeniorNotes43Due2028Member_70c611da-ee8f-4865-8915-6b229a545d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8b339c12-f72e-4e59-b2a4-d4b15a92982a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ff68466-d063-4174-aca6-f2684a0945a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ff68466-d063-4174-aca6-f2684a0945a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_91d2a162-0c2d-494d-821a-3887880670c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_91d2a162-0c2d-494d-821a-3887880670c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_323ff668-1c5d-4db2-a8dc-d2ecb973310a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_323ff668-1c5d-4db2-a8dc-d2ecb973310a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_25780077-572e-4ee6-995b-73b0e4cbd8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_25780077-572e-4ee6-995b-73b0e4cbd8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_8f11e250-40cc-49f0-882a-c7ba6f178f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_8f11e250-40cc-49f0-882a-c7ba6f178f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_eef2c50f-c5a7-40b5-a1a9-15beda8bfde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_eef2c50f-c5a7-40b5-a1a9-15beda8bfde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_99dc2b2d-daf1-485c-8b1e-143ca8157174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_99dc2b2d-daf1-485c-8b1e-143ca8157174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_f4e6c3f8-5ac1-497e-b80d-49f733324b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_f4e6c3f8-5ac1-497e-b80d-49f733324b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_c82acc94-0bf9-4f2b-a821-57a7688026dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_c82acc94-0bf9-4f2b-a821-57a7688026dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DebtExtinguishmentFees_e3b71a15-4ede-4b6e-8ee4-353983546414" xlink:href="cvs-20221231.xsd#cvs_DebtExtinguishmentFees"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_cvs_DebtExtinguishmentFees_e3b71a15-4ede-4b6e-8ee4-353983546414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b92d072a-f979-4590-905c-b58fd675ede3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6979c85a-cd79-4b63-8b02-a9bc38ffb3c6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b92d072a-f979-4590-905c-b58fd675ede3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_23618705-3e4f-42ca-9f8b-678a75ceff31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca17d525-fd8b-44f3-9937-345f4e3dc205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_23618705-3e4f-42ca-9f8b-678a75ceff31" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca17d525-fd8b-44f3-9937-345f4e3dc205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7b269835-505f-4ff1-8412-02f9aeca6387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca17d525-fd8b-44f3-9937-345f4e3dc205" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7b269835-505f-4ff1-8412-02f9aeca6387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_16947266-c468-4f30-971b-ac3cc4f135e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7b269835-505f-4ff1-8412-02f9aeca6387" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_16947266-c468-4f30-971b-ac3cc4f135e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f191fee1-886d-4997-b815-cee20a8ac4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_16947266-c468-4f30-971b-ac3cc4f135e8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f191fee1-886d-4997-b815-cee20a8ac4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4a761546-72f4-4367-ab0b-95b446f8c525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_16947266-c468-4f30-971b-ac3cc4f135e8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4a761546-72f4-4367-ab0b-95b446f8c525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f0064785-1dfe-46f0-b3b2-4d0c80e40334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca17d525-fd8b-44f3-9937-345f4e3dc205" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f0064785-1dfe-46f0-b3b2-4d0c80e40334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f0064785-1dfe-46f0-b3b2-4d0c80e40334" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_73ad60b5-cf16-4ed3-91f1-1ef857dc7ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_EquitySecuritiesMember_73ad60b5-cf16-4ed3-91f1-1ef857dc7ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_c2f19aee-62db-4fb3-ac70-bdef281ca360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_DebtSecuritiesMember_c2f19aee-62db-4fb3-ac70-bdef281ca360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateInvestmentMember_bdf39e4c-20da-42a4-873c-301cb10778c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstateInvestmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_RealEstateInvestmentMember_bdf39e4c-20da-42a4-873c-301cb10778c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_6fd40296-ea17-429c-aa20-3271fd363f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_PrivateEquityFundsMember_6fd40296-ea17-429c-aa20-3271fd363f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_cb2d7f52-728a-45d2-a1fe-68c2e84ab6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_e61cdd30-4ad0-49b0-b202-f6117dc61627" xlink:to="loc_us-gaap_HedgeFundsMember_cb2d7f52-728a-45d2-a1fe-68c2e84ab6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca17d525-fd8b-44f3-9937-345f4e3dc205" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_70a1ee15-f8a3-4378-b8ff-1754038b6dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_70a1ee15-f8a3-4378-b8ff-1754038b6dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_ce65fe06-f017-434b-af19-b1f5ba0b1036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_ce65fe06-f017-434b-af19-b1f5ba0b1036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_3d3d54e7-9fc0-4a3b-b762-60658fd123b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_3d3d54e7-9fc0-4a3b-b762-60658fd123b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution_a05a7303-922f-4bbf-878b-bdb5f4fb38d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MultiemployerPlanPensionInsignificantPlanContribution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution_a05a7303-922f-4bbf-878b-bdb5f4fb38d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_178147a3-5d4e-4088-ae0a-ef133d8c6678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_178147a3-5d4e-4088-ae0a-ef133d8c6678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_616cdbf9-a11d-4a82-bbe6-731ee31d5ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_80d82258-ff03-46f1-b4c0-fa6c67c173ea" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_616cdbf9-a11d-4a82-bbe6-731ee31d5ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d3968ca8-fce6-43c0-b89c-40561614ff54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d4964132-1135-4cea-82d4-3d8517c357d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d3968ca8-fce6-43c0-b89c-40561614ff54" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d4964132-1135-4cea-82d4-3d8517c357d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3548131f-0117-4ea7-ba8b-e17c3dc59302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d4964132-1135-4cea-82d4-3d8517c357d0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3548131f-0117-4ea7-ba8b-e17c3dc59302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_33dd804e-b72d-4c01-bbe6-d3be49e051e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3548131f-0117-4ea7-ba8b-e17c3dc59302" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_33dd804e-b72d-4c01-bbe6-d3be49e051e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3ceb5887-e7d3-4417-8879-f115f4599258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_33dd804e-b72d-4c01-bbe6-d3be49e051e5" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3ceb5887-e7d3-4417-8879-f115f4599258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d4964132-1135-4cea-82d4-3d8517c357d0" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5c9389d3-e0a4-46fe-9678-615c393dc298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5c9389d3-e0a4-46fe-9678-615c393dc298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_8ce2f2d9-0ceb-4700-9f2e-dc20902e7f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_8ce2f2d9-0ceb-4700-9f2e-dc20902e7f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_012a31d7-e385-4b4a-b1ea-52046bb48a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_012a31d7-e385-4b4a-b1ea-52046bb48a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7864a04a-6afc-4969-b54a-0d34fa1b9fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7864a04a-6afc-4969-b54a-0d34fa1b9fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_7dc68e24-04f9-4f3f-8fcb-2c114b79eacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement_7dc68e24-04f9-4f3f-8fcb-2c114b79eacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_e8fd8606-0e8e-4f2c-838a-f8d1c67ede12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0d87c9be-f76b-4bfd-8721-959ba178814a" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_e8fd8606-0e8e-4f2c-838a-f8d1c67ede12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_565acfe1-4495-4040-a3d9-133dcec1d60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_565acfe1-4495-4040-a3d9-133dcec1d60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_58404d8a-1705-488b-81a4-954be340bad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_58404d8a-1705-488b-81a4-954be340bad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6a23ea43-d2f7-4330-81fb-d6944b533386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6a23ea43-d2f7-4330-81fb-d6944b533386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_f70369db-20f7-4881-9a9e-450df2d88a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_f70369db-20f7-4881-9a9e-450df2d88a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_7d6107ed-f319-473d-b1b2-ef942a11eeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_7d6107ed-f319-473d-b1b2-ef942a11eeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_6520263b-3a65-4c4e-b311-40454ca14988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_de8bccb2-eb25-4cde-a396-eb8ba764e33c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_6520263b-3a65-4c4e-b311-40454ca14988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_73e564cb-f5be-4036-b04b-a6198398cc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_73e564cb-f5be-4036-b04b-a6198398cc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3447b0ee-0605-4470-9baf-a2eca89762be" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_067be5df-ceba-495b-8056-345639ce4a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_067be5df-ceba-495b-8056-345639ce4a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0b4599e6-57f6-430d-94fd-70acf0ef1b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_0b4599e6-57f6-430d-94fd-70acf0ef1b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_9c9a49cf-4869-456c-9b9f-59b35b2dad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_9c9a49cf-4869-456c-9b9f-59b35b2dad5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a7405dde-2a17-47a0-a53c-1872e09dbc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_46ab37fc-7f42-4cfe-b2e0-110ad23d1ee8" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a7405dde-2a17-47a0-a53c-1872e09dbc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f6a01f10-3467-40bf-aa50-3cb96c96d7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58430494-45b7-45fe-b955-83680ef1e1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f6a01f10-3467-40bf-aa50-3cb96c96d7c8" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58430494-45b7-45fe-b955-83680ef1e1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_acfb8e61-3a2f-492d-8288-20e3bb12759a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58430494-45b7-45fe-b955-83680ef1e1f3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_acfb8e61-3a2f-492d-8288-20e3bb12759a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_647c63dc-86fa-4778-9357-98fa2ae99104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_acfb8e61-3a2f-492d-8288-20e3bb12759a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_647c63dc-86fa-4778-9357-98fa2ae99104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7703ef52-db20-4220-afd4-ef687b7c5747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_647c63dc-86fa-4778-9357-98fa2ae99104" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7703ef52-db20-4220-afd4-ef687b7c5747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b450c83-ec4d-43a6-9fc6-e11d710bdd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_58430494-45b7-45fe-b955-83680ef1e1f3" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b450c83-ec4d-43a6-9fc6-e11d710bdd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b450c83-ec4d-43a6-9fc6-e11d710bdd1c" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_59f23e23-64f0-4c7f-bb35-a6f30ee5a452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_59f23e23-64f0-4c7f-bb35-a6f30ee5a452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ce4d8194-7cef-4556-bc93-234c9e070280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ce4d8194-7cef-4556-bc93-234c9e070280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f8cd8867-5c80-4706-907d-7019a4943dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f8cd8867-5c80-4706-907d-7019a4943dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_145b638b-db31-415b-867b-77c5da869c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_145b638b-db31-415b-867b-77c5da869c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8dc35475-33a8-4a06-8b1f-4a1cf3dd218d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6173d927-93f8-4a97-aa5c-892b1f173714" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8dc35475-33a8-4a06-8b1f-4a1cf3dd218d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0e288817-d31b-4b57-ad63-b87b9cbb1149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_929cdc0c-de9f-49c9-910c-d81664e781cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0e288817-d31b-4b57-ad63-b87b9cbb1149" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_929cdc0c-de9f-49c9-910c-d81664e781cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_21eae7da-e912-4eb0-9bae-4b73b1d31101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_929cdc0c-de9f-49c9-910c-d81664e781cc" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_21eae7da-e912-4eb0-9bae-4b73b1d31101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a298bfe-19e1-4c75-890e-bff97a8fc72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0e288817-d31b-4b57-ad63-b87b9cbb1149" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a298bfe-19e1-4c75-890e-bff97a8fc72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_a1c6d2fc-b95f-42af-97d4-816ad7786cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a298bfe-19e1-4c75-890e-bff97a8fc72d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_a1c6d2fc-b95f-42af-97d4-816ad7786cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_f06d4e2c-99f7-45ff-a388-7dde0f6810a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a298bfe-19e1-4c75-890e-bff97a8fc72d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_f06d4e2c-99f7-45ff-a388-7dde0f6810a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1de67d27-cdd7-4bc5-a979-ad0fd3031802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1de67d27-cdd7-4bc5-a979-ad0fd3031802" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_09d7807a-2532-4293-828e-fb72fca52c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_09d7807a-2532-4293-828e-fb72fca52c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8548764a-1ce7-4eb1-ad83-811fb89d89c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_09d7807a-2532-4293-828e-fb72fca52c40" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8548764a-1ce7-4eb1-ad83-811fb89d89c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_79b31135-ee8a-4b66-ba31-72ff7ee2f5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8548764a-1ce7-4eb1-ad83-811fb89d89c6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_79b31135-ee8a-4b66-ba31-72ff7ee2f5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2dd8ed8d-7dcc-4017-825e-68d1829dd548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2dd8ed8d-7dcc-4017-825e-68d1829dd548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2dd8ed8d-7dcc-4017-825e-68d1829dd548" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_0bb10ee4-f7d5-4ebc-a610-3a32655d6dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_0bb10ee4-f7d5-4ebc-a610-3a32655d6dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_c9c7f661-d5e9-41bc-8b58-8a1a003be4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_c9c7f661-d5e9-41bc-8b58-8a1a003be4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_f76754f5-db98-4e78-a333-530e79f35dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_f76754f5-db98-4e78-a333-530e79f35dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_bdf6c8ca-b102-411b-9bd6-73df855fdf86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_bdf6c8ca-b102-411b-9bd6-73df855fdf86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_02130056-893b-4719-b504-9273e0592614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_02130056-893b-4719-b504-9273e0592614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_0e7ba3ed-3a29-488c-858c-eb901dec17e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_0e7ba3ed-3a29-488c-858c-eb901dec17e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_243a36a8-2907-49b5-b117-5f5c0dfc0ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_243a36a8-2907-49b5-b117-5f5c0dfc0ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_9a00abd1-381e-42ff-997d-85167e8d2640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_9a00abd1-381e-42ff-997d-85167e8d2640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RedeemablePreferredSecuritiesMember_f2632931-9f46-4ff3-b427-b284135fa9b7" xlink:href="cvs-20221231.xsd#cvs_RedeemablePreferredSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_dab68bff-7fcb-4faa-af01-18a41382b7c6" xlink:to="loc_cvs_RedeemablePreferredSecuritiesMember_f2632931-9f46-4ff3-b427-b284135fa9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_32746672-f885-424e-88a8-2ae932efdaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_32746672-f885-424e-88a8-2ae932efdaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_971cf8c2-dc76-4453-957c-7095b3d8013d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_971cf8c2-dc76-4453-957c-7095b3d8013d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EquitySecuritiesDomesticRealEstateMember_8eea517a-c912-4be2-8f60-30e3d35dc472" xlink:href="cvs-20221231.xsd#cvs_EquitySecuritiesDomesticRealEstateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesMember_26a72bee-e9fc-4c2d-98f9-f782302a8171" xlink:to="loc_cvs_EquitySecuritiesDomesticRealEstateMember_8eea517a-c912-4be2-8f60-30e3d35dc472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_ccbc1662-1750-4e10-ad10-f5a2c6071a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_OtherInvestmentsMember_ccbc1662-1750-4e10-ad10-f5a2c6071a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_d0013d15-f643-4c8d-a0d2-6fda1023272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentsMember_ccbc1662-1750-4e10-ad10-f5a2c6071a0d" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_d0013d15-f643-4c8d-a0d2-6fda1023272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember_cdefde54-2134-445e-8503-07075c17eeff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentsMember_ccbc1662-1750-4e10-ad10-f5a2c6071a0d" xlink:to="loc_us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember_cdefde54-2134-445e-8503-07075c17eeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember_e58c7bda-7d43-4101-b2d2-9e67895f32ae" xlink:href="cvs-20221231.xsd#cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember_e58c7bda-7d43-4101-b2d2-9e67895f32ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember_693f6362-e316-4c07-bb92-7f00a65eae9b" xlink:href="cvs-20221231.xsd#cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember_693f6362-e316-4c07-bb92-7f00a65eae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_70692f0e-1ae0-4fe6-87e7-58f8e94d3f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_AccountsReceivableMember_70692f0e-1ae0-4fe6-87e7-58f8e94d3f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivateEquityFundsMember_e3cc271f-fb0b-434d-9fc7-30936ecd09d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivateEquityFundsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_PrivateEquityFundsMember_e3cc271f-fb0b-434d-9fc7-30936ecd09d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_5e9e0124-2831-47f0-b267-881e06c3b794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgeFundsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_fa9e3993-7df6-4dde-8be7-726bd6fe755e" xlink:to="loc_us-gaap_HedgeFundsMember_5e9e0124-2831-47f0-b267-881e06c3b794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88309e2d-b06d-409f-815c-89d7c53e4360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88309e2d-b06d-409f-815c-89d7c53e4360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de313573-0ccf-43a5-9339-a7b02107bc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_88309e2d-b06d-409f-815c-89d7c53e4360" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de313573-0ccf-43a5-9339-a7b02107bc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de313573-0ccf-43a5-9339-a7b02107bc3a" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_33bb5698-efff-4d7f-baf7-d5e3bbb9bdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_33bb5698-efff-4d7f-baf7-d5e3bbb9bdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_19abc357-194d-42ed-950a-b3c54f7f7352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_19abc357-194d-42ed-950a-b3c54f7f7352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2cc60adb-39b7-4577-841b-1c0d28eadbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member_ca4a3e94-f23a-4a0f-93b0-7ef41356cbcf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2cc60adb-39b7-4577-841b-1c0d28eadbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_a2e4d771-85c4-43fa-9989-6b051d82653e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de313573-0ccf-43a5-9339-a7b02107bc3a" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_a2e4d771-85c4-43fa-9989-6b051d82653e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_af85920c-814f-4516-85aa-3ddc75bdf684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_22640732-84b8-4ba6-afe4-4fb7817998cf" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_af85920c-814f-4516-85aa-3ddc75bdf684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1263228c-468e-4737-874f-16c0a4b9f12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_af85920c-814f-4516-85aa-3ddc75bdf684" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1263228c-468e-4737-874f-16c0a4b9f12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_5b784d85-3c9d-4948-ab95-c4a3c7e9807a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_af85920c-814f-4516-85aa-3ddc75bdf684" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount_5b784d85-3c9d-4948-ab95-c4a3c7e9807a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c7a2f0c3-6216-42ce-a68f-4989aceefba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c7a2f0c3-6216-42ce-a68f-4989aceefba1" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_cc1ded0a-ea60-46cb-b34e-be07d6be4b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_cc1ded0a-ea60-46cb-b34e-be07d6be4b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_2a04747e-ae56-4d4a-bfa3-7213bf5467f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_cc1ded0a-ea60-46cb-b34e-be07d6be4b5e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_2a04747e-ae56-4d4a-bfa3-7213bf5467f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_d75a0f05-b81e-42b7-8275-0ccf074bf1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_2a04747e-ae56-4d4a-bfa3-7213bf5467f7" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_d75a0f05-b81e-42b7-8275-0ccf074bf1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1519cd05-9384-4426-af59-173bd5970f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1519cd05-9384-4426-af59-173bd5970f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aad29a72-17e8-4165-9d51-4c5e5491bf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1519cd05-9384-4426-af59-173bd5970f18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aad29a72-17e8-4165-9d51-4c5e5491bf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0329fb80-37e9-4c2f-9b09-edeb21e9ea46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aad29a72-17e8-4165-9d51-4c5e5491bf9f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0329fb80-37e9-4c2f-9b09-edeb21e9ea46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_56a1896b-9fec-4118-9820-c50903065af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_56a1896b-9fec-4118-9820-c50903065af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_54e1f248-3806-44cd-8434-a7ac009eb64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_56a1896b-9fec-4118-9820-c50903065af3" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_54e1f248-3806-44cd-8434-a7ac009eb64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7678a176-9870-4701-9f95-3dfd99136199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_54e1f248-3806-44cd-8434-a7ac009eb64f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7678a176-9870-4701-9f95-3dfd99136199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0dc412de-515e-4286-a0d7-457dd0f69c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_0349a989-a123-4c1e-9453-ae3d22c1e007" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0dc412de-515e-4286-a0d7-457dd0f69c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0dc412de-515e-4286-a0d7-457dd0f69c4b" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7c331a75-c76f-4c41-935d-9da342ecb8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7c331a75-c76f-4c41-935d-9da342ecb8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_ef83f7d5-b9f9-498e-8657-e41eed7da0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_ef83f7d5-b9f9-498e-8657-e41eed7da0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_db515281-b9f9-484f-8036-2819f8d4f0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_db515281-b9f9-484f-8036-2819f8d4f0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_347d08fd-ce4b-4122-a1b9-723eb4c06e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_347d08fd-ce4b-4122-a1b9-723eb4c06e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_decde615-6489-4a4f-bef4-4c13f628200e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d55e2e57-efcd-49eb-8cbe-c5683a7293bc" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_decde615-6489-4a4f-bef4-4c13f628200e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_da92ba8d-f7dc-4f99-97c3-b085f916208a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7482b323-f9f4-4b77-a4c4-c55b5c511aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_da92ba8d-f7dc-4f99-97c3-b085f916208a" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7482b323-f9f4-4b77-a4c4-c55b5c511aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2c3cbd4c-cad8-4e68-80a8-f09bbd0b0a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7482b323-f9f4-4b77-a4c4-c55b5c511aee" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2c3cbd4c-cad8-4e68-80a8-f09bbd0b0a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4d803ebc-e368-40bd-bec9-a3842e1b7b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2c3cbd4c-cad8-4e68-80a8-f09bbd0b0a24" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4d803ebc-e368-40bd-bec9-a3842e1b7b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_98e5d542-d970-4f3e-9dc3-e64e54a94cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4d803ebc-e368-40bd-bec9-a3842e1b7b1f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_98e5d542-d970-4f3e-9dc3-e64e54a94cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_aaf698f2-5679-43e0-9af6-cf55385d7de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4d803ebc-e368-40bd-bec9-a3842e1b7b1f" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_aaf698f2-5679-43e0-9af6-cf55385d7de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7482b323-f9f4-4b77-a4c4-c55b5c511aee" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_4232cd7d-88e1-4a3a-845a-3c813ffd158f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_4232cd7d-88e1-4a3a-845a-3c813ffd158f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_42e51f1d-421f-409b-8c61-feb5d28e9629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_42e51f1d-421f-409b-8c61-feb5d28e9629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_6fdae6a0-cb2e-4182-b8f1-546610e05069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_6fdae6a0-cb2e-4182-b8f1-546610e05069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_814e0081-d1b9-4ca3-b01f-f4c679ffece3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_814e0081-d1b9-4ca3-b01f-f4c679ffece3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_7452f379-3ac3-43c3-ad30-b51f1eb2e799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_7452f379-3ac3-43c3-ad30-b51f1eb2e799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d69a9ad1-5e96-4151-93aa-8cbaf87699cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7b291578-a9b0-46ef-82ea-a6db1e5c8e64" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d69a9ad1-5e96-4151-93aa-8cbaf87699cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesIncomeTaxProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_94d1c82c-992e-45ef-963e-807d597d7f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_20fb9b93-985c-4222-a55b-c0e4ac9f681d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94d1c82c-992e-45ef-963e-807d597d7f08" xlink:to="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_20fb9b93-985c-4222-a55b-c0e4ac9f681d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11b9531f-ea2b-46d7-ba83-c689df4faeee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_20fb9b93-985c-4222-a55b-c0e4ac9f681d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11b9531f-ea2b-46d7-ba83-c689df4faeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5cdc585f-e645-425c-92bc-f9370e653435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11b9531f-ea2b-46d7-ba83-c689df4faeee" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5cdc585f-e645-425c-92bc-f9370e653435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_485d71cc-ef9a-407d-8082-d27937f06292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11b9531f-ea2b-46d7-ba83-c689df4faeee" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_485d71cc-ef9a-407d-8082-d27937f06292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0e65a635-1e68-46e4-96df-ab03c48df0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_11b9531f-ea2b-46d7-ba83-c689df4faeee" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0e65a635-1e68-46e4-96df-ab03c48df0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a9de443d-21d9-44f5-b70d-061b7d934d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_20fb9b93-985c-4222-a55b-c0e4ac9f681d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a9de443d-21d9-44f5-b70d-061b7d934d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d179d059-2886-4412-ba8d-1d573b6ebdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a9de443d-21d9-44f5-b70d-061b7d934d65" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d179d059-2886-4412-ba8d-1d573b6ebdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7fb609d7-05c1-4c3d-97f2-0635b35bf5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a9de443d-21d9-44f5-b70d-061b7d934d65" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7fb609d7-05c1-4c3d-97f2-0635b35bf5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_05b58692-9db3-4c00-bff0-0cccaee98b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a9de443d-21d9-44f5-b70d-061b7d934d65" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_05b58692-9db3-4c00-bff0-0cccaee98b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c0d23d76-8976-4d61-8da3-89d068fa9df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_20fb9b93-985c-4222-a55b-c0e4ac9f681d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c0d23d76-8976-4d61-8da3-89d068fa9df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesEffectiveTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2e92f5b8-202c-41e2-90f2-296c9488c5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e92f5b8-202c-41e2-90f2-296c9488c5a1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b925c701-3d50-459b-89d4-79b7c5fad462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b925c701-3d50-459b-89d4-79b7c5fad462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e2e22711-94b4-4d29-8132-fcc0870e0a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e2e22711-94b4-4d29-8132-fcc0870e0a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthInsurerFeeTaxEffectPercent_dc7642c7-30e1-45eb-8b09-bf1e7060467a" xlink:href="cvs-20221231.xsd#cvs_HealthInsurerFeeTaxEffectPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:to="loc_cvs_HealthInsurerFeeTaxEffectPercent_dc7642c7-30e1-45eb-8b09-bf1e7060467a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent_9f9030e8-0663-406d-9e5c-e8baf11412ba" xlink:href="cvs-20221231.xsd#cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:to="loc_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent_9f9030e8-0663-406d-9e5c-e8baf11412ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_60ad728a-f652-4007-85f4-b182eec0c403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_60ad728a-f652-4007-85f4-b182eec0c403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic_e7417b7b-d92f-4274-925f-cb212ff5aa45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic_e7417b7b-d92f-4274-925f-cb212ff5aa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cdb9b9ae-761c-4be9-a6e3-a47f9af4aa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cdb9b9ae-761c-4be9-a6e3-a47f9af4aa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5f1cae2c-a5c6-45c5-9ea7-a98deef1259a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_871da95c-840b-4bda-80ad-c406d2ed3d4a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5f1cae2c-a5c6-45c5-9ea7-a98deef1259a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bb429836-beb2-429c-ad69-e283bf4773f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_8186b765-f35f-41c8-8516-db6e734ad951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb429836-beb2-429c-ad69-e283bf4773f8" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_8186b765-f35f-41c8-8516-db6e734ad951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_05071c62-f8c1-4cb4-9fb3-544e0482e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_8186b765-f35f-41c8-8516-db6e734ad951" xlink:to="loc_us-gaap_ValuationAllowanceTable_05071c62-f8c1-4cb4-9fb3-544e0482e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_afa9476c-be56-4aec-8b94-784474892b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_05071c62-f8c1-4cb4-9fb3-544e0482e58f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_afa9476c-be56-4aec-8b94-784474892b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1754584e-0386-4cfd-a9d5-f9a584a08f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_afa9476c-be56-4aec-8b94-784474892b52" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1754584e-0386-4cfd-a9d5-f9a584a08f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_43bfe497-1d50-4344-b6cc-b705aa311c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1754584e-0386-4cfd-a9d5-f9a584a08f59" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_43bfe497-1d50-4344-b6cc-b705aa311c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_05071c62-f8c1-4cb4-9fb3-544e0482e58f" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1c5afea7-cd23-4364-a48a-163efe50806e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1c5afea7-cd23-4364-a48a-163efe50806e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_b5a8af75-d419-415a-83dd-1fe8e1b45727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_b5a8af75-d419-415a-83dd-1fe8e1b45727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1eeb780e-5232-4af3-baf2-e767d297b36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1eeb780e-5232-4af3-baf2-e767d297b36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_4fa04b24-ed6b-4abf-a7a8-ad76ceb39aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_4fa04b24-ed6b-4abf-a7a8-ad76ceb39aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances_3f96f93a-78aa-44e5-96cc-8e51a9a11694" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances_3f96f93a-78aa-44e5-96cc-8e51a9a11694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5f25b901-5961-40ed-9645-5d7aaacb97a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5f25b901-5961-40ed-9645-5d7aaacb97a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_94f1a04b-fff8-49be-a910-eee761c926ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_94f1a04b-fff8-49be-a910-eee761c926ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_5b34d959-5277-478d-806c-c17771c74031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_5b34d959-5277-478d-806c-c17771c74031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_be671905-1a87-4bfe-a986-00c6c277cc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_be671905-1a87-4bfe-a986-00c6c277cc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxAssetsPayrollTaxDeferral_2965fde3-da9c-42bb-8d02-337df011e789" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxAssetsPayrollTaxDeferral"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_cvs_DeferredTaxAssetsPayrollTaxDeferral_2965fde3-da9c-42bb-8d02-337df011e789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bdca91f0-5d71-4402-9294-42c2dc61b8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bdca91f0-5d71-4402-9294-42c2dc61b8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7d8b8735-baac-430f-8de7-9230b63a1208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7d8b8735-baac-430f-8de7-9230b63a1208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7190fe64-3409-42a2-80f4-d9c6cb15e964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_90e4da20-8cc3-4ac9-93e8-fde9e61c951e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7190fe64-3409-42a2-80f4-d9c6cb15e964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxLiabilitiesRetirementBenefits_ccc907f3-1b40-4f8c-9b10-c6be752456f5" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxLiabilitiesRetirementBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:to="loc_cvs_DeferredTaxLiabilitiesRetirementBenefits_ccc907f3-1b40-4f8c-9b10-c6be752456f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_1b268cb0-0bef-420e-9a5c-667b22b47a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_1b268cb0-0bef-420e-9a5c-667b22b47a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0d8511d9-57f7-4c2e-becd-0817f6a5e14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0d8511d9-57f7-4c2e-becd-0817f6a5e14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization_f23756f5-2c38-44d8-9873-be078833a99f" xlink:href="cvs-20221231.xsd#cvs_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_72114570-3649-49ae-9228-7a006c64ad98" xlink:to="loc_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization_f23756f5-2c38-44d8-9873-be078833a99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_79dc8c96-22bc-489d-a92f-3ad409f8633a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_79dc8c96-22bc-489d-a92f-3ad409f8633a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0f28a70b-0294-4381-8e0d-77e05ad55ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_f2ff9eb6-2aa5-4c32-8342-91cbf04309e6" xlink:to="loc_us-gaap_DeferredTaxLiabilities_0f28a70b-0294-4381-8e0d-77e05ad55ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_33f6f46b-f00f-431e-b53a-167e7c8e1b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_de37f8c6-26bc-4ed3-aa70-7ada28359a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33f6f46b-f00f-431e-b53a-167e7c8e1b3a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_de37f8c6-26bc-4ed3-aa70-7ada28359a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b2dbd05-8d84-4b9d-84f2-72a7d8affac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33f6f46b-f00f-431e-b53a-167e7c8e1b3a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b2dbd05-8d84-4b9d-84f2-72a7d8affac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b969de08-d286-4da0-a9e6-31d03c816793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33f6f46b-f00f-431e-b53a-167e7c8e1b3a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b969de08-d286-4da0-a9e6-31d03c816793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_66787f35-b29a-4ec5-912f-1d1a7261d033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33f6f46b-f00f-431e-b53a-167e7c8e1b3a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_66787f35-b29a-4ec5-912f-1d1a7261d033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_667728e3-0260-46ce-9476-79e1c02d72d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33f6f46b-f00f-431e-b53a-167e7c8e1b3a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_667728e3-0260-46ce-9476-79e1c02d72d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9d685f7b-a62a-487c-9c8e-75ad83912a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f58349dd-9420-457b-8a02-dcbf2e3d9139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9d685f7b-a62a-487c-9c8e-75ad83912a2e" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f58349dd-9420-457b-8a02-dcbf2e3d9139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_83296660-0e50-4e5f-864c-d25ce16a19dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f58349dd-9420-457b-8a02-dcbf2e3d9139" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_83296660-0e50-4e5f-864c-d25ce16a19dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1f3fc99b-12ab-445d-ba2b-c1bc6791ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f58349dd-9420-457b-8a02-dcbf2e3d9139" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1f3fc99b-12ab-445d-ba2b-c1bc6791ae48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ad306d50-fd6c-46ba-aaa2-a13e9cc26e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f58349dd-9420-457b-8a02-dcbf2e3d9139" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ad306d50-fd6c-46ba-aaa2-a13e9cc26e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_acc8901c-3795-4d9f-969b-e535f6c29335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f58349dd-9420-457b-8a02-dcbf2e3d9139" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_acc8901c-3795-4d9f-969b-e535f6c29335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_add522b6-a2f3-4f7e-b31d-998d2fec6d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f58349dd-9420-457b-8a02-dcbf2e3d9139" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_add522b6-a2f3-4f7e-b31d-998d2fec6d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e226a9e8-8d08-433c-a5c7-47f532888867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f58349dd-9420-457b-8a02-dcbf2e3d9139" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e226a9e8-8d08-433c-a5c7-47f532888867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_dabfb99f-ecd7-4dbd-88e1-a16e2fe4fb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f58349dd-9420-457b-8a02-dcbf2e3d9139" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_dabfb99f-ecd7-4dbd-88e1-a16e2fe4fb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5179ab7-827f-4ea8-9f80-e02bda82ec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5179ab7-827f-4ea8-9f80-e02bda82ec8d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bb8d57a0-75c3-4fe0-99d9-e460172ef1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:to="loc_us-gaap_PlanNameAxis_bb8d57a0-75c3-4fe0-99d9-e460172ef1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b14a1219-1024-4340-b536-22208d4e8dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bb8d57a0-75c3-4fe0-99d9-e460172ef1f1" xlink:to="loc_us-gaap_PlanNameDomain_b14a1219-1024-4340-b536-22208d4e8dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CVSHealth2017IncentiveCompensationPlanMember_72cfce9e-b30b-48ef-ac76-3417e08057a6" xlink:href="cvs-20221231.xsd#cvs_CVSHealth2017IncentiveCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b14a1219-1024-4340-b536-22208d4e8dab" xlink:to="loc_cvs_CVSHealth2017IncentiveCompensationPlanMember_72cfce9e-b30b-48ef-ac76-3417e08057a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AetnaInc2010StockIncentivePlanMember_0ad2fc90-4296-4656-b743-fb09e1fdbe1e" xlink:href="cvs-20221231.xsd#cvs_AetnaInc2010StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b14a1219-1024-4340-b536-22208d4e8dab" xlink:to="loc_cvs_AetnaInc2010StockIncentivePlanMember_0ad2fc90-4296-4656-b743-fb09e1fdbe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5045216f-6c71-4566-9541-8db627357a04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:to="loc_srt_RangeAxis_5045216f-6c71-4566-9541-8db627357a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d06c778e-edc6-4c5b-86d2-dbd1462e020e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5045216f-6c71-4566-9541-8db627357a04" xlink:to="loc_srt_RangeMember_d06c778e-edc6-4c5b-86d2-dbd1462e020e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f50fa0ca-022d-42b6-874e-f5d216ee69c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d06c778e-edc6-4c5b-86d2-dbd1462e020e" xlink:to="loc_srt_MinimumMember_f50fa0ca-022d-42b6-874e-f5d216ee69c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2392e4b-3994-4b97-b174-6949ebfd41a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d06c778e-edc6-4c5b-86d2-dbd1462e020e" xlink:to="loc_srt_MaximumMember_f2392e4b-3994-4b97-b174-6949ebfd41a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c02f23e-7d2a-4358-a25e-1f12db39f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:to="loc_us-gaap_AwardTypeAxis_5c02f23e-7d2a-4358-a25e-1f12db39f80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5c02f23e-7d2a-4358-a25e-1f12db39f80d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_bfb69f37-0e91-4837-b646-a55456932040" xlink:href="cvs-20221231.xsd#cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_bfb69f37-0e91-4837-b646-a55456932040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_b0a2b94a-c686-447b-b3d5-79be98d0fa16" xlink:href="cvs-20221231.xsd#cvs_EmployeeStockOptionsAndStockAppreciationRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_b0a2b94a-c686-447b-b3d5-79be98d0fa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6c0ba56c-c97e-45da-823f-022d3eb0005c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_us-gaap_EmployeeStockMember_6c0ba56c-c97e-45da-823f-022d3eb0005c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_45fc5c55-76d0-4d5d-987d-0feafed02f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_45fc5c55-76d0-4d5d-987d-0feafed02f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_254b803f-d58c-4b39-823b-e0e4cf242bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2e5aab-a254-4857-b0b2-47c301a29c9f" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_254b803f-d58c-4b39-823b-e0e4cf242bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4b2e707-2762-4f68-8abc-d989ac552c9f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bd8b672-2bb6-47ef-a9ed-dd81334c82b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bd8b672-2bb6-47ef-a9ed-dd81334c82b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e5bcc90-f232-428a-bc84-1517858e75c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e5bcc90-f232-428a-bc84-1517858e75c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8dc3b90b-7eab-43b1-b188-681bc9d22131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8dc3b90b-7eab-43b1-b188-681bc9d22131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a09d413a-193a-4d21-815e-c2e73c9343ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a09d413a-193a-4d21-815e-c2e73c9343ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_118c1108-4386-458c-a796-c8af256e0906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_118c1108-4386-458c-a796-c8af256e0906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_06418cb0-bbce-423b-8356-6b3a55a2e072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_06418cb0-bbce-423b-8356-6b3a55a2e072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99582f9f-f673-43ea-bb9a-ccf9d6644294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99582f9f-f673-43ea-bb9a-ccf9d6644294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_790dc8f5-699a-42ed-9a1c-2919eedc10c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_790dc8f5-699a-42ed-9a1c-2919eedc10c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f5da8bdc-9b02-4def-ac18-75d98bc3ca24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f5da8bdc-9b02-4def-ac18-75d98bc3ca24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_69ee6264-895d-42c7-b076-cb7ee3d4b407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_69ee6264-895d-42c7-b076-cb7ee3d4b407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_7ef596c9-327b-4ccd-81ba-f0abe0638dce" xlink:href="cvs-20221231.xsd#cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_7ef596c9-327b-4ccd-81ba-f0abe0638dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_baab8b7f-eb4c-4835-91dd-9213dead6633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_baab8b7f-eb4c-4835-91dd-9213dead6633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ce2dc1da-38c2-463e-b0ce-ec1da1966eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ce2dc1da-38c2-463e-b0ce-ec1da1966eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased_3886ca5d-7db2-4d81-97d5-79a64a09252a" xlink:href="cvs-20221231.xsd#cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a59258e9-fb40-4d31-a71f-7b2c031c93f1" xlink:to="loc_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased_3886ca5d-7db2-4d81-97d5-79a64a09252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlansRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_933c125a-69de-4ea0-9d3a-4ed4c5688f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b762f57-58a6-4ac1-9032-9427947c3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_933c125a-69de-4ea0-9d3a-4ed4c5688f30" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b762f57-58a6-4ac1-9032-9427947c3bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ff34b042-4e8d-4fda-85e4-7b3c378885de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b762f57-58a6-4ac1-9032-9427947c3bee" xlink:to="loc_us-gaap_AwardTypeAxis_ff34b042-4e8d-4fda-85e4-7b3c378885de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827059bf-73ff-4796-8ebc-da772b8eefdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ff34b042-4e8d-4fda-85e4-7b3c378885de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827059bf-73ff-4796-8ebc-da772b8eefdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_698ab91d-ac64-4842-ac63-0e230759614f" xlink:href="cvs-20221231.xsd#cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827059bf-73ff-4796-8ebc-da772b8eefdc" xlink:to="loc_cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember_698ab91d-ac64-4842-ac63-0e230759614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b762f57-58a6-4ac1-9032-9427947c3bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f3c4daf3-b9e5-4c4b-a677-73bcb5e7177d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f3c4daf3-b9e5-4c4b-a677-73bcb5e7177d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_35538de5-eae5-4f78-bd20-baf9b24d59cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_35538de5-eae5-4f78-bd20-baf9b24d59cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_010ff23c-6ac2-4dae-9a4a-69c9a6d0aed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_010ff23c-6ac2-4dae-9a4a-69c9a6d0aed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_359bde91-6b32-41d6-9caa-28294add139e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_359bde91-6b32-41d6-9caa-28294add139e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e286b8be-462b-4cf8-908d-388340207a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe055bf-1c22-4520-974e-05538f86d136" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e286b8be-462b-4cf8-908d-388340207a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc3aa443-0ace-465a-8be0-ac7fa9b67424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc3aa443-0ace-465a-8be0-ac7fa9b67424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c30a238a-a864-4380-a342-b80d7e6f206a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c30a238a-a864-4380-a342-b80d7e6f206a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_faa76300-169a-4285-9fe1-32863ff65629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_faa76300-169a-4285-9fe1-32863ff65629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3c1244f3-d820-4adb-82f9-cee8035e2d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3c1244f3-d820-4adb-82f9-cee8035e2d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a44b9bd7-c3bd-4bde-82b0-c8944a827292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e80d3e77-3e4e-43df-bc5f-4a9b1d52b9fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a44b9bd7-c3bd-4bde-82b0-c8944a827292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates_1a112330-6e25-479b-8ef1-b1319857d6a2" xlink:href="cvs-20221231.xsd#cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566a0063-546a-4444-88b1-c8c04964462d" xlink:to="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates_1a112330-6e25-479b-8ef1-b1319857d6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlansStockOptionandSARActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9bce033-c49f-481f-9459-4e9d82a568e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55b4cdb7-3000-4f04-ab67-9b8e186bf23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9bce033-c49f-481f-9459-4e9d82a568e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55b4cdb7-3000-4f04-ab67-9b8e186bf23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d20ff906-01e3-4c0b-8e31-85bfdd4e67fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55b4cdb7-3000-4f04-ab67-9b8e186bf23d" xlink:to="loc_us-gaap_AwardTypeAxis_d20ff906-01e3-4c0b-8e31-85bfdd4e67fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d20ff906-01e3-4c0b-8e31-85bfdd4e67fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member_12537b82-4456-455e-83af-c6c8144d499c" xlink:href="cvs-20221231.xsd#cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:to="loc_cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member_12537b82-4456-455e-83af-c6c8144d499c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member_9c752b55-79e4-4452-b3d9-61bd29309226" xlink:href="cvs-20221231.xsd#cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:to="loc_cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member_9c752b55-79e4-4452-b3d9-61bd29309226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_e6491ff2-de98-4da2-b1af-892a4f2fd77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_e6491ff2-de98-4da2-b1af-892a4f2fd77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_5b9b44e4-c8f2-42b3-8d22-72e7cddc9897" xlink:href="cvs-20221231.xsd#cvs_EmployeeStockOptionsAndStockAppreciationRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c45fd8c8-3297-4f40-a87a-2f01024aac1a" xlink:to="loc_cvs_EmployeeStockOptionsAndStockAppreciationRightsMember_5b9b44e4-c8f2-42b3-8d22-72e7cddc9897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55b4cdb7-3000-4f04-ab67-9b8e186bf23d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d43106f-b16e-4093-a629-bfbdbbb87995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d43106f-b16e-4093-a629-bfbdbbb87995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5f84a5c0-b2c1-4ab5-a36a-2f1b60d0f773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5f84a5c0-b2c1-4ab5-a36a-2f1b60d0f773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a544fdd6-fa07-4398-bb39-ad30d42ccf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a544fdd6-fa07-4398-bb39-ad30d42ccf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bf5cbc9d-9d04-4fe5-bdbf-6e047ca5d55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bf5cbc9d-9d04-4fe5-bdbf-6e047ca5d55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue_4d1dcf82-745f-4f51-90b4-90aec705d9e5" xlink:href="cvs-20221231.xsd#cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue_4d1dcf82-745f-4f51-90b4-90aec705d9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb9cee7c-25e3-4ff6-853a-62e3da8f5c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb9cee7c-25e3-4ff6-853a-62e3da8f5c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_39f10541-3015-4275-94d7-95c3fc02df8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_39f10541-3015-4275-94d7-95c3fc02df8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_980a2aeb-8014-47e2-9493-dafd34fef976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_980a2aeb-8014-47e2-9493-dafd34fef976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_594db97c-e8d2-4adb-a827-cc4e2bb04773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_594db97c-e8d2-4adb-a827-cc4e2bb04773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_26d7fa6b-35dd-4a83-a406-401002c4afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_26d7fa6b-35dd-4a83-a406-401002c4afc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a552056-cdbf-4b18-9cf2-5176ed8b372b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b801bcc6-6d8a-4115-95c2-f93333b38ab9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a552056-cdbf-4b18-9cf2-5176ed8b372b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5ca78b59-34d9-42be-bf47-1206c22bfdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5ca78b59-34d9-42be-bf47-1206c22bfdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_04797888-f9eb-4dcd-b14d-89bc8894cbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_04797888-f9eb-4dcd-b14d-89bc8894cbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f9f6d941-f9a5-47a8-a799-9f3ce4350ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f9f6d941-f9a5-47a8-a799-9f3ce4350ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cd2dd946-e73f-44a5-bda6-3b76b92c4ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cd2dd946-e73f-44a5-bda6-3b76b92c4ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f4203ca2-f14a-47ce-ba86-2328a2806c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f4203ca2-f14a-47ce-ba86-2328a2806c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21e38d91-4c48-4615-bb4a-bbb8816b4e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e6e092c5-b4b5-4810-84ff-5598b8be40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21e38d91-4c48-4615-bb4a-bbb8816b4e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff6244ae-e08b-42ad-a089-65d787c278c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56d006c2-133c-4c5b-a2a6-8ac84cfbb3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56d006c2-133c-4c5b-a2a6-8ac84cfbb3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aa7bbcbb-773b-496a-b1a0-20fb6210c4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_aa7bbcbb-773b-496a-b1a0-20fb6210c4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5845d750-090d-4d1a-b400-7c60e1a05f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5845d750-090d-4d1a-b400-7c60e1a05f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_79770381-32a8-4166-8bdf-6a9700712b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_79770381-32a8-4166-8bdf-6a9700712b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7d3ef423-bec9-411c-814e-4bd61bae5890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7d3ef423-bec9-411c-814e-4bd61bae5890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8d781751-dbbc-48e0-b137-d8ae1183beab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8d781751-dbbc-48e0-b137-d8ae1183beab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9b821b38-1942-4a3f-bf16-128583ea4fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9b821b38-1942-4a3f-bf16-128583ea4fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f230f03e-772f-43c3-be01-fd6a0d05b72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f230f03e-772f-43c3-be01-fd6a0d05b72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f4f7944a-68ad-4091-8886-470fd4750595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f4f7944a-68ad-4091-8886-470fd4750595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_41d81054-039d-4626-90ac-dd6246e11cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24c7e2b1-ed32-4b50-91fd-12a0a78ca00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_41d81054-039d-4626-90ac-dd6246e11cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#StockIncentivePlansValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59856770-7044-48ac-b8c4-2258bb8bdf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_818b78e7-ceab-47ca-890c-c05d082c9d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59856770-7044-48ac-b8c4-2258bb8bdf87" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_818b78e7-ceab-47ca-890c-c05d082c9d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5a4c111-4eda-4a8f-8886-8d26cffa7efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_818b78e7-ceab-47ca-890c-c05d082c9d3e" xlink:to="loc_us-gaap_AwardTypeAxis_f5a4c111-4eda-4a8f-8886-8d26cffa7efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1149c62c-35c3-491a-a2cb-5fed8250daff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f5a4c111-4eda-4a8f-8886-8d26cffa7efb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1149c62c-35c3-491a-a2cb-5fed8250daff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_62d3d0c4-b028-4a87-939e-b3446d0c6cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1149c62c-35c3-491a-a2cb-5fed8250daff" xlink:to="loc_us-gaap_EmployeeStockMember_62d3d0c4-b028-4a87-939e-b3446d0c6cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5cc5f191-053f-44e3-84ce-3cb102664df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1149c62c-35c3-491a-a2cb-5fed8250daff" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5cc5f191-053f-44e3-84ce-3cb102664df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_818b78e7-ceab-47ca-890c-c05d082c9d3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3649d0db-5680-4d4e-8b64-ae34fdb2ebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3649d0db-5680-4d4e-8b64-ae34fdb2ebc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd29f611-a80b-40d2-a869-e8d10ad3200a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd29f611-a80b-40d2-a869-e8d10ad3200a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33c314bc-68fc-4854-a6eb-986d5ac493e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33c314bc-68fc-4854-a6eb-986d5ac493e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9f50b9a7-d746-4229-b9b5-c4cbc823526d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9f50b9a7-d746-4229-b9b5-c4cbc823526d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3dd65992-111f-4de0-8db0-2cf4588b8d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c50a5c34-ef23-487b-a693-b073616f0e99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3dd65992-111f-4de0-8db0-2cf4588b8d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a56ad015-b281-4725-aaa1-add5b1217837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_9afddf42-f451-404b-b3b9-fd2bcaee749f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a56ad015-b281-4725-aaa1-add5b1217837" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_9afddf42-f451-404b-b3b9-fd2bcaee749f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_14741823-7cdd-4a0d-8dd5-cd4888b4ab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_9afddf42-f451-404b-b3b9-fd2bcaee749f" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_14741823-7cdd-4a0d-8dd5-cd4888b4ab4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f9cacc99-8603-4818-a1af-e7a36f18dd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_14741823-7cdd-4a0d-8dd5-cd4888b4ab4a" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f9cacc99-8603-4818-a1af-e7a36f18dd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_A2022RepurchaseProgramMember_f6aaab9d-50c4-42c3-9f57-f4f3c377735d" xlink:href="cvs-20221231.xsd#cvs_A2022RepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f9cacc99-8603-4818-a1af-e7a36f18dd3f" xlink:to="loc_cvs_A2022RepurchaseProgramMember_f6aaab9d-50c4-42c3-9f57-f4f3c377735d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_A2021RepurchaseProgramMember_46d18b62-1c1d-4bba-ba2a-fcd365a14833" xlink:href="cvs-20221231.xsd#cvs_A2021RepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f9cacc99-8603-4818-a1af-e7a36f18dd3f" xlink:to="loc_cvs_A2021RepurchaseProgramMember_46d18b62-1c1d-4bba-ba2a-fcd365a14833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_9afddf42-f451-404b-b3b9-fd2bcaee749f" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bc5fc789-be1d-4786-addc-eeedc342ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bc5fc789-be1d-4786-addc-eeedc342ca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_80155eec-3997-4398-9bea-e926a63ceb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_80155eec-3997-4398-9bea-e926a63ceb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_178ef011-6fb8-4dec-9238-8585381a0373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_178ef011-6fb8-4dec-9238-8585381a0373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f69a103a-9e7f-4572-a3e8-03d0136588b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e8982df-f868-4f6f-8a4d-9420b0dcf839" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f69a103a-9e7f-4572-a3e8-03d0136588b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityAcceleratedShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5a44a863-ce59-494d-a6b4-6803fb605401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5a44a863-ce59-494d-a6b4-6803fb605401" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_da320251-35fb-43c4-8303-bb428ac6e32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_da320251-35fb-43c4-8303-bb428ac6e32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_82526397-c131-4e5b-bc62-b115a34d0ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_da320251-35fb-43c4-8303-bb428ac6e32c" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_82526397-c131-4e5b-bc62-b115a34d0ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_A2021RepurchaseProgramMember_964a72ef-cf43-4fe9-bc0f-ee5da9b981ec" xlink:href="cvs-20221231.xsd#cvs_A2021RepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_82526397-c131-4e5b-bc62-b115a34d0ac9" xlink:to="loc_cvs_A2021RepurchaseProgramMember_964a72ef-cf43-4fe9-bc0f-ee5da9b981ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_367ba251-67a5-4565-8484-b89bbe2b3964" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:to="loc_srt_CounterpartyNameAxis_367ba251-67a5-4565-8484-b89bbe2b3964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62a5a929-1590-4a75-99ff-0c7f8f8c0897" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_367ba251-67a5-4565-8484-b89bbe2b3964" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62a5a929-1590-4a75-99ff-0c7f8f8c0897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_CitibankNAMember_adb6cba5-563d-49f0-911b-ca1751226a64" xlink:href="cvs-20221231.xsd#cvs_CitibankNAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62a5a929-1590-4a75-99ff-0c7f8f8c0897" xlink:to="loc_cvs_CitibankNAMember_adb6cba5-563d-49f0-911b-ca1751226a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BarclaysBankMember_7bf31570-b07a-46cc-b393-0ae5ed67ee0f" xlink:href="cvs-20221231.xsd#cvs_BarclaysBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_62a5a929-1590-4a75-99ff-0c7f8f8c0897" xlink:to="loc_cvs_BarclaysBankMember_7bf31570-b07a-46cc-b393-0ae5ed67ee0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fdb20b48-fd54-479f-9c64-676331884e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fdb20b48-fd54-479f-9c64-676331884e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9d712eb8-35ee-421c-976d-0e4ce65dff35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fdb20b48-fd54-479f-9c64-676331884e0b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9d712eb8-35ee-421c-976d-0e4ce65dff35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_12bbc846-4e2d-4c0f-917c-b1987344094d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d712eb8-35ee-421c-976d-0e4ce65dff35" xlink:to="loc_us-gaap_ForwardContractsMember_12bbc846-4e2d-4c0f-917c-b1987344094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e53b5f21-4f3b-4808-9a66-94eaa34634ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e53b5f21-4f3b-4808-9a66-94eaa34634ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_507cb298-3251-404a-825b-8da3a6d465a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e53b5f21-4f3b-4808-9a66-94eaa34634ef" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_507cb298-3251-404a-825b-8da3a6d465a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ea6f97ee-8919-4816-88c7-9047261575f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_507cb298-3251-404a-825b-8da3a6d465a5" xlink:to="loc_us-gaap_SubsequentEventMember_ea6f97ee-8919-4816-88c7-9047261575f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_a3bb0be5-0b9b-4930-9fc9-795c679e79c5" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesAgreementAmount_83170d42-a439-43d7-9156-361e1e1867de" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesAgreementAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchasesAgreementAmount_83170d42-a439-43d7-9156-361e1e1867de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PaymentsForAcceleratedShareRepurchasesAmount_a757aafd-5353-4370-81fe-aff41e24f13b" xlink:href="cvs-20221231.xsd#cvs_PaymentsForAcceleratedShareRepurchasesAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_PaymentsForAcceleratedShareRepurchasesAmount_a757aafd-5353-4370-81fe-aff41e24f13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares_851d9304-fe40-4b8a-b682-3dc0e74259b8" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares_851d9304-fe40-4b8a-b682-3dc0e74259b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased_db8bcb8b-8372-4c62-affa-ac2121ceebcc" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased_db8bcb8b-8372-4c62-affa-ac2121ceebcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_f69f0652-23fc-45aa-a105-021511185e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_us-gaap_SharePrice_f69f0652-23fc-45aa-a105-021511185e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram_d012fddf-e425-4452-982e-de913057ba0b" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram_d012fddf-e425-4452-982e-de913057ba0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares_555dd58b-e8d7-4652-9bd2-412e9f7276d8" xlink:href="cvs-20221231.xsd#cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares_555dd58b-e8d7-4652-9bd2-412e9f7276d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TransferOfSharesToTreasuryStockValue_9c5cd746-3786-435f-8a92-587c050d5e00" xlink:href="cvs-20221231.xsd#cvs_TransferOfSharesToTreasuryStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_cvs_TransferOfSharesToTreasuryStockValue_9c5cd746-3786-435f-8a92-587c050d5e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4f5af9b5-d4ee-4142-a4cb-2c43cf3b45e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6134431a-744c-4230-9c5c-a19143c95eb5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4f5af9b5-d4ee-4142-a4cb-2c43cf3b45e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7f4d8701-ff07-4f0a-8275-90bdf8417386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableTable_da5c0bd7-69e9-4c19-9551-3d1b041c4f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7f4d8701-ff07-4f0a-8275-90bdf8417386" xlink:to="loc_us-gaap_DividendsPayableTable_da5c0bd7-69e9-4c19-9551-3d1b041c4f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_39df9500-5bb2-4903-bcb5-63788e13cebe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_da5c0bd7-69e9-4c19-9551-3d1b041c4f52" xlink:to="loc_srt_StatementScenarioAxis_39df9500-5bb2-4903-bcb5-63788e13cebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9d2ca24f-6c5b-4329-84b9-6fd7e67a7140" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_39df9500-5bb2-4903-bcb5-63788e13cebe" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9d2ca24f-6c5b-4329-84b9-6fd7e67a7140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f108c2a1-9bec-46d7-bca0-6b681ff2462f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9d2ca24f-6c5b-4329-84b9-6fd7e67a7140" xlink:to="loc_srt_ScenarioForecastMember_f108c2a1-9bec-46d7-bca0-6b681ff2462f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableLineItems_a52e063d-ceb9-4689-b9c3-da0ee606e786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableTable_da5c0bd7-69e9-4c19-9551-3d1b041c4f52" xlink:to="loc_us-gaap_DividendsPayableLineItems_a52e063d-ceb9-4689-b9c3-da0ee606e786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_96c93b35-2369-414a-87ce-5e3d7d36fa71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_a52e063d-ceb9-4689-b9c3-da0ee606e786" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_96c93b35-2369-414a-87ce-5e3d7d36fa71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent_c62b7b1b-c58d-47a2-92d5-f7f9f9a5e6cb" xlink:href="cvs-20221231.xsd#cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPayableLineItems_a52e063d-ceb9-4689-b9c3-da0ee606e786" xlink:to="loc_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent_c62b7b1b-c58d-47a2-92d5-f7f9f9a5e6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityRegulatoryRequirementsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dddd9099-4edb-4509-9abe-acdd188d9eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesTable_4de0b853-8e55-4321-9c67-990fb83ddf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dddd9099-4edb-4509-9abe-acdd188d9eba" xlink:to="loc_us-gaap_StatutoryAccountingPracticesTable_4de0b853-8e55-4321-9c67-990fb83ddf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_46a4e1f3-226c-494d-9b91-0cc68e7a9070" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable_4de0b853-8e55-4321-9c67-990fb83ddf6f" xlink:to="loc_dei_LegalEntityAxis_46a4e1f3-226c-494d-9b91-0cc68e7a9070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fb57333e-2042-4f7a-92fd-f44b3bcdd09f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_46a4e1f3-226c-494d-9b91-0cc68e7a9070" xlink:to="loc_dei_EntityDomain_fb57333e-2042-4f7a-92fd-f44b3bcdd09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_InsuranceAndHMOMember_6c02ec73-80b6-4f52-9082-a098e05a8dd5" xlink:href="cvs-20221231.xsd#cvs_InsuranceAndHMOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fb57333e-2042-4f7a-92fd-f44b3bcdd09f" xlink:to="loc_cvs_InsuranceAndHMOMember_6c02ec73-80b6-4f52-9082-a098e05a8dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable_4de0b853-8e55-4321-9c67-990fb83ddf6f" xlink:to="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_a0b43931-4e78-4085-a321-c0aa480edd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_a0b43931-4e78-4085-a321-c0aa480edd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_abe7d079-5a94-4e61-aebe-b55cc4b8c872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_abe7d079-5a94-4e61-aebe-b55cc4b8c872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_86bc6659-e8f0-429f-9157-bc65755fc28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_86bc6659-e8f0-429f-9157-bc65755fc28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_b1307aa8-56a9-403c-8d6b-9832dcabe7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_b1307aa8-56a9-403c-8d6b-9832dcabe7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldByInsuranceRegulators_422d5eba-9066-454b-8ad8-6e462d50b9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldByInsuranceRegulators"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_AssetsHeldByInsuranceRegulators_422d5eba-9066-454b-8ad8-6e462d50b9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_c8d03667-0162-41e1-a12e-5ff478986b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_fb4adc90-ad70-47e7-866b-01cf23809818" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_c8d03667-0162-41e1-a12e-5ff478986b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ShareholdersEquityNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9a2d6ea1-c678-4eed-aaae-dccd69336282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_dfb9395b-5547-4075-b9a6-a5f31a6993d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a2d6ea1-c678-4eed-aaae-dccd69336282" xlink:to="loc_us-gaap_MinorityInterest_dfb9395b-5547-4075-b9a6-a5f31a6993d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_45178d91-64d5-491b-92ff-0d55b7df8dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1ae317bb-897e-4631-bd64-0f932ae7a870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_45178d91-64d5-491b-92ff-0d55b7df8dd9" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1ae317bb-897e-4631-bd64-0f932ae7a870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4dc0e1bb-fce2-436a-97b4-57515be57b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1ae317bb-897e-4631-bd64-0f932ae7a870" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4dc0e1bb-fce2-436a-97b4-57515be57b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4dc0e1bb-fce2-436a-97b4-57515be57b62" xlink:to="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_66516169-2ee4-4c19-b680-4249b5b6e96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_66516169-2ee4-4c19-b680-4249b5b6e96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_15671ead-73fc-49fe-9bf1-782c7f58d9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_15671ead-73fc-49fe-9bf1-782c7f58d9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_7737e54a-825f-452c-95d4-6d92a18d5902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_7737e54a-825f-452c-95d4-6d92a18d5902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_4f5c2c51-9391-4f3c-9947-c4145b2cc900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_4f5c2c51-9391-4f3c-9947-c4145b2cc900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_39bb6f9a-36fa-4759-9c50-673db7643da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ddb22fe2-458c-4923-8961-48b410ff80fa" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_39bb6f9a-36fa-4759-9c50-673db7643da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1ae317bb-897e-4631-bd64-0f932ae7a870" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27d80310-5d3b-4cf1-ad69-f82d6de4ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27d80310-5d3b-4cf1-ad69-f82d6de4ff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2d166e15-dfff-480e-9f24-db0097423670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2d166e15-dfff-480e-9f24-db0097423670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_b3a66778-97f5-4036-b788-9151ace26f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_b3a66778-97f5-4036-b788-9151ace26f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_81a15e62-459c-4bef-9b66-e3630b1b4d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_81a15e62-459c-4bef-9b66-e3630b1b4d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b06acd9-bd16-4fa2-acb2-3fe2bbbb0876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3e2013f1-5395-4a32-bfee-b5c3c7e35edd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b06acd9-bd16-4fa2-acb2-3fe2bbbb0876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_6a5cf8c4-f155-4cd1-bc4a-da18a9653e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_6a5cf8c4-f155-4cd1-bc4a-da18a9653e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_04173926-d992-4553-bd23-ba9644a23b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_04173926-d992-4553-bd23-ba9644a23b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_a347201e-3d64-43a0-89e6-3132fa06e5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_3318fec2-37ea-4a98-b96a-e5f1aef162d8" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_a347201e-3d64-43a0-89e6-3132fa06e5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_90fdeb43-1be7-4706-9da4-b018225011be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8401db28-d92a-48b1-9719-2376a459bd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_90fdeb43-1be7-4706-9da4-b018225011be" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8401db28-d92a-48b1-9719-2376a459bd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96c4aaa3-38c1-4449-adae-d5a16b5c4cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8401db28-d92a-48b1-9719-2376a459bd21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96c4aaa3-38c1-4449-adae-d5a16b5c4cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36da2664-6aff-47ae-add1-e2b098c9eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96c4aaa3-38c1-4449-adae-d5a16b5c4cff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36da2664-6aff-47ae-add1-e2b098c9eec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StockOptionsAndStockAppreciationRightsMember_70aa82e5-f7ae-4277-9844-5cd32137ab09" xlink:href="cvs-20221231.xsd#cvs_StockOptionsAndStockAppreciationRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36da2664-6aff-47ae-add1-e2b098c9eec8" xlink:to="loc_cvs_StockOptionsAndStockAppreciationRightsMember_70aa82e5-f7ae-4277-9844-5cd32137ab09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember_a278396f-4ae1-4f8b-a38b-77bb0bd05e82" xlink:href="cvs-20221231.xsd#cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36da2664-6aff-47ae-add1-e2b098c9eec8" xlink:to="loc_cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember_a278396f-4ae1-4f8b-a38b-77bb0bd05e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8401db28-d92a-48b1-9719-2376a459bd21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_87458c38-4530-48e3-aacb-0f9899f19e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_87458c38-4530-48e3-aacb-0f9899f19e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:href="cvs-20221231.xsd#cvs_NumeratorForEarningsPerShareCalculationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:to="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_88f2dd0d-ffe7-435d-a694-a4aff0132d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_88f2dd0d-ffe7-435d-a694-a4aff0132d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76781efa-ceac-4be8-a879-4ffb52457387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_76781efa-ceac-4be8-a879-4ffb52457387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_99c32665-e9fc-4ed2-90c7-0cc9c3e3a8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_NumeratorForEarningsPerShareCalculationAbstract_4fc88c6d-c7de-41be-9550-f11c53ddda5c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_99c32665-e9fc-4ed2-90c7-0cc9c3e3a8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:href="cvs-20221231.xsd#cvs_DenominatorForEarningsPerShareCalculationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:to="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ede8bcd-36cb-4749-8fe8-70d9688246b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ede8bcd-36cb-4749-8fe8-70d9688246b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a75ab444-528a-4703-9691-9cb30a2ca6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a75ab444-528a-4703-9691-9cb30a2ca6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1c278c60-3954-4e41-a69b-37349dba4f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_DenominatorForEarningsPerShareCalculationAbstract_3191b77e-eb68-4dea-a37b-98b203eba356" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1c278c60-3954-4e41-a69b-37349dba4f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_88a1a21c-efc8-4b44-937b-398e9bb5285f" xlink:href="cvs-20221231.xsd#cvs_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0022a4b5-9f36-4e9b-80f1-3633e55a7a7b" xlink:to="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_88a1a21c-efc8-4b44-937b-398e9bb5285f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b59c8e3d-3c9a-43cc-a837-99f811485f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_88a1a21c-efc8-4b44-937b-398e9bb5285f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b59c8e3d-3c9a-43cc-a837-99f811485f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9bd72b9e-f549-4e95-b9c1-1b424f5c0cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvs_EarningsPerShareBasicAndDilutedEPSAbstract_88a1a21c-efc8-4b44-937b-398e9bb5285f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9bd72b9e-f549-4e95-b9c1-1b424f5c0cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ReinsuranceNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_0e846220-3cc3-4e32-9ed8-e5b15955033e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_0c27c28a-4c59-4489-9442-0a879138107b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_0e846220-3cc3-4e32-9ed8-e5b15955033e" xlink:to="loc_us-gaap_CededCreditRiskTable_0c27c28a-4c59-4489-9442-0a879138107b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7accc59c-e6e0-4810-b28e-a9a723809a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_0c27c28a-4c59-4489-9442-0a879138107b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7accc59c-e6e0-4810-b28e-a9a723809a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_334425a1-41ef-45bc-847d-88707b74b5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7accc59c-e6e0-4810-b28e-a9a723809a11" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_334425a1-41ef-45bc-847d-88707b74b5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3493e77e-4b72-4d39-ab8c-e45da798b684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_334425a1-41ef-45bc-847d-88707b74b5d7" xlink:to="loc_us-gaap_SubsequentEventMember_3493e77e-4b72-4d39-ab8c-e45da798b684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_a8f69992-284f-43c9-8c06-ab4c9d2ab9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_0c27c28a-4c59-4489-9442-0a879138107b" xlink:to="loc_us-gaap_CededCreditRiskLineItems_a8f69992-284f-43c9-8c06-ab4c9d2ab9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberofReinsuranceContractsEnteredInto_0943a62c-795e-4480-98a4-20732edc31c8" xlink:href="cvs-20221231.xsd#cvs_NumberofReinsuranceContractsEnteredInto"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_a8f69992-284f-43c9-8c06-ab4c9d2ab9d8" xlink:to="loc_cvs_NumberofReinsuranceContractsEnteredInto_0943a62c-795e-4480-98a4-20732edc31c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer_90ca25f5-0874-48ac-9ab8-5bf1b34e89c1" xlink:href="cvs-20221231.xsd#cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_a8f69992-284f-43c9-8c06-ab4c9d2ab9d8" xlink:to="loc_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer_90ca25f5-0874-48ac-9ab8-5bf1b34e89c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ReinsuranceReinsuranceRecoverablesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_c01a046e-40ac-4a9f-939f-97d5a2ae62e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_1671a8a1-60c5-42b6-a1c0-ca6e2c3e352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_c01a046e-40ac-4a9f-939f-97d5a2ae62e9" xlink:to="loc_us-gaap_CededCreditRiskTable_1671a8a1-60c5-42b6-a1c0-ca6e2c3e352e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_2251b2c1-f34c-49c7-9a7d-e5a9e92bce90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_1671a8a1-60c5-42b6-a1c0-ca6e2c3e352e" xlink:to="loc_us-gaap_CededCreditRiskAxis_2251b2c1-f34c-49c7-9a7d-e5a9e92bce90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskAxis_2251b2c1-f34c-49c7-9a7d-e5a9e92bce90" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HartfordLifeAndAccidentInsuranceCompanyMember_ae0f48dc-7afe-4d27-be12-50a368b61d0e" xlink:href="cvs-20221231.xsd#cvs_HartfordLifeAndAccidentInsuranceCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_HartfordLifeAndAccidentInsuranceCompanyMember_ae0f48dc-7afe-4d27-be12-50a368b61d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember_133a29e3-0357-447a-b34d-174c1e874a6d" xlink:href="cvs-20221231.xsd#cvs_LincolnLifeAnnuityCompanyOfNewYorkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_LincolnLifeAnnuityCompanyOfNewYorkMember_133a29e3-0357-447a-b34d-174c1e874a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember_e9a19589-98be-441b-aa5a-402b1e9b5c1e" xlink:href="cvs-20221231.xsd#cvs_VOYARetirementInsuranceAndAnnuityCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_VOYARetirementInsuranceAndAnnuityCompanyMember_e9a19589-98be-441b-aa5a-402b1e9b5c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember_50e76484-c662-4f22-bee3-90e188983973" xlink:href="cvs-20221231.xsd#cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember_50e76484-c662-4f22-bee3-90e188983973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AllOtherReinsurersMember_5b96086e-c751-4528-9d7a-e93674f593f5" xlink:href="cvs-20221231.xsd#cvs_AllOtherReinsurersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_34e6249d-ef9b-4574-82a2-896ef09819f2" xlink:to="loc_cvs_AllOtherReinsurersMember_5b96086e-c751-4528-9d7a-e93674f593f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_6c687b68-6676-4b51-a39c-7bc1c729f269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_1671a8a1-60c5-42b6-a1c0-ca6e2c3e352e" xlink:to="loc_us-gaap_CededCreditRiskLineItems_6c687b68-6676-4b51-a39c-7bc1c729f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_85dc7927-08e4-4b25-bada-a14f56b98f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_6c687b68-6676-4b51-a39c-7bc1c729f269" xlink:to="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_85dc7927-08e4-4b25-bada-a14f56b98f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#ReinsuranceEffectsofReinsuranceDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_1e196c01-c04b-4d78-9113-e423d5c4fd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_86f0a414-1bd6-4d50-a41a-1aba8dfe2a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_1e196c01-c04b-4d78-9113-e423d5c4fd7e" xlink:to="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_86f0a414-1bd6-4d50-a41a-1aba8dfe2a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned_4ac8a221-ce2b-4b3d-833e-016c0de19d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_86f0a414-1bd6-4d50-a41a-1aba8dfe2a0e" xlink:to="loc_us-gaap_DirectPremiumsEarned_4ac8a221-ce2b-4b3d-833e-016c0de19d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned_6bb7da0d-bdd5-4dc0-97ba-b65507cc162b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_86f0a414-1bd6-4d50-a41a-1aba8dfe2a0e" xlink:to="loc_us-gaap_AssumedPremiumsEarned_6bb7da0d-bdd5-4dc0-97ba-b65507cc162b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned_d07179ea-92b1-4089-9bf2-0cfbf2033953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CededPremiumsEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_86f0a414-1bd6-4d50-a41a-1aba8dfe2a0e" xlink:to="loc_us-gaap_CededPremiumsEarned_d07179ea-92b1-4089-9bf2-0cfbf2033953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_b5a96399-055e-4ba0-aa09-028165e795c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_86f0a414-1bd6-4d50-a41a-1aba8dfe2a0e" xlink:to="loc_us-gaap_PremiumsEarnedNet_b5a96399-055e-4ba0-aa09-028165e795c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_1388115e-d329-46fa-af21-a070edf319ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_1e196c01-c04b-4d78-9113-e423d5c4fd7e" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_1388115e-d329-46fa-af21-a070edf319ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_9f8fc4fd-5a25-43dd-bea8-7c235011b913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_1388115e-d329-46fa-af21-a070edf319ad" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross_9f8fc4fd-5a25-43dd-bea8-7c235011b913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_7fda63a6-7d8b-4f00-bd29-8bec5b468ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_1388115e-d329-46fa-af21-a070edf319ad" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_7fda63a6-7d8b-4f00-bd29-8bec5b468ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_04baaa26-6555-4752-9c1d-b581d22d3c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_1388115e-d329-46fa-af21-a070edf319ad" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_04baaa26-6555-4752-9c1d-b581d22d3c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_fc53b349-a8ab-472e-b84c-b7fefc43b1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_1388115e-d329-46fa-af21-a070edf319ad" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_fc53b349-a8ab-472e-b84c-b7fefc43b1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_df1fa147-0ad5-47b9-907b-0862b1ba678d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_5f0d2306-3d22-46ff-9b39-03708482bdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_df1fa147-0ad5-47b9-907b-0862b1ba678d" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_5f0d2306-3d22-46ff-9b39-03708482bdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts_6f2afa89-5b61-4198-a6bc-db78907ca426" xlink:href="cvs-20221231.xsd#cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_df1fa147-0ad5-47b9-907b-0862b1ba678d" xlink:to="loc_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts_6f2afa89-5b61-4198-a6bc-db78907ca426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_GuarantorObligationsNumberOfLeases_9d27c0b8-6f99-495f-854b-056784bce556" xlink:href="cvs-20221231.xsd#cvs_GuarantorObligationsNumberOfLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_df1fa147-0ad5-47b9-907b-0862b1ba678d" xlink:to="loc_cvs_GuarantorObligationsNumberOfLeases_9d27c0b8-6f99-495f-854b-056784bce556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_df1fa147-0ad5-47b9-907b-0862b1ba678d" xlink:to="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c25584b8-cc5d-4ab0-b87f-8303a5ad7037" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_srt_LitigationCaseAxis_c25584b8-cc5d-4ab0-b87f-8303a5ad7037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c25584b8-cc5d-4ab0-b87f-8303a5ad7037" xlink:to="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FederalCourtInOhioJudgmentMember_abec6391-bb32-43f6-914d-4b0c3ec5eee5" xlink:href="cvs-20221231.xsd#cvs_FederalCourtInOhioJudgmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_FederalCourtInOhioJudgmentMember_abec6391-bb32-43f6-914d-4b0c3ec5eee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StateOfFloridaSettlementMember_df286afc-6ee5-4047-a5d1-6396f8781a43" xlink:href="cvs-20221231.xsd#cvs_StateOfFloridaSettlementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_StateOfFloridaSettlementMember_df286afc-6ee5-4047-a5d1-6396f8781a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SettlementFrameworkMember_18078d17-131e-4320-a51c-46430c35f50e" xlink:href="cvs-20221231.xsd#cvs_SettlementFrameworkMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_SettlementFrameworkMember_18078d17-131e-4320-a51c-46430c35f50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember_e27ad55c-06e9-474a-95c1-dc45ed9f6733" xlink:href="cvs-20221231.xsd#cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember_e27ad55c-06e9-474a-95c1-dc45ed9f6733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RadcliffAndFlaimVAetnaIncEtAlMember_a3a5c0ee-5228-4ce5-8f61-ac13de3c6ae5" xlink:href="cvs-20221231.xsd#cvs_RadcliffAndFlaimVAetnaIncEtAlMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40f6a9d7-676e-41fa-97f0-9af9c418295e" xlink:to="loc_cvs_RadcliffAndFlaimVAetnaIncEtAlMember_a3a5c0ee-5228-4ce5-8f61-ac13de3c6ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e3d3650c-a363-4b4a-a931-07d8d34007e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_us-gaap_LitigationStatusAxis_e3d3650c-a363-4b4a-a931-07d8d34007e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bc8a5d59-4747-4180-a717-3596d2124341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_e3d3650c-a363-4b4a-a931-07d8d34007e3" xlink:to="loc_us-gaap_LitigationStatusDomain_bc8a5d59-4747-4180-a717-3596d2124341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_5f482432-7cdf-4dd2-9b59-23403acabd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_bc8a5d59-4747-4180-a717-3596d2124341" xlink:to="loc_us-gaap_PendingLitigationMember_5f482432-7cdf-4dd2-9b59-23403acabd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fa22d0fb-1698-45d4-9a9e-1911659ad3b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_srt_CounterpartyNameAxis_fa22d0fb-1698-45d4-9a9e-1911659ad3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2bb8c5f6-af35-4000-956b-d056fc023f49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fa22d0fb-1698-45d4-9a9e-1911659ad3b4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2bb8c5f6-af35-4000-956b-d056fc023f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_TribalEntitiesMember_ea9444fc-3e2c-4755-bab8-84c829bd5fbd" xlink:href="cvs-20221231.xsd#cvs_TribalEntitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2bb8c5f6-af35-4000-956b-d056fc023f49" xlink:to="loc_cvs_TribalEntitiesMember_ea9444fc-3e2c-4755-bab8-84c829bd5fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b46ad9cd-55c1-4171-a45a-6f591ae6ef57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_srt_RangeAxis_b46ad9cd-55c1-4171-a45a-6f591ae6ef57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4deafc0c-82b2-435b-be2d-f22d15a96c0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b46ad9cd-55c1-4171-a45a-6f591ae6ef57" xlink:to="loc_srt_RangeMember_4deafc0c-82b2-435b-be2d-f22d15a96c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3efbddc2-559f-46ff-a3ff-e14a9f308e20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4deafc0c-82b2-435b-be2d-f22d15a96c0c" xlink:to="loc_srt_MaximumMember_3efbddc2-559f-46ff-a3ff-e14a9f308e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ade11304-8255-48ea-9bc1-0c17e53b6072" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_srt_StatementScenarioAxis_ade11304-8255-48ea-9bc1-0c17e53b6072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0132f079-7010-4a15-8925-fc048db5a8dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ade11304-8255-48ea-9bc1-0c17e53b6072" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0132f079-7010-4a15-8925-fc048db5a8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3a2ca889-87c5-41ed-84b0-c5b6fe55b227" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0132f079-7010-4a15-8925-fc048db5a8dc" xlink:to="loc_srt_ScenarioForecastMember_3a2ca889-87c5-41ed-84b0-c5b6fe55b227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_629f7c30-a0c8-4359-bd94-ecb6d710ae03" xlink:to="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a0af9cdc-65bc-4d75-a9e8-ae707910ca36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a0af9cdc-65bc-4d75-a9e8-ae707910ca36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LegalSettlementPeriodOfPayment_a739f43e-59c7-4a99-936b-c4d36a783564" xlink:href="cvs-20221231.xsd#cvs_LegalSettlementPeriodOfPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_cvs_LegalSettlementPeriodOfPayment_a739f43e-59c7-4a99-936b-c4d36a783564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_9994ab92-0132-477c-9031-4abad1d43df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_9994ab92-0132-477c-9031-4abad1d43df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_a916cbf7-49a0-4634-95d5-9cc7b828da21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_a916cbf7-49a0-4634-95d5-9cc7b828da21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_47f7d3a5-e00d-4a78-8017-5a98f9605169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LegalFees_47f7d3a5-e00d-4a78-8017-5a98f9605169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LitigationSettlementNumberOfStatesElectedToJoin_4fa07a41-5a52-49cf-b6cf-d97722b2bbbc" xlink:href="cvs-20221231.xsd#cvs_LitigationSettlementNumberOfStatesElectedToJoin"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_cvs_LitigationSettlementNumberOfStatesElectedToJoin_4fa07a41-5a52-49cf-b6cf-d97722b2bbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements_61559a6c-6a6d-460d-a3d6-0d17dca0b679" xlink:href="cvs-20221231.xsd#cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements_61559a6c-6a6d-460d-a3d6-0d17dca0b679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_9f2d0fdf-b7eb-4999-9977-f828337cbce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_9f2d0fdf-b7eb-4999-9977-f828337cbce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_3884f375-1a72-4747-ba7b-d4f50b74a307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_3884f375-1a72-4747-ba7b-d4f50b74a307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_d7a36f79-99fd-43d4-8e0b-71267e3c360e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6ad82b73-6fcf-41a9-aca6-a82c70ef3757" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_d7a36f79-99fd-43d4-8e0b-71267e3c360e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_25cdf6ce-e350-427d-a414-ac734f9633e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bf576e1d-a699-4acf-95bc-f281033d6c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_25cdf6ce-e350-427d-a414-ac734f9633e0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bf576e1d-a699-4acf-95bc-f281033d6c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_25cdf6ce-e350-427d-a414-ac734f9633e0" xlink:to="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7636a1f9-8d33-4da6-b60d-14ceeab832b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:to="loc_srt_MajorCustomersAxis_7636a1f9-8d33-4da6-b60d-14ceeab832b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_697befcf-e026-466c-95b8-c88a8041d626" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7636a1f9-8d33-4da6-b60d-14ceeab832b3" xlink:to="loc_srt_NameOfMajorCustomerDomain_697befcf-e026-466c-95b8-c88a8041d626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_USFederalGovernmentMember_531b1000-1c3a-4ca1-a37a-80b6b77ce0af" xlink:href="cvs-20221231.xsd#cvs_USFederalGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_697befcf-e026-466c-95b8-c88a8041d626" xlink:to="loc_cvs_USFederalGovernmentMember_531b1000-1c3a-4ca1-a37a-80b6b77ce0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_46074bbd-6580-4724-94ea-cdfa058f4beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_46074bbd-6580-4724-94ea-cdfa058f4beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_47f12957-2421-4682-a783-49fdbe1c74c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_46074bbd-6580-4724-94ea-cdfa058f4beb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_47f12957-2421-4682-a783-49fdbe1c74c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_75b566a6-3444-40f6-a513-c79d4a4ac5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_47f12957-2421-4682-a783-49fdbe1c74c0" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_75b566a6-3444-40f6-a513-c79d4a4ac5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f901c867-e591-429c-811a-40cfa893dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f901c867-e591-429c-811a-40cfa893dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3091948f-5314-4d7f-9611-a573cdece684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f901c867-e591-429c-811a-40cfa893dbe2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3091948f-5314-4d7f-9611-a573cdece684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d412b9bd-846b-4952-981b-66ff21e6a7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3091948f-5314-4d7f-9611-a573cdece684" xlink:to="loc_us-gaap_SalesRevenueNetMember_d412b9bd-846b-4952-981b-66ff21e6a7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7debd8df-82f2-42b5-9cb0-7a44102b8d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3f32698b-b85f-4a22-b7b3-25cf21f06b84" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7debd8df-82f2-42b5-9cb0-7a44102b8d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a82503ab-7ab0-4614-829a-44d7d05b28e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7debd8df-82f2-42b5-9cb0-7a44102b8d37" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a82503ab-7ab0-4614-829a-44d7d05b28e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e752735a-bd56-4602-8dc7-0dfafdce0e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b44b7a22-e81e-4985-b03d-c725c30cf4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e752735a-bd56-4602-8dc7-0dfafdce0e60" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b44b7a22-e81e-4985-b03d-c725c30cf4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2df2e650-810c-4ebc-8323-074a339b8f62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b44b7a22-e81e-4985-b03d-c725c30cf4ca" xlink:to="loc_srt_ConsolidationItemsAxis_2df2e650-810c-4ebc-8323-074a339b8f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_2df2e650-810c-4ebc-8323-074a339b8f62" xlink:to="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_182575df-c912-4b40-8d72-731187c74dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:to="loc_us-gaap_OperatingSegmentsMember_182575df-c912-4b40-8d72-731187c74dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_af40b6cc-0e82-47bb-85e2-6f619cee3c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:to="loc_us-gaap_IntersegmentEliminationMember_af40b6cc-0e82-47bb-85e2-6f619cee3c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a8e5ab57-a46f-407c-9d3f-c8973e2c8fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_92e3caab-edb5-432d-bd5d-6773f79668cc" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a8e5ab57-a46f-407c-9d3f-c8973e2c8fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_808eec75-91c7-4e99-a9db-473cec44ebae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b44b7a22-e81e-4985-b03d-c725c30cf4ca" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_808eec75-91c7-4e99-a9db-473cec44ebae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_808eec75-91c7-4e99-a9db-473cec44ebae" xlink:to="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_HealthCareBenefitsSegmentMember_025f8afd-9469-4e1c-ae46-68c3da4e7d43" xlink:href="cvs-20221231.xsd#cvs_HealthCareBenefitsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:to="loc_cvs_HealthCareBenefitsSegmentMember_025f8afd-9469-4e1c-ae46-68c3da4e7d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PharmacyServicesSegmentMember_498e958b-30ce-41c5-ab9d-25ec6845dd25" xlink:href="cvs-20221231.xsd#cvs_PharmacyServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:to="loc_cvs_PharmacyServicesSegmentMember_498e958b-30ce-41c5-ab9d-25ec6845dd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_RetailLongTermCareSegmentMember_49270477-6a56-4a3a-a989-1322c055b75d" xlink:href="cvs-20221231.xsd#cvs_RetailLongTermCareSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_05e3305a-3100-490c-8225-504d58b4e223" xlink:to="loc_cvs_RetailLongTermCareSegmentMember_49270477-6a56-4a3a-a989-1322c055b75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b44b7a22-e81e-4985-b03d-c725c30cf4ca" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_09b64e1c-9d8d-4d7c-8384-41c4e1065989" xlink:href="cvs-20221231.xsd#cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax_09b64e1c-9d8d-4d7c-8384-41c4e1065989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4282aea8-264b-4b85-8fe1-459c1f92686a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4282aea8-264b-4b85-8fe1-459c1f92686a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_9c1b2bb6-c5a9-453e-aee4-e8e3a4497516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_us-gaap_NetInvestmentIncome_9c1b2bb6-c5a9-453e-aee4-e8e3a4497516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_36212d72-0544-4828-84ad-8e514f71433b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_us-gaap_Revenues_36212d72-0544-4828-84ad-8e514f71433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AdjustedOperatingIncomeLoss_db03a088-8b2d-4b8e-ad1b-5c9d0eaf2385" xlink:href="cvs-20221231.xsd#cvs_AdjustedOperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_cvs_AdjustedOperatingIncomeLoss_db03a088-8b2d-4b8e-ad1b-5c9d0eaf2385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_681ad334-6c7f-4f23-8736-5966b30a768b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_681ad334-6c7f-4f23-8736-5966b30a768b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NetRevenuesRetailCoPayments_feb6b6ce-edea-4fd1-8130-15f1051acd97" xlink:href="cvs-20221231.xsd#cvs_NetRevenuesRetailCoPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2f191a91-1401-4404-98e4-1b4e42f0d3ae" xlink:to="loc_cvs_NetRevenuesRetailCoPayments_feb6b6ce-edea-4fd1-8130-15f1051acd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" xlink:type="simple" xlink:href="cvs-20221231.xsd#SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d4caaac1-1d93-4907-99ab-74d0ec6329b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3b79972-d4e9-41e4-9637-81af78198673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d4caaac1-1d93-4907-99ab-74d0ec6329b5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3b79972-d4e9-41e4-9637-81af78198673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ca3ca2d4-b4df-4268-9af8-de3a0a2315ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3b79972-d4e9-41e4-9637-81af78198673" xlink:to="loc_srt_LitigationCaseAxis_ca3ca2d4-b4df-4268-9af8-de3a0a2315ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d8831b72-52ef-46cb-9e4d-28d471231404" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ca3ca2d4-b4df-4268-9af8-de3a0a2315ef" xlink:to="loc_srt_LitigationCaseTypeDomain_d8831b72-52ef-46cb-9e4d-28d471231404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_bc6c2935-da74-4814-afe3-108f528235c9" xlink:href="cvs-20221231.xsd#cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d8831b72-52ef-46cb-9e4d-28d471231404" xlink:to="loc_cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember_bc6c2935-da74-4814-afe3-108f528235c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a211232a-924b-449f-b927-3c34022c792c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3b79972-d4e9-41e4-9637-81af78198673" xlink:to="loc_us-gaap_LitigationStatusAxis_a211232a-924b-449f-b927-3c34022c792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_5d7fe839-4838-4a3f-b5e0-31c677adaa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_a211232a-924b-449f-b927-3c34022c792c" xlink:to="loc_us-gaap_LitigationStatusDomain_5d7fe839-4838-4a3f-b5e0-31c677adaa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_cab5953f-ab78-4498-9f47-8ecb7a89964c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_5d7fe839-4838-4a3f-b5e0-31c677adaa6d" xlink:to="loc_us-gaap_SettledLitigationMember_cab5953f-ab78-4498-9f47-8ecb7a89964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d3b79972-d4e9-41e4-9637-81af78198673" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a9d2e8d-362d-49a6-a1b0-e7655d4a9440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a9d2e8d-362d-49a6-a1b0-e7655d4a9440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_06b044b1-c238-452f-825e-72da278b2b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_06b044b1-c238-452f-825e-72da278b2b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_OfficeRealEstateOptimizationCharges_09db7fe8-5c1e-498e-a76f-9f9f38bf041c" xlink:href="cvs-20221231.xsd#cvs_OfficeRealEstateOptimizationCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_OfficeRealEstateOptimizationCharges_09db7fe8-5c1e-498e-a76f-9f9f38bf041c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_c179a0b4-9f6e-45ba-bfd6-73d6d98a9917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_c179a0b4-9f6e-45ba-bfd6-73d6d98a9917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_156221d0-5761-4b0b-ab62-55c647ea3b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_156221d0-5761-4b0b-ab62-55c647ea3b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_42da805d-19ee-4118-aa07-d0a417cb5dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_42da805d-19ee-4118-aa07-d0a417cb5dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_ac805174-085f-43fe-82af-9e110fced7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_ac805174-085f-43fe-82af-9e110fced7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_StoreImpairmentCharges_b550f0bc-a4cf-4491-9bea-8e6edf451e2f" xlink:href="cvs-20221231.xsd#cvs_StoreImpairmentCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_StoreImpairmentCharges_b550f0bc-a4cf-4491-9bea-8e6edf451e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_eb13079d-454f-4dec-b81f-aaa342e77026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_eb13079d-454f-4dec-b81f-aaa342e77026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod_fd71e88b-a5b1-4067-8cef-9f284c9e650b" xlink:href="cvs-20221231.xsd#cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod_fd71e88b-a5b1-4067-8cef-9f284c9e650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_cfa46c2e-8464-4580-a5b4-75f8232497a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_cfa46c2e-8464-4580-a5b4-75f8232497a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_AdjustedOperatingIncomeLoss_c9db4f63-495c-4e1a-88c7-ec592fd84d45" xlink:href="cvs-20221231.xsd#cvs_AdjustedOperatingIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_AdjustedOperatingIncomeLoss_c9db4f63-495c-4e1a-88c7-ec592fd84d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_NumberOfStoresPlannedClosure_03d695e1-13c5-4846-b146-b8b40334e6e8" xlink:href="cvs-20221231.xsd#cvs_NumberOfStoresPlannedClosure"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_NumberOfStoresPlannedClosure_03d695e1-13c5-4846-b146-b8b40334e6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_7effa876-55de-41d3-b7a7-5beab6338f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_7effa876-55de-41d3-b7a7-5beab6338f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_7965e962-a59f-4e6d-89db-f61419616ecc" xlink:href="cvs-20221231.xsd#cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_39b05186-bbf6-4d0d-82fb-40e910f8da08" xlink:to="loc_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax_7965e962-a59f-4e6d-89db-f61419616ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvs-20221231_g1.jpg
<DESCRIPTION>CVS HEALTH LOGO
<TEXT>
begin 644 cvs-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  < )T# 2(  A$! Q$!_\0
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M>(O@BW@63PU_PLX3?\([?_V@?#O]N&P_L[S/M.S[=Y()\[9Y>[G;CY3\[?\
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&-FB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvs-20221231_g2.jpg
<DESCRIPTION>STOCK PERFORMANCE GRAPH
<TEXT>
begin 644 cvs-20221231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH X']I[XL>-_@3\#/$GQE\#?#FS\5S>%]'NM5O]%NM?.G
M//:V\$DTHAD\B96F(0!4<(I+<R+CGX?_ .">?_!>3XN_\%/?ASXO^)O[*'_!
M.;4M4M/!5[#::K8:A\4;"TNYY9(VD1(%EMUC<E5/WY$&< D=:^U?VS/^3/\
MXK?]DUUW_P!-\]?SP_\ !N9_P5 \*_\ !*W_ ()__';X]_$G]FOXB^,_#K>/
MM'M9-9\&PZ<]GI]W):3+!%>M/=QSVZ2, HF6&5 S*I.]U5@#]I?^"8/_  6I
M_9=_X*B:]XL^%WP^\->)O!7Q%\",_P#PE?P^\:VD4-];(DWD231M$[K+&DV(
MG^ZZ.RAD4,A;["K\3?\ @US_ &(?&/Q-^._Q,_X+D_$#XA>&6_X7%=:];Z+X
M-\,7SW#Z9->ZLMY>B\)1?)>-X42.+YB4D\PX!3/4R?\ !6GQG^VO^W[^TY\"
M8_VM=:^#7@7X':1=Z!\/+;PE9Q&]U_Q-'-/ VHW4KVTS2PQSVT@2V&R)TDCW
MASDD ^Z_^"L?_!1]O^"6'[,J?M5:S\$I?&_A^WUJWTW6+2Q\0K8W=JUP=L,B
M*\+K*A8%6^9"N5(#@MM]8_9!_:(TS]KC]EOX??M0:+X9GT6T\?\ A*QUVVTF
MZN%EDLTN85E$3.H 8J&P2  <5^*'_!1K]MWX^?MZ_P#!K'=_%O\ :E\ 7OA_
MXAZ/\3=*T'Q4MYHDFGC4)[>YC=+U('5=@EAFB+!0$\P2;0J@*/I2#XW?\%'O
M@S_P0G_9 C_X)Q?!+4?%6KZ]X2\+V7C35=%6T>^T31_L,;2R6ZW:O!%))C9]
MIFCEB@ +.ARK* ?K#7%_$+]H/X3_  N^*'@#X,^,O%4-MXF^)NK7VG^#M('S
M37LEGI]QJ%R^T<K%'!;-ND^Z'DB4\R+G\F?@;_P5 ^,WPT_X.*M#_8!^%G[8
M^H?&CX'_ !!T60--XAO;/4FTO4H]-NKB1K.^MH8]X2XM#&R O&!)(I&] 5\7
M_:*\$?&[XA?\'AG@WX,R?MA_$+39UT*^F\,>)[--+EN_#-M-X7U&[:RL8+BS
MDM$A^_$3) [LLC.SM*?, !^GG[8?_!6U_P!DS_@H_P#!#_@GPO[*/BWQ4/C(
ML3'QSI5QLM=(\RZDM^(O);[3Y/E^=<?O(_)@=)/GSMK[&K\>/^"AW[<'[>'[
M'?\ P73_ &5?V*/A[^V#XEU/X??$.R\++XTTK7-"T61]2DDU6>PNI#+%8QO$
M9X[=7<1E0KNYC"*55<W_ (*+_MW?M]?\$V_^"XWP@\!?&#]L3Q(W[+_Q9UFW
MN(+230=&C&F[Y/LUS9/=_8?-,%O<26T[-N\P6TZKO+@O0!^S-%?)&I_&SQ_\
M.OCC^T;^USXN^.WB:\^"OP6\&&(>!DM-/^RW&LV>G2ZEJT\4PMA<.D=O)8P(
MAF*BX6[#9*!5_,KPY_P6-_;8^,/_  3>UG_@I9X#_:>U:;XUQ?%-9/#7P$\/
M^'%NM"_X1M+R*UDTR2V6V:6X8H\MP]T9A. B[&C ((!^]E?%'BO_ (*I?M$:
M?8?'+X@^#O\ @G?JVH_#_P"!FIZ]::OXUU/XAV=@FLC2(GENWLK=H'ED"K&P
MR0$WY0.65@OU5\ ?BHOQT^!/@KXVIX<N]''C#PEIVMC2-0C9+BQ^U6T<_D2J
MP!5T\S8P(!!4Y KR_P#X*0:!H?AO_@F7^T3I_A[1[:Q@E^#/C2ZDAM(%C5IY
M],O9YI2% !>26221FZLSLQR230!\K_L1_P#!>OXV_P#!1'X!>,?VA_V3O^"9
MFM^)-,\$ZBUCJ>CGXFV,&HW,RVZW!6WADMPLIV,,+O#,WR@$XK[D_9.^/MG^
MU3^S)X!_:4T_PK<Z%!X\\(V&NQ:->S"2:Q6Y@240NP #,N[:3@<CI7Y+_P#!
MDC_R9#\8/^RJQ_\ IMMJ]E_X+1_\%)OBS^R_^U7^S7_P2B_8SUJ#P!JWQC\4
MZ1:^(O%FE:7;//H&A7>J1Z>B6$4T;PI*Y%R=[(?+$"[1E]R@'ZB5Q>L?M!?"
M?0_C]H?[,-[XJA/C;Q!X9O\ Q#8:'%\T@TVTFMX);B3'^K0RW,:(6^^1)MSY
M;X_./P7_ ,%$_CS^Q7_P7SL?^"3WQ4^,&L_$+X8_$KPK;7_@O5?%X@EU?PYJ
M3VD\@B-U#%&;F"62UE3;*K,AFBPP5&#_ ![^Q5\+_C]\7_\ @Z3_ &A?AC=_
MMU?$_2M<T#P?JL$/Q LH-&GU26RBN=+V67E7>GS6<-N/-&$AMX]OEKM(R^X
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M^-/QL^$W[.GPQU7XS_'/Q_IGA;PIHB1OJ^O:Q<"*VM%DE2%"[GINDD11[L*
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M_6_M/C+X*SQ^%]5663,LVE["VF7!']WR%:V!/):R<]Z /TPHK\9_VM?VX_\
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MJTQ_:"^!GBNZTB\LK/&QXXIK2SM8SI?GH)&CCW+.D;KEB\;NW<_\'H+!]?\
MV1W7H?%OB$C_ +[T6@#]T:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCL_#2>--8TOQCH,"7$]OJUQ>W9LH;S4(9Y(T28!3*D3,5(P!@GZ-_P"#BO\
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M$:7=!]@U".SFOTN4M;F(*TL/EF1'565"3)O_ &(HH _#[_@GA^QK_P %9O\
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M;VEQJ,$SV<;JDDRR*JSNJH08E<3;/_!*&^_X.!_B'^T_-K?_  5@^%OA_P
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M[7PA??\ "%:+I^SS;G56A9+4?.0H5961F)(^56KTNB@#Y[_X)3_LCR_L-?\
M!/3X5?LT:K;>7K6A^%XI_%1+AV?6;IFN[\E\G?\ Z3/, Q)RJK7K_P 7_@Y\
M*OV@/AQJ?P@^-WP]TGQ5X6UE(TU;0-=LDN+2[6.5)4$D;@JVV2-'&>A4'M72
MT4 >&_!#_@F7_P $]_V:OB):?%SX ?L:_#KP=XGL8I8K/7O#WA>WM;J%)4,<
MBK(B@@,C,I]02*[C]I/Q_P#&#X9?!?7?%WP#^!.H?$CQA!8R#P]X3L-6L+$7
M5V4;RC-/?7$$4< ?;O8,7"DE4<\5W5% 'QG^Q;_P3D_9PU7]EWP[J_[87_!-
M_P %7'Q8GTP7GQ(O_'W@[PUK&J:[X@G7[1J-V;N"2Y25);N6?R]\JE4VJ510
M!7YZ?\$Q?^":O_!4?_@EK_P6!\>?&GX+_L(^(KC]G'QQJFI:;-I0\>>%DO;7
M2)9S/8S+;G5L%[:0*@!;<86E  9]M?NO10!^0OQ[_8 _;Z\7_P#!S5X#_P""
MCOA?]DG6+SX1>%;6WTJ^\2+XMT".25?[+N[1[J.U?41.8EDNE."@D*HQ"$X!
M/^":W[ /[?7P._X.#OCS^WK\7_V2-8T+X8?%'3->T[0-=E\6Z!<26_GZEI]S
M!+/;V^HR3*CI9.,*CLK2("H&XK^O5% 'X^?\$XOV$/\ @H+^SO\ \%[/VA_^
M"@_Q6_8M\16/PX^)?A_Q':^&KJ'QAX;GNVDFU&PO;99((]4)0RI8N@R<*\L>
M\HN]UT_^#8'_ ()X_MX?\$]?%/QZLOVR?V9+_P &6WQ#U'2=2\.ZF/%6BZC"
MWV9[_P V"06-[-(CXNHRIV;"%?+ @!OUPHH _ +]A3_@F-_P5I_8A^ ?[:?[
M 'A[]B)/$R?&'PU?:?X1^(DWCC3K32)[?[%J%N-@>7S6GGCND$*,J*DI_?M$
MBLP]U_X)\_L)?\%;?V4/^#?7XL_L=^ _A)??#OX_OK5[=^"ICXNTB47MO=2V
MAG^R7=G>2K;W'V:.ZC1Y3%LE>)E88++^Q%% '\WG[37_  1:_P""Q?QW_P""
M2_P5_9]T[]@SPQHGB+X=^-=5O=>L+'XB6-QKWB:?42SOK%[YC);Q$;8HF!NI
MYF^4E8DCVCZV_P"#C#]@G_@I+_P4FM/V;;_]GO\ 8LN[_4? ;ZEJWC6VB\?Z
M%';V$MT=.,=E'+=W=N]Q*HM9-[+&(@2NUY <C]C:* *F@:E>:QHEIJNH^'[O
M2I[FW22;3+]X6GM6(R8Y#!))&67H2CNN1PQ'-6Z** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJV** .6UCPW8V%_I]M!<W6VYN"DFZZ;.,9XYK1_P"$'TC_ )^;W_P+:CQ+
M_P A?1_^OT_^@FMB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^
M$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/
M^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2
M/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;
MW_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO
M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VJEX@\+:?IFBW.H6US=^9%
M&67==,1G\ZZ6LWQC_P BQ>_]<#0!5M/!FE3VL4SW-YEXU8XNVZD5)_P@^D?\
M_-[_ .!;5I:=_P @^#_KBO\ (5-0!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_
M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
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M?"NF000S6EH=/@FECO+A'AM8I< 0H\T^X211))\6?\/>_P#@E5:?\%U/@_\
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
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M^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH
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M>Y?_ $F:@#W2BBB@ HHHH **** "BBB@ HHHH **** ,?P/_ ,@B7_K]F_\
M0JV*Q_ __((E_P"OV;_T*MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "L>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F:
M-BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0
M!3_X3'PQ_P!!J#_OJLNT\2Z"GBV[O7U2(1/:QJDF>"03D5T']G:?_P ^,/\
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M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"
MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0
MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
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MH_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
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M#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\
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M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
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M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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MM/[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V*Q_$O\ R%]'_P"OT_\
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M Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V*S?&/_(L7O_7
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MOX;^)5QXPA\%Z;-8W/B6ZVA[^[-S+)=.55G\L"X>51'N8QA0A8E23[+7B?\
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M]PEY:^'S%<D*SVR/+';R7XT^&9T4D0RR$X&37YJ^,_\ @FU_P;G?"FPUR_\
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M7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
MT*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%
M[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]
M"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H
M7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M%%% !1110 4444 %%%% !1110 4444 8]E_R.][_ ->47\S6Q6/9?\CO>_\
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MZW%Q$&V.%R"/R''0XYKJ:Q_$O_(7T?\ Z_3_ .@FMB@ HHHH **** "BBB@
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M'[K]H;]D'7/LT?\ K-?^'URFK6[#NY@R)8D'?<2<=J[#X9_MJ?LP?%F9=/\
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M^T2YDO/#<[GR,9Y;[-*6@/98WME[U^OU !1110 4444 %%%% !1110 4444
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M)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 0V7_([WO\
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M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*L?Q+_P A?1_^OT_^@FIO^$Q\,?\
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M\E]5TCPU//9VK'^*:1=L,"]Q(TK+R,BMWX1_\$8_^")_[-VOP^*_B=HFM_M
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M (__ %KX(K[Z_P""'7_-4/\ N"?^W] 'WI_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-10 R*VMH"3!;HA/4H@&:?110 4444 %%%% !5+Q)
MX=T+QAX=O_"7BC2H+_3-4LI;34;&Y3='<02(4DC<'JK*Q!'<&KM% 'YR?MP?
M\$F_^"6G[.7[,'@/4-4_83\#O\/O /BK2)?BGXAT;X=6<WB";P_;P3(UW<75
MM;B\F1;S[#/>-&=[VT=UD%2RGG?C-\9O^#3CX5?!._\ B+K'@_\ 8]UNP32I
M&BT?P;X/\/:AK=U\A"Q16]K$;E)FX 9MFUCN9TP6'V;_ ,%!?VY/!?\ P3_^
M 2?&7Q3\.?$GC/4-6\1V/ASPEX,\)68GU#7M8O7*6UG"I. 6*L23DX4[5=BJ
M-^;T>L>(3\35^.=G_P &>]N/%/GB\BU1]6\/1O\ :,[A.4^R;5FW?-YFW>&Y
MSF@#[P_X(M1>)X_^"6GP6?Q=\)K/P/=3>$O.@\,V.DQ6*VUI)<3/:R/#$B(L
MTMNT4\A"J6EF=B 6-?4->2_L,?&CXF_M#_LK>%/C-\9O ,OA/Q3KL=W-K?A2
M?)DT2=;R>,V#DJI9X @A9BJEFC)(!)%>M4 %<=X@_:%^!?A3XOZ!^S]XB^+G
MAZT\<^*8IY?#WA"758O[2OHH87FEE2WSYAC6.-V+D;1MQG) KL:_-']KCX9?
M#KP9_P ')'['7B[PAX%TC2M3\0^"_B!)KU_IVFQ03:C(FERE9)W1097!ED^9
MLGYCSS0!^EU<AJ?Q^^"^C?&[2_V;=3^)6E1>/=9T*?6M,\*-<@WL^GPR".2Z
M$8Y$8<[=QP"0P&=IQ5_:-^/7A?\ 9M^$VH?%#Q)IUWJ4L4D-GH?A_3%#7NN:
MG<2+#::=:J2 T\\SI&N2%7<68JBLP_-#X1_!CQ[\*_\ @Y*^''BGXU>(TU;X
MA^.?V8M9U[QU=6L[O9VMV^J-%'I]D&^[:6L$4-M'PID$33./,FD) /TV^,_[
M0OP2_9XTBQUOXU?$O2_#T6J7OV/2(KZ?]_J-SM+>3;0J#+<2;0S%(U9@JEB,
M FM+X7?%CX9_&[P19_$GX0^/-*\2:#?[Q::MHUZD\+LC%'3<I.'1U9&0X964
MJP!!%?GY^RA\0]4_:F_X.-/VC=<\62&[TK]GKX9Z+X0\"6DQS'82ZH([N_N4
M0\)-))"\1D'S&)%0G Q4W[&GQ%U+X,_\'#W[4/[&?A^X,7A+QU\/-'^*-OI"
MG$%CJZK8V%]-&O17NFG264_Q-$I[4 ?H[1110 5X7^UA_P EL^!__8]R_P#I
M,U>Z5X7^UA_R6SX'_P#8]R_^DS4 >Z4444 %%%% !1110 4444 %%%% !111
M0!C^!_\ D$2_]?LW_H5;%8_@?_D$2_\ 7[-_Z%6Q0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/9?\CO>_\ 7E%_,UL5
MCV7_ ".][_UY1?S- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% &/9?\ ([WO_7E%_,UL5CV7_([WO_7E%_,UL4 %
M%%% !1110 4444 %%%% !1110 445B^.OB3\.OA=HS>(_B9X^T7P[IRYW7^N
MZK#:0C'7+RLJ_K0!M45\A_&7_@O;_P $>?@5));^-/V_/ =]/&=IMO"%W+K\
MA?ILQID<_P V>,'H>N*\TO/^#@WP+X[MGE_9,_X)R_M/?%6'&8=>T_X8OI>B
M$=B]]>R((@<]3'TR>U 'Z#T5^6'C+_@L!_P5I\82-;_#W]B3X$?"5&R(+GXK
M_&T>(9@.S267A]&GB/K&1N'O7F_B;XX?\%B_B]*;7QQ_P4VMO"4,XS)I?P3^
M ENMO(#_  IJ.O317$(]'$9/M0!^R]>6?&C]N3]B_P#9S$R_'O\ :R^''@Z6
M#.^V\2>-+&SG)'\(BDE#LW^R 3[5^0]U_P $^/&7[0,LT7QQ^//Q_P#BE*S8
MFTSXD_&_4+G3)<\_N['18(?)4Y^X)C]:]*^#'_!$'X->$EAE\&?L6Z!IX3[L
M$_PTM[MU/&&COM=EN9T/HW7O0!](^,/^#DG_ ().:5J\OA7X6?&7Q)\4==BZ
MZ)\+_A_JFK3-Z;9! D#9YZ2=J\N\;_\ !Q9\6=8$L7[.O_!);XH7CC(C;XN^
M*])\%MC_ )Z>3/)/*R]\ 9(Z8->N>#_^";_B6/1X=!U#X;F:QC.8].\7>/II
M+6(_[,.FK"J@>@]*]2\$?L,ZWX5*/HK?#WPS(G2?1? L-Y./83W>9!]<T ?"
MC_\ !27_ (+Y?M&N(?@M\)/@SX+TZ=B"V@^&M=\4ZM;'/]YA#9L!SDGC\*XS
M]H']BS_@M3\=OA1JFH_MI?\ !0;XD0>$9YK5;NV\/:=HGA6)0US$J(;:S$LT
MNURA#,0<@$_=K]7$_9GUG4D">+_VA/'%ZH !@L-16RA(]"D:GCVS7@7_  5*
M^"ME\"?V _B/\6_@#X*OM:^(6F:=:#PU)?:X2[7,M];PC+7$JQ!<2,6S@[<X
MYQ0!\C?LY?LX?#W]F/X?1^ O <NI7K._FZGK>NZ@]W?ZE/CF6>9^6/8*,*HX
M4"N_KXE_X)A_M _MW6<$OP>_;Q^'\\@!:30O'DFM:=,[$G/V6Z2"8LW)^24+
M_LMV:OMJ@#.\2^%-!\76(T_7[!9XU<,GS%64^Q'(KZW_ &)_V;OAQX\_9S\-
M^(?%EQ?ZA8K/?I9: NL2-IUJ([^X3*(NTDL5+L23EF/%?CQ_P5.^.'[<?B/2
M#\"?V'?AY<K!<H#XB\=0:_86TF,\VEJ)9U=?]N4@<?*O4M7[(?\ !&C5?'FM
M_P#!,_X6:I\4?"_]B^(Y=/O_ .V],%Q%*L-R-2NQ)M>)F0J2"RX8\, <'(H
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MELEHCY#&8W&9AB98C%5)5*DG=RDW*3?=MW;^844459S&/XE_Y"^C_P#7Z?\
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MPQKGB6X;4?&ABG&JZ_-<A0D)<; Y^4Y')'4<5]>UX7^UA_R6SX'_ /8]R_\
MI,U 'KG_  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!
M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
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MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M&;^(9!JBZ4EVEI]H?>8]V#\W0GH=N=V.<8YKI_\ A!](_P"?F]_\"VK\X/\
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M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
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MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
M@6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO
M_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5
ML44 4=*T"RT>1Y+66=BZX/FS%A^M7J** "BBB@ HHHH **** "BBB@ HHHH
M***^*?C5^W/^US\-/^"RGP*_89O?"/@>R^&7Q/T+Q+J3ZE9W-S>:O='3K"XE
M17:1(HK4;_(8HBRD\CS,9! /M:BO'_VQ/B+^TWX7\):5X"_8W\"Z!J_Q#\5W
M[VVG:EXQ>==$\/VD<9DN-2OO(_>RHG[N)((R'DFN(AE4$CK\<_"O]NC_ (*@
M?L9?\%&?AI^P[_P4V7X=>.O"GQSAOHOAS\2_ASI$^GO9:G:0B66SNK>1B"N#
M&HP,_OT?S& D1 #])J*^2OBQ^V9\5/BS_P %$?\ AVI^RKXBTK0-0\+> QXN
M^+'CW4=)_M!]'@FE2*QTNSMV=$-W-O$[22[HXX!PCNXV:O[#?[;7C+XJ_M!_
M&+]A/]H=-+7XI?!34[)KK5-%M&MK/Q-H5_ MQ8:I% [N89-C>5<1!W5)0"K8
MD"* ?4%%%% !7A?[6'_);/@?_P!CW+_Z3-7NE>%_M8?\EL^!_P#V/<O_ *3-
M0![I1110 4444 %%%% !1110 4444 %%%% &/X'_ .01+_U^S?\ H5;%8_@?
M_D$2_P#7[-_Z%6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6/9?\CO>_P#7E%_,UL5CV7_([WO_ %Y1?S- &Q1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%8?B7XG?#GP;N'BOQUI&GLO
M6.[U"-'/T4G)/L!7F7Q%_P""@/[+WPRT.Z\2Z_X]+6%DI:[O4MS%!" ,DM-.
M8XP,<YW8H ]IHK\ZOB%_P<F_L/:9XFC\!?"/6E\<:[=Q,]AIO@N.Y\03SXP-
MH32H+A0Q)'#2+532?^"@'_!8G]I1$E_9Q_X)B^,O#EC,Q5M5^*-QI_A**)3T
M?RKN2ZO&!'/%L"/04 ?I!6)XE^)7P\\&Y'BOQQI.G,O6.\U".-S]%)R?P%?!
MFJ_LL_\ !4WQGIW]O?MC?\%$OAA\*M&?YIK'PK87>K28[H+O4KBTMD('?[&X
MR/2L'0?@!_P3JT34O[*U_P",_P <_P!H?Q!'S)I^D:Q=0PNQ[>1HL>GVDL9Y
M&U_-&.N3S0![A_P4)_; _92U_P#9VUSX6ZK\8-,MY]8GL5C>\N1:1,L5[!,^
M)9]BGY8V^Z3Z5\Q>&[GP_>:#:77A2ZM9M-D@5K*:RD5XGCQP59201[UW/[4_
MAR#X7?L>^-]=\ _\$]?!_P &_!$5I:3^(/$UP+*VU.:%+R!@[QP(),[U3>TS
M,=NXY)K\*_V8_P#@N)XZ^%7[5^OZU\1#>:E\)_$NK!%T8#=-HD" 1Q75NO\
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MDULT45Z48QA%1BK)'QE:M5Q%652K)RE)W;;NVWU;>K84444S,**** "BBB@
MHHHH **** ,?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\ Z":V* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?&/\
MR+%[_P!<#6E6;XQ_Y%B]_P"N!H N:=_R#X/^N*_R%35#IW_(/@_ZXK_(5-0
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M7=S/>6(V'[# ;=D,4<WSI,X(<I\J%=S&O'OA+^R)_P %O['Q3X0\*?%S]O\
M^$EE\-='U2P_MS0/AO\ #%M*O;C2K9T)T^VF)(M4D1!"6C"LB,=A4@4 >;_\
M$R[/4+'_ (.&?V_$\7AAJLMEX+ETXRCYFL3I_P A7U4)]G''H!VIWP!74[[_
M (.P/CI>:.&.FV'[+NEVVM,GW!>/>:5) &Q_%Y0D(SV!KZA^,O[$WCK1_P!M
M[3O^"B7[*>I>'[?QQ<>"I/"'CWPOXIGGMM-\4Z4)EGMI#<V\<KVEW;RH-LWD
MS!XF,150%8:G[%?[#\_[._Q(^*7[3WQ9\56/B3XM?&G7;74/&VM:;9M!965I
M:0"VT_2K-)&9_L]M"-OF.=\SEG8+E40 ^A:*** /+_BM\>?B5\/O%S^'/"_[
M,OBCQ3:+ D@U;29X5A9F'*8<YR.]>)?%WXW?$/Q_\<O@]%XG_9S\2^%UL_&A
M>!]5FA871:$J538>H!W'/85]>UX7^UA_R6SX'_\ 8]R_^DS4 >N?\)+J_P#T
M*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_
M 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"
MA>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_
M]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% '*>%=<U&UTZ2
M.'PW<S@W,C%T9< ENGX5I_\ "2ZO_P!"A>_]]+1X'_Y!$O\ U^S?^A5L4 8_
M_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2
MZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\
MPDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DN
MK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8_
M_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2
MZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\
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M (+9?&?:/@5_P3-_9_\ V>],E_U>K_&GQK+XKU5(^TL4.G@K'+WV2\#H3WH
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M#?[XCO\ "E_V<D_9BUH^$$U,:H_A?_A9\OV87)&!+M_M'\=OW=WS8SS7,_\
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M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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M7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% '*:YKFHSZCILDG
MANYC,=R61&9<R';T%:?_  DNK_\ 0H7O_?2T>)?^0OH__7Z?_036Q0!C_P#"
M2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO
M_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\
M)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J
M_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"
M2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO
M_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\
M)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J
M_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2U1\2Z]J=SH-U!-X8NH5:(@RNRX7W
M-=-6;XQ_Y%B]_P"N!H J67B/54LXD7PE>,!$H#!EP>.M2_\ "2ZO_P!"A>_]
M]+6EIW_(/@_ZXK_(5-0!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%%
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MGG+QG^E']I16]*:_[<;_ "N'^IE>7\/'867_ ',0C_Z7RGT[17S%_P -&?\
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M!_UQ7^0J:H=._P"0?!_UQ7^0J:@ HHHH **** "BBB@ HHHH **** "BBB@
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M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M_; U"_ _LS_@I[\%KC/ _M7PPEID<<G<5P?;IU]*N.:9;/X:\'_V]'_,Y:_
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MJ2K<_$W5/%OCB53N\WQ=X[OYR6]3Y4D8/Y8KN_!_[%7_  3Z\"[3X?\ V=/
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M[3_^?&'_ +]"C^SM/_Y\8?\ OT*]4^+*?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M,'41\*=7).K:?H]T3U-Q9(^><_Q*>]>6?M+_  %^!WQ"^"7B70_!?@+PM;Z_
M)I;R:1=VFBV\<XN(\2(B2! 5+E=F01PY[$U[C_9VG_\ /C#_ -^A1_9VG_\
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M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJL_Q1XH\/WGA^[M;758GD>(A$4\DUN?V=I__/C#_P!^A6=XNL;*/PU>/'9Q
M*PA."L8!% !8^+O#4=E#&^LPAEB4$$]#BI?^$Q\,?]!J#_OJIM/T^P:P@)LH
M23"N28QZ"IO[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L
M[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]
M]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC
M_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"/3];TG57:/3K^.9D&6
M"'H*M4R*VMH"3!;HA/4H@&:?0 4444 %%%% !1110 4444 %%%% !1110 45
ME^-O''@OX:>$=1\?_$7Q;IF@Z%I%H]UJNLZS?1VUK9P(,M+++(0D: =68@"N
M)^%W[87[-'QF\6Q^ /AW\7M,O-=N-/:_L=&N5EM+J^LU(#75O%<(CW,"EE!E
MB#(-ZY;YAD ]*HKC?C/^T+\$OV>-(L=;^-7Q+TOP]%JE[]CTB*^G_?ZC<[2W
MDVT*@RW$FT,Q2-68*I8C )K2^%WQ8^&?QN\$6?Q)^$/CS2O$F@W^\6FK:->I
M/"[(Q1TW*3AT=61D.&5E*L 010!T%%%% !7A?[6'_);/@?\ ]CW+_P"DS5[I
M7A?[6'_);/@?_P!CW+_Z3-0![I1110 4444 %%%% !1110 4444 ?$/_  6T
M_P""/?B3_@L'\-O!GPOTS]JK_A6.G>&=0O+K5-O@K^V&U;S1!Y<9_P!-MO*6
M-H2Y'S[B4/R[/F_/7P-_P9.>,/AGXPTWX@?#_P#X*SW>D:UI%VESINI6/P8*
M2V\JG(92-:_ @\$$@@@D5^]%% 'Y%_M@?\&X_P"TA^W_ .!-!\%?$#_@J'::
M)HNC1*NI:7HWP698M7OX^#>3 ZT/JL0^5"21DD$>+?"C_@RM\2?!WXDZ+\4/
M"/\ P5,\O4=#U".ZM\_!3"OM/S1MC6ONNNY&'<,17[B^!_\ D$2_]?LW_H5;
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/5/#V@:VI
M36M#L[P$8(NK9)./^! US6K?L\? #7\G7?@9X.O=WWOM?AFTDSU_O1GU/YFN
MQHJ)4J<_BBG\CJH8W&X;^#5E'TDU^3/*=6_84_8LUHEK_P#9/^'>YOO/#X/L
MXF/U*1@U^=/_  71_P"":_[#]WI_PUTB+]G_ $VRM;BXU:>XMM)O[NRCFEC6
MS6-W6"9 Q42R!<YQYC8ZFOULKS?]HK]E+X,?M1:3:6'Q8\/375QID%RFC7UO
M?S0O8O.$#R*J.$<YCC.)%8?+TY.<8X3"TY^TC37,NJ2O]YWU<^SW%X=X6OC*
MCI2M>,JDW'1IJ\;M.S2>SU5UJ?SH_P##K+]@_P#Z(5_Y<^J?_)-'_#K+]@__
M *(5_P"7/JG_ ,DU^@_Q^_8$^+WP#UFXCU'P/=ZQHJN3:Z_I,,DL#Q]C(%),
M+>JOCG."PYKS?PS\(M?\::HNB>$/ FIZI>,VT6NGVDTTF?\ =7)%?/UN+,'A
MZWLJE&HI=N5?_):GZ5@/!7/,TP*QN%Q^$G2:OS*I.R]?W6C75.S74^2-(_X)
MC_L0Z#JMKKFC?!>2VO+*X2>TN8?%.J!XI48,KJ?M/!! (^E?TJ^%?AS\/? D
M0@\$>!-&T9 ,!-*TN*W 'IB-17QI^R3_ ,$G?"*:3-XL_:F\+"YGNH@MAX:A
MU2:/[*,Y\R:2"127.,! Q !.[).%^Y*^@PU58JE&JZ;C?922NON;M_5S\RS7
M!SR;&U<%3Q,*J5KRI2DZ<FNS<8\UKM7M;>S:"BBBND\D**** "BBB@ HHHH
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MT?\ #NKX'_\ 0W>._P#PKYZ />J*\%_X=U? _P#Z&[QW_P"%?/1_P[J^!_\
MT-WCO_PKYZ />J*\%_X=U? __H;O'?\ X5\]'_#NKX'_ /0W>.__  KYZ />
MJ*\%_P"'=7P/_P"AN\=_^%?/1_P[J^!__0W>._\ PKYZ />J*\%_X=U? _\
MZ&[QW_X5\]'_  [J^!__ $-WCO\ \*^>@#WJBO!?^'=7P/\ ^AN\=_\ A7ST
M?\.ZO@?_ -#=X[_\*^>@#WJBO!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO
M_P *^>@#WJBO!?\ AW5\#_\ H;O'?_A7ST?\.ZO@?_T-WCO_ ,*^>@#WJBO!
M?^'=7P/_ .AN\=_^%?/1_P .ZO@?_P!#=X[_ /"OGH ]ZHKP7_AW5\#_ /H;
MO'?_ (5\]'_#NKX'_P#0W>.__"OGH ]ZK'LO^1WO?^O*+^9KQW_AW5\#_P#H
M;O'?_A7SUY9X3_8X^&>J_M<^+?A1=>*O%XTO2O"MA>VK)XFF$QEE=@VY^K+Q
MP.U 'V;17@O_  [J^!__ $-WCO\ \*^>C_AW5\#_ /H;O'?_ (5\] 'O5%>"
M_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\] 'O5%>"_\.ZO@?\ ]#=X
M[_\ "OGH_P"'=7P/_P"AN\=_^%?/0![U17@O_#NKX'_]#=X[_P#"OGH_X=U?
M _\ Z&[QW_X5\] 'O5%>"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\
MA7ST >]45X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7ST >]45X+_P
M[J^!_P#T-WCO_P *^>C_ (=U? __ *&[QW_X5\] 'O5%>"_\.ZO@?_T-WCO_
M ,*^>C_AW5\#_P#H;O'?_A7ST >]45X+_P .ZO@?_P!#=X[_ /"OGH_X=U?
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M#=X[_P#"OGH ]ZHKP7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\ 0W>._P#PKYZ
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M _\ Z&[QW_X5\]'_  [J^!__ $-WCO\ \*^>@#WJBO!?^'=7P/\ ^AN\=_\
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MOGH_X=U? _\ Z&[QW_X5\] 'O5%>"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\
M^AN\=_\ A7ST >]45X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7ST
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M,@=)$895E8<$$$$$<$&I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M25^.NK^-? VCZO=:%\-=4OM#O-1TZ*>73[A8PZRP.ZDQ/N1#N4@_*/2O3O\
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M@P+\Z_V%X;,5Q;Q3)T,<^KSZ6O/!$4@YP:^O* "BBB@ HHHH **** "BBB@
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M+=WNGI>7":;<3"3Y]\E@MK(2_P [;]S?,37U70 4444 %%%% !1110 4444
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M*+O7O"LFF>)EUVU2Z35)].O9[!YYTD#+(\CV8E8D<LV<"O(/^#9WP_HOA/\
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M'XX^&'PU^)MM!9_$GX>:'XAAM7+VL6N:3#=K"Q&"RB56"DC@D5)X*^'?P_\
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MSX?MKJ5(@21&'E1B%!9B%S@%CZUU-% '*>#_ ($? _X>:Q_PD7@#X->%-#U
M1-&+[1_#MM;3;&QN7?&@;!P,C.#BNKHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHKP/\ ;&_;K\)?LPHGA/1=,CUOQ7<P
M"6/3VEVPV<9^[).PYYZB,8)')*@@GFQ>,P^!H.M7ERQ7]?-GK9)D>:\1YC#
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MO]W&=W.<# !]=T5^1'_#T#]N?_HN/_ELZ9_\C4?\/0/VY_\ HN/_ );.F?\
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MWL,;M%]J@$"2;HM@:*[A+1H>7G_X*U_M$?'_ /9!_8.^('[5?[.NM>&HM;\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM>_$:R^'I\(_#_PAX<O+AM'\/V33-<SN][/"LUS<W$Q56N!;Q"*%0BQ.2S,
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M$H@4K+O#9R"ASE0#Z\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PK5O\
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M]J7_ (3C]F3XY_!^Y^%5_HD%M=>"/B)X9O1=Z7>*6\RZMKFQ(>XW_*2DK*H
MV@ _/7H7[-W[-;?!74_%?Q,\<^,5\4_$/X@7]O>>-O%4>FBRAG^SP^3:V=K;
M;Y#;6=O'N$<322/NDED>2225W(!\I?\ !KS)HZ?\$,/@F^G21@(/$9NVR 1+
M_P )%J9;=^&.O;%?D5\&M/\ $L__  1I_97\1ZQ'*O@JX_X*+07";@?)6R8N
MB-CH$#I>#/3)(ZFOV>\!_P#!.O\ :6_97^''Q._9:_8L^)W@S1/AC\2->U+5
M/#][X@M[IM3^'+:DN+Z"PMH5\G4(5<O-;+)+;>2\A#F=0 >N\>?\$A_V7O%?
M_!,:R_X)<:$E_HWA#1-$MX/#6O6S*VH:;JD$WVF+5E8!0;@W>Z>3&U7,DB_*
MKD4 ?./_  =JB\N?^"2[:-HB2-J^H_%3P[;:$D)_>M=F65D$>.=V%;&*_32W
M$P@07+*9 @\PJ."V.<5\C^,?V&?VB_VOO'7PCN_V]?%W@>[\,?!KQ+;^*;71
M?!,=TW_"8>)+:%XK34;P7"(+&"$R2RBQC-P&D<;IRB;&^NZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XSXW
M? #X6_M">%QX6^)WAQ;N.(EK.[B;R[BT<C!:.0<KVR#E3@9!Q79T5G5I4J]-
MTZB3B]T]4=.#QN+R_%0Q.%J.%2+NI1;33\FCXOU7_@CEX4FU0S:)\==0M[+=
M\MO=:%'-*!Z>8LJ#/OL_"O;OV<?V(/@G^S9<?V[X;L;C5-=:,H=<U9E>6,$8
M*Q*H"Q \C(&X@D%B*]BHKS<-D648.M[6E22EWU=O2[=OD?79MXC\;YY@7@\;
MC92I/1I*,;KM)QC%R7DVPHHHKUCX@**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \J_;!_8Q^ O[=WP@NO@'^TMHNKZ
MOX/U"2-]3T+3O$M[IL5\8Y8YHQ,;26-I522*-U5B0&4'%=O\,/ASH'PD\!Z9
M\./"MYJDVFZ/:I;6+:SJ\]_<+$HPJM/<.\DF   68G ZUO44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>!
M?MQ_L.?\-F_\(O\ \70_X1O_ (1O[;_S!/MGVC[1]G_Z;1;-OD>^=W;'/OM%
M 'P+_P ..O\ JY__ ,LK_P"[:/\ AQU_U<__ .65_P#=M??5% 'R)^R__P $
MJ_\ AF[XZ:'\:?\ A>_]M?V+]I_XEO\ PB_V;SO.M98/]9]J?;CS=WW3G;CC
M.1]=T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC1EB5IDCBD <D/)',O&"G.0 ?4]%<+^R_P",?$GQ$_9H^'?Q!\8ZC]LU?7?
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MX]TCP_-INIP:C;:?+=6]A=VYGEA^=(IY5GA*!_(9#%'MS* ?5%%%% !1110
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MC@_X]K;4KJ0K'#"I$;2;!++.(_+DE99)"U/P+_P3R_;.\+_\%B/$?_!5"_\
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MG1I=(OOBZ+358+Q(98C#)=KH C> W.UBP7[>(@_\.WY* /B7_@N%\3OV9O\
M@HE_P1 ^%'[<WPZ\'R_V?J7C?PT?"\%Y*\;Z,)=1%G>VOE1OY0D1HI;=G4'A
M#M;:>?JK]O;]G'X%_";1/@GX-F^-<G@?X4:9\2I;KQ'\(+&SO]6O?BA=R6[?
M9-)AABE>XNP)AYKVVV2)E!>10L6:@_:3_P""*WA3QA_P2 T/_@EK^S9\2O\
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M?[3X:ZII&I_M->-$LI?&>IW]E<:%>B2%6F\NVMYUU*%OW3" O:,"L@\XAUV
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M"\$T"IILEL8KF\MXOW,5S]K@ V(S1L0P< ^]HY$E198G#*P!5E.01ZBOR?\
MVZ8/BY<?\'0OP C^!VI^'+3Q'_PS=JYLYO%=C<7%ECS]7W!TMY8Y,D< AN#S
M@]*_4OP'X-TCX=>!M&^'WA]IVL-"TFVTZQ:YEWR&&")8TWM_$VU1D]S7Q/\
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M%V/V1-'?Q=\-_&?["IAT31D34=5U'X>ZEH4UU96\0!%Q=6:J$4)&"6)VKU.
M,5^@_P"S-\5]=^._[.7@'XW>)_!,WAK4O&'@W3-:O_#UQ*7?39KJUCF>W+$*
M6V,Y7)"DXY /  /R_P#^"8FM7FF?\'/7[;/AKXLR,OBO4O#&GW'ALW?#R:-$
M; ((R>J>3)8\#LOL<??G_!3GXT_'7]FC]AWXD_M*_L^:]X<M=>^'WA"_\0+:
M>*-!EO[6_2UA,S0%8KF!XRRHP#AC@D':0,'@/VZO^"6%O^T5^T1X+_;Q_9E^
M+[?"KX^_#Z$VND^+UTD7^GZYIQ#AM,U6TWQFX@99)$#HZR()6(W;4"P_M/\
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MO1/%/[']YK6NZ3INISP6USJ;^(98'OO+1PJ7!C1%,J@/\N<YR:\3_P"">W[
MW@G]N_XM_MI?!']IGXY_%G7?!/A3]H_4],T+01\3-325=D06":XO#,UQ>?9X
MPB0Q3.T2_,SI*Q4I].^$?^";?[<#_P#!53PG_P %*?B3^U/X#NYK'X/CP?XH
MT"R\$W/D2"349[J6UT^/[2C6T**T!2YGFN9'E\XM$J,D:>(?\$DY/VM-*_;-
M_;OU;X Z3X UW2KG]IK5+>YTCQEK5[I4EC=J"1=QW%M:W7VA&5PK6[1Q',2D
M3#<0 #O?^#=OXA_'KP_H'[07[!7QS^)NJ^-E_9U^,EUX8\)>+-<N&EN[K2&W
MFWAD=B2VP1%P"3L6<1CY40#UK_@X&_Y0S?M!_P#8BM_Z4P5Z=^P'^Q-8_L7?
M#WQ1'KGC!/$_CKXD>.=1\9_$OQ7'8_98]2UF]<-(((2SF"VB14BBB+MM5,D[
MF:LG_@JE^RO\;?VX_P!C#QC^R'\&M>\+Z&?'FF"PU7Q'XDFN'^P0B>*0^5;P
MQ'SF=4=<M(@3@X?.  ?%?[>&CWY_X-0/"'CG0/&_B?0=6\-_LW^!KK3;SPUX
MIO=-W%[32HI(YUMI46YB:)W0QS!T^;( 8!AR?_!2K]GG3OV3_P!F#]F;_@HO
M\,?BIX]?XQ6?Q*\"V6I>*]0\;7TL>HZ9>1;)]-:Q\T6<-H5VKY44*956W%S)
M(S_3?QI_X)P?M>?&7_@C/9_\$K;WQC\.;'5K;P-H?A!_'4=W?O!)8Z;]E"W'
MV,VX832):JA7S2H+EP>D=/\ V\O^"<W[7O[9O[$'PL_91TOQC\./#FK>!/$/
MA_5]6\0SW5_=P7LNDH5C2* 01M&LK;78M(Q0 H-^=X ,_P")OQ4_X;0_X+@3
M?\$[/B#<S2?"_P"$OP7'C37_  CY[);^*]<N[NWA@6_0$"ZLK>WG#BW?,;32
M!G5]B >7_LP_!#X9_LM?\',/Q:T/X8Z=<Z?X=F_9'@UBVT&*X>2VTH-K=J)+
M>SB9B+> O$\HA3"*\TFU5!Q7L7[7O_!,_P#:F\6_MH^!O^"HG[$/Q8\&>!OC
M3H_A7_A&?'GACQ7'=WOAOQ5I)<OY$LT"1W",C8PXCRWEPGY#%\\WP4_X)W_M
MS:)_P56NO^"E'QB_:'^&4B:S\([7P9KOA/P_X-OF0PK?"[>*V>6[5H=ICBQ<
MR&8R%Y<V\:E%0 ^;/V?O@I^T5_P6+_X)GR_M.:E\*?A]J'Q!^*L&MZCX/^*F
MI?&W6;#5/!=ZE]=0V$5C!:Z-*+""R:&%#;P3XG\EWE9I)G:O4/VW_P#@F7^T
MS^T#_P $DM&_X:%^/^D:9^TW\*/!S7DOQ0\->)[FUTO6&T\S2>1?S2I;^;;S
MVXS*\T:K%.[R#Y X?/\ @[_P2)_X*@_L"_$_Q1\/?^"9_P"WEX%\._ ;Q?XA
MGU>W\'_$3P=+JE[X-EN&S,NFJA"3A?X5DDC0X7>C-ND?Z<^(G[&/QFUFQ^$_
MP(\/^-=$UCX2^&M875?BQ;>*[JX.L^.;OS9;@M,\,7DB-KUQ?S18"7,BB B*
M NK@'A'_  1A\>_#[_@IC<W/_!3OQ_H>FZ-XXT>RMO R_#+2KJX2#P9<:?'B
MZEN;=]JM>W$DK-&[(3#9K:Q*V\3D_HK7Q)'_ ,$[/VF?@]_P5B\1_M_?LH^.
M/ _A_P $?$'P_9:?\4_AUJ3WG_%47D ;&K!HHC'9W:!E12%D#A9&8[KA]OVW
M0 4444 %%%% 'F5]^U?\-]/O9K"?0?$Y>"5HW,?AV9E)4X."!R..M1?\-=_#
M/_H7_%7_ (3<_P#A7J5% 'EO_#7?PS_Z%_Q5_P"$W/\ X5B>/?VX?A[X6\.3
MWVE^&]=EOV0K8V]_I3VT4DF.-SOC@=3C)_G7MM9'CKP+X8^)'ABZ\(>+],2Z
MLKI,.C<,C=G4_P + \@B@#\X?'?COQ1\2?%%UXO\7ZF]U>W3Y=SPJ+V11_"H
M'  K+@GGM9TNK69XY8W#1R1L0RL#D$$="#WKOOV@_P!GSQ/\!O%'V&^#W6DW
M3DZ7J@3"RK_<?^[(!U'?J..G*^!/ GBCXD^*+7PAX0TQ[J]NGPB#A47N['^%
M0.230!]/_L__ +<UA>^'$\,_%33]2N=6M4VQ7VFV)G-W&!]YU7D..Y P>O!K
MT3_AKOX9_P#0O^*O_";G_P *T?V?/V?/"_P&\+_8;$)=:M=(#JFJ,F&E;^XO
M]V,'H._4\UZ#0!Y;_P -=_#/_H7_ !5_X3<_^%'_  UW\,_^A?\ %7_A-S_X
M5ZE10!%8WD6H6,-_ KA)XED02+M8!AD9'8\]*_.3_@I/_P $9O%G[1_[1]U_
MP43_ ."8?[5TOPA_:-T2*/3==O;6ZWZ5XA:&&():Z@B!S%)Y/D*V^.6-XTB#
MPGAQ^D%?)>B?LS_\%"O@/^TS\7/CG\"OC)\.O%7A'XG>*[;68/A;XXL[[3_[
M(FATNRL6G@U:V%PR--]D!>%K21!M0JRL9-P!XY_P24_X*L?M,_&C]IGQ3_P3
M=_X*;?L\6G@']H7P3X;&J1ZKI*+_ &?XHTI9$1KB+:SJK9E1_P!T[Q2 R%1$
M8VC'@7_!2N/XY?\ !>K]F+QC\??V K.TTG0OV:?'<^H_"'Q9;+,_B#QQX@TT
M(UVVG-'(JV5FJ-F E99;FXAA(\@(0WW'\ _V!/B7JO[;WB#_ (*._MG>(_"]
M]\0+[X?)X%\)^%O Z7!TKPWH0N'N95-U<*DU]=2S2.3,8H0B$HJ8.1\\?L$?
M\$KO^"JO_!*Z3Q5^SM^QS^TY\%]?^"6N>)9]7\/'XH^'=5GUOPX\P565(K*6
M**Y&U(]P:=%=TWJ(=[@@'G7[-'QK^$?_  5#_8,^!?P1_P""?'Q(\5?"#X@>
M(?'"ZK\:'^'?C/4+35?#\5DJG7[W4KD3&:]>\=[:&WFNVEDE>]AD)/D3;/JO
M_@MUX-TKX??\$0_COX,T.^U:YM-/^&]Q'#/KFN76IW;CSHSF6ZNY))IFR3\S
MNQQ@= !7@S_\$,?VU_V-OVC[S]L7_@E9^W!H6F>-/' >3XR^&OBEX:5?#WBF
M\DGDN'NX[?38A]C"R2OY<*)N0$@3_/)O^@OVL?V'?VT?VEO^"</BW]COQ#\>
M/">M^.?B=9S)XW\=:O;75KIVEF22 _9],TZ)9"MNL47E*'F5MRF9_,>5\ '@
M/P\_8I_;;_X*'_\ !$[X#?LA+\;O 'P_^&GBKX+>"T\3:[I>BWE_KUWI$>FV
M4R6D<<DD<$$C^7&LDNYP1NPH!*G]%OV>?@3\/OV8/@5X0_9V^%%A+;>&_!/A
MVTT;18KB7?+]GMXEC5I&P-\C;=S-@;F8GO7$_P#!/WX)?&+]F3]D3X?_ +,W
MQEOO#>HWGPZ\':9X;L=;\-7,YCU*WLK9+:.9X9HE,#[(TRH>0$Y.5SM'L] '
MS#_P4"_X(\_L%?\ !36ZL]>_:P^%FHZGK^E:0VG:!XCTKQ/>V5SI41D:3,*1
MR^06WN23)$^["A@0J@?*_P"PA:_ME?LYZ/\ M=_\$F_BM\6]9^)47PI^'<6K
M_!7QWJSF34YM)U;3[\6UC<.22SPRVVQ,Y.5D"XC6)5^L?C?X'_X*NVO[4O\
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M::XB>18XR9DMS Q5)GS@?LX_\$^OVT_V??\ @IAI_P"T?\)=*^&7PQ^!FO\
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M&LGXC_L"?M@^,?\ @I7\&?V[YOB;X#U6T^$W@F_\/7NFWR75I=>('OX72YO
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M<\/?LT:)K^DZ=XDUJ?5]8T_4_&.HZI#/J$^SSKK;>SR[97\M-S+C=CFO:**
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581074384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-01011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CVS HEALTH CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">05-0494040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One CVS Drive,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Woonsocket,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">RI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">765-1500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,258,020,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,284,111,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following materials are incorporated by reference into this Form 10-K:</span></div><div style="margin-bottom:0.8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information contained in the definitive proxy statement for CVS Health Corporation&#8217;s 2023 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2022 (the &#8220;Proxy Statement&#8221;), is incorporated by reference in Parts III and IV to the extent described therein.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000064803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583877232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583719728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">$ 85,330<span></span>
</td>
<td class="nump">$ 76,132<span></span>
</td>
<td class="nump">$ 69,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">322,467<span></span>
</td>
<td class="nump">292,111<span></span>
</td>
<td class="nump">268,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">196,892<span></span>
</td>
<td class="nump">175,803<span></span>
</td>
<td class="nump">163,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare', window );">Benefit costs</a></td>
<td class="nump">71,281<span></span>
</td>
<td class="nump">64,260<span></span>
</td>
<td class="nump">55,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Opioid litigation charges</a></td>
<td class="nump">5,803<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on assets held for sale</a></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement', window );">Operating expenses</a></td>
<td class="nump">38,212<span></span>
</td>
<td class="nump">37,066<span></span>
</td>
<td class="nump">35,135<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs</a></td>
<td class="nump">314,721<span></span>
</td>
<td class="nump">278,918<span></span>
</td>
<td class="nump">254,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">7,746<span></span>
</td>
<td class="nump">13,193<span></span>
</td>
<td class="nump">13,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax provision</a></td>
<td class="nump">5,628<span></span>
</td>
<td class="nump">10,420<span></span>
</td>
<td class="nump">9,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">2,569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">4,165<span></span>
</td>
<td class="nump">7,898<span></span>
</td>
<td class="nump">7,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,165<span></span>
</td>
<td class="nump">7,898<span></span>
</td>
<td class="nump">7,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss attributable to noncontrolling interests</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to CVS Health</a></td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 7,910<span></span>
</td>
<td class="nump">$ 7,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to CVS Health (in dollars per share)</a></td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 5.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Loss from discontinued operations attributable to CVS Health (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to CVS Health (in dollars per share)</a></td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 5.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average basic shares outstanding (in shares)</a></td>
<td class="nump">1,312<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to CVS Health (in dollars per share)</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="nump">$ 5.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Loss from discontinued operations attributable to CVS Health (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to CVS Health (in dollars per share)</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average diluted shares outstanding (in shares)</a></td>
<td class="nump">1,323<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared per share (in dollars per share)</a></td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible List]</a></td>
<td class="text">Products<span></span>
</td>
<td class="text">Products<span></span>
</td>
<td class="text">Products<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 226,616<span></span>
</td>
<td class="nump">$ 203,738<span></span>
</td>
<td class="nump">$ 190,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 9,683<span></span>
</td>
<td class="nump">$ 11,042<span></span>
</td>
<td class="nump">$ 7,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Expenses, Excluding Store Impairments, Goodwill Impairments, Loss On Assets Held For Sale, And Loss On Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_StoreImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Store Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_StoreImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581810800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,165<span></span>
</td>
<td class="nump">$ 7,898<span></span>
</td>
<td class="nump">$ 7,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized investment gains (losses)</a></td>
<td class="num">(2,279)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net cash flow hedges</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Pension and other postretirement benefits</a></td>
<td class="num">(168)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,430)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">1,735<span></span>
</td>
<td class="nump">7,449<span></span>
</td>
<td class="nump">7,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Comprehensive (income) loss attributable to noncontrolling interests</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to CVS Health</a></td>
<td class="nump">$ 1,719<span></span>
</td>
<td class="nump">$ 7,461<span></span>
</td>
<td class="nump">$ 7,574<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581334352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,945<span></span>
</td>
<td class="nump">$ 9,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">2,778<span></span>
</td>
<td class="nump">3,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">27,276<span></span>
</td>
<td class="nump">24,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">19,090<span></span>
</td>
<td class="nump">17,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">5,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">65,682<span></span>
</td>
<td class="nump">60,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">21,096<span></span>
</td>
<td class="nump">23,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">12,873<span></span>
</td>
<td class="nump">12,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">17,872<span></span>
</td>
<td class="nump">19,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">78,150<span></span>
</td>
<td class="nump">79,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">24,754<span></span>
</td>
<td class="nump">29,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">3,228<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">4,714<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">228,275<span></span>
</td>
<td class="nump">232,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">14,838<span></span>
</td>
<td class="nump">12,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PharmacyClaimsAndDiscountsPayableCurrent', window );">Pharmacy claims and discounts payable</a></td>
<td class="nump">19,423<span></span>
</td>
<td class="nump">17,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Health care costs payable</a></td>
<td class="nump">10,406<span></span>
</td>
<td class="nump">8,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPolicyholderFunds', window );">Policyholders&#8217; funds</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">18,745<span></span>
</td>
<td class="nump">17,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherInsuranceLiabilitiesCurrent', window );">Other insurance liabilities</a></td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">1,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,678<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">4,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">69,736<span></span>
</td>
<td class="nump">67,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">18,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt (1)</a></td>
<td class="nump">50,476<span></span>
</td>
<td class="nump">51,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">3,880<span></span>
</td>
<td class="nump">6,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountsLiability', window );">Separate accounts liabilities</a></td>
<td class="nump">3,228<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherInsuranceLiabilitiesNoncurrent', window );">Other long-term insurance liabilities</a></td>
<td class="nump">6,108<span></span>
</td>
<td class="nump">6,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">6,732<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">156,960<span></span>
</td>
<td class="nump">157,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Common stock, par value $0.01: 3,200 shares authorized; 1,758 shares issued and 1,300 shares outstanding at December&#160;31, 2022 and 1,744 shares issued and 1,322 shares outstanding at December&#160;31, 2021 and capital surplus</a></td>
<td class="nump">48,193<span></span>
</td>
<td class="nump">47,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost: 458 and 422 shares at December&#160;31, 2022 and 2021</a></td>
<td class="num">(31,858)<span></span>
</td>
<td class="num">(28,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">56,145<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(1,465)<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total CVS Health shareholders&#8217; equity</a></td>
<td class="nump">71,015<span></span>
</td>
<td class="nump">75,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">71,315<span></span>
</td>
<td class="nump">75,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 228,275<span></span>
</td>
<td class="nump">$ 232,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OtherInsuranceLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Insurance Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OtherInsuranceLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OtherInsuranceLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Insurance Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OtherInsuranceLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PharmacyClaimsAndDiscountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pharmacy Claims And Discounts Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PharmacyClaimsAndDiscountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPolicyholderFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due to policyholders for funds held that are returnable under the terms of insurance contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPolicyholderFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset at fair value held for benefit of separate account policyholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124508989&amp;loc=d3e19393-158473<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6484091&amp;loc=d3e19268-158472<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=124505678&amp;loc=SL117422397-158474<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for variable contract in which all or portion of contract holder's funds is allocated to specific separate account and supported by assets held in separate account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124508989&amp;loc=SL117422267-158473<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=124505678&amp;loc=SL117422401-158474<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6484091&amp;loc=d3e19268-158472<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124508989&amp;loc=SL117422267-158473<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581809024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">3,200,000,000<span></span>
</td>
<td class="nump">3,200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">1,758,000,000<span></span>
</td>
<td class="nump">1,744,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="nump">1,322,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">458,000,000<span></span>
</td>
<td class="nump">422,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590035168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Cash receipts from customers</a></td>
<td class="nump">$ 313,662<span></span>
</td>
<td class="nump">$ 284,219<span></span>
</td>
<td class="nump">$ 264,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies', window );">Cash paid for inventory and prescriptions dispensed by retail network pharmacies</a></td>
<td class="num">(189,766)<span></span>
</td>
<td class="num">(165,783)<span></span>
</td>
<td class="num">(158,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PaymentsForInsuranceBenefits', window );">Insurance benefits paid</a></td>
<td class="num">(69,728)<span></span>
</td>
<td class="num">(63,598)<span></span>
</td>
<td class="num">(55,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliersAndEmployees', window );">Cash paid to other suppliers and employees</a></td>
<td class="num">(32,662)<span></span>
</td>
<td class="num">(31,652)<span></span>
</td>
<td class="num">(29,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestAndDividendsReceived', window );">Interest and investment income received</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="nump">894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="num">(2,239)<span></span>
</td>
<td class="num">(2,469)<span></span>
</td>
<td class="num">(2,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="num">(4,116)<span></span>
</td>
<td class="num">(3,195)<span></span>
</td>
<td class="num">(2,929)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">16,177<span></span>
</td>
<td class="nump">18,265<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">6,729<span></span>
</td>
<td class="nump">7,246<span></span>
</td>
<td class="nump">6,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(7,746)<span></span>
</td>
<td class="num">(9,963)<span></span>
</td>
<td class="num">(9,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,727)<span></span>
</td>
<td class="num">(2,520)<span></span>
</td>
<td class="num">(2,437)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity', window );">Proceeds from sale-leaseback transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions (net of cash acquired)</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="num">(866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,854, $0 and $9)</a></td>
<td class="num">(1,249)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(5,047)<span></span>
</td>
<td class="num">(5,261)<span></span>
</td>
<td class="num">(5,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">9,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(4,211)<span></span>
</td>
<td class="num">(10,254)<span></span>
</td>
<td class="num">(15,631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Derivative settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(3,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(2,907)<span></span>
</td>
<td class="num">(2,625)<span></span>
</td>
<td class="num">(2,624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for taxes related to net share settlement of equity awards</a></td>
<td class="num">(370)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(79)<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(10,516)<span></span>
</td>
<td class="num">(11,356)<span></span>
</td>
<td class="num">(7,696)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">12,691<span></span>
</td>
<td class="nump">11,043<span></span>
</td>
<td class="nump">8,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">13,305<span></span>
</td>
<td class="nump">12,691<span></span>
</td>
<td class="nump">11,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Reconciliation of net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,165<span></span>
</td>
<td class="nump">7,898<span></span>
</td>
<td class="nump">7,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,247<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
<td class="nump">4,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on assets held for sale</a></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of subsidiaries</a></td>
<td class="num">(475)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="num">(570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other noncash items</a></td>
<td class="nump">332<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(2,971)<span></span>
</td>
<td class="num">(2,703)<span></span>
</td>
<td class="num">(1,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,435)<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="num">(973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(566)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and pharmacy claims and discounts payable</a></td>
<td class="nump">4,260<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
<td class="nump">2,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities', window );">Health care costs payable and other insurance liabilities</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="num">(231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">6,468<span></span>
</td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">$ 16,177<span></span>
</td>
<td class="nump">$ 18,265<span></span>
</td>
<td class="nump">$ 15,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in operating assets and liabilities, net of effects from acquisitions:</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PaymentsForInsuranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Insurance Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PaymentsForInsuranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_StoreImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Store Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_StoreImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliersAndEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to suppliers for goods and services provided and to employees for services provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliersAndEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestAndDividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for dividends and interest on the entity's equity and debt investments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestAndDividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from principal payment received from sales-type and direct financing leases classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 230<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123398031&amp;loc=SL120154370-112784<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576632736">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><sup>[2]</sup></th>
<th class="th"><div>Total CVS Health Shareholders&#8217; Equity</div></th>
<th class="th">
<div>Total CVS Health Shareholders&#8217; Equity </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><sup>[2]</sup></th>
<th class="th"><div>Common Shares</div></th>
<th class="th" colspan="2"><div>Treasury Shares</div></th>
<th class="th"><div>Common Stock and Capital Surplus</div></th>
<th class="th"><sup>[3]</sup></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><sup>[2]</sup></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding, beginning of year balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares outstanding, beginning of year balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(425)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning of year balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 64,170<span></span>
</td>
<td colspan="2" class="num">$ (3)<span></span>
</td>
<td class="nump">$ 63,864<span></span>
</td>
<td colspan="2" class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,235)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">$ 45,972<span></span>
</td>
<td class="nump">$ 45,108<span></span>
</td>
<td colspan="2" class="num">$ (3)<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,192<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">7,179<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">7,179<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">395<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option activity, stock awards and other (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option activity, stock awards and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">541<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="nump">541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod', window );">ESPP issuances, net of purchase of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod', window );">ESPP issuances, net of purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Common stock dividends</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,644)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(2,644)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(2,644)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease', window );">Other increases (decreases) in noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding, end of year balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">End of year balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,701<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">69,389<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,178)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">46,513<span></span>
</td>
<td class="nump">49,640<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,898<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">7,910<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">7,910<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(449)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option activity, stock awards and other (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option activity, stock awards and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">864<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="nump">864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod', window );">ESPP issuances, net of purchase of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod', window );">ESPP issuances, net of purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Common stock dividends</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,644)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(2,644)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(2,644)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease', window );">Other increases (decreases) in noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding, end of year balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(422)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">End of year balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,381<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">75,075<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,173)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">47,377<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,165<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">4,149<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">4,149<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,430)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(2,430)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(2,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option activity, stock awards and other (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option activity, stock awards and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">816<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance', window );">Purchase of treasury shares, net of ESPP issuances (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance', window );">Purchase of treasury shares, net of ESPP issuances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,685)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(3,685)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,685)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Common stock dividends</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,910)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(2,910)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(2,910)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease', window );">Other increases (decreases) in noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding, end of year balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">End of year balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 71,315<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,015<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31,858)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">$ 48,193<span></span>
</td>
<td class="nump">$ 56,145<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">$ (1,465)<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr><td colspan="17"></td></tr>
<tr><td colspan="17"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Treasury shares include 1 million shares held in trust for each of the years ended December 31, 2022, 2021 and 2020. Treasury stock includes $29 million related to shares held in trust for each of the years ended December 31, 2022, 2021 and 2020. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzY1OTcwNjk3NjgxNzQ_dd91000a-d118-4a7c-8b68-d85f1dcfda5b">Accounting Standards Update (&#8220;ASU&#8221;) 2016-13</span>, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Topic 326), which resulted in a reduction to retained earnings of $3&#160;million during the year ended December 31, 2020.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Common stock and capital surplus includes the par value of common stock of $18&#160;million as of December 31, 2022 and $17 million as of December 31, 2021 and 2020.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ESPP Issuance, Net Of Treasury Stock, Shares, Acquired, Cost Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ESPP Issuance, Net Of Treasury Stock, Value, Acquired, Cost Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Other Period Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583852208">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parentheticals) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TreasuryStockSharesHeldinTrust', window );">Treasury shares held in trust (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TreasuryStockValueSharesHeldInTrust', window );">Treasury shares held in trust</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Reduction to retained earnings as a result of new accounting standard adoption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (64,170)<span></span>
</td>
<td class="num">(71,315)<span></span>
</td>
<td class="num">(75,381)<span></span>
</td>
<td class="num">(69,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">ASU 2016-13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Reduction to retained earnings as a result of new accounting standard adoption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (45,108)<span></span>
</td>
<td class="num">$ (56,145)<span></span>
</td>
<td class="num">$ (54,906)<span></span>
</td>
<td class="num">$ (49,640)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Reduction to retained earnings as a result of new accounting standard adoption</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Reduction to retained earnings as a result of new accounting standard adoption</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings | ASU 2016-13</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Reduction to retained earnings as a result of new accounting standard adoption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzY1OTcwNjk3NjgxNzQ_dd91000a-d118-4a7c-8b68-d85f1dcfda5b">Accounting Standards Update (&#8220;ASU&#8221;) 2016-13</span>, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Topic 326), which resulted in a reduction to retained earnings of $3&#160;million during the year ended December 31, 2020.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TreasuryStockSharesHeldinTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Shares, Held in Trust</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TreasuryStockSharesHeldinTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TreasuryStockValueSharesHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Value, Shares Held In Trust</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TreasuryStockValueSharesHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365587249728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Cash and restricted cash sold</a></td>
<td class="nump">$ 2,854<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590764640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business&#160; </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation, together with its subsidiaries (collectively, &#8220;CVS Health&#8221; or the &#8220;Company&#8221;), has more than 9,000 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with over 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (&#8220;PDP&#8221;). The Company believes its integrated health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus disease 2019 (&#8220;COVID-19&#8221;) and its emerging new variants continue to impact the economies of the U.S. and other countries around the world. The impact of COVID-19 on the Company&#8217;s businesses, operating results, cash flows and financial condition in the years ended December 31, 2022, 2021 and 2020, as well as information regarding certain expected impacts of COVID-19 on the Company, is discussed throughout this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment operates as one of the nation&#8217;s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers&#8217; compensation administrative services through its Coventry Health Care Workers&#8217; Compensation business (&#8220;Workers&#8217; Compensation business&#8221;) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment&#8217;s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (&#8220;providers&#8221;), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as &#8220;Insured&#8221; and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as &#8220;ASC.&#8221; In addition, effective January 2022, the Company entered the individual public health insurance exchanges (&#8220;Public Exchanges&#8221;) in eight states through which it sells Insured plans directly to individual consumers. The Company entered Public Exchanges in four additional states effective January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment provides a full range of pharmacy benefit management (&#8220;PBM&#8221;) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (&#8220;Covered Entities&#8221;). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers. The Pharmacy Services segment&#8217;s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (&#8220;LTC&#8221;) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">long-term care facilities and other care settings. As of December&#160;31, 2022, the Retail/LTC segment operated more than 9,000 retail locations, more than 1,100 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate/Other Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management and administrative expenses to support the Company&#8217;s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company&#8217;s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (&#8220;VIEs&#8221;) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other current assets on the consolidated balance sheets represents funds held on behalf of members, including health savings account (&#8220;HSA&#8221;) funds associated with high deductible health plans. Restricted cash included in other assets on the consolidated balance sheets represents amounts held in a trust in one of the Company&#8217;s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits and money market funds.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,691&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in restricted cash included in other current assets as of December 31, 2022 compared to December 31, 2021 was primarily due to a decrease in HSA funds held on behalf of customers as a result of the sale of Payflex Holdings, Inc. (&#8220;PayFlex&#8221;). See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information on the Company&#8217;s sale of PayFlex.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 &#8216;&#8216;Fair Value&#8217;&#8217; for additional information on how the Company estimates the fair value of these investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related (yield-related) components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income (loss). Interest is not accrued on debt securities when management believes the collection of interest is unlikely.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company&#8217;s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics:&#160;loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments consist primarily of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company&#8217;s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership&#8217;s investments through its review or prior to receiving the limited partnership&#8217;s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (&#8220;FHLBB&#8221;), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment income on the Company&#8217;s investments is recorded when earned and is reflected in the Company&#8217;s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders&#8217; accounts daily, based on the underlying investment experience and, therefore, does not impact the Company&#8217;s net income (as long as the contract&#8217;s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions&#8217; experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders&#8217; accounts through a charge to benefit costs. The contract holders&#8217; accounts are reflected in policyholders&#8217; funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments supporting large case pensions&#8217; experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders&#8217; accounts. The contract holders&#8217; accounts are reflected in policyholders&#8217; funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders&#8217; equity, net of tax, as a component of accumulated other comprehensive income (loss). Unrealized capital gains and losses on investments supporting large case pensions&#8217; experience-rated products are credited directly to contract holders&#8217; accounts. The contract holders&#8217; accounts are reflected in policyholders&#8217; funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company&#8217;s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations. Accounts receivable, net was composed of the following at December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vendor and manufacturer receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premium receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,431&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes accounts receivable of $227&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div style="text-indent:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s allowance for credit losses was $333&#160;million and $339&#160;million as of December&#160;31, 2022 and 2021, respectively. When developing an estimate of the Company&#8217;s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company&#8217;s accounts receivable are short duration in nature and typically settle in less than 30 days. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance Recoverables </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company&#8217;s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December&#160;31, 2022, the Company&#8217;s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Contract Acquisition Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations. At December&#160;31, 2022 and 2021, the balance of deferred acquisition costs was $1.2 billion and $895 million, respectively, comprised primarily of commissions paid on Medicare Supplement products within the Health Care Benefits segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from 1 to 40 years for buildings, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">building improvements and leasehold improvements and 3 to 10 years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31, 2022 and 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixtures and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,896&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes property and equipment of $244&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense (which includes the amortization of property and equipment under finance or capital leases) totaled $2.4 billion, $2.3 billion and $2.1 billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively. During the year ended December&#160;31, 2021, the Company recorded an impairment on property and equipment of $261&#160;million in connection with the planned closure of certain retail stores. See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for additional information about these impairment charges as well as the Company&#8217;s finance leases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right-of-Use Assets and Lease Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company&#8217;s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for additional information about right-of-use assets and lease liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not amortized, but is subject to impairment reviews annually, or more frequently, if necessary, as further described in &#8220;Recoverability of Long-Lived Assets&#8221; below. See Note 5 &#8216;&#8216;Goodwill and Other Intangibles&#8217;&#8217; for additional information about goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (&#8220;VOBA&#8221;). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently, if necessary, as further described in &#8220;Recoverability of Long-Lived Assets&#8221; below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5 &#8216;&#8216;Goodwill and Other Intangibles&#8217;&#8217; for additional information about intangible assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recoverability of Long-Lived Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group&#8217;s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group&#8217;s carrying value that exceeds the asset group&#8217;s estimated future cash flows (discounted). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded office real estate optimization charges of $117&#160;million primarily related to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to its new flexible work arrangement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company recorded a store impairment charge of approximately $1.4&#160;billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets during the year ended December 31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for additional information about the right-of-use asset charges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of both 2022 and 2020, the Company performed its required annual impairment tests of goodwill and concluded there were no goodwill impairments as of the testing dates or during the years ended December 31, 2022 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $431&#160;million goodwill impairment charge on the remaining goodwill of the LTC reporting unit. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December&#160;31, 2021. See Note 5 &#8216;&#8216;Goodwill and Other Intangibles&#8217;&#8217; for additional information about the goodwill impairment charge recorded during the year ended December&#160;31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value. There were no impairment losses recognized on indefinite-lived intangible assets in any of the years ended December&#160;31, 2022, 2021 or 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company&#8217;s other businesses. Deposits, withdrawals and net investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Costs Payable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment&#8217;s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company&#8217;s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, &#8220;IBNR&#8221;). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company&#8217;s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company&#8217;s estimate of IBNR in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate &#8220;completion factors.&#8221; The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within six months of the date of service, but it can take up to 48 months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month&#8217;s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company&#8217;s estimate of claims remaining to be paid as of the financial statement date and is included in the Company&#8217;s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company&#8217;s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company&#8217;s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company&#8217;s business. The health status of the Company&#8217;s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company&#8217;s health care cost trend rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December&#160;31, 2022; however, actual claim payments may differ from the Company&#8217;s estimates. A worsening (or improvement) of the Company&#8217;s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December&#160;31, 2022 would cause these estimates to change in the near term, and such a change could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company&#8217;s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company&#8217;s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company&#8217;s health care costs payable, see Note 7 &#8216;&#8216;Health Care Costs Payable.&#8217;&#8217; The Company&#8217;s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Insurance Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unpaid Claims</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company&#8217;s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company&#8217;s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company&#8217;s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company&#8217;s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company&#8217;s estimate of unpaid claims IBNR in 2022. As of December&#160;31, 2022, unpaid claims balances of $243 million and $1.1 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December&#160;31, 2021, unpaid claims balances of $324 million and $1.3 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Policy Benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from 3.0% to 11.3% in both the years ended December&#160;31, 2022 and 2021. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-duration long-term care contracts represent the Company&#8217;s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was 4.9% and 5.1% in the years ended December 31, 2022 and 2021, respectively. The Company&#8217;s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions. As of December&#160;31, 2022, future policy benefits balances of $385 million and $5.0 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December&#160;31, 2021, future policy benefits balances of $416 million and $5.1 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Deficiency Reserves</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company&#8217;s method of acquiring, servicing and measuring the profitability of such contracts. The Company did not have any premium deficiency reserves as of December&#160;31, 2022. As of December&#160;31, 2021, the Company established a premium deficiency reserve of $16 million related to Medicaid products in the Health Care Benefits segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policyholders&#8217; Funds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policyholders&#8217; funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In both 2022 and 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. Reserves for contracts subject to experience rating reflect the Company&#8217;s rights as well as the rights of policyholders and plan participants. The Company also held funds for HSAs on behalf of members associated with high deductible health plans prior to the sale of PayFlex in June 2022. These amounts were held to pay for qualified health care expenses incurred by these members. At December&#160;31, 2022, the Company did not hold any HSA funds as a result of the PayFlex sale. The HSA balance was approximately $2.9 billion at December 31, 2021 and was reflected in other current assets with a corresponding liability in policyholders&#8217; funds. These assets were considered restricted cash for cash flow statement purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policyholders&#8217; funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders&#8217; funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is self-insured for certain losses related to general liability, workers&#8217; compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company&#8217;s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company&#8217;s historical claims experience. As of both December&#160;31, 2022 and 2021, self-insurance liabilities totaled $1.1 billion and were recorded in accrued expenses and other long-term liabilities on the consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from foreign currency transactions and the effects of foreign currency remeasurements were not material in the years ended December&#160;31, 2022, 2021 or 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company&#8217;s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company&#8217;s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company&#8217;s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Premium Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (&#8220;MLR&#8221;) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the &#8220;ACA&#8221;) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment&#8217;s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company&#8217;s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor&#8217;s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting for Medicare Part D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include insurance premiums earned by the Company&#8217;s PDPs, which are determined based on the PDP&#8217;s annual bid and related contractual arrangements with the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). The insurance </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company&#8217;s retail pharmacy network. The Company&#8217;s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see &#8220;Drug Discounts&#8221; and &#8220;Guarantees&#8221; below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (&#8220;retail co-payments&#8221;), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by third party pharmacies in the Company&#8217;s retail pharmacy network and associated administrative fees are recognized at the Company&#8217;s point-of-sale, which is when the claim is adjudicated by the Company&#8217;s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Drug Discounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue net of manufacturers&#8217; rebates earned by its clients based on their plan members&#8217; utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers&#8217; rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers&#8217; rebate amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantees</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Retail Pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer returns are not material to the Company&#8217;s operating results or financial condition. Sales taxes are not included in revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Loyalty and Other Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer loyalty program, ExtraCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consists of two components, ExtraSavings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offers a subscription-based membership program, CarePass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-term Care</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company&#8217;s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Walk-In Medical Clinics</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For services provided by the Company&#8217;s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company&#8217;s revenue by major source in each segment for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:28.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(45,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">205,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">169,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">106,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(45,302)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">322,467&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">169,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">152,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">184,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">292,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">171,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75,467&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">268,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company&#8217;s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> claims picked up at a retail pharmacy, as well as prescriptions filled at the Company&#8217;s retail pharmacies under the Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily represent the Company&#8217;s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables and contract liabilities from contracts with customers as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables (included in accounts receivable, net)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities (included in accrued expenses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the contract liabilities balance includes increases related to customers&#8217; earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rewards earnings and gift card issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption and breakage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for cost of products sold as follows:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company&#8217;s mail service dispensing pharmacies and indirectly through the Company&#8217;s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company&#8217;s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients&#8217; benefit plans from the Company&#8217;s mail service dispensing pharmacies, net of any volume-related or other discounts (see &#8220;Vendor Allowances and Purchase Discounts&#8221; below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company&#8217;s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses. </span></div><div><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vendor Allowances and Purchase Discounts </span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for vendor allowances and purchase discounts as follows: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company&#8217;s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company&#8217;s consolidated financial statements in any of the periods presented. </span></div><div><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Reform</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Insurer Fee</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on January 1, 2014, the ACA imposed an annual premium-based health insurer fee (&#8220;HIF&#8221;) for each calendar year, payable in September, which was not deductible for tax purposes. The Company was required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was no expense related to the HIF in the years ended December&#160;31, 2022 and 2021. In the year ended December 31, 2020, operating expenses included $1.0&#160;billion related to the Company&#8217;s share of the HIF. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company&#8217;s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Corridor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) based on their ratio of allowable costs to target costs (as defined by the ACA). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company filed a lawsuit in August 2019 to recover the $313&#160;million it was owed under the ACA&#8217;s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA&#8217;s temporary risk corridor program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company received the $313&#160;million it was owed under the ACA&#8217;s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering offsetting items such as the ACA&#8217;s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $307&#160;million and after-tax income of $223&#160;million during the year ended December&#160;31, 2020. </span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs </span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $745 million, $707 million and $613 million in 2022, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMjY0_8d034ca5-401e-4526-8bb8-d8fed86877bb">three</span> to five years) using the straight-line method. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company&#8217;s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit pension plans (&#8220;pension plans&#8221;) and other postretirement employee benefit plans (&#8220;OPEB plans&#8221;) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit income for the Company&#8217;s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time.&#160;Non-service cost components of pension and postretirement net periodic benefit income are included in other income in the consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is computed using the treasury stock method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 &#8216;&#8216;Earnings Per Share&#8217;&#8217; for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Held in Trust</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains grantor trusts, which held approximately one million shares of its common stock at both December&#160;31, 2022 and 2021. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Primary Beneficiary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Company and Cardinal Health, Inc. (&#8220;Cardinal&#8221;) established Red Oak Sourcing, LLC (&#8220;Red Oak&#8221;), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December&#160;31, 2022, 2021 and 2020. The payments reduce the Company&#8217;s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Other Variable Interest Holder</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hedge fund and private equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Real estate partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not the primary beneficiary of these VIEs because the nature of the Company&#8217;s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE&#8217;s income or losses in net income.&#160;The Company&#8217;s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge fund investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in SureScripts, LLC (&#8220;SureScripts&#8221;), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $60 million, $52 million and $56 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million in the years ended December&#160;31, 2022, 2021 and 2020, respectively. The Company&#8217;s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in Heartland Healthcare Services, LLC (&#8220;Heartland&#8221;). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $87 million, $79 million and $77 million for pharmaceutical inventory purchases during the years ended December&#160;31, 2022, 2021 and 2020, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company&#8217;s investment in and equity in the earnings of Heartland for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, the Company made charitable contributions of&#160;$25&#160;million, $50 million and $50&#160;million, respectively,&#160;to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens &#8216;n Things and Bob&#8217;s Stores, each of which subsequently filed for bankruptcy. The Company&#8217;s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees. See &#8220;Lease Guarantees&#8221; in Note 16 &#8216;&#8216;Commitments and Contingencies&#8217;&#8217; for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results from discontinued operations were immaterial for the years ended December 31, 2022 and 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the results of discontinued operations for the year ended December 31, 2020. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.573%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Not Yet Adopted </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Insurance Contracts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board issued ASU 2018-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income (loss). The rate used to discount the Company&#8217;s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#8217;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company&#8217;s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company adopted this accounting standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented, January 1, 2021, also referred to as the transition date, for changes primarily related to the liability for future policy benefits and deferred acquisition costs. The Company is still in the process of  finalizing the impact of the new standard on its historical financial statements, but expects to record an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income on the transition date of approximately $1&#160;billion as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company&#8217;s expected investment yield under the existing guidance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586319712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures and Asset Sales<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions, Divestitures and Asset Sales</a></td>
<td class="text">Acquisitions, Divestitures and Asset Sales<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed Oak Street Health Acquisition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, the Company entered into a definitive merger agreement to acquire all of the outstanding shares of Oak Street Health, Inc. (&#8220;Oak Street Health&#8221;) for cash. Under the terms of the merger agreement, Oak Street Health stockholders will receive $39.00 per share in cash. The total value of the transaction is approximately $10.6&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proposed acquisition was approved by the Board of Directors at each of the respective companies and is subject to approval by a majority of Oak Street Health stockholders, receipt of regulatory approval and satisfaction of other customary closing conditions, including the expiration of the waiting period under the federal Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the merger agreement is terminated under certain specified circumstances and receipt of regulatory approval has not been obtained by such time, the Company will be required to pay Oak Street Health a termination fee of approximately $500&#160;million. If the merger agreement is terminated under other certain specified circumstances, including due to Oak Street Health accepting a superior proposal, Oak Street Health will be required to pay the Company a termination fee of approximately $300&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending Signify Health Acquisition </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2022, the Company entered into a definitive merger agreement to acquire all of the outstanding shares of Signify Health, Inc. (&#8220;Signify Health&#8221;) for cash. Under the terms of the merger agreement, Signify Health stockholders will receive $30.50 per share in cash. The total value of the transaction is approximately $8&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pending acquisition was approved by the Board of Directors at each of the respective companies and the Signify Health stockholders and remains subject to receipt of regulatory approval and satisfaction of other customary closing conditions. On October 19, 2022, Signify Health and CVS Health each received a request for additional information (also known as a &#8220;second request&#8221;) from the U.S. Department of Justice (the &#8220;DOJ&#8221;) in connection with the review of the transactions contemplated by the merger agreement by the DOJ under the federal Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in the second quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the merger agreement is terminated under certain specified circumstances and receipt of regulatory approval has not been obtained by such time, the Company will be required to pay Signify Health a termination fee in an amount equal to $380&#160;million. If the merger agreement is terminated under other certain specified circumstances, including due to Signify Health accepting a superior proposal, Signify Health will be required to pay the Company a termination fee in an amount equal to $228&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its Omnicare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> long-term care business (&#8220;LTC business&#8221;), which is included within the Retail/LTC segment, was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria to be classified as held for sale and the carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell. Accordingly, the Company recorded a loss on assets held for sale of $2.5 billion during the third quarter of 2022. As of December&#160;31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter, an incremental loss on assets held for sale of $12 million was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. The loss on assets held for sale represents the write-down of its customer contracts/relationships intangible assets and was recorded in the Company&#8217;s consolidated statement of operations within the Retail/LTC segment. The LTC business operating income was not material for the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LTC business met the criteria to be classified as held for sale at December&#160;31, 2022, but did not meet the criteria to be classified as discontinued operations. As a result, the related assets and liabilities were included in separate held-for-sale line items of the asset and liability sections of the consolidated balance sheet. As the assets held for sale are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, they are classified in Level 3 of the fair value hierarchy. The following table summarizes the assets and liabilities held for sale at December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of bswift</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company sold its wholly-owned subsidiary bswift LLC (&#8220;bswift&#8221;) for approximately $735 million. bswift offers software and services that streamline benefits and human resource administration. The results of this business have historically been recorded within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $250&#160;million in the year ended December&#160;31, 2022, which is reflected as a reduction of operating expenses in the Company&#8217;s consolidated statement of operations within the Health Care Benefits segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of PayFlex </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company sold PayFlex for approximately $775&#160;million. PayFlex provides services to employers, their employees, and their former employees in the areas of tax-advantaged account reimbursement administration (flexible spending, health reimbursement, health savings, transit and parking), Consolidated Omnibus Budget Reconciliation Act (&#8220;COBRA&#8221;) administration and special-member billing administration. The results of this business have historically been reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $225&#160;million in the year ended December&#160;31, 2022, which is reflected as a reduction of operating expenses in the Company&#8217;s consolidated statement of operations within the Health Care Benefits segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Thailand Health Care Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company reached an agreement to sell its international health care business domiciled in Thailand (&#8220;Thailand business&#8221;), comprised of approximately 266,000 medical members, which was included in the Commercial Business reporting unit within the Health Care Benefits segment. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and, accordingly, the Company recorded a $41 million loss on assets held for sale within the Health Care Benefits segment during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the consideration received and ultimate loss on the sale were not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Workers&#8217; Compensation Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company sold its Workers&#8217; Compensation business for approximately $850&#160;million. The results of this business were reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $269 million in the year ended December&#160;31, 2020, which is reflected as a reduction in operating expenses in the Company&#8217;s consolidated statement of operations within the Health Care Benefits segment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Health Care Benefits Renewal Rights Asset Sale</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company sold the renewal rights of approximately 200,000 international medical members outside of the Americas, Thailand and India in connection with an Asset Purchase Agreement. As part of this agreement, the Company will introduce and help migrate these existing international medical members to the purchaser upon renewal. The Company expects the migration process to occur between July 2022 and November 2023. The Company ceased writing any new or renewal business for international medical members outside of the Americas during the fourth quarter of 2022. The consideration received related to this agreement was not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365591674368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,113&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,891&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term investments of $17&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div style="padding-left:13.5pt;text-indent:6.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company held investments of $331 million and $450 million, respectively, related to the 2012 conversion of an existing group annuity contract from a participating to a non-participating contract. These investments are included in the total investments of large case pensions supporting non-experience-rated products. Although these investments are not accounted for as Separate Accounts assets, they are legally segregated and are not subject to claims that arise out of the Company&#8217;s business and only support future policy benefits obligations under that group annuity contract. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available for sale at December&#160;31, 2022 and 2021 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.441%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Amortized <br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allowance<br/>for Credit<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Amortized<br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,840)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Investment risks associated with the Company&#8217;s experience-rated products generally do not impact the Company&#8217;s consolidated operating results.&#160;At December&#160;31, 2022, debt securities with a fair value of $609 million, gross unrealized capital gains of $3 million and gross unrealized capital losses of </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$59 million, and at December&#160;31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of debt securities at December&#160;31, 2022 are shown below by contractual maturity.&#160;Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,063&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,280&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage-Backed and Other Asset-Backed Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s residential mortgage-backed securities at December&#160;31, 2022 were issued by the Government National Mortgage Association, the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation and carry agency guarantees and explicit or implicit guarantees by the U.S. Government.&#160;At December&#160;31, 2022, the Company&#8217;s residential mortgage-backed securities had an average credit quality rating of AAA and a weighted average duration of 5.7 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commercial mortgage-backed securities have underlying loans that are dispersed throughout the United States. Significant market observable inputs used to value these securities include loss severity and probability of default.&#160;At December&#160;31, 2022, these securities had an average credit quality rating of AAA and a weighted average duration of 5.6 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s other asset-backed securities have a variety of underlying collateral (e.g., automobile loans, credit card receivables, home equity loans and commercial loans). Significant market observable inputs used to value these securities include the unemployment rate, loss severity and probability of default.&#160;At December&#160;31, 2022, these securities had an average credit quality rating of AA and a weighted average duration of 1.0 year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the debt securities the Company held at December&#160;31, 2022 and 2021 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except number of securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company&#8217;s business.&#160;In performing this review, the Company considered factors such as the quality of the investment security based on research performed by the Company&#8217;s internal credit analysts and&#160;external rating agencies and the prospects of realizing the carrying value of the security based on the investment&#8217;s current prospects for recovery. Unrealized capital losses at December&#160;31, 2022 were generally caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. As of December&#160;31, 2022, the Company did not intend to sell these securities, and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity dates for debt securities in an unrealized capital loss position at December&#160;31, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting experience-<br/>rated products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting remaining<br/>products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s mortgage loans are collateralized by commercial real estate.&#160;During the years ended December 31, 2022 and 2021, the Company had the following activity in its mortgage loan portfolio:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New mortgage loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans fully repaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans foreclosed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses mortgage loans on a regular basis for credit impairments, and assigns a credit quality indicator to each loan.&#160;The Company&#8217;s credit quality indicator is internally developed and categorizes each loan in its portfolio on a scale from 1 to 7.&#160;These indicators are based upon several factors, including current loan-to-value ratios, current and future property cash flow, property condition, market trends, creditworthiness of the borrower and deal structure. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Category 1 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Represents loans of superior quality.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Categories 2 to 4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Represent loans where credit risk is minimal to acceptable; however, these loans may display some susceptibility to economic changes.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Categories 5 and 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Represent loans where credit risk is not substantial, but these loans warrant management&#8217;s close attention.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Category 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Represents loans where collections are potentially at risk; if necessary, an impairment is recorded.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company&#8217;s assessments at December&#160;31, 2022 and 2021, the amortized cost basis of the Company&#8217;s mortgage loans within each credit quality indicator by year of origination was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost Basis by Year of Origination</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except credit quality indicator</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prior</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 scheduled mortgage loan principal repayments were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sources of net investment income for the years ended December 31, 2022, 2021 and 2020 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross investment income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (excluding net realized capital gains or losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized capital gains (losses) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net realized capital losses include credit-related losses on debt securities of $13 million and yield-related impairment losses on debt securities of $143 million in the year ended December 31, 2022. Net realized capital gains are net of yield-related impairment losses on debt securities of $42 million and $49 million for the years ended December 31, 2021 and 2020, respectively. There were no credit-related losses on debt securities in the years ended December 31, 2021 and 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net investment income includes $35 million, $38 million and $42 million for the years ended December 31, 2022, 2021 and 2020, respectively, related to investments supporting experience-rated products. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital gains and losses recognized during the year ended December 31, 2022 related to investments in equity securities held as of December 31, 2022 were not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583872240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis.&#160;In this note, the Company provides details on the fair value of financial assets and liabilities and how it determines those fair values.&#160;The Company presents this information for those financial instruments that are measured at fair value for which the change in fair value impacts net income attributable to CVS Health or other comprehensive income (loss) separately from other financial assets and liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Measured at Fair Value on the Consolidated Balance Sheets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value on the consolidated balance sheets.&#160;The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by GAAP.&#160;The following are the levels of the hierarchy and a brief description of the type of valuation information (&#8220;valuation inputs&#8221;) that qualifies a financial asset or liability for each level:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Unadjusted quoted prices for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Valuation inputs other than Level 1 that are based on observable market data.&#160;These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, valuation inputs that are observable that are not prices (such as interest rates and credit risks) and valuation inputs that are derived from or corroborated by observable markets.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Developed from unobservable data, reflecting the Company&#8217;s assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation.&#160;When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities in Level 1.&#160;In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model.&#160;These financial assets and liabilities are classified in Level 2.&#160;If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment&#8217;s financial performance and cash flow projections.&#160;Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of the valuation methodologies used for the Company&#8217;s financial assets and liabilities that are measured at fair value, including the general classification of such assets and liabilities pursuant to the valuation hierarchy.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. When quoted prices are available in an active market, cash equivalents are classified in Level 1 of the fair value hierarchy. Fair values of cash equivalent instruments that do not trade on a regular basis in active markets are classified as Level 2.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Where quoted prices are available in an active market, debt securities are classified in Level 1 of the fair value hierarchy.&#160;The Company&#8217;s&#160;Level 1 debt securities consist primarily of U.S. Treasury securities.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s Level 2 debt securities are obtained using models, such as matrix pricing, which use quoted market prices of debt securities with similar characteristics or discounted cash flows to estimate fair value. The </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company reviews these prices to ensure they are based on observable market inputs that include quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets and inputs that are observable that are not prices (such as interest rates and credit risks). The Company also reviews the methodologies and the assumptions used to calculate prices from these observable inputs. On a quarterly basis, the Company selects a sample of its Level 2 debt securities&#8217; prices and compares them to prices provided by a secondary source. Variances over a specified threshold are identified and reviewed to confirm the price provided by the primary source represents an appropriate estimate of fair value. In addition, the Company&#8217;s internal investment team consistently compares the prices obtained for select Level 2 debt securities to the team&#8217;s own independent estimates of fair value for those securities.&#160;The Company obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December&#160;31, 2022 or 2021. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also values certain debt securities using Level 3 inputs.&#160;For Level 3 debt securities, fair values are determined by outside brokers or, in the case of certain private placement securities, are priced internally.&#160;Outside brokers determine the value of these debt securities through a combination of their knowledge of the current pricing environment and market flows.&#160;The Company did not have any broker quoted debt securities for the years ended December&#160;31, 2022 and 2021. For some private placement securities, the Company&#8217;s internal staff determines the value of these debt securities by analyzing spreads of corporate and sector indices as well as interest spreads of comparable public bonds.&#160;Examples of these private placement Level 3 debt securities include certain U.S. and foreign securities and certain tax-exempt municipal securities.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two classifications of equity securities:&#160;those that are publicly traded and those that are privately placed.&#160;Publicly-traded equity securities are classified in Level 1 because quoted prices are available for these securities in an active market.&#160;For privately placed equity securities, there is no active market; therefore, these securities are classified in Level 3 because the Company prices these securities through an internal analysis of each investment&#8217;s financial statements and cash flow projections. Significant unobservable inputs consist of earnings and revenue multiples, discount for lack of marketability and comparability adjustments. An increase or decrease in any of these unobservable inputs would have resulted in a change in the fair value measurement. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no financial liabilities measured at fair value on a recurring basis on the consolidated balance sheets at December&#160;31, 2022 or 2021. Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,407&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes cash and cash equivalents of $6&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/>&#160;and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other asset-<br/>backed<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital losses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in net unrealized capital losses included in other comprehensive loss associated with Level 3 financial assets which were held as of December&#160;31, 2022 was $9 million during the year ended December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/>&#160;and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other asset-<br/>backed<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Redeemable<br/>preferred<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in net unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December&#160;31, 2021 was $4&#160;million during the year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross transfers into (out of) Level 3 during the years ended December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers into Level 3</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers into (out of) Level 3</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value on the Consolidated Balance Sheets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Estimated Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information regarding the valuation of cost method investments. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term debt of $3&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts Measured at Fair Value on the Consolidated Balance Sheets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets relate to the Company&#8217;s large case pensions products which represent funds maintained to meet specific objectives of contract holders.&#160;Since contract holders bear the investment risk of these assets, a corresponding Separate Accounts liability has been established equal to the assets.&#160;These assets and liabilities are carried at fair value.&#160;Net investment income and capital gains and losses on Separate Accounts assets accrue directly to such contract holders.&#160;The assets of each account are legally segregated and are not subject to claims arising from the Company&#8217;s other businesses.&#160;Deposits, withdrawals, net investment income and realized and unrealized capital gains and losses on Separate Accounts assets are not reflected in the consolidated statements of operations, shareholders&#8217; equity or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets include debt and equity securities.&#160;The valuation methodologies used for these assets are similar to the methodologies described above in this Note 4 &#8216;&#8216;Fair Value.&#8217;&#8217;&#160;Separate Accounts assets also include investments in common/collective trusts that are carried at fair value. Common/collective trusts invest in other investment funds otherwise known as the underlying funds. The Separate Accounts&#8217; interests in the common/collective trust funds are based on the fair values of the investments of the underlying funds and therefore are classified in Level 2. The assets in the underlying funds primarily consist of equity securities. Investments in common/collective trust funds are valued at their respective net asset value (&#8220;NAV&#8221;) per share/unit on the valuation date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts financial assets at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common/collective trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $85 million of other payables and $70&#160;million of other receivables at December&#160;31, 2022 and 2021, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022 and 2021, the Company had no gross transfers of Separate Accounts financial assets into or out of Level 3.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365587232832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangibles</a></td>
<td class="text">Goodwill and Other Intangibles<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the changes in the carrying amount of goodwill by segment for the&#160;years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the decrease in the carrying amount of goodwill was primarily driven by the divestitures of bswift, PayFlex and the Thailand business. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information. During the year ended December&#160;31, 2021, the decrease in the carrying amount of goodwill was primarily driven by the impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated an impairment of the goodwill associated with the LTC reporting unit, as the reporting unit&#8217;s carrying value exceeded its fair value as of the testing date. The results of the impairment tests of the remaining reporting units indicated that there was no impairment of goodwill as of the testing date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the LTC reporting unit continued to face challenges that have impacted the Company&#8217;s ability to grow the LTC reporting unit&#8217;s business at the rate estimated when its 2020 goodwill impairment test was performed. These challenges include lower net facility admissions, net long-term care facility customer losses and the prolonged adverse impact of the COVID-19 pandemic and the emerging new variants, which resulted in more significant declines in occupancy rates experienced by the Company&#8217;s long-term care facility customers than previously anticipated. During the third quarter of 2021, LTC management updated their 2021 annual forecast and submitted their long-term plan which showed deterioration in the financial results for the remainder of 2021 and beyond. The Company utilized these updated projections in performing its annual impairment test, which indicated that the fair value of the LTC reporting unit was lower than its carrying value, resulting in a $431&#160;million goodwill impairment charge in the third quarter of 2021. The fair value of the LTC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. As of December&#160;31, 2021, there was no remaining goodwill balance in the LTC reporting unit. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both December&#160;31, 2022 and 2021, cumulative goodwill impairments were $6.6 billion.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company&#8217;s intangible assets as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions, except weighted average life</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,077)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,727)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes intangible assets of $28&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the reduction in the customer contracts/relationships intangible assets is primarily related to the Company&#8217;s loss on assets held for sale of $2.5&#160;billion to write-down the LTC business to its estimated fair value less costs to sell. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets totaled $1.8 billion, $2.3 billion and $2.3 billion for the years ended December 31, 2022, 2021 and 2020, respectively. The projected annual amortization expense for the Company&#8217;s intangible assets for the next five&#160;years is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590933264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of net lease cost for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for interest portion of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows paid for principal portion of finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except remaining lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,122</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,699</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,177</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,538</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining lease term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes operating lease right-of-use assets of $56&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes current portion of operating lease liabilities of $21&#160;million and long-term operating lease liabilities of $39&#160;million which have been accounted for as liabilities held for sale and are included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of lease liabilities under finance and operating leases as of December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating<br/>Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Future operating lease payments have not been reduced by minimum sublease rentals of $290 million due in the future under noncancelable subleases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.5 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale-Leaseback Transactions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2022 or 2021. Proceeds from sale-leaseback transactions totaled $101 million in the year ended December 31, 2020. Gains from sale-leaseback transactions totaled $3 million in the year ended December 31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Office Real Estate Optimization Charges </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company undertook an initiative to evaluate its corporate office real estate space in response to its new flexible work arrangement. As part of this initiative, the Company evaluated its current real estate space and changes in employee work arrangement requirements to ensure it had the appropriate space to support the business. As a result of this assessment, the Company determined that it would vacate and abandon certain leased corporate office spaces. Accordingly, in the three months ended December 31, 2022, the Company recorded office real estate optimization charges of $117&#160;million, primarily consisting of $71&#160;million related to operating lease right-of-use assets and $44&#160;million related to property and equipment, within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Store Impairment Charges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group&#8217;s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company&#8217;s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the &#8220;Board&#8221;) authorized the closing of approximately 900 retail stores, approximately 300 stores each year, between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores&#8217; asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1&#160;billion related to operating lease right-of-use assets and $261&#160;million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $356&#160;million and $185&#160;million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of net lease cost for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for interest portion of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows paid for principal portion of finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except remaining lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,122</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,699</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,177</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,538</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining lease term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes operating lease right-of-use assets of $56&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes current portion of operating lease liabilities of $21&#160;million and long-term operating lease liabilities of $39&#160;million which have been accounted for as liabilities held for sale and are included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of lease liabilities under finance and operating leases as of December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating<br/>Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Future operating lease payments have not been reduced by minimum sublease rentals of $290 million due in the future under noncancelable subleases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.5 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale-Leaseback Transactions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2022 or 2021. Proceeds from sale-leaseback transactions totaled $101 million in the year ended December 31, 2020. Gains from sale-leaseback transactions totaled $3 million in the year ended December 31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Office Real Estate Optimization Charges </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company undertook an initiative to evaluate its corporate office real estate space in response to its new flexible work arrangement. As part of this initiative, the Company evaluated its current real estate space and changes in employee work arrangement requirements to ensure it had the appropriate space to support the business. As a result of this assessment, the Company determined that it would vacate and abandon certain leased corporate office spaces. Accordingly, in the three months ended December 31, 2022, the Company recorded office real estate optimization charges of $117&#160;million, primarily consisting of $71&#160;million related to operating lease right-of-use assets and $44&#160;million related to property and equipment, within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Store Impairment Charges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group&#8217;s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company&#8217;s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the &#8220;Board&#8221;) authorized the closing of approximately 900 retail stores, approximately 300 stores each year, between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores&#8217; asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1&#160;billion related to operating lease right-of-use assets and $261&#160;million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $356&#160;million and $185&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590910576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Health Care Costs Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract', window );"><strong>Health Care and Other Insurance Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock', window );">Health Care Costs Payable</a></td>
<td class="text">Health Care Costs Payable<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is information about incurred and cumulative paid health care claims development as of December&#160;31, 2022, net of reinsurance, and the total IBNR liabilities plus expected development on reported claims included within the net incurred claims amounts. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for information on how the Company estimates IBNR reserves and health care costs payable as well as changes to those methodologies, if any. The Company&#8217;s estimate of IBNR liabilities is primarily based on trend and completion factors. Claim frequency is not used in the calculation of the Company&#8217;s liability. In addition, it is impracticable to disclose claim frequency information for health care claims due to the Company&#8217;s inability to gather consistent claim frequency information across its multiple claims processing systems. Any claim frequency count disclosure would not be comparable across the Company&#8217;s different claim processing systems and would not be consistent from period to period based on the volume of claims processed through each system. As a result, health care claim count frequency is not included in the disclosures below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information about incurred and paid health care claims development for the year ended December&#160;31, 2021 is presented as required unaudited supplemental information.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,444&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Paid Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All outstanding liabilities for health care costs payable prior to 2021, net of reinsurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outstanding liabilities for health care costs payable, net of reinsurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company&#8217;s liabilities for IBNR plus expected development on reported claims totaled approximately $7.8 billion. Substantially all of the Company&#8217;s liabilities for IBNR plus expected development on reported claims at December&#160;31, 2022 related to the current calendar year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the December&#160;31, 2022 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-duration health care costs payable, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total health care costs payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(788)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the years ended December&#160;31, 2022, 2021 and 2020 in the table above exclude $75 million, $59 million and $41 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and $319 million, $212 million and $221 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets. The incurred health care costs for the years ended December 31, 2021 and 2020 also exclude $16 million and $11 million, respectively, for premium deficiency reserves related to the Company&#8217;s Medicaid products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimates of prior years&#8217; health care costs payable decreased by $654 million, $788 million and $429 million in 2022, 2021 and 2020, respectively, because claims were settled for amounts less than originally estimated (i.e., the amount of claims incurred was lower than originally estimated), primarily due to lower health care cost trends as well as the actual claim submission time being faster than originally assumed (i.e., the Company&#8217;s completion factors were higher than originally assumed) in estimating health care costs payable at the end of the prior year. This development does not directly correspond to an increase in the Company&#8217;s operating results as these reductions were offset by estimated current period health care costs when the Company established the estimate of the current year health care costs payable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Care and Other Insurance Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for insurance products considered to be short-duration contracts because the contract provides insurance protection for a fixed period of short duration and enables the insurer to cancel the contract or to adjust the provisions of the contract at the end of any contract period, such as adjusting the amount of premiums charged or coverage provided, and on contracts on which amounts are paid but insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365587762448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings and Credit Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings and Credit Agreements</a></td>
<td class="text">Borrowings and Credit Agreements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company&#8217;s borrowings as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5% senior notes due July 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% senior notes due November 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8% senior notes due June 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4% senior notes due December 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.375% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.625% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5% senior notes due November 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5% senior notes due December 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1% senior notes due March 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% senior notes due July 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.875% senior notes due June 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3% senior notes due August 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.625% senior notes due April 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25% senior notes due June 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3% senior notes due August 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3% senior notes due March 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.25% senior notes due August 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.75% senior notes due April 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75% senior notes due August 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% senior notes due February 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.125% senior notes due September 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% senior notes due July 2035</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.625% senior notes due June 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.75% senior notes due December 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.78% senior notes due March 2038</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% senior notes due September 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.125% senior notes due April 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7% senior notes due August 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% senior notes due May 2041</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5% senior notes due May 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.125% senior notes due November 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3% senior notes due December 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75% senior notes due March 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.125% senior notes due July 2045</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% senior notes due August 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.05% senior notes due March 2048</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25% senior notes due April 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_136d726d-4e4c-47e6-89b0-66598c753e01"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_f7e749bb-d161-4304-bb3e-6fdb8d5e52ce">Finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt principal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discounts and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">__________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term debt of $3&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s required repayments of debt principal due during each of the next five&#160;years and thereafter, as of December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for a summary of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">maturities of the Company&#8217;s finance lease liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Borrowings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper and Back-up Credit Facilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any commercial paper outstanding as of December 31, 2022 or 2021. In connection with its commercial paper program, the Company maintains a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2025, a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 11, 2026, and a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2027. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company&#8217;s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of December&#160;31, 2022 and 2021, there were no borrowings outstanding under any of the Company&#8217;s back-up credit facilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Home Loan Bank of Boston (&#8220;FHLBB&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A subsidiary of the Company is a member of the FHLBB. As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of December&#160;31, 2022 was approximately $915 million. At both December&#160;31, 2022 and 2021, there were no outstanding advances from the FHLBB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Borrowings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise of Par Call Redemptions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company exercised the par call redemption on its outstanding 3.5% senior notes due July 2022 to redeem for cash on hand the entire $1.5&#160;billion aggregate principal amount. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company exercised the par call redemption on its outstanding 2.75% senior notes due November 2022 (issued by Aetna Inc. (&#8220;Aetna&#8221;)) to redeem for cash on hand the entire $1.0&#160;billion aggregate principal amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company exercised the par call redemptions on its outstanding 2.75% senior notes due December 2022 and 4.75% senior notes due December 2022 (including notes issued by Omnicare, Inc.) to redeem for cash on hand the entire aggregate principal amount of $1.25&#160;billion and $399&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 18, 2021, the Company issued $1.0&#160;billion aggregate principal amount of 2.125% unsecured senior notes due September 15, 2031 for total proceeds of $987&#160;million, net of discounts, underwriting fees and offering expenses. The net proceeds of this offering were used for the purchase of senior notes in connection with the Company&#8217;s cash tender offer in August 2021 as described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into several interest rate swap transactions to manage interest rate risk. These agreements were designated as cash flow hedges and were used to hedge the exposure to variability in future cash flows </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting from changes in interest rates related to the anticipated issuance of $750&#160;million aggregate principal amount of 3.625% unsecured senior notes due April 1, 2027, $1.5&#160;billion aggregate principal amount of 3.75% unsecured senior notes due April 1, 2030, $1.0&#160;billion aggregate principal amount of 4.125% unsecured senior notes due April 1, 2040 and $750&#160;million aggregate principal amount of 4.25% unsecured senior notes due April 1, 2050 (collectively, the &#8220;March 2020 Notes&#8221;). In connection with the issuance of the March 2020 Notes on March 31, 2020, the Company terminated all outstanding cash flow hedges. The Company paid a net amount of $7&#160;million to the hedge counterparties upon termination, which was recorded as a loss, net of tax, of $5&#160;million in accumulated other comprehensive income and will be reclassified as interest expense over the life of the March 2020 Notes. See Note 13 &#8216;&#8216;Other Comprehensive Income (Loss)&#8217;&#8217; for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Extinguishments of Debt</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company redeemed for cash the remaining $2.3&#160;billion of its outstanding 3.7% senior notes due 2023. In connection with the early redemption of such senior notes, the Company paid a make-whole premium of $80 million in excess of the aggregate principal amount of the senior notes that were redeemed, wrote-off $8 million of unamortized deferred financing costs and incurred $1 million in fees, for a total loss on early extinguishment of debt of $89&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company purchased approximately $2.0&#160;billion of its outstanding 4.3% senior notes due 2028 through a cash tender offer. In connection with the purchase of such senior notes, the Company paid a premium of $332 million&#160;in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $26&#160;million of unamortized deferred financing costs and incurred $5&#160;million in fees, for a total loss on early extinguishment of debt of $363&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company purchased $4.5&#160;billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $113&#160;million of its 4.0% senior notes due 2023, $1.4&#160;billion of its 3.7% senior notes due 2023, $1.0&#160;billion of its 4.1% senior notes due 2025 and $2.0&#160;billion of its 4.3% senior notes due 2028. In connection with the purchase of such senior notes, the Company paid a premium of $619&#160;million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $45&#160;million of unamortized deferred financing costs and incurred $10&#160;million in fees, for a total loss on early extinguishment of debt of $674&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company purchased $6.0&#160;billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $723&#160;million of its 4.0% senior notes due 2023, $2.3&#160;billion of its 3.7% senior notes due 2023 and $3.0&#160;billion of its 4.1% senior notes due 2025. In connection with the purchase of such senior notes, the Company paid a premium of $706&#160;million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $47&#160;million of unamortized deferred financing costs and incurred $13&#160;million in fees, for a total loss on early extinguishment of debt of $766&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Covenants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s back-up revolving credit facilities and unsecured senior notes contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company&#8217;s debt maturities in the event of a downgrade in the Company&#8217;s credit ratings. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of December&#160;31, 2022, the Company was in compliance with all of its debt covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365588536736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Plans and Other Postretirement Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension Plans and Other Postretirement Benefits</a></td>
<td class="text">Pension Plans and Other Postretirement Benefits<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company sponsors several active 401(k) savings plans that cover all employees who meet plan eligibility requirements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes matching contributions consistent with the provisions of the respective plans. At the participant&#8217;s option, account balances, including the Company&#8217;s matching contribution, can be invested among various investment options under each plan. The CVS Health Future Fund 401(k) Plan offers CVS Health Corporation&#8217;s common stock fund as an investment option. The Company also maintains nonqualified, unfunded deferred compensation plans for certain key employees. The plans provide participants the opportunity to defer portions of their eligible compensation and for certain nonqualified plans, participants receive matching contributions equivalent to what they could have received under the CVS Health Future Fund 401(k) Plan absent certain restrictions and limitations under the Internal Revenue Code. The Company&#8217;s contributions under its defined contribution plans were $567 million, $552 million and $520 million in the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a tax-qualified defined benefit pension plan that was frozen in 2010 and a nonqualified supplemental pension plan that was frozen in 2007. The Company also sponsors several other defined benefit pension plans that are unfunded nonqualified supplemental retirement plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Obligation and Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables outline the change in pension benefit obligation and plan assets over the specified periods:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the pension benefit obligation during the years ended December&#160;31, 2022 and 2021 was primarily driven by the change in the discount rate during each respective period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets (liabilities) recognized on the consolidated balance sheets at December&#160;31, 2022 and 2021 for the defined benefit pension plans consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets reflected in other assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities reflected in accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities reflected in other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic Benefit Cost (Income)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (income) for the years ended December&#160;31, 2022, 2021 and 2020 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost (income):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Plan Assumptions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a series of actuarial assumptions to determine its benefit obligation and net periodic benefit income, the most significant of which include discount rates and expected return on plan assets assumptions. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discount Rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate is determined using a yield curve as of the annual measurement date. The yield curve consists of a series of individual discount rates, with each discount rate corresponding to a single point in time, based on high-quality bonds. Projected benefit payments are discounted to the measurement date using the corresponding rate from the yield curve that is consistent with the maturity profile of the expected liability cash flows.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Return on Plan Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets is determined by using the plan&#8217;s target allocation and return expectations based on many factors including forecasted long-term capital market real returns and the inflationary outlook on a plan by plan basis. See &#8220;Pension Plan Assets&#8221; below for additional details regarding the pension plan assets as of December 31, 2022 and 2021.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers other assumptions including mortality, interest crediting rate, termination and retirement rates and cost of living adjustments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its benefit obligation based on the following weighted average assumptions as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan assets primarily include debt and equity securities held in separate accounts, common/collective trusts and real estate investments. The valuation methodologies used to value these debt and equity securities and common/collective trusts are similar to the methodologies described in Note 4 &#8220;Fair Value.&#8221; Pension plan assets also include investments in other assets that are carried at fair value. The following is a description of the valuation methodologies used to value real estate investments and these additional investments, including the general classification pursuant to the fair value hierarchy.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Real estate investments are valued by independent third party appraisers. The appraisals comply with the Uniform Standards of Professional Appraisal Practice, which include, among other things, the income, cost, and sales comparison approaches to estimating property value. Therefore, these investments are classified in Level 3.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private equity and hedge fund limited partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Private equity and hedge fund limited partnerships are carried at fair value which is estimated using the NAV per unit as reported by the administrator of the underlying investment fund as a practical expedient to fair value. Therefore, these investments have been excluded from the fair value table below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2022 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $104 million of equity securities and $203 million of debt securities. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $390 million of other receivables as well as $432 million of private equity limited partnership investments and $225 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2021 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $261 million of equity securities and $149 million of debt securities. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $76 million of other receivables as well as $583 million of private equity limited partnership investments and $237 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2021 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan invests in a diversified mix of assets designed to generate returns that will enable the plan to meet its future benefit obligations. The risk of unexpected investment and actuarial outcomes is regularly evaluated. This evaluation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is performed through forecasting and assessing ranges of investment outcomes over short- and long-term horizons and by assessing the pension plan&#8217;s liability characteristics. Complementary investment styles and strategies are utilized by professional investment management firms to further improve portfolio and operational risk characteristics. Public and private equity investments are used primarily to increase overall plan returns. Real estate investments are viewed favorably for their diversification benefits and above-average dividend generation. Fixed income investments provide diversification benefits and liability hedging attributes that are desirable, especially in falling interest rate environments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, target investment allocations for the Company&#8217;s pension plan were: 12% in equity securities, 77% in fixed income and debt securities, 5% in real estate, 3% in private equity limited partnerships and 3% in hedge funds. Actual asset allocations may differ from target allocations due to tactical decisions to overweight or underweight certain assets or as a result of normal fluctuations in asset values. Asset allocations are consistent with stated investment policies and, as a general rule, periodically rebalanced back to target asset allocations. Asset allocations and investment performance are formally reviewed periodically throughout the year by the pension plan&#8217;s Investment Subcommittee. Forecasting of asset and liability growth is performed at least annually.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally contributes to its tax-qualified pension plan based on minimum funding requirements determined under applicable federal laws and regulations. Employer contributions related to the nonqualified supplemental pension plans generally represent payments to retirees for current benefits. The Company contributed $27 million, $78 million and $25 million to its pension plans during 2022, 2021 and 2020, respectively. No contributions are required for the tax-qualified pension plan in 2023. The Company expects to make an immaterial amount of contributions for all other pension plans in 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December&#160;31, 2022: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Multiemployer Pension Plans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also contributes to a number of multiemployer pension plans under the terms of collective-bargaining agreements that cover its union-represented employees. The risks of participating in these multiemployer plans are different from single-employer pension plans in the following respects: (i) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (ii) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (iii) if the Company chooses to stop participating in some of its multiemployer plans, the Company may be required to pay those plans an amount based on the underfunded status of the applicable plan, which is referred to as a withdrawal liability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the multiemployer pension plans in which the Company participates are individually significant to the Company. The Company&#8217;s contributions to multiemployer pension plans were $20 million, $19 million and $19 million in 2022, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Postretirement Benefits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides postretirement health care and life insurance benefits to certain retirees who meet eligibility requirements. The Company&#8217;s funding policy is generally to pay covered expenses as they are incurred. For retiree medical plan accounting, the Company reviews external data and its own historical trends for health care costs to determine the health care cost trend rates. As of December&#160;31, 2022 and 2021, the Company&#8217;s other postretirement benefits had an accumulated postretirement benefit obligation of $159 million and $207 million, respectively. Net periodic benefit costs related to these other postretirement benefits were $4 million, $4 million and $12 million in 2022, 2021 and 2020, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December&#160;31, 2022: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:86.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Pursuant to various collective bargaining agreements, the Company also contributes to multiemployer health and welfare plans that cover certain union-represented employees. The plans provide postretirement health care and life insurance benefits to certain employees who meet eligibility requirements. The Company&#8217;s contributions to multiemployer health and welfare plans totaled $62 million, $60 million and $54 million in 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583822256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision for continuing operations consisted of the following for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,950&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the statutory income tax rate to the Company&#8217;s effective income tax rate for continuing operations for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurer fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis difference upon disposition of subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year refunds and unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of the Company&#8217;s deferred income tax assets and liabilities as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debts and other allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and capital loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax deferral</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,947)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,870)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,767)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,749)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes deferred income tax assets of $131&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating the realizability of deferred tax assets, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and the Company&#8217;s recent operating results. The Company established valuation allowances of $532 million and $325 million as of December&#160;31, 2022 and 2021, respectively, because it does not consider it more likely than not that certain deferred tax assets will be recovered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had net operating and capital loss carryovers of $266 million, which expire between 2023 and 2042.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2022, 2021 and 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of statutes of limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation and most of its subsidiaries are subject to U.S. federal income tax as well as income tax of numerous state and local jurisdictions. CVS Health Corporation participated in the Compliance Assurance Process through 2019, which is </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a program made available by the U.S. Internal Revenue Service (&#8220;IRS&#8221;) to certain qualifying large taxpayers, under which participants work collaboratively with the IRS to identify and resolve potential tax issues through open, cooperative and transparent interaction prior to the annual filing of their federal income tax returns. The IRS has completed its examinations of the Company&#8217;s consolidated U.S. federal income tax returns for tax years through and including 2013 and 2018 through 2019. The IRS has substantially completed its examinations of the Company&#8217;s consolidated U.S. federal income tax returns for tax years 2014 through 2017.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation and its subsidiaries are also currently under income tax examinations by a number of state and local tax authorities. As of December&#160;31, 2022, no examination has resulted in any proposed adjustments that would result in a material change to the Company&#8217;s operating results, financial condition or liquidity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all material state and local income tax matters have been concluded for fiscal years through 2015. Certain state exams are likely to be concluded and certain state statutes of limitations will lapse in 2023, but the change in the balance of the Company&#8217;s uncertain tax positions is projected to be immaterial. In addition, it is reasonably possible that the Company&#8217;s unrecognized tax benefits could change within the next twelve months due to the anticipated conclusion of various examinations with the IRS for certain previous years. An estimate of the range of the possible change cannot be made at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records interest expense related to unrecognized tax benefits and penalties in the income tax provision. The Company accrued interest expense of approximately $29 million, $40 million and $34 million in 2022, 2021 and 2020, respectively. The Company had approximately $112 million and $151 million accrued for interest and penalties as of December&#160;31, 2022 and 2021, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the total amount of unrecognized tax benefits that, if recognized, would affect the Company&#8217;s effective income tax rate is approximately $336 million, after considering the federal benefit of state income taxes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583881520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans</a></td>
<td class="text">Stock Incentive Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the CVS Health 2017 Incentive Compensation Plan (&#8220;ICP&#8221;) provide for grants of annual incentive and long-term performance awards to executive officers and other officers and employees of the Company or any subsidiary of the Company, as well as equity compensation to outside directors of CVS Health Corporation. Payment of such annual incentive and long-term performance awards will be in cash, stock, other awards or other property, at the discretion of the Management Planning and Development Committee (the &#8220;MP&amp;D Committee&#8221;) of the Board. The ICP allows for a maximum of 58 million shares of CVS Health Corporation common stock to be reserved and available for grants. As of December&#160;31, 2022, there were approximately 21 million shares of CVS Health Corporation common stock available for future grants under the ICP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the acquisition of Aetna (the &#8220;Aetna Acquisition&#8221;) on November 28, 2018, approximately 22 million shares of Aetna common stock subject to awards outstanding under the Amended Aetna Inc. 2010 Stock Incentive Plan (&#8220;SIP&#8221;) were assumed by CVS Health Corporation. In addition, in accordance with the merger agreement, shares which were available for future issuance under the SIP were converted into approximately 32 million shares of CVS Health Corporation common stock reserved and available for issuance pursuant to future awards. Subsequent to the expiration of the SIP on May 21, 2020, the ICP was the only compensation plan under which the Company grants stock options, restricted stock and other stock-based awards to its employees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzE3Nzc_8d034ca5-401e-4526-8bb8-d8fed86877bb">three</span> to five years) using the straight-line method. The following table is a summary of stock-based compensation for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units and performance stock units</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and stock appreciation rights (&#8220;SARs&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes the ESPP.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s restricted stock units and performance stock units are considered nonvested share awards and require no payment from the employee. The fair value of the restricted stock units is based on the market price of CVS Health Corporation common stock on the grant date and is recognized on a straight-line basis over the vesting period. For each restricted stock unit granted, employees receive one share of common stock, net of taxes, at the end of the vesting period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s performance stock units contain performance vesting conditions in addition to a service vesting condition. Vesting of the Company&#8217;s performance stock units is dependent upon the degree to which the Company achieves its performance goals, which are generally set for a three-year performance period and are approved at the time of grant by the MP&amp;D Committee. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance stock units granted with service and performance vesting conditions is based on the market price of CVS Health Corporation common stock on the grant date and is recognized over the vesting period. Certain of the performance stock units also contain a market vesting condition based on the performance of CVS Health Corporation common stock relative to a comparator group. The fair value of these performance stock units is determined using a Monte Carlo simulation as of the grant date and is recognized over the vesting period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $619 million of total unrecognized compensation cost related to the Company&#8217;s restricted stock units and performance stock units that are expected to vest. These costs are expected to be recognized over a weighted-average period of 2.1 years. The total fair value of restricted stock units vested during 2022, 2021 and 2020 was $328 million, $406 million and $229 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the restricted stock unit and performance stock unit activity for the&#160;year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In thousands, except weighted average grant date fair value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,421)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Vested performance stock units have been included at target level performance. Based on actual performance, the number of restricted stock units and performance stock units vested during the year ended December 31, 2022 was 8.0&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and SARs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock option grants are awarded at fair value on the date of grant. The fair value of stock options is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. Stock options granted generally become exercisable over a four-year period from the grant date. Stock options granted through 2018 generally expire seven years after the grant date. Stock options granted subsequent to 2018 generally expire ten years after the grant date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All unvested Aetna SARs outstanding upon the acquisition of Aetna were converted into replacement CVS Health Corporation SARs. The replacement SARs granted are settled in CVS Health Corporation common stock, net of taxes, based on the appreciation of the stock price on the exercise date over the market price on the date of grant. The fair value of SARs is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. SARs generally become exercisable over a three-year period from the grant date. SARs generally expire ten years after the grant date. No SARs have been granted subsequent to the Aetna Acquisition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of stock option and SAR activity that occurred for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from stock options exercised (including ESPP)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for taxes for net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of stock options and SARs exercised </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options and SARs vested </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#8217;s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected life represents the number of&#160;years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, unrecognized compensation expense related to unvested stock options totaled $41 million, which the Company expects to be recognized over a weighted-average period of 1.9 years. After considering anticipated forfeitures, the Company expects approximately 7 million of the unvested stock options to vest over the requisite service period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company&#8217;s stock option and SAR activity for the&#160;year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;thousands, except weighted average exercise price and remaining contractual term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,040&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,730&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested at end of year and expected to vest in the future</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;) provides for the purchase of up to 60&#160;million shares of CVS Health Corporation common stock. Under the ESPP, eligible employees may purchase common stock at the end of each six&#160;month offering period at a purchase price equal to 90% of the lower of the fair market value on the first day or the last day of the offering period. During 2022, approximately 2 million shares of common stock were purchased under the provisions of the ESPP at an average price of $78.55 per share. As of December&#160;31, 2022, approximately 29 million shares of common stock were available for issuance under the ESPP.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock-based compensation associated with the ESPP is estimated on the date of grant (the first day of the six&#160;month offering period) using the Black-Scholes option pricing model.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the assumptions used to value the ESPP awards for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#8217;s daily stock price over the previous six&#160;month period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six&#160;months).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected life is based on the semi-annual purchase period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365584101936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share repurchase programs have been authorized by the Board:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In billions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Authorization&#160;Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining as of<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 17, 2022 (&#8220;2022 Repurchase Program&#8221;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 9, 2021 (&#8220;2021 Repurchase Program&#8221;)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the share Repurchase Programs was effective immediately and permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (&#8220;ASR&#8221;) transactions, and/or other derivative transactions. Both the 2022 and 2021 Repurchase Programs can be modified or terminated by the Board at any time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company repurchased an aggregate of 34.1&#160;million shares of common stock for approximately $3.5&#160;billion pursuant to the 2021 Repurchase Program, including share repurchases under the $1.5&#160;billion fixed dollar ASR transaction described below. During the years ended December&#160;31, 2021 and 2020, the Company did not repurchase any shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $2.0&#160;billion fixed dollar ASR with Citibank, N.A. (&#8220;Citibank&#8221;). Upon payment of the $2.0&#160;billion purchase price on January 4, 2023, the Company received a number of shares of CVS Health Corporation&#8217;s common stock equal to 80% of the $2.0&#160;billion notional amount of the ASR or approximately 17.4 million shares at a price of $92.19 per share, which were placed into treasury stock in January 2023. At the conclusion of the ASR, the Company may receive additional shares representing the remaining 20% of the $2.0&#160;billion notional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Company&#8217;s stock over an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Citibank which, at the Company&#8217;s option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that could be delivered to the Company is 43.4 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5&#160;billion fixed dollar ASR with Barclays Bank PLC. Upon payment of the $1.5&#160;billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation&#8217;s common stock equal to 80% of the $1.5&#160;billion notional amount of the ASR or approximately 11.6&#160;million shares at a price of $103.34 per share, which were placed into treasury stock in January 2022. The ASR was accounted for as an initial treasury stock transaction for $1.2&#160;billion and a forward contract for $0.3&#160;billion. The forward contract was classified as an equity instrument and was recorded within capital surplus. In February 2022, the Company received approximately 2.7&#160;million shares of CVS Health Corporation&#8217;s common stock, representing the remaining </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20% of the $1.5&#160;billion notional amount of the ASR, thereby concluding the ASR. These shares were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quarterly cash dividend declared by the Board was $0.55 and $0.50 per share in 2022 and 2021, respectively. In December 2022, the Board authorized a 10% increase in the quarterly cash dividend to $0.605 per share effective in 2023. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company&#8217;s earnings, capital requirements, financial condition and other factors considered relevant by the Board.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s insurance business operations are conducted through subsidiaries that principally consist of health maintenance organizations (&#8220;HMOs&#8221;) and insurance companies. The Company&#8217;s HMO and insurance subsidiaries report their financial statements in accordance with accounting practices prescribed by state regulatory authorities which may differ from GAAP. The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December&#160;31, 2022, 2021 and 2020 for the Company&#8217;s insurance and HMO subsidiaries were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory net income </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated statutory capital and surplus</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s insurance and HMO subsidiaries paid $3.2 billion of gross dividends to the Company for the year ended December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to general state law restrictions on payments of dividends and other distributions to stockholders applicable to all corporations, HMOs and insurance companies are subject to further regulations that, among other things, may require those companies to maintain certain levels of equity and restrict the amount of dividends and other distributions that may be paid to their equity holders. In addition, in connection with the Aetna Acquisition, the Company made certain undertakings that require prior regulatory approval of dividends by certain of its HMOs and insurance companies. At December&#160;31, 2022, these amounts were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:88.196%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated minimum statutory surplus required by regulators</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments on deposit with regulatory bodies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated maximum dividend distributions permitted in 2023 without prior regulatory approval</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, noncontrolling interests were $300 million and $306 million, respectively, primarily related to third party interests in the Company&#8217;s operating entities.&#160;The noncontrolling entities&#8217; share is included in total shareholders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590996208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders&#8217; equity included the following activity in accumulated other comprehensive income (loss) in 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net unrealized investment gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(2,972), $(489) and $497 pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($315, $(32) and $31 pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,279)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($38, $0 and $(7) pretax)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(15), $(34) and $(35) pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(229), $20 and $(30) pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($3, $6 and $7 pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of year accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of year accumulated other comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,465)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590721936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is computed using the treasury stock method. Stock options and SARs to purchase 4 million, 7&#160;million, and 15&#160;million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share for the years ended December&#160;31, 2022, 2021 and 2020, respectively, because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions,&#160;except&#160;per&#160;share&#160;amounts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to CVS Health</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,149&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units and performance stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and SARs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share from continuing operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583881520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceTextBlock', window );">Reinsurance</a></td>
<td class="text">Reinsurance<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company&#8217;s primary liability as the direct insurer of the risks reinsured.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company entered into two four-year reinsurance agreements with an unrelated reinsurer that allow it to reduce required capital and provide collateralized excess of loss reinsurance coverage on a portion of the Health Care Benefits segment&#8217;s group Commercial Insured business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reinsurer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hartford Life and Accident Insurance Company</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Life &amp; Annuity Company of New York</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOYA Retirement Insurance and Annuity Company </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fresenius Medical Care Reinsurance Company (Cayman) Ltd. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,330&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of reinsurance on benefit costs for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net benefit costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,260&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is not a material difference between premiums on a written basis versus an earned basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various agreements with unrelated reinsurers that do not qualify for reinsurance accounting under GAAP, and consequently are accounted for using deposit accounting. The Company entered into these contracts to reduce the risk of catastrophic loss which in turn reduces the Company&#8217;s capital and surplus requirements. Total deposit assets and liabilities related to reinsurance agreements that do not qualify for reinsurance accounting under GAAP were not material as of December&#160;31, 2022 or 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27830-158548<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6816-158387<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27758-158548<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365587272672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The Company believes COVID-19&#8217;s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic&#8217;s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company&#8217;s knowledge and control. As a result, the impact COVID-19 will have on the Company&#8217;s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following significant guarantee arrangements at December&#160;31, 2022:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ASC Claim Funding Accounts - The Company has arrangements with certain banks for the processing of claim payments for its ASC customers. The banks maintain accounts to fund claims of the Company&#8217;s ASC customers. The customer is responsible for funding the amount paid by the bank each day. In these arrangements, the Company guarantees that the banks will not sustain losses if the responsible ASC customer does not properly fund its account. The aggregate maximum exposure under these arrangements is generally limited to $250 million. The Company can limit its exposure to these guarantees by suspending the payment of claims for ASC customers that have not adequately funded the amount paid by the bank. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Separate Accounts Assets - Certain Separate Accounts assets associated with the large case pensions business in the Corporate/Other segment represent funds maintained as a contractual requirement to fund specific pension annuities that the Company has guaranteed. Minimum contractual obligations underlying the guaranteed benefits in these Separate Accounts were approximately $941&#160;million and $1.3 billion at December&#160;31, 2022 and 2021, respectively. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information on Separate Accounts. Contract holders assume all investment and mortality risk and are required to maintain Separate Accounts balances at or above a specified level. The level of required funds is a function of the risk underlying the Separate Account&#8217;s investment strategy. If contract holders do not maintain the required level of Separate Accounts assets to meet the annuity guarantees, the Company would establish an additional liability. Contract holders&#8217; balances in the Separate Accounts at December&#160;31, 2022 exceeded the </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of the guaranteed benefit obligation. As a result, the Company was not required to maintain any additional liability for its related guarantees at December&#160;31, 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Guarantees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1995 and 1997, the Company sold or spun off a number of subsidiaries, including Bob&#8217;s Stores and Linens &#8216;n Things, each of which subsequently filed for bankruptcy, and Marshalls. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the former subsidiary&#8217;s lease obligations for the initial lease term and any extension thereof pursuant to a renewal option provided for in the lease prior to the time of the disposition. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company&#8217;s guarantees remained in place, although each initial purchaser agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries fail to make the required payments under a store lease, the Company could be required to satisfy those obligations, and any significant adverse impact of COVID-19 on such purchasers and/or former subsidiaries increases the risk that the Company will be required to satisfy those obligations. As of December&#160;31, 2022, the Company guaranteed 67 such store leases (excluding the lease guarantees related to Linens &#8216;n Things, which have been recorded as a liability on the consolidated balance sheets), with the maximum remaining lease term extending through 2034.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guaranty Fund Assessments, Market Stabilization and Other Non-Voluntary Risk Sharing Pools</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company&#8217;s assessments generally are based on a formula relating to the Company&#8217;s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payors such as not-for-profit consumer-governed health plans established under the ACA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, the Pennsylvania Insurance Commissioner placed long-term care insurer Penn Treaty Network America Insurance Company and one of its subsidiaries (collectively, &#8220;Penn Treaty&#8221;) in rehabilitation, an intermediate action before insolvency, and subsequently petitioned a state court to convert the rehabilitation into a liquidation. Penn Treaty was placed in liquidation in March 2017. The Company has recorded a liability for its estimated share of future assessments by applicable life and health insurance guaranty associations. It is reasonably possible that in the future the Company may record a liability and expense relating to other insolvencies which could have a material adverse effect on the Company&#8217;s operating results, financial condition and cash flows, and the risk is heightened by any significant adverse impact of the COVID-19 pandemic on the solvency of other insurers, including long-term care and life insurers. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HMOs in certain states in which the Company does business are subject to assessments, including market stabilization and other risk-sharing pools, for which the Company is assessed charges based on incurred claims, demographic membership mix and other factors. The Company establishes liabilities for these assessments based on applicable laws and regulations. In certain states, the ultimate assessments the Company pays are dependent upon the Company&#8217;s experience relative to other entities subject to the assessment, and the ultimate liability is not known at the financial statement date. While the ultimate amount of the assessment is dependent upon the experience of all pool participants, the Company believes it has adequate reserves to cover such assessments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s total guaranty fund assessments liability was immaterial at both December&#160;31, 2022 and 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been involved or is currently involved in numerous legal proceedings, including litigation, arbitration, government investigations, audits, reviews and claims. These include routine, regular and special investigations, audits and reviews by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CMS, state insurance and health and welfare departments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the U.S. Department of Justice (the &#8220;DOJ&#8221;), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state Attorneys General, the U.S. Drug Enforcement Administration (the &#8220;DEA&#8221;), the U.S. Federal Trade Commission (the &#8220;FTC&#8221;) and other governmental authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, and governmental special investigations, audits and reviews can be expensive and disruptive. Some of the litigation matters may purport or be determined </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. The Company also may be named from time to time in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions initiated by private third parties that could also be separately pursued by a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company does not establish an accrued liability. None of the Company&#8217;s accruals for outstanding legal matters are material individually or in the aggregate to the Company&#8217;s financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#8217;s financial position. Substantial unanticipated verdicts, fines and rulings, however, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or loss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations of proceedings could be material to the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Usual and Customary Pricing Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and certain current and former directors and officers are named as a defendant in a number of lawsuits that allege that the Company&#8217;s retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions are brought by a number of different types of plaintiffs, including plan members, private payors, government payors, and shareholders based on different legal theories. Some of these cases are brought as putative class actions, and in some instances, classes have been certified. In October 2022, one of the litigating shareholders made a litigation demand to the Board related to these and other issues after his amended derivative complaint was dismissed for failing to demonstrate demand futility. The Company is defending itself against these claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PBM Litigation and Investigations</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is facing multiple lawsuits, including by state Attorneys General, governmental subdivisions and several putative class actions, regarding drug pricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal theories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The Company is defending itself against these claims. The Company has also received subpoenas, civil investigative demands (&#8220;CIDs&#8221;), and other requests for documents and information from, and is being investigated by, the FTC and Attorneys General of several states and the District of Columbia regarding its PBM practices, including pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs, and requests for information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States ex rel. Behnke v. CVS Caremark Corporation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al. (U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court unsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused to be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true prices paid by the Company&#8217;s PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company&#8217;s PBM. The Company is defending itself against these claims.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Substances Litigation, Audits and Subpoenas</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against various defendants by plaintiffs such as counties, cities, hospitals, Indian tribes and third-party payors, alleging claims beginning as far back as the early 2000s generally concerning the impacts of widespread prescription opioid abuse. The consolidated multidistrict litigation captioned In re National Prescription Opiate Litigation (MDL No. 2804) is pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes hundreds of relevant federal court cases that name the Company as a defendant. A significant number of similar cases that name the Company as a defendant in some capacity are pending in state courts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has been named as a defendant in similar cases brought by certain state Attorneys General. The Company is defending itself against all such claims. Additionally, the Company has received subpoenas, CIDs, and/or other requests for information regarding opioids from state Attorneys General and insurance and other regulators of several U.S. jurisdictions. The Company has been cooperating with the government with respect to these subpoenas, CIDs, and other requests for information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company was among the chain pharmacies found liable by a jury in a trial in federal court in Ohio; in August 2022, the court issued a judgment jointly against the three defendants in the amount of $651&#160;million to be paid over 15 years, and also ordered certain injunctive relief. The Company is appealing the judgment and has not accrued a liability for this matter. In March 2022, CVS Health Corporation and CVS Pharmacy, Inc. entered into a settlement agreement with the State of Florida to resolve claims related to opioid medications dating back more than a decade. Under the terms of the settlement agreement, CVS Health Corporation settled all opioid claims against it and its subsidiaries by the State of Florida for $484&#160;million, which is to be paid over a period of 18 years. During the three months ended March 31, 2022, the Company recorded a $484&#160;million liability associated with this legal settlement. In August 2022, CVS Pharmacy, Inc. entered into an agreement with the State of New Mexico to settle all opioid claims against it and its parents and subsidiaries by the State of New Mexico and participating subdivisions. In September 2022, CVS Pharmacy, Inc. entered into an agreement with the State of West Virginia to settle all opioid claims against it and its parents and subsidiaries by the State of West Virginia and participating subdivisions. Also in September 2022, CVS Pharmacy, Inc. entered into an agreement with the Cherokee Nation to settle all opioid claims against it and its parents and subsidiaries by the Cherokee Nation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company agreed to a formal settlement agreement, the financial amounts of which were agreed to in principle in October 2022, with a leadership group of a number of state Attorneys General and the Plaintiffs&#8217; Executive Committee (&#8220;PEC&#8221;). The agreement would resolve substantially all opioid claims against Company entities by states and political subdivisions, but not private plaintiffs. The maximum amount payable by the Company under the settlement would be approximately $4.3&#160;billion in opioid remediation and $625&#160;million in attorneys&#8217; fees and costs and additional remediation. The amounts would be payable over 10 years, beginning in 2023. The agreement also contains injunctive terms relating to the dispensing of opioid medications. The settlement agreement is available at nationalopioidsettlement.com.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the settlement agreement, before the Company determines whether to enter into any final settlement, it will assess the number and identities of the governmental entities that will participate in any such settlement. The settlement agreement contemplates that if certain governmental entities do not agree to the settlement, but the Company nonetheless concludes that there is sufficient participation to warrant going forward with the settlement, there would be a corresponding reduction in the amount due from the Company to account for the governmental entities that did not agree. Those non-participating governmental entities would be entitled to pursue their claims against the Company and other defendants. Private plaintiff litigation will also continue.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been informed that 45 states, the District of Columbia, and all eligible United States territories have elected to join the settlement. Three states were the subject of earlier settlements. The Company has elected to proceed with the settlement process based on that level of participation. The settlement process will progress to the period during which subdivisions may elect to join.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company also agreed to a formal settlement agreement with a leadership group representing tribes throughout the United States. The agreement would resolve substantially all opioid claims against Company entities by such tribes. The maximum amount payable by the Company under the settlement would be $113&#160;million in opioid remediation and $18&#160;million in attorneys&#8217; fees and costs. The amounts would be payable over 10 years, beginning in 2023. The agreement is contingent upon sufficient participation by tribes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that settlement of opioid claims by governmental entities and tribes is probable, and the loss related thereto could be reasonably estimated. As a result of that conclusion, and its assessment of certain other opioid-related claims including those for which the Company reached agreement in August and September 2022, the Company recorded pre-tax charges of $5.2&#160;billion and $99 million during the three months ended September 30, 2022 and the three months ended December&#160;31, 2022, respectively, of which $4.8&#160;billion was recorded in other long-term liabilities on the consolidated balance sheet. In addition, the Company expects the cash impact in 2023 and 2024 to be less than $500&#160;million in each year. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment requires judgments about future events. Moreover, the settlement is in its early phases, and there is no assurance that contingencies will be satisfied. The amount of ultimate loss may differ materially from this accrual.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the many uncertainties associated with any settlement arrangement or other resolution of all opioid-related litigation matters, including the uncertain scope of participation by governmental entities, and given that the Company continues to actively defend ongoing litigation for which it believes it has defenses and assertions that have merit, the Company is not able to reasonably estimate the range of ultimate possible loss for all opioid-related litigation matters at this time. The outcome of these legal matters could have a material effect on the Company&#8217;s business, financial condition, operating results and/or cash flows.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the DOJ served the Company with a DEA administrative subpoena. The subpoena seeks documents relating to practices with respect to prescription opioids and other controlled substances at CVS pharmacy locations concerning potential violations of the federal Controlled Substances Act and the federal False Claims Act. In January 2022, the DOJ served the Company with a CID regarding similar subjects, and the Company is providing documents and information in response to these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prescription Processing Litigation and Investigations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its prescription processing practices, including the following:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ex rel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Bassan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> v. Omnicare, Inc. and CVS Health Corp. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. District Court for the Southern District of New York). In December 2019, the U.S. Attorney&#8217;s Office for the Southern District of New York (the &#8220;SDNY&#8221;) filed a complaint-in-intervention in this previously sealed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. The complaint alleges that for certain non-skilled nursing facilities, Omnicare improperly filled prescriptions beyond one year where a valid prescription did not exist and that these dispensing events violated the federal False Claims Act. The Company is defending itself against these claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Gill et al. v. CVS Health Corp. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. District Court for the Northern District of Illinois). In July 2022, the Delaware Attorney General&#8217;s Office moved for partial intervention as to allegations under the Delaware false claims act related to not escheating alleged overpayments in this previously sealed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. The federal government and the remaining states declined to intervene on other additional theories in the relator&#8217;s complaint. The Company is defending itself against all of the claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Company also received a subpoena from the California Department of Insurance requesting documents concerning the Company&#8217;s Omnicare pharmacies&#8217; cycle fill process for assisted living facilities. The Company has been cooperating with the California Department of Insurance and providing documents and information in response to this subpoena.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company received a CID from the U.S. Attorney&#8217;s Office for the Northern District of New York requesting documents and information in connection with a federal False Claims Act investigation concerning whether the Company&#8217;s retail pharmacies improperly submitted certain insulin claims to Part D of the Medicare program rather than Part B of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to this CID.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provider Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is named as a defendant in purported class actions and individual lawsuits arising out of its practices related to the payment of claims for services rendered to its members by providers with whom the Company has a contract and with whom the Company does not have a contract (&#8220;out-of-network providers&#8221;).&#160;Among other things, these lawsuits allege that the Company paid too little to its health plan members and/or providers for out-of-network services (including COVID-19 testing) and/or otherwise allege that the Company failed to timely or appropriately pay or administer claims and benefits (including the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s post payment audit and collection practices). Other major health insurers are the subject of similar litigation or have settled similar litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has received subpoenas and/or requests for documents and other information from, and been investigated by, state Attorneys General and other state and/or federal regulators, legislators and agencies relating to, and the Company is involved in other litigation regarding, its out-of-network benefit payment and administration practices. It is reasonably possible that others could initiate additional litigation or additional regulatory action against the Company with respect to its out-of-network benefit payment and/or administration practices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CMS Actions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS regularly audits the Company&#8217;s performance to determine its compliance with CMS&#8217;s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare beneficiaries. CMS uses various payment mechanisms to allocate and adjust premium payments to the Company&#8217;s and other companies&#8217; Medicare plans by considering the applicable health status of Medicare members as supported by information prepared, maintained and provided by providers. The Company collects claim and encounter data from providers and generally relies on providers to appropriately code their submissions to the Company and document their medical records, including the diagnosis data submitted to the Company with claims. CMS pays increased premiums to Medicare Advantage plans and Medicare PDP plans for members who have certain medical conditions identified with specific diagnosis codes. Federal regulators review and audit the providers&#8217; medical records to determine whether those records support the related diagnosis codes that determine the members&#8217; health status and the resulting risk-adjusted premium payments to the Company. In that regard, CMS has instituted risk adjustment data validation (&#8220;RADV&#8221;) audits of various Medicare Advantage plans, including certain of the Company&#8217;s plans, to validate coding practices and supporting medical record documentation maintained by providers and the resulting risk-adjusted premium payments to the plans. CMS may require the Company to refund premium payments if the Company&#8217;s risk-adjusted premiums are not properly supported by medical record data. The Office of the Inspector General of the HHS (the &#8220;OIG&#8221;) also is auditing the Company&#8217;s risk adjustment-related data and that of other companies. The Company expects CMS and the OIG to continue these types of audits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, in the &#8220;Notice of Final Payment Error Calculation for Part C Medicare Advantage Risk Adjustment Validation Data (RADV) Contract-Level Audits,&#8221; CMS revised its audit methodology for RADV contract-level audits to determine refunds payable by Medicare Advantage plans for contract year 2011 and forward. Under the revised methodology, among other things, CMS announced extrapolation of the error rate identified in the audit sample along with the application of a process to account for errors in the government&#8217;s traditional fee-for-service Medicare program (&#8220;FFS Adjuster&#8221;). For contract years prior to 2011, CMS did not extrapolate sample error rates to the entire contract, nor did CMS propose to apply a FFS adjuster. By applying the FFS Adjuster, Medicare Advantage organizations would have been liable for repayments only to the extent that their extrapolated payment errors exceeded the error rate in Original Medicare, which could have impacted the extrapolated repayments to which Medicare Advantage organizations are subject. This revised contract-level audit methodology increased the Company&#8217;s exposure to premium refunds to CMS based on incomplete medical records maintained by providers. In the RADV audit methodology CMS used from 2011-2013, CMS selected only a few of the Company&#8217;s Medicare Advantage contracts for various contract years for contract-level RADV audits. In October 2018, CMS in the proposed rule (&#8220;Proposed Rule&#8221;) announced a new methodology for RADV audits targeting certain health conditions and members with many diagnostic conditions along with extrapolation for the error rates identified without use of a FFS Adjuster. While the rule was under proposal, CMS initiated contract-level RADV audits for the years 2014 and 2015 with this new RADV methodology without a final rule. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2023, CMS released the final rule (&#8220;RADV Audit Rule&#8221;), announcing it may use extrapolation for payment years 2018 forward, for both RADV audits and OIG audits and eliminated the application of a FFS Adjuster in Part C contract-level RADV audits of Medicare Advantage organizations. In the RADV Audit Rule, CMS indicated that it will use more than one audit methodology going forward and indicated CMS will audit contracts it believes are at the highest risk for overpayments based on its statistical modeling, citing a 2016 Governmental Accountability Office report that recommended selection of contract-level RADV audits with a focus on contracts likely to have high rates of improper payment, the highest coding intensity scores, and contracts with high levels of unsupported diagnoses from prior RADV audits.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently unable to predict which of its Medicare Advantage contracts will be selected for future audit, the amounts of any retroactive refunds for years prior to 2018 or prospective adjustments to Medicare Advantage premium payments made to the Company, the effect of any such refunds or adjustments on the actuarial soundness of the Company&#8217;s Medicare Advantage bids, or whether any RADV audit findings would require the Company to change its method of estimating future premium revenue in future bid submissions to CMS or compromise premium assumptions made in the Company&#8217;s bids </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for prior contract years, the current contract year or future contract years. Any premium or fee refunds or adjustments resulting from regulatory audits, whether as a result of RADV, Public Exchange related or other audits by CMS, the OIG or otherwise, including audits of the Company&#8217;s MLR rebates, methodology and/or reports, could be material and could adversely affect the Company&#8217;s operating results, cash flows and/or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RADV Audit Rule does not apply to the CMS Part C Improper Payment Measures audits nor the HHS-RADV programs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare and Medicaid CIDs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received CIDs from the Civil Division of the DOJ in connection with a current investigation of the Company&#8217;s patient chart review processes related to risk adjustment data submissions under Parts C and D of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to these CIDs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company received a CID from the SDNY requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company&#8217;s LTC business unit. The Company and its current and former officers and directors are defending themselves against these claims. Since filing, several of the cases have been consolidated, and the first-filed federal case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">City of Miami Fire Fighters&#8217; and Police Officers&#8217; Retirement Trust, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al. (formerly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anarkat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), was dismissed with prejudice in February 2021. Plaintiffs appealed that decision to the First Circuit after their motion for reconsideration was denied, and in August 2022 the First Circuit affirmed the dismissal. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re CVS Health Corp. Securities Act Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (formerly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waterford</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re CVS Health Corp. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (formerly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">City of Warren</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Freundlich</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) have been stayed pending the outcome of the First Circuit appeal. Plaintiffs in both cases have since filed amended complaints, which the Company has moved to dismiss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August and September 2020, two class actions under the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;) were filed in the U.S. District Court for the District of Connecticut against CVS Health, Aetna, and several current and former executives, directors and/or members of Aetna&#8217;s Compensation and Talent Management Committee: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Radcliffe v. Aetna Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flaim v. Aetna Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al. The plaintiffs in these cases assert a variety of causes of action premised on allegations that the defendants breached fiduciary duties and engaged in prohibited transactions relating to participants in the Aetna 401(k) Plan&#8217;s investment in company stock between December 3, 2017 and February 20, 2019, claiming losses related to the performance of the Company&#8217;s LTC business unit. The district court consolidated the actions, and in October 2021, dismissed the consolidated action without prejudice. Plaintiffs filed an amended consolidated complaint, which the Company moved to dismiss. In October 2022, the court granted the Company&#8217;s motion to dismiss with prejudice. Plaintiffs have appealed this decision to the Second Circuit.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also received a related document request pursuant to ERISA &#167; 104(b), to which the Company has responded. The Company and its current and former officers and directors are defending themselves against these claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received a demand for inspection of books and records pursuant to Delaware Corporation Law Section 220 (the &#8220;Demand&#8221;). The Demand purports to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Legal and Regulatory Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a party to other legal proceedings and is subject to government investigations, inquiries and audits and has received and is cooperating with the government in response to CIDs, subpoenas, or similar process from various governmental agencies requesting information. These other legal proceedings and government actions include claims of or relating to bad faith, medical or professional malpractice, breach of fiduciary duty, claims processing, dispensing of medications, non-compliance with state and federal regulatory regimes, marketing misconduct, denial of or failure to timely or appropriately pay or administer claims and benefits, provider network structure (including the use of performance-based networks and termination of provider contracts), rescission of insurance coverage, improper disclosure or use of personal information, anticompetitive practices, general contractual matters, product liability, intellectual property litigation, and employment litigation. Some of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these other legal proceedings are or are purported to be class actions or derivative claims. The Company is defending itself against the claims brought in these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards to the Company and others of certain government contracts, particularly Medicaid contracts and other contracts with government customers in the Company&#8217;s Health Care Benefits segment, frequently are subject to protests by unsuccessful bidders. These protests may result in awards to the Company being reversed, delayed, or modified. The loss or delay in implementation of any government contract could adversely affect the Company&#8217;s operating results. The Company will continue to defend contract awards it receives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be a heightened level of review and/or audit by regulatory authorities and legislators of, and increased litigation regarding, the Company&#8217;s and the rest of the health care and related benefits industry&#8217;s business and reporting practices, including premium rate increases, utilization management, development and application of medical policies, complaint, grievance and appeal processing, information privacy, provider network structure (including provider network adequacy, the use of performance-based networks and termination of provider contracts), provider directory accuracy, calculation of minimum medical loss ratios and/or payment of related rebates, delegated arrangements, rescission of insurance coverage, limited benefit health products, student health products, pharmacy benefit management practices (including manufacturers&#8217; rebates, pricing, the use of narrow networks and the placement of drugs in formulary tiers), sales practices, customer service practices, vendor oversight, and claim payment practices (including payments to out-of-network providers).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a leading national health solutions company, the Company regularly is the subject of government actions of the types described above. These government actions may prevent or delay the Company from implementing planned premium rate increases and may result, and have resulted, in restrictions on the Company&#8217;s businesses, changes to or clarifications of the Company&#8217;s business practices, retroactive adjustments to premiums, refunds or other payments to members, beneficiaries, states or the federal government, withholding of premium payments to the Company by government agencies,&#160;assessments of damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company can give no assurance that its businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i)&#160;future enactment of new health care or other laws or regulations; (ii)&#160;the interpretation or application of existing laws or regulations as they may relate to one or more of the Company&#8217;s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iii)&#160;pending or future federal or state government investigations of one or more of the Company&#8217;s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iv)&#160;pending or future government audits, investigations or enforcement actions against the Company; (v)&#160;adverse developments in any pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit against the Company, whether sealed or unsealed, or in any future </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit that may be filed against the Company; or (vi)&#160;adverse developments in pending or future legal proceedings against the Company or affecting one or more of the industries in which the Company competes and/or the health care industry generally.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590778256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company&#8217;s segments maintain separate financial information, and the Company&#8217;s chief operating decision maker (the &#8220;CODM&#8221;) evaluates the segments&#8217; operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company&#8217;s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company&#8217;s business nor reflect the Company&#8217;s underlying business performance. See the reconciliation of consolidated operating income (GAAP measure) to consolidated adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company&#8217;s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.</span></div><div><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, revenues from the federal government accounted for 18%, 17% and 16%, respectively, of the Company&#8217;s consolidated total revenues, primarily related to contracts with CMS for coverage of Medicare-eligible individuals within the Health Care Benefits segment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of financial measures of the Company&#8217;s segments to the consolidated totals:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.003%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy&#160;<br/>Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eliminations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,302)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total revenues of the Pharmacy Services segment include approximately $12.6 billion, $11.6 billion and $10.9 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of retail co-payments for 2022, 2021 and 2020, respectively. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information about retail co-payments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services segment clients enrolled in Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> elect to pick up maintenance prescriptions at one of the Company&#8217;s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (GAAP measure)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office real estate optimization charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on divestiture of subsidiaries </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid litigation charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on assets held for sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition purchase price adjustment outside of measurement period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipt of fully reserved ACA risk corridor receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company&#8217;s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company&#8217;s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company&#8217;s insurance products, the services performed for the Company&#8217;s customers or the sale of the Company&#8217;s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company&#8217;s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company&#8217;s and investors&#8217; ability to compare the Company&#8217;s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company&#8217;s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company&#8217;s new flexible work arrangement. The office real estate optimization charges are reflected in the Company&#8217;s GAAP consolidated statement of operations in operating expenses within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift, which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022. In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers&#8217; Compensation business, which the Company sold in July 2020. The gains on divestitures are reflected as a reduction of operating expenses in the Company&#8217;s GAAP consolidated statements of operations within the Health Care Benefits segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities. The opioid litigation charges are reflected within the Corporate/Other segment.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the loss on assets held for sale relates to the LTC reporting unit within the Retail/LTC segment. The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the third quarter of 2022. As of December 31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter of 2022, an incremental loss on assets held for sale was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. During 2022, the loss on assets held for sale also relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its Thailand business, which was included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021 and 2020, acquisition-related integration costs relate to the acquisition of Aetna. The acquisition-related integration costs are reflected in the Company&#8217;s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. The store impairment charge is reflected within the Retail/LTC segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the goodwill impairment charge relates to an impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the Company received $61&#160;million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company&#8217;s GAAP consolidated statement of operations as a reduction of operating expenses within the Health Care Benefits segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">In 2020, the Company received $313&#160;million owed to it under the ACA&#8217;s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA&#8217;s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307&#160;million in the Company&#8217;s GAAP consolidated statement of operations within the Health Care Benefits segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365582689584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment operates as one of the nation&#8217;s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers&#8217; compensation administrative services through its Coventry Health Care Workers&#8217; Compensation business (&#8220;Workers&#8217; Compensation business&#8221;) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment&#8217;s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (&#8220;providers&#8221;), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as &#8220;Insured&#8221; and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as &#8220;ASC.&#8221; In addition, effective January 2022, the Company entered the individual public health insurance exchanges (&#8220;Public Exchanges&#8221;) in eight states through which it sells Insured plans directly to individual consumers. The Company entered Public Exchanges in four additional states effective January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment provides a full range of pharmacy benefit management (&#8220;PBM&#8221;) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (&#8220;Covered Entities&#8221;). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers. The Pharmacy Services segment&#8217;s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (&#8220;LTC&#8221;) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">long-term care facilities and other care settings. As of December&#160;31, 2022, the Retail/LTC segment operated more than 9,000 retail locations, more than 1,100 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate/Other Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management and administrative expenses to support the Company&#8217;s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company&#8217;s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (&#8220;VIEs&#8221;) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other current assets on the consolidated balance sheets represents funds held on behalf of members, including health savings account (&#8220;HSA&#8221;) funds associated with high deductible health plans. Restricted cash included in other assets on the consolidated balance sheets represents amounts held in a trust in one of the Company&#8217;s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits and money market funds.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 &#8216;&#8216;Fair Value&#8217;&#8217; for additional information on how the Company estimates the fair value of these investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related (yield-related) components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income (loss). Interest is not accrued on debt securities when management believes the collection of interest is unlikely.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company&#8217;s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics:&#160;loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments consist primarily of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company&#8217;s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership&#8217;s investments through its review or prior to receiving the limited partnership&#8217;s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (&#8220;FHLBB&#8221;), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment income on the Company&#8217;s investments is recorded when earned and is reflected in the Company&#8217;s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders&#8217; accounts daily, based on the underlying investment experience and, therefore, does not impact the Company&#8217;s net income (as long as the contract&#8217;s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions&#8217; experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders&#8217; accounts through a charge to benefit costs. The contract holders&#8217; accounts are reflected in policyholders&#8217; funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments supporting large case pensions&#8217; experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders&#8217; accounts. The contract holders&#8217; accounts are reflected in policyholders&#8217; funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders&#8217; equity, net of tax, as a component of accumulated other comprehensive income (loss). Unrealized capital gains and losses on investments supporting large case pensions&#8217; experience-rated products are credited directly to contract holders&#8217; accounts. The contract holders&#8217; accounts are reflected in policyholders&#8217; funds on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company&#8217;s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text">Accounts ReceivableAccounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations.When developing an estimate of the Company&#8217;s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company&#8217;s accounts receivable are short duration in nature and typically settle in less than 30 days.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">Inventories Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceAccountingPolicy', window );">Reinsurance Recoverables</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance Recoverables </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company&#8217;s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December&#160;31, 2022, the Company&#8217;s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy', window );">Health Care Contract Acquisition Costs</a></td>
<td class="text">Health Care Contract Acquisition CostsInsurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from 1 to 40 years for buildings, </span></div>building improvements and leasehold improvements and 3 to 10 years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Right-of-Use Assets and Lease Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right-of-Use Assets and Lease Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company&#8217;s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.</span></div>See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for additional information about right-of-use assets and lease liabilities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is </span></div>not amortized, but is subject to impairment reviews annually, or more frequently, if necessary, as further described in &#8220;Recoverability of Long-Lived Assets&#8221; below.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (&#8220;VOBA&#8221;). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently, if necessary, as further described in &#8220;Recoverability of Long-Lived Assets&#8221; below.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Recoverability of Long-Lived Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recoverability of Long-Lived Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group&#8217;s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group&#8217;s carrying value that exceeds the asset group&#8217;s estimated future cash flows (discounted). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded office real estate optimization charges of $117&#160;million primarily related to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to its new flexible work arrangement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company recorded a store impairment charge of approximately $1.4&#160;billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets during the year ended December 31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for additional information about the right-of-use asset charges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of both 2022 and 2020, the Company performed its required annual impairment tests of goodwill and concluded there were no goodwill impairments as of the testing dates or during the years ended December 31, 2022 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $431&#160;million goodwill impairment charge on the remaining goodwill of the LTC reporting unit. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December&#160;31, 2021. See Note 5 &#8216;&#8216;Goodwill and Other Intangibles&#8217;&#8217; for additional information about the goodwill impairment charge recorded during the year ended December&#160;31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the </span></div>income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountsPolicy', window );">Separate Accounts</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company&#8217;s other businesses. Deposits, withdrawals and net investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock', window );">Health Care Costs Payable</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Costs Payable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment&#8217;s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company&#8217;s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, &#8220;IBNR&#8221;). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company&#8217;s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company&#8217;s estimate of IBNR in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate &#8220;completion factors.&#8221; The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within six months of the date of service, but it can take up to 48 months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month&#8217;s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company&#8217;s estimate of claims remaining to be paid as of the financial statement date and is included in the Company&#8217;s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company&#8217;s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company&#8217;s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company&#8217;s business. The health status of the Company&#8217;s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company&#8217;s health care cost trend rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December&#160;31, 2022; however, actual claim payments may differ from the Company&#8217;s estimates. A worsening (or improvement) of the Company&#8217;s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December&#160;31, 2022 would cause these estimates to change in the near term, and such a change could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company&#8217;s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company&#8217;s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company&#8217;s health care costs payable, see Note 7 &#8216;&#8216;Health Care Costs Payable.&#8217;&#8217; The Company&#8217;s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy', window );">Other Insurance Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Insurance Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unpaid Claims</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company&#8217;s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company&#8217;s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company&#8217;s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company&#8217;s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company&#8217;s estimate of unpaid claims IBNR in 2022. As of December&#160;31, 2022, unpaid claims balances of $243 million and $1.1 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December&#160;31, 2021, unpaid claims balances of $324 million and $1.3 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Policy Benefits</span></div>Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from 3.0% to 11.3% in both the years ended December&#160;31, 2022 and 2021. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-duration long-term care contracts represent the Company&#8217;s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was 4.9% and 5.1% in the years ended December 31, 2022 and 2021, respectively. The Company&#8217;s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock', window );">Premium Deficiency Reserves</a></td>
<td class="text">Premium Deficiency ReservesThe Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company&#8217;s method of acquiring, servicing and measuring the profitability of such contracts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocationsToPolicyholdersPolicies', window );">Policyholders' Funds</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policyholders&#8217; Funds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policyholders&#8217; funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In both 2022 and 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. Reserves for contracts subject to experience rating reflect the Company&#8217;s rights as well as the rights of policyholders and plan participants. The Company also held funds for HSAs on behalf of members associated with high deductible health plans prior to the sale of PayFlex in June 2022. These amounts were held to pay for qualified health care expenses incurred by these members. At December&#160;31, 2022, the Company did not hold any HSA funds as a result of the PayFlex sale. The HSA balance was approximately $2.9 billion at December 31, 2021 and was reflected in other current assets with a corresponding liability in policyholders&#8217; funds. These assets were considered restricted cash for cash flow statement purposes.</span></div>Policyholders&#8217; funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders&#8217; funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReservePolicyTextBlock', window );">Self-Insurance Liabilities</a></td>
<td class="text">Self-Insurance LiabilitiesThe Company is self-insured for certain losses related to general liability, workers&#8217; compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company&#8217;s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company&#8217;s historical claims experience.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Transactions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company&#8217;s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company&#8217;s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company&#8217;s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Premium Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (&#8220;MLR&#8221;) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the &#8220;ACA&#8221;) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment&#8217;s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company&#8217;s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor&#8217;s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting for Medicare Part D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include insurance premiums earned by the Company&#8217;s PDPs, which are determined based on the PDP&#8217;s annual bid and related contractual arrangements with the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). The insurance </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company&#8217;s retail pharmacy network. The Company&#8217;s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see &#8220;Drug Discounts&#8221; and &#8220;Guarantees&#8221; below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (&#8220;retail co-payments&#8221;), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by third party pharmacies in the Company&#8217;s retail pharmacy network and associated administrative fees are recognized at the Company&#8217;s point-of-sale, which is when the claim is adjudicated by the Company&#8217;s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Drug Discounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue net of manufacturers&#8217; rebates earned by its clients based on their plan members&#8217; utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers&#8217; rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers&#8217; rebate amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantees</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Retail Pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#8217;s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer returns are not material to the Company&#8217;s operating results or financial condition. Sales taxes are not included in revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Loyalty and Other Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer loyalty program, ExtraCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consists of two components, ExtraSavings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offers a subscription-based membership program, CarePass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-term Care</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company&#8217;s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Walk-In Medical Clinics</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For services provided by the Company&#8217;s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily represent the Company&#8217;s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Products Sold</a></td>
<td class="text"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for cost of products sold as follows:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company&#8217;s mail service dispensing pharmacies and indirectly through the Company&#8217;s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company&#8217;s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients&#8217; benefit plans from the Company&#8217;s mail service dispensing pharmacies, net of any volume-related or other discounts (see &#8220;Vendor Allowances and Purchase Discounts&#8221; below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company&#8217;s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div>Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock', window );">Vendor Allowances and Purchase Discounts</a></td>
<td class="text"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vendor Allowances and Purchase Discounts </span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for vendor allowances and purchase discounts as follows: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company&#8217;s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div>Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company&#8217;s consolidated financial statements in any of the periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock', window );">Health Care Reform</a></td>
<td class="text"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Reform</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Insurer Fee</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on January 1, 2014, the ACA imposed an annual premium-based health insurer fee (&#8220;HIF&#8221;) for each calendar year, payable in September, which was not deductible for tax purposes. The Company was required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was no expense related to the HIF in the years ended December&#160;31, 2022 and 2021. In the year ended December 31, 2020, operating expenses included $1.0&#160;billion related to the Company&#8217;s share of the HIF. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company&#8217;s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Corridor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) based on their ratio of allowable costs to target costs (as defined by the ACA). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company filed a lawsuit in August 2019 to recover the $313&#160;million it was owed under the ACA&#8217;s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA&#8217;s temporary risk corridor program. </span></div>In October 2020, the Company received the $313&#160;million it was owed under the ACA&#8217;s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering offsetting items such as the ACA&#8217;s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $307&#160;million and after-tax income of $223&#160;million during the year ended December&#160;31, 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising Costs Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $745 million, $707 million and $613 million in 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based CompensationStock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMjY0_8d034ca5-401e-4526-8bb8-d8fed86877bb">three</span> to five years) using the straight-line method.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company&#8217;s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit pension plans (&#8220;pension plans&#8221;) and other postretirement employee benefit plans (&#8220;OPEB plans&#8221;) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit income for the Company&#8217;s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time.&#160;Non-service cost components of pension and postretirement net periodic benefit income are included in other income in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is computed using the treasury stock method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 &#8216;&#8216;Earnings Per Share&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_SharesHeldInTrustPolicyTextBlock', window );">Shares Held in Trust</a></td>
<td class="text">Shares Held in TrustThe Company maintains grantor trusts, which held approximately one million shares of its common stock at both December&#160;31, 2022 and 2021. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE&#8217;s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Primary Beneficiary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Company and Cardinal Health, Inc. (&#8220;Cardinal&#8221;) established Red Oak Sourcing, LLC (&#8220;Red Oak&#8221;), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December&#160;31, 2022, 2021 and 2020. The payments reduce the Company&#8217;s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Other Variable Interest Holder</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hedge fund and private equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Real estate partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not the primary beneficiary of these VIEs because the nature of the Company&#8217;s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE&#8217;s income or losses in net income.&#160;The Company&#8217;s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Related Party Transactions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in SureScripts, LLC (&#8220;SureScripts&#8221;), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $60 million, $52 million and $56 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million in the years ended December&#160;31, 2022, 2021 and 2020, respectively. The Company&#8217;s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in Heartland Healthcare Services, LLC (&#8220;Heartland&#8221;). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $87 million, $79 million and $77 million for pharmaceutical inventory purchases during the years ended December&#160;31, 2022, 2021 and 2020, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company&#8217;s investment in and equity in the earnings of Heartland for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, the Company made charitable contributions of&#160;$25&#160;million, $50 million and $50&#160;million, respectively,&#160;to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December&#160;31, 2022, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued OperationsIn connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens &#8216;n Things and Bob&#8217;s Stores, each of which subsequently filed for bankruptcy. The Company&#8217;s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements Recently Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Not Yet Adopted </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Insurance Contracts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board issued ASU 2018-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income (loss). The rate used to discount the Company&#8217;s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#8217;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company&#8217;s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company adopted this accounting standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented, January 1, 2021, also referred to as the transition date, for changes primarily related to the liability for future policy benefits and deferred acquisition costs. The Company is still in the process of  finalizing the impact of the new standard on its historical financial statements, but expects to record an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income on the transition date of approximately $1&#160;billion as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company&#8217;s expected investment yield under the existing guidance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_InsurancePremiumDeficiencyReservePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance Premium Deficiency Reserve [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_InsurancePremiumDeficiencyReservePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_SharesHeldInTrustPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Held In Trust [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_SharesHeldInTrustPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor Allowances And Purchase Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocationsToPolicyholdersPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining amounts of income and expenses allocated to policyholders and contract holders, excluding the method for determining dividends payable to policyholders and accounting policies pertaining to separate accounts for variable annuity contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6483535&amp;loc=d3e16392-158451<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocationsToPolicyholdersPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=35755530&amp;loc=d3e11264-158415<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accruing health care costs for a prepaid health care service provider.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6491204&amp;loc=d3e4879-115612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=49178521&amp;loc=d3e9162-115647<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareEntitiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for all health care policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareEntitiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contracts reported in separate accounts, including the extent and terms of minimum guarantees, basis of presentation for separate account assets and liabilities and related separate account activity, the liability valuation method and assumptions used in valuing each type of policyholder and contract holder account maintained by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27830-158548<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27758-158548<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReservePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReservePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14754-158437<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14784-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576405920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of reconciliation of cash and cash equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,691&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts receivable, net</a></td>
<td class="text">Accounts receivable, net was composed of the following at December&#160;31, 2022 and 2021:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vendor and manufacturer receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premium receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,431&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes accounts receivable of $227&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31, 2022 and 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixtures and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,896&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes property and equipment of $244&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company&#8217;s revenue by major source in each segment for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:28.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(45,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">205,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">169,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">106,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(45,302)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">322,467&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">169,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">152,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">184,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">292,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">171,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75,467&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">268,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company&#8217;s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> claims picked up at a retail pharmacy, as well as prescriptions filled at the Company&#8217;s retail pharmacies under the Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span>program.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of receivables and contract liabilities from contracts with customers</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables and contract liabilities from contracts with customers as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables (included in accounts receivable, net)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities (included in accrued expenses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the contract liabilities balance includes increases related to customers&#8217; earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rewards earnings and gift card issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption and breakage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of variable interest entities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge fund investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the results of discontinued operations for the year ended December 31, 2020. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.573%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590786544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures and Asset Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">Summary of Assets and Liabilities Held for Sale</a></td>
<td class="text">The following table summarizes the assets and liabilities held for sale at December&#160;31, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581337520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TotalInvestmentsTableTextBlock', window );">Schedule of Total Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,113&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,891&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term investments of $17&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Debt Securities Available For Sale</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available for sale at December&#160;31, 2022 and 2021 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.441%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Amortized <br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allowance<br/>for Credit<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Amortized<br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,840)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Investment risks associated with the Company&#8217;s experience-rated products generally do not impact the Company&#8217;s consolidated operating results.&#160;At December&#160;31, 2022, debt securities with a fair value of $609 million, gross unrealized capital gains of $3 million and gross unrealized capital losses of </span></div>$59 million, and at December&#160;31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Amortized Cost and Fair Value of Debt Securities by Contractual Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of debt securities at December&#160;31, 2022 are shown below by contractual maturity.&#160;Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,063&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,280&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of Debt Securities In An Unrealized Capital Loss Position</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the debt securities the Company held at December&#160;31, 2022 and 2021 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except number of securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity dates for debt securities in an unrealized capital loss position at December&#160;31, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting experience-<br/>rated products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting remaining<br/>products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ActivityInMortgageLoanPortfolioTableTextBlock', window );">Schedule of Activity in Mortgage Loan Portfolio</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s mortgage loans are collateralized by commercial real estate.&#160;During the years ended December 31, 2022 and 2021, the Company had the following activity in its mortgage loan portfolio:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New mortgage loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans fully repaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans foreclosed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 scheduled mortgage loan principal repayments were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock', window );">Schedule of Mortgage Loan Amortized Cost and Credit Quality Indicator</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company&#8217;s assessments at December&#160;31, 2022 and 2021, the amortized cost basis of the Company&#8217;s mortgage loans within each credit quality indicator by year of origination was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost Basis by Year of Origination</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except credit quality indicator</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prior</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeTextBlock', window );">Schedule of Net Investment Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sources of net investment income for the years ended December 31, 2022, 2021 and 2020 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross investment income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (excluding net realized capital gains or losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized capital gains (losses) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net realized capital losses include credit-related losses on debt securities of $13 million and yield-related impairment losses on debt securities of $143 million in the year ended December 31, 2022. Net realized capital gains are net of yield-related impairment losses on debt securities of $42 million and $49 million for the years ended December 31, 2021 and 2020, respectively. There were no credit-related losses on debt securities in the years ended December 31, 2021 and 2020.</span></div>(2)Net investment income includes $35 million, $38 million and $42 million for the years ended December 31, 2022, 2021 and 2020, respectively, related to investments supporting experience-rated products.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock', window );">Schedule of Proceeds and Related Gross Realized Capital Gains and Losses From the Sale of Debt Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ActivityInMortgageLoanPortfolioTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Table representing activities in mortgage loan portfolio during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ActivityInMortgageLoanPortfolioTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item includes proceeds from the sale of debt securities and the related gross realized capital gains and losses, excluding amounts related to experience-rated and discontinued products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule detailing credit quality information related to financing receivables by credit quality indicator and by class of financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TotalInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item includes total investments, both current and long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TotalInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583988560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text">Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,407&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes cash and cash equivalents of $6&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Level 3 Financial Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/>&#160;and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other asset-<br/>backed<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital losses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/>&#160;and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other asset-<br/>backed<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Redeemable<br/>preferred<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in net unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December&#160;31, 2021 was $4&#160;million during the year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross transfers into (out of) Level 3 during the years ended December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers into Level 3</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers into (out of) Level 3</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Carrying Value and Fair Value By Level of Fair Value Hierarchy</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Estimated Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information regarding the valuation of cost method investments. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term debt of $3&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock', window );">Schedule of Fair Value of Separate Accounts by Major Category of Investment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts financial assets at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common/collective trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $85 million of other payables and $70&#160;million of other receivables at December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of asset supporting separate account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124508989&amp;loc=d3e19393-158473<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124504833&amp;loc=d3e7104-158389<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=124505678&amp;loc=SL117422397-158474<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586667936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of Changes in Carrying Amount of Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the changes in the carrying amount of goodwill by segment for the&#160;years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company&#8217;s intangible assets as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions, except weighted average life</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,077)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,727)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes intangible assets of $28&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Projected Annual Amortization Expense for Intangible Assets for Next Five Years</a></td>
<td class="text">The projected annual amortization expense for the Company&#8217;s intangible assets for the next five&#160;years is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the cost, accumulated amortization and net balance of intangibles assets and amortization period, in total and by major class. Finite-lived intangible assets have a stated useful life over which their gross carrying value is amortized. Indefinite intangible assets have a projected indefinite period of benefit (hence are not amortized).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583844272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of the Components of Net Lease Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of net lease cost for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for interest portion of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows paid for principal portion of finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLeaseTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except remaining lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,122</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,699</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,177</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,538</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining lease term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes operating lease right-of-use assets of $56&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes current portion of operating lease liabilities of $21&#160;million and long-term operating lease liabilities of $39&#160;million which have been accounted for as liabilities held for sale and are included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of lease liabilities under finance and operating leases as of December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating<br/>Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Future operating lease payments have not been reduced by minimum sublease rentals of $290 million due in the future under noncancelable subleases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.5 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Finance Lease Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of lease liabilities under finance and operating leases as of December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating<br/>Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Future operating lease payments have not been reduced by minimum sublease rentals of $290 million due in the future under noncancelable subleases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.5 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590089712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Health Care Costs Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract', window );"><strong>Health Care and Other Insurance Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock', window );">Information about Incurred and Paid Health Care Claims Development</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information about incurred and paid health care claims development for the year ended December&#160;31, 2021 is presented as required unaudited supplemental information.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,444&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Paid Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All outstanding liabilities for health care costs payable prior to 2021, net of reinsurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outstanding liabilities for health care costs payable, net of reinsurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the December&#160;31, 2022 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-duration health care costs payable, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total health care costs payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock', window );">Components of Change in Health Care Costs Payable</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(788)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the years ended December&#160;31, 2022, 2021 and 2020 in the table above exclude $75 million, $59 million and $41 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and $319 million, $212 million and $221 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets. The incurred health care costs for the years ended December 31, 2021 and 2020 also exclude $16 million and $11 million, respectively, for premium deficiency reserves related to the Company&#8217;s Medicaid products.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Care and Other Insurance Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671315-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583851440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings and Credit Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Company's Borrowings</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company&#8217;s borrowings as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5% senior notes due July 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% senior notes due November 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8% senior notes due June 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4% senior notes due December 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.375% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.625% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5% senior notes due November 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5% senior notes due December 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1% senior notes due March 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% senior notes due July 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.875% senior notes due June 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3% senior notes due August 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.625% senior notes due April 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25% senior notes due June 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3% senior notes due August 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3% senior notes due March 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.25% senior notes due August 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.75% senior notes due April 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75% senior notes due August 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% senior notes due February 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.125% senior notes due September 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% senior notes due July 2035</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.625% senior notes due June 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.75% senior notes due December 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.78% senior notes due March 2038</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% senior notes due September 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.125% senior notes due April 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7% senior notes due August 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% senior notes due May 2041</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5% senior notes due May 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.125% senior notes due November 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3% senior notes due December 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75% senior notes due March 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.125% senior notes due July 2045</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% senior notes due August 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.05% senior notes due March 2048</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25% senior notes due April 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_136d726d-4e4c-47e6-89b0-66598c753e01"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_f7e749bb-d161-4304-bb3e-6fdb8d5e52ce">Finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt principal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discounts and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">__________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes long-term debt of $3&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s required repayments of debt principal due during each of the next five&#160;years and thereafter, as of December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See Note 6 &#8216;&#8216;Leases&#8217;&#8217; for a summary of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">maturities of the Company&#8217;s finance lease liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583859968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Plans and Other Postretirement Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock', window );">Schedule of Changes in Benefit Obligations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables outline the change in pension benefit obligation and plan assets over the specified periods:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Changes in Plan Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables outline the change in pension benefit obligation and plan assets over the specified periods:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock', window );">Schedule of Assets (Liabilities) Recognized in Balance Sheet</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets (liabilities) recognized on the consolidated balance sheets at December&#160;31, 2022 and 2021 for the defined benefit pension plans consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets reflected in other assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities reflected in accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities reflected in other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Periodic Benefit Cost (Income)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (income) for the years ended December&#160;31, 2022, 2021 and 2020 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost (income):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Weighted Average Assumptions Used in Determining Benefit Obligations and Net Benefit Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its benefit obligation based on the following weighted average assumptions as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Changes in Fair Value of Plan Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2022 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $104 million of equity securities and $203 million of debt securities. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $390 million of other receivables as well as $432 million of private equity limited partnership investments and $225 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2021 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $261 million of equity securities and $149 million of debt securities. </span></div>(2)Excludes $76 million of other receivables as well as $583 million of private equity limited partnership investments and $237 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock', window );">Schedule of Change in Level 3 Plan Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2021 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Future Benefits Payments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December&#160;31, 2022: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December&#160;31, 2022: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:86.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined benefit plan asset investment. Includes, but is not limited to, fair value of category of plan asset and its level within fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586675792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Provision</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision for continuing operations consisted of the following for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,950&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the statutory income tax rate to the Company&#8217;s effective income tax rate for continuing operations for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurer fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis difference upon disposition of subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year refunds and unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of the Company&#8217;s deferred income tax assets and liabilities as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debts and other allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and capital loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax deferral</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,947)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,870)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,767)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,749)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes deferred income tax assets of $131&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#8216;&#8216;Acquisitions, Divestitures and Asset Sales&#8217;&#8217; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Rollforward</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2022, 2021 and 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of statutes of limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586820608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation</a></td>
<td class="text">The following table is a summary of stock-based compensation for the&#160;years ended December&#160;31, 2022, 2021 and 2020:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units and performance stock units</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and stock appreciation rights (&#8220;SARs&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes the ESPP.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">RSU and Performance Share Unit Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the restricted stock unit and performance stock unit activity for the&#160;year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In thousands, except weighted average grant date fair value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,421)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Vested performance stock units have been included at target level performance. Based on actual performance, the number of restricted stock units and performance stock units vested during the year ended December 31, 2022 was 8.0&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock', window );">Summary of Stock Option and SAR Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of stock option and SAR activity that occurred for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from stock options exercised (including ESPP)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for taxes for net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of stock options and SARs exercised </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options and SARs vested </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#8217;s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected life represents the number of&#160;years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Stock Options and Stock Appreciation Rights Award Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company&#8217;s stock option and SAR activity for the&#160;year ended December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;thousands, except weighted average exercise price and remaining contractual term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,040&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,730&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested at end of year and expected to vest in the future</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule ESPP Valuation Assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the assumptions used to value the ESPP awards for the&#160;years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#8217;s daily stock price over the previous six&#160;month period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six&#160;months).</span></div>(4)The expected life is based on the semi-annual purchase period<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365591114960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Share Repurchase Programs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share repurchase programs have been authorized by the Board:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In billions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Authorization&#160;Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining as of<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 17, 2022 (&#8220;2022 Repurchase Program&#8221;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 9, 2021 (&#8220;2021 Repurchase Program&#8221;)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRegulatoryAssetsTextBlock', window );">Schedule of Regulatory Requirements</a></td>
<td class="text">The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December&#160;31, 2022, 2021 and 2020 for the Company&#8217;s insurance and HMO subsidiaries were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory net income </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated statutory capital and surplus</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock', window );">Statutory Accounting Practices Disclosure</a></td>
<td class="text">At December&#160;31, 2022, these amounts were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:88.196%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated minimum statutory surplus required by regulators</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments on deposit with regulatory bodies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated maximum dividend distributions permitted in 2023 without prior regulatory approval</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRegulatoryAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets that are created when regulatory agencies permit public utilities to defer certain costs included in rate-setting to the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6499975&amp;loc=d3e44250-110382<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 715<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501251&amp;loc=d3e52485-110419<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 340<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6499975&amp;loc=d3e44264-110382<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRegulatoryAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of how the entity's reporting under GAAP as of the balance sheet date differs from the results based on prescribed and permitted accounting practices of the state or country of domicile in which a relevant statutory filing is made, or differences in results based on the National Association of Insurance Commissioners (NAIC) prescribed practices, or a combination thereof. Describes the accounting practices used and the related monetary effect on statutory surplus, net income, and risk-based capital. If an insurance enterprise's risk-based capital would have triggered a regulatory event had it not used a permitted practice, that fact is disclosed in the financial statements. Permitted statutory accounting practices include practices not prescribed but allowed by the domiciliary state insurance department regulatory authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.23(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24708-158529<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24790-158529<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24746-158529<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 55<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=82848697&amp;loc=d3e24959-158530<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=82848697&amp;loc=d3e24938-158530<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590748800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders&#8217; equity included the following activity in accumulated other comprehensive income (loss) in 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net unrealized investment gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(2,972), $(489) and $497 pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($315, $(32) and $31 pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,279)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($38, $0 and $(7) pretax)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(15), $(34) and $(35) pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(229), $20 and $(30) pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($3, $6 and $7 pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of year accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of year accumulated other comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,465)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576576704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic and Diluted Earnings (Loss) Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions,&#160;except&#160;per&#160;share&#160;amounts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to CVS Health</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,149&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units and performance stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and SARs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share from continuing operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590760992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock', window );">Schedule of Reinsurance Recoverables</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reinsurer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hartford Life and Accident Insurance Company</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Life &amp; Annuity Company of New York</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOYA Retirement Insurance and Annuity Company </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fresenius Medical Care Reinsurance Company (Cayman) Ltd. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock', window );">Schedule of Direct, Assumed and Ceded Premiums Earned</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,330&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceTableTextBlock', window );">Schedule of Impact of Reinsurance on Benefit Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of reinsurance on benefit costs for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net benefit costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,260&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the supplemental schedule of reinsurance information. Reinsurance schedule includes, but is not limited to, the type of insurance, gross amount of premiums, premiums ceded to other entities, premiums assumed from other entities, net amount of premium revenue, and the percentage of the premiums assumed to net premium revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17)<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectsOfReinsuranceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectsOfReinsuranceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123600520&amp;loc=SL75241803-196195<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365587270640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summarized Financial Information Of Segments</a></td>
<td class="text"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.003%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy&#160;<br/>Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eliminations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,302)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total revenues of the Pharmacy Services segment include approximately $12.6 billion, $11.6 billion and $10.9 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of retail co-payments for 2022, 2021 and 2020, respectively. See Note 1 &#8216;&#8216;Significant Accounting Policies&#8217;&#8217; for additional information about retail co-payments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services segment clients enrolled in Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> elect to pick up maintenance prescriptions at one of the Company&#8217;s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation Of Consolidated Operating Income to Adjusted Operating Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December&#160;31, 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In&#160;millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (GAAP measure)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office real estate optimization charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on divestiture of subsidiaries </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid litigation charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on assets held for sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition purchase price adjustment outside of measurement period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipt of fully reserved ACA risk corridor receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company&#8217;s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company&#8217;s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company&#8217;s insurance products, the services performed for the Company&#8217;s customers or the sale of the Company&#8217;s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company&#8217;s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company&#8217;s and investors&#8217; ability to compare the Company&#8217;s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company&#8217;s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company&#8217;s new flexible work arrangement. The office real estate optimization charges are reflected in the Company&#8217;s GAAP consolidated statement of operations in operating expenses within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift, which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022. In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers&#8217; Compensation business, which the Company sold in July 2020. The gains on divestitures are reflected as a reduction of operating expenses in the Company&#8217;s GAAP consolidated statements of operations within the Health Care Benefits segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities. The opioid litigation charges are reflected within the Corporate/Other segment.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2022, the loss on assets held for sale relates to the LTC reporting unit within the Retail/LTC segment. The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the third quarter of 2022. As of December 31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter of 2022, an incremental loss on assets held for sale was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. During 2022, the loss on assets held for sale also relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its Thailand business, which was included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021 and 2020, acquisition-related integration costs relate to the acquisition of Aetna. The acquisition-related integration costs are reflected in the Company&#8217;s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. The store impairment charge is reflected within the Retail/LTC segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the goodwill impairment charge relates to an impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In 2021, the Company received $61&#160;million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company&#8217;s GAAP consolidated statement of operations as a reduction of operating expenses within the Health Care Benefits segment. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">In 2020, the Company received $313&#160;million owed to it under the ACA&#8217;s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA&#8217;s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307&#160;million in the Company&#8217;s GAAP consolidated statement of operations within the Health Care Benefits segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365574541424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details)<br> shares in Millions, people in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>state</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>people </div>
<div>store </div>
<div>clinic </div>
<div>state </div>
<div>patient </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>store </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>people </div>
<div>store </div>
<div>clinic </div>
<div>state </div>
<div>patient </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>store </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfPharmacyPlanMembers', window );">Number of pharmacy plan members | people</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfPatientsServedPerYear', window );">Number of patients served per year (more than) | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfPeopleServed', window );">Number of people served | people</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredPolicyAcquisitionCosts', window );">Deferred acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="nump">$ 895,000,000<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="nump">$ 895,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000,000<span></span>
</td>
<td class="nump">2,300,000,000<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OfficeRealEstateOptimizationCharges', window );">Office real estate optimization charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,358,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfStoresPlannedClosure', window );">Number of stores, planned closure | store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 431,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets, indefinite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts', window );">Assumed interest rates on long-duration group life and long-term care contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_HeathSavingsAccountBalance', window );">HSA balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,900,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PharmacyRebatePeriod', window );">Pharmacy rebate period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_HealthInsurerFee', window );">Health insurer fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 745,000,000<span></span>
</td>
<td class="nump">$ 707,000,000<span></span>
</td>
<td class="nump">$ 613,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TreasuryStockSharesHeldinTrust', window );">Treasury shares held in trust (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="nump">$ 52,000,000<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Other revenues from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000,000<span></span>
</td>
<td class="nump">79,000,000<span></span>
</td>
<td class="nump">77,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity', window );">Charitable contribution to CVS Health Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember', window );">U.S. Department of Health and Human Services, ACA Risk Corridor Receivables | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Gain contingency, unrecorded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,000,000<span></span>
</td>
<td class="nump">$ 313,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Amount awarded from other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax', window );">Former gain contingency, recognized in current period, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax', window );">Former gain contingency, recognized in current period, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=cvs_HeartlandHealthcareServicesMember', window );">Heartland Healthcare Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=cvs_OtherInsuranceLiabilitiesMember', window );">Other Insurance Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LiabilityForUnpaidClaims', window );">Liability for unpaid claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,000,000<span></span>
</td>
<td class="nump">$ 324,000,000<span></span>
</td>
<td class="nump">$ 243,000,000<span></span>
</td>
<td class="nump">324,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Liability for future policy benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000,000<span></span>
</td>
<td class="nump">416,000,000<span></span>
</td>
<td class="nump">385,000,000<span></span>
</td>
<td class="nump">416,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=cvs_OtherLongTermInsuranceLiabilitiesMember', window );">Other Long-Term Insurance Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LiabilityForUnpaidClaims', window );">Liability for unpaid claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Liability for future policy benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="nump">5,100,000,000<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="nump">$ 5,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OfficeRealEstateOptimizationCharges', window );">Office real estate optimization charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid', window );">Period after date of service a claim is paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LimitedPaymentsContracts', window );">Assumed interest rates on limited payment pension contracts on large case pension business (in hundredths)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PensionAndAnnuityInvestmentContractsInterest', window );">Interest rate for pension and annuity investment contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Fixtures, equipment and internally developed software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid', window );">Period after date of service a claim is paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LimitedPaymentsContracts', window );">Assumed interest rates on limited payment pension contracts on large case pension business (in hundredths)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PensionAndAnnuityInvestmentContractsInterest', window );">Interest rate for pension and annuity investment contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Fixtures, equipment and internally developed software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember', window );">Retail/ LTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStores', window );">Number of retail locations (more than) | store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfWalkInMedicalClinics', window );">Number of walk-in medical clinics (more than) | clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfStoresPlannedClosure', window );">Number of stores, planned closure | store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember', window );">Retail/ LTC | Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember', window );">Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates', window );">Number of states in which the Company has entered the individual public health insurance exchange | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember', window );">Health Care Benefits | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates', window );">Additional number of states in which the Company entered the individual public health insurance exchange | state</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember', window );">Health Insurance Product Line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumDeficiencyReserveLiability', window );">Premium deficiency reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Gain Contingency, Recognized In Current Period, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Gain Contingency, Recognized In Current Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Care Costs Payable, Period After Date Of Services Claims Are Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_HealthInsurerFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated amount of the health insurer fee accrued during the reporting period, as required by Health Care Reform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_HealthInsurerFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_HeathSavingsAccountBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Heath Savings Account Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_HeathSavingsAccountBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Individual Public Health Insurance Exchanges, Number Of Additional States</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Individual Public Health Insurance Exchanges, Number Of States</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeOperatingAndFinanceLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Finance Leases, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeOperatingAndFinanceLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LiabilityForUnpaidClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total liability on the balance sheet for unpaid claims for both short-duration and long-duration insurance contracts after reinsurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LiabilityForUnpaidClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LimitedPaymentsContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum assumed interest rates on limited payment contracts on large case pensions business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LimitedPaymentsContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberOfPatientsServedPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients Served Per Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberOfPatientsServedPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberOfPeopleServed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of People Served</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberOfPeopleServed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberOfPharmacyPlanMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Pharmacy Plan Members</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberOfPharmacyPlanMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberOfStoresPlannedClosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Stores, Planned Closure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberOfStoresPlannedClosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberOfWalkInMedicalClinics">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Walk In Medical Clinics</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberOfWalkInMedicalClinics</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OfficeRealEstateOptimizationCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office Real Estate Optimization Charges - Related to the abandonment of leased real estate and the related right-of-use assets and property and equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OfficeRealEstateOptimizationCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PensionAndAnnuityInvestmentContractsInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pension And Annuity Investment Contracts Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PensionAndAnnuityInvestmentContractsInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PharmacyRebatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pharmacy Rebate Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PharmacyRebatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PremiumDeficiencyReserveLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reserves related to expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), in excess of existing reserves plus anticipated future premiums and reinsurance recoveries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PremiumDeficiencyReserveLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Charitable Contribution To Non-Profit Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_StoreImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Store Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_StoreImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TreasuryStockSharesHeldinTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Shares, Held in Trust</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TreasuryStockSharesHeldinTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredPolicyAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred policy acquisition cost capitalized on contract remaining in force.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124505477&amp;loc=SL117422543-158416<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124505477&amp;loc=SL117422543-158416<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124506110&amp;loc=d3e32546-158582<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 55<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124504731&amp;loc=d3e11522-158419<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredPolicyAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 55<br> -Paragraph 29E<br> -URI https://asc.fasb.org/extlink&amp;oid=126561865&amp;loc=SL117819541-158441<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStores">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of stores.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStores</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cvs_HeartlandHealthcareServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cvs_HeartlandHealthcareServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=cvs_OtherInsuranceLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=cvs_OtherInsuranceLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=cvs_OtherLongTermInsuranceLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=cvs_OtherLongTermInsuranceLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586587344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Cash and Cash Equivalents, Restricted Cash and Cash Equivalents (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,945<span></span>
</td>
<td class="nump">$ 9,408<span></span>
</td>
<td class="nump">$ 7,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash (included in other current assets)</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">3,065<span></span>
</td>
<td class="nump">2,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash (included in other assets)</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows</a></td>
<td class="nump">$ 13,305<span></span>
</td>
<td class="nump">$ 12,691<span></span>
</td>
<td class="nump">$ 11,043<span></span>
</td>
<td class="nump">$ 8,408<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586604464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Trade receivables</a></td>
<td class="nump">$ 8,983<span></span>
</td>
<td class="nump">$ 7,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_VendorandManufacturerReceivables', window );">Vendor and manufacturer receivables</a></td>
<td class="nump">12,395<span></span>
</td>
<td class="nump">10,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsReceivableAtCarryingValue', window );">Premium receivables</a></td>
<td class="nump">2,676<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">3,449<span></span>
</td>
<td class="nump">3,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale', window );">Total accounts receivable, net</a></td>
<td class="nump">27,503<span></span>
</td>
<td class="nump">24,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale', window );">Total accounts receivable, net</a></td>
<td class="nump">$ 227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Including Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_VendorandManufacturerReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vendor and Manufacturer Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_VendorandManufacturerReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsReceivableAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsReceivableAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365575548448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 34,600<span></span>
</td>
<td class="nump">$ 33,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(21,483)<span></span>
</td>
<td class="num">(20,654)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale', window );">Property and equipment, net</a></td>
<td class="nump">13,117<span></span>
</td>
<td class="nump">12,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale', window );">Property and equipment, net</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,996<span></span>
</td>
<td class="nump">2,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,545<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Fixtures and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">12,978<span></span>
</td>
<td class="nump">13,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">6,238<span></span>
</td>
<td class="nump">6,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 8,843<span></span>
</td>
<td class="nump">$ 7,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, Net, Including Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576887808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 321,629<span></span>
</td>
<td class="nump">$ 290,912<span></span>
</td>
<td class="nump">$ 267,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">322,467<span></span>
</td>
<td class="nump">292,111<span></span>
</td>
<td class="nump">268,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_PharmacyRevenueMember', window );">Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">205,121<span></span>
</td>
<td class="nump">184,618<span></span>
</td>
<td class="nump">171,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_FrontStoreRevenueMember', window );">Front Store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22,780<span></span>
</td>
<td class="nump">21,315<span></span>
</td>
<td class="nump">19,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_PremiumsMember', window );">Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">85,330<span></span>
</td>
<td class="nump">76,132<span></span>
</td>
<td class="nump">69,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8,398<span></span>
</td>
<td class="nump">8,847<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">90,844<span></span>
</td>
<td class="nump">81,515<span></span>
</td>
<td class="nump">74,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">91,409<span></span>
</td>
<td class="nump">82,186<span></span>
</td>
<td class="nump">75,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Health Care Benefits | Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Health Care Benefits | Front Store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Health Care Benefits | Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">85,274<span></span>
</td>
<td class="nump">76,064<span></span>
</td>
<td class="nump">69,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Health Care Benefits | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,659<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
<td class="nump">5,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmacy Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">157,787<span></span>
</td>
<td class="nump">143,194<span></span>
</td>
<td class="nump">132,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">169,236<span></span>
</td>
<td class="nump">153,022<span></span>
</td>
<td class="nump">141,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmacy Services | Pharmacy network</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">97,668<span></span>
</td>
<td class="nump">91,715<span></span>
</td>
<td class="nump">85,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmacy Services | Mail choice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">70,466<span></span>
</td>
<td class="nump">60,547<span></span>
</td>
<td class="nump">56,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmacy Services | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="nump">822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmacy Services | Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">168,134<span></span>
</td>
<td class="nump">152,262<span></span>
</td>
<td class="nump">141,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmacy Services | Front Store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmacy Services | Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmacy Services | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="nump">822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Retail/ LTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">72,874<span></span>
</td>
<td class="nump">66,078<span></span>
</td>
<td class="nump">60,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">106,594<span></span>
</td>
<td class="nump">100,105<span></span>
</td>
<td class="nump">91,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Retail/ LTC | Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">82,010<span></span>
</td>
<td class="nump">76,121<span></span>
</td>
<td class="nump">70,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Retail/ LTC | Front Store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22,780<span></span>
</td>
<td class="nump">21,315<span></span>
</td>
<td class="nump">19,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Retail/ LTC | Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Retail/ LTC | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,848<span></span>
</td>
<td class="nump">2,652<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate/ Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate/ Other | Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate/ Other | Front Store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate/ Other | Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate/ Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(45,302)<span></span>
</td>
<td class="num">(43,923)<span></span>
</td>
<td class="num">(40,323)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(45,023)<span></span>
</td>
<td class="num">(43,765)<span></span>
</td>
<td class="num">(40,003)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Front Store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">$ (279)<span></span>
</td>
<td class="num">$ (158)<span></span>
</td>
<td class="num">$ (320)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cvs_PharmacyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cvs_PharmacyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cvs_FrontStoreRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cvs_FrontStoreRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cvs_PremiumsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cvs_PremiumsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=cvs_SalesChannelOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=cvs_SalesChannelOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365584009296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Receivables and Contracted Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Trade receivables (included in accounts receivable, net)</a></td>
<td class="nump">$ 8,983<span></span>
</td>
<td class="nump">$ 7,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities (included in accrued expenses)</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583676416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Contract Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Change in Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities, beginning of period</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance', window );">Rewards earnings and gift card issuances</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage', window );">Redemption and breakage</a></td>
<td class="num">(356)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities, end of period</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in contract liability recognized for loyalty program earnings and gift card issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ContractWithCustomerLiabilityRedemptionAndBreakage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Liability Redemption And Breakage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ContractWithCustomerLiabilityRedemptionAndBreakage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576561872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ProceedsFromVariableInterestEntity', window );">Proceeds from VIE</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">21,096<span></span>
</td>
<td class="nump">$ 23,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cvs_RedOakMember', window );">Red Oak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">VIE, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InitialContractualTerm', window );">Initial contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_VariableInterestEntityAmendedContractExtensionTerm', window );">Amended contract extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_VariableInterestEntityAmendedContractTerm', window );">Amended contract term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Hedge fund investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Private equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Real estate partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_InitialContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Initial Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_InitialContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ProceedsFromVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ProceedsFromVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_VariableInterestEntityAmendedContractExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Amended Contract Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_VariableInterestEntityAmendedContractExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_VariableInterestEntityAmendedContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Amended Contract Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_VariableInterestEntityAmendedContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cvs_RedOakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cvs_RedOakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_HedgeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_HedgeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_PrivateEquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_PrivateEquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RealEstateFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583675008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Discontinued Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583487408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - New Accounting Pronouncements Not Yet Adopted (Details)<br> $ in Billions</strong></div></th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201812Member', window );">Accounting Standards Update 2018-12 | Cumulative Effect, Period of Adoption, Adjustment | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Increase (decrease) to liability for future policy benefits</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 55<br> -Paragraph 29E<br> -URI https://asc.fasb.org/extlink&amp;oid=126561865&amp;loc=SL117819541-158441<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=d3e14931-158439<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201812Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201812Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365573378784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures and Asset Sales - Narrative (Details)<br> $ / shares in Units, member in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 07, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 02, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>member</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>member</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,533<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cvs_OakStreetHealthIncMember', window );">Oak Street Health Inc. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Cash to be received by shareholders in proposed/pending acquisition (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 39.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total value of proposed/pending acquisition</a></td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_BusinessCombinationTerminationFee', window );">Termination fee</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cvs_OakStreetHealthIncMember', window );">Oak Street Health Inc. | Oak Street Health Inc. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_BusinessCombinationTerminationFee', window );">Termination fee</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cvs_SignifyHealthIncMember', window );">Signify Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Cash to be received by shareholders in proposed/pending acquisition (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total value of proposed/pending acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_BusinessCombinationTerminationFee', window );">Termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cvs_SignifyHealthIncMember', window );">Signify Health, Inc. | Signify Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_BusinessCombinationTerminationFee', window );">Termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations | Omnicare Long-Term Care Business | Retail/ LTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | bswift LLC | Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Payflex | Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Thailand Business | Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfMedicalMembers', window );">Number of medical members | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | International Health Care Renewal Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold', window );">Number of international health care members, renewal rights sold | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Coventry Health Care Workers Compensation Business | Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_BusinessCombinationTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Termination Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_BusinessCombinationTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Number Of International Health Care Members, Renewal Rights Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberOfMedicalMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Medical Members</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberOfMedicalMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cvs_OakStreetHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cvs_OakStreetHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cvs_OakStreetHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cvs_OakStreetHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cvs_SignifyHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cvs_SignifyHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cvs_SignifyHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cvs_SignifyHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_OmnicareLongTermCareBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_OmnicareLongTermCareBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_BswiftLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_BswiftLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_PayflexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_PayflexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_ThailandBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_ThailandBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_InternationalHealthCareRenewalRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_InternationalHealthCareRenewalRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_CoventryHealthCareWorkersCompensationBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_CoventryHealthCareWorkersCompensationBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583541184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions, Divestitures and Asset Sales - Summary of Assets and Liabilities Held for Sale (Details) - Disposal Group, Held-for-sale, Not Discontinued Operations<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventories</a></td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets', window );">Deferred income taxes</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other</a></td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Other</a></td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale</a></td>
<td class="nump">$ 228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581087184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Total Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TotalInvestmentsLineItems', window );"><strong>Total Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current</a></td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="nump">$ 3,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LongTermInvestmentsIncludingAssetsHeldForSale', window );">Long-term</a></td>
<td class="nump">21,113<span></span>
</td>
<td class="nump">23,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total</a></td>
<td class="nump">23,891<span></span>
</td>
<td class="nump">26,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TotalInvestmentsLineItems', window );"><strong>Total Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LongTermInvestmentsIncludingAssetsHeldForSale', window );">Long-term</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TotalInvestmentsAxis=cvs_DebtAndEquitySecuritiesAvailableForSaleMember', window );">Debt securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TotalInvestmentsLineItems', window );"><strong>Total Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current</a></td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LongTermInvestmentsIncludingAssetsHeldForSale', window );">Long-term</a></td>
<td class="nump">17,562<span></span>
</td>
<td class="nump">20,231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total</a></td>
<td class="nump">20,280<span></span>
</td>
<td class="nump">23,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TotalInvestmentsAxis=cvs_MortgageLoansMember', window );">Mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TotalInvestmentsLineItems', window );"><strong>Total Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LongTermInvestmentsIncludingAssetsHeldForSale', window );">Long-term</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TotalInvestmentsAxis=us-gaap_OtherInvestmentsMember', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TotalInvestmentsLineItems', window );"><strong>Total Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LongTermInvestmentsIncludingAssetsHeldForSale', window );">Long-term</a></td>
<td class="nump">2,562<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total</a></td>
<td class="nump">$ 2,567<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LongTermInvestmentsIncludingAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Investments, Including Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LongTermInvestmentsIncludingAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TotalInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TotalInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TotalInvestmentsAxis=cvs_DebtAndEquitySecuritiesAvailableForSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TotalInvestmentsAxis=cvs_DebtAndEquitySecuritiesAvailableForSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TotalInvestmentsAxis=cvs_MortgageLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TotalInvestmentsAxis=cvs_MortgageLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TotalInvestmentsAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TotalInvestmentsAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581274736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Investments related to 2012 contract conversion</a></td>
<td class="nump">$ 331<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities', window );">Weighted average duration of securities</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Commercial mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities', window );">Weighted average duration of securities</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember', window );">Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities', window );">Weighted average duration of securities</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.6(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611133-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Footnote 11(c)))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365582796912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Gross Amortized Cost</a></td>
<td class="nump">$ 22,067<span></span>
</td>
<td class="nump">$ 22,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">22,063<span></span>
</td>
<td class="nump">22,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,840)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">20,280<span></span>
</td>
<td class="nump">23,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Gross Amortized Cost</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">2,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">2,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(182)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">2,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">States, municipalities and political subdivisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Gross Amortized Cost</a></td>
<td class="nump">2,393<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">2,393<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember', window );">U.S. corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Gross Amortized Cost</a></td>
<td class="nump">9,838<span></span>
</td>
<td class="nump">9,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">9,835<span></span>
</td>
<td class="nump">9,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(903)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">8,958<span></span>
</td>
<td class="nump">9,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember', window );">Foreign securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Gross Amortized Cost</a></td>
<td class="nump">2,780<span></span>
</td>
<td class="nump">2,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">2,779<span></span>
</td>
<td class="nump">2,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Gross Amortized Cost</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(89)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Commercial mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Gross Amortized Cost</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember', window );">Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Gross Amortized Cost</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(136)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,810<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable preferred securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Gross Amortized Cost</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember', window );">Supporting experience- rated products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365582085296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Debt Securities by Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than one year</a></td>
<td class="nump">$ 1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">One year through five years</a></td>
<td class="nump">6,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">After five years through ten years</a></td>
<td class="nump">4,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Greater than ten years</a></td>
<td class="nump">4,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">22,063<span></span>
</td>
<td class="nump">$ 22,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than one year</a></td>
<td class="nump">1,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">One year through five years</a></td>
<td class="nump">6,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">After five years through ten years</a></td>
<td class="nump">4,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Greater than ten years</a></td>
<td class="nump">3,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">20,280<span></span>
</td>
<td class="nump">23,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost', window );">Debt securities, maturity, without single maturity date</a></td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date</a></td>
<td class="nump">757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Commercial mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost', window );">Debt securities, maturity, without single maturity date</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember', window );">Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost', window );">Debt securities, maturity, without single maturity date</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Net Amortized Cost</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date</a></td>
<td class="nump">2,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 2,810<span></span>
</td>
<td class="nump">$ 2,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365572684784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Unrealized Loss Position (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Number of Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 months | security</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, Greater than 12 months | security</a></td>
<td class="nump">2,784<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Securities | security</a></td>
<td class="nump">12,284<span></span>
</td>
<td class="nump">4,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 14,228<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value, Greater than 12 months</a></td>
<td class="nump">4,264<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">18,492<span></span>
</td>
<td class="nump">7,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses, Less than 12 months</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Losses, Greater than 12 months</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 1,840<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Number of Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 months | security</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, Greater than 12 months | security</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Securities | security</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 1,620<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value, Greater than 12 months</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses, Less than 12 months</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Losses, Greater than 12 months</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">States, municipalities and political subdivisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Number of Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 months | security</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, Greater than 12 months | security</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Securities | security</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value, Greater than 12 months</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">1,692<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses, Less than 12 months</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Losses, Greater than 12 months</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember', window );">U.S. corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Number of Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 months | security</a></td>
<td class="nump">5,193<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, Greater than 12 months | security</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Securities | security</a></td>
<td class="nump">6,672<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 6,537<span></span>
</td>
<td class="nump">$ 2,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value, Greater than 12 months</a></td>
<td class="nump">1,822<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">8,359<span></span>
</td>
<td class="nump">2,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses, Less than 12 months</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Losses, Greater than 12 months</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 903<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember', window );">Foreign securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Number of Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 months | security</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, Greater than 12 months | security</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Securities | security</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value, Greater than 12 months</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">2,307<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses, Less than 12 months</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Losses, Greater than 12 months</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Number of Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 months | security</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, Greater than 12 months | security</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Securities | security</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value, Greater than 12 months</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses, Less than 12 months</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Losses, Greater than 12 months</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Commercial mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Number of Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 months | security</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, Greater than 12 months | security</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Securities | security</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 611<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value, Greater than 12 months</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses, Less than 12 months</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Losses, Greater than 12 months</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember', window );">Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Number of Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 months | security</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, Greater than 12 months | security</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Securities | security</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 1,893<span></span>
</td>
<td class="nump">$ 2,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value, Greater than 12 months</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses, Less than 12 months</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Losses, Greater than 12 months</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable preferred securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Number of Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Securities, Less than 12 months | security</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Securities, Greater than 12 months | security</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Securities | security</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value, Less than 12 months</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value, Greater than 12 months</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses, Less than 12 months</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Losses, Greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576776368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Unrealized Loss Position Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear', window );">Less than one year</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears', window );">One year through five years</a></td>
<td class="nump">5,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears', window );">After five years through ten years</a></td>
<td class="nump">3,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears', window );">Greater than ten years</a></td>
<td class="nump">3,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">18,492<span></span>
</td>
<td class="nump">$ 7,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss', window );">Less than one year</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss', window );">One year through five years</a></td>
<td class="nump">403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss', window );">After five years through ten years</a></td>
<td class="nump">511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss', window );">Greater than ten years</a></td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">1,840<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date, fair value</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss', window );">Debt securities, maturity, without single maturity date, unrealized losses</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Commercial mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date, fair value</a></td>
<td class="nump">992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss', window );">Debt securities, maturity, without single maturity date, unrealized losses</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember', window );">Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date, fair value</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss', window );">Debt securities, maturity, without single maturity date, unrealized losses</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember', window );">Supporting experience- rated products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear', window );">Less than one year</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears', window );">One year through five years</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears', window );">After five years through ten years</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears', window );">Greater than ten years</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss', window );">Less than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss', window );">One year through five years</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss', window );">After five years through ten years</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss', window );">Greater than ten years</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember', window );">Supporting experience- rated products | Residential mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date, fair value</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss', window );">Debt securities, maturity, without single maturity date, unrealized losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember', window );">Supporting experience- rated products | Commercial mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date, fair value</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss', window );">Debt securities, maturity, without single maturity date, unrealized losses</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember', window );">Supporting experience- rated products | Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date, fair value</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss', window );">Debt securities, maturity, without single maturity date, unrealized losses</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingRemainingProductsMember', window );">Supporting remaining products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear', window );">Less than one year</a></td>
<td class="nump">1,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears', window );">One year through five years</a></td>
<td class="nump">5,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears', window );">After five years through ten years</a></td>
<td class="nump">3,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears', window );">Greater than ten years</a></td>
<td class="nump">3,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">17,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss', window );">Less than one year</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss', window );">One year through five years</a></td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss', window );">After five years through ten years</a></td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss', window );">Greater than ten years</a></td>
<td class="nump">501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingRemainingProductsMember', window );">Supporting remaining products | Residential mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date, fair value</a></td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss', window );">Debt securities, maturity, without single maturity date, unrealized losses</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingRemainingProductsMember', window );">Supporting remaining products | Commercial mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date, fair value</a></td>
<td class="nump">960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss', window );">Debt securities, maturity, without single maturity date, unrealized losses</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingRemainingProductsMember', window );">Supporting remaining products | Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue', window );">Debt securities, maturity, without single maturity date, fair value</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss', window );">Debt securities, maturity, without single maturity date, unrealized losses</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cvs_SupportingRemainingProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cvs_SupportingRemainingProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583561984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Mortgage Loans (Details) - Commercial Real Estate - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans', window );">New mortgage loans</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_MortgageLoansOnRealEstateLoansFullyRepaid', window );">Mortgage loans fully repaid</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstateForeclosures', window );">Mortgage loans foreclosed</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateLoansFullyRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pertains to amount of mortgage loans fully repaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateLoansFullyRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstateForeclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from foreclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 310<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-29(Footnote 6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120402547&amp;loc=d3e617274-123014<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstateForeclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstateNewMortgageLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from new investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 310<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-29(Footnote 6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120402547&amp;loc=d3e617274-123014<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstateNewMortgageLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576430304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Mortgage Loans Credit Ratings Indicator (Details) - Commercial Real Estate - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">$ 1,044<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">Prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">1 | 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">1 | 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">1 | 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">1 | 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">1 | 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">1 | Prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2 to 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2 to 4 | 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2 to 4 | 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2 to 4 | 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2 to 4 | 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2 to 4 | 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">2 to 4 | Prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">5 and 6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">5 and 6 | 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">5 and 6 | 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">5 and 6 | 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">5 and 6 | 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">5 and 6 | 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">5 and 6 | Prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">7</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">7 | 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">7 | 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">7 | 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">7 | 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">7 | 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember', window );">7 | Prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">Mortgage loans</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 310<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-29(Column G))<br> -URI https://asc.fasb.org/extlink&amp;oid=120402547&amp;loc=d3e617274-123014<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPriorToPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateYearOfOriginationAxis=cvs_YearOfOriginationPriorToPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalCreditAssessmentAxis=cvs_Category1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalCreditAssessmentAxis=cvs_Category1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalCreditAssessmentAxis=cvs_Category2To4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalCreditAssessmentAxis=cvs_Category2To4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalCreditAssessmentAxis=cvs_Categories5And6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalCreditAssessmentAxis=cvs_Categories5And6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalCreditAssessmentAxis=cvs_Category7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalCreditAssessmentAxis=cvs_Category7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576358816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Mortgage Loan Principal Repayments (Details) - Commercial Real Estate<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet', window );">Total</a></td>
<td class="nump">$ 1,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Loans On Real Estate Collections Of Principal After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Loans On Real Estate Collections Of Principal In Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Loans On Real Estate Collections Of Principal In Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Loans On Real Estate Collections Of Principal In Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Loans On Real Estate Collections Of Principal In Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The balance represents the amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_CommercialRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365574426752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Net Investment Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Schedule of Investment Income, Reported Amounts, by Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Gross investment income</a></td>
<td class="nump">$ 1,201<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Investment expenses</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses', window );">Net investment income (excluding net realized capital gains or losses)</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized capital gains (losses)</a></td>
<td class="num">(320)<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Net investment income</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings', window );">Credit-related impairment loss</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings', window );">Yield-related impairment loss</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember', window );">Supporting experience- rated products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Schedule of Investment Income, Reported Amounts, by Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Net investment income</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Schedule of Investment Income, Reported Amounts, by Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Gross investment income</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=cvs_MortgageLoansMember', window );">Mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Schedule of Investment Income, Reported Amounts, by Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Gross investment income</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Schedule of Investment Income, Reported Amounts, by Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Gross investment income</a></td>
<td class="nump">$ 448<span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit-Related Impairment Loss, Debt Securities, Available-For-Sale, Recognized In Earnings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_InvestmentIncomeExcludingCapitalGainsOrLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Income, Excluding Capital Gains Or Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_InvestmentIncomeExcludingCapitalGainsOrLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cvs_SupportingExperienceRatedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=cvs_MortgageLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=cvs_MortgageLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583583184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Realized Gains (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales</a></td>
<td class="nump">$ 4,243<span></span>
</td>
<td class="nump">$ 3,572<span></span>
</td>
<td class="nump">$ 3,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized capital gains</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized capital losses</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365575853536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">$ 20,280<span></span>
</td>
<td class="nump">$ 23,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">2,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">States, municipalities and political subdivisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember', window );">U.S. corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">8,958<span></span>
</td>
<td class="nump">9,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember', window );">Foreign securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Commercial mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember', window );">Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,810<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable preferred securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">12,951<span></span>
</td>
<td class="nump">9,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">20,280<span></span>
</td>
<td class="nump">23,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">33,407<span></span>
</td>
<td class="nump">32,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">6,902<span></span>
</td>
<td class="nump">4,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">2,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">8,878<span></span>
</td>
<td class="nump">7,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">6,049<span></span>
</td>
<td class="nump">4,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">18,351<span></span>
</td>
<td class="nump">20,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">24,400<span></span>
</td>
<td class="nump">25,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">2,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">2,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | States, municipalities and political subdivisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | States, municipalities and political subdivisions | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | States, municipalities and political subdivisions | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">3,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | States, municipalities and political subdivisions | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">8,958<span></span>
</td>
<td class="nump">9,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. corporate securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. corporate securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">8,897<span></span>
</td>
<td class="nump">9,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. corporate securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Foreign securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Foreign securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Foreign securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,542<span></span>
</td>
<td class="nump">2,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Foreign securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Residential mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Residential mortgage-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Residential mortgage-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Residential mortgage-backed securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial mortgage-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial mortgage-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial mortgage-backed securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Other asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,810<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Other asset-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Other asset-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,810<span></span>
</td>
<td class="nump">2,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Other asset-backed securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Redeemable preferred securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Redeemable preferred securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Redeemable preferred securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Redeemable preferred securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365572713968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Changes in Level 3 Financial Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract', window );"><strong>Net realized and unrealized capital gains (losses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci', window );">Change in unrealized capital losses included in OCI associated with Level 3 financial assets</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract', window );"><strong>Net realized and unrealized capital gains (losses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Included in earnings</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Included in other comprehensive income (loss)</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">States, municipalities and political subdivisions | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract', window );"><strong>Net realized and unrealized capital gains (losses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Included in earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Included in other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember', window );">U.S. corporate securities | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract', window );"><strong>Net realized and unrealized capital gains (losses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Included in earnings</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Included in other comprehensive income (loss)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember', window );">Foreign securities | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract', window );"><strong>Net realized and unrealized capital gains (losses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Included in earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Included in other comprehensive income (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember', window );">Other asset-backed securities | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract', window );"><strong>Net realized and unrealized capital gains (losses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Included in earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Included in other comprehensive income (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable preferred securities | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract', window );"><strong>Net realized and unrealized capital gains (losses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Included in earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Included in other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract', window );"><strong>Net realized and unrealized capital gains (losses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Included in earnings</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Included in other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvs_OtherAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586420688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Gross Transfers Into (Out Of) Level 3 (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Net transfers into (out of) Level 3</a></td>
<td class="num">$ (29)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Gross transfers into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Gross transfers out of Level 3</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Net transfers into (out of) Level 3</a></td>
<td class="num">$ (29)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365575672864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Carrying Value and Fair Value Classified by Level (Details) - Nonrecurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgagesHeldForSaleFairValueDisclosure', window );">Mortgage loans</a></td>
<td class="nump">$ 1,044<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure', window );">Investment contract liabilities with a fixed maturity</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure', window );">Investment contracts liabilities without a fixed maturity</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt</a></td>
<td class="nump">52,257<span></span>
</td>
<td class="nump">56,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Carrying Value | Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgagesHeldForSaleFairValueDisclosure', window );">Mortgage loans</a></td>
<td class="nump">978<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure', window );">Investment contract liabilities with a fixed maturity</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure', window );">Investment contracts liabilities without a fixed maturity</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt</a></td>
<td class="nump">47,653<span></span>
</td>
<td class="nump">64,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 1 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgagesHeldForSaleFairValueDisclosure', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure', window );">Investment contract liabilities with a fixed maturity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure', window );">Investment contracts liabilities without a fixed maturity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt</a></td>
<td class="nump">47,653<span></span>
</td>
<td class="nump">64,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 2 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgagesHeldForSaleFairValueDisclosure', window );">Mortgage loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure', window );">Investment contract liabilities with a fixed maturity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure', window );">Investment contracts liabilities without a fixed maturity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 3 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgagesHeldForSaleFairValueDisclosure', window );">Mortgage loans</a></td>
<td class="nump">978<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure', window );">Investment contract liabilities with a fixed maturity</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure', window );">Investment contracts liabilities without a fixed maturity</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Contracts With Fixed Maturity, Fair Value Disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Contracts Without A Fixed Maturity, Fair Value Disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgagesHeldForSaleFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of mortgage loans held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgagesHeldForSaleFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365572571904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Separate Accounts Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">$ 3,228<span></span>
</td>
<td class="nump">$ 5,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountsLiability', window );">Separate accounts liabilities</a></td>
<td class="num">(3,228)<span></span>
</td>
<td class="num">(5,087)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">3,313<span></span>
</td>
<td class="nump">5,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountsLiability', window );">Separate accounts liabilities</a></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">2,677<span></span>
</td>
<td class="nump">4,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Common/collective trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Common/collective trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">3,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">3,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Common/collective trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Common/collective trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems', window );"><strong>Fair Value, Separate Account Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate accounts assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset at fair value held for benefit of separate account policyholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124508989&amp;loc=d3e19393-158473<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6484091&amp;loc=d3e19268-158472<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=124505678&amp;loc=SL117422397-158474<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for variable contract in which all or portion of contract holder's funds is allocated to specific separate account and supported by assets held in separate account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124508989&amp;loc=SL117422267-158473<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=124505678&amp;loc=SL117422401-158474<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6484091&amp;loc=d3e19268-158472<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124508989&amp;loc=SL117422267-158473<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssetCategoryAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssetCategoryAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssetCategoryAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssetCategoryAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssetCategoryAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssetCategoryAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssetCategoryAxis=cvs_CommonAndCollectiveTrustsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssetCategoryAxis=cvs_CommonAndCollectiveTrustsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576514480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Narrative (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="num">$ (29)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Separate Accounts, financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers into (out of) Level 3, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssetCategoryAxis=cvs_SeparateAccountFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssetCategoryAxis=cvs_SeparateAccountFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586773744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, beginning of the period</a></td>
<td class="nump">$ 79,121<span></span>
</td>
<td class="nump">$ 79,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(431)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, end of the period</a></td>
<td class="nump">78,150<span></span>
</td>
<td class="nump">79,121<span></span>
</td>
<td class="nump">79,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember', window );">Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, beginning of the period</a></td>
<td class="nump">45,130<span></span>
</td>
<td class="nump">45,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, end of the period</a></td>
<td class="nump">44,159<span></span>
</td>
<td class="nump">45,130<span></span>
</td>
<td class="nump">45,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember', window );">Health Care Benefits | Disposal Group, Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="num">(971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyServicesSegmentMember', window );">Pharmacy Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, beginning of the period</a></td>
<td class="nump">23,615<span></span>
</td>
<td class="nump">23,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, end of the period</a></td>
<td class="nump">23,615<span></span>
</td>
<td class="nump">23,615<span></span>
</td>
<td class="nump">23,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyServicesSegmentMember', window );">Pharmacy Services | Disposal Group, Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember', window );">Retail/ LTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, beginning of the period</a></td>
<td class="nump">10,376<span></span>
</td>
<td class="nump">10,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, end of the period</a></td>
<td class="nump">10,376<span></span>
</td>
<td class="nump">$ 10,376<span></span>
</td>
<td class="nump">$ 10,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember', window );">Retail/ LTC | Disposal Group, Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583748208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,150<span></span>
</td>
<td class="nump">79,121<span></span>
</td>
<td class="nump">$ 79,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cvs_LongTermCareReportingUnitMember', window );">Long-Term Care Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cvs_LongTermCareReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cvs_LongTermCareReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365573379504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherAcquiredIntangibleAssetsLineItems', window );"><strong>Other Intangible Assets[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets, Trademarks</a></td>
<td class="nump">$ 10,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,498<span></span>
</td>
<td class="nump">$ 10,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(13,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,077)<span></span>
</td>
<td class="num">(12,727)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross</a></td>
<td class="nump">37,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,859<span></span>
</td>
<td class="nump">41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale', window );">Intangible assets, net</a></td>
<td class="nump">24,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,782<span></span>
</td>
<td class="nump">$ 29,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension', window );">Weighted Average Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 10 months 24 days<span></span>
</td>
<td class="text">15 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,533<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">2,259<span></span>
</td>
<td class="nump">$ 2,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherAcquiredIntangibleAssetsLineItems', window );"><strong>Other Intangible Assets[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale', window );">Intangible assets, net</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations | Omnicare Long-Term Care Business | Retail/ LTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherAcquiredIntangibleAssetsLineItems', window );"><strong>Other Intangible Assets[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on assets held for sale</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember', window );">Customer contracts/relationships and covenants not to compete</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherAcquiredIntangibleAssetsLineItems', window );"><strong>Other Intangible Assets[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">21,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,206<span></span>
</td>
<td class="nump">25,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(10,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,668)<span></span>
</td>
<td class="num">(10,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net carrying amount</a></td>
<td class="nump">10,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,538<span></span>
</td>
<td class="nump">$ 14,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension', window );">Weighted Average Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 3 months 18 days<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherAcquiredIntangibleAssetsLineItems', window );"><strong>Other Intangible Assets[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">1,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(1,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net carrying amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension', window );">Weighted Average Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cvs_ProviderNetworksMember', window );">Provider networks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherAcquiredIntangibleAssetsLineItems', window );"><strong>Other Intangible Assets[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">4,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,203<span></span>
</td>
<td class="nump">$ 4,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(862)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net carrying amount</a></td>
<td class="nump">3,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,341<span></span>
</td>
<td class="nump">$ 3,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension', window );">Weighted Average Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cvs_ValueOfBusinessAcquiredMember', window );">Value of Business Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherAcquiredIntangibleAssetsLineItems', window );"><strong>Other Intangible Assets[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net carrying amount</a></td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension', window );">Weighted Average Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OtherAcquiredIntangibleAssetsLineItems', window );"><strong>Other Intangible Assets[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net carrying amount</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension', window );">Weighted Average Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Net (Excluding Goodwill), Including Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OtherAcquiredIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OtherAcquiredIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_OmnicareLongTermCareBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cvs_OmnicareLongTermCareBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cvs_ProviderNetworksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cvs_ProviderNetworksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cvs_ValueOfBusinessAcquiredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cvs_ValueOfBusinessAcquiredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590002624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">1,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2027</a></td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365574461184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>store</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>store</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity', window );">Proceeds from sale-leaseback transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 101.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">Gains from sale-leaseback transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OfficeRealEstateOptimizationCharges', window );">Office real estate optimization charges</a></td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfStoresPlannedClosure', window );">Number of stores, planned closure | store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1,358.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertySubjectToOperatingLeaseMember', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OfficeRealEstateOptimizationCharges', window );">Office real estate optimization charges</a></td>
<td class="nump">$ 71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember', window );">Retail/ LTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfStoresPlannedClosure', window );">Number of stores, planned closure | store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod', window );">Number of stores, annual planned closures for closure period | store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember', window );">Retail/ LTC | Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Operating lease, right-of-use asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Distribution centers and Corporate offices | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease term (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Distribution centers and Corporate offices | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term (in years)</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease term (in years)</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OfficeRealEstateOptimizationCharges', window );">Office real estate optimization charges</a></td>
<td class="nump">$ 44.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property and equipment | Retail/ LTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure', window );">Property and equipment, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Stores, Annual Planned Closures For Closure Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberOfStoresPlannedClosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Stores, Planned Closure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberOfStoresPlannedClosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OfficeRealEstateOptimizationCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office Real Estate Optimization Charges - Related to the abandonment of leased real estate and the related right-of-use assets and property and equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OfficeRealEstateOptimizationCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease, Right-of-Use Asset, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_StoreImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Store Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_StoreImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from principal payment received from sales-type and direct financing leases classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 230<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123398031&amp;loc=SL120154370-112784<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128295416&amp;loc=SL77919786-209982<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertySubjectToOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertySubjectToOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365573132848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of the Components of Net Lease Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,579<span></span>
</td>
<td class="nump">$ 2,633<span></span>
</td>
<td class="nump">$ 2,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FinanceLeaseCost', window );">Total finance lease costs</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Less: sublease income</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">$ 3,302<span></span>
</td>
<td class="nump">$ 3,327<span></span>
</td>
<td class="nump">$ 3,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365591940224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_CashFlowLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for operating leases</a></td>
<td class="nump">$ 2,689<span></span>
</td>
<td class="nump">$ 2,714<span></span>
</td>
<td class="nump">$ 2,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows paid for interest portion of finance leases</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows paid for principal portion of finance leases</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365575680832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 17,928<span></span>
</td>
<td class="nump">$ 19,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale', window );">Long-term operating lease liabilities</a></td>
<td class="nump">16,839<span></span>
</td>
<td class="nump">18,177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">18,538<span></span>
</td>
<td class="nump">19,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract', window );"><strong>Finance leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FinanceLeaseRightOfUseAssetGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,608<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation', window );">Accumulated depreciation</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FinanceLeaseRightOfUseAssetNet', window );">Property and equipment, net</a></td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term debt</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 1,465<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">12 years 2 months 12 days<span></span>
</td>
<td class="text">12 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">19 years 4 months 24 days<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LeasesWeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Assets And Liabilities, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Right-Of-Use Asset, Accumulated Depreciation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FinanceLeaseRightOfUseAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Right-Of-Use Asset, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FinanceLeaseRightOfUseAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FinanceLeaseRightOfUseAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Right-Of-Use Asset, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FinanceLeaseRightOfUseAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LeasesWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases, Weighted Average Discount Rate [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LeasesWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Assets And Liabilities, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Current, Including Liabilities Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Noncurrent, Including Liabilities Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Including Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365582150976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating and Finance Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">2,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">1,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">12,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">24,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(5,501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">18,538<span></span>
</td>
<td class="nump">$ 19,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLiabilityPaymentsYearOne', window );">2023</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">14,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">26,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LesseeLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(6,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">20,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future noncancelable subleases, future minimum payments</a></td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife', window );">Leases, amount due in excess of remaining estimated economic life</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Leases Liabilities Payments Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Liability, Payments, Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Liability, Payments, Due After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Liability, Payments, Due Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Liability, Payments, Due Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Liability, Payments, Due Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Liability, Payments, Due Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLiabilityPaymentsYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Liability, Payments, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLiabilityPaymentsYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LesseeLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Liability, Undiscounted Excess Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LesseeLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365591928144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details) - Health Insurance Product Line - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Incurred Health Care Claims, Net of Reinsurance</a></td>
<td class="nump">$ 131,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative Paid Health Care Claims, Net of Reinsurance</a></td>
<td class="nump">121,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented', window );">All outstanding liabilities for health care costs payable prior to 2021, net of reinsurance</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Total outstanding liabilities for health care costs payable, net of reinsurance</a></td>
<td class="nump">9,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Incurred Health Care Claims, Net of Reinsurance</a></td>
<td class="nump">62,259<span></span>
</td>
<td class="nump">$ 62,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative Paid Health Care Claims, Net of Reinsurance</a></td>
<td class="nump">62,144<span></span>
</td>
<td class="nump">$ 54,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Incurred Health Care Claims, Net of Reinsurance</a></td>
<td class="nump">69,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative Paid Health Care Claims, Net of Reinsurance</a></td>
<td class="nump">$ 59,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClaimsDevelopmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClaimsDevelopmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671315-158438<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts for accident years not separately presented in claim development information. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590774528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Health Care Costs Payable - Narrative (Details)<br> $ in Billions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember', window );">Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet', window );">Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) claims liability, net</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of incurred-but-not-reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671321-158438<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671317-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586530352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Health Care Costs Payable - Liability for Unpaid Claims and Claims Adjustment Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems', window );"><strong>Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Total health care costs payable</a></td>
<td class="nump">$ 10,406<span></span>
</td>
<td class="nump">$ 8,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember', window );">Health Insurance Product Line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems', window );"><strong>Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Short-duration health care costs payable, net of reinsurance</a></td>
<td class="nump">9,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Reinsurance recoverables</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem', window );">Insurance lines other than short duration</a></td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Total health care costs payable</a></td>
<td class="nump">$ 10,406<span></span>
</td>
<td class="nump">$ 8,808<span></span>
</td>
<td class="nump">$ 7,936<span></span>
</td>
<td class="nump">$ 6,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21412-158489<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671315-158438<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reconciling item for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671315-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365572535552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Health Care Costs Payable - Components of Change in Health Care Costs Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Health care costs payable, beginning of period</a></td>
<td class="nump">$ 8,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Less: Claims paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Health care costs payable, end of period</a></td>
<td class="nump">10,406<span></span>
</td>
<td class="nump">$ 8,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember', window );">Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Less: Claims paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts', window );">Benefit costs recorded in other insurance liabilities</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember', window );">Corporate/ Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Less: Claims paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts', window );">Benefit costs recorded in other insurance liabilities</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember', window );">Health Insurance Product Line</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Health care costs payable, beginning of period</a></td>
<td class="nump">8,808<span></span>
</td>
<td class="nump">7,936<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Less: Reinsurance recoverables</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Health care costs payable, beginning of period, net</a></td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">7,926<span></span>
</td>
<td class="nump">6,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Acquisitions, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Add: Components of incurred health care costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">71,541<span></span>
</td>
<td class="nump">64,761<span></span>
</td>
<td class="nump">55,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(654)<span></span>
</td>
<td class="num">(788)<span></span>
</td>
<td class="num">(429)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total incurred health care costs</a></td>
<td class="nump">70,887<span></span>
</td>
<td class="nump">63,973<span></span>
</td>
<td class="nump">55,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Less: Claims paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">61,640<span></span>
</td>
<td class="nump">56,323<span></span>
</td>
<td class="nump">48,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">7,646<span></span>
</td>
<td class="nump">6,792<span></span>
</td>
<td class="nump">6,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total claims paid</a></td>
<td class="nump">69,286<span></span>
</td>
<td class="nump">63,115<span></span>
</td>
<td class="nump">54,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumDeficiencyReserveLiability', window );">Add: Premium deficiency reserve</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Health care costs payable, end of period, net</a></td>
<td class="nump">10,401<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">7,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Add: Reinsurance recoverables</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Health care costs payable, end of period</a></td>
<td class="nump">10,406<span></span>
</td>
<td class="nump">8,808<span></span>
</td>
<td class="nump">7,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumDeficiencyReserveLiability', window );">Premium deficiency reserve</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PremiumDeficiencyReserveLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reserves related to expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), in excess of existing reserves plus anticipated future premiums and reinsurance recoveries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PremiumDeficiencyReserveLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21412-158489<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthInsuranceProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365569978224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings and Credit Agreements - Schedule of Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 18, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 51,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liabilities</a></td>
<td class="nump">1,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LongtermDebtGrossAndLeaseObligation', window );">Total debt principal</a></td>
<td class="nump">52,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt premiums</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet', window );">Debt discounts and deferred financing costs</a></td>
<td class="num">(696)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Long-term debt and lease obligation</a></td>
<td class="nump">52,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="num">(1,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale', window );">Long-term debt</a></td>
<td class="nump">$ 50,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-term debt (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Long-term debt (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.5% senior notes due July 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.75% senior notes due November 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.75% senior notes due December 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% senior notes due December 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.8% senior notes due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4% senior notes due December 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.375% senior notes due August 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.625% senior notes due August 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.5% senior notes due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5% senior notes due December 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5% senior notes due December 2024 | Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.1% senior notes due March 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% senior notes due July 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 2,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.875% senior notes due June 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">2.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3% senior notes due August 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.625% senior notes due April 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.25% senior notes due June 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.3% senior notes due August 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.3% senior notes due March 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.25% senior notes due August 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.75% senior notes due April 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.75% senior notes due August 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.875% senior notes due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">1.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.125% senior notes due September 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.875% senior notes due July 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.625% senior notes due June 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">6.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.75% senior notes due December 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.78% senior notes due March 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.125% senior notes due September 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.125% senior notes due April 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.7% senior notes due August 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% senior notes due May 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.5% senior notes due May 2042</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.125% senior notes due November 2042</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.3% senior notes due December 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% senior notes due March 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% senior notes due July 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% senior notes due August 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.05% senior notes due March 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">5.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.25% senior notes due April 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other Debt Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including liabilities held for sale, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LongtermDebtGrossAndLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Gross And Lease Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LongtermDebtGrossAndLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.5DueJuly2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.5DueJuly2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.75DueNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.75DueNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.75DueDecember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.75DueDecember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.75DueDecember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.75DueDecember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.8DueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.8DueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4DueDecember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4DueDecember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.375DueAugust2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.375DueAugust2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.625DueAugust2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.625DueAugust2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.5DueNovember2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.5DueNovember2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5DueDecember2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5DueDecember2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.1DueMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.1DueMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.875DueJuly2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.875DueJuly2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.875DueJune2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.875DueJune2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3DueAugust2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3DueAugust2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point625PercentApril2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point625PercentApril2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes6.25DueJune2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes6.25DueJune2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes1Point3PercentAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes1Point3PercentAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.3DueMarch2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.3DueMarch2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.25DueAugust2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.25DueAugust2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point75PercentApril2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point75PercentApril2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes1Point75PercentAugust2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes1Point75PercentAugust2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes1Point875PercentFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes1Point875PercentFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2Point125PercentDueSeptember2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2Point125PercentDueSeptember2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.875DueJuly2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.875DueJuly2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes6.625DueJune2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes6.625DueJune2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes6.75DueDecember2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes6.75DueDecember2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.78DueMarch2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.78DueMarch2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes6.125DueSeptember2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes6.125DueSeptember2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4Point125PercentApril2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4Point125PercentApril2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2Point7PercentAugust2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2Point7PercentAugust2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5.75DueMay2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5.75DueMay2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.5DueMay2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.5DueMay2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.125DueNovember2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.125DueNovember2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5.3DueDecember2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5.3DueDecember2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.75DueMarch2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.75DueMarch2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5.125DueJuly2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5.125DueJuly2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.875DueAugust2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.875DueAugust2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5.05DueMarch2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes5.05DueMarch2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4Point25PercentApril2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4Point25PercentApril2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365591851760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings and Credit Agreements - Debt Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">3,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">2,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">3,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">37,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Subtotal</a></td>
<td class="nump">51,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liabilities</a></td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LongtermDebtGrossAndLeaseObligation', window );">Total debt principal</a></td>
<td class="nump">$ 52,753<span></span>
</td>
<td class="nump">$ 56,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LongtermDebtGrossAndLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Gross And Lease Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LongtermDebtGrossAndLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583553120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings and Credit Agreements - Short-term Borrowings (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable', window );">Federal home loan bank advances maximum amount available</a></td>
<td class="nump">$ 915,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Back-Up Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility, Expiring May 16, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility, Expiring May 11, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility, Expiring May 16, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_FederalHomeLoanBankAdvancesMember', window );">Federal Home Loan Bank Advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum advances or credit lines available from the Federal Home Loan Bank (FHLB).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13(3)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6479118&amp;loc=d3e64650-112822<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22 (b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_BackUpCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_BackUpCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_RevolvingCreditFacilityExpiringMay162025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_RevolvingCreditFacilityExpiringMay162025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_RevolvingCreditFacilityExpiringMay112026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_RevolvingCreditFacilityExpiringMay112026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_RevolvingCreditFacilityExpiringMay162027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_RevolvingCreditFacilityExpiringMay162027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_FederalHomeLoanBankAdvancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_FederalHomeLoanBankAdvancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365574340048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings and Credit Agreements - Long-term Borrowings (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 18, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Redeemed principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,211,000,000<span></span>
</td>
<td class="nump">$ 10,254,000,000<span></span>
</td>
<td class="nump">$ 15,631,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt</a></td>
<td class="nump">$ 987,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Payments for derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Loss on net cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Premium paid in excess of debt principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="nump">$ 332,000,000<span></span>
</td>
<td class="nump">$ 619,000,000<span></span>
</td>
<td class="nump">$ 706,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of deferred debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DebtExtinguishmentFees', window );">Debt extinguishment fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,000,000<span></span>
</td>
<td class="nump">$ 363,000,000<span></span>
</td>
<td class="nump">674,000,000<span></span>
</td>
<td class="nump">766,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 452,000,000<span></span>
</td>
<td class="nump">$ 1,440,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.5% senior notes due July 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Redeemed principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.75% senior notes due November 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Redeemed principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.75% senior notes due December 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Redeemed principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% senior notes due December 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Redeemed principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.125% senior notes due September 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.625% senior notes due April 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.75% senior notes due April 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.125% senior notes due April 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.125%<span></span>
</td>
<td class="nump">4.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.25% senior notes due April 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.7% senior notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Aggregate principal of debt extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.3% senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Aggregate principal of debt extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Outstanding Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Aggregate principal of debt extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4% senior notes due December 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Aggregate principal of debt extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,000,000<span></span>
</td>
<td class="nump">$ 723,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.7% senior notes due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Aggregate principal of debt extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.1% senior notes due March 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Aggregate principal of debt extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.3% senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Aggregate principal of debt extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DebtExtinguishmentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Extinguishment Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DebtExtinguishmentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.5DueJuly2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.5DueJuly2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.75DueNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.75DueNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.75DueDecember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2.75DueDecember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.75DueDecember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.75DueDecember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2Point125PercentDueSeptember2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes2Point125PercentDueSeptember2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point625PercentApril2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point625PercentApril2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point75PercentApril2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point75PercentApril2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4Point125PercentApril2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4Point125PercentApril2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4Point25PercentApril2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4Point25PercentApril2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point70PercentDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3Point70PercentDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4PointThreePercentDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4PointThreePercentDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_OutstandingSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_OutstandingSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4DueDecember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4DueDecember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.7DueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes3.7DueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.1DueMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes4.1DueMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvs_SeniorNotes43Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvs_SeniorNotes43Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365582911632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Plans and Other Postretirement Benefits - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer contributions</a></td>
<td class="nump">$ 567<span></span>
</td>
<td class="nump">$ 552<span></span>
</td>
<td class="nump">$ 520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution', window );">Multiemployer plans, plan contributions</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation</a></td>
<td class="nump">4,740<span></span>
</td>
<td class="nump">6,009<span></span>
</td>
<td class="nump">6,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">$ (173)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target investment allocations</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target investment allocations</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Real estate investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target investment allocations</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Private equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target investment allocations</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan | Hedge fund investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target investment allocations</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution', window );">Multiemployer plans, plan contributions</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MultiemployerPlanPensionInsignificantPlanContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by multiemployer pension plan from all employers participating in multiemployer pension plan determined to be individually insignificant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=SL14450678-114947<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MultiemployerPlanPensionInsignificantPlanContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_RealEstateInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_RealEstateInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_PrivateEquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_PrivateEquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583920400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details) - Pension Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, beginning of year</a></td>
<td class="nump">$ 6,009<span></span>
</td>
<td class="nump">$ 6,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial gain</a></td>
<td class="num">(1,011)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefit payments</a></td>
<td class="num">(387)<span></span>
</td>
<td class="num">(408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement', window );">Settlements</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, end of year</a></td>
<td class="nump">4,740<span></span>
</td>
<td class="nump">6,009<span></span>
</td>
<td class="nump">6,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning balance</a></td>
<td class="nump">6,677<span></span>
</td>
<td class="nump">6,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(968)<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefit payments</a></td>
<td class="num">(387)<span></span>
</td>
<td class="num">(408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending balance</a></td>
<td class="nump">5,346<span></span>
</td>
<td class="nump">6,677<span></span>
</td>
<td class="nump">$ 6,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Assets (liabilities) recognized on the consolidated balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets reflected in other assets</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities reflected in accrued expenses</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities reflected in other long-term liabilities</a></td>
<td class="num">(197)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net assets</a></td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365574498640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Cost (Income) (Details) - Pension Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(309)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net actuarial loss</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (income)</a></td>
<td class="num">$ (173)<span></span>
</td>
<td class="num">$ (186)<span></span>
</td>
<td class="num">$ (218)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590074080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Assumptions used to determine benefit obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Assumptions used to determine net benefit costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected long-term rate of return on plan assets</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583230832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details) - Pension Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 5,346<span></span>
</td>
<td class="nump">$ 6,677<span></span>
</td>
<td class="nump">$ 6,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,299<span></span>
</td>
<td class="nump">5,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,225<span></span>
</td>
<td class="nump">3,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Cash and cash equivalents | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Cash and cash equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Cash and cash equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Cash and cash equivalents | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Debt securities | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,403<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,837<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. government securities | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. government securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. government securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. government securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">States, municipalities and political subdivisions | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">States, municipalities and political subdivisions | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">States, municipalities and political subdivisions | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">States, municipalities and political subdivisions | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. corporate securities | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">2,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. corporate securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. corporate securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">2,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. corporate securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Foreign securities | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Foreign securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Foreign securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Foreign securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Residential mortgage-backed securities | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Residential mortgage-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Residential mortgage-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Residential mortgage-backed securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Commercial mortgage-backed securities | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Commercial mortgage-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Commercial mortgage-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Commercial mortgage-backed securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other asset-backed securities | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other asset-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other asset-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other asset-backed securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Redeemable preferred securities | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Redeemable preferred securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Redeemable preferred securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Redeemable preferred securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Equity securities | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Equity securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Equity securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Equity securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. domestic | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. domestic | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. domestic | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">U.S. domestic | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">International | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">International | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">International | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">International | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Domestic real estate | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Domestic real estate | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Domestic real estate | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Domestic real estate | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other investments | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other investments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other investments | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other investments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Real estate | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Real estate | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Real estate | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Real estate | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Common/collective trusts | Total Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Common/collective trusts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Common/collective trusts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Common/collective trusts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Common/collective trusts, Equity Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Plan assets, investment within plan asset category, amount</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Common/collective trusts, Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount', window );">Plan assets, investment within plan asset category, amount</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other receivables | Fair Value Measured at Net Asset Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Private equity investments | Fair Value Measured at Net Asset Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Hedge fund investments | Fair Value Measured at Net Asset Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment within defined benefit plan asset category.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ForeignCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ForeignCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=cvs_RedeemablePreferredSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=cvs_RedeemablePreferredSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=cvs_EquitySecuritiesDomesticRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=cvs_EquitySecuritiesDomesticRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_PrivateEquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_PrivateEquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583687264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details) - Pension Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning balance</a></td>
<td class="nump">$ 6,677<span></span>
</td>
<td class="nump">$ 6,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending balance</a></td>
<td class="nump">5,346<span></span>
</td>
<td class="nump">6,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning balance</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Actual return on plan assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases, sales and settlements</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending balance</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember', window );">Real estate | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Beginning balance</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Actual return on plan assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases, sales and settlements</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Ending balance</a></td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(C)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365575724240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028-2032</a></td>
<td class="nump">1,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028-2032</a></td>
<td class="nump">$ 59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365591921440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Provision (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 2,803<span></span>
</td>
<td class="nump">$ 2,285<span></span>
</td>
<td class="nump">$ 2,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">665<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current taxes</a></td>
<td class="nump">3,538<span></span>
</td>
<td class="nump">2,950<span></span>
</td>
<td class="nump">3,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,569)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(506)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income taxes</a></td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="num">(564)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="nump">$ 2,522<span></span>
</td>
<td class="nump">$ 2,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365573136464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_HealthInsurerFeeTaxEffectPercent', window );">Health insurer fee</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent', window );">Legal charges</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Basis difference upon disposition of subsidiary</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic', window );">Prior year refunds and unrecognized tax benefits</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
<td class="nump">26.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal Charges, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_HealthInsurerFeeTaxEffectPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the tax effect of the health care reform's non-tax deductible health insurer fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_HealthInsurerFeeTaxEffectPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to domestic income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576714144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Lease and rents</a></td>
<td class="nump">$ 5,242<span></span>
</td>
<td class="nump">$ 5,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements', window );">Legal charges</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Employee benefits</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances', window );">Bad debts and other allowances</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss and capital loss carryforwards</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred income</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Insurance reserves</a></td>
<td class="nump">455<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investments</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DeferredTaxAssetsPayrollTaxDeferral', window );">Payroll tax deferral</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(532)<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets</a></td>
<td class="nump">8,121<span></span>
</td>
<td class="nump">7,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DeferredTaxLiabilitiesRetirementBenefits', window );">Retirement benefits</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease and rents</a></td>
<td class="num">(4,639)<span></span>
</td>
<td class="num">(4,947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(7,139)<span></span>
</td>
<td class="num">(8,381)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(11,870)<span></span>
</td>
<td class="num">(13,767)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income tax liabilities</a></td>
<td class="num">(3,749)<span></span>
</td>
<td class="num">$ (6,270)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DeferredTaxAssetsPayrollTaxDeferral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Payroll Tax Deferral</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DeferredTaxAssetsPayrollTaxDeferral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Depreciation and Amortization - Amount of deferred tax liability attributable to taxable temporary differences from depreciation and amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DeferredTaxLiabilitiesRetirementBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Retirement Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DeferredTaxLiabilitiesRetirementBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365587309408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss and capital loss carryforwards</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Income tax penalties and interest accrued</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">$ 336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365586303488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">$ 768<span></span>
</td>
<td class="nump">$ 655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior years</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(166)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Expiration of statutes of limitation</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 446<span></span>
</td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">$ 768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365574458464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued employee stock purchase plan (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased', window );">Average purchase price of shares purchased (in dollars per share)</a></td>
<td class="nump">$ 78.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember', window );">Restricted Stock Units and Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Compensation not yet recognized, other than options</a></td>
<td class="nump">$ 619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation not yet recognized, period for recognition</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Vested in period, fair value</a></td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvs_EmployeeStockOptionsAndStockAppreciationRightsMember', window );">Employee Stock Options and Stock Appreciation Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation not yet recognized, period for recognition</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation not yet recognized, options</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber', window );">Expected to vest (in shares)</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">29,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvs_CVSHealth2017IncentiveCompensationPlanMember', window );">CVS Health 2017 Incentive Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">58,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvs_AetnaInc2010StockIncentivePlanMember', window );">Aetna Inc 2010 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvs_EmployeeStockOptionsAndStockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvs_EmployeeStockOptionsAndStockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvs_CVSHealth2017IncentiveCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvs_CVSHealth2017IncentiveCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvs_AetnaInc2010StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvs_AetnaInc2010StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365591859088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Restricted Stock Activity (Details) - Restricted Stock Units and Performance Share Units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="nump">14,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">5,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(5,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(1,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="nump">12,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value (in dollars per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 63.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">101.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">58.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">72.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 80.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates', window );">Restricted stock units and performance stock units vested if actual payout rates are applied (in shares)</a></td>
<td class="nump">8,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Actual Payout Rates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581605968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Stock Option and SAR Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from stock options exercised (including ESPP)</a></td>
<td class="nump">$ 551,000<span></span>
</td>
<td class="nump">$ 549,000<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for taxes for net share settlement of equity awards</a></td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member', window );">Stock options granted through 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member', window );">Stock options granted subsequent to 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvs_EmployeeStockOptionsAndStockAppreciationRightsMember', window );">Employee Stock Options and Stock Appreciation Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from stock options exercised (including ESPP)</a></td>
<td class="nump">$ 551,000<span></span>
</td>
<td class="nump">549,000<span></span>
</td>
<td class="nump">264,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for taxes for net share settlement of equity awards</a></td>
<td class="nump">370,000<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options and SARs exercised</a></td>
<td class="nump">118,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue', window );">Fair value of stock options and SARs vested</a></td>
<td class="nump">$ 219,000<span></span>
</td>
<td class="nump">$ 224,000<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding at beginning of year (in shares)</a></td>
<td class="nump">19,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted (in shares)</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares exercised (in shares)</a></td>
<td class="num">(4,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares forfeited (in shares)</a></td>
<td class="num">(478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares expired (in shares)</a></td>
<td class="num">(615)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding at end of year (in shares)</a></td>
<td class="nump">15,040<span></span>
</td>
<td class="nump">19,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding at beginning of year ($ per share)</a></td>
<td class="nump">$ 71.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted ($ per share)</a></td>
<td class="nump">101.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised ($ per share)</a></td>
<td class="nump">75.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited ($ per share)</a></td>
<td class="nump">70.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired ($ per share)</a></td>
<td class="nump">99.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding at end of year ($ per share)</a></td>
<td class="nump">$ 73.15<span></span>
</td>
<td class="nump">$ 71.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term, outstanding at end of year</a></td>
<td class="text">4 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic value outstanding at end of year</a></td>
<td class="nump">$ 340,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable at end of year (in shares)</a></td>
<td class="nump">7,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price exercisable at end of year ($ per share)</a></td>
<td class="nump">$ 72.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term exercisable at end of year</a></td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value exercisable at end of year</a></td>
<td class="nump">$ 184,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares vested at end of year and expected to vest in the future (in shares)</a></td>
<td class="nump">14,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price vested at end of year and expected to vest in the future ($ per share)</a></td>
<td class="nump">$ 72.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term vested at end of year and expected to vest in the future</a></td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value vested at end of year and expected to vest in the future</a></td>
<td class="nump">$ 336,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvs_EmployeeStockOptionsAndStockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvs_EmployeeStockOptionsAndStockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581594336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Valuation Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">1.12%<span></span>
</td>
<td class="nump">1.34%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">23.54%<span></span>
</td>
<td class="nump">25.27%<span></span>
</td>
<td class="nump">37.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="nump">$ 12.55<span></span>
</td>
<td class="nump">$ 13.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">2.18%<span></span>
</td>
<td class="nump">2.68%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">27.34%<span></span>
</td>
<td class="nump">27.10%<span></span>
</td>
<td class="nump">25.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.46%<span></span>
</td>
<td class="nump">1.13%<span></span>
</td>
<td class="nump">0.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 24.15<span></span>
</td>
<td class="nump">$ 14.57<span></span>
</td>
<td class="nump">$ 8.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365572750144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Share Repurchases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Dec. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cvs_A2022RepurchaseProgramMember', window );">2022 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized repurchase amount</a></td>
<td class="nump">$ 10,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cvs_A2021RepurchaseProgramMember', window );">2021 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized repurchase amount</a></td>
<td class="nump">$ 6,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during the period (in shares)</a></td>
<td class="nump">34,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during period, value</a></td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cvs_A2022RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cvs_A2022RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cvs_A2021RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cvs_A2021RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576547952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Accelerated Share Repurchases (Details) - 2021 Repurchase Program - USD ($)<br> $ / shares in Units, shares in Millions, $ in Billions</strong></div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>Jan. 04, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cvs_A2021RepurchaseProgramMember', window );">Citibank, N.A. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AcceleratedShareRepurchasesAgreementAmount', window );">ASR agreement, amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PaymentsForAcceleratedShareRepurchasesAmount', window );">Payments for ASR, amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares', window );">ASR percent of notional amount received in shares</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased', window );">Shares repurchased under ASR agreement (in shares)</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 92.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram', window );">ASR, shares to be received at the end of program as a percent of notional amount</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares', window );">ASR, maximum amount of shares received or delivered</a></td>
<td class="nump">43.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cvs_A2021RepurchaseProgramMember', window );">Barclays Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AcceleratedShareRepurchasesAgreementAmount', window );">ASR agreement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PaymentsForAcceleratedShareRepurchasesAmount', window );">Payments for ASR, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares', window );">ASR percent of notional amount received in shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased', window );">Shares repurchased under ASR agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram', window );">ASR, shares to be received at the end of program as a percent of notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_TransferOfSharesToTreasuryStockValue', window );">Transfer of shares to treasury stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cvs_A2021RepurchaseProgramMember', window );">Barclays Bank | Forward Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Forward contract, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchase Program, Maximum Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AcceleratedShareRepurchasesAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AcceleratedShareRepurchasesAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Number Of Shares Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Percent Of Notional Amount In Shares To Be Received At End Of Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Percent Of Notional Amount Received In Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PaymentsForAcceleratedShareRepurchasesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Accelerated Share Repurchases, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PaymentsForAcceleratedShareRepurchasesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_TransferOfSharesToTreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Shares To Treasury Stock Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_TransferOfSharesToTreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cvs_A2021RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cvs_A2021RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvs_CitibankNAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvs_CitibankNAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvs_BarclaysBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvs_BarclaysBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365573815552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Dividends (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Cash dividend declared (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent', window );">Quarterly dividends declared, percent increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Cash dividend declared (USD per share)</a></td>
<td class="nump">$ 0.605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576293680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Regulatory Requirements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired', window );">Estimated minimum statutory surplus required by regulators</a></td>
<td class="nump">$ 7,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldByInsuranceRegulators', window );">Investments on deposit with regulatory bodies</a></td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval', window );">Estimated maximum dividend distributions permitted in 2023 without prior regulatory approval</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=cvs_InsuranceAndHMOMember', window );">Insurance and HMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount', window );">Statutory net income</a></td>
<td class="nump">2,851<span></span>
</td>
<td class="nump">$ 3,302<span></span>
</td>
<td class="nump">$ 3,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance', window );">Estimated statutory capital and surplus</a></td>
<td class="nump">15,503<span></span>
</td>
<td class="nump">$ 14,879<span></span>
</td>
<td class="nump">$ 13,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries', window );">Dividends paid</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldByInsuranceRegulators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of cash and investment securities on deposit with state regulatory authorities in connection with capital requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123600598&amp;loc=SL75763979-209797<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldByInsuranceRegulators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents disclosure of the aggregate cash dividends paid to the entity by consolidated subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividends that can be declared or paid without approval of regulatory agency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24708-158529<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24708-158529<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net income for the period determined using accounting principles prescribed or permitted by insurance regulators.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cvs_InsuranceAndHMOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cvs_InsuranceAndHMOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365581274224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365573593760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Changes in Accumulated Other Comprehensive Income (Loss) by Component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,381<span></span>
</td>
<td class="nump">$ 69,701<span></span>
</td>
<td class="nump">$ 64,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, net of tax</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,430)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">End of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,315<span></span>
</td>
<td class="nump">75,381<span></span>
</td>
<td class="nump">69,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Net unrealized investment gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Changes in Accumulated Other Comprehensive Income (Loss) by Component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,518)<span></span>
</td>
<td class="num">(410)<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,279)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">End of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,501)<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">OCI before reclassifications, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,972)<span></span>
</td>
<td class="num">(489)<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Amounts reclassified, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Changes in Accumulated Other Comprehensive Income (Loss) by Component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">End of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Net cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Changes in Accumulated Other Comprehensive Income (Loss) by Component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">End of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">OCI before reclassifications, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Amounts reclassified, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Amount expected to be reclassified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Pension and other postretirement benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Changes in Accumulated Other Comprehensive Income (Loss) by Component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(170)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">End of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">OCI before reclassifications, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Amounts reclassified, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">AOCI Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Changes in Accumulated Other Comprehensive Income (Loss) by Component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">End of year balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,465)<span></span>
</td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">$ 1,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365582916800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumeratorForEarningsPerShareCalculationAbstract', window );"><strong>Numerator for earnings per share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 4,165<span></span>
</td>
<td class="nump">$ 7,898<span></span>
</td>
<td class="nump">$ 7,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss attributable to noncontrolling interests</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations attributable to CVS Health</a></td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 7,910<span></span>
</td>
<td class="nump">$ 7,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DenominatorForEarningsPerShareCalculationAbstract', window );"><strong>Denominator for earnings per share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic (in shares)</a></td>
<td class="nump">1,312<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares, diluted (in shares)</a></td>
<td class="nump">1,323<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Earnings per share from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings per share from continuing operations, basic (USD per share)</a></td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 5.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings per share from continuing operations, diluted (USD per share)</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="nump">$ 5.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvs_StockOptionsAndStockAppreciationRightsMember', window );">Stock Options and Stock Appreciation Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of EPS (in shares)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DenominatorForEarningsPerShareCalculationAbstract', window );"><strong>Denominator for earnings per share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember', window );">Restricted Stock Units (RSUs) and Performance Stock Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_DenominatorForEarningsPerShareCalculationAbstract', window );"><strong>Denominator for earnings per share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_DenominatorForEarningsPerShareCalculationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denominator For Earnings Per Share Calculation [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_DenominatorForEarningsPerShareCalculationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic And Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumeratorForEarningsPerShareCalculationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Numerator For Earnings Per Share Calculation [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumeratorForEarningsPerShareCalculationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvs_StockOptionsAndStockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvs_StockOptionsAndStockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365590954496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance - Narrative (Details) - Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2023 </div>
<div>reinsurance_agreement</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberofReinsuranceContractsEnteredInto', window );">Number of reinsurance contracts entered into</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer', window );">Term of reinsurance agreements with unrelated issuer</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This line item represents the four years of a reinsurance agreement with an unrelated insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberofReinsuranceContractsEnteredInto">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reinsurance contracts entered into with an unrelated insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberofReinsuranceContractsEnteredInto</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365587296560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reinsurance - Reinsurance Recoverables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses', window );">Total reinsurance recoverables</a></td>
<td class="nump">$ 2,294<span></span>
</td>
<td class="nump">$ 2,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskAxis=cvs_HartfordLifeAndAccidentInsuranceCompanyMember', window );">Hartford Life and Accident Insurance Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses', window );">Total reinsurance recoverables</a></td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">1,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskAxis=cvs_LincolnLifeAnnuityCompanyOfNewYorkMember', window );">Lincoln Life &amp; Annuity Company of New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses', window );">Total reinsurance recoverables</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskAxis=cvs_VOYARetirementInsuranceAndAnnuityCompanyMember', window );">VOYA Retirement Insurance and Annuity Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses', window );">Total reinsurance recoverables</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskAxis=cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember', window );">Fresenius Medical Care Reinsurance Company (Cayman) Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses', window );">Total reinsurance recoverables</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskAxis=cvs_AllOtherReinsurersMember', window );">All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses', window );">Total reinsurance recoverables</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, policy benefits and policy reserves. Excludes premiums paid under reinsurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21412-158489<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21409-158489<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123600520&amp;loc=SL75241803-196195<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=cvs_HartfordLifeAndAccidentInsuranceCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=cvs_HartfordLifeAndAccidentInsuranceCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=cvs_LincolnLifeAnnuityCompanyOfNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=cvs_LincolnLifeAnnuityCompanyOfNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=cvs_VOYARetirementInsuranceAndAnnuityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=cvs_VOYARetirementInsuranceAndAnnuityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=cvs_AllOtherReinsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=cvs_AllOtherReinsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576710432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance - Effects of Reinsurance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract', window );"><strong>Premiums Earned, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectPremiumsEarned', window );">Direct</a></td>
<td class="nump">$ 85,670<span></span>
</td>
<td class="nump">$ 76,320<span></span>
</td>
<td class="nump">$ 69,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssumedPremiumsEarned', window );">Assumed</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededPremiumsEarned', window );">Ceded</a></td>
<td class="num">(772)<span></span>
</td>
<td class="num">(680)<span></span>
</td>
<td class="num">(825)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Net premiums</a></td>
<td class="nump">85,330<span></span>
</td>
<td class="nump">76,132<span></span>
</td>
<td class="nump">69,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract', window );"><strong>Policyholder Benefits and Claims Incurred, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross', window );">Direct</a></td>
<td class="nump">71,567<span></span>
</td>
<td class="nump">64,414<span></span>
</td>
<td class="nump">56,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed', window );">Assumed</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded', window );">Ceded</a></td>
<td class="num">(665)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
<td class="num">(727)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet', window );">Net benefit costs</a></td>
<td class="nump">$ 71,281<span></span>
</td>
<td class="nump">$ 64,260<span></span>
</td>
<td class="nump">$ 55,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedPremiumsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earned premiums assumed from other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedPremiumsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededPremiumsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earned premiums ceded to other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84167274&amp;loc=d3e27175-158546<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededPremiumsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectPremiumsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectPremiumsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of policy benefits and costs incurred for policies assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction of provision for policy benefits and costs incurred for policies ceded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365569909136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>state </div>
<div>lease</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>state </div>
<div>lease</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>state </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Guarantor obligations, maximum exposure</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts', window );">Contractual obligations underlying the guaranteed benefits</a></td>
<td class="nump">$ 941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_GuarantorObligationsNumberOfLeases', window );">Guarantor obligations, number of leases | lease</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Opioid litigation charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,803<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements', window );">Number of states subject to earlier settlements | state</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cvs_FederalCourtInOhioJudgmentMember', window );">Federal Court in Ohio Judgment | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Legal settlement awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LegalSettlementPeriodOfPayment', window );">Legal settlement, period of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cvs_StateOfFloridaSettlementMember', window );">State of Florida Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LegalSettlementPeriodOfPayment', window );">Legal settlement, period of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Opioid litigation charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Liability recorded in association with legal settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cvs_SettlementFrameworkMember', window );">Settlement Framework</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Legal settlement awarded to other party</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LegalSettlementPeriodOfPayment', window );">Legal settlement, period of payment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Attorneys' fees and costs</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LitigationSettlementNumberOfStatesElectedToJoin', window );">Number of states that elected to join the settlement | state</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cvs_SettlementFrameworkMember', window );">Settlement Framework | Tribal Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Legal settlement awarded to other party</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_LegalSettlementPeriodOfPayment', window );">Legal settlement, period of payment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Attorneys' fees and costs</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember', window );">Settlement Framework and Other Opioid-Related Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Opioid litigation charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent', window );">Long-term liability recorded in association with legal settlement</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember', window );">Settlement Framework and Other Opioid-Related Claims | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Cash impact of litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cvs_RadcliffAndFlaimVAetnaIncEtAlMember', window );">Radcliff and Flaim v Aetna Inc., et al | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the contractual obligation to maintain the required level of funding in Separate Accounts necessary to fund specific guaranteed pensions annuities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_GuarantorObligationsNumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guarantor Obligations, Number Of Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_GuarantorObligationsNumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LegalSettlementPeriodOfPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Settlement, Period Of Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LegalSettlementPeriodOfPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LitigationSettlementNumberOfStatesElectedToJoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Number Of States Elected To Join</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LitigationSettlementNumberOfStatesElectedToJoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Number Of States Subject To Earlier Settlements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cvs_FederalCourtInOhioJudgmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cvs_FederalCourtInOhioJudgmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cvs_StateOfFloridaSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cvs_StateOfFloridaSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cvs_SettlementFrameworkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cvs_SettlementFrameworkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvs_TribalEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvs_TribalEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cvs_RadcliffAndFlaimVAetnaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cvs_RadcliffAndFlaimVAetnaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365576385216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details) - Segment<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cvs_USFederalGovernmentMember', window );">US Federal Government | Customer Concentration Risk | Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percent</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cvs_USFederalGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cvs_USFederalGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365573524096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="nump">$ 321,629<span></span>
</td>
<td class="nump">$ 290,912<span></span>
</td>
<td class="nump">$ 267,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">322,467<span></span>
</td>
<td class="nump">292,111<span></span>
</td>
<td class="nump">268,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AdjustedOperatingIncomeLoss', window );">Adjusted operating income (loss)</a></td>
<td class="nump">17,532<span></span>
</td>
<td class="nump">17,312<span></span>
</td>
<td class="nump">16,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,247<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
<td class="nump">4,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="nump">90,844<span></span>
</td>
<td class="nump">81,515<span></span>
</td>
<td class="nump">74,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">91,409<span></span>
</td>
<td class="nump">82,186<span></span>
</td>
<td class="nump">75,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AdjustedOperatingIncomeLoss', window );">Adjusted operating income (loss)</a></td>
<td class="nump">5,984<span></span>
</td>
<td class="nump">5,012<span></span>
</td>
<td class="nump">6,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,629<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmacy Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="nump">157,787<span></span>
</td>
<td class="nump">143,194<span></span>
</td>
<td class="nump">132,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">169,236<span></span>
</td>
<td class="nump">153,022<span></span>
</td>
<td class="nump">141,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AdjustedOperatingIncomeLoss', window );">Adjusted operating income (loss)</a></td>
<td class="nump">7,356<span></span>
</td>
<td class="nump">6,859<span></span>
</td>
<td class="nump">5,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NetRevenuesRetailCoPayments', window );">Copayments</a></td>
<td class="nump">12,600<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Retail/ LTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="nump">72,874<span></span>
</td>
<td class="nump">66,078<span></span>
</td>
<td class="nump">60,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">106,594<span></span>
</td>
<td class="nump">100,105<span></span>
</td>
<td class="nump">91,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AdjustedOperatingIncomeLoss', window );">Adjusted operating income (loss)</a></td>
<td class="nump">6,705<span></span>
</td>
<td class="nump">7,623<span></span>
</td>
<td class="nump">6,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Intersegment revenues</a></td>
<td class="num">(45,302)<span></span>
</td>
<td class="num">(43,923)<span></span>
</td>
<td class="num">(40,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(45,302)<span></span>
</td>
<td class="num">(43,923)<span></span>
</td>
<td class="num">(40,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AdjustedOperatingIncomeLoss', window );">Adjusted operating income (loss)</a></td>
<td class="num">(728)<span></span>
</td>
<td class="num">(711)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Health Care Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Intersegment revenues</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Pharmacy Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Intersegment revenues</a></td>
<td class="nump">11,449<span></span>
</td>
<td class="nump">9,828<span></span>
</td>
<td class="nump">9,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Retail/ LTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Intersegment revenues</a></td>
<td class="nump">33,764<span></span>
</td>
<td class="nump">34,010<span></span>
</td>
<td class="nump">30,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate/ Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AdjustedOperatingIncomeLoss', window );">Adjusted operating income (loss)</a></td>
<td class="num">(1,785)<span></span>
</td>
<td class="num">(1,471)<span></span>
</td>
<td class="num">(1,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AdjustedOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Operating Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AdjustedOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NetRevenuesRetailCoPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Revenues, Retail CoPayments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NetRevenuesRetailCoPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140365583608592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>store</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (GAAP measure)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,746<span></span>
</td>
<td class="nump">$ 13,193<span></span>
</td>
<td class="nump">$ 13,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">2,259<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_OfficeRealEstateOptimizationCharges', window );">Office real estate optimization charges</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on divestiture of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Opioid litigation charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,803<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Acquisition-related integration costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_StoreImpairmentCharges', window );">Store impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod', window );">Acquisition purchase price adjustments outside of measurement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Receipt of fully reserved ACA risk corridor receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_AdjustedOperatingIncomeLoss', window );">Adjusted operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,532<span></span>
</td>
<td class="nump">$ 17,312<span></span>
</td>
<td class="nump">16,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_NumberOfStoresPlannedClosure', window );">Number of stores, planned closure | store</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember', window );">U.S. Department of Health and Human Services, ACA Risk Corridor Receivables | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Gain contingency, unrecorded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax', window );">Former gain contingency, recognized in current period, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_AdjustedOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Operating Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_AdjustedOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Purchase Price Adjustment, Outside Of Measurement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Gain Contingency, Recognized In Current Period, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_NumberOfStoresPlannedClosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Stores, Planned Closure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_NumberOfStoresPlannedClosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_OfficeRealEstateOptimizationCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office Real Estate Optimization Charges - Related to the abandonment of leased real estate and the related right-of-use assets and property and equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_OfficeRealEstateOptimizationCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvs_StoreImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Store Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvs_StoreImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>cvs-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvs="http://www.cvshealth.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cvs-20221231.xsd" xlink:type="simple"/>
    <context id="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieef592c79265415e9514a93ffb9ae4ac_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i40ddf3f5cfcf4be7a0d007238cbe2748_I20230201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="i21d91c5c532243ef9f94c642820dbac4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a740dd129184890b8bde10a27ca4208_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia465cf35ed0f45939b52004b01431e3d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6db92dc898a14220a458e7987f33b9ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icdce439e9a164fc590536f15958f67f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic793b82f8aae4503ad92cb8081fb8628_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b5114192110480ab4f260049ee8b103_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43471633110c4d35b96ffaf743cb0e4f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21ae6bc100814ca88c4440dbb572bbdc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i72a7763da9eb4043aa8f22f5c692da1a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if00d0ef5531f491687905cc2a31dbad1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id2a3fb0fbc894ec1b2c889d8507c98b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7b2f5710c3d416fa6c9cc7c92282465_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i888d803efa36451abbcddc3e49ab4600_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0d3c8cd4bb654446b90531ac0de6b52e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if44510fc0a4b415b835ac61565cbe142_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e66d5c8619f4ded8782d4028fa2b01b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifab9f0d4beab4f98ae87761afaae6ce3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ebc7adf3c3345cd9cae049928aa937b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife9cd17faa9b459393d314bd5dc139b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83a79211767d44618caf1f746ea964d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6dda31d68ee44ac380464c0d7b42864e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i506db4d0bb51485db8a39fec0af261da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id118cd6fcaeb4d16b525a15d0b586564_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic935f384ec884760808c5d3d56f93b58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96a2c447554b47278dafaa81be11f9d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i215e39f051a24c26a9fcfe870c6bb597_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia036bc4a7dac4d75a3807b027b89ffa5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10ac8c51a1484aa2a5345657f72786b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3b3a385f98e4970a3c4003641ffad00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06ea169a39a1448695c8f5079e17a681_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65ab1718255d495ebfab5b03525f0868_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d6dbba9b47e4c87b541de1f1350e1c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6a2b778a2b648ebbfa53406c5d05497_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i835f93d2a91243ffa5e213ffac78aa2e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib06f1a367c1c462cb54add04957c2b6d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ccf20c4b2cb4cbfa96ff019488ea873_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifedcfb6c0f5f44d9bedcaae64ac0cd39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2d25a04a6754b1498c8f7da3b006bcf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i90c39d6e1188460db9fc0eac4c5c73ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia074c2e908ba4d4d9f8528b440cb9e61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0ba6af5137d4355a39e538ff11c3f70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14bbd86e337e40b5b909ba5b0eec8986_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66c919cbd9e14d14b0126701eccb5f78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i403b748d2961411884d18591a7536a94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i972cf157c8074bc5ba5d6d1d1d0a0ee3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i109b0efa62914aa7a4f584e9303e07d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife2124c0776c4afab6cf27697b98714d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22bba5ead4dc4a12b105fb70a7664473_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if90073196b804847ae7989cfd2058161_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34594b0b5acd443a9120b077623df7ac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7bfa8a913ea04eee9d8522298e6fc681_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e1ce9835a2445c995772377b12325fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69b40434e129497fb044508149145574_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40913455599d4dbe8925b15950ed63ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief98321000924065a5a2817038f6cd96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81ef2fda83394a2d8e020112d6facee6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1778905608134b9da2d0fe7767917336_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc357653e2c74c68a77d7f6658e76744_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide6581f173394288a53fc090546c297c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib2ec77f9083d4e5aaa261f4838a994dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4fef13855a34463aaa68cd3b16edb43c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i780b19498a144075a22a573432132bda_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42d18c1100d94a559f0d7d4c757498bf_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="if18de26c953b4c36b64633eff1121e28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4974a8bfcfe4424d800583e6f9ed22ac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2ef0140101e7410aab67b7c7900a5d71_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7c831fb209894939826991737cbd7475_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvs:FixturesEquipmentAndInternallyDevelopedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie37cf62163d84a58bb4468ebd3f5cfed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvs:FixturesEquipmentAndInternallyDevelopedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6bbfa6bdf0b24740a26dec57554e595c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ada219a77914d62bea752d3c03e225f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c18d654fb324895a611580a5ec5b3dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie53b91392b604092b359e0652c0bf806_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fde8ef39b534e14afcac581de49b996_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0fb3a83ef19240adb23daa081377a140_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcd7ff4f57ff426ab9b84721b8a4497c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6748d4d91a3f4e1c9f9bf83409587fc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d2d5b42e5da4c468ab576df84378112_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e8b9d6224854f2aa4c4798da79217fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19b3fce48e974e0cba8970c7c61dfc90_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e0fac73260b479989119ffb924ad3e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0d6894378d3433197250c8e10ca47a7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cvs:LongTermCareReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if7945c60ae0e48268a21dc60ec7256ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cvs:OtherInsuranceLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide9ac130c868441a9b93b609dc8b28e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cvs:OtherLongTermInsuranceLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f6d2a400d30483eb5535b2a740cccbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cvs:OtherInsuranceLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc50f23b90eb443283a4ee5cf88abd97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cvs:OtherLongTermInsuranceLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic63500a3d0dc40e8b098d64a2fbfe2ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26333704d6224942a7b55db5b9a7c2cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3625815087434552b838d92f5f5f5e0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i262f23d50a0d45db8328a0d433a34f63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87aec70e323d4d80b7919dced5a91e73_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i72800db1d6214a588b0e32ee81cf20b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8fab4c813ab3488e9e07378a081f8db9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i82e7024e7b3e47b3b5530bee96e98c10_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1b832667ae304814964afa70f9b6228f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iab45872f08734ce1a3dacf338ff1195c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e4b2b74efa8424bb6186fd1ce6f571f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i428e6eaf7d9c401a824a54e771b1843c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia14f4ace6f2c42638909cf217d548c72_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i916017148df94c918c5f7fd143ce2d88_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if010e49d412b4111aabb4d53c35c0289_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia131689becf644f4bc5a732edb3c22e2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i78e819b5e8cb45e5ab8dbfaf05b504cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i209085ef2a2445ddb82ac68f9a34c386_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib59f410a5b084b5c88a7afb76702b6d0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iefc8faa2206e496e97d8bd1eff35cdf0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i317658c2ffcc45ea83ffebbec7222ac9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e5fcff7cb6c46f987a53e2a78bc0fb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i786d650a37ad452c813aff2f3ba2b66f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifefecdea33b5434f8044bd84cd050b73_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3279e91422224439968bc192db36cdb1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib5f8050b163245d58912d4aff32e4a28_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i875b6ff05a00444daa0d40d607318115_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6a4492c873942499213da78e615d60a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3dc263ef676c41c7a9714817863cd0b5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i531a5f41bdcc4e98bc63759f201375c0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i88b49c00627e4fb69a66285d6f3f5b64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">cvs:SalesChannelOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i33f9a334ea554cf6923ae16a198dd1f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5470c0948d3447daa6b553072d68b21c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b5218b8d02245eea6cb1c1964bc2d56_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ebe5b02e9154d92b2659182b87bcc17_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e66c2cd601c4549a5ef3b24ccbaf9fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ee9b96bd1eb4291996ceb2ce4ecb8c9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2694cdfde5e94542ba60918fc678d54a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1bebe76ce83e46589a14f0b7cb047cb7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i99cbec53a7ed47e3ab88190772305c5a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id57e0be74304456489f0a228ba4952ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6dee4299a044434bb9587326355c6d37_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15504530953c4bf689166fcfe8f7868d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88c90e55b42a466ca5aa922c38dd414e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4cde5b8c7bef4de38fb102a05d7d6a29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icba757607c0e44ffa9ce352a6dc203fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if86521d12a18428cb6850612e4806b2e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26cc5da453684e30b0e7f61d0c214207_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1a89142a03e46a08448375f4b02bc4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i10be60b83a684a8c8d1797644e6037e5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec13ef8ea98a4f52953499317400e068_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id041b9cf96944df2825c84f9dbb638ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74f8c85482214ae78d33982d2c28ceaa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9915652c392941698dd07b170ae9d044_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c774395798448abbb90933427cbc204_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if66c5e92146f4978aeaff863da389857_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85235bf2dc3145338feefdca3630aa3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf6ff2650b194f6f9b88d08a7d679daa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">cvs:SalesChannelOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i710619ea82ee47b2b0f1faa66681850c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe5733b07b8443d7b51ad01e0f283bc6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id91c69b620814b2a9f51d3084dada276_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d0cba2d7a4b49d68120f1ad1e3b59f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i047c32c6681c48a280f39c07fbb64103_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50a613e7cb5b4f9fabfb569ae06de8c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PharmacyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iafa8c79cb8ce4f9fa3d25b293e92eafd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b4cdb3407c14f1282544e57e58ecf04_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5bc5d4b76344af48fea40efd9a549c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie86040f73a11474b89670e351fab892e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00e8afb1516f445db8c04046e7f9619f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2b3c892261d42ae91d2522773ceeffa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:FrontStoreRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3f6f283d4c04e2dac7883355902fa5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icab6442d127e4d5abf45e0a1fd8044a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40a69bf319414885a2af9b145fb0daa3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25d1804d8c6b4ac494abb73ef6b710bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ed9c24157b04f799ff19ca1d9a73070_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52962d31d6d1400aa5bdf2bab550bd30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:PremiumsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae8e30495c1f4923ac883d572d156bd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8a458accfa84019adc7131cfcc882ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id854bc7a2aa64ef3bbcea56dffab6dbc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8aa3187fec8b406b816c24249fb2dbce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36b2481d581d48a38dab150c09f95d26_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8cfcca160913463291592340d0f000aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6504396ad13b404a809b4be1782f4962_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4e4149eed634db283cebe9c5c27cccb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c934f6d7dbd4623a30db94c93317b44_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">cvs:SalesChannelOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d26d3b0edca40eb8a286991043bc26b_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i40ea54e1ccb34d709c3b44454e7262f0_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ie7a79d946b244fbe83b985e471a79655_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia397b0104e7f454a9a66b55e5fdd1a14_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cvs:RedOakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i651ae9dd5f5d4e19b29b67ad25f2d822_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cvs:RedOakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i374b0364197f455da3648efc785175d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a9c3eb37cc44017ab6afa84684e32ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0122d8f1aa4d48aa8ad7d46a51217f28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fb39cc57c844ed0b532aa62c0a86627_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f81ec31a44f49e1b4a933ac7e20273c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4fc6318928c4432959e25e083008a4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38d3dc349650457fbc2c1be5f20979d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0dda9edc70414970a1c368f6c420d65d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie74c8e518d644daa9a788565f2dc3c08_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:HeartlandHealthcareServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd811ca9ceb5442fbd696e20ec9278ed_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201812Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i5acb58a875864a49b737f2cb40ddee47_I20230207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:OakStreetHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-07</instant>
        </period>
    </context>
    <context id="ia4dd0513fdda4dfdb136f1594d393298_D20230207-20230207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:OakStreetHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="i5afb8727270f42b8ade9125cb3443778_I20230207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:OakStreetHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:OakStreetHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-07</instant>
        </period>
    </context>
    <context id="i1773809e56854492867bb26fea3c6b89_I20220902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:SignifyHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-02</instant>
        </period>
    </context>
    <context id="i742e5d3d548546f4a2efaf4d89ecd9d1_D20220902-20220902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:SignifyHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-02</startDate>
            <endDate>2022-09-02</endDate>
        </period>
    </context>
    <context id="i2f859fc0dd5e47f0a5e763378f21729e_I20220902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cvs:SignifyHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:SignifyHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-02</instant>
        </period>
    </context>
    <context id="i2bf59ea1890f4d16a13351da96cf6411_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:OmnicareLongTermCareBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0d7bd61bc8784946b9cec8dcc1fcb6b8_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:OmnicareLongTermCareBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96e78b501bc842a2affc4033fa4a4eb3_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:BswiftLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="ie6fc4ecb20e54148beb244c5579a6256_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:BswiftLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i879da25a180b4cf6b770b94022fe1214_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:PayflexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9d6c8114b5924bed84e9fc58f5696afd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:PayflexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id8c3596e68a249cf9f084af72dd00f23_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:ThailandBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i36ec68c9bde84569ae25dc7eda071a52_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:ThailandBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i29b0f113479a4ec0b9e699b726fa4b6b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:ThailandBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i674eb260757d402f9e56019767496299_D20200731-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:CoventryHealthCareWorkersCompensationBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i3fa94d302f25457a8ffe0851c4d7bf19_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:CoventryHealthCareWorkersCompensationBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i779c59619b9643cbb118540ac3605d26_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:InternationalHealthCareRenewalRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i717e63c6c0e941a3ab348dc4fa490a30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">cvs:DebtAndEquitySecuritiesAvailableForSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a45d333346c4b16814c08207dbd06b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">cvs:DebtAndEquitySecuritiesAvailableForSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5de346073b1b4e83be2a8d87564b444d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">cvs:MortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fb1627c01b1430080b3f6a0a40addeb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">cvs:MortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7bc5f7c69e7441cb31da4729c7de4bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifdbc67676d794d47817f10d53a42b996_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvs:TotalInvestmentsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib28047fad8cc4d29952b1b382be9b6a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i794d05f87c014f5ea664e007d8ef553e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13df1984aa1d4ec0afb4004f690df554_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b200e63aac44dd6a20d4e917b3ee113_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2b50e93e4294e459e45a5d57d36fbff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7308db8487343dab3c870126d9b4513_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89f5f0dfc03c4227b89defd4fce33b30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebb5cbe4055e401f982b3b48cbcfac13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99148b9bb5954a1c86c55a80ac65caed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i221ef7845f854689af410277963cd5bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8de7e486f7b414bb32dfafca43b2196_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f2ec623c034486c985ed3eedbbba076_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37c5cdb5daef4b928eb50715ec99cb07_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i628bda68e4a846798004771ed7fa1e30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3def4d721b4452a9745ed4ff29dd91f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7ae5d28fdba744f89bd9b16b1f10ec56_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia58f18f7922d480dbb9758608a9e7dd8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie67471467f9945e5bba43415e678c6b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingRemainingProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40478cffecf64191b267758251c37050_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1af20438bbb64d5f8b78df4ed91c4fcf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingRemainingProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7d14838d61d4f28a334a6fa3ae5859e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3f4db8d8e9d486f9039b51a301eddcf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingRemainingProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc1e6e162ae5412285a67bd88bbd3ed8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bdd4738946f44c8961343c0e3d3fae3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingRemainingProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0fcec899c0a848d4b4ebc10f773df4c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c5943b5b1904c6b846ccf841c464d39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iecece3fcd8be4303aa5cbc5c092cf500_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9bb3635c7aa14bb79761106ea93cc68a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia7f8117025154ef69cad75e991abfff1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0458817c19b448f08f9c914f63356b8a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebda2282c15f4559817dfaba4fdac117_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifed8619550174d168c4c4cd42b101642_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd7eba7b3fa241f3aeeb456afa8bdd4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76ce9ddcb63246efb0e31193bee2ff73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia44809c2621249a5ae15e084e9a2de19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadc19163e572465e81ae33a610b8f94b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6de4c16e901d4eccb8965e3fae43dcc6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i828b576776fe424bae9270ea200522e2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id756e63e2e754f359f0f9ae581e0a94b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i360bfd4546d74642b59856ededd82514_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fbbf77e09bd41508b2178ad8c2442bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ec7149199d0463a92cc968f65f45f43_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf9ff2cb5e224b209b049e6f94fc2d50_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3fc6e014927402abca82128c1ddf524_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2597e031daaa40e6a6ec272f1341abcf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38c112ce5a634675b6bdc212a46b02b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief6f2a4d7a5a4af9a3d311013668f24f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72bbda77b88f4cdd9fb87a318a29fedc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia294054d10ac417787c1944ee543fe6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6beca7e4f8864e93aeba97040d6f5a37_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i97612fc3a2f44d73bb819a717d41d0a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if14f3e4b96e04557911ee9a9b62f5e0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52a9138a58c84726a45e23bb6e6167e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia570fc5031314098910825a767b2b0cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea6ac9f0b5a5421dbc9cb6e72f8396d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i707228ea268b4fa1b8fc7634fc9a941f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d7e7b8abcda4b75a158f71a15390c9f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i588aad1d73dc43329473d13fcb268e7c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18d1acd38b204e20a8c2a44bb0f10148_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf70115e4b0543e3a96629490f5ae0dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3808d834e07e4b3b9e287f3834d21fdf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5e10c1576ee434cbb42319cd9c8ab0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc6e024d3cf14d86a2923481e9e6e304_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia44ab5a60f90433cbd73992a1d0566db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4f2cc1ce7924cb5bfc1eed1de05f7bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib19d3a4e66794458812e357f78f43e74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34a5f10b00974911867bfe65ff417616_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i516ca7a24b4e45d98df8d70dc8459538_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife8c11020a34479a954004c76070a1b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c568b1356424e30b16ba09859cf6b43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f9b7af276014284bf1cbe79e6f1d940_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfda10eea1e946608a7bbd50cf284c24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category2To4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90857bdf1da64bc0b9e9cb8b2c306c07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie54c71d8deb84041b2ac5c9187940c7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4854a804064145bf94625cb963eff0eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c97f2c2663d47269fef701393c390f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53ebaa434a774f55944633b91503f6aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice10fbdb03344142bf872d80c624c2ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Categories5And6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44b39b49a3b54b80924c011dd5d61684_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08b6ec53ccf44d16bb1cf7ea10345d8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04ba64ca88a842a8b016d348b2518392_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id76d3139b44e495aa8b5d3c2e3fe365d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f39590e349c47e1b6655543883e658d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4503868833d04c6e92dd980faabe8e9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">cvs:Category7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b22cfb2e4fb49ef994eb2fe50637d3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b6f5d37438e4e24adc486dfc220e330_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75817f6d10a64edb95908711e7b84a5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd337cc2997f4c9a8bf96e1b1038b176_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3f411adda394690a887804f07c4085b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cvs:MortgageLoansOnRealEstateYearOfOriginationAxis">cvs:YearOfOriginationPriorToPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12a1e132dac44a7aa77f7b5045148074_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e80630b4afd497383aa2e7e0825756f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b0b007394094a3a81527483fd8a8975_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i548886065c29409da2eebb0e5740162b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie285042dfe4440d68f48b4adebe96861_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cvs:MortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b9bf6c2c8e24bf0a220cd7210ee97fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cvs:MortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide0bc2b4239f48e1a3a714d4cc3d7203_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cvs:MortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i313f0ade641941b4a6bef1dd870a48da_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74585cf162b14135ad3471e993c71df9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20751ec3912a4de2a34e1c394c86a641_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf5fc81ab5334092a75354e9e0cedebb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c9389120bf34657b8225887b8754f61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1333c10377854683a2d760e2dc527ff2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cvs:SupportingExperienceRatedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58f243d98dd94b418abfc33c268175f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d831efff9ed4012a3c45a15c640b22f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f6777feef9d4cb08a3526828f50afc8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc0c69d485444837bbae724a028fb845_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id39f877dc08449f49c5fa9feb476a432_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88708d7db67144f6b9034fc9b683ea9e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0a49e1f8ed54cc797d186700b9962e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic83971584eb546e2ac5fdc1e7bc8e84b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice45b349609443519e8d645943421f9c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a23915f279344c1bf1087035f0fdf12_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5c2d8598a124c19a68198d84bdafaf8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i785d19a7b609421eb9246c77f19956fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i67f0cd92f49b4b2ba3ae745e22916f37_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19e9b578731f4c5baff668f1e8bc6d6b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id86084968a414700a75a774a5a97ab5f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f1814e1657e4cec8407f309d332126f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idcb1f815761e4abf81f0b8c3d4f8c6c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a671ec5023946d19ee290bcc33442c9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied933a3ae1c44c37ab908d407bf9b9d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8590aa625abe4bb3957876a8242f244e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6fb3a28663f4a6ba9eddda9e82c83a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a985a5355bf4bfa9414b48bb67b83bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40b71f09b498454fa6e14cfd770e0f13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26131a59b6674c21be2b2f35ac3585d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85dd5660a59b410b8d5600445dd2db73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b09513b5025488bb89a6666751b3eec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icdc3450471ad405a95c9f384be0052d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f137c3bff994afabf3e08f84adaf0e2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08f51346b999445e9d94877366425a3a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia214d8b8ca6049f29665c2a7f42886ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f05a7cde4614b0ab28a1cca18e30c59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i624b1a999672495b9d45af07b54e6b76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7dd5e7556c1145898755e2b6da40bee8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9a5333835ad4c71aed5cd82b4c95855_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c8648eedc854d2cb3b880ba07b81e53_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ida77e918f5de47b4b67cfca0da2b8226_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6906b59b585c4d4b85fc1db92b4aad26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i795b096e03294f5da8368aac1b682f6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ideffc599afc64e2eb2ba34d383e611f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9e565524b0f4bf687a1dabcf4928828_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81efa365424d49cebe90328cadafba3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48ec5e8d0dd14482a058a46dd16eab76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i701d4495212945b99d951fd9a0dcd6c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7773f5873dab49a8ba60de1ef7a255d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i348bc1177736419fad69fa81d958c8ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32773f424e5649049efc564c1400fd60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddfb3509175a421fa38431213004bc2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i949fc998576e45bfb3cf3c21865aa98a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b4b742130f941fe94db85e807e7a06a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1bb4af948251483fb59540de78e273f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f4ad698b6cb4a918854adc5690c6f16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a543a47bdbf412ea03cd80a7e5147aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f2c37f0c80248f98f71a7fc479de9ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib999956c1a1844f0a5f0f337b58d6d66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fcc6959ebd747668932580c12c9b80c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia921c1e5944340c0aa0256f19c8b20a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6a2d79c756c41b2bea5dcf9fc87f998_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i206c3b9628b7444ea6df2624ea2118ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7f4bc4698994fcab1897c3d0a92ad88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ee0b6a29d934c78b07a74d71c61d1db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee7db71ae1ac40fd91ebfa23d481d8c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i190edd6b8c6944fd9697dfc9489f8a9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i387ffe71e44b4f0daa62a18eae1f74ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i431cc5a5826c442fa78d95415014f874_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6ddcd1cd3484e58887f45b9ad5e1006_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4eb6d4a5fe79457293a854403dbb6e69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ff589f47f514ece9b347067993f1a0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ae1a142a6834907b1e6b0fa40a2a994_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic83ed3a7dee542e08edcf3a6a2ea4b25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2050ac0edb04a31adf7f234fb6390a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75346ba9d76e4cf0980dea9c58ccaa81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07516a7d0c4d4a0eb9c8cf019d26a2e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43b6787f48b3442d8a63c30333c6b458_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f194dd99c7e4f68b3ff5746bc03b35e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i992ef56bb420411cbbef3826241d452f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i77abf1713bc54af78884466e31b453cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i15dac8898949438694ba2abf0c059910_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i95dfe2b0be4243cfad329e2e411e3303_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7975ad7519e54b6db43ace8eb80066d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44ee925bb3e5402b955f9868457737db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3892577d13a4a62a891505c7f399a79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia091e18719b84015824f1dd5f80bc7eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7619afe50a794a4a84a50dcfbf630c38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79c1ae91ff3442528fb1f71c91933d34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i662d2dd29a2a4a22b0b5e93c396ed6f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia37d53d84cb44bc39778f9546e36542d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvs:OtherAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66bcf7a88ef8420db041c82d229c682d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic858e8e5cf2d4617b20fa3fa03a4a293_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fe1938eb02c435297cc130427df950c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb6be9b43dab4ff69cd98c57e4510019_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c075490097946eb8ba4e98465055bd6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i734643ad1ae34563ab562dd2a9a185e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i699884ef14c74682af2d844bfa691e05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i863995f01893429ba0b90278c34784f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i355cdb170edb433ca79e61e309a40c6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53c500be5647438295ed663bd07d0536_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf216acef3094d348747eeef4045d573_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7844b63d898f426f84d9c961ce7de5ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e0582621bb34df0a6675d029c295a94_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e64cd8ab5fb4322a855fe783aaa1050_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd86471ead2541e4b8e2ee2e52429bcc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1caa2a8534f942fdb15c0e68a3ba7cb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d1901bac7f448c48fe0d4065b09e0e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i275d0ec6124c46a7ab946d9a16477a75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i749066de634e42b3816f92927cdd0c23_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f70ae1bf3c746fe82376b68d9bade16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76610efce5044b078fe774b073da1159_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i799622beabe24d068a330216378ec7d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i303c9460e5aa40ba8797ef57bc7a6665_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib69cb21ce24c45138129b0b0b0258605_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie43f9bbeac1c48f09d85ab8bda317b67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i790c87349c0545a0a15037b5863ea17b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i796a9a2e1f724310a3315d9fc1be5789_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9a6cb4a9a1a4a34a8a63c650df4220a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22d221a134574691acb5e35393d71d09_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id68f0f4d9e054479ba78b7c748a66258_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadc0567d043f4a288311dc383ab5b569_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if034f6862b3d4fd4936961827df503fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i960dac857f814d2aaf3da5e41ab12bea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e1564d3fac24665bd7b402ab4a1fdea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i769ac61262e54e7ea669fe5223c1a8a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieff1acae7f1f4a61995476442d7613e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b34eb9a40f14a1392d66709b0113c87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i842dc9cc1f984655976affbd54127c54_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d6d75b00af74666a638509a7b9e9285_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if35e951e7f7044a78bdf58c5c994e504_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f80eb74b06647c996981ce7bb5b9d6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ceec40d348b417d9dc7a41eb39aa1b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ad03180d40f4e7f900eaf9ce57d2f6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2314c70272ad44729021b8b7c81f68d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:CommonAndCollectiveTrustsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6247aa5d844b4cefa1e771f6ef8a7da7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i74b7d5d8bfba43248a819e81b1b296b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i194bc2ab09d84172aea4a9682706e5a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:SeparateAccountFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id206ebf70f104468bb9392e4f8e41a61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SeparateAccountAssetCategoryAxis">cvs:SeparateAccountFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i17f9799c87004ca590fa53584c7e24f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice6f1f557fab4461b4f09715be534c58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4751bc253ec4ddf90922f866ccf2b7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefb4b1c3d63e4323ae108f339bf86ea0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifffd3cc38a8b4021a53283d65a4c0964_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief7e4c14ecb14064a1e1cb88fae9be52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie09cd220413f4c58b188c10acdaca66c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief0e8d9ed04c418a948fd84835bca811_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i508064fb813a4f16a124a4de02fbcd59_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ef4eb7b015b4186b848a7d8272984a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96931f5310964061af361408b2ab6730_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if8d9089fdf7c4007bbe779a88d4715e8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic3b3902b297a43b9a015149f29e45bf7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c4edc5b99644fa3997863adf1255293_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9bc72442418741689eed1454ae87700b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cvs:LongTermCareReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i264d976e57564672b0babd9565bb98e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab7e8be7f4e347beb8eceb156d106b36_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i53d0930b2b2543929971d15fba0e45ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8e8c8634f0645dfb503773210e8249a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ProviderNetworksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibdf8ae9241fe4e3481243778aef0f6e7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ProviderNetworksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6b5b7dc71ff1469ab8a6a25decd8cfd6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ValueOfBusinessAcquiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21cba4373fef485faa84dab5def0f790_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ValueOfBusinessAcquiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if745b6dc0a754cd8914c4f5726b7f6bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea5c2c83314342409224f6f5d753bd47_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3a19e9a51cc547949bdde2b93fb44a8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7424dfa102ba4c84917a87df011344b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58636af2c05a4a5d816b65538e4b45c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8f8326f384345448eaf5b58a4b2a7df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ProviderNetworksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida22ed7ae3e1481db1884a9cb038c03f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ProviderNetworksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32bdea3056074d3b98bbd8937ef4391d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ValueOfBusinessAcquiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b7e0efc2e614022be02cce608679450_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cvs:ValueOfBusinessAcquiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd3a6f7782284dbb9c5b5e9b11d670b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9626105cd75b4a3a9391af2fd8b0ea24_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i749b13bb01c043f9a3cb673b0a199669_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cvs:OmnicareLongTermCareBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b05aa08f755455f9dc89cacf2875829_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i131cd8cfbdc94fcdb157a2c4f138ad2e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2a7b9e629c14bcc9865d4798fa5e15c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e150d3db673482e817a73aceedfec35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife6ff41a415343de94e5806faaabb281_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id427563c92b54e5f88ceb5b6ec87195c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i64f5c37ce66141f7a204dfe6e993bb22_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie936009c1c1e420dad0ba447530546c3_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60dd33f11cc2409080bad57679954d47_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id630be41a4e14306bcd92700167a1f05_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5695f9deb5d42f399db0a5df5333d03_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id562208e84834686a7620f76d36a5e86_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i13d80e15e3f94cb0927c69c6bbb18ad5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if99f5cc945cb4089b78aeb74c829d2d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic76c4e64c26444a5bf8225d71e995baf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6259c8555abd4bf5b6dac136069d1316_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9affe0606d974499b83f0e139cb17dd2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3477564c46a4d1d89c214c39d6753d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ac261a946f441689f0b6c8226695ff7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i376c8a46e57d495d82198a8924218c06_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthInsuranceProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d32e81675c1411abb9e6dc0a83223c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i104c7351c43f4dd9ba23acf27dc2da0d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2661ac2447ad404b9093ebf03b2f3a2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4d0589b63754b6d96499af470071fa3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96ea0975c6434c688a6304c9a35567b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueJuly2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23b4e48800ec47c1a7b0ec56d1d395fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueJuly2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d193754e1d94c0494f9956393440f77_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a906779cfe446a2987d8b5241fbf0da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if71e011d823142598cd37f46f2e49a05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueDecember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id1c181073c4542f099d25eb5c5d40655_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueDecember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61839e753d2f451b9587d89360867561_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueDecember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i62d2bd8ff5b14cb5a635a188ee174c8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueDecember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a3d976289814f1ebda72b277cfb0e32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.8DueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i35ba734b33ac429899c73244e0b3e4a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.8DueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e0c4baf78af43da8c871e2cf0d3776e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb44b3665b4246f1bf997c90b24c21d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d559325531a42c38fc46ff0a8fe2921_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.375DueAugust2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b0484677d3d443eb00b519000bfb3a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.375DueAugust2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56e27d861e9545b9aa31b1102e04c153_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.625DueAugust2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42ac987c67784c1186308edd0aea70d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.625DueAugust2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic180b72151a4402f8310dadcfc70fb01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueNovember2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i74b6f748466241afa934def47b3887ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueNovember2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b4ae74a63944a4ab738561dee76b7fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5DueDecember2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89e4d23924994b228cd71cb68d806750_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5DueDecember2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefa4fc8c856647a0a132eb36186e08b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie21a0aa5c9d141bdbe4a207bb4f293ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fb06588816f472bb29f99b8d68219cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.875DueJuly2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42c9969b99bb4ad798109c43cbdc6881_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.875DueJuly2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb8a5e549c1f40079912cf72b576f3e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.875DueJune2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c887883f1ce42688222f658a393184a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.875DueJune2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38b8c6c77f294a97b96b4e9060102c49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3DueAugust2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94f841196e9745d7a5bd741b956cb571_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3DueAugust2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3120aef7a1a74f9aa9ad6c90254ae7da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point625PercentApril2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie21b2c11292246968e32e95a7e2d5d46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point625PercentApril2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83a34a6019c9487ab8dc8717a85803b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.25DueJune2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32d2292eae624df88e3cb7a81e75175e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.25DueJune2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6a05b1ec70b4ceda24080b978863c80_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point3PercentAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9e78fd616384a38bdb3bfc812db60ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point3PercentAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i208edaa424b244c2a575cd9b2b4b9020_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.3DueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3609fe1a0966404993bebd381e7eda7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.3DueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5aa28ddd1e8430eb577239a8f77bef0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.25DueAugust2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f0fa0101d32487d87f11b2ff81e35e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.25DueAugust2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide032eb9e5684d3bae628ecb6f5fa55e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point75PercentApril2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i763321b4294a490a99ed2699ea5e64f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point75PercentApril2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id15f98dc5d2143468b8eb2d34e1a74e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point75PercentAugust2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b8b28c2e4ea4f158253162f1d64b8cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point75PercentAugust2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06e62497573243ac88b9afb7d5cd0de3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point875PercentFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fe1a138e88c4de09bec060efb8de7da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes1Point875PercentFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaceac4401a17451a9894899abe75d058_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point125PercentDueSeptember2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i609d3103caff4c93b86c00a3a2aed350_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point125PercentDueSeptember2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d4aa00402164f00b89144874d2e4a98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.875DueJuly2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide1da8f0468d4f0e87617230289c5bdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.875DueJuly2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe3a3d79b0d747d9803a516b3766b9b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.625DueJune2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f90f74479324fd08ed524bf5c875c87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.625DueJune2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia363edf7d95a413cb5fecebeb23ed972_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.75DueDecember2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac58136f46f242a19ec676141946c7f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.75DueDecember2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39294c665ef74fa1983f27c408f039c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.78DueMarch2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9cbfd1800fe44faa82ca6d39ee57704_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.78DueMarch2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1512c04482e5447b84fbd0e3188e529a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.125DueSeptember2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9699d6696c9c4911bb010f0b9af5282a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes6.125DueSeptember2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3de7f45720594c44b73f3eab7ce10e70_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point125PercentApril2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03f49a86ef2b485f829d66fae1ef44f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point125PercentApril2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id028ea3d52c44a2394695e4f43e9d046_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point7PercentAugust2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i650090a57c324b8498f059399f541fb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point7PercentAugust2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if44aa963bda44e8fa075b47f30535a24_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.75DueMay2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6591fe0e06444dcb90f36c98760ac910_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.75DueMay2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i472c295552a045b6bcce82be7abd296a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.5DueMay2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie807ae7adfd345cbb44996f1818e4a05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.5DueMay2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib71cdfc8616745bda08bb51063716d02_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.125DueNovember2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95b979d90da5452a905826924ce27d25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.125DueNovember2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64cb7a0107874445b5ef1241ac268ddb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.3DueDecember2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac6197c2e1f545da9f71938fe1794bba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.3DueDecember2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5c6a9cc0246481db45b0f13ad35ae23_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueMarch2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3054d36c450a4f1a949a59076296c836_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueMarch2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8a1d56e01764a95aa6ce0389dadcc42_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.125DueJuly2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d368fcdffdc46d3a0e01d94c43c30e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.125DueJuly2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c67e77d27e244a0a68d18b65e0bfd8a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.875DueAugust2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95d3bf9e9c15461f91c2413227e037e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.875DueAugust2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24053ea29d834108aadea2e1babdf1a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.05DueMarch2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8aad75638974bc3a8cc67695f56c0c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5.05DueMarch2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2904af2c2aa44bf0b544d9d2553f8e9e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point25PercentApril2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42e7542864f1465cbf09bf46b7a5efd8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point25PercentApril2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i142b09e623c74fd48e7fa4f8a407f130_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88943c99762a48acb5314b7f2e6035c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9857095e8f8462c8443313d13593edd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes5DueDecember2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i80a5bd02c59b48d08a90b3e9dc305deb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1fc6bc460b24a2d9f9e56bbbcc00fdd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i178a89f691034c3f89a0f58dd76f6e00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay162025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e8df175e7a746b1966ad9f58331ab59_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay162025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d1d90e160df4c6987e1a3d97b3ee6de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay112026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d274b43ce6b460b819a8816627a53ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay112026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09e418d01a724140b2e4c98ed177fb58_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay162027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81ac034e6bd446208baa342a62985862_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:RevolvingCreditFacilityExpiringMay162027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i69d9e769f3ec4ff9913f2a8111d4261a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:BackUpCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i672e486d94cb40d7a527afc4274d487f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:BackUpCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia959e4c514254a2b8079572e46d8906d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:BackUpCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee13a60d394448b5ac976fd2d9a8bc06_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1cf725ff0cd64d81815fe8e8b14333a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea5673d7807e4ec1a5450a0e6653c02a_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueJuly2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i65160d516bd047099c2e54b984917a8b_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.5DueJuly2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="ib1b72957684f401f892d85f44495d314_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="id5f6ffbd37304fc48f79a5e9b0b46aeb_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i822fccc0619141489184c841adb873a6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueDecember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9c47b439eae34e66b4c6b711b0356a0f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueDecember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic145b33260a44d0e8f2212d9f0defd82_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2.75DueDecember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iadc7cf66f76f4d89843f2feb6ead05a9_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.75DueDecember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4e5f9ad0e20745e2b8738a0b8561987b_I20210818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes2Point125PercentDueSeptember2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-18</instant>
        </period>
    </context>
    <context id="i79d2af0f86c541af9571d4910bbca9be_D20210818-20210818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2021-08-18</startDate>
            <endDate>2021-08-18</endDate>
        </period>
    </context>
    <context id="id5a0d766445d4eabbf62b2cae9bdafec_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point625PercentApril2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1250e762a87140739d6c5e728a186e5b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point75PercentApril2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i02d14dd77d014595a362cb2ecc741ab3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point125PercentApril2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i12df8267bbe141b3a7404c266a874107_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4Point25PercentApril2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibdbbb74b83b14c429e04b647517a9a11_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1c8ed04608904ccf99b54ecc1dc6986f_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point70PercentDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i261fa7d2be3a4e558c47f8185e46e39c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3Point70PercentDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a3e435c4d424340a17b5f25797bcf4c_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4PointThreePercentDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="ib2bac05524ef4721a76e0eb616aa0666_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4PointThreePercentDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="ifd21192d1e424d908a21238c5796151b_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:OutstandingSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25c312e3832345d184ca98519e12b9d1_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13f4471edaf148c9a01efea628761e98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa1dd2e3d7514370b3370e9417b8eb05_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.7DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i849a0c4d3cbb471192475ee1fb23de1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.7DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida81c2c8d73c4e8bb5a9daa090b941df_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f5b8050a2fb4ad5b42037c800d80489_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e6897a260054377ad600720e4fd68b9_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes43Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56faf938b6bd44ff9f91b9e6bc18f5ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes43Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e3f962b140e4d8bbed1c0e619a28998_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:OutstandingSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="iad0865b66832421a88a82f88e92f6b90_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="if76853d3efe14948b0d921504f1a2b1f_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4DueDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i6f8d117be10d448ba3e9812c1e7e4b01_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.7DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i91226dc64fe84ffcb8769e52de99bd30_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes3.7DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i8c996ffe9966457d93cce263d0c3eaac_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i2d884e077e99498da60db16f252f707a_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvs:SeniorNotes4.1DueMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ifc75d0fe4bd2436da019eb75a7875218_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i325dd5d5aff14a35ac1931e4f56f744d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1f77fd32daaf456d84374337f535221b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i13a134d0c0ea465cb742a54750a08aa5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia10042502b67476084251422c4796803_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id982dba0c5764350bf4b2c0dec65cd31_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if29585373b5145568d76c31491c626ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8ba0d622bb9e4ee59cdc9b56b5daa62d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iacd0213cc5bd41f29e44134f2087e2df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c02066515524b6ca358e7ec25ba43ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib6a598f7ffb4474aa216bbef8ffec30b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0242ebe0da9b43369d3dbd9a25daef7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9c35ee561744abb94e564009d6735fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08ea9fc5313346938adf5e13ee0bfcc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22f0ff1789f6444ab4732281654fe93d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i762b6378140b484aa6d1ca34c23de494_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e20cd8a6c7f4c69bb7918f0d9cd2739_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if267949f5fce4681b947f1a16a3838d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibeb053251d3444e3901668a924f82d40_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99f95fdf743e477a8ac66cfd99745de0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i252d55800dcb4295b654fd0658f6f573_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20101ed8d3e04a40b26eacb5e37c8c4f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifbc938e99b50474b91e168dd07faea18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b279e1f6f0b40a982401b8df9857736_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42da0c7a9d2b475584b0d47002072fc2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i06a50108c30e41368e58ccdb0e40fbda_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib79129f099714bef8ef8da1d8903ece5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bea816135474568b9b0446d98520e27_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6875cc4cb5c6442fa8caebb5f3329dd5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i92730350ea67406b893ebd2e0ed6b301_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8772a8c1e2e8403a88d7445ac2fed106_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifdbf916e80cb46918ba4e4c0df3ed889_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5ba20c704434ed2a8fab1c6dd389b1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaca7c2e9a27a4a1fa7a8bef02337334a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i162216dad2a6425bb441d4b6af324060_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01262b340a894b3c8b1efb258d3b571b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea00c6da074b480bb9fe7cc6bbcb98a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2ac6571e3d74f1dab3aee2141e35e2f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46dd8c46c55e411d908696c36b38b5c8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38e53b4aa76b4272aa433d30914b2324_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7900ae2c578549589f4451568700c87b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice5f3a8c54054f17989a4b4993615c41_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb4ffcb36d78416695e1e547f71c05d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a5a7f84e8ec40208e181a61a9d3aa89_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i860b2109de434ad680884c679dbcb1b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9aae37978eb34a42bbc35e64ec3c07a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8efc5986c964403b550888010f694f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87d7c0e5807e4c26ba8a3d14fdf19033_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e026ebe0d1141d08ec5920a50dddbad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide5901c6898f433fadeff64551df32fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0b828e6576e4f34bc10d207dbb869a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d343d8f5c2b4a6e8190984fc1f95d35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8cd82a6b704248499547541eb8ba6115_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab524d12dfb04d818c70ea4d09acb204_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2feba394cc284f1c8866c717b615d08c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic071fdd73a984fef8ee7bfd1c930b231_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6db2a706478c4614aec9544e1bfa5a50_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iefa80d56f1e74e55bffe7ec59a51f1f1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i674b362cb43f4f2cafbbd57f9e56a196_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d54224ea00f46f9a1e275c80a61b003_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ce41f46d8e84b7789c994f5feff9651_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if82b640a199e4868b36a915526dc2053_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i124f4f560a234bdfb5ec62a90aa60693_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib411c0d8ea7a4e8192645865166e5bc4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7d545bbe52647728f7c485d029e3b33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i282d5c6bb1c644ce9a4a5ffafc468287_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a6639e48973497fa396c0a952816890_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27b6f9af914a43a38de124a97f2cc7b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie55eb2e1866d4936acc91c5cfaf163e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94f3dfc3b0af4263962bc11ed03e1717_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i981507be87f94c918c4f5777451702ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i530d696f8fca4111b2384705d88e2528_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b34d8cf62304c8ab8b6b20efdeddbbb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c03a30159a84819aa7bf2d4b44b4940_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61796b34679f4c6cbef7783824db21ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8311648bcc5f4c0e9ba53519e18563bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95da6fe526324fc7915c89f6c760058b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if634ee5b01e4418e9eecd02c2b108b45_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ef579c6f5d94978a2551abaa400aaad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe781c3ffb934d7283abdcde5259b578_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22c76370e6bf4af2ba18b89ca655b55b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2a1ee87f2954456af17415d6e80fd4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i800dc1b5ac544829a5f96bf812a6959d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8dcf8da529f3410db68a945ba211481d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5889f8a183f94f0986fc8d265f0b65e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87a9186dc3884c56aed01709c057e146_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac90be0d15f44066902ebe3c398edd6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a27b2b60c0a4875ae1e21929139b434_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i448d068b73fe457c9473c2cf2c869646_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2be3d440d0034da59689eb9cb1b8e2a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id07efc7eec504e4dbd1c06bcc97776e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80434d583b9145699f6467db52e671d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c53fd3ce91e4d35b310ab8338e5a336_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a0c74c41ebd402f965dc97f83e3927e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i433675d63b154f81aec4043380ed969c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ec12e1923db4bf5b50d8480155727db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id027a3124e1a442f91f769b2d20a79cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc2ae24835514052914a58a5ed8c6960_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i276e89b1f499438e87a8b8ff11bfb821_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a32ea5d8145486abd0eee9eb65e2bc4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a17a9c673d747659358cf61fca64e75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb420b7594364d6893ae2d9594cf961d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a86bf692f18486d933d45d22e8027f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaef94353787243699d29dbbef2ede4aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3962569b68340cc9aacb0b0b4055650_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b93f4fc09a3435ea3369ffd815f169f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6c1ec54592a466aa4dc5711ca9dfd07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9d5c1701e6c488d94354e33e98ea977_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i107ab07b1f1242c2a31146ba192ea630_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d9fe69ee87141b0a74150684361d6d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c75d0c4c0d64349a39b959decd4ec41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fea1b150cad403f92fe062910c70247_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie818f0ce1b2d4700bf8a50b52e1ea2aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib37677b4bebe40289a4b9b7576269f3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib765d894de694d2094ea42b1892d468e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32eee2f391f44fae9f98ce3ecd31a02b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7671aaeacd046c9838da466ff4e34b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i414e18de330f46b88b7101cb98dd39ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:RedeemablePreferredSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i733ba5d142df4f60938808824882bdfc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20703722f40e44c4835113f54e1e12c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie12f7e25dae34ed19c14ceed1716dd91_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f089b62038641eca565000d9846ae75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idad31584585d475ea5dc99cd84a40282_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d3653f149da49b29def0497a05f984f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2a6c29224644307a2a9eb78032ad4e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbd0bc158bfa4d8c9a1eef38aeb153e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6419521af8914bc08f951b1558c156a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia201e25566f84e35aa96a9f051384c05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id46442f3513e4d8ead71ef391f535a91_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdbe5c58d7d04ef294e397fd28124004_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd84d2bfaae34c2589bfdb10af6646d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbdafb297a2242e5b3fb68a537d6f098_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08dd758138b84d4bb3085c8c44048020_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4696cfd2126a49aca34be6569c415e4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:EquitySecuritiesDomesticRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibdf302d352334c7eb29f6daa43872807_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9eb696de5db242c795422c37920e7842_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i077b6285cc31461598b42554e2d8d9c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28aea62135614aab87e0943dbebccb07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ee69f393002463ebc8b873e9f00a9e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d019c669092417cad902aabe452c43a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8340f5ec7e64baf9924bad129344c57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieeb435009ac34bbba8afb4a9051ebcbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff3f6572a7984acc83891d6ffe51dac6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i721f414643aa4d48a77204540a59ca02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95b3e6fd20854c36bac655b5705bd8c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i714696085e3846d5996660ba69ae9916_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i616fe276b0c14b9ea335de3ffe9e254b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89296715dad54dadab6556fc2a883b22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i236e33efcde54e91a4243a0e24ed6b08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5af8d0600cbc4be881c45d46a38b22c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6812d37c933b481db36130a6e153ad52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26e065eea181432cb10971a1ef6fa9dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia048e730866c404db59cbf7a969bb920_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic430f4dcb0f043c8b9a2999c5816e5e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1381345c3d5840459cf0370ce99902da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i766450bb0604426f8bdb03f539b684e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">cvs:DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia34c0f80bd2e4e66bd5efc598c7695bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00ba36ca870d489badec2a4b43f49a11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2ab04d328c64e48a9513092777617a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41df18924e1d461c9545e50ad75b2b04_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5e58d7651f6c4f319612d35334a716cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d63903b589946129164b093427d20a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bb557e906c74f7e8c3d94d93011a01b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91633285ed494358864442a95f7cd753_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieeb33c37ed48461980e0c720a0c2fc11_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida2e4bf976d74179b0af33275865eebe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a8ccea9aa6e45ac9a3904384d0f7055_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib0119b0ae5984713b7d9259c8207911d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i05bf309692224b32a5d32bdbc5a3fbfa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:PrivateEquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8fef45f25f3a4337982d480409e2d989_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55e008f794224642a71737a4f1c9d5ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f60b453fe2047f2af3b79714d2105b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80161528cfbe4d46ab7481e07799b74f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idad61766b42d4fafb3023b422e73ce62_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48c5af8bad60417f9e93bd229edece75_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5bd0c40f6d4d4d38ad212af3d36f1535_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvs:CVSHealth2017IncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia59ded7dac1144889cba911dcf81ff67_I20181128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvs:AetnaInc2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-28</instant>
        </period>
    </context>
    <context id="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ef82093f7f0425d98a812a8346206e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7dac89aa5750413097fe5ef4affd611a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idde68710333b4abcb62273527c7aef07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a23a3d9f60548f3aed4bd07d81cc620_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b8b6ee31b984216878b4a06ea213f22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:RestrictedStockUnitsAndPerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9667bb2fd2c24aae86f872138c4421cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63eef8534a884ca5866ee784287deaab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b15b8c19a5e466e8372796316b9b51c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iadc5be713ef141589563587eda40b96e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0254b09e69d04105bd0d52aecaece8a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77dc266c0f374e01a14893d1a6ea3f8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvs:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iadb4c5c9645e411fbac5109bc755e0aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i225620d3fec84216a7b76440b5de5139_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7d5aaeea5cd4364a999d22bc0e526c2_I20221117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2022RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="ice5463bac593422d85e68f6a31c6cd24_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2022RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i51eec47e53dc4a1c9685a39a8e5b3b47_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="i5316d30a5a634b0eb7ebde97e6094f70_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8233d450fa5745639d54e56448f03464_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic28fda85c05b4594a00f0a3402b95859_D20220104-20220104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:BarclaysBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-04</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <context id="i3dba707cd749450ca1bc96a22ff0d254_I20230104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:CitibankNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="i8ff381caf73a4c2db6637a9d0b8f3632_D20230104-20230104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:CitibankNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-04</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="i2c14530c00c646478ca97544065c4fbb_I20220104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:BarclaysBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-04</instant>
        </period>
    </context>
    <context id="ie70904e10fad41e29c390bf6b19d6203_I20220104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:BarclaysBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-04</instant>
        </period>
    </context>
    <context id="ia5c40ac9da1342d08ae7f70b317ddf53_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:BarclaysBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cvs:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="id5735f8f8c5444a2a0384aa456ca592f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i97d782259b904c979e113b78787ed48d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9289877d9c2c4ffcbaa2d99b1945576b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idc9209a44ddd41178541daa30bd6749f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i82a1252a04a84b3898c7e327a9c92b60_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i95e56c9158aa4a519e48b89d4b91b42a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="icfd8499c4fb34af58a98efbc5d640ce2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b5561cc39474810bff93b9bc55eddd3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec46daf9900b4a90868ccafe21f74ebb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibfbc41d71b734bae909dc80277dec2bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i297b60290a1245cc886da0051e954eac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66102a5aa12440b29e51c2d516b74676_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cvs:InsuranceAndHMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50e896501d7c436b96f31503738ed740_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia18c761ce4364ea2973eb59d2fd584ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5c2106ba1184ea692fbc96551d6d7b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8cb15071b54d40feb50954c737252518_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d4ff8f1d92a425284f720815593c158_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a0eaddda21c4a00be59a3852a2fda53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d6c784677034efab4d3c3761a6becc8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90e299f2c18e43bdae5d151661e82ef0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6a7074798cd4f7da8207ad643b5286e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7348d8b55d1847e59482a4dd6cabd5cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1acf0930000a47a28b1f1859847b12aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb67b8f18d2a41819af3ed1f45173118_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70d024dd953342978e381ef9ad09e97d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34691a75be1a40a485b08377e0d95591_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7cab5985f934b68b073707b0db81f68_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i053181ca045a4428aee792436b90324f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40550f17612e4e1c9a2bdb2e12646807_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae0bd8dfb5cf4f9e8b8252cd49e75e9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75fd10d334be4f38bba49ac3d51dd978_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7e3ddd79ec9406fbd5b0334e0a7cf99_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1de85626af2543b182ac0c8049528d59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48cedd332752429fb7fdcab29fe151c0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea5dc45a20214840ba91115d7f1be610_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63a9007fcb714cb09cc20b1eca666273_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id41faef8f0db4ed59ca3aaf9b30913d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9dbbb5af69624415b1974a87c4e00ef6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie82b5c6e85e2408ab675d8ef44a98158_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:StockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42a690cfa922477e90e45bfe9cff5f29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:StockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0842c61fceff4047b49c7ff6a4a293a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:StockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc14f04c8d094020a89b8124e4d67afd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic36f054975aa46feb063b56007b02a5c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf686621016a49b4a70be7291894b149_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e2b473c47f6447294d190668407b467_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="ieae0c3b0cc27418aa65414f0b7e927c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:HartfordLifeAndAccidentInsuranceCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic60de804b23546b8a91437fbf72dc2da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:HartfordLifeAndAccidentInsuranceCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf72aa41b4d449d0a2ac299a8c83a884_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:LincolnLifeAnnuityCompanyOfNewYorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b933e2ca792484e85ec73f2fc18e41a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:LincolnLifeAnnuityCompanyOfNewYorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic81da46ae9e64349a9aa6e17d4d8c486_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:VOYARetirementInsuranceAndAnnuityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f47abf8fc3f40f983bcf19e1da82db5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:VOYARetirementInsuranceAndAnnuityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ad53a23fba3447a8ca121fa57cf7591_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibde18ae73cba460eb19c034e2419cf09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9822742126ab4315872808cfba42b81c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:AllOtherReinsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id80e156bb7874df1abefdc699fdc0426_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">cvs:AllOtherReinsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib94af6bb921a4ca98da673595b30f6b8_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:FederalCourtInOhioJudgmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i674238d29a96415e993c632fa76902ca_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:FederalCourtInOhioJudgmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i3c90b72fd40546a18c44fdd0f007e70d_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:StateOfFloridaSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5f7c5a81f337450ca2ce09d3e8db9ce6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:StateOfFloridaSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2fce56acdb3745c9979b048ae472c0b0_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5a63bb22a404440f94e6605a0d60ed27_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57858d852b8743a5b17a414d3e2943ec_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:TribalEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b86d678e65d40eb8ee5c07845a9969a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvs:TribalEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibaf08dadd0964ffeadc4c69adb91d80b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i636ddceefabd4069a95a70b2bdaf5197_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7962defddb614936891d31be39fb3eac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f3002f09a51435f89d2352f78379bf9_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i9fe8dd796c0b4f6ea8bd03f8afa02daa_D20240101-20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:SettlementFrameworkAndOtherOpioidRelatedClaimsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i3a4ebb735c614e6f82dbc3e891377121_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:RadcliffAndFlaimVAetnaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaeb70648911a491891b5b5b40830d2fe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cvs:USFederalGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3a7e1c1a8e154045870fe18d7ed128a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cvs:USFederalGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd64cbb3284d45b6bf1aa429308ea5b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cvs:USFederalGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5aff3de0cc7c488a8aaa1c33fd802ab1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i14525e9b549048f4b399842e4567a558_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i55c34d747b754e57bfd880817586c1fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if7714f3521cb4944817a68243192c7b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24e89b8dd8884731928828b40d4e94d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15c6773f805e4bd59d68e8f7a0aa3308_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3fe920a5d654530aaf6d123f400d878_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:HealthCareBenefitsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id26c945fe20b40d684582e97afbd1616_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:PharmacyServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99de3811ad9244d2987587cc4326b954_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cvs:RetailLongTermCareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51c77ad05d064fde8d6341467c3515ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000064803</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="store">
        <measure>cvs:store</measure>
    </unit>
    <unit id="clinic">
        <measure>cvs:clinic</measure>
    </unit>
    <unit id="people">
        <measure>cvs:people</measure>
    </unit>
    <unit id="patient">
        <measure>cvs:patient</measure>
    </unit>
    <unit id="segment">
        <measure>cvs:Segment</measure>
    </unit>
    <unit id="state">
        <measure>cvs:state</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="member">
        <measure>cvs:member</measure>
    </unit>
    <unit id="security">
        <measure>cvs:security</measure>
    </unit>
    <unit id="reinsurance_agreement">
        <measure>cvs:reinsurance_agreement</measure>
    </unit>
    <unit id="lease">
        <measure>cvs:lease</measure>
    </unit>
    <unit id="claim">
        <measure>cvs:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl80L2ZyYWc6ZjgyN2RiNGQ3NDU4NDNlYjk2NjM1MjBhN2JiMGMyNmIvdGFibGU6NGQzYjAxZWZmMzY4NGI3ZjljODVhOThlMTY2OTdkNDMvdGFibGVyYW5nZTo0ZDNiMDFlZmYzNjg0YjdmOWM4NWE5OGUxNjY5N2Q0M18zLTEtMS0xLTE2NzkwOA_89719c21-d57e-416a-9b72-f668398848e0">0000064803</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl80L2ZyYWc6ZjgyN2RiNGQ3NDU4NDNlYjk2NjM1MjBhN2JiMGMyNmIvdGFibGU6NGQzYjAxZWZmMzY4NGI3ZjljODVhOThlMTY2OTdkNDMvdGFibGVyYW5nZTo0ZDNiMDFlZmYzNjg0YjdmOWM4NWE5OGUxNjY5N2Q0M180LTEtMS0xLTE2NzkwOA_d243e4a7-bf75-475b-ae32-7eb70d17eac5">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl80L2ZyYWc6ZjgyN2RiNGQ3NDU4NDNlYjk2NjM1MjBhN2JiMGMyNmIvdGFibGU6NGQzYjAxZWZmMzY4NGI3ZjljODVhOThlMTY2OTdkNDMvdGFibGVyYW5nZTo0ZDNiMDFlZmYzNjg0YjdmOWM4NWE5OGUxNjY5N2Q0M181LTEtMS0xLTE2NzkwOA_ada4dcd3-f6e2-4911-9ea5-e298327076c9">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl80L2ZyYWc6ZjgyN2RiNGQ3NDU4NDNlYjk2NjM1MjBhN2JiMGMyNmIvdGFibGU6NGQzYjAxZWZmMzY4NGI3ZjljODVhOThlMTY2OTdkNDMvdGFibGVyYW5nZTo0ZDNiMDFlZmYzNjg0YjdmOWM4NWE5OGUxNjY5N2Q0M182LTEtMS0xLTE2NzkwOA_6a243782-4cdb-44d6-a0de-009e7e05e5ae">false</dei:AmendmentFlag>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMC0xLTEtMTY3OTA4_1e4004b0-6498-4ea3-8ab1-ac09269493b2">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMC0xLTEtMTY3OTA4_3e2cf2f7-df85-4376-a35e-0669e17c468e">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMC0xLTEtMTY3OTA4_5eed1e85-5f6b-489c-9018-e11e62bf23d7">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ide6581f173394288a53fc090546c297c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzY1OTcwNjk3NjgxNzQ_dd91000a-d118-4a7c-8b68-d85f1dcfda5b">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMjY0_8d034ca5-401e-4526-8bb8-d8fed86877bb">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="i5b05aa08f755455f9dc89cacf2875829_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xOTIxL2ZyYWc6NTYyZjZjNjAyNmU1NGY1NWE3MzkwZmUyODc1YTAzZDUvdGFibGU6MmNjODdkOWQwNmJjNDA0NGI5NWMzYzZmOGJlYjkzYzAvdGFibGVyYW5nZToyY2M4N2Q5ZDA2YmM0MDQ0Yjk1YzNjNmY4YmViOTNjMF8xLTEtMS0xLTIyODk0Ng_a478b74f-99e9-416c-8cd7-d78631080796">P0Y</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="i131cd8cfbdc94fcdb157a2c4f138ad2e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xOTIxL2ZyYWc6NTYyZjZjNjAyNmU1NGY1NWE3MzkwZmUyODc1YTAzZDUvdGFibGU6MmNjODdkOWQwNmJjNDA0NGI5NWMzYzZmOGJlYjkzYzAvdGFibGVyYW5nZToyY2M4N2Q5ZDA2YmM0MDQ0Yjk1YzNjNmY4YmViOTNjMF8yLTEtMS0xLTIyODk0OA_91c2161e-2c81-4de2-92bb-7a77b0d82e37">P0Y</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_136d726d-4e4c-47e6-89b0-66598c753e01">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_f7e749bb-d161-4304-bb3e-6fdb8d5e52ce">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzE3Nzc_8d034ca5-401e-4526-8bb8-d8fed86877bb">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzcy_c6bf79c6-edfe-4b51-88c3-f4dd1962b553">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzcz_5710ef66-543f-4928-a3e4-4b9edf41b03f">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8yMTY_7a8e17a8-5eb5-4755-8bbc-e9b916cc9d01">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8yMTY_1e6ebf93-9114-44f8-b42f-eb07c5a70eb6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzY4_45f35a18-2a92-449c-8c31-4f67ccdf8752">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzc0_8c6dfbbe-40d2-4731-9eef-958003a205f9">001-01011</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzY5_d0ed2d06-1179-406d-85df-6c0ffe07964b">CVS HEALTH CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6YzZkNzdiMWUzZGU4NDkzZThhMTlkZTk4YzIzMjMzYmUvdGFibGVyYW5nZTpjNmQ3N2IxZTNkZTg0OTNlOGExOWRlOThjMjMyMzNiZV8wLTAtMS0xLTE2NzkwOA_f9ca81a9-3a01-4ba9-8632-c89b3720b640">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6YzZkNzdiMWUzZGU4NDkzZThhMTlkZTk4YzIzMjMzYmUvdGFibGVyYW5nZTpjNmQ3N2IxZTNkZTg0OTNlOGExOWRlOThjMjMyMzNiZV8wLTEtMS0xLTE2NzkwOA_5353ce62-c449-48bf-8218-65ba20d1d757">05-0494040</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6N2UwNGY2NWJhZWY0NDUwMzkzZDIyNDhhZmVmNDdhOTAvdGFibGVyYW5nZTo3ZTA0ZjY1YmFlZjQ0NTAzOTNkMjI0OGFmZWY0N2E5MF8wLTAtMS0xLTE2NzkwOA_30c0d94c-6202-4ff8-9e2b-d5700283df03">One CVS Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6N2UwNGY2NWJhZWY0NDUwMzkzZDIyNDhhZmVmNDdhOTAvdGFibGVyYW5nZTo3ZTA0ZjY1YmFlZjQ0NTAzOTNkMjI0OGFmZWY0N2E5MF8wLTEtMS0xLTE2NzkwOA_42aaa699-e645-4727-834d-412ebf58e2cb">Woonsocket,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6N2UwNGY2NWJhZWY0NDUwMzkzZDIyNDhhZmVmNDdhOTAvdGFibGVyYW5nZTo3ZTA0ZjY1YmFlZjQ0NTAzOTNkMjI0OGFmZWY0N2E5MF8wLTItMS0xLTE2NzkwOA_05587c8e-819c-400b-941e-02a430d1abef">RI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6N2UwNGY2NWJhZWY0NDUwMzkzZDIyNDhhZmVmNDdhOTAvdGFibGVyYW5nZTo3ZTA0ZjY1YmFlZjQ0NTAzOTNkMjI0OGFmZWY0N2E5MF8wLTMtMS0xLTE2NzkwOA_bf39c512-788d-4901-ad2d-478e3cfa7c4d">02895</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzQ2MTFjYTA5M2I2NDZmY2FhNjU1NWQ0NmVhMTgwNjcvdGFibGVyYW5nZTozNDYxMWNhMDkzYjY0NmZjYWE2NTU1ZDQ2ZWExODA2N18wLTEtMS0xLTE2NzkwOA_a8d7af59-14d4-4688-8156-d34fdeb14da3">(401)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzQ2MTFjYTA5M2I2NDZmY2FhNjU1NWQ0NmVhMTgwNjcvdGFibGVyYW5nZTozNDYxMWNhMDkzYjY0NmZjYWE2NTU1ZDQ2ZWExODA2N18wLTItMS0xLTE2NzkwOA_bcb5c5d7-a88b-4e8c-b130-a550d1e13680">765-1500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MWJkYjYzODQ1OWI2NDdjNGFiNzI1MmYxZGMzNTJkOTEvdGFibGVyYW5nZToxYmRiNjM4NDU5YjY0N2M0YWI3MjUyZjFkYzM1MmQ5MV8yLTAtMS0xLTE2NzkwOA_23ff76f9-7c5b-4685-934f-e83130c453d1">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MWJkYjYzODQ1OWI2NDdjNGFiNzI1MmYxZGMzNTJkOTEvdGFibGVyYW5nZToxYmRiNjM4NDU5YjY0N2M0YWI3MjUyZjFkYzM1MmQ5MV8yLTEtMS0xLTE2NzkwOA_2f5a6a11-7293-4433-90f9-965820df1844">CVS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MWJkYjYzODQ1OWI2NDdjNGFiNzI1MmYxZGMzNTJkOTEvdGFibGVyYW5nZToxYmRiNjM4NDU5YjY0N2M0YWI3MjUyZjFkYzM1MmQ5MV8yLTItMS0xLTE2NzkwOA_241b0c7c-ccb8-49ce-ae32-df414c287d6e">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8wLTUtMS0xLTE2NzkwOA_cd65779b-edd2-475b-b7f1-5dfc711987cf">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8xLTctMS0xLTE2NzkwOA_9db59914-4329-46b5-ac16-893342238494">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8yLTUtMS0xLTE2NzkwOA_97055b92-edac-4b28-8f2b-80594b9b3a7f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8zLTUtMS0xLTE2NzkwOA_dfe22229-12d8-4b70-bea2-f34894a746b4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF81LTAtMS0xLTE2NzkwOA_94d5da12-098f-49ee-81e4-9f3f96eb0fc5">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF82LTctMS0xLTE2NzkwOA_f05a2f14-da98-4bbf-b85f-661932c8109d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF83LTctMS0xLTE2NzkwOA_1bb66db2-e71f-4f65-be94-bcb670887527">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF85LTctMS0xLTE2NzkwOA_9a424a65-038c-4df2-91b3-2a91e978d810">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGFibGU6MzNlMzAwODVhNDBhNGRhMzk3Yjk2NTBhMzA5Mjc3MWQvdGFibGVyYW5nZTozM2UzMDA4NWE0MGE0ZGEzOTdiOTY1MGEzMDkyNzcxZF8xMi00LTEtMS0yMjU4ODc_9ae6be34-066c-4207-ba17-9a8e3153e8c8">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ieef592c79265415e9514a93ffb9ae4ac_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF81OTQ_d88a31ef-7a29-49b4-9d48-a99ae8c52dc5"
      unitRef="usd">121258020752</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i40ddf3f5cfcf4be7a0d007238cbe2748_I20230201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF84NTk_1f1cbee8-9ef2-407a-a639-7effdaef8987"
      unitRef="shares">1284111667</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xL2ZyYWc6YTI5YjhlOWY1ODdkNGFmMzhkZTJiYjg3ZjRhNWVjMGQvdGV4dHJlZ2lvbjphMjliOGU5ZjU4N2Q0YWYzOGRlMmJiODdmNGE1ZWMwZF8xMzcx_b0aa3516-5075-4d83-81fc-c29a545bf56a">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following materials are incorporated by reference into this Form 10-K:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Information contained in the definitive proxy statement for CVS Health Corporation&#x2019;s 2023 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2022 (the &#x201c;Proxy Statement&#x201d;), is incorporated by reference in Parts III and IV to the extent described therein.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDAvZnJhZzpiNWEyYjQwNGQ0M2M0NGFhYjRlMmJiMmI4MTBmM2Y5Yy90YWJsZToyNWRlMDZiNWFlYTA0OTA1YWY1Y2ZmNWQ3NDAzNWM4Yi90YWJsZXJhbmdlOjI1ZGUwNmI1YWVhMDQ5MDVhZjVjZmY1ZDc0MDM1YzhiXzEzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmNlNTc2MTUxMzM3NDQ1ZTliNzJlYjViOTdjMWY5OTA5XzEwOA_2eacdf94-6bb9-44d2-86a0-c72ee972e7e1">42</dei:AuditorFirmId>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21d91c5c532243ef9f94c642820dbac4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMtMS0xLTEtMTY3OTA4_479f11c4-79fa-43b6-a193-ed099d687983"
      unitRef="usd">226616000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a740dd129184890b8bde10a27ca4208_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMtMy0xLTEtMTY3OTA4_badde249-5a2e-49eb-8b5b-f7364e7152bf"
      unitRef="usd">203738000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia465cf35ed0f45939b52004b01431e3d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMtNS0xLTEtMTY3OTA4_3e68c4ae-7387-4008-847c-29f561d5f8a8"
      unitRef="usd">190688000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PremiumsEarnedNet
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzQtMS0xLTEtMTY3OTA4_1354c69b-7405-4503-9852-07875175fe82"
      unitRef="usd">85330000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzQtMy0xLTEtMTY3OTA4_a7816565-33f5-418a-a2d0-3c2af99eaa90"
      unitRef="usd">76132000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzQtNS0xLTEtMTY3OTA4_9441a206-7f66-4168-90d1-6e740391ee3f"
      unitRef="usd">69364000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6db92dc898a14220a458e7987f33b9ff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzUtMS0xLTEtMTY3OTA4_a2df9ca0-86e8-4e28-b32b-f3a5674729e4"
      unitRef="usd">9683000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdce439e9a164fc590536f15958f67f9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzUtMy0xLTEtMTY3OTA4_811a9f1c-4d3f-4440-ac66-4a64786d3823"
      unitRef="usd">11042000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic793b82f8aae4503ad92cb8081fb8628_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzUtNS0xLTEtMTY3OTA4_35b82836-18d4-4e02-ad9a-0e5cde0a4bba"
      unitRef="usd">7856000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetInvestmentIncome
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzYtMS0xLTEtMTY3OTA4_efaca6be-afc0-45cb-bd32-fd2c915eb1b0"
      unitRef="usd">838000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzYtMy0xLTEtMTY3OTA4_ef1a4656-b233-46b4-9fb5-4b4442627c15"
      unitRef="usd">1199000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzYtNS0xLTEtMTY3OTA4_232068a4-95e2-4cbb-b151-f2fb3b425910"
      unitRef="usd">798000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzctMS0xLTEtMTY3OTA4_9f004c42-1157-432f-a2f0-914bb1b2a7e2"
      unitRef="usd">322467000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzctMy0xLTEtMTY3OTA4_682b9399-e100-4493-ba8e-da2852a1a3a1"
      unitRef="usd">292111000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzctNS0xLTEtMTY3OTA4_ab63edc4-f029-40b1-965b-653749dfad43"
      unitRef="usd">268706000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMS0xLTEtMTY3OTA4_bd00b793-35f5-4c24-b653-08672e9be2d1"
      unitRef="usd">196892000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktMy0xLTEtMTY3OTA4_3c4c0bf3-35cb-4c4b-b623-085f391ba77a"
      unitRef="usd">175803000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzktNS0xLTEtMTY3OTA4_afc80d66-9ee1-4365-8f0d-cba28a05f7e7"
      unitRef="usd">163981000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEwLTEtMS0xLTE2NzkwOA_5e639e29-50b1-4cc8-a287-d3f139df18b8"
      unitRef="usd">71281000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEwLTMtMS0xLTE2NzkwOA_120bda64-f68c-4288-a48a-a8ae18ae3bd1"
      unitRef="usd">64260000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEwLTUtMS0xLTE2NzkwOA_5c518517-a52a-4425-be3f-e9519f8fdd35"
      unitRef="usd">55679000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTEtMS0xLTE5OTE2Mg_5383cce1-9300-429a-af7d-02b284114736"
      unitRef="usd">-5803000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTMtMS0xLTE5OTE2Mg_b88b3392-8e11-4d4e-9d10-9df43ae01003"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTUtMS0xLTE5OTE2Mg_a920327e-82b4-429f-b6e5-586526cd1e22"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTEtMS0xLTE5OTE2Mg_c1d1c1e1-8c22-4c01-a725-54d07f3cd028"
      unitRef="usd">2533000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTMtMS0xLTE5OTE2Mg_d694b2b6-916e-488b-b9a1-5db4a1ea3441"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTUtMS0xLTE5OTE2Mg_94d8994a-915f-4a9f-be6f-5c8cccedce78"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <cvs:StoreImpairmentCharges
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTEtMS0xLTE2NzkwOA_58caeb19-1c5e-483b-aa06-fd0e7abf68ca"
      unitRef="usd">0</cvs:StoreImpairmentCharges>
    <cvs:StoreImpairmentCharges
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTMtMS0xLTE2NzkwOA_f16f11c3-2628-426e-82ea-7433d863f396"
      unitRef="usd">1358000000</cvs:StoreImpairmentCharges>
    <cvs:StoreImpairmentCharges
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzExLTUtMS0xLTE2NzkwOA_f20784f3-ad06-41d4-b7b8-91c40b9fc8cf"
      unitRef="usd">0</cvs:StoreImpairmentCharges>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTEtMS0xLTE2NzkwOA_da20fed1-ad27-4aa9-bdfa-6ea3e80be346"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTMtMS0xLTE2NzkwOA_2b1b5c98-5694-426f-a9a0-e4f3b1962c41"
      unitRef="usd">431000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEyLTUtMS0xLTE2NzkwOA_9a9acd7c-fc54-47b6-b37a-fb8b55f1abe7"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <cvs:OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEzLTEtMS0xLTE2NzkwOA_4f17f163-6b50-4819-8bc4-b89a553a7e3f"
      unitRef="usd">38212000000</cvs:OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement>
    <cvs:OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEzLTMtMS0xLTE2NzkwOA_48b853c3-7066-4974-85f1-c2c6f60ca5f0"
      unitRef="usd">37066000000</cvs:OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement>
    <cvs:OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzEzLTUtMS0xLTE2NzkwOA_a9fb233b-fa2d-496e-a9ac-681d6f79438f"
      unitRef="usd">35135000000</cvs:OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement>
    <us-gaap:CostsAndExpenses
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE0LTEtMS0xLTE2NzkwOA_501013f6-2c30-40e0-96c8-62ff84b644ac"
      unitRef="usd">314721000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE0LTMtMS0xLTE2NzkwOA_6694e6ec-e784-4120-8379-322d21bc0136"
      unitRef="usd">278918000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE0LTUtMS0xLTE2NzkwOA_ff9309b1-9d24-4973-ad2e-57b584ef8eb4"
      unitRef="usd">254795000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE1LTEtMS0xLTE2NzkwOA_4935b40e-b9c1-4963-81bd-8a8fe9d3e8c2"
      unitRef="usd">7746000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE1LTMtMS0xLTE2NzkwOA_6e2b78d3-9384-4f3b-ab4b-0f53c9ae9bc4"
      unitRef="usd">13193000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE1LTUtMS0xLTE2NzkwOA_6935221f-f715-4050-8c12-9c39414741f5"
      unitRef="usd">13911000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE2LTEtMS0xLTE2NzkwOA_0860d32f-3425-456f-a036-9fa009c08c71"
      unitRef="usd">2287000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE2LTMtMS0xLTE2NzkwOA_f970e5f1-56fc-49b9-8f99-60804bf298f0"
      unitRef="usd">2503000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE2LTUtMS0xLTE2NzkwOA_42e81952-af47-4d0b-b4d9-15649a24548f"
      unitRef="usd">2907000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE3LTEtMS0xLTE2NzkwOA_454cd8c1-add2-4e5c-9567-e081e08c8ead"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE3LTMtMS0xLTE2NzkwOA_24894c70-29be-4f18-8b37-405c0641f3e8"
      unitRef="usd">-452000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE3LTUtMS0xLTE2NzkwOA_a07696b0-3fd4-49e9-85ac-1f6521018315"
      unitRef="usd">-1440000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE4LTEtMS0xLTE2NzkwOA_5723ef22-2243-4a7b-8bae-504ff9ddabbc"
      unitRef="usd">169000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE4LTMtMS0xLTE2NzkwOA_8329b71d-1751-4ac1-86d6-5b70945c4320"
      unitRef="usd">182000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE4LTUtMS0xLTE2NzkwOA_1f25a498-e901-4ab5-a63f-0ef19d8a5adf"
      unitRef="usd">206000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE5LTEtMS0xLTE2NzkwOA_cbe7c529-b61e-4952-8d48-6638a89c693c"
      unitRef="usd">5628000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE5LTMtMS0xLTE2NzkwOA_9dce002e-eac6-479a-86d6-0c29449947eb"
      unitRef="usd">10420000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzE5LTUtMS0xLTE2NzkwOA_02319f88-3bd9-4550-8745-abb6c17d4e0d"
      unitRef="usd">9770000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIwLTEtMS0xLTE2NzkwOA_fe3a4840-68a2-451b-bf45-e9ec8052a9d2"
      unitRef="usd">1463000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIwLTMtMS0xLTE2NzkwOA_20c963c2-ad1d-430b-b4a2-31e18b842901"
      unitRef="usd">2522000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIwLTUtMS0xLTE2NzkwOA_0e7585f4-8159-4f5c-9764-f2c3c878d951"
      unitRef="usd">2569000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIxLTEtMS0xLTE2NzkwOA_18e1c5d3-ac2b-405d-9c12-878ab7111207"
      unitRef="usd">4165000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIxLTMtMS0xLTE2NzkwOA_5bd267c4-77aa-4034-b029-72ddc823e2b9"
      unitRef="usd">7898000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIxLTUtMS0xLTE2NzkwOA_9474086a-57ce-45e1-b125-4780ebc7b517"
      unitRef="usd">7201000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIyLTEtMS0xLTE2NzkwOA_2286d232-26f0-487c-93bf-9f9eafdb9fe0"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIyLTMtMS0xLTE2NzkwOA_ced6bb05-3423-4dfe-bf1c-7a3e454063cb"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIyLTUtMS0xLTE2NzkwOA_9974005a-d3fb-4a4e-b91a-4ccad4e063bc"
      unitRef="usd">-9000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIzLTEtMS0xLTE2NzkwOA_aaaf6e99-4146-437f-a302-445346162eeb"
      unitRef="usd">4165000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIzLTMtMS0xLTE2NzkwOA_ca11db01-5f6a-4254-a20e-2cbc60f67f05"
      unitRef="usd">7898000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzIzLTUtMS0xLTE2NzkwOA_1b582bad-c97b-4ec0-a875-5deeb4b4b270"
      unitRef="usd">7192000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI0LTEtMS0xLTE2NzkwOA_d9d0c7fc-7bd1-493c-8348-e86d5a3bcfa1"
      unitRef="usd">16000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI0LTMtMS0xLTE2NzkwOA_3632fe89-9ace-41a0-8656-7cb88506b169"
      unitRef="usd">-12000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI0LTUtMS0xLTE2NzkwOA_b193f8e0-b351-4c4d-9ed6-ed56405c6a44"
      unitRef="usd">13000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI1LTEtMS0xLTE2NzkwOA_ac218e4e-a0b5-4d1a-80e6-e08c5a26a59c"
      unitRef="usd">4149000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI1LTMtMS0xLTE2NzkwOA_01a53cd5-01cc-4234-b2c0-74cb5c530c06"
      unitRef="usd">7910000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI1LTUtMS0xLTE2NzkwOA_30ba5e70-57f0-4707-80f5-50b91f1f0ded"
      unitRef="usd">7179000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI4LTEtMS0xLTE2NzkwOA_2af0e80e-bb25-4126-96b7-f5bc9c5d9fc4"
      unitRef="usdPerShare">3.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI4LTMtMS0xLTE2NzkwOA_6429b5e9-c836-40ff-b67e-d453d59ab93b"
      unitRef="usdPerShare">6.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI4LTUtMS0xLTE2NzkwOA_2575dd51-e664-4ab0-93f2-c15f470aeb05"
      unitRef="usdPerShare">5.49</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI5LTEtMS0xLTE2NzkwOA_080d095c-6439-44e3-b503-6245f0feabf0"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI5LTMtMS0xLTE2NzkwOA_625b81ea-0e56-414c-ac90-f08b7c8429a3"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzI5LTUtMS0xLTE2NzkwOA_b72add1c-fd97-40ac-afd2-56a71a43c51e"
      unitRef="usdPerShare">-0.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMwLTEtMS0xLTE2NzkwOA_dbe59e61-0e41-4053-bd73-5f1469cd5159"
      unitRef="usdPerShare">3.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMwLTMtMS0xLTE2NzkwOA_42ae7028-cca0-46f3-9e89-26315f803164"
      unitRef="usdPerShare">6.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMwLTUtMS0xLTE2NzkwOA_9b50c973-b401-4168-95a1-b061687c2ab0"
      unitRef="usdPerShare">5.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMxLTEtMS0xLTE2NzkwOA_69afecf8-2c92-41ea-954a-b3ac18270135"
      unitRef="shares">1312000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMxLTMtMS0xLTE2NzkwOA_20d3c409-9529-43cb-972b-5de40e9a3982"
      unitRef="shares">1319000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMxLTUtMS0xLTE2NzkwOA_daaad5f3-3c44-46de-84c9-fdbcfef9c838"
      unitRef="shares">1309000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMzLTEtMS0xLTE2NzkwOA_6764d1d1-011b-4370-80f6-9ef991bec0fc"
      unitRef="usdPerShare">3.14</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMzLTMtMS0xLTE2NzkwOA_9e42b177-a1fd-4d30-9a90-5148839ee8dd"
      unitRef="usdPerShare">5.95</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzMzLTUtMS0xLTE2NzkwOA_60db5555-33cd-465c-9ac3-8d5691776f72"
      unitRef="usdPerShare">5.47</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM0LTEtMS0xLTE2NzkwOA_0b7c8b83-ad58-4ef9-a507-6198e29bc717"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM0LTMtMS0xLTE2NzkwOA_46f15270-44ef-46c1-b465-2720578a06aa"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM0LTUtMS0xLTE2NzkwOA_0f48500c-8aa3-4266-bc99-df49ce1cbd0d"
      unitRef="usdPerShare">-0.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM1LTEtMS0xLTE2NzkwOA_ec6f2a5e-aa12-483e-8c99-849494a016bc"
      unitRef="usdPerShare">3.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM1LTMtMS0xLTE2NzkwOA_ed4de78c-366d-436e-820c-9e3f7827aa9c"
      unitRef="usdPerShare">5.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM1LTUtMS0xLTE2NzkwOA_084d5f3b-cead-44f4-8fde-7020d54dace6"
      unitRef="usdPerShare">5.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM2LTEtMS0xLTE2NzkwOA_689e7e1d-7ba7-494d-9791-17e5e5a375a0"
      unitRef="shares">1323000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM2LTMtMS0xLTE2NzkwOA_75fdec06-9847-46bb-a5a8-3222dd3cfccf"
      unitRef="shares">1329000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM2LTUtMS0xLTE2NzkwOA_65709379-3da3-4358-a9c4-8f5e9d8d48d6"
      unitRef="shares">1314000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM3LTEtMS0xLTE2NzkwOA_18332b5b-edbf-44d5-8d88-fd070fd15f2f"
      unitRef="usdPerShare">2.20</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM3LTMtMS0xLTE2NzkwOA_0a0e653b-a3bb-40f6-9c3c-7e9385b5f740"
      unitRef="usdPerShare">2.00</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDMvZnJhZzo3NjhiOWQ1ODQ1M2U0YjJmOTE0ODBkYTdkODU4ZGQ3My90YWJsZTo3MmZiMWE2ZTIyODM0OGZiODMwYTY1NDRmN2Q0ZjJjMS90YWJsZXJhbmdlOjcyZmIxYTZlMjI4MzQ4ZmI4MzBhNjU0NGY3ZDRmMmMxXzM3LTUtMS0xLTE2NzkwOA_80ea5baa-41e5-4699-8d1d-55e0d179f459"
      unitRef="usdPerShare">2.00</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzItMS0xLTEtMTY3OTA4_aaaf6e99-4146-437f-a302-445346162eeb"
      unitRef="usd">4165000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzItMy0xLTEtMTY3OTA4_ca11db01-5f6a-4254-a20e-2cbc60f67f05"
      unitRef="usd">7898000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzItNS0xLTEtMTY3OTA4_1b582bad-c97b-4ec0-a875-5deeb4b4b270"
      unitRef="usd">7192000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzQtMS0xLTEtMTY3OTA4_ac3f207f-ee1b-45dd-9d34-d4ee708644c0"
      unitRef="usd">-2279000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzQtMy0xLTEtMTY3OTA4_bf8dc250-1323-46f7-a2a1-d1d93ff32282"
      unitRef="usd">-436000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzQtNS0xLTEtMTY3OTA4_3ab1e12e-19d3-4394-9ba7-f78355970461"
      unitRef="usd">440000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzUtMS0xLTEtMTY3OTA4_7fed84dd-005f-4836-ad01-1ea773092926"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzUtMy0xLTEtMTY3OTA4_7d9c6392-cfed-44a4-9aab-8006f0a4f3b0"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzUtNS0xLTEtMTY3OTA4_04296959-18b5-4a21-b2a9-04ccc09566b6"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzYtMS0xLTEtMTY3OTA4_44d8b245-5c2e-4b58-82c2-5c92a25d08fd"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzYtMy0xLTEtMTY3OTA4_b4b4880c-4d97-4762-a9df-048e8d8890df"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzYtNS0xLTEtMTY3OTA4_02c10882-ade1-45f8-9aa0-d3449687b500"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzctMS0xLTEtMTY3OTA4_71e2bc7f-2e57-429b-ab63-1e897bdb63a7"
      unitRef="usd">168000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzctMy0xLTEtMTY3OTA4_10dd053e-4e4a-44bf-a92d-6beea2020211"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzctNS0xLTEtMTY3OTA4_63bf1a6d-bb3a-4e86-ae63-2ed18fa45dae"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzgtMS0xLTEtMTY3OTA4_f53021cd-5423-4a97-863d-3286bf7d3205"
      unitRef="usd">-2430000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzgtMy0xLTEtMTY3OTA4_2194d3cf-9f3a-44ba-a312-6d65376fe997"
      unitRef="usd">-449000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzgtNS0xLTEtMTY3OTA4_8a87fd00-8593-4fc8-9a9c-0b420cda3d84"
      unitRef="usd">395000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzktMS0xLTEtMTY3OTA4_18eb2f21-6b45-4bd4-abcc-46b7a4a3010a"
      unitRef="usd">1735000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzktMy0xLTEtMTY3OTA4_54d08d08-3883-48c8-bb4b-f9e0d1d72b5a"
      unitRef="usd">7449000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzktNS0xLTEtMTY3OTA4_b06f394b-5bc1-493f-baff-40bcad29514b"
      unitRef="usd">7587000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzEwLTEtMS0xLTE2NzkwOA_65b51aa1-f36b-4a3e-b694-d8873dcddeed"
      unitRef="usd">16000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzEwLTMtMS0xLTE2NzkwOA_65cb226b-3fab-419a-b12f-15be6fbb611f"
      unitRef="usd">-12000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzEwLTUtMS0xLTE2NzkwOA_63b8b294-d3c9-4827-9740-7f50dce32739"
      unitRef="usd">13000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzExLTEtMS0xLTE2NzkwOA_d9a333c7-dbca-437b-bf7a-935fb7caf283"
      unitRef="usd">1719000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzExLTMtMS0xLTE2NzkwOA_743ac195-278a-4a50-80a1-8c5ba344a648"
      unitRef="usd">7461000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDYvZnJhZzo3MjEwZGNlODQ5NTY0MDAzYWZmYzdhMWMxODQwYWEyYy90YWJsZTo5ZjYzOTExMTc3OTk0MWIwYjQzMGYzYzJiMjIxNzYxOC90YWJsZXJhbmdlOjlmNjM5MTExNzc5OTQxYjBiNDMwZjNjMmIyMjE3NjE4XzExLTUtMS0xLTE2NzkwOA_0bccc0eb-832f-4fbe-b8a6-17eed6d437c4"
      unitRef="usd">7574000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMtMS0xLTEtMTY3OTA4_f7255fd6-69e2-42a1-9f49-c68f0f0b49c4"
      unitRef="usd">12945000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMtMy0xLTEtMTY3OTA4_4a733a18-a12b-40b6-8610-d1cbebec85f7"
      unitRef="usd">9408000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQtMS0xLTEtMTY3OTA4_3c2acd80-33bd-420c-990a-6ad81f89c1a2"
      unitRef="usd">2778000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQtMy0xLTEtMTY3OTA4_5eda9dc3-a094-4223-884c-6fae5f53c393"
      unitRef="usd">3117000000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzUtMS0xLTEtMTY3OTA4_1e92d328-f74f-4d3c-9eb9-4b87de109598"
      unitRef="usd">27276000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzUtMy0xLTEtMTY3OTA4_091039c0-775b-4e42-9665-dc672c2b55d2"
      unitRef="usd">24431000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzYtMS0xLTEtMTY3OTA4_b16584bb-3bc8-4fbd-a6e4-e0507807343a"
      unitRef="usd">19090000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzYtMy0xLTEtMTY3OTA4_013d4488-72b8-4e70-9e45-d17d502a507d"
      unitRef="usd">17760000000</us-gaap:InventoryNet>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzctMS0xLTEtMTk5MTg0_4ba8c0d7-6936-435e-8ee7-2dc80b68bc3f"
      unitRef="usd">908000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzctMy0xLTEtMTk5MTg0_f0f4ef04-f0a8-401b-aa22-fad09fe3c3fd"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzctMS0xLTEtMTY3OTA4_07764d79-3c96-442c-9ec5-48778c3e6e67"
      unitRef="usd">2685000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzctMy0xLTEtMTY3OTA4_82a0be26-576b-4861-b849-9648b4025df8"
      unitRef="usd">5292000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzgtMS0xLTEtMTY3OTA4_36544427-7a3e-4086-b789-cf351c05ae1b"
      unitRef="usd">65682000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzgtMy0xLTEtMTY3OTA4_5330fdfb-ab47-46c6-9fe8-d5afdcd8b175"
      unitRef="usd">60008000000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzktMS0xLTEtMTY3OTA4_c11c9c71-0d30-4f42-9448-74b652d0857a"
      unitRef="usd">21096000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzktMy0xLTEtMTY3OTA4_7d4f964b-caef-402a-9b9f-8948c256deb7"
      unitRef="usd">23025000000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEwLTEtMS0xLTE2NzkwOA_42d96e01-9cac-4510-9254-eda2214f8b17"
      unitRef="usd">12873000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEwLTMtMS0xLTE2NzkwOA_2a1bdaed-f546-41b8-8a60-56dc94010583"
      unitRef="usd">12896000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzExLTEtMS0xLTE2NzkwOA_43b97263-a430-4a5a-a984-7df8a7599847"
      unitRef="usd">17872000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzExLTMtMS0xLTE2NzkwOA_2827b636-9156-43a0-bf95-acca173f4808"
      unitRef="usd">19122000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEyLTEtMS0xLTE2NzkwOA_8c4ecd21-719c-41e9-9475-595329a53fb3"
      unitRef="usd">78150000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEyLTMtMS0xLTE2NzkwOA_094293ab-1e88-4a9c-ac8f-27c706fb6890"
      unitRef="usd">79121000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEzLTEtMS0xLTE2NzkwOA_ecc846f8-4bfb-49e7-84b1-1a94b727bd03"
      unitRef="usd">24754000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzEzLTMtMS0xLTE2NzkwOA_48f65a06-85d5-4242-89db-df1d510b80cc"
      unitRef="usd">29026000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:SeparateAccountAssets
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE0LTEtMS0xLTE2NzkwOA_c3a3c354-e5f5-4ea9-b4a2-06e1f945fe82"
      unitRef="usd">3228000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE0LTMtMS0xLTE2NzkwOA_07089818-b39e-42ec-a8f5-d7261fed1780"
      unitRef="usd">5087000000</us-gaap:SeparateAccountAssets>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE1LTEtMS0xLTE2NzkwOA_93dd7a8c-79c3-4457-96fc-0113dce33ab1"
      unitRef="usd">4620000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE1LTMtMS0xLTE2NzkwOA_05a1107f-c1ef-4c65-89a2-e827ab54a24e"
      unitRef="usd">4714000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE2LTEtMS0xLTE2NzkwOA_5cd4cb0e-be14-45ff-a712-6f6850c556d7"
      unitRef="usd">228275000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE2LTMtMS0xLTE2NzkwOA_1b48b835-7d64-4335-826a-4b68b1b0dc96"
      unitRef="usd">232999000000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE5LTEtMS0xLTE2NzkwOA_79db4803-790d-4be1-bebc-57935ef5d8af"
      unitRef="usd">14838000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzE5LTMtMS0xLTE2NzkwOA_3785f330-3e5c-467f-9102-34cca46f7c23"
      unitRef="usd">12544000000</us-gaap:AccountsPayableTradeCurrent>
    <cvs:PharmacyClaimsAndDiscountsPayableCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIwLTEtMS0xLTE2NzkwOA_e8f0978f-1d8f-4cac-9a42-0ee519c3aae9"
      unitRef="usd">19423000000</cvs:PharmacyClaimsAndDiscountsPayableCurrent>
    <cvs:PharmacyClaimsAndDiscountsPayableCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIwLTMtMS0xLTE2NzkwOA_6f890bbc-2015-4d4b-983a-c25c5d6956b9"
      unitRef="usd">17330000000</cvs:PharmacyClaimsAndDiscountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIxLTEtMS0xLTE2NzkwOA_f87618d1-4277-4b66-8927-166fa1dad87e"
      unitRef="usd">10406000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIxLTMtMS0xLTE2NzkwOA_60e679d2-a21e-4982-a3ec-77c8dcf6a483"
      unitRef="usd">8808000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:OtherPolicyholderFunds
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIyLTEtMS0xLTE2NzkwOA_5b588b41-3153-4c05-b0f5-456397d24980"
      unitRef="usd">1500000000</us-gaap:OtherPolicyholderFunds>
    <us-gaap:OtherPolicyholderFunds
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIyLTMtMS0xLTE2NzkwOA_1f4b3e5a-95f4-4990-a1e6-ebae5cd82764"
      unitRef="usd">4301000000</us-gaap:OtherPolicyholderFunds>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIzLTEtMS0xLTE2NzkwOA_2a78fdd2-301e-4be8-b60f-91975c871ffd"
      unitRef="usd">18745000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzIzLTMtMS0xLTE2NzkwOA_4af4fcd0-2f8f-49cf-91c1-2f010562e561"
      unitRef="usd">17670000000</us-gaap:AccruedLiabilitiesCurrent>
    <cvs:OtherInsuranceLiabilitiesCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI0LTEtMS0xLTE2NzkwOA_63ce9e79-e6b1-490e-be6d-f3bf698738d5"
      unitRef="usd">1140000000</cvs:OtherInsuranceLiabilitiesCurrent>
    <cvs:OtherInsuranceLiabilitiesCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI0LTMtMS0xLTE2NzkwOA_84d81c79-e6a2-4567-acaf-35f3837a8009"
      unitRef="usd">1303000000</cvs:OtherInsuranceLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI1LTEtMS0xLTE2NzkwOA_3937310a-0af7-4d77-8d02-8e3e5a9684b5"
      unitRef="usd">1678000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI1LTMtMS0xLTE2NzkwOA_d9c7b4cc-1753-4d82-b7eb-7fcb2f2709f4"
      unitRef="usd">1646000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI3LTEtMS0xLTE2NzkwOA_9bf339b7-1dad-44f6-92e6-e8732e7f3c5c"
      unitRef="usd">1778000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI3LTMtMS0xLTE2NzkwOA_7e95e145-27ae-40a2-a241-a83bb5b36eca"
      unitRef="usd">4205000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI5LTEtMS0xLTE5OTI1Mw_d3b12a35-c2e6-4e20-af88-2b2bc105f939"
      unitRef="usd">228000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI5LTMtMS0xLTE5OTI1Mw_e931ebf1-497a-41ca-a826-e2df2bd50c4e"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI4LTEtMS0xLTE2NzkwOA_cff76885-ed0a-495d-988f-d06ac1f0e16d"
      unitRef="usd">69736000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI4LTMtMS0xLTE2NzkwOA_3fd04bcb-7e4a-4d16-88b3-7207969e389e"
      unitRef="usd">67807000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI5LTEtMS0xLTE2NzkwOA_45f95f69-7a9e-4b36-a230-a38d4cbb2827"
      unitRef="usd">16800000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzI5LTMtMS0xLTE2NzkwOA_db70339f-71d9-4ec0-b528-497db79fc993"
      unitRef="usd">18177000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMwLTEtMS0xLTE2NzkwOA_39afec39-26e8-41b8-a303-f1590958ead8"
      unitRef="usd">50476000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMwLTMtMS0xLTE2NzkwOA_9496aa6a-f9da-4926-bec9-b5e2e18f31c4"
      unitRef="usd">51971000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMxLTEtMS0xLTE2NzkwOA_d2b4c510-2d8e-4fb7-955b-ccb0d50fda94"
      unitRef="usd">3880000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMxLTMtMS0xLTE2NzkwOA_987f5d05-0c66-456d-9a9a-4e153efd9de9"
      unitRef="usd">6270000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:SeparateAccountsLiability
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMyLTEtMS0xLTE2NzkwOA_6bbdff50-9979-4769-aa4a-3edb652cdf39"
      unitRef="usd">3228000000</us-gaap:SeparateAccountsLiability>
    <us-gaap:SeparateAccountsLiability
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMyLTMtMS0xLTE2NzkwOA_778cc845-d9ab-4ff8-b981-103ea27a2ed0"
      unitRef="usd">5087000000</us-gaap:SeparateAccountsLiability>
    <cvs:OtherInsuranceLiabilitiesNoncurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMzLTEtMS0xLTE2NzkwOA_087c70be-7e87-4bca-b967-2f83bea03678"
      unitRef="usd">6108000000</cvs:OtherInsuranceLiabilitiesNoncurrent>
    <cvs:OtherInsuranceLiabilitiesNoncurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzMzLTMtMS0xLTE2NzkwOA_c5553a6c-0578-4681-9221-9d9c4002cac2"
      unitRef="usd">6402000000</cvs:OtherInsuranceLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM0LTEtMS0xLTE2NzkwOA_40e557e9-15c9-485b-b94b-e9876a256232"
      unitRef="usd">6732000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM0LTMtMS0xLTE2NzkwOA_0a4f7a26-23f7-4eef-8539-763fd00c2ddb"
      unitRef="usd">1904000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM1LTEtMS0xLTE2NzkwOA_1bdc23fc-3b3e-43a9-8958-c1bc5d0763d3"
      unitRef="usd">156960000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM1LTMtMS0xLTE2NzkwOA_21189d50-95c8-45fa-8efa-a80a1ae86314"
      unitRef="usd">157618000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM2LTEtMS0xLTE2NzkwOA_04f4bece-882e-4c51-bcaf-b0ba3fdc78cd"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM2LTMtMS0xLTE2NzkwOA_d2199c79-bf8a-4be7-b5e8-31368b569a15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzMx_a6c807b3-1587-4ecc-b330-06f53023f341"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzMx_e6960ba5-f774-4d46-8d43-6b641dde2699"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzM1_2d7aa49e-3454-45c6-96b3-b10982e5f4cf"
      unitRef="shares">100000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzM1_d2a5e9cf-2fd4-4ecc-b735-84c30a02b261"
      unitRef="shares">100000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzU3_1a44ddd7-2f3c-411d-9729-6a5d148be903"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzU3_1fe54f29-fb8e-45b5-a9a9-175c4080b52f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzU3_60a0c875-67cd-4e31-b0e5-0532ac653ad6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU2MGU3N2FkYzUwMDRjZGZiODk3OTg0NWJlN2YzYzI0XzU3_7be62911-4f32-4214-9166-c260dd62eeee"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTEtMS0xLTE2NzkwOA_fa554981-6dd1-4b2b-826a-0786e4e9aa14"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzM5LTMtMS0xLTE2NzkwOA_607289ad-a289-4227-9d9c-88ff4f45698b"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzI4_68e4e44a-ac16-4f3d-a939-45b742b8d93b"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzI4_7d9cac7d-d38f-472e-9b8e-328835619659"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzMy_474cb969-d73f-40b1-a950-3e66a35ee0e3"
      unitRef="shares">3200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzMy_c53ca34c-48c5-4b47-95dd-382bf3e8d7a5"
      unitRef="shares">3200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzU0_50172e10-d61e-47c9-8a20-609a85be49a0"
      unitRef="shares">1758000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1Xzc1_f3d685bf-0be0-490b-9b0c-9c4e7837f10f"
      unitRef="shares">1300000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzEwNw_b9926396-899e-46f3-8314-73b90ed0ef1e"
      unitRef="shares">1744000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmU3ZWIwNDkzYTExODQ4ODZiM2JkYzc4NGQwMTBjNGQ1XzEyOA_f63ee4e4-ec17-410b-aa62-ab3445873d8f"
      unitRef="shares">1322000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTEtMS0xLTE2NzkwOA_19593fca-e8a2-4b12-aefd-15aa06f97191"
      unitRef="usd">48193000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQwLTMtMS0xLTE2NzkwOA_32a09429-aede-422a-928b-21678baee627"
      unitRef="usd">47377000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjViNGY1M2I5MDgyNjRmY2I4YWUyOTIzODgxZGM0Mjg5XzI5_2d938b53-28d5-4c4e-baf0-4adc8ae679f2"
      unitRef="shares">458000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjViNGY1M2I5MDgyNjRmY2I4YWUyOTIzODgxZGM0Mjg5XzM2_c743bfde-d055-41b8-9d6a-d8f5fb43ca5b"
      unitRef="shares">422000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQxLTEtMS0xLTE2NzkwOA_7919042d-64a5-4a23-9e36-318f9553e513"
      unitRef="usd">31858000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQxLTMtMS0xLTE2NzkwOA_1631e77f-004b-4548-97d6-efa90c9dbbb0"
      unitRef="usd">28173000000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQyLTEtMS0xLTE2NzkwOA_a4553852-8ac7-45b3-8a57-bd97a1d8b879"
      unitRef="usd">56145000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQyLTMtMS0xLTE2NzkwOA_3d7dff6e-6122-4410-9de7-08fb9228abc6"
      unitRef="usd">54906000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQzLTEtMS0xLTE2NzkwOA_340d8469-771e-490f-9cde-e0a6a1950d1e"
      unitRef="usd">-1465000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQzLTMtMS0xLTE2NzkwOA_358d1615-d1d9-4d4f-8e7a-14a307c9f6a3"
      unitRef="usd">965000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ0LTEtMS0xLTE2NzkwOA_76ff3588-0b3f-42a1-b3f1-b3bf62666dab"
      unitRef="usd">71015000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ0LTMtMS0xLTE2NzkwOA_d956759e-2387-4322-afe3-054e066cd7c9"
      unitRef="usd">75075000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ1LTEtMS0xLTE2NzkwOA_e1ac868c-7aa5-471e-a5b9-446a1466cd49"
      unitRef="usd">300000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ1LTMtMS0xLTE2NzkwOA_261fad85-a9bc-43e0-bd90-88e0336d5fe2"
      unitRef="usd">306000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ2LTEtMS0xLTE2NzkwOA_524281e3-c4c0-44b7-9577-26b7ad19b33e"
      unitRef="usd">71315000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ2LTMtMS0xLTE2NzkwOA_08bfe77d-6b6e-446d-99b1-c1087976b27c"
      unitRef="usd">75381000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ3LTEtMS0xLTE2NzkwOA_613f5980-6d3a-4f08-b7a5-5de27763e858"
      unitRef="usd">228275000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMDkvZnJhZzpkN2NhOWEzOGE5OTI0NjE1YmI5OGUzM2ZkMWVlMWQ3ZS90YWJsZTo3YTk2NmRlNWMzMjQ0ZTdhOGVjNTk5ZDg0OWYwMTdiZC90YWJsZXJhbmdlOjdhOTY2ZGU1YzMyNDRlN2E4ZWM1OTlkODQ5ZjAxN2JkXzQ3LTMtMS0xLTE2NzkwOA_a60acfef-49b3-45b4-ba76-d48ceef81f7e"
      unitRef="usd">232999000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProceedsFromCustomers
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMtMS0xLTEtMTY3OTA4_f327b92e-dcc9-4966-8315-ce6af5116306"
      unitRef="usd">313662000000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMtMy0xLTEtMTY3OTA4_a7daaa12-79d2-4e83-b7a5-242e8cffc1d4"
      unitRef="usd">284219000000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMtNS0xLTEtMTY3OTA4_a70e8792-3446-4e60-8195-4e9359ef8711"
      unitRef="usd">264327000000</us-gaap:ProceedsFromCustomers>
    <cvs:PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzQtMS0xLTEtMTY3OTA4_25a05191-af50-4d47-a70d-41f8e7127ecf"
      unitRef="usd">189766000000</cvs:PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies>
    <cvs:PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzQtMy0xLTEtMTY3OTA4_ce6140d8-7edc-45f6-a941-1f1b10c178f9"
      unitRef="usd">165783000000</cvs:PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies>
    <cvs:PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzQtNS0xLTEtMTY3OTA4_db2a2d30-a6da-425a-b064-d975b5e95705"
      unitRef="usd">158636000000</cvs:PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies>
    <cvs:PaymentsForInsuranceBenefits
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzUtMS0xLTEtMTY3OTA4_0a9ecbc6-1daf-4b51-9741-7d3b4e23bd0f"
      unitRef="usd">69728000000</cvs:PaymentsForInsuranceBenefits>
    <cvs:PaymentsForInsuranceBenefits
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzUtMy0xLTEtMTY3OTA4_46604cde-8cd9-4420-a15b-f6ca2ddbad2a"
      unitRef="usd">63598000000</cvs:PaymentsForInsuranceBenefits>
    <cvs:PaymentsForInsuranceBenefits
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzUtNS0xLTEtMTY3OTA4_f76e8170-6baf-459a-8461-2baa9f47f704"
      unitRef="usd">55124000000</cvs:PaymentsForInsuranceBenefits>
    <us-gaap:PaymentsToSuppliersAndEmployees
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzYtMS0xLTEtMTY3OTA4_3ef17e18-2420-476c-bc50-b4f1800fdcce"
      unitRef="usd">32662000000</us-gaap:PaymentsToSuppliersAndEmployees>
    <us-gaap:PaymentsToSuppliersAndEmployees
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzYtMy0xLTEtMTY3OTA4_7dd09792-1137-4a5e-98e7-b5f7e527d160"
      unitRef="usd">31652000000</us-gaap:PaymentsToSuppliersAndEmployees>
    <us-gaap:PaymentsToSuppliersAndEmployees
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzYtNS0xLTEtMTY3OTA4_ea154a35-9fd5-46ad-b2b9-4ea18ae0478f"
      unitRef="usd">29763000000</us-gaap:PaymentsToSuppliersAndEmployees>
    <us-gaap:ProceedsFromInterestAndDividendsReceived
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzctMS0xLTEtMTY3OTA4_806b3a89-4210-417c-99d7-829b2791e3c8"
      unitRef="usd">1026000000</us-gaap:ProceedsFromInterestAndDividendsReceived>
    <us-gaap:ProceedsFromInterestAndDividendsReceived
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzctMy0xLTEtMTY3OTA4_a67d9b9d-55f9-431e-a578-7670765665c7"
      unitRef="usd">743000000</us-gaap:ProceedsFromInterestAndDividendsReceived>
    <us-gaap:ProceedsFromInterestAndDividendsReceived
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzctNS0xLTEtMTY3OTA4_f3d5d4ef-3694-416d-a797-4084cb936348"
      unitRef="usd">894000000</us-gaap:ProceedsFromInterestAndDividendsReceived>
    <us-gaap:InterestPaidNet
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzgtMS0xLTEtMTY3OTA4_912ce461-ce3a-4190-8054-444ec7e9a5cd"
      unitRef="usd">2239000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzgtMy0xLTEtMTY3OTA4_6e2d9b70-84b2-4094-bb1e-a56bb72837d6"
      unitRef="usd">2469000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzgtNS0xLTEtMTY3OTA4_911eb1ee-957b-49f7-a3f4-f52e1dc61fac"
      unitRef="usd">2904000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzktMS0xLTEtMTY3OTA4_64646629-c7bd-4bb1-a570-99c856828032"
      unitRef="usd">4116000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzktMy0xLTEtMTY3OTA4_3785e3d0-69e9-4769-8f5d-d0132cb017e5"
      unitRef="usd">3195000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzktNS0xLTEtMTY3OTA4_bcd2ecdf-28c2-437f-ba6f-deb3bc76f33c"
      unitRef="usd">2929000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEwLTEtMS0xLTE2NzkwOA_43a88107-834d-4eae-a568-16170e15c3fe"
      unitRef="usd">16177000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEwLTMtMS0xLTE2NzkwOA_ada6a4cc-91c6-45a6-a868-695da71a2fe5"
      unitRef="usd">18265000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEwLTUtMS0xLTE2NzkwOA_2dac7f1c-97e2-400c-84ee-d52acc2276ab"
      unitRef="usd">15865000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEzLTEtMS0xLTE2NzkwOA_1d428cac-5864-4af0-9728-3e51f919f42a"
      unitRef="usd">6729000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEzLTMtMS0xLTE2NzkwOA_719c1776-079b-4318-90c7-a44ed6398a4d"
      unitRef="usd">7246000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzEzLTUtMS0xLTE2NzkwOA_b1c4c3ca-4e08-420b-8f60-85b96d502f02"
      unitRef="usd">6467000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE0LTEtMS0xLTE2NzkwOA_d65d5470-5c19-4d9f-aebf-1e43e276bbf7"
      unitRef="usd">7746000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE0LTMtMS0xLTE2NzkwOA_ad0c754d-53e5-430b-95f5-9ac32863cde9"
      unitRef="usd">9963000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE0LTUtMS0xLTE2NzkwOA_4a0fa656-bc63-4ef9-ae2f-5198abc590f6"
      unitRef="usd">9639000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE1LTEtMS0xLTE2NzkwOA_a93a49e8-bd66-464a-86d2-8055da065125"
      unitRef="usd">2727000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE1LTMtMS0xLTE2NzkwOA_0346ea7d-d54a-4550-9296-85ed35600bb9"
      unitRef="usd">2520000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE1LTUtMS0xLTE2NzkwOA_e2b50a65-f0bf-4129-9527-8870a8175cc6"
      unitRef="usd">2437000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE2LTEtMS0xLTE2NzkwOA_4179571f-2623-41e1-bf48-92c9c268414e"
      unitRef="usd">0</us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity>
    <us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE2LTMtMS0xLTE2NzkwOA_68ad3f5b-5077-4ace-bfcf-8495279deeb9"
      unitRef="usd">0</us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity>
    <us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE2LTUtMS0xLTE2NzkwOA_e9f6b8c5-2656-457c-a8a7-d043a67c0eed"
      unitRef="usd">101000000</us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE3LTEtMS0xLTE2NzkwOA_20dd1c68-8c7a-4967-865d-ed63340659b3"
      unitRef="usd">139000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE3LTMtMS0xLTE2NzkwOA_15f293db-fa97-4fae-ac85-0475e446e202"
      unitRef="usd">146000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE3LTUtMS0xLTE2NzkwOA_0959e627-9e23-4e65-8d88-935e4f43a6f9"
      unitRef="usd">866000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmI4YTZjNmQ3ZDQ2ODQ3M2ZiYjg3OGU0Y2U0YzQwMTQwXzIxOTkwMjMyNTU2NjY_8321a82b-130a-4d07-9703-6534ab79f35e"
      unitRef="usd">2854000000</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmI4YTZjNmQ3ZDQ2ODQ3M2ZiYjg3OGU0Y2U0YzQwMTQwXzIxOTkwMjMyNTU2NTc_18f49b18-2672-4942-ad50-daf3d338b6dc"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmI4YTZjNmQ3ZDQ2ODQ3M2ZiYjg3OGU0Y2U0YzQwMTQwXzIxOTkwMjMyNTU2NTI_81002130-db9b-43bb-8c24-9f22ba5afcd4"
      unitRef="usd">9000000</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTEtMS0xLTE2NzkwOA_7d8c9d5e-d6ce-4f1d-9ebf-929ba01512bc"
      unitRef="usd">-1249000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTMtMS0xLTE2NzkwOA_a136ec02-b175-4fe3-9861-bb98188b09de"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE4LTUtMS0xLTE2NzkwOA_9beb2241-be86-4adb-b206-920ea9ca3a3f"
      unitRef="usd">840000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE5LTEtMS0xLTE2NzkwOA_b86f55ef-60c8-4d34-953c-a641e0270bdc"
      unitRef="usd">-85000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE5LTMtMS0xLTE2NzkwOA_00b39dd2-31e8-43fa-9630-b79b67df3612"
      unitRef="usd">-122000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzE5LTUtMS0xLTE2NzkwOA_1b44b089-7dd8-4f2a-a553-90f8c9786145"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzIwLTEtMS0xLTE2NzkwOA_799bdbed-4b00-4b63-bb9e-02a8a78f6c84"
      unitRef="usd">-5047000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzIwLTMtMS0xLTE2NzkwOA_90c758fe-0423-4683-aaba-03f08cc86f77"
      unitRef="usd">-5261000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzIwLTUtMS0xLTE2NzkwOA_231915a8-38d8-4684-893b-cf73b58a7716"
      unitRef="usd">-5534000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI0LTEtMS0xLTE2NzkwOA_11d9feba-5fc4-4500-8b13-5e859ad41ef7"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI0LTMtMS0xLTE2NzkwOA_906f94b3-8367-4f5c-a038-1c8335997a72"
      unitRef="usd">987000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI0LTUtMS0xLTE2NzkwOA_e9fd5efb-cd89-4ded-846f-1d98e140f6df"
      unitRef="usd">9958000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI1LTEtMS0xLTE2NzkwOA_e7f1fc4b-b720-4bc4-b8c0-21e27e189069"
      unitRef="usd">4211000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI1LTMtMS0xLTE2NzkwOA_8e4c53cf-904e-41b0-9332-43d456b72d7a"
      unitRef="usd">10254000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI1LTUtMS0xLTE2NzkwOA_e0806f98-aa78-4e05-926a-f2761572b504"
      unitRef="usd">15631000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI2LTEtMS0xLTE2NzkwOA_d5841a7e-a24a-48f6-85c3-d50e4a8c2246"
      unitRef="usd">0</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI2LTMtMS0xLTE2NzkwOA_aa53f89b-6f4a-414e-81d5-d0e35d2962c0"
      unitRef="usd">0</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI2LTUtMS0xLTE2NzkwOA_3a8cc537-27ad-49c6-b7de-97579965901d"
      unitRef="usd">7000000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI3LTEtMS0xLTE2NzkwOA_e04b3edb-050f-4e51-ad8f-00a8fe66ca49"
      unitRef="usd">3500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI3LTMtMS0xLTE2NzkwOA_e5dbc154-8d67-47eb-a45e-58a48dc39010"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI3LTUtMS0xLTE2NzkwOA_a451850b-afb3-4409-ae59-cb0023a59669"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI4LTEtMS0xLTE2NzkwOA_ca028360-cbd5-4503-bd54-2d69fbbf5640"
      unitRef="usd">2907000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI4LTMtMS0xLTE2NzkwOA_cbbb7a58-dd10-4dd6-adae-4a010b73dcdf"
      unitRef="usd">2625000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI4LTUtMS0xLTE2NzkwOA_9ae2346f-c7c8-4254-9ea5-cf025e4f090c"
      unitRef="usd">2624000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI5LTEtMS0xLTE2NzkwOA_b02d0aec-4993-47c3-8fd0-2c443bbd1904"
      unitRef="usd">551000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI5LTMtMS0xLTE2NzkwOA_80e0c0e9-4446-4623-8d0c-a32895fc4866"
      unitRef="usd">549000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzI5LTUtMS0xLTE2NzkwOA_c7d2b7c1-f7ff-4f6e-89b1-80fedd3ea239"
      unitRef="usd">264000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMwLTEtMS0xLTE2NzkwOA_465159b1-ec73-45a3-81df-800346af6695"
      unitRef="usd">370000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMwLTMtMS0xLTE2NzkwOA_17e81c76-9916-4645-b135-af78c13a1bf2"
      unitRef="usd">168000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMwLTUtMS0xLTE2NzkwOA_b8a662d2-dbf5-481f-a530-3e34842fe836"
      unitRef="usd">88000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMxLTEtMS0xLTE2NzkwOA_b79d8699-cb62-4123-864b-e401857b30f4"
      unitRef="usd">-79000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMxLTMtMS0xLTE2NzkwOA_9dfc4bb7-2d9f-4ff9-969f-c11af50f8055"
      unitRef="usd">155000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMxLTUtMS0xLTE2NzkwOA_0f9d9ed3-b3cf-4514-b39f-effb03971c64"
      unitRef="usd">432000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMyLTEtMS0xLTE2NzkwOA_0b231df6-a409-4a98-a2b1-3427db800a13"
      unitRef="usd">-10516000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMyLTMtMS0xLTE2NzkwOA_d5ddff58-2527-4a73-913a-11a997c6b10b"
      unitRef="usd">-11356000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzMyLTUtMS0xLTE2NzkwOA_984d50ef-183a-4983-98fb-af20f44ad9ac"
      unitRef="usd">-7696000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM0LTEtMS0xLTE2NzkwOA_8ec84b00-2c7a-4067-9056-5cefc5a6fe37"
      unitRef="usd">614000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM0LTMtMS0xLTE2NzkwOA_39ba9418-0eaa-4b62-9227-dffc7ef3aac9"
      unitRef="usd">1648000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM0LTUtMS0xLTE2NzkwOA_11ec4ed0-7dde-48b6-8d55-9eddfb2a8b84"
      unitRef="usd">2635000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM1LTEtMS0xLTE2NzkwOA_9c7794a9-41f9-4234-a6fd-3454b9f55fb4"
      unitRef="usd">12691000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM1LTMtMS0xLTE2NzkwOA_425f9eac-1842-4f57-aabd-a5b71c3216a7"
      unitRef="usd">11043000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i21ae6bc100814ca88c4440dbb572bbdc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM1LTUtMS0xLTE2NzkwOA_b553f239-ded0-48d7-acc9-61d71348f1d2"
      unitRef="usd">8408000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM2LTEtMS0xLTE2NzkwOA_4f391019-f4d5-4623-abfe-2be12003b63d"
      unitRef="usd">13305000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM2LTMtMS0xLTE2NzkwOA_683005f3-75f8-46af-b3ed-1c6481584bbc"
      unitRef="usd">12691000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZToyODQzMjIzMDQzZjc0NGIyODM2MGQyYTJiZGU5ZGZiYS90YWJsZXJhbmdlOjI4NDMyMjMwNDNmNzQ0YjI4MzYwZDJhMmJkZTlkZmJhXzM2LTUtMS0xLTE2NzkwOA_8d168ed4-91c4-4816-8bb9-8c1cd970ee8b"
      unitRef="usd">11043000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ProfitLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzMtMS0xLTEtMTY3OTA4_aaaf6e99-4146-437f-a302-445346162eeb"
      unitRef="usd">4165000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzMtMy0xLTEtMTY3OTA4_ca11db01-5f6a-4254-a20e-2cbc60f67f05"
      unitRef="usd">7898000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzMtNS0xLTEtMTY3OTA4_94e5a3b9-abf6-44f7-beba-ba392f0e04ee"
      unitRef="usd">7192000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzUtMS0xLTEtMTY3OTA4_b2b13358-4379-4495-b5fd-8e90d4b97728"
      unitRef="usd">4247000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzUtMy0xLTEtMTY3OTA4_c83d9adf-79ad-49a9-bb03-e2d6fa16484d"
      unitRef="usd">4512000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzUtNS0xLTEtMTY3OTA4_5d03a0e1-821b-49c8-838c-6c03b3bc3e00"
      unitRef="usd">4441000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtMS0xLTEtMTk5Mjc4_6dd16334-dd03-429c-bb6d-673d77ffdf65"
      unitRef="usd">2533000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtMy0xLTEtMTk5Mjc4_4fe0d745-2bfd-43ea-b014-72fd64d65996"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtNS0xLTEtMTk5Mjkx_7223f339-726f-4ce4-8d89-a2d2c48608bc"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <cvs:StoreImpairmentCharges
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtMS0xLTEtMTY3OTA4_5742872c-6706-419a-9b35-1c6789bbc75d"
      unitRef="usd">0</cvs:StoreImpairmentCharges>
    <cvs:StoreImpairmentCharges
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtMy0xLTEtMTY3OTA4_715e5914-73eb-4f35-8ccf-0019e0d3d743"
      unitRef="usd">1358000000</cvs:StoreImpairmentCharges>
    <cvs:StoreImpairmentCharges
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzYtNS0xLTEtMTY3OTA4_0f7dc44b-95f7-409c-9d13-bb0aa233fa56"
      unitRef="usd">0</cvs:StoreImpairmentCharges>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzctMS0xLTEtMTY3OTA4_e50e334f-c963-4c60-a356-d1ee1f9aa9fa"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzctMy0xLTEtMTY3OTA4_a1a72e86-fd4e-4406-831c-5ebf6d5f41e7"
      unitRef="usd">431000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzctNS0xLTEtMTY3OTA4_a94d1a72-051e-43f2-85cd-91faaa3dfc04"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzktMS0xLTEtMTY3OTA4_7a5d9f0c-1fa6-4386-ac67-f4ce8db48cf2"
      unitRef="usd">447000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzktMy0xLTEtMTY3OTA4_edad8786-2001-4943-a847-c2ca235d5ebf"
      unitRef="usd">484000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzktNS0xLTEtMTY3OTA4_3ac79989-76cf-4fae-92e4-e9923e0c4030"
      unitRef="usd">400000000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEwLTEtMS0xLTE2NzkwOA_f8f56965-eb40-4b63-a0e5-b4efe5095740"
      unitRef="usd">475000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEwLTMtMS0xLTE2NzkwOA_69dac48d-5d10-4660-91bc-bbde57c7609d"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEwLTUtMS0xLTE2NzkwOA_fadda63f-0a1d-4c14-b8ea-045633a32cec"
      unitRef="usd">269000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzExLTEtMS0xLTE2NzkwOA_2b4910f2-139d-4d64-80b1-b46d974c32ee"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzExLTMtMS0xLTE2NzkwOA_4cb70dbd-aa51-4509-bb28-a243372ba530"
      unitRef="usd">-452000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzExLTUtMS0xLTE2NzkwOA_e28f05d0-45c1-46ad-8dbd-7af4f87e2459"
      unitRef="usd">-1440000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTEtMS0xLTIxNjEwMw_d82a0ab6-75f6-4e2e-b91a-4c4f168c5bbc"
      unitRef="usd">-2075000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTMtMS0xLTIxNjEwMw_7d5d363b-7f10-4db4-9ff9-31f8606dddf3"
      unitRef="usd">-428000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTUtMS0xLTIxNjEwMw_c1a2c1a0-863e-4d61-a5fd-5480f30e4685"
      unitRef="usd">-570000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEzLTEtMS0xLTE2NzkwOA_1450c1e6-f62f-4092-bba5-942012a0a2f8"
      unitRef="usd">-332000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEzLTMtMS0xLTE2NzkwOA_499ba8a0-a59f-489d-9b13-a26fd28e419c"
      unitRef="usd">390000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzEzLTUtMS0xLTE2NzkwOA_cc056025-2175-451f-a898-3217a90f2374"
      unitRef="usd">-72000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTEtMS0xLTE2NzkwOA_b5750ce1-6d5f-4e72-8a6c-5818789767f3"
      unitRef="usd">2971000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTMtMS0xLTE2NzkwOA_51da59cf-9b94-4391-ac86-32c8d3a49fc6"
      unitRef="usd">2703000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE1LTUtMS0xLTE2NzkwOA_bdd17985-777d-4213-9ebd-ae271ea6df42"
      unitRef="usd">1510000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE2LTEtMS0xLTE2NzkwOA_c2f07549-2c85-4a6c-920c-a02f432c0046"
      unitRef="usd">1435000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE2LTMtMS0xLTE2NzkwOA_59f928bc-b595-423a-9a5b-b94f0bca2cdd"
      unitRef="usd">-735000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE2LTUtMS0xLTE2NzkwOA_3afb9e29-a9cf-414a-bd96-1ade0e1fde2c"
      unitRef="usd">973000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE3LTEtMS0xLTE2NzkwOA_dd4f737e-9c3e-4d39-8b52-e68d2d922a19"
      unitRef="usd">566000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE3LTMtMS0xLTE2NzkwOA_b8c5c095-1d7a-4867-aafe-040c01570dda"
      unitRef="usd">3000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE3LTUtMS0xLTE2NzkwOA_a86f91ae-a25d-433c-9c59-60d8aab91ac4"
      unitRef="usd">-364000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE4LTEtMS0xLTE2NzkwOA_71680d1e-72e8-40f6-a8c1-db50a27fbccb"
      unitRef="usd">4260000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE4LTMtMS0xLTE2NzkwOA_c1120119-22d6-48f6-a687-c122fd9717a4"
      unitRef="usd">2898000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE4LTUtMS0xLTE2NzkwOA_819e45cd-ed87-4db9-890b-ebb92e0ab221"
      unitRef="usd">2769000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE5LTEtMS0xLTE2NzkwOA_a383562b-f1c9-44da-ab6e-2419ff98c521"
      unitRef="usd">1247000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE5LTMtMS0xLTE2NzkwOA_3b628673-61f0-4b3b-a99f-f152b4765009"
      unitRef="usd">169000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzE5LTUtMS0xLTE2NzkwOA_f87a7dfb-1ac3-4138-9302-749187a2163d"
      unitRef="usd">-231000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIwLTEtMS0xLTE2NzkwOA_e5bfb917-a0a2-47af-a221-c7fb5ec0099c"
      unitRef="usd">6468000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIwLTMtMS0xLTE2NzkwOA_9427c126-9f55-45e1-b838-7514dd4e0741"
      unitRef="usd">2852000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIwLTUtMS0xLTE2NzkwOA_d814bc69-98ce-4505-8b93-c0322de3bb59"
      unitRef="usd">2740000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIxLTEtMS0xLTE2NzkwOA_e8e35ba8-9040-4969-a814-5ca38844a242"
      unitRef="usd">16177000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIxLTMtMS0xLTE2NzkwOA_75f6a739-4504-4b6d-b6bc-7bd19ce03985"
      unitRef="usd">18265000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTIvZnJhZzo1YjE4NmFmNjM3ZGY0ZmVkYjg1ZmQ0ZGMzNWM2ODNkYS90YWJsZTo2ZjJjODQ4NzNkMTU0ZmE4ODRkMTlkMjBjMTVmYmYyNC90YWJsZXJhbmdlOjZmMmM4NDg3M2QxNTRmYTg4NGQxOWQyMGMxNWZiZjI0XzIxLTUtMS0xLTE2NzkwOA_78825d4f-f11d-4ad8-bfe5-5f3a9b08cd51"
      unitRef="usd">15865000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SharesOutstanding
      contextRef="i72a7763da9eb4043aa8f22f5c692da1a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMS0xLTEtMTY3OTA4_9ffd091f-e34f-4e1f-8ae1-9b3c5fef2855"
      unitRef="shares">1727000000</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="if00d0ef5531f491687905cc2a31dbad1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMi0xLTEtMTY3OTA4_a1102af3-6a6d-4ab7-9a37-152583f52aed"
      unitRef="shares">425000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2a3fb0fbc894ec1b2c889d8507c98b4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNC0xLTEtMTY3OTA4_419c9387-c859-4bde-b2b7-4f1cf9bbe844"
      unitRef="usd">45972000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if00d0ef5531f491687905cc2a31dbad1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNS0xLTEtMTY3OTA4_899a6f82-b6f8-43bd-b579-b98c84fb2c90"
      unitRef="usd">-28235000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7b2f5710c3d416fa6c9cc7c92282465_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNi0xLTEtMTY3OTA4_a911109d-821e-4c8d-8182-40a1a2719e1a"
      unitRef="usd">45108000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i888d803efa36451abbcddc3e49ab4600_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNy0xLTEtMTY3OTA4_aa437aa1-422c-4c5a-a1d8-c76c1d3a7d9f"
      unitRef="usd">1019000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d3c8cd4bb654446b90531ac0de6b52e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtOC0xLTEtMTY3OTA4_a8342b75-30a8-4287-b357-7ff0f560fec9"
      unitRef="usd">63864000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if44510fc0a4b415b835ac61565cbe142_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtOS0xLTEtMTY3OTA4_84edb210-a8df-4141-ab41-ec19dc6d85ca"
      unitRef="usd">306000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21ae6bc100814ca88c4440dbb572bbdc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMTAtMS0xLTE2NzkwOA_315d22e6-6d40-4889-abcd-a9ace845350d"
      unitRef="usd">64170000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e66d5c8619f4ded8782d4028fa2b01b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtNi0xLTEtMTY3OTA4_99031c0f-9bb1-4e9b-a04b-d1f529a110ab"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifab9f0d4beab4f98ae87761afaae6ce3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtOC0xLTEtMTY3OTA4_e9262b61-efbc-4ef7-a559-88549e16e324"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ebc7adf3c3345cd9cae049928aa937b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtMTAtMS0xLTE2NzkwOA_4d9dee0a-de0c-4824-96a7-b2568bdfa528"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ife9cd17faa9b459393d314bd5dc139b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzUtNi0xLTEtMTY3OTA4_5acf5a21-c3a3-46aa-985e-135b943536bd"
      unitRef="usd">7179000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzUtOC0xLTEtMTY3OTA4_6aa86387-862b-41fb-a7cd-4bb3c49ef16d"
      unitRef="usd">7179000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6dda31d68ee44ac380464c0d7b42864e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzUtOS0xLTEtMTY3OTA4_83bb214a-40a7-4a0c-bff9-a37de8d9838c"
      unitRef="usd">13000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzUtMTAtMS0xLTE2NzkwOA_849d37d3-1a48-4469-9085-e7a63c955c6b"
      unitRef="usd">7192000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i506db4d0bb51485db8a39fec0af261da_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzYtNy0xLTEtMTY3OTA4_c20f1228-9624-4a57-83e4-96cb1032bb93"
      unitRef="usd">395000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzYtOC0xLTEtMTY3OTA4_27fb790b-6693-4df7-98c9-00e6215e42e0"
      unitRef="usd">395000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzYtMTAtMS0xLTE2NzkwOA_214a387f-31ba-4482-9778-603c357a3a5b"
      unitRef="usd">395000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id118cd6fcaeb4d16b525a15d0b586564_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMS0xLTEtMTY3OTA4_eb87a6b0-80ad-4100-a428-390a36dfdc69"
      unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic935f384ec884760808c5d3d56f93b58_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMi0xLTEtMTY3OTA4_cc9c228e-d25e-42a5-afe7-dd4be4f4ded9"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i96a2c447554b47278dafaa81be11f9d1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtNC0xLTEtMTY3OTA4_2a36882f-dd82-4bf8-897e-323895e9187e"
      unitRef="usd">541000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtOC0xLTEtMTY3OTA4_38ba164f-bdda-48ad-849b-647546e58dee"
      unitRef="usd">541000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMTAtMS0xLTE2NzkwOA_cc822afd-68fb-4a9a-a999-5366785d8134"
      unitRef="usd">541000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cvs:ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod
      contextRef="ic935f384ec884760808c5d3d56f93b58_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktMi0xLTEtMTY3OTA4_cf85c9c6-30f6-47f0-9d82-59780ed91d16"
      unitRef="shares">2000000</cvs:ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod>
    <cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
      contextRef="ic935f384ec884760808c5d3d56f93b58_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktNS0xLTEtMTY3OTA4_4b2d1fa7-2942-4c9a-bc7e-a667d42a0eb9"
      unitRef="usd">57000000</cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod>
    <cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
      contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktOC0xLTEtMTY3OTA4_3fe7c230-91f7-4495-8e70-f610807326ce"
      unitRef="usd">57000000</cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod>
    <cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktMTAtMS0xLTE2NzkwOA_7d213755-2ad6-4bf2-ba0a-c278be20131a"
      unitRef="usd">57000000</cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod>
    <us-gaap:DividendsCommonStock
      contextRef="ife9cd17faa9b459393d314bd5dc139b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEwLTYtMS0xLTE2NzkwOA_e993f91f-1a04-4e8a-a65f-72d892524248"
      unitRef="usd">2644000000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="i83a79211767d44618caf1f746ea964d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEwLTgtMS0xLTE2NzkwOA_7bc0dbbf-1862-4427-b5b9-731d392d8cfd"
      unitRef="usd">2644000000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEwLTEwLTEtMS0xNjc5MDg_5a577054-efb1-4e31-aafc-ac1ac4ad8921"
      unitRef="usd">2644000000</us-gaap:DividendsCommonStock>
    <cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease
      contextRef="i6dda31d68ee44ac380464c0d7b42864e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEyLTktMS0xLTE2NzkwOA_593fb463-1059-49ce-98b3-295aa1722f25"
      unitRef="usd">-7000000</cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease>
    <cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEyLTEwLTEtMS0xNjc5MDg_7d44a44b-1bde-48f0-9861-d19b08bf02cb"
      unitRef="usd">-7000000</cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i215e39f051a24c26a9fcfe870c6bb597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTEtMS0xLTE2NzkwOA_badb8685-fcc4-4533-a798-421aa6ac7e18"
      unitRef="shares">1733000000</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia036bc4a7dac4d75a3807b027b89ffa5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTItMS0xLTE2NzkwOA_a802b61d-e3fc-401c-8a0e-c9a451456886"
      unitRef="shares">423000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10ac8c51a1484aa2a5345657f72786b6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTQtMS0xLTE2NzkwOA_da19b8fb-1267-4760-a39d-cc06e134509c"
      unitRef="usd">46513000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia036bc4a7dac4d75a3807b027b89ffa5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTUtMS0xLTE2NzkwOA_a3020230-8e8d-4d1f-be1c-451c50e0569a"
      unitRef="usd">-28178000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3b3a385f98e4970a3c4003641ffad00_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTYtMS0xLTE2NzkwOA_3da62930-22ba-479c-91a1-767d2c159b39"
      unitRef="usd">49640000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06ea169a39a1448695c8f5079e17a681_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTctMS0xLTE2NzkwOA_1f0a730f-e5f9-4fc7-8a39-c62be6f4e82e"
      unitRef="usd">1414000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65ab1718255d495ebfab5b03525f0868_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTgtMS0xLTE2NzkwOA_b59ad877-6d28-4f0b-a3d0-8a72bc1ef6cc"
      unitRef="usd">69389000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d6dbba9b47e4c87b541de1f1350e1c7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTktMS0xLTE2NzkwOA_d1948a20-9d0a-4ca4-aeb5-8ae6302f6ea3"
      unitRef="usd">312000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTEwLTEtMS0xNjc5MDg_f3f1fbb2-5a3c-44f8-90e3-3440a074e5b2"
      unitRef="usd">69701000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic6a2b778a2b648ebbfa53406c5d05497_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE1LTYtMS0xLTE2NzkwOA_a320e897-90eb-4ec9-88e9-da879fb87d54"
      unitRef="usd">7910000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE1LTgtMS0xLTE2NzkwOA_66c9de42-aa8f-4d84-bac4-05cb16b159cc"
      unitRef="usd">7910000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i835f93d2a91243ffa5e213ffac78aa2e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE1LTktMS0xLTE2NzkwOA_e45665ab-6bd2-46e4-b573-27a31ae28788"
      unitRef="usd">-12000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE1LTEwLTEtMS0xNjc5MDg_1feffd38-ffd1-4549-be52-dd1a43d14b0f"
      unitRef="usd">7898000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib06f1a367c1c462cb54add04957c2b6d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE2LTctMS0xLTE2NzkwOA_1dfefbc7-3a9d-40dd-9aa8-39455915fa15"
      unitRef="usd">-449000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE2LTgtMS0xLTE2NzkwOA_afa8f760-05c2-439d-b213-31327f5120fe"
      unitRef="usd">-449000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE2LTEwLTEtMS0xNjc5MDg_450410dc-4c5a-4d7f-8c11-92a35c51f3a9"
      unitRef="usd">-449000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9ccf20c4b2cb4cbfa96ff019488ea873_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTEtMS0xLTE2NzkwOA_49a1645b-45fb-476c-a34a-a5daa190418b"
      unitRef="shares">11000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifedcfb6c0f5f44d9bedcaae64ac0cd39_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTQtMS0xLTE2NzkwOA_33f5dc1a-2a4b-4a8a-b80d-440f0c6eb9d5"
      unitRef="usd">864000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTgtMS0xLTE2NzkwOA_99f968a4-962b-4a56-af2a-4206445f4726"
      unitRef="usd">864000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTEwLTEtMS0xNjc5MDg_9e06f13b-2394-4f44-b227-38bdc4af457d"
      unitRef="usd">864000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cvs:ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod
      contextRef="if2d25a04a6754b1498c8f7da3b006bcf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTItMS0xLTE2NzkwOA_61a94270-718d-49f2-8a89-ac9a52290499"
      unitRef="shares">1000000</cvs:ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod>
    <cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
      contextRef="if2d25a04a6754b1498c8f7da3b006bcf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTUtMS0xLTE2NzkwOA_6b7272ad-9760-4165-8a9f-eef3576673fb"
      unitRef="usd">5000000</cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod>
    <cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
      contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTgtMS0xLTE2NzkwOA_24ba5806-8cd7-4b30-8dd8-d99e0ebd0a73"
      unitRef="usd">5000000</cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod>
    <cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTEwLTEtMS0xNjc5MDg_685e1491-de9b-4ca7-87ea-2c00ee23037e"
      unitRef="usd">5000000</cvs:ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod>
    <us-gaap:DividendsCommonStock
      contextRef="ic6a2b778a2b648ebbfa53406c5d05497_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIwLTYtMS0xLTE2NzkwOA_4582a648-42c1-4b92-8316-e7fa66d51720"
      unitRef="usd">2644000000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="if016d0338d374c3d8fbbc6749a791679_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIwLTgtMS0xLTE2NzkwOA_0f146955-d8fc-476d-b480-50dcfc541658"
      unitRef="usd">2644000000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIwLTEwLTEtMS0xNjc5MDg_d9178586-f0bb-42bb-ad80-cba48058db8a"
      unitRef="usd">2644000000</us-gaap:DividendsCommonStock>
    <cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease
      contextRef="i835f93d2a91243ffa5e213ffac78aa2e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIyLTktMS0xLTE2NzkwOA_d1388906-7265-4d9a-873f-736a8193a3ca"
      unitRef="usd">6000000</cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease>
    <cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIyLTEwLTEtMS0xNjc5MDg_75cbf495-bd13-4347-8103-0aaa672d03c2"
      unitRef="usd">6000000</cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i90c39d6e1188460db9fc0eac4c5c73ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTEtMS0xLTE2NzkwOA_70ff4c7f-34a3-4ca2-a552-d50aea7095d4"
      unitRef="shares">1744000000</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia074c2e908ba4d4d9f8528b440cb9e61_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTItMS0xLTE2NzkwOA_803aff9c-7641-44f4-b3a5-a5093fcbccd2"
      unitRef="shares">422000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0ba6af5137d4355a39e538ff11c3f70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTQtMS0xLTE2NzkwOA_915df060-9a88-4dd4-b0c9-35ddb417b3c1"
      unitRef="usd">47377000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia074c2e908ba4d4d9f8528b440cb9e61_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTUtMS0xLTE2NzkwOA_6be73b7d-7940-4a20-a6a2-d323e75cf34c"
      unitRef="usd">-28173000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14bbd86e337e40b5b909ba5b0eec8986_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTYtMS0xLTE2NzkwOA_678a854d-b8ef-48ec-bc42-809204df615f"
      unitRef="usd">54906000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66c919cbd9e14d14b0126701eccb5f78_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTctMS0xLTE2NzkwOA_12bc8c4d-0245-4bff-b6c8-ac30afafe9f9"
      unitRef="usd">965000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i403b748d2961411884d18591a7536a94_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTgtMS0xLTE2NzkwOA_435c215a-241a-4ca4-abb3-b781325af5e7"
      unitRef="usd">75075000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i972cf157c8074bc5ba5d6d1d1d0a0ee3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTktMS0xLTE2NzkwOA_81ce7d6c-1dc6-43f0-a753-406b7275fc48"
      unitRef="usd">306000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTEwLTEtMS0xNjc5MDg_c9269ede-b4a0-41f2-b87b-b4e40b8ffcef"
      unitRef="usd">75381000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i109b0efa62914aa7a4f584e9303e07d8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI1LTYtMS0xLTE2NzkwOA_a1de8e83-6626-4077-a4a6-08e714d008e3"
      unitRef="usd">4149000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI1LTgtMS0xLTE2NzkwOA_67076d76-e3b5-4eec-a2ed-e7c1e0b7868b"
      unitRef="usd">4149000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ife2124c0776c4afab6cf27697b98714d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI1LTktMS0xLTE2NzkwOA_287ad968-299e-4c0f-915c-8619c6a5f1ab"
      unitRef="usd">16000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI1LTEwLTEtMS0xNjc5MDg_df357cb1-3fc5-4ead-959d-d11ba8601441"
      unitRef="usd">4165000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i22bba5ead4dc4a12b105fb70a7664473_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI2LTctMS0xLTE2NzkwOA_2f7e3b94-42e4-462d-90a5-2d1d885f8782"
      unitRef="usd">-2430000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI2LTgtMS0xLTE2NzkwOA_bbefc2b8-83a6-4695-a8e2-96162110523c"
      unitRef="usd">-2430000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI2LTEwLTEtMS0xNjc5MDg_2f9f138f-16a4-4a27-906a-eb851128b518"
      unitRef="usd">-2430000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if90073196b804847ae7989cfd2058161_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTEtMS0xLTE2NzkwOA_847d1b1b-6374-4470-b667-4358e9be087d"
      unitRef="shares">14000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i34594b0b5acd443a9120b077623df7ac_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTQtMS0xLTE2NzkwOA_7dbb9dc7-db89-4602-a8ab-d1b447187c94"
      unitRef="usd">816000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTgtMS0xLTE2NzkwOA_89ee2102-b97c-4b0e-9f01-e3525a527c88"
      unitRef="usd">816000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTEwLTEtMS0xNjc5MDg_64259e37-6203-488b-a9b1-e0c251e43f6c"
      unitRef="usd">816000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cvs:TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance
      contextRef="i7bfa8a913ea04eee9d8522298e6fc681_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTItMS0xLTE2NzkwOA_b320eab6-797c-4b05-8ca2-c960aa530c2e"
      unitRef="shares">36000000</cvs:TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance>
    <cvs:TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
      contextRef="i7bfa8a913ea04eee9d8522298e6fc681_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTUtMS0xLTE2NzkwOA_d103f2c8-8949-463e-a6a6-bc4b87160d51"
      unitRef="usd">3685000000</cvs:TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance>
    <cvs:TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
      contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTgtMS0xLTE2NzkwOA_c644804d-189e-4ce9-bfb3-1b91a983ac30"
      unitRef="usd">3685000000</cvs:TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance>
    <cvs:TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTEwLTEtMS0xNjc5MDg_ea17e7e1-f761-4b20-b815-dffa0e98633e"
      unitRef="usd">3685000000</cvs:TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance>
    <us-gaap:DividendsCommonStock
      contextRef="i109b0efa62914aa7a4f584e9303e07d8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI5LTYtMS0xLTE2NzkwOA_1f3c0e9e-3723-4d2c-a47f-628cb52bd45f"
      unitRef="usd">2910000000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="i6960fddf88dc48b5abce9f8336a02532_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI5LTgtMS0xLTE2NzkwOA_b45c11fc-8fa8-44aa-bf63-919f0e6a8226"
      unitRef="usd">2910000000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI5LTEwLTEtMS0xNjc5MDg_a49d80d5-0663-4bec-86ba-ca54926447ef"
      unitRef="usd">2910000000</us-gaap:DividendsCommonStock>
    <cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease
      contextRef="ife2124c0776c4afab6cf27697b98714d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMwLTktMS0xLTE2NzkwOA_4801e04f-ffe1-4690-912b-673ce2073fde"
      unitRef="usd">-22000000</cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease>
    <cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMwLTEwLTEtMS0xNjc5MDg_4e9f78a3-3fbb-4f2f-b58c-7a6d8cef2d5d"
      unitRef="usd">-22000000</cvs:NoncontrollingInterestOtherPeriodIncreaseDecrease>
    <us-gaap:SharesOutstanding
      contextRef="i2e1ce9835a2445c995772377b12325fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTEtMS0xLTE2NzkwOA_bc64b42c-cc95-4a3d-974b-1691c53afaa4"
      unitRef="shares">1758000000</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i69b40434e129497fb044508149145574_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTItMS0xLTE2NzkwOA_2493e6ed-878f-4a03-8082-5b7df50b5510"
      unitRef="shares">458000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40913455599d4dbe8925b15950ed63ec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTQtMS0xLTE2NzkwOA_7048f323-3d7b-43fa-8f4f-ce5446e41c03"
      unitRef="usd">48193000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69b40434e129497fb044508149145574_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTUtMS0xLTE2NzkwOA_ed5a3e75-ed47-445a-843f-f11cccade6f4"
      unitRef="usd">-31858000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief98321000924065a5a2817038f6cd96_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTYtMS0xLTE2NzkwOA_ef9602b4-a57b-4d99-816b-bd5a8fd96bd4"
      unitRef="usd">56145000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81ef2fda83394a2d8e020112d6facee6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTctMS0xLTE2NzkwOA_24076103-40f0-4623-9393-40d9b45756e0"
      unitRef="usd">-1465000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1778905608134b9da2d0fe7767917336_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTgtMS0xLTE2NzkwOA_552ab9f1-d744-4252-8200-ecfdabf019ae"
      unitRef="usd">71015000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc357653e2c74c68a77d7f6658e76744_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTktMS0xLTE2NzkwOA_9c40dd89-2c4f-4773-a568-12e32b40fcf7"
      unitRef="usd">300000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTEwLTEtMS0xNjc5MDg_3dff9097-e2e0-4ade-8639-1ebef2129c39"
      unitRef="usd">71315000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <cvs:TreasuryStockSharesHeldinTrust
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzEyNg_105927de-e680-4d24-b0f5-9cd519d0065f"
      unitRef="shares">1000000</cvs:TreasuryStockSharesHeldinTrust>
    <cvs:TreasuryStockSharesHeldinTrust
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzEyNg_127df6ca-42c7-4f97-8c60-698ee4655459"
      unitRef="shares">1000000</cvs:TreasuryStockSharesHeldinTrust>
    <cvs:TreasuryStockSharesHeldinTrust
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzEyNg_37fc7689-5b3b-46ac-9f50-ead383303ff8"
      unitRef="shares">1000000</cvs:TreasuryStockSharesHeldinTrust>
    <cvs:TreasuryStockValueSharesHeldInTrust
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzIzNg_384a1f9f-f1f2-4e85-bcdb-d5be6bbf79a7"
      unitRef="usd">29000000</cvs:TreasuryStockValueSharesHeldInTrust>
    <cvs:TreasuryStockValueSharesHeldInTrust
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzIzNg_d193c228-d655-4240-a9c3-ee43a0bd8d6b"
      unitRef="usd">29000000</cvs:TreasuryStockValueSharesHeldInTrust>
    <cvs:TreasuryStockValueSharesHeldInTrust
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzIzNg_f91d5859-8832-40e1-ba20-01c506b0c0e3"
      unitRef="usd">29000000</cvs:TreasuryStockValueSharesHeldInTrust>
    <us-gaap:CommonStockValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzU0OTc1NTgxNTA4Mw_9cb20ea8-31db-4490-b77d-195c6d4edea2"
      unitRef="usd">18000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzQ0Mw_53250b4a-1f2f-4230-a152-a0d37e322541"
      unitRef="usd">17000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzQ0Mw_f059008e-35fd-40b6-a73b-2e26f165ed89"
      unitRef="usd">17000000</us-gaap:CommonStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2ec77f9083d4e5aaa261f4838a994dd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzgxNw_d71a7bb0-f241-4720-a980-d2b126c61c22"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzc0_e9bf8512-8bf6-4255-aeae-e312c03fb069">Significant Accounting Policies &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&#160; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CVS Health Corporation, together with its subsidiaries (collectively, &#x201c;CVS Health&#x201d; or the &#x201c;Company&#x201d;), has more than 9,000 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with over 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (&#x201c;PDP&#x201d;). The Company believes its integrated health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) and its emerging new variants continue to impact the economies of the U.S. and other countries around the world. The impact of COVID-19 on the Company&#x2019;s businesses, operating results, cash flows and financial condition in the years ended December 31, 2022, 2021 and 2020, as well as information regarding certain expected impacts of COVID-19 on the Company, is discussed throughout this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Care Benefits Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Health Care Benefits segment operates as one of the nation&#x2019;s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers&#x2019; compensation administrative services through its Coventry Health Care Workers&#x2019; Compensation business (&#x201c;Workers&#x2019; Compensation business&#x201d;) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment&#x2019;s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (&#x201c;providers&#x201d;), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as &#x201c;Insured&#x201d; and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as &#x201c;ASC.&#x201d; In addition, effective January 2022, the Company entered the individual public health insurance exchanges (&#x201c;Public Exchanges&#x201d;) in eight states through which it sells Insured plans directly to individual consumers. The Company entered Public Exchanges in four additional states effective January 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmacy Services Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmacy Services segment provides a full range of pharmacy benefit management (&#x201c;PBM&#x201d;) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (&#x201c;Covered Entities&#x201d;). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers. The Pharmacy Services segment&#x2019;s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retail/LTC Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (&#x201c;LTC&#x201d;) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;long-term care facilities and other care settings. As of December&#160;31, 2022, the Retail/LTC segment operated more than 9,000 retail locations, more than 1,100 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Corporate/Other Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Management and administrative expenses to support the Company&#x2019;s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company&#x2019;s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (&#x201c;VIEs&#x201d;) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash included in other current assets on the consolidated balance sheets represents funds held on behalf of members, including health savings account (&#x201c;HSA&#x201d;) funds associated with high deductible health plans. Restricted cash included in other assets on the consolidated balance sheets represents amounts held in a trust in one of the Company&#x2019;s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits and money market funds.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (included in other current assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (included in other assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in restricted cash included in other current assets as of December 31, 2022 compared to December 31, 2021 was primarily due to a decrease in HSA funds held on behalf of customers as a result of the sale of Payflex Holdings, Inc. (&#x201c;PayFlex&#x201d;). See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information on the Company&#x2019;s sale of PayFlex.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 &#x2018;&#x2018;Fair Value&#x2019;&#x2019; for additional information on how the Company estimates the fair value of these investments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related (yield-related) components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income (loss). Interest is not accrued on debt securities when management believes the collection of interest is unlikely.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company&#x2019;s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mortgage Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics:&#160;loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other investments consist primarily of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company&#x2019;s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership&#x2019;s investments through its review or prior to receiving the limited partnership&#x2019;s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (&#x201c;FHLBB&#x201d;), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Investment Income&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net investment income on the Company&#x2019;s investments is recorded when earned and is reflected in the Company&#x2019;s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders&#x2019; accounts daily, based on the underlying investment experience and, therefore, does not impact the Company&#x2019;s net income (as long as the contract&#x2019;s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions&#x2019; experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders&#x2019; accounts through a charge to benefit costs. The contract holders&#x2019; accounts are reflected in policyholders&#x2019; funds on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized capital gains and losses on investments supporting large case pensions&#x2019; experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders&#x2019; accounts. The contract holders&#x2019; accounts are reflected in policyholders&#x2019; funds on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders&#x2019; equity, net of tax, as a component of accumulated other comprehensive income (loss). Unrealized capital gains and losses on investments supporting large case pensions&#x2019; experience-rated products are credited directly to contract holders&#x2019; accounts. The contract holders&#x2019; accounts are reflected in policyholders&#x2019; funds on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company&#x2019;s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations. Accounts receivable, net was composed of the following at December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vendor and manufacturer receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premium receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total accounts receivable, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes accounts receivable of $227&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s allowance for credit losses was $333&#160;million and $339&#160;million as of December&#160;31, 2022 and 2021, respectively. When developing an estimate of the Company&#x2019;s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company&#x2019;s accounts receivable are short duration in nature and typically settle in less than 30 days. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reinsurance Recoverables &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company&#x2019;s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December&#160;31, 2022, the Company&#x2019;s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Health Care Contract Acquisition Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Insurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations. At December&#160;31, 2022 and 2021, the balance of deferred acquisition costs was $1.2 billion and $895 million, respectively, comprised primarily of commissions paid on Medicare Supplement products within the Health Care Benefits segment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from 1 to 40 years for buildings, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;building improvements and leasehold improvements and 3 to 10 years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixtures and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes property and equipment of $244&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense (which includes the amortization of property and equipment under finance or capital leases) totaled $2.4 billion, $2.3 billion and $2.1 billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively. During the year ended December&#160;31, 2021, the Company recorded an impairment on property and equipment of $261&#160;million in connection with the planned closure of certain retail stores. See Note 6 &#x2018;&#x2018;Leases&#x2019;&#x2019; for additional information about these impairment charges as well as the Company&#x2019;s finance leases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Right-of-Use Assets and Lease Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company&#x2019;s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 &#x2018;&#x2018;Leases&#x2019;&#x2019; for additional information about right-of-use assets and lease liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;not amortized, but is subject to impairment reviews annually, or more frequently, if necessary, as further described in &#x201c;Recoverability of Long-Lived Assets&#x201d; below. See Note 5 &#x2018;&#x2018;Goodwill and Other Intangibles&#x2019;&#x2019; for additional information about goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (&#x201c;VOBA&#x201d;). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently, if necessary, as further described in &#x201c;Recoverability of Long-Lived Assets&#x201d; below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 5 &#x2018;&#x2018;Goodwill and Other Intangibles&#x2019;&#x2019; for additional information about intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recoverability of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group&#x2019;s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group&#x2019;s carrying value that exceeds the asset group&#x2019;s estimated future cash flows (discounted). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, the Company recorded office real estate optimization charges of $117&#160;million primarily related to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to its new flexible work arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company recorded a store impairment charge of approximately $1.4&#160;billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets during the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 &#x2018;&#x2018;Leases&#x2019;&#x2019; for additional information about the right-of-use asset charges. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of both 2022 and 2020, the Company performed its required annual impairment tests of goodwill and concluded there were no goodwill impairments as of the testing dates or during the years ended December 31, 2022 and 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $431&#160;million goodwill impairment charge on the remaining goodwill of the LTC reporting unit. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December&#160;31, 2021. See Note 5 &#x2018;&#x2018;Goodwill and Other Intangibles&#x2019;&#x2019; for additional information about the goodwill impairment charge recorded during the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value. There were no impairment losses recognized on indefinite-lived intangible assets in any of the years ended December&#160;31, 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separate Accounts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company&#x2019;s other businesses. Deposits, withdrawals and net investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Health Care Costs Payable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment&#x2019;s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company&#x2019;s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, &#x201c;IBNR&#x201d;). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company&#x2019;s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company&#x2019;s estimate of IBNR in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate &#x201c;completion factors.&#x201d; The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within six months of the date of service, but it can take up to 48 months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month&#x2019;s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company&#x2019;s estimate of claims remaining to be paid as of the financial statement date and is included in the Company&#x2019;s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company&#x2019;s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company&#x2019;s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company&#x2019;s business. The health status of the Company&#x2019;s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company&#x2019;s health care cost trend rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December&#160;31, 2022; however, actual claim payments may differ from the Company&#x2019;s estimates. A worsening (or improvement) of the Company&#x2019;s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December&#160;31, 2022 would cause these estimates to change in the near term, and such a change could be material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company&#x2019;s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company&#x2019;s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company&#x2019;s health care costs payable, see Note 7 &#x2018;&#x2018;Health Care Costs Payable.&#x2019;&#x2019; The Company&#x2019;s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Insurance Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unpaid Claims&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company&#x2019;s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company&#x2019;s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company&#x2019;s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company&#x2019;s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company&#x2019;s estimate of unpaid claims IBNR in 2022. As of December&#160;31, 2022, unpaid claims balances of $243 million and $1.1 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December&#160;31, 2021, unpaid claims balances of $324 million and $1.3 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Future Policy Benefits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from 3.0% to 11.3% in both the years ended December&#160;31, 2022 and 2021. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-duration long-term care contracts represent the Company&#x2019;s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was 4.9% and 5.1% in the years ended December 31, 2022 and 2021, respectively. The Company&#x2019;s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions. As of December&#160;31, 2022, future policy benefits balances of $385 million and $5.0 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December&#160;31, 2021, future policy benefits balances of $416 million and $5.1 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Deficiency Reserves&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company&#x2019;s method of acquiring, servicing and measuring the profitability of such contracts. The Company did not have any premium deficiency reserves as of December&#160;31, 2022. As of December&#160;31, 2021, the Company established a premium deficiency reserve of $16 million related to Medicaid products in the Health Care Benefits segment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Policyholders&#x2019; Funds&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Policyholders&#x2019; funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In both 2022 and 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. Reserves for contracts subject to experience rating reflect the Company&#x2019;s rights as well as the rights of policyholders and plan participants. The Company also held funds for HSAs on behalf of members associated with high deductible health plans prior to the sale of PayFlex in June 2022. These amounts were held to pay for qualified health care expenses incurred by these members. At December&#160;31, 2022, the Company did not hold any HSA funds as a result of the PayFlex sale. The HSA balance was approximately $2.9 billion at December 31, 2021 and was reflected in other current assets with a corresponding liability in policyholders&#x2019; funds. These assets were considered restricted cash for cash flow statement purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Policyholders&#x2019; funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders&#x2019; funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Self-Insurance Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is self-insured for certain losses related to general liability, workers&#x2019; compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company&#x2019;s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company&#x2019;s historical claims experience. As of both December&#160;31, 2022 and 2021, self-insurance liabilities totaled $1.1 billion and were recorded in accrued expenses and other long-term liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from foreign currency transactions and the effects of foreign currency remeasurements were not material in the years ended December&#160;31, 2022, 2021 or 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Care Benefits Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company&#x2019;s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company&#x2019;s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company&#x2019;s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Premium Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (&#x201c;MLR&#x201d;) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the &#x201c;ACA&#x201d;) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment&#x2019;s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company&#x2019;s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor&#x2019;s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting for Medicare Part D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues include insurance premiums earned by the Company&#x2019;s PDPs, which are determined based on the PDP&#x2019;s annual bid and related contractual arrangements with the U.S. Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;). The insurance &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmacy Services Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company&#x2019;s retail pharmacy network. The Company&#x2019;s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see &#x201c;Drug Discounts&#x201d; and &#x201c;Guarantees&#x201d; below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (&#x201c;retail co-payments&#x201d;), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Revenues generated from prescription drugs sold by third party pharmacies in the Company&#x2019;s retail pharmacy network and associated administrative fees are recognized at the Company&#x2019;s point-of-sale, which is when the claim is adjudicated by the Company&#x2019;s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Drug Discounts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records revenue net of manufacturers&#x2019; rebates earned by its clients based on their plan members&#x2019; utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers&#x2019; rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers&#x2019; rebate amounts has not been material to the Company&#x2019;s operating results or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#x2019;s operating results or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retail/LTC Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Retail Pharmacy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#x2019;s operating results or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer returns are not material to the Company&#x2019;s operating results or financial condition. Sales taxes are not included in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Loyalty and Other Programs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customer loyalty program, ExtraCare&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, consists of two components, ExtraSavings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ExtraBucks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also offers a subscription-based membership program, CarePass&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Long-term Care&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company&#x2019;s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Walk-In Medical Clinics&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For services provided by the Company&#x2019;s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table disaggregates the Company&#x2019;s revenue by major source in each segment for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Health Care&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmacy&lt;br/&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retail/&lt;br/&gt;LTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Corporate/&lt;br/&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;br/&gt;Totals&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Major goods/services lines:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(45,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;205,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Front Store&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;85,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;85,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net investment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;91,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;169,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;106,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(45,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;322,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy Services distribution channel:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy network&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;97,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Mail choice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;70,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;169,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Major goods/services lines:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;152,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;76,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(43,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;184,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Front Store&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;76,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;76,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;153,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;100,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(43,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;292,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy Services distribution channel:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy network&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; (1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;91,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Mail choice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;60,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;153,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Major goods/services lines:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;141,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;70,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(40,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;171,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Front Store&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;141,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;91,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(40,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;268,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy Services distribution channel:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy network&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;85,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Mail choice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;141,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company&#x2019;s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; claims picked up at a retail pharmacy, as well as prescriptions filled at the Company&#x2019;s retail pharmacies under the Maintenance Choice&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities primarily represent the Company&#x2019;s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables and contract liabilities from contracts with customers as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables (included in accounts receivable, net)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities (included in accrued expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, the contract liabilities balance includes increases related to customers&#x2019; earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rewards earnings and gift card issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redemption and breakage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for cost of products sold as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmacy Services Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company&#x2019;s mail service dispensing pharmacies and indirectly through the Company&#x2019;s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company&#x2019;s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients&#x2019; benefit plans from the Company&#x2019;s mail service dispensing pharmacies, net of any volume-related or other discounts (see &#x201c;Vendor Allowances and Purchase Discounts&#x201d; below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company&#x2019;s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retail/LTC Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vendor Allowances and Purchase Discounts &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for vendor allowances and purchase discounts as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmacy Services Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company&#x2019;s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retail/LTC Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company&#x2019;s consolidated financial statements in any of the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Health Care Reform&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Insurer Fee&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning on January 1, 2014, the ACA imposed an annual premium-based health insurer fee (&#x201c;HIF&#x201d;) for each calendar year, payable in September, which was not deductible for tax purposes. The Company was required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was no expense related to the HIF in the years ended December&#160;31, 2022 and 2021. In the year ended December 31, 2020, operating expenses included $1.0&#160;billion related to the Company&#x2019;s share of the HIF. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company&#x2019;s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Corridor&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) based on their ratio of allowable costs to target costs (as defined by the ACA). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company filed a lawsuit in August 2019 to recover the $313&#160;million it was owed under the ACA&#x2019;s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA&#x2019;s temporary risk corridor program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company received the $313&#160;million it was owed under the ACA&#x2019;s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering offsetting items such as the ACA&#x2019;s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $307&#160;million and after-tax income of $223&#160;million during the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $745 million, $707 million and $613 million in 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMjY0_8d034ca5-401e-4526-8bb8-d8fed86877bb"&gt;three&lt;/span&gt; to five years) using the straight-line method. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company&#x2019;s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors defined benefit pension plans (&#x201c;pension plans&#x201d;) and other postretirement employee benefit plans (&#x201c;OPEB plans&#x201d;) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit income for the Company&#x2019;s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time.&#160;Non-service cost components of pension and postretirement net periodic benefit income are included in other income in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share is computed using the treasury stock method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 &#x2018;&#x2018;Earnings Per Share&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shares Held in Trust&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains grantor trusts, which held approximately one million shares of its common stock at both December&#160;31, 2022 and 2021. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE&#x2019;s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities - Primary Beneficiary&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2014, the Company and Cardinal Health, Inc. (&#x201c;Cardinal&#x201d;) established Red Oak Sourcing, LLC (&#x201c;Red Oak&#x201d;), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December&#160;31, 2022, 2021 and 2020. The payments reduce the Company&#x2019;s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities - Other Variable Interest Holder&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Hedge fund and private equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Real estate partnerships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not the primary beneficiary of these VIEs because the nature of the Company&#x2019;s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE&#x2019;s income or losses in net income.&#160;The Company&#x2019;s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge fund investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an equity method investment in SureScripts, LLC (&#x201c;SureScripts&#x201d;), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $60 million, $52 million and $56 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million in the years ended December&#160;31, 2022, 2021 and 2020, respectively. The Company&#x2019;s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an equity method investment in Heartland Healthcare Services, LLC (&#x201c;Heartland&#x201d;). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $87 million, $79 million and $77 million for pharmaceutical inventory purchases during the years ended December&#160;31, 2022, 2021 and 2020, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company&#x2019;s investment in and equity in the earnings of Heartland for all periods presented is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, the Company made charitable contributions of&#160;$25&#160;million, $50 million and $50&#160;million, respectively,&#160;to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens &#x2018;n Things and Bob&#x2019;s Stores, each of which subsequently filed for bankruptcy. The Company&#x2019;s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees. See &#x201c;Lease Guarantees&#x201d; in Note 16 &#x2018;&#x2018;Commitments and Contingencies&#x2019;&#x2019; for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Results from discontinued operations were immaterial for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the results of discontinued operations for the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Targeted Improvements to the Accounting for Long-Duration Insurance Contracts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Financial Accounting Standards Board issued ASU 2018-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Targeted Improvements to the Accounting for Long-Duration Contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income (loss). The rate used to discount the Company&#x2019;s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#x2019;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company&#x2019;s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company adopted this accounting standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented, January 1, 2021, also referred to as the transition date, for changes primarily related to the liability for future policy benefits and deferred acquisition costs. The Company is still in the process of  finalizing the impact of the new standard on its historical financial statements, but expects to record an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income on the transition date of approximately $1&#160;billion as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company&#x2019;s expected investment yield under the existing guidance.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfStores
      contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzE4Mw_6d839566-ba36-4db2-a4c4-3dbda813e61e"
      unitRef="store">9000</us-gaap:NumberOfStores>
    <cvs:NumberOfWalkInMedicalClinics
      contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIxMQ_47169163-f676-4df7-8ae9-fb9ece9b046b"
      unitRef="clinic">1100</cvs:NumberOfWalkInMedicalClinics>
    <cvs:NumberOfPharmacyPlanMembers
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzI5NA_37ed37de-030e-4671-b034-03dcf46f7a63"
      unitRef="people">110000000</cvs:NumberOfPharmacyPlanMembers>
    <cvs:NumberOfPatientsServedPerYear
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQxOA_26b020c2-dd84-4e3d-93dc-3de9c0e280eb"
      unitRef="patient">1000000</cvs:NumberOfPatientsServedPerYear>
    <cvs:NumberOfPeopleServed
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ3Nw_caca9968-1b7c-4207-a506-e82a05491abd"
      unitRef="people">35000000</cvs:NumberOfPeopleServed>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzgx_4c612b84-af96-4693-b85c-77772f74368e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Care Benefits Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Health Care Benefits segment operates as one of the nation&#x2019;s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers&#x2019; compensation administrative services through its Coventry Health Care Workers&#x2019; Compensation business (&#x201c;Workers&#x2019; Compensation business&#x201d;) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment&#x2019;s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (&#x201c;providers&#x201d;), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as &#x201c;Insured&#x201d; and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as &#x201c;ASC.&#x201d; In addition, effective January 2022, the Company entered the individual public health insurance exchanges (&#x201c;Public Exchanges&#x201d;) in eight states through which it sells Insured plans directly to individual consumers. The Company entered Public Exchanges in four additional states effective January 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmacy Services Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmacy Services segment provides a full range of pharmacy benefit management (&#x201c;PBM&#x201d;) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (&#x201c;Covered Entities&#x201d;). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers. The Pharmacy Services segment&#x2019;s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retail/LTC Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (&#x201c;LTC&#x201d;) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;long-term care facilities and other care settings. As of December&#160;31, 2022, the Retail/LTC segment operated more than 9,000 retail locations, more than 1,100 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Corporate/Other Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Management and administrative expenses to support the Company&#x2019;s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company&#x2019;s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzEzMzc_aaa075f0-7767-4352-95da-a3844fde28af"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <cvs:IndividualPublicHealthInsuranceExchangesNumberOfStates
      contextRef="i780b19498a144075a22a573432132bda_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDAx_524957c7-0839-4284-b120-fb68a9b41442"
      unitRef="state">8</cvs:IndividualPublicHealthInsuranceExchangesNumberOfStates>
    <cvs:IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates
      contextRef="i42d18c1100d94a559f0d7d4c757498bf_D20230101-20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjUwNjE_9ae74e1b-6d8b-4c7a-8df5-216aa64cf043"
      unitRef="state">4</cvs:IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates>
    <us-gaap:NumberOfStores
      contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ5ODM_93e9f057-27aa-453d-a12f-3a977a79a897"
      unitRef="store">9000</us-gaap:NumberOfStores>
    <cvs:NumberOfWalkInMedicalClinics
      contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzUwMTE_8215efbb-9eb9-4591-9b49-3037f20d9e17"
      unitRef="clinic">1100</cvs:NumberOfWalkInMedicalClinics>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzcx_b87a0d62-5116-4f64-8866-67cee5a2b5a2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (&#x201c;VIEs&#x201d;) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDEz_96285995-e297-4876-ab4b-33415e14e279">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzEw_0ad14921-9fdd-4672-b59e-9a9d7c952f83">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash included in other current assets on the consolidated balance sheets represents funds held on behalf of members, including health savings account (&#x201c;HSA&#x201d;) funds associated with high deductible health plans. Restricted cash included in other assets on the consolidated balance sheets represents amounts held in a trust in one of the Company&#x2019;s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits and money market funds.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzU3_e516bac8-00d4-4532-b1b5-b3122382d8c6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (included in other current assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (included in other assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzEtMS0xLTEtMTY3OTA4_f7255fd6-69e2-42a1-9f49-c68f0f0b49c4"
      unitRef="usd">12945000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzEtMy0xLTEtMTY3OTA4_4a733a18-a12b-40b6-8610-d1cbebec85f7"
      unitRef="usd">9408000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzEtNS0xLTEtMTY3OTA4_e89b7677-68d2-40d2-bea7-afd88403a6e0"
      unitRef="usd">7854000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzItMS0xLTEtMTY3OTA4_e5db1869-62a3-4aaa-bf5b-842487ea0982"
      unitRef="usd">144000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzItMy0xLTEtMTY3OTA4_308e407d-1776-4663-95a3-b0c1683ad497"
      unitRef="usd">3065000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzItNS0xLTEtMTY3OTA4_e0e35de5-a457-4b7e-93f5-e1bd1a77b6bf"
      unitRef="usd">2913000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzMtMS0xLTEtMTY3OTA4_7a63318a-619e-462d-96a7-71a78106918e"
      unitRef="usd">216000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzMtMy0xLTEtMTY3OTA4_dfe5a126-796b-48de-9f0c-d5e75d9872ed"
      unitRef="usd">218000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzMtNS0xLTEtMTY3OTA4_862e915d-d269-4a30-bdbd-f3bfdb7263c7"
      unitRef="usd">276000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzQtMS0xLTEtMTY3OTA4_e272c9fa-fd9d-46e8-8c8d-f65241f244b8"
      unitRef="usd">13305000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzQtMy0xLTEtMTY3OTA4_532ba4a4-b400-44a2-907b-7b253bbb3309"
      unitRef="usd">12691000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo0OGExY2JlOGRhNTA0MzgxOTE1N2M2NmE0ODcwNmRhNS90YWJsZXJhbmdlOjQ4YTFjYmU4ZGE1MDQzODE5MTU3YzY2YTQ4NzA2ZGE1XzQtNS0xLTEtMTY3OTA4_3ac14fde-bee6-44df-be9e-b9bdcccc959e"
      unitRef="usd">11043000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDA2_e26375c6-13f3-472e-bcf3-978b8841e6f6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 &#x2018;&#x2018;Fair Value&#x2019;&#x2019; for additional information on how the Company estimates the fair value of these investments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related (yield-related) components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income (loss). Interest is not accrued on debt securities when management believes the collection of interest is unlikely.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company&#x2019;s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mortgage Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics:&#160;loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other investments consist primarily of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company&#x2019;s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership&#x2019;s investments through its review or prior to receiving the limited partnership&#x2019;s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (&#x201c;FHLBB&#x201d;), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Investment Income&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net investment income on the Company&#x2019;s investments is recorded when earned and is reflected in the Company&#x2019;s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders&#x2019; accounts daily, based on the underlying investment experience and, therefore, does not impact the Company&#x2019;s net income (as long as the contract&#x2019;s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions&#x2019; experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders&#x2019; accounts through a charge to benefit costs. The contract holders&#x2019; accounts are reflected in policyholders&#x2019; funds on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized capital gains and losses on investments supporting large case pensions&#x2019; experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders&#x2019; accounts. The contract holders&#x2019; accounts are reflected in policyholders&#x2019; funds on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders&#x2019; equity, net of tax, as a component of accumulated other comprehensive income (loss). Unrealized capital gains and losses on investments supporting large case pensions&#x2019; experience-rated products are credited directly to contract holders&#x2019; accounts. The contract holders&#x2019; accounts are reflected in policyholders&#x2019; funds on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzM4_b7afe912-d7cc-48b7-9405-bb4258cd2c74">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company&#x2019;s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzQy_7add3d18-456e-492b-bebd-6e14abb063fb">Accounts ReceivableAccounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations.When developing an estimate of the Company&#x2019;s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company&#x2019;s accounts receivable are short duration in nature and typically settle in less than 30 days.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDM3_f5f05ca4-4193-4ede-98c8-11b0a989ec33">Accounts receivable, net was composed of the following at December&#160;31, 2022 and 2021:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vendor and manufacturer receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premium receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total accounts receivable, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes accounts receivable of $227&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzEtMS0xLTEtMTY3OTA4_2a6c325c-9fb2-44ef-ad5c-dc5d68dfd45a"
      unitRef="usd">8983000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzEtMy0xLTEtMTY3OTA4_c877a934-8fb7-4e42-9c8d-ac5342bf2740"
      unitRef="usd">7932000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <cvs:VendorandManufacturerReceivables
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzItMS0xLTEtMTY3OTA4_590b7a4e-942f-4bb4-b78c-11acff873e5a"
      unitRef="usd">12395000000</cvs:VendorandManufacturerReceivables>
    <cvs:VendorandManufacturerReceivables
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzItMy0xLTEtMTY3OTA4_c60be454-602a-4cf4-9b29-92ac7044ed58"
      unitRef="usd">10573000000</cvs:VendorandManufacturerReceivables>
    <us-gaap:PremiumsReceivableAtCarryingValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzMtMS0xLTEtMTY3OTA4_2be64380-3130-487a-a12f-9ade78a61797"
      unitRef="usd">2676000000</us-gaap:PremiumsReceivableAtCarryingValue>
    <us-gaap:PremiumsReceivableAtCarryingValue
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzMtMy0xLTEtMTY3OTA4_111ddf92-d66b-445d-8726-97b06c3c9808"
      unitRef="usd">2537000000</us-gaap:PremiumsReceivableAtCarryingValue>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzQtMS0xLTEtMTY3OTA4_3a27b260-da60-42ef-ac84-7500e9665356"
      unitRef="usd">3449000000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzQtMy0xLTEtMTY3OTA4_860077ec-e546-4e55-8af0-43f398997eb5"
      unitRef="usd">3389000000</us-gaap:OtherReceivablesNetCurrent>
    <cvs:AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzUtMS0xLTEtMTY3OTA4_db29b9bc-8f1e-4748-a71b-18a3380c5d68"
      unitRef="usd">27503000000</cvs:AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale>
    <cvs:AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo4OTZhNTkwMzYyYjY0MTU4OGRhNzI2N2NlMzc2MzNiYi90YWJsZXJhbmdlOjg5NmE1OTAzNjJiNjQxNTg4ZGE3MjY3Y2UzNzYzM2JiXzUtMy0xLTEtMTY3OTA4_70ad81b1-d8ba-46b4-bb93-597aaca98219"
      unitRef="usd">24431000000</cvs:AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale>
    <cvs:AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIxOTkwMjMzNDk1MjE_43f242b8-6f6e-4349-b36a-2fedf0d77033"
      unitRef="usd">227000000</cvs:AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzE5MjA1_c4c477af-2a81-48c0-8334-2ea32b4559b2"
      unitRef="usd">333000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzE5MjEy_ce501987-9b7d-493e-ad6b-89b06879ed9f"
      unitRef="usd">339000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDUx_8bb97368-69c1-42e7-ac14-e30315c12360">Inventories Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ReinsuranceAccountingPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzQx_10dbf94c-f4c7-4dc2-a4e0-ae0e9f6da4fe">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reinsurance Recoverables &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company&#x2019;s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December&#160;31, 2022, the Company&#x2019;s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReinsuranceAccountingPolicy>
    <us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDA3_2aeaf068-9faf-4d97-b0eb-cfb19d29965e">Health Care Contract Acquisition CostsInsurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations.</us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy>
    <us-gaap:DeferredPolicyAcquisitionCosts
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyMjc1_05837e6a-54c5-4867-a3f3-86759f60a6c4"
      unitRef="usd">1200000000</us-gaap:DeferredPolicyAcquisitionCosts>
    <us-gaap:DeferredPolicyAcquisitionCosts
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyMjgy_d56d2dfe-4dff-448c-8ca2-d62fe6186fa9"
      unitRef="usd">895000000</us-gaap:DeferredPolicyAcquisitionCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDIx_f37b1e86-a2d5-42fc-a108-e871f10d612b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from 1 to 40 years for buildings, &lt;/span&gt;&lt;/div&gt;building improvements and leasehold improvements and 3 to 10 years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4974a8bfcfe4424d800583e6f9ed22ac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyNzg2_ec4d6529-bacd-4197-9ea8-d2726a416369">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2ef0140101e7410aab67b7c7900a5d71_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyNzky_730362ea-b18f-4e54-98fd-c4061528641c">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7c831fb209894939826991737cbd7475_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyODY5_892ca965-428b-4173-8760-c4815f24d106">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie37cf62163d84a58bb4468ebd3f5cfed_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIyODc1_3a477ab6-1631-4627-a1b3-c65b35e237fb">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzQ0_4d77d0c8-a04c-4d9b-8f95-366ea3d41998">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixtures and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes property and equipment of $244&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6bbfa6bdf0b24740a26dec57554e595c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzEtMS0xLTEtMTY3OTA4_b3c27dca-0e64-42ba-acff-a3c765b44a6c"
      unitRef="usd">1996000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4ada219a77914d62bea752d3c03e225f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzEtMy0xLTEtMTY3OTA4_227d63e8-1e93-4738-92c7-df5e389e378c"
      unitRef="usd">2038000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6c18d654fb324895a611580a5ec5b3dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzItMS0xLTEtMTY3OTA4_36590bbb-2507-4a0b-ad00-9c276c9273d5"
      unitRef="usd">4545000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie53b91392b604092b359e0652c0bf806_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzItMy0xLTEtMTY3OTA4_49d5f6b3-a795-4fd4-9e1c-f1a5f93e4f74"
      unitRef="usd">4225000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0fde8ef39b534e14afcac581de49b996_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzMtMS0xLTEtMTY3OTA4_a71d3e84-3244-4ab7-88a7-e4578dcb2ab0"
      unitRef="usd">12978000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0fb3a83ef19240adb23daa081377a140_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzMtMy0xLTEtMTY3OTA4_d8caa384-99e2-411e-8ec9-53da2b200716"
      unitRef="usd">13619000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifcd7ff4f57ff426ab9b84721b8a4497c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzQtMS0xLTEtMTY3OTA4_7e173426-731e-4faf-a703-35b126694e3a"
      unitRef="usd">6238000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6748d4d91a3f4e1c9f9bf83409587fc3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzQtMy0xLTEtMTY3OTA4_2afc5deb-4de8-4780-80f6-f45e0bb00ba9"
      unitRef="usd">6242000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9d2d5b42e5da4c468ab576df84378112_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzUtMS0xLTEtMTY3OTA4_89607997-5a6d-43fb-a800-25fa29a7fa15"
      unitRef="usd">8843000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8e8b9d6224854f2aa4c4798da79217fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzUtMy0xLTEtMTY3OTA4_30cb0e7c-132e-415f-b7da-22c53e3e38f8"
      unitRef="usd">7426000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzYtMS0xLTEtMTY3OTA4_874c2108-5aed-4352-8c3d-0e296f502a43"
      unitRef="usd">34600000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzYtMy0xLTEtMTY3OTA4_f8a631ca-4ea6-413c-867d-c64bae848d1c"
      unitRef="usd">33550000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzctMS0xLTEtMTY3OTA4_dbc8e065-99a4-40dd-b401-b3cbf862ac2e"
      unitRef="usd">21483000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzctMy0xLTEtMTY3OTA4_5563e3f0-302b-48ad-bc2a-ca5f5840601e"
      unitRef="usd">20654000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <cvs:PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzgtMS0xLTEtMTY3OTA4_c761a288-85f2-4ff3-b94d-c9bdf787cca6"
      unitRef="usd">13117000000</cvs:PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale>
    <cvs:PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3ZDFkZTc1NDJlYzM0NTA0ODNlMGE5ODQ0MmFjOWFjYy90YWJsZXJhbmdlOjdkMWRlNzU0MmVjMzQ1MDQ4M2UwYTk4NDQyYWM5YWNjXzgtMy0xLTEtMTY3OTA4_28e65ddf-3cff-4790-a786-796d75cc27b4"
      unitRef="usd">12896000000</cvs:PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale>
    <cvs:PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjUwODU_ac2a807e-c784-45c4-a159-7634526880e7"
      unitRef="usd">244000000</cvs:PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale>
    <us-gaap:Depreciation
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIzNDQ5_d688cb50-afc7-40a1-8961-d620037bedfa"
      unitRef="usd">2400000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIzNDUz_0b3d5c21-a9ac-42a5-9378-d730ac2ad63e"
      unitRef="usd">2300000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIzNDYw_2000fd3a-0348-4853-9d98-2699344de5d7"
      unitRef="usd">2100000000</us-gaap:Depreciation>
    <cvs:StoreImpairmentCharges
      contextRef="i19b3fce48e974e0cba8970c7c61dfc90_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIxOTkwMjMzNjA2ODI_b97286fb-7efe-45ec-8cca-2d3d4d550182"
      unitRef="usd">261000000</cvs:StoreImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzQ5_dfc081ea-e42f-4aad-9020-5c20413c984e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Right-of-Use Assets and Lease Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company&#x2019;s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;See Note 6 &#x2018;&#x2018;Leases&#x2019;&#x2019; for additional information about right-of-use assets and lease liabilities.</us-gaap:LesseeLeasesPolicyTextBlock>
    <cvs:LesseeOperatingAndFinanceLeasesRenewalTerm
      contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzI0ODA0_b83746f0-02b8-4b4a-bbde-c32b973d84c7">P5Y</cvs:LesseeOperatingAndFinanceLeasesRenewalTerm>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDM4_ed0fee4a-5906-4d79-9aff-fb5346764b51">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is &lt;/span&gt;&lt;/div&gt;not amortized, but is subject to impairment reviews annually, or more frequently, if necessary, as further described in &#x201c;Recoverability of Long-Lived Assets&#x201d; below.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzU5_0ab2ef98-fbf3-4659-b2dc-f6962834a7f2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (&#x201c;VOBA&#x201d;). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently, if necessary, as further described in &#x201c;Recoverability of Long-Lived Assets&#x201d; below.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzkw_b5e4ce75-b95d-4143-8151-3768bae1e40e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recoverability of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group&#x2019;s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group&#x2019;s carrying value that exceeds the asset group&#x2019;s estimated future cash flows (discounted). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, the Company recorded office real estate optimization charges of $117&#160;million primarily related to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to its new flexible work arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company recorded a store impairment charge of approximately $1.4&#160;billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets during the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 &#x2018;&#x2018;Leases&#x2019;&#x2019; for additional information about the right-of-use asset charges. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of both 2022 and 2020, the Company performed its required annual impairment tests of goodwill and concluded there were no goodwill impairments as of the testing dates or during the years ended December 31, 2022 and 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $431&#160;million goodwill impairment charge on the remaining goodwill of the LTC reporting unit. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December&#160;31, 2021. See Note 5 &#x2018;&#x2018;Goodwill and Other Intangibles&#x2019;&#x2019; for additional information about the goodwill impairment charge recorded during the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the &lt;/span&gt;&lt;/div&gt;income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <cvs:OfficeRealEstateOptimizationCharges
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzEwOTk1MTE2MzgxMTc5_49130952-8ae5-4f6f-b25e-45d660073354"
      unitRef="usd">117000000</cvs:OfficeRealEstateOptimizationCharges>
    <cvs:StoreImpairmentCharges
      contextRef="i1e0fac73260b479989119ffb924ad3e9_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzU0OTc1NTkwMDk5MQ_22eeb21c-0595-4657-b25f-50f5bc97a720"
      unitRef="usd">1400000000</cvs:StoreImpairmentCharges>
    <cvs:NumberOfStoresPlannedClosure
      contextRef="i1e0fac73260b479989119ffb924ad3e9_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzI5Mzg4_3aaa14aa-93d9-4bfb-b7ce-8fafe2a822e0"
      unitRef="store">900</cvs:NumberOfStoresPlannedClosure>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjUwOTY_06bb3fff-63ea-4b75-9b54-a6a2618fe117"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjUwOTY_b83614f4-accd-4642-a34f-c353672c26f4"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie0d6894378d3433197250c8e10ca47a7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzMwNDYw_2a53c550-bba0-443d-88c9-22f7b32a8c68"
      unitRef="usd">431000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzMxNDQx_647c1092-d032-4d6f-bb99-adfd37c47270"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzMxNDQx_aad69f7f-da33-4840-86b9-40079566f7ff"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzMxNDQx_f598dca6-5593-4919-b260-3d79025ff0fc"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:PolicyholderAccountsPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDAz_f6955a3f-017d-47ff-a1d5-f27336bef7a4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separate Accounts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company&#x2019;s other businesses. Deposits, withdrawals and net investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned.&lt;/span&gt;&lt;/div&gt;</us-gaap:PolicyholderAccountsPolicy>
    <us-gaap:HealthCareCostsPolicyPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDA0_61aa71a7-7f3d-4bfb-8421-25a642a4a616">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Health Care Costs Payable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment&#x2019;s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company&#x2019;s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, &#x201c;IBNR&#x201d;). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company&#x2019;s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company&#x2019;s estimate of IBNR in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate &#x201c;completion factors.&#x201d; The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within six months of the date of service, but it can take up to 48 months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month&#x2019;s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company&#x2019;s estimate of claims remaining to be paid as of the financial statement date and is included in the Company&#x2019;s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company&#x2019;s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company&#x2019;s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company&#x2019;s business. The health status of the Company&#x2019;s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company&#x2019;s health care cost trend rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December&#160;31, 2022; however, actual claim payments may differ from the Company&#x2019;s estimates. A worsening (or improvement) of the Company&#x2019;s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December&#160;31, 2022 would cause these estimates to change in the near term, and such a change could be material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company&#x2019;s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company&#x2019;s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company&#x2019;s health care costs payable, see Note 7 &#x2018;&#x2018;Health Care Costs Payable.&#x2019;&#x2019; The Company&#x2019;s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.&lt;/span&gt;&lt;/div&gt;</us-gaap:HealthCareCostsPolicyPolicyTextBlock>
    <cvs:HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid
      contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzM1NjM5_e593c914-955f-4b46-8ea4-cfbaa388c197">P6M</cvs:HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid>
    <cvs:HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid
      contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzM1Njg4_2478af1f-f4b3-4f6c-b2d1-b5703db8d32b">P48M</cvs:HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid>
    <us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mjk1_299d359d-5988-4c0d-a1b4-11d07f4e23e6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Insurance Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unpaid Claims&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company&#x2019;s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company&#x2019;s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company&#x2019;s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company&#x2019;s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company&#x2019;s estimate of unpaid claims IBNR in 2022. As of December&#160;31, 2022, unpaid claims balances of $243 million and $1.1 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December&#160;31, 2021, unpaid claims balances of $324 million and $1.3 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Future Policy Benefits&lt;/span&gt;&lt;/div&gt;Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from 3.0% to 11.3% in both the years ended December&#160;31, 2022 and 2021. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-duration long-term care contracts represent the Company&#x2019;s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was 4.9% and 5.1% in the years ended December 31, 2022 and 2021, respectively. The Company&#x2019;s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions.</us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy>
    <cvs:LiabilityForUnpaidClaims
      contextRef="if7945c60ae0e48268a21dc60ec7256ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQyODEy_c160dc4a-1489-4350-b19c-0a2a784cdc2f"
      unitRef="usd">243000000</cvs:LiabilityForUnpaidClaims>
    <cvs:LiabilityForUnpaidClaims
      contextRef="ide9ac130c868441a9b93b609dc8b28e0_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQyODE5_c2c3770e-1db8-4099-bbf2-646ec61f3a82"
      unitRef="usd">1100000000</cvs:LiabilityForUnpaidClaims>
    <cvs:LiabilityForUnpaidClaims
      contextRef="i9f6d2a400d30483eb5535b2a740cccbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQyOTYw_ad84c3da-1abc-4df2-abf3-557e1b1f50ad"
      unitRef="usd">324000000</cvs:LiabilityForUnpaidClaims>
    <cvs:LiabilityForUnpaidClaims
      contextRef="icc50f23b90eb443283a4ee5cf88abd97_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQyOTY3_61201c23-c631-469d-8d78-4c695083979f"
      unitRef="usd">1300000000</cvs:LiabilityForUnpaidClaims>
    <cvs:LimitedPaymentsContracts
      contextRef="ic63500a3d0dc40e8b098d64a2fbfe2ab_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQzODIw_011bed3d-f2e2-4667-ac15-62c35aa9848d"
      unitRef="number">0.030</cvs:LimitedPaymentsContracts>
    <cvs:LimitedPaymentsContracts
      contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQzODIw_2a0eaf06-00cf-47f8-967b-69f45eb4aa94"
      unitRef="number">0.030</cvs:LimitedPaymentsContracts>
    <cvs:LimitedPaymentsContracts
      contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQzODI2_17ccad57-3420-4cf6-8306-6d4e1d4b4ce9"
      unitRef="number">0.113</cvs:LimitedPaymentsContracts>
    <cvs:LimitedPaymentsContracts
      contextRef="i26333704d6224942a7b55db5b9a7c2cf_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQzODI2_af38cace-5ec8-41f0-846c-aca5f8efdf83"
      unitRef="number">0.113</cvs:LimitedPaymentsContracts>
    <cvs:AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0Mjk4_21886d6c-99b5-46a4-8a88-28a3380327e1"
      unitRef="number">0.049</cvs:AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts>
    <cvs:AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzk4OTU2MDQ3NTI3MTg_cf30799f-0d36-4970-bb2c-d2182d4f662c"
      unitRef="number">0.051</cvs:AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts>
    <us-gaap:LiabilityForFuturePolicyBenefits
      contextRef="if7945c60ae0e48268a21dc60ec7256ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0NTQ2_a21792e9-ab3d-4c75-9364-12e58ec1629d"
      unitRef="usd">385000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefits
      contextRef="ide9ac130c868441a9b93b609dc8b28e0_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0NTUz_9023015e-23b7-4f29-a4d7-0f85353e22c9"
      unitRef="usd">5000000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefits
      contextRef="i9f6d2a400d30483eb5535b2a740cccbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0NzAz_f2c3069e-689d-4cc0-884e-4392a01198b8"
      unitRef="usd">416000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefits
      contextRef="icc50f23b90eb443283a4ee5cf88abd97_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ0NzEw_5c63a062-caab-48cc-8bfe-05209ed437f4"
      unitRef="usd">5100000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <cvs:InsurancePremiumDeficiencyReservePolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzk1_88d6d65b-01b2-4bf0-a25a-1864f4c876ce">Premium Deficiency ReservesThe Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company&#x2019;s method of acquiring, servicing and measuring the profitability of such contracts.</cvs:InsurancePremiumDeficiencyReservePolicyTextBlock>
    <cvs:PremiumDeficiencyReserveLiability
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzEwOTk1MTE2MzgxMDg0_793990e3-923f-4bcc-b8d1-7f420b16c42e"
      unitRef="usd">0</cvs:PremiumDeficiencyReserveLiability>
    <cvs:PremiumDeficiencyReserveLiability
      contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ1NjE2_f0574f20-aedc-4b4a-8c75-a5797df37879"
      unitRef="usd">16000000</cvs:PremiumDeficiencyReserveLiability>
    <us-gaap:AllocationsToPolicyholdersPolicies
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDMz_852eea0c-cfcc-418a-829b-7f94e1fcfa4b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Policyholders&#x2019; Funds&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Policyholders&#x2019; funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In both 2022 and 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. Reserves for contracts subject to experience rating reflect the Company&#x2019;s rights as well as the rights of policyholders and plan participants. The Company also held funds for HSAs on behalf of members associated with high deductible health plans prior to the sale of PayFlex in June 2022. These amounts were held to pay for qualified health care expenses incurred by these members. At December&#160;31, 2022, the Company did not hold any HSA funds as a result of the PayFlex sale. The HSA balance was approximately $2.9 billion at December 31, 2021 and was reflected in other current assets with a corresponding liability in policyholders&#x2019; funds. These assets were considered restricted cash for cash flow statement purposes.&lt;/span&gt;&lt;/div&gt;Policyholders&#x2019; funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders&#x2019; funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets.</us-gaap:AllocationsToPolicyholdersPolicies>
    <cvs:PensionAndAnnuityInvestmentContractsInterest
      contextRef="ic63500a3d0dc40e8b098d64a2fbfe2ab_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2MTIw_a196a71c-f869-470d-b95f-744f7c46ea04"
      unitRef="number">0.035</cvs:PensionAndAnnuityInvestmentContractsInterest>
    <cvs:PensionAndAnnuityInvestmentContractsInterest
      contextRef="ied68e73a46294b128f6f8f76c61401fa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2MTIw_c7f051f9-12ce-41cf-bac6-d2ca43cd13d1"
      unitRef="number">0.035</cvs:PensionAndAnnuityInvestmentContractsInterest>
    <cvs:PensionAndAnnuityInvestmentContractsInterest
      contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2MTI2_2eb33c3a-6e05-49df-9620-bc98bea2d2ed"
      unitRef="number">0.048</cvs:PensionAndAnnuityInvestmentContractsInterest>
    <cvs:PensionAndAnnuityInvestmentContractsInterest
      contextRef="i26333704d6224942a7b55db5b9a7c2cf_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2MTI2_771f306f-68b9-4449-9d95-4e4b71df903c"
      unitRef="number">0.048</cvs:PensionAndAnnuityInvestmentContractsInterest>
    <cvs:HeathSavingsAccountBalance
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY1OTcwNjk4NjkwNTI_cb52629b-abc4-4da9-a074-d977588e376a"
      unitRef="usd">0</cvs:HeathSavingsAccountBalance>
    <cvs:HeathSavingsAccountBalance
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ2NjA0_7eaf0f5d-1cf4-45fc-96f8-8d8b611632a8"
      unitRef="usd">2900000000</cvs:HeathSavingsAccountBalance>
    <us-gaap:SelfInsuranceReservePolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzAy_f9e51cc3-54fd-48e8-8c86-f73beee2bbf1">Self-Insurance LiabilitiesThe Company is self-insured for certain losses related to general liability, workers&#x2019; compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company&#x2019;s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company&#x2019;s historical claims experience.</us-gaap:SelfInsuranceReservePolicyTextBlock>
    <us-gaap:SelfInsuranceReserve
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ3Nzg5_3db6385f-8d43-4877-8c88-680ad316c7e8"
      unitRef="usd">1100000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzQ3Nzg5_69134b11-a455-4c0f-aed0-0a5586180558"
      unitRef="usd">1100000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDQ1_7f7dcf84-a39f-4d66-9984-ee1af5e65f7f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDEx_357e2c15-f6a3-49d5-8bcc-c5ade57a6d6d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Care Benefits Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company&#x2019;s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company&#x2019;s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company&#x2019;s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Premium Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (&#x201c;MLR&#x201d;) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the &#x201c;ACA&#x201d;) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment&#x2019;s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company&#x2019;s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor&#x2019;s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting for Medicare Part D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues include insurance premiums earned by the Company&#x2019;s PDPs, which are determined based on the PDP&#x2019;s annual bid and related contractual arrangements with the U.S. Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;). The insurance &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmacy Services Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company&#x2019;s retail pharmacy network. The Company&#x2019;s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see &#x201c;Drug Discounts&#x201d; and &#x201c;Guarantees&#x201d; below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (&#x201c;retail co-payments&#x201d;), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Revenues generated from prescription drugs sold by third party pharmacies in the Company&#x2019;s retail pharmacy network and associated administrative fees are recognized at the Company&#x2019;s point-of-sale, which is when the claim is adjudicated by the Company&#x2019;s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Drug Discounts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records revenue net of manufacturers&#x2019; rebates earned by its clients based on their plan members&#x2019; utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers&#x2019; rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers&#x2019; rebate amounts has not been material to the Company&#x2019;s operating results or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#x2019;s operating results or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retail/LTC Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Retail Pharmacy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company&#x2019;s operating results or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer returns are not material to the Company&#x2019;s operating results or financial condition. Sales taxes are not included in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Loyalty and Other Programs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customer loyalty program, ExtraCare&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, consists of two components, ExtraSavings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ExtraBucks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also offers a subscription-based membership program, CarePass&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Long-term Care&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company&#x2019;s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Walk-In Medical Clinics&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For services provided by the Company&#x2019;s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities primarily represent the Company&#x2019;s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mjk2_f1821b24-2077-4030-bf43-46b67f5983fd">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table disaggregates the Company&#x2019;s revenue by major source in each segment for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Health Care&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmacy&lt;br/&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retail/&lt;br/&gt;LTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Corporate/&lt;br/&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;br/&gt;Totals&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Major goods/services lines:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(45,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;205,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Front Store&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;85,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;85,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net investment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;91,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;169,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;106,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(45,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;322,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy Services distribution channel:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy network&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;97,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Mail choice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;70,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;169,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Major goods/services lines:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;152,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;76,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(43,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;184,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Front Store&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;76,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;76,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;153,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;100,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(43,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;292,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy Services distribution channel:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy network&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; (1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;91,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Mail choice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;60,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;153,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Major goods/services lines:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;141,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;70,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(40,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;171,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Front Store&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;141,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;91,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(40,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;268,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy Services distribution channel:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Pharmacy network&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;85,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Mail choice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;141,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company&#x2019;s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; claims picked up at a retail pharmacy, as well as prescriptions filled at the Company&#x2019;s retail pharmacies under the Maintenance Choice&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;program.</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87aec70e323d4d80b7919dced5a91e73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtMS0xLTEtMTY3OTA4_01726c97-3538-4068-9f58-32c94fa1e8f1"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72800db1d6214a588b0e32ee81cf20b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtMy0xLTEtMTY3OTA4_9fb06661-3f2c-40ae-ba6d-60e4929bb177"
      unitRef="usd">168134000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fab4c813ab3488e9e07378a081f8db9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtNS0xLTEtMTY3OTA4_1b5a047d-bad7-48b9-80ae-c53401fb30a1"
      unitRef="usd">82010000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82e7024e7b3e47b3b5530bee96e98c10_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtNy0xLTEtMTY3OTA4_3c4fc6c9-a104-4158-88c5-ad386e775040"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b832667ae304814964afa70f9b6228f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtOS0xLTEtMTY3OTA4_7b314c30-b2d0-4055-a8cb-677a8485f1e5"
      unitRef="usd">-45023000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab45872f08734ce1a3dacf338ff1195c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMtMTEtMS0xLTE2NzkwOA_37fe5274-92c1-472f-8be7-0ad09e518be0"
      unitRef="usd">205121000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e4b2b74efa8424bb6186fd1ce6f571f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtMS0xLTEtMTY3OTA4_e0950529-c171-4a97-8b23-3892ec466c6a"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i428e6eaf7d9c401a824a54e771b1843c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtMy0xLTEtMTY3OTA4_c6b83028-7490-4f0f-9fc9-a885faaad9ea"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia14f4ace6f2c42638909cf217d548c72_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtNS0xLTEtMTY3OTA4_b6c0f20b-d7e3-496d-bd58-452abe4e6f08"
      unitRef="usd">22780000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i916017148df94c918c5f7fd143ce2d88_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtNy0xLTEtMTY3OTA4_cec53c2a-55ec-44c6-ae74-4388f8a67fe9"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if010e49d412b4111aabb4d53c35c0289_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtOS0xLTEtMTY3OTA4_3198ed93-3225-490a-9557-8d5c44a1ea17"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia131689becf644f4bc5a732edb3c22e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQtMTEtMS0xLTE2NzkwOA_1e6de8b7-d789-4e85-bb9c-2308346cd004"
      unitRef="usd">22780000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78e819b5e8cb45e5ab8dbfaf05b504cb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtMS0xLTEtMTY3OTA4_2d3dcaa7-046f-4d57-bc79-2bf2195fad67"
      unitRef="usd">85274000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i209085ef2a2445ddb82ac68f9a34c386_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtMy0xLTEtMTY3OTA4_89d1d120-dd2a-402a-9a17-ae9d55801c62"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib59f410a5b084b5c88a7afb76702b6d0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtNS0xLTEtMTY3OTA4_eda2ebc9-fae7-4138-8f41-d45b090ccfef"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefc8faa2206e496e97d8bd1eff35cdf0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtNy0xLTEtMTY3OTA4_565ca3bd-6c6c-4dc9-99f0-193307521c6c"
      unitRef="usd">56000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i317658c2ffcc45ea83ffebbec7222ac9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtOS0xLTEtMTY3OTA4_f78f5681-98cf-4fac-8b7f-6c333866909f"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e5fcff7cb6c46f987a53e2a78bc0fb8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzUtMTEtMS0xLTE2NzkwOA_fc122059-3537-4f79-84c2-f8efd8786020"
      unitRef="usd">85330000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetInvestmentIncome
      contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtMS0xLTEtMTY3OTA4_a32b2e7a-0050-4810-b6e6-f6f1eae453ca"
      unitRef="usd">476000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtMy0xLTEtMTY3OTA4_cd255e30-de0b-4a52-b7f4-d655c51cde6d"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtNS0xLTEtMTY3OTA4_058d67a7-2155-4811-add2-553bf382ebaa"
      unitRef="usd">-44000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtNy0xLTEtMTY3OTA4_2180c008-314c-4655-800c-197fbd99d553"
      unitRef="usd">406000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtOS0xLTEtMTY3OTA4_72ed392c-6cb2-479c-a2fe-ab83fc4243d6"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzYtMTEtMS0xLTE2NzkwOA_a532d65d-5a0f-45ce-bfac-d48772268e3e"
      unitRef="usd">838000000</us-gaap:NetInvestmentIncome>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i786d650a37ad452c813aff2f3ba2b66f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctMS0xLTEtMTY3OTA4_e0b8382a-b011-4c1a-8da6-c93fd5d09e53"
      unitRef="usd">5659000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifefecdea33b5434f8044bd84cd050b73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctMy0xLTEtMTY3OTA4_0ee44515-ddd8-44be-ba7f-e0b0677dbee5"
      unitRef="usd">1102000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3279e91422224439968bc192db36cdb1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctNS0xLTEtMTY3OTA4_a9e86640-777f-4751-ae53-f0c82f1b812f"
      unitRef="usd">1848000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5f8050b163245d58912d4aff32e4a28_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctNy0xLTEtMTY3OTA4_d06170d2-d9bd-43c1-b8a2-22f4caa241a5"
      unitRef="usd">68000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i875b6ff05a00444daa0d40d607318115_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctOS0xLTEtMTY3OTA4_a48e68a3-ed43-4735-9927-b24233a94b34"
      unitRef="usd">-279000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6a4492c873942499213da78e615d60a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzctMTEtMS0xLTE2NzkwOA_3b88cb35-1369-4555-8bd7-d4aa6848bc84"
      unitRef="usd">8398000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMS0xLTEtMTY3OTA4_a718b28d-82d7-49e5-94a0-2cf3f8e9f7b6"
      unitRef="usd">91409000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMS0xLTEtMTY3OTA4_cce8e3dd-bd18-471d-ab21-c43bd2ef29d8"
      unitRef="usd">91409000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMy0xLTEtMTY3OTA4_4ef0244b-4664-4ea7-ba4f-ffc775187874"
      unitRef="usd">169236000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMy0xLTEtMTY3OTA4_f88c8356-5dc6-493c-b62c-56e4daac4ce0"
      unitRef="usd">169236000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtNS0xLTEtMTY3OTA4_65dea28f-1fa0-43e5-ad5a-99629043103b"
      unitRef="usd">106594000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtNS0xLTEtMTY3OTA4_fed8c70a-6eae-4c76-8377-4d6e99e43da4"
      unitRef="usd">106594000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtNy0xLTEtMTY3OTA4_2ae9bbab-ccc2-4f9d-9093-f41008861d3c"
      unitRef="usd">530000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtNy0xLTEtMTY3OTA4_a87d0a1e-6cdf-4fe4-b4a5-d2c454b0e25a"
      unitRef="usd">530000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtOS0xLTEtMTY3OTA4_1e1f225c-a0aa-4a84-8d00-a03daa3d1341"
      unitRef="usd">-45302000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtOS0xLTEtMTY3OTA4_40850830-19f6-4605-a95d-77138e55935e"
      unitRef="usd">-45302000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzgtMTEtMS0xLTE2NzkwOA_ec736ae0-87a4-4316-8cfa-e1a3e9ebc50c"
      unitRef="usd">322467000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3dc263ef676c41c7a9714817863cd0b5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzExLTMtMS0xLTE2NzkwOA_40bfc0e8-cc67-4c08-ad01-9bd2ad517724"
      unitRef="usd">97668000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i531a5f41bdcc4e98bc63759f201375c0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzEyLTMtMS0xLTE2NzkwOA_ae28d32b-c98a-4472-aefb-315c14bef3c5"
      unitRef="usd">70466000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i88b49c00627e4fb69a66285d6f3f5b64_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzEzLTMtMS0xLTE2NzkwOA_9fe40e03-7fe6-4e55-b838-ab30c35364df"
      unitRef="usd">1102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE0LTMtMS0xLTE2NzkwOA_d774bf3d-a7a9-4763-bbe4-2fd0189236b8"
      unitRef="usd">169236000000</us-gaap:Revenues>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33f9a334ea554cf6923ae16a198dd1f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTEtMS0xLTE2NzkwOA_5cd1bf04-39a1-44ba-a910-2c085f1a7083"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5470c0948d3447daa6b553072d68b21c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTMtMS0xLTE2NzkwOA_194ef024-c756-49ac-8f8c-38a953b53ec1"
      unitRef="usd">152262000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b5218b8d02245eea6cb1c1964bc2d56_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTUtMS0xLTE2NzkwOA_fe929311-9871-434e-af30-18754bc524ab"
      unitRef="usd">76121000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ebe5b02e9154d92b2659182b87bcc17_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTctMS0xLTE2NzkwOA_073331ca-be10-48e7-90cb-1e3b7d539100"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e66c2cd601c4549a5ef3b24ccbaf9fa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTktMS0xLTE2NzkwOA_b8ec7996-5866-43c4-b850-7ab9f7c0b86d"
      unitRef="usd">-43765000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ee9b96bd1eb4291996ceb2ce4ecb8c9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE4LTExLTEtMS0xNjc5MDg_0adf3d30-b14d-42fb-9d78-35272036a735"
      unitRef="usd">184618000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2694cdfde5e94542ba60918fc678d54a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTEtMS0xLTE2NzkwOA_15e9a3c1-ed94-45fc-9f4d-9e37bbe926d5"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bebe76ce83e46589a14f0b7cb047cb7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTMtMS0xLTE2NzkwOA_d72f6ca5-10a0-4d83-8b47-95bc8fab2f62"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99cbec53a7ed47e3ab88190772305c5a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTUtMS0xLTE2NzkwOA_69b5d3b5-d214-4012-b7f6-681e463e945d"
      unitRef="usd">21315000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id57e0be74304456489f0a228ba4952ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTctMS0xLTE2NzkwOA_d8638ce0-0635-4f6e-8916-44cdda7083a5"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dee4299a044434bb9587326355c6d37_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTktMS0xLTE2NzkwOA_25baab59-4a8a-4918-9e05-9cd756d1dfa4"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15504530953c4bf689166fcfe8f7868d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzE5LTExLTEtMS0xNjc5MDg_0fd567d1-787d-481c-b290-fbd0bdc9571b"
      unitRef="usd">21315000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88c90e55b42a466ca5aa922c38dd414e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTEtMS0xLTE2NzkwOA_fa030d03-21cc-425b-a466-e7e13e0762aa"
      unitRef="usd">76064000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cde5b8c7bef4de38fb102a05d7d6a29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTMtMS0xLTE2NzkwOA_549188f5-a0ad-4c3c-a6bc-31c23302b897"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icba757607c0e44ffa9ce352a6dc203fa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTUtMS0xLTE2NzkwOA_a79aaadb-10aa-45f8-a2f4-471b872c0f4d"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if86521d12a18428cb6850612e4806b2e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTctMS0xLTE2NzkwOA_361cb803-8473-44f5-9eb1-ccbb1b641071"
      unitRef="usd">68000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26cc5da453684e30b0e7f61d0c214207_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTktMS0xLTE2NzkwOA_9ee462c5-3b9e-4770-939a-f1a2311f54fe"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1a89142a03e46a08448375f4b02bc4f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIwLTExLTEtMS0xNjc5MDg_6358e80c-dfec-4379-bff7-16982a11b38d"
      unitRef="usd">76132000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetInvestmentIncome
      contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTEtMS0xLTE2NzkwOA_a94497d1-ea6b-4a6a-a9e0-ed96b5b6e070"
      unitRef="usd">586000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTMtMS0xLTE2NzkwOA_64d76e69-110c-46c0-9314-1be298a541cd"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTUtMS0xLTE2NzkwOA_edbda917-d4f3-406c-8fd6-9e5686015e49"
      unitRef="usd">17000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTctMS0xLTE2NzkwOA_e07c5084-b890-444d-be9d-36594699115c"
      unitRef="usd">596000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTktMS0xLTE2NzkwOA_1da31008-0453-4b71-a84c-5d5befeb09a1"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIxLTExLTEtMS0xNjc5MDg_6f649bdf-0964-4d52-9021-0612daec302d"
      unitRef="usd">1199000000</us-gaap:NetInvestmentIncome>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10be60b83a684a8c8d1797644e6037e5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTEtMS0xLTE2NzkwOA_57788b75-d52a-45bb-a6e3-b1fcb2cd2326"
      unitRef="usd">5536000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec13ef8ea98a4f52953499317400e068_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTMtMS0xLTE2NzkwOA_eaaea8ba-72f3-4bec-8a5b-be557fb5415c"
      unitRef="usd">760000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id041b9cf96944df2825c84f9dbb638ea_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTUtMS0xLTE2NzkwOA_9824966b-8533-4062-a76a-42cf14b4d903"
      unitRef="usd">2652000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74f8c85482214ae78d33982d2c28ceaa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTctMS0xLTE2NzkwOA_3bc71bbf-1e9b-4419-b978-7c386600baa1"
      unitRef="usd">57000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9915652c392941698dd07b170ae9d044_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTktMS0xLTE2NzkwOA_c98e1198-df5d-401e-8009-58eb0e450661"
      unitRef="usd">-158000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c774395798448abbb90933427cbc204_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIyLTExLTEtMS0xNjc5MDg_137fd649-040b-4e8e-8ae8-2a8ddc11fada"
      unitRef="usd">8847000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTEtMS0xLTE2NzkwOA_1c180e62-2e53-48e9-8b1b-b956ad6122e2"
      unitRef="usd">82186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTMtMS0xLTE2NzkwOA_b4735515-afa6-424b-bb7d-82461273cd33"
      unitRef="usd">153022000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTUtMS0xLTE2NzkwOA_f37c2b19-4d29-4aef-8b9f-aac5c224ef9f"
      unitRef="usd">100105000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTctMS0xLTE2NzkwOA_12cc1ca0-d675-4406-9797-00937e1ac0f8"
      unitRef="usd">721000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTktMS0xLTE2NzkwOA_c8a6f7b8-77b4-448d-8455-419ba3e984df"
      unitRef="usd">-43923000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzIzLTExLTEtMS0xNjc5MDg_9eaa3e6e-7823-4e51-9cb0-657c2e36a6ec"
      unitRef="usd">292111000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if66c5e92146f4978aeaff863da389857_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzI2LTMtMS0xLTE2NzkwOA_5718560b-3534-41dd-acb9-68e58ddc419f"
      unitRef="usd">91715000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85235bf2dc3145338feefdca3630aa3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzI3LTMtMS0xLTE2NzkwOA_5e0c7d7c-2d55-4a45-954f-cb3bb17af79f"
      unitRef="usd">60547000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf6ff2650b194f6f9b88d08a7d679daa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzI4LTMtMS0xLTE2NzkwOA_39c515e2-c2a1-4e4b-86b5-16c9b87ed970"
      unitRef="usd">760000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzI5LTMtMS0xLTE2NzkwOA_2e91e53d-791d-4633-bd0c-f024a3ccbd9b"
      unitRef="usd">153022000000</us-gaap:Revenues>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i710619ea82ee47b2b0f1faa66681850c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTEtMS0xLTE2NzkwOA_05a59d5d-50ea-436a-a730-5d860db8dcc9"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe5733b07b8443d7b51ad01e0f283bc6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTMtMS0xLTE2NzkwOA_e4a54d5e-aa77-4f19-99b2-0c7b489fe00f"
      unitRef="usd">141116000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id91c69b620814b2a9f51d3084dada276_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTUtMS0xLTE2NzkwOA_710f641a-e559-4ad6-91d9-336dd01424e0"
      unitRef="usd">70176000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d0cba2d7a4b49d68120f1ad1e3b59f7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTctMS0xLTE2NzkwOA_cf5d9f4f-23c1-4c40-ac00-42adf5fc9246"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i047c32c6681c48a280f39c07fbb64103_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTktMS0xLTE2NzkwOA_164251f6-caeb-4512-9b73-dd4636b2937f"
      unitRef="usd">-40003000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50a613e7cb5b4f9fabfb569ae06de8c5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzMzLTExLTEtMS0xNjc5MDg_1fa6caba-01c1-4efd-8af4-32b94fe6ca39"
      unitRef="usd">171289000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafa8c79cb8ce4f9fa3d25b293e92eafd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTEtMS0xLTE2NzkwOA_e1ef2bf8-dd8d-420f-aecf-64f5329cf330"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b4cdb3407c14f1282544e57e58ecf04_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTMtMS0xLTE2NzkwOA_2853151e-c824-4480-bb65-532cad7143aa"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5bc5d4b76344af48fea40efd9a549c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTUtMS0xLTE2NzkwOA_c231605e-d45c-41b7-a80f-210485e2c4fe"
      unitRef="usd">19655000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie86040f73a11474b89670e351fab892e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTctMS0xLTE2NzkwOA_4d18c220-eecc-4ddd-9e2a-2c51c27c1ba1"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00e8afb1516f445db8c04046e7f9619f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTktMS0xLTE2NzkwOA_417b76be-1064-4b3a-becb-01234a3938b8"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b3c892261d42ae91d2522773ceeffa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM0LTExLTEtMS0xNjc5MDg_687dde71-bab0-40fd-9ef6-57330700dd2e"
      unitRef="usd">19655000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3f6f283d4c04e2dac7883355902fa5d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTEtMS0xLTE2NzkwOA_1c76b722-8725-4af8-bb2d-30a8dd27d0c9"
      unitRef="usd">69301000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icab6442d127e4d5abf45e0a1fd8044a5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTMtMS0xLTE2NzkwOA_9efb9263-24e7-4100-9b75-ba9b1604e0c7"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40a69bf319414885a2af9b145fb0daa3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTUtMS0xLTE2NzkwOA_a1975dba-df06-47a2-8d3b-61fcc4186bbb"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25d1804d8c6b4ac494abb73ef6b710bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTctMS0xLTE2NzkwOA_48d8a216-2014-40c7-83ef-77ce231d76be"
      unitRef="usd">63000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ed9c24157b04f799ff19ca1d9a73070_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTktMS0xLTE2NzkwOA_086639d6-1fba-44fd-b034-c60a1e010508"
      unitRef="usd">0</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52962d31d6d1400aa5bdf2bab550bd30_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM1LTExLTEtMS0xNjc5MDg_db896fce-d38f-45ba-8efb-39a1373d9659"
      unitRef="usd">69364000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetInvestmentIncome
      contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTEtMS0xLTE2NzkwOA_9349fcb3-7a57-4d7d-899b-5cc117caf45a"
      unitRef="usd">483000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTMtMS0xLTE2NzkwOA_b08d464c-a503-474c-aa9d-694b1e19df95"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTUtMS0xLTE2NzkwOA_a30ed86e-27bf-4528-b9c4-6122b7dabcd3"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTctMS0xLTE2NzkwOA_4263b992-5eaa-4693-81fb-eb30ec62f21f"
      unitRef="usd">315000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTktMS0xLTE2NzkwOA_5225e211-abea-4a01-8291-b23211580098"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM2LTExLTEtMS0xNjc5MDg_92bbf988-df85-4c21-92fd-4e26d0205fc0"
      unitRef="usd">798000000</us-gaap:NetInvestmentIncome>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae8e30495c1f4923ac883d572d156bd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTEtMS0xLTE2NzkwOA_46108488-842a-4c08-8f64-7b1572b41a89"
      unitRef="usd">5683000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8a458accfa84019adc7131cfcc882ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTMtMS0xLTE2NzkwOA_aeeebe87-9924-428d-bf19-67392b6d1abe"
      unitRef="usd">822000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id854bc7a2aa64ef3bbcea56dffab6dbc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTUtMS0xLTE2NzkwOA_ff9825db-44cf-4050-8134-20e7a8af8f34"
      unitRef="usd">1367000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aa3187fec8b406b816c24249fb2dbce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTctMS0xLTE2NzkwOA_16becb41-55b8-495d-b106-1b4e620f0f09"
      unitRef="usd">48000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36b2481d581d48a38dab150c09f95d26_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTktMS0xLTE2NzkwOA_10d2ff06-6895-4417-bb60-ebc22654e61a"
      unitRef="usd">-320000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cfcca160913463291592340d0f000aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM3LTExLTEtMS0xNjc5MDg_75cfcf41-567f-4559-8943-eb9bd24b25b8"
      unitRef="usd">7600000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTEtMS0xLTE2NzkwOA_031a6f31-3f10-45f6-b7c2-961f08a6369a"
      unitRef="usd">75467000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTMtMS0xLTE2NzkwOA_76e97c61-3f84-4255-becf-517551f69a06"
      unitRef="usd">141938000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTUtMS0xLTE2NzkwOA_c6bde48c-cf2c-4997-bac0-858740e4e957"
      unitRef="usd">91198000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTctMS0xLTE2NzkwOA_99b95830-8a3e-4996-89ba-07fb2bd65ef9"
      unitRef="usd">426000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTktMS0xLTE2NzkwOA_93279363-0d9e-418c-b6a8-f91c79c62b84"
      unitRef="usd">-40323000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzM4LTExLTEtMS0xNjc5MDg_243861ff-1866-4bd9-a918-d39b46b3a6e6"
      unitRef="usd">268706000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6504396ad13b404a809b4be1782f4962_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQxLTMtMS0xLTE2NzkwOA_05110450-b899-496d-b038-ecff996410e8"
      unitRef="usd">85045000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4e4149eed634db283cebe9c5c27cccb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQyLTMtMS0xLTE2NzkwOA_20eaa3dc-7ef1-4e71-a10c-da4bd2425bc4"
      unitRef="usd">56071000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c934f6d7dbd4623a30db94c93317b44_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQzLTMtMS0xLTE2NzkwOA_24807dc3-2325-42a5-9b7d-ab9196c5f96f"
      unitRef="usd">822000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1YTMyOGI1MDAwMzM0YTA1OWE3NDg4ZmEzNzI2N2RiMS90YWJsZXJhbmdlOjVhMzI4YjUwMDAzMzRhMDU5YTc0ODhmYTM3MjY3ZGIxXzQ0LTMtMS0xLTE2NzkwOA_21b358f1-4966-44bf-9d67-bec7226d2d32"
      unitRef="usd">141938000000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzkz_4ce0924a-ee62-4123-8ac9-39f5e1f9c562">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables and contract liabilities from contracts with customers as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables (included in accounts receivable, net)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities (included in accrued expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, the contract liabilities balance includes increases related to customers&#x2019; earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rewards earnings and gift card issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redemption and breakage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3NTBiMDljMzlhNWY0NjM3OGZmNjNlODk3MjVkMDBhMi90YWJsZXJhbmdlOjc1MGIwOWMzOWE1ZjQ2Mzc4ZmY2M2U4OTcyNWQwMGEyXzEtMS0xLTEtMTY3OTA4_2a6c325c-9fb2-44ef-ad5c-dc5d68dfd45a"
      unitRef="usd">8983000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3NTBiMDljMzlhNWY0NjM3OGZmNjNlODk3MjVkMDBhMi90YWJsZXJhbmdlOjc1MGIwOWMzOWE1ZjQ2Mzc4ZmY2M2U4OTcyNWQwMGEyXzEtMy0xLTEtMTY3OTA4_c877a934-8fb7-4e42-9c8d-ac5342bf2740"
      unitRef="usd">7932000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3NTBiMDljMzlhNWY0NjM3OGZmNjNlODk3MjVkMDBhMi90YWJsZXJhbmdlOjc1MGIwOWMzOWE1ZjQ2Mzc4ZmY2M2U4OTcyNWQwMGEyXzItMS0xLTEtMTY3OTA4_752169dc-7c06-448e-ae76-4503bfbdb5dd"
      unitRef="usd">71000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo3NTBiMDljMzlhNWY0NjM3OGZmNjNlODk3MjVkMDBhMi90YWJsZXJhbmdlOjc1MGIwOWMzOWE1ZjQ2Mzc4ZmY2M2U4OTcyNWQwMGEyXzItMy0xLTEtMTY3OTA4_a49af498-d0af-4b9c-8c9b-eed7ee37b98a"
      unitRef="usd">87000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzEtMS0xLTEtMTY3OTA4_418dc22e-32d6-4bc2-97cc-a6bc40f7d5d2"
      unitRef="usd">87000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzEtMy0xLTEtMTY3OTA4_557bc92f-eaf3-4e4b-ac43-8f4d3326c786"
      unitRef="usd">71000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <cvs:ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzMtMS0xLTEtMTY3OTA4_1271addf-255d-410e-9736-0a593bc71f4c"
      unitRef="usd">340000000</cvs:ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance>
    <cvs:ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzMtMy0xLTEtMTY3OTA4_918c6349-fd75-47ec-be3d-04f2cce2279d"
      unitRef="usd">387000000</cvs:ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance>
    <cvs:ContractWithCustomerLiabilityRedemptionAndBreakage
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzQtMS0xLTEtMTY3OTA4_81e771f5-9183-4ce7-a2ab-b6f1b3214e78"
      unitRef="usd">356000000</cvs:ContractWithCustomerLiabilityRedemptionAndBreakage>
    <cvs:ContractWithCustomerLiabilityRedemptionAndBreakage
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzQtMy0xLTEtMTY3OTA4_6f0b1ca5-e897-478a-b151-a5db216eeabc"
      unitRef="usd">371000000</cvs:ContractWithCustomerLiabilityRedemptionAndBreakage>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzUtMS0xLTEtMTY3OTA4_81ce14a1-b46b-41f1-9361-f93bfbc6ecc3"
      unitRef="usd">71000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZToyYmVkZTlmNjFhM2M0N2Y4OTg1MzA1ZTRhY2JiNzUzZC90YWJsZXJhbmdlOjJiZWRlOWY2MWEzYzQ3Zjg5ODUzMDVlNGFjYmI3NTNkXzUtMy0xLTEtMTY3OTA4_b7ed0690-b1a6-4201-989c-9f3d6bd75aef"
      unitRef="usd">87000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzM5_ed2a8a41-bc31-490d-b22d-d8eaa393e8e7">&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for cost of products sold as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmacy Services Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company&#x2019;s mail service dispensing pharmacies and indirectly through the Company&#x2019;s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company&#x2019;s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients&#x2019; benefit plans from the Company&#x2019;s mail service dispensing pharmacies, net of any volume-related or other discounts (see &#x201c;Vendor Allowances and Purchase Discounts&#x201d; below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company&#x2019;s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retail/LTC Segment&lt;/span&gt;&lt;/div&gt;Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses.</us-gaap:CostOfSalesPolicyTextBlock>
    <cvs:VendorAllowancesAndPurchaseDiscountsPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzA0_ef431078-e577-4a6d-9356-bf12f8ecaac1">&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vendor Allowances and Purchase Discounts &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for vendor allowances and purchase discounts as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmacy Services Segment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company&#x2019;s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retail/LTC Segment&lt;/span&gt;&lt;/div&gt;Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company&#x2019;s consolidated financial statements in any of the periods presented.</cvs:VendorAllowancesAndPurchaseDiscountsPolicyTextBlock>
    <cvs:PharmacyRebatePeriod
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzY3OTMy_30c89a79-8ade-4fb1-b67b-9b44bbf46dfa">P30D</cvs:PharmacyRebatePeriod>
    <us-gaap:HealthCareEntitiesPolicyPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzU1_4db7ebf1-3c71-4986-b102-dbb239b0ab87">&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Health Care Reform&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Insurer Fee&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning on January 1, 2014, the ACA imposed an annual premium-based health insurer fee (&#x201c;HIF&#x201d;) for each calendar year, payable in September, which was not deductible for tax purposes. The Company was required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was no expense related to the HIF in the years ended December&#160;31, 2022 and 2021. In the year ended December 31, 2020, operating expenses included $1.0&#160;billion related to the Company&#x2019;s share of the HIF. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company&#x2019;s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Corridor&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) based on their ratio of allowable costs to target costs (as defined by the ACA). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company filed a lawsuit in August 2019 to recover the $313&#160;million it was owed under the ACA&#x2019;s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA&#x2019;s temporary risk corridor program. &lt;/span&gt;&lt;/div&gt;In October 2020, the Company received the $313&#160;million it was owed under the ACA&#x2019;s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering offsetting items such as the ACA&#x2019;s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $307&#160;million and after-tax income of $223&#160;million during the year ended December&#160;31, 2020.</us-gaap:HealthCareEntitiesPolicyPolicyTextBlock>
    <cvs:HealthInsurerFee
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcwNjky_2f21e681-2894-4ac5-a645-8659a3521599"
      unitRef="usd">0</cvs:HealthInsurerFee>
    <cvs:HealthInsurerFee
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcwNjky_5eb766c5-4564-4d62-a273-8648a83fc773"
      unitRef="usd">0</cvs:HealthInsurerFee>
    <cvs:HealthInsurerFee
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzU0OTc1NTkwMDUzMw_86ed97c5-17fe-4b1b-99b4-869cb8ccbdf6"
      unitRef="usd">1000000000</cvs:HealthInsurerFee>
    <us-gaap:GainContingencyUnrecordedAmount
      contextRef="i5d26d3b0edca40eb8a286991043bc26b_I20190831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcyMDcz_2ccaf3a4-c514-4a0d-a296-733a29391fbd"
      unitRef="usd">313000000</us-gaap:GainContingencyUnrecordedAmount>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i40ea54e1ccb34d709c3b44454e7262f0_D20201001-20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcyNDE2_66dd82a1-9960-4859-8ee8-c975f709feb9"
      unitRef="usd">313000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <cvs:FormerGainContingencyRecognizedInCurrentPeriodBeforeTax
      contextRef="ie7a79d946b244fbe83b985e471a79655_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzU0OTc1NTkwNzUxOA_cbb775e4-8d12-4ed5-8473-2ad409822586"
      unitRef="usd">307000000</cvs:FormerGainContingencyRecognizedInCurrentPeriodBeforeTax>
    <cvs:FormerGainContingencyRecognizedInCurrentPeriodNetOfTax
      contextRef="ie7a79d946b244fbe83b985e471a79655_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzcyNzU4_beec21f5-0f7f-4d58-bf2d-37f5d6560f65"
      unitRef="usd">223000000</cvs:FormerGainContingencyRecognizedInCurrentPeriodNetOfTax>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzg4_4750fc67-b90f-4455-928e-d9d4eb07f5e8">Advertising Costs Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $745 million, $707 million and $613 million in 2022, 2021 and 2020, respectively.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMDA1_6ee41f32-5321-4639-a806-736071add2f3"
      unitRef="usd">745000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMDA5_a0530eff-ac48-4cb8-a0be-e993f4986f5a"
      unitRef="usd">707000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMDE2_4527eb80-8bf8-471d-ab1f-8ab2b75944b4"
      unitRef="usd">613000000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDIy_0502ff4a-1f78-45a6-8d1f-670d7640c5cc">Stock-Based CompensationStock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzczMjY0_8d034ca5-401e-4526-8bb8-d8fed86877bb"&gt;three&lt;/span&gt; to five years) using the straight-line method.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzcy_026b74eb-56d2-402d-bc2d-c3c5e3c040e0">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzE3_037b8108-265f-446d-93ed-2936f0596bd9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company&#x2019;s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDE2_9ffd2f63-d909-4771-8ae4-4d349d46d1fb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors defined benefit pension plans (&#x201c;pension plans&#x201d;) and other postretirement employee benefit plans (&#x201c;OPEB plans&#x201d;) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit income for the Company&#x2019;s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time.&#160;Non-service cost components of pension and postretirement net periodic benefit income are included in other income in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzgw_9bb3328b-69a7-4a2e-8de9-ad295ab0cf92">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share is computed using the treasury stock method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 &#x2018;&#x2018;Earnings Per Share&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <cvs:SharesHeldInTrustPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDQ0_972e4490-0f88-4396-838e-f6bfac2b6c93">Shares Held in TrustThe Company maintains grantor trusts, which held approximately one million shares of its common stock at both December&#160;31, 2022 and 2021. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding.</cvs:SharesHeldInTrustPolicyTextBlock>
    <cvs:TreasuryStockSharesHeldinTrust
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc2Nzkz_1dc6be3d-fb2c-4c39-9329-3a90392d77a2"
      unitRef="shares">1000000</cvs:TreasuryStockSharesHeldinTrust>
    <cvs:TreasuryStockSharesHeldinTrust
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc2Nzkz_e78c0411-c695-4607-8369-29eea9d7f7fb"
      unitRef="shares">1000000</cvs:TreasuryStockSharesHeldinTrust>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzE4_ae57165c-be70-42e9-8816-f602105dc407">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE&#x2019;s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities - Primary Beneficiary&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2014, the Company and Cardinal Health, Inc. (&#x201c;Cardinal&#x201d;) established Red Oak Sourcing, LLC (&#x201c;Red Oak&#x201d;), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December&#160;31, 2022, 2021 and 2020. The payments reduce the Company&#x2019;s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities - Other Variable Interest Holder&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Hedge fund and private equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Real estate partnerships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not the primary beneficiary of these VIEs because the nature of the Company&#x2019;s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE&#x2019;s income or losses in net income.&#160;The Company&#x2019;s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="ia397b0104e7f454a9a66b55e5fdd1a14_D20140101-20141231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc4MDI5_188e4f95-ff4b-4b19-9c0e-2c0558998c98"
      unitRef="number">0.50</us-gaap:VariableInterestEntityOwnershipPercentage>
    <cvs:InitialContractualTerm
      contextRef="ia397b0104e7f454a9a66b55e5fdd1a14_D20140101-20141231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc4MDgw_44c61351-d43d-43bb-a19d-e03ffe37f145">P10Y</cvs:InitialContractualTerm>
    <cvs:VariableInterestEntityAmendedContractExtensionTerm
      contextRef="i651ae9dd5f5d4e19b29b67ad25f2d822_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc4MTcw_3a809760-ecc7-4dd4-b7a1-9618ef24a9ef">P5Y</cvs:VariableInterestEntityAmendedContractExtensionTerm>
    <cvs:VariableInterestEntityAmendedContractTerm
      contextRef="i651ae9dd5f5d4e19b29b67ad25f2d822_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc4MTk0_fc3dc45b-4bbd-4155-860a-ec8e71c258bc">P15Y</cvs:VariableInterestEntityAmendedContractTerm>
    <cvs:ProceedsFromVariableInterestEntity
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc5MTEy_0bf8c718-931e-426c-8273-d1b80c8e76f4"
      unitRef="usd">183000000</cvs:ProceedsFromVariableInterestEntity>
    <cvs:ProceedsFromVariableInterestEntity
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc5MTEy_1f3816dc-b9f9-41a1-8188-3467b4eab093"
      unitRef="usd">183000000</cvs:ProceedsFromVariableInterestEntity>
    <cvs:ProceedsFromVariableInterestEntity
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzc5MTEy_a40de631-67c8-45bc-94a5-9f217a679500"
      unitRef="usd">183000000</cvs:ProceedsFromVariableInterestEntity>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzMw_0c5c7d2a-3dbb-4551-a6b1-066f8f985c29">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge fund investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:LongTermInvestments
      contextRef="i374b0364197f455da3648efc785175d8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzEtMS0xLTEtMTY3OTA4_34e39059-129e-481d-86c8-d9f7f1606e61"
      unitRef="usd">589000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i8a9c3eb37cc44017ab6afa84684e32ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzEtMy0xLTEtMTY3OTA4_e50e9157-ad10-4998-b87f-2dfddda2cad4"
      unitRef="usd">463000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i0122d8f1aa4d48aa8ad7d46a51217f28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzItMS0xLTEtMTY3OTA4_c84d6579-ceee-4dfc-8338-e1fe89232057"
      unitRef="usd">707000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i4fb39cc57c844ed0b532aa62c0a86627_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzItMy0xLTEtMTY3OTA4_8fa4a24a-d8d7-4b85-b4ac-097b9f80bf32"
      unitRef="usd">601000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i6f81ec31a44f49e1b4a933ac7e20273c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzMtMS0xLTEtMTY3OTA4_4a2c278b-46e5-4de4-a6b3-11bef344193b"
      unitRef="usd">241000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ie4fc6318928c4432959e25e083008a4f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzMtMy0xLTEtMTY3OTA4_c9782d7d-22d2-4cf0-ae5b-8f081949ed80"
      unitRef="usd">225000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i38d3dc349650457fbc2c1be5f20979d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzQtMS0xLTEtMTY3OTA4_40ca8791-0108-4fc5-a6c1-67de1b4e667f"
      unitRef="usd">1537000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i0dda9edc70414970a1c368f6c420d65d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTpjNmNiNmM5MGM5MmY0NDUzOGY2MWJiNjIzMWE1MTBkNC90YWJsZXJhbmdlOmM2Y2I2YzkwYzkyZjQ0NTM4ZjYxYmI2MjMxYTUxMGQ0XzQtMy0xLTEtMTY3OTA4_bc7b2620-2d5f-4d8a-b350-dcd9838eeb1e"
      unitRef="usd">1289000000</us-gaap:LongTermInvestments>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzY0_18307a50-56c3-4748-99c7-50b05ccdecf6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an equity method investment in SureScripts, LLC (&#x201c;SureScripts&#x201d;), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $60 million, $52 million and $56 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million in the years ended December&#160;31, 2022, 2021 and 2020, respectively. The Company&#x2019;s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an equity method investment in Heartland Healthcare Services, LLC (&#x201c;Heartland&#x201d;). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $87 million, $79 million and $77 million for pharmaceutical inventory purchases during the years ended December&#160;31, 2022, 2021 and 2020, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company&#x2019;s investment in and equity in the earnings of Heartland for all periods presented is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, the Company made charitable contributions of&#160;$25&#160;million, $50 million and $50&#160;million, respectively,&#160;to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNDMx_830900fa-780f-4d7a-90aa-bc9aad82ec06"
      unitRef="usd">60000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNDM1_b7019845-df29-4eeb-8b7f-a7f3d408e8ba"
      unitRef="usd">52000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNDQy_268e2c64-dbec-4975-94f9-e74eb63e111f"
      unitRef="usd">56000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="ie74c8e518d644daa9a788565f2dc3c08_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNzQ3_e16f7ff7-2414-4d2d-a32d-12aaff7d8be9"
      unitRef="state">4</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNzg1_2432a6d5-a477-463f-8bb9-731ba95fe4a3"
      unitRef="usd">87000000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNzg5_57676420-4f75-41fa-a93b-b0f177b9a563"
      unitRef="usd">79000000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgxNzk2_d5b12efe-59c9-4bcc-a349-8b11480a14f2"
      unitRef="usd">77000000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <cvs:RelatedPartyTransactionCharitableContributionToNonProfitEntity
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgyMjI2_f07f825a-3da6-4427-ae50-97061722fc12"
      unitRef="usd">25000000</cvs:RelatedPartyTransactionCharitableContributionToNonProfitEntity>
    <cvs:RelatedPartyTransactionCharitableContributionToNonProfitEntity
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgyMjMw_89f8dc64-d0a8-4c83-aa97-8d467e5fb0a8"
      unitRef="usd">50000000</cvs:RelatedPartyTransactionCharitableContributionToNonProfitEntity>
    <cvs:RelatedPartyTransactionCharitableContributionToNonProfitEntity
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzgyMjM3_ef6c0e0e-d2de-410e-b610-47804dc46661"
      unitRef="usd">50000000</cvs:RelatedPartyTransactionCharitableContributionToNonProfitEntity>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2NDQw_119ed71b-cec3-4cc7-98d4-8ffed917d986">Discontinued OperationsIn connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens &#x2018;n Things and Bob&#x2019;s Stores, each of which subsequently filed for bankruptcy. The Company&#x2019;s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees.</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2Mzky_ca03c773-51ae-4da2-82cd-c5796f6be6cd">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the results of discontinued operations for the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1ZjM5YjllZWQxMDE0ZmMyYWFjN2M4NDA4NmM3ZGY5Yy90YWJsZXJhbmdlOjVmMzliOWVlZDEwMTRmYzJhYWM3Yzg0MDg2YzdkZjljXzEtMS0xLTEtMTY3OTA4_80a2b96e-ef86-4e96-9e23-34c5d83a85e1"
      unitRef="usd">-12000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1ZjM5YjllZWQxMDE0ZmMyYWFjN2M4NDA4NmM3ZGY5Yy90YWJsZXJhbmdlOjVmMzliOWVlZDEwMTRmYzJhYWM3Yzg0MDg2YzdkZjljXzItMS0xLTEtMTY3OTA4_06b65866-9124-4005-b1a3-9924745472fb"
      unitRef="usd">-3000000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90YWJsZTo1ZjM5YjllZWQxMDE0ZmMyYWFjN2M4NDA4NmM3ZGY5Yy90YWJsZXJhbmdlOjVmMzliOWVlZDEwMTRmYzJhYWM3Yzg0MDg2YzdkZjljXzMtMS0xLTEtMTY3OTA4_d8bb3af5-1c4e-42eb-b46e-7165d200ca97"
      unitRef="usd">-9000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3Xzg2MzEz_f2213c3c-8c9b-44c9-9c2d-c8b914ce4b53">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Targeted Improvements to the Accounting for Long-Duration Insurance Contracts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Financial Accounting Standards Board issued ASU 2018-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Targeted Improvements to the Accounting for Long-Duration Contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income (loss). The rate used to discount the Company&#x2019;s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company&#x2019;s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company&#x2019;s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company adopted this accounting standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented, January 1, 2021, also referred to as the transition date, for changes primarily related to the liability for future policy benefits and deferred acquisition costs. The Company is still in the process of  finalizing the impact of the new standard on its historical financial statements, but expects to record an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income on the transition date of approximately $1&#160;billion as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company&#x2019;s expected investment yield under the existing guidance.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LiabilityForFuturePolicyBenefits
      contextRef="ibd811ca9ceb5442fbd696e20ec9278ed_I20230101"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjEvZnJhZzo4NGQ1NDA0MWRjMGI0YjgwYmJmNDE3ZjQ5M2Q5YWQzNy90ZXh0cmVnaW9uOjg0ZDU0MDQxZGMwYjRiODBiYmY0MTdmNDkzZDlhZDM3XzIxOTkwMjMzNTMzNjQ_6b18cd0a-7235-4714-9e61-ea8bdc8d19c4"
      unitRef="usd">1000000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzEwODQ_c65dd59f-7035-4c6c-8382-9375a7e1f9dc">Acquisitions, Divestitures and Asset Sales&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proposed Oak Street Health Acquisition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 7, 2023, the Company entered into a definitive merger agreement to acquire all of the outstanding shares of Oak Street Health, Inc. (&#x201c;Oak Street Health&#x201d;) for cash. Under the terms of the merger agreement, Oak Street Health stockholders will receive $39.00 per share in cash. The total value of the transaction is approximately $10.6&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proposed acquisition was approved by the Board of Directors at each of the respective companies and is subject to approval by a majority of Oak Street Health stockholders, receipt of regulatory approval and satisfaction of other customary closing conditions, including the expiration of the waiting period under the federal Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the merger agreement is terminated under certain specified circumstances and receipt of regulatory approval has not been obtained by such time, the Company will be required to pay Oak Street Health a termination fee of approximately $500&#160;million. If the merger agreement is terminated under other certain specified circumstances, including due to Oak Street Health accepting a superior proposal, Oak Street Health will be required to pay the Company a termination fee of approximately $300&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pending Signify Health Acquisition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 2, 2022, the Company entered into a definitive merger agreement to acquire all of the outstanding shares of Signify Health, Inc. (&#x201c;Signify Health&#x201d;) for cash. Under the terms of the merger agreement, Signify Health stockholders will receive $30.50 per share in cash. The total value of the transaction is approximately $8&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pending acquisition was approved by the Board of Directors at each of the respective companies and the Signify Health stockholders and remains subject to receipt of regulatory approval and satisfaction of other customary closing conditions. On October 19, 2022, Signify Health and CVS Health each received a request for additional information (also known as a &#x201c;second request&#x201d;) from the U.S. Department of Justice (the &#x201c;DOJ&#x201d;) in connection with the review of the transactions contemplated by the merger agreement by the DOJ under the federal Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in the second quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the merger agreement is terminated under certain specified circumstances and receipt of regulatory approval has not been obtained by such time, the Company will be required to pay Signify Health a termination fee in an amount equal to $380&#160;million. If the merger agreement is terminated under other certain specified circumstances, including due to Signify Health accepting a superior proposal, Signify Health will be required to pay the Company a termination fee in an amount equal to $228&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Held For Sale&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its Omnicare&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; long-term care business (&#x201c;LTC business&#x201d;), which is included within the Retail/LTC segment, was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria to be classified as held for sale and the carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell. Accordingly, the Company recorded a loss on assets held for sale of $2.5 billion during the third quarter of 2022. As of December&#160;31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter, an incremental loss on assets held for sale of $12 million was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. The loss on assets held for sale represents the write-down of its customer contracts/relationships intangible assets and was recorded in the Company&#x2019;s consolidated statement of operations within the Retail/LTC segment. The LTC business operating income was not material for the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The LTC business met the criteria to be classified as held for sale at December&#160;31, 2022, but did not meet the criteria to be classified as discontinued operations. As a result, the related assets and liabilities were included in separate held-for-sale line items of the asset and liability sections of the consolidated balance sheet. As the assets held for sale are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, they are classified in Level 3 of the fair value hierarchy. The following table summarizes the assets and liabilities held for sale at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of bswift&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company sold its wholly-owned subsidiary bswift LLC (&#x201c;bswift&#x201d;) for approximately $735 million. bswift offers software and services that streamline benefits and human resource administration. The results of this business have historically been recorded within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $250&#160;million in the year ended December&#160;31, 2022, which is reflected as a reduction of operating expenses in the Company&#x2019;s consolidated statement of operations within the Health Care Benefits segment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of PayFlex &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company sold PayFlex for approximately $775&#160;million. PayFlex provides services to employers, their employees, and their former employees in the areas of tax-advantaged account reimbursement administration (flexible spending, health reimbursement, health savings, transit and parking), Consolidated Omnibus Budget Reconciliation Act (&#x201c;COBRA&#x201d;) administration and special-member billing administration. The results of this business have historically been reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $225&#160;million in the year ended December&#160;31, 2022, which is reflected as a reduction of operating expenses in the Company&#x2019;s consolidated statement of operations within the Health Care Benefits segment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of Thailand Health Care Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company reached an agreement to sell its international health care business domiciled in Thailand (&#x201c;Thailand business&#x201d;), comprised of approximately 266,000 medical members, which was included in the Commercial Business reporting unit within the Health Care Benefits segment. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and, accordingly, the Company recorded a $41 million loss on assets held for sale within the Health Care Benefits segment during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the consideration received and ultimate loss on the sale were not material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of Workers&#x2019; Compensation Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2020, the Company sold its Workers&#x2019; Compensation business for approximately $850&#160;million. The results of this business were reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $269 million in the year ended December&#160;31, 2020, which is reflected as a reduction in operating expenses in the Company&#x2019;s consolidated statement of operations within the Health Care Benefits segment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;International Health Care Benefits Renewal Rights Asset Sale&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company sold the renewal rights of approximately 200,000 international medical members outside of the Americas, Thailand and India in connection with an Asset Purchase Agreement. As part of this agreement, the Company will introduce and help migrate these existing international medical members to the purchaser upon renewal. The Company expects the migration process to occur between July 2022 and November 2023. The Company ceased writing any new or renewal business for international medical members outside of the Americas during the fourth quarter of 2022. The consideration received related to this agreement was not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i5acb58a875864a49b737f2cb40ddee47_I20230207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzk4OTU2MDQ2Nzg2ODE_9b84613e-cc05-40ba-ba6e-48b7cc289835"
      unitRef="usdPerShare">39.00</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia4dd0513fdda4dfdb136f1594d393298_D20230207-20230207"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzk4OTU2MDQ2Nzg2ODk_9410eaa4-5eed-47cb-9226-8e79ef4f4b46"
      unitRef="usd">10600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <cvs:BusinessCombinationTerminationFee
      contextRef="i5acb58a875864a49b737f2cb40ddee47_I20230207"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzk4OTU2MDQ2Nzg3MDQ_2304f264-6108-4976-acfe-8062ea7c2589"
      unitRef="usd">500000000</cvs:BusinessCombinationTerminationFee>
    <cvs:BusinessCombinationTerminationFee
      contextRef="i5afb8727270f42b8ade9125cb3443778_I20230207"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzk4OTU2MDQ2Nzg3MTg_2aa94558-2844-4a40-bafc-119399e573f7"
      unitRef="usd">300000000</cvs:BusinessCombinationTerminationFee>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i1773809e56854492867bb26fea3c6b89_I20220902"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTE5NA_808b180a-bb54-4f12-8ac4-72623e85bdad"
      unitRef="usdPerShare">30.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i742e5d3d548546f4a2efaf4d89ecd9d1_D20220902-20220902"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTIwMg_7d1bdfd9-c6f8-4231-bf77-3743ffbc1725"
      unitRef="usd">8000000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <cvs:BusinessCombinationTerminationFee
      contextRef="i1773809e56854492867bb26fea3c6b89_I20220902"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTIxNA_f6872050-da5b-4341-88d1-51a1a49f3864"
      unitRef="usd">380000000</cvs:BusinessCombinationTerminationFee>
    <cvs:BusinessCombinationTerminationFee
      contextRef="i2f859fc0dd5e47f0a5e763378f21729e_I20220902"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTIyOA_503341b5-23b2-4e71-bfad-7a88351024ca"
      unitRef="usd">228000000</cvs:BusinessCombinationTerminationFee>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i2bf59ea1890f4d16a13351da96cf6411_D20220701-20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzEwOTk1MTE2Mjk3ODY1_60aafa87-5f2c-4345-b2fa-37ff4b4c7a54"
      unitRef="usd">2500000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i0d7bd61bc8784946b9cec8dcc1fcb6b8_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzEwOTk1MTE2Mjk3Nzkx_015c4f3a-1295-4738-a284-f09640c8b02d"
      unitRef="usd">12000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzY1OTcwNjk3ODQyNzA_751a9a3a-0c88-44a7-b3e1-fdd3be61b4eb">The following table summarizes the assets and liabilities held for sale at December&#160;31, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzItMS0xLTEtMjA4NDEx_e2ac0fb3-7a09-4d51-bdbd-a99208d93ba5"
      unitRef="usd">227000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzMtMS0xLTEtMjA4NDEx_623dd2ce-128a-444b-b5d7-ca6e7086c0d4"
      unitRef="usd">188000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzQtMS0xLTEtMjA4NDEx_36adbc2d-5210-47be-8ad0-cce5182d9d69"
      unitRef="usd">244000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzYtMS0xLTEtMjA4NDE0_13601ae1-b4be-4c55-95a3-3597e6236d14"
      unitRef="usd">131000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzctMS0xLTEtMjA4NDE0_01b9f58f-8fb6-4f5a-abc0-d897a30a8217"
      unitRef="usd">118000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzgtMS0xLTEtMjA4NDE0_b4f7d29a-9c45-4972-9d76-2f70c8d68fcd"
      unitRef="usd">908000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzExLTEtMS0xLTIwODQxNg_ca2b73fb-1a85-47b1-862f-5d911f9d4791"
      unitRef="usd">86000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzEyLTEtMS0xLTIwODQxNg_c18420e5-e33f-4167-bc1c-a94dea115b49"
      unitRef="usd">71000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzEzLTEtMS0xLTIwODQxNg_615ece20-7a7b-40ec-bdae-58ac6f8278cc"
      unitRef="usd">71000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90YWJsZTo2MmUxYmI2NGIwZTM0ODk1YjBiOTlhZTI5ZTllMWY4OC90YWJsZXJhbmdlOjYyZTFiYjY0YjBlMzQ4OTViMGI5OWFlMjllOWUxZjg4XzE0LTEtMS0xLTIwODQxNg_6be42021-c716-445d-89c7-564fb4166aae"
      unitRef="usd">228000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i96e78b501bc842a2affc4033fa4a4eb3_D20221101-20221130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgzMTkxMw_00f0c47e-5db3-458b-8d76-5db93ddca001"
      unitRef="usd">735000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ie6fc4ecb20e54148beb244c5579a6256_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzgyNDYzMzcyMjU5Nzg_685540d1-2771-4f68-a990-ef2283510580"
      unitRef="usd">250000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i879da25a180b4cf6b770b94022fe1214_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzY1OTcwNjk3ODQyODU_a2203efb-bd40-48a6-8e48-4e95619e8d65"
      unitRef="usd">775000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i9d6c8114b5924bed84e9fc58f5696afd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzY1OTcwNjk3ODQyOTk_cae29cd3-6165-49f1-9e2b-fabe9d0f045a"
      unitRef="usd">225000000</us-gaap:GainLossOnSaleOfBusiness>
    <cvs:NumberOfMedicalMembers
      contextRef="id8c3596e68a249cf9f084af72dd00f23_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgyOTQwMw_eacf964d-1500-4bb0-97b0-ecbc1ffa5cfe"
      unitRef="member">266000</cvs:NumberOfMedicalMembers>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i36ec68c9bde84569ae25dc7eda071a52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzIxOTkwMjMyNzIwODk_79e8ff0b-ba73-41a4-a5f0-f9193084f6ae"
      unitRef="usd">41000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i29b0f113479a4ec0b9e699b726fa4b6b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzIxOTkwMjMyNzIwODk_d462afec-ce6c-4621-b0fe-43c753069877"
      unitRef="usd">41000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i674eb260757d402f9e56019767496299_D20200731-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzE1NQ_d77bca59-8f57-4e26-8847-56448d1d9886"
      unitRef="usd">850000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i3fa94d302f25457a8ffe0851c4d7bf19_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzU0OTc1NTgxNDk5Mw_b2da0313-2750-4c54-a1df-85b4bd095ccc"
      unitRef="usd">269000000</us-gaap:GainLossOnSaleOfBusiness>
    <cvs:DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold
      contextRef="i779c59619b9643cbb118540ac3605d26_I20220531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjQvZnJhZzphNWU2M2QwYTcwMDU0MGVmYjdkZjU5ZTBlNGViMzE3Mi90ZXh0cmVnaW9uOmE1ZTYzZDBhNzAwNTQwZWZiN2RmNTllMGU0ZWIzMTcyXzEwOTk1MTE2Mjk3MDMw_20c8bb2a-2847-4db5-98e9-bcf86a211f98"
      unitRef="member">200000</cvs:DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MDY_913a4050-8941-4544-bd92-83cdb48a5381">Investments&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total investments at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes long-term investments of $17&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-indent:6.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, the Company held investments of $331 million and $450 million, respectively, related to the 2012 conversion of an existing group annuity contract from a participating to a non-participating contract. These investments are included in the total investments of large case pensions supporting non-experience-rated products. Although these investments are not accounted for as Separate Accounts assets, they are legally segregated and are not subject to claims that arise out of the Company&#x2019;s business and only support future policy benefits obligations under that group annuity contract. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities available for sale at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allowance&lt;br/&gt;for Credit&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Investment risks associated with the Company&#x2019;s experience-rated products generally do not impact the Company&#x2019;s consolidated operating results.&#160;At December&#160;31, 2022, debt securities with a fair value of $609 million, gross unrealized capital gains of $3 million and gross unrealized capital losses of &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$59 million, and at December&#160;31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and fair value of debt securities at December&#160;31, 2022 are shown below by contractual maturity.&#160;Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due to mature:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mortgage-Backed and Other Asset-Backed Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s residential mortgage-backed securities at December&#160;31, 2022 were issued by the Government National Mortgage Association, the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation and carry agency guarantees and explicit or implicit guarantees by the U.S. Government.&#160;At December&#160;31, 2022, the Company&#x2019;s residential mortgage-backed securities had an average credit quality rating of AAA and a weighted average duration of 5.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s commercial mortgage-backed securities have underlying loans that are dispersed throughout the United States. Significant market observable inputs used to value these securities include loss severity and probability of default.&#160;At December&#160;31, 2022, these securities had an average credit quality rating of AAA and a weighted average duration of 5.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s other asset-backed securities have a variety of underlying collateral (e.g., automobile loans, credit card receivables, home equity loans and commercial loans). Significant market observable inputs used to value these securities include the unemployment rate, loss severity and probability of default.&#160;At December&#160;31, 2022, these securities had an average credit quality rating of AA and a weighted average duration of 1.0 year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized below are the debt securities the Company held at December&#160;31, 2022 and 2021 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions, except number of securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company&#x2019;s business.&#160;In performing this review, the Company considered factors such as the quality of the investment security based on research performed by the Company&#x2019;s internal credit analysts and&#160;external rating agencies and the prospects of realizing the carrying value of the security based on the investment&#x2019;s current prospects for recovery. Unrealized capital losses at December&#160;31, 2022 were generally caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. As of December&#160;31, 2022, the Company did not intend to sell these securities, and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity dates for debt securities in an unrealized capital loss position at December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supporting experience-&lt;br/&gt;rated products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supporting remaining&lt;br/&gt;products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due to mature:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mortgage Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s mortgage loans are collateralized by commercial real estate.&#160;During the years ended December 31, 2022 and 2021, the Company had the following activity in its mortgage loan portfolio:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans fully repaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans foreclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses mortgage loans on a regular basis for credit impairments, and assigns a credit quality indicator to each loan.&#160;The Company&#x2019;s credit quality indicator is internally developed and categorizes each loan in its portfolio on a scale from 1 to 7.&#160;These indicators are based upon several factors, including current loan-to-value ratios, current and future property cash flow, property condition, market trends, creditworthiness of the borrower and deal structure. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Category 1 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Represents loans of superior quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Categories 2 to 4 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- Represent loans where credit risk is minimal to acceptable; however, these loans may display some susceptibility to economic changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Categories 5 and 6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Represent loans where credit risk is not substantial, but these loans warrant management&#x2019;s close attention.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Category 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Represents loans where collections are potentially at risk; if necessary, an impairment is recorded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon the Company&#x2019;s assessments at December&#160;31, 2022 and 2021, the amortized cost basis of the Company&#x2019;s mortgage loans within each credit quality indicator by year of origination was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost Basis by Year of Origination&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions, except credit quality indicator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 and 6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 and 6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 scheduled mortgage loan principal repayments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Investment Income&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sources of net investment income for the years ended December 31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income (excluding net realized capital gains or losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized capital gains (losses) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Net realized capital losses include credit-related losses on debt securities of $13 million and yield-related impairment losses on debt securities of $143 million in the year ended December 31, 2022. Net realized capital gains are net of yield-related impairment losses on debt securities of $42 million and $49 million for the years ended December 31, 2021 and 2020, respectively. There were no credit-related losses on debt securities in the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Net investment income includes $35 million, $38 million and $42 million for the years ended December 31, 2022, 2021 and 2020, respectively, related to investments supporting experience-rated products. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital gains and losses recognized during the year ended December 31, 2022 related to investments in equity securities held as of December 31, 2022 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized capital gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <cvs:TotalInvestmentsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MDE_38d151d7-8bfb-4c20-878c-55e99710527a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total investments at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes long-term investments of $17&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</cvs:TotalInvestmentsTableTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="i717e63c6c0e941a3ab348dc4fa490a30_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItMS0xLTEtMTY3OTA4_d9bf7818-c12a-4593-8c01-e922d406c3a2"
      unitRef="usd">2718000000</us-gaap:ShortTermInvestments>
    <cvs:LongTermInvestmentsIncludingAssetsHeldForSale
      contextRef="i717e63c6c0e941a3ab348dc4fa490a30_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItMy0xLTEtMTY3OTA4_8210c72f-6c2a-4661-9b4c-127893689852"
      unitRef="usd">17562000000</cvs:LongTermInvestmentsIncludingAssetsHeldForSale>
    <us-gaap:Investments
      contextRef="i717e63c6c0e941a3ab348dc4fa490a30_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItNS0xLTEtMTY3OTA4_4ee5a045-762e-42a2-9d07-a07968cf927b"
      unitRef="usd">20280000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments
      contextRef="i1a45d333346c4b16814c08207dbd06b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItNy0xLTEtMTY3OTA4_72c1138d-f899-4916-be2e-a1edd4c2537c"
      unitRef="usd">3009000000</us-gaap:ShortTermInvestments>
    <cvs:LongTermInvestmentsIncludingAssetsHeldForSale
      contextRef="i1a45d333346c4b16814c08207dbd06b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItOS0xLTEtMTY3OTA4_62a74890-8b80-4dd8-9219-7b3e46c88553"
      unitRef="usd">20231000000</cvs:LongTermInvestmentsIncludingAssetsHeldForSale>
    <us-gaap:Investments
      contextRef="i1a45d333346c4b16814c08207dbd06b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzItMTEtMS0xLTE2NzkwOA_15926d97-f05a-4d6a-a9d4-3d8b16c8d66f"
      unitRef="usd">23240000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments
      contextRef="i5de346073b1b4e83be2a8d87564b444d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtMS0xLTEtMTY3OTA4_cfdd15e8-8ae5-400e-a45f-076b1b71c733"
      unitRef="usd">55000000</us-gaap:ShortTermInvestments>
    <cvs:LongTermInvestmentsIncludingAssetsHeldForSale
      contextRef="i5de346073b1b4e83be2a8d87564b444d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtMy0xLTEtMTY3OTA4_5307740f-dad7-4528-8f68-85486fa6fab2"
      unitRef="usd">989000000</cvs:LongTermInvestmentsIncludingAssetsHeldForSale>
    <us-gaap:Investments
      contextRef="i5de346073b1b4e83be2a8d87564b444d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtNS0xLTEtMTY3OTA4_bb75b304-f52b-4de7-9a07-a78d97d5a003"
      unitRef="usd">1044000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments
      contextRef="i1fb1627c01b1430080b3f6a0a40addeb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtNy0xLTEtMTY3OTA4_7f50cae5-4e9f-4230-94cd-256869574960"
      unitRef="usd">58000000</us-gaap:ShortTermInvestments>
    <cvs:LongTermInvestmentsIncludingAssetsHeldForSale
      contextRef="i1fb1627c01b1430080b3f6a0a40addeb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtOS0xLTEtMTY3OTA4_085ba161-6c94-4c9e-bdb2-95adc8ed0a39"
      unitRef="usd">844000000</cvs:LongTermInvestmentsIncludingAssetsHeldForSale>
    <us-gaap:Investments
      contextRef="i1fb1627c01b1430080b3f6a0a40addeb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzMtMTEtMS0xLTE2NzkwOA_028ce5ac-c52b-4347-9004-d436dcb6aa41"
      unitRef="usd">902000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments
      contextRef="ic7bc5f7c69e7441cb31da4729c7de4bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtMS0xLTEtMTY3OTA4_2c542c01-44cd-4d46-b928-744397c4deb7"
      unitRef="usd">5000000</us-gaap:ShortTermInvestments>
    <cvs:LongTermInvestmentsIncludingAssetsHeldForSale
      contextRef="ic7bc5f7c69e7441cb31da4729c7de4bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtMy0xLTEtMTY3OTA4_037907a1-b292-495e-9ec1-c3bcf072bc28"
      unitRef="usd">2562000000</cvs:LongTermInvestmentsIncludingAssetsHeldForSale>
    <us-gaap:Investments
      contextRef="ic7bc5f7c69e7441cb31da4729c7de4bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtNS0xLTEtMTY3OTA4_672553cd-a778-4760-93ee-1962ba6631cb"
      unitRef="usd">2567000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments
      contextRef="ifdbc67676d794d47817f10d53a42b996_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtNy0xLTEtMTY3OTA4_5e3e4750-eacd-4a6a-b5ce-faa53bd3cb80"
      unitRef="usd">50000000</us-gaap:ShortTermInvestments>
    <cvs:LongTermInvestmentsIncludingAssetsHeldForSale
      contextRef="ifdbc67676d794d47817f10d53a42b996_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtOS0xLTEtMTY3OTA4_50ced201-8f18-4cfa-9d8f-7636fe5f921b"
      unitRef="usd">1950000000</cvs:LongTermInvestmentsIncludingAssetsHeldForSale>
    <us-gaap:Investments
      contextRef="ifdbc67676d794d47817f10d53a42b996_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzQtMTEtMS0xLTE2NzkwOA_db5c92bd-57a4-4314-ab83-3fa963508e39"
      unitRef="usd">2000000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtMS0xLTEtMTY3OTA4_0ab17696-3e19-41c8-8193-de22d35764ea"
      unitRef="usd">2778000000</us-gaap:ShortTermInvestments>
    <cvs:LongTermInvestmentsIncludingAssetsHeldForSale
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtMy0xLTEtMTY3OTA4_10c62bbe-d31e-4a71-b076-4bea0f1975d4"
      unitRef="usd">21113000000</cvs:LongTermInvestmentsIncludingAssetsHeldForSale>
    <us-gaap:Investments
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtNS0xLTEtMTY3OTA4_e1d33416-2fd5-48aa-9e26-cc2acdfe8f4b"
      unitRef="usd">23891000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtNy0xLTEtMTY3OTA4_7a0eb3a6-886b-4e3b-aa61-be4cf3a6fb56"
      unitRef="usd">3117000000</us-gaap:ShortTermInvestments>
    <cvs:LongTermInvestmentsIncludingAssetsHeldForSale
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtOS0xLTEtMTY3OTA4_9979c923-dcf1-43b7-bd04-f775de99627d"
      unitRef="usd">23025000000</cvs:LongTermInvestmentsIncludingAssetsHeldForSale>
    <us-gaap:Investments
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpjMWZhMjgxZGM4Zjg0NTFiYjIzZmNiZWE4MGI3ZDZiOC90YWJsZXJhbmdlOmMxZmEyODFkYzhmODQ1MWJiMjNmY2JlYTgwYjdkNmI4XzUtMTEtMS0xLTE2NzkwOA_659d8b85-a8df-46b0-b116-9d5b499c92db"
      unitRef="usd">26142000000</us-gaap:Investments>
    <cvs:LongTermInvestmentsIncludingAssetsHeldForSale
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzIxOTkwMjMyNjgxMzE_ea0d5ad1-86b9-49ce-b52e-42e689adaa82"
      unitRef="usd">17000000</cvs:LongTermInvestmentsIncludingAssetsHeldForSale>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzEzMw_807071d6-3ca1-4a25-9fd0-b08c774d0752"
      unitRef="usd">331000000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzE0MA_e0e230b7-4240-4c0d-b6ab-4612a10fb384"
      unitRef="usd">450000000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MTU_81803ca1-82b0-40be-a7c4-2890e2462812">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities available for sale at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allowance&lt;br/&gt;for Credit&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Investment risks associated with the Company&#x2019;s experience-rated products generally do not impact the Company&#x2019;s consolidated operating results.&#160;At December&#160;31, 2022, debt securities with a fair value of $609 million, gross unrealized capital gains of $3 million and gross unrealized capital losses of &lt;/span&gt;&lt;/div&gt;$59 million, and at December&#160;31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income (loss).</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtNS0xLTEtMTY3OTA4_ea53e0ef-7343-4266-8fda-5a8d33037080"
      unitRef="usd">2074000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtNy0xLTEtMTk5OTkz_bfc213bb-6f7c-41f9-adc3-1bccfe948bd0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtOS0xLTEtMTk5OTkz_832ff0d2-7962-450e-b466-80ea94a6883b"
      unitRef="usd">2074000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtNy0xLTEtMTY3OTA4_a76f2e3b-21b7-4c9e-9073-0e8ad3235872"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtOS0xLTEtMTY3OTA4_74ba6270-870f-4e4e-b495-b054824dff4a"
      unitRef="usd">182000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzMtMTEtMS0xLTE2NzkwOA_b35fb7dd-49e8-4fb4-8b9d-14fb11464558"
      unitRef="usd">1892000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtNS0xLTEtMTY3OTA4_f89eb6c8-41df-49f8-b47e-4a6adc0edba9"
      unitRef="usd">2393000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtNy0xLTEtMTk5OTkz_b0e6f09e-a9f1-4bf6-906c-e968899d0f82"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtOS0xLTEtMTk5OTkz_a580d5e9-c3d2-4c60-bec5-e28d2cc1c67a"
      unitRef="usd">2393000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtNy0xLTEtMTY3OTA4_d9a816db-46cf-42df-a7b8-46fb28fe0402"
      unitRef="usd">8000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtOS0xLTEtMTY3OTA4_6caa4e79-f1f9-48d7-8ad4-61db9d88a25f"
      unitRef="usd">129000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzQtMTEtMS0xLTE2NzkwOA_46f48520-bf86-4d41-b781-fe99202d405d"
      unitRef="usd">2272000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtNS0xLTEtMTY3OTA4_278c6373-c43e-4b08-8429-b42897df269c"
      unitRef="usd">9838000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtNy0xLTEtMTk5OTkz_97d0de34-90f7-41cb-b1b7-b8ff5ea22e5f"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtOS0xLTEtMTk5OTkz_68256bad-14a7-4518-8530-17d5f02aa9ab"
      unitRef="usd">9835000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtNy0xLTEtMTY3OTA4_45fd548c-a217-4d42-b7c1-66dbea8eec89"
      unitRef="usd">26000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtOS0xLTEtMTY3OTA4_f707ec90-b9f9-414d-aaee-e513926f925e"
      unitRef="usd">903000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzUtMTEtMS0xLTE2NzkwOA_56538c6a-cc71-49c3-bddc-882b7621451b"
      unitRef="usd">8958000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtNS0xLTEtMTY3OTA4_4c2c6a2c-fa35-4be4-8504-c94961180330"
      unitRef="usd">2780000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtNy0xLTEtMTk5OTkz_2d644779-1020-428c-b118-f5615ee487b3"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtOS0xLTEtMTk5OTkz_60f200d6-0a4b-40be-b461-bad47020cbe0"
      unitRef="usd">2779000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtNy0xLTEtMTY3OTA4_922121ce-0ca8-4942-9f62-4b208149250b"
      unitRef="usd">15000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtOS0xLTEtMTY3OTA4_1fdb70ab-1efc-4364-be0a-f47aac63f49d"
      unitRef="usd">244000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzYtMTEtMS0xLTE2NzkwOA_9e8d8473-1c09-4032-a980-23e713eade3c"
      unitRef="usd">2550000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctNS0xLTEtMTY3OTA4_952492e6-537e-4d28-8736-d930d7f7c435"
      unitRef="usd">845000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctNy0xLTEtMTk5OTkz_8226cb7e-6fc4-4dfc-a078-b58768cb4b5e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctOS0xLTEtMTk5OTkz_82fc1812-ff36-49d2-a5a8-20187e2bc81b"
      unitRef="usd">845000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctNy0xLTEtMTY3OTA4_81fef57c-72ee-4af3-a31f-e8273419b126"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctOS0xLTEtMTY3OTA4_64e2eb06-01c4-4580-9ca2-bca6829a76e0"
      unitRef="usd">89000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzctMTEtMS0xLTE2NzkwOA_8a8b1d54-245f-4d90-a5a4-3d322197c083"
      unitRef="usd">757000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtNS0xLTEtMTY3OTA4_6e0c235f-1a5c-4106-b519-adcbcac538fa"
      unitRef="usd">1172000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtNy0xLTEtMTk5OTkz_6a0f71e8-e705-4030-a3d0-583a2efb38ed"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtOS0xLTEtMTk5OTkz_b773927e-0bd7-4c54-a430-e7b54c4a70d7"
      unitRef="usd">1172000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtNy0xLTEtMTY3OTA4_c1e6b5bb-f755-4642-8849-2dc24ea511eb"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtOS0xLTEtMTY3OTA4_57d6ec0f-60c3-4c10-bc7f-a31561731635"
      unitRef="usd">155000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzgtMTEtMS0xLTE2NzkwOA_6a7af3e4-b70c-4c84-beb0-1fdaa3bf49d8"
      unitRef="usd">1018000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktNS0xLTEtMTY3OTA4_9217b0d0-42b5-431b-90b9-4e48f7fb87c3"
      unitRef="usd">2940000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktNy0xLTEtMTk5OTkz_a62f7468-de02-482b-aa0f-b585338f5efa"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktOS0xLTEtMTk5OTkz_215e5f1b-a6f8-4f7f-97fe-790f1d42cbd3"
      unitRef="usd">2940000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktNy0xLTEtMTY3OTA4_a43afeb4-1432-4a33-ba97-a068ab6f0511"
      unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktOS0xLTEtMTY3OTA4_9ac3a060-8f56-40f4-8624-3c82eaac87d3"
      unitRef="usd">136000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzktMTEtMS0xLTE2NzkwOA_d4d3780f-05d9-4575-b1f8-3b640a4479d9"
      unitRef="usd">2810000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTUtMS0xLTE2NzkwOA_a54fd348-82b6-43db-8ac5-223485e694cb"
      unitRef="usd">25000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTctMS0xLTE5OTk5Mw_f2b52267-bbbb-45fd-8f9d-7f1ff6f44332"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTktMS0xLTE5OTk5Mw_779bab5a-cb47-4534-a528-eda1e0c0b7d4"
      unitRef="usd">25000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTctMS0xLTE2NzkwOA_7d1a936d-4ad0-4fbd-84bb-38a546c27990"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTktMS0xLTE2NzkwOA_8ca1b4d8-d9ac-4aa2-9d02-f19e64c92853"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzEwLTExLTEtMS0xNjc5MDg_4e639371-49b4-41d7-84b7-b1ff947cd83a"
      unitRef="usd">23000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTUtMS0xLTE2NzkwOA_332b4128-3320-4dc4-b884-aa33e6301743"
      unitRef="usd">22067000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTctMS0xLTIwMDAwMw_a3922f20-28ca-4e6a-93b9-c0472237cbe9"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTktMS0xLTIwMDAwMw_4b478252-c4b0-4772-91c4-e7913f8b1ecf"
      unitRef="usd">22063000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTctMS0xLTE2NzkwOA_2df7c34f-0478-4239-bd84-c4e740678de8"
      unitRef="usd">57000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTktMS0xLTE2NzkwOA_86a7030a-6825-4564-89b2-2b2e84d5e1dd"
      unitRef="usd">1840000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzExLTExLTEtMS0xNjc5MDg_f83a6067-91b9-49dd-a4f3-fc81a1481f58"
      unitRef="usd">20280000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTUtMS0xLTE2NzkwOA_ebbeca85-64e9-40ad-9109-39c6fbd82581"
      unitRef="usd">2349000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTctMS0xLTIwMDAzMA_e27c1d19-39d9-48b0-a507-f80681cd9e30"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTktMS0xLTIwMDAzMA_00792f1b-0fbd-4f50-b3b6-d3cf22ab7c45"
      unitRef="usd">2349000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTctMS0xLTE2NzkwOA_39134485-4e3d-4ef4-af2e-76885990dff8"
      unitRef="usd">70000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTktMS0xLTE2NzkwOA_7ad73e4a-bda2-4fc5-b8cb-2ec0d174fdf9"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE1LTExLTEtMS0xNjc5MDg_906e3236-8999-4cdd-9f99-a61800a61611"
      unitRef="usd">2416000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTUtMS0xLTE2NzkwOA_2662b091-1b87-43d8-a94c-e213dd4a721e"
      unitRef="usd">2947000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTctMS0xLTIwMDAzMA_5920a4a1-384f-45c7-b3b7-a79e6714c2ee"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTktMS0xLTIwMDAzMA_171b51a6-0ac6-46ad-aa51-2f721f3235da"
      unitRef="usd">2947000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTctMS0xLTE2NzkwOA_1450b3cb-f21b-4dca-97e8-da2928d27bf1"
      unitRef="usd">148000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTktMS0xLTE2NzkwOA_954c7870-6a95-4634-a593-3f8851804f33"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE2LTExLTEtMS0xNjc5MDg_668ddcc5-5963-4ea9-87f4-c2a315972267"
      unitRef="usd">3091000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTUtMS0xLTE2NzkwOA_fa2bafc2-fb01-4a94-926d-8b51bfd1e772"
      unitRef="usd">9093000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTctMS0xLTIwMDAzMA_0ff62898-e4d6-4851-beea-588f77c8b9a0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTktMS0xLTIwMDAzMA_fb0a7703-f3b3-4a8d-b477-d6f241dab89a"
      unitRef="usd">9093000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTctMS0xLTE2NzkwOA_6a84ac6f-06a8-42e7-8272-7024ccfd9455"
      unitRef="usd">682000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTktMS0xLTE2NzkwOA_071e0971-ea5d-4d51-8ad0-446dcab6d59c"
      unitRef="usd">40000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE3LTExLTEtMS0xNjc5MDg_069ab895-346b-4797-9f85-d8f66d722875"
      unitRef="usd">9735000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTUtMS0xLTE2NzkwOA_434be7a9-2e32-41a6-8a79-cf23b129dc07"
      unitRef="usd">2821000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTctMS0xLTIwMDAzMA_94d27b97-c295-4c18-8191-aff1b1fede57"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTktMS0xLTIwMDAzMA_13b462b2-f3cb-4520-9a9e-718b36b51182"
      unitRef="usd">2821000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTctMS0xLTE2NzkwOA_2ce72cee-881e-4896-9d4f-122a0833bd43"
      unitRef="usd">196000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTktMS0xLTE2NzkwOA_6c207f9b-6f8c-4ea9-a5fe-b23bb1cedc37"
      unitRef="usd">24000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE4LTExLTEtMS0xNjc5MDg_eb5c4dec-38a4-4b10-90a5-8511de199063"
      unitRef="usd">2993000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTUtMS0xLTE2NzkwOA_81f48214-1f9c-41d3-b23a-30df4adf6290"
      unitRef="usd">870000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTctMS0xLTIwMDAzMA_3bb85cca-c500-43ba-b618-03ca26130ca3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTktMS0xLTIwMDAzMA_2b3b2061-cd8d-49cd-aa93-8448d51f79f4"
      unitRef="usd">870000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTctMS0xLTE2NzkwOA_e5c6da22-d987-4f0a-a099-5c91187f3726"
      unitRef="usd">15000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTktMS0xLTE2NzkwOA_802715ee-709f-49b9-9169-3db2252ceb93"
      unitRef="usd">10000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzE5LTExLTEtMS0xNjc5MDg_77cf007b-2bc5-43eb-9525-a75883972f0c"
      unitRef="usd">875000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTUtMS0xLTE2NzkwOA_68c114aa-76bc-4c68-b26b-dfd644437737"
      unitRef="usd">1278000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTctMS0xLTIwMDAzMA_cf09fadd-6f0c-421a-9c7c-ddd9b676b253"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTktMS0xLTIwMDAzMA_de31f18d-8e84-472a-95ef-42ccbd960038"
      unitRef="usd">1278000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTctMS0xLTE2NzkwOA_00fc9052-9d2c-4aac-a705-571d2b414a6d"
      unitRef="usd">44000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTktMS0xLTE2NzkwOA_e1769293-bcbe-408a-a0f4-07e9cb52b957"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIwLTExLTEtMS0xNjc5MDg_2c4e2dab-fc81-4018-82dc-38f81035b72a"
      unitRef="usd">1310000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTUtMS0xLTE2NzkwOA_400d84cc-73c7-4ca7-9822-59a296bd8fb1"
      unitRef="usd">2791000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTctMS0xLTIwMDAzMA_bd207022-1717-4568-8a0f-2b88fee37615"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTktMS0xLTIwMDAzMA_bb011473-5d53-4cb2-a69c-22eaadd888b5"
      unitRef="usd">2791000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTctMS0xLTE2NzkwOA_c8f7c5ea-466f-43c6-8232-24f72749bb41"
      unitRef="usd">14000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTktMS0xLTE2NzkwOA_bdee02f7-123a-4fb3-a006-509421554409"
      unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIxLTExLTEtMS0xNjc5MDg_8bc68a84-eb6d-466f-a62a-94bb5e2a8a17"
      unitRef="usd">2792000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTUtMS0xLTE2NzkwOA_8c6095d4-7263-408e-9d31-eccddc267839"
      unitRef="usd">25000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTctMS0xLTIwMDAzMA_e39dac0a-0a7a-4f7f-b99f-2ffe2b1237d7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTktMS0xLTIwMDAzMA_17acdb91-8b1a-46e2-b9e2-35f1f60bfba7"
      unitRef="usd">25000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTctMS0xLTE2NzkwOA_715c35aa-d345-4cc4-b599-dd785c153827"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTktMS0xLTE2NzkwOA_5ca898bf-3340-463f-b58a-ddeb6fce3cf6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIyLTExLTEtMS0xNjc5MDg_42d2b457-3e28-4cc5-a74f-38b792fc8d18"
      unitRef="usd">28000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTUtMS0xLTE2NzkwOA_e36c6736-5887-45b1-9be6-90cb3fea95e2"
      unitRef="usd">22174000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTctMS0xLTIwMDAzMA_6563dda0-ee6b-4e7c-ac11-8c37b2dcfac8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTktMS0xLTIwMDAzMA_60a5ba5e-3cc6-40a5-9888-baf754438e27"
      unitRef="usd">22174000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTctMS0xLTE2NzkwOA_76acce54-4473-4f3d-a4b0-10f8a698a193"
      unitRef="usd">1172000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTktMS0xLTE2NzkwOA_f7b39ac8-69a1-4337-b608-e13c66d1880f"
      unitRef="usd">106000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo2ZGZiYmQzZDI0OTM0NDRlOTIyNjdjMjNjZGQxNmI1OC90YWJsZXJhbmdlOjZkZmJiZDNkMjQ5MzQ0NGU5MjI2N2MyM2NkZDE2YjU4XzIzLTExLTEtMS0xNjc5MDg_82590d2c-d981-449c-b7ff-4fd4fbe4e55f"
      unitRef="usd">23240000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzExMDE_1fab81c2-69e9-453f-9aeb-69c2112c3005"
      unitRef="usd">609000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzExMzk_8a856ce2-f877-4cbe-8399-72e4bcb26faa"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzExODE_e0240f5d-2d85-44d4-8dca-0853778f3181"
      unitRef="usd">59000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i628bda68e4a846798004771ed7fa1e30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzEyMzI_5e985741-3181-49aa-9d72-07b426d73842"
      unitRef="usd">864000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i628bda68e4a846798004771ed7fa1e30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzEyNzA_ba7e78e5-a283-47a8-985a-d79adf866568"
      unitRef="usd">94000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i628bda68e4a846798004771ed7fa1e30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzEyNzc_eb6d1c85-83c4-4785-986a-382bb8c91f5c"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MDI_322b0e87-8c79-47d1-b855-7bdcddeacde3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and fair value of debt securities at December&#160;31, 2022 are shown below by contractual maturity.&#160;Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due to mature:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzItMS0xLTEtMTY3OTA4_020fc357-d7a8-44b4-acaa-329c35fd29dd"
      unitRef="usd">1315000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzItMy0xLTEtMTY3OTA4_ae81c728-4d5c-4670-8d1c-5cb60be8efa9"
      unitRef="usd">1305000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzMtMS0xLTEtMTY3OTA4_a9314e8b-363c-40ba-b178-aad6fa438939"
      unitRef="usd">6596000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzMtMy0xLTEtMTY3OTA4_8e7505db-f691-4441-8c14-5184f1582a8c"
      unitRef="usd">6206000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzQtMS0xLTEtMTY3OTA4_eee2ee53-24ba-4e5b-b2a1-ae0600139a75"
      unitRef="usd">4899000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzQtMy0xLTEtMTY3OTA4_6707e0f9-4f0d-4952-b93b-f76e230acb92"
      unitRef="usd">4401000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzUtMS0xLTEtMTY3OTA4_ca9d2edb-0b89-4093-b6e9-ae19de265e1a"
      unitRef="usd">4296000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzUtMy0xLTEtMTY3OTA4_60f97a53-af1c-4946-8cd7-dca0ff0989e5"
      unitRef="usd">3783000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzYtMS0xLTEtMTY3OTA4_93d7b0ef-eb06-4866-a57b-dc5bd8f9df33"
      unitRef="usd">845000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzYtMy0xLTEtMTY3OTA4_00a47223-2f39-4e8b-b979-724c14e22cfc"
      unitRef="usd">757000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzctMS0xLTEtMTY3OTA4_f54488a1-da6b-4b45-9202-9ffd7f17d4cd"
      unitRef="usd">1172000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzctMy0xLTEtMTY3OTA4_3dda8789-f9da-47e2-85b2-5c9725e3d47c"
      unitRef="usd">1018000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzgtMS0xLTEtMTY3OTA4_602577a1-c36a-44d8-9e00-348f8e368dec"
      unitRef="usd">2940000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzgtMy0xLTEtMTY3OTA4_5e50d0df-213e-4215-a693-dad62a9ce16b"
      unitRef="usd">2810000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzktMS0xLTEtMTY3OTA4_96687db6-7735-4e5c-9afd-3837641d6c65"
      unitRef="usd">22063000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTozZmQwNTg0YzE1OGI0NjAxOTVjYzcxNTBlODA3YzM4My90YWJsZXJhbmdlOjNmZDA1ODRjMTU4YjQ2MDE5NWNjNzE1MGU4MDdjMzgzXzktMy0xLTEtMTY3OTA4_cb33caab-6595-475f-9e8d-e591688012a8"
      unitRef="usd">20280000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <cvs:DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities
      contextRef="id3def4d721b4452a9745ed4ff29dd91f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzIyOTU_7f4f3a2c-a603-4953-a8e8-9848796da05b">P5Y8M12D</cvs:DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities>
    <cvs:DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities
      contextRef="i7ae5d28fdba744f89bd9b16b1f10ec56_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzI2NDM_4494d97d-d458-451f-b787-43c3aab51638">P5Y7M6D</cvs:DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities>
    <cvs:DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities
      contextRef="ia58f18f7922d480dbb9758608a9e7dd8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzMwNjY_b37e5821-ca7d-4d96-9830-be0878d886ff">P1Y</cvs:DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MjY_be633d1d-e92b-48be-95c8-af25a8af5dda">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized below are the debt securities the Company held at December&#160;31, 2022 and 2021 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Greater than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions, except number of securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity dates for debt securities in an unrealized capital loss position at December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supporting experience-&lt;br/&gt;rated products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supporting remaining&lt;br/&gt;products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due to mature:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMS0xLTEtMTY3OTA4_55ba085f-c372-4537-9bd8-72475ea51984"
      unitRef="security">519</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMy0xLTEtMTY3OTA4_b22acc9c-6dd2-4115-b3c0-f0d585b9229e"
      unitRef="usd">1620000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtNS0xLTEtMTY3OTA4_ef6b7d6d-8329-4738-93d0-d502d8f38773"
      unitRef="usd">164000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtNy0xLTEtMTY3OTA4_965961af-52af-412f-9d6b-836a7679a034"
      unitRef="security">35</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtOS0xLTEtMTY3OTA4_c5e91240-e9eb-4449-a655-702b2ca7b228"
      unitRef="usd">191000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMTEtMS0xLTE2NzkwOA_4635f346-6960-4d2d-a3fd-23fb8a45bac2"
      unitRef="usd">18000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMTMtMS0xLTE2NzkwOA_07fd97cf-4ade-47cf-a3ac-03963678ce61"
      unitRef="security">554</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMTUtMS0xLTE2NzkwOA_e3ed8082-7321-4036-8ba5-d3db19e465a9"
      unitRef="usd">1811000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic7458b83ae264cb0b8e0b9ec8bfb29ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzQtMTctMS0xLTE2NzkwOA_17025096-8923-4c75-b907-f5795a10f702"
      unitRef="usd">182000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMS0xLTEtMTY3OTA4_bd5dc37b-a288-4e93-8a1c-1c785c2fab98"
      unitRef="security">859</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMy0xLTEtMTY3OTA4_6177e0e2-3ddd-4dd6-910c-d1955895e566"
      unitRef="usd">1370000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtNS0xLTEtMTY3OTA4_ef6790c4-3fe4-4383-a399-7e357cfb4ccb"
      unitRef="usd">95000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtNy0xLTEtMTY3OTA4_1d7c5b5f-13d2-454a-b57a-f7d280e7d947"
      unitRef="security">196</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtOS0xLTEtMTY3OTA4_cc68d991-d843-4197-b797-9d04b3082e4b"
      unitRef="usd">322000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMTEtMS0xLTE2NzkwOA_1d3a9bfd-942d-4dda-a704-ac8030106d97"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMTMtMS0xLTE2NzkwOA_ac03c805-43fb-422a-93bb-c93043b32a9a"
      unitRef="security">1055</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMTUtMS0xLTE2NzkwOA_c0504ce7-222e-4b7f-9df0-3bd8690679f9"
      unitRef="usd">1692000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ib28047fad8cc4d29952b1b382be9b6a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzUtMTctMS0xLTE2NzkwOA_a28b733a-a70a-431c-a100-355eead08c6d"
      unitRef="usd">129000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMS0xLTEtMTY3OTA4_13fa25e8-f80b-49d3-baa0-b0464a8bfbc5"
      unitRef="security">5193</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMy0xLTEtMTY3OTA4_93b05f6f-a152-4dc7-825e-c850a7dda93a"
      unitRef="usd">6537000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtNS0xLTEtMTY3OTA4_30a0d4f0-dadc-4e5c-a932-7dd2f521debc"
      unitRef="usd">622000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtNy0xLTEtMTY3OTA4_55dc2746-d9eb-48e8-b0e4-e72504643641"
      unitRef="security">1479</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtOS0xLTEtMTY3OTA4_845067eb-ff7b-4b19-b2e0-71e52af3128f"
      unitRef="usd">1822000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMTEtMS0xLTE2NzkwOA_2d47e258-f38c-4f39-9430-162abe54b178"
      unitRef="usd">281000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMTMtMS0xLTE2NzkwOA_59a20b30-1d18-4f0b-9ccf-3f9d8f90e6fc"
      unitRef="security">6672</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMTUtMS0xLTE2NzkwOA_c6e0f478-b37b-4737-9fe8-e822fd83b277"
      unitRef="usd">8359000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i794d05f87c014f5ea664e007d8ef553e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzYtMTctMS0xLTE2NzkwOA_9a181b51-426c-41e1-938c-401a9e8776a0"
      unitRef="usd">903000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMS0xLTEtMTY3OTA4_983d5e41-410f-4e1c-a3f9-a9f72bd5587b"
      unitRef="security">1168</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMy0xLTEtMTY3OTA4_a928fc51-16b7-44b6-a72c-d719e5ae73fa"
      unitRef="usd">1715000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctNS0xLTEtMTY3OTA4_44eb0bc2-4ed7-4184-bca8-474752dc745d"
      unitRef="usd">147000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctNy0xLTEtMTY3OTA4_a35d75d6-7955-4499-85dc-fe6ea23598b4"
      unitRef="security">403</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctOS0xLTEtMTY3OTA4_07cd5737-a650-4026-90e8-d6bda034a88d"
      unitRef="usd">592000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMTEtMS0xLTE2NzkwOA_a42f72f1-c73f-4d0f-9b3e-7dfb48e70d9e"
      unitRef="usd">97000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMTMtMS0xLTE2NzkwOA_8a9aae60-426b-4f27-96bc-9f5151c8aad1"
      unitRef="security">1571</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMTUtMS0xLTE2NzkwOA_3416a4d6-935d-4be8-b073-c832f30419c0"
      unitRef="usd">2307000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i13df1984aa1d4ec0afb4004f690df554_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzctMTctMS0xLTE2NzkwOA_8fc5fc5e-a8b1-4f38-856a-119942998d80"
      unitRef="usd">244000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMS0xLTEtMTY3OTA4_c277bbed-7a6c-4b70-9189-9f847aead046"
      unitRef="security">452</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMy0xLTEtMTY3OTA4_191d32f6-52cc-4f02-a87e-8e28eea1fa55"
      unitRef="usd">464000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtNS0xLTEtMTY3OTA4_713e64d6-880b-45a8-ad6f-475c15ee29f0"
      unitRef="usd">39000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtNy0xLTEtMTY3OTA4_4337ff27-6c50-48ac-91bb-f62cc040acf8"
      unitRef="security">91</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtOS0xLTEtMTY3OTA4_30df8775-7937-411f-8aa8-f013b30d7919"
      unitRef="usd">257000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMTEtMS0xLTE2NzkwOA_42cd4f9a-5097-46d1-ae0e-4b9179e6961e"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMTMtMS0xLTE2NzkwOA_6fefef19-20f0-4ef1-a540-4bfeaffaaa99"
      unitRef="security">543</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMTUtMS0xLTE2NzkwOA_e6fcdb54-91fc-427c-8600-4b78b99c35ea"
      unitRef="usd">721000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzgtMTctMS0xLTE2NzkwOA_59792875-537f-4430-97ae-cb77d1bb2a6d"
      unitRef="usd">89000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMS0xLTEtMTY3OTA4_f563e249-1556-42c1-8041-afc639b96639"
      unitRef="security">288</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMy0xLTEtMTY3OTA4_479a0ae5-ae23-46db-8cad-8402547ac80f"
      unitRef="usd">611000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktNS0xLTEtMTY3OTA4_e16ecc01-6dd1-4896-8409-27944b1a22db"
      unitRef="usd">69000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktNy0xLTEtMTY3OTA4_977931b3-bc50-49bb-9486-9fba530d60eb"
      unitRef="security">187</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktOS0xLTEtMTY3OTA4_680eb5ff-a3dd-42fe-a7f7-e57587fd040a"
      unitRef="usd">381000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMTEtMS0xLTE2NzkwOA_0d315d15-4ae7-439d-b933-265a3c8682a2"
      unitRef="usd">86000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMTMtMS0xLTE2NzkwOA_a503c6bc-d737-4db5-83ad-b9b3389b720f"
      unitRef="security">475</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMTUtMS0xLTE2NzkwOA_769b03bd-9c4d-41fb-9ac9-bb4dbd71ff5c"
      unitRef="usd">992000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzktMTctMS0xLTE2NzkwOA_a443eda1-5982-4212-a6da-85cd7cc70065"
      unitRef="usd">155000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTEtMS0xLTE2NzkwOA_c139759d-6f68-425d-8f7d-a32561a59bcc"
      unitRef="security">1008</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTMtMS0xLTE2NzkwOA_9591b5c1-829e-41c8-94f7-c1fa726f0351"
      unitRef="usd">1893000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTUtMS0xLTE2NzkwOA_6627609b-f5b1-4b29-aef2-b4ccee1349f1"
      unitRef="usd">88000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTctMS0xLTE2NzkwOA_08f35a98-a935-401f-bebd-2be0c6e2994f"
      unitRef="security">391</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTktMS0xLTE2NzkwOA_cef66028-0b6a-4ca9-8419-d9ade2ebc392"
      unitRef="usd">694000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTExLTEtMS0xNjc5MDg_6413460d-461c-4daa-bcd4-985a66eb4f77"
      unitRef="usd">48000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTEzLTEtMS0xNjc5MDg_453ca32c-492a-4bb1-afa0-9871b28ba694"
      unitRef="security">1399</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTE1LTEtMS0xNjc5MDg_728b51b2-fb59-46c3-a70e-eb2385fa4a82"
      unitRef="usd">2587000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEwLTE3LTEtMS0xNjc5MDg_edd4aa55-4cac-49e3-bdf7-0c4a836a4782"
      unitRef="usd">136000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTEtMS0xLTE2NzkwOA_3fc1a7bb-e9f2-4121-ad7a-43077d65592d"
      unitRef="security">13</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTMtMS0xLTE2NzkwOA_d3fc59a4-aefb-493e-b641-4976b68ce40c"
      unitRef="usd">18000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTUtMS0xLTE2NzkwOA_a1709da5-9a6e-4fea-922f-c2d825ccd31e"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTctMS0xLTE2NzkwOA_e4862c93-824e-4a0f-8477-316accf42e10"
      unitRef="security">2</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTktMS0xLTE2NzkwOA_ad9af765-eed1-4da4-ae69-dc7d52d6000b"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTExLTEtMS0xNjc5MDg_50b87f56-76d4-449b-bd60-06fe10e1471e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTEzLTEtMS0xNjc5MDg_d7bfb979-a11b-4f9e-a8e5-c446f4857a7b"
      unitRef="security">15</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTE1LTEtMS0xNjc5MDg_fc1e79d7-c315-4787-b5e7-cad36822fd41"
      unitRef="usd">23000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5018ba9dc3d44a889aa8a3ead3ce6ade_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzExLTE3LTEtMS0xNjc5MDg_15426571-d363-49ca-8ba8-396133f069bd"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTEtMS0xLTE2NzkwOA_87068b00-bd58-416a-af85-9c8cda43b6c1"
      unitRef="security">9500</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTMtMS0xLTE2NzkwOA_1b6b766d-dfaf-4f3d-8a5d-70ea52b96d69"
      unitRef="usd">14228000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTUtMS0xLTE2NzkwOA_62611916-bb78-4a87-bebf-99b83b736a2d"
      unitRef="usd">1226000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTctMS0xLTE2NzkwOA_0ad0ce0e-3fab-428c-ad7e-fc2c5a06e52d"
      unitRef="security">2784</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTktMS0xLTE2NzkwOA_7d2f6dc1-bcfb-4580-9fb1-0096128e9d96"
      unitRef="usd">4264000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTExLTEtMS0xNjc5MDg_b878cc57-4b01-4694-8921-a3d773dd9033"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTEzLTEtMS0xNjc5MDg_c9219ea0-6db3-42c4-a667-3b92af47d72f"
      unitRef="security">12284</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTE1LTEtMS0xNjc5MDg_408da80e-e8ed-49e1-8dad-d75200be2dce"
      unitRef="usd">18492000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzEyLTE3LTEtMS0xNjc5MDg_d2a9faf8-a62d-44da-b9c8-5451c5f88e7b"
      unitRef="usd">1840000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTEtMS0xLTE2NzkwOA_fe5e836c-73a9-43c4-af59-d2d295d2ddf3"
      unitRef="security">43</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTMtMS0xLTE2NzkwOA_ef3c14b5-d80d-418f-99fe-0949a72d7f9d"
      unitRef="usd">242000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTUtMS0xLTE2NzkwOA_574405eb-bba8-4a75-8ae3-11e34c5d89f0"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTctMS0xLTE2NzkwOA_a568de6d-12ab-4cac-ba40-9bc0cee85c1d"
      unitRef="security">10</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTktMS0xLTE2NzkwOA_f59faa0d-da7d-4f76-b926-bc7099418ac5"
      unitRef="usd">40000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTExLTEtMS0xNjc5MDg_5a91a8b6-bf0d-4946-b4bf-8896ab52eab1"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTEzLTEtMS0xNjc5MDg_6a5f407b-6bee-462e-94df-5229e4d63d54"
      unitRef="security">53</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTE1LTEtMS0xNjc5MDg_f8b75004-4c03-4610-a1db-a681265da055"
      unitRef="usd">282000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i89f5f0dfc03c4227b89defd4fce33b30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE2LTE3LTEtMS0xNjc5MDg_a0a317a1-0924-45b9-83e8-d10865431223"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTEtMS0xLTE2NzkwOA_5a0ac97d-e1d7-4382-9512-c403c9b9fa5a"
      unitRef="security">233</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTMtMS0xLTE2NzkwOA_6c3eb8c6-2961-4ead-aac7-5f51f7b9cc95"
      unitRef="usd">428000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTUtMS0xLTE2NzkwOA_994473f6-7dd9-424e-a52e-4fb9c585be12"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTctMS0xLTE2NzkwOA_37fbad75-6797-4bdd-86d7-76f3185180e2"
      unitRef="security">13</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTktMS0xLTE2NzkwOA_7b346232-9f22-412c-9bf8-61cb951b546c"
      unitRef="usd">33000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTExLTEtMS0xNjc5MDg_c692d364-c375-4c61-bdf7-dbf44febfbcc"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTEzLTEtMS0xNjc5MDg_2914c60c-aa70-4652-82f4-04e8c5ba0513"
      unitRef="security">246</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTE1LTEtMS0xNjc5MDg_56e94630-0c2c-4498-bf8b-49564add30a7"
      unitRef="usd">461000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic05c780a2bb24c87b8bf8b72d7ef7abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE3LTE3LTEtMS0xNjc5MDg_f5e2d7dc-910b-41ac-98bf-4b62687aafd6"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTEtMS0xLTE2NzkwOA_9db09456-df20-4bf0-91b2-32e863adce76"
      unitRef="security">1610</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTMtMS0xLTE2NzkwOA_569d9427-2efa-4c34-b5ef-79dbdd2aedc5"
      unitRef="usd">2296000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTUtMS0xLTE2NzkwOA_f0f8ed17-ea14-468f-8d18-4a5162ec8ce6"
      unitRef="usd">31000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTctMS0xLTE2NzkwOA_1ffa11cf-0a4f-4b65-89da-d888d53fea7c"
      unitRef="security">165</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTktMS0xLTE2NzkwOA_a5a74ee0-2a72-4ea7-9b47-800a4a341232"
      unitRef="usd">238000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTExLTEtMS0xNjc5MDg_178de012-fe6d-40e2-a4a3-7dca0c5fabea"
      unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTEzLTEtMS0xNjc5MDg_d9e28f04-03d4-4d43-86d1-25f4ee83a875"
      unitRef="security">1775</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTE1LTEtMS0xNjc5MDg_bb6302b0-4531-4742-95d9-327e822e836c"
      unitRef="usd">2534000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iebb5cbe4055e401f982b3b48cbcfac13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE4LTE3LTEtMS0xNjc5MDg_869e442d-383d-49fe-b283-5ee80fb1cb7a"
      unitRef="usd">40000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTEtMS0xLTE2NzkwOA_2793a9d0-a13b-4f35-b72e-b22847903a7f"
      unitRef="security">449</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTMtMS0xLTE2NzkwOA_9b782b98-c62e-4ac5-9a38-dd8acc0b1091"
      unitRef="usd">747000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTUtMS0xLTE2NzkwOA_1016d53f-a4dc-4ca8-8aab-25428c283b51"
      unitRef="usd">20000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTctMS0xLTE2NzkwOA_98167bac-1130-42bd-92b5-092f2fdbe3f9"
      unitRef="security">57</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTktMS0xLTE2NzkwOA_d60ff4d9-93c2-4166-905b-eb3c6a41135c"
      unitRef="usd">91000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTExLTEtMS0xNjc5MDg_1ba423b4-0120-40cd-abf9-334161f8e46f"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTEzLTEtMS0xNjc5MDg_5295a940-21e0-4604-97c1-9f6507c27b7a"
      unitRef="security">506</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTE1LTEtMS0xNjc5MDg_30975ecd-d0f1-4ac9-a42e-fd05c41be672"
      unitRef="usd">838000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i99148b9bb5954a1c86c55a80ac65caed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzE5LTE3LTEtMS0xNjc5MDg_0fbfe70b-464b-4b4c-bb47-bca4ea0f8ec2"
      unitRef="usd">24000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTEtMS0xLTE2NzkwOA_1f6ca240-8ab3-4484-88f3-66fd5d2bdc6e"
      unitRef="security">165</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTMtMS0xLTE2NzkwOA_676f2f36-0fee-4b5d-ab65-d8746ddca179"
      unitRef="usd">593000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTUtMS0xLTE2NzkwOA_f45758e8-fce2-4b29-bc1a-b2f6086b047f"
      unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTctMS0xLTE2NzkwOA_330f90ac-41ec-4114-ba90-177b9651ed2f"
      unitRef="security">10</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTktMS0xLTE2NzkwOA_9806ddab-8d9a-4f3e-a175-74d04867cee4"
      unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTExLTEtMS0xNjc5MDg_c0422936-47c5-493a-8393-f90318a0bf1e"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTEzLTEtMS0xNjc5MDg_986b828a-f63f-4ae6-8f4f-eb9afa4e07c1"
      unitRef="security">175</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTE1LTEtMS0xNjc5MDg_b704f0b7-0e6b-469a-827f-d30a2d402f7b"
      unitRef="usd">629000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i221ef7845f854689af410277963cd5bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIwLTE3LTEtMS0xNjc5MDg_62352ac3-0342-4075-bf60-7b5122e60afd"
      unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTEtMS0xLTE2NzkwOA_cd84e5b1-32b0-488d-aa63-de1aeccc25e0"
      unitRef="security">188</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTMtMS0xLTE2NzkwOA_b6f42e17-ce59-400f-8b10-5ec7053b8b25"
      unitRef="usd">462000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTUtMS0xLTE2NzkwOA_90ba7b2d-fa35-4050-9e68-1ab589e92553"
      unitRef="usd">7000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTctMS0xLTE2NzkwOA_d3f799c2-8f3e-4da3-901f-c179a100e41e"
      unitRef="security">35</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTktMS0xLTE2NzkwOA_13f4bda8-9d18-46e2-a460-2dcc99fa8214"
      unitRef="usd">112000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTExLTEtMS0xNjc5MDg_3834e20b-d568-4e13-8c50-408418ffca4b"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTEzLTEtMS0xNjc5MDg_c6b3c69c-41ef-4f67-8dc9-fd5f83aa4e69"
      unitRef="security">223</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTE1LTEtMS0xNjc5MDg_6c6e03e3-5b20-45c3-9102-2ac9b3588385"
      unitRef="usd">574000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia6f9712c50cd4cdf9d5bbb7ce03c7087_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIxLTE3LTEtMS0xNjc5MDg_e69788c9-5a7c-4132-9654-60a1120c020e"
      unitRef="usd">12000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTEtMS0xLTE2NzkwOA_8076e96e-0661-480b-92d0-9f9f985ce106"
      unitRef="security">1011</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTMtMS0xLTE2NzkwOA_1daabca2-7206-4a15-b777-848096481260"
      unitRef="usd">2030000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTUtMS0xLTE2NzkwOA_b888e1b6-8e4e-4e01-8108-f99cad625538"
      unitRef="usd">12000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTctMS0xLTE2NzkwOA_341abcf5-30da-47e2-87fb-3f42c0946628"
      unitRef="security">26</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTktMS0xLTE2NzkwOA_44872f1d-ba15-46c3-9c19-e99c6177d54f"
      unitRef="usd">31000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTExLTEtMS0xNjc5MDg_a5df4d2e-8eac-4889-9c3f-aecca6d39b02"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTEzLTEtMS0xNjc5MDg_3dab3da6-4287-4549-8dc7-b0851bdbb6a2"
      unitRef="security">1037</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTE1LTEtMS0xNjc5MDg_5c6eae09-ab9b-4503-80ec-c3ea75346ec0"
      unitRef="usd">2061000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic8de7e486f7b414bb32dfafca43b2196_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIyLTE3LTEtMS0xNjc5MDg_0d065aec-65c7-4ac1-8676-32eee3f04b2c"
      unitRef="usd">13000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTEtMS0xLTE2NzkwOA_b56c5293-914f-4ba8-8236-659676b768a0"
      unitRef="security">1</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTMtMS0xLTE2NzkwOA_f2250a94-ba8f-491e-9a75-dcfa71a2aa9e"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTUtMS0xLTE2NzkwOA_8f9e4ea8-11f9-4f34-b235-69ee16550aae"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTctMS0xLTE2NzkwOA_95ba0410-0ea8-4f4f-a19a-c160095a9e06"
      unitRef="security">1</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTktMS0xLTE2NzkwOA_776fffd1-a6d2-489f-b7ac-20df225d8019"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTExLTEtMS0xNjc5MDg_2b6ca99a-2bce-4693-918e-137b24afe447"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTEzLTEtMS0xNjc5MDg_e56ebd0b-2878-4c69-a698-7e42c36ac17a"
      unitRef="security">2</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTE1LTEtMS0xNjc5MDg_8cfa26b8-dd2e-4afb-b331-ae42e11b3508"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i1f2ec623c034486c985ed3eedbbba076_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzIzLTE3LTEtMS0xNjc5MDg_5c57180e-a3d6-493a-9ed7-92e727434f33"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTEtMS0xLTE2NzkwOA_b50b1b2d-7e18-41f1-a97a-40e7a819c574"
      unitRef="security">3700</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTMtMS0xLTE2NzkwOA_a76d0c1b-7ee5-4fe4-b817-bc7c092f40dc"
      unitRef="usd">6800000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTUtMS0xLTE2NzkwOA_d3e3da55-41a6-4a30-90b7-81341881c08c"
      unitRef="usd">84000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTctMS0xLTE2NzkwOA_5c251bf7-b0b0-4fa5-b6d7-fc7322c3f6df"
      unitRef="security">317</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTktMS0xLTE2NzkwOA_a139714b-6156-4a5c-8c96-21457d55ee0c"
      unitRef="usd">584000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTExLTEtMS0xNjc5MDg_0ba5ab5c-9782-4430-9534-e61e8f9435ea"
      unitRef="usd">22000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTEzLTEtMS0xNjc5MDg_151cad92-c0f1-4059-b307-8f877ea2fe4f"
      unitRef="security">4017</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTE1LTEtMS0xNjc5MDg_c6b9b130-22c4-4959-9568-9edd53657966"
      unitRef="usd">7384000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTowODY1Nzg5ODljZDA0YTY0YjI2MGQ5ZWQ3YTg5YjFmZC90YWJsZXJhbmdlOjA4NjU3ODk4OWNkMDRhNjRiMjYwZDllZDdhODliMWZkXzI0LTE3LTEtMS0xNjc5MDg_f53de482-cce7-424c-9819-32ff90fe1fdd"
      unitRef="usd">106000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtMS0xLTEtMTY3OTA4_ed76415f-15e0-413d-8365-d447abe7811a"
      unitRef="usd">33000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtMy0xLTEtMTY3OTA4_d14b86d0-6234-469c-81c9-a6f0abf4e847"
      unitRef="usd">0</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtNS0xLTEtMTY3OTA4_edd1dd71-7679-45eb-8425-51591bfe69f1"
      unitRef="usd">1161000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtNy0xLTEtMTY3OTA4_390769ad-9682-48c4-9e49-aac2ede5f356"
      unitRef="usd">14000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtOS0xLTEtMTY3OTA4_c0d4e86f-4d28-46d3-aabc-f27a399d7ce3"
      unitRef="usd">1194000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzMtMTEtMS0xLTE2NzkwOA_5a6b4326-835d-4b2a-8913-73207fb434f8"
      unitRef="usd">14000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtMS0xLTEtMTY3OTA4_5423f6df-8789-4004-9a3f-acb506eec084"
      unitRef="usd">126000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtMy0xLTEtMTY3OTA4_425558ec-cdfe-4fd3-8c7a-d55fec223ccb"
      unitRef="usd">5000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtNS0xLTEtMTY3OTA4_c1a6e3c3-8c53-4352-b0a9-c7dab93143e4"
      unitRef="usd">5583000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtNy0xLTEtMTY3OTA4_ef26a1e9-3941-432f-89fd-f1cf4ff8bafe"
      unitRef="usd">398000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtOS0xLTEtMTY3OTA4_3397a800-f7b5-4ad7-a1d8-eea4ddfc86ca"
      unitRef="usd">5709000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzQtMTEtMS0xLTE2NzkwOA_7967c452-91d2-4937-89fb-57b2d421a4fa"
      unitRef="usd">403000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtMS0xLTEtMTY3OTA4_05601571-63bd-4d7f-8a1a-5bba155bc024"
      unitRef="usd">142000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtMy0xLTEtMTY3OTA4_8c385cda-5de0-443e-b040-6a1521f60904"
      unitRef="usd">17000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtNS0xLTEtMTY3OTA4_39380fe1-bdb4-412d-aab7-1228a71b4042"
      unitRef="usd">3787000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtNy0xLTEtMTY3OTA4_4c6aedc0-0f93-4db3-8743-b527cdedaef8"
      unitRef="usd">494000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtOS0xLTEtMTY3OTA4_bcb9d6cb-e333-42d1-b878-fe0bb44f2e1c"
      unitRef="usd">3929000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzUtMTEtMS0xLTE2NzkwOA_75beec4f-4e48-466a-b66c-5959c5f9da86"
      unitRef="usd">511000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtMS0xLTEtMTY3OTA4_a60d07ba-a99e-4ef5-a049-8eaba191f20a"
      unitRef="usd">207000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtMy0xLTEtMTY3OTA4_04f5b2f1-5299-403b-81ae-a48f3344935d"
      unitRef="usd">31000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtNS0xLTEtMTY3OTA4_fb820f46-d046-4612-b353-b19f791e74a2"
      unitRef="usd">3153000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtNy0xLTEtMTY3OTA4_23fcb20b-2354-4518-a8d8-854938d8d6eb"
      unitRef="usd">501000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtOS0xLTEtMTY3OTA4_0aad088d-1a5e-40a6-b316-f7e429a23808"
      unitRef="usd">3360000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzYtMTEtMS0xLTE2NzkwOA_dc4423f0-4981-4ed0-a9fa-5f0d9307c43e"
      unitRef="usd">532000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue
      contextRef="i40478cffecf64191b267758251c37050_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctMS0xLTEtMTY3OTA4_fc55cd2a-9094-43e0-a44f-2b01ba97b840"
      unitRef="usd">11000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss
      contextRef="i40478cffecf64191b267758251c37050_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctMy0xLTEtMTY3OTA4_a91e4e65-ceff-4f04-8336-ad2954fd7d36"
      unitRef="usd">1000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue
      contextRef="i1af20438bbb64d5f8b78df4ed91c4fcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctNS0xLTEtMTY3OTA4_fc6d6cac-5fea-47d3-bcf8-6c3ed2470628"
      unitRef="usd">710000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss
      contextRef="i1af20438bbb64d5f8b78df4ed91c4fcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctNy0xLTEtMTY3OTA4_e29fc90e-5515-4051-abfc-044ca75ac756"
      unitRef="usd">88000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctOS0xLTEtMTY3OTA4_f0130c59-a35c-4c0d-be95-90b7f8fa3bdd"
      unitRef="usd">721000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss
      contextRef="i9b200e63aac44dd6a20d4e917b3ee113_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzctMTEtMS0xLTE2NzkwOA_f73079f6-0679-4e8a-9371-c592547a4a87"
      unitRef="usd">89000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue
      contextRef="if7d14838d61d4f28a334a6fa3ae5859e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtMS0xLTEtMTY3OTA4_9233c667-bfb9-428c-a0ed-6d33d768d58a"
      unitRef="usd">32000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss
      contextRef="if7d14838d61d4f28a334a6fa3ae5859e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtMy0xLTEtMTY3OTA4_fd731755-ab00-4ef6-942c-902e10d4fb81"
      unitRef="usd">3000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue
      contextRef="ie3f4db8d8e9d486f9039b51a301eddcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtNS0xLTEtMTY3OTA4_05149d5a-79f5-4774-b749-6afaeb63eafd"
      unitRef="usd">960000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss
      contextRef="ie3f4db8d8e9d486f9039b51a301eddcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtNy0xLTEtMTY3OTA4_aec64ece-ccf2-4dda-934b-851f20879a32"
      unitRef="usd">152000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtOS0xLTEtMTY3OTA4_53924432-fdc4-4bc2-a8dd-94d538bf02a8"
      unitRef="usd">992000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss
      contextRef="ic2b50e93e4294e459e45a5d57d36fbff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzgtMTEtMS0xLTE2NzkwOA_b1840fe1-4878-4be3-8bd4-e3bf0fe1b9a0"
      unitRef="usd">155000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue
      contextRef="ibc1e6e162ae5412285a67bd88bbd3ed8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktMS0xLTEtMTY3OTA4_839d4089-b479-42f8-87d6-37bdff00ae76"
      unitRef="usd">17000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss
      contextRef="ibc1e6e162ae5412285a67bd88bbd3ed8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktMy0xLTEtMTY3OTA4_099c1c9a-ce2d-4536-8b24-88caf833b2ca"
      unitRef="usd">2000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue
      contextRef="i0bdd4738946f44c8961343c0e3d3fae3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktNS0xLTEtMTY3OTA4_1f1d68ae-197f-468b-8098-e8e9b4ccdf96"
      unitRef="usd">2570000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss
      contextRef="i0bdd4738946f44c8961343c0e3d3fae3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktNy0xLTEtMTY3OTA4_d4ad1e23-9a0b-4d76-9d9e-afe9fabcc725"
      unitRef="usd">134000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktOS0xLTEtMTY3OTA4_4f07ac87-6515-442c-8491-9374613d33cd"
      unitRef="usd">2587000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue>
    <cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss
      contextRef="if7308db8487343dab3c870126d9b4513_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzktMTEtMS0xLTE2NzkwOA_41a4ecd4-4122-44aa-a209-7984b90e0806"
      unitRef="usd">136000000</cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTEtMS0xLTE2NzkwOA_662b6135-b0d3-446a-bb26-6b86aac5f5c5"
      unitRef="usd">568000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i37c5cdb5daef4b928eb50715ec99cb07_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTMtMS0xLTE2NzkwOA_7b9f6dc0-2dd1-4a4d-8e02-6bedad880cfa"
      unitRef="usd">59000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTUtMS0xLTE2NzkwOA_02e2c52d-abbc-4a4c-94ac-490600a9d1a5"
      unitRef="usd">17924000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ie67471467f9945e5bba43415e678c6b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTctMS0xLTE2NzkwOA_84f4fd15-4f89-4374-bfab-71500830210f"
      unitRef="usd">1781000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTktMS0xLTE2NzkwOA_00333398-dd03-4715-a5fb-1f735853c5b0"
      unitRef="usd">18492000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4YzVjMzRhZDk1Mjg0YjNmYTk2OWRlYWUyNjRkYjA1My90YWJsZXJhbmdlOjhjNWMzNGFkOTUyODRiM2ZhOTY5ZGVhZTI2NGRiMDUzXzEwLTExLTEtMS0xNjc5MDg_07174f36-7431-48b3-8400-e51eb3ce3fb2"
      unitRef="usd">1840000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <cvs:ActivityInMortgageLoanPortfolioTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MTI_636ea122-7cef-4ac1-8068-c315b16f7b12">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s mortgage loans are collateralized by commercial real estate.&#160;During the years ended December 31, 2022 and 2021, the Company had the following activity in its mortgage loan portfolio:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans fully repaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans foreclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 scheduled mortgage loan principal repayments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cvs:ActivityInMortgageLoanPortfolioTableTextBlock>
    <us-gaap:MortgageLoansOnRealEstateNewMortgageLoans
      contextRef="iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzEtMS0xLTEtMTY3OTA4_79c804d7-b312-46c6-b0f1-7518f995945d"
      unitRef="usd">356000000</us-gaap:MortgageLoansOnRealEstateNewMortgageLoans>
    <us-gaap:MortgageLoansOnRealEstateNewMortgageLoans
      contextRef="i0fcec899c0a848d4b4ebc10f773df4c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzEtMy0xLTEtMTY3OTA4_9e0551c1-fd41-431a-be20-8b3fe2bc2ac8"
      unitRef="usd">262000000</us-gaap:MortgageLoansOnRealEstateNewMortgageLoans>
    <cvs:MortgageLoansOnRealEstateLoansFullyRepaid
      contextRef="iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzItMS0xLTEtMTY3OTA4_42772320-624f-4664-935f-261876d69e88"
      unitRef="usd">178000000</cvs:MortgageLoansOnRealEstateLoansFullyRepaid>
    <cvs:MortgageLoansOnRealEstateLoansFullyRepaid
      contextRef="i0fcec899c0a848d4b4ebc10f773df4c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzItMy0xLTEtMTY3OTA4_6a6ad660-ba4a-48f6-b599-22e0b59fdc2b"
      unitRef="usd">373000000</cvs:MortgageLoansOnRealEstateLoansFullyRepaid>
    <us-gaap:MortgageLoansOnRealEstateForeclosures
      contextRef="iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzMtMS0xLTEtMTY3OTA4_7aa67540-7450-448d-9194-78f5f1786643"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstateForeclosures>
    <us-gaap:MortgageLoansOnRealEstateForeclosures
      contextRef="i0fcec899c0a848d4b4ebc10f773df4c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTpmN2JiMGE2ZGY3MmY0Y2NiOWVjZjJjMDlmOTkyZTdhMy90YWJsZXJhbmdlOmY3YmIwYTZkZjcyZjRjY2I5ZWNmMmMwOWY5OTJlN2EzXzMtMy0xLTEtMTY3OTA4_ceb35c44-1479-4f89-afc3-b0ce8a4c3599"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstateForeclosures>
    <cvs:ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MTE_834c1f24-6b42-43ec-940f-0190a1c2779c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon the Company&#x2019;s assessments at December&#160;31, 2022 and 2021, the amortized cost basis of the Company&#x2019;s mortgage loans within each credit quality indicator by year of origination was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost Basis by Year of Origination&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions, except credit quality indicator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 and 6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 and 6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cvs:ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i3c5943b5b1904c6b846ccf841c464d39_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtMS0xLTEtMTY3OTA4_e0ee791d-ac1c-46e4-b5d6-72b954857beb"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="iecece3fcd8be4303aa5cbc5c092cf500_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtMy0xLTEtMTY3OTA4_67233128-180f-4b00-b68e-c8bc29dd63da"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i9bb3635c7aa14bb79761106ea93cc68a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtNS0xLTEtMTY3OTA4_a8728e34-c418-4ec0-8be0-5e7e178271e9"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ia7f8117025154ef69cad75e991abfff1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtNy0xLTEtMTY3OTA4_13ea6a01-cef7-4fa8-a8b9-c8349711d608"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i0458817c19b448f08f9c914f63356b8a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtOS0xLTEtMTY3OTA4_4370403b-c2bc-4ffd-853d-8d26c5d0bedb"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="iebda2282c15f4559817dfaba4fdac117_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtMTEtMS0xLTE2NzkwOA_ca822b50-5c14-4658-8a96-117b4baa7a25"
      unitRef="usd">15000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ifed8619550174d168c4c4cd42b101642_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzMtMTMtMS0xLTE2NzkwOA_906a9998-8e79-463a-ba86-e6a99de7f53d"
      unitRef="usd">15000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ibd7eba7b3fa241f3aeeb456afa8bdd4e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtMS0xLTEtMTY3OTA4_74826400-f7b8-4c21-bddb-101da21a3cd8"
      unitRef="usd">326000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i76ce9ddcb63246efb0e31193bee2ff73_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtMy0xLTEtMTY3OTA4_cd04e844-bd1c-4388-9127-6f348aba0afc"
      unitRef="usd">247000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ia44809c2621249a5ae15e084e9a2de19_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtNS0xLTEtMTY3OTA4_4784594c-5150-4e00-be0e-f9823517b70e"
      unitRef="usd">36000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="iadc19163e572465e81ae33a610b8f94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtNy0xLTEtMTY3OTA4_1c78d767-fbea-458d-a72a-385791bd826b"
      unitRef="usd">11000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i6de4c16e901d4eccb8965e3fae43dcc6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtOS0xLTEtMTY3OTA4_80fc49ec-48e9-4768-99da-a6e16e8134fc"
      unitRef="usd">52000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i828b576776fe424bae9270ea200522e2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtMTEtMS0xLTE2NzkwOA_9459ebd1-902a-4dfc-95fc-57276b13e7bf"
      unitRef="usd">350000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="id756e63e2e754f359f0f9ae581e0a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzQtMTMtMS0xLTE2NzkwOA_07636a73-2bb1-4dd0-82ae-15c46e1d29cc"
      unitRef="usd">1022000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i360bfd4546d74642b59856ededd82514_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtMS0xLTEtMTY3OTA4_0088953d-0d0f-482a-b8bb-3a5ed7c71089"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i1fbbf77e09bd41508b2178ad8c2442bb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtMy0xLTEtMTY3OTA4_49af8ead-277e-495d-bc72-172c623fbceb"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i7ec7149199d0463a92cc968f65f45f43_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtNS0xLTEtMTY3OTA4_45821f3b-e43b-4837-9829-c2475921bad2"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ibf9ff2cb5e224b209b049e6f94fc2d50_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtNy0xLTEtMTY3OTA4_db7f999a-4045-406c-aa58-e27989b99d9d"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="id3fc6e014927402abca82128c1ddf524_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtOS0xLTEtMTY3OTA4_69d339cb-5ce8-408f-af9f-d6cbe60ebf00"
      unitRef="usd">3000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i2597e031daaa40e6a6ec272f1341abcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtMTEtMS0xLTE2NzkwOA_0484fdf0-73a6-41d6-a148-2e727a485c44"
      unitRef="usd">4000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i38c112ce5a634675b6bdc212a46b02b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzUtMTMtMS0xLTE2NzkwOA_3924fd1f-3a6c-49b9-ae3e-b459e71f1f29"
      unitRef="usd">7000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ief6f2a4d7a5a4af9a3d311013668f24f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtMS0xLTEtMTY3OTA4_9e51e251-a000-4550-8486-d45c4858c321"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i72bbda77b88f4cdd9fb87a318a29fedc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtMy0xLTEtMTY3OTA4_74438232-6ff5-44d4-983d-0d8cc13cbb90"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ia294054d10ac417787c1944ee543fe6c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtNS0xLTEtMTY3OTA4_2aad16bd-c3a5-4ef7-a890-151edb04640d"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i6beca7e4f8864e93aeba97040d6f5a37_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtNy0xLTEtMTY3OTA4_78a80ed1-5fad-4d70-8b27-88ccd5079328"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i97612fc3a2f44d73bb819a717d41d0a3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtOS0xLTEtMTY3OTA4_1e7633ec-840f-43d8-b9ab-25b78a8b38d6"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="if14f3e4b96e04557911ee9a9b62f5e0f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtMTEtMS0xLTE2NzkwOA_57b0826b-c2a6-496a-90f4-579a7cd98162"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i52a9138a58c84726a45e23bb6e6167e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzYtMTMtMS0xLTE2NzkwOA_e80adeb6-4eb0-4098-b7fc-3459ed70a2b0"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ia570fc5031314098910825a767b2b0cc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctMS0xLTEtMTY3OTA4_585a24c9-1a1f-4e4f-96b9-7fdd4a206f10"
      unitRef="usd">326000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="iea6ac9f0b5a5421dbc9cb6e72f8396d7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctMy0xLTEtMTY3OTA4_a9b6105d-066e-45a4-bce2-ea39cc76b550"
      unitRef="usd">247000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i707228ea268b4fa1b8fc7634fc9a941f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctNS0xLTEtMTY3OTA4_9f1eb0a1-7998-484a-a9d6-e446c3fe66e7"
      unitRef="usd">36000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i1d7e7b8abcda4b75a158f71a15390c9f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctNy0xLTEtMTY3OTA4_5bd80ea1-48c7-4e06-8f9a-35766213249d"
      unitRef="usd">11000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i588aad1d73dc43329473d13fcb268e7c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctOS0xLTEtMTY3OTA4_5ca70603-c37f-4292-9494-e8d773f85159"
      unitRef="usd">55000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i18d1acd38b204e20a8c2a44bb0f10148_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctMTEtMS0xLTE2NzkwOA_7d6d6685-ea04-4d70-ab47-57cce2a2eb7e"
      unitRef="usd">369000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzctMTMtMS0xLTE2NzkwOA_d93b60c0-ab9c-4021-95c5-daee7b5a8161"
      unitRef="usd">1044000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i3808d834e07e4b3b9e287f3834d21fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTMtMS0xLTE2NzkwOA_a0880258-3b1a-44c8-b5cb-79d1d68fcd0e"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ic5e10c1576ee434cbb42319cd9c8ab0d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTUtMS0xLTE2NzkwOA_f903b498-5405-42be-b70c-665e3b681266"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ifc6e024d3cf14d86a2923481e9e6e304_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTctMS0xLTE2NzkwOA_ccc3e7eb-1d7c-4c57-b893-9124d68c4c76"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ia44ab5a60f90433cbd73992a1d0566db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTktMS0xLTE2NzkwOA_6f7c945b-f7b7-4886-b20b-4c17b49cd2b6"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="id4f2cc1ce7924cb5bfc1eed1de05f7bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTExLTEtMS0xNjc5MDg_b7698c1d-0677-4afc-a328-00eeee0ada5e"
      unitRef="usd">28000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ib19d3a4e66794458812e357f78f43e74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEwLTEzLTEtMS0xNjc5MDg_bebfeefa-7630-40b7-ae5d-dcba5178a14a"
      unitRef="usd">28000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i34a5f10b00974911867bfe65ff417616_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTMtMS0xLTE2NzkwOA_3239d9bd-89f9-4fd3-a52e-6514e7f1a960"
      unitRef="usd">255000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i516ca7a24b4e45d98df8d70dc8459538_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTUtMS0xLTE2NzkwOA_edfeab85-2f7a-41aa-bfa6-40da16d9a333"
      unitRef="usd">48000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ife8c11020a34479a954004c76070a1b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTctMS0xLTE2NzkwOA_f208bc1d-a254-485c-9714-106550ab4e43"
      unitRef="usd">40000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i2c568b1356424e30b16ba09859cf6b43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTktMS0xLTE2NzkwOA_094d8257-6442-42bc-8586-1ee0098b9b74"
      unitRef="usd">72000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i5f9b7af276014284bf1cbe79e6f1d940_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTExLTEtMS0xNjc5MDg_eb80b65c-b1d7-41d4-aba9-18a70895db3f"
      unitRef="usd">446000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="idfda10eea1e946608a7bbd50cf284c24_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzExLTEzLTEtMS0xNjc5MDg_35d7ec3f-9e6e-4991-bee6-4bebc9229129"
      unitRef="usd">861000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i90857bdf1da64bc0b9e9cb8b2c306c07_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTMtMS0xLTE2NzkwOA_9093d4ca-92ca-446d-baa9-c7504662ba19"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ie54c71d8deb84041b2ac5c9187940c7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTUtMS0xLTE2NzkwOA_9eaca4d4-aea0-43e5-9891-540568c6f275"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i4854a804064145bf94625cb963eff0eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTctMS0xLTE2NzkwOA_1e7ca881-c788-4368-9c8f-ee85c1941572"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i9c97f2c2663d47269fef701393c390f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTktMS0xLTE2NzkwOA_a0c1e925-d5a5-4ebf-8242-ab58b34d3364"
      unitRef="usd">3000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i53ebaa434a774f55944633b91503f6aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTExLTEtMS0xNjc5MDg_9ccd83ff-bd4c-4d25-95e1-b82c95e36f0c"
      unitRef="usd">10000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ice10fbdb03344142bf872d80c624c2ba_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEyLTEzLTEtMS0xNjc5MDg_093b9284-5bfa-42ce-8f27-3ebf7f2d2dfc"
      unitRef="usd">13000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i44b39b49a3b54b80924c011dd5d61684_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTMtMS0xLTE2NzkwOA_9f0d945b-bf76-4993-97ef-3ba565557ebe"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i08b6ec53ccf44d16bb1cf7ea10345d8f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTUtMS0xLTE2NzkwOA_b1758c6d-533d-4bd5-994e-c6a59bbf0344"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i04ba64ca88a842a8b016d348b2518392_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTctMS0xLTE2NzkwOA_2f86c2bc-59e2-473d-9347-6d9dcec98f99"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="id76d3139b44e495aa8b5d3c2e3fe365d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTktMS0xLTE2NzkwOA_16f423cb-dc5a-41b7-ae50-cc9d242fb835"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i7f39590e349c47e1b6655543883e658d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTExLTEtMS0xNjc5MDg_1228cf4a-4463-4dc8-86c8-59f82dea0f31"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i4503868833d04c6e92dd980faabe8e9d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzEzLTEzLTEtMS0xNjc5MDg_1226b48a-b47a-44b8-a4df-ddcfdb1e2054"
      unitRef="usd">0</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i9b22cfb2e4fb49ef994eb2fe50637d3e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTMtMS0xLTE2NzkwOA_f1895522-aad1-4453-b2fe-c6e642df50fe"
      unitRef="usd">255000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i1b6f5d37438e4e24adc486dfc220e330_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTUtMS0xLTE2NzkwOA_330d8057-15b9-4759-be1c-6ba471b6491e"
      unitRef="usd">48000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i75817f6d10a64edb95908711e7b84a5f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTctMS0xLTE2NzkwOA_32dc6442-c50d-4ed5-a6dd-44e64fb25273"
      unitRef="usd">40000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="ibd337cc2997f4c9a8bf96e1b1038b176_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTktMS0xLTE2NzkwOA_c87c3c86-2945-47c5-a6cf-1eaf3ba55369"
      unitRef="usd">75000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="if3f411adda394690a887804f07c4085b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTExLTEtMS0xNjc5MDg_494e749e-7841-4981-8f60-3a199fae4ffb"
      unitRef="usd">484000000</us-gaap:MortgageLoansOnRealEstate>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i12a1e132dac44a7aa77f7b5045148074_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZToyNTQyZDZiZjk2NTQ0NGVmOTcxZDI5NTYyMzNmMTU5Mi90YWJsZXJhbmdlOjI1NDJkNmJmOTY1NDQ0ZWY5NzFkMjk1NjIzM2YxNTkyXzE0LTEzLTEtMS0xNjc5MDg_397eca72-0d3a-407c-95ad-105f62beaed7"
      unitRef="usd">902000000</us-gaap:MortgageLoansOnRealEstate>
    <cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths
      contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzEtMS0xLTEtMTY3OTA4_1dbb980e-4d22-454c-b299-342cb8cdd7ac"
      unitRef="usd">55000000</cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths>
    <cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo
      contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzItMS0xLTEtMTY3OTA4_ac0c6fad-b957-46eb-acb8-82385f124828"
      unitRef="usd">152000000</cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo>
    <cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree
      contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzMtMS0xLTEtMTY3OTA4_2f70c66c-d34c-473b-adbe-1f48fa464bef"
      unitRef="usd">90000000</cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree>
    <cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour
      contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzQtMS0xLTEtMTY3OTA4_b7cc1ed1-a32a-4547-b89e-05f9b45d8acb"
      unitRef="usd">168000000</cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour>
    <cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive
      contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzUtMS0xLTEtMTY3OTA4_b60fca18-9126-4cc3-9edc-65674644cc85"
      unitRef="usd">203000000</cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive>
    <cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive
      contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzYtMS0xLTEtMTY3OTA4_5f2b2da5-d02a-4969-8a69-37cbde9dc5c9"
      unitRef="usd">376000000</cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive>
    <us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet
      contextRef="ibf70115e4b0543e3a96629490f5ae0dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTphYjY2OGJiMzJiZGQ0NWU5ODUzYjFlMzI2NzM1Mzk4OC90YWJsZXJhbmdlOmFiNjY4YmIzMmJkZDQ1ZTk4NTNiMWUzMjY3MzUzOTg4XzctMS0xLTEtMTY3OTA4_663ec625-ad28-48ad-8031-db0626df6194"
      unitRef="usd">1044000000</us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet>
    <us-gaap:InvestmentIncomeTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4Mjg_513a97ae-ccef-43ee-9896-0576d543abd8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sources of net investment income for the years ended December 31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income (excluding net realized capital gains or losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized capital gains (losses) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Net realized capital losses include credit-related losses on debt securities of $13 million and yield-related impairment losses on debt securities of $143 million in the year ended December 31, 2022. Net realized capital gains are net of yield-related impairment losses on debt securities of $42 million and $49 million for the years ended December 31, 2021 and 2020, respectively. There were no credit-related losses on debt securities in the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;(2)Net investment income includes $35 million, $38 million and $42 million for the years ended December 31, 2022, 2021 and 2020, respectively, related to investments supporting experience-rated products.</us-gaap:InvestmentIncomeTextBlock>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i7e80630b4afd497383aa2e7e0825756f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzEtMS0xLTEtMTY3OTA4_a56c06e1-1af5-4b4c-b1bf-f7ff593441c8"
      unitRef="usd">702000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i9b0b007394094a3a81527483fd8a8975_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzEtMy0xLTEtMTY3OTA4_a84599a3-61c5-4900-8159-c96aaf0cab70"
      unitRef="usd">634000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i548886065c29409da2eebb0e5740162b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzEtNS0xLTEtMTY3OTA4_e267dd9f-f2cb-4cbd-8afb-8fa4b26c6be0"
      unitRef="usd">598000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="ie285042dfe4440d68f48b4adebe96861_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzItMS0xLTEtMTY3OTA4_b3dbc7c6-b818-428a-8112-4f929eb83d74"
      unitRef="usd">51000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i5b9bf6c2c8e24bf0a220cd7210ee97fc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzItMy0xLTEtMTY3OTA4_2269a106-819b-4203-8140-0a472aab7f76"
      unitRef="usd">55000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="ide0bc2b4239f48e1a3a714d4cc3d7203_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzItNS0xLTEtMTY3OTA4_8b13e37a-bbb9-4ecf-84ed-8465c6ef4394"
      unitRef="usd">60000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i313f0ade641941b4a6bef1dd870a48da_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzMtMS0xLTEtMTY3OTA4_9e52935a-e854-4c91-a96f-9f3c5b6ab1c0"
      unitRef="usd">448000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i74585cf162b14135ad3471e993c71df9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzMtMy0xLTEtMTY3OTA4_8032cd23-728c-4dcc-9db4-adb0332dab04"
      unitRef="usd">381000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i20751ec3912a4de2a34e1c394c86a641_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzMtNS0xLTEtMTY3OTA4_7ff4c2de-141c-4cfd-b710-28658716463d"
      unitRef="usd">123000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzQtMS0xLTEtMTY3OTA4_ab0a5b2a-7c41-4f53-91c4-eeb83d962356"
      unitRef="usd">1201000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzQtMy0xLTEtMTY3OTA4_5b22b8b8-d9db-4d1c-a12e-47dfb2250d8f"
      unitRef="usd">1070000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzQtNS0xLTEtMTY3OTA4_4ff59ac2-3e73-4f12-aa3f-4d3fdf59cb02"
      unitRef="usd">781000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzUtMS0xLTEtMTY3OTA4_1178b9df-2ef6-4a49-b030-8df835af4435"
      unitRef="usd">43000000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzUtMy0xLTEtMTY3OTA4_eb4d55ce-a4f3-40bf-ab84-66477120a37e"
      unitRef="usd">47000000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzUtNS0xLTEtMTY3OTA4_cb2b8528-9882-4091-a286-2a6b171549a1"
      unitRef="usd">35000000</us-gaap:InvestmentIncomeInvestmentExpense>
    <cvs:InvestmentIncomeExcludingCapitalGainsOrLosses
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzYtMS0xLTEtMTY3OTA4_31180e0d-d3f4-45df-a8fc-0ac258e0aa88"
      unitRef="usd">1158000000</cvs:InvestmentIncomeExcludingCapitalGainsOrLosses>
    <cvs:InvestmentIncomeExcludingCapitalGainsOrLosses
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzYtMy0xLTEtMTY3OTA4_7ae5c35a-c542-46fe-98b7-63188314d5ee"
      unitRef="usd">1023000000</cvs:InvestmentIncomeExcludingCapitalGainsOrLosses>
    <cvs:InvestmentIncomeExcludingCapitalGainsOrLosses
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzYtNS0xLTEtMTY3OTA4_0f68e911-2849-421e-995e-40e2d09339d5"
      unitRef="usd">746000000</cvs:InvestmentIncomeExcludingCapitalGainsOrLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzctMS0xLTEtMTY3OTA4_8afe3a92-8398-4cbb-824e-00a36f9cebb7"
      unitRef="usd">-320000000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzctMy0xLTEtMTY3OTA4_196f9bb3-066a-486e-a62a-e89e63c0dd1d"
      unitRef="usd">176000000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzctNS0xLTEtMTY3OTA4_69fea21c-b173-41d2-b7fb-16c581ff6bab"
      unitRef="usd">52000000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:InvestmentIncomeNet
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzgtMS0xLTEtMTY3OTA4_bef3ec70-a321-4c92-8590-19af9ae9dcfc"
      unitRef="usd">838000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzgtMy0xLTEtMTY3OTA4_e3a6350d-5c23-42c3-b1db-6dc3dab4acec"
      unitRef="usd">1199000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo0NjAxNWU2ZjJmM2E0NzE0OWIxMjEzYWI5NzgyOGVmOS90YWJsZXJhbmdlOjQ2MDE1ZTZmMmYzYTQ3MTQ5YjEyMTNhYjk3ODI4ZWY5XzgtNS0xLTEtMTY3OTA4_f510d7db-cf09-4592-b29a-d9f43796c5d4"
      unitRef="usd">798000000</us-gaap:InvestmentIncomeNet>
    <cvs:CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzI3NDg3NzkwODIwNDM_ead5ffb5-c384-4e6e-bdd1-01fc69fe5637"
      unitRef="usd">13000000</cvs:CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <cvs:YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzI3NDg3NzkwODIwNjA_f0f50c15-2369-4eb2-be2b-a23478d16f43"
      unitRef="usd">143000000</cvs:YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <cvs:YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzU0OTc1NTgyNTMzOA_31938dfc-6302-4dca-98e7-1b3d65a69ce4"
      unitRef="usd">42000000</cvs:YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <cvs:YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzU0OTc1NTgyNTM1NQ_df8555e4-9b42-41ac-8b6e-fb59c188800e"
      unitRef="usd">49000000</cvs:YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <cvs:CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzgyNDYzMzcyMjA5NDk_2439273e-300d-43ba-b716-272c280bf612"
      unitRef="usd">0</cvs:CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <cvs:CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzgyNDYzMzcyMjA5NDk_d0716621-5e81-455a-8ad7-a19f97140b3e"
      unitRef="usd">0</cvs:CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:InvestmentIncomeNet
      contextRef="iaf5fc81ab5334092a75354e9e0cedebb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzYyNTk_a6b32b5c-42ed-49ad-b84f-467a1b94387a"
      unitRef="usd">35000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i4c9389120bf34657b8225887b8754f61_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzYyNjM_a890c261-d165-4739-8acf-ed6c9e93319d"
      unitRef="usd">38000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i1333c10377854683a2d760e2dc527ff2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzYyNzA_dba32b45-56d4-47c2-b314-0c4dbf96483e"
      unitRef="usd">42000000</us-gaap:InvestmentIncomeNet>
    <cvs:ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90ZXh0cmVnaW9uOjlhOTk4NjE2NDFmNDRhNzhhNTQyY2FmNTc1NmQ5YTlkXzY4MzA_343b2378-148f-47e7-8d58-93e1b0eec8c4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized capital gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross realized capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cvs:ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzEtMS0xLTEtMTY3OTA4_d460bece-c22b-449d-b4c6-aa6a595afae1"
      unitRef="usd">4243000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzEtMy0xLTEtMTY3OTA4_a4991bb3-ddcd-4853-9e9d-6d946fcfaad2"
      unitRef="usd">3572000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzEtNS0xLTEtMTY3OTA4_516299a0-14c3-4690-8c07-69ac14772d2e"
      unitRef="usd">3913000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzItMS0xLTEtMTY3OTA4_dae5c93b-e4e3-4a07-9a68-92a1c228d9d6"
      unitRef="usd">24000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzItMy0xLTEtMTY3OTA4_a4150e2e-17c7-43b2-9870-b79372f573b5"
      unitRef="usd">72000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzItNS0xLTEtMTY3OTA4_19f1ca6e-a592-492f-a46c-62c98b90de7d"
      unitRef="usd">80000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzMtMS0xLTEtMTY3OTA4_a5fac807-5f6a-4d49-bb4a-05bcc95fd60f"
      unitRef="usd">177000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzMtMy0xLTEtMTY3OTA4_1453c8f1-3d8c-4f21-8ea3-b0dac37f78eb"
      unitRef="usd">14000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMjcvZnJhZzo5YTk5ODYxNjQxZjQ0YTc4YTU0MmNhZjU3NTZkOWE5ZC90YWJsZTo4OTc1MTNlZTRiYTU0MWY5OTMxMWFjM2JiMGFiN2ExYy90YWJsZXJhbmdlOjg5NzUxM2VlNGJhNTQxZjk5MzExYWMzYmIwYWI3YTFjXzMtNS0xLTEtMTY3OTA4_19620041-8351-4f49-89da-fac28fe0cf2d"
      unitRef="usd">62000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjI2_07b68a6e-be83-45b3-97ae-53a3ec9ac56c">Fair Value&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s consolidated financial statements requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis.&#160;In this note, the Company provides details on the fair value of financial assets and liabilities and how it determines those fair values.&#160;The Company presents this information for those financial instruments that are measured at fair value for which the change in fair value impacts net income attributable to CVS Health or other comprehensive income (loss) separately from other financial assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Instruments Measured at Fair Value on the Consolidated Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value on the consolidated balance sheets.&#160;The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by GAAP.&#160;The following are the levels of the hierarchy and a brief description of the type of valuation information (&#x201c;valuation inputs&#x201d;) that qualifies a financial asset or liability for each level:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Unadjusted quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Valuation inputs other than Level 1 that are based on observable market data.&#160;These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, valuation inputs that are observable that are not prices (such as interest rates and credit risks) and valuation inputs that are derived from or corroborated by observable markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Developed from unobservable data, reflecting the Company&#x2019;s assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation.&#160;When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities in Level 1.&#160;In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model.&#160;These financial assets and liabilities are classified in Level 2.&#160;If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment&#x2019;s financial performance and cash flow projections.&#160;Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a description of the valuation methodologies used for the Company&#x2019;s financial assets and liabilities that are measured at fair value, including the general classification of such assets and liabilities pursuant to the valuation hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. When quoted prices are available in an active market, cash equivalents are classified in Level 1 of the fair value hierarchy. Fair values of cash equivalent instruments that do not trade on a regular basis in active markets are classified as Level 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Where quoted prices are available in an active market, debt securities are classified in Level 1 of the fair value hierarchy.&#160;The Company&#x2019;s&#160;Level 1 debt securities consist primarily of U.S. Treasury securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s Level 2 debt securities are obtained using models, such as matrix pricing, which use quoted market prices of debt securities with similar characteristics or discounted cash flows to estimate fair value. The &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company reviews these prices to ensure they are based on observable market inputs that include quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets and inputs that are observable that are not prices (such as interest rates and credit risks). The Company also reviews the methodologies and the assumptions used to calculate prices from these observable inputs. On a quarterly basis, the Company selects a sample of its Level 2 debt securities&#x2019; prices and compares them to prices provided by a secondary source. Variances over a specified threshold are identified and reviewed to confirm the price provided by the primary source represents an appropriate estimate of fair value. In addition, the Company&#x2019;s internal investment team consistently compares the prices obtained for select Level 2 debt securities to the team&#x2019;s own independent estimates of fair value for those securities.&#160;The Company obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December&#160;31, 2022 or 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also values certain debt securities using Level 3 inputs.&#160;For Level 3 debt securities, fair values are determined by outside brokers or, in the case of certain private placement securities, are priced internally.&#160;Outside brokers determine the value of these debt securities through a combination of their knowledge of the current pricing environment and market flows.&#160;The Company did not have any broker quoted debt securities for the years ended December&#160;31, 2022 and 2021. For some private placement securities, the Company&#x2019;s internal staff determines the value of these debt securities by analyzing spreads of corporate and sector indices as well as interest spreads of comparable public bonds.&#160;Examples of these private placement Level 3 debt securities include certain U.S. and foreign securities and certain tax-exempt municipal securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company currently has two classifications of equity securities:&#160;those that are publicly traded and those that are privately placed.&#160;Publicly-traded equity securities are classified in Level 1 because quoted prices are available for these securities in an active market.&#160;For privately placed equity securities, there is no active market; therefore, these securities are classified in Level 3 because the Company prices these securities through an internal analysis of each investment&#x2019;s financial statements and cash flow projections. Significant unobservable inputs consist of earnings and revenue multiples, discount for lack of marketability and comparability adjustments. An increase or decrease in any of these unobservable inputs would have resulted in a change in the fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no financial liabilities measured at fair value on a recurring basis on the consolidated balance sheets at December&#160;31, 2022 or 2021. Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes cash and cash equivalents of $6&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;States, &lt;br/&gt;municipalities&lt;br/&gt;&#160;and political &lt;br/&gt;subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S.&lt;br/&gt;corporate&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other asset-&lt;br/&gt;backed&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized and unrealized capital losses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in earnings&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in net unrealized capital losses included in other comprehensive loss associated with Level 3 financial assets which were held as of December&#160;31, 2022 was $9 million during the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;States, &lt;br/&gt;municipalities&lt;br/&gt;&#160;and political &lt;br/&gt;subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S.&lt;br/&gt;corporate&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other asset-&lt;br/&gt;backed&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Redeemable&lt;br/&gt;preferred&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized and unrealized capital gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in net unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December&#160;31, 2021 was $4&#160;million during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total gross transfers into (out of) Level 3 during the years ended December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net transfers into (out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Instruments Not Measured at Fair Value on the Consolidated Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;With a fixed maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Without a fixed maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;With a fixed maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Without a fixed maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 &#x2018;&#x2018;Significant Accounting Policies&#x2019;&#x2019; for additional information regarding the valuation of cost method investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes long-term debt of $3&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separate Accounts Measured at Fair Value on the Consolidated Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separate Accounts assets relate to the Company&#x2019;s large case pensions products which represent funds maintained to meet specific objectives of contract holders.&#160;Since contract holders bear the investment risk of these assets, a corresponding Separate Accounts liability has been established equal to the assets.&#160;These assets and liabilities are carried at fair value.&#160;Net investment income and capital gains and losses on Separate Accounts assets accrue directly to such contract holders.&#160;The assets of each account are legally segregated and are not subject to claims arising from the Company&#x2019;s other businesses.&#160;Deposits, withdrawals, net investment income and realized and unrealized capital gains and losses on Separate Accounts assets are not reflected in the consolidated statements of operations, shareholders&#x2019; equity or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separate Accounts assets include debt and equity securities.&#160;The valuation methodologies used for these assets are similar to the methodologies described above in this Note 4 &#x2018;&#x2018;Fair Value.&#x2019;&#x2019;&#160;Separate Accounts assets also include investments in common/collective trusts that are carried at fair value. Common/collective trusts invest in other investment funds otherwise known as the underlying funds. The Separate Accounts&#x2019; interests in the common/collective trust funds are based on the fair values of the investments of the underlying funds and therefore are classified in Level 2. The assets in the underlying funds primarily consist of equity securities. Investments in common/collective trust funds are valued at their respective net asset value (&#x201c;NAV&#x201d;) per share/unit on the valuation date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separate Accounts financial assets at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common/collective trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Excludes $85 million of other payables and $70&#160;million of other receivables at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2022 and 2021, the Company had no gross transfers of Separate Accounts financial assets into or out of Level 3.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzY3MjE_68f5095f-fcde-4aa9-aa35-f9559c0f82e0"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzY3MjE_87de695b-1373-4865-b29c-929b57064d78"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjI3_f4f9db63-18f2-4448-b1b3-3cf40075be4a">Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December&#160;31, 2022 and 2021 were as follows:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes cash and cash equivalents of $6&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzItMS0xLTEtMTY3OTA4_61362b7c-fb93-4f7c-88bb-f49404962f41"
      unitRef="usd">6902000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibc0c69d485444837bbae724a028fb845_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzItMy0xLTEtMTY3OTA4_dd9fe26e-d20c-4e64-8883-63e1027cf89b"
      unitRef="usd">6049000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzItNS0xLTEtMTY3OTA4_08a84284-fc80-4b5e-8596-379f87c7d973"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzItNy0xLTEtMTY3OTA4_04f2fdba-6f4f-4e1a-8818-7d134c84ec6b"
      unitRef="usd">12951000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88708d7db67144f6b9034fc9b683ea9e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzQtMS0xLTEtMTY3OTA4_a8414798-a40f-487c-8c5d-a49e185b9b01"
      unitRef="usd">1860000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0a49e1f8ed54cc797d186700b9962e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzQtMy0xLTEtMTY3OTA4_820437e9-969f-4b63-931e-187a12344265"
      unitRef="usd">32000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic83971584eb546e2ac5fdc1e7bc8e84b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzQtNS0xLTEtMTY3OTA4_d68d31ad-33a4-4e78-8923-e672a328c98b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice45b349609443519e8d645943421f9c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzQtNy0xLTEtMTY3OTA4_174d44b2-eb62-422d-9058-352512d937a8"
      unitRef="usd">1892000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a23915f279344c1bf1087035f0fdf12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzUtMS0xLTEtMTY3OTA4_55e9af35-ed64-4f31-add5-c319f96d5b7c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5c2d8598a124c19a68198d84bdafaf8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzUtMy0xLTEtMTY3OTA4_3da656d6-29d0-46de-9869-fab68d888edd"
      unitRef="usd">2272000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i785d19a7b609421eb9246c77f19956fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzUtNS0xLTEtMTY3OTA4_0537dbc4-b6bb-42fa-ac74-d954789a6be5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67f0cd92f49b4b2ba3ae745e22916f37_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzUtNy0xLTEtMTY3OTA4_a8fda15b-1684-4615-83b1-b6cd79c0153a"
      unitRef="usd">2272000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19e9b578731f4c5baff668f1e8bc6d6b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzYtMS0xLTEtMTY3OTA4_4f29f213-00d9-460c-b9d4-e81f7a4c684d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id86084968a414700a75a774a5a97ab5f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzYtMy0xLTEtMTY3OTA4_aa68440a-a606-4189-aa71-07c7dbf074f1"
      unitRef="usd">8897000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f1814e1657e4cec8407f309d332126f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzYtNS0xLTEtMTY3OTA4_ff2fb2ea-0543-4b61-9aba-9245b9a7ffc3"
      unitRef="usd">61000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idcb1f815761e4abf81f0b8c3d4f8c6c2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzYtNy0xLTEtMTY3OTA4_039af3bf-6c5d-477f-97c2-d2d6fbe11393"
      unitRef="usd">8958000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a671ec5023946d19ee290bcc33442c9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzctMS0xLTEtMTY3OTA4_2deb1c89-eb12-448e-846e-829ed744aff4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied933a3ae1c44c37ab908d407bf9b9d2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzctMy0xLTEtMTY3OTA4_a8d2873d-5571-45c4-95c7-db473495a093"
      unitRef="usd">2542000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8590aa625abe4bb3957876a8242f244e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzctNS0xLTEtMTY3OTA4_3ea272e8-f323-442d-891a-894eef5b49b4"
      unitRef="usd">8000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6fb3a28663f4a6ba9eddda9e82c83a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzctNy0xLTEtMTY3OTA4_ccdddcad-6cfc-49c4-bedc-38ec545fe8f8"
      unitRef="usd">2550000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a985a5355bf4bfa9414b48bb67b83bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzgtMS0xLTEtMTY3OTA4_601b95fb-547d-4b57-850b-b476123075bc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40b71f09b498454fa6e14cfd770e0f13_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzgtMy0xLTEtMTY3OTA4_85082d07-0f8a-4767-9a4b-f481a3130e5b"
      unitRef="usd">757000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26131a59b6674c21be2b2f35ac3585d0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzgtNS0xLTEtMTY3OTA4_1baf0e09-d279-402f-ba71-54b4a41bc00a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85dd5660a59b410b8d5600445dd2db73_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzgtNy0xLTEtMTY3OTA4_7a0ff74f-b302-415d-b2f7-522b5e58f5d1"
      unitRef="usd">757000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b09513b5025488bb89a6666751b3eec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzktMS0xLTEtMTY3OTA4_e540bd86-a151-43f5-be7f-eb505966ac1e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icdc3450471ad405a95c9f384be0052d2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzktMy0xLTEtMTY3OTA4_93ba9ed5-0344-4dd7-bf49-0b47981d0307"
      unitRef="usd">1018000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f137c3bff994afabf3e08f84adaf0e2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzktNS0xLTEtMTY3OTA4_426f1436-a4d9-4209-8e50-608d415c7111"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08f51346b999445e9d94877366425a3a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzktNy0xLTEtMTY3OTA4_723c972e-3781-405e-add9-4d14e3547426"
      unitRef="usd">1018000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia214d8b8ca6049f29665c2a7f42886ea_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEwLTEtMS0xLTE2NzkwOA_53da28c8-92a5-459a-8b08-325d86c93797"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1f05a7cde4614b0ab28a1cca18e30c59_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEwLTMtMS0xLTE2NzkwOA_8afad807-51be-4082-9579-ac617f3f837c"
      unitRef="usd">2810000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i624b1a999672495b9d45af07b54e6b76_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEwLTUtMS0xLTE2NzkwOA_3f8da63a-a804-4786-8150-cd1c5726041f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7dd5e7556c1145898755e2b6da40bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEwLTctMS0xLTE2NzkwOA_96668b67-b1a4-4403-8922-937b207c13b4"
      unitRef="usd">2810000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id9a5333835ad4c71aed5cd82b4c95855_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzExLTEtMS0xLTE2NzkwOA_6c699c3b-ba20-4968-b533-9cdc402c036e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c8648eedc854d2cb3b880ba07b81e53_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzExLTMtMS0xLTE2NzkwOA_5951b4a8-096a-451d-8873-341a2bade346"
      unitRef="usd">23000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ida77e918f5de47b4b67cfca0da2b8226_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzExLTUtMS0xLTE2NzkwOA_8862ffa7-ce3d-4a96-a39f-466dd46d2d51"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6906b59b585c4d4b85fc1db92b4aad26_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzExLTctMS0xLTE2NzkwOA_dc588a5b-1ef9-4c40-8b62-549e09f79019"
      unitRef="usd">23000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEyLTEtMS0xLTE2NzkwOA_3949a073-c737-4971-993c-b10052b3a273"
      unitRef="usd">1860000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc0c69d485444837bbae724a028fb845_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEyLTMtMS0xLTE2NzkwOA_7751fb51-ab9a-4750-af65-1966a17c2a2a"
      unitRef="usd">18351000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEyLTUtMS0xLTE2NzkwOA_c442b7d0-ebda-4519-89fa-d8877d92f31d"
      unitRef="usd">69000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEyLTctMS0xLTE2NzkwOA_147ca4f8-99bb-4897-8d7a-9bf79e2b2a0b"
      unitRef="usd">20280000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEzLTEtMS0xLTE2NzkwOA_dc455027-8ff4-4a58-9821-3ce6de66c5b9"
      unitRef="usd">116000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibc0c69d485444837bbae724a028fb845_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEzLTMtMS0xLTE2NzkwOA_6d387caa-8b63-41ac-916f-5907fd63776c"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEzLTUtMS0xLTE2NzkwOA_be6dd545-a3c4-4cf7-9f65-88f6589bad25"
      unitRef="usd">60000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzEzLTctMS0xLTE2NzkwOA_21361bd8-f7f9-42d9-a917-2701c2c94322"
      unitRef="usd">176000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE0LTEtMS0xLTE2NzkwOA_a4f9a298-ba90-48d4-86de-ffc0f53c2804"
      unitRef="usd">8878000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibc0c69d485444837bbae724a028fb845_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE0LTMtMS0xLTE2NzkwOA_feef0d76-0a43-4698-a408-79d67bcf770b"
      unitRef="usd">24400000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE0LTUtMS0xLTE2NzkwOA_a54cc68d-f1e4-4f6f-80d8-d923462c994f"
      unitRef="usd">129000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE0LTctMS0xLTE2NzkwOA_4ba8ea1a-9088-41bf-b134-76a7b7cc7411"
      unitRef="usd">33407000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE3LTEtMS0xLTE2NzkwOA_e622a32c-8f83-4ceb-aef9-cafd04af7421"
      unitRef="usd">4954000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE3LTMtMS0xLTE2NzkwOA_479db81d-6c30-40fe-8d3f-2c9839e4b43e"
      unitRef="usd">4454000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE3LTUtMS0xLTE2NzkwOA_2afbdda7-8da0-4ef8-a3e5-89cfff9de8e9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE3LTctMS0xLTE2NzkwOA_8ec735b9-dd4c-435b-a786-53771222650c"
      unitRef="usd">9408000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9e565524b0f4bf687a1dabcf4928828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE5LTEtMS0xLTE2NzkwOA_434328b2-c479-42e2-a850-4c497c65b7f7"
      unitRef="usd">2372000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81efa365424d49cebe90328cadafba3e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE5LTMtMS0xLTE2NzkwOA_14fe5c38-58cb-43b8-a989-52fa43ccc1c0"
      unitRef="usd">44000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i48ec5e8d0dd14482a058a46dd16eab76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE5LTUtMS0xLTE2NzkwOA_1779d074-ab59-4fce-805c-d5d4d882720d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i701d4495212945b99d951fd9a0dcd6c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzE5LTctMS0xLTE2NzkwOA_fdf06035-a600-437d-bb51-d17af045908a"
      unitRef="usd">2416000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7773f5873dab49a8ba60de1ef7a255d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIwLTEtMS0xLTE2NzkwOA_8e936cba-0731-49ac-8fb4-5ee7be91db16"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i348bc1177736419fad69fa81d958c8ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIwLTMtMS0xLTE2NzkwOA_51d7ad56-6673-439c-8301-faad60195762"
      unitRef="usd">3086000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32773f424e5649049efc564c1400fd60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIwLTUtMS0xLTE2NzkwOA_5a30b82d-3088-4d8f-9884-a98b2d21544d"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddfb3509175a421fa38431213004bc2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIwLTctMS0xLTE2NzkwOA_90e4a554-7347-438a-aa27-5ad6e47e176a"
      unitRef="usd">3091000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i949fc998576e45bfb3cf3c21865aa98a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIxLTEtMS0xLTE2NzkwOA_79314325-4b30-4fbf-b2a6-a11fadf2f59f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b4b742130f941fe94db85e807e7a06a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIxLTMtMS0xLTE2NzkwOA_e41faabe-2bbd-490e-ba57-410b1d2478cb"
      unitRef="usd">9697000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bb4af948251483fb59540de78e273f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIxLTUtMS0xLTE2NzkwOA_70fe08bf-ff84-43b4-9c89-9a9a68e518f5"
      unitRef="usd">38000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f4ad698b6cb4a918854adc5690c6f16_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIxLTctMS0xLTE2NzkwOA_7a1c6113-dce8-45dc-850a-acae2c26a558"
      unitRef="usd">9735000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a543a47bdbf412ea03cd80a7e5147aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIyLTEtMS0xLTE2NzkwOA_f8688575-5cb2-460e-9e2d-3044492416b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f2c37f0c80248f98f71a7fc479de9ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIyLTMtMS0xLTE2NzkwOA_082c9c6d-5b58-4477-872a-e721da04ada2"
      unitRef="usd">2983000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib999956c1a1844f0a5f0f337b58d6d66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIyLTUtMS0xLTE2NzkwOA_b571700c-7a0f-441b-9354-067e97ff57c0"
      unitRef="usd">10000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9fcc6959ebd747668932580c12c9b80c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIyLTctMS0xLTE2NzkwOA_c3cdea17-68d3-4fd5-b0d5-212eb8b99763"
      unitRef="usd">2993000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia921c1e5944340c0aa0256f19c8b20a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIzLTEtMS0xLTE2NzkwOA_81a114f7-8862-44a7-8da3-8a1c4d76c17c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6a2d79c756c41b2bea5dcf9fc87f998_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIzLTMtMS0xLTE2NzkwOA_486f7f17-7be2-4e2b-a08e-4900c8cd82b9"
      unitRef="usd">875000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i206c3b9628b7444ea6df2624ea2118ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIzLTUtMS0xLTE2NzkwOA_b3b15c52-16d2-4180-9a71-d6e1f272a242"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7f4bc4698994fcab1897c3d0a92ad88_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzIzLTctMS0xLTE2NzkwOA_e87c9d85-db41-470b-ba62-cb674ca9a7be"
      unitRef="usd">875000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ee0b6a29d934c78b07a74d71c61d1db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI0LTEtMS0xLTE2NzkwOA_496664bd-0e61-48c0-a0b7-7c1504899ca9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee7db71ae1ac40fd91ebfa23d481d8c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI0LTMtMS0xLTE2NzkwOA_6de92705-8b23-47cb-8317-3addcae5d607"
      unitRef="usd">1310000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i190edd6b8c6944fd9697dfc9489f8a9c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI0LTUtMS0xLTE2NzkwOA_b72d368f-dcff-436c-a21f-e7d945ede3ba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i387ffe71e44b4f0daa62a18eae1f74ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI0LTctMS0xLTE2NzkwOA_7ce502af-8cd5-404a-8566-df556c729844"
      unitRef="usd">1310000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i431cc5a5826c442fa78d95415014f874_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI1LTEtMS0xLTE2NzkwOA_163e3d5a-6d9b-4516-8327-4cfc24d32389"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6ddcd1cd3484e58887f45b9ad5e1006_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI1LTMtMS0xLTE2NzkwOA_6f16c947-18d3-497b-85b0-faeb45e7fe6e"
      unitRef="usd">2789000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4eb6d4a5fe79457293a854403dbb6e69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI1LTUtMS0xLTE2NzkwOA_aa43489a-cc6f-4a81-9bf2-82122ba7907f"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ff589f47f514ece9b347067993f1a0a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI1LTctMS0xLTE2NzkwOA_60c1b19e-3500-465c-809c-a5dc2ca2b171"
      unitRef="usd">2792000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ae1a142a6834907b1e6b0fa40a2a994_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI2LTEtMS0xLTE2NzkwOA_608437ae-ec10-4f4a-ade6-e9a5dc1f18f8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic83ed3a7dee542e08edcf3a6a2ea4b25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI2LTMtMS0xLTE2NzkwOA_4dc34266-7bb6-4b7c-8af3-8c5f1e2d4c5e"
      unitRef="usd">28000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2050ac0edb04a31adf7f234fb6390a1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI2LTUtMS0xLTE2NzkwOA_29af8a39-6b6b-4c97-98a6-371f1ae97fec"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75346ba9d76e4cf0980dea9c58ccaa81_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI2LTctMS0xLTE2NzkwOA_978bf76f-eed1-4d8c-97cc-84859f8fb8ec"
      unitRef="usd">28000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI3LTEtMS0xLTE2NzkwOA_c7c0abd3-f3c2-4547-8805-5ab9cc5af7f2"
      unitRef="usd">2372000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI3LTMtMS0xLTE2NzkwOA_02e91343-e571-4479-bdbf-eeef270c256d"
      unitRef="usd">20812000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI3LTUtMS0xLTE2NzkwOA_182ef995-10d6-4acb-bda7-26d5258a165e"
      unitRef="usd">56000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI3LTctMS0xLTE2NzkwOA_cfe167dd-11d8-4647-9dc9-3b4f71d2e077"
      unitRef="usd">23240000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI4LTEtMS0xLTE2NzkwOA_99aafbe9-ea00-4bd3-9932-fc5e3edafc29"
      unitRef="usd">114000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI4LTMtMS0xLTE2NzkwOA_32c2d295-78f4-4578-9b7e-791b8ae7430d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI4LTUtMS0xLTE2NzkwOA_9ce0b912-cf60-4506-a565-2d98c7daef07"
      unitRef="usd">55000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI4LTctMS0xLTE2NzkwOA_1a12364f-baa2-4637-aa58-9c243e95b47e"
      unitRef="usd">169000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI5LTEtMS0xLTE2NzkwOA_efd75ff2-37f1-4b7c-b347-d09c9fb80ca5"
      unitRef="usd">7440000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI5LTMtMS0xLTE2NzkwOA_ebe95828-438f-4b2a-967b-e567fb6e6cd4"
      unitRef="usd">25266000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI5LTUtMS0xLTE2NzkwOA_8ef5f053-1c07-4802-ac29-51561860e0e4"
      unitRef="usd">111000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo4NGFiNzYzYzM0ZGI0MDlkOTdmODBkMGM1M2EwY2Y5Yy90YWJsZXJhbmdlOjg0YWI3NjNjMzRkYjQwOWQ5N2Y4MGQwYzUzYTBjZjljXzI5LTctMS0xLTE2NzkwOA_f06bd42c-f869-4d3f-9fd1-aef8b6ba8654"
      unitRef="usd">32817000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i07516a7d0c4d4a0eb9c8cf019d26a2e9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzI3NDg3NzkwODE1MDA_214f0100-634f-40ff-9d1a-61e0743a819c"
      unitRef="usd">6000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjMz_d07fcf78-b6f1-448a-9304-49704d1b49d5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;States, &lt;br/&gt;municipalities&lt;br/&gt;&#160;and political &lt;br/&gt;subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S.&lt;br/&gt;corporate&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other asset-&lt;br/&gt;backed&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized and unrealized capital losses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in earnings&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balances of Level 3 financial assets during the year ended December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;States, &lt;br/&gt;municipalities&lt;br/&gt;&#160;and political &lt;br/&gt;subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S.&lt;br/&gt;corporate&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other asset-&lt;br/&gt;backed&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Redeemable&lt;br/&gt;preferred&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized and unrealized capital gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in net unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December&#160;31, 2021 was $4&#160;million during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total gross transfers into (out of) Level 3 during the years ended December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net transfers into (out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="iddfb3509175a421fa38431213004bc2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtMS0xLTEtMTY3OTA4_8c953488-4f08-44db-a136-9cf7482cbc9c"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i9f4ad698b6cb4a918854adc5690c6f16_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtMy0xLTEtMTY3OTA4_0a60c53d-5920-46fb-8ca3-635babccb53e"
      unitRef="usd">38000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i43b6787f48b3442d8a63c30333c6b458_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtNS0xLTEtMTY3OTA4_5877e1f1-c886-4c4d-9b99-8de130c18d19"
      unitRef="usd">10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i0ff589f47f514ece9b347067993f1a0a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtNy0xLTEtMTY3OTA4_59e68da5-ff3f-4740-96d0-4b080da4096a"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i1f194dd99c7e4f68b3ff5746bc03b35e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtMTEtMS0xLTE2NzkwOA_0c361d6d-e5ac-45f3-ab8a-289522ec9d3f"
      unitRef="usd">55000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzEtMTMtMS0xLTE2NzkwOA_7c976f16-4cb0-47cf-85cb-03fbbd8adbe7"
      unitRef="usd">111000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtMS0xLTEtMTY3OTA4_2dfed2ec-3d0e-4673-b24e-e2f2aee23ff0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtMy0xLTEtMTY3OTA4_3261cdd2-371a-472a-80b6-2749942ee825"
      unitRef="usd">-8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtNS0xLTEtMTY3OTA4_48153f01-31b3-442e-aa00-1ee62062ecff"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtNy0xLTEtMTY3OTA4_eeea398f-7c9f-4b30-ba0c-c21bb6bebb3b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtMTEtMS0xLTE2NzkwOA_86647c83-2940-4ee7-89f6-81191fa3f2c2"
      unitRef="usd">-1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzMtMTMtMS0xLTE2NzkwOA_f8191f4b-c923-4145-bbf0-8d7d3f9fa373"
      unitRef="usd">-9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtMS0xLTEtMTY3OTA4_3f7d1795-0e14-4ff9-8f24-ae9ec5dcbb5d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtMy0xLTEtMTY3OTA4_f7bfebb3-f6b9-406b-afd8-d10932a83065"
      unitRef="usd">-5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtNS0xLTEtMTY3OTA4_c120aab1-df52-4a70-8159-c8be83a28f96"
      unitRef="usd">-2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtNy0xLTEtMTY3OTA4_5d032de5-6c5d-4625-87fe-251c03e9f4d5"
      unitRef="usd">-2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtMTEtMS0xLTE2NzkwOA_a2b059ef-db06-4523-bc49-cb6f54bfe441"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzQtMTMtMS0xLTE2NzkwOA_3a297691-10d5-4d2c-b239-82b32e82f692"
      unitRef="usd">-9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtMS0xLTEtMTY3OTA4_decf5c37-94bb-4d0a-8a27-22e1afa88c6f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtMy0xLTEtMTY3OTA4_ca23e75c-269d-46e3-9d03-ffdf42064448"
      unitRef="usd">36000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtNS0xLTEtMTY3OTA4_34285878-f1a8-416a-ae24-2da0fd4a0746"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtNy0xLTEtMTY3OTA4_b4e1e3f5-0bb6-4a77-a4d6-048f8232338d"
      unitRef="usd">30000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtMTEtMS0xLTE2NzkwOA_4fb681e2-925d-44b1-9400-4ef9cff5cce5"
      unitRef="usd">29000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzUtMTMtMS0xLTE2NzkwOA_edd3ecd6-ada5-4b57-b148-fa2f23f46859"
      unitRef="usd">95000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtMS0xLTEtMTY3OTA4_3f442fe8-c206-4504-a2d3-2af9cf9c2ad9"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtMy0xLTEtMTY3OTA4_9673ffea-484e-4837-b26a-86b2654b26c4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtNS0xLTEtMTY3OTA4_75259c98-1172-4180-849c-16f8af34f0bd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtNy0xLTEtMTY3OTA4_72e5ef8c-d025-45ae-9d93-24591878061b"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtMTEtMS0xLTE2NzkwOA_134f3b79-fd52-4257-841d-9770d8846ee5"
      unitRef="usd">23000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzYtMTMtMS0xLTE2NzkwOA_1dc5af40-57bf-44da-b2d3-66624938ff60"
      unitRef="usd">30000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctMS0xLTEtMTY3OTA4_1567ff11-0419-4d15-8670-7ef35074f933"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctMy0xLTEtMTY3OTA4_615b4a42-eae5-4c39-94b2-c28aeb42bcab"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctNS0xLTEtMTY3OTA4_d756194b-5f51-4b9b-9192-43aa958390e2"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctNy0xLTEtMTY3OTA4_30d6d99a-b360-4ac3-8753-eb761a95fc8b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctMTEtMS0xLTE2NzkwOA_6a0a8549-670b-47d7-ab86-57d26f314d77"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzctMTMtMS0xLTE2NzkwOA_ed31a081-e8a6-424f-b314-7ea669ca43e6"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i992ef56bb420411cbbef3826241d452f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtMS0xLTEtMTY3OTA4_1134e4fe-2297-4fd1-88e6-06b0d64d40b2"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i77abf1713bc54af78884466e31b453cc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtMy0xLTEtMTY3OTA4_8918cc91-d9dc-41ad-bff4-303772ef3360"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i15dac8898949438694ba2abf0c059910_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtNS0xLTEtMTY3OTA4_94223afe-1f30-403c-bf1e-86773943241c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i173b2e33cec54df586bf8687e5d5869b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtNy0xLTEtMTY3OTA4_94ab2d81-4334-460f-8843-466417591deb"
      unitRef="usd">-29000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i5eb949578d154fdeb5ff430dad445f19_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtMTEtMS0xLTE2NzkwOA_9756a864-6011-42d1-88f7-8d75ca70d69b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzgtMTMtMS0xLTE2NzkwOA_4389e444-c85c-4104-b1b8-8c2b35fa2bcd"
      unitRef="usd">-29000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i67f0cd92f49b4b2ba3ae745e22916f37_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktMS0xLTEtMTY3OTA4_d6a4dc83-b5a9-4065-a294-07e6e44cc20e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="idcb1f815761e4abf81f0b8c3d4f8c6c2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktMy0xLTEtMTY3OTA4_251c3b12-59e1-45bc-8f2f-313534d81e71"
      unitRef="usd">61000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i95dfe2b0be4243cfad329e2e411e3303_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktNS0xLTEtMTY3OTA4_1a76fa30-14b3-4fad-a629-0bcc2b594bbc"
      unitRef="usd">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i7dd5e7556c1145898755e2b6da40bee8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktNy0xLTEtMTY3OTA4_abeefd41-3131-487f-9b12-a64191732b94"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i7975ad7519e54b6db43ace8eb80066d2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktMTEtMS0xLTE2NzkwOA_eaca69a4-95a1-41fe-8d90-99190e87de36"
      unitRef="usd">60000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTphY2QzNWNjN2UwNDE0MTY5YmM3NDkyMDQyZDUyODdlZi90YWJsZXJhbmdlOmFjZDM1Y2M3ZTA0MTQxNjliYzc0OTIwNDJkNTI4N2VmXzktMTMtMS0xLTE2NzkwOA_201639bb-d762-4227-8ced-1100c46f6482"
      unitRef="usd">129000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzcyMTc_6cd263c6-ad5b-4f6a-b714-623ee2d67cf1"
      unitRef="usd">-9000000</us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i44ee925bb3e5402b955f9868457737db_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtMS0xLTEtMTY3OTA4_976cc7ff-2a37-4f51-bb0e-0924289c1cdd"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="if3892577d13a4a62a891505c7f399a79_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtMy0xLTEtMTY3OTA4_713baab9-c1a8-4e25-89e0-43dfc7f3909c"
      unitRef="usd">52000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ia091e18719b84015824f1dd5f80bc7eb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtNS0xLTEtMTY3OTA4_c249d96f-9062-4fbe-9aeb-87373cbbb056"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i7619afe50a794a4a84a50dcfbf630c38_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtNy0xLTEtMTY3OTA4_1f138d42-590d-4474-9aec-09a563fe3fb8"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i79c1ae91ff3442528fb1f71c91933d34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtOS0xLTEtMTY3OTA4_db955d24-8d0b-41ac-8766-84fc239fa202"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i662d2dd29a2a4a22b0b5e93c396ed6f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtMTEtMS0xLTE4MDU1Mg_2469364b-4bda-4828-92fb-966ee4c44ec9"
      unitRef="usd">30000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ia37d53d84cb44bc39778f9546e36542d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzEtMTMtMS0xLTE4MDU1Mg_aeeaab73-22df-447b-9925-b06f0b24e60d"
      unitRef="usd">84000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtMS0xLTEtMTY3OTA4_0ca30c9c-fe21-45b2-a774-6fd7f71ad68c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtMy0xLTEtMTY3OTA4_894a4f1f-4cef-4da3-94d2-892b1a516f67"
      unitRef="usd">-10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtNS0xLTEtMTY3OTA4_b4d34b16-936b-4fc4-b8e7-187cd1c87f0e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtNy0xLTEtMTY3OTA4_06718c07-dfde-4f08-8c93-1d502d4ebf73"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtOS0xLTEtMTY3OTA4_a3193098-e268-40fb-a45b-f5a0d5131f2a"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtMTEtMS0xLTE4MDU1Mg_736a5eb5-f507-47ac-b395-ff32d3247d1e"
      unitRef="usd">13000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzMtMTMtMS0xLTE4MDU1Mg_40ab7a63-ec9d-4f00-b576-5acf6c7823a6"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtMS0xLTEtMTY3OTA4_45d3361e-1942-43eb-8430-f6e53db7accd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtMy0xLTEtMTY3OTA4_9571fd59-2e84-431d-97cb-09ec7ccaffbe"
      unitRef="usd">-3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtNS0xLTEtMTY3OTA4_72823ea5-d3de-457e-bc90-608466f27a91"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtNy0xLTEtMTY3OTA4_bf9fccab-4775-43fd-a965-42ef4418e196"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtOS0xLTEtMTY3OTA4_e257ac10-7f1f-46b5-a2d5-874b2d3fbd83"
      unitRef="usd">-1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtMTEtMS0xLTE4MDU1Mg_2881a5e6-8d64-49cb-86af-5f5bb6003033"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzQtMTMtMS0xLTE4MDU1Mg_e063cf78-2956-46f4-a460-55bfae5bead6"
      unitRef="usd">-4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtMS0xLTEtMTY3OTA4_76102c43-bfc7-435f-b551-5e326c1d56d6"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtMy0xLTEtMTY3OTA4_af5324cb-a9b1-4b18-9826-ebb22b5c998c"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtNS0xLTEtMTY3OTA4_87c5698e-3efd-4bd2-b813-36af0001572c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtNy0xLTEtMTY3OTA4_17bfa1e5-d79f-4d20-873e-0f6c6e1d6cc4"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtOS0xLTEtMTY3OTA4_ffc106f2-c44e-4824-aaa4-9b46d09603c5"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtMTEtMS0xLTE4MDU1Mg_9a395354-f885-4f27-acea-ffa6246b6bac"
      unitRef="usd">13000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzUtMTMtMS0xLTE4MDU1Mg_82732880-bb62-4ea2-8897-b66bdc43e979"
      unitRef="usd">17000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtMS0xLTEtMTY3OTA4_97ad9ebb-06a9-47a3-bbc5-4280ead4e4a2"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtMy0xLTEtMTY3OTA4_04c6c56c-ca12-412b-b0b2-6d9145fd7cef"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtNS0xLTEtMTY3OTA4_1a0a691f-c239-41cf-9bf2-00a80fba4114"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtNy0xLTEtMTY3OTA4_29fef5fc-645e-4cc6-b1a4-cab8e8d79a82"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtOS0xLTEtMTY3OTA4_335b5546-6c1a-4265-b7c8-1d9544a9a296"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtMTEtMS0xLTE4MDU1Mg_ff38958a-dc40-4343-b697-759f1ad253f7"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
      contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzYtMTMtMS0xLTE4MDU1Mg_5600d4be-420c-48e6-a500-7c35ca59d975"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctMS0xLTEtMTY3OTA4_55183619-d238-4a72-b5d7-7a1508c6a929"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctMy0xLTEtMTY3OTA4_9c782071-a937-42a9-a337-d295f35bf080"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctNS0xLTEtMTY3OTA4_8c34c450-2c16-4dee-bda3-2c9cbbae03a6"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctNy0xLTEtMTY3OTA4_9580579f-fc5a-4355-93f7-86ad62af0d97"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctOS0xLTEtMTY3OTA4_84fac741-5ea0-4dcb-9cdf-1a28ff1901ec"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctMTEtMS0xLTE4MDU1Mg_9fc66548-3cc8-4dec-a329-d82f49162e01"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzctMTMtMS0xLTE4MDU1Mg_c94d7a11-d1de-42bd-bf77-2fb2a79d5da7"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="ice6815e58c2d479e84039b48a9655a95_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtMS0xLTEtMTY3OTA4_f0acb6d8-bb72-433e-99ac-61039d3e2c16"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i768f6d7b4817418cb05c5a1d824d305d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtMy0xLTEtMTY3OTA4_44dfe49f-7222-4f7b-bae4-4924e36d2278"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i9da084dc1e80427ea1b4e6ce54713c65_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtNS0xLTEtMTY3OTA4_e16acc70-63ef-4c2b-8711-b9f45e6ac4c5"
      unitRef="usd">10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i4efcbcd2c5f54edfaeb5233aa51a0cff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtNy0xLTEtMTY3OTA4_04916c3c-227c-4c8b-99b3-9f7945594ed7"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="ie5a7cce5fc144237bf24d75f459c7e41_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtOS0xLTEtMTY3OTA4_8ffc5aa8-60ee-405b-a15f-18f93916b483"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="if65bf1b3a8804bbb81391fcb4e599da4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtMTEtMS0xLTE4MDU1Mg_0e8fa97a-927c-427a-aa32-92048ba6e3fc"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i4f54b0d31c514eef9eebdf4489e6999a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzgtMTMtMS0xLTE4MDU1Mg_60729c3a-e7a4-448f-963d-52864390717e"
      unitRef="usd">15000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="iddfb3509175a421fa38431213004bc2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktMS0xLTEtMTY3OTA4_21378612-6489-448f-8d05-26d6003f022a"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i9f4ad698b6cb4a918854adc5690c6f16_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktMy0xLTEtMTY3OTA4_816dda2e-398b-4e45-ae1e-63ffb5e5b977"
      unitRef="usd">38000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i43b6787f48b3442d8a63c30333c6b458_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktNS0xLTEtMTY3OTA4_f1e48793-9ce0-4aab-ac10-06e0fdf9864b"
      unitRef="usd">10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i0ff589f47f514ece9b347067993f1a0a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktNy0xLTEtMTY3OTA4_20a25326-936b-4487-9191-41fca9c2fdf2"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i75346ba9d76e4cf0980dea9c58ccaa81_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktOS0xLTEtMTY3OTA4_28bd6d47-57ed-4239-90f8-5b8447b5e81e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i1f194dd99c7e4f68b3ff5746bc03b35e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktMTEtMS0xLTE4MDU1Mg_59ab7f62-6d92-4ffd-bec7-9bd85daaa02c"
      unitRef="usd">55000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTpiZTg3YmUyYWZjZWM0NjA2OTFmMDQwYjYzM2Q0Zjk1NS90YWJsZXJhbmdlOmJlODdiZTJhZmNlYzQ2MDY5MWYwNDBiNjMzZDRmOTU1XzktMTMtMS0xLTE4MDU1Mg_0f167766-69f8-4985-9207-fe3dab27fa29"
      unitRef="usd">111000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzc0OTg_c55b6b75-feda-4c68-abc9-f50831dfa812"
      unitRef="usd">-4000000</us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="i66bcf7a88ef8420db041c82d229c682d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzEtMS0xLTEtMTY3OTA4_2d34b7ca-e86c-463c-851a-d9284c5684d4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="ic858e8e5cf2d4617b20fa3fa03a4a293_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzEtMy0xLTEtMTY3OTA4_cf3a26d6-0c3a-4d46-84cd-02bc34b558e6"
      unitRef="usd">15000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i66bcf7a88ef8420db041c82d229c682d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzItMS0xLTEtMTY3OTA4_e4e448a3-935a-4280-a3cd-5423f041f58b"
      unitRef="usd">29000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ic858e8e5cf2d4617b20fa3fa03a4a293_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzItMy0xLTEtMTY3OTA4_0b1ea96e-d686-4a5d-a1cc-3a8308138efd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i66bcf7a88ef8420db041c82d229c682d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzMtMS0xLTEtMTY3OTA4_9fb4a528-842a-4e7a-9d02-9b0691d75154"
      unitRef="usd">-29000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="ic858e8e5cf2d4617b20fa3fa03a4a293_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTo1MzdhODMwODcwYjc0MGM4YWE3ZWQ5NWYwODEzNzdiNS90YWJsZXJhbmdlOjUzN2E4MzA4NzBiNzQwYzhhYTdlZDk1ZjA4MTM3N2I1XzMtMy0xLTEtMTY3OTA4_0ca0884f-f5d2-466c-bba5-b82e8c8546d3"
      unitRef="usd">15000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjM3_ddd3cf9f-598f-4f6e-87f9-e93cabdff09d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;With a fixed maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Without a fixed maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;With a fixed maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Without a fixed maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 &#x2018;&#x2018;Significant Accounting Policies&#x2019;&#x2019; for additional information regarding the valuation of cost method investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes long-term debt of $3&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="i5fe1938eb02c435297cc130427df950c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtMS0xLTEtMTY3OTA4_9b592639-1222-46f9-8fdb-964c907dce72"
      unitRef="usd">1044000000</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtMy0xLTEtMTY3OTA4_0f378cb1-f0b1-410b-b080-7353e184287d"
      unitRef="usd">0</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="ibb6be9b43dab4ff69cd98c57e4510019_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtNS0xLTEtMTY3OTA4_04caee0b-f315-455b-be84-1cb2cccb5a93"
      unitRef="usd">0</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="i0c075490097946eb8ba4e98465055bd6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtNy0xLTEtMTY3OTA4_afe6317b-4863-43f1-bbdd-c7bb9411a50d"
      unitRef="usd">978000000</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="i734643ad1ae34563ab562dd2a9a185e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzQtOS0xLTEtMTY3OTA4_7cadf7aa-0cc2-427a-b673-edaa46836972"
      unitRef="usd">978000000</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i5fe1938eb02c435297cc130427df950c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzUtMS0xLTEtMTY3OTA4_06b69b0a-c475-4296-94e4-103b2de4b437"
      unitRef="usd">411000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="i5fe1938eb02c435297cc130427df950c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtMS0xLTEtMTY3OTA4_af9f1c8a-d127-41ea-a540-5fef356ab087"
      unitRef="usd">3000000</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtMy0xLTEtMTY3OTA4_6142c92c-9291-450e-8f9f-8dd59ef911b7"
      unitRef="usd">0</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="ibb6be9b43dab4ff69cd98c57e4510019_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtNS0xLTEtMTY3OTA4_bf3e8dce-0074-4fed-b0c6-7a9e5c3d6971"
      unitRef="usd">0</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="i0c075490097946eb8ba4e98465055bd6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtNy0xLTEtMTY3OTA4_c310a6cb-1b60-49ba-9960-e3f3257d37f3"
      unitRef="usd">3000000</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="i734643ad1ae34563ab562dd2a9a185e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzgtOS0xLTEtMTY3OTA4_12080207-3d15-4deb-a83e-0eb2acacc1d6"
      unitRef="usd">3000000</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="i5fe1938eb02c435297cc130427df950c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktMS0xLTEtMTY3OTA4_6f75d39b-db2c-4b03-aeb2-37597b8fd7e2"
      unitRef="usd">332000000</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktMy0xLTEtMTY3OTA4_797f23ad-6793-4951-a6fa-a3f0b26ab14e"
      unitRef="usd">0</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="ibb6be9b43dab4ff69cd98c57e4510019_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktNS0xLTEtMTY3OTA4_ecfebc8d-b8d8-440b-87b9-9ed88fa5e953"
      unitRef="usd">0</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="i0c075490097946eb8ba4e98465055bd6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktNy0xLTEtMTY3OTA4_497d1455-bce8-4f81-8f65-c8c1bbfd6a3a"
      unitRef="usd">305000000</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="i734643ad1ae34563ab562dd2a9a185e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzktOS0xLTEtMTY3OTA4_4e5609b9-4bb0-45c4-b671-1cf0ce533811"
      unitRef="usd">305000000</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5fe1938eb02c435297cc130427df950c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTEtMS0xLTE2NzkwOA_7d3cfc70-8e3f-48be-80f7-664674352b73"
      unitRef="usd">52257000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id9c8006781ea4a2dbc4c787feacb1a8b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTMtMS0xLTE2NzkwOA_e5f39bb3-aee9-4225-a720-363422a15e45"
      unitRef="usd">47653000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ibb6be9b43dab4ff69cd98c57e4510019_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTUtMS0xLTE2NzkwOA_6301a198-ef6d-4bea-a68e-892043266a69"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i0c075490097946eb8ba4e98465055bd6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTctMS0xLTE2NzkwOA_efa88c34-71b9-4e3a-805d-c40728884f0a"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i734643ad1ae34563ab562dd2a9a185e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzEwLTktMS0xLTE2NzkwOA_fc669bf7-bb1f-475e-a6f5-685615b2242f"
      unitRef="usd">47653000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="i699884ef14c74682af2d844bfa691e05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTEtMS0xLTE2NzkwOA_eff5bd59-bf06-4305-8c8e-d06844560c0b"
      unitRef="usd">902000000</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="i863995f01893429ba0b90278c34784f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTMtMS0xLTE2NzkwOA_6ee62110-f737-47c0-8d18-fb5a8191a095"
      unitRef="usd">0</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="i355cdb170edb433ca79e61e309a40c6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTUtMS0xLTE2NzkwOA_60c78e6c-7733-43ed-a53a-e9fda11a6478"
      unitRef="usd">0</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="i53c500be5647438295ed663bd07d0536_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTctMS0xLTE2NzkwOA_f9ef2169-90cd-4395-8da3-92bde1b3c053"
      unitRef="usd">907000000</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:MortgagesHeldForSaleFairValueDisclosure
      contextRef="iaf216acef3094d348747eeef4045d573_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE0LTktMS0xLTE2NzkwOA_c51cdef8-d88c-44f5-bf2e-4983deb7b026"
      unitRef="usd">907000000</us-gaap:MortgagesHeldForSaleFairValueDisclosure>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i699884ef14c74682af2d844bfa691e05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE1LTEtMS0xLTE2NzkwOA_8ed456a4-97d1-40f7-bdba-89acac25619d"
      unitRef="usd">126000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="i699884ef14c74682af2d844bfa691e05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTEtMS0xLTE2NzkwOA_26f96c01-c069-4b09-adba-a1ba0c7cd67e"
      unitRef="usd">5000000</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="i863995f01893429ba0b90278c34784f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTMtMS0xLTE2NzkwOA_ffaf4687-0de9-4a69-97d4-9dd5113683a8"
      unitRef="usd">0</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="i355cdb170edb433ca79e61e309a40c6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTUtMS0xLTE2NzkwOA_70f85ed4-85a9-4a04-9146-d944a2a87146"
      unitRef="usd">0</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="i53c500be5647438295ed663bd07d0536_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTctMS0xLTE2NzkwOA_f42287af-5bfa-4949-ac12-763843e27cd0"
      unitRef="usd">5000000</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure
      contextRef="iaf216acef3094d348747eeef4045d573_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE4LTktMS0xLTE2NzkwOA_c56a3a10-29bc-41c9-b4b8-78f8760791cd"
      unitRef="usd">5000000</cvs:InvestmentContractsWithFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="i699884ef14c74682af2d844bfa691e05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTEtMS0xLTE2NzkwOA_9b95d19e-36e1-4afe-a7ff-685c804ba2ce"
      unitRef="usd">336000000</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="i863995f01893429ba0b90278c34784f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTMtMS0xLTE2NzkwOA_a7101b6d-d77f-4a89-97df-de3279d7b163"
      unitRef="usd">0</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="i355cdb170edb433ca79e61e309a40c6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTUtMS0xLTE2NzkwOA_7bfe8b98-0f83-40a1-93ff-d3db9d50c164"
      unitRef="usd">0</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="i53c500be5647438295ed663bd07d0536_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTctMS0xLTE2NzkwOA_520c58fe-e320-40df-b803-4c5a347ede98"
      unitRef="usd">373000000</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure
      contextRef="iaf216acef3094d348747eeef4045d573_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzE5LTktMS0xLTE2NzkwOA_561de765-160c-404a-9ea5-8e737dcbb316"
      unitRef="usd">373000000</cvs:InvestmentContractsWithoutFixedMaturityFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i699884ef14c74682af2d844bfa691e05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTEtMS0xLTE2NzkwOA_44aad2c0-b3e6-43b9-94e0-c0f38f1e1e8d"
      unitRef="usd">56176000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i863995f01893429ba0b90278c34784f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTMtMS0xLTE2NzkwOA_a907b5db-7f0c-485f-be7f-b6e7eafe0b72"
      unitRef="usd">64157000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i355cdb170edb433ca79e61e309a40c6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTUtMS0xLTE2NzkwOA_29491703-954a-4735-aabb-66a2f4bc39f1"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i53c500be5647438295ed663bd07d0536_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTctMS0xLTE2NzkwOA_d5505119-bd1f-4935-9cbc-5a01314c645b"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iaf216acef3094d348747eeef4045d573_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZTplNTFlYmJiYzQ0NzM0MTgwODA5NDE1NDQwNTllNjNhNS90YWJsZXJhbmdlOmU1MWViYmJjNDQ3MzQxODA4MDk0MTU0NDA1OWU2M2E1XzIwLTktMS0xLTE2NzkwOA_ff69a0ce-5c2f-4e0d-a386-37f86c2925a0"
      unitRef="usd">64157000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i7844b63d898f426f84d9c961ce7de5ab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzI3NDg3NzkwODE4MDg_1900634a-efaf-4609-9bcd-e1ab2bfa0e8e"
      unitRef="usd">3000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMjM1_63661af3-f6f0-45fa-be23-abe39b47b5f9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separate Accounts financial assets at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common/collective trusts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Excludes $85 million of other payables and $70&#160;million of other receivables at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock>
    <us-gaap:SeparateAccountAssets
      contextRef="i0e0582621bb34df0a6675d029c295a94_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMS0xLTEtMTY3OTA4_e0117d24-f033-476e-b5ca-f1d5eeb995f3"
      unitRef="usd">2000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i9e64cd8ab5fb4322a855fe783aaa1050_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMy0xLTEtMTY3OTA4_63918100-fb23-4ffb-a400-254ec9170859"
      unitRef="usd">154000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="ibd86471ead2541e4b8e2ee2e52429bcc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItNS0xLTEtMTY3OTA4_e0924231-bc5d-44b5-b0f5-85b599ceb909"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i1caa2a8534f942fdb15c0e68a3ba7cb3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItNy0xLTEtMTY3OTA4_8ab7cd81-9077-49d4-acc1-684954af2c3a"
      unitRef="usd">156000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i2d1901bac7f448c48fe0d4065b09e0e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItOS0xLTEtMTY3OTA4_3164b44a-4008-41f5-a3d5-0c8eff0614cc"
      unitRef="usd">2000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i275d0ec6124c46a7ab946d9a16477a75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMTEtMS0xLTE2NzkwOA_5e9a4e98-0bb1-4c49-8bc8-34f0ec09ac98"
      unitRef="usd">186000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i749066de634e42b3816f92927cdd0c23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMTMtMS0xLTE2NzkwOA_4a696873-cf05-49d8-866e-d4b218a77c2f"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i4f70ae1bf3c746fe82376b68d9bade16_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzItMTUtMS0xLTE2NzkwOA_70db5a20-21e0-4355-b9fd-5f2af572f951"
      unitRef="usd">188000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i76610efce5044b078fe774b073da1159_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMS0xLTEtMTY3OTA4_4bf63c4f-d4d3-48b2-ab65-4d44624896b1"
      unitRef="usd">712000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i799622beabe24d068a330216378ec7d8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMy0xLTEtMTY3OTA4_4bfef901-a81c-4411-8be1-8992c863b761"
      unitRef="usd">1965000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i303c9460e5aa40ba8797ef57bc7a6665_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtNS0xLTEtMTY3OTA4_855ac785-2c2c-411f-b131-d196e612fc7f"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="ib69cb21ce24c45138129b0b0b0258605_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtNy0xLTEtMTY3OTA4_97ea7335-bfdc-47c8-9e33-98762ffa00fa"
      unitRef="usd">2677000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="ie43f9bbeac1c48f09d85ab8bda317b67_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtOS0xLTEtMTY3OTA4_6858ff1f-8010-4e4e-b774-e6c5ea73673a"
      unitRef="usd">1233000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i790c87349c0545a0a15037b5863ea17b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMTEtMS0xLTE2NzkwOA_70b87e3a-94fd-4a0f-8f45-0bfd1edbb352"
      unitRef="usd">3048000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i796a9a2e1f724310a3315d9fc1be5789_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMTMtMS0xLTE2NzkwOA_0d2a9540-68ad-48c4-88ba-474585bb069c"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="ib9a6cb4a9a1a4a34a8a63c650df4220a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzMtMTUtMS0xLTE2NzkwOA_ab1450ed-8e4f-40a2-98e4-76ffad3516e7"
      unitRef="usd">4281000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i22d221a134574691acb5e35393d71d09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMS0xLTEtMTY3OTA4_0c3091eb-bdb2-4abb-9dd2-87baa8e3d5f4"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="id68f0f4d9e054479ba78b7c748a66258_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMy0xLTEtMTY3OTA4_29487353-1776-4b3a-93e5-83848badf1cd"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="iadc0567d043f4a288311dc383ab5b569_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtNS0xLTEtMTY3OTA4_6afd835e-1115-48fd-9693-a5a52a94453e"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="if034f6862b3d4fd4936961827df503fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtNy0xLTEtMTY3OTA4_f991885b-2246-44e1-846d-23007b5d980b"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i960dac857f814d2aaf3da5e41ab12bea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtOS0xLTEtMTY3OTA4_211b4887-18ef-41de-b0ba-6bdeeabfcbd5"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i9e1564d3fac24665bd7b402ab4a1fdea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMTEtMS0xLTE2NzkwOA_f17972e5-64ad-4411-8249-6980cc32ef96"
      unitRef="usd">1000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i769ac61262e54e7ea669fe5223c1a8a5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMTMtMS0xLTE2NzkwOA_90c855c7-7062-4247-9445-6bb5a9d1cffb"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="ieff1acae7f1f4a61995476442d7613e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzQtMTUtMS0xLTE2NzkwOA_0fbce9fa-4a94-462a-9dc4-42403f0d0d23"
      unitRef="usd">1000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i9b34eb9a40f14a1392d66709b0113c87_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMS0xLTEtMTY3OTA4_60bb84c4-bef6-40b9-9925-26388ae2f167"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i842dc9cc1f984655976affbd54127c54_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMy0xLTEtMTY3OTA4_3c75f1ba-f388-4517-b356-552279c8c18e"
      unitRef="usd">480000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i0d6d75b00af74666a638509a7b9e9285_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtNS0xLTEtMTY3OTA4_a1c70f5a-35ac-44a7-9214-a93da9abe9fc"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="if35e951e7f7044a78bdf58c5c994e504_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtNy0xLTEtMTY3OTA4_729ef065-116c-4766-870b-9489d10df521"
      unitRef="usd">480000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i8f80eb74b06647c996981ce7bb5b9d6a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtOS0xLTEtMTY3OTA4_fbc76e97-f2e5-4015-9458-61fcf5df10ad"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i0ceec40d348b417d9dc7a41eb39aa1b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMTEtMS0xLTE2NzkwOA_54dc04cb-0b70-4641-bbeb-a711b0a89420"
      unitRef="usd">547000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i5ad03180d40f4e7f900eaf9ce57d2f6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMTMtMS0xLTE2NzkwOA_83b0f1e2-c97a-4ffb-b080-e262705360d2"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i2314c70272ad44729021b8b7c81f68d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzUtMTUtMS0xLTE2NzkwOA_b5cd9c12-6508-402e-a021-6642c6895a98"
      unitRef="usd">547000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i4f6777feef9d4cb08a3526828f50afc8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMS0xLTEtMTY3OTA4_e7683847-11bb-4699-9d3d-2cc400c7c5a6"
      unitRef="usd">714000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="ibc0c69d485444837bbae724a028fb845_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMy0xLTEtMTY3OTA4_3b50b8f0-95d3-4ff1-a139-8b7fa0933bcc"
      unitRef="usd">2599000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="id39f877dc08449f49c5fa9feb476a432_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtNS0xLTEtMTY3OTA4_22d6453e-5229-4d82-adfa-c0c8e2f08eed"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i58f243d98dd94b418abfc33c268175f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtNy0xLTEtMTY3OTA4_1bfec79c-3d46-41f6-9129-19e44220be4d"
      unitRef="usd">3313000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="iebec3ddc87aa4f2e8d9a97a6aea365d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtOS0xLTEtMTY3OTA4_798e0d93-0dd2-4211-92aa-65431e61d8e9"
      unitRef="usd">1235000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i795b096e03294f5da8368aac1b682f6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMTEtMS0xLTE2NzkwOA_0a5470f4-62f3-4f15-92b9-c78f44707cf7"
      unitRef="usd">3782000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="ideffc599afc64e2eb2ba34d383e611f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMTMtMS0xLTE2NzkwOA_53ca08a0-8ca5-4ee6-ba65-e4b650acf29b"
      unitRef="usd">0</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets
      contextRef="i1d831efff9ed4012a3c45a15c640b22f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90YWJsZToyZjAwODU0ZDFlMTY0OTNmOTBkNTkzNjhkZGIxZGU0Yy90YWJsZXJhbmdlOjJmMDA4NTRkMWUxNjQ5M2Y5MGQ1OTM2OGRkYjFkZTRjXzYtMTUtMS0xLTE2NzkwOA_0d6f32f0-e351-4029-993b-cd370a7a16ed"
      unitRef="usd">5017000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountsLiability
      contextRef="i6247aa5d844b4cefa1e771f6ef8a7da7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMDIy_336ebc6f-bf50-4893-93ba-c07958a378de"
      unitRef="usd">85000000</us-gaap:SeparateAccountsLiability>
    <us-gaap:SeparateAccountAssets
      contextRef="i74b7d5d8bfba43248a819e81b1b296b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMDI5_b1b77d1a-11ea-412e-a5b1-f1ec2ae76637"
      unitRef="usd">70000000</us-gaap:SeparateAccountAssets>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i194bc2ab09d84172aea4a9682706e5a8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMTQ1_cf8a3aa4-09c2-44cc-b54e-224214bac73d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="id206ebf70f104468bb9392e4f8e41a61_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzAvZnJhZzozMTg3MjAwYzNkMzM0NTgzYWZmMjIxMDRlMDhmNzI3ZC90ZXh0cmVnaW9uOjMxODcyMDBjM2QzMzQ1ODNhZmYyMjEwNGUwOGY3MjdkXzEwMTQ1_d958ea13-c566-47f9-a80b-40498e01fb77"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyODk_e635c5b9-33b8-4821-9eee-b86a67145fcf">Goodwill and Other Intangibles&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the changes in the carrying amount of goodwill by segment for the&#160;years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Health Care&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmacy&lt;br/&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retail/&lt;br/&gt;LTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt;padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the decrease in the carrying amount of goodwill was primarily driven by the divestitures of bswift, PayFlex and the Thailand business. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information. During the year ended December&#160;31, 2021, the decrease in the carrying amount of goodwill was primarily driven by the impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated an impairment of the goodwill associated with the LTC reporting unit, as the reporting unit&#x2019;s carrying value exceeded its fair value as of the testing date. The results of the impairment tests of the remaining reporting units indicated that there was no impairment of goodwill as of the testing date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the LTC reporting unit continued to face challenges that have impacted the Company&#x2019;s ability to grow the LTC reporting unit&#x2019;s business at the rate estimated when its 2020 goodwill impairment test was performed. These challenges include lower net facility admissions, net long-term care facility customer losses and the prolonged adverse impact of the COVID-19 pandemic and the emerging new variants, which resulted in more significant declines in occupancy rates experienced by the Company&#x2019;s long-term care facility customers than previously anticipated. During the third quarter of 2021, LTC management updated their 2021 annual forecast and submitted their long-term plan which showed deterioration in the financial results for the remainder of 2021 and beyond. The Company utilized these updated projections in performing its annual impairment test, which indicated that the fair value of the LTC reporting unit was lower than its carrying value, resulting in a $431&#160;million goodwill impairment charge in the third quarter of 2021. The fair value of the LTC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. As of December&#160;31, 2021, there was no remaining goodwill balance in the LTC reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At both December&#160;31, 2022 and 2021, cumulative goodwill impairments were $6.6 billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the Company&#x2019;s intangible assets as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions, except weighted average life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks (indefinite-lived)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts/relationships and covenants not to compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider networks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of Business Acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks (indefinite-lived)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts/relationships and covenants not to compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider networks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of Business Acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes intangible assets of $28&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the reduction in the customer contracts/relationships intangible assets is primarily related to the Company&#x2019;s loss on assets held for sale of $2.5&#160;billion to write-down the LTC business to its estimated fair value less costs to sell. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for intangible assets totaled $1.8 billion, $2.3 billion and $2.3 billion for the years ended December 31, 2022, 2021 and 2020, respectively. The projected annual amortization expense for the Company&#x2019;s intangible assets for the next five&#160;years is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyOTA_e506d9b8-1195-415a-b224-140554322b69">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the changes in the carrying amount of goodwill by segment for the&#160;years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Health Care&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmacy&lt;br/&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retail/&lt;br/&gt;LTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt;padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i17f9799c87004ca590fa53584c7e24f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEtMS0xLTEtMTY3OTA4_4e52efcb-64bf-4914-9fc0-9ca985fd69f8"
      unitRef="usd">45130000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ice6f1f557fab4461b4f09715be534c58_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEtMy0xLTEtMTY3OTA4_282cc25c-cbcd-482e-a34e-823be426beed"
      unitRef="usd">23615000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib4751bc253ec4ddf90922f866ccf2b7f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEtNS0xLTEtMTY3OTA4_ce4ceb3a-d2e8-4ca9-bc9f-b277dd5ddb8c"
      unitRef="usd">10807000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEtNy0xLTEtMTY3OTA4_606a19bf-aa97-4e17-8044-94254e157d7c"
      unitRef="usd">79552000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iefb4b1c3d63e4323ae108f339bf86ea0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzUtMS0xLTEtMTY3OTA4_2345b7c2-9328-4c99-9c5a-fb96bf843363"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ifffd3cc38a8b4021a53283d65a4c0964_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzUtMy0xLTEtMTY3OTA4_eafd042e-1b24-4605-a0d8-00f58f8aead8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1e0fac73260b479989119ffb924ad3e9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzUtNS0xLTEtMTY3OTA4_f20e94b8-7103-4aba-9d72-a3f4aef5abe3"
      unitRef="usd">431000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzUtNy0xLTEtMTY3OTA4_a3ec6914-8889-4b8f-8a5c-c8f6b4338d02"
      unitRef="usd">431000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ief7e4c14ecb14064a1e1cb88fae9be52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzYtMS0xLTEtMTY3OTA4_bd2e85cc-28fa-45c3-903d-6a3c974d5dc4"
      unitRef="usd">45130000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie09cd220413f4c58b188c10acdaca66c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzYtMy0xLTEtMTY3OTA4_01dc82eb-3819-455c-8291-ba6237df2581"
      unitRef="usd">23615000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ief0e8d9ed04c418a948fd84835bca811_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzYtNS0xLTEtMTY3OTA4_e76098e5-5f76-4ee2-8e52-2a8da4cb4e95"
      unitRef="usd">10376000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzYtNy0xLTEtMTY3OTA4_287a31e7-d519-434c-8599-6c8b0537426e"
      unitRef="usd">79121000000</us-gaap:Goodwill>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i508064fb813a4f16a124a4de02fbcd59_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzktMS0xLTEtMjE2MTMx_8b2d0e84-2f2d-4f86-b62e-1bdd3f90f0ec"
      unitRef="usd">971000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i6ef4eb7b015b4186b848a7d8272984a6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzktMy0xLTEtMjE2MTMx_916f1d74-d1cf-413a-a9c7-050a62a864db"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i96931f5310964061af361408b2ab6730_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzktNS0xLTEtMjE2MTMx_eac527dd-0b08-4064-9410-6594f7efba81"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="if8d9089fdf7c4007bbe779a88d4715e8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzktNy0xLTEtMjE2MTMx_be7c9659-140b-4a3d-8e54-0373c5cd1dae"
      unitRef="usd">971000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:Goodwill
      contextRef="ic3b3902b297a43b9a015149f29e45bf7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEwLTEtMS0xLTE2NzkwOA_62abb7cb-fb0c-4be0-acd1-e37569d32722"
      unitRef="usd">44159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8c4edc5b99644fa3997863adf1255293_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEwLTMtMS0xLTE2NzkwOA_91661278-6978-4f46-950a-d15318b92d3b"
      unitRef="usd">23615000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4fef13855a34463aaa68cd3b16edb43c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEwLTUtMS0xLTE2NzkwOA_4cdb6ac9-5044-4d49-a53d-47d0549c8aab"
      unitRef="usd">10376000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTo1ZGJmMmY1YTRmZmY0YzVhOWE1NjQ4MTA0ODMxNTFjYS90YWJsZXJhbmdlOjVkYmYyZjVhNGZmZjRjNWE5YTU2NDgxMDQ4MzE1MWNhXzEwLTctMS0xLTE2NzkwOA_1f7004fe-54e4-4380-900a-c9aa8e8c7c75"
      unitRef="usd">78150000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie0d6894378d3433197250c8e10ca47a7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzIxMDM_2a53c550-bba0-443d-88c9-22f7b32a8c68"
      unitRef="usd">431000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i9bc72442418741689eed1454ae87700b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyODE_c7fb74a3-92e8-4d00-98ab-aa1a21ff441e"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzIxOTkwMjMyNjYzOTU_24ffe6a6-8290-45a9-a38a-fc683587d6ca"
      unitRef="usd">6600000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzIxOTkwMjMyNjYzOTU_9bf9ca4f-01ab-4dd3-a5c7-3c709c926c07"
      unitRef="usd">6600000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <cvs:FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyODU_29cf2f62-906c-415e-8ae7-a87704623021">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the Company&#x2019;s intangible assets as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions, except weighted average life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks (indefinite-lived)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts/relationships and covenants not to compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider networks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of Business Acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks (indefinite-lived)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts/relationships and covenants not to compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider networks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of Business Acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes intangible assets of $28&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</cvs:FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzItMS0xLTEtMTY3OTA4_d926de93-8213-4ac4-8b0b-4324c6a65687"
      unitRef="usd">10498000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzItNS0xLTEtMTY3OTA4_5e7b241a-1999-4207-a918-389337433577"
      unitRef="usd">10498000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i264d976e57564672b0babd9565bb98e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzMtMS0xLTEtMTY3OTA4_8d6dfb59-f40b-4d88-9c90-74a7316426ab"
      unitRef="usd">21206000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i264d976e57564672b0babd9565bb98e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzMtMy0xLTEtMTY3OTA4_3e707306-aff0-4743-a7b2-37e8e0f50a16"
      unitRef="usd">10668000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i264d976e57564672b0babd9565bb98e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzMtNS0xLTEtMTY3OTA4_4649f8da-7e0f-4e05-9be2-9986baf17bdb"
      unitRef="usd">10538000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="iab7e8be7f4e347beb8eceb156d106b36_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzMtNy0xLTEtMTY3OTA4_764b75a2-5fae-435f-979d-7854b5b3ab04">P13Y3M18D</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i53d0930b2b2543929971d15fba0e45ea_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzQtMS0xLTEtMTY3OTA4_b08834d8-e6a8-4015-96db-f5894cb49c2f"
      unitRef="usd">1060000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i53d0930b2b2543929971d15fba0e45ea_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzQtMy0xLTEtMTY3OTA4_319fe20b-8e02-438b-8a68-bc15a547bfef"
      unitRef="usd">1060000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i53d0930b2b2543929971d15fba0e45ea_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzQtNS0xLTEtMTY3OTA4_068ff31b-7461-4da7-adce-43e54a32c902"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib8e8c8634f0645dfb503773210e8249a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzUtMS0xLTEtMTY3OTA4_221cbbc7-c1c2-4881-8c19-d8c61fab764c"
      unitRef="usd">4203000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib8e8c8634f0645dfb503773210e8249a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzUtMy0xLTEtMTY3OTA4_f94f4441-b588-4f54-b182-e7605bb87f97"
      unitRef="usd">862000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib8e8c8634f0645dfb503773210e8249a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzUtNS0xLTEtMTY3OTA4_5a85977c-411b-4e1a-9789-5e00e973a20b"
      unitRef="usd">3341000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="ibdf8ae9241fe4e3481243778aef0f6e7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzUtNy0xLTEtMTY3OTA4_6b377cef-ad24-4ed8-afd8-98580f7ed778">P20Y</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6b5b7dc71ff1469ab8a6a25decd8cfd6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzYtMS0xLTEtMTY3OTA4_af478ec1-f459-42f7-8f70-d8b3af003078"
      unitRef="usd">590000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6b5b7dc71ff1469ab8a6a25decd8cfd6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzYtMy0xLTEtMTY3OTA4_46714254-3ff2-49f1-8a25-bbe9f052bc63"
      unitRef="usd">223000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6b5b7dc71ff1469ab8a6a25decd8cfd6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzYtNS0xLTEtMTY3OTA4_5d3b218a-6684-44a4-b96c-f596fc57904b"
      unitRef="usd">367000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="i21cba4373fef485faa84dab5def0f790_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzYtNy0xLTEtMTY3OTA4_7e70b598-165c-4982-8882-4806f401d989">P20Y</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if745b6dc0a754cd8914c4f5726b7f6bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzctMS0xLTEtMTY3OTA4_ce32679f-6e9f-4f2e-af1f-1c8d9917648a"
      unitRef="usd">302000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if745b6dc0a754cd8914c4f5726b7f6bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzctMy0xLTEtMTY3OTA4_fe9c4afd-e981-4e5b-b5e5-4f5a1f6ee229"
      unitRef="usd">264000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if745b6dc0a754cd8914c4f5726b7f6bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzctNS0xLTEtMTY3OTA4_b85409a5-b7c3-4764-a0db-4610b0aaa3f1"
      unitRef="usd">38000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="iea5c2c83314342409224f6f5d753bd47_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzctNy0xLTEtMTY3OTA4_f38b8260-807a-403d-9369-655e2f3ed10f">P12Y4M24D</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzgtMS0xLTEtMTY3OTA4_01d9bda7-b70c-457f-a288-c78fbae4ece3"
      unitRef="usd">37859000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzgtMy0xLTEtMTY3OTA4_5ba72533-738e-4c61-9117-79ed493f9f75"
      unitRef="usd">13077000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cvs:IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzgtNS0xLTEtMTY3OTA4_2432ffba-35c9-4377-8d75-86fcf380a7cf"
      unitRef="usd">24782000000</cvs:IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzgtNy0xLTEtMTY3OTA4_f482e107-59d0-43af-92ea-3d537f204aba">P13Y10M24D</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzExLTEtMS0xLTE2NzkwOA_0710f8b7-afc7-4431-a314-1d3299f905ab"
      unitRef="usd">10498000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzExLTUtMS0xLTE2NzkwOA_b4f6a630-496a-4b6a-823e-c551b95c882f"
      unitRef="usd">10498000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3a19e9a51cc547949bdde2b93fb44a8e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEyLTEtMS0xLTE2NzkwOA_2fb5627a-9870-43ed-b377-11d34b46458d"
      unitRef="usd">25084000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3a19e9a51cc547949bdde2b93fb44a8e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEyLTMtMS0xLTE2NzkwOA_fc1a93a3-adaa-4d6b-a203-a5e9b76d963b"
      unitRef="usd">10564000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3a19e9a51cc547949bdde2b93fb44a8e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEyLTUtMS0xLTE2NzkwOA_d3686f09-d3b3-42f8-8c58-e76cf72d671b"
      unitRef="usd">14520000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="i7424dfa102ba4c84917a87df011344b5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEyLTctMS0xLTE2NzkwOA_35b0e845-c134-4ba8-8ea7-8ed283e8bc7c">P15Y</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i58636af2c05a4a5d816b65538e4b45c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEzLTEtMS0xLTE2NzkwOA_83eb2765-8967-465a-88b1-4382b7cb8e65"
      unitRef="usd">1060000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i58636af2c05a4a5d816b65538e4b45c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEzLTMtMS0xLTE2NzkwOA_47b39030-6795-4459-b1f3-9e2586819a5e"
      unitRef="usd">1060000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i58636af2c05a4a5d816b65538e4b45c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzEzLTUtMS0xLTE2NzkwOA_cec3b7ff-a2e9-4f2a-87e8-a71690326e75"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id8f8326f384345448eaf5b58a4b2a7df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE0LTEtMS0xLTE2NzkwOA_15b8c836-c68a-4125-b763-d65d069c5cda"
      unitRef="usd">4203000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id8f8326f384345448eaf5b58a4b2a7df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE0LTMtMS0xLTE2NzkwOA_a8bdae57-a559-458e-8d3c-f78aac938e02"
      unitRef="usd">651000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id8f8326f384345448eaf5b58a4b2a7df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE0LTUtMS0xLTE2NzkwOA_21968bcd-72b2-4b5f-8908-6534c898d834"
      unitRef="usd">3552000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="ida22ed7ae3e1481db1884a9cb038c03f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE0LTctMS0xLTE2NzkwOA_72a5319d-a715-4e1a-aadd-039e8feb90f4">P20Y</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i32bdea3056074d3b98bbd8937ef4391d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE1LTEtMS0xLTE2NzkwOA_7d963010-24e6-4b15-8da9-94d8157bfd5f"
      unitRef="usd">590000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i32bdea3056074d3b98bbd8937ef4391d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE1LTMtMS0xLTE2NzkwOA_7f115c9f-96e1-4200-b118-7ee3f3a92c16"
      unitRef="usd">173000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i32bdea3056074d3b98bbd8937ef4391d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE1LTUtMS0xLTE2NzkwOA_06b086e2-715f-49d6-a409-47df45b42492"
      unitRef="usd">417000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="i8b7e0efc2e614022be02cce608679450_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE1LTctMS0xLTE2NzkwOA_abbe8b66-f0d8-498c-9270-fdd462e2d743">P20Y</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifd3a6f7782284dbb9c5b5e9b11d670b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE2LTEtMS0xLTE2NzkwOA_503a197c-247c-46c1-80f9-f2192da899a5"
      unitRef="usd">318000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifd3a6f7782284dbb9c5b5e9b11d670b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE2LTMtMS0xLTE2NzkwOA_2a93bb08-0bd2-467a-a044-7bf763537783"
      unitRef="usd">279000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifd3a6f7782284dbb9c5b5e9b11d670b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE2LTUtMS0xLTE2NzkwOA_7be3ffcf-1724-411c-943f-64862c54f686"
      unitRef="usd">39000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="i9626105cd75b4a3a9391af2fd8b0ea24_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE2LTctMS0xLTE2NzkwOA_35a24589-97ad-4577-9429-6228a6a4271f">P8Y4M24D</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE3LTEtMS0xLTE2NzkwOA_a1cc6565-62e9-4dc7-8dc4-ddbe1f7a4864"
      unitRef="usd">41753000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE3LTMtMS0xLTE2NzkwOA_e2705d7e-78fc-4383-8bbe-40c8c6af501f"
      unitRef="usd">12727000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cvs:IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE3LTUtMS0xLTE2NzkwOA_5f06427e-0daa-4d17-ac17-03de123e7ab9"
      unitRef="usd">29026000000</cvs:IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTowOTJhZmZkNWZhZjM0YTJmYjU3OTdjZWVkYzg5NDNjMi90YWJsZXJhbmdlOjA5MmFmZmQ1ZmFmMzRhMmZiNTc5N2NlZWRjODk0M2MyXzE3LTctMS0xLTE2NzkwOA_38d9ded8-f259-4990-9360-872b78cab71d">P15Y3M18D</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <cvs:IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzgyNDYzMzcyMTM4NTQ_b72325ad-adb8-4902-9aa8-c4813f114600"
      unitRef="usd">28000000</cvs:IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i749b13bb01c043f9a3cb673b0a199669_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5Xzk4OTU2MDQ2NTg0MjM_90553cb1-9a10-4dfd-95b6-1ec8d2d55bd8"
      unitRef="usd">2500000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMwODY_d5fae5d6-9b1e-4efd-ad8b-c67b652105d4"
      unitRef="usd">1800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMwOTA_42aea2ae-cc09-4d8a-bcbf-565e6f42092e"
      unitRef="usd">2300000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMwOTc_5180d960-af76-45af-8dfe-45a6858b23e0"
      unitRef="usd">2300000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90ZXh0cmVnaW9uOmNlMGFiM2ExZTlkYzQ5Y2JhYWJlNDE3MzA1YmIyMjk5XzMyODQ_57ee9463-1d50-4c8e-a2e8-0ca3cd76277b">The projected annual amortization expense for the Company&#x2019;s intangible assets for the next five&#160;years is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzEtMS0xLTEtMTY3OTA4_e7fdc3a9-f1e5-44b5-a51d-c76d74c6456e"
      unitRef="usd">1620000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzItMS0xLTEtMTY3OTA4_0cbb9ef3-09e5-42f9-a2fb-3d16ab06e9a9"
      unitRef="usd">1577000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzMtMS0xLTEtMTY3OTA4_e9f5c7b0-abd8-48bb-96ea-12d8beaaf720"
      unitRef="usd">1526000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzQtMS0xLTEtMTY3OTA4_d1ef15ec-d542-4d68-bedd-c20fe8876e21"
      unitRef="usd">1290000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzMvZnJhZzpjZTBhYjNhMWU5ZGM0OWNiYWFiZTQxNzMwNWJiMjI5OS90YWJsZTpkODc4OWZkZjJjOWQ0OTdkYjc1ZGI4OWJjYWVlYTJiNC90YWJsZXJhbmdlOmQ4Nzg5ZmRmMmM5ZDQ5N2RiNzVkYjg5YmNhZWVhMmI0XzUtMS0xLTEtMTY3OTA4_f6d54604-e0f1-451c-ac6b-9757ddc4207c"
      unitRef="usd">1200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3Njg_14665906-0fd7-43fd-b97f-0646b189bbf9">Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the components of net lease cost for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for interest portion of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows paid for principal portion of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions, except remaining lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,928&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,122&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,699&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,177&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,538&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,823&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance leases:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(284)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,324&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining lease term &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes operating lease right-of-use assets of $56&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes current portion of operating lease liabilities of $21&#160;million and long-term operating lease liabilities of $39&#160;million which have been accounted for as liabilities held for sale and are included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturity of lease liabilities under finance and operating leases as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating&lt;br/&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Future operating lease payments have not been reduced by minimum sublease rentals of $290 million due in the future under noncancelable subleases.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.5 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale-Leaseback Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2022 or 2021. Proceeds from sale-leaseback transactions totaled $101 million in the year ended December 31, 2020. Gains from sale-leaseback transactions totaled $3 million in the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Office Real Estate Optimization Charges &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022, the Company undertook an initiative to evaluate its corporate office real estate space in response to its new flexible work arrangement. As part of this initiative, the Company evaluated its current real estate space and changes in employee work arrangement requirements to ensure it had the appropriate space to support the business. As a result of this assessment, the Company determined that it would vacate and abandon certain leased corporate office spaces. Accordingly, in the three months ended December 31, 2022, the Company recorded office real estate optimization charges of $117&#160;million, primarily consisting of $71&#160;million related to operating lease right-of-use assets and $44&#160;million related to property and equipment, within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Store Impairment Charges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group&#x2019;s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company&#x2019;s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the &#x201c;Board&#x201d;) authorized the closing of approximately 900 retail stores, approximately 300 stores each year, between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores&#x2019; asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1&#160;billion related to operating lease right-of-use assets and $261&#160;million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $356&#160;million and $185&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzA_c8247dd6-2a00-4515-a0ea-cddb544b27de">Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the components of net lease cost for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for interest portion of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows paid for principal portion of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions, except remaining lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,928&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,122&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,699&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,177&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,538&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,823&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance leases:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(284)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,324&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining lease term &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes operating lease right-of-use assets of $56&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes current portion of operating lease liabilities of $21&#160;million and long-term operating lease liabilities of $39&#160;million which have been accounted for as liabilities held for sale and are included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturity of lease liabilities under finance and operating leases as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating&lt;br/&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Future operating lease payments have not been reduced by minimum sublease rentals of $290 million due in the future under noncancelable subleases.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.5 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale-Leaseback Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2022 or 2021. Proceeds from sale-leaseback transactions totaled $101 million in the year ended December 31, 2020. Gains from sale-leaseback transactions totaled $3 million in the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Office Real Estate Optimization Charges &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022, the Company undertook an initiative to evaluate its corporate office real estate space in response to its new flexible work arrangement. As part of this initiative, the Company evaluated its current real estate space and changes in employee work arrangement requirements to ensure it had the appropriate space to support the business. As a result of this assessment, the Company determined that it would vacate and abandon certain leased corporate office spaces. Accordingly, in the three months ended December 31, 2022, the Company recorded office real estate optimization charges of $117&#160;million, primarily consisting of $71&#160;million related to operating lease right-of-use assets and $44&#160;million related to property and equipment, within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Store Impairment Charges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group&#x2019;s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company&#x2019;s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the &#x201c;Board&#x201d;) authorized the closing of approximately 900 retail stores, approximately 300 stores each year, between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores&#x2019; asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1&#160;billion related to operating lease right-of-use assets and $261&#160;million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $356&#160;million and $185&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ic2a7b9e629c14bcc9865d4798fa5e15c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzIxOTkwMjMyNzM4MTI_794bc65c-b583-44a9-bf35-ac34fa281853">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="ic2a7b9e629c14bcc9865d4798fa5e15c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzIxOTkwMjMyNzM4MTI_aed016fb-72ee-44f5-be1e-0d7f4aa062eb">P15Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i2e150d3db673482e817a73aceedfec35_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzQ_0e1c117e-fd6c-4c3d-b87d-b5ebe91fae1b">P25Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i2e150d3db673482e817a73aceedfec35_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzQ_8f220399-e5f2-4db3-a3e7-4f9d641a5324">P25Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ife6ff41a415343de94e5806faaabb281_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzIxOTkwMjMyNzM4MjA_1a1b4726-1469-49c3-8d93-c21eb63a453a">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="ife6ff41a415343de94e5806faaabb281_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzIxOTkwMjMyNzM4MjA_8f744123-ee14-4dcc-bb45-9d94a32f8e50">P3Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="id427563c92b54e5f88ceb5b6ec87195c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzE_4f7c045a-ea47-4cbe-ae7b-56a349ed5aaa">P10Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id427563c92b54e5f88ceb5b6ec87195c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzE_e795ccd5-4334-4d88-bdc5-5cd04e4ef1ca">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzI_42abfb33-a9ae-4ff1-ade7-dee9be123362">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the components of net lease cost for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for interest portion of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows paid for principal portion of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzEtMS0xLTEtMTY3OTA4_4af92a2f-7f7c-40b1-bc83-d4fccd23852c"
      unitRef="usd">2579000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzEtMy0xLTEtMTY3OTA4_9a3c9f3a-6c10-46ae-8c03-b99c5b448d8a"
      unitRef="usd">2633000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzEtNS0xLTEtMTY3OTA4_93e1a19a-f4ed-4615-b9eb-eeadbe48e47c"
      unitRef="usd">2670000000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzMtMS0xLTEtMTY3OTA4_5aa9cb14-4129-4e3a-b4bd-a4b4495f1b41"
      unitRef="usd">79000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzMtMy0xLTEtMTY3OTA4_587a6107-515a-44bc-8455-46f1b0698b30"
      unitRef="usd">62000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzMtNS0xLTEtMTY3OTA4_d0927cff-4514-4ae6-8ba0-eb3f8396c4c5"
      unitRef="usd">56000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzQtMS0xLTEtMTY3OTA4_6f1a008f-2177-4587-98b2-5dd6623cfb07"
      unitRef="usd">68000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzQtMy0xLTEtMTY3OTA4_b523b8e1-07b3-4188-aee5-ce4e3373c8ed"
      unitRef="usd">62000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzQtNS0xLTEtMTY3OTA4_412074d2-b1a9-4bd0-af25-c2c9b3ddebe6"
      unitRef="usd">58000000</us-gaap:FinanceLeaseInterestExpense>
    <cvs:FinanceLeaseCost
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzUtMS0xLTEtMTY3OTA4_d1d0a764-085b-42fc-8e80-244f4fbbf4fb"
      unitRef="usd">147000000</cvs:FinanceLeaseCost>
    <cvs:FinanceLeaseCost
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzUtMy0xLTEtMTY3OTA4_99f7cc91-0c1e-4ff4-8aff-e1cc942a242f"
      unitRef="usd">124000000</cvs:FinanceLeaseCost>
    <cvs:FinanceLeaseCost
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzUtNS0xLTEtMTY3OTA4_62d1b4ae-732c-46d1-bb2a-981eebd8fd14"
      unitRef="usd">114000000</cvs:FinanceLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzYtMS0xLTEtMTY3OTA4_310100c0-c927-4127-8ab0-a7771a5962da"
      unitRef="usd">27000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzYtMy0xLTEtMTY3OTA4_d1bbdfe1-f8a1-43a2-bd87-8b25c0590a11"
      unitRef="usd">25000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzYtNS0xLTEtMTY3OTA4_b2c565db-9b97-4035-b2c7-00711e8c0941"
      unitRef="usd">22000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzctMS0xLTEtMTY3OTA4_d20e5a6c-3115-4e6a-8d41-743bfd2db79c"
      unitRef="usd">610000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzctMy0xLTEtMTY3OTA4_9b9d8ebc-bfc3-4b1d-80dd-0583a481fbf0"
      unitRef="usd">604000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzctNS0xLTEtMTY3OTA4_7bffa87c-9205-4562-b368-1f4a10286f1c"
      unitRef="usd">599000000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzgtMS0xLTEtMTY3OTA4_cd70e476-b7b1-4ade-8b3f-30145c3d7277"
      unitRef="usd">61000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzgtMy0xLTEtMTY3OTA4_3c54918d-8e4f-4d97-9f84-4dc9122e076d"
      unitRef="usd">59000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzgtNS0xLTEtMTY3OTA4_683ce484-e847-4a3d-bf31-611adbdbccbf"
      unitRef="usd">55000000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzktMS0xLTEtMTY3OTA4_ddabeb85-213d-41c0-af52-65e047b00d78"
      unitRef="usd">3302000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzktMy0xLTEtMTY3OTA4_92a64bb9-d1b8-49fd-aee1-f5c15e97ae3d"
      unitRef="usd">3327000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxMzBjZWRiMDhkMzc0NDdkYmVmNzA5ODIzODlhOGY3Ny90YWJsZXJhbmdlOjEzMGNlZGIwOGQzNzQ0N2RiZWY3MDk4MjM4OWE4Zjc3XzktNS0xLTEtMTY3OTA4_25fb4f8a-aa5d-4234-b39b-02fb7d94f015"
      unitRef="usd">3350000000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzItMS0xLTEtMTY3OTA4_772fd34c-5f4e-49db-b32c-ded51cc2c271"
      unitRef="usd">2689000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzItMy0xLTEtMTY3OTA4_3012b09a-0f97-43dd-8bb7-c5278a251272"
      unitRef="usd">2714000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzItNS0xLTEtMTY3OTA4_6a2cc99e-fe93-42ce-8674-0ff4479e2c8b"
      unitRef="usd">2724000000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzMtMS0xLTEtMTY3OTA4_fc74a6ef-e626-4f59-9e74-ec8fa4b4c480"
      unitRef="usd">68000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzMtMy0xLTEtMTY3OTA4_7be46d50-37a7-47db-b366-062eb0167384"
      unitRef="usd">62000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzMtNS0xLTEtMTY3OTA4_7d45f7b1-6f70-4e14-a4e9-b00fb5a0945b"
      unitRef="usd">58000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzQtMS0xLTEtMTY3OTA4_6379f5bf-7042-4a67-adab-ac63537d943a"
      unitRef="usd">62000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzQtMy0xLTEtMTY3OTA4_13cf0088-bbbc-4c27-bdcd-ae75a976490a"
      unitRef="usd">50000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzQtNS0xLTEtMTY3OTA4_580b192a-1bdc-4a60-93b8-c9bea5564a76"
      unitRef="usd">34000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzYtMS0xLTEtMTY3OTA4_dfdb9d30-22f4-4d60-870d-0da86f8f9063"
      unitRef="usd">591000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzYtMy0xLTEtMTY3OTA4_0e180ed3-333a-4ba0-9cd6-fcd6ee9a3852"
      unitRef="usd">1254000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzYtNS0xLTEtMTY3OTA4_2eaf6b9d-e779-47ae-af25-a475ef719dbe"
      unitRef="usd">1679000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzctMS0xLTEtMTY3OTA4_cdf4c869-1140-4373-9de2-247bc122345b"
      unitRef="usd">232000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzctMy0xLTEtMTY3OTA4_bca2bb13-f0a5-4930-9e56-3ab9bb5092c4"
      unitRef="usd">278000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZToxYTgxMDQ3ZjZjNzA0NDIzYmU2ZDNlZTVjZmU1NjVlMC90YWJsZXJhbmdlOjFhODEwNDdmNmM3MDQ0MjNiZTZkM2VlNWNmZTU2NWUwXzctNS0xLTEtMTY3OTA4_f6bb9af6-a9b5-47c2-a4f8-9d5e325693d8"
      unitRef="usd">313000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <cvs:LesseeLeaseTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3NzY_778273b2-4c58-4bd7-881c-b6071d8fb7ef">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases as of December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions, except remaining lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,928&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,122&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,699&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,177&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,538&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,823&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance leases:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(284)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,324&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining lease term &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes operating lease right-of-use assets of $56&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes current portion of operating lease liabilities of $21&#160;million and long-term operating lease liabilities of $39&#160;million which have been accounted for as liabilities held for sale and are included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</cvs:LesseeLeaseTableTextBlock>
    <cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzItMS0xLTEtMTY3OTA4_916c3fed-ff4e-4f9c-81bd-bd18153cb848"
      unitRef="usd">17928000000</cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale>
    <cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzItMy0xLTEtMTY3OTA4_d7ccd18b-e5e7-48df-ae0c-511623021f78"
      unitRef="usd">19122000000</cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale>
    <cvs:OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzQtMS0xLTEtMTY3OTA4_52b6f1c5-1b81-4ac7-b782-81c0d153b935"
      unitRef="usd">1699000000</cvs:OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale>
    <cvs:OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzQtMy0xLTEtMTY3OTA4_132de6cf-53ce-4d1e-81ba-2e6b30ee0b71"
      unitRef="usd">1646000000</cvs:OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale>
    <cvs:OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzUtMS0xLTEtMTY3OTA4_3cb18170-6c5f-4bb8-b22e-01ac5cdfa2ba"
      unitRef="usd">16839000000</cvs:OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale>
    <cvs:OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzUtMy0xLTEtMTY3OTA4_deb912a2-ffef-44c8-8895-f0952be82d1a"
      unitRef="usd">18177000000</cvs:OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale>
    <us-gaap:OperatingLeaseLiability
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzYtMS0xLTEtMTY3OTA4_7398c491-d351-443f-82a1-5bc847d5be4c"
      unitRef="usd">18538000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzYtMy0xLTEtMTY3OTA4_8e88b11e-d074-4278-ac3c-7dd2674b8e61"
      unitRef="usd">19823000000</us-gaap:OperatingLeaseLiability>
    <cvs:FinanceLeaseRightOfUseAssetGross
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzktMS0xLTEtMTY3OTA4_5a183af9-d693-466a-a3a5-97ded7ce6514"
      unitRef="usd">1608000000</cvs:FinanceLeaseRightOfUseAssetGross>
    <cvs:FinanceLeaseRightOfUseAssetGross
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzktMy0xLTEtMTY3OTA4_8af09414-1f1f-434c-b8ba-ef19331a7bd8"
      unitRef="usd">1375000000</cvs:FinanceLeaseRightOfUseAssetGross>
    <cvs:FinanceLeaseRightOfUseAssetAccumulatedDepreciation
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzEwLTEtMS0xLTE2NzkwOA_0aa3adbc-ceea-40ff-8f6d-83763a755954"
      unitRef="usd">284000000</cvs:FinanceLeaseRightOfUseAssetAccumulatedDepreciation>
    <cvs:FinanceLeaseRightOfUseAssetAccumulatedDepreciation
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzEwLTMtMS0xLTE2NzkwOA_68591a61-3242-4ed0-bc7a-5c0c37ca7f52"
      unitRef="usd">188000000</cvs:FinanceLeaseRightOfUseAssetAccumulatedDepreciation>
    <cvs:FinanceLeaseRightOfUseAssetNet
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzExLTEtMS0xLTE2NzkwOA_d03d14d0-a302-4c5f-b7d3-91faf0e21d9d"
      unitRef="usd">1324000000</cvs:FinanceLeaseRightOfUseAssetNet>
    <cvs:FinanceLeaseRightOfUseAssetNet
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzExLTMtMS0xLTE2NzkwOA_254dcff1-50e4-4b74-8eb8-16926f46c277"
      unitRef="usd">1187000000</cvs:FinanceLeaseRightOfUseAssetNet>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzEzLTEtMS0xLTE2NzkwOA_669d4f7d-e60b-4907-9939-413e61bb0517"
      unitRef="usd">59000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzEzLTMtMS0xLTE2NzkwOA_0650c60f-bfa4-47b6-a14c-ecb8889216bf"
      unitRef="usd">50000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE0LTEtMS0xLTE2NzkwOA_02e972cd-ec62-4cb6-821c-17d0405b01cb"
      unitRef="usd">1406000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE0LTMtMS0xLTE2NzkwOA_1be2f287-5992-4a0c-968a-4b1640b8fcda"
      unitRef="usd">1250000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE1LTEtMS0xLTE2NzkwOA_d8bae112-3caf-461a-8db2-d5d3b9b70f32"
      unitRef="usd">1465000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE1LTMtMS0xLTE2NzkwOA_43c11955-04f3-4e48-86a6-f028e1fd628f"
      unitRef="usd">1300000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE4LTEtMS0xLTE2NzkwOA_34ab8d30-46f9-4b8c-b1b1-ca668f9a2b84">P12Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE4LTMtMS0xLTE2NzkwOA_d90b2e6d-2522-494f-ade8-00b81725e184">P12Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE5LTEtMS0xLTE2NzkwOA_71d91cb6-582a-4c7b-bb9f-f0a4c02957b0">P19Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzE5LTMtMS0xLTE2NzkwOA_2edd14fd-efc9-4f30-a55f-0999956fa803">P20Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzIyLTEtMS0xLTE2NzkwOA_f4cb9296-d819-4f53-bc49-91fc17c75cd4"
      unitRef="number">0.044</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzIyLTMtMS0xLTE2NzkwOA_ae253f84-6af6-40d2-9e79-8e5479d2c186"
      unitRef="number">0.044</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzIzLTEtMS0xLTE2NzkwOA_ad0526bc-7521-4867-a046-ce5e99eea2f6"
      unitRef="number">0.049</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTpmNTUyMzE3ZWQwN2U0NWVmOGMxNTgzZjdlYTJlMzBiMi90YWJsZXJhbmdlOmY1NTIzMTdlZDA3ZTQ1ZWY4YzE1ODNmN2VhMmUzMGIyXzIzLTMtMS0xLTE2NzkwOA_12759060-f13c-4d55-8878-0c242db6acc1"
      unitRef="number">0.050</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzgyNDYzMzcyMTY3NDU_9a0aea9f-fbd1-4c26-8105-5bb23b382c1b"
      unitRef="usd">56000000</cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale>
    <cvs:OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzgyNDYzMzcyMTY3MzM_c9946f83-c5aa-47ba-8f3f-4b57634df89d"
      unitRef="usd">21000000</cvs:OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale>
    <cvs:OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEwOTk1MTE2Mjk1NDE2_b68a0c1e-045e-480e-a69a-e749abf59ee9"
      unitRef="usd">39000000</cvs:OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3Nzc_1d820dba-4837-46a6-ae1f-51621fb133fb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturity of lease liabilities under finance and operating leases as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating&lt;br/&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Future operating lease payments have not been reduced by minimum sublease rentals of $290 million due in the future under noncancelable subleases.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.5 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzY3Nzg_6db5e56b-2f8c-42d8-b50d-2f4f540e0a68">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturity of lease liabilities under finance and operating leases as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating&lt;br/&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Future operating lease payments have not been reduced by minimum sublease rentals of $290 million due in the future under noncancelable subleases.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.5 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzEtMS0xLTEtMTY3OTA4_68bc5b18-b544-4a9c-8dfb-e98789f55cc3"
      unitRef="usd">139000000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzEtMy0xLTEtMTY3OTA4_6af85966-8432-42a1-b86d-a0db402d0a03"
      unitRef="usd">2685000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <cvs:LesseeLiabilityPaymentsYearOne
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzEtNS0xLTEtMTY3OTA4_d968a16d-45df-44a8-8120-e35d78a5e76c"
      unitRef="usd">2824000000</cvs:LesseeLiabilityPaymentsYearOne>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzItMS0xLTEtMTY3OTA4_24a209af-0add-4f2f-add9-21be9bf0f57c"
      unitRef="usd">130000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzItMy0xLTEtMTY3OTA4_0b51e3f4-1d25-408c-809e-0513519b9ebe"
      unitRef="usd">2499000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <cvs:LesseeLiabilityPaymentsDueYearTwo
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzItNS0xLTEtMTY3OTA4_8e8e4c72-f6a9-4559-86c3-030cdf228db2"
      unitRef="usd">2629000000</cvs:LesseeLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzMtMS0xLTEtMTY3OTA4_4ff49f78-6dc8-49eb-abcc-8a99b1c41333"
      unitRef="usd">128000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzMtMy0xLTEtMTY3OTA4_0d8bfd38-d6e8-4a38-8d0e-295070c547df"
      unitRef="usd">2313000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <cvs:LesseeLiabilityPaymentsDueYearThree
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzMtNS0xLTEtMTY3OTA4_181f1706-4fce-4978-9ae9-a44c93bbdf84"
      unitRef="usd">2441000000</cvs:LesseeLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzQtMS0xLTEtMTY3OTA4_d6d5c8b6-8242-49cb-b280-0339874db5d9"
      unitRef="usd">127000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzQtMy0xLTEtMTY3OTA4_6930f71d-78a5-495f-a34c-9dd445a8408e"
      unitRef="usd">2142000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <cvs:LesseeLiabilityPaymentsDueYearFour
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzQtNS0xLTEtMTY3OTA4_e3c4fd33-3fc5-4f44-9d9f-8ffc2dee1493"
      unitRef="usd">2269000000</cvs:LesseeLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzUtMS0xLTEtMTY3OTA4_c8e76d97-15ea-4fb9-84c3-989be563b252"
      unitRef="usd">124000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzUtMy0xLTEtMTY3OTA4_8f5938a7-a1a3-4ea4-81a1-737773095a6d"
      unitRef="usd">1989000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <cvs:LesseeLiabilityPaymentsDueYearFive
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzUtNS0xLTEtMTY3OTA4_80654949-c57b-4c4a-9c05-afc38f06a48d"
      unitRef="usd">2113000000</cvs:LesseeLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzYtMS0xLTEtMTY3OTA4_ec252632-38c8-401a-9b6c-3cf5edbf4065"
      unitRef="usd">1640000000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzYtMy0xLTEtMTY3OTA4_87193b7d-268e-451d-bfee-569b69f0a238"
      unitRef="usd">12411000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <cvs:LesseeLiabilityPaymentsDueAfterYearFive
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzYtNS0xLTEtMTY3OTA4_5a56c67d-5d9e-458a-bb12-402dc8a53649"
      unitRef="usd">14051000000</cvs:LesseeLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzctMS0xLTEtMTY3OTA4_9f4af7de-450b-4be5-9620-25027f16505b"
      unitRef="usd">2288000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzctMy0xLTEtMTY3OTA4_f6cf67b4-e629-4d4e-a73c-0ccc357b5657"
      unitRef="usd">24039000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <cvs:LesseeLiabilityPaymentsDue
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzctNS0xLTEtMTY3OTA4_3fadc3de-ca5a-4a1c-9992-baa0c199069a"
      unitRef="usd">26327000000</cvs:LesseeLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzgtMS0xLTEtMTY3OTA4_e4165326-1a4c-4ee8-85f6-8ff9bca8f304"
      unitRef="usd">823000000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzgtMy0xLTEtMTY3OTA4_16bb3dcc-f245-4776-9dbf-ab7311f7418b"
      unitRef="usd">5501000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <cvs:LesseeLiabilityUndiscountedExcessAmount
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzgtNS0xLTEtMTY3OTA4_26704fba-dea3-4cee-be05-1065cf7372f3"
      unitRef="usd">6324000000</cvs:LesseeLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzktMS0xLTEtMTY3OTA4_d92ef56b-a070-497d-93ab-370713ac961b"
      unitRef="usd">1465000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzktMy0xLTEtMTY3OTA4_dcf490a8-35b1-485a-9c8d-145e2bd11cde"
      unitRef="usd">18538000000</us-gaap:OperatingLeaseLiability>
    <cvs:LeaseLiability
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90YWJsZTo1Nzc4NzMzZjEyMTY0ODUxOGQ3NGYxYWU1NDMzNGQxYS90YWJsZXJhbmdlOjU3Nzg3MzNmMTIxNjQ4NTE4ZDc0ZjFhZTU0MzM0ZDFhXzktNS0xLTEtMTY3OTA4_41564ba9-990f-4b6a-ba0b-19f6b98bff45"
      unitRef="usd">20003000000</cvs:LeaseLiability>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEzODY_793baa2b-b203-4d6b-8917-d7ad0f071f1c"
      unitRef="usd">290000000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <cvs:OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzE2OTQ_97b17059-ff96-46fa-8028-e409a4cee37c"
      unitRef="usd">2500000000</cvs:OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife>
    <us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzI1Njk_59813f2c-785a-4a19-9acc-05f0687854a6"
      unitRef="usd">101000000</us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzU0OTc1NTgyMDgyNw_c59395f8-eab0-4056-9529-ac5060fffbbb"
      unitRef="usd">3000000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <cvs:OfficeRealEstateOptimizationCharges
      contextRef="i64f5c37ce66141f7a204dfe6e993bb22_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEzNzQzODk1MzY1NDg5_6232c1a9-e5a0-4f84-9d24-17b0d5b88d50"
      unitRef="usd">117000000</cvs:OfficeRealEstateOptimizationCharges>
    <cvs:OfficeRealEstateOptimizationCharges
      contextRef="ie936009c1c1e420dad0ba447530546c3_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEwOTk1MTE2Mjg4MTMw_85146ce7-42f2-453f-8148-8a0a06f459b4"
      unitRef="usd">71000000</cvs:OfficeRealEstateOptimizationCharges>
    <cvs:OfficeRealEstateOptimizationCharges
      contextRef="i60dd33f11cc2409080bad57679954d47_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzEwOTk1MTE2Mjg4MTQy_49332b4b-8c5a-437f-95d5-6dd365b29552"
      unitRef="usd">44000000</cvs:OfficeRealEstateOptimizationCharges>
    <cvs:NumberOfStoresPlannedClosure
      contextRef="id630be41a4e14306bcd92700167a1f05_D20211001-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzUwMjQ_e7eedaf9-f977-4a73-8065-bb6724d32312"
      unitRef="store">900</cvs:NumberOfStoresPlannedClosure>
    <cvs:NumberOfStoresAnnualPlannedClosuresForClosurePeriod
      contextRef="id630be41a4e14306bcd92700167a1f05_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzUxMDI_43e6fba4-9d3d-4d35-8277-086a17cc57c4"
      unitRef="store">300</cvs:NumberOfStoresAnnualPlannedClosuresForClosurePeriod>
    <cvs:StoreImpairmentCharges
      contextRef="id630be41a4e14306bcd92700167a1f05_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzU0OTc1NTgyMDg0NQ_33b37c7e-6c64-4aa4-bc71-1bd7db9d69c6"
      unitRef="usd">1400000000</cvs:StoreImpairmentCharges>
    <cvs:StoreImpairmentCharges
      contextRef="if5695f9deb5d42f399db0a5df5333d03_D20211001-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzU3Njk_db1717e7-893b-4cc9-a663-b0b49ec89180"
      unitRef="usd">1100000000</cvs:StoreImpairmentCharges>
    <cvs:StoreImpairmentCharges
      contextRef="id562208e84834686a7620f76d36a5e86_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzU4MjM_2ca12bf1-d3ab-4058-bb57-cd5536794683"
      unitRef="usd">261000000</cvs:StoreImpairmentCharges>
    <cvs:OperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i13d80e15e3f94cb0927c69c6bbb18ad5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzYwMjg_6a703786-c3d9-447a-9bf3-ab3b2c018ca2"
      unitRef="usd">356000000</cvs:OperatingLeaseRightOfUseAssetFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentFairValueDisclosure
      contextRef="if99f5cc945cb4089b78aeb74c829d2d6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzYvZnJhZzo4ZGQxMzBiNDgxYzU0NjYxOWRkYzcyYzg4OTJjOWNhNi90ZXh0cmVnaW9uOjhkZDEzMGI0ODFjNTQ2NjE5ZGRjNzJjODg5MmM5Y2E2XzYwMzU_215af2c1-b418-4948-be89-367fc84e1ff1"
      unitRef="usd">185000000</us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzMzMDI_a1a52320-c292-4679-b3f4-cb244f362490">Health Care Costs Payable&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is information about incurred and cumulative paid health care claims development as of December&#160;31, 2022, net of reinsurance, and the total IBNR liabilities plus expected development on reported claims included within the net incurred claims amounts. See Note 1 &#x2018;&#x2018;Significant Accounting Policies&#x2019;&#x2019; for information on how the Company estimates IBNR reserves and health care costs payable as well as changes to those methodologies, if any. The Company&#x2019;s estimate of IBNR liabilities is primarily based on trend and completion factors. Claim frequency is not used in the calculation of the Company&#x2019;s liability. In addition, it is impracticable to disclose claim frequency information for health care claims due to the Company&#x2019;s inability to gather consistent claim frequency information across its multiple claims processing systems. Any claim frequency count disclosure would not be comparable across the Company&#x2019;s different claim processing systems and would not be consistent from period to period based on the volume of claims processed through each system. As a result, health care claim count frequency is not included in the disclosures below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information about incurred and paid health care claims development for the year ended December&#160;31, 2021 is presented as required unaudited supplemental information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Incurred Health Care Claims,&lt;br/&gt;Net of Reinsurance&lt;br/&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Health Care Claims,&lt;br/&gt;Net of Reinsurance&lt;br/&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All outstanding liabilities for health care costs payable prior to 2021, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total outstanding liabilities for health care costs payable, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company&#x2019;s liabilities for IBNR plus expected development on reported claims totaled approximately $7.8 billion. Substantially all of the Company&#x2019;s liabilities for IBNR plus expected development on reported claims at December&#160;31, 2022 related to the current calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the December&#160;31, 2022 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-duration health care costs payable, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance recoverables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance lines other than short duration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total health care costs payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the components of the change in health care costs payable during the years ended December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care costs payable, beginning of period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance recoverables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care costs payable, beginning of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Components of incurred health care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total incurred health care costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Premium deficiency reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care costs payable, end of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance recoverables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care costs payable, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Total incurred health care costs for the years ended December&#160;31, 2022, 2021 and 2020 in the table above exclude $75 million, $59 million and $41 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and $319 million, $212 million and $221 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets. The incurred health care costs for the years ended December 31, 2021 and 2020 also exclude $16 million and $11 million, respectively, for premium deficiency reserves related to the Company&#x2019;s Medicaid products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s estimates of prior years&#x2019; health care costs payable decreased by $654 million, $788 million and $429 million in 2022, 2021 and 2020, respectively, because claims were settled for amounts less than originally estimated (i.e., the amount of claims incurred was lower than originally estimated), primarily due to lower health care cost trends as well as the actual claim submission time being faster than originally assumed (i.e., the Company&#x2019;s completion factors were higher than originally assumed) in estimating health care costs payable at the end of the prior year. This development does not directly correspond to an increase in the Company&#x2019;s operating results as these reductions were offset by estimated current period health care costs when the Company established the estimate of the current year health care costs payable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock>
    <us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzMzMDY_01399349-033e-494e-baa4-679f8abb1c9a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information about incurred and paid health care claims development for the year ended December&#160;31, 2021 is presented as required unaudited supplemental information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Incurred Health Care Claims,&lt;br/&gt;Net of Reinsurance&lt;br/&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Health Care Claims,&lt;br/&gt;Net of Reinsurance&lt;br/&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All outstanding liabilities for health care costs payable prior to 2021, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total outstanding liabilities for health care costs payable, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ic76c4e64c26444a5bf8225d71e995baf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzMtMS0xLTEtMTY3OTA4_359858cb-4e1b-4917-9921-206fe4dead3b"
      unitRef="usd">62830000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i6259c8555abd4bf5b6dac136069d1316_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzMtMy0xLTEtMTY3OTA4_4839ddf4-0550-4648-9b47-1aac228c9bc8"
      unitRef="usd">62259000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i9affe0606d974499b83f0e139cb17dd2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzQtMy0xLTEtMTY3OTA4_ea5b5601-e3e8-4a88-aaf3-775d083467be"
      unitRef="usd">69185000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzUtMy0xLTEtMTY3OTA4_0c22799f-517c-4e46-a906-c30ff3d5a40d"
      unitRef="usd">131444000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ic76c4e64c26444a5bf8225d71e995baf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzEwLTEtMS0xLTE2NzkwOA_b08d90b6-0eef-4492-bb5c-f2ecd76ff846"
      unitRef="usd">54600000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i6259c8555abd4bf5b6dac136069d1316_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzEwLTMtMS0xLTE2NzkwOA_f223a4f7-412b-453e-b758-cb9e32f528d5"
      unitRef="usd">62144000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i9affe0606d974499b83f0e139cb17dd2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzExLTMtMS0xLTE2NzkwOA_a5436c0a-6103-4f96-b393-6c52d43124d5"
      unitRef="usd">59570000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzEyLTMtMS0xLTE2NzkwOA_8152ac0e-bb37-46af-bb63-0aed07ca7943"
      unitRef="usd">121714000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzEzLTMtMS0xLTE2NzkwOA_a38b5293-e0ef-4f63-99c4-fac1200b37ec"
      unitRef="usd">196000000</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5NDFhZGQ1MGEyMWI0MjIzODNjZDI4NDkwYjcwNzMwNC90YWJsZXJhbmdlOjk0MWFkZDUwYTIxYjQyMjM4M2NkMjg0OTBiNzA3MzA0XzE0LTMtMS0xLTE2NzkwOA_796ff7ca-6f1e-4f17-a4b7-b74645448fe2"
      unitRef="usd">9926000000</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
      contextRef="ic3b3902b297a43b9a015149f29e45bf7_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzE0MDg_234f5cd2-9917-4abe-961f-1a9ad21d3d04"
      unitRef="usd">7800000000</us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzMzMDc_9aa03b32-0d1c-4ff9-b2f8-d1a24dabf579">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the December&#160;31, 2022 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-duration health care costs payable, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance recoverables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance lines other than short duration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total health care costs payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5ZjMxMmU1YzI2MzY0YzA2ODFmMjZjZWFhYzE2ODE1ZC90YWJsZXJhbmdlOjlmMzEyZTVjMjYzNjRjMDY4MWYyNmNlYWFjMTY4MTVkXzEtMS0xLTEtMTY3OTA4_796ff7ca-6f1e-4f17-a4b7-b74645448fe2"
      unitRef="usd">9926000000</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5ZjMxMmU1YzI2MzY0YzA2ODFmMjZjZWFhYzE2ODE1ZC90YWJsZXJhbmdlOjlmMzEyZTVjMjYzNjRjMDY4MWYyNmNlYWFjMTY4MTVkXzItMS0xLTEtMTY3OTA4_3e863fdc-d906-4802-9065-fa3eaad2f842"
      unitRef="usd">5000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5ZjMxMmU1YzI2MzY0YzA2ODFmMjZjZWFhYzE2ODE1ZC90YWJsZXJhbmdlOjlmMzEyZTVjMjYzNjRjMDY4MWYyNmNlYWFjMTY4MTVkXzQtMS0xLTEtMTY3OTA4_db5131df-8ae2-4386-b47e-d49456d6d819"
      unitRef="usd">475000000</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo5ZjMxMmU1YzI2MzY0YzA2ODFmMjZjZWFhYzE2ODE1ZC90YWJsZXJhbmdlOjlmMzEyZTVjMjYzNjRjMDY4MWYyNmNlYWFjMTY4MTVkXzUtMS0xLTEtMTY3OTA4_c22f038a-20eb-4917-b297-c60524fa0ae9"
      unitRef="usd">10406000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzMzMDg_d600034d-942b-4c72-b79f-3948baf491b7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the components of the change in health care costs payable during the years ended December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care costs payable, beginning of period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance recoverables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care costs payable, beginning of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Components of incurred health care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total incurred health care costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Premium deficiency reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care costs payable, end of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance recoverables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care costs payable, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Total incurred health care costs for the years ended December&#160;31, 2022, 2021 and 2020 in the table above exclude $75 million, $59 million and $41 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and $319 million, $212 million and $221 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets. The incurred health care costs for the years ended December 31, 2021 and 2020 also exclude $16 million and $11 million, respectively, for premium deficiency reserves related to the Company&#x2019;s Medicaid products.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEtMS0xLTEtMTY3OTA4_c049a945-156c-4ad9-87f4-b661634c7c31"
      unitRef="usd">8808000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEtMy0xLTEtMTY3OTA4_bb77e198-5adf-437d-9e17-6553ca542b84"
      unitRef="usd">7936000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i0ac261a946f441689f0b6c8226695ff7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEtNS0xLTEtMTY3OTA4_aca53c53-9f8c-47e0-b071-7a6b20179fef"
      unitRef="usd">6879000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzItMS0xLTEtMTY3OTA4_204c0b38-3f55-49ff-a3c9-f11d34038bdf"
      unitRef="usd">8000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzItMy0xLTEtMTY3OTA4_4d37a48b-b4c1-48dd-a5fd-cfeee0dd63ba"
      unitRef="usd">10000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i0ac261a946f441689f0b6c8226695ff7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzItNS0xLTEtMTY3OTA4_650f7a51-73da-445c-9a11-0ab6a1166285"
      unitRef="usd">5000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzMtMS0xLTEtMTY3OTA4_c66a2069-8093-4777-8034-13926f9528c5"
      unitRef="usd">8800000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzMtMy0xLTEtMTY3OTA4_9e716e79-8fd7-4525-b7f8-3dfbd5255226"
      unitRef="usd">7926000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i0ac261a946f441689f0b6c8226695ff7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzMtNS0xLTEtMTY3OTA4_0f4cdb46-a118-49d3-b510-c4f454b9a2a3"
      unitRef="usd">6874000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzQtMS0xLTEtMTY3OTA4_977cdb00-3be4-4a04-903a-6f05b9933958"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzQtMy0xLTEtMTY3OTA4_0f1a4cb4-04a2-4b93-89cf-eface9fca95c"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzQtNS0xLTEtMTY3OTA4_58894f8f-dcd7-4dab-9fa9-55e225bb240b"
      unitRef="usd">414000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzctMS0xLTEtMTY3OTA4_2c9d53e9-117b-4cf9-bddc-17fcadf252fd"
      unitRef="usd">71541000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzctMy0xLTEtMTY3OTA4_4d8fc20a-281d-4064-b946-1d019bb2729a"
      unitRef="usd">64761000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzctNS0xLTEtMTY3OTA4_3c5b2f09-b693-410a-8a60-7e1efe0538e7"
      unitRef="usd">55835000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzgtMS0xLTEtMTY3OTA4_7f03a581-abad-482a-98e1-35b1a57fde50"
      unitRef="usd">-654000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzgtMy0xLTEtMTY3OTA4_0aefb807-19ad-4b21-8a0b-724709f650fe"
      unitRef="usd">-788000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzgtNS0xLTEtMTY3OTA4_71b628fd-f316-4a90-89ca-7d46126a0cc0"
      unitRef="usd">-429000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzktMS0xLTEtMTY3OTA4_c748074c-9d5c-4712-9bf6-4c1b8c7b8e48"
      unitRef="usd">70887000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzktMy0xLTEtMTY3OTA4_97e859f7-3cf1-4f66-9138-74ee2a11ddf3"
      unitRef="usd">63973000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzktNS0xLTEtMTY3OTA4_c5f74141-9403-4911-8abc-4e4dfaa1d602"
      unitRef="usd">55406000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzExLTEtMS0xLTE2NzkwOA_d38359e9-b8da-4a97-95e0-251676e303e5"
      unitRef="usd">61640000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzExLTMtMS0xLTE2NzkwOA_d056b949-f3df-44e4-a560-bae3786d5103"
      unitRef="usd">56323000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzExLTUtMS0xLTE2NzkwOA_62a36256-4c8a-481f-ab9a-ecd987f4cad0"
      unitRef="usd">48770000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEyLTEtMS0xLTE2NzkwOA_44de877d-db96-4fdd-9d3d-6f5daf15f138"
      unitRef="usd">7646000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEyLTMtMS0xLTE2NzkwOA_20216e9b-24cf-418a-b306-50cfbdeeabd4"
      unitRef="usd">6792000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEyLTUtMS0xLTE2NzkwOA_a0593880-6557-4bb6-b5a9-014b903a3eaa"
      unitRef="usd">6009000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEzLTEtMS0xLTE2NzkwOA_daa043e9-f885-4daf-9f6a-b82146675a7c"
      unitRef="usd">69286000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEzLTMtMS0xLTE2NzkwOA_5b1dfc7b-c1c0-47cc-b976-62e3f9deca2a"
      unitRef="usd">63115000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzEzLTUtMS0xLTE2NzkwOA_cc4baf18-cbc6-4719-8b8c-2a377a46ed6e"
      unitRef="usd">54779000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <cvs:PremiumDeficiencyReserveLiability
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE0LTEtMS0xLTE2NzkwOA_793990e3-923f-4bcc-b8d1-7f420b16c42e"
      unitRef="usd">0</cvs:PremiumDeficiencyReserveLiability>
    <cvs:PremiumDeficiencyReserveLiability
      contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE0LTMtMS0xLTE2NzkwOA_f0574f20-aedc-4b4a-8c75-a5797df37879"
      unitRef="usd">16000000</cvs:PremiumDeficiencyReserveLiability>
    <cvs:PremiumDeficiencyReserveLiability
      contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE0LTUtMS0xLTE2NzkwOA_287c6b46-81d3-4dd6-b434-58bca857d38f"
      unitRef="usd">11000000</cvs:PremiumDeficiencyReserveLiability>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE1LTEtMS0xLTE2NzkwOA_ae7fdfb9-4d8f-48c7-af08-25cde580bcda"
      unitRef="usd">10401000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE1LTMtMS0xLTE2NzkwOA_ff8a23ef-da46-4960-ad69-adae26c121e6"
      unitRef="usd">8800000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE1LTUtMS0xLTE2NzkwOA_f799c300-dba5-4f91-a512-d481838acfdc"
      unitRef="usd">7926000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE2LTEtMS0xLTE2NzkwOA_5b85367f-5601-40d8-b86c-ae2ed6a32fd9"
      unitRef="usd">5000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE2LTMtMS0xLTE2NzkwOA_51b67e87-d658-421b-abfe-a75ae0a2731d"
      unitRef="usd">8000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE2LTUtMS0xLTE2NzkwOA_10835f06-9c22-4ec7-b071-1f3c4dde69f1"
      unitRef="usd">10000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i3625815087434552b838d92f5f5f5e0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE3LTEtMS0xLTE2NzkwOA_e2e874f8-cfac-402d-8fa2-a56144963492"
      unitRef="usd">10406000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE3LTMtMS0xLTE2NzkwOA_9bfe07f8-5a30-4558-9070-fed2d4af783f"
      unitRef="usd">8808000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90YWJsZTo2Nzg1MDliNTY1MmU0YWQ5OGZjZjY5OGZhNjU5YzllMy90YWJsZXJhbmdlOjY3ODUwOWI1NjUyZTRhZDk4ZmNmNjk4ZmE2NTljOWUzXzE3LTUtMS0xLTE2NzkwOA_76ef7038-5679-42d7-b02a-b83487b3c5d5"
      unitRef="usd">7936000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts
      contextRef="i780b19498a144075a22a573432132bda_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIxMzc_924480db-ce02-4bb2-8486-e9506df4fba1"
      unitRef="usd">75000000</cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts>
    <cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts
      contextRef="iefb4b1c3d63e4323ae108f339bf86ea0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIxNDE_c5e9bb54-77bf-4af5-b223-81ea0dbba54c"
      unitRef="usd">59000000</cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts>
    <cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts
      contextRef="i2d32e81675c1411abb9e6dc0a83223c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIxNDg_5e655430-2c56-48cb-894f-6e5cc0531ec5"
      unitRef="usd">41000000</cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts>
    <cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts
      contextRef="i104c7351c43f4dd9ba23acf27dc2da0d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIzMjI_19959611-846f-4861-941d-0494a3717d5d"
      unitRef="usd">319000000</cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts>
    <cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts
      contextRef="i2661ac2447ad404b9093ebf03b2f3a2c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIzMjY_f9cab839-c0d8-4647-a513-86c7fbb570b3"
      unitRef="usd">212000000</cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts>
    <cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts
      contextRef="ie4d0589b63754b6d96499af470071fa3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzIzMzM_aea38c94-91a5-4c58-af52-1d03f422e2ce"
      unitRef="usd">221000000</cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts>
    <cvs:PremiumDeficiencyReserveLiability
      contextRef="i262f23d50a0d45db8328a0d433a34f63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzEwOTk1MTE2MjgxMjM4_f0574f20-aedc-4b4a-8c75-a5797df37879"
      unitRef="usd">16000000</cvs:PremiumDeficiencyReserveLiability>
    <cvs:PremiumDeficiencyReserveLiability
      contextRef="id3477564c46a4d1d89c214c39d6753d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzEwOTk1MTE2MjgxMjQ2_287c6b46-81d3-4dd6-b434-58bca857d38f"
      unitRef="usd">11000000</cvs:PremiumDeficiencyReserveLiability>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i376c8a46e57d495d82198a8924218c06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzI1NzM_7f03a581-abad-482a-98e1-35b1a57fde50"
      unitRef="usd">-654000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i675975cebc364fdd8685be9dd79c31d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzI1Nzc_0aefb807-19ad-4b21-8a0b-724709f650fe"
      unitRef="usd">-788000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3625b0066c2d48f789f973e87cb59b6c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMzkvZnJhZzo5Mjk3NzZiMDBjM2I0OWNhOGJjNjRiZjI1ZWRmYjU1My90ZXh0cmVnaW9uOjkyOTc3NmIwMGMzYjQ5Y2E4YmM2NGJmMjVlZGZiNTUzXzI1ODQ_71b628fd-f316-4a90-89ca-7d46126a0cc0"
      unitRef="usd">-429000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc5MDE_04316a5d-95dc-460c-bdff-22e8082db06e">Borrowings and Credit Agreements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the Company&#x2019;s borrowings as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5% senior notes due July 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75% senior notes due November 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75% senior notes due December 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75% senior notes due December 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8% senior notes due June 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4% senior notes due December 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.375% senior notes due August 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.625% senior notes due August 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5% senior notes due November 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5% senior notes due December 2024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1% senior notes due March 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% senior notes due July 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.875% senior notes due June 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3% senior notes due August 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.625% senior notes due April 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25% senior notes due June 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3% senior notes due August 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3% senior notes due March 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.25% senior notes due August 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.75% senior notes due April 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.75% senior notes due August 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.875% senior notes due February 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.125% senior notes due September 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% senior notes due July 2035&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.625% senior notes due June 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.75% senior notes due December 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.78% senior notes due March 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% senior notes due September 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.125% senior notes due April 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7% senior notes due August 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% senior notes due May 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5% senior notes due May 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.125% senior notes due November 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3% senior notes due December 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75% senior notes due March 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.125% senior notes due July 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% senior notes due August 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.05% senior notes due March 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.25% senior notes due April 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_136d726d-4e4c-47e6-89b0-66598c753e01"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_f7e749bb-d161-4304-bb3e-6fdb8d5e52ce"&gt;Finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt discounts and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;__________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes long-term debt of $3&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s required repayments of debt principal due during each of the next five&#160;years and thereafter, as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;See Note 6 &#x2018;&#x2018;Leases&#x2019;&#x2019; for a summary of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;maturities of the Company&#x2019;s finance lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Paper and Back-up Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any commercial paper outstanding as of December 31, 2022 or 2021. In connection with its commercial paper program, the Company maintains a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2025, a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 11, 2026, and a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2027. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company&#x2019;s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of December&#160;31, 2022 and 2021, there were no borrowings outstanding under any of the Company&#x2019;s back-up credit facilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Federal Home Loan Bank of Boston (&#x201c;FHLBB&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A subsidiary of the Company is a member of the FHLBB. As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of December&#160;31, 2022 was approximately $915 million. At both December&#160;31, 2022 and 2021, there were no outstanding advances from the FHLBB.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise of Par Call Redemptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company exercised the par call redemption on its outstanding 3.5% senior notes due July 2022 to redeem for cash on hand the entire $1.5&#160;billion aggregate principal amount. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company exercised the par call redemption on its outstanding 2.75% senior notes due November 2022 (issued by Aetna Inc. (&#x201c;Aetna&#x201d;)) to redeem for cash on hand the entire $1.0&#160;billion aggregate principal amount.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Company exercised the par call redemptions on its outstanding 2.75% senior notes due December 2022 and 4.75% senior notes due December 2022 (including notes issued by Omnicare, Inc.) to redeem for cash on hand the entire aggregate principal amount of $1.25&#160;billion and $399&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 18, 2021, the Company issued $1.0&#160;billion aggregate principal amount of 2.125% unsecured senior notes due September 15, 2031 for total proceeds of $987&#160;million, net of discounts, underwriting fees and offering expenses. The net proceeds of this offering were used for the purchase of senior notes in connection with the Company&#x2019;s cash tender offer in August 2021 as described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During March 2020, the Company entered into several interest rate swap transactions to manage interest rate risk. These agreements were designated as cash flow hedges and were used to hedge the exposure to variability in future cash flows &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;resulting from changes in interest rates related to the anticipated issuance of $750&#160;million aggregate principal amount of 3.625% unsecured senior notes due April 1, 2027, $1.5&#160;billion aggregate principal amount of 3.75% unsecured senior notes due April 1, 2030, $1.0&#160;billion aggregate principal amount of 4.125% unsecured senior notes due April 1, 2040 and $750&#160;million aggregate principal amount of 4.25% unsecured senior notes due April 1, 2050 (collectively, the &#x201c;March 2020 Notes&#x201d;). In connection with the issuance of the March 2020 Notes on March 31, 2020, the Company terminated all outstanding cash flow hedges. The Company paid a net amount of $7&#160;million to the hedge counterparties upon termination, which was recorded as a loss, net of tax, of $5&#160;million in accumulated other comprehensive income and will be reclassified as interest expense over the life of the March 2020 Notes. See Note 13 &#x2018;&#x2018;Other Comprehensive Income (Loss)&#x2019;&#x2019; for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Early Extinguishments of Debt&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company redeemed for cash the remaining $2.3&#160;billion of its outstanding 3.7% senior notes due 2023. In connection with the early redemption of such senior notes, the Company paid a make-whole premium of $80 million in excess of the aggregate principal amount of the senior notes that were redeemed, wrote-off $8 million of unamortized deferred financing costs and incurred $1 million in fees, for a total loss on early extinguishment of debt of $89&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company purchased approximately $2.0&#160;billion of its outstanding 4.3% senior notes due 2028 through a cash tender offer. In connection with the purchase of such senior notes, the Company paid a premium of $332 million&#160;in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $26&#160;million of unamortized deferred financing costs and incurred $5&#160;million in fees, for a total loss on early extinguishment of debt of $363&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company purchased $4.5&#160;billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $113&#160;million of its 4.0% senior notes due 2023, $1.4&#160;billion of its 3.7% senior notes due 2023, $1.0&#160;billion of its 4.1% senior notes due 2025 and $2.0&#160;billion of its 4.3% senior notes due 2028. In connection with the purchase of such senior notes, the Company paid a premium of $619&#160;million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $45&#160;million of unamortized deferred financing costs and incurred $10&#160;million in fees, for a total loss on early extinguishment of debt of $674&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company purchased $6.0&#160;billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $723&#160;million of its 4.0% senior notes due 2023, $2.3&#160;billion of its 3.7% senior notes due 2023 and $3.0&#160;billion of its 4.1% senior notes due 2025. In connection with the purchase of such senior notes, the Company paid a premium of $706&#160;million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $47&#160;million of unamortized deferred financing costs and incurred $13&#160;million in fees, for a total loss on early extinguishment of debt of $766&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Covenants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s back-up revolving credit facilities and unsecured senior notes contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company&#x2019;s debt maturities in the event of a downgrade in the Company&#x2019;s credit ratings. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of December&#160;31, 2022, the Company was in compliance with all of its debt covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4MzI_a0b0f680-355f-4877-91c1-8a45a41a7ac2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the Company&#x2019;s borrowings as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5% senior notes due July 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75% senior notes due November 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75% senior notes due December 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75% senior notes due December 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8% senior notes due June 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4% senior notes due December 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.375% senior notes due August 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.625% senior notes due August 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5% senior notes due November 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5% senior notes due December 2024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1% senior notes due March 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% senior notes due July 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.875% senior notes due June 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3% senior notes due August 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.625% senior notes due April 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25% senior notes due June 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3% senior notes due August 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3% senior notes due March 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.25% senior notes due August 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.75% senior notes due April 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.75% senior notes due August 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.875% senior notes due February 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.125% senior notes due September 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% senior notes due July 2035&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.625% senior notes due June 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.75% senior notes due December 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.78% senior notes due March 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% senior notes due September 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.125% senior notes due April 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7% senior notes due August 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% senior notes due May 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5% senior notes due May 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.125% senior notes due November 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3% senior notes due December 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75% senior notes due March 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.125% senior notes due July 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% senior notes due August 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.05% senior notes due March 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.25% senior notes due April 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_136d726d-4e4c-47e6-89b0-66598c753e01"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTAtMS0xLTE2NzkwOA_f7e749bb-d161-4304-bb3e-6fdb8d5e52ce"&gt;Finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt discounts and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;__________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes long-term debt of $3&#160;million which has been accounted for as liabilities held for sale and is included in liabilities held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i96ea0975c6434c688a6304c9a35567b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEyLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjMwY2Q2OWRiY2Q3MzQ2ZDQ5ZWRmZDk5OWU4NzU1ODE0XzQ_e250dd9e-6e04-4889-b79a-be54e5acbbf8"
      unitRef="number">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i96ea0975c6434c688a6304c9a35567b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEyLTEtMS0xLTE2NzkwOA_d91b5102-b6b7-4aab-9f59-ca0506d66be9"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i23b4e48800ec47c1a7b0ec56d1d395fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEyLTMtMS0xLTE2NzkwOA_9e44f218-329c-4aa6-a41f-5541638e3fde"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2d193754e1d94c0494f9956393440f77_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjVlMThiYzZlMjBmYTQwMDI4ZDFmNWJhMGJjMzgzNjFjXzQ_b8868717-6204-4ab5-b7a7-e49748ff40fc"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2d193754e1d94c0494f9956393440f77_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEzLTEtMS0xLTE2NzkwOA_119e9f5c-db6e-44fb-8a6b-dfdc486d08da"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2a906779cfe446a2987d8b5241fbf0da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzEzLTMtMS0xLTE2NzkwOA_f387fcf1-8a5b-48c5-9aff-4b0721f0d881"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if71e011d823142598cd37f46f2e49a05_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE0LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmE4OTJmMmNjYWM4ZjQ3YmZhYTQ4OWY2YzEzMTVkYzU3XzQ_ed6bb8bc-24f3-4c40-be8d-3a16d9a984b1"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if71e011d823142598cd37f46f2e49a05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE0LTEtMS0xLTE2NzkwOA_e4e36839-14b1-4590-8450-da13585e837b"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id1c181073c4542f099d25eb5c5d40655_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE0LTMtMS0xLTE2NzkwOA_21ab147e-6ce2-4b3b-821c-3cb309da60b1"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i61839e753d2f451b9587d89360867561_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjc4M2JhZGY0OTk3YjRjNzFiZWFlMmIzYWY5ZTdkZDhhXzQ_9ba46b35-653d-4da6-8cfd-7150e14235b0"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i61839e753d2f451b9587d89360867561_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE1LTEtMS0xLTE2NzkwOA_bac55596-fea7-4a45-a5cd-e985daf236fe"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i62d2bd8ff5b14cb5a635a188ee174c8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE1LTMtMS0xLTE2NzkwOA_ea27553d-6f6e-4f66-afe6-6bfa33bff45f"
      unitRef="usd">399000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8a3d976289814f1ebda72b277cfb0e32_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE3LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjU5MTM4YmMxZmJmYTRmNDlhMjgzMTZmMTM0OThmNTUxXzQ_34e0b75c-7fc6-4479-8979-d8630cd327f7"
      unitRef="number">0.028</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8a3d976289814f1ebda72b277cfb0e32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE3LTEtMS0xLTE2NzkwOA_73950778-7c02-4f78-97c5-431fe8b5c1a5"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i35ba734b33ac429899c73244e0b3e4a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE3LTMtMS0xLTE2NzkwOA_df7deb5e-7056-483f-b85b-f401c8ca6725"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1e0c4baf78af43da8c871e2cf0d3776e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmMwOTMxNmEwYmRmZjRhY2JhODczZjlkNTE5OTQ5OTY3XzQ_28c7c2db-1887-4f80-b3af-b77ace4e3d9a"
      unitRef="number">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1e0c4baf78af43da8c871e2cf0d3776e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE4LTEtMS0xLTE2NzkwOA_f0623bae-27f0-45b6-ba1d-4370c8641c2e"
      unitRef="usd">414000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idb44b3665b4246f1bf997c90b24c21d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE4LTMtMS0xLTE2NzkwOA_825f4c29-eedd-4b90-bf21-5cebf59610ae"
      unitRef="usd">414000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d559325531a42c38fc46ff0a8fe2921_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjRjNmVhZjRlNWQxZTQzYzI5YWUzYmM5ZDI3MGY2Yzg1XzQ_4b6fa7c5-0737-41ba-80cd-eecb086cff8c"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4d559325531a42c38fc46ff0a8fe2921_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE5LTEtMS0xLTE2NzkwOA_c9faeae0-7cc3-4803-9811-06913f3b8ff2"
      unitRef="usd">650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0b0484677d3d443eb00b519000bfb3a6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzE5LTMtMS0xLTE2NzkwOA_91653c3a-46b7-4b19-83a3-0e1fb584467b"
      unitRef="usd">650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i56e27d861e9545b9aa31b1102e04c153_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjg2NDdlN2YwMWE4MzRjZGI4ZDlkYmIwMjBiYjNmMmIwXzQ_83692015-26e8-4180-a1d4-577c1964058a"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i56e27d861e9545b9aa31b1102e04c153_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIwLTEtMS0xLTE2NzkwOA_7d21363e-9b0a-474a-a454-53f090666c37"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i42ac987c67784c1186308edd0aea70d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIwLTMtMS0xLTE2NzkwOA_226eacef-0a38-4d44-aa45-2ec0426b50f3"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic180b72151a4402f8310dadcfc70fb01_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmFkYjg3N2IzOWMyMjRmYWE4Y2NkZjllNGQ5MDE0Yzc3XzQ_36ed2b84-f390-4bcf-9bb9-1451014b61c9"
      unitRef="number">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic180b72151a4402f8310dadcfc70fb01_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIxLTEtMS0xLTE2NzkwOA_483fb23e-5b23-44e4-8f5b-b4fd4d963cab"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i74b6f748466241afa934def47b3887ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIxLTMtMS0xLTE2NzkwOA_ec8a4784-0fb7-4546-a9ca-edbc3fab9d1b"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4b4ae74a63944a4ab738561dee76b7fd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIyLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjIwZWM0N2Y4YjUwYjRiM2ViMWRiMzIyM2RjZDhlYTk1XzQ_7aaf2d6d-b974-4c4a-b62c-437ba9828e6c"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4b4ae74a63944a4ab738561dee76b7fd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIyLTEtMS0xLTE2NzkwOA_699e7a92-35fc-4aae-bc54-ddecf2876fc0"
      unitRef="usd">299000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i89e4d23924994b228cd71cb68d806750_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIyLTMtMS0xLTE2NzkwOA_bd577eda-0968-4e6e-844b-08ca852ceaae"
      unitRef="usd">299000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iefa4fc8c856647a0a132eb36186e08b5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQ4ODM1YzkwMTkwMjQzNDBiODA3NjVlOTA2NzZlZTZlXzQ_b7675cef-19b8-4ce9-8366-919f10b58ab5"
      unitRef="number">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iefa4fc8c856647a0a132eb36186e08b5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIzLTEtMS0xLTE2NzkwOA_3fe5572f-1b9b-425c-a21d-6f4de0f8836b"
      unitRef="usd">950000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie21a0aa5c9d141bdbe4a207bb4f293ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzIzLTMtMS0xLTE2NzkwOA_f5cb2453-cedb-4703-b387-395d21131143"
      unitRef="usd">950000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9fb06588816f472bb29f99b8d68219cc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI0LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmY0MWUyZTA5YjliMDQ3MjQ5NjJiNzc2YWRmYjk0N2EwXzQ_5cf6fef0-8f16-43e7-92e3-23d8d7304b2c"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9fb06588816f472bb29f99b8d68219cc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI0LTEtMS0xLTE2NzkwOA_863c0911-79b6-47d6-b5c4-25d3a0ab8240"
      unitRef="usd">2828000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i42c9969b99bb4ad798109c43cbdc6881_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI0LTMtMS0xLTE2NzkwOA_175898ec-eca8-4907-870f-a0fd84316c96"
      unitRef="usd">2828000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieb8a5e549c1f40079912cf72b576f3e7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjI4ZmRkYWQ2YWZlZjRlMTM5ODUxMmIwMDY0NmJlMjllXzQ_60783301-e81b-4ac6-8085-1f8bd5142029"
      unitRef="number">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieb8a5e549c1f40079912cf72b576f3e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI1LTEtMS0xLTE2NzkwOA_bd75636e-0338-4cbd-bbcd-0e54d378e090"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7c887883f1ce42688222f658a393184a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI1LTMtMS0xLTE2NzkwOA_758d0117-7309-4291-a28d-a993a7fc1e4b"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i38b8c6c77f294a97b96b4e9060102c49_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmMxNDBmMjcxNDBiNjRkYWI4ZDJjZGZjYzBlNGNkZWI5XzQ_bcd39f42-7981-4cc6-bdf4-63a8f391c8a1"
      unitRef="number">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i38b8c6c77f294a97b96b4e9060102c49_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI2LTEtMS0xLTE2NzkwOA_0dbd6198-bd40-42f9-bed1-72997da7ef75"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i94f841196e9745d7a5bd741b956cb571_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI2LTMtMS0xLTE2NzkwOA_7dd23291-a644-41ed-a5a1-6fe691e0ec44"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3120aef7a1a74f9aa9ad6c90254ae7da_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI3LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjQ1NjNjNjNkOTYyODQ4MjM5MmNhMTQyM2VhMmY2YmMxXzQ_7978d98a-8b8c-4448-aaed-c61290eccd8c"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3120aef7a1a74f9aa9ad6c90254ae7da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI3LTEtMS0xLTE2NzkwOA_119ad780-8b60-4867-b8f4-dbd500ad13bd"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie21b2c11292246968e32e95a7e2d5d46_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI3LTMtMS0xLTE2NzkwOA_ef640853-89d1-4239-8acf-cdbd2bec4f25"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i83a34a6019c9487ab8dc8717a85803b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmRiNmM4OTM3MWI5MjRlN2ZiNGMzOGQxMTc1MzUxYzQzXzQ_c71f743b-e155-4aae-becc-a00574d4619c"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i83a34a6019c9487ab8dc8717a85803b9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI4LTEtMS0xLTE2NzkwOA_e76e6b4c-14f1-4300-81ec-2ab0197d5b0b"
      unitRef="usd">372000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i32d2292eae624df88e3cb7a81e75175e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI4LTMtMS0xLTE2NzkwOA_22b97f2d-7b94-49c7-ad37-bfc97b8b3218"
      unitRef="usd">372000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib6a05b1ec70b4ceda24080b978863c80_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjZiZDJjMmVlMDliMDQyNDBiYjkxY2MxYWFhOTY5YmI1XzQ_827afc07-6750-4cdc-a9f4-4c8d06e55aec"
      unitRef="number">0.013</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib6a05b1ec70b4ceda24080b978863c80_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI5LTEtMS0xLTE2NzkwOA_ab7a1dd1-01bb-46e1-9d29-b5699ba370b5"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib9e78fd616384a38bdb3bfc812db60ab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzI5LTMtMS0xLTE2NzkwOA_f0e81737-ef03-4119-8420-0f9953459718"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i208edaa424b244c2a575cd9b2b4b9020_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQwOTIyZDQ3NzFiMzRmZDViZGVhMWQyNGI2NGRkOGNhXzQ_ecae7c2b-7105-4431-98e6-ee7a97548281"
      unitRef="number">0.043</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i208edaa424b244c2a575cd9b2b4b9020_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMwLTEtMS0xLTE2NzkwOA_6f3f90de-9139-4875-9352-bea0d7162407"
      unitRef="usd">5000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3609fe1a0966404993bebd381e7eda7c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMwLTMtMS0xLTE2NzkwOA_53330b49-509e-4ab8-91a6-ded257d23ff1"
      unitRef="usd">5000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if5aa28ddd1e8430eb577239a8f77bef0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmIwMmUyOTY3ZmEyYzRhOGNiOTg3YjJjNWZhYzA4ODg4XzQ_57529ed2-3154-4aec-8bbc-7f5dfc6c4caa"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if5aa28ddd1e8430eb577239a8f77bef0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMxLTEtMS0xLTE2NzkwOA_1db55507-3028-4ce7-97ee-f10fd87b638a"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4f0fa0101d32487d87f11b2ff81e35e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMxLTMtMS0xLTE2NzkwOA_6022a61b-817a-4163-9293-2cafdc0d2fb3"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ide032eb9e5684d3bae628ecb6f5fa55e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMyLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmY5ODNkYzc1NDM3NDQwNjZiOTAwMDBkZWI3NDE1OGZiXzQ_a1d477ca-06ad-48c2-b8a1-b8b1564134d8"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ide032eb9e5684d3bae628ecb6f5fa55e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMyLTEtMS0xLTE2NzkwOA_c4641f6a-40e3-4618-b54e-47f70437de73"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i763321b4294a490a99ed2699ea5e64f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMyLTMtMS0xLTE2NzkwOA_def3f3f9-2787-4934-908b-23ae26b6bf6d"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id15f98dc5d2143468b8eb2d34e1a74e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjI5MTM5ODRhZTczMTQxYmVhZmViNjg0NWY4MjMwOGZmXzQ_86b726e3-613d-492b-bb8e-cc944c550c88"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id15f98dc5d2143468b8eb2d34e1a74e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMzLTEtMS0xLTE2NzkwOA_88e23172-2936-40b3-8624-f466085389e0"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2b8b28c2e4ea4f158253162f1d64b8cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzMzLTMtMS0xLTE2NzkwOA_6fda3253-f869-4020-9bf0-2194f3dcab02"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06e62497573243ac88b9afb7d5cd0de3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM0LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmE5MjY1MWIwMWY1MTRhZDA5ZmRjYmNiNGVjZmU4ZjI5XzQ_4ecea5ce-0aa5-4339-9103-a321f2666700"
      unitRef="number">0.01875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i06e62497573243ac88b9afb7d5cd0de3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM0LTEtMS0xLTE2NzkwOA_28cf7f2f-07b6-4f52-be1c-94274005f8f2"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1fe1a138e88c4de09bec060efb8de7da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM0LTMtMS0xLTE2NzkwOA_edac0d64-6878-43dd-a5ff-d2b7d2cd2b3e"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaceac4401a17451a9894899abe75d058_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmYzMDNhOTAyNDU3NTQ4ZmE4YThlNmQ3OWIyM2IwODc5XzQ_8f705426-de42-4be3-94a7-475caf35516d"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaceac4401a17451a9894899abe75d058_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM1LTEtMS0xLTE2NzkwOA_bf4d5c8f-26ff-4b8b-8349-7d651af069a4"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i609d3103caff4c93b86c00a3a2aed350_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM1LTMtMS0xLTE2NzkwOA_549e1a0a-96ae-489e-83d7-29dd6e289483"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4aa00402164f00b89144874d2e4a98_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQ3ZWI2M2VhOWIxMzQ3ZGNiNDA5Yjg3ODIzOWM2M2EyXzQ_daf67db7-f0e2-4c37-88d5-5a837219169a"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4d4aa00402164f00b89144874d2e4a98_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM2LTEtMS0xLTE2NzkwOA_4f819043-3e86-4899-aef5-e45575cb6b55"
      unitRef="usd">652000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ide1da8f0468d4f0e87617230289c5bdb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM2LTMtMS0xLTE2NzkwOA_92f2c7dd-3f21-4d3e-bab9-db96bb40acda"
      unitRef="usd">652000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibe3a3d79b0d747d9803a516b3766b9b8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM3LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjVjZmEwNGM3MWVkODQ0NWZiOTliYmRlZjgxMWRlMzg0XzQ_43a76470-1a31-4eb5-804d-f96a904a2c37"
      unitRef="number">0.06625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibe3a3d79b0d747d9803a516b3766b9b8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM3LTEtMS0xLTE2NzkwOA_f7a50d98-cdfa-4841-a8b7-8e0cbc779738"
      unitRef="usd">771000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2f90f74479324fd08ed524bf5c875c87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM3LTMtMS0xLTE2NzkwOA_a768652d-180f-4e37-b2cd-cc3aadf77102"
      unitRef="usd">771000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia363edf7d95a413cb5fecebeb23ed972_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjFhNDA4NjUxODkzYzQ0ZmU4NmFkN2IwMjkyMjM4YTlkXzQ_f6ca6ce7-32ab-41d7-9447-ef0997dbdee0"
      unitRef="number">0.0675</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia363edf7d95a413cb5fecebeb23ed972_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM4LTEtMS0xLTE2NzkwOA_88860727-50a4-4176-898e-765e669b35cd"
      unitRef="usd">533000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iac58136f46f242a19ec676141946c7f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM4LTMtMS0xLTE2NzkwOA_06a1954a-24ff-4a2e-8e46-045182880a49"
      unitRef="usd">533000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i39294c665ef74fa1983f27c408f039c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjcxZDQ0MGI5OWUxMTQwOTg4MDU5YzI5OWVhNzdkODBhXzQ_bf7c6608-28c2-4bb1-875d-0a799d1de550"
      unitRef="number">0.0478</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i39294c665ef74fa1983f27c408f039c1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM5LTEtMS0xLTE2NzkwOA_a4d5a3a5-ed26-4c25-8e08-c3d8a9b33e8a"
      unitRef="usd">5000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib9cbfd1800fe44faa82ca6d39ee57704_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzM5LTMtMS0xLTE2NzkwOA_3192e6a4-0370-4d63-b4ff-ffbafdf06cf9"
      unitRef="usd">5000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1512c04482e5447b84fbd0e3188e529a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjgxMzkzNmYzODc1YTQwN2NiN2UwODc0YTIyZjdiYTliXzQ_7d005f3d-7138-46ae-899c-31cb206d90f3"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1512c04482e5447b84fbd0e3188e529a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQwLTEtMS0xLTE2NzkwOA_205d18bb-3b32-4f96-95a5-41864e880203"
      unitRef="usd">447000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9699d6696c9c4911bb010f0b9af5282a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQwLTMtMS0xLTE2NzkwOA_05156a23-7694-4b7c-a00b-c89481812ac7"
      unitRef="usd">447000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3de7f45720594c44b73f3eab7ce10e70_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQ3OWViZGJlYmM3ODRmZTM4NGZlYjI4YTJhOWVmMDA5XzQ_66422226-3c27-46e6-800f-bbb02794cb17"
      unitRef="number">0.04125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3de7f45720594c44b73f3eab7ce10e70_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQxLTEtMS0xLTE2NzkwOA_0fe3aad8-6d83-4c4e-ace6-b9cdd0c1c54a"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i03f49a86ef2b485f829d66fae1ef44f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQxLTMtMS0xLTE2NzkwOA_d6e18eab-7d8a-4685-8a2e-672f01175573"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id028ea3d52c44a2394695e4f43e9d046_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQyLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmQyMDE2N2YxNjk2NjQ5YjM4ODhkYzcyMTMwZmFiNjVhXzQ_ad6887fc-65b3-41b8-8adc-d4fc3dfa7e28"
      unitRef="number">0.027</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id028ea3d52c44a2394695e4f43e9d046_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQyLTEtMS0xLTE2NzkwOA_85a6bb18-a79b-4927-a99f-8eda1dd22120"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i650090a57c324b8498f059399f541fb4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQyLTMtMS0xLTE2NzkwOA_01c492b8-4930-4c36-80e4-2a8c6b8f62e7"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if44aa963bda44e8fa075b47f30535a24_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQzLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjEwMjQwMjFjNzFiMTQ0ODU5NTA2NjBiZjZhYWJiZjI3XzQ_51b3c45a-6137-43d9-aedb-f1f9e40e40ff"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if44aa963bda44e8fa075b47f30535a24_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQzLTEtMS0xLTE2NzkwOA_caca8e71-e5f1-44d1-aff3-b2e50ca88ca4"
      unitRef="usd">133000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6591fe0e06444dcb90f36c98760ac910_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQzLTMtMS0xLTE2NzkwOA_d6518a8c-c961-4bb5-87b9-5ecf8201b4d9"
      unitRef="usd">133000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i472c295552a045b6bcce82be7abd296a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ0LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmY5Y2MyNThhYzEzOTQwYTNhOGIzYzRhMTIwY2Q0NDkzXzQ_d5b1002c-2a8e-47b4-8b14-650fdbdd92b4"
      unitRef="number">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i472c295552a045b6bcce82be7abd296a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ0LTEtMS0xLTE2NzkwOA_b3e44c55-4408-4388-a90d-45c4ba9554f4"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie807ae7adfd345cbb44996f1818e4a05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ0LTMtMS0xLTE2NzkwOA_a1207e44-98e9-46ee-aa0a-9f0ec2838874"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib71cdfc8616745bda08bb51063716d02_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjhjMGFiNzJhZWJiNTRiM2Q5MzE2MTQ0OTdkN2YyYjVmXzQ_d81a4bef-9e8d-466c-bb3b-2f38fdb901f0"
      unitRef="number">0.04125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib71cdfc8616745bda08bb51063716d02_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ1LTEtMS0xLTE2NzkwOA_2a8a6a8c-31a9-41e0-be00-999bdbcf0948"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i95b979d90da5452a905826924ce27d25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ1LTMtMS0xLTE2NzkwOA_5b75d9e1-0d8c-4714-b286-e6dae2e0d82a"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i64cb7a0107874445b5ef1241ac268ddb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmUxODgyODNmMDNiODQ0ZmNhMGY1ZjRkNzI5NWJiMzVkXzQ_7aa8fa6e-9876-42b8-a029-cc218201effe"
      unitRef="number">0.053</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i64cb7a0107874445b5ef1241ac268ddb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ2LTEtMS0xLTE2NzkwOA_a24053eb-b0df-4c3c-8e69-033bc618ad3d"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iac6197c2e1f545da9f71938fe1794bba_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ2LTMtMS0xLTE2NzkwOA_73e4267e-2c26-4899-b816-767ce8835c78"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if5c6a9cc0246481db45b0f13ad35ae23_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ3LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjMwNjJhM2ZiZDE3NzRlZmFiMTliNTcyNzU3ZWI1YWE0XzQ_30aa3756-420c-4f2f-8aa6-1638219ed333"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if5c6a9cc0246481db45b0f13ad35ae23_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ3LTEtMS0xLTE2NzkwOA_bc1e92d8-abc9-446b-aef3-99ea6840a494"
      unitRef="usd">375000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3054d36c450a4f1a949a59076296c836_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ3LTMtMS0xLTE2NzkwOA_b2d22193-ee2d-43e1-8d75-84673784c59a"
      unitRef="usd">375000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8a1d56e01764a95aa6ce0389dadcc42_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmExNzI0MGRjZDVlZDRhYzBhNzc3MzQzNmMzZDQ3NTcwXzQ_d0f8dd21-0f3b-4770-8dfe-ecdadc620eda"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic8a1d56e01764a95aa6ce0389dadcc42_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ4LTEtMS0xLTE2NzkwOA_4a6a89c0-cfa0-4ad1-8442-4da32d51935f"
      unitRef="usd">3500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3d368fcdffdc46d3a0e01d94c43c30e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ4LTMtMS0xLTE2NzkwOA_62184001-c7ab-4875-aba7-cfc1ae28014b"
      unitRef="usd">3500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7c67e77d27e244a0a68d18b65e0bfd8a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmUzMWQyMDM4ZTEyODRiNzY5ZjI0MzBlYzdkMDYyNmJjXzQ_340f4794-6b96-4834-b6f4-961e592e9089"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7c67e77d27e244a0a68d18b65e0bfd8a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ5LTEtMS0xLTE2NzkwOA_e004160d-77a6-4bdf-b332-24a773fece9c"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i95d3bf9e9c15461f91c2413227e037e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzQ5LTMtMS0xLTE2NzkwOA_d82307fa-9f16-49cd-888e-04651983d42d"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i24053ea29d834108aadea2e1babdf1a7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUwLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOmExOWZjY2NkOGE5YzRhNjE4MzBhMzVmYjA3NTYyYmY1XzQ_6d6bb9f7-597b-4d61-bbda-b97d754a6a1c"
      unitRef="number">0.0505</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i24053ea29d834108aadea2e1babdf1a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUwLTEtMS0xLTE2NzkwOA_c4bb2f78-27d2-4945-a453-05ca32ea2613"
      unitRef="usd">8000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib8aad75638974bc3a8cc67695f56c0c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUwLTMtMS0xLTE2NzkwOA_907ca6da-abd0-48d9-bce4-aa63e3609b9d"
      unitRef="usd">8000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2904af2c2aa44bf0b544d9d2553f8e9e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUxLTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjNkOWRlNTE3NmFmODQzMzNhNzJkN2ZlNjhjOGEwMmIyXzQ_6c873d16-e6d8-4c1a-8584-2bfab1c50482"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2904af2c2aa44bf0b544d9d2553f8e9e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUxLTEtMS0xLTE2NzkwOA_075f39f1-7a83-4179-9fb7-7aecb3974e3c"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i42e7542864f1465cbf09bf46b7a5efd8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUxLTMtMS0xLTE2NzkwOA_b90a2614-b20d-4658-aab4-ba84050d4400"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTEtMS0xLTE2NzkwOA_eff8f712-4e80-48d5-b8a0-ee207c1c95c8"
      unitRef="usd">1465000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUyLTMtMS0xLTE2NzkwOA_0886477e-d511-43fe-a954-0bb0612a187f"
      unitRef="usd">1300000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i142b09e623c74fd48e7fa4f8a407f130_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUzLTEtMS0xLTE2NzkwOA_8d145742-a371-4641-aad9-12898f8e12c2"
      unitRef="usd">314000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i88943c99762a48acb5314b7f2e6035c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzUzLTMtMS0xLTE2NzkwOA_04000f93-6128-4d43-9ec5-dd9c5b333b06"
      unitRef="usd">320000000</us-gaap:DebtInstrumentCarryingAmount>
    <cvs:LongtermDebtGrossAndLeaseObligation
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU0LTEtMS0xLTE2NzkwOA_6c1666d2-4e8e-48f7-9078-125c04d0c354"
      unitRef="usd">52753000000</cvs:LongtermDebtGrossAndLeaseObligation>
    <cvs:LongtermDebtGrossAndLeaseObligation
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU0LTMtMS0xLTE2NzkwOA_8209d4b4-9cde-451b-8219-d288c4e5fd07"
      unitRef="usd">56743000000</cvs:LongtermDebtGrossAndLeaseObligation>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU1LTEtMS0xLTE2NzkwOA_f8db4a3b-46de-4801-9474-c5b761a814fb"
      unitRef="usd">200000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU1LTMtMS0xLTE2NzkwOA_c0a655db-0745-4eb0-b278-667af69cb1c9"
      unitRef="usd">219000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <cvs:DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU2LTEtMS0xLTE2NzkwOA_45d37f13-bd59-4bf6-9db6-0298ff30fb35"
      unitRef="usd">696000000</cvs:DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet>
    <cvs:DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU2LTMtMS0xLTE2NzkwOA_a356a182-ddd1-4e00-9b95-e7518831bbbb"
      unitRef="usd">786000000</cvs:DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU3LTEtMS0xLTE2NzkwOA_b3f078c6-1c29-41ce-b38d-c1843641e422"
      unitRef="usd">52257000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzU3LTMtMS0xLTE2NzkwOA_51fc593d-4671-4628-b901-d61d92591327"
      unitRef="usd">56176000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzYwLTEtMS0xLTE2NzkwOA_baf8b78a-78af-40eb-a99f-cfb7bc4e2471"
      unitRef="usd">1778000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzYwLTMtMS0xLTE2NzkwOA_8eb2dcc3-314d-41a4-9700-95164adf7867"
      unitRef="usd">4205000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <cvs:LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzYxLTEtMS0xLTE2NzkwOA_1d8420c5-3633-4076-aa7b-35020dea903e"
      unitRef="usd">50479000000</cvs:LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale>
    <cvs:LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTpjODQyZjkwOTY0MzM0ZTM0ODk2Y2IwZThkMGYwMzI0ZS90YWJsZXJhbmdlOmM4NDJmOTA5NjQzMzRlMzQ4OTZjYjBlOGQwZjAzMjRlXzYxLTMtMS0xLTE2NzkwOA_1fe67f2d-6e4b-4de4-92f8-ab7549cecabe"
      unitRef="usd">51971000000</cvs:LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic9857095e8f8462c8443313d13593edd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzk1Njg_ddb8c119-c1f1-42b6-9e2c-a3dfffd30489"
      unitRef="usd">3000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4MjA_61a5ec1d-fada-40cb-bcd3-059465c1cd7c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s required repayments of debt principal due during each of the next five&#160;years and thereafter, as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;See Note 6 &#x2018;&#x2018;Leases&#x2019;&#x2019; for a summary of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;maturities of the Company&#x2019;s finance lease liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzEtMS0xLTEtMTY3OTA4_0e3611e9-206e-4fda-87a2-8c50c1478081"
      unitRef="usd">1719000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzItMS0xLTEtMTY3OTA4_1b98066b-d26d-4b1b-b720-6622e513b967"
      unitRef="usd">2706000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzMtMS0xLTEtMTY3OTA4_7fa300f8-686d-4ec5-98f2-7ca5077f6166"
      unitRef="usd">3785000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzQtMS0xLTEtMTY3OTA4_7836553b-2324-4cde-a08b-1a30b1a32de9"
      unitRef="usd">2507000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzUtMS0xLTEtMTY3OTA4_eda0c75a-78a0-4f1e-a9a6-8e8e724f295e"
      unitRef="usd">3379000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzYtMS0xLTEtMTY3OTA4_42aa06f0-10da-4792-a672-b93c357f0011"
      unitRef="usd">37192000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzctMS0xLTEtMTY3OTA4_1736d927-e74c-4de2-acdd-8d2ed4c473f7"
      unitRef="usd">51288000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzgtMS0xLTEtMTY3OTA4_eff8f712-4e80-48d5-b8a0-ee207c1c95c8"
      unitRef="usd">1465000000</us-gaap:FinanceLeaseLiability>
    <cvs:LongtermDebtGrossAndLeaseObligation
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90YWJsZTo4YzNiMDJlZGQyMGY0OTdmODllYWU1YmYxNWQ1ZTdmMC90YWJsZXJhbmdlOjhjM2IwMmVkZDIwZjQ5N2Y4OWVhZTViZjE1ZDVlN2YwXzktMS0xLTEtMTY3OTA4_2e530404-85c9-459a-bf20-9d0badf5a6b4"
      unitRef="usd">52753000000</cvs:LongtermDebtGrossAndLeaseObligation>
    <us-gaap:ShortTermBorrowings
      contextRef="i80a5bd02c59b48d08a90b3e9dc305deb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ4MQ_efca53e3-6ebd-40ac-a5e3-19dbaab0616d"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="ia1fc6bc460b24a2d9f9e56bbbcc00fdd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ4MQ_f1c73486-82e7-4de3-b029-9fafe27a7c13"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i178a89f691034c3f89a0f58dd76f6e00_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYyOQ_be320a14-8d90-4553-9bcd-23adcfb50d10"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i9e8df175e7a746b1966ad9f58331ab59_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4NTc_313e64a8-1b3f-4573-85e6-cbf3bbfa9f0c">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9d1d90e160df4c6987e1a3d97b3ee6de_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzcxOQ_71faed32-6af6-401e-a624-10bea526e635"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i7d274b43ce6b460b819a8816627a53ce_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4NTE_930daf5e-317d-4b90-913e-932a82998a91">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i09e418d01a724140b2e4c98ed177fb58_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzgxMw_90b43e57-3a60-461e-948b-bcc01644154a"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i81ac034e6bd446208baa342a62985862_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzc4NjI_428e6a90-ff08-4d89-9cb1-ce134fc4cd86">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i69d9e769f3ec4ff9913f2a8111d4261a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzExMTc_fa87094e-800a-4bd3-8617-cd036397b254"
      unitRef="number">0.0003</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:ShortTermBorrowings
      contextRef="i672e486d94cb40d7a527afc4274d487f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzExNzA_a25adbae-7ce0-4532-a05b-ba3f68725a7e"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="ia959e4c514254a2b8079572e46d8906d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzExNzA_a5392d2f-bfcd-4586-a9b9-ed4596284d95"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE1NTI_e475f555-0cde-4697-820e-00a7102e6c1d"
      unitRef="usd">915000000</us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable>
    <us-gaap:ShortTermBorrowings
      contextRef="iee13a60d394448b5ac976fd2d9a8bc06_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE1ODY_35b4217c-1142-4a03-a01e-a9a4d025a8c8"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i1cf725ff0cd64d81815fe8e8b14333a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE1ODY_f027e1b3-e463-4ef8-a9fd-b4cd0b574dcd"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iea5673d7807e4ec1a5450a0e6653c02a_I20220531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwNDI_10bc7eef-602b-4c99-8713-ad5f7c8085a5"
      unitRef="number">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i65160d516bd047099c2e54b984917a8b_D20220501-20220531"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwNTE_37372966-7e93-4752-a383-887120153af7"
      unitRef="usd">1500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib1b72957684f401f892d85f44495d314_I20220831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwNjc_1d1ead36-8041-4937-97f3-ac7d7a50ebc4"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id5f6ffbd37304fc48f79a5e9b0b46aeb_D20220801-20220831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwNzU_5c9fb118-c854-494f-92c3-06e3a1d584a3"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i822fccc0619141489184c841adb873a6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwOTE_ca866cc8-c688-45a7-92e1-f20e2a0f6644"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9c47b439eae34e66b4c6b711b0356a0f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkwOTk_bd3cb408-2e23-4e4d-9e62-bf9f5e67005b"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic145b33260a44d0e8f2212d9f0defd82_D20220901-20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzEzNzQzODk1MzYxMzYz_6de0d55e-86ba-4d24-bded-bc5a55ae6958"
      unitRef="usd">1250000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iadc7cf66f76f4d89843f2feb6ead05a9_D20220901-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzI3NDg3NzkwNzkxMDk_b80c119b-b7e6-429e-a026-6b3f69d7bbee"
      unitRef="usd">399000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4e5f9ad0e20745e2b8738a0b8561987b_I20210818"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE2OTk_ff45480f-d87c-43ab-a161-8d25a34f95d9"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4e5f9ad0e20745e2b8738a0b8561987b_I20210818"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE3MzI_540f7107-56ed-4dde-9f23-abfab4650b2a"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i79d2af0f86c541af9571d4910bbca9be_D20210818-20210818"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzE4MDM_d5ccf101-7cd7-4ab4-8ed1-006f6f6ad54e"
      unitRef="usd">987000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id5a0d766445d4eabbf62b2cae9bdafec_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzYzMg_44e926da-9e93-4fa3-b129-bdf99ccbd34b"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id5a0d766445d4eabbf62b2cae9bdafec_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY0Ng_a6873e0b-1c34-435b-bec0-90c8ec9ac381"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1250e762a87140739d6c5e728a186e5b_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY1NA_7d0e9305-bd75-45d0-ab85-fd068920f6d4"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1250e762a87140739d6c5e728a186e5b_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY2OA_94436392-9313-4797-9a8a-998141ab4419"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i02d14dd77d014595a362cb2ecc741ab3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY3NQ_69d94966-f2fc-414c-a8c4-59132e8011f4"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i02d14dd77d014595a362cb2ecc741ab3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY4OQ_4ea00836-524f-4e58-bb0d-20b7c2f3fcf8"
      unitRef="number">0.04125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i12df8267bbe141b3a7404c266a874107_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzY5Nw_18beb7ea-6859-4525-a76c-5eb588de77aa"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i12df8267bbe141b3a7404c266a874107_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0OTc1NTgyNzcxMQ_23aebda9-73e1-4571-a634-94c41a416c8e"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="ibdbbb74b83b14c429e04b647517a9a11_D20200301-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQxMTY_50508e1b-2dc3-43d0-a646-65cb49a3adb6"
      unitRef="usd">7000000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibdbbb74b83b14c429e04b647517a9a11_D20200301-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQyMTA_4ee6cd00-47ec-4a40-b91f-c5cd50b9fd5d"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i1c8ed04608904ccf99b54ecc1dc6986f_D20211201-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ0Njg_57159691-8054-42e9-a698-3d6bca9f7823"
      unitRef="usd">2300000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i261fa7d2be3a4e558c47f8185e46e39c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ0OTA_8a19e90f-4af5-4e09-9d46-8a2d21bb23d2"
      unitRef="number">0.037</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ2MTk_58870ef0-2d6f-42a3-aad1-743df68d380a"
      unitRef="usd">-80000000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ3MTY_d84c20e4-4516-4c79-b777-5d58202ff360"
      unitRef="usd">8000000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <cvs:DebtExtinguishmentFees
      contextRef="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ3NzI_d8abf2e7-875e-4b30-87b2-e5abd42f7ce4"
      unitRef="usd">1000000</cvs:DebtExtinguishmentFees>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id04fc7fd59e14f45961a01d6f8c7d9bf_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ4MzY_6d5734ef-ce73-4bc1-be0b-4177b963658d"
      unitRef="usd">-89000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i6a3e435c4d424340a17b5f25797bcf4c_D20210801-20210831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ4OTM_8da6c06c-3445-4541-9beb-1e1e3d882356"
      unitRef="usd">2000000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib2bac05524ef4721a76e0eb616aa0666_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzQ5MTU_2bc58bd2-7df8-4ad1-b152-e52d9cdb4758"
      unitRef="number">0.043</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUwNTM_cc479c7d-a9f7-49ea-a55e-f882412e5b86"
      unitRef="usd">-332000000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUxNTE_bd01253e-13fb-45f8-81af-e4e4f98a4624"
      unitRef="usd">26000000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <cvs:DebtExtinguishmentFees
      contextRef="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUyMDc_b32542c6-53bb-406f-a991-c73c68046b0d"
      unitRef="usd">5000000</cvs:DebtExtinguishmentFees>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5647e8af3c1b40d5b96f954a5b1d5fc1_D20210801-20210831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUyNzE_e6f8814e-2247-4753-98d6-d5a29e76fc5d"
      unitRef="usd">-363000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ifd21192d1e424d908a21238c5796151b_D20201201-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzUzMTY_25935609-f650-46b0-832c-4257bb459419"
      unitRef="usd">4500000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i25c312e3832345d184ca98519e12b9d1_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0MzA_49438a47-6a91-443d-b0d7-7419d0e1f944"
      unitRef="usd">113000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i13f4471edaf148c9a01efea628761e98_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0NDA_c2062c56-2656-4dc0-b4eb-9b2d17c1017c"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ifa1dd2e3d7514370b3370e9417b8eb05_D20201201-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0NjY_4f3a9f09-1b42-4294-ae2c-193a0be918be"
      unitRef="usd">1400000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i849a0c4d3cbb471192475ee1fb23de1b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU0NzY_801155e5-4bd7-4df5-a33a-91fb71383fea"
      unitRef="number">0.037</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ida81c2c8d73c4e8bb5a9daa090b941df_D20201201-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU1MDI_f05eaa87-f56c-4bf0-a092-1c25a478ff25"
      unitRef="usd">1000000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4f5b8050a2fb4ad5b42037c800d80489_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU1MTI_18b6c595-dcac-4f5b-bff4-2b75aa717c76"
      unitRef="number">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i8e6897a260054377ad600720e4fd68b9_D20201201-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU1NDE_46d82395-bf72-46ac-98b4-9253182771ec"
      unitRef="usd">2000000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i56faf938b6bd44ff9f91b9e6bc18f5ec_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU1NTE_098be5de-57b5-424e-8f38-19fb3187f8d0"
      unitRef="number">0.043</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU2NjE_7891a137-9b7f-416f-b4c3-fbb4a739d4a0"
      unitRef="usd">-619000000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU3NTk_75e569ff-85e4-4dff-81f9-09f1af8afec5"
      unitRef="usd">45000000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <cvs:DebtExtinguishmentFees
      contextRef="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU4MTU_25b59a7b-6e09-413b-a234-751ece34bd09"
      unitRef="usd">10000000</cvs:DebtExtinguishmentFees>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2cdf3b4ccd474aea9d37fed418eeac29_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU4Nzk_d9b56349-8b80-4f2b-9175-a10b5c006881"
      unitRef="usd">-674000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i0e3f962b140e4d8bbed1c0e619a28998_D20200801-20200831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzU5MjI_a0cb604d-54a8-46b9-aff5-17f93843e2c6"
      unitRef="usd">6000000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="iad0865b66832421a88a82f88e92f6b90_D20200801-20200831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYwMzY_4f5ac5d6-ef7b-4457-8dcc-b031da722a1f"
      unitRef="usd">723000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if76853d3efe14948b0d921504f1a2b1f_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYwNDY_fea767e5-9be5-43a1-b26b-f1c53bc98d79"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i6f8d117be10d448ba3e9812c1e7e4b01_D20200801-20200831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYwNzI_aa78c619-600b-4740-8a52-8f890e9afffa"
      unitRef="usd">2300000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i91226dc64fe84ffcb8769e52de99bd30_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYwODI_c27607e8-b634-4d16-9d37-1e0b786e87a4"
      unitRef="number">0.037</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i8c996ffe9966457d93cce263d0c3eaac_D20200801-20200831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYxMTE_3960e599-e9c0-43bf-9692-707daef4cedb"
      unitRef="usd">3000000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2d884e077e99498da60db16f252f707a_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYxMjE_ea2fca2d-8435-49f6-b39f-6f2893a28640"
      unitRef="number">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYyMzE_3e9bbf03-ad31-43f6-bc9b-eaa4e00b808a"
      unitRef="usd">-706000000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYzMjk_61a31365-4213-4020-b62c-c70f18f76e30"
      unitRef="usd">47000000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <cvs:DebtExtinguishmentFees
      contextRef="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzYzODU_9cfe7507-7a98-476c-91ba-48c70c285b5f"
      unitRef="usd">13000000</cvs:DebtExtinguishmentFees>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8bbee4c1691c4163927584382f7eee8d_D20200801-20200831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDIvZnJhZzpkOTY5Yjg1ODFiYjY0ODllYmI2ZjkzOGVjZDYwNzUwYS90ZXh0cmVnaW9uOmQ5NjliODU4MWJiNjQ4OWViYjZmOTM4ZWNkNjA3NTBhXzY0NDk_12dc4b77-a7fd-49b2-9a5b-911701e9bb05"
      unitRef="usd">-766000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTE4_f3319996-04b5-4f4a-a507-3656d7b10437">Pension Plans and Other Postretirement Benefits&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company sponsors several active 401(k) savings plans that cover all employees who meet plan eligibility requirements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes matching contributions consistent with the provisions of the respective plans. At the participant&#x2019;s option, account balances, including the Company&#x2019;s matching contribution, can be invested among various investment options under each plan. The CVS Health Future Fund 401(k) Plan offers CVS Health Corporation&#x2019;s common stock fund as an investment option. The Company also maintains nonqualified, unfunded deferred compensation plans for certain key employees. The plans provide participants the opportunity to defer portions of their eligible compensation and for certain nonqualified plans, participants receive matching contributions equivalent to what they could have received under the CVS Health Future Fund 401(k) Plan absent certain restrictions and limitations under the Internal Revenue Code. The Company&#x2019;s contributions under its defined contribution plans were $567 million, $552 million and $520 million in the years ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a tax-qualified defined benefit pension plan that was frozen in 2010 and a nonqualified supplemental pension plan that was frozen in 2007. The Company also sponsors several other defined benefit pension plans that are unfunded nonqualified supplemental retirement plans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pension Benefit Obligation and Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables outline the change in pension benefit obligation and plan assets over the specified periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the pension benefit obligation during the years ended December&#160;31, 2022 and 2021 was primarily driven by the change in the discount rate during each respective period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets (liabilities) recognized on the consolidated balance sheets at December&#160;31, 2022 and 2021 for the defined benefit pension plans consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent assets reflected in other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities reflected in accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities reflected in other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Periodic Benefit Cost (Income)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost (income) for the years ended December&#160;31, 2022, 2021 and 2020 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit cost (income):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (income)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pension Plan Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a series of actuarial assumptions to determine its benefit obligation and net periodic benefit income, the most significant of which include discount rates and expected return on plan assets assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discount Rates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate is determined using a yield curve as of the annual measurement date. The yield curve consists of a series of individual discount rates, with each discount rate corresponding to a single point in time, based on high-quality bonds. Projected benefit payments are discounted to the measurement date using the corresponding rate from the yield curve that is consistent with the maturity profile of the expected liability cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Return on Plan Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected long-term rate of return on plan assets is determined by using the plan&#x2019;s target allocation and return expectations based on many factors including forecasted long-term capital market real returns and the inflationary outlook on a plan by plan basis. See &#x201c;Pension Plan Assets&#x201d; below for additional details regarding the pension plan assets as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also considers other assumptions including mortality, interest crediting rate, termination and retirement rates and cost of living adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined its benefit obligation based on the following weighted average assumptions as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pension Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s pension plan assets primarily include debt and equity securities held in separate accounts, common/collective trusts and real estate investments. The valuation methodologies used to value these debt and equity securities and common/collective trusts are similar to the methodologies described in Note 4 &#x201c;Fair Value.&#x201d; Pension plan assets also include investments in other assets that are carried at fair value. The following is a description of the valuation methodologies used to value real estate investments and these additional investments, including the general classification pursuant to the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Real Estate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Real estate investments are valued by independent third party appraisers. The appraisals comply with the Uniform Standards of Professional Appraisal Practice, which include, among other things, the income, cost, and sales comparison approaches to estimating property value. Therefore, these investments are classified in Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private equity and hedge fund limited partnerships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Private equity and hedge fund limited partnerships are carried at fair value which is estimated using the NAV per unit as reported by the administrator of the underlying investment fund as a practical expedient to fair value. Therefore, these investments have been excluded from the fair value table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2022 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Domestic real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Common/collective trusts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The assets in the underlying funds of common/collective trusts consist of $104 million of equity securities and $203 million of debt securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Excludes $390 million of other receivables as well as $432 million of private equity limited partnership investments and $225 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2021 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Domestic real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Common/collective trusts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The assets in the underlying funds of common/collective trusts consist of $261 million of equity securities and $149 million of debt securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Excludes $76 million of other receivables as well as $583 million of private equity limited partnership investments and $237 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s pension plan invests in a diversified mix of assets designed to generate returns that will enable the plan to meet its future benefit obligations. The risk of unexpected investment and actuarial outcomes is regularly evaluated. This evaluation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is performed through forecasting and assessing ranges of investment outcomes over short- and long-term horizons and by assessing the pension plan&#x2019;s liability characteristics. Complementary investment styles and strategies are utilized by professional investment management firms to further improve portfolio and operational risk characteristics. Public and private equity investments are used primarily to increase overall plan returns. Real estate investments are viewed favorably for their diversification benefits and above-average dividend generation. Fixed income investments provide diversification benefits and liability hedging attributes that are desirable, especially in falling interest rate environments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, target investment allocations for the Company&#x2019;s pension plan were: 12% in equity securities, 77% in fixed income and debt securities, 5% in real estate, 3% in private equity limited partnerships and 3% in hedge funds. Actual asset allocations may differ from target allocations due to tactical decisions to overweight or underweight certain assets or as a result of normal fluctuations in asset values. Asset allocations are consistent with stated investment policies and, as a general rule, periodically rebalanced back to target asset allocations. Asset allocations and investment performance are formally reviewed periodically throughout the year by the pension plan&#x2019;s Investment Subcommittee. Forecasting of asset and liability growth is performed at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally contributes to its tax-qualified pension plan based on minimum funding requirements determined under applicable federal laws and regulations. Employer contributions related to the nonqualified supplemental pension plans generally represent payments to retirees for current benefits. The Company contributed $27 million, $78 million and $25 million to its pension plans during 2022, 2021 and 2020, respectively. No contributions are required for the tax-qualified pension plan in 2023. The Company expects to make an immaterial amount of contributions for all other pension plans in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Multiemployer Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also contributes to a number of multiemployer pension plans under the terms of collective-bargaining agreements that cover its union-represented employees. The risks of participating in these multiemployer plans are different from single-employer pension plans in the following respects: (i) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (ii) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (iii) if the Company chooses to stop participating in some of its multiemployer plans, the Company may be required to pay those plans an amount based on the underfunded status of the applicable plan, which is referred to as a withdrawal liability. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the multiemployer pension plans in which the Company participates are individually significant to the Company. The Company&#x2019;s contributions to multiemployer pension plans were $20 million, $19 million and $19 million in 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Postretirement Benefits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides postretirement health care and life insurance benefits to certain retirees who meet eligibility requirements. The Company&#x2019;s funding policy is generally to pay covered expenses as they are incurred. For retiree medical plan accounting, the Company reviews external data and its own historical trends for health care costs to determine the health care cost trend rates. As of December&#160;31, 2022 and 2021, the Company&#x2019;s other postretirement benefits had an accumulated postretirement benefit obligation of $159 million and $207 million, respectively. Net periodic benefit costs related to these other postretirement benefits were $4 million, $4 million and $12 million in 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Pursuant to various collective bargaining agreements, the Company also contributes to multiemployer health and welfare plans that cover certain union-represented employees. The plans provide postretirement health care and life insurance benefits to certain employees who meet eligibility requirements. The Company&#x2019;s contributions to multiemployer health and welfare plans totaled $62 million, $60 million and $54 million in 2022, 2021 and 2020, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExMDU_185c2adc-300d-4420-a42a-4044c013390e"
      unitRef="usd">567000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExMDk_14253e30-360d-404b-8d7d-b5ae2d0a7895"
      unitRef="usd">552000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExMTY_9f9d91d3-397a-40bf-a4d3-8d9a9ad0a2bc"
      unitRef="usd">520000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTEy_7783c863-f5f0-492a-80c4-91867ed1e08a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables outline the change in pension benefit obligation and plan assets over the specified periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTMx_15e4f53e-8e8f-416a-9162-8bed52eca5c4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables outline the change in pension benefit obligation and plan assets over the specified periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzItMS0xLTEtMTY3OTA4_0c62fb4f-2497-4ccf-811f-d617ea80d063"
      unitRef="usd">6009000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i325dd5d5aff14a35ac1931e4f56f744d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzItMy0xLTEtMTY3OTA4_a4408c15-5891-43ec-abeb-61e90b4346d3"
      unitRef="usd">6462000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzQtMS0xLTEtMTY3OTA4_49af9157-64d9-4057-8bdf-296ed68e6311"
      unitRef="usd">132000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzQtMy0xLTEtMTY3OTA4_e4cdd871-cf18-49f8-b495-e0938590ae1e"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzUtMS0xLTEtMTY3OTA4_ad2878a7-5194-4a4c-b797-8bb3a6f3ccca"
      unitRef="usd">1011000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzUtMy0xLTEtMTY3OTA4_8ecddfe0-d428-40a9-b588-5bc6baf83397"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzYtMS0xLTEtMTY3OTA4_4432a6c8-e215-4b4a-b20e-bab01a616021"
      unitRef="usd">387000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzYtMy0xLTEtMTY3OTA4_5eae5e7d-7a5a-483e-9d09-b7374a91146c"
      unitRef="usd">408000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzctMS0xLTEtMTY3OTA4_dd08954f-767e-4db3-b2b8-44b9d27322da"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzctMy0xLTEtMTY3OTA4_9d0bca82-e183-44e1-8d7b-dcf234189fde"
      unitRef="usd">53000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzctMy0xLTEtMTY3OTA4_b9456bc9-5223-41b2-91ad-2e79ecd654ad"
      unitRef="usd">53000000</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzgtMS0xLTEtMTY3OTA4_0cce0df3-c73e-4f56-b2ee-a8508818f07e"
      unitRef="usd">4740000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzgtMy0xLTEtMTY3OTA4_e9063ced-a5ed-407d-a49d-4e980f80a0e3"
      unitRef="usd">6009000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzExLTEtMS0xLTE2NzkwOA_dbabdce6-64a5-4289-85a3-8246586f8b53"
      unitRef="usd">6677000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i325dd5d5aff14a35ac1931e4f56f744d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzExLTMtMS0xLTE2NzkwOA_b5ee7dca-a65c-4690-b4f8-648252c64812"
      unitRef="usd">6845000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzEzLTEtMS0xLTE2NzkwOA_9061a87e-0aed-4547-8bda-e0e82cfedfd8"
      unitRef="usd">-968000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzEzLTMtMS0xLTE2NzkwOA_fddbca23-8cdd-4897-9787-84c6b0112987"
      unitRef="usd">215000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE0LTEtMS0xLTE2NzkwOA_ec5b89cc-c92d-443e-a753-4cf22bc85438"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE0LTMtMS0xLTE2NzkwOA_ad1697f9-6669-42ea-bcf4-b0c750187e74"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE1LTEtMS0xLTE2NzkwOA_8e9bbf42-ff4c-4f21-bb43-1366702fa7e9"
      unitRef="usd">387000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE1LTMtMS0xLTE2NzkwOA_6480a199-e0d3-409d-8c66-d77fc1a1fb81"
      unitRef="usd">408000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE2LTEtMS0xLTE2NzkwOA_f2fe3e50-dff2-4cf3-9a5d-a291e0a8a215"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE2LTMtMS0xLTE2NzkwOA_9d0bca82-e183-44e1-8d7b-dcf234189fde"
      unitRef="usd">53000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE2LTMtMS0xLTE2NzkwOA_b9456bc9-5223-41b2-91ad-2e79ecd654ad"
      unitRef="usd">53000000</us-gaap:DefinedBenefitPlanBenefitObligationPaymentForSettlement>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE3LTEtMS0xLTE2NzkwOA_2f3f90a1-51f1-4922-aeee-252f19367aeb"
      unitRef="usd">5346000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE3LTMtMS0xLTE2NzkwOA_053b23b9-5337-472e-af78-d872032d2773"
      unitRef="usd">6677000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE5LTEtMS0xLTE2NzkwOA_66000f10-3b45-42e6-a0d1-4705fed1c120"
      unitRef="usd">606000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo0NWNkOGNhZWI5MmI0OGQwYjJiODlmMjFlOTYwZGVmOC90YWJsZXJhbmdlOjQ1Y2Q4Y2FlYjkyYjQ4ZDBiMmI4OWYyMWU5NjBkZWY4XzE5LTMtMS0xLTE2NzkwOA_3bfaf862-ac13-486d-8a67-2a406b49fff3"
      unitRef="usd">668000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTI1_b79a2a47-3a34-4cfd-8f35-67a50da96e3e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets (liabilities) recognized on the consolidated balance sheets at December&#160;31, 2022 and 2021 for the defined benefit pension plans consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent assets reflected in other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities reflected in accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities reflected in other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzEtMS0xLTEtMTY3OTA4_8b1aac68-2cec-4eba-91cf-1de6a1ee1680"
      unitRef="usd">827000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzEtMy0xLTEtMTY3OTA4_ca44bf39-7d06-4773-a752-922001965ef7"
      unitRef="usd">946000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzItMS0xLTEtMTY3OTA4_28e09be1-42c2-4c49-9f9f-ca4a016e6358"
      unitRef="usd">24000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzItMy0xLTEtMTY3OTA4_e127e02e-666e-4e69-91a4-f4c0d52f0767"
      unitRef="usd">28000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzMtMS0xLTEtMTY3OTA4_63dbea12-83ae-4a38-9870-56fce5a74dc3"
      unitRef="usd">197000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzMtMy0xLTEtMTY3OTA4_518906bc-be3a-4e74-b672-8055e11e9a22"
      unitRef="usd">250000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzQtMS0xLTEtMTY3OTA4_583a9854-130f-463f-94dd-eb5097c9eaad"
      unitRef="usd">606000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="ifc75d0fe4bd2436da019eb75a7875218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo3MDAwMDJhNTYyODc0Y2ExYjM5NmRhMjUwM2FhMTNkMi90YWJsZXJhbmdlOjcwMDAwMmE1NjI4NzRjYTFiMzk2ZGEyNTAzYWExM2QyXzQtMy0xLTEtMTY3OTA4_793a0dd2-7a94-42bb-b70a-0526245883e7"
      unitRef="usd">668000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTM2_60b21ce6-be8e-4baa-99c9-6073f82fb4b4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost (income) for the years ended December&#160;31, 2022, 2021 and 2020 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit cost (income):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (income)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzItMS0xLTEtMTY3OTA4_ca47f97d-f486-45de-9af9-44eb00be85f1"
      unitRef="usd">132000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzItMy0xLTEtMTY3OTA4_a1fa309f-55f6-4547-9356-d65292f2b91e"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia10042502b67476084251422c4796803_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzItNS0xLTEtMTY3OTA4_d4d9283d-cd38-4e9b-97a4-1b21cc463b1a"
      unitRef="usd">168000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzMtMS0xLTEtMTY3OTA4_4711c82d-a472-4a03-a335-34c758ace153"
      unitRef="usd">309000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzMtMy0xLTEtMTY3OTA4_3a6273e2-1718-4b15-b87a-5d8789103c93"
      unitRef="usd">317000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia10042502b67476084251422c4796803_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzMtNS0xLTEtMTY3OTA4_f4fd3f1a-d0ba-4e0c-b44d-bc34a05e26c8"
      unitRef="usd">388000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzQtMS0xLTEtMTY3OTA4_8b296fa2-c3b6-4427-86a0-fbea7b248d0a"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzQtMy0xLTEtMTY3OTA4_c60ebf68-3417-4cd7-b8a0-f7f77c0095c3"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ia10042502b67476084251422c4796803_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzQtNS0xLTEtMTY3OTA4_3da7bb87-9632-46a0-81db-58ecc4a48b11"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzUtMS0xLTEtMTY3OTA4_ae7c25b0-e9b2-40cb-9807-1f2b130831af"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzUtMy0xLTEtMTY3OTA4_1beb1486-8211-4f74-843f-a51f30f6239c"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ia10042502b67476084251422c4796803_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzUtNS0xLTEtMTY3OTA4_bd8a5bbf-1d0b-4ff2-9fdd-0a7598a8ebdf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzYtMS0xLTEtMTY3OTA4_8cd93a5b-c891-416f-8bb0-9c0440544c42"
      unitRef="usd">-173000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzYtMy0xLTEtMTY3OTA4_9cd6101d-bf2c-435b-98ff-f22406b20d43"
      unitRef="usd">-186000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia10042502b67476084251422c4796803_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyYzllN2E4MzkxYzk0NjljODc1OGYzNmJiYmNjNTI4Ni90YWJsZXJhbmdlOjJjOWU3YTgzOTFjOTQ2OWM4NzU4ZjM2YmJiY2M1Mjg2XzYtNS0xLTEtMTY3OTA4_e1ce34f3-c733-4de7-b6c0-3c323b9a5787"
      unitRef="usd">-218000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTM0_9e54c71f-4517-487c-ae70-b99d7a04781d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined its benefit obligation based on the following weighted average assumptions as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpjYjg1M2ZiOTUxMjE0NjExYTYzYTU4NmY0MGFhZWIyZS90YWJsZXJhbmdlOmNiODUzZmI5NTEyMTQ2MTFhNjNhNTg2ZjQwYWFlYjJlXzEtMS0xLTEtMTY3OTA4_78b1e3e7-ceab-48f6-836a-e98991438ede"
      unitRef="number">0.052</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpjYjg1M2ZiOTUxMjE0NjExYTYzYTU4NmY0MGFhZWIyZS90YWJsZXJhbmdlOmNiODUzZmI5NTEyMTQ2MTFhNjNhNTg2ZjQwYWFlYjJlXzEtMy0xLTEtMTY3OTA4_57175156-6e47-4ec6-b80a-0a0abcfea641"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzEtMS0xLTEtMTY3OTA4_734d194b-7b62-46ff-b14b-0e927a4328ba"
      unitRef="number">0.023</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzEtMy0xLTEtMTY3OTA4_f454bf7e-d046-46be-a315-11c1e3d4ed2e"
      unitRef="number">0.018</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzEtNS0xLTEtMTY3OTA4_7e40a335-e971-4316-b0f2-4a274ea35da3"
      unitRef="number">0.029</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzItMS0xLTEtMTY3OTA4_8e0bdd5e-e6d0-40a9-8589-5eaf60626586"
      unitRef="number">0.048</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzItMy0xLTEtMTY3OTA4_40fda278-4230-471b-a0d0-194c3d42e431"
      unitRef="number">0.048</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpiOWQ4NWE5Y2Q0NDY0YzViOWRkZTZkYzk3M2UxMDdhMi90YWJsZXJhbmdlOmI5ZDg1YTljZDQ0NjRjNWI5ZGRlNmRjOTczZTEwN2EyXzItNS0xLTEtMTY3OTA4_86ef0ff7-8025-4e04-9ac7-fcf5d89079b6"
      unitRef="number">0.063</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTIz_61129dc8-11b3-44a7-8446-6c946500ff91">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2022 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Domestic real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Common/collective trusts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The assets in the underlying funds of common/collective trusts consist of $104 million of equity securities and $203 million of debt securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Excludes $390 million of other receivables as well as $432 million of private equity limited partnership investments and $225 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension plan assets with changes in fair value measured on a recurring basis at December&#160;31, 2021 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;States, municipalities and political subdivisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. corporate securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Residential mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Redeemable preferred securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Domestic real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Common/collective trusts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pension investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The assets in the underlying funds of common/collective trusts consist of $261 million of equity securities and $149 million of debt securities. &lt;/span&gt;&lt;/div&gt;(2)Excludes $76 million of other receivables as well as $583 million of private equity limited partnership investments and $237 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy.</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id982dba0c5764350bf4b2c0dec65cd31_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEtMS0xLTEtMTY3OTA4_2bbcabc7-8065-4304-a794-3d7098d168ad"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if29585373b5145568d76c31491c626ad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEtMy0xLTEtMTY3OTA4_5da9e13e-626a-48f0-96f6-5fe8794a627b"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8ba0d622bb9e4ee59cdc9b56b5daa62d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEtNS0xLTEtMTY3OTA4_0b208424-aa33-4a3c-bec7-318b1d3698f6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iacd0213cc5bd41f29e44134f2087e2df_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEtNy0xLTEtMTY3OTA4_d852918b-dcf5-47da-b638-3010cc51990a"
      unitRef="usd">88000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7c02066515524b6ca358e7ec25ba43ab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzMtMS0xLTEtMTY3OTA4_e786bae6-665f-4c88-90bf-7f2e8b6f6cc4"
      unitRef="usd">566000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib6a598f7ffb4474aa216bbef8ffec30b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzMtMy0xLTEtMTY3OTA4_5aa3c99d-cbfb-45df-b8ac-5552e0bdcf4c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0242ebe0da9b43369d3dbd9a25daef7a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzMtNS0xLTEtMTY3OTA4_bf46110a-160e-4e59-be15-e54fb0f83cc0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib9c35ee561744abb94e564009d6735fc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzMtNy0xLTEtMTY3OTA4_4cd7192f-786c-4005-bce3-0a9ee1217ae2"
      unitRef="usd">570000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i08ea9fc5313346938adf5e13ee0bfcc5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzQtMS0xLTEtMTY3OTA4_19f38f8d-c836-4eb1-92f7-6102bf661585"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i22f0ff1789f6444ab4732281654fe93d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzQtMy0xLTEtMTY3OTA4_4e51f8b2-a2cd-4959-8bd7-814d7c05c96c"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i762b6378140b484aa6d1ca34c23de494_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzQtNS0xLTEtMTY3OTA4_99e319ed-e7c7-450b-a658-3b0b06882c24"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0e20cd8a6c7f4c69bb7918f0d9cd2739_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzQtNy0xLTEtMTY3OTA4_5aee6289-a9c6-47ea-a858-1c25a4c46941"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if267949f5fce4681b947f1a16a3838d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzUtMS0xLTEtMTY3OTA4_f5cebae9-9ed8-4aa8-b1d5-96478ff2fcc6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibeb053251d3444e3901668a924f82d40_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzUtMy0xLTEtMTY3OTA4_c589c29a-26a8-4c47-8652-e739fc6c42ed"
      unitRef="usd">2611000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i99f95fdf743e477a8ac66cfd99745de0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzUtNS0xLTEtMTY3OTA4_3cce879a-6616-4f66-be6e-6606c999c1c2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i252d55800dcb4295b654fd0658f6f573_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzUtNy0xLTEtMTY3OTA4_3b51fdc1-0e1a-4a45-9dae-ecef4d56f40f"
      unitRef="usd">2611000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20101ed8d3e04a40b26eacb5e37c8c4f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzYtMS0xLTEtMTY3OTA4_20b69068-4bb4-4b6b-bbe0-a6b4bab9bd4a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbc938e99b50474b91e168dd07faea18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzYtMy0xLTEtMTY3OTA4_a1cd0d1b-7cea-4976-a2aa-26a1d04ea038"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3b279e1f6f0b40a982401b8df9857736_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzYtNS0xLTEtMTY3OTA4_da7cd8e2-9650-4217-83ee-524b41b18c4a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i42da0c7a9d2b475584b0d47002072fc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzYtNy0xLTEtMTY3OTA4_bb763c42-3487-41a2-b8cc-810e435a2586"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i06a50108c30e41368e58ccdb0e40fbda_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzctMS0xLTEtMTY3OTA4_6ceef0ba-7388-4223-9af1-2b940815f092"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib79129f099714bef8ef8da1d8903ece5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzctMy0xLTEtMTY3OTA4_3e6d71c3-f75f-4c06-8d7b-ececb54cc48f"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2bea816135474568b9b0446d98520e27_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzctNS0xLTEtMTY3OTA4_016ac3d2-de68-4b42-b346-3830c6c604e6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6875cc4cb5c6442fa8caebb5f3329dd5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzctNy0xLTEtMTY3OTA4_973a4348-9ea2-4607-8752-63242d0b3bfb"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i92730350ea67406b893ebd2e0ed6b301_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzgtMS0xLTEtMTY3OTA4_e8feed8d-7e66-43eb-9dc4-1afadcd7166b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8772a8c1e2e8403a88d7445ac2fed106_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzgtMy0xLTEtMTY3OTA4_85e53ccb-9d8d-4651-9d02-607b35971ed9"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifdbf916e80cb46918ba4e4c0df3ed889_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzgtNS0xLTEtMTY3OTA4_3775e0d2-540a-4993-9035-107ad17d9dc6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if5ba20c704434ed2a8fab1c6dd389b1b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzgtNy0xLTEtMTY3OTA4_b940904e-a61d-4da7-a4a0-f286bbd50cac"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaca7c2e9a27a4a1fa7a8bef02337334a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzktMS0xLTEtMTY3OTA4_7eecc447-c631-42a6-babc-e57e50f7e7c0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i162216dad2a6425bb441d4b6af324060_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzktMy0xLTEtMTY3OTA4_a6a730c9-7b25-4843-a223-f927f6457957"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i01262b340a894b3c8b1efb258d3b571b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzktNS0xLTEtMTY3OTA4_0f09525c-7876-4b08-844c-b35b299b20a7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iea00c6da074b480bb9fe7cc6bbcb98a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzktNy0xLTEtMTY3OTA4_e9017f2e-c98a-4bb3-a8ef-ddfb622f1dbe"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2ac6571e3d74f1dab3aee2141e35e2f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEwLTEtMS0xLTE2NzkwOA_3e6a8090-0b4e-41cf-9db8-b9c267dec99f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i46dd8c46c55e411d908696c36b38b5c8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEwLTMtMS0xLTE2NzkwOA_8d8a0bad-98d6-4887-bee6-20e200461e5a"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i38e53b4aa76b4272aa433d30914b2324_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEwLTUtMS0xLTE2NzkwOA_5fd45caf-712b-4ddb-8ed4-a25858c246b0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7900ae2c578549589f4451568700c87b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEwLTctMS0xLTE2NzkwOA_07a40f84-53b6-4152-8d7d-dbf66dacdee6"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ice5f3a8c54054f17989a4b4993615c41_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzExLTEtMS0xLTE2NzkwOA_bcda81c1-ba81-4148-b87e-ae706a365b23"
      unitRef="usd">566000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idb4ffcb36d78416695e1e547f71c05d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzExLTMtMS0xLTE2NzkwOA_98db60eb-1daa-4aa5-8dbe-d30559b23e41"
      unitRef="usd">2837000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5a5a7f84e8ec40208e181a61a9d3aa89_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzExLTUtMS0xLTE2NzkwOA_29836e8d-ea34-4c3d-9ee9-c633dcb9f8a0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i860b2109de434ad680884c679dbcb1b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzExLTctMS0xLTE2NzkwOA_bfe2ad36-57ac-424e-89ab-0097eb963639"
      unitRef="usd">3403000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9aae37978eb34a42bbc35e64ec3c07a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEzLTEtMS0xLTE2NzkwOA_952c106b-69e1-444e-88bb-b7b1ea2bb4b7"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia8efc5986c964403b550888010f694f5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEzLTMtMS0xLTE2NzkwOA_6a976af9-72ac-4226-9565-0433f0d0451b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87d7c0e5807e4c26ba8a3d14fdf19033_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEzLTUtMS0xLTE2NzkwOA_07977013-cc2c-4ce5-88d6-d267f5cc43f3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5e026ebe0d1141d08ec5920a50dddbad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzEzLTctMS0xLTE2NzkwOA_3b9b14b0-3726-445f-9915-8dc306b2aaec"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ide5901c6898f433fadeff64551df32fb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE0LTEtMS0xLTE2NzkwOA_7113cabe-8665-4495-83be-b254f6f7fea3"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia0b828e6576e4f34bc10d207dbb869a0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE0LTMtMS0xLTE2NzkwOA_28b67b92-f74a-4b6f-806b-0e0b19b06873"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d343d8f5c2b4a6e8190984fc1f95d35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE0LTUtMS0xLTE2NzkwOA_adb13c71-d4c5-4281-91d3-6863a94e51ef"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8cd82a6b704248499547541eb8ba6115_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE0LTctMS0xLTE2NzkwOA_efdf9ff9-222c-458e-8e19-92528b95b729"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iab524d12dfb04d818c70ea4d09acb204_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE1LTEtMS0xLTE2NzkwOA_c9222b10-f146-4d4e-865b-35e062426c08"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2feba394cc284f1c8866c717b615d08c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE1LTMtMS0xLTE2NzkwOA_f6593dd6-a6da-4dfc-ab6b-bb3b55e83c4d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic071fdd73a984fef8ee7bfd1c930b231_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE1LTUtMS0xLTE2NzkwOA_f613e60a-dd2f-457a-ab9e-391229ffce83"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6db2a706478c4614aec9544e1bfa5a50_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE1LTctMS0xLTE2NzkwOA_da2ef53e-fc22-4207-9969-47ef2265cc24"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iefa80d56f1e74e55bffe7ec59a51f1f1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE2LTEtMS0xLTE2NzkwOA_009de54f-d5ca-4921-84ec-e920d796781a"
      unitRef="usd">176000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i674b362cb43f4f2cafbbd57f9e56a196_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE2LTMtMS0xLTE2NzkwOA_d646368a-be32-4bd3-98da-2bd8f6911d66"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7d54224ea00f46f9a1e275c80a61b003_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE2LTUtMS0xLTE2NzkwOA_c8b4af9e-84d7-4492-8248-d61ae583cc3c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5ce41f46d8e84b7789c994f5feff9651_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE2LTctMS0xLTE2NzkwOA_d466845e-50ba-448d-a876-f753e8f5f0b4"
      unitRef="usd">176000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if82b640a199e4868b36a915526dc2053_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE4LTEtMS0xLTE2NzkwOA_ddb97e32-491b-4f6f-8371-9a01c97ebdd8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i124f4f560a234bdfb5ec62a90aa60693_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE4LTMtMS0xLTE2NzkwOA_b3aec0fa-6db8-493d-9c17-8a5d3246002d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib411c0d8ea7a4e8192645865166e5bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE4LTUtMS0xLTE2NzkwOA_5e12461c-46df-435a-97a5-d9956ccd8654"
      unitRef="usd">325000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7d545bbe52647728f7c485d029e3b33_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE4LTctMS0xLTE2NzkwOA_7e63135a-5c8a-4d2b-b9a5-48a5d9b47872"
      unitRef="usd">325000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i282d5c6bb1c644ce9a4a5ffafc468287_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE5LTEtMS0xLTE2NzkwOA_cc4b596b-89ff-428a-9095-618d3b650888"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a6639e48973497fa396c0a952816890_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE5LTMtMS0xLTE2NzkwOA_c875dccf-13da-4c5c-b1c9-63ef54492619"
      unitRef="usd">307000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27b6f9af914a43a38de124a97f2cc7b2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE5LTUtMS0xLTE2NzkwOA_d0da5d58-63e1-4844-bc90-4635c004466a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie55eb2e1866d4936acc91c5cfaf163e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzE5LTctMS0xLTE2NzkwOA_9291a793-8f66-48e6-bb7a-6aa9f6a72056"
      unitRef="usd">307000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i94f3dfc3b0af4263962bc11ed03e1717_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIxLTEtMS0xLTE2NzkwOA_4a6dda61-b1cc-40fb-8abb-6c71a15671f0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i981507be87f94c918c4f5777451702ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIxLTMtMS0xLTE2NzkwOA_e64d182b-2924-4349-9a0a-7a495fbcd1f1"
      unitRef="usd">307000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i530d696f8fca4111b2384705d88e2528_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIxLTUtMS0xLTE2NzkwOA_fb5fc5a2-bfe5-4240-a8a9-a9e453a7cfd6"
      unitRef="usd">325000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3b34d8cf62304c8ab8b6b20efdeddbbb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIxLTctMS0xLTE2NzkwOA_ee26b096-a523-4ce5-94e2-5ebced293470"
      unitRef="usd">632000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c03a30159a84819aa7bf2d4b44b4940_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIyLTEtMS0xLTE2NzkwOA_15c45d0e-eafa-4b66-ac60-6d0e30dbd76b"
      unitRef="usd">749000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i61796b34679f4c6cbef7783824db21ad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIyLTMtMS0xLTE2NzkwOA_69ba9265-e344-44e6-9325-775dbd8cb7da"
      unitRef="usd">3225000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8311648bcc5f4c0e9ba53519e18563bb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIyLTUtMS0xLTE2NzkwOA_a429feeb-1981-43f3-a42a-2c13e18cc0e1"
      unitRef="usd">325000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i95da6fe526324fc7915c89f6c760058b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTphMWU3MTQ5M2UwNTM0YjFlOGRlNDBhZDlkNzdiMjhhZS90YWJsZXJhbmdlOmExZTcxNDkzZTA1MzRiMWU4ZGU0MGFkOWQ3N2IyOGFlXzIyLTctMS0xLTE2NzkwOA_6d002305-52cc-46cc-93d9-fd31851f287a"
      unitRef="usd">4299000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="if634ee5b01e4418e9eecd02c2b108b45_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU0NTc_b063427b-3fe6-4ea3-98e2-eed0ddff80bb"
      unitRef="usd">104000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i0ef579c6f5d94978a2551abaa400aaad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU0ODU_0f12bef5-182f-4246-8fbb-c9dc66000d15"
      unitRef="usd">203000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe781c3ffb934d7283abdcde5259b578_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU1MTg_b94ad2e9-2a71-4b71-b62a-1a3e9537acc8"
      unitRef="usd">390000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i22c76370e6bf4af2ba18b89ca655b55b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU1NTM_ee534579-9edc-4f99-a4d4-080cdbe7bcf7"
      unitRef="usd">432000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia2a1ee87f2954456af17415d6e80fd4e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzU2MTA_5e90c159-0cd9-4854-ae96-a50392b990fc"
      unitRef="usd">225000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i800dc1b5ac544829a5f96bf812a6959d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEtMS0xLTEtMTY3OTA4_d845af00-495d-454c-a0a1-295af097217e"
      unitRef="usd">60000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8dcf8da529f3410db68a945ba211481d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEtMy0xLTEtMTY3OTA4_b32e1058-4b62-4d82-a93f-73566fe31a59"
      unitRef="usd">97000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5889f8a183f94f0986fc8d265f0b65e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEtNS0xLTEtMTY3OTA4_a7def39b-3a51-43fd-a0e2-8c1b2c859363"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87a9186dc3884c56aed01709c057e146_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEtNy0xLTEtMTY3OTA4_bdfec78f-a9fa-4d0f-b604-3c439b23ed2a"
      unitRef="usd">157000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iac90be0d15f44066902ebe3c398edd6a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzMtMS0xLTEtMTY3OTA4_32f9d678-7862-4957-827b-c3de22b16b81"
      unitRef="usd">1223000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7a27b2b60c0a4875ae1e21929139b434_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzMtMy0xLTEtMTY3OTA4_d56131bf-aa1e-4963-a7e1-217a6ffb8104"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i448d068b73fe457c9473c2cf2c869646_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzMtNS0xLTEtMTY3OTA4_d8e9d4ec-d0b2-49f9-ace8-ab10788ac86a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2be3d440d0034da59689eb9cb1b8e2a5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzMtNy0xLTEtMTY3OTA4_30d7e0f9-63c1-4f70-ab53-02a5da5f49e2"
      unitRef="usd">1224000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id07efc7eec504e4dbd1c06bcc97776e7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzQtMS0xLTEtMTY3OTA4_f2671b50-aa79-44c9-ae37-e966b62666f4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80434d583b9145699f6467db52e671d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzQtMy0xLTEtMTY3OTA4_a0c2cc61-84ab-4597-9bd7-6143a1f9f77f"
      unitRef="usd">150000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8c53fd3ce91e4d35b310ab8338e5a336_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzQtNS0xLTEtMTY3OTA4_10a5ec72-9bd4-43c0-86bd-a62de4afdb4d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5a0c74c41ebd402f965dc97f83e3927e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzQtNy0xLTEtMTY3OTA4_74e5a6ed-ebfa-41a9-a99b-f6263d76ecd1"
      unitRef="usd">150000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i433675d63b154f81aec4043380ed969c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzUtMS0xLTEtMTY3OTA4_04b3b796-f9c0-4f9e-aa59-37534ce75a48"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9ec12e1923db4bf5b50d8480155727db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzUtMy0xLTEtMTY3OTA4_d250fefd-3880-43f1-b187-ad244cc52905"
      unitRef="usd">2458000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id027a3124e1a442f91f769b2d20a79cd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzUtNS0xLTEtMTY3OTA4_4b786eda-b975-486d-9fa2-2b32245db3e3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icc2ae24835514052914a58a5ed8c6960_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzUtNy0xLTEtMTY3OTA4_e38938d6-4f46-4c39-aca6-9a13f8f5ed6f"
      unitRef="usd">2458000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i276e89b1f499438e87a8b8ff11bfb821_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzYtMS0xLTEtMTY3OTA4_227446f0-8e57-4986-b9b7-02c90b662910"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a32ea5d8145486abd0eee9eb65e2bc4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzYtMy0xLTEtMTY3OTA4_33a5b214-cb4e-4b77-86dc-d461109ca216"
      unitRef="usd">202000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0a17a9c673d747659358cf61fca64e75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzYtNS0xLTEtMTY3OTA4_e7593daf-e316-4ec5-9049-ba6b41acbd54"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb420b7594364d6893ae2d9594cf961d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzYtNy0xLTEtMTY3OTA4_d1eb08ce-27cf-4652-a5d8-2aa4e1b26a2e"
      unitRef="usd">202000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4a86bf692f18486d933d45d22e8027f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzctMS0xLTEtMTY3OTA4_be9ddb35-24f6-48c8-900c-6c86c1e3a2a0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaef94353787243699d29dbbef2ede4aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzctMy0xLTEtMTY3OTA4_0943d0f2-20cf-44f6-bc15-7a42e7021ab3"
      unitRef="usd">277000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id3962569b68340cc9aacb0b0b4055650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzctNS0xLTEtMTY3OTA4_180ebfa9-c15d-4430-9e66-5a71133e5fa9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b93f4fc09a3435ea3369ffd815f169f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzctNy0xLTEtMTY3OTA4_76d66cea-72ee-4035-92ad-e1faf0e0f21d"
      unitRef="usd">277000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib6c1ec54592a466aa4dc5711ca9dfd07_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzgtMS0xLTEtMTY3OTA4_53967840-1589-4f10-bc78-f86f40a3db39"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie9d5c1701e6c488d94354e33e98ea977_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzgtMy0xLTEtMTY3OTA4_99005534-d113-4636-b267-fedd6cf4ce20"
      unitRef="usd">76000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i107ab07b1f1242c2a31146ba192ea630_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzgtNS0xLTEtMTY3OTA4_9f322ba4-61c0-4454-9ff4-4f54ebfe642f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d9fe69ee87141b0a74150684361d6d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzgtNy0xLTEtMTY3OTA4_2aea8937-e18d-4ab0-89fb-6d5ced567cc6"
      unitRef="usd">76000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1c75d0c4c0d64349a39b959decd4ec41_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzktMS0xLTEtMTY3OTA4_0184b672-9ed6-4a40-9df6-bda8f21d7506"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7fea1b150cad403f92fe062910c70247_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzktMy0xLTEtMTY3OTA4_091b40a5-cbe7-42d8-91bf-5f048c9025c2"
      unitRef="usd">162000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie818f0ce1b2d4700bf8a50b52e1ea2aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzktNS0xLTEtMTY3OTA4_7e0fb94f-99b6-4545-82f5-01bc9d768b0d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib37677b4bebe40289a4b9b7576269f3c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzktNy0xLTEtMTY3OTA4_878673d8-b9f2-4f7a-a6de-b8434e93bfa6"
      unitRef="usd">162000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib765d894de694d2094ea42b1892d468e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEwLTEtMS0xLTE2NzkwOA_a9c624f2-b3f9-43ad-bdcf-fdfc5852973c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i32eee2f391f44fae9f98ce3ecd31a02b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEwLTMtMS0xLTE2NzkwOA_df9b6d2b-72c8-40b5-ae84-a19a75feaf63"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id7671aaeacd046c9838da466ff4e34b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEwLTUtMS0xLTE2NzkwOA_4767adec-cfb2-4052-912f-63424ac7aceb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i414e18de330f46b88b7101cb98dd39ab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEwLTctMS0xLTE2NzkwOA_b63741cf-9866-4d43-8617-e67befb99687"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i733ba5d142df4f60938808824882bdfc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzExLTEtMS0xLTE2NzkwOA_99380d82-985e-4c2c-95b0-dee3d88d23d1"
      unitRef="usd">1223000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20703722f40e44c4835113f54e1e12c3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzExLTMtMS0xLTE2NzkwOA_3c385a4c-9d7b-41af-bbf0-9a406cea75e5"
      unitRef="usd">3330000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie12f7e25dae34ed19c14ceed1716dd91_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzExLTUtMS0xLTE2NzkwOA_1e061174-3a2b-4ab7-a82f-724698feb341"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1f089b62038641eca565000d9846ae75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzExLTctMS0xLTE2NzkwOA_8cf9b183-772d-4d87-84aa-3f075bb248c4"
      unitRef="usd">4553000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idad31584585d475ea5dc99cd84a40282_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEzLTEtMS0xLTE2NzkwOA_3f89fdc1-2583-4209-94d9-3bd7cb1f7b51"
      unitRef="usd">201000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d3653f149da49b29def0497a05f984f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEzLTMtMS0xLTE2NzkwOA_d26738cc-3410-470b-a519-0800c11d4a92"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib2a6c29224644307a2a9eb78032ad4e7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEzLTUtMS0xLTE2NzkwOA_890c8bda-ecea-446c-bd36-23a7944c6211"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icbd0bc158bfa4d8c9a1eef38aeb153e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzEzLTctMS0xLTE2NzkwOA_932fad68-2cf1-4438-886b-84f9c1c5447e"
      unitRef="usd">201000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6419521af8914bc08f951b1558c156a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE0LTEtMS0xLTE2NzkwOA_7c959718-ed0b-4b1f-be00-5c67e052084b"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia201e25566f84e35aa96a9f051384c05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE0LTMtMS0xLTE2NzkwOA_eccc40f2-ad8b-4a39-b1aa-42047c2e54be"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id46442f3513e4d8ead71ef391f535a91_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE0LTUtMS0xLTE2NzkwOA_0ae46bfc-c9f7-49df-8ea6-39785c4d5470"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icdbe5c58d7d04ef294e397fd28124004_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE0LTctMS0xLTE2NzkwOA_9a4b38d6-6c44-4790-b915-cd759f95e1e5"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd84d2bfaae34c2589bfdb10af6646d9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE1LTEtMS0xLTE2NzkwOA_7e95c77b-a09a-4d6b-b8f4-8c06385580d2"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbdafb297a2242e5b3fb68a537d6f098_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE1LTMtMS0xLTE2NzkwOA_8869b66f-311f-4980-932f-5b6ac47a5278"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i08dd758138b84d4bb3085c8c44048020_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE1LTUtMS0xLTE2NzkwOA_3de7d614-b268-4a6c-9b4d-3bc37dda77e5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4696cfd2126a49aca34be6569c415e4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE1LTctMS0xLTE2NzkwOA_cd70125d-b35f-4558-b777-15cffae5db97"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibdf302d352334c7eb29f6daa43872807_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE2LTEtMS0xLTE2NzkwOA_fa07fad5-d0c9-4d2a-a2f4-0d9003dd3a8e"
      unitRef="usd">283000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9eb696de5db242c795422c37920e7842_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE2LTMtMS0xLTE2NzkwOA_8576b275-882e-4815-b4e8-3538d4c9adcf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i077b6285cc31461598b42554e2d8d9c7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE2LTUtMS0xLTE2NzkwOA_4d82c000-8692-4eb9-9bd2-956a2577e57e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i28aea62135614aab87e0943dbebccb07_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE2LTctMS0xLTE2NzkwOA_51a6cc20-5efa-418b-bc61-d2bff68b5d5b"
      unitRef="usd">283000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5ee69f393002463ebc8b873e9f00a9e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE4LTEtMS0xLTE2NzkwOA_6ad1c2fb-52b6-4af1-8651-02a74ce36ad1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1d019c669092417cad902aabe452c43a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE4LTMtMS0xLTE2NzkwOA_a723c768-9011-4726-ae17-11099209dc23"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8340f5ec7e64baf9924bad129344c57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE4LTUtMS0xLTE2NzkwOA_e1922452-0e83-4d3d-a7b8-40ee2e69d748"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieeb435009ac34bbba8afb4a9051ebcbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE4LTctMS0xLTE2NzkwOA_7fa6b5c2-dc5b-45b8-bc5e-e4473d4fc611"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iff3f6572a7984acc83891d6ffe51dac6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE5LTEtMS0xLTE2NzkwOA_2852223a-60dd-46fb-9e4b-83e22b3194c6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i721f414643aa4d48a77204540a59ca02_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE5LTMtMS0xLTE2NzkwOA_9335d15c-5148-4b23-bccc-9aa92377faa5"
      unitRef="usd">410000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i95b3e6fd20854c36bac655b5705bd8c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE5LTUtMS0xLTE2NzkwOA_6218d9a0-c7d2-4c96-af61-8fdc9a39a5bf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i714696085e3846d5996660ba69ae9916_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzE5LTctMS0xLTE2NzkwOA_07171084-c2e9-40d5-bf41-d407f08add4f"
      unitRef="usd">410000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i616fe276b0c14b9ea335de3ffe9e254b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIxLTEtMS0xLTE2NzkwOA_550e7df0-5597-4357-be5b-af7ad685378a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89296715dad54dadab6556fc2a883b22_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIxLTMtMS0xLTE2NzkwOA_a60f352b-5ac6-491a-9210-b313c5e9a071"
      unitRef="usd">410000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i236e33efcde54e91a4243a0e24ed6b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIxLTUtMS0xLTE2NzkwOA_abe55351-0b73-48e2-83fa-23d5c7015d02"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5af8d0600cbc4be881c45d46a38b22c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIxLTctMS0xLTE2NzkwOA_fa074fa6-4ebf-4cd7-a780-302e507063ec"
      unitRef="usd">788000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6812d37c933b481db36130a6e153ad52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIyLTEtMS0xLTE2NzkwOA_d876aff3-ed1e-4ad1-932d-24124fa9d8bc"
      unitRef="usd">1566000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i26e065eea181432cb10971a1ef6fa9dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIyLTMtMS0xLTE2NzkwOA_d0c73f14-8852-41b5-85f3-99e5d25d3d7d"
      unitRef="usd">3837000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia048e730866c404db59cbf7a969bb920_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIyLTUtMS0xLTE2NzkwOA_922300b8-a6fd-4b23-ae2f-1179381a648c"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic430f4dcb0f043c8b9a2999c5816e5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5YWNmNjE1YTgwN2U0OGM2OGE3ODM3ZjAyYzU2MWU2ZC90YWJsZXJhbmdlOjlhY2Y2MTVhODA3ZTQ4YzY4YTc4MzdmMDJjNTYxZTZkXzIyLTctMS0xLTE2NzkwOA_ab1e264b-277b-4afd-bf59-4f717934fe55"
      unitRef="usd">5781000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i1381345c3d5840459cf0370ce99902da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYwMTM_6de9ff35-e42d-42c2-bc9f-674e00d46442"
      unitRef="usd">261000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount
      contextRef="i766450bb0604426f8bdb03f539b684e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYwNDE_f16ccd5c-652a-4bfd-ae1e-b669a29f1698"
      unitRef="usd">149000000</us-gaap:DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia34c0f80bd2e4e66bd5efc598c7695bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYwNzQ_2f3d0f5e-69a8-4c63-ae3c-fa78551814b5"
      unitRef="usd">76000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i00ba36ca870d489badec2a4b43f49a11_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYxMDk_5924547b-a315-4985-9e0a-76319a76e588"
      unitRef="usd">583000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if2ab04d328c64e48a9513092777617a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzYxNjY_39fea597-aad3-4437-a16a-ca52440b4c7d"
      unitRef="usd">237000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsCategoryTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTI2_d4356e74-1613-473d-adb7-b250f3c20769">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balances of Level 3 pension plan assets during the year ended December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DefinedBenefitPlanPlanAssetsCategoryTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8340f5ec7e64baf9924bad129344c57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzEtMS0xLTEtMTY3OTA4_ec463bf2-d2f0-4108-9ad5-8e8a6d99177b"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia048e730866c404db59cbf7a969bb920_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzEtNS0xLTEtMTY3OTA4_77729fdf-8c2c-4e7c-8c20-2a976baec8fc"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i41df18924e1d461c9545e50ad75b2b04_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzItMS0xLTEtMTY3OTA4_91b7f1d5-13fe-485c-a1a6-8b973604494b"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i5e58d7651f6c4f319612d35334a716cb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzItNS0xLTEtMTY3OTA4_a4aa0e13-6de2-46ae-960f-87c2a52cca79"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i41df18924e1d461c9545e50ad75b2b04_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzMtMS0xLTEtMTY3OTA4_2a965d22-9d67-4b9f-82de-4c7cce903afc"
      unitRef="usd">-74000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i5e58d7651f6c4f319612d35334a716cb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzMtNS0xLTEtMTY3OTA4_c1788010-8c49-4da0-a2b4-695584cafad2"
      unitRef="usd">-74000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i41df18924e1d461c9545e50ad75b2b04_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzQtMS0xLTEtMTY3OTA4_a266f805-8e3c-4547-af72-a5fd8cfcfc70"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i5e58d7651f6c4f319612d35334a716cb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzQtNS0xLTEtMTY3OTA4_3b637f54-a779-48c2-bc4c-7d5d1a3b972f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib411c0d8ea7a4e8192645865166e5bc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzUtMS0xLTEtMTY3OTA4_85cbff0c-0102-40df-9559-7c803e81d42e"
      unitRef="usd">325000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8311648bcc5f4c0e9ba53519e18563bb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTpmOTM3Yzg2NDI4NGY0ODZkOTMwZjJjMTA5NDZkNjIyZi90YWJsZXJhbmdlOmY5MzdjODY0Mjg0ZjQ4NmQ5MzBmMmMxMDk0NmQ2MjJmXzUtNS0xLTEtMTY3OTA4_2a4c4e65-bdd9-4e80-a045-1b4972ac5b5a"
      unitRef="usd">325000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5d63903b589946129164b093427d20a7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzEtMS0xLTEtMTY3OTA4_847c67cd-d189-473c-b05e-51824cc5cdea"
      unitRef="usd">343000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3bb557e906c74f7e8c3d94d93011a01b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzEtNS0xLTEtMTY3OTA4_fd680cc8-074d-49d2-817b-4af77cb96932"
      unitRef="usd">343000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i91633285ed494358864442a95f7cd753_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzItMS0xLTEtMTY3OTA4_4440572f-b061-4bf7-83af-87037e969cbf"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ieeb33c37ed48461980e0c720a0c2fc11_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzItNS0xLTEtMTY3OTA4_6f9bbdaa-7fe2-459f-88e4-1c5c99b9cc9b"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i91633285ed494358864442a95f7cd753_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzMtMS0xLTEtMTY3OTA4_e91b1837-947e-4a52-b40c-1615111e3101"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ieeb33c37ed48461980e0c720a0c2fc11_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzMtNS0xLTEtMTY3OTA4_aa6ae25b-b484-416a-9ad7-283b60bd0ad3"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i91633285ed494358864442a95f7cd753_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzQtMS0xLTEtMTY3OTA4_fd0f77ff-f4f2-498c-8595-ceaedb8789b5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="ieeb33c37ed48461980e0c720a0c2fc11_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzQtNS0xLTEtMTY3OTA4_094f1cb3-920a-4bb1-a278-ba83f09b6367"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8340f5ec7e64baf9924bad129344c57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzUtMS0xLTEtMTY3OTA4_211c7f84-4e5d-48d8-9c0c-18008c521cf9"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia048e730866c404db59cbf7a969bb920_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTo5NTZhYjE4MzU2NDU0MWE2ODhhMTllMjI3M2JmNzQwNy90YWJsZXJhbmdlOjk1NmFiMTgzNTY0NTQxYTY4OGExOWUyMjczYmY3NDA3XzUtNS0xLTEtMTY3OTA4_e42bb373-e993-40f7-ab92-f3ce451bb805"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ida2e4bf976d74179b0af33275865eebe_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc2MDU_472debd3-b748-40da-ab25-3945ba66da6c"
      unitRef="number">0.12</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i9a8ccea9aa6e45ac9a3904384d0f7055_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc2MzA_5dea5ff2-7520-4a42-aa6c-8f75efb175b7"
      unitRef="number">0.77</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ib0119b0ae5984713b7d9259c8207911d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc2NzA_c9338134-3f08-4c50-9d48-57a1cc889cd6"
      unitRef="number">0.05</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i05bf309692224b32a5d32bdbc5a3fbfa_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc2ODk_90f94e83-2bf6-4106-b46c-c71a8df82b37"
      unitRef="number">0.03</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i8fef45f25f3a4337982d480409e2d989_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzc3MzU_924b6d73-c5f0-4c99-a407-a5f2e56b64c1"
      unitRef="number">0.03</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzg2NDg_cc911412-9535-4e13-867b-fcc21853b03e"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzg2NTI_883b8425-55ed-4b5c-ae45-7709671daf33"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ia10042502b67476084251422c4796803_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzg2NTk_e5ce817d-2c0c-4573-b218-4c155ef997d0"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNTE1_1c8c9bf4-9473-4d06-b925-bae4aeee545d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzEtMS0xLTEtMTY3OTA4_84cf56ef-dcd5-4cd1-b818-f1cb6cb01d30"
      unitRef="usd">368000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzItMS0xLTEtMTY3OTA4_45786f4a-6978-4a76-b231-2c77348905e1"
      unitRef="usd">369000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzMtMS0xLTEtMTY3OTA4_e2f833e7-87d4-495c-883b-5c8a7c3ccc29"
      unitRef="usd">372000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzQtMS0xLTEtMTY3OTA4_e0db4cf6-225c-4d47-b5dc-5b78bfb00845"
      unitRef="usd">369000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzUtMS0xLTEtMTY3OTA4_b7108985-b7bc-49d7-96e9-1a12b885174c"
      unitRef="usd">367000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i13a134d0c0ea465cb742a54750a08aa5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZToyZGY5MzMzMGI0ZWQ0OGRmOTM2M2QyNTg3NTkzNjE4Mi90YWJsZXJhbmdlOjJkZjkzMzMwYjRlZDQ4ZGY5MzYzZDI1ODc1OTM2MTgyXzYtMS0xLTEtMTY3OTA4_8f179578-e88c-4190-9bb8-2fe5eb0bf330"
      unitRef="usd">1776000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:MultiemployerPlanPensionInsignificantPlanContribution
      contextRef="icf13dd948a9949f397b838135c67fd6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwMTQ0_b7412dd6-6d8a-4ec0-95d6-e9e3cb36d8a0"
      unitRef="usd">20000000</us-gaap:MultiemployerPlanPensionInsignificantPlanContribution>
    <us-gaap:MultiemployerPlanPensionInsignificantPlanContribution
      contextRef="i1f77fd32daaf456d84374337f535221b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwMTQ4_4d1a7f5a-8ba0-454a-bfac-82c703f58591"
      unitRef="usd">19000000</us-gaap:MultiemployerPlanPensionInsignificantPlanContribution>
    <us-gaap:MultiemployerPlanPensionInsignificantPlanContribution
      contextRef="ia10042502b67476084251422c4796803_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwMTU1_ef075eab-14cd-4bb2-9209-2413be11cfc0"
      unitRef="usd">19000000</us-gaap:MultiemployerPlanPensionInsignificantPlanContribution>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwNzI5_dd66ed59-4c9f-46ec-9f95-b2f4fcc17ee5"
      unitRef="usd">159000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i9f60b453fe2047f2af3b79714d2105b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwNzM2_359e0976-c1df-4a3a-85b3-9fc033b52024"
      unitRef="usd">207000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i80161528cfbe4d46ab7481e07799b74f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwODMz_dad81c33-b86a-4cb6-b17a-24eb3ce948b7"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="idad61766b42d4fafb3023b422e73ce62_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwODM3_158e09ba-e75c-4a7b-aa2e-613d2f938977"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i48c5af8bad60417f9e93bd229edece75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzEwODQ0_572d5709-16fb-4b20-a3fd-3fbba421199a"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzEtMS0xLTEtMTY3OTA4_ec58d04d-3f26-4538-a1da-e90297237f14"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzItMS0xLTEtMTY3OTA4_61ce53f6-d61d-481e-a2b7-981b68625bd1"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzMtMS0xLTEtMTY3OTA4_676f9f99-0338-444d-b2a3-0a69c3c180f4"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzQtMS0xLTEtMTY3OTA4_80f0eefa-3fea-4cb8-b0d5-bc7c45f338ed"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzUtMS0xLTEtMTY3OTA4_f19bcb0a-38df-4edc-b1f9-c290929cb43c"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i55e008f794224642a71737a4f1c9d5ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90YWJsZTowYzY2MzA3ODUzM2M0MDg0YjM5YjZhNmZmZjc2OGFjMS90YWJsZXJhbmdlOjBjNjYzMDc4NTMzYzQwODRiMzliNmE2ZmZmNzY4YWMxXzYtMS0xLTEtMTY3OTA4_32b67472-ea96-419b-8a33-ea1b8afc6503"
      unitRef="usd">59000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:MultiemployerPlanPensionInsignificantPlanContribution
      contextRef="i80161528cfbe4d46ab7481e07799b74f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNDY2_0e4aa696-f0b0-409a-a400-056ef855880c"
      unitRef="usd">62000000</us-gaap:MultiemployerPlanPensionInsignificantPlanContribution>
    <us-gaap:MultiemployerPlanPensionInsignificantPlanContribution
      contextRef="idad61766b42d4fafb3023b422e73ce62_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNDcw_be7d61bc-e67b-4df8-9a4f-80aff96ca374"
      unitRef="usd">60000000</us-gaap:MultiemployerPlanPensionInsignificantPlanContribution>
    <us-gaap:MultiemployerPlanPensionInsignificantPlanContribution
      contextRef="i48c5af8bad60417f9e93bd229edece75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNDUvZnJhZzo2OWNkNjYyNzZjODY0YTkxYTc5OWQ5ZGZiZjY5NDlkMi90ZXh0cmVnaW9uOjY5Y2Q2NjI3NmM4NjRhOTFhNzk5ZDlkZmJmNjk0OWQyXzExNDc3_8cd6ac50-3648-40a3-8248-03deae7380ea"
      unitRef="usd">54000000</us-gaap:MultiemployerPlanPensionInsignificantPlanContribution>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NTk_cc94889b-2094-4bfd-ba5f-400909443077">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision for continuing operations consisted of the following for the&#160;years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a reconciliation of the statutory income tax rate to the Company&#x2019;s effective income tax rate for continuing operations for the&#160;years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health insurer fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis difference upon disposition of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year refunds and unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the components of the Company&#x2019;s deferred income tax assets and liabilities as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease and rents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad debts and other allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll tax deferral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease and rents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes deferred income tax assets of $131&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When evaluating the realizability of deferred tax assets, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and the Company&#x2019;s recent operating results. The Company established valuation allowances of $532 million and $325 million as of December&#160;31, 2022 and 2021, respectively, because it does not consider it more likely than not that certain deferred tax assets will be recovered.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had net operating and capital loss carryovers of $266 million, which expire between 2023 and 2042.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiration of statutes of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CVS Health Corporation and most of its subsidiaries are subject to U.S. federal income tax as well as income tax of numerous state and local jurisdictions. CVS Health Corporation participated in the Compliance Assurance Process through 2019, which is &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a program made available by the U.S. Internal Revenue Service (&#x201c;IRS&#x201d;) to certain qualifying large taxpayers, under which participants work collaboratively with the IRS to identify and resolve potential tax issues through open, cooperative and transparent interaction prior to the annual filing of their federal income tax returns. The IRS has completed its examinations of the Company&#x2019;s consolidated U.S. federal income tax returns for tax years through and including 2013 and 2018 through 2019. The IRS has substantially completed its examinations of the Company&#x2019;s consolidated U.S. federal income tax returns for tax years 2014 through 2017.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CVS Health Corporation and its subsidiaries are also currently under income tax examinations by a number of state and local tax authorities. As of December&#160;31, 2022, no examination has resulted in any proposed adjustments that would result in a material change to the Company&#x2019;s operating results, financial condition or liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all material state and local income tax matters have been concluded for fiscal years through 2015. Certain state exams are likely to be concluded and certain state statutes of limitations will lapse in 2023, but the change in the balance of the Company&#x2019;s uncertain tax positions is projected to be immaterial. In addition, it is reasonably possible that the Company&#x2019;s unrecognized tax benefits could change within the next twelve months due to the anticipated conclusion of various examinations with the IRS for certain previous years. An estimate of the range of the possible change cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records interest expense related to unrecognized tax benefits and penalties in the income tax provision. The Company accrued interest expense of approximately $29 million, $40 million and $34 million in 2022, 2021 and 2020, respectively. The Company had approximately $112 million and $151 million accrued for interest and penalties as of December&#160;31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the total amount of unrecognized tax benefits that, if recognized, would affect the Company&#x2019;s effective income tax rate is approximately $336 million, after considering the federal benefit of state income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NTQ_aa21ac8c-d7ed-445d-8bb7-9959d5332f37">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision for continuing operations consisted of the following for the&#160;years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzItMS0xLTEtMTY3OTA4_8ab46591-1bb9-43ba-9dc5-eb4c15fd1e75"
      unitRef="usd">2803000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzItMy0xLTEtMTY3OTA4_b2be9598-38da-4bd9-8f81-e70746f3a34e"
      unitRef="usd">2285000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzItNS0xLTEtMTY3OTA4_d277e59e-2c2d-454d-b35b-24636a47c846"
      unitRef="usd">2615000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzMtMS0xLTEtMTY3OTA4_fb378b06-aeba-4a94-947d-3b640f7b43a9"
      unitRef="usd">735000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzMtMy0xLTEtMTY3OTA4_5f6c4094-0353-4f6f-82ad-bd2db10f36ea"
      unitRef="usd">665000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzMtNS0xLTEtMTY3OTA4_7f13d794-7963-4738-878d-e2595fb85a22"
      unitRef="usd">518000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzQtMS0xLTEtMTY3OTA4_b14fc4fe-515f-413c-a187-449efa0f21c8"
      unitRef="usd">3538000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzQtMy0xLTEtMTY3OTA4_fe311379-d284-4593-8a24-c852de24471a"
      unitRef="usd">2950000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzQtNS0xLTEtMTY3OTA4_ae98b693-2647-4cb7-926d-923fc3b35fb2"
      unitRef="usd">3133000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzYtMS0xLTEtMTY3OTA4_9df95e97-424c-46f1-9174-988d2bb27519"
      unitRef="usd">-1569000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzYtMy0xLTEtMTY3OTA4_f19bc860-8cdc-42d9-b4fd-a03dfa7897fc"
      unitRef="usd">-306000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzYtNS0xLTEtMTY3OTA4_bd7872a7-1a2b-42db-bce4-9baea59a81e0"
      unitRef="usd">-450000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzctMS0xLTEtMTY3OTA4_e45350ed-a1f4-4d06-a029-e6e1579e9a76"
      unitRef="usd">-506000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzctMy0xLTEtMTY3OTA4_2c814769-2630-475e-8a0c-2cd115aa10b6"
      unitRef="usd">-122000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzctNS0xLTEtMTY3OTA4_7ae2095d-3b38-432a-b98a-dad0d700095e"
      unitRef="usd">-114000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzgtMS0xLTEtMTY3OTA4_bfb38526-e1c2-406a-ba79-1fcd8882e21a"
      unitRef="usd">-2075000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzgtMy0xLTEtMTY3OTA4_ddf6e053-a640-414f-a475-c69a27a117c2"
      unitRef="usd">-428000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzgtNS0xLTEtMTY3OTA4_fef7d097-7a67-43c7-96e3-b3312bf3a490"
      unitRef="usd">-564000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzktMS0xLTEtMTY3OTA4_ecca47ed-fbc4-4884-96bd-3d5e7f9f22b4"
      unitRef="usd">1463000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzktMy0xLTEtMTY3OTA4_6dcb7847-e0c6-4674-b52f-946694bde641"
      unitRef="usd">2522000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTpiMzIxNDk5OTQ2YWU0ODRjOTc1OTU4NTg4MjVjZTczYy90YWJsZXJhbmdlOmIzMjE0OTk5NDZhZTQ4NGM5NzU5NTg1ODgyNWNlNzNjXzktNS0xLTEtMTY3OTA4_588903f1-24b3-48f0-a2c2-ad56cdc2824e"
      unitRef="usd">2569000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NTU_002392ec-d5ce-47fa-9688-bdf1dd6a6f60">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a reconciliation of the statutory income tax rate to the Company&#x2019;s effective income tax rate for continuing operations for the&#160;years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health insurer fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis difference upon disposition of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year refunds and unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzEtMS0xLTEtMTY3OTA4_82164472-5ca8-4ff0-a346-b326bd175836"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzEtMy0xLTEtMTY3OTA4_b10791a8-dca5-43bd-92e2-781879d89260"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzEtNS0xLTEtMTY3OTA4_a32c8671-40fa-486e-b80a-5a6d06d503dd"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzItMS0xLTEtMTY3OTA4_e66d8820-c55f-4451-a26c-edc347f6d021"
      unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzItMy0xLTEtMTY3OTA4_0bd00b5b-387c-475f-9fe2-6b221ce8a36e"
      unitRef="number">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzItNS0xLTEtMTY3OTA4_2c8786f3-ac88-45c1-aad9-99b9d04c77f8"
      unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <cvs:HealthInsurerFeeTaxEffectPercent
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzMtMS0xLTEtMTY3OTA4_309b4c89-c191-4ef0-9983-064a1eb33aec"
      unitRef="number">0</cvs:HealthInsurerFeeTaxEffectPercent>
    <cvs:HealthInsurerFeeTaxEffectPercent
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzMtMy0xLTEtMTY3OTA4_e77830f7-e183-4e14-bb3f-4a9a262603e9"
      unitRef="number">0</cvs:HealthInsurerFeeTaxEffectPercent>
    <cvs:HealthInsurerFeeTaxEffectPercent
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzMtNS0xLTEtMTY3OTA4_aa6261a7-9815-4e75-b381-b6d0a84ac730"
      unitRef="number">0.022</cvs:HealthInsurerFeeTaxEffectPercent>
    <cvs:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtMS0xLTEtMjIzMDYz_45265613-0708-4ed2-bac8-f568b98cd1a9"
      unitRef="number">0.035</cvs:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent>
    <cvs:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtMy0xLTEtMjIzMDYz_811c98b5-7d4d-44b2-9e69-a3fcf34011c9"
      unitRef="number">0</cvs:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent>
    <cvs:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtNS0xLTEtMjIzMDYz_e00ebc16-62b7-4f34-9122-a2fc43aeffc5"
      unitRef="number">0</cvs:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtMS0xLTEtMTY3OTA4_df5b3bf5-31b9-441a-85b4-1aee1e340a7e"
      unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtMy0xLTEtMTY3OTA4_7bda2687-bcda-4eab-945d-5a02464735c7"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzQtNS0xLTEtMTY3OTA4_5b862906-3b9d-4e0d-92e9-49ee23680750"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzUtMS0xLTEtMTY3OTA4_ddc0a468-4681-48e3-83de-e96aaaf18b58"
      unitRef="number">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzUtMy0xLTEtMTY3OTA4_35a243b5-d0c8-4fe4-bf64-56adaf4487d9"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzUtNS0xLTEtMTY3OTA4_14ec5cb4-0625-4847-9c7b-04d2b1f85322"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzYtMS0xLTEtMTY3OTA4_d875dc3b-a604-4c54-b0a1-4a0cfda8da54"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzYtMy0xLTEtMTY3OTA4_cd0ff6cb-328f-464a-bc36-6a48ced20d7d"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzYtNS0xLTEtMTY3OTA4_4e1d28f2-2e5b-44f8-b92c-7dcb42342ffb"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzctMS0xLTEtMTY3OTA4_37150dca-9916-44bb-bc3d-cc1e9fe90254"
      unitRef="number">0.260</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzctMy0xLTEtMTY3OTA4_93c1285c-aa45-4bb4-a4e3-658adc22308f"
      unitRef="number">0.242</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplZTlhNDg1NTY2NDE0M2IwOGI1OWE4YmJkYjVkZGVkMy90YWJsZXJhbmdlOmVlOWE0ODU1NjY0MTQzYjA4YjU5YThiYmRiNWRkZWQzXzctNS0xLTEtMTY3OTA4_cb8a501e-56f0-439b-bf74-cd7558265bd7"
      unitRef="number">0.263</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NjI_4729e463-bc03-41e2-97e1-0db3e0c4ae31">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the components of the Company&#x2019;s deferred income tax assets and liabilities as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease and rents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad debts and other allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll tax deferral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease and rents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes deferred income tax assets of $131&#160;million which have been accounted for as assets held for sale and are included in assets held for sale on the consolidated balance sheet at December 31, 2022. See Note 2 &#x2018;&#x2018;Acquisitions, Divestitures and Asset Sales&#x2019;&#x2019; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzItMS0xLTEtMTY3OTA4_780acc8c-48c4-4825-920c-045721feb4c7"
      unitRef="usd">5242000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzItMy0xLTEtMTY3OTA4_91dab4d2-7466-454c-87ca-2b83576c2b85"
      unitRef="usd">5563000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzMtMS0xLTEtMjIzMDc3_aa3ab52e-f02a-421e-a762-aa7e5140c0d4"
      unitRef="usd">1260000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzMtMy0xLTEtMjIzMDc3_bd57a54d-63ff-4043-a843-be11da40fc62"
      unitRef="usd">19000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzMtMS0xLTEtMTY3OTA4_62a344ff-d3d1-4fc3-8b26-fb09e3c84b78"
      unitRef="usd">103000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzMtMy0xLTEtMTY3OTA4_da69d434-2b6f-42ba-9ee8-8e5fb0f5a685"
      unitRef="usd">99000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzQtMS0xLTEtMTY3OTA4_b5526503-7544-4b5d-97b6-965b6013dec4"
      unitRef="usd">153000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzQtMy0xLTEtMTY3OTA4_cd7f71d0-8760-4eed-9d79-b95a26273fca"
      unitRef="usd">193000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <cvs:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzUtMS0xLTEtMTY3OTA4_74df03e9-b9fb-4612-897b-1056e7fbbe7c"
      unitRef="usd">480000000</cvs:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances>
    <cvs:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzUtMy0xLTEtMTY3OTA4_b59ec915-f013-496d-8de2-b40f5667f5c8"
      unitRef="usd">489000000</cvs:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzctMS0xLTEtMTY3OTA4_1c900f18-7892-40d5-9c67-8806c3a2a5ff"
      unitRef="usd">266000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzctMy0xLTEtMTY3OTA4_84518d6f-537b-4aa8-9a96-f454db525952"
      unitRef="usd">416000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzgtMS0xLTEtMTY3OTA4_e4605ef7-023a-4b29-a616-55ff4242dc37"
      unitRef="usd">66000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzgtMy0xLTEtMTY3OTA4_d79d5c45-2081-4878-ba61-d8eee869b48f"
      unitRef="usd">78000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzktMS0xLTEtMTY3OTA4_c5eb6881-6e1b-42e3-ab68-9490de9f4c6d"
      unitRef="usd">455000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzktMy0xLTEtMTY3OTA4_af604ea2-c77e-48f1-9fae-475f191d9067"
      unitRef="usd">501000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzExLTEtMS0xLTIyMzA4NQ_bf8ee500-fd01-426d-95ba-1a733158755e"
      unitRef="usd">293000000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzExLTMtMS0xLTIyMzA4NQ_18279d10-bd56-4b44-bcc7-e9bab07af4ba"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInvestments>
    <cvs:DeferredTaxAssetsPayrollTaxDeferral
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEwLTEtMS0xLTE2NzkwOA_a06905af-680c-47b5-af8b-cefe027a44bc"
      unitRef="usd">0</cvs:DeferredTaxAssetsPayrollTaxDeferral>
    <cvs:DeferredTaxAssetsPayrollTaxDeferral
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEwLTMtMS0xLTE2NzkwOA_fb747cd9-8738-4f53-b007-4f8bbf2990ef"
      unitRef="usd">87000000</cvs:DeferredTaxAssetsPayrollTaxDeferral>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzExLTEtMS0xLTE2NzkwOA_8bf59f8b-e453-4703-9b6e-7c5a919d7b5a"
      unitRef="usd">335000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzExLTMtMS0xLTE2NzkwOA_bcb58c7a-009b-419c-b58f-fc09497e51fa"
      unitRef="usd">377000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEyLTEtMS0xLTE2NzkwOA_243db7d3-9e31-457a-bc3f-b935c5f14133"
      unitRef="usd">532000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEyLTMtMS0xLTE2NzkwOA_0f525ba2-32ef-424a-908b-eab94a371156"
      unitRef="usd">325000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEzLTEtMS0xLTE2NzkwOA_af9dab44-0c35-4343-9b0b-4a517ff1a3db"
      unitRef="usd">8121000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzEzLTMtMS0xLTE2NzkwOA_e84639aa-1e25-488c-bb83-a5e54a84935e"
      unitRef="usd">7497000000</us-gaap:DeferredTaxAssetsNet>
    <cvs:DeferredTaxLiabilitiesRetirementBenefits
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE1LTEtMS0xLTE2NzkwOA_052f6dee-1900-4c4b-993a-3a78ce48b6e8"
      unitRef="usd">92000000</cvs:DeferredTaxLiabilitiesRetirementBenefits>
    <cvs:DeferredTaxLiabilitiesRetirementBenefits
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE1LTMtMS0xLTE2NzkwOA_72344e78-7b77-482c-b6f5-b83cc4910f4e"
      unitRef="usd">105000000</cvs:DeferredTaxLiabilitiesRetirementBenefits>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE2LTEtMS0xLTE2NzkwOA_5d5bb76a-4690-46b6-a7b7-d6b78494aaf1"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE2LTMtMS0xLTE2NzkwOA_a1bf7566-dc00-4e18-bef9-f9bc4a52cdd1"
      unitRef="usd">334000000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE3LTEtMS0xLTE2NzkwOA_0bb13cba-8cbb-483e-a701-0d42f993a2c5"
      unitRef="usd">4639000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE3LTMtMS0xLTE2NzkwOA_33e5942d-2066-4e9f-b3db-03d2c99f2047"
      unitRef="usd">4947000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <cvs:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE4LTEtMS0xLTE2NzkwOA_da5273f8-13ea-4085-85ea-f5f07b2f27d1"
      unitRef="usd">7139000000</cvs:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <cvs:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE4LTMtMS0xLTE2NzkwOA_c9918d81-2b13-46c6-b052-779298212fbf"
      unitRef="usd">8381000000</cvs:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE5LTEtMS0xLTE2NzkwOA_df6c1aab-8847-49e5-9d7b-edac8bd1a9bb"
      unitRef="usd">11870000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzE5LTMtMS0xLTE2NzkwOA_13ef7879-3334-4ba9-9b76-7713aa4041f5"
      unitRef="usd">13767000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzIwLTEtMS0xLTE2NzkwOA_1682058a-7e14-4de3-a1c0-4a6022cfb244"
      unitRef="usd">3749000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTplNjNlNTg5ZjBlNjE0NWMyYTI2YTViNGQzM2MwN2VhMC90YWJsZXJhbmdlOmU2M2U1ODlmMGU2MTQ1YzJhMjZhNWI0ZDMzYzA3ZWEwXzIwLTMtMS0xLTE2NzkwOA_645e6616-dbb4-46c7-9ea1-8eb6427b815a"
      unitRef="usd">6270000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="if18de26c953b4c36b64633eff1121e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5Xzg3OTYwOTMwMjYwMDQ_3f3dab3a-04cd-4a1d-9b99-217c52913ff3"
      unitRef="usd">131000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5Xzg1NA_243db7d3-9e31-457a-bc3f-b935c5f14133"
      unitRef="usd">532000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzEyMDk0NjI3OTA5ODU1_0f525ba2-32ef-424a-908b-eab94a371156"
      unitRef="usd">325000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzU0OTc1NTgxNzkxMw_1c900f18-7892-40d5-9c67-8806c3a2a5ff"
      unitRef="usd">266000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzM0NTg_9710f2a6-34c5-4b62-a0f7-9ec571b2496b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiration of statutes of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzEtMS0xLTEtMTY3OTA4_37462a83-4a43-4ccd-8f05-c7e24690aa48"
      unitRef="usd">782000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzEtMy0xLTEtMTY3OTA4_2e9359ea-9750-4bd2-a5f2-258acf7e0ec9"
      unitRef="usd">768000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i21ae6bc100814ca88c4440dbb572bbdc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzEtNS0xLTEtMTY3OTA4_cd10efbc-df29-4f96-8714-20862afbeb89"
      unitRef="usd">655000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzItMS0xLTEtMTY3OTA4_a3d0223a-434d-4380-87e6-a41c302c0cff"
      unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzItMy0xLTEtMTY3OTA4_1cc71028-63cf-43c7-ba27-94b4632e98a4"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzItNS0xLTEtMTY3OTA4_4bfeb1a3-9e40-47eb-a500-a59d0b84c404"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzMtMS0xLTEtMTY3OTA4_5b4d2192-a2c3-411e-bb44-5bbf039e5a83"
      unitRef="usd">42000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzMtMy0xLTEtMTY3OTA4_de18459a-dfdd-47be-976e-1cd4f87d87c9"
      unitRef="usd">52000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzMtNS0xLTEtMTY3OTA4_ea5da00f-d6b7-4dad-abd4-cd158572ae3f"
      unitRef="usd">182000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzQtMS0xLTEtMTY3OTA4_b04b12f1-6dbf-4aef-8cc7-0d4cf9735dfb"
      unitRef="usd">166000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzQtMy0xLTEtMTY3OTA4_391aafbb-4ce4-4ad4-80f0-016c0c89ebaf"
      unitRef="usd">33000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzQtNS0xLTEtMTY3OTA4_903ac1bc-6475-4134-8f7d-578288319fb4"
      unitRef="usd">56000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzUtMS0xLTEtMTY3OTA4_106ff2fa-83f7-433a-ab2b-1e44ce2c1500"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzUtMy0xLTEtMTY3OTA4_4e33369f-bb1b-44fe-b46c-716688b99089"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzUtNS0xLTEtMTY3OTA4_9f7c5168-5bf9-4861-b1ad-94dd3f54491a"
      unitRef="usd">2000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzYtMS0xLTEtMTY3OTA4_adc0c4f3-aac6-4e86-8de8-e30a83067118"
      unitRef="usd">213000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzYtMy0xLTEtMTY3OTA4_549a6d23-64da-480c-a095-d87fc179d065"
      unitRef="usd">7000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzYtNS0xLTEtMTY3OTA4_976d273c-45e6-4d7e-91bb-2b02dbfa680d"
      unitRef="usd">14000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzctMS0xLTEtMTY3OTA4_ee4b6d21-fc16-4337-9c06-c2e30883dadd"
      unitRef="usd">446000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzctMy0xLTEtMTY3OTA4_2aaa79de-09a9-4851-b12f-4db195291b64"
      unitRef="usd">782000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i43471633110c4d35b96ffaf743cb0e4f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90YWJsZTo0NjRjMzA0Y2E1YTM0Y2UzOGZmNThlZTg3OGJlOTdiOS90YWJsZXJhbmdlOjQ2NGMzMDRjYTVhMzRjZTM4ZmY1OGVlODc4YmU5N2I5XzctNS0xLTEtMTY3OTA4_a3e68c38-4963-4f02-8eed-ad7ccc2d0cd1"
      unitRef="usd">768000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMwODY_c3e43743-fd58-46b3-b4f7-a658faaf32c8"
      unitRef="usd">29000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMwOTA_19859130-f162-41b1-a4be-fa6572cce01a"
      unitRef="usd">40000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMwOTc_0f0ddd7f-91e4-4f33-ad75-647f512305a2"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMxNjI_7229f6fe-af34-4bc4-be42-0bedeafd3efa"
      unitRef="usd">112000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMxNjk_e29915e9-4b58-427b-a6d1-a7b979e15d36"
      unitRef="usd">151000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTEvZnJhZzphOTI5N2NjZjQ4Njc0ZTY2YWU4MDNjMjZlNmU0ZjBjOS90ZXh0cmVnaW9uOmE5Mjk3Y2NmNDg2NzRlNjZhZTgwM2MyNmU2ZTRmMGM5XzMzODc_d9a34ea5-48c1-4691-8934-4f87125f12a6"
      unitRef="usd">336000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzM_ef2b3322-a2fe-4726-86ff-164120b0049b">Stock Incentive Plans&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the CVS Health 2017 Incentive Compensation Plan (&#x201c;ICP&#x201d;) provide for grants of annual incentive and long-term performance awards to executive officers and other officers and employees of the Company or any subsidiary of the Company, as well as equity compensation to outside directors of CVS Health Corporation. Payment of such annual incentive and long-term performance awards will be in cash, stock, other awards or other property, at the discretion of the Management Planning and Development Committee (the &#x201c;MP&amp;amp;D Committee&#x201d;) of the Board. The ICP allows for a maximum of 58 million shares of CVS Health Corporation common stock to be reserved and available for grants. As of December&#160;31, 2022, there were approximately 21 million shares of CVS Health Corporation common stock available for future grants under the ICP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the acquisition of Aetna (the &#x201c;Aetna Acquisition&#x201d;) on November 28, 2018, approximately 22 million shares of Aetna common stock subject to awards outstanding under the Amended Aetna Inc. 2010 Stock Incentive Plan (&#x201c;SIP&#x201d;) were assumed by CVS Health Corporation. In addition, in accordance with the merger agreement, shares which were available for future issuance under the SIP were converted into approximately 32 million shares of CVS Health Corporation common stock reserved and available for issuance pursuant to future awards. Subsequent to the expiration of the SIP on May 21, 2020, the ICP was the only compensation plan under which the Company grants stock options, restricted stock and other stock-based awards to its employees.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzE3Nzc_8d034ca5-401e-4526-8bb8-d8fed86877bb"&gt;three&lt;/span&gt; to five years) using the straight-line method. The following table is a summary of stock-based compensation for the&#160;years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and stock appreciation rights (&#x201c;SARs&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units and Performance Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s restricted stock units and performance stock units are considered nonvested share awards and require no payment from the employee. The fair value of the restricted stock units is based on the market price of CVS Health Corporation common stock on the grant date and is recognized on a straight-line basis over the vesting period. For each restricted stock unit granted, employees receive one share of common stock, net of taxes, at the end of the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s performance stock units contain performance vesting conditions in addition to a service vesting condition. Vesting of the Company&#x2019;s performance stock units is dependent upon the degree to which the Company achieves its performance goals, which are generally set for a three-year performance period and are approved at the time of grant by the MP&amp;amp;D Committee. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of performance stock units granted with service and performance vesting conditions is based on the market price of CVS Health Corporation common stock on the grant date and is recognized over the vesting period. Certain of the performance stock units also contain a market vesting condition based on the performance of CVS Health Corporation common stock relative to a comparator group. The fair value of these performance stock units is determined using a Monte Carlo simulation as of the grant date and is recognized over the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $619 million of total unrecognized compensation cost related to the Company&#x2019;s restricted stock units and performance stock units that are expected to vest. These costs are expected to be recognized over a weighted-average period of 2.1 years. The total fair value of restricted stock units vested during 2022, 2021 and 2020 was $328 million, $406 million and $229 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the restricted stock unit and performance stock unit activity for the&#160;year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In thousands, except weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year, nonvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year, nonvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Vested performance stock units have been included at target level performance. Based on actual performance, the number of restricted stock units and performance stock units vested during the year ended December 31, 2022 was 8.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and SARs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock option grants are awarded at fair value on the date of grant. The fair value of stock options is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. Stock options granted generally become exercisable over a four-year period from the grant date. Stock options granted through 2018 generally expire seven years after the grant date. Stock options granted subsequent to 2018 generally expire ten years after the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All unvested Aetna SARs outstanding upon the acquisition of Aetna were converted into replacement CVS Health Corporation SARs. The replacement SARs granted are settled in CVS Health Corporation common stock, net of taxes, based on the appreciation of the stock price on the exercise date over the market price on the date of grant. The fair value of SARs is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. SARs generally become exercisable over a three-year period from the grant date. SARs generally expire ten years after the grant date. No SARs have been granted subsequent to the Aetna Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of stock option and SAR activity that occurred for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received from stock options exercised (including ESPP)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for taxes for net share settlement of equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of stock options and SARs exercised &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options and SARs vested &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#x2019;s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The expected life represents the number of&#160;years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, unrecognized compensation expense related to unvested stock options totaled $41 million, which the Company expects to be recognized over a weighted-average period of 1.9 years. After considering anticipated forfeitures, the Company expects approximately 7 million of the unvested stock options to vest over the requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the Company&#x2019;s stock option and SAR activity for the&#160;year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;thousands, except weighted average exercise price and remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(478)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested at end of year and expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) provides for the purchase of up to 60&#160;million shares of CVS Health Corporation common stock. Under the ESPP, eligible employees may purchase common stock at the end of each six&#160;month offering period at a purchase price equal to 90% of the lower of the fair market value on the first day or the last day of the offering period. During 2022, approximately 2 million shares of common stock were purchased under the provisions of the ESPP at an average price of $78.55 per share. As of December&#160;31, 2022, approximately 29 million shares of common stock were available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock-based compensation associated with the ESPP is estimated on the date of grant (the first day of the six&#160;month offering period) using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the assumptions used to value the ESPP awards for the&#160;years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#x2019;s daily stock price over the previous six&#160;month period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six&#160;months).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The expected life is based on the semi-annual purchase period.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5bd0c40f6d4d4d38ad212af3d36f1535_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzYxNQ_e9e25456-70ed-496a-b307-60fde586ac8a"
      unitRef="shares">58000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5bd0c40f6d4d4d38ad212af3d36f1535_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzc0MA_2eb6e571-2958-4a4a-98da-e663fc00b2d7"
      unitRef="shares">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia59ded7dac1144889cba911dcf81ff67_I20181128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzkyNQ_39ee9fa1-9624-4ce6-9a15-fbb16132494f"
      unitRef="shares">22000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia59ded7dac1144889cba911dcf81ff67_I20181128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzEyNDA_e537454f-1318-4929-8ae5-4f78b96ab412"
      unitRef="shares">32000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i80ec887936004ee9bb53da69fa890ff9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxODI_fd3bc7df-2c94-4af2-8f82-2a03cfa5ef04">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzk_f06bbd1f-a765-425d-a582-d3d99d1c4fce">The following table is a summary of stock-based compensation for the&#160;years ended December&#160;31, 2022, 2021 and 2020:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and stock appreciation rights (&#x201c;SARs&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzItMS0xLTEtMTY3OTA4_a6416041-2eaa-4a71-99db-12d0f76f9bf6"
      unitRef="usd">369000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0ef82093f7f0425d98a812a8346206e7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzItMy0xLTEtMTY3OTA4_5b4c1a52-000e-4b19-bab7-4293dfb1b114"
      unitRef="usd">404000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7dac89aa5750413097fe5ef4affd611a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzItNS0xLTEtMTY3OTA4_76ffe5a6-050f-4b51-be8d-9ee9adf78a7e"
      unitRef="usd">329000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtMS0xLTEtMjI2MDI2_653adec3-d862-4929-a130-0fe08e48faab"
      unitRef="usd">78000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtMy0xLTEtMjI2MDI2_a489f99e-d4ca-4985-9039-8566b9b97846"
      unitRef="usd">80000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtNS0xLTEtMjI2MDI2_5306734c-a824-4072-a44e-a34979b6cc65"
      unitRef="usd">71000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtMS0xLTEtMTY3OTA4_6fa78901-8a29-41e8-978a-694c2991d2c2"
      unitRef="usd">447000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtMy0xLTEtMTY3OTA4_ef09b316-68fa-425b-86f4-d5c7c7488a94"
      unitRef="usd">484000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmMjI5NDg3ZDI1MTQ0MzVlODE4Y2VkNTNkYzVlODA2Yy90YWJsZXJhbmdlOmYyMjk0ODdkMjUxNDQzNWU4MThjZWQ1M2RjNWU4MDZjXzMtNS0xLTEtMTY3OTA4_f44cde28-1219-40fb-acb6-c8181375a156"
      unitRef="usd">400000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i9a23a3d9f60548f3aed4bd07d81cc620_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzQ5OTE_60011a91-e643-4d54-b8e4-169e24a4c3ee"
      unitRef="usd">619000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzUyMTM_944872f3-feeb-4d33-bc1e-331cc1c1b537">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzUyOTY_1474034a-9e88-4b38-9140-8c92727fec54"
      unitRef="usd">328000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i0ef82093f7f0425d98a812a8346206e7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzUzMDA_6b82d351-c40d-4039-addb-5a827c498b8d"
      unitRef="usd">406000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7dac89aa5750413097fe5ef4affd611a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzUzMDc_7617f0b2-2502-42b9-9434-2a94d365b904"
      unitRef="usd">229000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxODQ_4eeb5b41-a771-4fa9-a2bf-9e98aab1c296">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the restricted stock unit and performance stock unit activity for the&#160;year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In thousands, except weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year, nonvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year, nonvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Vested performance stock units have been included at target level performance. Based on actual performance, the number of restricted stock units and performance stock units vested during the year ended December 31, 2022 was 8.0&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5b8b6ee31b984216878b4a06ea213f22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzEtMS0xLTEtMTY3OTA4_30b73d6f-67b3-4269-8891-1b5cda7c89a2"
      unitRef="shares">14330000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5b8b6ee31b984216878b4a06ea213f22_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzEtMy0xLTEtMTY3OTA4_2ece799c-0002-41b5-b76c-42477016f137"
      unitRef="usdPerShare">63.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzItMS0xLTEtMTY3OTA4_c0abee7f-2aaf-4ddb-9da1-2aa5c55be3d5"
      unitRef="shares">5398000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzItMy0xLTEtMTY3OTA4_64535ded-477a-4ab0-b9f1-1c9fe7e69bc5"
      unitRef="usdPerShare">101.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzMtMS0xLTEtMTY3OTA4_e0845595-33de-421e-8803-ab2ef8d6db5c"
      unitRef="shares">5626000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzMtMy0xLTEtMTY3OTA4_32cdd6cb-286a-4529-9485-2b01154ec73f"
      unitRef="usdPerShare">58.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzQtMS0xLTEtMTY3OTA4_4fe03d36-292d-4069-8d20-f448ac343e97"
      unitRef="shares">1421000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzQtMy0xLTEtMTY3OTA4_14966fb6-af68-45aa-9efd-11812485235c"
      unitRef="usdPerShare">72.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9a23a3d9f60548f3aed4bd07d81cc620_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzUtMS0xLTEtMTY3OTA4_78ede00e-d5b6-46f2-822c-5f3e07729b68"
      unitRef="shares">12681000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9a23a3d9f60548f3aed4bd07d81cc620_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZToyZWU2MmJmM2MwZDI0NTc2YWUzMjhhYjZkNzFlYTQ2ZC90YWJsZXJhbmdlOjJlZTYyYmYzYzBkMjQ1NzZhZTMyOGFiNmQ3MWVhNDZkXzUtMy0xLTEtMTY3OTA4_b16c9cc1-0ef9-4b47-9892-4624e4ce0a2c"
      unitRef="usdPerShare">80.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates
      contextRef="i1081556cdd8e4b3da10eac03d64e1779_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzk4OTU2MDQ2NTg5Mzc_b508f7cb-6332-471e-9afd-f432a48a992d"
      unitRef="shares">8000000</cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzQ_f89d2283-38ec-49d0-84ae-23e5a2b02698">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i9667bb2fd2c24aae86f872138c4421cb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzU4ODY_a3a93972-ff4b-4d8b-9389-f4318b9b43dc">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i63eef8534a884ca5866ee784287deaab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzU5Njk_939a502e-c92e-48c2-8c6e-75b342b41b7f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9b15b8c19a5e466e8372796316b9b51c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNjk_5c3f9322-cd5d-4af7-9fa4-b05299a155a8">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i9b15b8c19a5e466e8372796316b9b51c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzY2MTE_0963ef08-1d49-4fc3-857c-501f3315017c">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzU_8300e9a7-2424-450f-817e-c5e9079399be">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of stock option and SAR activity that occurred for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received from stock options exercised (including ESPP)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for taxes for net share settlement of equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of stock options and SARs exercised &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options and SARs vested &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzEtMS0xLTEtMTY3OTA4_8db9134f-da5f-4830-aed9-ba9421714f75"
      unitRef="usd">551000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzEtMy0xLTEtMTY3OTA4_587a8677-11cf-4e5c-98ce-95b75ae9023a"
      unitRef="usd">549000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzEtNS0xLTEtMTY3OTA4_33e93c65-4f12-40be-90d3-fb058e38eede"
      unitRef="usd">264000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzItMS0xLTEtMTY3OTA4_dbdb0ce3-1487-4788-82ed-c06c357021a3"
      unitRef="usd">370000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzItMy0xLTEtMTY3OTA4_f9b03287-70fe-4e24-b9e5-5780324cd43f"
      unitRef="usd">168000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzItNS0xLTEtMTY3OTA4_e5a5ee27-832f-4c09-b5fd-c9ed65cde0ec"
      unitRef="usd">88000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzMtMS0xLTEtMTY3OTA4_bc282831-11b6-4d92-a67e-0b71a8950e98"
      unitRef="usd">118000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzMtMy0xLTEtMTY3OTA4_a4560292-1ad5-49f5-871f-b381babed485"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzMtNS0xLTEtMTY3OTA4_9a88340e-d657-4e26-b67e-8e35b24eed0e"
      unitRef="usd">24000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzQtMS0xLTEtMTY3OTA4_7ba664e4-9cf1-4d6c-a6da-6ab4397f77ee"
      unitRef="usd">219000000</cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue>
    <cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue
      contextRef="i4c198b31f40c4cc6840265ef8a67fdde_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzQtMy0xLTEtMTY3OTA4_51e225bf-b92f-45f2-9280-e52434611b04"
      unitRef="usd">224000000</cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue>
    <cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue
      contextRef="idde68710333b4abcb62273527c7aef07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTpmYmYwYmYzNjJhOTg0OTZlYjJlNTQ1NzgyOGExMGUwMS90YWJsZXJhbmdlOmZiZjBiZjM2MmE5ODQ5NmViMmU1NDU3ODI4YTEwZTAxXzQtNS0xLTEtMTY3OTA4_3b9b7e90-097d-4ba0-89b1-8b9ff0dfba75"
      unitRef="usd">252000000</cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxODU_7fb7d535-b8d5-4957-a866-eab84fd1c7b2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#x2019;s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The expected life represents the number of&#160;years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzEtMS0xLTEtMTY3OTA4_62d75605-3aaa-4361-a9c3-2250f9b0bb01"
      unitRef="number">0.0218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzEtMy0xLTEtMTY3OTA4_eba19caf-9c73-4578-8628-a7fbe13dddae"
      unitRef="number">0.0268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzEtNS0xLTEtMTY3OTA4_bd77b5a4-76cc-438b-b685-1c2c8af629de"
      unitRef="number">0.0342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzItMS0xLTEtMTY3OTA4_5a7bc619-8d67-44e0-b0ff-eb2319edfe7f"
      unitRef="number">0.2734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzItMy0xLTEtMTY3OTA4_13b3d951-79e7-4768-b629-81d791331609"
      unitRef="number">0.2710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzItNS0xLTEtMTY3OTA4_b345555c-c0d5-4adb-a172-93b78043d892"
      unitRef="number">0.2522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzMtMS0xLTEtMTY3OTA4_4fcbbad6-93b8-4d86-82ee-b75e40b0f6cf"
      unitRef="number">0.0246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzMtMy0xLTEtMTY3OTA4_fa6c3ff0-3c35-4cef-ad3a-ea2144bb8f10"
      unitRef="number">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzMtNS0xLTEtMTY3OTA4_dac4874d-4b45-45ae-9a92-84fe0c35be8e"
      unitRef="number">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzQtMS0xLTEtMTY3OTA4_e1f14916-fec6-4bd3-979c-791226e79bb7">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzQtMy0xLTEtMTY3OTA4_1a41001f-5e3d-4472-aa7c-c2ee8cb54be0">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzQtNS0xLTEtMTY3OTA4_e89c666c-1f84-4927-a0ce-bdeab328b6bc">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i13f2332fadcf433cab73c5cde3f64df3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzUtMS0xLTEtMTY3OTA4_83afb822-88e9-4746-8e9e-87b1fbe0ab7f"
      unitRef="usdPerShare">24.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia8ee2e185a774a8f8ec32cbdde482622_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzUtMy0xLTEtMTY3OTA4_865526f6-c7a8-425a-baab-9ff3e74bd7bb"
      unitRef="usdPerShare">14.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iadc5be713ef141589563587eda40b96e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTowY2U1YjFjZjEzY2U0YTIwYjgyNjM1MzQ3NGYyZTczNy90YWJsZXJhbmdlOjBjZTViMWNmMTNjZTRhMjBiODI2MzUzNDc0ZjJlNzM3XzUtNS0xLTEtMTY3OTA4_54efac05-9b15-4343-8264-d37869deaaf2"
      unitRef="usdPerShare">8.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzc4MTk_fa1207ed-8829-4caf-a603-8ae0d69d475b"
      unitRef="usd">41000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzc5MDA_6b9524d7-bfc3-47d8-aecb-0f68bb004b5e">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzc5ODE_ab11b34f-d4f0-48b7-bd35-143a4da5fa6b"
      unitRef="shares">7000000</cvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzgxNzc_3c80f0da-0326-48dc-981e-ad8661501779">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the Company&#x2019;s stock option and SAR activity for the&#160;year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;thousands, except weighted average exercise price and remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(478)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested at end of year and expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i77dc266c0f374e01a14893d1a6ea3f8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzEtMS0xLTEtMTY3OTA4_1bdb9c14-4b6b-41ee-a69b-61f78db9ba23"
      unitRef="shares">19061000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i77dc266c0f374e01a14893d1a6ea3f8e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzEtMy0xLTEtMTY3OTA4_97244ea1-ae94-436a-aaa9-5274d6b59e01"
      unitRef="usdPerShare">71.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzItMS0xLTEtMTY3OTA4_4a2a50aa-fcba-44c6-a064-56cb0270c6f8"
      unitRef="shares">1993000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzItMy0xLTEtMTY3OTA4_65f2a447-2836-4ba5-8798-4c8680fca095"
      unitRef="usdPerShare">101.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzMtMS0xLTEtMTY3OTA4_f44a1984-7f7a-4215-ad06-c02dfc3d0935"
      unitRef="shares">4921000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzMtMy0xLTEtMTY3OTA4_ad35ed7f-dcd0-48c9-a33c-12fd4600d3a0"
      unitRef="usdPerShare">75.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzQtMS0xLTEtMTY3OTA4_a3f21b5b-25f0-4597-8648-a023ba7917bc"
      unitRef="shares">478000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzQtMy0xLTEtMTY3OTA4_6d03e434-531a-4a84-b481-ae7ee913ea20"
      unitRef="usdPerShare">70.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzUtMS0xLTEtMTY3OTA4_6f565340-5cea-4c9c-acb1-a2d6594772d5"
      unitRef="shares">615000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzUtMy0xLTEtMTY3OTA4_f515786b-c4e2-420f-b301-3392b62f28b6"
      unitRef="usdPerShare">99.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzYtMS0xLTEtMTY3OTA4_1187f910-720d-46ac-9055-48db14d903ab"
      unitRef="shares">15040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzYtMy0xLTEtMTY3OTA4_20a7dd71-a01d-463e-bd73-8a75a7070b21"
      unitRef="usdPerShare">73.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzYtNS0xLTEtMTY3OTA4_d0a73297-a7fd-4370-82ac-1668893665b6">P4Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzYtNy0xLTEtMTY3OTA4_0f97c231-8d67-4f35-924c-07c0bf9c34e4"
      unitRef="usd">340507000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzctMS0xLTEtMTY3OTA4_0bdb923a-883b-4e2a-8af0-ed4b173e057e"
      unitRef="shares">7730000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzctMy0xLTEtMTY3OTA4_4c190065-1ca9-4b10-a214-a23e01354e93"
      unitRef="usdPerShare">72.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzctNS0xLTEtMTY3OTA4_399c5020-2909-4763-9b89-c29436ee5536">P2Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzctNy0xLTEtMTY3OTA4_058ca142-f880-439a-bc22-7459124b47dd"
      unitRef="usd">184904000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzgtMS0xLTEtMTY3OTA4_9b6aaf53-d9db-4729-9826-47f555b06cf5"
      unitRef="shares">14757000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzgtMy0xLTEtMTY3OTA4_616dee7b-7cf2-4884-a30b-3f1f4dccd148"
      unitRef="usdPerShare">72.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i03e43adee10e4d1dbff3e117e050d677_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzgtNS0xLTEtMTY3OTA4_3b407bfe-deed-437c-a07e-7a94fc829624">P4Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i0254b09e69d04105bd0d52aecaece8a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo2YTU4MmI3YWQ1MDk0YmQwYjdiZmE3ZmI4YzM0Y2NhOS90YWJsZXJhbmdlOjZhNTgyYjdhZDUwOTRiZDBiN2JmYTdmYjhjMzRjY2E5XzgtNy0xLTEtMTY3OTA4_9c4ce3e0-f13a-4def-8a21-5807b85b1224"
      unitRef="usd">336664000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iadb4c5c9645e411fbac5109bc755e0aa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzI3NDg3NzkwODM2MjQ_f257d887-1b6c-44d0-a282-e0470731cf8e"
      unitRef="shares">60000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzE0MjAx_d4e5b195-e70e-470a-929d-5f192e17f1b1"
      unitRef="number">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzE0MjA5_1113f6cc-ea09-4a73-b422-d6c11afe029c"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <cvs:StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzI3NDg3NzkwODI1ODQ_92bdf90d-38b2-47d6-b86e-dc405493916d"
      unitRef="usdPerShare">78.55</cvs:StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iadb4c5c9645e411fbac5109bc755e0aa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzI3NDg3NzkwODI2MjQ_5729b6f9-4745-42cd-941c-486234384260"
      unitRef="shares">29000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90ZXh0cmVnaW9uOmEwMmNjMDY2M2QyMDRlZGM4YjliYmJjMjRiMTJiNjNkXzY1OTcwNjk3ODIzODA_d8499f74-2035-4ce6-85f9-770446c64e03">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the assumptions used to value the ESPP awards for the&#160;years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The expected volatility is estimated based on the historical volatility of CVS Health Corporation&#x2019;s daily stock price over the previous six&#160;month period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six&#160;months).&lt;/span&gt;&lt;/div&gt;(4)The expected life is based on the semi-annual purchase period</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzEtMS0xLTEtMjI1OTU5_d8e1083f-e464-49cf-9d23-875052544fad"
      unitRef="number">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzEtMy0xLTEtMjI1OTU5_0e6ea05d-7486-49c1-90b9-509a79444368"
      unitRef="number">0.0134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzEtNS0xLTEtMjI1OTU5_04b5a38c-7c4f-441b-98ca-37da407226cc"
      unitRef="number">0.0146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzItMS0xLTEtMjI1OTU5_b7704ae2-8d69-433e-8166-0b887aa8be77"
      unitRef="number">0.2354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzItMy0xLTEtMjI1OTU5_39175578-5153-4134-b862-976a281ae836"
      unitRef="number">0.2527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzItNS0xLTEtMjI1OTU5_6ae4f6c2-684c-45b5-8a1a-9cd4903d2dce"
      unitRef="number">0.3721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzMtMS0xLTEtMjI1OTU5_415e8491-134f-4c05-a3bc-2a3db11be018"
      unitRef="number">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzMtMy0xLTEtMjI1OTU5_e40dd734-309d-4dd3-8328-3eaf67a468fe"
      unitRef="number">0.0008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzMtNS0xLTEtMjI1OTU5_ac0e948e-34b4-4df8-a369-8c5d6b07f9ea"
      unitRef="number">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzQtMS0xLTEtMjI1OTU5_eb54737b-26db-47f3-bc64-e40878fa7046">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzQtMy0xLTEtMjI1OTU5_9632a575-bb60-449f-8199-de2400c2c934">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzQtNS0xLTEtMjI1OTU5_3ef10942-bea5-47c4-b335-4e363ff6fc9e">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzUtMS0xLTEtMjI1OTU5_45de48cc-6188-4f56-95e4-17036ffba0df"
      unitRef="usdPerShare">16.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i225620d3fec84216a7b76440b5de5139_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzUtMy0xLTEtMjI1OTU5_66cff1d8-eec8-453f-9787-3dd0c8f35414"
      unitRef="usdPerShare">12.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3791bc01af064941adf2bdbdeb4e25b9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTQvZnJhZzphMDJjYzA2NjNkMjA0ZWRjOGI5YmJiYzI0YjEyYjYzZC90YWJsZTo0ZmVkOTNlZDM0NmQ0ZDk1YjA3OWExMzhlOTgyY2JkZC90YWJsZXJhbmdlOjRmZWQ5M2VkMzQ2ZDRkOTViMDc5YTEzOGU5ODJjYmRkXzUtNS0xLTEtMjI1OTU5_286cf4e8-e7a4-4021-a792-35a25596c955"
      unitRef="usdPerShare">13.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM5MTY_b982213f-c88c-4238-a0f8-9e43854a82a1">Shareholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following share repurchase programs have been authorized by the Board:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In billions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Authorization&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining as of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 17, 2022 (&#x201c;2022 Repurchase Program&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 9, 2021 (&#x201c;2021 Repurchase Program&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the share Repurchase Programs was effective immediately and permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (&#x201c;ASR&#x201d;) transactions, and/or other derivative transactions. Both the 2022 and 2021 Repurchase Programs can be modified or terminated by the Board at any time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the Company repurchased an aggregate of 34.1&#160;million shares of common stock for approximately $3.5&#160;billion pursuant to the 2021 Repurchase Program, including share repurchases under the $1.5&#160;billion fixed dollar ASR transaction described below. During the years ended December&#160;31, 2021 and 2020, the Company did not repurchase any shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $2.0&#160;billion fixed dollar ASR with Citibank, N.A. (&#x201c;Citibank&#x201d;). Upon payment of the $2.0&#160;billion purchase price on January 4, 2023, the Company received a number of shares of CVS Health Corporation&#x2019;s common stock equal to 80% of the $2.0&#160;billion notional amount of the ASR or approximately 17.4 million shares at a price of $92.19 per share, which were placed into treasury stock in January 2023. At the conclusion of the ASR, the Company may receive additional shares representing the remaining 20% of the $2.0&#160;billion notional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Company&#x2019;s stock over an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Citibank which, at the Company&#x2019;s option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that could be delivered to the Company is 43.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5&#160;billion fixed dollar ASR with Barclays Bank PLC. Upon payment of the $1.5&#160;billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation&#x2019;s common stock equal to 80% of the $1.5&#160;billion notional amount of the ASR or approximately 11.6&#160;million shares at a price of $103.34 per share, which were placed into treasury stock in January 2022. The ASR was accounted for as an initial treasury stock transaction for $1.2&#160;billion and a forward contract for $0.3&#160;billion. The forward contract was classified as an equity instrument and was recorded within capital surplus. In February 2022, the Company received approximately 2.7&#160;million shares of CVS Health Corporation&#x2019;s common stock, representing the remaining &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20% of the $1.5&#160;billion notional amount of the ASR, thereby concluding the ASR. These shares were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quarterly cash dividend declared by the Board was $0.55 and $0.50 per share in 2022 and 2021, respectively. In December 2022, the Board authorized a 10% increase in the quarterly cash dividend to $0.605 per share effective in 2023. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company&#x2019;s earnings, capital requirements, financial condition and other factors considered relevant by the Board.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Requirements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s insurance business operations are conducted through subsidiaries that principally consist of health maintenance organizations (&#x201c;HMOs&#x201d;) and insurance companies. The Company&#x2019;s HMO and insurance subsidiaries report their financial statements in accordance with accounting practices prescribed by state regulatory authorities which may differ from GAAP. The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December&#160;31, 2022, 2021 and 2020 for the Company&#x2019;s insurance and HMO subsidiaries were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory net income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated statutory capital and surplus&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s insurance and HMO subsidiaries paid $3.2 billion of gross dividends to the Company for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to general state law restrictions on payments of dividends and other distributions to stockholders applicable to all corporations, HMOs and insurance companies are subject to further regulations that, among other things, may require those companies to maintain certain levels of equity and restrict the amount of dividends and other distributions that may be paid to their equity holders. In addition, in connection with the Aetna Acquisition, the Company made certain undertakings that require prior regulatory approval of dividends by certain of its HMOs and insurance companies. At December&#160;31, 2022, these amounts were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated minimum statutory surplus required by regulators&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments on deposit with regulatory bodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated maximum dividend distributions permitted in 2023 without prior regulatory approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, noncontrolling interests were $300 million and $306 million, respectively, primarily related to third party interests in the Company&#x2019;s operating entities.&#160;The noncontrolling entities&#x2019; share is included in total shareholders&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; equity on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM5MDg_3d9d7ebd-19fe-4823-8b68-9a21777ac175">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following share repurchase programs have been authorized by the Board:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In billions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Authorization&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining as of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 17, 2022 (&#x201c;2022 Repurchase Program&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 9, 2021 (&#x201c;2021 Repurchase Program&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="id7d5aaeea5cd4364a999d22bc0e526c2_I20221117"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNWJiMTRkNDYyMTA0MzMzODUyZTIzMTFjN2JlMjljNC90YWJsZXJhbmdlOjA1YmIxNGQ0NjIxMDQzMzM4NTJlMjMxMWM3YmUyOWM0XzEtMS0xLTEtMjA1NzI0_f744fc13-b400-41e2-89e9-157f1f80891f"
      unitRef="usd">10000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ice5463bac593422d85e68f6a31c6cd24_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNWJiMTRkNDYyMTA0MzMzODUyZTIzMTFjN2JlMjljNC90YWJsZXJhbmdlOjA1YmIxNGQ0NjIxMDQzMzM4NTJlMjMxMWM3YmUyOWM0XzEtMy0xLTEtMjA1NzMy_0a472085-2718-4ca9-8528-90943377ea9a"
      unitRef="usd">10000000000.0</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i51eec47e53dc4a1c9685a39a8e5b3b47_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNWJiMTRkNDYyMTA0MzMzODUyZTIzMTFjN2JlMjljNC90YWJsZXJhbmdlOjA1YmIxNGQ0NjIxMDQzMzM4NTJlMjMxMWM3YmUyOWM0XzEtMS0xLTEtMTY3OTA4_c9a95b5f-212c-43b8-a7b2-2b1717b01dd0"
      unitRef="usd">10000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i5316d30a5a634b0eb7ebde97e6094f70_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNWJiMTRkNDYyMTA0MzMzODUyZTIzMTFjN2JlMjljNC90YWJsZXJhbmdlOjA1YmIxNGQ0NjIxMDQzMzM4NTJlMjMxMWM3YmUyOWM0XzEtMy0xLTEtMTY3OTA4_864e8949-5870-4f16-9882-75605d143e57"
      unitRef="usd">6500000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8233d450fa5745639d54e56448f03464_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODE0MzQ_1351dfdf-da03-4f46-b8ea-473e9bd353d7"
      unitRef="shares">34100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8233d450fa5745639d54e56448f03464_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODE0NTI_76a04ab8-7684-4a5d-a117-f456c18f7a9e"
      unitRef="usd">3500000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <cvs:PaymentsForAcceleratedShareRepurchasesAmount
      contextRef="ic28fda85c05b4594a00f0a3402b95859_D20220104-20220104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzEwOTk1MTE2Mjk0NDQ4_5e47b3cf-2de6-404a-adf7-d46b2d7198d7"
      unitRef="usd">1500000000</cvs:PaymentsForAcceleratedShareRepurchasesAmount>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NTk_6320e137-0f04-497e-9579-4ffef4120b64"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NTk_abfc773f-3def-49dd-a357-c9389434431c"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <cvs:AcceleratedShareRepurchasesAgreementAmount
      contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE2NTU_e35af428-26f0-484a-bbc9-6f8a18361e16"
      unitRef="usd">2000000000</cvs:AcceleratedShareRepurchasesAgreementAmount>
    <cvs:PaymentsForAcceleratedShareRepurchasesAmount
      contextRef="i8ff381caf73a4c2db6637a9d0b8f3632_D20230104-20230104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE2NzA_3be461e3-9a48-42e7-8717-256389445502"
      unitRef="usd">2000000000</cvs:PaymentsForAcceleratedShareRepurchasesAmount>
    <cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares
      contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE2ODc_76da89ae-62ae-4cc2-bbdd-b4f03f6a0bc9"
      unitRef="number">0.80</cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares>
    <cvs:AcceleratedShareRepurchasesAgreementAmount
      contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE2OTM_7e70543e-bf24-47b4-b006-85b7ceed7d78"
      unitRef="usd">2000000000</cvs:AcceleratedShareRepurchasesAgreementAmount>
    <cvs:AcceleratedShareRepurchasesNumberOfSharesRepurchased
      contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzU0OTc1NTgzMDU4OA_e11d0d04-36e9-4095-b712-7b03a087d828"
      unitRef="shares">17400000</cvs:AcceleratedShareRepurchasesNumberOfSharesRepurchased>
    <us-gaap:SharePrice
      contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzU0OTc1NTgzMDU5Ng_1c8c2fc2-a28f-421b-b382-745b07dfc075"
      unitRef="usdPerShare">92.19</us-gaap:SharePrice>
    <cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram
      contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE3Mjc_824ac1ba-e7db-461c-9a6a-8020ab101eac"
      unitRef="number">0.20</cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram>
    <cvs:AcceleratedShareRepurchasesAgreementAmount
      contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzIxOTkwMjMyNzE3MzM_cd3fb13c-51b7-4f5c-8b7d-bd2eff77ae9a"
      unitRef="usd">2000000000</cvs:AcceleratedShareRepurchasesAgreementAmount>
    <cvs:AcceleratedShareRepurchaseProgramMaximumNumberOfShares
      contextRef="i3dba707cd749450ca1bc96a22ff0d254_I20230104"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzU0OTc1NTgzMDYxNw_448781f4-51fb-4e2b-93d0-b0533ea7c5df"
      unitRef="shares">43400000</cvs:AcceleratedShareRepurchaseProgramMaximumNumberOfShares>
    <cvs:AcceleratedShareRepurchasesAgreementAmount
      contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODA5Njg_3b468df1-0762-45f2-aa4d-bf3669c372bd"
      unitRef="usd">1500000000</cvs:AcceleratedShareRepurchasesAgreementAmount>
    <cvs:PaymentsForAcceleratedShareRepurchasesAmount
      contextRef="ic28fda85c05b4594a00f0a3402b95859_D20220104-20220104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODA5ODM_5e47b3cf-2de6-404a-adf7-d46b2d7198d7"
      unitRef="usd">1500000000</cvs:PaymentsForAcceleratedShareRepurchasesAmount>
    <cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares
      contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwMDI_2de84610-cc30-4487-bc05-33843140a7ce"
      unitRef="number">0.80</cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares>
    <cvs:AcceleratedShareRepurchasesAgreementAmount
      contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwMDg_18ce42a1-5708-467e-92ea-e028c7d20717"
      unitRef="usd">1500000000</cvs:AcceleratedShareRepurchasesAgreementAmount>
    <cvs:AcceleratedShareRepurchasesNumberOfSharesRepurchased
      contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwMjM_5cba7002-e215-4fab-9cf6-59bb3e871155"
      unitRef="shares">11600000</cvs:AcceleratedShareRepurchasesNumberOfSharesRepurchased>
    <us-gaap:SharePrice
      contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwNzA_136d83a8-f732-43f7-8513-fc4d8ca9295d"
      unitRef="usdPerShare">103.34</us-gaap:SharePrice>
    <cvs:TransferOfSharesToTreasuryStockValue
      contextRef="i2c14530c00c646478ca97544065c4fbb_I20220104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwNDA_7e4dfb8c-7f92-4ebe-b068-1a06c0c52842"
      unitRef="usd">1200000000</cvs:TransferOfSharesToTreasuryStockValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie70904e10fad41e29c390bf6b19d6203_I20220104"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzEzNzQzODk1MzY3ODIy_de8d5799-7503-4fd1-a61e-eec5f600e746"
      unitRef="usd">300000000</us-gaap:DerivativeNotionalAmount>
    <cvs:AcceleratedShareRepurchasesNumberOfSharesRepurchased
      contextRef="ia5c40ac9da1342d08ae7f70b317ddf53_I20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzEzNzQzODk1MzY3ODM3_8b801c8e-fbdb-4bdf-8a39-9575359bfaab"
      unitRef="shares">2700000</cvs:AcceleratedShareRepurchasesNumberOfSharesRepurchased>
    <cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram
      contextRef="ia5c40ac9da1342d08ae7f70b317ddf53_I20220228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI3NDg3NzkwODEwNTk_ccda23fb-39a5-4f5a-857b-020b7f8ce5ff"
      unitRef="number">0.20</cvs:AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram>
    <cvs:AcceleratedShareRepurchasesAgreementAmount
      contextRef="ia5c40ac9da1342d08ae7f70b317ddf53_I20220228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzEzNzQzODk1MzY3ODUx_e58901bc-d0a2-49e8-826a-ae2f006700a8"
      unitRef="usd">1500000000</cvs:AcceleratedShareRepurchasesAgreementAmount>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0Njg_006422a0-2c0a-4b05-acfa-7f31bde8271e"
      unitRef="usdPerShare">0.55</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="ieef592c79265415e9514a93ffb9ae4ac_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0Njg_582861c3-893c-4b42-a3d4-9b22965941b7"
      unitRef="usdPerShare">0.55</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="id5735f8f8c5444a2a0384aa456ca592f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0Njg_658f4ab7-45c8-4a7f-a263-e7ed459e1356"
      unitRef="usdPerShare">0.55</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i97d782259b904c979e113b78787ed48d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0Njg_bea01a34-cecf-4e60-8f5d-82f6849ea6f7"
      unitRef="usdPerShare">0.55</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i9289877d9c2c4ffcbaa2d99b1945576b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NzU_2d5f1531-46af-4c59-a7fe-e1d946075601"
      unitRef="usdPerShare">0.50</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="idc9209a44ddd41178541daa30bd6749f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NzU_37752729-fb43-4205-8726-34dbb46089d1"
      unitRef="usdPerShare">0.50</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i82a1252a04a84b3898c7e327a9c92b60_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NzU_65f81111-958f-4d71-9fe3-c936d6b98667"
      unitRef="usdPerShare">0.50</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0Xzg3OTYwOTMwMzQ0NzU_81554b5f-0b5f-44ee-ac19-f5b7f61fb59c"
      unitRef="usdPerShare">0.50</us-gaap:DividendsPayableAmountPerShare>
    <cvs:DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzY1OTcwNjk3ODY0Njk_962edeef-ddb5-4fcd-864c-0200d257e208"
      unitRef="number">0.10</cvs:DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i95e56c9158aa4a519e48b89d4b91b42a_I20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzU0OTc1NTgzMDQ5Mw_d6a73d64-c561-4019-b7f6-13939a295d85"
      unitRef="usdPerShare">0.605</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:ScheduleOfRegulatoryAssetsTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM5MTA_10e01607-bf3c-408c-ac5d-3d0c741c7951">The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December&#160;31, 2022, 2021 and 2020 for the Company&#x2019;s insurance and HMO subsidiaries were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory net income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated statutory capital and surplus&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRegulatoryAssetsTextBlock>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount
      contextRef="icfd8499c4fb34af58a98efbc5d640ce2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzEtMS0xLTEtMTY3OTA4_5d740c63-0dc2-43cd-a065-4995bfaf3ab7"
      unitRef="usd">2851000000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount
      contextRef="i7b5561cc39474810bff93b9bc55eddd3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzEtMy0xLTEtMTY3OTA4_5e98a541-b201-4e3d-9374-79eef6123a33"
      unitRef="usd">3302000000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount
      contextRef="iec46daf9900b4a90868ccafe21f74ebb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzEtNS0xLTEtMTY3OTA4_ee22503a-aff3-41e4-8480-97212b86fc49"
      unitRef="usd">3667000000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance
      contextRef="ibfbc41d71b734bae909dc80277dec2bd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzItMS0xLTEtMTY3OTA4_91aa3d56-bcd8-42ad-9c12-6f248b979c62"
      unitRef="usd">15503000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance
      contextRef="i297b60290a1245cc886da0051e954eac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzItMy0xLTEtMTY3OTA4_37f690f3-52c1-4789-9189-7b6bd32c25ba"
      unitRef="usd">14879000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance
      contextRef="i66102a5aa12440b29e51c2d516b74676_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTowNDY2OTczM2I5NGQ0MzRhODM4NzdmODBkMTU5N2U1NC90YWJsZXJhbmdlOjA0NjY5NzMzYjk0ZDQzNGE4Mzg3N2Y4MGQxNTk3ZTU0XzItNS0xLTEtMTY3OTA4_e4bad0aa-dd67-4646-8346-f5572fc90bb6"
      unitRef="usd">13238000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries
      contextRef="icfd8499c4fb34af58a98efbc5d640ce2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzI5MTI_9508652a-06f4-4a92-9c02-bcca1318b77d"
      unitRef="usd">3200000000</us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries>
    <us-gaap:StatutoryAccountingPracticesDisclosureTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM5MDA_2dcff450-aba0-4198-9d3f-7c8794f95e36">At December&#160;31, 2022, these amounts were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated minimum statutory surplus required by regulators&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments on deposit with regulatory bodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated maximum dividend distributions permitted in 2023 without prior regulatory approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StatutoryAccountingPracticesDisclosureTextBlock>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTozNmU5MTg0OWVlNjc0ZmZiYmQzNDkyM2M4MTM0NWE4NC90YWJsZXJhbmdlOjM2ZTkxODQ5ZWU2NzRmZmJiZDM0OTIzYzgxMzQ1YTg0XzEtMS0xLTEtMTY3OTA4_3af0feb9-1da9-41b3-8629-dcbc53ed4140"
      unitRef="usd">7741000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:AssetsHeldByInsuranceRegulators
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTozNmU5MTg0OWVlNjc0ZmZiYmQzNDkyM2M4MTM0NWE4NC90YWJsZXJhbmdlOjM2ZTkxODQ5ZWU2NzRmZmJiZDM0OTIzYzgxMzQ1YTg0XzItMS0xLTEtMTY3OTA4_573ef415-1589-43cc-81a2-dd2048f9f769"
      unitRef="usd">652000000</us-gaap:AssetsHeldByInsuranceRegulators>
    <us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90YWJsZTozNmU5MTg0OWVlNjc0ZmZiYmQzNDkyM2M4MTM0NWE4NC90YWJsZXJhbmdlOjM2ZTkxODQ5ZWU2NzRmZmJiZDM0OTIzYzgxMzQ1YTg0XzMtMS0xLTEtMTY3OTA4_e32b0144-4746-4710-8acf-7bbe10cc7c3e"
      unitRef="usd">2706000000</us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval>
    <us-gaap:MinorityInterest
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM2Nzg_e1ac868c-7aa5-471e-a5b9-446a1466cd49"
      unitRef="usd">300000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNTcvZnJhZzpiNWY0MzZlYWU4Nzk0MTg5YjlhOWRkZWRiYzU1MWNhNC90ZXh0cmVnaW9uOmI1ZjQzNmVhZTg3OTQxODliOWE5ZGRlZGJjNTUxY2E0XzM2ODU_261fad85-a9bc-43e0-bd90-88e0336d5fe2"
      unitRef="usd">306000000</us-gaap:MinorityInterest>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90ZXh0cmVnaW9uOmE0N2ViZTQ2NmJhMjRjZjI4ODVlOGY3OGEwNTA2MTRhXzEyNzk_c2cb4f3b-a6a3-4045-9f31-6ba6fcf5b9e0">Other Comprehensive Income (Loss)&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shareholders&#x2019; equity included the following activity in accumulated other comprehensive income (loss) in 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net unrealized investment gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($(2,972), $(489) and $497 pretax)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($315, $(32) and $31 pretax)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign currency translation adjustments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($38, $0 and $(7) pretax)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($(15), $(34) and $(35) pretax)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension and other postretirement benefits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($(229), $20 and $(30) pretax)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($3, $6 and $7 pretax)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total beginning of year accumulated other comprehensive income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total end of year accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90ZXh0cmVnaW9uOmE0N2ViZTQ2NmJhMjRjZjI4ODVlOGY3OGEwNTA2MTRhXzEyNzc_de25885a-84f8-49cc-b038-9e8b012d67ef">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shareholders&#x2019; equity included the following activity in accumulated other comprehensive income (loss) in 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net unrealized investment gains (losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($(2,972), $(489) and $497 pretax)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($315, $(32) and $31 pretax)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign currency translation adjustments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($38, $0 and $(7) pretax)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($(15), $(34) and $(35) pretax)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension and other postretirement benefits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($(229), $20 and $(30) pretax)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;($3, $6 and $7 pretax)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total beginning of year accumulated other comprehensive income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total end of year accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50e896501d7c436b96f31503738ed740_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMtMS0xLTEtMTY3OTA4_abc6bc47-db13-42e3-9fcb-195e9d916f5d"
      unitRef="usd">778000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia18c761ce4364ea2973eb59d2fd584ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMtMy0xLTEtMTY3OTA4_3de034bb-764b-4781-bc13-d4c887104faf"
      unitRef="usd">1214000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5c2106ba1184ea692fbc96551d6d7b2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMtNS0xLTEtMTY3OTA4_8e9dc813-bb61-4620-971c-be5e0d9d79c1"
      unitRef="usd">774000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246ZmRmN2U5ZjRlMmQ1NDQxMzg4ZmI4YTFmYmEwMmRiNDVfNjQ_9112e157-7ee4-4030-a18a-159ffce57c84"
      unitRef="usd">-2972000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246ZmRmN2U5ZjRlMmQ1NDQxMzg4ZmI4YTFmYmEwMmRiNDVfNjg_0fcf855b-a471-487a-b14c-d04a3daefe43"
      unitRef="usd">-489000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246ZmRmN2U5ZjRlMmQ1NDQxMzg4ZmI4YTFmYmEwMmRiNDVfNzU_ac3c40b1-7af3-423b-97c1-acb6e1d9db4a"
      unitRef="usd">497000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMS0xLTEtMTY3OTA4_175907a6-18c8-44ff-937a-0421bd61c508"
      unitRef="usd">-2518000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtMy0xLTEtMTY3OTA4_81eacf53-fa3c-4eaf-96bf-f8e8da4dda93"
      unitRef="usd">-410000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzQtNS0xLTEtMTY3OTA4_2c30ecbf-b5d8-459d-9952-011e9d302e74"
      unitRef="usd">415000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246YWYzY2ZiODUyNWZmNDQzNjg2YTJiYTBkNzk1NWU0OTBfNzA_0da94ac2-89ba-4d12-9636-646d56c77f8d"
      unitRef="usd">315000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246YWYzY2ZiODUyNWZmNDQzNjg2YTJiYTBkNzk1NWU0OTBfNzQ_95cb1bf2-a055-491f-a8f8-a4bf551fec4d"
      unitRef="usd">-32000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMC0xLTEtMTY3OTA4L3RleHRyZWdpb246YWYzY2ZiODUyNWZmNDQzNjg2YTJiYTBkNzk1NWU0OTBfODE_b15b80c0-7603-4dc8-92f5-4e3237e3516f"
      unitRef="usd">31000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMS0xLTEtMTY3OTA4_62a90ea9-b80b-4c5f-944c-d4a5ac5cf5c0"
      unitRef="usd">-239000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtMy0xLTEtMTY3OTA4_7025e528-d22c-4305-9ed0-4cf043399a6c"
      unitRef="usd">26000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzUtNS0xLTEtMTY3OTA4_86672c34-0e42-4dbd-b88e-b51f51db7153"
      unitRef="usd">-25000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8cb15071b54d40feb50954c737252518_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzYtMS0xLTEtMTY3OTA4_6a073fe1-a19c-4c93-806e-c2b973c79a21"
      unitRef="usd">-2279000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1e9a2c66568a4938b3bbb64def1fb3a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzYtMy0xLTEtMTY3OTA4_a1555d39-efe9-402a-8985-ac154c1b70f6"
      unitRef="usd">-436000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0ecddfcac6084d5ab73eba2c210ce646_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzYtNS0xLTEtMTY3OTA4_f34171a8-7ba2-48a1-a428-cedb9c52e862"
      unitRef="usd">440000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d4ff8f1d92a425284f720815593c158_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzctMS0xLTEtMTY3OTA4_7599cac1-d20e-493a-aa95-f74047688401"
      unitRef="usd">-1501000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50e896501d7c436b96f31503738ed740_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzctMy0xLTEtMTY3OTA4_b4cbbab9-59fa-4bb4-8f48-9c8a024eacdc"
      unitRef="usd">778000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia18c761ce4364ea2973eb59d2fd584ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzctNS0xLTEtMTY3OTA4_be8795b4-54af-4813-bca3-3dfd9d8bad05"
      unitRef="usd">1214000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a0eaddda21c4a00be59a3852a2fda53_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEwLTEtMS0xLTE2NzkwOA_15b0c7e7-80b3-44d7-9918-da453e367bd8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d6c784677034efab4d3c3761a6becc8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEwLTMtMS0xLTE2NzkwOA_503a0171-454c-4966-bea5-fb9db944f10c"
      unitRef="usd">7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90e299f2c18e43bdae5d151661e82ef0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEwLTUtMS0xLTE2NzkwOA_d6180e36-3f3b-43c1-bfb8-ef37b5292f44"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id6a7074798cd4f7da8207ad643b5286e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzExLTEtMS0xLTE2NzkwOA_4b07872a-3d99-4a31-8d59-f3d0b96991a1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7348d8b55d1847e59482a4dd6cabd5cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzExLTMtMS0xLTE2NzkwOA_677feb57-f894-4712-9b8d-8841737d10b0"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1acf0930000a47a28b1f1859847b12aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzExLTUtMS0xLTE2NzkwOA_664e0d1c-8375-4ef0-aa15-bbc8003dfe54"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id6a7074798cd4f7da8207ad643b5286e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEzLTEtMS0xLTE2NzkwOA_93ef9339-3533-4bf9-9f47-7de0f8a14c1f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7348d8b55d1847e59482a4dd6cabd5cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEzLTMtMS0xLTE2NzkwOA_580b5323-8ae3-40e6-a6f1-a1b44116a7ce"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1acf0930000a47a28b1f1859847b12aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzEzLTUtMS0xLTE2NzkwOA_988a2357-536a-46fd-989f-637cf0c83fb2"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb67b8f18d2a41819af3ed1f45173118_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE0LTEtMS0xLTE2NzkwOA_64b48a00-06b9-4641-a4e8-a036c306b602"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a0eaddda21c4a00be59a3852a2fda53_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE0LTMtMS0xLTE2NzkwOA_f49427dd-fc57-405e-8e34-4aa62010cc5e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d6c784677034efab4d3c3761a6becc8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE0LTUtMS0xLTE2NzkwOA_709a8475-e044-409e-90b9-76b6141185b4"
      unitRef="usd">7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70d024dd953342978e381ef9ad09e97d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE3LTEtMS0xLTE2NzkwOA_1abf5dff-e921-4a81-8f07-2e12e4125e4b"
      unitRef="usd">222000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34691a75be1a40a485b08377e0d95591_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE3LTMtMS0xLTE2NzkwOA_a7946419-fbc6-488c-9c16-e262308b9c46"
      unitRef="usd">248000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7cab5985f934b68b073707b0db81f68_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE3LTUtMS0xLTE2NzkwOA_e3f58e6b-84c3-424b-b0b7-66fcf786056c"
      unitRef="usd">279000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjgzNGIzNDFmOWEyODQ4N2JiNTlmY2IyN2YzYzUxZjQ4XzU1_067d1681-e05d-4fc8-9ceb-df8602337dcc"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjgzNGIzNDFmOWEyODQ4N2JiNTlmY2IyN2YzYzUxZjQ4XzU5_6f1f9ae9-ee1b-477e-802d-10b5d7841ce7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjgzNGIzNDFmOWEyODQ4N2JiNTlmY2IyN2YzYzUxZjQ4XzY2_afe697ee-1d59-496b-bd2f-27ebefabfd21"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTEtMS0xLTE2NzkwOA_699d8d41-4957-4d05-b837-e9e649b9a4b2"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTMtMS0xLTE2NzkwOA_c6913660-ef85-418b-9618-7b99c3c06731"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE4LTUtMS0xLTE2NzkwOA_3f2abbe0-5e9a-4705-aeac-f82347343e79"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBiNjI3ZmE1NDYzMDQ0NGRhNTc3ODY3NDgyNzQ1OGRkXzcw_2819d842-90c6-4559-bf2d-264358eae9d5"
      unitRef="usd">-15000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBiNjI3ZmE1NDYzMDQ0NGRhNTc3ODY3NDgyNzQ1OGRkXzc0_ee8b4f96-daa3-41c8-89d2-7af5a164c71b"
      unitRef="usd">-34000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBiNjI3ZmE1NDYzMDQ0NGRhNTc3ODY3NDgyNzQ1OGRkXzgx_544c54da-25d5-49a3-95a6-7b2c49800092"
      unitRef="usd">-35000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTEtMS0xLTE2NzkwOA_577b90e4-ac85-4a25-84df-6999927e199d"
      unitRef="usd">11000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTMtMS0xLTE2NzkwOA_8391d7b7-6ad2-4285-b777-890b6a3a3ee1"
      unitRef="usd">26000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzE5LTUtMS0xLTE2NzkwOA_5dab683f-d3d8-4bc6-899c-245fe8f762cc"
      unitRef="usd">26000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3fb10e0277244801a2ed4e269ff712f8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIwLTEtMS0xLTE2NzkwOA_3f2062a7-4120-41de-a9e9-f206784b9869"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i053181ca045a4428aee792436b90324f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIwLTMtMS0xLTE2NzkwOA_6df55d83-2ad6-428b-bd25-00d4699f7b37"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i15aebf8f99db4d8e97edddfd74dddc4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIwLTUtMS0xLTE2NzkwOA_2551a779-f362-4851-a51d-71c8a3dde6ef"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40550f17612e4e1c9a2bdb2e12646807_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIxLTEtMS0xLTE2NzkwOA_7787a82f-cb91-42e4-989c-626d179b2bd6"
      unitRef="usd">239000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70d024dd953342978e381ef9ad09e97d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIxLTMtMS0xLTE2NzkwOA_9a6e0c3b-45ae-4992-854c-5fd04e3a3667"
      unitRef="usd">222000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34691a75be1a40a485b08377e0d95591_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzIxLTUtMS0xLTE2NzkwOA_b668dc35-b751-4080-bdd5-27d6bcafc1ce"
      unitRef="usd">248000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae0bd8dfb5cf4f9e8b8252cd49e75e9c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI0LTEtMS0xLTE2NzkwOA_0a06f792-4c64-425f-9771-f27df7a25027"
      unitRef="usd">-35000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75fd10d334be4f38bba49ac3d51dd978_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI0LTMtMS0xLTE2NzkwOA_ced08393-1a6f-49db-bbde-a1b54e3f25d8"
      unitRef="usd">-55000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7e3ddd79ec9406fbd5b0334e0a7cf99_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI0LTUtMS0xLTE2NzkwOA_96ecf6d5-21d1-471c-b32f-2f57f91cacc2"
      unitRef="usd">-38000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBhNDc3MDM4YWFkMDQxMjFhMzZmNDY2YmZjZDgzNzhlXzY0_d0e774bb-9ff1-4d0f-ad67-aa9c573922f2"
      unitRef="usd">-229000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBhNDc3MDM4YWFkMDQxMjFhMzZmNDY2YmZjZDgzNzhlXzY4_a3167549-7a8f-461d-8d86-cc5e3ef516fa"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjBhNDc3MDM4YWFkMDQxMjFhMzZmNDY2YmZjZDgzNzhlXzc1_454019ee-de18-4283-ab47-65916a8dd074"
      unitRef="usd">-30000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTEtMS0xLTE2NzkwOA_bf49dfb4-5769-454b-a472-8b856646edc8"
      unitRef="usd">-170000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTMtMS0xLTE2NzkwOA_26eec451-e360-43b2-b22b-b289cdec3c54"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI1LTUtMS0xLTE2NzkwOA_7d1ae275-b632-438b-b4e2-5bf935eef759"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjQ3NTk4ZGI5MjRiYjQ0NDViNDM0ODQyYzc4M2E0NDFiXzY4_89936955-ed23-47f9-b72d-644973260dcd"
      unitRef="usd">3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjQ3NTk4ZGI5MjRiYjQ0NDViNDM0ODQyYzc4M2E0NDFiXzcy_c703d2eb-e63f-4dbc-b988-cd58012bb63f"
      unitRef="usd">6000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTAtMS0xLTE2NzkwOC90ZXh0cmVnaW9uOjQ3NTk4ZGI5MjRiYjQ0NDViNDM0ODQyYzc4M2E0NDFiXzc5_5d59e84d-d2c0-46bd-8641-4f86ba581126"
      unitRef="usd">7000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTEtMS0xLTE2NzkwOA_6587ac8a-5c39-4af9-bb2b-a1c39c45908f"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTMtMS0xLTE2NzkwOA_32f97a1d-ac50-446e-b621-9fd49671bed6"
      unitRef="usd">-5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI2LTUtMS0xLTE2NzkwOA_41262452-72ea-48aa-b207-41961a497c18"
      unitRef="usd">-5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2c25993ba2e84ef39f27578b7ce34a76_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI3LTEtMS0xLTE2NzkwOA_648a6cf8-07fb-43e0-9c72-fa6d61006ac6"
      unitRef="usd">-168000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1de85626af2543b182ac0c8049528d59_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI3LTMtMS0xLTE2NzkwOA_89a05d3a-a565-4308-94c0-86923decb4d2"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic1977865eeda428881fef84c8d6b4f98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI3LTUtMS0xLTE2NzkwOA_91aedb74-a122-4294-be3a-94eeb3425091"
      unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48cedd332752429fb7fdcab29fe151c0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI4LTEtMS0xLTE2NzkwOA_d6ae0eab-e423-4b70-999a-5495361f32c0"
      unitRef="usd">-203000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae0bd8dfb5cf4f9e8b8252cd49e75e9c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI4LTMtMS0xLTE2NzkwOA_84839afd-a4d6-4a5d-8440-197f7ad173b8"
      unitRef="usd">-35000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75fd10d334be4f38bba49ac3d51dd978_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzI4LTUtMS0xLTE2NzkwOA_9fb81d3d-e3ea-45f6-b8c9-9013f8594e35"
      unitRef="usd">-55000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea5dc45a20214840ba91115d7f1be610_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMwLTEtMS0xLTE2NzkwOA_9400e333-3934-44b8-b463-ed954d72f117"
      unitRef="usd">965000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63a9007fcb714cb09cc20b1eca666273_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMwLTMtMS0xLTE2NzkwOA_672fd680-c73d-4982-a15f-400cdc51c90f"
      unitRef="usd">1414000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id41faef8f0db4ed59ca3aaf9b30913d8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMwLTUtMS0xLTE2NzkwOA_dd7e444e-fc63-42a3-b629-4d816dfac030"
      unitRef="usd">1019000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMxLTEtMS0xLTE2NzkwOA_f53021cd-5423-4a97-863d-3286bf7d3205"
      unitRef="usd">-2430000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMxLTMtMS0xLTE2NzkwOA_2194d3cf-9f3a-44ba-a312-6d65376fe997"
      unitRef="usd">-449000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMxLTUtMS0xLTE2NzkwOA_8a87fd00-8593-4fc8-9a9c-0b420cda3d84"
      unitRef="usd">395000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9dbbb5af69624415b1974a87c4e00ef6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMyLTEtMS0xLTE2NzkwOA_1c0b988c-0a1e-4a17-96c5-4747cb5a24c8"
      unitRef="usd">-1465000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea5dc45a20214840ba91115d7f1be610_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMyLTMtMS0xLTE2NzkwOA_16a5d8db-20d3-4d50-9dd5-de777b68391c"
      unitRef="usd">965000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63a9007fcb714cb09cc20b1eca666273_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90YWJsZTo2MmYzNmZjYzRlMGM0YzFlOTdlZWQxN2M0YjVjYmFmNC90YWJsZXJhbmdlOjYyZjM2ZmNjNGUwYzRjMWU5N2VlZDE3YzRiNWNiYWY0XzMyLTUtMS0xLTE2NzkwOA_4475830c-75e1-4088-a6d8-e069728efcc0"
      unitRef="usd">1414000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="i40550f17612e4e1c9a2bdb2e12646807_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjAvZnJhZzphNDdlYmU0NjZiYTI0Y2YyODg1ZThmNzhhMDUwNjE0YS90ZXh0cmVnaW9uOmE0N2ViZTQ2NmJhMjRjZjI4ODVlOGY3OGEwNTA2MTRhXzI3NDg3NzkwNzE2NzI_25830e71-75b8-4002-96e9-77cebfb19be0"
      unitRef="usd">11000000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzU3MQ_646d3480-9a03-422b-8130-b83637c282cb">Earnings Per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share is computed using the treasury stock method. Stock options and SARs to purchase 4 million, 7&#160;million, and 15&#160;million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share for the years ended December&#160;31, 2022, 2021 and 2020, respectively, because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions,&#160;except&#160;per&#160;share&#160;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator for earnings per share calculation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to CVS Health&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for earnings per share calculation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share from continuing operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie82b5c6e85e2408ab675d8ef44a98158_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzExNA_f8855d32-61bf-435e-9bf6-e7a6e4bd8813"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i42a690cfa922477e90e45bfe9cff5f29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzExOA_fa535aaf-6e0f-437f-992f-2e061af3a345"
      unitRef="shares">7000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0842c61fceff4047b49c7ff6a4a293a7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzEyNg_8b5f940d-4e36-491e-8063-b1ecbac8e2fc"
      unitRef="shares">15000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90ZXh0cmVnaW9uOmY2M2Y5ODMwMjU1MzQ5NDM5ZGZjOTI4NDg2ZGVlNWEyXzU3NA_332da34a-9ac8-49b3-b1a8-393709e1758c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions,&#160;except&#160;per&#160;share&#160;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator for earnings per share calculation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to CVS Health&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for earnings per share calculation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share from continuing operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzItMS0xLTEtMTY3OTA4_18e1c5d3-ac2b-405d-9c12-878ab7111207"
      unitRef="usd">4165000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzItMy0xLTEtMTY3OTA4_5bd267c4-77aa-4034-b029-72ddc823e2b9"
      unitRef="usd">7898000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzItNS0xLTEtMTY3OTA4_aace3cda-1d66-48c3-85c5-66a73c8111ca"
      unitRef="usd">7201000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzQtMS0xLTEtMTY3OTA4_0087ed16-f0b0-40ff-bea1-43dfccd75161"
      unitRef="usd">16000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzQtMy0xLTEtMTY3OTA4_e6798578-c62f-4f7f-b31f-bda80b066ade"
      unitRef="usd">-12000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzQtNS0xLTEtMTY3OTA4_186165f7-e212-4d1e-ba33-7abe46f1f347"
      unitRef="usd">13000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzUtMS0xLTEtMTY3OTA4_629cabdb-4f43-4604-94b7-2fbbe728847d"
      unitRef="usd">4149000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzUtMy0xLTEtMTY3OTA4_3e976533-b362-4fc9-85db-a00b33960beb"
      unitRef="usd">7910000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzUtNS0xLTEtMTY3OTA4_5cc297f3-7b13-4225-b96e-d7ea826f50a5"
      unitRef="usd">7188000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzgtMS0xLTEtMTY3OTA4_69afecf8-2c92-41ea-954a-b3ac18270135"
      unitRef="shares">1312000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzgtMy0xLTEtMTY3OTA4_20d3c409-9529-43cb-972b-5de40e9a3982"
      unitRef="shares">1319000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzgtNS0xLTEtMTY3OTA4_daaad5f3-3c44-46de-84c9-fdbcfef9c838"
      unitRef="shares">1309000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ifc14f04c8d094020a89b8124e4d67afd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktMS0xLTEtMjAwMjA3_b7228abd-9bb8-4230-bfeb-bf047409d99b"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic36f054975aa46feb063b56007b02a5c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktMy0xLTEtMjAwMTEw_c7a7eda5-c5ec-4780-ae00-22ca83ac618c"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iaf686621016a49b4a70be7291894b149_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktNS0xLTEtMjAwMTIy_be31414e-d658-427d-8e08-7102ea429ad2"
      unitRef="shares">4000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie82b5c6e85e2408ab675d8ef44a98158_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktMS0xLTEtMTY3OTA4_618d5bc8-ba99-406b-84e2-8881879a5070"
      unitRef="shares">5000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i42a690cfa922477e90e45bfe9cff5f29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktMy0xLTEtMTY3OTA4_8123485f-fa8f-405b-96ff-0613d23cb6b0"
      unitRef="shares">4000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0842c61fceff4047b49c7ff6a4a293a7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzktNS0xLTEtMTY3OTA4_f60d3bf3-05d7-4cb8-912e-54fccfc67645"
      unitRef="shares">1000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEwLTEtMS0xLTE2NzkwOA_689e7e1d-7ba7-494d-9791-17e5e5a375a0"
      unitRef="shares">1323000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEwLTMtMS0xLTE2NzkwOA_75fdec06-9847-46bb-a5a8-3222dd3cfccf"
      unitRef="shares">1329000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEwLTUtMS0xLTE2NzkwOA_65709379-3da3-4358-a9c4-8f5e9d8d48d6"
      unitRef="shares">1314000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEzLTEtMS0xLTE2NzkwOA_2af0e80e-bb25-4126-96b7-f5bc9c5d9fc4"
      unitRef="usdPerShare">3.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEzLTMtMS0xLTE2NzkwOA_6429b5e9-c836-40ff-b67e-d453d59ab93b"
      unitRef="usdPerShare">6.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzEzLTUtMS0xLTE2NzkwOA_2575dd51-e664-4ab0-93f2-c15f470aeb05"
      unitRef="usdPerShare">5.49</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzE0LTEtMS0xLTE2NzkwOA_6764d1d1-011b-4370-80f6-9ef991bec0fc"
      unitRef="usdPerShare">3.14</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzE0LTMtMS0xLTE2NzkwOA_9e42b177-a1fd-4d30-9a90-5148839ee8dd"
      unitRef="usdPerShare">5.95</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjMvZnJhZzpmNjNmOTgzMDI1NTM0OTQzOWRmYzkyODQ4NmRlZTVhMi90YWJsZTozZWE4MmQ3MGQzMDI0M2Y2YWM2ZWVjNjQzY2JlN2RlNC90YWJsZXJhbmdlOjNlYTgyZDcwZDMwMjQzZjZhYzZlZWM2NDNjYmU3ZGU0XzE0LTUtMS0xLTE2NzkwOA_60db5555-33cd-465c-9ac3-8d5691776f72"
      unitRef="usdPerShare">5.47</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:ReinsuranceTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIwOTk_cb0d9384-298a-4708-a6e9-29e203bd9524">Reinsurance&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company&#x2019;s primary liability as the direct insurer of the risks reinsured.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company entered into two four-year reinsurance agreements with an unrelated reinsurer that allow it to reduce required capital and provide collateralized excess of loss reinsurance coverage on a portion of the Health Care Benefits segment&#x2019;s group Commercial Insured business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reinsurer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hartford Life and Accident Insurance Company&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lincoln Life &amp;amp; Annuity Company of New York&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VOYA Retirement Insurance and Annuity Company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fresenius Medical Care Reinsurance Company (Cayman) Ltd. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net premiums&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impact of reinsurance on benefit costs for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is not a material difference between premiums on a written basis versus an earned basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has various agreements with unrelated reinsurers that do not qualify for reinsurance accounting under GAAP, and consequently are accounted for using deposit accounting. The Company entered into these contracts to reduce the risk of catastrophic loss which in turn reduces the Company&#x2019;s capital and surplus requirements. Total deposit assets and liabilities related to reinsurance agreements that do not qualify for reinsurance accounting under GAAP were not material as of December&#160;31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReinsuranceTextBlock>
    <cvs:NumberofReinsuranceContractsEnteredInto
      contextRef="i2e2b473c47f6447294d190668407b467_D20230101-20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzkxMg_0e826903-4a68-4da0-a036-d1f86d366ccc"
      unitRef="reinsurance_agreement">2</cvs:NumberofReinsuranceContractsEnteredInto>
    <cvs:FourYearsReinsuranceAgreementWithUnrelatedInsurer
      contextRef="i2e2b473c47f6447294d190668407b467_D20230101-20230131"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIxMTA_aa9fbf65-3204-40bc-82e6-ebb4b9432364">P4Y</cvs:FourYearsReinsuranceAgreementWithUnrelatedInsurer>
    <us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIxMDk_5c14da3b-c6a9-41c5-a014-29001b57f5d4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reinsurer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hartford Life and Accident Insurance Company&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lincoln Life &amp;amp; Annuity Company of New York&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VOYA Retirement Insurance and Annuity Company &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fresenius Medical Care Reinsurance Company (Cayman) Ltd. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="ieae0c3b0cc27418aa65414f0b7e927c7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzItMS0xLTEtMTY3OTA4_2afe6b52-4103-4958-a015-e278696173de"
      unitRef="usd">1593000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="ic60de804b23546b8a91437fbf72dc2da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzItMy0xLTEtMTY3OTA4_3f671b28-171b-49c6-b107-15b5c2914194"
      unitRef="usd">1887000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="idf72aa41b4d449d0a2ac299a8c83a884_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzMtMS0xLTEtMTY3OTA4_d77f10a0-fd91-4de8-8b4b-e4b4cf04d081"
      unitRef="usd">385000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="i8b933e2ca792484e85ec73f2fc18e41a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzMtMy0xLTEtMTY3OTA4_ad5ce061-c54e-4e94-ae92-d3503a401ad5"
      unitRef="usd">395000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="ic81da46ae9e64349a9aa6e17d4d8c486_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzQtMS0xLTEtMTY3OTA4_a81f327c-1fff-47d0-849e-a3c54390e06f"
      unitRef="usd">159000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="i2f47abf8fc3f40f983bcf19e1da82db5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzQtMy0xLTEtMTY3OTA4_fe82e499-a17d-4830-974a-be913ede55f5"
      unitRef="usd">167000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="i2ad53a23fba3447a8ca121fa57cf7591_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzUtMS0xLTEtMjIxOTgy_b498744c-1b91-42fd-ae0e-39a2b2bde761"
      unitRef="usd">102000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="ibde18ae73cba460eb19c034e2419cf09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzUtMy0xLTEtMjIxOTgy_440b62c1-820e-4b89-bd36-81c387aaca3f"
      unitRef="usd">46000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="i9822742126ab4315872808cfba42b81c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzUtMS0xLTEtMTY3OTA4_225e0640-187a-4fdf-8be7-d2e4b118d294"
      unitRef="usd">55000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="id80e156bb7874df1abefdc699fdc0426_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzUtMy0xLTEtMTY3OTA4_e9dd358b-2c6c-4256-92be-ac0727687bde"
      unitRef="usd">54000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzYtMS0xLTEtMTY3OTA4_360b37dd-7cbd-4dc0-ab9f-3807962900f1"
      unitRef="usd">2294000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTpkOWZiMTI5MGVlOWE0ODI0OTYyYmEzNzEyNmRlZDFmMi90YWJsZXJhbmdlOmQ5ZmIxMjkwZWU5YTQ4MjQ5NjJiYTM3MTI2ZGVkMWYyXzYtMy0xLTEtMTY3OTA4_cc02478b-01e0-430b-98db-bae542f63778"
      unitRef="usd">2549000000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIxMDI_a041f572-3f38-40b9-894e-0d6f8ad0b3a4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct, assumed and ceded premiums earned for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net premiums&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock>
    <us-gaap:DirectPremiumsEarned
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzEtMS0xLTEtMTY3OTA4_290623b1-cb2e-47ba-aa59-168e1b0c8eda"
      unitRef="usd">85670000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:DirectPremiumsEarned
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzEtMy0xLTEtMTY3OTA4_e75317f3-cd1a-45a9-bc39-660c3785728b"
      unitRef="usd">76320000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:DirectPremiumsEarned
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzEtNS0xLTEtMTY3OTA4_40f72871-d6ea-4931-b456-9b917d56edad"
      unitRef="usd">69711000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzItMS0xLTEtMTY3OTA4_0601ad14-fcf2-4d09-8b16-f9d030176401"
      unitRef="usd">432000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzItMy0xLTEtMTY3OTA4_f63cb0e1-bddd-45d3-b46a-fffe668f0563"
      unitRef="usd">492000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzItNS0xLTEtMTY3OTA4_c0ed8b37-0aaa-4a3b-98db-1a14fdfb8e67"
      unitRef="usd">478000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:CededPremiumsEarned
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzMtMS0xLTEtMTY3OTA4_b4c6cadf-fd2a-44b7-b4f6-7f9065aa3664"
      unitRef="usd">772000000</us-gaap:CededPremiumsEarned>
    <us-gaap:CededPremiumsEarned
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzMtMy0xLTEtMTY3OTA4_26929ceb-8a9a-4262-b9c9-716afbf836b2"
      unitRef="usd">680000000</us-gaap:CededPremiumsEarned>
    <us-gaap:CededPremiumsEarned
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzMtNS0xLTEtMTY3OTA4_5be54b7a-bbdc-4acd-87b1-99e7de4b1f27"
      unitRef="usd">825000000</us-gaap:CededPremiumsEarned>
    <us-gaap:PremiumsEarnedNet
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzQtMS0xLTEtMTY3OTA4_0e0d7fb5-fac8-4824-9c56-ded0fbd276a7"
      unitRef="usd">85330000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzQtMy0xLTEtMTY3OTA4_db3e870b-8d21-4a30-8a9f-69cd53bcb354"
      unitRef="usd">76132000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTo1ZDdkNTcyOTdhMjE0YzBkOGEzMTAwZDYzNmE2YmZhOS90YWJsZXJhbmdlOjVkN2Q1NzI5N2EyMTRjMGQ4YTMxMDBkNjM2YTZiZmE5XzQtNS0xLTEtMTY3OTA4_7fcbb260-6d2e-4dc5-b064-75a0b82d926f"
      unitRef="usd">69364000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:EffectsOfReinsuranceTableTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90ZXh0cmVnaW9uOmZhM2QyNmY2YTc1NDRlYjNiMzA5OThmOGY5OWJiZTZhXzIxMDY_1f45e1fe-0bb6-45ef-b8a1-fcadc2d33386">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impact of reinsurance on benefit costs for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EffectsOfReinsuranceTableTextBlock>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredGross
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzEtMS0xLTEtMTY3OTA4_d1c43128-dd42-4539-9c4e-e717317f920b"
      unitRef="usd">71567000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredGross>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredGross
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzEtMy0xLTEtMTY3OTA4_cadca1a3-9801-453b-a615-7f80ff332bf9"
      unitRef="usd">64414000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredGross>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredGross
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzEtNS0xLTEtMTY3OTA4_3f306e47-99a4-4f4e-8c1c-091b59655c5d"
      unitRef="usd">56077000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredGross>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzItMS0xLTEtMTY3OTA4_5789831c-e47b-4a4b-a498-0ad8d141dcb5"
      unitRef="usd">379000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzItMy0xLTEtMTY3OTA4_c9a2ecba-d017-4eda-8edf-7233b63ac09a"
      unitRef="usd">398000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzItNS0xLTEtMTY3OTA4_438ce59a-7c3a-46c1-afc5-7e5583ccfdab"
      unitRef="usd">329000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzMtMS0xLTEtMTY3OTA4_5f458d85-a325-4d22-ad74-4a6c1f0f6ca4"
      unitRef="usd">665000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzMtMy0xLTEtMTY3OTA4_08592fdc-5ac8-4e80-bc0a-737057eafb0e"
      unitRef="usd">552000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzMtNS0xLTEtMTY3OTA4_41353221-6844-4c7a-ac38-bfc7b5ea2513"
      unitRef="usd">727000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzQtMS0xLTEtMTY3OTA4_27b0395f-fbdd-4202-a896-b2960ac5e0a0"
      unitRef="usd">71281000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzQtMy0xLTEtMTY3OTA4_777b0e59-cbb7-4c96-8d2c-4ded9bb57908"
      unitRef="usd">64260000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjYvZnJhZzpmYTNkMjZmNmE3NTQ0ZWIzYjMwOTk4ZjhmOTliYmU2YS90YWJsZTozMjhmODNhYmJmZjA0M2YxOTdiNmFhMTRjZTk0YTJhMy90YWJsZXJhbmdlOjMyOGY4M2FiYmZmMDQzZjE5N2I2YWExNGNlOTRhMmEzXzQtNS0xLTEtMTY3OTA4_97859ad9-6de0-47db-aba0-664cf26d40ca"
      unitRef="usd">55679000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTIxMjQ_eb9acffa-130d-4072-b2d7-8de923ca357c">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic continues to evolve. The Company believes COVID-19&#x2019;s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic&#x2019;s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company&#x2019;s knowledge and control. As a result, the impact COVID-19 will have on the Company&#x2019;s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the following significant guarantee arrangements at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;ASC Claim Funding Accounts - The Company has arrangements with certain banks for the processing of claim payments for its ASC customers. The banks maintain accounts to fund claims of the Company&#x2019;s ASC customers. The customer is responsible for funding the amount paid by the bank each day. In these arrangements, the Company guarantees that the banks will not sustain losses if the responsible ASC customer does not properly fund its account. The aggregate maximum exposure under these arrangements is generally limited to $250 million. The Company can limit its exposure to these guarantees by suspending the payment of claims for ASC customers that have not adequately funded the amount paid by the bank. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Separate Accounts Assets - Certain Separate Accounts assets associated with the large case pensions business in the Corporate/Other segment represent funds maintained as a contractual requirement to fund specific pension annuities that the Company has guaranteed. Minimum contractual obligations underlying the guaranteed benefits in these Separate Accounts were approximately $941&#160;million and $1.3 billion at December&#160;31, 2022 and 2021, respectively. See Note 1 &#x2018;&#x2018;Significant Accounting Policies&#x2019;&#x2019; for additional information on Separate Accounts. Contract holders assume all investment and mortality risk and are required to maintain Separate Accounts balances at or above a specified level. The level of required funds is a function of the risk underlying the Separate Account&#x2019;s investment strategy. If contract holders do not maintain the required level of Separate Accounts assets to meet the annuity guarantees, the Company would establish an additional liability. Contract holders&#x2019; balances in the Separate Accounts at December&#160;31, 2022 exceeded the &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;value of the guaranteed benefit obligation. As a result, the Company was not required to maintain any additional liability for its related guarantees at December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between 1995 and 1997, the Company sold or spun off a number of subsidiaries, including Bob&#x2019;s Stores and Linens &#x2018;n Things, each of which subsequently filed for bankruptcy, and Marshalls. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the former subsidiary&#x2019;s lease obligations for the initial lease term and any extension thereof pursuant to a renewal option provided for in the lease prior to the time of the disposition. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company&#x2019;s guarantees remained in place, although each initial purchaser agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries fail to make the required payments under a store lease, the Company could be required to satisfy those obligations, and any significant adverse impact of COVID-19 on such purchasers and/or former subsidiaries increases the risk that the Company will be required to satisfy those obligations. As of December&#160;31, 2022, the Company guaranteed 67 such store leases (excluding the lease guarantees related to Linens &#x2018;n Things, which have been recorded as a liability on the consolidated balance sheets), with the maximum remaining lease term extending through 2034.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guaranty Fund Assessments, Market Stabilization and Other Non-Voluntary Risk Sharing Pools&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company&#x2019;s assessments generally are based on a formula relating to the Company&#x2019;s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payors such as not-for-profit consumer-governed health plans established under the ACA.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2009, the Pennsylvania Insurance Commissioner placed long-term care insurer Penn Treaty Network America Insurance Company and one of its subsidiaries (collectively, &#x201c;Penn Treaty&#x201d;) in rehabilitation, an intermediate action before insolvency, and subsequently petitioned a state court to convert the rehabilitation into a liquidation. Penn Treaty was placed in liquidation in March 2017. The Company has recorded a liability for its estimated share of future assessments by applicable life and health insurance guaranty associations. It is reasonably possible that in the future the Company may record a liability and expense relating to other insolvencies which could have a material adverse effect on the Company&#x2019;s operating results, financial condition and cash flows, and the risk is heightened by any significant adverse impact of the COVID-19 pandemic on the solvency of other insurers, including long-term care and life insurers. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HMOs in certain states in which the Company does business are subject to assessments, including market stabilization and other risk-sharing pools, for which the Company is assessed charges based on incurred claims, demographic membership mix and other factors. The Company establishes liabilities for these assessments based on applicable laws and regulations. In certain states, the ultimate assessments the Company pays are dependent upon the Company&#x2019;s experience relative to other entities subject to the assessment, and the ultimate liability is not known at the financial statement date. While the ultimate amount of the assessment is dependent upon the experience of all pool participants, the Company believes it has adequate reserves to cover such assessments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s total guaranty fund assessments liability was immaterial at both December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation and Regulatory Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has been involved or is currently involved in numerous legal proceedings, including litigation, arbitration, government investigations, audits, reviews and claims. These include routine, regular and special investigations, audits and reviews by&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CMS, state insurance and health and welfare departments, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the U.S. Department of Justice (the &#x201c;DOJ&#x201d;), &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;state Attorneys General, the U.S. Drug Enforcement Administration (the &#x201c;DEA&#x201d;), the U.S. Federal Trade Commission (the &#x201c;FTC&#x201d;) and other governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, and governmental special investigations, audits and reviews can be expensive and disruptive. Some of the litigation matters may purport or be determined &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. The Company also may be named from time to time in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; actions initiated by private third parties that could also be separately pursued by a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company does not establish an accrued liability. None of the Company&#x2019;s accruals for outstanding legal matters are material individually or in the aggregate to the Company&#x2019;s financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#x2019;s financial position. Substantial unanticipated verdicts, fines and rulings, however, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or loss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations of proceedings could be material to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Usual and Customary Pricing Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and certain current and former directors and officers are named as a defendant in a number of lawsuits that allege that the Company&#x2019;s retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions are brought by a number of different types of plaintiffs, including plan members, private payors, government payors, and shareholders based on different legal theories. Some of these cases are brought as putative class actions, and in some instances, classes have been certified. In October 2022, one of the litigating shareholders made a litigation demand to the Board related to these and other issues after his amended derivative complaint was dismissed for failing to demonstrate demand futility. The Company is defending itself against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;PBM Litigation and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is facing multiple lawsuits, including by state Attorneys General, governmental subdivisions and several putative class actions, regarding drug pricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal theories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The Company is defending itself against these claims. The Company has also received subpoenas, civil investigative demands (&#x201c;CIDs&#x201d;), and other requests for documents and information from, and is being investigated by, the FTC and Attorneys General of several states and the District of Columbia regarding its PBM practices, including pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs, and requests for information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States ex rel. Behnke v. CVS Caremark Corporation, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;et al. (U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court unsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused to be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true prices paid by the Company&#x2019;s PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company&#x2019;s PBM. The Company is defending itself against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Controlled Substances Litigation, Audits and Subpoenas&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against various defendants by plaintiffs such as counties, cities, hospitals, Indian tribes and third-party payors, alleging claims beginning as far back as the early 2000s generally concerning the impacts of widespread prescription opioid abuse. The consolidated multidistrict litigation captioned In re National Prescription Opiate Litigation (MDL No. 2804) is pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes hundreds of relevant federal court cases that name the Company as a defendant. A significant number of similar cases that name the Company as a defendant in some capacity are pending in state courts. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has been named as a defendant in similar cases brought by certain state Attorneys General. The Company is defending itself against all such claims. Additionally, the Company has received subpoenas, CIDs, and/or other requests for information regarding opioids from state Attorneys General and insurance and other regulators of several U.S. jurisdictions. The Company has been cooperating with the government with respect to these subpoenas, CIDs, and other requests for information. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company was among the chain pharmacies found liable by a jury in a trial in federal court in Ohio; in August 2022, the court issued a judgment jointly against the three defendants in the amount of $651&#160;million to be paid over 15 years, and also ordered certain injunctive relief. The Company is appealing the judgment and has not accrued a liability for this matter. In March 2022, CVS Health Corporation and CVS Pharmacy, Inc. entered into a settlement agreement with the State of Florida to resolve claims related to opioid medications dating back more than a decade. Under the terms of the settlement agreement, CVS Health Corporation settled all opioid claims against it and its subsidiaries by the State of Florida for $484&#160;million, which is to be paid over a period of 18 years. During the three months ended March 31, 2022, the Company recorded a $484&#160;million liability associated with this legal settlement. In August 2022, CVS Pharmacy, Inc. entered into an agreement with the State of New Mexico to settle all opioid claims against it and its parents and subsidiaries by the State of New Mexico and participating subdivisions. In September 2022, CVS Pharmacy, Inc. entered into an agreement with the State of West Virginia to settle all opioid claims against it and its parents and subsidiaries by the State of West Virginia and participating subdivisions. Also in September 2022, CVS Pharmacy, Inc. entered into an agreement with the Cherokee Nation to settle all opioid claims against it and its parents and subsidiaries by the Cherokee Nation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company agreed to a formal settlement agreement, the financial amounts of which were agreed to in principle in October 2022, with a leadership group of a number of state Attorneys General and the Plaintiffs&#x2019; Executive Committee (&#x201c;PEC&#x201d;). The agreement would resolve substantially all opioid claims against Company entities by states and political subdivisions, but not private plaintiffs. The maximum amount payable by the Company under the settlement would be approximately $4.3&#160;billion in opioid remediation and $625&#160;million in attorneys&#x2019; fees and costs and additional remediation. The amounts would be payable over 10 years, beginning in 2023. The agreement also contains injunctive terms relating to the dispensing of opioid medications. The settlement agreement is available at nationalopioidsettlement.com.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the settlement agreement, before the Company determines whether to enter into any final settlement, it will assess the number and identities of the governmental entities that will participate in any such settlement. The settlement agreement contemplates that if certain governmental entities do not agree to the settlement, but the Company nonetheless concludes that there is sufficient participation to warrant going forward with the settlement, there would be a corresponding reduction in the amount due from the Company to account for the governmental entities that did not agree. Those non-participating governmental entities would be entitled to pursue their claims against the Company and other defendants. Private plaintiff litigation will also continue.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has been informed that 45 states, the District of Columbia, and all eligible United States territories have elected to join the settlement. Three states were the subject of earlier settlements. The Company has elected to proceed with the settlement process based on that level of participation. The settlement process will progress to the period during which subdivisions may elect to join.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company also agreed to a formal settlement agreement with a leadership group representing tribes throughout the United States. The agreement would resolve substantially all opioid claims against Company entities by such tribes. The maximum amount payable by the Company under the settlement would be $113&#160;million in opioid remediation and $18&#160;million in attorneys&#x2019; fees and costs. The amounts would be payable over 10 years, beginning in 2023. The agreement is contingent upon sufficient participation by tribes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has concluded that settlement of opioid claims by governmental entities and tribes is probable, and the loss related thereto could be reasonably estimated. As a result of that conclusion, and its assessment of certain other opioid-related claims including those for which the Company reached agreement in August and September 2022, the Company recorded pre-tax charges of $5.2&#160;billion and $99 million during the three months ended September 30, 2022 and the three months ended December&#160;31, 2022, respectively, of which $4.8&#160;billion was recorded in other long-term liabilities on the consolidated balance sheet. In addition, the Company expects the cash impact in 2023 and 2024 to be less than $500&#160;million in each year. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment requires judgments about future events. Moreover, the settlement is in its early phases, and there is no assurance that contingencies will be satisfied. The amount of ultimate loss may differ materially from this accrual.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the many uncertainties associated with any settlement arrangement or other resolution of all opioid-related litigation matters, including the uncertain scope of participation by governmental entities, and given that the Company continues to actively defend ongoing litigation for which it believes it has defenses and assertions that have merit, the Company is not able to reasonably estimate the range of ultimate possible loss for all opioid-related litigation matters at this time. The outcome of these legal matters could have a material effect on the Company&#x2019;s business, financial condition, operating results and/or cash flows.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the DOJ served the Company with a DEA administrative subpoena. The subpoena seeks documents relating to practices with respect to prescription opioids and other controlled substances at CVS pharmacy locations concerning potential violations of the federal Controlled Substances Act and the federal False Claims Act. In January 2022, the DOJ served the Company with a CID regarding similar subjects, and the Company is providing documents and information in response to these matters.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prescription Processing Litigation and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its prescription processing practices, including the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ex rel.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Bassan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; v. Omnicare, Inc. and CVS Health Corp. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(U.S. District Court for the Southern District of New York). In December 2019, the U.S. Attorney&#x2019;s Office for the Southern District of New York (the &#x201c;SDNY&#x201d;) filed a complaint-in-intervention in this previously sealed &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; case. The complaint alleges that for certain non-skilled nursing facilities, Omnicare improperly filled prescriptions beyond one year where a valid prescription did not exist and that these dispensing events violated the federal False Claims Act. The Company is defending itself against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Gill et al. v. CVS Health Corp. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (U.S. District Court for the Northern District of Illinois). In July 2022, the Delaware Attorney General&#x2019;s Office moved for partial intervention as to allegations under the Delaware false claims act related to not escheating alleged overpayments in this previously sealed &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; case. The federal government and the remaining states declined to intervene on other additional theories in the relator&#x2019;s complaint. The Company is defending itself against all of the claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2017, the Company also received a subpoena from the California Department of Insurance requesting documents concerning the Company&#x2019;s Omnicare pharmacies&#x2019; cycle fill process for assisted living facilities. The Company has been cooperating with the California Department of Insurance and providing documents and information in response to this subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company received a CID from the U.S. Attorney&#x2019;s Office for the Northern District of New York requesting documents and information in connection with a federal False Claims Act investigation concerning whether the Company&#x2019;s retail pharmacies improperly submitted certain insulin claims to Part D of the Medicare program rather than Part B of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to this CID.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Provider Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is named as a defendant in purported class actions and individual lawsuits arising out of its practices related to the payment of claims for services rendered to its members by providers with whom the Company has a contract and with whom the Company does not have a contract (&#x201c;out-of-network providers&#x201d;).&#160;Among other things, these lawsuits allege that the Company paid too little to its health plan members and/or providers for out-of-network services (including COVID-19 testing) and/or otherwise allege that the Company failed to timely or appropriately pay or administer claims and benefits (including the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s post payment audit and collection practices). Other major health insurers are the subject of similar litigation or have settled similar litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has received subpoenas and/or requests for documents and other information from, and been investigated by, state Attorneys General and other state and/or federal regulators, legislators and agencies relating to, and the Company is involved in other litigation regarding, its out-of-network benefit payment and administration practices. It is reasonably possible that others could initiate additional litigation or additional regulatory action against the Company with respect to its out-of-network benefit payment and/or administration practices.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;CMS Actions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS regularly audits the Company&#x2019;s performance to determine its compliance with CMS&#x2019;s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare beneficiaries. CMS uses various payment mechanisms to allocate and adjust premium payments to the Company&#x2019;s and other companies&#x2019; Medicare plans by considering the applicable health status of Medicare members as supported by information prepared, maintained and provided by providers. The Company collects claim and encounter data from providers and generally relies on providers to appropriately code their submissions to the Company and document their medical records, including the diagnosis data submitted to the Company with claims. CMS pays increased premiums to Medicare Advantage plans and Medicare PDP plans for members who have certain medical conditions identified with specific diagnosis codes. Federal regulators review and audit the providers&#x2019; medical records to determine whether those records support the related diagnosis codes that determine the members&#x2019; health status and the resulting risk-adjusted premium payments to the Company. In that regard, CMS has instituted risk adjustment data validation (&#x201c;RADV&#x201d;) audits of various Medicare Advantage plans, including certain of the Company&#x2019;s plans, to validate coding practices and supporting medical record documentation maintained by providers and the resulting risk-adjusted premium payments to the plans. CMS may require the Company to refund premium payments if the Company&#x2019;s risk-adjusted premiums are not properly supported by medical record data. The Office of the Inspector General of the HHS (the &#x201c;OIG&#x201d;) also is auditing the Company&#x2019;s risk adjustment-related data and that of other companies. The Company expects CMS and the OIG to continue these types of audits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012, in the &#x201c;Notice of Final Payment Error Calculation for Part C Medicare Advantage Risk Adjustment Validation Data (RADV) Contract-Level Audits,&#x201d; CMS revised its audit methodology for RADV contract-level audits to determine refunds payable by Medicare Advantage plans for contract year 2011 and forward. Under the revised methodology, among other things, CMS announced extrapolation of the error rate identified in the audit sample along with the application of a process to account for errors in the government&#x2019;s traditional fee-for-service Medicare program (&#x201c;FFS Adjuster&#x201d;). For contract years prior to 2011, CMS did not extrapolate sample error rates to the entire contract, nor did CMS propose to apply a FFS adjuster. By applying the FFS Adjuster, Medicare Advantage organizations would have been liable for repayments only to the extent that their extrapolated payment errors exceeded the error rate in Original Medicare, which could have impacted the extrapolated repayments to which Medicare Advantage organizations are subject. This revised contract-level audit methodology increased the Company&#x2019;s exposure to premium refunds to CMS based on incomplete medical records maintained by providers. In the RADV audit methodology CMS used from 2011-2013, CMS selected only a few of the Company&#x2019;s Medicare Advantage contracts for various contract years for contract-level RADV audits. In October 2018, CMS in the proposed rule (&#x201c;Proposed Rule&#x201d;) announced a new methodology for RADV audits targeting certain health conditions and members with many diagnostic conditions along with extrapolation for the error rates identified without use of a FFS Adjuster. While the rule was under proposal, CMS initiated contract-level RADV audits for the years 2014 and 2015 with this new RADV methodology without a final rule. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 30, 2023, CMS released the final rule (&#x201c;RADV Audit Rule&#x201d;), announcing it may use extrapolation for payment years 2018 forward, for both RADV audits and OIG audits and eliminated the application of a FFS Adjuster in Part C contract-level RADV audits of Medicare Advantage organizations. In the RADV Audit Rule, CMS indicated that it will use more than one audit methodology going forward and indicated CMS will audit contracts it believes are at the highest risk for overpayments based on its statistical modeling, citing a 2016 Governmental Accountability Office report that recommended selection of contract-level RADV audits with a focus on contracts likely to have high rates of improper payment, the highest coding intensity scores, and contracts with high levels of unsupported diagnoses from prior RADV audits.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently unable to predict which of its Medicare Advantage contracts will be selected for future audit, the amounts of any retroactive refunds for years prior to 2018 or prospective adjustments to Medicare Advantage premium payments made to the Company, the effect of any such refunds or adjustments on the actuarial soundness of the Company&#x2019;s Medicare Advantage bids, or whether any RADV audit findings would require the Company to change its method of estimating future premium revenue in future bid submissions to CMS or compromise premium assumptions made in the Company&#x2019;s bids &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for prior contract years, the current contract year or future contract years. Any premium or fee refunds or adjustments resulting from regulatory audits, whether as a result of RADV, Public Exchange related or other audits by CMS, the OIG or otherwise, including audits of the Company&#x2019;s MLR rebates, methodology and/or reports, could be material and could adversely affect the Company&#x2019;s operating results, cash flows and/or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RADV Audit Rule does not apply to the CMS Part C Improper Payment Measures audits nor the HHS-RADV programs. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare and Medicaid CIDs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received CIDs from the Civil Division of the DOJ in connection with a current investigation of the Company&#x2019;s patient chart review processes related to risk adjustment data submissions under Parts C and D of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to these CIDs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company received a CID from the SDNY requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stockholder Matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company&#x2019;s LTC business unit. The Company and its current and former officers and directors are defending themselves against these claims. Since filing, several of the cases have been consolidated, and the first-filed federal case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;City of Miami Fire Fighters&#x2019; and Police Officers&#x2019; Retirement Trust, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;et al. (formerly known as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Anarkat&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), was dismissed with prejudice in February 2021. Plaintiffs appealed that decision to the First Circuit after their motion for reconsideration was denied, and in August 2022 the First Circuit affirmed the dismissal. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re CVS Health Corp. Securities Act Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (formerly known as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Waterford&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re CVS Health Corp. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (formerly known as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;City of Warren&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Freundlich&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) have been stayed pending the outcome of the First Circuit appeal. Plaintiffs in both cases have since filed amended complaints, which the Company has moved to dismiss. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August and September 2020, two class actions under the Employee Retirement Income Security Act of 1974 (&#x201c;ERISA&#x201d;) were filed in the U.S. District Court for the District of Connecticut against CVS Health, Aetna, and several current and former executives, directors and/or members of Aetna&#x2019;s Compensation and Talent Management Committee: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Radcliffe v. Aetna Inc., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Flaim v. Aetna Inc., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;et al. The plaintiffs in these cases assert a variety of causes of action premised on allegations that the defendants breached fiduciary duties and engaged in prohibited transactions relating to participants in the Aetna 401(k) Plan&#x2019;s investment in company stock between December 3, 2017 and February 20, 2019, claiming losses related to the performance of the Company&#x2019;s LTC business unit. The district court consolidated the actions, and in October 2021, dismissed the consolidated action without prejudice. Plaintiffs filed an amended consolidated complaint, which the Company moved to dismiss. In October 2022, the court granted the Company&#x2019;s motion to dismiss with prejudice. Plaintiffs have appealed this decision to the Second Circuit.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also received a related document request pursuant to ERISA &#xa7; 104(b), to which the Company has responded. The Company and its current and former officers and directors are defending themselves against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company received a demand for inspection of books and records pursuant to Delaware Corporation Law Section 220 (the &#x201c;Demand&#x201d;). The Demand purports to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Legal and Regulatory Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a party to other legal proceedings and is subject to government investigations, inquiries and audits and has received and is cooperating with the government in response to CIDs, subpoenas, or similar process from various governmental agencies requesting information. These other legal proceedings and government actions include claims of or relating to bad faith, medical or professional malpractice, breach of fiduciary duty, claims processing, dispensing of medications, non-compliance with state and federal regulatory regimes, marketing misconduct, denial of or failure to timely or appropriately pay or administer claims and benefits, provider network structure (including the use of performance-based networks and termination of provider contracts), rescission of insurance coverage, improper disclosure or use of personal information, anticompetitive practices, general contractual matters, product liability, intellectual property litigation, and employment litigation. Some of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;these other legal proceedings are or are purported to be class actions or derivative claims. The Company is defending itself against the claims brought in these matters.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards to the Company and others of certain government contracts, particularly Medicaid contracts and other contracts with government customers in the Company&#x2019;s Health Care Benefits segment, frequently are subject to protests by unsuccessful bidders. These protests may result in awards to the Company being reversed, delayed, or modified. The loss or delay in implementation of any government contract could adversely affect the Company&#x2019;s operating results. The Company will continue to defend contract awards it receives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There also continues to be a heightened level of review and/or audit by regulatory authorities and legislators of, and increased litigation regarding, the Company&#x2019;s and the rest of the health care and related benefits industry&#x2019;s business and reporting practices, including premium rate increases, utilization management, development and application of medical policies, complaint, grievance and appeal processing, information privacy, provider network structure (including provider network adequacy, the use of performance-based networks and termination of provider contracts), provider directory accuracy, calculation of minimum medical loss ratios and/or payment of related rebates, delegated arrangements, rescission of insurance coverage, limited benefit health products, student health products, pharmacy benefit management practices (including manufacturers&#x2019; rebates, pricing, the use of narrow networks and the placement of drugs in formulary tiers), sales practices, customer service practices, vendor oversight, and claim payment practices (including payments to out-of-network providers).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a leading national health solutions company, the Company regularly is the subject of government actions of the types described above. These government actions may prevent or delay the Company from implementing planned premium rate increases and may result, and have resulted, in restrictions on the Company&#x2019;s businesses, changes to or clarifications of the Company&#x2019;s business practices, retroactive adjustments to premiums, refunds or other payments to members, beneficiaries, states or the federal government, withholding of premium payments to the Company by government agencies,&#160;assessments of damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company can give no assurance that its businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i)&#160;future enactment of new health care or other laws or regulations; (ii)&#160;the interpretation or application of existing laws or regulations as they may relate to one or more of the Company&#x2019;s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iii)&#160;pending or future federal or state government investigations of one or more of the Company&#x2019;s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iv)&#160;pending or future government audits, investigations or enforcement actions against the Company; (v)&#160;adverse developments in any pending &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuit against the Company, whether sealed or unsealed, or in any future &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuit that may be filed against the Company; or (vi)&#160;adverse developments in pending or future legal proceedings against the Company or affecting one or more of the industries in which the Company competes and/or the health care industry generally.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzE1Mzc_115be952-87c1-4ff6-81c7-3cd083897199"
      unitRef="usd">250000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <cvs:ContractualObligationsToMaintainLevelsOfSeparateAccounts
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIwODk_e82273c8-d9c2-437e-82bd-d0fa4d08a5cc"
      unitRef="usd">941000000</cvs:ContractualObligationsToMaintainLevelsOfSeparateAccounts>
    <cvs:ContractualObligationsToMaintainLevelsOfSeparateAccounts
      contextRef="i5b5114192110480ab4f260049ee8b103_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIwOTY_1150d26a-9fe8-4c39-a429-5deee4f21af6"
      unitRef="usd">1300000000</cvs:ContractualObligationsToMaintainLevelsOfSeparateAccounts>
    <cvs:GuarantorObligationsNumberOfLeases
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzM5NjA_d25fc9a3-12b4-4a21-b250-985488054631"
      unitRef="lease">67</cvs:GuarantorObligationsNumberOfLeases>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ib94af6bb921a4ca98da673595b30f6b8_D20220801-20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5MDM_f0912149-13ae-4546-8fe0-4ac99ed1e3a3"
      unitRef="usd">651000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <cvs:LegalSettlementPeriodOfPayment
      contextRef="i674238d29a96415e993c632fa76902ca_I20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5MjU_ccaf666b-4ae5-4176-a035-0f6c1c2464e1">P15Y</cvs:LegalSettlementPeriodOfPayment>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i3c90b72fd40546a18c44fdd0f007e70d_D20220301-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5NDA_2b491511-8454-4f41-b915-49e1055dcdef"
      unitRef="usd">-484000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <cvs:LegalSettlementPeriodOfPayment
      contextRef="i5f7c5a81f337450ca2ce09d3e8db9ce6_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5ODk_ee3782e1-59c0-4543-a3fd-ee692d98ec3a">P18Y</cvs:LegalSettlementPeriodOfPayment>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i5f7c5a81f337450ca2ce09d3e8db9ce6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTI5Njc_11d3d0cb-ea9b-4579-8224-852419b703f8"
      unitRef="usd">484000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i2fce56acdb3745c9979b048ae472c0b0_D20221201-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4MDI_6eaaff43-6d37-4e7f-95ca-0db6189711b4"
      unitRef="usd">4300000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LegalFees
      contextRef="i2fce56acdb3745c9979b048ae472c0b0_D20221201-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4MTY_b92a3bf1-1390-4f42-9a05-d8e1d1f83ca6"
      unitRef="usd">625000000</us-gaap:LegalFees>
    <cvs:LegalSettlementPeriodOfPayment
      contextRef="i5a63bb22a404440f94e6605a0d60ed27_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4Mjk_20eeecca-54ce-4726-861e-6add18feb41b">P10Y</cvs:LegalSettlementPeriodOfPayment>
    <cvs:LitigationSettlementNumberOfStatesElectedToJoin
      contextRef="i5a63bb22a404440f94e6605a0d60ed27_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTIxMjA_f01f6b9b-b4f9-4aa7-9640-1c9efed26533"
      unitRef="state">45</cvs:LitigationSettlementNumberOfStatesElectedToJoin>
    <cvs:LitigationSettlementNumberOfStatesSubjectToEarlierSettlements
      contextRef="id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTIxMjM_4ab64207-1119-4a82-b61e-fc0cc158a761"
      unitRef="state">3</cvs:LitigationSettlementNumberOfStatesSubjectToEarlierSettlements>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i57858d852b8743a5b17a414d3e2943ec_D20221201-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4MzE_c5d40c4a-a78f-48df-b3a9-6f8defe11894"
      unitRef="usd">113000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LegalFees
      contextRef="i57858d852b8743a5b17a414d3e2943ec_D20221201-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4NDc_988cc5c9-6c26-4ab0-a047-b6dea3fc3ba3"
      unitRef="usd">18000000</us-gaap:LegalFees>
    <cvs:LegalSettlementPeriodOfPayment
      contextRef="i0b86d678e65d40eb8ee5c07845a9969a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTA4NTk_7311b880-32e8-4876-951e-1707e34164e1">P10Y</cvs:LegalSettlementPeriodOfPayment>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ibaf08dadd0964ffeadc4c69adb91d80b_D20220701-20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTMwOTY_03dfe1e5-e4e2-40e5-ac2a-9119034797b7"
      unitRef="usd">-5200000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i636ddceefabd4069a95a70b2bdaf5197_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzEyNjQ0MzgzNzY0OTgy_cd5b8faf-030f-4f4f-ad8e-ff505893a8ef"
      unitRef="usd">-99000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LossContingencyAccrualCarryingValueNoncurrent
      contextRef="i7962defddb614936891d31be39fb3eac_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzY1OTcwNjk4MTI3MzA_67c6248c-51cb-47ef-b969-d67e9f4755b3"
      unitRef="usd">4800000000</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i8f3002f09a51435f89d2352f78379bf9_D20230101-20231231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTMxMjM_083750e5-37a9-4367-90d8-910285d1ccf8"
      unitRef="usd">500000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i9fe8dd796c0b4f6ea8bd03f8afa02daa_D20240101-20241231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIxOTkwMjMyOTMxMjM_e85145bb-4500-4168-9e14-28632fbe3e9d"
      unitRef="usd">500000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i3a4ebb735c614e6f82dbc3e891377121_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNjkvZnJhZzo1ZDYyNjBhZjU3MDM0N2VmYTA5MmI3MmRlMTIyYzgyZi90ZXh0cmVnaW9uOjVkNjI2MGFmNTcwMzQ3ZWZhMDkyYjcyZGUxMjJjODJmXzIzNjY5_414de537-90b7-434f-8685-1a5253145d6f"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzc1NTg_388ea5f9-2139-4d90-bfc2-a0f52384d389">Segment Reporting&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company&#x2019;s segments maintain separate financial information, and the Company&#x2019;s chief operating decision maker (the &#x201c;CODM&#x201d;) evaluates the segments&#x2019; operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company&#x2019;s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company&#x2019;s business nor reflect the Company&#x2019;s underlying business performance. See the reconciliation of consolidated operating income (GAAP measure) to consolidated adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company&#x2019;s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, 2021 and 2020, revenues from the federal government accounted for 18%, 17% and 16%, respectively, of the Company&#x2019;s consolidated total revenues, primarily related to contracts with CMS for coverage of Medicare-eligible individuals within the Health Care Benefits segment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of financial measures of the Company&#x2019;s segments to the consolidated totals:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Health Care&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmacy&#160;&lt;br/&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retail/&lt;br/&gt;LTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Corporate/&lt;br/&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Eliminations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;br/&gt;Totals&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Adjusted operating income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Adjusted operating income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Adjusted operating income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Total revenues of the Pharmacy Services segment include approximately $12.6 billion, $11.6 billion and $10.9 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;of retail co-payments for 2022, 2021 and 2020, respectively. See Note 1 &#x2018;&#x2018;Significant Accounting Policies&#x2019;&#x2019; for additional information about retail co-payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services segment clients enrolled in Maintenance Choice&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; elect to pick up maintenance prescriptions at one of the Company&#x2019;s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (GAAP measure)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office real estate optimization charges &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on divestiture of subsidiaries &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Opioid litigation charges &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on assets held for sale &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related integration costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Store impairments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(8)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition purchase price adjustment outside of measurement period &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(9)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receipt of fully reserved ACA risk corridor receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(10)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted operating income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company&#x2019;s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company&#x2019;s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company&#x2019;s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company&#x2019;s insurance products, the services performed for the Company&#x2019;s customers or the sale of the Company&#x2019;s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company&#x2019;s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company&#x2019;s and investors&#x2019; ability to compare the Company&#x2019;s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company&#x2019;s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company&#x2019;s new flexible work arrangement. The office real estate optimization charges are reflected in the Company&#x2019;s GAAP consolidated statement of operations in operating expenses within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift, which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022. In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers&#x2019; Compensation business, which the Company sold in July 2020. The gains on divestitures are reflected as a reduction of operating expenses in the Company&#x2019;s GAAP consolidated statements of operations within the Health Care Benefits segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2022, the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities. The opioid litigation charges are reflected within the Corporate/Other segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2022, the loss on assets held for sale relates to the LTC reporting unit within the Retail/LTC segment. The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the third quarter of 2022. As of December 31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter of 2022, an incremental loss on assets held for sale was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. During 2022, the loss on assets held for sale also relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its Thailand business, which was included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2021 and 2020, acquisition-related integration costs relate to the acquisition of Aetna. The acquisition-related integration costs are reflected in the Company&#x2019;s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. The store impairment charge is reflected within the Retail/LTC segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2021, the goodwill impairment charge relates to an impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(9)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2021, the Company received $61&#160;million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company&#x2019;s GAAP consolidated statement of operations as a reduction of operating expenses within the Health Care Benefits segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt"&gt;In 2020, the Company received $313&#160;million owed to it under the ACA&#x2019;s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA&#x2019;s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307&#160;million in the Company&#x2019;s GAAP consolidated statement of operations within the Health Care Benefits segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzQx_8c786a14-e49f-4e8b-88ed-abaee5bead3c"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaeb70648911a491891b5b5b40830d2fe_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzE1NzY_38c1526b-1c94-4054-bc0e-5323b95c1f8a"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3a7e1c1a8e154045870fe18d7ed128a2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzE1ODA_77456349-8cab-4c89-b4c9-89fca10f80ba"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idd64cbb3284d45b6bf1aa429308ea5b6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzE1ODc_20b7d2d0-980a-4174-bf69-5b14f7310d49"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzc1NTk_5d35aba7-92b9-43af-a73e-38eca4e1ccf1">&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Health Care&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmacy&#160;&lt;br/&gt;Services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retail/&lt;br/&gt;LTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Corporate/&lt;br/&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Eliminations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;br/&gt;Totals&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Adjusted operating income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Adjusted operating income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Adjusted operating income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Total revenues of the Pharmacy Services segment include approximately $12.6 billion, $11.6 billion and $10.9 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;of retail co-payments for 2022, 2021 and 2020, respectively. See Note 1 &#x2018;&#x2018;Significant Accounting Policies&#x2019;&#x2019; for additional information about retail co-payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services segment clients enrolled in Maintenance Choice&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; elect to pick up maintenance prescriptions at one of the Company&#x2019;s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItMS0xLTEtMTY3OTA4_efcacc5e-7c9e-4a19-b322-5f0b02316c2b"
      unitRef="usd">90844000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItMy0xLTEtMTY3OTA4_095a9fa6-2c20-452b-be04-0c90039795c2"
      unitRef="usd">157787000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItNS0xLTEtMTY3OTA4_174b76c6-cab5-45f6-8e69-ac9f37f0faee"
      unitRef="usd">72874000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItNy0xLTEtMTY3OTA4_6317208b-a42c-4911-8c44-7ed1187edc42"
      unitRef="usd">124000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzItMTEtMS0xLTE2NzkwOA_06d1e9d7-5208-4f87-96f9-5a6252c0cda6"
      unitRef="usd">321629000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aff3de0cc7c488a8aaa1c33fd802ab1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzMtMS0xLTEtMTY3OTA4_402bd981-f392-4d08-95f9-0a7e65b36ace"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14525e9b549048f4b399842e4567a558_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzMtMy0xLTEtMTY3OTA4_9d4813e3-5677-4e4e-b5c6-32ac22a8d630"
      unitRef="usd">11449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55c34d747b754e57bfd880817586c1fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzMtNS0xLTEtMTY3OTA4_1522ebba-e4e5-47c8-8e4e-721a8bfc8b44"
      unitRef="usd">33764000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzMtOS0xLTEtMTY3OTA4_9880ab81-f8c4-4f72-8aeb-6006370d986e"
      unitRef="usd">-45302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetInvestmentIncome
      contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtMS0xLTEtMTY3OTA4_a32b2e7a-0050-4810-b6e6-f6f1eae453ca"
      unitRef="usd">476000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtMy0xLTEtMTY3OTA4_cd255e30-de0b-4a52-b7f4-d655c51cde6d"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtNS0xLTEtMTY3OTA4_058d67a7-2155-4811-add2-553bf382ebaa"
      unitRef="usd">-44000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtNy0xLTEtMTY3OTA4_2180c008-314c-4655-800c-197fbd99d553"
      unitRef="usd">406000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtOS0xLTEtMTY3OTA4_72ed392c-6cb2-479c-a2fe-ab83fc4243d6"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzQtMTEtMS0xLTE2NzkwOA_5b80f155-a5c0-4ad8-a120-e575439d6a25"
      unitRef="usd">838000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues
      contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMS0xLTEtMTY3OTA4_a718b28d-82d7-49e5-94a0-2cf3f8e9f7b6"
      unitRef="usd">91409000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMS0xLTEtMTY3OTA4_cce8e3dd-bd18-471d-ab21-c43bd2ef29d8"
      unitRef="usd">91409000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMy0xLTEtMTY3OTA4_4ef0244b-4664-4ea7-ba4f-ffc775187874"
      unitRef="usd">169236000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMy0xLTEtMTY3OTA4_f88c8356-5dc6-493c-b62c-56e4daac4ce0"
      unitRef="usd">169236000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtNS0xLTEtMTY3OTA4_65dea28f-1fa0-43e5-ad5a-99629043103b"
      unitRef="usd">106594000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtNS0xLTEtMTY3OTA4_fed8c70a-6eae-4c76-8377-4d6e99e43da4"
      unitRef="usd">106594000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtNy0xLTEtMTY3OTA4_2ae9bbab-ccc2-4f9d-9093-f41008861d3c"
      unitRef="usd">530000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtNy0xLTEtMTY3OTA4_a87d0a1e-6cdf-4fe4-b4a5-d2c454b0e25a"
      unitRef="usd">530000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtOS0xLTEtMTY3OTA4_1e1f225c-a0aa-4a84-8d00-a03daa3d1341"
      unitRef="usd">-45302000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtOS0xLTEtMTY3OTA4_40850830-19f6-4605-a95d-77138e55935e"
      unitRef="usd">-45302000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzUtMTEtMS0xLTE2NzkwOA_379d3685-8fd2-4d66-9862-941bf277f76d"
      unitRef="usd">322467000000</us-gaap:Revenues>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtMS0xLTEtMTY3OTA4_0e6c6708-826a-4d5e-9e25-c113f196d20d"
      unitRef="usd">5984000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtMy0xLTEtMTY3OTA4_91550341-d05a-4a5e-857e-3f3b300d2383"
      unitRef="usd">7356000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtNS0xLTEtMTY3OTA4_c9aee013-bb7f-4730-8f65-5a5da5123a55"
      unitRef="usd">6705000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtNy0xLTEtMTY3OTA4_5545bbed-ecf7-4b7d-923e-9a3703e7d071"
      unitRef="usd">-1785000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtOS0xLTEtMTY3OTA4_d14fb90e-6662-45a6-9a76-98d576569a8d"
      unitRef="usd">-728000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzYtMTEtMS0xLTE2NzkwOA_ed390f8d-7659-4215-b5d7-ff057ad4628e"
      unitRef="usd">17532000000</cvs:AdjustedOperatingIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctMS0xLTEtMTY3OTA4_e6b86021-e793-4441-afd0-8352a279a8f8"
      unitRef="usd">1629000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctMy0xLTEtMTY3OTA4_c9654708-4996-48fa-acfb-e4a7f0e0249f"
      unitRef="usd">567000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i91010ed9c1dd4d2cbd5bcca2fd5615e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctNS0xLTEtMTY3OTA4_550921e4-401f-4229-b267-750bb7c16416"
      unitRef="usd">1813000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2ea4259a69e74e2a8b1fc8a28a2343bc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctNy0xLTEtMTY3OTA4_c66b29b2-6e07-4132-b1f1-8aba1eb2be36"
      unitRef="usd">238000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icdab8c6f4f0f438bbff2315a6a678380_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctOS0xLTEtMTY3OTA4_eb8a2deb-13a2-45e7-9298-e3f882e626fb"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzctMTEtMS0xLTE2NzkwOA_3648433e-1b20-4482-bf44-aa1c2df6e909"
      unitRef="usd">4247000000</us-gaap:DepreciationDepletionAndAmortization>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktMS0xLTEtMTY3OTA4_9dbd460d-c076-47b6-b95e-41a70b963040"
      unitRef="usd">81515000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktMy0xLTEtMTY3OTA4_2a00bdef-cb11-4681-a44c-89c129fbc6d5"
      unitRef="usd">143194000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktNS0xLTEtMTY3OTA4_d484da23-2dc3-462a-aa38-0db20583f9b9"
      unitRef="usd">66078000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktNy0xLTEtMTY3OTA4_91dc587c-a607-4392-86f1-42b3ea0ef182"
      unitRef="usd">125000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzktMTEtMS0xLTE2NzkwOA_18daf97d-0a0d-442c-aa99-e03133bf875a"
      unitRef="usd">290912000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7714f3521cb4944817a68243192c7b1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEwLTEtMS0xLTE2NzkwOA_fdd1e171-99b2-4dd4-a0c1-cd112507ac4c"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24e89b8dd8884731928828b40d4e94d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEwLTMtMS0xLTE2NzkwOA_71792485-1fa1-4f78-917b-7fe9096ca85b"
      unitRef="usd">9828000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15c6773f805e4bd59d68e8f7a0aa3308_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEwLTUtMS0xLTE2NzkwOA_4bda0fde-fdcb-41e0-b48f-c34ba0f2f50a"
      unitRef="usd">34010000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEwLTktMS0xLTE2NzkwOA_480e229f-f5ed-484c-967c-7c3098c4cc2b"
      unitRef="usd">-43923000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetInvestmentIncome
      contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTEtMS0xLTE2NzkwOA_c0f36c9e-b64e-48b0-9c38-e72f5b9321dc"
      unitRef="usd">586000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTMtMS0xLTE2NzkwOA_7eff9f76-e474-4e25-aa8f-45e3c32d7c8e"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTUtMS0xLTE2NzkwOA_062b683e-8128-426d-b387-6cbbba9ca0c0"
      unitRef="usd">17000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTctMS0xLTE2NzkwOA_215b8391-3f0e-4327-9ad4-1dad57fa5c49"
      unitRef="usd">596000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTktMS0xLTE2NzkwOA_6aef284f-8e82-4cbe-b670-5b47e52db74b"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzExLTExLTEtMS0xNjc5MDg_5adf357e-76fb-42f9-8b02-26349158834c"
      unitRef="usd">1199000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues
      contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTEtMS0xLTE2NzkwOA_411ade52-fff4-4873-9074-e6dcaf3c5df0"
      unitRef="usd">82186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTMtMS0xLTE2NzkwOA_0337b6fe-3dfe-47ee-92ac-7ea8bbe0f5f0"
      unitRef="usd">153022000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTUtMS0xLTE2NzkwOA_380c6467-d797-417f-a7cb-c32512eba616"
      unitRef="usd">100105000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTctMS0xLTE2NzkwOA_7b2b9fbd-1e99-4df2-98b6-cb0f0942e234"
      unitRef="usd">721000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTktMS0xLTE2NzkwOA_fab02010-9f53-499f-9942-ada6fbce3476"
      unitRef="usd">-43923000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEyLTExLTEtMS0xNjc5MDg_760bde49-9d17-4943-9931-6a4b673a1cad"
      unitRef="usd">292111000000</us-gaap:Revenues>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTEtMS0xLTE2NzkwOA_54699239-17aa-4595-8441-41f3d6a046be"
      unitRef="usd">5012000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTMtMS0xLTE2NzkwOA_9f4a2630-a34c-4ea0-8497-b1a1860b9065"
      unitRef="usd">6859000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTUtMS0xLTE2NzkwOA_f753762f-d388-467d-8f04-d5136cbda1c3"
      unitRef="usd">7623000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTctMS0xLTE2NzkwOA_ed786146-cd4b-41e3-9041-e70ce92d1535"
      unitRef="usd">-1471000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTktMS0xLTE2NzkwOA_3090868f-e49e-4fef-8660-69673b48502d"
      unitRef="usd">-711000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzEzLTExLTEtMS0xNjc5MDg_bcbe1a52-f5e3-4c05-ae43-229486c23833"
      unitRef="usd">17312000000</cvs:AdjustedOperatingIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i43f953b7883c4c4189f1bef868f3e177_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTEtMS0xLTE2NzkwOA_0766d67e-74a6-42fb-b47c-653b21f7909f"
      unitRef="usd">1837000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTMtMS0xLTE2NzkwOA_73ba48b6-b977-4ff3-ab3b-be0c3df57b37"
      unitRef="usd">576000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id79cf3c31a07452f96021f0bfda9c68f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTUtMS0xLTE2NzkwOA_e23ad140-5eb7-45f3-a53d-8f604ca28852"
      unitRef="usd">1884000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3a86428f4abe4f7a9fa138d3b3f13fa2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTctMS0xLTE2NzkwOA_8295de76-9a56-47d0-ab04-bc86bba6ab3d"
      unitRef="usd">215000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7d2958fd6c6b4353baf19a814f5b7f78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTktMS0xLTE2NzkwOA_e6ec3336-b788-4981-81b0-c7caa7b2c903"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE0LTExLTEtMS0xNjc5MDg_b4e5cc24-e384-465a-8f1d-416fe74fcbaf"
      unitRef="usd">4512000000</us-gaap:DepreciationDepletionAndAmortization>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTEtMS0xLTE2NzkwOA_1c42bcc5-9d45-4e5c-99eb-9837fe798e9f"
      unitRef="usd">74926000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTMtMS0xLTE2NzkwOA_4bd58cd2-db8c-4dac-8571-177e8c43d4f5"
      unitRef="usd">132663000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTUtMS0xLTE2NzkwOA_1326239e-9830-41e9-b4d8-e8918438fac9"
      unitRef="usd">60208000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTctMS0xLTE2NzkwOA_7c82410e-156b-4ca4-848f-6a8fd909c36a"
      unitRef="usd">111000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE2LTExLTEtMS0xNjc5MDg_17fdaf31-3101-476c-8980-901fcf26c869"
      unitRef="usd">267908000000</cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3fe920a5d654530aaf6d123f400d878_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE3LTEtMS0xLTE2NzkwOA_49a76d93-11b3-4407-b81b-6fc9aed412aa"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id26c945fe20b40d684582e97afbd1616_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE3LTMtMS0xLTE2NzkwOA_bdcc529a-8561-483d-80a5-0335314c1cd9"
      unitRef="usd">9275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99de3811ad9244d2987587cc4326b954_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE3LTUtMS0xLTE2NzkwOA_28a6c2ee-1c0f-409d-ab4c-b7dc70dac051"
      unitRef="usd">30990000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE3LTktMS0xLTE2NzkwOA_e518a53c-3d40-41bc-9427-bd03e417c7a2"
      unitRef="usd">-40323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetInvestmentIncome
      contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTEtMS0xLTE2NzkwOA_507ad542-d180-4513-af00-c4d70fbc2915"
      unitRef="usd">483000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTMtMS0xLTE2NzkwOA_47fba327-65dc-457a-87b7-434885926f03"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTUtMS0xLTE2NzkwOA_35ab4a29-5b06-4908-8f75-be08573c19f8"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTctMS0xLTE2NzkwOA_a42d7b2e-5613-453f-86d3-76560dca13c6"
      unitRef="usd">315000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTktMS0xLTE2NzkwOA_07fc4485-3f4a-4c35-a44d-194aa7a356a6"
      unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE4LTExLTEtMS0xNjc5MDg_4b183423-00ed-44c8-9d70-0dff6066e1ab"
      unitRef="usd">798000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues
      contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTEtMS0xLTE2NzkwOA_a10f74a2-a63c-45c4-8fc3-6191e9861281"
      unitRef="usd">75467000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTMtMS0xLTE2NzkwOA_b036dc54-ac0f-41f1-95ca-434d314c7552"
      unitRef="usd">141938000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTUtMS0xLTE2NzkwOA_ef35134a-8836-4c4e-9987-72650f503964"
      unitRef="usd">91198000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTctMS0xLTE2NzkwOA_58282756-cd61-48c0-929a-b81ade4ac52c"
      unitRef="usd">426000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTktMS0xLTE2NzkwOA_7af0f785-8f9d-48aa-8c0e-6d577d57ab72"
      unitRef="usd">-40323000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzE5LTExLTEtMS0xNjc5MDg_f0ffc924-48dd-4a73-8e90-52427bb19000"
      unitRef="usd">268706000000</us-gaap:Revenues>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTEtMS0xLTE2NzkwOA_832b7892-5596-4e70-a1d2-ae023451b497"
      unitRef="usd">6188000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTMtMS0xLTE2NzkwOA_f593b718-e514-46a2-9cf2-d054ed260533"
      unitRef="usd">5688000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTUtMS0xLTE2NzkwOA_e3169ca1-59bd-4611-a61d-7837bfe4e075"
      unitRef="usd">6146000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTctMS0xLTE2NzkwOA_5b365e40-c080-432c-8c97-f172ad5728e1"
      unitRef="usd">-1306000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTktMS0xLTE2NzkwOA_4991426a-fc63-46e6-a0ca-7cea1119139b"
      unitRef="usd">-708000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIwLTExLTEtMS0xNjc5MDg_55807ed2-8967-424e-aa1d-2c7d3ae21a46"
      unitRef="usd">16008000000</cvs:AdjustedOperatingIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i98f6191883ad4d0380c752c62d9fb2c1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTEtMS0xLTE2NzkwOA_1464a6a6-2cd9-4292-95e5-2a520dc7403d"
      unitRef="usd">1832000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTMtMS0xLTE2NzkwOA_a3d97aaf-bf4e-49f7-9f97-ab8f364efbb0"
      unitRef="usd">612000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i28eeeb149fb64382859d0b27efc526d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTUtMS0xLTE2NzkwOA_b602ca44-41e2-43b8-9888-d9640c1f7726"
      unitRef="usd">1801000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic6675c33b5454a11972c19cf6c2aa0c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTctMS0xLTE2NzkwOA_1e6bbc89-785b-4ca9-9477-01a74ea8be15"
      unitRef="usd">196000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i018840b33c8f459ead3a92ca9ad08c11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTktMS0xLTE2NzkwOA_51c54a64-fc63-4d42-8908-d68e0be045cc"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTpkNjg5ODdmOWE2ZWM0YTc3YTBiYTA4ODBkZmQ0NDQ4Mi90YWJsZXJhbmdlOmQ2ODk4N2Y5YTZlYzRhNzdhMGJhMDg4MGRmZDQ0NDgyXzIxLTExLTEtMS0xNjc5MDg_fd6b5b5a-88f4-4863-abb1-0dbd83da7d06"
      unitRef="usd">4441000000</us-gaap:DepreciationDepletionAndAmortization>
    <cvs:NetRevenuesRetailCoPayments
      contextRef="if0f02ba5f7eb4876ba0bda8579c25cf5_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzIwMTc_ad4b4ff7-dc8f-4862-a10e-23dc0f3f98e8"
      unitRef="usd">12600000000</cvs:NetRevenuesRetailCoPayments>
    <cvs:NetRevenuesRetailCoPayments
      contextRef="id6b989c388b64876a6667f48ff8a1785_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzIwMjE_18c00fcd-0882-496f-886b-930cc6cc954a"
      unitRef="usd">11600000000</cvs:NetRevenuesRetailCoPayments>
    <cvs:NetRevenuesRetailCoPayments
      contextRef="if4d4c78494854b9cb9a8b1b9cd72a2f0_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzIwMjg_961f3edc-97e8-4ee0-bd48-39af280a9ca2"
      unitRef="usd">10900000000</cvs:NetRevenuesRetailCoPayments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzc1NDk_95a32427-babd-49b3-921c-4a7f325b1502">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December&#160;31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;In&#160;millions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (GAAP measure)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office real estate optimization charges &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on divestiture of subsidiaries &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Opioid litigation charges &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on assets held for sale &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related integration costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Store impairments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(8)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition purchase price adjustment outside of measurement period &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(9)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receipt of fully reserved ACA risk corridor receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(10)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted operating income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_____________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company&#x2019;s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company&#x2019;s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company&#x2019;s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company&#x2019;s insurance products, the services performed for the Company&#x2019;s customers or the sale of the Company&#x2019;s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company&#x2019;s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company&#x2019;s and investors&#x2019; ability to compare the Company&#x2019;s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company&#x2019;s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company&#x2019;s new flexible work arrangement. The office real estate optimization charges are reflected in the Company&#x2019;s GAAP consolidated statement of operations in operating expenses within the Health Care Benefits, Corporate/Other and Pharmacy Services segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift, which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022. In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers&#x2019; Compensation business, which the Company sold in July 2020. The gains on divestitures are reflected as a reduction of operating expenses in the Company&#x2019;s GAAP consolidated statements of operations within the Health Care Benefits segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2022, the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities. The opioid litigation charges are reflected within the Corporate/Other segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2022, the loss on assets held for sale relates to the LTC reporting unit within the Retail/LTC segment. The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the third quarter of 2022. As of December 31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter of 2022, an incremental loss on assets held for sale was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. During 2022, the loss on assets held for sale also relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its Thailand business, which was included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2021 and 2020, acquisition-related integration costs relate to the acquisition of Aetna. The acquisition-related integration costs are reflected in the Company&#x2019;s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. The store impairment charge is reflected within the Retail/LTC segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2021, the goodwill impairment charge relates to an impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(9)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;In 2021, the Company received $61&#160;million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company&#x2019;s GAAP consolidated statement of operations as a reduction of operating expenses within the Health Care Benefits segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt"&gt;In 2020, the Company received $313&#160;million owed to it under the ACA&#x2019;s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA&#x2019;s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307&#160;million in the Company&#x2019;s GAAP consolidated statement of operations within the Health Care Benefits segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzEtMS0xLTEtMTY3OTA4_6e1f3681-7c76-4716-a9da-f741edb594f0"
      unitRef="usd">7746000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzEtMy0xLTEtMTY3OTA4_ddf26fea-ec14-4237-99fc-1ec40c140033"
      unitRef="usd">13193000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzEtNS0xLTEtMTY3OTA4_4a96bd9e-ce29-4736-94ec-7c3960f05205"
      unitRef="usd">13911000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzItMS0xLTEtMTY3OTA4_b9543cb2-d9c9-478d-b27c-7a7604491c1f"
      unitRef="usd">1808000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzItMy0xLTEtMTY3OTA4_eb6a781b-9f51-48cf-b465-feba4d8da1f1"
      unitRef="usd">2259000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzItNS0xLTEtMTY3OTA4_6f49f668-84b9-4ab8-9ef7-19c6b968e6b4"
      unitRef="usd">2341000000</us-gaap:AmortizationOfIntangibleAssets>
    <cvs:OfficeRealEstateOptimizationCharges
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMS0xLTEtMjA1MDQx_54321e3c-1363-4836-bafe-98544abe9332"
      unitRef="usd">117000000</cvs:OfficeRealEstateOptimizationCharges>
    <cvs:OfficeRealEstateOptimizationCharges
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMy0xLTEtMjA1MDQ5_91d2ddb4-e77c-4dbf-8bbf-2a263ed413ad"
      unitRef="usd">0</cvs:OfficeRealEstateOptimizationCharges>
    <cvs:OfficeRealEstateOptimizationCharges
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtNS0xLTEtMjA1MDU3_4fc360b2-813d-4a63-9d1c-9c224e0a5b3d"
      unitRef="usd">0</cvs:OfficeRealEstateOptimizationCharges>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMS0xLTEtMjEyOTk0_202d8385-7a51-4e18-84ed-57c6645f32fe"
      unitRef="usd">475000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMy0xLTEtMjEyOTk0_4aff3041-2e0b-428f-aad6-121dff6e3dbb"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtNS0xLTEtMjEyOTk0_397843c3-0097-45e5-bcb1-85457c9fb879"
      unitRef="usd">269000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMS0xLTEtMTk5MjEz_cfead81b-2e34-4db1-b80a-5f6019f47ec7"
      unitRef="usd">-5803000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMy0xLTEtMTk5MjI3_373ffe44-71c7-4951-9f7e-bba29122f112"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtNS0xLTEtMTk5MjQy_b623bbfe-7f43-4e3b-8233-1136fdb93f9e"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMS0xLTEtMTk5MjEz_f44f1c2b-fc7a-43af-b088-9b69e02ef6ae"
      unitRef="usd">2533000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMy0xLTEtMTk5MjI3_b7a7fd62-2841-4f1e-832d-10b8ab4daae8"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtNS0xLTEtMTk5MjQy_e435394a-969c-4618-ae27-f122d78de7c3"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMS0xLTEtMTY3OTA4_8688194d-e90a-4dcc-8bb4-5089e364c91e"
      unitRef="usd">0</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtMy0xLTEtMTY3OTA4_e28d0a4a-a69d-46fd-95d1-261479f89971"
      unitRef="usd">132000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzMtNS0xLTEtMTY3OTA4_961c87fe-65c9-4686-8e7d-b69ddad5c570"
      unitRef="usd">332000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <cvs:StoreImpairmentCharges
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMS0xLTEtMTY3OTA4_ddf2c31e-94fd-4ac5-bc92-2c20e90b340c"
      unitRef="usd">0</cvs:StoreImpairmentCharges>
    <cvs:StoreImpairmentCharges
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtMy0xLTEtMTY3OTA4_c74e89d0-7363-472e-878c-7dce7911a0e2"
      unitRef="usd">1358000000</cvs:StoreImpairmentCharges>
    <cvs:StoreImpairmentCharges
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzQtNS0xLTEtMTY3OTA4_8229dfec-7b48-46c6-967f-802460e88113"
      unitRef="usd">0</cvs:StoreImpairmentCharges>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzUtMS0xLTEtMTY3OTA4_42c3a0fe-c552-4d25-a1f1-086a0cbbf797"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzUtMy0xLTEtMTY3OTA4_425ecedd-0f24-4483-b4e1-5e3563d114e8"
      unitRef="usd">431000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzUtNS0xLTEtMTY3OTA4_b9e886ec-b066-4152-bab4-48061d55850b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzYtMS0xLTEtMTY3OTA4_b14f53b5-128d-404a-a439-b8086f1176ce"
      unitRef="usd">0</cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod>
    <cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzYtMy0xLTEtMTY3OTA4_36467592-263b-4c25-8c4f-f2a774d4e1bd"
      unitRef="usd">61000000</cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod>
    <cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzYtNS0xLTEtMTY3OTA4_fdf8c5d0-f8d1-4e87-bb20-084d9fc9dfb8"
      unitRef="usd">0</cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzgtMS0xLTEtMTY3OTA4_51b2942f-b1f6-4992-bc9c-79e11ca79ec4"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzgtMy0xLTEtMTY3OTA4_ab46efb0-4f69-4247-9f31-a248c51b628a"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzgtNS0xLTEtMTY3OTA4_cd0afc84-3e08-42ad-89a4-bb6eece8b473"
      unitRef="usd">307000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzktMS0xLTEtMTY3OTA4_149489ea-faba-45e6-9293-526771a891b3"
      unitRef="usd">17532000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzktMy0xLTEtMTY3OTA4_bcbe1a52-f5e3-4c05-ae43-229486c23833"
      unitRef="usd">17312000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:AdjustedOperatingIncomeLoss
      contextRef="i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90YWJsZTo2NzJiZjg3ODFlODQ0YWMyYTU1ZTMzMzkyZTc5MTViZS90YWJsZXJhbmdlOjY3MmJmODc4MWU4NDRhYzJhNTVlMzMzOTJlNzkxNWJlXzktNS0xLTEtMTY3OTA4_55807ed2-8967-424e-aa1d-2c7d3ae21a46"
      unitRef="usd">16008000000</cvs:AdjustedOperatingIncomeLoss>
    <cvs:NumberOfStoresPlannedClosure
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzUzODI_74b680d3-ef03-4a79-8936-1e6060669882"
      unitRef="store">900</cvs:NumberOfStoresPlannedClosure>
    <cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
      contextRef="i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzU5Njc_5cc63af6-bb7d-44ce-a8fa-ed44d068eeed"
      unitRef="usd">61000000</cvs:BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod>
    <us-gaap:GainContingencyUnrecordedAmount
      contextRef="i51c77ad05d064fde8d6341467c3515ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzcxNzc_d697bb92-e4df-4c08-89c1-3b68cdd630be"
      unitRef="usd">313000000</us-gaap:GainContingencyUnrecordedAmount>
    <cvs:FormerGainContingencyRecognizedInCurrentPeriodBeforeTax
      contextRef="ie7a79d946b244fbe83b985e471a79655_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzIvZnJhZzowZDYzMzM4Mzk5M2Q0NjYyYThhNzZiNDYyYjhjMzU5Yi90ZXh0cmVnaW9uOjBkNjMzMzgzOTkzZDQ2NjJhOGE3NmI0NjJiOGMzNTliXzc0Mzk_cf459587-ed05-4053-b8a8-26b38fada4bc"
      unitRef="usd">307000000</cvs:FormerGainContingencyRecognizedInCurrentPeriodBeforeTax>
    <dei:AuditorName
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzUvZnJhZzphYTZjMzRmZTMxYjE0YTZiODcyOWI0NzAxMzA1N2ZiNi90ZXh0cmVnaW9uOmFhNmMzNGZlMzFiMTRhNmI4NzI5YjQ3MDEzMDU3ZmI2XzM4NzU_c792fdfc-2391-4e0e-969e-6655500d254d">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="if7774b520eae495587e1c8cd72f169e5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xNzUvZnJhZzphYTZjMzRmZTMxYjE0YTZiODcyOWI0NzAxMzA1N2ZiNi90ZXh0cmVnaW9uOmFhNmMzNGZlMzFiMTRhNmI4NzI5YjQ3MDEzMDU3ZmI2XzM4NzQ_e6ce0747-693b-4f59-89da-805c57dff2b1">Boston, Massachusetts</dei:AuditorLocation>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtMTAtMS0xLTE2NzkwOA_4d9dee0a-de0c-4824-96a7-b2568bdfa528"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtMTAtMS0xLTE2NzkwOA_4d9dee0a-de0c-4824-96a7-b2568bdfa528"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtOC0xLTEtMTY3OTA4_e9262b61-efbc-4ef7-a559-88549e16e324"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtOC0xLTEtMTY3OTA4_e9262b61-efbc-4ef7-a559-88549e16e324"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtNi0xLTEtMTY3OTA4_99031c0f-9bb1-4e9b-a04b-d1f529a110ab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtNi0xLTEtMTY3OTA4_99031c0f-9bb1-4e9b-a04b-d1f529a110ab"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyMw_46f4594b-33de-4e6a-93d6-a2d142101981" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyMw_46f4594b-33de-4e6a-93d6-a2d142101981" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the adoption of <xhtml:span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzY1OTcwNjk3NjgxNzQ_dd91000a-d118-4a7c-8b68-d85f1dcfda5b">Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13</xhtml:span>, </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Topic 326), which resulted in a reduction to retained earnings of $3&#160;million during the year ended December 31, 2020.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtMTAtMS0xLTE2NzkwOA_4d9dee0a-de0c-4824-96a7-b2568bdfa528"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyMw_46f4594b-33de-4e6a-93d6-a2d142101981"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtOC0xLTEtMTY3OTA4_e9262b61-efbc-4ef7-a559-88549e16e324"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyMw_46f4594b-33de-4e6a-93d6-a2d142101981"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzQtNi0xLTEtMTY3OTA4_99031c0f-9bb1-4e9b-a04b-d1f529a110ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyMw_46f4594b-33de-4e6a-93d6-a2d142101981"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktMi0xLTEtMTY3OTA4_cf85c9c6-30f6-47f0-9d82-59780ed91d16"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktMi0xLTEtMTY3OTA4_cf85c9c6-30f6-47f0-9d82-59780ed91d16"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTUtMS0xLTE2NzkwOA_6b7272ad-9760-4165-8a9f-eef3576673fb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTUtMS0xLTE2NzkwOA_6b7272ad-9760-4165-8a9f-eef3576673fb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTItMS0xLTE2NzkwOA_b320eab6-797c-4b05-8ca2-c960aa530c2e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTItMS0xLTE2NzkwOA_b320eab6-797c-4b05-8ca2-c960aa530c2e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTUtMS0xLTE2NzkwOA_a3020230-8e8d-4d1f-be1c-451c50e0569a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTUtMS0xLTE2NzkwOA_a3020230-8e8d-4d1f-be1c-451c50e0569a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTUtMS0xLTE2NzkwOA_ed5a3e75-ed47-445a-843f-f11cccade6f4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTUtMS0xLTE2NzkwOA_ed5a3e75-ed47-445a-843f-f11cccade6f4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTItMS0xLTE2NzkwOA_a802b61d-e3fc-401c-8a0e-c9a451456886"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTItMS0xLTE2NzkwOA_a802b61d-e3fc-401c-8a0e-c9a451456886"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTItMS0xLTE2NzkwOA_61a94270-718d-49f2-8a89-ac9a52290499"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTItMS0xLTE2NzkwOA_61a94270-718d-49f2-8a89-ac9a52290499"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTUtMS0xLTE2NzkwOA_d103f2c8-8949-463e-a6a6-bc4b87160d51"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTUtMS0xLTE2NzkwOA_d103f2c8-8949-463e-a6a6-bc4b87160d51"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTItMS0xLTE2NzkwOA_2493e6ed-878f-4a03-8082-5b7df50b5510"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTItMS0xLTE2NzkwOA_2493e6ed-878f-4a03-8082-5b7df50b5510"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMi0xLTEtMTY3OTA4_a1102af3-6a6d-4ab7-9a37-152583f52aed"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMi0xLTEtMTY3OTA4_a1102af3-6a6d-4ab7-9a37-152583f52aed"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktNS0xLTEtMTY3OTA4_4b2d1fa7-2942-4c9a-bc7e-a667d42a0eb9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktNS0xLTEtMTY3OTA4_4b2d1fa7-2942-4c9a-bc7e-a667d42a0eb9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTUtMS0xLTE2NzkwOA_6be73b7d-7940-4a20-a6a2-d323e75cf34c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTUtMS0xLTE2NzkwOA_6be73b7d-7940-4a20-a6a2-d323e75cf34c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNS0xLTEtMTY3OTA4_899a6f82-b6f8-43bd-b579-b98c84fb2c90"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNS0xLTEtMTY3OTA4_899a6f82-b6f8-43bd-b579-b98c84fb2c90"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMi0xLTEtMTY3OTA4_cc9c228e-d25e-42a5-afe7-dd4be4f4ded9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMi0xLTEtMTY3OTA4_cc9c228e-d25e-42a5-afe7-dd4be4f4ded9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTItMS0xLTE2NzkwOA_803aff9c-7641-44f4-b3a5-a5093fcbccd2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTItMS0xLTE2NzkwOA_803aff9c-7641-44f4-b3a5-a5093fcbccd2"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Treasury shares include 1 million shares held in trust for each of the years ended December 31, 2022, 2021 and 2020. Treasury stock includes $29 million related to shares held in trust for each of the years ended December 31, 2022, 2021 and 2020. See Note 1 &#x2018;&#x2018;Significant Accounting Policies&#x2019;&#x2019; for additional information.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktMi0xLTEtMTY3OTA4_cf85c9c6-30f6-47f0-9d82-59780ed91d16"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTUtMS0xLTE2NzkwOA_6b7272ad-9760-4165-8a9f-eef3576673fb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTItMS0xLTE2NzkwOA_b320eab6-797c-4b05-8ca2-c960aa530c2e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTUtMS0xLTE2NzkwOA_a3020230-8e8d-4d1f-be1c-451c50e0569a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTUtMS0xLTE2NzkwOA_ed5a3e75-ed47-445a-843f-f11cccade6f4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTItMS0xLTE2NzkwOA_a802b61d-e3fc-401c-8a0e-c9a451456886"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE5LTItMS0xLTE2NzkwOA_61a94270-718d-49f2-8a89-ac9a52290499"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI4LTUtMS0xLTE2NzkwOA_d103f2c8-8949-463e-a6a6-bc4b87160d51"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTItMS0xLTE2NzkwOA_2493e6ed-878f-4a03-8082-5b7df50b5510"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtMi0xLTEtMTY3OTA4_a1102af3-6a6d-4ab7-9a37-152583f52aed"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzktNS0xLTEtMTY3OTA4_4b2d1fa7-2942-4c9a-bc7e-a667d42a0eb9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTUtMS0xLTE2NzkwOA_6be73b7d-7940-4a20-a6a2-d323e75cf34c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNS0xLTEtMTY3OTA4_899a6f82-b6f8-43bd-b579-b98c84fb2c90"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtMi0xLTEtMTY3OTA4_cc9c228e-d25e-42a5-afe7-dd4be4f4ded9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTItMS0xLTE2NzkwOA_803aff9c-7641-44f4-b3a5-a5093fcbccd2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkyOQ_53a0f2da-8fc0-4792-af23-108743f65ab3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTQtMS0xLTE2NzkwOA_7dbb9dc7-db89-4602-a8ab-d1b447187c94"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTQtMS0xLTE2NzkwOA_7dbb9dc7-db89-4602-a8ab-d1b447187c94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNC0xLTEtMTY3OTA4_419c9387-c859-4bde-b2b7-4f1cf9bbe844"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNC0xLTEtMTY3OTA4_419c9387-c859-4bde-b2b7-4f1cf9bbe844"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTQtMS0xLTE2NzkwOA_915df060-9a88-4dd4-b0c9-35ddb417b3c1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTQtMS0xLTE2NzkwOA_915df060-9a88-4dd4-b0c9-35ddb417b3c1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTQtMS0xLTE2NzkwOA_7048f323-3d7b-43fa-8f4f-ce5446e41c03"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTQtMS0xLTE2NzkwOA_7048f323-3d7b-43fa-8f4f-ce5446e41c03"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTQtMS0xLTE2NzkwOA_33f5dc1a-2a4b-4a8a-b80d-440f0c6eb9d5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTQtMS0xLTE2NzkwOA_33f5dc1a-2a4b-4a8a-b80d-440f0c6eb9d5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTQtMS0xLTE2NzkwOA_da19b8fb-1267-4760-a39d-cc06e134509c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTQtMS0xLTE2NzkwOA_da19b8fb-1267-4760-a39d-cc06e134509c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtNC0xLTEtMTY3OTA4_2a36882f-dd82-4bf8-897e-323895e9187e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtNC0xLTEtMTY3OTA4_2a36882f-dd82-4bf8-897e-323895e9187e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock and capital surplus includes the par value of common stock of $18&#160;million as of December 31, 2022 and $17 million as of December 31, 2021 and 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzI3LTQtMS0xLTE2NzkwOA_7dbb9dc7-db89-4602-a8ab-d1b447187c94"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMtNC0xLTEtMTY3OTA4_419c9387-c859-4bde-b2b7-4f1cf9bbe844"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzIzLTQtMS0xLTE2NzkwOA_915df060-9a88-4dd4-b0c9-35ddb417b3c1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzMxLTQtMS0xLTE2NzkwOA_7048f323-3d7b-43fa-8f4f-ce5446e41c03"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzE4LTQtMS0xLTE2NzkwOA_33f5dc1a-2a4b-4a8a-b80d-440f0c6eb9d5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzEzLTQtMS0xLTE2NzkwOA_da19b8fb-1267-4760-a39d-cc06e134509c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90YWJsZTpjOTBkM2I1OGJkMTU0ZDUzYmFhNTE1YWRlODNkZWI2Yy90YWJsZXJhbmdlOmM5MGQzYjU4YmQxNTRkNTNiYWE1MTVhZGU4M2RlYjZjXzgtNC0xLTEtMTY3OTA4_2a36882f-dd82-4bf8-897e-323895e9187e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjFhZThlOGNmNGRhNjQ5ZTRhZmEyYjA3MzkzOTk5OWQyL3NlYzoxYWU4ZThjZjRkYTY0OWU0YWZhMmIwNzM5Mzk5OTlkMl8xMTUvZnJhZzoxZjMzMGNlNTc3NjA0ZmQ1OTllMjAwNGE3MTJmMWU0Yy90ZXh0cmVnaW9uOjFmMzMwY2U1Nzc2MDRmZDU5OWUyMDA0YTcxMmYxZTRjXzkzMA_1a580a73-995e-4151-9251-c5cad9fca1b9"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>137
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +$T2%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "Q-$A6G=9RSNX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$F@&R;UI:.G#@8K;.QF;+4UBV-C:R1]^R5>FS*V!]C1TN]/
MGT"M#D+[B,_1!XQD,=V-KNN3T&'-3D1! "1]0J=2.27ZJ7GPT2F:GO$(0>D/
M=42H.5^!0U)&D8(96(2%R&1KM- 1%?EXP1N]X,-G[#+,:, .'?:4H"HK8'*>
M&,YCU\(-,,,(HTO?!30+,5?_Q.8.L$MR3'9)#<-0#DW.33M4\/:T>\GK%K9/
MI'J-TZ]D!9T#KMEU\FNS>=QOF:QYW12\+OC#OJI$<R_XZGUV_>%W$W;>V(/]
MQ\970=G"K[N07U!+ P04    " "Q-$A6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M +$T2%:$=_DE&P@   XP   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9OO;]HX&,?_%8N;3IM42N+P:UN+1*&]<=M:5+I-N].],(F!:$G,V4YI__M[
MG !I*L>0D]F+DH0\W]@?;.?Y)L\N-HS_$BM*)7J*HT1<-E92KC^T6L)?T9B(
M<[:F"7RS8#PF$G;YLB76G)(@"XJC%G:<;BLF8=(87&3'IGQPP5(9A0F=<B32
M.";\^8I&;'/9<!N[ _?A<B75@=;@8DV6=$;EM_64PUYKKQ*$,4U$R!+$Z>*R
M,70_C+V>"LC.^![2C7BQC517YHS]4CN3X++AJ!;1B/I221#X>*0C&D5*"=KQ
M[U:TL;^F"GRYO5._R3H/G9D304<L^A$&<G79Z#=00!<DC>0]VWRBVPYUE)[/
M(I']19O\W':[@?Q42!9O@Z$%<9CDG^1I"^)%0-^I",#; /PJP*VZ@K<-\%X'
M]"H"VMN =D8F[TK&84PD&5QPMD%<G0UJ:B.#F45#]\-$_>XSR>';$.+D8,0>
M*4=3^(E1$WV;C=';-^\N6A*4U?<M?ZMRE:O@"A47HZ\LD2N!KI. !F6!%C1I
MWRZ\:]<5-BJ.J7^.//<,80=C38-&YO ;.C]'3A[N:<+'YO _TP2N[NBN7NJ-
MMZ?L97J>D?+?P[F0'$;Z/SK"N4);KZ"F_P>Q)CZ];,#\%I0_TL;@]]_<KO-1
M1\>FV-B26(E<>T^N;5(?C)F?PC(CT</SFNJPF<-=I_E9Q\<859>/);$2G\Z>
M3^<X/L,D24F$[NF:<:D#9=:1/-7A'1FCZH*R)%8"U=V#ZAX':DIYR *U4"%8
M,;5CZH#2;FFJ7)N,\76A61(K0>OMH?6,71VEG"MF-Z'P87#]I(0;P9G5FDT7
M-SU71\P86)>8);$2L?Z>6/_(]8H32(ZRW*9Z3IJU%B02VDEI#*M+RY)8B=;[
M/:WWQAY>)S*4SS"\(HINTWA.N8Z26<-QW*;C.JYV7!E#ZY*R)%8BY3I%HN8<
MP^J>+D.51< 0NR6Q=A8>$!I]GZ%/U\,O#Y_0Z.Y^>G<_?)C<W>KHF87JXK.E
M5N;W(M%UC^$W27S&83X2-37/T$S"4H881R.6)I(_PV>@AVI6'U]K 1J#:@.T
MI%8&B N ^!B #^0)30)8XL)%Z&<4#5/W@*33:3KM]VVG[6CI&8-KT[.D5J97
M. #7F";OZ V# -3%V6X#?8'ST%VB'W-F28A":C*/.5CG,RU!JS[ EEJ98.$$
M7',N_YK@2.W!S'U@FT1+SRSW@[%$,/\7E7IT5BV"+;4RNL(DN.;L_C6Z_:HW
MY>PQ3'S]Z#-KWD^TV*P:!EMJ96R%97#-F?YK;%,F)*3!?X7KZMN$6='!_?<=
M+3>KGL&66IE;X1K< [8AH\8IJ<9D%GC;=ES=8ZB1.:XVIE,X!;>P"JXYO__"
ME*F:KEABRGX/B/2ZG:;;<?0W4*M&P99:F59A%5QSGO\02G );(%<_';^#LVH
MGW(89UID9J41BV/(6F825O\SM 9/^TBBE*(WSKGCHC7E2*P(USHOLW)MHJ=P
M%+AP%-AL!,"B!F&R1+/G>,XB'<@# I!\:!_-6K4-MM3*D K;@,V)_6Z<H>LG
M?T62):VT70>$;G_.M![!'%:;UBD\ BX\ C[*(_R@4=3\E4!B!O.4"%C@ C01
M(M6O< <T?U*AY6;5'=A2*W,KW $^RAU\9Q&X4,+S1R)<U^^K TJW3 O+JA&P
MI5:&51@!?)01V#V<S!^O90L9I+6I'II9L6J(6?4 MM3*U H/@(_R )-$4IZ_
M;56/<<D.HY::6;&*FE4+8$NM3*VP /@H"Y!-1S0"U[1D7)MS'-#Y0CC<.H:^
M3T$(9()<4LO/JA6PI5;F5U@!;,[DM_QF,8DB=)4*^%KH9ZA9I_)9N#FN-JU3
M. )<. )L3N:WM*YCRI=J0?L#%.0*7%2\)HE^V/W/5PCFN-K83F$-<&$-L#FA
MGXQN[M$P#4+).!I*2<&F9P\F;R*RU%(SZU6]##6'U89VBNS?*[)_[ZCW";,5
MY&JF$79 IG*$F>-JUR"<P@5XA0OPCGIY,$WG4>C#L&)$>\,TJ]0NXK#J#+9J
MG4Q-E8,]#ESLXD[?P4ZO@R]:CSI"1>;O'97YE[WU3/EH@>Y2"3,R46932\UF
M)C_:JG5+_>RW7=?M=GO[7FZ9G"+K]UY4!9ES]=W+8O'BK11D!G/UEF]!(2O3
M/Y@]H/JPHFC!HHAMU"TD!DD>PB1%\%.@\-5U^.XZ\(UD2*Y"@50]'5*%,Q^@
M67EEH5I+?0;.)%1.+DS@1*JJZ\(DS!+)-6=/STBMNC1[^;U0+]34:T9*HNS^
MM7_C]OMO?>SV/HJL,&M7M/*5TBQ_9XM\X*Q8%(#[.4/0I#ET!C*E &U"4%+7
MW3KR$ 86C*G"EZNA%XJL(%&="ZUTL8,"\@SG+0!"%DPA BZC-A=Y4<.S*FJ@
MJFP-C:E/U6.X?>$9>JM.5&W&SL=IULG9KI/94??CNS,$S$Q<T91P]1-/)EE[
M)]]11AK:\B05K( *GX=S"(2#G(;)N798VRWI.H6#\PH'YQWGX*#[''Z""=!_
M0I^I_OYCEG+4OVZ[[^C*_$;FX-K43N'@O,+!>4?6>KTLQ[F!@]J$^H!85>V2
M.:PVL5.X-Z]P;]Z115];8MO:KVIF9KF;GUIB5OV:+;4RL<*O>6:?-01<08ZL
M(G<^(%"=#UHU:K;4<DRM%P74RGMEA>@";GEI(O-:ZOW1?;'[,"OQ;A6GYY7R
M7XFR;@)%= &ASGD/9@#/B\_S'<G663GVG$G)XFQS10G<[]0)\/V",;G;41?8
M_Q> P7]02P,$%     @ L31(5C0*P9<\ @  OP4  !@   !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6R-E&UOFS 0Q[^*Q:2^J@(A#YM20$J:5HN43%&K;9JF
MO7#@ E:QS>RC=-]^MB$LDQ+4-]AGW_W\/^.[J)'J11< 2-YX*73L%8C5PO=U
M6@"G>B0K$&;G*!6G:$R5^[I20#,7Q$L_#(*YSRD37A*YM;U*(EECR03L%=$U
MYU3]64$IF]@;>Z>%)Y87:!?\)*IH#L^ 7ZN],I;?4S+&06@F!5%PC+WE>+&:
M6W_G\(U!H\_FQ&9RD/+%&ILL]@(K"$I(T1*H&5[A'LK2@HR,WQW3ZX^T@>?S
M$_W1Y6YR.5 -][+\SC(L8N^31S(XTKK$)]E\ABZ?F>6ELM3N2YK6=V).3&N-
MDG?!QN9,M"-]Z^[A+" ,KP2$74#H=+<'.95KBC2)E&R(LMZ&9B<N51=MQ#%A
M?\HS*K/+3!PFRSIC2#:B_;WFGB(?#=9N^FF'6+6(\ IB')*=%%AH\B RR/X'
M^$9/+RH\B5J%@\0UI",R&=^2, C# =ZD3W+B>).A)*4Z3Y/\7!XT*O,H?EW*
MN.5-+_-LH2QT15.(/5,)&M0K>,G-A_$\N!M0.^W53H?HO=HOE,,E;</1#TIH
M)#>45W?DAZQ%3K;;_8"J6:]J]BY56YE>?2?#A)4TKUG<DAW5FJ9%K0%1#RB;
M]\KF[U+VR!0GF_4E8<. Z<4WYI\5%0>5N]:A26KN%-OZZE?[[K1LB_*?>]O:
M=E3E3&A2PM&$!J./YJ)4VRY: V7E2O0@T12\FQ:FPX*R#F;_*"6>#'M W[.3
MOU!+ P04    " "Q-$A6"*A*2A0(  !P*P  &    'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;+U:;6_C-A+^*X1;'+K ;BR2>LTE!AJKO2[0O0TVU_;#H1\4
MBXZ%RJ(KT4[Z[X^4%-,B1[2S)_1+8LG/C/G,D#./*-X\\_J/9L.80"_;LFIN
M9QLA=M?S>;/:L&W67/$=J^0W:UYO,R$OZZ=YLZM9EK=&VW)./"^<;[.BFBUN
MVGOW]>*&[T595.R^1LU^N\WJO^Y8R9]O9WCV>N-+\;01ZL9\<;/+GM@#$[_L
M[FMY-3]ZR8LMJYJ"5ZAFZ]O9]_@Z]7UET")^+=AS<_(9*2J/G/^A+C[FMS-/
MC8B5;"64BTS^.[ E*TOE28[CS][I[/B;RO#T\ZOW'UORDLQCUK E+W\K<K&Y
MG<4SE+-UMB_%%_[\$^L)!<K?BI=-^Q<]]UAOAE;[1O!M;RQ'L"VJ[G_VT@?B
MQ "'(P:D-R"F@3]B0'L#>JF!WQNTH9YW5-HXI)G(%C<U?T:U0DMOZD,;S-9:
MTB\JE?<'4<MO"VDG%DM>-;PL\DRP'#T(^4\F532(K]'G':LSE9P&?4"_/*3H
MNV_?H6:3U:Q!184^%66IOGR/OCV]O)D+.2SE?+[JAW#7#8&,# $3](E78M.@
M'ZJ<Y4,'<\GG2(J\DKHC3H\I6UTABM\CXA$"#&AYN3D&S-/+S3T'&WI,$6W]
MT1%_7]B!57O67$.A[4Q]V%05C>MFEZW8[4Q6A8;5!S9;_.,;''K_A,(RI;-T
M(F>#D/G'D/DN[XO[FFV+_1:<C)UET%JJJGA8Q &E,E&'TU#8J"C$E Q1J8T*
M$QKZ1]1@\,%Q\(%S\/^6U;ZH#JP1:BG*CRN^91"3SDUXRH3&!@\;@W&2&#1L
M4)3$,(GP2")TDO@/%UDI&T,W=:'1A]:/4D+\,#((V#"2$(RQ00& A7'DA3"+
MZ,@B<BZ]O@163VC%&P&OP&C*%3BELW0B9X/(Q<?(Q<[\+V6\5!/9U3S?KV1#
MD5TFA\(7VQ,T">/$6&E+ !8%L4>-:0# 0IK$&)X&R9%,XB1SQRJV+D0W"2 2
MB;V ,(F-.;JT4:%/0J/RI#8J",(H@1E@3_=YS\GA\Z[@18[*0A1/;5='*]G*
MG^"UV?L:#,(*]A) F62<D"&3$\6"G4Q^YHW4)U(R-@V3$VO#RAQ) 8R:K 3+
M9.]N4!MDQ3?)V"B+C LR)$,T&>(D\R!XS5"QW65%W2HOD $Y-[8E ,$TB$T&
M+D=#!EJ=8&<G7_R+\_Q9BK\3$B '>IZ##?&I6>B=?H84M%K ;KF@RSQ[D0]4
MS<BB\.V.%1-L5BH()AM1:/( 8(%,V0@7+1ZP6SUTC9</&Q=(Q^[Z%/L1,:L6
M@"-1G&!K;@&XP(^2,49:26"WE-#9&9="V.[_4>2')A4;A2E.S"8"PA(\TD2P
M%A/8V7$7'RO!9*<5K[,,)!+9422Q*8H@5& U0PB5>-$(#=W9L;NUO]9?EM7E
M7Y*+2LV^:#:M6I4M/V>/< 6PF[-5 6R('YBB&P!AWQ\K KK'8W>3_RPVK'9-
M,;LQ?\!A8C* 4+%% 4"1,;%*=(\G[A[_L1T\>F3KMJET5R)[42KL4*BM&H@8
M 9I]2,P'"0"%/9^8/1* )5$TDARB>SYQ]_R/EW*Q6S3V0[/7 R@2$#-)("H<
M$6)$=WSB[O@]E77-M[(X5W+U[%5MX\?=%I"7W;A]' 8F+QLE*[59J"$4\4:J
M&]$Z@+AU0%L66E9YT?3$6'["ZSVJ6%L@9!9!CN<5PGE("D ^C.5,"P3B%@C=
M(_E892!V*X>28Z.@Y  H?/(T-"2@50$YOZ?P7<?@'2I5IC(AZN)Q+[+'4JXK
MCBI>J:35O"R[5MOU*G@VVJU>ED*3+[#U8"TQR!$=(:L% W$+!ITMB^7RUP?T
M$\M*L0%YA=9^CH]]L\0#J"C!UCP$4'CL,8YH#4'<.Q)W65.L5.NM9)8:)!=7
MMR4+;DV02?<F)O663N5M&$<M8HA;Q)RMPHZIHU82RN5"R>J3#+P#,]"-(CH5
MV5?V4HGM?41S.MF.@BM_;#IIT4/<HN=LT9XH#+;>L4K[64C:0^+3:N%=C74N
MJF43=<NFB^K%&]CV/W<FZ3W*E73 D4SZR,XLU6**NL74;^W+,)GF["#3_,34
MBS-95/I7.WPO&I%5N5H.BG-W&R8*J"UJ/1##*',/&D1Y(Q.<:K5%B;->ID6Y
M5U0OK)C4J=W>_#YE2F_I5-Z&D3QY"^76=W]3Q>Q'82P>WYQ3-BJX2@)S3D$H
M?^0!F&HU2-UJ\&\JFM26@F;1/ ])>\BE15,K2GK)6ZH)BV9P4=YM%)1W".6/
M/%Y3K2NI6U=:=3/OB\M75$YHBXF8SZDPRJJ<X*[6R$M(JI4F=>]6I<6AR%F5
M-RAG*YE R?.8P;?D-;)R0:ZL%A%9O=!\5'!"AA2U"*3G7U*]1_?=*RHD,X<>
M9-DL5@S]]X<7H0ZWJ!G]<]&(WT%J;N^]7^@):OGUINE7F0X#I.4A=<M#QSCN
MW*9O;I53>DNG\C8\?* %I>\Y18?SQ(;O%*-OC=NDWM*IO WCIH6I[Q:F7QS'
M!7K3P?HG86C):@CGT<@\&)$".)QX83RBKGVM./TS;_2Z$@*3F%1>3NHMG<K;
M,&Q:7OK_QRDG?])C3I-Z2Z?R-HS;R4DGMQAUKAG[?%(2QJ;* %!8;>V;"P8X
M$A4'IJB:GQQ%W++ZJ3W2V<@'AGTEN@-\Q[O'8Z/?MX<EC?MW^#KM#G]J-]U9
MU$]9_51(D5VRM73I745R2'5WO+.[$'S7'GA\Y$+P;?MQP[*<U0H@OU]S+EXO
MU \<#]DN_@=02P,$%     @ L31(5GY7Z&4.!   N@X  !@   !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6RM5]]OVS80_E<(K1@2H(E$29;LS#:0V"O:A[1!
MC78/PQYHZ6QIE4B/I.UT?_V.DJ+8$NUD0%YL_?CNXWUWISMRO!?RA\H -'DL
M"ZXF3J;UYL9U59)!R=2UV #'-RLA2Z;Q5JY=M9' TLJH+%S?\R*W9#EWIN/J
MV8.<CL56%SF'!TG4MBR9_'D'A=A/'.H\/?B:KS-M'KC3\8:M80'ZV^9!XIW;
MLJ1Y"5SE@A,)JXES2V_F-# &%>)[#GMU<$V,E*40/\S-IW3B>,8C*"#1AH+A
MWPYF4!2&"?WXIR%UVC6-X>'U$_N'2CR*63(%,U'\D:<ZFSA#AZ2P8MM"?Q7[
MC] (&AB^1!2J^B7[&AO[#DFV2HNR,48/RIS7_^RQ"<2! 8U.&/B-@=\U"$\8
M!(U!\%J#L#$(J\C44JHXS)EFT[$4>R(-&MG,117,RAKEY]SD?:$EOLW13D]G
M@BM1Y"G3D)*%QC],JE9$K,A,E%A*F<GQ#L@GGH@2R!7YMIB3BW>7Y!W).;G/
MBP+3I\:N1F<,I9LT"]_5"_LG%J8^N1=<9XK\SE-(CPE<5-%*\9^DW/EG&>>0
M7). OB>^Y_L6AV:O-Z<6\_GKS;TS:H(V,4'%%YS@:W-Q,A5_WBZ5EOCA_&6+
M?LT>VME--[E1&Y; Q$%B!7('SO377VCD_6:+W%N2S=^(["BJ81O5\!S[]#-V
MTKP*GRUFM>V@LC4-<S<-:308N[O#6/1!\7 T/ ;-+2 Z\EO0D>^#UO?!V8KX
MHC.0)#DJA5H+N2B$4I?O"8>J7#1[O+'I&[QE3;PEV?R-R([B&K5QC5ZLB2W'
MH5GD_V(3S/D.E*Z^O#7.354'%]2E+:(U<W20YRO?CT>=DK&@PB#JE$P?%(:>
MO6+B5EE\5AE.1IQ['.>(E,"3GP3;!5<%JR=N^O>VUFGMWG'/':^CJH^XBCN:
M^I# KFC8*AJ^F*N$J8RL<,-",DC78/5^V%N8=GR;]2%7?C<G%DQ [0I&K8+1
M604/S9Z)\92(ZHO>"&SCH'-9M_LE<%CE]J2,^O[0J--[9GV0WTG=W,83VW51
M[WDGX9U5]F)_LFX2/$L:PJ!;:S98&':^L[D%%8P&)W0=[)#H65TSBR*K%&HI
MNJ [/BRHV*+$@AH,3Z7(?Y;B_P\I%[662V*R0YC6,E]N-5L60+0@7.!;KJ7
M'1Y?HVX-V'OM==DLVRG,KO(^B/I=W3:B$SV#/F^EZ-D]A36#/;VS[POR$8>
MSJP*@]Y$ISC2NQ+[J#B,:%>D!36(PXY*]V!37X)<5X<CA=_7ENMZ4]P^;0]@
MM]6QH_/\SAS,JL/",TU]JKMG<FTF7 $KI/2N8W1)U@>E^D:+375T6 J-!Y'J
M,L/#)4@#P/<K(?33C5F@/:Y._P-02P,$%     @ L31(5G*?9W'D!P  N",
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MZ03[-@%P^0Y<'@7WAUX)9;*K4F;T4#E A<#E_IRE^71;^$8)+2@,L-@!+*(
M_Y2Z;%X!L/#Z3I,TIQ.$@!7&H9U+L&,.' 7YJ^P>3K50K2&'Z"X>_1R,(\'%
M=(= 9@S3)(!SC^%(%.>-,J)'Z><A'=I,N+9(@]MY]':P'VB>L2E:T&POJ$.T
MCIM(E!86?QBLI:Z[!]0((T^0LCKD5-Z?;LQ#>"6,7@]W<9Y-EP)D5A :6*[$
ML0V)T\U/4BZ?C#X H3&OSRPGR30-068&6B!#$L<PY!C%Z+)[J$T&'X<O//,
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M"5@QS )8':?1.*==C1)V+=5P:B/OD9P(G&/P?0XCJ5<#@E8\0,G4,1V-,QT
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MV^'C2I0&O#4PO]]+H[G&!_ORQNYEG<7_4$L#!!0    ( +$T2%9X$Z_G#0,
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M0R=*O0P?/E.K\DH+WI&K1<RNT+MHD+W+X*2X5'.M>-3)BBMSVAK@(Q9Y,F(
M"8<)Z9^:9L$;=W%F$=MW[6HPL8$5$'GNFA@F(F$FVH/$3B^B1 -.LY K I!-
M'#%[9 %E),&6-5 64P_R$<-)!+\)(E:B48NI,R""!/GKK1!QT6CYI:(=Y]2
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M55Q2/%91I 2L8@E*?,%F/BDVJ[BD>*RB2 E8Q1)4  1; 4BQ6<4EQ6,514K
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MYBJT!<%Q)CUKRJD8C84>'XU)QD@2AXCC$$RY^!%NPQD@,S"-$,4124),V6_
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MTG6@N95&)RUBC@N[VXFD3:P[,-VM1-(VZ<#MFNV)!)KKMU53??CD:9X@68P
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M%C7'3RO\C8!V#KB_4,IN%^Z _L>4_0-02P,$%     @ L31(5F<$?T4C*
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M*M$"/)\9X^L?Q*#YZN[B/U!+ P04    " "Q-$A6:GJE!1D2  "?-P  &0
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M7ENG)?JLQ.%L.F76=0:,RR4E=("_H#$P'$!2^5=9[#3RH3ZL^]2A:HN%3I0
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MXR^'XN);".&66X]*>DR"KUM*5T>=.A<#[RY0J-]D]+_L;8I(K_7M!5\O>%;
M!7V>E3B=(3]!,WPB74/9IWJ9_3@157D*A,%3_Z-S-_JG*83Z*_[7,*I @)CT
M_T_UK?U_G]WK?[H:NNM_7?MSJE9$5R&7&&K/HN *@)S_'4R_--66_P5K7C5-
MM>''M4P74E$'_+ZL@.;-"RW0_T_>^_\"4$L#!!0    ( +$T2%86E;$S31(
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M*>R43?Z:[HTN\= N/X$OB.43:B4\'L)+=[:G.95#VR/@,_ISN"*4NL(T;6L
MJ]%IKQI5(\6HO_3:KTAE.^J.-_[_497>F7/N5F%_Y*QZGY9)*TI!1PO,7G-W
M"R[EY<YLAQ[TYT^TR9_4L<M('#;9MLX3/+$"H57O+ /1#(5I=OEC5FQHE^'>
M'$ZR+@"W_2$FX\X#LMQ]#UC@>M/1VV['0Q:-^>C)!+1=6@([AT+G=_UI-R>]
M'<K\$^P"#XI;:6BJ]@#DJ6./)LBVEN&O*./P6+897]Y-_(FDSAI!E:.J FLH
M0=N)+$&(N-56Z&-"?3E^=LR[?2%C2N;HV@ZWJ,%][]"<*U.8V),NJB8UT6&+
ME,L,YRAI]]V>/.GAQ'PP@WOT N>!9\$.!1@$Z 33VJ3D#QS/->6C(CFO1CI7
M5&8JS7<]<L#DO>TP$%-Q$/H;)3Q^A5[6B-.:JMD.+$KOG-20D;KS1GI?E[P<
M)7G=F*GU=,X930]]I7#'H0Q*V]WT*= -RG%3W)L]+JFTVYIUW%;C0ZXZ?FE<
MLGA4H_F&I(E4,!#H,BMR_! PU68.^3:DD][AJA%#N1WKJ =H2B@/.MK;T.L'
M"0+"(Q&X"$DR@=_P]!-AMJ8M>A1U;U)VMG:S7S4P&63(#-HZU-:.Z.X,H"\:
M\ZK+E#WUI;>-3YV?]NS9,-BCU9Q8]+=G^Y#[>);*O(G2M+S/Z-"[FJ9HS/H3
M&IW-V$]Q?KSY0G?X]0T8E;:FZSJ'3,8(K $]6N*0%?5/(3^M].BW[:? YQ<@
MIW\]M4L443$YZQ2N"_O+:M'^9=7;-V++,(*J9KUHLN H6"R7\"Z:3G&#9];L
M4LR":!4.9.?GKGR&WMVH4;K!5I/!^_ELV;K70M+[NLL011$%\W5[5W<:3,,I
ME6_1E)9B@N6J78;,@\FY>R$TUOMO)N&\7,U=?HENGAS)@1]QG4_;X.5RTF\!
M05;(>]/H%/8"SR3PW->[IRZ,M$]G[CF>Q^HMP@!?9Q@)K6K@1Y2M=9"KH<^!
MK[TOM3,!:1Y^CXZ'.X"R_FC;O76?O-_H+[V;YOI[^1\@2\3@G(HM=)U<+><7
MD)_1-^CZH2H.]-WWIJBJ(J/;O>#@P; !_+XM(#J9!QS _1\!O/D/4$L#!!0
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MR4=(^ACOO,]A;Q[(+JNT:#+!4#KAO!72$[3S<O*LE,;X5$8+A:K6;^'B)3F
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M%R@6F@BPOE+PMO:##NC_7^'L/U!+ P04    " "Q-$A6D?EOH,,.   !4
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MPD(:(].58C6HSY%2L>5A1A$"D^S*%AIHI6*A0#/;Z$@D>JDJ>HM2)S'&04;
M&MVRYQ:Q;>E!,4I*.#SN0F822$915J:L]KR$F9!V:(HCQ:)LY;<S>9NE%CL/
M5I)=4%NX8UNGL;[7,:FL+0&LUJ@#$W &MLP2Q"%BH6"U:PRM(E*U>@1ALY2$
MISLI(J.3):+%ETYISDZ$(O 3@"ZU66"W*_CB_R';*3[TGY$Y;722P)HL#W#/
MZ9GXK;;:QBJ78A",IW.^3H9#=YWVQ4]-D7CH,W&SR4RA_Y+LM6#84"!ZFBV?
MEK25SD% :C(0XPD8P8XH4F+JB21:+BHPF,QXV$Q\S HH=7FTFA7A:"K"P4B$
MX4C<K;'R4][BYI#!E+P:0OXNC68M-Y].X&23_DB,YW/Q3EG[#.I?N $ZA>J5
MN)J$3\35>$[_QD_$K^T-N!3#8-@?N"N6XNNX+^[*/$_89L%Y).U:++'3H.DR
M%Y=$)&QS18TMW[*;8@L-0K'>ENS9W;TE1G*I8^<K&W(52X(Z+P(HT/(;<%,:
MY]78P:.->=:PDEHTNZ>;M6W(.GN9.?N98J?XBET[3T97QI&313EK:CO1WD*<
M)3Y$*3<04>?DF ^3 IV^&([$AQ,&FRT(\YV&@'-KPB.F['23+1*]XDUMZ<93
M'L]#$0:#,:P47C-O>PVV:(@=FLZPO\.VU2QDPN-<.GS><B2#PY&M5%82,K*<
MMI& D3LO&GC8 $LB@$#,H"HXYNY-ZE#2(]E/.O\5W.E2A--@/IC1AWD0@N!M
M:0S96V.##LRH!0V7I,OYW%U'$_$N2U?.]<_-"B?!;#@7X2P(IU./*N?&7PV8
MU5DP'GI69X/AP?X]$^\-T2AVK*LZ+0C$RF36<]KGZ<%P.A8W451N2K=_L4(B
M%VFWJ5>#V0@8$\YF3QXD2>C/A 8COH:SZ2G-);4V8K6@&6/2%,S[7?M!&(SZ
M$[;-_DF,/=3X:#)VR_?[X@^N,""$O(<"5^JT^5S!81C-GAS[13CH#>C?[- C
MPGEO! OKG5BD;8I')$>8^+W_?T!TU)OCYAA$OQ?_^9H_-MBW#B+MD;F<LG#L
MP"6"FW<PGV.M(8)8*)56*8KR(&RK:6N5N%M6(DC1SE/:T 3GDP.SU*<)J<T2
M';-AM:$#J=$1,O3$G5+BUXP<6OSPW6P03I[[RTT$@[.<; (<WJ!,17I4E%7B
M?D-,B#LL;7G"]+F_.'%\F@I;:B!6CUVI5F+T=<Y.^@3<5/HD)I)'^3M-A+\_
M>B.:<[^\&P^/_GMLR:D$U.6>^B^?-6-H:72Q.YD&^#JG@@PN@PX=\H&XU$Y2
M*D_=NS.YG ,DC*9\,QSZ[',VYNML0 A!B=^PCZ\CA (\',SIYAB@,L-7"JAX
M-.+<!S!'B6 0CA"\@L&$1_K<,9C/:'J(\=")47()R^+ TL> 8!0B?H^"_CCT
M/#E-Y'+')0F;-DC.L"9&@='!A%-!ET[J35X6;# ^F[E"#*%<,ACW*;&DL:,G
M+<H/P&X5A@;]H-\??@.(_522R1QY3"T(>P8J1><=1L5E1(:[HTZ/WI2;?6IL
M.$/QGCGOUQX6EZI*(I=N,6<C[>*R(F,=+)QH'=3U$Y?["9:/?&F[--E&?)1F
M!8._]7T MN8;G\PV<B-;PMW/FZ<A69;4E*,@L\CN54^\/R@_/6$O&R5+UE;%
MV=?7D%R.Y[G)/O/P9 <-]L9B48&;<5NPYXKUB?3-.Z@F88CBHQ?$7$NED:+B
M0M;0])7U?8_QY2FW>Q8R^B0^XI&5W,ULMW^\QJF4;0 \=8&X(8'4XUXEF>N=
M0 \K(S=8VV3E:LWP^32IUR@::SC REUFI/WFK52*+:4^"I V)EBE%(G:KN)>
M)J4*/.COQS5TCWQ8:E,-) -Q6VK+I&DD^[E_0EUZN:NCP5$ .30PQ_.1V7&W
MPJU#<\FD70NA*>]1O"'FV AL9:E-K<<9[I/EL!?3'6[V4-$"WFB_P0"IO (B
M6]%L-.5J(M#1O8X=G54IP5:AJ&_EVDAL1G+_8!\>*BP)B#@637V[F[M<O-@7
M-A@R<T&;9N>&$G6N0R :E2(]RIA=^XFU>6YJ04@+K5R&_7U.X55!J>H#=7>_
M)_X!=7[- L.O(_\;-S/%!P6?_-$6+L&%CU?-E-LUP9X5;Q"2*6!S^"X-% N[
M9/?&-K@.0;-)Q@A<D$?(U#<:Z=4# :0BTZ=UR#D/NZJP'S"B'",.?#5%!9M3
M#XRFTZQ4;5%MJ\^:P(E>>;0QXX:J<..;9-HVUF\S67$2.U9\?GC, <<#+K_9
M!M0F3[*=.EX94Y$QN1Z&95%3:FF .OS#^3D#06[TGCB'C)PPRR,HP!98SU)(
M[Z^U))2+6^O*LJ8DL2(\9;]C-\>*VZP$-MW+B)9B[%C@/S>U72^9#>FXK^W8
MHO6!,X; G)J.%1*L#>3>N+<>#[:*FIRAU*1^>WQJ?[.FH47>T"BZA^&TLN*
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M =XOE;+-#U+0_A?%W?\ 4$L#!!0    ( +$T2%:\J\=OL P  .,J   9
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M_KR IS[[<PG+Q=IG-@';DLJ'%T@%%R*':ZU3M]Z,NM#FN0E:BJ'*8'S-9>$
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MVO^NLIWN?YWZ#>Q&HJX*L<#207\RZC'M?_'Q#U:MW*\L<V6M*MWM4J!"-$W
M]PL%[A(>:(/V9[>K_P!02P,$%     @ L31(5@T!ASCI#0  C"T  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&ULY5KK;]M&$O]7%FY:) !-DQ3URL.
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MLO$S[ME\)%!?F"ZQH]%!R0DVD8-B^N6PC$"LK+<#*48/\TT.B6T$Q'W.:DW
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M=FP+,H$>F66UPFZW6Y[U4 ;> 1VO#PTTKKA>^T[0*:Z?/;WG0:FTM0@%P1D
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M&[\!ZVNMW7[@%1P>9XN_ 5!+ P04    " "Q-$A6@'[3TM,%  " #0  &0
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ML"?9M:GOH]118.AKLP$P !6!C\\!U\3.%\*LNY>4? G\XT!E(":(NW'UINQ
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M#DLN#@1X;B.5UW8$<TIX]O,3(!SG.&7[3(MT-;J9JR:4RY2]5:&O9\L&+F"
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M#G;2]]CYF'$3'U_G@J.D>L,N&"P]WQ!.S&[53J=TBYW2";GNPE'X_(3GT^1
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MM3";EE>*S(BG!'S//F4"7%0BH_YEKF%.MU3&F4G4.ID+B+3NWM<JBI>'WM!
MU[Q)=,$UT:_CE<\:85;-:AMWWNGJQ[VNTVV!]S=8ZJFVR4..$]/A-/<?CSZ2
M3OFY;*5L?'8B7N6GGPMJ#\W;;<6!N7Q['LJ:'?<J:,I=_#'Y1 <6?%*M3P/+
MT RPD\6?**SYQ,.N8LG3QY(G(!RS1Y*4W]*(OYWNG(WK#?>>WEK7Q#9 2L5(
M>GZZHGHN%>CTRG?@_1F>&4<7C)%Y]A!D7KR_3(HM6D<2U]I/MCS_Y3Z(T+2<
M%1>OXHRZ_S_[J3)^2";J3;:3$(%T*N#W7&H*+1R@+L#B2)?&[5'Q:=U2/X+D
M&K6PD*3BO]+,<0U2O5-)Q73O?[GNYO$X>CA]D=39-0L7I/D3=7\^;.GLT-7U
MY<?_"J>NI.X>^T,.;7NHO1XQ["8V,K=8E&_0LE!7B1[5B8T@L<LD:P5)&Z4P
MOO8WE@2FA7"9\@-E)6[-+. 8?9(PO(\O3PGK=9@F=C:B!X+I',R X@PJ.ZJV
M:Z!/ T%$1$IMC4BR5>PEB+";KTGO0TNQ?=:!D7'8C^@P1/[:8::'- A-5N??
M@XO6.NN9IWX>FDS#@%J]0Q0K3VEB=\Q;:Z?GNLBJ4UTRX8R2#312.IV-ES]C
M07C38++JTSH9GW !5Y^U//,,UY/",*$_PWY*JZ3D&X[JAV$UDI:8[FURZG0G
M>=5>^@HU 27=3@%9@>G_7'5>[(CR1233Z7<328-0H"^CN8SI+V!YH!*64O*3
MH'&HAE2R<RLPZEL9^PM!%&/I6J/K:EOA-%#)FE *A8=D>>Q=0A?G-A?L/U.Q
M?\!V*+__5^P:&Q5Q/D;J]MN=2%)1CE8W8/M!ZGA2*H,ZGJ3&!.Q H%8&LXO]
MWZ>.<IN84C:DN2<HO-OBGVC=T)F75/8]GK!1:?YZOQY0EA\-9I0N?;/OTK_8
MT?'O\ $0%5T;FB?7[3V1?H_G(F=T.;N1'\=-#M(E3DUGN2@R]#K4)GJU>6/]
MGK&OZ!?*U2TW7<B1(SF_P&=D>4?B*-^M1CGR539!E0^73UX8#I))E!%NT8(>
M[./0+0Y;F>03'ARK?.?4 ^.$"<(I(F\2I$R?0N'.@MXYC)9Z#L/P\F1R4=BT
MA"EQXW+@,04N8.Y1]/W""):>9?%QUNQ$QQ7W08=G%818$+'Q64FJ^6TZ*\>.
M2_XR]',&&]@FDV(?Y9[H6#XW.&U,68%.FDM*L]'W-00& FSSO+1U^0<\=S1E
MBW(PHR1\F"\5O7B\D49/22?)[B439[JG^\?BI):][>8ZW6:JZ5R'0.0-Y_<5
MI.4TF0YMIW%_HBQC6]DL#)/10U2E)F^28',RC$H'3TAB+B(NA&0SXM(1\^GX
MTT!)*MQF Q62 R!?F:A$S]8$@)Z.SV>BIO3,"L2CH3F3M:EQ>/VP_1PGO+Z[
MI8L/UVBD2#OBWS(K PL.W&X\R?RF(\Z@9)N+E5N"B)PN2[\1P+!J8M7"2)J0
MJE;EY</EA9QM2DJZ_QQX,C'U'HJ^L+TJ%C)XP6YE'=V\PP'33-JZK+A9FPJL
MG_5K=98QT6"$!?[ C+:.20HN[YXSUFE*0P8&JCL6K2E-=)MOPUG>,*@]'N45
MU4 SFRB=$>X."A6=I(W8MODV$U& ED;ES;*AW,$,ZYP&4<6C0>BLM[Q,ML>[
M0/AHR&K'/?Q\?#,H<DH2AC9KZB:DS'>\ G&:Z=W*U5J )0?&<ZDNQZD<E&9E
M)%=S@T*C<Q/&28+:ELO6>>L9T.@<C5;FX^O:;@]<0;.-=-)5&(J5,]-YC3W0
MH(J$@ A>^/'J\DJ^1A6J- )SS;HZG",6^$-&STM? LW%)K#"6/2X&427C]-:
MD@9<GF;"C$J6A]R2U,8CYXVPE@MJ=#V=-^$28:T82^$1P1P@J<^'A2CKS1O7
M!^=<',,\S%Q2#A.';K&$):/(]LB8O*: #HFA(I\1Y="PH7JT_8!K\+QR6E&'
M0$FV07KLQ2WZ?'[Y6YQJP_H-I$P5PSZBIPP72FG3DQWD>MB#/!XS+W66XY+V
M-,(TG1_,Z!1X7[/009(S!_*O8I7@8^[G43%4G!EW:G2&IDWM+&*G-SWY:#G[
MG+[I(=-<XVT#R5@E2;@F"(; <D,'J]/#:_C#3S]=9[FS3^]_C*2EKD3/)-[G
MP8V8)M0 ],22V/3%6+./YJ1(P2Z8+=S!^Q]EZB052\2O#B<FF?%DA.?IV4RS
M%[*1CZZ7_;^C9J<K,5=ONPZP !%X)2:4E [%;A=3K$OS>,^C4/P6Y0'?M%4\
M0FEX'(;.'_Y"?1E\R&@FJ!27X-;2(<M>, JT [U1N\8MN?4;5PIV_) ;/-1]
M2+4.\Y5/NP_V*EK*3&I<0VE$0-:I'KG'IJ6TRTQA3"";29]_'N,PG5J']3$<
M9PGK;Z2 H)QE"-%TPCE1T]KC1 CPY7I#7:DNC7[%DH>Z74C C)J?Z $A:15C
MYCCZK2N#:[@PAB;&BMNS&\FK<GOW[EK(;;H8Y[T;H]''<>R(4,9(3,,J/HSN
M,6(C*!'$26?"LC.XM:,ER*B"M#N.Y1$?>(0"(1/U@.5HGFH:WN60PCV;X@?7
M+4'P_B5NXUTLKU$D(F<U%A30!$WEVF8;P,7!UWV(%&V7;C,,1U>J9&]-2%FA
M+3YU=DDBJ4#.=@>=AK=RR9/C<Q+HL V/;OSJ;I,IEW*D2SE]2MPRP8R.S93V
M2]]UHWI>Q1.^0DJFXRW1IS?X,IZ14[''/NG+A5@S[,(F/KD,&D,^/(3_/6%F
M]-I>1D3$Q-K=/G,[@;\83B!+J&D?B4"J7 2!$5(_FM* )W<1+I%787"::9.T
M4.NWG^';9'*>:IJR:&$;DXI3-24VP_2ICZ'3L:/;2"/>U,U$M4,-!^*B]?PZ
MNW!M5$ZYFM-$:"K9(W\4\V#2UE!F IJ.UJ3]8V,,UQ88+SC8@)&EP^'VXSE
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MQL]5Q7R6<F'U>3B;K4.A7, $C)T0 W^J.$YTP;4FXL1%1^0W9GE# NZ< B&
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M#K?]4 ,!5N6_"S0KT&_3L.EC!I_/#N#(2"\*#IT<1?ADU 52"I\'6?15^;[
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M8C/WQ!-2E2QWVHE6K[A[[,%Q6*@X-J8DF^/@<;8C3G$BODO=')IR3![%)O;
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M>*%%!J[=BYSQB+\B%!7-5*=>"IQ90JC6 TZ0$*.D1\2I7[I:"V(EIA%=O&*
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MU<5)_=%69T^+Y0TU6&7.SMW.9^-T0\Q7#%-\2@]@'/L9NYX"\@#YK4T *F2
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M(_.?B)O3@TYB1-/H2 /(>#GPI^8D<"#8KN9)K[+<O41R5[&?]S+[&V)=SLW
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M*$V1<!+ 8![^B-HKS.G8<8D@6SF2K\C%;8(O@.*7H.">6<?/L&=A)\"^B%_
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M9A QY"7Y6 #PLPQ\6))/[(EEQ*E:MVH]\K54(.Z0ZCV5:TTZP0[[<\M!=%:
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ML3F//0)["YVY]UIPQE'0Z[\6G%X'8N;I5'!&\1SB$;3@^2?#,NYVQV%IM@[
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MC8$PFJ8'/YY]#L!7*F.Y]M3]F2^U7P4M)$0SV/RMZ@# (@58\]"J,W=^WG^
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M>*SU!L=:>>!4VP'+R-&6]Q/\X<G_[\?;J$EUT5^X]<:G1[:A^E*I H/$'/-
M_P!Q[F%X58H=3FL==BS7O<!\P&)0/KTRG0SG#L/:Z4GE^-MC5XBNKD7\O;HG
MK-_$8?]-/+A4))$#9P-K'K:1S;7"*((QU_/P]L]OK[!\RXV=D8A[ZO'2Z?3P
MWJXL\"N7_HP'%2\4"K)3[ONQ/=H/_*C7-T8RE_Z1@Z9PK6#>O_+W+,_Q=$IV
M/5W)6U'<3RV!99]Z4:9YO?]>!9%I'#0Q V!J2OD-W>DO;GK;II$]G"$ +K"/
M9M(Q[%DP56Z,B;+=J"O..A\)<R96^E,HU%L(=?.]L!EMOK;>FH^,[73SJ?:!
MBA6>-3.VA*7V111,B#"?/\V#*C?ZD^.B5*K,=7?-:,H$3H#WRQ*"4O6 #)IO
MT#?_!5!+ P04    " "Q-$A6@-US7W %  "J#0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6S%5UEOXS80_BL#[V*1 *HM49>=PX"3[)&'38,DW451
M% 4MC2UV*=%+TG'27]\A)6N3QC4"]*%^,*_AS#<W=;)1^INI$"T\U+(QIX/*
MVM71:&2*"FMNAFJ%#9TLE*ZYI:5>CLQ*(R_]I5J.6!AFHYJ+9C ]\7O7>GJB
MUE:*!J\UF'5=<_UXAE)M3@?18+MQ(Y:5=1NCZ<F*+_$6[2^K:TVK4<^E%#4V
M1J@&-"Y.![/HZ"QS])[@B\"->3('I\E<J6]N<5F>#D('""46UG'@--SC.4KI
M&!&,[QW/02_277PZWW+_X'4G7>;<X+F27T5IJ]/!>  E+OA:VANU^82=/JGC
M5RAI_#]L.MIP ,7:6%5WEPE!+9IVY ^='5YS@747F,?="O(H+[CETQ.M-J =
M-7%S$Z^JOTW@1..<<FLUG0JZ9Z<?E2HW0DK@30D_VPHU7#:6-TLQEVC@X(Z[
M\?!D9$F8NS(J.L9G+6/V+XPC!I]58RL#[YL2R^<,1H2RA\JV4,_87HX76 PA
MC@)@(6-[^,6]ZK'G%[]&]1]*P\P8M 8NA"FD,FN-\-ML;JRF /I]EQU:*<EN
M*2ZICLR*%W@ZH*PQJ.]Q,'WW)LK"XSTZ)+T.R3[NT]LVET MX+PB!<AEHH%S
MKO6C:)8PJ]6ZL>YTJ^PN!?:*V*V SV80!O@VG9T0"A\H?L#PRRT4WD-9;NT^
M?P2#2\IP"U1=//DC<FT 7<0 ^1OK.07DUN?>432)CLA=E Q24EX;^(1<VLHI
MC7!=<4K5XA%NT'(A1W"G+)=PQB5O"@1N7W -X2TD:1#%;L+B((M2FD1A, YS
MFN23($T97-8K+K2'^N[-F$7LN!\/DC@Z[/[WR(FV4CH9)"'.,\<_HK,+*DW&
M"DO11DDWR8G7"SE^=X\$YC1)@BB=_$,3)X<T&=-1"'N"+NV#+GUMT+U(FUWQ
MM9_;';E]H23%DPL3Z^K-SL Z5^2#YM&;(S]V =:+YFW&<N-H7QDV >!#@2L+
M&U^X*=[X/6KJ0R#% N&C5L; K"C6]5IR=WQ%'?+KEM;SO=.\I!9)[1,.!(7L
M0C3"XD^2?%D>MJ9/)F.:;%W8;UV-9G#NBSOA+*A,NN)B1AI)E -7B97QL MU
MCPUO2+E&6;"*-NH56@06!2S,X( 89MGXT#%.XS%$\3"&.RRJ1DFU?(0H"+.0
MJ-SP,J2NM;H7)4%HT/IG "3$-8:#<<8.(0[B)")-AR%\X7*-SKAG:T/N\Y;Y
MOA::+)%.B#]C,=%G>4O=MI$X9'20)71 N-@PZ7+Q('*VB?-@[ /U((J#,,_=
M'DN"?,R<#I,V8_Y7 Z=!.$Z\@5.G1)0$*16+*"4%_[N!LS1R!G:EY54&CG(R
M<!(]-W T)@/G$V(T@7%O7RH"49"GL;<M"W+6VG82A"QS\&/XXS4_[Z?+II#K
M$G<E&V%]R\;;=()-)8H**LHAF".ZUU;AZCWA=Z6=F^VU"F6[9;CC11YP95NT
M<DK7-782JJZ;D.N4%*5/R'E7"MO'ZZZ".(1;1+A2SIVM3[+C;O#F-<*VI>!9
M^76@?#&#6Q)MNH+3#:TZ9>EODK5%TSZ,:37<4UJSOK1F^TLK/;K+M?2A0,'S
M)[U=2=-9TZQ)%G5S;<5?7AB\?Z!WN4&/Y^7CQ>U>X8.%#Z09_.JZZJ[*O!?,
M[L[ORO6J1\9;9/PI,GR"['6%>TO9.,0+A[A]!PA?T]OF8)XW?7*OB_ HR"@I
M:9'0-,U=?K#432G6F0_X@$T\0>ZFX>[^-WKR?J:"L?1?"09\!+=/Z7ZW_Q"9
MM>_O'^3M5\QGKI>"\$E<T-5PF%/ST^V70;NP:N5?XW-EJ3KY:44?4Z@= 9TO
M%(5KMW "^L^SZ=]02P,$%     @ L31(5FN@Z#!]!P  8AD  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL[5GM;]LV$_]7#EXW)(!JZ]URF@1(TA4K
MT&Y!DVT?A@</:(FVB4FB1E)-L[]^=Z0DV[&CM=NG <T'4R_'X[W\[L>C<OX@
MU>]ZP[F!3U59ZXO)QICF;#;3^8973$]EPVM\LY*J8@9OU7JF&\5982=5Y2ST
M_716,5%/+L_MLUMU>2Y;4XJ:WRK0;54Q]7C-2_EP,0DF_8,/8KTQ]&!V>=ZP
M-;_CYN?F5N'=;-!2B(K76L@:%%]=3*Z"L^LYR5N!7P1_T#O70)XLI?R=;MX6
M%Q.?#.(ESPUI8#A\Y#>\+$D1FO%'IW,R+$D3=Z][[6^L[^C+DFE^(\M?16$V
M%Y-L @5?L;8T'^3##[SS)R%]N2RU_84')QO'$\A;;635348+*E&[D7WJXK S
M(?.?F1!V$T)KMUO(6OF:&79YKN0#*))&;71A7;6ST3A14U+NC,*W N>9RW<<
M7=)P<L^6)=>GYS.#2NG5+.\47#L%X3,*@A#>R]IL-'Q?%[S85S!#:P:3PMZD
MZW!4XVN>3R$*/ C],!S1%PTN1E9?-.[B;U=+;12BX'_'G'0JXN,JJ#+.=,-R
M?C%!Z&NN/O+)Y7??!*G_:L3 ># P'M-^>><* N0*S(;#C:P:6?/::'KR(Q:F
M]0"?:W/,]%'EQTV_QV56LL2*%/4:#.4>A ;6UV9O2KYG2HVFE-:4'$U!!<H*
M/7*F-'#*/F#N>+7D:LB?_0V U05=^&?PMD88ER56I+8"[CV]@Y\:KI@ABW96
M>0&AE\P7=DRCR(US']Z(FM4YWQ$]@ZM**B/^9+;>T6!%)?E2KEZV*,*TYN@'
MJDI#2%(TQ' ,B &4=4I*P9:B%$8@6M+,BF5P+PTK876PFH8@GD,0QA $,=QM
M<.67J+#:$PGG$": 3O["E+!1WGV;!CZD?@S)8H$IUOH,P[]T J+&T',X28-3
M.$D6]).<6BSLA2;R(C]T(RYEQ\2'N[9I2H[,29;G3&]@A9E&G8[#'9V6S&"^
MC'0*]3_*)CQ@!#&P'9;T:'9OR)"&B<(NQ2K9$JS0T;*EM41MEZ_0FE99XRF#
M!XDYVT')X)K>ZI7[&-(.+YG#SQPS94?,VK@:T8.C(40Y-.UA8 <A#HG/:6H4
MNB@:S,2(*M3C0Q3#AR. E4N#>ZN+$/^4;UB]YE:SBXU<EF)MD[H7FTYSL@@@
M\,($48I5L]BO&DQ1A!F:9YC?"$:(+!F(+/D;(ML!WC4K[5)WMK=XNP7?,0[[
M KW+3J_K6<9!S2QO'<"X!W!@2>\X?#T*-F\,:J7>9LM*MLA)02%T3B &##G?
M0?O3)!RDY2@OG6"EOX!@[BW"C"X67H *;UJEJ!1VL/,$X7NL]8+2O%BX,4[A
MG:S7CI7&9@6IET4+"#(OF,\[PAN3/PFMJ9F71)VI61@]@=89W"K281YMK/@?
MK6@H@1ZLE=2=I;Z=[D7S!*[RO*U:E[^"XTZ5"Y?4DS"+D?Z"+#M]5B5M3%91
M&-LQR.;'(E<.T2CXDF8D%"FLO'?[+P(O]E-;-OY1^G\:\3A-W/*^#[_:-A"=
M8!\Q@%BI1^%S@K5LB?;TL&2#<!K23_:T6(/%-$:$38\LL@_% Y4Q3ORV^WVB
M-)XN\&&"2K^%_W_)GP7L6\?>^@ NQQ".&7B!^VY78/"P$?D&-N@"+#FG_MRZ
MP+O]0??3-KQTCS3#_9,RSQ3?VS>."LJZZV!J+4M16&#M4P<SA\PPA3O.X4=)
M!0W??9.%0?JJ&ZYR!)P6QI'#:SQ+:",,[E7:&G5%1L =+JWMA/FK;G#N%(6=
MB5C:8:RI+:4AB/F7%3O%$^FFCR<947Y6O=-$K/?/3L3NW+_/QO/2_XF4C&R#
MZ; -IJ/;U7N&-@RAWE:C:^/?;>-S;"<<5WVL<7<]N_@3E[,=E%O]\6C[!"TV
M=FK@,XK20<?TS*:YW]SU-++UCOC L25*4Y\>1%W7GB5VS$*B+VJ8(Q]O8]RG
M\&6XH(<),EZ&M]2(X*O8]HS(P=1 >T&,.ZL7IE:RZ[F]14;3 Y3'F"C.5@A[
MN^OY*.#% ?8]L><G06>3BT3#'BM[FJ&Z0Y49KHE2:&B8VA;:M>&B:EICT=QU
M@2>XP5$/[B4^->0D&Y_N:7YF3^CWR-#W?#_Z!PS[IB4\'Y3SX(@MVUH:5[J*
M%VU.5?5(WPI$U5;;(X6R[5-'&PM_*/^BY7WSO7*+.8S4LLXIQ64',J=&.\ZZ
M[\ZIK'[L8=-L&-90[C;G'($K<K '3U@I6<$]4VNLQANID-XZ]KOJ#@$[C9MN
MD8O&X:G(EQ5]UJ$=<"D_\BG<]HL[7_O31><;=7):]X?:[8Y,=%'9E3F2DJS0
MXE*L>"^X;$59H)R=R9I&R4]6O'S$"$X36/;,JUP*ME;9>&)OV16H(&=(XV<O
MB',U'2DY'<K8P)OV^T6+H',<[V8U3WQ7BHX(!(\Q,IL/9#;_ C+KR_ZSJ&Q<
M\5<J^TIE7ZGL*Y7]"RJ;[7SWKC@FA;[N8Q]-$7.?P(>GPS\0KMQW\ZVX^^_#
M>\RI0#(H^0JG^M-Y,G&'F/[&R,9^15]*8V1E+S><(;I( -^O)':HW0TM,/Q;
MY?(O4$L#!!0    ( +$T2%9$XF9RZ 4  /L0   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;+58;6_;-A#^*P<W*!) BR59ENPT,9"X'5J@Q8*FW3X,
MPT!+C,V5$E62BI-_OSM25N3&=M,.RX?HC;Q[[IY[CJ3/UTI_,2O.+=R7LC(7
M@Y6U]=EP:/(5+YDY536O\,NMTB6S^*B70U-KS@HWJ93#. S38<E$-9B=NW?7
M>G:N&BM%Q:\UF*8LF7ZXXE*M+P;18//BHUBN++T8SLYKMN0WW'ZNKS4^#3LK
MA2AY982J0//;B\%E=':5TG@WX'?!UZ9W#Q3)0JDO]/"NN!B$!(A+GENRP/!R
MQ^=<2C*$,+ZV-@>=2YK8O]]8_]7%CK$LF.%S)?\0A5U=#"8#*/@M:Z3]J-9O
M>1O/F.SE2AKW']9^;!8.(&^,564[&1&4HO)7=M_FH3=ALF]"W$Z('6[OR*%\
MS2R;G6NU!DVCT1K=N%#=; 0G*B+EQFK\*G">G;WE3-H5S)GF,%?&&KAF#VPA
M.1Q_HHLY.1]:]$.CAWEK\\K;C/?8C&+XH"J[,O"F*GBQ;6"( #N4\0;E57S0
MXFN>G\(H"B .X_B O5$7]<C9&STC:E85\)M=<0WO*M-H5N4<W@NV$%)8P0W\
M>;DP5F/U_+4K$]Y/LML/*>K,U"SG%P.4C.'ZC@]F+U]$:?CJ0!1)%T5RR/KL
M7>5%Z:I[@8K#"/)&:UZXH*Z9*&"+7\E$:> UOT,MUJ@LNRNB@SYW1_1IQ4$\
M 2/Z8&H"L_)@<@*3>S#%(QA  X!$P -G&CB5#F+->;E ;EKR(Q &G./*DF6#
MC>%K(\A+4[&F$/36-'4M.9EDLH_K%/.#&I(2[\UCKIZF* #4$@=U"S<8H,""
M<*ZI^.#X\\;/B7][!&D<3$:AOXG'4S\NG0;19 R?%($X@@@#2))D"\&\*1O)
MJ"OMX^H'@8R3( U;(!$Z<^/&TV"<A8] XBC(H@0NI01DR5AD1U1+D+V2)R*V
MN'*-H6X;0ZT%$:6<UP J7#D0H.:BDT\T35M_/^5AI\TCF ;3.(4#NAEWNAD?
MU,T-KFQ%(UU>-TI_<) ^5ZY.6Z%0W;:WE\4_V(M=E;ZYQP71\%W2.>AVOW0T
MSU65(PJO'D1%*OBV]..MA%&&G@ILAZBLZ^)$%QG=SZKL$H$0:"AB,DJ*@I&D
M%DPZ%OQ&8<VI;Q*+$A=U<[95U4]QWZR4MK\42*2+[^=X_]A[1PF[X]I'-N[U
M;4JY >6ZN5VQ"O&B:^A<)]E&D?L3@1()@R0\6&EI5VGIP4J;J[)6%=)@**PY
M(EI2IX2]J^ZNJCKL@@K(\T :<VQ3U&O3DM@'X-YT(/:G //EC+6]V.QIQG';
MDJG\\";<K@-'_:9=A9N0=[&^X$M15>01,=8<VTN!+$R"23C!:Q9,1RGUM&"2
M3>$]-UAO>XMA@N1A1?R8,U]WY"\D;UALY M;9(Y+BQ%4.<:/>?EB$D?QJ^Z:
M4",MBC/8)KH3YM,4S^D#RM*M<5D4C),(TB3(T@C&8UQ&QG#MVJO/^W$Z3D[@
M.)M,\'\23T_:ZCW@X#@Z@2P,)I,,TE$PS49DE\K99Z[M9[[-];&D49 FF+LT
M&,4C2"9!AHM&'TN&WRDSV107MR ,IRV6O&<1%[UXDI+C*!K3<I0A92Y!UYJ7
MHBEIPRQRP:O\ =H>V"4S2B&*#E&'5?@M:4ZJT19WSMV!;N%*Y+E>'KO!MP7Y
M]W/^'!O?I:R_[WFNUDC -,<+'C=<F$A^G\NFP Z&7:Z580!'N"%I']SD(RRX
M[B-24'-W+I(/ 46]X!429%M@E#E-:%IG_;9UY4<:,'SI%YH5LT!?,%*"X6;Y
M5BQZ#?IQ#_#==<:OP$>C:-H+!TME.YXX_OF YDK7"M<&/O0G@/\QEE/PN^3_
M5 4]_IDTZI%QU,Y64J*].2$W]5XQ4HJD0]]N&*BQL>K!:31[9> #+T1.4J^U
M*IH<X]JU3 Y[!]*2ZZ4[=AL,M*FL/YMV;[N3_:4_T#X.]S\+?& :&[8!R6]Q
M:GB:X29+^Z.V?["J=L?;A;)X6':WF-R":QJ WV^5LIL'<M#]WC'[%U!+ P04
M    " "Q-$A60)\#7/D%   M$0  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6R56'MOVS80_RJ$FW4)X-D2]70>!O)8L0[M5C39]L<P#+1TMHE*HDM2
M2?/M=R0EQ4XE)0M 68][W^^.QYP_"/E%;0$T^586E;J8;+7>G<[G*MM"R=1,
M[*#"+VLA2Z;Q46[F:B>!Y9:I+.;4\^)YR7@U69[;=Y_D\ES4NN 5?))$U67)
MY.,5%.+A8N)/VA>?^6:KS8OY\GS'-G +^H_=)XE/\TY*SDNH%!<5D;"^F%SZ
MIU>1H;<$?W)X4'OWQ'BR$N*+>7B?7TP\8Q 4D&DC@>'//5Q#41A!:,;71N:D
M4VD8]^];Z>^L[^C+BBFX%L5?/-?;BTDZ(3FL65WHS^+A%VC\L09FHE#V2AX<
M;4@G)*N5%F7#C!:4O'*_[%L3ASV&U!M@H T#M78[1=;*&Z;9\ER*!R(--4HS
M-]95RXW&\<HDY59+_,J13R^OA$0.7FT4855.KB7D7)/+C03 T&M%CN_8J@!U
M<C[7J,XPS;-&])4330=$^Y1\%)7>*O)SE4-^*&".6CMC:6OL%1V5> /9C 3^
ME%"/TA%Y0>=\8.4%@_)6FMQPE15"U1+(WY<KI24"Y9\^;YVLL%^6*9Y3M6,9
M7$RP.A3(>Y@LW[[Q8^]LQ-*PLS0<D[Z\=35#Q)I<BW+'JL<?%7G*79^YXP+O
MMD#6HB@L/]$FQX0C!MKJ-)HTTC3:WKY)J9^<*;+:PXLR1)@3*%<@N[Q8'.&-
M?TK>5PC9HL#J4^Z3>4T^B&KSDP998O5@_(-9] -14'$A224T*)+70'ZMBT?'
M<T2L<GJ&=_XT\CQ"9TD?RV_BWEEBV5HF?^H-LW3&/V.AD4?"_\,2+!:H(^UU
MI )#&Z#8 "UQU_ %R0$)_="N8!;TVG%9;[ [&-J0Q&BN6706TY=H73S<M3_T
M^W$,28)RS7HI%B$Y]D\(-7' %<[\'OJ/3&9;0QR1!8HT*YBEO>ZU^8\(G:8T
M;:^#U"[(,3IFC'778#04<>=:,!2VG>2%(4TZTGC62]GJ3TB04+O\V;CV!#TR
M**,-UOJHNW"E)++YBIJLO9#DQ6$4^G'<.A=X354UUP'J5K@EIU%W'4C(.UC)
MVK01Y/ /..C,[S7_%G:Z!9-E>8)I.(Z1($+P4[<&,MGD)\"<)[Y=\8O5'20D
M"@*[L!7TE7:;G^ P/_%K/,02"1.W!LC;!(7>03"PDXWE)SS,3]3OYD=F A=B
MF-$[WWHX0D:)049D,]%OZU[+V*..>E&]%^(PZ IKH-NV(0ZQ$2:17=& #0T:
M0J2R2&ZN ]AY"EAR$-YHYHW:D9+4TJ4-,D=3U_AFUCM>L2H#4@".D*3@;,4+
MKCDR^-,PCIIMX7?<<LU.BMY2C]P)S0JW2:+ *N,[?(PH5C7",IXF&+X;]Q%*
M7I=FCT5\^ OW-L>Y1M1FA#,;,@ZJ('&X(VMKB-GT,Z',?!<OXA-RG*1XC4PW
M2HQL/XG)!U#JE%S7R%:A$B'M&(U;?G&X@1]CGTE2E!%.T>63Y_N[V1:.$ _3
M,%F8&W^ZP/K[]]5_5L#[*BOJ'*/U3#=:<Q2T0P9YV'+,TA8'DQ6 F?AM (S3
MF!Y\NQ_V+13NO6(X^I@0X?C#G1J\KT:(49,9C3(<:T3!<V8TK%AA\^M.4DQ_
M/Q?-L &82M'8B=S<$)\U/Y?9UYHK;N*KICB0WH/27.-$ZG)WJ13*O$75JIG#
MFA_G5YY;3L0&K]PI#9]F(T-GU V=T?C0B2? O#8.K[$ T!X7#'RR*;XS63!0
MZYL^QR4?3I^OF3LE8(@,?B7LV*,[FB#IL^(PQ9>CG2@4&$*A$5;!-XW OP?R
M"$RZH)I* [9&*$V')MGO!MC CJ )5I@=>+ 2O=@-*<$T22,W55#L.TDS#$P#
MQ/Q=IPG[U]1?4');K[2M;2P&FJ8CS<%@WS6(WF9PU+:#UY=36U$=&.-G8/Q@
MC.@%VGZ.R@,\]&5L/>14+S3G>T?8$N3&'M05L07L3K/=V^Y_ 9?N"/Q$[OZ1
M@+UZPS%A!:R1U<.-94*D.YR[!RUV]D"\$AJ/U_9V"RP':0CP^UI@7)H'HZ#[
M#\GR/U!+ P04    " "Q-$A6@H-?\KP)  #](P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6SM6GMOVS@2_RJ$U[=( -?66[(W"9"D*:[ /H*D[?YQ
M.!QHF;9YE40M2<7-?OJ;H1Z6;5EQ6A1W!VS12!1%#N?]&]*ZV CY6:T9T^1+
MFF3J<K#6.I]-)BI>LY2JL<A9!F^60J94PZ-<350N&5V826DR<2PKF*249X.K
M"]-W+Z\N1*$3GK%[2521IE0^W[!$;"X']J#N>."KM<:.R=5%3E?LD>F/^;V$
MITE#9<%3EBDN,B+9\G)P;<]N;#/!C/C$V4:UV@1%F0OQ&1_>+RX'%G+$$A9K
M)$'A]L1N69(@)>#CCXKHH%D3)[;;-?5W1G@09DX5NQ7)[WRAUY>#:$ 6;$F+
M1#^(S=]9)9"/]&*1*',EFVJL-2!QH;1(J\G 0<JS\DZ_5(HX98)337 ,W^5"
MALNW5-.K"RDV1.)HH(8-(ZJ9#<SQ#*WRJ"6\Y3!/7]U7"KY/:*8(S1;D-[UF
MDMP+I2737#(P@28W+&-+KA4Y^T#G"5/G%Q,-JR.-25RM=%.NY!Q9R7;(+R+3
M:T7NL@5;[!*8 -L-[T[-^XW32_$MB\?$M4?$L1RGAY[;Z,(U]-PC]!XZY/W'
M]1P4 ;[SSRZ)2WI>-ST,J)G*:<PN!Q QBLDG-KCZ\0<[L'[JX=9KN/7ZJ%\]
M0H NBH01L22W:YJMF"(\JSDGO\T3OJ+H^:J+\U[:W9Q_6#.R% G$,<]61!L_
M(%6@$W :$ALND(F\\JIYQ8QHF#$NEH.S$:H4 P6+)_ VG*UR%O,E9_":22X6
M:D;>9^#R28(R&!OCQ:Z$Q64.R<\:^;=](QBWXEF&7(.NGAF59$B"D65-S=T+
M'%A),Q!4DQC\GMBN0VS;(M>Q+JCD-"$KR&_DS!Y9MGT.=\LY;Q;*Z3.Z#(2&
M&X7PTK.B<P+93">L[H=>WSWO9(V!.FJFO%'H615C6R%;RIJ1=Y1+\D23PIB]
M]:I+R& 4A"%<(\\O14D@C^I"9D3LD"5GTP!X=FR?W*5Y(I[!(C&$JN3S0I?*
M#TD8?87$/>RV!?='KA=4[+XK,#L0I:DN%-K'"O :1*0G9OPF9OROB1E,?N3:
M,-85*[TT_XJ5OV+E_RI6@B96@I-CY;J2_6=.YSSAFD,%0!Y8+%89_Q,X0-RA
MP'',R".6(EU1U+O:\2BJU9ZTEY;;I<$\)IY ]2+A"ZJA;U[Q8LHBJ&HT@5*!
MI7.P55TNF-@R(0*5K:$ I1SPM&@"I8[+W%1&2)\K) [JT.WH/A9ZOXHL+J3$
M:J*2 >I-+$9+?0E39E5OAB0"MQF2*9CVMIK4$GAW)HUC64"3?4$6X>V9XX$/
M.>!8K36/3B\73D2V>@-QG.X,/+.GZ*2.;P$MIK?LG>198>-9X<F>A:O<FQS&
MXR9H;C&QG+W/8I&RSDJSG_X'XP]I+C(38;!*QG25*6&5VL F?9WQ<I7&#3#(
M%$8<:.O :T:E:2O?L0B5Z&1B@^D5O.&8*YBQMZ_D:+:7:(<FU0Y-LH4KF.(.
M',!8]4BF<JTI&-.UT:1N!.YQG0JI^9\EN%1,T"9O)T(IXA*?.*T$97K!,VQ8
MD?SX0^38SD_&:"^H<PB^%+KE/0K,W;&C\Q[OB1KOB7JM^[O9:('4UX"&L''$
MY%2D>9E\/ZK2R=\R]&UN4GQ'16PLB%*T/:X3^_MY04]#N]+L&?)'N20R -KO
M@'/</38):UL=;&J!:"40;0E$C;<<3U^SEIN]Y2H6!=A,0A8D_M@A?R/..()K
M#Y\GA,;7\/TUX33;#YE=@9RQ"Z+81B!G/(5K$P#;;&9&@L:Z0\(SD\MK@.1Z
M_'':^./T:VI* ^>?:CA_H<+L7:$;&^];\%2+M^%Z7566AH?EMJ1(&56%+,U(
M$3\!)M"(8%M^!"$WD'S0_TJ+[Y68/[,GED!6*.].=7?)!Z$AE=Q2M39FC;'!
M_B@X<&%2WY @SD4V7.IL H\1+#_71"%;!HEFY./X<4Q66/%F)@]MWQ$_"(C7
M3/=#BSQ"!<2@4$J+C,<\IQ6<F?I9X$,,3*EBON!/7!G^Z]E0GNZTS;*QD+DP
MGM1:M1[EC +;WGMZ)R0$0]8UW+;LG?8#4WP! F'&Q72\@LAY,Z?Q9RSD#J<'
MK19$<,ID?.+,UK+5F8[QDKX9=KOYP!:,I;AS(>!U2R;ER^N4UE_LVM+8RQE%
M;MB,=$>>Y9([\ O]?&CU!60=!38#P'.;*<TBT&> ,3-)%9;S#@=!U]N:B&0P
MAF&-S [&[=]+_MD^7\0.@T-&H*_4*\^>@+XIYV>@MN/+N8YO_M"0(L.S.W,X
M^01;0EDHA&S8,36#K7"G7?(F]E?<&8/$ Z@2RK%U!=L>?>8@%H<>;N?<D0/C
MAV;6$'94SG1*_O6:?X;?5I'.2XC 78E,GC&]+*%M$"P^)G)56..8H6UY=8;!
MYT,[8$ /'7"=UJ@];QL;$>^^Q$FQ@!E#=VJU1Y?Z@_S'("6973EDN U+$KP/
M/=!=:W N81#8L6(DX2E'M,FIU!F3:LWS'=V6W($R6R0 &P 940TO3U>H/07:
M3!'TE*DNF[P-*?K7ZT\(U5!QXAL 6,C\V]QJEL<7F="8Z_X->B9:D 0SL\%K
M0(?*0BU@6', ;QFOG\?D>T.*_;T@)<"*>!KN8(KMAZ\"%1N"P6TG,WCVO@58
M?&NG?0JP>'ZT]]0#+$X+N;#]2F!QPG"G_3IP:>7#)@V^""^!L],^%6"\5JL;
M8$K;N2/7W>K<&_G^"1#CM.!YJTU[#V*BPT'0U0DQAR/MH[#B1(?0A7VOA94P
M,G\GP8IG6SOMEV %QR#Q$(JTEV#%'B'4([ @V _-O"'Q1R$HZ[\*+$Y@GP L
M-J!B'[#T;!9L:_M[F_7*[0)*5^>Z%_8)_;2/'Z*U$CCJL3H?,_JK5\X[DO^B
M, F]WL<=V\;UI_6VYY8.=-.<OM8'=;6KX+7W]!5WAC:Y+P"P8%,*B5G1I#*?
M:A^JAG@BAI</DF8*<HLY?6_+NQ]$=]EBCZ.F-OKN&GP!&$_4(!2]Y;57@_ >
M_K^LP>C<_'V#_AJ+]L5-ZW=J^^2X:?;][PH0D6U_K;VO3ML[8Z>7_O'8J<]-
M,-6G6 WL'8,L2Q[F>P?^([)9\WAM*C(H$N(B,4?3A:K]0=&4M4[?VH<G!9ZW
M0.E655AF>-_/1-UG1 >GD<8_@@B;'C2FV( -26B.7(*Z!W8108B-Z U4V@XD
M]1 @_G]($S2.B[0B4N)6OONQPC>JR'9*#95WO[H'U3VL[I5V_&FG>T]:7V1
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M=(&[:48O)E16@/[OI33-PAIHWV"K?P!02P,$%     @ L31(5F,5OR4'!0
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M5DQ WV?6^LV&%6S'VLF_4$L#!!0    ( +$T2%8B8H'A;0,  /\'   9
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M%Z$E K<MS%JP=0.6O (6)_!)25L8>"]SS'\%"$E9)R\YR5LG5Q'O,1O"*!Y
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MX]$$+CYZWA8CV'4"BXSPB^O!B&R1A".R14A1 <>$Z,_; @:%SG$51B+JN=,
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M)]?DRZ\/-K&Z:_<5*Y060&D42F-06@BE<2A-H&BF?K5A./4NVMN80BT_*"V
MTBB4QJ"T$$KC4)I T4R!:P-QZC80]9Y<>=U4DR2;UVO7%>2[=;V?[2I*OZ\W
MY,KL3XSN +TE#C4-6]K^XK0WW47LH#'963%#:$P.I0D4S92DM@RGYVX3]QHE
MO_\8IV0M%ZH)3LA<%8WGA\ILWK5*$VHJ0FG!M+MU6[6X]J$TH6;A63%#:$P.
MI0D4S92F-@:G;F/PL6H$*Y<OBO-F.,7Q!3[=J-[B@WI]4!IM:?O+A7JC(TN
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MK0]?JORAJ?7\+:^J?-M\O-?IK2[V@/KO=WE>O7S9;^!48/SB_U!+ P04
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MAP0K'(\$7R-AO#6;&5@Q+5JG3Y@Y]KD2>I5HG(KGI& D)REF"DW2E"^9(JQ
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M[).<OF-GV_5YMR#3A-Y:&.).#>:*1R-:?X'/*V/H>>';=3=L\[]02P,$%
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M4&AL<.QP@CTH2". WT="Z-7$&,B[VMX?4$L#!!0    ( +$T2%:(%.^%2P@
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M&'@2/SS]ID]L&A(B^Z8/J&B48$=JAIK$3\W=\_RBK#9EI=W_S..\/];HS8A
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M6EPN*9E1GA=0[^>,R>>;_)"S.M0>_0]02P,$%     @ L31(5LY56G2)"P
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M-[7/>!+"RQ+4!Q$4EQ;^9IJ_F;OV[<7?+&H-/):TJ<4Z)F#NF&!Y9,A@KER
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M?[^MZ^[+EV$2]GGT^=7_ 5!+ P04    " "Q-$A6D8H?E>D(   Q4P  &0
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M8A= ?8>.!\UH,&(1,W>CWYM]X/A@_+B"^TPNOXVIA@\4X@<V.Y&45:BBJ:4
M5O'Q0<H1G<CT-^CAJZ+!QA]A11_8P<?9P7/^&QL'GN.ND_? QHC#!Q+Q0YOM
M2,HK5-'44@"O^/BTY(AV%%JKN<-NM $:/H"&CX-&U[?FEU'2>0=5-'6A@"U^
M;+-O2=F&*IHZ)P>V"? 1RQ&3<O=@WZ(F:F) &@%.&ETS&N<_N.O4':"*IBX4
MJ"6P*=D$I'A#%4TM14^UF2W;!(>;$3-1$P/8"'#8V#6C>0*$NT[> 1MCCP#0
M);"IW@2D<$,532T%P$TP5\$)= E':T;,1$T,4"/ 4:-K1N,,"'>=O ,V>"0
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MGI0=(V4^4K9?5#;VHT8]:G0,-?*A1GNH.$K\J'&/&A]$_:@ N_#2@/(!QWO
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M>>7\YT/3@/-+S3?5?Z'@//<F@'O37KMOJUVVXN>+YN*L>/G(%Q=__QN+W']
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M3(Z:J#T3H)58UEK1- >I'6_!>J2F6'%+!-@E\RJZ)J2T1^5-#9XDKS2ZZ)H
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MY?)0WM1L L(I7C%WDA=4+X;9M#WA#04S-<]X!C!EDU?9G461W7M[=B!O:DZ
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MO=IEK4EO,+',^0!X&M#7T!@!2NW>XS60-S4G /&@.\0QC1&X;YBC)FIX@.H
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M4L$5UP(.;Q,-MZ,CN,89,JC"81\UH4P=&<0]AHF4E(_-^/&A#X<'1W  E,.
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M.#']'$IK8/9'0NC%Q!Y0=(C!'U!+ P04    " "Q-$A6;;$4B&$%  ##(@
M&0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6R]6MMNVS@4_!5"6RQ:(*E$
M4KXD:QMHD]Z 9#=HT.XS;=,V44ET2=I.@/WXI61%-"V)MA.V+XDNYXS.D-*9
M$:W!AHL?<D&I @]IDLEAL%!J>1F&<K*@*9%O^9)F^LR,BY0HO2OFH5P*2J9%
M4IJ$*(JZ84I8%HP&Q;$[,1KPE4I81N\$D*LT)>+Q/4WX9AC X.G 5S9?J/Q
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MH=EDC?YCI^[ZZ\CE=5R3Y0RQZS>ZCMVZ[K4CX\,6P!EB<]CY0<"])'"X(Y<
MSL)<(79A1JZQ6ZZWG1B?T(G=@"<_&[_B;1X;M<>=9_]2X_0))_/TA&;S-(X
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M"7?P+JU<H+9K6_EES+I6/JS8'KZFE>$O#'!,S-\ PG&2B G7:A<RR@E/*&%
M7 >LHET+_]9SVQ#8DA*=2HG.AVKXSB:%VQ#8DG!A\&0F@G=I^1)V\6H.GG5\
M;4A!UU^P03G*H7.'"EP3%TZB6JT<Z+'S7<_6^]:9.GOU!%/8VDLBAY0K8)@9
MR&#_P/"1A5,L)EJ,G=FZ%]I8-S<<&7>-T@:8]YD0>CZQ&U1^/?X'4$L#!!0
M   ( +$T2%9Y!RU6? 4  ,\G   9    >&PO=V]R:W-H965T<R]S:&5E=#<T
M+GAM;+5:6V_;-A3^*X16#"V01A)E^9+9!FIS:P,L:Y"LV\.P!UJB;:&2Z$IT
MW +[\:,ND41;H>3@^,76Y9R/YWPDCSY1G!YX\C7=,B;0]RB,TYFQ%6)W8YJI
MMV413:_YCL7RSIHG$17R--F8Z2YAU,^=HM#$EC4T(QK$QGR:7[M/YE.^%V$0
ML_L$I?LHHLF/!0OY86;8QO.%AV"S%=D%<S[=T0U[9.++[CZ19V:%X@<1B].
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MAQIL$Y98@FT9['L/7^'>?U]IW=)#M[A56ES3.CX1$EL35LZZ&Z5. 3PS-:9
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M5"NW51MY-B]7&GO(\CQ+RH\S'DZX* Y0WT^S+'_9* +4Z^>-_@-02P,$%
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M!!Y?/[N_M_ :9D4DW//J3[I6Y<*;>&@-&[*OU"=^^!5:H,3X%;R2]B\ZM-K
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M73+.# -]TY>8YN!A_\&VV]SHBF8P]["=:%!/X"7OW@3QX,^^H%Z2++T0V5[
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M2W!"N Y0OZ\9D\\W^DM?^V5W\1]02P,$%     @ L31(5N]W8O72!   @QP
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M8[_5V*_8^V]H?)!B)96D%^!>@HD2,G<@='H([])?_+^YX D^[[GI',*/!^:
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M')#[!Y2O'% <#BC./: \'%#Z!Q2O'% =#JC._1[JPP'UN2^I.1S0G'O ]'#
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M]OB;]SO_U]7Z[T\U/OX?4$L#!!0    ( +$T2%:+N!DC'0,  /H*   9
M>&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;*V676^;,!2&_XK%JJF5VO(5(.D2
MI#91M4FK5#7KIFG:A4-.$JO&9K:3M/]^-A!&"*55M!NPL=_7SSD8?(9;+I[D
M"D"AYY0R.;)62F57MBV3%:187O(,F!Y9<)%BI;MB:<M, )[GHI3:GN.$=HH)
ML^)A_NQ>Q$.^5I0PN!=(KM,4BY<;H'P[LEQK]^"!+%?*/+#C88:7, 7UF-T+
MW;,KESE)@4G"&1*P&%G7[M78S07YC.\$MK+61B:4&>=/IO-E/K(<0P04$F4L
ML+YM8 R4&B?-\:<TM:HUC;#>WKG?YL'K8&98PIC3'V2N5B.K;Z$Y+/":J@>^
M_0QE0('Q2SB5^15MR[F.A9*U5#PMQ9H@):RXX^<R$36!VWM%X)4"[[T"OQ3X
M>: %61[6!"L<#P7?(F%F:S?3R'.3JW4TA)G7.%5"CQ*M4_$-%UI!V%(BS.9H
M+&!.%+I>"@#]LI1$%V@",X7NL%H+H@A(=#H!A0F59WKL<3I!IR=GZ 01ANX(
MI?K5R*&M-)GQMY.2XJ:@\%ZAF$!RB7SW''F.Y[7(Q^^7N_MR6T=7)<6KDN+E
M?OXK?E\Y6UXH$&D>^SFZ)3+!%/T$+':)>$&_KF=2";T-?[?%6RS0:U_ ?)M7
M,L,)C"S]\4D0&[#BCQ_<T/G4%OU_,MO+A5_EPN]RCW5*_;8 "U60J\R_8A.[
MD3L8VILZ>*?UD>"]"KSW%GBO#;Q0A35P+W+"!GBG]9'@004>O 4>M($'!^!^
MU \:X)W61X*'%7CX%GC8!AX>9CQPH@9XI_61X%$%'KT%'K6!1X<9]Z/F'N^T
M/A*\7X'W.\&_K4"?W0O]JVK#[[=L&'?@-?@[5SB2?U#Q#SKYI^N9X@K3-OK!
M 7W@>OU^@[[3_TAZU_EW>#J=_+>$898 HJ K"40)GA&:'Y*M1Z!S$)';"YL?
M<#EK[\?J.TXU:Y^T=LR[W3O%I%G7-_HHSP1A"<G:LU[:U)</O"CPFY0MT\*H
MYS<P[5IA8JK".RR6A$F=KX76.9>1-A!%H55T%,_R6F7&E:Y\\N9*%Z<@S 0]
MON!<[3JF_*G*W?@O4$L#!!0    ( +$T2%8NKJ6WAP0  /X9   9    >&PO
M=V]R:W-H965T<R]S:&5E=#@Y+GAM;+59;6_B.!#^*U;N=-J5M@TV!4H/D K=
M:E?:2E6K[GXXW0>3#& UB3G;0"OMCS\["7EA4R]0DP^0%\\S\XQGDB?.8,/%
MLUP */021XD<>@NEEE>^+X,%Q%2>\R4D^LJ,BY@J?2CFOEP*H&%J%$<^:;6Z
M?DQ9XHT&Z;E[,1KPE8I8 O<"R54<4_$ZAHAOAA[VMB<>V'RAS E_-%C2.3R"
M>EK>"WWD%R@ABR&1C"=(P&SH7>.K">D:@W3$=P8;6=E'ALJ4\V=S\#4<>BT3
M$400* -!]=\:)A!%!DG'\5\.ZA4^C6%U?XM^FY+79*94PH1'/UBH%D/OTD,A
MS.@J4@]\\P5R0AV#%_!(IK]HDXWM]3P4K*3B<6ZL(XA9DOW3ESP1%0/<?<.
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MB)=[FO#MN 5;^P=/;+%4^8/V9+0B"_I,U=?55.B[=H42LY1FDO$,"#H?MS[
M.]P)<H?"XD]&M_+@&N2AS#C_EM]\CL>M(.\136BD<@BB?S;T@29)CJ3[\;T$
M;55MYHZ'UWOT7XO@=3 S(ND#3_YBL5J.6X,6B.F<K!/UQ+>?:!E0+\>+>"*+
MOV!;V@8M$*VEXFGIK'N0LFSW2WZ41!PXP/"$ RH=D.G0/>'0*1TZYSIT2X=N
MP<PNE(('3!29C 3? I%;:[3\HB"S\-;ALRS_[L]*Z+=,^ZG)M/R$TX1D$I L
M!K^K)15@RJ425#%!]4=6X)YF=,Z4!._!%R($R3\6>(NI(BR1[_33K\\8O'WS
M#KP!+ ./+$DTJ!RUE>YBWE [*KMSO^L..M$=B, CS]12@H]93.,F0%O'5@6(
M]@'>(R<BIM$MZ, ;@ *$+!UZ.-\=6MSQ^>Z!(YI.];DZ!5[G)-Y</XGWWZ/X
M;  S&25<K@4%?_^F7X//BJ;R'QO[._2N'3V?8^[DBD1TW-*3B*1B0UN3GW^"
M8?"+C3F?8-@36(/5;L5JUX5>L1KIH2?8;%W,2"M-[0V@Z2KA+UH0A^^L WO7
M1*]H(I]M-Y->V!^U-X>,66QZJ&F#+3;YT-E8XNM5\?6<\1V*W-9UI_>EH\(G
M&/8$UF MK%@+KZJUT">K/L&P)[ &J_V*U;YS+'X\6U [G/! ",C4T[%)?V#(
MR8+2LZMI4$4P<$;PJ%,*5LT+^30A;XJ?UT,:''<F,$(Z-H%#(R2G22.D8172
MT!G2?HCS6<(6).^^K??#HW:[_:[9_V.C, C,""Q&W1#98X!!G<H$SBB^Z#1Y
M107C,8O K PITHF,-0\)CN;9][#?,:(IK<*&U2 TPK%9(3@X$<]!:@;/GK;!
MO^#C]S53+T#2:"V8'H'V],H)>>FLXQ4-^T)KTHEJ.M%5Y_,2WA>U/M&P+[0F
MM756"IWIV>0/(A9:?"S;4*F*@H$D"8_(R8FPQ,N%4TDFN(7(E)_7%-,76I.D
M.LF$[BS3D#.F,_6:F)V %X\XGVC8%UJ3S#JCA;WKBMEKSNL5#?M":U);I[W0
MF?_]#S&'-C'WS63-W>S%)%TCB85U%@O=::PAYB=*$J#I(HH>$&<ERXE[\<#S
MB89]H34YK?-J.+BNIIUY^\74^D3#OM":U-;Y/70G^)=K>FC3=- S->UL]F*2
M/*$U%PKK^@&YZP=#TU/!-KF>Z2[OKKFS$N;&OG3P>47#OM":O-9U#()7U37R
M6M-X1<.^T)K4UC4-<B;VE^NZQ#-U;=:][F8O)ND:U0FJJQ/DKDX,77^B\8*"
M^3J+7]6TU^5RKVC8%UJ3T[J80=WK:MIK:>,5#?M":U);ES;(O5I_N:9[YVG:
M:Y'B"ZU)4EVD('>1XMREM)+D=3G>*QKVA=;DLJYE4/^Z6O9:TGA%P[[0FM36
M)0VZVEY!B7RX0!V:ZV/H>"L@-!;DL<6FU[4O3:.ZGD ^-@S0\3H_[ W-&(Z-
M4- W@[A&9="I*X..QYV%SO'.0M>(^743;#&!Y@Y)^^#<1TKU?XW\_(S4'5MG
M:G="HGI:G='Y4)Q,,9[?PSN\.VE3P^P._CSJ?T8LDR"A<PT9W/9UA\3N+,WN
M1O%5<;IDQI7B:7&YI"2F(C?0[^><J_U-WD!UHFGR'U!+ P04    " "Q-$A6
M L>:LB0%  !7&   &0   'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6RM65%S
MVC@0_BL:7^>FG6F"98R!'#"3X';:A[1,,[U[%D: IK;$22(D]^M/LHUM+*%0
M#R_!-KO+?M_*NY^4R8'Q7V*+L00O64K%U-M*N;OK]42RQ1D2MVR'J?IFS7B&
MI+KEFY[8<8Q6N5.6]@+?CWH9(M2;3?)G"SZ;L+U,"<4+#L0^RQ!_?< I.TP]
MZ!T?_"";K=0/>K/)#FWP$Y8_=PNN[GI5E!7),!6$4<#Q>NK=P[LX"+1#;O$W
MP0?1N 8:RI*Q7_KFZVKJ^3HCG.)$ZA!(?3SC.4Y3'4GE\6\9U*M^4SLVKX_1
M/^?@%9@E$GC.TG_(2FZGWL@#*[Q&^U3^8(<ON 0TT/$2EHK\+SB4MKX'DKV0
M+"N=5089H<4G>BF):#C Z(Q#4#H$;8?PC$._=.A?ZA"6#F'.3 $EYR%&$LTF
MG!T U]8JFK[(R<R]%7Q"==V?)%??$N4G9XNRA(L440$078'O<HLY6# A.9:$
M8U5D"1XPQ6LB!;@Y7H+ORY1LD"Y>X:<C@'LAL+)Z'V.)2"H^*/OF+ZC;GT\Q
M>/_N W@'" 6/)$UU@$E/*BPZHUY2YOU0Y!V<R1L&X)%1N17@$UWAU6F GB*A
M8B(X,O$0."/&.+D%??@1!'X06!*:7^X.+>[QY>Z^ TV_JFL_C]<_$V^^172#
M-<?+LEZLJM>=C>XB7&@/I[O/G=BA!$\]U5X$YL_8F_WY!XS\OVQ473-8?*5@
M)S2&%8VA*_KLP2#OHR)T0R@E= /8&KQBQ&UT%F$'>5C=>Y]GD>^/)[WG)DT6
MHS *3HUB9X(=X0\J^ ,G_*]48A55@D2U QO,PCUJ((#]%H"YQ0;Z+9 #@PD8
MC2J;D]RC*O?(F?M](O>($Y2"C1I_MN0C([$;Z$/82M]JU2Z2,Y6.11I60(<7
MK=$=>M6]VMI,AR:(_FC80FHQ"OU1"ZDSEXY(1Q72D1.I4B$RQ6=!CBP@6Q M
M)H.63>S,H2/"<85P_-O]!JOAZN@T8P-2. Q;[]?<-#+;46PQ:K:C$T#0KP6&
M?^$DVFD%@'*%8!U!9: KS:"K1HNO%>V4Q(9*@V^LB^/,62+%8H*M_$&S@-&P
M_9;;K$;AH+46W/ETQ1O4>(.WFW>J-A9RSRE@)VO'"CTP7^QQ-&I#-ZT":"!W
M9M85>:W;H%//S#YENY2]*@6>*'G+R7(OSPKDOHG&*+9I,VQW=%N<P9FWOM9-
M\#+AY!I*98@WII+-RAQ+[G2Z5JW62= ME-Z83-#40,9HLMD8L\F=1E>8M:2"
M;DVE]EIO]2!3+@WZ8=3&:EJ9G2HNK0;G.M4IB%HN0;=>^KS7.T8@)))[>[5,
M(13Y!@2+4;OAQ.Y,NI:KEDMPY!R]Q]UX2M"2I$02K';D'"=L0\E_B@+55]5F
M7W<:P5*R0E(]*VL+\B,%*SM7TD<EC=>,%E\KVBG?M7B#;O7VC=%DS[D^,"E&
ME3X9TR=<BE>E?UA^LN(88J8 &YD=W30:M]^OV)UG1QZ"6O(%3C4TFY<D--;=
M*1,H2?A>7>*7':8"6]DH?^.D'P9ABPVK4?LM=&?;E8U:NP5N[=98%6<)*99&
MRNCF1NVXLZ:AE1M3P]W <7NIV*R"07OK[<Z^*SNUT@O<2N\;EHY7HG0>.%NQ
MS<AHQ>XT?A=FKW'BFF&^R4^NA>JD>RJ+(\?J:74Z?I^?";>>/\"[N#CCKL,4
M1^Z/B"O-+T"*URJD?SM4^'AQBEW<2+;+SW673$J6Y9=;C%:8:P/U_9HQ>;S1
M/U#]+V'V/U!+ P04    " "Q-$A6.;UUTCP#   ("@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Y,RYX;6RM5EUSVC@4_2L:;V<GF6GB+S!L%CP3H)W-0U*F
MF7:?%?L"FLJ25Q(AW5_?*]FXQ B:A[Z )9][=,Z]LJXF.ZF^Z0V (2\5%WH:
M;(RI;\)0%QNHJ+Z6-0A\LY*JH@:':AWJ6@$M75#%PR2*LK"B3 3YQ,TM53Z1
M6\.9@*4B>EM55'V? 9>[:1 '^XG/;+TQ=B+,)S5=PR.8+_52X2CL6$I6@=!,
M"J)@-0UNXYO%V.(=X"N#G3YX)M;)DY3?[."NG :1%00<"F,9*/X]PQPXMT0H
MX[^6,^B6M(&'SWOVC\X[>GFB&N:2_\M*LYD&XX"4L*);;C[+W3_0^AE:OD)R
M[7[)KL5& 2FVVLBJ#48%%1/-/WUI\W 0$&<G I(V(.D'#$X$I&U ^M: 01LP
M<)EIK+@\+*BA^43)'5$6C6SVP2731:-])FS9'XW"MPSC3+YL*[CD5&A"14D^
MF0THLI3:*#!, =;8D!D(6#&CR15YP+VX!,5DR8K]/)DCG%S<B4)6<$DN%F H
MX_H2X8<+X/#+XX)<O+LD[P@3Y)YQCN_T)#1HQ0H*BU;VK)&=G) =)^1>"K/1
MY(,HH7Q-$&(.ND0D^T3,DK.,"RBN21J_)TF4)!Y!\[>'QY[PQ=O#HS-NTJZL
MJ>-+3_#-955+@9731*Z(P)+5^Y(]M24K7,E84[(;7PF:)0;^)>QY=*-K6L T
MP -'@WJ&(/_SCSB+_O:E[W>2+7X3V:O4#KK4#LZQYW?" +(V"?2EK0D?NG![
MZC[G<8H[ZODP&QY,'+W&+#R8;-QA7FD?=MJ'9[5_>*GQO(42#VRS58+@=UG;
M[Y)J#<;[&39\V8&(JS3ZJ^?&!XI'/3L^T/B$GZSSDYWU<UM)9=C_U+60=J-C
M)]E2Q2@G7&JOI^Q(2=HS=(P8]MP<(Q*_E5%G9736"C98PYO#UNH&K_+1T:IQ
M3[D'D?6D'T,BO_1Q)WU\5OK#+X\7GY?QT?:^BD?]0OA X[XA#RB)^SLK/.B1
M%:BUNVMHE+D5IND2W6QWG;EU7;PW/\-K3G,K^4G3W)'NJ5HS[*(<5D@978]0
MDFKN'<W R-IUXB=IL*^[QPU>U4!9 +Y?26GV [M =_G+?P!02P,$%     @
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M(O26@J))%-J47JTQ5G$M2RNHYH"B213:E%JM.59 R]+*;UGRETA^17-WK*7
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MI^5+V_?M]OC'!U7?JNY0,'S_KFW[\8O+ ?]KV_UZ?(VK_P=02P,$%     @
ML31(5O^9[R?< P  LA   !D   !X;"]W;W)K<VAE971S+W-H965T.38N>&UL
MK5CO;]LV$/U7"*TH6J")1$FV[,P6$#L;5F#!C&3M/C/RV1)*D2Y)VQVP/[ZD
MI$B6)7%)ZR^V?MP]O7<B[_D\.W+Q1:8 "GW+*9-S)U5J=^.Z,DDA)_*:[X#I
M.QLN<J+TJ=BZ<B> K(NDG+J^YXW=G&3,B6?%M96(9WRO:,9@)9#<YSD1_RZ
M\N/<P<[SA8=LFRISP8UG.[*%1U"?=BNAS]P:99WEP&3&&1*PF3NW^&:)IR:A
MB/B<P5&>'",CY8GS+^;DXWKN>(814$B4@2#ZZP!+H-0@:1Y?*U"G?J9)/#U^
M1O^]$*_%/!$)2T[_R=8JG3L3!ZUA0_94/?#C'U )&AF\A%-9?*)C%>LY*-E+
MQ?,J63/(,U9^DV]5(4X2\'@@P:\2_/.$<" AJ!*"0FC)K)!U1Q2)9X(?D3#1
M&LT<%+4ILK6:C)G7^*B$OIOI/!6OJC>RHH1)1-@:_:52$&C%I1*@,@'ZG2FT
M  :;3$ETA98I85N0*&/H3S@ 10$Z!4&W4H(.?'<'BF14OM<IK?M7Z-/C'7KW
MYCUZ8S#N,TKU/3ESE99C2+E)17U14O<'J&,?W7.F4HE^8VM8MP%<78>Z&/YS
M,1:^%?$.DFL4X _(]WR_A]#RY>G80B>HWTU0X 4#>&6E39%VIG"D*.Q-7Z%*
MG+ ?QW2"&[DC"<P=O=4EB ,X\=M?\-C[M4_DA<!:DL-:<FA#CQ>PS1C+V%;O
M3:TY@3ZU)<2H@#!MZA"/QU$T<P^G*GJ")N&H#FJQ&]7L1E9V>IW]#[4R?WSR
MU%$0CL^H=8-:_%O4QC6UL95:M17[.%D37[LX+@36TAC5&J,+[8?HDI(O!-:2
M/*DE3WY^/TPZZRF()F=KKB<F#/J7W+3F-K5RNTW4GE#MY6HO&.*MM])'<]JA
M8+IDBV4W9(@D]AJ#\ZPT5WN1I-KHY0<D"872Y#1'10MKZS<>KT/D*@K/R/8%
M30;8GM@QMK+]6V@?WH"02/_F0GR#+!N[@CHEX)USM(6T*?H-1?\GNV %T%IM
M_NB<6D]0-%2_QC*QU9[B!]!+$J0B"M!_UN)=U#,OA=96W;@F#B_4&;'5?U\M
M^T)H;=F-'6.['[^H.^*NW7;;8U_08.MI/!G;3?FU';*"L[;(GIA!HHVQ8JN)
M_5B/C%[2(WN"AO9XXXG8;HJOZI%=X^OT2%M(FV)CC=CNC2_HD=/.#]2>'MD3
MU.F1[LGTEX/8%D.Q1 G?,U7./O75>O"^+<;-L^L+,Y 74V4#4T[S]T3HG281
MA8V&]*XCS4B4 W)YHOBNF#&?N-(3:W&8 EF#, 'Z_H9S]7QB'E#_31%_!U!+
M P04    " "Q-$A6I&I.9O("   8"P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Y-RYX;6RU5EUOVC 4_2M65DVMM#9Q @ET$&F43:NT:JA5MX=I#VZX@%4G
MSFSSL7\_.X1 AY.@:7TA_CKWG&OK'NY@S<6S7  HM$E9)H?.0JG\VG5ELH"4
MR"N>0Z9W9ERD1.FIF+LR%T"F!2AEKN]YH9L2FCGQH%B;B'C EXK1#"8"R66:
M$O%[!(ROAPYV=@OW=+Y09L&-!SF9PP.HQWPB],RMHDQI"IFD/$,"9D/G [X>
MX<@ BA/?**SEP1B95)XX?S:3V^G0\8PB8) H$X+HSPIN@#$32>OX509U*DX#
M/!SOHG\JDM?)/!$)-YQ]IU.U&#H]!TUA1I9,W?/U9R@3ZIIX"6>R^$7K\JSG
MH&0I%4]+L%:0TFS[)9OR(@X OE\#\$N 7^C>$A4JQT21>"#X&@ES6D<S@R+5
M JW%T<R\RH,2>I=JG(HGY05/&,DD(MD4?54+$&C"I1*@J #]! J-((,951)=
MHK$>9##=+97(CYM<W_/!\OD8%*%,7J S1#-T1QG3/'+@*JW:<+M)J7"T5>C7
M*!Q#<H4"_ [YGN^CQX<Q.C^[>!G&U4E7F?M5YGX1MW-"YC95C6A3+-<R)PD,
M'5T-$L0*G/CM&QQZ[QNT!96VH(@>U.9\?,=H3&7"N%P*0#^^Z&UTJR"5/VW:
M@U?0WJFT=QKO53]38-.T174+E/&*51R$O8&[LE!U*ZIN&U7'1K5%A2^H^G:J
ML*(*VZBZ-JKPF"KR[511116U484VJNCTK'H55:^-*K)1]2Q4D9VJ7U'UVZAZ
ME[X7^#:^_A$?CJ+03HB]O;5YC92-3F8UHL9X_U@W^,"*\:M6?1G^/\O?^REN
M-M2ZPB]A+UZWID3PWB!QHX?5EGX).XEL[VBXU=*LQ5_"3B+;>QIN-35K^>-C
M5ZLEV[L:;K4UJP'@8U^K)=O[&FXUMGH+*+&'_P_=O]W-/>AS3,]X1\2<ZN:#
MP4R#O*M(H\6V#=M.%,^+UN>)*]U(%<.%;EU!F -Z?\:YVDU,-U4UP_$?4$L#
M!!0    ( +$T2%;!5I[21@,  !\,   9    >&PO=V]R:W-H965T<R]S:&5E
M=#DX+GAM;*U76V^;,!C]*Q:KIE9:"^:6RQ*D)JQ:'RI5O6S/+GQ)4 %GMI-T
M_WZV(900)ZNJO#08SCD^YS,V7T<;RE[Y D"@MR(O^=A:"+$<VC9/%E 0?D67
M4,HG,\H*(N20S6V^9$!232IRVW6<T"Y(5EK12-^[9]&(KD2>E7#/$%\5!6%_
M)Y#3S=C"UO;&0S9?"'7#CD9+,H='$,_+>R9'=J.29@64/*,E8C ;6]=X&&--
MT(A?&6QXZQJI*"^4OJK!;3JV'.4(<DB$DB#R9PU3R'.E)'W\J46M9DY%;%]O
MU6]T>!GFA7"8TOQWEHK%V.I;*(496>7B@6Y^0ATH4'H)S;G^BS85MN=8*%EQ
M08N:+!T465G]DK>Z$"T"#@\0W)K@=@G^ 8)7$[R/$OR:X.O*5%%T'6(B2#1B
M=(.80DLU=:&+J=DR?E:J=7\43#[-)$]$MV5""T!/Y TXND3O0W3/Z#K3RWL>
M@R!9SB\DX/DQ1N=G%^@,926ZR_)< OC(%M**$K23>MI)-:U[8%KLHCM:B@5'
M/\H4TET!6V9H@KC;(!/WJ&(,R17R\#?D.JYK,#3].!T;Z/''Z<Z1-%ZS+)[6
M\P[H35>,02F&ILI63-_,5.?$D"]) F-+'@0<V!JLZ.L7'#K?354YI5A\(K&=
MBOE-Q?QCZM$-I,!(;BI810PT49V#Z\CM.][(7K<+80"Y_6 7%!M (7X'[1@/
M&N/!4>./@@@PV:YH86NRGM<Q--W'A&'7]#XFP'VSY[#Q'![U_$0%R>7QI%]2
M)-3A84H0[LWL!5Z_$V$?Y X"IY/!H(0]SQRBUX3H'=UC,<Q !DB-FZQWRDUV
M2K'X1&([)>LW)>M_=I/U]U;H$@?AH+/8!I3GA)W%-H#\UANQXWS0.!]\;I<-
M]B<+NHZF!A!67YD=VR80]LVVL?/^?78^L-72^EV57UW]@3ZXY6JU'1>NT^N>
M&R:8[W:V9FQ"!>&A2*V6 _\_DM$\WCM?L1]V3VH#R@WV5L.(:KV/E7>[U3D5
MP.:Z ^4HH:M25+U'<[?I<J]U;]>Y/U'=K^[(WF6JUOF.L'E6<I3#3$HZ5SUI
MB57=:#40=*G[LQ<J9+>G+Q>R@P>F /+YC%*Q':@)FO\)HG]02P,$%     @
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MK?@\C8]#27N./)"X9\@#.9&JR\[/Y5D_V$(9#M@R&6\J+CT;QKUCOO& 1KW
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M@@R<@MRS0BH)I IX-1LHQ^LRS4^8*.>B:GJ RN]/]9E- ><QCLWND+ ($D:
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M-U5;8P]:+P"E1: T D4S]6GJ!>&IZP4A:+T E!:!T@@4S92RJ1>$;J,/DO-
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M!VAY +2\X61;'(E\()R3K+C<8!1C*@W$_U>$\/V-K.!P#'?^+U!+ P04
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M<@LD :X!ZOLU8_+M1@]0'W?-_P502P,$%     @ L31(5I01.50.!   G1L
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M?5:>)=MJ+5\26LB8\>0?E7IIQHI<]MD]"#_7;DR8APGS*]BDE=MMJ_GK9OD
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MK'F3;IY^_5R+DD:P,-3[10 _@N']^<IVK8]=+L6$^9BP%29LC0G;8,*VF+
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MH)[O&9./ WT\V!ZS>[\ 4$L#!!0    ( +$T2%:V3;KVU ,  /P.   :
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MH0?@^R7GZNU!?Z I>.?_ 5!+ P04    " "Q-$A61#(8?24"   /!0  &@
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M\\_9_:^LN:'J L,L+JJ_SGV#=0=.N"MXEC3!X@J2**W_!P^-$ <!@@<.P$T
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MZ!$P)2W1U(,VIM:6]$FL_+X23'XE4D_,;Q&+2;SE8(D96.T0P^#<QP*1D%^
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MG.86\T<5!4IAJ9R<BY'RYL711S&0;)V?'CPP*5F6WZX )\"U@7J_9$SN!_I
MHCJ "O\ 4$L#!!0    ( +$T2%;1#5Z_E0,  !L-   :    >&PO=V]R:W-H
M965T<R]S:&5E=#$Q-BYX;6RM5]&.FS@4_16+K:I6:@<P8&":1)J$5MN'68UF
MU-V'J@\.F,0JX*SM3-J_7QL8AA@G.QKE)<%PSO&YU_;E,CLP_E-L"9'@5UTU
M8NYLI=Q=NZ[(MZ3&XHKM2*.>E(S76*HAW[ABQPDN6E)=N=#SD%MCVCB+67OO
MCB]F;"\KVI [#L2^KC'_O205.\P=WWFZ<4\W6ZEON(O9#F_( Y'?=G=<C=Q!
MI: U:01E#>"DG#LW_G7F0TUH$7]3<A"C:Z!#63/V4P^^%G/'TXY(17*I);#Z
M>R0K4E5:2?GXMQ=UACDU<7S]I/ZE#5X%L\:"K%CU#RWD=NXD#BA(B?>5O&>'
M/TD?4*3U<E:)]A<<.FRL9LSW0K*Z)ZMQ39ON'__J$S$B^.@$ ?8$:!+"$X2@
M)P0O)80](6PSTX72YB'#$B]FG!T UVBEIB_:9+9L%3YM]+H_2*Z>4L63BWM"
M&['GN,D)^ @^EZ5:#P%8"<8/WF5$8EJ)]PKR[2$#[]Z\!V\ ;< MK2JU>F+F
M2N5%*[IY/^^RFQ>>F->'X)8U<BO YZ8@Q;& JX(8(H%/D2SA6<6,Y%<@\#\
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M7FZQ),L.KK%^9_DVQ)4BREHOK2Z1EU9(S$1B%A*C2,Q&8@X2<Y&8A\1\),9
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M"]4\J.9#-8;2FNFM2XAT=0G1WUF5/2[:T;3#6S"HNS\[G-#["4$U"M5LJ.9
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MLVN6),V!R90S(F YMJ[=JVBH[8W!CQ1V\J!-="0+SI]UYS896XY>$&00*\U
M\;>%*629)L)E_*XXK=JE!AZV]^PW)G:,94$E3'GV,TW4>FQ=6B2!)=UD:L9W
MWZ"*9Z#Y8IY)\R6[TC;P+1)OI.)Y!<85Y"DK__2ETN$ X 8G %X%\%X#^B<
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MO=X?VAJ ON2J),P^$K:TM8@N]F^  Z^ ;=DV^+1VP=LWO[0%9@;&?3T,/,(
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M&F4_]Q@%F"D#>7U+J3@>J '*STCF_P%02P,$%     @ L31(5L+8JOQ3 P
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MB:+Z/;CS/@I6[ZE@_1_:X5]02P,$%     @ L31(5I>*NQS     $P(   L
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MFILE +VCZAT!>D?5.P+TCJIW!.@=5>\(T#NJWA&@=U2](T#OI'HG@-Y)]4X
MO9/JG0!Z)]4[ ?1.YF8W0.^D>B> WDGU3@"]D^J= 'HGU3L!]$ZJ=P+HG57O
M#- [J]X9H'=6O3- [ZQZ9X#>6?7. +VS^6<E0.^L>F> WEGUS@"]L^J= 7IG
MU3L#]"ZJ=P'H753O M"[J-X%H'=1O0M [Z)Z%X#>1?4N +V+>=@$H'=1O0M
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ L31(5IW6<L[N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
ML31(5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "Q-$A6A'?Y)1L(   .,   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
ML31(5C0*P9<\ @  OP4  !@              ("!7A   'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +$T2%8(J$I*% @  ' K   8
M          " @= 2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "Q-$A6?E?H90X$  "Z#@  &               @($:&P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ L31(5G*?9W'D!P  N",
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M965T.2YX;6Q02P$"% ,4    " "Q-$A6C?;!IGT"  "D!@  &0
M    @(')2P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M +$T2%9G!']%(R@  +N'   9              " @7U.  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ L31(5J_\;GOW"P  @2<  !D
M             ("!UW8  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "Q-$A6:GJE!1D2  "?-P  &0              @($%@P  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +$T2%86E;$S31(
M !1    9              " @565  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ L31(5EP%YQU_"   8Q@  !D              ("!
MV:<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "Q-$A6
MD?EOH,,.   !4   &0              @(&/L   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( +$T2%8?SW87A@@  *X8   9
M      " @8F_  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ L31(5KRKQV^P#   XRH  !D              ("!1L@  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "Q-$A60]1PW<03   F0
M&0              @($MU0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( +$T2%;%#O;Q?@H  ((;   9              " @2CI  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ L31(5@T!ASCI
M#0  C"T  !D              ("!W?,  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "Q-$A63$T4/ED*  #6'   &0
M@('] 0$ >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( +$T
M2%9PX'E,]@0  .H.   9              " @8T, 0!X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ L31(5E'5Z4L(!   J D  !D
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M=#(X+GAM;%!+ 0(4 Q0    ( +$T2%;FL#"E? H  !(@   9
M  " @26N 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
ML31(5OB:O('F @  = 8  !D              ("!V+@! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "Q-$A6C3 <#U8-  ".*@  &0
M            @('UNP$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( +$T2%:P>)+,*PD  (\>   9              " @8+) 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ L31(5H#=<U]P!0
MJ@T  !D              ("!Y-(! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " "Q-$A6:Z#H,'T'  !B&0  &0              @(&+
MV $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( +$T2%9$
MXF9RZ 4  /L0   9              " @3_@ 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ L31(5D"? USY!0  +1$  !D
M     ("!7N8! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +$T2%9C%;\E!P4  .(.   9              "
M@?P) @!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ L31(
M5B)B@>%M P  _P<  !D              ("!.@\" 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " "Q-$A6:?<:+ @$   /"@  &0
M        @('>$@( >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( +$T2%8#TN/)H X  *LL   9              " @1T7 @!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ L31(5K>U7=C3$P  R_
M !D              ("!]"4" 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " "Q-$A6_4@'IAT#  #+"@  &0              @('^.0(
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( +$T2%:\K%61
M6 ,  (D+   9              " @5(] @!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ L31(5HJH9K \!   UQ8  !D
M ("!X4 " 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "Q
M-$A6?=_Z,&0,  !L?   &0              @(%410( >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +$T2%;VXDLQD (  #T'   9
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M970U-"YX;6Q02P$"% ,4    " "Q-$A6D)%1,8X,  #"L0  &0
M    @(']8@( >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M +$T2%95@;>G+@,  &\)   9              " @<)O @!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ L31(5IZZFPX.!   ,10  !D
M             ("!)W," 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " "Q-$A6>$O.0V$#  #A#@  &0              @(%L=P( >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( +$T2%:(%.^%2P@
M #T[   9              " @01[ @!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ L31(5G&SA(_\!   X!X  !D              ("!
MAH," 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " "Q-$A6
MSE5:=(D+   &70  &0              @(&YB ( >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( +$T2%:1BA^5Z0@  #%3   9
M      " @7F4 @!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ L31(5F\<\AFH @  $P<  !D              ("!F9T" 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "Q-$A6K'2F9 ()   :70
M&0              @(%XH ( >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( +$T2%:/T M[B (  -,&   9              " @;&I @!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ L31(5A2S;D_.
M!   O1D  !D              ("!<*P" 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    " "Q-$A6W%)EUKL"   7"   &0
M@(%UL0( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( +$T
M2%8(G#;HD0T  %B1   9              " @6>T @!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ L31(5D5OLQ@-"0  ZD$  !D
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M=#<S+GAM;%!+ 0(4 Q0    ( +$T2%9Y!RU6? 4  ,\G   9
M  " @>O> @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
ML31(5NZ,8JQ= P   1   !D              ("!GN0" 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    " "Q-$A6@"_V+24)  !04   &0
M            @($RZ ( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4
M Q0    ( +$T2%9[+#9Z?P(  "@&   9              " @8[Q @!X;"]W
M;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ L31(5@[AGEO*!P
M2T\  !D              ("!1/0" 'AL+W=O<FMS:&5E=',O<VAE970W."YX
M;6Q02P$"% ,4    " "Q-$A615#3A:4#  !/#0  &0              @(%%
M_ ( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( +$T2%8(
M#H5A:P,  * +   9              " @2$  P!X;"]W;W)K<VAE971S+W-H
M965T.# N>&UL4$L! A0#%     @ L31(5KI#0S:T!   Y14  !D
M     ("!PP,# 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +$T2%8H4KV>& 8  .\A   9              "
M@=@7 P!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ L31(
M5G!O1Y:^'   *0L" !D              ("!)QX# 'AL+W=O<FMS:&5E=',O
M<VAE970X-RYX;6Q02P$"% ,4    " "Q-$A6B[@9(QT#  #Z"@  &0
M        @($<.P, >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0
M   ( +$T2%8NKJ6WAP0  /X9   9              " @7 ^ P!X;"]W;W)K
M<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ L31(5OXT"8$:$0  !2 !
M !D              ("!+D,# 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q0
M2P$"% ,4    " "Q-$A6W"PZDV8%  #=)   &0              @(%_5 ,
M>&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( +$T2%8"QYJR
M) 4  %<8   9              " @1Q: P!X;"]W;W)K<VAE971S+W-H965T
M.3(N>&UL4$L! A0#%     @ L31(5CF]==(\ P  " H  !D
M ("!=U\# 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4    " "Q
M-$A6D",91/("  #C"0  &0              @('J8@, >&PO=V]R:W-H965T
M<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( +$T2%:<C',+\!4  ((B 0 9
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M970Y.2YX;6Q02P$"% ,4    " "Q-$A6,,G(A<0$  "*%   &@
M    @('+B@, >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4
M" "Q-$A6P.])GTD#  #/"@  &@              @(''CP, >&PO=V]R:W-H
M965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " "Q-$A6Q8*4#9H#  #7"P
M&@              @(%(DP, >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q0
M2P$"% ,4    " "Q-$A6*75C.RP(  #J1@  &@              @($:EP,
M>&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " "Q-$A64;,-
M_Y #  #3"P  &@              @(%^GP, >&PO=V]R:W-H965T<R]S:&5E
M=#$P-"YX;6Q02P$"% ,4    " "Q-$A6':59+6$(  "2.P  &@
M    @(%&HP, >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"% ,4
M" "Q-$A6YQ@;^DD$  #Z$@  &@              @('?JP, >&PO=V]R:W-H
M965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " "Q-$A6E!$Y5 X$  "=&P
M&@              @(%@L , >&PO=V]R:W-H965T<R]S:&5E=#$P-RYX;6Q0
M2P$"% ,4    " "Q-$A61YFDOA<%  "7'0  &@              @(&FM ,
M>&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4    " "Q-$A6>L,%
MUXH#  !R%P  &@              @('UN0, >&PO=V]R:W-H965T<R]S:&5E
M=#$P.2YX;6Q02P$"% ,4    " "Q-$A6MDVZ]M0#  #\#@  &@
M    @(&WO0, >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6Q02P$"% ,4
M" "Q-$A61#(8?24"   /!0  &@              @('#P0, >&PO=V]R:W-H
M965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    " "Q-$A60K%LN 8(  "7/0
M&@              @($@Q , >&PO=V]R:W-H965T<R]S:&5E=#$Q,BYX;6Q0
M2P$"% ,4    " "Q-$A6^WGA\0T%  "N&   &@              @(%>S ,
M>&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4    " "Q-$A6"6V#
M@FH"  ""!0  &@              @(&CT0, >&PO=V]R:W-H965T<R]S:&5E
M=#$Q-"YX;6Q02P$"% ,4    " "Q-$A6E_HM6KP#  ",$@  &@
M    @(%%U , >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX;6Q02P$"% ,4
M" "Q-$A6T0U>OY4#   ;#0  &@              @($YV , >&PO=V]R:W-H
M965T<R]S:&5E=#$Q-BYX;6Q02P$"% ,4    " "Q-$A6N@_N;?,*  !1C@
M&@              @($&W , >&PO=V]R:W-H965T<R]S:&5E=#$Q-RYX;6Q0
M2P$"% ,4    " "Q-$A6=JJ-*.<"  !5"@  &@              @($QYP,
M>&PO=V]R:W-H965T<R]S:&5E=#$Q."YX;6Q02P$"% ,4    " "Q-$A6::WT
M/R4(   ,-P  &@              @(%0Z@, >&PO=V]R:W-H965T<R]S:&5E
M=#$Q.2YX;6Q02P$"% ,4    " "Q-$A625WVS$0&  !2(@  &@
M    @(&M\@, >&PO=V]R:W-H965T<R]S:&5E=#$R,"YX;6Q02P$"% ,4
M" "Q-$A6PMBJ_%,#  "N%0  #0              @ $I^0, >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( +$T2%:7BKL<P    !,"   +              "
M :?\ P!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +$T2%:M:QDW, @  .!.   /
M              "  9#] P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "Q
M-$A6;/*&>TP#  !K1@  &@              @ 'M!00 >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "Q-$A6@_^P6I<"  "+0P  $P
M            @ %Q"00 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     @ "
+ $PC   Y# 0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>978</ContextCount>
  <ElementCount>746</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>232</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Acquisitions, Divestitures and Asset Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSales</Role>
      <ShortName>Acquisitions, Divestitures and Asset Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Goodwill and Other Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/GoodwillandOtherIntangibles</Role>
      <ShortName>Goodwill and Other Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Health Care Costs Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/HealthCareCostsPayable</Role>
      <ShortName>Health Care Costs Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Borrowings and Credit Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/BorrowingsandCreditAgreements</Role>
      <ShortName>Borrowings and Credit Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Pension Plans and Other Postretirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits</Role>
      <ShortName>Pension Plans and Other Postretirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stock Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/StockIncentivePlans</Role>
      <ShortName>Stock Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Reinsurance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/Reinsurance</Role>
      <ShortName>Reinsurance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Acquisitions, Divestitures and Asset Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesTables</Role>
      <ShortName>Acquisitions, Divestitures and Asset Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSales</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/Investments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/FairValue</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Goodwill and Other Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables</Role>
      <ShortName>Goodwill and Other Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/GoodwillandOtherIntangibles</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Health Care Costs Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/HealthCareCostsPayableTables</Role>
      <ShortName>Health Care Costs Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/HealthCareCostsPayable</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Borrowings and Credit Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables</Role>
      <ShortName>Borrowings and Credit Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/BorrowingsandCreditAgreements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Pension Plans and Other Postretirement Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables</Role>
      <ShortName>Pension Plans and Other Postretirement Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/StockIncentivePlansTables</Role>
      <ShortName>Stock Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/StockIncentivePlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/ShareholdersEquity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/OtherComprehensiveIncomeTables</Role>
      <ShortName>Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/EarningsPerShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Reinsurance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ReinsuranceTables</Role>
      <ShortName>Reinsurance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/Reinsurance</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/SegmentReporting</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Significant Accounting Policies - Cash and Cash Equivalents, Restricted Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails</Role>
      <ShortName>Significant Accounting Policies - Cash and Cash Equivalents, Restricted Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Significant Accounting Policies - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>Significant Accounting Policies - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Significant Accounting Policies - Receivables and Contracted Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails</Role>
      <ShortName>Significant Accounting Policies - Receivables and Contracted Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Significant Accounting Policies - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails</Role>
      <ShortName>Significant Accounting Policies - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Significant Accounting Policies - Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails</Role>
      <ShortName>Significant Accounting Policies - Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Significant Accounting Policies - Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails</Role>
      <ShortName>Significant Accounting Policies - Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Significant Accounting Policies - New Accounting Pronouncements Not Yet Adopted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails</Role>
      <ShortName>Significant Accounting Policies - New Accounting Pronouncements Not Yet Adopted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Acquisitions, Divestitures and Asset Sales - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails</Role>
      <ShortName>Acquisitions, Divestitures and Asset Sales - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Acquisitions, Divestitures and Asset Sales - Summary of Assets and Liabilities Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails</Role>
      <ShortName>Acquisitions, Divestitures and Asset Sales - Summary of Assets and Liabilities Held for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Investments - Schedule of Total Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Total Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Investments - Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails</Role>
      <ShortName>Investments - Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Investments - Debt Securities by Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails</Role>
      <ShortName>Investments - Debt Securities by Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Investments - Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails</Role>
      <ShortName>Investments - Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Investments - Unrealized Loss Position Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails</Role>
      <ShortName>Investments - Unrealized Loss Position Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Investments - Mortgage Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails</Role>
      <ShortName>Investments - Mortgage Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Investments - Mortgage Loans Credit Ratings Indicator (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails</Role>
      <ShortName>Investments - Mortgage Loans Credit Ratings Indicator (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Investments - Mortgage Loan Principal Repayments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails</Role>
      <ShortName>Investments - Mortgage Loan Principal Repayments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Investments - Net Investment Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails</Role>
      <ShortName>Investments - Net Investment Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Investments - Realized Gains (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails</Role>
      <ShortName>Investments - Realized Gains (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Fair Value - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Fair Value - Changes in Level 3 Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails</Role>
      <ShortName>Fair Value - Changes in Level 3 Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Fair Value - Gross Transfers Into (Out Of) Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details</Role>
      <ShortName>Fair Value - Gross Transfers Into (Out Of) Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Fair Value - Carrying Value and Fair Value Classified by Level (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails</Role>
      <ShortName>Fair Value - Carrying Value and Fair Value Classified by Level (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Fair Value - Separate Accounts Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails</Role>
      <ShortName>Fair Value - Separate Accounts Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Fair Value - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/FairValueNarrativeDetails</Role>
      <ShortName>Fair Value - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Goodwill and Other Intangibles - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Goodwill and Other Intangibles - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Leases - Summary of the Components of Net Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails</Role>
      <ShortName>Leases - Summary of the Components of Net Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails</Role>
      <ShortName>Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Health Care Costs Payable - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails</Role>
      <ShortName>Health Care Costs Payable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Health Care Costs Payable - Liability for Unpaid Claims and Claims Adjustment Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails</Role>
      <ShortName>Health Care Costs Payable - Liability for Unpaid Claims and Claims Adjustment Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Health Care Costs Payable - Components of Change in Health Care Costs Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails</Role>
      <ShortName>Health Care Costs Payable - Components of Change in Health Care Costs Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Borrowings and Credit Agreements - Schedule of Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails</Role>
      <ShortName>Borrowings and Credit Agreements - Schedule of Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Borrowings and Credit Agreements - Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails</Role>
      <ShortName>Borrowings and Credit Agreements - Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Borrowings and Credit Agreements - Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails</Role>
      <ShortName>Borrowings and Credit Agreements - Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Borrowings and Credit Agreements - Long-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails</Role>
      <ShortName>Borrowings and Credit Agreements - Long-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Pension Plans and Other Postretirement Benefits - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails</Role>
      <ShortName>Pension Plans and Other Postretirement Benefits - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails</Role>
      <ShortName>Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Cost (Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails</Role>
      <ShortName>Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Cost (Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails</Role>
      <ShortName>Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails</Role>
      <ShortName>Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails</Role>
      <ShortName>Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails</Role>
      <ShortName>Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Income Taxes - Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails</Role>
      <ShortName>Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Stock Incentive Plans - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails</Role>
      <ShortName>Stock Incentive Plans - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Stock Incentive Plans - Stock Option and SAR Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails</Role>
      <ShortName>Stock Incentive Plans - Stock Option and SAR Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - Stock Incentive Plans - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails</Role>
      <ShortName>Stock Incentive Plans - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - Shareholders' Equity - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails</Role>
      <ShortName>Shareholders' Equity - Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0000108 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails</Role>
      <ShortName>Shareholders' Equity - Accelerated Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0000109 - Disclosure - Shareholders' Equity - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails</Role>
      <ShortName>Shareholders' Equity - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0000110 - Disclosure - Shareholders' Equity - Regulatory Requirements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails</Role>
      <ShortName>Shareholders' Equity - Regulatory Requirements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>0000111 - Disclosure - Shareholders' Equity - Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails</Role>
      <ShortName>Shareholders' Equity - Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>0000112 - Disclosure - Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/OtherComprehensiveIncomeTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>0000113 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/EarningsPerShareTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>0000114 - Disclosure - Reinsurance - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ReinsuranceNarrativeDetails</Role>
      <ShortName>Reinsurance - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>0000115 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails</Role>
      <ShortName>Reinsurance - Reinsurance Recoverables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>0000116 - Disclosure - Reinsurance - Effects of Reinsurance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails</Role>
      <ShortName>Reinsurance - Effects of Reinsurance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>0000117 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvshealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>0000118 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>0000119 - Disclosure - Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="cvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>0000120 - Disclosure - Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails</Role>
      <ShortName>Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  cvs-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="cvs-20221231.htm">cvs-20221231.htm</File>
    <File>cvs-20221231.xsd</File>
    <File>cvs-20221231_cal.xml</File>
    <File>cvs-20221231_def.xml</File>
    <File>cvs-20221231_lab.xml</File>
    <File>cvs-20221231_pre.xml</File>
    <File>exhibit211-2022.htm</File>
    <File>exhibit231-2022.htm</File>
    <File>exhibit311-2022.htm</File>
    <File>exhibit312-2022.htm</File>
    <File>exhibit321-2022.htm</File>
    <File>exhibit322-2022.htm</File>
    <File>exhibit421-2022.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvs-20221231_g1.jpg</File>
    <File>cvs-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="2599">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>143
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cvs-20221231.htm": {
   "axisCustom": 2,
   "axisStandard": 47,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 2599,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 978,
   "dts": {
    "calculationLink": {
     "local": [
      "cvs-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvs-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cvs-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvs-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvs-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cvs-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 1227,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 10,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 14
   },
   "keyCustom": 134,
   "keyStandard": 612,
   "memberCustom": 118,
   "memberStandard": 97,
   "nsprefix": "cvs",
   "nsuri": "http://www.cvshealth.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cvshealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashDivestedFromDeconsolidation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "menuCat": "Statements",
     "order": "10",
     "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashDivestedFromDeconsolidation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5b5114192110480ab4f260049ee8b103_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i21ae6bc100814ca88c4440dbb572bbdc_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails",
     "shortName": "Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5b8b6ee31b984216878b4a06ea213f22_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Stock Incentive Plans - Restricted Stock Activity (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails",
     "shortName": "Stock Incentive Plans - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5b8b6ee31b984216878b4a06ea213f22_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Stock Incentive Plans - Stock Option and SAR Activity (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails",
     "shortName": "Stock Incentive Plans - Stock Option and SAR Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i9667bb2fd2c24aae86f872138c4421cb_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - Stock Incentive Plans - Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails",
     "shortName": "Stock Incentive Plans - Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i0683e51167f4495ea6a0dfb31f35d1dc_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockRepurchasedDuringPeriodShares",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - Shareholders' Equity - Share Repurchases (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails",
     "shortName": "Shareholders' Equity - Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockRepurchasedDuringPeriodShares",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i00ad339b1a7a4fcf9231bb9f05ba8942_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i3dba707cd749450ca1bc96a22ff0d254_I20230104",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cvs:AcceleratedShareRepurchasesAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000108 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails",
     "shortName": "Shareholders' Equity - Accelerated Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i3dba707cd749450ca1bc96a22ff0d254_I20230104",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cvs:AcceleratedShareRepurchasesAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableAmountPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000109 - Disclosure - Shareholders' Equity - Dividends (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails",
     "shortName": "Shareholders' Equity - Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableAmountPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000110 - Disclosure - Shareholders' Equity - Regulatory Requirements (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails",
     "shortName": "Shareholders' Equity - Regulatory Requirements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000111 - Disclosure - Shareholders' Equity - Noncontrolling Interests (Details)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails",
     "shortName": "Shareholders' Equity - Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5b5114192110480ab4f260049ee8b103_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000112 - Disclosure - Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if5c2106ba1184ea692fbc96551d6d7b2_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000113 - Disclosure - Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.cvshealth.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i2e2b473c47f6447294d190668407b467_D20230101-20230131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cvs:NumberofReinsuranceContractsEnteredInto",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reinsurance_agreement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000114 - Disclosure - Reinsurance - Narrative (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails",
     "shortName": "Reinsurance - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i2e2b473c47f6447294d190668407b467_D20230101-20230131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cvs:NumberofReinsuranceContractsEnteredInto",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reinsurance_agreement",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000115 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails",
     "shortName": "Reinsurance - Reinsurance Recoverables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DirectPremiumsEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000116 - Disclosure - Reinsurance - Effects of Reinsurance (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails",
     "shortName": "Reinsurance - Effects of Reinsurance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DirectPremiumsEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000117 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5b5114192110480ab4f260049ee8b103_I20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "cvs:ContractualObligationsToMaintainLevelsOfSeparateAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000118 - Disclosure - Segment Reporting - Narrative (Details)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails",
     "shortName": "Segment Reporting - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000119 - Disclosure - Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
     "shortName": "Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ida72eed4d03c4e7ba48dbe3fd421cec7_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cvs:AdjustedOperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Acquisitions, Divestitures and Asset Sales",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSales",
     "shortName": "Acquisitions, Divestitures and Asset Sales",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000120 - Disclosure - Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
     "shortName": "Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cvshealth.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Fair Value",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cvshealth.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Goodwill and Other Intangibles",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangibles",
     "shortName": "Goodwill and Other Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cvshealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Health Care Costs Payable",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cvshealth.com/role/HealthCareCostsPayable",
     "shortName": "Health Care Costs Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Borrowings and Credit Agreements",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreements",
     "shortName": "Borrowings and Credit Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Pension Plans and Other Postretirement Benefits",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits",
     "shortName": "Pension Plans and Other Postretirement Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.cvshealth.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.cvshealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stock Incentive Plans",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.cvshealth.com/role/StockIncentivePlans",
     "shortName": "Stock Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.cvshealth.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Other Comprehensive Income (Loss)",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.cvshealth.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.cvshealth.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReinsuranceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Reinsurance",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.cvshealth.com/role/Reinsurance",
     "shortName": "Reinsurance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReinsuranceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.cvshealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.cvshealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Acquisitions, Divestitures and Asset Sales (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesTables",
     "shortName": "Acquisitions, Divestitures and Asset Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvs:TotalInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Investments (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.cvshealth.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvs:TotalInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Fair Value (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.cvshealth.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Goodwill and Other Intangibles (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables",
     "shortName": "Goodwill and Other Intangibles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.cvshealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Health Care Costs Payable (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.cvshealth.com/role/HealthCareCostsPayableTables",
     "shortName": "Health Care Costs Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Borrowings and Credit Agreements (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables",
     "shortName": "Borrowings and Credit Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Pension Plans and Other Postretirement Benefits (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables",
     "shortName": "Pension Plans and Other Postretirement Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.cvshealth.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock Incentive Plans (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.cvshealth.com/role/StockIncentivePlansTables",
     "shortName": "Stock Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Shareholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.cvshealth.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Other Comprehensive Income (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.cvshealth.com/role/OtherComprehensiveIncomeTables",
     "shortName": "Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.cvshealth.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Reinsurance (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.cvshealth.com/role/ReinsuranceTables",
     "shortName": "Reinsurance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.cvshealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:NumberOfPharmacyPlanMembers",
      "reportCount": 1,
      "unitRef": "people",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Significant Accounting Policies - Cash and Cash Equivalents, Restricted Cash and Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails",
     "shortName": "Significant Accounting Policies - Cash and Cash Equivalents, Restricted Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i43471633110c4d35b96ffaf743cb0e4f_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Significant Accounting Policies - Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails",
     "shortName": "Significant Accounting Policies - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cvs:VendorandManufacturerReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Significant Accounting Policies - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "shortName": "Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "iab45872f08734ce1a3dacf338ff1195c_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Significant Accounting Policies - Receivables and Contracted Balances (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails",
     "shortName": "Significant Accounting Policies - Receivables and Contracted Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5b5114192110480ab4f260049ee8b103_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Significant Accounting Policies - Contract Balances (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails",
     "shortName": "Significant Accounting Policies - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cvs:ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConsolidationVariableInterestEntityPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:ProceedsFromVariableInterestEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Significant Accounting Policies - Variable Interest Entities (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails",
     "shortName": "Significant Accounting Policies - Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConsolidationVariableInterestEntityPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:ProceedsFromVariableInterestEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Significant Accounting Policies - Discontinued Operations (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails",
     "shortName": "Significant Accounting Policies - Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ibd811ca9ceb5442fbd696e20ec9278ed_I20230101",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Significant Accounting Policies - New Accounting Pronouncements Not Yet Adopted (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails",
     "shortName": "Significant Accounting Policies - New Accounting Pronouncements Not Yet Adopted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ibd811ca9ceb5442fbd696e20ec9278ed_I20230101",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Acquisitions, Divestitures and Asset Sales - Narrative (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
     "shortName": "Acquisitions, Divestitures and Asset Sales - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5acb58a875864a49b737f2cb40ddee47_I20230207",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if18de26c953b4c36b64633eff1121e28_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Acquisitions, Divestitures and Asset Sales - Summary of Assets and Liabilities Held for Sale (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails",
     "shortName": "Acquisitions, Divestitures and Asset Sales - Summary of Assets and Liabilities Held for Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if18de26c953b4c36b64633eff1121e28_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Investments - Schedule of Total Investments (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails",
     "shortName": "Investments - Schedule of Total Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:TotalInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cvs:LongTermInvestmentsIncludingAssetsHeldForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedInvestmentsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Investments - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.cvshealth.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedInvestmentsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Investments - Debt Securities (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
     "shortName": "Investments - Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Investments - Debt Securities by Maturity (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails",
     "shortName": "Investments - Debt Securities by Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Investments - Unrealized Loss Position (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
     "shortName": "Investments - Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Investments - Unrealized Loss Position Maturities (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails",
     "shortName": "Investments - Unrealized Loss Position Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:ActivityInMortgageLoanPortfolioTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MortgageLoansOnRealEstateNewMortgageLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Investments - Mortgage Loans (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails",
     "shortName": "Investments - Mortgage Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:ActivityInMortgageLoanPortfolioTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "iadc87d588d8e4c20a29310e3ab074495_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MortgageLoansOnRealEstateNewMortgageLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ibf70115e4b0543e3a96629490f5ae0dc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MortgageLoansOnRealEstate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Investments - Mortgage Loans Credit Ratings Indicator (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails",
     "shortName": "Investments - Mortgage Loans Credit Ratings Indicator (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ibf70115e4b0543e3a96629490f5ae0dc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MortgageLoansOnRealEstate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ibf70115e4b0543e3a96629490f5ae0dc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Investments - Mortgage Loan Principal Repayments (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails",
     "shortName": "Investments - Mortgage Loan Principal Repayments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ibf70115e4b0543e3a96629490f5ae0dc_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentIncomeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterestAndDividend",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Investments - Net Investment Income (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails",
     "shortName": "Investments - Net Investment Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentIncomeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterestAndDividend",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Investments - Realized Gains (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails",
     "shortName": "Investments - Realized Gains (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Fair Value - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
     "shortName": "Fair Value - Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i58f243d98dd94b418abfc33c268175f2_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Fair Value - Changes in Level 3 Financial Assets (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
     "shortName": "Fair Value - Changes in Level 3 Financial Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Fair Value - Gross Transfers Into (Out Of) Level 3 (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
     "shortName": "Fair Value - Gross Transfers Into (Out Of) Level 3 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i66bcf7a88ef8420db041c82d229c682d_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5fe1938eb02c435297cc130427df950c_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MortgagesHeldForSaleFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Fair Value - Carrying Value and Fair Value Classified by Level (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
     "shortName": "Fair Value - Carrying Value and Fair Value Classified by Level (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5fe1938eb02c435297cc130427df950c_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MortgagesHeldForSaleFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeparateAccountAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Fair Value - Separate Accounts Fair Value (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
     "shortName": "Fair Value - Separate Accounts Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i58f243d98dd94b418abfc33c268175f2_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SeparateAccountAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i2d8dcd4c47c4463f9c402488fd95553f_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Fair Value - Narrative (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.cvshealth.com/role/FairValueNarrativeDetails",
     "shortName": "Fair Value - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id206ebf70f104468bb9392e4f8e41a61_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5b5114192110480ab4f260049ee8b103_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Goodwill and Other Intangibles - Goodwill (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
     "shortName": "Goodwill and Other Intangibles - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if8d9089fdf7c4007bbe779a88d4715e8_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
     "shortName": "Goodwill and Other Intangibles - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Goodwill and Other Intangibles - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangibles - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5b5114192110480ab4f260049ee8b103_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.cvshealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i6cecd52e63104ff3825bfd6f3712ef14_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SaleAndLeasebackTransactionGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Leases - Summary of the Components of Net Lease Cost (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails",
     "shortName": "Leases - Summary of the Components of Net Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i72a7763da9eb4043aa8f22f5c692da1a_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Shareholders' Equity",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i72a7763da9eb4043aa8f22f5c692da1a_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:LesseeLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cvs:LesseeLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i3625815087434552b838d92f5f5f5e0e_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails",
     "shortName": "Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i3625815087434552b838d92f5f5f5e0e_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ic3b3902b297a43b9a015149f29e45bf7_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Health Care Costs Payable - Narrative (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails",
     "shortName": "Health Care Costs Payable - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ic3b3902b297a43b9a015149f29e45bf7_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Health Care Costs Payable - Liability for Unpaid Claims and Claims Adjustment Expense (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails",
     "shortName": "Health Care Costs Payable - Liability for Unpaid Claims and Claims Adjustment Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i3625815087434552b838d92f5f5f5e0e_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5b5114192110480ab4f260049ee8b103_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Health Care Costs Payable - Components of Change in Health Care Costs Payable (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
     "shortName": "Health Care Costs Payable - Components of Change in Health Care Costs Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i780b19498a144075a22a573432132bda_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Borrowings and Credit Agreements - Schedule of Borrowings (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails",
     "shortName": "Borrowings and Credit Agreements - Schedule of Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Borrowings and Credit Agreements - Debt Maturities (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails",
     "shortName": "Borrowings and Credit Agreements - Debt Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Borrowings and Credit Agreements - Short-term Borrowings (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails",
     "shortName": "Borrowings and Credit Agreements - Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cvs:TreasuryStockSharesHeldinTrust",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "cvs:TreasuryStockValueSharesHeldInTrust",
       "cvs:TreasuryStockValueSharesHeldInTrust",
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cvs:TreasuryStockValueSharesHeldInTrust",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Borrowings and Credit Agreements - Long-term Borrowings (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
     "shortName": "Borrowings and Credit Agreements - Long-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i79d2af0f86c541af9571d4910bbca9be_D20210818-20210818",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Pension Plans and Other Postretirement Benefits - Narrative (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails",
     "shortName": "Pension Plans and Other Postretirement Benefits - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ifc75d0fe4bd2436da019eb75a7875218_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
     "shortName": "Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "icf13dd948a9949f397b838135c67fd6a_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "icf13dd948a9949f397b838135c67fd6a_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanInterestCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Cost (Income) (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails",
     "shortName": "Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Cost (Income) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "icf13dd948a9949f397b838135c67fd6a_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails",
     "shortName": "Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "id47fa8b4bae0480bb8f5fbd8fb56c3b3_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i13a134d0c0ea465cb742a54750a08aa5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
     "shortName": "Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i95da6fe526324fc7915c89f6c760058b_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "ifc75d0fe4bd2436da019eb75a7875218_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
     "shortName": "Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DefinedBenefitPlanPlanAssetsCategoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i5e58d7651f6c4f319612d35334a716cb_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i13a134d0c0ea465cb742a54750a08aa5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails",
     "shortName": "Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "i13a134d0c0ea465cb742a54750a08aa5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Income Taxes - Income Tax Provision (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails",
     "shortName": "Income Taxes - Income Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Effective Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvs-20221231.htm",
      "contextRef": "if7774b520eae495587e1c8cd72f169e5_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 232,
   "tag": {
    "cvs_A2021RepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Repurchase Program",
        "label": "2021 Repurchase Program [Member]",
        "terseLabel": "2021 Repurchase Program"
       }
      }
     },
     "localname": "A2021RepurchaseProgramMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_A2022RepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Repurchase Program",
        "label": "2022 Repurchase Program [Member]",
        "terseLabel": "2022 Repurchase Program"
       }
      }
     },
     "localname": "A2022RepurchaseProgramMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchase Program, Maximum Number Of Shares",
        "label": "Accelerated Share Repurchase Program, Maximum Number Of Shares",
        "terseLabel": "ASR, maximum amount of shares received or delivered"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseProgramMaximumNumberOfShares",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvs_AcceleratedShareRepurchasesAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchases Agreement, Amount",
        "label": "Accelerated Share Repurchases Agreement, Amount",
        "terseLabel": "ASR agreement, amount"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesAgreementAmount",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_AcceleratedShareRepurchasesNumberOfSharesRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchases, Number Of Shares Repurchased",
        "label": "Accelerated Share Repurchases, Number Of Shares Repurchased",
        "terseLabel": "Shares repurchased under ASR agreement (in shares)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesNumberOfSharesRepurchased",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchases, Percent Of Notional Amount In Shares To Be Received At End Of Program",
        "label": "Accelerated Share Repurchases, Percent Of Notional Amount In Shares To Be Received At End Of Program",
        "terseLabel": "ASR, shares to be received at the end of program as a percent of notional amount"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchases, Percent Of Notional Amount Received In Shares",
        "label": "Accelerated Share Repurchases, Percent Of Notional Amount Received In Shares",
        "terseLabel": "ASR percent of notional amount received in shares"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Including Assets Held For Sale",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Including Assets Held For Sale",
        "totalLabel": "Total accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_ActivityInMortgageLoanPortfolioTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table representing activities in mortgage loan portfolio during the period.",
        "label": "Activity In Mortgage Loan Portfolio [Table Text Block]",
        "verboseLabel": "Schedule of Activity in Mortgage Loan Portfolio"
       }
      }
     },
     "localname": "ActivityInMortgageLoanPortfolioTableTextBlock",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvs_AdjustedOperatingIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Operating Income (Loss)",
        "label": "Adjusted Operating Income (Loss)",
        "terseLabel": "Adjusted operating income",
        "verboseLabel": "Adjusted operating income (loss)"
       }
      }
     },
     "localname": "AdjustedOperatingIncomeLoss",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_AetnaInc2010StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aetna Inc 2010 Stock Incentive Plan [Member]",
        "label": "Aetna Inc 2010 Stock Incentive Plan [Member]",
        "terseLabel": "Aetna Inc 2010 Stock Incentive Plan"
       }
      }
     },
     "localname": "AetnaInc2010StockIncentivePlanMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_AllOtherReinsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Reinsurers [Member]",
        "label": "All Other Reinsurers [Member]",
        "terseLabel": "All Other"
       }
      }
     },
     "localname": "AllOtherReinsurersMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts",
        "label": "Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts",
        "terseLabel": "Assumed interest rates on long-duration group life and long-term care contracts"
       }
      }
     },
     "localname": "AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvs_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information [Abstract]",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvs_BackUpCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Back-Up Credit Facilities [Member]",
        "label": "Back-Up Credit Facilities [Member]",
        "terseLabel": "Back-Up Credit Facilities"
       }
      }
     },
     "localname": "BackUpCreditFacilitiesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_BarclaysBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Barclays Bank",
        "label": "Barclays Bank [Member]",
        "terseLabel": "Barclays Bank"
       }
      }
     },
     "localname": "BarclaysBankMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_BswiftLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bswift LLC",
        "label": "bswift LLC [Member]",
        "terseLabel": "bswift LLC"
       }
      }
     },
     "localname": "BswiftLLCMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Purchase Price Adjustment, Outside Of Measurement Period",
        "label": "Business Combination, Purchase Price Adjustment, Outside Of Measurement Period",
        "negatedTerseLabel": "Acquisition purchase price adjustments outside of measurement period"
       }
      }
     },
     "localname": "BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_BusinessCombinationTerminationFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Termination Fee",
        "label": "Business Combination, Termination Fee",
        "terseLabel": "Termination fee"
       }
      }
     },
     "localname": "BusinessCombinationTerminationFee",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_CVSHealth2017IncentiveCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVS Health 2017 Incentive Compensation Plan [Member]",
        "label": "CVS Health 2017 Incentive Compensation Plan [Member]",
        "terseLabel": "CVS Health 2017 Incentive Compensation Plan"
       }
      }
     },
     "localname": "CVSHealth2017IncentiveCompensationPlanMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_Categories5And6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage loan credit quality indicator - Categories 5 and 6",
        "label": "Categories 5 And 6 [Member]",
        "terseLabel": "5 and 6"
       }
      }
     },
     "localname": "Categories5And6Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_Category1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loan Credit Quality Indicator - Category 1 [Member].",
        "label": "Category 1 [Member]",
        "terseLabel": "1"
       }
      }
     },
     "localname": "Category1Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_Category2To4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loan Credit Quality Indicator - Category 2 to 4 [Member].",
        "label": "Category 2 To 4 [Member]",
        "terseLabel": "2 to 4"
       }
      }
     },
     "localname": "Category2To4Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_Category7Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage loan credit quality indicator - Category 7",
        "label": "Category 7 [Member]",
        "terseLabel": "7"
       }
      }
     },
     "localname": "Category7Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Change in Contract with Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in operating assets and liabilities, net of effects from acquisitions:",
        "label": "Change in operating assets and liabilities, net of effects from acquisitions: [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions:"
       }
      }
     },
     "localname": "ChangeInOperatingAssetsAndLiabilitiesNetOfEffectsFromAcquisitionsAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_CitibankNAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Citibank, N.A.",
        "label": "Citibank, N.A. [Member]",
        "terseLabel": "Citibank, N.A."
       }
      }
     },
     "localname": "CitibankNAMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_CommonAndCollectiveTrustsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of Common/Collective Trusts held by the company, primarily related to investment funds otherwise known as underlying funds.",
        "label": "Common And Collective Trusts [Member]",
        "terseLabel": "Common/collective trusts"
       }
      }
     },
     "localname": "CommonAndCollectiveTrustsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in contract liability recognized for loyalty program earnings and gift card issuance.",
        "label": "Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance",
        "terseLabel": "Rewards earnings and gift card issuances"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_ContractWithCustomerLiabilityRedemptionAndBreakage": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer Liability Redemption And Breakage",
        "label": "Contract With Customer Liability Redemption And Breakage",
        "negatedTerseLabel": "Redemption and breakage"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRedemptionAndBreakage",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the contractual obligation to maintain the required level of funding in Separate Accounts necessary to fund specific guaranteed pensions annuities.",
        "label": "Contractual Obligations To Maintain Levels Of Separate Accounts",
        "terseLabel": "Contractual obligations underlying the guaranteed benefits"
       }
      }
     },
     "localname": "ContractualObligationsToMaintainLevelsOfSeparateAccounts",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_CoventryHealthCareWorkersCompensationBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coventry Health Care Workers Compensation Business",
        "label": "Coventry Health Care Workers Compensation Business [Member]",
        "terseLabel": "Coventry Health Care Workers Compensation Business"
       }
      }
     },
     "localname": "CoventryHealthCareWorkersCompensationBusinessMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit-Related Impairment Loss, Debt Securities, Available-For-Sale, Recognized In Earnings",
        "label": "Credit-Related Impairment Loss, Debt Securities, Available-For-Sale, Recognized In Earnings",
        "terseLabel": "Credit-related impairment loss"
       }
      }
     },
     "localname": "CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtAndEquitySecuritiesAvailableForSaleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt and equity securities which are categorized neither as trading securities nor held-to-maturity securities. Such securities are reported at fair value; unrealized gains and losses related to Available-for-sale securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income)",
        "label": "Debt And Equity Securities Available For Sale [Member]",
        "terseLabel": "Debt securities available for sale"
       }
      }
     },
     "localname": "DebtAndEquitySecuritiesAvailableForSaleMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_DebtExtinguishmentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Extinguishment Fees",
        "label": "Debt Extinguishment Fees",
        "terseLabel": "Debt extinguishment fees"
       }
      }
     },
     "localname": "DebtExtinguishmentFees",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net",
        "label": "Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net",
        "negatedTerseLabel": "Debt discounts and deferred financing costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years",
        "terseLabel": "After five years through ten years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss",
        "terseLabel": "After five years through ten years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years",
        "terseLabel": "One year through five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss",
        "terseLabel": "One year through five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years",
        "terseLabel": "Greater than ten years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss",
        "terseLabel": "Greater than ten years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Accumulated Loss",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Accumulated Loss",
        "terseLabel": "Debt securities, maturity, without single maturity date, unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateAccumulatedLoss",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Fair Value",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Without Single Maturity Date, Fair Value",
        "terseLabel": "Debt securities, maturity, without single maturity date, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionWithoutSingleMaturityDateFairValue",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]",
        "label": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities",
        "label": "Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities",
        "terseLabel": "Weighted average duration of securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvs_DeferredTaxAssetsPayrollTaxDeferral": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Payroll Tax Deferral",
        "label": "Deferred Tax Assets, Payroll Tax Deferral",
        "terseLabel": "Payroll tax deferral"
       }
      }
     },
     "localname": "DeferredTaxAssetsPayrollTaxDeferral",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances",
        "terseLabel": "Bad debts and other allowances"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Depreciation and Amortization - Amount of deferred tax liability attributable to taxable temporary differences from depreciation and amortization",
        "label": "Deferred Tax Liabilities, Depreciation And Amortization",
        "negatedTerseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DeferredTaxLiabilitiesRetirementBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Retirement Benefits",
        "label": "Deferred Tax Liabilities, Retirement Benefits",
        "negatedTerseLabel": "Retirement benefits"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRetirementBenefits",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Common Collective Trust, Debt Securities [Member]",
        "label": "Defined Benefit Plan, Common Collective Trust, Debt Securities [Member]",
        "terseLabel": "Common/collective trusts, Debt Securities"
       }
      }
     },
     "localname": "DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Common Collective Trust, Equity Securities [Member]",
        "label": "Defined Benefit Plan, Common Collective Trust, Equity Securities [Member]",
        "terseLabel": "Common/collective trusts, Equity Securities"
       }
      }
     },
     "localname": "DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_DenominatorForEarningsPerShareCalculationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator For Earnings Per Share Calculation [Abstract]",
        "label": "Denominator For Earnings Per Share Calculation [Abstract]",
        "terseLabel": "Denominator for earnings per share calculation:"
       }
      }
     },
     "localname": "DenominatorForEarningsPerShareCalculationAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Number Of International Health Care Members, Renewal Rights Sold",
        "label": "Disposal Group, Not Discontinued Operation, Number Of International Health Care Members, Renewal Rights Sold",
        "terseLabel": "Number of international health care members, renewal rights sold"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationNumberOfInternationalHealthCareMembersRenewalRightsSold",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent",
        "label": "Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent",
        "terseLabel": "Quarterly dividends declared, percent increase"
       }
      }
     },
     "localname": "DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP Issuance, Net Of Treasury Stock, Shares, Acquired, Cost Method",
        "label": "ESPP Issuance, Net Of Treasury Stock, Shares, Acquired, Cost Method",
        "terseLabel": "ESPP issuances, net of purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP Issuance, Net Of Treasury Stock, Value, Acquired, Cost Method",
        "label": "ESPP Issuance, Net Of Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "ESPP issuances, net of purchase of treasury shares"
       }
      }
     },
     "localname": "ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic And Diluted EPS",
        "label": "Earnings Per Share, Basic And Diluted EPS [Abstract]",
        "terseLabel": "Earnings per share from continuing operations:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal Charges, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal Charges, Percent",
        "terseLabel": "Legal charges"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvs_EmployeeStockOptionsAndStockAppreciationRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options and Stock Appreciation Rights [Member]",
        "label": "Employee Stock Options And Stock Appreciation Rights [Member]",
        "terseLabel": "Employee Stock Options and Stock Appreciation Rights"
       }
      }
     },
     "localname": "EmployeeStockOptionsAndStockAppreciationRightsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_EquitySecuritiesDomesticRealEstateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about ownership interests or the right to acquire ownership interests in domestic real estate whose ownership interest is represented by shares of common or preferred stock (which is neither mandatorily redeemable no redeemable at the option of the holder), convertible securities, stock rights, or stock warrants categorized by other type.",
        "label": "Equity Securities Domestic Real Estate [Member]",
        "terseLabel": "Domestic real estate"
       }
      }
     },
     "localname": "EquitySecuritiesDomesticRealEstateMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract]",
        "label": "Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract]",
        "terseLabel": "Net realized and unrealized capital gains (losses):"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_FederalCourtInOhioJudgmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Court In Ohio Judgment",
        "label": "Federal Court In Ohio Judgment [Member]",
        "terseLabel": "Federal Court in Ohio Judgment"
       }
      }
     },
     "localname": "FederalCourtInOhioJudgmentMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Assets And Liabilities, Lessee [Abstract]",
        "label": "Finance Lease, Assets And Liabilities, Lessee [Abstract]",
        "terseLabel": "Finance leases:"
       }
      }
     },
     "localname": "FinanceLeaseAssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease Cost",
        "label": "Finance Lease Cost",
        "totalLabel": "Total finance lease costs"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "cvs_FinanceLeaseRightOfUseAssetNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Right-Of-Use Asset, Accumulated Depreciation",
        "label": "Finance Lease, Right-Of-Use Asset, Accumulated Depreciation",
        "negatedTerseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedDepreciation",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_FinanceLeaseRightOfUseAssetGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "cvs_FinanceLeaseRightOfUseAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Right-Of-Use Asset, Gross",
        "label": "Finance Lease, Right-Of-Use Asset, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetGross",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_FinanceLeaseRightOfUseAssetNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Right-Of-Use Asset, Net",
        "label": "Finance Lease, Right-Of-Use Asset, Net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetNet",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the cost, accumulated amortization and net balance of intangibles assets and amortization period, in total and by major class. Finite-lived intangible assets have a stated useful life over which their gross carrying value is amortized. Indefinite intangible assets have a projected indefinite period of benefit (hence are not amortized).",
        "label": "Finite Lived And Indefinite Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixtures, Equipment And Internally Developed Software [Member]",
        "label": "Fixtures, Equipment And Internally Developed Software [Member]",
        "terseLabel": "Fixtures, equipment and internally developed software"
       }
      }
     },
     "localname": "FixturesEquipmentAndInternallyDevelopedSoftwareMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Gain Contingency, Recognized In Current Period, Before Tax",
        "label": "Former Gain Contingency, Recognized In Current Period, Before Tax",
        "terseLabel": "Former gain contingency, recognized in current period, before tax"
       }
      }
     },
     "localname": "FormerGainContingencyRecognizedInCurrentPeriodBeforeTax",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Gain Contingency, Recognized In Current Period, Net of Tax",
        "label": "Former Gain Contingency, Recognized In Current Period, Net of Tax",
        "terseLabel": "Former gain contingency, recognized in current period, net of tax"
       }
      }
     },
     "localname": "FormerGainContingencyRecognizedInCurrentPeriodNetOfTax",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This line item represents the four years of a reinsurance agreement with an unrelated insurer.",
        "label": "Four Years Reinsurance Agreement With Unrelated Insurer",
        "terseLabel": "Term of reinsurance agreements with unrelated issuer"
       }
      }
     },
     "localname": "FourYearsReinsuranceAgreementWithUnrelatedInsurer",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvs_FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fresenius Medical Care Reinsurance Company (Cayman) Ltd.",
        "label": "Fresenius Medical Care Reinsurance Company (Cayman) Ltd. [Member]",
        "terseLabel": "Fresenius Medical Care Reinsurance Company (Cayman) Ltd."
       }
      }
     },
     "localname": "FreseniusMedicalCareReinsuranceCompanyCaymanLtdMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_FrontStoreRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Front Store Revenue [Member]",
        "label": "Front Store Revenue [Member]",
        "terseLabel": "Front Store"
       }
      }
     },
     "localname": "FrontStoreRevenueMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_GuarantorObligationsNumberOfLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guarantor Obligations, Number Of Leases",
        "label": "Guarantor Obligations, Number Of Leases",
        "terseLabel": "Guarantor obligations, number of leases"
       }
      }
     },
     "localname": "GuarantorObligationsNumberOfLeases",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_HartfordLifeAndAccidentInsuranceCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hartford Life And Accident Insurance Company [Member]",
        "label": "Hartford Life And Accident Insurance Company [Member]",
        "terseLabel": "Hartford Life and Accident Insurance Company"
       }
      }
     },
     "localname": "HartfordLifeAndAccidentInsuranceCompanyMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_HealthCareAndOtherInsuranceLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care and Other Insurance Liabilities",
        "label": "Health Care and Other Insurance Liabilities [Abstract]"
       }
      }
     },
     "localname": "HealthCareAndOtherInsuranceLiabilitiesAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cvs_HealthCareBenefitsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Benefits Segment [Member]",
        "label": "Health Care Benefits Segment [Member]",
        "terseLabel": "Health Care Benefits"
       }
      }
     },
     "localname": "HealthCareBenefitsSegmentMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Costs Payable, Period After Date Of Services Claims Are Paid",
        "label": "Health Care Costs Payable, Period After Date Of Services Claims Are Paid",
        "terseLabel": "Period after date of service a claim is paid"
       }
      }
     },
     "localname": "HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvs_HealthInsurerFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated amount of the health insurer fee accrued during the reporting period, as required by Health Care Reform.",
        "label": "Health Insurer Fee",
        "terseLabel": "Health insurer fee"
       }
      }
     },
     "localname": "HealthInsurerFee",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_HealthInsurerFeeTaxEffectPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the tax effect of the health care reform's non-tax deductible health insurer fee.",
        "label": "Health Insurer Fee Tax Effect, Percent",
        "terseLabel": "Health insurer fee"
       }
      }
     },
     "localname": "HealthInsurerFeeTaxEffectPercent",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvs_HeartlandHealthcareServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heartland Healthcare Services [Member]",
        "label": "Heartland Healthcare Services [Member]",
        "terseLabel": "Heartland Healthcare Services"
       }
      }
     },
     "localname": "HeartlandHealthcareServicesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_HeathSavingsAccountBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heath Savings Account Balance",
        "label": "Heath Savings Account Balance",
        "terseLabel": "HSA balances"
       }
      }
     },
     "localname": "HeathSavingsAccountBalance",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individual Public Health Insurance Exchanges, Number Of Additional States",
        "label": "Individual Public Health Insurance Exchanges, Number Of Additional States",
        "terseLabel": "Additional number of states in which the Company entered the individual public health insurance exchange"
       }
      }
     },
     "localname": "IndividualPublicHealthInsuranceExchangesNumberOfAdditionalStates",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_IndividualPublicHealthInsuranceExchangesNumberOfStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individual Public Health Insurance Exchanges, Number Of States",
        "label": "Individual Public Health Insurance Exchanges, Number Of States",
        "terseLabel": "Number of states in which the Company has entered the individual public health insurance exchange"
       }
      }
     },
     "localname": "IndividualPublicHealthInsuranceExchangesNumberOfStates",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_InitialContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, Initial Contractual Term",
        "label": "Initial Contractual Term",
        "terseLabel": "Initial contractual term (in years)"
       }
      }
     },
     "localname": "InitialContractualTerm",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvs_InsuranceAndHMOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance and HMO subsidiaries [Member].",
        "label": "Insurance And HMO [Member]",
        "terseLabel": "Insurance and HMO"
       }
      }
     },
     "localname": "InsuranceAndHMOMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_InsurancePremiumDeficiencyReservePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Premium Deficiency Reserve [Policy Text Block]",
        "label": "Insurance Premium Deficiency Reserve [Policy Text Block]",
        "terseLabel": "Premium Deficiency Reserves"
       }
      }
     },
     "localname": "InsurancePremiumDeficiencyReservePolicyTextBlock",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets, Net (Excluding Goodwill), Including Assets Held For Sale",
        "label": "Intangible Assets, Net (Excluding Goodwill), Including Assets Held For Sale",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_InternationalHealthCareRenewalRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Health Care Renewal Rights",
        "label": "International Health Care Renewal Rights [Member]",
        "terseLabel": "International Health Care Renewal Rights"
       }
      }
     },
     "localname": "InternationalHealthCareRenewalRightsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Contracts With Fixed Maturity, Fair Value Disclosure.",
        "label": "Investment Contracts With Fixed Maturity, Fair Value Disclosure",
        "terseLabel": "Investment contract liabilities with a fixed maturity"
       }
      }
     },
     "localname": "InvestmentContractsWithFixedMaturityFairValueDisclosure",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Contracts Without A Fixed Maturity, Fair Value Disclosure.",
        "label": "Investment Contracts Without A Fixed Maturity, Fair Value Disclosure",
        "terseLabel": "Investment contracts liabilities without a fixed maturity"
       }
      }
     },
     "localname": "InvestmentContractsWithoutFixedMaturityFairValueDisclosure",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_InvestmentIncomeExcludingCapitalGainsOrLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentIncomeNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Income, Excluding Capital Gains Or Losses",
        "label": "Investment Income, Excluding Capital Gains Or Losses",
        "totalLabel": "Net investment income (excluding net realized capital gains or losses)"
       }
      }
     },
     "localname": "InvestmentIncomeExcludingCapitalGainsOrLosses",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LeasesWeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases, Weighted Average Discount Rate [Abstract]",
        "label": "Leases, Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "LeasesWeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_LegalSettlementPeriodOfPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Settlement, Period Of Payment",
        "label": "Legal Settlement, Period Of Payment",
        "terseLabel": "Legal settlement, period of payment"
       }
      }
     },
     "localname": "LegalSettlementPeriodOfPayment",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvs_LesseeLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease [Table Text Block]",
        "label": "Lessee, Lease [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "LesseeLeaseTableTextBlock",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Leases Liabilities Payments Due [Abstract]",
        "label": "Lessee, Leases Liabilities Payments Due [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LesseeLeasesLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_LesseeLiabilityPaymentsDue": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Liability, Payments, Due",
        "label": "Lessee, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeLiabilityPaymentsDue",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LesseeLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Liability, Payments, Due After Year Five",
        "label": "Lessee, Liability, Payments, Due After Year Five",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LesseeLiabilityPaymentsDueYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Liability, Payments, Due Year Five",
        "label": "Lessee, Liability, Payments, Due Year Five",
        "totalLabel": "2027"
       }
      }
     },
     "localname": "LesseeLiabilityPaymentsDueYearFive",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LesseeLiabilityPaymentsDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Liability, Payments, Due Year Four",
        "label": "Lessee, Liability, Payments, Due Year Four",
        "totalLabel": "2026"
       }
      }
     },
     "localname": "LesseeLiabilityPaymentsDueYearFour",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LesseeLiabilityPaymentsDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Liability, Payments, Due Year Three",
        "label": "Lessee, Liability, Payments, Due Year Three",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "LesseeLiabilityPaymentsDueYearThree",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LesseeLiabilityPaymentsDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Liability, Payments, Due Year Two",
        "label": "Lessee, Liability, Payments, Due Year Two",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "LesseeLiabilityPaymentsDueYearTwo",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LesseeLiabilityPaymentsYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Liability, Payments, Year One",
        "label": "Lessee, Liability, Payments, Year One",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "LesseeLiabilityPaymentsYearOne",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LesseeLiabilityUndiscountedExcessAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Liability, Undiscounted Excess Amount",
        "label": "Lessee, Liability, Undiscounted Excess Amount",
        "negatedTotalLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeLiabilityUndiscountedExcessAmount",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LesseeOperatingAndFinanceLeasesRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating And Finance Leases, Renewal Term",
        "label": "Lessee, Operating And Finance Leases, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeasesRenewalTerm",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvs_LiabilityForUnpaidClaims": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total liability on the balance sheet for unpaid claims for both short-duration and long-duration insurance contracts after reinsurance.",
        "label": "Liability For Unpaid Claims",
        "terseLabel": "Liability for unpaid claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaims",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs",
        "label": "Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs",
        "terseLabel": "Benefit costs recorded in other insurance liabilities"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LimitedPaymentsContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum assumed interest rates on limited payment contracts on large case pensions business.",
        "label": "Limited Payments Contracts",
        "terseLabel": "Assumed interest rates on limited payment pension contracts on large case pension business (in hundredths)"
       }
      }
     },
     "localname": "LimitedPaymentsContracts",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvs_LincolnLifeAnnuityCompanyOfNewYorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Life &amp; Annuity Company Of New York [Member]",
        "label": "Lincoln Life &amp; Annuity Company Of New York [Member]",
        "terseLabel": "Lincoln Life &amp; Annuity Company of New York"
       }
      }
     },
     "localname": "LincolnLifeAnnuityCompanyOfNewYorkMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_LitigationSettlementNumberOfStatesElectedToJoin": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Number Of States Elected To Join",
        "label": "Litigation Settlement, Number Of States Elected To Join",
        "terseLabel": "Number of states that elected to join the settlement"
       }
      }
     },
     "localname": "LitigationSettlementNumberOfStatesElectedToJoin",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_LitigationSettlementNumberOfStatesSubjectToEarlierSettlements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Number Of States Subject To Earlier Settlements",
        "label": "Litigation Settlement, Number Of States Subject To Earlier Settlements",
        "terseLabel": "Number of states subject to earlier settlements"
       }
      }
     },
     "localname": "LitigationSettlementNumberOfStatesSubjectToEarlierSettlements",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_LongTermCareReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Care Reporting Unit [Member]",
        "label": "Long-Term Care Reporting Unit [Member]",
        "terseLabel": "Long-Term Care Reporting Unit"
       }
      }
     },
     "localname": "LongTermCareReportingUnitMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including liabilities held for sale, classified as noncurrent.",
        "label": "Long-Term Debt And Lease Obligation, Including Liabilities Held For Sale",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LongTermInvestmentsIncludingAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Investments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Investments, Including Assets Held For Sale",
        "label": "Long-Term Investments, Including Assets Held For Sale",
        "terseLabel": "Long-term"
       }
      }
     },
     "localname": "LongTermInvestmentsIncludingAssetsHeldForSale",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_LongtermDebtGrossAndLeaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Gross And Lease Obligation",
        "label": "Long-term Debt, Gross And Lease Obligation",
        "totalLabel": "Total debt principal"
       }
      }
     },
     "localname": "LongtermDebtGrossAndLeaseObligation",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_MortgageLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents mortgage loans for the reporting period measured at carrying value. We carry the value of our mortgage loan investments on our balance sheet at the unpaid principal balance, net of impairment reserves.",
        "label": "Mortgage Loans [Member]",
        "terseLabel": "Mortgage loans"
       }
      }
     },
     "localname": "MortgageLoansMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails",
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loans On Real Estate Collections Of Principal After Year Five",
        "label": "Mortgage Loans On Real Estate Collections Of Principal After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months",
        "label": "Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Five",
        "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Four",
        "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Three",
        "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Two",
        "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_MortgageLoansOnRealEstateLoansFullyRepaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertains to amount of mortgage loans fully repaid.",
        "label": "Mortgage Loans on Real Estate, Loans Fully Repaid",
        "terseLabel": "Mortgage loans fully repaid"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateLoansFullyRepaid",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_MortgageLoansOnRealEstateYearOfOriginationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loans On Real Estate Year Of Origination",
        "label": "Mortgage Loans On Real Estate Year Of Origination [Axis]",
        "terseLabel": "Mortgage Loans On Real Estate Year Of Origination [Axis]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateYearOfOriginationAxis",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_MortgageLoansOnRealEstateYearOfOriginationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Loans On Real Estate Year Of Origination",
        "label": "Mortgage Loans On Real Estate Year Of Origination [Domain]",
        "terseLabel": "Mortgage Loans On Real Estate Year Of Origination [Domain]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateYearOfOriginationDomain",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_NetRevenuesRetailCoPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Revenues, Retail CoPayments",
        "label": "Net Revenues, Retail CoPayments",
        "terseLabel": "Copayments"
       }
      }
     },
     "localname": "NetRevenuesRetailCoPayments",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_NoncontrollingInterestOtherPeriodIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Other Period Increase (Decrease)",
        "label": "Noncontrolling Interest, Other Period Increase (Decrease)",
        "terseLabel": "Other increases (decreases) in noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestOtherPeriodIncreaseDecrease",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_NumberOfMedicalMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Medical Members",
        "label": "Number Of Medical Members",
        "terseLabel": "Number of medical members"
       }
      }
     },
     "localname": "NumberOfMedicalMembers",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_NumberOfPatientsServedPerYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Patients Served Per Year",
        "label": "Number Of Patients Served Per Year",
        "terseLabel": "Number of patients served per year (more than)"
       }
      }
     },
     "localname": "NumberOfPatientsServedPerYear",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_NumberOfPeopleServed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of People Served",
        "label": "Number Of People Served",
        "terseLabel": "Number of people served"
       }
      }
     },
     "localname": "NumberOfPeopleServed",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_NumberOfPharmacyPlanMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Pharmacy Plan Members",
        "label": "Number Of Pharmacy Plan Members",
        "terseLabel": "Number of pharmacy plan members"
       }
      }
     },
     "localname": "NumberOfPharmacyPlanMembers",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Stores, Annual Planned Closures For Closure Period",
        "label": "Number Of Stores, Annual Planned Closures For Closure Period",
        "terseLabel": "Number of stores, annual planned closures for closure period"
       }
      }
     },
     "localname": "NumberOfStoresAnnualPlannedClosuresForClosurePeriod",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_NumberOfStoresPlannedClosure": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Stores, Planned Closure",
        "label": "Number Of Stores, Planned Closure",
        "terseLabel": "Number of stores, planned closure"
       }
      }
     },
     "localname": "NumberOfStoresPlannedClosure",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_NumberOfWalkInMedicalClinics": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Walk In Medical Clinics",
        "label": "Number Of Walk In Medical Clinics",
        "terseLabel": "Number of walk-in medical clinics (more than)"
       }
      }
     },
     "localname": "NumberOfWalkInMedicalClinics",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_NumberofReinsuranceContractsEnteredInto": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reinsurance contracts entered into with an unrelated insurer.",
        "label": "Number of Reinsurance Contracts Entered Into",
        "terseLabel": "Number of reinsurance contracts entered into"
       }
      }
     },
     "localname": "NumberofReinsuranceContractsEnteredInto",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvs_NumeratorForEarningsPerShareCalculationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator For Earnings Per Share Calculation [Abstract]",
        "label": "Numerator For Earnings Per Share Calculation [Abstract]",
        "terseLabel": "Numerator for earnings per share calculation:"
       }
      }
     },
     "localname": "NumeratorForEarningsPerShareCalculationAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_OakStreetHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oak Street Health Inc.",
        "label": "Oak Street Health Inc. [Member]",
        "terseLabel": "Oak Street Health Inc."
       }
      }
     },
     "localname": "OakStreetHealthIncMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_OfficeRealEstateOptimizationCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Real Estate Optimization Charges - Related to the abandonment of leased real estate and the related right-of-use assets and property and equipment",
        "label": "Office Real Estate Optimization Charges",
        "terseLabel": "Office real estate optimization charges"
       }
      }
     },
     "localname": "OfficeRealEstateOptimizationCharges",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_OmnicareLongTermCareBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnicare Long-Term Care Business",
        "label": "Omnicare Long-Term Care Business [Member]",
        "terseLabel": "Omnicare Long-Term Care Business"
       }
      }
     },
     "localname": "OmnicareLongTermCareBusinessMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life",
        "label": "Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life",
        "terseLabel": "Leases, amount due in excess of remaining estimated economic life"
       }
      }
     },
     "localname": "OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Expenses, Excluding Store Impairments, Goodwill Impairments, Loss On Assets Held For Sale, And Loss On Litigation Settlement",
        "label": "Operating Expenses, Excluding Store Impairments, Goodwill Impairments, Loss On Assets Held For Sale, And Loss On Litigation Settlement",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesExcludingStoreImpairmentsGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Assets And Liabilities, Lessee [Abstract]",
        "label": "Operating Lease, Assets And Liabilities, Lessee [Abstract]",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Current, Including Liabilities Held For Sale",
        "label": "Operating Lease, Liability, Current, Including Liabilities Held For Sale",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Noncurrent, Including Liabilities Held For Sale",
        "label": "Operating Lease, Liability, Noncurrent, Including Liabilities Held For Sale",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, Right-of-Use Asset, Fair Value Disclosure",
        "label": "Operating lease, Right-of-Use Asset, Fair Value Disclosure",
        "terseLabel": "Operating lease, right-of-use asset, fair value"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetFairValueDisclosure",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset, Including Assets Held For Sale",
        "label": "Operating Lease, Right-Of-Use Asset, Including Assets Held For Sale",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_OtherAcquiredIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Other Acquired Intangible Assets [Line Items]",
        "terseLabel": "Other Intangible Assets[Line Items]"
       }
      }
     },
     "localname": "OtherAcquiredIntangibleAssetsLineItems",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_OtherAcquiredIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Other Acquired Intangible Assets [Table]",
        "terseLabel": "Other Intangible Assets [Table]"
       }
      }
     },
     "localname": "OtherAcquiredIntangibleAssetsTable",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_OtherAssetBackedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by a variety of assets such as automobile loans, credit card receivables, home equity loans, etc.",
        "label": "Other Asset-Backed Securities [Member]",
        "terseLabel": "Other asset-backed securities"
       }
      }
     },
     "localname": "OtherAssetBackedSecuritiesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails",
      "http://www.cvshealth.com/role/InvestmentsNarrativeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_OtherInsuranceLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Insurance Liabilities, Current",
        "label": "Other Insurance Liabilities, Current",
        "terseLabel": "Other insurance liabilities"
       }
      }
     },
     "localname": "OtherInsuranceLiabilitiesCurrent",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_OtherInsuranceLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Insurance Liabilities [Member]",
        "label": "Other Insurance Liabilities [Member]",
        "terseLabel": "Other Insurance Liabilities"
       }
      }
     },
     "localname": "OtherInsuranceLiabilitiesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_OtherInsuranceLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Insurance Liabilities, Noncurrent",
        "label": "Other Insurance Liabilities, Noncurrent",
        "terseLabel": "Other long-term insurance liabilities"
       }
      }
     },
     "localname": "OtherInsuranceLiabilitiesNoncurrent",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_OtherLongTermInsuranceLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-Term Insurance Liabilities [Member]",
        "label": "Other Long-Term Insurance Liabilities [Member]",
        "terseLabel": "Other Long-Term Insurance Liabilities"
       }
      }
     },
     "localname": "OtherLongTermInsuranceLiabilitiesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_OutstandingSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding Senior Notes [Member]",
        "label": "Outstanding Senior Notes [Member]",
        "terseLabel": "Outstanding Senior Notes"
       }
      }
     },
     "localname": "OutstandingSeniorNotesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_PayflexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payflex",
        "label": "Payflex [Member]",
        "terseLabel": "Payflex"
       }
      }
     },
     "localname": "PayflexMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_PaymentsForAcceleratedShareRepurchasesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Accelerated Share Repurchases, Amount",
        "label": "Payments For Accelerated Share Repurchases, Amount",
        "terseLabel": "Payments for ASR, amount"
       }
      }
     },
     "localname": "PaymentsForAcceleratedShareRepurchasesAmount",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_PaymentsForInsuranceBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Insurance Benefits",
        "label": "Payments For Insurance Benefits",
        "negatedTerseLabel": "Insurance benefits paid"
       }
      }
     },
     "localname": "PaymentsForInsuranceBenefits",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies",
        "label": "Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies",
        "negatedTerseLabel": "Cash paid for inventory and prescriptions dispensed by retail network pharmacies"
       }
      }
     },
     "localname": "PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_PensionAndAnnuityInvestmentContractsInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension And Annuity Investment Contracts Interest",
        "label": "Pension And Annuity Investment Contracts Interest",
        "terseLabel": "Interest rate for pension and annuity investment contracts"
       }
      }
     },
     "localname": "PensionAndAnnuityInvestmentContractsInterest",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvs_PharmacyClaimsAndDiscountsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Claims And Discounts Payable, Current",
        "label": "Pharmacy Claims And Discounts Payable, Current",
        "terseLabel": "Pharmacy claims and discounts payable"
       }
      }
     },
     "localname": "PharmacyClaimsAndDiscountsPayableCurrent",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_PharmacyRebatePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Rebate Period",
        "label": "Pharmacy Rebate Period",
        "terseLabel": "Pharmacy rebate period"
       }
      }
     },
     "localname": "PharmacyRebatePeriod",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvs_PharmacyRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Revenue [Member]",
        "label": "Pharmacy Revenue [Member]",
        "terseLabel": "Pharmacy"
       }
      }
     },
     "localname": "PharmacyRevenueMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_PharmacyServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Services Segment [Member]",
        "label": "Pharmacy Services Segment [Member]",
        "terseLabel": "Pharmacy Services"
       }
      }
     },
     "localname": "PharmacyServicesSegmentMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_PremiumDeficiencyReserveLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reserves related to expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), in excess of existing reserves plus anticipated future premiums and reinsurance recoveries.",
        "label": "Premium Deficiency Reserve Liability",
        "terseLabel": "Add: Premium deficiency reserve",
        "verboseLabel": "Premium deficiency reserve"
       }
      }
     },
     "localname": "PremiumDeficiencyReserveLiability",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax",
        "label": "Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues from external customers",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_PremiumsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums [Member]",
        "label": "Premiums [Member]",
        "terseLabel": "Premiums"
       }
      }
     },
     "localname": "PremiumsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item includes proceeds from the sale of debt securities and the related gross realized capital gains and losses, excluding amounts related to experience-rated and discontinued products.",
        "label": "Proceeds And Related Gross Realized Capital Gains Losses From Sale Of Debt Securities [Table Text Block]",
        "verboseLabel": "Schedule of Proceeds and Related Gross Realized Capital Gains and Losses From the Sale of Debt Securities"
       }
      }
     },
     "localname": "ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvs_ProceedsFromVariableInterestEntity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Variable Interest Entity",
        "label": "Proceeds From Variable Interest Entity",
        "terseLabel": "Proceeds from VIE"
       }
      }
     },
     "localname": "ProceedsFromVariableInterestEntity",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant And Equipment, Net, Including Assets Held For Sale",
        "label": "Property, Plant And Equipment, Net, Including Assets Held For Sale",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_ProviderNetworksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired in a business combination or other transaction. This item represents the value ascribed to the relationships with the acquiree's physicians, hospitals and other health care providers network.",
        "label": "Provider Networks [Member]",
        "terseLabel": "Provider networks"
       }
      }
     },
     "localname": "ProviderNetworksMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RadcliffAndFlaimVAetnaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Radcliff and Flaim v Aetna Inc., et al",
        "label": "Radcliff and Flaim v Aetna Inc., et al [Member]",
        "terseLabel": "Radcliff and Flaim v Aetna Inc., et al"
       }
      }
     },
     "localname": "RadcliffAndFlaimVAetnaIncEtAlMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RedOakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Red Oak",
        "label": "Red Oak [Member]",
        "terseLabel": "Red Oak"
       }
      }
     },
     "localname": "RedOakMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RedeemablePreferredSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Preferred Securities [Member]",
        "label": "Redeemable Preferred Securities [Member]",
        "terseLabel": "Redeemable preferred securities"
       }
      }
     },
     "localname": "RedeemablePreferredSecuritiesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Charitable Contribution To Non-Profit Entity",
        "label": "Related Party Transaction, Charitable Contribution To Non-Profit Entity",
        "terseLabel": "Charitable contribution to CVS Health Foundation"
       }
      }
     },
     "localname": "RelatedPartyTransactionCharitableContributionToNonProfitEntity",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_RestrictedStockUnitsAndPerformanceShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units and Performance Share Units [Member]",
        "label": "Restricted Stock Units And Performance Share Units [Member]",
        "terseLabel": "Restricted Stock Units and Performance Share Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPerformanceShareUnitsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units (RSUs) And Performance Stock Units (PSUs)",
        "label": "Restricted Stock Units (RSUs) And Performance Stock Units (PSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) and Performance Stock Units (PSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RetailLongTermCareSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retail Long-Term Care Segment [Member]",
        "label": "Retail Long-Term Care Segment [Member]",
        "terseLabel": "Retail/ LTC"
       }
      }
     },
     "localname": "RetailLongTermCareSegmentMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails",
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RevolvingCreditFacilityExpiringMay112026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility, Expiring May 11, 2026",
        "label": "Revolving Credit Facility, Expiring May 11, 2026 [Member]",
        "terseLabel": "Revolving Credit Facility, Expiring May 11, 2026"
       }
      }
     },
     "localname": "RevolvingCreditFacilityExpiringMay112026Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RevolvingCreditFacilityExpiringMay162025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility, Expiring May 16, 2025",
        "label": "Revolving Credit Facility, Expiring May 16, 2025 [Member]",
        "terseLabel": "Revolving Credit Facility, Expiring May 16, 2025"
       }
      }
     },
     "localname": "RevolvingCreditFacilityExpiringMay162025Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RevolvingCreditFacilityExpiringMay162027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility, Expiring May 16, 2027",
        "label": "Revolving Credit Facility, Expiring May 16, 2027 [Member]",
        "terseLabel": "Revolving Credit Facility, Expiring May 16, 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityExpiringMay162027Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_SalesChannelOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Channel, Other [Member]",
        "label": "Sales Channel, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "SalesChannelOtherMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing credit quality information related to financing receivables by credit quality indicator and by class of financing receivable.",
        "label": "Schedule Of Mortgage Loan Internal Credit Ratings [Table Text Block]",
        "verboseLabel": "Schedule of Mortgage Loan Amortized Cost and Credit Quality Indicator"
       }
      }
     },
     "localname": "ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvs_SeniorNotes1Point3PercentAugust2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 1 Point 3 Percent, August 2027",
        "label": "Senior Notes, 1 Point 3 Percent, August 2027 [Member]",
        "terseLabel": "1.3% senior notes due August 2027"
       }
      }
     },
     "localname": "SeniorNotes1Point3PercentAugust2027Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes1Point75PercentAugust2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 1 Point 75 Percent, August 2030",
        "label": "Senior Notes, 1 Point 75 Percent, August 2030 [Member]",
        "terseLabel": "1.75% senior notes due August 2030"
       }
      }
     },
     "localname": "SeniorNotes1Point75PercentAugust2030Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes1Point875PercentFebruary2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 1 Point 875 Percent, February 2031",
        "label": "Senior Notes, 1 Point 875 Percent, February 2031 [Member]",
        "terseLabel": "1.875% senior notes due February 2031"
       }
      }
     },
     "localname": "SeniorNotes1Point875PercentFebruary2031Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes2.625DueAugust2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 2.625%, Due August 2024 [Member]",
        "label": "Senior Notes, 2.625%, Due August 2024 [Member]",
        "terseLabel": "2.625% senior notes due August 2024"
       }
      }
     },
     "localname": "SeniorNotes2.625DueAugust2024Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes2.75DueDecember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 2.75%, Due December 2022 [Member]",
        "label": "Senior Notes, 2.75%, Due December 2022 [Member]",
        "terseLabel": "2.75% senior notes due December 2022"
       }
      }
     },
     "localname": "SeniorNotes2.75DueDecember2022Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes2.75DueNovember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 2.75%, Due November 2022 [Member]",
        "label": "Senior Notes, 2.75%, Due November 2022 [Member]",
        "terseLabel": "2.75% senior notes due November 2022"
       }
      }
     },
     "localname": "SeniorNotes2.75DueNovember2022Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes2.875DueJune2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 2.875%, Due June 2026 [Member]",
        "label": "Senior Notes, 2.875%, Due June 2026 [Member]",
        "terseLabel": "2.875% senior notes due June 2026"
       }
      }
     },
     "localname": "SeniorNotes2.875DueJune2026Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes2.8DueJune2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 2.8%, Due June 2023 [Member]",
        "label": "Senior Notes, 2.8%, Due June 2023 [Member]",
        "terseLabel": "2.8% senior notes due June 2023"
       }
      }
     },
     "localname": "SeniorNotes2.8DueJune2023Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes2Point125PercentDueSeptember2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 2 Point 125 Percent, Due September 2031",
        "label": "Senior Notes, 2 Point 125 Percent, Due September 2031 [Member]",
        "terseLabel": "2.125% senior notes due September 2031"
       }
      }
     },
     "localname": "SeniorNotes2Point125PercentDueSeptember2031Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes2Point7PercentAugust2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 2 Point 7 Percent, August 2040",
        "label": "Senior Notes, 2 Point 7 Percent, August 2040 [Member]",
        "terseLabel": "2.7% senior notes due August 2040"
       }
      }
     },
     "localname": "SeniorNotes2Point7PercentAugust2040Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3.25DueAugust2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3.25%, Due August 2029 [Member]",
        "label": "Senior Notes, 3.25%, Due August 2029 [Member]",
        "terseLabel": "3.25% senior notes due August 2029"
       }
      }
     },
     "localname": "SeniorNotes3.25DueAugust2029Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3.375DueAugust2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3.375%, Due August 2024 [Member]",
        "label": "Senior Notes, 3.375%, Due August 2024 [Member]",
        "terseLabel": "3.375% senior notes due August 2024"
       }
      }
     },
     "localname": "SeniorNotes3.375DueAugust2024Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3.5DueJuly2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3.5%, Due July 2022 [Member]",
        "label": "Senior Notes, 3.5%, Due July 2022 [Member]",
        "terseLabel": "3.5% senior notes due July 2022"
       }
      }
     },
     "localname": "SeniorNotes3.5DueJuly2022Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3.5DueNovember2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3.5%, Due November 2024 [Member]",
        "label": "Senior Notes, 3.5%, Due November 2024 [Member]",
        "terseLabel": "3.5% senior notes due November 2024"
       }
      }
     },
     "localname": "SeniorNotes3.5DueNovember2024Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3.7DueMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3.7%, Due March 2023 [Member]",
        "label": "Senior Notes, 3.7%, Due March 2023 [Member]",
        "terseLabel": "3.7% senior notes due March 2023"
       }
      }
     },
     "localname": "SeniorNotes3.7DueMarch2023Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3.875DueAugust2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3.875%, Due August 2047 [Member]",
        "label": "Senior Notes, 3.875%, Due August 2047 [Member]",
        "terseLabel": "3.875% senior notes due August 2047"
       }
      }
     },
     "localname": "SeniorNotes3.875DueAugust2047Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3.875DueJuly2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3.875%, Due July 2025 [Member]",
        "label": "Senior Notes, 3.875%, Due July 2025 [Member]",
        "terseLabel": "3.875% senior notes due July 2025"
       }
      }
     },
     "localname": "SeniorNotes3.875DueJuly2025Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3DueAugust2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3%, Due August 2026 [Member]",
        "label": "Senior Notes, 3%, Due August 2026 [Member]",
        "terseLabel": "3% senior notes due August 2026"
       }
      }
     },
     "localname": "SeniorNotes3DueAugust2026Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3Point625PercentApril2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3 Point 625 Percent, April 2027",
        "label": "Senior Notes, 3 Point 625 Percent, April 2027 [Member]",
        "terseLabel": "3.625% senior notes due April 2027"
       }
      }
     },
     "localname": "SeniorNotes3Point625PercentApril2027Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3Point70PercentDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3 Point 70 Percent, Due 2023",
        "label": "Senior Notes, 3 Point 70 Percent, Due 2023 [Member]",
        "terseLabel": "3.7% senior notes due 2023"
       }
      }
     },
     "localname": "SeniorNotes3Point70PercentDue2023Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes3Point75PercentApril2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 3 Point 75 Percent, April 2030",
        "label": "Senior Notes, 3 Point 75 Percent, April 2030 [Member]",
        "terseLabel": "3.75% senior notes due April 2030"
       }
      }
     },
     "localname": "SeniorNotes3Point75PercentApril2030Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4.125DueNovember2042Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents senior notes due 2042 with a coupon rate of 4.125%.",
        "label": "Senior Notes, 4.125%, Due November 2042 [Member]",
        "terseLabel": "4.125% senior notes due November 2042"
       }
      }
     },
     "localname": "SeniorNotes4.125DueNovember2042Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4.1DueMarch2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.1%, Due March 2025 [Member]",
        "label": "Senior Notes, 4.1%, Due March 2025 [Member]",
        "terseLabel": "4.1% senior notes due March 2025"
       }
      }
     },
     "localname": "SeniorNotes4.1DueMarch2025Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4.3DueMarch2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.3%, Due March 2028 [Member]",
        "label": "Senior Notes, 4.3%, Due March 2028 [Member]",
        "terseLabel": "4.3% senior notes due March 2028"
       }
      }
     },
     "localname": "SeniorNotes4.3DueMarch2028Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4.5DueMay2042Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.5%, Due May 2042 [Member]",
        "label": "Senior Notes, 4.5%, Due May 2042 [Member]",
        "terseLabel": "4.5% senior notes due May 2042"
       }
      }
     },
     "localname": "SeniorNotes4.5DueMay2042Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4.75DueDecember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.75%, Due December 2022 [Member]",
        "label": "Senior Notes, 4.75%, Due December 2022 [Member]",
        "terseLabel": "4.75% senior notes due December 2022"
       }
      }
     },
     "localname": "SeniorNotes4.75DueDecember2022Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4.75DueMarch2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.75%, Due March 2044 [Member]",
        "label": "Senior Notes, 4.75%, Due March 2044 [Member]",
        "terseLabel": "4.75% senior notes due March 2044"
       }
      }
     },
     "localname": "SeniorNotes4.75DueMarch2044Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4.78DueMarch2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.78%, Due March 2038 [Member]",
        "label": "Senior Notes, 4.78%, Due March 2038 [Member]",
        "terseLabel": "4.78% senior notes due March 2038"
       }
      }
     },
     "localname": "SeniorNotes4.78DueMarch2038Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4.875DueJuly2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.875%, Due July 2035 [Member]",
        "label": "Senior Notes, 4.875%, Due July 2035 [Member]",
        "terseLabel": "4.875% senior notes due July 2035"
       }
      }
     },
     "localname": "SeniorNotes4.875DueJuly2035Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes43Due2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.3%, Due 2028",
        "label": "Senior Notes, 4.3%, Due 2028 [Member]",
        "terseLabel": "4.3% senior notes due 2028"
       }
      }
     },
     "localname": "SeniorNotes43Due2028Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4DueDecember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4%, Due December 2023 [Member]",
        "label": "Senior Notes, 4%, Due December 2023 [Member]",
        "terseLabel": "4% senior notes due December 2023"
       }
      }
     },
     "localname": "SeniorNotes4DueDecember2023Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4Point125PercentApril2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4 Point 125 Percent, April 2040",
        "label": "Senior Notes, 4 Point 125 Percent, April 2040 [Member]",
        "terseLabel": "4.125% senior notes due April 2040"
       }
      }
     },
     "localname": "SeniorNotes4Point125PercentApril2040Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4Point25PercentApril2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4 Point 25 Percent, April 2050",
        "label": "Senior Notes, 4 Point 25 Percent, April 2050 [Member]",
        "terseLabel": "4.25% senior notes due April 2050"
       }
      }
     },
     "localname": "SeniorNotes4Point25PercentApril2050Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes4PointThreePercentDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4 Point Three Percent, Due 2028",
        "label": "Senior Notes, 4 Point Three Percent, Due 2028 [Member]",
        "terseLabel": "4.3% senior notes due 2028"
       }
      }
     },
     "localname": "SeniorNotes4PointThreePercentDue2028Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes5.05DueMarch2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.05%, Due March 2048 [Member]",
        "label": "Senior Notes, 5.05%, Due March 2048 [Member]",
        "terseLabel": "5.05% senior notes due March 2048"
       }
      }
     },
     "localname": "SeniorNotes5.05DueMarch2048Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes5.125DueJuly2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.125%, Due July 2045 [Member]",
        "label": "Senior Notes, 5.125%, Due July 2045 [Member]",
        "terseLabel": "5.125% senior notes due July 2045"
       }
      }
     },
     "localname": "SeniorNotes5.125DueJuly2045Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes5.3DueDecember2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.3%, Due December 2043 [Member]",
        "label": "Senior Notes, 5.3%, Due December 2043 [Member]",
        "terseLabel": "5.3% senior notes due December 2043"
       }
      }
     },
     "localname": "SeniorNotes5.3DueDecember2043Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes5.75DueMay2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.75%, Due May 2041 [Member]",
        "label": "Senior Notes, 5.75%, Due May 2041 [Member]",
        "terseLabel": "5.75% senior notes due May 2041"
       }
      }
     },
     "localname": "SeniorNotes5.75DueMay2041Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes5DueDecember2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5%, Due December 2024 [Member]",
        "label": "Senior Notes, 5%, Due December 2024 [Member]",
        "terseLabel": "5% senior notes due December 2024"
       }
      }
     },
     "localname": "SeniorNotes5DueDecember2024Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes6.125DueSeptember2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.125%, Due September 2039 [Member]",
        "label": "Senior Notes, 6.125%, Due September 2039 [Member]",
        "terseLabel": "6.125% senior notes due September 2039"
       }
      }
     },
     "localname": "SeniorNotes6.125DueSeptember2039Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes6.25DueJune2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.25%, Due June 2027 [Member]",
        "label": "Senior Notes, 6.25%, Due June 2027 [Member]",
        "terseLabel": "6.25% senior notes due June 2027"
       }
      }
     },
     "localname": "SeniorNotes6.25DueJune2027Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes6.625DueJune2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.625%, Due June 2036 [Member]",
        "label": "Senior Notes, 6.625%, Due June 2036 [Member]",
        "terseLabel": "6.625% senior notes due June 2036"
       }
      }
     },
     "localname": "SeniorNotes6.625DueJune2036Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeniorNotes6.75DueDecember2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.75%, Due December 2037 [Member]",
        "label": "Senior Notes, 6.75%, Due December 2037 [Member]",
        "terseLabel": "6.75% senior notes due December 2037"
       }
      }
     },
     "localname": "SeniorNotes6.75DueDecember2037Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SeparateAccountFinancialAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separate Account, Financial Assets",
        "label": "Separate Account, Financial Assets [Member]",
        "terseLabel": "Separate Accounts, financial assets"
       }
      }
     },
     "localname": "SeparateAccountFinancialAssetsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SettlementFrameworkAndOtherOpioidRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Framework And Other Opioid-Related Claims",
        "label": "Settlement Framework And Other Opioid-Related Claims [Member]",
        "terseLabel": "Settlement Framework and Other Opioid-Related Claims"
       }
      }
     },
     "localname": "SettlementFrameworkAndOtherOpioidRelatedClaimsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SettlementFrameworkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Framework",
        "label": "Settlement Framework [Member]",
        "terseLabel": "Settlement Framework"
       }
      }
     },
     "localname": "SettlementFrameworkMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Actual Payout Rates",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Actual Payout Rates",
        "terseLabel": "Restricted stock units and performance stock units vested if actual payout rates are applied (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodActualPayoutRates",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value",
        "terseLabel": "Fair value of stock options and SARs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "terseLabel": "Expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Option, Granted Prior Through 2018",
        "label": "Share-Based Payment Arrangement, Option, Granted Prior Through 2018 [Member]",
        "terseLabel": "Stock options granted through 2018"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Option, Granted Subsequent to 2018",
        "label": "Share-Based Payment Arrangement, Option, Granted Subsequent to 2018 [Member]",
        "terseLabel": "Stock options granted subsequent to 2018"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SharesHeldInTrustPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Held In Trust [Policy Text Block]",
        "label": "Shares Held In Trust [Policy Text Block]",
        "terseLabel": "Shares Held in Trust"
       }
      }
     },
     "localname": "SharesHeldInTrustPolicyTextBlock",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvs_SignifyHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Signify Health, Inc.",
        "label": "Signify Health, Inc. [Member]",
        "terseLabel": "Signify Health, Inc."
       }
      }
     },
     "localname": "SignifyHealthIncMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_StateOfFloridaSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Of Florida Settlement",
        "label": "State Of Florida Settlement [Member]",
        "terseLabel": "State of Florida Settlement"
       }
      }
     },
     "localname": "StateOfFloridaSettlementMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased",
        "label": "Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased",
        "terseLabel": "Average purchase price of shares purchased (in dollars per share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvs_StockOptionsAndStockAppreciationRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Stock Appreciation Rights",
        "label": "Stock Options And Stock Appreciation Rights [Member]",
        "terseLabel": "Stock Options and Stock Appreciation Rights"
       }
      }
     },
     "localname": "StockOptionsAndStockAppreciationRightsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_StoreImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Store Impairment Charges",
        "label": "Store Impairment Charges",
        "terseLabel": "Store impairments",
        "verboseLabel": "Store impairment charges"
       }
      }
     },
     "localname": "StoreImpairmentCharges",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_SupportingExperienceRatedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supporting discontinued and experience-rated products.",
        "label": "Supporting Experience Rated Products [Member]",
        "terseLabel": "Supporting experience- rated products"
       }
      }
     },
     "localname": "SupportingExperienceRatedProductsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_SupportingRemainingProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities in an unrealized capital loss position supporting remaining products.",
        "label": "Supporting Remaining Products [Member]",
        "terseLabel": "Supporting remaining products"
       }
      }
     },
     "localname": "SupportingRemainingProductsMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_ThailandBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Thailand Business",
        "label": "Thailand Business [Member]",
        "terseLabel": "Thailand Business"
       }
      }
     },
     "localname": "ThailandBusinessMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_TotalInvestmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Investments [Axis]",
        "terseLabel": "Total Investments [Axis]"
       }
      }
     },
     "localname": "TotalInvestmentsAxis",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_TotalInvestmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Investments [Domain]",
        "terseLabel": "Total Investments [Domain]"
       }
      }
     },
     "localname": "TotalInvestmentsDomain",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_TotalInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Investments [Line Items]",
        "terseLabel": "Total Investments [Line Items]"
       }
      }
     },
     "localname": "TotalInvestmentsLineItems",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_TotalInvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Investments [Table]",
        "terseLabel": "Total Investments [Table]"
       }
      }
     },
     "localname": "TotalInvestmentsTable",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_TotalInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item includes total investments, both current and long-term.",
        "label": "Total Investments [Table Text Block]",
        "verboseLabel": "Schedule of Total Investments"
       }
      }
     },
     "localname": "TotalInvestmentsTableTextBlock",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvs_TransferOfSharesToTreasuryStockValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer Of Shares To Treasury Stock Value",
        "label": "Transfer Of Shares To Treasury Stock Value",
        "terseLabel": "Transfer of shares to treasury stock value"
       }
      }
     },
     "localname": "TransferOfSharesToTreasuryStockValue",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance",
        "label": "Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance",
        "negatedTerseLabel": "Purchase of treasury shares, net of ESPP issuances (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvs_TreasuryStockSharesHeldinTrust": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock, Shares, Held in Trust",
        "label": "Treasury Stock, Shares, Held in Trust",
        "terseLabel": "Treasury shares held in trust (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesHeldinTrust",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance",
        "label": "Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance",
        "negatedTerseLabel": "Purchase of treasury shares, net of ESPP issuances"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_TreasuryStockValueSharesHeldInTrust": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock, Value, Shares Held In Trust",
        "label": "Treasury Stock, Value, Shares Held In Trust",
        "terseLabel": "Treasury shares held in trust"
       }
      }
     },
     "localname": "TreasuryStockValueSharesHeldInTrust",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_TribalEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tribal Entities",
        "label": "Tribal Entities [Member]",
        "terseLabel": "Tribal Entities"
       }
      }
     },
     "localname": "TribalEntitiesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Department Of Health And Human Services, ACA Risk Corridor Receivables",
        "label": "U.S. Department Of Health And Human Services, ACA Risk Corridor Receivables [Member]",
        "terseLabel": "U.S. Department of Health and Human Services, ACA Risk Corridor Receivables"
       }
      }
     },
     "localname": "USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_USFederalGovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Federal Government",
        "label": "US Federal Government [Member]",
        "terseLabel": "US Federal Government"
       }
      }
     },
     "localname": "USFederalGovernmentMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_VOYARetirementInsuranceAndAnnuityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VOYA Retirement Insurance And Annuity Company [Member]",
        "label": "VOYA Retirement Insurance And Annuity Company [Member]",
        "terseLabel": "VOYA Retirement Insurance and Annuity Company"
       }
      }
     },
     "localname": "VOYARetirementInsuranceAndAnnuityCompanyMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_ValueOfBusinessAcquiredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value Of Business Acquired [Member]",
        "label": "Value Of Business Acquired [Member]",
        "terseLabel": "Value of Business Acquired"
       }
      }
     },
     "localname": "ValueOfBusinessAcquiredMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_VariableInterestEntityAmendedContractExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, Amended Contract Extension Term",
        "label": "Variable Interest Entity, Amended Contract Extension Term",
        "terseLabel": "Amended contract extension term"
       }
      }
     },
     "localname": "VariableInterestEntityAmendedContractExtensionTerm",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvs_VariableInterestEntityAmendedContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, Amended Contract Term",
        "label": "Variable Interest Entity, Amended Contract Term",
        "terseLabel": "Amended contract term (in years)"
       }
      }
     },
     "localname": "VariableInterestEntityAmendedContractTerm",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor Allowances And Purchase Discounts",
        "label": "Vendor Allowances And Purchase Discounts [Policy Text Block]",
        "terseLabel": "Vendor Allowances and Purchase Discounts"
       }
      }
     },
     "localname": "VendorAllowancesAndPurchaseDiscountsPolicyTextBlock",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvs_VendorandManufacturerReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor and Manufacturer Receivables",
        "label": "Vendor and Manufacturer Receivables",
        "terseLabel": "Vendor and manufacturer receivables"
       }
      }
     },
     "localname": "VendorandManufacturerReceivables",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvs_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term [Abstract]",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvs_YearOfOriginationPeriodFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year Of Origination Period Five",
        "label": "Year Of Origination Period Five [Member]",
        "terseLabel": "2018"
       }
      }
     },
     "localname": "YearOfOriginationPeriodFiveMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_YearOfOriginationPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year Of Origination Period Four",
        "label": "Year Of Origination Period Four [Member]",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "YearOfOriginationPeriodFourMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_YearOfOriginationPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year Of Origination Period One",
        "label": "Year Of Origination Period One [Member]",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "YearOfOriginationPeriodOneMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_YearOfOriginationPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year Of Origination Period Three",
        "label": "Year Of Origination Period Three [Member]",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "YearOfOriginationPeriodThreeMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_YearOfOriginationPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year Of Origination Period Two",
        "label": "Year Of Origination Period Two [Member]",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "YearOfOriginationPeriodTwoMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_YearOfOriginationPriorToPeriodFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year Of Origination Prior To Period Five",
        "label": "Year Of Origination Prior To Period Five [Member]",
        "terseLabel": "Prior"
       }
      }
     },
     "localname": "YearOfOriginationPriorToPeriodFiveMember",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings",
        "label": "Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings",
        "terseLabel": "Yield-related impairment loss"
       }
      }
     },
     "localname": "YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
     "nsuri": "http://www.cvshealth.com/20221231",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r1166",
      "r1167",
      "r1168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r1166",
      "r1167",
      "r1168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r1166",
      "r1167",
      "r1168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r1166",
      "r1167",
      "r1168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r1169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r1163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r1170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r1163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r1163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r1171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r1166",
      "r1167",
      "r1168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r417",
      "r819",
      "r820",
      "r825",
      "r826",
      "r914",
      "r1071",
      "r1076",
      "r1238",
      "r1241",
      "r1242",
      "r1328",
      "r1331",
      "r1332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r417",
      "r819",
      "r820",
      "r825",
      "r826",
      "r914",
      "r1071",
      "r1076",
      "r1238",
      "r1241",
      "r1242",
      "r1328",
      "r1331",
      "r1332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r417",
      "r461",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r489",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r586",
      "r588",
      "r589",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1239",
      "r1240",
      "r1329",
      "r1330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r417",
      "r461",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r489",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r586",
      "r588",
      "r589",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1239",
      "r1240",
      "r1329",
      "r1330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r414",
      "r415",
      "r594",
      "r621",
      "r1097",
      "r1101",
      "r1103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r352",
      "r422",
      "r429",
      "r435",
      "r525",
      "r767",
      "r768",
      "r769",
      "r800",
      "r801",
      "r833",
      "r836",
      "r838",
      "r839",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r352",
      "r422",
      "r429",
      "r435",
      "r525",
      "r767",
      "r768",
      "r769",
      "r800",
      "r801",
      "r833",
      "r836",
      "r838",
      "r839",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r352",
      "r422",
      "r429",
      "r435",
      "r525",
      "r767",
      "r768",
      "r769",
      "r800",
      "r801",
      "r833",
      "r836",
      "r838",
      "r839",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r494",
      "r1125",
      "r1247",
      "r1316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r574",
      "r575",
      "r576",
      "r577",
      "r725",
      "r949",
      "r1003",
      "r1072",
      "r1073",
      "r1122",
      "r1140",
      "r1153",
      "r1243",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r574",
      "r575",
      "r576",
      "r577",
      "r725",
      "r949",
      "r1003",
      "r1072",
      "r1073",
      "r1122",
      "r1140",
      "r1153",
      "r1243",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "auth_ref": [
      "r1050",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1075",
      "r1077"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of real estate property.",
        "label": "Real Estate, Type of Property [Axis]",
        "terseLabel": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MortgageLoansOnRealEstateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]",
        "terseLabel": "Mortgage Loans on Real Estate [Line Items]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "auth_ref": [
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1075",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Land and any structures permanently fixed to it.",
        "label": "Real Estate [Domain]",
        "terseLabel": "Real Estate [Domain]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateScheduleTable": {
     "auth_ref": [
      "r1052",
      "r1087"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.",
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table]",
        "terseLabel": "Mortgage Loans on Real Estate [Table]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateScheduleTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r494",
      "r1125",
      "r1247",
      "r1316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r491",
      "r951",
      "r1123",
      "r1151",
      "r1234",
      "r1235",
      "r1247",
      "r1315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r491",
      "r951",
      "r1123",
      "r1151",
      "r1234",
      "r1235",
      "r1247",
      "r1315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r574",
      "r575",
      "r576",
      "r577",
      "r675",
      "r725",
      "r758",
      "r759",
      "r760",
      "r922",
      "r949",
      "r1003",
      "r1072",
      "r1073",
      "r1122",
      "r1140",
      "r1153",
      "r1230",
      "r1243",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r574",
      "r575",
      "r576",
      "r577",
      "r675",
      "r725",
      "r758",
      "r759",
      "r760",
      "r922",
      "r949",
      "r1003",
      "r1072",
      "r1073",
      "r1122",
      "r1140",
      "r1153",
      "r1230",
      "r1243",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r414",
      "r415",
      "r594",
      "r621",
      "r1102",
      "r1103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r726",
      "r1196",
      "r1327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r435",
      "r726",
      "r1172",
      "r1196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r435",
      "r726",
      "r1172",
      "r1173",
      "r1196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock": {
     "auth_ref": [
      "r992",
      "r1086"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the supplemental schedule of reinsurance information. Reinsurance schedule includes, but is not limited to, the type of insurance, gross amount of premiums, premiums ceded to other entities, premiums assumed from other entities, net amount of premium revenue, and the percentage of the premiums assumed to net premium revenue.",
        "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Text Block]",
        "terseLabel": "Schedule of Direct, Assumed and Ceded Premiums Earned"
       }
      }
     },
     "localname": "SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASU 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201812Member": {
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-12 Financial Services-Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts.",
        "label": "Accounting Standards Update 2018-12 [Member]",
        "terseLabel": "Accounting Standards Update 2018-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201812Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r423",
      "r424",
      "r425",
      "r499",
      "r500",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r767",
      "r768",
      "r769",
      "r800",
      "r801",
      "r815",
      "r816",
      "r817",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r876",
      "r877",
      "r880",
      "r881",
      "r882",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r23",
      "r40"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r1056"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r58",
      "r63",
      "r227",
      "r388",
      "r1178",
      "r1179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Pension and other postretirement benefits"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r153",
      "r364"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r57",
      "r63",
      "r227",
      "r388",
      "r1178",
      "r1179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r381",
      "r388",
      "r823",
      "r1178",
      "r1179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Net cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r381",
      "r388",
      "r1178",
      "r1179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Net unrealized investment gains (losses)"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r370",
      "r979",
      "r1011",
      "r1015"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r60",
      "r63",
      "r227",
      "r913",
      "r1006",
      "r1007",
      "r1177",
      "r1178",
      "r1179",
      "r1192",
      "r1193",
      "r1194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r423",
      "r424",
      "r425",
      "r426",
      "r435",
      "r499",
      "r500",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r767",
      "r768",
      "r769",
      "r798",
      "r799",
      "r800",
      "r801",
      "r815",
      "r816",
      "r817",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r876",
      "r877",
      "r880",
      "r881",
      "r882",
      "r883",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r953",
      "r954",
      "r955",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r773"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r762"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocationsToPolicyholdersPolicies": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining amounts of income and expenses allocated to policyholders and contract holders, excluding the method for determining dividends payable to policyholders and accounting policies pertaining to separate accounts for variable annuity contracts.",
        "label": "Allocations to Policyholders, Policies [Policy Text Block]",
        "terseLabel": "Policyholders' Funds"
       }
      }
     },
     "localname": "AllocationsToPolicyholdersPolicies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r371",
      "r498",
      "r528",
      "r530",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "negatedTerseLabel": "Receipt of fully reserved ACA risk corridor receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r93",
      "r136",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities excluded from computation of EPS (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r60",
      "r63",
      "r227",
      "r1177",
      "r1178",
      "r1179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r1130",
      "r1208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Other asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r273",
      "r300",
      "r368",
      "r411",
      "r469",
      "r481",
      "r487",
      "r520",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r585",
      "r587",
      "r589",
      "r590",
      "r819",
      "r825",
      "r858",
      "r1148",
      "r1239",
      "r1240",
      "r1302"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r358",
      "r375",
      "r411",
      "r520",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r585",
      "r587",
      "r589",
      "r590",
      "r819",
      "r825",
      "r858",
      "r1148",
      "r1239",
      "r1240",
      "r1302"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldByInsuranceRegulators": {
     "auth_ref": [
      "r1029"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of cash and investment securities on deposit with state regulatory authorities in connection with capital requirements.",
        "label": "Assets Held by Insurance Regulators",
        "terseLabel": "Investments on deposit with regulatory bodies"
       }
      }
     },
     "localname": "AssetsHeldByInsuranceRegulators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "totalLabel": "Total assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r150",
      "r155",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssumedPremiumsEarned": {
     "auth_ref": [
      "r313",
      "r990",
      "r1019",
      "r1022"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PremiumsEarnedNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earned premiums assumed from other entities.",
        "label": "Assumed Premiums Earned",
        "terseLabel": "Assumed"
       }
      }
     },
     "localname": "AssumedPremiumsEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r502",
      "r537"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Gross Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "After five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r125",
      "r506",
      "r969"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "After five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "One year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r125",
      "r505",
      "r968"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "One year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Greater than ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r125",
      "r507",
      "r970"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Greater than ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r125",
      "r504",
      "r967"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": {
     "auth_ref": [
      "r508"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost",
        "terseLabel": "Debt securities, maturity, without single maturity date"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "auth_ref": [
      "r130",
      "r971"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value",
        "terseLabel": "Debt securities, maturity, without single maturity date"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r122",
      "r501",
      "r537",
      "r958"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Debt securities",
        "totalLabel": "Total",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]",
        "terseLabel": "Number of Securities"
       }
      }
     },
     "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r244",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings, building improvements and leasehold improvements",
        "verboseLabel": "Building and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Distribution centers and Corporate offices"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r814",
      "r1134",
      "r1137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r814",
      "r1134",
      "r1137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Cash to be received by shareholders in proposed/pending acquisition (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r216",
      "r217",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total value of proposed/pending acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "verboseLabel": "Acquisition-related integration costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.",
        "label": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]",
        "terseLabel": "Health Care Contract Acquisition Costs"
       }
      }
     },
     "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r95",
      "r361",
      "r1098"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r96",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r95",
      "r99"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "totalLabel": "Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r88",
      "r263"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "terseLabel": "Cash and restricted cash sold"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents disclosure of the aggregate cash dividends paid to the entity by consolidated subsidiaries.",
        "label": "SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Consolidated Subsidiaries",
        "terseLabel": "Dividends paid"
       }
      }
     },
     "localname": "CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.",
        "label": "Cash Proceeds Received and Tax Benefit from Share-Based Payment Awards [Table Text Block]",
        "terseLabel": "Summary of Stock Option and SAR Activity"
       }
      }
     },
     "localname": "CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CededCreditRiskAxis": {
     "auth_ref": [
      "r1311",
      "r1319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of reinsurer or group of reinsurers in reinsurance contract.",
        "label": "Reinsurer, Name [Axis]",
        "terseLabel": "Ceded Credit Risk, Reinsurer [Axis]"
       }
      }
     },
     "localname": "CededCreditRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CededCreditRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Ceded Credit Risk [Line Items]",
        "terseLabel": "Ceded Credit Risk [Line Items]"
       }
      }
     },
     "localname": "CededCreditRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails",
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CededCreditRiskReinsurerDomain": {
     "auth_ref": [
      "r1311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of reinsurer or group of reinsurers in reinsurance contract.",
        "label": "Reinsurer, Name [Domain]",
        "terseLabel": "Ceded Credit Risk, Reinsurer [Domain]"
       }
      }
     },
     "localname": "CededCreditRiskReinsurerDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CededCreditRiskTable": {
     "auth_ref": [
      "r1031"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.",
        "label": "Ceded Credit Risk [Table]",
        "terseLabel": "Ceded Credit Risk [Table]"
       }
      }
     },
     "localname": "CededCreditRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails",
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CededPremiumsEarned": {
     "auth_ref": [
      "r313",
      "r989",
      "r1016",
      "r1017",
      "r1020",
      "r1022"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PremiumsEarnedNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earned premiums ceded to other entities.",
        "label": "Ceded Premiums Earned",
        "negatedTerseLabel": "Ceded"
       }
      }
     },
     "localname": "CededPremiumsEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Change in Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClaimsDevelopmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Claims Development [Line Items]",
        "terseLabel": "Claims Development [Line Items]"
       }
      }
     },
     "localname": "ClaimsDevelopmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r130",
      "r1251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by commercial real estate mortgage loans.",
        "label": "Commercial Mortgage-Backed Securities [Member]",
        "terseLabel": "Commercial mortgage-backed securities"
       }
      }
     },
     "localname": "CommercialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails",
      "http://www.cvshealth.com/role/InvestmentsNarrativeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialRealEstateMember": {
     "auth_ref": [
      "r1111",
      "r1251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property that is solely used for business purposes.",
        "label": "Commercial Real Estate [Member]",
        "terseLabel": "Commercial Real Estate"
       }
      }
     },
     "localname": "CommercialRealEstateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails",
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r282",
      "r307"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r158",
      "r571",
      "r572",
      "r1058",
      "r1237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Capital shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "terseLabel": "Common Stock and Capital Surplus"
       }
      }
     },
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r1192",
      "r1193",
      "r1293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r34",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r34",
      "r1148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r34",
      "r35",
      "r174"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.",
        "label": "Common Stocks, Including Additional Paid in Capital",
        "terseLabel": "Common stock, par value $0.01: 3,200 shares authorized; 1,758 shares issued and 1,300 shares outstanding at December\u00a031, 2022 and 1,744 shares issued and 1,322 shares outstanding at December\u00a031, 2021 and capital surplus"
       }
      }
     },
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r64",
      "r384",
      "r386",
      "r395",
      "r962",
      "r985"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to CVS Health"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r223",
      "r239",
      "r384",
      "r386",
      "r394",
      "r961",
      "r984"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r77",
      "r393",
      "r960",
      "r982"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r106",
      "r107",
      "r259",
      "r260",
      "r494",
      "r1056"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r106",
      "r107",
      "r259",
      "r260",
      "r494",
      "r1031",
      "r1056"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r106",
      "r107",
      "r259",
      "r260",
      "r494",
      "r1056",
      "r1319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r106",
      "r107",
      "r259",
      "r260",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percent"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r104",
      "r106",
      "r107",
      "r108",
      "r259",
      "r261",
      "r1056"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r106",
      "r107",
      "r259",
      "r260",
      "r494",
      "r1056"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r228",
      "r230",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r1246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of receivables and contract liabilities from contracts with customers"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r635",
      "r637",
      "r648"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": {
       "order": 4.0,
       "parentTag": "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade receivables (included in accounts receivable, net)",
        "verboseLabel": "Trade receivables"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r635",
      "r636",
      "r648"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Contract liabilities, end of period",
        "periodStartLabel": "Contract liabilities, beginning of period",
        "terseLabel": "Contract liabilities (included in accrued expenses)"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "auth_ref": [
      "r1129",
      "r1247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by sales channel for delivery of good or service in contract with customer.",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "terseLabel": "Contract with Customer, Sales Channel [Axis]"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "auth_ref": [
      "r1129",
      "r1247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "terseLabel": "Contract with Customer, Sales Channel [Domain]"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateAndOtherMember": {
     "auth_ref": [
      "r1199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate and Other [Member]",
        "terseLabel": "Corporate/ Other"
       }
      }
     },
     "localname": "CorporateAndOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r117",
      "r480",
      "r481",
      "r482",
      "r483",
      "r489",
      "r1201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate/ Other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r72",
      "r951"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r1249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Products Sold"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r1190",
      "r1286",
      "r1288"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r212",
      "r795",
      "r805",
      "r1190"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r1190",
      "r1286",
      "r1288"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r105",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships.",
        "label": "Customer-Related Intangible Assets [Member]",
        "terseLabel": "Customer contracts/relationships and covenants not to compete"
       }
      }
     },
     "localname": "CustomerRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r167",
      "r409",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r607",
      "r614",
      "r615",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Borrowings and Credit Agreements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r274",
      "r276",
      "r296",
      "r417",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r879",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r29",
      "r276",
      "r296",
      "r618"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "cvs_LongtermDebtGrossAndLeaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r265",
      "r267",
      "r591",
      "r879",
      "r1118",
      "r1119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r605",
      "r857",
      "r1118",
      "r1119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r47",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48",
      "r417",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r879",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r48",
      "r170",
      "r171",
      "r172",
      "r173",
      "r264",
      "r265",
      "r267",
      "r291",
      "r417",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r879",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r264",
      "r267",
      "r1244"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Debt premiums"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r503",
      "r537",
      "r544",
      "r545"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "negatedTerseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r1207"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss",
        "totalLabel": "Net Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r514",
      "r542",
      "r1114"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair Value, Greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r514",
      "r542"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Unrealized Losses, Greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r1217"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of Securities, Greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r514",
      "r542",
      "r1114"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "verboseLabel": "Fair Value, Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r514",
      "r542"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "verboseLabel": "Unrealized Losses, Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r1217"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of Securities, Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "terseLabel": "Gross realized capital gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "terseLabel": "Gross realized capital losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails",
      "http://www.cvshealth.com/role/InvestmentsNarrativeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r1210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Debt Securities Available For Sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r511",
      "r538",
      "r1114"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r512",
      "r539"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "totalLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r513",
      "r540"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "totalLabel": "Number of Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r1190",
      "r1287",
      "r1288"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r93",
      "r212",
      "r796",
      "r804",
      "r805",
      "r1190"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r31",
      "r32",
      "r275",
      "r295",
      "r791"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r777",
      "r778"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredPolicyAcquisitionCosts": {
     "auth_ref": [
      "r980",
      "r993",
      "r994",
      "r1009",
      "r1028",
      "r1150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred policy acquisition cost capitalized on contract remaining in force.",
        "label": "Deferred Policy Acquisition Cost",
        "terseLabel": "Deferred acquisition costs"
       }
      }
     },
     "localname": "DeferredPolicyAcquisitionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r1190",
      "r1287",
      "r1288"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r210",
      "r1285"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred income"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r210",
      "r1285"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Assets, Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r1284"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r210",
      "r1285"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss and capital loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r210",
      "r1285"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r210",
      "r1285"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r210",
      "r1285"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent",
        "terseLabel": "Lease and rents"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements": {
     "auth_ref": [
      "r210",
      "r1285"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements",
        "terseLabel": "Legal charges"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "auth_ref": [
      "r210",
      "r1285"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "terseLabel": "Insurance reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r792"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r206",
      "r1284"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Liabilities, Investments",
        "negatedLabel": "Investments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r210",
      "r1285"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Lease and rents"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r666",
      "r1132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": {
     "auth_ref": [
      "r680",
      "r1132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial gain"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r652",
      "r691",
      "r713",
      "r1132",
      "r1133"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Amortization of net actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r182",
      "r185"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Net assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Assets (liabilities) recognized on the consolidated balance sheet"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r272",
      "r299",
      "r650",
      "r651",
      "r674",
      "r1132"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Noncurrent assets reflected in other assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r699",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "terseLabel": "Expected long-term rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation, end of year",
        "periodStartLabel": "Benefit obligation, beginning of year",
        "terseLabel": "Benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r661",
      "r721"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedTerseLabel": "Benefit payments"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement": {
     "auth_ref": [
      "r1250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement.",
        "label": "Defined Benefit Plan, Benefit Obligation, Payment for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationPaymentForSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r702",
      "r1130",
      "r1131",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r1130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in benefit obligation:"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember": {
     "auth_ref": [
      "r1251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulated trust, responsible for collective investment and reinvestment of asset from employee benefit plan maintained by more than one employer, in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Common Collective Trust [Member]",
        "verboseLabel": "Common/collective trusts"
       }
      }
     },
     "localname": "DefinedBenefitPlanCommonCollectiveTrustMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r668",
      "r678",
      "r717",
      "r1130",
      "r1131",
      "r1132",
      "r1133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contributions",
        "verboseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": {
     "auth_ref": [
      "r1130",
      "r1131",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": {
     "auth_ref": [
      "r1130",
      "r1131",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, US [Member]",
        "terseLabel": "U.S. domestic"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2028-2032"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r652",
      "r690",
      "r712",
      "r1132",
      "r1133"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r665",
      "r676",
      "r678",
      "r679",
      "r1130",
      "r1131",
      "r1132"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r650",
      "r674",
      "r1132"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "totalLabel": "Funded status"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r652",
      "r657",
      "r689",
      "r711",
      "r1132",
      "r1133"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r687",
      "r709",
      "r1132",
      "r1133"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "terseLabel": "Net periodic benefit cost",
        "totalLabel": "Net periodic benefit cost (income)"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "terseLabel": "Components of net periodic benefit cost (income):"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r670",
      "r1253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefit payments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock": {
     "auth_ref": [
      "r1251",
      "r1252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of defined benefit plan asset investment. Includes, but is not limited to, fair value of category of plan asset and its level within fair value hierarchy.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Table Text Block]",
        "terseLabel": "Schedule of Change in Level 3 Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsCategoryTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount": {
     "auth_ref": [
      "r1251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment within defined benefit plan asset category.",
        "label": "Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount",
        "terseLabel": "Plan assets, investment within plan asset category, amount"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r675",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Target investment allocations"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": {
     "auth_ref": [
      "r681",
      "r1132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement",
        "verboseLabel": "Purchases, sales and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRealEstateMember": {
     "auth_ref": [
      "r1130",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Real Estate [Member]",
        "terseLabel": "Real estate"
       }
      }
     },
     "localname": "DefinedBenefitPlanRealEstateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r653",
      "r694",
      "r716"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlement losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r673"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": {
     "auth_ref": [
      "r682",
      "r1132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3",
        "terseLabel": "Transfers out of Level 3"
       }
      }
     },
     "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Assumptions used to determine benefit obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Assumptions used to determine net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r93",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r93",
      "r464"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r245",
      "r246",
      "r248",
      "r249",
      "r1103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r1290",
      "r1291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Forward contract, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r250",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DirectPremiumsEarned": {
     "auth_ref": [
      "r313",
      "r988",
      "r1018",
      "r1021"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PremiumsEarnedNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Direct Premiums Earned",
        "terseLabel": "Direct"
       }
      }
     },
     "localname": "DirectPremiumsEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r647",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r1247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r732",
      "r763",
      "r764",
      "r766",
      "r771",
      "r1141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).",
        "label": "Disclosure of Long-Lived Assets Held-for-sale [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Held for Sale"
       }
      }
     },
     "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r14",
      "r68",
      "r315"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Loss from discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "terseLabel": "Loss from discontinued operations attributable to CVS Health (in dollars per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "terseLabel": "Loss from discontinued operations attributable to CVS Health (in dollars per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r14",
      "r17",
      "r779",
      "r803",
      "r809"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "negatedTerseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails",
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails",
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails",
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails",
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails",
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails",
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r149",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r147",
      "r156",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails",
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails",
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails",
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r1134",
      "r1137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r174",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "negatedTerseLabel": "Common stock dividends"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends Payable, Amount Per Share",
        "terseLabel": "Cash dividend declared (USD per share)"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DividendsPayableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Dividends Payable [Line Items]",
        "terseLabel": "Dividends Payable [Line Items]"
       }
      }
     },
     "localname": "DividendsPayableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableTable": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.",
        "label": "Dividends Payable [Table]",
        "terseLabel": "Dividends Payable [Table]"
       }
      }
     },
     "localname": "DividendsPayableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r121",
      "r1132",
      "r1251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by corporation domiciled in United States of America (US).",
        "label": "Debt Security, Corporate, US [Member]",
        "terseLabel": "U.S. corporate securities"
       }
      }
     },
     "localname": "DomesticCorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r396",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r436",
      "r438",
      "r443",
      "r444",
      "r445",
      "r449",
      "r839",
      "r840",
      "r963",
      "r986",
      "r1108"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income attributable to CVS Health (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "verboseLabel": "Basic earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r396",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r438",
      "r443",
      "r444",
      "r445",
      "r449",
      "r839",
      "r840",
      "r963",
      "r986",
      "r1108"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income attributable to CVS Health (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r446",
      "r447",
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r780"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r412",
      "r780",
      "r806"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r1282",
      "r1289"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "terseLabel": "Basis difference upon disposition of subsidiary"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1282",
      "r1289"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r1282",
      "r1289"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic": {
     "auth_ref": [
      "r1282",
      "r1289"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to domestic income tax settlement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Domestic, Percent",
        "terseLabel": "Prior year refunds and unrecognized tax benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectsOfReinsuranceTableTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.",
        "label": "Effects of Reinsurance [Table Text Block]",
        "terseLabel": "Schedule of Impact of Reinsurance on Benefit Costs"
       }
      }
     },
     "localname": "EffectsOfReinsuranceTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r1281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation not yet recognized, other than options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r1281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation not yet recognized, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r169",
      "r352",
      "r388",
      "r389",
      "r390",
      "r419",
      "r420",
      "r421",
      "r424",
      "r432",
      "r434",
      "r452",
      "r525",
      "r634",
      "r767",
      "r768",
      "r769",
      "r800",
      "r801",
      "r838",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r873",
      "r913",
      "r1006",
      "r1007",
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r87",
      "r133",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r369",
      "r855",
      "r1100"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r132",
      "r297",
      "r1159",
      "r1160",
      "r1161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r517"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r605",
      "r857",
      "r1118",
      "r1119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "verboseLabel": "Aggregate principal of debt extinguished"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci": {
     "auth_ref": [
      "r850"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), OCI",
        "negatedTerseLabel": "Change in unrealized capital losses included in OCI associated with Level 3 financial assets"
       }
      }
     },
     "localname": "FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
      "http://www.cvshealth.com/role/FairValueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r843",
      "r844",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
      "http://www.cvshealth.com/role/FairValueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r253",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Level 3 Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r252",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r252",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of Carrying Value and Fair Value By Level of Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r605",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r844",
      "r919",
      "r920",
      "r921",
      "r1118",
      "r1119",
      "r1130",
      "r1131",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
      "http://www.cvshealth.com/role/FairValueNarrativeDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r252",
      "r256",
      "r605",
      "r1118",
      "r1119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r843",
      "r844",
      "r845",
      "r846",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
      "http://www.cvshealth.com/role/FairValueNarrativeDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r605",
      "r1118",
      "r1119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "auth_ref": [
      "r1252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).",
        "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]",
        "terseLabel": "Total Fair Value, Inputs, Level 1, 2 and 3"
       }
      }
     },
     "localname": "FairValueInputsLevel12And3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r605",
      "r678",
      "r683",
      "r844",
      "r919",
      "r1130",
      "r1131",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r605",
      "r678",
      "r683",
      "r844",
      "r920",
      "r1118",
      "r1119",
      "r1130",
      "r1131",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r605",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r844",
      "r921",
      "r1118",
      "r1119",
      "r1130",
      "r1131",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
      "http://www.cvshealth.com/role/FairValueNarrativeDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r678",
      "r842",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Fair Value Measured at Net Asset Value Per Share"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
      "http://www.cvshealth.com/role/FairValueNarrativeDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r847"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Included in earnings"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "auth_ref": [
      "r848"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Included in other comprehensive income (loss)"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "terseLabel": "Purchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales",
        "negatedTerseLabel": "Sales"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r849"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Gross transfers into Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "terseLabel": "Transfers into (out of) Level 3, net",
        "totalLabel": "Net transfers into (out of) Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
      "http://www.cvshealth.com/role/FairValueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r849"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "negatedTerseLabel": "Gross transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r605",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r919",
      "r920",
      "r921",
      "r1118",
      "r1119",
      "r1130",
      "r1131",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
      "http://www.cvshealth.com/role/FairValueNarrativeDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r843",
      "r844",
      "r845",
      "r846",
      "r851",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r852",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details",
      "http://www.cvshealth.com/role/FairValueNarrativeDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable": {
     "auth_ref": [
      "r46",
      "r281",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum advances or credit lines available from the Federal Home Loan Bank (FHLB).",
        "label": "Federal Home Loan Bank, Advances, General Debt Obligations, Maximum Amount Available",
        "terseLabel": "Federal home loan bank advances maximum amount available"
       }
      }
     },
     "localname": "FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalHomeLoanBankAdvancesMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans.",
        "label": "Federal Home Loan Bank Advances [Member]",
        "terseLabel": "Federal Home Loan Bank Advances"
       }
      }
     },
     "localname": "FederalHomeLoanBankAdvancesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r887",
      "r893",
      "r1147"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "cvs_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r889",
      "r899"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows paid for interest portion of finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r885",
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "cvs_LongtermDebtGrossAndLeaseObligation",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total finance lease liabilities",
        "totalLabel": "Total finance lease liabilities",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails",
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails",
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r885"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r1301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Maturities of Finance Lease Liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r885"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDueAfterYearFive",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsYearOne",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDueYearFive",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDueYearFour",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDueYearThree",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDueYearTwo",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability.",
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "cvs_LesseeLiabilityUndiscountedExcessAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r888",
      "r899"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash flows paid for principal portion of finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r887",
      "r893",
      "r1147"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "cvs_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r902",
      "r1147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r901",
      "r1147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r509",
      "r510",
      "r529",
      "r533",
      "r534",
      "r535",
      "r536",
      "r541",
      "r543",
      "r546",
      "r616",
      "r632",
      "r828",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r1114",
      "r1211",
      "r1212",
      "r1213",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails",
      "http://www.cvshealth.com/role/InvestmentsNarrativeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension",
        "terseLabel": "Weighted Average Life (years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r366",
      "r566"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r564",
      "r565",
      "r566",
      "r567",
      "r952",
      "r956"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r141",
      "r956"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r137",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r141",
      "r952"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "cvs_IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-lived intangible assets, net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r121",
      "r1251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by corporation not domiciled in United States of America (US).",
        "label": "Debt Security, Corporate, Non-US [Member]",
        "terseLabel": "Foreign securities"
       }
      }
     },
     "localname": "ForeignCorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term debt securities issued by a national, local, or municipal government not within the country of domicile of the reporting entity.",
        "label": "Foreign Government Short-Term Debt Securities [Member]",
        "terseLabel": "Foreign securities"
       }
      }
     },
     "localname": "ForeignGovernmentShorttermDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r1292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward Contracts"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Fixtures and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyUnrecordedAmount": {
     "auth_ref": [
      "r1236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.",
        "label": "Gain Contingency, Unrecorded Amount",
        "terseLabel": "Gain contingency, unrecorded amount"
       }
      }
     },
     "localname": "GainContingencyUnrecordedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r824",
      "r1186"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedLabel": "Gain on divestiture of subsidiaries",
        "negatedTerseLabel": "Gain on sale of subsidiaries",
        "terseLabel": "Gain (loss) on sale of subsidiaries"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r1231"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Opioid litigation charges"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r93",
      "r165",
      "r166"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on early extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.",
        "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost",
        "negatedTerseLabel": "Premium paid in excess of debt principal"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r365",
      "r550",
      "r957",
      "r1115",
      "r1148",
      "r1218",
      "r1225"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance, end of the period",
        "periodStartLabel": "Balance, beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Other Intangibles"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r562",
      "r563",
      "r1115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r552",
      "r559",
      "r1115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Cumulative goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r93",
      "r551",
      "r556",
      "r562",
      "r1115"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r555",
      "r1115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Divestitures"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "terseLabel": "Guarantor obligations, maximum exposure"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareCostsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r1057",
      "r1059"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accruing health care costs for a prepaid health care service provider.",
        "label": "Health Care Costs, Policy [Policy Text Block]",
        "terseLabel": "Health Care Costs Payable"
       }
      }
     },
     "localname": "HealthCareCostsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthCareEntitiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for all health care policies.",
        "label": "Health Care Entities, Policy [Policy Text Block]",
        "terseLabel": "Health Care Reform"
       }
      }
     },
     "localname": "HealthCareEntitiesPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthInsuranceProductLineMember": {
     "auth_ref": [
      "r1317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product line consisting of insurance against loss by illness or injury.",
        "label": "Health Insurance Product Line [Member]",
        "terseLabel": "Health Insurance Product Line"
       }
      }
     },
     "localname": "HealthInsuranceProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgeFundsMember": {
     "auth_ref": [
      "r1251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in registered hedge funds.",
        "label": "Hedge Funds [Member]",
        "verboseLabel": "Hedge fund investments"
       }
      }
     },
     "localname": "HedgeFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r1186",
      "r1229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets, indefinite-lived"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r93",
      "r148"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Loss on assets held for sale"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Recoverability of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r71",
      "r94",
      "r222",
      "r427",
      "r428",
      "r429",
      "r430",
      "r442",
      "r445"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Income from continuing operations attributable to CVS Health"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r269",
      "r284",
      "r318",
      "r469",
      "r480",
      "r486",
      "r489",
      "r965",
      "r1110"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax provision"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r223",
      "r411",
      "r423",
      "r469",
      "r480",
      "r486",
      "r489",
      "r520",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r585",
      "r587",
      "r589",
      "r590",
      "r840",
      "r858",
      "r1110",
      "r1239"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Income from continuing operations",
        "verboseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r66",
      "r283",
      "r285",
      "r314",
      "r396",
      "r423",
      "r427",
      "r428",
      "r429",
      "r430",
      "r438",
      "r443",
      "r444",
      "r840",
      "r963"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from continuing operations attributable to CVS Health (in dollars per share)",
        "verboseLabel": "Earnings per share from continuing operations, basic (USD per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r66",
      "r314",
      "r317",
      "r396",
      "r423",
      "r427",
      "r428",
      "r429",
      "r430",
      "r438",
      "r443",
      "r444",
      "r445",
      "r840",
      "r963",
      "r986"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from continuing operations attributable to CVS Health (in dollars per share)",
        "verboseLabel": "Earnings per share from continuing operations, diluted (USD per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r17",
      "r315",
      "r357",
      "r810"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations, net of tax",
        "totalLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r1134",
      "r1137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r412",
      "r781",
      "r789",
      "r794",
      "r802",
      "r807",
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r413",
      "r433",
      "r434",
      "r467",
      "r779",
      "r803",
      "r808",
      "r987"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total",
        "verboseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r387",
      "r775",
      "r776",
      "r789",
      "r790",
      "r793",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "negatedTerseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and pharmacy claims and discounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInsuranceLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in insurance liability balances during the period.",
        "label": "Increase (Decrease) in Insurance Liabilities",
        "terseLabel": "Health care costs payable and other insurance liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r445",
      "r731"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets, Trademarks"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r135",
      "r139"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r266",
      "r287",
      "r391",
      "r463",
      "r878"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r402",
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "terseLabel": "Amount expected to be reclassified"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalCreditAssessmentAxis": {
     "auth_ref": [
      "r118",
      "r827",
      "r1112",
      "r1113",
      "r1116",
      "r1215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by entity-defined rating.",
        "label": "Internal Credit Assessment [Axis]",
        "terseLabel": "Internal Credit Assessment [Axis]"
       }
      }
     },
     "localname": "InternalCreditAssessmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InternalCreditAssessmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity defined credit risk rating.",
        "label": "Internal Credit Assessment [Domain]",
        "terseLabel": "Internal Credit Assessment [Domain]"
       }
      }
     },
     "localname": "InternalCreditAssessmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r461",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment Eliminations"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r373",
      "r1099",
      "r1148"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r360",
      "r372",
      "r451",
      "r547",
      "r548",
      "r549",
      "r950",
      "r1105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": {
       "order": 1.0,
       "parentTag": "cvs_InvestmentIncomeExcludingCapitalGainsOrLosses",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Gross investment income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "auth_ref": [
      "r76",
      "r319"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": {
       "order": 2.0,
       "parentTag": "cvs_InvestmentIncomeExcludingCapitalGainsOrLosses",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the generation of investment income.",
        "label": "Investment Income, Investment Expense",
        "negatedLabel": "Investment expenses"
       }
      }
     },
     "localname": "InvestmentIncomeInvestmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r74",
      "r75"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "totalLabel": "Net investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeTextBlock": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table Text Block]",
        "verboseLabel": "Schedule of Net Investment Income"
       }
      }
     },
     "localname": "InvestmentIncomeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r519",
      "r1313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]",
        "terseLabel": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Schedule of Amortized Cost and Fair Value of Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r270",
      "r288",
      "r345",
      "r1074"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r1248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r903",
      "r1147"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r1300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of the Components of Net Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Attorneys' fees and costs"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r1299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Finance lease term (in years)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Right-of-Use Assets and Lease Liabilities"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r1301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDueAfterYearFive",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "cvs_LesseeLiabilityPaymentsDueYearFour",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "cvs_LesseeLiabilityUndiscountedExcessAmount",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r1299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r906"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Future noncancelable subleases, future minimum payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r411",
      "r520",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r585",
      "r587",
      "r589",
      "r590",
      "r820",
      "r825",
      "r826",
      "r858",
      "r1109",
      "r1239",
      "r1302",
      "r1303"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r39",
      "r278",
      "r305",
      "r1148",
      "r1189",
      "r1214",
      "r1296"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r359",
      "r411",
      "r520",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r585",
      "r587",
      "r589",
      "r590",
      "r820",
      "r825",
      "r826",
      "r858",
      "r1148",
      "r1239",
      "r1302",
      "r1303"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r155",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r150",
      "r155",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r323",
      "r326"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Health care costs payable, end of period",
        "periodStartLabel": "Health care costs payable, beginning of period",
        "totalLabel": "Total health care costs payable",
        "verboseLabel": "Health care costs payable"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.",
        "label": "Liability for Claims and Claims Adjustment Expense [Table]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefits": {
     "auth_ref": [
      "r976",
      "r1001",
      "r1002",
      "r1009",
      "r1152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.",
        "label": "Liability for Future Policy Benefit, before Reinsurance",
        "terseLabel": "Increase (decrease) to liability for future policy benefits",
        "verboseLabel": "Liability for future policy benefits"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "verboseLabel": "Acquisitions, net"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]",
        "terseLabel": "Less: Claims paid"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Prior years"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total incurred health care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]",
        "terseLabel": "Add: Components of incurred health care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": {
     "auth_ref": [
      "r294",
      "r323",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net",
        "periodEndLabel": "Health care costs payable, end of period, net",
        "periodStartLabel": "Health care costs payable, beginning of period, net"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Amount awarded from other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Legal settlement awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r1231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r1231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term debt (1)"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "negatedTerseLabel": "Current portion of long-term debt",
        "verboseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails",
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities",
        "totalLabel": "Long-term debt and lease obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r163",
      "r417",
      "r1245"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r163",
      "r417",
      "r609"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r163",
      "r417",
      "r609"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r163",
      "r417",
      "r609"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r163",
      "r417",
      "r609"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r163",
      "r417",
      "r609"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "verboseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r48",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r159",
      "r160",
      "r573",
      "r574",
      "r575",
      "r1232",
      "r1233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r573",
      "r1172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Liability recorded in association with legal settlement"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.",
        "label": "Loss Contingency, Accrual, Noncurrent",
        "terseLabel": "Long-term liability recorded in association with legal settlement"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r1232",
      "r1233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r22",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "verboseLabel": "Acquisitions, Divestitures and Asset Sales"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r55",
      "r277",
      "r304",
      "r411",
      "r520",
      "r578",
      "r581",
      "r582",
      "r583",
      "r589",
      "r590",
      "r858"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageLoansOnRealEstate": {
     "auth_ref": [
      "r1049"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.",
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate",
        "terseLabel": "Mortgage loans"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The balance represents the amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio.",
        "label": "Mortgage Loans on Real Estate, Commercial and Consumer, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateCommercialAndConsumerNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoanPrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageLoansOnRealEstateForeclosures": {
     "auth_ref": [
      "r1051"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from foreclosure.",
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Foreclosure",
        "terseLabel": "Mortgage loans foreclosed"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateForeclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageLoansOnRealEstateNewMortgageLoans": {
     "auth_ref": [
      "r1051"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from new investment.",
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, New Mortgage Loan",
        "terseLabel": "New mortgage loans"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateNewMortgageLoans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgagesHeldForSaleFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of mortgage loans held-for-sale.",
        "label": "Mortgages Held-for-sale, Fair Value Disclosure",
        "terseLabel": "Mortgage loans"
       }
      }
     },
     "localname": "MortgagesHeldForSaleFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MultiemployerPlanPensionInsignificantPlanContribution": {
     "auth_ref": [
      "r1254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by multiemployer pension plan from all employers participating in multiemployer pension plan determined to be individually insignificant.",
        "label": "Multiemployer Plan, Pension, Insignificant, Plan Contribution",
        "terseLabel": "Multiemployer plans, plan contributions"
       }
      }
     },
     "localname": "MultiemployerPlanPensionInsignificantPlanContribution",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Reconciliation of net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r69",
      "r94",
      "r286",
      "r316",
      "r357",
      "r382",
      "r385",
      "r390",
      "r411",
      "r423",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r442",
      "r469",
      "r480",
      "r486",
      "r489",
      "r520",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r585",
      "r587",
      "r589",
      "r590",
      "r840",
      "r858",
      "r1110",
      "r1239"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to CVS Health"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r225",
      "r238",
      "r382",
      "r385",
      "r433",
      "r434",
      "r1179"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.cvshealth.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss attributable to noncontrolling interests",
        "negatedTerseLabel": "Comprehensive (income) loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentIncome": {
     "auth_ref": [
      "r983"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.",
        "label": "Net Investment Income",
        "terseLabel": "Net investment income",
        "verboseLabel": "Net investment income (loss)"
       }
      }
     },
     "localname": "NetInvestmentIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "verboseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r101",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r435",
      "r449",
      "r499",
      "r500",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r767",
      "r768",
      "r769",
      "r798",
      "r799",
      "r800",
      "r801",
      "r815",
      "r816",
      "r817",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r876",
      "r877",
      "r880",
      "r881",
      "r882",
      "r883",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r953",
      "r954",
      "r955",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "verboseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r220",
      "r634",
      "r1192",
      "r1193",
      "r1194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r1200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r1200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStores": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of stores.",
        "label": "Number of Stores",
        "terseLabel": "Number of retail locations (more than)"
       }
      }
     },
     "localname": "NumberOfStores",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating costs:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r469",
      "r480",
      "r486",
      "r489",
      "r1110"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "netLabel": "Operating income (GAAP measure)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r894",
      "r1147"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r885"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "cvs_LeaseLiability",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails",
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r885"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r885"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r890",
      "r899"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows paid for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r884"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r902",
      "r1147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r901",
      "r1147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r374",
      "r1148"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r223",
      "r224",
      "r226"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Net unrealized investment gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": {
     "auth_ref": [
      "r63",
      "r389",
      "r867",
      "r869",
      "r873",
      "r1177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax",
        "terseLabel": "OCI before reclassifications, pre-tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r389",
      "r867",
      "r869",
      "r873",
      "r1177"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "negatedTerseLabel": "Loss on net cash flow hedges",
        "verboseLabel": "Other comprehensive income (loss) before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r376",
      "r380"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r65",
      "r169",
      "r383",
      "r386",
      "r393",
      "r867",
      "r872",
      "r873",
      "r960",
      "r982",
      "r1177",
      "r1178"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r59",
      "r61"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Pension and other postretirement benefits"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r1209",
      "r1216",
      "r1251",
      "r1295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other Debt Obligations"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other investments.",
        "label": "Other Investments [Member]",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "OtherInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails",
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other noncash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPolicyholderFunds": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due to policyholders for funds held that are returnable under the terms of insurance contracts, classified as other.",
        "label": "Other Policyholder Funds",
        "terseLabel": "Policyholders\u2019 funds"
       }
      }
     },
     "localname": "OtherPolicyholderFunds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r181",
      "r650",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r702",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r722",
      "r723",
      "r724",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other Postretirement Benefits"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total CVS Health Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r400",
      "r1104"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Payments for Derivative Instrument, Financing Activities",
        "negatedTerseLabel": "Derivative settlements",
        "terseLabel": "Payments for derivative instruments"
       }
      }
     },
     "localname": "PaymentsForDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Cash impact of litigation settlement"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r90",
      "r325"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "totalLabel": "Total claims paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r1180",
      "r1181"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments for taxes related to net share settlement of equity awards",
        "terseLabel": "Payments for taxes for net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions (net of cash acquired)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToSuppliersAndEmployees": {
     "auth_ref": [
      "r406",
      "r1184",
      "r1185"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.",
        "label": "Payments to Suppliers and Employees",
        "negatedTerseLabel": "Cash paid to other suppliers and employees"
       }
      }
     },
     "localname": "PaymentsToSuppliersAndEmployees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r1231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r675",
      "r677",
      "r683",
      "r701",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r719",
      "r720",
      "r722",
      "r728",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "Pension Plans and Other Postretirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r28",
      "r650",
      "r651",
      "r674",
      "r1132"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedTerseLabel": "Current liabilities reflected in accrued expenses"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r30",
      "r650",
      "r651",
      "r674",
      "r1132"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedTerseLabel": "Noncurrent liabilities reflected in other long-term liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r189",
      "r194",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r180",
      "r650",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r702",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r722",
      "r723",
      "r727",
      "r1132",
      "r1133",
      "r1137",
      "r1138",
      "r1139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r702",
      "r1130",
      "r1131",
      "r1132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyholderAccountsPolicy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contracts reported in separate accounts, including the extent and terms of minimum guarantees, basis of presentation for separate account assets and liabilities and related separate account activity, the liability valuation method and assumptions used in valuing each type of policyholder and contract holder account maintained by the entity.",
        "label": "Policyholder Accounts, Policy [Policy Text Block]",
        "terseLabel": "Separate Accounts"
       }
      }
     },
     "localname": "PolicyholderAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredGross": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred.",
        "label": "Policyholder Benefits and Claims Incurred, Direct",
        "terseLabel": "Direct"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.",
        "label": "Policyholder Benefits and Claims Incurred, Net, Health",
        "terseLabel": "Benefit costs"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredHealthCare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": {
     "auth_ref": [
      "r292",
      "r321"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.",
        "label": "Policyholder Benefits and Claims Incurred, Net",
        "totalLabel": "Net benefit costs"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Policyholder Benefits and Claims Incurred, Net [Abstract]",
        "terseLabel": "Policyholder Benefits and Claims Incurred, Net [Abstract]"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r33",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r33",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r33",
      "r1148"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsEarnedNet": {
     "auth_ref": [
      "r959",
      "r981",
      "r991",
      "r1023"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Premiums Earned, Net",
        "terseLabel": "Premiums",
        "totalLabel": "Net premiums"
       }
      }
     },
     "localname": "PremiumsEarnedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsReceivableAtCarryingValue": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": {
       "order": 3.0,
       "parentTag": "cvs_AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.",
        "label": "Premiums Receivable, Net",
        "terseLabel": "Premium receivables"
       }
      }
     },
     "localname": "PremiumsReceivableAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivateEquityFundsMember": {
     "auth_ref": [
      "r1251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments held in private equity funds.",
        "label": "Private Equity Funds [Member]",
        "verboseLabel": "Private equity investments"
       }
      }
     },
     "localname": "PrivateEquityFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCustomers": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.",
        "label": "Proceeds from Customers",
        "terseLabel": "Cash receipts from customers"
       }
      }
     },
     "localname": "ProceedsFromCustomers",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "verboseLabel": "Proceeds from divestiture of subsidiary"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,854, $0 and $9)"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestAndDividendsReceived": {
     "auth_ref": [
      "r401",
      "r405"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for dividends and interest on the entity's equity and debt investments during the current period.",
        "label": "Proceeds from Interest and Dividends Received",
        "terseLabel": "Interest and investment income received"
       }
      }
     },
     "localname": "ProceedsFromInterestAndDividendsReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity": {
     "auth_ref": [
      "r964"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from principal payment received from sales-type and direct financing leases classified as investing activity.",
        "label": "Proceeds from Lease Payment, Sales-Type and Direct Financing Leases, Investing Activity",
        "terseLabel": "Proceeds from sale-leaseback transactions"
       }
      }
     },
     "localname": "ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r1182",
      "r1183"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r78",
      "r120",
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r83",
      "r204"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Cash received from stock options exercised (including ESPP)"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r1248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r1123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Products"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r357",
      "r382",
      "r385",
      "r403",
      "r411",
      "r423",
      "r433",
      "r434",
      "r469",
      "r480",
      "r486",
      "r489",
      "r520",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r585",
      "r587",
      "r589",
      "r590",
      "r818",
      "r821",
      "r822",
      "r840",
      "r858",
      "r965",
      "r1110",
      "r1145",
      "r1146",
      "r1179",
      "r1239"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": {
     "auth_ref": [
      "r1294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant, and Equipment, Fair Value Disclosure",
        "terseLabel": "Property and equipment, fair value"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r152",
      "r363"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "cvs_PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r154",
      "r306",
      "r972",
      "r1148"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r1060",
      "r1061"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life of property plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PropertySubjectToOperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property subject to an operating lease.",
        "label": "Property Subject to Operating Lease [Member]",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "PropertySubjectToOperatingLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "terseLabel": "Property Subject to or Available for Operating Lease [Axis]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease.",
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "terseLabel": "Property Subject to or Available for Operating Lease [Domain]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealEstateFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in funds that invest in commercial or residential real estate.",
        "label": "Real Estate Funds [Member]",
        "verboseLabel": "Real estate partnerships"
       }
      }
     },
     "localname": "RealEstateFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealEstateInvestmentMember": {
     "auth_ref": [
      "r1046",
      "r1047",
      "r1048",
      "r1158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents direct equity investments in real estate projects (Land, buildings and improvements owned for income production and capital accretion potential) and certain loans accounted for as real estate investments. For loans accounted for as real estate investments, the entity (lender) has virtually the same risks and rewards as those of owners or joint venture participants. Such arrangements are treated as if the entity actually has an ownership interest in the property. In such arrangements, the entity (lender) participates in expected residual profits, which may be in the form of an equity kicker or a higher than usual effective interest rate. At the outset and during the construction and development of the property, the borrower generally has little or no equity in the property and the entity's (lender's) only source of repayment is the property. The entity (lender) generally (a) agrees to provide substantially all funds to acquire, develop, and construct the property, (b) funds the commitment or origination fees or both, and (c) funds interest during the development and construction of the property.",
        "label": "Real Estate Investment [Member]",
        "terseLabel": "Real estate investment"
       }
      }
     },
     "localname": "RealEstateInvestmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentIncomeNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Net realized capital gains (losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r1202",
      "r1203",
      "r1204",
      "r1205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r63",
      "r389",
      "r867",
      "r871",
      "r873",
      "r1177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "terseLabel": "Amounts reclassified, pre-tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r389",
      "r867",
      "r871",
      "r873",
      "r1177"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "Changes in Accumulated Other Comprehensive Income (Loss) by Component"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r114",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation Of Consolidated Operating Income to Adjusted Operating Income"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemablePreferredStockMember": {
     "auth_ref": [
      "r25",
      "r168",
      "r411",
      "r520",
      "r578",
      "r581",
      "r582",
      "r583",
      "r589",
      "r590",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series.",
        "label": "Redeemable Preferred Stock [Member]",
        "terseLabel": "Redeemable preferred securities"
       }
      }
     },
     "localname": "RedeemablePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReinsuranceAccountingPolicy": {
     "auth_ref": [
      "r1032",
      "r1154",
      "r1155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.",
        "label": "Reinsurance Accounting Policy [Policy Text Block]",
        "terseLabel": "Reinsurance Recoverables"
       }
      }
     },
     "localname": "ReinsuranceAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReinsuranceDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reinsurance Disclosures [Abstract]",
        "terseLabel": "Reinsurance Disclosures [Abstract]"
       }
      }
     },
     "localname": "ReinsuranceDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of policy benefits and costs incurred for policies assumed.",
        "label": "Policyholder Benefits and Claims Incurred, Assumed",
        "terseLabel": "Assumed"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction of provision for policy benefits and costs incurred for policies ceded.",
        "label": "Policyholder Benefits and Claims Incurred, Ceded",
        "negatedTerseLabel": "Ceded"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Premiums Earned, Net [Abstract]",
        "terseLabel": "Premiums Earned, Net [Abstract]"
       }
      }
     },
     "localname": "ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": {
     "auth_ref": [
      "r323",
      "r326",
      "r1312",
      "r1314"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.",
        "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments",
        "periodEndLabel": "Add: Reinsurance recoverables",
        "periodStartLabel": "Less: Reinsurance recoverables",
        "terseLabel": "Reinsurance recoverables"
       }
      }
     },
     "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses": {
     "auth_ref": [
      "r975",
      "r995",
      "r996",
      "r1030"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, policy benefits and policy reserves. Excludes premiums paid under reinsurance contracts.",
        "label": "Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments",
        "terseLabel": "Total reinsurance recoverables"
       }
      }
     },
     "localname": "ReinsuranceRecoverablesOnPaidAndUnpaidLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsuranceTextBlock": {
     "auth_ref": [
      "r973",
      "r974",
      "r1032",
      "r1154",
      "r1155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts.",
        "label": "Reinsurance [Text Block]",
        "terseLabel": "Reinsurance"
       }
      }
     },
     "localname": "ReinsuranceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/Reinsurance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "terseLabel": "Other revenues from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Redeemed principal amount"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r561",
      "r562",
      "r1115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r561",
      "r562",
      "r1115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResidentialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r1206",
      "r1251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by residential real estate mortgage loans.",
        "label": "Residential Mortgage-Backed Securities [Member]",
        "terseLabel": "Residential mortgage-backed securities"
       }
      }
     },
     "localname": "ResidentialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails",
      "http://www.cvshealth.com/role/InvestmentsNarrativeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1174",
      "r1187"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash (included in other current assets)"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r1054",
      "r1175",
      "r1187"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash (included in other assets)"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesCashandCashEquivalentsRestrictedCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsAtFairValue": {
     "auth_ref": [
      "r344",
      "r1042",
      "r1053",
      "r1055"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of all restricted investments.",
        "label": "Restricted Investments, at Fair Value",
        "terseLabel": "Investments related to 2012 contract conversion"
       }
      }
     },
     "localname": "RestrictedInvestmentsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r36",
      "r174",
      "r302",
      "r1010",
      "r1015",
      "r1148"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r352",
      "r419",
      "r420",
      "r421",
      "r424",
      "r432",
      "r434",
      "r525",
      "r767",
      "r768",
      "r769",
      "r800",
      "r801",
      "r838",
      "r1006",
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r650",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r702",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r722",
      "r723",
      "r724",
      "r727",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r650",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r702",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r722",
      "r723",
      "r724",
      "r727",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r460",
      "r461",
      "r479",
      "r484",
      "r485",
      "r491",
      "r492",
      "r494",
      "r646",
      "r647",
      "r951"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Intersegment revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r649",
      "r1106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r392",
      "r411",
      "r460",
      "r461",
      "r479",
      "r484",
      "r485",
      "r491",
      "r492",
      "r494",
      "r520",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r585",
      "r587",
      "r589",
      "r590",
      "r858",
      "r965",
      "r1239"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r900",
      "r1147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r900",
      "r1147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleAndLeasebackTransactionGainLossNet": {
     "auth_ref": [
      "r898",
      "r907",
      "r1147"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.",
        "label": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "terseLabel": "Gains from sale-leaseback transactions"
       }
      }
     },
     "localname": "SaleAndLeasebackTransactionGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesChannelDirectlyToConsumerMember": {
     "auth_ref": [
      "r1129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred directly to consumer.",
        "label": "Sales Channel, Directly to Consumer [Member]",
        "terseLabel": "Mail choice"
       }
      }
     },
     "localname": "SalesChannelDirectlyToConsumerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesChannelThroughIntermediaryMember": {
     "auth_ref": [
      "r1129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred through intermediary.",
        "label": "Sales Channel, Through Intermediary [Member]",
        "terseLabel": "Pharmacy network"
       }
      }
     },
     "localname": "SalesChannelThroughIntermediaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r494",
      "r1198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable, net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r63",
      "r1297",
      "r1298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.",
        "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of Assets (Liabilities) Recognized in Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Weighted Average Assumptions Used in Determining Benefit Obligations and Net Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails",
      "http://www.cvshealth.com/role/InvestmentsNarrativeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r213",
      "r214",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesSummaryofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock": {
     "auth_ref": [
      "r1319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.",
        "label": "Ceded Credit Risk [Table Text Block]",
        "terseLabel": "Schedule of Reinsurance Recoverables"
       }
      }
     },
     "localname": "ScheduleOfCededCreditRiskByReinsurerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ReinsuranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.",
        "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Changes in Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.",
        "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]",
        "terseLabel": "Schedule of Changes in Benefit Obligations"
       }
      }
     },
     "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r48",
      "r170",
      "r171",
      "r172",
      "r173",
      "r264",
      "r265",
      "r267",
      "r291",
      "r1118",
      "r1120",
      "r1191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Company's Borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r16",
      "r18",
      "r19",
      "r20",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of discontinued operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r1197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic and Diluted Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r202",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Schedule of Expected Future Benefits Payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r843",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Separate Account Investment [Line Items]",
        "terseLabel": "Fair Value, Separate Account Investment [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable": {
     "auth_ref": [
      "r1149",
      "r1156",
      "r1318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about fair value of asset supporting separate account.",
        "label": "Fair Value, Separate Account Investment [Table]",
        "terseLabel": "Fair Value, Separate Account Investment [Table]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock": {
     "auth_ref": [
      "r293",
      "r1156",
      "r1318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of asset supporting separate account.",
        "label": "Fair Value, Separate Account Investment [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value of Separate Accounts by Major Category of Investment"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r1115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r1115",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary of Changes in Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Net Investment Income [Line Items]",
        "terseLabel": "Schedule of Investment Income, Reported Amounts, by Category [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table]",
        "terseLabel": "Schedule of Investment Income, Reported Amounts, by Category [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Periodic Benefit Cost (Income)"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "RSU and Performance Share Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRegulatoryAssetsTextBlock": {
     "auth_ref": [
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets that are created when regulatory agencies permit public utilities to defer certain costs included in rate-setting to the balance sheet.",
        "label": "Schedule of Regulatory Assets [Table Text Block]",
        "terseLabel": "Schedule of Regulatory Requirements"
       }
      }
     },
     "localname": "ScheduleOfRegulatoryAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r112",
      "r113",
      "r115",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r112",
      "r113",
      "r115",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summarized Financial Information Of Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r729",
      "r730",
      "r733",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options and Stock Appreciation Rights Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule ESPP Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Share Repurchase Programs"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "verboseLabel": "Schedule of Debt Securities In An Unrealized Capital Loss Position"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r1144",
      "r1283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Rollforward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r229",
      "r231",
      "r234",
      "r235",
      "r236",
      "r819",
      "r820",
      "r825",
      "r826",
      "r930",
      "r931",
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r229",
      "r231",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of variable interest entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "verboseLabel": "Schedule of Projected Annual Amortization Expense for Intangible Assets for Next Five Years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r457",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r494",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r569",
      "r570",
      "r1115",
      "r1315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails",
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r469",
      "r472",
      "r483",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelfInsuranceReserve": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.",
        "label": "Self Insurance Reserve",
        "terseLabel": "Self insurance liabilities"
       }
      }
     },
     "localname": "SelfInsuranceReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelfInsuranceReservePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).",
        "label": "Self Insurance Reserve [Policy Text Block]",
        "terseLabel": "Self-Insurance Liabilities"
       }
      }
     },
     "localname": "SelfInsuranceReservePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails",
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeparateAccountAssetCategoryAxis": {
     "auth_ref": [
      "r1025",
      "r1156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by separate account asset investment.",
        "label": "Separate Account Asset Category [Axis]",
        "terseLabel": "Separate Account Asset Category [Axis]"
       }
      }
     },
     "localname": "SeparateAccountAssetCategoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueNarrativeDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeparateAccountAssetCategoryDomain": {
     "auth_ref": [
      "r1025",
      "r1156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separate account asset investment.",
        "label": "Separate Account Asset Category [Domain]",
        "terseLabel": "Separate Account Asset Category [Domain]"
       }
      }
     },
     "localname": "SeparateAccountAssetCategoryDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueNarrativeDetails",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeparateAccountAssets": {
     "auth_ref": [
      "r977",
      "r1024",
      "r1025",
      "r1156"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset at fair value held for benefit of separate account policyholder.",
        "label": "Separate Account Asset",
        "terseLabel": "Separate accounts assets"
       }
      }
     },
     "localname": "SeparateAccountAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeparateAccountsLiability": {
     "auth_ref": [
      "r978",
      "r1024",
      "r1026",
      "r1027",
      "r1157"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for variable contract in which all or portion of contract holder's funds is allocated to specific separate account and supported by assets held in separate account.",
        "label": "Separate Account, Liability",
        "negatedTerseLabel": "Separate accounts liabilities",
        "terseLabel": "Separate accounts liabilities"
       }
      }
     },
     "localname": "SeparateAccountsLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r1123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r1231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r1141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Weighted-average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at end of period (in shares)",
        "periodStartLabel": "Unvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested at end of year (in dollars per share)",
        "periodStartLabel": "Unvested at beginning of year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r752"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Vested in period, fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r1143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares exercisable at end of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price exercisable at end of year ($ per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r752"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options and SARs exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Shares expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Shares forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic value outstanding at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding at end of year (in shares)",
        "periodStartLabel": "Shares, Outstanding at beginning of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, outstanding at end of year ($ per share)",
        "periodStartLabel": "Weighted average exercise price, outstanding at beginning of year ($ per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r753"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value vested at end of year and expected to vest in the future"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares vested at end of year and expected to vest in the future (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price vested at end of year and expected to vest in the future ($ per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised ($ per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, expired ($ per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, forfeited ($ per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted ($ per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r736",
      "r755",
      "r756",
      "r757",
      "r758",
      "r761",
      "r770",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r1142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value exercisable at end of year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term exercisable at end of year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term, outstanding at end of year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term vested at end of year and expected to vest in the future"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Shares outstanding, end of year balance (in shares)",
        "periodStartLabel": "Shares outstanding, beginning of year balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for insurance products considered to be short-duration contracts because the contract provides insurance protection for a fixed period of short duration and enables the insurer to cancel the contract or to adjust the provisions of the contract at the end of any contract period, such as adjusting the amount of premiums charged or coverage provided, and on contracts on which amounts are paid but insurance risk is not transferred.",
        "label": "Short-Duration Insurance and Deposit Contracts [Text Block]",
        "terseLabel": "Health Care Costs Payable"
       }
      }
     },
     "localname": "ShortDurationInsuranceAndDepositContractsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2019Member": {
     "auth_ref": [
      "r1000"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year 2019 in which covered event occurs under terms of short-duration insurance contract.",
        "label": "Short-Duration Insurance Contract, Accident Year 2019 [Member]",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "ShortDurationInsuranceContractAccidentYear2019Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2020Member": {
     "auth_ref": [
      "r1000"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year 2020 in which covered event occurs under terms of short-duration insurance contract.",
        "label": "Short-Duration Insurance Contract, Accident Year 2020 [Member]",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "ShortDurationInsuranceContractAccidentYear2020Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r26",
      "r274",
      "r301",
      "r1148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Short-term debt"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r279",
      "r280",
      "r298",
      "r1176"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Investments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Investments",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r895",
      "r1147"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract.",
        "label": "Short-Duration Insurance Contracts, Accident Year [Axis]",
        "terseLabel": "Short-duration Insurance Contracts, Accident Year [Axis]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsAccidentYearAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract.",
        "label": "Short-Duration Insurance Contracts, Accident Year [Domain]",
        "terseLabel": "Short-duration Insurance Contracts, Accident Year [Domain]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsAccidentYearDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Claims Development [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table Text Block]",
        "terseLabel": "Information about Incurred and Paid Health Care Claims Development"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net",
        "terseLabel": "Cumulative Paid Health Care Claims, Net of Reinsurance"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undiscounted amount, after reinsurance, of incurred-but-not-reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net",
        "verboseLabel": "Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) claims liability, net"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net",
        "terseLabel": "Incurred Health Care Claims, Net of Reinsurance"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net",
        "terseLabel": "Short-duration health care costs payable, net of reinsurance",
        "totalLabel": "Total outstanding liabilities for health care costs payable, net of reinsurance"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts for accident years not separately presented in claim development information. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented",
        "terseLabel": "All outstanding liabilities for health care costs payable prior to 2021, net of reinsurance"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reconciling item for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts, classified as other.",
        "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item",
        "terseLabel": "Insurance lines other than short duration"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableLiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]",
        "terseLabel": "Components of Change in Health Care Costs Payable"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r355",
      "r457",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r494",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r568",
      "r569",
      "r570",
      "r1115",
      "r1315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails",
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails",
      "http://www.cvshealth.com/role/LeasesNarrativeDetails",
      "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r53",
      "r169",
      "r352",
      "r388",
      "r389",
      "r390",
      "r419",
      "r420",
      "r421",
      "r424",
      "r432",
      "r434",
      "r452",
      "r525",
      "r634",
      "r767",
      "r768",
      "r769",
      "r800",
      "r801",
      "r838",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r873",
      "r913",
      "r1006",
      "r1007",
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r452",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatutoryAccountingPracticesDisclosureTextBlock": {
     "auth_ref": [
      "r312",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of how the entity's reporting under GAAP as of the balance sheet date differs from the results based on prescribed and permitted accounting practices of the state or country of domicile in which a relevant statutory filing is made, or differences in results based on the National Association of Insurance Commissioners (NAIC) prescribed practices, or a combination thereof. Describes the accounting practices used and the related monetary effect on statutory surplus, net income, and risk-based capital. If an insurance enterprise's risk-based capital would have triggered a regulatory event had it not used a permitted practice, that fact is disclosed in the financial statements. Permitted statutory accounting practices include practices not prescribed but allowed by the domiciliary state insurance department regulatory authority.",
        "label": "Statutory Accounting Practices Disclosure [Table Text Block]",
        "terseLabel": "Statutory Accounting Practices Disclosure"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatutoryAccountingPracticesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statutory Accounting Practices [Line Items]",
        "terseLabel": "Statutory Accounting Practices [Line Items]"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of dividends that can be declared or paid without approval of regulatory agency.",
        "label": "Statutory Accounting Practices, Statutory Amount Available for Dividend Payments without Regulatory Approval",
        "terseLabel": "Estimated maximum dividend distributions permitted in 2023 without prior regulatory approval"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance": {
     "auth_ref": [
      "r303",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus, Balance",
        "terseLabel": "Estimated statutory capital and surplus"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required",
        "terseLabel": "Estimated minimum statutory surplus required by regulators"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net income for the period determined using accounting principles prescribed or permitted by insurance regulators.",
        "label": "Statutory Accounting Practices, Statutory Net Income Amount",
        "terseLabel": "Statutory net income"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesStatutoryNetIncomeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatutoryAccountingPracticesTable": {
     "auth_ref": [
      "r312",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail by state, country, or other jurisdiction of domicile in which financial statements are filed reflecting statutory capital and surplus, net income and the differences between financial reports which are in conformity with generally accepted accounting principles and the statutory financial statements which also use state permitted or prescribed accounting practices.",
        "label": "Statutory Accounting Practices [Table]",
        "terseLabel": "Statutory Accounting Practices [Table]"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r33",
      "r34",
      "r169",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r34",
      "r169",
      "r174",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Shares exercised (in shares)",
        "verboseLabel": "Stock option activity, stock awards and other (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r169",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock option activity, stock awards and other"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r33",
      "r34",
      "r169",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchased during the period (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r33",
      "r34",
      "r169",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Stock repurchased during period, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r34",
      "r37",
      "r38",
      "r119",
      "r1148",
      "r1189",
      "r1214",
      "r1296"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total CVS Health shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r220",
      "r221",
      "r237",
      "r352",
      "r353",
      "r389",
      "r419",
      "r420",
      "r421",
      "r424",
      "r432",
      "r525",
      "r634",
      "r767",
      "r768",
      "r769",
      "r800",
      "r801",
      "r838",
      "r867",
      "r868",
      "r873",
      "r913",
      "r1007",
      "r1008",
      "r1189",
      "r1214",
      "r1296"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Reduction to retained earnings as a result of new accounting standard adoption",
        "periodEndLabel": "End of year balance",
        "periodStartLabel": "Beginning of year balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
      "http://www.cvshealth.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r410",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r897",
      "r1147"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Less: sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r874",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r874",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r874",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/AcquisitionsDivestituresandAssetSalesNarrativeDetails",
      "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails",
      "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r998"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r998"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "negatedTerseLabel": "Decrease in prior years' healthcare costs payable",
        "verboseLabel": "Prior years"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/HealthCareCostsPayableComponentsofChangeinHealthCareCostsPayableDetails",
      "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r509",
      "r510",
      "r616",
      "r632",
      "r828",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r1211",
      "r1212",
      "r1213",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails",
      "http://www.cvshealth.com/role/InvestmentsNarrativeDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "negatedPeriodEndLabel": "Treasury shares outstanding, end of year balance (in shares)",
        "negatedPeriodStartLabel": "Treasury shares outstanding, beginning of year balance (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r52",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r52",
      "r175",
      "r178"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost: 458 and 422 shares at December\u00a031, 2022 and 2021"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r423",
      "r424",
      "r425",
      "r426",
      "r435",
      "r499",
      "r500",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r767",
      "r768",
      "r769",
      "r798",
      "r799",
      "r800",
      "r801",
      "r815",
      "r816",
      "r817",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r876",
      "r877",
      "r880",
      "r881",
      "r882",
      "r883",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r953",
      "r954",
      "r955",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals",
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesNewAccountingPronouncementsNotYetAdoptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "auth_ref": [
      "r1248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of cost from product sold and service rendered.",
        "label": "Cost, Product and Service [Extensible Enumeration]",
        "terseLabel": "Cost, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r1107",
      "r1130",
      "r1310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r1130",
      "r1318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "States, municipalities and political subdivisions",
        "verboseLabel": "States, municipalities and political subdivisions"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails",
      "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails",
      "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails",
      "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails",
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r966",
      "r1130",
      "r1318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy": {
     "auth_ref": [
      "r997",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]",
        "terseLabel": "Other Insurance Liabilities"
       }
      }
     },
     "localname": "UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r774",
      "r783"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r784"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r786"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r782"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Income tax penalties and interest accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r782"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r785"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r784"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r787"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Expiration of statutes of limitation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r788"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation Allowance [Line Items]",
        "terseLabel": "Valuation Allowance [Line Items]"
       }
      }
     },
     "localname": "ValuationAllowanceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceTable": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.",
        "label": "Valuation Allowance [Table]",
        "terseLabel": "Valuation Allowance [Table]"
       }
      }
     },
     "localname": "ValuationAllowanceTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "VIE, ownership percentage"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r896",
      "r1147"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r437",
      "r445"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average diluted shares outstanding (in shares)",
        "totalLabel": "Weighted average shares, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r436",
      "r445"
     ],
     "calculation": {
      "http://www.cvshealth.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average basic shares outstanding (in shares)",
        "verboseLabel": "Weighted average shares, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations",
      "http://www.cvshealth.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Write off of deferred debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvshealth.com/role/BorrowingsandCreditAgreementsLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=84167274&loc=d3e27175-158546",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(a)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6484091&loc=d3e19268-158472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506110&loc=d3e32546-158582",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600598&loc=SL75763979-209797",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org/topic&trid=2303980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1037": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1038": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Column G))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 6))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1056": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1057": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1058": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1059": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "720",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=49178521&loc=d3e9162-115647",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1060": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1061": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1062": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1063": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1064": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1065": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1066": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1067": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1068": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1069": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1070": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1071": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1072": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1073": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1074": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1075": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1076": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1077": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1078": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1079": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1080": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1081": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1082": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1083": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1084": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1085": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1086": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1087": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1088": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1089": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1090": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1091": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1092": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1093": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1094": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(C)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1095": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1096": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1097": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1098": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1099": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3505-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921842-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124504731&loc=d3e11522-158419",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819541-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99379264&loc=d3e27758-158548",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99379264&loc=d3e27830-158548",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505678&loc=SL117422397-158474",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505678&loc=SL117422401-158474",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r1162": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1163": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1164": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1165": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1166": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1167": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1168": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1169": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1170": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1171": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953659-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450678-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=122147696&loc=SL65671395-207642",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1320": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1321": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1322": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1323": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1324": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1325": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1326": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1327": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1328": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1329": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(ii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1330": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1331": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1332": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2599-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(3)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6479118&loc=d3e64650-112822",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),5)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.14)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.23(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.5)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=35755530&loc=d3e11264-158415",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671317-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671321-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6483535&loc=d3e16392-158451",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24746-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24790-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=82848697&loc=d3e24938-158530",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=82848697&loc=d3e24959-158530",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org/topic&trid=2303980",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.6(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=6499975&loc=d3e44250-110382",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=6499975&loc=d3e44264-110382",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "715",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=6501251&loc=d3e52485-110419",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(b))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22 (b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919786-209982",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=SL120154370-112784",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6816-158387",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(7))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21409-158489",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14754-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14784-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>144
<FILENAME>0000064803-23-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000064803-23-000009-xbrl.zip
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MJH:THQ=G[/GGWKWW]C+YW:'6[7C[[BM.WSE_?OXEWWUPHSYYWT1:**ZFXF(
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M-/P"J99<S;EP#B;5HMYU:R!Z;_3</JH')SP[>GR->555QH,[../;1V<US)%
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M7$RIS=G$ 7)-8\F83.3=^#R]C="WV&ALLI"Y%:C%YAI:4NF@9E<<YS'LO39
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M/\9E+UW8"'TS067R8%*UT&R?[@*@@:B$++6=E>6&3=\MH,[F8]Q1DE<"U<!
M*7H [ MN!,%(XX(!2AV+<I_(N_$I6INA;XX&3$L>K84$E$M,1GRP*@1S.5NO
M/M%W\.M -A-Z&LG8R 8;&T!@U9]*)HB26HFVM(D\EQ?ICI) Z,A7-3,N6@:'
M4JP&+LZEY*M(.^OQ<I4(-$H4Q;?8ZT,,.OS%,=:^JMV'4(QK&*;P<\"Z:! -
M&#;"VHH4 1S;OAD?!Z0&00S:QMFHDA]+XFO(2GJ;>Z)MA+-@,!9JWA:PD'-
MAZV0A=#(,.*VY/J':>6F&/,K6>L"6[6IG/MR<:Q0 (E2W\R:DC4T!GTPS.+F
M%ELZ*URJ QL2&6BIE-9LJ6BY8/(FF2WAS#;W1-M,.=.5Z-A;CFS!&,1 W!PA
MA:"6QH^%-U<3O));M,5J\(@,;'PV-057%=#2R%4[ O"V-9 <)9\:,-2457#D
M %0J%<S45]9S<NC:6(S!]H5XHV23RR*BP9;:H@@^NQP*&W))6@TN\EC*U$-F
MTY4*BVJ,*53O*4  M+8D=7&EME@=HJG;8IVN2BU,90L8\K[F!J$(LL?B*A9D
MDZL=@W:9BE,?%J<DBS=00K4-BO-859AR2(YMB,1C2!!OJQK]"S'41MLD;&9-
M5T8(&6MMJ!;*JD&JR7I;6U5"GV][-VP>;Q.')O7]=<N[>@A7$ZHVBM!W?:<J
M&"*WAA29QK"L=F+QI/IG&=';G)K43& B9:MZ'UR/*IW2>"P3[@95#+EZ/MU'
M<I M!_T_9/29D6S0H+&T$MAMRV+7J]43;3/VJ.M M-$4ZR%Z5VS06 <,FV9Z
M_60D3)K@/-NF.!CP)2);K^X%,)M"0&)3=AK$1C<2. ?>3F?JB;;)2  $+!01
MCAZ87/952$H-U:5:*TT4'^K$O1'V1-M,I:D6#RUR8F*(SJ,W3 7T56\3P51I
M6@N_KF9/M,W,RM&0A#T9X=H71U)O4Q%+L:I5J+I(_[FM+"XF#Y/'O\R.9X]7
M)+Z.R_>FXCRX=T.>Z^WKI]IOIPETE9C_/#G$HW-0KUV_=G>V?*;A\&+&\\5=
MJ3)[@:2L6Q?3WEU=Y]S)1V/LGAP?'PB_.VC]])H=*8GTV [ACLGO,>;\G:]@
MC+($ XA5?ZY./IE25<\"Z$O)Q;=3-ZPY-X%FHLX(J?.19;+F\RV36=/:I82I
M<(&>3X%&DCV5' 22U==C&$.1;^+9"#P@^I)(::3VJ_7I'@5CI! D-&:+=B7I
M+)SQS,)0>79/OY%/#F2_W?R?$[VH73E^,N?;1R]DN>+8[U\5V<-#>3_9S_OX
M[&(AMO#9$.NAZTN]V+XC!8<6-$2UA5RAF)!=:(ZS&\L>A^. >$/;6"8@XR/8
MTD=Q8-3'65I-.=@4.'<=Z]P0D7V743_'\?[KYQ]E2?\I_%A^.CGBM10=WT5_
MPC?[39C)1X;_7[B8=3^S2IGI5:V.>KTW/[ZSF!WBXO7I1)3Z&9FTOZ1:G?N0
M'W]!M694G2KD4ZV@QCPAQ=Z;"V(&\:ZU%3\&.?(G?OPQ/^S:^*'Z45U!LXC0
MRW:8D1-#Q&"=3<V-W'XH+"\4S5,'<05YLCX[HI&(+[6&5#. L*'@^[P75PWF
M&%T:MQVYZCQ9GSV)+5OIN[1K[ I%+&E@X3W6)/HUR=?AVI/+1FPMQ+VK\?/-
M9<_L?@YKAV),!%J-WN;BLJH2[THHXH*8[(WIN^0.UYA,)+DT2^(S>ZX>2I]
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MJ19-E06B!3)(+J.M%6T6;VH8<Q'ITBDS2=$-5+(<D$7UW3$Y*($*0U -FBB
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MH$BK^JA:,*9Q-!.3)W$Z#B8S-_+!%)L"]AU?T&?PUEEO#%!U.#%Y(L\?DJ=
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M$EZ>9E4M147OKY\W?<2_#GWVQ_ME$,]&4,XC3(M@[WFJ#>C,M?8&S2J0)][
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M&0I50%7C%DFPN(7U;E<C&ZY9!F^<8(I8FK!(22EC+9-;GA27D)&22AR9XJN
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M3:E !@^G5/)HE.I2['0?N!X#\2?\!'--F"M "KI!8#L: GO9]-9CT,.S-$F
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M"#E(6M5&9!F<WE1K*V_-LY%G:]A.!4.(D;>:UN,UZ[Z7==_,,?*BP/*\.'+
MR*/,)+$3FF'BQ&9H>1&)H]BEP4\S\I[_+*Z<HOO+&7FWR%B4/2!VAFE=@Z 2
M&8B?LLAQ*MF-(6!:-\8^1B\HD[5"N[2FQAME"DZ(X.X9?=NP[YP\%N=CU2/)
M.#%/C1<(<1^\<EQGJ_5>IA*J:X1074\MC]5X6S$KJM_60G0I#NY/P.=JR1VI
M7<O4M1"]3XA^G2-$>2(<^"\R;8>'($0#RXP%=<S$)6%$*)!G3-9"=&G/XEJ(
M]D)V&2W!I*2,@1 M*4I"E"L8K\OG?FL N9MS?ZB&('WA+66CQ\-J#F$-;C;1
MJH7'@2F(V0#GQGE97->#YN<M ZQ<(0<G X02/UF6_6*MH0/SO&6(\F?[57/9
MO1?</L#F0C1M]<6W#+:YL@EAVJ!;.XVQWK?0OT4N/Z"1V4^\='6J5G\*4G6Y
M Q1W7I0W<U+DY$62%IF^:+FSY7Z.2+;GY%U'A'N<VHYI12%V"1((]"&(&25N
M$ODBMA+F;;Q^-Y]3/#("TX)&=;Y)9[Z5.3Q,\"V<3-^>W?,5W.(I5>QQ.75=
MC)Y+'YNC4?P*^_=K'=&3V]2O5=OJ)U<[Y$K^,:[@S54UV=PJ2;\(#M/*JJ4N
M\/HYBH8S)_:96!Z%O2 FIQ':_G%BQJ&7F+YO1Z[#0MN*^+T]?[Z%._]DY7])
MF<?>?'-LS3J^D74TZ_A6+N..6L4U"_EN%N+.82%V'/L^CQU3!':"S<(\,Q81
M,6,6^X$58M>PX =8B&,OG8:WG]SA_T'@J <F^&'81P9[0$O$3+^Z,,:5<AW!
MS%5#T#D]N(I2OBN[P9=?I_!J>*V1P]0*5$>NTDIJG3G-&9YET$6QM05>7-4T
MY[3DE8'XG"F_K<#(?4%_^U$OT%(PJ >;(<M(I=\<@M0I/EJE19 #]"#2NA:(
MZ8J4 42"K7Q@:/1<IL*T^&FTJD![PZ\:PA%)(F0 )]>PAWAGBG&='#8094%9
M9$8!R]4CUDZ;'@/Y=YFLQ"(]M)436L84'FL>?<G$C<P@>F%[QH>MDZT=(W!\
M1&;Y#>?=35)7T\49R*'>B4C2<JA"E2-X-<6+X!#)(@\N!TS'/*WUL%:._)]0
M/N^SI-S&M2O*[8Z WF3T?!4[<_Y4(>W-RW&DQ"$41+/EALPD/'',R(Y=;/5I
MBR@(.6CZ/<?:+Y+HF!A5EW (A_M;(9UNE>5])MHQ+XE\K1($B]EL?@DGJ<K%
MU&TZK3#)9+8A?,6*LA1MYQ14,<H2$PT+9$Y7:3&NLIN&-\U[ZP($-M?QVG5V
M_ZILU"\;6$=S0C*P JP1Q8,ZUM0PTAZSD_I3F]>%^B,K9-(:J(G93956NA$4
M!A"OA!E3-%#0A!%YI?1*S"V#GV3Z>/OV/OO\KVH&*[NL^NEI)1A25\AGVY=K
M<ZG/YU6V&^JLEOW*(=:6;>V:-O#\U4P[6[/.)=FH->M<%=8Y+R>I&H@L:]Q#
MQHLYR $3:3>@=ZX>/WKZ(!(N\MH!_,/U<P>I96D(M)N#BP_D:)>!<2G\6+C$
MM'P?C$O'"D"&VX$9T5"XMN>*D(4/\P O/V=;BZ EV:AY(F@&)^I9VJ:? I.G
MY^<@)E".H/@0M4;4G-%[6_\J4QB<E<1- UXG5669O)J@)P&>5,GR"CH:E<67
M%+B?R&Z,_Z?Y[AN92P_WC_-4<=UQQ3<FV; 0B1<Y+(@<WR.V)R+/)C1RDR2&
M\T\H^V=?LF'?M39 @#%X15;]SX8URXK?2R_KFZR@]20GSL=#DQ>UJ>\&L@)2
M$?(92\B7/Q+^YU_99R>[BB]&@X.++#UZ^\'[##SST/D;WG7V]>CM<78P_"N%
M9\&X]^S/GPZN,2'PZ/3O?W@84M<6B1E0+$J.8F)&G(0FC6"U0^8Y'#, ;<?>
M=+QPTW*LS<!S&M[:;.=KA"$"FOEKG NT;:Q7KK5IX#9M&LK**I2SB65%A9;2
M"#AR2V43)*4OO 6@;\MX T8@F%(C, FKKDZ(9DR7$VW"$[!8:=9(PQ@"3]%Z
M+$IE/'(!AF-3L]2CWQGJ[]2@9SVPVW)H;T1<CBD8EK9<8G=S-H3"C5O/FT3(
MK::.'+$X3]S$8PE+2"P":G'+"APW9+%P A+*(^?"YMO]([=_^&9.U:G<3+EK
M)_)51^-:AOM@V]>G<,XI)(>GE__8B0U++;#M:>*8Q JH27TW,@.1))R*)(S"
M $[AIA.23=NV-WT_F#V#:FN11"9/5+<!LW3<4/ DHN!<F-;GZ;BR>[3SX6#O
M\/3$V#_<.3I^?W2\?;JW:_QQ9ASOO=D[WCO<V9N<U-,I^+L%&TM'TW[;2USP
M/V[@V:(4.1.G\*(_,ECR7XN OQR ROY/;%'J>K9O>E;@F82'KAG:"3.9$U&/
M>''B^73#$'#&1["<=3D6&W<0H/L,?0I:G2@ILJRX1C&%V@MJN$I<I+UM1ZVG
M;#8>H\F%DD0@GH:&;9G_^_*!1\W:"F%@6J'5\,O/T:7!44X%Q:!18N#)H8UW
MH%]%=(4UN,67FR[@(U-!L#/SGX)F]<#8T<L$CVGU1A0@QG:>C\%>.!!"!KV!
M4TE!,2@R#A)Z<P+ 0R:43&%UH AO\T!0TJ15A6/%:U,,FRD$#)#EM?:!"+A#
MB_,D10%CW A:&BJG95<P@:V6#%>)4L=X@1?J4J7W<I(GS21UB=)OF^A,N8L4
MC/<444GV]_?E>/<_&I(X="Y-#>M8L3*-4?$8P$UI/L65I^W6A8*1C;RMR'*_
M$T4V) _KXO--[0C#+9?<_O,//):$CP]V^I2C?1C@JW:!-A?HXZ_X[4-Z(SA;
MWEWP[]:<G[\ASW;]KD5]U]WXUH-&JN#C7H%Q)C,%7Y8"C;(KT6%0_VM2ZC="
ML+N%QC"8<3U[BQ*(K_\[+G]_/<4P>__BLZ7R98/U"O9K0CCU220(3:@36X$;
MN1'\QYU_@HWFGD%[&D;T7)AQ*>BE*47(2YI=@SS9^'U2@ //;":,T_W6D?8>
M-2'WW2TWZ.D"JMF"_O+)M7';>I Z?KK]Q[L]X^B-L7-T>(IJ^:UJS@]/;=X"
M/M;SEP9[/=HBCO_H\B*TMGS'>_3'^EO^ V''G[6(X\&-2)X@9?;^8P9THD;&
M!=-*]$N9@XI7;;Q^3\_G-!Z8$>BV=X=$7]JJ]^?:$%SVLE:>S?V?@$"P?*MV
M2Y :3">U:O8/MJR^?5YW.6.3Y,DF=]<9_6^Z,&,Q!B6ZOO[C?GW(=C=>-\6/
M__T[G=9<'G_7[C)JU_OY*/OIW+*1*\A?MM<,9L$)TB4;KX_3ZM)X0V4(;LUD
M5F-/7?+K<)D_UEQFT2DRV'C](2]%5628QWU2TR21H0)5F+)F.:NPP?ZOH]@X
M:XZSX 1)K(W7[\MBA&LLUBQF17;T%V(Q[IK%+#I!@BW_3IS3S !&PX2$/U]S
MFA796-_]93@-67.:12=(?^/U =QBG-!$U#?&;EIASO:X7&LVJ[*]/\IO?BS2
MNC["3[['T60B)XV+<6T4X]+8:XLBCG11Q/I,K\9^^_?X8-?9 3\K.V"='O ]
MBJ&W5@P7G,MX'BB&JD04L_V/9RM#5>67L??O<5K?;,(5F<R.[V7X&P>(X:=+
M\53/>>/]N&0#JHOYU+V]C/^U?%H-RO']7\;&]=>L;-$),MQX?2S@_5>"KQG,
M:NRG'_XR#"98,Y@%)TC?1EUI!IH8?6EC5;"("M!V#Y3N38NBN5/D7,%LXS7
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M6-?/X5TQ<LV&>F%\5:%&Q$&N5'A0]=CNUN2WC/VD0YLIVFV%<4R.7?-?1'/
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M%R-@.=>H.U])_Y*X43AOZ @8T/Q\SDCQ9KPR19 GP244V*1R+0<+NFYN1)M
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M3*XW"DVL,FJC9MXL#"Z!I7K<B;@<HTVH%@593.<@P0O40'&QFL%J48ZNQV;
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M P^T1WZ&F?B-Q7Y+<[!G3\++9]5>3K5'5 NVQDE2M>$9E0^V(V,(U>2IDVW
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M@%%&*.!)E4Z,[[DTFR%W*>PXLZ78]].[])8N>B$/'\Q1M2^&L_-[*<R)+\"
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M$\:'7"KA)[5VDNF0R[PN$E/]A?ME)QT4<M.Z<.;9<^MLGPIE;#ZNU%!WK%.
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MBR]IZD2D@53$DA5/Q/_5_+KED$HP#@N5-7K>HFMV+Y7]P3$Q @&D9=D9MFG
M?*-FY%O&";HA[@%K*H4")%;,>H)N5)["%$]4#8)1J[YIKS,;,!=,DI5^U,ZA
M-<F+P:K(&NA\53302XUJAC#EB>U:P/]%\P;4>@JZ6:JT0C>;[IXX&L=9U\:C
MDS_BBVQLU<L(>:^NW&M^Z#$?0Y[4+JE9[:RBQ;26R.)5>SI5M*F_F'U(A_G]
M*YK!3X\!WRW;]O13)=4HYJZ)>WLJ\K<SP@?<^>Q@_]5L%63'./*F_8)>?)7!
MW8L'-#LY3>#J/*>R-7J*61A;<S+DV_Q6#!U)1H*YXG/?.:?=U]3H)[-;NW3A
MZ6)[E2AL/C!1> 7DX@-YE][)EW,E&P)55KHG42ZR5Q*M2TLIU&J5KH9E#$W$
M64/\RD;P@T(#CS1:D'Y[H\XHP:L;Q#<PF*\FNW?(&/B#F)"^=)8+R1KS:?;P
M8K(OXLS=FQ,0@_*=,T]6ZJ,"G^E)Y[)IH)S7R@OT< 6BQ=#L07KUVR7V5K^_
MTA(G5NV&PGQHM0?T6!79E=+_VL/:4Z[[,K\#5L;-P:WOY!$LO6I9/6T?W$@9
MS]J0!GHQ&T5'K8.N_I(NHDF2V9R9A2*X4NA6X!K*7D:P,LIZ;0.GZ\3E2%M+
MK1.>;;8)C%()3S6&R<3+$A>U[(6A)B8XX2V5,>PV?Q 5AZ:#9NLTRWDO#Z0=
M@'PR.EHQ&T1?/&P4(#6HJ<R4QG>MM-K&%ZR62&"299,P*=MF2)"L2J?>R7!H
MVXJ]2:&K8:]5DN&F@39HL2F5BKC 8#!:61B=0J.'ZF8++<8>W32Z,D>E+ZE1
M87&$H"73K9^D[.X-6 _S%Q"N$B=#!\?[-5ZR!+S?7J(E"*V6WNF2;>3L5(8L
M!AA5O+>1V%VYI#F_%+P+W7>J9^,]:.R5)I;6I&S*'AM*X9Q^_0/ ?U)5X=JQ
MK/%(ZK^R=5WO8$AU/8&=Z%",\=D2JZMU9%S+3NX*.6]B.94VUS@Q@!1SF6>O
M%U>/11VLYHDM$Y&'5&I$N>B&,4?&R1^5E+MN6\KKP:"#'C%MU!&LQ#TCNFO)
M)!.;VV+BSH66Z7B8]MPRG3ETJ)$D9>2F-&SRKTW\1[["=O\UW>;F%F<_LNLB
M2[FDFKJH55J ?/F6[+K]0S2JM82[0< GIC&9C!S@I()(32H(OVM2#UK+=.XN
M+3^3>YQ:#JG2+?U:W(L8,,>]I%V.';?$3[H!D-)_E;K;Z4;H@&A9@XI= 36B
M/QL7M<M"Z=*XI"9'$=N(=9X-S"6[T9X8I6BT6!V:2_%QUZ,*N9WJI?P&-365
ME"7=8BJ=>N+-2?JE.6S-"_J/6.U]?MLL R;=J9707B19BS+E1%(IX"I_*M=F
MS>SV)'?0SJ0"V&TB2#J4.*!<25BJ<0Z2KY=GV31NGD*9Z,BL$? *=Z)!!%8I
M$Y/#>X5]8;$+XB;Z9X92M5<IX[J%P72TN<5.TD_MP#:+4E_10)VV GY3>RIU
MM08<E4*WB&E64ZFQW4KK$G797FMRP)5$D"K;XERIFZITQ8Q>2ZVV_QAI'J69
M]@5+^7&E[EG'F1NJ]Q8JSKR ;$&1%Y YPG479=5U]VB[#& )V4CE%;Y15#O3
MD P#BADJWXWF" >=2MT1#_6$SUH3KS3KJUHUS)0Z:$O >-#PR/.+L;R %]?Y
M-9AUAG(YI%I7NL(@EVQ$36_Z1P4/E]9SNFD]JA-L ;>QSVLQ,?B6ACF(,S7'
M_NH5"/UY<+39@+_?!5H*M]Q22W0'NF&#GJR*'*>!&C?E6%KG1NLI;:25:%)L
MC!>PQ]J]Q.A(9SUWT/H*::N%3)8%WEI?Z!'BIO*93L27%="@#)>VT7C5B4/3
M8B+Q\(?=M+I$307LK 2 JL>2/MZN3"G-DZS)H.L\^_T"2A""P'Z:W#"]TCAO
M-<N[<!O[PI!F3+=&;/MMR!7LUJI=(P72B,NQ-44<_19%LBRFNC3G5)U.$%&6
M#M-ZKF$"HK9056T%B/R$7A6JBR.*8)E/772279HKLY=L&=O:^P:#;QK5]PEE
M#O+<1'GL? B:4KN1VCJQ:;>9="I6<S#G9)2M?56S)TCH.!O@/3KTCBXM]2X=
M!WC?1.]&&$N8FL4$+NFDC[L;^QQ#3N6T:](9<YE,H @;T[$5G]:)Q526,^$7
MZ":4,<@:,0ID($G7<#3&9LNVU1$8MN[Q4BCOH!Y^WSQ7YZZM[IZJD-:DUZL+
MDALNUU[Z9^?#GO8P#+*L#Z%9->H2JF<]_+)VY"JK7:ZUSJK7; 3=ILHQW4_Z
MF!>XK,3<1U>3@JKE'MT[V@/0PV"1:8:ZQ?V6VO=2E;3/ 77H,,Y[A[TYH\JT
MP: "B )1]EFD_(@AZLX-(/=>7?@ U7IAFE/=*_?> TM#NGM?%G6O:&E;U^X#
MHY!F_3:KV[/=-_?QN[VVDN,8*^>9+*_ /[=5MU;'LBWC1>,=5RZ87JK*]DZ7
MI:(:-_=ESB2?F,0-;^EC,@U 'ZJ)*_2[)LH_F]2<]]+:E76)C5^Q5XH,8R R
M+T)M_@O,)8/OO-^F\7[B(A]7[0%50@RL Z&ZGL]AZQAMGBA(E>A[( )U%VIG
MP@J\XS:93PNG=%RID]":HIJ'W>+ON@V-7?,X_7"X6<;/\8U5;R%PYV^?OG:-
MD2WCC_ZYOB4K6VH*MR,5./:_OF$.;<!7IJKG>DY2TLXN'79E0'9"8?/)EJ5F
MN=E4;,O5#(/O>7LLD'AF7N\\X/63K/ [ELS>@I.8J S_)A^LQ5#$UQ^KUS<'
M0'>_Z)W)'A+.L3(#.AT1A#7KU*.'%%W7$BM#.2=NJSJ;+,Q>;7OCN'5DW EM
M2<O6MNR<2MJC(1.<98,.S%MIS3>I?R!8[VHOH#*$)O-6)*A;:PRIY9@'L8A1
MZ@F546KW34*:LJ][JH",G4XL\J:! YJ('\F09V?85*]F4XN5+BW376]T:IK$
MRL%TT&JF]K:7BJC;G+8F8\HG3<8&^*IS:_54764JM5EM>OPRNRZ=#>@W!HL<
M7:NQRC]O-=/:LLBZ-PJE-,)E8XH1,01\!N.#STGBT6ILI7(%I"[;1?_:CI$M
M'&"[+IVO>G;WMV[YON?,;G#VM.M00E\4"C8D;WW:FRUV IKCBH\-&U=^'ZF@
MCQ,D<3S0DA/]QO(3L$-2%NB(E-PD_8:V_V]WGU0OFPQ?&8*O2ZS^FG0%].RT
MS<EQ52TF1).VB<J7RA7H>B=U[VLG F]%)0SSJM,F57[.=."Z.$O/=0*RQ#AI
M?=7-*LB4\=DL3+GA4G6^QAJA^68IF'N-0C'77IVSR5,G0+JBY^"EJE+[JK7[
MX<<,'H5#D*?DE^"@$O6SSS9K!12##*ANT)O4*E6W!*%TE7.J8)]RK9FT63GS
M^?#-5!&UWH.Y+7- @RRTDZ1AJK<]%*,4B%'2F=VM==88W(ILVOR@M&1@B#;\
MKZMA2)-)&4%35> M<01O.K=-V2I'O7RO9CV5@Z0'CK L-N$M_5EF:U+F-+[5
M#3*+F223?G.#-_JWO?8W;5.VT>,F >[-WI]_M-:A[L+4TL'L8W9%VR_]HW),
MS?1P:CU(1E<=G#3IXO6@J$0O_/D0KU'G-'IDGY$:V _XCI:!WOYH@Z328K2)
MAD+8V<;:U@(-H7Z63Z[R<B0PB2G!<'#O-GM &/^?O7=M;AO)M@7_"J/G]@T[
M E))MNL=IR)DV57E/N6VQG)WQYTO)T 2%-$F 5X E,S^]9-[[4?N!$#)=E>5
MJ6J?F+E=%DD@D<C<N1]KKR6M%?F[=$?'/&+PG7>3MU5]4S& .4654ATR3+KO
MI?GYQ8\1Z?FBLIB+AONMX)]>_#BY 5O/)EQ+4MUA9Q3$KP)G@H@G.H[K3^YJ
M-]()N/71J/_HKW6P@Z<8Y^E7W\O_7+KI.F.4#$W A?#,2,2ES2:#OJ!O>GU!
M8RF(JYK+1["(2.NXI)[N)_;>PBML6=J#$H8$0:6Y21B(PJ,: NV61_XH\WG'
MB?P?5]+]ZJ!*N@<-8+HL\I9V9]GM[H,A?7,'8L[S'S8=L7RZ2K0DV('[+#AO
M0TS]8=<KW\Z#\J$ *6U6$ (G@!(^_J*CJ(@4;2.C"T *(8]]&YHPTWOW& #$
M:/>E1>HMY,LW]8RPQU+EXI"#O_"@'!]P?&8MC66NA!F'CG.!,IUMYT=/J= P
MPS*'X9,B[19LM9G6\840;X+@3 7W3\DN[0J<;#=A[N%K$PR?IP>I 0-[]U1N
M7:,*YB;VX-T+#_-9;RT4:'NS0S4EJ.4E2%-U_NKO+YX=G7[KLY6W(D2IDA_?
M)X4L5"NF0!A,A7#']I)9"&DQ'7#Y!K -N[\>5>K\6OE84'VQ".I'$N%2<]P]
M7+/BT!B)AXK._U6R6*6>G;'(KXIV0HGX#_2>3WU[!J79WM,\D;?E[9.^'D*!
M$;&+LHP.WA)7])NPK743HU 05TJ?=(\9R' 1%1R7^N, ZI8EK]V_<K6$\[B.
M0O!AO1P=\5,S?Q$+6U,6J;XI7(88& *KEDI=\GCB9KFEZMM<'RM[OSM13Q<]
M[3Q3P!]7)/!\SO.FA X&)+T %"?54Y ES!,#Z:<VQ.[>O:?/P]YMW!C3UU.#
M!.=*9#=DPJ)]G3?!*ZNT#MUNR+#J#C8*'HH0B-$6K43.;JB9USALDMSDMBD2
M.6XE/.IQ2J0GPA]H9Y[\&SN3";M'MV>R(DC1_B5U#67#%#@3%:=VTX>"C;:#
M]X% UM9=!J-9(,025@T&^(1KK2+"IY"JM%=8%P[.X\G?W&5#@)-SCS@HAYU9
MD-VBCLM96+$KF<%IL NP\PK9)6FYG$?SEVVP)/0U">OSV1*5B'@<I&:&MP[B
MJV3-M5QDI]O!8 T5ND=?17A11%US*%F"7X6[)ASC!3,^'LA3W>FR^R5O,ER:
MX:!53$XH3B5YM.LB\R9Q6[ 7P=VGU9:Q.52S-Z)H6C$][FB]6JW%;OF'9@72
M3D/?K@"<]ZI<%+&-0'[/V6+!V\3$"]GC2.JFU+]B3G'@:JF\P[=@F26WQ<-
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MD+-]K7!_LR^LP>JVM&I:N]8TYN,G)T]%$5VP#,J-K#4O(^DVE5GYX+E\$%M
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MBXJ;8((KLYI A-TU(4;0"^NW]%BY3<XE.;.,L7(>_-6.UR-OQ0TPN7#HF<Z
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M2A3:?<*=2_=M#0LU3S@%\MFVZSOK0.2RPIPP)!"Y'4>M[-#N,KLS=>_F6-,
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M/0]P%_ZUOJY_J:_*=_?54?RDO<UU!60_4<)ONV7=6-M=7:\4(:AG+A_/K.J
M8ZK-KUF--VGZ74#A7'-IC*.9<C]11,MH**KH&&*YE/N@OKOM@F%D(%R"RD&$
MH]0D**)$*&/XKH!\]B0&))SI#>Z>9M!_0MOD16R;?.7;)@\Y3_2Y]?,]6C\/
M?5&^;R?["X>&NN1:X8$\VL<7?)P'F)=K" U:'HPP9_3$4'AHPFL7>>'9,O@J
M>+F\KIGBA<&CG,$);CSSRT#/C0H85*RE1>/K$3Y-E+E;HW\J[7R7K@CF'$59
M!UN,^VJ-L2DL1 =XX\4N-8GGU96NXO"?88[NZQ'[27TG1WPEE&$&AHF0D]55
M.'N[Y;J5I#@'FF9?R!YI5Q!7 <,U)(D)+1G*5<8FP:9FGFV<TCU;I**-7,GF
MA.T*#"?,3+JJM_,CCCWCT!6GN4%+W*S0>K^!(H,+WH1)HI7OL*^*$*JER"[\
MWQV-N)*8O)N\+7:,+V)^=$3T3E*VDH4M[=1I(ZBOSWEJLPB8XJ(!E10X%11U
MH=ODP>MMXV<60[?-W-56^J<WX,K_3!7\9EGX]RR7Q:!8)8A"JA+:XRM,0-C8
M5UH2D,U)7?JT;JRC+)%)GS)PU5H@ 4'M5 6:S@X"HN;MV_!J+OO4P:TR[&)5
M*;7<MKG5@-%==?TY'H#Q;RM4VMFU>6KU>"ALSJI=!-@:I7T8^"LC?HL\%QJ>
MQH=Z_FZ#R.^S-?IP:Q3%ZE'<(#@,+PH4!Z94>,7TR_'0<^;[R30T]/COMR!X
M@9.& VR[HC.,*SIA4=<@ON:DF+-+UG=LJ]4R%[&AFY8KJ]@:75\<&(C=J/69
M1G533&U=_F'\*.F".I#'^> H??A OS-I28^6Y$/H2++?D(ODHA^W-$9 BJ*S
M=:]JA:7L]P(JNIH38=ZLNK;_P?OP30H&O66V;TLP0B#$BCZ,J54@[&Q9S$BZ
MH]\K/R'IL*)2Q@;+'0Q3!&-HO5O0.G<[XZ:>$05)S9/N$4G MHCD2I^3XN,G
M_?!SCN]//W;O)'S7^3_)@X9/MA^IEZR1JNY,.!3]8V#6^..\Q7NHZC:BY*.G
M0R+E9C)/ E-S;0Z&AU0I.(:U?$=*S$Q_!,!SK+M9ABE<]#K$Z[3QH^02FP^R
M<FG*R-,HO,\U.%%I;8=[>>K:[R'!/#K2)!.; UUBM!&#6,^*4GP,<&PW0,RX
M2"O>4LB1+63TB"!N0Y,F5=?&AV'O&3<3,R/-$ FS7:F,?GOM?CI#!ZMZC>JP
M+E;%.[+*OK7]B,BAP;WC$VO^$)Q2ORA.;@2T]J$J]E5%,:<!^/M+>!=BCUD(
M%F.R64@UA@]@#D3OYIV7(_D>?WIP73Z,(2A:?TE6,_)26Z(F<GK=CCY>0I?9
M:Z!%E8!$#$J['T&]:/%5C+3!,I[%%BVDA8S_^S.J0PW5Z<EG6,</#XKCJ^.,
MQ%/61=I_3JL\N-DO()WZ,*-EU(J,5/"51&]3UUC":2_7I"T88GS@]R[AG;4Q
M%T+M<V$%Y.&HX.RJ!UJ_VG3;]>MWR;?9"^>,)C?ZM6N0.0DJ>$7]U#3&#SWX
MWY-@]M&C3T\PRYVT7_SRYOR^,<NZD:N]:POJ@!SQW'$J3FZ0W&A#H,8G2 S6
M.#>P6E4,#'5V7'G=U]P=1%B#+!9Y$G5E.V8<8]W+L@IVBS':DYM\]?:(^)U4
MH1M_;MWU])-YF5]5X5P)/Q(9[2RA3KH.WD)9Y1$16O+8'68CA'&K;5']*W>J
MY5CB%+VMK% J'?PDKW 4+KU6K3XY4A3:&V;9Z#I]EI3QR29G,T+'9&H80M"P
M0NCEL/BFV!0A+$15LD)?OC^[>V,4 */FG_F7\B; UA*V[1GV^6T4ER.K2*J0
M(@X!<?9O?>.Q-0=G[ANG6;#,Z>NV[WF/4*KJ?1?OIIB&LXX.71I)C[BPKH[H
M0_?GCR'S''E2X?(\/?[J8P@\)S]*M?7#V$0=\KC?5WW\S9\UJ.>$8'^:TM&-
M-J(<B/GZP!#-O9P+;W[N*-8?E%$^(U%#F"_M9:/&M8\QRN&B1^9IJT.P$HV/
MK@1H/1)&]4MG_)$SV,?118Y[TB1.4WZY?A[. 5/N9+X..Z*IP55?H[ 4XB@H
MU$3I1Z*'#)<Z0O0GH%"A+R"&&O-Y3/1[2N";77HDL;X7G1]>J3+%(B@ HO7S
M(#K2RH73BUJY&\]DR6[3S_7A=EN'6TG:A!2#*54;%7U1)-B7N(LJJ'D3YFG>
MHV-U?8],@L->&X BE311E&'2;NKM"F)7DU7YMH B!54])V16&JJJ<22L'0Y#
M.W@,HQN/-7M?4330PMNQ1:R'6N\L&YYBX\C&/8<&HT!S%-H*SEZ-N1N'8O#>
M@Z\%<VYYMNF.,W.F^<20'U"\D5-#?+7M=WMCR[&0K\.:LS"28!%AJX5WL&F+
M[_0_OJ?S9Y7OOBMQ%!_A1]^O<R+7.)+8<Z14A_OQQS$4.S[A<*QKPO\_USO+
MQ\?XZ(MN/OSLZY/C;[_^:N_')\>G>S^[];+'WYQ^\U%7O?VSQ]\\^4\?ZZ/]
MG_JK?H&5P*N!\-QA[?[7GQ[_J:=G]]W)Y!1"=GH]^^KIEX/O/MJ\HV]_/UCP
M@V(R%N>OG?GX]JXP$CO@(IPR85#Y5<&>7[W@_WTMN]VV\:\Q2?&KLL>IP!Z^
M2[7F<C[1A[U7$TAN<C))_\8#_Z=-W.GGB?NXB3OYD&TYS6=OZ8BNYD<RPMFL
M"*[5;4^]*A9#S(L^\Z?P1DZ2>MBG@@F=?#1,Z,'IPUZNM[]4']W]PMY[#9],
M1MXIM%A_GX7\GN_SZZ^.O^7CIF\(?K69H$\Q(X<]$W]^'TMXUS[>:P7_,Y?6
MR>>E]7EI?;9:O]O2>L_HX-YX&SXG& L5]]#U>/3^KL<]W(Z/'A^?WKH=[_W&
M^LAH^WZ_U2=WG-^?W^I]?*M_^+WZ[\;BOX*C):GPQV'ZYO66$NLZ"7O]C_OH
MAB&+_V_Y8?_N1-W+!?IY77Y>EX<Q49_7Y>=U>8@3-7*@?X%:\V]7C?]-.U3_
MYT/^;V_97E[D$<7JWYU^HZN]!'/Q=T?TEU_[?7WS?JCEF%G_W>_^?3(KWQQ_
MA5FP,H5Q* .SDBMXD_\K%341#:HWS$7K@="*Y.2/#,P9,Q()ZF:_>N7AOL!'
MA_8"9<9?T?2JL%]3$(@(;2 K]/L //K(<(_RF]&D4;P&BNJ*,-N!%)B(D</(
M:Y%R0>O+H6"#/I"_2!?^9UXS9P0,-V4K: "@[99-41PM:M*W!%1N!/)KEPEK
M1DFF&:)+A72L-2H,WX;^ZX-R'7 .&C<$J"QI?4)C4 9+_ _$&PA2Q"BP-@##
M67_&G"]@S7KS8DT@R\T2B'EN!R'*"33KGJVI83C\<U-OA'Q80)6L]'-%2AS!
MQL7VIR&4+QN#]TT+N@ T$(#UKA<=$?QS]^&B;(A?OF35O7FQ(%2S"+9(%['@
M\AD K?S1"B<DSH(>TU-$?M(/J ,-U_-X_U1#KXCH?O>E3%MM2F %+\*$L\OV
MC%!V-]UR[_L=0M/MC9B,'6"D915^P)!=ZH$FJN!-41/-(P";QGB2I>PKQM
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MCG ;(2R8/N4,8^&N-16E8D@G7-=D\P@.V0V.,BXFRL%!W)K8\P #3(EHUGS
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M)^O'KPY.?J&.*_WO9+U3F*D=5\/BDW+9\S B?:>TE!Y/+LNP>:CG)AN=%9H
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M1#H43W:)Z!28V>?PQ?02G. LF<O\91XOQ(/Z4?1K)C\23(#8S$.\<%TV6UJ
M\AK/@MOIQ<9ZOPD?)P)0O(7C=<XHYGU-->0%UY.?2P=S>+L,\QW<X?SL]?/+
MY,* QTA>C][>RSS$MWAWD1*R&S[/F41D&)->5)VF-K$V7>VZA@#CXV8:6[U:
MD5DCD%\Y->,P'J;_!S^N=9R!A0TPR2,2D4,L7E9PREZ@0#(?%V!FN;SN<'#^
M=SO/-K6>%K!EY, ":1B!RIEV-@,9)'F!B@^#P]U^T@FGUHF*">M!QCAG8AQN
M0$*R(Z%@E--"1-GDOO86'\@(YN3@BR8Z$_T&5[(.%N1*K:X?'940=!@/D:*B
M?3LV6!/Z-?H^8K4DI)G)2\M0CB=_@XYPLC93:6P6F<9$NC0/GG);E;*&M$E@
M+/UDC]T);A7]<I$[Q ,_UF%7SE;,(1PF=EK/PZ:@6@+3@YVUM#6@4(WL82_S
MY(=-YHGB$Q1&F&-0Q.Z-Z3Y]:I\4D20YT1S,53B;=C?M]='9F4_^UY/'$^4K
M7"A13UR3)DGNEF/&_1=:<[@!YB;X@U4DLZ#S8!YSA>,C.A2/XT.W:+Y")*HG
MQ;Q8% TB#(&AYD8A#B"ELMVS&"8);G!KGEGP+G\7QAN5H,0^?YWQ^3I%,]-:
M\'/8[=AAX2\,XFO1ZX=,F297:27<U-3)@!BGI20N?R*1Y92LK+)=3H3H\A1+
MO/_71VDM"-QI_*;QY#T.S/_UU=<G*0NF0&M&GCJ.=WXK&Z>.Y"0="4NT44X;
MYQ7-]_@SA]FP2]ECNG7IOMS_[B,$P98I&-M_]V$5G]<5@U;5#:!',(F(X*W,
MMDP%AU7N?8338+T@0L?V7C)W&<NJ2*)2TUVNV)=-+MBE?/Y.\BF$$J#39EUN
MR0I.@TD4K"LDQ=CS"AOKB*0&UHA0RF!ZMOE*Q09G5,'/K_-RI<>!;Q#BG[6J
M/ 9ZSB="]>D+'QMR4,+Z6Y5A P'G$671'K&1?%$M5JI*H1!/FA<:-=>K2;L'
MGBY/95NX)U(T:;C>EUF2UP777; #Y8(795&1%H LN_ X8U-V/TH)+U)<XK@W
MF?6/:]V&^Q;B\&2,G:#S=+7%-!=)Y#9L21%'&S4?+^"4R8T.O+34CE1R)?!D
M0BJ3N&TXU;?!D1%X=A.CR\\E9RLY?_.YY/S#:,1N4A4^[Y@;H(X5 +G\C$B-
MO#\8)RRQ; !N06 \%B%Y3V"_!VMN:38>LSE.0?W]D:[X&+8)\(<>6%"TX?1'
M,2JXQ]2?S7F *Q(M(O>EK.?L,=F1SY R.@V0I,03QY$(:P$,BF;<N<DK>E?^
MYXN"1K6NY\2ON51V-@D*[:I.+E7 3%J*M.2$*<>Z[[*E$B0:; 1Q7JP*ID9M
MK'_4U[8M6,OV&1]G1B3A<$P0OUW$//6^#FPY#9&K65*%]60:!#:(K8L&8O($
M+?'SE=BX?!<O0V\H7H#H,[LE(\'"-LF4C )"*[&"0UC!,NG><"HR*5]E12[4
M35E96[0K&&N;;^_![\7YUR^E.S0O8MD%14ST@!JBS<(WP%6N6Y0#R]X[1V%0
M_!;%^M=H4Q])H5%3G:TW[D]QEZ*& _E1"NE5X"7-Q/^A7OUSB E?HAUS%1=C
M#[GWSRUM]7SE>%:MU=-![*G 3(IY8;$)@S4O @@ < .14P=(TI])^2$I&J>9
M41^2&V+!FA^X'TP9L74R"1K R(94:;"5IX8K<)3Z $<&/AN\M+!^YGFGB0LU
MJVPCD80IN--(351IK5+I.VJ2+@[INP#9N%HE][".$357YF!FN_! "\DCP%DG
M/0SF*9Q1&U8M\GL>_K>MU+>^*CJ[&XE4LI')+87GZK8M"7TU](Z#+>6>ERLF
M()?,I: $' X""5O3:+0).E9QN*+E?'*.-CGV_SG2O)90X;8'JMCO$_@Y7SUF
M-_R"<?-_+PS-F9W.*]32?"I>HA?*O41M:^F'4:Q6;-=DE#G/,@Y(Z8X1@L+M
M!NEONO6DR3<ATK95_^K-.3R*R5MD7 %:T%@-_WQ\<C3/=W+L'P?#.)823J]"
M1C,)KT3.5.+NL(4-8Y93!DK3QMBH;42(J;.5["LZXDRN6U'K_*0P)I2A[(&A
M$QN9V4%I5[%4I718BDQRT@[A!X%?(WL4P3UY,'%10YRI1)$G)?^.IJ9-';8V
MC2:A^X2=%#PGI%ZE,ABOF3RK,57!3Q D1=@>%#"'BT3I>H')*&^!M*K"Q6NE
M3>(^)=DO*9L L0\.W[ CX&FWVW;#,;S+/XU4W/2(-&ACXD<6QK&EBX6.0%8^
M"O/6DF3(=J5Y\7:[)G1&A_U6MDAWZ?J*S0K)\B7.=!+[78JH*#PVSA#4JH9(
MY2JN5<G:BYA5W&80?%Q#/;.*U43FQMUETAE+^60ESN&ZF7,U+"NLU&"#;[#:
M@!S*>4=X.LB-B6X\;9FW57T3IN6J,$^VJ5>4*[?$4B;9/74TI3KA*7=B8U];
M#,M-HR$78^D-=T>[ (>H$,Q],"IW!,I$3VJ= QS:L7%%;V%Y;:^'=[*#,D5N
MGO;>TE+<59)_J5UHE]+;N0]G<YAD5[<\M'O(UTG5*9Q?#FHE2C^?E#YV<M1O
MJ'7._<!=AGH*^CGH,:$,$N&RX8?"1H H8Y67:Y]Q\^14]/8'J&[WW>$-XQ8^
MBE*%/5LDZIL7)DAF %BX'*3:DFOQ1/N9%!-/7NB6M5[@?KN6_J19S+]-EDLG
M8]"'YX:SFMS1>;[.K[0%O'BGU%GP0%FNL=R8J^IN,_Y<EW3\)(/V^>P?@U<1
MWB//^A!ND'ZHF( LN025+(_>EK.WTWSV%O-.W![^.F?_?1E_RB]F@4OKVYXI
MB\C8I5KV;TCR5]PU?W<EX>BH[SUL(^-;<)V<<?$A8Q\E+S/)-??F0-'CC.6N
MU&/FI=IQY9O.N4W92)3*GS Z.6>V"(X>Y">4HO./G&'E-'/&:F%\25^#/EU\
MNYD"HN-P"(9M=)]40873I6FD;*PJW?3MRO!&;NDD7:R 6=#@L2OVKV[R4GG/
M",QC,+TWZ'\K.\/I8F7GNM-BJUU8-P=SBMU.-A;LSXCU218YMB"78IEZKTNK
M5-3/2.3YGW&-_;,F+#?9Y2& :;M5,)*DG*0[76&/Y(*11[E:](MV(^#=8._5
MDFK%.V(<;^T"[V.E#9JJW:BK73_;I=YBK/\.]@0-D?N=$VOUQCV%F;B(NG26
MBIET2NJEQG9J@"N@08ZV5_%CA>\#! J94,GO>7!5I*#L!.LR;.1FNA#4]H-I
MZJ07)&)*;6"2R''B.KQ<M!BA (CX_27*Q-%#Y@I8F,EEN>&YB7.B'1!Q1@"?
MX"$Q7H4I05UK4*/8"SY:.34MBE]FZ08F<W0^Z9O6I!O&4G'R<!-^N(T"HF,W
M/Y[\7?PE/MY$I4@J[;HHL!P.RQ2.>[+T5L[.SP[ .0VC\'PRJYA_F8_8:F@*
M(E]E/-=204\0##ZT1A^7I'4IXUA6Y7J[MA3GBLB[$&I&$.W+7UY'#7LDM&)N
M#4P,NK84IJC)DLS=:%'D'3KI? O*U$C$YZK6(M?5- [S,Q!7(A7+6O\5EX'#
MC*PI<W/5!-=VHE2ZJ-V4LX3G@H1PJ">;O%5?^6/X.,>R#Z(5B9*_);0!@:^C
M2:"6EXTWQY0[K#JQE:X3]&'FN'$Q 2E9R:@"WCQ8C5TL$HZ%BLI91H9LPWQ&
MC$>*Z;"N]:O"H"CH+R=;5.(0^5S1MXK^MY\K^C_ *?\ 5@6W#GUM-@9]R,OJ
M22VV8<(*4Y)/NBK(>]\L+5=)-BH<3*CGS/.#:=2X"Q#TEVU5"/\CDHP5#LU+
M/B(OM[3_:/Z($&)>MI1!(+!KK"<*%S2:CG,V9M7<L,%76T6QA4."TVVD%5UV
M6\T,,EJ<K%2C(H?A'EM6YJTWP=;C!@4.?7$%Z6+X(JPKYT%-&%8(D/"9"-M3
M9N-X\ORZ0!E!.7GI*H2*G1>$B)BD U/V$,KB5E1N#/]<4>EN&GDGYU3CKQNV
MHV6EU)8*<*#8<U.P6QS^"ST<H#"2%C;!M7E$UJK4EC!F.[><&XTU871!G_S$
M4PR3CNIV=>7Z$-'=3"G3AA$.>Z!8?77(;MRG!Y5)#V3ZCIE 9(3>DW6R\U(0
MQGP24J:WZ7JN V=<D[;.'BGG2+K7W5?I =0[T%.Y[R \=0Z"EN+]GA[KU_)4
M?-Q6CTJ78AWOSY9?:262JI"ZW=@]4((< MX,7P^Q@;5">8K>(S<EY:"3'#!J
M28N<?OGEUVXU'Z<?Q&@B&!GID.<K<, XS=N2)8W#+J*D4)BL;.*:_\LK2N&W
MQ;ML O%H>J7A4HXDM0?&,.(#;>^_5OHJ60SI3"BJ@'D*U2\*]YN Q++N=AOZ
M,?V!B+,IJ&B8@Q5_W/(@E:DKH]"28E06&Q:[%^;MBD*P'5L,CHNM6@$4Q!3]
M-QP$O>O-%>]->)L4/Z*LJ_.7/@S%>\![S+GH44^ \ZAJQ("K^"4I[Z[@S!_8
M\AX/B\RQ=XW21Y^4X?G-B/VP49X1)JVCJKN9%.D)%7RL<CZ\P@H/[\87V&^]
M3@U\&(KR'%*-?'E(S6]?NJ1Z<J&)RCV75'Q"<BP,G_+BV<7=%Y=LNM"5D/M@
M7T^3*,0<SAQ8A,OF,&PX/4(/PZ=EM12. ]+F'GY7D8<'ML+?@\K!4S@ZL&>U
MU4P/8-+)>49\7?0>W?N)2($^0L[ 462:[?O*O$O018T'^;V%N]#!(FY<^&+Q
M-F;N@Q]1"18BN(DWZ34Y.449ITQA&^.G_<10,%4(P0P+1A7Z'K\"^T9T*T!I
M;EU^PFE7J?^OLA4SGH+69<OW3\-@0FW'Z(O1;QA6%S5Z$Y7M;DVGC+HB87AU
M*R0QVG^6,DJ S@7%^PC-\V4(",\,$*%:-M\:FT#OBHS1XHR:?W ^54?;W5U\
ME;RJ'F90"G<$U%68VS8F=>NV2 [O+R2QT13DY@.>UV+O-U=,Z6R$'+'@\B/A
M[][E+%*EDVX]LYI@HB02SMH1RYF\;DIQ3YX)PV9XC=]\^>?@VB^"2S5J<P<_
M5- H/7%R^S"F*0(Q[F)K"@0?K3KVNN8[10E)2XXQ;\'VD97$#,D6^S>&)FV1
M<4P+$)C=-B3#B/.Y<?Z26N(EW+88 76&!(T29K'?A9SDA-,CX79@4!A,Z62'
MU!$<F0!]6@:C$<1_710<#X5WBC>"%'[_@>_;P7&;(T(KFP[LY& .3O-U"?\?
M-L"]2T;0];F,/>&YPT@YYJH>L5P$%VC-;M.K&PUMC&AS$>%HYC%Y/;8LZ#A$
MGF:A,!V8@)&I>!7+O)/76_JBQ$HXYDZ?9!$W[](<:2=(XLB,S#)L!G,;B]TF
MDXLNZI>72:%Y(BP(,(#R,[0'<UD%;^/'R!@65B]U6:17X*OV^<M6I<9)^RMG
M_*9#B#(KVSX+4F9*&M6<@<.E,/93NA;11*]2IR0U,>%!A4)[SI'^<'U&(ZK;
M-ZELMSQ0%-W Z?U#;/9VDL__N665BMB\XJJ3@$78L>Q+R.IY'D^>KPJ'C0JO
MIW_A=4$+KFS72<YC6L0$FBFAC+"%_&5+(60*\GCVZB\I/N358D'?D7&^J'"$
MATGZB:N7^@&%^OXZKU[\E"1 :&[#O!:K!6%9S%GK'\Y['W#L0.<IX76&%^A)
MCHQ./%?\[D 0P*5PV2G8AT&SQ=#KV9>]F"PI>OUY"2\"QXH"BOA;5H=6U\V!
MH=)31QIM]!!;[6XI?#Q0![#/<?YPB#1*C)$8N_MVP A_RS5S(WBUB41'U-OI
MZ%9WU*<!S(XF>5VD9HU(FGME:F*WN?2=C][U&.N<3G>*3:R\Y)N_R/XR/R12
M4LG:P2).&V>X;*:>J+A;XFIQCP.NV4J%H:4SBAJ3AU^\F])L6!(/H835QH.[
M0SELX=UY0!B.NI&4%<%XP86AVCF>H37R#3&%/;!P<^H9'(#A6-C-#S4B!0>L
MK^D?>ARP7-U+_?A24O"%\I880E I!@'E"X_),BB&Z1MC2J..F;(#>FNPV&@1
M>*^E?Z;L\V#N2'3LRVM$MTFRZRZEWG=0#)[BEJ];]JD_10Y#,,@?ZH#^QU9+
M'YU\KI;^D, -PV[^:_ 1E4GC)'8G:=[7X/VKR6N$?O"%$U_"_3WZ)AS_%RM.
M4 M(T=%@D^IL.">:*<61# PR1E[GB)[]]Z7@@R3LQ%=9D*@(7YX)$"(X(7RH
M$+-S$C"P2YA)$8[QT-+'>E,'^]!,JKQI$(*Z,;4"Y! 2%<W&FIR&<A+A0M2=
M0^BMHWIQM*EG="!PYU+.OKPT@M#SA)7$0]3S+(0MN7'Y4YR>#(*^!0I3-P4\
MLW /\E8=5P$^"7Q,[,RF+D4T+E^Q?PPB4X3NX358"FM1N+YH5B^5B91>)I86
MH'"^C,W0JW#"F!>U8)3:\>1%)Y7>%7'$J H!?=\O'TT/B$?((N$F6;#O]>)7
MPGM%?K,1EKNAQ,OX\95:".'H4DYMZ_>:BE < 8C!:Z>4M.R]8M%PC&-Y#9D@
MX1>2,X'?XD4Z?I"?L2X,SH8S80# ,>VVT<7YR[/^_@F+EO%RT+!I&:RW@&1&
M/B$\)GK4*G&'$%RLB.ZX-]\9(^TX2R*/EKP.N-[AC>'E"CN+M>X/=Y.0_Q$<
MJ=X(8UU.VW:5WY#^8C!2(?I06D X$,%D$6=+DRM'/?/N,<W4*<.'!$UH)$O<
M?ZS=5ABN%B9=2^57L6JWAQ0F\\QZ"9.,XAG=[?V\1)J8QX_NA1.>UG?I<1[]
MV:>LF:_, '86?3[=SJF7^%Q(Y>W-G)Y*.]P\4WW-7E)#<->@K@MK,MPN4;:,
MH0S;%UX3<2#+?,YUQO?K\[L7+^&G6JCZ;D(<D_+C*&8B>* 2OK_XB?\C!/99
MO\'&&N!E>2-'8#11?23%K D&AWJUK9L?LCYD/H/''*/G?G3IP8/#M$I&B:HV
MZX47&Y:G;GMMESX>B<)7UHD8_'8B0  S1ZN*ML0%-ML]-&(0&B)EC94:.^5'
MD'(VQLT!./*Z$M A_IOES&W,\7AL N!BI;CMD[#,"SNNF-514\18X#;-PKW1
MX@DLM5&/9: T6V@,!W.-26?<PL'E^;F$';+WG&WEGX<+EBWY2 1;E:8M\21<
MJB+FSX,[!ZA >.SIMB$25I3^6G)8R*.8FI(C<;OHV!BV)GPD)+6AP%-]I3@Z
MM>=36S+%OD*%4OP1I]S9.[G#3MJ2XJ-4B>_#WN7U "$E6PZUB2K1O(OB.FOQ
MXHCVTBZZ;!B9HDV\W-?34X#RF:[J=NCB@9F].\ 79V Y_Z2PBR,7XS<TI3RD
M4317T:#W$1"!>J*-XH7@"U/JFW!5^V&_[B%X1"DA6:)!=BZYZBV/@,@/)45N
MU:W2*$GV&1>M&219R%XE@]/[(OK2S]4&LY.K C=\3PW?SI[]/>:">:)(1HFY
M'G!LW%HL YT)GS12+:2J&"D+TK21#\$# WV$,E-J&>ZN5->^&VKM&04X_(4>
M@X<?_<&(A(B?1G$\06YR>9T=DW <\V% AP)]>Y\NW^CD\FUS%@''46ZQ2QS3
MB"M@G]'M_;%N0QB[78K7P*A96EE88\^1+7L1I0:"1_VL(!J<"(0\?_',=4J$
MV#KS)W;PQ>K9-B:;TBYA\6QPEV<EXQCT?09O9JPQ,C=0;J* H/2C&KY2^;Z;
MB/9H[#88Z[0<>PVQUUEQ Q= TYXS=>H^/^A^'%"O(IW,XQ-F.L_$V T2-@B6
M7",X@K=SVTE'G(%\37-X%N?P&<WAWZ.=$'.>9'QH-^'O2=:'5V3OPY@#XJ'U
M!%-RRCX<A75U9( :#"6\-5VD/_YX*>.S=L2'LAB2YW!;G("-$:A-MQ4&O.)=
M^,E&.V"I$0_>CEF]NV!RPBKO1L0['L&P$?IPA?@1_LH%/PB4<]4\/65R[E85
M7\.$=]65+)J&5%J?[IAE2<V1'T!VYZ EOD?+&X(M*OFN"LDJ1;:_:K73Y ZX
M 3O+%I2-F[E(8LS#(Q@2B8O(3.-O:-D9Q>:E!#D8$WNA^G-_'S<ZTW^]&\D8
MJ[V>@[RW+C,.PK3K'=SVF=63T/+A5Y3C163ZX_""O]'LO5 B)5\@47K0@B4K
M3LGS1W>"?ZOC>XF"$4R9]_Z]?E:/?\BQEF3_KK06L!W&K,*E-#MU>F16B@ B
M1WIL-BFB646^/&@!AJ?.YQ$\A-7()>)X])/\-/&5$2: N>>Y9D\9JU;J[_2F
M$MR#E?=!A$&@A5;BDWI>4&___7*OJ1MW\AIO[%.SDYQI2PM,:SZ^.2D1X)QF
MW^<;O"R?44Z^*<:_I:?E]=D>:S/Z&RZBZ0>3=M>2J)N&Z=3/3 YBP4[V.IR+
MK(DHV4JVPQZRX%QR$5Y@?RFV:<^634V T+ T*TX+:$(W\U$"2LE"RF743"TM
MN04#'8XGKVAA[YFG5E%+D=G+/688W1.O!AH>] $9D_#W+_G?#QD;K457YN#3
MAYO6U593X<&@4U?%K-]B.6!V>A_P.@U<\RI#Q"ZC@EG8Y<JGQBR9G@)>51Q.
M\B-E,TG6P&@-UG^#/5A* OG0KIW5C1J-@0X=W4H5F>1% NLE61*SNF%-M>'X
MC'+9TFH6*_/6K'0\=,KZ@\:L)".G\W+6U<IK/_ZLPY_I/,+)2+P+/@O$O=Z[
MYO!L>C$L,EY<I%?"M8"<E2%6E*"C1<5+R4L9A%$]"7Z*1U(-!LHK*DP1I<-P
M;K]W].>0$OTMP,]0MA)1R10T-<@1'YW^>?+ #@!'YNZ1BK0.RI649/*AYL*C
MA^#21S GH*!OOO[SYS;D6%@__5Q8_V':6_N/1NP6Z*'G#:EF&4+2""810TQ.
M^6>>=G)LCYP5795/_JH]<!<7K]3SHZ6_(?8%*I4_.?Z2ENOC8SD@\"4XDI'(
M<. 0<A560*88<J/PE=[FXZ?JC]6?6:K ,APOFRVJ*O5]QLFJKJ[ 7)@>93'[
MUCO3S! YOFXR2&1PK$6V_YBV^^<0,3/&7\66Z7QB4"-$GIK"2H7$VP'#>_?1
M,Y2)9=:,CDLU,\TN\9J8&WX%I"Q5:]+3@9NQ.:>,DRM\)3:0F$4\OANH;))/
MO!Q6G- ,[^^QF.);&A7Z&%R;_81%7F#EDL>,63KI/!4'/CZ;.'X XKT%V]4R
M5U;A\*@4*(PN62I<YD1DE,C@&LBZIT4+AC'4K*BX#5I;9J*7WICPYBEAIE1[
MO1-==#BY56!R-B-&LO 9<0-_B(-E30D]*#&=QMSZD>R5,-*5I!.2O5+T(L31
MLH/!8)$=X=O3? $5FVD5*C9M*4!//@BSL8#X=A-"_T-KC[@CNM(BW&ORAS]Q
M>$6Z-YNF7$DY'QAM:4&@C 32*@3TGY&!Z82GCO\,W^N6$J6X^S_>^F5\2?QX
M WF8EY4+8[0G,];>/;5I(Q<U55.*6H[#L:Z(4TNUA\>DW/!:T!]C Z,X'QX]
ML3E6<PJJ)C\6TX:E)'U:--))J +$8,:L/9J.C/>8M#=\OH]^M9'NM@6_!S"G
MHY;*M\@,PZ3\TB,3Z@^+#YS01\>/OOYU)A1S![E-ELK8@JG?)9<Q \CR:>X'
M<T2GMS GY[I\'WM%SA$N1 -DLQ9%#>YNQ[$O/E4P?(OR:MM8QDS*S;NHWMV'
M&MS6P4<&R\ZVS*YQ4[K;<YY.VF-,9D%.0U*9Z^"F:'V]*J["XD+_DG47F,J!
M#)&Q#?RDQ)1/=C><"':3)NJ<7)?NUN-MNI'#VO)B=H;%\*Q+*T- ;_$ZY!8B
M\4HJ"FEI?!(F$S2#Y<0I)ZG@C#$_BO/LMS<SC#:9 0!.8H7146NX7ZA0%56&
M>5"OT Q"UD7+V9P>_D7.GM84L(W[@.ZA]3?BD=AVJ[I^JWI?W!%V'\ZHQT].
MGDZ>$53C0J :0E+\28\IK /)R>T=H>HQFHL"O8&P9)X3 89 =ZUI?\A^R,%,
M@B>A:"0G_HUB RH,:A#*M/4</'-4Z1",#>LM<!I&-&E?6RL*?6!"S&>I?K'I
M,K^^/(MEKA>5H*5S5V*^#?P2=N>5[WC 'E4!J?Y<:(PSNIT4_*30Q-BBR[<'
M7JQI:%%+S\(+UD5FEB=ZC@FT@7PSUJH@]G=6@%;B[W3\M-FVS50-H'+3X>J7
MQ::+PHUR#\GQ:5%G1-Y>DKY4\T9Q)?+6K34# B#3GJ8/LH.0K1VY=(_=/T8=
M(:ZL^YV'+U(,_"-Y '$<$NX4%2: Y:"WMLQ#0-#=MO+3%44E^++=4(\+K;_5
M5M%T,R=(H90 ]!0>A8X01]8  '0(:AA,ATT5%GOXCD#<3:L"]9MM*^V9K#^S
MIGI0HHU+7_Z_VY)5?(&M)N =',KB!HA1U[GE6OE#1),B/M][-?=7[BY9MR/J
ME84UCHZ]<W]^9_BE&Y2K (\=87GZBGS/>?]QF%\UO3K@<\E^>:\M_,>$@9T1
MN_CK8KVM)!5.Q+&?.I+Z49S.57X3V:8R:BLUSE'2_;H"3D?Y;''F4.L<HG7S
MFBBRWG$HS.K<^0[_VP)9V1E?AI#A9DG60W)&5##?1.B8UKI<ZT<6*=9I,[KI
M!&C)8*"-4S;V7<H2+^B92OQO=+32+D&"!#6!0A@SC%*W;B0YH"$/N>8H(E-#
M($KI(]H CM=XGT3 .&O^F3L^/2^OY^.EB66X96Q\2>47X_@W2A*,Q)N+,-#5
M>3RYO%5S8#AJ,.4GDP]^<5$90I<D>?%E6PM[O!!R\37XY%I0)_K[J0S\=K(+
MY]9#4U8@#V2->=:R'?O) -BM$5,<66/MB'(Z2=3BBFC1W^&BE) $H#X5YB#?
M4D"<MQV'!/ETVPIY&VIIBZZ0;*ELH+ &QG^4PLD$60ZDP9#4Z"/[DB/E2SDW
M"V[-RI2 8,_BNKRJ&SINR=0DYY2XGR+E%"9C6<%1]$UQLR41;L:<^'B\->B"
MQL%2MLQ%]($MT??E3.D::,V%6?Q;M<A+D#H;__&GQ1J_T=X,/6;>-&0O'7S?
MH&QOSAV"3==L87T2R)F3(3/!1<NYRQ6V_/ =[F!?T\,BDOC+]]9%"*SG+"T9
MY\N %'\E\E19K4SO'T%BW&8F<89BEE*&6.V[OBWTH70Q=-=\@"+9%^J@XU-E
MOYI-GKQ[>2S/?<UR-T*H@0-W>*Q_AR[*:4.7J$BB/.EXX$:3*>=M=.+OB.@R
M[J7LI*@73!5V))%4\N/2N<H][\&5,!?7\E+3G73T25MFN);. 0_<"%"3(7'O
M*,;;FU0$,MK\)7R^8;E%04;E2FLL\)#5Q=VM0NE)L[Y8,.L6=ZAN5VA&D: C
M*JT%J[RIPV.S-(%;S;A39:29B14$46C)\=L%_W>PA<36U9ET3OH"O=:7/ZG\
MWZUE94_G:!9?@)4V&, CNN,ADMR06@>=%PD \G.-WVK\CS[7^'\8U ?#[D)U
MD]IF@1!BUH@DGR'=QAOTF$-3DF!!E S5CZBV_?=+6Z09_A6M![E=X3#OBO,P
M(L)LH5DU#\:P_+];^/3&U$AM;7P/27.A^_BIT=HTVIV\BRFOEB7>C.D\AC9C
M[H?9)1^MLVUN"SEHJ@53VX+B._8,2##AXB&>W((2'-*_*&$7U6O(^39#?PW@
M$-B-Z+]=[Y]C4R*KJJ<&$QC*<6(^EIT]"='8/7&#+FC,,XY$S]TDDPU][1HE
M/W&P_?(6;(G3^)1(1*+8$"UO0@!%AXZP-U,7*Q7.ITG9 >=R6 BBSL53L& \
MNU]KZG%=O'@1FYM4&DJKF:C%Q^XN1U W]$,V;O*YS23X:CB^.$K5AGWVM5-$
M>M2:]\H7R27M:I0$N-I24,%,SW2TN0<;L,:'!TQ[C+>JCRMS2'VHQ9%.5"&C
M!S0TS.&.CTK'P+=M-OC1S3(<XC9?(5A/9(UCH<;JCQ8-X>++\ ^45V?4/$D
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M:UI8\DYKF>$>/!KYY9NF/(ICBF5>(Z+*/3=H]+YZN746/9&RKW4US_MR']E
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MFT6I<,H+QNG25,K1AJNP[A"3E8I$$18F#B0EA$@)#;PT8B0PL%F)S0E<:/.
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M\I>>AKQ0L@*B*P5)]U&\S-$9^B'C J#[S;<;K\?4,]F4 FW.PGG)VM]E-[_
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ML)Q6@"*3"U)D\:E!-U^BW*=(3(V1_=#DL_.\WH93:I[&?[V_J,#\Y,3?"K^
M1TKPQ)<M.UZYV.+TQR,0P#?X4$13"+:]"F1YB;NO@DM/Q!+-QB_^1.-]1#+I
M[V79B_V8O8WS1R0W0EG]/VE:Z"75;X>D0ME98.H'P/,AU;LA(V-#65:-F=TJ
M(\XOV>#(DQVMZVUOQ7Y0@!E^U>\?\U[=79QDQ8"^1M^A\"SG(][GP0Z3'R5>
ML-0]7_#F28!L3F0+(M?9B+SXS<N.3 F67-4GA<9AIIL\.*FL\Y)L*2DU365W
M"8.]XX=RFW?CJ5#Q.--[&1O*!678/\Z,A85;1V*"R;"SVN#02^:D:EP"+6]N
MXF%'$[L,A;\"S;<H,69.*K7*YE7=S<7T;M[S=FFHD7+H0_C@3 ,GLQCJ'/WK
M+3SI34[DKM1D?EZ8T@.D\?T$97Q^P/A'?1 >QJD6WM^K$;I7//"C?E8#"GBC
MZ2M#!1>TRF;A.S"(J1$D5X'+S#2)X:,LW=4*XF.:"3$@L_=9V0I1Z.-H85VO
M:6H-H76\B.8!W8].%B(U=K]/FDH:D<DNU#24)&;BJ!2C3_3<&'_2*!?CB);9
MALUK(?#<5[ ;H3DG9ZHB*L:N7092=:0>44/JC_K8-YY,CX9U-#LL.!F74[_<
M^4TK*1W2P9ULPZ8?JLN8_#9-,>EC/8A-]M-%U2TH0MG%TS(KL>)5F?F#%\6/
MI@Q,LLMWNP-?$P&B%RBSI^/"5'J/@<ZSD1GOUH$5VG+MGBP42^?OV[<0C/WI
M[8D>*JJOJZ)HY#AQS47U+D$UZR01WN>LB^+D?<ZS8U7G% [9W;-<2 (US4%W
M9O6>1W1?(SRCDB=]H^VL%3K_R42GPCU<R:^XR"7E<G=4'-WI4O5'!3QZ)T3.
MJM^])^1<2HGMEVU7]0NE>L""RR@;,Y5"K4.+#IEPURK!1X,E@/@E\4&6\=_B
M7$7/O5[DL0<>$M+"&*FP5MYD]1U]TI\DVU-7E[((&#G4]_'+T R=G<10-G'Y
M<#6B(<V"O\9_+]J5^5_A8R7"?QNF>%)2J.<=/DJUQ'O&OWWS>G.5+5,OM);S
MI!O=!4<(2.6RC!"Q"@*D%B,/?,K"!8,:U91^-#029XBUXK(A'ORTQ#)W(D[P
MT9Q+O&J"GLV"SF5R2/D#I><473NG.UUP!7(3O[!<LCO?04UAJN[[S+$.L;GC
M*]A5J<_#B6<]RHM;B7'L)DQC/!XWI19[+'=?D8B7_(.H\.,$Q?$OS]K.276Q
MD!>FF5HIMTQF 16P79%LLGL5KI2IC/B>X8%E9B4,FM_DG22T.LM3;:-UCU^8
MLY?4,W&%S8E28P0A6]>SBKX%[1,I-",<>39$MO"#4I\%H4V$FT.KEXW3;.;G
MCQYGEZ3E1:-=&08&LGYLO49=S*K_Z9J XL'%>)H)P140M001)7-[BZ4^R+(F
M,VA@H7IG<)GI6@UAOT26BR(\;)&SKHH.-JF.YAN&LA+X6W3= ]24*5B5N7+%
M=RK(QMD>%FH!FBC$R>BXUK$0[Y[>@)7GAL7=OQ[/GO,346HD+MPG6:KR[W_U
MGR=#>K_LZ/31?H+1/$TC#/_S'J@)8J(<^SQ1*I&%B'];L=XF+(/DKRK-D="1
M>LXPP!WE2[ :+LN:3]72)MJE<UMJ:!)2?*8.(E>1_LN\@JPC7S1UR_1QJ>6&
MB63CH/R:HJ&IXT S';F74JEA!<LHUTY8$XE*N&G?M=L-@ ;>#:  (\%@M#?;
M0CT^'27Q:'G -#Z"+<+ %9,[>!$O3) ;#0Y7P_/6(01=AC[.\/'LOU52.&7O
M,/,I<3<Y1MP0H/I\Y."%I&9$VYM$CER&)S%ZJV)1$AAEAZT+(T6+<L9K,S0$
MT+L,!)Z@)YQ0&MQEP)[W2:H:-_C^(U,T$5U#16.?V9#WWY]:N4/3<R_>_!<O
MI]S 4"JQF1H9#ED@/0$><2I\2^QL6@@VO+0.^4V!J$M!ERAB->'CME>KG+N4
MI"1@NC Z(I=I*@7XTU^4G9:P-_P:3B01JVF;'Q5T&%0F<"Z/ET LE-XQ'*I-
M(5X3U81J70\VS@.RP:_I1/LQG6C)J;IK@ZP*Q#4+84Z#'O;KO3I V]3)/0![
MHDAL-S+[2K&\ 6?#7B] M>F9ND^$Z#G^YU32 ;%@B(5O#XB%_Y@N/ S0Q]>=
MYI/+D XI) C:YH@.@_PT-V'"=)0_!#.5BO>*5CYA&3+1%;@';N,U,^6<$#FF
M/_4^:NDF<+IFTC2'\N;ER6ER_/$OERYD#T \AC[%^REN=YK"5""+#\DZ)?)@
M++Q&/[#\1J^*N.<M>7%:PX+:'PGXC:(RB7PQ[O'P#5T73V)I8/")DZ;LYFT,
M%7L\',:("]",W_$E RLJY()UY%_6U3*D?J*K4*[%QUN5/9GG3;>5_$AR]C87
M0.N;US%ZU6(X(. CH-'<V61YK_<:V=!\<?31=80>F$=.2,IMSQZ>],@?PBY&
MP^R]RN!R!Z_*84WC*5?K5OBF##Z1]0\C-4$J(BDQP:8;%R=CD 3R+A+P@5C?
MIHOL687.<9/D>NK%# )K+%15GH5: LZ\B;KW&370%2VB][KKJ]X^]T $:;P>
MK-4%@H]VK64^Z:T>W.>QX'$:UY<=G9%$%Y9S69(/[GF!AT2\Q0Q1(.FZ:*\8
MWU'J-_.V1^9T3B+S\=)0++%FQ+QO8MFV@#F$U=2>_/0*<*:&D#LV!RT)L/2;
MEO1AI?Q+;WY?-B-=\2_(SE7S&VS/'S5%Z=Q_2/%X\SI)\_<^G&/8[\E;7]^@
MF(/?\$J3#4M(S&Z)[X[ ;3/CQ.,^DA3S]?SNGXQ-KCL"!"%4< FQT)*/MEJD
MLVA?BTDJ)6(Z)N=(GC,3HWX@OM\E2JWAZHY]O!>5) *1ONC:<GX14I^:J_\Y
M9P_3A/(,T96YI,WZHJK;OHW_$SAAX>5TJ#\X[UJ:MDN).U1!BO&%]B^ /;++
M7!Y1<$03# 4WM2V&^>F3TY/""'I,N,D:?=N&[XC;IW0E$Q%+ LVU0G.'H@=W
M#4%M7DN*<+38="E=F&'LC'4R:^#ENY>;$:5QP>E!Z'M38H#@HV+3C4G0BBRI
M91=G<.^PJ-R]IR=&D:BL^/; D9122QK2_GM,D?(J_0J"6,XUW(PB=OQ=1VEA
ML"3O0\#;Z51H48&R4@*BW'75?Y! 0O_J:T*/KUM=E+RQ BG>)<1=ECF_MJ6$
MQXW7M&!<\9_WY>B]UII\C]>2Z98R&+W8#Z_?, H)BI[0D*NBOS9W4S*4Q0)?
MC<.."P+%QP<9OF#@_^1/T.LCC))H;!P@DE@UR;#9XPG@ 41,X:JLCR%/JV4&
MGF8XP68E-CG]RI1I2TU#&::?,&^[5(XL,C<O52D5=[Z.#Y@)&)'AOL0C9N-P
M73^53RTZ.4KG%&K".8W7V[=OBMGKT_C_)G!#\8E^>GMRI!=*&*$)69 \%]2'
M&WY;]A!O$9X\G466=,,CBP#NB%.^,(2LUKQHAXG=C!?(5R.OP2&>[G.;PA4@
M/.X.'U=\5$1C:8=8X05VM*UTV95;0NE?(F6/:7:U><)C2LG>=H$1"HH4M%R3
MT)=".F9-1OX,O6<F9]J)>J='EQ/'/9'M<-<Y?I\](_,GI5 ^52M>IQ/;6.@_
M*R!*^/05[\FP<K[+]%JGB%JH,9^$LD@MCNG@.WW]7EQX[NO$LC#BAU=I\= C
M)'EJ.*\]7M=5UG[,5'YY@_(JS& VVFYD!'C6B9:>CS774''+\@J$])J1 '7'
MR"(Q;PFM)>J28P6V:Q?O#6FL#NI[G^91^L^.I&Q%GU6,XV7[(4S:/4,58G(!
M4@)060^G9X=YNKUY>B\31#K12<-0#1;[H4,GW&$\3/+H,$E_R"0E>K!1Q.PM
MI!P8>@ <9N?V6=L#G\>#EKGIO(3?8H3 &N4>G+1-'KL/V"4FKW^8[EMG=57&
M.XH80F)G5^3,80IN4\TY=!2L3SL3X^9X=UZ1<[G3Z<(W+E#',59]@_&/?Y/G
MZPX3?-N:/T@#;)"*9O;)Q2];!IM+8"0-M@Z7/>QB7A.8T2C7\EDM7 ^(K ;I
M/CS,[!] 5?RII+]DUV,@9XWCO31[*2#LFHGZYX.<?7>O(&>'#?,[;IA)VV:9
MHV&50B0&1,\NRS SOJ&I-B* K/ID6K2BSCB5S3M8P3\B9)BR@JZMRB7B13F;
MJ#S@_,=)J@FXM:@H";=4FI<$^OH'"".HU>F20/Q4A7TFI]W-F9@/DWG]9'X_
MSILDPCR6=AMD443D>WM65W/K7^A!C+&!3 P5"D'#1[@42H*6,]#JMEP9$&3D
MMD&1N&U0BDH:XJD<[/K#0' '?!(,!QA-A,1 E@15*<YVLQ]^>&_$Y0-F@7M6
M!;AYYVJ"K17&H\[UCSYE&(W]8.I+CF:1\N^>O);'\:QM/Z@C*NV(@S:==KLA
MZ@E.\W,Y5'3-9;M7YT8W2KR#A:](ZL518H/4B_"<4JA2K;C#C_[7G1$F"1:?
M8]W&L-0_,1SFT)M094KOXYK% +$S!=7QY82$P$W1$J7O3^(!T35AE]I;TQ-(
MO<YSM>:WR( /KKF%(8%":]UV#P3A[:1DWTK-\:W+\/S=9WC>.>3$'=>NWN[+
M0N68;ZG,4VYR&F:8_=BA5&SC20&I99'N3*! *_B%F%#LH)IY=_L5.JQ44V%V
M'C?:6O;I)?L\^G14%!>H:B$L:KX1F-NI'?65490:!(X6WO[TJP,L4>:5W@H/
MV7!=G  $>&=]2G CMZB*&3+=*L7Q1""64J#( 1>79"+]4DTT_2,=-(0&H/*P
MZ'NBHYC>F@  O30K;O;C4[H;AF;T:E;")DA,').R1['0(7*6:"2?I2-*4$\"
M_AX=E+S2'LPY P)R4TO87.1 +$5#$+JJ%XL]"86&;S_@+;,A<39#.<(89L4M
ME'P/;D=0ER"--HXU=0K ]UUM5*C"*&^I8BKVEZ*&8_( /&-9:5^X[O4(Z9!@
MX*[_<4UB-IY/,/=+$&IP>S"5GT)@,@>]:[S8(^JRO](3X[%3P45/0X_L'3UW
M@M=,/"$SE/<>C[=F[\M),^:@DU3"=C]2E$L##!.UYLI)*C#OF[\CD59>.VON
M]7X2.LW5687.NW0J)_(]>J[L#0"#$8!(/&>W'2V 1:A9^3JU7-\,A'GMIE>R
MCCGKT SQG40&_?Q=/P)XD83)P*P+AP7CK\CR)540#SARS0 )[JEY/&4>0]=.
M)Y6SJPNPPZ ?P%]&?L+?XNG90WW=M;^$^7VDNKW>2!%(23=-[]D_:7"__=._
M,9,%FIOD@'&&)RLO??ODW\1A)#3:5CGVZ1#>^]/$["V8VOP92B:&V5(/"#%C
MRJY8UFW;V6Y8M@GOPKC. :>K8]5BV#L8"1>!VU11#<@I: 0#F[%44<8Y^5['
MZ%Z;>J/\;HSCB8M]T:XWRC[B25;S!\5 #!YE$995HRE."^]T%== ,%,,4^A@
M@,]$B6?VW8FIV>,C4SVRNAR<4&*_#/4K#H2"CY@2SD.+D\[#F%+7=ZFYYSF>
MO=[W<+1NI#5,L#IFHY*/9<0 G'+*X=<E +1=HYDN/2*G%F^T3D!K!E(PR:["
M EG\X,YJR)F&M2D3*FW^7)4@UX9;];@&R[[+N%%RC)[L'<B;*H>%)TP8<FNR
MRZG!X77,F7X93'EW]RU,^F3_2MY1(L<LC;D>K#;Z?IG*']TJF$3&6>0/N_+E
MDR^_XC#V(]?NJ:F5;A@7)>Q2?E=9!GJ_&/%C@;22.MW@Y$O'I9P;I*DU/)8\
MZ)Z<2:/9,04M%RMQ>"7,6KY78*BKQ;$426OQEAW)$] E-HFW2G[L^+30"R9]
M#'OXGC.'2W6H@&\\"S82/)(<":C\64_2]H(D\A"&@2, AHU/G2SL& T<+MUT
M?H@HN-SVQCIB7HR0*?*CL4](657]DP=F)HS^^%T4_UA7'T)=7: ICTS(- !<
M%_,>E_&JBJ]]%DA6)BP*4;IBLD,X</B;][BB92,3EGPK,9BP$!WST3P(I^5U
M.N&G8]2<57)/$#E.5[@T Y9I.F&L'Z,JN6@RM":N>4"2ILI>3C#S"W*;SL+F
M*L1%A4B?GYAZ!5QWG+B9^D5. :3 ?V'=5X/(GY;XCOT+[C/PI//Z*!+$,->A
M5;5=N4!;)O G^96+\WIZ\$$+$[_!N+THC9UK<RCMJDA%&CK#GD7;>=2LW;?3
M:#II9XCD>]75[9LL0_@@N@ H]('#GMOLXOJZRC1XBAFYZ]$TG5=GTE>=_T73
MT0U%0"1$X+I#,&_<M!\^;HSX<Q<=L+A$3])AD9_:2A8AEDT[.#TSG=4^<E0I
MDQ"09P,R.>,$D=Q2TL5D6Z%\CK_I=8ULMO+;Q1BS$Q]U=E*Z%Z!-L>+JP+K<
M33#7&TM7VR<QPP=AF0>=Q:76']4Y815.<9M3 BB!^H'PWZ,Y,R$AP%1S$F9A
M -NUWGH>#U<V=4DBI,S\7QBD#0[%Z(QH?,LQX[XG&&KI$"8SN4W6HAD-0=DM
M:J*M6YK$:JD]9,ZB9D\$/2SVC1#]X9Y'W%F$1XD/S.2<G#@6A_, ;=&5]]63
M>P5MN9M!T'8M/H<E&6+],VCR$X:ZC=:<R8<<)ACAQ%Y4T7I;:KB9VC&<^1AO
MEF'^ V[);\AGR$-P3H2X8H/&!;3).1><H1BTA4Y4%]G5,)92U^AG.);BP60N
M1N-\R%L\D%PK<R)-"Y/:K%J _PQ4 O"@2+T(BMFSIU]F*44(X&AQR33>L9\7
M7;O&CYX^U>^W:,-[WV[C4+XH/[2;TO/_\OVH7:Y7;= X]_^UC:./I(<H9_!&
M1O8R7D==JE"/Y)Y<O2I=/'[LA!XE:X&IQ;5JWL1\^"JR0H_[)%''#$03_#46
M7D.,(\X5ZR^U";(KS X"!R#63+Q+W.](^?(8&9< JB3P$I,6;D?G.1YQ/$W1
MKZWQ%N<7Z(0\1QAMDN(#S6OS4^+>NRA9P&@7T)[>!#+-K0KN)@>5"D!VG;CM
M\%T\.WX<X_A^"_HRU'\PD'H'O="#V!9Q.N,J>UJDP7U]^B:.6(E<1C.L5Z6<
M%"M&2^D)8WJ%;FMT9M>DJ"7V-%[[2;ITUD]*WZ44ORWQ)D9$M+G\U9WUIQ1,
M=, ,H;#W1)'@>U#K0JJ/?*M+_$L68+OM!K[FL:B3:-C@SQ__!AD/../+N#V;
M%8-%;\X(HZ++'8BK+C[X>0S$+]%D*[E">Q'67VB!BW@0ZP?'4J+TR_NJ?I?
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M$Q7.2\ /7\9[Q><A^9S9B1A,0</01ZRL,RM=GF1V\E>/ 2%%Z@_5_,-9.?]
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MTQPKK3\GPL9;T-4I4A)V]"U-Q_Z<,KDQ@JS1&$%45VZS+0/$0-IN_SL]#,K
MEY+@YOK%6WC3 JN]-R5V;^X=VX!F'G)3,,[LC\RA^9HL'Z _[\%R,PIR7 %
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M9Y&(BF.MI6, 7V;I;M=CA0'B/X:%72,5?"N>]OW+\WCFMAX&S#;=&BIY[JE
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M>X'S3U89Z?2CBK-Z P+G7Y2;4DK5^:G+U>7H?;2P'(QEDBPNFCP#E!N[(:[
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MLM)SDR)K[RSEJ#7"G]SI]V;+X)>SK^H0M,3NE'1Z*=[/&G0XPLC[+XA/ST[
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MI14BR^'9?K-BT[H%P69\>F372".<P@*(Z"VZ@5GXJ/G)?Y4>('63MS"$\E2
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MUQ5U0ED7=Y?  T1/QF?Z5Y"O2AKQQFG]T]D__ K"TNG':EO^NGVUE=;HWIK
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M LFXDE![J@!J-J9F6Y%[/X>W0SGVSQ\\SH]XGOU#*#OH5.AJZI%:YGT <ZT
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MOU0>)&ER->@?18B 55=\[*K\@OQ(F.)BKR>\6E?R5M=[DHU98!N\0"<U(C\
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M4<$,QVUWS\C8?MQ"ADK'ROK0,G2$#IS3PN #0S<+!T5T? C#=T5+6+RK/^
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ML<8HV2U$63C63E+03.9%W"$*0[R[/^!S91EL$<IK"EL1<2FQF]MV\1O]0,!
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MY$A*4EA#LXVJMDFX_-,G2K](W;8SQO*ZSZ%63*PVFCU+-8OY_"#U^:@-R=^
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M@8BM2$?ZH)A'KI\075W?=I[$WC94D=6JU.=G5<V*2EVUNA]A26OD4U$VJK]
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MC:[>\<R!#@4T,+E8PH8I.65^W QGB@^Z2A+RJEMT2=P+ _,*LBG>K?#"O33
M"#L=C%YRS,06X*0CTB/*,<&A$*36@0GYMEV[-F$8;5Z)#W%=B0+1MKTT?;\)
MS]+(#2"MHAR-.Y_;SBB=\Z.F>"#/L(7PQ>,'3-*?S-MU.M<.K1+#V9D6:U7:
M9A%<%NX*!'44_6)1QPJ:,\YMQ^P.3'<3;)%RO L)0\(\!GYWA]Z3FJSDR6S+
M4#<#6F5S:E%M?X5U:X1;BJ]/CC:>I@2QP]% C]]#\^4.Y)N3@MLIR[/QC<X$
M!*XP8XY-RDBAG#)^N(2TDNOS!:FZ;PO&KGXOC@<E_8PD<IZ+UL?S^E[QW2D*
M)8,FD(=V]C/I:Q -S=;8/-134$%(&CPZ/$ZH( ,+WG5T&KM(. Y@3+=I!$[
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M&(>^O$$'+S/DK;EF :<:I>\\O&N(A;?-VFTU*M_Q!"7O2Y/99IAVX!>XL>U
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M6R!-M>?-7_.0DRCQI::1&$VD_XJ2#P?#CF-1ST8M699,#HPO+H&CYKQ'_NJ
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MMS!!EO#!'@&[:;OHO;X^A<.U@%^YS=V>%-TW,XI6S0W;W]RPJ2)I "+I@Q,
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M;GY.?7[1JVQD.<!0SE<>8)W-Z;:-B##X*08H8Q2%L(3/[Z9D*!,+S>%4+#\
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M"<@,#19*O?.KL1+'%05I.1DGJ#4JHY@E>BB)TS+ND7M17 D)1?;[GLQ1,CS
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M&+[ YPF&Y1$,+TD]7=I@$MOLZH-#6UPU9O+,*X:"+@W!UF"HC\P#QX8K!+<
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M&Z$H^4="/?Y(G/F])8N6JN@87OG)6?WFLV_:GT,?H0#\_SYPC6Q)\;5<4]>
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M'#Q+Q- _Q&_3P$LJ3;Z(N1ACGTCZSMTJZ<M)1MOARY65/ZS"RW>UMPCE7UC
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M8]AK!E9=?H)7X6##( *\0,\MU3&;@Y4<1CR7.N>Q+(I$@3/ER[J_I9. ?1V
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M!IQ)N/!<S^=N[I<YB"3$X0T:-%;G+OM /D^?FW<_2I,+L0.HY+&NW"9ZYO1
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MI#7X]E[:@GD=5:E7'*A>L ,7W&E$?V&)Q05A&F.]4+G1G'#9ELZ*5ZS!W]-
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M.T,E.BX6OP.C@1,NSB\YKJ%F_6T84]NGK&,HX'#[*.A+#6,#[>O=_2ZBJ13
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MGV6L;,!64B?-U^LP$,BJ >T2^ MBLQ,A4H6%MYTB?@V:AE];M;!>Y!>@K()
MFBG0#<Z67K0@CI6(.Q'E%3_4C8&(K6VSD83XC[.6F="\B911:^D!.YP*$5GL
M"_G6(A& 4<B_ 'AQ))R-\!+7$5_QQ2F\RX-]( ^:P48]V""M!O<.DC"3R*>*
M?1U8SQ?R[TJ"*I)AY$,IC^P.GH0U@]CO.!:\5B)+@ED*;V><UY"8)_'*^36(
M\DR\AUL(9@2;78#"'R CEJ<E*OS5B^ $1(!YRGM/S4MAGP)H.D?7#&[8XKM(
M5^)KD!+4)%3A'CW[4* .!+P36"B(\*?./,^0F0-,@I2VE8B%ER#*;"V'/XP
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M[9+=M;P5'LHQV9*3X#*ALV[?Q: X%>RVTH/*>C,!]?)*G R"G$7MF3E%CB*
M-2-V7<!WJZ9@-*WXFJSAV5X1[#N!6<6?Q"P&/&V0TZ+V(-7$JF*0B*CO9!*3
M\UD0:C>$GU1N,9$7$*0F=S=$-3\!M5NF1A@CTDX,<>8"G1Q!&#)!J@P3(+U/
M9M&$+_;?E(HDY;UZDD-*%!@C=<-5$K!LB2%-B(1DBG)%NMJOH9QTL#;G!8/
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MR08: ;>?TF69!%D5$J%SJTH(U'6P/8PP*?HE%1]_-L_#.4>?Y7KQ"GTB6$O
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MCKC]C__3&P^/&.SX[B]NH;H,Q"^YW>.(C6$"[6?O#CLCG!YT__CUF) E\B(
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M<+_>V,:V*J2[E%R4Z&>70VZ+U;E\EPSO=GJ7E>9R<^)I+@T2MCBW/I-)U+K
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M.Z#K,]J'6*W#>".VWZP8N$XNE(DD >992!<$!C_726 6QXK@?(V<G*UGU(]
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M]UQ5,%<F&S0Z49=IMZN;EJ]Z>%NDZ-HTA&NK<S=>]M9LNMND'YJYB].Y3-G
M_9X_C[L<5K_R="=Z^*5!SU]8GVOJN7@/I*,WC,'7F#<TO-#]U,APQM!8&3'I
M"::JSY@[6;N=G^?Z3,_VWUQ,=:[ZA)]<G,7N""5_9OUU4U: 4KFJ8KP-KJ4Z
MHVOVZ&D,H,D77PWG>.TE=,V:N8HW<XJKE<XX1ZTY,^<;*0#SMV<:9B-3<[F/
MYGQ^YO5EXV4NT/1[;MPL=9C,:-@6$;TE5T*S?.AYJD/\55]$,&[)=*YVW\5L
ML\E)N2W7<L(*]L^XN54MC"TI-,8I#_*B#)R,FL>^.@?1EDG 4G=D^*[W_:PW
M24PRJ1//5NEVLV!BBD$M]"6(FM?29].(8W^XR"O6.QU7"EGR]B6.^LL^UWQV
M2NW\KJ+YK[HU5JQ<KW\Z_+VBW?I^MRX?6[4:3<HQ/>-PG?7>*-=CNA9E_]"H
M&S=KH=(57RU2LM$7W$-3HNHR4MR;D_*(AQ7!8I5Y'G V.I(2E\+TFZNV4B.7
M;+^RRFHXZTN8>&.F"3KS*5+'BQZIRX]';SQ7!W@:_I'NEV+**EZE*<6$G9(C
MJOQDU*.2V[A.O*V"IE5CFU%JJ#@^UU7CPMB\-N;,)#/\_<C7--XIK&='YS4G
M6%G ."O'7"!S<Y'R87@VK[$D338<@-K*CPLT*@.7-4-K^46-X&K:URE1UR#F
M\$2^] KW@W7O?>DX1PN.\S<-*V5_1@;[:^1Z[MW6<[Y(@]:\,(:KZ?]*/N#X
ME:4C(J#2^]88)#>QH!< K"D80Y.XCLO(6YVQU1O498]Q5>J+N783EG@QK!,
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M$N=@P^V1-,[99Q<^\GZ8 D<E8^-N9W^<@KAG_27JS>M&%/NGGIZ5U(;O=9F
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M$1+B7D8.T%@[4A_$9/LG'M4R;5R?AOMOKLM@C"S.B<Y<V\&I$GI)D_N9?I0
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M+FGWQ3_]9%PJTY#.AO)ALD*SD4R9W+QIXWZ7:3$!*Q0KN )"QU:0AG"@,8%
M$QF[BQ@LL=C90SR@W+J*"=JAWZS1*?-446##&389!3;NE9DFV1@!"5$%$,@I
M0+V%P# LHY,FO*0*JQ1)Q8%(W%G7N1<4>&+I++_DW)46YJYDV%H?;!VLXH@E
M2A?>$@4P]P&LD)%!;X$$%(@IJ)CTVLF=/0:[5*S+.;.E+IC'+=;WF[62Q7J]
M8KVDC2BJN-9<@T*YZ'/%'!AO55!)//9(%@19&L0:=97(Y"D/)I\O?.&#=NXZ
MO8$=GOK.1'_)Q46;5SWJ97^=5OU8?VFXA@]]-I76"4ZK.&$=-M0R! %VT@-:
M& $48P98:Z!CL'!:!7 B72G;1+Z04U5:JG)D<;Y7<5[6-:0HF(,,0,MY+'!V
M0&D5M Z/&/&%4RZVF>!=G+E4'DXNW_@S/=(3W]%U>\3,IG*/*D>]_'4#KZF'
M-J/3&M%I%1<L-\85!8- *:$ %5P!K:D&Q#O#&;:NB%FQI+N&O-CLWVBO(*]+
MV<B"?$^"O%R!(Z2UDC+@E#;!:B@D,$HB$#;/:RPT]@[N[+$NE.O*)<D>C6^D
M;)O5 :^/O.U)F$0;)6_+P>"-8-4JIMB 059 XX'P,G:]L3I@%1>1;I(8KR'A
M0D:3"+6J,4;V<+1,Z<CB_"#BO*1Z6,88T=P"R(0$E >M0P48!LHI&PX)MMKB
M*,X4XA:)\Q/S<"RJ'MF_<=^-;C(X;1J<5G'%4N@9$UX!Q*P"5#(3= UJ@%=2
M<(T9QR2!DR!W!J?LX&BO)*^UV4V6Y'N0Y"4U VI:"(TYP"2R+@9% $A&%! \
M%M) BYTSD4!(0=HB25Z3AZ/5ND59RKOIBI?'G^Z^@2K>C$IK1*557+#(.!L
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M10(S@$QPKIE#V;@=9:UGM<$87H)(^'X,U[-0RP1X2U-$9C(7!Y*Q[6GI*A[
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MI8,L&Q)Q'ID/86=7SX%N/6[?;?QV3"M4W-X%MRT=P#$Y&YD%+"I?4('@@E5
M,402:0J1^9U=J^\B[[N:[M9U%3#+=9O%NFI(X3YE0#,3+R[#C[-^L95]%F,?
M/L?D#T$DS74$ZYMD6V[!Y)F$J$Q@P3*&U.[L2J6ZX8.HSL4'&#6HV%T*=EL6
MOS->>I*-?1HT@C!* V**0 3QA$I-0L"=W1H6>$#([42^6T7PBA#<LOW1J&0I
M1D F PC.?=Z'I05%@D$LITZ]R A67:J0O55A@$_Y1:=X7J)B3<+;Z1&.3]"?
M]_PQ#DYF27!A,/GRG5L6->B66KB<MI>SN:B!@R7RF)BC(C15A@0:H?0Z T&2
M C2>0G"2(-/)>>]V=D6?J3O7^*C>Q^XB>XT92!79*T%V2V/X/$N$4@N,!94U
M1D&V,AH\92P%JVF>Z9)^9.R=>YE79'<7V6M,0:K(7@FR6]K#4!M%:6(80\:S
M",Z"L<1!S(S-(D&73:\FL7!.M=_.=C3<K/##_XMX/#WJ>1S'?+.3:S)DU 0G
M!L/)V1B'/EX]A[-EL8INB8^]RQGY]?.$5#9;(IO).0H$N>%2,0>)>@M"! 1T
M*@(3M-3^,5X6-J-]5GL#;C*\UZ! YL.[(GA!!+>4!G>*&:4Y*)I*WQ_N *U-
M&="2.:&5)*34";V[-5+QV^%PY#JC&A7)2T%RNXN(T:A#<D#1<Q"4&["<,-#"
MTOP2HXJ'K"QX1TXB;E5 8Y;1=%>IL!4^C[5G-56]L!*.VIO793#F;<59JJ$4
M\P*A,0'F.02ODY/19UNC5 M2?:&J7W.#,;[V[*>*\95AO*4H\OQI3YD"FV0I
M+10I.).-$2VI"$%$HD7CX31W;RY2,=Y=C*\A=E$QOB:,M[1&,%0XKRQ8XV-I
M'R3!.,O!$\Y8B-RYTEV$]?7=NXMT+XK1::5Q$*>]ID3PZ7CT;A!BZ+GSJP7$
M\AR\FZM OC4(;C0.<0RSFWO,\Q2$T5D)BES>T\4;IJ/3QV6")J/C0?CTXC>Y
MKG,#^=_W.$ ;LPDL7<SEY?TTK^Z7%XO[I_,_)Z4L_.<DV4_KN^X!2]P#YK6"
MC";R8J^#):5CO,V[ >9M :1';HP0R)I*&JI/];*"/\N#V#V[GBO95K+MOJJN
M9'M?9-L2U:4I%FINBZTM0#@5P"GG0;M K8^$V]*=@YH^4W>N-%#)MI)M)=MU
MNS<JV=X7V;:\&]KDV0RB)$'0  *# 9>B!)DX6D>R?I$EJTGVS0:1;>,<^6%:
M\ASS[S!XM_L_S8_9?;CQ#[N?[NG+%]<(4E9 ^D>,/?1^=)+_]GGQ:0Q'T_SM
MTU$!:#,N.(VAEP9#'/H!'N?KRT^4UL.31ZU;N+SXB[\@2E'XT]&L:OKC<3S.
MT'L7?WP_"-.C2XZX\JF+Z2*?/X(N7\'9].:/7)D4GR\ICM=/=<THTE+?\.I@
M7/U9KK<A#XI9Y1F?1$ E;!28D#F2[1!N\_\">TVIW+G\U-'X\B9.\4T$-X[X
M-V#*]_@8C]_C^63GAR^&XF0PA*OC?M.07:QN:!;Q8_5(RV9[OV'44EK9J,T0
ME8EV5"@YSW;&<1R7=^7+P<Y<2^]H7+:H_[K%[!%2:BZ&^*' Y^E5^/S\"3Y_
M?(+/__R -Y' /(9H@6S]:U_/7?M?W.CGVRL=%/XXPG$\&AWGL9S\G_\RC.H?
M>\__<S:8GM]('2<X?I-7<F'FV<)L./0S132\G6_M&$\G\?'E@Q_#8')ZC.>/
M!\/F IL/_7CQ71>\4D!QC;.;(9R]_!DOC\@,,Q>N[8N_?/'RH^:E:_O0Q6OJ
M4=[I;GR9/*(W?_0K7ZL><:DZ]*U??XT;L8)KM>+F5S=E7+^ZM,@C(>S2O]8^
M8F;Y YLOEDJ]DHN]W=KZ1F#JF\%F=?NW+O"M>6N__MXY\G;&Y.N1<>9;]#ZK
M'C"=C@?N;$;#95_[UQ^]V9F>6W3!N>L 7DSE-;N2D=G.L*SI?1#S<'!VXN*X
M[*J3LJM.&A-A=#;-]OBPW,629F,\>M]*N5A +-W:5;-.0^9V _QT='(R&O9N
MM$PZ<IE_3$?^[W)VKNL7^A1/!U,\[OIE_G$V/CT^FWR:]Z5>@GS$;G$1<S1R
M 1NP1Z9MLSJ<Q)E(^@?[O]<DPE?<O+?!\&W:>-WU>Y;(+]WCZ"?>GYV<'1<E
MU-!SDU+5/,KD<IJE4!Q.\NPVS\R:,/;^\>MH,FD=&=B:$3L<%8IH1NBS75'^
M.4\Z-B]<TX]+W^T>Z/#-&:^;ANL.1M6]!F0^#4GSA8_+YC+PWR;7K[B9]H8S
M_W*^BN/2V/$V?1TW!GHS>^?SXEGEW3\P4_"PI,2>C6_V4G7D.F?S]A!-%WI[
MT^4[-&1=@>M5(]NQ !\$J_\>IYB?G-F?SW$\S%=^&V9_4#=9^ICG-XU'>=L>
MONE=V-/Y(F.I+S//V+GKP=C[L7CT(WFK\?@)CYOJ.3CM/8L^-HXB3OL]1JB]
MR]G8NZ7JK#$CY;8#=6-*RLRG=BTK13/46O& -CI!!$<TB;$DO;(L(,77>V6
MOYV,,MNF7WSVU3V4G),_+W-./OSU=O_C_B\'QP>'GA^\?4+^.OF-YO<=[[]]
M\O[@E^=\__"?)_OEN\XO<TY.W[XX_.GO?;9'7_SRSUG.R;,_/[XZ^?GHX/ Y
M??7OWX]+CLI?_]YCGSYSF7-RDJ_CE]\^OGK[IWAUTN2<_'UP>#!X]>_G=/_P
M7T=__?*GV&>_'[_*=_&_'S\E]TWW#U_Q%X=/Q&N;4B"6)HA<E#["^9'!2,$Z
M[F6*B1E9TOOZFK53J5>RE;67Y_R,J>\[S+/6S,%M9(V;:W_,I8U$2" Q2<EI
M$I8JHRV1WC/D-#@,]+:T<6D#-C;63*W]<?'W*D,LQA"#:PR!E!*&B8-"57+2
MG :+7 .53!J>),,8=G8%6T*+P,[D]7[CK.UJ4=T]F^GV>;L+#T#'Z6R!O-R0
M22LYDIPW5D1/'?/&V& DT=X:)VYM 14*N_!.SCR2>T-_?%:&[.5H7*[B:ICY
M</2E@7]IVE>S:9FD>/#T&BD*:KWEI2ZRD1:$"Q$<R\PH$O7).A>-$)D49=_J
M=JV!:C?-9>;*JMO"J@OUFOMN"_&&NG"57SO(K]=EJ;$653(,7/X)@KL 3FH+
MSAIO1,I[JR4[N\STV3):4U=VJ^QV+S:CUXXEJ2GQ/ BJ$BIOO<_V(F.&"26K
MS?B .:TEI"W-4MH&,(Q&$-[D1S13G"!(D6EJ(\7&9J2D78.NVHR552NKWHY5
MC3'!$!X3<B4D1>=\")Y'8=$)14AEU0?,JN?7614%UX@4!&,^LZI$0!H,>*T\
M#1QUL*D$,)KP7B752JJ55+^OQDO@I7Z6<$Y)(81R689SBIZ$J)QDL9+JPR75
M%]?=FVBX8$Y+X 2S_&9&@^-2@TZ))*E(BM[N["K>-W-:U596K:Q:6?66WDV1
M#522/$'A!)7.<(E>4:FD=Y$*MFY6K<2Y&'&V_)8B!L<H 30A@:""0M8<%**G
M-G@5C/19XW.B*FM6UJRL^9VLR2AFH]/GSQDJ/!KCLT5*@G-2,^>"K[;HPZ74
M_<,GK4YA5 ;&H@(52KU78VPF51\ +?IHA.22A&R-BC[5[:+?E5?OOQSY\BMV
MW78"GH31:<,FH]0;YN_$6=/AD@G?)!CC.*QD@8A'1M_B F\^D:'8UXYD]/[!
MOW4FXX&UEKL]H@RC[,=NM "L8US;+-9YJF-<Q_A.8[Q(.IB,2@7IC:(VB5!:
MV1N6K4)FF@J#U-U;.E@U\Q<P\W]K9T=82SCU)(%UCH*(U@$2X2#0))DMAQ#0
M[>SR;K00W0)05N+K%O$E+ T5@G 1G4C68#1:*XH),2H?>26^AT%\K5A;M$PQ
MIRC$Y'PFOJ0!I;1@C!0V4A4Y$Y7X*O%MTA@O0GPD.J\Q).XY%]('ZS$282TS
MB);K:O$]$.*;X]@5P888"4*()%.?80*L0@V.265<2"B9Z0SU;5AUC)N;. Z:
M:GN;TB=^M;2_HC[ =8QKK^4Z3W6,ZQC?:8P7D=?1^D!U5M/6"6FYY8%3X8(,
MGG+KU,)=M5Z.1VDP+15K:W[ \LS(/]N.0XD^2604/$<.0B&"-3("Y=)9P257
M+NSLZC[5[0, %7V5X1[T&"]R*HJCMHQ2K7000E'C,=&DA8IHE0BF,EQ'&*[E
M(<R49E0I-F(4<R!H<H#:!Q#.<2]L3%15ANLX^E0(I6*%,C$*@9X;(I3P)&@G
MF%$BW@E]%6"+ :R5M<V=8U1@.8JM02#QX%*R@%R':((UW/B=7=IV1%5T=01=
MR^Z)6_>VU4!OCA/8"!LRSCA0% :R96+!$B,A:E3<6RF]<LWN9MN5M.X/?^M.
MH;T7!#8]67K^:C^6"^]P[Q\'HVGL47YS.Y8-#5W5\."6C7%-0'T8\U3'N(YQ
M'>/.CO$B.;Y$!2<"<4Y2861P!KE-T1-,3-& "UOSC1WS15NY64>Y8M\?Q.F+
M=(@?JBF_D"G_JEV)QS.2*&,&K&(BJVBIP?!84CJ\HX0SYRS?V>6V7;"Q J\;
MP%NZB[@";P7 :_F'F4Y.6^) *<M!A*3!&F^!D*@8E5&P2"KPJE6Q@6-\GS["
M2FXK(+<Y#L+BF>=&)^#4(0AA&%BM#2C"/9<:.4K7-7K[AGLP#":GQWA>+C9^
MW>=0W]FE=VY%#O"L3^5%W82"I'>#Z7D_7T9Y&M_C.$QZ. R]4=.Q>\O2A!=K
M;Q5HMJ'S'N,Q9D%+2Z%$B51F:2N-DFKQ/:>9F[W)Y"R&9V?C<F(AW\<HS'I=
M-2^^:.9M\OQ#'/O!)(:Z RVT [UIM\B+SFA4CH A&$#D=0 HLLSEEB!7(06O
M2C'$#@6G*@ZOU]FW7&:+3T1OC-"*&&*\##Q(E2S/6%P+#J_&D=/@0PSP,8Y'
M%9^+XO-Z JCWUC-F(@0F(PB&$C!%#:$<EA5-E0#[28UU%*7U,,(R))Y5R+P0
M6DKAA&;:A'(\VE 7*4TVT&7!_%]X?!;K;KL,-+<ZJ[&\IQK#4H9OZ8WAD@%C
M=03.N+$R6FIT-L>EH!U%\H:BL"9SUS&N8US'N.L1I[ICKWK';H6?N'%(E4C@
M0D 0)HMD(ZP#E0VQ/)'2A%AW[,ITFSC&]QE^JDRW<D]#.Q;EO6$,4P!ED@.!
M%@&MM2"Y4MK(8"@77>.ZK4A5?_['RY>]048##GV<]'O#."TUGT_/QOX()[$\
MGHXC3L[&Y[V9B[ FKM=TA WQ2OMWD\<% 'L7ZW^6?7"QW)N]8.:8?N+_<S88
MQ_!T-)GNQ^G1J.X)B^T)?\_Q/B<CO?4*.$D*A$X$;/%<2:L-B<'20-7.[IV/
M+M7##94O-V^,%VF5O3ZR;$SHRI5WYLJ#ZY%TX5B@"34P*Q@(GZUGYW4$5,7]
MPY!$9[/UK#M*EAL*PDIT=8PW88SOP^U<-Y-U;29MMW.*VC.>S>T\<R"$E6"B
M)I 4S<:!YDSY6#>32G2;-\;WX76N1+<V#T/;ZZP#HUQ+"0R#*CDQ#!P2!,^T
M<3%/&Z?8,:K;BDSYIZ.3D]'P(C,^#-X-0AR&[W,L/^ @6 TT;MD8UV35AS%/
M=8SK&*^C,]6R2V<_N]Q)9_MK8UW6,GS+LS&?O__U\-5U&S-:RU.6TD"1"!#1
M(*"2"30+QC+)!!-F9Y?UE1!WZ,=245B9KEMCO C3+3U;M3+=ZIGN34M-.T^"
M<YGIC&(@!-/@I+.@.0W<9KKS*52FJTRW:6.\"-,M/5NU,MWJF:[YKV&[@[=>
M[C][\UJBU)I(47J+EJ;*G )B\H">HA=8+#O:*:JK=5,V\IU;D8(\JY:=Z:M$
M1?+W#H:]X1>M0_,SL]ZA&YQ[K+^VO5_>]CV9&#4D62>X9M3617+_BZ1.<)W@
M.L%U@NL$UPFN$UPG^+Z\?'=O2CC)=YP?74T3//A"].Y=:-Y&'<^.J.\-9Q+Y
MV854KJZ^Q5Q]Y[\>_GT]J"$M3TXH#I1("\+Z"-8X#LQ*1*H92TSN[+8S!&_O
MY:LP[+"SO<+P7F#8]KB7P# *X8"Z$$&8<AS8* J!6D>,2X1YUQD<;EB2[GR+
MYR<\+@GK/9SV\DJ/)RZ.>YSV>P5*=TG5=:-QB&.8CDX?E_&?C(X'H7=Y/P^1
MLA8K7E :BW";B*3(A&<*;?(I&DV\<DY:_7KOEF5LFB]_<3:=3'%8QJQ&!9?(
M41\O^>F*J> P.*.,A.2] "$Y!]36@& 44:'7D9J=7=K7?%D-CV\-E35%[S<.
MNC=;&W.QBX0KYP7J@%X$+3%;_MH1IIVQ*:&\+7:_./]S$=B_^'L5I@O"=.\Z
M3-$0YA0-$'GR( CU8)!$\!:%I$(J8]3.KF!MD"X<N5\K/M=T>F#C,+Z H* $
MO?%Y9Z;""$2&DN?U(G4J-;&54[?>FPNNCT;'>2 GS_]S-IB>9\UP?%:&[N5H
M7*[BR70Z'KBS*;KC>#B:+SGJAKY<IOCM.E,$S.*BU*.C3&DHQ5$ N<V \$1%
MFJ>>6)^90O4EK3OZ T'[(OZ#[]_.K[D-*NZ[C/L_6Q8"S]-:*B"8: *(0!.X
MF,V$;!YX22*1RN+.+C-]JLT#,Q*V$?(+(#YPQS/*9;(F"JL)<I^_DRM!,]X#
M(76#?\A ;YW-X@$5LQGHC)4.B-IZL-FX@W(.A7DJK>,V;_"VKP2I&_S&H3U;
M<4@SEW.;#7IAE)7>)$FTC52C,K2B_2&CW5]'.TT$-2<)8N9W$,GK+/RY!:^8
MBRJ):%@L_CE!VTG[%>P/'>Q*HJ.:&B9E$%9&E]!)1[AD,A&C3 7[0P9[ZS"B
MDQ:#T1I48":#G;BLW4,VZ5$SYVE,RF?MKFR?&UO1OG%H9T$%YTKA!!V%-]I)
M04.DB?(LX*B_?11M26BO@%X0T*U$G$"M,,A*%7"2;76/ C ZF0$=5=;K*=MR
M?&>7TSM7!*]H[AR:!1>:*LXI)5X$+IU568\G+;AW)(I4]^Z'#/5VLD_BB2;G
M&$CD'H1(!BR)'+@0!(D643K6;-Z:+*LAS,KAOA5'-0_BM#?(F#F)FWL2L]9G
MK6-<SR,^F'FJ8US'> U=5!0RIW46*$X)$YU+)3>$*"\#D<+J)M6<7J::TV^;
MJB_'HS28_CJ:3*JYN41SD\Z) B%G)!JKBXWI0$1OP9AH(:#1-CFC@Q0[N[IO
MZ9V#0!5_E>.Z-<:+U",E5 7"N0E<"\^#R1+-*RTL:DN5MI7C.L-Q+7>X4MZ&
M*!@@F@0B& %Y&0L@TCNJ')6VN,,KQW4Z'\UPF2P/#"UE@I<,M,AH^>VSX8$L
MW@* -R2F745B!=N"8&NYJJ.0JH0;0;G 0*B8P28U!Z:14XS,:%,.@K0]U?70
MZ+UO<H1@X-PZBAI%\LEF$#E7SF,Y-%:PNLEU!G=MOS%-,:7 #>2?%$067N"B
M9! "1<$#%8ZDLLL9V\[;K"U=UE#$SX].3L?Q* XG@W>Q=YQ!T?O'P6@:>Y2W
MN&^1X-A#)*5:FG?+QKBV=WD8\U3'N(YQ'>/.CO$BBMD1E2ARI3WU0C'OI,AW
M3(25VC.GPO<KYL:>>7K5G-EKXM[%T)_U<,0/U:9?S*9G\Y*V0[;IG=? T080
M) 2PB :X%5):*A-2N;,K1#N)L[:4N'_\+<%E7/&W3ORU',>8T*1R\IE(ST"4
MX\^.40Z<<J:3I(RD6/%7;8S-&N-%.&X)'L/*<>ODN+;?4$@B* D>A)<((N@$
MQE,*EB&77M*4C8\.D5QMYK*1[]R*#.$F!;\W.FU8M8#HW6!ZWN_-6GWC>QR'
M20^'H3<JW+=M2<2+51NSWB=&O'!9UPKO$I93$:0<DS$1C>8+AZJ:N=F;3,YB
M>'8V+H<BFGJFL])CS8LOFGF;//\0QWXPB:'N/HOM/F).V< LAJ@2TH&0R94J
M0QZ0"P24 9':O#,9M[-+[WS0H8:,'VSN6<TU7TK^6@P^.>5)DDF(8%W^-V)4
M CWQ@2^>OW8#7_X+C\]BI<OET&6K*!OGJ31 1V H,EVB07"&!!"").)5=#;(
MG5VC[ES#H?+E@^7+.L9UC.L8=W:,[S/GO.[9J]^S6T$$:Y-5!@58Q<J>+15@
M8@B"$26R[!&:J;IG5Z[;P#&^S]3CRG5K<.>T@@DVEJ03[H!Q*T!DJ0F.,0W<
MN. %)B%UZ!K9;44*\O,_7K[L#3(<2MN:2;\WC-/>*/5.S\;^"">Q/)Y>-%[H
MS1RN-26YAI;OU\>?6& 2B4"EI7!46.--T@&Y(T0YGVZ])Y3.904 >Q?K?Q8_
MOMIG9.;F?^+_<S88Q_!T-)GNQ^G1J&X*"VX*<D[/$44Q;^":@*:EHKA-#$S>
MTP&]1<F8)<+:G=UEU3*JB>N5,3=HC!=Q%ZR/+ALKNK+E$MBRU7]!.<TTPP"V
M)!X*JDJ51YL@KV NM5*:)[>S*SO*EAN*PLIT=8PW88SOP_E<=Y/U[28MYS,3
M#J4A"HP/&H0K?7U",!"LC22Z4)H"U-VD,MW&C?%]N)XKTZV/Z=JN9V5DS**'
M0HC6E1KI&HR.",P3$B/CA.O8+:K;BISG60??BQSG,'@W"'$8OL^Y_( C837:
MN&5C7+-6'\8\U3&N8[R&<Y)++Y'\['(GG>VOC759:ZPMS\;<>S^G6+*0AF&>
M/Q#,TZRF+0/#J8*H$RH5)-6,[.RROA+M_(9:WK RW4,=XS57O:A,MVZF:_D-
M2:)"62DASY\OY_(".&$(2!)\\K*$I4QENLITFS;&:ZY]49ENW4S7]AL&2[61
M1D$BSF7++O_ D*G..\R,)TUP!CM%=;4"QD:^<RO2D&>5D =#7Z(B^7L'P][P
MBSZ3^9E9H\F:?URC@IL]QC6S]&',4QWC.L9UC.L8US&N8]R-C*4E],+ZG+$T
MO\][8ZC/CLSN75CKS^+L=_4Z+.9U.)_3)2M0;HPE"C13$D2P"$;S!)HK--1R
MY!YW=E6'DI4J E>6,U@1N'H$MOU^6GJ7A)7@,AA!<*'!4,*!(*+2+!#N6;<@
MN&'Y@GHN"'_"XY([V\-I+R_W>.+BN,=IOU=@=)>L03<:ASB&Z>CT<1G_R>AX
M$'J7][-1;#6_7BKQW 85*35&*!(R5WD2T0LOO>887^_=LJQ&\^4OSJ:3*0[+
MF-4 Q1*)ZN.<$JF:I"2\3L %\I+7S !EZ>LG"4;4Q,H@=G9I7\^)3WQ?K/#6
M4%E3(''CH'MSE'$N=I%HX5FTQ#@4(1N+R4AFG!#$.QL5O2UVOSB*<!%CO/A[
M%:8+PK15Y< 0CBE9#UH)"D(D 8ZCS%@EEB?OO _9G!!L"8UOUXK/-24R;QS&
M%TD.)0X5)DFY#H)+B=Q&R4U*E'J>-+GUWEQP?30ZS@,Y>?Z?L\'T/ N'X[,R
M="]'XW(53Z;3\<"=3=$=Q\/1?-U1-_3E,D6KB*^E,B2B"%@T)FO_D)F"> M<
MAN $U8Y[FIE"][G6=4=_&&A?)&_H^[?S&UKE5-QW$?=S*GM$S9T.H*T@() 1
MR+2?#7G.>-32)R[\SBXS?:KY S,2MA'R"R">"N>"49%S'05QTEEB'4I'8O3&
M&E4W^(<,]-8Q$:4-&BD".!,3"!,]."\8&&(9$2$I*M/.KA1]2^[L7JQH[QS:
ME?*66N^"C52$C'U"F=*$1N^=3-JL&^T5T L"NMV'ESEO? 8T84*"<"F!4]X
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MFJL8!$%_,;K_XG@UGP9,9C(K%!4L 7,!BT>'W$^C/,KA/Q$>@QIZY.XZK5J
M>2()KR3[2)B".3YETW-V43_ZI4^ 0'W===^T9 X[Z&2A/F&.K)I2=[9JAD%
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M>[D?;_S:WPLV?G?98[.]C&Z^\[*G7OY=E-$'/];K[=8OFA(,-0#!(>'^?X_
ME.G'D9Z&B\]>X*)(AKXP?+*66:G)[;8C2_G-H9U_><7PU[->>?_6"K++=;.5
M,)EUWWDM+IGYH^<HE6XP)Q]G].BGFG[PL*?O]Z9_!9,#D/AXHBL_$3O"HI!2
MJ6=;P?U78PS_4B?!D!"NFK15PZBD8<XZWBL\-_[NBOC>?5B7_[F[^7?GK1M$
M;-7$?T3KS5'/Z?[R!:LJ=,G<I\Y]7VG9O/_W/^O_',W]-W]_]?E]^$\8'XSM
M".[]<O+YS=&KX# \" _/7OEO7A;GAV?PW5M[S__^\Y2?B>F;#W_2]T>_?7A_
M!F/]^ZL K*(O;UZ^B@^.WD7OO[P/WQ_]20^_[(?XW?]^>;4\>.M__OT(?AZ]
MC]X<[=-CE89QK$1"P/ ,"0T9^FQI3HHD4[[R.<T+^NAY$$YRNE[0T:"".^,8
M_/:&G'.)3KI2; _UVD[R[23?7;4GW4F^[R[Y+@:2C[(TBEB085X^-UU/LR3P
MB0@*+KDLLECI#'WJ;VIAO!-\.\'W0 3?K777W@F^[RWX#H>0#_L&I4F:DB03
M /E\^(=+EA*F1)91/V*)]!\]3R=93.^+X+NQQ:[T?_?*8A]&]QY?%<=\LM&G
M$]YL94;%^+T69[=EP?:S@%Z8Y=])J!M)J-?K1JF,!0^R)"=)R")"&6.$JYB3
MC(8T2R7S\RP$HY1^LWP:%P-WBKT&K]SH3'WP/'I;MM8&'MU!C%MDX*%M%?F9
MI'XJ2)!B7ZLDB4@> RMSOPB2+&*"XNGG:.(GW^Q4VK'P]K+P;5D-.Q:^<Q9>
MMQ)\&<5"QH31."64IY+DD8J)#+@(6)KRA*M'S\-)'FQJ!O\C6/@AA.ZN80A\
MBP$PLB(_GV2Z&P/@<#XK=C; 5\B?@W4; )L91D'&2!+DV.PP%"1/6$JP\$\6
M^$D>9!+D3Y#<DH]BB_RO.S:]6QM@QZ9?SZ9#I"^4C%D0)B3-$TYH)@ F*+\@
M(I9I+/(L#:5 -KVM&,J.3;>03>\&Y^_8]*O9= W-9TDH\R 61(1)3BB+?,(%
M%T1%7 F>ADE4@$$>IMND36_)J:_?G>ZE\9;#^J.;)N2/'=/=E)!_4UO,1FS:
M@E">F*\P^=ZMPX.- =_^ OTT:N V\P*O.F[=_Z!SY<XM='N*Y,^1T$R8AD6N
M&%$BQY/=,B-9D8$B2>*0!BJDE&>/G@?1)/)OR[5[>ZSV@QW#.Z&[$[I;:R+O
MA.[V"-VAD1U'(6>44<*!7 BE+"2YGW*2\C"...=1Y.<Z23O)@YW0W0G=G="]
M)PZ/G=#=&J&[YC*)6!%@SW#"I4Q Z H%O^7P9\Y% ?_E<2ZQ4\/$I[<5 ?WQ
M0E?[7'[11^:WKD+@E343@/0KW8FMG(TX2ZXH^M*O6."Z#(>F:HEN\CI?^S;P
MSEG=*<0M5KK@#^N-Y!]O]S?6B&FKX#)3Y0$+IKF**JX-\A_L0DWE9^\?\RGN
M;SWQ7L^*O;95'[OX#;YNJU^^E=([G"^E%^HFMT'RS/[8;PLEPT->EE@,I<0>
M9L:_M(\+X;V%M[JFS:YW,U:K[#1[[%:&GL]&J[]TQHZ#^[;RO ^[$TRTY9U@
MKNSL,B@0&5 N5>('2L8@7Z.4\U@RWT]B/Y)<TN3.:WN^;NJ<[4HPPSO"8QDF
M41H7"0DB%1&:AD!*!?R6IQG/,AK(1"7#750IF)N,%7D6Q306 9>"%TS*-$.S
M,^';7-VO)8!MJ>>W<0+C0N$EEKY[VY:^VQ(=_')0D<^5&VP5)&B$=WMO][PC
MU(ZKRM17!M$UPW:-S8VZW<WR1(LT@$H8UNA\US8TT*T(YI7$'K1\KNNE-7V7
M!M4!][SAX-8K!<JRAPNPQ&%3=KY;&Q'[X0FK^,JJ:5^_TGU!FXJ)JYDND-@K
M[PQR#$>)Y<]T*<-9Y[G=NH0SD$C>\EQ./[F"BUA%SA:,UM7QRR76A1I4.G0#
MO[+^TW56@WUBY5376T+MK_6YWBR\D%65OFKI*08K\ D/;75P!QW@CM_P(GVR
MZT:XXG1^WEN^MJ(M?MJ^V>(EC;::7=K;$LZ^E&%>*XT5VZVX,%7JD#)6,^"1
M*3P,NQ]@%TH+79K&'FY93DUM2D-=RX:X-(*T3YT@,1N2T8VDIN5'B0WBL9_4
M;+XTI3.[SSPOX0FZ>OC8XP# (MOIHF1@35RX3C8,V5:/&%MN()^4M6EJ-O9-
M W,[4S^'7V 68/:<SW3_>JROV&ZTF[HI)2R1H,M:#^-DII\.2S>36)D04#M0
MY*VLKYC#AN,JF?587VE3(_Z&B]L^T#Y%M\'X^A5V#^>E6E5%PR4E?%I66K[
MJ.<>F"7 ;DV;%!PZ("UB/F[:.SZ^*,%4<5<],>UO9YJML.>VQ-U@NGK_^:DT
M":?>X!%Z3>5G;$O4'Z!6"J:#M:Z:+Y=Z=MA-&1L(-\4RG^J[0!#:I6ZKY7<(
M M;<2EDVVTAHST#&P"+66B0:86,[?BNT@V&OW*"Q+!XN6EVO3'\FUF$A+:T%
M&&RX'95W(K$%S0)&A3*1/3.5^]F%:3P+H$=WAQX2^3,W@VGGR_9]/7YPE;QK
M6^M1M,T%="=PW3=!E\S5+S4M;CR]QK:)LYU/9?9J^'Q^@2:G^<[H8%._U]3[
M=)</**8A!<=YE;#Z C@'2Q9J-8."W1($$H)T"0SCC#II>*[_ZA'*[+U^Q*:'
MKRMYBJUC=.E1?+KW&(?P!"G7KEYI^)D5!4!3K<F'M81U6>-.474NIZ7\9'D*
M"PW*PM5A+#M/!9VOF?]>*)^C*S972$0^);:[X!?6#8*D8CI4Z-JPK?[ME'[$
M/E"%Y2;>K!:6D#>5W[MJR0D#38*Z9BNK 0IP; '2X(\N+("1@O0Q$J&S%XQC
MY\V+(8E/.K5CKZ&!M,+XZNE=2Q:MC[ K&PT_7<5+34<P>&%YIANC\(LN^S0:
M9Y.D'!O9UA2DOI1H?X/%&!H'G<;#Z,$:LQF&BZRE4.T$Q*HV_8L]J9LBH.C0
M"K!%^D!Q)0I;W?L8&S9<M T0M)JRT%1X6*=U?H8=&TLUE/[:#ODWBI86RL(5
MW0<:R6T&/!R-$;AL6JP:;55)A=3G6?.C>0Q\)9R%U!V[6FFEY*[KU6L?Z<WF
M4LRZZ(F)#ZNZHRR[-'>N&SUH6*-5O\0_A#5ISM>7%SO3L,5BBL8$[$'A>O$T
M;LH-#&W&8*:Z$?UM"3G?T+3'^ XL=&O<;PGCV7%U=23NA"MYW[$6&YECK,HS
M;>D/K45SM\,IL'&=KWZR'3VPXLK[?<YFV[*=S:"F\YX7XEK5HW%;]5;I3<6K
M5S,P,T0'D]H[)GK[$$A?JM'VO-YX+&TQYTZY,,)LKLV,^=D9VHA=.6R^=OZ3
MKMMDK!_$#;PDW6X6J%LTDG4FC^Y7J$=;G^HFWZ"+IZSRJK+^B)2-/B'8')#T
MA584$Z]47CV?>!CZ6]B^A^8!NJB^OF\QGT\M^M1\@XJI01R#->N.KK6JEKWB
MX<-QZ$>/V&\WF<Q3$]S$R\ER3BS3(CX#3;NHL'4I6B\7"X#><N]D;P($ )86
M$(/I5 QPW[4-G3B3JF33)Y.N3>4:'D^ T@J&_L&J:6;4O*.QY^X'>'G1[A^&
M^F3UR<K(#M2V6,1>A'1]!CLT%T;!GJVFRQ+U97TIV^FFL,R2EV.,+H5I$M0&
MX*R#7=IWPO)BU L8TI#9V#<=FN-SB[(;4M4OUG?58#=I'G98"7:/=_"ZOE)(
MQ6!J>Q[B.WA%.1>:5BLY[(_';%,5;1G#Q7.NFT TAH/!/+;%KG-? FJJ7:M<
M.\ &IW5\ I9:87%@W (T#I*[:S$Z\>398CK7 N=)'U$:.&(ZF'96P"Y9W05J
MMHF,'=+X./JKP.4%?#/>+/ .%V.(F3%K0,_D%(3 ''LO3KM3+&<-$5\FLNX#
ME[9N F,=(/P'KD$_E&Y0!.0[E6>&;A^7>Q(H1K=E&="U)>DGN"\Z&<$XA"QK
ME'7C?K XVGJZ2FM[R[.AB5FZ_5R>6K7M(G)Z7X!>T$SV=-EVSW3<+4]*]*L/
M1X#[5'?](<U$NY.KW>RT5U/;C8D/JO8"AP?+]M^5%> @=68?J]5B66C'6*D?
M4Z"QB7X])#C3B^3)P%FK%U9;UM8 U36I&QMF/FNUHY4;(P_5\G,)%+^T;BA4
M,JMJ9@PK*Q>OZ.,RFH[P@#,.Z/9D'%S58F<]'>'*]()!(#L-PYC["M8T3RCS
M0YZP2(JP4$D4Y+%2F[H[7AD WRHCY(U&>5<'OK\WL9EQ=>V/T:!Q#]2N-XRY
M5NI0OP-,A.R\Z_J^:0B;NKZ7GQ $2N,,0&5T*L6)Z8K7.",1W,\ %IZ6B\97
MB5+:MCN3.FAO@:[6?.9I%N>BL=ATA][SWFEU!@"VMA<88%+8>J&]"'#/<]6/
MT_>O&WJ\[ BPM[,>MKO.M$#1[^D\VB3S@3KZ5(K6]VJ;5[O9HR8T 81J?706
M76WJL6V6K-,-&Q=O)7!Q][S]]43!)?9V;N([H!IEN6B^M+8>BJV.'WTX>KV!
M=KQF=/UPNAY#.Z*F92RF22],SF.G/Z0W92=]^Q0 9"G/Z]XCD0HZ\4DP;Z8
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M8E,=F[DAM]6K,]E+)V@S-3 4 2P.3/1!N\7G$TPD0"/&3M\<=$*X?K8Z\T[
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MVS*%MLB_LV/FEIEYQ+)(JB /J<\$#R/!F)\%49JR@/H[;+&%S#S$%B(K&(N
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M^ 5H,]@"G-&04":XKZ*LM:NFLSKMM)#LV];KYMMJ;'.G]=SY"X9$<L8$.H6
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MT?AZ??C;)9E6:CUOW4DA+81>N9P2IYAV-MHZ5OI\"-<=)S0M (>&1/A12*C
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MXO2K&GW=F1D>97T.1(<'#>M:096?.->[L;-%^VTX#9 $.K6YEY7[+5UE.TE
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MFQ[:>7\*(_\"TGO6.ZLR.4OZ<)U2LCC%T?CSY.1SOE2_+I2C+;I1IK$.)7;
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MJ>:"U=)1>;^677)C!#\=U;D0)<:BNNK5\JN1BE8T6O;KQ5'!I#:L9W%;ZUI
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MH^%2YB6PWT61OUF]M74/F(>WN^^.[U40+14-\@;^?.X_/<#MN__+":+?E\R
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MM>UJ@57T=4FPJWA,QHA%B:FWG0=UO*OY5Y.2U3&I:NME=VN=?FUGHS5@JY-
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MH"R(H11FCWQZO4?_UL6,F*(/T3+F!&<\:<RY"YK[@ 5V^]#HJ"?]&Y+^JIT
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M8^;323('CE_,S3J;'3]7C]]L-83Z:?OOWKR:>U10I. 8J>^<,.'"(^>9%.9
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M&2-I;G!@?@4ULC^>VAMF8Z$J4HT/9<_,%B!$"W2M?,77!!7XLO($5GK/I-9
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M5X&8LB!',LX0"QS 8[;I=RP;R[3/I%-4R,1S2W-%4T!=JV1N?,YI;?THJHC
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MRXY%2] M@;[*"[HUDA^$)+EK%NK 55E;,1TKM(B$%L'K0X7Q2:V>.BGT/U$
MZ?>&)^59R)]3O>,2F0ZJ-^ ^FNGJBLR[Y6SYJ\GR%T_]V,&9$9J2\U?I(N>5
M$>16I,'?EUO_)TX$86M>P_;&Z.^Y:/&<9[D'Q);6Y;R@<#;FC!E+C>/,)2Y]
M3!+AA3WQ+<+G:.6>P.Q%6]JXJ19.V&6/7D'J%([[.I%LHS)-1]-S TF::6.1
M_[M6"-!*A/9PS#B;/=1Q3 "]W-3?.]4!ICF5P[KJ6'7-#![I2*[=&2*[=FCI
MY#$+8S5 "Y?"9!.+ ]? 9(1=U#D!"L>#(%F :E8V,UMC!NZXU]<PVU\#XW+9
M.QMCYQO.ZO#P@(XQ2Q8^O0SO;0PT#,=?[JOK=M+ZOD9#3DH8]8$YN=SL_(#*
M&C'S9D'T0 O#V_X [0L_;U+.(=V'Y^\%L?K])5Q_5&14206"!0@1@G"N"J)3
M1XFW-M4.0(8[/8\_F<TY\P!3G&F>YTPXJW*KF60J!3F$SR?H' 2!MMOMGP?Q
M-C)[!X9Q ):9M3V_YVZ)"[_=.K%G@6=\*2#?V,&GQ$^>;29T-0?YM_*34[99
M"-D2E%]#4%Z+WL^.F[Q)[!\D'=R#/QU9>3Q6?KO%Y-Z/73C!D7A@NN"GPLU9
M\2,-JS 'A,_ QGD?6M3G1J2YK(OK385YEYJN5%C'<B.S5'.3YCKG>9K"WJ&4
M4<=B,/4M;%(SI6ZNKW13KSDLBX29W7_UH:M_3];?GAL]>=-418S)=D\_7AR>
M[K"]/W;./QWL)OO;7^CAYU<E/!_:O0/W@0#Y[R'??SU/C'EX^>G@;7GX^3"!
MZ[N[5^_Y_@$\_X\=Z,O;[N[G;A?:??'I\S&?(47^O,7WMM]<'#FF3.)U2@J5
M2,)M1HFVVA(E)4N$E:E6&?H\%RM4M[3(/XRT/9;[+MUJ^>4ZMO8EO7]^;.V/
M $_UO%S2%H;N!$.[BS"4L]1:9ARA3"A0?KDF.K,%,2IW12)RDZ"N1\6JT(N[
MTO2N4<&(IP)#R#4!S8F4BA@G=18][DN$P+:(Q"/"4CU/[[JJAP4!W]13U:+4
MG5#J_2)*I;FR&EF8,Q8J76M'A+() 5#)J&!6VER"L,3YTQ&6:KL8--:]N%9W
M7G;E3R:);=<\DN6DCDXKDZT5^-4S=* NHE6H!;T[@=[A/.@E1S3-$ZH<Z(4<
M\(Z;+",R4RE),UDXD-MR2WE%\M>*9H^S)_<Q9KX5PM8(A\*,M CT#0AD%A$H
MH5KZ3'@BO,X)]YDB2IN$6"$+E28* XD @>B]E</ULU&M->P<A%3H9<$0#U;<
M\5G["^[6^1:.Y^ XPFLHEWA;6&ZQ^$Y8?+R(Q9K[PC*IB#0\0]HB1J0M<L)\
MD1AA<^&-??%2)@]EJ+O=YK@G2L]%9%(6"]]_F^PXXR6^XS,:O5U2.NQA_-!/
M\*#Y:QJ(="\O?^O(;SCRS]1EB)QJ/?BM!_][>_#?Q;76'K]W.G[?Q*,W',$[
M2.)^L7=\9!331>HUH4I@_HFF1.3,D\Q*BB3NO)#TQ4NQBACV">M"3PAA!QCB
MCM0EO6%K(%XW1,+):4@4+2C=#90NEX$2%9PE+B,N33WA-"^(-M00);EUBM),
M<_GB9=&:B%L3<8M$31-QBT/?C$-72W HIYDSCB6D4(4F/'&&:*L<R81"LCY6
M"&,> H?63SA::_")AN*5Z40_KL;ZLU9>'WAT6FQ?47\2UF]K=/Z.P)XL W;M
M.&;A$U/0G'">62*D*4B6<Z]!WLR5<M=1<SW2)KK7H?"?D*2XC&'@:1&+->K
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MIPMB@SK[C;XYG1\_!;W\]-7[%T^H'8!] OF)X)<W<V0ICS]]YY^MK#1?%%I
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M:%<R%3N1_ U!HD^!&348C#)[FXV)ONGV3(Y4>J;B$7 J7I.I0(V)7 R@2"O
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M^NJ"4H6CU9)2<,9;X6,@5XKOA/)0A/+BW<M??OHY:4>&008Y,JLPMUAV*;2
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M^>'7=Z^>_8Q6FZK1@@U6 !95(.I:0.F:?$3#ZUXQ>8UI:$T/K1YQ:'4]T'L
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M[, S%T#V1D172@PZ3O?MGM&N8[]COVN''A/:!]HA+:(H6 646#(@&8YE@E;
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M?!W>>U.@T:%[( DJ#&\3(C9A0&)711,DBY*_<S99GPE%$P3VEE\=W5T/],C
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MT.UC$5D59:MT%AJ9M7+PAHHF8J\T1>%&I"7J@<A=R.S#-7*A9&PV*C2!,U;
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M\=/FQT]BZ^.;DTU);7GWZ7AA<'_F.5LO$L,H(@.3@06=#+,R> U.VY##TF*
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MS6,AW$;9G.;W =4YI[G2R>:H"JO19@R\%RSD3&9JR"%Z*;VHQTD[LZRZ6^U
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M(7DNL3S_=9#W1_-908_<J_*WU3)=IG^_'L]&XZ1K<=*"^FI"6!=\*HSDAF&
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MP\[9.7^CSJVP/SCL$3]2MW#WV36P<$''7X)W_\S _-=P$'-.HY?[4W=7=S#
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M>*@%0T7BBMM:NXB+MI_XB%%=?74VJE"*]X %0U&9N^( 4[4O6T6?507TG$,
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M0<MB5HD!>L-0U>:CQJ0$)LFD6_[ -H#:>&Z"]H&TZ0@)@M,EBA0\J=B(Z39
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MF&L";\>)8))RI$'4PT=&,1 866V0S;3GMB2CK#7K*U': -Q? *_+%]"D[%J
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M<G2Q">L;0+KK&+ R*>,*2[$4!LI$AE(41M3M0>>45< FK+< U,K94K(5&2!
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MZIT]^P#6[4]= XZ^<0RF,6ICU-XZEAJCWA&C=EQ,)!.]=M(Q4*X0HTIDWMC
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MB%M1@GSKF:#7<8W&!&MG@DYT(UEM!#UUIHL6#((/S LO&2A$KYWR/,O&!-O
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M_E?ZWJ.C%\_2Z(_]U^*/5S_ P;,#=2@?B]_?/UIQ+"DI"#8BR\Y$!D9%YK1
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M!.0^-N!J +\_3KT&\+L#>,>OEV/)(;K$@DN. ?# G V>^9R<*ZBSU^L[+]H
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ME26:Y9!5S(S"_-(R*WX7%[\TI!0DC4):+YF)+@8#DB4O' #SMCJ\']6.G5(
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M9"*1G0FX8 A5%#0:R%K&^358J0!?7( [[03+2K"2ET8U@RPTDQ1Y'[PV@E:
M+P7 M\8%=X*@N(F14$\M*3%(XB2C1"LGLTG90_%S5X O)\!G4<&SC8Y:EV,V
M >]FO$_&.+ V2L-4LE4%7RPDCXMJ7*[@$+:E=J@G$D0L;FQ)J# BJ!!9A+1
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M'.,;MGOX[FSSX+/ZZ_S3V=;&[OGF>3C;W-F46SOO/WK#!5<0"41?L@8I)P[
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M\]<OS74\E$$-C!G8NSFY9V3BP.W'!MB%]CZ"?X?\"5R7TZ"J:6<GTB"3PAY
M[BA-;FBBC1=B?,OJMR"W$3[)(_U4>:(K:1ZN^F49V;.#RV94MJ! +V31K *
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M!(5<AH)CH8&H"H5\$())9>"EY(;5<H;@TQ2Q@Z^5WOSM/]M_C$,!:[6_C]T
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M+LKD%2B3TQN4";Q\:CT&$NX8<')I4RY]S1"V,6#EK3*<K:P32E85>6E1Y*O
M*1]%UI=/RD%X:KWCH\&1/:CJ.5^N(C)1=^-*'9/#?BO'&WNCBL23=6">U B8
M@L!/%U%_G?3^F1#Y/^-J+Y]Z_6\'A[.A<J-W]'=N/E15&OYK7"6AP/%L<'QV
M$[=GV@D*9![>= )N#TALC.>P*SVA& -&1P]P;&XKB#DKL9]>TIX-BU\L97\8
M&L\-?^=#_D?E1&[8#,4ZF-L"+?=F?F7*JI@0<]19^ :=I8Q,"4P%)!.)H+.(
M0I8[A9SBD@O.=8JYA<ZJH8_66G,7Q4=IM=^J0DR7JPM?+G.YG"W.WA_=6@_R
MKJ* 8S56U2N<J0ID54DRE]!Z<'<*SQPSF#IJE.7,&8N)(-PD:B(7+JE;0$8_
M,,/]PW'FMU]'T]AT!_TAV)R#T-28LOAN%L]=6>XCKF_L_J0L=[D/%*@KR3VU
M7$1&DH2(-390$EC N4/VFKZUU<FPOP!PJ:.6[<!VL=G6O;MLY<-WJ+U-)"ZW
M2:B*:(XZ?N:W>Q!LOZHBMT15$/U>#,>=N)7NT)>C'Z[KR3>W4W,-1/_36(L!
M72C"@7A07<D@1Y-&@5C*@W5)*+-<-1!SRZ@##R_W2BW76_;O9:/C2N7=\W*)
M-Y1(K)3:8+SG;_<BG=>+'9<EO=+VUME.1M?:8"_&4:L..QC5.AZ\>X4%$C5;
MDT;,O^8@7R-XNMN^EG,!CSU",M64ER^O_7JON/DFN;\$D[PB:&C,T![G,IE;
MXOYK\V;,//_BK"C.BCD[*W;:]5_U[C?2/-ND0-1P\^P]W=KX!!1MI[WSX]->
M\^PC_/LCV9EP5G2Z];./ISO;W]OU=O,,GM&N;S1Y_4?S%&;::?[XU*YOP[^W
MO^^#,3)9@NL9714/.""TD+2:EX!NEXY+5@08QE:1U%LIP%TQQFDSR O6 =9=
M6OFO%PM_OUDY*%@U$U9MWE N,&K)4O HY%/]7&.*3.Y,GBR+U@8P4SE@U:/K
MPSQ?CO382(/!QKOS^&[ZYEL@P.=DHI8_&]1Z5?N3JB7U()..VIAU/ CXWD1V
M].))WLW<;BN_RJ]CY\W![N91[!:,G DCOTQB9'"",!(2TC92Q)F6R'$54>"&
M"QEDT,2LK'/UFJIH77ZV6E-BR3%MF!IQJRV_P"C\*S/L2YK"DRN%RZA_?T2E
M6/+S0OYOD\CO*4V8:8LHCJ-BVCE C+S$@O)DL8V _ 2O<OPVLPZ>.SA5NZ_7
M<NF/?%M_9(%O[X_\W)V.;VRY.D4+U84V^/MZ)2BZE28;_O7.H;OT_MO8_1DD
M;&G& S(\'\+VBB*G3$+,<.UL CAU$PU^EZ5+[B@BO-<[&8S"SMW#WD'V.8VC
MX</FK+EOY>W1:]A,U<U&O0 'UYH!UB[2HJIN@#E@#C_@UQBYEFS-"#W_R#5<
M*![6,7 !K?U>VF#E[1^_V)R P7,6FGRA60)3UFAX0*73ES+]::HFON+IXS>7
M%O)_;\\#<1'TY$%6Y*#Z1ZVR2R9(R02YQQ]$)4V4!8$M#EP$IQG5^4?&+,MG
M[J8MKE?\0=?\0;1QMDOJ&QTP-IJDWLW/^2*V/N_ LYOY;QCO-]$\ZW3.KSGW
M!S79UL:WDZT?FP2^<UK-:6.?[W1AGNW\]T?:V.ZT8>QG-V9V>,R--5P@(J1'
MW :#M$H<.2F)9&#A>'B9ZWI5X\FL\R7-[)C3P>N"?P7_KN%?8%PI(;GGTO)
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M^F!P#6HV#[K3R7]73_='Q^..$;7!L>NV!H.\&G#_")-M'>S6DAT<W3 &.Q@
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M3BO']NO=[YWZ1G5NZS3'_9OM_5]-6H<U^;17S:^[697NTE39Y+%"N9@+XCX
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MP5"1RD2C4-AF@Z\:=>]F</,JS3-R5KQ>(+BO)Z,!@B<!@BGV8CEU209)7$P
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M] 0AZ!=VIBM;TID'Y_?S(@7_G;OI0W_P)^Q"S4ZUP)UJ5HTIEBPV-%9$:"&
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M]WYXV34K^:VN>L-9P7(%PU07?(-G89UX2<#-+)=\-5;@;OU!!;UOP);*@]H
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MXSW&C8E;8YEK)=A&YNF-3;T*B?*H7 #CAUKO:!#9I2BH L(]NR3%Q_:'J8Q
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M.=4\*DVXAA\R14J"S(&X -!O(J/P ]%EVE-US3GW?#DUQ;.40/.344P*0X.
M'QD@S02; U7-+O,8<K"_O2.+P!;)C@"-Y5@T2Q*?89=A3G@:LL/H>4RID;?;
M9>8L["E!V:/$<H(!$ !H!_"U#'"#81:9A4;S%[WBI]L[F":E5%;8Z \(<BJ*
M>"$\<3#MAL%>#-@[5X3+?)J?O&611YO KI/9AJ"\2]Y31P.H?RJ-YC^\'+"-
M]8\[A:KLO36D* VL,A1*8!4X@=510 5L*5S=)IGN3IHOBPJ6*NIY"=(G[+E#
M!79!H EL?>L:S5_TBF]]Q$PH'953)$4/*UXP&[\427@PRGL#.[[15:K<+35?
MS9T59[.VSGBN*56P[1N?X#>#L28E:1M<H_R/( KM]?<[V&23"Q"%4 QL^QKD
MP=D@B>-*,,L-T/$XQT'E?,JO=/'%"9!&['==BBN.!9=UB,P6-:G*T2C_XE9\
MZ_T.A?7-*F6B3("]GV.[WR(L$+T28,E-L8G.=3CY] >0/*8B@HPQ22-]!AXA
M3,E),INSC_Q&-&D.()].)GE[__V.L8YYAFT\@BE$,EVP09L@!<P!C[4WI >9
MU.R&&* %QK+>^P!R 3+9'$ N2,;@WZ\[8% J[4HAF#>!Y@[\QHHCU!7FB\4J
M4$!SY4T'2P]^ +DPP6D.(.<6%%E%[ZB@G#>!:$SZD$P$XKF0Q"C@0EF M4RQ
MGO%-90(>[03R"7>_1I"N$Z3VZ=>=Y(+20CIBP<0%,XL'XIA1Q#,:5*146RQZ
MILUU+K5G=@)Y'MFZD/-'FD5QF@<FP2I,-H2<6*092(#GUCD[SN"VDPSN)I9U
M\6*L-O8_[G@:@Z8R$26]Q?-'1WPIBC"#MIL4F4<-8GR76-9E.7_TB5JM@M96
M<,F9M]9;7JS-CA=X7GJ3K#7GC_>6M>UCS 601?FHDB:YP 8LI3+$IAA)H((E
M;SCWK*R\-?Q!SA^+T5:))(#2,>FD#30YSA250! !A\JX&$\3*[VH%6]C@^[L
MC39987R\PNX1C 2N RDL*A&BL\FX!SQ_U,4FQDS(C"8)2^Y%=I;QR++),E#6
M[#*/(0>GL,MX8R-L[D13S/TQDA+K%2>V6$>S@QVG^#FR[>?L),<XUREJ6;*5
MI<1@C788K9^="TG01O,7O.*;ZQ]W(C>:FFQ)P(I;,C%-T'0A+--@K,[6>#G7
M^>/\IQ#1.0T, WYJV&J2$S%FKD6B463O8Z/\#R\*WS>PK;73-"OG2'81+"41
M"G':<6*H23X7&7,** H/<@K!D[4R4V- #J3#S"V: M.%*UY@ +Y1_D6O^/[[
MG>QYB9XG @8$;/NN:!*$*P2FW3H!%IZ6=*XCR*<_A4 3-<O(M&-1,JQ=;!0\
M'1@2)N=LTRV,B.84XHED\F3C%% HNQ *%<0GP0"%4":C"P2V L '&BRU6""4
MWI2CLD2G$ N0R>848D$R=KJQ_W5',R^8T'CPBF7-8<Z!_O!(HJ&%6;! LT#<
MNZG*XH.?0BQ,<)I3B/D%!3ZWXV+)1E%#C'<6["$=B6/8VM:"J$1N55!EY>V-
M@=B/=@KQA+M?(TC7"!)MKW_=83Q%&8PAWI0$3"MPXKS"HPAF*,,MCRK8U?0-
MN]JRG$)<6W32S.[MAJ+\2_];!EP<7==P;JE.4BX473YK$8CE+\G186N0O_6[
MWRIX!T#OC%K%1^STUAFWA[NF(C4JJL=NA$?#$0QP@-7FP$SI5!6I)WL&<A)L
MBGB8!WY4[R#C69OTJSM[H97Z>.6)ZQV^AS57<[?Z9KT[S6IT6,$*Z.G1H!XQ
MC*BJ?_=M##L>KGO<VQWXE"?O3?5*K!^['N&5"M6I#]?$887<[<!%QS4XQP^*
M3?G&\U =&N"[EYX)RZT,8!8 $7TI8$54IN3YY,!LGL]-Z>;OG;K)WEKKW;B*
M:9V 5VO-N/HVOVQ@'/MQ5\B#PVZG*N-=F2E5)>[:=*WFZ'SF;]&K[X<B7$,>
M\]EF&XL$VU:Z+'WQ/&!/&^'@?XGO, D0<.%;9VWN$A[3D&XNHS?<@/A6??HZ
MO00K]H;@*P_>IV^V6KNSF7G\N_]T:5J86U/5--3@V0;;'^3MZL&",3(H3K//
MTBEE36;1QF1X8>AG'/>(9^,>\?4)_95BYU@RN-][UTM5(>$_@-T-\J@SJ/I'
M_IQ[N8#TK'>&L5LU@MR">__<[<>O3[[I_37>]/I\L]J<MD_:IU_V-]>WZ?;6
MU^_;6Q&OK;[\^J7S97];M=?A>YTKFQZ\OLT_\?;^1]$^V)#M_<][FUL?]MIP
MGR_P^2\'OQVT][]2'./_G+[':@-RIPC!0+8UH1*C'(O$DA; IH!ZZV0"HU*8
MFL& ,N7T#LE#U#)0H.$R<RZ#2];%D,'J2T%'J6E9:67@$H?8KG)PE%?>CM>D
M]4<79*D"S[K(\^7%:4U69[*_CD7DNOUFEB9W9G:"O'&XEQ_/9@W(FG7R\/14
M2NL<%P+^I%CX'4,1EFOC+A52_P*?''3"T>ALII_#)G[[+6%X"#M3?S \ZRSK
MZUU94O:OK_]N#3UN]\/6825CE6<@5K7(<<_(L(WT3["=\?%>OW60L7$Q?*X%
M^]_N>'>"#?!_C\:2.%R:RN&W)4!5A=MJ:XY[-24Y%X9J.Q]VAB/4L7-OWZ#_
MK3.LWAZS$&  AW7OC7H28;\>U1_%K@3HC.F-SOA%_[#N2P!TIG+/!-_%;1KL
MIYKKX"!F\9*9(UQM19B]@&3F&] 0K.QVT(?/8(?>_M%P_')M=!W6CU0UJ@:[
M+.Y5@QT3G+__;/UW]EUXQ ]U-]\/\+F)A*!.C.,D+G[RE_[@L%_SL7/VU#^
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M-5@QG*V\%78ZN>GV4-3X))98A1^!030JO% 5OLHF5/9999.(\0H+7XE,7*)
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M020I,M*D>*%&8P&T^R09-\D?=_6,74L\:O=8M]_;):,\.+CXP::8R=)QD N
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M&KE+V@=954/2 G4N B+;#2$5+X*"XK.T.;J\]9AAW%%[?U'KG4[.>%YSF2
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M2?LNA=<3R\L50)7#;(H6A08O/!L2R8 3)AB97782J$?I;0*B7?"6F9L)/#L
M73%DI)1L-4;'<@MQMQVY-T/N12D<O4%@HU]$8IL?G/2"EU +9S3H(I-)-:V7
M%-[DT_V?)OO[-,VW8/5OA%LR:F^DL9+0>9 NA6@H%4V2BDM&KKY-3-<W5L!:
MKR^I 1@JM< -X<DY ;R*(I8,0F'%TFJ<.)?Z0<,&(#IXKUG'4*0I@#08V(0$
ML)AUI:+DZH\..W)OAMR+^D:P9$W.#:\,7W!6\6^2]0WID['1*RIQZ_$Z'3-T
MS*XZ2*>D&I6C(',"UPJK(Q!D6:IA3@^KSQ?N4G@E6%X.^O?>DF2KWX)LP3O1
MB,CJE5#28U&^L$A>G=7?$;W&B+8)M<Q> IN25%@B5TPJNU),B$GU:KQWC=RE
MX_X(,DH@@4ZQ%"[H!0)*475P*14K,^;UDL*;?-C_?+Y+TQ&VO=_/^&_29P=]
MUA11>][<JJ+'D*A*;8PW!OH9_UJRU=ME:]\3Y0S@179&"=#H& 8I"[*>K*R>
M?*\WO!&(5H[QZ@JRAN% VY0 5('DL!H-TJT^7;@C]V;(70KO=^B-S%'XI*V
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M+L@0(#L?2\I)I=Z 8+TI8<F%D2II+,8)ZS$+T$""3;PDI(R>4G3&F;CUV#P
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M/K)'@]]+-@C*2I\H^!J!5;^0H5KO/5CEI:ZUZW]WC?HE7PPY*"KH)'34(,!
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MI\G^/DWS+5C^F^&:;&9AMF!YDX-SB%"R91F5,99:9*\#L):\]7K9\K>L.OH
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MD3Z@ 3\L!LG7FM*<QTP+*Y:UTVG[P(EW8.%U/9FP3]-41O]Q@Y.;7)4I)4+
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M873N?K.(NV"03IJ@J+#B,C'+>,P 0K6H *0"D"4 B/31!T&C9 3SE)BFPJ4
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MOWRJ@@>P =!'LP&<+?)OG#< ?@SNL?\L40;E=T0/D+K>#+'9?8?R*\O&'OV
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M>([12@OF%AL(1HL0E*PJA]B/%1H]%QI]F,XA'.:.P! B&5Q"W,:$M/<JBZ)
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M.A]VB^L-=J\Z'!W'NRH<73KF38:CC()52.\0U=)FJ>#<%:8%H@X3(GCTBB7
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M5U(V7<H^G<-X27WW$ZT?G^#&Y@X_$)$KQSQ$YB%*Q$'DD U)H<"EHT$1HS-
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M?\\"3I7M6T IV*T?J*BPX"PBERB$!\IQY#"62 NG?(Q!!:4?@DB=H>;5;+$
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M<#%-I9GS6TP7+2:6<>2C3XA'B1$8MP#N=)(:'&LKD\JYS"E-U6=XH?":9K'
MAFJCE0K&4\]3\LY:&HQQQ' AE"RW1T@%VG,3C<NO!S2(1 0CB$L+HN&%0:#K
M$442#,\-%24FLX&V-Z#%EO,0 B=$:;##P5J&79"*FS1<S$K/Y[B83"E!%34H
M.<X0I^!.:44E8CPX!ZNI39AM,7-_/BIHYG?2W#%04Z\BH\H:6&4G\7 Q*PL\
MQ\64X/(0^(>,R(?"@H+?4F29=40&Z8R6<C9W2CA!"">&$I(#'>MXHA)CL -1
M.S+<9'P(O4RUF ]>3$V$X)E.&N<?G,<(@0X!115.)4D@QC2^L,"32<U9+/!5
MBB(G4&[Q7>9=FOYIR0O:NB@V#J_HWJ\W#H?<EM<=]^PC:S5G"Z9OY=G'I6MG
ME 6X>F-S&/]O=7S.G5W+7T["O^>4^A[9WO7GC>,3MKVY!Q[@R8&1- 8(BE$(
M+J?4/3A_DON<4L]G9E2D..=2IZ74F\/9S:(T^$DV9M"=S>D3$43"$*$AHK."
MF,BU T/%G2$00MJKTSRW)(556#3#V9P=43\_"-(J%B0$ T*"VX<!A3(&(9([
M3MM<=:5%AB*))Z.!&\!R@UVX,SQ'/'VSN'9D^[53VPRWY:5?B]]C[V(D3K4^
MR%GN].F[[:)C7.WTS+6*)K)%#<-:[?/9X R^]TK>AJ<<^M/._(V?@AOE;E>O
M$N^]7&S1*S9FX-6<A^[XG)4&V2P/Q16(65(*)WCZ;F_8D3X49W1ZL16_YX,_
M-U./2YH/_A(/<YJ\"XOQY<:L/.YAQIJN#K?CV0OT(+\[;SPN!<U._ZQG"S$[
M W'+AS>[I[&4TGXM"W5>_;.B/?R(Y[I_YF#-F[;7')UH/.V!I#9/;:MU44I$
MO]BY."H%/Q<\#&*G^)9N[]!VAH?!^E<45?^N;_>OB*RSD%T/JY3U9CYU.6W\
M<.78!;=&UXN@<L4&3+-W0Z+[ SLH5[383?&YDJBXN#A#-*Q\+$ZU%EKNX4ZY
MC&-$?WE1W@#N?B4E0[]@D+^T++[,1W!#$Q"A5VYO_;&Q\=?:R&5X_G;0UQ*\
MT>_'P?MN!;V[<4!PQ 2"]WS.S /$:P_>I@B(!>P5)UX9,=%N75K)2*!2&.8Y
MQ.J:L2AH A\.>TU4&&\=O5LP1F0*^$S:#B)R5LA&)PZRQ]!M%UNA$WRI67QC
MOSS5':9=GS\POCD*2G<70?DMMM6K;[Q;\?-'LQK=4IQBDQ*,5-F/NO_A ?WB
MIY;)W#N%R]2"6JT9+.;>U5FO:3YKE^F7[D"];&-]V&H]4[/LQ>^3W1[OD_U&
MNBQ/-%%^7TVFLP5XWX^/7[6%]IV^/Y@>\1KN?S$M?T]S2*:WFI^YG^1[;SK[
MAOO.IJ"Y,?E,%N,V"6V-CLF!"RW!E8OTOBXC<I*(?2B.&U?AUE^C:.OJO48<
M;!6"^IA*T64]]W#5%FYSCV[O^LLZW1*YQ5O]\LO1]F8=K@_M[<V/)_7=KZ)!
MOY(I;>%PXWA/P'@N]XY/\/XFA$A_?.+URT/6H'N\_L<.C.V$[>]^G=[@400%
M:RD9PL'GXX<^((NE0+#NPB6;F,W5*G15B[L:W3R;(BUK"^X*$-\J("HGA"3>
M,\,5UP2[E QS!A!1Q! "NZ<U106("PB(XWTR133:"DZ0 \N&>&0!&:8X4@:D
M7L*26L96UMDJPW<=AJT L0+$=P*(T7,9;#(&8\>MP5IJ[VV*E"3%HW/W-&:J
M ''Q +$Q[B'&2*G S"*;$D.<1(XTUQ@9!1Z_TS)Y;C(@2GG7>=J% \1')P>F
M]S1>\N3 IZL-B.M]A]&>0]X@&.X[3$\75,W11QCH("+F)"CB%,N%/@:;X#6F
M2@$$41?N:(X^&_3]7J[/1B?\7:[.1]O*.SH5!LX/ [<FHV1#K&5!2.1\R*UU
M+#B%GE D$^7:&66\S/PH8A6 <H'ZI\\(;W<FA]^]KE.CG,348$LH%]YK#>X/
MQH)$(W@<GJ>:5]Q7Z?J+Z/IX ,A4D@:#JR.HAP!0:8,,@1^P\BXPZJEP%G2=
MKVHUV8:BTO4WH^M2$DRML%G5.7;41$$\#8)(I[A4LM#U>84TE:Z_A*Y/QC;@
ML 5L+0I!*L0EET@S^)&$4#1Y@YV3H.MLE3*]0+I>Q"__*NIAIK$(+?I!]D?6
M)15%LX]B[Y[WOM7OMG]TH[*Z&7:[?]E>[ R&3_+QXO=NIPA3"^J3&X.O>$[N
M8+L1]=VM R.PEH):A&7BB%M#P:W&%+QL;PDCVJE<+<:FT [61JPFW50#->OW
M;Q14CS76N%E_][-VY<M!+;)UW:\D/^AA[,3>J+JUUK+G^5S+H-?T9;'M-0M^
M06-V/4?75=VAF3_OSLH+X)8%[\I1MQ5BKY^9\EH 0[E:+W=C:.7*\*N2]OYJ
M5M;^7=6[12DQ:/)Q]$5GB'36*[YQ6$);?M^1':QF1IK<%J9X-Q/[Y0KULIU-
M48<-KW7[-V\,-RL*C&WF  2@S/]MQ>^Q53SED#\PCVHT&657BBO>FP?,0RYQ
MSD-PL<2?4JB:O='=AQ-4G!P:+<AJKBP&).K$$J**RN*"1R<..K:VX>'2_O"3
MMSOWA'CU'$6UUL">%!PKQ3!&LW#::W9[MPJ0,XWA=UC]6X^4:7R&]X+7FX/^
M3Q?I^<N3?^+^;#;[OM6%,<5W7:J\N7% @T^)"XRLLQAQ8C0R@26D/$09/!D1
MF1PO578J&J9$Y%YCCKG3SMH$+JKP,4H2]'BI\L;=]<.#@N.I5) 9"H''DILY
M<5NF-:?6!]\[[I>N#S9F36$U2WFPUFO$R+F7L9HUB1]6'%N5L<Y8\_C2]8&O
MF^!O-SM%<[+K1/_H4,'0N!0G7*Y,R\2L/F96WNCN[MO<P)WM@/*\DAS#<W9O
MG-MXF.4 ?^ K1#V'\!W_M!K''N^W]YM[;? 3-D\NZK3.Z[MUW/CVB4]F.>IT
M?_<$? AXGF]?:>/R2WN__6=S?[..MW>W+O<N#W_4+W?('MQ[:HT?LPFGZ PB
MP1IP+AQ#6E*#@H>8F,7 "<<KZVI5\7G5^"WC)NUK:.I6YSM$*,/XK)-/[V;:
MYC)PN.'HNVX 5_U.4_?N4[7S0K'RV.2_8RM\O-@:Q4I7IRK[%1(]"HFF[*,*
MQ6+B1" BM,G5QAYI8BD*@<+")9.4-"OK4CRYM&[>R=;WXRD.V]A>LXO>RHN<
MQEZ[.1A2TF:Z@P*KNF>#N[,3,\'60_W*"K8>ZGR5M7(;WVVSE>/DS]W>**,]
MZD_YK5S)&Z?(ARM8N6?S \7Z)"A&1ATFG".NN(0?!"-M?4+*N4BP]\JSF(]@
M*'Q7TZ]7<\\6=@_JD=P?C6ZG8"KOMEJ9 F*K:$'<?RSYQZN1C4]/Z]T@N^K<
M?K[FZ/G*5-]C]M;FA5GU9B=S9UR,IOIM8\P3TL. )X<'D5B?:ZN1LKD5A"(1
M60$!'>?2$BZE#T4-+IXDKAHERNYG(YT+/5ZUT+,O]/;FUP,J2;)!"V2-\^ @
M1XQ<,& 0=,2,R2!2I'FA)RW!:*%O,]NM9K^L;7L .[6B>5 <;F4U>YDZJE?T
MV1J!07,Z:]20' AP(_<TRG0W:R70Y+W\,609?6)X\8A]+]\[-Y8H_<9!MZ U
MR6\-M]%&4'H3/^]TZE\*6(?/,&UL+S6$T6[CD,_+WZ@RJ+FR0@CF,4+0.K9Y
M/;6UU(.8J]YAWREY=]^I/-X"B(B-.FJ?>+ 2,)#;9,%K4YDL#OX%>@ *L?):
MW:INW&KHVJ$<8GZ@:A0M-3O@Z0\^H/S*L\_S=!^+L+674:5I7__;K7DA?.UJ
M?_(9M[XSD +$Q4X?5*<\L=3H#A9GK_MX8V3CCAJ;H;77_HH;QQ#T[&[A/;IW
ML;UY2.!>[<;ET5%]\^MYX_@3WOM[W,9]P@WZ3W-_=X<VVG\>U8^_P'=O\>W-
M?V#<$.#\D7M9;= ZC/L_EY\NP'X>>.K!F6 .66D9XI@+9!(C2#HKDT_@UT0\
MOM?MC128@Y.I ^7:*R,5Q$@JL$ ]"]J-[W5O%S4=MQ:@5JY [9?_Z?;[OSZ
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M(Y [!T8 8+E$D<4B=]\E"5F=-++<)2%(BIYG@9R277_]Y&8EB6]%$K<W/QV
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M(,<#G5I#O*",(Y7:OX-REPH 9@: R>-WQ,;@%$>6T-SAQ7#D(N"!X3$ZQJG
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MPQ)%GHC$%;;18;&R+M:>3C1:51G,S"0TO9C@R4<J%NY!WVNGM$4*3V]N8U0
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MH19_^-CO9RC- 'YK% 70Y^.8@#JWX#YC5=E6L_9[KC#]&#LQ91O0CX=YU%=
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ML?H4#&$4L>#C%E$:!!2Q\408Q'VM\=:+V&4+6LH@HAE8T$&H T+C0)"<*4%
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M"!2R1LL2J$"#1$/#S9NA)FAG:&QV@;"3^C_'QNJN]*DAEYF^ $&(/R$--&H
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MT3,CLJ(@IH\[V7II,ETFT%E5+HT#&O0</*XW<W.&KK( !8\-41Y-)^0?<#7
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M:*YIGB0LTZ$T.!%%F.8Z>;^/U1Y!&""(6A2%41PNEZ.^L;&_OWP49+_.E)S
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MT_9,:^[71MN<^]VBQP9MQWO:4Q=_9_ODX,?J+O741X+*&U'B)2@I!'_@NW0
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M,?_R<<+5N%7[QZY6I]GD?%<NL?(07Y9G^(P?X>E0!952\1R*_FU:!3-)0/R
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MQNY2N&9 ?[!BZLQCD"O&<9:^6)$FC61J%1PP#]2 ."!N:!&2A,RWP\!W&/%
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M:@Z5II'5RZC*#Z6@/ZL\VV-=VAN%>TQ2F9,AT7RB5<93RM*2=$Z[8)'! 'H
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MXDP.YR1:]J9]?L"QO&<DZO"453RQ1K5P\XP&-%XCJU:&D;<W'$LV[2/?0_D
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MON<.WHWWDCB(-&ZRXYAP%=VQ0_!;YMM:T97C#NW=,BWM:<<PK#SKUF#.D@3
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MZ>KT3^VJK7T\^GQ]>M72SMLG[9;VI0/_*%JM:/5AT^I?69+D[('C@W;A&5O
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MQ5<:<G57::X:/Z_G+U8K6J_^3K/R\V+Y#F?$2W;^FWM93.1JM$D"^L!:UNH
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MTBG5^S[@]M2-*5T\8HS?,]=U"/'W'&I^'WU7P>8U^K1'F1 MFQC/1B&HP/9
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M?[1#\9LE(V\6Y\WXNAR)/_[HW@?B.S!RE./P^^F9".^E]EZ#""U\J5Y!"MX
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M-.VR:%)L,90HBO)!CO CYXS]M\M-WC)69JHB>&S3YUBN$$6HP$%M5B)FU':
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MO@O8I8&$'UF)S$J6/B1%&HQ+ICW=.:HNL0B%IGT6)<.(!V(-G+.36(H++ I
M4ZL)2>WJ)/. 7H"VEL=JHN9FK)36RX[H-%RT 7+Q8I>E<UDQ7@1+@1AWF>]&
ME( EKU";B/$2%1&%XD14PB8U5G3R\XK)MV]C.Y8TG$W[<:N5=VE72EZLX9X:
MI#]67>\ZFIY=GWS*MS:I2'XU_$8UR+]Z+S+XNB*[9]EKE)IHF<I4^IZ\9TEJ
M#+Z0\R&#";'YG)U3< W5)K>0Y['ON]KE'<L^XC:ZRGF[(!9"^1F$?9.DAW:J
M_],(P/LH8F6.)\$TUX5%SW%_A10SY*1,\^Q!2_R3:O'>7"B?Z[(WXWPS2_@K
M$KV#NEK#\S5^IYS0/G!MJ=;6T<U?FDU'$^G0*0;AC/15MHXR!\"=TLG%Z()Y
M*;:.:XL_Q/6R6][1!=]/]W$]8/S*S[ZIB<T]"6;33LK$1M(U1Z^:H6@XRV5A
MM23JP)T\\XY75D)55D<ILY*-M^7+J(;JJ9??@)^8;PL^NJ&37NI;L%EW:;N)
M:0Z?5S0=#O^(ZBSQ(X\-QF?!.B]M<"PG3<W%>4:7-A@6(J_ .<]1MRYG&V<E
M4PHA&\OH<]TV 5%H9GY1Z7Y?SFDP06/ K#QSF=IRFA 0IE#H-("QH"K7S2?_
MOAKDI$+8D:5Q7 XV$[0O.UI#N?J*J[Z#O[>+!.OK^D<WW^+3G=GJK[>;?A.7
MM'%F%G>"4")1A$^-!XMD":QD0A0#TOB2<^O;X*^$V,"B/)S#QCDZ2HO5\N$-
M3UFX>_8N]E!NXC?Z\)/LCY7(,:<EHQZ-3$NE46XRNDO)^1IE,%FW)M)PU%.R
M%&-*Y1&S<4E^C[US#XB#J+L\2U$H+:5B*E&E;9(6(1K.LB_<2FF"XJV/#UX%
M<$I1V"6E;SPNCAN"W4)'S4VH*/>A#46_JC\\.S\B._&+FP1HYRRB4;QV@SJG
MVRYZBA%WT[%FU>@"5#;*+1I][;-A%.B3QX&>9C7%-&_7> !B</ZD6U./FR=?
M.S,R*16D8;DDRS10SR..'DZ(-()#V)1\\Z*#(SBF9-^&<?\@<S*4ZLULTE6/
M%$ ;^10*:BPNDC",9^?0/-)=U2 JR^A<"^$J_C(U%H"C0*9D8]I*P'"ZMYO#
M >4 2'75@]6!"9<DTS55NKL,-%=:%V=<C=8W%H C,"8UD+$M_X<2O1GW;U;S
M+G^[7\V1FH]U+%?+\GX>NP4=OU""8[=:*%SF1'T0 )V87:8X5M11A<>HP"<7
MFY>#GXKM(C3X<[WJ^YD6SJ&.KBP4*OKB&/Q'&PS3!;>G4;FXW-HTGHYN4@9S
M#+EZOHM&8ERSS77@KEXO'[#]<,WR$>;58K7%*/7!+LR*Y@6X!&8"I1!%"LQ'
M7YF1%E#K^"I,Z\KAL\%.RDI?0NPNP]8WE,*==9IQK7GBH&@J&/[0U:,W@O9-
M<*6$KJHJW[J"\$RHTW(4IBF"K^?IN.<1G^".SN)NX1]*[2SOGG;!7-6/W1)7
MU\7Y7Q"I*2M&^OL_Z3>K]ZMECV0N5)OQ>;797:8[]_QB)"!-SCLN0:1&YR.W
M\!666^AG:&9+RD$Q")E*"C&2"1DC&6=L N<]0&E]EO[X[B9)O,<*_WTC1.6X
MEI122KGB5LV1LR!<8<H%&X5) FIK+7@$QI1<N[,X?33;-H#436Y4',1TJ#WW
MJWM,,:YCWGSI-O?OM[BC%K#^\.\^(TTEK_BO[ J^-!>1&XN18/%,6^^9Y_B_
MC'&\+356&?0+6J@AG"GY8X-DY:U8U-#S>CU0[SU9:,>JSXI<1-P./&EFP63/
M5<VB^?3&D63L4G? FNBCL5EUHC.U?TX_4NSA]]_^ U!+ P04    " "Q-$A6
MU_3DQ"D9 0#ZP P %    &-V<RTR,#(R,3(S,5]D968N>&UL[+UIDULYKB;\
M?7Y%O35?7W1Q7SINWPF7EVY'N,L.V]4]\TG!!;0UI91\):7+OK]^0"VY*C./
M)!XI%W=TN)1I^? A\!P2 $'@/_[7MY/13U]Q.AM.QG_[F?^%_?P3CM,D#\>?
M_O;S[Q]?@?OY?_WG__@?__'_ ?SO7]^_^>G%))V>X'C^T_,IACGFG_X<SC__
M].^,LS]^*M/)R4__GDS_&'X- /^Y^$?/)U^^3X>?/L]_$DS(JW\[_2LS(J"Q
M"E+R%A26#(XG ]EY^@=!9J79___IKZ4DJ;AU@$)Q4$EPB#%RL%';[&5PVO'%
M0T?#\1]_K7_$,,.?:'+CV>+'O_W\>3[_\M=??OGSSS__\BU.1W^93#_](AB3
MOZR__?/JZ]^N??]/N?@V]][_LOC;LZ_.AIN^2(_EO_SO?[[YD#[C28#A>#8/
MXW0^  V?YV?_\"(:_<OR+^FKL^%?9XM__V:2PGRAGCNG\-.-WZ@_P?IK4'\%
M7(#D?_DVRS__Y__XZ:>EY,(T32<C?(_EI]7'W]^_OHYT.)[_DH<GOZR^\TL8
MC0CQX@GS[U_P;S_/AB=?1KC^W><IEAO1KZ=<0>D*YW_6I_VR-Z;/!&2:3B,"
M_1;'E> -,6YZ^OZ8SYX%&4LX'<T;(K[^[*9X)R=AV%+ UQ[= .WB07"")Q&G
M+:%>>NX%G&N05Q'61Z:OL\\81O//?TF3DU\6^)Y/QK/):)CKNOIA3G_6A78V
M*6^):HL58'8W:'HL 1."B^6[_3\[//0"8J+&<#RLOWY#/ZZ>7,&UQH[?YCC.
MF'_^:9C_]O/0AVB$-QBDY$I)&6@/\,GIS%B.M <,.CR_SF(]C]$D71IN5-?0
MR9G21R'B:/';P>D,/H7P97#V4)HXOJ:/LX%14D=E"^B  I35 8*3#H2PGJ$N
MW*5TG3*S-05+F,4%:59#_%+U\@N.YK/U;Q::6FCI9A1+[>P^K_?X%<>G.'L6
M9_-I2/,!CYEQ1 ]HDP=E9 :?O(&49<C&V"1":#RKJQ@NS^F<<\^FZ]FM7MD=
MW^EJB#35[GS24*A+S=$$?OYI,LTX_=O/K)&27]&\Z4590/HWV67/3V?SR0E.
M7WY+H]-JTCV;S9#^GS^&;P/)<]+,,,BY%%!!" @VT_RUURXG(UPN_?!@&YB'
MI\I^NMU,E-X4<YU+?%\NO9OBR?#T9/8R3,>8?T,20%8YE*@@!Y9 21\A2DNB
MB%H7R4PNW#1FRC40#YP'^PGUNI;%OEHF"*_'7W$VKXOB:_+X3G 0.2LZ6 TH
M&:V(V0OPJ!D(I24WY--P;*WG#3 >N*;W%>QU7<M6)L# %6=E00.EQ "*8P+G
M,X/H ](_<TR8OK;^!Z[5G41X795J7U6NS-WQIY??OI![=&%V-J$,9#Q#R('3
M['2!:'($Y81WQ0:?0VZLVQO!/'C[KHV8>]B<GT]F\[?E[Y-)GCT;YP\X_3I,
M./LP&>6!0W2*6P:H)3$S<@T.LP<>'=>1%Y:X;TR F]$<G@&-5#;I1=Y]F&GD
M#:?OGPD)3G_%,4EX7B$^'X7AR8SVG=/I%/,_%E[Z\S#%03)%<>$8\,7K0-XV
M>.X#($9GI.<VH&MMQ&T'\;%PID_-]& )_ITD]68RF[W'40VN?)R\(:E_6L14
M/N!\/EHLJP/MG?7694@5'YFNC$R81.X)]TYYDWV1K6W#3L >"VG::Z$'0_+U
MR9<PG%8D;\N;R?C3F^%7S-5UG<\^3G[%%\/9EPDYL6_+((>D4&* [*,$A8[,
M),$8*)8D^:^T;"K9F"Z=P3T6RO2CC89&:_HZ(\-L,L5SI,\_A^DG,J-#%.@S
MF>'""TTX?"(+VEN0+L?(.(O(KEBKUP+;-S_]H2NXD=RN:U+OO5>0(?3G<#0Z
M!U;7K(%.)F$* D3RQ"J>!03R;8$II772UL;0VK;8C.2A:[ZAG*]KW^SS'E^;
MYUGH\@I39]>QSRKXM^/ETO0/'.57D^F',$(RBI9_LW&OBTDYGF6B]0IILM$8
M",9QL$+':!V2?Z<Z+!$'!_[0.7C_M7V=VK:%7UV-]/5\!YR9P(TA[XY52TM)
M\NY$H=766B^9+%:FUJ<C5S$\="(UD>UU7;MF,;1E=':QLO(H0S*8@*.F?95<
M=XA!.)#:.F6-,+*T#IYL@/%XXF8[BK8']_;U>(Y3G,U7[!NPHK7$C(3$$YSB
M:BP>,Y3DC*+]4Q&HUI[)90@/7LO[B+0'K[2ZSHM-!VES>?FMTN]T./N\=(Q>
M8*35BYP=FJP'IDT )6K07JH$GDRF8$QB(FW(_=D[>'$KJ ?/@K9B[^.L9/X9
MI[]-QI/+B]*:M5SS$+139&(D11M9"> \04Q6\!1%3,*WWN%O1_3@&=%0X#WX
MKN=;TCH;8S@^)9#G&62_8JG&[>)['\.W:O62]4/C#\=A^GTA'YI=JGD<D]%H
M,;_E0C@0VDJ'-H*.Y),I26LAD9Q#1FVUYC[0-M=\4^EM.@^>B/=%U0U]\,M3
M(\BKMVIUP##PD066R*;V3I"!KK4!AXS\IYP%MU8@TZH7!EZ#\DC8LY^(>W!1
M[R8U?6/II+^;3!<2G\^GPW@Z#W&$'R<W\+EPG5P(!;PHY'@[13X>=P6JV:X,
MM]JHUMM@/S-Y)+P[JH)[\+8OS^K%<):6$\-\/J_?D$S&FOI8BN/16 ?,JTSB
M<YZPDM=H,[.*"^]HC>V5C+?C>V04:ZB,Z\3Q^^>A3FC57800A.)*"Z)P6@2,
MG$5P67%P+NJ@ZB&Y;NV_G8_^X)6^HR WY*SLG:>^2(Y<4[#3ZB5+\<9:!HQ)
M!%6DJ!-G(*P0645#ME<O.:G;@'SP#.E7+1N(M'?VTR7$-3I=,$1.<P_D61*1
M(:;$04A>,L/,@^5]DN1Q$6 K<6Y0[MXAVYHD3V2;O</IA\]ABK^&V3"=I_%:
M2V9X45"<U4 ;D83 HH=<$J92<I2>-5;VK8 >O/+;B7L#&?;/.;K3*B;<"\@+
M\(.88R[6$'E%S9!0G'8W'@F^T#Q61ZW$UFO!EA /3YB&&M[:9]E=.STDS6ZT
M>#L8Q6N;^,ID8C8B>@^">P<J%DGK)'K@ KDO/EK=_%Y4TPD\)B(>3[,]G%EN
M%-,@...X#9X<L)HGX12Y]$7[>J0:47(I8VZ=9;41R&.BS?Z2[N% \]]8"Z9@
M?O:52/H)?SNMTGE;%@!G;T_GM9I(C0(MP2(C RVCA2@T Y6Y!I\$;?W!*5.T
M4$*WOM2U%<#'1)?^--/#^>=5,;P8CDXK]C-!&&^D# @Z"TN"()8'9P6M=)EE
MR0,CHO>\GER!].A,Z7U$OL'\V9L2G<RU%>CE3F@]28.V/3",P"KAZ_%'C! 4
MK_\W*NG6B5%;@SS^"K.7GG<QJ7?6T?TTJB]-Q\ABO9 :4G89E(\&@F0>M)%*
M9Z-Y<*TWM,93>%R$/*9^#V!<K[ -R-ZSV29#-K^DW=HJ!X'S "F0O4>84\[Q
M,-OAXZ)/"WD?SLB^R-2+%MU >N6]T0DDXR0"I3A$\@(A>R1S+B,SN76"Q980
M'Q=M^M1/#\;V\\G)R63\83Y)?[P8?AUF'.=SL6 :T7_R@+',6;$2BL :5H@*
M7"KD8=KD253T0K#6.UL77 _>[&XN_ U6TM[YAQ_I>V]+O0Q1[\R\G:Z*";RL
MA?!FPSC"-\,9O3+:)QYT!J=M)%LN,G!!:;",1Q=%*"ZV+N/1"=B#YTA[\6\@
MR=[I?6>3_EB/7P=8Z'\8$IBZ/2IN%1 ^#L(9Y3)JK7SK"/-E! W5?J%&;._*
MWD.,FQRDGY85/_^:1O5"]=]^GD]/\?R79/CBM_G+Y46VO_T\PT_7KP%V9\)L
M.J\9&_DTS<](^NS;<#90&C6Y<@:*K1M<O03L?0G 978J",E"[I0$0P-<X ']
M=,Z!F\9NR();JO+>PHH=U#AI*,Z&3O,%/!<KRKQ8K(F=0 VNE ;>7]?7@;1<
M[6\J:7RN[C8ZNJ[P1@(^F/9=,3863N:R" &4K+70$RJ02I#Q(I0-K.$;?BBM
M7RH,?12E;R/77@IJ+H#]<V'O#+)Q+*.Q4)RA1<QE#KZ4"-5)L4IF&X5HG\MX
M#N!PAEQ#I5S/:-Q1HCW4WEW-:P4FHA$8C0);DRM5=!Z<0PW26\68BD;JYA;;
M10"/0;V[2_3&M_<_?KDB#[(S_VA>J'WA<"X+?\U>_M?I</[],K"]"K9O>'B?
MA=OOFLO5 NY)IVR=,SS2.Q>SSXE'$U 6[;U*]L8"[AO&:5[(/9G$,*L,)L5Z
M<R<:B$H)HI!T& 2ZW#SNTKZ0^^MQFF*8U8#&XK^OEP&/2Z)[/QF-7DVF?X9I
M'D3#/)/TW@ANZKV/@+7<J2<9I&)]R*78YB6XMH-X+V(*VW!CPU%=;RKI8Z>Z
M%C3UF0N;:&UF4BI00=>;^X6!DRFQDCC&T/K,XQZ$K7M5V]6];"^9]V"-?JQ3
M/IU^7TQY%3A=8!QDSM%'9X!(3]-,EC!AR""CT4$4IY5H?1/P1C"/FQ1M=-##
MV>CU*>]TY3 %[0.+#FCGUZ $22G8Y(!E;ESP*?#F/DX;Y(^;=D?0;@\'MQ>N
MLW$M=- H06>LV9G.01#:@BW"&&Z33\TS18YY+_"07-E1RGV5<:%%\@NY"36F
M]!7/<T_.[JJB==*0W0;,6P/*.TE.HM" VA=463C9/$VM"Z['S9'FFNFAZLMB
M]J]GLU/,+TZG=:7#Z7"RRA]8_.7;+XNDNI??<)J&,R21Y.P$RQ8<4S5MUWKP
MQDKPF5P$<A:0E=:WC;='^;B9U;/6>JC+<@/B?X71*6X&+#CG06H$:T@TBF='
MT!<]8DH*/@8;L/4]QJU!/DF6-=)9PQ(PM23KRP_OWE6LM9'L<G&]Z$0LWXQG
MB>0SQ5RS'/Z)\\^3/%!H,7O)P%I9"W>J M&A )>8S@G)9M-76+:QBNYNHS].
M^AQ(&PUKL=R->,'Y#8 Q6E'0"!#&T^YMJC\JO01>O'$D(4S![DV?&P9_JNQI
MH8N&]5@JX$[L7LSDXM0&F=LH@S/@I21/43(-+C(!Q<?B4RQ*RKM.0W8?_?'2
MYP#::%G\Y1KD&PA^';'461DAR'?0Q'.E. G(R C9*Y,8?9(B;LN?KH,_$?KT
MHHL^*KZ<)?9>2/8=2!Z%S9J!R9DH[5@D>RR7>JF$O "?$[F:S:\*7<?Q.+G2
M3/(M:\14 F^.2RZB$4L+_JIT!B5PD3-96P5KZ<9:<2(DEVN!FRQB]%['U&$A
MV7K@QTF,_G701R&9ZR=Q(O@2R?*&B"83(I*"#XY@B2"M2"8&UKH4_!VGGRV/
M\Y E(9'3Q 2C!3LE ;YV*F7*QA@D2?QJBZ5#'><=[5R*>1&350*(X>2^^\ @
M%D'"X4%ED;7$YL7D^CB7VOM:@<@*.6W;X)RM%V#J)ZT"_5@\"04C:W[S_]Y<
M*]@GWV,/,1[[6L&U*2S)6*/WDW'-Q%KDWD8GM'$Y0[;2DW"*I\70,] V:)6<
M\DKT1HQ-@.[)Q8.M%'T39_86> _)(%<PK7(WNX#:YA;"%FS8".BPMQ%Z4-S5
M&]'-I'XP2EC+F,P209<:N$1)II(6M(>*8KE6DKGFYZL'I,(-5Q2.Q81MA-W'
M?06RV,;KY'H5@HU<AMK#)=?L:P4QUTK0-52-,FC;O"+WQ?&/<*=]?Y5<3:78
M59X]I(!><.%7@.JIE7"*@?.UU)W3!3RW&K(R4FJ9<FQ>__\:B,-K>7>=W'SU
M? >!'B:_<P5,B\($K^>6T==Z[L71-*6 HA1Z*4WAI74%BQO!/&"-MQ%P#\F;
M%ZAXYF,^RWDAUS!Z%X;Y]?AY^#*<A]$*<'"EMA-V$$P*!#AXLFM% J^\S<Y$
MPYI?$=@:Y -F2K\*Z2&U\CW.24"8UW5=UKR.M.LQIH",F473\ (N)PXA:>E%
MS5=NOG!L1O* N=! M#WD5CY+Z?3D=%3O9-V4S+=FIM'11#)[#*(&%<@/=H8^
M8796Z91B":U/6CJ#>\"TZ$<!/>11;HY+KK 5$;21M:E?CJPV].40T07PN1"[
MT<6<6Z>RW8;G,3@-S>3=N'K!\R5=B9TO2\$T7Q[VO"W/\F21++=PB1TZFG<1
MX(*O#9X3;6B>Y"!RUL$+FT2W,.(=A0RZ8'G $<1>Q-W0[NR";WT;O /"AG5-
MNJ$Z?)&3]MK<@BI[J.+ :\@**>9(RQM*<I^1ECIIR2S2KH"IO6(9F<2\6X/>
M>TR66VJCW >N;*.!0^\S^?^>SN8G%ZPPKV-0M>IQ#);L(T-6F,T">"S<.9),
M,IVZ(^R[YUS!==AZ''WH=9O=:!^EW!CM/%;MCJ61_QGGPQ1&L\LP&U?RN#+4
M8>MZW#;/*U4^A*Y'YUZ[[(MBR@61>"YJD3 3B#A;5/FX,FKSFA]&!W*A=02I
MT^+>&0-7^XZGS(AZFEN)K?M M:OY<4.6[S]PE(?CCU-ZR08F,RNES(!&U3[4
M-%.?LJ47V3"EF?;.F#OX>?<H]Z)"QS::O"-->E<!-CR)V9R!>P[O]0I>"C()
MSPW4&[:@R%\$YVG6M(9JE3Q/]-+ME/M\;:C'H^0&HNSA1.9"&'@!<!"XS8R5
M!&S!O& ,1%\DL)Q"3![))6R]-%W%\&!UWD2H][=RAM&I,,\5Z&P9J"@%+4J!
M+#,C:ZMNQ57S2-I#K9S1F%!'4& /)SC/4IJ<UD8<GS[4!.,PS;/?OU1K[$J=
M:_(2C0B)@V*+:#*]*$&3G1XYZA*1/ #>.I^G([0'3Z0^5-##T<^5 *7A)@GI
M%7!%3IJJ-^=C*!I*#L46BZK(QUMI?*]E8V<Q'CLEN'.421A=6"JU[$ND295@
M:@F/#$)'P1W2=/DA G'W*)R_E9JW#>=O(^[C1&:[(/P1SM]!F]N':'=1Q7%(
M$ZWD(B@+C-6R89;1.\-$@B2<C58ILI Z99+>8[+L&\[OF2O;:.#8X7PN78J1
M1"$-+;-*% ->N5R[A<>"F O*3J7=GD(X?RN][A/.WT8I?=2OO34/G]?R*5*;
MFGB/H @I@4,&$9E@AOS_8-J[SO?_[M(NIDI[@??1QW%CSDT74$_][M)6BNMT
M8V47J1_N[I(K/@47(&M,H")+A"M(X!9-SBKD<+6&T4.BPEYWE]HS81MA]\"
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M>QNNU3O2!5E/+M+-J([C&;717@=*["'Z/FS:FQ&ZXK*UGLPE)64]&>,07>2
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M&^?>AN=0^5F]*KZ9P(^=D55+PM'F-2.C+B_FLI#-LI2@$!(M;5!R$56UNM9
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M G*<7("&BKK6965?*??28><B*)]Y2;JD>E)=Z[XE 5%D!5J'6M;"\]3\<.4
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MMMZ/I%)<YKH?I1QJGX_J8@M:UIS+-/LL8K=:=AU5?7GTPYH"C=2R0=%[R/1
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MXK[]TE ,HW\L@FO/R0M>3>,]CO'/,'H__/1Y/OLP&>5!2HPG31.1J,F<5#&
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M/<,C$>4.D_ X/-E&_*T/"\,?'^:$9+[<$E^/T_K0JGAC=(V!9:-!.9_ &1*
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M V2DQAB#JRF@S44V!-FKEEASZGJD),V_X9*PO9\OOL\7JW*>C[P%.@0I&'K
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M<XI_%%8$Z7@ ;4P]9"^!AE0\%*V#SBEFY[N%K1]Q_&,S*>P0VCB&DD/%I0V
M^!;:N">UNP2H[<#+@23D@V:YME=)I110M2F#1^M .&XC<UH2\2]%.@U"&WLK
M9PP=4P5XW VINBXPE'DL(EDH1LO+@@^!#$:0";GUT0M:EZ<([7@([3ANZ?>B
M=4@XQYZ<'"[&,7NG$;& 3?54F#/R%GG.P'3,,2KCLLW]#)UCCG&<P-9I1<S!
MPQ>'@'T+7VS)^%XQ9KO0=?#P18):@HD2LN/TSM7*1MX8"TE[%GF,7+JW\,6#
M2VL,2Q.%+_+K^J^<EUK/"+PRM.F[6A5+.0DEN,RD,UJIV$M #^$<AV'4B,@!
MX8N[L-#3++H#35Q!"S87&VT!*1+6"QJ"%KFJK5Z3,P9+3MT"U1[">6T"V86%
MB0.@+;<)LR%K'FN9-!HD!$YN@RN":Y-98JY;19?G%P#=6B"[L-#3,KYW+'%9
MX*+NM2%SG[/0(-"0?IG+Y/<E!<%J%ATW181N_<0?A_0:7*F]J>APQ?5QOEA-
M\^VEVR.7MM>KW@"HG3RH$3 /[C_M3_-\6HYZ[E"W .MMWV7 W4VCL\"EJM>Y
M0BD'RDA:'[.J!=:,Y#)R+4OS /(!N [M)#773W,R.@AFC,95\-D9&8%F@=6V
M4($V;9F 9H*V<RD)+W\9Z\](DZ<9OWLL0&/(Z> [76<>?<+O!!KSY21LAALQ
MU%,' ^@BKUG^A6:$UW906;!"_UATZ[/ED1"GUU,WNN?3<=4C:V!Y?OHMG..'
M,F!>3'+>H2]@ A/D!9 #X#47$(M3F)0J6K7N"C<&W\L553>6>@0CGBZ_SY?A
M;.5M7*=&IE55PM6FGZS@*40/N=[^*2L+!,2Z<&=?H@Q2Y-;)S%L@O5@WK245
M'?HI/0'O^B1C ,!.SME6<(=QR9I2.EPN>_#18=/:#E0YKH-CM;BUSZ"<),]"
M:TGN!=,YZ43O36L+Z$""V>*"'58O8VCHK9.:O5GF"_H6_YB?UUUS/CL_G5U@
M_D!K]@KU38O>K-!RC9!T#6YRMM1:$G6."+!,(@36NLS=CE"G-WD:D_Z4I#HQ
M-G5MCL_X/=1^O>]26OFNMY;;_J4XMGYVT\H;XT:R5F@C.)N*U(Q[5 J9#CII
MCA%CD2$IGT^&/V:_5>%S^HKYXNRN,?VAK#_SEY__"/\U7[RG'WV9+WY^*+?9
M0;_?1/E++;/-WH N*Y.>!X@V('!77#$JE9):7TLU [_OVKKVS,M$Z!/R/#CW
MUH%&2[X'S0%X*31D3H:J,_0JLM9W,(\"F7Y=/(RJUM?/_5GI<'RU/@O7V5<_
M3YA(OEC) #/]I7)4]3*1?!V!A?G@R,=I'3Z[$<R;9/9AIX/UMN_T7/K/PCJ/
M9 . 2+$>$3,-,7 !PIN(*4J50FM;K@GPJ5+=CD2$DW/]G)+B;/*1H]&@#>=D
MW7('044!W N6>12IQ&Y9!L>7%'< K>S2$& $9X=J"#  XEO6W)[4[M(08 =>
M#B2A%(0PF1LH*6I0/).;[Z2!J'C +$1)KEL6RS/,FNNMG#%T'*HA ";&DTNJ
M'M 0QL B.)<29,:YC2I8GJ?H(?$\&@*,(G27A@!CV#A<LIPGN]))FVB?KK'K
M @,$C0P8QN(->FNP8U6 (TR6.RH;J!5S!\^F&P+V+9NN)>-[I3SM0M?!L^F"
MD<[1D@L&12;DV8+G7D/ DBPMZ"*'23+&GV,VW732&L/2Q-ETG*EB><D0;#*@
MI$-:M+6 XC4/-B>;=;< X^>733>*R!'9=&-8F#B;+F9& %!#5CK5.L02Z*61
M8"(W5F:CC.K6/>GY9=.U%L@N+$R<31>EERD% SHG\D*M2Q *&8 I,W( I#(A
MM@XU?\;9=*T%L@L+'2SCQVX*KSV%U69KLC:BYJIS;VFSQ8+@4C%@G>!2>Q2.
M=[Z;>X#I]7I;3=GJD''W%+[KMCP#$'9RKK:C.XQ'U9;5$9+9@Y(>%[W;D0;)
MO&<UH"L'6H2Y\1"$<U D,[0X9U="Z\R#0XEFBZMT:,V,8:*#5MZ'Y==WLUS_
MI_9&^!'.ZN9]G6)ABN(^<&"V-HLSUI)Y;@*9YRK7/#&4LG6EFJ?P'""BI#%_
M#W*;&DU^!X^H5EN^[9-QG3CLK"V"X&@G(RBAR$N3G(-/7!C%C);-;9C'<+PX
M(>P]V1/TO[E"Q;C26O!(RR%3H#(B>"L3L"R$S[;(V#R6^W$D+TX$#2:\H5]3
M*_B_GW_[1A-**]3\[ S3^>D/_'-QL;Q9H@1W+@7&H"3I:Y0XA\B%!&01?8Y8
MU'J\[J,M%;8\YL40W7I*._@==_/F?I_?R6LAUUJ63"Z6DD5"O2T%;ZJS'1+7
M1FO&>.N:8YNPO%ZOM0D['1(/'\-U]9X,0=;)2]V,ZC#>:1OV!DABCZGO8$<\
M@; HM)HS V@8N5;:<W"Z-@=)**PJ*F37.KMA:E%L\3ZGUL28&>^@A>M5\F/X
M61?#Z[L?KXU-C$/BG)9$0<A"5 &T]XH629FU:+VW/ ID>D.C%5/SUM/<P:&\
M!O4)$Y*K>XLKT$R7VK4G(]E3*N5$(Q4%F"Y9,"6C\:TO8#=A>7$*V&NR-RX
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MQT6=E0_E,_T*+C^>A=D,\_O+NX@3E"$+83P47\O'<BTA"D?BI 5-69.9Q3"
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M':/JB<;V*B1_C#KIX&>-F=G+4[9L!>W(6("Q6-L0.ZSU"<@AE=[1VRM+^^:
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M/8O/RI!-;:"?"C>UA)6.44[F?^U8I0F63<WG=JU'LG_+I9&J5MO5[R[G3DW
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M"S$!N<D^)*U%6JV\;CC\M>%"]E6/=PP</QY&'$L%8-W%?X2OEV,28W19V\#
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ME3 6G6+R&7QFJHY#T4 G=@&#3-DZY$TW;WVUCW6].)(?'5D:IL:T&)5,SNC
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M10JFBZ+3TG// EC+@D8 I:W2V#QS;C^4R[(D6LB[CR[<#V%M*-\%6%]71H=
MG>F^J(7JGJ;#"7+OXZ;H($##78HRU'&)ZY)]8%Z:R'P&!39K:Z"US3 P(9ZZ
M(QJ4#\>(NW\>;(>D@BV!W%[F@PBU>M,R[Y-C@6LG+;G*IC1OK[0/R!GNC]HH
MZG'U/T/*!TV$OLM9M\/MFA:O/GAH/Z6JCV/?*4PUI217<L;HM(Z^#@65RNO(
MK<OTU?L]A:D/GG^B*[=]W#OX6@V27[ZE18&1R&N4,6$DIMC:#C DQ3)P1,LM
M.M^ZA]5!,"<[K#L/7J?JO</Y2KZC8%-041DFE0TU98\^,Y>0&539964+-.\:
M^#BB,[@J37CPP%UM)_?&T>Q=9/_W%N9+G$_N?U]I0B#SS]-4S?8[[+6N8)2L
MC"[6R+OQM44F2!9D-JRX$DH @S9UJ?$X$<:/SI.A-=%'+&P'_MJMRV 2C]DQ
M&Y"$D>BL#:;F^601N19)%R-[WE$&S;,=9OLX7K;GSJRMUTN_+6&Y>MIOQ%>8
MCV?K^]Z02S"<,Q.C),>_9GVE:)A5SGL4M>%IIR$!3]R"[UW\7&&0!OJ<M91K
MXQ2(+8[?IXO/F,9EC'F;G]$!5,,$F8- AD^(::"D65\2'DS](<L$4A=FDZEI
MGC(P,O(#LR4[M(ZL'-VIQ_G+4OLC&2Y#:?T8P?:D[;>S.298;/WK(KA/$D1M
M7IWHN*-M+2;@S$;K12E26]DIUMU1U=^O/FS:1".U[%'T"3(]6\SB/7Z\G52^
MT-_H!_/UT)*6 8S'5^@GFG'$6^V$-B (M,(J96/0F=L0LXX*K30:DA?[>FX]
MOMBI/;MA>5L??952]1YJH^AZ=39.N+@S5DO4D%/@#++CY$N@8][:R+A(12K/
M@Q>^L=G>"=CI'<L/+_+M=[_BDCRLV0UN&P#QJ%58):T[SS3WAH&2@B4.H#W'
MG%WSVHUGX#Q#O+8YEQYV-N]97[U,[>B ^35\'B]A<C7-O]W./T]N%Z]@ M.$
M(WJ>R]P%9B!H>@,K&) YP*(Q*>GHDW>M'>:3 /]I6==$@SW$85[#XM,]_W*<
M/\S>T0%34SEO/L/TZZNOKV?3Q6PRSJOF#K=Q,<YC,C9J1RH;D[4F,/2%9"9K
M0HXPU<BPQAE3DO2M:UN?C_82B3>0[GH9!?*<3V9CWN11%(H[ ,^,A4!;MDK,
M9Q):\$KF5+^H]G>>)R&^1/8-J,,>4G:O%@M<+OZ&D_SJZ\_3Q>V\;L;?+.G%
M2$N9#49@@5O+M-&1><B>622W*1L> [9.OWL"TB5RJ*46^DC)ZD+QM1EY]86\
MK1J7)2=\NR=O^X;^UWCY:7:[O//3KCY_GL^^P&24?.;*6D?"LK7M$=+A+R0R
M4XIV/M NW;QBH.]WND2:OB@>-&R>UN7]UI<-.B./WBCFT9@:FA(U^=JQ$'B)
M7N5<;/-<U*= #75)=UY^'2__<U_>91R/?L&/,'E#;[+\NHIA:PL:15%,2IN8
M#G4V5:RS@%.R'AT$_NBXT@6F__UQ]N7?Z-%KZM!?[ABS9\%S7=4UUN2LC40;
M^HT5RAK%)FC=!4>'.[JG-7Q_U6$OY$X6_ZRA[/K498G&*:60!*_I&"J.#"]9
M,BM:1Q53SOS1\7HO08<';M=Z4^$Q(FM<'?[-8";OZF]_O][<^MC$)29'^PN/
M9#*7VE.3>\F 3B#D!NIPI@X95GL?/IQM=YJ<9RV%--#5V/7R$\YKX&:.GRJ9
M:PU<C5+_,EN<<!W6Y:DMKL".1K]S[56\- $<S\H;+6P"Y "AD&:ET"+Z49<%
M3C."W]=TN<5B7,;T;U92YW_<+I;5$+J^75X7.M!O;ZK=COD0ENOI7>7:/<NP
M5B<63)(IA\ T!,]BL,#0% %8R.+?[3-\LNW<U[N<ZFCLXGI+'WP',*]OYS6L
MN1Y1^RO2&WR /Z[B8E7%-U(HN5!%,*,"652@)(L%:P0]J>10&<RM0S5]O,?P
MCO.+8/RN+W1VBO1RQS=+__SNSIY 3VYS]0YF\Y7HE\OY.-XN5^E]LU]GT^J3
MD2[IB1]_KBTU<+$<29<]5X(SDVM54Z+W@6P#H\TSVXRZ%-,I]_$H)[P%\O-3
M>W@6[1NZ/2P%>K@M?.P4?H5E5OOY?2_XQ5:*(YF%M2@,RZ646I.'+!2I68Z<
M!Z>ELH^& )[#WA/@_D79P93=P_UB2UF.H@)KG?,LN&+J395ET7E?+TP%))2V
MV-8Y%BWQ_\7D\]&AAXO+Q[[*;QB] &&P7B68D)B.6%B(UC)45O$HHLZB=6I&
M%UQ_4;&]^GJY]FQBJ_#(+:0<6*3#@.D"DD&*Y!04E)'^P[UK70G;A[DZB)6T
M_G'5O063ZKQ=5D2]'TA9L)@TL S"0[!&(>_4$[A?,^D;WO-_TB_":QU,Y3T8
M]2WVR+N7X5HX%:1E.82Z@1E%W[^D/^A-M :IVJ<T-'V!OPA]9E+TX YL-_;W
M!+TF3;Z=S/[U-\P?\=])/_43W<RUV[PQYI]NYW0>_(I_+(7\.QT0G^K9/ *E
M'9W\R%2VFFD%G/F EBFA9 %NT4"G#LQ'4+L-\K\X?2X:].  [(JVJT#7Z0<D
M)"5<C 39(=-6T5E37X.7H"2@ ]\\"G,2X*&2?%XD88=3];ESAN[GSZR>N)E
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M759P%]>WR\42IO7$?@6+<1IQS.ACRB0'\DJTTX'Y0ONEXSE8[Z6VL76+ZJ,
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MX%B4,ZTO.0^C.=5Y_86T^W&52OT;+I?KF-FZP>C5OX#(G3_,5A_,.S*UOXZ
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M^#<5AC]AK+WN7\/G\1(FOR#9S]=QLF'JHO5[=%OT#%_]00T^V,J/DMO!7?O
M=[OY<?TCTA/_S__Z_U!+ P04    " "Q-$A61__R*<0.  !^#P  $P   &-V
M<RTR,#(R,3(S,5]G,2YJ<&>=EGLX5&O?QQ?&:9 F(:&)1#4..\="9E=;2-@1
M(2)2QFF29&28'"?&(><B3844)N=#"..X2YKP4#,T!J&#R<Q.8S&G=SS7\[[O
M/^\?[_-\U[VNM:[KOG]K_3[W]W>O=0L_"AG ]M.G'$X!8F)B@+_H (33P$E
M7$QLJ_U+$I(26Y*"0"0DI:6DI;=.&5DY61D9J(RT-%0!"I63%TE:=INB@ORV
MK?NMAVR%;T6)FKR,M(S\ORUA+P"3 32 ,@DQ;4 <)B8!$Q,. '  $),4^Z>
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MCO'EF*M]=/VN?0,E6$;M1;B.:ER-?<&E,98=E?QG8V-X4%8Z_E=(QN*@_]<
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M02OH_('*I#1:Q5US$:N0^E]02P,$%     @ L31(5L^D!!OA5 $ <]4! !,
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M$#94C@[O;\QH55*OL-5U(XF.VTZ'6RP]>7+R>45*[Q8&35)U_6*Y7D5EX1L
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M& 7<1//54^G->2X)'5M%0UO>1)W28KC HZ*Z@ "/("%-/T+S)387H?E "0>
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MWR#&U'4_K\(HW3#A^J:\-'KI1/BWKREZ!,U?E-5'N7;:H$8CS/"LVK5?AG.
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M$352'PB3USHDDQ\U8_GS!4RU_ZK]S]9B[B+ ;V+C1'9",MMMCP^<=-@)S'.
MW_-[I_?2/4RI3OI$?;K<9[S!Y[!0LA"<J ?:*AS9D:7S@ND7"%T56.KA  <[
M.8!.IAX<8(]X5J;B(3);*(IAB^^%N1B)J8X *\U4#CR&US+"F?#8MWTZV5_J
MEZN6.T=G;$>_W%GVV3@CM_M'ZS\)K/\KUG;3DID)LJ25I@'4SPS!GJ93F'!L
M7VW8DNL@51RQ0V(BTK+LX?JHGU*L8N'7/1TQ;U5D*L[(OG9_.+[I6G*)#1VI
M $__>3B?YDJ&WO&W2R?_[I/>?[IZRT-1F!C+/>U,R6V86P=E^M9Y_/3HBY8
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M+L5KV+R<N'!#9 >%V^JAV-J;SXB(<G(L''7)(^0F4CDIAJUV MN"X)NK<)Z
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MA&0HLDYR@;[S6; L7@Y\A:K:E,O<S (^UOG2"N5W5RS(8DY]9(G2QHR;HKE
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MV!D!7$ &RYR*;3%$-VWY_/[%S,\#!\PX,RD:*'FMNUX]?Q6QMV"W0$[@ FV
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M/)NASP8Y*TR]AV3K&?R?5@FD]2&VYPU 7+#?-Q#'$J\@/D=5NTU:1==@AKE
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M1D^B4^"@'3FQ-P/%P^F6Q77*6Z<.>^ $.!L<B^LBN, 63[U?/9=/&,J=LJH
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M(2VG4[Q^+?%F<"->B"4*^;W$:(%.M<HI3S;U*#T^;+5;.=-6L5!+S.KJTZW
MQK Z-0N]IFNDDKA\Y(W[I0]R/71?=OYXM++@LD20]JWC?^@*4_L EN_<?\O6
M?Z;O0IY4;>V'_3\N>&@X4A_6SGC]ZC]O@HW '8K^GX(0&]N4=CS_K,IA8Y']
M4Q[.U8OI$0A>SR/?0RC& SIRSCV680I99$&4UC5<$UQD#+K5??F>V>C9.J>S
M$I7]Q5],S\M5#L$$YGI]XAKD9O?4:.T#WY+T< T]LS)%Y#=<8*ZN0]SGZI07
M*/33EY&IUD'B^XQK&)5$"1CL-GR*+%TT&I<I.3+5C/3A]!Y:%7KSF?WT<=W\
M6VK9U[&GMO8&!#!(_%Q=*H6YV^S#B[B//S(>KVV]J[6\ZYS@9\*;F JF47 B
MXP+XNGJ=?RVO.FDX-/J"GIGFB?1U>R4[BS\BM>W;V ;"HR-;&W(V&Q_4Q[\>
MBL8U:'^%J+ISEA/Y2(^[49.'9/ LU<C#T9M*V+D!C'>U",OGN(,B9(U#*8><
M9XTV8GTX8PIJ8',L2\Z#*3H3-+Z[-.:KP8ZI@6#E&I, +0^?-Y%";1IM-%S=
MQ=M/;6<D?$-7YJA,?:C0_BU=,@&Q(5CS0K^FTF$G*@IRZ/7(\QMX-GZX(_Q]
M%FQ]]V<$MI%:(3CO1->ED9N1PU4,Z"UT*!R<99YV=(^EJ.LWE3@YC37=91>9
M8B>/ODR!(93O*NKE]C?8GTR17<IK@9>:LL3+S-:_/V"E,;IT79;$AP5;^F=J
MV3(GUX.^BR7\\8J7M[*.J;T_X<WN13DS&F%>=26QEC]"C4&[=.E$003P#O O
M6JV#T]3PXL93\2S-/$0%VMW[RJ#"!ZT N8U54H\NZ-Y1^O+J:/?1+%@W_C89
MYKJ>_FGPI+7NE!>6^HWD"E5*IZH]B"CSIZG_U*F7%QM?.;WMTZ;I]A"-QJ#X
M>.D1(]0G85KNT#P/,F^L8^<A)W(59%VKP4T$6K@F+>AVW7&A,?3K;I]']SU[
M'=].FF755M@9-"M+KT28G^)?(,?AMF)E,4Y@?^96B BN&-,1^ .)2C56<?Z/
MT=[/AGZ6)+A>5PH\.EE>;BA\$FQ)]J)11=P'TP,)+ALHKE==?-Y0T&))^_?L
MVI(@" ! EO#%\R9 "*X9/:Q&([9H2B*3#<X3H>?C\Q-F9T*MXKY5QGINY2_9
MIO4C;"@>X\1^1%+ [(:^@J%3%)GI>!_9\_3L!-^"V:7+T4)"OF^.K9XU50J0
MLQVJ^!-5VFHNL!F1R@60NF1H9S^N$?8"U]VYP-E8<9-7/W !,&H&OK3$ _ZW
MO4U9N]9,6:QQ7FQUM&GFP?A_@N6'8-O&FL#L/'/MOL^1&M?/B=$>7-'QX$6I
M_W&+/^CL_7,>\O]62_M')(F^%W3+@2@KOU)]]V&SM][#2LLZ X-_+^&T@=_=
M /X[6\=UG>/?M7S^]ZT.E)@ +K\?Q']9_GO+:615;#-,'B/%?E!WB:Y&>UW-
MSBB>(5]E2BP,/\]H7](LGL3=NW3]F.G5MJ-=IKMD(%L:>I[*#($F04^9V):5
MV#/17"!D%]CU>&L3;@,7R,&Z50U&($]X$PTV4W=J8*7)<==EGL^8!SXBN(=_
M,_R$U#T1*E\]EN*;XI7'!>[ ><&;D$%E"7NR>)C@SE0S;V*D\7H2S@6$)(88
MW2.D/G;.-X)N9U>0VZ_6,[Y]"5U0+C.(,XX5K-.+(=#KO_6IX,;:,%HO=P@A
MWU&_4U,7EK-@?3#H^"_\ZFH]%WA7F</9'J[(P:)QH'HAA0NX$D<E&UP89F!:
M,VZD;(H+1/L[6=M(MLQ:TS5*7'(/-.K/QMV-=A';JN2).*>5E'G+$R[)JT7L
M<%<7A-,23:#[15#E.5])UJY,P8&*M\J(R!]=(Q:N#/7]^;R& __0)21-L!<Y
M_6V%"VP8(1G0!5D[%5OTYCJO@L(<H5&Z19.URXJML^K +^^=@\:C?#X_?2*6
MQVXB8MZB9#DCO/?@@!8;E3<V8F>2-K&4^U2Y@&W8E+JC[9!RM/ZSKO2+&V.9
M'=59,#+N=ZVD<X1[KADKI:5Y%ASN&$H"%"I6E:>LY' -QHC=5/,<S+HJ?>?X
M)V._U&V)H$N#GLU3)OYZ=57L^8R\HIRAJ,MW"*"Y)N0^=F@>H1ELS;@/T?S4
M;AA:3)*;Y!WT[5-N'2D;&S4IRU,PXY??R_^K;,IT?I57KPVSG[&^DW2PG\G;
M6$B_39C.(TN3(OEU4Z_5[QEK83=[35NZ<;9)K5/>?_P_[+U[/)1MNS<^W2IE
M-Q&1W2B*;".;0J82DI"$LIL[DB2F0L28JPC9AR+$5 C93/9E-_:*9$^(F4'9
MS3!C,RYF]QMKK??SW/>][GNM]WE_[_M9S]K\<?TQ\[G.ZSRNXSR/X_A^S^L\
MCZ.J;)8-*7O)AHBAM>>U2;9.<"*L6<7A(F>\Q_GO2@I6#9R07FM'27%NECA-
MM"VIHP"D:(IE@\_5*3?:Z[<.^'EU-J1&?Q_]\]3+KNXB3@1E0\##-\H"$]1:
M<*,F-A\C=^[(?)35?+L$NICU??_7DQ0%KI]%2!8O-_T6ZA0_C,2Y?SN:&OM2
M")ID#?93_<]3RI.GRNI"-<MPM]^\9-FT@1&T$$[O@ZCS.VJ-Z!?17?B=A7+'
MX^"[ GP<J*I%4'I7\(^13Q/I#MQUZ,>@'6LWE7XLP.=V6DJ$G]-]-P['JIZH
MNWL04WAN3I -J5?JUS] 22*Z-T]*-.#X5U6D'OXTUS$-WP>W-=J.N7>3:SEN
MF 9E%AOH.;3Z4;-8/$BZ$\,P:IH30DTH/_NZ&])\-^:SO[7?KQ%XX!BG%S7+
MX/#CG116ET] .DO("4E3Z*_H.F^T@V%(C9@TSIF42%E:>3?^Q+2["#=P'SOX
M3H%K"KZ5*^>\ _(QM1 !S:6H-;=8"!I(@HK#EFZPM:%1)0_3]1ORWX?1<$(Z
MC+=B9&A]TBZ^UFA2+^S$"K9XGR'&\>LAY+#6JI?PMJE1;I(L71M$'Y"4%LCT
MJN-;7W9E;9PIV+2SS$%WX7:L:L!,*2HQ KKGWJNR(?39&%;%.,?5/P6YSU3%
M&"(/]1V,?R[TXR'L8>YO7=7_Q3CB;%?(^@3L)J&5OP4L\EZMK2F(^9R3J(^!
M)Z]$ ,%UQ[HK@MQ<P136F4TX$XUA;N_9]@\=%G_?TL3?WR-WM#,8\)/<8[C_
MP=O4INQ;.\W4]2'<<FG:XN8ULFI_\W/YI:".8<CAS*"%\K.7OBX%-/QS8AAY
M3M^$;+3 (,/R+@5+TP?]WJ&N4WWEKR\0WPK.;@9)<SG.J^IG(_R^"ZA_-+]N
M1-_+ZL%7\!44H?& E+2YN+$ CJ=>JDLE[FE6<6=!3&0QL\UX5\='D9^=ZK&F
MQZ^YDF%^V7:%E1LFJ1LP-[/0=X0Y$\',H2NZ7D[&9FFU*>L*AW.PII=]"9OF
MB0PS9C4+VCB97[^7U3FQCPIM@TN8+-<_)RR4#NTS?[FS&G<B7/B3S%/$]E_)
MA45Z-!@S!_ H8Q;0D0QD^CD*@Q$?AA- 7@\9?,J&=.IUMATVBSNZ7_3'IX[W
MV%R#_8PCH"?%L^D]*$NT?.2+@\YILR'S)-\"K3!>UQWI-SM+%KN23WXN#LF=
M%[FK.SGS!??< X:YBAK'5<?"AUX*F"U2:+ 14Z!S,SG?::/=XKR!\U>#7B_R
MU4:&*C/-@)<A3.D+@!-U0F4HK+07A\<N&"!>?&M;O[9R#D]65P[VS/Y=%/CV
MID[AC/!DUH[KU;)3)6(OC35J"^S27TXO_C@\AJQ!VC(O '\1K5RBLO;"_O8[
M[P^/?<AQA;_Q_?&_>4I1E +7LV%]I5S[>=W;ZMWWSJX?<JQH%MHY,?$\]W?S
M+^!OUC#4^I\)M_RCM[2!"8%F%TIZO(N)'ZI5),\^7%<VF51Z^[NZIY=+*<[/
M55Y>JNCZ:7](7M0\[KG:;TT^.8,-D0'A"U%LR 'K__@W^E<MK?K*>56D31*'
MKGZK)FR4[8,5.?]EQ8;Z(^ @W8<U#.>'$THQO^"NI>-W@=*=Q)06)F]+==*\
MK;^.3EI=;W^AZB&C^PD'HP:0RV)OE+.7];]<WP.MR,/"F"4&!UG]:%%*\G."
MVC=\0_5.+!7:ZK_DE7O+6?W!\%D*,_MNJJJ6TI+L>ND;]*)<B(:T:?'!_9>%
M=!D^'%\WNY5K%MV&H%AAPC'OEQC"(VBI@(4FC"2Q/IK8W8*+T#V[&31RZ_[3
M2+>RZJJ$)TJAXC%\+";LRZ]R9R',PV_JSX,E]!NHRV 9A\5S GO$+71'_<&^
M<G[#I@DN:56P9&K<Q)35$RR].^=<H6^-WGU?0W]MJIZIZNS4PSMQB]JW6,U
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MFOC'+/'!*.T8XY&*#Y)B/ZH_():VN_0:]>[:_B.R@7L12\JG##?JL"%\A7Y
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MV?+GS/!]'TQ;?0KS*8Z0A=A3+P$F=C<"$AP(7PRZ_#2*K."=T1B?^WA<:+>
M_95VJI+0J?W6;4,;#%%Q E5D4'?@^]Z%(&QF%#YRTQM817=K?*F^\G+GX>.1
M1D[-"4T68\OTODMHRV2F5JE!XE9-3I3@,!MR'?H-TX O\^MN6F#*LP0]@[X=
M[$?8T-U')H,6(K-.*YD=N%9JU/[U?HR:6,.ZVF]<\TWY\)_"'RM3K\<9\4L^
M&;&]I+%+-B_7;A333=8D??GS F:>+E&0?Z/R6:7"*[[_9@T+NWP<!]P'?$?D
M*.-?;N@E?HKI3!68"*FN;N>XP;!58),)W]S]BNO_,'IV4#EN93]EJMG?0!U\
M-%FG=[;O=K_?4-:[";D]'&_L+P-=.'\IQF:L5#5#\?D[1=_)[^FEIDZ5FX<&
M8W[733?5I(4);Q3G[XY"N5^OMDAU@Z4^R)NW*SF]?3=SQO_7=R<_8S%KL+&5
M2029"]!YS(80,MD0+E74KP6RAO 6I$B[:@:Q4YM[1\*+W=X=F?EBUCVQ384@
M@K6[ R]4L8!\@J\"6IEFD_55VT,\+:'G^#$1OL.K41WZN\_1<Z;I!/[/:2O.
MUY2-7QSW84,>S$%Q9& L?S.+-+RKK^-2?HL6BQ.,+=Y\I$(_]U=?QBUJOMK,
M^_1U@"-%5KTV.!SD0X1^DZ>A!FJ!!WQO)>+%YFL*&7HN4_D>WW9^E*V]2Y:[
M5SAH;<0,0WE1X^VKJ,/DC:EQGTD;DD9DD;Y$K@X-"%]=)^T;U1 G8"TUSO *
M[+>O+^GU-1=MMC>O#R6.'QRV+"E_8N+IYN9=8L0C$/7DU0ZN'CZ;=_L<%^IO
M.S)SU^^'<!A[(!LRUL4(<41(EJJF0'NNV%25XPP..E?8.Z:0C37I.BI?79O-
M7 E=/&/-TGM 9\TB[0YUJ4S,V['6[7MD6,)GMUT.VF;W^[&N5,":RCU/H/J\
MG#?_ZDV>'QNO)_V;4^^MZ3\F _BWVW9XIOW,,LAZ^UD^?-%5_7ORV1N.G^ZO
M_I$>_*LO//\ :/J_6MM!F-#":,;74+_M$V+58?8'^8H[P]:U^G^[#*)X-2#>
MQNQX NI00,/95T?=&J>*S'[78\YOUD;^00FIL&^1[?K%A+Z%LYD#BM.:V=?J
M/A0,_-6^6KNNB:T*U^FH Y2MQ>P&.,7BB($X2*R].K4@=8G6V2*:*978:1(E
MP7MU)J4S<\K52?TH::=P .O.A8QMD$WCJ!7\:#KM%7B"+H'B&<;=Q,2Q#@;K
M-:=M5W#7II&U6K\OZ[;N**HU6S'7+ZTV?J);%O-4PR0C0(U&WX>30(E2>&G)
MX(Y):)CN3,L8;SHFPAQ[JU*G<K-PB%I8-M?WV4.IJ/A5PM&D3UZ?YF&=R<;&
M%[>MGA29A,/@7A@!E *X0,2-Z!%QS4RS=KR(OO4;1\_D3,$^-9E*<QV3D-/"
M:1G,+Z1]0]\Z.GGV2)NZ>>7%1K@-,)^Q(;?5(O 53E51J^:PLP.U)Z:@$1,'
M@[DGH8_6EI3(FR*@U<&=ZGKMFGO/=BKK");)E52>YI,2YAK*VRIJSJ$ GM -
M%0P7&T(*2F%#3-/J^FK5:._9D,01"IS5_A%83<WC&O_33VS81P#A VZ%,Z<6
M==B02A%J;A,^K"KS>*UX^"NL0"HO:_ETXXMX F(^*/@F%ZWJ]TF4<#"T#$J\
MI_9TMAI#]OZ>*Q-CAV66GRIV<%,J]=B0BN&AVO.;;2L7:I,L!U0R][^^5VH\
MM>/<*^C$IL*;ASR_N[+]SPW4Q@D+9+_D@=@KQG9'Z1^[?JZ6*A)S9>'G^!LV
MY-C58;A(O>A5H'VF)>,7M<V%PE.XKCPN=-34(G!3[5%RJ ;#F4+D6(Q]BQH;
M\JJDD(X=S:(%EG>G4^TN'&=#,HWP;,AIZU/2CXP>H#COZ4X:XWK@.GDJ@:ZL
M:S,VLQPMW W>M@RU!CYIK75V6Y:":,+,BM58&F1-5ZD33BS45U%CA-;O VDK
MK+I:Y9F-]UDL<7<;#BUZZD_"4Z7BF?JSO-"5ISW<^;W.5SFD=VGR>3<C%'!;
MVFL0&/QN<1>@GQ3'@1IA-73C[VQ(>P0IYR@WN%CKYB$-Y__X"FK]IK:,M1<W
M6KW -&GP$NH_:3 X^1@5?%_E 3<YB&Z"0H((H@-T-\.XGC(<?IUJ9L8?,N?S
MO=/G3L(&^E:D]L;=;3_;=KMD+V[X=$$<F5C \WMP =&D*=::WNNIVU7#XN>[
M #]\=U6J*T"T"1H]H0*J38*U#D2SS "SSA.[EXO??#U_G&62IQ_U(^\5M _^
M&"Y:*TO-:E(/*&OR=XY\X'Y VJOPPP])0+8GSN@*5:<5&\;B_UY_! S-^E:]
M%AY\1OV?UPD0Z?9 "V([ZOA D1\\TOEH1>_J;F\K/P_LVP]7G/?<:VRMOR[#
MQ^QMU%K [ ,([^"4,XB17TASXNMD#JBZ-"2;U!%A2HE!3D:O:-\YV)KH6'YO
M;YLDUIDS9=X>9F(-A"<N#-7O*J%R1QVV#A6-6-V?,].O*HR6Z8<3O= ]$X<W
M4/OINB=CS->1^N9%)@(&[U^I;0Y_?@HT<BB]!RY.4!7#AFS?.N)\E'&/6E03
M6^E\ $R2RGVTZG%Y-?D(=O^7WK@//-F$1Z$6<'X.V)EB0T81F/WH7@2$#;G1
M)3VU:$A \'P/J')\!+520I2.BI+$-79 @ETFH,Q"_?-O+051",I2^!M9-5A$
MN?6],YO(#[+<W^V^(LH1Y Q.S^^9:0R08ZH<3IN9$12$Q%0&H *^.SL>UHTG
M,8^;WL&M=Y^LMCN.HR!3FJ$Q%]0 PBMXE1UY!W4CYT1-#\J<RN.E=LH'W]F_
MRH:H=7!_$-H,M,MFG&2F<V2-1E LR/&4!<)PXQ+WK>3C8_X>V:>!HL.Z-US*
MG&&M\2>63DEO(V) )?F&>.GGE1P=(-F01AFT#LKS/AL2#Q5V#)"@BYY*H>?2
MK6WDW@:NB$VED5X-X C3L%$-D<H>Q@ZZ/OJ+/5^HA)82/5X4#.F13M^^S7>]
M'?4H*>9NVJ8L2P+C0,4O NZ($61[ICJ4E65=5^8D;Y[4$QT=/_\FGH0$%;I;
MH1N[P>8&')_R]=DTF^@%\1C7#ZY']NQ=+-^V\@5#,<1%8<0G/=D04,&2(=+/
MT7^KV(@9 @2:-FNE^2G,3ZP#AV(?WBX^%G/NPWY.A($"+@"H0Z?Q?(BMW4^!
M$AT\;;_J%Z0O'*9:%":YYR5/CYOO39JUPUYS7H$Q]LXT&J@F(.$WU6*D=<&(
MPX8G,RLF=\N4<&,_([WM?NWV:K'+8^B"NRG61,E;&'ZTR*R]4E[[J++OMR&.
MLPMT1");TB#+T9:C;,@D,J;(M1]^ _^MLW4SXYU,W/!%ZL'6UU>V<VW+TIBN
MWO9MA_ZOES&4AUM)F='RC EU<(0(C;A_R:^,@GXR&C;1O5A>=5:QBF[:5__H
MS4-]H7;6[G&*YY7:>#MP>!(OQC"N,YZ0H_I''DX41M(./GGSC@TI]>=9P_V"
MD@>O4>J[23 ! ^F;U<)&]TOG[&]?%-WZEAK2_GUZ^+011-C:+5GAH$?N<ZL]
M;AEC$.@ESS!J!-F<?HQA,%%_G/E:?V]V=? LEF'E(9RZNJO/6_X;3]1SCTMV
M+Q.=O=MM1;EBVRV3^,];!V>)RJ_+?5V.VNAN 2BVEM]XFZL0([VHX%";&GE!
M^YNZ6N25<\$BK\.><M" 31I R U4>Q+>_1A7@F]7V^?-AMCXNQ,.A_0P;Z09
MC;$AJ&'>KM(!TKO6^L\K\(^.F[=0V]K*0EY21#Q:U_)%+>"@B(4-B+&T0AQE
M0YJMM_16>VV9 >=,TSO:J;S!789M,$%2$8T-J4.*I\+M=V 9(BMMF(4URT?U
M/)5HS(W02P-(V<VE%A-*#C/7 M&<>P(82T3$/+-"S%MHQ-,GU/C-A@7/(V?$
M-0H.S7ENP/ZE)UGTA+3J1KT<IT,S+8> ]*6K ?"&?;KH;C>,SXG-!!.&+K[!
M66:#I<P:0$B@W&N87O4?J0(V50:=D@KI=F.:P4@I>*C ,)@CPH9D?^2F<?-R
M0M#$L0 S5FUO$9RI)\Y+K4H=8TW@!$FU_'15L$G"<L_HV+Q_FLNHPVA%7V&?
MW'([7[IP1ONZ]TS<P[VCN",%JV\!4*Z=9)H=@+ NI\ :.X/ACM7OT_2DT"LV
MM369H\2G8>G'+C#"99Y"/GU:0F2@=2AVD?62(,>D&U@:?=FE ZN=R2&+HU8=
M[Q>A?K+;CQ)"=A&&&^[&Z@>U6!<Y'S$>LO4^OUY?U*9;0YL%SH.B4<3 !]Y*
MVY)M,TSS\S\/Y(K?\V@ULE?/MZ6:GWQ0_++B_/S&92O[^EU;W<@&5#8WL/C[
MLNL&UO2>A_2-'NA47[1TXY(K(4!,"7;MQAHOG[D4C]"+[,OS+CT_GV@58^U5
M)V1F.S:;L.Y.^LB&[%!B)G((]+%F PC82ETQ[ZLURYI[\Y751AN=\C63>!:A
M*JO@LRN&TH[5#XVWZP>V4I^^KRR(+V4-.O.8M\>7+U@UXV'+_=Y*Q: #A8NC
M[>:EL$#19@[2Y)VS3Z$9IXK4KHOJ^B)G.D37$U$-S!GENZPA12<SFA<SH^(E
M!V:AN"@V$TMU- ROO6FF.L,J<Y!N(11WUX370N".EUQ%#/;-_$8&\S; Y;X_
M(N(% R_HK*FN;OWR1\!@3F=A>I]JU%VG-].C]MKK&JO=8VJT,T-WF<_IUHP3
M'^1A<L[:[U6Z\U;N*0'FX +%Q+Z=!F^#\XPOPM1&:@V]#@=T4SZ2N^Y5IY".
MT47G-W1PI?[-B5T9W:*AREFNF$L)H5?$4QA[#6F\@SXT[(AG4WX-=J1(7'J#
M#4F^_:$X^N="-NRKV:I[!HEA@&'4MAJRON? F9^Y1C7)P)FAG;X9M_IFI3$W
M/MJMLX2";XVCQO(XT_H CI"A^[JKFS1R$[>V-,E_'L84O:>8R] 5I1TIGSE%
MF8GR3?HV-Z$[D );'^C"<U.$ZXIO5^5PSUEQ@-[[S0B();%]TG4A+!=9YX*?
M#M8S0K4 A.< MQ<P[0S2J5GGVL=97>#S.S7!;3^\&<RM8E&W;FE+@OXLGAUT
M8_NIQ?:[5#%'X_H7MJ&YSHS>M9>M2,/%-.8E*,E; -.85L%2UA]F)9W 6/0B
MU('F':R>-']&-(YR"1/5Z[H(>)AX/%C].KU_:NUG/'@=/H:WG&KF\)#+&2Y'
M#99H*4UUJDLKWZ?TT;7]FS_5D>$I'1>9-T*9CL01QO[!'2S%@!R.6?:DKI)%
M5D09"FJ@XDY.J)1&4"Y"^6XA:(*@C1>4%97$F.90N%UJ#)'F"S_;IZH:,RRE
M=N80@V9]\)@C.&@.#/&NJKD+($"7TZ%KEMO4B#_!JZB%=C;$[/7>N5&EGVKE
M0*-K.6ZM&B#]>"<S-VU>?%HVV!_UB@8K@E%*<83"- 0#0']A0WBT+OBQOE S
M6B3J,^]1,7,FM&>VJV]QY#8V1"EB,]49T=Q^S8T-\=D3STKIV-)T*QO"OY]C
M,]K]\"DZ:W=CUJV !68Z-:2)?_S#BNO4<.;$*M!\G356*<D)F10SO% ;QPS<
M46?Z.>YW542:#<DM4B,[ZESI K[K8AA/@+S4[_4\'SP"78_&,B<X8>S1EF($
MMW9.,6[V;U"Y&7O]IY1=<32_L H\*U2&C.GQSV))>WFXM3_!7;,<U;%HQR<C
MPP]-<@UH?/5Y]'D20ZO<ACQ<YWIHXQ4;<O%X$4-85HTRF*/&/'Q[\W[41C1+
MNH:RLY]EK!8&W^>+"EXBPR-T/*N&]?Q]I^!6)@P#*$V@G U)B)BTK<AV7>)
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MH>"3=-J!V_=0_-2]\BRB,>YLP?^OI-X0 7>6P/ZA-2=_VD/FXWHNIPMX2EP
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MH^"2K*.HVZPV-B2L@BIAR^'WLIL7 KUCF?F^;O1#[X*_#<,+)$L:/A\7R6]
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MK5?>>BM6<R8/GQ9^-*FQ-6FI_5I!SABVY(K.T^ 21Y49AL@Z3;,FX17HEQ>
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MZ?/E=2&--CBYMS<LD50?EN #O@0$J?BTUB!*2_K/1)(W@,.*_WV=9S-]W;I
MWE^_L@,"Q'P3=/N/#A$0"EEH\CL2<-XP#:J:LS))&YJ&4WH>T9);Y2/ &%:W
MI*U!6[^9_'I-R,.!9Q(&4W ML>L/6-U_.=E%?B;E[[R[PT+"9!S"PRT3I+4N
M%MSSZWP+R7."B$ *6ED$S*[(XS+,/(9.KU+D6_71J\#?DN=R&3V==L7R6I^.
M"QU[#]^U!;FU!9ER9B8SCI;L!O48:P24YMA$-_9%W6@D9##Z1I7DS'3 SJ4?
MQT0"TI#7:K.F-(_G_#?VYH1*O2L\T3*( D]7%QVQTD H7$VZ/&S,.4BZ.-R@
MY_K%[=ZCGEJ"D?I2WV?"]\EGX!J3SGEHI01B7(&<;%B@A,05+S#F<F;7B#'A
M>&/RRLO\2-%D9_&$ Y^_?T1\G1#_EG1"O<':VC\VX)U[]]O%R?"KGC_.U)ZT
M-!*TETIUR4_CESS)?_ODN\#_H.B&02*F<46$63*H;K>8&T]9KJC160G 8+XV
MU='0:;+A;O;\_*&S1:Y216(^"<[[9EXPGC%.J'=;^_+4JA!8HRDDU)/2\<*M
MD:\13PG%@]4?1R)G!"]FKXZL:]B15&NDLXV$^BPE;2]>M6IBA7+[9E7!#RBA
M94P]+*6R]7SQ,_-;F]>;7Z%+25]VI'YVAXT3(O?X[P]=J<7-$<MO]^TJ3+,2
M6XK1H6M3G;*-EB\<+_M$63YNKB>7E9Q[5-_^3HQDA'>28W%@""4V,]W5C';I
MZ^IW$4&MO!B1G[C=2#2HR3H=I(R]C^)'NGVS]"D/+/Y!M'KW%HQPSEZ?%07S
M3 M^#$CI>LE?V8"<%[VV+@11BY-K9P?R7$K T!25VNL$]C/<'(8-&\S\GSJ.
MO+Y7S%Q2K)D?5*L_.VIY<=5KG?_ T\)P)3D\T$+%$F!9LSM'4?O9:@QN#C5'
M?%DRFNC=\F+I\(R'U[ZS>7D]9QL5Y32/"=B9[<F D/ZC>JC6*.9+GKHFHKI(
M-2ZS167<<4S]1A);-/K#RT<.HW_I7IJ?/CV0+G-)OG%:\=KE_J9 RP!+MU+V
M?V]?3JA$+I 4MRV3##*6+*'P??F"1R]Y31)7&B$V7!.<<ECV^^N[QX[-UT7B
MIZ.8-L!"MQ]@>Y7SDFT00KT[1AD-&-4>E^&H<Z^)F5SJYU:IO./;[Q#EG[]Q
M<-PB-58B$Z; E4/N N/>(:^ DPP%:P"3>A=QIKFDC2I^UL+!P5]+EZ25K*M]
M_\*1 E\(_T-=OM)7K85,+TXKS"]LVF/T8@OG,3H()HQ8611 -X34B[MK?ZP3
MLW,MD$F7NI(HEY'B*\1/GK1EE#/S0!F6A6?0(W80^/)-H'2PF\2N=/^HP\&5
M9\\XKFNW->\JN)/^V[2@L@%UHWT^WB)&3X:"[\*G811;I<J1#N!%6IQ>%TI]
MG/R[?C#8&N?P-/AQ_Z5+=OVNA)VO _:\$^27\KS[']QFA&/4\8&8!%@MB? 4
MDXFOAW?C)4 ]@DF>OG.PM^88K2%I\-9*ND,NSJ:#F%EP2Y7OA-ISN7E\G2D]
MBZ6/FBJ1:6;@5[",WYU<RU']@_S*#[BJXY?NU3U.=-GW0 VH@]CM+KVMI*0Z
MM@51@05#IPC,.[CJ$90)TG<8"8M[[SD0[E,V\T.^N616/WIRIQ#!_J=M+BX$
MYQ&J\N3Z!3[<8;;2&'<?N-&N;E@S\:(AIV-V;YS-O%*I[Z2([_X:NU]W(@9C
MQ&^ ?CU64@QLBGYK-)DDNTAL3'OGKCW__,-B4\U0<&3H\J=]V9>UU8U>2[8_
M//DUN!LGNP7IN(0G/]N"J.*,FE;^ 4G,,3"2:J@4/22FO+N0BM N6#KS]6?3
MWL8?AR!Y-0IFEV+X3JAO6+N-1X88GAP]:-P6<:FIMK8^H:REI:7(+T-Q3/KK
M:I? A1U:C^(%(DB[N*9L*$_>1"6Z)1+@TO5A"HA0ZOK\Q*0WP-GT\G R:!WB
M[SQV(?^A?F[SZJ63!V[;O=A=]A^=E-.LCJ.&83O1_O@T4Y@".A"?B8(";JDA
M6E?*)EIMW_4&"Q9/34D7:B*SDAH4]+^;[:J%W0B;5F%>X=19ZD32T%-PVD(*
M.[KLRE4A8R7VL?>OZ0'[^=\[*EI0;D >JMF0C8R.O9 X6V7!3 0#XAB%9/Q]
MG,)B\3-7-^799Q/#7N=3\HSLCNVY8ROWE%''K.$\@P7H+8OKT )Z#!0(&\0W
MK4WRRB$S'<'OZ-3>Y[?W/#A:<B9:97YZKHSR*=7ZGI4B(R<9&4QQ,%1'F':;
MWZM\N>1J'UT>;!ZR$D&<\6Q>M2_-%[9]\([_D)9D1#$D*KD^"'F,XGB$,/JE
M]G@J1KRE+VG'9YOW=DRS2A' *04&7,:".K!>PP>5+"OD'DZ#E1HBL\<[@K K
MZ0U8(NS?G'ODDT%?2),81.N#]5?9DOC)U\@8SBL4/W< O3L4=9 [C)9GP\A8
M,:)=C6,E(L<Y>T+"N*Y6^Z#-/Q7!FP?=JV^+0^[==2OF?B$UFJ[4L&X@SB_W
M;$%J\;U#HN#O<]4?)6\> 2-<[(E?+PE?+CX4U?EEQQ[SK/;KUR.\\_\G[7/_
M^T.6?;I\2;DQ(>Y-D/F7XLCQP6<UGC>E;*J8M4:2M>^;Q"X_;%???0R;M 4A
ME_/"]_.&/*X08* 6K!LO% ROFTS1OV5I ) NX88M3Q'/&'Q A_2&TH.BF",X
MY$:=UQ."Q;&@V1MN/[2NH7Y/1#Z'$HJ/D^XC3[^?OG+EBJ=]>%Q<K'FW>*ON
MFQ)[M?N7K2_8^YZ 2 ?_AG7! /<U4(M$]V.\$H?3X/1/Y! ]2B$!*RV*$46X
M76A].$!MNSGA-'-S(U RP3],8[4^X5.!B\)Y2#8QWA++%3E9Q1TF"<#(]WD\
M-5R18WAVF3]O>H [BL!T0"6L- 8,!BI_Q-RMKIB9ZM>U:!W*FR6>QCQ'?K,7
MBZ!#@?"AC%'F<<YCKAB*B!'^0!ENP">@E?_H94G5_TH^$21#,'ZS6K"3)C_:
M,=?#>+"SYBUM9PV:7--<MOV,O##/144B3;:SIU&]RC<JJ3,ZY,*>2E/J[H*)
MS:NY@]A?FUYCC1N_/4[OD3YZ+;7(/=^A]^:7%Q5[0R3 @\^;DM'D-W ![@Y4
M)ZDN)[-^36X&>0-\4XI(7(J37PS5K ="7CL[QG[HN_#\H6'13CT3_CP[J3M;
M$ -(; !; 4O!$##W88 ]/+L9GX44+UW:\% @>%UBG6X=N_NKO-#IXQ7"AVJ+
M=X>M?I[^9 ?3_8/=1@115YS>;S=XQPDLWFMNZ$YN@NUL/2P;-?'4<OI>B/)W
M89F8VM5+=TSUQ!(>VLH1T!T1?[V.V/*^.XGZ]GNI.5F^W["3?EZH)/J48(%=
MHTW2<?>BQ(2Q/$C5&E<XY?UB\21;)IB)'CL:9R/Z5H7<E#+F&*8;J=_L6%O=
MMRJT)[M+ZH2Z$LL+U4$"[+<@WVV9JHS)7MZ_R,^ANR+[+87)TT\KS>'2;)/1
M!J_3;F/W9!LR8BO>7B^9#\XLSS!:M[ XVEH2_ -/+B+59N%73K,$V :<)[C>
M,!ZB347NATQV?[#+Q54>,S5=?1^OZ]I<? ="WBEX\S<:U,U $TZBQF!U32MJ
M02R6>$!/+=(63-K)7N:D4.KDNEN==4ZK;K9N>OSND+([UH'%_J]#E/>HO:-_
MQ3U/X$;JG]]P-%^:_WJELD&HU"W674G(W<4S]8#=-0E!U?'/E1^6S6%I1V/Q
MDF":2V-U=75C'G5SDQF9H8*XZ&"99R'Y-N-%7E<\1.N;8 <&<-Z"@#H*;!D,
M!<.6AE))R<;8J>7. A-U>3#L'3RP9&^(AOP$K)'6=*^^A14$MXJ=JOKB\_Q9
M_=H1O57I0S!3=(>=,8EH02YG2T&9UIQ$G!XBS;F14=B3(P-J4A:ZW/T_1;;D
MG"^0BVTYIBT85;3N.6T7\1M;++PW.\[Y_XTF;D=K/4O%.FQ9':[P.##-%=G+
M4@TJ;LJ\BTF$*]>3[IM[>B[>L37!ERY&79HF#0:)Q=L-)RK[WW Q5*LP2OR0
M$F^")],P<N4KL:S];$6>$99Q)Y0&HW=RC7^Y*6L&#0O%C^BD!CO,Z OT&)0G
M#631% 7\+O8(Q"K\[ZB"#(_:Q6F$+5?$!8"3%58,6&9@RWF&UV1/6(:'Z?V#
MY<.A!50+IUU$ZZ.3S5]2A*=V_GNH47?-7BM!P7!]\AL,N,IQ.S?,$]R'\'K+
MS:J7 K4.0(MSHD[)A82Y/(/<%T.N-ZZ]B-2*U^7[QOM/Q?CU[+!X&/,,6V\+
M4I;IP?[*R4.'A<1RA9]3MB#I4, F;-J!/#B^!>E1@W?%_"5UBGLS7CH:4D>"
MB2F$#N/NE96:4W1CP@?L$;^!]%?S@5V&FQ>W(/R$\;LSP5SA.H#OPG"#T$%*
M6").P:5 ..FE_TA(?JI-M)B09@W_/6PB_GK8E"ES&_X^1W?HH_81>1;@_/2Y
M>K#7,(=M'\6HZ"(.=KEN-L4;5W@.//EP[L[GDW4-C:,C8P3Y,^*B,('KR/@X
M#F\^*N=)*YREB.K$BZ+],5#P)R+' [!--JB?<7+-FGF5YR]0;)89WZ,X$'WQ
M)]]<3Y'HMU@OY#O>AZ<G8$'BO.7"@:A+G ^&#2IX)8S$D.KD9NL=@YG5DL)"
MX;(?Y[3^;?1?:ZR5WH)8A/T@'3;^Z_4_;VBUG89$@P/M^-JR-IJ3,OLLB 7<
M".K'& HY6&'&+BQ-0F(:WC=A+]T15MZ[H!GM6G,JXY5V9UU];;6AWJ.5!L"0
M_I=GPZ,Y:?6P!\V%*X)4V#2< )/02ATS[$;+JUUY,Y$?M.]TD(FXI&_S@X%/
MWA=S:GH<%H8"'T,0@FR9B(O;M<[/T( #A@<.DD%#RV5@E("6M8Q]CQJZYW:G
MGKD%\:W-JJQ<B,=%$=M^[-W1/\.,BLC[V52&ZL74F::TAF]!=O4VQ5L&A'%>
MQC(4R*$-U!FT6YN?P>!\PUM"^+NJ4OVL@CR*#N*ZNV*>V/ZASWICMU"ZJ([M
M]WMROL=2U]@R"UQA.FU0TP5@/@5*G,2F;ZJKC;Y)L_YVO:6^1-Q\ZGKD1<V]
M:5_V*\;=3XJ^]$NE&Q\ )>+/@#SAV44A@4=ZIT:XVDA+T/\]TF#,<L<Q05<G
M^=.R1*_L H/)@[]_'&M$C/,I9/N'YPY"XK9/#7U 6C2/91">),'8ZN ;UHF@
MB1+=ELE6O7U%5/_)D$N+QO9_EJ=6U*-'3@QH]C%]7;7N##X369< 3:((FX;)
M6Y ;3CDE<L!LH4#V\S+4I+I)?75MPWTM5\!&/U?36O7 ^WB(*D0@3H(W5PSG
M$=*>)8+N,+*21'TIL<HR:!C:C;CR Y'QPTZ$2)J]ZHB.W$TA1$=<[7N:)GC#
M5NYW$UO%@8K>C<@D*]!E[ZK%?/T-:R!EA0I.A;IL02(,OQ./F<$B>P_,[-ZM
MNQ,.[K/M7L9"T1VW8*%84;9/LR@M1&2CLU%=JA8':TOJK)Z^JC@Q[IF?\+ID
M_\_I^!&O4M4"N>TW"#\P7'H[,:"!+7V8I0#*AX%-3(_)M-;@-T$/GWDNQN#*
MRPDFKS4N=D:/GA/5I9G0(!'>-![/]H"BO(^_ 5\K_%C!7)ZJ[ZX:RJGWW#=J
MJ?T6H=(54Y5/S9$Z.[5>'VL]$AJR:KQ?Z\;W1GK;B7M:!\)\>M =8MM>$F7$
MR6$+,*#,?)!.-C#M),G@CH,-K=98T/:L/P*I5U9Q]BY'U6P+XJZUW[)2JTB[
MY-SA.T^_\ZTN_0_/A?Z/PS*8JZC O#S9&D2#I\/EN"*@7Z^5!N,OQ6K/.-N'
MP@K^I]RO<<7@#\C^&79@0O?BY3,?7>\5N K,W4&;;]>P%V?C>2ODK37Q*G>:
M5*_3$5T.3RU1 5_29IR9L;4M^>5-++G'(2%AE@*_<>.K%*'=Y]?J6IX5:K=M
M09C;;TJV<@E$:(^7 Y./ :7S;'I:WNF;"E1\YNX/EY;/UC_:6_]TU_W#7C;^
M/["ZO=]IVK\7ZL^:?OA_I1"*? -XOZ&IIYVS/)XE^4VWJQ]IXGYK S,!4P]&
M*+YBMJ9@_K?'F,_'L<F+!38#]K<?M1KI/[#?);LP)S>]7?YCT&K VULW'O'^
MO.B^OI<>7D:@>6(E J-(@<.MUK<*[WD4?/*/./BXN.W+I9UU5U]Y_*A5$#@]
MV[]GQ[C(O[05&LOM%T8$1OYAP=-(!,L<WH5-PX@U.*4TI\7K[%GJI_;Y/G6H
M&>ENGIN-33,94G[AR_A2972LJH4,[<$G\M8=1F)+39,Q'1AB14^,21'MXJNX
MIXY &[>J8'[M*NY3WN:23J'XG,>TXSUN7)_KY3.?/V0S>O?L@G9AOJ]1A@AK
MH!F);-@%^_Z[O3@LN8H*.E!#G&F#V)25O*\CRW:!@R6/-Z3.R)L4>"Y<$U9Y
MYJX7\3.<Y^GYY\&T]Z@)*. %G=:C*3SX:2K)5J@&-@@YD).'?S2'O,Z*,BF=
M2^JLG[SG:^/3+W Y3];-FJ6X_4@@3U(*S6US-($-'OFW2!)L=W"!@>EVO8C(
MH'5Z(-=_+!6F25D+M/J'!Y5=Z<#[6E#-_ IL@W0*; M5F : ,"<53?Z(;I"(
MYVK\L"[[!:M'/2I%L"A5E7%[,L1/Q0I\S'2KM;VE=]768*'8E_]CO/X3HCU$
M;+NY -MZ#+==LQ6*#X%]A]E]U.Q8OQH(EV);E/'=_\/BV/2,_[V4.7QF0^%P
MWPG:'?FE!5AIPS^>HO+7@G THXDK\H;EC>ZX4#_WVU**)NYF#Y@2O#RLKDU4
M_LFT,V@0G8Y:-*B[2NRI^9)<FE\89!'\Q_5_J7(BOPTS\+6V'8;9) 5+&,./
M%I;X9PLBCQ$.:I+GR@\;LX16/]Q=?IKF'(ZL[E-2GLLS>^4N-",M?$IJP1[C
MB'V")K_F@=><*0)7F/8BD*=KF0RWSF:W;,O@_4U :B'5RXX0++(.O=BVOTBS
M-HV_YB+.=:=NPCTRWX)$ JG6+8$KR>-'O_=!1N%*$D7%4 0TATY])J(?;,+3
M0@I(Y^)0&\Z/5@[7'TY0C;KD.2V:N#.GP"3B][EN.KIC-V[O$J8AC9[""D(1
MU4T>SMXT8+S!J8.^05R_\D#E V9-C<G0OW;<F$&-*K[/#JHEP7A.(IK\8ON=
MM=<,5"'+E#L(;<C*Z<9GH*5;3T96("I<AV]=+]CP'+.N*5B[U!*2*5?9>J&]
MIE?I6HVUK#QC%S$#P<.B^&0>A[[S,<<XU;#KL ?*;64)(5CVV:?4H?BPO\&O
MFY)< .[K+&:Z3]0>L]H\V<0(MMCE$D7I'?V\E>K^$85F6EEPFF'DQ^I:$X;7
MP"BR1!8U3N9<S;,> ^3Q*J^K,U=_A<OMZ;Y)G:!*RXA51.^_),P/X^[>CA?C
M4%\GX34!B?IX?VR"N@* [D%8Z2$";$"5MZ#AJ:91PSUC96TG?&P;K35D&[*I
MY*3U\JDSSZ*C%?#DO$U,/#Y@QH))X/T= FK8VZ !B")@'J#EJQK08L'%E$.5
MDRGU4Z$^HW\%+IE6-YM>BC[\UE!W_?.NWS(ZG230 ,J6AE.CNA5A(6%$.',&
ML'GZ[A<Q;A!/,-S1'V[\!2==_?Q$R9)_JJGTTJ3=^UK%#2&-[GKKNG"#=L%?
M&]E<)9"/BD^:!Q2Z,0*!7)V1@P]%!TVOCE _-3Y+V'AP2>]@3&ZO6@4Y!S1V
MY$<#9^ I?>;B?EWQ:/(Z$_<;<.O"2R"&*-Z/& FT3\/USSU/)KD)8VT:1]VG
M!T2^"'06:.QS"7LFL_[PI*5;.QZX>1[[YB8<L)9(DX]!E?*/N@?/:F:OZ[X1
M^V81;'KGP$?5=[J_VM6_2)P^ 2V]^[_J6LH;T87=\"E-<F%O6&8)%*QA-'7$
MH#.=DNNG,]&B@<6<Y"A7\\A!PKN/N"O7Q;+N]*M>U$\.3>=_*?3[]1"/W7SX
MZUB^[>;M27FM7C3#*<%.$V\YX"ZL+K]^"Z+T![][V@#W9).S6J[SW2_0;Z?9
MZNNF1@5^ :C^K87YHDP.E&?>>1\GOD9]A0).:GQG %(7/ ,G-](:3G-WQ"<?
MQ4LOV:A<<7NXF;5XKE_ML9EV1M9ZM=09T2;U"!8_3^9.;AL\>RK'D!G&*88%
MJT ST;)<;43BLBO#M?+5]WZ#U::WF7X&LV_N3<OK>2)>)OAE&W7X9N@:4,4;
M9.-O0X'3V/LQY70?E@^*"&],RWIM6IR)# I+PRD6HY\L$G=E9!O07PIR+L%*
MZNPJXM?S>G6*Y_#DQS$".=T8->X,%#@K(1VL4(VT  1[&%;I9>[G_>1QZI,'
MJT*K[IIE//1M" \.%Q9.=6DM#.)/-!_ZWU4PF72>H2P<8PNPK!9)C5"VO HS
M@Q&"3<*ILOW AL@*T._JI'!*:*M!V4#$;LS; [EM*</-C_JS3D;;%EPP?5($
M*=V"" KS^&6%#PC&?J_KD(?73K;GB((PFB54KO5(*5)\#*GPTG.Q\.%-9^\7
MATJG-7)%/'K#;Y_\Y[SRZKQE:PX.IX/J(PEPC[%=@(5N>':)U&BKCT[RT7=T
M]I'2Y<V[;B8F"FYB^$#\%2VQ5)XE+747,OB_+6DR5YXW<R!OI_*V(#(XW0Y6
M\'9%9>-:XM$9)YO1U1"N$F*W0WJ5/Y"?O,2_X:Q_^&.A:[.UR\/>CR?E#5X9
M/$T/M4KB-*+)U= ZP94X(+:=J\5 =ZDI$$H.@A5EGC] %0+7_),)VC<U,#F5
MY6PW8!\6LA,S*S#0M_RSMS 48JE'CEK))Z.38< =M\Q6?]8>T&:@$[<[C7FG
M$4.S*J1,^S>-0N%M8S]98B%BUVS5Q@J8G>3XTKFL9^S1P^@1(AC&W#Z+2N(M
MX^"C[DWX"HEU%#5A I/G[F>?90A,5%(K/:UK\CQGPB[*]WBVG:4WZKLV,D[O
M[%7U3^R6O>#9I7)S/ROO?^VO_AM#+UC9*I>JMF_AY.2?BN!EE>_JH@-Z??)7
MRM,37&UM^(T>VNU)%#+NVH(0=+@#L#\A<%[0#V35;$%H+J3A$W)'#?A. 8TY
M8122V*_&XGN8 ,F,D9[.*9]4?C4Y*8B+>KMOC>4.P)D\V9E)=[H,>@*%!"OE
M3Q/EO_]F9O&=;*K+XWJ?_U<LZZQW)_I6B>/=L0N[H-E6BDAC\&F( *8+DU8,
MO>_3<(=9$UQ\SC185"KQL[:KB!TY]Q)"CT+BF8W4YNO%.@0,7^"FP./1HOGZ
MX:-]E1K19]\7B9QY+RKGHJ1I=L%"Y/NK>*/M3O" &WL?'JC%4R1X4D/1Y YP
MOW!)W*$<.M[WMR6I]A\+.:3SY1^[E;[=>VGBS7]P0^S2D 6U8^Q^%/%B>=.E
MX6_6BH3 7/Y/47WGKO8*S=*=2G9:DB?YE>NL(3P#P?-LM4,<%3<>U6S-6VAP
M_%ZQ?,)+A*=M$["6>M?3T<*I[KYUD)_/K6K"SMT9]^,/Y%P[[/KKQ>Z =JB
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M;9KQ2\TN>T,;F_-]^:M/K)=*OJB3//*@YF\5;P?F+*& )AE-&/3C2AM"D,I
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M4BU=]:#OM;URK0?L)([6MH9KY.V(EI7>90>@ISQY" 2X!)MVHAS,8CF!D]2
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MB$5G"5]PMV<F5L;I]D22?5!X;^&=1V&/P@Z?&CGP[/U#B::WV'2N,6H2UA#
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MI^F/T_0C3TX-_@8LFRN28SV!@_[BJHYSY<%IZ^9@+U<'O4J;R%8%YGI839'
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MBG>*/ ?)+Y8?W=$/30LY._0^,:NX8&UT[\S!([\PS__\7Z"!,2(VV\ :I-0
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MW&M^WT!Y4&X!ADE1#4_XHYZDX0@T<1W!4$6.7H;B5UD",$VPA'O&\%E'Q#]
MNUNOJ5"K1* =FI?7$0EDRJNGR CB__/+?K#$OXX"#ZHOK'+#P3=7@;CF-"&\
M^;=WC>CBSM P]53#32'/VU4#N(B$.83YV/SS!R?(SW\\11[EEU.\T\;6$9QJ
M_A.>"5<'&JBY=!6'[OAJ\F+:6)-6F\%":BMY11FO!L@')S!H$-LA]@=QGZ$3
M'0L>LN8IA=.[&BWH6G)DUAGNGA_W#Q<^_54Z\ZM):L!2>(_+K,\SDSTAZOFW
M$-?[)V(_\<W_/=6@ARH'B^BQKTW2>%EPD"3)LU9(JI+ 6K#S?(D!)Z_6WWWC
M3U!U"?^AKK[ /7?K<TK#UMM6H0XL)*  B65P;:&^Z;W\AXUAC*7(:=170_^G
MDS[*6F#F4PGG\+.NQV95A*EC0;Z,9?_9=(6'=@6077+3[5%9Q#IB8T'??AUQ
M?UJ0GT_8PCO-S\=KK"-$LY,HOB?^<%&1$++AO;QHL%J/C8%U^&Y)?_]2:9^>
M&;LQBRN7+ ,P7]+&1NC$6#0MF00XRX*[X$$6)IT=,E+ !PQZL3M;L HG)T=Q
M#BV0W@/R."]/*2G'GS7EF.2SJ*;=)^3U*4%%^K/?0MK$*K0E^ W/'G3@'J<L
M2+#?(6.A4_Q,1540$\ZP#&DH_U![I5I";BGK16VE4QMKMYE$O:?/IP>R) [,
MBZ*L"4,HP(X:=8FG!G]ZS?,!@XO&?@I:]DG\) DVZMPV3+GQ$>@DGN*\_7:!
MO?LAY>L>\TUSJ^EU8K+_5N+-H0C@0]_@WG12:CK;D*D4N>!2) .53 Y&WG?;
MRG9HV^7&M.[G'0DQ\S]247!GAU^9\T]Y3X^MVA//XJ>N.G1S2MDQ:-JOOH1O
M>.FX5MOY7UPUYQQW]I5L47]5U'BN/4UY4D=E<?3,P5:!6.TSJ-.$%DR%.D]>
MB[ZOY"G^$+^2B+46PO71BZ.*$_Z4&K<:[:J/;C=22T6"G)K!=T4:.X^42%7E
M"55\45G^GIEE(7X9T.+)='.^ !2>O$H;$; 37T?(X7726]NH$DS JC.BD#)H
M..$BG/4->P*;4J/ZR/*FTF9AV[>7HW_W;UY'+/AM%"]D][6B)^88"CPY<<Y[
ML/L%KIO1F5(5U/\G7*=E33?+62OFS_UMKVHCK%33^S0T&T_W3)SL6B8=R5WC
M=C1) JMMZ,WS$((=G#'Y\^1LCA&I9,+LCJJF9N/7JG]VI^]S.&OS.,#4?L>G
MW1%^%^OZQE5:48IX;P#=!LGS\XW4QW!:G?KU%QZ"F';%K.3<F*;\T"'5]"G(
M22%YVYF.!7IYE,!?A_^CCOIYW&5H"Y.VRPP2@V%1",]6;@"8]N MX*:;$>BN
M%;^X%(12\$G2+NV1?M&3?K+B>>7R0N&5Q\,G!(\O46YU3TR%09*6_/MX[]*Q
M/O]G-TD2>/=]:1(,FAD^*&DU$^F^VT*S6;DA_,U/:W&H&U-;RU(#J%:@&=SZ
M ; $>,UMX:S:5X*D<Z =G0M.P(K-*W-?HE+7DF?[AS==BKK#0&M.Q-BLF8PA
M=@R:)I;-$X:?T^?@ "X 5DRTHF4@2?"SE@Q>GZTYDW?5I>BC4/W (M/4(<R@
MSBQSOZG#=C/;\_[7D \W\C7]2J@P+CJB:4_NZ<<:'WM%./1K5=5DM?V1S4__
M(-P<-K/A5)F$/B315#FHNX[8"4W<-3JTU= ,Q0IEH%F1^_GT[AG'M:AI7Y'"
M>8UYI""A'25EI )-Y.JSN%S7>65%K#0.U1+BA@(]:'U;^@*#B\'P@+XUPK/5
MD*/&:KV3/^--]R0>+Q0.5#GZP#:;HPYV<@VA$:H4S (PH\4V0!@RN3XX'DR@
MD96NNCJ/O2N_D2;75.FG]]:V[&ZBJ04K^:;Z0?*<Z=@GD5XJ8&(WN(2FP702
ML/EP\Y,^1XEG ["JMJ*'JA=L;D;1M/Q;#S10-# PZC4'$F>VD:H<^.GY\)"?
MRV6AKVF-AK62RN9:>D-:Y]K]&<3MX%+'O;1D@AKNL\N>6^.S#42MG$#MLSMX
M\0[B.R\M^L=''^IQRJWER79SL.  ]SK4 >GS'Q&V_E+>\6T?&/GTJL]:=KRA
MY:EFUY.BQS;[T&+W_9[*P/TM2MXS3B#81QB=X<<1O=<1X'Y2VD;V'[7R5&?+
MTCBU]2@8H"6!VV3;  37MJ+WKLV91#&M"QC=7(MJ!8&F+ZF*9P*VYIVGZW^_
M9\V3#>%$LA52T+1B5,4(3T;"T*+$!XZ/3Z9WL]7;O+Z1OU>1G"L'=/_.57UK
M_)'CZC]3H.!WWW;KPV<=%SN#L4^)M"<41),.]!E5OHZ(1'M2D\>S8X,MT^*:
M%,K[@U@AK3J30H/^K&=2JNEG#&]>"T^,B%C>;)#6U3*RL8O\(.PGM_TP->@$
M2('PE2K8I.X,*C'-FE'2Q\H!;EM]:L&(O8)-=YFK;S;;]/.2_\F.USTI'P3\
MG\9=.VT4R*^X%4"D95(VBLR/A72B*@QU<$3Z:B=5D0(S\81UQ%;=,=<@EZ2$
M"QJ>KR?&O;NKWR?WL%0?'EPR/WUB<J9V'7$MQ>$C%;#'CFMP2F!^YO"T.,D0
M#<PQY>9:TQ X):=,ZL7^/_R31](QG?X/HI;GO4,59R)SA/P43QYDD8,QHP-,
M(DN=:XT_PB^F^'?QY&X826CRJ9$\)$UCHH'KM))7ER4R='AQD1:9]SG!/'9L
MC[++IR\#YF<C.V%P$)W@GH,Z,;7J;=3Q 8XDVR&*W*C%;F)H6C*L6ZBHJ:E1
MX\WO=_P3[&JT-BR>9?JH6\-2Z,&#A>]_(VY)1>")P"HD9L ]0VS6@:2)S:>)
MWII^[;GD%!;%LR'_\!*MHYK1\%YK\>W"RO)EZ[*& ENW60V'K+'LT$-=L^]H
MKR/O8< #<0L:@#^:-MTG@P]BRWUY_A9_!2VN2Y7^19$K'E+S][[:])Y[:,0W
M\$Y#T/ _?RM,:_P?JR0_39'MN!_N0>\#51U:L=MY0N#&GLGQ.VU=#&MY:*!V
M*8R-;KNGEE.5V%]D*9_O[[XS1>70,;'XZ[Z6E9]V3+KSJH%39I HK&>$;[/1
M/!F/=A1@::U,&*9N7B%M-J/?!U:C\?[HV&J]D8"J3S?2%H9KDV:W:_+JF%=^
M2WE?CY>)Q9XZ;<3F)Q*_]S9)$\>T^XE_IH3Q*UP\])6SCJ@B=<)1!=Q;VXR4
M_#%.26K:S=.A#!+V^S7M29D9P.^@^WZL#(N-53=K:,HL-HF:NI%\("AS<K]
M4RH_'9+EF8%R7'U0B];9CD'Y*JL/&QZ@-VCN=<6:]-\8<']OZ8>CFR[?J'L2
MMT>[9^=FU0?Q1C;L/I8[C._O^!5_,.#!K6C K@_<M]I)WN0SK37,4U>(A?;@
MU!F9F=]S+Y9[*K9%O*TY\\*X1MRC3+@MZS/WD]=9@8V,%GW&2 L%5"<TL']!
MHNW<T)_.520E(YF?#HJ8EB7IUE*WEZ4,BKBKMEIJ)OWOUO:%%[D,E[NI2CI2
M#]\QO819WX/YIO\6;>XBR:\C;BR-85L)"AM;Q7R02CQS,"?LA7$@D[P-I'2L
MKE5=_[N\A+V9+6-XNU4*>\!9SWAWLL'W J.K_ HT+1Y=169-O/&A5%/;T1/J
MYH #2X,65TV,+=@+>M.-_0IQA..JH29OG]&_?Z!(6ZCH6!TJO'S<\G;I0:L_
MM0M:&_EL=O1?/S=6VH1W\HOPX@Q_^V[S<*US_4;R/T*..7O$I:MG7/K@%Z7(
M8#4^.G<E=7^A?9Z/QX%Q@054E5FK=31:D2 *)M%&6*+%CFXX@W8.:O3>5,'S
MP.^=M[-OU?S<AH]*UTW?VW$E5EIVW/@Z90\/P]6"P?@:D385KF$+DKA(GFD&
M)YZ?':1SN+ 4?Y!]/XZ+:947L^Q5:WCZ^=GA6>T)B1PMU:S']O?XE_@-%&^B
M(F$859&61/3NBR-*BT17DZ4ZO95)C/)-Y]>,V\.$UA$WS]F^^)Y\SDGAG]C;
M3RNB'$.M4Z&-=2-70V_ PY9?L 0[X][0E7Q%U[U<QH^JH6N-YI[QK6KC/P3U
M(R99UYL)TWN1/ /">028#8G'L TX7O_NJ&O>9B1+F*1*-J*T.(073*($2KPY
M5*-C[4BVC7Q(3=,5[(RHU+.LJ?PS=,GA\="U-QP._PE!F+?OJY$H> R;\@\.
M13?-81]T(4OQ=I=74H;(A/VN70'4&]_<8P^X,19$XW(Y$S<2'BD\/-N>&\W)
M@-O4P%WN0 'F$DA(U(][#'\>9L[7P",_LYMDV8<;?#F9V3;530H55L$[<3"U
M3LB]Z_]$Q>I!T>%68PXLGJ/N$)O/0OJ\B_P"RBVJ&#2(D7@&3@'6#L->[\L&
M\7M"%>Z_6UAQ<?0_[/\TQCO]IYBQC(#*ISZ5BPN*V\H[(I1]82>AU@T%4<%#
M6BPS[@$?@@ ;TXJ.K2>U8B1Q<=8@9E]3%M.X,?^<SE6GE&/SYG^&\QT;-*M>
MGSEX<?B2S"<T[1$%L*(($YO/HSVPR00E_FNB3UI2;INB%DN4P5=O24.V&8#?
M!P+V'&._?*'S-Z9:_.DSO<T_NA4/X<[9+E?RHP$4)%K-O8X_#'?F&9C-X;&S
M61[T4]Y6[*6(H%Y4QYI==N3T,/W=K>];L]9P.O7.X_A7^CVK.IG:AVGM7M;Y
M%%ID-&=D8!WA34WSX!"K0+_7OHHDEA[S7$5VQ[U\?F9'S#W5&&?LX?'IX,%"
M[-21B _/!2N0Q^-<(W;J+U WRBE$@-WKB,T]T!!5$NU+5'0%\]I1FZU3H%U=
M#/^S7EG,*]'655'FW]/-U(H\%?;M[K&4BPF1'E,?-0SDGL5?!+ +L+P1^LU/
M;]K>+:3);FB=WC&@]_>PX>7 PM+9/$]Z? #U(M1?'17*,AK0'V-X)VHO%-RX
M1L[Y$/ZF#0.<EPC[2 (LR JP[1XG>B\I_W0@[ ;C/%ZKIQ#VX)I.[-5?BWVU
MM*_P]7;-H57SG@F5N']>[SY] ZN%C&;#(N<WDS*>#8GF ]D<<_9(AQ)J,]X.
ME-J<H-6JE6BTU7?&TM7L?&7JN%)-HDFB>=OK'-S0A,?;?S1J^A\)F-&]>3(4
MSA"H \.""N#-LN"BP3MT[Q9LC+ZBVI=L=AH].Y:P[^9:)CF^(CT\:VWZBY7R
M^+1X7='1C-W[72]%40WB_AJT$W<UB?&.LV&E,UH,B9\ &MJ(8H1#N-;.^L%U
MA 3LJ']+9[,MATN]*>G^>BJ#=,\P2T=WO["[Y9.:]Z4R\[J\[G'[.'K\+ KM
ME2W8>HZ-_;?:$X!.9ADJLM"QC?K 2 O+8W,Q<<;PP*OY.Y_B/7'?+,1<3!3/
MJ@4_FGF6AE5@AT"B5.YMZ!NI?',#/!3S_.<\.R"OK4E^Y+"S.#HAPX*PUI10
M+-ZL*Y9[*ZM#(Z\;1[DCUS=.VW1=Q[3MR&WDA^</U4RRU+>^%;"__,#L%;EK
M'3'Q$IF4C0*"M#YN@41N$G96L5$\G;OO;LVR75/:V[,,^9C;0;59)[3-$+&T
MW]'?*+8\$=J4"GTDL@H;-XWR'6\]^\V_ZI?\^VQ\[/:]C@-A1!E_FXS)$9C*
MPP--*T#7.+1I@1I+$?"'5XKJ24:*$[XD) \93+=$"UZ=GM_L;_K%XYY;R <7
MO/$!O[+F<X=?JXAG=]U$ $A033(5C46"!T;:D./>D-CEM]U^7#M"7V4?O5>=
M+I?_;-Q'6>&;FO0AYW=/DK]9$2HUVR@_I<WO_OTQ<9O3T[3$O<YS ?/8K9!8
M-QT+J@<DT$B28%Y+O=E'%U)\+C6:9\/T^R#6VJ9_V6^354R VW@'F^Q>:_XR
MT(<=[[HHE.KX,2*(6KO*DT$RL)W(<2*]F">+Y!P WS_C:8-,FOI)0NGK^;5;
MM?<PB4$*]MHP23SW:?F5Q_+Q/5$-_^RX[O.7#.X7X4G_YKSEOS'T!QHX-!B[
M?%!(_%[^2X*"TZ0O9VV:M'5U;7/MR_.+SATS:LGF>[L_?=S^?=.73/-_;,\A
M/O$S*;0<5%5?"RF%L@NOQGZ)VN1,Z";*-AY._XD6^H.*7_M2%K3+W3#-T*6Z
M/>9Q5 =-O#A]^^1AY_V\B@AF*Y$6C:[LC!V ),:KP&:@DI%):B'&NZD!^LEO
M#QMISBLL_STIZULZCW [V:7=+M96]CSTM>S+WK^?3G!;.4?Y3RBWTI#S"J3M
M%%HAL0H59WB'V9VB:*5D\8TG4FB47^BCB(>1HJ5%U2BX9U7ZS"8+W;KQW2DJ
MYP1Z2!H\91CE% D#!=OAO_8;&[FCSO-,^.1&/?6(PV_UE-"QXZ0XWAY=Y_NF
M3'M7VQ,K%JI/$@1[2G=$"9_VJ,N^\^E<&,+0F"E93"-&H&4HUTCQU/+.:$/7
MHLXW/&]@*8IGQW[I8OK-'7SA$;XE==DE*716OS[QRZ<1\3LA\BVJ]E%.FS:C
MSD*C]5XE="WP.(5SHNXK+X1!*L-5MD GLQT ?E\BV?L;[Y>KI&>BX]NBS*>U
MX14/.E2MV@3'#(>PR13@_!)X$,5" 21.^#HBIIQ[#:]2S:[]B$S(1<97&?@K
M?=0O-J6D74S)8"G$+ JWMW=?1T^U^.\9]W03-U-U(V_ [1;^&V@_L=G<" %-
MK*FWH85<?:F"?R0<+F18#3O/*E%EC(K=.2X-V3Z[CSH=4?_'-.G@3.CN8T.(
MWTOQF.6JS@CT0J\6965/0271BXRD_D #@536)F 2#H_MJVN[^A9^%U$G?J[U
M)0>+#PW,O/\0<4%3,32_]%+9H1(IN[.=UVPB3A$[4&6UK!/OB,WNC6@8_/9_
MXUG1[(#A&*#>&K&.:%$[-43[4%>1SG&I;?K=)BQ];7FK<?6C^Q.S@A/#Z#AT
M62?+DD8"-:PW!-YSAZ;=@-QP)!,3E]4D%=<B19U^,?7D6(7)(0?3[Q./0KQ2
M:LUF(IY=VE2;G8WX:PF)DKA2O)-\LI$^80(M1/%%)Y!D#)U@'R1\U:_WRJ0W
M;&PNJI^1WWEV5<'W]N'%'HMJ%8N7N)& Y62NJSO_/LP>B1->?9#$"["0H17E
M=GBDT8YM0*^"#@*K4=4)W6XWDSR]\38WSAKK5IZYN?PX=GO:/CU$A'"X*Q<!
MM9*J:Q=\V7Z<.+"$X>]'I\;W=2S%AQAIEY55#"Z5HLL7BR;?^*JF^*F3MI]]
M_^C@L4OY<029YB#KL4HFEB?M (F*L"]S@L%2KBV(/<T62>,YA/L!U,YIB=^T
M]W%N;.&6=JS/WO>C>]MZ.EEGKUV/;XSSSFB,"$6S2FGDV'OK")X,; #Z8#6,
MTCSV=(,W^S)#/=50XT5--;#445M/C,?[>MSQZ2MM+YD>NY =HJ2,UF:$/JEN
M>#[S_-!'J(UW"KB8#TQ\'+>.T$W!. YJ!H5M*=W=Q):L#2S!7'Q5:-P7_,^2
M7EO<#E]5+R_#=+_?'A]1%68\!0_.N:_4=JH$SYLK]CC(:H>,S5 P*JX^*T9O
M*+/QM%1@L-=KJ;.FHM?ODB]'',4\74=4ZK>'AS I"S,T5,JT.G!A6G&PT9TV
MI>-, 5;:7E"M<N>'3Q1,EHNY>)RX^J"(^0")V+2\CH!$$TK=?$G G1%6)9V<
MI*T-DFV!#E(@O3*DM>OYN5N"6[KF"RYD&4IV+P2NSL%QCFG=B1E[SMD%9G#/
M0WVYJW&:P4MQT]LH;,%QW/,S6= P7]-=1U?X^OM(YJ%7'X][1)T9/]U,0P>0
M0;48"DN.>PZGQ6'S<PA:M2WD- JR\%B]==*(A<(:X7WQ-GI5K_T WHNQV4GU
M](]?>T4=4R8N'4)7P30#!1X@LV*XFK@&F#/ 1J_>8C]M /0.1S*T=OD:'1BN
M=E*I>1_?JCL\?B5+OEEUM,?.;65PYXTRD=VH;<3FRP2]C=7WJHTI>"26&X+'
M@(5&&4Q_[(7^X"0_8FSM6D%,L0GVU<V:K&_.5UU*_R3AFR[$Y:PB_GK:Z?U"
M 5<HFQWAAU D>I"3-V9TTL:XC+ZT:E0R2NJ/*ZIEM;XO@7=9#R+)%P8&Q:\U
MWOUG,77Z1LH+'Z;UI$FU2JIJ<D7M2\(H!3!')J)@645++5""8=0$OQ6L?MKL
M_O)'KE%."3C7GO7[4*]\?C#VGQ2YTOHRS4,/:(L/M@Q>$Q7W)$3Q7Z$]=J$A
M,0&NF!^E0H$5O3E?N#.QRIQ5[6_<XB!M(9?_1_M0&<8YAVEO6VFR\]DQ(4F/
M0[^RKB%AODXKI91GQ\(/#ZI?)'-O$#JF#PWC#["3:-4I611/]CY-K]!JE*RJ
MSKG:<C_M3PO!CHM[?5VSF+AIA>U72[X3M'CVV8QLGIPX))K!O0!Z7Z@#/HQT
MHC>!SZ^R:S*+W2QE]><@*1>--S[O/+;*>T5,F;_^(HY ]'VNXTR9<83X3= I
M0L<Q-' 1,TYE.K3^H@J6YJ>F,<@);G+<>V!2V[A:47E9S;'+IKO+WA<<]TCU
M*PR\?619+EY'\ .2)WL9$NUB9S =4M'>?>,HCA*[+QJ/8JXCQCH=FHR0W_"^
MQ5<M"Z=]0X9OCTV.7="TSM^^K5FQ\&+T[<_IVQ&A;B7/S]")X(GQOH]N\I1!
MW0\R[>AR_FSUNY\G XH-Y4=.YH&QCLK<;C.Q[,VZ)MJOD,MS)[K^/04OC/!Q
M6I3? &E"XQ@AHB\IE2@?3!4"+W/2!O_TBI]!R>CI9MX])R_Z3FMK;V H!]>B
M>O0"2YK7\U-#[L"?I?M$6AZQ=M/&/L"-U![A ["[7 8E%_U0T<QF:'__H4:9
M.]_-50>]Z[-&K--8^X?[GU4)'_;.G37+_J(I_5S5EX$"+$Z@_:PT.+W\AA5L
MQ$GK"+VI@W.<W"'-Q:"T'7X.]5>R]&^**@1.NCA/A1?NN*KA4A6XLZWH@OXV
MA $5U,<R4)UDY ]4E<*"'+N/$?"&Z<G/)VB[XCQ:W Z-'%9T:2C=4YN'NW%7
MM:99ZK:H@7S@]K\VB!4R>%P)NM3+A</\:")U[;+PO9 %$:Z,(]1.1>)ME-\S
MA=CHU"95W)P-F]1&D>OTX#BN:'JMM)KOOE_Y6/.9B?FS^ ;_*UT&.6_4-\X%
MTN#Y\^O6$1[([= GXN;J)?$?WIVYU\J&\&8,BW>HA6T)C =_[8$V_&RPV=6J
M>)GHN"\(D79B;6P:@4@;1&[!S9UF4Q+^[')I)582(]]53?1)X%ZN6DVZ#9Q/
M-)]S\;4)N.Z3W]]Y).AO!>+:]G^(@"UY;.XB'S9Y+^18'B2F!70RBM,P3#E2
M&UEP[*:;QJ"A?_BA>ZDYH?)=?X;+?YL\.19SEYPI>R#3?O)JEPIZ@*A(I#U!
M5<]U8$"54R2>=,UJ!UKR5K ?=I,/81MQEUD( ;#P>,E_I-DYVEOGKIMP\Y5#
M[T'Q;)&B()A^=T.BO5PW:(Q2+M+2-V9FR4YK39.\.2W$1L:MA+NTZ4QAIIK#
M#J?'>)@_W6;Z]6UI]6A5\B7!:$)(Q%8X@%+DT/0J-*U.AMAL8+1[LE>]!5;5
M%.'.%+UUQ):_"UF0QLCA118]$MN_[?#;4M:<I";U:-6WS<'A\2+94 ]:R&@'
MU(T![B#;2Y'TU/P[Q>!=[)BRQ/6),XGT[S7?HOWN/K,,.YX37QO1:+T_YDCB
M;XOJ*SL=R@DC%.#".F(\KYU2DQ8)ZQE2.;(];3-.B7DQC8X!3?&A]#2YSI P
M.D7.5ZW[KW2OH-GMY)3DXVF:,RT$8X4^_>:-DBRLWF?$9KMW%-H+U':*#S'6
M=E\ED#K2G+MTGX>F3<P:BU'%:Q/'9AKLXWQ3#UW]Y*6MD'V,76)R&IF']EZ*
M(E4Y\.2U8):AQ3I1@C\ AK_"GP'?;*Y]!:(9+U^P:YW*A@P5[F6/7!HU\1!^
ME[*_+*JK,$:B489!5)NV]]UWEWR)7[NQA$6LZF/!'B>4_I5"+R2@?RIZL_2!
MY\V]H5KM2 E<P>R(Y;"2M8[%=TSO09>_-;\GDC__-GTCN[B,?' <OXZ(AN&9
M!!Y$+HBST>TH))&6LU& (1)O "BU0WM(#K4 L<U:Q/*U&WC,);:G^^7K;1DQ
MD%RZ>3\]Y/FQGZB???&D\K0.?Z]..OIC&A(<.3=L) WZ.;HZ,-IK$Q??258R
M\RC'7*(&#(^&[CWV(9"HZRAZ9V_\ED3!>9KR1LD"=_92ZQ)X(*6WCR>[U+FF
MG/<<QS2KJ &T>=K?WKV31FZ^ZLMFS+ODA8R7A@6JOOW:L.?(6.G;\Q-MWZ'$
MD;:',-(8H'U)T53 7DL*HE(KTE(-D?2-]:(S #^+Q+:F#Q>MDMA7W$XK*9;Y
M/#LZ-O74TV3/#4EY4X]Z.H=?^]_7^I4]P[D.//V!):\RTAGV"9R:SV0G?2S'
MXG)TE(A*:K4"3X_:BEY3X-G!YCFYCJ"[O3!!A&+_Y[N.!:?X=01ET*4U@^I+
M4!KQI-S0\, 27YRJLK5(U3=@1@XRU?^.U R;I3:*T],2E+?7 W%)?]KJ*^HO
MG-3?FC(&ZW#Q39_V1J"/XV%.(XNW8)N,)/$P)1^&6 ,SD\"K#P_-@%<[$1J'
M1>>J\P^7>N%F4EK-5&\9:VQZ<&;7EE._FO@P(_+ND^%M9IN-8J.G?/4O7LQ^
M+=3RF3))7/PD8D-]Q2S6H%D+XIXSK!,U\7OH$D<7R0&D+=$Q)HL+Q)C3WS-.
MHZRA/M@$]&*6XF1:T7*Z_/-S]M56Y1C?FGUW0K:C0H=")0T>'+D'^'U%T]]!
M.]81_10&F;=O;ATA]I5/@J.5.&\S0!F]==;UYHBY9,EK;?<7V$6M50^1ITN#
MO]VB3RN[K",D0H ^*&8=(4>DZZ,W3I_\O]]P*+$Y+>4X;?+*L94H6&?!<-IF
MWN"X><>.76FG-'YG0&+6\/AZL;U9**[9%+'Y'.P$CXG5090M1)\IZ?U_INYR
MAG\1,AGRL=NCG.>W1/;8AAJ=K0%G4ICFT2VXP+4S&+4?I$HT3U:#AF;IL.\P
M21_)R23)1CLZ*F%:HV;X&NC"3#)@H;E[?8(:-.0+))Q'KVKK4F\(T_TLMOF?
M??OVQJ0 DP186(,'.^'_?\[)85OS9$(@,7^NH3-.A!,#6,=VE"B_*7H&#P7X
M_+R3E")#\^U\:0[<SZ EV8A/5\YY^'1&$IO/,\$9.$;.\Q\W>K!7.8*55=^"
MM,:*.^_,H[?@G6Y5HN,- QD2NBJN-4^^?GKCZ?5J+"(SRR4OWEWETQ;C\$X
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M:J04;YZ0\@LW\+:;TK14:>D_4J/Q9[EI)U#+DQYABBQ8<:^ ?9Q\&"ANX&V
M+TE/>1>;%-814DU;<&M?:#[Z]V*=4J#\$+]Z?^WK3LL%%]BD(RF%MGJGMY+
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M5.^'9)*EFI&8LFXL^/+VEV921&!5 .1P!/X2,(N@A)-@&#NRH!4.1."KAF)
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M\5P#VQN=VOE\RZV-,?59WA>E.0ZX*]::;U\]OM9;O)NB?/RP:9P3T"!-DRB
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M9FADTNM/3JT:K'4#K7*@UFX&:OU J^!L]S2V3<['Z0@\S@1XXEK/PDW*T.,
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M=_4_\#O X#J3]6WU7KII8:U_Z/[6IBL]\8$ONX)U51<WU/]X+M,PRF)3YB/
MFNYQK.F>1(E),XJ)>;<28=5<81SQ+LT([634;-$([5S+TN?<V=JJYYJ1T:W;
M1HDZ>;-1;5;_O/F@56_V]#S4^#TZ%6=@,Z7][WBML3D"^OYJ<OH4;NH:GB,
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M!W;J[9*G*G.V7INU5M&<UNQ[A)I?@KV:^PA4I:E/)WLL*WCSJKT+.+$;/1;
MAW[S:#/U[ ^J$_I-).OIHZ3.,=(^D1NCE,1QDD$II( H5,XR#7,&6<(CS-)
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M4@F1H!AF- H@(01%4<"HC*RZ/UV89VZLVK3S;F4%M;!M#I9KL_/CT)ZG38^
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M=>Q=ZXE$M5HY\)-6[R]-=,Z)CS;Q.DK-*\/(C::^F7DD&_C+=_,JW=09<&-
M>R0G;I1IW"]]OXE5L2X_KS>B0E_6Q6KS77T-]!+%Q&KS;BN4>;/FU%NM#GF<
MR0@F)$'ZN#&!),Q2F,98I!2'4@:1[8VO_;1SXWWT<_SOH#+B@Y66'W#E?VEY
M[2\F'4"_?/D[#I0CDVTM-#!27P$$C.# 2 X:T:_ NP;8'H5S'!"VO_<=!^F)
M+GV=$/=SV>N.UYF;7H?!)KOF=5>P>\?;X^G^)Q=%?8E\O>)OS:IR*U9,'Z#N
M>DWL$C8SEM P0QB2)%#[ !IE,)<\A2&.TCP*F ABJ\">7K//C>T[PIO;B&?B
M=SJ<]ZXP[F8;^\.-41"?X)C#%]B]CCN<0?-X\&$_]^1'(,ZP'#L,<1]DD#,;
M_YRE6)'H]?9V6VVB *7-<B\3GD192F'*!=,Q\B$D^I@CR0GG)$MEP*UK.UC,
M-S=",W(><6!KN8$6O)>7=1)O)P?6!XJ3>JXUG+7CU(%PF,=Z$LM>KJH/3%_%
M1^V-;5\G]1)2=M[IR5%>PRV]I-()?_3B8^Z1AM_8G>#;I;B1=;7@7\7F;LWW
M\8V'OQ7BL_JN7/]95 N1$1:D5!<L2!-%VB2!E,H,<AFQ0 H>XS"P#4P<(LC<
MV'PO]170,BK/2$EIR3J#K7*>VJ?$>F3.=X79*7C2!T8#8BT'33]9:*8/D+J1
MG%[&Z[<;W_7UVKN^U;[CJ9"<)B'BD+- IW#F'&9I@&">\S#&F(@L=^Q1>W8^
MEY=LFD:T%NWS>L!JMW'V!M7(?+3'J+,K'JMAK!4HGC;"Y^>:=.-KI?;+C:[=
M0[X#QNL-]7:]K7Y;E8(L==2COD;ZLJZ*IJSB]GYKZF?H7^].D^*49#@*$:1Y
MP"&2(H.YX )2B7D:)B3 =HT11I-P;N[67GA3G<:UH*Q_"]K1VJO:9>Q;>YM8
M\Q=V ZUZI@IMJV#]IS&.%D?#?_1(\[[RS23P?""\]G'H0R=R#TO_7A*="_CM
MZ9ZNEPLI4Q[' 89)DDF(\H1!(E(, XX2P4@F<6!U9W,P\MP8N!$.U-+9AYH_
MA^L\;0X"862ZL]3?*7S\J*Z] L:?CS19B/A1!;I!X<<_T#<7Y$.Q%)^WYD V
MR2-,:(1A1-),>5 !@22()>1Y1D/=Z#&15N=2QP:?VZO79#)H 4$MH6NF1P>X
MRV_@$#A&?@D=D.B1QW&H\H#DC<Y@$V=L'*IQF*9QY#,]6R;?K<O-NVT;1Z?V
M7;H.U_6*OQ,/>@G6Z[-><#LG @G/XE3@ *:!#G<."%*O+D8P$@F/>8X1P4[)
ML^XBS.T%;V*3WY*RJ30'OI G[>XXMN5TMX7=-F9<A,>^-M3"PU9ZL!/?!#HT
M"H"=!B,=Y?1'T%<;37<!IFV9V1N@@_:8_4?J&>0EN.!O2\&+S=>B^N=74>A)
M1?EN?4^*U8($NBX3(I BW5(<12G,!4)02)$(E(M<9K%35-?9Z>9&;49:4(L+
MM+Q78"<Q^*.6V35PZSS>=I3F#\61Z6LG67L!=@DS]_@K*RA\!5R=GVS:""LK
MQ0]"JNR>&A1#A7\.(QT%\-_;Y5,4(-Q$H5 615$>$BAQGNM-CX0TS93[E+(L
MQSFG ;-*%+.:;6Y,8J0\$C^EI=;A*;A7Q,\)I,^3B'?\QG:!GD7WU$#6T3T[
M\(;%39U L5?4U' T7R5FJB>J?2.FSJ-D%R]U8HS7B)8ZK\Z)6*D+#_4,$BA6
MQ49\*AYU\?J-LG>A]F%UX;>FL(GY6KVO&QOJ>B<?U#=J$458*AERR$-3P U+
MF(4RAH@'G.$DBC*[ F[#Q)@;9ZMO7^(83- /?CNG;WQ01R;R6@%H- ![%>JR
MD5= "\[TA5I7FZ9DD];$8VC"("1]Q2ST$V+:8(9!0!U$.0P;K><1GUI(M^KK
M\'3-V'IK,@B^Z UTP;I)!/LSI8!0EJ280XJS1'FIE$(:Q"GDL0B5!TLY%DZE
M6!SGGQL'[L0'>_G!3H%.&)'C89^C52Q/^L;#>FP?UQ9F\,=W4Q=BG'.^?OCY
M.N1SG'W:$[Y^T!P<[_4<QGT__D%M]$NR?*N^HIN/JYN[8OW?6WZK-Q9M6GZ$
MPXAA!(,<I1#IG3C-(PR12,(T3>,(86F[';\TV=Q8K9$7&(%U#UHM,FAEMM]$
M7@3Y\D[<)W1C^V_/4/OX K4>>_"+\-EOP7W".-$._#R<?O;<MK"<V7)?'&*R
M';>M,MT-M_4S/;W+73[ /@>@KL?R53PHEU9PY=DJGJ_>/+TE&W&KF-^LWXN<
M",GR1$*>I@*BC%"8HRR':A\NPE!$7+&RDYO94Y"Y,7.KA^E?MM.D*::D;U]J
M94"CS16@3Z!5J/&-'"]D>IO0TB>=P# C\_Z!'2X"[>YY#D3)EPO:5XQI?=&!
M8!TXI4/'ZUF(4)3%HUICU91?ULN"/76RF1+, DPCB"*=S:2OGG,:9C#.TT!F
M-(@H=KIU/CW5W/AO+RGX4*S(BA6FW5:U*8U+XI@Y< 9B._;R ]S(_-01\@K4
M8H(_FO\?99]\&15?-?%.3S1M>;N+"A]4JKO\1-^0/5**-Z32!=KO]4&A\=*O
MRU)](X1^1=X\[3_RA3SI7UW_("6O4S,[K]+-YDZ4W^_(ZN;!%-[\10VAV^5\
M4:*O^2*D-,%YFD(BL.:@,(59D"!(XECY9B(6L6N@WS2"SXW1C'3*8].U2TV]
MTLJQ8.ED%K=TZ&9HQ[%/)[4^T"@$NDJ#CM;:$>]^KM$<&-6O0*U\=R4#1OVZ
MRTH#P!6H(= G,C4(/F,8IS6;M\C'B<2>.%YR6F,<1EE./'^_M>Z]E+IEYZ.H
MO?'OY,^OII.G21HK5K>[^J[50C 6HI0%,)-(N<VA%)!&ZI^44X[B*%6_#A:;
M]88L[58K^ZF=UIN= ..1U4YRQ2)FL[HA?P(EJ^,-E0/V=NO&.(B.S/Q[,)N=
MOQ(;:+G!5Z'?]6)9--?T3?U)?X3MCI<GRG68>%+2= ?D)>WU&*$?<7TI=3W[
MS=,7]67:7*\,;3YHOCQ2Z&"!XR".&68PBD@,49 )F F10<1I&J%4YC%U.@IU
MF7QNSG(KNTGO$*W@5T#JRAV/[M5-G QAQV-CP3LRD[5B*Z;2@E\9A-_O$3Y:
M&\4?F_5!S1.?.4T]*:/U >4EI_4:HV\]Y)5>XFJ*U-'S;Y[>B!6[NR?E/TUA
M,T1$FB!)(:,)@XAB#$DH4RA%0F0N$,'"*JW7=L*YL=<S>4V^#-C)ZU1BSAIQ
M.\KRB>/(-#4$PAZUB^UP\5:N^,)T$U<HME/^L"BQY7/]2.:W2A>7JS;%O7+-
MJD4B6<@CE$%!=:4 2D)(.,]@S@2E*.=I@)W"$9\//S<"4=+IB]^=?&YL\0(Z
M.V[H#\C(3/ 2BVFN-H[#X8D 7@P^Z>M^7+&7+_>)3_6LO%95VWO!OY3BOMC>
M5^])N1)\(025,D0(1CRA.NXN@40&(4Q#$6,<JU<Z94[5TX[-,K<7NQ'2L>[9
M4?SL7NO!J(S\=C?R@59 4$OHL7C8.0!\%0 [.L>T1;S.J7E0B.OLA]UC;#^M
M5[??17FOB\FIK<<G011]T&5QV_;E6FYU_:!/!:'%TA3\^IM8\J8*V$*BC.$P
M11 ALUL@#&9A+&&FUO8\9EE*[(IO#99D;F2AE8%JHGO E3KVX:3#S'&>5R8%
M>63N,?AJ18"I@JA4 487L%?&M"^LU0$=?8!6"'S0762);7V7X9:QCP*>S$(3
MA0C7<5?:#5P^>R?,X=72V&S=L5FQL]FR8[,[;3.I;%:9HI9L2:JJD(5:?$@%
M5HIFMV6I5/G93\2Q%Q.<"4<>-OYDL<I>8.@&,OL9L)\CJT8O]7SO1/W_'U=-
M^DK55'I:!'G. HHSB+GD$(E(0D)2#FDDXIRE$1>Y<'%J+\XXMS6K%0\\U/*9
M-_3ACI3W1&W5U#M7W-?-J4S7W^XGW7SBRZ:P\X^] CSR>M7*"GYJI?V+CA#9
M07ZIW)BS[VP-CB<_^O)\D_K4UNJ_]*_M'^S'0U^%*87[A92;I^\E654Z<VZ]
M,C$87\6C6&V%Z8';^5OU]V)SUWUND>19QD**8&A\[YR$BJ52##E*.&=!D"*6
MN5"5#Z'FQF9U:%;92%\WK]YTY <_E +J[W4![ >M@AN->;&D'=--;9^1R; 1
M"QBY0$?HJR:@[NLSJWT_L-JS ?QQID^8/=&J%Y$F95Z?(+XD9Z]C#RBWRE\6
M-]R5-'Q;USHO'L474O"WQF=2KN[UTGS[1/V;:_X_VZ;73ETGXK/8+"@+<\R2
M%.9I3B'B&='E&S(8IH+1E& :N[F?8PDZ-Y[?*P*T)N!9*5>CUA508NL-:%,I
M3N/0HZ[K&$:WH_\YF'+D)>%DC=B=EE?@I:7?[G<D.UWK7X*]MJ!1UWP)/)>3
M'=$D/HO.CB'F]*5I1P3[: ';,><;FJC].RD+O1?YN%(,*ZJ-*2E>B*I.ZN64
MH23&"(H J94DP0DDL8@ABM,D21"A+'7J8FXY[]P6AFX:=BLX:"4'K>A#$Z[/
MF\*2W_T#/#9=^\%V0(ZU%5+>4ZK/S_I*&=164)Q.F+9[W%.X81-B3VY%N" L
M"@01!&**J2Y3ED*2APF,.2%Y3/,\Y4YQ0><FFQLY/8^1*TU9[H<+Z0?N"-O1
MCR_<1N:<P[#"7<:&DG3$B,(C<(P53=B=ZG4C"8\H?3&*\-@S?4])=SNU3I4Q
M$S.V0 $6&4(1Y(1E$ 4T@#26.>0!B3&C+$@BI^"C,W/-C34ZHIKDI4=1:I)V
MC#$\!Z[M>:07R$8_9MRCU2U).$$(H@5 W@X(3\\T\;G?194/C_,N/S*HBG_\
M95VL-DF$&V:Z?BB+I8(P;6JS!4+RE(8,9EDL(2)Y!+-<'\&A*,G".,PQM:X?
M:#_MW%@E_CDY6M??B VTW+U*TE\"_SS5C ?IV%NC9T7I8V $!TKRUEFYZ@ [
MK.C_)81[5?_WB/2KM &X@+CW/@"6>-DU!+@TV&MT!K!4\$2+ -NG!_%\HAG,
M]"%8B2B(D^;[G\9A*!/=Y#N,A=I@YCG,$RX@8TG.**62)E97*E:SS8W5DQ.L
MKJ4&6NQ>E',":2<N'X[?I!1> ]GV%6G &T;<)U#LQ=?#T7P5FNZ):E^6/H^2
M'3F?&.,U./F\.B>H^,)#O>,JZS(,QTK>QY',:)+$4# B=.<]#/.(8ABSA,<L
M9R&F3B=\YR:;&__NBXVX[L_/0FJW0?<%U,A$VRG(\JP]P!A;<AM(_,5"GIYJ
MZC#(BTH?B8"\_(R[N_;;MW="1]GIE>9&UE$:URO^M^T]67T3Y:-N'W#]]EJ?
M([Y=EV7!U^57P43Q:$ZXFA42$\X(3P4D81Y#E"IGCN X@X0'>9;'(DX3;.O1
M^1!H;J3SV\_??@9[M?3U7!,/HZ,DC&J@U4WMBMY>U^GYK7Z@HZ"]8^/%LI<]
MR*GM-3+WO335S<Y4UZZFZN&,>K&9O;\ZM>TF<FD]VM"/Q^L3YS-.L9=I)O.;
M?8+2=:V]CNN^H/ZZ+C>WY%9\6I-5=;/ZJN9_7VU,,;3E4M3!KS?R2UFL6/%
MEA]7G]4J_OV'6#Z*7]>KS5VU$(+(1+(4JH630$2P5*LICF%.(\K#3.8\M"H/
M[$6:N2VEZDL?V_/I<&-<7@ GA7CDU:_5!1AEP,T*:'5 K0_H**0Y=:>2[C"C
ME0*U5J!6:THKV2]YDUIKHO5N$JLY+7C>4#ZSV@V?8[*ESAL<W77.WZ#NB]S'
M%2\>"[XERR];NBQ8O<KN8G+?_\GN=+WCZO-6KZ8W4C>G$]4B8)*S) VAD"B
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M_VF?Q^[/RN?)]]5L-S(;>S5;K\JT_BQH7Z3@52PY4?V":5Y$I[(&WN$^4_'
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M0H$S2D@@D7"YT[.9=&[LN:^S<*5+.31R R,X:"7O%REL90.[TUK?R([,HWY
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M/-9.#:TV)6&;11 D84BC"$91&$#$4P8SSC.(HBCGC.*42*?6@^XBS(V M/A
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MYG0*B3 B*9<PR+(,(D8$I*ER2D1 A"0DH90CVTOJB[/-C6S0OX/*R Q66FC
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M[_\4)2LJP1=$%V,FVD4,8P(12G7((D=0L""-*:,!SIQ.$R[..#<>:@4&VK!
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MY+?56X&B$.-00IPK,R"2JQ="Z+Z+&.5IRN.<Q>Y!^Z-88H+8_*-V:,XX1K.
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MN:JRF71N>]"Z?P9[UC^C:/IG+'7_#'_-3G:X,YPE F&L($\RG?3)8!ZB%)*
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M1J)%AL#+Z6G+S6]UJYMY5-I5:0-CY0"XPCU*J+^U4!.*Z'<%TBUPW_GI/6.
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MS] /27M_G&]$1_*Y>4#6R:7F M,)MYG58T9SC;DHU75_.=W7/R*L.F:Z576
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MH_G_("1S'A]/O')BH%&IY+S"K]G#XHY^A+&M#?MQ57S<K+7]5#^V8:ARSL.
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M$K!TLWY8%<9]^9^:-Y82Y&6YT;>NBFYU6#<*.30/=NQQ(;H#$\<.V&\UL)6
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MZ1#B_)!3H]=6XCJLJ]X$[&RA_C62+<"W]3'ZA'1PE^/%:/9P/]H"Y,T;>7;
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M,X;%'3TK6VFCL8D)BFD2!Q+%,$:$FS;P$22295")E"0RQ$F<.I6AV3UZ:K:
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MZ6L&J.Q-Q?3"4W8B_E6#4_9 'C T97^LGIVAJJ(<M^K%.?#I8^ YCR*:A*;
M)8KT0D"S!+(DP9 DBI"$H31F=+Y>K>G";B'H(8,3SV\E&8Y6OILQ *UKW#RT
M35=*YZ8K?:;#CM<'!GE@VGX9AF*.21K!05=RL!6]H66?;:7ZX^>KQU0/"<9M
M.-4?HKWN4Q<\JF_JWUJ_<*;*1SWV%[G^\+,9KZT0,,<X"X*0**@"O4U&" G(
ML@A!DJ8I"R*%>)JZ)?>='W1J)NU.YH;OJOJ]KKEZ%F#;\9IO" <FL@YZ-PUZ
M)JCDEZW,H!7Z>!!/C^PY>XR\Y<=9##ER!IP]"/LY;@[WNA\+WVE3,-\\MJ=K
M+)*1DC2%24HP1#@-(&,X@R'",L,IPS2U:L.Y_^BI<4DKG?W9Y"NHSA_D]@=@
M:.=^(UB/ ]I7(-B?QO8'8Z2C5WM0G(Y-#^M]XHSTU0VC'8@>%K1[^GGDBAZQ
M*'*9KXHOJ[4LDS=9\E[O2NES%*"P?:NB6&"5,"ACQ$RO%@&I2 AD 24,98H&
M@96M8S'6U&C)R/B_0%D)#99&:B V$FB9@1':(9+B#,;GZ<LC<@/S62TIJ$2=
M@0K"&7C?@:U/),JY=]0^#L4?CB-1H0<\W4)+[! Z%5ARY@GCA978J?(BJ,3R
M%G>>;3:HRWMSKEL'#GV6QG-75XQZ;T(,M3$I2[W=W0:T?"C7^:/))?B@U5T]
MYOQSKN0<*<%P&"D8FX1A%&42,D)#F*HPP(D,4DRM:D+Y%6MJ[%VK,0.T4J1B
M[GP)9*6+B=[?!6?)5AT@&WW 0BMDST\>Y_;\4G"=&1MXU=@J!6Y,6$L36-=.
M8:U9Q7J?EJ!6SC1$V84Y;O4#K8+@\[6FT'XUNLY4CK1PC3VE3JN<?^1/+(@>
M!QMM[?0/4'>9'>#I%T9(U Z=YD!.W+XZ:]L[F7MY,/>.+OAF49_1=8H0QRC@
M/(Q"2,* 0!3@ .( (\A2%:<QP5F&G2H.#2GLU%;O[@%]TS.BU1>LEOO'[_MG
M]GM']AW%+ZHW/>@[XQB=<>4W8<0HC>N]!/T#-@:<'=^!&T.(>IT C@%!/QK(
M,>28/:OA5=49\Q]Z0+YZE-_ISZ]ZZ7PYL/YEI[3)>WV97F'Y/ EX' 49@T$8
MA!"%&$,2A0E,)!)1PFA"N' JE-=;E*DM2G>%<<4\FQ!8_?EMEJ*.PC<I07QU
MOZR2@M;T)V!-"+=C8;W^4V:W:HPS$0.O"5LE0*U%U57*Z+%']>8/.UUFH%5F
M9BKY<>FU6/K%R/HJY]=?D'$K_5T,V%X1P,N?V(]IWQF-E^LZ^N1K7O[[[;/I
M('/S,R_G,N.4<Z0@"Q-F<L(BR)@0,(VDBC-$%)=.?3E/C#4UKGPA*C"R B,J
M^,,(ZVAQGX+8COH\ 3<PM_7$S)FN+-#PQ$>G1AJ5<"Q4?LTH-K?T[.^PZWS7
M9'[,(\%#DDD!D9(Q1!%*(:8I@EG&4:*(C#-3%,0^F'9_"">"&"U6EC?I18N^
MG3@/8&E'"9<A-# 3=(33>]9:/(^](8ZJ[JM'Q/X X_:*.*K@7L^(XU?V^[:_
MRB8K_?=EOF[+-S(9TB104&(20<1D8OI $$B52'@@@S3#5M4\3HPQM>5_*R(P
M,O:LRG@(2[N/^T*$!OZZ7<%Q_L!/J._I"S\TPJB?^ D57W_CIRZ]M%7W#>?F
MQ**L0@8^K^C2Y&U_S)=4[SI,90HN\Q\O6T!3_;G3(*%01"2%"&M:8!G+8!RQ
MB"#!2("<@L<OD&5JI-'M&DT;94"QE;M'A/DE$V7'-"/!/S C=9%O]9BU04>5
M+I6G:ZL-V*DS4N_NWNAZ[]_M+LF5>GCWANQX'^_^C^Q9A*=8/<EB_?QMP_XE
M^?K[ZK:X^4'SA1GCXZK8GB-7I\>-A9!RPAD6(>0L8A )S;)$_PH*@4E"2*J_
M!2?_=0\9ID:LK0J@T<$4-ET58*M&E::X"]BH-.EIL_69,3NF'7@>!F;88:;
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M 'L&W>L:U4"EVPQT9O'N]"RZNW%](^[+V>M-KG%=PK[AW',<>Q_ 0^_LTS5
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MI;E,H(B$A$@F#%(1AU $+$A9@#(:6474'YUA;@>.MHIB*R4P8@(EIVN]R9=
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M#S;_7%"WLP='PG)D1N^D!K]T<O^J\R<:='>R]RU(?U;C ,0\F9$N,T]J5PZ
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ML)BD5H$7-I/-CH2:$X\66&<J&9$=SKKGH+5P3G@$;&S:Z6'UN<4*_-G("[3
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M+,O4T3T-$51?- :S-$D"%D9YFCL%>IR9;VZ<WXEKSHVBD]6QF]X9B.VL58_
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MTRK6!G(M=#%&_7NMAHGSTGK4[J%>%RS?:?8:>34FRO7M4'\6&;8 G18+H/4
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M4WLI2H[9Q8Z;C?/HN+%W,/OUF?_.YOAH#K5=.J*ET^[!C@_YT<;N!$U>-1O
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MJ5X;_A=GLU[=F+X5SN]MJ^_65M)BP1E'+ DC&"7"5C9/(YO!*6'(!(ZDYBI
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MP@4DL4HAI53#2.)$ISB(4."U&'>ZF;F-9+658&>F7UA\!DNWF/AZA$8>9([
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MS<^-EO<)F*"Q'[!->72M=*'^FPUD2B_\^-BS:]R8=SS 1^987ZQ'4*;HA]U
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MU4I=DWJO+1Y&5%"9(DAPJB")D884$P(YHW&0BH#1Q"N7IZ<=<PM[_67=^W;
M]<PW$*RO27]V7O^DQ"'UC2/T?B66$W!AEQ6S(40'J'Q8T>5Q/:M<K+-[$UP]
MV@K.O[--O8+]53W56O-W^DN^S,3RB:T^9K;1#\; !4I"2CD3,)$VR1$9=N1Q
M'$+!24P2K1#67FE%O:R8(2TFGM4N>H'O1HJC0SHR)5K[H74 6 ]N0.W#<TU[
MUMH!RUM< ]90)2YZV3!MF8MK8#HJ=7'5P_JQ73-U+V?IS)8]/*Q5O]_%LW8M
M>(H$#RB"*I0$DB0-;;$RPW8R2@2.$0ZQ5QEE7P/FQG&[!;5RW:Q@WE+TWCW@
MQG9CXCHRT;V$U)IJUY.MD2_JE>W\@7J=0WO9</37%[V!F,^[^4E)KR\XAWS7
M^SG^^0-5%:%S=8.J"(Y'DA%JWB:5<$BB5!I."P@484@Y344<TL0U:>!R<W/+
M%' /U1SAO+RY/RQ(8P=?=<FQ5H6QQN ;8$QVB,'ZH.B^>3\LFA/MV ^ JM<^
MO3M('9OS#@^9;$?>W:'V-KS'73UEE52E0_*>Y=DRNV_2&$6BPUB' D8RL9/D
M,(!I@&(81K&.F51AC",OS:23S<PM0FRL!(V9GII(I[%TBP*O1VAD7CT"9X1D
MSVX0AE(@.MW(M/)"G8X>:0=U7]US/KF;J^[.&R\2S! 1DD.:!!$D0938JM82
MIF&*61I&6@5AL\WJ.&D\;J7'%NK(W_W.M!XU[D_!Z#COZPG-1%.[VKIR0G=1
M$\%_VG;>^:%F9B=:F';R==[%H_E5QZ4]#_RK>_O$K^K)+K]G]Q\S*TY:!HF?
M]K51 Q')(&&0!H)"(K0M2Q@1F%"DPR1)M")>1>Q=&IW;F%_;#'9&@Y;5UYSV
M=^D -Z(8&M:1F6, 1/V/^GM --1)?Y<FISWH[P'"T3E_GWO[4=+[QZ?5^EFI
M;RK_L13JM*+2YW69>*QDG7=F%U3:?W^[+C:?UYO_5,94L;[/['&(,G^U5E-:
M8*ZUBJ6$*-4<$LXDY$Q'D*(PE(E@88J\5KTGL7INI/A"+RY;;\!S>?JD,?T&
MK"N[_2AQFA? C5-GUZUCD_*I-.&]>MD-V/G:B/]5/EC1IV)CSPF7[\#7UCMP
M^V@%08;C\$F[9*!!8!J;)QU%)NV&PV%HVL;[C6/VZ(L]]_)5E;E^W]>?EIOE
M?=GR-[79K,H/:B'3@"""S3A$,8($80*IP#&,)$X1UBC0*>V1L>S4>(\9]A1)
MRG=/R_52@M7.8B!,_][[;L.ZX>\V# P'YS0T;NT%OUB+_P%JFVV%E;W58&_V
M<,SLA=) S.K6YJ3,Z 7#(;/YW>Q?-.[;]NFI>@A;?1,/2F[M-NU7M<R*;6Y5
MQ;_DZG&Y?;1ZHQ^;?[.LR;*E*O;'KLQ[)Z-4I! EMB8E00*F)$0PB *>1DHS
M1)W6! :T:6[1<>-*M31FPF(3/MT6Q?:Q/J/U5DD;9=6^E>OERG%5<<B>[&;
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M 46A-L5.<.RW]5K^M5RM%HGF+ JB"(8BQI (06&*.(<1BC4F:8I#)'PHR=>
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M1H(%F)N_1K%3]3N_9N=&/N178^K_!$7I ,BL!X9^S'!LS0;6;O>5,0_P+Z]
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MKQX>UJ8S$=C*"7YH05^Y,:3:KZ7S;B>O;R9]],/7_E/YUSQ_G>V]%$;E29[
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MK6NP[QG<+K^1@BO"KA-BOZQ*'?=$LCQ "0YA3!+%ICHN7;T,D?*W<"(R@83
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M>RNYYS!$5["\%<FV'';DJMEN8!R6T7:\OQ]97?T@A3D-^+Q:?R<+\3K%I#G
MT9Q;5HI8E1,;94+D82YAS$4,D8@32#F.H0PXSW@0,TF$BW'N*L#4+.Q?UZNR
M!%LY@1;4C;*<I\".NH8$=G *>Y6J-@-;7:!<K:'69F8+N3.+]<7-$YLY#S\J
MJ_4%YRV[]7Y.3Y.L*)]7)5FHCW7S?+-DBXUN;:I^JXO2%LN-X,UASVJIJW@N
MU1OR$LZ#5#%=( C,PBR 2!+362B"/%3_$R1I'H5.>6Z]I)@:W[62.0=A]YL#
M2S-M:&2')KQ&?F 4T"7(&Q7 O@Y@JT1=I-RHX=%\NP1$7[9<+QG&->PN@>G
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M+-1G/@)2Q@E,HR2D@N,D"D/;TA7'!I@:Z;8R@K414@>!*BGM*RP<!;&;,GU
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M7SZ3@E\O2/%D^I?6/_!_;$K3T[1I@JPX6M<Y;/_<[LV%@N(D$(HO$Q1!)+,
M$AI*F(8T0BF)4RF=ZK?Z$FQJA*K,YG\W>Q2KI4GL7$EMTAG!VTT)1M8"L%7I
MFB?K;2[M*/<]9FA@$MZJ9 H!U$J!6MHZ+;?^<:=8V]#=A ;4D]A<,\2&KF_$
M/5&U-[%&)6_?8+ZE<^_/[QOK]D/4H]RK!UPK3_UAM2[^VRPC30J]3$D0IIC!
M6&+E6F=Q O,DRR#!69ZGA,M0.%'W^2&G1LH[B=6'^W'U1(JE<\#769CM6-4O
M>(-OZCK@UB/JR18*;\%*9P<<.<;(%H##T"#K.]UHI5Q7\^],+,FZ6"EB$XR4
M5=O,)(L1#0,*$T(5C> D@S1@,:092J1@89AE5C1R>HBIT48KG1U5=$#730U^
M !F8"EK!/%8J.:]WUW>O[M[[YM6_=M][QX-'^;[/*]9^SQ97CMR3?MM%Z:HL
M-T]UBZ2[HOSGY[40IIZLXAT=93,7220DP1&,,Q'K_33=C3Y#D":ZK[A@*<FE
M6\W=P65V^9S&J="KI812B:F<Q%I.L%:"CM09W'JN[4R;2<W?P'3HH1OXKK<=
MV--[!K3F0*L.6MU-O.($^H"[SM-[=P"WEO>OT?O;%7YO7;^=!_9UL//A1?_7
MG"&U-JXHKWX6Y1R'3,0Y2J',F>[O'0I(<2HA"T2015'(8NI4>-1A[*E9J<=/
M%O1_=PV,:@5>P!]: 4?7UV5:^A[F> '[74YP>N'LX<CF+&*#G=.<'OF=#V?.
M0G+^1.;\(]S+='QLXKET,LYJ_;S2!A[_\'*GS\2%4O5>_*P^*,W^.1=<1F&0
M42@ETFTL$(?J50P@Y2R282IYD%J7[K >=7)TU@H.]B77MM16=OO2'O;8=S/7
M8(@.S5GGP01_:,&!D=Q3"1]GI'K5"[$?9;0:(LZ*[]<5<;_9EYFU9];]KJU#
MLF";!=%1\P<GT_N)-LH((W$DD@ F3.\(1AQ#2@F!DM L9@%G>1)=9H3UE&QR
MG-8FGKD[]_YFJZ]M-L(<O(OEMJ<7^-WX\3O-CH3CS%ZG#PYIVUV(^&"67U^Y
MWMDNO!#.\U;CI0-XX_$GG>M4GP+=RE])L2QU-151SC,9)CE. V54ALI=CE,&
M\P0)*-6/RG=FJ7*9>Y0^<A#!B@[&KX>T+Z^.U5GJHA&LVI"U[E2YZ"H!=/&D
M]";DBS!^5\I]@[:6'?RBA3_= <4'GYX#;#C&/#GR>W/B.4@L6._L(_KQ6K/S
M6-Z)A6&!U3WYJ1NM/:X6NI*%KGU[="-SSGG.(Y:G$&%)%,DE"<PQ2F&6!H)G
M(L_"A/4@N;[R3)3Q6G5,"%Q%?IHN148S4*T,_YF>1* 45;6HSS'4EZJ;>U0O
M@.CM8$=*[#V?62X2',8YQ%+/)U?+%TF4CX$SGJ8XR$3H%K$_Z$2.Z$T<F4']
MTY2FSFYI&V-"!E[G&A5F)A5I3_;9\9._W5F+O_7N4A0]+7Z]Q1AU);P4K+?+
MXL7/NRRL7^].+[EIA:5'5.3SR7SM<UV,)* H@13K6J<X2""FRN"G)*)<YFD4
MDW1>K2JRL./.<P,Z<>1VV.&^RWL]!ECLI#;QW88>&[G_U__ 49C][X8>^T7B
MGX3?CO]\@CHPSWUY@^2G;M1ZA[Z?@\)S2/O)X=XE5/V<\J="T,_>UW.#8;^4
M7'<EN6_KE?JQ,J=GNCB='O]9$^,<12)ABGH@IS+79UJ:B/(0ZDX0-(M31#.G
M6F\^A)J<0=<(:KXLT4HYTQ:=X^Z#CQFSW)88>1Z&WJ]X50KT?"70&6BUJD,
MJBTK/ONU[GSB[&N;PX=(X^Y_> 3Q8&/$Y[/=BU(=1FSM?(Q;LR?]J_JW,DV_
MK8O5^OY12?GP& 4A;CO(TS"404Q@S$@$4888I'$4PPR+3-F0*,\8L:U)=:$L
M4Z/ENC/ZJCDB>JA%!U4M-M!RV]<JNG2:NDEY9/ 'YN(SGO,,U.K,0*,0,!J!
M^[V).9^EX'V&[(M)C3A3(]62\C!C?JI(>8*VHXC4I2.,5D/*$Q3[):1\/=)]
ME;L3/U:+'VI=O5X+7E2?"3.IMY]^/A=K]=O?R$N8JJE*FF]1^14TH5$&DY2I
M12WA'%*$.,21B&*:YCC.J.VBYC;TU-:PK?2@%A^T\L] JP%0*H PG0&MA3U?
M.D[)^05L.* '7J]<,>ZQ.#F";;\6#0?Z2$N/MQ?<:9WI!UO'LN+XP-%6D7Z*
M[B\:/9\P5KF;^M??])6Z.,.RTNU0P[GDF<0FG3'-8OC_5_=ES9'CV+GO_A5X
M\ UW1R3&7,#-#XY0;3,54=V2J]0]X>B'#*P2/:E,#9FIZO*OOP"X)"5E,@$2
MI.B'Z2E))''.!_+@[ =E02 /CQA#%O P0@E-$+&*/;HB;&GG2TV;GI8^=3>;
M,UMEYVN?<P-F\LD/Z&93_TDQ)W^H]_"_^_9PAF8V_8"_63.;,V0MO)E-/YCC
MF]E<>/XP\?VB)^U-L6,'NO^2;WG3R@9%"?-)!L,011 Q[,$L3##T/2](6,IQ
MZEE%$RXMN#1Q^ZI%<TTQ4"3;R=^+6)O)59<(3BPO>\%SV-?"%AI'DNWB<K-*
M+%/F7THBX_L&*HB[[9W\4!\^<*);Y^BJ53_$F!$?P11G2$J5P(<8)RGDF"$_
MC42(0ZLQNZ<669HD431"12105*Z HG-0>?!)1 UULI$X3:U?*8AN[2"R5Y-Z
M,'"E\IQ:8E[UI8?)5ZI(W[4#F^&H0,Y7_BA?C'M<*IER5^"'KUSU,U.C80[[
M>]4]B[/C-5</JDK#7_,X([[P!(PR+.U 3#%,TR"!,0Z)1TD:<68E&H:3LC0!
M4D7'BI9,\%CQLI*_J[D!N&6G>R'6#%GVN!F^A6:R:)Z-F3IRIO?D2"&X:?:D
M900<.>E>>-6_)_8]9D;#Z:IYS'!"YNT*,QJP5^U>QC_1/E!3)9Y]X_10Z+RT
M#SOYMNYS^E6J=1_U.*?:NN!"*EQ,".@%F9J%Q2C,XCB&/*0IPHAY@3#J=6"S
MZ-)$:$.G%(YX [BFU#PF8 SUY=#+% !.+.HJDL&19M"BJ:@&%=D#0BW&L)H'
M6:: =Z;PRNU]7@+:M+7)=7J3GL@F=L5#5<>'R>ZP![OO6_G%W.>/;2>[$JCR
ME'L."C6J4Q4782J!*/C):_,M8"<^!_#]?E>>N@/DJF[I4?Z3;^N6%CJ[6W=<
MI[N'!U5A6$BEI!D+4^JS\:=JD)R\><MS25P!'O"6J<,LW_R0#V1<RD>RX6"[
MZ_Z$]YJ3*A=(K:!^JG)M?U[)Y;9/O-CGZLJRW>55O:1F7_XDJ:E^\1VKL/F^
MQ56?Q9+^G:9'[>%?W$2I;-^[GOB4\:-FBTS9,M>-25G?.\SN^/CPN-G]X/P;
M+YYR-;G[9/^UC=Y$743YE=/=W5:]#S>\R'?R.OEI?&F&=*^]T!=IY%-Y7*(,
MHM#W8<H1DV<F%YAAED1Q9&.,.*9O:<=KE95$SF<EU:YL5D5+\&.^QQO%W*I6
MA\$?VC.HF;/TBKC>>C,CY@TW=&K+YE*&F9N]M+9S)D+<D?'CFKI9+:*)H'UI
M)DVUS+ C0SU\JS(DZL7JW/'MG33?1+Y7!?:?)%+U=./R=O=^MRUWFYQ5Y>--
M-[,0T8BF 8-)$*00<19"3% ,(X_1R/,]85DZ[8:LI1T0S[E2PTV[9(.6R7JD
MH%)AJSCHB3_:'0^.MMGL5)A_\R8^#%[LFU3'C[M1\50W%0%*JH"&,;5_SS;X
MCUNMW#OM?S<-Z([. T=$S7H,N 7RI?1W_'1[AYD*<WS\4ZUXR,M[M<@GSLMU
M&'DHB2B'%$<,HCCQI*HOY+\2CJF(P@B;9S"?7F)IPEA1"?@S,H'@-O/ ST!Y
MV?TU'J")!9[&YCF%X),+;,Q]6.,QFLEC98V5E4NE'X8>!\J9&V=SE_03WG6.
M7+AR7%.GV]U5Y03LC)9:T\PC-,H(I*$G15Q !<2"9M!+O,2/8T:B!#>-F\ST
MU;[EC-[9YWV9)A9]-W7XI9X6V5(ZK%G/28C--,71L,W:=$<K=#6AX+,!;(-;
MZ_3AX;A]SLFEWJ1%3A_3Y]K@]-YCKQRU:6!76_:W7Z[KP(NOQ 3G"8PB&D,D
M0JD;13&#(4I%''I12#TCX_;L"DM3C8X9B\JY)<DT/_=/(WA9)1J-R\0BX C)
M507)@$C?:6S,5:+1&,VD$;UZ?4!Y(&7.<JRF&[3 .0HZ]:+2HR"=OF\V_:B7
M[*YZU'_A@ 8.*MQT+3YM=H6T*K^UK?N:/(DTS4*NFO9R:0TB+%0I*V<0<\[]
MF C/3XTRWB\OM32IIZE5&E%-+S@2;%'5WX_N94'H#K.I(R0:KNM3< WIAM"/
MFT6S V?XS=7+X#R.CGH4&"'2UX*@_P'S=1@P8N19 P&S.X:9F+]MBS8R<XO_
MK#L5EY5[7O[BAF_QINZ5UDPMNZ*T.'"V)DG&8B12R*AJ-8OE?S(6A3 A4IF,
MHRST4JM)%B-H69H8;F(?^$_PV%"M%8DV$P=7A-M9JV-VR\R8G6D/)A;K72YT
MD]F&CU43E5*_O'FV,^W<R*L+.V-M$#O U)&]/(:26<UI!Y"]M+9=/'+HS FR
M/Z9-73WA?*-":*K-+=YPE3ZE:%*]X-=>&'DL8AZ,.9$B%2$NK?1 #3.3OT;<
M"YFPJIPP7WII$O2OQ:XL=5*C_HAIE9P"[E3'?-OI$L;PF\G(:4"=(QKRK9-G
MV=(-Q:Z BO(5:&C7,R9<#I>P!<S9; GCA6<>+6$+R.O)$M9/&":\7CZZD_\I
M2?@%[^N?ON7;NPVO?_[Q0:JL]:@+KG-]WN$R+Z](N2\PW:\#%J11' J8H5@5
MB 7J7Y$/11BS@(DP(W9B;@HBER806TJ!(M5.!$ZRB6;"\JVW9@EBM>%*_K5*
MB:LS+BN>VS\#Q74[[Z?>:/!'P[7#/)LI-\61Z)Z$Q%F%_)0@OSP.)EUK8-,
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M<EZ#(;,6WOQUF'46PQ)>BX&3&R;=**/)#M-0\ :3'R:%\O1DB&F7'!JUK'J
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MC;IN"DN/OGWQ$;,IS*;,=#5>XWL&MBP>JE#K_R@E6O4PT"3YZR@CB(5>!$7
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MSR+-XIA[(J26#<<<DK<T*=G0!@I)G'5PRN6^&8>UWF@WI@^(*<::6#A0K*U
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MI;K Q",X2404RI], SPG5UB:U1%IK3HV#SJ<QNURN&8T&A,+E2-](-))N_&
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MC1U/E5H]4,P=(&7HA(FK]3G2)ZQH+3'7A^">R"^N7BMAAI)<;7?G%#'1_&'
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M4R045UK0?DE#3K$^;G-9U4&'40=5RU9TZ\#Y:O61YHV?"#$'2K4#*S24=E_
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M7'J+B-S<2.3=*OC<9[UQ#4\KL)Q,PAT8G@L9?7^Y6%[R=OZ'RS=Y%].K&8I
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M?%Z? 7ZIWS)!EX5-F=BR68+*A1-O:('B+<PJ29[;)U)VIJ[+_/&C0;"-TOH
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M;,%3I 4"LZASRTU0K9^__9BJW6IM?[9[B\;:Z !?[W%6+O?0/5M&.FY-J /
M!%I0C%$88P(%\BY)FTEVB*T!M@-9NR'L9[N;:*V/#B#V<K'$Z<?YLS-:F^SR
MAV7MMYXNQH\/?YUM]M0M1A4B^0 %*'Q.M15_H/@9L?;C+Y;%FC%J'74>3.QN
M</S9KC0>1W<=@/0=?L7Y&;XDP5Y,A?G'E$(F\DP7GVLG\^O<>9E51BE!2%59
M)'$Z:P19>1]X<"YRU;I]SGX4[@;'G^WJXX1:Z@"#-39_4]Z'.XH#4<L<5/3
M0JE31*P&%P6O380<QR0CQM9%=?=3LQNV?K8;C4;2'SD2_3O.\V)9_=3?JP=1
MK?3;LV7Z5%OD35?;6<6MNVE55!*U#MYI <K:.O$A%,!L-0N!%R9NM!.Y,Q@]
M8.G=D/2S7"4\AOP[,%-7R<07)+OUQ2ON6_E$170KEDI-W=1IH=F E\E EMX%
M)P*+N?49N2-IN\'N9[M .(5>.H#;D_P5E^OIBL2UE;S>JIL/S#C%,H3@6"UR
M*$"VNC9]0..\B-9AZZ/Q!R3M!J^?[0ZAI1XZ@-55E_SM/OIOOIR/2+H^YN(\
M(\U<*%(E"ZR&,\KQ -&B J>0%984U[XUU X@<S?X_6P7"*?65P>0O)QP<^OQ
MOI(9$R_D(-3BP60#T([*(%*($B,K6%K7V-U'RV[@^EEN$)I*O@,$/3A_;7MG
M*&6R+,6#Y[4(-4@$GZ4A#HV.(2C.L74'P5UIVZW5PL]V<W 2S72 N)N-CF]=
MM_&4E?0:I+")?(%$,O.YEJX8:P,WJC1O5?D#DG;#U\]V;]!2#R.G, ;Z5W_!
M&1WJ'Y9GJUO/,H+*10K4@#Q3%!,5!\\8)SD5;Y.0R&YV@[DS7_&C=78#RL^2
MT6\NV0Z,S[/%?$4<Y$$I?P_+:7U8_6I."^!J/03!Y\'OQ#CR^)Q4D%R6H+00
MY 32+[ZRA%Y(R9KW>]F5N-UP]K.EZD^CFPY MYF&]!NN/]7I(Q>]12Z.;^%-
M+)IIL+5R27$4$(6)D+G)1B"/&%K?E3](T&[@^MER]>UTT &@AKQPE=$9YC=?
M<'GW?:J1000>:&^$R.LNH5@VU!'R6EEO/<4CK/5=^$Z$[0:PGR6%?SJ== "T
MO^+O6^):+N;TQX1;.^?6O5=&9W) $EX9^E.240[H:O$Y2HF6_BL;8VY?&G>#
MW\^6RC^IIKH=$O%@I^ /0].<ZSP<W^OX_%,?H=/Q7?2?OL]Q"9SS+!-DQ^@H
MM S!NTPP0>.,R\QXWKJWP G['*=/F,]F=?1M6'UZ.5O\_O[L"P&@[HLPVQK&
M,LCZ:G,PGC1C1D,06=1I;0@NN^H>(!:IN!>Y>?WB8:1VVPMY'QS=RMP_@MHZ
M.%VOV+QXO55G!JY>+\)0*_=R.@_S1+*]:@&V52S'18@F:6 <2:C94=P=BZ\M
M)U0H4<AD6U^5'T%NMWV4VZ#TM.KK *GW]C_9ZDR>+4_*TK9CL9 DR;UUM0V4
M5$9([1POLO5+Y1]3U6T3YF-PUU@9'<"++'KX^'&)'\^;.YT7;=ZP[CDPY'4X
M!X7DY!ZKXL#57TAP.DGON;:M#^6=".NVU?(Q(&NOD@YP=E<%\/ :GW;1ZVF(
MT]ET_?T6BU%11,3!!IXH8I<60O8%4DG>>U0BYO:3T_8FL]L^S,=@\-3JZ@"1
M5S[$G0GO&@5>^0QH+3(N@*,H0T<Q"M9U!C1*&^&C;&__]B"OVQ[.;5R\MNKI
M"GD7O4O^O%R<?;EJ6')W0G-3]_*>-#M$8T_#K!8MO_^$PZY\DO/0A/%ZD':U
M.7,V64N*SURIKRNRA8C1T5[-PF;M"D5L)T/PH['9;1OJ-CNA3[ATFZ+<:DVZ
M>EZ;P9/=J&R&^:9#T/!\Y.!4Y3Z?WB9E>3 _C5*73\]6TSFN5L\6GR-%V.?%
MG!NWX(JT2\P;9@H/UD.6]>4K-QJBC''H<VUD]09RZW3F?A2VN O<[)Q;O:=J
MV<;+Q;)J9&M3>2YT'=(CC.:@LB67G24#U@HOA%;<R]:)HSU)'#>E>4)\W75E
M>"K5=6L/MR[?#[9ZMS^CC6W[ 6V-+-C6*E='L_/2RZ&I""?5AB@@<D&_F)2D
M,\R;YE'F'60<4X/W8;$.LYL"W*H3<XR1#ZQH8]2R:*,0G*=M$Z/,&"QSUL@?
M:/W'JXQK.8[5ZW;=74-I-AQ6>\PDHKA^C^EL.01-3[Z&Z:QR=&'BKG.73'3:
M"@0C+/FI669PP4LPK@0?2V"Y^3R0?>@;]S*C%<I.KID.8MPM63V;A=5J6J:8
MGWZ_R"N=A=EO85TY__Z< I0;O)84H\N%@^=L*#),$&J!!*-CU@DF@RTG-,E[
MTSON54=K5#Z:YKJPCE?!]=_F2ZQ3+HB(Q6KU9G[_$5!B?9UFZ\1-%D')K&NO
M.P<:9::]* *JUNWY#R!SW+N1UJ@\M9Y&!6-U.YZD]?0K;:I7\]\6R_7'\!'K
M;?9;^G-9S*:+&ZQQB<F*)&L;*6*-<PI[G..0G"<QHHYHV X^W5Z+CGO1T=+%
M.YVL1X?1U3[99FU(G<_#[!F1,UV_"S5'><NQC1J]+ F2U+51&2J(20G@4@L?
MF'=.I1T@=3 !X]YBM(37X^B@B^/S2FSGKW*O,B;&Z.)]?8?K/ E/>R"3JZ D
M9I,4D8?F4^'N)6;<:X'3.6C'R'QT2_5VN:B]#VN]UCN<D2N9_[RD _W=^>%^
M/G7LSV$Z7]6#'E>UD5@-C.H$LNW Z6:@I)RMS2U 2JQ7%SJ 0^T ->,I<UE\
MW.5H/!%YXTZY;&GE>M!?0Q"W3K:^#-/EW\/LO&[GD%3KS4]HDVA]D*Y&:=;+
M-;;N%J_2]C(KZSWIEV)$"A%M@"C10*ICO.FT*]ZUCIX>HJ== 'FYRN8>8:M2
MAD#^&X:Z;'XS?U>!OZ3#_VE836^"7VIIBN49!#*DS<@X1&$5H!5*!9EX=*>[
MIF_ P+AIX&:XNS_Z?&PE=^'EW6#Z/C;_-E_$V@-Y4ZSSY6Q-_[R8)Q+.@("M
M1BW%\X*Z /?"@5*6(JI"=MYSG5S(-C'7.K_7F(5Q$]$GP_F8BNX@:7W)_M/O
MV^4R0[D-\;Z56<HA!"-+'0[EZ_3N!-%I!=8ZFXM(@LF3 ?@'M(V;C#X],ENJ
MI@/(W7&RO"GOD:1-'O7%XY:GWW\+_[%8/J,O?5PLO[\I5W[\UL.#P$V4N3::
M#_4%5AVV')&1B+VQ,6O+2NL93<V('S=7_9ANPR,HM^.@Z&(093COK'4UF>_P
MBI0??V:;P&E/VAN%4@^,[KQ"ZR588RF^Y)0A9%-; ED.@? !6E 0[YVET[AU
MYYR]"&QG+2^6W?(U-#G1J!(XM.15&]JRP0D&(7EF!'HF?.N^BP^0,VX@=#K4
MW&_BCM/(R&W,7D[GTS5NJ@"KS#*6JZ_<%.&-<$X([:T1Y'%PC* V@E1UA+,5
MR:+@)-P=$HY'D#!N-')ZL#VFACKR"1?EY?TLOCRKM=]//B^6Z^E_#;H^'\AW
M,]D@N5$^*-"IRIL+ ]YX#5D8)YWD.?C6;6%:TC]N.//X=O31==ZQM_@:P^H(
MQ_#:C[?Q >^GJ)&[MUG@$E%,D[*DTE!"IF"6ISI5TRFH>4(7%=FNYI.<KU-P
MK"D;/JUVH+^!4&V**#G6!U#6@6)6U_EH#@R3487L>(ZMG;5[2!G743M"WS<M
M2 M1C^R%O48R<S@P<H,)FV)D5D;P&#@HE\BI+"Q!]LBEERJS$G?PL>Y=8%P/
MJ@$*VHFO P=HP\CY4\;YQX&CRU?G%]6G-\\\&Q0=OB0E4Z^-L_7@-+E\S'H1
M@E,ZG<"B[$WFN.Y,4VMS6A5U@,)-%R'<B37D+H8H"R1?6PF94@?)Y@0^>QL5
M0RE*ZZ=]>Y W;GJU(>I.I9)NG^Q=C8G:C/$)WP<F#W6)'_RX-B[R[A0?Z3+7
M$^]JL2>76=GS<;Q;U_*7T-,^)86,0>2<7"&M#3@5$@3+=2R>1\'M#E[$?JL>
M/_N(PKU\MGG5?[G0Q7.,^D9C^GGU'+_B;+%I1?7_L_=FRVTD2=KHJQS[[WTF
M]L7LW*BD4H_,U)*.I.JVN:+%XB%AF@0T *@JS=,?CP2XB +)!!")3'+^L3$U
MMT+X\D6$NX<O=[JR.!M*]!PTBMIL--5)3]Q"<5(RK*WC0W/__RB*QS'(!T;3
MKP.23J;4"=RD-T'BZT/[]6+YQ_Q;F.4-JR3P[1?YORXWCU_;T 99#1A%+A(D
M60B@/!FP,2H!)GD;;$:>O&L-X"/H'<>3.#5\3Z70*8#WX:WZ<^K+^_+KUEW<
MUS!+><-117+%'6UE94P ^HFH14HA>I$5&2VG/9H/9V8<QV9:I_:)H#!98_6W
MQ7*Y^+.6M03:_5V9RXLO2\3C.D[T^=0VINO>]#<*^M9T^!W/"5+KXFPR=$YB
M!N6BJ>D>=.=KZ61![81H'='834G#?F?T^;1OULO+C4QOLK9DBJGVW]<I65"1
M\.^8]<!M\8K@CYZU[A7T.%7CAH8;H.*!3F(M%#&%R_FFU&X3!:"C?M/1YS,N
M+RJ7=_N4.^5]I),_*55 H300 K-@(EHE<R8#6@T&M'XTCAN+'A1V RAILK?A
M=HAD-RXR[)PD^1O.L<R.N!KW7J+-/7D<9XTNS=N#A;L2M*NU=X 778DJVP#,
MU?Z@NAYJ07,P1A@;#3)R1QIO^CW(:SAIXVN8?\'5F_F'Y>*_,*TQ;Q7Q/I[/
M-NVD[Z;&((_,T9X GDP"E;,&7S3KFO;:1 >^<ZW+=(^A=]PK>2C,/3"$8UB-
M3NH&O^;U5K)T/6-VIG0YIX/S4=2ANV[;E"$+ YE;%7+0PC>?B7P8I>/>YB,B
MMK46)X75%Q==[G[U^+_,:[GSF_GMLI2[6[((9%I*T+;6$)3"(4BD'8K,.629
M%S%<^_"]2!WW??KT:!U.CY."ZSN\,LFZ1[F[[_*!Z5B4!X/*U?;I"F)M Y"3
M"$HHG5D:KNCX0=+&?;@^/1S;Z6E2\*.S__+B6V>L_+'"?(<M8U#GF#QH8@24
M9!%<KC71(9:8([>^M$YR[$G:N!VO1C@-F^EI6O [[_ZZB\G?:XI(9WC*II8'
MR-JY,!KP(F6(/'FFO*R;;S@4]J!PW/Y8(X"QM=8F@,E7M6CEVH>K7-UP=E4
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M*!):KFFV"F4 CT)"<+HDPQW+S8>?[$GBN.&NEF@;4#63-9>Z/@?5AB53I'9
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M1@[M;>GO4O4W'*Q>+2[";'XFN-+*%@:NU*Z6M/5J&KZ%K$U2AAL64Z^JC7Y
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M!0QG.FG!>>*YSX6WX[/[@>69Q?R;"'K\"^PJKQR7KQ'//#D00G.$J+P$E7*
M*(N!%(./692<;)_PZ-W/[0>09QMO/U# $[BB_A9F\VJBD52J?_#'?(FIJBN_
MN*C".DO&*8G%@E325&/-@ ^1 !]+D"SG&%CKQ\E'2.H'M6<6@1]"71- WZWF
M>UW/O&XP7<?)BS]#9>LUR;\;I/$A+,E;C5DF%UD DE0!58J$:'F&)+3S3BJ%
M_:8S'];JL@^)_=H7/+-0_RG4.?8LR\7R I=WMM]'VGQ?YK/_J6'EEY?+JJ"-
MB? ;EL42/X>_SD2BK>=R38ZJB<!&! C&&$ ;$H_(B9,^D?\#E^^'QF<8[3^%
MNIX4(M_A^GVI'!;F0PZY@ Z<@PK>@0O%0RGH.)*_XU6?K,G#5N^'QV<6W3^1
MLB9PG;_(WW&YGJV(O]__^H;S%3G5GM,)7V=F15/'%9-IXKP-X$R.&FE/R=(Z
MR_)7*OK![IG%_QLI90*P^D1../X65IA?+BXJ!UO5+:OD-O/>;_YDFVO0&1S=
M/__ 52?5;F?Q,Q>]Y]PS(&_,DX5L"P2K&'2CLU/PEI76,X!;TM\/RL_LB6%T
M((Q\U7]>8EA=+G]\6B_2OSH.5_^!=4#\Y^7E:GW&,"598@113!TQ15\%@PJ"
MUB6E:%(.OL>5_O J_8#W#)\C&@I_ F?I1SP/7486^5^?:=^L0JHZW-X,J^J@
MW?KQZI^S]=?;_\F9]0%+G0./T7<I,&211$>[ABQD9J,PT?7JV[W'\7DDR?V
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MQ65<E\OS7R5RAM8F:R0#J35Q5;@#7TC62'M5<9;H&F@].Z\?9>-.^3[)23F
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M2NZ^"DGJ)*(*K=%[&LZF,G;A!'[3!*$R@0VT%X.WFE\FJX0HGDX@9^F<X,6
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M.T@H/,5?A3Y(FV4&Y/69*E9R<47V*M'JE+UUUK3F-SR$D&[6;J5]HI>6]N\
M1DW[#KG@+/' @;LZLM8H!X$V5BC.RX1&.^9;9W-_?$*Z48":DI!NC'<[0/9P
M2@EE-!TK1D-)CLX4;BE&S8E#RC(8S2E<]7WS@YP&)=TH_.S-#S+&F1V@=#"I
M1$*?!/("4H7:!J$+1+D;R":<]3II-*T)EIKR@YP&+]TA&)W$E;WS@X28C$*Z
M4PEE RC)'3CG$'(=N1KHJB^\'' 7:<(/<AK\<OM K+DK.MCYQA5#Q61+KD5^
MQLE26RP-T'V>0]%)"2G1V.8<7NVI&28#Z-27G>E\U0$0A\[P>%B#JH/$8KFD
M6-R+&II[\+QPB)%)*U-F@LTU\V>_UJ5.J!1& 6C/:3Z'>7/F8_FPTIHZ.SK5
M)&D]SAX,IOEN6.F"Q<I/&BA"\6@JEYFA0X4+8-D'I[S-49L!Y_O1!.ZUDK$I
M^ 9WZ\V%A!]X>3PUVG1A(PL4?F5(/D6@OTEP(2.4H$LQY-&$?.:5\I3LO58M
MGN*B:8*/'WW]/#(>=1%E*=PS3?8QKM;5U>EDR@ WW&KCLA+,]K!^'I&]UQ+'
MDUT_A^+C1U\_-T9Q47$99 "G%'E0(!G%D2]U3JQF.YF]7S\_SZ(9M5)FGZU[
M0BME+R2<]/(8,(:U%!M$8@C<<T^A:C 0HDX0,8=8M&;J?@W6!*OB1YFZV\MB
M:.SW#A)/>[4AQSIB6%H$P5FF,-(P\!H]!)LD"]%+J7MH CF-L;QML'TT?_Z0
M;>6,%^:8,&3L^@;&-(/ 2@$6#$>T6+1K7; T3UMY)[Q0TR17C^']DPY;1J3:
M[G=\2511R-IBIACM23I2:">*!<Z--SYH7@J;.<A_3OY>4[)'@>P<J=I#\/,#
MK[&G,G,/S,4Y(Z-(,-[KVF!9(*JD(3.=HPG&Z"/<'IJHTFM>]T=:>5.@ZD=?
MA(^D]Q[P9&3KI><9<F84I2C+:U=B !L3<Q2JI&)\#XOP955Z30[_<(NP,:I^
M]$7XE(V$-D)D1,!8IY-F'\$IYL PKT)4'%T>4M$WE_R]9IA_N.76 C\GO<:>
M3$C>MXAQRD@?!7CN)<7?/H'7J>XZW!H6K5%8)E]10Z7M-2E]6NMG$FR<:,KZ
M 7-38,[IHH$9K(<P%^"*X^0688S S"07WR^'DZ$QFB&A?<QU,1<*3H'&Z+KG
MX]=U6+7A+'KT-S8G*'I9[@G9B#1#*^H,2?+X+A?MP">A0%II??1&6-6Z@+HA
M&U'M5/_.?.]6[\G0OVS))WB=E+\LOF<QAI0Y Y>5KL37!9RFVX<+5EFAN>*L
M!8G,,&GZXR :@X.[+"$36']F8IDG-?H9MVFS_%*]5'N,WI4_-NLON#G_=DFS
M(EABG-4)9+Y.?$T4=%O/0 >F9$F(?-BK\+[X>E:Z^0A'IL#'$/BU<U:O</P]
M?,9KI:J*5\UMMLY JFD5]$CA+*=(MK:OU_FO(IGBG5>#YBKNB\/'Q>H0@ T1
M,@20#=S5P>WCML/V5K/KYD<EC7)9@U=&@"HR4S@I.$ADVJLB2G2##MB]VJ/O
M2],AWEH X,E^YX.\T>L.=ULQD;7@)14%5B>*3@)/$$)D0,*&C"FXP@<Q2>Z[
MJ?TZ[_SO.0_2_9S0P5;U]$+$O[[[=PL1+)/6*,@1Z2(N!.WU)GBP'D4TCB4I
M9>.=:[!P'6YD>R)B?0SWS)S.?MIF]1^\N3@[^_8>OX1E7HB,07GIH+#**<1-
M@IB%H6U?T/:LO)-Z2*_:X ]VN'$=AJ/IS-WSWO5FO<&K$:G;A<%"'W>:3O98
MYR$5.NV]RL"-1*<HK BN-2'-(,'F>6^?<\_:VRW-L':LO.IK$G!Y_CY4'L?M
MVU5>[J#</MOZ_'>FS<&.T''"S*R))J C>!9.UP%5)VMXQ1*8J)/@B,A\QSSQ
M(T)6%3.+EA150M%56R4&H:0Z5J3H$+*BJ%5/&=QWGID=@X,],K-CK-_K1?'Y
M5$YBQ68N$.AF%&MJFX$7.8!-*60O%6W_@Q;2_\W,["A\')Z9'>.L7N'X1*9'
MEIA<8AXPNUJ6PQ1X5QAPQC@OL?BL)GTA^$$RLZ,0<D!F=HR[.K@R/),+]+)@
MUEH 3X6#TB5#0.X@,"=*X$HPWOJ-]T?(S(X"P/#,[!AO=("KMROZ7:MP=AD4
M5_;#[?:6&=EJLI!%,$;45V,6()C (!D58F*!!Q&:QZA/R]-ADN/PP[2Y(SH&
MU?6(@<A"L"5!8L;0#1HMN%JCQ)W05@M3-+9.R#XOT=RW@E:>'PBI/=PP<^+U
M-2VUC^O--W[+Q"IL(:LX(QCMW9@@1F[!<&^]"$&H00V;]WYMGS#8QUOK-J;K
MQ.OBS[6Z)A]G.ED9(SA$.K1#\N"4%^!2(:UD+@7#",??_N9Y._DF]OV>!NS#
M_4O<ZE>K;*X4*"9GQE0FU*I261(Y^!PUQ*QD5!9+*$/X,A_]Y?-VDDT+@@/,
MV <.OMDKT3GM4%865YO*%$780D,(CH,6+#ICHA(VCM@#[ C?3];6-/$&L(_I
M>GUKK3U1[\J[S?+C<G7IGQHGR91$B;P AN"K9@R<-1E\T,8I$:J1#GEP??2K
M';Z$'7XAF=CX)P.KJZ6')J(P.8+6M&Y4_2-@5+7P2A41BL3[=6\' FO.*\G4
MOM\+8GLX8F:0/5#A#]PLU_G=ZCI)1'&7RE8:$+R6X_-:P:4%K5";/1W +HO[
M3_N/@NJE[YP"B/;Q[GHB4_<)FS__6E_I(IF.6?!(:RVKF@R0M)W[ "6:S'*(
M%"$,B7Q>^LX\=Z$>8+.?J3N%#2'@>A$(+AVSHE#4*&F3#BCIPA<"<%9)R;)F
M=!D\ #BW7YHG(NH".GN:NT_PO%E?;*XWT!+K_ $-.=4^UI ,!!$SE"RU]^B*
M2@><5;<?FN<"U@-T]C1VI\A9?KU9!MGS$%4D\-<#5TB*"D5*P)3.AF/*R0_)
MTK[XH7D8%;I SG[&[@XYI,OFS_4#G9P7 4W2E4B(_A"<=#+.T@6#+,>U=]D-
MF5@P]'OS,!#,C*,&IN^U4.?76TK6X"3S08&668+*P4!4AO[@T0C/1?##2B2.
MTV#4_)";LQYL/R=T\(C]I$8+GFW*NAA@M!(N!V4$(3(DQ.Q3T"RGHS44=5AO
MLZ?'AQ;CCS+_J17@TW:\2LLOM:[H2_AV.=6T=?'],]^8M/!^J&X3%MU;IISV
M4H+(H<[P*+P2]3) 9-H$RS#<'X%THD7WV023M1,0M: ;J+.TZ"@D -3!N9AH
M/;)!TUQ_T*+[,3C8H^A^C/5[#9Z>K])5UK(<@X?@LJ'XDY,!K:WMZ!0A!&FY
MB6I*?)UVT?TH?!Q>=#_&6;W"\8DBWD0:1<P<%&($%8R&H#2"0ZES<%I&.RD.
M?Y"B^U$(.:#H?HR[.K@"/%/F30>(8]G5Z=X[BC]?)]A8!MHSZ8U%7;#UN/0?
MH>A^% "&%]V/\4:O.]SMM2G0B4 +KQ9F!@;*% 7><PDQERR48^B&1:D_/AU*
M\X-T/R?T6M/R>GUVAJGZ:ULW_*OKU]O5[W3%^O,O//N*OZU7YY^V"QT,_0\%
M,.$+J)(C^&04K23!"Z-@6..0*9<'"]+A1K8G(H94NDSBGE/#8LU(__G7>I&%
MCA&C!:NB(^NF +46G4X&6^G.L[%ER%"8?;_?X58W _+V<<9) JX^UI.6B24I
M'&!46 N",KAD+,3$94F\Z.+$9)"K$G18/SH7Z$8[Y!1A5Q_Z%TY8%JV(D&TF
M)4,H$(R7( 23%!WS& ^K5'Y)@ Z?H&8"W6AWG"3FEE]Q47*63.M*+6(J;:#+
MM*9(26]UBHPT='FRG:X*,$^%1I>8&^N.T\+<;G#-C9XL1V9$L+2V0B4_-9)N
M^_0W+T1!99S(?DB]ZB$RS%/3T1?R]G=*!SFX9W2]3@>]6N77I/$%_?@[GB],
M$F353&84M?K2^D11A([ I!1"83):M6;6&BWD(%C:$X+E<=QU"G-*2*?;G]ZN
MZ#_!)D_XS_S>YL_V0W68\*F^F%H)2W%9")6A?3<GW@:$C-+KY$)291 G]#Q/
M]0\GA]^WYWO\0DL%\ZO/ZPOZX$_?KGLU+S.;@6FK9 X@=669#(:N0MHHT,QD
MS^E6GIH/;ME7UOZ>]\=@Y_X&=A2/=7"NWFI7GV=VKX 1C29I(R3-R6Q8+/A
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M#(7:GG[I &H_79!%:4W>4&%:530BE*3K@ ?-(5H50!O&G(J)!]\:5=]+T"F
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M>@6CHT=E+/B41#7(:I&TU&!LU$&J'+R=\E0]K[>X(9@YOEYAB.KZ>!7Y\05
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MX$?\=ENMR6K;1EX$T>YJYUHD7U07#P6#R20P5+:UU[Z;DHE=]9,\2QPF]I[
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M&!'!V< K7TP^G&FY'WZ>6K"G26UCP*>)H/M!CWIPMMYPI;9<92\-8\R %C:
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MO%S[P8CZB=_CY;9KA+6E2!/!U[-123006'3@,4>7N5=T:@Y]7-BQSGX8.<N
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MR+\NEU?K%KTN11D\"V!S;1HA X? G0/C>(@^"<&;#Y3>>Y/CYDQZPOFP\NT
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M7\*J7X4Y#B;GWH;X9R;<:>1P[:^^74SCNA]%N>Y'83+S(FH(*NCZI)*!4Z6
MUM[5)LZ*86_WD_M3N9.VV>ZTK;OT\!"@ZB&\/PV')CJB=4%[D"KY6EB<(11E
M@0MFHA"AI'RFNO9LTLR#('P<A=P+;N>3F'ZPFGJ7EJ8_,HC"3%]'>9.#DLFJ
MII@@<)7 ^1"=\RH&//FHFG;D/9M$=A<Z.1+LSN%T?(HU/Y4[/<J=XHM)7G'B
M#M8>2.@ K??@BXQ92<U*&:0L_V04/IND^UGHY7#@>PZJ>4]N]E'^Q"02\<=
MMI)B:H6U*!$-R&!-(!FK@+8WY=R3QF>3_S\+]1P2@,]!0>_) S]NP)1@,J*
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M,A013?-N <?O>CQ?\K3P/;%\^S6SO]2S+:>?]';"H[#D*C&07M>9>8K7X"Z
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M8:<,T#Y,[\^C7D>H0F@>1.10I*K#@*(E6TIA1M;HLQ<A9M^ZB?H]V^C*/3I
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M](3(?UAT9*$?(K)Y"_Z-+/CUW5(]_=['/,/%=+Y&/Z;,N62UN5Y]*N'J\_!
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MOFG?4[W%4FM&$JF3S8$4JT8EI%-0Z.B6TL8Z[O,D'M4#&]P)B^Y,L#B\B#K
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M'AMA[]<-H19F4Q!.;\,+!?U.U,=4GSAX^!!]"?4Z+O5(_*6V=P[5]SA]=.B
M*L3;C>V\GW7Q%USZW%/"F \5Y &3DHT^'HS+9["=B4'?'PAJ4\RI>DUVB]K?
M^NB,8%<Z2@;YF'&LI7[)%S6W8+L+/^PY%?J.&1"7/2#,"1+I3^][-N%+O@#"
M$IT0BXP&ZI*=[0U]6S71 U572?46'/W'YU38U-(7!R"0NJ6Q1[^'ORX<]N A
MZJ&Q>EM/_8H@HH%FX)%'R_5M]?%N.1OI5T6N^KBI#^LQJ5Y!^$J76 19;#16
MKZ]^$7LV>F"^:^LK-O2;Z%_&PR$G0Z4A-M2EGE WN2_53]$O/QTTFUM'0@DD
MO:46UJL0?XQ)\.3VT?*%W$!8J)=7-"3A(T0%LLFMXFSKM^WY+D';FUO-MP_O
M]$OTR-!WP^_?W_RSD5W:4W(^QK:M]-NF2V[5*BHY/PIN**K6RI,?-[=-2'XV
M80I8[1W%G[QZ!70TRV:W\4&ST.OVB7%UF5JLCF<UT%O];O]4.\"[;)0_[*Y'
MN<W4O:!N$_6VOVZ,F,?$&%ND".##_:UF18 7?80YP,T8;UO=C4K_WBF\-AEY
M5$[0N;05Z&-U3_@V!L[E<.YX2LEX.#2;-M!YX[S15I1/B(L?U!)DQ)R""JJF
M=%73=3 ?86L2ZYJ>PVR".L)5NU+&!=K9^U%19[@9(M0M(CT<(>X2SQ,3]U[M
M_EE5S=X.J)JEJB9D&]DZ9\S5SPNE;L[;*5V#LH$^W*J5+->+]FYC=^\)<&UJ
MJN/1+>-*G",)3WZ04;X!>U[L$6CF>42=62Q?@H2;1?U)?1RJ;$/ ;!3S9Z+.
MW10P&\9\@=6O F2#F^(%M1PZQ%X,/'H(S,T*MGZ[/P@79 *DS9/.X97:WJK7
MB?QP;[>VG(^)E.JTM@YND.IB4EW@< ZHBZ&^)H]8 &.SR@..YR]E %XYE$7
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M)> W@O\S9P_J?Z?_]:DLZ!@#Y/F0]W5^DU8R+T+[U5LI$>5OVOW%U9NMFR<
MXIU/O*?@/_F>C3YWBU'?7S-R^D/X'I=1+Y0C '*>D7B2?!^=,_/EA /GS)PE
MX5Y@C^L.G:'[MN(S_8\!N]W1021UG;>!^HU??FHV=X]03TFW.@$I">\WT+G_
M2$8#93H,LP;PM@[J1;Z6"OR88%].UAU' *BSI-3AT=A5F@3UL1+P#UM'ZF!/
MT#%QR7>,SJ]/6NCM,<??J5LOS?+L>.1::I:=QOXT -?'MY3K)@?<4A> B)O=
M-/N28TF&U$(]HKO\:E=*E]-[]4-T3D=4$CLR6."\6<YY\PNU/3))SV,#&\6,
M;*=(/\FV / 5@6_9]]BSE!:Y)I;CJ4\VI("_0KG7O?1/*'8G@A;,'=W:6;\Y
M[6O>3P\;AS'ZS?Y96VVDZOPYM='!:6MB$TV<M$%-(^,OY*S]$4!;#A%2?\>S
MV<24%=F)P+H0:Z+,;'3Z:#G8&V;NE3^;E7LXGY4+U)^C'M6OI%I;/UO1 OT+
M,J[Z(?0O #68\X:\XCI]AJ%/RY)/\TU0!-[/\.ZVEG N,'X58#\'.ZZBO+HG
M7! LT)7GQE4?P+@<QCW4#C:]%PH"OFK 79]PR5"/6@S-ULM,U49R!0 O0:*5
MX"H;_PZEN +L"F&CJ I>3DH1=E#?SZCO7A^U./W.TBDST0] Q-=''*%$8?2/
M\70%#& N59)WFGL'Z#-U!R3P3P)D(Y#W=S^@+E%'0M 7IAA',JP$>K]9%#+L
M>\_M>X^IFL3PX)*S_A/D> 7B8U\(HG>]5")N-%P/\*Z/]S-C]H1@/DL8]'!I
M@/L.N;VEQ+51ZYYX/HBR.=)!H\H;/,#" <JF*%\[ZE6%.E(SXM%'4!N&,-\H
M(58_DLQ#YW@TF.5<:=>45XTY.$VWEP12"G6^!=S/X98Z2;F-QU3J>I]D,+7Z
M?6!<#N/KRR4B/1V&!Z1+(LW52^I$-CP+NMIBP5>/^1OAD%E0!>R31JMQTXA[
M!&,AL.7X@DB9U7@&NJOH1A'M)2%8R((M$76@*2RI&W2VF>N/!A0OP[[@4EB"
M]9?@5"=SC#D5!'75]AAD?>-;(B?HB@^Q1[_'>^8+]6!ZW? ;UXWC1NR1OB:/
M&#1X"5@_8QYZ\XZ)VAEGC^65]\E[W:0)X\.E.CMZ%D"7 5JQ]= )&PC=/+^X
M0P\HKZ+,@TENLJ'V0M^=Q7Q!]:D\^QPW +T"])EZ5AL1>EKTW5IQ ,"\"C-S
MU9%[,@L8#N(E\F5WFWU_3'J/<$ T ;AC8V=9+G3P'$ N 3)[6&;!Z:< \?J(
MOZA7PV()Y/!)P%P"YFC.SC+0SX[A =1949\SW8#AA/O#*-,9)2=K.&V;8J['
MIV%OF;:>/@^PUX=]@?DD.*(L9AT_#:A+0$W<>^JZ!/5(4 HTG0T(F;HFXK3'
MQ'5'3/>/"I(=7VPDSJL&?4$]7Y)PH@*,P3%-6+?A&JJO)]5?V2V*1FCEF*D%
M74<RBL+V%K0=@=NTI-N4WP5'WRBZ'#\$Y6B8>EP '(X8SQ?6 .K%J+?UA\(V
MBX<IA8\ NE'H4:@#1+U2ZE'8'ZA72OU,'2PH34S>\#% -PH]#E:_3+?Q'Y5Z
M[,<O[-D'\,7 3QW,Q7W.@+X8^J#TJE@E%B OBCQT\8,A4S'V5$'+&D4NP+\8
M_TLRX%C<X71<(/P)@#<,/M7X?;U^\+ $Q9?@@CS.M(%,?@;PC<*_<BB+]+W^
M*] V2_O.Q;I-2$P\>@C4S5+G9#@MIPL? '&CQ-.=UL&2KQ1]NEP4T%>*?K8M
MSIKM<F 1BBU"4- +@E\I\Z\2.XFXZT< W"CP;U3/R)KNK?%#H&Z4>M)Z#FS)
M"JE383%/T%1;H^F/ 'W)Z,/A/>D52%HX0[35)/FN,Q'4HMA#78XM19Y,K9E\
M74H >5;DU\0ESNP<;9#RRI$G8MX2@JD[0"=T0V.>$OD+H?\=C^FRLJKD"@!>
M#G#]_5;0UD\#ZA)0J]]97IH9/0N@UP<=1Z.7D,X9K ;4*U$_H#_T+,UE%?7)
M!17A+NL+-U^>>?,)\]W&[EZ G7%EE'S8*68![N\U/M0#<BS8>[LU$NQYR.BZ
M=76&SNF(2F(#84.$KX"P2<)O.[I0U;/?%9!FV %7[8 !X3A>MFP7G+D(#(_U
ML>O\GX53-',D!@'@58"C=)\E$ITS&Z@N5ETM><?*^FKD44OWE>\1?>@N[.$#
MN5XEUT$8;)E4YXF1 >85F--)5<M&U:<N >0E(.=,3U"?DD8GE!-+PM9H&G1"
M.-OX V@ED[65S#:TDH$[,\>=V2,VNL)W.KF16^HYL)_*1YQ2<4LV=A@"8V(D
M[C,N!AAS6?J,W'C*XA+B,(6Q1-@Z#W<)YQPINH!X!>)OA(_T!UE,.7H60)<
M.LIP7D8Z7P(TH%Z!^D;!1?TQI[K7>(]A&T9L&Y]DOEBJDPL =PFXB>N.,9<>
MX7"&,4!72/2,EIZY!J"7 #VN@U@&/&>=!,!>!9LQ6VD+&YT0R1F5\Y/J+(<.
M,9 N@?2_J&>ALS!+_)MN,L=SA.U&6.N7S<BO>Z"=P0"^ /C<%1'@@L_J@F\6
M<\&_'S![HO[GR)'[^_\#4$L#!!0    ( +$T2%9J@&2JQ0,  -X-   3
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MP%HTMZ&1I"4QQ7KTAM#ND=Y?*B2%'E'KXRK?<9H\>#<W'WL'._T34$L#!!0
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M?QPU\B_/)V+M:Z$%L%UEU%T,X2'07=GU(5_XP*B^^L^=W(=7Y_\!4$L#!!0
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M8 $\,3@I/(&Z6ANWIZXBVPE,PO.!N2)[(\.!1;B6/[?!L:6S$%<;B)W '(.
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MBSHWD[X817%!OZ-08DY#Y&^^>O+=\P@'Q"%E5\P8&NA/9^31B400,CREE+9
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M,#(R,3(S,2YX<V102P$"% ,4    " "Q-$A6R#05]JM3  #W@0, %
M        @ 'N;P@ 8W9S+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "Q
M-$A6U_3DQ"D9 0#ZP P %               @ '+PP@ 8W9S+3(P,C(Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " "Q-$A61__R*<0.  !^#P  $P
M    @ $FW0D 8W9S+3(P,C(Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( +$T2%;/
MI 0;X50! '/5 0 3              "  1OL"0!C=G,M,C R,C$R,S%?9S(N
M:G!G4$L! A0#%     @ L31(5EX.V\>G:0( !Q\9 !0              ( !
M+4$+ &-V<RTR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ L31(5LH^EAIJ
M?0$ (J81 !0              ( !!JL- &-V<RTR,#(R,3(S,5]P<F4N>&UL
M4$L! A0#%     @ L31(5AC(>%_#(@  YOD" !,              ( !HB@/
M &5X:&EB:70R,3$M,C R,BYH=&U02P$"% ,4    " "Q-$A6:H!DJL4#  #>
M#0  $P              @ &62P\ 97AH:6)I=#(S,2TR,#(R+FAT;5!+ 0(4
M Q0    ( +$T2%; Q7S^$@@  -,E   3              "  8Q/#P!E>&AI
M8FET,S$Q+3(P,C(N:'1M4$L! A0#%     @ L31(5EPTZ"0F"   VR4  !,
M             ( !SU</ &5X:&EB:70S,3(M,C R,BYH=&U02P$"% ,4
M" "Q-$A6Z. PF>0$  #_$P  $P              @ $F8 \ 97AH:6)I=#,R
M,2TR,#(R+FAT;5!+ 0(4 Q0    ( +$T2%;8VYJQ\ 0  #H3   3
M      "  3ME#P!E>&AI8FET,S(R+3(P,C(N:'1M4$L! A0#%     @ L31(
M5JD7K,;=$P  15$  !,              ( !7&H/ &5X:&EB:70T,C$M,C R
;,BYH=&U02P4&      \ #P#- P  :GX/

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
